PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Gallyas, F; Pal, J; Farkas, O; Doczi, T				Gallyas, F; Pal, J; Farkas, O; Doczi, T			The fate of axons subjected to traumatic ultrastructural (neurofilament) compaction: an electron-microscopic study	ACTA NEUROPATHOLOGICA			English	Article						recovery; degeneration; regeneration; electron microscopy	INJURED AXONS; BRAIN INJURY; LIGHT; NEURONS; ARGYROPHILIA; PERMEABILITY; ENVIRONMENT; IMMEDIATE; RECOVERY; DEATH	By means of a new head-injury apparatus, a 0.75-mm-deep depression was produced momentarily at a predetermined site of the rat calvaria. This immediately evoked ultrastructural (neurofilament) compaction in many myelinated axon segments in layers IV and V of the neocortex under the impact site. The affected axon segments run quasi-parallel to the brain surface in a diffuse distribution among normal axons. Other kinds of damage to the brain tissue were insignificant; the conditions were therefore favorable for investigation of the fate of the compacted axons. Quantitative analysis of the findings on groups of ten rats that were sacrificed either immediately after the head injury or following a 1 day or a 1 week survival period showed that around 50% of the compacted axons recovered in 1 day, and a further less than 10% did so in 1 week. Electron microscopy revealed that the non-recovering compacted axons underwent a sequence of degenerative morphological changes including homogenization, fragmentation and resorption of the fragments. However, the myelin sheaths around these degenerating axons remained apparently unchanged even in the long-surviving rats, and hardly any phagocytotic cells were encountered. On the other hand, many such myelin sheaths contained axolemma-bound, normal-looking axoplasm besides the above morphological signs of axon-degeneration. It is concluded that the non-recovering compacted axons undergo an uncommon (non-Wallerian) kind of degeneration, which is mostly reversible.	Univ Pecs, Fac Med, Dept Neurosurg, H-7623 Pecs, Hungary; Univ Pecs, Hungarian Acad Sci, Clin Neurosci Res Grp, H-7623 Pecs, Hungary	Gallyas, F (corresponding author), Univ Pecs, Fac Med, Dept Neurosurg, Ret Utca 2, H-7623 Pecs, Hungary.	ferenc.gallyas.sen@aok.pte.hu	Gallyas, Ferenc/C-5450-2009; Doczi, Tamas/C-5750-2009; Pal, Jozsef/I-3416-2013; Pal, Jozsef/C-4073-2009	Pal, Jozsef/0000-0001-6468-6409			Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; AUER RN, 1985, ACTA NEUROPATHOL, V67, P13, DOI 10.1007/BF00688120; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CAMMERMEYER JAN, 1961, ACTA NEUROPATHOL, V1, P245; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Csordas A, 2003, ACTA NEUROPATHOL, V106, P37, DOI 10.1007/s00401-003-0694-1; Elder GA, 1998, J CELL BIOL, V141, P727, DOI 10.1083/jcb.141.3.727; GALLYAS F, 1993, J NEUROSCI METH, V50, P159, DOI 10.1016/0165-0270(93)90004-B; Gallyas F, 2004, BIOL CELL, V96, P313, DOI 10.1016/j.biolcel.2004.01.009; Gallyas F, 2002, ACTA NEUROPATHOL, V103, P36, DOI 10.1007/s004010100424; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P386, DOI 10.1007/BF00713530; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; HAYAT MA, 1981, FIXATION ELECT MICRO, P88; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Narciso MS, 2001, AN ACAD BRAS CIENC, V73, P231, DOI 10.1590/S0001-37652001000200008; PAL J, IN PRESS J NEUROSCI; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Zsombok A, 2005, J NEUROSCI METH, V142, P145, DOI 10.1016/j.jneumeth.2004.08.005	22	13	13	0	0	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	MAR	2006	111	3					229	237		10.1007/s00401-006-0034-3			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	030HA	WOS:000236624000004	16485106				2021-06-18	
J	Sagar, P; Grant, PE				Sagar, P; Grant, PE			Diffusion-weighted MR imaging: Pediatric clinical applications	NEUROIMAGING CLINICS OF NORTH AMERICA			English	Article							SYRUP-URINE-DISEASE; ACUTE DISSEMINATED ENCEPHALOMYELITIS; TRAUMATIC BRAIN-INJURY; KEARNS-SAYRE-SYNDROME; MULTIPLE-SCLEROSIS; WATER DIFFUSION; WHITE-MATTER; MITOCHONDRIAL ENCEPHALOMYOPATHY; HEPATIC-ENCEPHALOPATHY; LACTIC-ACIDOSIS	We have summarized the diffusion-weighed imaging (DWI) findings in a number of different cerebral disorders. in many cases, DWI with the accompanying apparent diffusion coefficient (ADC) map provides additional useful information to the standard imaging sequences. Pathophysiologic mechanisms resulting in baseline normal ADC values and changes with disease processes are not well understood; therefore, caution should be used when prognosticating the outcome of regions with abnormal ADCs. DWI should be used as an adjunct to routine imaging and interpreted in the context of the routine imaging findings and clinical scenario. As our understanding of ADC mechanisms increases and we begin to incorporate information about tissue organization from diffusion tensor imaging or diffusion spectrum imaging, the role of these methods in clinical diagnosis should continue to increase.	Massachusetts Gen Hosp, Dept Radiol, Div Pediat Radiol, Boston, MA 02114 USA	Sagar, P (corresponding author), Massachusetts Gen Hosp, Dept Radiol, Div Pediat Radiol, 34 Fruit St, Boston, MA 02114 USA.	psagar@partners.org					Abe K, 2004, NEURORADIOLOGY, V46, P113, DOI 10.1007/s00234-003-1138-2; Albayram S, 2004, AM J NEURORADIOL, V25, P792; Asao C, 2005, AM J NEURORADIOL, V26, P1455; Axer H, 2005, J NEUROL NEUROSUR PS, V76, P996, DOI 10.1136/jnnp.2004.045500; Barker PB, 2004, J CHILD NEUROL, V19, P559, DOI 10.1177/088307380401900801; Barkovich AJ, 1998, AM J NEURORADIOL, V19, P523; Barkovich AJ, 2001, AM J NEURORADIOL, V22, P1786; Bernarding J, 2002, J MAGN RESON IMAGING, V15, P96, DOI 10.1002/jmri.10045; Buttner A, 2000, FORENSIC SCI INT, V113, P435, DOI 10.1016/S0379-0738(00)00204-8; Casey SO, 2004, NEURORADIOLOGY, V46, P272, DOI 10.1007/s00234-003-1053-6; Cavalleri F, 2002, NEURORADIOLOGY, V44, P499, DOI 10.1007/s00234-002-0771-5; Chan YL, 2003, PEDIATR RADIOL, V33, P574, DOI 10.1007/s00247-003-0949-y; Chang SC, 2002, CLIN IMAG, V26, P227, DOI 10.1016/S0899-7071(02)00436-9; Chang YW, 2003, PEDIATR RADIOL, V33, P836, DOI 10.1007/s00247-003-0968-8; Chu BC, 1999, NEURORADIOLOGY, V41, P759, DOI 10.1007/s002340050838; Covarrubias DJ, 2002, AM J NEURORADIOL, V23, P1038; Darquie A, 2001, P NATL ACAD SCI USA, V98, P9391, DOI 10.1073/pnas.151125698; De Vries LS, 2005, NEUROPEDIATRICS, V36, P12, DOI 10.1055/s-2005-837544; deVeber G, 2001, NEW ENGL J MED, V345, P417, DOI 10.1056/NEJM200108093450604; Dublin AB, 2002, AM J NEURORADIOL, V23, P484; Ducreux D, 2001, AM J NEURORADIOL, V22, P261; duPlessis AJ, 1997, CLIN PERINATOL, V24, P627; Eichler FS, 2002, AM J NEURORADIOL, V23, P833; Elster AW, 2004, J COMPUT ASSIST TOMO, V28, P98, DOI 10.1097/00004728-200401000-00016; Engelbrecht V, 2002, RADIOLOGY, V222, P410, DOI 10.1148/radiol.2222010492; Erdem E, 2001, NEURORADIOLOGY, V43, P927, DOI 10.1007/s002340100603; Fisher MJ, 2005, AM J NEURORADIOL, V26, P1686; Forbes KPN, 2002, RADIOLOGY, V222, P405, DOI 10.1148/radiol.2222010179; Gabis LV, 2004, PEDIATR NEUROL, V30, P324, DOI 10.1016/j.pediatrneurol.2003.11.005; Ganesan V, 2003, ANN NEUROL, V53, P167, DOI 10.1002/ana.10423; Gaviani P, 2005, AM J NEURORADIOL, V26, P1115; GEAN A, 1994, WHITE MATTER SHEARIN, P207; Grant P Ellen, 2003, Magn Reson Imaging Clin N Am, V11, P493, DOI 10.1016/S1064-9689(03)00070-9; Grant PE, 2001, RADIOLOGY, V221, P43, DOI 10.1148/radiol.2211001523; GRANT PE, IN PRESS MAGN RESON; Ha JS, 2004, PEDIATR RADIOL, V34, P163, DOI 10.1007/s00247-003-1058-7; Harada M, 2000, JMRI-J MAGN RESON IM, V11, P559, DOI 10.1002/(SICI)1522-2586(200005)11:5<559::AID-JMRI12>3.0.CO;2-C; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hunt RW, 2004, PEDIATRICS, V114, P999, DOI 10.1542/peds.2003-0935-L; Inglese M, 2002, AM J NEURORADIOL, V23, P267; Jalan R, 2005, NEUROCHEM INT, V47, P78, DOI 10.1016/j.neuint.2005.04.010; Jan W, 2003, NEURORADIOLOGY, V45, P634, DOI 10.1007/s00234-003-1035-8; Jan W, 2003, NEURORADIOLOGY, V45, P393, DOI 10.1007/s00234-003-0955-7; JENNETTE JC, 1994, SEMIN NEUROL, V14, P291, DOI 10.1055/s-2008-1041088; Kawamata T, 2000, ACTA NEUROCHIR SUPPL, V76, P9; Khong PL, 2004, J CHILD NEUROL, V19, P872, DOI 10.1177/08830738040190110501; Kim JA, 2001, AM J NEURORADIOL, V22, P1149; Kuker W, 2004, CHILD NERV SYST, V20, P742, DOI 10.1007/s00381-004-0988-1; Kuker W, 2004, NEURORADIOLOGY, V46, P421, DOI 10.1007/s00234-004-1203-5; Lansberg MG, 1999, NEUROLOGY, V52, P1021, DOI 10.1212/WNL.52.5.1021; Leite CC, 2005, RADIOLOGY, V235, P190, DOI 10.1148/radiol.2351031963; Lie JT, 1997, NEUROL CLIN, V15, P805, DOI 10.1016/S0733-8619(05)70348-0; Lin JT, 2003, AM J NEURORADIOL, V24, P102; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Lonergan GJ, 2003, RADIOGRAPHICS, V23, P811, DOI 10.1148/rg.234035030; LOREK A, 1994, PEDIATR RES, V36, P699, DOI 10.1203/00006450-199412000-00003; Lovblad KO, 2003, NEURORADIOLOGY, V45, P400, DOI 10.1007/s00234-003-1009-x; Lynch JK, 2002, PEDIATRICS, V109, P116, DOI 10.1542/peds.109.1.116; Mader I, 2002, STROKE, V33, P1142, DOI 10.1161/hs0402.105883; Majoie CB, 2002, AM J NEURORADIOL, V23, P813; Majoie CBLM, 2004, AM J NEURORADIOL, V25, P32; Mazumdar A, 2003, AM J NEURORADIOL, V24, P1057; Miyasaka N, 2000, RADIOLOGY, V215, P199, DOI 10.1148/radiology.215.1.r00ap24199; Moran CJ, 1998, RADIOLOGY, V206, P311, DOI 10.1148/radiology.206.2.9457180; Moritani T, 2004, CLIN IMAG, V28, P261, DOI 10.1016/S0899-7071(03)00191-8; Naegele T, 2000, RADIOLOGY, V216, P683, DOI 10.1148/radiology.216.3.r00se27683; Neil JJ, 1998, RADIOLOGY, V209, P57, DOI 10.1148/radiology.209.1.9769812; Nusbaum AO, 2000, AM J ROENTGENOL, V175, P821, DOI 10.2214/ajr.175.3.1750821; Oguz KK, 2005, NEURORADIOLOGY, V47, P229, DOI 10.1007/s00234-005-1350-3; Oksuzler YF, 2005, PEDIATR NEUROL, V32, P325, DOI 10.1016/j.pediatrneurol.2004.12.007; Oppenheim C, 2000, J NEUROL NEUROSUR PS, V69, P248, DOI 10.1136/jnnp.69.2.248; Patay Z, 2005, EUR RADIOL, V15, P2284, DOI 10.1007/s00330-005-2846-2; PECTASIDES M, 2004, 12 ANN INT SOC MAGN; PECTASIDES M, 2005, 48 ANN SOC PED RAD N; Roach E S, 2000, Semin Pediatr Neurol, V7, P244; Rollins N, 2004, AM J NEURORADIOL, V25, P1688; ROSS BD, 1994, RADIOLOGY, V193, P457, DOI 10.1148/radiology.193.2.7972763; Roychowdhury S, 2000, AM J NEURORADIOL, V21, P869; Sacher M, 2005, NEURORADIOLOGY, V47, P241, DOI 10.1007/s00234-004-1314-z; Scanderberg AC, 2000, AM J NEURORADIOL, V21, P862; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Shanmuganathan K, 2004, AM J NEURORADIOL, V25, P539; Steen RG, 2003, RADIOLOGY, V228, P216, DOI 10.1148/radiol.2281020943; Szabo K, 2005, BRAIN, V128, P1369, DOI 10.1093/brain/awh454; Teixeira J, 2001, NEURORADIOLOGY, V43, P1031, DOI 10.1007/s002340100625; Thornton JS, 1998, MAGN RESON MED, V39, P920, DOI 10.1002/mrm.1910390609; Toft PB, 1996, J COMPUT ASSIST TOMO, V20, P1006, DOI 10.1097/00004728-199611000-00029; VALENTE RM, 1994, SEMIN NEUROL, V14, P380, DOI 10.1055/s-2008-1041098; Vella S, 2003, NEUROPEDIATRICS, V34, P100; Volpe JJ, 1997, BRAIN DEV-JPN, V19, P519, DOI 10.1016/S0387-7604(97)00078-8; Wang XY, 2003, NEURORADIOLOGY, V45, P640, DOI 10.1007/s00234-003-1029-6; Wong AM, 2004, AM J NEURORADIOL, V25, P1016; Yonemura K, 2001, AM J NEURORADIOL, V22, P269; Zarifi MK, 2002, RADIOLOGY, V225, P859, DOI 10.1148/radiol.2253011797	95	13	13	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1052-5149	1557-9867		NEUROIMAG CLIN N AM	Neuroimaging Clin. N. Am.	FEB	2006	16	1					45	+		10.1016/j.nic.2005.11.003			31	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	029DI	WOS:000236538200005	16543085				2021-06-18	
J	Stapert, S; Houx, P; De Kruijk, J; Ponds, R; Jolles, J				Stapert, S; Houx, P; De Kruijk, J; Ponds, R; Jolles, J			Neurocognitive fitness in the sub-acute stage after mild TBI: The effect of age	BRAIN INJURY			English	Article						mild TBI; age; brain reserve capacity; neurocognitive performance	TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURIES; SYMPTOMS; CONCUSSION; SEQUELAE	Objective: Age is assumed to be a negative prognostic factor in recovery from moderate-to-severe traumatic brain injury (TBI). Little is known on cognitive performance after mild TBI in relation to age in the sub-acute stage after injury. Method: Ninety-nine mild TBI subjects (age 15-75) were compared with 91 healthy control subjects (age 14-74) in a case-control design. Patients were matched on age, sex and level of education, with control subjects. Mean interval between injury and cognitive assessment was 13 days. Neurocognitive test battery contained tests of verbal memory, selective attention, general speed of information processing and verbal fluency. Results: An overall effect was found of a single mild TBI on neurocognitive performance in the sub-acute stage after injury. Age did not add significantly to the effect of mild TBI on cognitive functioning. Conclusion: Patients suffering from mild TBI are characterized by subtle neurocognitive deficits in the weeks directly following the trauma. The notion that elderly subjects have a worse outcome in the sub-acute period after mild TBI is at least not in line with the results of this study.	Maastricht Univ, Dept Psychol, Inst Brain & Behav, NL-6200 MD Maastricht, Netherlands; Univ Hosp, Dept Neurol, Maastricht, Netherlands; Maastricht Univ, Dept Psychiat & Neuropsychol, Inst Brain & Behav, NL-6200 MD Maastricht, Netherlands	Stapert, S (corresponding author), Maastricht Univ, Dept Psychol, Inst Brain & Behav, POB 616, NL-6200 MD Maastricht, Netherlands.	s.stapert@psychology.unimaas.nl					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ALEXANDER MP, 1982, PSYCHIAT ASPECTS NEU, P219; American Congress of Rehabilitation Medicine (ACRM), 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BRAND N, 1985, J GEN PSYCHOL, V112, P201, DOI 10.1080/00221309.1985.9711004; FIELDS RB, 1994, TXB GERIATRIC NEUROP, P479; Fogel Barry S., 1994, P413; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; HOUX PJ, 1991, BRAIN COGNITION, V15, P246, DOI 10.1016/0278-2626(91)90029-8; Jennett B., 1982, NEUROLOGICAL DISORDE, P202; Jolles J, 1995, MAASTRICHT AGING STU; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Klein M, 1997, J CLIN EXP NEUROPSYC, V19, P77, DOI 10.1080/01688639708403838; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Luteijn F., 1983, Handleiding Groninger Intelligentie Test [Manual Groningen Intelligence Test]; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Miller JR, 1989, MILD MODERATE HEAD I, P125; MOULTON RJ, 1992, CAN J SURG, V35, P35; Rapoport MJ, 2001, BRAIN INJURY, V15, P857, DOI 10.1080/02699050110065303; REY A, 1964, EXAMEN PSYCHOL ENCEP; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Smith A., 1968, LEARNING DISORDERS, P83; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010	29	13	14	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2006	20	2					161	165		10.1080/02699050500442949			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	003KX	WOS:000234681700006	16421065				2021-06-18	
J	Inglese, M; Grossman, RI; Diller, L; Babb, JS; Gonen, O; Silver, JMA; Rusinek, H				Inglese, M; Grossman, RI; Diller, L; Babb, JS; Gonen, O; Silver, JMA; Rusinek, H			Clinical significance of dilated Virchow-Robin spaces in mild traumatic brain injury	BRAIN INJURY			English	Article						mild traumatic brain injury (TBI); Virchow-Robin spaces (VRS); neuropsychological testing	MINOR HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS; PERIVASCULAR SPACES; SPECTRUM	Primary objective: To investigate the relationship between the number of dilated Virchow-Robin spaces (VRS) and neurocognitive findings in patients with traumatic brain injury (TBI). Research design: Thirty-eight patients with TBI and 21 controls were studied. Methods and procedures: Fifteen patients underwent MRI within a mean interval of 5.4 (range 1-12) days from the brain injury and 23 after an average period of 5.5 (range 0.2-31) years. All subjects were examined with a battery of 13 neuropsychological tests (NP). Main outcomes and results: The average number of VRS was significantly higher in patients than in controls. There were no significant differences between patients and controls in terms of NP tests. The number of VRS showed a significant inverse correlation with processing speed and a positive correlation with visual perceptual of attention only in patients studied within a short delay of trauma. Conclusions: VRS are not directly associated to neurocognitive findings, suggesting that they may represent a result of the shear-strain injury.	NYU, Sch Med, Dept Radiol, New York, NY 10016 USA; Rusk Inst Rehabil Med, Dept Psychol, New York, NY USA; Lenox Hill Hosp, New York, NY 10021 USA	Inglese, M (corresponding author), NYU, Sch Med, Dept Radiol, 650 1St Ave, New York, NY 10016 USA.	matilde.inglese@med.nyu.edu	Inglese, Matilde/AAH-3189-2020	Inglese, Matilde/0000-0002-9610-0297; Gonen, Oded/0000-0002-3148-2028; Diller, Leonard/0000-0001-7295-7846; Babb, James/0000-0003-1798-1186	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR 00096] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 39135] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039135] Funding Source: NIH RePORTER		Achiron A, 2002, AM J NEURORADIOL, V23, P376; BEN-YISHAY Y, 1970, Journal of Abnormal Psychology, V76, P378, DOI 10.1037/h0030404; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; Di Constanzo A, 2001, EUR NEUROL, V46, P131, DOI 10.1159/000050786; DILLER L, 1993, ADV STROKE REHABILIT; DOWNEY J, 1923, WILL TEMPERAMENT ITS; Erlanger DM, 2002, J HEAD TRAUMA REHAB, V17, P458, DOI 10.1097/00001199-200210000-00007; ESIRI MM, 1990, J NEUROL SCI, V100, P3, DOI 10.1016/0022-510X(90)90004-7; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; HEIER LA, 1989, AM J NEURORADIOL, V10, P929; Holbourn AHS, 1943, LANCET, V2, P438; Inglese M, 2005, AM J NEURORADIOL, V26, P719; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; MacLullich AMJ, 2004, J NEUROL NEUROSUR PS, V75, P1519, DOI 10.1136/jnnp.2003.030858; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; MIRFAKHRAEE M, 1986, RADIOLOGY, V158, P715, DOI 10.1148/radiology.158.3.3945745; Miszkiel KA, 1996, CLIN RADIOL, V51, P842, DOI 10.1016/S0009-9260(96)80080-8; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Rath JF, 2004, ARCH CLIN NEUROPSYCH, V19, P613, DOI 10.1016/j.acn.2003.08.006; RATTOK J, 1992, NEUROPSYCHOLOGIA, V6, P395, DOI DOI 10.1037/0894-4105.6.4.395; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROLLINS NK, 1993, RADIOLOGY, V189, P53, DOI 10.1148/radiology.189.1.7690491; Schick A, 1999, STAT PROBABIL LETT, V41, P287, DOI 10.1016/S0167-7152(98)00165-5; Spreen O., 1977, NEUROSENSORY CTR COM; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; WATERLOO K, 1997, ACTA NEUROCHIR, P31	39	13	13	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2006	20	1					15	21		10.1080/02699050500309593			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	001AQ	WOS:000234505000002	16403696				2021-06-18	
J	Zhu, Q; Prange, M; Margulies, S				Zhu, Qiliang; Prange, Michael; Margulies, Susan			Predicting unconsciousness from a pediatric brain injury threshold	DEVELOPMENTAL NEUROSCIENCE			English	Article						pediatric traumatic brain injury; biomechanics; axonal injury; tissue injury threshold; finite element analysis	DIFFUSE AXONAL INJURY; CLOSED-HEAD INJURY; DAMAGE; MODEL; COMA	The objective of this study was to utilize tissue deformation thresholds associated with acute axonal injury in the immature brain to predict the duration of unconsciousness. Ten anesthetized 3- to 5-day-old piglets were subjected to non-impact axial rotations (110-260 rad/s) producing graded injury, with periods of unconsciousness from 0 to 80 min. Coronal sections of the perfusion-fixed brain were immunostained with neurofilament antibody (NF-68) and examined microscopically to identify regions of swollen axons and terminal retraction balls. Each experiment was simulated with a finite element computational model of the piglet brain and the recorded head velocity traces to estimate the local tissue deformation (strain), the strain rate and their product. Using thresholds associated with 50, 80 and 90% probability of axonal injury, white matter regions experiencing suprathreshold responses were determined and expressed as a fraction of the total white matter volume. These volume fractions were then correlated with the duration of unconsciousness, assuming a linear relationship. The thresholds for 80 and 90% probability of predicting injury were found to correlate better with injury severity than those for 50%, and the product of strain and strain rate was the best predictor of injury severity (p = 0.02). Predictive capacity of the linear relationship was confirmed with additional (n = 13) animal experiments. We conclude that the suprathreshold injured volume can provide a satisfactory prediction of injury severity in the immature brain. Copyright (c) 2006 S. Karger AG, Basel.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Margulies, S (corresponding author), Univ Penn, Dept Bioengn, 3320 Smith Walk, Philadelphia, PA 19104 USA.	margulies@seas.upenn.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS39679] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49-CCR312712] Funding Source: Medline		Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bandak F.A, 1994, STAPP CAR CRASH C SO, P145; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GOSCH HH, 1970, J TRAUM, V10, P370, DOI 10.1097/00005373-197005000-00002; GURDJIAN ES, 1968, J NEUROSURG, V29, P70, DOI 10.3171/jns.1968.29.1.0070; Hardy W N, 2001, Stapp Car Crash J, V45, P337; HODGSON VR, 1966, J NEUROSURG, V25, P549, DOI 10.3171/jns.1966.25.5.0549; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; King A.I., 2003, IRCOBI C LISB PORT, P1; LANGLOIS L, 2004, TRAUMATIC BRAIN INJU; LAU IV, 1986, P 30 STAPP CAR CRASH, P123; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LUERSSEN T, 1993, PEDIAT TRAUMA; LUERSSEN TG, 1991, CONC PED N, V11, P87; Lusardi TA, 2003, BIORHEOLOGY, V40, P401; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MARGULIES SS, 1999, COMP DIFFUSE BRAIN I; McElhaney JH., 1976, HDB HUMAN TOLERANCE; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; NEWMAN J, 1975, STAPP CAR CRASH C P, V19, P615; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PRANGE M, 1999, 43 STAPP CAR CRASH C; PRANGE M, 2002, BIOMECHANICS TRAUMAT; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; WANG JT, 1989, J BIOMECH ENG-T ASME, V111, P128, DOI 10.1115/1.3168353; YOSHIKAWA T, 1968, ATLAS BRAINS DOMESTI, P1	41	13	13	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					388	395		10.1159/000094165			8	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600016	16943662				2021-06-18	
J	Ellis, C; Rosenbek, JC; Rittman, MR; Boylstein, CA				Ellis, Charles; Rosenbek, John C.; Rittman, Maude R.; Boylstein, Craig A.			Recovery of cohesion in narrative discourse after left-hemisphere stroke	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						aphasia; cohesion; cohesive markers; cohesive ties; communication; discourse; language; narratives; speech; stroke	CLOSED-HEAD-INJURY; SUBCORTICAL APHASIA; ELICITATION TASK; LANGUAGE; ADULTS; COHERENCE; PATTERNS; DEFICITS; NEGLECT	Little is known about the recovery of narrative discourse after stroke. While several studies have analyzed the recovery of language in individuals with aphasia, few known studies exist on the recovery of narrative discourse in stroke survivors, particularly those who have not been diagnosed with aphasia. In this study, we evaluated the cohesiveness of narrative discourse in a cohort of individuals who had suffered a left-hemisphere stroke and had not been diagnosed with expressive language impairment. We analyzed their narrative discourse at 1, 6, and 12 months poststroke. Our findings indicate that, while the mean number of cohesive ties in narrative discourse remained generally constant during the first year poststroke, the percentage correct use of cohesive ties increased significantly during the same time period. These findings suggest that subtle disruptions in expressive language can be present initially in narrative discourse, and recovery from these disruptions can occur naturally over time.	Rehabil Outcomes Res Ctr, Dept Vet Affairs, Gainesville, FL USA; Univ Florida, Dept Communicat Disorders, Gainesville, FL 32611 USA	Ellis, C (corresponding author), Med Univ S Carolina, Dept Rehabil Sci, Coll Hlth Profess, 151-B Rutledge Ave,POB 250965, Charleston, SC 29425 USA.	ellisc@musc.edu					Bays C L, 2001, J Neurosci Nurs, V33, P310; Bloom RL, 1996, INT J NEUROSCI, V88, P125, DOI 10.3109/00207459608999818; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Copland DA, 2000, J MED SPEECH-LANG PA, V8, P1; Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003; ELLIS C, 2004, AM SPEECH LANG HEAR; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; GLOSSER G, 1993, NARRATIVE DISCOURSE IN NEUROLOGICALLY IMPAIRED AND NORMAL AGING ADULTS, P191; HALLIDAY M, 1976, COHESIONE NGLISH; Han MK, 2003, STROKE, V34, P259; HARTLEY LL, 1990, BRAIN INJURY, V6, P271; HARTMAN J, 1981, ANN NEUROL, V9, P89, DOI 10.1002/ana.410090119; Hillis AE, 2004, BRAIN LANG, V89, P524, DOI 10.1016/j.bandl.2004.01.007; Hillis AE, 2002, BRAIN, V125, P1094, DOI 10.1093/brain/awf113; Hunt K. W, 1965, GRAMMATICAL STRUCTUR; Kauhanen ML, 2000, CEREBROVASC DIS, V10, P455, DOI 10.1159/000016107; King RB, 1996, STROKE, V27, P1467, DOI 10.1161/01.STR.27.9.1467; Lapointe Leonard L., 1999, Seminars in Speech and Language, V20, P5, DOI 10.1055/s-2008-1064005; Laska AC, 2001, J INTERN MED, V249, P413, DOI 10.1046/j.1365-2796.2001.00812.x; Lemme M.L., 1984, P CLIN APH C SEABR I, P215; LENDREM W, 1985, J NEUROL NEUROSUR PS, V48, P743, DOI 10.1136/jnnp.48.8.743; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; Lock S, 1997, CLIN LINGUIST PHONET, V11, P299, DOI 10.3109/02699209708985197; LOMAS J, 1978, BRAIN LANG, V5, P388, DOI 10.1016/0093-934X(78)90034-2; Mackenzie C, 2000, INT J LANG COMM DIS, V35, P269, DOI 10.1080/136828200247188; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Nadeau SE, 1997, BRAIN LANG, V58, P355, DOI 10.1006/brln.1997.1707; NORTH AJ, 1986, INT J AGING HUM DEV, V23, P267, DOI 10.2190/BPF0-2BWD-BGNQ-HWCW; Pedersen PM, 2004, CEREBROVASC DIS, V17, P35, DOI 10.1159/000073896; Radanovic M, 2003, BRAIN LANG, V84, P337, DOI 10.1016/S0093-934X(02)00554-0; ROSENBEK JC, 1989, CLIN APPROACH; STOVER SE, 1989, CLIN LINGUIST PHONET, V3, P137, DOI 10.3109/02699208908985277; Ulatowska H.K., 1990, DISCOURSE ABILITY BR, P180, DOI [10.1007/978-1-4612-3262-9_8, DOI 10.1007/978-1-4612-3262-9_8]; Ulatowska HK, 1997, J NARRAT LIFE HIST, V7, P259, DOI 10.1075/jnlh.7.1-4.32som; ULATOWSKA HK, 1981, BRAIN LANG, V13, P345, DOI 10.1016/0093-934X(81)90100-0; ULATOWSKA HK, 1986, BRAIN LANG, V28, P24, DOI 10.1016/0093-934X(86)90088-X; ULATOWSKA HK, 1983, BRAIN LANG, V19, P317, DOI 10.1016/0093-934X(83)90074-3; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; WADE DT, 1986, J NEUROL NEUROSUR PS, V49, P11, DOI 10.1136/jnnp.49.1.11; WEILLER C, 1993, BRAIN, V116, P1509, DOI 10.1093/brain/116.6.1509	44	13	14	0	4	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.	NOV-DEC	2005	42	6					737	746		10.1682/JRRD.2005.02.0026			10	Rehabilitation	Rehabilitation	047MQ	WOS:000237883800004	16680611	Bronze			2021-06-18	
J	Mintzer, MZ; Griffiths, RR				Mintzer, MZ; Griffiths, RR			Drugs, memory, and metamemory: A dose-effect study with lorazepam and scopolamine	EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY			English	Article						memory; metamemory; benzodiazepine; lorazepam; scopolamine	TRIAZOLAM-INDUCED AMNESIA; TRAUMATIC BRAIN-INJURY; PEOPLES JUDGMENTS; MIDAZOLAM AMNESIA; FALSE RECOGNITION; SEMANTIC MEMORY; LEARNING JOLS; ACCURACY; CUE; PHARMACOKINETICS	This experiment was designed to use the graded dose-related amnesia produced by the benzodiazepine lorazepam (1.0, 2.0 mg/70 kg, oral) and the anticholinergic scopolamine (0.3, 0.6 mg/70 kg, subcutaneous) as a tool to explore the cognitive and neurochemical mechanisms underlying metamemory in the judgment of learning paradigm, with a placebo-controlled independent groups design in healthy volunteers (n = 12/group). Results provide evidence for a pharmacological dissociation between effects on memory versus metamemory (relative accuracy of item-by-item monitoring) across a range of levels of memory performance and suggest that the drugs selectively impair those aspects of metamnemonic monitoring that require participants' awareness of their overall current state of functioning (absolute accuracy of prospective item-by-item monitoring, prospective global monitoring) but not those that rely solely on assessment of individual item characteristics (relative accuracy of item-by-item monitoring).	Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Behav Biol Res Ctr, Baltimore, MD 21224 USA	Mintzer, MZ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Behav Biol Res Ctr, 5510 Nathan Shock Dr, Baltimore, MD 21224 USA.	mmintzer@jhmi.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-11936, DA-03889] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA011936, R01DA003889] Funding Source: NIH RePORTER		Bacon E, 1998, PSYCHOPHARMACOLOGY, V138, P318, DOI 10.1007/s002130050677; Bishop KI, 1996, EXP CLIN PSYCHOPHARM, V4, P292; Connor LT, 1997, PSYCHOL AGING, V12, P50, DOI 10.1037/0882-7974.12.1.50; CURRAN HV, 1991, PSYCHOPHARMACOLOGY, V105, P1; CURRAN HV, 2000, NEW COGNITIVE NEUROS, P797; Duka T, 1996, BEHAV PHARMACOL, V7, P401; DUNLOSKY J, 1992, MEM COGNITION, V20, P374, DOI 10.3758/BF03210921; DUNLOSKY J, 1994, J MEM LANG, V33, P545, DOI 10.1006/jmla.1994.1026; Dunlosky J, 1997, J MEM LANG, V36, P34, DOI 10.1006/jmla.1996.2476; Dunlosky J, 1998, EXP CLIN PSYCHOPHARM, V6, P77, DOI 10.1037/1064-1297.6.1.77; Ebert U, 1998, J CLIN PHARMACOL, V38, P720, DOI 10.1002/j.1552-4604.1998.tb04812.x; FLAVELL JH, 1971, HUM DEV, V14, P272, DOI 10.1159/000271221; GOODMAN LA, 1954, J AM STAT ASSOC, V49, P732, DOI 10.2307/2281536; GREENBLATT DJ, 1981, CLIN PHARMACOKINET, V6, P89, DOI 10.2165/00003088-198106020-00001; Hertzog C, 2003, J EXP PSYCHOL LEARN, V29, P22, DOI 10.1037/0278-7393.29.1.22; Hirshman E, 2002, J MEM LANG, V47, P499, DOI 10.1016/S0749-596X(02)00017-7; Hirshman E, 2001, J EXP PSYCHOL GEN, V130, P453, DOI 10.1037/0096-3445.130.3.453; Izaute M, 2005, NEUROPSYCHOPHARMACOL, V30, P196, DOI 10.1038/sj.npp.1300564; JANOWSKY JS, 1989, PSYCHOBIOLOGY, V17, P3; Kennedy MRT, 2001, BRAIN INJURY, V15, P469, DOI 10.1080/02699050120517; Kennedy MRT, 2000, J SPEECH LANG HEAR R, V43, P1072, DOI 10.1044/jslhr.4305.1072; Keppel, 1991, DESIGN ANAL RES HDB; KETCHUM JS, 1973, PSYCHOPHARMACOLOGIA, V28, P121, DOI 10.1007/BF00421398; KING JF, 1980, AM J PSYCHOL, V93, P329, DOI 10.2307/1422236; KOPELMAN MD, 1986, Q J EXP PSYCHOL-A, V38, P535, DOI 10.1080/14640748608401614; Koriat A, 1997, J EXP PSYCHOL GEN, V126, P349, DOI 10.1037/0096-3445.126.4.349; Massin-Krauss M, 2002, CONSCIOUS COGN, V11, P123, DOI 10.1006/ccog.2001.0538; MCGLYNN SM, 1991, J COGNITIVE NEUROSCI, V3, P183, DOI 10.1162/jocn.1991.3.2.183; Merritt P, 2005, PSYCHOPHARMACOLOGY, V177, P336, DOI 10.1007/s00213-004-1958-8; Metcalfe J, 1994, METACOGNITION KNOWIN; Mintzer MZ, 1997, BEHAV PHARMACOL, V8, P561, DOI 10.1097/00008877-199711000-00014; Mintzer MZ, 2003, EXP CLIN PSYCHOPHARM, V11, P56, DOI 10.1037/1064-1297.11.1.56; Mintzer MZ, 2003, J MEM LANG, V48, P596, DOI 10.1016/S0749-596X(03)00004-4; Mintzer MZ, 2001, J MEM LANG, V44, P475, DOI 10.1006/jmla.2000.2746; Mintzer MZ, 2001, PSYCHOPHARMACOLOGY, V153, P425, DOI 10.1007/s002130000592; MOHLER H, 1977, SCIENCE, V198, P849, DOI 10.1126/science.918669; Nelson T. O., 1990, PSYCHOL LEARN MOTIV, V26, P125, DOI DOI 10.1016/S0079-7421(08)60053-5; NELSON TO, 1986, J EXP PSYCHOL GEN, V115, P247, DOI 10.1037/0096-3445.115.3.247; NELSON TO, 1991, PSYCHOL SCI, V2, P267, DOI 10.1111/j.1467-9280.1991.tb00147.x; NELSON TO, 1984, PSYCHOL BULL, V95, P109, DOI 10.1037/0033-2909.95.1.109; Nelson TO, 1998, METACOGNITION AND COGNITIVE NEUROPSYCHOLOGY, P161; Pocock SJ, 1983, CLIN TRIALS PRACTICA; POLSTER MR, 1993, PSYCHOL BULL, V114, P477, DOI 10.1037/0033-2909.114.3.477; ROACHE JD, 1985, J PHARMACOL EXP THER, V234, P120; SCHACTER DL, 1986, J CLIN EXP NEUROPSYC, V8, P130; SHIMAMURA AP, 1986, J EXP PSYCHOL LEARN, V12, P452, DOI 10.1037/0278-7393.12.3.452; SQUIRES RF, 1977, NATURE, V266, P732, DOI 10.1038/266732a0; WEINGARTNER HJ, 1993, J PSYCHOPHARMACOL, V7, P303; WESNES K, 1988, HUMAN PSYCHOPHARMACO, V3, P27, DOI DOI 10.1002/HUP.470030106	49	13	13	0	6	AMER PSYCHOLOGICAL ASSOC/EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1064-1297			EXP CLIN PSYCHOPHARM	Exp. Clin. Psychopharmacol.	NOV	2005	13	4					336	347		10.1037/1064-1297.13.4.336			12	Psychology, Biological; Psychology, Clinical; Pharmacology & Pharmacy; Psychiatry	Psychology; Pharmacology & Pharmacy; Psychiatry	994YU	WOS:000234067900008	16366764				2021-06-18	
J	Krismer, AC; Wenzel, V; Lindner, KH; Haslinger, CW; Oroszy, S; Stadlbauer, KH; Konigsrainer, A; Boville, B; Hormann, C				Krismer, AC; Wenzel, V; Lindner, KH; Haslinger, CW; Oroszy, S; Stadlbauer, KH; Konigsrainer, A; Boville, B; Hormann, C			Influence of positive end-expiratory pressure ventilation on survival during severe hemorrhagic shock	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	76th Annual Scientific Session of the American-Heart-Association	NOV 07-12, 2003	ORLANDO, FL	Amer Heart Assoc			SEVERE HEAD-INJURY; TRAUMATIC BRAIN-INJURY; ENDOTRACHEAL INTUBATION; CARDIOPULMONARY-RESUSCITATION; CARDIAC-ARREST; FIELD; PEEP	Study objective: Although a moderate positive end-expiratory pressure (PEEP) level is widely recommended, it is unknown whether moderate PEEP during mechanical ventilation has adverse effects during severe hemorrhagic shock. Therefore, the purpose of our study was to evaluate the effects of O cm H2O PEEP versus 5 cm H2O PEEP versus 10 cm H2O PEEP on short-term survival in a porcine model of severe hemorrhagic shock. Secondary study endpoints were hemodynamic variables and blood gases. Methods: Twenty-four anesthetized pigs were bled approximately 45 mL/kg, randomized into 3 groups, and then ventilated with 0, 5, or 10 cm H2O PEEP. Survival rates were compared using Kaplan-Meier methods with log rank (Mantel Cox) comparison of cumulative survival by treatment group. Results: Seven of 8 O cm H2O PEEP animals survived the 120-minute study period, but 8 of 8 5 cm H2O PEEP animals died within 30 minutes, and 8 of 8 10 cm H2O PEEP animals were dead within 20 minutes (P<.0001). Ventilation with O cm H2O PEEP prevented a further reduction of mean arterial blood pressure and cardiac output. When compared with the O cm H2O PEEP group, end-tidal CO2 declined in the 5 cm H2O PEEP and 10 cm H2O PEEP animals. Compared with the O cm H2O PEEP animals, those ventilated with 5 or 10 cm H2O PEEP had higher lactate levels after 10 minutes. Conclusion: When compared with pigs ventilated with either 5 or 10 cm H2O PEEP, those ventilated with O cm H2O PEEP during untreated, severe hemorrhagic shock had significantly improved short-term survival.	Innsbruck Med Univ, Dept Anesthesiol & Crit Care Med, A-6020 Innsbruck, Austria; Innsbruck Med Univ, Dept Surg, A-6020 Innsbruck, Austria; Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA	Krismer, AC (corresponding author), Innsbruck Med Univ, Dept Anesthesiol & Crit Care Med, Anichstr 35, A-6020 Innsbruck, Austria.	anette.krismer@uibk.ac.at					Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Brown LH, 1996, AM J EMERG MED, V14, P43, DOI 10.1016/S0735-6757(96)90012-1; DAMMANN JF, 1979, CRIT CARE MED, V7, P14, DOI 10.1097/00003246-197901000-00004; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Falk J L, 1999, Prehosp Emerg Care, V3, P273, DOI 10.1080/10903129908958953; Falke KJ, 2003, INTENS CARE MED, V29, P1233, DOI 10.1007/s00134-003-1832-x; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; HANNON JP, 1990, LAB ANIM SCI, V40, P293; HEINRICHS W, 1992, ANAESTHESIST, V41, P653; Helm M, 2003, BRIT J ANAESTH, V90, P327, DOI 10.1093/bja/aeg069; Helm M, 2002, BRIT J ANAESTH, V88, P345, DOI 10.1093/bja/88.3.345; Jellinek H, 2000, CRIT CARE MED, V28, P672, DOI 10.1097/00003246-200003000-00012; MCSWAIN NE, 2003, PHTLS BASIC ADV PREH; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; PEPE PE, 1993, ANN EMERG MED, V22, P393, DOI 10.1016/S0196-0644(05)80470-6; PUTENSEN C, 1994, CRIT CARE MED, V22, P67, DOI 10.1097/00003246-199401000-00015; Roberts I, 2001, LANCET, V357, P385, DOI 10.1016/S0140-6736(00)03653-9; ROSEMURGY AS, 1993, J TRAUMA, V35, P468, DOI 10.1097/00005373-199309000-00022; Trupka A, 1994, Eur J Emerg Med, V1, P1, DOI 10.1097/00063110-199403000-00002; Wenzel V, 2000, COMPARATIVE MED, V50, P644; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	22	13	13	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	OCT	2005	46	4					337	342		10.1016/j.annemergmed.2005.02.022			6	Emergency Medicine	Emergency Medicine	972CC	WOS:000232430500008	16187467				2021-06-18	
J	Lind, CRP; Heppner, PA; Robins, TM; Mee, EW				Lind, CRP; Heppner, PA; Robins, TM; Mee, EW			Transfer of intubated patients with traumatic brain injury to Auckland City Hospital	ANZ JOURNAL OF SURGERY			English	Article						intracranial haematoma; neurosurgery; patient transfer; traumatic brain injury; triage	ACUTE SUBDURAL-HEMATOMA; SPECIALIST RETRIEVAL TEAM; EXTRADURAL HEMATOMA; EPIDURAL HEMATOMAS; COMATOSE PATIENTS; TRANSPORT; CARE; MANAGEMENT; HEMORRHAGE; REDUCTION	Background: Delays in patient transfer to definitive neurosurgical care after traumatic brain injury are important in determining neurological outcome. The efficiency of interhospital transfer of patients to Auckland City Hospital (ACH) was analysed and compared with international standards. Methods: The ACH Department of Critical Care Medicine database for the year 2002 was reviewed, with supplementary information obtained from transfer organizations, hospital notes, radiology archives. and operative loghooks, Results: Thirty-four adult patients with traumatic brain injury and no special reasons for delayed transfer were transported intubated from other hospitals in the North Island of New Zealand. The median time from injury to arrival it ACH was 6.5 h. It took a median 4.4 h for patients to get from initial computed tornographic imaging to ACH, For those requiring evacuation of haematomas, the mean time from arrival at ACH to the start of the operation was 1.4 h. Only 33% of patients from other metropolitan Auckland hospitals, and none from hospitals outside the city arrived within 4 h from the time of injury. Conclusion: Transfer times for brain trauma patients are currently longer than recommended for optimal neurological outcome. Referring hospitals and transfer organizations should review their systems to identify areas for improvement. Direct admission to theatre needs to be expedited within ACH when required. Triage of all trauma patients in metropolitan Auckland with it Glasgow Coma Scale score of less than 14 to ACH would be likely to improve time to treatment. A mobile acute neurosurgical service based in Auckland that would support general surgeons initiating acute decompressive cranial operations would be likely to reduce time to surgery and improve outcomes for patients admitted to hospitals outside Auckland, The development ofa mobile acute neurosurgery service which would complete decompressive procedures started by general surgeons would likely improve trauma outcomes for patients injured outside Auckland.	Auckland City Hosp, Dept Neurosurg, Auckland, New Zealand	Heppner, PA (corresponding author), Auckland City Hosp, Dept Neurosurg, Auckland, New Zealand.	peterheppner@hotmail.com	Lind, Christopher/K-3629-2012	Lind, Christopher/0000-0001-9991-1725			*AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP D; Bartlett J, 1998, BRIT J NEUROSURG, V12, P349, DOI 10.1080/02688699844871; Beddingfield FC, 1996, PEDIATR EMERG CARE, V12, P416, DOI 10.1097/00006565-199612000-00007; Bellingan G, 2000, INTENS CARE MED, V26, P740; Brain Trauma Foundation, SURG MAN TRAUM BRAIN; Civil I, 2003, INJURY, V34, P740, DOI 10.1016/j.injury.2003.08.013; CIVIL ID, 2004, NZ MED J, V117, P1042; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; Gilligan JE, 1999, MED J AUSTRALIA, V171, P617, DOI 10.5694/j.1326-5377.1999.tb123822.x; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; HAVILL JH, 1995, NEW ZEAL MED J, V108, P378; Holmen CD, 2002, J TRAUMA, V53, P345, DOI 10.1097/00005373-200208000-00026; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; Lee EJ, 1998, J TRAUMA, V45, P946, DOI 10.1097/00005373-199811000-00017; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marsh H, 1989, Br J Neurosurg, V3, P13, DOI 10.3109/02688698909001021; MENDELOW AD, 1979, BRIT MED J, V2, P134, DOI 10.1136/bmj.2.6182.134-a; *NEUR SOC AUSTR TR, 2000, MAN AC NEUR RUR REM; POON WS, 1991, INJURY, V22, P323, DOI 10.1016/0020-1383(91)90016-8; *ROYAL AUSTR COLL, 1994, GUID STRUCT APPR PRO; Schoettker P, 2003, INJURY, V34, P187, DOI 10.1016/S0020-1383(02)00280-2; *SCOTT INT GUID NE, 2000, SCOTT INT GUID NETW; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SIMPSON DA, 1988, INJURY, V19, P307, DOI 10.1016/0020-1383(88)90100-3; Vos GD, 2004, INTENS CARE MED, V30, P302, DOI 10.1007/s00134-003-2066-7; Wester K, 1999, NEUROSURGERY, V44, P495, DOI 10.1097/00006123-199903000-00034; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Young JS, 1998, AM SURGEON, V64, P88	28	13	13	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1445-1433	1445-2197		ANZ J SURG	ANZ J. Surg.	OCT	2005	75	10					858	862		10.1111/j.1445-2197.2005.03574.x			5	Surgery	Surgery	987RV	WOS:000233535900006	16176225				2021-06-18	
J	Barney, MC; Max, JE				Barney, MC; Max, JE			The McMaster family assessment device and clinical rating scale: Questionnaire vs interview in childhood traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury (TBI); McMaster structured interview for families (McSIFF); family assessment device (FAD); children and adolescents	PSYCHIATRIC-DISORDERS; ORTHOPEDIC INJURY; SHORT-TERM; CHILDREN; ADOLESCENTS; BEHAVIOR; PREDICTORS; OUTCOMES; MODEL	Two modalities of family assessment based on the McMaster Model of Family Functioning (MMFF), including a self-report questionairre (Family Assessment Device-FAD) and a clinical interview (McMaster Structured Interview For Families-McSIFF) as scored on the McMaster Clinical Rating Scale (MCRS) were compared in an attempt to explore the inter-changeability of the two. Significant correlations were hypothesized between the FAD and MCRS in both prospective and retrospective groups and that correlations would increase over three data points in the prospective study. The sample included 50 children and adolescents (ages 6-4) with traumatic brain injury (TBI) from a prospective study. In addition, 72 children and adolescents (ages 5-14), consisting of 24 patients with severe TBI, individually matched to a comparison group of 24 mild TBI patients and a control group of 24 orthopaedic patients were included from a retrospective study. Significant correlations between the FAD and MCRS were found across both studies, with increasing correlations at each successive data point in the prospective study. Agreement between the two measures regarding classification of families as clinical vs healthy was also statistically significant at the majority of assessment occasions; however, most specific indices of agreement were only modest. The clinical and research implications of these findings are discussed.	Childrens Hosp & Hlth Ctr, San Diego, CA 92123 USA; Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA	Max, JE (corresponding author), Childrens Hosp & Hlth Ctr, 3020 Childrens Way,Mail Code 5033, San Diego, CA 92123 USA.	jmax@ucsd.edu	Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH01800-05] Funding Source: Medline		Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Beck AT, 1961, ARCH GEN PSYCHIAT, V4, P53, DOI DOI 10.1001/ARCHPSYC.1961.01710120031004; BIEDERMAN J, 1993, J CHILD PSYCHOL PSYC, V34, P1241, DOI 10.1111/j.1469-7610.1993.tb01785.x; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; EPSTEIN NB, 1981, HDB FAMILY THERAPY, P444; FRISTAD MA, 1989, J MARITAL FAM THER, V15, P259, DOI 10.1111/j.1752-0606.1989.tb00808.x; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; McCubbin HI, 1980, FAMILY ASSESSMENT RE; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MOOS RH, 1990, FAM PROCESS, V29, P199, DOI 10.1111/j.1545-5300.1990.00199.x; MOOS RH, 1990, FAM PROCESS, V29, P209; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Rosner B., 2000, FUNDAMENTALS BIOSTAT; STEVENSONHINDE J, 1995, FAM PROCESS, V34, P337, DOI 10.1111/j.1545-5300.1995.00337.x; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wassenberg R, 2004, BRAIN INJURY, V18, P377, DOI 10.1080/02699050310001617325; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	27	13	14	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2005	19	10					801	809		10.1080/02699050400024961			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	945EI	WOS:000230484800006	16175840				2021-06-18	
J	Keel, M; Mica, L; Stover, J; Stocker, R; Trentz, O; Harter, L				Keel, M; Mica, L; Stover, J; Stocker, R; Trentz, O; Harter, L			Thiopental-induced apoptosis in lymphocytes is independent of CD95 activation	ANESTHESIOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; DRUG-INDUCED APOPTOSIS; APO-1/FAS RECEPTOR/LIGAND SYSTEM; SEVERE HEAD-INJURY; CELL-DEATH; KAPPA-B; NEUTROPHIL APOPTOSIS; CEREBROSPINAL-FLUID; LEUKEMIA-CELLS; NUCLEAR-FACTOR	Background. Barbiturate coma is used in patients with traumatic brain injury whenever increases in intracranial pressure remain unresponsive to less aggressive therapeutic regimens. However, barbiturate-mediated neuroprotection correlates with lymphopenia, which increases the risk of infection. The mechanisms by which barbiturates lead to lymphopenia remain to be determined. Methods: Freshly isolated human lymphocytes and Jurkat cells were incubated with the barbiturate thiopental for 24 and 48 h. Apoptosis was measured by fluorescein isothiocyanate-Annexin and propidium iodide staining, rhodamine 123 staining, and the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling method. Caspase-3 activity was detected by Western blot and substrate cleavage assay. Results: Thiopental dose-dependently (5-500 mu g/ml) increased apoptosis in Jurkat cells from basal levels (4.4 +/- 1.9%) to 29.7 +/- 2.8% after 24 h and 39.7 +/- 3.2% after 48 h, whereas in lymphocytes, thiopental-induced necrosis was observed. Parallel to apoptosis, thiopental dose-dependently increased caspase-3-like activity in Jurkat cells. However, the pan-caspase inhibitor z-VAD-fmk (20 mu m) only marginally reduced thiopental-induced (250 mu g/ml) apoptosis in Jurkat cells (20.2 +/- 2.5 to 17.2 +/- 2.5%) and necrosis in lymphocytes (39.2 +/- 7.5 to 30.7 +/- 14%). In contrast, anti-CD95-induced apoptosis in Jurkat cells (27.0 +/- 2.0%) was completely blocked by z-VAD-fmk (8.1 +/- 1.8%). Neither expression of CD95 on Jurkat cells nor pretreatment with a neutralizing anti-CD95 antibody influenced thiopental-induced apoptosis, indicating that thiopental induces apoptosis independently of the CD95 system. The nuclear factor kappa B inhibitor gliotoxin accelerated both thiopental- and CD95-mediated apoptosis, indicating a mutual control mechanism of thiopental- and CD95-induced apoptosis. Conclusions: Thiopental directly induces cell death in lymphocytes and Jurkat cells by a CD95-independent mechanism.	Univ Zurich Hosp, Div Trauma Surg, Dept Surg, CH-8091 Zurich, Switzerland	Keel, M (corresponding author), Univ Zurich Hosp, Div Trauma Surg, Dept Surg, Raemisstr 100, CH-8091 Zurich, Switzerland.	marius.keel@usz.ch					Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Cohen JJ, 1999, J ALLERGY CLIN IMMUN, V103, P548, DOI 10.1016/S0091-6749(99)70222-8; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Delogu G, 2004, J CLIN ANESTH, V16, P189, DOI 10.1016/j.jclinane.2003.07.007; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DONEGAN JH, 1985, AM J PHYSIOL, V249, pH421; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Grimm L M, 1999, Results Probl Cell Differ, V23, P209; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Harter L, 2001, J TRAUMA, V50, P982; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Humar M, 2004, J PHARMACOL EXP THER, V311, P1232, DOI 10.1124/jpet.104.071332; Humar M, 2004, MOL PHARMACOL, V65, P350, DOI 10.1124/mol.65.2.350; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Keel M, 1997, BLOOD, V90, P3356, DOI 10.1182/blood.V90.9.3356; Loop T, 2003, ANESTHESIOLOGY, V99, P360, DOI 10.1097/00000542-200308000-00017; MICHENFE.JD, 1974, ANESTHESIOLOGY, V41, P231, DOI 10.1097/00000542-197409000-00004; MILLER JD, 1971, BRAIN RES, V34, P411; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nair MPN, 1997, CLIN DIAGN LAB IMMUN, V4, P127, DOI 10.1128/CDLI.4.2.127-132.1997; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; NEUWELT EA, 1982, J NEUROSURG, V56, P254, DOI 10.3171/jns.1982.56.2.0254; Oka M, 1996, ANN SURG, V223, P434, DOI 10.1097/00000658-199604000-00013; PAHL HL, 1999, ONCOGENE, V189, P321; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; Roberts Lewis R., 1999, Cell Biochemistry and Biophysics, V30, P71, DOI 10.1007/BF02737885; SATO M, 1989, RESUSCITATION, V17, P233, DOI 10.1016/0300-9572(89)90039-7; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; SMETS LA, 1994, ANTI-CANCER DRUG, V5, P3, DOI 10.1097/00001813-199402000-00001; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Stover JF, 1998, EUR J CLIN PHARMACOL, V54, P529, DOI 10.1007/s002280050508; Stover JF, 1998, EUR NEUROL, V39, P223, DOI 10.1159/000007938; Thornberry NA, 1998, CHEM BIOL, V5, pR97, DOI 10.1016/S1074-5521(98)90615-9; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; Vermes I, 1997, ACTA HAEMATOL-BASEL, V98, P8; Villunger A, 1997, CANCER RES, V57, P3331; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Xie HJ, 1997, MOL IMMUNOL, V34, P987, DOI 10.1016/S0161-5890(97)00128-4; Yin DL, 1999, NATURE, V397, P218, DOI 10.1038/16612; Yin DL, 2000, J EXP MED, V191, P1423, DOI 10.1084/jem.191.8.1423	47	13	14	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	SEP	2005	103	3					576	584		10.1097/00000542-200509000-00021			9	Anesthesiology	Anesthesiology	960EZ	WOS:000231574300019	16129983	Green Accepted			2021-06-18	
J	Schuster, R; Waxman, K				Schuster, R; Waxman, K			Is repeated head computed tomography necessary for traumatic intracranial hemorrhage?	AMERICAN SURGEON			English	Article; Proceedings Paper	Annual Meeting of the Southern California Chapter of the American-College-of-Surgeons	JAN 21-23, 2005	Santa Barbara, CA	Amer Coll Surg, So Calif Chapter			BRAIN-INJURY; MANAGEMENT	This study was performed to determine the need for repeat head computed tomography (CT) in patients with blunt traumatic intracranial hemorrhage (ICH) who were initially treated nonoperatively and to determine which factors predicted observation failure or success. A total of 1,462 patients were admitted to our level 11 trauma center for treatment of head injury. Seventeen per cent (255/1,462) were diagnosed with ICH on initial head CT. Craniotomy was initially performed in 15.7 per cent (40/255) of patients with ICH. Two hundred sixteen patients with ICH were initially observed. Ninety-seven per cent (179/184) of observed patients with ICH and repeat head CT never underwent a craniotomy, 2.7 per cent (5/184) of patients with ICH initially observed underwent craniotomy after repeat head CT, and four patients (80%) had deteriorating neurologic status. Multivariate analysis revealed the following significant admission risk factors were associated with a need for repeat head CT indicating the need for craniotomy: treatment with anticoagulation and/or antiplatelet medications, elevated prothrombin time (PT), and age greater than 70 years. In patients with blunt traumatic intracranial hemorrhage initially observed, there is little utility of repeated head CT in the absence of deteriorating neurologic status. The only admission risk factors for a repeat CT indicating the need for craniotomy were advanced age and coagulopathy.	Santa Barbara Cottage Hosp, Dept Surg Educ, Santa Barbara, CA 93102 USA	Waxman, K (corresponding author), Santa Barbara Cottage Hosp, Dept Surg Educ, POB 689, Santa Barbara, CA 93102 USA.						Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; *COTT HOSP RAD DEP, 2004, 2004 HOSP CHARG COMP; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; VALADKA AB, 2000, TRAUMA, P377	12	13	13	0	0	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	SEP	2005	71	9			SI		701	704					4	Surgery	Surgery	969NP	WOS:000232241300001	16468501				2021-06-18	
J	Hainsworth, AH; Bermpohl, D; Webb, TE; Darwish, R; Fiskum, G; Qiu, JH; McCarthy, D; Moskowitz, MA; Whalen, MJ				Hainsworth, AH; Bermpohl, D; Webb, TE; Darwish, R; Fiskum, G; Qiu, JH; McCarthy, D; Moskowitz, MA; Whalen, MJ			Expression of cellular FLICE inhibitory proteins (cFLIP) in normal and traumatic murine and human cerebral cortex	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						caspases; human; mice; neuronal cell death; programmed cell death; reactive astrocytes; trauma; traumatic brian injury	SPINAL-CORD-INJURY; TRAIL-INDUCED APOPTOSIS; BRAIN-INJURY; DEATH RECEPTOR; MEDIATED APOPTOSIS; FAS RECEPTOR; TNF-ALPHA; C-FLIP; ALZHEIMERS-DISEASE; UP-REGULATION	Cellular Fas-associated death domain-like interleukin-1-beta converting enzyme (FLICE) inhibitory proteins (cFLIPs) are endogenous caspase homologues that inhibit programmed cell death. We hypothesized that cFLIPs are differentially expressed in response to traumatic brain injury (TBI). cFLIP-alpha and cFLIP-delta mRNA were expressed in normal mouse brain-specifically cFLIP-delta (but not cFLIP-alpha) protein was robustly expressed. After controlled cortical impact (CCl), cFLIP-alpha expression increased initially then decreased to control levels at 12 h, increasing again at 24-72 h (P<0.05). cFLIP-delta expression was decreased in brain homogenates by 12 h after CCl, then increased again at 24 to 72 h (P<0.05). cFLIP-delta immunostaining was markedly reduced in injured cortex, but not hippocampus, at 3 to 72 h after CCl. In cortex, reduced cFLIP-delta staining was found in TUNEL-positive cells, but in hippocampus TUNEL-positive cells expressed cFLIP-delta immunoreactivity. cFLIP-delta was increased in a subset of reactive astrocytes in pericontusional cortex and hippocampus at 48 to 72 h. Low levels of both cFLIP isoforms were detected in human cortical tissue with no TBI, from four patients undergoing brain surgery for epilepsy and <24 h post mortem from three patients without CNS pathologic assessment. In cortical tissue surgically removed <18 h after severe TBI (n=3), cFLIP-alpha expression was increased relative to epilepsy controls (P<0.05) but not relative to post-mortem controls. The data suggest differential spatial and temporal regulation of cFLIP-alpha and cFLIP-delta expression that may influence the magnitude of cell death and further implicate programmed mechanisms of cell death after TBI.	Harvard Univ, Massachusetts Gen Hosp, Ctr Neurosci, Sch Med, Charlestown, MA 02129 USA; De Montfort Univ, Pharmacol Res Grp, Leicester Sch Pharm, Leicester, Leics, England; Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA	Whalen, MJ (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Ctr Neurosci, Sch Med, Charlestown, MA 02129 USA.	mwhalen@bics.bwh.harvard.edu	Hainsworth, Atticus H./J-8657-2019; Moskowitz, Michael A/D-9916-2011	Hainsworth, Atticus H./0000-0001-7877-8013; Darwish, Ribal/0000-0003-0727-0401	Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [C17893] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS041969, R01NS37141, KO8NS41969, R01 NS037141] Funding Source: Medline; Alzheimers Research UKAlzheimer&apos;s Research UK (ARUK) [ART-PPG2005A-2] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS041969, R01NS037141] Funding Source: NIH RePORTER		Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Bermpohl D, 2004, J NEUROTRAUM, V21, P1332; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; Demjen D, 2004, NAT MED, V10, P389, DOI 10.1038/nm1007; Engidawork E, 2001, BIOCHEM BIOPH RES CO, V281, P84, DOI 10.1006/bbrc.2001.4306; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Grambihler A, 2003, J BIOL CHEM, V278, P26831, DOI 10.1074/jbc.M303229200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Higuchi H, 2003, J BIOL CHEM, V278, P454, DOI 10.1074/jbc.M209387200; Imanishi T, 2000, CARDIOVASC RES, V48, P101, DOI 10.1016/S0008-6363(00)00154-1; Imanishi T, 2000, AM J PATHOL, V156, P125, DOI 10.1016/S0002-9440(10)64712-8; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Krautwald S, 2004, J BIOL CHEM, V279, P44005, DOI 10.1074/jbc.M401327200; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Micheau O, 2003, EXPERT OPIN THER TAR, V7, P559, DOI 10.1517/14728222.7.4.559; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Nuttall ME, 2001, DRUG DISCOV TODAY, V6, P85, DOI 10.1016/S1359-6446(00)01601-9; Petito CK, 1998, J NEUROPATH EXP NEUR, V57, P231, DOI 10.1097/00005072-199803000-00004; Qiu JH, 2002, J NEUROSCI, V22, P3504; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Raoul C, 1999, J CELL BIOL, V147, P1049, DOI 10.1083/jcb.147.5.1049; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Robertson GS, 2000, BRAIN PATHOL, V10, P283, DOI 10.1111/j.1750-3639.2000.tb00262.x; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Siegmund D, 2002, MOL MED, V8, P725, DOI 10.1007/BF03402036; Siegmund D, 2001, J BIOL CHEM, V276, P32585, DOI 10.1074/jbc.M100444200; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Suzuki A, 2003, ONCOGENE, V22, P6177, DOI 10.1038/sj.onc.1206899; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Vanden Berghe T, 2004, J BIOL CHEM, V279, P7925, DOI 10.1074/jbc.M307807200; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Wajant H, 2003, CYTOKINE GROWTH F R, V14, P53, DOI 10.1016/S1359-6101(02)00072-2; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang WL, 2002, J BIOL CHEM, V277, P21723, DOI 10.1074/jbc.M202224200; Wang X, 2003, J BIOL CHEM, V278, P29184, DOI 10.1074/jbc.M301624200; Wu SS, 2004, MOL BRAIN RES, V122, P79, DOI 10.1016/j.molbrainres.2003.12.007; Zhang H, 2003, RESPIROLOGY, V8, P17, DOI 10.1046/j.1440-1843.2003.00433.x; Zhao M, 2003, NEUROCHEM RES, V28, P307, DOI 10.1023/A:1022337519035	54	13	13	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2005	25	8					1030	1040		10.1038/sj.jcbfm.9600104			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	950SL	WOS:000230877600010	15815586	Green Accepted, Bronze			2021-06-18	
J	Ashwal, S				Ashwal, S			Recovery of consciousness and life expectancy of children in a vegetative state	NEUROPSYCHOLOGICAL REHABILITATION			English	Article; Proceedings Paper	Conference of the International-Neuropsychological-Society	JUL 16-19, 2003	Berlin, GERMANY	Int Neuropsychol Soc			MEDICAL ASPECTS	The vegetative state does occur in children and is most commonly due to acquired traumatic and non-traumatic injuries. However, neurometabolic and degenerative diseases, as well as certain developmental brain malformations such as anencephaly, can also cause this condition. There are limited data available in children concerning recovery of consciousness and function from the vegetative state as well as life expectancy. This review concentrates on these issues and is based primarily on the data published in the Multi-Society Task Force Report on PVS which was published in 1994 as well as other epidemiological studies. Children in a vegetative state do have a poor prognosis for recovery of consciousness and function and do have a shortened life expectancy. Further research is needed to better understand what variables might contribute to recovery and what therapies might be of benefit.	Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA	Ashwal, S (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, 11175 Campus St, Loma Linda, CA 92350 USA.	sashwal@ahs.llumc.edu					ASHWAL S, 1994, PEDIATR NEUROL, V10, P27, DOI 10.1016/0887-8994(94)90063-9; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; ASHWAL S, 1992, ANN NEUROL, V32, P570, DOI 10.1002/ana.410320414; Heindl UT, 1996, NEUROPEDIATRICS, V27, P94, DOI 10.1055/s-2007-973756; KRIEL RL, 1993, PEDIATR NEUROL, V9, P362, DOI 10.1016/0887-8994(93)90104-K; Strauss DJ, 1999, PEDIATR NEUROL, V21, P626, DOI 10.1016/S0887-8994(99)00051-X; Strauss DJ, 2000, PEDIATR NEUROL, V23, P312, DOI 10.1016/S0887-8994(00)00194-6; STUMPF DA, 1990, NEW ENGL J MED, V322, P669	9	13	13	0	2	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL-SEP	2005	15	3-4					190	197		10.1080/09602010443000281			8	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	965PE	WOS:000231961900006	16350962				2021-06-18	
J	Baguley, IJ; Bailey, KM; Slewa-Younan, S				Baguley, IJ; Bailey, KM; Slewa-Younan, S			Prolonged anti-spasticity effects of bolus intrathecal baclofen	BRAIN INJURY			English	Article						traumatic brain injury; spasticity; intrathecal baclofen 2	HYPERTONIA	Anecdotal patient reports have suggested prolonged benefit from the initial bolus dose of intrathecal baclofen ( bolus ITB) that have not been evident on the Modified Ashworth Scale (MAS). This case study assessed this effect utilizing surface electromyography (SEMG) as an adjunct to clinical observations. Overall, SEMG recordings were consistent with MAS findings. However, SEMG also revealed a marked and persisting reduction in abnormal muscle activity for 96 hours post-bolus ITB, well beyond the pharmacological washout period of baclofen in the CSF.	Westmead Hosp, Brain Injury Rehabil Serv, Wentworthville, NSW 2145, Australia; Univ Sydney, Dept Rehabil Med, Sydney, NSW, Australia	Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2145, Australia.	ianb@biru.wsahs.nsw.gov.au	Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; 			BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; GIANINO JM, 1996, INTRATHECAL DRUG THE, P95; JONES RF, 1970, J NEUROL NEUROSUR PS, V33, P464, DOI 10.1136/jnnp.33.4.464; KATZ RT, 1992, ARCH PHYS MED REHAB, V73, P339, DOI 10.1016/0003-9993(92)90007-J; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; Perotto AO, 1994, ANATOMICAL GUIDE ELE; PRICE R, 1993, ARCH PHYS MED REHAB, V74, P300; SNOW BJ, 1990, ANN NEUROL, V28, P512, DOI 10.1002/ana.410280407	8	13	13	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2005	19	7					545	548		10.1080/02699050400025075			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	933IQ	WOS:000229622500009	16134742				2021-06-18	
J	Pickard, JD; Coleman, MR; Czosnyka, M				Pickard, JD; Coleman, MR; Czosnyka, M			Hydrocephalus, ventriculomegaly and the vegetative state: A review	NEUROPSYCHOLOGICAL REHABILITATION			English	Article; Proceedings Paper	Conference of the International-Neuropsychological-Society	JUL 16-19, 2003	Berlin, GERMANY	Int Neuropsychol Soc			NORMAL-PRESSURE HYDROCEPHALUS; CLOSED-HEAD-INJURY; POSTTRAUMATIC HYDROCEPHALUS; COMPUTERIZED TOMOGRAPHY; EXTERNAL HYDROCEPHALUS; ALZHEIMERS-DISEASE; MANAGEMENT; DIAGNOSIS; ENLARGEMENT; TRAUMA	The revised guidelines from the Royal College of Physicians make it clear that structural problems such as hydrocephalus should be excluded before the diagnosis of vegetative state (VS) can be made. Ventriculornegaly is common after severe head injury but the distinction between atrophy and potentially treatable hydrocephalus cannot be made on the basis of conventional computerised tomographic (CT) or magnetic resonance (MR) scanning alone-physiological measurements of intracranial pressure (ICP) and cerebrospinal fluid (CSF) outflow resistance may be helpful. These techniques are reviewed together with the limited literature available that documents the effect of CSF diversion on outcome in "vegetative" patients.	Univ Cambridge, Addenbrookes Hosp, Cambridge CB2 2QQ, England	Pickard, JD (corresponding author), Univ Cambridge, Acad Neurosurg Unit, Box 167, Cambridge CB2 2QQ, England.	jdp.secretary@medschl.cam.ac.uk			Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		Bates D, 2003, CLIN MED, V3, P249; BEYERL B, 1984, NEUROSURGERY, V15, P257, DOI 10.1227/00006123-198408000-00020; CARDOSO ER, 1985, SURG NEUROL, V23, P261, DOI 10.1016/0090-3019(85)90092-8; Cohadon F, 2000, SORTIR COMA; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Czosnyka M, 1996, J NEUROL NEUROSUR PS, V60, P549, DOI 10.1136/jnnp.60.5.549; Czosnyka M, 2000, J NEUROL NEUROSUR PS, V68, P246; Dandy WE, 1914, AM J DIS CHILD, V8, P406; DOLCE G, 2002, POST TRAUMATIC VEGET; EARNEST MP, 1974, ARCH NEUROL-CHICAGO, V31, P262, DOI 10.1001/archneur.1974.00490400076009; FRENCH BN, 1977, SURG NEUROL, V7, P171; Fujimoto Y, 2004, PEDIATR NEUROSURG, V40, P32, DOI 10.1159/000076575; GRANHOLM L, 1972, J REHABILITATION MED, V4, P31; Groswasser Z, 1988, Brain Inj, V2, P267, DOI 10.3109/02699058809150897; GUDEMAN SK, 1981, RADIOLOGY, V141, P397, DOI 10.1148/radiology.141.2.6974874; GURDJIAN E, 1966, HEAD INJURY C P, P550; Hakim S, 1965, J Neurol Sci, V2, P307, DOI 10.1016/0022-510X(65)90016-X; HAWKINS TD, 1976, CLIN RADIOL, V27, P279, DOI 10.1016/S0009-9260(76)80069-4; Iddon JL, 1999, J NEUROL NEUROSUR PS, V67, P723, DOI 10.1136/jnnp.67.6.723; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Jennett B., 2002, VEGETATIVE STATE MED; KALISKY Z, 1985, ARCH PHYS MED REHAB, V66, P25; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; KATZ RT, 1989, AM J PHYS MED REHAB, V68, P91, DOI 10.1097/00002060-198904000-00009; KISHORE PRS, 1978, NEURORADIOLOGY, V16, P261, DOI 10.1007/BF00395266; KOO AH, 1977, RADIOLOGY, V123, P345, DOI 10.1148/123.2.345; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEWIN W, 1968, BRIT J SURG, V55, P747, DOI 10.1002/bjs.1800551008; Licata C, 2001, J Neurosurg Sci, V45, P141; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; MERINODEVILLASANTE J, 1976, AM J ROENTGENOL, V126, P765, DOI 10.2214/ajr.126.4.765; MEYERS CA, 1983, J NEUROL NEUROSUR PS, V46, P1092, DOI 10.1136/jnnp.46.12.1092; Paoletti P, 1983, J Neurosurg Sci, V27, P171; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; Silver B V, 1997, Pediatr Rehabil, V1, P123; Silverberg GD, 2003, LANCET NEUROL, V2, P506, DOI 10.1016/S1474-4422(03)00487-3; Tribl G, 2000, BRAIN INJURY, V14, P345; Yoshimoto Y, 1998, J NEUROSURG, V88, P485, DOI 10.3171/jns.1998.88.3.0485	40	13	14	0	2	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL-SEP	2005	15	3-4					224	236		10.1080/09602010443000614			13	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	965PE	WOS:000231961900009	16350965				2021-06-18	
J	Shiel, A; Wilson, BA				Shiel, A; Wilson, BA			Can behaviours observed in the early stages of recovery after traumatic brain injury predict poor outcome?	NEUROPSYCHOLOGICAL REHABILITATION			English	Article; Proceedings Paper	Joint Conference of the International-Neuropsychological-Society/German-Society-for-Neuropsychology	JUL 16-19, 2003	Berlin, GERMANY	Int Neuropsychol Soc, German Soc Neuropsychol			SEVERE HEAD-INJURY; GLASGOW COMA SCALE	Diagnosis of the vegetative state (VS) or minimally conscious state (MCS) is dependent on the presence or absence of behavioural variables. Diagnosis of the VS in the case of those who have had a severe head injury does not occur for several months after injury. If such outcomes could be predicted it would facilitate appropriate and timely referrals to specialist rehabilitation units. This paper describes a follow up study of patients observed prospectively after severe head injury and followed up four years later. Thirty patients had made a moderate or good recovery and eight met criteria for MCS. Analysis of early observations together with outcome data suggest that the duration of time taken to achieve some early behaviours may be predictive of poorer outcome.	NUI, Fac Med & Hlth Sci, Galway, Ireland; MRC, Cognit & Brain Sci Unit, Cambridge, England	Shiel, A (corresponding author), NUI, Fac Med & Hlth Sci, Galway, Ireland.	agnes.shiel@nuigalway.ie	Shiel, Agnes/AAA-4211-2019				ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/s001340050269; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; PHUENPATHOM N, 1993, SURG NEUROL, V40, P22, DOI 10.1016/0090-3019(93)90164-V; POLIN RS, 1995, NEUROSURG CLIN N AM, V6, P689; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; SALCMAN M, 1981, NEUROSURGERY, V8, P15; SAZBON L, 1991, J NEUROL NEUROSUR PS, V54, P149, DOI 10.1136/jnnp.54.2.149; Shiel A, 2000, CLIN REHABIL, V14, P408, DOI 10.1191/0269215500cr326oa; Shiel A, 2000, WESSEX HEAD INJURY M; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; STAMBROOK M, 1993, ARCH CLIN NEUROPSYCH, V8, P95; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; Zasler ND, 1996, NEUROREHABILITATION, V6, P3, DOI 10.3233/NRE-1996-6102	23	13	13	0	1	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL-SEP	2005	15	3-4					494	502		10.1080/09602010443000551			9	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	965PE	WOS:000231961900034	16350990				2021-06-18	
J	Miller, BA; Sun, F; Christensen, RN; Ferguson, AR; Bresnahan, JC; Beattie, MS				Miller, BA; Sun, F; Christensen, RN; Ferguson, AR; Bresnahan, JC; Beattie, MS			A sublethal dose of TNF alpha potentiates kainate-induced excitotoxicity in optic nerve oligodendrocytes	NEUROCHEMICAL RESEARCH			English	Article						AMPA; excitotoxicity; glutamate; oligodendrocyte; TNF alpha	TUMOR-NECROSIS-FACTOR; SPINAL-CORD-INJURY; MULTIPLE-SCLEROSIS LESIONS; EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN-INJURY; DEATH IN-VITRO; AMPA RECEPTORS; MATURE OLIGODENDROCYTES; SYNAPTIC PLASTICITY; WHITE-MATTER	Glutamate receptor-induced cell death, known as excitotoxicity in both neurons and oligodendrocytes, has been implicated as a common pathway of cell death in numerous central nervous system (CNS) diseases and trauma. Research in both neuronal and oligodendrocyte excitotoxicity has examined glutamate's receptor-mediated effects on CNS cells, and explored strategies to protect cells exposed to the elevated glutamate levels that occur in CNS trauma and disease. Proinflammatory cytokines are also elevated in the injured CNS, and have also been implicated in CNS cell death. Recently, several laboratories have examined cytokines' effects on neuronal and glial excitotoxicity. Here, we review literature concerning the dynamic susceptibility of both neurons and oligodendrocytes to excitotoxicity, and present new data from our laboratory showing that the susceptibility of oligodendrocytes to excitotoxicity is acutely potentiated by the proinflammatory cytokine TNF alpha.	Ohio State Univ, Coll Med, Dept Neurosci, Columbus, OH 43210 USA	Bresnahan, JC (corresponding author), Ohio State Univ, Coll Med, Dept Neurosci, 333 W 10th Ave, Columbus, OH 43210 USA.	bresnahan.1@osu.edu	Beattie, Michael S/A-8953-2009	Ferguson, Adam/0000-0001-7102-1608; Christensen, Randolph/0000-0002-3528-2074	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 38079] Funding Source: Medline		Alberch J, 2002, BRAIN RES BULL, V57, P817, DOI 10.1016/S0361-9230(01)00775-4; Alberdi E, 2002, NEUROBIOL DIS, V9, P234, DOI 10.1006/nbdi.2001.0457; Arevalo-Martin A, 2003, J NEUROSCI, V23, P2511; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Beal MF, 1998, ANN NEUROL, V44, pS110; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Benjamins JA, 2003, NEUROCHEM RES, V28, P143, DOI 10.1023/A:1021612615554; Benveniste EN, 1997, J MOL MED-JMM, V75, P165, DOI 10.1007/s001090050101; Bitsch A, 2000, GLIA, V29, P366, DOI 10.1002/(SICI)1098-1136(20000215)29:4<366::AID-GLIA7>3.0.CO;2-Y; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Chew LJ, 1997, J NEUROSCI, V17, P227; Chittajallu R, 1999, TRENDS PHARMACOL SCI, V20, P26, DOI 10.1016/S0165-6147(98)01286-3; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Cohen J., 1977, STAT POWER ANAL BEHA, P1; Du J, 2004, J NEUROSCI, V24, P6578, DOI 10.1523/JNEUROSCI.1258-04.2004; Eskes C, 2003, J NEUROSCI RES, V71, P583, DOI 10.1002/jnr.10508; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Follett PL, 2000, J NEUROSCI, V20, P9235; Ha BK, 2002, J NEUROCHEM, V83, P934, DOI 10.1046/j.1471-4159.2002.01203.x; Hayes KC, 2002, J NEUROTRAUM, V19, P753, DOI 10.1089/08977150260139129; Haynes RL, 2003, J NEUROPATH EXP NEUR, V62, P441, DOI 10.1093/jnen/62.5.441; Hermann GE, 2001, NEUROBIOL DIS, V8, P590, DOI 10.1006/nbdi.2001.0414; Himi T, 2003, J NEUROSCI RES, V71, P679, DOI 10.1002/jnr.10510; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Ito A, 2001, J IMMUNOL, V167, P542, DOI 10.4049/jimmunol.167.1.542; Itoh T, 2002, J NEUROCHEM, V81, P390, DOI 10.1046/j.1471-4159.2002.00866.x; Jensen FE, 2002, INT J DEV NEUROSCI, V20, P339, DOI 10.1016/S0736-5748(02)00012-6; Jones TL, 2004, J PHARMACOL EXP THER, V310, P223, DOI 10.1124/jpet.103.064741; Kadhim H, 2001, NEUROLOGY, V56, P1278, DOI 10.1212/WNL.56.10.1278; Leuchtmann EA, 2003, NEUROBIOL DIS, V14, P336, DOI 10.1016/j.nbd.2003.07.004; Li JR, 2003, J NEUROSCI, V23, P5816; Li S, 1999, J NEUROSCI, V19, P1; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Man HY, 2000, CELL MOL LIFE SCI, V57, P1526, DOI 10.1007/PL00000637; Matute C, 2001, TRENDS NEUROSCI, V24, P224, DOI 10.1016/S0166-2236(00)01746-X; Matute C, 1997, P NATL ACAD SCI USA, V94, P8830, DOI 10.1073/pnas.94.16.8830; McAdoo DJ, 1999, EXP NEUROL, V159, P538, DOI 10.1006/exnr.1999.7166; McDonald JW, 1998, NEUROREPORT, V9, P2757, DOI 10.1097/00001756-199808240-00014; MCLAURIN J, 1995, INT J DEV NEUROSCI, V13, P369, DOI 10.1016/0736-5748(95)00012-6; Mergenthaler P, 2004, METAB BRAIN DIS, V19, P151, DOI 10.1023/B:MEBR.0000043966.46964.e6; Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5; Nargi-Aizenman JL, 2004, ANN NEUROL, V55, P541, DOI 10.1002/ana.20033; Nicholas R, 2003, NEUROREPORT, V14, P1001, DOI 10.1097/00001756-200305230-00019; Nicholas RS, 2002, J NEUROIMMUNOL, V124, P36, DOI 10.1016/S0165-5728(02)00011-5; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; Pan WH, 2003, J MOL NEUROSCI, V21, P173, DOI 10.1385/JMN:21:2:173; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Park E, 2003, EXP NEUROL, V182, P35, DOI 10.1016/S0014-4886(03)00084-0; Park M, 2004, SCIENCE, V305, P1972, DOI 10.1126/science.1102026; Peterson JW, 2002, J NEUROPATH EXP NEUR, V61, P539, DOI 10.1093/jnen/61.6.539; Petralia RS, 1999, NAT NEUROSCI, V2, P31; Pitt D, 2003, NEUROLOGY, V61, P1113, DOI 10.1212/01.WNL.0000090564.88719.37; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Ritz MF, 2004, BRAIN RES, V1022, P157, DOI 10.1016/j.brainres.2004.07.004; Rosenberg PA, 2003, J NEUROSCI RES, V71, P237, DOI 10.1002/jnr.10472; Rosin C, 2004, J NEUROCHEM, V90, P1173, DOI 10.1111/j.1471-4159.2004.02584.x; Sanchez-Gomez MV, 1999, NEUROBIOL DIS, V6, P475, DOI 10.1006/nbdi.1999.0264; Sanchez-Gomez MV, 2003, J NEUROSCI, V23, P9519; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; Shaked I, 2005, J NEUROCHEM, V92, P997, DOI 10.1111/j.1471-4159.2004.02954.x; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; Sriram S, 1997, NEUROLOGY, V48, P464, DOI 10.1212/WNL.48.2.464; Stellwagen D, 2005, J NEUROSCI, V25, P3219, DOI 10.1523/JNEUROSCI.4486-04.2005; Takahashi JL, 2003, ANN NEUROL, V53, P588, DOI 10.1002/ana.10519; Tanaka H, 2000, BRAIN RES, V886, P190, DOI 10.1016/S0006-8993(00)02951-6; Wang CX, 2002, NEUROREPORT, V13, P1391, DOI 10.1097/00001756-200208070-00008; Werner P, 2001, ANN NEUROL, V50, P169, DOI 10.1002/ana.1077; Wilke SR, 2004, J NEUROPATH EXP NEUR, V63, P872, DOI 10.1093/jnen/63.8.872; Wisman LAB, 2003, NEUROREPORT, V14, P1967, DOI 10.1097/00001756-200310270-00017; Wosik K, 2004, BRAIN, V127, P2636, DOI 10.1093/brain/awh302; Wrathall JR, 1997, EXP NEUROL, V145, P565, DOI 10.1006/exnr.1997.6506; Ye P, 1999, ENDOCRINOLOGY, V140, P3063, DOI 10.1210/en.140.7.3063; YOSHIOKA A, 1995, J NEUROCHEM, V64, P2442; ZAJICEK JP, 1992, BRAIN, V115, P1611, DOI 10.1093/brain/115.6.1611; Zhao LX, 2004, J NEUROSCI, V24, P2226, DOI 10.1523/JNEUROSCI.4922-03.2004	80	13	13	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	JUN	2005	30	6-7					867	875		10.1007/s11064-005-6880-x			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	968LG	WOS:000232163400017	16187221				2021-06-18	
J	Sakamoto, T; Takasu, A; Saitoh, D; Kaneko, N; Yanagawa, Y; Okada, Y				Sakamoto, T; Takasu, A; Saitoh, D; Kaneko, N; Yanagawa, Y; Okada, Y			Ionized magnesium in the cerebrospinal fluid of patients with head injuries	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; ionized magnesium; ionized calcium; cerebrospinal fluid; Glasgow Coma Scale	TRAUMATIC BRAIN-INJURY; SULFATE; SERUM; CALCIUM; BLOOD; DEFICIENCY	Background. In head injury patients, a decrease in the serum ionized magnesium (iMg) concentration is considered to be related to the severity of the injury, however, this phenomenon is still not completely understood. The cerebrospinal fluid (CSF) iMg concentration has not been well documented under such conditions and, moreover, its normal value has not yet been established. We hereby intended to investigate the role of the iMg concentration and other parameters in both the serum and CSF of head injury patients and identify any relationship with other parameters. Materials and Methods. The subjects consisted of head injury patients without any other serious injuries. Ten healthy volunteers were selected as control subjects. Arterial blood and CSF specimens were simultaneously obtained and measured. We measured the Glasgow Coma Scale scores (GCS), the intracranial pressure (ICP), pH, PO2, PCO2, sodium, potassium, iCa, iMg, glucose, lactate, urea nitrogen. All data are expressed as the mean +/- SD and the units of iMg and iCa (corrected under pH 7.40) are given in mmol/L. Results. In the healthy subjects, the iMg concentration in the serum/CSF was 0.48 +/- 0.02 / 0.66 +/- 0.14, and iCa was 1.14 +/- 0.05 / 0.94 +/- 0.07. The GCS of the 15 head injury subjects at examination was 8.7 +/- 4.5. When the subjects were divided into 3 groups according to the GCS level (3 and 4, 5-8, and >= 9) at the time of examination, the serum iMg concentration was thus found to be related to the severity of injury based on the GCS level (p = 0.028), but not the CSF iMg concentration (p = 0.89). No relationship was observed between the iMg concentration in the serum and CSF when all specimens were compared, but an extremely close correlation was seen in the group with GCS 3 and 4 (p < 0.0001, r = 0.995), although no such correlation was seen in the other 2 groups (p = 0.12, r = -0.56 in the group with GCS 5-8, and p = 0.26, r = -0.35 in the group with GCS >= 9). There was a significant correlation between the serum iMg and iCa (p = 0.0093, r = 0.47), and also between the CSF iMg and iCa concentrations (p < 0.0001, r 0.67). Conclusion: The serum iMg concentration has been suggested to possibly affect the neurologic state through CSF iMg in patients with the most severe head injury. In patients with moderate or mild head injuries, however, the ionized magnesium concentration is also probably associated with the degree of neurologic deficit based on the ionized calcium level. The CSF and serum ionized magnesium dissociation may thus result from the slow movement of ionized magnesium through the blood brain barrier.			tskmt@me.ndmc.ac.jp; atakasu@me.ndmc.ac.jp; ds0711@me.ndmc; nk8639@me.ndmc.ac.jp; yanagawa@me.ndmc.ac.jp; trauma@me.ndmc.ac.jp		Takasu, Akira/0000-0003-3430-0119			ALTURA BM, 1984, DRUGS, V28, P120, DOI 10.2165/00003495-198400281-00013; ALTURA BM, 1994, SCAND J CLINN L S217, V54; ALTURA BM, 1995, SCI AM SCI MED, V2, P28; ALTURA BT, 1994, SCAND J CLIN LAB INV, V54, P53, DOI 10.3109/00365519409095211; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; Brewer RP, 2001, CLIN NEUROPHARMACOL, V24, P341, DOI 10.1097/00002826-200111000-00005; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; CHUTKOW JG, 1968, NEUROLOGY, V18, P963, DOI 10.1212/WNL.18.10.963; FONG J, 1995, OBSTET GYNECOL, V85, P444, DOI 10.1016/0029-7844(94)00413-8; FRECKENSTEIN A, 1973, RECENT ADV STUDIES C, V2, P455; HANDWERKER SM, 1995, J REPROD MED, V40, P201; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; KOST GJ, 1993, CRIT REV CL LAB SCI, V30, P153, DOI 10.3109/10408369309084667; KUGIYAMA K, 1988, J AM COLL CARDIOL, V12, P1177, DOI 10.1016/0735-1097(88)92597-1; Lampl Y, 1998, J NEUROL, V245, P584, DOI 10.1007/s004150050249; LUCAS MJ, 1995, NEW ENGL J MED, V333, P201, DOI 10.1056/NEJM199507273330401; MAUSKOP A, 1993, HEADACHE, V33, P135, DOI 10.1111/j.1526-4610.1993.hed3303135.x; MAUSKOP A, 1995, CLIN SCI, V89, P633, DOI 10.1042/cs0890633; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; MIURA K, 1988, Neurological Surgery, V16, P1251; MIYAGI H, 1989, CIRCULATION, V79, P597, DOI 10.1161/01.CIR.79.3.597; MIYAMOTO Y, 2003, MARIA MED COLL, V31, P315; Morris M E, 1992, Magnes Res, V5, P303; Nishimuta M, 1988, MAGNESIUM, V7, P123; OHTOMO T, 1994, CURRENT CONCEPTS MAG, V6, P11; OPPELT WW, 1963, AM J PHYSIOL, V205, P959; Shibata M, 1999, ANGIOLOGY, V50, P573, DOI 10.1177/000331979905000707; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; TURLAPATY PDMV, 1980, SCIENCE, V208, P198, DOI 10.1126/science.7361117; WOODBURY J, 1968, NEUROLOGY, V18, P700, DOI 10.1212/WNL.18.7.700; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; ZHANG A, 1992, BIOCHIM BIOPHYS ACTA, V1134, P25, DOI 10.1016/0167-4889(92)90024-6	33	13	16	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2005	58	6					1103	1109		10.1097/01.TA.0000169950.51735.C4			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	943EU	WOS:000230336100003	15995455				2021-06-18	
J	Andres, AGC; Herrero, PA; Diez, FJM; Diaz-Hellin, V; Cabrero, EL; Anton, JAP; de Nicolas, JLM				Andres, AGC; Herrero, PA; Diez, FJM; Diaz-Hellin, V; Cabrero, EL; Anton, JAP; de Nicolas, JLM			Medical and surgical management of noniatrogenic traumatic tracheobronchial injuries	ARCHIVOS DE BRONCONEUMOLOGIA			Spanish	Article						tracheobronchial injuries; trauma; bronchial rupture; subcutaneous emphysema; bronchoscopy; thoracotomy	TRACHEAL RUPTURE; IATROGENIC RUPTURES; EARLY-DIAGNOSIS; INTUBATION; EXPERIENCE; LACERATION; BRONCHI; BLUNT; TREE	OBJECTIVE: To describe the medical and surgical management of noniatrogenic traumatic tracheobronchial injuries. PATIENTS AND METHOD: From January 1993 to July 2004, 15 cases of traumatic tracheobronchial injury were treated in our department. The diagnosis was established by bronchoscopy and a computed tomography chest scan was performed on all patients. Surgical treatment was selected for patients with unstable vital signs, an open tracheal wound, associated esophageal lesions, progression of subcutaneous or mediastinal emphysema, mediastinitis or suspicious mediastinal secretions on imaging tests, or difficulties with mechanical ventilation due to the traumatic tracheobronchial injury. Results: The mean (SD) age of the patients was 35.5 (18.9) years and 12 (80%) were male. Of the 15 cases, 13 (86.7%) had penetrating trauma and 2 (13.3%) blunt trauma. The most common location of the injury was in the bronchi (9 cases; 60%) followed by the cervical trachea (4 cases; 26.6%), followed by both the thoracic trachea and bronchi (2 cases; 13.4%). The most common initial symptom was Subcutaneous emphysema, which presented in 11 (73.3%) patients. Chest (12 cases; 86.7%) and orthopedic injuries (9 cases; 60%) were the most common associated injuries. Surgery was the treatment of choice in 11 (73.3%) cases and conservative medical treatment in 4 (26.7%). An irreversible brain injury caused the death of 1 patient receiving conservative treatment. CONCLUSIONS: Tracheobronchial injuries may be treated conservatively if they meet strict selection criteria. Size and location should not be used as selection criteria for surgical treatment.	Hosp Univ 12 Octubre, Serv Cirugia Torac, Madrid 28041, Spain; Hosp Univ 12 Octubre, Serv Neumol, Madrid 28041, Spain	Andres, AGC (corresponding author), Hosp Univ 12 Octubre, Serv Cirugia Torac, Ctra Andalucia,Km 5,400, Madrid 28041, Spain.	abelitov@yahoo.es					ANGELILLOMACKINLAY T, 1995, ANN THORAC SURG, V59, P531, DOI 10.1016/0003-4975(94)00882-8; ANGOOD PB, 1986, J TRAUMA, V26, P869, DOI 10.1097/00005373-198610000-00002; Balci AE, 2002, EUR J CARDIO-THORAC, V22, P984, DOI 10.1016/S1010-7940(02)00591-2; Borasio P, 1997, EUR J CARDIO-THORAC, V12, P98, DOI 10.1016/S1010-7940(97)00111-5; Buitrago L J, 1997, Arch Bronconeumol, V33, P151; BURKE JF, 1962, JAMA-J AM MED ASSOC, V181, P682, DOI 10.1001/jama.1962.03050340020005; Carbognani P, 2004, ANN THORAC SURG, V77, P406, DOI 10.1016/S0003-4975(03)01344-4; Cassada DC, 2000, ANN THORAC SURG, V69, P1563, DOI 10.1016/S0003-4975(00)01077-8; Gabor S, 2001, EUR J CARDIO-THORAC, V20, P399, DOI 10.1016/S1010-7940(01)00798-9; Hofmann HS, 2002, EUR J CARDIO-THORAC, V21, P649, DOI 10.1016/S1010-7940(02)00037-4; Huh J, 1997, AM SURGEON, V63, P896; Jougon J, 2000, ANN THORAC SURG, V69, P216, DOI 10.1016/S0003-4975(99)01129-7; Kaloud H, 1997, CHEST, V112, P774, DOI 10.1378/chest.112.3.774; Kaptanoglu M, 2002, INT J PEDIATR OTORHI, V62, P123, DOI 10.1016/S0165-5876(01)00600-0; Kiser AC, 2001, ANN THORAC SURG, V71, P2059, DOI 10.1016/S0003-4975(00)02453-X; Mussi A, 2001, EUR J CARDIO-THORAC, V20, P46, DOI 10.1016/S1010-7940(01)00702-3; Richardson JD, 2004, J TRAUMA, V56, P30, DOI 10.1097/01.TA.0000108631.72315.78; Ross HM, 1997, ANN THORAC SURG, V63, P240; Rossbach MM, 1998, ANN THORAC SURG, V65, P182, DOI 10.1016/S0003-4975(97)01001-1; Sternfeld D, 2003, ANN EMERG MED, V42, P88, DOI 10.1067/mem.2003.278; Tcherveniakov A, 2001, EUR J CARDIO-THORAC, V19, P19, DOI 10.1016/S1010-7940(00)00610-2; Zapatero J, 1996, Arch Bronconeumol, V32, P222	22	13	15	0	0	ELSEVIER DOYMA SL	BARCELONA	TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN	0300-2896	1579-2129		ARCH BRONCONEUMOL	Arch. Bronconeumol.	MAY	2005	41	5					249	254					6	Respiratory System	Respiratory System	934QE	WOS:000229722500003	15919005				2021-06-18	
J	Lange, RT; Sullivan, K; Anderson, D				Lange, RT; Sullivan, K; Anderson, D			Ecological validity of the WMS-III Rarely Missed Index in personal injury litigation	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MILD HEAD-INJURY; ADULT INTELLIGENCE SCALE; RECOGNITION MEMORY TEST; TRAUMATIC BRAIN INJURY; VERBAL-LEARNING TEST; CARD SORTING TEST; NEUROPSYCHOLOGICAL TESTS; INCOMPLETE EFFORT; CROSS-VALIDATION; PERFORMANCE	The purpose of this study was to evaluate the clinical utility of the Rarely Missed Index (RMI) to detect cognitive exaggeration in 78 nonlitigant patients (i.e., Mixed Clinical group) and 158 personal injury litigants (i.e., 20 Suspected Exaggerators, 12 Borderline Exaggerators, 126 Genuine Responders). The base rate for probable malingered neurocognitive dysfunction in the litigant sample was 12.7%. The false positive error rate of the RMI in the Genuine Responder and Mixed Clinical group ranged from 5.4% to 8.6%. Positive RMI scores were found in 25% and 41.7% of the Suspected Exaggerator and Borderline Exaggerator groups respectively. The clinical utility of the RMI to identify Suspected Exaggerators versus individuals in the Genuine Responder and Mixed Clinical groups revealed low sensitivity (sensitivity = .25), very high specificity (range = .91 to .95), moderate positive predictive power (range = .50 to .71), and moderate to high negative predictive power (range = .68 to .83). These results do not support the use of the RMI as a reliable predictor of cognitive exaggeration.	Riverview Hosp, ECT & Neuropsychiat Program, Coquitlam, BC V3C 4J2, Canada; Queensland Univ Technol, Brisbane, Qld, Australia	Lange, RT (corresponding author), Riverview Hosp, ECT & Neuropsychiat Program, Room 124,Adm Bldg,2601 Lougheed Highway, Coquitlam, BC V3C 4J2, Canada.	rlange@bcmbs.bc.ca	Anderson, Debra/I-9637-2012				Allen L.M., 1997, CARB 97 MANUAL COMPU; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Axelrod B. N., 1999, J FORENSIC NEUROPSYC, V1, P15; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; Gfeller JD, 1998, J CLIN PSYCHOL, V54, P431, DOI 10.1002/(SICI)1097-4679(199806)54:4<431::AID-JCLP5>3.0.CO;2-Q; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 1996, WORD MEMORY TEST USE; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; Iverson GL, 1998, BRAIN INJURY, V12, P275, DOI 10.1080/026990598122575; Iverson GL, 2000, J CLIN EXP NEUROPSYC, V22, P191, DOI 10.1076/1380-3395(200004)22:2;1-1;FT191; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; IVERSON GL, 2001, AM J FORENSIC PSYCH, V19, P5; Johnson JL, 1997, ARCH CLIN NEUROPSYCH, V12, P231, DOI 10.1016/S0887-6177(96)00040-6; Killgore WDS, 2000, J CLIN EXP NEUROPSYC, V22, P761; LANGE R, 2003, NAT AC NEUR ANN C DA; LANGE RT, IN PRESS J CLIN EXPT; Langeluddecke PM, 2003, ARCH CLIN NEUROPSYCH, V18, P181, DOI 10.1016/S0887-6177(01)00195-0; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; MATEER CA, 2000, NEUROPSYCHOLOGICAL M; Meyers J E, 1999, Appl Neuropsychol, V6, P208, DOI 10.1207/s15324826an0604_3; Meyers JE, 1998, APPL NEUROPSYCHOL, V5, P120, DOI 10.1207/s15324826an0503_2; MILLIS SR, 1994, J CLIN PSYCHOL, V50, P601, DOI 10.1002/1097-4679(199407)50:4<601::AID-JCLP2270500417>3.0.CO;2-9; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 1998, J CLIN EXP NEUROPSYC, V20, P167, DOI 10.1076/jcen.20.2.167.1171; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; Naugle, 1999, J FORENSIC NEUROPSYC, V1, P5, DOI [10.1300/J151v01n04_02, DOI 10.1300/J151V01N04_02]; Slick D., 1997, VICTORIA SYMPTOM VAL; Slick D J, 2001, Appl Neuropsychol, V8, P185, DOI 10.1207/S15324826AN0803_9; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spreen O., 1998, COMPENDIUM NEUROPSYC; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Sullivan K, 2002, ARCH CLIN NEUROPSYCH, V17, P223, DOI 10.1016/S0887-6177(01)00110-X; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; Tombaugh T.N., 2003, J FORENSIC NEUROPSYC, V2, P69, DOI [DOI 10.1300/J151V02N03_04, 10.1300/J151v02n03_04]; Tombaugh TN, 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; WARRINGTON, 1984, RECOGNITION MEMORY T; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Weinborn M, 2003, J CLIN EXP NEUROPSYC, V25, P979, DOI 10.1076/jcen.25.7.979.16481; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	56	13	13	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAY	2005	27	4					412	424		10.1080/13803390490520319			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	914XH	WOS:000228260900003	15962688	Green Published			2021-06-18	
J	Bartlett, SC; Armstrong, E; Roberts, J				Bartlett, SC; Armstrong, E; Roberts, J			Linguistic resources of individuals with Asperger syndrome	CLINICAL LINGUISTICS & PHONETICS			English	Article						Asperger syndrome; autism; sociolinguistics; pragmatics	HIGH-FUNCTIONING AUTISM; TRAUMATIC BRAIN-INJURY; DIFFERENT COMMUNICATION PARTNERS; NORMALLY DEVELOPING-CHILDREN; PRAGMATIC ASPECTS; DISCOURSE; LANGUAGE; DISORDER; MIND; CONVERSATION	In this paper the available literature on the communication skills of individuals with Asperger Syndrome (AS) is reviewed. Current issues regarding diagnosing and understanding disorders with a core social deficit are examined as well as the potential application of sociolinguistic analyses to the study of Asperger Syndrome, such as that provided from within a Systemic Functional Linguistic framework. The need for investigations that address a broader view of "language'' and its use in social situations by individuals with AS as opposed to their mastery of syntactic aspects of language, will be discussed.	Macquarie Univ, Dept Linguist, N Ryde, NSW 2010, Australia	Bartlett, SC (corresponding author), Macquarie Univ, Dept Linguist, N Ryde, NSW 2010, Australia.	sclan000@student.mq.edu.au		Armstrong, Elizabeth/0000-0003-4469-1117			ADAMS C, 1989, BRIT J DISORD COMMUN, V24, P211; Adams C, 2002, J CHILD PSYCHOL PSYC, V43, P679, DOI 10.1111/1469-7610.00056; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Armstrong E, 2001, APHASIOLOGY, V15, P1029, DOI 10.1080/02687040143000375; Asperger H, 1944, ARCH PSYCHIAT NERVEN, V117, P76, DOI 10.1007/BF01837709; BALTAXE CAM, 1992, J AUTISM DEV DISORD, V22, P1, DOI 10.1007/BF01046399; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; Baron-Cohen S, 2001, INT REV RES MENT RET, V23, P169; BARONCOHEN S, 1988, J AUTISM DEV DISORD, V18, P379, DOI 10.1007/BF02212194; BaronCohen S, 1997, ISRAEL J PSYCHIAT, V34, P174; BARTOLUCCI G, 1980, J AUTISM DEV DISORD, V10, P39, DOI 10.1007/BF02408431; Bishop DVM, 1998, APPL PSYCHOLINGUIST, V19, P415, DOI 10.1017/S0142716400010249; Bishop DVM, 2000, DEV PSYCHOPATHOL, V12, P177, DOI 10.1017/S0954579400002042; Bishop DVM, 2001, DEV MED CHILD NEUROL, V43, P809, DOI 10.1017/S0012162201001475; BOWLER DM, 1992, J CHILD PSYCHOL PSYC, V33, P877, DOI 10.1111/j.1469-7610.1992.tb01962.x; Capps L., 1998, AUTISM, V2, P325, DOI [DOI 10.1177/1362361398024002, 10.1177/1362361398024002]; Carrington S, 2001, AUTISM, V5, P37, DOI 10.1177/1362361301005001004; Dobbinson S, 1998, J COMMUN DISORD, V31, P113, DOI 10.1016/S0021-9924(97)00085-3; Eisenmajer R, 1996, J AM ACAD CHILD PSY, V35, P1523, DOI 10.1097/00004583-199611000-00022; FERGUSON A, 1992, J NEUROLINGUIST, V7, P277, DOI 10.1016/0911-6044(92)90019-S; FINE J, 1994, J AUTISM DEV DISORD, V24, P315, DOI 10.1007/BF02172230; Ghaziuddin M, 2000, J AUTISM DEV DISORD, V30, P67, DOI 10.1023/A:1005416212615; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; Halliday M., 1975, LEARNING MEAN EXPLOR; Halliday M., 1994, INTRO FUNCTIONAL GRA, V3rd; Heavey L, 2000, J AUTISM DEV DISORD, V30, P225, DOI 10.1023/A:1005544518785; Kanner L, 1943, NERV CHILD, V2, P217; OZONOFF S, 1991, J CHILD PSYCHOL PSYC, V32, P1107, DOI 10.1111/j.1469-7610.1991.tb00352.x; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; SACKS H, 1974, LANGUAGE, V50, P696, DOI 10.2307/412243; Simmons-Mackie N, 2002, APHASIOLOGY, V16, P837, DOI 10.1080/02687030244000185; TAGERFLUSBERG H, 1990, J AUTISM DEV DISORD, V20, P1, DOI 10.1007/BF02206853; THOMSON J, 1997, SPEECH PATH AUSTR NA; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1998, APHASIOLOGY, V12, P755, DOI 10.1080/02687039808249571; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; Togher L, 1996, DISABIL REHABIL, V18, P559, DOI 10.3109/09638289609166317; Togher L, 2001, J COMMUN DISORD, V34, P131, DOI 10.1016/S0021-9924(00)00045-9; VOLKMAR R, 2000, ASPERGER SYNDROME; WING L, 1981, PSYCHOL MED, V11, P115, DOI 10.1017/S0033291700053332; World Health Organization, 1993, INT CLASS DIS 10 REV	42	13	13	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9206	1464-5076		CLIN LINGUIST PHONET	Clin. Linguist. Phon.	APR-MAY	2005	19	3					203	213		10.1080/02699200410001698634			11	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	913VC	WOS:000228182300006	15823956				2021-06-18	
J	Schuerer, DJE; Whinney, RR; Freeman, BD; Nash, J; Prasad, S; Krem, MM; Mazuski, JE; Buchman, TG				Schuerer, DJE; Whinney, RR; Freeman, BD; Nash, J; Prasad, S; Krem, MM; Mazuski, JE; Buchman, TG			Evaluation of the applicability, efficacy, and safety of a thromboembolic event prophylaxis guideline designed for quality improvement of the traumatically injured patient	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	63rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 29-OCT 02, 2004	Maui, HI	Amer Assoc Surg Trauma		deep vein thrombosis; trauma; pulmonary embolism; prophylaxis; heparin	MOLECULAR-WEIGHT HEPARIN; VENOUS THROMBOEMBOLISM; PULMONARY-EMBOLISM; TRAUMA PATIENTS; MAJOR TRAUMA; THROMBOSIS	Background:. Thromboembolic events (TE) such as deep venous thrombosis (DVT) and pulmonary embolism (PE) are common after trauma. Our Trauma Practice Management Committee developed an evidence-based DVT/PE prophylaxis guideline using a modified Delphi approach to standardize care and reduce TE rates. Our objective was to evaluate the applicability, efficacy, and safety of this guideline in the traumatized patient, especially those admitted first to the intensive care unit (ICU). Methods: We developed a risk-stratifled DVT/PE prophylaxis guideline incorporating specific injuries, pertinent history, and physiologic parameters, favoring aggressive therapy in those at highest risk of dying from a PE. We prospectively collected data using this guideline in all patients admitted to the trauma or orthopedic-trauma services that were expected to stay for more than 48 hours (March-December 2003). Comparison was made with historical controls. Data collected included DVT, PE, prophylaxis level chosen, inferior vena cava filters, admission service and location, TRISS scores, length of stay, outcomes, adverse events, and specific risk factors. Results: TE rates after implementation of the guideline were lower than historical controls for all patients (1.9% vs. 1.0%, p = 0.059) and for patients admitted first to the ICU (6.3% vs. 2%, p = 0.018). Completed sheets were collected for 46% of the targeted population. No bleeding events caused by guideline anticoagulation were noted, and one death occurred after inferior vena. cava filter placement. Nine of the 12 TEs in the treatment group were in patients with spine or closed-head injury, delaying chemical prophylaxis. Conclusion: Form-based, risk-adjusted prophylaxis against TE leads to lower TE rates in a general and orthopedic ICU trauma population. Protocol compliance should be enforced.	Washington Univ, Dept Surg, Crit Care Sect, St Louis, MO 63130 USA; Barnes Jewish Hosp, St Louis, MO 63110 USA	Schuerer, DJE (corresponding author), 660 S Euclid Ave,Campus Box 8109, St Louis, MO 63110 USA.	schuererd@wustl.edu		Buchman, Timothy/0000-0001-7350-5921			GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Goldhaber SZ, 1999, LANCET, V353, P1386, DOI 10.1016/S0140-6736(98)07534-5; Ibrahim EH, 2002, CRIT CARE MED, V30, P771, DOI 10.1097/00003246-200204000-00008; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; Maxwell RA, 2002, J TRAUMA, V52, P902, DOI 10.1097/00005373-200205000-00013; McMurtry AL, 1999, J AM COLL SURGEONS, V189, P314, DOI 10.1016/S1072-7515(99)00137-4; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; ROGER FB, MANAGEMENT VENOUS TH	9	13	17	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2005	58	4					731	+		10.1097/01.TA.0000158247.77198.AD			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	919VS	WOS:000228646300020	15824649				2021-06-18	
J	Barnes, EF; Frank, EM; Montgomery, A; Nichols, M				Barnes, EF; Frank, EM; Montgomery, A; Nichols, M			Factors predicting rehabilitative service provision in adults with traumatic brain injury	JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY			English	Article							RETURN; WORK	Approximately 300,000 people sustain a traumatic brain injury (TBI) each year; however, a limited number receive formal speech-language, occupational, and physical therapy rehabilitation. Consequently, a large number of individuals may not meet their maximum potential outcomes following TBI. Little is known about the factors that may affect access to rehabilitation, the amount of rehabilitation provided in varying settings, or participation patterns in rehabilitation programs. This project addressed three research goals: defining the relationship between a number of independent variables following TBI and patient access to rehabilitative services, the relationship between the independent variables and the amount of TBI rehabilitative service provided, and the relationship between independent variables and discharge disposition following inpatient care for TBI. The medical records of 712 adults incurring TBI as a result of motor vehicle accidents were examined. Logistic regression, odds ratio, t-tests, analysis of variance, analysis of covariance, and multinomial regression were used to evaluate the relationship between the independent and dependent variables in the study. Results indicate that admission to the intensive care unit (ICU), diagnosis of orthopedic impairment, and discharge disposition were significant predictors of physical, occupational, and speech therapy service provision following TBI. Gender and primary insurance provider were significant predictors of speech therapy, but not physical or occupational therapies. Admission to the ICU was a significant predictor of the amount of occupational and speech therapy provided following TBI. Age, admission to the ICU, length of stay, and primary insurance provider were significant predictors of discharge disposition following initial hospitalization.	Univ S Carolina, Columbia, SC 29208 USA	Barnes, EF (corresponding author), 1012 Broyhill Hall Court, Wake Forest, NC 27587 USA.	barnes@mail.fpg.unc.edu					Brzuzy S, 1996, J HEAD TRAUMA REHAB, V11, P74, DOI 10.1097/00001199-199606000-00011; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; Coelho CA, 1996, J SPEECH HEAR RES, V39, pS5, DOI 10.1044/jshr.3905.s5; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; Horn W, 2000, DISABIL REHABIL, V22, P358, DOI 10.1080/096382800296601; Kramer AM, 1997, JAMA-J AM MED ASSOC, V277, P396, DOI 10.1001/jama.277.5.396; Liu XF, 2000, MED CARE RES REV, V57, P182, DOI 10.1177/107755870005700203; Rosenfeld M., 2002, REPORT ASHA SPEECH L; YLVISAKER M, 1994, TOP LANG DISORD, V15, P37, DOI 10.1097/00011363-199411000-00005	13	13	13	0	10	DELMAR LEARNING	CLIFTON PARK	EXECUTIVE WOODS, 5 MAXWELL DR, CLIFTON PARK, NY 12065 USA	1065-1438			J MED SPEECH-LANG PA	J. Med. Speech-Lang. Pathol.	MAR	2005	13	1					69	84					16	Audiology & Speech-Language Pathology; Clinical Neurology	Audiology & Speech-Language Pathology; Neurosciences & Neurology	914WM	WOS:000228258700007					2021-06-18	
J	Mendez, DR; Corbett, R; Macias, C; Laptook, A				Mendez, DR; Corbett, R; Macias, C; Laptook, A			Total and ionized plasma magnesium concentrations in children after traumatic brain injury	PEDIATRIC RESEARCH			English	Article							PHOSPHOLIPASE-C ACTIVITY; HEAD-INJURY; BLOOD; SERUM	This study examined 1) whether plasma total Mg (TMg) and ionized Mg (IMg) concentrations in children are reduced by traumatic brain injury (TBI) and 2) whether the extent of reduction correlates with severity of trauma assessed by the Glasgow Coma Scale (GSC) score. This was a prospective cohort study of 98 pediatric patients who had TBI and were admitted through the emergency department. A GCS score was assigned and blood was obtained upon presentation and 24 h later. Plasma was analyzed for TMg and IMg. Patients were grouped into three categories-GCS scores 13-15, 8-12, and <8-to designate mild (n = 21), moderate (n = 37), and severe (n = 40) TBI, respectively. Blood was obtained from 50 healthy children before elective surgery as controls. Control subjects had a TMg and an IMg of 0.94 +/- 0.08 and 0.550 +/- 0.06 mM. TBI patients had an initial TMg and IMg of 0.83 +/- 0.09 and 0.520 +/- 0.05 mM, respectively. Initial TMg for mild, moderate, and severe TBI subgroups (0.87 +/- 0.16, 0.81 +/- 0.15, and 0.83 +/- 0.14 mM, respectively) was reduced from control subjects (p < 0.01). IMg was reduced only in the severe TBI subgroup (0.516 +/- 0.07 mM; p = 0.016). Twenty-four hours later, TMg remained lower than in control subjects for all subgroups of TBI; however, IMg normalized. TBI in children is associated with a reduction in TMg, whereas IMg decreased only with severe TBI. IMg returned to control values by 24 h despite a continued lower TMg, suggesting mechanisms to maintain IMg. Changes in plasma IMg may serve as a marker for TBI but only over a limited time interval.	Baylor Coll Med, Dept Pediat Emergency Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Dept Radiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pediat Neonatol, Dallas, TX 75390 USA	Mendez, DR (corresponding author), Baylor Coll Med, Dept Pediat Emergency Med, 6211 Fannin St,Room A210, Houston, TX 77030 USA.	drmendez@texaschildrenshospital.org					ALTURA BM, 1980, PROSTAG LEUKOTR ESS, V4, P255, DOI 10.1016/0161-4630(80)90020-8; ALTURA BM, 1984, MICROCIRC ENDOTH LYM, V1, P185; ALTURA BT, 1992, METHOD FIND EXP CLIN, V14, P297; ALTURA BT, 1980, MED HYPOTHESES, V6, P753, DOI 10.1016/0306-9877(80)90093-6; Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; Batista A, 2000, MAGNESIUM RES, V13, P3; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Corbett R, 1999, MAGNESIUM RES, V12, P79; DEMEDIUK P, 1988, Journal of Neurotrauma, V5, P105, DOI 10.1089/neu.1988.5.105; DOLAN M, 1997, PEDIAT EMERGENCY MED, P243; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; Heath DL, 1998, SCAND J CLIN LAB INV, V58, P161, DOI 10.1080/00365519850186751; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Hoane MR, 1998, BRAIN RES BULL, V45, P45, DOI 10.1016/S0361-9230(97)00288-8; Hoshino K, 2001, MAGNESIUM RES, V14, P203; JOBORN H, 1985, CLIN ENDOCRINOL, V23, P219, DOI 10.1111/j.1365-2265.1985.tb00217.x; KING LR, 1973, ANN SURG, V177, P126, DOI 10.1097/00000658-197301000-00022; KRAUS JF, 1987, PEDIATRICS, V79, P501; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; KRAUS JF, 1995, TRAUMATIC HEAD INJUR, P23; MATTHEWS DSF, 1995, PEDIATR RES, V37, P409, DOI 10.1203/00006450-199504000-00005; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCLAURIN RL, 1976, HDB CLIN NEUROLOGY, P109; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; RAYSSIGUIER Y, 1977, HORM METAB RES, V9, P309, DOI 10.1055/s-0028-1093519; RYZEN E, 1990, J AM COLL NUTR, V9, P114; SEGLERSTAHL K, 1985, NEUROCHEM RES, V10, P563, DOI 10.1007/BF00964658; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; VINK R, 1989, BIOCHEM BIOPH RES CO, V165, P913, DOI 10.1016/S0006-291X(89)80053-1; Vink R, 1990, Magnes Res, V3, P163; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WHYTE KF, 1987, CLIN SCI, V72, P135, DOI 10.1042/cs0720135; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617	39	13	14	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0031-3998	1530-0447		PEDIATR RES	Pediatr. Res.	MAR	2005	57	3					347	352		10.1203/01.PDR.0000150803.36315.FF			6	Pediatrics	Pediatrics	899NU	WOS:000227152100007	15585675	Bronze			2021-06-18	
J	Warschausky, S; Kay, JB; Chi, P; Donders, J				Warschausky, S; Kay, JB; Chi, P; Donders, J			Hierarchical linear modeling of California Verbal Learning Test-Children's Version learning curve characteristics following childhood traumatic head injury	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; memory; neuropsychology	BRAIN-INJURY; WORKING-MEMORY; RECOVERY; PATTERNS; GROWTH	California Verbal Learning Test-Children's Version (CVLT-C) indices have been shown to be sensitive to the neurocognitive effects of traumatic brain injury (TBI). The effects of TBI on the learning process were examined with a growth curve analysis of CVLT-C raw scores across the 5 learning trials. The sample with history of TBI comprised 86 children, ages 6-16 years, at a mean of 10.0 (SD = 19.5) months postinjury: 37.2% had severe injury, 27.9% moderate, and 34.9% mild. The best-fit model for verbal learning was with I quadratic function. Greater TBI severity was associated with lower rate of acquisition and more gradual deceleration in the rate of acquisition. Intelligence test index scores, previously shown to be sensitive to severity of TBI, were positively correlated with rate of acquisition. Results provide evidence that the CVLT-C learning slope is not a simple linear function and further support for specific effects of TBI on verbal learning.	Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA	Warschausky, S (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, 325 E Eisenhower,Suite 100, Ann Arbor, MI 48109 USA.	sethaw@umich.edu					Anastasi A., 1988, PSYCHOL TESTING; Anderson VA, 2000, BRAIN INJURY, V14, P679; BLACHSTEIN H, 1993, NEUROPSYCHOLOGY, V7, P530, DOI DOI 10.1037/0894-4105.7.4.530; Bryk A.S., 1992, HIERARCHICAL LINEAR; BRYK AS, 1987, PSYCHOL BULL, V101, P147, DOI 10.1037/0033-2909.101.1.147; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; Delis D, 1994, CALIFORNIA VERBAL LE; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; Fry AF, 1996, PSYCHOL SCI, V7, P237, DOI 10.1111/j.1467-9280.1996.tb00366.x; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; Kay JB, 1999, J CLIN EXP NEUROPSYC, V21, P186, DOI 10.1076/jcen.21.2.186.927; LESCOHIER I, 1993, PEDIATRICS, V91, P721; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; Stricker JL, 2002, J INT NEUROPSYCH SOC, V8, P425, DOI 10.1017/S1355617702813224; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Towse JN, 1998, J MEM LANG, V39, P195, DOI 10.1006/jmla.1998.2574; van Strien JW, 1999, CHILD NEUROPSYCHOL, V5, P145, DOI 10.1076/chin.5.3.145.7336; WECHSLEER D, 1991, WECHSLER INTELLIGENC; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	23	13	13	0	4	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAR	2005	19	2					193	198		10.1037/0894-4105.19.2.193			6	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	906DE	WOS:000227619900006	15769203				2021-06-18	
J	Heitger, MH; MacAskill, MR; Jones, RD; Anderson, TJ				Heitger, MH; MacAskill, MR; Jones, RD; Anderson, TJ			The impact of mild closed head injury on involuntary saccadic adaptation: Evidence for the preservation of implicit motor learning	BRAIN INJURY			English	Article							TRAUMATIC BRAIN-INJURY; EYE-MOVEMENTS; ADAPTIVE-CONTROL; TECHNETIUM-99M-HMPAO SPECT; COMPUTED-TOMOGRAPHY; WHIPLASH SYNDROME; GAIN ADAPTATION; LESIONS; MECHANISMS; PURSUIT	Objective: Mild closed head injury (CHI) can impair performance on volitional saccades (fast eye movements), with poorer saccade accuracy being one of the principal deficits. Assessing a patient group with known deficits of volitional saccades, the authors investigated whether mild CHI similarly impairs the implicit adaptation of visually-guided (reflexive) saccades, an important process which maintains saccadic accuracy. Methods: Within 2 weeks following mild CHI, 30 patients and 30 matched controls were compared on a computerized paradigm, which artificially induced saccadic adaptation. In response to an initial stimulus, subjects made a saccade during which the stimulus was displaced centripetally causing the initial (primary) saccade to be inaccurate. While these intra-saccadic changes remained unnoticed by the subjects, the displacements gradually caused adaptive saccadic hypometria. Results: No differences in adaptation were found between the CHI group and the controls (F(l, 29) = 0.5 1, p = 0.48). This finding indicates that mild CHI does not impair implicit reflexive saccade adaptation and suggests that cerebellar function and functions of deeper brain structures such as the thalamus, superior colliculus and the basal ganglia may be largely preserved following mild CHI. The current results support the notion that the profile of oculomotor function after mild CHI reflects a centripetal gradient of impairment and relates closely to the functional integrity of the injured brain.	Christchurch Brain Res Grp, Christchurch, New Zealand; Christchurch Sch Med & Hlth Sci, Dept Med, Christchurch, New Zealand; Christchurch Hosp, Dept Neurol, Christchurch, New Zealand; Christchurch Hosp, Dept Med Phys & Bioengn, Christchurch, New Zealand	Heitger, MH (corresponding author), Van der Veer Inst Parkinsons & Brain Res, POB 2682,16 St Asaph St, Christchurch 8001, New Zealand.	marcus.heitger@chmeds.ac.nz	MacAskill, Michael/C-3467-2009	MacAskill, Michael/0000-0001-9073-0346; Jones, Richard/0000-0003-2287-3358			ABEL LA, 1978, ANN NEUROL, V4, P313, DOI 10.1002/ana.410040405; Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; Bicik I, 1998, NEUROLOGY, V51, P345, DOI 10.1212/WNL.51.2.345; BRIDGEMAN B, 1975, VISION RES, V15, P719, DOI 10.1016/0042-6989(75)90290-4; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; CHERASKIN E, 1992, J NATL MED ASSOC, V84, P873; Desmurget M, 2000, EXP BRAIN RES, V132, P243, DOI 10.1007/s002210000342; Deubel H, 1996, VISION RES, V36, P985, DOI 10.1016/0042-6989(95)00203-0; DEUBEL H, 1995, VISION RES, V35, P3529, DOI 10.1016/0042-6989(95)00058-M; Deubel H, 1999, ATTENTION PERFORM, V17, P697; DEUBEL H, 1995, EYE MOVEMENT RES, P117; Frens MA, 1997, BRAIN RES BULL, V43, P473, DOI 10.1016/S0361-9230(97)80001-9; FRENS MA, 1994, EXP BRAIN RES, V100, P293, DOI 10.1007/BF00227199; Gaymard B, 2001, EUR J NEUROSCI, V14, P554, DOI 10.1046/j.0953-816x.2001.01669.x; GRAY BG, 1992, J NUCL MED, V33, P52; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Heitger MH, 2002, PROG BRAIN RES, V140, P433; HEITGER MH, 2003, BRAIN INJURY, V17, P49; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Inaba N, 2003, NEUROSCI RES, V46, P359, DOI 10.1016/S0168-0102(03)00098-1; Jacobs A, 1996, J NUCL MED, V37, P1605; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; KANAYAMA R, 1994, J NEUROL NEUROSUR PS, V57, P1081, DOI 10.1136/jnnp.57.9.1081; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Leigh R.J., 1999, NEUROLOGY EYE MOVEME, V3rd ed.; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; MacAskill MR, 1999, CURRENT OCULOMOTOR RESEARCH, P93; MacAskill MR, 2002, BRAIN, V125, P1570, DOI 10.1093/brain/awf168; MacAskill MR, 2002, PROG BRAIN RES, V140, P417; McDowall J, 1996, NEW ZEAL J PSYCHOL, V25, P2; MCLAUGHLIN SC, 1967, PERCEPT PSYCHOPHYS, V2, P359, DOI 10.3758/BF03210071; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Muir S. R., 2003, Australasian Physical & Engineering Sciences in Medicine, V26, P18; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPTICAN LM, 1980, J NEUROPHYSIOL, V44, P1058; OPTICAN LM, 1986, EXP BRAIN RES, V64, P596, DOI 10.1007/BF00340497; OPTICAN LM, 1985, J NEUROPHYSIOL, V54, P110; Otte A, 1997, J NEUROL NEUROSUR PS, V63, P368, DOI 10.1136/jnnp.63.3.368; Pierrot-Deseilligny C, 1992, Baillieres Clin Neurol, V1, P435; Reitan RM, 2003, ARCH CLIN NEUROPSYCH, V18, P11, DOI 10.1016/S0887-6177(01)00177-9; REULEN JPH, 1988, MED BIOL ENG COMPUT, V26, P20, DOI 10.1007/BF02441823; Servadei P, 1994, J Neurosurg Sci, V38, P129; Shum D, 1996, J HEAD TRAUMA REHAB, V11, P43, DOI 10.1097/00001199-199604000-00005; Straube A, 1997, ANN NEUROL, V42, P891, DOI 10.1002/ana.410420611; Straube A, 1997, J NEUROPHYSIOL, V77, P874; Straube A, 2001, NEUROLOGY, V57, P2105, DOI 10.1212/WNL.57.11.2105; SWAINE BR, 1992, ARCH PHYS MED REHAB, V73, P55; Takagi M, 1998, J NEUROPHYSIOL, V80, P1911; VAKIL E, 1994, J CLIN EXP NEUROPSYC, V16, P539, DOI 10.1080/01688639408402665; WAESPE W, 1992, BRAIN, V115, P1125, DOI 10.1093/brain/115.4.1125; WILSON J T L, 1990, Brain Injury, V4, P349; Wrightson P, 1998, NEW ZEAL MED J, V111, P99	54	13	13	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2005	19	2					109	117		10.1080/02699050410001720095			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	990JR	WOS:000233739600005	15841755				2021-06-18	
J	Lange, RT; Schoenberg, MR; Chelune, GJ; Scott, JG; Adams, RL				Lange, RT; Schoenberg, MR; Chelune, GJ; Scott, JG; Adams, RL			Development of the WAIS-III General Ability Index Estimate (GAI-E)	CLINICAL NEUROPSYCHOLOGIST			English	Article							TRAUMATIC BRAIN INJURY; PREMORBID INTELLIGENCE; DEMOGRAPHIC-VARIABLES; COMBINED PERFORMANCE; CLINICAL UTILITY; SAMPLES; OPIE-3	The WAIS-III General Ability Index (GAI; Tulsky, Saklofske, Wilkins, T Weiss, 2001) is a recently developed, 6-subtest measure of global intellectual functioning. However, clinical use of the GAI is currently limited by the absence of a method to estimate premorbid functioning as measured by this index. The purpose of this study was to develop regression equations to estimate GAI scores from demographic variables and WAIS-III subtest performance. Participants consisted of those subjects in the WAIS-III standardization sample that had complete demographic data (N = 2,401) and were randomly divided into two groups. The first group (n = 1,200) was used to develop the formulas (i.e., Development group) and the second (n 1,201) group was used to validate the prediction algorithms (i.e., Validation group). Demographic variables included age, education, ethnicity, gender, and region of the country. Subtest variables included vocabulary, information, picture completion, and matrix reasoning raw scores. Ten regression algorithms were generated designed to estimate GAL The GAI-Estimate (GAI-E) algorithms accounted for 58% to 82% of the variance. The standard error of estimate ranged from 6.44 to 9.57. The correlation between actual and estimated GAI ranged from r = .76 to r = .90. These algorithms provided accurate estimates of GAI in the WAIS-III standardization sample. Implications for estimating GAI in patients with known or suspected neurological dysfunction is discussed and future research is proposed.	Riverview Hosp, ECT & Neuropsychiat Program, Coquitlam, BC V3C 4J2, Canada; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA	Lange, RT (corresponding author), Riverview Hosp, ECT & Neuropsychiat Program, Room 318,HEY Bldg,2601 Lougheed Highway, Coquitlam, BC V3C 4J2, Canada.	rlange@bcmhs.bc.ca	Schoenberg, Mike R/J-9018-2012	Schoenberg, Mike/0000-0003-1355-3651			Anastasi A, 1997, PSYCHOL TESTING, V7th; Axelrod BN, 1999, ARCH CLIN NEUROPSYCH, V14, P341, DOI 10.1016/S0887-6177(98)00028-6; Baade LE, 2004, ARCH CLIN NEUROPSYCH, V19, P227, DOI 10.1016/S0887-6177(03)00092-1; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; Hawkins KA, 1998, CLIN NEUROPSYCHOL, V12, P535, DOI 10.1076/clin.12.4.535.7236; IVERSON GL, 2004, IN PRESS ARCH CLIN N; Kaufman A. S., 1990, ASSESSING ADOLESCENT; KRULL KR, 1995, CLIN NEUROPSYCHOL, V9, P83, DOI 10.1080/13854049508402063; LARRABEE GJ, 1985, J CLIN EXP NEUROPSYC, V7, P497, DOI 10.1080/01688638508401281; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; *PSYCH CORP, 1997, WAIS III WMS III TEC; Psychological Corporation, 2001, MAN WECHSL TEST AD R; Schoenberg MR, 2003, CLIN NEUROPSYCHOL, V17, P308, DOI 10.1076/clin.17.3.308.18088; Schoenberg MR, 2002, CLIN NEUROPSYCHOL, V16, P426, DOI 10.1076/clin.16.4.426.13913; SCHOENBERG MR, 2004, INT NEUR SOC ANN M P, P104; SCHOENBERG MR, IN PRESS ARCH CLIN N; Scott JG, 1997, CLIN NEUROPSYCHOL, V11, P146, DOI 10.1080/13854049708407043; SELLERS AH, 1999, AM PSYCH ASS ANN C B; Tabachnick BG, 2013, USING MULTIVARIATE S; Tulsky DS, 2000, PSYCHOL ASSESSMENT, V12, P253, DOI 10.1037//1040-3590.12.3.253; Tulsky DS, 2001, PSYCHOL ASSESSMENT, V13, P566, DOI 10.1037/1040-3590.13.4.566; VANDERPLOEG RD, 1995, ARCH CLIN NEUROPSYCH, V10, P225, DOI 10.1016/0887-6177(94)00042-O; Veiel HOF, 2001, PSYCHOL ASSESSMENT, V13, P356, DOI 10.1037/1040-3590.13.3.356; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 2008, WECHSLER ADULT INTEL; Wechsler D, 1997, WAIS 3 ADM SCORING M	29	13	13	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB	2005	19	1					73	86		10.1080/13854040490888549			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	912YF	WOS:000228115300005	15814479				2021-06-18	
S	Faden, AI; Knoblach, SM; Movsesyan, VA; Lea, PM; Cernak, I		Slikker, W; Andrews, RJ; Trembly, B		Faden, AI; Knoblach, SM; Movsesyan, VA; Lea, PM; Cernak, I			Novel neuroprotective tripeptides and dipeptides.	NEUROPROTECTIVE AGENTS	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	7th International Conference on Neuroprotective Agents	NOV 14-19, 2004	Pacific Grove, CA	Cent Arkansas Chapter SIGMA XI, FDA, Natl Ctr Toxicol Res, US EPA		TRH analogues; dipeptides; tripeptides; CNS injury; neuroprotection	THYROTROPIN-RELEASING-HORMONE; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; TRH-ANALOG; YM-14673; RECOVERY; THERAPY; RAT	It has long been recognized that thyrotropin-releasing hormone (TRH) and certain TRH analogues are neuroprotective in a variety of animal models of CNS trauma. In addition to these neuroprotective actions, TRH and most TRH analogues have other physiological actions that may not be desirable for treatment of acute injury, such as analeptic, autonomic, and endocrine effects. We have developed a series of dual-substituted TRH analogues that have strong neuroprotective actions, but are largely devoid of these other physiological actions. In addition, we have developed a family of cyclized dipeptides (diketopiperazines), structurally somewhat related to a metabolic product of TRH, that appear even more effective as neuroprotective agents in vitro and in vivo, and may have nootropic properties. Here, we review these novel tripeptide and dipeptide compounds.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, 3970 Reservoir Rd NW,Res Bldg,Room EP04, Washington, DC 20057 USA.	fadena@georgetown.edu	Cernak, Ibolja/A-6399-2008	Ibolja, Cernak/0000-0003-3214-698X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD40677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS41119] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD040677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041119] Funding Source: NIH RePORTER		AKDEMIR H, 1993, RES EXP MED, V193, P297, DOI 10.1007/BF02576237; BEHRMANN DL, 1993, EXP NEUROL, V119, P258, DOI 10.1006/exnr.1993.1028; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; Brunetti L, 2002, FARMACO, V57, P479, DOI 10.1016/S0014-827X(02)01232-6; Castagnola E, 2004, CLIN MICROBIOL INFEC, V10, P255, DOI 10.1111/j.1198-743X.2004.00837.x; CEYLAN S, 1992, RES EXP MED, V192, P23, DOI 10.1007/BF02576254; CEYLAN S, 1990, RES EXP MED, V190, P111, DOI 10.1007/PL00020013; Cirone P, 2004, HUM GENE THER, V15, P945, DOI 10.1089/hum.2004.15.945; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Faden A I, 1988, Adv Neurol, V47, P531; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196; FADEN AI, 1981, NEW ENGL J MED, V305, P1063, DOI 10.1056/NEJM198110293051806; FADEN AI, 1983, NEUROLOGY, V33, P673, DOI 10.1212/WNL.33.6.673; Faden AI, 2004, J ALZHEIMERS DIS, V6, pS93; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; FADEN AI, 1990, J PHARMACOL EXP THER, V255, P608; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1993, J NEUROTRAUM, V10, P101, DOI 10.1089/neu.1993.10.101; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; FADEN AI, 1989, ANN NY ACAD SCI, V553, P380; FEUERSTEIN G, 1984, CIRC SHOCK, V13, P255; FEUERSTEIN G, 1983, PROSTAGLANDINS, V26, P711, DOI 10.1016/0090-6980(83)90056-4; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; MAPELLI C, 1990, BIOPOLYMERS, V29, P407, DOI 10.1002/bip.360290212; PITTS LH, 1995, J NEUROTRAUM, V12, P235, DOI 10.1089/neu.1995.12.235; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; PRASAD C, 1988, NEUROSCI BIOBEHAV R, V12, P19, DOI 10.1016/S0149-7634(88)80069-1; PRASAD C, 1995, PEPTIDES, V16, P151, DOI 10.1016/0196-9781(94)00017-Z; Prokai L, 2004, J MED CHEM, V47, P6025, DOI 10.1021/jm020531t; Prokai-Tatrai K, 2003, BIOORG MED CHEM LETT, V13, P1011, DOI 10.1016/S0960-894X(03)00081-7; Puniak MA, 1991, J NEUROTRAUM, V8, P193, DOI 10.1089/neu.1991.8.193; REDDING TW, 1969, P SOC EXP BIOL MED, V131, P415; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; SZIRTES T, 1986, J MED CHEM, V29, P1654, DOI 10.1021/jm00159a015; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; Yakovlev Alexander G, 2004, NeuroRx, V1, P5, DOI 10.1007/BF03206563	39	13	14	0	5	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-578-8	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2005	1053						472	481		10.1196/annals.1344.041			10	Multidisciplinary Sciences; Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy	BDR63	WOS:000235109800048	16179555				2021-06-18	
J	Kaymaz, M; Emmez, H; Bukan, N; Dursun, A; Kurt, G; Pasaoglu, H; Pasaoglu, A				Kaymaz, M; Emmez, H; Bukan, N; Dursun, A; Kurt, G; Pasaoglu, H; Pasaoglu, A			Effectiveness of FK506 on lipid peroxidation in the spinal cord following experimental traumatic injury	SPINAL CORD			English	Article						spinal cord injury; FK-506; lipid peroxidation; methylprednisolone	NITRIC-OXIDE; CYCLOSPORINE-A; SIGNAL TRANSDUCTION; RAT-BRAIN; CALCINEURIN; ISCHEMIA; FK-506; ACTIVATION; PROTEIN; ENZYME	Study design: An in vivo study in Wistar albino rats with injured spinal cord. Setting Department of Neurosurgery, Biochemistry and Pathology, Gazi University, Ankara, Turkey. Objectives: The aim of this study was to investigate and compare the effects of FK506 an immunosupressive agent with methylprednisolone (MP) on lipid peroxidation (LP) in injured spinal cord tissue. Method: A total of 28 adult healthy Wistar albino rats were subjected to traumatic spinal cord injuries (SCI) by using an aneurysmal clip compression technique, and they were divided into four groups. The G1 group (n=8) received FK506 (1 mg/kg); the G2 group (n=8) received FK506 (1 mg/kg) and MP (30 mg/kg); the G3 group (n=6) received only MP (30 mg/kg); and the G4 group (n=6) received no medication. The injured spinal cord tissue was studied by means of lipid peroxides, malondialdehyde (MDA), with thiobarbituric acid reaction and additionally the FK506 (G1); the MP ( G3) groups were studied for histopathologic alterations 72 h after SCI with eight separate animals. Results: Although LP values of G1, G2, G3 showed no statistical difference between intergroup analyses (P=0.547), a histopathological examination revealed that in the group that received MP, the oedema pattern was more significant than the group that received FK506. Another interesting finding was the presence of polymorphonuclear leucocytes in the MP group, whereas no infiltration was found in the FK506 group. Conclusion: Analysis of the results indicated that FK506 is a valuable pharmacological agent that could be used to decrease the LP and polymorphonuclear leucocyte infiltration and in. amatory reactions in the injured spinal cord tissue.	Gazi Univ, Sch Med, Dept Neurosurg, Ankara, Turkey; Gazi Univ, Sch Med, Dept Biochem, Ankara, Turkey; Gazi Univ, Sch Med, Dept Pathol, Ankara, Turkey	Kaymaz, M (corresponding author), Hokukcu Dostlar Sitesi 31, TR-06530 Ankara, Turkey.						Adams DH, 1996, HEPATOLOGY, V23, P1476, DOI 10.1053/jhep.1996.v23.pm0008675167; AMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P117; Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; ASPBERG A, 1994, FREE RADICAL BIO MED, V17, P511, DOI 10.1016/0891-5849(94)90090-6; Banik N L, 1984, Cent Nerv Syst Trauma, V1, P131; Bavetta S, 1999, EXP NEUROL, V158, P382, DOI 10.1006/exnr.1999.7119; BLIGHT AR, 1992, J NEUROTRAUM, V9, P147, DOI 10.1089/neu.1992.9.147; BRAUGHLER JM, 1985, J NEUROSURG, V62, P806, DOI 10.3171/jns.1985.62.6.0806; BRAUGHLER JM, 1982, J NEUROSURG, V56, P838, DOI 10.3171/jns.1982.56.6.0838; BULKLEY GB, 1983, SURGERY, V94, P407; BURNETT D, 1994, BIOCHEM PHARMACOL, V48, P1081, DOI 10.1016/0006-2952(94)90143-0; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DEFRANCO AL, 1991, NATURE, V352, P754, DOI 10.1038/352754a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOTO S, 1986, BRAIN RES, V397, P161, DOI 10.1016/0006-8993(86)91381-8; HALL ED, 1986, J NEUROSURG, V64, P951, DOI 10.3171/jns.1986.64.6.0951; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; HOM JT, 1993, CLIN IMMUNOL IMMUNOP, V68, P293, DOI 10.1006/clin.1993.1130; KANDEL ER, 1991, VOLTAGE GATED ION CH, P104; Kaptanoglu E, 2000, J NEUROSURG, V93, P77, DOI 10.3171/spi.2000.93.1.0077; Kaptanoglu E, 1999, J NEUROSURG, V91, P200, DOI 10.3171/spi.1999.91.2.0200; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Morioka M, 1999, PROG NEUROBIOL, V58, P1, DOI 10.1016/S0301-0082(98)00073-2; NISHINAKA Y, 1993, J CARDIOVASC PHARM, V21, P448, DOI 10.1097/00005344-199303000-00015; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, J IMMUNOL, V143, P1580; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; STARZL TE, 1989, LANCET, V2, P1000; Taoka Y, 1998, J NEUROSCI, V18, P1393; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Toung TJ, 1999, STROKE, V30, P1279, DOI 10.1161/01.STR.30.6.1279; Vaquero J, 1999, J NEUROSURG, V90, P220, DOI 10.3171/spi.1999.90.2.0220; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1	39	13	18	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393			SPINAL CORD	Spinal Cord	JAN	2005	43	1					22	26		10.1038/sj.sc.3101621			5	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	884ZP	WOS:000226125500003	15111998	Bronze			2021-06-18	
J	Mulholland, PJ; Stepanyan, TD; Self, RL; Hensley, AK; Harris, BR; Kowalski, A; Littleton, JM; Prendergast, MA				Mulholland, PJ; Stepanyan, TD; Self, RL; Hensley, AK; Harris, BR; Kowalski, A; Littleton, JM; Prendergast, MA			Corticosterone and dexamethasone potentiate cytotoxicity associated with oxygen-glucose deprivation in organotypic cerebellar slice cultures	NEUROSCIENCE			English	Article						glucocorticoids; stroke; RU486; trolox; neuronal damage	METHYL-D-ASPARTATE; TRAUMATIC BRAIN-INJURY; GLOBAL CEREBRAL-ISCHEMIA; PITUITARY-ADRENAL AXIS; MESSENGER-RNA LEVELS; NEURONAL CELL-DEATH; RAT-BRAIN; HIPPOCAMPAL-NEURONS; ACUTE STROKE; IN-VITRO	Many patients display elevated levels of serum cortisol following acute ischemic stroke. Given that glucocorticoids may potentiate some forms of insult, these studies examined the effects of corticosterone or dexamethasone exposure on cytotoxicity following oxygen-glucose deprivation in the cerebellum, a brain region susceptible to stroke. In organotypic cerebellar slice cultures prepared from neonatal rat pups, 90-min of oxygen-glucose deprivation at 15 days in vitro resulted in significant cytotoxicity at 24-, 48-, and 72-h post-oxygen-glucose deprivation, as measured by uptake of propidium iodide. Exposure of cultures following oxygen-glucose deprivation to the antioxidant trolox (500 mu M), but not to the glucocorticoid receptor antagonist RU486 (10 mu M), completely blocked oxygen-glucose deprivation-induced cytotoxicity. Corticosterone (1 mu M) or dexamethasone (10 mu M) exposure alone did not significantly increase propidium iodide uptake above levels observed in control cultures. However, corticosterone or dexamethasone exposure after oxygen-glucose deprivation potentiated oxygen-glucose deprivation-mediated propidium iodide uptake at each time point. Trolox, as well as RU486, co-exposure of cultures to corticosterone or dexamethasone after oxygen-glucose deprivation abolished all cytotoxicity. In conclusion, these data demonstrated that glucocorticoid exposure modulated oxygen-glucose deprivation-mediated propidium iodide uptake, which likely involved glucocorticoid receptor activation and pro-oxidant effects. (c) 2005 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Kentucky, Dept Psychol, Lexington, KY 40506 USA; Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40506 USA; Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, AB Chandler Med Ctr, Lexington, KY 40536 USA	Mulholland, PJ (corresponding author), Med Univ S Carolina, Ctr Drug & Alcohol Progams IOP4N, Charleston, SC 29425 USA.	mulholl@musc.edu	Mulholland, Patrick J/L-9353-2017				Adachi N, 1998, J CEREBR BLOOD F MET, V18, P274, DOI 10.1097/00004647-199803000-00005; AGARDH CD, 1981, J CEREBR BLOOD F MET, V1, P71, DOI 10.1038/jcbfm.1981.8; AGARWAL MK, 1993, NEUROENDOCRINOLOGY, V58, P575, DOI 10.1159/000126593; AMARENCO P, 1991, NEUROLOGY, V41, P973, DOI 10.1212/WNL.41.7.973; Antonawich FJ, 1999, NEUROSCIENCE, V88, P319, DOI 10.1016/S0306-4522(98)00213-9; ARMANINI MP, 1990, BRAIN RES, V532, P7, DOI 10.1016/0006-8993(90)91734-X; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; BARTANUSZ V, 1995, NEUROSCIENCE, V66, P247, DOI 10.1016/0306-4522(95)00084-V; BAULIEU E, 1986, J STEROID BIOCHEM, V25, P847, DOI 10.1016/0022-4731(86)90315-8; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; Behl C, 1997, EUR J NEUROSCI, V9, P912, DOI 10.1111/j.1460-9568.1997.tb01442.x; BIRMINGHAM MK, 1993, CELL MOL NEUROBIOL, V13, P373, DOI 10.1007/BF00711578; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; CERVOSNAVARRO J, 1991, CRIT REV NEUROBIOL, V6, P149; Cherubini A, 2000, STROKE, V31, P2295, DOI 10.1161/01.STR.31.10.2295; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Christensen H, 2004, J NEUROL SCI, V217, P175, DOI 10.1016/j.jns.2003.09.013; CLEMENS JA, 1994, ANN NY ACAD SCI, V738, P250; DEKLOET R, 1975, ENDOCRINOLOGY, V96, P598, DOI 10.1210/endo-96-3-598; DOBKIN B, 1995, NEUROLOGY, V45, P6; Dobkin B H, 1991, Clin Geriatr Med, V7, P507; FASSBENDER K, 1994, STROKE, V25, P1105, DOI 10.1161/01.STR.25.6.1105; FEIBEL JH, 1977, JAMA-J AM MED ASSOC, V238, P1374, DOI 10.1001/jama.238.13.1374; FRANCESCHINI R, 1994, STROKE, V25, P2142, DOI 10.1161/01.STR.25.11.2142; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Gottesman RF, 2003, INT REV PSYCHIATR, V15, P302, DOI 10.1080/09540260310001606683; Guerra-Araiza C, 2001, BRAIN RES BULL, V54, P13, DOI 10.1016/S0361-9230(00)00410-X; HEROS RC, 1982, STROKE, V13, P106, DOI 10.1161/01.STR.13.1.106; HEROS RC, 1992, STROKE, V23, P937, DOI 10.1161/01.STR.23.7.937; Jauss M, 1999, J NEUROL, V246, P257, DOI 10.1007/s004150050344; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; JUURLINK BHJ, 1993, DEV BRAIN RES, V71, P239, DOI 10.1016/0165-3806(93)90175-A; Kaasik A, 2001, NEUROSCIENCE, V102, P427, DOI 10.1016/S0306-4522(00)00489-9; KARST H, 1994, EUR J PHARM-ENVIRON, V270, P357, DOI 10.1016/0926-6917(94)90012-4; Kil HY, 1996, J CEREBR BLOOD F MET, V16, P100, DOI 10.1097/00004647-199601000-00012; KINUTA Y, 1989, J NEUROSURG, V71, P421, DOI 10.3171/jns.1989.71.3.0421; Krugers HJ, 2000, STROKE, V31, P1162, DOI 10.1161/01.STR.31.5.1162; KRUGERS HJ, 1995, BRAIN RES, V690, P41, DOI 10.1016/0006-8993(95)00585-E; KRUGERS HJ, 1993, NEUROSCI LETT, V154, P73, DOI 10.1016/0304-3940(93)90174-J; LAWRENCE MS, 1994, BRAIN RES, V646, P303, DOI 10.1016/0006-8993(94)90094-9; Lin H, 2004, COMP BIOCHEM PHYS B, V139, P745, DOI 10.1016/j.cbpc.2004.09.014; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; Meijer OC, 1998, ENDOCRINOLOGY, V139, P1789, DOI 10.1210/en.139.4.1789; Mizuhashi S, 2000, NEUROSCI RES, V38, P35, DOI 10.1016/S0168-0102(00)00137-1; MJAATVEDT AE, 1991, J NEUROCYTOL, V20, P2, DOI 10.1007/BF01187130; MORSE JK, 1990, EXP NEUROL, V110, P86, DOI 10.1016/0014-4886(90)90053-U; Mulholland PJ, 2004, NEUROSCIENCE, V125, P671, DOI 10.1016/j.neuroscience.2004.02.007; MURROS K, 1993, J NEUROL SCI, V116, P12, DOI 10.1016/0022-510X(93)90083-B; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; OLSSON T, 1992, STROKE, V23, P1573, DOI 10.1161/01.STR.23.11.1573; OZMEN I, 1992, J ENZYM INHIB MED CH, V20, P19; PACKAN DR, 1990, NEUROENDOCRINOLOGY, V51, P613, DOI 10.1159/000125400; PARTHASARATHY S, 1994, J CLIN INVEST, V94, P1990, DOI 10.1172/JCI117551; Payne RS, 2003, BRAIN RES, V971, P9, DOI 10.1016/S0006-8993(03)02276-5; Payne RS, 2001, NEUROREPORT, V12, P1261, DOI 10.1097/00001756-200105080-00041; QIZILBASH N, 2002, COCHRANE DB SYST REV, V2; SAKAMOTO A, 1991, FREE RADICAL BIO MED, V11, P385, DOI 10.1016/0891-5849(91)90155-V; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; SAPOLSKY RM, 1986, J NEUROSCI, V6, P2240; Schurr A, 2002, NEUROCHEM INT, V41, P1, DOI 10.1016/S0197-0186(01)00142-5; Sherrard RM, 1997, J ANAT, V191, P177, DOI 10.1046/j.1469-7580.1997.19120177.x; Sousa N, 1999, NEUROSCIENCE, V89, P1079, DOI 10.1016/S0306-4522(98)00311-X; SOUSA RJ, 1989, MOL ENDOCRINOL, V3, P481, DOI 10.1210/mend-3-3-481; STEINBEHRENS BA, 1994, J NEUROCHEM, V63, P596; STEINBEHRENS BA, 1992, J NEUROCHEM, V58, P1730, DOI 10.1111/j.1471-4159.1992.tb10047.x; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Takahashi T, 2002, J NEUROCHEM, V83, P1441, DOI 10.1046/j.1471-4159.2002.01251.x; TOHGI H, 1993, STROKE, V24, P1697, DOI 10.1161/01.STR.24.11.1697; TRACEY F, 1993, Q J MED, V86, P439; Turgut M, 1996, ANGIOLOGY, V47, P841, DOI 10.1177/000331979604700902; TYMIANSKI M, 1994, BRAIN RES, V648, P291, DOI 10.1016/0006-8993(94)91129-0; VIELKIND U, 1990, J NEUROSCI RES, V27, P360, DOI 10.1002/jnr.490270315; VIRGIN CE, 1991, J NEUROCHEM, V57, P1422, DOI 10.1111/j.1471-4159.1991.tb08309.x; WADDINGTON G, 1982, J NEUROCHEM, V38, P1588, DOI 10.1111/j.1471-4159.1982.tb06637.x; Weiland NG, 1997, NEUROSCIENCE, V78, P653, DOI 10.1016/S0306-4522(96)00619-7; WHITE BC, 1993, ANN EMERG MED, V22, P970, DOI 10.1016/S0196-0644(05)82737-4; Williams GR, 1999, STROKE, V30, P2523, DOI 10.1161/01.STR.30.12.2523; Yuan HB, 2004, ANESTHESIOLOGY, V100, P331, DOI 10.1097/00000542-200402000-00023; Yusim A, 2000, BRAIN RES, V870, P109, DOI 10.1016/S0006-8993(00)02407-0; Zheng S, 2003, NEUROSCIENCE, V118, P99, DOI 10.1016/S0306-4522(02)00767-4; Zimmer J, 2000, AMINO ACIDS, V19, P7, DOI 10.1007/s007260070029; ZINI I, 1992, NEUROSCI LETT, V138, P279, DOI 10.1016/0304-3940(92)90933-X	84	13	13	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2005	136	1					259	267		10.1016/j.neuroscience.2005.07.043			9	Neurosciences	Neurosciences & Neurology	985OH	WOS:000233386900023	16182452				2021-06-18	
J	Carre, E; Cantais, E; Darbin, O; Terrier, JP; Lonjon, M; Palmier, B; Risso, JJ				Carre, E; Cantais, E; Darbin, O; Terrier, JP; Lonjon, M; Palmier, B; Risso, JJ			Technical aspects of an impact acceleration traumatic brain injury rat model with potential suitability for both microdialysis and PtiO2 monitoring	JOURNAL OF NEUROSCIENCE METHODS			English	Article; Proceedings Paper	10th International Conference on In Vivo Methods	JUN 24-27, 2003	Karolinska Inst, Stockholm, SWEDEN		Karolinska Inst	traumatic brain injury; microdialysis; PuO2; weight-drop; impact acceleration; diffuse axonal injury; neuroprotection; methodology	AXONAL INJURY; HEAD-INJURY; NEUROPROTECTION	This report describes technical adaptations of a traumatic brain injury (TBI) model-largely inspired by Marmarou-in order to monitor microdialysis data and PtiO2 (brain tissue oxygen) before, during and after injury. We particularly focalize on our model requirements which allows us to re-create some drastic pathological characteristics experienced by severely head-injured patients: impact on a closed skull. no ventilation immediately after impact. presence of diffuse axonal injuries and secondary brain insults from systemic origin... We notably give priority to minimize anaesthesia duration in order to tend to banish any neuroprotection. Our new model will henceforth allow a better understanding of neurochemical and biochemical alterations resulting from traumatic brain injury, using microdialysis and PtiO2 techniques already monitored in our Intensive Care Unit. Studies on efficiency and therapeutic window of neuroprotective pharmacological molecules are now conceivable to ameliorate severe head-injury treatment. (C) 2004 Elsevier B.V. All rights reserved.	IMNSSA, Dept Neurochem, F-83800 Toulon, France; HIA St Anne, Intens Care Unit, F-83800 Toulon, France; Sch Med, Dept Neurol, Springfield, IL USA; HIA St Anne, Dept Pathol, F-83800 Toulon, France; CHU Pasteur, Dept Neurosurg, Nice, France	Carre, E (corresponding author), IMNSSA, Dept Neurochem, BP 610, F-83800 Toulon, France.	emilie_carre@hotmail.com		Darbin, Olivier/0000-0003-1461-8517			Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; *FRENCH SOC AN INT, 1999, ANN FR ANESTH, V18, P1; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Kawaguchi M, 2000, ANESTHESIOLOGY, V92, P1335, DOI 10.1097/00000542-200005000-00023; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; PAXINOS J, 1982, RAT BRAIN STEREOTAXI; Piper IR, 1996, J NEUROSCI METH, V69, P171, DOI 10.1016/S0165-0270(96)00046-5; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Warner DS, 2000, ANESTHESIOLOGY, V92, P1226	12	13	15	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270			J NEUROSCI METH	J. Neurosci. Methods	DEC 30	2004	140	1-2					23	28		10.1016/j.jneumeth.2004.04.037			6	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	885TO	WOS:000226180100005	15589330				2021-06-18	
J	Krakowski, MI; Czobor, P				Krakowski, MI; Czobor, P			Psychosocial risk factors associated with suicide attempts and violence among psychiatric inpatients	PSYCHIATRIC SERVICES			English	Article							TRAUMATIC BRAIN INJURY; CHILDREN; BEHAVIOR; PERSONALITY; AGGRESSION	Objectives: To better understand the relationship between suicidal behavior and violence directed toward others among patients with major psychiatric disorders, this study examined how suicide attempts and violent behaviors were associated with various psychosocial problems. Methods: Participants were inpatients in two psychiatric state hospitals. They included 216 inpatients who had physically assaulted another patient or a staff member and a comparison group of 81 inpatients who had not assaulted anyone. History of suicide attempts and historical information about various risk factors for violence and suicide were obtained through chart review and patient interviews. Results: Patients in the violent group did not differ from those in the nonviolent group in whether they had attempted suicide. Suicide attempts and violence were associated with different historical variables. Suicide attempts were associated with a history of head trauma, harsh parental discipline, and parental psychopathology. Violence against others was associated with having a history of school truancy and foster home placement. Conclusions: Among inpatients with major psychiatric disorders, violence and suicide attempts were not related to each other and were associated with dissimilar psychosocial risk factors.	Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA; NYU, Dept Psychiat, New York, NY USA; Nathan S Kline Inst Psychiat Res, Orangeburg, NY USA; DOV Pharmaceut, Hackensack, NJ USA	Krakowski, MI (corresponding author), Nathan S Kline Inst Psychiat Res, 140 Old Orangeburg Rd, Orangeburg, NY 10962 USA.	krakow@nki.rfmh.org			NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01-MH-58341] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH058341] Funding Source: NIH RePORTER		ANGST J, 1986, COMPR PSYCHIAT, V27, P511, DOI 10.1016/0010-440X(86)90055-6; BERG I, 1982, BRIT J PSYCHIAT, V141, P208, DOI 10.1192/bjp.141.2.208; Brodsky BS, 1997, AM J PSYCHIAT, V154, P1715, DOI 10.1176/ajp.154.12.1715; CAMPBELL SB, 1995, J CHILD PSYCHOL PSYC, V36, P113, DOI 10.1111/j.1469-7610.1995.tb01657.x; CICCHETTI D, 1991, ROCH S DEV PSYCH, V16; DOWNEY G, 1990, PSYCHOL BULL, V108, P50, DOI 10.1037/0033-2909.108.1.50; FERGUSSON DM, 1995, NEW ZEAL J EDUC STUD, V30, P25; GARFINKEL BD, 1982, AM J PSYCHIAT, V139, P1257; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; KIENHORST CWM, 1990, SUICIDE LIFE-THREAT, V20, P101; Krakowski M, 1999, SCHIZOPHRENIA BULL, V25, P505, DOI 10.1093/oxfordjournals.schbul.a033397; Krakowski M, 1988, NEUROPSY NEUROPSY BE, V1, P21; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; LISHMAN WA, 1987, PSYCHOL CONSEQUENCES; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; Monahan J., 2001, RETHINKING RISK ASSE; ROMANOV K, 1994, PSYCHOSOM MED, V56, P328, DOI 10.1097/00006842-199407000-00008; ROY A, 1986, SUICIDE LIFE-THREAT, V16, P244; Rutter M, 1999, J CHILD PSYCHOL PSYC, V40, P19, DOI 10.1111/1469-7610.00423; Santa Mina EE, 1998, CAN J PSYCHIAT, V43, P793; Schwab-Stone M, 1999, J AM ACAD CHILD PSY, V38, P359, DOI 10.1097/00004583-199904000-00007; SHAUNESEY K, 1993, AM J ORTHOPSYCHIAT, V63, P113, DOI 10.1037/h0079411; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Steadman HJ, 1998, ARCH GEN PSYCHIAT, V55, P393, DOI 10.1001/archpsyc.55.5.393; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; VANDERKOLK BA, 1991, AM J PSYCHIAT, V148, P1665; WEISS B, 1992, CHILD DEV, V63, P1321, DOI 10.1111/j.1467-8624.1992.tb01697.x; Zuravin SJ, 1997, SOC WORK RES, V21, P34, DOI 10.1093/swr/21.1.34; 1991, BLUEPRINT FOSTERING	30	13	13	0	7	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	1075-2730	1557-9700		PSYCHIAT SERV	Psychiatr. Serv.	DEC	2004	55	12					1414	1419		10.1176/appi.ps.55.12.1414			6	Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry	Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry	876LU	WOS:000225499200011	15572570				2021-06-18	
J	Parry, L; Shores, A; Rae, C; Kemp, A; Waugh, MC; Chaseling, R; Joy, P				Parry, L; Shores, A; Rae, C; Kemp, A; Waugh, MC; Chaseling, R; Joy, P			An investigation of neuronal integrity in severe paediatric traumatic brain injury	CHILD NEUROPSYCHOLOGY			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; PROTON MR SPECTROSCOPY; HEAD-INJURY; LOCALIZED PROTON; AXONAL INJURY; WHITE-MATTER; QUANTIFICATION; DAMAGE	Magnetic Resonance Spectroscopy (MRS) and its association with neuropsychological functioning was examined in the chronic injury phase of paediatric traumatic brain injury (TBI), Fifteen children, aged 10-16 years, with severe TBIs were compared with 15 controls, matched for age and gender. The TBI group was found to have significantly lower levels of N-acetyl aspartate (NAA) and Choline (Cho) in the right frontal lobe and generally displayed reduced performances on neuropsychological tests. A correlation between metabolites and reaction times was also obtained. Findings indicate a role of proton MRS as a measure of neuronal integrity following severe paediatric TBI and suggest a potential association of MRS with specific neuropsychological impairments.	Childrens Hosp, Rehabil Dept, Westmead, NSW 2145, Australia; Childrens Hosp, Dept Radiol, Westmead, NSW, Australia; Childrens Hosp, Dept Neurosurg, Westmead, NSW, Australia; Childrens Hosp, Dept Dev Cognit Neuropsychol Res Unit, Westmead, NSW, Australia; Macquarie Univ, Dept Psychol & Linguist, Epping, NSW, Australia; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; Childrens Hosp, Child Dev Unit, Westmead, NSW, Australia	Parry, L (corresponding author), Childrens Hosp, Rehabil Dept, Cnr Hainsworth St,Hawkesbury Rd, Westmead, NSW 2145, Australia.		Rae, Caroline/B-7537-2008	Rae, Caroline/0000-0003-0673-8084; Shores, Edwin A/0000-0003-1553-5131			Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; BROMAN M, 1995, TRAUMATIC HEAD INJUR; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; *CENES, 1999, CANTAB WIND; Cheng L. L., 2001, P INT SOC MAGN RES M, V9, P1672; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; Cohen M.J., 1997, CHILDRENS MEMORY SCA; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; Danielsen ER, 1999, MAGNETIC RESONANCE S; Elliot C.D, 1990, DIFFERENTIAL ABILITY; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2001, CURR OPIN NEUROL, V14, P753, DOI 10.1097/00019052-200112000-00012; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; JENNETT B, 1975, LANCET, V1, P480; Jones NR, 1998, J CLIN NEUROSCI, V5, P73, DOI 10.1016/S0967-5868(98)90207-7; Jung RE, 1999, NEUROREPORT, V10, P3327, DOI 10.1097/00001756-199911080-00014; Jung RE, 1999, P ROY SOC B-BIOL SCI, V266, P1375, DOI 10.1098/rspb.1999.0790; Kolb B., 1996, FUNDAMENTALS HUMAN N; Komoroski RA, 1999, MAGN RESON IMAGING, V17, P427, DOI 10.1016/S0730-725X(98)00186-6; MAROSSZEKY NEV, 1993, CLIN NEUROPSYCHOL, V7, P85, DOI 10.1080/13854049308401890; Naressi A, 2001, MAGN RESON MATER PHY, V12, P141, DOI 10.1007/BF02668096; Novotny E, 1998, PEDIATR RES, V44, P1, DOI 10.1203/00006450-199807000-00001; PIJNAPPEL WWF, 1992, J MAGN RESON, V97, P122, DOI 10.1016/0022-2364(92)90241-X; Ponsford J., 1995, TRAUMATIC BRAIN INJU; ROSS BD, 1998, J MAGNETIC RESONANCE, V8; Sinson G, 2001, AM J NEURORADIOL, V22, P143; TZIKA AA, 1993, JMRI-J MAGN RESON IM, V3, P719, DOI 10.1002/jmri.1880030506; Valenzuela MJ, 2000, NEUROIMAGE, V12, P747, DOI 10.1006/nimg.2000.0629; VANDERKNAAP MS, 1990, RADIOLOGY, V176, P509, DOI 10.1148/radiology.176.2.2164237; Vanhamme L, 1997, J MAGN RESON, V129, P35, DOI 10.1006/jmre.1997.1244; Wang Y, 1998, MAGNET RESON MED, V39, P28, DOI 10.1002/mrm.1910390107; Wechsler D., 1991, WECHSLER INTELLIGENC; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	44	13	14	0	0	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	DEC	2004	10	4					248	261		10.1080/09297040490909279			14	Clinical Neurology	Neurosciences & Neurology	888KR	WOS:000226373300002	15621848				2021-06-18	
J	Hartemink, KJ; Wisselink, W; Rauwerda, JA; Girbes, ARJ; Polderman, KH				Hartemink, KJ; Wisselink, W; Rauwerda, JA; Girbes, ARJ; Polderman, KH			Novel applications of therapeutic hypothermia: report of three cases	CRITICAL CARE			English	Article						neurological injury; neuroprotection; outcome; postanoxic injury; spinal cord ischaemia; therapeutic hypothermia	TRAUMATIC BRAIN-INJURY; PROMISING TREATMENT MODALITY; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; CARDIAC-ARREST; SPINAL-CORD; ISCHEMIA; OPPORTUNITIES; HYPERTHERMIA; TEMPERATURE	Therapeutic hypothermia can provide neuroprotection in various situations where global or focal neurological injury has occurred. Hypothermia has been shown to be effective in a large number of animal experiments. In clinical trials, hypothermia has been used in patients with postanoxic injury following cardiopulmonary resuscitation, in traumatic brain injury with high intracranial pressure, in the perioperative setting during various surgical procedures and for various other indications. There is thus evidence that hypothermia can be effective in various situations of neurological injury, although a number of questions remain unanswered. We describe three patients with unusual causes of neurological injury, whose clinical situation was in fundamental aspects analogous to conditions where hypothermia has been shown to be effective.	VU Univ Med Ctr, Dept Intens Care, Amsterdam, Netherlands; VU Univ Med Ctr, Dept Intens Care & Surg, Amsterdam, Netherlands; VU Univ Med Ctr, Dept Surg, Div Vasc Surg, Amsterdam, Netherlands	Polderman, KH (corresponding author), VU Univ Med Ctr, Dept Intens Care, Amsterdam, Netherlands.	k.polderman@tip.nl	Polderman, Kees H/K-3623-2012				Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Bernard SA, 2003, CRIT CARE MED, V31, P2041, DOI 10.1097/01.CCM.0000069731.18472.61; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Cambria RP, 1997, J VASC SURG, V25, P234, DOI 10.1016/S0741-5214(97)70365-3; Dixon SR, 2002, J AM COLL CARDIOL, V40, P1928, DOI 10.1016/S0735-1097(02)02567-6; FRANK SM, 1994, J VASC SURG, V19, P687, DOI 10.1016/S0741-5214(94)70043-5; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; Kimura A, 2002, CRIT CARE MED, V30, P1499, DOI 10.1097/00003246-200207000-00017; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; MELLERGARD P, 1991, NEUROSURGERY, V28, P709, DOI 10.1227/00006123-199105000-00012; MEZROW CK, 1992, ANN THORAC SURG, V54, P609, DOI 10.1016/0003-4975(92)91002-Q; Nagao S, 2003, J CLIN NEUROSCI, V10, P208, DOI 10.1016/S0967-5868(02)00322-3; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2001, J NEUROSURG, V94, P853; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; Svensson LG, 1998, ANN THORAC SURG, V66, P132, DOI 10.1016/S0003-4975(98)00359-2; Thome C, 2001, ACTA NEUROCHIR SUPPL, V77, P255; WISSELINK W, 1994, J VASC SURG, V19, P788, DOI 10.1016/S0741-5214(94)70003-6	28	13	16	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	OCT	2004	8	5					R343	R346		10.1186/cc2928			4	Critical Care Medicine	General & Internal Medicine	869SG	WOS:000225003800036	15469578	DOAJ Gold, Green Published			2021-06-18	
J	Kim, MD; Min, DS; Sim, KB; Cho, HJ; Shin, T				Kim, MD; Min, DS; Sim, KB; Cho, HJ; Shin, T			Expression and potential role of phospholipase D1 in cryoinjured cerebral cortex of rats	HISTOLOGY AND HISTOPATHOLOGY			English	Article						brain injury; cryoinjury; macrophage; phospholipase D1	TRAUMATIC BRAIN-INJURY; UP-REGULATION; SPINAL-CORDS; CELLS; MACROPHAGES; DIFFERENTIATION; ASTROCYTES; APOPTOSIS	The expression and potential role of phospholipase D1 (PLD1) were studied in the cerebral cortex of rats after freeze injury. Histopathologic ally, cryoinjury, by exposing cerebral cortex to a prechilled rod for 1 minute, produced consistent pathological lesions, specifically neuronal death, infiltration of macrophages into the center of the cryoinjury, and reactive astrogliosis at the periphery, which caused the lesion site to become encased. Western blot analysis showed that PLD1 expression in the ipsilateral cerebral cortex increased significantly during days 1 to 3 after cryoinjury and declined slightly at post-injury day 7. PLD1 immunoreactivity was very low in the brains of sham-operated control adults. After cryoinjury, there was substantial PLD1 immunostaining of numerous inflammatory cells in the ipsilateral cortex, which were identical to ED1-positive macrophages. In addition, PLD1 immunoreactivity was increased in some neurons and astrocytes at the periphery of the cryoinjury at postinjury days 3 and 7. These findings suggest that cryoinjury by means of prechilled rods induced consistent histopathological changes in the cerebral cortex. In addition, expression of a cell activation signal, PLD1, was upregulated in macrophages and astrocytes in the ipsilateral cerebral cortex after cryoinjury.	Jeju Natl Univ, Dept Vet Med, Cheju 690756, South Korea; Jeju Natl Univ, Coll Med, Dept Psychiat, Cheju, South Korea; Pusan Natl Univ, Coll Nat Sci, Dept Biol Mol, Pusan 609735, South Korea; Jeju Natl Univ, Coll Med, Dept Neurosurg, Cheju, South Korea; Kyungpook Natl Univ, Sch Med, Dept Anat, Taegu 702701, South Korea	Shin, T (corresponding author), Jeju Natl Univ, Dept Vet Med, Cheju 690756, South Korea.	shint@cheju.ac.kr		SHIN, Taekyun/0000-0002-9851-4354			Ahn M, 2001, NEUROSCI LETT, V316, P95, DOI 10.1016/S0304-3940(01)02383-7; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Baldwin SA, 1996, GLIA, V16, P266; BOARDER MR, 1994, TRENDS PHARMACOL SCI, V15, P57, DOI 10.1016/0165-6147(94)90111-2; Cockcroft S, 1996, CHEM PHYS LIPIDS, V80, P59, DOI 10.1016/0009-3084(96)02546-7; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; diMarzo V, 1996, BIOCHEM J, V316, P977, DOI 10.1042/bj3160977; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Jung KS, 2003, NEUROSCI LETT, V336, P126, DOI 10.1016/S0304-3940(02)01155-2; Lee MY, 2000, BRAIN RES, V864, P52, DOI 10.1016/S0006-8993(00)02134-X; Lee MY, 2000, GLIA, V30, P311, DOI 10.1002/(SICI)1098-1136(200005)30:3<311::AID-GLIA10>3.0.CO;2-K; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Min DS, 1999, FEBS LETT, V454, P197, DOI 10.1016/S0014-5793(99)00798-X; Min DS, 2001, NEUROSCI LETT, V310, P125, DOI 10.1016/S0304-3940(01)02091-2; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nakashima S, 1999, CHEM PHYS LIPIDS, V98, P153, DOI 10.1016/S0009-3084(99)00027-4; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Soares HD, 1995, J NEUROSCI, V15, P8223; Sun D, 2000, J NEUROPATH EXP NEUR, V59, P1031, DOI 10.1093/jnen/59.12.1031; Yoshimura S, 1997, J NEUROCHEM, V69, P713	22	13	14	0	0	F HERNANDEZ	MURCIA	PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN	0213-3911	1699-5848		HISTOL HISTOPATHOL	Histol. Histopath.	OCT	2004	19	4					1015	1019					5	Cell Biology; Pathology	Cell Biology; Pathology	864NF	WOS:000224639500001	15375744				2021-06-18	
J	Cherian, L; Hlatky, R; Robertson, CS				Cherian, L; Hlatky, R; Robertson, CS			Comparison of tetrahydrobiopterin and L-arginine on cerebral blood flow after controlled cortical impact injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						L-arginine; cortical impact injury; hypotension; intracranial hypertension; nitric oxide; tetrahydrobiopterin; traumatic brain injury	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; ENDOTHELIUM-DEPENDENT RELAXATIONS; COFACTOR; ARTERY; SUPEROXIDE; ISCHEMIA; BIOSYNTHESIS; RESTORATION; REPERFUSION	The purpose of this study was to compare the effects of L-arginine and tetrahydrobiopterin administration on post-traumatic cerebral blood flow (CBF) and tissue levels of NO in injured brain tissue. Rats were anesthetized with isoflurane. Mean blood pressure, intracranial pressure, cerebral blood flow using laser Doppler flowmetry (LDF) and brain tissue nitric oxide (NO) concentrations were measured prior to, and for 2 h after a controlled cortical impact injury. L-Arginine, 300 mg/kg, tetrahydrobiopterin, 10 mg/kg, or equal volume of saline was given at 5 min after injury. In the saline-treated animals, LDF decreased to 34 +/- 4% of baseline values after injury. NO concentration also decreased by approximately 20 pmol/ml from baseline values. L-Arginine and tetrahydrobiopterin administration both resulted in a significant preservation of tissue NO concentrations and an improvement in LDF, compared to control animals given saline. These studies demonstrate that tetrahydrobiopterin administration has a beneficial effect on cerebral blood flow that is similar to L-arginine administration, and may suggest that depletion of tetrahydrobiopterin plays a role in the post-traumatic hypoperfusion of the brain.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Cherian, L (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.	lcherian@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS 38660] Funding Source: Medline		Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; Ashwal S, 1998, STROKE, V29, P1037, DOI 10.1161/01.STR.29.5.1037; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Cho S, 1999, J NEUROSCI, V19, P878; Cosentino F, 2001, ARTERIOSCL THROM VAS, V21, P496, DOI 10.1161/01.ATV.21.4.496; Cosentino F, 1998, J CLIN INVEST, V101, P1530, DOI 10.1172/JCI650; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; Golding EM, 1998, J NEUROTRAUM, V15, P635, DOI 10.1089/neu.1998.15.635; Goodman JC, 2002, NEUROLOGY, V58, pA196; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; Higman DJ, 1996, ARTERIOSCL THROM VAS, V16, P546, DOI 10.1161/01.ATV.16.4.546; IIJIMA S, 1986, STROKE, V17, P529, DOI 10.1161/01.STR.17.3.529; KAUFMAN S, 1993, ANNU REV NUTR, V13, P261, DOI 10.1146/annurev.nu.13.070193.001401; Kinoshita H, 1997, AM J PHYSIOL-HEART C, V273, pH718; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Maier W, 2000, J CARDIOVASC PHARM, V35, P173, DOI 10.1097/00005344-200002000-00001; Milstien S, 1999, BIOCHEM BIOPH RES CO, V263, P681, DOI 10.1006/bbrc.1999.1422; Pieper GM, 1997, J CARDIOVASC PHARM, V29, P8, DOI 10.1097/00005344-199701000-00002; Sharma AC, 1998, NEUROL RES, V20, P632; Stroes E, 1997, J CLIN INVEST, V99, P41, DOI 10.1172/JCI119131; Sun H, 2001, AM J PHYSIOL-HEART C, V281, pH1863; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Tiefenbacher CP, 1996, CIRCULATION, V94, P1423, DOI 10.1161/01.CIR.94.6.1423; Tsutsui M, 1996, CIRC RES, V79, P336, DOI 10.1161/01.RES.79.2.336; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842	37	13	15	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2004	21	9					1196	1203					8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	855HC	WOS:000223962900008	15453989				2021-06-18	
J	Hung, YC; Montazem, A; Costello, MA				Hung, YC; Montazem, A; Costello, MA			The correlation between mandible fractures and loss of consciousness	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							CLOSED-HEAD INJURIES; FACIAL FRACTURES; IMPACT	Purpose: The purpose of the study was to evaluate the relationship between mandible fractures and loss of consciousness (LOC) in patients sustaining maxillofacial trauma in a level I trauma center. Patients and Methods: The study was a retrospective chart review performed at Lincoln Medical and Mental Health Center, a level I trauma center. A total of 225 hospital charts of patients who sustained mandible fractures during the period from 1997 to 2001 were reviewed. The site of fracture, number of fractures per mandible, degree of displacement, and mechanism of injury were recorded. Percentages of each category were compared among patients with positive and negative LOC. Patients with any concomitant craniofacial fractures or injuries were excluded from the study. Results: The incidence of LOC in patients sustaining mandible fractures was 17.6%. Young men were most likely to sustain mandibular fractures. The male-to-female ratio was 5.6:1. More than 70% of mandible fractures were due to interpersonal violence. Among various causes of interpersonal violence, use of a fist was most common. Overall, the number of fractures per patient, the incidence of singular versus multiple mandibular fractures, and the degree of displacement were less in the group with positive LOC. Body and angle regions were subjected to higher numbers of fractures, with slight variation among the 2 groups. The most common locations for mandibular fractures were the body (26% in negative LOC group; 42% in positive LOC group) and the angle (31% in negative LOC group; 26% in positive LOC group). Conclusion: Nearly 1 in 5 mandible fractures was associated with positive LOC. The patient group with a positive LOC, on average, sustained fewer fractures. It is possible that when the mandible sustained fewer fractures, the dissipation of energy was reduced and more force was transmitted to the cranial vault, thereby resulting in a higher incidence of LOC. (C) 2004 American Association of Oral and Ataxillofacial Surgeons.	Mt Sinai Hosp, Dept Oral & Maxillofacial Surg, Residency Training Program, New York, NY 10029 USA; Lincoln Med & Mental Hlth Ctr, Bronx, NY 10451 USA	Montazem, A (corresponding author), Mt Sinai Hosp, Dept Oral & Maxillofacial Surg, Residency Training Program, 1 Gustave L Levy Pl,Box 1187, New York, NY 10029 USA.	Andre.Montazem@mssm.edu					BAILEY BJ, 1967, LARYNGOSCOPE, V77, P1137, DOI 10.1288/00005537-196707000-00007; DAVIDOFF G, 1988, ANN EMERG MED, V17, P6, DOI 10.1016/S0196-0644(88)80492-X; ELLIS E, 1985, ORAL SURG ORAL MED O, V59, P120, DOI 10.1016/0030-4220(85)90002-7; FRIDRICH KL, 1992, J ORAL MAXIL SURG, V50, P586, DOI 10.1016/0278-2391(92)90438-6; Halazonetis J A, 1968, Br J Oral Surg, V6, P37, DOI 10.1016/S0007-117X(68)80025-3; HAUG HZ, 1992, J ORAL MAXIL SURG, V50, P218, DOI 10.1016/0278-2391(92)90315-Q; HAUG RH, 1990, J ORAL MAXIL SURG, V48, P926, DOI 10.1016/0278-2391(90)90004-L; KELLY DE, 1975, J ORAL SURG, V33, P146; LEE KF, 1987, J NEUROSURG, V66, P542, DOI 10.3171/jns.1987.66.4.0542; Murray J F, 1975, Clin Plast Surg, V2, P131; Nahum A M, 1975, Clin Plast Surg, V2, P59; OLSON RA, 1982, J ORAL MAXIL SURG, V40, P23, DOI 10.1016/S0278-2391(82)80011-6	12	13	13	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	AUG	2004	62	8					938	942		10.1016/j.joms.2004.01.018			5	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	842RS	WOS:000223022300006	15278857				2021-06-18	
J	Davis, JE; Eberwine, JH; Hinkle, DA; Marciano, PG; Meaney, DF; McIntosh, TK				Davis, JE; Eberwine, JH; Hinkle, DA; Marciano, PG; Meaney, DF; McIntosh, TK			Methodological considerations regarding single-cell gene expression profiling for brain injury	NEUROCHEMICAL RESEARCH			English	Article						brain injury; cDNA array; gene expression profiling; microarray standardization; RNA amplification; single cell	MESSENGER-RNA; MICROARRAY ANALYSIS; SERIAL ANALYSIS; ALTERED EXPRESSION; MOUSE HIPPOCAMPUS; CEREBRAL-ISCHEMIA; RAT; CORTEX; NEURONS; TISSUE	Genomic microarrays are rapidly becoming ubiquitous throughout a wide variety of biological disciplines. As their use has grown during the past few years, many important discoveries have been made in the fields of central nervous system (CNS) injury and disease using this emerging technology. In addition, single-cell mRNA amplification techniques are now being used along with microarrays to overcome many of the difficulties associated with the cellular heterogeneity of the brain. This development has extended the utility of gene expression pro. ling and has provided researchers with exciting new insights into the neuropathology of CNS injury and disease at a molecular and cellular level. New methodological, standardization, and statistical techniques are currently being developed to improve the reproducibility of microarrays and facilitate the analysis of large amounts of data. In this review, we will discuss the application of these techniques to experimental, clinically relevant models of traumatic brain injury.	Univ Penn, Sch Med, Head Injury Ctr, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	McIntosh, TK (corresponding author), Univ Penn, Sch Med, Head Injury Ctr, Dept Neurosurg, 105C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	mcintosh@seas.upenn.edu	Eberwine, James/B-2247-2010	Meaney, David/0000-0002-0954-4122	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40978, NS08803] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [41699] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, P01NS008803, P50NS008803] Funding Source: NIH RePORTER		Ball CA, 2002, SCIENCE, V298, P539; BENES V, 2000, TRENDS BIOCHEM SCI, V28, P244; Blalock EM, 2003, J NEUROSCI, V23, P3807; *BRAIN INJ ASS AM, 2004, DAT COMP ARR BAS DAT; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Butte A, 2002, NAT REV DRUG DISCOV, V1, P951, DOI 10.1038/nrd961; Centers for Disease Control, 2001, TRAUM BRAIN INJ US R; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; Churchill GA, 2002, NAT GENET, V32, P490, DOI 10.1038/ng1031; Clark RSB, 1997, J NEUROSCI, V17, P9172; Constans A, 2003, SCIENTIST, V17, P34; Conti AC, 1998, J NEUROSCI, V18, P5663; Crino PB, 1996, P NATL ACAD SCI USA, V93, P14152, DOI 10.1073/pnas.93.24.14152; Datson NA, 1999, NUCLEIC ACIDS RES, V27, P1300, DOI 10.1093/nar/27.5.1300; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Eberwine J, 2001, J NEUROSCI, V21, P8310; EBERWINE J, 1997, CURR PROTOCOLS NEURS, V5, P1; Elliott RC, 2003, J NEUROSCI, V23, P2218; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Evans SJ, 2002, EUR J NEUROSCI, V16, P409, DOI 10.1046/j.1460-9568.2002.02097.x; French PJ, 2001, EUR J NEUROSCI, V14, P2037, DOI 10.1046/j.0953-816x.2001.01818.x; Geschwind DH, 2000, P NATL ACAD SCI USA, V97, P10676, DOI 10.1073/pnas.97.20.10676; Hemby SE, 2002, ARCH GEN PSYCHIAT, V59, P631, DOI 10.1001/archpsyc.59.7.631; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Jain K K, 2000, Pharmacogenomics, V1, P289, DOI 10.1517/14622416.1.3.289; Kamme F, 2003, J NEUROSCI, V23, P3607; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; KOGURE K, 1993, STROKE, V24, P2121, DOI 10.1161/01.STR.24.12.2121; Levsky JM, 2003, TRENDS CELL BIOL, V13, P4, DOI 10.1016/S0962-8924(02)00002-8; LEWIN ICF, 1992, COST DISORDERS BRAIN; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Lukasiuk K, 2003, EUR J NEUROSCI, V17, P271, DOI 10.1046/j.1460-9568.2003.02461.x; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; MARCIANO PG, IN PRESS J NEUROSCIE; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Mirnics K, 2001, NAT REV NEUROSCI, V2, P444, DOI 10.1038/35077587; MIYASHIRO K, 1994, P NATL ACAD SCI USA, V91, P10800, DOI 10.1073/pnas.91.23.10800; Nogawa S, 1997, J NEUROSCI, V17, P2746; O'Dell DM, 2000, J NEUROSCI, V20, P4821; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rao SA, 2002, GENET RESOUR CROP EV, V49, P83; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; Schmidt-Kastner R, 2002, MOL BRAIN RES, V108, P81, DOI 10.1016/S0169-328X(02)00516-8; Shilling PD, 2002, PHARMACOGENOMICS, V3, P31, DOI 10.1517/14622416.3.1.31; SUTCLIFFE JG, 1988, ANNU REV NEUROSCI, V11, P157, DOI 10.1146/annurev.neuro.11.1.157; Telfeian AE, 2003, EPILEPSIA, V44, P143, DOI 10.1046/j.1528-1157.2003.06102.x; Tietjen I, 2003, NEURON, V38, P161, DOI 10.1016/S0896-6273(03)00229-0; Todd R, 2002, TRENDS MOL MED, V8, P254, DOI 10.1016/S1471-4914(02)02350-X; Trendelenburg G, 2002, J NEUROSCI, V22, P5879; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Zhang HT, 2001, P NATL ACAD SCI USA, V98, P5497, DOI 10.1073/pnas.101124598	58	13	13	0	2	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	JUN	2004	29	6					1113	1121		10.1023/B:NERE.0000023598.04937.83			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	812CB	WOS:000220816500009	15176468	Green Published			2021-06-18	
J	Morgan, A; Ward, E; Murdoch, B				Morgan, A; Ward, E; Murdoch, B			Clinical characteristics of acute dysphagia in pediatric patients following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; dysphagia; laryngeal; oral-motor; pediatric	CHILDREN; SPEECH; INGESTION; IMPROVES	Primary Objective: To document the clinical characteristics of acute dysphagia in a group of pediatric patients after traumatic brain injury (TBI). Research Design: Prospective group study. Methods: Fourteen subjects (7 males, 7 females), aged 4 years 1 month to 15 years, with moderate or severe TBI (Glasgow Coma Scale [GCS] < 12). Subjects were assessed via clinical bedside examination documenting cognitive status, oromotor function, feeding function, dietary recommendations, and an indication of overall feeding severity Results: A pattern of impaired cognition, altered behavior related to feeding, severe tonal and postural deficits, oromotor, respiratory, and laryngeal impairments, and oral sensitivity issues was revealed. Conclusions: Swallowing impairment was affected by multilevel deficits, which both individually and in combination had a negative impact on swallowing competence and safety. In light of deficits identified, which could not be observed on videofluoroscopic investigation alone, this study highlighted the importance of the clinical bedside examination in assessing dysphagia in pediatric patients post-TBI for identifying targets for intervention.	Univ Queensland, Dept Speech Pathol & Audiol, Brisbane, Qld, Australia; Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld, Australia	Morgan, A (corresponding author), Inst Child Hlth, Dev Cognit Neurosci Unit, 30 Guilford St, London WC1N 1EH, England.	angela.morgan@ich.ucl.ac.uk	Ward, Elizabeth/F-9652-2010; Murdoch, Bruce E/C-1397-2012; Morgan, Angela/J-5235-2017	Ward, Elizabeth/0000-0002-2680-8978; Morgan, Angela/0000-0003-1147-7405			Arvedson JC, 1998, PEDIAT VIDEOFLUOROSC; BROOKE MM, 1991, ARCH PHYS MED REHAB, V72, P106; Cahill LM, 2002, BRAIN INJURY, V16, P415, DOI 10.1080/02699050110119871; Christensen J R, 1989, Dysphagia, V3, P131, DOI 10.1007/BF02407131; ENDERBY PM, 1983, FRENCHAY DYSARTHRIA; Field L H, 1989, Brain Inj, V3, P19, DOI 10.3109/02699058909008069; Gisel E G, 1998, Int J Orofacial Myology, V24, P27; GISEL EG, 1995, DYSPHAGIA, V10, P268, DOI 10.1007/BF00431421; Hagen C., 1972, LEVELS COGNITIVE FUN; Hayden D.A., 1999, VERBAL MOTOR PRODUCT; LARNERT G, 1995, ACTA PAEDIATR, V84, P689, DOI 10.1111/j.1651-2227.1995.tb13730.x; Leopold NA, 1997, DYSPHAGIA, V12, P202, DOI 10.1007/PL00009537; LEOPOLD NA, 1983, ARCH PHYS MED REHAB, V64, P371; Logemann J. A., 1998, EVALUATION TREATMENT; Logemann JA, 1999, DYSPHAGIA, V14, P44, DOI 10.1007/PL00009583; LOGEMANN JA, 1988, OTOLARYNG CLIN N AM, V21, P613; Logemann JA, 1994, J HEAD TRAUMA REHAB, V9, P43; LOGEMANN JA, 1989, J HEAD TRAUMA REHAB, V4, P24; Mackay LE, 1999, J HEAD TRAUMA REHAB, V14, P435, DOI 10.1097/00001199-199910000-00004; McHenry M, 2000, LARYNGOSCOPE, V110, P1157, DOI 10.1097/00005537-200007000-00017; Morgan AT, 2001, ASIA PACIFIC J SPEEC, V6, P9; MURDOCH BE, 1994, EUR J DISORDER COMM, V29, P379; NEWMAN I, 2000, SEMIN SPEECH LANG, V21, P281; PERLMAN A, 1999, NUTR CLIN PRACT, V14, pS1; REILLY JJ, 1995, TUNN UNDERGR SP TECH, V10, P3, DOI 10.1016/0886-7798(95)93307-S; Rowe LA, 1999, J HEAD TRAUMA REHAB, V14, P497, DOI 10.1097/00001199-199910000-00010; Schurr MJ, 1999, J TRAUMA, V46, P817, DOI 10.1097/00005373-199905000-00009; STARR S, 1998, FEEDING ASSESSMENT R, V2; Sullivan PB, 1997, BAILLIERE CLIN GASTR, V11, P529, DOI 10.1016/S0950-3528(97)90030-0; *WESTM HOSP COMM H, 1998, PARR HOSP ASS DYSPH; WINSTEIN CJ, 1983, PHYS THER, V63, P1992, DOI 10.1093/ptj/63.12.1992; Ylvisaker M, 1989, J HEAD TRAUMA REHAB, V4, P51; Ylvisaker M, 1985, HEAD INJURY REHABILI, P195	33	13	13	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2004	19	3					226	240		10.1097/00001199-200405000-00004			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	826JB	WOS:000221824300004	15247845				2021-06-18	
J	Levin, K				Levin, K			Paediatric traumatic brain injury in South Africa: some thoughts and considerations	DISABILITY AND REHABILITATION			English	Article								Purpose: This paper endeavours to describe the socio-political and economic backdrop to the assessment and management of traumatic brain injury (TBI) in children in South Africa. Outcomes: The argument put forward is that huge disparities in socio-economic status, diverse socio-cultural influences, and widely differing educational systems and educational attainment which characterize the country's population, render the management of TBI different from approaches adopted in developed countries. The main causes of TBI can be attributed to the high rates of violence in the country, as well as an inordinately high incidence of motor vehicle accidents. Compensation through existing national legislative and insurance agencies is unavailable to most of the population, and markedly insufficient in many cases. The access to medical care and rehabilitation is inadequate for the majority of South African children, although there are valiant efforts on the part of professionals working within the primary health care model to provide the support to the children and their families not offered by existing educational and school structures. Conclusion: The impact of the HIV/AIDS pandemic on the clinical picture of children and their families is profound and guides many of the decisions that are made by health care professionals. Given this bleak scenario, a re-focus on the strengths of existing structures and the creation of new possibilities is suggested as a positive and constructive approach to prevention, rehabilitation, and education.	Univ Witwatersrand, ZA-2050 Johannesburg, Johannesburg, South Africa	Levin, K (corresponding author), Univ Witwatersrand, Private Bag 3, ZA-2050 Johannesburg, Johannesburg, South Africa.						ANDERSON G, 2002, DISABLED CHILDREN LI, P6; BEALE P, 2003, HEAD TRAUM C PAED NE; BIGLER ED, 1997, CHILDHOOD TRAUMATIC; Blosser J, 2003, PEDIAT TRAUMATIC BRA; Bowley DMG, 2002, LANCET, V359, P1352, DOI 10.1016/S0140-6736(02)08305-8; *DEP SOC DEV, 2000, STAT S AFR POP REP; FIEGGEN G, 2003, HEAD TRAUM C PAED NE; Jaffe MP, 2000, BRAIN INJURY, V14, P35, DOI 10.1080/026990500120916; Meier Eileen, 2002, Pediatr Nurs, V28, P532; *NAT COUNC PROV, 2003, REPORT; *ROAD ACC FUND DEP, 2003, ROAD ACC FUND COMM R; *S AFR LAW COMM, 1997, REPORT; SACHS J, 2000, CURRENT ISSUES COMP, V3, P1; *UN, 2002, 14 INT C AIDS BARC 7; *UN, 2002, INT NARC CONTR BOARD; van As AB, 2001, SAMJ S AFR MED J, V91, P1035; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU; 2002, ROAD ACCIDENT FUND S, V1, P1	18	13	15	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	MAR 4	2004	26	5					306	314		10.1080/0963828032000174089			9	Rehabilitation	Rehabilitation	801WV	WOS:000220126900007	15200246				2021-06-18	
J	Rouxel, JPM; Tazarourte, K; Le Moigno, S; Ract, C; Vigue, B				Rouxel, JPM; Tazarourte, K; Le Moigno, S; Ract, C; Vigue, B			Medical prehospital rescue in head injury	ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION			French	Article						head injury; medical prehospital transport; secondary brain damage; hypoxemia; hypotension; outcome	TRAUMATIC BRAIN-INJURY; CEREBRAL PERFUSION-PRESSURE; MANAGEMENT; HYPOTENSION; MANNITOL; SCALE; SCORE; CARE; GUIDELINES; MORTALITY	Objective. - To evaluate the effectiveness of prehospital medical care in head-injured patients. Patients and methods. - All head-injured patients admitted in Bicetre hospital from 1995 to 1999 were retrospectively studied. Glasgow Coma Scale (GCS) score, mean arterial pressure (MAP) and SpO(2) measured on the field were compared to GCS, MAP and SpO(2) on arrival in the hospital. All treatments given during transport and first data recorded in the hospital were noted. Each parameter was compared to outcome at 6 months. Then, significant parameters were compared with a multivariate analysis. Results. - Three hundred and four patients were included, 80% had a GCS less than or equal to8 and 45% a GCS = 3. At 6 months, 43% of the patients had no or mild sequelae and 45% died. Prehospital time was 2 h 55 min +/-1 h 40 min. During transport, 75% of hypoxemic events were corrected, but GCS and MAP decreased significantly. None of the patients with non-reactive mydriasis received any osmotherapy and all patients with non-reactive mydriasis until hospital admission died (n = 55). After multivariate analysis, parameters significantly related to outcome were, on the field, MAP (p < 0.025) and at hospital SAPS II (p < 0.001), GCS (p < 0.001), non-reactive mydriasis (p < 0.025), hyperglycernia (p < 0.025) and low haemoglobinemia (p < 0.001). Conclusion. - Respect of guidelines is important to improve medical care. Prehospital management corrected hypoxemia but not hypotension. The lack of osmotherapy after mydriasis cannot be explained and is probably an error. Patient route must be simplified to decrease time delay from field to hospital. Improvement in prehospital care may decrease mortality in head-injured patients. (C) 2003 Elsevier SAS. Tous droits reserves.	CHU Bicetre, Dept Anesthesie Reanimat, F-94275 Le Kremlin Bicetre, France; Ctr Hosp Marc Jacquet, F-77000 Melun, France	Vigue, B (corresponding author), CHU Bicetre, Dept Anesthesie Reanimat, F-94275 Le Kremlin Bicetre, France.	bemard.vigue@bct.ap-hop-paris.fr		tazarourte, karim/0000-0002-3376-1258			Agenor PR, 1999, J INT MONEY FINANC, V18, P1, DOI 10.1016/S0261-5606(98)00043-6; ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bissonnette B, 2000, ANN FR ANESTH, V19, P270; Bruder N, 2000, ANN FR ANESTH, V19, P316; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CARLI P, 1990, JEUR, V3, P23; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; Clavier N, 2000, ANN FR ANESTH, V19, P304; Cruz J, 2002, NEUROSURGERY, V51, P628, DOI 10.1097/00006123-200209000-00006; Cruz J, 2001, NEUROSURGERY, V49, P864; DUPONT M, 2000, JEUR, V13, pA78; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRAHAM DI, 1971, LANCET, V1, P265; Grol R, 2001, JAMA-J AM MED ASSOC, V286, P2578, DOI 10.1001/jama.286.20.2578; Helm M, 2002, BRIT J ANAESTH, V88, P345, DOI 10.1093/bja/88.3.345; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JEFFREYS RV, 1981, LANCET, V2, P459; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENNETT B, 1975, LANCET, V1, P480; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lenfant F, 1997, ANN FR ANESTH, V16, P239, DOI 10.1016/S0750-7658(97)86408-8; Liberman M, 2000, J TRAUMA, V49, P584, DOI 10.1097/00005373-200010000-00003; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Maas A. I., 2000, CURR OPIN CRIT CARE, V6, P281; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Peytel E, 2001, INTENS CARE MED, V27, P1756, DOI 10.1007/s00134-001-1119-z; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; RUMMOND JC, 1994, ANESTHESIA, P630; Schrot RJ, 2002, LANCET, V359, P1633, DOI 10.1016/S0140-6736(02)08545-8; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 2000, NEUROSURGERY, V46, P70; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Trupka A, 1994, Eur J Emerg Med, V1, P1, DOI 10.1097/00063110-199403000-00002; Vigue B, 1999, INTENS CARE MED, V25, P445, DOI 10.1007/s001340050878; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	48	13	13	0	2	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0750-7658	1769-6623		ANN FR ANESTH	Ann. Fr. Anest. Reanim.	FEB	2004	23	1					6	14		10.1016/j.annfar.2003.09.021			9	Anesthesiology	Anesthesiology	800DR	WOS:000220009600003	14980318				2021-06-18	
J	Swan, L; Alderman, N				Swan, L; Alderman, N			Measuring the relationship between overt aggression and expectations: a methodology for determining clinical outcomes	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; BRAIN-INJURY; OAS-MNR; BEHAVIOR; MANAGEMENT; REHABILITATION; CARBAMAZEPINE; VERSION; SCALE; MILD	The presence of aggressive behaviour following traumatic brain injury imposes special challenges within rehabilitation centres. Survivors of traumatic brain injury constitute a heterogeneous population amongst whom problems with increased irritability and aggression are characteristic. There is a clear need to determine what treatment approaches might be helpful in reducing aggressive behaviour. Whilst single-case experimental methodologies including reversal and multiple baseline designs seem ideal for this purpose, the compelling need to minimize risk can compromise their deployment, especially when aggression takes the form of physical assaults on others. When this is the case, there are difficulties in assessing whether a change in aggressive behaviour represents a successful response to treatment or is simply a function of reduced demand in the environment. The contributions made to understanding the relationship between aggression and expectations made on patients participating within rehabilitation will be explored here. A possible means of quantifying demands using the Neurobehavioural Expectations Scale will be described. Three case studies are presented that suggest that a methodology that employs concurrent use of this tool with the Overt Aggression Scale Modified for Neurorehabilitation, can enable objective evaluation to be made of the effects of rehabilitation on behaviour, without increasing risk.	St Andrews Hosp, Kemsley Div, Northampton NN1 5DG, England	Alderman, N (corresponding author), St Andrews Hosp, Kemsley Div, Billing Rd, Northampton NN1 5DG, England.	nalderman@standrew.co.uk		Alderman, Nick/0000-0002-8523-4142			Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; Alderman N, 2001, BRAIN DAM B, P175; ALDERMAN N, 1991, Brain Injury, V5, P77, DOI 10.3109/02699059108998516; Alderman N, 2002, BRAIN INJURY, V16, P469, DOI 10.1080/02699050110118458; Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Alderman N, 1999, BRAIN INJURY, V13, P669; Alderman N, 1997, BRAIN INJURY, V11, P79, DOI 10.1080/026990597123683; ALDERMAN N, 2002, EVIDENCE MENTAL HLTH, P142; ALDERMAN N, 1992, PHYSIOTHERAPY, V78, P335; Azouvi P, 1999, BRAIN INJURY, V13, P797, DOI 10.1080/026990599121188; BARLOW PH, 1984, SINGLE CASE EXPT DES; BOLTON D, 2002, EVIDENCE MENTAL HLTH, P3; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BURKE WH, 1988, INT J REHABIL RES, V11, P235, DOI 10.1097/00004356-198809000-00003; COLTHEART M, 1991, HDB BEHAV THERAPY PS, P216; DAVIS JR, 1994, BRAIN INJURY, V8, P589, DOI 10.3109/02699059409151011; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; EAMES P, 1988, J HEAD TRAUMA REHAB, V3, P1; Eames PG, 2001, BRAIN DAM B, P29; FOSTER HG, 1989, PROG NEURO-PSYCHOPH, V13, P865, DOI 10.1016/0278-5846(89)90038-9; FUSSEY I, 1988, REHABILITATION SEVER; GILES GM, 1988, REHABILITATION SEVER, P69; GLOAG D, 1985, BRIT MED J, V290, P913, DOI 10.1136/bmj.290.6472.913; GREENWOOD RJ, 1993, CLIN REHABIL, V7, P248; JAMES P, 2002, EVIDENCE MENTAL HLTH, P28; Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; Knight C, 2002, BRAIN INJURY, V16, P75, DOI 10.1080/02699050110082188; Mateer C. A., 1990, NEUROBEHAVIOURAL SEQ, P275; Mattes J A, 1990, J Neuropsychiatry Clin Neurosci, V2, P159; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McLean A Jr, 1987, Brain Inj, V1, P145, DOI 10.3109/02699058709034453; McMillan TM, 2001, BRAIN DAM B, P257; MILLER E, 1981, BRIT J CLIN PSYCHOL, V20, P69, DOI 10.1111/j.2044-8260.1981.tb00498.x; MILLER L, 1994, J OFFENDER REHABILIT, V21, P91, DOI DOI 10.1300/J076; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1987, BNI Q, V3, P2; Treadwell K, 1996, J HEAD TRAUMA REHAB, V11, P62, DOI 10.1097/00001199-199602000-00008; UOMOTO JM, 1992, ARCH PHYS MED REHAB, V73, P674; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Warrington E., 1991, VISUAL OBJECT SPACE; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wilson, 1991, NATL ADULT READING T; WILSON BA, 1991, HDB BEHAV THERAPY PS, P227; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wood R. L., 1987, BRAIN INJURY REHABIL; Wood RL, 2001, BRAIN DAM B, P133; Wood RL, 2001, BRAIN DAM B, P107; Wood RL, 2001, BRAIN DAM B, P3; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	53	13	13	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2004	18	2					143	160		10.1080/02699050310001596923			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	751DR	WOS:000187038000004	14660227				2021-06-18	
J	Ramirez, RM; Chirivella-Garrido, J; Caballero, MC; Ferri-Campos, J; Noe-Sebastian, E				Ramirez, RM; Chirivella-Garrido, J; Caballero, MC; Ferri-Campos, J; Noe-Sebastian, E			Intelligence, memory and malingering: Correlation between scales	REVISTA DE NEUROLOGIA			Spanish	Article						intelligence; malingering; test of memory malingering; Wechsler adult intelligence-III	EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN-INJURY; VERBAL-LEARNING TEST; HEAD-INJURY; PRACTICAL SCALE; PERFORMANCE	Objectives. To validate the test of memory malingering (TOMM), and to study the influence of intelligence and memory on its performance in brain injury patients. Patients and methods. A total of 30 patients with traumatic head injury were included in the study. All patients were assessed with the Complutense verbal learning test, the Visual Reproduction subtest of the Wechsler memory scale-revised, the Boston naming test, two fluency tests (FAS, and animals), the Wechsler adult intelligence test-III, and with the TOMM. Cognitive results below 1 standard deviation (SD) from normative data were considered 'abnormal'. A parametric correlation between TOMM scores and cognitive tests was used to detect whether memory and intelligence were affecting TOMM performance. Statistical significance was set up at p < 0.05. Results. Between 46,1% (Boston) and 81.4% (WAIS-III performance IQ) of the sample presented cognitive deficits. Up to 83.3% of the patients scored above the cutoff point suggestive of malingering in the TOMM (45/50). Significance correlations were found between TOMM scores and memory or intelligence indexes. Discussion. The TOMM is a useful tool to detect malingering in head injured patients. Effects of low intelligence coefficients, as well as memory deficits should be considered in clinical practice when evaluating patients with TOMM scores suggestive of malingering.	Hosp NISA Valencia Mar, Serv Dano Cerebral, Valencia, Spain	Noe-Sebastian, E (corresponding author), Univ Valencia, Hosp Mar, Serv Dano Cerebral, Rio Tajo 1, E-46011 Valencia, Spain.	enoe@comv.es		Noe Sebastian, Enrique/0000-0002-2547-8727			Altrocchi PH, 1996, NEUROLOGY, V46, P278; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; BENEDET MJ, 1999, TEST APRENDIZAJE VER; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BURIEL Y, 2002, NEUROLOGIA, V17, P557; Colby F, 2001, NEUROREHABILITATION, V16, P311; Ellwanger J, 1999, J CLIN EXP NEUROPSYC, V21, P866, DOI 10.1076/jcen.21.6.866.850; FERREROARIAS J, 1998, EVALUACION DETERICO; FRANZEN M D, 1990, Neuropsychology Review, V1, P247, DOI 10.1007/BF01112573; GARCIAALBEA J, 1998, TEST BOSTON DIAGNEST; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Millis SR, 1998, J CLIN EXP NEUROPSYC, V20, P167, DOI 10.1076/jcen.20.2.167.1171; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Munoz-Cespedes JM, 2001, REV NEUROLOGIA, V32, P773, DOI 10.33588/rn.3208.2000186; REES L, 1988, PSYCHOL ASSESSMENT, V10, P10; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; Tardif HP, 2002, INT J PSYCHOPHYSIOL, V46, P147, DOI 10.1016/S0167-8760(02)00090-9; TEASDALE G, 1974, LANCET, V2, P81; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 1999, ESCALA INTELIGENCIA, V3; Wilson J, 1996, J NUCL MED, V37, P1256	26	13	13	0	4	REVISTA DE NEUROLOGIA	BARCELONA	C/O CESAR VIGUERA, EDITOR, APDO 94121, 08080 BARCELONA, SPAIN	0210-0010	1576-6578		REV NEUROLOGIA	Rev. Neurologia	JAN 1	2004	38	1					28	33		10.33588/rn.3801.2003533			6	Clinical Neurology	Neurosciences & Neurology	770YV	WOS:000188759700007	14730487				2021-06-18	
J	Miller, LA; Caine, D; Watson, JDG				Miller, LA; Caine, D; Watson, JDG			A role for the thalamus in memory for unique entities	NEUROCASE			English	Article							FOCAL RETROGRADE-AMNESIA; CLOSED-HEAD INJURY; TEMPORAL-LOBE; ANTEROGRADE AMNESIA; AUTOBIOGRAPHICAL MEMORY; SEMANTIC AMNESIA; PATIENT; KNOWLEDGE; PEOPLE; DISSOCIATION	Recent case studies of amnesic patients have yielded patterns of impairment that challenge Tulving's (1972) division of retrograde memory into two categories (namely, episodic and semantic memory). Here we describe a patient (JIG) who developed partially blocked access to previously stored knowledge following the onset of a medial thalamic infarction. Having previously demonstrated that JG has a dense, pervasive amnesia for autobiographical material, famous people and famous events (Miller et al, 2001), in this study, we show that he is unable to access information about unique entities across a range of domains. In contrast, his memory for more general semantic knowledge (such as word meanings) is intact. JG's memory impairment is discussed in the context of a model of neural functioning put forward by Damasio (1990), in which it was proposed that recall of unique entities depends on many cortical regions being activated in synchrony. This activity, thought to be triggered and coordinated by anterior temporal and frontal lobe regions is, in turn, modulated by projections from the thalamus. We propose that JG's thalamic lesion has disrupted the coordination of the diffuse cortical networks necessary to generate highly specific memories from the past, be they episodic or semantic.	Royal Prince Alfred Hosp, Neuropsychol Unit, Camperdown, NSW 2050, Australia; Univ Sydney, Sydney, NSW 2006, Australia	Miller, LA (corresponding author), Royal Prince Alfred Hosp, Neuropsychol Unit, Camperdown, NSW 2050, Australia.	lamiller@mail.usyd.edu.au		Miller, Laurie/0000-0001-6329-2969; Watson, John/0000-0003-0988-2583			Aggleton JP, 1997, MEMORY, V5, P49, DOI 10.1080/741941143; AGGLETON JP, 1986, J COMP NEUROL, V243, P409, DOI 10.1002/cne.902430310; Bozeat S, 2000, NEUROPSYCHOLOGIA, V38, P1207, DOI 10.1016/S0028-3932(00)00034-8; CERMAK LS, 1983, NEUROPSYCHOLOGIA, V21, P213, DOI 10.1016/0028-3932(83)90039-8; Cipolotti L, 2001, NEUROPSYCHOLOGIA, V39, P151, DOI 10.1016/S0028-3932(00)00103-2; Damasio A.R., 1990, SEMIN NEUROSCI, V2, P287; DAMASIO AR, 1990, BEHAV BRAIN RES, V40, P193, DOI 10.1016/0166-4328(90)90076-Q; De Renzi E, 2002, CORTEX, V38, P678, DOI 10.1016/S0010-9452(08)70036-4; DERENZI E, 1987, CORTEX, V23, P575, DOI 10.1016/S0010-9452(87)80050-3; DERENZI E, 1993, CORTEX, V29, P449, DOI 10.1016/S0010-9452(13)80253-5; DERENZI E, 1995, CORTEX, V31, P531, DOI 10.1016/S0010-9452(13)80064-0; Donaldson W., 1972, ORG MEMORY, P381, DOI [DOI 10.1016/B978-0-12-809324-5.21037-7, DOI 10.1017/S0140525X00047257]; EDDY JK, 1981, J VERB LEARN VERB BE, V20, P333, DOI 10.1016/S0022-5371(81)90483-7; ELLIS AW, 1989, BRAIN, V112, P1469, DOI 10.1093/brain/112.6.1469; Eslinger PJ, 1996, CEREB CORTEX, V6, P530, DOI 10.1093/cercor/6.3.530; EVANS JJ, 1995, BRAIN, V118, P1, DOI 10.1093/brain/118.1.1; Gentileschi V, 2001, COGN NEUROPSYCHOL, V18, P439, DOI 10.1080/02643290125835; GROSSI D, 1988, CORTEX, V24, P457, DOI 10.1016/S0010-9452(88)80009-1; Halpern AR, 1999, CEREB CORTEX, V9, P697, DOI 10.1093/cercor/9.7.697; HANLEY JR, 1989, COGNITIVE NEUROPSYCH, V6, P179, DOI 10.1080/02643298908253418; Haslam C, 2001, NEUROCASE, V7, P189, DOI 10.1093/neucas/7.3.189; Hodges JR, 2002, CORTEX, V38, P674, DOI 10.1016/S0010-9452(08)70035-2; HODGES JR, 1993, BRAIN, V116, P921, DOI 10.1093/brain/116.4.921; Howard D., 1992, PYRAMIDS PALM TREES; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P509, DOI 10.1016/0028-3932(94)00136-D; JACKENDOFF R, 1987, COGNITION, V26, P89, DOI 10.1016/0010-0277(87)90026-6; Jones RD, 1998, NEUROCASE, V4, P471, DOI 10.1093/neucas/4.6.471; Kapur N, 2000, COGN NEUROPSYCHOL, V17, P623, DOI 10.1080/026432900750002181; Kapur N, 2002, CORTEX, V38, P660, DOI 10.1016/S0010-9452(08)70032-7; KAPUR N, 1992, BRAIN, V115, P73, DOI 10.1093/brain/115.1.73; Kartsounis LD, 1996, CORTEX, V32, P109, DOI 10.1016/S0010-9452(96)80020-7; KARTSOUNIS LD, 1995, J NEUROL NEUROSUR PS, V59, P95, DOI 10.1136/jnnp.59.1.95; Kitchener EG, 1999, COGNITIVE NEUROPSYCH, V16, P589, DOI 10.1080/026432999380744; Kopelman MD, 2000, COGNITIVE NEUROPSYCH, V17, P585, DOI 10.1080/026432900750002172; Kopelman MD, 2002, CORTEX, V38, P655, DOI 10.1016/S0010-9452(08)70031-5; Kroll NEA, 1997, BRAIN, V120, P1377, DOI 10.1093/brain/120.8.1377; Lucchelli F, 1998, NEUROCASE, V4, P447, DOI 10.1093/neucas/4.6.447; Lucchelli F, 2002, CORTEX, V38, P665, DOI 10.1016/S0010-9452(08)70033-9; Lucchelli F, 1998, COGNITIVE NEUROPSYCH, V3, P91; Luzzi S, 2000, CORTEX, V36, P427, DOI 10.1016/S0010-9452(08)70851-7; MACKENZIE SJ, 1997, CORTEX, V33, P733; Mai J. K., 1997, ATLAS HUMAN BRAIN; MARKOWITSCH HJ, 1993, J CLIN EXP NEUROPSYC, V15, P627, DOI 10.1080/01688639308402586; Markowitsch HJ, 2002, CORTEX, V38, P651, DOI 10.1016/S0010-9452(08)70030-3; MARKOWITSCH HJ, 1993, J CLIN EXP NEUROPSYC, V15, P947, DOI 10.1080/01688639308402610; Mayes AR, 1997, CORTEX, V33, P197, DOI 10.1016/S0010-9452(08)70001-7; Mayes AR, 2002, CORTEX, V38, P670, DOI 10.1016/S0010-9452(08)70034-0; MCCARTHY RA, 1992, NEUROPSYCHOLOGIA, V30, P633, DOI 10.1016/0028-3932(92)90068-W; Miller LA, 2001, NEUROPSYCHOLOGIA, V39, P1037, DOI 10.1016/S0028-3932(01)00041-0; OCONNOR M, 1992, J CLIN EXP NEUROPSYC, V14, P159, DOI 10.1080/01688639208402821; Peru A, 1997, BRAIN COGNITION, V33, P278, DOI 10.1006/brcg.1997.0868; Rogers TT, 2002, BRAIN DAM B, P251; Ross SJM, 1997, CORTEX, V33, P733, DOI 10.1016/S0010-9452(08)70730-5; SANDERS H I, 1975, Cortex, V11, P397; Schmidtke K, 1997, NEUROPSYCHOLOGIA, V35, P505, DOI 10.1016/S0028-3932(96)00109-1; Sirigu A, 1996, CORTEX, V32, P83, DOI 10.1016/S0010-9452(96)80018-9; STRACCIARI A, 1994, CORTEX, V30, P459, DOI 10.1016/S0010-9452(13)80341-3; STUSS DT, 1988, BRAIN COGNITION, V8, P348, DOI 10.1016/0278-2626(88)90059-0; STUSS DT, 1988, BRAIN COGNITION, V8, P21, DOI 10.1016/0278-2626(88)90036-X; Takahashi N, 1997, NEUROLOGY, V49, P464, DOI 10.1212/WNL.49.2.464; Verfaellie M, 1995, J Int Neuropsychol Soc, V1, P443; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; WILSON SJ, 1999, MUSIC MED MUSIC THER, P47; Yasuda K, 1997, CORTEX, V33, P623, DOI 10.1016/S0010-9452(08)70721-4	64	13	13	0	3	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1355-4794	1465-3656		NEUROCASE	Neurocase	DEC	2003	9	6					504	514		10.1076/neur.9.6.504.29375			11	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	754HC	WOS:000187309200004	16210232				2021-06-18	
J	Wilson, FC; Manly, T				Wilson, FC; Manly, T			Sustained attention training and errorless learning facilitates self-care functioning in chronic ipsilesional neglect following severe traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							UNILATERAL LEFT NEGLECT; REHABILITATION; ACTIVATION; RECOVERY; PATTERNS; HAND; HEMIPLEGIA	Limb activation studies involving contralesional spatiomotor cueing document a reduction of neglect for left space (Robertson & North, 1992, 1993, 1994; Samuel et al., 2000). A number of studies applying this approach have produced positive findings (Robertson, Hogg, McMillan, 1998; Robertson, North, Geggie, 1992; Robertson, McMillan, MacLeod, Edgeworth, Brock, 2002; Samuel et al., 2000). An alternative theoretical approach which aims to facilitate spatial awareness via the modulation of non-lateralised deficits in sustained attention/arousal (Robertson et al., 1997; Samuelsson et al., 1998) has also shown promising results (Robertson et al., 1995; Wilson, Manly, Coyle, & Robertson, 2000) in terms of improved contralesional unilateral neglect as well as activities of daily living.	Green Pk Healthcare Trust, Joss Cardwell Ctr, Belfast BT4 2LS, Antrim, North Ireland; MRC, Cognit & Brain Sci Unit, Cambridge, England	Wilson, FC (corresponding author), Green Pk Healthcare Trust, Joss Cardwell Ctr, 401 Holywood Rd, Belfast BT4 2LS, Antrim, North Ireland.	f.colinwilson@btopenworld.com					ANTONUCCI G, 1995, J CLIN EXP NEUROPSYC, V17, P383, DOI 10.1080/01688639508405131; Beschin N, 1997, CORTEX, V33, P379, DOI 10.1016/S0010-9452(08)70013-3; BLANCGARIN J, 1994, NEUROPSYCHOL REHABIL, V4, P359, DOI 10.1080/09602019408401606; BRADSHAW JL, 1995, CLIN NEUROPSYCHOLOGY, P124; DENES G, 1982, BRAIN, V105, P543, DOI 10.1093/brain/105.3.543; Edgeworth J. A., 1998, BALLOONS TEST; Eskes GA, 2003, ARCH PHYS MED REHAB, V84, P323, DOI 10.1053/apmr.2003.50012; GIALANELLA B, 1992, NEUROPSYCHOL REHABIL, V2, P169, DOI DOI 10.1080/09602019208401406; Gottman J. M., 1978, SINGLE SUBJECT RES S, P197; Kerkhoff G, 2003, PROG BRAIN RES, V142, P255; Kinsella G, 1985, Int Rehabil Med, V7, P102; KINSELLA G, 1980, MED J AUSTRALIA, V2, P663; Maguire AM, 2002, NEUROPSYCHOLOGIA, V40, P879, DOI 10.1016/S0028-3932(01)00169-5; Mahoney F. I., 1965, MD STATE MED J, V14, P62; McIntosh RD, 2000, CORTEX, V36, P289, DOI 10.1016/S0010-9452(08)70530-6; McIntosh RD, 2002, CORTEX, V38, P309, DOI 10.1016/S0010-9452(08)70662-2; POSNER MI, 1993, ATTENTION SELECTION, P390; Robertson I. H., 1994, TEST EVERYDAY ATTENT; ROBERTSON IH, 1993, NEUROPSYCHOLOGIA, V31, P293, DOI 10.1016/0028-3932(93)90093-F; ROBERTSON IH, 1992, J NEUROL NEUROSUR PS, V55, P799, DOI 10.1136/jnnp.55.9.799; ROBERTSON IH, 1992, NEUROPSYCHOLOGIA, V30, P553, DOI 10.1016/0028-3932(92)90058-T; ROBERTSON IH, 1994, NEUROPSYCHOLOGIA, V32, P1, DOI 10.1016/0028-3932(94)90064-7; ROBERTSON IH, 1995, J CLIN EXP NEUROPSYC, V17, P416, DOI 10.1080/01688639508405133; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P1527, DOI 10.1016/S0028-3932(97)00084-5; Robertson IH, 1998, NATURE, V395, P169, DOI 10.1038/25993; Robertson IH, 1998, NEUROPSYCHOL REHABIL, V8, P19, DOI 10.1080/713755556; Robertson IH, 2002, NEUROPSYCHOL REHABIL, V12, P439, DOI 10.1080/09602010244000228; ROBERTSON IH, 1994, NEUROPSYCHOLOGIA, V32, P1495, DOI 10.1016/0028-3932(94)90121-X; Robertson IH, 1999, SPATIAL NEGLECT CLIN; Rossetti Y, 1998, NATURE, V395, P166, DOI 10.1038/25988; Samuel C, 2000, NEUROPSYCHOL REHABIL, V10, P385, DOI 10.1080/096020100411970; Samuelsson H, 1998, J CLIN EXP NEUROPSYC, V20, P73, DOI 10.1076/jcen.20.1.73.1481; SEA MJC, 1993, ARCH PHYS MED REHAB, V74, P355; SHEIL A, 1990, CLIN REHABIL, V4, P173; Tham K, 1996, NEUROPSYCHOL REHABIL, V6, P19, DOI 10.1080/713755496; Vallar G., 1993, UNILATERAL NEGLECT C, P27; WEBSTER JS, 1984, BEHAV THER, V15, P129, DOI 10.1016/S0005-7894(84)80015-5; WEINBERG J, 1977, ARCH PHYS MED REHAB, V58, P479; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8; Wilson B., 1987, BEHAV INATTENTION TE; Wilson FC, 2000, RESTOR NEUROL NEUROS, V16, P1	41	13	13	0	12	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	DEC	2003	13	5					537	548		10.1080/09602010343000200			12	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	742PB	WOS:000186525500003					2021-06-18	
J	Bono, CM; Sirkin, M; Sabatino, CT; Reilly, MC; Tarkin, I; Behrens, FF				Bono, CM; Sirkin, M; Sabatino, CT; Reilly, MC; Tarkin, I; Behrens, FF			Neurovascular and tendinous damage with placement of anteroposterior distal locking bolts in the tibia	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						tibia; nail; neurovascular injury; tendon injury; distal locking		Objective: To determine the proximity of anteroposterior locking bolts inserted into the distal metaphyseal tibia to nearby neural, vascular, and tendinous structures. Design: A cadaver study. Setting: University trauma center. Methods: Sixteen legs (8 matched pairs) were nailed in either neutral (Group 1) or 10degrees of internal rotation (Group 2) and locked using one anteroposterior bolt. The anterior tibial and extensor hallucis longus tendons and neurovascular bundle were identified, and their respective locations in relation to the bolt head were measured. Average distances were calculated for each structure in each group and statistically compared. Damage to any structure was noted at final dissection. Results: Average distances from the bolt head to the neurovascular bundle, extensor hallucis longus, and anterior tibial tendons were 0.6, 0.5, and 1.6 mm, respectively, for Group 1 and 1.0, 1.5, and 1.8 mm, respectively, for Group 2 legs. Statistical comparison of distances for each anatomic entity for the two groups revealed no detectable significant differences (P = 0.7, 0.4, 0.7, respectively). For all specimens, the rate of nerve, artery, extensor hallucis longus, and anterior tibial tendon injury was 25%, 19%, 0%, and 6%, respectively. However, the incidence of at least one structure damage in Group I legs was 63% versus 12% in Group 2 specimens (P = 0.2). Conclusion: Anteroposterior distal tibial locking bolts lie in close proximity to the neurovascular bundle. With standard percutaneous techniques, these structures can be damaged. Although 10degrees of internal rotation does not statistically affect the measured distance of the locking bolt to the neurovascular bundle, it appears to decrease the incidence of neurovascular injury. This difference may best be explained by the necessary path the drill bit must take through the soft tissues to reach the underlying bone. Regardless of nail orientation, larger incisions with careful dissection and clear visualization of the anatomy are recommended to help prevent this complication.	Boston Univ, Med Ctr, Sch Med, Dept Orthopaed Surg, Boston, MA 02118 USA; Univ Nebraska, Med Ctr, Dept Orthopaed Surg, Omaha, NE USA; Univ Med & Dent New Jersey, Dept Orthopaed Surg, Newark, NJ USA	Bono, CM (corresponding author), Boston Univ, Med Ctr, Sch Med, Dept Orthopaed Surg, Dowling 2 N,1 Boston Med Ctr Pl, Boston, MA 02118 USA.	bonocm@prodigy.net					Bonnevialle P, 1996, REV CHIR ORTHOP, V82, P428; Chen A L, 2001, Bull Hosp Jt Dis, V60, P80; Ebraheim NA, 1998, SURG RADIOL ANAT, V20, P259, DOI 10.1007/BF01628486; FREEDMAN EL, 1995, CLIN ORTHOP RELAT R, V315, P25; HENLEY MB, 1993, J ORTHOP TRAUMA, V7, P311, DOI 10.1097/00005131-199308000-00003; Koval K J, 1991, J Orthop Trauma, V5, P184, DOI 10.1097/00005131-199105020-00011; Krettek C, 1999, J ORTHOP TRAUMA, V13, P550, DOI 10.1097/00005131-199911000-00006; Mosheiff R, 1999, INJURY, V30, P83, DOI 10.1016/S0020-1383(98)00213-7; Richter D, 1997, LANGENG ARC, VSUPPL, P1259; Roberts CS, 1999, J ORTHOP TRAUMA, V13, P27, DOI 10.1097/00005131-199901000-00007; URBAN WP, 1995, J TRAUMA, V38, P804, DOI 10.1097/00005373-199505000-00022; WILLIAMS J, 1995, J ORTHOP TRAUMA, V9, P476, DOI 10.1097/00005131-199509060-00004; WILLIAMSON DM, 1989, INJURY, V20, P310, DOI 10.1016/0020-1383(89)90181-2	13	13	14	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0890-5339	1531-2291		J ORTHOP TRAUMA	J. Orthop. Trauma	NOV-DEC	2003	17	10					677	682		10.1097/00005131-200311000-00003			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	742VJ	WOS:000186538500003	14600566				2021-06-18	
J	Cui, FZ; Tian, WM; Fan, YW; Hou, SP; Xu, QY; Lee, IS				Cui, FZ; Tian, WM; Fan, YW; Hou, SP; Xu, QY; Lee, IS			Cerebrum repair with PHPMA hydrogel immobilized with neurite-promoting peptides in traumatic brain injury of adult rat model	JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS			English	Article						CNS repair; peptide immobilization; hydrogel; angiogenesis	CELL-BINDING SEQUENCES; AXONAL REGENERATION; SCHWANN-CELLS; A-CHAIN; LAMININ; IDENTIFICATION; EXPRESSION; OUTGROWTH; GROWTH; EXTENSION	A poly[N-(2-hydroxypropyl) methacrylamidel (PHPMA) hydrogel immobilized with the neurite-promoting peptide sequence of xIKVAVx was synthesized and its structure was characterized. The PHPMA-IKVAV hydrogel displayed an interconnected porous structure. The ability of the hydrogel to support axonal outgrowth in the injured adult rats cerebrum cavity and to promote tissue regeneration was evaluated. After implantation for 4, 6, 12 and 18 weeks, the brain sections were processed for histological staining. The observations of the sections showed that the polymer hydrogel provided a structural, three-dimensional continuity across the defect and favoured reorganization of local wound-repair cells, angiogenesis and axonal growth into the hydrogel scaffold. Compared with the unmodified PHPMA hydrogel, the PHPMA-IKVAV hydrogel displayed greater ability to repair tissue defects in the cerebrum nervous system.	Tsinghua Univ, Dept Mat Sci & Engn, Biomat Lab, Beijing 100084, Peoples R China; Capital Univ Med Sci, Beijing Inst Neurosci, Beijing 100054, Peoples R China; Yonsei Univ, Atom Scale Surface Sci Res Ctr, Seoul 120749, South Korea	Cui, FZ (corresponding author), Tsinghua Univ, Dept Mat Sci & Engn, Biomat Lab, Beijing 100084, Peoples R China.	cuifz@mail.tsinghua.edu.cn	Fan, Yuwei/A-2951-2009	Fan, Yuwei/0000-0001-8477-8458; Tian, Weiming/0000-0003-4958-4118			BARKER RA, 1999, NEUROPSY REHABIL MOD, P1; Bartsch U, 1996, J NEUROCYTOL, V25, P303, DOI 10.1007/BF02284804; BELLAMKONDA R, 1995, J NEUROSCI RES, V41, P501, DOI 10.1002/jnr.490410409; Chamberlain LJ, 1998, EXP NEUROL, V154, P315, DOI 10.1006/exnr.1998.6955; COLTON CK, 1995, CELL TRANSPLANT, V4, P415, DOI 10.1016/0963-6897(95)00025-S; Dillon GP, 1998, J BIOMAT SCI-POLYM E, V9, P1049, DOI 10.1163/156856298X00325; Dubey N, 2001, BIOMATERIALS, V22, P1065, DOI 10.1016/S0142-9612(00)00341-0; FAWCETT JW, 1989, DEV BIOL, V135, P449, DOI 10.1016/0012-1606(89)90193-0; Gao J, 1998, MICROSC RES TECHNIQ, V41, P323, DOI 10.1002/(SICI)1097-0029(19980515)41:4<323::AID-JEMT5>3.0.CO;2-R; Goldberg JL, 1998, CURR BIOL, V8, pR310, DOI 10.1016/S0960-9822(98)70195-2; Gong HP, 2000, J BIOMED MATER RES, V52, P285; HEARN MTW, 1987, METHOD ENZYMOL, V135, P102; Herbert CB, 1998, J BIOMED MATER RES, V40, P551, DOI 10.1002/(SICI)1097-4636(19980615)40:4<551::AID-JBM6>3.0.CO;2-E; Iivanainen A, 1999, J BIOL CHEM, V274, P14107, DOI 10.1074/jbc.274.20.14107; Imaizumi T, 2000, BRAIN RES, V854, P70, DOI 10.1016/S0006-8993(99)02285-4; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KOPECEK J, 1973, EUR POLYM J, V9, P7, DOI 10.1016/0014-3057(73)90063-3; KREWSON CE, 1986, BIOTECHNOL ENG, V43, P555; LIUZZI FJ, 1987, SCIENCE, V237, P642, DOI 10.1126/science.3603044; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Nomizu M, 1997, J BIOL CHEM, V272, P32198, DOI 10.1074/jbc.272.51.32198; Nomizu M, 1998, J BIOL CHEM, V273, P32491, DOI 10.1074/jbc.273.49.32491; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Nomizu M, 2000, ARCH BIOCHEM BIOPHYS, V378, P311, DOI 10.1006/abbi.2000.1828; NOVOTNY E, 1974, STAIN TECHNOL, V49, P273, DOI 10.3109/10520297409116993; Plant GW, 1997, EXP NEUROL, V143, P287, DOI 10.1006/exnr.1997.6407; PLANT GW, 1995, BRAIN RES, V671, P119, DOI 10.1016/0006-8993(94)01312-6; RUDGE JS, 1990, J NEUROSCI, V10, P3594; SCHWAB ME, 1991, PHILOS T ROY SOC B, V331, P303, DOI 10.1098/rstb.1991.0021; Spilker MH, 2001, RESTOR NEUROL NEUROS, V18, P23; STICHEL CC, 1994, J NEUROCYTOL, V23, P615, DOI 10.1007/BF01191556; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; Tate MC, 2001, BIOMATERIALS, V22, P1113, DOI 10.1016/S0142-9612(00)00348-3; TOMASELLI KJ, 1988, NEURON, V1, P33, DOI 10.1016/0896-6273(88)90207-3; Woerly S, 1998, J BIOMAT SCI-POLYM E, V9, P681, DOI 10.1163/156856298X00091; Woerly S, 2001, BIOMATERIALS, V22, P1095, DOI 10.1016/S0142-9612(00)00354-9; WOERLY S, 1990, BIOMATERIALS, V11, P97, DOI 10.1016/0142-9612(90)90123-8; WOERLY S, 1999, Patent No. 5863551	38	13	13	1	14	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0883-9115	1530-8030		J BIOACT COMPAT POL	J. Bioact. Compat. Polym.	NOV	2003	18	6					413	432		10.1177/0883911503040470			20	Biotechnology & Applied Microbiology; Materials Science, Biomaterials; Polymer Science	Biotechnology & Applied Microbiology; Materials Science; Polymer Science	767FP	WOS:000188429800001					2021-06-18	
J	Hess, DW; Marwitz, JH; Kreutzer, JS				Hess, DW; Marwitz, JH; Kreutzer, JS			Neuropsychological impairments after spinal cord injury: A comparative study with mild traumatic brain injury	REHABILITATION PSYCHOLOGY			English	Article							MINOR HEAD-INJURY; DEFICITS; CONCUSSION; LONG; RECOVERY; SEQUELAE; SYMPTOMS; HISTORY; SYSTEMS; TASK	To determine if individuals with mild traumatic brain injury (MTBI) perform differently on neuropsychological measures than individuals with spinal cord injury (SCI) having no loss of consciousness. Design and Participants: Data were collected prospectively on 33 matched pairs of individuals with SCI or MTBI. Independent t tests were performed to identify differences between the SCI and MTBI groups. Results: Although those with SCI generally outperformed individuals with MTBI, no meaningful between-groups differences were noted on 5 of the 10 neuropsychological tests administered. Greater than 40% of the SCI patients were identified as having impairments in processing speed, motor speed, and verbal learning. Conclusions: Treatment planning after SCI should include procedures to identify cognitive deficits that may complicate adjustment to disability and delay acquisition of new skills.	Virginia Commonwealth Univ, Hlth Syst, Dept Phys Med & Rehabil, Richmond, VA 23298 USA	Hess, DW (corresponding author), Virginia Commonwealth Univ, Hlth Syst, Dept Phys Med & Rehabil, Box 980661, Richmond, VA 23298 USA.	dwhess@vcu.edu					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; BERNSTEIN DM, 1996, J INT NEUROPSYCH SOC, V2, P18; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P41; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dowler R N, 1995, Appl Neuropsychol, V2, P124, DOI 10.1207/s15324826an0203&4_4; Dowler RN, 1997, J INT NEUROPSYCH SOC, V3, P464, DOI 10.1017/S1355617797004645; Elovic E, 1999, TOP SPINAL CORD INJ, V5, P1, DOI DOI 10.1310/V75J-RE76-20GH-X7BY; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Kreutzer J., 1987, GEN HLTH HIST QUESTI; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Nobunaga AI, 1999, ARCH PHYS MED REHAB, V80, P1372, DOI 10.1016/S0003-9993(99)90247-2; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; RICHARDS JS, 1991, ARCH PHYS MED REHAB, V72, P275; Ricker J.H., 1999, TOP SPINAL CORD INJ, V5, P76; Rosenthal M, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P49, DOI 10.1037/10361-003; SABOE LA, 1991, J TRAUMA, V31, P43, DOI 10.1097/00005373-199101000-00010; SCHMIDT M, 1999, REY AUDITORY VERBAL; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; Steudel W I, 1988, Acta Neurochir Suppl (Wien), V43, P85; Stover SL, 1999, ARCH PHYS MED REHAB, V80, P1365, DOI 10.1016/S0003-9993(99)90246-0; STOVER SL, 1986, SPINAL CORD INJURY F; Stutts M, 1991, NEUROREHABILITATION, V1; Trieschmann R.B., 1988, SPINAL CORD INJURIES, V2nd edition; Wechsler D., 1987, WECHSLER MEMORY SCAL; WEHMAN P, 2000, TRAUMATIC BRAIN INJU, P201	44	13	15	0	5	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2003	48	3					151	156		10.1037/0090-5550.48.3.151			6	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	717FY	WOS:000185077900004					2021-06-18	
J	Bell, B; Dow, C; Watson, ER; Woodard, A; Hermann, B; Seidenberg, M				Bell, B; Dow, C; Watson, ER; Woodard, A; Hermann, B; Seidenberg, M			Narrative and procedural discourse in temporal lobe epilepsy	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						temporal lobe epilepsy; discourse; language; speech; complex partial seizures	TRAUMATIC BRAIN INJURY; INTERICTAL EPILEPTIFORM DISCHARGES; QUALITY-OF-LIFE; LANGUAGE FUNCTION; SEIZURE ONSET; SCALP EEG; FOLLOW-UP; LOBECTOMY; DEFICITS; MEMORY	It is well established that some individuals with temporal lobe epilepsy (TLE) demonstrate language deficits at the single word level. However, discourse production rarely has been examined quantitatively within this group. This study compared adult TLE patients with an early seizure onset (less than or equal to age 14 years, n = 27) to a control group (n = 28) on narrative and procedural discourse tasks. As a group, the TLE patients performed normally on the procedural discourse task, but differed significantly from the controls on several narrative discourse variables. At the individual level, 30% of the TLE patients versus 4% of the controls demonstrated impaired discourse ability (p < .01). Within this early onset TLE group, discourse performance was not associated with demographic or seizure history variables. Considering the cognitive domain, discourse performance correlated significantly with working memory. In summary, mild discourse dysfunction was present in a significant minority of early onset TLE patients, but this deficit was not closely associated with other language measures. Discourse ability and its neuropsychological, neuroanatomical and conversational speech correlates deserve further study in TLE patients.	Univ Wisconsin, Dept Neurol, Madison, WI 53792 USA; Finch Univ Hlth Sci Chicago Med Sch, Dept Psychol, Chicago, IL USA; Chicago Med Sch, Madison, WI 53792 USA	Bell, B (corresponding author), Univ Wisconsin, Dept Neurol, 600 Highland Ave, Madison, WI 53792 USA.				NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR003186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037738, K23NS042251] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [MO1 RR03186] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS37738, NS42251] Funding Source: Medline		Beck A., 1987, MANUAL BECK DEPRESSI; Bell BD, 2001, NEUROPSYCHOLOGY, V15, P434, DOI 10.1037//0894-4105.15.4.434; Benton A., 1994, MULTILINGUAL APHASIA; Benton A. L., 1994, CONTRIBUTIONS NEUROP; Body R, 1998, BRAIN INJURY, V12, P963, DOI 10.1080/026990598122016; Breier JI, 1997, J CLIN EXP NEUROPSYC, V19, P161, DOI 10.1080/01688639708403847; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; CAMFIELD PR, 1984, ANN NEUROL, V15, P122, DOI 10.1002/ana.410150203; CAPLAN R, 1993, J AM ACAD CHILD PSY, V32, P604, DOI 10.1097/00004583-199305000-00017; Caplan R, 2001, BRAIN LANG, V78, P82, DOI 10.1006/brln.2000.2447; Cascino GD, 1996, EPILEPSIA, V37, P651, DOI 10.1111/j.1528-1157.1996.tb00629.x; CHELUNE GJ, 1991, NEUROLOGY, V41, P399, DOI 10.1212/WNL.41.3.399; COEHLO CA, 1995, BRAIN INJURY, V9, P471; COOPER PV, 1990, J GERONTOL B-PSYCHOL, V45, P210; DANEMAN M, 1991, J PSYCHOLINGUIST RES, V20, P445, DOI 10.1007/BF01067637; DAVENPORT L, 1986, J CLIN EXP NEUROPSYC, V8, P347, DOI 10.1080/01688638608401326; Davies KG, 1999, EPILEPSY RES, V33, P117, DOI 10.1016/S0920-1211(98)00081-3; DAVIES KG, 1995, EPILEPSIA, V36, P130, DOI 10.1111/j.1528-1157.1995.tb00971.x; DEVINSKY O, 1995, EPILEPSIA, V36, P1089, DOI 10.1111/j.1528-1157.1995.tb00467.x; DIKMEN S, 1977, EPILEPSIA, V18, P31, DOI 10.1111/j.1528-1157.1977.tb05584.x; DIKMEN S, 1987, NEUROBEHAVIORAL RECO, P73; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; Engel J, 1996, EPILEPSY RES, V26, P141, DOI 10.1016/S0920-1211(96)00043-5; Ergene E, 2000, EPILEPSIA, V41, P213, DOI 10.1111/j.1528-1157.2000.tb00142.x; Field SJ, 2000, BRAIN LANG, V74, P213, DOI 10.1006/brln.2000.2335; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Glosser G, 1997, J Int Neuropsychol Soc, V3, P252; Glosser G., 1990, BRAIN LANG, V40, P67; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; Halliday M. A., 1976, COHESION SPOKEN WRIT; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HEATON RK, 1978, PSYCHOL BULL, V85, P141, DOI 10.1037/0033-2909.85.1.141; Hermann B, 2002, EPILEPSIA, V43, P1062, DOI 10.1046/j.1528-1157.2002.49901.x; Hermann BP, 1997, ARCH NEUROL-CHICAGO, V54, P369, DOI 10.1001/archneur.1997.00550160019010; HERMANN BP, 1988, ANN NEUROL, V23, P585, DOI 10.1002/ana.410230610; HIRSCH LJ, 1991, ANN NEUROL, V30, P340, DOI 10.1002/ana.410300305; HOEPPNER JB, 1987, EPILEPSIA, V28, P35, DOI 10.1111/j.1528-1157.1987.tb03619.x; HOWELL RA, 1994, CORTEX, V30, P469, DOI 10.1016/S0010-9452(13)80342-5; KING D, 1995, EPILEPSIA, V36, P905, DOI 10.1111/j.1528-1157.1995.tb01634.x; Kongs SK, 2000, WISCONSIN CARD SORTI; KUZNIECKY R, 1991, EPILEPSIA, V232, P335; *LAF INSTR CO, PURD PEGB TEST; Langfitt JT, 1996, ARCH NEUROL-CHICAGO, V53, P72, DOI 10.1001/archneur.1996.00550010090021; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; Loban W., 1976, 18 NAT COUNC TEACH E; Marsh L, 1997, EPILEPSIA, V38, P576, DOI 10.1111/j.1528-1157.1997.tb01143.x; Maton B, 2001, EPILEPSIA, V42, P417, DOI 10.1046/j.1528-1157.2001.25999.x; MAYEUX R, 1980, NEUROLOGY, V30, P120, DOI 10.1212/WNL.30.2.120; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Pilgrim B, 2000, APPL NEUROPSYCHOL, V6, P243; Reitan RM, 1979, MANUAL ADM NEUROPSYC; SAYKIN AJ, 1995, EPILEPSIA, V36, P1071, DOI 10.1111/j.1528-1157.1995.tb00464.x; SAYKIN AJ, 1991, ARCH GEN PSYCHIAT, V48, P618; Schwartz TH, 1998, J NEUROSURG, V89, P962, DOI 10.3171/jns.1998.89.6.0962; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Snow P, 1997, BRAIN INJURY, V11, P409; STEINHOFF BJ, 1995, NEUROLOGY, V45, P889, DOI 10.1212/WNL.45.5.889; Strauss E, 1995, J CLIN EXP NEUROPSYC, V17, P909, DOI 10.1080/01688639508402439; Ulatowska H.K., 1990, DISCOURSE ABILITY BR, P180, DOI [10.1007/978-1-4612-3262-9_8, DOI 10.1007/978-1-4612-3262-9_8]; Vasconcellos E, 2001, EPILEPSIA, V42, P268; WARD LC, 1987, J CLIN PSYCHOL, V43, P276, DOI 10.1002/1097-4679(198703)43:2<276::AID-JCLP2270430219>3.0.CO;2-U; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; WEINAND ME, 1992, J NEUROSURG, V77, P20, DOI 10.3171/jns.1992.77.1.0020; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; YORKSTON KM, 1980, J SPEECH HEAR DISORD, V45, P27, DOI 10.1044/jshd.4501.27	66	13	14	0	4	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4221 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2003	9	5					733	739		10.1017/S1355617703950065			7	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	694AK	WOS:000183750400006	12901779				2021-06-18	
J	Armstead, WM				Armstead, WM			Cyclooxygenase-2-dependent superoxide generation contributes to age-dependent impairment of G protein-mediated cerebrovasodilation	ANESTHESIOLOGY			English	Article							TRAUMATIC BRAIN INJURY; K-ATP; CEREBRAL-CORTEX; ACTIVATION; RAT; EXPRESSION; NEURONS; COX-2; MASTOPARAN; RESPONSES	Background: Previous studies have observed that activation of cyclooxygenase-2 contributes to generation of superoxide anion after fluid percussion brain injury (FPI). This study was designed to characterize the effects of FPI on the vascular activity of two activators of a pertussis toxin-sensitive G protein, mastoparan and mastoparan-7, and the role of cyclooxygenase-2-dependent superoxide anion generation in such effects as a function of age. Methods: Lateral FPI was induced in anesthetized newborn (1-5-day-old) and juvenile (3-4-week-old) pigs equipped with a closed cranial window. Results: Mastoparan (10(-8), 10(-6) M) elicited pial artery dilation that was blunted more in newborn versus juvenile pigs (9 +/- 1 and 16 +/- 1 vs. 3 +/- 1 and 5 +/- 1%, newborn; 9 +/- 1 and 15 +/- 1 vs. 6 +/- 1 and 9 +/- 1%, juveniles). similar results were observed for mastoparan-7 but the inactive analog mastoparan-17 had no effect on pial artery diameter. Indomethacin (a cyclooxygenase-1 and cyclooxygenase-2 inhibitor), NS398 (a cyclooxygenase-2 inhibitor), and polyethylene glycol superoxide dismutase and catalase (free radical scavengers) partially restored impaired mastoparan dilation after FPI in the newborn in a roughly equivalent manner but not in the juvenile (3 1 and 5 +/- 1 vs. 8 +/- 1 and 13 +/- 1% newborn, 6 +/- 1 and 9 +/- 1 vs. 7 +/- 1 and 10 +/- 1% juvenile for NS398 pretreatment). Conclusions: These data show that G protein activation elicits cerebrovasodilation that is blunted following FPI in an age-dependent manner, and suggest that cyclooxygenase-2-dependent superoxide anion generation contributes to G protein activation-induced dilator impairment after the insult in an age-dependent manner.	Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	Armstead, WM (corresponding author), Univ Penn, Dept Anesthesia, 3400 Spruce St, Philadelphia, PA 19104 USA.						Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH1272; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 2002, BRAIN RES, V957, P369, DOI 10.1016/S0006-8993(02)03698-3; Armstead WM, 1999, BRAIN RES, V816, P158, DOI 10.1016/S0006-8993(98)01146-9; Armstead WM, 1999, J NEUROTRAUM, V16, P391, DOI 10.1089/neu.1999.16.391; ARMSTEAD WM, 1999, AM J PHYSIOL, V274, pH1888; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Dobbing J, 1981, SCI F PAEDIATRICS, P744; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; Gong C, 2001, BRAIN RES, V901, P38, DOI 10.1016/S0006-8993(01)02186-2; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; KLINKER JF, 1994, BIOCHEM J, V304, P377, DOI 10.1042/bj3040377; Klinker JF, 1996, BIOCHEM PHARMACOL, V51, P217, DOI 10.1016/0006-2952(95)02119-1; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kulkarni M, 2002, J NEUROTRAUM, V19, P965, DOI 10.1089/089771502320317113; Kulkarni M, 2000, STROKE, V31, P1990, DOI 10.1161/01.STR.31.8.1990; Lapchak PA, 2001, STROKE, V32, P1220, DOI 10.1161/01.STR.32.5.1220; Leffler CW, 1993, REGULATION CEREBRAL, P297; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Niwa K, 2001, CIRC RES, V88, P600, DOI 10.1161/01.RES.88.6.600; Niwa K, 2000, J NEUROSCI, V20, P763, DOI 10.1523/JNEUROSCI.20-02-00763.2000; Resnick DK, 1998, J NEUROTRAUM, V15, P1005, DOI 10.1089/neu.1998.15.1005; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P625, DOI 10.1001/archpedi.1990.02150300019014; Sairanen T, 1998, ANN NEUROL, V43, P738, DOI 10.1002/ana.410430608; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Tepas J J 3rd, 1995, Semin Pediatr Surg, V4, P120; Thorogood MC, 1996, ANESTHESIOLOGY, V84, P614, DOI 10.1097/00000542-199603000-00017; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	37	13	13	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	JUN	2003	98	6					1378	1383		10.1097/00000542-200306000-00012			6	Anesthesiology	Anesthesiology	682DE	WOS:000183075400011	12766646				2021-06-18	
J	Butterwick, DJ; Meeuwisse, WH				Butterwick, DJ; Meeuwisse, WH			Bull riding injuries in professional rodeo - Data for prevention and care	PHYSICIAN AND SPORTSMEDICINE			English	Article							EPIDEMIOLOGIC ANALYSIS	BACKGROUND: Recent tragedies in bull riding have highlighted the need for prospective epidemiologic investigation of injury patterns. OBJECTIVE: To document the frequency, type, severity, anatomic location, and mechanism of injury to bull riders participating in professional rodeo in Canada. DESIGN: Five-year prospective cohort study examining 4,375 competitor exposures during bull riding events at selected rodeos. Certified athletic therapists gathered data at 63 of 323 professional rodeos in Canada from 1995 through 1999. Data were included when a registered bull rider was injured and the Canadian Pro Rodeo Sport Medicine Team was officially present and providing services. The main outcome measures were the frequency, severity, and anatomic location of injuries to bull riders. RESULTS: According to the injury classification system (severe, minor, or other), 36% of injuries to bull riders were severe. Fractures were the most common severe injury. Concussions constituted 10.6% of all injuries; neck injuries and concussion with other head and facial injuries accounted for 28.9%. About half (48%) of injuries were minor. The knee and shoulder were the most commonly injured joints. CONCLUSION: Injuries to the head, neck, and face may deserve more attention by both researchers and those interested in preventing injury to bull riders. Epidemiologic information will give on-site physicians a better foundation in preparing to care for injured rodeo participants.	Univ Calgary, Fac Kinesiol, Ctr Sports Med, Calgary, AB T2N 1N4, Canada	Butterwick, DJ (corresponding author), Univ Calgary, Fac Kinesiol, Ctr Sports Med, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.						Brandenburg MA, 2002, CLIN J SPORT MED, V12, P360, DOI 10.1097/00042752-200211000-00007; Butterwick DJ, 1996, CLIN J SPORT MED, V6, P171, DOI 10.1097/00042752-199607000-00006; Butterwick DJ, 2002, CLIN J SPORT MED, V12, P30, DOI 10.1097/00042752-200201000-00009; Butterwick DJ, 2002, AM J SPORT MED, V30, P193, DOI 10.1177/03635465020300020801; GRIFFIN R, 1987, Physician and Sportsmedicine, V15, P105; Griffin R, 1983, Phys Sportsmed, V11, P110, DOI 10.1080/00913847.1983.11708608; Ketai LH, 2000, INJURY, V31, P757, DOI 10.1016/S0020-1383(00)00108-X; MEYERS MC, 1990, AM J SPORT MED, V18, P87, DOI 10.1177/036354659001800114; NEBERGALL RW, 1992, PHYSICIAN SPORTSMED, V20, P85, DOI 10.1080/00913847.1992.11947504	9	13	13	0	7	MCGRAW HILL HEALTHCARE PUBLICATIONS	MINNEAPOLIS	4530 WEST 77TH ST, MINNEAPOLIS, MN 55435-5000 USA	0091-3847			PHYSICIAN SPORTSMED	Physician Sportsmed.	JUN	2003	31	6					37	41		10.1080/00913847.2003.11440607			5	Primary Health Care; Orthopedics; Sport Sciences	General & Internal Medicine; Orthopedics; Sport Sciences	686DV	WOS:000183306800007	20086479				2021-06-18	
J	Stierman, KL; Lloyd, KM; De Luca-Pytell, DM; Phillips, LG; Calhoun, KH				Stierman, KL; Lloyd, KM; De Luca-Pytell, DM; Phillips, LG; Calhoun, KH			Treatment and outcome of human bites in the head and neck	OTOLARYNGOLOGY-HEAD AND NECK SURGERY			English	Article; Proceedings Paper	105th Annual Meeting of the American-Academy-of-Otolaryngology-Head-and-Neck-Surgery	SEP 09-14, 2001	DENVER, COLORADO	Amer Acad Otolaryngol Head & Neck Surg			PRIMARY CLOSURE; WOUNDS; MANAGEMENT; FACE; INJURIES	OBJECTIVE., Our goal was to review head and neck human bite injuries for demographic, treatment, and outcome data to identify factors influencing infection. STUDY DESIGN: Retrospective chart review of all human bite injuries (adult and pediatric) over 10 years. SETTING: Tertiary referral medical center. RESULTS: We reviewed 40 human bites (average follow-up, 139 days). Young males were the most common victims, altercation was the most common etiology, and auricular avulsion was the most common injury. Six wounds closed primarily became infected (40%) versus no wound infection with delayed closure. Primary wound closure (P < .01), exposed cartilage (P < .07), and less than 48 hours of intravenous antibiotics. (P < .06) were associated with postoperative infection (P < .01). CONCLUSION: Human bites to the head and neck, especially those with, exposed cartilage, are best, treated with at least 48 hours of intravenous antibiotics and delayed surgical closure (>24 hours postinjury) to prevent infection. SIGNIFICANCE: This information enables the clinician who sees these bite wounds infrequently to understand the treatment associated with avoiding infection.	Univ Texas, Med Branch, Dept Otolaryngol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Div Plast Surg, Galveston, TX 77550 USA	Calhoun, KH (corresponding author), Univ Texas, Med Branch, Dept Otolaryngol, Galveston, TX 77555 USA.						Bunzli WF, 1998, PHARMACOTHERAPY, V18, P227; Burgess L P, 1985, Ear Nose Throat J, V64, P546; CALLAHAM M, 1988, ANN EMERG MED, V17, P1321, DOI 10.1016/S0196-0644(88)80359-7; Chidzonga MM, 1998, S AFR MED J, V88, P150; Donkor P, 1997, J ORAL MAXIL SURG, V55, P479, DOI 10.1016/S0278-2391(97)90695-9; EARLEY MJ, 1984, BRIT J PLAST SURG, V37, P458, DOI 10.1016/0007-1226(84)90130-9; GOLDSTEIN EJC, 1989, J AM ACAD DERMATOL, V21, P1275, DOI 10.1016/S0190-9622(89)70343-1; GRIEGO RD, 1995, J AM ACAD DERMATOL, V33, P1019, DOI 10.1016/0190-9622(95)90296-1; HANER ML, 1975, ANN SURG, V181, P819; HEGGERS JP, 1991, QUANTITATIVE BACTER, P74; Presutti RJ, 1997, POSTGRAD MED, V101, P243, DOI 10.3810/pgm.1997.04.207; RUSKIN JD, 1993, J ORAL MAXIL SURG, V51, P174, DOI 10.1016/S0278-2391(10)80017-5; Ruskin JD, 1997, J ORAL MAXIL SURG, V55, P481, DOI 10.1016/S0278-2391(97)90696-0; Smith PF, 2000, J CLIN PHARM THER, V25, P85; STUCKER FJ, 1990, ARCH OTOLARYNGOL, V116, P789	15	13	13	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0194-5998			OTOLARYNG HEAD NECK	Otolaryngol. Head Neck Surg.	JUN	2003	128	6					795	801		10.1016/S0194-5998(03)00254-7			7	Otorhinolaryngology; Surgery	Otorhinolaryngology; Surgery	694CC	WOS:000183755400005	12825029				2021-06-18	
J	Witta, J; Buzas, B; Cox, BM				Witta, J; Buzas, B; Cox, BM			Traumatic brain injury induces nociceptin/orphanin FQ expression in neurons of the rat cerebral cortex	JOURNAL OF NEUROTRAUMA			English	Article						brain; enkephalin; nociceptin; NOP receptor; ORL-1; orphanin FQ; traumatic injury	ORPHANIN-FQ; OXIDATIVE STRESS; GENE-EXPRESSION; NEUROTROPHIC FACTORS; MICE LACKING; IN-VITRO; RECEPTOR; FQ/NOCICEPTIN; ASTROCYTES; INHIBITION	Nociceptin/orphanin FQ (N/OFQ) is a recently identified opioid-related neuropeptide. Earlier in vitro studies revealed regulation of N/OFQ expression by injury-induced factors, such as ciliary neurotrophic factor, inflammatory cytokines, and reactive oxygen species. We have extended our studies to in vivo experiments investigating the effect of traumatic brain injury on N/OFQ gene expression and peptide levels in the rat brain. Stab wound injury to the rat cerebral cortex led to a significant increase in N/OFQ mRNA levels in the vicinity of the injury, with the largest induction being seen at 24 h post-injury. Quantitative in situ hybridization revealed an almost twofold increase in the number of cells expressing N/OFQ, and the signal intensities within cells were also elevated. Stab wound injury leads to proliferation and hypertrophy of astrocytes, which respond to injury-related factors in vitro by up-regulating N/OFQ expression. However, in vivo N/OFQ co-localized exclusively with the neuronal marker, NeuN, following injury. N/OFQ expression was not detected in caspase-3-positive neurons undergoing apoptosis following injury, and increased N/OFQ expression was spatially more extended than the secondary injury-induced responses, such as astrogliosis and neuronal degeneration. Elevation of N/OFQ immunoreactivity closely followed the increase in N/OFQ gene expression as determined by immunohistochemistry. N/OFQ selectively activates the NOP receptor (ORL-1), but we did not detect parallel changes in levels of NOP receptor mRNA following injury, indicating regulation of the nociceptin system at the peptide and not the receptor level. In summary, a profound and prolonged up-regulation of N/OFQ expression in neurons surrounding a stab wound lesion to cerebral cortex was detected. The function of N/OFQ up-regulation in injury-induced responses in the brain is currently under investigation.	Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA	Cox, BM (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pharmacol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.						Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Armstead WM, 2000, BRAIN RES, V869, P231, DOI 10.1016/S0006-8993(00)02367-2; Buzas B, 1998, J NEUROCHEM, V71, P556; Buzas B, 1999, J NEUROCHEM, V72, P1882, DOI 10.1046/j.1471-4159.1999.0721882.x; Buzas B, 2002, GLIA, V39, P237, DOI 10.1002/glia.10106; Connor M, 1996, BRIT J PHARMACOL, V119, P1614, DOI 10.1111/j.1476-5381.1996.tb16080.x; Connor M, 1996, BRIT J PHARMACOL, V118, P205, DOI 10.1111/j.1476-5381.1996.tb15387.x; FADEN AI, 1985, ANN NEUROL, V17, P386, DOI 10.1002/ana.410170414; Helyes Z, 1997, BRIT J PHARMACOL, V121, P613, DOI 10.1038/sj.bjp.0701209; Jenck F, 1997, P NATL ACAD SCI USA, V94, P14854, DOI 10.1073/pnas.94.26.14854; King M, 1998, BIOCHEM PHARMACOL, V55, P1537, DOI 10.1016/S0006-2952(98)00023-9; Koster A, 1999, P NATL ACAD SCI USA, V96, P10444, DOI 10.1073/pnas.96.18.10444; Laudenbach V, 2001, J CLIN INVEST, V107, P457, DOI 10.1172/JCI9716; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lou LG, 1998, J NEUROCHEM, V70, P1316; Love S, 1999, BRAIN PATHOL, V9, P119; Manabe T, 1998, NATURE, V394, P577; Matthes H, 1996, MOL PHARMACOL, V50, P447; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Mogil JS, 2001, PHARMACOL REV, V53, P381; Nishi M, 1997, EMBO J, V16, P1858, DOI 10.1093/emboj/16.8.1858; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Rosenberger J, 2001, J NEUROCHEM, V79, P35, DOI 10.1046/j.1471-4159.2001.00520.x; Serhan CN, 2001, J IMMUNOL, V166, P3650, DOI 10.4049/jimmunol.166.6.3650; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Van Bree L, 1999, NEUROREPORT, V10, P2993, DOI 10.1097/00001756-199909290-00022; Vaughan CW, 1997, J PHYSIOL-LONDON, V498, P463, DOI 10.1113/jphysiol.1997.sp021872	29	13	13	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2003	20	6					523	532		10.1089/089771503767168456			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	697DL	WOS:000183926900001	12906737				2021-06-18	
J	Othman, MM; Klueber, KM; Roisen, FJ				Othman, MM; Klueber, KM; Roisen, FJ			Identification and culture of olfactory neural progenitors from GFP mice	BIOTECHNIC & HISTOCHEMISTRY			English	Article						GFP mouse; green fluorescent protein; olfactory epithelium; progenitors; stem cells	GREEN FLUORESCENT PROTEIN; EPITHELIUM IN-VITRO; GLOBOSE BASAL-CELLS; NERVE GROWTH-FACTOR; CNS STEM-CELLS; ADULT-MOUSE; SENSORY NEURONS; TRANSGENIC MICE; SPINAL-CORD; RECEPTOR NEURONS	The olfactory epithelium (OE) is one of the best sources for obtaining adult stem cells from the nervous system, because it contains neural progenitors that regenerate continuously throughout life. The OE is accessible through the nasal cavity, which facilitates stem cell harvest for examination and transplantation. The mitotic activity of CE progenitors can be stimulated by intranasal irrigation with zinc sulfate (ZnSO4). In the study reported here, we focused on OE from a transgenic mouse line transfected with green fluorescent protein (GFP). Histological examination demonstrated the site of highest yield of CE in the transgenic and wild type littermates. Cultures were established from that site four days in vitro following ZnSO4 exposure. The GFP-derived primary cultures contained a heterogeneous population of fluorescent cells. After 10-12 days, a population of round, mitotically active cells emerged that formed fluorescent neurospheres. The neurosphere forming cells (NSFCs) were collected and subcultured up to four times. The NSFCs were primarily neuronal with only a few cells of glial lineage. Furthermore, the NSFCs were nestin positive and keratin negative, suggesting that they were neural progenitors. The endogenous GFP fluorescence of these cells provides a readily identifiable label that will facilitate their identification following transplantation into nontransfected hosts. They should provide a useful model for evaluating the potential therapeutic utility of OE progenitors in neurodegenerative diseases and neurotrauma repair.	Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA	Roisen, FJ (corresponding author), Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA.	fjrois01@gwise.louisville.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [1920RR15576] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015576] Funding Source: NIH RePORTER		ALBERTS JR, 1971, PHYSIOL BEHAV, V6, P619, DOI 10.1016/0031-9384(71)90218-6; ALLISON AC, 1953, BIOL REV, V28, P195, DOI 10.1111/j.1469-185X.1953.tb01376.x; ANDREWS PM, 1974, AM J ANAT, V139, P399, DOI 10.1002/aja.1001390308; AUBIN JE, 1979, J HISTOCHEM CYTOCHEM, V27, P36, DOI 10.1177/27.1.220325; BAYER SA, 1982, SCIENCE, V216, P890, DOI 10.1126/science.7079742; BENSON RC, 1979, J HISTOCHEM CYTOCHEM, V27, P44, DOI 10.1177/27.1.438504; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CAGGIANO M, 1994, NEURON, V13, P339, DOI 10.1016/0896-6273(94)90351-4; CALOF AL, 1989, NEURON, V3, P115, DOI 10.1016/0896-6273(89)90120-7; Carpenter MK, 1997, EXP NEUROL, V148, P187, DOI 10.1006/exnr.1997.6657; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHUAH MI, 1991, J NEUROSCI RES, V29, P172, DOI 10.1002/jnr.490290206; COON HG, 1989, P NATL ACAD SCI USA, V86, P1703, DOI 10.1073/pnas.86.5.1703; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; DOUCETTE R, 1990, GLIA, V3, P433, DOI 10.1002/glia.440030602; DUPREY P, 1995, INT J DEV BIOL, V39, P443; Farbman AI, 1996, J NEUROBIOL, V30, P267, DOI 10.1002/(SICI)1097-4695(199606)30:2<267::AID-NEU8>3.0.CO;2-3; Farbman Albert I., 1994, Seminars in Cell Biology, V5, P3; Feron F, 1999, NEUROSCIENCE, V88, P571, DOI 10.1016/S0306-4522(98)00233-4; Franklin RJM, 1996, EXP NEUROL, V137, P263, DOI 10.1006/exnr.1996.0025; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; Goldstein BJ, 1996, J NEUROSCI, V16, P4005; Goldstein BJ, 1997, J NEUROBIOL, V33, P411; GRAZIADEI PP, 1973, TISSUE CELL, V5, P113, DOI 10.1016/S0040-8166(73)80010-2; GRAZIADEI PPC, 1979, J NEUROCYTOL, V8, P1, DOI 10.1007/BF01206454; Gritti A, 1999, J NEUROSCI, V19, P3287; Guntinas-Lichius O, 2002, J NEUROSCI, V22, P7121; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Huard JMT, 1998, J COMP NEUROL, V400, P469; IKAWA M, 1995, FEBS LETT, V375, P125, DOI 10.1016/0014-5793(95)01162-8; Ishii K, 2001, J NEUROSCI RES, V65, P500, DOI 10.1002/jnr.1180; Kalyani AJ, 1998, BIOCHEM CELL BIOL, V76, P1051, DOI 10.1139/bcb-76-6-1051; Kawaguchi A, 2001, MOL CELL NEUROSCI, V17, P259, DOI 10.1006/mcne.2000.0925; KELLER A, 1975, J NEUROCHEM, V24, P1101, DOI 10.1111/j.1471-4159.1975.tb03883.x; KSANDER GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1831, DOI 10.1177/38.12.2254647; Kukekov VG, 1997, GLIA, V21, P399, DOI 10.1002/(SICI)1098-1136(199712)21:4<399::AID-GLIA7>3.0.CO;2-Z; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LEVEY MS, 1991, J NEUROSCI, V11, P3556; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; Liu N, 1998, EXP NEUROL, V151, P173, DOI 10.1006/exnr.1998.6810; Liu Y, 1999, J NEUROSCI, V19, P4370; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Lu J, 2001, BRAIN RES, V889, P344, DOI 10.1016/S0006-8993(00)03235-2; MacDonald KPA, 1996, J NEUROSCI RES, V44, P27, DOI 10.1002/(SICI)1097-4547(19960401)44:1<27::AID-JNR4>3.0.CO;2-K; MAHANTHAPPA NK, 1993, NEURON, V10, P293, DOI 10.1016/0896-6273(93)90319-M; MARUNIAK JA, 1990, BRAIN RES, V526, P65, DOI 10.1016/0006-8993(90)90250-F; MENCO BPM, 1987, J ANAT, V152, P145; Mumm JS, 1996, P NATL ACAD SCI USA, V93, P11167, DOI 10.1073/pnas.93.20.11167; Nakanishi T, 1999, FEBS LETT, V449, P277, DOI 10.1016/S0014-5793(99)00433-0; Newman MP, 2000, NEUROSCIENCE, V99, P343, DOI 10.1016/S0306-4522(00)00194-9; NISWENDER KD, 1995, J MICROSC-OXFORD, V180, P109, DOI 10.1111/j.1365-2818.1995.tb03665.x; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; PIXLEY SK, 1992, GLIA, V5, P269, DOI 10.1002/glia.440050405; Pratt T, 2000, DEV BIOL, V228, P19, DOI 10.1006/dbio.2000.9935; Raaf J, 1944, AM J ANAT, V75, P151, DOI 10.1002/aja.1000750203; Raisman G, 2001, NAT REV NEUROSCI, V2, P369, DOI 10.1038/35072576; Rao MS, 1999, ANAT RECORD, V257, P137; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; Roisen FJ, 2001, BRAIN RES, V890, P11, DOI 10.1016/S0006-8993(00)03016-X; Roskams AJI, 1996, J NEUROSCI, V16, P1294; SATOH M, 1995, DEV BRAIN RES, V87, P111, DOI 10.1016/0165-3806(95)00057-K; Sawamoto K, 2001, P NATL ACAD SCI USA, V98, P6423, DOI 10.1073/pnas.111152398; SCHULTZ EW, 1960, AM J PATHOL, V37, P1; SCHWOB JE, 1994, CHEM SENSES, V19, P671, DOI 10.1093/chemse/19.6.671; SCHWOB JE, 1995, J COMP NEUROL, V359, P15, DOI 10.1002/cne.903590103; SCHWOB JE, 1992, J NEUROSCI, V12, P3896; SCHWOB JE, 1986, J NEUROSCI, V6, P208; SOSNOWSKI JS, 1995, BRAIN RES, V702, P37, DOI 10.1016/0006-8993(95)00960-7; Suzuki Y, 1998, ANAT EMBRYOL, V198, P43, DOI 10.1007/s004290050163; SUZUKI Y, 1991, CELL TISSUE RES, V266, P239, DOI 10.1007/BF00318179; Suzuki Y, 2000, EXP NEUROL, V165, P35, DOI 10.1006/exnr.2000.7465; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; WOLOZIN B, 1992, J MOL NEUROSCI, V3, P137, DOI 10.1007/BF02919405; Yasuno H, 2000, BRAIN RES, V887, P53, DOI 10.1016/S0006-8993(00)02966-8	76	13	16	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1052-0295	1473-7760		BIOTECH HISTOCHEM	Biotech. Histochem.	APR	2003	78	2					57	70		10.1080/10520290310001593801			14	Biotechnology & Applied Microbiology; Cell Biology	Biotechnology & Applied Microbiology; Cell Biology	724RJ	WOS:000185500300001	14533842				2021-06-18	
J	Mewasingh, LD; Christophe, C; Fonteyne, C; Dachy, B; Ziereisen, F; Christiaens, F; Deltenre, P; De Maertelaer, V; Dan, B				Mewasingh, LD; Christophe, C; Fonteyne, C; Dachy, B; Ziereisen, F; Christiaens, F; Deltenre, P; De Maertelaer, V; Dan, B			Predictive value of electrophysiology in children with hypoxic coma	PEDIATRIC NEUROLOGY			English	Article							SOMATOSENSORY-EVOKED-POTENTIALS; MORTALITY PRISM SCORE; ANOXIC-ISCHEMIC COMA; VEGETATIVE STATE; PEDIATRIC RISK; BRAIN INJURY; PROGNOSTIC VALUE; HEAD-INJURY; SEPS	Assessment of prognosis of children in hypoxic coma is difficult. The value of clinical evaluation is often limited. The usefulness of electrophysiologic tests has been documented mostly in adults and neonates and in cases of traumatic coma. We reviewed retrospectively 39 consecutive children with nontraumatic hypoxic coma to assess the prognostic value of EEG, visual, and auditory evoked potentials. Correlation between electrophysiology and neurologic outcome after mean follow-up period of 30 months was significant (r(s) = 0.6, P < 0.001). In contrast there was no correlation between Pediatric Risk of Mortality score (PRISM) and outcome (r(s) = -0.42, P = 0.8). Combining magnetic resonance imaging with electrophysiology further enhanced their prognostic value (r(s) = 0.69, P < 0.001). Neuroimaging was highly sensitive but less specific, and electrophysiologic tests were highly specific but less sensitive. We conclude that early electrophysiology can contribute to predicting outcome in pediatric hypoxic coma. (C) 2003 by Elsevier Inc. All rights reserved.	Univ Brussels, Childrens Hosp Queen Fabiola, Dept Neurol, B-1020 Brussels, Belgium; Univ Brussels, Childrens Hosp Queen Fabiola, Dept Neuroradiol, B-1020 Brussels, Belgium; Univ Brussels, Childrens Hosp Queen Fabiola, Intens Care Unit, B-1020 Brussels, Belgium; Hop Univ Brugmann, Dept Neurophysiol, Brussels, Belgium; Free Univ Brussels, IRIBHM, Stat Unit, Brussels, Belgium	Mewasingh, LD (corresponding author), Univ Brussels, Childrens Hosp Queen Fabiola, Dept Neurol, Ave JJ Crocq 15, B-1020 Brussels, Belgium.			Dan, Bernard/0000-0002-2051-9876			Biagioni E, 2001, PEDIATRICS, V107, P461, DOI 10.1542/peds.107.3.461; Carter BG, 1999, INTENS CARE MED, V25, P722, DOI 10.1007/s001340050936; Chen R, 1996, CRIT CARE MED, V24, P672, DOI 10.1097/00003246-199604000-00020; Christophe C, 2002, AM J NEURORADIOL, V23, P716; Christophe C, 2000, J RADIOL, V81, P25; DEUSCHL G, 1999, ELECTROENCEPHALOGR S, V52; DOUGHERTY JH, 1981, NEUROLOGY, V31, P991, DOI 10.1212/WNL.31.8.991; FRANK LM, 1985, NEUROLOGY, V35, P931, DOI 10.1212/WNL.35.6.931; HECOX KE, 1981, NEUROLOGY, V31, P832, DOI 10.1212/WNL.31.7.832; Heindl UT, 1996, NEUROPEDIATRICS, V27, P94, DOI 10.1055/s-2007-973756; KARMEL BZ, 1988, ELECTROEN CLIN NEURO, V71, P429, DOI 10.1016/0168-5597(88)90047-0; KOHT A, 1988, ANESTH ANALG, V67, P435; KRUUS S, 1979, ACTA PAEDIATR SCAND, V68, P315, DOI 10.1111/j.1651-2227.1979.tb05013.x; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; LUTSCHG J, 1983, AM J DIS CHILD, V137, P421; MaulenRadovan I, 1996, ARCH MED RES, V27, P553; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; PAMPIGLI.G, 1968, LANCET, V1, P1261; PARAIN D, 1989, Neurophysiologie Clinique, V19, P489, DOI 10.1016/S0987-7053(89)80005-X; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; Rothstein TL, 2000, J CLIN NEUROPHYSIOL, V17, P486, DOI 10.1097/00004691-200009000-00007; ROTHSTEIN TL, 1991, ELECTROEN CLIN NEURO, V79, P101, DOI 10.1016/0013-4694(91)90046-7; SCOLLOLAVIZZARI G, 1987, EUR NEUROL, V26, P161, DOI 10.1159/000116329; Shewmon DA, 2000, J CLIN NEUROPHYSIOL, V17, P467, DOI 10.1097/00004691-200009000-00005; Sonnet M. L., 1993, Neurophysiologie Clinique, V23, P227, DOI 10.1016/S0987-7053(05)80232-1; STRICKBINEVANREET P, 1984, AM J DIS CHILD, V138, P492; TAYLOR MJ, 1989, PEDIATR NEUROL, V5, P145, DOI 10.1016/0887-8994(89)90063-5; van Brakel MJM, 2000, EUR J PEDIATR, V159, P232, DOI 10.1007/s004310050060; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8; Zuckerman GB, 1998, ARCH PEDIAT ADOL MED, V152, P134	31	13	14	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994			PEDIATR NEUROL	Pediatr. Neurol.	MAR	2003	28	3					178	183		10.1016/S0887-8994(02)00509-X			6	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	684LV	WOS:000183209600003	12770669				2021-06-18	
J	Verburg, G; Borthwick, B; Bennett, B; Rumney, P				Verburg, G; Borthwick, B; Bennett, B; Rumney, P			Online support to facilitate the reintegration of students with brain injury: Trials and errors	NEUROREHABILITATION			English	Article						telerehabilitation; reintegration; students; acquired/traumatic brain injury (ABI/TBI) online	WORLD-WIDE-WEB; EDUCATION; CHILDREN; INTERNET; TELEREHABILITATION; PROFESSIONALS; TELEHEALTH; QUALITY; NEEDS	The reintegration of students after acquired/traumatic brain injury (ABI/TBI) continues to be fraught with difficulties. Presented are (1) case studies exploring the potential of online support for teachers of students with ABI after returning from a paediatric rehabilitation centre; (2) results of Internet-based courses about reintegrating students with ABI; (3) outcomes of videoconferencing-based and Internet email-based support; (4) development of an online support process that uses Questions and Answers as a quick and immediate resource for teachers. The authors recommend that a collaborative process be instituted, in order to generate a relatively small number of high quality online resources about re-integrating students into their school and community. A second recommendation focuses on the development of online support network which may be text or email based or which may use videoconferencing over the Internet. Such networks allow students with ABI to maintain contact with their family and friends in the home community and facilitate their reintegration An Internet-based support structure also allows professionals to provide consultation, collaboration and continuing input.	BMCC, Toronto, ON M4G 1R8, Canada; Bloorview MacMillan Sch Author, Toronto, ON, Canada	Verburg, G (corresponding author), BMCC, 350 Rumsey Rd, Toronto, ON M4G 1R8, Canada.	gverburg@bloorview-macmillan.on.ca					Arroyos-Jurado E, 2000, J SCHOOL PSYCHOL, V38, P571, DOI 10.1016/S0022-4405(00)00053-4; Bashshur RL, 2002, TELEMED J E-HEALTH, V8, P95, DOI 10.1089/15305620252933437; Berkowicz DA, 1998, J AM MED INFORM ASSN, P116; Borowitz SM, 2001, MED INFORM INTERNET, V26, P283, DOI 10.1080/14639230110086295; BROWN E, 2002, CANADIAN HEALTHCARE, P39; Chapman PM, 2000, ENVIRON TOXICOL CHEM, V19, P3, DOI [10.1897/1551-5028(2000)019&lt;0003:WETTUL&gt;2.3.CO;2, 10.1002/etc.5620190102]; Chen HC, 1998, J AM SOC INFORM SCI, V49, P582, DOI 10.1002/(SICI)1097-4571(1998)49:7<582::AID-ASI2>3.0.CO;2-V; Cimino JJ, 2000, J AM MED INFORM ASSN, P151; Cumbo A, 2002, CANCER PRACT, V10, P155, DOI 10.1046/j.1523-5394.2002.103007.x; DePompei R, 1987, LANG SPEECH HEAR SER, V18, P292, DOI 10.1044/0161-1461.1804.292; DOWNES S, 2000, LEARNING OBJECTS; Eysenbach G, 2002, JAMA-J AM MED ASSOC, V287, P2691, DOI 10.1001/jama.287.20.2691; FEENEY T, 1997, STUDENTS ACQUIRED BR, P229; Glang A, 1997, J HEAD TRAUMA REHAB, V12, P32, DOI 10.1097/00001199-199704000-00005; GLANG A, 1993, 387967 ERIC ED US DE, P1; Hailey D, 2001, J TELEMED TELECARE, V7, P73, DOI 10.1258/1357633011937218; Harris JR, 1997, J HEAD TRAUMA REHAB, V12, P67, DOI 10.1097/00001199-199704000-00007; HILL HC, 2002, AM CLIN LAB, V21, P21; Hughes E, 2002, J TELEMED TELECARE, V8, P36, DOI 10.1258/13576330260440790; Jones JM, 2001, PATIENT EDUC COUNS, V44, P271, DOI 10.1016/S0738-3991(00)00204-4; JONES JM, 2001, PATIENT ED CONSELLIN, V44, P398; Kaplan B, 2001, J AM MED INFORM ASSN, V8, P309, DOI 10.1136/jamia.2001.0080309; Krupinski E, 2002, TELEMED J E-HEALTH, V8, P13, DOI 10.1089/15305620252933374; Lemaire ED, 2002, J TELEMED TELECARE, V8, P19, DOI 10.1258/1357633021937415; Liu LL, 2000, J TELEMED TELECARE, V6, P47, DOI 10.1258/1357633001935554; RADER MC, 1995, J JUST CARING ED, V1, P191; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; Savage RC, 2001, NEUROREHABILITATION, V16, P49; Sax CL, 2002, DISABIL REHABIL, V24, P144, DOI 10.1080/09638280110066802; SCHATZ B, 2001, SHEAF LINDS DIG LIB; Simpson J, 2001, J TELEMED TELECARE, V7, P90, DOI 10.1258/1357633011936219; Steckler A, 2001, HEALTH EDUC RES, V16, P735, DOI 10.1093/her/16.6.735; STRECHNER VJ, 2002, CANADIAN HEALTHCARE, P34; Wagner TH, 2001, J HEALTH ECON, V20, P1059, DOI 10.1016/S0167-6296(01)00107-2; WITTE R, 1998, TEACHING EXCEPTIONAL, P56; Ylvisaker M, 2001, J HEAD TRAUMA REHAB, V16, P76, DOI 10.1097/00001199-200102000-00009	36	13	13	0	8	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2003	18	2					113	123					11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	743ZU	WOS:000186604100004	12867674				2021-06-18	
J	Tomlin, P; Clarke, M; Robinson, G; Roach, J				Tomlin, P; Clarke, M; Robinson, G; Roach, J			Rehabilitation in severe head injury in children: outcome and provision of care	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							TRAUMATIC BRAIN INJURY; FOLLOW-UP; RECOVERY; ADOLESCENTS	Functional outcome and provision of care to 82 children (males: females 2.7: 1; age range 0 to 16 years) with severe head injury were investigated. The children were admitted to the intensive care units of the Regional Neuroscience Units of the Greater Manchester and Lancashire districts of the North West Region of the UK between 1994 and 1996. A questionnaire was devised based on 12 areas of recovery and data were collected at discharge and 6 weeks, 6 months and 12 months from discharge. Data were collected during home visits and at joint assessment at 12 months with the district consultant community paediatrician (CCP). Early involvement of the CCP enhanced the provision of needs at discharge and 6 weeks after discharge, as did a period of stay in district-level care before discharge home. CCPs received formal notification of the injured child in only 32% of cases by discharge, and 54% of cases by 6 months. Sixty-five per cent of children required early educational support but structured help reached only 55% of these children by the end of the study. Integrated planning between health and education was achieved in about half of the study population. Good physical recovery was achieved by the majority of children but parents said they did not feel prepared for the degree of help which their child still required 12 months after discharge. Children who required anticonvulsants at 12 months' follow-up scored significantly lower on cognitive potential. Psychosocial family functioning deteriorated in a substantial number of families according to parental perception. Prevalence of this perception did not diminish over the study period. Aspects of caregivers' understanding and the child's language deficits, self-care skills, fine and gross motor performance, as well as family, social, and financial consequences were assessed. A dedicated and integrated approach to assessment and provision of care across the domains of hospital, education, and community is discussed.	Preston Acute Hosp Trust, Preston, Lancs, England; Stepping Hill Hosp, Stockport SK2 7JE, Lancs, England; Royal Manchester Childrens Hosp, Manchester M27 1HA, Lancs, England	Tomlin, P (corresponding author), Royal Preston Hosp, Dept Paediat Neurol, Sharoe Green Lane, Preston PR2 9HT, Lancs, England.						BRINK JD, 1978, ORTHOP CLIN N AM, V9, P451; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; Clark E, 1996, J LEARN DISABIL, V29, P549, DOI 10.1177/002221949602900509; CROUCHMAN M, 1990, ARCH DIS CHILD, V65, P1286, DOI 10.1136/adc.65.11.1286; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; Emanuelson I, 1996, CHILD NERV SYST, V12, P460, DOI 10.1007/BF00261625; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; Farmer JE, 1996, J LEARN DISABIL-US, V29, P532, DOI 10.1177/002221949602900508; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; LEVIN HS, 1993, CURR OPIN NEUROL, V6, P841, DOI 10.1097/00019052-199312000-00003; Morse S, 1999, Pediatr Rehabil, V3, P139; Osberg JS, 1997, BRAIN INJURY, V11, P11; RIVARA JB, 1994, PEDIATR ANN, V23, P38, DOI 10.3928/0090-4481-19940101-09; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016	17	13	14	1	5	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4221 USA	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	DEC	2002	44	12					828	837					10	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	619FH	WOS:000179464800006	12455859				2021-06-18	
J	de Cleen, M				de Cleen, M			Obliteration of pulp canal space after concussion and subluxation: Endodontic considerations	QUINTESSENCE INTERNATIONAL			English	Article						concussion; dental trauma; pulp space obliteration; root canal treatment; subluxation	TRAUMA; TEETH	Concussion and subluxation injuries to permanent teeth lead to obliteration of the pulp canal space in 3% to 11% of cases, depending on the severity of the injury and the developmental stage of the tooth. Obliteration of the pulp canal space may make root canal treatment necessary because of the development of apical periodontitis or for cosmetic reasons. If carefully executed, root canal treatment in teeth with an obliterated pulp canal space is highly successful and may act as a basis for internal bleaching.		de Cleen, M (corresponding author), Schubertstr 40-1, NL-1077 GV Amsterdam, Netherlands.						ANDREASEN F M, 1985, Endodontics and Dental Traumatology, V1, P207; ANDREASEN FM, 1987, ENDOD DENT TRAUMATOL, V3, P101; Andreasen JO., 1994, TXB COLOR ATLAS TRAU, V3; BAGHDADY VS, 1981, J DENT RES, V60, P677, DOI 10.1177/00220345810600030201; BARTHEL CR, 1999, ENDODONTIE, V8, P21; Clarkson B H, 1973, J Int Assoc Dent Child, V4, P21; CRONALARSSON G, 1989, ENDOD DENT TRAUMATOL, V5, P176; CVEK M, 1982, ACTA ODONTOL SCAND, V40, P223, DOI 10.3109/00016358209019816; De Cleen M., 1994, ENDODONTIE, V3, P39; EBERLESEDER KA, 1999, ENDODONTIE, V8, P101; Herforth V A, 1976, Dtsch Zahnarztl Z, V31, P938; JACOBSEN I, 1977, SCAND J DENT RES, V85, P588; JARVINEN S, 1979, ACTA ODONTOL SCAND, V37, P47, DOI 10.3109/00016357909004684; PETERS LB, 1992, ENDODONTIE, V1, P57; Robertson A, 1996, J ENDODONT, V22, P557, DOI 10.1016/S0099-2399(96)80018-5; Simon JHS, 1999, ENDOD DENT TRAUMATOL, V15, P145; WEIGER R, 1992, ENDODONTIE, V1, P109	17	13	14	0	6	QUINTESSENCE PUBL CO INC	CAROL STREAM	551 NORTH KIMBERLY DR, CAROL STREAM, IL 60188-1881 USA	0033-6572			QUINTESSENCE INT	Quintessence Int.	OCT	2002	33	9					661	669					9	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	611NL	WOS:000179024100004	12666890				2021-06-18	
J	Demery, JA; Pedraza, O; Hanlon, RE				Demery, JA; Pedraza, O; Hanlon, RE			Differential profiles of verbal learning in traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							SUBGROUPS; SUBTYPES	Several recent investigations have utilized cluster analytic procedures to elucidate profiles of verbal learning on the California Verbal Learning Test following traumatic brain injury (TBI). Although the results of these studies have contributed to our understanding of verbal learning following TBI, limitations in sample composition and methodology render the results difficult to evaluate. The current study provides an analysis of verbal learning clusters in the most comprehensive sample (n=160) of TBI patients reported thus far. Results obtained from multiple hierarchical agglomerative clustering procedures suggested the presence of two distinct clusters, the first consisting of performance patterns falling within normal limits and the second consisting of moderate-to-severe impairment. Two iterative partitioning analyses further suggested a reliable solution with better-than-chance agreement (kappa coefficients >.85, p<.001). Thus, it is concluded that a two-cluster classification solution provides a parsimonious understanding of verbal learning profiles after TBI.	Univ Florida, Hlth Sci Ctr, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA; Northwestern Univ, Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA	Demery, JA (corresponding author), Univ Florida, Hlth Sci Ctr, Dept Clin & Hlth Psychol, POB 100165, Gainesville, FL 32610 USA.						Aldenderfer M.S., 1984, CLUSTER ANAL; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Benton A, 1989, MULTILINGUAL APHASIA; Blashfield R.K., 1988, HDB MULTIVARIATE EXP, P447; Bonafina MA, 2000, J LEARN DISABIL-US, V33, P297, DOI 10.1177/002221940003300307; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; DELIS D, 1987, CALIFORNIA VERBAL LE; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; Everitt B.S., 1993, CLUSTER ANAL; Fisher NJ, 1996, J CLIN EXP NEUROPSYC, V18, P349, DOI 10.1080/01688639608408993; Fletcher J. M., 1988, HDB NEUROPSYCHOLOGY, V1, P83; Fridlund A, 1987, CVLT RES EDITION ADM; Hair JF., 2000, READING UNDERSTANDIN, P147; Halstead WC, 1985, HALSTEAD REITAN NEUR; Haut M., 1992, NEUROPSYCHOLOGY, V6, P51; KAPLAN E, 1983, BOSTON NAMING; KUIPER FK, 1975, BIOMETRICS, V31, P777, DOI 10.2307/2529565; MILLIGAN GW, 1980, PSYCHOMETRIKA, V45, P325, DOI 10.1007/BF02293907; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; MOJENA R, 1977, COMPUT J, V20, P359, DOI 10.1093/comjnl/20.4.359; Morris RD, 1998, J EDUC PSYCHOL, V90, P347, DOI 10.1037/0022-0663.90.3.347; MORRIS RD, 1988, J CLIN EXP NEUROPSYC, V10, P640, DOI 10.1080/01688638808402801; Sneath P. H. A., 1973, NUMERICAL TAXONOMY; SOKAL ROBERT R., 1958, UNIV KANSAS SCI BULL, V38, P1409; TEASDALE G, 1974, LANCET, V2, P81; van Gorp W. G., 1993, NEUROPSYCHOLOGY, V7, P62, DOI DOI 10.1037/0894-4105.7.1.62; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925	33	13	13	0	0	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	SEP	2002	24	6					818	827		10.1076/jcen.24.6.818.8400			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	611UM	WOS:000179036200010	12424655				2021-06-18	
J	Greve, KW; Love, JM; Sherwin, E; Mathias, CW; Houston, RJ; Brennan, A				Greve, KW; Love, JM; Sherwin, E; Mathias, CW; Houston, RJ; Brennan, A			Temporal stability of the Wisconsin Card Sorting Test in a chronic traumatic brain injury sample	ASSESSMENT			English	Article						WCST; reliability; psychometrics; assessment; neuropsychology	RELIABILITY	The aim of the present study was to investigate the temporal stability of the Wisconsin Card Sorting Test (WCST) in a clinical population with documented brain pathology, stable cognitive deficits, and for whom repeated testing is common: chronic severe traumatic brain injury (TBI). Participants were 34 patients at least 1 year postsevere TBI living at a large residential rehabilitation facility. The WCST was administered in standard fashion with both the standard and 64-card versions scored. All derived scores with norms were examined. Results indicated acceptable temporal stability of most scores for both the standard and short WCST, although the stability of the WCST-64 was poorer than for the standard WCST Three sets of significant change indices are provided for clinical use.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Georgia So Univ, Statesboro, GA 30460 USA; Univ New Orleans, New Orleans, LA 70148 USA	Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu		Mathias, Charles/0000-0003-1902-673X			*AM PSYCH ASS, 1992, AM PSYCHOL, V47, P1597, DOI DOI 10.1037/0003-066X.47.12.1597; Basso MR, 1999, CLIN NEUROPSYCHOL, V13, P283, DOI 10.1076/clin.13.3.283.1743; BEDARD MA, 1991, J CLIN EXP NEUROPSYC, V13, P950, DOI 10.1080/01688639108405110; BUTLER M, 1991, PROF PSYCHOL-RES PR, V22, P510, DOI 10.1037/0735-7028.22.6.510; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; CICCHETTI DV, 1981, AM J MENT DEF, V86, P127; Greve KW, 2002, BRAIN INJURY, V16, P29, DOI 10.1080/0269905011008803; Greve KW, 2001, CLIN NEUROPSYCHOL, V15, P228, DOI 10.1076/clin.15.2.228.1901; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton RK., 1999, WISCONSIN CARD SORTI; HEATON RK, 2000, WCST 64 COMPUTER VER; Ingram F, 1999, BRIT J CLIN PSYCHOL, V38, P209, DOI 10.1348/014466599162764; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; KIRK RE, 1999, STAT INTRO; Kongs SK, 2000, WISCONSIN CARD SORTI; Lord F., 1968, STAT THEORIES MENTAL; MATARAZZO JD, 1984, J CLIN NEUROPSYCHOL, V6, P351, DOI 10.1080/01688638408401227; NAEGELE B, 1995, SLEEP, V18, P43; Paolo A. M., 1996, ASSESSMENT, V3, P137, DOI [10.1177/107319119600300205, DOI 10.1177/107319119600300205]; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Tate RL, 1998, CLIN NEUROPSYCHOL, V12, P348, DOI 10.1076/clin.12.3.348.1988	21	13	13	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	SEP	2002	9	3					271	277		10.1177/1073191102009003006			7	Psychology, Clinical	Psychology	588YL	WOS:000177729800006	12216784				2021-06-18	
J	Dolberg, OT; Klag, E; Gross, Y; Schreiber, S				Dolberg, OT; Klag, E; Gross, Y; Schreiber, S			Relief of serotonin selective reuptake inhibitor induced sexual dysfunction with low-dose mianserin in patients with traumatic brain injury	PSYCHOPHARMACOLOGY			English	Article						serotonin selective reuptake inhibitor; sxual dysfunction; traumatic brain injury; SSRI-induced sexual dysfunction; mianserin	ANTAGONIST; FLUOXETINE; PAROXETINE	Rationale: Serotonin selective reuptake inhibitors (SSRI) are commonly used in the treatment of many psychiatric disorders. Although possessing a relatively mild side effect profile, these drugs can cause a number of difficulties, including sexual dysfunction. A variety of strategies have been reported in the management of SSRI-induced sexual dysfunction, including dose reduction, drug holidays, substitution of another antidepressant drug, and various augmentation strategies, including use of sildenafil citrate (Viagra), buspirone, and others. Objectives: We aimed to examine the effect of adding another medication, mianserin, a mainly postsynaptic serotonin 2A agonist, to ongoing SSRI treatment in order to alleviate sexual side effects caused by SSRIs. Methods: The patients included in this study suffered from traumatic brain injury and from psychiatric complications that necessitated the use of SSRIs. Seventeen patients were included in this study, all were being treated with SSRIs, and all complained of sexual dysfunction. Mianserin was added to on-going treatment at low doses, 7.5-15 mg/day. Patients were followed for at least 3 months. Results: Fifteen of the 17 patients (88%) included in this study reported improvement in sexual dysfunction following this intervention. Ten (59%) reported that sexual function achieved pretreatment level. Five (29%) reported "significant improvement," and two (12%) did not respond to this intervention and were given sildenafil citrate, with good results. Side effects were minimal and included dry mouth, drowsiness, headaches, and agitation. Conclusions: The use of low-dose mianserin as an add-on treatment to SSRIs appears to be an effective and well tolerated intervention for sexual dysfunction caused by SSRIs.	Psychiat Day Hosp, Sheba Med Ctr, Div Psychiat, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel; Neuropsychol Unit Treatment & Rehabil, Tel Aviv, Israel; Hebrew Univ Jerusalem, Dept Psychol, Jerusalem, Israel; Bar Ilan Univ, Dept Psychol, Bar Ilan, Israel; Tel Aviv Sourasky Med Ctr, Dept Psychiat, Tel Aviv, Israel	Dolberg, OT (corresponding author), Psychiat Day Hosp, Sheba Med Ctr, Div Psychiat, IL-52621 Tel Hashomer, Israel.	otdol@email.com	Schreiber, Shaul/E-5821-2010	Schreiber, Shaul/0000-0002-2189-0693			AIZENBERG D, 1995, CLIN NEUROPHARMACOL, V18, P320, DOI 10.1097/00002826-199508000-00003; Aizenberg D, 1997, CLIN NEUROPHARMACOL, V20, P210, DOI 10.1097/00002826-199706000-00004; Aizenberg D, 1999, CLIN NEUROPHARMACOL, V22, P347; Clayton AH, 2001, J CLIN PSYCHIAT, V62, P185, DOI 10.4088/JCP.v62n0309; FINBERG N, 1991, SEROTONIN SLEEP MENT, P131; HERMAN JB, 1990, J CLIN PSYCHIAT, V51, P25; Hibbard MR, 2000, NEUROREHABILITATION, V15, P109; Hirschfeld RMA, 1999, J CLIN PSYCHIAT, V60, P27; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kennedy SH, 2000, J CLIN PSYCHIAT, V61, P276, DOI 10.4088/JCP.v61n0406; KOPERA H, 1983, ACTA PSYCHIAT SCAND, V302, pS81; Kotler M, 2000, PSYCHOTHER PSYCHOSOM, V69, P309, DOI 10.1159/000012413; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Masand PS, 1999, HARVARD REV PSYCHIAT, V7, P69, DOI 10.1093/hrp/7.2.69; Norden M.J., 1994, DEPRESSION, V2, P109, DOI DOI 10.1002/depr.3050020208; Rosen RC, 1999, J CLIN PSYCHOPHARM, V19, P67, DOI 10.1097/00004714-199902000-00013; Schreiber S, 1998, EUR NEUROPSYCHOPHARM, V8, P297, DOI 10.1016/S0924-977X(97)00088-6; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Waldinger MD, 1998, J CLIN PSYCHOPHARM, V18, P274, DOI 10.1097/00004714-199808000-00004	19	13	13	0	3	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0033-3158	1432-2072		PSYCHOPHARMACOLOGY	Psychopharmacology	JUN	2002	161	4					404	407		10.1007/s00213-002-1097-z			4	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	568YV	WOS:000176573300010	12073168				2021-06-18	
J	Murillo-Cabezas, F; Arteta-Arteta, D; Flores-Cordero, JM; Munoz-Sanchez, MA; Rincon-Ferrari, MD; Rivera-Fernandez, MV; Alarcon-Cruz, JC				Murillo-Cabezas, F; Arteta-Arteta, D; Flores-Cordero, JM; Munoz-Sanchez, MA; Rincon-Ferrari, MD; Rivera-Fernandez, MV; Alarcon-Cruz, JC			Usefulness of transcranial Doppler ultrasound in the early phase of the acute head injury	NEUROCIRUGIA			Spanish	Article						head injury; transcranial Doppler ultrasound; cerebral hypoperfusion; intracranial hypertension status	CEREBRAL BLOOD-FLOW; INTRACRANIAL HYPERTENSION; CARBON-DIOXIDE; BRAIN INJURY; VELOCITY; VASOSPASM; HYPEREMIA; HEMODYNAMICS; ISCHEMIA; PRESSURE	Objectives: 1) To know the transcranial Doppler (TCD) patterns in the early phase of the severe and moderate head injury and its prognostic implications. 2) To ascertain the TCD measurements concordance among different operators. Material and methods: A prospective observational study in 275 consecutive intensive care unit patients with severe or moderate head injury was designed. Within 12 hrs. of the traumatic event a TCD study was done and a second one within the first 24 hrs. All patients were managed following a protocol made with the aim of promoting the early evacuation of the intracranial space occupying mass, preventing delayed brain damage and keeping the intracranial pressure (ICP) < 20 mm Hg and the cerebral perfusion pressure (CPP) > 60 mm Hg. The patient outcome was categorized with the Glasgow Outcome Score (GOS) at the discharge of the ICU. The mean velocity (MV) and the pulsatily index (PI) were measured in both middle cerebral arteries (MCA) and in the intracranial part of the internal carotid arteries in order to calculate the Lindegaard index. The presence of hypoperfusion, hyperaemia, vasospasm and cerebral circulatory arrest was registered. The presence of high intracranial pressure (HICP), the ICP peak and mode, the lowest CPP, the CPP mode, the minor medium arterial pressure (MAP) and the MAP mode were also recorded. A concordance analysis was made to ascertain the validity of the TCD data obtained by different operators. Results: The concordance analysis among observers showed a kappa index of 0,7863 (p<0,0001). The median stay in ICU was 7 days (Q1-Q3 of 3-15 days). The intra-ICU mortality was 20,72% (57/275) and the 53,44% of patients (147/275) showed favourable outcome (GOS 4-5) at the discharge of the ICU. The initial TCD showed a MV decreased and a PI increased in the MCA. Eighty of the e 275 patients showed a normal haemodynamic pattern whereas the pattern was abnormal in the remaining 195,1 the hypoperfusion pattern predominated overall (181/275, 61,87%). HIPO was registered in 123 patients (58,01) an not in 89 (41,99%). A statistic significant correlation was found between the HICP and the DTC data. The early hypoperfusion pattern was related with a higher incidence of HICP (p>0,05). The decrease in the MV and the increase in the PI were significantly associated with a higher mortality and a worse functional outcome (except for the MV within the first day). The PI was high within the first 24 h in the group of patients who died but was normalised among the survivals group. Conclusions: Early TCD detects a cerebral hypoperfusion status in the severe and moderate head injury that may imply therapeutic considerations. This hypoperfusion strongly correlates with the severity of the injury, the incidence of HICP and the functional outcome at the ICU discharge. In experienced hands, TCD measurements are reliable when done by different operators.	Hosp Univ Virgen Rocio, Serv Cuidados Crit & Urgencias, Unidad Neurotraumatol, Seville, Spain; Hosp Univ Virgen Rocio, Serv Neurocirugia, Seville, Spain			IBIS, NEUROCRITICOS/C-1805-2016; Murillo-Cabezas, Francisco/AAO-3348-2021; Arteta-Arteta, Donaldo S/D-3894-2014	Arteta-Arteta, Donaldo S/0000-0001-8909-563X			AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; AUER L, 1978, EUR NEUROL, V17, P351, DOI 10.1159/000114974; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CABEZAS FM, 1993, MONITORIZACION PACIE, P69; CABEZAS FM, 1993, MED INTENSIVA, V17, P490; CHAN KH, 1992, NEUROSURGERY, V30, P697; de Nadal M, 2000, ANESTHESIOLOGY, V92, P11, DOI 10.1097/00000542-200001000-00008; Ducrocq X, 1998, J NEUROL SCI, V159, P145, DOI 10.1016/S0022-510X(98)00158-0; Egido JA, 2000, REV NEUROLOGIA, V31, P179, DOI 10.33588/rn.3102.2000064; Fukushima U, 1999, J VET MED SCI, V61, P1293, DOI 10.1292/jvms.61.1293; GILLER CA, 1993, NEUROSURGERY, V32, P737, DOI 10.1227/00006123-199305000-00006; GOMEZ CR, 1991, SURG NEUROL, V35, P30, DOI 10.1016/0090-3019(91)90198-I; Hadani M, 1997, J NEUROTRAUM, V14, P629, DOI 10.1089/neu.1997.14.629; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; HOMBURG AM, 1993, ACTA NEUROL SCAND, V87, P488; Iida K, 1997, AM J EMERG MED, V15, P587, DOI 10.1016/S0735-6757(97)90164-9; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; LEE EJ, PROGNOSTIC SIGNIFICA; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; MARSHALL LF, 1991, J NEUROSURG, V75, pS59; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; McQuire JC, 1998, J NEUROSURG, V89, P526, DOI 10.3171/jns.1998.89.4.0526; Minassian AT, 1998, J NEUROSURG, V88, P996, DOI 10.3171/jns.1998.88.6.0996; RINGELSTEIN EB, 1989, NUEVAS TENDENCIAS DI, P3; Romner B, 1996, J NEUROSURG, V85, P90, DOI 10.3171/jns.1996.85.1.0090; Sahuquillo J, 1997, NEUROCIRUGIA, V8, P260; Schramm WM, 1997, ACTA ANAESTH SCAND, V41, P1319, DOI 10.1111/j.1399-6576.1997.tb04651.x; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SHIGEMORI M, 1989, Neurological Research, V11, P165; SHIGEMORI M, 1990, ACTA NEUROCHIR, V107, P5, DOI 10.1007/BF01402605; Smielewski P, 1997, J NEUROSURG, V86, P773, DOI 10.3171/jns.1997.86.5.0773; Steiger HJ, 1996, STROKE, V27, P2048, DOI 10.1161/01.STR.27.11.2048; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; VANSANTBRINK H, 1994, INTRACRANIAL PRESSUR, V9, P585; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; ZURYNSKI YA, 1995, J NEUROL SCI, V134, P41, DOI 10.1016/0022-510X(95)00178-X; ZURYNSKI YA, 1995, J NEUROL SCI, V134, P33, DOI 10.1016/0022-510X(95)00172-9	42	13	13	0	4	ELSEVIER DOYMA SL	BARCELONA	TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN	1130-1473			NEUROCIRUGIA	Neurocirugia	JUN	2002	13	3					196	208					13	Neurosciences; Surgery	Neurosciences & Neurology; Surgery	575YY	WOS:000176977100005	12148164				2021-06-18	
J	Singh, S; Salib, RJ; Oates, J				Singh, S; Salib, RJ; Oates, J			Traumatic fracture of the stapes suprastructure following minor head injury	JOURNAL OF LARYNGOLOGY AND OTOLOGY			English	Article						head injuries, closed; ear, middle; stapes; fracture; ossicular prosthesis	SIGN	Traumatic fracture of the stapes occurs rarely following head injury. Ossicular dislocation is more commonly encountered. When present, stapes fractures are usually associated with an underlying temporal bone fracture. A higher incidence has been reported in childhood, possibly because of the greater flexibility of the skull in this age group. This report highlights the fact that these fractures can be associated with a relatively minor head injury. This possibility should be kept in mind when evaluating patients, especially children, who have a persistent conductive deafness of more than 30 dB with an intact tympanic membrane following any form of head injury. An exploratory tympanotomy with appropriate ossicular reconstruction, as described in this case, can yield excellent results.	Queens Hosp, Dept Otolaryngol Head & Neck Surg, Burton Upon Trent, Staffs, England	Salib, RJ (corresponding author), 3 Stephenson Way,Hedge End, Southampton SO30 2WR, Hants, England.						Demaldent J E, 1984, Ann Otolaryngol Chir Cervicofac, V101, P467; DOES IES, 1965, ARCHIV OTOLARYNGOL, V82, P331; ELBROND O, 1960, ACTA OTOLARYNGOL, V51, P469; HAMMOND VT, 1980, J LARYNGOL OTOL, V94, P117, DOI 10.1017/S0022215100088551; HOUGH JVD, 1968, LARYNGOSCOPE, V78, P899, DOI 10.1288/00005537-196806000-00003; Li STT, 2000, AM J ROENTGENOL, V174, P1296, DOI 10.2214/ajr.174.5.1741296; LOURENCO MTC, 1995, AM J OTOL, V16, P387; MAFEE MF, 1984, AM J OTOL, V5, P374; Meriot P, 1997, RADIOGRAPHICS, V17, P1445, DOI 10.1148/radiographics.17.6.9397457; Swartz JD, 1998, RADIOL CLIN N AM, V36, P819, DOI 10.1016/S0033-8389(05)70066-X	10	13	15	0	3	HEADLEY BROTHERS LTD	ASHFORD	INVICTA PRESS, ASHFORD TN24 8HH, KENT, ENGLAND	0022-2151			J LARYNGOL OTOL	J. Laryngol. Otol.	JUN	2002	116	6					457	459		10.1258/0022215021911068			3	Otorhinolaryngology	Otorhinolaryngology	579CU	WOS:000177159500013	12385361				2021-06-18	
J	Castejon, OJ; Castejon, HV; Zavala, M; Sanchez, E; Diaz, M				Castejon, OJ; Castejon, HV; Zavala, M; Sanchez, E; Diaz, M			A light and electron microscopic study of oedematous human cerebral cortex in two patients with post-traumatic seizures	BRAIN INJURY			English	Article							INDUCED STATUS EPILEPTICUS; CA3 PYRAMIDAL CELLS; DENTATE GYRUS; NEURONS; SYNAPSES; EPILEPSY; RATS; INJURY; DEATH	Primary objective: Brain cortical biopsies of two patients with clinical diagnosis of complicated brain trauma who had seizures, were studied by means of light and electron microscopes in order to correlate structural alterations with seizure activity. Methods and procedures: Biopsy samples of left frontal cortex and right parietal cortex were processed by current techniques for light and transmission electron microscopy. Results: The tissue showed severe vasogenic oedema with perivascular and intraparenchymatous haemorrhages. At the capillary wall, increased vesicular and vacuolar transendothelial transport, open endothelial junctions, thickened basement membrane and swollen perivascular astrocytic end-feet were observed. Some pyramidal and non-pyramidal nerve cells appeared dense and shrunken and others exhibited marked intraneuronal enlargement of membrane compartment. The myelinated axons displayed signs of degeneration and a process of axonal sprouting. Numerous swollen asymmetrical axo-dendritic synaptic contacts were observed in the neuropil, which exhibited mostly closely aggregated spheroidal synaptic vesicles toward the presynaptic membrane and numerous exocytotic vesicles sites. The perisynaptic astrocytic ensheathment appeared retracted or absent, whereas the extracellular space appeared notably dilated. Synaptic disassembly was also observed. Conclusion: The findings demonstrate, in two patients with post-traumatic seizure activity, brain brarrier dysfunction, vasogenic oedema, anoxic-ischaemic neurons, axonal sprouting, numerous altered excitatory synapses and synaptic disassembly. Some considerations on clinical and research applications are discussed.	Univ Zulia, Fac Med, Inst Invest Biol, Maracaibo 4003A, Venezuela	Castejon, OJ (corresponding author), Univ Zulia, Fac Med, Inst Invest Biol, Apartado 526, Maracaibo 4003A, Venezuela.	ocastejo@cantv.net					BECKER DP, 1989, J CEREBRAL BLOOD S1, V9, P302; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; BUNDMAN MC, 1994, HIPPOCAMPUS, V4, P611, DOI 10.1002/hipo.450040511; Castejon O J, 1995, J Neurosurg Sci, V39, P47; CASTEJON OJ, 1990, J SUBMICR CYTOL PATH, V22, P281; Castejon OJ, 1999, BRAIN INJURY, V13, P291, DOI 10.1080/026990599121665; Castejon OJ, 1997, BRAIN INJURY, V11, P363, DOI 10.1080/026990597123520; Castejon OJ, 1998, BRAIN INJURY, V12, P409, DOI 10.1080/026990598122539; DELANEROLLE NC, 1992, EPILEPSY RES, P235; Drakew A, 1996, NEUROSCIENCE, V70, P31, DOI 10.1016/0306-4522(95)00379-W; Friedman LK, 1998, HIPPOCAMPUS, V8, P511, DOI 10.1002/(SICI)1098-1063(1998)8:5<511::AID-HIPO9>3.0.CO;2-W; Fujikawa DG, 1999, EUR J NEUROSCI, V11, P1605, DOI 10.1046/j.1460-9568.1999.00573.x; Kotti T, 1997, EXP NEUROL, V146, P323, DOI 10.1006/exnr.1997.6553; LERANTH C, 1992, EPILEPSY RES, P49; LU CH, 1991, CHUNG HUA PING LI HS, V20, P198; Marco P, 1997, BRAIN RES BULL, V44, P47, DOI 10.1016/S0361-9230(97)00090-7; MCDONALD JW, 1993, J NEUROSCI, V13, P4445; Morin F, 1999, NEUROSCIENCE, V93, P457, DOI 10.1016/S0306-4522(99)00199-2; Pierce JP, 1999, HIPPOCAMPUS, V9, P255, DOI 10.1002/(SICI)1098-1063(1999)9:3<255::AID-HIPO6>3.0.CO;2-S; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; REPRESA A, 1992, EPILEPSY RES, P261; Ribak CE, 1996, DEV BRAIN RES, V91, P245, DOI 10.1016/0165-3806(95)00183-2; Ribak CE, 1998, J COMP NEUROL, V401, P266; Salin P, 1995, J NEUROSCI, V15, P8234; Sankar R, 1998, J NEUROSCI, V18, P8382; SCHORMAIR C, 1993, BRAIN RES BULL, V32, P329, DOI 10.1016/0361-9230(93)90196-I; Zavala M, 2001, REV NEUROLOGIA, V33, P401, DOI 10.33588/rn.3305.2001093	28	13	13	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2002	16	4					331	346		10.1080/02699050110088209			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	541CM	WOS:000174967700005	11953004				2021-06-18	
J	Schlund, MW				Schlund, MW			The effects of brain injury on choice and sensitivity to remote consequences: deficits in discriminating response-consequence relations	BRAIN INJURY			English	Article							ANTICIPATORY BEHAVIOR DEFICITS; CLOSED-HEAD-INJURY; PREFRONTAL CORTEX; LESIONS; DAMAGE	Primary objective: One characteristic of some decision-making deficits is a failure to respond adaptively to consequences that follow choices. This investigation examined the sensitivity of choice to remote consequences with a high overall reinforcement rate and proximal consequences with a low overall reinforcement rate. Methods: Three control and three subjects with brain injury made repeated choices between two reinforcement schedules: a fixed time schedule (FT) that delayed reinforcement by 12 seconds, and a progressive time schedule (PT) that progressively increased reinforcement delay by 2 seconds with each consecutive choice and reset to 0 seconds with each choice of the fixed schedule. Switching to the FT schedule at PT 6 seconds maximized overall reinforcement rate. Results: Subjects with brain injury were less sensitive to contingencies and earned less reinforcement relative to controls because switching occurred at lengthy PT delays (delays far exceeding 6 seconds). Conclusions: Some deficits in decision-making and adaptation following injury may reflect a reduction in sensitivity to contingencies.	Kennedy Krieger Inst, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA	Schlund, MW (corresponding author), Kennedy Krieger Inst, 333 Cassell Dr,Triad Technol Bldg Suite 4200, Baltimore, MD 21224 USA.	schlund@kennedykrieger.org					Al-Adawi S, 1998, NEUROPSYCHOLOGY, V12, P115, DOI 10.1037/0894-4105.12.1.115; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; BLEIBERG J, 1985, INT J CLIN NEUROPSYC, V7, P153; CHARNOV EL, 1976, THEOR POPUL BIOL, V9, P129, DOI 10.1016/0040-5809(76)90040-X; FINDLEY JD, 1958, J EXP ANAL BEHAV, V1, P123, DOI 10.1901/jeab.1958.1-123; FREEDMAN PE, 1987, J NEUROL NEUROSUR PS, V50, P398, DOI 10.1136/jnnp.50.4.398; Hackenberg T. D., 1998, HDB RES METHODS HUMA, P541; Heaton R., 1993, WISCONSIN CARD SORTI; HINELINE PN, 1987, QUANTITATIVE ANAL BE, V5, P141; HODOS W, 1967, J EXP ANAL BEHAV, V10, P503, DOI 10.1901/jeab.1967.10-503; Jacobs EA, 1996, J EXP ANAL BEHAV, V65, P5, DOI 10.1901/jeab.1996.65-5; KOSMIDIS MH, 1995, J CLIN EXP NEUROPSYC, V17, P622, DOI 10.1080/01688639508405150; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Nabors NA, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199706000-00008; *NO CA NEUR GROUP, 1995, MAN COGN; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Schlund MW, 2001, BRAIN INJURY, V15, P1061, DOI 10.1080/02699050110086887; Schlund MW, 2000, BRAIN INJURY, V14, P573, DOI 10.1080/026990500120475; Schlund MW, 2000, BEHAV INTERVENT, V15, P155, DOI 10.1002/1099-078X(200007/09)15:3<155::AID-BIN53>3.0.CO;2-F; SCHLUND MW, IN PRESS BRAIN INJUR; Shallice T, 1993, ATTENTION SELECTION, P171; WANCHISEN BA, 1988, J EXP ANAL BEHAV, V50, P375, DOI 10.1901/jeab.1988.50-375	23	13	13	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2002	16	4					347	357		10.1080/02699050110103977			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	541CM	WOS:000174967700006	11953005				2021-06-18	
J	Dieterich, DC; Bockers, TM; Gundelfinger, ED; Kreutz, MR				Dieterich, DC; Bockers, TM; Gundelfinger, ED; Kreutz, MR			Screening for differentially expressed genes in the rat inner retina and optic nerve after optic nerve crush	NEUROSCIENCE LETTERS			English	Article						subtractive hybridization; differential gene expression; kinesin light chain; ferritin; rat Y-box binding protein-A; retinal ganglion cells	RECEPTOR; INJURY; IRON; METABOLISM; FERRITIN; PROTEIN; BRAIN	Limited optic nerve crush is a model of diffuse mechanical axon injury, the most prevalent cause of secondary neurodegeneration after closed head neurotrauma. In this report, a protocol is presented which allows for the rapid screening of differential gene expression in the inner retina, as well as the optic nerve, in response to partial nerve crush. To prove the reliability of the method, prototypically, the differential expression profiles of three candidate genes (kinesin light chain, ferritin, RYB-A) were verified. The method seems to be suitable to address the question of how differential gene expression contributes to degeneration, survival and axonal repair after partial nerve crush. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.	Leibniz Inst Neurobiol, Dept Neurochem Mol Biol, AG Mol Mech Plast, D-39108 Magdeburg, Germany; Univ Munster, Inst Anat, AG Mol Neurobiol, D-4400 Munster, Germany	Kreutz, MR (corresponding author), Leibniz Inst Neurobiol, Dept Neurochem Mol Biol, AG Mol Mech Plast, POB 1860, D-39108 Magdeburg, Germany.			Dieterich, Daniela C./0000-0002-9880-1214			Bien A, 1999, J NEUROTRAUM, V16, P153, DOI 10.1089/neu.1999.16.153; Cheepsunthorn P, 1998, J COMP NEUROL, V400, P73; Curtis ARJ, 2001, NAT GENET, V28, P350, DOI 10.1038/ng571; Engelmann R, 2001, BRAIN RES, V889, P251, DOI 10.1016/S0006-8993(00)03145-0; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; ITO K, 1994, NUCLEIC ACIDS RES, V22, P2036, DOI 10.1093/nar/22.11.2036; Kreutz MR, 1998, J NEUROSCI, V18, P8278; Kreutz MR, 1997, MOL BRAIN RES, V45, P283, DOI 10.1016/S0169-328X(96)00264-1; Levin LA, 1998, INVEST OPHTH VIS SCI, V39, P157; Sambrook J., 1989, MOL CLONING LAB; SO QN, 1997, EUR J NEUROSCI, V9, P1542; Waggoner DJ, 1999, NEUROBIOL DIS, V6, P221, DOI 10.1006/nbdi.1999.0250; Yefimova MG, 2000, INVEST OPHTH VIS SCI, V41, P2343	15	13	13	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JAN 4	2002	317	1					29	32		10.1016/S0304-3940(01)02418-1			4	Neurosciences	Neurosciences & Neurology	512HZ	WOS:000173320100008	11750989				2021-06-18	
J	Sanz, O; Acarin, L; Gonzalez, B; Castellano, B				Sanz, O; Acarin, L; Gonzalez, B; Castellano, B			Expression of 27 kDa heat shock protein (Hsp27) in immature rat brain after a cortical aspiration lesion	GLIA			English	Article						astrocytes; brain injury; Hsp27; microglia; postnatal development; stress response; vimentin	ALPHA-B-CRYSTALLIN; STRESS GENES; TNF-ALPHA; GLUTATHIONE; INDUCTION; STABILIZATION; ASTROCYTES; VIMENTIN; SYSTEM; HSP70	The 27 kDa heat shock protein (Hsp27) is a well-known member of the astroglial response to injury, playing a protective role against oxidative stress, apoptosis, and cytoskeletal destruction. Although several studies have been focused on the damaged adult brain, little is known about Hsp27 expression in the immature brain. In this work, we have examined the spatiotemporal pattern of Hsp27 expression in the normal postnatal rat brain following a cortical aspiration lesion at postnatal day 9. In the immature brain, Hsp27 is mainly observed in the internal capsule, although some scattered cells are also found in the ependyma, the corpus callosum, the septum, and hypothalamic glia limitans. In the internal capsule, Hsp27 expression is developmentally regulated, being significantly decreased from postnatal day 14. After a cortical aspiration lesion, de novo expression of Hsp27 is observed in cortical injured areas as well as in the secondary affected thalamus. In the cortex, expression of Hsp27 is first seen at day 1 postlesion (PL) surrounding the neurodegenerative area, becoming restricted to the glial scar at longer survival times. Although a pulse-like expression of Hsp27 is observed in some microglial cells at day 1 PL, most Hsp27-labeled cells are reactive astrocytes, which show GFAP overexpression and coexpress vimentin from day 3 PL. In the thalamus, astroglial Hsp27 expression is delayed, being first observed at day 5 PL. Thalamic Hsp27-labeled astrocytes do not show vimentin expression. Our observations demonstrate astroglial expression of Hsp27 in areas of tissue damage following postnatal traumatic injury, suggesting an involvement of this cytoskeleton-stabilizing protein in the remodeling processes following postnatal brain damage. (C) 2001 Wiley-Liss, Inc.	Autonomous Univ Barcelona, Fac Med, Dept Cell Biol Physiol & Immunol, Unit Histol, E-08193 Bellaterra, Spain	Acarin, L (corresponding author), Autonomous Univ Barcelona, Fac Med, Dept Cell Biol Physiol & Immunol, Unit Histol, E-08193 Bellaterra, Spain.	laia.acarin@uab.es	Acarin, Laia/G-2620-2010; Castellano, Bernardo/G-1428-2010; Gonzalez, Berta/G-1428-2010	Castellano, Bernardo/0000-0003-1976-971X; Gonzalez, Berta/0000-0002-1860-3980			ACARIN L, 1994, J HISTOCHEM CYTOCHEM, V42, P1033, DOI 10.1177/42.8.8027523; Arrigo AP, 1995, NEUROPATH APPL NEURO, V21, P488, DOI 10.1111/j.1365-2990.1995.tb01094.x; Bancroft J., 1996, THEORY PRACTICE HIST, P735; Bergeron M, 1998, DEV BRAIN RES, V105, P181, DOI 10.1016/S0165-3806(97)00169-7; Brown IR, 1999, HANDB EXP PHARM, V136, P243; Brown IR, 1998, ANN NY ACAD SCI, V851, P123, DOI 10.1111/j.1749-6632.1998.tb08985.x; Costigan M, 1998, J NEUROSCI, V18, P5891; Earle KL, 1998, J NEUROCYTOL, V27, P127, DOI 10.1023/A:1006951423251; Ehrnsperger M, 1998, ANAL BIOCHEM, V259, P218, DOI 10.1006/abio.1998.2630; FERRER I, 1992, PROG NEUROBIOL, V39, P1, DOI 10.1016/0301-0082(92)90029-E; GERNOLD M, 1993, DEV GENET, V14, P103, DOI 10.1002/dvg.1020140204; Hopkins DA, 1998, EXP NEUROL, V153, P173, DOI 10.1006/exnr.1998.6870; HUTCHINS JB, 1989, GLIA, V2, P55, DOI 10.1002/glia.440020107; KATO H, 1995, BRAIN RES, V679, P1, DOI 10.1016/0006-8993(95)00198-Y; Kato K, 1999, J NEUROCHEM, V73, P229, DOI 10.1046/j.1471-4159.1999.0730229.x; Kolb B, 1996, BEHAV BRAIN RES, V79, P1, DOI 10.1016/0166-4328(95)00254-5; KOLB B, 1994, BRAIN RES, V645, P85, DOI 10.1016/0006-8993(94)91641-1; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; Lewis SE, 1999, J NEUROSCI, V19, P8945, DOI 10.1523/JNEUROSCI.19-20-08945.1999; MAKAR TK, 1994, J NEUROCHEM, V62, P45; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Morange M, 1999, HANDB EXP PHARM, V136, P305; Perng MD, 1999, J CELL SCI, V112, P2099; Peuchen S, 1997, PROG NEUROBIOL, V52, P261, DOI 10.1016/S0301-0082(97)00010-5; Piotrowicz RS, 1997, J BIOL CHEM, V272, P7042, DOI 10.1074/jbc.272.11.7042; Piotrowicz RS, 1998, FASEB J, V12, P1481; PIXLEY SKR, 1984, DEV BRAIN RES, V15, P201, DOI 10.1016/0165-3806(84)90097-X; Plumier JCL, 1997, J CEREBR BLOOD F MET, V17, P781; Plumier JCL, 1997, MOL BRAIN RES, V45, P239, DOI 10.1016/S0169-328X(96)00255-0; Plumier JCL, 1996, NEUROSCIENCE, V75, P849, DOI 10.1016/0306-4522(96)00317-X; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P511; SCHIFFER D, 1986, BRAIN RES, V374, P110, DOI 10.1016/0006-8993(86)90399-9; Smith GM, 1997, J NEUROSCI, V17, P9624; Snyder SE, 1998, J COMP NEUROL, V394, P64; Walsh D, 1997, CELL MOL LIFE SCI, V53, P198, DOI 10.1007/PL00000592; Warr W.B., 1981, NEUROANATOMICAL TRAC, P207; Werther GA, 1998, HORM RES, V49, P37, DOI 10.1159/000053066	39	13	14	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	DEC	2001	36	3					259	270		10.1002/glia.1114			12	Neurosciences	Neurosciences & Neurology	497TW	WOS:000172472400002	11746764				2021-06-18	
J	Jaeger, M; Frohlich, M; Hertrich, I; Ackermann, H; Schonle, PW				Jaeger, M; Frohlich, M; Hertrich, I; Ackermann, H; Schonle, PW			Dysphonia subsequent to severe traumatic brain injury: Comparative perceptual, acoustic and electroglottographic analyses	FOLIA PHONIATRICA ET LOGOPAEDICA			English	Article						traumatic brain injury; dysphonia; perceptual analysis; acoustic analysis; electroglottographic analysis	CLOSED-HEAD-INJURY; COMBINED GLOTTOGRAPHY; PATHOLOGICAL VOICES; DYSFUNCTIONS; FEATURES	We tested the applicability of the Goettinger Hoarseness Diagram (GHD) for quantitative evaluation of voice disorders after severe traumatic brain injury (TBI) and compared the obtained data with those from established voice analysis systems such as the Multi-Dimensional Voice Program (MDVP), electroglottography (EGG) and perceptual ratings using sustained vowel productions from 10 patients with TBI dysarthrophonia at late stages postinjury and of 10 healthy control speakers. Statistical analyses revealed significant intergroup differences with re-spect to various acoustic and perceptual measures, i.e., irregularity component, noise component, noise-to-harmonic ratio, shimmer, jitter, roughness, creakiness, strained-strangledness, hypernasality. By contrast, the considered EGG estimates, i.e., open quotient and speed quotient, did not allow for separation of patients and controls. In addition, the two GHD components exhibited close correlations to perceived roughness and creakiness, on the one hand, and breathiness and, to some degree, nasality, on the other, whereas the MDVP parameters failed to differentiate between these two perceptual modes of phonation. Copyright (C) 2001 S. Karger AG, Basel.	Univ Konstanz, Lurija Inst Hlth & Rehabil Sci, D-7750 Constance, Germany; Rehabil Clin Schmieder, Allensbach, Germany; Univ Tubingen, Dept Neurol, D-7400 Tubingen, Germany; Univ Gottingen, Inst Phys 3, D-3400 Gottingen, Germany	Jaeger, M (corresponding author), Kliniken Schmieder Allensbach, Lurija Inst, Postfach 240, D-78473 Allensbach, Germany.		Hertrich, Ingo/T-1154-2018	Hertrich, Ingo/0000-0001-8965-6249			ABBERTON ERM, 1989, CLIN LINGUIST PHONET, V3, P281, DOI 10.3109/02699208908985291; ACKERMANN H, 1994, ANN OTO RHINOL LARYN, V103, P98, DOI 10.1177/000348949410300203; ARONSON AE, 1994, BRAIN INJURY, V8, P663, DOI 10.3109/02699059409151019; BLAUSTEIN S, 1983, J COMMUN DISORD, V16, P157, DOI 10.1016/0021-9924(83)90046-1; CHILDERS DG, 1985, CRC CLIN REV BIOMED, V12, P14; COLTON RH, 1990, J VOICE, V4, P10, DOI 10.1016/S0892-1997(05)80077-3; GERRATT BR, 1987, LARYNGEAL FUNCTION P, P521; HAMMARBERG B, 1980, ACTA OTO-LARYNGOL, V90, P441, DOI 10.3109/00016488009131746; HARTMANN E, 1984, J COMMUN DISORD, V17, P425, DOI 10.1016/0021-9924(84)90004-2; HERTRICH I, 1995, ANN OTO RHINOL LARYN, V104, P197, DOI 10.1177/000348949510400304; Hertrich I, 1997, J ACOUST SOC AM, V102, P652, DOI 10.1121/1.419711; HERTRICH I, 1996, SPRACHE-STIMME-GEHOR, V20, P169; HERTRICH I, 1998, CLIN PHONETICS LINGU, P448; HOUBEN GB, 1992, FOLIA PHONIATR, V44, P269, DOI 10.1159/000266161; Michaelis D, 1997, ACUSTICA, V83, P700; Michaelis D, 1998, J ACOUST SOC AM, V103, P1628, DOI 10.1121/1.421305; MORASCH H, 1987, LARYNGO RHINO OTOL, V66, P214, DOI 10.1055/s-2007-998641; MOTTA G, 1990, FOLIA PHONIATR, V42, P111, DOI 10.1159/000266054; MURTY GE, 1991, CLIN OTOLARYNGOL, V16, P399, DOI 10.1111/j.1365-2273.1991.tb00957.x; MURTY GE, 1991, CLIN OTOLARYNGOL, V16, P298, DOI 10.1111/j.1365-2273.1991.tb00935.x; Ondrackova J, 1972, Folia Phoniatr (Basel), V24, P405; ORLIKOFF RF, 1991, J SPEECH HEAR RES, V34, P1066, DOI 10.1044/jshr.3405.1066; Schonle PW., 2000, INT HDB NEUROPSYCHOL, P327, DOI [10.1007/978-1-4757-5569-5_22, DOI 10.1007/978-1-4757-5569-5_22]; THEODOROS D, 1993, BRAIN INJURY, V7, P59, DOI 10.3109/02699059309008157; THEODOROS DG, 1994, BRAIN INJURY, V8, P667, DOI 10.3109/02699059409151021; THEODOROS DG, 1995, BRAIN INJURY, V9, P671, DOI 10.3109/02699059509008225; VOGEL M, 1982, FOLIA PHONIATR, V34, P150, DOI 10.1159/000265644; WOO P, 1989, LARYNGOSCOPE, V99, P725; YORKSTON KM, 1988, CLIN MANAGEMENT DYSA, P97; ZWIRNER P, 1998, AKTUELLE PHONIATRISC, P63	30	13	13	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1021-7762			FOLIA PHONIATR LOGO	Folia Phoniatr. Logop.	NOV-DEC	2001	53	6					326	337		10.1159/000052686			12	Audiology & Speech-Language Pathology; Otorhinolaryngology; Rehabilitation	Audiology & Speech-Language Pathology; Otorhinolaryngology; Rehabilitation	498LZ	WOS:000172513800004	11721139				2021-06-18	
J	Bartnik, BL; Kendall, EJ; Obenaus, A				Bartnik, BL; Kendall, EJ; Obenaus, A			Cortical devascularization: quantitative diffusion weighted magnetic resonance imaging and histological findings	BRAIN RESEARCH			English	Article						cortical devascularization; ischemia; rat; traumatic brain injury; diaschisis	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; WATER DIFFUSION; ARTERY OCCLUSION; TIME-COURSE; RATS; TISSUE; DAMAGE; MRI; DIASCHISIS	This study investigates the development of a small focal cortical lesion produced in a model of brain injury. Two approaches were chosen: diffusion weighted magnetic resonance imaging (DWI) and histology. DW images were collected before devascularization and at 0.5, 1, 2, 3, 5, 7 and 14 days after treatment. Apparent diffusion coefficient (ADC) maps were calculated from the DW images to quantify lesion development. As a second measure of injury, tissue morphology was analyzed using cresyl violet histochemistry. A significant reduction in ADC values within the cortex below the injury site by 0.5 days after surgery was observed. Between 5 and 14 days the ADC values recovered to control levels. ADC changes were also observed in the contralateral cortex at 0.5, 1 and 5 days. The decrease in ADC observed at the early time points suggested cytotoxic edema, whereas the recovery to control levels at later time points suggested infarct formation. This model of brain injury resulted in progressive but relatively slow formation of a pan-necrotic infarct within 14 days. In particular, substantial amounts of cell death were not observed until 2 days after surgery.. Overall, the quantitative and histological measures of this lesion are consistent with those observed for an ischemic type of injury, however, the time course of these lesions' development are consistent with other models of traumatic brain injury. Our data demonstrates that DWI is a highly sensitive metric for ischemic-type damage that results from brain injury. (C) 2001 Elsevier Science BY. All rights reserved.	Univ Saskatchewan, Coll Med, Dept Anat & Cell Biol, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Coll Med, Acad Dept Med Imaging, Saskatoon, SK S7N 0W8, Canada; Loma Linda Univ, Dept Radiat Med, Radiobiol Program, Loma Linda, CA 92354 USA	Obenaus, A (corresponding author), Univ Saskatchewan, Coll Med, Dept Anat & Cell Biol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	aobenaus@dominion.llumc.edu		Kendall, Edward/0000-0002-9638-9254; Bartnik-Olson, Brenda/0000-0002-1137-9437			Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; ANDREWS RJ, 1991, STROKE, V22, P943, DOI 10.1161/01.STR.22.7.943; Armitage PA, 1998, MAGN RESON MATER PHY, V6, P28, DOI 10.1016/S1352-8661(98)00007-6; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BENVENISTE H, 1992, STROKE, V23, P746, DOI 10.1161/01.STR.23.5.746; Berezovskaya O, 1996, ACTA NEUROPATHOL, V92, P479, DOI 10.1007/s004010050550; BUSZA AL, 1992, STROKE, V23, P1602, DOI 10.1161/01.STR.23.11.1602; Calamante F, 1999, MAGN RESON MED, V41, P479; CLARK RK, 1993, BRAIN RES BULL, V31, P565, DOI 10.1016/0361-9230(93)90124-T; de Crespigny A, 1998, J CEREBR BLOOD F MET, V18, P1008; Dijkhuizen RM, 1999, BRAIN RES, V840, P194, DOI 10.1016/S0006-8993(99)01769-2; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; GILL R, 1995, J CEREBR BLOOD F MET, V15, P1, DOI 10.1038/jcbfm.1995.1; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HERRERA DG, 1992, NEUROSCIENCE, V49, P781, DOI 10.1016/0306-4522(92)90356-7; Iadecola C, 1997, ANN NY ACAD SCI, V835, P203, DOI 10.1111/j.1749-6632.1997.tb48631.x; Kastrup A, 1999, J NEUROL SCI, V166, P91, DOI 10.1016/S0022-510X(99)00121-5; KEMPINSKY WH, 1958, ARCH NEURO PSYCHIATR, V79, P376, DOI 10.1001/archneurpsyc.1958.02340040020002; KNIGHT RA, 1994, STROKE, V25, P1252, DOI 10.1161/01.STR.25.6.1252; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; Li FH, 2000, STROKE, V31, P946, DOI 10.1161/01.STR.31.4.946; MATSUMOTO K, 1995, AM J NEURORADIOL, V16, P1107; Merten CL, 1999, NEURORADIOLOGY, V41, P242, DOI 10.1007/s002340050740; MINEMATSU K, 1992, NEUROLOGY, V42, P235, DOI 10.1212/WNL.42.1.235; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; PAXINOS G, 1998, RAT BRAIN STEREOTAXI; PIERPAOLI C, 1993, RADIOLOGY, V189, P439, DOI 10.1148/radiology.189.2.8210373; REITH W, 1995, AM J NEURORADIOL, V16, P53; Rumpel H, 1997, PEDIATR RES, V42, P54, DOI 10.1203/00006450-199707000-00009; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; Small DL, 1999, PROG CARDIOVASC DIS, V42, P185, DOI 10.1016/S0033-0620(99)70002-2; Sweeney MI, 1995, CAN J PHYSIOL PHARM, V73, P1525, DOI 10.1139/y95-211; Sykova E, 1997, NEUROSCIENTIST, V3, P28, DOI 10.1177/107385849700300113; SYKOVA E, 1993, J CHEM NEUROANAT, V6, P247, DOI 10.1016/0891-0618(93)90046-7; VANBRUGGEN N, 1994, BRAIN METAB REV, V6, P180; VANGELDEREN P, 1994, MAGNET RESON MED, V31, P154, DOI 10.1002/mrm.1910310209; WAHNSCHAFFE U, 1993, BRAIN RES, V615, P295, DOI 10.1016/0006-8993(93)90041-K; Wall CJ, 2000, AM J NEURORADIOL, V21, P1841; Zilles Karl, 1995, P649	44	13	14	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 12	2001	915	2					133	142		10.1016/S0006-8993(01)02805-0			10	Neurosciences	Neurosciences & Neurology	486JC	WOS:000171813800002	11595202				2021-06-18	
J	Flesher, MR; Delahanty, DL; Raimonde, AJ; Spoonster, E				Flesher, MR; Delahanty, DL; Raimonde, AJ; Spoonster, E			Amnesia, neuroendocrine levels and PTSD in motor vehicle accident victims	BRAIN INJURY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; GLUCOCORTICOID-RECEPTOR NUMBER; URINARY CORTISOL; CATECHOLAMINE EXCRETION; COMBAT VETERANS; CONSCIOUSNESS; ACTIVATION; SEVERITY; SYMPTOMS	Primary objective: To examine the initial neuroendocrine responses and subsequent PTSD symptomatology among amnesic and non-amnesic victims of motor vehicle accidents. It was hypothesized that amnesic patients would be less likely to meet PTSD criteria at 1 month follow-up and would display lower catechalomine levels and higher basal cortisol than non-amnesics. Methods and procedure: Fifteen-hour urinary hormone samples were collected from 70 MVA victims upon hospital admission. Participants were assessed for PTSD symptomatology 1 month later. Main outcomes and results: Amnesic patients displayed lower NE/cortisol ratios than non-amnesics, were less likely than non-amnesics to develop PTSD, and displayed fewer PTSD symptoms than non-amnesics. Conclusions : Amnesics may physiologically experience a motor vehicle accident differently from non-amnesics and have lower subsequent PTSD incidence. These results provide partial support for the hypothesis that amnesia for a traumatic event can serve as a buffering function in the development of subsequent PTSD among MVA victims.	Kent State Univ, Dept Psychol, Kent, OH 44242 USA; Summa Hlth Syst, Akron, OH USA	Delahanty, DL (corresponding author), Kent State Univ, Dept Psychol, 118 Kent Hall, Kent, OH 44242 USA.	ddelahan@kent.edu					Adler A, 1943, J AMER MED ASSOC, V123, P1098, DOI 10.1001/jama.1943.02840520014004; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; CAHILL L, 1994, NATURE, V371, P702, DOI 10.1038/371702a0; Delahanty DL, 2000, BIOL PSYCHIAT, V48, P940, DOI 10.1016/S0006-3223(00)00896-9; Dziedzic L, 1998, AM J EMERG MED, V16, P686, DOI 10.1016/S0735-6757(98)90177-2; First M.B., 1996, STRUCTURED CLIN INTE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Friedman MJ, 1991, J TRAUMA STRESS, V4, P67; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; HOVENS JE, 1992, J ANXIETY DISORD, V6, P147, DOI 10.1016/0887-6185(92)90013-W; Joseph S, 1999, J TRAUMA STRESS, V12, P437, DOI 10.1023/A:1024762919372; KOSTEN TR, 1987, PSYCHONEUROENDOCRINO, V12, P13, DOI 10.1016/0306-4530(87)90017-5; LEMIEUX AM, 1995, PSYCHOSOM MED, V57, P105, DOI 10.1097/00006842-199503000-00002; MASON JR, 1988, AM J PSYCHIAT, V102, P670; MASON JW, 1986, J NERV MENT DIS, V174, P149; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; McFarlane AC, 1997, ANN NY ACAD SCI, V821, P437, DOI 10.1111/j.1749-6632.1997.tb48299.x; MCGAUGH JL, 1990, PSYCHOL SCI, V1, P15, DOI 10.1111/j.1467-9280.1990.tb00060.x; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Miller L, 1998, J COGNITIVE REHABILI, V16, P10; NAUGLE RI, 1998, INTRO CLIN NEUROPSYC; NELSON A, 1986, J NERV MENT DIS, V174, P73, DOI 10.1097/00005053-198602000-00002; O'Brien M, 1998, BRIT J PSYCHIAT, V173, P102, DOI 10.1192/bjp.173.2.102; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; PITMAN RK, 1990, BIOL PSYCHIAT, V27, P245, DOI 10.1016/0006-3223(90)90654-K; Price K. P., 1994, DEF LAW J, V43, P113; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SBORDONE RJ, 1991, NEUROPSYCHOLOGY ATTO; Sherman JJ, 1998, J TRAUMA STRESS, V11, P413, DOI 10.1023/A:1024444410595; SOLOMON Z, 1993, ISRAEL J PSYCHIAT, V30, P110; TEASDALE G, 1974, LANCET, V2, P81; YEHUDA R, 1990, J NERV MENT DIS, V178, P366, DOI 10.1097/00005053-199006000-00004; YEHUDA R, 1992, J NERV MENT DIS, V180, P321, DOI 10.1097/00005053-199205000-00006; YEHUDA R, 1991, AM J PSYCHIAT, V148, P499; YEHUDA R, 1993, BIOL PSYCHIAT, V34, P18, DOI 10.1016/0006-3223(93)90252-9; YEHUDA R, 1995, ARCH GEN PSYCHIAT, V52, P583; Yehuda R, 1997, NATO ADV SCI I A-LIF, V291, P221	42	13	13	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2001	15	10					879	889		10.1080/02699050110065682			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	483HF	WOS:000171627000004	11595084				2021-06-18	
J	Hotz, G; Helm-Estabrooks, N; Nelson, NW				Hotz, G; Helm-Estabrooks, N; Nelson, NW			Development of the pediatric test of brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assessment; brain injury; children and adolescents; language; neurocognitive	CLOSED-HEAD-INJURY; CHILDREN; ADOLESCENTS; PLASTICITY; CHILDHOOD; RECOVERY; ATTENTION; DISCOURSE; SEQUELAE; TRAUMA	Objective: The Pediatric Test of Traumatic Brain Injury (PTBI)(1) (currently in its research edition) is a tool for assessing the cognitive-linguistic skills of school-aged children and adolescents in acute care and rehabilitation settings after traumatic brain injury. Development of the PTBI was motivated by the fact that, to date, no standardized test has been available to assess the full range of cognitive-linguistic impairments associated with pediatric brain injury. In this article we describe how the research edition of the PTBI was developed, provide rationale for the areas of assessment, discuss a plan for standardization, and illustrate its use with three children with TBI. Design: The PTBI was constructed to sample the attention, memory, language, reading, writing, metalinguistic, and metacognitive skills that are particularly at risk in pediatric brain injury and that are relevant to the general education curriculum. Material: The test material for the PTBI was selected on the basis of clinical and experimental evidence that children and adolescents with TBI demonstrate a wide range of cognitive and language deficits. These first appear in the early stages of recovery and often persist but change over time. Conclusion: Our goal is to standardize the PTBI so it can he used to establish baseline behaviors and track cognitive-linguistic recovery.	Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Boston Univ, Sch Med, Dept Speech Pathol, Boston, MA 02215 USA; Western Michigan Univ, Dept Speech Pathol & Audiol, Kalamazoo, MI 49008 USA	Hotz, G (corresponding author), Ryder Trauma Ctr T405, Div Neurorehabil, 1800 NW 10th Ave, Miami, FL 33136 USA.						*AG HLTH CAR POL R, 1999, 2 AG HLTH CAR POL RE; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; ANNEGERS JF, 1983, PEDIAT HEAD TRAUMA; Bishop D., 1988, LANGUAGE DEV EXCEPTI; BISHOP DVM, 1981, DEV MED CHILD NEUROL, V23, P251; BLOSSER J, 1994, PEDIAT TRAUMATIC BRA; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; BUCHWALD JS, 1990, CLIN PERINATOL, V17, P57; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; Catts H. W., 1999, LANGUAGE READING DIS; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P3; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; DENNIS MB, 1994, HDB PERCEPTION COGNI, V15, P210; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1985, HEAD INJURY REHABILI, P71; Fletcher JM, 1987, NEUROBEHAVIORAL RECO, P279; FULD PA, 1977, DEV MED CHILD NEUROL, V19, P495; GOLDSTEIN FC, 1989, CORTEX, V25, P541, DOI 10.1016/S0010-9452(89)80016-4; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; Hagen C., 1979, LEVELS COGNITIVE FUN; Hartley L. L., 1995, COGNITIVE COMMUNICAT; Helm-Estabrooks N., 1990, BRIEF TEST HEAD INJU; HOTZ GH, 2000, PEDIAT TEST BRAIN IN; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KRAUS JF, 1995, TRAUMATIC HEAD INJUR; Lahey M., 1988, LANGUAGE DISORDERS L; Lenneberg Eric H., 1967, BIOL FDN LANGUAGE; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; Levin H. S., 1989, J CLIN EXP NEUROPSYC, V12, P129; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; Mattingly I. G., 1984, LANGUAGE AWARENESS L, P9, DOI 10.1007/978-1-4613-8248-5_2; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; MILTON SB, 1991, J HEAD TRAUMA REHAB, V6, P35; Morse S, 1999, Pediatr Rehabil, V3, P139; Nelson N. W., 1998, CHILDHOOD LANGUAGE D; NELSON NW, 1991, COMMUNICATION DISORD, P191; NELSON NW, 2000, TEST INTEGRATED CURR; Nippold M., 1998, LATER LANGUAGE DEV S; Paris S., 1990, DIMENSIONS THINKING, P15; PARIS SG, 1987, INTELLIGENCE EXCEPTI, P215; Paul R., 1995, LANGUAGE DISORDERS I; PAUL R, 2000, LANGUAGE DISORDERS I; RICHARDS J, 1985, LONGMAN DICT APPL LI; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; RUTTER M, 1981, AM J PSYCHIAT, V17, P187; SCHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592; SCHNEIDER GE, 1979, NEUROPSYCHOLOGIA, V17, P557, DOI 10.1016/0028-3932(79)90033-2; SZEKERES SF, 1994, TOP LANG DISORD, V15, P21, DOI 10.1097/00011363-199411000-00004; Taylor HG, 1996, DEV NEUROPSYCHOL, V12, P35, DOI 10.1080/87565649609540639; TEASDALE G, 1974, LANCET, V2, P81; Timmermans SR, 1991, COGNITIVE REHABILITA, V9, P26; Wilde MC, 1995, J CLIN EXP NEUROPSYC, V17, P849, DOI 10.1080/01688639508402434; YLVISAKER M, 1994, TOP LANG DISORD, V15, P1, DOI 10.1097/00011363-199411000-00003	63	13	13	0	7	ASPEN PUBL INC	GAITHERSBURG	200 ORCHARD RIDGE DR, STE 200, GAITHERSBURG, MD 20878 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2001	16	5					426	440		10.1097/00001199-200110000-00003			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	483JF	WOS:000171631700003	11574039				2021-06-18	
J	Thomale, UW; Schaser, KD; Unterberg, AW; Stover, JF				Thomale, UW; Schaser, KD; Unterberg, AW; Stover, JF			Visualization of rat pial microcirculation using the novel orthogonal polarized spectral (OPS) imaging after brain injury	JOURNAL OF NEUROSCIENCE METHODS			English	Article						arterioles; cerebral blood flow; intravital microscopy; traumatic brain injury; venules	CRANIAL WINDOW TECHNIQUE; CORTICAL IMPACT INJURY; CEREBRAL MICROCIRCULATION; DETAILED DESCRIPTION; VELOCITY	Recently, the novel optical system, orthogonal polarized spectral (OPS) imaging was developed to visualize microcirculation. Investigation of changes in microcirculation is essential for physiological, pathophysiological, and pharmacological studies. In the present study applicability of OPS imaging was assessed to study,pial microcirculation in normal and traumatized rat brain. High quality images of rat pial microcirculation in normal and traumatized rats were generated with the OPS imaging, allowing to easily differentiate arterioles and venules with the dura remaining intact. In non-traumatized rats, mean vessel diameter of arterioles and venules of five different cortical regions was 19.1 +/- 2.7 and 22.2 +/- 1.4 gm, respectively. In the early phase following focal cortical contusion vessel diameter was significantly decreased in arterioles by 28% while diameter in venules was significantly increased by 27%. For technical reasons velocity in arterioles was not measurable. In venules, mean flow velocity of 0.68 +/- 0.08 mm/s was significantly decreased by 50% at 30 min after trauma. OPS imaging is an easy to use optical system allowing to generate high quality images and to reliably investigate pial microcirculation without having to remove the dura. This technique opens the possibility to perform longitudinal studies investigating changes in pial microcirculation. (C) 2001 Elsevier Science B.V. All rights reserved.	Humboldt Univ, Dept Neurosurg, Charite Virchow Med Ctr, D-13353 Berlin, Germany; Charite Virchow Med Ctr, Dept Trauma & Reconstruct Surg, D-13353 Berlin, Germany	Stover, JF (corresponding author), Humboldt Univ, Dept Neurosurg, Charite Virchow Med Ctr, Augustenburger Pl 1, D-13353 Berlin, Germany.						Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; BAEZ S, 1974, MICROCIRCULATION, V1, P23; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; Forbes HS, 1928, ARCH NEURO PSYCHIATR, V19, P751, DOI 10.1001/archneurpsyc.1928.02210110003001; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457; Groner W, 1999, NAT MED, V5, P1209; Harris AG, 2000, J VASC RES, V37, P469, DOI 10.1159/000054079; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; Klyscz T, 1997, BIOMED TECH, V42, P168, DOI 10.1515/bmte.1997.42.6.168; KUSHCHINKSY W, 1980, MICROVASC RES, V19, P385; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; MA YP, 1974, MICROVASC RES, V8, P1, DOI 10.1016/0026-2862(74)90059-4; MORII S, 1986, J CEREBR BLOOD F MET, V6, P34, DOI 10.1038/jcbfm.1986.5; NAVARI RM, 1978, MICROVASC RES, V16, P304, DOI 10.1016/0026-2862(78)90064-X; RAJADHYAKSHA M, 1995, J INVEST DERMATOL, V104, P946, DOI 10.1111/1523-1747.ep12606215; ROSENBLUM WI, 1963, ARCH NEUROL-CHICAGO, V9, P414, DOI 10.1001/archneur.1963.00460100102012; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Uhl E, 2000, PROG APPL MICROCIR, V24, P72; UNTERBERG A, 1984, J CEREBR BLOOD F MET, V4, P574, DOI 10.1038/jcbfm.1984.82; WOLF S, 1994, HYPERTENSION, V23, P464, DOI 10.1161/01.HYP.23.4.464; ZWEIFACH BW, 1974, CIRC RES, V34, P843, DOI 10.1161/01.RES.34.6.841	21	13	13	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270			J NEUROSCI METH	J. Neurosci. Methods	JUL 15	2001	108	1					85	90		10.1016/S0165-0270(01)00375-2			6	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	465FH	WOS:000170578600010	11459621				2021-06-18	
J	Rowin, ME; Xue, V; Irazuzta, J				Rowin, ME; Xue, V; Irazuzta, J			Hypothermia attenuates beta 1 integrin expression on extravasated neutrophils in an animal model of meningitis	INFLAMMATION			English	Article						integrin; hypothermia; meningitis; neutrophils	TRAUMATIC BRAIN-INJURY; INFANT RAT MODEL; BACTERIAL-MENINGITIS; POSTTRAUMATIC HYPOTHERMIA; ALPHA-5-BETA-1 INTEGRIN; CARDIOPULMONARY BYPASS; MONOCLONAL-ANTIBODIES; MODERATE HYPOTHERMIA; REDUCES INJURY; CELL-ADHESION	Brain injury in meningitis occurs in part as a consequence of leukocyte migration and activation. Leukocyte integrins are pivotal in the inflammatory response by mediating adhesion to vascular endothelium and extracellular matrix proteins. We have demonstrated that moderate hypothermia early in the course of meningitis decreases leukocyte sequestration within the brain parenchyma. This study examines whether hypothermia alters neutrophil integrin expression in a rabbit model of bacterial meningitis. Prior to the induction of meningitis, peripheral blood samples were obtained and the neutrophils isolated. Sixteen hours after inducing group B streptococcal meningitis, animals were treated with antibiotics, IV fluids, and mechanically ventilated. Animals were randomized to hypothermia (32-33 degreesC) or normothermia conditions. After 10 hours of hypothermia or normothermia, neutrophils were isolated from the blood and cerebral spinal fluid (CSF), stained for beta1 and beta2 integrins, and analyzed using flow cytometry. Cerebral spinal fluid neutrophil beta1 integrin expression was significantly decreased in hypothermic animals. Beta-1 integrins can assume a higher affinity or "activated" state following inflammatory stimulation. Expression of "activated" beta1 integrins was also significantly decreased in hypothermic animals. Beta2 CSF neutrophil integrin expression was decreased in hypothermic animals, but failed to reach significance. These data suggest hypothermia may attenuate extravasated leukocyte expression of both total and "activated" beta1 integrins.	Childrens Hosp, Med Ctr, Div Pediat Crit Care Med, Cincinnati, OH 45229 USA	Rowin, ME (corresponding author), Childrens Hosp, Med Ctr, Div Pediat Crit Care Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA.						ALBELDA SM, 1990, FASEB J, V4, P2868; ARNAOUT MA, 1990, BLOOD, V75, P1037; ATTIBELE N, 1993, J VIROL, V67, P1075, DOI 10.1128/JVI.67.2.1075-1079.1993; Bavbek M, 1998, STROKE, V29, P1930, DOI 10.1161/01.STR.29.9.1930; BERGELSON JM, 1993, J CLIN INVEST, V92, P232, DOI 10.1172/JCI116555; BERING EA, 1961, AM J PHYSIOL, V200, P417; Bogdan I, 1997, J INFECT DIS, V176, P693, DOI 10.1086/514092; BOHNSACK JF, 1990, J EXP MED, V171, P1221, DOI 10.1084/jem.171.4.1221; BOHNSACK JF, 1992, J IMMUNOL, V149, P1340; Boldt J, 1996, J CARDIOTHOR VASC AN, V10, P342, DOI 10.1016/S1053-0770(96)80094-2; Brower DL, 1997, P NATL ACAD SCI USA, V94, P9182, DOI 10.1073/pnas.94.17.9182; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHRISTENSEN JP, 1995, J IMMUNOL, V154, P5293; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Cornejo CJ, 1998, SHOCK, V9, P116, DOI 10.1097/00024382-199802000-00007; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DOERSCHUK CM, 1990, J IMMUNOL, V144, P2327; EnomotoIwamoto M, 1997, J BONE MINER RES, V12, P1124, DOI 10.1359/jbmr.1997.12.7.1124; Espinosa G, 1996, KIDNEY INT, V50, P776, DOI 10.1038/ki.1996.376; FINN A, 1993, AGENTS ACTIONS, V38, pC44, DOI 10.1007/BF01991132; Gao JX, 1997, IMMUNOLOGY, V90, P448, DOI 10.1111/j.1365-2567.1997.00448.x; GAO JX, 1995, IMMUNOLOGY, V85, P485; GARBULINSKI T, 1991, Polish Journal of Pharmacology and Pharmacy, V43, P353; GRANERT C, 1994, J CLIN INVEST, V93, P929, DOI 10.1172/JCI117098; Hansbrough JF, 1996, J SURG RES, V61, P17, DOI 10.1006/jsre.1996.0074; HANSEN PR, 1994, CARDIOVASC RES, V28, P565, DOI 10.1093/cvr/28.4.565; HAWKINS HK, 1992, PEDIATR PATHOL, V12, P119, DOI 10.3109/15513819209023288; HELLMAN P, 1994, AIDS RES HUM RETROV, V10, P391, DOI 10.1089/aid.1994.10.391; IRAZUZTA J, 2000, IN PRESS BRAIN RES; Irazuzta JE, 1999, BRAIN RES, V847, P143, DOI 10.1016/S0006-8993(99)02120-4; Jaeschke H, 1996, SHOCK, V6, P351, DOI 10.1097/00024382-199611000-00009; JAESCHKE H, 1990, FASEB J, V4, P3355; KORNELISSE RF, 1995, EUR J PEDIATR, V154, P85; KUBES P, 1995, FASEB J, V9, P1103; Lahrtz F, 1998, J NEUROIMMUNOL, V85, P33, DOI 10.1016/S0165-5728(97)00267-1; Leblond V, 2000, AIDS RES HUM RETROV, V16, P423, DOI 10.1089/088922200309089; Leib SL, 1996, J CLIN INVEST, V98, P2632, DOI 10.1172/JCI119084; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Matthay M A, 1993, New Horiz, V1, P613; MENASCHE P, 1995, CIRCULATION, V92, P334, DOI 10.1161/01.CIR.92.9.334; Miotla JM, 1996, AM J RESP CELL MOL, V14, P363, DOI 10.1165/ajrcmb.14.4.8600941; Paugam C, 1997, J CARDIOTHOR VASC AN, V11, P575, DOI 10.1016/S1053-0770(97)90007-0; Pretzlaff R, 1999, CRIT CARE MED, V27, pA129, DOI 10.1097/00003246-199901001-00357; RAO SP, 1993, INFECT IMMUN, V61, P663, DOI 10.1128/IAI.61.2.663-670.1993; Reinhardt PH, 1997, BLOOD, V89, P3837, DOI 10.1182/blood.V89.10.3837.3837_3837_3846; Rogers C, 1998, P NATL ACAD SCI USA, V95, P10134, DOI 10.1073/pnas.95.17.10134; Rowin ME, 1999, PEDIATR RES, V45, p173A, DOI 10.1203/00006450-199904020-01028; Rowin ME, 2000, INFLAMMATION, V24, P157, DOI 10.1023/A:1007085627268; SAEZLLORENS X, 1991, J CLIN INVEST, V88, P2003, DOI 10.1172/JCI115527; Tan TQ, 1997, J ANTIMICROB CHEMOTH, V39, P209, DOI 10.1093/jac/39.2.209; TUOMANEN E, 1989, Pediatric Infectious Disease Journal, V8, P923, DOI 10.1097/00006454-198912000-00047; VEDDER NB, 1988, J CLIN INVEST, V81, P939, DOI 10.1172/JCI113407; WEEKS BS, 1991, J CELL BIOL, V114, P847, DOI 10.1083/jcb.114.4.847; Whalen MJ, 1997, ACT NEUR S, V70, P260; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Williams HJ, 1998, PERFUSION-UK, V13, P322, DOI 10.1177/026765919801300507; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740; Yenari MA, 1998, EXP NEUROL, V153, P223, DOI 10.1006/exnr.1998.6876	61	13	14	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0360-3997	1573-2576		INFLAMMATION	Inflammation	JUN	2001	25	3					137	144		10.1023/A:1011044312536			8	Cell Biology; Immunology	Cell Biology; Immunology	438FR	WOS:000169043400001	11403204	Green Published			2021-06-18	
J	Kaipio, ML; Novitski, N; Tervaniemi, M; Alho, K; Ohman, J; Salonen, O; Naatanen, R				Kaipio, ML; Novitski, N; Tervaniemi, M; Alho, K; Ohman, J; Salonen, O; Naatanen, R			Fast vigilance decrement in closed head injury patients as reflected by the mismatch negativity (MMN)	NEUROREPORT			English	Article						attention; audition; closed bead injury (CHI); event-related brain potential (ERP); mismatch negativity (MMN); vigilance	EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN INJURY; DISTRACTIBILITY; ATTENTION; FREQUENCY	Event-related potentials (ERPs) were measured from 24 chronic closed head injury (CHI) patients and 18 age- and education-matched controls. The oddball paradigm was applied while subjects were watching a silent movie. The standard (P=0.8) sound of 75 ms duration had a basic frequency of 500 Hz with harmonic partials of 1000 Hz and 1500 Hz, whereas these frequencies for the pitch deviant were each 10% higher. The frequencies of the duration deviant matched with those of the standard but was 25 ms in duration. The MMN (mismatch negativity), generated by the brain's automatic auditory change-detector mechanism, was elicited by both deviants. No significant differences in the MMN latency or amplitude for either pitch or duration deviants were found between the groups. However, the MMN amplitude for the pitch deviant decreased in the patient group during the experiment considerably faster than in controls, suggesting a faster vigilance decrement in the patients. NeuroReport 12:1517-1522 (C) 2001 Lippincott Williams & Wilkins.	Univ Helsinki, Dept Psychol, Cognit Brain Res Unit, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Neurosurg, SF-00260 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Radiol, SF-00260 Helsinki, Finland	Kaipio, ML (corresponding author), Univ Helsinki, Dept Psychol, Cognit Brain Res Unit, POB 13, FIN-00014 Helsinki, Finland.		Alho, Kimmo/G-2997-2013; Novitskiy, Nikolay/ABF-3029-2020; Novitskiy, Nikolay/G-8703-2015	Alho, Kimmo/0000-0001-8563-2792; Novitskiy, Nikolay/0000-0002-4039-5209; Novitskiy, Nikolay/0000-0002-4039-5209; Tervaniemi, Mari/0000-0002-9651-2929; Ohman, Juha/0000-0002-6592-1367			Alain C, 1998, BRAIN RES, V812, P23, DOI 10.1016/S0006-8993(98)00851-8; ALHO K, 1994, ELECTROEN CLIN NEURO, V91, P353, DOI 10.1016/0013-4694(94)00173-1; Damasio A., 1994, DESCARTESERROR EMOTI; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hsiang JNK, 1998, J NEUROSURG, V88, P613; Kaipio ML, 1999, NEUROREPORT, V10, P2125, DOI 10.1097/00001756-199907130-00024; Kaipio ML, 2000, NEUROREPORT, V11, P1463; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; LANG AH, 1995, EAR HEARING, V16, P118, DOI 10.1097/00003446-199502000-00009; LEVIN HS, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P89; MCGEE TJ, 1999, ASS RES OT FLOR US F; NAATANEN R, 1978, ACTA PSYCHOL, V42, P313, DOI 10.1016/0001-6918(78)90006-9; Naatanen R, 2000, AUDIOL NEURO-OTOL, V5, P105, DOI 10.1159/000013874; NAATANEN R, 1993, PSYCHOPHYSIOLOGY, V30, P436, DOI 10.1111/j.1469-8986.1993.tb02067.x; Niemann H, 1996, NEUROPSYCHOL REV, V6, P11, DOI 10.1007/BF01875418; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; PEKKONEN E, 1995, EVOKED POTENTIAL, V96, P546, DOI 10.1016/0013-4694(95)00148-R; Schroger E, 1998, BEHAV RES METH INS C, V30, P131, DOI 10.3758/BF03209423; Sinkkonen J, 2000, AUDIOL NEURO-OTOL, V5, P235, DOI 10.1159/000013885; Tervaniemi M, 1999, CLIN NEUROPHYSIOL, V110, P1388, DOI 10.1016/S1388-2457(99)00108-X; TREJO LJ, 1995, PSYCHOPHYSIOLOGY, V32, P319, DOI 10.1111/j.1469-8986.1995.tb01214.x; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1994, CLIN NEUROPSYCHOLOGY, P63	24	13	13	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	MAY 25	2001	12	7					1517	1522		10.1097/00001756-200105250-00043			6	Neurosciences	Neurosciences & Neurology	438WT	WOS:000169077800039	11388440				2021-06-18	
J	Pelegrin-Valero, C; Gomez-Hernandez, R; Munoz-Cespedes, JM; Fernandez-Guinea, S; Tirapu-Ustarroz, J				Pelegrin-Valero, C; Gomez-Hernandez, R; Munoz-Cespedes, JM; Fernandez-Guinea, S; Tirapu-Ustarroz, J			Nosologic aspects of personality change due to head trauma	REVISTA DE NEUROLOGIA			Spanish	Article						head injury; neuropsychiatric posttraumatic disorders personality change; prevalence	INJURY	Introduction. Personality change due to head injury is one of the most prevalent neuropsychiatric posttraumatic disorders and causes significant impairment in familial, social or occupational functioning. Objectives. To study the prevalence and clinical characteristics of personality changes secondary to severe closed head injuries, according to DSM-IV criteria. Patients and methods. Fifty-five patients (aged 15-65 years) with severe head trauma were studied during the chronic stage (11-3 months) with the following instruments, the Revised Iowa Collateral Head Injury Interview for the assessment of posttraumatic frontal symptoms, the Standardized Polyvalent Psychiatric interview of Lobo et al, assessment of premorbid personality and its exacerbation, and the Scale of Aggressiveness of Yudofsky. Results. thirty-three patients (60% of the sample) fulfilled DSM-IV criteria for 'personality change due to head injury; two thirds of them were combined or mixed type, which consists in the association of two or more types specified in the DSM-IV. The most prevalent types were apathic, unstable, desinhibited, aggressive, which are related with lesions in prefrontal cortex. There were nine patients with 'unspecified' symptoms, stich as 'unappropriate euphoria' and 'poor insight', and other symptoms related to executive dysfunction. Conclusions. One third of cases of personality changes were related to premorbid features; this fact argues against the exclusion of the criterium 'excerbation of premorbid personality traits' in DSM-IV Only one third of posttraumatic personality changes can be classified according to DSM-IV and ICD-10 criteria. The high prevalence of symptoms related to deficit in self-awareness and executive dysfunction suggest the need of further investigations about nosology in this field.	Hosp Miguel Servet, Serv Psiquiatria, E-50009 Zaragoza, Spain; Hosp Miguel Servet, Serv Psiquiatria, E-50009 Zaragoza, Spain; Univ Complutense Madrid, Fac Psicol, Madrid, Spain; Fdn Argibide, Serv Neuropsicol, Pamplona, Spain; Univ Jaen, Dept Psicol, Jaen, Spain		cpelegrinv@medynet.com					*AS PSIQ AM, 1995, DSM 4 MAN DIAGN EST; *AS PSIQ AM, 1988, DSM 3 R MAN DIAGN ES; Berrios G E, 1990, Behav Neurol, V3, P247, DOI 10.3233/BEN-1990-3404; BLUMER D, 1976, PSYCHIAT ASPECTS NEU, P151; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CASSILETH BR, 1984, NEW ENGL J MED, V311, P506, DOI 10.1056/NEJM198408233110805; FORDYCE JJ, 1983, J NEUROL NEUROSUR PS, V43, P373; JABLENSKY A, 1991, PSYCHOL MED S, V20; JASPERS K, 1980, PSICOPATOLOGIA GEN, P559; KLEIST K, 1931, MONATSSCH PSYCHIAT, V71, P338; Lezak M. D., 1989, ASSESSMENT BEHAV CON, P113; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LOBO A, 1993, PSYCHOL MED, V23, P505, DOI 10.1017/S0033291700028592; Mann R. S., 1996, REV PSYCHIAT, V15, P205; MARTZKE JS, 1991, NEUROPSYCHOLOGY, V5, P213, DOI DOI 10.1037/0894-4105.5.3.213; MORENO P, 1996, NEUROPSIQUIATRIA DAN, P11; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; *ORG MUND SAL, 1994, CIE 10 TRAST MENT CO; PELEGRIN C, 1996, NEUROPSIQUIATRIA DAN, P97; PELEGRIN C, 1996, ANN M AM PSYCH ASS N; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; SANCHEZ P, 1999, INFORMACIONES PSIQUI; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Tyrer P, 1996, AM J PSYCHIAT, V153, P1593; URBACH JR, 1991, PSYCHOSOMATICS, V32, P24, DOI 10.1016/S0033-3182(91)72108-7; Widiger TA, 1995, DIAG TR MEN, P433; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35; Yudofsky SC, 1987, TXB NEUROPSYCHIATRY, P179; 1995, B OFICIAL ESTADO, V268	31	13	14	0	4	REVISTA DE NEUROLOGIA	BARCELONA	C/O CESAR VIGUERA, EDITOR, APDO 94121, 08080 BARCELONA, SPAIN	0210-0010	1576-6578		REV NEUROLOGIA	Rev. Neurologia	APR 1	2001	32	7					681	687		10.33588/rn.3207.2000180			7	Clinical Neurology	Neurosciences & Neurology	435VB	WOS:000168901900016	11391499				2021-06-18	
J	Seguin, P; Bleichner, JP; Branger, B; Guillou, YM; Feuillu, A; Malledant, Y				Seguin, P; Bleichner, JP; Branger, B; Guillou, YM; Feuillu, A; Malledant, Y			End-tidal carbon dioxide tension is not a pertinent parameter for monitoring severe head trauma	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			French	Article							MECHANICAL VENTILATION; ARTERIAL; CAPNOGRAPHY; GRADIENT; PCO2	Purpose: To evaluate the agreement between end-tidal carbon dioxide (PETCO2) and arterial CO2 (PaCO2) in patients with traumatic brain injury and to document the course of the (PaCO2 - PETCO2) gradient over time. Methods: Twenty one traumatic brain injury patients (Coma Glasgow Scale less than or equal to 8) were included in this prospective observational study over a period of sir months. Simultaneous determinations of PoCO2 and PETCO2 (by infrared capnometry) were recorded. Agreement between PaCO2 and PETCO2 was determined by the statistical method described by Blond and Altman, Changes in PETCO2 over time were compared with changes in PaCO2. Factors likely to explain a gradient superior to +/- 4 mmHg were explored. Results: One hundred and eleven data pairs were obtained. The bios was 5.5 mmHg with a precision of 5.1 mmHg and limits of agreement ranged from -4.5 mmHg to 15.5 mmHg. The latter exceeded the predefined limits of agreement established to determine interchange-ability between methods (+/- 4 mmHg). PETCO2 and PaCO2 changed in opposite directions in 20% of 90 consecutive measurements. Only the duration of ventilation was found to be significantly associated with a gradient superior to +/- 4 mmHg. Conclusions In this selected population of patients with severe traumatic brain injury, measurements of PETCO2 and PaCO2 ore not interchangeable. Further, the PaCO2 - PETCO2 gradient is not stable over time and cannot predict variations of PaCO2. The use of PETCO2 instead of PaCO2 could be deleterious in patients in whom strict control of PaCO2 values is required.	Serv Anesthesie Reanimat Chirurg, Rennes, France; Hosp Rennes, Dept Hyg, Rennes, France; Biochim Lab, Rennes, France	Seguin, P (corresponding author), CHRU Pontchaillou, Serv Reanimat Chirurg, 2 Rue Henri Courriel, F-35033 Rennes, France.		Seguin, Philippe/P-9487-2019	Seguin, Philippe/0000-0002-7774-4257; Malledant, yannick/0000-0001-6680-5184			BHAVANISHANKAR K, 1992, CAN J ANAESTH, V39, P617, DOI 10.1007/BF03008330; BLANCH L, 1987, CHEST, V92, P451, DOI 10.1378/chest.92.3.451; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bullock MR, 1996, J NEUROTRAUM, V13, P653; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; ENGOREN M, 1992, J NEUROSURG ANESTH, V4, P241, DOI 10.1097/00008506-199210000-00002; HEALEY CJ, 1987, CRIT CARE MED, V15, P764, DOI 10.1097/00003246-198708000-00011; HOFFMAN RA, 1989, AM REV RESPIR DIS, V140, P1265, DOI 10.1164/ajrccm/140.5.1265; ISERT P, 1994, ANAESTH INTENS CARE, V22, P435, DOI 10.1177/0310057X9402200419; Kerr ME, 1996, CRIT CARE MED, V24, P785, DOI 10.1097/00003246-199605000-00010; MACKERSIE RC, 1990, CRIT CARE MED, V18, P764, DOI 10.1097/00003246-199007000-00017; RUSSELL GB, 1994, J TRAUMA, V36, P317, DOI 10.1097/00005373-199403000-00006; RUSSELL GB, 1990, CAN J ANAESTH, V37, P560, DOI 10.1007/BF03006326; RUSSELL GB, 1992, J NEUROSURG ANESTH, V4, P245, DOI 10.1097/00008506-199210000-00003; TOBIN MJ, 1990, JAMA-J AM MED ASSOC, V264, P244, DOI 10.1001/jama.264.2.244; WAHBA RWM, 1991, CAN J ANAESTH, V38, P384, DOI 10.1007/BF03007630; YAMANAKA MK, 1987, CHEST, V92, P832, DOI 10.1378/chest.92.5.832	17	13	13	0	1	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	APR	2001	48	4					396	400		10.1007/BF03014971			5	Anesthesiology	Anesthesiology	422QU	WOS:000168131400015	11341245	Bronze			2021-06-18	
J	Finnie, JW; Van den Heuvel, C; Gebski, V; Manavis, J; Summersides, GE; Blumbergs, PC				Finnie, JW; Van den Heuvel, C; Gebski, V; Manavis, J; Summersides, GE; Blumbergs, PC			Effect of impact on different regions of the head of lambs	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article							AMYLOID PRECURSOR PROTEIN; AXONAL INJURY; BRAIN INJURY; MODEL	The heads of anaesthetized lambs aged 4 5 weeks were subject to impact (temporal, frontal or occipital) of constant strength with a humane stunner. Two hours later, the brains were perfusion-fixed with 4 degrees paraformaldehyde and serial whole coronal slices processed by routine methods. Sections were stained with haematoxylin and eosin or labelled with a monoclonal antibody to amyloid precursor protein, a sensitive marker of axonal injury and neuronal reaction. Microscopical evaluation of axonal, neuronal and vascular damage was performed with a quantitative grid system. Frontal impact produced the greatest damage, followed by occipital then temporal impact. An unusual lesion found in the majority of lambs subjected to impact was multifocal necrosis of the cerebellar granular layer. The findings should assist clinicians in evaluating the probable outcome of traumatic head injury in domestic animals. (C) 2001 Harcourt Publishers Ltd.	Inst Med & Vet Sci, Vet Serv Div, Adelaide, SA 5000, Australia; Inst Med & Vet Sci, Neuropathol Lab, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Pathol, Adelaide, SA 5000, Australia; Univ Sydney, NHMRC, Clin Trials Ctr, Sydney, NSW 2006, Australia	Finnie, JW (corresponding author), Inst Med & Vet Sci, Vet Serv Div, Adelaide, SA 5000, Australia.			, Corinna/0000-0003-0664-8935			Blumbergs P. C., 1997, HEAD INJURY PATHOPHY, P39; DALY CC, 1986, RES VET SCI, V41, P353, DOI 10.1016/S0034-5288(18)30629-5; Finnie J, 1999, J CLIN NEUROSCI, V6, P38, DOI 10.1016/S0967-5868(99)90601-X; Finnie JW, 1997, AUST VET J, V75, P204, DOI 10.1111/j.1751-0813.1997.tb10067.x; Finnie JW, 1999, VET PATHOL, V36, P256, DOI 10.1354/vp.36-3-256; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; Lighthall J.W., 1994, NEUROBIOLOGY CENTRAL, P3; Mattson MP, 1997, PHYSIOL REV, V77, P1081; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SUMMERS BA, 1995, VET NEUROPATHOLOGY, P189; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Ward JD, 1996, NEUROTRAUMA, P859; ZEGAR S, 1986, BIOMETRICS, V42, P121	17	13	16	0	2	ACADEMIC PRESS LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0021-9975			J COMP PATHOL	J. Comp. Pathol.	FEB-APR	2001	124	2-3					159	164		10.1053/jcpa.2000.0446			6	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	404ZL	WOS:000167132700010	11222013				2021-06-18	
J	Azian, AA; Nurulazman, AA; Shuaib, IL; Mahayidin, M; Ariff, AR; Naing, NN; Abdullah, J				Azian, AA; Nurulazman, AA; Shuaib, IL; Mahayidin, M; Ariff, AR; Naing, NN; Abdullah, J			Computed tomography of the brain in predicting outcome of traumatic intracranial haemorrhage in Malaysian patients	ACTA NEUROCHIRURGICA			English	Article						computed tomography; head injury; predictors; Malaysia	SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; SUBARACHNOID HEMORRHAGE; CT SCAN; INTRACEREBRAL HEMATOMA; EXTRADURAL HEMATOMAS; PROGNOSTIC FACTORS; SYSTEM	Head injury is a significant economic, social and medical problem all over the world. Road accidents are the most frequent cause of head injury in Malaysia with highest risk in the young (15 to 24 years old). The associated outcomes include good recovery, possibility of death for the severely injured, which may cause disruption of the lives of their family members. It is important to predict the outcome as it will provide sound information to assist clinicians in Malaysia in providing prognostic information to patients and their families, to assess the effectiveness of different modes of treatment in promoting recovery and to document the significance of head injury as a public health problem. Results. A total of 103 cases with intracranial haemorrhage i.e. intracerebral haemorrhage, extradural haemorrhage, subdural haemorrhage, intraventricular haemorrhage, haemorrhagic contusion and subarachnoid haemorrhage, following motor vehicle accidents was undertaken to study factors contributing to either good or poor outcome according to the Glasgow Outcome Scale. Patients below 12 years of age were excluded. The end point of the study was taken at 24 months post injury. The selected variables were incorporated into models generated by logistic regression techniques of multivariate analysis to see the significant predictors of outcome as well as the correlation between the CT findings with GCS. Conclusion. Significant predictors of outcome were GCS on arrival in the accident emergency department, papillary reflex and the CT scan findings. The CT predictors of outcome include ICH, EDH, IVH, present of SAH, site of ICH, volumes of EDH and SDH as well as midline shift.	Hosp Univ Sains Malaysia, Dept Radiol, Kelantan, Malaysia; Univ Sci Malaysia, Sch Med Sci, Unit Epidemiol & Med Stat, Kelantan, Malaysia; Hosp Univ Sains Malaysia, Dept Neurosci, Div Neurosurg, Kelantan, Malaysia	Abdullah, J (corresponding author), Hosp Univ Sci Malaysia, Dept Neurosci, Div Neurosurg, Kubang Kerian Kelantan 16150, Malaysia.		Naing, Nyi Nyi/AAB-3851-2021; Naing, Nyi Nyi/M-3455-2015; Shuaib, Ibrahim Lutfi/B-5380-2009; Abdullah, J/C-2828-2011	Naing, Nyi Nyi/0000-0001-8308-5625; Abdullah, J/0000-0002-0258-7410			Abraszko RA, 1995, BRIT J NEUROSURG, V9, P769, DOI 10.1080/02688699550040747; Athiappan S., 1993, Annals Academy of Medicine Singapore, V22, P452; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; CAPLAN LR, 1994, INTRACEREBRAL HEMORR, P221; CHOKSEY M, 1993, BRIT J NEUROSURG, V7, P611, DOI 10.3109/02688699308995090; COOK RJ, 1988, ACTA NEUROCHIR, V95, P90, DOI 10.1007/BF01790766; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; DEWEERD AW, 1979, J NEUROL, V222, P45; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; FELDMAN Z, 1996, NEUROTRAUMA, P805; FRANKE CL, 1992, J NEUROL NEUROSUR PS, V55, P653, DOI 10.1136/jnnp.55.8.653; GAETANI P, 1995, J NEUROL NEUROSUR PS, V59, P635, DOI 10.1136/jnnp.59.6.635; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GERBER CJ, 1993, ACTA NEUROCHIR, V122, P11, DOI 10.1007/BF01446981; Graham DI, 1996, NEUROTRAUMA, P43; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; HIJDRA A, 1990, STROKE, V21, P1156, DOI 10.1161/01.STR.21.8.1156; HIJDRA A, 1988, STROKE, V19, P1250, DOI 10.1161/01.STR.19.10.1250; ISHIBASHI A, 1991, Kurume Medical Journal, V38, P167; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; KASE CS, 1994, INTRACEREBRAL HEMORR, P467; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; KISHORE PRS, 1981, AM J ROENTGENOL, V137, P829, DOI 10.2214/ajr.137.4.829; KUDAY C, 1994, ACTA NEUROCHIR, V131, P203, DOI 10.1007/BF01808613; Kunishio Katsuzo, 1992, Neurological Surgery, V20, P959; LANE B, 1999, DIAGNOSTIC RADIOLOGY, P2001; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; LIPPER MH, 1985, AM J ROENTGENOL, V144, P483, DOI 10.2214/ajr.144.3.483; LOBATO RD, 1983, J NEUROSURG, V12, P161; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Orrison William W. Jr., 1996, P71; PAPO I, 1982, ACTA NEUROCHIR, V62, P47, DOI 10.1007/BF01402210; SELLADURAI BM, 1992, BRIT J NEUROSURG, V6, P549, DOI 10.3109/02688699209002372; SERVADEI F, 2000, EUR BRAIN INJ CONSUT, V46, P70; SERVADEI F, 1997, ACTA NEUROCHIR WIEN, V139, P272; STEINER I, 1984, STROKE, V15, P279, DOI 10.1161/01.STR.15.2.279; SWEET RC, 1978, NEUROSURGERY, V3, P16, DOI 10.1227/00006123-197807000-00003; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; Torner James C., 1996, P19; TOUTANT SM, 1984, J NEUROSURG, V2, P323; TSAI FY, 1978, J COMPUT ASSIST TOMO, V2, P323, DOI 10.1097/00004728-197807000-00018; TUHRIM S, 1988, ANN NEUROL, V24, P258, DOI 10.1002/ana.410240213; Valadka AB, 1996, NEUROTRAUMA, P119; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; WOODRUFF WW, 1993, FUNDAMENTALS NEUROIM, P121; YAMAURA A, 1981, Neurologia Medico-Chirurgica, V21, P685; YASUKAWA K, 1988, Neurological Surgery, V16, P482; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	54	13	14	0	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		2001	143	7					711	720		10.1007/s007010170051			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	456NW	WOS:000170089900025	11534693				2021-06-18	
J	Mayr, JM; Seebacher, U; Lawrenz, K; Pesendorfer, P; Berghold, A; Baradaran, S				Mayr, JM; Seebacher, U; Lawrenz, K; Pesendorfer, P; Berghold, A; Baradaran, S			Bunk beds - a still underestimated risk for accidents in childhood?	EUROPEAN JOURNAL OF PEDIATRICS			English	Article						injury prevention; bunk bed; child; fall; side-rail	CHILDREN FALL; INJURIES; TRAUMA	A retrospective analysis of 218 bunk-bed accidents and a random sample survey with 991 family interviews were performed in order to establish guidelines for bunk-bed accident prevention. Falls from the top bed during sleep (35.1%) or while playing (34.4%) and falling off the ladder (23.2%) are the leading causes of bunk-bed accidents. Of the 218 children. 91 (41.7%) had sustained major injuries, including 3 polytrauma, 7 skull fractures, 44 cerebral concussions. 33 long bone fractures, 2 Lisfranc injuries, and 2 lacerations of the spleen. Of these accidents, 58.3% resulted in minor injuries with 18 fractures in other locations than the long bones or cranial vault, 89 contusions and sprains, 18 skin lacerations and 2 tooth fractures. A total of 23.8% of the accidents occurred in children under 3 years of age. The random sample survey demonstrated that in relation to age groups of children 30.8% (0%-45.8%) of families interviewed had been using bunk beds, with peaks at 3 years (29.8%), 7 years (36.5%) and 11 years (45.8%) of age. Of these bunk beds, 75.3% were equipped with side-rails, 57.3% had placed carpets alongside the bunk bed and 43.0% had used night lights. Conclusion There is only one recommendation: no bunk beds!!!	Graz Univ, Dept Paediat Surg, A-8036 Graz, Austria; Graz Univ, Inst Med Informat, A-8036 Graz, Austria	Mayr, JM (corresponding author), Graz Univ, Dept Paediat Surg, Auenbruggerpl 34, A-8036 Graz, Austria.						*AS NZS, 1994, 4220 ASNZS; DAKLIA F, 1995, ARCH PEDIATR, V2, P185; Gaig P, 1999, ANN ALLERG ASTHMA IM, V82, P531, DOI 10.1016/S1081-1206(10)63160-2; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; HELFER RE, 1977, PEDIATRICS, V60, P533; JAFFE D, 1991, NEW ENGL J MED, V324, P1477; JOHNSON GF, 1981, AM J ROENTGENOL, V137, P1041, DOI 10.2214/ajr.137.5.1041; LYONS TJ, 1993, PEDIATRICS, V92, P125; NIMITYONGSKUL P, 1987, J PEDIATR ORTHOPED, V7, P184, DOI 10.1097/01241398-198703000-00014; SELBST SM, 1990, AM J DIS CHILD, V144, P721, DOI 10.1001/archpedi.1990.02150300121031; *US CONS PROD SAF, 1985, 71 US CONS PROD SAF; *US CONS PROD SAF, 1987, UN FURN PROV BUNK BE; *US CONS PROD SAF, 1996, 828296 US CPSC; *US CONS PROD SAF, 1997, 97095 US CPSC; WATSON W, 1999, INT J CONSUMER PRODU, V6, P87	15	13	13	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0340-6199			EUR J PEDIATR	Eur. J. Pediatr.	JUN	2000	159	6					440	443		10.1007/s004310051303			4	Pediatrics	Pediatrics	320VQ	WOS:000087421900009	10867850				2021-06-18	
J	Kaplan, CP				Kaplan, CP			Community integration questionnaire for patients with brain tumor - A comparative study	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						community integration; handicap; brain tumor; assessment		Objectives: This study compares mean scores obtained on the Community Integration Questionnaire among patients with brain tumor and published data for traumatic brain injury and nonpatient groups. Design: Subjects included 33 adult outpatients with biopsy-confirmed high-grade malignant brain tumors. Both sexes were represented. Subjects were older and better educated than historic samples. The Community Integration Questionnaire was positively skewed. Results: Subjects had higher scores on the Social Integration Scale than on Productivity. Higher education was associated with Productivity and the Community Integration Questionnaire total score. However, greater age was associated with lower scores. Significant gender effects were obtained. Conclusions: Women with brain tumors had significantly higher Home Integration Scores than males with tumors. However, Home Integration was lower for persons with brain tumors than for either the corresponding gender in the traumatic brain injury model systems group for males and females, respectively. Similarly, compared with community-dwelling persons with traumatic brain injury, males, but not females, with cerebral tumors had significantly lower Social Integration scores. When compared with nondisabled adults, persons with brain tumors reported significantly lower Productivity and Community Integration Questionnaire total scores.	Med Univ S Carolina, Dept Phys Med & Rehabil, Charleston, SC 29425 USA	Kaplan, CP (corresponding author), Med Univ S Carolina, Dept Phys Med & Rehabil, 150 Ashley Ave,POB 250583, Charleston, SC 29425 USA.						Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Kaplan CP, 1997, BRAIN INJURY, V11, P129; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Willer B., 1993, BRAIN INJURY REHABIL, P355; World Health Organization, 1980, INT CLASS IMP DIS HA	7	13	13	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAY-JUN	2000	79	3					243	246		10.1097/00002060-200005000-00005			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	313FK	WOS:000086989500005	10821309				2021-06-18	
J	Pentland, LM; Anderson, VA; Wrennall, JA				Pentland, LM; Anderson, VA; Wrennall, JA			The implications of childhood bacterial meningitis for language development	CHILD NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; INFLUENZAE MENINGITIS; NARRATIVE DISCOURSE; ADVERSE OUTCOMES; CHILDREN; SEQUELAE; AGE; SURVIVORS; IRRADIATION; ADOLESCENTS	Bacterial meningitis is a life threatening infection of the central nervous system. This illness is most prevalent early in life when the healthy child is rapidly acquiring language. This study investigated whether children with a history of bacterial meningitis were at risk for language difficulties post illness. Thirty post-meningitic children, aged between 9 years 0 months and 11 years 0 months, participated in this study. Each subject was administered a measure of non-verbal cognitive ability and a range of language tasks. These children performed poorly on applied language tasks, which tap skills used in effective discourse. These deficits occurred despite age appropriate performances on measures of linguistic/grammatical knowledge. These findings clearly illustrate that bacterial meningitis has implications for ongoing language development, which emphasises the importance of long term follow up. In developmental terms, this discrepancy between verbal knowledge and problem solving represents a dissociation between language skills which develop early in life and those which emerge later. This pattern of results suggests that bacterial meningitis may result in a delay in language development. A young age at illness was identified as an additional risk factor for adverse outcome. This study highlights the need to inform parents/guardians that post-meningitic children are at risk for experiencing language difficulties throughout childhood.	Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; Univ Melbourne, Parkville, Vic 3052, Australia	Pentland, LM (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	l.pentland@pgrad.unimelb.edu.au					ALAJOUANINE T, 1965, BRAIN, V88, P653, DOI 10.1093/brain/88.4.653; Anderson RC, 1997, ADV OCCUP MED REHAB, V3, P47; ANDERSON V, 1994, ARCH DIS CHILD, V70, P476, DOI 10.1136/adc.70.6.476; Anderson V, 1997, J Int Neuropsychol Soc, V3, P147; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 1997, Pediatr Rehabil, V1, P63; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; BARAFF LJ, 1993, PEDIATR INFECT DIS J, V12, P389, DOI 10.1097/00006454-199305000-00008; Barnes MA, 1996, READING COMPREHENSION DIFFICULTIES, P251; BASSER LS, 1962, BRAIN, V85, P427, DOI 10.1093/brain/85.3.427; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Daniel A. E., 1983, POWER PRIVILEGE PRES; DAVIES PA, 1994, CLIN DEV MED, V132; Dennis M, 1996, J NEURO-ONCOL, V29, P91, DOI 10.1007/BF00165522; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; DENNIS M, 1996, TRAUMATIC HEAD INJUR, P165; DENNIS M, 1990, DISCOURSE ABILITY BR, P199; DORVAL B, 1984, MONOGR SOC RES CHILD, V49, P1, DOI 10.2307/1165872; EISER C, 1978, ARCH DIS CHILD, V53, P391, DOI 10.1136/adc.53.5.391; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; FEIGN RD, 1992, TXB PEDIAT INFECT DI, P439; FRANCO SM, 1992, AM J DIS CHILD, V146, P567, DOI 10.1001/archpedi.1992.02160170047014; FRASER DW, 1982, EPIDEMIOLOGY HAEMOPH; GRIMWOOD K, 1995, PEDIATRICS, V95, P646; Grimwood K, 1996, J PAEDIATR CHILD H, V32, P457, DOI 10.1111/j.1440-1754.1996.tb00949.x; HEMPHILL L, 1994, J COMMUN DISORD, V27, P107, DOI 10.1016/0021-9924(94)90037-X; HERSON VC, 1977, PEDIATRICS, V59, P35; HORN JL, 1967, ACTA PSYCHOL, V26, P107, DOI 10.1016/0001-6918(67)90011-X; JADAVJI T, 1986, PEDIATRICS, V78, P21; Kennard MA, 1936, AM J PHYSIOL, V115, P138; KLEIN JO, 1986, PEDIATRICS, V75, P959; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; *LANG LEARN DIS SP, 1995, LANG LEARN CHECKL LA; LENNENBERG EH, 1967, BIOL FDN LANGUAGE; McGhee P. E., 1979, HUMOR ITS ORIGINS DE; Pan B. A., 1999, DEV LANGUAGE, P229; RUBENSTEIN CL, 1990, J DEV BEHAV PEDIATR, V11, P301; Schank R., 1977, SCRIPTS PLANS GOALS; Secord, 1989, TEST LANGUAGE COMPET; SELL S, 1983, PEDIATR INFECT DIS J, V6, P775; Semel E. M., 1995, CLIN EVALUATION LANG; SNOW CE, 1977, J CHILD LANG, V4, P1, DOI 10.1017/S0305000900000453; TAKAHASHI K, 1992, J MATER SCI LETT, V11, P15, DOI 10.1007/BF00720768; TAYLOR HG, 1990, NEW ENGL J MED, V323, P1657, DOI 10.1056/NEJM199012133232403; TEUBER H, 1962, DEV MED CHILD NEUROL, V4, P20; Wechsler D., 1991, WECHSLER INTELLIGENC; WRIGHT M, 1994, ARCH DIS CHILD, V71, P64, DOI 10.1136/adc.71.1.64; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375	52	13	13	0	3	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.		2000	6	2					87	100		10.1076/chin.6.2.87.7055			14	Clinical Neurology	Neurosciences & Neurology	378GZ	WOS:000165577800002	16210206				2021-06-18	
J	Rashid, MA; Wikstrom, T; Ortenwall, P				Rashid, MA; Wikstrom, T; Ortenwall, P			Cardiac injuries: a ten-year experience	EUROPEAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	European Symposium on Trauma	SEP, 1998	LINKOPING, SWEDEN			heart injuries; pericardial tamponade; myocardial contusion; commotio cordis	PERICARDIAL TAMPONADE; MYOCARDIAL CONTUSION; TRAUMA; DIAGNOSIS; WOUNDS; HEART	Objective: To present our experience of cardiac injuries treated at one Swedish emergency department in the 10 years 1988-97. Design: Retrospective study. Setting: Teaching hospital. Subjects: 11 patients (9 men and 2 women, mean age 33 years, range 19-54); in 7 they were penetrating injuries and in 4 blunt. Main outcome measures: Morbidity and mortality. Results: The mechanisms of injury were stab wound (n = 7), and car crash, fall, boat crash, and abuse (n = 1 each); drug or alcohol misuse played a part in all those with penetrating injuries. The penetrating wounds involved the left ventricle (n = 3), the right ventricle (n = 2, and the pericardium (n = 2). All 5 patients with ventricular wounds presented with cardiac tamponade, in 1 of whom it was fatal Ore bled to death during emergency thoracotomy). The main complications were anoxic brain damage and postpericardiotomy syndrome (1 each). There was no case of myocardial concussion. Conclusion: Our data reflect the Swedish experience of heart trauma: there are few cases, alcohol and drug misuse is the principal risk factor, and there were no gunshot wounds.	Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Surg, Div Vasc & Trauma Surg, Gothenburg, Sweden	Rashid, MA (corresponding author), Trebackegatan 11, SE-41674 Gothenburg, Sweden.						AALAND MO, 1994, AM SURGEON, V60, P412; AROM KV, 1977, ANN THORAC SURG, V23, P545, DOI 10.1016/S0003-4975(10)63699-5; Asensio JA, 1998, J AM COLL SURGEONS, V186, P24, DOI 10.1016/S1072-7515(97)00144-0; Baker JM, 1998, ARCH SURG-CHICAGO, V133, P855, DOI 10.1001/archsurg.133.8.855; Beck CS, 1935, J AMER MED ASSOC, V104, P714, DOI 10.1001/jama.1935.02760090018005; Campbell NC, 1997, BRIT J SURG, V84, P1737, DOI 10.1046/j.1365-2168.1997.02819.x; DEMETRIADES D, 1986, ANN SURG, V203, P315, DOI 10.1097/00000658-198603000-00018; FRAZEE RC, 1986, J TRAUMA, V26, P510, DOI 10.1097/00005373-198606000-00004; FULDA G, 1991, J TRAUMA, V31, P167, DOI 10.1097/00005373-199131020-00003; Godwin J D, 1987, J Thorac Imaging, V2, P32, DOI 10.1097/00005382-198707000-00007; GUEST TM, 1995, JAMA-J AM MED ASSOC, V273, P1945, DOI 10.1001/jama.273.24.1945; JONES JW, 1975, ANN SURG, V181, P567, DOI 10.1097/00000658-197505000-00009; MARON BJ, 1995, NEW ENGL J MED, V333, P337, DOI 10.1056/NEJM199508103330602; MASON LB, 1958, J THORAC SURG, V29, P524; MATTOX KL, 1992, J TRAUMA, V33, P649; MAYORDAVIES JA, 1992, S AFR J SURG, V30, P18; MORENO C, 1986, J TRAUMA, V26, P821, DOI 10.1097/00005373-198609000-00007; ORALIAGUET G, 1993, J TRAUMA, V34, P455; PARMLEY LF, 1958, CIRCULATION, V18, P371, DOI 10.1161/01.CIR.18.3.371; Rhee PM, 1998, J TRAUMA, V45, P366, DOI 10.1097/00005373-199808000-00028; RuDusky BM, 1996, CHEST, V109, P1413, DOI 10.1378/chest.109.5.1413-a; SUGG WL, 1968, J THORAC CARDIOV SUR, V56, P531, DOI 10.1016/S0022-5223(19)42812-2; TENZER ML, 1985, J TRAUMA, V25, P620, DOI 10.1097/00005373-198507000-00008; WILSON RF, 1966, J AMER MED ASSOC, V195, P513, DOI 10.1001/jama.195.7.513	24	13	14	0	0	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	1102-4151			EUR J SURG	Eur. J. Surg.	JAN	2000	166	1					18	21					4	Surgery	Surgery	278XY	WOS:000085015300003	10688211				2021-06-18	
J	Sarno, S; Erasmus, LP; Lipert, G; Frey, M; Lipp, B; Schlaegel, W				Sarno, S; Erasmus, LP; Lipert, G; Frey, M; Lipp, B; Schlaegel, W			Electrophysiological correlates of visual impairments after traumatic brain injury	VISION RESEARCH			English	Article						visual evoked potentials; traumatic brain injury; visual attention; synchronization	CONTRAST LETTER CHARTS; SELECTIVE ATTENTION; CORTEX; SYNCHRONIZATION	Our aims were to investigate: (i) the VEP correlates of functional visual impairments following traumatic brain injury (TBI), in particular of the reduced spatial form perception; and (ii) the VEP correlates of visual sustained arousal in TBI patients. We used two approaches: (i) the analysis of latency and amplitude of the peaks; and (ii) the study of the correlations among the latencies of the peaks as a label of temporal synchronization. Thirty-five severe TBI outcome inpatients and 35 matching controls were studied. Pattern-reversal VEPs were recorded at Oz-Fz and Cz-Al, first without counting, then with counting of the reversals. Seven peaks of the waveform at Oz and eight peaks at Cz were measured. We found several differences in amplitude and latency between patients and controls, and between nocount/count. The temporal binding of the peaks within each channel and between the two channels was calculated by correlation matrices, and tested by factor analysis. Results indicated that the synchronization of the peaks within each channel did not differ between patients and controls. The temporal covariation between peaks occurring at Oz and Cz, however, was highly significantly altered in patients. This suggests that visual impairments in TBI patients may be due to a deranged synchronization of the activity of different brain regions. (C) 2000 Elsevier Science Ltd. All rights reserved.	Therapiezentrum Burgau, D-89331 Burgau, Germany; Marianne Strauss Klin, D-82335 Berg Kempfenhausen, Germany	Sarno, S (corresponding author), Therapiezentrum Burgau, Dr Friedl Str 1, D-89331 Burgau, Germany.	lerasmus@aol.com					AKSIONOFF EB, 1992, J AM OPTOMETRY ASS, V63, P542; ALTER I, 1990, Brain Injury, V4, P19, DOI 10.3109/02699059009026144; CELESIA CG, 1985, EVOKED POTENTIALS NE, P245; CIGANEK L, 1967, ELECTROEN CLIN NEURO, V26, P70; Clark VP, 1996, J COGNITIVE NEUROSCI, V8, P387, DOI 10.1162/jocn.1996.8.5.387; CREMONAMETEYARD SL, 1994, BRAIN INJURY, V8, P541, DOI 10.3109/02699059409151006; Daffner KR, 2000, J NEUROL NEUROSUR PS, V68, P18, DOI 10.1136/jnnp.68.1.18; DOWNING CJ, 1988, J EXP PSYCHOL HUMAN, V14, P188, DOI 10.1037/0096-1523.14.2.188; EASON RG, 1969, PHYSIOL BEHAV, V4, P283, DOI 10.1016/0031-9384(69)90176-0; EASON RG, 1981, B PSYCHONOMIC SOC, V18, P203; Engel AK, 1997, CEREB CORTEX, V7, P571, DOI 10.1093/cercor/7.6.571; Freed S, 1997, BRAIN INJURY, V11, P25, DOI 10.1080/026990597123782; GARCIAAUSTT E, 1994, ELECTROEN CLIN NEURO, V17, P136; GUPTA NK, 1986, NEUROLOGY, V36, P578, DOI 10.1212/WNL.36.4.578; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; Husain M, 1996, J NEUROL, V243, P652, DOI 10.1007/BF00878662; KEITH RA, 1987, ADV CLIN REHABILITAT, V2, P6; KONIG P, 1993, EUR J NEUROSCI, V5, P501, DOI 10.1111/j.1460-9568.1993.tb00516.x; LUCK SJ, 1994, J EXP PSYCHOL HUMAN, V20, P887, DOI 10.1037/0096-1523.20.4.887; Lumer ED, 1999, P NATL ACAD SCI USA, V96, P1669, DOI 10.1073/pnas.96.4.1669; Lumer ED, 1998, SCIENCE, V280, P1930, DOI 10.1126/science.280.5371.1930; NAKAMURA RK, 1986, EXP BRAIN RES, V63, P173; PADULA WV, 1994, BRAIN INJURY, V8, P125, DOI 10.3109/02699059409150964; PRATTJOHNSON JA, 1973, BRIT J OPHTHALMOL, V57, P347, DOI 10.1136/bjo.57.5.347; REGAN D, 1983, OPHTHALMOLOGY, V90, P1192; REGAN D, 1984, BRIT J OPHTHALMOL, V68, P885, DOI 10.1136/bjo.68.12.885; REGAN D, 1977, BRAIN, V100, P563, DOI 10.1093/brain/100.3.563; Rodriguez E, 1999, NATURE, V397, P430, DOI 10.1038/17120; ROELFSEMA PR, 1994, EUR J NEUROSCI, V6, P1645, DOI 10.1111/j.1460-9568.1994.tb00556.x; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; SPONG P, 1968, ELECTROEN CLIN NEURO, V24, P396; Staiman K, 1998, CLIN EYE VISUAL CARE, V10, P119; Tierney D W, 1988, J Am Optom Assoc, V59, P614; Whyte J, 1998, J INT NEUROPSYCH SOC, V4, P127, DOI 10.1017/S1355617798001271; ZIHL J, 1989, ELECTROEN CLIN NEURO, V74, P394, DOI 10.1016/0168-5597(89)90007-5	35	13	13	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0042-6989	1878-5646		VISION RES	Vision Res.		2000	40	21					3029	3038		10.1016/S0042-6989(00)00137-1			10	Neurosciences; Ophthalmology; Psychology	Neurosciences & Neurology; Ophthalmology; Psychology	349EP	WOS:000089030900011	11000399				2021-06-18	
J	Viola, L; Zotta, D; Martino, V; Barbato, R; Schisano, G				Viola, L; Zotta, D; Martino, V; Barbato, R; Schisano, G			Minor head injuries: One year experience according to the new Italian guideline	ACTA NEUROCHIRURGICA			English	Article						Italian guideline; mild head injury; Glasgow Coma Scale score	HEMATOMA; MANAGEMENT; CLASSIFICATION; CONCUSSION; SEQUELAE; SYMPTOMS; RISK	Background The data concerning a consecutive series of 4,536 adult patients suffering from minor head injuries treated at the Department of Neurosurgery over a period of one year are reported. Method The patients' age, sex and the circumstances of the injury have been taken into consideration. The patients, according to the new method, were divided into four groups. Group 0 (3,864 patients) included all patients with Glasgow Coma Scale (GCS) score 15. They did not present any clinical features such as loss of consciousness (LOC), post-traumatic amnesia (PTA), headache or vomiting. No risk factors (RF) such as coagulopaties, alcoholism, drug abuse, epilepsy, previous neurological treatment or disabled elderly patients were detected. Group 1 (600 patients) included patients with GCS score 15. The patients presented one or more clinical features (LOC, PTA, headache, vomiting). No RF were presented. Group 2 (24 patients) included patients with GCS score 14 with or without clinical features (LOC, PTA, headache, vomiting) and with or without RF. Group 0-1R (48 patients) included patients with GCS score 15 with or without clinical features (LOC, PTA, headache, vomiting). All of them presented RF. The presence of focal neurological signs, open injury and GCS score less than or equal to 13 were considered criteria for exclusion. Findings. All the patients from groups 1, 0-1R, 2 and 187 patients from group 0 underwent CT scan for a total of 859 exams which are analyzed and discussed. 458 patients were admitted and are divided as follows: 216 from group 0, 192 from group 1, 26 from group 0-1R and all the 24 belonging to group 2. Six patients were treated surgically (3 extradural haematomas, 2 lobe contusions, 1 acute subdural haematoma) and one of them (0.02% of the total) died (extradural haematoma). The patients who were not admitted were sent home with an information sheet after at least a six hour observation period. Interpretation. The authors draw the conclusion that they have evaluated the applicability and efficacy of guidelines, developed by the study group on head injury of the Italian Society of Neurosurgery [19]. A critical parr of our guidelines is not only to identify all the intracranial lesions, but to identify patients harbouring relevant intracranial mass before clinical deterioration.	Nuovo Pellegrini Hosp, Dept Neurosurg, ASL Naples 1, I-80144 Naples, Italy	Viola, L (corresponding author), Nuovo Pellegrini Hosp, Dept Neurosurg, ASL Naples 1, Via Filippo Maria Briganti 255, I-80144 Naples, Italy.						Arienta C, 1997, SURG NEUROL, V48, P213, DOI 10.1016/S0090-3019(97)00019-0; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; CHAN KH, 1990, J NEUROSURG, V72, P189, DOI 10.3171/jns.1990.72.2.0189; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; LUCCHI S, 1995, RIV NEURORADIOL, V8, P415, DOI 10.1177/197140099500800308; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; POON WS, 1992, NEUROSURGERY, V30, P681; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; Study Group on Head Injury of the Italian Society for Neurosurgery, 1996, J NEUROSURG SCI, V40, P11; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; YOUNG HA, 1984, NEUROSURGERY, V14, P22, DOI 10.1227/00006123-198401000-00006	21	13	13	0	2	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		2000	142	11					1281	1285		10.1007/s007010070026			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	387GW	WOS:000166115700024	11201644				2021-06-18	
J	Lang, JK; Ludwig, HC; Mursch, K; Zimmerer, B; Markakis, E				Lang, JK; Ludwig, HC; Mursch, K; Zimmerer, B; Markakis, E			Elevated cerebral perfusion pressure and low colloid osmotic pressure as a risk factor for subdural space-occupying hygromas?	SURGICAL NEUROLOGY			English	Article						traumatic brain injury; cerebral perfusion pressure; colloid osmotic pressure; subdural hygroma		BACKGROUND Space-occupying subdural hygromas are a late complication of severe traumatic brain injury (TBI) and may delay the patient's recovery. To evaluate the risk factors involved, we performed a semiretrospective, -prospective analysis of three groups of patients, which differed with regard to the techniques used in the management of their cerebral perfusion pressure (CPP) and colloid osmotic pressure (COP) to determine the occurrence of space-occupying subdural hygromas. PATIENTS AND METHODS Between 1989 and 1997 we examined 696 patients after a severe TBI: Group 1. 1989-1994 mean CPP: 67 (elevated for therapeutic reasons by catecholamines, if necessary), mean COP: 19. Group 2. January 1995-October 1996, mean CPP: 77, mean COP: 20. Group 3. November 1996-December 1997, mean CPP: 79, mean COP: 23 (elevated for therapeutic reasons by infusions of colloids). The groups were comparable for other criteria. RESULTS Compared to Group 1, Group 2, with a high CPP but lower COP, showed a significantly higher (p < 0.01; chi(2)-test with correction of Yates) percentage of posttraumatic subdural hygromas with space-occupying aspects, clinical signs of bradycardia, hypertension and impaired consciousness requiring surgery (Group 1: 1.75%; Group 2. 10.46%; Group 3. 0%). In Group 3 we saw no patient with a space-occupying hygroma. CONCLUSION We conclude that iatrogenic elevated CPP, which has been reported to be helpful in preventing secondary ischemic damage after a severe TBI, may be harmful to a patient if the COP is not maintained within physiological ranges. (C) 1999 by Elsevier Science Inc.	Univ Gottingen, Dept Neurosurg, D-37075 Gottingen, Germany	Lang, JK (corresponding author), Univ Gottingen, Dept Neurosurg, Robert-Koch-Str 40, D-37075 Gottingen, Germany.						BALDWIN AL, 1993, LYMPHOLOGY, V26, P4; CHAN KH, 1993, NEUROSURGERY, V32, P547; da Costa DG, 1941, ARCH SURG-CHICAGO, V43, P559, DOI 10.1001/archsurg.1941.01210160020003; FRENCH BN, 1978, SURG NEUROL, V9, P145; Giulioni M, 1996, NEUROSURGERY, V39, P1005, DOI 10.1097/00006123-199611000-00024; GUTIERREZ FA, 1974, AM J DIS CHILD, V128, P327, DOI 10.1001/archpedi.1974.02110280057007; HANS P, 1994, ANN FR ANESTH, V13, P123, DOI 10.1016/S0750-7658(94)80195-9; HEISEY SR, 1983, AM J PHYSIOL, V244, P224; HOFF J, 1973, J TRAUMA, V13, P870, DOI 10.1097/00005373-197313100-00005; Ishibashi Akira, 1994, Kurume Medical Journal, V41, P81; JACCARD E, 1983, NEUROCHIRURGIE, V29, P333; KARANKO MS, 1987, CRIT CARE MED, V15, P737, DOI 10.1097/00003246-198708000-00005; KUNZ U, 1993, UNFALLCHIRURG, V96, P595; LAMKE L O, 1976, Resuscitation, V5, P85, DOI 10.1016/0300-9572(76)90028-9; LANG J, 1997, ZENTRALBL NEUROCHI S; LUSINS JO, 1993, MT SINAI J MED, V60, P161; MIRCEVSKI M, 1986, CHILD NERV SYST, V2, P314, DOI 10.1007/BF00271946; NAFFZIGER HC, 1924, JAMA-J AM MED ASSOC, V82, P1751; NILSSON C, 1991, J CEREBR BLOOD F MET, V11, P861, DOI 10.1038/jcbfm.1991.146; Prior FGR, 1996, INT J ARTIF ORGANS, V19, P487; SIBBALD WJ, 1981, J APPL PHYSIOL, V50, P1337; VanderLinden P, 1996, ANN FR ANESTH, V15, P456, DOI 10.1016/0750-7658(96)83206-0; WEISS MH, 1978, ARCH NEUROL-CHICAGO, V35, P527, DOI 10.1001/archneur.1978.00500320047010; WETTERLING T, 1986, ACTA NEUROCHIR, V83, P99, DOI 10.1007/BF01402385; WETTERLING T, 1988, ACTA NEUROCHIR, V91, P79, DOI 10.1007/BF01400533; WINESTOCK DP, 1975, RADIOLOGY, V115, P373, DOI 10.1148/115.2.373	26	13	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	0090-3019			SURG NEUROL	Surg. Neurol.	DEC	1999	52	6					630	637		10.1016/S0090-3019(99)00144-5			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	277LQ	WOS:000084935400033	10660033				2021-06-18	
J	Talmor, D; Merkind, V; Artru, AA; Shapiro, O; Geva, D; Roytblat, L; Shapira, Y				Talmor, D; Merkind, V; Artru, AA; Shapiro, O; Geva, D; Roytblat, L; Shapira, Y			Treatments to support blood pressure increases bleeding and/or decreases survival in a rat model of closed head trauma combined with uncontrolled hemorrhage	ANESTHESIA AND ANALGESIA			English	Article							INDUCED HYPERTENSION; HYPOTENSION; INJURY; SALINE; EDEMA	Hemorrhagic hypotension may aggravate the detrimental effects of head trauma on neurologic outcome. Our study examined whether using phenylephrine or large volumes of saline IV to increase mean arterial blood pressure (MAP) to 70, 80, or 90 mm Hg during the combination of head trauma and uncontrolled hemorrhage would improve neurologic outcome. Rats were assigned to one of 17 groups. In Groups 1-5, the variables were head trauma (yes/no), hemorrhage (yes/no), 0 or 3 mL saline per milliliter of blood lost, and no target MAP. In Groups 6-11, hemorrhage was or was not combined with head trauma, and large volumes of saline were given IV to achieve target MAPs of 70, 80, or 90 mm Hg. Groups 12-17 were similar to Groups 6-11 except that phenylephrine was used rather than saline to achieve target MAPs. Saline increased blood loss at 2 h to approximately 16 and 25 mL at a MAP of 80 and 90 mm Hg respectively, increased (worsened) the neurodeficit score but not cerebral edema at 24 h, and decreased survival rate at 2 and 24 h. Because phenylephrine was fatal for 62 of 63 rats, group mean values for blood loss, neurodeficit score, and brain tissue specific gravity could not be calculated. We conclude that supporting MAP with either phenylephrine or large volumes of saline worsened the neurodeficit score and/or survival and did not affect cerebral edema formation in our rat model of head trauma combined with hemorrhage. Implications: The results of this study indicate that maintaining mean arterial blood pressure at 70, 80, or 90 mm Hg with either phenylephrine or large volumes of saline worsened the neurodeficit score and/or survival and did not affect cerebral edema formation in our rat model of head trauma combined with hemorrhage.	Univ Washington, Sch Med, Dept Anesthesiol, Seattle, WA 98195 USA; Ben Gurion Univ Negev, Fac Hlth Sci, Div Anesthesiol, Soroka Med Ctr, Beer Sheva, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, Div Neurosurg, Soroka Med Ctr, Beer Sheva, Israel; Kaplan Hosp, Dept Anesthesiol, IL-76100 Rehovot, Israel	Artru, AA (corresponding author), Univ Washington, Sch Med, Dept Anesthesiol, Box 356540, Seattle, WA 98195 USA.						AVELLINO AM, 1997, TXB NEUROANESTHESIA, P1137; Bedell EA, 1998, ANESTH ANALG, V87, P751; DRUMMOND JC, 1992, STROKE, V75, P238; Feldman Z, 1997, J TRAUMA, V43, P667, DOI 10.1097/00005373-199710000-00017; Gurevich B, 1998, RESUSCITATION, V38, P25, DOI 10.1016/S0300-9572(98)00067-7; KRAUSZ MM, 1992, J TRAUMA, V33, P6, DOI 10.1097/00005373-199207000-00002; RABINOVICI R, 1989, SURG GYNECOL OBSTET, V169, P137; SHAFTAN GW, 1965, SURGERY, V58, P851; SHAPIRA Y, 1995, J NEUROSURG ANESTH, V7, P17, DOI 10.1097/00008506-199501000-00004; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Talmor D, 1998, ANESTH ANALG, V87, P574, DOI 10.1097/00000539-199809000-00014	11	13	13	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	1999	89	4					950	956		10.1097/00000539-199910000-00024			7	Anesthesiology	Anesthesiology	240LP	WOS:000082827700024	10512270				2021-06-18	
J	Shiller, AD; Burke, DT; Kim, HJ; Calvanio, R; Dechman, KG; Santini, C				Shiller, AD; Burke, DT; Kim, HJ; Calvanio, R; Dechman, KG; Santini, C			Treatment with amantadine potentiated motor learning in a patient with traumatic brain injury of 15 years' duration	BRAIN INJURY			English	Article								This study sought to determine whether pharmacotherapy with amantadine potentiates motor recovery in an 18-year-old man with traumatic brain injury (TBI) of 15 years' duration. This uncontrolled single-case multiple-baseline design allowed preliminary evaluation of amantadine within the context of standard data-collection procedures on the TBI unit. Measurements tracked speed of wheelchair propulsion, wheelchair transfer, donning shirt, and inserting pegs into holes. Data were collected during a 3-week practice period, followed by a 6-week period of practice plus daily treatment with amantadine. The rate at which performance improved was significantly increased with drug treatment in the wheelchair transfer task. There was a statistically insignificant trend toward improvement in donning shia. Amantadine did not appear to potentiate recovery in the wheelchair propulsion or peg placement tasks. The results suggest that amantadine facilitates some measures of motor recovery in chronic brain injury. Further trials are warranted to investigate this issue.	Spaulding Rehabil Hosp, Dept PM&R, Boston, MA 02114 USA	Shiller, AD (corresponding author), Spaulding Rehabil Hosp, Dept PM&R, 125 Nashua St, Boston, MA 02114 USA.	ashiller@alum.mit.edu					GIANUTSOS G, 1985, EUR J PHARMACOL, V110, P357, DOI 10.1016/0014-2999(85)90564-3; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Vogenthaler D R, 1987, Brain Inj, V1, P113	7	13	16	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	1999	13	9					715	721					7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	239YX	WOS:000082799300004	10507453				2021-06-18	
J	Togher, L; Hand, L				Togher, L; Hand, L			The macrostructure of the interview: Are traumatic brain injury interactions structured differently to control interactions?	APHASIOLOGY			English	Article							HEAD-INJURY; DISCOURSE; POPULATION; ADULTS	Previous descriptions of discourse deficits following traumatic brain injury (TBI) at a macrostructural level have used analyses such as cohesion and story structure. This paper proposes a macrolinguistic analysis called generic structure potential analysis (GSP) (Ventola 1979) which describes the overall structuring of the unfolding process of two types of interviews. Seven TBI subjects are compared with matched control subjects across two conditions: a community education information-giving encounter to two 16 year old school students and an information requesting interaction with the researcher. The possible GSP elements of these types of encounters include greeting, identification, approaches which enable interactants to establish interpersonal links, centring which directly relate to the purpose of the interviews, leave-taking and goodbye. The GSP of student interactions was similar for TBI and control subjects but differences were noted in the researcher condition. The value of placing TBI subjects in information giving roles and the importance of the communication partner's contributions to the interaction is highlighted. GSP analysis allows the clinician/researcher to analyse the interview context by taking the contextual configuration into account. It map provide a valuable clinical tool in the assessment and treatment of discourse deficits which commonly follow TBI.	Univ Sydney, Sch Commun Sci & Disorders, Fac Hlth Sci, Lidcombe, NSW 2141, Australia; Liverpool Area Hlth Serv, Brain Injury Rehabil Unit, Sydney, NSW, Australia	Togher, L (corresponding author), Univ Sydney, Sch Commun Sci & Disorders, Fac Hlth Sci, POB 170, Lidcombe, NSW 2141, Australia.		Togher, Leanne/AAC-7083-2019	Togher, Leanne/0000-0002-4518-6748			Adamovich B. B., 1992, SCALES COGNITIVE ABI; BONDCHAPMAN S, 1995, J HEAD TRAUMA REHAB, V10, P36; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; EGGINS S, 1990, THESIS U SYDNEY SYDN; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Hartley L. L., 1995, COGNITIVE COMMUNICAT; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Perkins M. R., 1995, CASE STUDIES CLIN LI, P293; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Szekeres Shirley F., 1992, Seminars in Speech and Language, V13, P293, DOI 10.1055/s-2008-1064204; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; VENTOLA E, 1979, J PRAGMATICS, V3, P267, DOI 10.1016/0378-2166(79)90034-1	18	13	14	0	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0268-7038			APHASIOLOGY	Aphasiology	SEP-NOV	1999	13	9-11					709	723		10.1080/026870399401821			15	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	248MM	WOS:000083279200009					2021-06-18	
J	Kuhnen, G; Bauer, R; Walter, B				Kuhnen, G; Bauer, R; Walter, B			Controlled brain hypothermia by extracorporeal carotid blood cooling at normothermic trunk temperatures in pigs	JOURNAL OF NEUROSCIENCE METHODS			English	Article						ECoG; hypothermia; isolated brain cooling; regional brain temperatures; arterial blood pressure	MODERATE HYPOTHERMIA; CEREBRAL-ISCHEMIA; CANINE BRAIN; INJURY; SIGNALS; DAMAGE; PERFUSION; GOAT; RATS	Cerebral hypothermia improves outcomes after brain injury. A technique is presented for isolated brain cooling in pigs by cooling the natural blood supply of the brain. Under general anesthesia both common carotid arteries were exteriorized. One proximal carotid artery was connected to both distal carotid arteries and a heat exchanger in this line controlled brain temperature. The second proximal carotid artery was connected to an external jugular vein and a heat exchanger in this arteriovenous shunt was used to clamp trunk temperature. Thalamic brain temperatures of anesthetized juvenile pigs (N = 8) were clamped at 38, 25, and 30 degrees C while trunk core temperature was clamped at 38 degrees C. Approximately 7 min were needed to decrease brain temperature from 38 to 25 degrees C, reducing brain electric activity by 76% and increasing the temperature differences between different brain sites. Mean arterial blood pressure, heart rate, and cardiac output showed no significant change. Re-establishment of normothermic brain temperature led to a virtually complete recovery of brain electric activity. The technique is suitable for investigations of ischemic and traumatic injuries. (C) 1999 Elsevier Science B.V. All rights reserved.	Univ Giessen, Inst Physiol, D-35392 Giessen, Germany; Klinikum Friedrich Schiller Univ, Inst Pathophysiol, Jena, Germany	Kuhnen, G (corresponding author), Univ Giessen, Inst Physiol, Aulweg 129, D-35392 Giessen, Germany.						*AM PHYSL SOC, 1996, AM J PHYSIOL, P271; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; Commission for Thermal Physiology of the International Union of Physiological Sciences (IUPS), 1987, PFLUGERS ARCH, V410, P567; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1996, NEUROTRAUMA, P1491; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; Gelman B, 1996, CRIT CARE MED, V24, P1009, DOI 10.1097/00003246-199606000-00022; Ginsberg MD, 1997, CEREBROVASC DIS, V7, P7, DOI 10.1159/000108237; HAYWARD JN, 1969, BRAIN RES, V16, P417, DOI 10.1016/0006-8993(69)90236-4; HORN M, 1991, ACTA NEUROPATHOL, V81, P443, DOI 10.1007/BF00293466; HUNTER WS, 1966, J APPL PHYSIOL, V21, P873; INGRAM DL, 1973, PFLUG ARCH EUR J PHY, V339, P299, DOI 10.1007/BF00594165; JESSEN C, 1990, PFLUG ARCH EUR J PHY, V416, P428, DOI 10.1007/BF00370750; JESSEN C, 1984, AM J PHYSIOL, V247, pR456; KUHNEN G, 1991, PFLUG ARCH EUR J PHY, V418, P176, DOI 10.1007/BF00370468; KUHNEN G, 1994, AM J PHYSIOL, V267, pR355; KULUZ JW, 1992, STROKE, V23, P1792, DOI 10.1161/01.STR.23.12.1792; KULUZ JW, 1993, AM J PHYSIOL, V265, pH824; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; LANGER T, 1994, TEMPERATURE REGULATI, P145; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MELLERGARD P, 1992, NEUROSURGERY, V31, P671; MICHENFELDER JD, 1991, ANESTHESIOLOGY, V75, P130, DOI 10.1097/00000542-199107000-00021; Ohta T, 1996, NEUROSURGERY, V38, P1211, DOI 10.1097/00006123-199606000-00032; Schmied H, 1996, LANCET, V347, P289, DOI 10.1016/S0140-6736(96)90466-3; Schwartz AE, 1996, NEUROSURGERY, V39, P577; STEEN PA, 1983, ANESTHESIOLOGY, V58, P527, DOI 10.1097/00000542-198306000-00009; TAYLOR CA, 1991, THERMOREGULATION PAT, P363; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013; WHITE RJ, 1983, RESUSCITATION, V10, P193, DOI 10.1016/0300-9572(83)90008-4	32	13	14	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270			J NEUROSCI METH	J. Neurosci. Methods	JUL 15	1999	89	2					167	174		10.1016/S0165-0270(99)00070-9			8	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	231XE	WOS:000082336000011	10491948				2021-06-18	
J	McCrory, P				McCrory, P			The eighth wonder of the world: the mythology of concussion management	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							2ND IMPACT SYNDROME; STANDARDIZED ASSESSMENT; FOOTBALL PLAYERS; AUSTRALIAN RULES		Olymp Pk Sports Med Ctr, Melbourne, Vic 3004, Australia	McCrory, P (corresponding author), Olymp Pk Sports Med Ctr, Melbourne, Vic 3004, Australia.		McCrory, Paul/Q-8688-2019				Barth JT., 1989, MILD HEAD INJURY, P257; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; Congress of Neurological Surgeon, 1966, CLIN NEUROSURG, V12, P386; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; MADDOCKS DL, 1991, J CLIN EXP NEUROPSYC, V13, P439; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; STENGER JM, 1964, J AM DENT ASSOC, V69, P273, DOI 10.14219/jada.archive.1964.0290; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006	18	13	13	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	1999	33	2					136	137		10.1136/bjsm.33.2.136			2	Sport Sciences	Sport Sciences	184CT	WOS:000079592300028	10205701	Green Published, Bronze			2021-06-18	
J	Turkstra, LS				Turkstra, LS			Language testing in adolescents with brain injury: A consideration of the CELF-3	LANGUAGE SPEECH AND HEARING SERVICES IN SCHOOLS			English	Article						assessment; communication; traumatic; head injury	TEST-PERFORMANCE; WORKING-MEMORY; SYNTAX	The validity of the Clinical Evaluation of Language Fundamentals-Third Edition (CELF-3, Semel, Wiig, & Secord, 1995 for the identification and description of language disorders following traumatic brain injury :TBI) was considered in 11 adolescents with TBI. In general, the CELF-3 identified only the individuals who had previously been diagnosed as language impaired,, not the individuals with verbal information processing impairments but no diagnosis of language impairment. the test did not permit the identification of strengths acid weaknesses. Intercorrelations among subtest standard scores were as high in the TBI group as in the standardization sample, which is consistent with the CELF-3 beina a one-factor test, Test performance may have been influenced by the interaction of the subjects memory abilities and the subtests' memory demands, although this relationship was not statistically significant in the present data.	Univ Arizona, Tucson, AZ 85721 USA	Turkstra, LS (corresponding author), Case Western Reserve Univ, Dept Commun Sci, Cleveland, OH 44106 USA.						BLOSSER J, 1994, PEDIAT TRAUMATIC BRA; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; FLETCHER RH, 1988, CLIN EPIDEMIOLOGY ES; GAULIN CA, 1994, PERCEPT MOTOR SKILL, V79, P55, DOI 10.2466/pms.1994.79.1.55; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; HAMMILL D, 1991, DETROIT TESTS LEARNI; Hartley L. L., 1995, COGNITIVE COMMUNICAT; McCauley RJ, 1996, LANG SPEECH HEAR SER, V27, P122, DOI 10.1044/0161-1461.2702.122; OBRZUT JE, 1987, J LEARN DISABIL, V20, P596, DOI 10.1177/002221948702001005; Plante E, 1996, LANG SPEECH HEAR SER, V27, P99, DOI 10.1044/0161-1461.2702.99; Ponsford J., 1995, TRAUMATIC BRAIN INJU; PRIGATANO GP, 1987, J LEARN DISABIL-US, V20, P603, DOI 10.1177/002221948702001006; Semel E., 1987, CLIN EVALUATION LANG; SEMEL W, 1995, CLIN EVALUATION LANG; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; TOWNE RL, 1993, LANG SPEECH HEAR SER, V24, P100; Turkstra LS, 1998, APHASIOLOGY, V12, P421, DOI 10.1080/02687039808249541; Turkstra LS, 1998, J SPEECH LANG HEAR R, V41, P137, DOI 10.1044/jslhr.4101.137; TURKSTRA LS, 1997, UNPUB SUPPLEMENTARY; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU	20	13	13	0	6	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA	0161-1461			LANG SPEECH HEAR SER	Lang. Speech Hear. Serv. Sch.	APR	1999	30	2					132	140		10.1044/0161-1461.3002.132			9	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	186BN	WOS:000079707100003	27764275				2021-06-18	
J	Uhl, E; Pickelmann, S; Rohrich, F; Baethmann, A; Schurer, L				Uhl, E; Pickelmann, S; Rohrich, F; Baethmann, A; Schurer, L			Influence of platelet-activating factor on cerebral microcirculation in rats part 2. Local application	STROKE			English	Article						cerebral circulation; leukocytes; microcirculation; platelet activating factor; rats	FACTOR PAF; INTRAVITAL MICROSCOPY; LEUKOCYTE ADHESION; ENDOTHELIAL-CELLS; ARTERY OCCLUSION; BRAIN INJURY; BOVINE BRAIN; DAMAGE; ARTERIOLES; ANTAGONIST	Background and Pupose-Platelet-activating factor (AF) is involved in the development of secondary brain damage after ischemic and traumatic brain injury. On the basis of data from studies in peripheral organs, we hypothesized that PAF-mediated effects after cerebral injury could be secondary to alterations in cerebral microcirculation. Methods-Changes in cerebral microcirculation focusing on leukocyte-endothelium interactions were quantified with the use of a closed cranial window model in Sprague-Dawley rats (n=33) by means of intravital fluorescence microscopy. The brain surface was superfused with PAF in concentrations from 10(-3) (n=3) to 10(-12) mol/L (n=6) for 20 minutes (5 mL/h), Results-PAF 10(-4) mol/L (n=4) increased the number of rolling and adherent leukocytes in venules from 9.7+/-0.4 to 19.7+/-2.3 cells/100 mm min (P=NS versus control) and from 2.2+/-0.5 to 4.3+/-0.7 cells/100 mm min (P<0.05 versus control), respectively. Lower concentrations did not elicit leukocyte-endothelium interactions. Vessel diameters remained unchanged except for a transient increase of arteriolar diameters during superfusion with PAF 10(-4) and 10(-6) mol/L (n=6). Although only a limited area of the brain surface was exposed to PAF, the mediator induced a significant dose-dependent transitory arterial hypotension and caused irreversible circulatory shock at the high concentration (PAF 10(-3) mol/L), Arterial hypotension after administration of PAF 10(-3) mol/L could be attenuated by the intravenous pretreatment with the PAF antagonist WEB 2170BS. Conclusions-PAF, when locally released after brain injury, can penetrate the blood-brain barrier and induce systemic effects, including arterial hypotension. Its role as a mediator in the development of secondary brain damage seems, at least in the initial phase, nut to be associated with disturbances of cerebral microcirculation or activation of leukocytes.	Grosshadern Univ Hosp, Dept Neurosurg, D-81377 Munich, Germany; Grosshadern Univ Hosp, Dept Surg, D-81377 Munich, Germany; Grosshadern Univ Hosp, Inst Surg Res, D-81377 Munich, Germany; Zent Klinikum Bad Berka, Dept Neurosurg, Bad Berka, Germany; Univ Hosp, Dept Neurosurg, Mannheim, Germany	Uhl, E (corresponding author), Grosshadern Univ Hosp, Dept Neurosurg, Marchioninistr 15, D-81377 Munich, Germany.	Eberhard.Uhl@nc.med.uni-muenchen.de	Hungerer, Sven/H-5818-2013	Hungerer, Sven/0000-0002-1615-1423			ARMSTEAD WM, 1988, CIRC RES, V62, P1, DOI 10.1161/01.RES.62.1.1; BEKKER AY, 1988, MICROCIRC ENDOTH LYM, V4, P433; BJORK J, 1983, EUR J PHARMACOL, V96, P87, DOI 10.1016/0014-2999(83)90532-0; BLANK ML, 1981, J BIOL CHEM, V256, P175; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; CHIBA Y, 1990, N-S ARCH PHARMACOL, V341, P68; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; DILLON PK, 1988, CIRC RES, V62, P732, DOI 10.1161/01.RES.62.4.732; DILLON PK, 1988, INFLAMMATION, V12, P563, DOI 10.1007/BF00914318; DOMINGO MT, 1994, BRAIN RES, V640, P268, DOI 10.1016/0006-8993(94)91882-1; EDWARDS RM, 1991, J LIPID MEDIATOR, V3, P161; Feuerstein G, 1988, Prog Biochem Pharmacol, V22, P181; FRERICHS KU, 1990, J NEUROSURG, V73, P223, DOI 10.3171/jns.1990.73.2.0223; GRIGORIAN GY, 1987, CIRC RES, V61, P389, DOI 10.1161/01.RES.61.3.389; HEUER HO, 1990, J PHARMACOL EXP THER, V255, P962; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; KUMAR R, 1988, BIOCHIM BIOPHYS ACTA, V963, P375, DOI 10.1016/0005-2760(88)90304-9; LAI FM, 1983, LIFE SCI, V32, P1159, DOI 10.1016/0024-3205(83)90122-4; LINDSBERG PJ, 1990, J LIPID MEDIATOR, V2, P41; MATSUO Y, 1995, J CEREBR BLOOD F MET, V15, P941, DOI 10.1038/jcbfm.1995.119; MUACEVIC G, 1992, ARZNEIMITTEL-FORSCH, V42-2, P1001; NAMM DH, 1982, THROMB RES, V25, P341, DOI 10.1016/0049-3848(82)90234-1; OBERPICHLER H, 1990, J CEREBR BLOOD F MET, V10, P133, DOI 10.1038/jcbfm.1990.17; SATOH K, 1992, ACTA NEUROL SCAND, V85, P122, DOI 10.1111/j.1600-0404.1992.tb04010.x; SAWYER DB, 1989, BIOCHIM BIOPHYS ACTA, V987, P129, DOI 10.1016/0005-2736(89)90464-1; SPINNEWYN B, 1987, PROSTAGLANDINS, V34, P337, DOI 10.1016/0090-6980(87)90079-7; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TOKUMURA A, 1987, BIOCHEM BIOPH RES CO, V145, P415, DOI 10.1016/0006-291X(87)91338-6; Uhl E, 1999, STROKE, V30, P873, DOI 10.1161/01.STR.30.4.873; USKI TK, 1990, J CEREBR BLOOD F MET, V10, P428, DOI 10.1038/jcbfm.1990.74; YOSHIDA JI, 1986, J PHARM PHARMACOL, V38, P878, DOI 10.1111/j.2042-7158.1986.tb03375.x; YUE TL, 1994, CRIT REV NEUROBIOL, V8, P11; ZEINTL H, 1989, INT J MICROCIRC, V8, P293	34	13	14	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	APR	1999	30	4					880	886		10.1161/01.STR.30.4.880			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	180TP	WOS:000079401500034	10187895	Bronze, Green Published			2021-06-18	
J	Katz, S; Aloni, R				Katz, S; Aloni, R			Sexual dysfunction of persons after traumatic brain injury: perceptions of professionals	INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH			English	Article						professionals; sexuality; traumatic brain injury		The purpose of this paper was to study the perceptions of professionals in the field of rehabilitation in Israel concerning sexual dysfunction of persons after traumatic brain injury. Thirty professionals filled out an open-ended questionnaire that focused on problems of sexual functioning, dyadic and social relationships, and suggestions for the most appropriate interventions for these problems. The results indicated that for persons with TBI, the physical changes were not identified as the primary obstacle preventing persons after TBI from achieving sexual satisfaction, but rather the cognitive and emotional sequelae of TBI. A number of possible intenvention techniques were also suggested.	Bar Ilan Univ, Dept Psychol, IL-52900 Ramat Gan, Israel; Beit Loewenstein Hosp, Raanana, Israel	Katz, S (corresponding author), Bar Ilan Univ, Dept Psychol, IL-52900 Ramat Gan, Israel.						ALONI R, 1996, THESIS UNION COLL CI; ANDERSON DW, 1980, J NEUROSURGERY S, V53; Berrol S, 1981, SEXUALITY PHYSICAL D, P203; Blackerby WF, 1990, J HEAD TRAUMA REHAB, V5, P73; BLACKERBY WF, 1993, HDI PROFESSIONAL SER, V10; DAVIS DL, 1990, J HEAD TRAUMA REHAB, V5, P31, DOI DOI 10.1097/00001199-199005020-00006; Griffith ER, 1993, SEXUALITY PERSON TRA; KATZ S, 1987, INT J PSYCHIAT MED, V16, P325; *NHIF, 1984, SIL EP; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; PONSFORD J, 1995, TRAUMATIC BRAIN INJU, P254; PRIGATANO GP, 1988, 13 ANN C SOC STUD BR; ZASLER ND, 1990, J HEAD TRAUMA REHAB, V5, P14, DOI DOI 10.1097/00001199-199005020-00004; Zasler ND, 1991, SEX DISABIL, V9, P11	14	13	13	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0342-5282			INT J REHABIL RES	Int. J. Rehabil. Res.	MAR	1999	22	1					45	53		10.1097/00004356-199903000-00006			9	Rehabilitation	Rehabilitation	188VJ	WOS:000079869200006	10207751				2021-06-18	
J	Overweg-Plandsoen, WCG; Kodde, A; van Straaten, M; van der Linden, EAM; Neyens, LGJ; Aldenkamp, AP; Vermeulen, M				Overweg-Plandsoen, WCG; Kodde, A; van Straaten, M; van der Linden, EAM; Neyens, LGJ; Aldenkamp, AP; Vermeulen, M			Mild closed head injury in children compared to traumatic fractured bone; neurobehavioural sequelae in daily life 2 years after the accident	EUROPEAN JOURNAL OF PEDIATRICS			English	Article						mild head injury; fractured bone; late sequelae; children	ADOLESCENTS; SCALE; COMA; PARAMETERS; RECOVERY	Two years after an accident resulting in either a mild head injury or a fractured bone, two groups of 22 children each, aged 4-14 years, were examined for the existence of any neurobehavioural symptoms by means of a standardized questionnaire filled out by their caretakers. Selection of the children was based on reports of the Accident and Emergency Department in 1 year. Significantly more symptoms were reported after mild head injury. The main symptoms reported were headache, dizziness, fatigue and memory problems. The total number of symptoms in the children with mild head injury exceeded four times this in the group of children with a fractured bone. Conclusion Even 2 years after a mild head injury there are still residual symptoms in daily life.	Univ Amsterdam, Dept Neurol, Acad Med Ctr, NL-1100 DE Amsterdam, Netherlands; Epilepsy Ctr Meer & Bosch, Dept Psychol, NL-2103 SW Heemstede, Netherlands; Epilepsy Ctr Kempenhaeghe, Dept Behav Sci & Psychol Serv, NL-5590 AB Heeze, Netherlands	Overweg-Plandsoen, WCG (corresponding author), Epilepsy Ctr Kempenhaeghe, Dept Neurol, POB 61, NL-5590 AB Heeze, Netherlands.						ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BINDER LM, 1989, ASSESSMENT BEHAV CON, P37; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BRUYN GW, 1990, HDB CLIN NEUROLOGY, V13, P421; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; HOCKADAY JM, 1986, HDB CLIN NEUROLOGY, V4, P31; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1989, MILD HEAD INJURY, P189; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; PARKER RS, 1994, SEMIN NEUROL, V14, P67, DOI 10.1055/s-2008-1041061; RUIJS MBM, 1994, CLIN NEUROL NEUROSUR, V96, P273, DOI 10.1016/0303-8467(94)90114-7; RUIJS MBM, 1993, EUR J PEDIATR, V152, P844, DOI 10.1007/BF02073384; SCHANK SC, 1993, BIOMASS BIOENERG, V4, P1, DOI 10.1016/0961-9534(93)90021-U; SIEGEL S, 1956, NONPARAMETRIC STAT; SIMPSON D, 1982, LANCET, V2, P450; TEASDALE G, 1974, LANCET, V2, P81; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21	22	13	13	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0340-6199			EUR J PEDIATR	Eur. J. Pediatr.	MAR	1999	158	3					249	252		10.1007/s004310051061			4	Pediatrics	Pediatrics	171VL	WOS:000078884700015	10094450				2021-06-18	
J	Armstead, WM				Armstead, WM			Cerebral hemodynamics after traumatic brain injury of immature brain	EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	IIIrd International Congress of Pathophysiology	JUN 28-JUL 03, 1998	LAHTI, FINLAND			newborn, cerebral circulation; brain injury; fluid percussion; cerebral hemodynamic effects; cerebral oxygenation; K+ channels; K-ATP channel function; dilator responsiveness	SENSITIVE K+ CHANNELS; PIAL ARTERY VASODILATION; SPINAL-CORD INJURY; SUPEROXIDE-DISMUTASE; ENDOGENOUS OPIOIDS; HEAD-INJURY; BLOOD-FLOW; FLUID; NEWBORN; CATS	These studies were designed to characterize the cerebral hemodynamic effects of fluid percussion brain injury (FPI) in the newborn pig equipped with a closed cranial window. Reductions in cerebral blood flow, pial artery diameter, and cerebral oxygenation following FPI were greater in newborn (1-3 days old) vs. juvenile (3-4 weeks old) pigs, suggesting that newborns were exquisitely sensitive to brain injury. Additionally, in piglets, there was decremented dilation to nitric oxide, cGMP, and cAMP dependent stimuli following FPI. The membrane potential of vascular muscle is an important contributor to vascular tone and the activity of K+ channels is an important regulator of membrane potential. Recent studies indicate that altered dilator responsiveness and cerebral hemodynamic control following FPI results from impaired K+ ATP sensitive (K-ATP) and calcium sensitive (K-Ca(+2)) channel function. Impaired K-ATP channel function results, at least in part, from protein kinase C activation by the peptide endothelin-l. These observations indicate that the effects of brain injury on cerebral hemodynamics in the newborn are multifaceted and multifactorial.	Childrens Hosp Philadelphia, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	Armstead, WM (corresponding author), Childrens Hosp Philadelphia, Dept Anesthesia, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.						ARMSTEAD WM, 1994, BRAIN RES, V660, P19, DOI 10.1016/0006-8993(94)90834-6; ARMSTEAD WM, 1991, CIRC RES, V68, P922, DOI 10.1161/01.RES.68.4.922; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1997, BRAIN RES, V747, P252, DOI 10.1016/S0006-8993(96)01284-X; Armstead WM, 1997, BRAIN RES, V768, P177, DOI 10.1016/S0006-8993(97)00641-0; Armstead WM, 1997, STROKE, V28, P2273, DOI 10.1161/01.STR.28.11.2273; Armstead WM, 1997, AM J PHYSIOL-HEART C, V272, pH1785; Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH423; Bari F, 1996, STROKE, V27, P1874, DOI 10.1161/01.STR.27.10.1874; BASKIN DS, 1985, NEUROPEPTIDES, V5, P307, DOI 10.1016/0143-4179(85)90014-9; CROCKARD HA, 1977, SURG NEUROL, V7, P281; DEVINE JO, 1995, BRAIN RES, V675, P257, DOI 10.1016/0006-8993(95)00081-Z; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; FADEN AI, 1988, J PHARMACOL EXP THER, V245, P742; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; HALL ED, 1987, BRAIN RES, V435, P174, DOI 10.1016/0006-8993(87)91599-X; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; IMAIZUMI S, 1990, STROKE, V21, P1312, DOI 10.1161/01.STR.21.9.1312; Kasemsri T, 1997, AM J PHYSIOL-HEART C, V273, pH2639; Kasemsri T, 1997, STROKE, V28, P190, DOI 10.1161/01.STR.28.1.190; KITAZONO T, 1995, STROKE, V26, P1713, DOI 10.1161/01.STR.26.9.1713; KITAZONO T, 1993, AM J PHYSIOL, V265, pH581; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KUBO M, 1994, CIRC RES, V74, P471, DOI 10.1161/01.RES.74.3.471; LEFFLER CW, 1990, AM J PHYSIOL, V259, pH1230, DOI 10.1152/ajpheart.1990.259.4.H1230; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P373, DOI 10.1089/neu.1993.10.373; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1988, PHARM APPROACH TREAT, P89; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799; SHANKAR V, 1995, AM J PHYSIOL, pH997; Thorogood MC, 1996, ANESTHESIOLOGY, V84, P614, DOI 10.1097/00000542-199603000-00017; THOROGOOD MC, 1995, AM J PHYSIOL-HEART C, V269, pH1776; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VINK R, 1990, J NEUROSCI, V10, P3524; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1985, CIRC RES, V57, P781, DOI 10.1161/01.RES.57.5.781; WEI EP, 1986, AM J PHYSIOL, pH693; Wilderman MJ, 1996, AM J PHYSIOL-HEART C, V270, pH869; ZIMMERMAN RS, 1990, J NEUROSURG, V6, P764	48	13	14	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0940-2993	1618-1433		EXP TOXICOL PATHOL	Exp. Toxicol. Pathol.	FEB	1999	51	2					137	142		10.1016/S0940-2993(99)80087-6			6	Pathology; Toxicology	Pathology; Toxicology	177NZ	WOS:000079218000005	10192582				2021-06-18	
J	Beni-Adani, L; Flores, I; Spektor, S; Umansky, F; Constantini, S				Beni-Adani, L; Flores, I; Spektor, S; Umansky, F; Constantini, S			Epidural hematoma in infants: A different entity?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	4th International Neuro-Trauma Symposium	SEP, 1997	SEOUL, SOUTH KOREA			head trauma; infants; EDH; score; GCS; CT	TRAUMATIC EXTRADURAL HEMATOMAS; PEDIATRIC COMA SCALE; HEAD-INJURIES; POSTERIOR-FOSSA; YOUNG-CHILDREN; AGE; TOMOGRAPHY; CHILDHOOD	Background: Epidural hematoma (EDH) in infants may be difficult to diagnose. The mechanism of injury and the clinical presentation are different from those in older children.We characterized the clinical and radiologic parameters of EDH in infants and correlated them with outcome. Because there are no optimal prognostic tools or clear guidelines to perform computed tomography in this unique population, a new approach of neurotrauma scoring is suggested. Methods: Eleven infants (<2 years old) operated on for EDH were studied. Children's Glasgow Coma Scale (CCS) score was applied, and diagnosis was confirmed by computed tomography. Results: Age was 13 +/- 5 months. Seven infants (63.6%) fell from less than 1 m, CCS score on admission was 10.7 +/- 3.9. Five infants (45%) were unconscious, yet two (18.2%) had CCS scores of 15, Pupillary abnormalities were found in two infants and lateralizing signs in five infants, Eight infants (72.7%) had subgaleal hematomas. Mortality and morbidity were 9% each. Conclusion: We suggest that a Trauma Infant Neurologic Score be used when dealing with EDH in infants. Lateralizing signs, pupillary abnormalities, mechanism of trauma, and scalp injuries should be included because these are objective relevant parameters.	Hadassah Univ Hosp, Dept Neurosurg, IL-91120 Jerusalem, Israel; Sourasky Med Ctr, Dana Childrens Hosp, Div Pediat Neurosurg, Tel Aviv, Israel	Beni-Adani, L (corresponding author), Hadassah Ein Karem, Dept Neurosurg, IL-91120 Jerusalem, Israel.						ASHKENAZI E, 1994, J TRAUMA, V36, P406, DOI 10.1097/00005373-199403000-00023; ASHKENAZI E, 1990, J TRAUMA, V30, P613, DOI 10.1097/00005373-199005000-00015; Bejjani GK, 1996, PEDIATR NEUROSURG, V25, P302, DOI 10.1159/000121144; BERNEY J, 1994, CHILD NERV SYST, V10, P517, DOI 10.1007/BF00335074; BOWER A J, 1990, British Journal of Neurosurgery, V4, P253, DOI 10.3109/02688699008992734; Clara JMC, 1996, CHILD NERV SYST, V12, P145, DOI 10.1007/BF00266818; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HENNES H, 1988, AM J DIS CHILD, V142, P1045, DOI 10.1001/archpedi.1988.02150100039021; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; MOHANTY A, 1995, PEDIATR NEUROSURG, V23, P57, DOI 10.1159/000120936; MOLLOY CJ, 1990, CHILD NERV SYST, V6, P383, DOI 10.1007/BF00302223; MORRAY JP, 1984, CRIT CARE MED, V12, P1018, DOI 10.1097/00003246-198412000-00002; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; PASAOGLU A, 1990, ACTA NEUROCHIR, V106, P136, DOI 10.1007/BF01809456; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; REILLY PL, 1988, CHILD NERV SYST, V4, P30; RORKE LB, 1992, BRAIN PATHOL, V2, P211, DOI 10.1111/j.1750-3639.1992.tb00694.x; SCHUTZMAN SA, 1993, ANN EMERG MED, V22, P535, DOI 10.1016/S0196-0644(05)81938-9; SESHIA SS, 1977, DEV MED CHILD NEUROL, V19, P614; SIMPSON D, 1982, LANCET, V2, P450; SIMPSON DA, 1991, CHILD NERV SYST, V7, P183; YAGER JY, 1990, AM J DIS CHILD, V144, P1088, DOI 10.1001/archpedi.1990.02150340032019	24	13	17	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	1999	46	2					306	311		10.1097/00005373-199902000-00018			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	166TT	WOS:000078593800020	10029038				2021-06-18	
J	Marciani, RD; Caldwell, GT; Levine, HJ				Marciani, RD; Caldwell, GT; Levine, HJ			Maxillofacial injuries associated with all-terrain vehicles	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article								Purpose: The purpose of this article is to report the pattern and frequency of maxillofacial injuries resulting from all-terrain vehicle (ATV) accidents, to evaluate the mechanisms of injury, to document the length of hospital stay, and to characterize other associated injuries in patients presenting to a level 1 trauma center. Patients and Methods: The records of patients admitted to the University of Kentucky Medical Center from July 1, 1995 through August 1996 with an ATV-related injury were reviewed. Patients were included in the study if the events of their injury, demographic data, and the specifics of their perioperative care were sufficiently documented to provide the information pertinent to the investigation. Age, sex, mechanism of injury, facial injuries, associated injuries, and length of stay were the factors considered for the study. Results: Seventy-two patients met the criteria for the study. Fifty-nine (82%) were male, and 13 (18%) were female. Forty patients required operative intervention. Twenty-five (35%) had soft tissue or bony injuries to the maxillofacial region. One mandibular and 13 midface fractures were identified. Twelve of the patients with midface injuries had multiple facial fractures. Orbital floor fractures occurred in seven patients. Two patients required unilateral enucleation of the globe. Ten soft tissue injuries were diagnosed. Extremity fractures (n = 16) and closed head injuries (n = 17) were the most commonly associated injuries. The length of hospital stay for all the subjects identified in the study averaged 4.7 days. ATV rollover and being thrown from a moving ATV were the most common mechanisms of injury. Conclusions: Head and maxillofacial injuries, particularly midface injuries, are common findings after Ani accidents. Orbital trauma with serious globe injury was a striking feature of this study. Multiple systems injuries should always be anticipated and identified. The public should be alerted to the hazards of imprudent recreational vehicle use.	Univ Kentucky, Coll Dent, Div Oral & Maxillofacial Surg, Lexington, KY 40536 USA; Dept Vet Affairs, Lexington, KY USA	Marciani, RD (corresponding author), Univ Kentucky, Coll Dent, Div Oral & Maxillofacial Surg, Lexington, KY 40536 USA.						ALLAN DG, 1988, CAN J SURG, V31, P233; BENEL D, 1986, ALL TERRAIN VEHICLE, P19; DEMAS PN, 1992, J ORAL MAXIL SURG, V50, P1280, DOI 10.1016/0278-2391(92)90227-Q; DOLAN MA, 1989, PEDIATRICS, V84, P694; FRIEDMAN R, 1988, LARYNGOSCOPE, V98, P1251; GANOS D, 1988, AM SURGEON, V54, P429; GREENE MA, 1988, J TRAUMA, V28, P391, DOI 10.1097/00005373-198803000-00016; HARGARTEN SW, 1991, AM J EMERG MED, V9, P149, DOI 10.1016/0735-6757(91)90178-M; MARGOLIS JL, 1988, J TRAUMA, V28, P395, DOI 10.1097/00005373-198803000-00017; POLLACK CV, 1990, J TRAUMA, V30, P888, DOI 10.1097/00005373-199007000-00021; RODGERS GB, 1990, ACCIDENT ANAL PREV, V22, P47, DOI 10.1016/0001-4575(90)90006-7; RODGERS GB, 1993, ACCIDENT ANAL PREV, V25, P335, DOI 10.1016/0001-4575(93)90027-T; *US CONS PROD SAF, 1991, UPD ALL TERR VEH DEA; *US CONS PROD SAF, 1997, UPD ALL TERR VEH DEA; *US PUBL INT RES G, 1989, ATVS CHILDR STILL RI	15	13	13	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0278-2391			J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	FEB	1999	57	2					119	123		10.1016/S0278-2391(99)90221-5			5	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	163ED	WOS:000078389300005	9973117				2021-06-18	
S	Carbonell, WS; Grady, MS		Trembly, B; Slikker, W		Carbonell, WS; Grady, MS			Evidence disputing the importance of excitotoxicity in hippocampal neuron death after experimental traumatic brain injury	NEUROPROTECTIVE AGENTS: FOURTH INTERNATIONAL CONFERENCE	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	4th International Conference on Neuroprotective Agents - Clinical and Experimental Aspects	NOV 15-19, 1998	ANNAPOLIS, MD	US FDA, Natl Ctr Toxicol Res, Dept Vet Affairs Med Ctr			CONTROLLED CORTICAL IMPACT; CELL-DEATH; GLUTAMATE; NMDA; RECEPTORS; NEUROTOXICITY; VULNERABILITY; CONSEQUENCES; DYSFUNCTION; DISORDERS	The hippocampus is selectively vulnerable to experimental traumatic brain injury (TBI). Beneficial effects of glutamate receptor antagonists and increased extracellular levels of glutamate have suggested that glutamate-mediated excitotoxicity may be responsible for this selective damage. In order to clarify this important issue, we applied a severe parasagittal fluid percussion injury (FPI) to strains of mice shown to be susceptible and resistant to kainic acid (KA)-induced excitotoxic hippocampal damage. Dystrophic neurons were present by 10 min after FPI in the hippocampi of both strains, Damaged hippocampal neurons were absent at 4 days and 7 days. Additionally, there was no significant difference (p = 1.00) in CA3 neuron survival between KA-susceptible and -resistant mice at 4 days. In conclusion, excitotoxicity does not significantly contribute to hippocampal neuron loss after FPI and, in contrast to classic studies of excitotoxicity in vivo, the pattern of hippocampal cell death after TBI is extremely acute.	Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA	Grady, MS (corresponding author), Univ Penn, Hosp Univ Penn, Dept Neurosurg, 3400 Spruce St, Philadelphia, PA 19104 USA.	grady@mail.med.upenn.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS33107, NS30305] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033107, P50NS030305] Funding Source: NIH RePORTER		BAREYRE FM, 1998, J NEUROTRAUM, V15, P857; BEAUCHAMP GK, 1993, PHYSIOL BEHAV, V54, P179, DOI 10.1016/0031-9384(93)90063-L; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P273, DOI 10.1016/0166-2236(87)90172-X; DAMBROSIO R, 1998, J NEUROTRAUM, V15, P864; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Forbes ML, 1998, J NEUROSURG, V88, P549, DOI 10.3171/jns.1998.88.3.0549; GRADY MS, 1996, J NEUROTRAUM, V13, P508; GREENAMYRE JT, 1985, J PHARMACOL EXP THER, V233, P254; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Iijima T, 1998, J NEUROTRAUM, V15, P277, DOI 10.1089/neu.1998.15.277; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; KOH JY, 1990, J NEUROSCI, V10, P693; KUBOTA M, 1989, Brain and Nerve (Tokyo), V41, P799; Kurschner VC, 1998, BRAIN RES, V780, P1, DOI 10.1016/S0006-8993(97)01081-0; Lassmann H, 1986, Adv Exp Med Biol, V203, P223; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4; OBRENOVITCH TP, 1998, IN PRESS PHARM CEREB; PERRY EK, 1993, HIPPOCAMPUS, V3, P307, DOI 10.1002/hipo.450030306; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Sheldon RA, 1998, BRAIN RES, V810, P114, DOI 10.1016/S0006-8993(98)00892-0; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Toth Z, 1997, J NEUROSCI, V17, P8106; VORNOV JJ, 1991, EXP NEUROL, V114, P11, DOI 10.1016/0014-4886(91)90079-R; Watanabe M, 1998, EUR J NEUROSCI, V10, P478, DOI 10.1046/j.1460-9568.1998.00063.x; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; Yang GM, 1997, BRAIN RES, V752, P209, DOI 10.1016/S0006-8993(96)01453-9; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	41	13	16	0	2	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-223-1; 1-57331-222-3	ANN NY ACAD SCI	Ann.NY Acad.Sci.		1999	890						287	298		10.1111/j.1749-6632.1999.tb08005.x			12	Biochemistry & Molecular Biology; Multidisciplinary Sciences; Clinical Neurology; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy	BP50F	WOS:000085330700026	10668434				2021-06-18	
J	Clark, E; Russman, S; Orme, S				Clark, E; Russman, S; Orme, S			Traumatic brain injury: Effects on school functioning and intervention strategies	SCHOOL PSYCHOLOGY REVIEW			English	Article							CHILDREN; ADOLESCENTS; REMEDIATION; PREDICTORS; CHILDHOOD	Children and adolescents who sustain traumatic brain injuries are at risk for both acute and chronic problems. Although research indicates that the majority of brain injuries are mild and have minimal impact upon learning and development, in cases in which injuries are more severe children are often left with serious cognitive and behavioral impairments, some of which are permanent. This article is intended to provide information for educators about the range of problems that children and their families face following a brain injury. Suggestions for assessment and intervention practices are included with brief case examples.	Univ Utah, Salt Lake City, UT 84112 USA	Clark, E (corresponding author), Univ Utah, 1705 E Campus Ctr Dr,Room 327, Salt Lake City, UT 84112 USA.						Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; BAKER SP, 1994, AM J PUBLIC HEALTH, V84, P649, DOI 10.2105/AJPH.84.4.649; Bohnert AM, 1997, DEV NEUROPSYCHOL, V13, P477, DOI 10.1080/87565649709540688; Bowen JM, 1997, DEV MED CHILD NEUROL, V39, P17; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; CLARK E, 1995, TRAUMATIC BRAIN INJU; D'Amato R. C., 1997, CHILDHOOD TRAUMATIC, P213; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FARMER JE, 1997, CHILDHOOD TRAUMATIC, P33; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; Franzen KM, 1996, CHILD NEUROPSYCHOL, V2, P176, DOI 10.1080/09297049608402250; Glang A, 1997, J HEAD TRAUMA REHAB, V12, P32, DOI 10.1097/00001199-199704000-00005; GLANG A, 1992, J HEAD TRAUMA REHAB, V7, P93; JANNETT B, 1984, CLOSED HEAD INJURY P; Kehle T. J., 1997, CHILDHOOD TRAUMATIC, P135; Kehle TJ, 1996, J LEARN DISABIL, V29, P633, DOI 10.1177/002221949602900607; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KREUTZER JS, 1989, REHABIL PSYCHOL, V34, P117; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Mateer C., 1997, CHILDHOOD TRAUMATIC, P153; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; ORME SF, 1997, THESIS U UTAH SALT L; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RUSSMAN S, 1997, THESIS U UTAH SALT L; Suzman KB, 1997, J BEHAV THER EXP PSY, V28, P203, DOI 10.1016/S0005-7916(97)00023-2; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; WADE SL, 1997, CHILDHOOD TRAUMATIC, P115	35	13	13	0	1	NATL ASSOC SCHOOL PSYCHOLOGISTS	BETHESDA	4340 EAST WEST HWY, STE 402, BETHESDA, MD 20814 USA	0279-6015			SCHOOL PSYCHOL REV	Sch. Psychol. Rev.		1999	28	2					242	250					9	Psychology, Educational	Psychology	214XB	WOS:000081351900008					2021-06-18	
J	DeHope, E; Finegan, J				DeHope, E; Finegan, J			The self determination model: an approach to develop awareness for survivors of traumatic brain injury	NEUROREHABILITATION			English	Article						brain injury; clinical treatment; self-awareness; self-determination; community re-entry	CLOSED HEAD-INJURY; REHABILITATION	This article reports on the use of a theoretical model addressing integrated self-awareness in the treatment of individuals with traumatic brain injury. The Self- Determination Model, developed by ReMed a community-based provider of post-acute services, is presented here along with three case studies. The ability for an individual with a traumatic brain injury to monitor their own behavior is essential to increase their levels of independence in their activities of daily living and in handling social situations. The Self-determination Model is an interventive practice model to assist individuals in home and community based long-term rehabilitation settings in developing self-awareness.	ReMed, Supported Living Syst, Conshohocken, PA 19428 USA	DeHope, E (corresponding author), ReMed, Supported Living Syst, 625 Ridge Pike,Bldg C, Conshohocken, PA 19428 USA.	edehop@remed.com; finegan@remed.com					BANDURA A, 1986, SOCIAL FDN ACTION SO; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BURLEIGH S, 1997, AM J OCCUPATIONA SEP; COLE JR, 1985, ARCH PHYS MED REHAB, V66, P38; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; DATTILO J, 1994, INCLUSIVE LEISURE SE; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; HPAY H, 1971, INT S HEAD INJ ED SC; KARPMAN T, 1985, J APPL REHABILITATIO, V17, P28; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1984, CLOSED HEAD INJURY, P109; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Rogers P M, 1984, J Neurosurg Nurs, V16, P343; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; WARD MJ, 1988, NICHCY TRANSITION SU, V5, P2; WEHMEYER ML, 1994, EDUC TRAIN MENT RET, V29, P9; WILLER B, 1994, BRAIN INJURY, V8, P647, DOI 10.3109/02699059409151017; YLKVISAKER M, 1987, COMMUNITY REENTRY HE	23	13	13	0	7	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		1999	13	1					3	12					10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	244UT	WOS:000083069700002					2021-06-18	
J	Ross, RT; Ochsner, MG; Boyd, CR				Ross, RT; Ochsner, MG; Boyd, CR			Acute intracranial boxing-related injuries in US Marine Corps recruits: Report of two cases	MILITARY MEDICINE			English	Article								Serious acute intracranial injuries from boxing are a recognized, albeit rare, event. Acute brain injuries such as concussion, hemorrhage, and contusion are easily recognized because of their rapid onset of neurological impairment. The sequelae of such injuries range from transient diminished cognitive function to irreversible brain damage and, on occasion, death. The more serious injuries are certainly minimized as a result of regulatory policy, improved medical awareness, and the use of safety equipment. The incidence of serious acute head injury in amateur boxing and noncompetitive boxing is lower than that found in the professional ranks. Our survey of instructional boxing in U.S. Marine Corps basic training during an 8-year period detected only three serious acute brain injuries incurred by approximately 180,000 participants, equating to one serious head injury per 60,000 participants. Serious head injuries constituted an extremely small percentage (0.3%) of the approximately 1,100 total boxing-related Injuries surveyed during the period. We present two cases of serious acute brain injury incurred during noncompetitive boxing skills instruction as a part of U.S. Marine Corps basic training. A review of the data leads us to conclude that the risk of serious head injury in a well-supervised, instructional boxing program is relatively minimal. In any case, we recommend that any boxing be appropriately supervised and that specialized trauma care and an adequate transport mechanism to secure that care be readily available.	Mem Med Ctr, Savannah, GA 31403 USA	Ross, RT (corresponding author), Mem Med Ctr, POB 22084, Savannah, GA 31403 USA.						HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; JORDAN BD, 1987, ARCH NEUROL-CHICAGO, V44, P453, DOI 10.1001/archneur.1987.00520160083020; LEGWOLD G, 1982, PHYSICIAN SPORTSMED, V10, P43; RYAN AJ, 1987, CLIN SPORT MED, V6, P31; Sawauchi S, 1996, NEUROL SURG TOKYO, V24, P905; UNTERHARNSCHEIDT F, 1970, TEX REP BIOL MED, V28, P421	6	13	14	0	1	ASSN MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075			MIL MED	Milit. Med.	JAN	1999	164	1					68	70					3	Medicine, General & Internal	General & Internal Medicine	157HH	WOS:000078055200016	9922649				2021-06-18	
J	Stilwell, P; Stilwell, J; Hawley, C; Davies, C				Stilwell, P; Stilwell, J; Hawley, C; Davies, C			Measuring outcome in community-based rehabilitation services for people who have suffered traumatic brain injury: the Community Outcome Scale	CLINICAL REHABILITATION			English	Article							MODEL	Objective: To develop a way of measuring long-term outcomes after traumatic brain injury (TBI) that takes account of individual circumstances. Design: Reports by head-injured people and their families about problems and coping strategies were elicited via semi-structured interviews. Specially designed computer software was used to record problems and strengths and to measure their impact for the individual on four handicap dimensions. Setting: Interviews took place in the respondents' homes. Subjects: Between 1992 and 1997 the services at 10 rehabilitation centres in England were evaluated. Subjects were men and women aged between 16 and 65 who had suffered TBI and who had been referred for treatment to one of the centres under study. Interventions: Head-injured people and their families were interviewed three months, 18 months and in some cases 36 months after recruitment. Main outcome measures: The Hospital Anxiety and Depression Scale (HAD) and the Functional Independence/Assessment Measure (FIM/FAM) were used to validate relevant dimensions of the new scale. Results: A measure of long-term outcome was developed and called the Community Outcome Scale. Relevant dimensions of the scale showed significant correlation with the HAD and with items of the FIM/FAM. Conclusion: The scale captures information which no other instrument does, and merits further validation.	Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England	Stilwell, P (corresponding author), Lower Farm Cottage, Stourbridge DY9 0EJ, W Midlands, England.		Hawley, Carol/AAG-3830-2019				AITKEN C, 1982, LANCET          1106, P1034; Brisenden S., 1986, DISABILITY HANDICAP, V1, P173, DOI [10.1080/02674648666780171, DOI 10.1080/02674648666780171]; BROOKS N, 1991, Brain Injury, V5, P103, DOI 10.3109/02699059109008082; *CAN I HLTH INT, 1996, CIHI DIR ICIS, P3; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; *MED DIS SOC, 1988, REP WORK PART MAN TR; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; SCHALEN W, 1994, BRAIN INJURY, V8, P37, DOI 10.3109/02699059409150957; *STAT U BUFF, 1987, FUNCT IND MEAS; STILWELL J, 1998, NATL TRAUMATIC BRAIN; TAPPE MK, 1992, HEALTH EDUC RES, V7, P277, DOI 10.1093/her/7.2.277; TEASDALE G, 1974, LANCET, V2, P81; Tennant A, 1997, DISABIL REHABIL, V19, P278, DOI 10.3109/09638289709166539; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; *WHO, 1980, INT CLASS IMP DIS HA, P42; WILLER B, 1994, BRAIN INJURY, V8, P647, DOI 10.3109/02699059409151017; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	21	13	13	0	1	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON, ENGLAND NW1 3BH	0269-2155			CLIN REHABIL	Clin. Rehabil.	DEC	1998	12	6					521	531		10.1191/026921598673761855			11	Rehabilitation	Rehabilitation	146HL	WOS:000077423200009	9869256				2021-06-18	
J	Body, R; Perkins, MR				Body, R; Perkins, MR			Ecological validity in assessment of discourse in traumatic brain injury: ratings by clinicians and non-clinicians	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; PRAGMATIC LANGUAGE-SKILLS; ADULTS	Researcher; studying discourse after traumatic brain injury (TBI) increasingly recognize the need to take account of variation within the non-brain-damaged (NBD) population in order to validate their findings. This study investigated the use of ratings by professional clinicians trained in speech pathology (P raters) and by peers of TBI individuals (NP raters) as a method of placing TBI individuals' communication in context. Twenty TBI adults and 20 NBD controls matched for age, sex, education and social background retold a 1400 word story presented on audiotape, following which the narratives were transcribed and segmented. Raters used two ii-point scales, representing independent parameters of Content and Clarity, to rate the transcripts. Statistical analysis demonstrated that P raters tended to give higher ratings across the board than NP rates but that P and NP ratings were also highly correlated. In general, the ratings assigned to the two subject groups overlapped and exhibited an even spread across the range of mean ratings. On the evidence of this study clinicians appear to share perceptions regarding discourse performance with peers of the TBI subjects. In addition, many TBI subjects perform as well or better than NBD controls on high-level tasks.	St Georges Community Hlth Ctr, Community Brain Injury Rehabil Team, Sheffield S3 7ND, S Yorkshire, England; Univ Sheffield, Dept Human Commun Sci, Sheffield, S Yorkshire, England	Body, R (corresponding author), St Georges Community Hlth Ctr, Community Brain Injury Rehabil Team, Winter St, Sheffield S3 7ND, S Yorkshire, England.						ARMSTRONG EM, 1987, CLIN APHASIOLOGY, P210; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; DERENZI E, 1978, CORTEX, V14, P41, DOI 10.1016/S0010-9452(78)80006-9; DIKMEN S, 1987, NEUROBEHAVIORAL RECO, P73; Ehrlich J, 1989, Brain Inj, V3, P193, DOI 10.3109/02699058909004552; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; ELLMO WJ, 1995, MEASURE COGNITIVE LI; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Glosser G., 1990, BRAIN LANG, V40, P67; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; LEINONEN E, 1993, INTERDISCIPLINARY PE, P252; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; Linscott RJ, 1996, BRAIN INJURY, V10, P397, DOI 10.1080/026990596124269; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 1995, BRAIN INJURY, V9, P255, DOI 10.3109/02699059509008197; MCGANN W, 1995, BRAIN INJURY, V9, P93, DOI 10.3109/02699059509004575; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; MILLER TK, 1991, CLIN MANAGEMENT COMM, P27; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow P, 1997, BRAIN INJURY, V11, P409; SPENCE SE, 1993, BRIT J CLIN PSYCHOL, V32, P309, DOI 10.1111/j.2044-8260.1993.tb01061.x; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; TYKKYLAINEN T, 1992, STUDIES LOGOPEDICS P, V3, P253; ULATOWSKA HK, 1981, BRAIN LANG, V13, P345, DOI 10.1016/0093-934X(81)90100-0	29	13	13	0	10	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	1998	12	11					963	976		10.1080/026990598122016			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	143NR	WOS:000077262300005	9839029				2021-06-18	
J	Hiscock, M; Caroselli, JS; Kimball, LE				Hiscock, M; Caroselli, JS; Kimball, LE			Paced serial addition: Modality-specific and arithmetic-specific factors	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							NUMBER; RETRIEVAL; MECHANISMS; BILINGUALS; CONCUSSION; MEMORY; TESTS	Tests of paced serial addition are used to detect diminished information-processing capacity. Nonetheless, performance might be influenced by modality-specific interference or by variables that specifically affect numerical processing. In a series of three experiments with normal adults, we manipulated, respectively, the modality in which addends were presented, the modality in which responses were produced, and the format in which visual addends were displayed. Performance was enhanced when stimuli were presented visually and when responses were made manually. When visual addends were used, Arabic numerals were processed more effectively than number words. Thus, performance was influenced by modality-specific interference and by presentation format. We conclude that paced serial addition tasks may not provide a pure measure of general information-processing capacity.	Univ Houston, Dept Psychol, Houston, TX 77204 USA	Hiscock, M (corresponding author), Univ Houston, Dept Psychol, Houston, TX 77204 USA.						CAMPBELL JID, 1988, J EXP PSYCHOL GEN, V117, P204, DOI 10.1037/0096-3445.117.2.204; CAMPBELL JID, 1994, COGNITION, V53, P1, DOI 10.1016/0010-0277(94)90075-2; CAMPBELL JID, 1991, MEM COGNITION, V19, P197, DOI 10.3758/BF03197119; CAMPBELL JID, 1990, CAN J PSYCHOL, V44, P445, DOI 10.1037/h0084266; CAMPBELL JID, 1989, J EXP PSYCHOL LEARN, V15, P920, DOI 10.1037/0278-7393.15.5.920; CLARK JM, 1991, BRAIN COGNITION, V17, P204, DOI 10.1016/0278-2626(91)90075-J; Diamond BJ, 1997, J CLIN EXP NEUROPSYC, V19, P34, DOI 10.1080/01688639708403834; FEINSTEIN A, 1994, J CLIN EXP NEUROPSYC, V16, P436, DOI 10.1080/01688639408402654; FRENCKMESTRE C, 1993, MEM COGNITION, V21, P809, DOI 10.3758/BF03202748; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Kahneman D., 1973, ATTENTION EFFORT; MCCLOSKEY M, 1991, BRAIN COGNITION, V17, P154, DOI 10.1016/0278-2626(91)90074-I; MCCLOSKEY M, 1985, BRAIN COGNITION, V4, P171, DOI 10.1016/0278-2626(85)90069-7; NAVON D, 1984, PSYCHOL REV, V91, P216, DOI 10.1037/0033-295X.91.2.216; ODONNELL JP, 1994, J CLIN PSYCHOL, V50, P596, DOI 10.1002/1097-4679(199407)50:4<596::AID-JCLP2270500416>3.0.CO;2-S; SOKOL SM, 1989, J EXP PSYCHOL GEN, V118, P105; Stuss D.T., 1987, CLIN NEUROPSYCHOL, V1, P139, DOI DOI 10.1080/13854048708520046; VAID J, 1991, BRAIN COGNITION, V17, P272, DOI 10.1016/0278-2626(91)90077-L	21	13	13	0	2	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	1998	20	4					463	472		10.1076/jcen.20.4.463.1466			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	153JY	WOS:000077831000004	9892050				2021-06-18	
J	Jacobs, DG; Westerband, A				Jacobs, DG; Westerband, A			Antibiotic prophylaxis for intracranial pressure monitors	JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION			English	Article; Proceedings Paper	54th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 29-OCT 01, 1994	SAN DIEGO, CALIFORNIA	Amer Assoc Surg Trauma		antibiotic prophylaxis; intracranial pressure monitor	RISK-FACTORS; SURGERY; PNEUMONIA; INFECTIONS; VENTRICULOSTOMY; TRIAL	To determine the safety and efficacy of prophylactic antibiotics in head-injured patients requiring intracranial pressure monitors, the Files of 30 consecutive patients with isolated, severe head injuries admitted over a 1-year period were reviewed. Patients .15 years with severe closed-head injury who did not have severe concomitant, extracranial injury (Abbreviated Injury Score ,3) and survived .48 hours following hospital admission were included. Fourteen patients underwent intracranial pressure monitor placement and received prophylactic antibiotics for the duration of monitoring and the remaining 16 patients were neither monitored nor given prophylactic antibiotics. Length of hospital stay, length of intensive care stay, overall and septic complication rate, and death rate were compared For the two treatment groups. The groups were similar with regard to patient characteristics, associated injuries, and injury severity. Patients who received prophylactic antibiotics demonstrated statistically higher septic morbidity rates (78.6% versus 31.3%) and statistically higher pneumonia rates (57.1% ver sus 18.8%) compared with patients who did not. No patient developed central nervous system infection related to the monitor itself. These results indicate that the administration of prophylactic antibiotics to head-injured patients for the duration of intracranial pressure monitoring is unnecessary and potentially detrimental. Antibiotics, if given at all, should be limited to the period immediately surrounding intracranial pressure monitor placement.	Carolinas Med Ctr, Dept Surg, Charlotte, NC 28232 USA	Jacobs, DG (corresponding author), Carolinas Med Ctr, Dept Surg, POB 32861, Charlotte, NC 28232 USA.						AUCOIN PJ, 1986, AM J MED, V80, P369, DOI 10.1016/0002-9343(86)90708-4; BLOMSTEDT GC, 1985, J NEUROSURG, V62, P694, DOI 10.3171/jns.1985.62.5.0694; BURNETT JW, 1980, J BONE JOINT SURG AM, V62, P457, DOI 10.2106/00004623-198062030-00017; CHOLE RA, 1987, ARCH OTOLARYNGOL, V113, P1055; CONDON RE, 1991, CURR PROB SURG, V28, P801; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; HAINES SJ, 1989, NEUROSURGERY, V24, P401, DOI 10.1227/00006123-198903000-00016; HAUSER WE, 1982, AM J MED, V72, P711, DOI 10.1016/0002-9343(82)90534-4; HELLING TS, 1988, J TRAUMA, V28, P1575, DOI 10.1097/00005373-198811000-00009; KAISER AB, 1986, NEW ENGL J MED, V315, P1129; Luerssen T.G., 1993, INTRACRANIAL PRESSUR, VVIII, P42; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; NAZIRI W, 1994, ANN SURG, V219, P632, DOI 10.1097/00000658-199406000-00006; OSTRUP RC, 1987, J NEUROSURG, V67, P206, DOI 10.3171/jns.1987.67.2.0206; PATZAKIS MJ, 1974, J BONE JOINT SURG AM, VA 56, P532, DOI 10.2106/00004623-197456030-00010; PLATT R, 1990, NEW ENGL J MED, V322, P153, DOI 10.1056/NEJM199001183220303; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; ROWLANDS BJ, 1982, ARCH SURG-CHICAGO, V117, P195; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; STONE HH, 1976, ANN SURG, V184, P443, DOI 10.1097/00000658-197610000-00007; ULUALP K, 1992, INFECT DIS CLIN N AM, V6, P613	23	13	14	0	0	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	0027-9684			J NATL MED ASSOC	J. Natl. Med. Assoc.	JUL	1998	90	7					417	423					7	Medicine, General & Internal	General & Internal Medicine	103HB	WOS:000075151000006	9685777				2021-06-18	
J	Hermann, DM; Mies, G; Hossmann, KA				Hermann, DM; Mies, G; Hossmann, KA			Effects of a traumatic neocortical lesion on cerebral metabolism and gene expression of rats	NEUROREPORT			English	Article						bioluminescence imaging; cerebral protein synthesis rate; cortical spreading depression; umbelliferone fluoroscopy	CORTICAL SPREADING DEPRESSION; NUCLEAR-MAGNETIC-RESONANCE; EXPERIMENTAL BRAIN INJURY; LACTATE; PROTEIN; DAMAGE; FLUID; P-31; H-1	THE effects of a traumatic neocortical lesion, induced by transcranial cold injury, on brain metabolism and gene expression were examined. The surrounding of the lesions was characterized by increased glucose and lactate levels without major disturbances of protein synthesis or energy state. A transient pH decrease by 0.4 units was noticed Ih post-injury, which shifted towards alkaline values by 3 h. The metabolic disturbances did not differ between injured animals with spontaneous spreading depressions (SD, n = 14) and those without SD (n = 7). In SD animals, c-fos mRNA was strongly elevated in the injury-remote cortex, but hsp72 mRNA was not enhanced. Thus, in contrast to focal ischemia, the metabolic dysfunction around traumatic cortical lesions is not aggravated by SD. (C) 1998 Rapid Science Ltd.	Max Planck Inst Neurol Res, Dept Expt Neurol, D-50931 Cologne, Germany	Hermann, DM (corresponding author), Max Planck Inst Neurol Res, Dept Expt Neurol, Gleueler Str 50, D-50931 Cologne, Germany.		Hermann, Dirk M/AAP-5538-2020				BACK T, 1994, J CEREBR BLOOD F MET, V14, P12, DOI 10.1038/jcbfm.1994.3; CORBETT RJT, 1992, J NEUROCHEM, V59, P216, DOI 10.1111/j.1471-4159.1992.tb08894.x; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HUSZ T, 1992, NEUROREPORT, V3, P51, DOI 10.1097/00001756-199201000-00013; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; KAMEZAWA T, 1994, ACTA NEUROCHIR, P499; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KOCHER M, 1990, J CEREBR BLOOD F MET, V10, P564, DOI 10.1038/jcbfm.1990.99; Marmarou A, 1993, Acta Neurochir Suppl (Wien), V57, P160; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MIES G, 1993, J NEUROCHEM, V60, P360, DOI 10.1111/j.1471-4159.1993.tb05860.x; MIES G, 1993, NEUROREPORT, V4, P709, DOI 10.1097/00001756-199306000-00027; NEUMANNHAEFELIN T, 1994, J CEREBR BLOOD F MET, V14, P206, DOI 10.1038/jcbfm.1994.27; NOWAK TS, 1990, STROKE, V21, P107; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; Siesjo BK, 1996, ADV NEUROL, V71, P209; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; WOLF AL, 1993, J NEUROSURG, V78, P54, DOI 10.3171/jns.1993.78.1.0054	24	13	13	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	JUN 1	1998	9	8					1917	1921		10.1097/00001756-199806010-00046			5	Neurosciences	Neurosciences & Neurology	ZU455	WOS:000074198700046	9665626				2021-06-18	
J	Saeki, N; Yamaura, A; Sunami, K				Saeki, N; Yamaura, A; Sunami, K			Brain stem contusion due to tentorial coup injury: case report and pathomechanical analysis from normal cadavers	BRITISH JOURNAL OF NEUROSURGERY			English	Article						brain stem; head injury; MRI; tentorial incisura	LESIONS	This report is in two parts. First, a case report on a 20-year-old man with a localized brain stem contusion. Second, in order to elucidate the mechanism of this injury, an anatomical study was performed. Ten cadaver heads were analysed to reveal the variations of spatial anatomy around the tentorial incisura. The lateral tentorial incisura (lateral to brain stem) was situated at the level of pontomesencephalic junction and nearest to the brain stem along its course. The shortest distance between them averaged 1.0 mm (0-4 mm). Based on these findings, primary brain stem injury caused by tentorial incisura occurs at its lateral portion due to the shortest distance to the brain stem and near the level of pontomesencephalic junction. In patients with a tentorial incisura closely related to or touching the brain stem, tentorial coup injury to the brain stem may occur even with a relatively minor injury. In our case, repeated CT and MRI proved that the location of contusion was at the pontomesencephalic junction, coinciding with the level of the tentorial edge. The injury started at the surface of brain stem. The tentorial edge was close to brain stem in this case. These radiological findings support the hypothesis that the brain stem contusion was caused by a tentorial coup injury.	Kawatetsu Chiba Hosp, Sch Med, Dept Neurol Surg, Chiba, Japan	Saeki, N (corresponding author), 1-8-1 Inohana,Chuhoh Ku, Chiba 260, Japan.						ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; BRITT RH, 1980, NEUROSURGERY, V6, P623, DOI 10.1227/00006123-198006000-00002; CORSELLIS JAN, 1958, J NEUROL NEUROSUR PS, V21, P279, DOI 10.1136/jnnp.21.4.279; COURVILLE CB, 1945, P ASS RES NERV MENTA, V21, P131; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; HASHIMOTO T, 1993, NEUROSURG REV, V16, P291, DOI 10.1007/BF00383839; Lindenberg R, 1964, Clin Neurosurg, V12, P129; MEYER CA, 1991, RADIOLOGY, V179, P813, DOI 10.1148/radiology.179.3.2027997; MICHELL DE, 1973, LANCET, V2, P215; Ommaya AK, 1976, HEAD INJURIES, P49; ONO M, 1984, J NEUROSURG, V60, P365, DOI 10.3171/jns.1984.60.2.0365; THOMPSON RK, 1988, NEUROSURGERY, V22, P629, DOI 10.1227/00006123-198804000-00002; TSAI FY, 1980, AM J ROENTGENOL, V134, P717, DOI 10.2214/ajr.134.4.717; ZIMMERMAN RA, 1978, AM J ROENTGENOL, V131, P27, DOI 10.2214/ajr.131.1.27; ZUCCARELLO M, 1983, ACTA NEUROCHIR, V67, P103, DOI 10.1007/BF01401670	15	13	14	0	0	CARFAX PUBL CO	ABINGDON	PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	APR	1998	12	2					151	155		10.1080/02688699845302			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	ZM366	WOS:000073531300010	11013669				2021-06-18	
J	Baker, KA; Schmidt, MF; Heinemann, AW; Langley, M; Miranti, SV				Baker, KA; Schmidt, MF; Heinemann, AW; Langley, M; Miranti, SV			The validity of the Katz Adjustment Scale among people with traumatic brain injury	REHABILITATION PSYCHOLOGY			English	Article							REHABILITATION SAMPLE; HEAD-INJURY	Deficits in self-and social awareness can impair adjustment following traumatic brain injury (TBT) and draw into question the accuracy of self-report measures of adjustment. This study evaluates the validity of Katz Adjustment Scale (KAS) factor components identified by R. J. Fabiano and D. A. Goran (1992). The KAS is an observer rating scale often used to assess the social adjustment of people with traumatic brain injury. The responses of 105 individuals with TBI to the Symptom Checklist 90-Revised (SCL-90-R; L. R. Derogatis, 1983), a self-report measure of distress, were correlated with observer ratings on the KAS. Results support the use of observer ratings and self-report to assess adjustment and social behavior following TBI. Each contributes valuable information that can guide treatment and enhance adaptive functioning.	Northwestern Univ, Sch Med, Evanston, IL 60208 USA; Rehabil Inst Chicago, Chicago, IL 60611 USA; Clin Psychol Associates, Burlington, WI USA; Schwab Rehabil Hosp & Care Network, Chicago, IL USA	Schmidt, MF (corresponding author), Lutheran Gen Hosp, 1775 W Dempster,Pk Ridge, Pk Ridge, IL 60068 USA.		Heinemann, Allen W./AAI-2790-2021; Heinemann, Allen W/K-6283-2012	Heinemann, Allen W./0000-0003-2782-7326; Heinemann, Allen W/0000-0003-2782-7326			CRIPE LI, 1989, REHABIL PSYCHOL, V34, P93; DEROGATIS LR, 1983, SYMPTOM CHECKLIST 90; FABIANO RJ, 1992, REHABIL PSYCHOL, V37, P75, DOI 10.1037/h0079096; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GORAN DA, 1993, BRAIN INJURY, V7, P219, DOI 10.3109/02699059309029674; JACKSON H F, 1992, Brain Injury, V6, P109, DOI 10.3109/02699059209029650; KAPLAN S, 1991, CLIN NEUROPSYCHOL, V5, P360, DOI DOI 10.1080/13854049108404103; Kaplan S. P., 1988, J APPLIED REHABILITA, V19, P3; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1984, CLOSED HEAD INJURY P, P108; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano G.P., 1991, J HEAD TRAUMA REHAB, V6, P1; STAMBROOK M, 1990, COGNITIVE REHABILITA, V1, P26; WOESSNER R, 1995, J HEAD TRAUMA REHAB, V10, P78, DOI 10.1097/00001199-199504000-00009	19	13	13	0	2	SPRINGER PUBL CO	NEW YORK	536 BROADWAY, NEW YORK, NY 10010-3955 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	SPR	1998	43	1					30	40		10.1037/0090-5550.43.1.30			11	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	ZL354	WOS:000073424500003					2021-06-18	
J	Jaffe, MS; Dijkers, MP; Zametis, M				Jaffe, MS; Dijkers, MP; Zametis, M			A population-based survey of in-line skaters' injuries and skating practices	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article								Objective: To describe in-line skating interests and practices, protective gear usage, and injury patterns in a population-based group of in-line skaters. Design: A two-page questionnaire with multiple choice questions and one write-in response question. Participants: The survey was sent to 1,000 members of an in-line skating club in Detroit, MI and 45 other states. Main Outcome Measures: The study was designed to profile skater injury patterns. The effects of protective gear and skater lessons on injury were examined. Results: Of the 435 skaters returning questionnaires, 56.7% were men. The mean age was 35 years. The frequency of inline skating lessons was 31.7%. Of respondents, 72.5% wear some kind of protective gear while skating, and 79.8% reported that they had been injured while skating. Of those who had skated for 5 or more years, 93.7% had been injured. Upper extremity injuries were reported by 58.8% of skaters and lower extremity injuries by 66.7%. The majority suffered abrasions and bruises only. More serious injuries were reported by very few skaters: fractures by 5.5% and concussions by 2.1%. Only 3% of respondents required orthopedic surgery. Conclusion: Lessons and protective gear decrease the risk of injury. However, risk of incurring minor injury exists even if full protective gear is used. Those who have skated for more than 5 years are almost certain to report having been injured. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	INST REHABIL,DETROIT,MI				Dijkers, Marcel/0000-0002-8362-5596			*AM SPORTS DAT, 1995, AM SPROTS AN REP; CALLE SC, 1993, J TRAUMA, V35, P946, DOI 10.1097/00005373-199312000-00024; FEDEL FJ, 1995, MED SCI SPORT EXER, V27, P682; SCHIEBER RA, 1994, JAMA-J AM MED ASSOC, V271, P1856, DOI 10.1001/jama.271.23.1856; *US CONS PROD SAF, 1993, NAT EL INJ SURV SYST	5	13	13	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	1997	78	12					1352	1357		10.1016/S0003-9993(97)90309-9			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	YK894	WOS:A1997YK89400012	9421990				2021-06-18	
J	Pike, BR; Hamm, RJ; Temple, MD; Buck, DL; Lyeth, BG				Pike, BR; Hamm, RJ; Temple, MD; Buck, DL; Lyeth, BG			Effect of tetrahydroaminoacridine, a cholinesterase inhibitor, on cognitive performance following experimental brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cholinergic; cholinesterase; Morris water maze; muscarinic; rats; tacrine (THA); traumatic brain injury; treatment	CLOSED-HEAD-INJURY; MUSCARINIC RECEPTOR SUBTYPES; FLUID-PERCUSSION INJURY; EXCITATORY AMINO-ACIDS; ALZHEIMERS-DISEASE; CHOLINERGIC MODULATION; CONTROLLED TRIAL; SENILE DEMENTIA; TIME-COURSE; RATS	An emerging literature exists in support of deficits in cholinergic neurotransmission days to weeks following experimental traumatic brain injury (TBI). In addition, novel cholinomimetic therapeutics have been demonstrated to improve cognitive outcome following TBI in rats. We examined the effects of repeated postinjury administration of a cholinesterase inhibitor, tetrahydroaminoacridine (THA), on cognitive performance following experimental TBI. Rats were either injured at a moderate level of central fluid percussion TBI (2.1 +/- 0.1 atm) or were surgically prepared but not delivered a fluid pulse (sham injury). Beginning 24 h after TBI or sham injury, rats were injected (IF) daily for 15 days with an equal volume (1.0 ml/kg) of either 0.0, 1.0, 3.0, or 9.0 mg/kg THA (TBI: n = 8, 8, 10, and 7, respectively, and Sham: n = 5, 7, 8, 7, respectively). Cognitive performance was assessed on Days 11-15 after injury in a Morris water maze (MWM). Analysis of maze latencies over days indicated that chronic administration of THA produced a dose-related impairment in MWM performance in both the injured and sham groups, with the 9.0 mg/kg dose producing the largest deficit. The 1.0 and 3.0 mg/kg doses of THA impaired MWM performance without affecting swimming speeds. Thus, the results of this investigation do not support the use of THA as a cholinomimetic therapeutic for the treatment of cognitive deficits following TBI.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Psychol, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23284 USA	Hamm, RJ (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Psychol, Box 842018,808 W Franklin St, Richmond, VA 23284 USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER		ALBIN RL, 1988, NEUROSCI LETT, V88, P303, DOI 10.1016/0304-3940(88)90228-5; ALONSO R, 1990, NEUROCHEM INT, V17, P457, DOI 10.1016/0197-0186(90)90028-R; BECKER RE, 1988, DRUG DEVELOP RES, V12, P163, DOI 10.1002/ddr.430120302; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BUYUKUYSAL RL, 1989, BRAIN RES, V482, P371; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; CHOU C-L, 1991, Society for Neuroscience Abstracts, V17, P722; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; DEWITT DS, 1988, ANESTHESIOLOGY REV, V15, P31; Dixon C. E., 1995, Society for Neuroscience Abstracts, V21, P762; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1995, NEUROSCI LETT, V198, P111, DOI 10.1016/0304-3940(95)11979-7; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DOODS H, 1993, EUR J PHARMACOL, V242, P23, DOI 10.1016/0014-2999(93)90005-3; Doods Henri N., 1995, Drugs of the Future, V20, P157; DOODS HN, 1993, LIFE SCI, V52, P497, DOI 10.1016/0024-3205(93)90307-O; EAGGER S, 1992, BRIT J PSYCHIAT, V160, P36, DOI 10.1192/bjp.160.1.36; ENZ A, 1993, PROG BRAIN RES, V98, P431; FARLOW M, 1992, JAMA-J AM MED ASSOC, V268, P2523, DOI 10.1001/jama.268.18.2523; FLOOD JF, 1981, BRAIN RES, V215, P177, DOI 10.1016/0006-8993(81)90500-X; FLYNN DD, 1989, J PHARMACOL EXP THER, V250, P573; FORTUNA S, 1994, NEUROTOXICOLOGY, V15, P735; GAITHER S, 1991, CAN J NEUROL SCI, V18, P439; GAITHIER S, 1990, NEW ENGL J MED, V322, P1272; Grady M. S., 1992, Society for Neuroscience Abstracts, V18, P172; GRAY JA, 1989, TRENDS PHARM SCI S, V10, P85; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAMM RJ, 1994, J NEUROSURG, V81, P267, DOI 10.3171/jns.1994.81.2.0267; HAROUTUNIAN V, 1985, PSYCHOPHARMACOLOGY, V87, P266, DOI 10.1007/BF00432705; HODGES H, 1990, PHARMACOL BIOCHEM BE, V36, P291, DOI 10.1016/0091-3057(90)90406-8; KIEFERDAY JS, 1992, PHARMACOLOGY, V44, P71, DOI 10.1159/000138875; KNAPP MJ, 1994, JAMA-J AM MED ASSOC, V271, P985, DOI 10.1001/jama.271.13.985; KWOONYUEN PF, 1990, EXP NEUROL, V108, P221, DOI 10.1016/0014-4886(90)90126-D; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; Liu S. J., 1993, Society for Neuroscience Abstracts, V19, P1881; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARCHI M, 1989, J PHARMACOL EXP THER, V248, P1255; MOLLOY DW, 1991, CAN MED ASSOC J, V144, P29; Moltzen Ejner K., 1995, Drugs of the Future, V20, P37; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MRZLJAK L, 1993, P NATL ACAD SCI USA, V90, P5194, DOI 10.1073/pnas.90.11.5194; NIELSEN JA, 1989, EUR J PHARMACOL, V173, P53, DOI 10.1016/0014-2999(89)90008-3; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; Pierce J. E. S., 1994, Society for Neuroscience Abstracts, V20, P196; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; Pike BR, 1997, PHARMACOL BIOCHEM BE, V57, P785, DOI 10.1016/S0091-3057(96)00453-4; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; PINTOR A, 1994, NEUROCHEM RES, V19, P1311, DOI 10.1007/BF01006823; POTTER LT, 1984, TRENDS PHARM SCI S, V5, P22; RICHARDS MH, 1990, BRIT J PHARMACOL, V99, P753, DOI 10.1111/j.1476-5381.1990.tb13002.x; RIEKKINEN P, 1991, PHYSIOL BEHAV, V49, P1147, DOI 10.1016/0031-9384(91)90342-L; RIEKKINEN P, 1990, PHARMACOL BIOCHEM BE, V36, P237, DOI 10.1016/0091-3057(90)90397-Z; SANTUCCI AC, 1989, PSYCHOPHARMACOLOGY, V99, P70, DOI 10.1007/BF00634455; SARTER M, 1990, PSYCHOPHARMACOLOGY, V101, P1, DOI 10.1007/BF02253710; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; Sinson G., 1995, Society for Neuroscience Abstracts, V21, P2121; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SUMMERS WK, 1986, NEW ENGL J MED, V315, P1241, DOI 10.1056/NEJM198611133152001; Temple MD, 1996, BRAIN RES, V741, P246, DOI 10.1016/S0006-8993(96)00940-7; UEKI A, 1989, J NEUROL SCI, V90, P775; VILARO MT, 1992, NEUROSCIENCE, V47, P367, DOI 10.1016/0306-4522(92)90253-X; VIZI ES, 1989, NEUROSCIENCE, V31, P259, DOI 10.1016/0306-4522(89)90048-1; WHITEHOUSE PJ, 1988, NEUROLOGY, V38, P307, DOI 10.1212/WNL.38.2.307; WLKER TM, 1995, HUM EXP TOXICOL, V14, P469	71	13	13	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1997	14	12					897	905		10.1089/neu.1997.14.897			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	YU127	WOS:000071685000002	9475371				2021-06-18	
J	McAllister, TW				McAllister, TW			Evaluation of brain injury related behavioral disturbances in community mental health centers	COMMUNITY MENTAL HEALTH JOURNAL			English	Article							CLOSED-HEAD-INJURY; RIGHT-HEMISPHERE; DEPRESSION; MANIA; MILD; TRAUMA; DISORDER; SEQUELAE; DIAGNOSIS; DEFICITS	As a result of improved emergency trauma services, more individuals suffering a traumatic brain injury are surviving. Unfortunately, most of these survivors suffer chronic neuropsychiatric sequelae related to both the brain damage and the psychosocial impact of the injury on self-esteem, self-image, primary role, and vocational function. Current community supports are often inadequate to deal with the complex array of neurologic and psychiatric difficulties. This article outlines common features of brain injury, explores the link between these features and the common neuropsychiatric sequelae of brain injury, and suggests some principles helpful in the evaluation of the behaviorally challenged brain injured patient.	DARTMOUTH COLL SCH MED, HANOVER, NH USA							ADAMS RD, 1985, PRINCIPLES NEUROLOGY; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; AUERBACH SH, 1989, PHYSICAL MED REHABIL, V3, P1; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BRACKEN P, 1987, BRIT J PSYCHIAT, V150, P690, DOI 10.1192/bjp.150.5.690; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; BURKE J M, 1990, Brain Injury, V4, P223, DOI 10.3109/02699059009026171; Burke J M, 1989, Brain Inj, V3, P35, DOI 10.3109/02699058909008071; COPE DN, 1987, J HEAD TRAUMA REHAB, V2, P1; Cripe LI, 1987, COGNITIVE REHABILITA, V5, P18; Cummings JL, 1985, CLIN NEUROPSYCHIATRY; DAVIS DL, 1990, J HEAD TRAUMA REHAB, V5, P31, DOI DOI 10.1097/00001199-199005020-00006; Davison K, 1969, BRIT J PSYCHIATRY SP, V4, P113; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; FREEDMAN PE, 1987, J NEUROL NEUROSUR PS, V50, P398, DOI 10.1136/jnnp.50.4.398; GAULTIERI CT, 1988, BRAIN INJURY, V2, P101; Gaultieri T, 1991, BRAIN INJURY, V5, P219; Gennarelli T. A., 1987, HEAD INJURY, P108; GENTILINI M, 1989, MILD HEAD INJURY, P163; GRAHAM DI, 1987, HEAD INJURY; GREEN RL, 1987, AM J PSYCHIAT, V144, P442; Gronwall D, 1989, MILD HEAD INJURY, P153; HALE MS, 1982, J NERV MENT DIS, V170, P362, DOI 10.1097/00005053-198206000-00006; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; HOOPER R S, 1945, J Ment Sci, V91, P458; Horn LJ, 1990, J HEAD TRAUMA REHAB, V5, P1; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KRAUS JF, 1987, HEAD INJURY; KWENTUS JA, 1985, PSYCHOSOMATICS, V26, P8, DOI 10.1016/S0033-3182(85)72900-3; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1987, HEAD INJURY; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCALLISTER TW, 1992, COMPR PSYCHIAT, V33, P296, DOI 10.1016/0010-440X(92)90036-P; MCALLISTER TW, 1987, COMPR PSYCHIAT, V28, P14, DOI 10.1016/0010-440X(87)90039-3; MCALLISTER TW, 1994, PSYCHIAT ASPECTS TRA; MCALLISTER TW, 1990, DEPRESSION NEW DIREC; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; MEYER A, 1974, BRAIN, V97, P565, DOI 10.1093/brain/97.1.565; MONRADKROHN GH, 1947, BRAIN, V70, P405, DOI 10.1093/brain/70.4.405; NASRALLAH HA, 1981, PSYCHOSOMATICS, V22, P359; NIZAMIE SH, 1988, ACTA PSYCHIAT SCAND, V77, P637, DOI 10.1111/j.1600-0447.1988.tb05181.x; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; POPE HG, 1988, COMPR PSYCHIAT, V29, P34, DOI 10.1016/0010-440X(88)90035-1; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; RIESS H, 1987, J CLIN PSYCHIAT, V48, P29; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Robinson R G, 1990, J Neuropsychiatry Clin Neurosci, V2, P1; ROBINSON RG, 1988, AM J PSYCHIAT, V145, P172; ROSS ED, 1979, ARCH NEUROL-CHICAGO, V36, P144, DOI 10.1001/archneur.1979.00500390062006; ROSS ED, 1981, ARCH GEN PSYCHIAT, V38, P1344; Ruff R.M., 1989, MILD HEAD INJURY, P176; Rutherford W. H., 1989, MILD HEAD INJURY, P217; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; SHUKLA S, 1987, AM J PSYCHIAT, V144, P93; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; STARKSTEIN SE, 1990, ANN NEUROL, V27, P652, DOI 10.1002/ana.410270612; STARKSTEIN SE, 1988, J NERV MENT DIS, V176, P87, DOI 10.1097/00005053-198802000-00004; STEWART JT, 1988, J CLIN PSYCHIAT, V49, P74; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TEASDALE G, 1974, LANCET, V2, P81; Trimble M R, 1991, Adv Neurol, V55, P143; TRIMBLE MR, 1982, TEMPORAL LOBE EPILEP; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; *US DEP HHS, 1989, DEP HLTH HUM SERV IN; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WEINTRAUB S, 1981, ARCH NEUROL-CHICAGO, V38, P742, DOI 10.1001/archneur.1981.00510120042004; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILSON J T L, 1990, Brain Injury, V4, P349; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; WOOD RL, 1989, TRAUMATIC BRAIN INJU, V3; ZASLER ND, 1990, J HEAD TRAUMA REHAB, V5, P14, DOI DOI 10.1097/00001199-199005020-00004; ZWIL AS, 1992, INT J PSYCHIAT MED, V22, P377, DOI 10.2190/J71J-FTML-JY1E-RKKG; ZWIL AS, 1993, BRAIN INJURY, V7, P147, DOI 10.3109/02699059309008168	95	13	13	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0010-3853	1573-2789		COMMUNITY MENT HLT J	Community Ment. Health J.	AUG	1997	33	4					341	358		10.1023/A:1025055426260			18	Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry	Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry	XK755	WOS:A1997XK75500009	9250431				2021-06-18	
J	Prielipp, RC; Robinson, JC; Wilson, JA; MacGregor, DA; Scuderi, PE				Prielipp, RC; Robinson, JC; Wilson, JA; MacGregor, DA; Scuderi, PE			Dose response, recovery, and cost of doxacurium as a continuous infusion in neurosurgical intensive care unit patients	CRITICAL CARE MEDICINE			English	Article						doxacurium; drug cost; drug therapy; intensive care unit; intracranial pressure; muscle relaxants; neuromuscular blocking drugs; neurosurgery; paralytic agents	NEUROMUSCULAR BLOCKING-DRUGS; CRITICALLY ILL PATIENTS; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; PROLONGED PARALYSIS; NITROUS-OXIDE; VECURONIUM; BLOCKADE; ATRACURIUM; CHLORIDE	Objectives: To determine the optimal dosing of doxacurium as a continuous infusion in neurosurgical patients with traumatic brain injury; to determine the effects of bolus administration of doxacurium on heart rate (HR), blood pressure (BP), and intracranial pressure (ICP); to monitor neuromuscular recovery after discontinuation of prolonged doxacurium infusion; and to compare the cost of doxacurium with other current neuromuscular blocking drugs. Design: Prospective, open-label study. Setting: Neurosurgical intensive care unit (ICU) of a university-affiliated teaching hospital. Patients: Eight critically ill, mechanically ventilated patients with traumatic head injury and normal renal and hepatic function. Patients had ICP monitoring. Interventions: A bolus injection of doxacurium (0.05 mg/kg) followed by a continuous infusion (0.015 mg/kg/hr), adjusted to maintain one twitch during Train-of-Four nerve stimulation of the adductor pollicis muscle. Measurements and Main Results: Bolus injections of doxacurium did not alter the HR, BP, or ICP. Patients were paralyzed 66 +/- 12 (SEM) hrs, with recovery of the fourth twitch occurring 118 +/- 19 mins after infusion of the doxacurium was discontined. There were no incidences of prolonged weakness, myopathy, or other adverse events. Conclusions: Continuous infusion of doxacurium provides stable neuromuscular blockade for neurosurgical patients with traumatic brain injury. Doxacurium is devoid of clinically important interactions with HR, BP, or ICP and is less costly than other neuromuscular blockers used in the ICU.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT NEUROSURG,WINSTON SALEM,NC; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,WINSTON SALEM,NC 27103	Prielipp, RC (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT ANESTHESIOL,SECT CRIT CARE,300 S HAWTHORNE RD,WINSTON SALEM,NC 27103, USA.						BAROHN RJ, 1994, MUSCLE NERVE, V17, P647, DOI 10.1002/mus.880170613; BASTA SJ, 1988, ANESTHESIOLOGY, V69, P478, DOI 10.1097/00000542-198810000-00006; BOLTON CF, 1994, CHEST, V106, P1; COOK DR, 1991, ANESTH ANALG, V72, P145; COURSIN DB, 1995, AM J HEALTH-SYST PH, V52, P635, DOI 10.1093/ajhp/52.6.635; COURSIN DB, 1992, CHEST, V102, P988, DOI 10.1378/chest.102.4.988; Coursin DB, 1993, CURRENT OPINION ANES, V6, P341; DANON MJ, 1991, MUSCLE NERVE, V14, P1131, DOI 10.1002/mus.880141115; DECOUL AAWO, 1985, CLIN NEUROL NEUROSUR, V87, P17, DOI 10.1016/0303-8467(85)90060-5; EMMOTT RS, 1990, BRIT J ANAESTH, V65, P480, DOI 10.1093/bja/65.4.480; ERKOLA O, 1993, ANESTHESIOL CLIN N A, V11, P426; FERNANDO PUE, 1987, ACTA ANAESTH SCAND, V31, P593, DOI 10.1111/j.1399-6576.1987.tb02627.x; HANSENFLASCHEN J, 1993, AM REV RESPIR DIS, V147, P234, DOI 10.1164/ajrccm/147.1.234; HARPER NJN, 1993, INTENS CARE MED, V19, pS80, DOI 10.1007/BF01708806; Hoyt J W, 1994, New Horiz, V2, P48; HSIANG JK, 1994, CRIT CARE MED, V22, P1471, DOI 10.1097/00003246-199409000-00019; HUNTER JM, 1995, NEW ENGL J MED, V332, P1691, DOI 10.1056/NEJM199506223322507; JENSEN E, 1988, ACTA ANAESTH SCAND, V32, P49, DOI 10.1111/j.1399-6576.1988.tb02687.x; KATZ JA, 1989, ANESTHESIOLOGY, V70, P432, DOI 10.1097/00000542-198903000-00012; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LENNON RL, 1989, ANESTH ANALG, V68, P255; Marik PE, 1996, CRIT CARE MED, V24, P1266, DOI 10.1097/00003246-199607000-00034; MEYER KC, 1994, ANESTH ANALG, V78, P772; MILLER RD, 1995, ANESTH ANALG, V81, P1; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MURRAY MJ, 1993, INTENS CARE MED, V19, pS40, DOI 10.1007/BF01708799; MURRAY MJ, 1995, CRIT CARE MED, V23, P450, DOI 10.1097/00003246-199503000-00007; Prielipp R C, 1995, New Horiz, V3, P456; PRIELIPP RC, 1995, ANESTH ANALG, V81, P3, DOI 10.1097/00000539-199507000-00002; PRIELIPP RC, 1994, ANESTH ANALG, V78, P775; PROUGH DS, 1994, CRIT CARE MED, V22, P1349; SEGREDO V, 1992, NEW ENGL J MED, V327, P524, DOI 10.1056/NEJM199208203270804; STOOPS CM, 1988, ANESTHESIOLOGY, V69, P365, DOI 10.1097/00000542-198809000-00013; WATLING SM, 1994, CRIT CARE MED, V22, P884, DOI 10.1097/00003246-199405000-00028; WERBA A, 1993, ANAESTHESIA, V48, P301, DOI 10.1111/j.1365-2044.1993.tb06947.x; WERBA A, 1991, ANAESTHESIST, V40, P328; WILSON JA, 1994, J NEUROSURG ANESTHES, V2, P139	37	13	14	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0090-3493			CRIT CARE MED	Crit. Care Med.	JUL	1997	25	7					1236	1241		10.1097/00003246-199707000-00028			6	Critical Care Medicine	General & Internal Medicine	XL366	WOS:A1997XL36600038	9233753				2021-06-18	
J	Crepeau, F; Scherzer, BP; Belleville, S; Desmarais, G				Crepeau, F; Scherzer, BP; Belleville, S; Desmarais, G			A qualitative analysis of central executive disorders in a real-life work situation	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							FRONTAL-LOBE DAMAGE; HEAD-INJURY; TEST-PERFORMANCE; DEFICITS	This paper addresses the problem of understanding the performance of an individual with traumatic brain injury (TBI) in a real-life work situation. The approach is based on a four-component problem-solving model: analysis, formulation of a solution, planning, and monitoring. Four target and control tests were selected to measure performance of each component and their underlying cognitive processes. Participants were seven adults with severe TBI and seven paired normal controls. Performances on neuropsychological tests were compared with those on four corresponding work tasks on a photocopy machine. Performance of the control group was superior to that of the TBI group on the tests and tasks. Inter-individual comparisons on work tasks revealed various patterns of deficits, suggesting the partial independence of problem-solving components. Specific associations between tests and photocopy tasks were not as predicted. Some alternative explanations raised by qualitative observations are discussed.	CTR HOSP COTE DES NEIGES, CTR RECH, MONTREAL, PQ H3W 1W5, CANADA; UNIV MONTREAL, DEPT PSYCHOL, MONTREAL, PQ H3C 3J7, CANADA; UNIV QUEBEC, DEPT PSYCHOL, MONTREAL, PQ H3C 3P8, CANADA							AINSLEY J, 1989, COGNITIVE REHABI NOV, P28; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BENYISHAY Y, 1983, REHABILITATION HEAD; BUTLER RW, 1989, CLIN NEUROPSYCHOL, V3, P235; CHRISTENSEN AL, 1989, NEUROPSYCHOLOGICAL T; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; GOLDSTEIN FC, 1987, NEUROPSYCHOL REHABIL, P327; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; KAPLAN E, 1989, CLIN NEUROPSYCHOLOGY; Kaplan E, 1978, BOSTON NAMING TEST; LACROIX J, 1991, EMPLOYMENT IMMIGRATI; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; LHERMITTE F, 1972, REV NEUROL-FRANCE, V127, P415; LURIA AR, 1967, TROUBLES RESOLUTION; MATHESON LN, 1982, UNPUB WORK CAPACITY; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MELAMED S, 1985, SCAND J REHABIL MED, P21; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Norman D, 1986, CONSCIOUSNESS SELF R, VIV; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; Sale P., 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [DOI 10.1097/00001199-199109000-00004, 10.1097/00001199-199109000-00004.]; SERON X, 1991, SCHWEIZ Z PSYCHOL, V50, P186; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1991, FRONTAL LOBE FUNCTIO; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P157; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VILKKI J, 1988, CORTEX, V24, P119, DOI 10.1016/S0010-9452(88)80020-0; VILKKI J, 1989, NEUROPSYCHOLOGIA, V27, P971, DOI 10.1016/0028-3932(89)90072-9; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; VONCRAMON DY, 1992, NEUROPSYCHOL REHABIL, V2, P207; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WIEGERSMA S, 1990, NEUROPSYCHOLOGIA, V28, P95, DOI 10.1016/0028-3932(90)90089-7	40	13	13	0	4	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	APR	1997	7	2					147	165		10.1080/713755525			19	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	XA640	WOS:A1997XA64000004					2021-06-18	
J	Counihan, T; Napolitano, LM; Heard, SO				Counihan, T; Napolitano, LM; Heard, SO			Transnasal insertion of percutaneous endoscopic gastrostomy in a patient with intermaxillary fixation: Case report	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							MAJOR ABDOMINAL-TRAUMA; BUMPER SYNDROME; COMPLICATIONS; PREVENTION; BENEFITS; REMOVAL	We describe successful placement of a percutaneous endoscopic gastrostomy via the transnasal approach in a patient mho required intermaxillary fixation for an open mandible fracture, and required enteral nutrition for chronic respiratory failure and traumatic brain injury. This method may be useful in other cases where the transoral route is not available for endoscopic insertion of enterostomy tubes.	UNIV MARYLAND, MED CTR, DEPT SURG, BALTIMORE, MD 21201 USA; UNIV MASSACHUSETTS, DEPT SURG, WORCESTER, MA 01605 USA							BOYD JW, 1995, GASTROINTEST ENDOSC, V41, P508, DOI 10.1016/S0016-5107(05)80013-6; CALTON WC, 1992, MIL MED, V157, P358; DUCKWORTH PF, 1991, GASTROINTEST ENDOSC, V37, P241; GRAHM TW, 1989, NEUROSURGERY, V25, P729, DOI 10.1227/00006123-198911000-00007; MA MM, 1995, GASTROINTEST ENDOSC, V41, P505, DOI 10.1016/S0016-5107(05)80012-4; MILLER RE, 1986, ANN SURG, V204, P543, DOI 10.1097/00000658-198611000-00006; MOCHIZUKI H, 1984, ANN SURG, V200, P297, DOI 10.1097/00000658-198409000-00007; MOORE EE, 1986, J TRAUMA, V26, P874, DOI 10.1097/00005373-198610000-00003; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; MOORE FA, 1992, ANN SURG, V216, P172, DOI 10.1097/00000658-199208000-00008; NAPOLITANO LM, 1994, PROCEDURES TECHNIQUE, P219; PONSKY JL, 1985, AM J SURG, V149, P102, DOI 10.1016/S0002-9610(85)80017-9; RUSSELL TR, 1984, AM J SURG, V148, P132, DOI 10.1016/0002-9610(84)90300-3	13	13	13	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	1996	41	3					530	532		10.1097/00005373-199609000-00025			3	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	VH571	WOS:A1996VH57100029	8810976				2021-06-18	
J	Keenan, MAE; Haider, T				Keenan, MAE; Haider, T			The formation of heterotopic ossification after traumatic brain injury: A biopsy study with ultrastructural analysis	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						calcification; heterotopic ossification; spastic quadriparesis	BONE; HIP	Heterotopic bone with different maturation stages was obtained from seven patients with spasticity secondary to traumatic brain injury. The specimens were studied under light and electron microscopy to determine the nature and sequence of formation of heterotopic ossification (HO). The findings revealed that immature heterotopic bone was made up of well-ordered collagen fibers with speckles of calcification distributed throughout the collagen network. No osteoid was observed in any specimen. Inflammation appears to be a secondary process beginning after the initial stages of calcification. The appearance of osteoblasts and osteoclasts with remodeling of the immature bone occurs as a very late process. These findings provide a new insight into the nature of HO and may influence future treatments.	TEMPLE UNIV, SCH MED, PHILADELPHIA, PA 19122 USA; UNIV COLORADO, DEPT ORTHOPAED SURG, DENVER, CO 80202 USA	Keenan, MAE (corresponding author), ALBERT EINSTEIN MED CTR, DEPT ORTHOPAED SURG, 5501 OLD YORK RD, PHILADELPHIA, PA 19141 USA.		Keenan, Mary Ann/ABB-1551-2020				BLANE CE, 1981, SKELETAL RADIOL, V7, P21, DOI 10.1007/BF00347167; BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629; CONOR JM, 1983, SOFT TISSUE OSSIFICA; COVENTRY MB, 1981, J BONE JOINT SURG AM, V63, P201, DOI 10.2106/00004623-198163020-00004; FREED JH, 1982, PARAPLEGIA, V20, P208, DOI 10.1038/sc.1982.39; GARLAND DE, 1985, J BONE JOINT SURG AM, V67A, P1261, DOI 10.2106/00004623-198567080-00019; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GARLAND DE, 1988, CLIN ORTHOP RELAT R, V233, P86; HURVITZ EA, 1992, ARCH PHYS MED REHAB, V73, P459; ILIZAROV GA, 1989, CLIN ORTHOP RELAT R, P249, DOI 10.1097/00003086-198901000-00038; ILIZAROV GA, 1989, CLIN ORTHOP RELAT R, P263; ORZEL JA, 1985, J NUCL MED, V26, P125; REDDI AH, 1972, P NATL ACAD SCI USA, V69, P1601, DOI 10.1073/pnas.69.6.1601; REDDI AH, 1976, J CELL BIOL, V69, P557, DOI 10.1083/jcb.69.3.557; RITTER MA, 1977, J BONE JOINT SURG AM, V59, P345, DOI 10.2106/00004623-197759030-00009; RITTER MA, 1985, CLIN ORTHOP RELAT R, V196, P217; SODEMANN B, 1988, CLIN ORTHOP RELAT R, P150; THOMAS BJ, 1985, J BONE JOINT SURG AM, V67A, P400, DOI 10.2106/00004623-198567030-00008; Tsur Atzmon, 1992, Harefuah, V123, P86; URIST MR, 1983, SCIENCE, V220, P680, DOI 10.1126/science.6403986; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; URIST MR, 1982, CLIN ORTHOP RELAT R, P219; WHARTON GW, 1975, CLIN ORTHOP RELAT R, P142	23	13	13	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1996	11	4					8	22		10.1097/00001199-199608000-00004			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	VA386	WOS:A1996VA38600004					2021-06-18	
J	Kolessar, DJ; Katz, SD; Keenan, MA				Kolessar, DJ; Katz, SD; Keenan, MA			Functional outcome following surgical resection of heterotopic ossification in patients with brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						heterotopic ossification; surgical resection; traumatic brain injury	LONG-TERM COMA; BONE-FORMATION; HEAD-INJURIES; MANAGEMENT	Significant periarticular heterotopic ossification (HO) may occur following traumatic brain injury (TBI). This can result in profound functional loss of motion, disability, and pain. Thirty-three consecutive cases of surgical resection of heterotopic bone were retrospectively reviewed. Twenty-four cases (11 hips, 10 elbows, 3 knees) were suitable for study. Clinical results demonstrated dramatic improvement in motion in all patients. Functional goals were achieved in 83.3% of patients and ambulatory level advancement occurred in 75% of suitable candidates. Subjective satisfaction with functional outcome was 91.3%. The overall radiographic recurrence rate was 23.8%, but only one (4.8%) was considered functionally significant. In summary, surgical excision of periarticular HO following TBI results in a significant improvement in functional range of motion, quality of life, independence, and social integration.	ALBERT EINSTEIN MED CTR, DEPT ORTHOPAED SURG, PHILADELPHIA, PA USA; TEMPLE UNIV, SCH MED, DEPT ORTHOPAED SURG, PHILADELPHIA, PA 19122 USA	Kolessar, DJ (corresponding author), GEISINGER WYOMING VALLEY HOSP, GEISINGER MED GRP, DEPT SURG, 1000 E MT DR, WILKES BARRE, PA 18711 USA.		Keenan, Mary Ann/ABB-1551-2020				BINDER SM, 1990, J BONE JOINT SURG AM, V72, P1144; BONTKE CB, 1988, J HEAD TRAUMA REHAB, V3, P86; BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629; COHEN RB, 1993, J BONE JOINT SURG AM, V75A, P215, DOI 10.2106/00004623-199302000-00008; CONNOR JM, 1982, J BONE JOINT SURG BR, V64, P76; COVENTRY MB, 1981, J BONE JOINT SURG AM, V63, P201, DOI 10.2106/00004623-198163020-00004; FREED JH, 1982, PARAPLEGIA, V20, P208, DOI 10.1038/sc.1982.39; GARLAND DE, 1978, CLIN ORTHOP RELAT R, P111; GARLAND DE, 1983, PHYS THER, V63, P2004, DOI 10.1093/ptj/63.12.2004; GARLAND DE, 1984, ARCH PHYS MED REHAB, V65, P531; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P59; GARLAND DE, 1982, CLIN ORTHOP RELAT R, P133; GARLAND DE, 1985, J BONE JOINT SURG AM, V67A, P1261, DOI 10.2106/00004623-198567080-00019; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13; GARLAND DE, 1993, PHYS MED REHABIL STA, V7, P611; Gennarelli T A, 1988, Brain Inj, V2, P175, DOI 10.3109/02699058809150942; HAIDER T, 1990, T ORTHOP RES SOC, V14, P309; HUNTER T, 1980, RHEUMATOL REHABIL, V19, P97, DOI 10.1093/rheumatology/19.2.97; KAPLAN FS, 1993, J BONE JOINT SURG AM, V75A, P220, DOI 10.2106/00004623-199302000-00009; LARSON JM, 1981, RHEUMATOL REHABIL, V20, P193, DOI 10.1093/rheumatology/20.4.193; MENDELSON L, 1975, SCAND J REHABIL MED, V7, P141; MIELANTS H, 1975, ACTA ORTHOP SCAND, V46, P190, DOI 10.3109/17453677508989207; MINAIRE P, 1980, ARCH PHYS MED REHAB, V61, P214; MITAL MA, 1987, J PEDIATR ORTHOPED, V7, P83, DOI 10.1097/01241398-198701000-00017; Moore T J, 1993, J Orthop Trauma, V7, P11, DOI 10.1097/00005131-199302000-00003; Pittenger D E, 1991, Orthop Rev, V20, P33; ROBERTS JB, 1979, J BONE JOINT SURG AM, V61, P760, DOI 10.2106/00004623-197961050-00018; Rogers R C, 1988, Brain Inj, V2, P169, DOI 10.3109/02699058809150941; SAZBON L, 1981, J BONE JOINT SURG BR, V63, P120; SCHMIDT SA, 1988, J BONE JOINT SURG AM, V70A, P834, DOI 10.2106/00004623-198870060-00005; SPIELMAN G, 1983, ARCH PHYS MED REHAB, V64, P539; STOVER SL, 1991, CLIN ORTHOP RELAT R, P71; STOVER SL, 1986, MANAGEMENT SPINAL CO; VARGHESE G, 1992, PHYS MED REH CLIN N, V3, P407; WEISS S, 1979, J RHEUMATOL, V6, P88; WENNER SM, 1986, CLIN ORTHOP RELAT R, P231	37	13	14	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1996	11	4					78	87		10.1097/00001199-199608000-00010			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	VA386	WOS:A1996VA38600010					2021-06-18	
J	Keller, T; Chappell, T				Keller, T; Chappell, T			The rise and fall of Erichsen's disease (railroad spine)	SPINE			English	Article						Erichsen's disease; spinal concussion; traumatic neurosis		The railroad represented one of the major technologic achievements of the 19th century. Sadly, railroad collisions, which resulted in major injuries, and loss of life, began to tarnish the image of this popular mode of transportation. Public alarm about rail travel intensified in 1866, when notes British surgeion John Eric Erichsen described a peculiar progressive spinal disorder, similar to spinal concussion, that was a sequela to railroad accident or injury. The history of this disorder, which came to be known as ''railroad spine'' or ''Erichsen's disease,'' represents a little known yet important chapter in the evolution of the modern comprehension of functional illness that can complicate or even replace an initial substrate of organic disease.		Keller, T (corresponding author), UNIV CALIF DAVIS E BAY,DIV NEUROSURG,DEPT SURG,PACIFIC NEUROSCI INST,1411 E 31ST ST,OAKLAND,CA 94602, USA.						Beard GM, 1869, BOSTON MED SURG J, V80, P217; BUZZARD T, 1867, LANCET, V1, P389; CAPLAN EM, 1995, B HIST MED, V69, P387; CHARCOT JM, 1895, LECONS MALADIES SYST, V3, P344; CLEVENGER SV, 1989, SPINAL CONCUSSION SU; ERB WH, 1878, CYCLOPEDIA PRACTICE, P344; ERICHSEN JE, 1896, BRIT MED J, V2, P885; ERICHSEN JE, 1894, TEXAS SANITARIAN, V3, P448; Erichsen John Eric, 1866, RAILWAY OTHER INJURI; GOETZ CG, 1995, CHARCOTS MAJOR NEURO, P99; HAMILTON AM, 1894, RAILWAY OTHER ACCIDE, P15; LEYDEN E, 1875, KLINIK RUCKENMARKS K, V3, P84; LIDELL JA, 1864, AM J MED SCI, V48, P305; Mitchell SW, 1908, J AMER MED ASSOC, V50, P2033; PAGE H, 1885, INJURIES SPINE SPINA, P14; PHILLIPS L, 1905, YONDER COMES TRAIN, P30; POWER D, 1930, JE ERICHSEN PLARRS L, V1, P378; RONTGEN K, 1895, SITZBER PHYSICK MED, V137, P132; SPARHAWK CW, 1887, BOSTON MED SURG J, V116, P477; Walton G. L., 1881, BOSTON MED SURG J, V109, P337, DOI 10.1056/NEJM188310111091501; 1862, LANCET, V1, P79	21	13	13	0	2	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0362-2436			SPINE	SPINE	JUL 1	1996	21	13					1597	1601		10.1097/00007632-199607010-00022			5	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	UV647	WOS:A1996UV64700022	8817791				2021-06-18	
J	Sessa, S; Lascombes, P; Prevot, J; Gagneux, E				Sessa, S; Lascombes, P; Prevot, J; Gagneux, E			Fractures of the radial head and associated elbow injuries in children	JOURNAL OF PEDIATRIC ORTHOPAEDICS-PART B			English	Article						associated injuries; children; closed intramedullary pinning; radial head fracture; treatment	NECK FRACTURES	Fractures of the radial head are frequently associated with elbow injuries in children. Thirty-seven patients with this association treated at the Nancy Children's Hospital were analyzed to ascertain the mechanism and the unfavorable factors of prognosis. The mechanism responsible was a valgus strain on the elbow at the moment of impact, associated with forces of compression and distraction. At an average follow-up of 2 years, 76% excellent and good results were obtained. Conservative treatment was always effective in minimally displaced fractures. With surgical reduction by closed intramedullary pinning (CIMP), there were only three failures in severely displaced fractures. With open reduction, results were always poor; 88% patients with fair and poor results had an associated fracture of the olecranon. The unfavorable prognostic factors were the severity of the initial tilting and displacement, the presence of associated elbow injuries, the inadequacy of reduction, and the open reduction procedure.	HOP ENFANTS,DEPT PEDIAT ORTHOPED,F-54511 VANDOEUVRE NANCY,FRANCE			Sessa, Sergio/AAA-7655-2020				DSOUZA S, 1993, J PEDIATR ORTHOPED, V13, P233; FOWLES JV, 1986, J PEDIATR ORTHOPED, V6, P51; HENRIKSON B, 1969, ACTA ORTHOP SCAND, V40, P246, DOI 10.3109/17453676908989505; Jeffery C C, 1972, J Bone Joint Surg Br, V54, P717; JEFFERY CC, 1950, J BONE JOINT SURG BR, V32, P314; JONES E R L, 1971, Journal of Bone and Joint Surgery British Volume, V53, P429; JUDET R, 1962, ANN CHIR, V16, P1377; KOLHER R, 1991, REV CHIR ORTHOP S1, V77, P140; LINDHAM S, 1979, ACTA ORTHOP SCAND, V50, P79, DOI 10.3109/17453677909024093; MARION J, 1962, REV CHIR ORTHOP, V48, P333; MCBRIDE ED, 1960, CLIN ORTHOP RELAT R, V16, P264; METAIZEAU JP, 1980, REV CHIR ORTHOP, V66, P47; METAIZEAU JP, 1993, J PEDIATR ORTHOPED, V13, P355, DOI 10.1097/01241398-199305000-00015; METAIZEAU JP, 1990, FRACTURES MEMBRES CH, P233; NEWMAN JH, 1977, INJURY, V9, P114, DOI 10.1016/0020-1383(77)90004-3; Pennecot G F, 1987, Rev Chir Orthop Reparatrice Appar Mot, V73, P473; REIDY JA, 1963, J BONE JOINT SURG AM, V45, P1355, DOI 10.2106/00004623-196345070-00002; SALTER RB, 1963, J BONE JOINT SURG AM, V45, P587, DOI 10.2106/00004623-196345030-00019; TACHDJIAN MO, 1990, PEDIAT ORTHOPAEDICS, V4, P3137; THEODOROU S D, 1969, Journal of Bone and Joint Surgery British Volume, V51, P700; TIBONE JE, 1981, J BONE JOINT SURG AM, V63, P90; WILKINS KE, 1984, FRACTURES CHILDREN, V3, P501	22	13	15	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	1060-152X			J PEDIATR ORTHOP B	J. Pediatr. Orthop.-Part B	SUM	1996	5	3					200	209		10.1097/01202412-199605030-00012			10	Orthopedics; Pediatrics	Orthopedics; Pediatrics	VG424	WOS:A1996VG42400012	8866287				2021-06-18	
J	Hamilton, SM; Breakey, P				Hamilton, SM; Breakey, P			Fluid resuscitation of the trauma patient: How much is enough?	CANADIAN JOURNAL OF SURGERY			English	Article							SEVERE HEAD-INJURY; MULTIPLE-ORGAN-FAILURE; BACTERIAL TRANSLOCATION; HEMORRHAGIC-SHOCK; MORTALITY; GUT; SWINE; PERMEABILITY; PERSPECTIVE; PRESSURE	Patient management in the prehospital resuscitative phase after trauma is vitally important to the outcome. Early definitive care remains the essential element in improving morbidity and mortality. In Canada, where a large proportion of trauma occurs at sites distant From a trauma centre, the prehospital resuscitative phase is long and has even greater potential to affect outcome. Conventional teaching about the end points of resuscitation has promoted the concept of normalization of hemodynamic parameters with maintenance of end-organ perfusion, as measured by the hourly urine output. Recent work in patients with a closed head injury and in patients with penetrating torso trauma challenge the notion that trauma patients are homogeneous with respect to these end points. In the Canadian setting of blunt injury, where a dosed head injury is usually suspected and often present, the evidence from clinical studies suggests that an aggressive approach to maintaining blood pressure is warranted. In penetrating torso injury in an urban setting, there is evidence to suggest that delaying resuscitation until hemorrhage is controlled is beneficial. More Canadian clinical trials are required in this area. In the meantime, the priorities of resuscitation must be carefully assessed for each patient and pattern of injury.	UNIV ALBERTA HOSP,DEPT SURG,EDMONTON,AB T6G 2B7,CANADA							ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ALEXANDER JW, 1991, ANN SURG, V213, P558, DOI 10.1097/00000658-199106000-00005; ALEXANDER JW, 1990, ANN SURG, V212, P496, DOI 10.1097/00000658-199010000-00012; BAKER J W, 1987, Surgical Forum (Chicago), V38, P73; BAKER JW, 1988, J TRAUMA, V28, P896, DOI 10.1097/00005373-198807000-00002; BAKER SP, 1988, J TRAUMA, V28, P741, DOI 10.1097/00005373-198806000-00003; BAKER SP, 1987, NEW ENGL J MED, V316, P1384, DOI 10.1056/NEJM198705283162206; BICKELL WH, 1991, SURGERY, V110, P529; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BICKELL WH, 1992, ANN EMERG MED, V21, P1077, DOI 10.1016/S0196-0644(05)80648-1; BORDER JR, 1987, ANN SURG, V206, P427, DOI 10.1097/00000658-198710000-00004; BORDER JR, 1983, J TRAUMA, V23, P708, DOI 10.1097/00005373-198308000-00005; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; Capono A, 1993, J TRAUMA, V35, P984; CARRICO CJ, 1986, ARCH SURG-CHICAGO, V121, P196; CHANG MC, 1994, J TRAUMA, V37, P488, DOI 10.1097/00005373-199409000-00026; DEITCH EA, 1990, CRIT CARE MED, V18, P529, DOI 10.1097/00003246-199005000-00014; DEITCH EA, 1987, ARCH SURG-CHICAGO, V122, P185; DEITCH EA, 1989, J CLIN INVEST, V84, P36, DOI 10.1172/JCI114164; DEITCH EA, 1992, ANN SURG, V216, P177; DEMLING R, 1993, CURR PROB SURG, V30, P345; FINK MP, 1991, SURGERY, V110, P154; FINK MP, 1991, CRIT CARE MED, V19, P627, DOI 10.1097/00003246-199105000-00009; GELFAND GAJ, 1991, J TRAUMA, V31, P867, DOI 10.1097/00005373-199106000-00020; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; JACOBS LM, 1984, J TRAUMA, V24, P8, DOI 10.1097/00005373-198401000-00002; JOHNSON KD, 1985, J TRAUMA, V25, P375, DOI 10.1097/00005373-198505000-00001; MARSHALL JC, 1988, ARCH SURG-CHICAGO, V123, P309; MOORE FA, 1992, ARCH SURG-CHICAGO, V127, P893; MOORE FA, 1991, J TRAUMA, V31, P629, DOI 10.1097/00005373-199105000-00006; MORRIS JA, 1991, J TRAUMA, V31, P1584, DOI 10.1097/00005373-199112000-00003; NACHT A, 1992, CRIT CARE CLIN, V8, P255; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SMITH JP, 1983, J TRAUMA, V23, P317, DOI 10.1097/00005373-198304000-00008; Southard P, 1990, J Emerg Nurs, V16, P321; TURNBULL RG, 1995, J TRAUMA, V38, P705, DOI 10.1097/00005373-199505000-00005; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; 1993, CANADIAN MOTOR VEHIC; 1989, ADV TRAUMA LIFE SUPP	39	13	13	0	0	CANADIAN MEDICAL ASSOCIATION	OTTAWA	1867 ALTA VISTA DR, OTTAWA ON K1G 3Y6, CANADA	0008-428X			CAN J SURG	Can. J. Surg.	FEB	1996	39	1					11	16					6	Surgery	Surgery	TV948	WOS:A1996TV94800006	8599784				2021-06-18	
J	Buder, EH; Kent, RD; Kent, JF; Milenkovic, P; Workinger, M				Buder, EH; Kent, RD; Kent, JF; Milenkovic, P; Workinger, M			FORMOFFA: An automated formant, moment, fundamental frequency, amplitude analysis of normal and disordered speech	CLINICAL LINGUISTICS & PHONETICS			English	Article						acoustic analysis; dysarthria; spectral moments	STATISTICAL-ANALYSIS; ANALYSIS SYSTEMS; CHILDREN; INTELLIGIBILITY; DYSARTHRIA; KURTOSIS	A system for semi-automatic, multi-parameter acoustic analysis is described. The system, called FORMOFFA (For = FORmants, Mo = MOments, FF = Fundamental Frequency, A = Amplitude), operates on a PC microcomputer by adaptations of commercially available software. Data displays include a deterministic time record of instantaneous values, and an ergodic time-compressed distribution. In this report the technique is developed with a one-word example, and some measurement and reliability issues are described. The analysis possibilities are then illustrated with several applications: (1) segmental analysis of normal speech, (2) acoustic assessment of the effects of a progressive neurological disease (amyotrophic lateral sclerosis) on sentence production, (3) acoustic study of palatal lift management of a patient with traumatic brain injury, and (4) phonetic assessment of word production by a subject with dysarthria. Although the current technique is recommended as a research tool, this kind of analysis promises several advantages for clinical application, including semi-automaticity, efficiency, parsimony, and relevance to both segmental and suprasegmental levels of analysis.	UNIV WISCONSIN,WAISMAN CTR,MADISON,WI 53705; UNIV WISCONSIN,DEPT ELECT & COMP ENGN,MADISON,WI 53706; MARSHFIELD CLIN FDN MED RES & EDUC,MARSHFIELD,WI 54449	Buder, EH (corresponding author), UNIV WASHINGTON,DEPT SPEECH & HEARING SCI,SEATTLE,WA 98195, USA.		Kent, Raymond D/AAI-1928-2020				ATLAS L, 1991, IEEE P PACIFIC RIM C; Baken R. J., 1987, CLIN MEASUREMENT SPE; BAKEN RJ, 1991, READINGS CLIN SPECTR; BARLOW S M, 1989, Journal of Voice, V3, P283, DOI 10.1016/S0892-1997(89)80050-5; COLLINS M, 1984, COMMUNICATION DISORD, V5, P159; DARLINGT.RB, 1970, AM STAT, V24, P19, DOI 10.2307/2681925; Davis S. B., 1979, SPEECH LANGUAGE ADV, V1; DEJONCKERE PH, 1991, 1ST INT CLIN PHON LI; ELASHOFF JD, 1978, INT ENCY STATISTICS; FORREST K, 1988, J ACOUST SOC AM, V84, P115, DOI 10.1121/1.396977; FORREST K, 1990, CLIN LINGUIST PHONET, V4, P327, DOI 10.3109/02699209008985495; Frokjaer-Jensen B., 1976, Bruel and Kjaer Technical Review, P3; HARMEGNIES B, 1988, THESIS U MONS FRANCE; JOHNSON M, 1993, J ACOUST SOC AM, V94, P1865; Kent R.D., 1992, INTELLIGIBILITY SPEE; KENT RD, 1991, J SPEECH HEAR RES, V34, P1269, DOI 10.1044/jshr.3406.1269; KENT RD, 1989, J SPEECH HEAR DISORD, V54, P482, DOI 10.1044/jshd.5404.482; KENT RD, 1992, NIDCD MONOGRAPH, P17; KITAWAKI N, 1991, ADV SPEECH SIGNAL PR; KLINGHOLZ F, 1989, FOLIA PHONIATR, V41, P23, DOI 10.1159/000265929; MICCERI T, 1989, PSYCHOL BULL, V105, P156, DOI 10.1037/0033-2909.105.1.156; MILENKOVIC P, 1994, CSPEECH VERSION 4 X; NEWELL KM, 1984, J MOTOR BEHAV, V16, P320; NITTROUER S, 1989, J SPEECH HEAR RES, V32, P120, DOI 10.1044/jshr.3201.120; PINTO NB, 1990, J ACOUST SOC AM, V87, P1278, DOI 10.1121/1.398803; POBURKA BJ, 1993, J ACOUST SOC AM, V94, P1782; READ C, 1992, J SPEECH HEAR RES, V35, P314, DOI 10.1044/jshr.3502.314; READ C, 1990, J SPEECH HEAR RES, V33, P363, DOI 10.1044/jshr.3302.363; SHEARD C, 1991, J SPEECH HEAR RES, V34, P285, DOI 10.1044/jshr.3402.285; SHIKANO K, 1991, ADV SPEECH SIGNAL PR; SOUTHWOOD J, 1990, THESIS U WISCONSIN M; STOELGAMMON C, 1994, PHONETICA, V51, P146, DOI 10.1159/000261966; STRAND EA, 1994, J VOICE, V8, P327, DOI 10.1016/S0892-1997(05)80281-4; WALDSTEIN RS, 1991, J SPEECH HEAR RES, V34, P1276, DOI 10.1044/jshr.3406.1276; WEISMER G, 1988, J ACOUST SOC AM, V38, P1281; ZYSKI BJ, 1987, J COMMUN DISORD, V20, P367, DOI 10.1016/0021-9924(87)90025-6	36	13	13	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9206			CLIN LINGUIST PHONET	Clin. Linguist. Phon.	JAN-MAR	1996	10	1					31	54		10.3109/02699209608985160			24	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	TR033	WOS:A1996TR03300003	20426513				2021-06-18	
J	Varney, NR; Roberts, RJ; Struchen, MA; Hanson, TV; Franzen, KM; Connell, SK				Varney, NR; Roberts, RJ; Struchen, MA; Hanson, TV; Franzen, KM; Connell, SK			Design fluency among normals and patients with closed head injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article								A Design Fluency task was administered to 86 patients who had suffered closed head injury (CHI) with loss of consciousness and 87 normal control subjects. Subjects were asked to draw as many novel designs as they could in 5 minutes without scribbling, drawing a nameable object, or repeating a design that had been drawn previously. The mean performance of the CHI group was significantly poorer than that of the control group, with 47% of head injured performing defectively (below the 5th percentile of controls). There was no significant relationship between Design Fluency and prorated Ia psychomotor speed, or Word Fluency. The findings demonstrate that a standardized version of the ''free condition'' of Design Fluency is likely to be useful in the evaluation of patients with closed head injury.		Varney, NR (corresponding author), VET ADM MED CTR, PSYCHIAT SERV 116B, IOWA CITY, IA 52246 USA.						AXELROD BN, 1989, THESIS WAYNE STATE U; Benton A, 1989, MULTILINGUAL APHASIA; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BIGLER E, IN PRESS APPL NEUROP; Bigler ED, 1988, NEUROPSYCHOLOGY, V2, P127, DOI 10.1037//0894-4105.2.3-4.127; DAIGNEAULT S, 1992, DEV NEUROPSYCHOL, V8, P99, DOI 10.1080/87565649209540518; DAIGNEAULT S, 1988, J CLIN EXP NEUROPSYC, V10, P58; GURDJIAN ES, 1976, J TRAUMA, V16, P35, DOI 10.1097/00005373-197601000-00005; Jennett B, 1981, MANAGEMENT HEAD INJU; JONESGOTMAN M, 1977, NEUROPSYCHOLOGIA, V15, P653, DOI 10.1016/0028-3932(77)90070-7; JONESGOTMAN M, 1991, EPILEPSIA, V32, pS41; LEZAK MD, 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LIM YK, 1984, SPINE, V9, P329; MCCARTHY RA, 1990, COGNITIVE NEUROPSYCH; MITTENBERG W, 1989, J CLIN EXP NEUROPSYC, V11, P918, DOI 10.1080/01688638908400945; Ruff R. M., 1988, RUFF FIGURAL FLUENCY; RUFF RM, 1994, ARCH CLIN NEUROPSYCH, V9, P41, DOI 10.1016/0887-6177(94)90013-2; RUFF RM, 1987, DEV NEUROPSYCHOL, V3, P37, DOI 10.1080/87565648709540362; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; VARNEY NR, 1995, APPL NEUROPSYCHOLOGY, V2, P1	21	13	13	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.		1996	11	4					345	353		10.1016/0887-6177(95)00015-1			9	Psychology, Clinical; Psychology	Psychology	UN858	WOS:A1996UN85800009	14588939	Bronze			2021-06-18	
J	EWINGCOBBS, L; DUHAIME, AC; FLETCHER, JM				EWINGCOBBS, L; DUHAIME, AC; FLETCHER, JM			INFLICTED AND NONINFLICTED TRAUMATIC BRAIN INJURY IN INFANTS AND PRESCHOOLERS	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							CLOSED-HEAD-INJURY; PHYSICAL CHILD-ABUSE; FOLLOW-UP; ADOLESCENTS; SEQUELAE; COMA; AGE; EPIDEMIOLOGY; RETARDATION; MECHANISMS	Infants and preschoolers sustaining traumatic brain injury represent a distinct group in terms of injury characteristics, medical management, and outcome. Although the majority of traumatic brain injuries occurring during early childhood are mild, severe injuries are associated with high rates of mortality and morbidity. The less favorable neurobehavioral outcome frequently identified in infants and preschoolers in relation to outcome in other pediatric age groups is likely due to the high rate of inflicted injury in young children. inflicted injury often subjects the brain to rotational acceleration-deceleration forces that produce diffuse damage, leading to a high rate of death or persistent disability.	UNIV PENN,SCH MED,PHILADELPHIA,PA 19104; CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA 19104	EWINGCOBBS, L (corresponding author), UNIV TEXAS,HLTH SCI CTR,HOUSTON,TX 77225, USA.		Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019				APPELBAUM AS, 1977, J ABNORM CHILD PSYCH, V5, P417, DOI 10.1007/BF00915089; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; CAFFEY J, 1974, PEDIATRICS, V54, P396; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHRISTOFFEL KK, 1990, AM J DIS CHILD, V144, P697, DOI 10.1001/archpedi.1990.02150300095025; Cohn Anne, 1983, APPROACH PREVENTING; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; DUHAIME AC, IN PRESS PRACTICE NE; DUHAIME AC, IN PRESS NEUROLOGICA; ERICKSON MF, 1989, CHILD MALTREATMENT T; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FITCH MJ, 1976, J PEDIATR PSYCHOL, V1, P32; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FRIEDRICH WN, 1983, J CONSULT CLIN PSYCH, V51, P313, DOI 10.1037/0022-006X.51.2.313; GENNARELLI TA, 1985, NEUROSURGERY, V2; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; HAHN YS, 1983, CHILD BRAIN, V10, P229; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HELFER RE, 1977, PEDIATRICS, V60, P533; HELFER RE, 1984, PEDIATR ANN, V13, P745; HOFFMANPLOTKIN D, 1984, CHILD DEV, V55, P794, DOI 10.1111/j.1467-8624.1984.tb03816.x; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; JOFFE M, 1988, PEDIATRICS, V82, P457; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LANGECOSACK H, 1979, NEUROPADIATRIE, V10, P105, DOI 10.1055/s-0028-1085318; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; OATES RK, 1984, AM J DIS CHILD, V138, P764, DOI 10.1001/archpedi.1984.02140460053018; PANG D, 1989, J TRAUMA, V29, P654, DOI 10.1097/00005373-198905000-00021; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; RIVARA FP, 1994, PEDIATR ANN, V23, P12, DOI 10.3928/0090-4481-19940101-06; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; SATO Y, 1989, RADIOLOGY, V173, P653, DOI 10.1148/radiology.173.3.2813768; TEASDALE G, 1974, LANCET, V2, P81; TRICKETT PK, 1991, DEV PSYCHOL, V27, P148, DOI 10.1037/0012-1649.27.1.148; WOLFF DA, 1988, BEHAVIORAL ASSESSMEN; YAGER JY, 1990, AM J DIS CHILD, V144, P1088, DOI 10.1001/archpedi.1990.02150340032019; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687; 1990, AM J DIS CHILD, V144, P627	58	13	13	0	3	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1995	10	5					13	24		10.1097/00001199-199510000-00004			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RY617	WOS:A1995RY61700004					2021-06-18	
J	SHURTLEFF, HA; MASSAGLI, TL; HAYS, RM; ROSS, B; SPRUNKGREENFIELD, H				SHURTLEFF, HA; MASSAGLI, TL; HAYS, RM; ROSS, B; SPRUNKGREENFIELD, H			SCREENING CHILDREN AND ADOLESCENTS WITH MILD OR MODERATE TRAUMATIC BRAIN INJURY TO ASSIST SCHOOL REENTRY	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							MINOR HEAD-INJURY; WISC-R; ACADEMIC-ACHIEVEMENT; BEHAVIORAL SEQUELAE; HALSTEAD-REITAN; AMNESIA TEST; SEVERITY; INTELLIGENCE; ORIENTATION; BATTERY	Children with mild to moderate traumatic brain injury (TBI) do not usually require inpatient rehabilitation treatment and thus do not receive the extensive school reentry pi arming activated for children with more severe injuries. Yet such children are at risk for frustration or failure at school as a result of their brain injuries. A screening tool of selected neuropsychological tests was developed and a clinical protocol for evaluation implemented to assess children with mild to moderate TBI. The screening tool and clinical protocol are described and illustrative cases presented.	UNIV WASHINGTON,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; GREEN MT REHABIL MED,BREMERTON,WA; CHILDRENS HOSP & MED CTR,DEPT EDUC,SEATTLE,WA 98105	SHURTLEFF, HA (corresponding author), CHILDRENS HOSP & MED CTR,DIV REHABIL PSYCHOL,SEATTLE,WA 98105, USA.						BIJUR PE, 1990, PEDIATRICS, V86, P337; Blosser JL, 1991, J HEAD TRAUMA REHAB, V6, P73; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; CARNEY J, 1994, PEDIATR ANN, V23, P47, DOI 10.3928/0090-4481-19940101-10; CARNEY J, 1990, Pediatrician, V17, P222; CLARREN SGB, 1987, THESIS U WASHINGTON; DAMATO RC, 1988, J SCHOOL PSYCHOL, V26, P283, DOI 10.1016/0022-4405(88)90007-6; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; FLETCHER JM, 1984, J CLIN NEUROPSYCHOL, V6, P39, DOI 10.1080/01688638408401195; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; Halstead WC, 1949, J SPEECH HEAR DISORD, V14, P9, DOI 10.1044/jshd.1401.09; HINSHAW SP, 1986, INT J CLIN NEUROPSYC, V8, P3; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KLESGES RC, 1983, INT J CLIN NEUROPSYC, V5, P28; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Kreutzer JS, 1993, J HEAD TRAUMA REHAB, V8, P47; Lehr E, 1990, PSYCHOL MANAGEMENT T; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MASSAGLI TL, 1994, PEDIATR ANN, V23, P29, DOI 10.3928/0090-4481-19940101-08; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MILTON SB, 1991, J HEAD TRAUMA REHAB, V6, P35; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; REITAN RM, 1985, J CLIN PSYCHOL, V41, P245, DOI 10.1002/1097-4679(198503)41:2<245::AID-JCLP2270410219>3.0.CO;2-D; REITAN RM, 1985, J CLIN PSYCHOL, V41, P643, DOI 10.1002/1097-4679(198509)41:5<643::AID-JCLP2270410510>3.0.CO;2-A; REITAN RM, 1994, J CLIN PSYCHOL, V50, P47, DOI 10.1002/1097-4679(199401)50:1<47::AID-JCLP2270500106>3.0.CO;2-X; REITAN RM, 1992, CLIN NEUROPSYCHOL, V6, P287; RETZLAFF P, 1992, J CLIN PSYCHOL, V48, P666, DOI 10.1002/1097-4679(199209)48:5<666::AID-JCLP2270480514>3.0.CO;2-J; Rosen CD, 1986, HEAD TRAUMA ED REINT; Rourke BP, 1983, CHILD NEUROPSYCHOLOG; RUIJS MBM, 1992, DEV MED CHILD NEUROL, V34, P885; SATTLER JM, 1992, ASSESSMENT CHILDRENS; SAVAGE RC, 1991, J HEAD TRAUMA REHAB, V6, P1; SEIDENBERG M, 1983, J CONSULT CLIN PSYCH, V51, P406, DOI 10.1037/0022-006X.51.3.406; Shurtleff H. A., 1988, J PSYCHOEDUCATIONAL, V6, P298, DOI 10.1177/073428298800600313; SHURTLEFF HA, 1993, DEV NEUROPSYCHOL, V9, P55, DOI 10.1080/87565649309540544; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; STROM DA, 1987, J PSYCHOEDUCATIONAL, V5, P157; Sutter E. G., 1986, J PSYCHOEDUCATIONAL, V4, P73; SWEET JJ, 1986, INT J CLIN NEUROPSYC, V8, P177; TELZROW CF, 1987, J SCHOOL PSYCHOL, V25, P93, DOI 10.1016/0022-4405(87)90064-1; TELZROW CF, 1991, J HEAD TRAUMA REHAB, V6, P23; TOWNES BD, 1980, J CONSULT CLIN PSYCH, V48, P675, DOI 10.1037/0022-006X.48.6.675; TRAMONTANA MG, 1984, INT J CLIN NEUROPSYC, V6, P1; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1991, WECHSLER INTELLIGENC; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; Ylvisaker M, 1991, J HEAD TRAUMA REHAB, V6, P10, DOI DOI 10.1097/00001199-199103000-00006	61	13	13	0	4	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1995	10	5					64	79		10.1097/00001199-199510000-00008			16	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RY617	WOS:A1995RY61700008					2021-06-18	
J	GOTSCHALL, CS; PAPERO, PH; SNYDER, HM; JOHNSON, DL; SACCO, WJ; EICHELBERGER, MR				GOTSCHALL, CS; PAPERO, PH; SNYDER, HM; JOHNSON, DL; SACCO, WJ; EICHELBERGER, MR			COMPARISON OF 3 MEASURES OF INJURY SEVERITY IN CHILDREN WITH TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Head Injury 1994 - International Symposium on Head Injury Research	OCT 12-14, 1994	WASHINGTON, DC	Natl Highway Traff Safety Adm, Head Injury Res Program, George Washington Univ		BRAIN INJURY; CHILDREN; INJURY SEVERITY; GLASGOW COMA SCALE; OUTCOME; TRAUMA; HEAD INJURY	CLOSED-HEAD-INJURY; MORTALITY; SCORE; ADOLESCENTS; TRISS	Eighty-six traumatically brain-injured children aged 6 to 15 years who were consecutively admitted to a pediatric Level I trauma center were recruited for participation in the study. A comprehensive battery of behavioral, cognitive, commuuicative, social, motoric, and neurological tests was administered to the children from 12 to 36 months postinjury. The performance of three severity indices, the Glasgow Coma Scale (GCS), the ASCOT probability of survival, and the head injury component of the Anatomic Profile, was compared with respect to their association with longterm outcomes in five neurological domains, as assessed by linear regression models. The ASCOT probability of survival was correlated to test scores in all five domains. The GCS and the head injury component of the Anatomic Profile were each correlated to outcome in only one domain. The ASCOT probability of survival, which includes coded variables for the GCS, systolic blood pressure, and respiratory rates on admission, as well as a measure of multisystem anatomic injury, was the most sensitive indicator of head injury severity and was associated with outcomes beyond survival and death in this population. Probability of survival is a promising brain injury severity index that may be useful in efforts to assess new medical and rehabilitative therapies for children with traumatic brain injury.	CHILDRENS NATL MED CTR,DEPT PSYCHOL,WASHINGTON,DC 20010; CHILDRENS NATL MED CTR,DEPT NEUROSURG,WASHINGTON,DC 20010; TRI ANALYT INC,BEL AIR,MD	GOTSCHALL, CS (corresponding author), CHILDRENS NATL MED CTR,EMERGENCY TRAUMA SERV,111 MICHIGAN AVE NW,WASHINGTON,DC 20010, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCH-114001] Funding Source: Medline		BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BRAAKMAN R, 1980, NEUROSURGERY, V6, P595; BRUCE DA, 1979, CHILD BRAIN, V5, P174; BRUCE DA, 1993, PEDIATRIC TRAUMA PRE, P353; CHAMPION HR, 1990, J TRAUMA, V30, P539, DOI 10.1097/00005373-199005000-00003; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHOI SC, 1983, J NEUROSURG, V75, P251; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; COPES WS, 1990, J TRAUMA, V30, P1200, DOI 10.1097/00005373-199010000-00003; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; EICHELBERGER MR, 1989, ANN EMERG MED, V18, P939, DOI 10.1016/S0196-0644(89)80457-3; EICHELBERGER MR, 1993, J TRAUMA, V34, P319, DOI 10.1097/00005373-199303000-00001; EICHELBERGER MR, 1990, EMSC ASSESSMENT BATT; ESPARZA J, 1985, CHILD NERV SYST, V1, P109, DOI 10.1007/BF00706691; Flach J, 1972, Scand J Rehabil Med, V4, P9; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; Hammill DD, 1985, DETROIT TESTS LEARNI; HENNES H, 1988, AM J DIS CHILD, V142, P1045, DOI 10.1001/archpedi.1988.02150100039021; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KNIGHTS RM, 1968, PERCEPT MOTOR SKILL, V26, P463; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; LUERSSEN TG, 1993, PEDIATRIC TRAUMA PRE, P345; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; PECLET MH, 1990, J PEDIATR SURG, V25, P961, DOI 10.1016/0022-3468(90)90238-5; Reitan RM., 1985, HALSTEAD REITAN NEUR; TEASDALE G, 1974, LANCET, V2, P81; Tukey JW, 1977, EXPLORATORY DATA ANA, P498; WALKER ML, 1985, CONCEPTS PEDIATR NEU, V6, P84; Wechsler D., 1974, WECHSLER ADULT INTEL; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; ZUCCARELLO M, 1985, CHILD NERV SYST, V1, P158, DOI 10.1007/BF00735731; 1985, ABBREVIATED INJURY S	39	13	15	0	8	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1995	12	4					611	619		10.1089/neu.1995.12.611			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	RY920	WOS:A1995RY92000012	8683612				2021-06-18	
J	LYETH, BG; JIANG, JY; GONG, QZ; HAMM, RJ; YOUNG, HF				LYETH, BG; JIANG, JY; GONG, QZ; HAMM, RJ; YOUNG, HF			EFFECTS OF MU-OPIOID AGONIST AND ANTAGONIST ON NEUROLOGICAL OUTCOME FOLLOWING TRAUMATIC BRAIN INJURY IN THE RAT	NEUROPEPTIDES			English	Article							FLUID-PERCUSSION MODEL; CEREBRAL BLOOD-FLOW; BETA-FUNALTREXAMINE; ENDOGENOUS OPIOIDS; EXTRACELLULAR LEVELS; AMINO-ACIDS; RESPONSES; OPIATE; SCOPOLAMINE; GLUTAMATE	We examined the effects of an exogenous mu opioid agonist and antagonist on systemic physiology and neurological outcome following TBI in the rat. Experiment I: [D-Ala(2),N-Me-Phe(4),Gly(5)-ol]-enkephalin (DAMGO) (0.1 nMol or 0.3 nMol in 5 mu l) (n = 10) or artificial CSF (n = 10) was administered 5 min prior to fluid-percussion brain injury (2.1 atmospheres). Motor performance was assessed on days 1-5 after TBI. The mu receptor agonist, DAMGO significantly reduced both beam-walking latency and body weight loss after injury (p < 0.05). DAMGO-treated rats (n = 5) did not differ from CSF-treated rats (n = 5) on either systemic arterial blood pressure or heart rate responses to injury. Experiment II: Beta-funaltrexamine (beta-FNA) (20.0 nMol in 5.0 mu l) (n = 10) or artificial CSF (n = 10) was administered (icv) to rats 5 min prior to fluid percussion brain injury (1.8 atmospheres). Motor performance was assessed on days 1-5 after TBI. The mu receptor antagonist, beta-FNA, significantly increased beam-walking latency after injury (p < 0.05). beta-FNA-treated rats (n = 5) did not differ from CSF-treated rats (n = 5) on either systemic arterial blood pressure or heart rate responses to injury. Experiment III: Neither beta-FNA nor DAMGO affected motor performance in uninjured rats. These results suggest that activation of mu opioid receptors by exogenous agonists may provide protection against deficits in motor performance produced by fluid percussion brain injury.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,RICHMOND,VA 23298	LYETH, BG (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,RICHMOND,VA 23298, USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29995] Funding Source: Medline		ADAMS JU, 1990, J PHARMACOL EXP THER, V255, P1027; BRADLEY PB, 1984, BRIT J PHARMACOL, V83, P763, DOI 10.1111/j.1476-5381.1984.tb16231.x; CHOU C-L, 1991, Society for Neuroscience Abstracts, V17, P722; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GLOBUS MYT, 1991, J NEUROCHEM, V57, P470, DOI 10.1111/j.1471-4159.1991.tb03775.x; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; HAYES RL, 1988, J NEUROTRAUM, V5, P287; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LAPCHAK P A, 1987, Society for Neuroscience Abstracts, V13, P1192; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARTIN TJ, 1993, J PHARMACOL EXP THER, V267, P506; MCINTOSH T K, 1988, Society for Neuroscience Abstracts, V14, P1152; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; NICOLL RA, 1977, P NATL ACAD SCI USA, V74, P2584, DOI 10.1073/pnas.74.6.2584; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; SIMONDS WF, 1988, ENDOCR REV, V9, P200, DOI 10.1210/edrv-9-2-200; VINK R, 1991, AM J PHYSIOL, V261, pR1527; VINK R, 1990, J NEUROSCI, V10, P3524; WARD SJ, 1982, EUR J PHARMACOL, V80, P377, DOI 10.1016/0014-2999(82)90083-8; WARD SJ, 1982, J PHARMACOL EXP THER, V220, P494; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAO JJ, 1988, NEUROPEPTIDES, V12, P177, DOI 10.1016/0143-4179(88)90051-0; ZIMMERMAN RS, 1990, NEUROSURGERY, V26, P764, DOI 10.1227/00006123-199005000-00005	40	13	14	0	1	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH, MIDLOTHIAN, SCOTLAND EH1 3AF	0143-4179			NEUROPEPTIDES	Neuropeptides	JUL	1995	29	1					11	19		10.1016/0143-4179(95)90051-9			9	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	RH553	WOS:A1995RH55300002	7566508				2021-06-18	
J	SCHWARTZ, SM				SCHWARTZ, SM			ADULTS WITH TRAUMATIC BRAIN INJURY - 3 CASE-STUDIES OF COGNITIVE REHABILITATION IN THE HOME SETTING	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						ACTIVITIES OF DAILY LIVING; MEMORY	CLOSED-HEAD-INJURY; MEMORY DISORDERS; AMNESIC PATIENTS; ACQUISITION; RETENTION; KNOWLEDGE; COMPUTER; LEARN; SKILL	This article discusses the use of occupational therapy in the home setting and the individual application of treatment methods. Three case studies are presented that involve adults with acquired brain injury with memory deficits. The treatment methods used were (a) saturational cuing with behavioral chaining and positive reinforcement, (b) a coordinated team approach incorporating family or significant others and other therapists, and (c) environmental adaptations. A decision-making model and the dynamic assessment approach were used as framework for treatment planning. The treatment technique chosen depended on the skill to be learned and the patient's learning style. Each case required the selection of environmental adaptations including (a) use of family and attendants as cotherapists; (b) a tape-recorded message, played daily; and (c) an appointment book for daily things to do. Each case demonstrated prolonged therapy for skill acquisition with this patient population.	REHAB PLUS,NEW YORK,NY; MANHATTAN CTR EARLY INTERVENT INC,EARLY INTERVENT PROGRAM,NEW YORK,NY							AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; BATT RC, 1990, AM J OCCUP THER, V44, P364, DOI 10.5014/ajot.44.4.364; BEN-YISHAY Y, 1970, Journal of Abnormal Psychology, V76, P378, DOI 10.1037/h0030404; BENYISHAY Y, 1970, J ABNORM PSYCHOL, V75, P248, DOI 10.1037/h0029368; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BROOKS DN, 1976, NEUROPSYCHOLOGIA, V14, P111, DOI 10.1016/0028-3932(76)90012-9; Campione J.C., 1987, DYNAMIC ASSESSMENT I, P82; CARBERRY H, 1992, J COGNITIVE REHABILI, V10, P24; CERMAK LS, 1976, NEUROPSYCHOLOGIA, V14, P311, DOI 10.1016/0028-3932(76)90025-7; Cicerone K. D., 1986, CLIN NEUROPSYCHOLOGY, P59; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; CROSSAN B, 1989, J HEAD TRAUMA REHABI, V4, P35; CROSSON B, 1984, J CLIN NEUROPSYCHOL, V6, P287, DOI 10.1080/01688638408401219; DEPOY E, 1990, OCCUPATIONAL THERAPY, P55; DILLER L, 1986, HDB CLIN NEUROPSYCHO, V2, P702; DOLAN MP, 1977, J CLIN PSYCHOL, V33, P496, DOI 10.1002/1097-4679(197704)33:2<496::AID-JCLP2270330236>3.0.CO;2-X; DURGIN C, 1989, COGNITIVE REHABILITA, V7, P22; EAMES P, 1988, J HEAD TRAUMA REHAB, V3, P1; GIANUTSOS R, 1979, Journal of Clinical Neuropsychology, V1, P117, DOI 10.1080/01688637908414446; GILES G, 1989, AM J OCCUPATIONAL TH, V43, P404; GILES GM, 1989, ARCH PHYS MED REHAB, V70, P156; GILES GM, 1988, AM J OCCUP THER, V42, P658, DOI 10.5014/ajot.42.10.658; GLISKY EL, 1988, J LEARN DISABIL-US, V21, P333, DOI 10.1177/002221948802100604; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GOODWIN R, 1991, J COGNITIVE REHABILI, V9, P12; GRAF P, 1984, J EXP PSYCHOL LEARN, V10, P164, DOI 10.1037/0278-7393.10.1.164; Hagen C., 1972, LEVELS COGNITIVE FUN; HARRELL MM, 1991, COGNITIVE REHABILITA, V9, P12; HARRIS J, 1983, EVERYDAY MEMORY ACTI, P70; KAY T, 1988, J HEAD TRAUMA REHAB, V3, P65; Kreutzer J S, 1988, Brain Inj, V2, P205, DOI 10.3109/02699058809150945; Kreutzer JS, 1989, COGNITIVE REHABILITA, V7, P30; LAWSON MJ, 1989, J CLIN EXP NEUROPSYC, V11, P842, DOI 10.1080/01688638908400939; LIDZ C, 1991, PRACTITIONERS GUIDE, P117; LIDZ CS, 1991, PRACTITIONERS GUIDE, P3; LURIA A, 1968, HDB CLIN NEUROLOGY, P368; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; McKinlay WW, 1988, J HEAD TRAUMA REHAB, p[3, 64]; MEACHAM JA, 1977, J PSYCHOL, V97, P191, DOI 10.1080/00223980.1977.9923962; MILLER L, 1991, COGNITIVE REHABILITA, V9, P16; Moffat N., 1984, CLIN MANAGEMENT MEMO, P63; NAUGLE R, 1988, COGNITIVE REHABILITA, V6, P22; NISSEN M, 1986, J HEAD TRAUMA REHAB, V1, P13; PARENTE R, 1991, COGNITIVE REHABILITA, P147; Parente R., 1989, J HEAD TRAUMA REHAB, V4, P55; Pollens RD, 1988, COGNITIVE REHABILITA, V6, P26; PRIGATANO G, 1986, NEUROPSYCHOLOGICAL R, P51; Prigatano GP, 1986, CLIN NEUROPSYCHOLOGY, P135; Romano M. D., 1989, J HEAD TRAUMA REHAB, V4, P33; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; SCHACTER DL, 1985, J CLIN EXP NEUROPSYC, V7, P79, DOI 10.1080/01688638508401243; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; SQUIRE LR, 1986, SCIENCE, V232, P1612, DOI 10.1126/science.3086978; STARCH S, 1990, COGNITIVE REHABILITA, V8, P28; Toglia J. P., 1989, OCCUPATIONAL THERAPY, V1, P36; TOGLIA JP, 1991, AM J OCCUP THER, V45, P505, DOI 10.5014/ajot.45.6.505; Vygotsky L., 1978, READINGS DEV CHILDRE, P79, DOI DOI 10.1525/AA.1979.81.4.02A00580; WEBB D, 1991, COGNITIVE REHABILITA, V9, P28; WHEATLEY CJ, 1989, WORK PROGRESS OCCUPA, P197; WILSON B, 1982, CORTEX, V18, P581, DOI 10.1016/S0010-9452(82)80055-5; WILSON B, 1983, EVERYDAY MEMORY ACTI, P209; Wilson B. A, 1984, CLIN MANAGEMENT MEMO, P89; WILSON BA, 1989, CORTEX, V25, P115, DOI 10.1016/S0010-9452(89)80011-5	63	13	13	0	2	AMER OCCUPATION THERAPY ASSN	ROCKVILLE	1383 PICCARD DRIVE PO BOX ROCKVILLE, MD 20850-4375	0272-9490			AM J OCCUP THER	Am. J. Occup. Ther.	JUL-AUG	1995	49	7					655	667		10.5014/ajot.49.7.655			13	Rehabilitation	Rehabilitation	RK198	WOS:A1995RK19800009	7573337				2021-06-18	
J	SJOSTROM, A; UVEBRANT, P; ROOS, A				SJOSTROM, A; UVEBRANT, P; ROOS, A			THE LIGHT-FLASH-EVOKED RESPONSE AS A POSSIBLE INDICATOR OF INCREASED INTRACRANIAL-PRESSURE IN HYDROCEPHALUS	CHILDS NERVOUS SYSTEM			English	Article						HYDROCEPHALUS; INTRACRANIAL PRESSURE; VISUAL EVOKED RESPONSE; VISUAL EVOKED POTENTIALS; PSEUDOTUMOR CEREBRI	HYPERTENSION PSEUDOTUMOR-CEREBRI; BRAIN-STEM RESPONSES; INFANTILE HYDROCEPHALUS; VENTRICULAR DILATATION; POTENTIALS; CHILDREN; EPIDEMIOLOGY; PRETERM; SWEDEN; SIZE	Surgical treatment of in fantile hydrocephalus by shunt implantation may result in suboptimal intracranial pressure. Major neurological impairments and death are usually prevented by shunt treatment, but minor sequelae may persist or develop. The introduction of adjustable shunts has improved the possibilities of optimizing shunt function and minimizing the risk of such impairments. However, it is still impossible to determine the intracranial pressure without invasive measurements. Clinical findings and procedures such as computed tomography (CT) are not always enough to allow a conclusion as to whether a child's signs and symptoms are the result of suboptimal intracranial pressure (shunt dysfunction) or are of another etiology. With the aim of reducing the number of invasive pressure measurements and CT scans, we investigated the effect of increased intracranial pressure on the visual evoked response (VER). Binocular light flash stimuli of supramaximal intensity were used and VER recordings were performed from Oz and Ct. The VER results from a group of 31 infants and children with hydrocephalus and 2 children with pseudotumor cerebri were compared with responses from a control group of 35 healthy children. The results show that a subpotential, P' (P-prime), usually just preceding P1 (P100), had an increased latency (>96 ms) in all hydrocephalic children before surgery. The P' latency in this group was usually even above 110 ms. The latencies of other VER potentials were also increased but not as consistently as P'. After surgical intervention the VER latencies decreased and usually normalized. The P' latency in four children in the control group was just above the borderline latency, but was less than 110 ms. In the remaining 31 children the VER P' latency was 96 ms or below. The VER provides information about the physiological condition of the visual system and seems to be related to intracranial pressure. The method was found to be useful in the clinical examination of hydrocephalic children. In addition, the VER may be used to monitor patients' clinical condition and the effect of treatment, e.g., in cases of pseudotumor cerebri or traumatic brain injury.	GOTHENBURG UNIV,INST CLIN NEUROSCI,DEPT PEDIAT NEUROL,GOTHENBURG,SWEDEN; GOTHENBURG UNIV,INST CLIN NEUROSCI,DEPT NEUROSURG,GOTHENBURG,SWEDEN	SJOSTROM, A (corresponding author), OSTRA HOSP,INST CLIN NEUROSCI,PEDIAT EYE CLIN,S-41685 GOTHENBURG,SWEDEN.						ALANI SM, 1985, J NEUROSURG, V62, P234, DOI 10.3171/jns.1985.62.2.0234; BAKER RS, 1989, PEDIATR NEUROL, V5, P5, DOI 10.1016/0887-8994(89)90002-7; BAKER RS, 1985, ARCH OPHTHALMOL-CHIC, V103, P1681, DOI 10.1001/archopht.1985.01050110075029; CONNOLLY MB, 1991, ARCH NEUROL-CHICAGO, V48, P956, DOI 10.1001/archneur.1991.00530210082028; CONSTANTINI S, 1987, CHILD NERV SYST, V3, P379, DOI 10.1007/BF00270713; COUPLAND SG, 1987, DOC OPHTHALMOL, V66, P321, DOI 10.1007/BF00213660; Creutzfeldt O.D., 1973, HDB SENSORY PHYSIOLO, P595; DEVRIES LS, 1990, NEUROPEDIATRICS, V21, P136, DOI 10.1055/s-2008-1071480; FAULHAUER K, 1978, ACTA NEUROCHIR, V45, P89, DOI 10.1007/BF01774384; FERNELL E, 1993, ACTA PAEDIATR, V82, P45, DOI 10.1111/j.1651-2227.1993.tb12513.x; FERNELL E, 1986, ACTA PAEDIATR SCAND, V75, P975, DOI 10.1111/j.1651-2227.1986.tb10326.x; FERNELL E, 1990, ACTA PAEDIATR SCAND, V79, P1080, DOI 10.1111/j.1651-2227.1990.tb11387.x; FERNELL E, 1988, NEUROPEDIATRICS, V19, P143, DOI 10.1055/s-2008-1052418; FERNELL E, 1991, ACTA PAEDIATR SCAND, V80, P451, DOI 10.1111/j.1651-2227.1991.tb11881.x; FERNELL E, 1988, NEUROPEDIATRICS, V19, P135, DOI 10.1055/s-2008-1052417; FERNELL E, 1991, DEV MED CHILD NEUROL, V33, P388; FERNELL E, 1994, ARCH DIS CHILD, V70, P123; GUTHKELCH AN, 1982, NEUROSURGERY, V11, P599; GUTHKELCH AN, 1984, NEUROSURGERY, V14, P283; HADENIUS AM, 1962, ACTA PAEDIATR SCAND, V51, P117; HAGBERG B, 1970, ACTA PAEDIATR SCAND, V59, P328, DOI 10.1111/j.1651-2227.1970.tb09012.x; JAMES HE, 1990, PEDIATR NEUROSURG, V16, P305; KRAUS N, 1984, ELECTROEN CLIN NEURO, V59, P310, DOI 10.1016/0168-5597(84)90048-0; LARY S, 1989, ARCH DIS CHILD-FETAL, V64, P17, DOI 10.1136/adc.64.1_Spec_No.17; MCSHERRY JW, 1982, ELECTROEN CLIN NEURO, V53, P331, DOI 10.1016/0013-4694(82)90092-X; SJOSTROM A, 1994, ACTA OPHTHALMOL, V72, P195; SJOSTROM A, 1993, NEUROSCI LETT S, V6, P375; SKLAR FH, 1979, NEUROSURGERY, V4, P529, DOI 10.1227/00006123-197906000-00007; SUTTON LN, 1986, NEUROSURGERY, V18, P756, DOI 10.1227/00006123-198606000-00013; UVEBRANT P, 1992, CHILD NERV SYST, V8, P76, DOI 10.1007/BF00298444; YORK D, 1984, NEUROSURGERY, V14, P456, DOI 10.1227/00006123-198404000-00011	31	13	15	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	JUL	1995	11	7					381	387		10.1007/BF00717400			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	RJ664	WOS:A1995RJ66400003	7585664				2021-06-18	
J	RICHARDSON, JTE; CHAN, RCB				RICHARDSON, JTE; CHAN, RCB			THE CONSTITUENT STRUCTURE OF SUBJECTIVE MEMORY QUESTIONNAIRES - EVIDENCE FROM MULTIPLE-SCLEROSIS	MEMORY			English	Article; Proceedings Paper	5th Conference of the European-Society-for-Cognitive-Psychology	SEP 12-16, 1992	PARIS, FRANCE	European Soc Cognit Psychol			EVERYDAY MEMORY; HEAD-INJURY; SELF-REPORT; NEUROPSYCHOLOGY; PERFORMANCE; FAILURES; SKILLS; SMQ	A number of different instruments have been devised for investigating individual differences in memory on the basis of subjective reports. One such questionnaire was mailed to individuals on a register of patients with multiple sclerosis, a condition that is known to be associated with objective impairments in cognition and memory. A similar questionnaire was enclosed to be completed about each patient by a close relative. The patients' and relatives' responses were found to share a factor structure identifying memory problems in five areas: receptive communication, route finding, absent-mindedness, face recognition, and expressive communication. These were dominated by a single second-order factor representing st global subjective memory impairment. There were some minor differences between the patients and relatives in their factor scores, but there was generally a high degree of concordance in their responses.		RICHARDSON, JTE (corresponding author), BRUNEL UNIV,DEPT HUMAN SCI,UXBRIDGE UB8 3PH,MIDDX,ENGLAND.			Richardson, John/0000-0002-6267-0603			Babbie ER, 1973, SURVEY RES METHODS; BADDELEY A, 1982, ALZHEIMERS DISEASE R, P141; BENNETTLEVY J, 1980, BRIT J SOC CLIN PSYC, V19, P177, DOI 10.1111/j.2044-8260.1980.tb00946.x; BENNETTLEVY J, 1980, CORTEX, V16, P543, DOI 10.1016/S0010-9452(80)80002-5; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Cattell R. B., 1965, STUDIES PSYCHOL, P223; CATTELL RB, 1966, MULTIVAR BEHAV RES, V1, P245, DOI 10.1207/s15327906mbr0102_10; CHAFFIN R, 1985, HUM LEARN, V4, P233; CLIFF N, 1988, PSYCHOL BULL, V103, P276, DOI 10.1037/0033-2909.103.2.276; COMREY AL, 1973, FIRST COURSE FACTOR; Corcoran R, 1992, Seizure, V1, P37, DOI 10.1016/1059-1311(92)90053-4; CURETON EE, 1983, FACTOR ANAL APPLIED; FISCHER JS, 1989, MENTAL DISORDERS COG, P39; GILEWSKI MJ, 1986, HDB CLIN MEMORY ASSE, P93, DOI DOI 10.1037/10057-008; GRANT I, 1989, MENTAL DISORDERS COG, P17; Herrmann D. J., 1984, EVERYDAY MEMORY ACTI, P133; HERRMANN DJ, 1982, PSYCHOL BULL, V92, P434, DOI 10.1037/0033-2909.92.2.434; Herrmann DJ, 1978, PRACTICAL ASPECTS ME, P35; HERRMANN DJ, IN PRESS EFFECTS MED; HERRMANN DJ, 1990, SELF DIRECTEDNESS CA, P199; HERTZOG C, 1989, DEV PSYCHOL, V25, P687, DOI 10.1037/0012-1649.25.5.687; HICKOX A, 1992, HDB NEUROPSYCHOLOGIC, P103; KAPUR N, 1983, BRIT J PSYCHOL, V74, P409, DOI 10.1111/j.2044-8295.1983.tb01872.x; Kidder L.H., 1981, RES METHODS SOCIAL R; MARTIN M, 1984, EVERYDAY MEMORY ACTI, P173; Maylor E. A., 1993, ADULT INFORMATION PR, P529; MCMILLAN TM, 1984, CORTEX, V20, P333, DOI 10.1016/S0010-9452(84)80002-7; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; MONTANELLI RG, 1976, PSYCHOMETRIKA, V41, P341, DOI 10.1007/BF02293559; Morris P. E, 1984, EVERYDAY MEMORY ACTI, P153; NORUSIS M, 1986, SPSSIPC ADV STATISTI; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; RAO SM, 1986, J CLIN EXP NEUROPSYC, V8, P503, DOI 10.1080/01688638608405173; RAO SM, 1989, NEUROLOGY, V39, P161, DOI 10.1212/WNL.39.2.161; ROSS M, 1989, PSYCHOL REV, V96, P341, DOI 10.1037/0033-295X.96.2.341; RUMMEL RJ, 1970, APPLIED FACTOR ANAL; SEHULSTER JR, 1981, MEM COGNITION, V9, P263, DOI 10.3758/BF03196960; SUNDERLAND A, 1986, J GERONTOL, V41, P376, DOI 10.1093/geronj/41.3.376; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; Sunderland A, 1984, EVERYDAY MEMORY ACTI, P191; WALTON JN, 1977, BRAINS DISEASES NERV	42	13	13	0	0	LAWRENCE ERLBAUM ASSOC LTD	HOVE	27 PALMEIRA MANSIONS CHURCH RD, HOVE, E SUSSEX, ENGLAND BN3 2FA	0965-8211			MEMORY	Memory	JUN	1995	3	2					187	200		10.1080/09658219508258965			14	Psychology, Experimental	Psychology	RG094	WOS:A1995RG09400004	7796304				2021-06-18	
J	MAYR, J; RUSSE, O; SPITZER, P; MAYRKOCI, M; HOLLWARTH, ME				MAYR, J; RUSSE, O; SPITZER, P; MAYRKOCI, M; HOLLWARTH, ME			PLAYGROUND ACCIDENTS	ACTA PAEDIATRICA			English	Article						ACCIDENT; CHILDREN; EQUIPMENT; PLAYGROUND; SAFETY		To study the causes and sequelae of playground accidents we analysed, in a retrospective study, 374 playground accidents. Questionnaires were sent to the parents and 103 parents (28%) provided detailed information on the playground accidents of their children. Thirty-one percent of the children injured in playground accidents sustained fractures of the extremities or concussion of the brain. Swings, slides, climbing frames, metal bars and merry-go-round accidents accounted for 71% of the 338 playground equipment-related accidents, whereas 36 accidents (10%) occurred without the use of playground equipment. The majority of these accidents were caused by children fighting. Rope-plank-type swings were frequently involved in backward falling accidents and 86% of the slide accidents were fall accidents. Climbing frames should not be taller than 1.6 m. Further efforts are mandatory to create and maintain playgrounds which help children develop their skills with a minimal risk to injury.	RUHR UNIV BOCHUM,BERUFSGENOSSENSCHAFTLICHE KLINIKEN BERGSMANNSHEIL,BOCHUM,GERMANY; AUSTRIAN COMM PAEDIAT ACCID PREVENT,GRAZ,AUSTRIA	MAYR, J (corresponding author), GRAZ UNIV,DEPT PAEDIAT SURG,AUENBRUGGERPL 34,A-8036 GRAZ,AUSTRIA.						BAUER R, 1993, UNFALLSTATISTIK 1992, P20; BOULTON MJ, 1993, BRIT J EDUC PSYCHOL, V63, P231, DOI 10.1111/j.2044-8279.1993.tb01054.x; LEWIS LM, 1993, J TRAUMA, V35, P932, DOI 10.1097/00005373-199312000-00020; SACKS JJ, 1989, JAMA-J AM MED ASSOC, V262, P1641, DOI 10.1001/jama.262.12.1641; TIPP G, 1987, P C PLAYGROUND RELAT, P53	5	13	14	1	5	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	0803-5253			ACTA PAEDIATR	Acta Paediatr.	MAY	1995	84	5					573	576		10.1111/j.1651-2227.1995.tb13698.x			4	Pediatrics	Pediatrics	RA524	WOS:A1995RA52400022	7633157				2021-06-18	
J	COPPENS, P				COPPENS, P			SUBPOPULATIONS IN CLOSED-HEAD INJURY - PRELIMINARY-RESULTS	BRAIN INJURY			English	Article							VERBAL IMPAIRMENT; NARRATIVES; LANGUAGE; COHESION; TRAUMA; ADULTS; SCALE; COMA	The classification systems currently utilized to categorize closed-head injury (CHI) patients are all based on severity levels. However, these scales are unable to account for the wide variability among CHI patients. Another way to classify these patients is to use the clinical picture independent of the overall severity level. That approach is used with aphasic patients but not with the CHI population. These preliminary data indicate that there are distinct subgroups in the CHI population. These subgroups can be identified by their overall pattern of performance on a battery of tests covering language, memory, visuospatial, cognitive and discourse skills. The characteristics of the tentative subgroups are described, but a more extensive study is needed to confirm the robustness of this classification.		COPPENS, P (corresponding author), MOORHEAD STATE UNIV,MOORHEAD,MN 56563, USA.						ADAMOVICH BL, 1981, CLIN APHASIOLOGY C P, P244; BERNSTEINELLIS E, 1985, CLIN APHASIOLOGY C P, P97; BOLLER F, 1966, BRAIN, V89, P815, DOI 10.1093/brain/89.4.815; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GLASS GV, 1984, STATISTICAL METHODS; Goodglass H., 1983, ASSESSMENT APHASIA R; GROHER M, 1977, J SPEECH HEAR RES, V20, P212, DOI 10.1044/jshr.2002.212; Hagen C, 1981, TOP LANG DIS, V1, P73; Hagen C, 1979, REHABILITATION HEAD; HAGEN C, 1982, COGNITIVE REHABILITA, P131; Hagen C, 1984, LANGUAGE DISORDERS A, P245; Halliday Michael A. K., 1976, COHESION ENGLISH; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; Hooper, 1983, HOOPER VISUAL ORG TE; HORN JL, 1965, PSYCHOMETRIKA, V30, P179, DOI 10.1007/BF02289447; Kaplan E., 1983, BOSTON NAMING TEST; Kertesz A., 1982, W APHASIA BATTERY; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; McNeil M. R., 1978, REVISED TOKEN TEST; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; PARSONS CL, 1989, AUSTR J HUMAN COMMUN, V17, P37; PEACH R, 1988, AM SPEECH LANGUAGE H; Penn C, 1988, Brain Inj, V2, P3, DOI 10.3109/02699058809150928; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P18; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Raven JC, 1990, COLOURED PROGR MATRI; Raven JC, 1984, MANUAL RAVENS PROGR; Rey A., 1970, EXAMEN CLIN PSYCHOL; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; Stevens J., 1986, APPLIED MULTIVARIATE; TAYLOR EM, 1959, PSYCHOL APPRAISAL CH, P396; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; THOMSEN IV, 1976, FOLIA PHONIATR, V28, P362, DOI 10.1159/000264060; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wiig E. H., 1988, NEUROPSYCHOLOGICAL S, P186; WILSON B, 1991, Brain Injury, V5, P189, DOI 10.3109/02699059109008089; WILSON J T L, 1990, Brain Injury, V4, P349; YORKSTON KM, 1980, J SPEECH HEAR DISORD, V45, P27, DOI 10.1044/jshd.4501.27	52	13	13	0	0	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB-MAR	1995	9	2					195	208		10.3109/02699059509008192			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	QN628	WOS:A1995QN62800008	7787839				2021-06-18	
J	FICK, DS				FICK, DS			MANAGEMENT OF CONCUSSION IN COLLISION SPORTS - GUIDELINES FOR THE SIDELINES	POSTGRADUATE MEDICINE			English	Article							2ND IMPACT; HEAD; FOOTBALL; PREVENTION; INJURY	During high-risk sports events, it is important for team physicians to be alert to the possibility of concussion in athletes who may not realize they have been injured or may want to conceal their injury. If concussion is suspected and the player is conscious, history taking should include inquiries about loss of consciousness, loss of memory of events before and after the impact, headache, visual abnormalities, motor and sensory changes, and back, neck, and extremity pain. In an unconscious player, the airway, breathing, circulation, and cervical spine should be checked. The cervical spine must be stabilized before the player is moved if injury to it is suspected. Athletes with such an injury and those who have lost consciousness require hospital evaluation. If there is no cervical spine injury, a complete neurologic evaluation should be carried out on the sidelines and the player checked for signs of skull fracture. The Colorado Medical Society guidelines for grading concussions and deciding when athletes may return to competition are an excellent aid to clinical judgment.	UNIV IOWA,COLL MED,DEPT ORTHOPAED SURG,IOWA CITY,IA 52242	FICK, DS (corresponding author), UNIV IOWA,COLL MED,DEPT FAMILY PRACTICE,IOWA CITY,IA 52242, USA.						ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; FRANKOWSKI RF, 1985, BETHESDA NATIONAL I, P33; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; Nelson W. E., 1984, PHYSICIAN SPORTSMED, V12, P103; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P3439, DOI 10.1001/jama.254.24.3439; WHITE RJ, 1992, NEW ENGL J MED, V327, P1507; 1992, PREPARTICIPATION PHY; 1991, REPORT SPORTS MED CO	15	13	13	0	5	MCGRAW HILL HEALTHCARE PUBLICATIONS	MINNEAPOLIS	4530 WEST 77TH ST, MINNEAPOLIS, MN 55435-5000	0032-5481			POSTGRAD MED	Postgrad. Med.	FEB	1995	97	2					53	&					0	Medicine, General & Internal	General & Internal Medicine	QF766	WOS:A1995QF76600005	7855035				2021-06-18	
J	SPIKMAN, JM; BERG, IJ; DEELMAN, BG				SPIKMAN, JM; BERG, IJ; DEELMAN, BG			SPARED RECOGNITION CAPACITY IN ELDERLY AND CLOSED-HEAD-INJURY SUBJECTS WITH CLINICAL MEMORY DEFICITS	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article								This study describes the performance of three groups of subjects on a pictorial forced-recognition task, the Hundred Pictures Test. The aim was to determine whether subjects with memory deficits (elderly and closed-head-injured subjects) would perform as well as healthy young subjects, both on immediate and very long-term recognition. The results indicate that memory for complex meaningful pictures is spared in subjects with an otherwise impaired memory, and that despite increasing forgetting rates with increasing retention intervals (up to 27 weeks), still no differences are found between performance of these subjects and healthy young controls. It will be discussed how this result might be interpreted.	UNIV GRONINGEN,DEPT NEUROPSYCHOL,GRONINGEN,NETHERLANDS				Spikman, Jacoba/0000-0002-6477-0763			Berg I. J., 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI [DOI 10.1080/09602019108401384, 10.1080/09602019108401384]; BERG IJ, 1993, THESIS STATE U GRONI; BROWN J, 1977, Q J EXP PSYCHOL, V29, P461, DOI 10.1080/14640747708400622; Craik F.I.M., 1986, HUMAN MEMORY COGNITI, P409; CRAIK FIM, 1987, J EXPT PSYCHOL LEARN, V13, P1; Deelman B. G., 1980, NEUROPSYCHOLOGIE NED, P253; GOLDSTEIN AG, 1970, PERCEPT PSYCHOPHYS, V9, P237; HOWARD DV, 1991, ANN REV GERONTOLOGY, V11, P1; HUPPERT FA, 1989, NEUROPSYCHOLOGIA, V27, P849, DOI 10.1016/0028-3932(89)90008-0; HUPPERT FA, 1978, NATURE, V275, P317, DOI 10.1038/275317a0; NICKERSON RS, 1968, PSYCHON SCI, V11, P58, DOI 10.3758/BF03330991; *RIJKS BUR, 1952, CLASS BER NAAR HUN O; SALTHOUSE TA, 1982, ADULT COGNITION; SCHACTER DL, 1986, J CLIN EXP NEUROPSYC, V8, P727, DOI 10.1080/01688638608405192; SHEPARD RN, 1967, J VERB LEARN VERB BE, V6, P156, DOI 10.1016/S0022-5371(67)80067-7; STANDING L, 1970, PSYCHON SCI, V19, P73, DOI 10.3758/BF03337426; Verhage F, 1964, INTELLIGENTIE LEEFTI; Warrington EK., 1984, RECOGNITION MEMORY T; WISEMAN S, 1974, AM J PSYCHOL, V87, P675, DOI 10.2307/1421974; ZOMEREN AH, 1990, HDB CLIN NEUROLOGY, V13, P397	20	13	13	0	1	SWETS ZEITLINGER BV	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	1995	17	1					29	34		10.1080/13803399508406578			6	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	QJ150	WOS:A1995QJ15000004	7608299				2021-06-18	
S	Boller, F; Traykov, L; DaoCastellana, MH; FontaineDabernard, A; Zilbovicius, M; Rancurel, G; Pappata, S; Samson, Y		Grafman, J; Holyoak, KJ; Boller, F		Boller, F; Traykov, L; DaoCastellana, MH; FontaineDabernard, A; Zilbovicius, M; Rancurel, G; Pappata, S; Samson, Y			Cognitive functioning in 'diffuse' pathology - Role of prefrontal and limbic structures	STRUCTURE AND FUNCTIONS OF THE HUMAN PREFRONTAL CORTEX	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	Workshop on Structure and Functions of the Human Prefrontal Cortex	MAR 02-04, 1995	NEW YORK, NY	New York Acad Sci			MARCHIAFAVA-BIGNAMI DISEASE; FRONTAL-LOBE DEGENERATION; CEREBRAL BLOOD-FLOW; POSITRON EMISSION TOMOGRAPHY; CLOSED HEAD-INJURY; NON-ALZHEIMER TYPE; ALCOHOLICS; CORTEX; SPECT	The precise anatomical correlates of ''executive functions'' are still a matter of debate. The assessment of cognitive functions in patients with frontal lobe lesions has led to the term frontal functions'' and ''frontal lobe syndrome'' to characterize patients with disorders of executive functions. The very nature of executive functions implies a process of integration and the coordination of several cognitive processes. A fairly large number of tests are currently used to assess executive functions, but their specificity has not always been clearly established. These tests may at times be affected by lesions of nonfrontal areas or, paradoxically, may be spared by lesions that clearly affect the frontal lobes.' This does not necessarily imply that the tasks are not specific for the evaluation of executive functions, but rather that several nonfrontal structures, neural networks, and subordinate cognitive operations may participate in their performance. The frontal lobes are not a homogeneous anatomical entity, but rather an agglomerate of structures which differ from a cytoarchitectonic viewpoint, reflecting differences in myelogenesis and ontogenesis of the human brain.(2) In addition, from the point of view of anatomy, the frontal lobe represents a ''crossroads'' dense with extrinsic connections that cannot always be taken into account in focal lesions studies. Numerous studies using functional imaging and particularly positron emission tomography (PET) have attempted to define changes that occur at the level of the frontal lobes as a result of pathology, either focal or more widespread. This paper reviews clinical data and previous PET studies and combines them with some new data to show that impairments in executive functions occur in lesions not limited to the frontal lobes and that cortical structures outside the prefrontal areas may play an important role in these functions.	CEA,SERV HOSP FREDERIC JOLIOT,F-91406 ORSAY,FRANCE; INSERM,U334,ORSAY,FRANCE; HOP LA PITIE SALPETRIERE,PARIS,FRANCE	Boller, F (corresponding author), INSERM,U324,2TER RUE ALESIA,F-75014 PARIS,FRANCE.		samson, yves/C-5647-2013	samson, yves/0000-0002-8080-1427			ADAMS RD, 1989, PRINCIPLES NEUROLOGY, P837; ALBERT M, 1993, NEUROBIOL AGING, V14, P623, DOI 10.1016/0197-4580(93)90049-H; BENCH CJ, 1993, NEUROPSYCHOLOGIA, V31, P907, DOI 10.1016/0028-3932(93)90147-R; BOLLER F, NEUROPSYCHOLOGIE CLI; BOWEN M, 1989, BRAIN INJURY, V2, P109; CANNAPLE S, 1992, REV NEUROL, V148, P638; CHANG KH, 1992, NEURORADIOLOGY, V34, P480, DOI 10.1007/BF00598954; CHELUNE GJ, 1981, CLIN PSYCHOL REV, V1, P181; DAIGNEAULT S, 1992, DEV NEUROPSYCHOL, V8, P99, DOI 10.1080/87565649209540518; ELFGREN C, 1993, DEMENTIA, V4, P214, DOI 10.1159/000107325; FRISTON KJ, 1991, P ROY SOC B-BIOL SCI, V244, P101, DOI 10.1098/rspb.1991.0057; FRITH CD, 1991, NEUROPSYCHOLOGIA, V29, P1137, DOI 10.1016/0028-3932(91)90029-8; GILMAN S, 1990, ANN NEUROL, V28, P775, DOI 10.1002/ana.410280608; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; GUSTAFSON L, 1993, DEMENTIA, V4, P143, DOI 10.1159/000107313; Handler J., 1994, HANDB NEUR, P125; HARPER C, 1989, J NEUROL SCI, V92, P81, DOI 10.1016/0022-510X(89)90177-9; HEEPE P, 1988, EUR ARCH PSY CLIN N, V237, P74, DOI 10.1007/BF00382370; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; HUMBERT T, 1992, EUR ARCH PSY CLIN N, V242, P69, DOI 10.1007/BF02191548; JAGUST W J, 1989, American Journal of Physiologic Imaging, V4, P89; KAWAMURA M, 1985, ANN NEUROL, V18, P103, DOI 10.1002/ana.410180123; KNOPMAN D, 1993, HDB NEUROPSYCHOLOGY, V8, P295; LANGFITT TW, 1987, NEUROBEHAVIORAL RECO, P30; Levin HS, 1989, NEUROPSYCHOLOGY, V3, P243, DOI 10.1037//0894-4105.3.4.243; LEVIN HS, 1987, NEUROBEHAVIORAL RECO, P321; LHERMITTE F, 1986, ANN NEUROL, V19, P326, DOI 10.1002/ana.410190404; LHERMITTE F, 1977, ARCH NEUROL-CHICAGO, V34, P254, DOI 10.1001/archneur.1977.00500160068015; LONG JA, 1974, Q J STUD ALCOHOL, V35, P1220; MANGIN JF, 1994, J CEREBR BLOOD F MET, V14, P749, DOI 10.1038/jcbfm.1994.96; MARTIN AJ, 1991, J CEREBR BLOOD F MET, V11, P684, DOI 10.1038/jcbfm.1991.121; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MILLER BL, 1991, NEUROLOGY, V41, P1374, DOI 10.1212/WNL.41.9.1374; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Pandya D. N., 1987, FRONTAL LOBES REVISI, P41; PAPPATA S, 1994, J NEURAL TRANSM-PARK, V8, P131, DOI 10.1007/BF02250924; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; PETRIDES M, 1994, HDB NEUROPSYCHOLOGY, V9, P17; RENNER JA, 1994, HDB DEMENTING ILLNES, V22, P393; RISBERG J, 1987, ARCH GERONTOL GERIAT, V6, P225, DOI 10.1016/0167-4943(87)90023-9; Ruff R. M., 1989, NEUROPSY NEUROPSY BE, V2, P103; RYAN C, 1980, ALCOHOL CLIN EXP RES, V4, P288, DOI 10.1111/j.1530-0277.1980.tb04816.x; SAMSON Y, 1986, J NEUROL NEUROSUR PS, V49, P1165, DOI 10.1136/jnnp.49.10.1165; SMITH JW, 1973, Q J STUD ALCOHOL, V34, P414; TARTER RE, 1983, RECENT DEV ALCOHOLIS, P449; TERRY RD, 1987, ANN NEUROL, V21, P530, DOI 10.1002/ana.410210603; Whelihan WM, 1985, DEV NEUROPSYCHOL, V1, P371, DOI 10.1080/87565648509540321; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; ZILBOVICIUS M, 1993, NEUROLOGY, V43, pA213; ZILBOVICIUS M, 1989, J CEREB BLOOD FLO S1, V9, pS521	51	13	14	0	5	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021	0077-8923		0-89766-991-6	ANN NY ACAD SCI	Ann.NY Acad.Sci.		1995	769						23	39		10.1111/j.1749-6632.1995.tb38129.x			17	Multidisciplinary Sciences; Neurosciences; Psychology	Science & Technology - Other Topics; Neurosciences & Neurology; Psychology	BE92F	WOS:A1995BE92F00003	8595028				2021-06-18	
J	Freeman, MR; Ryan, JJ; Lopez, SJ; Mittenberg, W				Freeman, MR; Ryan, JJ; Lopez, SJ; Mittenberg, W			Cognitive estimation in traumatic brain injury: Relationships with measures of intelligence, memory, and affect	INTERNATIONAL JOURNAL OF NEUROSCIENCE			English	Article						cognitive estimation; traumatic brain injury; prose memory		Brain injury is associated with a reduced capacity to engage in effective cognitive estimation. The current study utilized two measures of this construct, the Cognitive Estimation Test (GET) and Luria Memory Test (Luria), to investigate the relationships between cognitive estimation and intelligence, memory, and affect in a sample of 30 traumatically brain-injured individuals. Results demonstrated significant correlations between cognitive estimation and tests of intelligence and memory. However, measures of depression and state anxiety were not meaningfully associated with cognitive estimation. The ability to recall stories accounted for the greatest portion of the variance for both the CET and Luria. Specifically, the 30-minute Logical Memory subtest from the Wechsler Memory Scale-Revised accounted for 38% of the variance in the GET, while the Logical Memory 30-minute savings score accounted for 47% of the variance in the Luria. intellectual and affective variables explained only negligible amounts of variance on cognitive estimation tasks.	NOVA SE UNIV,SCH PSYCHOL,FT LAUDERDALE,FL	Freeman, MR (corresponding author), DWIGHT D EISENHOWER VET AFFAIRS MED CTR,PSYCHOL SERV 116B,LEAVENWORTH,KS 66048, USA.						Axelrod B. N., 1994, ASSESSMENT, V1, P269, DOI DOI 10.1177/107319119400100307; Christensen AL., 1975, LURIAS NEUROPSYCHOLO; DELLIS DC, 1987, CALIFORNIA VERBAL LE; Golden C. J., 1980, LURIA NEBRASKA NEURO; HARRISPETERSON MR, 1991, FEB ANN C INT NEUR S; Kaufman A.S., 1990, KAUFMAN BRIEF INTELL; OCARROLL R, 1994, BRIT J CLIN PSYCHOL, V33, P193, DOI 10.1111/j.2044-8260.1994.tb01110.x; Schretlen D, 1992, J CLIN EXPT NEUROPSY, V14, P77; SHALLICE T, 1978, CORTEX, V14, P294, DOI 10.1016/S0010-9452(78)80055-0; SMITH ML, 1984, NEUROPSYCHOLOGIA, V22, P697, DOI 10.1016/0028-3932(84)90096-4; SMITH ML, 1988, NEUROPSYCHOLOGIA, V26, P297, DOI 10.1016/0028-3932(88)90082-6; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; YOUNG RK, 1982, COMMUNITY NURSING WO	15	13	14	0	1	GORDON BREACH SCI PUBL LTD	READING	C/O STBS LTD PO BOX 90, READING, BERKS, ENGLAND RG1 8JL	0020-7454			INT J NEUROSCI	Int. J. Neurosci.		1995	83	3-4					269	273		10.3109/00207459508986343			5	Neurosciences	Neurosciences & Neurology	TQ880	WOS:A1995TQ88000010	8869432				2021-06-18	
J	MUTTER, SA; HOWARD, JH; HOWARD, DV				MUTTER, SA; HOWARD, JH; HOWARD, DV			SERIAL PATTERN LEARNING AFTER HEAD-INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MEMORY FUNCTION; AMNESIA; IMPLICIT; DISSOCIATION; PERFORMANCE; KNOWLEDGE; EXPLICIT; SYSTEMS	Nonverbal serial pattern learning in patients with traumatic brain injury was examined using a serial reaction time task developed by Nissen and Bullemer (1987). During four blocks of pattern acquisition trials, subjects responded to asterisks appearing in repetitions of a 10-element spatial sequence. An indirect measure of pattern learning was obtained by comparing response times in the fourth pattern acquisition block with response times in a fifth block where asterisks occurred in random sequence. A direct measure of pattern memory was provided by accuracy scores in a final pattern generation block in which subjects predicted the spatial sequence of asterisks. Prior research with this task has shown that individuals from several special populations - including the normal elderly, Korsakoff's syndrome patients, and Alzheimer's patients - show intact performance on the indirect measure of pattern learning, but are impaired on the direct measure. In contrast to these earlier findings, the results of this study showed that mild to moderately severe traumatic brain injury does not cause a marked disruption in the ability to learn and remember serial pattern information. There was evidence that the amount of practice required to learn the serial pattern increases after moderately severe head injury; however, the ability to use pattern memory to enhance prediction accuracy appears to be normal.	CATHOLIC UNIV AMER,WASHINGTON,DC 20064; GEORGETOWN UNIV,WASHINGTON,DC 20057	MUTTER, SA (corresponding author), WESTERN KENTUCKY UNIV,DEPT PSYCHOL,TATE C PAGE HALL,BOWLING GREEN,KY 42101, USA.				NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R37 AG02751] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR302583-0] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R37AG002751] Funding Source: NIH RePORTER		BADDELEY A, 1986, Q J EXP PSYCHOL-A, V38, P527, DOI 10.1080/14640748608401613; BADDELEY A, 1987, NEUROBEHAVIORAL RECO, P295; Brooks D N, 1979, Int Rehabil Med, V1, P166; BROOKS D N, 1974, Cortex, V10, P224; BROOKS DN, 1976, NEUROPSYCHOLOGIA, V14, P111, DOI 10.1016/0028-3932(76)90012-9; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; Brooks N., 1984, CLOSED HEAD INJURY P; CAINE ED, 1981, PSYCHOPHARMACOLOGY, V74, P74, DOI 10.1007/BF00431761; Cohen N.J., 1984, NEUROPSYCHOLOGY MEMO, P83; COHEN NJ, 1985, ANN NY ACAD SCI, V444, P54, DOI 10.1111/j.1749-6632.1985.tb37579.x; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; DRACHMAN DA, 1974, ARCH NEUROL-CHICAGO, V30, P113, DOI 10.1001/archneur.1974.00490320001001; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HOWARD DV, 1989, PSYCHOL AGING, V4, P357, DOI 10.1037/0882-7974.4.3.357; JACOBY LL, 1983, J EXP PSYCHOL LEARN, V9, P21, DOI 10.1037//0278-7393.9.1.21; JOHNSON MK, 1987, ANNU REV PSYCHOL, V38, P631, DOI 10.1146/annurev.ps.38.020187.003215; KEMPER T, 1984, CLIN NEUROLOGY AGING, P9; KNOPMAN DS, 1987, NEUROLOGY, V37, P784, DOI 10.1212/WNL.37.5.784; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Moscovitch M., 1984, NEUROPSYCHOLOGY MEMO, P104; MUTTER SA, 1990, COGNITIVE NEUROPSYCH, V7, P329, DOI 10.1080/02643299008253447; NISSEN MJ, 1989, NEUROPSYCHOLOGIA, V27, P341, DOI 10.1016/0028-3932(89)90023-7; NISSEN MJ, 1987, NEUROLOGY, V37, P789, DOI 10.1212/WNL.37.5.789; NISSEN MJ, 1987, COGNITIVE PSYCHOL, V19, P1, DOI 10.1016/0010-0285(87)90002-8; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; RICHARDSONKLAVEHN A, 1988, ANNU REV PSYCHOL, V39, P475, DOI 10.1146/annurev.ps.39.020188.002355; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Roediger HL, 1987, MEMORY COGNITIVE PRO, P349; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SHIMAMURA AP, 1986, Q J EXP PSYCHOL-A, V38, P619, DOI 10.1080/14640748608401617; TEASDALE G, 1984, CLOSED HEAD INJURY P, P4; TWEEDY JR, 1988, J CLIN EXP NEUROPSYC, V10, P664, DOI 10.1080/01688638808402803; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; WARRINGTON EK, 1968, NATURE, V217, P972, DOI 10.1038/217972a0; WARRINGTON EK, 1970, NATURE, V228, P629; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILLINGHAM DB, 1989, J EXP PSYCHOL LEARN, V15, P1047, DOI 10.1037/0278-7393.15.6.1047	40	13	13	0	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR	1994	16	2					271	288		10.1080/01688639408402638			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	NG556	WOS:A1994NG55600012	8021314				2021-06-18	
J	FULLER, MG; FISHMAN, E; TAYLOR, CA; WOOD, RB				FULLER, MG; FISHMAN, E; TAYLOR, CA; WOOD, RB			SCREENING PATIENTS WITH TRAUMATIC BRAIN INJURIES FOR SUBSTANCE-ABUSE	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article								Substance abuse frequently accompanies and complicates serious traumatic brain injury (TBI). An important prerequisite to providing assistance to TBI patients is the ability to identify substance abuse accurately. The authors prospectively evaluated 10 consecutive admissions to a TBI program using four substance abuse screening tools: the CAGE questions, the Brief Michigan Alcohol Screening Test (BMAST) the Substance Abuse Subtle Screening Inventory, and the Addiction Severity Index. The CAGE questions and the BMAST were found to be easy to administer and very sensitive as well as specific for substance abuse in this population. The authors conclude that all patients with traumatic brain injuries should be screened for substance abuse by using either the CAGE questions or the BMAST.		FULLER, MG (corresponding author), ALLEGHENY GEN HOSP,ALLEGHENY NEUROPSYCHIAT INST,320 E N AVE,PITTSBURGH,PA 15212, USA.						EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LANGLEY M J, 1990, Brain Injury, V4, P77, DOI 10.3109/02699059009026151; MCCLELLAND AT, 1980, J NERV MENT DIS, V168, P26; Miller G.A., 1985, SUBSTANCE ABUSE SUBT, V2nd; Parkerson J B Jr, 1990, Md Med J, V39, P259; PORKORNY AD, 1972, AM J PSYCHIAT, V129, P342; SODERSTROM CA, 1987, ARCH SURG-CHICAGO, V122, P1067; 1988, SPSS PCPLUS V2 0 BAS; 1988, WHITE PAPER SUBSTANC; 1988, MANUAL NEUROBEHAVIOR; 1990, ALCOHOL ALERT, V8, P1; 1989, ALCOHOL ALERT, V3, P1	14	13	13	0	3	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SPR	1994	6	2					143	146					4	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	NJ963	WOS:A1994NJ96300006	8044035				2021-06-18	
J	CARNEY, J; SCHOENBRODT, L				CARNEY, J; SCHOENBRODT, L			EDUCATIONAL-IMPLICATIONS OF TRAUMATIC BRAIN INJURY	PEDIATRIC ANNALS			English	Article										CARNEY, J (corresponding author), KENNEDY KRIEGER INST,707 N BROADWAY,BALTIMORE,MD 21205, USA.							0	13	13	0	0	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086	0090-4481			PEDIATR ANN	Pediatr. Annu.	JAN	1994	23	1					47	52		10.3928/0090-4481-19940101-10			6	Pediatrics	Pediatrics	MU563	WOS:A1994MU56300007	8152864				2021-06-18	
J	DOBERSTEIN, C; FINEMAN, I; HOVDA, DA; MARTIN, NA; KEENLY, L; BECKER, DP				DOBERSTEIN, C; FINEMAN, I; HOVDA, DA; MARTIN, NA; KEENLY, L; BECKER, DP			METABOLIC ALTERATIONS ACCOMPANY IONIC DISTURBANCES AND CELLULAR SWELLING DURING A HYPOXIC INSULT TO THE RETINA - AN IN-VITRO STUDY	ACTA NEUROCHIRURGICA			English	Article						BRAIN INJURY; HYPOXIA; IONIC FLUX; METABOLISM	POTASSIUM; DEATH	To study the ionic, metabolic, and morphologic derangements that occur following brain injury we utilized a retina in vitro model of hypoxia. Retinas were dissected into oxygenated (95% O2, 5% CO2) Ames medium, a physiologic solution resembling cerebrospinal fluid, and randomly assigned to either experimental hypoxic conditions (95% N2, 5% CO2) or control conditions. All retinas were incubated and maintained at 37-degrees-C. Changes in extracellular K+ and lactate concentration, intracellular incorporation of Ca-45 and C-14-leucine, uptake of glucose using [C-14]-2-deoxy-D-glucose (2DG), and cell size were determined at 10, 20, 30, and 60 minute time intervals. The results show that compared to control retinas hypoxia produced: (1) an early increase in extracellular concentration of K+ and lactate, (2) a delayed increase in the intracellular incorporation of Ca-45, (3) an early onset of cellular swelling, and (4) a decrease in the intracellular incorporation of C-14-leucine, and (5) increased glucose utilization. All of the results were statistically significant (p < 0.05) and exhibited a dose response relationship with the exception of intracellular incorporation of Ca-45 which did not become significantly different until 30 minutes post-hypoxia. A 16% increase in cell size was noted after 10 minutes of hypoxia. Increased hypoxic cell size persisted for 30 minutes but after 60 minutes the control retinas appeared enlarged as well. Our results suggest that ionic, metabolic, and morphologic derangements can be demonstrated utilizing an in vitro model of hypoxia which are similar to those seen following in vivo traumatic brain injury. With use of this model the mechanisms behind these ionic-metabolic relationships can be addressed at the molecular level.	UNIV CALIF LOS ANGELES, SCH MED, DIV NEUROSURG, 74-140 CHS, LOS ANGELES, CA 90024 USA				Martin, Neil/0000-0002-6565-4131			AMES A, 1983, STROKE, V14, P219, DOI 10.1161/01.STR.14.2.219; AMES A, 1981, J NEUROCHEM, V37, P867, DOI 10.1111/j.1471-4159.1981.tb04473.x; FINEMAN I, 1993, IN PRESS BRAIN RES; HUBSCHMANN OR, 1983, J NEUROSURG, V59, P289, DOI 10.3171/jns.1983.59.2.0289; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; NEDERGAARD M, 1988, J CEREBR BLOOD F MET, V8, P763, DOI 10.1038/jcbfm.1988.125; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169	8	13	13	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		1994				60			41	44					4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	NX226	WOS:A1994NX22600011	7526627				2021-06-18	
J	MELLER, D; BELLANDER, BM; SCHMIDTKASTNER, R; INGVAR, M				MELLER, D; BELLANDER, BM; SCHMIDTKASTNER, R; INGVAR, M			IMMUNOHISTOCHEMICAL STUDIES WITH ANTIBODIES TO NEUROFILAMENT PROTEINS ON AXONAL DAMAGE IN EXPERIMENTAL FOCAL LESIONS IN RAT	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						NEUROFILAMENT PROTEIN; IMMUNOHISTOCHEMISTRY; AXONAL DAMAGE; FOCAL CORTICAL LESION; STATUS EPILEPTICUS	FIBRILLARY ACIDIC PROTEIN; MONOCLONAL-ANTIBODIES; NERVOUS-SYSTEM; CYTOSKELETAL PROTEINS; STATUS EPILEPTICUS; SUBSTANTIA-NIGRA; SPINAL-CORD; PHOSPHORYLATION; NEURONS; BRAIN	Immunohistochemistry with monoclonal antibodies against neurofilament (NF) proteins of middle and high molecular weight class, NF-M and NF-H, was used to study axonal injury in the borderzone of focal lesions in rats. Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion. Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus. Immunohistochemical staining for NFs showed characteristic terminal clubs of axons in the borderzone of lesions. Differences in the labelling pattern occurred with different antibodies which apparently depended on molecular weight class of NFs and phosphorylation state. These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions	KAROLINSKA INST,DEPT CLIN NEUROPHYSIOL,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA HOSP,DEPT NEUROSURG,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,DEPT NEUROSURG,S-10401 STOCKHOLM 60,SWEDEN	INGVAR, M (corresponding author), KAROLINSKA HOSP,DEPT CLIN NEUROPHYSIOL,POB 60500,S-10401 STOCKHOLM 60,SWEDEN.			Ingvar, Martin/0000-0002-9041-5714			Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; BIGNAMI A, 1981, J NEUROPATH EXP NEUR, V40, P537, DOI 10.1097/00005072-198109000-00005; Brierley JB, 1984, GREENFIELDS NEUROPAT, P125; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CREUTZFELDT OD, 1977, EXP BRAIN RES, V27, P419; DAHL D, 1988, J COMP NEUROL, V271, P445, DOI 10.1002/cne.902710311; DAHL D, 1983, EXP CELL RES, V149, P397, DOI 10.1016/0014-4827(83)90352-X; DAHL D, 1989, BRAIN RES BULL, V22, P225, DOI 10.1016/0361-9230(89)90047-6; de Olmos JS, 1981, NEUROANATOMICAL TRAC, P117; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; DRAGER UC, 1984, NATURE, V309, P624, DOI 10.1038/309624a0; ERIKSDOTTERNILSSON M, 1987, EXP BRAIN RES, V69, P155; GIACOBINI MMJ, 1991, EXP BRAIN RES, V86, P73; GOLDSTEIN ME, 1987, J NEUROSCI, V7, P1586; Guillery R., 1970, CONT RES METHODS NEU, P77; HICKEY WF, 1983, J HISTOCHEM CYTOCHEM, V31, P1126, DOI 10.1177/31.9.6193166; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P223, DOI 10.1083/jcb.108.2.223; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; IIZUKA H, 1989, STROKE, V20, P1396, DOI 10.1161/01.STR.20.10.1396; INGVAR M, 1987, J CEREBR BLOOD F MET, V7, P103, DOI 10.1038/jcbfm.1987.15; KAO CC, 1983, SPINAL CORD RECONSTR, P41; KATAOKA K, 1989, STROKE, V20, P1226, DOI 10.1161/01.STR.20.9.1226; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; KOEPPEN AH, 1985, HDB NEUROCHEMISTRY, V9, P443; KOLIATSOS VE, 1989, BRAIN RES, V482, P205, DOI 10.1016/0006-8993(89)91183-9; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; KRISTT DA, 1987, J NEUROPATH EXP NEUR, V46, P668, DOI 10.1097/00005072-198711000-00006; LEE VMY, 1987, J NEUROSCI, V7, P3474; MANSOUR H, 1989, J COMP NEUROL, V283, P481, DOI 10.1002/cne.902830404; MATTHEWS MA, 1973, J NEUROCYTOL, V2, P265, DOI 10.1007/BF01104030; MATUS A, 1988, TRENDS NEUROSCI, V11, P291, DOI 10.1016/0166-2236(88)90086-0; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; MELLER D, 1993, IN PRESS J COMP NEUR, V330; MOSS TH, 1983, J NEUROL SCI, V60, P267, DOI 10.1016/0022-510X(83)90068-0; NAGASAWA H, 1990, BRAIN RES, V524, P196, DOI 10.1016/0006-8993(90)90690-D; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; OESTREICHER AB, 1988, BRAIN RES BULL, V21, P713, DOI 10.1016/0361-9230(88)90037-8; Paxinos G., 1982, RAT BRAIN STEREOTAXI; PETITO CK, 1987, J CEREBR BLOOD F MET, V7, P625, DOI 10.1038/jcbfm.1987.115; Ramon y Cajal S, 1928, DEGENERATION REGENER, V2; ROBINSON PA, 1988, REV NEUROSCI, V2, P1; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SCHLAEPFER WW, 1987, J NEUROPATH EXP NEUR, V46, P117, DOI 10.1097/00005072-198703000-00001; SCHMIDT ML, 1991, LAB INVEST, V64, P352; SCHMIDTKASTNER R, 1991, EXP BRAIN RES, V86, P125; SCHMIDTKASTNER R, 1988, ACTA NEUROPATHOL, V76, P411, DOI 10.1007/BF00686979; SHAW G, 1981, EUR J CELL BIOL, V26, P68; SHAW G, 1986, EUR J CELL BIOL, V42, P1; SHAW G, 1988, BRAIN RES, V460, P227, DOI 10.1016/0006-8993(88)90367-8; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; TETZLAFF W, 1988, J NEUROSCI, V8, P3181; TROJANOWSKI JQ, 1985, J HISTOCHEM CYTOCHEM, V33, P557, DOI 10.1177/33.6.3889140; TROJANOWSKI JQ, 1986, J NEUROSCI, V6, P650; TURSKI WA, 1983, BEHAV BRAIN RES, V9, P315, DOI 10.1016/0166-4328(83)90136-5; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	57	13	13	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	JUL	1993	117	1-2					164	174		10.1016/0022-510X(93)90169-Y			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	LN639	WOS:A1993LN63900025	8410052				2021-06-18	
J	SHELL, D; CARICO, GA; PATTON, RM				SHELL, D; CARICO, GA; PATTON, RM			CAN SUBDURAL-HEMATOMA RESULT FROM REPEATED MINOR HEAD-INJURY	PHYSICIAN AND SPORTSMEDICINE			English	Article								A 17-year-old male high school football player sustained two mild concussions in 7 days. Five weeks later, he ran 50 yd in a game and fell to his knees complaining of severe headache, nausea, facial pain, and difficulty breathing. An immediate on-field physical examination was normal, but the boy progressively became lethargic, stuporous, then comatose. CT scan revealed a right subdural hematoma, perhaps a long-term complication of the two mild concussions. Rules requiring neurocognitive testing after head injury and a physician's written clearance to return to play may be needed to prevent life-threatening injury or permanent neuropsychological sequelae in head-injured athletes.		SHELL, D (corresponding author), OHIO STATE UNIV,UNIV HOSP CLIN,DEPT FAMILY MED,456 W 10TH AVE,COLUMBUS,OH 43210, USA.							0	13	14	0	4	MCGRAW HILL HEALTHCARE PUBLICATIONS	MINNEAPOLIS	4530 WEST 77TH ST, MINNEAPOLIS, MN 55435-5000	0091-3847			PHYSICIAN SPORTSMED	Physician Sportsmed.	APR	1993	21	4					74	&					0	Primary Health Care; Orthopedics; Sport Sciences	General & Internal Medicine; Orthopedics; Sport Sciences	KU264	WOS:A1993KU26400008	27447770				2021-06-18	
J	DENNIS, M				DENNIS, M			WORD FINDING IN CHILDREN AND ADOLESCENTS WITH A HISTORY OF BRAIN INJURY	TOPICS IN LANGUAGE DISORDERS			English	Article							CLOSED-HEAD-INJURY; ACQUIRED APHASIA; HEMIDECORTICATE ADOLESCENTS; SPINA-BIFIDA; LANGUAGE; DISCOURSE; ANOMIA; COMPREHENSION; HYDROCEPHALUS; RETRIEVAL			DENNIS, M (corresponding author), HOSP SICK CHILDREN, DEPT PSYCHOL, TORONTO M5G 1X8, ONTARIO, CANADA.						ALAJOUANINE T, 1965, BRAIN, V88, P653, DOI 10.1093/brain/88.4.653; ANDERSON E, 1977, CHILD SPINA BIFIDA; ARAM DM, 1987, BRAIN LANG, V31, P61, DOI 10.1016/0093-934X(87)90061-7; Baddeley A. D., 1987, WORKING MEMORY; BADELLRIBERA A, 1966, PEDIATRICS, V37, P787; Bagnato SJ, 1986, DEV NEUROPSYCHOL, V2, P213, DOI 10.1080/87565648609540343; BENEDET MJ, 1989, J PSYCHOLINGUIST RES, V18, P485, DOI 10.1007/BF01067312; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; CHEVRIEMULLER C, 1987, APHASIOLOGY, V1, P347; CROSS JA, 1990, ACQUIRED NEUROLOGICA, P66; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DENNIS M, 1976, BRAIN LANG, V3, P147, DOI 10.1016/0093-934X(76)90013-4; DENNIS M, 1987, J CLIN EXP NEUROPSYC, V9, P593, DOI 10.1080/01688638708410771; DENNIS M, 1980, LANGUAGE DEV APHASIA, P45; DENNIS M, IN PRESS BRAIN LANGU; Dennis M., 1979, STUDIES NEUROLINGUIS, V4, P211; DENNIS M, 1992, UNPUB WORD FINDING B; DENNIS M, 1980, BIOL STUDIES MENTAL, P159; DENNIS M, 1992, UNPUB NEUROPSYCHOLOG; DENNIS M, 1992, CANADIAN PSYCHOL, V33, P435; DENNIS M, 1990, DISCOURSE ABILITY BR, P199; DENNIS M, 1988, MASTER LECTURE SERIE, P85; DILLER L, 1966, REHABILITATION MONOG, V31; Ewing-Cobbs L., 1985, SPEECH LANGUAGE EVAL, P97; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FLEMING CP, 1968, DEV MED CHILD NE S15, V10, P74; Fodor J. A., 1983, MODULARITY MIND; GAIDOLFI E, 1980, ITAL J NEUROL SCI, V1, P65; Garrett M.F., 1975, PSYCHOL LEARN MOTIV, P133, DOI DOI 10.1016/S0079-7421(08)60270-4; German D.J., 1991, TEST WORD FINDING DI; GERMAN DJ, 1989, BRIT J DISORD COMMUN, V24, P21; GOODGLASS H, 1976, BRAIN LANG, V3, P359, DOI 10.1016/0093-934X(76)90032-8; Goodglass H., 1976, STUD NEUROLINGUISTIC, V1, P237; Goodglass H., 1972, ASSESSMENT APHASIA R; GROSSMAN M, 1981, BRAIN LANG, V12, P313, DOI 10.1016/0093-934X(81)90022-5; Guttmann E, 1942, BRAIN, V65, P205, DOI 10.1093/brain/65.2.205; HADENIUS AM, 1962, ACTA PAEDIATR SCAND, V51, P117; HART J, 1985, NATURE, V316, P439, DOI 10.1038/316439a0; HARWOODNASH DCF, 1976, NEURORADIOLOGY INFAN, V2, P609; HECAEN H, 1976, BRAIN LANG, V3, P114, DOI 10.1016/0093-934X(76)90009-2; HOFFMAN HJ, 1989, PERINATAL BRAIN LESI, P219; HORN DG, 1985, DEV MED CHILD NEUROL, V27, P713; HOWARD D, 1984, ADV NEUROLOGY, V42; HOWES D, 1979, PSYCHOLINGUISTIC RES, P435; INGRAM TTS, 1962, DEV MED CHILD NEUROL, V4, P287; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; JORDAN FM, 1990, ACQUIRED NEUROLOGICA, P124; KEMPEN G, 1978, RECENT ADV PSYCHOL L, V2, P103; KEMPEN G, 1977, SENTENCE PRODUCTION, P259; KHAN AU, 1975, DEV MED CHILD NEUROL, V17, P116; KIESSLING LS, 1983, DEV MED CHILD NEUROL, V25, P727; LECOURS AR, 1979, APHASIA; LEDORZE G, 1989, BRAIN LANG, V37, P381; LESSER R, 1989, COGNITIVE APPROACHES, P65; Levelt W. J. M., 1989, SPEAKING INTENTION A; LEVELT WJM, 1991, PSYCHOL REV, V98, P122, DOI 10.1037/0033-295X.98.1.122; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LOVETT MW, 1986, BRAIN LANG, V29, P224, DOI 10.1016/0093-934X(86)90046-5; MACNAB GH, 1965, DEV MED CHILD NE S11, V8, P1; MARCHMAN VA, 1991, APPL PSYCHOLINGUIST, V12, P1, DOI 10.1017/S0142716400009358; Markman E. M., 1989, CATEGORIZATION NAMIN; MCCLEARY C, 1986, BRAIN LANG, V27, P199, DOI 10.1016/0093-934X(86)90015-5; NEWMAN JE, 1986, TOP LANG DISORD, V7, P31, DOI 10.1097/00011363-198612000-00006; NIEBERGALL G, 1976, Z KLIN PSYCHOL-FORSC, V5, P194; OELSCHLAEGER ML, 1976, J COMMUN DISORD, V9, P281; Ozanne AE, 1990, ACQUIRED NEUROLOGICA, P1; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SATZ P, 1981, ACQUIRED APHASIA, P399; SCHILDER P, 1964, CONTRIBUTIONS DEV NE; SWISHER LP, 1971, DEV MED CHILD NEUROL, V13, P746; TAYLOR EM, 1961, PSYCHOL APPRAISAL CH; TEW B, 1979, Z KINDERCHIR, V28, P360; TEW B, 1979, BRIT J DISORD COMMUN, V14, P89, DOI 10.3109/13682827909011349; TEW BJ, 1972, DEV MED CHILD NEUROL, V14, P124; THAL DJ, 1991, BRAIN LANG, V40, P491, DOI 10.1016/0093-934X(91)90145-Q; VANDONGEN HR, 1977, CORTEX, V13, P131, DOI 10.1016/S0010-9452(77)80004-X; VISCHBRINK EG, 1984, BRAIN LANG, V23, P258, DOI 10.1016/0093-934X(84)90067-1; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; WHITEHOUSE P, 1978, BRAIN LANG, V6, P63, DOI 10.1016/0093-934X(78)90044-5; WIEGELCRUMP CA, 1986, BRAIN LANG, V27, P1, DOI 10.1016/0093-934X(86)90001-5; Wiig E. H., 1984, TOP LANG DISORD, V4, P1; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; ZINGESER LB, 1990, BRAIN LANG, V39, P14, DOI 10.1016/0093-934X(90)90002-X; ZINGESER LB, 1988, COGNITIVE NEUROPSYCH, V5, P473, DOI 10.1080/02643298808253270	85	13	13	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0271-8294	1550-3259		TOP LANG DISORD	Top. Lang. Disord.	NOV	1992	13	1					66	82		10.1097/00011363-199211000-00008			17	Linguistics; Rehabilitation	Linguistics; Rehabilitation	JT442	WOS:A1992JT44200008					2021-06-18	
J	PANIAK, CE; SHORE, DL; ROURKE, BP; FINLAYSON, MAJ; MOUSTACALIS, E				PANIAK, CE; SHORE, DL; ROURKE, BP; FINLAYSON, MAJ; MOUSTACALIS, E			LONG-TERM VOCATIONAL FUNCTIONING AFTER SEVERE CLOSED HEAD-INJURY - A CONTROLLED-STUDY	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	MEETING OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOC	FEB   16, 1991	SAN ANTONIO, TX	INT NEUROPSYCHOL SOC			FOLLOW-UP; SOCIAL-ADJUSTMENT; BRAIN INJURY; PROGNOSIS; LIFE	Vocational functioning at least 2 years postinjury was examined in a group of 57 severely closed-head injured (CHI) patients and 50 nonbrain-injured spinal-cord injured (SCI) patients. The two groups were equated on the following preinjury parameters: age, education, socioeconomic status (SES), male/female ratio, and marital status. The CHI and SCI patients had a similar number of members who were employed at follow-up. However mean follow-up socioeconomic status was significantly lower in the CHI group and premorbidly employed CHI patients suffered a greater loss of SES than did premorbidly employed SCI patients. These results indicate that the degree of vocational impairment after severe CHI goes beyond impairment seen with another chronic disabling condition (i.e., SCI) that is associated with severe physical impairment but not neuropsychological impairment. In the CHI group, the following variables were all correlated with SES at follow-up: preinjury education, posttraumatic amnesia duration, degree of neuropsychological impairment soon after injury, and emotional adjustment at follow-up.	UNIV WINDSOR,WINDSOR N9B 3P4,ONTARIO,CANADA; CHEDOKE MCMASTER HOSP,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,HAMILTON L8S 4L8,ONTARIO,CANADA	PANIAK, CE (corresponding author), GLENROSE REHAB HOSP,DEPT PSYCHOL,10230-111 AVE,EDMONTON T5G 0B7,ALBERTA,CANADA.						ADEY C, 1963, BRISTOL MEDICO CHIRU, V82, P58; BLISHEN BR, 1976, CAN REV SOC ANTHROP, V13, P71, DOI 10.1111/j.1755-618X.1976.tb00759.x; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Bruckner F E, 1972, Rheumatol Phys Med, V11, P344, DOI 10.1093/rheumatology/11.7.344; Cartlidge N E, 1981, HEAD INJURY; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DEROGATIS LR, 1983, PSYCHOSOCIAL ADJUSTM, V1; EGGERT GM, 1973, THESIS BRANDEIS U WA; GILCHRIST E, 1979, ARCH NEUROL-CHICAGO, V36, P355, DOI 10.1001/archneur.1979.00500420065008; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; KREUTZER JS, 1990, SEP COGN REH COMM IN; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PRIGATANO GP, 1989, B MENNINGER CLIN, V53, P414; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Rimel R W, 1981, J Neurosurg Nurs, V13, P132; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; RUSSELL EW, 1970, ASSESSMENT BRAIN DAM; STAMBROOK M, 1989, JUN M CAN PSYCH ASS; STAPLETON M, 1989, COGNITIVE REHABILITA, V7, P18; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	30	13	13	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV-DEC	1992	7	6					529	540		10.1016/0887-6177(92)90143-B			12	Psychology, Clinical; Psychology	Psychology	JQ229	WOS:A1992JQ22900007	14591404				2021-06-18	
J	WILLMORE, LJ				WILLMORE, LJ			POSTTRAUMATIC EPILEPSY	NEUROLOGIC CLINICS			English	Article							POST-TRAUMATIC EPILEPSY; STIMULATED LIPID-PEROXIDATION; PENETRATING HEAD-INJURY; HUMAN TEMPORAL-LOBE; VITAMIN-E; SUPEROXIDE RADICALS; GROWTH-FACTOR; RAT-BRAIN; SEIZURES; PHENYTOIN			WILLMORE, LJ (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT NEUROL,6431 FANNIN 7044,HOUSTON,TX 77030, USA.						AISEN P, 1977, CIBA F S, P1; Anderson D.K., 1983, NEUROCHEM PATHOL, V1, P249; AUST SD, 1982, FREE RADICALS BIOL, P1; BAKER N, 1966, J LIPID RES, V7, P341; CALLAGHAN N, 1988, NEW ENGL J MED, V318, P942, DOI 10.1056/NEJM198804143181502; CARLSSON J, 1980, J BACTERIOL, V142, P319, DOI 10.1128/JB.142.1.319-321.1980; CAVENESS WF, 1976, EPILEPSIA, V17, P207, DOI 10.1111/j.1528-1157.1976.tb03398.x; CHADWICK D, 1985, BRIT MED J, V290, P1885, DOI 10.1136/bmj.290.6485.1885; CHAN PH, 1980, J NEUROCHEM, V35, P1004, DOI 10.1111/j.1471-4159.1980.tb07100.x; CZAPSKI G, 1978, PHOTOCHEM PHOTOBIOL, V28, P651, DOI 10.1111/j.1751-1097.1978.tb06988.x; DECAROLIS P, 1984, J NEUROL NEUROSUR PS, V47, P1345, DOI 10.1136/jnnp.47.12.1345; DICHTER MA, 1987, SCIENCE, V237, P157, DOI 10.1126/science.3037700; DIPLOCK AT, 1973, FEBS LETT, V29, P205, DOI 10.1016/0014-5793(73)80020-1; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAUGHT E, 1989, NEUROLOGY, V39, P1089, DOI 10.1212/WNL.39.8.1089; FEENEY DM, 1979, ARCH NEUROL-CHICAGO, V36, P8, DOI 10.1001/archneur.1979.00500370038005; FISHMAN RA, 1979, NEUROLOGY, V29, P546; FONG KL, 1976, CHEM-BIOL INTERACT, V15, P77, DOI 10.1016/0009-2797(76)90130-7; FONG KL, 1973, J BIOL CHEM, V248, P7792; FRIDOVICH I, 1974, ADV ENZYMOL RAMB, V41, P35; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GREEN RC, 1989, ANN NEUROL, V26, P347, DOI 10.1002/ana.410260307; GUTTERIDGE JMC, 1987, BIOCHIM BIOPHYS ACTA, V917, P219, DOI 10.1016/0005-2760(87)90125-1; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; JENNETT B, 1975, J NEUROL NEUROSUR PS, V38, P378, DOI 10.1136/jnnp.38.4.378; Jennett B, 1981, MANAGEMENT HEAD INJU; KAPLAN HA, 1961, EPILEPSIA, V2, P111; KOPPENOL WH, 1978, PHOTOCHEM PHOTOBIOL, V28, P655, DOI 10.1111/j.1751-1097.1978.tb06989.x; LANGFITT TW, 1966, HEAD INJURY, P172; LEVITT P, 1971, J NEUROSURG, V35, P185, DOI 10.3171/jns.1971.35.2.0185; LINGREN SO, 1966, ACTA CHIR SCAND S360, V132, P1; LUCY JA, 1972, ANN NY ACAD SCI, V203, P4, DOI 10.1111/j.1749-6632.1972.tb27849.x; McCay P. B., 1980, Vitamin E, P289; NIEHAUS WG, 1968, EUR J BIOCHEM, V6, P126, DOI 10.1111/j.1432-1033.1968.tb00428.x; NIETOSAMPEDRO M, 1988, SCIENCE, V240, P1784, DOI 10.1126/science.3289118; Orlowski M, 1976, Int Rev Neurobiol, V19, P75, DOI 10.1016/S0074-7742(08)60702-3; PANTER SS, 1985, J EXP MED, V161, P748, DOI 10.1084/jem.161.4.748; PAYAN H, 1970, EPILEPSIA, V11, P81, DOI 10.1111/j.1528-1157.1970.tb03869.x; PENRY JK, 1979, NEUROLOGY, V29, P600; PRINCE DA, 1984, ANN NEUROL, V16, pS59, DOI 10.1002/ana.410160710; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; RAPPORT RL, 1972, EPILEPSIA, V13, P295; REHNCRONA S, 1980, J NEUROCHEM, V34, P1630, DOI 10.1111/j.1471-4159.1980.tb11254.x; RIBAK CE, 1979, SCIENCE, V205, P211, DOI 10.1126/science.109922; RICHARDSON E P Jr, 1954, Epilepsia, V3, P49, DOI 10.1111/j.1528-1157.1954.tb03153.x; RISH BL, 1973, J NEUROSURG, V38, P155, DOI 10.3171/jns.1973.38.2.0155; SAJI M, 1987, SCIENCE, V235, P66, DOI 10.1126/science.3798095; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SMITH GJ, 1962, ARCH BIOCHEM BIOPHYS, V98, P46, DOI 10.1016/0003-9861(62)90142-X; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; SVINGEN BA, 1978, PHOTOCHEM PHOTOBIOL, V28, P803, DOI 10.1111/j.1751-1097.1978.tb07022.x; TAPPEL AL, 1972, ANN NY ACAD SCI, V203, P12, DOI 10.1111/j.1749-6632.1972.tb27851.x; TAPPEL AL, 1973, FED PROC, V32, P1870; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; TORNHEIM PA, 1983, J NEUROSURG, V59, P431, DOI 10.3171/jns.1983.59.3.0431; TRIGGS WJ, 1984, J NEUROCHEM, V42, P976, DOI 10.1111/j.1471-4159.1984.tb12699.x; UNTERHARNSCHEID.F, 1966, HEAD INJURY C P, P321; WAGNER FC, 1981, J NEUROSURG, V54, P8802; WALKER AE, 1970, EPILEPSIA, V11, P17, DOI 10.1111/j.1528-1157.1970.tb03861.x; WEISS GH, 1986, ARCH NEUROL-CHICAGO, V43, P771, DOI 10.1001/archneur.1986.00520080019013; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; WILLMORE LJ, 1983, BRAIN RES, V277, P393, DOI 10.1016/0006-8993(83)90954-X; WILLMORE LJ, 1981, NEUROLOGY, V31, P63, DOI 10.1212/WNL.31.1.63; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; WILLMORE LJ, 1984, EXP NEUROL, V83, P62, DOI 10.1016/0014-4886(84)90046-3; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; WILLMORE LJ, 1991, MED TREATMENT EPILEP, P73; Witting LA, 1980, FREE RADICAL BIO MED, V4, P295; WOHNS RNW, 1979, J NEUROSURG, V51, P507, DOI 10.3171/jns.1979.51.4.0507; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1979, EPILEPSIA, V20, P671, DOI 10.1111/j.1528-1157.1979.tb04851.x	73	13	14	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0733-8619			NEUROL CLIN	Neurol. Clin.	NOV	1992	10	4					869	878					10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	JW158	WOS:A1992JW15800004	1435661				2021-06-18	
J	KOIZUMI, MS				KOIZUMI, MS			INJURY PATTERNS IN MOTORCYCLE ACCIDENT VICTIMS	REVISTA DE SAUDE PUBLICA			Portuguese	Article						WOUNDS AND INJURIES, EPIDEMIOLOGY; ACCIDENTS, TRAFFIC; MOTORCYCLES	SAO-PAULO CITY; SEVERITY SCORE; VEHICLE ACCIDENTS; HEAD-INJURY; TRAUMA; SCALE; MORTALITY; BRAZIL; COST; COMA	An analysis of the injury patterns presented by inpatients of a government teaching hospital, known as one of the emergency centers of S. Paulo city, Brazil, is given the majority of victims are young, male adults and most of them were later discharged from the hospital. In relation to the injuries the majority of the patients were classified as being of minor injury grade (ISS between 1 and 9) and the most frequent injuries were extremity and pelvic fractures, surface trauma, traumatic brain injury and extremity and pelvic dislocations. Besides extremity and pelvic fractures, the victims who died showed abdominal organ injury and traumatic brain injury and the ISS was over 20. Head injury patients who had a high Glasgow Coma Scale score had a low ISS and vice-versa.	UNIV SAO PAULO,ESCOLA ENFERMAGEM,DEPT ENFERMAGEN MEDICO CIRURG,SAO PAULO,BRAZIL							ANDREW TA, 1979, INJURY, V10, P317, DOI 10.1016/0020-1383(79)90053-6; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BRAY T, 1985, JAMA-J AM MED ASSOC, V254, P2452, DOI 10.1001/jama.254.17.2452; BRIED JM, 1987, CLIN ORTHOPAEDICS, V223, P252; BULL JP, 1985, ACCIDENT ANAL PREV, V17, P387, DOI 10.1016/0001-4575(85)90093-4; CAIN CMJ, 1989, AUST NZ J SURG, V59, P15; CANNELL H, 1982, BRIT J ORAL SURG, V20, P183, DOI 10.1016/S0007-117X(82)80036-X; CARR WP, 1981, MINN MED, V64, P521; CARROL CL, 1980, ANAL FATAL NONFATAL; COOKRO DV, 1979, ARIZ MED, V36, P605; CRAIG GR, 1983, INJURY, V15, P163, DOI 10.1016/0020-1383(83)90005-0; Dodson C F Jr, 1976, J Ark Med Soc, V73, P115; EDNA TH, 1987, ACTA NEUROCHIR, V85, P40, DOI 10.1007/BF01402368; FIUZA RM, 1988, ARQ BRAS NEUROCIRURG, V7, P191; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; HADDAD JP, 1976, J TRAUMA, V16, P550, DOI 10.1097/00005373-197607000-00006; HARMS PL, 1981, TRRL651 CROWTH TRANS; HENDERSON SA, 1987, BRIT MED J, V294, P1259, DOI 10.1136/bmj.294.6582.1259; KEANE JR, 1989, ARCH NEUROL-CHICAGO, V46, P761, DOI 10.1001/archneur.1989.00520430055017; KNIGHT RL, 1987, CRIT CARE NURSE, V6, P65; KOIZUMI MS, 1985, REV SAUDE PUBL, V19, P475, DOI 10.1590/S0034-89101985000500011; KOIZUMI MS, 1985, REV SAUDE PUBL, V19, P543, DOI 10.1590/S0034-89101985000600006; KOIZUMI MS, 1984, THESIS FACULDADE SAU; KOIZUMI MS, 1990, THESIS ESCOLA ENFERM; KUMAR B, 1989, MED SCI LAW, V29, P333, DOI 10.1177/002580248902900414; LEUNG PC, 1983, INJURY, V15, P23, DOI 10.1016/0020-1383(83)90157-2; MACDONALD JW, 1987, INJURY, V18, P196; May C, 1989, J Emerg Nurs, V15, P389; McGinnis G S, 1989, J Neurosci Nurs, V21, P201; MORGAN TO, 1988, HEART LUNG, V17, P258; *ORG MUND SAUD, 1975, MAN CLASS EST INT DO; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; PURDUE GF, 1985, J TRAUMA, V25, P216, DOI 10.1097/00005373-198503000-00008; RIVARA FP, 1988, JAMA-J AM MED ASSOC, V260, P221; ROSS DJ, 1983, INJURY, V15, P75, DOI 10.1016/0020-1383(83)90030-X; ROSSON JW, 1988, INJURY, V19, P4, DOI 10.1016/0020-1383(88)90162-3; SURACI AJ, 1986, J TRAUMA, V26, P458, DOI 10.1097/00005373-198605000-00008; TEASDALE G, 1974, LANCET, V2, P81; ZETTAS JP, 1979, J TRAUMA, V19, P833, DOI 10.1097/00005373-197911000-00007	39	13	21	0	4	REVISTA DE SAUDE PUBLICA	SAO PAULO	FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01255 SAO PAULO, BRAZIL	0034-8910			REV SAUDE PUBL	Rev. Saude Publica	OCT	1992	26	5					306	315		10.1590/S0034-89101992000500002			10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	KR631	WOS:A1992KR63100002	1342518	DOAJ Gold			2021-06-18	
J	SCHELLER, D; KOLB, J; TEGTMEIER, F; LEHMENKUHLER, A				SCHELLER, D; KOLB, J; TEGTMEIER, F; LEHMENKUHLER, A			EXTRACELLULAR CHANGES OF INORGANIC-PHOSPHATE ARE DIFFERENT DURING SPREADING DEPRESSION AND GLOBAL CEREBRAL-ISCHEMIA OF RATS	NEUROSCIENCE LETTERS			English	Article						SPREADING DEPRESSION; ISCHEMIA; TRAUMATIC INJURY; EXTRACELLULAR INORGANIC PHOSPHATE; EXTRACELLULAR LACTATE; MICRODIALYSIS; MEMBRANE PERMEABILITY	BRAIN	Tissue levels of inorganic phosphate (iP-) and lactate (lac) increase during cerebral ischemia and cortical spreading depression (SD). Since cell membranes become leaky during these insults, iP- and lac were expected to leak into the extracellular space (ECS). In order to find out whether this occurs or does not, a microdialysis (MD) fiber was implanted into the cortex of anesthetized rats and extracellular lactate (lac(c)) and extracellular iP- (iP(e)-) were determined during various insults. Extracellular lactate increased to about the same extent during ischemia and SD. In contrast, iP(e)- increased during ischemia but not during SD. Instead, iP(e)- started to rise after SD and reached its maximum about 45 min later. The distinct pattern of iP(e)- in comparison to lac(e) during the above mentioned insults points to a qualitative difference of the underlying mechanisms: whereas lac appears within the ECS at any stressful situation, elevation of iP- within the ECS indicates depletion of energy stores in parallel to the lack of control of ion homeostasis.	UNIV MUNICH,INST PHYSIOL,W-8000 MUNICH 2,GERMANY	SCHELLER, D (corresponding author), JANSSEN RES FDN,RAIFFEISENSTR 8,W-4040 NEUSS 21,GERMANY.		, Lehmenkuhler/AAG-3679-2019				BURES J, 1974, MECHANISM APPLICATIO; HANSEN AJ, 1985, PHYSIOL REV, V65, P101; HORIKAWA Y, 1985, J CEREBR BLOOD F MET, V5, P235, DOI 10.1038/jcbfm.1985.30; KRAIG RP, 1978, NEUROSCIENCE, V3, P1045, DOI 10.1016/0306-4522(78)90122-7; KRIVANEK J, 1961, J NEUROCHEM, V6, P183, DOI 10.1111/j.1471-4159.1961.tb13463.x; LAURITZEN M, 1990, J CEREBR BLOOD F MET, V10, P115, DOI 10.1038/jcbfm.1990.14; LEHMENKUHLER A, 1990, EEG-EMG-Z ELEK ELEKT, V21, P1; MUTCH WAC, 1984, J CEREBR BLOOD F MET, V4, P17, DOI 10.1038/jcbfm.1984.3; Nicholson C., 1981, APPLICATION ION SELE, P217; PHILLIPS JM, 1979, BRAIN RES, V173, P567, DOI 10.1016/0006-8993(79)90254-3; SCHELLER D, 1991, J NEUROSCI METH, V40, P31, DOI 10.1016/0165-0270(91)90114-F; SCHELLER D, 1992, NEUROSCI LETT, V135, P83, DOI 10.1016/0304-3940(92)90141-S; Siesj_o B K, 1978, BRAIN ENERGY METABOL; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; STRAUB RW, 1979, TRENDS PHARMACOL SCI, V12, P106; STRAUB RW, 1976, TRANSMEMBRANE TRANSP; TOMSIG JL, 1991, BRAIN RES, V568, P92, DOI 10.1016/0006-8993(91)91383-C; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WALZ W, 1990, GLIA, V3, P522, DOI 10.1002/glia.440030611	19	13	13	0	2	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JUL 20	1992	141	2					269	272		10.1016/0304-3940(92)90911-P			4	Neurosciences	Neurosciences & Neurology	JH045	WOS:A1992JH04500034	1436648				2021-06-18	
J	HART, RP; COLENDA, CC; DOUGHERTY, LM; WADE, JB				HART, RP; COLENDA, CC; DOUGHERTY, LM; WADE, JB			RECALL OF CLUSTERED AND UNCLUSTERED WORD LISTS IN ELDERLY ADULTS	JOURNAL OF CLINICAL PSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; COGNITIVE-PROCESSES; PARKINSONS-DISEASE; VERBAL MEMORY; DEPRESSION; DEMENTIA; COMPREHENSION	We present descriptive data for alternate forms of clustered and unclustered word list recall in 102 healthy elderly adults and test results for 11 patients with Parkinson's disease. The word list test provided a relatively stable measure of verbal memory. Alternate forms were equivalent except for a tendency of the unclustered list of Form 1 to be easier than those of the other three forms. Verbal intelligence, total word recall, and the ability to cluster related words at recall were related significantly. There were modest effects of education on word recall; female subjects tended to recall more words than males.	WAKE FOREST UNIV,WINSTON SALEM,NC 27109	HART, RP (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHIAT,BOX 268,RICHMOND,VA 23298, USA.				NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [1T01MH19071] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T01MH019071] Funding Source: NIH RePORTER		BATTIG WF, 1969, J EXP PSYCHOL, V80, P1, DOI 10.1037/h0027577; CAVANAUGH JC, 1983, J GERONTOL, V38, P190, DOI 10.1093/geronj/38.2.190; Craik F. I. M, 1977, HDB PSYCHOL AGING, P384; Derogatis L.R, 1975, SCL 90 R; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; HART RP, 1987, J CONSULT CLIN PSYCH, V55, P101, DOI 10.1037/0022-006X.55.1.101; HART RP, 1991, AM J PSYCHIAT, V148, P73; HART RP, 1987, J CONSULT CLIN PSYCH, V55, P236; LAWSON MJ, 1989, J CLIN EXP NEUROPSYC, V11, P842, DOI 10.1080/01688638908400939; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; POON LW, 1985, HDB PSYCHOL AGING, P427; PORKORNY AD, 1972, AM J PSYCHIAT, V129, P342; RUFF RM, 1988, J CLIN EXPT NEUROPSY, V11, P539; SATZ P, 1962, J CLIN PSYCHOL, V18, P77, DOI 10.1002/1097-4679(196201)18:1<77::AID-JCLP2270180124>3.0.CO;2-R; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; TAUB HA, 1979, EXP AGING RES, V5, P3, DOI 10.1080/03610737908257184; TAYLOR AE, 1986, BRAIN, V109, P845, DOI 10.1093/brain/109.5.845; Wechsler D., 1987, WECHSLER MEMORY SCAL; WEINGARTNER H, 1981, J ABNORM PSYCHOL, V90, P187, DOI 10.1037/0021-843X.90.3.187; WEINGARTNER H, 1981, ARCH GEN PSYCHIAT, V38, P42; WEINGARTNER H, 1984, PSYCHIAT RES, V11, P223, DOI 10.1016/0165-1781(84)90071-4	22	13	13	0	0	CLINICAL PSYCHOLOGY PUBL CO	BRANDON	4 CONANT SQUARE, BRANDON, VT 05733	0021-9762			J CLIN PSYCHOL	J. Clin. Psychol.	MAY	1992	48	3					341	354		10.1002/1097-4679(199205)48:3<341::AID-JCLP2270480312>3.0.CO;2-U			14	Psychology, Clinical	Psychology	HV121	WOS:A1992HV12100011	1602024				2021-06-18	
J	KULBER, DA; SANTORA, TA; SHABOT, MM; HIATT, JR				KULBER, DA; SANTORA, TA; SHABOT, MM; HIATT, JR			EARLY DIAGNOSIS AND TREATMENT OF SINUSITIS IN THE CRITICALLY ILL TRAUMA PATIENT	AMERICAN SURGEON			English	Article; Proceedings Paper	1991 ANNUAL MEETING OF THE SOUTHERN CALIFORNIA CHAPTER OF THE AMERICAN COLLEGE OF SURGEONS	JAN 18-20, 1991	SAN DIEGO, CA	AMER COLL SURGEONS, SO CALIF CHAPTER			PARA-NASAL SINUSITIS; NASOTRACHEAL INTUBATION; SEPSIS	Sinusitis is as an important cause of sepsis in the critically ill patient and may be difficult to diagnose. Four patients admitted to the surgical intensive care unit with closed head trauma were found to have sinusitis as the cause of persistent bacteremia. All patients received pharmacologic doses of corticosteroids for treatment of head injury and had prolonged nasotracheal and/or nasogastric intubation. A bedside procedure was used for diagnosis and management. Under local anesthesia, a 16-gauge angiocatheter was inserted under the inferior turbinate and into the maxillary sinus. After purulent fluid was aspirated, the sinuses were irrigated with normal saline. All four patients defervesced within 24 to 48 hours of this procedure, and facial x rays demonstrated clearing of the maxillary sinus. It was concluded that: 1) Sinusitis is a complication of closed head trauma in critically ill patients and should be included in the differential diagnosis when persistent bacteremia occurs; 2) The use of corticosteroids in the treatment of head injury may increase the risk of sinus infection; 3) Facial x rays showing air-fluid levels and/or opacification are a valuable screening test for paranasal sinusitis; and 4) bedside aspiration of the maxillary sinus is an effective diagnostic and therapeutic technique for management of sinusitis in the critically ill.	CEDARS SINAI MED CTR,DEPT SURG,SUITE 8215,8700 BEVERLY BLVD,LOS ANGELES,CA 90048; MED COLL PENN,DEPT SURG,SURG INTENS CARE UNIT,PHILADELPHIA,PA 19129; UNIV CALIF LOS ANGELES,SCH MED,DEPT SURG,LOS ANGELES,CA 90024	HIATT, JR (corresponding author), CEDARS SINAI MED CTR,DEPT SURG,SUITE 8215,8700 BEVERLY BLVD,LOS ANGELES,CA 90048, USA.						AEBERT H, 1988, INTENS CARE MED, V15, P27; BERG O, 1990, ANN OTO RHINOL LARYN, V99, P192; BILANIUK LT, 1982, RADIOL CLIN N AM, V20, P51; CAPLAN ES, 1982, JAMA-J AM MED ASSOC, V247, P639, DOI 10.1001/jama.247.5.639; CARENFELT C, 1981, ACTA OTOLARYNGOL STO, V93, P237; CARTER BL, 1983, RADIOLOGY, V147, P739, DOI 10.1148/radiology.147.3.6844609; CHIDEKEL N, 1970, ACTA RADIOL DIAGN, V10, P433, DOI 10.1177/028418517001000510; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; ENGQUIST S, 1983, ACTA OTOLARYNGOL STO, V93, P153; GRINDLINGER GA, 1987, CRIT CARE MED, V15, P214, DOI 10.1097/00003246-198703000-00006; HAMMORY BH, 1979, J INFECT DIS, V139, P197; HANSEN M, 1988, BRIT J ANAESTH, V61, P231, DOI 10.1093/bja/61.2.231; KRONBERG FG, 1985, LARYNGOSCOPE, V95, P936; Kurien M, 1989, Singapore Med J, V30, P565; MANN W, 1981, J OTORHINOLARYNGOL, V43, P274; OREILLY MJ, 1984, AM J SURG, V147, P601, DOI 10.1016/0002-9610(84)90122-3	16	13	13	0	0	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	1776 PEACHTREE RD, NW., SUITE 410N, ATLANTA, GA 30309-2352	0003-1348			AM SURGEON	Am. Surg.	DEC	1991	57	12					775	779					5	Surgery	Surgery	GU984	WOS:A1991GU98400008	1746793				2021-06-18	
J	CROOKS, DA; SCHOLTZ, CL; VOWLES, G; GREENWALD, S; EVANS, S				CROOKS, DA; SCHOLTZ, CL; VOWLES, G; GREENWALD, S; EVANS, S			THE GLIAL REACTION IN CLOSED HEAD-INJURIES	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						HEAD INJURY; PATHOLOGY; GLIAL REACTION; ASTROCYTES	DIFFUSE AXONAL INJURY; BRAIN-DAMAGE	The development of the glial reaction in human closed head injury has been investigated using morphometry and statistical analysis. The brains of eight individuals that survived less than 48 h following closed head injury were analysed using immunoperoxidase for glial fibrillary acidic protein (GFAP). Controls were eight patients without neurological disease. The density of reactive astrocytes was estimated in 25 fields in each of 10 different areas sampled bilaterally avoiding the subpial and subependymal zones, and the perivascular white matter. There was great variation between the zones within and between groups, and considerable variation between individuals. The raw data were expressed as logarithms averaged and analysed using the median and non-parametric statistics. The corpus callosum in the head injury group showed the highest densities of reactive astrocytes, particularly in the splenium which achieved statistical significance using the non-parametric tests. This pattern was not reproduced in the control group. Although there was overlap between the head injured and control individuals, the head injury group had relatively higher densities in all zones, and showed an overall increase in the density of reactive astrocytes. This achieved statistical significance in the corpus callosum, the occipital subcortical white matter, and the cerebellum. This study has shown that the glial reaction is often prominent in the corpus callosum irrespective of the presence of a primary lesion although the pattern varies from case to case.	LONDON HOSP,DEPT EPIDEMIOL & MED STAT,LONDON E1 1BB,ENGLAND	CROOKS, DA (corresponding author), ROYAL LONDON HOSP,DEPT MORBID ANAT,LONDON E1 1BB,ENGLAND.		Greenwald, Stephen E/C-6928-2012	Greenwald, Stephen/0000-0002-8471-7070			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; BARRON KD, 1988, ACTA NEUROPATHOL, V75, P295, DOI 10.1007/BF00690538; BLINKOV SM, 1968, HUMAN BRAIN FIGURES, P1; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; LINDENBERG R, 1955, AM J PATHOL, V31, P297; MORI S, 1969, J COMP NEUROL, V137, P197, DOI 10.1002/cne.901370206; RIPPERGER EA, 1973, P INT C BIOKINETICS, P259; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; UNTERHARNSCHEID.F, 1969, LATE EFFECTS HEAD IN, P158; UNTERHARNSCHEID.FJ, 1972, 15TH STAPP CAR CRASH, P767; UNTERHARNSCHEIDT F, 1969, ACTA NEUROPATHOL, V12, P200, DOI 10.1007/BF00692508	15	13	14	0	1	BLACKWELL SCIENCE LTD	OXFORD	OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL	0305-1846			NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	OCT	1991	17	5					407	414		10.1111/j.1365-2990.1991.tb00740.x			8	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	GL170	WOS:A1991GL17000006	1758571				2021-06-18	
J	MOULTON, R; KRESTA, P; RAMIREZ, M; TUCKER, W				MOULTON, R; KRESTA, P; RAMIREZ, M; TUCKER, W			CONTINUOUS AUTOMATED MONITORING OF SOMATOSENSORY EVOKED-POTENTIALS IN POSTTRAUMATIC COMA	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	50TH ANNUAL SESSION OF THE AMERICAN ASSOC FOR THE SURGERY OF TRAUMA	SEP 06-08, 1990	TUCSON, AZ	AMER ASSOC SURG TRAUMA			SEVERE HEAD-INJURY; BRAIN-FUNCTION; DYSFUNCTION; CONDUCTION; PREDICTION; TRAUMA	Using a microcomputer system, 36 patients were continuously monitored with somatosensory evoked potentials (SSEPs) following closed head injury. The mean duration of monitoring was five days. The patients' GCS scores at the start of monitoring ranged from 3-10. Mortality was 44%. Of 14 patients who had initial absence of SSEP activity after the N20 wave or lost this activity during the period of monitoring, 12 died and two remained vegetative. Eighteen of 22 patients who had preservation or enhancement of this activity had a functional survival (3-month outcomes, p < 0.001). The best outcomes were observed in the patients with the greatest number of peaks and highest amplitudes in the SSEPs, often in spite of increased intracranial pressure (ICP). The management of three patients was altered as a result of SSEP monitoring. We conclude that continuous monitoring of SSEPs is a useful adjunct in the management of comatose head-injured patients.	UNIV TORONTO,ST MICHAELS HOSP,DEPT SURG,TORONTO M5B 1W8,ONTARIO,CANADA; UNIV TORONTO,ST MICHAELS HOSP,DEPT BIOMED ENGN,TORONTO M5B 1W8,ONTARIO,CANADA							BERTRAND O, 1987, ELECTROEN CLIN NEURO, V68, P433, DOI 10.1016/0168-5597(87)90055-4; FRIEDMAN VA, 1988, CLIN NEUROSURG, V34, P187; GARCIALARREA L, 1987, ELECTROEN CLIN NEURO, V68, P446, DOI 10.1016/0168-5597(87)90056-6; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; GREENBERG RP, 1982, J NEUROSURG, V56, P1, DOI 10.3171/jns.1982.56.1.0001; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; LINDSAY KW, 1981, J NEUROL NEUROSUR PS, V44, P796, DOI 10.1136/jnnp.44.9.796; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NEWLON PG, 1982, J NEUROSURG, V57, P168, DOI 10.3171/jns.1982.57.2.0168; PAPANICOLAOU AC, 1986, NEUROSURGERY, V18, P173, DOI 10.1227/00006123-198602000-00009; RAPPAPORT M, 1981, CLIN ELECTROENCEPHAL, V12, P154, DOI 10.1177/155005948101200402; RAPPAPORT M, 1981, CLIN ELECTROENCEPHAL, V12, P167, DOI 10.1177/155005948101200403; TEASDALE G, 1974, LANCET, V2, P81; YAMADA T, 1988, NEUROL CLIN, V6, P705, DOI 10.1016/S0733-8619(18)30839-9	20	13	13	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	1991	31	5					676	685		10.1097/00005373-199105000-00012			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	FM521	WOS:A1991FM52100012	2030515				2021-06-18	
J	KONDZIOLKA, D; SCHWARTZ, ML; WALTERS, BC; MCNEILL, I				KONDZIOLKA, D; SCHWARTZ, ML; WALTERS, BC; MCNEILL, I			THE SUNNYBROOK NEUROTRAUMA ASSESSMENT RECORD - IMPROVING TRAUMA DATA-COLLECTION	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article									UNIV TORONTO,SUNNYBROOK MED CTR,DIV NEUROL,2075 BAYVIEW AVE,TORONTO M4N 3M5,ONTARIO,CANADA; UNIV TORONTO,SUNNYBROOK MED CTR,REG TRAUMA UNIT,TORONTO M4N 3M5,ONTARIO,CANADA			Walters, Beverly/R-8411-2019	Walters, Beverly/0000-0002-5244-4282			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; GREENES RA, 1970, NEW ENGL J MED, V282, P307, DOI 10.1056/NEJM197002052820605; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; TASKER RR, 1982, PHYSL ATLAS USING EL, P41	4	13	14	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	1989	29	6					730	735		10.1097/00005373-198906000-00005			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AC920	WOS:A1989AC92000005	2738969				2021-06-18	
J	PROCTOR, HJ; PALLADINO, GW; FILLIPO, D				PROCTOR, HJ; PALLADINO, GW; FILLIPO, D			FAILURE OF AUTO-REGULATION AFTER CLOSED HEAD-INJURY - AN EXPERIMENTAL-MODEL	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article										PROCTOR, HJ (corresponding author), UNIV N CAROLINA,SCH MED,DEPT SURG,TRAUMA SECT,215 BURNETT WOMACK CLIN SCI BLDG 229H,CHAPEL HILL,NC 27514, USA.						AUER LM, 1978, ACTA NEUROCHIM S, V28, P1; BRAZY JE, 1985, PEDIATRICS, V75, P217; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; FILLIPO DC, 1983, SURG FORUM, V34, P523; FOX EJ, IN PRESS ADV EXP MED; KONTOS HA, 1981, AM J PHYSIOL, V240, pH511; KREISMAN NR, 1983, J CEREBR BLOOD F MET, V3, P330, DOI 10.1038/jcbfm.1983.48; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P146; MACKENZIE ET, 1976, CIRC RES, V39, P33, DOI 10.1161/01.RES.39.1.33; PONTEN U, 1966, ACTA PHYSIOL SCAND, V68, P152, DOI 10.1111/j.1748-1716.1966.tb03413.x; POVLISHOCK JT, 1983, AM J PATHOL, V110, P148; PROCTOR HJ, 1985, SURG GYNECOL OBSTET, V161, P145; PROCTOR HJ, 1984, SURGERY, V96, P278; RAMSAY F, 1984, ADV EPILEPTOLOGY, P105; ROSNER MJ, 1982, 4TH CHIC S NEUR TRAU, pCH10; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95	18	13	13	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	1988	28	3					347	352		10.1097/00005373-198803000-00010			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	M8911	WOS:A1988M891100010	2832618				2021-06-18	
J	RANDOLPH, C; MILLER, MH				RANDOLPH, C; MILLER, MH			EEG AND COGNITIVE PERFORMANCE FOLLOWING CLOSED HEAD-INJURY	NEUROPSYCHOBIOLOGY			English	Article									UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PSYCHIAT,POB 101,PISCATAWAY,NJ 08854							AMOCHAEV S, 1979, PSYCHOPHYSIOLOGY, V16, P247; Benton A. L., 1969, EMBEDDED FIGURES TES; BUCY PC, 1970, JOM-J OCCUP MED, V12, P318; DOLCE G, 1974, ELECTROEN CLIN NEURO, V36, P577, DOI 10.1016/0013-4694(74)90224-7; DROHOCKI Z, 1948, REV NEUROL, V80, P619; DYE OA, 1981, J CLIN PSYCHOL, V37, P472, DOI 10.1002/1097-4679(198107)37:3<472::AID-JCLP2270370304>3.0.CO;2-Q; FRANZ SI, 1920, HDB MENTAL EXAMINATI; GIANUTSOS R, 1981, COGNITIVE REHABILITA; GOLDSTEIN L, 1975, HEMISPHERIC ASYMMETR, P237; GRUBB RL, 1978, NEUROLOGICAL PATHOPH; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; KOUFEN H, 1978, FORTSCHR NEUROL PSYC, V46, P165; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; MCGEE DH, 1981, THESIS RUTGERS U NEW; SCHERZER E, 1970, ELECTROENCEPH CLIN N, V29; SHAW JC, 1976, PSYCHOL MED, V6, P307, DOI 10.1017/S0033291700013878; SHAW JC, 1976, PSYCHOL MED, V6, P316; VOGEL W, 1968, ELECTROEN CLIN NEURO, V24, P166, DOI 10.1016/0013-4694(68)90122-3; Walsh K.W, 1978, NEUROPSYCHOLOGY; 1985, SAS STATTM DISCRIM P	21	13	14	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0302-282X			NEUROPSYCHOBIOLOGY	Neuropsychobiology		1988	20	1					43	50		10.1159/000118471			8	Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	T3131	WOS:A1988T313100007	3231300				2021-06-18	
J	KMIECIAKKOLADA, K; FELINSKA, W; STACHURA, Z; MAJCHRZAK, H; HERMAN, ZS				KMIECIAKKOLADA, K; FELINSKA, W; STACHURA, Z; MAJCHRZAK, H; HERMAN, ZS			CONCENTRATION OF BIOGENIC-AMINES AND THEIR METABOLITES IN DIFFERENT PARTS OF BRAIN AFTER EXPERIMENTAL CEREBRAL CONCUSSION	POLISH JOURNAL OF PHARMACOLOGY AND PHARMACY			English	Article									SILESIAN MED ACAD,DEPT PHARMACOL,PL-41808 ZABRZE,POLAND; SILESIAN MED ACAD,CENT CLIN HOSP,DIV NEUROSURG,PL-40752 KATOWICE,POLAND	KMIECIAKKOLADA, K (corresponding author), SILESIAN MED ACAD,DEPT CLIN PHARMACOL,MEDYKOW 18,PL-40752 KATOWICE,POLAND.						BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; BOISMARE E, 1976, CR SOC BIOL, V5, P170; COSTA JL, 1974, NATURE, V248, P135, DOI 10.1038/248135a0; COX RH, 1973, J NEUROCHEM, V20, P1777, DOI 10.1111/j.1471-4159.1973.tb00294.x; DEGROOT J, 1963, RAT FOREBRAIN STEREO; DENNYBROWN D, 1961, ARCH NEUROL-CHICAGO, V5, P1; HUGER F, 1979, J NEUROCHEM, V33, P89, DOI 10.1111/j.1471-4159.1979.tb11710.x; KOBAYASHI R, 1975, CATECHOLAMINES STRES, P29; KORF J, 1975, CATECHOLAMINES STRES, P105; KVETNANSKY R, 1975, CATECHOLAMINES STRES, P39; LJUNGGREN B, 1975, INTRACRANIAL PRESSUR, V2, P189; MILLER F P, 1970, Biochemical Pharmacology, V19, P435, DOI 10.1016/0006-2952(70)90199-1; MRSULJA BB, 1978, J NEURAL TRANSM    S, V14, P23; OSTERHOLM JL, 1972, J NEUROSURG, V36, P386, DOI 10.3171/jns.1972.36.4.0386; OSTERHOLM JL, 1969, J NEUROSURG, V31, P408, DOI 10.3171/jns.1969.31.4.0408; PLECH A, 1981, POL J PHARMACOL PHAR, V33, P393; PORTA M, 1975, EUR NEUROL, V13, P545, DOI 10.1159/000114710; WELCH KMA, 1973, J NEUROL NEUROSUR PS, V36, P724, DOI 10.1136/jnnp.36.5.724; WESTERGAARD E, 1975, ACTA NEUROPATHOL, V32, P27, DOI 10.1007/BF00686065; WESTERINK BHC, 1976, EUR J PHARM, V38, P282; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617	21	13	13	0	0	POLISH ACAD SCIENCES INST PHARMACOLOGY	KRAKOW	SMETNA 12, 31-343 KRAKOW, POLAND	0301-0244			POL J PHARMACOL PHAR			1987	39	1					47	53					7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	H9856	WOS:A1987H985600008	2444951				2021-06-18	
J	MIZRAHI, EM; KELLAWAY, P				MIZRAHI, EM; KELLAWAY, P			CEREBRAL CONCUSSION IN CHILDREN - ASSESSMENT OF INJURY BY ELECTROENCEPHALOGRAPHY	PEDIATRICS			English	Article									METHODIST HOSP,BAYLOR COLL MED,DEPT PEDIAT,PEDIAT NEUROL SECT,HOUSTON,TX 77030; TEXAS CHILDRENS HOSP,HOUSTON,TX 77030	MIZRAHI, EM (corresponding author), METHODIST HOSP,BAYLOR COLL MED,DEPT NEUROL,NEUROPHYSIOL SECT,HOUSTON,TX 77030, USA.						Bricolo A, 1979, Acta Neurochir Suppl (Wien), V28, P35; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1961, ARCH NEUROL-CHICAGO, V5, P1; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296; DEVIVO DC, 1971, PEDIATRICS, V48, P129; GROAT R, 1950, J NEUROPATH EXP NEUR, V9, P150, DOI 10.1097/00005072-195004000-00003; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; JASPER H, 1945, RES PUBL ASS NERV ME, V24, P388; Jennett B, 1981, MANAGEMENT HEAD INJU; Jennett B, 1975, EPILEPSY NONMISSILE; KELLAWAY P, 1955, ELECTROEN CLIN NEURO, V7, P497; KELLAWAY P, 1979, CURRENT PRACTICE CLI, P69; Kellaway P, 1981, CURRENT CLIN NEUROPH, P151; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KOUFEN H, 1977, EEG-EMG-Z ELEK ELEKT, V8, P29; LANDAUFEREY J, 1980, ELECTROEN CLIN NEURO, V49, P173, DOI 10.1016/0013-4694(80)90364-8; MENKES JH, 1980, TXB NEUROLOGY, P411; OLOFSON O, 1971, NEUROPADIATRIE, V2, P375; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1966, HEAD INJURY, P260; Plum F., 1980, DIAGNOSIS STUPOR COM, V3; SILVERMAN D, 1962, NEUROLOGY, V12, P273, DOI 10.1212/WNL.12.4.273; SINGER HS, 1978, PEDIATRICS, V62, P819; SYMONDS C, 1962, LANCET, V1, P1; Trotter W, 1924, LANCET, V1, P935; WALKER AE, 1966, HEAD INJURY, P18; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561; WINDLE WF, 1945, ANAT REC, V93, P201, DOI 10.1002/ar.1090930210	28	13	13	0	0	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD, ELK GROVE VILLAGE, IL 60007-1098	0031-4005			PEDIATRICS	Pediatrics		1984	73	4					419	425					7	Pediatrics	Pediatrics	SL090	WOS:A1984SL09000001	6709421				2021-06-18	
J	LEVIN, HS; GROSSMAN, RG; KELLY, PJ				LEVIN, HS; GROSSMAN, RG; KELLY, PJ			IMPAIRMENT OF FACIAL RECOGNITION AFTER CLOSED HEAD-INJURIES OF VARYING SEVERITY	CORTEX			English	Article									UNIV TEXAS,MED BRANCH,DEPT SURG,DIV NEUROSURG,GALVESTON,TX 77550					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2P01 NS 07377-06] Funding Source: Medline		Benton A., 1968, CORTEX, V4, P344, DOI DOI 10.1016/S0010-9452(68)80018-8; BENTON AL, 1969, J NEUROL SCI, V9, P39, DOI 10.1016/0022-510X(69)90057-4; BENTON AL, 1964, J NERV MENT DIS, V139, P110, DOI 10.1097/00005053-196408000-00003; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; DERENZI E, 1966, NEUROLOGY, V16, P145, DOI 10.1212/WNL.16.2_Part_1.145; Klove H, 1972, Scand J Rehabil Med, V4, P55; LEVIN HS, 1975, J PSYCHOL, V91, P223, DOI 10.1080/00223980.1975.9923946; LEVIN HS, 1976, CORTEX, V12, P175, DOI 10.1016/S0010-9452(76)80021-4; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; SPREEN O, 1966, MANUAL NEUROSENSORY; Warrington E. K., 1967, CORTEX, V3, P317, DOI [DOI 10.1016/S0010-9452(67)80020-0, 10.1016/S0010-9452(67)80020-0]	12	13	13	0	0	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex		1977	13	2					119	130		10.1016/S0010-9452(77)80003-8			12	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	DN815	WOS:A1977DN81500002	16295956				2021-06-18	
J	JACOBSON, SA				JACOBSON, SA			PROTRACTED UNCONSCIOUSNESS DUE TO CLOSED HEAD INJURY	NEUROLOGY			English	Article																CAIRNS H, 1952, BRAIN, V75, P109, DOI 10.1093/brain/75.2.109; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; ECHOLS D H, 1949, New Orleans Med Surg J, V102, P97; ECHOLS DH, 1950, SURGERY, V28, P801; FOREGGER R, 1947, JAMA-J AM MED ASSOC, V133, P1200, DOI 10.1001/jama.1947.02880160026005; JASPER H, 1943, A RES NERV MENT DIS, V24, P388; MUNRO D, TREATMENT INJURIES C, P86; SHIENKER M, 1949, NEUROSURGICAL PATHOL, P42; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223; Williams D, 1941, J NEUROL PSYCHIATRY, V4, P107, DOI 10.1136/jnnp.4.2.107	10	13	13	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0028-3878			NEUROLOGY	Neurology		1956	6	4					281	287		10.1212/WNL.6.4.281			7	Clinical Neurology	Neurosciences & Neurology	WC989	WOS:A1956WC98900005	13309608				2021-06-18	
J	Sas, AR; Carbajal, KS; Jerome, AD; Menon, R; Yoon, C; Kalinski, AL; Giger, RJ; Segal, BM				Sas, Andrew R.; Carbajal, Kevin S.; Jerome, Andrew D.; Menon, Rajasree; Yoon, Choya; Kalinski, Ashley L.; Giger, Roman J.; Segal, Benjamin M.			A new neutrophil subset promotes CNS neuron survival and axon regeneration	NATURE IMMUNOLOGY			English	Article							CELL-LINE HL-60; BRAIN-INJURY; MACROPHAGES; DIFFERENTIATION; INFLAMMATION; PHENOTYPE; EXPRESSION; PLASTICITY	Segal and colleagues identify a neuroprotective immature-like neutrophil subset that participates in dectin-1-dependent axon repair and regeneration in the central nervous system. Transected axons typically fail to regenerate in the central nervous system (CNS), resulting in chronic neurological disability in individuals with traumatic brain or spinal cord injury, glaucoma and ischemia-reperfusion injury of the eye. Although neuroinflammation is often depicted as detrimental, there is growing evidence that alternatively activated, reparative leukocyte subsets and their products can be deployed to improve neurological outcomes. In the current study, we identify a unique granulocyte subset, with characteristics of an immature neutrophil, that had neuroprotective properties and drove CNS axon regeneration in vivo, in part via secretion of a cocktail of growth factors. This pro-regenerative neutrophil promoted repair in the optic nerve and spinal cord, demonstrating its relevance across CNS compartments and neuronal populations. Our findings could ultimately lead to the development of new immunotherapies that reverse CNS damage and restore lost neurological function across a spectrum of diseases.	[Sas, Andrew R.; Jerome, Andrew D.; Segal, Benjamin M.] Ohio State Univ, Dept Neurol, Wexner Med Ctr, Columbus, OH 43210 USA; [Sas, Andrew R.; Jerome, Andrew D.; Segal, Benjamin M.] Ohio State Univ, Neurosci Res Inst, Columbus, OH 43210 USA; [Sas, Andrew R.; Carbajal, Kevin S.; Segal, Benjamin M.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA; [Menon, Rajasree] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA; [Yoon, Choya; Kalinski, Ashley L.; Giger, Roman J.] Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; [Giger, Roman J.] Univ Michigan, Neurosci Grad Program, Ann Arbor, MI 48109 USA	Segal, BM (corresponding author), Ohio State Univ, Dept Neurol, Wexner Med Ctr, Columbus, OH 43210 USA.; Segal, BM (corresponding author), Ohio State Univ, Neurosci Res Inst, Columbus, OH 43210 USA.; Segal, BM (corresponding author), Univ Michigan, Dept Neurol, Ann Arbor, MI USA.	benjamin.segal@osumc.edu		Kalinski, Ashley/0000-0001-7611-0810; Menon, Rajasree/0000-0001-6280-9639; Segal, Benjamin/0000-0002-0906-6319	National Eye Institute (NEI), National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY029159, R01EY028350, K08EY029362]; Wings of Life Foundation; Dr. Miriam and Sheldon G. Adelson Research Foundation	We thank S. Atkins for technical support. Financial support for this research was provided by the National Eye Institute (NEI), National Institutes of Health (R01EY029159 and R01EY028350 to B.M.S. and R.J.G; K08EY029362 to A.R.S.), the Wings of Life Foundation (C.Y.) and the Dr. Miriam and Sheldon G. Adelson Research Foundation (R.J.G.). B.M.S. holds the Stanley D. and Joan H. Ross chair in neuromodulation at the Ohio State University.	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Baldwin KT, 2015, P NATL ACAD SCI USA, V112, P2581, DOI 10.1073/pnas.1423221112; Benowitz LI, 2017, EXP NEUROL, V287, P365, DOI 10.1016/j.expneurol.2015.12.015; Bollaerts I, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/9478542; BOSS MA, 1980, BLOOD, V56, P910; Brennan FH, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.98254; Chen F, 2014, NAT IMMUNOL, V15, P938, DOI 10.1038/ni.2984; Chinetti-Gbaguidi G, 2015, NAT REV CARDIOL, V12, P10, DOI 10.1038/nrcardio.2014.173; Cloke T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048939; Dai XM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09544-9; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Giles DA, 2018, J CLIN INVEST, V128, P5322, DOI 10.1172/JCI123708; Giles DA, 2018, ANN NEUROL, V83, P131, DOI 10.1002/ana.25128; Gliem M, 2016, BBA-MOL BASIS DIS, V1862, P329, DOI 10.1016/j.bbadis.2015.11.004; Grifka-Walk HM, 2015, EUR J IMMUNOL, V45, P2780, DOI 10.1002/eji.201545800; Herz J, 2015, STROKE, V46, P2916, DOI 10.1161/STROKEAHA.115.010620; Horckmans M, 2017, EUR HEART J, V38, P187, DOI 10.1093/eurheartj/ehw002; Hou Y, 2019, INT IMMUNOPHARMACOL, V77, DOI 10.1016/j.intimp.2019.105970; Cuartero MI, 2013, STROKE, V44, P3498, DOI 10.1161/STROKEAHA.113.002470; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Kurimoto T, 2013, J NEUROSCI, V33, P14816, DOI 10.1523/JNEUROSCI.5511-12.2013; Leon S, 2000, J NEUROSCI, V20, P4615, DOI 10.1523/JNEUROSCI.20-12-04615.2000; Liu CY, 2010, J CANCER RES CLIN, V136, P35, DOI 10.1007/s00432-009-0634-0; Lorber B, 2009, J NEUROSCI RES, V87, P2645, DOI 10.1002/jnr.22095; Lucas T, 2010, J IMMUNOL, V184, P3964, DOI 10.4049/jimmunol.0903356; Ma SF, 2015, BRAIN BEHAV IMMUN, V45, P157, DOI 10.1016/j.bbi.2014.11.007; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Mistry P, 2019, P NATL ACAD SCI USA, V116, P25222, DOI 10.1073/pnas.1908576116; Neumann S, 1999, NEURON, V23, P83, DOI 10.1016/S0896-6273(00)80755-2; NEWBURGER PE, 1979, J CELL BIOL, V82, P315, DOI 10.1083/jcb.82.2.315; OLSSON I, 1981, EXP CELL RES, V131, P225, DOI 10.1016/0014-4827(81)90422-5; Park J, 2018, SCIENCE, V360, P758, DOI 10.1126/science.aar2131; Rodriguez PC, 2009, CANCER RES, V69, P1553, DOI 10.1158/0008-5472.CAN-08-1921; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Ruschel J, 2015, SCIENCE, V348, P347, DOI 10.1126/science.aaa2958; Sagiv JY, 2015, CELL REP, V10, P562, DOI 10.1016/j.celrep.2014.12.039; Schwartz M, 2010, BRAIN BEHAV IMMUN, V24, P1054, DOI 10.1016/j.bbi.2010.01.010; Segal BM, 2005, J NEUROL SCI, V228, P210, DOI 10.1016/j.jns.2004.10.014; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Shi KB, 2019, LANCET NEUROL, V18, P1058, DOI 10.1016/S1474-4422(19)30078-X; Ssemaganda A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085696; Stoolman JS, 2014, J IMMUNOL, V193, P564, DOI 10.4049/jimmunol.1400825; Tourki B, 2017, FASEB J, V31, P4226, DOI 10.1096/fj.201700109R; Tsuda Y, 2004, IMMUNITY, V21, P215, DOI 10.1016/j.immuni.2004.07.006; von Leden RE, 2019, EXP NEUROL, V317, P144, DOI 10.1016/j.expneurol.2019.03.004; Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015; Yin YQ, 2003, J NEUROSCI, V23, P2284; Yoon C, 2013, J BIOL CHEM, V288, P26557, DOI 10.1074/jbc.M113.478552	48	12	12	8	16	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1529-2908	1529-2916		NAT IMMUNOL	Nat. Immunol.	DEC	2020	21	12					1496	+		10.1038/s41590-020-00813-0		OCT 2020	20	Immunology	Immunology	OT0EL	WOS:000583963700002	33106668	Green Accepted			2021-06-18	
J	Shahim, P; Politis, A; van der Merwe, A; Moore, B; Ekanayake, V; Lippa, SM; Chou, YY; Pham, DL; Butman, JA; Diaz-Arrastia, R; Zetterberg, H; Blennow, K; Gill, JM; Brody, DL; Chan, L				Shahim, Pashtun; Politis, Adam; van der Merwe, Andre; Moore, Brian; Ekanayake, Vindhya; Lippa, Sara M.; Chou, Yi-Yu; Pham, Dzung L.; Butman, John A.; Diaz-Arrastia, Ramon; Zetterberg, Henrik; Blennow, Kaj; Gill, Jessica M.; Brody, David L.; Chan, Leighton			Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; NEUROCHEMICAL AFTERMATH; NEUROFILAMENT LIGHT; BLOOD BIOMARKERS; PROTEIN	Objective To determine whether neurofilament light (NfL), glial fibrillary acidic protein (GFAP), tau, and ubiquitin C-terminal hydrolase-L1 (UCH-L1) measured in serum relate to traumatic brain injury (TBI) diagnosis, injury severity, brain volume, and diffusion tensor imaging (DTI) measures of traumatic axonal injury (TAI) in patients with TBI. Methods Patients with TBI (n = 162) and controls (n = 68) were prospectively enrolled between 2011 and 2019. Patients with TBI also underwent serum, functional outcome, and imaging assessments at 30 (n = 30), 90 (n = 48), and 180 (n = 59) days, and 1 (n = 84), 2 (n = 57), 3 (n = 46), 4 (n = 38), and 5 (n = 29) years after injury. Results At enrollment, patients with TBI had increased serum NfL compared to controls (p < 0.0001). Serum NfL decreased over the course of 5 years but remained significantly elevated compared to controls. Serum NfL at 30 days distinguished patients with mild, moderate, and severe TBI from controls with an area under the receiver-operating characteristic curve (AUROC) of 0.84, 0.92, and 0.92, respectively. At enrollment, serum GFAP was elevated in patients with TBI compared to controls (p < 0.001). GFAP showed a biphasic release in serum, with levels decreasing during the first 6 months of injury but increasing over the subsequent study visits. The highest AUROC for GFAP was measured at 30 days, distinguishing patients with moderate and severe TBI from controls (both 0.89). Serum tau and UCH-L1 showed weak associations with TBI severity and neuroimaging measures. Longitudinally, serum NfL was the only biomarker that was associated with the likely rate of MRI brain atrophy and DTI measures of progression of TAI. Conclusions Serum NfL shows greater diagnostic and prognostic utility than GFAP, tau, and UCH-L1 for subacute and chronic TBI. Classification of evidence This study provides Class III evidence that serum NfL distinguishes patients with mild TBI from healthy controls.	[Shahim, Pashtun; Lippa, Sara M.; Chou, Yi-Yu; Pham, Dzung L.; Butman, John A.; Gill, Jessica M.; Brody, David L.; Chan, Leighton] NIH, Bldg 10, Bethesda, MD 20892 USA; [Shahim, Pashtun; van der Merwe, Andre; Moore, Brian; Ekanayake, Vindhya; Chou, Yi-Yu; Pham, Dzung L.; Butman, John A.; Gill, Jessica M.; Brody, David L.; Chan, Leighton] Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Shahim, Pashtun; van der Merwe, Andre; Moore, Brian; Ekanayake, Vindhya; Brody, David L.] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD 20817 USA; [Shahim, Pashtun; Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden; [Shahim, Pashtun; Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Lippa, Sara M.] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bethesda, MD USA; [Lippa, Sara M.] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Diaz-Arrastia, Ramon] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Zetterberg, Henrik] UK Dementia Res Inst UCL, London, England; [Zetterberg, Henrik] UCL Inst Neurol, Dept Neurodegenerat Dis, London, England; [Brody, David L.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	Shahim, P (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.; Shahim, P (corresponding author), Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA.; Shahim, P (corresponding author), Henry M Jackson Fdn Adv Mil Med, Bethesda, MD 20817 USA.; Shahim, P (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden.; Shahim, P (corresponding author), Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden.	pashtun-poh.shahim@nih.gov	Butman, John/J-2780-2013	Butman, John/0000-0002-1547-9195	Intramural Research Program at the NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; DoD (Center for Neuroscience and Regenerative Medicine)United States Department of Defense	Funding provided by the Intramural Research Program at the NIH and the DoD (Center for Neuroscience and Regenerative Medicine).	Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Bazarian JJ, 2018, LANCET NEUROL, V17, P782, DOI 10.1016/S1474-4422(18)30231-X; Bazin PL, 2011, NEUROIMAGE, V58, P458, DOI 10.1016/j.neuroimage.2011.06.020; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; Cole JH, 2018, BRAIN, V141, P822, DOI 10.1093/brain/awx354; Department of Veterans Affairs Department of Defense, VA DOD CLIN PRACT GU; FRIEDE RL, 1970, ANAT REC, V167, P379, DOI 10.1002/ar.1091670402; Gill J, 2018, NEUROLOGY, V91, pE1385, DOI 10.1212/WNL.0000000000006321; Goddeyne C, 2015, J NEUROPHYSIOL, V113, P3268, DOI 10.1152/jn.00970.2014; Gravesteijn BY, 2020, J NEUROTRAUM, V37, P1002, DOI 10.1089/neu.2019.6764; Hossain I, 2019, J NEUROTRAUM, V36, P1551, DOI 10.1089/neu.2018.5952; Hsu ET, 2018, ACTA NEUROPATHOL, V136, P955, DOI 10.1007/s00401-018-1902-3; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Hunter LE, 2019, J NEUROTRAUM, V36, P1222, DOI 10.1089/neu.2018.5838; Iverson GL, 2019, J NEUROTRAUM, V36, P2400, DOI 10.1089/neu.2018.6341; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Ljungqvist J, 2017, J NEUROTRAUM, V34, P1124, DOI 10.1089/neu.2016.4496; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Marion CM, 2018, J NEUROSCI, V38, P8723, DOI 10.1523/JNEUROSCI.0819-18.2018; Mouzon B, 2019, J NEUROTRAUM, V36, P576, DOI 10.1089/neu.2018.5720; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Pierpaoli C, 2010, ISMRM 18 ANN M MAY 1; Roy S, 2017, NEUROIMAGE, V146, P132, DOI 10.1016/j.neuroimage.2016.11.017; Shahim P, 2018, NEUROLOGY, V90, pE1780, DOI 10.1212/WNL.0000000000005518; Shahim P, 2016, JAMA NEUROL, V73, P1308, DOI 10.1001/jamaneurol.2016.2038; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; Tustison NJ, 2010, IEEE T MED IMAGING, V29, P1310, DOI 10.1109/TMI.2010.2046908; WILKINSON KD, 1992, BIOCHEM SOC T, V20, P631, DOI 10.1042/bst0200631; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yuan AD, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a018309; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277	37	12	12	4	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	AUG 11	2020	95	6					E623	E636		10.1212/WNL.0000000000009985			14	Clinical Neurology	Neurosciences & Neurology	OH2AX	WOS:000582373300017	32641529				2021-06-18	
J	Whiting, D; Deane, F; McLeod, H; Ciarrochi, J; Simpson, G				Whiting, Diane; Deane, Frank; McLeod, Hamish; Ciarrochi, Joseph; Simpson, Grahame			Can acceptance and commitment therapy facilitate psychological adjustment after a severe traumatic brain injury? A pilot randomized controlled trial	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Acceptance and commitment therapy; Randomized controlled trial; Depression; Anxiety; Stress; Traumatic brain injury; Psychological flexibility	COGNITIVE-BEHAVIORAL THERAPY; SCHEDULED TELEPHONE INTERVENTION; ANXIETY STRESS SCALES; DEPRESSIVE SYMPTOMS; EMOTIONAL DISTRESS; GOAL ATTAINMENT; 1ST YEAR; ACT; REHABILITATION; REINTEGRATION	This study i & x2060;nvestigated if an Acceptance and Commitment Therapy (ACT) intervention (ACT-Adjust) can facilitate psychological adjustment and reduce psychological distress following severe traumatic brain injury (TBI). The study design comprised a single centre, two-armed, Phase II pilot randomized controlled trial. Nineteen individuals with severe TBI (PTA >= 7 days) who met a clinical threshold for psychological distress (Depression Anxiety Stress Scales-21; DASS > 9) were randomly allocated to either ACT-Adjust (n = 10) or an active control, Befriending Therapy (n = 9), in conjunction with a holistic rehabilitation programme. Primary (psychological flexibility, rehabilitation participation) and secondary (depression, anxiety & stress) outcomes were measured at three-time points (pre, post and follow up). Significant decreases were found for DASS-depression (group by time interaction,F-1,F-17 = 5.35,p = .03) and DASS-stress (group by time interaction,F-1,F-17 = 5.69,p = .03) in comparison to the Befriending group, but not for the primary outcome measures. The reduction in stress post-treatment was classed as clinically significant, however interaction differences for stress and depression were not maintained at one month follow up. Preliminary investigations indicate potential for ACT in decreasing psychological distress for individuals with a severe TBI with further sessions required to maintain treatment gains. The pilot results suggest further investigation is warranted in a larger scale clinical trial.	[Whiting, Diane; Simpson, Grahame] Ingham Inst Appl Med Res, Brain Injury Rehabil Res Grp, 1 Campbell St Liverpool, Sydney, NSW 2170, Australia; [Whiting, Diane; Deane, Frank] Univ Wollongong, Sch Psychol, Wollongong, NSW, Australia; [McLeod, Hamish] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland; [Ciarrochi, Joseph] Australian Catholic Univ, Inst Hlth & Wellbeing, Strathfield, Australia; [Simpson, Grahame] Univ Sydney, Kolling Inst Med Res, John Walsh Ctr Rehabil Res, Sydney, NSW, Australia	Whiting, D (corresponding author), Ingham Inst Appl Med Res, 1 Campbell St, Liverpool, NSW 2170, Australia.	dwhiting@bigpond.net.au	Whiting, Diane/AAN-2522-2021; Ciarrochi, Joseph/F-5823-2016	Ciarrochi, Joseph/0000-0003-0471-8100; Simpson, Grahame/0000-0001-8156-9060; Whiting, Diane/0000-0003-1912-6626			Antonak R. F., 1993, J HEAD TRAUMA REHAB, V8, P87, DOI DOI 10.1097/00001199-199312000-00009; Ashman T, 2014, J HEAD TRAUMA REHAB, V29, P467, DOI 10.1097/HTR.0000000000000098; Bay E, 2002, J NURS SCHOLARSHIP, V34, P221, DOI 10.1111/j.1547-5069.2002.00221.x; Bay E, 2009, BIOL RES NURS, V10, P213, DOI 10.1177/1099800408326453; Bedard M, 2014, J HEAD TRAUMA REHAB, V29, pE13, DOI 10.1097/HTR.0b013e3182a615a0; Bell KR, 2011, ARCH PHYS MED REHAB, V92, P1552, DOI 10.1016/j.apmr.2011.05.018; Bendall S., 2003, BEFRIENDING MANUAL; Bendall S, 2006, BEHAV COGN PSYCHOTH, V34, P277, DOI 10.1017/S1352465806002815; Blevins D, 2011, PROF PSYCHOL-RES PR, V42, P32, DOI 10.1037/a0022321; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; Bomyea J, 2017, J HEAD TRAUMA REHAB, V32, pE35, DOI 10.1097/HTR.0000000000000278; Bond FW, 2011, BEHAV THER, V42, P676, DOI 10.1016/j.beth.2011.03.007; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Brenner LA, 2018, J HEAD TRAUMA REHAB, V33, pE64, DOI 10.1097/HTR.0000000000000351; Brenner LA, 2012, J HEAD TRAUMA REHAB, V27, pE57, DOI 10.1097/HTR.0b013e318273414c; Brinkborg H, 2011, BEHAV RES THER, V49, P389, DOI 10.1016/j.brat.2011.03.009; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Chervinsky AB, 1998, ARCH CLIN NEUROPSYCH, V13, P433, DOI 10.1016/S0887-6177(97)00016-4; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; Ciarrochi J., 2008, CBT PRACTITIONERS GU; Ciarrochi J., 2010, ASSESSING MINDFULNES, P51; Craig Peter, 2008, BMJ, V337, pa1655, DOI 10.1136/bmj.a1655; Cumming G, 2013, AUST PSYCHOL, V48, P161, DOI 10.1111/ap.12018; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Eifert G. H., 2006, ACT LIFE NOT ANGER N; Fann JR, 2015, J NEUROTRAUM, V32, P45, DOI 10.1089/neu.2014.3423; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Feise Ronald J, 2002, BMC Med Res Methodol, V2, P8, DOI 10.1186/1471-2288-2-8; Freedland KE, 2011, PSYCHOSOM MED, V73, P323, DOI 10.1097/PSY.0b013e318218e1fb; Freeman A, 2015, NEUROPSYCHOL REHABIL, V25, P189, DOI 10.1080/09602011.2014.917686; Gallagher M, 2019, NEUROPSYCHOL REHABIL, V29, P1, DOI 10.1080/09602011.2016.1258367; Gertler P, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009871.pub2; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gracey F., 2016, NEURO DISABILITY PSY, V3, P154; Graham CD, 2016, CLIN PSYCHOL REV, V46, P46, DOI 10.1016/j.cpr.2016.04.009; Hardy GE, 1999, PSYCHOL ASSESSMENT, V11, P159, DOI 10.1037/1040-3590.11.2.159; Hart T, 2008, NEUROPSYCHOL REHABIL, V18, P1, DOI 10.1080/09602010601082359; Hayes S., 2003, ACCEPTANCE COMMITMEN; Hayes SC, 2006, BEHAV RES THER, V44, P1, DOI 10.1016/j.brat.2005.06.006; Hodgson J, 2005, BRAIN IMPAIR, V6, P169, DOI DOI 10.1375/BRIM.2005.6.3.169; Hsieh MY, 2012, NEUROPSYCHOL REHABIL, V22, P585, DOI 10.1080/09602011.2012.678860; IBM Corp, 2013, SPSS STAT WIND VERS; Jackson HJ, 2008, PSYCHOL MED, V38, P725, DOI 10.1017/S0033291707002061; Kangas M, 2011, NEUROPSYCHOL REHABIL, V21, P250, DOI 10.1080/09602011.2010.540920; Karlovits T, 1999, BRAIN INJURY, V13, P845; Kashdan TB, 2010, CLIN PSYCHOL REV, V30, P865, DOI 10.1016/j.cpr.2010.03.001; Lang AJ, 2017, PSYCHOL TRAUMA-US, V9, P74, DOI 10.1037/tra0000127; Lang AJ, 2012, CONTEMP CLIN TRIALS, V33, P116, DOI 10.1016/j.cct.2011.08.007; Lovibond S.H., 1995, MANUAL DEPRESSION AN; Malec JF, 1999, NEUROPSYCHOL REHABIL, V9, P253, DOI 10.1080/096020199389365; McHugh L, 2011, WORLD J BIOL PSYCHIA, V12, P76, DOI 10.3109/15622975.2011.603225; Mead N, 2010, BRIT J PSYCHIAT, V196, P96, DOI 10.1192/bjp.bp.109.064089; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Ownsworth T, 2008, J REHABIL MED, V40, P81, DOI 10.2340/16501977-0124; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Ponsford J, 2016, PSYCHOL MED, V46, P1079, DOI 10.1017/S0033291715002640; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Randall D, 2017, J HEAD TRAUMA REHAB, V32, P134, DOI 10.1097/HTR.0000000000000250; Randolph C., 1998, RBANS MANUAL REPEATA; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Roundhill S.J., 2007, QUAL RES PSYCHOL, V4, P241, DOI [10.1080/14780880701473540, DOI 10.1080/14780880701473540]; Schonberger M, 2010, PSYCHIAT RES, V179, P342, DOI 10.1016/j.psychres.2009.07.003; Schulz KF, 2010, J CLIN EPIDEMIOL, V63, P834, DOI [10.1016/j.jclinepi.2010.02.005, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18]; Shields C, 2016, NEUROPSYCHOL REHABIL, V26, P410, DOI 10.1080/09602011.2015.1037772; Simpson GK, 2011, J HEAD TRAUMA REHAB, V26, P290, DOI 10.1097/HTR.0b013e3182225250; Soo C, 2011, BRAIN IMPAIR, V12, P54, DOI 10.1375/brim.12.1.54; Sylvester M., 2011, THESIS; Tate RL, 2004, BRAIN IMPAIR, V5, P81, DOI [10.1375/brim.5.1.81.35408, DOI 10.1375/brim.5.1.81.35408, DOI 10.1375/BRIM.5.1.81.35408]; Tate RL, 2011, J REHABIL MED, V43, P609, DOI 10.2340/16501977-0829; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Whiting DL, 2018, CLIN PSYCHOL-UK, V22, P230, DOI 10.1111/cp.12118; Whiting DL, 2017, NEUROPSYCHOL REHABIL, V27, P263, DOI 10.1080/09602011.2015.1062115; Whiting DL, 2015, PSYCHOL ASSESSMENT, V27, P415, DOI 10.1037/pas0000050; Whiting DL, 2012, BRAIN IMPAIR, V13, P360, DOI 10.1017/BrImp.2012.28; Wilson KG, 2009, MINDFULNESS 2 ACCEPT; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	80	12	12	8	16	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	AUG 8	2020	30	7					1348	1371		10.1080/09602011.2019.1583582			24	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	MH9SO	WOS:000547060000007	30789059	Green Accepted			2021-06-18	
J	Conway, FN; Domingues, M; Monaco, R; Lesnewich, LM; Ray, AE; Alderman, BL; Todaro, SM; Buckman, JF				Conway, Fiona N.; Domingues, Marianne; Monaco, Robert; Lesnewich, Laura M.; Ray, Anne E.; Alderman, Brandon L.; Todaro, Sabrina M.; Buckman, Jennifer F.			Concussion Symptom Underreporting Among Incoming National Collegiate Athletic Association Division I College Athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						sport; brain injury; diagnosis; attitude; reporting; safety	SMOKING-CESSATION; EPIDEMIOLOGY; BEHAVIOR; SUPPORT; MANAGEMENT; IMPACT	Objective: Accurate diagnosis of sport-related concussions relies heavily on truthful self-reporting of symptom severity. Previous studies have emphasized lack of knowledge as a factor in symptom nondisclosure. This study sought to examine concussion knowledge and the relationship of knowledge to reasons for symptom nondisclosure. Design: Cross-sectional study. Setting: Data were collected during preparticipation athletic evaluations via electronic survey. Participants: One hundred fifty-six incoming National Collegiate Athletic Association Division I student-athletes. Main Outcome Measures: Survey items included previous concussion diagnosis, concussion fact and symptom knowledge, reasons and situational contexts for nondisclosure, and stakeholder attitudes. Results: Participants, on average, had substantial concussion symptom and fact knowledge. Unexpectedly, participants with higher concussion fact knowledge endorsed more reasons that athletes may hide symptoms. Concussion symptom knowledge was unrelated to reasons for nondisclosure. Athletes believed that symptom reporting was less likely in high-stakes versus low-stakes situations and consistently identified their teammates as holding attitudes that support underreporting and athletic trainers as engaging in behaviors that support player safety. Conclusions: Greater concussion knowledge did not reduce the number of reasons that participants viewed as drivers for concussion nondisclosure. In other words, participants understood why athletes choose to hide symptoms even when they also understood the symptoms, risks, sequelae, and consequences of concussion (and potential harm of nondisclosure). Situational contexts and important stakeholder attitudes also appeared to importantly influence symptom disclosure decisions. A multifaceted approach that goes beyond current educational strategies to addresses situational, social, and athletic pressures may be needed to initiate a widespread cultural shift away from concussion nondisclosure.	[Conway, Fiona N.; Lesnewich, Laura M.; Todaro, Sabrina M.; Buckman, Jennifer F.] Rutgers State Univ, Ctr Alcohol Studies, New Brunswick, NJ USA; [Domingues, Marianne] New York Presbyterian Weill Cornell Med Ctr, Dept Cardiol Crit Care, New York, NY USA; [Monaco, Robert] Atlantic Sports Hlth, Morristown, NJ USA; [Ray, Anne E.] Real Prevent LLC, Clifton, NJ USA; [Alderman, Brandon L.; Buckman, Jennifer F.] Rutgers State Univ, Dept Kinesiol & Hlth, New Brunswick, NJ USA	Buckman, JF (corresponding author), Rutgers State Univ, Rutgers Ctr Alcohol Studies, 607 Allison Rd, Piscataway, NJ 08854 USA.	jbuckman@rutgers.edu		Conway, Fiona/0000-0003-2626-4752	NJ Commission on Brain Injury Research [NJCBIR13IRG028]	J. F. Buckman received a grant from the NJ Commission on Brain Injury Research (NJCBIR13IRG028) to conduct this study. The remaining authors report no conflicts of interest.	Andreyeva T, 2010, AM J PUBLIC HEALTH, V100, P216, DOI 10.2105/AJPH.2008.151415; Baugh CM, 2014, J LAW MED ETHICS, V42, P314, DOI 10.1111/jlme.12148; Center for Disease Control and Prevention, 2016, TYRENDS CURR CIG SMO; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Concannon LG, 2016, PHYS MED REH CLIN N, V27, P513, DOI 10.1016/j.pmr.2015.12.006; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Delaney JS, 2015, CLIN J SPORT MED, V25, P113, DOI 10.1097/JSM.0000000000000112; Fichtenberg CM, 2002, BMJ-BRIT MED J, V325, P188, DOI 10.1136/bmj.325.7357.188; FISHER RJ, 1993, J CONSUM RES, V20, P303, DOI 10.1086/209351; Gardner M, 2005, DEV PSYCHOL, V41, P625, DOI 10.1037/0012-1649.41.4.625; Guskiewicz Kevin, 2014, Neurosurgery, V75 Suppl 4, pS113, DOI 10.1227/NEU.0000000000000494; Junn C, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0519-7; Kelly MP, 2016, PUBLIC HEALTH, V136, P109, DOI 10.1016/j.puhe.2016.03.030; Kerr HA, 2014, PEDIATR ANN, V43, pE309, DOI 10.3928/00904481-20141124-10; Kerr ZY, 2016, AM J SPORT MED, V44, P220, DOI 10.1177/0363546515612082; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; LaRoche AA, 2016, CLIN J SPORT MED, V26, P33, DOI 10.1097/JSM.0000000000000192; LoGalbo A, 2014, PROG NEUROL SURG, V28, P184, DOI 10.1159/000358779; Lovell MR, 2008, CURR SPORT MED REP, V7, P12, DOI 10.1097/01.CSMR.0000308671.45558.e2; Lowrey K.M., 2015, J BUS TECH LAW, V10, P61; Makdissi Michael, 2015, Neurol Clin Pract, V5, P2, DOI 10.1212/CPJ.0000000000000061; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Maruta J, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00035; McCrory P, 2013, PM&R, V5, P255, DOI 10.1016/j.pmrj.2013.02.012; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Miller MB, 2013, PSYCHOL ADDICT BEHAV, V27, P909, DOI 10.1037/a0031174; National Highway Traffic Safety Administration, 2001, 5 6 REP C EFF OCC PR; Park EW, 2004, ANN FAM MED, V2, P170, DOI 10.1370/afm.64; Peralta RL., 2002, GEND ISSUES, V20, P23, DOI [10.1007/s12147-002-0021-5, DOI 10.1007/S12147-002-0021-5]; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; RUSSELL MAH, 1979, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6184.231; Ryan P, 2009, CLIN NURSE SPEC, V23, P161, DOI 10.1097/NUR.0b013e3181a42373; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Shahab L, 2009, ADDICTION, V104, P1792, DOI 10.1111/j.1360-0443.2009.02710.x; Wakefield M, 2003, J HEALTH COMMUN, V8, P229, DOI 10.1080/10810730305686; Wakefield MA, 2008, AM J PUBLIC HEALTH, V98, P1443, DOI 10.2105/AJPH.2007.128991; Wasserman EB, 2016, AM J SPORT MED, V44, P226, DOI 10.1177/0363546515610537; Whelan R, 2009, PSYCHOL REC, V59, P247, DOI 10.1007/BF03395661; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	39	12	12	3	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2020	30	3					203	209		10.1097/JSM.0000000000000557			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	LL1OQ	WOS:000531324800003	32341286	Green Accepted			2021-06-18	
J	Libeson, L; Downing, M; Ross, P; Ponsford, J				Libeson, Lauren; Downing, Marina; Ross, Pamela; Ponsford, Jennie			The experience of return to work in individuals with traumatic brain injury (TBI): A qualitative study	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury; vocational rehabilitation; employment; return to work	VOCATIONAL-REHABILITATION; EMPLOYMENT; STABILITY; INTEGRATION; OUTCOMES; PEOPLE; MEMORY; MILD; LIFE	Traumatic Brain Injury (TBI) is a leading cause of disability in young people, with return to work (RTW) a major goal of recovery. This qualitative study aimed to understand the RTW experience of individuals with TBI who received comprehensive vocational rehabilitation, and to identify facilitating and limiting factors in the RTW process. Semi-structured interviews were conducted with 15 individuals (mean age = 47.33 years) approximately 4.5 years post-injury, of whom 14 had moderate to severe TBI. Twelve individuals had successfully returned to work. Thematic analysis of transcribed interviews identified three key factors affecting RTW: client, work and rehabilitation factors. Across these factors, 12 themes reported to be critical to the success or failure of the RTW programme were identified. Client themes included social support, cognitive difficulties and motivation, with RTW too early associated with unfavourable outcomes. Work themes included work modifications, employer support and financial incentives. Rehabilitation themes included the RTW programme, the role of the vocational occupational therapist and work preparation. These key factors were reported to have impacted the RTW outcome, comprising three further themes: work satisfaction, future vocational outlook, and quality of life. Consideration of these factors can inform vocational rehabilitation programmes, potentially improving employment outcomes following TBI.	[Libeson, Lauren; Downing, Marina; Ponsford, Jennie] Monash Univ, Sch Psychol Sci, Melbourne, Vic, Australia; [Downing, Marina; Ponsford, Jennie] Monash Epworth Rehabil Res Ctr, Dept Rehabil Psychol & Psychotherapy, Melbourne, Vic, Australia; [Ross, Pamela] Epworth Healthcare, Richmond, Australia	Ponsford, J (corresponding author), Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu	Downing, Marina/AAX-2380-2020; Ponsford, Jennie/H-8341-2014	Downing, Marina/0000-0002-3126-6632; Ponsford, Jennie/0000-0003-0430-125X; Libeson, Lauren/0000-0003-4648-4023	Epworth Research Institute by a Feasibility grant	This work was supported by Epworth Research Institute by a Feasibility grant.	Aas R, 2009, INT J DISABILITY MAN, V4, P1, DOI DOI 10.1375/JDMR.4.1.1; Access Economics, 2009, EC COST SPINAL CORD, P31; Agency for Clinical Innovation, 2016, INV VOC PROGR OUTC P; Almeida OP, 2015, INT J GERIATR PSYCH, V30, P1215, DOI 10.1002/gps.4276; Andelic N, 2012, BRAIN INJURY, V26, P261, DOI 10.3109/02699052.2012.654589; Barbour RS, 2001, BMJ-BRIT MED J, V322, P1115, DOI 10.1136/bmj.322.7294.1115; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Braun V, 2013, SUCCESSFUL QUALITATI; Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]; Bush EJ, 2016, BRAIN INJURY, V30, P422, DOI 10.3109/02699052.2015.1131849; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Colantonio A, 2016, ARCH PHYS MED REHAB, V97, pS1, DOI 10.1016/j.apmr.2015.12.002; Creswell JW, 2009, RES DESIGNQUALITATIV; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; Donker-Cools BHPM, 2018, DISABIL REHABIL, V40, P185, DOI 10.1080/09638288.2016.1250118; Fadyl JK, 2009, J HEAD TRAUMA REHAB, V24, P195, DOI 10.1097/HTR.0b013e3181a0d458; Forslund MV, 2013, J REHABIL MED, V45, P801, DOI 10.2340/16501977-1168; Gagnon A, 2016, DISABIL REHABIL, V38, P433, DOI 10.3109/09638288.2015.1044035; Gilworth G, 2008, J REHABIL MED, V40, P334, DOI 10.2340/16501977-0169; Gilworth G, 2006, BRAIN INJURY, V20, P835, DOI 10.1080/02699050600832221; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Goverover Y, 2010, AM J OCCUP THER, V64, P540, DOI 10.5014/ajot.2010.09020; Graham C. W., 2016, CAMPBELL SYSTEMATIC, V2016, P6; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; Hart T, 2006, J HEAD TRAUMA REHAB, V21, P467, DOI 10.1097/00001199-200611000-00002; Hooson JM, 2013, NEUROPSYCHOL REHABIL, V23, P19, DOI 10.1080/09602011.2012.713314; Jourdan C, 2013, BRAIN INJURY, V27, P1000, DOI 10.3109/02699052.2013.794971; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Levack W, 2004, DISABIL REHABIL, V26, P290, DOI 10.1080/09638280310001647615; Liaset IF, 2016, SCAND J OCCUP THER, V23, P446, DOI 10.3109/11038128.2016.1152294; Little Deborah M, 2015, Handb Clin Neurol, V131, P465, DOI 10.1016/B978-0-444-62627-1.00027-5; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; Materne M, 2017, WORK, V56, P125, DOI 10.3233/WOR-162468; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; Mcrae P, 2016, AUST J REHABIL COUNS, V22, P76, DOI 10.1017/jrc.2016.14; Mitrushina M, 2019, NEUROPSYCHOL REHABIL, V29, P1313, DOI 10.1080/09602011.2017.1395746; Moller Claire-Lynn, 2017, S. Afr. j. occup. ther., V47, P17, DOI 10.17159/2310-3833/2017/v47n3a4; Murphy L, 2006, BRAIN INJURY, V20, P1119, DOI 10.1080/02699050600664335; Nightingale EJ, 2007, BRAIN IMPAIR, V8, P101, DOI [10.1375/brim.8.2.101, DOI 10.1375/BRIM.8.2.101]; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Phillips J., 2014, ADV CLIN NEUROSCIENC, V14, P1473; Ponsford J, 2014, J HEAD TRAUMA REHAB, V29, P321, DOI 10.1097/HTR.0000000000000072; Ponsford JL, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000033; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Rassovsky Y, 2015, J CLIN EXP NEUROPSYC, V37, P354, DOI 10.1080/13803395.2015.1015498; Ruddle JA., 2011, SOCIAL CARE NEURODIS, V2, P200, DOI [10.1108/20420911111188452, DOI 10.1108/20420911111188452]; Ryan GW, 2003, FIELD METHOD, V15, P85, DOI [DOI 10.1177/1525822X02239569, 10.1177/1525822X02239569]; SANDELOWSKI M, 1995, RES NURS HEALTH, V18, P371, DOI 10.1002/nur.4770180411; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Stergiou-Kita M, 2012, DISABIL REHABIL, V34, P179, DOI 10.3109/09638288.2011.591881; Stergiou-Kita M, 2011, J OCCUP REHABIL, V21, P374, DOI 10.1007/s10926-010-9282-0; Tam S, 2015, BRAIN INJURY, V29, P813, DOI 10.3109/02699052.2015.1005134; van Velzen JM, 2011, DISABIL REHABIL, V33, P2237, DOI 10.3109/09638288.2011.563821; Viera AJ, 2005, FAM MED, V37, P360; Williams MW, 2014, REHABIL PSYCHOL, V59, P298, DOI 10.1037/a0037164	56	12	12	8	12	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR 15	2020	30	3					412	429		10.1080/09602011.2018.1470987			18	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	MB2FW	WOS:000542421300003	29745289				2021-06-18	
J	Bernini, A; Masoodi, M; Solari, D; Miroz, JP; Carteron, L; Christinat, N; Morelli, P; Beaumont, M; Abed-Maillard, S; Hartweg, M; Foltzer, F; Eckert, P; Cuenoud, B; Oddo, M				Bernini, Adriano; Masoodi, Mojgan; Solari, Daria; Miroz, John-Paul; Carteron, Laurent; Christinat, Nicolas; Morelli, Paola; Beaumont, Maurice; Abed-Maillard, Samia; Hartweg, Mickael; Foltzer, Fabien; Eckert, Philippe; Cuenoud, Bernard; Oddo, Mauro			Modulation of cerebral ketone metabolism following traumatic brain injury in humans	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article; Proceedings Paper	Journal-of-Cerebral-Blood-Flow-and-Metabolism (JCBFM) Symposium at International Symposium on Cerebral Blood Flow, Metabolism and Function (BRAIN)	JUL 07, 2019	Yokohama, JAPAN	Journal Cerebral Blood Flow & Metab		Traumatic brain injury; ketones; cerebral metabolism; glucose; nutrition	CORTICAL IMPACT INJURY; KETOGENIC DIET; BETA-HYDROXYBUTYRATE; LACTATE INCREASE; GLUCOSE; HYPERKETONEMIA; MICRODIALYSIS; OXYGEN; ACID	Adaptive metabolic response to injury includes the utilization of alternative energy substrates - such as ketone bodies (KB) - to protect the brain against further damage. Here, we examined cerebral ketone metabolism in patients with traumatic brain injury (TBI; n = 34 subjects) monitored with cerebral microdialysis to measure total brain interstitial tissue KB levels (acetoacetate and beta-hydroxybutyrate). Nutrition - from fasting vs. stable nutrition state - was associated with a significant decrease of brain KB (34.7 [10th-90th percentiles 10.7-189] mu mol/L vs. 13.1 [6.5-64.3] mu mol/L, p < 0.001) and blood KB (668 [168.4-3824.9] vs. 129.4 [82.6-1033.8] mu mol/L, p < 0.01). Blood KB correlated with brain KB (Spearman's rho 0.56, p = 0.0013). Continuous feeding with medium-chain triglycerides-enriched enteral nutrition did not increase blood KB, and provided a modest increase in blood and brain free medium chain fatty acids. Higher brain KB at the acute TBI phase correlated with age and brain lactate, pyruvate and glutamate, but not brain glucose. These novel findings suggest that nutritional ketosis was the main determinant of cerebral KB metabolism following TBI. Age and cerebral metabolic distress contributed to brain KB supporting the hypothesis that ketones might act as alternative energy substrates to glucose. Further studies testing KB supplementation after TBI are warranted.	[Bernini, Adriano; Solari, Daria; Miroz, John-Paul; Carteron, Laurent; Morelli, Paola; Abed-Maillard, Samia; Eckert, Philippe; Oddo, Mauro] CHUV Univ Hosp, Dept Intens Care Med, Neurosci Crit Care Res Grp, Lausanne, Switzerland; [Bernini, Adriano; Solari, Daria; Miroz, John-Paul; Carteron, Laurent; Morelli, Paola; Abed-Maillard, Samia; Eckert, Philippe; Oddo, Mauro] Fac Biol & Med, Rue Bugnon 46, CH-1011 Lausanne, Switzerland; [Masoodi, Mojgan; Christinat, Nicolas] Nestle Inst Hlth Sci, Lausanne, Switzerland; [Beaumont, Maurice; Hartweg, Mickael; Foltzer, Fabien] Nestle Res Ctr, Clin Dev Unit, Lausanne, Switzerland; [Cuenoud, Bernard] Nestle Hlth Sci, Lausanne, Switzerland	Oddo, M (corresponding author), Fac Biol & Med, Rue Bugnon 46, CH-1011 Lausanne, Switzerland.; Oddo, M (corresponding author), CHUV Univ Hosp, Dept Intens Care Med, Rue Bugnon 46, CH-1011 Lausanne, Switzerland.	mauro.oddo@chuv.ch	Bernini, Adriano/AAR-7408-2020; Abed-Maillard, Samia/AAI-1052-2021; MIROZ, John-Paul/AAR-7445-2020	Bernini, Adriano/0000-0003-0207-0064; Hartweg, Mickael/0000-0002-2228-9103			Al-Dorzi HM, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1539-3; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Augustin K, 2018, LANCET NEUROL, V17, P84, DOI 10.1016/S1474-4422(17)30408-8; Bouteldja N, 2014, METABOLISM, V63, P1375, DOI 10.1016/j.metabol.2014.08.001; Brownlow ML, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00129; Casaer MP, 2015, LANCET DIABETES ENDO, V3, P734, DOI 10.1016/S2213-8587(15)00222-3; Chang P, 2016, BRAIN, V139, P431, DOI 10.1093/brain/awv325; Courchesne-Loyer A, 2017, J CEREBR BLOOD F MET, V37, P2485, DOI 10.1177/0271678X16669366; Cox PJ, 2016, CELL METAB, V24, P256, DOI 10.1016/j.cmet.2016.07.010; Croteau E, 2018, EXP GERONTOL, V107, P18, DOI 10.1016/j.exger.2017.07.004; Cunnane SC, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00053; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; Dienel GA, 2016, J CEREBR BLOOD F MET, V36, P1844, DOI 10.1177/0271678X16666552; Ghosh S, 2018, GLIA, V66, P1200, DOI 10.1002/glia.23271; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Jalloh I, 2015, J CEREBR BLOOD F MET, V35, P111, DOI 10.1038/jcbfm.2014.177; Jiang LH, 2011, J CEREBR BLOOD F MET, V31, P2313, DOI 10.1038/jcbfm.2011.91; LaManna JC, 2009, ADV EXP MED BIOL, V645, P301, DOI 10.1007/978-0-387-85998-9_45; LONDON ED, 1986, J GERONTOL, V41, P599, DOI 10.1093/geronj/41.5.599; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Magistretti PJ, 2018, NAT REV NEUROSCI, V19, P235, DOI 10.1038/nrn.2018.19; Mattson MP, 2018, NAT REV NEUROSCI, V19, P81, DOI 10.1038/nrn.2017.156; Morris AAM, 2005, J INHERIT METAB DIS, V28, P109, DOI 10.1007/s10545-005-5518-0; Neal EG, 2008, LANCET NEUROL, V7, P500, DOI 10.1016/S1474-4422(08)70092-9; Oddo M, 2018, INTENS CARE MED, V44, P1945, DOI 10.1007/s00134-017-5031-6; OWEN OE, 1974, METABOLISM, V23, P7, DOI 10.1016/0026-0495(74)90098-5; Pan JW, 2001, J NEUROCHEM, V79, P539, DOI 10.1046/j.1471-4159.2001.00575.x; Pan JW, 2000, J CEREBR BLOOD F MET, V20, P1502, DOI 10.1097/00004647-200010000-00012; Patet C, 2015, J NEUROTRAUM, V32, P1560, DOI 10.1089/neu.2014.3781; Prins M, 2008, EPILEPSIA, V49, P111, DOI 10.1111/j.1528-1167.2008.01852.x; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Prins ML, 2014, J LIPID RES, V55, P2450, DOI 10.1194/jlr.R046706; Prins ML, 2012, EPILEPSY RES, V100, P218, DOI 10.1016/j.eplepsyres.2011.09.027; Prins ML, 2009, J NEUROTRAUM, V26, P1083, DOI [10.1089/neu.2008.0769, 10.1089/neu.2008-0769]; Puchalska P, 2017, CELL METAB, V25, P262, DOI 10.1016/j.cmet.2016.12.022; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Samala R, 2011, NEUROCHEM INT, V58, P5, DOI 10.1016/j.neuint.2010.10.011; Stubbs BJ, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00848; Svart M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190556; Valdebenito R, 2016, J CEREBR BLOOD F MET, V36, P1813, DOI 10.1177/0271678X15613955; White H, 2017, NEUROL RES, V39, P1, DOI 10.1080/01616412.2016.1251695; White H, 2013, INTENS CARE MED, V39, P727, DOI 10.1007/s00134-012-2790-y; White H, 2011, CRIT CARE, V15, DOI 10.1186/cc10020; Wolahan SM, 2017, NEUROCRIT CARE, V26, P239, DOI 10.1007/s12028-016-0313-3; Xu K, 2017, ADV EXP MED BIOL, V977, P205, DOI 10.1007/978-3-319-55231-6_28; Zhang YF, 2013, J CEREBR BLOOD F MET, V33, P1307, DOI 10.1038/jcbfm.2013.87	47	12	12	2	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2020	40	1					177	186		10.1177/0271678X18808947			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	JX2IE	WOS:000503564000015	30353770	Green Published, Bronze			2021-06-18	
J	Bland, ML; McNally, C; Zuby, DS; Mueller, BC; Rowson, S				Bland, Megan L.; McNally, Craig; Zuby, David S.; Mueller, Becky C.; Rowson, Steven			Development of the STAR Evaluation System for Assessing Bicycle Helmet Protective Performance	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Concussion; Cycling; Injury risk; Impact; Biomechanics	HEAD-INJURY; REAL-WORLD; CONCUSSION; RISK	Cycling is a leading cause of mild traumatic brain injury in the US. While bicycle helmets help protect cyclists who crash, limited biomechanical data exist differentiating helmet protective capabilities. This paper describes the development of a bicycle helmet evaluation scheme based in real-world cyclist accidents and brain injury mechanisms. Thirty helmet models were subjected to oblique impacts at six helmet locations and two impact velocities. The summation of tests for the analysis of risk (STAR) equation, which condenses helmet performance from a range of tests into a single value, was used to summarize measured linear and rotational head kinematics in the context of concussion risk. STAR values varied between helmets (10.9-25.3), with lower values representing superior protection. Road helmets produced lower STAR values than urban helmets. Helmets with slip planes produced lower STAR values than helmets without. This bicycle helmet evaluation protocol can educate consumers on the relative impact performance of various helmets and stimulate safer helmet design.	[Bland, Megan L.; McNally, Craig; Rowson, Steven] Virginia Tech, Dept Biomed Engn & Mech, Ctr Injury Biomech, 440 Kelly Hall,325 Stanger St, Blacksburg, VA 24061 USA; [Zuby, David S.; Mueller, Becky C.] Insurance Inst Highway Safety, 988 Dairy Rd, Ruckersville, VA 22968 USA	Bland, ML (corresponding author), Virginia Tech, Dept Biomed Engn & Mech, Ctr Injury Biomech, 440 Kelly Hall,325 Stanger St, Blacksburg, VA 24061 USA.	mbland27@vt.edu	Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596	Virginia Tech Institute for Critical Technology and Applied Science (Blacksburg, VA); Insurance Institute for Highway Safety (Ruckersville, VA)	The authors would like to thank the Virginia Tech Institute for Critical Technology and Applied Science (Blacksburg, VA) and the Insurance Institute for Highway Safety (Ruckersville, VA) for their funding and support.	Bland M. L. C., 2018, IRCOBI C ATH GREEC, P413; Bland ML, 2018, J BIOMECH ENG-T ASME, V140, DOI 10.1115/1.4040019; Bland ML, 2018, TRAFFIC INJ PREV, V19, pS158, DOI 10.1080/15389588.2017.1388915; Bonugli E., 2015, THESIS; Bourdet N, 2014, INT J CRASHWORTHINES, V19, P222, DOI 10.1080/13588265.2013.805293; Butz RC, 2015, J BIOMECH, V48, P3816, DOI 10.1016/j.jbiomech.2015.09.032; Cobb BR, 2018, P I MECH ENG P-J SPO, V232, P176, DOI 10.1177/1754337117708092; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; ECE, 1999, R2205 ECE UN EC COMM; Eckersley C. P, 2017, P IRCOBI C ANTW BELG, P685; European Committee for Standardization, 1997, 1078 CEN EUR COMM ST; Fahlstedt M., 2016, IR1664; Fischer P., 2017, RIGHT ROAD UNDERSTAN; Gaither TW, 2018, INJURY PREV, V24, P135, DOI 10.1136/injuryprev-2016-042281; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; HARDY WN, 1994, INT J IMPACT ENG, V15, P561, DOI 10.1016/0734-743X(94)80034-7; King A.I., 2003, IRCOBI C LISB PORT, P1; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Laituri T. R., 2015, 2015011437 SAE; McIntosh AS, 2013, TRAFFIC INJ PREV, V14, P501, DOI 10.1080/15389588.2012.727217; Mertz Harold J, 2003, Stapp Car Crash J, V47, P155; Mills NJ, 2008, INT J IMPACT ENG, V35, P1075, DOI 10.1016/j.ijimpeng.2007.05.005; Mills NJ, 2010, INT J CRASHWORTHINES, V15, P331, DOI 10.1080/13588260903251000; Mills N J, 1990, Br J Sports Med, V24, P55; Milne G, 2014, INT J CRASHWORTHINES, V19, P323, DOI 10.1080/13588265.2013.859470; Nelson TS, 2010, TRAFFIC INJ PREV, V11, P309, DOI 10.1080/15389581003614870; Olivier J, 2017, INT J EPIDEMIOL, V46, P278, DOI 10.1093/ije/dyw153; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Peng Y, 2012, SAFETY SCI, V50, P1749, DOI 10.1016/j.ssci.2012.03.005; Rowson B, 2015, ANN BIOMED ENG, V43, P2429, DOI 10.1007/s10439-015-1278-7; Rowson S, 2016, SPORTS MED ARTHROSC, V24, P100, DOI 10.1097/JSA.0000000000000121; Rowson S, 2014, J NEUROSURG, V120, P919, DOI 10.3171/2014.1.JNS13916; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Sances A. J., BIOMED SCI INSTRUM, V38, P459; SMITH TA, 1994, ACCIDENT ANAL PREV, V26, P795, DOI 10.1016/0001-4575(94)90055-8; Stigson H., 2017, C P INT RES COUNC BI, P173; Verschueren P., 2009, BIOMECHANICAL ANAL H; WILLIAMS M, 1991, ACCIDENT ANAL PREV, V23, P119, DOI 10.1016/0001-4575(91)90043-5; Yu HY, 2019, J BIOMECH ENG-T ASME, V141, DOI 10.1115/1.4040944; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	43	12	12	1	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2020	48	1					47	57		10.1007/s10439-019-02330-0			11	Engineering, Biomedical	Engineering	KI8PN	WOS:000511620300007	31372859	Green Published, Other Gold			2021-06-18	
J	Eagle, SR; Kontos, AP; Pepping, GJ; Johnson, CD; Sinnott, A; Lagoy, A; Connaboy, C				Eagle, Shawn R.; Kontos, Anthony P.; Pepping, Gert-Jan; Johnson, Caleb D.; Sinnott, Aaron; Lagoy, Alice; Connaboy, Chris			Increased Risk of Musculoskeletal Injury Following Sport-Related Concussion: A Perception-Action Coupling Approach	SPORTS MEDICINE			English	Article							SUBSEQUENT INJURY; GAIT STABILITY; SCHEMA THEORY; ATTENTION; AFFORDANCES; CALIBRATION; INFORMATION; DISORDERS; CHILDREN; DEFICITS	Recent studies have concluded that athletes have increased risk of musculoskeletal injury following sport-related concussion. While an underlying explanation is still unknown, perceptual-motor control may be implicated in this increased risk. Some authors have purported that indirect perception (i.e., a "top-down" view of neuromuscular control) may be disrupted following sport-related concussion. Direct perception theory states that the athlete and environment are inextricably linked in a continuous perception-action coupling loop. That is, the athlete is able to directly perceive opportunities for action (e.g., "affordances") in the environment. Based on these notions, the aim of the current paper was to introduce a theoretical model that argues that sport-related concussion may dysregulate the direct perception process, potentially increasing behavioral risk of musculoskeletal injury during sport. Our model is integrated with a sport-related concussion clinical treatment model, which highlights individualized profiles that characterize the heterogeneous response to sport-related concussion. These profiles have a typical constellation of symptoms (e. g., anxiety, fatigue, ocular dysfunction, etc.), which themselves have been associated with disrupted perception-action coupling, independent of sport-related concussion. Therefore, we argue that athletes who have not re-established perception-action coupling loops following sport-related concussion may be at increased risk of subsequent musculoskeletal injury.	[Eagle, Shawn R.; Sinnott, Aaron; Lagoy, Alice; Connaboy, Chris] Univ Pittsburgh, Warrior Human Performance Res Ctr, Neuromuscular Res Lab, 3860 S Water St, Pittsburgh, PA 15203 USA; [Kontos, Anthony P.] Univ Pittsburgh, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, Pittsburgh, PA USA; [Pepping, Gert-Jan] Australian Catholic Univ, Sch Behav & Hlth Sci, Brisbane, Qld, Australia; [Johnson, Caleb D.] Harvard Univ, Harvard Med Sch, Spaulding Natl Running Ctr, Cambridge, MA 02138 USA	Eagle, SR (corresponding author), Univ Pittsburgh, Warrior Human Performance Res Ctr, Neuromuscular Res Lab, 3860 S Water St, Pittsburgh, PA 15203 USA.	seagle@pitt.edu	Connaboy, Christopher/AAH-4514-2020; Pepping, Gert-Jan/Y-8545-2019; Pepping, Gert-Jan/B-2197-2010; Eagle, Shawn/ABG-1388-2020	Connaboy, Christopher/0000-0002-9031-2192; Pepping, Gert-Jan/0000-0002-5926-2000; Pepping, Gert-Jan/0000-0002-5926-2000; Eagle, Shawn/0000-0001-6767-1042			Araujo D, 2019, INT REV SPORT EXER P, V12, P1, DOI 10.1080/1750984X.2017.1349826; Bernstein N. A., 1967, CONTROL REGULATION M; Bourrelly A, 2015, COGN PROCESS, V16, pS171, DOI 10.1007/s10339-015-0692-y; Brault S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037494; Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Burman E., 2016, BMJ OPEN SPORT EXERC, V2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Collins MW, 2016, NEUROSURGERY, V79, P912, DOI 10.1227/NEU.0000000000001447; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Connaboy C, 2019, AEROSP MED HUM PERF, V90, P77, DOI 10.3357/AMHP.5190.2019; Cordovil R, 2015, NEW IDEAS PSYCHOL, V36, P50, DOI 10.1016/j.newideapsych.2014.10.007; Craig CM, 2006, NATURWISSENSCHAFTEN, V93, P97, DOI 10.1007/s00114-005-0071-0; Cripps A, 2018, BRAIN INJURY, V32, P1566, DOI 10.1080/02699052.2018.1497812; Cross M, 2016, BRIT J SPORT MED, V50, P926, DOI 10.1136/bjsports-2015-094982; Daviaux Y, 2016, PSYCHOL RES-PSYCH FO, V80, P224, DOI 10.1007/s00426-015-0653-1; Daviaux Y, 2014, EXP BRAIN RES, V232, P2243, DOI 10.1007/s00221-014-3915-z; Davids K, 2003, SPORTS MED, V33, P245, DOI 10.2165/00007256-200333040-00001; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; Eagle SR, 2019, CLIN J SPORT MED, DOI [10.1097/jsm0000000000000731, DOI 10.1097/JSM0000000000000731]; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Fait P, 2009, BRAIN INJURY, V23, P362, DOI 10.1080/02699050902788485; Fajen BR, 2005, J EXP PSYCHOL HUMAN, V31, P480, DOI 10.1037/0096-1523.31.3.480; Fajen BR, 2005, PERCEPTION, V34, P717, DOI 10.1068/p5405; Fajen BR, 2007, ECOL PSYCHOL, V19, P383, DOI 10.1080/10407410701557877; Fajen BR, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00085; Fajen BR, 2011, HUM MOVEMENT SCI, V30, P504, DOI 10.1016/j.humov.2010.07.016; Fajen BR, 2009, INT J SPORT PSYCHOL, V40, P79; Fernandez-Ruiz J, 2000, COGNITIVE BRAIN RES, V9, P223, DOI 10.1016/S0926-6410(99)00057-9; Franchak JM, 2019, J EXP CHILD PSYCHOL, V183, P100, DOI 10.1016/j.jecp.2019.01.016; Gibson J.J., 1979, ECOLOGICAL APPROACH, P127; Gibson JJ., 1966, SENSES CONSIDERED PE; Gilbert FC, 2016, SPORTS HEALTH, V8, P661, DOI 10.1177/1941738116666509; Grants L, 2017, INT J SPORTS PHYS TH, V12, P1011, DOI 10.26603/ijspt20171011; Graydon MM, 2012, COGNITION EMOTION, V26, P1301, DOI 10.1080/02699931.2012.667391; Harmon KG, 2019, BRIT J SPORT MED, V53, P213, DOI 10.1136/bjsports-2018-100338; Herman DC, 2017, SPORTS MED, V47, P1003, DOI 10.1007/s40279-016-0607-9; Hirsh JB, 2012, PSYCHOL REV, V119, P304, DOI 10.1037/a0026767; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2018, SPORTS MED, V48, P1097, DOI 10.1007/s40279-018-0871-y; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Kontos A.P., 2018, CONCUSSION CLIN PROF; Kontos AP, 2019, CURR SPORT MED REP, V18, P82, DOI 10.1249/JSR.0000000000000573; Kontos AP, 2017, J ATHL TRAINING, V52, P256, DOI 10.4085/1062-6050-51.11.05; Kontos AP, 2016, BRAIN IMAGING BEHAV, V10, P594, DOI 10.1007/s11682-015-9412-6; Leddy J, 2017, J ATHL TRAINING, V52, P299, DOI 10.4085/1062-6050-51.11.08; Lopez C, 2012, NEUROPSYCHOLOGIA, V50, P1830, DOI 10.1016/j.neuropsychologia.2012.04.008; Lopez C, 2011, BRAIN RES REV, V67, P119, DOI 10.1016/j.brainresrev.2010.12.002; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Makdissi M, 2009, AM J SPORT MED, V37, P877, DOI 10.1177/0363546508328118; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McGuckian TB, 2019, ECOL PSYCHOL, V31, P30, DOI 10.1080/10407413.2018.1495548; McGuckian TB, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02520; McGuckian TB, 2018, J SPORT SCI, V36, P861, DOI 10.1080/02640414.2017.1344780; McPherson AL, 2019, AM J SPORT MED, V47, P1754, DOI 10.1177/0363546518785901; Michaels CF., 1981, DIRECT PERCEPTION; Moore DR, 2016, INT J PSYCHOPHYSIOL, V99, P85, DOI 10.1016/j.ijpsycho.2015.11.010; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Murdaugh DL, 2018, ARCH PHYS MED REHAB, V99, P960, DOI 10.1016/j.apmr.2018.01.005; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Nyberg G., 2015, CURRENT RES CONCUSSI, V2, P109; Palacios EM, 2017, J NEUROTRAUM, V34, P1546, DOI 10.1089/neu.2016.4752; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Pietrosimone B, 2015, MED SCI SPORT EXER, V47, P2366, DOI 10.1249/MSS.0000000000000684; Pijpers JR, 2007, J SPORT SCI, V25, P97, DOI 10.1080/02640410600630894; Pijpers JR, 2006, ECOL PSYCHOL, V18, P131, DOI 10.1207/s15326969eco1803_1; PLUMERT JM, 1995, DEV PSYCHOL, V31, P866, DOI 10.1037/0012-1649.31.5.866; Poltavski D, 2017, OPTOMETRY VISION SCI, V94, P742, DOI 10.1097/OPX.0000000000001094; SCHMIDT RA, 1975, PSYCHOL REV, V82, P225, DOI 10.1037/h0076770; Schmidt RA, 2003, RES Q EXERCISE SPORT, V74, P366, DOI 10.1080/02701367.2003.10609106; Tkachenko N, 2016, PEDIATR NEUROL, V57, P46, DOI 10.1016/j.pediatrneurol.2015.12.019; van Andel S, 2017, HUM MOVEMENT SCI, V51, P59, DOI 10.1016/j.humov.2016.11.004; Watson G, 2011, HUM MOVEMENT SCI, V30, P942, DOI 10.1016/j.humov.2010.08.004; Withagen R, 2012, NEW IDEAS PSYCHOL, V30, P250, DOI 10.1016/j.newideapsych.2011.12.003	75	12	12	1	2	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.	JAN	2020	50	1					15	23		10.1007/s40279-019-01144-3			9	Sport Sciences	Sport Sciences	KH7QB	WOS:000510843600002	31228023				2021-06-18	
J	Wettervik, TS; Howells, T; Hillered, L; Nilsson, P; Engquist, H; Lewen, A; Enblad, P; Rostami, E				Wettervik, Teodor Svedung; Howells, Timothy; Hillered, Lars; Nilsson, Pelle; Engquist, Henrik; Lewen, Anders; Enblad, Per; Rostami, Elham			Mild Hyperventilation in Traumatic Brain Injury-Relation to Cerebral Energy Metabolism, Pressure Autoregulation, and Clinical Outcome	WORLD NEUROSURGERY			English	Article						Cerebral energy metabolism; Clinical outcome; Hyperventilation; Neurointensive care; Pressure reactivity; Traumatic brain injury	SEVERE HEAD-INJURY; BLOOD-FLOW; PROLONGED HYPERVENTILATION; MODERATE HYPERVENTILATION; NEUROINTENSIVE CARE; REACTIVITY; MANAGEMENT; THERAPY	OBJECTIVE: Hyperventilation is a controversial treatment in traumatic brain injury (TBI). Prophylactic severe hyperventilation (below 3.3 kPa/25 mm Hg) is generally avoided, due to the risk of cerebral ischemia. Mild hyperventilation (arterial pCO(2) within 4.0-4.5 kPa/30-34 mm Hg) in cases of intracranial hypertension is commonly used, but its safety and benefits are not fully elucidated. The aim of this study was to evaluate the use of mild hyperventilation and its relation to cerebral energy metabolism, pressure autoregulation, and clinical outcome in TBI. METHODS: This retrospective study was based on 120 patients with severe TBI treated at the neurointensive care unit, Uppsala University Hospital, Sweden, between 2008 and 2018. Data from cerebral microdialysis (glucose, pyruvate, and lactate), arterial pCO(2), and pressure reactivity index were analyzed for the first 3 days post-injury. RESULTS: Mild hyperventilation, 4.0-4.5 kPa (30-34 mm Hg), was more frequently used early and the patients were gradually normoventilated. Low pCO(2) was associated with slightly higher intracranial pressure and slightly lower cerebral perfusion pressure (P < 0.01). There was no univariate correlation between low pCO(2) and worse cerebral energy metabolism. Multiple linear regression analysis showed that mild hyperventilation was associated with lower pressure reactivity index on day 2 (P = 0.03), suggesting better pressure autoregulation. Younger age and lower intracranial pressure were also associated with lower pressure reactivity index. CONCLUSIONS: These findings support the notion that mild hyperventilation is safe and may improve cerebravascular reactivity.	[Wettervik, Teodor Svedung; Howells, Timothy; Hillered, Lars; Nilsson, Pelle; Lewen, Anders; Enblad, Per; Rostami, Elham] Uppsala Univ, Dept Neurosci, Sect Neurosurg, Uppsala, Sweden; [Engquist, Henrik] Uppsala Univ, Dept Surg Sci Anesthesia & Intens Care, Uppsala, Sweden	Wettervik, TS (corresponding author), Uppsala Univ, Dept Neurosci, Sect Neurosurg, Uppsala, Sweden.	teodor.svedung-wettervik@neuro.uu.se	Wettervik, Teodor Mikael Svedung/S-5356-2017	Engquist, Henrik/0000-0002-9826-1422; enblad, per/0000-0003-4364-1919			Brandi G, 2019, CRIT CARE, V23, DOI 10.1186/s13054-018-2304-6; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Carrera E, 2010, J NEUROL NEUROSUR PS, V81, P793, DOI 10.1136/jnnp.2009.174425; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Godoy DA, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00250; Haubrich Christina, 2012, Acta Neurochir Suppl, V114, P153, DOI 10.1007/978-3-7091-0956-4_28; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Howells T, 2015, J CLIN MONIT COMPUT, V29, P97, DOI 10.1007/s10877-014-9573-7; KONTOS HA, 1977, STROKE, V8, P358, DOI 10.1161/01.STR.8.3.358; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; Marklund N, 2014, J NEUROTRAUM, V31, P42, DOI 10.1089/neu.2013.2964; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUIZELAAR JP, 1988, J NEUROSURG, V69, P923, DOI 10.3171/jns.1988.69.6.0923; Neumann JO, 2008, INTENS CARE MED, V34, P1676, DOI 10.1007/s00134-008-1123-7; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; Nyholm L, 2013, UPSALA J MED SCI, V118, P169, DOI 10.3109/03009734.2013.806616; Piechnik SK, 1999, ANESTH ANALG, V89, P944, DOI 10.1097/00000539-199910000-00023; Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397; Steiner LA, 2005, ACTA NEUROCHIR SUPPL, V95, P17; STRINGER WA, 1993, AM J NEURORADIOL, V14, P475; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Wettervik TS, 2019, J NEUROTRAUM, V36, P1818, DOI 10.1089/neu.2018.6157; Wilson JL, 1988, J NEUROTRAUM, V15, P573; Zhang Y, 2016, ACTA NEUROCHIR SUPPL, V122, P205, DOI 10.1007/978-3-319-22533-3_41	30	12	12	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JAN	2020	133						E567	E575		10.1016/j.wneu.2019.09.099			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	JX8QN	WOS:000503993700118	31561041				2021-06-18	
J	Guan, FX; Zhou, XK; Li, P; Wang, YP; Liu, M; Li, FF; Cui, YB; Huang, TJ; Yao, MH; Zhang, YT; Ma, JJ; Ma, SS				Guan, Fangxia; Zhou, Xinkui; Li, Peng; Wang, Yaping; Liu, Ming; Li, Fangfang; Cui, Yuanbo; Huang, Tuanjie; Yao, Minghao; Zhang, Yanting; Ma, Jianjie; Ma, Shanshan			MG53 attenuates lipopolysaccharide-induced neurotoxicity and neuroinflammation via inhibiting TLR4/NF-kappa B pathway in vitro and in vivo	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY			English	Article						MG53 protein; Lipopolysaccharide; Neurotoxicity; Cognitive impairment; TLR4/NF-kappa B pathway	TRAUMATIC BRAIN-INJURY; TOLL-LIKE RECEPTORS; NF-KAPPA-B; MEMBRANE REPAIR; ALZHEIMERS-DISEASE; MICE; (-)-EPICATECHIN; MICROGLIA	Neuroinflammation plays important roles in the pathogenesis and development of neurodegenerative disorders. Lipopolysaccharide (LPS) induces neuroinflammation and causes neurotoxicity, which results in cell damage or memory impairment in different cells and animals. In the present study, we investigated the neuroprotective effects of MG53, a member of the TRIM family proteins, against LPS-induced neuroinflammation and neurotoxicity in vitro and in vivo. MG53 significantly protected HT22 cells against LPS-induced cell apoptosis and cell cycle arrest by inhibiting TNF-alpha, IL-6 and IL-1 beta expression. In addition, MG53 ameliorated LPS-induced memory impairment and neuronal cell death in mice. Interestingly, MG53 significantly promoted newborn cell survival, improved neurogenesis, and mitigated neuroinflammation evidenced by lower production of IL-1 beta and IL-6, less activation of microglia in the hippocampus of LPS treated mice. Further studies demonstrated that MG53 significantly inhibited TLR4 expression and nuclear factor-kappa B (NF-kappa B) phosphorylation in LPS treated HT22 cells and mice. Taken together, our results suggested that MG53 attenuated LPS-induced neurotoxicity and neuroinflammation partly by inhibiting TLR4/NF-kappa B pathway in vitro and in vivo.	[Guan, Fangxia; Zhou, Xinkui; Li, Peng; Wang, Yaping; Liu, Ming; Li, Fangfang; Cui, Yuanbo; Huang, Tuanjie; Yao, Minghao; Zhang, Yanting; Ma, Shanshan] Zhengzhou Univ, Sch Life Sci, 100 Sci Ave, Zhengzhou 450001, Henan, Peoples R China; [Guan, Fangxia] Henan Prov Peoples Hosp, Zhengzhou 450003, Henan, Peoples R China; [Li, Peng] Zhumadian Hosp Tradit Chinese Med, Clin Lab, Zhumadian 463000, Henan, Peoples R China; [Ma, Jianjie] Ohio State Univ, Davis Heart & Lung Res Inst, Dept Surg, Columbus, OH 43210 USA	Ma, SS (corresponding author), Zhengzhou Univ, Sch Life Sci, 100 Sci Ave, Zhengzhou 450001, Henan, Peoples R China.; Ma, JJ (corresponding author), Ohio State Univ, Davis Heart & Lung Res Inst, Dept Surg, Columbus, OH 43210 USA.	Jianjie.Ma@osumc.edu; mss@zzu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81601078]; Science and Technology Research Project form Henan Province [152102310272]; Key Research Project of Higher Education of Henan Province [17A310012]; US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1-AR061385, RO1-DK106394, RO1-AR070752]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR061385, R01AR070752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK106394] Funding Source: NIH RePORTER	This study was supported by the National Natural Science Foundation of China (81601078), Science and Technology Research Project form Henan Province (152102310272), the Key Research Project of Higher Education of Henan Province (17A310012). US National Institutes of Health (RO1-AR061385, RO1-DK106394 and RO1-AR070752).	Backhed F, 2003, MICROBES INFECT, V5, P1057, DOI 10.1016/S1286-4579(03)00207-7; Bansal D, 2004, TRENDS CELL BIOL, V14, P206, DOI 10.1016/j.tcb.2004.03.001; Barcia C, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.17; Cai CX, 2009, J BIOL CHEM, V284, P15894, DOI 10.1074/jbc.M109.009589; Cai CX, 2009, NAT CELL BIOL, V11, P56, DOI 10.1038/ncb1812; Cao CM, 2010, CIRCULATION, V121, P2565, DOI 10.1161/CIRCULATIONAHA.110.954628; Cheng T, 2016, FREE RADICAL BIO MED, V92, P15, DOI 10.1016/j.freeradbiomed.2015.12.027; Cheng X, 2018, INT IMMUNOPHARMACOL, V56, P29, DOI 10.1016/j.intimp.2018.01.002; Choi YH, 2019, GEN PHYSIOL BIOPHYS, V38, P111, DOI 10.4149/gpb-2018044; Cui YB, 2017, BEHAV BRAIN RES, V320, P291, DOI 10.1016/j.bbr.2016.12.021; de Miranda AS, 2017, J NEUROL SCI, V372, P482, DOI 10.1016/j.jns.2016.10.052; Prince PD, 2017, REDOX BIOL, V11, P342, DOI 10.1016/j.redox.2016.12.023; Du SH, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00409; Duann P, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010755; Gao HW, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.389; Gao W, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00508; Heredia L, 2014, J PHARMACOL TOX MET, V69, P108, DOI 10.1016/j.vascn.2013.12.005; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Jia YL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5387; Johnson Victoria E, 2015, Handb Clin Neurol, V127, P115, DOI 10.1016/B978-0-444-52892-6.00008-8; Khan A, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01383; Khan S, 2018, CANCER CHEMOTH PHARM, V82, P31, DOI 10.1007/s00280-018-3605-9; Koh EJ, 2017, MOLECULES, V22, DOI 10.3390/molecules22081363; Lane CA, 2018, EUR J NEUROL, V25, P59, DOI 10.1111/ene.13439; Lee DS, 2014, EUR J PHARMACOL, V728, P1, DOI 10.1016/j.ejphar.2013.12.041; Li YT, 2015, BIOCHEM BIOPH RES CO, V458, P763, DOI 10.1016/j.bbrc.2015.01.155; Lim KH, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011247; Ma SS, 2014, MOL CELL BIOCHEM, V385, P277, DOI 10.1007/s11010-013-1836-y; McElhanon KE, 2018, LIFE SCI, V192, P166, DOI 10.1016/j.lfs.2017.11.035; Mouton PR, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.09.025; Muccigrosso MM, 2016, BRAIN BEHAV IMMUN, V54, P95, DOI 10.1016/j.bbi.2016.01.009; Musa NH, 2017, J DAIRY RES, V84, P488, DOI 10.1017/S0022029917000620; Ngwenya LB, 2019, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.01014; Nyati KK, 2017, NUCLEIC ACIDS RES, V45, P2687, DOI 10.1093/nar/gkx064; Ramon-Canellas P, 2019, NEUROSCIENCE, V399, P39, DOI 10.1016/j.neuroscience.2018.12.014; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Sawikr Y, 2017, ADV PROTEIN CHEM STR, V108, P33, DOI 10.1016/bs.apcsb.2017.02.001; Shih RH, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00077; Shirjang S, 2017, CELL IMMUNOL, V315, P1, DOI 10.1016/j.cellimm.2016.12.005; Sun JH, 2015, MOL PHARMACOL, V88, P437, DOI 10.1124/mol.115.098269; Ha VT, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/354843; Vu A, 2017, EUR J PHARMACOL, V808, P1, DOI 10.1016/j.ejphar.2016.10.018; Wang XX, 2018, BEHAV BRAIN RES, V339, P297, DOI 10.1016/j.bbr.2017.10.032; Wang XX, 2016, MOL CELLS, V39, P418, DOI 10.14348/molcells.2016.2345; Weisleder Noah, 2009, Commun Integr Biol, V2, P225; Weisleder N, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003921; Wu X, 2019, PROG NEURO-PSYCHOPH, V88, P360, DOI 10.1016/j.pnpbp.2018.08.016; Xu L, 2019, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00498; Yao YG, 2016, ONCOTARGET, V7, P22474, DOI 10.18632/oncotarget.7965; Yuan X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.334; Zhang Y, 2011, CARDIOVASC RES, V91, P108, DOI 10.1093/cvr/cvr029; Zhao M, 2014, NEUROSCIENCE, V269, P93, DOI 10.1016/j.neuroscience.2014.03.039	52	12	12	2	93	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0278-5846	1878-4216		PROG NEURO-PSYCHOPH	Prog. Neuro-Psychopharmacol. Biol. Psychiatry	DEC 20	2019	95								109684	10.1016/j.pnpbp.2019.109684			11	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	IZ6PL	WOS:000487204500014	31260721	Green Accepted			2021-06-18	
J	Broglio, SP; Harezlak, J; Katz, B; Zhao, S; McAllister, T; McCrea, M; Hazzard, J; Kelly, L; Campbell, D; Jackson, J; McGinty, G; O'Donnell, P; Cameron, K; Susmarski, A; Goldman, J; Giza, C; Buckley, T; Kaminski, T; Clugston, J; Schmidt, J; Feigenbaum, L; Eckner, JT; Anderson, S; Master, C; Kontos, A; Chrisman, S; Brooks, A				Broglio, Steven P.; Harezlak, Jaroslaw; Katz, Barry; Zhao, Shi; McAllister, Thomas; McCrea, Michael; Hazzard, Joseph; Kelly, Louise; Campbell, Darren; Jackson, Jonathan; McGinty, Gerald; O'Donnell, Patrick; Cameron, Kenneth; Susmarski, Adam; Goldman, Josh; Giza, Christopher; Buckley, Thomas; Kaminski, Thomas; Clugston, James; Schmidt, Julianne; Feigenbaum, Luis; Eckner, James T.; Anderson, Scott; Master, Christina; Kontos, Anthony; Chrisman, Sara; Brooks, Alison		CARE Consortium Investigators	Acute Sport Concussion Assessment Optimization: A Prospective Assessment from the CARE Consortium	SPORTS MEDICINE			English	Article							HIGH-SCHOOL; POSITION STATEMENT; RELIABILITY; MANAGEMENT; RECOVERY; VALIDITY	Background Numerous medical organizations recommend a multifaceted approach to the assessment of concussion occurring during sporting events. A number of tools are available to clinicians, with a wide breadth of sensitivity and specificity; however, little work has been done to evaluate the combined efficiency of these tools in concussed male and female athletes from a broad array of collegiate sports and with variable time from the pre-season baseline evaluation. Objective The aim of this study was to optimize the concussion assessment battery for application within the first 72 h of injury, and to identify the necessary baseline retesting frequency. Methods Between 2014 and 2017, a total of 1458 National Collegiate Athletic Association (NCAA) athletes sustaining 1640 diagnosed concussions completed a baseline assessment each year of the investigation and were evaluated up to three times within the first 72 h of injury using a standardized assessment protocol. Classification and regression tree analyses were implemented to identify the most efficient multifaceted assessment pathway to quantify concussion-related outcomes. Results were optimized for assessments occurring within 1 h post-injury, 1-24 h post-injury, and 24-72 h post-injury when using the raw post-injury assessment performance, difference scores from baseline evaluations occurring in the same year, and difference scores from baseline evaluations occurring the year prior. Results At each of the assessment time points, the analyses indicated that alone or in combination, a symptom evaluation, Balance Error Scoring System (BESS) scores collected on the firm surface, and Standardized Assessment of Concussion (SAC) total score offered the best overall performance when compared with pre-morbid performance captured in the same season. Optimized sensitivity of the multifaceted approach was 61% within 1 h of injury, 67% at the 1-24 h interval, and 55% at the 24-72 h interval when difference scores from the same-season baseline were available. Conclusions This investigation identified key concussion assessments in quantifying post-concussion performance among student athletes, that were maximized when same-season pre-morbid evaluations were available. Consistent with clinical recommendations, medical professionals should continue to focus on symptom reporting, postural control, and neurocognitive screening to support the clinical examination when making a concussion diagnosis.	[Broglio, Steven P.] Univ Michigan, Michigan Concuss Ctr, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA; [Harezlak, Jaroslaw] Indiana Univ, Dept Epidemiol & Biostat, Bloomington, IN USA; [Katz, Barry] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA; [Zhao, Shi] Eli Lilly & Co, Indianapolis, IN 46285 USA; [McAllister, Thomas] Indiana Univ, Dept Psychiat, Bloomington, IN USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Hazzard, Joseph] Bloomsburg Univ, Bloomsburg, PA USA; [Kelly, Louise] Calif Lutheran Univ, Thousand Oaks, CA USA; [Campbell, Darren; Jackson, Jonathan; McGinty, Gerald] US Air Force Acad, Washington, DC USA; [O'Donnell, Patrick] US Coast Guard Acad, New London, CT USA; [Cameron, Kenneth] US Mil Acad, West Point, NY 10996 USA; [Susmarski, Adam] US Naval Acad, Annapolis, MD 21402 USA; [Goldman, Josh; Giza, Christopher] Univ Calif Los Angeles, Los Angeles, CA USA; [Buckley, Thomas; Kaminski, Thomas] Univ Delaware, Newark, DE 19716 USA; [Clugston, James] Univ Florida, Gainesville, FL 32611 USA; [Schmidt, Julianne] Univ Georgia, Athens, GA 30602 USA; [Feigenbaum, Luis] Univ Miami, Coral Gables, FL 33124 USA; [Eckner, James T.] Univ Michigan, Ann Arbor, MI 48109 USA; [Anderson, Scott] Univ Oklahoma, Norman, OK 73019 USA; [Master, Christina] Univ Penn, Philadelphia, PA 19104 USA; [Kontos, Anthony] Univ Pittsburgh, Pittsburgh, PA 15260 USA; [Chrisman, Sara] Univ Washington, Seattle, WA 98195 USA; [Brooks, Alison] Univ Wisconsin, Madison, WI 53706 USA	Broglio, SP (corresponding author), Univ Michigan, Michigan Concuss Ctr, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA.	broglio@umich.edu	Buckley, Thomas A/B-7525-2016; Harezlak, Jaroslaw/P-8557-2014	Buckley, Thomas A/0000-0002-0515-0150; Chrisman, Sara/0000-0001-5373-7223; Susmarski, Adam/0000-0003-3698-4163; Master, Christina/0000-0002-6717-4270; Harezlak, Jaroslaw/0000-0002-3070-7686; Clugston, James/0000-0002-2103-1039; Cameron, Kenneth/0000-0002-6276-4482	Grand Alliance CARE Consortium - NCAA; Department of DefenseUnited States Department of Defense; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]; US Army Medical Research Acquisition Activity, Chandler Street, Fort Detrick, MD, USA	This publication was made possible, in part, by support from the Grand Alliance CARE Consortium, funded by the NCAA and the Department of Defense. The US Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014, USA, is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award no. W81XWH-14-2-0151. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense (Defense Health Program funds).	[Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2018, SPORTS MED, V48, P1255, DOI 10.1007/s40279-017-0813-0; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brooks BL, 2016, AM J SPORT MED, V44, P3243, DOI 10.1177/0363546516655095; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Chin EY, 2016, AM J SPORT MED, V44, P2276, DOI 10.1177/0363546516648141; Davis GA, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097415; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P848, DOI 10.1136/bjsports-2017-097506; Garcia GGP, 2018, SPORTS MED, V48, P1739, DOI 10.1007/s40279-018-0880-x; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Harmon KG, 2019, BRIT J SPORT MED, V53, P213, DOI 10.1136/bjsports-2018-100338; Hunt TN, 2009, J ATHL TRAINING, V44, P405, DOI 10.4085/1062-6050-44.4.405; Kerr ZY, 2016, AM J SPORT MED, V44, P220, DOI 10.1177/0363546515612082; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Resch JE, 2013, NEUROPSYCHOL REV, V23, P335, DOI 10.1007/s11065-013-9242-5; Resch JE., 2016, BMJ OPEN SPORT EXERC, V2, P000012, DOI [10.1136/bmjsem-2015-000012, DOI 10.1136/BMJSEM-2015-000012]; Williams RM, 2015, SPORTS MED, V45, P893, DOI 10.1007/s40279-015-0325-8; Zimmer A, 2013, J ATHL TRAINING, V48, P659, DOI 10.4085/1062-6050-48.5.06	24	12	12	0	9	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.	DEC	2019	49	12					1977	1987		10.1007/s40279-019-01155-0			11	Sport Sciences	Sport Sciences	JM2BT	WOS:000496026500012	31347086				2021-06-18	
J	Myer, GD; Foss, KB; Thomas, S; Galloway, R; DiCesare, CA; Dudley, J; Gadd, B; Leach, J; Smith, D; Gubanich, P; Meehan, WP; Altaye, M; Lavin, P; Yuan, WH				Myer, Gregory D.; Foss, Kim Barber; Thomas, Staci; Galloway, Ryan; DiCesare, Christopher A.; Dudley, Jonathan; Gadd, Brooke; Leach, James; Smith, David; Gubanich, Paul; Meehan, William P., III; Altaye, Mekibib; Lavin, Philip; Yuan, Weihong			Altered brain microstructure in association with repetitive subconcussive head impacts and the potential protective effect of jugular vein compression: a longitudinal study of female soccer athletes	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORTS-RELATED CONCUSSION; WHITE-MATTER DEVELOPMENT; DEFAULT MODE NETWORK; STATES HIGH-SCHOOL; DIFFUSION-TENSOR; SEX-DIFFERENCES; SPATIAL STATISTICS; CORPUS-CALLOSUM; INJURY; ADOLESCENCE	Purpose To (1) quantify white matter (WM) alterations in female high school athletes during a soccer season and characterise the potential for normalisation during the off-season rest period, (2) determine the association between WM alterations and exposure to repetitive subconcussive head impacts, and (3) evaluate the efficacy of a jugular vein compression collar to prevent WM alterations associated with head impact exposure. Methods Diffusion tensor imaging (DTI) data were prospectively collected from high school female soccer participants (14-18 years) at up to three time points over 9 months. Head impacts were monitored using accelerometers during all practices and games. Participants were assigned to a collar (n=24) or non-collar group (n=22). The Tract-Based Spatial Statistics approach was used in the analysis of within-group longitudinal change and between-group comparisons. Results DTI analyses revealed significant pre-season to post-season WM changes in the non-collar group in mean diffusivity (2.83%+/- 2.46%), axial diffusivity (2.58%+/- 2.34%) and radial diffusivity (3.52%+/- 2.60%), but there was no significant change in the collar group despite similar head impact exposure. Significant correlation was found between head impact exposure and pre-season to post-season DTI changes in the non-collar group. WM changes in the non-collar group partially resolved at 3 months off-season follow-up. Discussion Microstructural changes in WM occurred during a season of female high school soccer among athletes who did not wear the collar device. In comparison, there were no changes in players who wore the collar, suggesting a potential prophylactic effect of the collar device in preventing changes associated with repetitive head impacts. In those without collar use, the microstructural changes showed a reversal towards normal over time in the off-season follow-up period.	[Myer, Gregory D.; Foss, Kim Barber; Thomas, Staci; Galloway, Ryan; DiCesare, Christopher A.; Gadd, Brooke; Smith, David; Gubanich, Paul] Cincinnati Childrens Hosp Med Ctr, SPORT Ctr, Div Sports Med, Cincinnati, OH 45229 USA; [Myer, Gregory D.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Myer, Gregory D.] Univ Cincinnati, Coll Med, Dept Orthopaed Surg, Cincinnati, OH USA; [Myer, Gregory D.; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Myer, Gregory D.] Duke Univ, Sch Med, Durham, NC USA; [Galloway, Ryan; Yuan, Weihong] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Dudley, Jonathan; Yuan, Weihong] Cincinnati Childrens Hosp Med Ctr, Pediat Neuroimaging Res Consortium, Cincinnati, OH 45229 USA; [Leach, James] Cincinnati Childrens Hosp Med Ctr, Div Radiol, Cincinnati, OH 45229 USA; [Altaye, Mekibib] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Lavin, Philip] Boston Biostat Res Fdn, Framingham, MA USA	Myer, GD (corresponding author), Cincinnati Childrens Hosp, 3333 Burnet Ave,MLC 10001, Cincinnati, OH 45229 USA.	greg.myer@cchmc.org	DiCesare, Christopher/ABH-9573-2020; DiCesare, Christopher/AAA-3327-2021; Myer, Gregory/H-6572-2016	DiCesare, Christopher/0000-0002-6576-4904; Myer, Gregory/0000-0002-9983-8422; Dudley, Jonathan/0000-0002-5189-9568	Heidt Family Foundation; Robert S Heidt Sr Wellington Foundation; Q30 Sports Sciences, LLC	The authors acknowledge funding support from The Heidt Family Foundation, Robert S Heidt Sr Wellington Foundation and Q30 Sports Sciences, LLC.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Abbas K, 2015, DEV NEUROPSYCHOL, V40, P51, DOI 10.1080/87565641.2014.990455; Allison MA, 2015, ANN BIOMED ENG, V43, P1896, DOI 10.1007/s10439-014-1197-z; Aoki Y, 2016, NEUROSCI BIOBEHAV R, V66, P119, DOI 10.1016/j.neubiorev.2016.04.021; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Barnea-Goraly N, 2005, CEREB CORTEX, V15, P1848, DOI 10.1093/cercor/bhi062; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Berz K, 2013, PHYSICIAN SPORTSMED, V41, P58, DOI 10.3810/psm.2013.05.2015; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Campbell KR, 2016, ANN BIOMED ENG, V44, P1246, DOI 10.1007/s10439-015-1391-7; Chamard E, 2016, J NEUROTRAUM, V33, P1220, DOI 10.1089/neu.2015.3948; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Cortes N, 2017, AM J SPORT MED, V45, P2379, DOI 10.1177/0363546517706703; Covassin T, 2016, J ATHL TRAINING, V51, P189, DOI 10.4085/1062-6050-51.3.05; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Kemp S, 2016, BRAIN INJURY, V30, P1068, DOI 10.3109/02699052.2016.1148776; Khodaee M, 2017, BR J SPORTS MED, V51; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koolschijn PCMP, 2013, DEV COGN NEUROS-NETH, V5, P106, DOI 10.1016/j.dcn.2013.02.003; Leach J, 2018, VANC BC AM SOC NEUR; Leach JL, 2013, AM SOC NEUR ANN M; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Madhyastha T, 2014, HUM BRAIN MAPP, V35, P4544, DOI 10.1002/hbm.22493; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Markey KA, 2016, J PAIN RES, V9, P223, DOI 10.2147/JPR.S80824; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; Mori S., 2005, MRI ATLAS HUMAN WHIT; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Myer GD, 2016, BRIT J SPORT MED, V50, P1276, DOI 10.1136/bjsports-2016-096134; Myer GD, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00074; Narayana PA, 2015, NEUROIMAGE-CLIN, V7, P87, DOI 10.1016/j.nicl.2014.07.010; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Robinson S, 2017, J NEUROSCI RES, V95, P1025, DOI 10.1002/jnr.23848; Sandel NK, 2017, AM J SPORT MED, V45, P937, DOI 10.1177/0363546516677246; Schmithorst VJ, 2002, RADIOLOGY, V222, P212, DOI 10.1148/radiol.2221010626; Seunarine KK, 2016, BRAIN CONNECT, V6, P37, DOI 10.1089/brain.2015.0340; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Smith D, 2018, FRONT PHYS, V6, DOI 10.3389/fphy.2018.00093; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Strain JF, 2017, J NEUROTRAUM, V34, P372, DOI 10.1089/neu.2016.4446; Svaldi DO, 2017, BRAIN IMAGING BEHAV, V11, P98, DOI 10.1007/s11682-016-9509-6; Svaldi DO, 2015, DEV NEUROPSYCHOL, V40, P80, DOI 10.1080/87565641.2014.973959; Szeszko PR, 2003, NEUROREPORT, V14, P2469, DOI 10.1097/00001756-200312190-00035; Tournier JD, 2011, MAGN RESON MED, V65, P1532, DOI 10.1002/mrm.22924; Vann Jones SA, 2014, BR J SPORTS MED, V48; Veeramuthu V, 2015, J NEUROTRAUM, V32, P1497, DOI 10.1089/neu.2014.3750; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wang YY, 2012, BRAIN RES, V1478, P1, DOI 10.1016/j.brainres.2012.08.038; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Wunderle K, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000006; Yang YL, 2009, PSYCHIAT RES-NEUROIM, V174, P81, DOI 10.1016/j.pscychresns.2009.03.012; Yeh PH, 2017, HUM BRAIN MAPP, V38, P352, DOI 10.1002/hbm.23365; Yuan WH, 2018, HUM BRAIN MAPP, V39, P491, DOI 10.1002/hbm.23859; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	70	12	12	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	DEC	2019	53	24					1539	+		10.1136/bjsports-2018-099571			14	Sport Sciences	Sport Sciences	JX6FI	WOS:000503828000009	30323056				2021-06-18	
J	Poynter, K; Boone, KB; Ermshar, A; Miora, D; Cottingham, M; Victor, TL; Ziegler, E; Zeller, MA; Wright, M				Poynter, Kellie; Boone, Kyle Brauer; Ermshar, Annette; Miora, Deborah; Cottingham, Maria; Victor, Tara L.; Ziegler, Elizabeth; Zeller, Michelle A.; Wright, Matthew			Wait, There's a Baby in this Bath Water! Update on Quantitative and Qualitative Cut-Offs for Rey 15-Item Recall and Recognition	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Rey 15-item plus recognition; Performance validity; Malingering	TRAUMATIC BRAIN-INJURY; CROSS-VALIDATION; MEMORY TEST; B TEST; PERFORMANCE; SPECIFICITY; SENSITIVITY; SCORES; TRIAL; NEUROPSYCHOLOGISTS	Objective: Evaluate the effectiveness of Rey 15-item plus recognition data in a large neuropsychological sample. Method: Rey 15-item plus recognition scores were compared in credible (n = 138) and noncredible (n = 353) neuropsychology referrals. Results: Noncredible patients scored significantly worse than credible patients on all Rey 15-item plus recognition scores. When cut-offs were selected to maintain at least 89.9% specificity, cut-offs could be made more stringent, with the highest sensitivity found for recognition correct (cut-off <= 11; 62.6% sensitivity) and the combination score (recall + recognition - false positives; cut-off <= 22; 60.6% sensitivity), followed by recall correct (cut-off <= 11; 49.3% sensitivity), and recognition false positive errors (>= 3; 17.9% sensitivity). A cut-off of >= 4 applied to a summed qualitative error score for the recall trial resulted in 19.4% sensitivity. Approximately 10% of credible subjects failed either recall correct or recognition correct, whereas two-thirds of noncredible patients (67.7%) showed this pattern. Thirteen percent of credible patients failed either recall correct, recognition correct, or the recall qualitative error score, whereas nearly 70% of noncredible patients failed at least one of the three. Some individual qualitative recognition errors had low false positive rates (<2%) indicating that their presence was virtually pathognomonic for noncredible performance. Older age (>50) and IQ < 80 were associated with increased false positive rates in credible patients. Conclusions: Data on a larger sample than that available in the 2002 validation study show that Rey 15-item plus recognition cut-offs can be made more stringent, and thereby detect up to 70% of noncredible test takers, but the test should be used cautiously in older individuals and in individuals with lowered IQ.	[Poynter, Kellie; Boone, Kyle Brauer; Ermshar, Annette; Miora, Deborah] Alliant Int Univ, Calif Sch Forens Studies, Los Angeles, CA 91803 USA; [Cottingham, Maria] Vet Adm Tennessee Valley Healthcare Syst, Mental Hlth Care Line, Nashville, TN 37212 USA; [Victor, Tara L.] Calif State Univ Dominguez Hills, Carson, CA 90747 USA; [Zeller, Michelle A.] West Los Angeles Vet Adm Med Ctr, Los Angeles, CA 90073 USA; [Wright, Matthew] Harbor UCLA Med Ctr, Torrance, CA 90509 USA	Boone, KB (corresponding author), Alliant Int Univ, Calif Sch Forens Studies, Los Angeles, CA 91803 USA.	kboone@kyleboonephd.com					Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Bailey KC, 2018, CLIN NEUROPSYCHOL, V32, P119, DOI 10.1080/13854046.2017.1333151; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone K. B, 2017, TXB CLIN NEUROPSYCHO; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P1224, DOI 10.1080/13854046.2014.987167; Dean AC, 2008, CLIN NEUROPSYCHOL, V22, P705, DOI 10.1080/13854040701440493; Dean AC, 2009, CLIN NEUROPSYCHOL, V23, P133, DOI 10.1080/13854040701819050; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Griffin GAE, 1996, PSYCHOL ASSESSMENT, V8, P383; Keary TA, 2013, J INT NEUROPSYCH SOC, V19, P314, DOI 10.1017/S1355617712001397; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; LaDuke C, 2018, CLIN NEUROPSYCHOL, V32, P145, DOI 10.1080/13854046.2017.1346711; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Love CM, 2014, ASSESSMENT, V21, P618, DOI 10.1177/1073191114528028; Marshall P, 2007, CLIN NEUROPSYCHOL, V21, P826, DOI 10.1080/13854040600801001; Martin PK, 2015, CLIN NEUROPSYCHOL, V29, P741, DOI 10.1080/13854046.2015.1087597; McCaul C, 2018, CLIN NEUROPSYCHOL, V32, P1054, DOI 10.1080/13854046.2018.1425481; Morse CL, 2013, CLIN NEUROPSYCHOL, V27, P1395, DOI 10.1080/13854046.2013.832385; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Roberson CJ, 2013, CLIN NEUROPSYCHOL, V27, P495, DOI 10.1080/13854046.2012.737027; Robles L, 2015, J CLIN EXP NEUROPSYC, V37, P614, DOI 10.1080/13803395.2015.1039961; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Schroeder RW, 2016, CLIN NEUROPSYCHOL, V30, P515, DOI 10.1080/13854046.2016.1177118; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Smith K, 2014, CLIN NEUROPSYCHOL, V28, P1048, DOI 10.1080/13854046.2014.931465; Solomon RE, 2010, CLIN NEUROPSYCHOL, V24, P1243, DOI 10.1080/13854046.2010.514864; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Whiteside D, 2011, CLIN NEUROPSYCHOL, V25, P287, DOI 10.1080/13854046.2010.538436; Young JC, 2016, CLIN NEUROPSYCHOL, V30, P497, DOI 10.1080/13854046.2016.1159730	34	12	12	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	DEC	2019	34	8					1367	1380		10.1093/arclin/acy087			14	Psychology, Clinical; Psychology	Psychology	KF8XX	WOS:000509521200007	30395181	Bronze			2021-06-18	
J	Willer, BS; Haider, MN; Bezherano, I; Wilber, CG; Mannix, R; Kozlowski, K; Leddy, JJ				Willer, Barry S.; Haider, Mohammad N.; Bezherano, Itai; Wilber, Charles G.; Mannix, Rebekah; Kozlowski, Katherine; Leddy, John J.			Comparison of Rest to Aerobic Exercise and Placebo-like Treatment of Acute Sport-Related Concussion in Male and Female Adolescents	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Interagency Conference on TBI	JUN 12, 2018	Washington, DC			Adolescent; Brain concussion; Exercise; Exercise test; Post-concussion syndrome; Rehabilitation	TRAUMATIC BRAIN-INJURY; POSTCONCUSSION SYNDROME; GENDER-DIFFERENCES; HIGH-SCHOOL; RECOVERY; SYMPTOMS; RECOMMENDATIONS; RELIABILITY; RUMINATION; MEDICINE	Objective: To compare a sample of adolescents with sport-related concussion (SRC) who were prescribed rest with 2 arms of a randomized controlled trial comparing aerobic exercise with placebo-like stretching. We also compared sex differences across the 3 approaches to treatment. Design: Quasi-experimental trial. Setting: University concussion management clinics. Participants: Adolescent athletes (aged 13-18 years) presenting within 10 days of SRC (mean, 5 days after injury) received a recommendation for rest (rest group ERG], n=48, 15.4 +/- 1y, 25% female). Their outcomes were compared with matched samples of adolescents assigned to aerobic exercise (exercise group [EG], n=52, 15.3 +/- 2y, 46% female) or placebo-like stretching (placebo group [PG], n=51, 15.4 +/- 2y, 47% female) (N=151). Main Outcome Measures: The primary outcome was median days from injury to recovery. The secondary outcome was proportion classified as normal recovery (<30d) or delayed recovery (>= 30d). Results: The RG recovered in 16 days (interquartile range, 9.25-23.25d), which was significantly delayed (P=.020) compared with EG (13d; interquartile range, 10-18.5d). The PG recovered in 17 days (interquartile range, 13-23d). Four percent of the EG, 14% of the PG, and 13% of the RG had delayed recovery (P=.190). There was no difference in recovery time or delayed recovery between male participants and female participants across groups. Female participants prescribed rest experienced an increase in symptoms vs the other groups (P=.013). Conclusion: Relative rest and a placebo-like stretching program were very similar in days to recovery and symptom improvement pattern after SRC. Both conditions were less effective than subsymptom threshold aerobic exercise. Female adolescents appear to be susceptible to symptom increase when prescribed rest. (C) 2019 by the American Congress of Rehabilitation Medicine	[Willer, Barry S.] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Psychiat, Buffalo, NY USA; [Haider, Mohammad N.; Wilber, Charles G.; Leddy, John J.] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, UBMD Dept Orthopaed & Sports Med, Buffalo, NY USA; [Haider, Mohammad N.] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, PhD Program Biomed Sci, Neurosci, Buffalo, NY USA; [Bezherano, Itai; Kozlowski, Katherine] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Nutr & Exercise Sci, Buffalo, NY USA; [Mannix, Rebekah] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA	Willer, BS (corresponding author), 3435 Main St,160 Farber Hall, Buffalo, NY 14214 USA.	bswiller@buffalo.edu	Mannix, Rebekah/AAD-8702-2020		National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [IR0INS094444]; National Center for Advancing Translational Sciences of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [ULITR001412]; State University of New York at Buffalo; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094444] Funding Source: NIH RePORTER	Supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (award no. IR0INS094444) and the National Center for Advancing Translational Sciences of the National Institutes of Health (award no. ULITR001412) to the State University of New York at Buffalo. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Arbogast KB, 2013, CLIN PEDIATR, V52, P397, DOI 10.1177/0009922813478160; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Baker JG, 2016, CLIN PEDIATR, V55, P771, DOI 10.1177/0009922815606417; Barth JT, 2001, J ATHL TRAINING, V36, P253; Bishop S, 2016, J CEREBR BLOOD F MET, V36, P292; Blake TA, 2016, BRAIN INJURY, V30, P132, DOI 10.3109/02699052.2015.1093659; Chin EY, 2016, AM J SPORT MED, V44, P2276, DOI 10.1177/0363546516648141; Clausen M, 2016, J HEAD TRAUMA REHAB, V31, P215, DOI 10.1097/HTR.0000000000000145; Davis GA, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097415; Esterov D, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7080100; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gabrys RL, 2016, CLIN J SPORT MED; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Grool AM, 2016, JAMA-J AM MED ASSOC, V316, P2504, DOI 10.1001/jama.2016.17396; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Haider MN, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00395; Haider MN, 2018, BRIT J SPORT MED, V52, DOI 10.1136/bjsports-2016-096551; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; Itoh T, 2011, J NEURAL TRANSM, V118, P193, DOI 10.1007/s00702-010-0495-3; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Jacotte-Simancas A, 2015, J NEUROTRAUM, V32, P739, DOI 10.1089/neu.2014.3502; Johnson DP, 2013, PERS INDIV DIFFER, V55, P367, DOI 10.1016/j.paid.2013.03.019; Kelly J, 2000, STANDARDIZED ASSESSM, P2; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leddy J, 2018, CLIN J SPORT MED; Leddy J, 2017, J ATHL TRAINING, V52, P299, DOI 10.4085/1062-6050-51.11.08; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2019, JAMA PEDIATR, V173, P319, DOI 10.1001/jamapediatrics.2018.4397; Leddy JJ, 2018, CURR SPORT MED REP, V17, P262, DOI 10.1249/JSR.0000000000000505; Leddy JJ, 2018, CLIN J SPORT MED, V28, P13, DOI 10.1097/JSM.0000000000000431; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Lempke L, 2019, J SPORT REHABIL, V28, P99, DOI 10.1123/jsr.2017-0217; Lohaus A, 2013, PSYCHOL HEALTH, V28, P1032, DOI 10.1080/08870446.2013.780606; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrory P, 2005, PHYSICIAN SPORTSMED, V33, P29, DOI 10.3810/psm.2005.04.76; McCrory P, 2009, BR J SPORTS MED S1, V43, pi85; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Moser RS, 2015, BRAIN INJURY, V29, P58, DOI 10.3109/02699052.2014.964771; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; OVERALL JE, 1967, PSYCHOL REP, V21, P70, DOI 10.2466/pr0.1967.21.1.70; Schneider KJ, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097475; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Serrador J, 2015, FASEB J, V29; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Suzuki T, 2013, PLOS ONE, V8, DOI DOI 10.1371/JOURNAL.PONE.0061483; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Willer, 2018, CLIN J SPORT MED, DOI 10.1097/JSM.0000000000000687	50	12	13	0	22	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2019	100	12					2267	2275		10.1016/j.apmr.2019.07.003			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	JW5QY	WOS:000503107600006	31377190	Green Accepted			2021-06-18	
J	Churchill, NW; Hutchison, MG; Graham, SJ; Schweizer, TA				Churchill, Nathan W.; Hutchison, Michael G.; Graham, Simon J.; Schweizer, Tom A.			Mapping brain recovery after concussion From acute injury to 1 year after medical clearance	NEUROLOGY			English	Article							CEREBRAL-BLOOD-FLOW; WHITE-MATTER INTEGRITY; RECURRENT CONCUSSION; SPORTS; NETWORK; CONNECTIVITY	Objective To test the hypothesis that concussion-related brain alterations seen at symptomatic injury and medical clearance to return to play (RTP) will have dissipated by 1 year after RTP. Methods For this observational study, 24 athletes with concussion were scanned longitudinally within 1 week after injury, at RTP, and 1 year after RTP. A large control cohort of 122 athletes were also scanned before the season. Each imaging session assessed global functional connectivity (Gconn) and cerebral blood flow (CBF), along with white matter fractional anisotropy (FA) and mean diffusivity (MD). The main effects of concussion on MRI parameters were evaluated at each postinjury time point. In addition, covariation was assessed between MRI parameters and clinical measures of acute symptom severity and time to RTP. Results Different aspects of brain physiology showed different patterns of recovery over time. Both Gconn and FA displayed no significant effects at 1 year after RTP, whereas CBF and MD exhibited persistent long-term effects. The effects of concussion on MRI parameters were also dependent on acute symptom severity and time to RTP for all postinjury time points. Conclusion This study provides the first longitudinal evaluation of concussion focused on time of RTP and 1 year after medical clearance, using multiple different MRI measures to assess brain structure and function. These findings significantly enhance our understanding of the natural course of brain recovery after a concussion.	[Churchill, Nathan W.; Hutchison, Michael G.; Schweizer, Tom A.] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Churchill, Nathan W.; Schweizer, Tom A.] St Michaels Hosp, Neurosci Res Program, Toronto, ON, Canada; [Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Graham, Simon J.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Fac Med Neurosurg, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada; [Graham, Simon J.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Phys Sci Platform, Toronto, ON, Canada	Schweizer, TA (corresponding author), St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.; Schweizer, TA (corresponding author), St Michaels Hosp, Neurosci Res Program, Toronto, ON, Canada.; Schweizer, TA (corresponding author), Univ Toronto, Fac Med Neurosurg, Toronto, ON, Canada.; Schweizer, TA (corresponding author), Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada.	SchweizerT@smh.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [RN356342-401065, RN294001-367456]; Canadian Institute for Military and Veterans Health Research [W7714-145967]; Siemens Healthineers Canada	This work was supported by the Canadian Institutes of Health Research (grants RN356342-401065, RN294001-367456), the Canadian Institute for Military and Veterans Health Research (grant W7714-145967), and Siemens Healthineers Canada.	Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Churchill N, 2017, J NEUROTRAUM, V34, P765, DOI 10.1089/neu.2016.4531; Churchill NW, 2018, NEUROIMAGE-CLIN, V18, P518, DOI 10.1016/j.nicl.2018.02.011; Churchill NW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07742-3; Churchill NW, 2017, NEUROIMAGE-CLIN, V16, P234, DOI 10.1016/j.nicl.2017.07.019; Churchill NW, 2017, NEUROIMAGE-CLIN, V14, P480, DOI 10.1016/j.nicl.2017.02.015; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dean PJA, 2015, BRAIN INJURY, V29, P1211, DOI 10.3109/02699052.2015.1035334; Di Battista AP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159929; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P895, DOI 10.1136/bjsports-2016-097466; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hillary FG, 2017, TRENDS COGN SCI, V21, P385, DOI 10.1016/j.tics.2017.03.003; Hillary FG, 2015, NEUROPSYCHOLOGY, V29, P59, DOI 10.1037/neu0000110; HUBER PJ, 1964, ANN MATH STAT, V35, P73, DOI 10.1214/aoms/1177703732; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Liu H, 2017, AGEING RES REV, V34, P64, DOI 10.1016/j.arr.2016.11.006; Manley G, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097791; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLendon LA, 2016, PEDIATR NEUROL, V62, P9, DOI 10.1016/j.pediatrneurol.2016.03.009; Meehan WP, 2016, J NEUROTRAUM, V33, P254, DOI 10.1089/neu.2015.3930; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Murrell CJ, 2013, AGE, V35, P905, DOI 10.1007/s11357-012-9414-x; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Sankar SB, 2019, NEUROBIOL DIS, V124, P544, DOI 10.1016/j.nbd.2018.12.018; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Tan H, 2009, J MAGN RESON IMAGING, V29, P1134, DOI 10.1002/jmri.21721; Tarumi T, 2018, J NEUROCHEM, V144, P595, DOI 10.1111/jnc.14234; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; van der Horn HJ, 2016, J NEUROTRAUM, V33, P1, DOI 10.1089/neu.2015.3905; Voss MW, 2013, HUM BRAIN MAPP, V34, P2972, DOI 10.1002/hbm.22119; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	47	12	12	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	NOV 19	2019	93	21					E1980	E1992		10.1212/WNL.0000000000008523			13	Clinical Neurology	Neurosciences & Neurology	KK3FD	WOS:000512631100007	31619480	Green Published			2021-06-18	
J	VanItallie, TB				VanItallie, Theodore B.			Traumatic brain injury (TBI) in collision sports: Possible mechanisms of transformation into chronic traumatic encephalopathy (CTE)	METABOLISM-CLINICAL AND EXPERIMENTAL			English	Article						Acquired seizure disorder; Alzheimer's disease; Parkinson's disease; Amyotrophic lateral sclerosis; Soccer ball 'heading'	AMYOTROPHIC-LATERAL-SCLEROSIS; HEAD-INJURY; RISK; NEUROINFLAMMATION; NEUROPATHOLOGY; DIAGNOSIS; PATHOLOGY; PLAYERS; DISEASE	Traumatic brain injury (TBI) is a leading cause of death and disability, contributing to -30% of all injuryrelated deaths in the US. TBI occurs when a force transmitted to the head causes neuropathologic damage and impairment of brain function. TBI doubles risk of suicide and is the major determinant of acquired seizure disorders. TBI arising from closed head trauma (CHT) significantly increases the risk of developing Alzheimer's disease (AD), Parkinson's disease (PD) and chronic traumatic encephalopathy (CU). Evidence for a possible role of TBI as a risk factor for sporadic amyotrophic lateral sclerosis (sALS) has been provided by studies of professional players of European football. Depending on age, genetic make-up (in particular, being a carrier of one or two ApoE4 alleles), the number of TBIs sustained, their severity, the time periods involved, and many other factors that affect vulnerability, decades may pass after occurrence of one or more TBIs before sequelae such as AD, PD, sALS or CTE become clinically evident. Among college and professional football players who experience repeated concussions and sub-concussive blows to the head, the risk of developing CTE increases with the number of years actively devoted to the sport, and the degree of exposure to physical impacts inherent in the position played. Following a moderate or severe concussion, or a series of mild blows to the head, the brain may undergo subtle pathophysiological changes that are unlikely to be detected with confidence using available diagnostic methods. Biomarkers are being sought that can help the attending physician infer the likely presence of an ongoing occult neurodegenerative process. One example of the adverse effect of collision on the brain is "heading" the soccer ball a feat that, repeated over years of competition, has been found to produce severe brain damage in veteran players. CTE has attracted increasing national attention because of its devastating effects in a high proportion of retired professional players of American football. In a study of brains from deceased former football players, contributed mostly by family members, CTE was neuropathologically diagnosed in 110 of 111 of National Football League (NFL) veterans. In the CU-positive subjects, the authors observed extensive brain atrophy, astrogliosis, myelinated axonopathy, microvascular injury, perivascular neuroinflammation, and phosphorylated tau protein pathology. CTE's neuropathology has been formally defined as a tauopathy characterized by a distinct perivascular accumulation of hyperphosphorylated tau in neurons and astrocytes within cerebral sulci. Although the mechanism that underlies the unforeseen emergence of CTE long after the occurrence of one or more closed head traumas is unknown, an explanation proposed by Albayram and associates is persuasive. They discovered TBI-induced neuronal production of the toxic compound cis P-tau, an abnormal and destructive isomer of the normal and benign trans P-tau, in mouse models of CTE. Cis P-tau produced a CTE-like syndrome via a process they termed cistauosis. Cistauosis can be blocked in laboratory animals by cis P-tau monoclonal antibody, which prevents later development of tau tangles, brain atrophy and virtual CU. In a subsequent study, the same group found in human samples obtained post-TBI from a variety of causes, that cis P-tau is induced in cortical axons and cerebrospinal fluid and positively correlates with axonal injury and clinical outcome. Thus, cis P-tau appears to contribute to short-term and long-term sequelae after TBI, but may be subject to neutralization by cis-antibody treatment. (C) 2019 Published by Elsevier Inc.	[VanItallie, Theodore B.] Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA	VanItallie, TB (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.				College International de Recherche Servier	This article is part of a supplement entitled 'Role of Environment in Initiation and Progression of Illnesses' which is sponsored by the College International de Recherche Servier.	Abner EL, 2014, DEMENT GERIATR COGN, V37, P294, DOI 10.1159/000355478; Albayram O, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01068-4; [Anonymous], 2018, HEALTHDAY NEWS  0118; [Anonymous], 2001, NATL HOSP DISCHARGE; Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Bazarian JJ, 2018, LANCET NEUROL, V17, P782, DOI 10.1016/S1474-4422(18)30231-X; Belli S, 2005, EUR J EPIDEMIOL, V20, P237, DOI 10.1007/s10654-004-6879-7; Castellani RJ, 2017, J ALZHEIMERS DIS, V60, P1209, DOI 10.3233/JAD-170669; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Clark M., 2016, TRANSLATIONAL RES TR; Collins-Praino LE, 2017, BRAIN BEHAV IMMUN, V60, P369, DOI 10.1016/j.bbi.2016.09.027; Donat CK, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00208; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Holleran L, 2017, ACTA NEUROPATHOL, V133, P367, DOI 10.1007/s00401-017-1686-x; Josephs KA, 2017, MAYO CLIN PROC, V92, P1291, DOI 10.1016/j.mayocp.2017.04.016; Kumar A, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0819-4; Leo P., 2016, TRANSLATIONAL RES TR; McKee AC, 2015, HDB CLIN NEUROL, V227, P45; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Oliver JM, 2019, J NEUROSURG, V130, P1655, DOI 10.3171/2017.12.JNS172035; Pasinetti Giulio M, 2012, Am J Neurodegener Dis, V1, P88; Perl DP, 2010, MT SINAI J MED, V77, P32, DOI 10.1002/msj.20157; Seo JS, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.56; Stewart WF, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00240; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; Turner RC, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00186; Veech RL, 2012, IUBMB LIFE, V64, P203, DOI 10.1002/iub.590; Wortzel HS, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/424280	34	12	12	6	47	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0026-0495	1532-8600		METABOLISM	Metab.-Clin. Exp.	NOV	2019	100			S					153943	10.1016/j.metabol.2019.07.007			6	Endocrinology & Metabolism	Endocrinology & Metabolism	JI9PY	WOS:000493795600007	31610856				2021-06-18	
J	Daglas, M; Draxler, DF; Ho, H; McCutcheon, F; Galle, A; Au, AE; Larsson, P; Gregory, J; Alderuccio, F; Sashindranath, M; Medcalf, RL				Daglas, Maria; Draxler, Dominik F.; Ho, Heidi; McCutcheon, Fiona; Galle, Adam; Au, Amanda E.; Larsson, Pia; Gregory, Julia; Alderuccio, Frank; Sashindranath, Maithili; Medcalf, Robert L.			Activated CD8(+) T Cells Cause Long-Term Neurological Impairment after Traumatic Brain Injury in Mice	CELL REPORTS			English	Article							SPINAL-CORD-INJURY; LIMIT CNS INFLAMMATION; EXPERIMENTAL STROKE; MULTIPLE-SCLEROSIS; MYELIN CLEARANCE; GAIT IMPAIRMENT; DEFICIENT MICE; LYMPHOCYTES; SYSTEM; MOTOR	Traumatic brain injury (TBI) leaves many survivors with long-term disabilities. A prolonged immune response in the brain may cause neurodegeneration, resulting in chronic neurological disturbances. In this study, using a TBI mouse model, we correlate changes in the local immune response with neurodegeneration/neurological dysfunction over an 8-month period. Flow cytometric analysis reveals a protracted increase in effector/memory CD8(+) T cells (expressing granzyme B) in the injured brain. This precedes interleukin-17(+)CD4(+) T cell infiltration and is associated with progressive neurological/motor impairment, increased circulating brain-specific autoantibodies, and myelin-related pathology. Genetic deficiency or pharmacological depletion of CD8(+) T cells, but not depletion of CD4(+) T cells, improves neurological outcomes and produces a neuroprotective Th2/Th17 immunological shift, indicating a persistent detrimental role for cytotoxic T cells post-TBI. B cell deficiency results in severe neurological dysfunction and a heightened immune reaction. Targeting these adaptive immune cells offers a promising approach to improve recovery following TBI.	[Daglas, Maria; Draxler, Dominik F.; Ho, Heidi; McCutcheon, Fiona; Galle, Adam; Au, Amanda E.; Larsson, Pia; Gregory, Julia; Sashindranath, Maithili; Medcalf, Robert L.] Monash Univ, Mol Neurotrauma & Haemostasis, Australian Ctr Blood Dis, Cent Clin Sch, Melbourne, Vic 3004, Australia; [Alderuccio, Frank] Monash Univ, Dept Immunol & Pathol, Cent Clin Sch, Melbourne, Vic 3004, Australia	Sashindranath, M; Medcalf, RL (corresponding author), Monash Univ, Mol Neurotrauma & Haemostasis, Australian Ctr Blood Dis, Cent Clin Sch, Melbourne, Vic 3004, Australia.	maithili.sashindranath@monash.edu; robert.medcalf@monash.edu	Gregory, Julia/AAW-6017-2020; Sashindranath, Maithili/AAI-7408-2021; Gregory, Julia L/K-8726-2012	Gregory, Julia/0000-0003-2408-677X; Sashindranath, Maithili/0000-0002-9712-4784; Au, Amanda/0000-0003-3656-2673	NHMRC of AustraliaNational Health and Medical Research Council of Australia [APP1045755, APP1126636, APP1044152]; Monash University, Faculty of Medicine, Nursing, and Health SciencesMonash University	The authors acknowledge the facilities, and scientific and technical assistance of Mr. Steve Cody at Monash Micro Imaging and members of the AMREP Flow Cytometry Core Facility at Monash University. We also acknowledge Dr. Rachael Borg, Dr. Evelyn Tsantikos, Dr. Jie-Yu Chung, Dr. Zeyad Nasa, Professor Magdalena Plebanski, Dr. Jennifer Boer, and Volga Tarlac for their assistance with experiments and for technical assistance. We acknowledge Professor Fabienne Mackay for supplying the mu-MT mice, Dr. Linda Wakim for the design of the antibody depletion experiment, Professor Joseph Trapani and Dr. Vivien Sutton (Peter MacCallum Cancer Centre) for help with the GrB and FasL analyses, and Dr. Nigel Jones and Dr. Bridgette Semple for assistance with the Morris water maze procedure. This study was supported by grants (APP1045755 and APP1126636) and a Fellowship (APP1044152) awarded to R.L.M. by the NHMRC of Australia, and by a Monash University, Faculty of Medicine, Nursing, and Health Sciences, Early Career Strategic Grant awarded to M.S.	Abromson-Leeman S, 2004, AM J PATHOL, V165, P1519, DOI 10.1016/S0002-9440(10)63410-4; Acharya D, 2017, J VIROL, V91, DOI [10.1128/JVI.01529-16, 10.1128/jvi.01529-16]; Adelson JD, 2012, NEURON, V73, P1100, DOI 10.1016/j.neuron.2012.01.020; Amor S, 2010, IMMUNOLOGY, V129, P154, DOI 10.1111/j.1365-2567.2009.03225.x; Ankeny DP, 2006, J NEUROCHEM, V99, P1073, DOI 10.1111/j.1471-4159.2006.04147.x; Ankeny DP, 2009, J CLIN INVEST, V119, P2990, DOI 10.1172/JCI39780; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; Bodhankar S, 2015, METAB BRAIN DIS, V30, P911, DOI 10.1007/s11011-014-9639-8; Bodhankar S, 2013, METAB BRAIN DIS, V28, P375, DOI 10.1007/s11011-013-9413-3; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Braun M, 2017, J IMMUNOL, V198, P3615, DOI 10.4049/jimmunol.1601948; Bromley-Brits Kelley, 2011, J Vis Exp, DOI 10.3791/2920; Callaway JK, 2012, EUR J ANAESTH, V29, P239, DOI 10.1097/EJA.0b013e32835103c1; Chaitanya GV, 2010, NEUROSCIENCE, V165, P1203, DOI 10.1016/j.neuroscience.2009.10.067; Chaitanya GV, 2009, NEUROPATHOLOGY, V29, P270, DOI 10.1111/j.1440-1789.2008.00980.x; Christianson GJ, 1997, J IMMUNOL, V159, P4781; Dardiotis E., 2012, TRAUMATIC BRAIN INJU; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Doyle KP, 2015, J NEUROSCI, V35, P2133, DOI 10.1523/JNEUROSCI.4098-14.2015; Duan MC, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/898053; Elkins J, 2017, LANCET NEUROL, V16, P217, DOI 10.1016/S1474-4422(16)30357-X; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Godfrey DI, 2004, NAT REV IMMUNOL, V4, P231, DOI 10.1038/nri1309; Gonzalez-Quintela A, 2008, CLIN EXP IMMUNOL, V151, P42, DOI 10.1111/j.1365-2249.2007.03545.x; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; Hillhouse EE, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00006; Hurn PD, 2007, J CEREBR BLOOD F MET, V27, P1798, DOI 10.1038/sj.jcbfm.9600482; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Jazayeri MH., 2013, BIOMED AGING PATHOL, V3, DOI [DOI 10.1016/j.biomag.2013.09.002, 10.1016/j.biomag.2013.09.002, DOI 10.1016/J.BIOMAG.2013.09.002]; Kapitza S, 2012, EXP NEUROL, V236, P179, DOI 10.1016/j.expneurol.2012.04.023; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Kruisbeek A. M., 2001, CURR PROTOC IMMUNOL; Kumar V, 2014, IMMUNOLOGY, V142, P321, DOI 10.1111/imm.12247; Kuric E, 2014, EUR J NEUROSCI, V40, P2463, DOI 10.1111/ejn.12598; Liu ZX, 2019, BIOCHEM BIOPH RES CO, V512, P367, DOI 10.1016/j.bbrc.2019.03.002; Lunny CA, 2014, J NEUROL SCI, V336, P13, DOI 10.1016/j.jns.2013.08.011; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mars LT, 2011, BBA-MOL BASIS DIS, V1812, P151, DOI 10.1016/j.bbadis.2010.07.006; Mracsko E, 2014, J NEUROSCI, V34, P16784, DOI 10.1523/JNEUROSCI.1867-14.2014; Nasa Z, 2012, AM J TRANSPLANT, V12, P2062, DOI 10.1111/j.1600-6143.2012.04068.x; Neumann M, 2009, J NEUROSCI METH, V176, P34, DOI 10.1016/j.jneumeth.2008.08.026; Ngankam L, 2011, ZH NEVROL PSIKHIATR, V111, P61; Ortega SB, 2015, DISCOV MED, V19, P381; Plesnila N, 2016, CURR OPIN PHARMACOL, V26, P110, DOI 10.1016/j.coph.2015.10.008; Pohl HBF, 2011, J NEUROSCI, V31, P1069, DOI 10.1523/JNEUROSCI.5035-10.2011; Porter JR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138220; Raad M, 2014, NEUROSCIENCE, V281, P16, DOI 10.1016/j.neuroscience.2014.08.045; Ren XF, 2011, J NEUROSCI, V31, P8556, DOI 10.1523/JNEUROSCI.1623-11.2011; Rothhammer V, 2011, J EXP MED, V208, P2465, DOI 10.1084/jem.20110434; Rudehill S, 2006, ACTA NEUROCHIR, V148, P199, DOI 10.1007/s00701-005-0673-5; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Sashindranath M, 2015, BEHAV BRAIN RES, V286, P33, DOI 10.1016/j.bbr.2015.02.038; Sashindranath M, 2012, BRAIN, V135, P3251, DOI 10.1093/brain/aws178; Sashindranath M, 2011, LAB INVEST, V91, P1079, DOI 10.1038/labinvest.2011.67; Scheidtmann K, 2001, LANCET, V358, P787, DOI 10.1016/S0140-6736(01)05966-9; Semple BD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143386; Shelton SB, 2008, J NEUROSCI METH, V168, P431, DOI 10.1016/j.jneumeth.2007.11.003; Shibata D, 2012, J NEUROIMMUNOL, V252, P106, DOI 10.1016/j.jneuroim.2012.08.006; Shichita T, 2009, NAT MED, V15, P946, DOI 10.1038/nm.1999; Siebold L, 2018, EXP NEUROL, V310, P48, DOI 10.1016/j.expneurol.2018.07.004; Sundman MH., 2014, J ALZHEIMERS DIS PAR, V4, P137; Takeuchi A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00194; Tripathi RB, 2010, J NEUROSCI, V30, P16383, DOI 10.1523/JNEUROSCI.3411-10.2010; Vargas ME, 2010, P NATL ACAD SCI USA, V107, P11993, DOI 10.1073/pnas.1001948107; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Walsh JT, 2015, J CLIN INVEST, V125, P699, DOI [10.1172/JCI176210, 10.1172/JCI76210]; Weckbach S, 2012, J NEUROTRAUM, V29, P1233, DOI 10.1089/neu.2011.2169; Wright DK, 2017, CEREB CORTEX, V27, P4503, DOI 10.1093/cercor/bhw254; Wu B, 2012, EXP NEUROL, V237, P274, DOI 10.1016/j.expneurol.2012.07.016; Wu L, 2021, J NEUROTRAUM, V38, P1450, DOI 10.1089/neu.2017.5607; Yilmaz G, 2006, CIRCULATION, V113, P2105, DOI 10.1161/CIRCULATIONAHA.105.593046; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	75	12	12	3	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	2211-1247			CELL REP	Cell Reports	OCT 29	2019	29	5					1178	+		10.1016/j.celrep.2019.09.046			20	Cell Biology	Cell Biology	JJ1GB	WOS:000493907800010	31665632	DOAJ Gold			2021-06-18	
J	Bugay, V; Bozdemir, E; Vigil, FA; Chun, SH; Holstein, DM; Elliott, WR; Sprague, CJ; Cavazos, JE; Zamora, DO; Rule, G; Shapiro, MS; Lechleiter, JD; Brenner, R				Bugay, Vladislav; Bozdemir, Eda; Vigil, Fabio A.; Chun, Sang H.; Holstein, Deborah M.; Elliott, William R.; Sprague, Cassie J.; Cavazos, Jose E.; Zamora, David O.; Rule, Gregory; Shapiro, Mark S.; Lechleiter, James D.; Brenner, Robert			A Mouse Model of Repetitive Blast Traumatic Brain Injury Reveals Post-Trauma Seizures and Increased Neuronal Excitability	JOURNAL OF NEUROTRAUMA			English	Article						blast; epilepsy; mild traumatic brain injury; repetitive mTBI; seizure; traumatic brain injury	DENTATE GYRUS; EPILEPTIFORM ACTIVITY; TAU PHOSPHORYLATION; GABAERGIC INHIBITION; NERVOUS-SYSTEM; SERINE 396; EPILEPSY; INVOLVEMENT; INFLAMMATION; HIPPOCAMPUS	Repetitive blast traumatic brain injury (TBI) affects numerous soldiers on the battlefield. Mild TBI has been shown to have long-lasting effects with repeated injury. We have investigated effects on neuronal excitability after repetitive, mild TBI in a mouse model of blast-induced brain injury. We exposed mice to mild blast trauma of an average peak overpressure of 14.6 psi, repeated across three consecutive days. While a single exposure did not reveal trauma as indicated by the glial fibrillary acidic protein indicator, three repetitive blasts did show significant increases. As well, mice had an increased indicator of inflammation (Iba-1) and increased tau, tau phosphorylation, and altered cytokine levels in the spleen. Video-electroencephalographic monitoring 48 h after the final blast exposure demonstrated seizures in 50% (12/24) of the mice, most of which were non-convulsive seizures. Long-term monitoring revealed that spontaneous seizures developed in at least 46% (6/13) of the mice. Patch clamp recording of dentate gyrus hippocampus neurons 48 h post-blast TBI demonstrated a shortened latency to the first spike and hyperpolarization of action potential threshold. We also found that evoked excitatory postsynaptic current amplitudes were significantly increased. These findings indicate that mild, repetitive blast exposures cause increases in neuronal excitability and seizures and eventual epilepsy development in some animals. The non-convulsive nature of the seizures suggests that subclinical seizures may occur in individuals experiencing even mild blast events, if repeated.	[Bugay, Vladislav; Vigil, Fabio A.; Cavazos, Jose E.; Shapiro, Mark S.; Brenner, Robert] Univ Texas Hlth San Antonio, Cell & Integrat Physiol, San Antonio, TX 78229 USA; [Bozdemir, Eda; Chun, Sang H.; Holstein, Deborah M.; Lechleiter, James D.] Univ Texas Hlth San Antonio, Dept Cell Syst & Anat, San Antonio, TX 78229 USA; [Cavazos, Jose E.] Univ Texas Hlth San Antonio, Dept Neurol, San Antonio, TX 78229 USA; [Elliott, William R.; Sprague, Cassie J.; Zamora, David O.] US Army, Sensory Trauma, Inst Surg Res, San Antonio, TX USA; [Rule, Gregory] Appl Res Associates, San Antonio, TX USA	Brenner, R (corresponding author), Univ Texas Hlth San Antonio, Dept Cellular & Integrat Physiol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.	brennerr@uthscsa.edu	; Cavazos, Jose/J-4122-2016	Brenner, Robert/0000-0002-1036-8031; Cavazos, Jose/0000-0001-5777-2608; Vigil, Fabio Antonio/0000-0001-5302-0388	DoD CDMRPUnited States Department of Defense [W81XWH-15-1-0284, W81XWH-13-1-0284]; NSFNational Science Foundation (NSF) [1456862]; Morrison Trust Foundation grants	We would like to thank the following: Nameer B. Kirma and Nicholas D. Lucio from the Bioanalytics and Single-Cell Facility at UT Health San Antonio for the multiplex immunoassays. We also thank Brian J. Lund at the San Antonio Military Medical Center for advice on use of the blast facility, and Amy E. Pletz for her expert technical assistance. This study was supported by DoD CDMRP grants W81XWH-15-1-0284 (M.S.S. and R.B.) and W81XWH-13-1-0284 (J.D.L.), NSF grant 1456862 (R.B.) and the Morrison Trust Foundation grants (R.B. and M.S.S.)	ABOUD R, 1993, BRIT J PHARMACOL, V109, P80, DOI 10.1111/j.1476-5381.1993.tb13534.x; Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Arun P, 2013, NEUROSCI LETT, V552, P87, DOI 10.1016/j.neulet.2013.07.047; Bailes JE, 2014, PROG NEUROL SURG, V28, P50, DOI 10.1159/000358765; Bhaskar K, 2010, NEURON, V68, P19, DOI 10.1016/j.neuron.2010.08.023; Blume WT, 2006, EPILEPSIA, V47, P71, DOI 10.1111/j.1528-1167.2006.00665.x; Bolton-Hall AN, 2019, J NEUROTRAUM, V36, P1203, DOI 10.1089/neu.2018.6096; Bonaz B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01452; Brenner R, 2005, NAT NEUROSCI, V8, P1752, DOI 10.1038/nn1573; Briones TL, 2015, ANNU REV NURS RES-SE, V33, P31, DOI 10.1891/0739-6686.33.31; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Buki A, 2015, ADV TECH STAND NEURO, V42, P147, DOI 10.1007/978-3-319-09066-5_8; Butler CR, 2017, ENEURO, V4, DOI 10.1523/ENEURO.0134-17.2017; Butler CR, 2016, EXP NEUROL, V280, P30, DOI 10.1016/j.expneurol.2016.03.022; Butler CR, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00163; Carlson KF, 2013, BRAIN INJURY, V27, P640, DOI 10.3109/02699052.2013.771795; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Chen JWY, 2009, J REHABIL RES DEV, V46, P685, DOI 10.1682/JRRD.2008.09.0130; Denes A, 2013, DIS MODEL MECH, V6, P1043, DOI 10.1242/dmm.011601; Despres C, 2017, P NATL ACAD SCI USA, V114, P9080, DOI 10.1073/pnas.1708448114; Devos SL, 2013, J NEUROSCI, V33, P12887, DOI 10.1523/JNEUROSCI.2107-13.2013; Du XP, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4159357; Dudek FE, 2007, PROG BRAIN RES, V163, P755, DOI 10.1016/S0079-6123(07)63041-6; Edwards G, 2017, BIOCHEM BIOPH RES CO, V483, P1137, DOI 10.1016/j.bbrc.2016.07.123; Effgen GB, 2014, J NEUROTRAUM, V31, P1202, DOI 10.1089/neu.2013.3227; Evans DB, 2000, J BIOL CHEM, V275, P24977, DOI 10.1074/jbc.M000808200; Fettelschoss A, 2011, P NATL ACAD SCI USA, V108, P18055, DOI 10.1073/pnas.1109176108; FRIEDLANDER FG, 1946, PROC R SOC LON SER-A, V186, P356, DOI 10.1098/rspa.1946.0049; Ganti L, 2015, MIL MED, V180, P380, DOI 10.7205/MILMED-D-14-00316; Golarai G, 2001, J NEUROSCI, V21, P8523; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greene NT, 2018, HEARING RES, V365, P149, DOI 10.1016/j.heares.2018.05.014; Hammad A, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1066-z; Hauser WA, 2002, PROG BRAIN RES, V135, P215; HEINEMANN U, 1992, EPILEPSY RES, P273; Holth JK, 2013, J NEUROSCI, V33, P1651, DOI 10.1523/JNEUROSCI.3191-12.2013; Horvath A, 2016, ALZ DIS ASSOC DIS, V30, P186, DOI 10.1097/WAD.0000000000000134; Hsu D, 2007, PROG BRAIN RES, V163, P601, DOI 10.1016/S0079-6123(07)63032-5; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Janigro D, 2013, EPILEPSIA, V54, P30, DOI 10.1111/epi.12271; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Johnston GR, 2009, BRIT J ANAESTH, V102, P453, DOI 10.1093/bja/aep037; Keller CJ, 2010, BRAIN, V133, P1668, DOI 10.1093/brain/awq112; Kenney Kimbra, 2018, Brain Inj, V32, P1276, DOI 10.1080/02699052.2018.1483530; Kenney MJ, 2014, COMPR PHYSIOL, V4, P1177, DOI 10.1002/cphy.c130051; Kim E, 2014, J CEREBR BLOOD F MET, V34, P1411, DOI 10.1038/jcbfm.2014.101; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Lau KM, 2016, BRAIN INJURY, V30, P287, DOI 10.3109/02699052.2015.1089601; Li ZY, 2014, NEUROBIOL AGING, V35, P2617, DOI 10.1016/j.neurobiolaging.2014.05.001; Ling G, 2015, Handb Clin Neurol, V127, P173, DOI 10.1016/B978-0-444-52892-6.00011-8; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Lippmann K, 2017, J CEREBR BLOOD F MET, V37, P1803, DOI 10.1177/0271678X16652631; Liu X, 2013, NEUROSCI BULL, V29, P565, DOI 10.1007/s12264-013-1326-y; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; LOTHMAN EW, 1992, EPILEPSY RES, P301; Luheshi NM, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-186; Lund BJ, 2014, INVEST OPHTH VIS SCI, V55, P1348, DOI 10.1167/iovs.13-13337; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; Meabon JS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaa9585; Miller KJ, 2013, J HEAD TRAUMA REHAB, V28, P31, DOI 10.1097/HTR.0b013e318255ceae; Mishra V, 2016, SCI REP-UK, V6, DOI 10.1038/srep26992; Mondragon-Rodriguez S, 2014, NEUROPATH APPL NEURO, V40, P121, DOI 10.1111/nan.12084; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Mtchedlishvili Z, 2010, NEUROBIOL DIS, V38, P464, DOI 10.1016/j.nbd.2010.03.012; Murray KN, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00018; Nance DM, 2007, BRAIN BEHAV IMMUN, V21, P736, DOI 10.1016/j.bbi.2007.03.008; Nizamutdinov D, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7010011; Noebels J, 2011, EPILEPSIA, V52, P39, DOI 10.1111/j.1528-1167.2010.02909.x; Ojo JO, 2016, EXP NEUROL, V275, P389, DOI 10.1016/j.expneurol.2015.06.003; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Rasouli J, 2011, Einstein J Biol Med, V27, P74; Regan P, 2015, J NEUROSCI, V35, P4804, DOI 10.1523/JNEUROSCI.2842-14.2015; Rhine T, 2016, BRAIN INJURY, V30, P1231, DOI 10.1080/02699052.2016.1178396; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Rowe RK, 2016, MOL PAIN, V12, DOI 10.1177/1744806916647055; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Sahota P, 2013, INT J STROKE, V8, P60, DOI 10.1111/ijs.12022; Schwulst SJ, 2013, J TRAUMA ACUTE CARE, V75, P780, DOI 10.1097/TA.0b013e318299616a; Scott TE, 2017, BRIT J ANAESTH, V118, P311, DOI 10.1093/bja/aew385; Seifert HA, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1239-9; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Simic G, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6010006; SmithSwintosky VL, 1997, J NEUROCHEM, V69, P1890; Su E., 2016, TRANSLATIONAL RES TR; Suppl e (U.S.). Committee on Gulf War and Health: Long term effects of blast exposures, 2014, GULF WAR HLTH LONG T; Sylvia FR, 2001, MIL MED, V166, P918; Tai XY, 2016, BRAIN, V139, P2441, DOI 10.1093/brain/aww187; TEASDALE G, 1974, LANCET, V2, P81; Terrone G, 2017, CURR PHARM DESIGN, V23, P5569, DOI 10.2174/1381612823666170926113754; Tumer N, 2013, NEUROSCI LETT, V544, P62, DOI 10.1016/j.neulet.2013.03.042; Verellen Rebecca M, 2010, Therapy, V7, P527, DOI 10.2217/thy.10.57; Vogel EW, 2017, J NEUROTRAUM, V34, P1063, DOI 10.1089/neu.2016.4578; Vogel EW, 2016, J NEUROTRAUM, V33, P652, DOI 10.1089/neu.2015.4045; Vossel KA, 2013, JAMA NEUROL, V70, P1158, DOI 10.1001/jamaneurol.2013.136; Walilko T.J., 2016, MECH BIOL SYSTEMS MA, V6; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Yan XX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048782; Yang WJ, 2017, ACTA NEUROL SCAND, V135, P622, DOI 10.1111/ane.12644; Yokobori S, 2013, TRANSL STROKE RES, V4, P25, DOI 10.1007/s12975-012-0226-1; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zollman F., 2016, MANUAL TRAUMATIC BRA, V2nd ed.	106	12	12	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2020	37	2					248	261		10.1089/neu.2018.6333		OCT 2019	14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	JZ2YM	WOS:000492083900001	31025597	Green Published			2021-06-18	
J	Duma, C; Kopyov, O; Kopyov, A; Berman, M; Lander, E; Elam, M; Arata, M; Weiland, D; Cannell, R; Caraway, C; Berman, S; Scord, K; Stemler, L; Chung, K; Khoudari, S; McRory, R; Duma, C; Farmer, S; Bravo, A; Yassa, C; Sanathara, A; Singh, E; Rapaport, B				Duma, Christopher; Kopyov, Oleg; Kopyov, Alex; Berman, Mark; Lander, Elliot; Elam, Michael; Arata, Michael; Weiland, David; Cannell, Ruslana; Caraway, Chad; Berman, Sean; Scord, Kristin; Stemler, Lian; Chung, Karlyssa; Khoudari, Samuel; McRory, Rory; Duma, Chace; Farmer, Sawyer; Bravo, Anthony; Yassa, Christian; Sanathara, Ami; Singh, Elisa; Rapaport, Benjamin			Human intracerebroventricular (ICV) injection of autologous, non-engineered, adipose-derived stromal vascular fraction (ADSVF) for neurodegenerative disorders: results of a 3-year phase 1 study of 113 injections in 31 patients	MOLECULAR BIOLOGY REPORTS			English	Article						Intracerebroventricular; Stem cells; Autologous stem cells; ADSC; Neurodegenerative disease; Alzheimer's disease; ALS; Multiple sclerosis; Stromal vascular fraction	MESENCHYMAL STEM-CELLS; ALZHEIMERS-DISEASE; BONE-MARROW; MOUSE MODEL; MULTIPLE-SCLEROSIS; INTRANASAL DELIVERY; CONDITIONED MEDIUM; LIPOID MENINGITIS; OMMAYA RESERVOIR; TRANSPLANTATION	We have chosen to test the safety of human intracerebroventricular (ICV) brain injections of autologous non-genetically-modified adipose-derived stromal vascular fraction (ADSVF). In this IRB-approved trial, 24 patients received ICV ADSVF via an implanted reservoir between 5/22/14 and 5/22/17. Seven others were injected via their ventriculo-peritoneal shunts. Ten patients had Alzheimer's disease (AD), 6 had amyotrophic lateral sclerosis (ALS), 6 had progressive multiple sclerosis (MS-P), 6 had Parkinson's "Plus" (PD+), 1 had spinal cord injury, 1 had traumatic brain injury, and 1 had stroke. Median age was 74 (range 41-83). Injections were planned every 2-3 months. Thirty-one patients had 113 injections. Patients received SVF injection volumes of 3.5-20 cc (median:4 cc) containing 4.05 x 10(5) to 6.2 x 10(7) cells/cc, which contained an average of 8% hematopoietic and 7.5% adipose stem cells. Follow-up ranged from 0 to 36 months (median: 9.2 months). MRIs post injection(s) were unchanged, except for one AD patient whose hippocampal volume increased from < 5th percentile to 48th percentile -(NeuroQuant (R) volumetric MRI). Of the 10 AD patients, 8 were stable or improved in tests of cognition. Two showed improvement in P-tau and beta-amyloid levels. Of the 6 MS-P patients all are stable or improved. Four of 6 ALS patients died of disease progression. Twelve of 111 injections (11%) led to 1-4 days of transient meningismus, and mild temperature elevation, which resolved with acetaminophen and/or dexamethasone. Two (1.8% of injections) required hospitalization for these symptoms. One patient (0.9% of injections) had his reservoir removed and later replaced for presumed infection. In this Phase 1 safety trial, ADSVF was safely injected into the human brain ventricular system in patients with no other treatment options. Secondary endpoints of clinical improvement or stability were particularly promising in the AD and MS-P groups. These results will be submitted for a Phase 2 FDA-approved trial.	[Duma, Christopher; Kopyov, Oleg; Kopyov, Alex; Scord, Kristin; Stemler, Lian; Chung, Karlyssa; Khoudari, Samuel; McRory, Rory; Duma, Chace; Farmer, Sawyer; Bravo, Anthony; Yassa, Christian; Sanathara, Ami; Singh, Elisa; Rapaport, Benjamin] Brain & Spine Surg Orange Cty, Neurosurg, Newport Beach, CA 92660 USA; [Berman, Mark; Lander, Elliot; Elam, Michael; Arata, Michael; Berman, Sean] Cell Surg Network, Los Angeles, CA USA; [Weiland, David] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA; [Cannell, Ruslana; Caraway, Chad] Univ Calif Irvine, Dept Neurobiol, Irvine, CA USA	Duma, C (corresponding author), Brain & Spine Surg Orange Cty, Neurosurg, Newport Beach, CA 92660 USA.	cduma@brainandspineoc.com; okopyov@cellavie.com; akopyov@cellavie.com; mark@cellsurgicalnetwork.com; elliot@cellsurgicalnetwork.com; info@michaelelammd.com; marata@drarata.com; djweilan@uci.edu; rcannell@uci.edu; ccaraway@uci.edu; sean@cellsurgicalnetwork.com; kscordpac@newportbeachdps.com; lstemler@stanford.edu; kchung@brainandspineoc.com; samuel.khoudari@hoag.org; rmccrory@brainandspineoc.com; chaceduma@ucsb.edu; shfarmer@ucsd.edu; aabravo@uci.edu; cyassa123@berkeley.edu; sanathaa@coyote.csusb.edu; elisa.singh@hoag.org; brapaport@brainandspineoc.com		Duma, Christopher/0000-0003-3943-2030			Abdallah AN, 2019, RES VET SCI, V125, P71, DOI 10.1016/j.rvsc.2019.05.016; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Al Jumah MA, 2012, INT J MOL SCI, V13, P9298, DOI 10.3390/ijms13079298; del Barrio JLA, 2017, CORNEA, V36, P952, DOI 10.1097/ICO.0000000000001228; Alonso A, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000164; Argibay B, 2017, SCI REP-UK, V7, DOI 10.1038/srep40758; Baek W, 2012, J NEUROSURG SCI, V56, P261; Bagheri-Mohammadi S, 2019, MOL BIOL REP, V46, P4293, DOI 10.1007/s11033-019-04883-8; Berg J, 2015, STEM CELL REV REP, V11, P133, DOI 10.1007/s12015-014-9551-y; Berman M., 2017, AM J COSMETIC SURG, V34, P1, DOI [10.1177/0748806817691152, DOI 10.1177/0748806817691152]; Berman S, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8060112; Bonafede R, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00080; Bonafede R, 2016, EXP CELL RES, V340, P150, DOI 10.1016/j.yexcr.2015.12.009; Bowles AC, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1099-3; Bowles AC, 2017, STEM CELLS, V35, P532, DOI 10.1002/stem.2516; Busser H, 2015, STEM CELLS DEV, V24, P2142, DOI 10.1089/scd.2015.0172; Chan TM, 2014, CELL TRANSPLANT, V23, P549, DOI 10.3727/096368914X678445; Chang KA, 2014, NEURODEGENER DIS, V13, P99, DOI 10.1159/000355261; Chang YH, 2016, CELL TRANSPLANT, V25, P937, DOI 10.3727/096368915X690288; Chernoff G, 2018, FACIAL PLAST SURG CL, V26, P487, DOI 10.1016/j.fsc.2018.06.009; Chi K, 2018, CELL TRANSPLANT, V27, P456, DOI 10.1177/0963689718757408; Chung JY, 2012, J NEUROL SCI, V317, P40, DOI 10.1016/j.jns.2012.02.035; Cobo M, 2013, CELL TRANSPLANT, V22, P839, DOI 10.3727/096368912X657404; Collins-Praino LE, 2018, BEHAV BRAIN RES, V336, P22, DOI 10.1016/j.bbr.2017.08.035; D'Andrea MR, 2005, MED HYPOTHESES, V64, P458, DOI 10.1016/j.mehy.2004.08.024; Darlington PJ, 2011, EXPERT REV NEUROTHER, V11, P1295, DOI [10.1586/ERN.11.113, 10.1586/ern.11.113]; Egashira Y, 2012, BRAIN RES, V1461, P87, DOI 10.1016/j.brainres.2012.04.033; Farinazzo A, 2015, CYTOTHERAPY, V17, P571, DOI 10.1016/j.jcyt.2015.01.005; Faustini M, 2010, TISSUE ENG PART C-ME, V16, P1515, DOI [10.1089/ten.tec.2010.0214, 10.1089/ten.TEC.2010.0214]; Fauzi AA, 2016, J STEM CELLS REGEN, V12, pP100; Fernandez O, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195891; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Forostyak S, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00591; Forostyak S, 2014, STEM CELLS, V32, P3163, DOI 10.1002/stem.1812; Gentile P, 2012, STEM CELL TRANSL MED, V1, P230, DOI 10.5966/sctm.2011-0054; Ghorabi MT, 2017, CELL MOL BIOL, V63, P1, DOI 10.14715/cmb/2017.63.3.1; Giacoppo S, 2017, ARCH IMMUNOL THER EX, V65, P363, DOI 10.1007/s00005-017-0460-z; Gir P, 2012, PLAST RECONSTR SURG, V129, P1277, DOI 10.1097/PRS.0b013e31824ecae6; Ha S, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.5.051206; Habisch HJ, 2007, J NEURAL TRANSM, V114, P1395, DOI 10.1007/s00702-007-0748-y; Haddad-Mashadrizeh A, 2013, CYTOTHERAPY, V15, P951, DOI 10.1016/j.jcyt.2013.03.003; Hammadi AM, 2017, EXP CLIN TRANSPLANT, V15, P147, DOI 10.6002/ect.mesot2016.P26; Harach T, 2017, NEUROBIOL AGING, V51, P83, DOI 10.1016/j.neurobiolaging.2016.11.009; Hedayatpour A, 2013, CELL J, V15, P142; Higgins Joseph J, 2013, MLO Med Lab Obs, V45, P52; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Hoyer C, 2016, J CLIN VIROL, V84, P82, DOI 10.1016/j.jcv.2016.10.006; Hsiao STF, 2012, STEM CELLS DEV, V21, P2189, DOI 10.1089/scd.2011.0674; Hwang PH, 1996, LARYNGOSCOPE, V106, P1482, DOI 10.1097/00005537-199612000-00007; Iwasa SN, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/4276927; Jiang YJ, 2011, EXPERT OPIN DRUG DEL, V8, P623, DOI 10.1517/17425247.2011.566267; Jozwiak S, 2010, CELL MED, V1, P71, DOI 10.3727/215517910X536618; Kantake M, 2017, REGEN MED, V12, P575, DOI 10.2217/rme-2017-0043; Katsuda Takeshi, 2015, Methods Mol Biol, V1212, P171, DOI 10.1007/7651_2014_98; Kilinc MO, 2018, CLIN TRANSL MED, V7, DOI 10.1186/s40169-018-0183-8; Kim HW, 2018, CELL TRANSPLANT, V27, P814, DOI 10.1177/0963689718766324; Kim KS, 2014, CELL TRANSPLANT, V23, P1585, DOI 10.3727/096368913X673450; Kim S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045757; Knippenberg S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036857; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Laso-Garcia F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202590; Lee M, 2018, BRAIN RES, V1691, P87, DOI 10.1016/j.brainres.2018.03.034; Lee M, 2016, BIOCHEM BIOPH RES CO, V479, P434, DOI 10.1016/j.bbrc.2016.09.069; Lehrer S, 2015, AM J ALZHEIMERS DIS, V30, P225, DOI 10.1177/1533317514545478; Li YH, 2015, EXP MOL PATHOL, V98, P145, DOI 10.1016/j.yexmp.2015.01.016; Liew LC, 2017, INT IMMUNOL, V29, P11, DOI 10.1093/intimm/dxx002; Liu DZ, 2012, TRANSL STROKE RES, V3, pS62, DOI 10.1007/s12975-012-0147-z; Liu DZ, 2010, ANN NEUROL, V67, P526, DOI 10.1002/ana.21924; Liu XF, 2014, PROG NEUROBIOL, V115, P92, DOI 10.1016/j.pneurobio.2013.11.007; Lo Furno D, 2016, STEM CELLS DEV, V25, P1615, DOI 10.1089/scd.2016.0135; Luan Zuo, 2005, Zhonghua Er Ke Za Zhi, V43, P580; Lucchinetti CF, 2011, NEW ENGL J MED, V365, P2188, DOI 10.1056/NEJMoa1100648; Ma T, 2013, CELL TRANSPLANT, V22, pS113, DOI 10.3727/096368913X672181; Marconi S, 2013, NEUROSCIENCE, V248, P333, DOI 10.1016/j.neuroscience.2013.05.034; Marfia G, 2016, STEM CELLS DEV, V25, P1095, DOI 10.1089/scd.2015.0268; Matchynski-Franks JJ, 2016, CELL TRANSPLANT, V25, P687, DOI 10.3727/096368916X690818; Mazzini L, 2012, PROG BRAIN RES, V201, P333, DOI 10.1016/B978-0-444-59544-7.00016-0; Mazzini L, 2009, AMYOTROPH LATERAL SC, V10, P123, DOI 10.1080/17482960802572707; MCCARTHY M, 2014, BMJ-BRIT MED J, V348, DOI DOI 10.1136/BMJ.G1397; McIntosh K, 2006, STEM CELLS, V24, P1246, DOI 10.1634/stemcells.2005-0235; Moon SM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/539051; Mosna F, 2010, STEM CELLS DEV, V19, P1449, DOI 10.1089/scd.2010.0140; Nasiri E, 2019, METAB BRAIN DIS, V34, P1131, DOI 10.1007/s11011-019-00421-4; Ogura F, 2014, STEM CELLS DEV, V23, P717, DOI 10.1089/scd.2013.0473; OMMAYA AK, 1963, LANCET, V2, P983; Oppliger B, 2016, STEM CELLS DEV, V25, P1234, DOI 10.1089/scd.2016.0027; Peng LY, 2008, STEM CELLS DEV, V17, P761, DOI 10.1089/scd.2007.0217; Ra J-CK, 2017, J CLIN CASE REP, V7, P1040; Ra JC, 2011, STEM CELLS DEV, V20, P1297, DOI 10.1089/scd.2010.0466; Ragerdi Kashani Iraj, 2012, Acta Med Iran, V50, P789; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Reza-Zaldivar EE, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00317; Ricaurte JC, 2000, CLIN INFECT DIS, V30, P613, DOI 10.1086/313732; Safford KM, 2002, BIOCHEM BIOPH RES CO, V294, P371, DOI 10.1016/S0006-291X(02)00469-2; Scherberich Arnaud, 2013, World J Stem Cells, V5, P1, DOI 10.4252/wjsc.v5.i1.1; Sengenes C, 2005, J CELL PHYSIOL, V205, P114, DOI 10.1002/jcp.20381; Shakhbazau A, 2016, CYTOTHERAPY, V18, P1245, DOI 10.1016/j.jcyt.2016.06.001; Shankle WR, 2009, ALZHEIMERS DEMENT, V5, P295, DOI 10.1016/j.jalz.2008.11.001; Siennicka K, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5762916; Simard PF, 2011, TRANSL STROKE RES, V2, P227, DOI 10.1007/s12975-011-0070-8; Smith OJ, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0505-8; Sowa Y, 2012, STEM CELLS DEV, V21, P1852, DOI 10.1089/scd.2011.0403; Staff NP, 2016, NEUROLOGY, V87, P2230, DOI 10.1212/WNL.0000000000003359; Stepien A, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/5302120; Strioga M, 2012, STEM CELLS DEV, V21, P2724, DOI 10.1089/scd.2011.0722; Sugaya K, 2006, PANMINERVA MED, V48, P87; Sun H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072926; Tang BL, 2017, REV NEUROSCIENCE, V28, P725, DOI 10.1515/revneuro-2017-0018; Wootla B, 2012, AUTOIMMUN DIS, V2012, DOI 10.1155/2012/969657; Wu JH, 2016, CHINESE MED J-PEKING, V129, P1592, DOI 10.4103/0366-6999.184464; Yamazaki H, 2015, NEUROSCI LETT, V609, P53, DOI 10.1016/j.neulet.2015.10.023; Yan YF, 2014, NEURAL REGEN RES, V9, P798, DOI 10.4103/1673-5374.131596; Yang YF, 2016, CELL TRANSPLANT, V25, P1177, DOI 10.3727/096368915X688957; Yeh DC, 2015, CELL TRANSPLANT, V24, P487, DOI 10.3727/096368915X686940; Zack-Williams SDL, 2015, WORLD J STEM CELLS, V7, P51, DOI 10.4252/wjsc.v7.i1.51; Zhao CP, 2007, CYTOTHERAPY, V9, P414, DOI 10.1080/14653240701376413; Zhou LH, 2017, SCI REP-UK, V7, DOI 10.1038/srep44058; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	118	12	12	2	4	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0301-4851	1573-4978		MOL BIOL REP	Mol. Biol. Rep.	OCT	2019	46	5					5257	5272		10.1007/s11033-019-04983-5			16	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	JL5SH	WOS:000495590600057	31327120	Other Gold			2021-06-18	
J	Anderson, MN; Womble, MN; Mohler, SA; Said, A; Stephenson-Brown, K; Kontos, AP; Elbin, RJ				Anderson, Melissa N.; Womble, Melissa N.; Mohler, Samantha A.; Said, Azkya; Stephenson-Brown, Katie; Kontos, Anthony P.; Elbin, R. J.			Preliminary Study of Fear of Re-Injury following Sport-Related Concussion in High School Athletes	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							CRUCIATE LIGAMENT RECONSTRUCTION; LOW-BACK-PAIN; CHRONIC MUSCULOSKELETAL PAIN; TEST-RETEST RELIABILITY; NEUROCOGNITIVE PERFORMANCE; AVOIDANCE BELIEFS; TAMPA SCALE; RETURN; RECOVERY; IMPACT	The influence of fear of re-injury that this variable has on recovery outcomes following sports-related concussion remains unknown. We examined changes in fear of re-injury throughout concussion recovery, and compared changes in neurocognitive, symptom, vestibular/ocular motor, and recovery time outcomes between concussed adolescent athletes who endorsed high and low fear of re-injury. Individuals with high fear of re-injury were more symptomatic and more likely to exhibit vestibular/ocular motor symptoms over clinical cutoffs than those with low fear of re-injury. Recovery time was not significantly different between the groups. These findings may help explain performance on more subjective concussion assessments.	[Anderson, Melissa N.] Univ Georgia, Dept Kinesiol, Concuss Res Lab, Athens, GA 30602 USA; [Womble, Melissa N.] Inova Med Grp, Inova Sports Med Concuss Program, Dept Orthopaed & Sports Med, Fairfax, VA USA; [Mohler, Samantha A.; Said, Azkya; Stephenson-Brown, Katie; Elbin, R. J.] Univ Arkansas, Off Sport Related Concuss Res, Dept Hlth Human Performance & Recreat, Fayetteville, AR 72701 USA; [Kontos, Anthony P.] Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, Pittsburgh, PA USA	Elbin, RJ (corresponding author), Univ Arkansas, Dept Hlth Human Performance & Recreat, Off Sport Concuss Res, 155 Stadium Dr, Fayetteville, AR 72701 USA.	rjelbin@uark.edu					Ardern CL, 2011, BRIT J SPORT MED, V45, P596, DOI 10.1136/bjsm.2010.076364; Bandura A., 1981, CULTIVATING COMPETEN, P13; Buer N, 2002, PAIN, V99, P485, DOI 10.1016/S0304-3959(02)00265-8; Chmielewski TL, 2008, J ORTHOP SPORT PHYS, V38, P746, DOI 10.2519/jospt.2008.2887; Collins MW, 2016, NEUROSURGERY, V79, P912, DOI 10.1227/NEU.0000000000001447; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; Elbin RJ, 2018, J NEUROL PHYS THER, V42, P142, DOI 10.1097/NPT.0000000000000230; Elbin RJ, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0910; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; HANSON SJ, 1992, J SPORT EXERCISE PSY, V14, P262, DOI 10.1123/jsep.14.3.262; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Johnson MH, 1997, PAIN, V69, P43, DOI 10.1016/S0304-3959(96)03272-1; Johnston LH, 2000, J SPORT REHABIL, V9, P290, DOI 10.1123/jsr.9.4.290; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Kori S., 1990, PAIN MANAG, V3, P35; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lentz TA, 2015, AM J SPORT MED, V43, P345, DOI 10.1177/0363546514559707; Mainwaring L. M., 2004, EMOTIONAL REACTION V, P17; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCullough KA, 2012, AM J SPORT MED, V40, P2523, DOI 10.1177/0363546512456836; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Podlog L, 2006, J APPL SPORT PSYCHOL, V18, P44, DOI 10.1080/10413200500471319; REESOR KA, 1988, PAIN, V32, P35, DOI 10.1016/0304-3959(88)90021-8; Roelofs J, 2007, PAIN, V131, P181, DOI 10.1016/j.pain.2007.01.008; Rusu AC, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-280; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Swinkels-Meewisse EJCM, 2003, MANUAL THER, V8, P29, DOI 10.1054/math.2002.0484; Tripp DA, 2007, REHABIL PSYCHOL, V52, P74, DOI 10.1037/0090-5550.52.1.74; VLAEYEN JWS, 1995, PAIN, V62, P363, DOI 10.1016/0304-3959(94)00279-N; Vlaeyen JWS, 2000, PAIN, V85, P317, DOI 10.1016/S0304-3959(99)00242-0; Vlaeyen JWS, 1999, MANUAL THER, V4, P187, DOI 10.1054/math.1999.0199; Wiese-Bjornstal DM, 2010, SCAND J MED SCI SPOR, V20, P103, DOI 10.1111/j.1600-0838.2010.01195.x; Yorke AM, 2017, SPORTS HEALTH, V9, P174, DOI 10.1177/1941738116678411; Zur O, 2015, DISABIL REHABIL, V37, P2197, DOI 10.3109/09638288.2014.1002577	38	12	12	1	12	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	AUG 18	2019	44	6					443	451		10.1080/87565641.2019.1667995		SEP 2019	9	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	JA0RH	WOS:000487033100001	31537099				2021-06-18	
J	Wang, CF; Zhao, CC; Liu, WL; Huang, XJ; Deng, YF; Jiang, JY; Li, WP				Wang, Chuan-fang; Zhao, Cheng-cheng; Liu, Wen-lan; Huang, Xian-jian; Deng, Yue-fei; Jiang, Ji-yao; Li, Wei-ping			Depletion of Microglia Attenuates Dendritic Spine Loss and Neuronal Apoptosis in the Acute Stage of Moderate Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article; Early Access						apoptosis; colony-stimulating factor 1 receptor inhibitor; microglia; spines; traumatic brain injury	CELL-DEATH; STRESS; ACCUMULATION; IMPACT; GAP-43; MODEL	Microglia are the primary immune cells in the central nervous system and undergo significant morphological and transcriptional changes after traumatic brain injury (TBI). However, their exact contribution to the pathogenesis of TBI is still debated and remains to be elucidated. In the present study, thy-1 GFP mice received a colony-stimulating factor 1 receptor inhibitor (PLX3397) for 21 consecutive days, then were subjected to moderate fluid percussion injury (FPI). Brain samples were collected at 1 day and 3 days after FPI for flow cytometry analysis, immunofluorescence, dendrite spine quantification, terminal deoxynucleotidyl transferase dUTP nick end labeling assay, and Western blot. We found that PLX3397 treatment significantly attenuated the percentages of resident microglia and infiltrated immune cells. Depletion of microglia promoted neurite outgrowth, preserved dendritic spines and reduced total brain cell and neuronal apoptosis after FPI, which was accompanied by decreased the protein levels of endoplasmic reticulum stress marker proteins, C/EBP-homologous protein and inositol-requiring kinase 1 alpha. Taken together, these findings suggest that microglial depletion may exert beneficial effects in the acute stage of FPI.	[Wang, Chuan-fang; Liu, Wen-lan; Huang, Xian-jian; Li, Wei-ping] Shenzhen Univ, Peoples Hosp 2, Affiliated Hosp 1, Brain Ctr,Shenzhen Key Lab Neurosurg, Shenzhen, Guangdong, Peoples R China; [Zhao, Cheng-cheng; Deng, Yue-fei] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China; [Jiang, Ji-yao] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Neurosurg, Shanghai, Peoples R China	Li, WP (corresponding author), Shenzhen Univ, Shenzhen Peoples Hosp 2, Brain Ctr, Shenzhen Key Lab Neurosurg, 3002 Sungang Rd, Shenzhen 518035, Guangdong, Peoples R China.	wpli@szu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81772685, 81772058]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2018M643330]; Natural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [2018A030310042]; international cooperation research projects of Shenzhen Science and Technology Program [GJHZ20160301163419476]; Shenzhen Science and Technology Program [JCYJ20170413173149177]; Shenzhen Development and Reform Commissions Stroke Screening and Prevention Public Service Platform improving program	This research was supported by grants from the National Natural Science Foundation of China (81772685; 81772058), the China Postdoctoral Science Foundation (2018M643330), the Natural Science Foundation of Guangdong Province (2018A030310042), the international cooperation research projects of Shenzhen Science and Technology Program (GJHZ20160301163419476), the basic research projects (subject arrangement) of Shenzhen Science and Technology Program (JCYJ20170413173149177) and Shenzhen Development and Reform Commissions Stroke Screening and Prevention Public Service Platform improving program.	Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Campbell JN, 2012, J NEUROTRAUM, V29, P201, DOI 10.1089/neu.2011.1761; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Chourbaji S, 2008, FASEB J, V22, P3129, DOI 10.1096/fj.08-106450; Corrigan F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0738-9; Dammeijer F, 2017, CANCER IMMUNOL RES, V5, P535, DOI 10.1158/2326-6066.CIR-16-0309; DANI JW, 1991, NEUROSCIENCE, V40, P277, DOI 10.1016/0306-4522(91)90190-Y; Dewan MC, 2019, J NEUROSURG, V130, P1080, DOI 10.3171/2017.10.JNS17352; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Doran SJ, 2019, J NEUROTRAUM, V36, P1040, DOI 10.1089/neu.2018.6019; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Erblich B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026317; Erturk A, 2016, J NEUROSCI, V36, P9962, DOI 10.1523/JNEUROSCI.1898-15.2016; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Hong S, 2016, SCIENCE, V352, P712, DOI 10.1126/science.aad8373; Hood KN, 2018, J NEUROSCI, V38, P2372, DOI 10.1523/JNEUROSCI.1756-17.2018; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Jin WN, 2017, J CEREBR BLOOD F MET, V37, P2224, DOI 10.1177/0271678X17694185; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Lafrenaye AD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0405-6; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; LAWSON LJ, 1992, NEUROSCIENCE, V48, P405, DOI 10.1016/0306-4522(92)90500-2; Li MS, 2017, J CEREBR BLOOD F MET, V37, P2383, DOI 10.1177/0271678X16666551; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Madathil SK, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00964; Migaud M, 1998, NATURE, V396, P433; Morrison H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13581-z; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; Peranzoni E, 2018, P NATL ACAD SCI USA, V115, pE4041, DOI 10.1073/pnas.1720948115; Popescu C, 2015, J Med Life, V8, P272; Rice RA, 2015, J NEUROSCI, V35, P9977, DOI 10.1523/JNEUROSCI.0336-15.2015; Rodriguez A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001997; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Salter MW, 2014, CELL, V158, P15, DOI 10.1016/j.cell.2014.06.008; Sauter KA, 2014, J LEUKOCYTE BIOL, V96, P265, DOI 10.1189/jlb.2A0114-006R; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Shi QQ, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf6295; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Sword J, 2013, BRAIN, V136, P1446, DOI 10.1093/brain/awt026; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Thored P, 2009, GLIA, V57, P835, DOI 10.1002/glia.20810; Tremblay ME, 2011, J NEUROSCI, V31, P16064, DOI 10.1523/JNEUROSCI.4158-11.2011; Wearne SL, 2005, NEUROSCIENCE, V136, P661, DOI 10.1016/j.neuroscience.2005.05.053; Winston CN, 2013, J NEUROTRAUM, V30, P1966, DOI 10.1089/neu.2013.2960; Witcher KG, 2018, GLIA, V66, P2719, DOI 10.1002/glia.23523; Wofford KL, 2017, EXP NEUROL, V290, P85, DOI 10.1016/j.expneurol.2017.01.004; Xavier AL, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0593; Zhao CC, 2017, J NEUROTRAUM, V34, P1636, DOI 10.1089/neu.2016.4759; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247	58	12	12	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma												10.1089/neu.2019.6460		SEP 2019	12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	IZ0PE	WOS:000486792100001	31397209				2021-06-18	
J	Chen, W; Zhao, L; Zhang, JX; Wang, BB; Xu, GH; Lin, C; Liu, N				Chen, Wei; Zhao, Lin; Zhang, Junxia; Wang, Binbin; Xu, Guanhua; Lin, Chao; Liu, Ning			Elevated expression of miR-302 cluster improves traumatic brain injury by inhibiting phosphorylation of connexin43 via ERK signaling	JOURNAL OF CHEMICAL NEUROANATOMY			English	Article						Traumatic brain injury (TBI); Connexin43; ERK1/2; miR-302 cluster; Cognitive function	MORRIS WATER MAZE; MICRORNA; DIFFERENTIATION; MODELS	We have previously found that connexin43 is phosphorylated by extracellular-signal-regulated kinase (ERK)1/2 in rats of cerebral ischemia. Here, we investigated the potential roles of microRNA (miR)-302 cluster in the regulation of ERK1/2 mediated connexin43 phosphorylation and protection from traumatic brain injury (TBI) induced brain damage. We examined apoptosis and ERK1/2 and connexin43 phosphorylation in SH-SY5Y cells undergoing pulsatile shear stress treatment. We assessed expression of miR-302 cluster members and exogenously expressed miR-302 cluster in stressed cells to determine its effect on ERK1/2 and connexin43 phosphorylation. Finally, we investigated the effects of elevated miR-302 expression on cognitive function and brain damage in TBI rats generated by the controlled cortical impact method. Pulsatile shear stress leads to increased apoptosis and upregulation of ERK1/2 and connexin43 phosphorylation in vitro. Additionally, pulsatile shear stress significantly suppressed miR-302 expression and exogenously expression of miR-302 cluster inhibited ERK1/2 and connexin43 phosphorylation. Finally, elevated expression of miR-302 cluster not only improved cognitive function of TBI rats but also attenuated brain damage by suppressing edema and reducing contusion volume. Our study suggests that miR-302 protects rats from TBI induced brain damage and cognitive impairment and may represent an effective therapeutic strategy for TBI.	[Chen, Wei; Zhao, Lin; Zhang, Junxia; Wang, Binbin; Xu, Guanhua; Lin, Chao; Liu, Ning] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China	Zhao, L; Liu, N (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	liuning_1958@sina.com; zl_nirvana@126.com			Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BK20160047]; Livelihood Project of Shanghai Science and Technology Commission [PKJ2016-Y31]	Natural Science Foundation of Jiangsu Province (BK20160047), Livelihood Project of Shanghai Science and Technology Commission (PKJ2016-Y31).	Anokye-Danso F, 2011, CELL STEM CELL, V8, P376, DOI 10.1016/j.stem.2011.03.001; Chen T, 2017, CELL MOL NEUROBIOL, V37, P43, DOI 10.1007/s10571-016-0341-8; Chen W. P., 2017, SCI REP, V7, P1, DOI DOI 10.1038/S41598-017-09923-6; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Gao ZQ, 2015, OPEN BIOL, V5, DOI 10.1098/rsob.150138; Georgiou AP, 2013, BRIT J ANAESTH, V110, P357, DOI 10.1093/bja/aes500; Ghasemi-Kasman M, 2017, BIOMED PHARMACOTHER, V96, P1222, DOI 10.1016/j.biopha.2017.11.094; Ghasemi-Kasman M, 2018, MOL CELL NEUROSCI, V86, P50, DOI 10.1016/j.mcn.2017.11.012; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Lipchina I, 2012, CELL CYCLE, V11, P1517, DOI 10.4161/cc.19846; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Pan YB, 2017, NEUROSCIENCE, V367, P189, DOI 10.1016/j.neuroscience.2017.10.046; Parchem RJ, 2015, CELL REP, V12, P760, DOI 10.1016/j.celrep.2015.06.074; Pi JJ, 2017, CIRC RES, V120, P85, DOI 10.1161/CIRCRESAHA.116.309757; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Triyoso DH, 1999, J PHYSIOL-LONDON, V515, P355, DOI 10.1111/j.1469-7793.1999.355ac.x; Tucker LB, 2018, NEUROSCI BIOBEHAV R, V88, P187, DOI 10.1016/j.neubiorev.2018.03.010; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wang H, 2013, NEUROL SCI, V34, P11, DOI 10.1007/s10072-012-1145-3; Whiting MD, 2016, METHODS MOL BIOL, V1462, P553, DOI 10.1007/978-1-4939-3816-2_30; Yang SL, 2015, DEV BIOL, V408, P140, DOI 10.1016/j.ydbio.2015.09.020; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085	27	12	14	2	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0891-0618	1873-6300		J CHEM NEUROANAT	J. Chem. Neuroanat.	SEP	2019	99						1	8		10.1016/j.jchemneu.2019.05.003			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	IQ3SJ	WOS:000480671100001	31096001				2021-06-18	
J	Dreyer, NA; Mack, CD; Anderson, RB; Wojtys, EM; Hershman, EB; Sills, A				Dreyer, Nancy A.; Mack, Christina D.; Anderson, Robert B.; Wojtys, Edward M.; Hershman, Elliott B.; Sills, Allen			Lessons on Data Collection and Curation From the NFL Injury Surveillance Program	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						football; data curation; epidemiology surveillance; electronic health records	NATIONAL FOOTBALL LEAGUE; PLAYING SURFACES; HEALTH-CARE	Background: "Research-ready" evidence platforms that link sports data with anonymized electronic health records (EHRs) or other data are important tools for evaluating injury occurrence in response to changes in games, training, rules, and other factors. While there is agreement that high-quality data are essential, there is little evidence to guide data curation. Hypothesis: We hypothesized that an EHR used in the course of clinical care and curated for research readiness can provide a robust evidence platform. Our purpose was to describe the data curation used for active injury surveillance by the National Football League (NFL). Study Design: Dynamic cohort study. Methods: Players provide informed consent for research activities through the collective bargaining process. A league-wide EHR is used to record injuries that come to the attention of the teams' athletic trainers and physicians, NFL medical spotters, or unaffiliated neurotrauma consultants. Information about football activities and injuries are linkable by player, setting, and event to other sports-related data, including game statistics and game-day stadium quality measures, using a unique player identification designed to protect player privacy. Ongoing data curation is used to review data completeness and accuracy and is adjusted over time in response to findings. Results: The core data curation activities include monthly injury summaries to team staff, queries to resolve incomplete reporting, and periodic external checks. Experiences derived from producing more than 100 reports per year on diverse topics are used to update coding training and related guidance documents in response to missing data or inconsistent coding that is observed. Roughly 20% more injuries were recorded for the same "reportable" injuries after switching from targeted reporting to an EHR. Conclusion: Research-ready databases need systematic curation for quality and completeness, along with related action plans. More injuries were reported through EHR than through targeted reporting.	[Dreyer, Nancy A.] IQVIA, Real World & Analyt Solut, Ctr Adv Evidence Generat, 201 Broadway,5th Floor, Cambridge, MA 02139 USA; [Mack, Christina D.] IQVIA, Real World & Analyt Solut, Ctr Adv Evidence Generat, Res Triangle Pk, NC USA; [Anderson, Robert B.] OrthoCarolina, Foot & Ankle Inst, Charlotte, NC USA; [Anderson, Robert B.] Titletown Sports Med, Sports Foot Ankle, Green Bay, WI USA; [Wojtys, Edward M.] Univ Michigan, Dept Orthopaed Surg, MedSport, Ann Arbor, MI 48109 USA; [Hershman, Elliott B.] North Shore LIJ Healthcare Syst, North Shore LIJ Orthopaed Inst, Lenox Hill Hosp, Dept Orthopaed Surg, New York, NY USA; [Sills, Allen] Natl Football League, New York, NY USA	Dreyer, NA (corresponding author), IQVIA, Real World & Analyt Solut, Ctr Adv Evidence Generat, 201 Broadway,5th Floor, Cambridge, MA 02139 USA.	nancy.dreyer@iqvia.com			NFL	N.A.D. and C.D.M. are employed by IQVIA; R.B.A. received consulting fees from Amniox, Artelon, Arthrex, Bioventus, DJO, Wright Medical, and Zimmer Biomet, and royalties from Arthrex, Biomet, Wright Medical, and Zimmer Biomet; E.M.W. received travel payments from the National Football League (NFL) and AOSSM and payments from the NFL and NIAMS/KAI, he also serves as editor in chief for Sports Health; E.B.H. received consulting fees and royalties from Active Implants Corp and royalties from Zimmer Biomet; and A.S. is employed by the NFL. This research program was funded by the NFL and approved by the National Football League Players Association under a collectively bargained agreement pertaining to NFL player research. The authors assert that these results are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation.	Califf RM, 2017, JAMA-J AM MED ASSOC, V317, P693, DOI 10.1001/jama.2017.0410; Califf RM, 2016, NEW ENGL J MED, V375, P2395, DOI 10.1056/NEJMsb1610128; Daniel G, 2018, WHITE PAPER CHARACTE; Dreyer NA, 2018, THER INNOV REGUL SCI, V52, P362, DOI 10.1177/2168479018763591; Dreyer NA, 2016, CURR MED RES OPIN, V32, P1697, DOI 10.1080/03007995.2016.1203768; Gliklich RE., 2014, REGISTRIES EVALUATIN, V3rd ed; Gliklich RE, 2018, 21 CENTURY PATIENT R; Hershman EB, 2012, AM J SPORT MED, V40, P2200, DOI 10.1177/0363546512458888; Jacobs JJ, 2013, J BONE JOINT SURG AM, V95A, P1629, DOI [10.2106/JBJS.L.01370, 10.2106/JBJS.M.00137]; Lessley DJ, 2018, AM J SPORT MED, V46, P3502, DOI 10.1177/0363546518804498; Mack CD, 2019, AM J SPORT MED, V47, P189, DOI 10.1177/0363546518808499; Matava MJ, 2016, J KNEE SURG, V29, P370, DOI 10.1055/s-0036-1584313; Miksad RA, 2018, CLIN PHARMACOL THER, V103, P202, DOI 10.1002/cpt.946; POWELL JW, 1992, AM J SPORT MED, V20, P686, DOI 10.1177/036354659202000609; Sherman RE, 2016, NEW ENGL J MED, V375, P2293, DOI 10.1056/NEJMsb1609216; U.S. Food and Drug Administration: Center for Devices and Radiological Health Center for Biologics Evaluation and Research, US REAL WORLD EV SUP; US Food and Drug Administration, 2018, US EL HLTH REC DAT C	17	12	12	0	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	SEP	2019	11	5					440	445		10.1177/1941738119854759			6	Sport Sciences	Sport Sciences	IT6GH	WOS:000482968400008	31265352	Green Published			2021-06-18	
J	Purkayastha, S; Williams, B; Murphy, M; Lyng, S; Sabo, T; Bell, KR				Purkayastha, Sushmita; Williams, Benjamin; Murphy, Megan; Lyng, Sydney; Sabo, Tonia; Bell, Kathleen R.			Reduced heart rate variability and lower cerebral blood flow associated with poor cognition during recovery following concussion	AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL			English	Article						Concussion; Traumatic brain injury; Autonomic nervous system; Heart rate variability; Cerebral blood flow	AUTONOMIC NEURAL-CONTROL; RESISTANCE; REST; VASCULATURE; CONDUCTANCE; DYSFUNCTION; HUMANS	Although physiological deficits such as altered cerebral blood flow (CBF), and autonomic nervous system (ANS) dysregulation have been reported following a concussion, the relationship between CBF and ANS with functional outcome post-injury remains unclear. Our present study was designed to examine heart-rate variability (HRV) using percentage of successive NN intervals (pNN50) and CBF on day-3 (T1), day-21 (T2), and day-90 (T3) following a concussion in collegiate athletes (N = 31) in comparison to non-injured controls (N = 31). Continuous RR-interval (3-lead electrocardiogram), middle cerebral artery blood velocity (MCAV; transcranial Doppler ultrasonography), mean arterial pressure (MAP; finger photoplethysmography) were obtained at rest. Cerebrovascular conductance index (CVCi) was estimated as a ratio of MCAV to MAP. Cognition was evaluated with standard assessment of concussion (SAC), and Trails A & B. Compared to the controls, lower HRV (43 +/- 15 vs. 27 +/- 20%; p < 0.0001) was observed at T1 with normalization at T2 and T3. No difference in MCAV between the control and the concussed groups across the three time points were observed. However, post-hoc analyses indicated a positive relationship between MCAV at T1 phase with HRV and CVCi during T2, and T3 phases. Higher MCAV at T1 was also associated with better cognition scores during the asymptomatic T2 phase in the concussed athletes. Therefore, our results indicate ANS dysregulation during the acute recovery phase after a concussion. Differences in CBF may be one of the underlying causes behind heterogeneity in clinical symptoms and functional outcomes after a concussion and future studies are warranted to validate this finding.	[Purkayastha, Sushmita; Murphy, Megan; Lyng, Sydney] Southern Methodist Univ, Dept Appl Physiol & Wellness, Simmons Sch Educ & Human Dev, 3101 Univ Blvd,Rm 118 A, Dallas, TX 75205 USA; [Purkayastha, Sushmita; Bell, Kathleen R.] Univ Texas Southwestern Med Ctr, Dept Phys Med & Rehabil, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Williams, Benjamin] Southern Methodist Univ, Dept Stat Sci, 3225 Daniel Ave, Dallas, TX 75205 USA; [Sabo, Tonia] Univ Texas Southwestern Med Ctr, Dept Pediat, Div Pediat Neurol & Pain Management, 5323 Harry Hines Blvd, Dallas, TX 75390 USA	Purkayastha, S (corresponding author), Southern Methodist Univ, Dept Appl Physiol & Wellness, Simmons Sch Educ & Human Dev, 3101 Univ Blvd,Rm 118 A, Dallas, TX 75205 USA.	spurkayastha@smu.edu	Purkaysastha, Sushmita/Y-8908-2019	Williams, Benjamin/0000-0001-8474-5066; Sabo, Tonia/0000-0002-7293-4764; Bell, Kathleen/0000-0002-0928-2046	University Research Council Grant at the Southern Methodist University (SMU), Dallas, Texas; Texas Institute for Brain Injury & Repair (TIBIR) at University of Texas Southwestern Medical Center, Dallas, Texas; Athletic Department at SMU	This study was supported in part by funds provided by the University Research Council Grant at the Southern Methodist University (SMU), Dallas, Texas and the Texas Institute for Brain Injury & Repair (TIBIR) at University of Texas Southwestern Medical Center, Dallas, Texas. The authors also wish to thank the athletes for volunteering in the study and the Athletic Department at SMU for their support.	AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; Abaji JP, 2016, J NEUROTRAUM, V33, P811, DOI 10.1089/neu.2015.3989; Allen B, 2015, PSYCHOPHYSIOLOGY, V52, P277, DOI 10.1111/psyp.12321; Billman GE, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00026; Bishop SA, 2018, CLIN PHYSIOL FUNCT I, V38, P733, DOI 10.1111/cpf.12487; Bowie CR, 2006, NAT PROTOC, V1, P2277, DOI 10.1038/nprot.2006.390; Camm AJ, 1996, EUR HEART J, V17, P354; Churchill NW, 2017, NEUROIMAGE-CLIN, V14, P480, DOI 10.1016/j.nicl.2017.02.015; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dobson JL, 2017, AM J PHYSIOL-REG I, V312, pR575, DOI 10.1152/ajpregu.00499.2016; Draghici AE, 2016, J PHYSIOL ANTHROPOL, V35, DOI 10.1186/s40101-016-0113-7; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Giza CC, 2018, JAMA NEUROL, V75, P399, DOI 10.1001/jamaneurol.2018.0006; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Hilz MJ, 2015, J NEUROTRAUM, V32, P1796, DOI 10.1089/neu.2014.3842; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kamins J, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097464; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kemp AH, 2017, NEUROSCI BIOBEHAV R, V83, P547, DOI 10.1016/j.neubiorev.2017.09.006; Kemp AH, 2016, BIOL PSYCHOL, V117, P216, DOI 10.1016/j.biopsycho.2016.04.006; Kim DH, 2006, J AM GERIATR SOC, V54, P1751, DOI 10.1111/j.1532-5415.2006.00940.x; La Fountaine MF, 2018, INT J PSYCHOPHYSIOL, V132, P155, DOI 10.1016/j.ijpsycho.2017.11.016; La Fountaine MF, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00013; Laborde S, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00213; LAUTT WW, 1989, MICROVASC RES, V37, P230, DOI 10.1016/0026-2862(89)90040-X; Leddy J, 2017, J ATHL TRAINING, V52, P299, DOI 10.4085/1062-6050-51.11.08; MacFarlane MP, 2015, BRAIN INJURY, V29, P139, DOI 10.3109/02699052.2014.965208; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Metting Z, 2014, BRAIN COGNITION, V86, P24, DOI 10.1016/j.bandc.2014.01.012; Ogoh S, 2008, STROKE, V39, P1979, DOI 10.1161/STROKEAHA.107.510008; OLEARY DS, 1991, AM J PHYSIOL, V260, pH632; Purkayastha S, 2012, SEMIN NEUROL, V32, P411, DOI 10.1055/s-0032-1331812; Purkayastha S, 2013, EXP PHYSIOL, V98, P451, DOI 10.1113/expphysiol.2012.066118; Quintana DS, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.73; Saus ER, 2006, MIL PSYCHOL, V18, pS3, DOI 10.1207/s15327876mp1803s_2; Senthinathan A, 2017, CLIN J SPORT MED, V27, P288, DOI 10.1097/JSM.0000000000000337; Serrador JM, 2000, STROKE, V31, P1672, DOI 10.1161/01.STR.31.7.1672; SMITH JJ, 1994, J CLIN PHARMACOL, V34, P375, DOI 10.1002/j.1552-4604.1994.tb04977.x; Tarvainen MP, 2014, COMPUT METH PROG BIO, V113, P210, DOI 10.1016/j.cmpb.2013.07.024; Thayer JF, 2009, ANN BEHAV MED, V37, P141, DOI 10.1007/s12160-009-9101-z; Thayer JF, 2009, NEUROSCI BIOBEHAV R, V33, P81, DOI 10.1016/j.neubiorev.2008.08.004; Ture U, 2000, J NEUROSURG, V92, P676, DOI 10.3171/jns.2000.92.4.0676; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072; Zhang R, 2002, CIRCULATION, V106, P1814, DOI 10.1161/01.CIR.0000031798.07790.FE	47	12	12	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1566-0702	1872-7484		AUTON NEUROSCI-BASIC	Auton. Neurosci-Basic Clin.	SEP	2019	220								102548	10.1016/j.autneu.2019.04.004			7	Neurosciences	Neurosciences & Neurology	IN5JF	WOS:000478711000008	31331690				2021-06-18	
J	Zhang, LM; Zhang, DX; Fu, L; Li, Y; Wang, XP; Qi, MM; Li, CC; Song, PP; Wang, XD; Kong, XJ				Zhang, Li-Min; Zhang, Dong-Xue; Fu, Lan; Li, Yan; Wang, Xu-Peng; Qi, Man-Man; Li, Chen-Chen; Song, Pan-Pan; Wang, Xiao-Dong; Kong, Xiang-Jun			Carbon monoxide-releasing molecule-3 protects against cortical pyroptosis induced by hemorrhagic shock and resuscitation via mitochondrial regulation	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Carbon monoxide; Neuroprotection; Pyroptosis; Soluble guanylate-cyclase; Cyclic guanosine monophosphate	TRAUMATIC BRAIN-INJURY; RAT MODEL; SEVOFLURANE; INFLAMMASOME; ISCHEMIA; DEFICITS	Objective: Carbon monoxide (CO) releasing molecule (CORM)-3, a water-soluble CORM, has protective effects against inflammatory and ischemia/reperfusion injury. We determined the effect of CORM-3 against neuronal pyroptosis in a model of hemorrhagic shock and resuscitation (HSR) in rats via mitochondrial regulation. Methods: Rats were treated with CORM-3 (4 mg/kg) in vitro after HSR. We measured cortical CO content 3-24 h after HSR; assessed neuronal pyroptosis, mitochondrial morphology, ROS production, and mitochondrial membrane potential at 12 h after HSR; and evaluated brain magnetic resonance imaging at 24 h after HSR and learning ability 30 days after HSR. We also measured soluble guanylate-cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signaling pathway activity using a blocker of sGC, NS2028, and I-125-cGMP assay. Results: Among rats that underwent HSR, CORM-3-treated rats had more CO in the cortical tissue than sham-and iCORM-3-treated rats. CORM-3-treated rats had significantly less neuronal pyroptosis in the cortical tissue; higher sGC activity and cGMP content; lower ROS production; better mitochondrial morphology, function, and membrane potential; and enhanced learning/memory ability than HSR-treated rats. However, these neuroprotective effects of CORM-3 were partially inhibited by NS2028. Conclusion: CORM-3 may alleviate neuronal pyroptosis and improve neurological recovery in HSR through mitochondrial regulation mediated by the sGC-cGMP pathway. Thus, CO administration could be a promising therapeutic strategy for hemorrhagic shock.	[Zhang, Li-Min; Li, Yan; Wang, Xu-Peng; Qi, Man-Man; Li, Chen-Chen; Song, Pan-Pan; Wang, Xiao-Dong] Cangzhou Cent Hosp, Dept Anesthesiol, Cangzhou, Peoples R China; [Zhang, Dong-Xue] Cangzhou Cent Hosp, Dept Gerontol, Cangzhou, Peoples R China; [Fu, Lan] Cangzhou Cent Hosp, Dept Radiodiag, Cangzhou, Peoples R China; [Kong, Xiang-Jun] Cangzhou Cent Hosp, Cent Lab, Cangzhou, Peoples R China	Zhang, LM (corresponding author), Cangzhou Cent Hosp, Dept Anesthesiol, Cangzhou, Peoples R China.	azai2010@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81701296]	This work was supported by grants from the National Natural Science Foundation of China (81701296).	Ampawong S, 2017, EXP BIOL MED, V242, P411, DOI 10.1177/1535370216681553; Budinich CS, 2013, PHARMACOL BIOCHEM BE, V108, P66, DOI 10.1016/j.pbb.2013.04.001; Cheng YY, 2017, CURR PHARM DESIGN, V23, P3884, DOI 10.2174/1381612823666170413122439; Choi EY, 2015, EUR J PHARMACOL, V764, P22, DOI 10.1016/j.ejphar.2015.06.039; Choi YK, 2016, NAT MED, V22, P1335, DOI 10.1038/nm.4188; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Egemnazarov B., 2009, AM J PHYSL LUNG CELL, V296; Eroglu O., 2017, INJ INT J CARE INJUR, V48; Feng SY, 2018, J MOL BIOL, V430, P3068, DOI 10.1016/j.jmb.2018.07.002; Fine JM, 2017, J NEUROL SCI, V380, P164, DOI 10.1016/j.jns.2017.07.028; Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703; Fujisaki N, 2016, MED GAS RES, V6, P122, DOI 10.4103/2045-9912.191357; Georgoff PE, 2017, J NEUROTRAUM, V34, P2167, DOI 10.1089/neu.2016.4859; Han YC, 2018, REDOX BIOL, V16, P32, DOI 10.1016/j.redox.2018.02.013; He YG, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/935738; Henninger N, 2007, BRAIN RES, V1163, P119, DOI 10.1016/j.brainres.2007.06.006; Hu XW, 2016, J SURG RES, V206, P307, DOI 10.1016/j.jss.2016.08.026; Ida K. K., 2017, BR J ADDICT BR J ANA, V120, P1245; Inoue K, 2008, SHOCK, V29, P252, DOI 10.1097/shk.0b013e3180cab913; Ito M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8360; Joe Y, 2015, AM J PATHOL, V185, P2867, DOI 10.1016/j.ajpath.2015.07.002; Kudo Y, 2006, CRIT CARE MED, V34, P2820, DOI 10.1097/01.CCM.0000242522.48734.64; Lee HM, 2010, ACTA ANAESTH SCAND, V54, P328, DOI 10.1111/j.1399-6576.2009.02129.x; Lu YH, 2016, BIOMATERIALS, V90, P27, DOI 10.1016/j.biomaterials.2016.03.003; Mariappan N., 2007, AM J PHYSL HEART CIR, V293; Misawa T, 2013, NAT IMMUNOL, V14, P454, DOI 10.1038/ni.2550; Nils S., 2013, PLOS ONE, V8; Ryter SW, 2016, TRANSL RES, V167, P7, DOI 10.1016/j.trsl.2015.06.011; Sanna N. M., 2014, EMBO J, V32, P86; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sekerdag E, 2018, CURR NEUROPHARMACOL, V16, P1396, DOI 10.2174/1570159X16666180302115544; Suliman HB, 2016, PHARMACOL REV, V68, P20, DOI 10.1124/pr.115.011502; Wu HY, 2016, CELL PHYSIOL BIOCHEM, V40, P1692, DOI 10.1159/000453218; Wu J., 2017, FRONT PHYSL, V8; Xia PP, 2018, CELL PHYSIOL BIOCHEM, V45, P2351, DOI 10.1159/000488183; Yamanaka R, 2013, FEBS LETT, V587, P2643, DOI 10.1016/j.febslet.2013.06.049; Yang J., 2014, AM J PHYSL RENAL PHY, V306; Zhang DX, 2017, BIOMED PHARMACOTHER, V87, P332, DOI 10.1016/j.biopha.2016.12.115; Zhang LM, 2019, J SURG RES, V235, P591, DOI 10.1016/j.jss.2018.10.046; Zheng G., 2019, EBIOMEDICINE; Zhou XY, 2017, BEHAV BRAIN RES, V322, P70, DOI 10.1016/j.bbr.2016.12.046; Zhu S, 2019, NEUROCHEM INT, V124, P141, DOI 10.1016/j.neuint.2019.01.003	42	12	14	1	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	SEP	2019	141						299	309		10.1016/j.freeradbiomed.2019.06.031			11	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	IU9SG	WOS:000483920100027	31265876				2021-06-18	
J	Hegyi, A; Lahti, J; Giacomo, JP; Gerus, P; Cronin, NJ; Morin, JB				Hegyi, Andras; Lahti, Johan; Giacomo, Jean-Patrick; Gerus, Pauline; Cronin, Neil J.; Morin, Jean-Benoit			Impact of Hip Flexion Angle on Unilateral and Bilateral Nordic Hamstring Exercise Torque and High-Density Electromyography Activity	JOURNAL OF ORTHOPAEDIC & SPORTS PHYSICAL THERAPY			English	Article						biceps femoris; rehabilitation; semitendinosus; strain injury	BICEPS FEMORIS; PROFESSIONAL FOOTBALL; TISSUE STRAINS; MUSCLE; INJURIES; EMG; SEMITENDINOSUS; ACTIVATION; SOCCER; RISK	BACKGROUND: In the bilateral Nordic hamstring exercise (NHE). hamstrings operate at relatively short lengths, which may limit the efficacy of the NHE in hamstring injury prevention. OBJECTIVES: To examine knee flexion torque and biceps femoris long head (BFLH) and semitendinosus (ST) high-density electromyography (EMG) activity during the unilateral and bilateral NHE, performed with either neutral (NHE0) or 90 degrees-flexed (NHE90) hips. METHODS: In this laboratory study, exercises were performed on a novel device at the eccentric 1-repetition maximum load defined for 90 degrees to 15 degrees of knee range of motion. Torque and EMG signals normalized to maximal voluntary isometric activity were compared in different phases of the exercises with statistical parametric mapping. RESULTS: The EMG levels were lower in NHE90 than in NHEO, mainly in the second half of the movement. Knee flexor eccentric torque was higher in NHE90 than in NHEO from the beginning to 87% of the bilateral movement, and over the entire unilateral movement. In NHEO, ST activity compared to BFLH activity was higher during the initial movement phase and lower when the movement was close to knee extension. Torque and EMG activity were generally similar in the bilateral and unilateral modes. CONCLUSION: If performed with neutral hips. the NHE selectively activates the BFLH near full knee extension. Performing the NHE with hips flexed to 90 degrees is preferable when higher passive torque and ST selectivity are targeted at a longer muscle length. Performing these exercises unilaterally could help train each limb separately, with similar torque and EMG output to those of the bilateral conditions.	[Hegyi, Andras; Cronin, Neil J.] Univ Jyvaskyla, Fac Sport & Hlth Sci, Neuromuscular Res Ctr, Jyvaskyla, Finland; [Lahti, Johan; Gerus, Pauline; Morin, Jean-Benoit] Univ Cote dAzur, LAMHESS, Nice, France; [Giacomo, Jean-Patrick] Ctr Evaluat & Anal Performance Sport, Carros, France	Hegyi, A (corresponding author), Off LL 175,POB 35, Jyvaskyla 40014, Finland.	andras.a.hegyi@jyu.fi	Cronin, Neil/B-3860-2011	Cronin, Neil/0000-0002-5332-1188; Morin, Jean-Benoit/0000-0003-3808-6762			Adler R.J., 2007, RANDOM FIELDS GEOMET; Askling C., 2011, BRIT J SPORT MED, V45, pe2, DOI DOI 10.1136/BJSM.2010.081570.15; Askling CM, 2014, BRIT J SPORT MED, V48, P532, DOI 10.1136/bjsports-2013-093214; Askling CM, 2013, BRIT J SPORT MED, V47, DOI 10.1136/bjsports-2013-092165; Bourne MN, 2016, SCAND J MED SCI SPOR, V26, P666, DOI 10.1111/sms.12494; Bourne MN, 2018, SPORTS MED, V48, P251, DOI 10.1007/s40279-017-0796-x; Bourne MN, 2017, BRIT J SPORT MED, V51, P1021, DOI 10.1136/bjsports-2015-095739; Brooks JHM, 2006, AM J SPORT MED, V34, P1297, DOI 10.1177/0363546505286022; CAROLAN B, 1992, J APPL PHYSIOL, V73, P911; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Connell DA, 2004, AM J ROENTGENOL, V183, P975, DOI 10.2214/ajr.183.4.1830975; De Luca CJ, 2012, J BIOMECH, V45, P555, DOI 10.1016/j.jbiomech.2011.11.010; De Smet AA, 2000, AM J ROENTGENOL, V174, P393, DOI 10.2214/ajr.174.2.1740393; Ditroilo M, 2013, J ELECTROMYOGR KINES, V23, P1111, DOI 10.1016/j.jelekin.2013.05.008; Ekstrand J, 2016, BRIT J SPORT MED, V50, P731, DOI 10.1136/bjsports-2015-095359; Fernandez-Gonzalo R, 2016, INT J SPORTS MED, V37, P559, DOI 10.1055/s-0042-100290; Fiorentino NM, 2014, J BIOMECH, V47, P3325, DOI 10.1016/j.jbiomech.2014.08.010; Fiorentino NM, 2012, J BIOMECH, V45, P647, DOI 10.1016/j.jbiomech.2011.12.015; Fousekis K, 2011, BRIT J SPORT MED, V45, P709, DOI 10.1136/bjsm.2010.077560; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Fyfe JJ, 2013, J ELECTROMYOGR KINES, V23, P523, DOI 10.1016/j.jelekin.2012.12.006; Hagglund M, 2013, BRIT J SPORT MED, V47, P738, DOI 10.1136/bjsports-2013-092215; Hegyi A, 2018, SCAND J MED SCI SPOR, V28, P992, DOI 10.1111/sms.13016; Hickey J, 2014, BRIT J SPORT MED, V48, P729, DOI 10.1136/bjsports-2013-092884; Kellis E, 2017, MLTJ-MUSCLE LIGAMENT, V7, P286, DOI 10.11138/mltj/2017.7.2.286; Koulouris G, 2007, AM J SPORT MED, V35, P1500, DOI 10.1177/0363546507301258; Le Sant G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139272; Marshall PWM, 2015, J STRENGTH COND RES, V29, P3124, DOI 10.1519/JSC.0000000000000966; McHugh MP, 1999, SPORTS MED, V27, P157, DOI 10.2165/00007256-199927030-00002; Mendiguchia J, 2013, J STRENGTH COND RES, V27, P3426, DOI 10.1519/JSC.0b013e31828fd3e7; Messer D, 2017, J SCI MED SPORT SUPP, V20, pe125, DOI [10.1016/j.jsams.2017.01.221, DOI 10.1016/J.JSAMS.2017.01.221]; Mohamed F, 2002, CLIN BIOMECH, V17, P569, DOI 10.1016/S0268-0033(02)00070-0; Morici JF, 2015, FRONT PHARMACOL, V6, DOI [10.3389/fphar.2015.00298, 10.3389/fphys.2015.00404]; Onishi H, 2002, J ELECTROMYOGR KINES, V12, P399, DOI 10.1016/S1050-6411(02)00033-0; Roe M, 2018, J SCI MED SPORT, V21, P155, DOI 10.1016/j.jsams.2017.08.023; Saw R, 2018, SPORTS HEALTH, V10, P208, DOI 10.1177/1941738117726070; Schache AG, 2013, EUR J APPL PHYSIOL, V113, P2813, DOI 10.1007/s00421-013-2713-9; Schuermans J, 2014, BRIT J SPORT MED, V48, P1599, DOI 10.1136/bjsports-2014-094017; Severini G, 2018, SCAND J MED SCI SPOR, V28, P2536, DOI 10.1111/sms.13288; Timmins RG, 2016, BRIT J SPORT MED, V50, P1524, DOI 10.1136/bjsports-2015-095362; Tsaklis P, 2015, OPEN ACCESS J SPORTS, V6, P209, DOI 10.2147/OAJSM.S79189; Zebis MK, 2013, BRIT J SPORT MED, V47, P1192, DOI 10.1136/bjsports-2011-090281	42	12	12	1	21	J O S P T	ALEXANDRIA	1111 NORTH FAIRFAX ST, STE 100, ALEXANDRIA, VA 22314-1436 USA	0190-6011	1938-1344		J ORTHOP SPORT PHYS	J. Orthop. Sports Phys. Ther.	AUG	2019	49	8					584	+		10.2519/jospt.2019.8801			20	Orthopedics; Rehabilitation; Sport Sciences	Orthopedics; Rehabilitation; Sport Sciences	IM5HI	WOS:000478024600005	30913969				2021-06-18	
J	Ko, IG; Kim, CJ; Kim, H				Ko, Il-Gyu; Kim, Chang-Ju; Kim, Hong			Treadmill exercise improves memory by up-regulating dopamine and down-regulating D-2 dopamine receptor in traumatic brain injury rats	JOURNAL OF EXERCISE REHABILITATION			English	Article						Brain injuries; Exercise; Memory; Dopamine; Dopamine D-2 receptor	COGNITIVE DYSFUNCTION; EXPRESSION; LTP	Traumatic brain injury (TBI) causes a variety of neuropathological manifestations including cognitive, emotional, physiological and psychological deficits. Physical exercise is known to ameliorate neurological impairments induced by various brain injuries. We investigated the effects of treadmill exercise on memory impairments due to TBI in relation to dopamine and D-2 dopamine receptor. TBI was induced with an electromagnetic-controlled cortical impact device. The rats in the exercise groups were scheduled to run on a treadmill for 30 min once a day for 28 days after TBI induction. Then, step-down avoidance task, radial 8-arm maze test, immunohistochemistry for tyrosine hydroxylase (TH), and western blot for D-2 dopamine receptor were performed. TBI impaired short-term and spatial learning memories. TBI decreased TH expressions in the prefrontal cortex (PFC), striatum, hippocampus dentate gyrus, and substantia nigra (SN). By contrast, the expressions of D-2 dopamine receptor in the PFC, striatum, hippocampus, and SN were increased by TBI. Treadmill exercise alleviated the impairments of short-term and spatial learning memories observed in TBI rats. TH expression was decreased and D-2 dopamine receptor expression was increased in TBI rats. Treadmill exercise enhanced TH expression and suppressed D-2 dopamine receptor expression in TBI rats. TBI deteriorated short-term and spatial learning memories, in contrast treadmill exercise alleviated the TBI-induced memory impairments by up-regulating dopamine level and down-regulating D-2 dopamine receptor expression.	[Ko, Il-Gyu; Kim, Chang-Ju] Kyung Hee Univ, Coll Med, Dept Physiol, Seoul, South Korea; [Kim, Hong] Daegu Haany Univ, Coll Biomed Sci, Dept Oriental Sports Med, 1 Haanydae Ro, Gyongsan 38610, South Korea	Kim, H (corresponding author), Daegu Haany Univ, Coll Biomed Sci, Dept Oriental Sports Med, 1 Haanydae Ro, Gyongsan 38610, South Korea.	joshua@dhu.ac.kr			National Research Foundation of Korea Grant Funded by the Korean GovernmentNational Research Foundation of Korea [NRF-2011-327-G00121]	This work was supported by the National Research Foundation of Korea Grant Funded by the Korean Government (NRF-2011-327-G00121).	Archer T, 2012, ACTA NEUROL SCAND, V125, P293, DOI 10.1111/j.1600-0404.2011.01638.x; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Beaulieu JM, 2011, PHARMACOL REV, V63, P182, DOI 10.1124/pr.110.002642; Crosson B, 2003, J INT NEUROPSYCH SOC, V9, P1027, DOI 10.1017/S1355617703970068; Granado N, 2008, CEREB CORTEX, V18, P1, DOI 10.1093/cercor/bhm026; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Huang EYK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086354; Kim DH, 2010, PHYSIOL BEHAV, V101, P660, DOI 10.1016/j.physbeh.2010.09.021; Klinker F, 2013, BEHAV BRAIN RES, V242, P117, DOI 10.1016/j.bbr.2012.12.038; Ko IG, 2018, J EXERC REHABIL, V14, P327, DOI 10.12965/jer.1836248.124; Ko IG, 2013, MOL MED REP, V8, P393, DOI 10.3892/mmr.2013.1531; Lee JM, 2018, J EXERC REHABIL, V14, P713, DOI 10.12965/jer.36394.197; Lenard L, 2017, BEHAV BRAIN RES, V321, P99, DOI 10.1016/j.bbr.2017.01.005; Li SM, 2003, NAT NEUROSCI, V6, P526, DOI 10.1038/nn1049; Mabandla MV, 2009, METAB BRAIN DIS, V24, P525, DOI 10.1007/s11011-009-9161-6; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; O'Dell SJ, 2007, NEUROSCIENCE, V144, P1141, DOI 10.1016/j.neuroscience.2006.10.042; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Sung YH, 2012, LIFE SCI, V91, P1309, DOI 10.1016/j.lfs.2012.10.003; Wagner AK, 2014, J CEREBR BLOOD F MET, V34, P1328, DOI 10.1038/jcbfm.2014.87; Zhang X, 2015, JPEN-PARENTER ENTER, V39, P114, DOI 10.1177/0148607113501881	24	12	13	1	5	KOREAN SOC EXERCISE REHABILITATION	SEOUL	264 BAEKJEGOBUN-RO, SONGPA-GU, SEOUL, 138-841, SOUTH KOREA	2288-176X	2288-1778		J EXERC REHABIL	J. Exerc. Rehabil.	AUG	2019	15	4					504	511		10.12965/jer.1938316.158			8	Rehabilitation	Rehabilitation	IV0RW	WOS:000483987300003	31523669	DOAJ Gold, Green Published			2021-06-18	
J	Luo, WS; Liu, T; Li, SS; Wen, HM; Zhou, FH; Zafonte, R; Luo, X; Xu, MZ; Black-Schaffer, R; Wood, LJ; Wang, YL; Wang, QM				Luo, Wenshu; Liu, Tao; Li, Shanshan; Wen, Hongmei; Zhou, Fenghua; Zafonte, Ross; Luo, Xun; Xu, Minghzu; Black-Schaffer, Randie; Wood, Lisa J.; Wang, Yulong; Wang, Qing Mei			The Serum BDNF Level Offers Minimum Predictive Value for Motor Function Recovery After Stroke	TRANSLATIONAL STROKE RESEARCH			English	Article						Stroke rehabilitation; BDNF (brain-derived neurotrophic factor); FIM (functional independence measure); FA (fractional anisotropy)	NEUROTROPHIC FACTOR LEVELS; TRAUMATIC BRAIN-INJURY; CORTICOSPINAL TRACT; FRACTIONAL ANISOTROPY; SYNAPTIC PLASTICITY; ACTIVATION; NEUROPLASTICITY; REHABILITATION; EXERCISE	Brain-derived neurotrophic factor (BDNF) plays an important role in neuroplasticity and neurogenesis following ischemic and non-ischemic brain injury. The predictive value of BDNF for short-term outcome after stroke is controversial. The objective of this study was to investigate the relationship among serum BDNF level, fractional anisotropy (FA), and functional outcome during post-acute stroke rehabilitation. Serum BDNF levels were measured on admission to an acute inpatient rehabilitation hospital. The primary functional outcome was functional independence measure (FIM) motor subscore at discharge. The secondary outcome measures were FIM total score at discharge, FIM motor subscore on admission, length of stay in the hospital, and discharge destination. We investigated the relationship among the level of serum BDNF and FA as well as functional outcome measures. Three hundred forty-eight consecutive stroke subjects were included in the analysis. Serum BDNF levels on admission were statistically but not clinically correlated with FIM motor subscore at discharge (r=0.173, P=0.001) and FIM total score at discharge (r=0.155, P=0.004). Receiver operating characteristic (ROC) analysis of BDNF as a predictor for FIM motor subscore improvement showed low accuracy of prediction with an area under the curve (AUC) of 0.581 (P=0.026). Serum BDNF significantly correlated with FA in the high FIM motor group (n=10, r=0.609, P=0.031) but not in the low FIM motor group (n=11, r=-0.132, P=0.349). The serum BDNF level alone offers minimum predictive value for recovery of motor function during post-acute rehabilitation. Our findings suggest that serum BDNF level may be correlated with FA.	[Luo, Wenshu; Liu, Tao; Li, Shanshan; Wen, Hongmei; Zhou, Fenghua; Xu, Minghzu; Wang, Qing Mei] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Stroke Biol Recovery Lab, Charlestown, MA 02129 USA; [Luo, Wenshu] Shenzhen Tradit Chinese Med Hosp, Dept Acupuncture & Moxibust, Shenzhen 518033, Guangdong, Peoples R China; [Liu, Tao] Huaiyin Inst Technol, Jiangsu Prov Key Lab Intervent Med Devices, Huaian 223003, Jiangsu, Peoples R China; [Li, Shanshan] Rutgers State Univ, New Jersey Med Sch, Dept Microbiol Biochem & Mol Genet, Newark, NJ 07103 USA; [Wen, Hongmei] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Rehabil Med, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China; [Zhou, Fenghua] China Med Univ, Shengjing Hosp, Dept Phys Med & Rehabil, Shenyang 110003, Liaoning, Peoples R China; [Zafonte, Ross; Black-Schaffer, Randie; Wang, Qing Mei] Harvard Med Sch, Brigham & Womens Hosp, Spaulding Rehabil Hosp Network, Dept Phys Med, Boston, MA 02115 USA; [Zafonte, Ross; Black-Schaffer, Randie; Wang, Qing Mei] Harvard Med Sch, Brigham & Womens Hosp, Spaulding Rehabil Hosp Network, Dept Rehabil, Boston, MA 02115 USA; [Zafonte, Ross; Black-Schaffer, Randie; Wang, Qing Mei] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Luo, Xun] Kerry Rehabil Med Res Inst, Shenzhen 518048, Guangdong, Peoples R China; [Luo, Xun] Harvard Med Sch, Spaulding Rehabil Hosp, Shenzhen Sanming Project Grp, Charlestown, MA 02129 USA; [Wood, Lisa J.] MGH Inst Hlth Profess, Sch Nursing, Charlestown, MA 02129 USA; [Wang, Yulong] Shenzhen Univ, Shenzhen Second Peoples Hosp, Affiliated Hosp 1, Shenzhen 518035, Guangdong, Peoples R China	Wang, QM (corresponding author), Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Stroke Biol Recovery Lab, Charlestown, MA 02129 USA.; Wang, QM (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Spaulding Rehabil Hosp Network, Dept Phys Med, Boston, MA 02115 USA.; Wang, QM (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Spaulding Rehabil Hosp Network, Dept Rehabil, Boston, MA 02115 USA.; Wang, QM (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.; Wang, YL (corresponding author), Shenzhen Univ, Shenzhen Second Peoples Hosp, Affiliated Hosp 1, Shenzhen 518035, Guangdong, Peoples R China.	ylwang66@126.com; wang.qingmei@mgh.harvard.edu	LI, SHANSHAN/G-5246-2015; Li, Shanshan/S-4184-2019	LI, SHANSHAN/0000-0002-3420-0567; Li, Shanshan/0000-0002-3420-0567; Wood, Lisa/0000-0003-1145-3649	Harvard Catalyst/The Harvard Clinical and Translational Science Center (National Center for Research Resources); Harvard Catalyst/The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health) [UL1 TR001102]; Harvard University and its affiliated academic health care centers; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [12ykpy39]; Shenzhen "Sanming project" [SZSM201610039]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001102] Funding Source: NIH RePORTER	This study was supported by the Harvard Catalyst/The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health award no. UL1 TR001102); Harvard University and its affiliated academic health care centers; and Fundamental Research Funds for the Central Universities (grant no. 12ykpy39). The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, or the National Institutes of Health.r This study was also supported by Shenzhen "Sanming project" (SZSM201610039).	Ahn YH, 2006, NEUROREPORT, V17, P987, DOI 10.1097/01.wnr.0000220128.01597.e0; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bejot Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029405; Benjamin EJ, 2017, CIRCULATION, V135, pE146, DOI 10.1161/CIR.0000000000000485; Bramham CR, 2005, PROG NEUROBIOL, V76, P99, DOI 10.1016/j.pneurobio.2005.06.003; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Dalby RB, 2013, ACTA PSYCHIAT SCAND, V128, P387, DOI 10.1111/acps.12085; Dimyan MA, 2011, NAT REV NEUROL, V7, P76, DOI 10.1038/nrneurol.2010.200; Dwivedi Y, 2013, AM J GERIAT PSYCHIAT, V21, P433, DOI 10.1016/j.jagp.2012.10.026; Elkabes S, 1996, J NEUROSCI, V16, P2508; Farmer J, 2004, NEUROSCIENCE, V124, P71, DOI 10.1016/j.neuroscience.2003.09.029; Jang SH, 2004, NEUROREPORT, V15, P395, DOI 10.1097/00001756-200403010-00002; Jiang YJ, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/372423; Jickling GC, 2015, STROKE, V46, P915, DOI 10.1161/STROKEAHA.114.005604; Jin JF, 2017, WORLD J EMERG MED, V8, P99, DOI 10.5847/wjem.j.1920-8642.2017.02.003; Johansen-Berg H, 2004, P NATL ACAD SCI USA, V101, P13335, DOI 10.1073/pnas.0403743101; Kaess BM, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.114.001544; Karege F, 2002, NEUROSCI LETT, V328, P261, DOI 10.1016/S0304-3940(02)00529-3; Kim B, 2017, NEUROREHAB NEURAL RE, V31, P3, DOI 10.1177/1545968316662708; Kim EJ, 2016, EUR J NEUROL, V23, P76, DOI 10.1111/ene.12791; Klein AB, 2011, INT J NEUROPSYCHOPH, V14, P347, DOI 10.1017/S1461145710000738; Korley FK, 2016, J HEAD TRAUMA REHAB, V31, P379, DOI 10.1097/HTR.0000000000000187; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Lommatzsch M, 2005, NEUROBIOL AGING, V26, P115, DOI 10.1016/j.neurobiolaging.2004.03.002; Lu B, 2005, NAT REV NEUROSCI, V6, P603, DOI 10.1038/nrn1726; Mang CS, 2013, PHYS THER, V93, P1707, DOI 10.2522/ptj.20130053; Munkholm K, 2014, PSYCHONEUROENDOCRINO, V47, P199, DOI 10.1016/j.psyneuen.2014.05.011; Naegelin Y, 2018, ENEURO, V5, DOI 10.1523/ENEURO.0419-17.2018; Nalichowski R, 2006, AMIA ANN S P, V1044; Pan WH, 1998, NEUROPHARMACOLOGY, V37, P1553, DOI 10.1016/S0028-3908(98)00141-5; Pearson-Fuhrhop KM, 2010, PM&R, V2, pS227, DOI 10.1016/j.pmrj.2010.09.011; Polyakova M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061189; Puig J, 2013, STROKE, V44, P2016, DOI 10.1161/STROKEAHA.111.000382; Simon NG, 2014, NEUROLOGY, V83, P1382, DOI 10.1212/WNL.0000000000000861; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Spampinato MV, 2017, AM J NEURORADIOL, V38, P1328, DOI 10.3174/ajnr.A5180; Stanne TM, 2016, STROKE, V47, P1943, DOI 10.1161/STROKEAHA.115.012383; Tsuchimine S, 2014, NEUROPSYCHOBIOLOGY, V69, P83, DOI 10.1159/000358061; Wang J, 2017, MOL NEUROBIOL, V54, P7335, DOI 10.1007/s12035-016-0236-1; Ward NS, 2006, BRAIN, V129, P809, DOI 10.1093/brain/awl002; Weinstein G, 2014, JAMA NEUROL, V71, P55, DOI 10.1001/jamaneurol.2013.4781; Wen HM, 2016, ARCH PHYS MED REHAB, V97, P1487, DOI 10.1016/j.apmr.2016.04.010; Yang LL, 2011, INT J GERIATR PSYCH, V26, P495, DOI 10.1002/gps.2552	47	12	14	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	AUG	2019	10	4					342	351		10.1007/s12975-018-0648-5			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	IJ0YS	WOS:000475626500002	30074228	Green Accepted			2021-06-18	
J	Hubbard, WB; Harwood, CL; Prajapati, P; Springer, JE; Saatman, KE; Sullivan, PG				Hubbard, W. Brad; Harwood, Christopher L.; Prajapati, Paresh; Springer, Joe E.; Saatman, Kathryn E.; Sullivan, Patrick G.			Fractionated mitochondrial magnetic separation for isolation of synaptic mitochondria from brain tissue	SCIENTIFIC REPORTS			English	Article							RAT-BRAIN; MOUSE MODEL; DYSFUNCTION; INJURY; DAMAGE; PURIFICATION; MEMBRANES; NEURONS; MICE	While mitochondria maintain essential cellular functions, such as energy production, calcium homeostasis, and regulating programmed cellular death, they also play a major role in pathophysiology of many neurological disorders. Furthermore, several neurodegenerative diseases are closely linked with synaptic damage and synaptic mitochondrial dysfunction. Unfortunately, the ability to assess mitochondrial dysfunction and the efficacy of mitochondrial-targeted therapies in experimental models of neurodegenerative disease and CNS injury is limited by current mitochondrial isolation techniques. Density gradient ultracentrifugation (UC) is currently the only technique that can separate synaptic and non-synaptic mitochondrial sub-populations, though small brain regions cannot be assayed due to low mitochondrial yield. To address this limitation, we used fractionated mitochondrial magnetic separation (FMMS), employing magnetic anti-Tom22 antibodies, to develop a novel strategy for isolation of functional synaptic and non-synaptic mitochondria from mouse cortex and hippocampus without the usage of UC. We compared the yield and functionality of mitochondria derived using FMMS to those derived by UC. FMMS produced 3x more synaptic mitochondrial protein yield compared to UC from the same amount of tissue, a mouse hippocampus. FMMS also has increased sensitivity, compared to UC separation, to measure decreased mitochondrial respiration, demonstrated in a paradigm of mild closed head injury. Taken together, FMMS enables improved brain-derived mitochondrial yield for mitochondrial assessments and better detection of mitochondrial impairment in CNS injury and neurodegenerative disease.	[Hubbard, W. Brad; Harwood, Christopher L.; Prajapati, Paresh; Springer, Joe E.; Saatman, Kathryn E.; Sullivan, Patrick G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40506 USA; [Hubbard, W. Brad; Harwood, Christopher L.; Prajapati, Paresh; Springer, Joe E.; Sullivan, Patrick G.] Univ Kentucky, Dept Neurosci, Lexington, KY 40506 USA; [Hubbard, W. Brad; Saatman, Kathryn E.] Univ Kentucky, Dept Physiol, Lexington, KY USA; [Sullivan, Patrick G.] Lexington VAMC, Lexington, KY 40502 USA	Sullivan, PG (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40506 USA.; Sullivan, PG (corresponding author), Univ Kentucky, Dept Neurosci, Lexington, KY 40506 USA.; Sullivan, PG (corresponding author), Lexington VAMC, Lexington, KY 40502 USA.	patsullivan@uky.edu	Prajapati, Paresh/P-1058-2019	Prajapati, Paresh/0000-0002-3734-4662	NSF EPSCoR Seed Grant (National Science Foundation Grant) [4978/111315, 1539068]; Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT) [14-13 A]; VA Merit AwardUS Department of Veterans Affairs [1I01BX003405-01A1]; Veterans AffairsUS Department of Veterans Affairs [I01BX003405] Funding Source: NIH RePORTER	The authors would like to thank Malinda Spry, Binoy Joseph, Ph.D., Jennifer Gooch, and Hemendra Vekaria, Ph.D. for their technical assistance. We would also like to acknowledge the Biomedical Illustration team of Matt Hazzard and Tom Dolan in University of Kentucky Information Technology. This work was supported by NSF EPSCoR Seed Grant 4978/111315 (National Science Foundation Grant No. 1539068), Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT) Grant 14-13 A, and VA Merit Award 1I01BX003405-01A1.	Afanasyeva MA, 2018, BIOCHEMISTRY-MOSCOW+, V83, P76, DOI 10.1134/S0006297918010108; Ahier A, 2018, NAT CELL BIOL, V20, P352, DOI 10.1038/s41556-017-0023-x; Amigo I., 2016, BIO-PROTOCOL, V6, pe1810, DOI [10.21769/BioProtoc.1810, DOI 10.21769/BIOPROTOC.1810]; Banik Bhabatosh, 2017, Curr Protoc Cell Biol, V76, DOI 10.1002/cpcb.26; Bolton AN, 2014, J NEUROPATH EXP NEUR, V73, P933, DOI 10.1097/NEN.0000000000000115; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200; Chinopoulos C, 2011, METHODS MOL BIOL, V793, P311, DOI 10.1007/978-1-61779-328-8_20; Damiano M, 2010, BBA-MOL BASIS DIS, V1802, P52, DOI 10.1016/j.bbadis.2009.07.012; Devall M, 2015, BIOTECHNIQUES, V59, P241, DOI 10.2144/000114343; Di Pietro V, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09587-2; Du H, 2010, P NATL ACAD SCI USA, V107, P18670, DOI 10.1073/pnas.1006586107; Franko A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082392; Hamilton J, 2016, HUM MOL GENET, V25, P2762, DOI 10.1093/hmg/ddw133; Harris JJ, 2012, NEURON, V75, P762, DOI 10.1016/j.neuron.2012.08.019; Hornig-Do HT, 2009, ANAL BIOCHEM, V389, P1, DOI 10.1016/j.ab.2009.02.040; Hubbard W.B., 2018, ACUTE NEURONAL INJUR, P63, DOI [10.1007/978-3-319-77495-4_4, DOI 10.1007/978-3-319-77495-4_4]; Hubbard WB, 2019, J NEUROTRAUM, V36, P1252, DOI 10.1089/neu.2018.5990; Hubbard WB, 2018, J NEUROSCI RES, V96, P1677, DOI 10.1002/jnr.24271; Jeanneteau F, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/3985063; Johri A, 2012, J PHARMACOL EXP THER, V342, P619, DOI 10.1124/jpet.112.192138; Kappler L, 2016, SCI REP-UK, V6, DOI 10.1038/srep21107; Keane PC, 2011, PARKINSONS DIS-US, V2011, DOI 10.4061/2011/716871; Khattar NK, 2016, J NEUROSCI METH, V263, P1, DOI 10.1016/j.jneumeth.2016.01.017; Kristian T., 2010, CURR PROTOC NEUROSCI, V7, P22, DOI DOI 10.1002/0471142301.NS0722S52; Kulbe JR, 2017, J NEUROTRAUM, V34, P1291, DOI 10.1089/neu.2016.4628; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Ly CV, 2006, NEUROSCIENTIST, V12, P291, DOI 10.1177/1073858406287661; Macheiner T, 2016, SCI REP-UK, V6, DOI 10.1038/srep35571; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; Pellman JJ, 2015, J NEUROCHEM, V134, P652, DOI 10.1111/jnc.13165; Picard M, 2016, MITOCHONDRION, V30, P105, DOI 10.1016/j.mito.2016.07.003; Raichle ME, 2002, P NATL ACAD SCI USA, V99, P10237, DOI 10.1073/pnas.172399499; Reddy PH, 2008, TRENDS MOL MED, V14, P45, DOI 10.1016/j.molmed.2007.12.002; Reddy PH, 2009, CNS SPECTRUMS, V14, P8, DOI 10.1017/S1092852900024901; RENDON A, 1985, J NEUROSCI METH, V14, P41, DOI 10.1016/0165-0270(85)90113-X; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Sauerbeck A, 2012, EXP NEUROL, V234, P85, DOI 10.1016/j.expneurol.2011.12.012; Sims NR, 2008, NAT PROTOC, V3, P1228, DOI 10.1038/nprot.2008.105; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Tang B, 2012, MOL MED REP, V5, P1271, DOI 10.3892/mmr.2012.806; Vos Melissa, 2010, Front Synaptic Neurosci, V2, P139, DOI 10.3389/fnsyn.2010.00139; Wang WX, 2017, PROG NEURO-PSYCHOPH, V73, P104, DOI 10.1016/j.pnpbp.2016.02.011; Wang XL, 2009, J NEUROSCI, V29, P9090, DOI 10.1523/JNEUROSCI.1357-09.2009; Wieckowski MR, 2009, NAT PROTOC, V4, P1582, DOI 10.1038/nprot.2009.151; Zhang L, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.65	48	12	12	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUL 4	2019	9								9656	10.1038/s41598-019-45568-3			13	Multidisciplinary Sciences	Science & Technology - Other Topics	IH1AL	WOS:000474223600002	31273236	DOAJ Gold, Green Published			2021-06-18	
J	Leeper, CM; Yazer, MH; Cladis, FP; Saladino, R; Triulzi, DJ; Gaines, BA				Leeper, Christine M.; Yazer, Mark H.; Cladis, Franklyn P.; Saladino, Richard; Triulzi, Darrell J.; Gaines, Barbara A.			Cold-stored whole blood platelet function is preserved in injured children with hemorrhagic shock	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	32nd Annual Scientific Assembly of the Eastern-Association-for-Surgery-of-Trauma (EAST)	JAN 15-19, 2019	Austin, TX	Eastern Assoc Surg Trauma		Whole blood; transfusion; pediatric; coagulopathy; platelets	ACUTE TRAUMATIC COAGULOPATHY; MORTALITY; TRANSFUSION; FRESH; FEASIBILITY; 4-DEGREES-C; DEFINITION; ADMISSION	BACKGROUND Recent data demonstrate the safety of uncrossmatched cold-stored whole blood (WB) transfusion in pediatric trauma patients. The hemostatic capabilities of platelets within the cold-stored WB unit have been demonstrated via in vitro studies and animal models. However, platelet function has not been evaluated in pediatric recipients of cold-stored WB transfusions. METHODS Injured children, 2 years or older and 10 kg or greater with hemorrhagic shock received up to 30 mL/kg of cold-stored, low titer (<50) anti-A and -B, leukoreduced, group O- WB during their initial resuscitation. Patients were included if (1) they received WB and no conventional platelets, and (2) platelet count and thromboelastography maximum amplitude were measured both before and after transfusion. These data and relevant clinical outcomes (mortality, intensive care unit length of stay [LOS], hospital LOS and ventilator days) were compared to a historical cohort of pediatric trauma patients who received uncrossmatched red blood cells (RBC) and conventional room temperature platelets. RESULTS Twenty-two children were included in the study; 14 in the component cohort versus 8 in the WB cohort. Neither posttransfusion platelet count (129 x 109/L vs. 135 x 109/L) nor function (thromboelastography maximum amplitude, 59.5 mm vs. 60.2 mm) differed significantly between children receiving cold-stored platelets within the WB unit versus children who received conventional warm platelets. Median (interquartile range) weight-adjusted platelet transfusion volume in the historical cohort was 4.6 (2.5-7.7) mL/kg vs. 2.4 (1.3-4.0) mL/kg in the WB cohort (p = 0.03). There was no difference between groups in age, race, mechanism of injury, Injury Severity Score, vital signs, and severe traumatic brain injury (TBI). Outcomes, including mortality, intensive care unit LOS, hospital LOS, and ventilator days, were not significantly different between groups. CONCLUSION No difference was seen in posttransfusion platelet number or function in severely injured children receiving cold-stored WB platelets as compared to those receiving conventional room temperature-stored platelets. Larger cohorts are required to confirm these findings. Copyright (c) 2019 Wolters Kluwer Health, Inc. All rights reserved.	[Leeper, Christine M.; Gaines, Barbara A.] Univ Pittsburgh, Med Ctr, Dept Surg, Pittsburgh, PA USA; [Yazer, Mark H.; Triulzi, Darrell J.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA; [Leeper, Christine M.; Gaines, Barbara A.] Childrens Hosp Pittsburgh UPMC, Dept Surg, Pittsburgh, PA USA; [Saladino, Richard] Childrens Hosp Pittsburgh UPMC, Div Pediat Emergency Med, Pittsburgh, PA USA; [Cladis, Franklyn P.] Childrens Hosp Pittsburgh UPMC, Dept Anesthesiol & Perioperat Med, Pittsburgh, PA USA	Leeper, CM (corresponding author), 7th Floor,Fac Pavil,One Childrens Hosp Dr, Pittsburgh, PA 15224 USA.	leepercm@upmc.edu					Bassett Aaron K, 2016, J Spec Oper Med, V16, P5; BECKER GA, 1973, TRANSFUSION, V13, P61, DOI 10.1111/j.1537-2995.1973.tb05442.x; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Centers for Disease Control and Prevention, 2013, 10 LEAD CAUS DEATH A; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; Christiaans SC, 2014, SHOCK, V41, P476, DOI 10.1097/SHK.0000000000000151; Cinat ME, 1999, ARCH SURG-CHICAGO, V134, P964, DOI 10.1001/archsurg.134.9.964; Cohen MJ, 2013, J TRAUMA ACUTE CARE, V75, pS40, DOI 10.1097/TA.0b013e31828fa43d; Daniel Y, 2017, J TRAUMA ACUTE CARE; Epstein DS, 2014, INJURY, V45, P819, DOI 10.1016/j.injury.2014.01.011; Hendrickson JE, 2012, J PEDIATR-US, V160, P204, DOI 10.1016/j.jpeds.2011.08.019; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P348, DOI 10.1097/01.PCC.0000270837.66217.3B; Jobes D, 2011, TRANSFUSION, V51, P43, DOI 10.1111/j.1537-2995.2010.02772.x; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Lao ZQ, 2012, INT J PREVENTIVE MED, V3, P303; Leeper CM, 2018, J TRAUMA ACUTE CARE, V85, P674, DOI 10.1097/TA.0000000000001823; Leeper CM, 2018, JAMA PEDIATR, V172, P491, DOI 10.1001/jamapediatrics.2017.5238; Leeper CM, 2017, J TRAUMA ACUTE CARE, V82, P27, DOI 10.1097/TA.0000000000001308; Leeper CM, 2016, J TRAUMA ACUTE CARE; Leeper CM, 2017, SURGERY; Liras IN, 2017, J AM COLL SURG; Maegele M, 2014, SHOCK, V41, P21, DOI 10.1097/SHK.0000000000000088; Marton E, 2007, CHILD NERV SYST, V23, P873, DOI 10.1007/s00381-007-0314-9; Nair PM, 2017, BRIT J HAEMATOL, V178, P119, DOI 10.1111/bjh.14751; Nair PM, 2014, J TRAUMA ACUTE CARE, V77, pS88, DOI 10.1097/TA.0000000000000327; Nessen SC, 2013, TRANSFUSION, V53, p107S, DOI 10.1111/trf.12044; Patregnani JT, 2012, PEDIATR CRIT CARE ME, V13, P273, DOI 10.1097/PCC.0b013e31822f1727; Peltan ID, 2015, CRIT CARE MED, V43, P1429, DOI 10.1097/CCM.0000000000000981; Pidcoke HF, 2013, TRANSFUSION, V53, p137S, DOI 10.1111/trf.12048; Reddoch KM, 2014, SHOCK, V41, P54, DOI 10.1097/SHK.0000000000000082; Remy KE, 2018, J TRAUMA ACUTE CARE, V84, pS104, DOI 10.1097/TA.0000000000001870; Seheult JN, 2017, TRANSFUSION MED, V27, P30, DOI 10.1111/tme.12372; Spinella PC, 2016, TRANSFUSION, V56, pS190, DOI 10.1111/trf.13491; Strandenes G, 2015, J TRAUMA ACUTE CARE, V78, pS31, DOI 10.1097/TA.0000000000000628; Torres IP, 2017, J THROMB HAEMOST, V15, P163, DOI 10.1111/jth.13556; Whittaker B, 2013, SHOCK, V39, P421, DOI 10.1097/SHK.0b013e31828e08cb; Wu XW, 2017, BRIT J HAEMATOL, V179, P802, DOI 10.1111/bjh.14999; Yazer MH, 2016, J TRAUMA ACUTE CARE, V81, P21, DOI 10.1097/TA.0000000000001100	38	12	12	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2019	87	1					49	53		10.1097/TA.0000000000002340			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	IH6VR	WOS:000474640900007	31033893				2021-06-18	
J	Adzemovic, T; Murray, T; Jenkins, P; Ottosen, J; Iyegha, U; Raghavendran, K; Napolitano, LM; Hemmila, MR; Gipson, J; Park, P; Tignanelli, CJ				Adzemovic, Tessa; Murray, Thomas; Jenkins, Peter; Ottosen, Julie; Iyegha, Uroghupatei; Raghavendran, Krishnan; Napolitano, Lena M.; Hemmila, Mark R.; Gipson, Jonathan; Park, Pauline; Tignanelli, Christopher J.			Should they stay or should they go? Who benefits from interfacility transfer to a higher-level trauma center following initial presentation at a lower-level trauma center	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	77th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST) / Clinical Congress of Acute Care Surgery / 4th World Trauma Congress	SEP 26-29, 2018	San Diego, CA	Amer Assoc Surg Trauma		Interfacility transfer; triage; secondary overtriage; undertriage; trauma systems	SECONDARY OVERTRIAGE; SURGEONS COMMITTEE; AMERICAN-COLLEGE; MAJOR TRAUMA; IMPACT	BACKGROUND Interfacility transfer of patients from Level III/IV to Level I/II (tertiary) trauma centers has been associated with improved outcomes. However, little data are available classifying the specific subsets of patients that derive maximal benefit from transfer to a tertiary trauma center. Drawbacks to transfer include increased secondary overtriage. Here, we ask which injury patterns are associated with improved survival following interfacility transfer. METHODS Data from the National Trauma Data Bank was utilized. Inclusion criteria were adults (>= 16 years). Patients with Injury Severity Score of 10 or less or those who arrived with no signs of life were excluded. Patients were divided into two cohorts: those admitted to a Level III/IV trauma center versus those transferred into a tertiary trauma center. Multiple imputation was performed for missing values, and propensity scores were generated based on demographics, injury patterns, and disease severity. Using propensity score-stratified Cox proportional hazards regression, the hazard ratio for time to death was estimated. RESULTS Twelve thousand five hundred thirty-four (5.2%) were admitted to Level III/IV trauma centers, and 227,315 (94.8%) were transferred to a tertiary trauma center. Patients transferred to a tertiary trauma center had reduced mortality (hazard ratio, 0.69; p < 0.001). We identified that patients with traumatic brain injury with Glasgow Coma Scale score less than 13, pelvic fracture, penetrating mechanism, solid organ injury, great vessel injury, respiratory distress, and tachycardia benefited from interfacility transfer to a tertiary trauma center. In this sample, 56.8% of the patients benefitted from transfer. Among those not transferred, 49.5% would have benefited from being transferred. CONCLUSION Interfacility transfer is associated with a survival benefit for specific patients. These data support implementation of minimum evidence-based criteria for interfacility transfer.	[Adzemovic, Tessa] Univ Michigan, Sch Med, Ann Arbor, MI USA; [Murray, Thomas] Univ Minnesota, Div Biostat, Minneapolis, MN USA; [Jenkins, Peter] Indiana Univ, Dept Surg, Indianapolis, IN 46204 USA; [Ottosen, Julie; Tignanelli, Christopher J.] Univ Minnesota, Dept Surg, 420 Delaware St SE,MMC 195, Minneapolis, MN 55455 USA; [Ottosen, Julie; Gipson, Jonathan; Tignanelli, Christopher J.] North Mem Hlth Hosp, Dept Surg, Robbinsdale, MN USA; [Iyegha, Uroghupatei] Reg Hosp, Dept Surg, St Paul, MN USA; [Raghavendran, Krishnan; Napolitano, Lena M.; Hemmila, Mark R.; Park, Pauline] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Tignanelli, Christopher J.] Univ Minnesota, Inst Hlth Informat, Minneapolis, MN USA	Tignanelli, CJ (corresponding author), Univ Minnesota, Dept Surg, 420 Delaware St SE,MMC 195, Minneapolis, MN 55455 USA.	ctignane@umn.edu		Tignanelli, Christopher/0000-0002-8079-5565			American College of Surgeons, 2012, ADV TRAUM LIF SUPP S; American College of Surgeons Committee on Trauma, 2014, RES OPT CAR INJ PAT, V6th; Bible JE, 2014, SPINE J, V14, P2877, DOI 10.1016/j.spinee.2014.01.065; Brasel KJ, 2013, J TRAUMA ACUTE CARE, V74, P1363, DOI 10.1097/TA.0b013e31828b82f5; Brier G.W., 1950, MONTHLY WEATHER REV, V78, P1, DOI 2.0.CO;2; Ciesla DJ, 2008, J AM COLL SURGEONS, V206, P131, DOI 10.1016/j.jamcollsurg.2007.06.285; Con J, 2015, J SURG RES, V198, P462, DOI 10.1016/j.jss.2015.03.077; Garwe T, 2010, ACAD EMERG MED, V17, P1223, DOI 10.1111/j.1553-2712.2010.00918.x; Glance LG, 2009, ANN SURG, V249, P1032, DOI 10.1097/SLA.0b013e3181a38f28; Haas B, 2012, J TRAUMA ACUTE CARE, V72, P1510, DOI 10.1097/TA.0b013e318252510a; Hill AD, 2011, J TRAUMA, V71, P1885, DOI 10.1097/TA.0b013e31823ac642; Imbens GW, 2015, CAUSAL INFERENCE FOR STATISTICS, SOCIAL, AND BIOMEDICAL SCIENCES: AN INTRODUCTION, P1, DOI 10.1017/CBO9781139025751; Lynch KT, 2016, J SURG RES, V204, P460, DOI 10.1016/j.jss.2016.05.035; Newgard CD, 2007, J TRAUMA, V63, P965, DOI 10.1097/TA.0b013e31803c5665; Osen HB, 2010, J TRAUMA, V69, P602, DOI 10.1097/TA.0b013e3181e7db37; Pickering A, 2015, J TRAUMA ACUTE CARE, V78, P164, DOI 10.1097/TA.0000000000000483; R Core Team, 2013, R LANG ENV STAT COMP; Ruppert D. M., 2003, CAMBRIDGE SERIES STA; Schuster T, 2016, J CLIN EPIDEMIOL, V80, P97, DOI 10.1016/j.jclinepi.2016.05.017; Sorensen MJ, 2013, JAMA SURG, V148, P763, DOI 10.1001/jamasurg.2013.2132; Tignanelli CJ, 2018, J TRAUMA ACUTE CARE, V84, P273, DOI 10.1097/TA.0000000000001743; Tignanelli CJ, 2018, J TRAUMA ACUTE CARE, V84, P287, DOI 10.1097/TA.0000000000001745; van Buuren S, 2011, J STAT SOFTW, V45, P1	23	12	12	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUN	2019	86	6					952	960		10.1097/TA.0000000000002248			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	IB1CM	WOS:000470001200003	31124892				2021-06-18	
J	Dai, XP; Yi, M; Wang, DS; Chen, YY; Xu, X				Dai, Xingping; Yi, Min; Wang, Dongsheng; Chen, Yanyi; Xu, Xia			Changqin NO. 1 inhibits neuronal apoptosis via suppressing GAS5 expression in a traumatic brain injury mice model	BIOLOGICAL CHEMISTRY			English	Article						GAS5; long non-coding RNA; neuronal apoptosis; Rasa1; traditional Chinese medicine; traumatic brain injury	TRADITIONAL CHINESE MEDICINE; LONG NONCODING RNAS; SURVIVIN EXPRESSION; MIR-335; PATHWAY	The present study was designed to investigate the mechanism of the traditional Chinese medicine Changqin NO. 1 on the amelioration of traumatic brain injury (TBI). Adult male C57BL/6J mice and newborn mice were used to generate a mouse TBI model and harvest primary neurons, respectively. The localizations of specific neural markers neuropilin-1 (Nrp-1), growth-associated protein-43 (GAP-43) and microtubule-associated protein Tau (Tau) were examined in brain tissues by immunohistochemistry. Terminal deoxynucleotidyl transferase dUTP nick end labeling apoptotic cell detection in tissue sections and the CCK-8 cell viability assay were performed to examine neuronal apoptosis. Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot were also carried out in this study. The association between long non-coding RNA (lncRNA) growth-arrest specific 5 (GAS5), miR-335 and RAS p21 GTPase activating protein 1 (Rasa1) was disclosed using the dual-luciferase reporter assay. Changqin NO. 1 inhibited TBI-induced neuronal apoptosis in vivo and in vitro. GAS5 functioned as a competing endogenous RNA (ceRNA) by sponging miR-335 to upregulate Rasa1 expression in mouse neuronal cells. Further investigations demonstrated that GAS5 promoted neuronal apoptosis following TBI via the miR-335/Rasa1 axis. In vivo experiments indicated that Changqin NO. 1 exerted neuroprotection during TBI via the GAS5/miR-335/Rasa1 axis. Changqin NO. 1 promoted neuroprotective effects by inhibiting neuronal apoptosis via the GAS5/miR-335/Rasa1 axis in TBI.	[Dai, Xingping; Yi, Min; Wang, Dongsheng; Chen, Yanyi; Xu, Xia] Cent S Univ, Xiangya Hosp, Dept Integrated Tradit Chinese & Western Med, 87 Xiangya Rd, Changsha 410078, Hunan, Peoples R China	Dai, XP (corresponding author), Cent S Univ, Xiangya Hosp, Dept Integrated Tradit Chinese & Western Med, 87 Xiangya Rd, Changsha 410078, Hunan, Peoples R China.	xingpingd@yeah.net		Yi, Min/0000-0002-8752-0054			Chen LL, 2014, ADV EXP MED BIOL, V825, P129, DOI 10.1007/978-1-4939-1221-6_4; [陈彦伊 Chen Yanyi], 2017, [中国中医药信息杂志, Chinese Journal of Information on Traditional Chinese Medicine], V24, P17; Coupland KG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157924; Dong HY, 2014, MOLECULES, V19, P5634, DOI 10.3390/molecules19055634; Hancock ML, 2014, J NEUROSCI, V34, P66, DOI 10.1523/JNEUROSCI.3371-13.2014; Hao NB, 2017, ONCOTARGET, V8, P81572, DOI 10.18632/oncotarget.19197; Hsieh TT, 2017, CONT CLIN TRIAL COMM, V6, P127, DOI 10.1016/j.conctc.2017.04.005; Huang LP, 2016, BEHAV BRAIN RES, V313, P370, DOI 10.1016/j.bbr.2016.07.028; Lapinski PE, 2012, J CLIN INVEST, V122, P733, DOI 10.1172/JCI46116; Liu HJ, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00661; Liu ZF, 2016, EUR REV MED PHARMACO, V20, P1251; Ning BL, 2016, NEUROCHEM RES, V41, P2097, DOI 10.1007/s11064-016-1922-0; Santoro M, 2016, J MOL NEUROSCI, V59, P18, DOI 10.1007/s12031-016-0741-8; Surgucheva I, 2014, MOL CELL NEUROSCI, V63, P114, DOI 10.1016/j.mcn.2014.10.005; Tsai MC, 2015, J NEUROIMMUNE PHARM, V10, P45, DOI 10.1007/s11481-014-9570-0; Tsai P.C., 2014, LANG COGNIT PROCESSE, V15, P87; Walder B, 2013, J NEUROTRAUM, V30, P1934, DOI 10.1089/neu.2013.2955; Wang CF, 2017, J NEUROTRAUM, V34, P2100, DOI 10.1089/neu.2016.4642; Wang F, 2018, HEPATOLOGY, V67, P940, DOI 10.1002/hep.29586; Wu XM, 2013, INT J CLIN EXP PATHO, V6, P1282; Xing ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep20040; Yang BR, 2016, TUMOR BIOL, V37, P1771, DOI 10.1007/s13277-015-3951-8	22	12	13	2	12	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1431-6730	1437-4315		BIOL CHEM	Biol. Chem.	JUN	2019	400	6					753	763		10.1515/hsz-2018-0340			11	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	HX6RT	WOS:000467531700006	30653462				2021-06-18	
J	Killien, EY; Farris, RWD; Watson, RS; Dervan, LA; Zimmerman, JJ				Killien, Elizabeth Y.; Farris, Reid W. D.; Watson, R. Scott; Dervan, Leslie A.; Zimmerman, Jerry J.			Health-Related Quality of Life Among Survivors of Pediatric Sepsis	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						child; intensive care units; outcome assessment; quality of life; risk factors; sepsis	GENERIC CORE SCALES; TRAUMATIC BRAIN-INJURY; FUNCTIONAL OUTCOMES; CONSTRUCT-VALIDITY; ORGAN DYSFUNCTION; INFANT SCALES; SEPTIC SHOCK; CHILDREN; EPIDEMIOLOGY; RELIABILITY	Objectives: Mortality from pediatric sepsis has steadily declined over the past several decades; however, little is known about morbidity among survivors. We aimed to determine the prevalence of and risk factors for failure to recover to baseline health-related quality of life following community-acquired pediatric sepsis. Design: Retrospective cohort study. Setting: Seattle Children's Hospital. Patients: Children aged 1 month to 21 years admitted to the inpatient wards or ICUs from 2012 to 2015 who met 2005 consensus sepsis criteria within 4 hours of hospitalization and were enrolled in the hospital's Outcomes Assessment Program with baseline, admission, and post-discharge health-related quality of life data available. Interventions: None. Measurements and Main Results: We assessed health-related quality of life with the Pediatric Quality of Life Inventory for preadmission baseline, admission, and post-discharge (median, 31 d) status. We determined associations between patient and illness characteristics with failure to recover within 4.5 points of baseline at follow-up (the minimum clinically significant difference between two scores). Of 790 patients, 23.8% failed to recover to baseline health-related quality of life at follow-up. Factors associated with failure to recover were septic shock, older age, private insurance, complex chronic disease, immune compromise, CNS infection or bacteremia, ICU admission, and longer length of stay. On multivariable analysis controlling for time to follow-up, failure to recover was independently associated with septic shock (relative risk, 1.79; 95% CI, 1.24-2.58), older age (relative risk, 1.02/yr; 95% CI, 1.01-1.05), immune compromise (relative risk, 1.83; 95% CI, 1.40-2.40), and length of stay (relative risk, 1.03/d; 95% CI, 1.01-1.04). Conclusions: Nearly one-quarter of children surviving hospitalization for community-acquired sepsis experienced a clinically significant deterioration in health-related quality of life. We identify risk factors for poor outcomes following sepsis and highlight the need for ongoing evaluation and treatment by primary and specialty care providers for pediatric sepsis survivors after hospital discharge.	[Killien, Elizabeth Y.; Farris, Reid W. D.; Watson, R. Scott; Dervan, Leslie A.; Zimmerman, Jerry J.] Univ Washington, Dept Pediat, Div Pediat Crit Care Med, Seattle, WA 98195 USA; [Killien, Elizabeth Y.] Harborview Injury Prevent Res Ctr, Seattle, WA 98104 USA; [Farris, Reid W. D.; Dervan, Leslie A.; Zimmerman, Jerry J.] Seattle Childrens Res Inst, Ctr Clin & Translat Res, Seattle, WA USA; [Watson, R. Scott] Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, Seattle, WA USA; Seattle Childrens Hosp, Seattle, WA USA	Killien, EY (corresponding author), Univ Washington, Dept Pediat, Div Pediat Crit Care Med, Seattle, WA 98195 USA.; Killien, EY (corresponding author), Harborview Injury Prevent Res Ctr, Seattle, WA 98104 USA.	elizabeth.killien@seattlechil-drens.org	/AAD-2116-2020; Dervan, Leslie/ABH-4983-2020	Dervan, Leslie/0000-0002-4521-354X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD057822] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD057822] Funding Source: Medline		Aspesberro F, 2016, PEDIATR CRIT CARE ME, V17, pE272, DOI 10.1097/PCC.0000000000000727; Aspesberro F, 2015, INTENS CARE MED, V41, P1235, DOI 10.1007/s00134-015-3780-7; Balamuth F, 2014, PEDIATR CRIT CARE ME, V15, P798, DOI 10.1097/PCC.0000000000000225; Bronner MB, 2009, PEDIATR CRIT CARE ME, V10, P636, DOI 10.1097/PCC.0b013e3181ae5c1a; Buysse CMP, 2008, CRIT CARE MED, V36, P596, DOI 10.1097/01.CCM.0000299740.65484.CA; Colville GA, 2013, PEDIATR CRIT CARE ME, V14, pE85, DOI 10.1097/PCC.0b013e3182712997; Conlon NP, 2009, PEDIATR CRIT CARE ME, V10, P41, DOI 10.1097/PCC.0b013e31819371f6; Czaja AS, 2009, PEDIATRICS, V123, P849, DOI 10.1542/peds.2008-0856; de Souza DC, 2017, SHOCK, V47, P2, DOI 10.1097/SHK.0000000000000699; Desai AD, 2014, JAMA PEDIATR, V168, P1114, DOI 10.1001/jamapediatrics.2014.1600; Ebrahim S, 2013, PEDIATR CRIT CARE ME, V14, P10, DOI 10.1097/PCC.0b013e31825b64b3; Edmond K, 2010, PEDIATR INFECT DIS J, V29, P1023, DOI 10.1097/INF.0b013e3181e598ea; Edwards JD, 2012, CRIT CARE MED, V40, P2196, DOI 10.1097/CCM.0b013e31824e68cf; Farris RWD, 2013, PEDIATR CRIT CARE ME, V14, P835, DOI 10.1097/PCC.0b013e3182a551c8; Gebara Bassam M, 2005, Pediatr Crit Care Med, V6, P500, DOI 10.1097/01.PCC.0000164344.07588.83; Gebara BM, 2005, PEDIATR CRIT CARE ME, V6, P501; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; Gupta S, 2016, CHEST, V150, P1251, DOI 10.1016/j.chest.2016.08.1460; Hartman ME, 2013, PEDIATR CRIT CARE ME, V14, P686, DOI 10.1097/PCC.0b013e3182917fad; Kruse S, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/s12955-014-0168-2; Leteurtre S, 1999, MED DECIS MAKING, V19, P399, DOI 10.1177/0272989X9901900408; Limbers CA, 2009, ANN EPIDEMIOL, V19, P575, DOI 10.1016/j.annepidem.2009.04.004; Menon K, 2017, PEDIATR CRIT CARE ME, V18, pE146, DOI 10.1097/PCC.0000000000001078; Morrison Anne L, 2002, Pediatr Crit Care Med, V3, P1, DOI 10.1097/00130478-200201000-00001; Namachivayam P, 2012, PEDIATR CRIT CARE ME, V13, P520, DOI 10.1097/PCC.0b013e31824fb989; Nielsen KR, 2016, J INTENSIVE CARE MED, V31, P660, DOI 10.1177/0885066615571893; Phua J, 2013, CRIT CARE, V17, DOI 10.1186/cc12896; Polic B, 2013, EUR J PEDIATR, V172, P85, DOI 10.1007/s00431-012-1843-0; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Rabbitts JA, 2015, J PAIN, V16, P1334, DOI 10.1016/j.jpain.2015.09.005; Rivara FP, 2012, J NEUROTRAUM, V29, P2499, DOI 10.1089/neu.2012.2434; Ruth A, 2014, PEDIATR CRIT CARE ME, V15, P828, DOI 10.1097/PCC.0000000000000254; Simon TD, 2014, PEDIATRICS, V133, pE1647, DOI 10.1542/peds.2013-3875; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-2; Varni JW, 2011, QUAL LIFE RES, V20, P45, DOI 10.1007/s11136-010-9730-5; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Weiss SL, 2015, AM J RESP CRIT CARE, V191, P1147, DOI 10.1164/rccm.201412-2323OC; Zonfrillo MR, 2014, J NEUROTRAUM, V31, P722, DOI 10.1089/neu.2013.3088	39	12	12	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JUN	2019	20	6					501	509		10.1097/PCC.0000000000001886			9	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	IQ4HF	WOS:000480711000007	30720672	Green Accepted			2021-06-18	
J	Lepage, C; Muehlmann, M; Tripodis, Y; Hufschmidt, J; Stamm, J; Green, K; Wrobel, P; Schultz, V; Weir, I; Alosco, ML; Baugh, CM; Fritts, NG; Martin, BM; Chaisson, C; Coleman, MJ; Lin, AP; Pasternak, O; Makris, N; Stern, RA; Shenton, ME; Koerte, IK				Lepage, Christian; Muehlmann, Marc; Tripodis, Yorghos; Hufschmidt, Jakob; Stamm, Julie; Green, Katie; Wrobel, Pawel; Schultz, Vivian; Weir, Isabelle; Alosco, Michael L.; Baugh, Christine M.; Fritts, Nathan G.; Martin, Brett M.; Chaisson, Christine; Coleman, Michael J.; Lin, Alexander P.; Pasternak, Ofer; Makris, Nikos; Stern, Robert A.; Shenton, Martha E.; Koerte, Inga K.			Limbic system structure volumes and associated neurocognitive functioning in former NFL players	BRAIN IMAGING AND BEHAVIOR			English	Article						Volumetric MRI; Chronic Traumatic Encephalopathy; Hippocampus; Limbic System; Repetitive Head Impacts	TRAUMATIC BRAIN-INJURY; HIPPOCAMPAL VOLUME; 1ST EXPOSURE; FOOTBALL; ENCEPHALOPATHY; CONCUSSION; HISTORY; NEUROCHEMISTRY; AMYGDALA; NETWORK	Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with exposure to repetitive head impacts. CTE has been linked to disruptions in cognition, mood, and behavior. Unfortunately, the diagnosis of CTE can only be made post-mortem. Neuropathological evidence suggests limbic structures may provide an opportunity to characterize CTE in the living. Using 3T magnetic resonance imaging, we compared select limbic brain regional volumes - the amygdala, hippocampus, and cingulate gyrus - between symptomatic former National Football League (NFL) players (n=86) and controls (n=22). Moreover, within the group of former NFL players, we examined the relationship between those limbic structures and neurobehavioral functioning (n=75). The former NFL group comprised eighty-six men (mean age=55.2 +/- 8.0years) with at least 12years of organized football experience, at least 2years of active participation in the NFL, and self-reported declines in cognition, mood, and behavior within the last 6months. The control group consisted of men (mean age=57.0 +/- 6.6years) with no history of contact-sport involvement or traumatic brain injury. All control participants provided neurobehavioral data. Compared to controls, former NFL players exhibited reduced volumes of the amygdala, hippocampus, and cingulate gyrus. Within the NFL group, reduced bilateral cingulate gyrus volume was associated with worse attention and psychomotor speed (r=0.4 (right), r=0.42 (left); both p<0.001), while decreased right hippocampal volume was associated with worse visual memory (r=0.25, p=0.027). Reduced volumes of limbic system structures in former NFL players are associated with neurocognitive features of CTE. Volume reductions in the amygdala, hippocampus, and cingulate gyrus may be potential biomarkers of neurodegeneration in those at risk for CTE.	[Lepage, Christian; Muehlmann, Marc; Hufschmidt, Jakob; Stamm, Julie; Green, Katie; Wrobel, Pawel; Schultz, Vivian; Coleman, Michael J.; Lin, Alexander P.; Pasternak, Ofer; Makris, Nikos; Shenton, Martha E.; Koerte, Inga K.] Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat, Psychiat Neuroimaging Lab, Boston, MA 02115 USA; [Lepage, Christian] Univ Ottawa, Dept Psychol, Ottawa, ON, Canada; [Makris, Nikos] Massachusetts Gen Hosp, Ctr Morphometr Anal, Boston, MA 02114 USA; [Muehlmann, Marc] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Radiol, Munich, Germany; [Tripodis, Yorghos; Stamm, Julie; Alosco, Michael L.; Baugh, Christine M.; Fritts, Nathan G.; Chaisson, Christine; Stern, Robert A.] Boston Univ, BU Alzheimers Dis & CTE Ctr, Boston, MA 02215 USA; [Tripodis, Yorghos; Weir, Isabelle] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Hufschmidt, Jakob; Wrobel, Pawel; Schultz, Vivian; Koerte, Inga K.] Ludwig Maximilians Univ Munchen, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany; [Stamm, Julie; Stern, Robert A.] Univ Wisconsin, Dept Kinesiol, Madison, WI USA; [Alosco, Michael L.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Baugh, Christine M.] Harvard Univ, Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA; [Martin, Brett M.; Chaisson, Christine] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA USA; [Lin, Alexander P.] Brigham & Womens Hosp, Ctr Clin Spect, 75 Francis St, Boston, MA 02115 USA; [Pasternak, Ofer; Makris, Nikos; Shenton, Martha E.] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA; [Makris, Nikos] Massachusetts Gen Hosp, Ctr Neural Syst Invest, Boston, MA 02114 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton Div, Brockton, MA USA	Koerte, IK (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat, Psychiat Neuroimaging Lab, Boston, MA 02115 USA.; Koerte, IK (corresponding author), Ludwig Maximilians Univ Munchen, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany.	clepage@uottawa.ca; marc.muehlmann@med.lmu.de; yorghos@bu.edu; j.f.d.hufschmidt@web.de; jmstamm@bu.edu; katiefg@gmail.com; pwrob93@googlemail.com; vschultz@bwh.harvard.edu; iweir@bu.edu; malosco@bu.edu; cbaugh@g.harvard.edu; frittsn@ohsu.edu; brmartin@bu.edu; chaisson@bu.edu; mjc@bwh.harvard.edu; aplin@partners.org; ofer@bwh.harvard.edu; nikos@cma.mgh.harvard.edu; bobstern@bu.edu; shenton@bwh.harvard.edu; ikoerte@bwh.harvard.edu	Shenton, Martha/V-8780-2019; Baugh, Christine/AAG-2324-2020; , Bob/ABA-8507-2020	Baugh, Christine/0000-0002-9340-6338; Tripodis, Yorghos/0000-0003-2190-7608	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS 078337, F31 NS 081957, 1F32NS096803-01, P30 AG13846, UL1-TR000157, P41 EB015902, T32GM074905, R01NS100952]; JetBlue Airlines; National Football League; NFL Players Association; Else Kroner-Fresenius Foundation, Germany; VA Merit AwardUS Department of Veterans Affairs; German Academic Exchange Service PROMOS award; Canadian Institutes of Health Research Frederick Banting and Charles Best Doctoral AwardCanadian Institutes of Health Research (CIHR); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM074905] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS096803, K23NS102399, R01NS100952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	The authors extend their appreciation to the study participants who make this work possible. This study was supported by the NIH (R01 NS 078337 (RAS, YT, CMB, NGF, BMM, CC); F31 NS 081957 (JMS); 1F32NS096803-01 (MLA), P30 AG13846 (RAS, YT, MLA, CMB, BMM, CC); UL1-TR000157 (RAS); P41 EB015902 (OP); T32GM074905 (IW); R01NS100952: IKK, APL), and participant travel was partially funded by JetBlue Airlines, the National Football League, and the NFL Players Association. This study was also partly supported by the Else Kroner-Fresenius Foundation, Germany (IK, MM) and by a VA Merit Award (MES, MC). VS was supported by the German Academic Exchange Service PROMOS award. CL was supported by the Canadian Institutes of Health Research Frederick Banting and Charles Best Doctoral Award. The sponsors had no role in the design and conduct of the study, the collection, analysis, or the interpretation of the data, nor in the preparation, review, or approval of the manuscript, or the decision of submission for publication. This work was completed in partial fulfillment of JH's Ph.D. dissertation.	Alosco Michael L, 2018, Alzheimers Dement (Amst), V10, P56, DOI 10.1016/j.dadm.2017.10.003; Alosco ML, 2017, J NEUROTRAUM, V34, P772, DOI 10.1089/neu.2016.4536; Amaral DG, 2003, NEUROPSYCHOLOGIA, V41, P235, DOI 10.1016/S0028-3932(02)00154-9; Banks SJ, 2014, J NEUROPSYCH CLIN N, V26, P44, DOI 10.1176/appi.neuropsych.12070185; Baugh CM, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0306-5; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bernick C, 2015, BRIT J SPORT MED, V49, P1007, DOI 10.1136/bjsports-2014-093877; Blaylock R. L., 2011, SURG NEUROLOGY INT, V2; Cicchetti D.V., 1994, PSYCHOL ASSESS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Davis KD, 2000, J NEUROPHYSIOL, V83, P3575; Drummond SPA, 2005, SLEEP, V28, P1059; EFRON B, 1987, J AM STAT ASSOC, V82, P171, DOI 10.2307/2289144; Efron B., 1994, INTRO BOOTSTRAP; Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Gurvits TV, 1996, BIOL PSYCHIAT, V40, P1091, DOI 10.1016/S0006-3223(96)00229-6; Hay J, 2016, ANNU REV PATHOL-MECH, V11, P21, DOI 10.1146/annurev-pathol-012615-044116; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Kilpatrick L, 2003, NEUROIMAGE, V20, P2091, DOI 10.1016/j.neuroimage.2003.08.006; Koerte IK, 2016, J NEUROTRAUM, V33, P346, DOI 10.1089/neu.2015.3880; Koerte IK, 2015, J NEUROTRAUM, V32, P1287, DOI 10.1089/neu.2014.3715; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Lin AP, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0094-5; Mannix R, 2017, J NEUROTRAUM, V34, P495, DOI 10.1089/neu.2016.4457; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Provenzano FA, 2010, NUCL MED COMMUN, V31, P952, DOI 10.1097/MNM.0b013e32833e37c4; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Robinson S, 2017, J NEUROSCI RES, V95, P1025, DOI 10.1002/jnr.23848; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; SATTERTHWAITE FE, 1946, BIOMETRICS BULL, V2, P110, DOI 10.2307/3002019; Schultz V, 2018, J NEUROTRAUM, V35, P278, DOI 10.1089/neu.2017.5145; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Sparks P, 2020, CLIN J SPORT MED, V30, pS1, DOI 10.1097/JSM.0000000000000541; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Strain JF, 2015, JAMA NEUROL, V72, P773, DOI 10.1001/jamaneurol.2015.0206; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	48	12	12	0	16	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2019	13	3					725	734		10.1007/s11682-018-9895-z			10	Neuroimaging	Neurosciences & Neurology	IA1VV	WOS:000469351500014	29779184	Green Accepted			2021-06-18	
J	Romeu-Mejia, R; Giza, CC; Goldman, JT				Romeu-Mejia, Rafael; Giza, Christopher C.; Goldman, Joshua T.			Concussion Pathophysiology and Injury Biomechanics	CURRENT REVIEWS IN MUSCULOSKELETAL MEDICINE			English	Article						Concussion pathophysiology; Mild traumatic brain injury; Neurometabolic cascade; Biomechanical impact; Concussion threshold; Linear-rotational acceleration	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; CORTICAL IMPACT INJURY; LONG-TERM POTENTIATION; DIFFUSE AXONAL INJURY; SYNAPTIC PLASTICITY; BARRIER DISRUPTION; KETOGENIC DIET; CELL-DEATH; SPORTS	Purpose of ReviewThe concussion public health burden has increased alongside our knowledge of the pathophysiology of mild traumatic brain injury (mTBI). The purpose of this review is to summarize our current understanding of mTBI pathophysiology and biomechanics and how these underlying principles correlate with clinical manifestations of mTBI.Recent FindingsChanges in post-mTBI glutamate and GABA concentrations seem to be region-specific and time-dependent. Genetic variability may predict recovery and symptom severity while gender differences appear to be associated with the neuroinflammatory response and neuroplasticity. Ongoing biomechanical research has shown a growing body of evidence in support of an individual-specific threshold for mTBI that varies based on individual intrinsic factors.SummaryThe literature demonstrates a well-characterized timeframe for mTBI pathophysiologic changes in animal models while work in this area continues to grow in humans. Current human research shows that these underlying post-mTBI effects are multifactorial and may correlate with symptomatology and recovery. While wearable sensor technology has advanced biomechanical impact research, a definitive concussion threshold remains elusive.	[Romeu-Mejia, Rafael; Giza, Christopher C.; Goldman, Joshua T.] UCLA, Steve Tisch BrainSPORT Program, Dept Neurosurg, Los Angeles, CA 90095 USA; [Romeu-Mejia, Rafael; Giza, Christopher C.] UCLA, Brain Injury Res Ctr, Los Angeles, CA USA; [Giza, Christopher C.] UCLA, Mattel Childrens Hosp, Dept Pediat Pediat Neurol, Los Angeles, CA USA; [Goldman, Joshua T.] UCLA, Dept Family Med, Div Sports Med, Los Angeles, CA 90095 USA; [Goldman, Joshua T.] UCLA, Dept Orthoped Surg, Los Angeles, CA 90095 USA; [Goldman, Joshua T.] UCLA, Dept Intercollegiate Athlet, Los Angeles, CA 90095 USA; [Goldman, Joshua T.] Orthoped Inst Children, Ctr Sports Med, Los Angeles, CA 90007 USA	Goldman, JT (corresponding author), UCLA, Steve Tisch BrainSPORT Program, Dept Neurosurg, Los Angeles, CA 90095 USA.; Goldman, JT (corresponding author), UCLA, Dept Family Med, Div Sports Med, Los Angeles, CA 90095 USA.; Goldman, JT (corresponding author), UCLA, Dept Orthoped Surg, Los Angeles, CA 90095 USA.; Goldman, JT (corresponding author), UCLA, Dept Intercollegiate Athlet, Los Angeles, CA 90095 USA.; Goldman, JT (corresponding author), Orthoped Inst Children, Ctr Sports Med, Los Angeles, CA 90007 USA.	jgoldman@mednet.ucla.edu					Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ahmadzadeh H, 2014, BIOPHYS J, V106, P1123, DOI 10.1016/j.bpj.2014.01.024; [Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Belanger M, 2011, J NEUROCHEM, V116, P564, DOI 10.1111/j.1471-4159.2010.07135.x; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6; Brennan JH, 2017, SPORTS MED, V47, P469, DOI 10.1007/s40279-016-0582-1; Byrnes Kimberly R, 2014, Front Neuroenergetics, V5, P13, DOI 10.3389/fnene.2013.00013; Caccese JB, 2017, SPORTS BIOMECH, V3141, P1; Cantu D, 2015, CEREB CORTEX, V25, P2306, DOI 10.1093/cercor/bhu041; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Choe MC, 2016, J CHILD NEUROL, V31, P109, DOI 10.1177/0883073815572685; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Churchill NW, 2017, NEUROIMAGE-CLIN, V14, P480, DOI 10.1016/j.nicl.2017.02.015; Clausen M, 2016, J HEAD TRAUMA REHAB, V31, P215, DOI 10.1097/HTR.0000000000000145; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Coronado VG, 2010, TRAUMATIC BRAIN INJU, P891, DOI [10.1016/B978-0-444-52910-7.00011-8, DOI 10.1016/B978-0-444-52910-7.00011-8]; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Covassin T, 2016, J ATHL TRAINING, V51, P189, DOI 10.4085/1062-6050-51.3.05; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DeMatteo CA, 2010, PEDIATRICS, V125, P327, DOI 10.1542/peds.2008-2720; Dennis EL, 2015, J NEUROSCI, V35, P10202, DOI 10.1523/JNEUROSCI.1595-15.2015; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Fidan E, 2018, ASN NEURO, V10, DOI 10.1177/1759091418770543; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Fu M, 2011, TRENDS NEUROSCI, V34, P177, DOI 10.1016/j.tins.2011.02.001; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Gurkoff GG, 2017, NEW THER TRAUMA BRAI; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; Institute NSS, 2017, INT CONS DIAGN MAN S, P1, DOI [10.1002/app.21943, DOI 10.1002/APP.21943]; Johnson VE, 2018, ACTA NEUROPATHOL, V135, P711, DOI 10.1007/s00401-018-1824-0; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; KALIMO H, 1981, J CEREBR BLOOD F MET, V1, P313, DOI 10.1038/jcbfm.1981.35; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kerr ZY, 2017, J ATHL TRAINING, V52, P167, DOI 10.4085/1062-6050-51.6.05; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Liu XX, 2017, J NEUROTRAUM, V34, P2445, DOI 10.1089/neu.2016.4823; Livingston WS, 2017, J NEUROTRAUM, V34, P853, DOI 10.1089/neu.2016.4479; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lumba-Brown A, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2018.2853; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MacFarlane MP, 2015, BRAIN INJURY, V29, P139, DOI 10.3109/02699052.2014.965208; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mayer AR, 2015, J NEUROTRAUM, V32, P723, DOI 10.1089/neu.2014.3534; Mc Fie S, 2018, J SPORT SCI, V36, P2226, DOI 10.1080/02640414.2018.1448570; McCrory P, 2017, BRIT J SPORT MED, V51, P877, DOI 10.1136/bjsports-2016-097393; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McDevitt J, 2016, ORTHOP J SPORTS MED, V4; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Monaghan KG, 2000, AM J MED GENET, V94, P120, DOI 10.1002/1096-8628(20000911)94:2<120::AID-AJMG4>3.0.CO;2-N; Monti JM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00041; Nag S, 2009, NEUROPATH APPL NEURO, V35, P417, DOI 10.1111/j.1365-2990.2008.01009.x; Nahum A. M., 1977, P 21 STAPP CAR CRASH; NIXON RA, 1993, BRAIN PATHOL, V3, P29, DOI 10.1111/j.1750-3639.1993.tb00723.x; O'Connor KL, 2017, J ATHL TRAINING, V52, P206, DOI 10.4085/1062-6050.52.2.05; Obenaus A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00161-4; Ommaya AK, 1996, P 10 STAPP CAR CRASH, P314; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Post A, 2015, J BIOMECH ENG-T ASME, V137, DOI 10.1115/1.4028983; Prange M T, 2000, Stapp Car Crash J, V44, P205; Press JN, 2017, CLIN J SPORT MED, V27, P104, DOI 10.1097/JSM.0000000000000313; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Prins ML, 2009, J NEUROTRAUM, V26, P1083, DOI [10.1089/neu.2008.0769, 10.1089/neu.2008-0769]; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; Redell JB, 2013, J NEUROTRAUM, V30, P752, DOI 10.1089/neu.2012.2437; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2; Rowson S, 2018, J NEUROTRAUM, V35, P681, DOI 10.1089/neu.2017.5169; Rowson S, 2016, SPORTS MED ARTHROSC, V24, P100, DOI 10.1097/JSA.0000000000000121; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Sharp David J, 2015, Pract Neurol, V15, P172, DOI 10.1136/practneurol-2015-001087; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Spader HS, 2019, J NEUROSURG, V130, P1321, DOI 10.3171/2017.12.JNS171597; Steenerson K, 2017, NEUROL CLIN, V35, P403, DOI 10.1016/j.ncl.2017.03.011; Su SH, 2014, BRAIN BEHAV IMMUN, V38, P111, DOI 10.1016/j.bbi.2014.01.009; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; Thibeault CM, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00200; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Villapol S, 2017, GLIA, V65, P1423, DOI 10.1002/glia.23171; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072; Weissberg I, 2014, JAMA NEUROL, V71, P1453, DOI 10.1001/jamaneurol.2014.2682; White ER, 2017, J NEUROTRAUM, V34, P1111, DOI 10.1089/neu.2016.4638; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Yasen AL, 2018, J NEUROPHYSIOL, V120, P1318, DOI 10.1152/jn.00896.2017; Yeung D, 2008, ACTA NEUROPATHOL, V115, P635, DOI 10.1007/s00401-008-0364-4; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zagorchev L, 2016, J NEUROTRAUM, V33, P29, DOI 10.1089/neu.2014.3831; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	128	12	13	1	14	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1935-973X	1935-9748		CURR REV MUSCULOSKE	Curr. Rev. Musculoskelet. Med.	JUN	2019	12	2					105	116		10.1007/s12178-019-09536-8			12	Orthopedics	Orthopedics	IA8NP	WOS:000469815900006	30820754	Green Published			2021-06-18	
J	Kuriakose, M; Younger, D; Ravula, AR; Alay, E; Rao, KVR; Chandra, N				Kuriakose, Matthew; Younger, Daniel; Ravula, Arun Reddy; Alay, Eren; Rao, Kakulavarapu V. Rama; Chandra, Namas			Synergistic Role of Oxidative Stress and Blood-Brain Barrier Permeability as Injury Mechanisms in the Acute Pathophysiology of Blast-induced Neurotrauma	SCIENTIFIC REPORTS			English	Article							NADPH OXIDASE ACTIVITY; MATRIX METALLOPROTEINASES; FLUID PERCUSSION; CLINICAL-TRIALS; APOCYNIN; MATRIX-METALLOPROTEINASE-9; INHIBITOR; EDEMA; NEUROPROTECTION; BIOAVAILABILITY	Blast-induced traumatic brain injury (bTBI) has been recognized as the common mode of neurotrauma amongst military and civilian personnel due to an increased insurgent activity domestically and abroad. Previous studies from our laboratory have identified enhanced blood-brain barrier (BBB) permeability as a significant, sub-acute (four hours post-blast) pathological change in bTBI. We also found that NADPH oxidase (NOX)-mediated oxidative stress occurs at the same time post-blast when the BBB permeability changes. We therefore hypothesized that oxidative stress is a major causative factor in the BBB breakdown in the sub-acute stages. This work therefore examined the role of NOX1 and its downstream effects on BBB permeability in the frontal cortex (a region previously shown to be the most vulnerable) immediately and four hours post-blast exposure. Rats were injured by primary blast waves in a compressed gas-driven shock tube at 180 kPa and the BBB integrity was assessed by extravasation of Evans blue and changes in tight junction proteins (TJPs) as well as translocation of macromolecules from blood to brain and vice versa. NOX1 abundance was also assessed in neurovascular endothelial cells. Blast injury resulted in increased extravasation and reduced levels of TJPs in tissues consistent with our previous observations. NOX1 levels were significantly increased in endothelial cells followed by increased superoxide production within 4 hours of blast. Blast injury also increased the levels/activation of matrix metalloproteinase 3 and 9. To test the role of oxidative stress, rats were administered apocynin, which is known to inhibit the assembly of NOX subunits and arrests its function. We found apocynin completely inhibited dye extravasation as well as restored TJP levels to that of controls and reduced matrix metalloproteinase activation in the sub-acute stages following blast. Together these data strongly suggest that NOX-mediated oxidative stress contributes to enhanced BBB permeability in bTBI through a pathway involving increased matrix metalloproteinase activation.	[Kuriakose, Matthew; Younger, Daniel; Ravula, Arun Reddy; Alay, Eren; Rao, Kakulavarapu V. Rama; Chandra, Namas] New Jersey Inst Technol, Dept Biomed Engn, Ctr Injury Biomech Mat & Med CIBM3, Newark, NJ 07102 USA	Rao, KVR; Chandra, N (corresponding author), New Jersey Inst Technol, Dept Biomed Engn, Ctr Injury Biomech Mat & Med CIBM3, Newark, NJ 07102 USA.	kakulava@njit.edu; namas.chandra@njit.edu			U. S Army Medical Research and Materiel Command project Primary Blast Injury Criteria for Animal/Human TBI Models using Field Validated Shock Tube [14059001]	This work was supported by U. S Army Medical Research and Materiel Command project Primary Blast Injury Criteria for Animal/Human TBI Models using Field Validated Shock Tube, grant number: 14059001 (PI: Dr. Namas Chandra). Authors gratefully acknowledge Jose Rodrigues, Stephanie Iring, Madison Taylor, and Smit Shah and Madhuvika Murugan for their contributions to this work.	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Anter HM, 2018, DRUG DES DEV THER, V12, P2981, DOI 10.2147/DDDT.S176850; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Bochicchio GV, 2008, AM SURGEON, V74, P267; Chandasana H, 2015, J CHROMATOGR B, V985, P180, DOI 10.1016/j.jchromb.2015.01.025; Chandra N., 2011, U.S. provisional patent application, Patent No. 61542354; Chandra N, 2017, MIL MED, V182, P105, DOI 10.7205/MILMED-D-16-00144; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; DuBose JJ, 2011, J TRAUMA, V70, P11, DOI 10.1097/TA.0b013e318207c563; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; FERNANDEZ V, 1985, ENDOCRINOLOGY, V117, P496, DOI 10.1210/endo-117-2-496; Galli A, 2005, HEPATOLOGY, V41, P1074, DOI 10.1002/hep.20683; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; Ghosh A, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-241; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Hanumegowda UM, 2003, TOXICOL SCI, V76, P237, DOI 10.1093/toxsci/kfg222; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hue CD, 2015, J CEREBR BLOOD F MET, V35, P1191, DOI 10.1038/jcbfm.2015.38; Infanger DW, 2006, ANTIOXID REDOX SIGN, V8, P1583, DOI 10.1089/ars.2006.8.1583; JENNER P, 1994, LANCET, V344, P796, DOI 10.1016/S0140-6736(94)92347-7; Jia F, 2010, J NEUROTRAUM, V27, P1059, DOI 10.1089/neu.2009.1067; Kahles T, 2007, STROKE, V38, P3000, DOI 10.1161/STROKEAHA.107.489765; Kawoos U, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167510; Kim GW, 2003, J NEUROSCI, V23, P8733; Kim JH, 2013, BRAIN RES, V1499, P163, DOI 10.1016/j.brainres.2013.01.007; Kim SY, 2012, IMMUNOL CELL BIOL, V90, P441, DOI 10.1038/icb.2011.60; Koppula S, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/823902; Kuriakose M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26813-7; Kuriakose M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161597; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Ling G. S., 2013, CURRENT OPINION ANES, V24, P124; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lu XY, 2014, NEUROCHEM INT, V69, P14, DOI 10.1016/j.neuint.2014.02.006; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Machado LS, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-56; Mathews ZR, 2015, J EMERG MED, V49, P573, DOI 10.1016/j.jemermed.2015.03.013; Mishra V, 2016, SCI REP-UK, V6, DOI 10.1038/srep26992; Mitazaki S, 2016, TOXICOL REP, V3, P357, DOI 10.1016/j.toxrep.2016.02.003; Moore B., 2015, AUSTRALASIAN J PARAM, V4; Muneer PMA, 2012, ARTERIOSCL THROM VAS, V32, P1167, DOI 10.1161/ATVBAHA.112.247668; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Paracatu LC, 2017, MED CHEM, V13, P93, DOI 10.2174/1573406412666160610093216; Parrado-Fernandez C, 2018, J CELL MOL MED, V22, P5151, DOI 10.1111/jcmm.13767; Paterniti I, 2010, J LEUKOCYTE BIOL, V88, P993, DOI 10.1189/jlb.0610322; Qin YY, 2017, FREE RADICAL BIO MED, V104, P333, DOI 10.1016/j.freeradbiomed.2017.01.034; Rama Rao K. V., 2018, J NEUROTRAUMA; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reid MW, 2015, MOL CELL NEUROSCI, V66, P123, DOI 10.1016/j.mcn.2015.03.014; Reijerkerk A, 2006, FASEB J, V20, P2550, DOI 10.1096/fj.06-6099fje; Rochfort KD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101815; Rosell A, 2006, STROKE, V37, P1399, DOI 10.1161/01.STR.0000223001.06264.af; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shetty A, 2014, FRONTIERS CELLULAR N, V8; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Tang XN, 2008, NEUROSCIENCE, V154, P556, DOI 10.1016/j.neuroscience.2008.03.090; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; Wang Q, 2008, PHYTOMEDICINE, V15, P496, DOI 10.1016/j.phymed.2007.09.019; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	66	12	12	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	MAY 22	2019	9								7717	10.1038/s41598-019-44147-w			12	Multidisciplinary Sciences	Science & Technology - Other Topics	HZ1IS	WOS:000468600800011	31118451	DOAJ Gold, Green Published			2021-06-18	
J	De Blasio, D; Fumagalli, S; Orsini, F; Neglia, L; Perego, C; Ortolano, F; Zanier, ER; Picetti, E; Locatelli, M; Stocchetti, N; Longhi, L; Garred, P; De Simoni, MG				De Blasio, Daiana; Fumagalli, Stefano; Orsini, Franca; Neglia, Laura; Perego, Carlo; Ortolano, Fabrizio; Zanier, Elisa R.; Picetti, Edoardo; Locatelli, Marco; Stocchetti, Nino; Longhi, Luca; Garred, Peter; De Simoni, Maria-Grazia			Human brain trauma severity is associated with lectin complement pathway activation	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Traumatic brain injury; complement system; lectin complement pathway; neuroinflammation; MBL-associated serine proteases	MANNOSE-BINDING LECTIN; MONOCLONAL-ANTIBODIES; SERINE PROTEASE-3; INJURY; EXPRESSION; DYSFUNCTION; INHIBITION; COMPONENTS; NEOANTIGEN; FICOLIN-3	We explored the involvement of the lectin pathway of complement in post-traumatic brain injury (TBI) pathophysiology in humans. Brain samples were obtained from 28 patients who had undergone therapeutic contusion removal, within 12 h (early) or from >12 h until five days (late) from injury, and from five non-TBI patients. Imaging analysis indicated that lectin pathway initiator molecules (MBL, ficolin-1, ficolin-2 and ficolin-3), the key enzymes MASP-2 and MASP-3, and the downstream complement components (C3 fragments and TCC) were present inside and outside brain vessels in all contusions. Only ficolin-1 was found in the parenchyma of non-TBI tissues. Immunoassays in brain homogenates showed that MBL, ficolin-2 and ficolin-3 increased in TBI compared to non-TBI (2.0, 2.2 and 6.0-times) samples. MASP-2 increased with subarachnoid hemorrhage and abnormal pupil reactivity, two indicators of structural and functional damage. C3 fragments and TCC increased, respectively, by 3.5 - and 4.0-fold in TBI compared to non-TBI tissue and significantly correlated with MBL, ficolin-2, ficolin-3, MASP-2 and MASP-3 levels in the homogenates. In conclusion, we show for the first time the direct presence of lectin pathway components in human cerebral contusions and their association with injury severity, suggesting a central role for the lectin pathway in the post-traumatic pathophysiology of human TBI.	[De Blasio, Daiana; Fumagalli, Stefano; Orsini, Franca; Neglia, Laura; Perego, Carlo; Zanier, Elisa R.; De Simoni, Maria-Grazia] Ist Ric Farmacol Mario Negri, IRCCS, Via Giuseppe La Masa 19, I-20156 Milan, Italy; [Ortolano, Fabrizio; Stocchetti, Nino] Osped Maggiore Policlin, Dept Anesthesia & Crit Care Med, Fdn IRCCS Ca Granda, Milan, Italy; [Picetti, Edoardo] Azienda Osped Univ Parma, Div Anesthesia & Intens Care, Parma, Italy; [Locatelli, Marco] Osped Maggiore Policlin, Dept Neurosurg, Fdn IRCCS Ca Granda, Milan, Italy; [Stocchetti, Nino] Milan Univ, Dept Physiopathol & Transplantat, Milan, Italy; [Longhi, Luca] Azienda Socio Sanit Terr Papa Giovanni XXIII, Dept Anesthesia & Crit Care Med, Neurosurg Intens Care Unit, Bergamo, Italy; [Garred, Peter] Univ Copenhagen, Fac Med & Hlth Sci, Rigshosp, Lab Mol Med,Dept Clin Immunol, Copenhagen, Denmark	De Simoni, MG (corresponding author), Ist Ric Farmacol Mario Negri, IRCCS, Via Giuseppe La Masa 19, I-20156 Milan, Italy.	desimoni@marionegri.it	Perego, Carlo/AAA-6513-2020; Zanier, Elisa/AAA-8095-2020; De Simoni, Maria Grazia/I-6021-2012; Longhi, Luca/AAF-9903-2021	Perego, Carlo/0000-0002-0259-0003; De Simoni, Maria Grazia/0000-0001-6695-5297; Longhi, Luca/0000-0001-9894-8788; Garred, Peter/0000-0002-2876-8586; Orsini, Franca/0000-0001-7415-9936; Fumagalli, Stefano/0000-0003-3598-6263; Zanier, Elisa/0000-0002-3011-8718; locatelli, marco/0000-0003-0778-3653	Fondazione CariploFondazione Cariplo [2012-0590]; Italian Ministry of Health (Ministero della Salute)Ministry of Health, Italy; ERANET-NEURON, JTC 2016: New therapeutic strategies in the treatment of traumatic brain injury by targeting the LEctin Activation Pathway of complement (LEAP) [NEURON9-FP-044]; Novo Nordisk Research FoundationNovo Nordisk Foundation; Danish Research Council for Independent ResearchDet Frie Forskningsrad (DFF)	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Financial support including Drs De Blasio and Fumagalli fellowships was provided by Fondazione Cariplo (grant number 2012-0590). This study was partially supported by Italian Ministry of Health (Ministero della Salute) and ERANET-NEURON, JTC 2016: New therapeutic strategies in the treatment of traumatic brain injury by targeting the LEctin Activation Pathway of complement (LEAP, NEURON9-FP-044). The study was supported by grants from the Novo Nordisk Research Foundation and the Danish Research Council for Independent Research (PG).	[Anonymous], 2008, BMJ-BRIT MED J, V336, P425, DOI DOI 10.1136/bmj.39461.643438.25; BECKER P, 1987, ANAESTHESIST, V36, P301; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Brennan FH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-137; Burk AM, 2012, SHOCK, V37, P348, DOI 10.1097/SHK.0b013e3182471795; Cervera A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008433; De Blasio D, 2017, J CEREBR BLOOD F MET, V37, P938, DOI 10.1177/0271678X16647397; DEAN RB, 1951, ANAL CHEM, V23, P636, DOI 10.1021/ac60052a025; Dobo J, 2016, IMMUNOL REV, V274, P98, DOI 10.1111/imr.12460; Dobo J, 2016, SCI REP-UK, V6, DOI 10.1038/srep31877; Endo Y, 2011, INT J BIOCHEM CELL B, V43, P705, DOI 10.1016/j.biocel.2011.02.003; Finnie JW, 2016, J COMP PATHOL, V154, P323, DOI 10.1016/j.jcpa.2016.03.005; Fumagalli S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00288; Fumagalli S, 2016, STROKE, V47, P3067, DOI 10.1161/STROKEAHA.116.012407; Garred P, 2016, IMMUNOL REV, V274, P74, DOI 10.1111/imr.12468; GASQUE P, 1992, J IMMUNOL, V149, P1381; Gesuete R, 2009, ANN NEUROL, V66, P332, DOI 10.1002/ana.21740; Iwaki D, 2011, J IMMUNOL, V187, P3751, DOI 10.4049/jimmunol.1100280; Kennedy AD, 2003, BLOOD, V101, P1071, DOI 10.1182/blood-2002-03-0876; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Kuraya M, 2003, INT IMMUNOL, V15, P109, DOI 10.1093/intimm/dxg008; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Longhi L, 2014, CRIT CARE MED, V42, P1910, DOI 10.1097/CCM.0000000000000399; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Markiewski MM, 2007, TRENDS IMMUNOL, V28, P184, DOI 10.1016/j.it.2007.02.006; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MOLLNES TE, 1985, SCAND J IMMUNOL, V22, P197, DOI 10.1111/j.1365-3083.1985.tb01871.x; MOLLNES TE, 1985, SCAND J IMMUNOL, V22, P183, DOI 10.1111/j.1365-3083.1985.tb01870.x; Orsini F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0684-6; Orsini F, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00380; Orsini F, 2012, CIRCULATION, V126, P1484, DOI 10.1161/CIRCULATIONAHA.112.103051; Ortolano F, 2009, J NEUROPATH EXP NEUR, V68, P964, DOI 10.1097/NEN.0b013e3181b20670; Osthoff M, 2017, J NEUROTRAUM, V34, P2560, DOI 10.1089/neu.2016.4941; Pan JW, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0444-z; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; RORABACHER DB, 1991, ANAL CHEM, V63, P139, DOI 10.1021/ac00002a010; Rosbjerg A, 2014, J IMMUNOL, V192, P4352, DOI 10.4049/jimmunol.1303263; Ruseva MM, 2015, P NATL ACAD SCI USA, V112, P14319, DOI 10.1073/pnas.1513698112; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Skjoedt MO, 2010, IMMUNOBIOLOGY, V215, P921, DOI 10.1016/j.imbio.2009.10.006; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Veenith TV, 2016, JAMA NEUROL, V73, P542, DOI 10.1001/jamaneurol.2016.0091; Wallis R, 2010, IMMUNOBIOLOGY, V215, P1, DOI 10.1016/j.imbio.2009.08.006; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497; Yu W, 2015, CLIN CHIM ACTA, V451, P111, DOI 10.1016/j.cca.2015.10.017; Zangari R, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0481-2; Zanier ER, 2014, NEUROLOGY, V82, P126, DOI 10.1212/WNL.0000000000000020; Zanier ER, 2011, INTENS CARE MED, V37, P302, DOI 10.1007/s00134-010-2075-2	57	12	12	1	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2019	39	5								10.1177/0271678X18758881			14	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	HY5YS	WOS:000468206000004	29425056	Green Published, Other Gold			2021-06-18	
J	Guley, NM; Del Mar, NA; Ragsdale, T; Li, CY; Perry, AM; Moor, BM; Honig, MG; Reiner, A				Guley, Natalie M.; Del Mar, Nobel A.; Ragsdale, Tyler; Li, Chunyan; Perry, Aaron M.; Moor, Bob M.; Honig, Marcia G.; Reiner, Anton			Amelioration of visual deficits and visual system pathology after mild TBI with the cannabinoid type-2 receptor inverse agonist SMM-189	EXPERIMENTAL EYE RESEARCH			English	Article						TBI; Visual deficits; Microglia; CB2 receptors; Cannabinoid therapy	TRAUMATIC BRAIN-INJURY; OPTIC-NERVE HEAD; SPINAL-CORD; CB2 RECEPTOR; MICROGLIAL POLARIZATION; CELL RESPONSES; AXONAL INJURY; ACTIVATION; MOUSE; DYSFUNCTION	Mild TBI is often accompanied by visual system dysfunction and injury, which is at least partly caused by microglial neuroinflammatory processes initiated by the injury. Using our focal cranial blast mouse model of closed-skull mild TBI, we evaluated the ability of the cannabinoid type-2 (CB2) receptor inverse agonist SMM-189, which biases microglia from the harmful M1 state to the beneficial M2 state, to mitigate visual system dysfunction and injury after TBI. Male C57BL/6 or Thyl-EYFP reporter mice received a closed-head blast of either 0-psi (sham) or 50-psi to the left side of the cranium. Blast mice received vehicle or 6 mg/kg SMM-189 daily beginning 2 h after blast. Sham mice received vehicle. In some mice, retina and optic nerve/tract were assessed morphologically at 3-7 days after blast, while other mice were assessed functionally by Optomotry >= 30 days after blast and morphologically at >= 30 days after blast. Mice sacrificed at 3-7 days were treated daily until sacrificed, while those assessed 30 days after blast were treated daily for 2 weeks post blast. Axon damage was evident in the left optic nerve and its continuation as the right optic tract at 3 days post blast in vehicle-treated blast mice in the form of swollen axon bulbs, and was accompanied by a significant increase in the abundance of microglia. Testing at 30 days post blast revealed that the contrast sensitivity function was significantly reduced in both eyes in vehicle-treated blast mice compared to vehicle-treated sham blast mice, and axon counts at >= 30 days after blast revealed a similar to 10% loss in left optic nerve in vehicle-treated blast mice. Left optic nerve axon loss was highly correlated with the left eye deficit in contrast sensitivity. Immurtolabeling at 30 days post blast showed a significant increase in the abundance of microglia in the retinas of both eyes and in GFAP + Muller cell processes traversing the inner plexiform layer in the left eye of vehicle-treated blast mice. SMM-189 treatment reduced axon injury and microglial abundance at 3 days, and mitigated axon loss, contrast sensitivity deficits, microglial abundance, and Muller cell GFAP upregulation at >= 30 days after blast injury. Analysis of right optic tract microglia at 3 days post blast for Ml versus M2 markers revealed that SMM-189 biased microglia toward the M2 state, with this action of SMM-189 being linked to reduced axonal injury. Taken together, our results show that focal left side cranial blast resulted in impaired contrast sensitivity and retinal pathology bilaterally and optic nerve loss ipsilaterally. The novel cannabinoid drug SMM-189 significantly mitigated the functional deficit and the associated pathologies. Our findings suggest the value of combatting visual system injury after TBI by using CB2 inverse agonists such as SMM-189, which appear to target microglia and bias them away from the pro-inflammatory Ml state, toward the protective M2 state.	[Guley, Natalie M.; Del Mar, Nobel A.; Ragsdale, Tyler; Li, Chunyan; Perry, Aaron M.; Honig, Marcia G.; Reiner, Anton] Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, 855 Monroe Ave, Memphis, TN 38163 USA; [Reiner, Anton] Univ Tennessee, Dept Ophthalmol, Hlth Sci Ctr, Memphis, TN 38163 USA; [Moor, Bob M.] Univ Tennessee, Dept Pharmaceut Sci, Hlth Sci Ctr, Memphis, TN 38163 USA	Reiner, A (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, 855 Monroe Ave, Memphis, TN 38163 USA.	areiner@uthsc.edu	Reiner, Anton/AAG-8860-2020	Reiner, Anton/0000-0002-2146-5232	University of Tennessee Neuroscience Institute; The Office of the Dean of the College of Medicine at The University of Tennessee Health Science Center; Office of the Dean of the College of Graduate Health Sciences at The University of Tennessee Health Science Center; Methodist Hospitals Endowed Professorship in Neuroscience; College of Pharmacy; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [EY-005298]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY005298] Funding Source: NIH RePORTER	This work was supported by The University of Tennessee Neuroscience Institute (AR, NMG), The Office of the Dean of the College of Medicine at The University of Tennessee Health Science Center (AR), The Office of the Dean of the College of Graduate Health Sciences at The University of Tennessee Health Science Center (NMG), The Methodist Hospitals Endowed Professorship in Neuroscience (AR), The College of Pharmacy (BMM), and NIH grant EY-005298 (AR). The funding sources played no role in the design or execution of the study, or in the choice of journal for publication.	Alvarez TL, 2012, OPTOMETRY VISION SCI, V89, P1740, DOI 10.1097/OPX.0b013e3182772dce; Ashton JC, 2007, CURR NEUROPHARMACOL, V5, P73, DOI 10.2174/157015907780866884; Atwood BK, 2012, PROG NEURO-PSYCHOPH, V38, P16, DOI 10.1016/j.pnpbp.2011.12.001; Bae EJ, 2012, J NEUROSCI, V32, P13454, DOI 10.1523/JNEUROSCI.1292-12.2012; Bosco A, 2016, EXP EYE RES, V150, P34, DOI 10.1016/j.exer.2016.01.014; Bosco A, 2011, J COMP NEUROL, V519, P599, DOI 10.1002/cne.22516; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Bringmann A, 2012, OPHTHALMOLOGICA, V227, P1, DOI 10.1159/000328979; Bruce BB, 2006, J NEUROL NEUROSUR PS, V77, P986, DOI 10.1136/jnnp.2006.088799; Bu W, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00449; Burgoyne CF, 2011, EXP EYE RES, V93, P120, DOI 10.1016/j.exer.2010.09.005; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Cao L, 2013, NEUROSCI BULL, V29, P189, DOI 10.1007/s12264-013-1324-0; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Pena-Philippides JC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0753-x; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Cockerham GC, 2013, OCUL SURF, V11, P25, DOI 10.1016/j.jtos.2012.09.004; Cockerham GC, 2011, NEW ENGL J MED, V364, P2172, DOI 10.1056/NEJMc1010683; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Das M., 2018, REV NEUROSCI; Davis BM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01747-8; del Mar N, 2015, EXP NEUROL, V271, P53, DOI 10.1016/j.expneurol.2015.04.023; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Doble JE, 2010, PM&R, V2, P244, DOI 10.1016/j.pmrj.2010.01.011; Donat CK, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00208; Donat CK, 2014, ACTA NEUROBIOL EXP, V74, P197; Douglas RM, 2005, VISUAL NEUROSCI, V22, P677, DOI 10.1017/S0952523805225166; Du T, 2005, BRAIN INJURY, V19, P1125, DOI 10.1080/02699050500149817; Erkenstam NH, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00286; Evanson NK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197346; Franco R, 2015, PROG NEUROBIOL, V131, P65, DOI 10.1016/j.pneurobio.2015.05.003; Fujinaga M, 2010, BIOORG MED CHEM LETT, V20, P1565, DOI 10.1016/j.bmcl.2010.01.074; Gaucher D, 2007, VISION RES, V47, P612, DOI 10.1016/j.visres.2006.11.017; Gaudet AD, 2016, J NEUROSCI, V36, P8516, DOI 10.1523/JNEUROSCI.0735-16.2016; Gazi U, 2009, IMMUNOBIOLOGY, V214, P554, DOI 10.1016/j.imbio.2008.11.004; Godbout JP, 2005, FASEB J, V19, P1329, DOI 10.1096/fj.05-3776fje; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Green W, 2010, J REHABIL RES DEV, V47, P183, DOI 10.1682/JRRD.2009.04.0041; Guley NH, 2016, J NEUROTRAUM, V33, P403, DOI 10.1089/neu.2015.3886; Hanisch UK, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00065; Heldt SA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00002; Hippert C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120415; Howell GR, 2007, J CELL BIOL, V179, P1523, DOI 10.1083/jcb.200706181; HUMPHREY MF, 1993, J COMP NEUROL, V334, P545, DOI 10.1002/cne.903340404; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Jin H, 2010, INJURY, V41, P918, DOI 10.1016/j.injury.2010.03.007; Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010; Kerschensteiner M, 2005, NAT MED, V11, P572, DOI 10.1038/nm1229; Kimble TDH, 2006, EXP EYE RES, V83, P1017, DOI 10.1016/j.exer.2006.05.006; Kondo Y, 2013, J NEUROSCI, V33, P3514, DOI 10.1523/JNEUROSCI.4849-12.2013; Lachapelle J, 2004, VISION RES, V44, P2835, DOI 10.1016/j.visres.2004.06.007; Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Lee SJ, 2002, SCIENCE, V295, P1898, DOI 10.1126/science.1069540; Levy C, 2015, J COMP NEUROL, V523, P629, DOI 10.1002/cne.23701; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Liu Y, 2017, BMC BIOCHEM, V18, DOI 10.1186/s12858-017-0079-z; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Lunn CA, 2008, BRIT J PHARMACOL, V153, P226, DOI 10.1038/sj.bjp.0707480; Madathil SK, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00964; McCloy RA, 2014, CELL CYCLE, V13, P1400, DOI 10.4161/cc.28401; Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001; Ohgidani M, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00676; Ouyang YB, 2007, J NEUROSCI, V27, P4253, DOI 10.1523/JNEUROSCI.0211-07.2007; Patterson ZR, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00058; Peferoen LAN, 2015, J NEUROPATH EXP NEUR, V74, P48, DOI 10.1097/NEN.0000000000000149; Presley C, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.159; Prusky GT, 2004, INVEST OPHTH VIS SCI, V45, P4611, DOI 10.1167/iovs.04-0541; SCHNITZER J, 1990, J COMP NEUROL, V302, P779, DOI 10.1002/cne.903020410; Schomberg D, 2012, EXP NEUROL, V234, P262, DOI 10.1016/j.expneurol.2011.12.021; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Stella N, 2010, GLIA, V58, P1017, DOI 10.1002/glia.20983; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Stempel AV, 2016, NEURON, V90, P795, DOI 10.1016/j.neuron.2016.03.034; STERNBERGER LA, 1982, P NATL ACAD SCI-BIOL, V79, P1326, DOI 10.1073/pnas.79.4.1326; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; Sun D, 2009, J COMP NEUROL, V516, P1, DOI 10.1002/cne.22058; Swanson JA, 2004, J LEUKOCYTE BIOL, V76, P1093, DOI 10.1189/jlb.0804439; Walker DG, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0139-9; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Xu FT, 2016, NEUROSCI LETT, V617, P6, DOI 10.1016/j.neulet.2016.01.038; Yi JH, 2012, J COMP NEUROL, V520, P3295, DOI 10.1002/cne.23156; Zeng XX, 2000, VISUAL NEUROSCI, V17, P463, DOI 10.1017/S0952523800173122; 2006, J PHARMACOL EXP THER, V316, P780, DOI DOI 10.1124/JPET.105.093500; 2014, INVESTIG OPHTHALMOL, V55, P4853, DOI DOI 10.1167/IOVS.14-14353; 2008, ANESTHESIOLOGY, V108, P722; 2012, EXP NEUROL, V233, P364, DOI DOI 10.1016/J.EXPNEUROL.2011.10.030; 2015, INT J MOL SCI, V16, P758, DOI DOI 10.3390/IJMS16010758	94	12	12	1	3	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0014-4835	1096-0007		EXP EYE RES	Exp. Eye Res.	MAY	2019	182						109	124		10.1016/j.exer.2019.03.013			16	Ophthalmology	Ophthalmology	HY6RV	WOS:000468258300013	30922891	Green Accepted, Other Gold			2021-06-18	
J	Howell, DR; Oldham, JR; Meehan, WP; DiFabio, MS; Buckley, TA				Howell, David R.; Oldham, Jessie R.; Meehan, William P., III; DiFabio, Melissa S.; Buckley, Thomas A.			Dual-Task Tandem Gait and Average Walking Speed in Healthy Collegiate Athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; dual-task; tandem gait; SCAT3; SCAT5	BALANCE CONTROL; BASE-LINE; SINGLE-TASK; CONCUSSION; SPORT; ADOLESCENTS; PERFORMANCE; RECOVERY; DEFICITS; CONSISTENCY	Objectives: To (1) examine the association between a commonly used concussion test, tandem gait, in single/dual-task conditions with single-task and dual-task average walking speed, (2) characterize the prevalence of tandem gait false positives, and (3) develop a normative reference range of dual-task tandem gait times. Design: Cross-sectional study. Setting: Two NCAA collegiate athletic facilities. Independent Variables: Athletes completed the tandem gait test and a gait evaluation in single/dual-task conditions during a preseason examination. Main Outcome Measures: Associations between tandem gait times and average walking speeds were evaluated using multiple linear regression models. Various tandem gait test time pass/fail cutoffs were calculated to examine false-positive rates. Results: Among the 171 participants (103 men, 19.8 +/- 1.2 years of age), dual-task tandem gait completion times were independently associated with dual-task average walking speed [beta = -4.018; 95% confidence interval (CI), -7.153 to -0.883], but single-task associations were not found. Male gender was associated with faster tandem gait times in both single-task (beta = -0.880, 95% CI, -1.731 to -0.029) and dual-task conditions (beta = -2.225, 95% CI, - 3.691 to -0.759). A pass/fail cutoff threshold of 14 seconds resulted in a 2% false-positive rate for single-task tandem gait, while it resulted in a 29% false-positive rate during dual-task tandem gait. Conclusions: Average walking speed and dual-task tandem gait represent objective measures that are useful in concussion management. While a single-task tandem gait cutoff of 14 seconds seems appropriate for males, adjustments may be necessary based on sex and alternate pass/fail criteria may be appropriate for dual-task tandem gait.	[Howell, David R.; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Howell, David R.; Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, Dept Orthopaed, Boston, MA USA; [Howell, David R.; Meehan, William P., III] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA; [Oldham, Jessie R.; DiFabio, Melissa S.; Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE USA; [Meehan, William P., III] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Meehan, William P., III] Harvard Med Sch, Dept Orthopaed Surg, Boston, MA 02115 USA; [DiFabio, Melissa S.; Buckley, Thomas A.] Univ Delaware, Interdisciplinary Program Biomech & Movement Sci, Newark, DE USA	Howell, DR (corresponding author), Boston Childrens Hosp, Div Sports Med, Dept Orthopaed, Micheli Ctr Sports Injury Prevent, 9 Hope Ave, Waltham, MA 02453 USA.	David.Howell2@childrens.harvard.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150			Baugh CM, 2016, AM J SPORT MED, V44, P1391, DOI 10.1177/0363546516635639; Buckley TA, 2015, J ATHL TRAINING, V50, P879, DOI 10.4085/1062-6050-50.7.04; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Fino PC, 2016, J NEUROENG REHABIL, V13, DOI 10.1186/s12984-016-0177-y; Guralnik JM, 2000, J GERONTOL A-BIOL, V55, pM221, DOI 10.1093/gerona/55.4.M221; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Hanninen T, 2016, J SCI MED SPORT, V19, P636, DOI 10.1016/j.jsams.2015.08.005; Horak F, 2015, PHYS THER, V95, P461, DOI 10.2522/ptj.20140253; Howel DR, 2017, J APPL BIOMECH, V33, P24, DOI 10.1123/jab.2015-0323; Howell D, 2015, J BIOMECH, V48, P3364, DOI 10.1016/j.jbiomech.2015.06.014; Howell DR, 2017, J SCI MED SPORT, V20, P622, DOI 10.1016/j.jsams.2016.11.020; Howell DR, 2017, GAIT POSTURE, V54, P284, DOI 10.1016/j.gaitpost.2017.03.034; Howell DR, 2017, J NEUROTRAUM, V34, P838, DOI 10.1089/neu.2016.4609; Howell DR, 2016, GAIT POSTURE, V49, P176, DOI 10.1016/j.gaitpost.2016.07.008; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Kerrigan DC, 1998, AM J PHYS MED REHAB, V77, P2, DOI 10.1097/00002060-199801000-00002; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Mancini Martina, 2011, J Bioeng Biomed Sci, VSuppl 1, P007; Mancini M, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-59; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Nelson LD, 2017, CLIN J SPORT MED, V27, P381, DOI 10.1097/JSM.0000000000000369; Oldham JR, 2017, SPORTS HEALTH, V9, P305, DOI 10.1177/1941738116680999; Oldham JR, 2016, GAIT POSTURE, V49, P437, DOI 10.1016/j.gaitpost.2016.07.327; Powers KC, 2014, GAIT POSTURE, V39, P611, DOI 10.1016/j.gaitpost.2013.05.026; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Schneiders AG, 2010, J SCI MED SPORT, V13, P196, DOI 10.1016/j.jsams.2009.05.004; Studenski S, 2003, J AM GERIATR SOC, V51, P314, DOI 10.1046/j.1532-5415.2003.51104.x; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720; Zimmer A, 2015, APPL NEUROPSYCH-ADUL, V22, P132, DOI 10.1080/23279095.2013.867265; Zimmer A, 2013, J ATHL TRAINING, V48, P659, DOI 10.4085/1062-6050-48.5.06	38	12	12	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2019	29	3					238	244		10.1097/JSM.0000000000000509			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	IQ4QT	WOS:000480736100011	31033618				2021-06-18	
J	Howell, DR; Wilson, JC; Brilliant, AN; Gardner, AJ; Iverson, GL; Meehan, WP				Howell, David R.; Wilson, Julie C.; Brilliant, Anna N.; Gardner, Andrew J.; Iverson, Grant L.; Meehan, William P., III			Objective clinical tests of dual-task dynamic postural control in youth athletes with concussion	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Gait; Balance; Mild traumatic brain injury; Sports medicine	SINGLE-TASK; TANDEM GAIT; RELIABILITY; ADOLESCENTS; BALANCE; PERFORMANCE; DURATION; DEFICITS; INJURY; BRAIN	Objectives: To prospectively evaluate single/dual-task timed-up-and-go (TUG) and tandem gait performance among children and adolescents with concussion and healthy controls. Design: Repeated measures. Methods: Participants with concussion (n =23; age = 14.1 +/- 2.5 years; 52% female) completed single/dualtask TUG, tandem gait, and symptom assessments 6.7 +/- 2.6 and 23.3 +/- 6.1 days post injury. The control group (n =27; age =14.1 +/- 2.3 years; 48% female) completed the same protocol initially and 10.7 +/- 16.1 days later. All participants completed single-task (undivided attention) and dual-task (divided attention) tests. The primary outcome variable was test completion time. Results: The concussion group completed single-task (concussion group mean =11.1 +/- 1.9 vs. control group mean 9.9 +/- 1.4 s, p = 0.027) and dual-task (concussion group mean = 14.4 +/- 3.3 vs. control group mean 12.7 +/- 1.9 s, p= 0.047) TUG tests slower than the control group across both time points. The concussion group completed dual-task tandem gait tests slower than the control group at both time points (21.3 +/- 6.3 vs. 16.8 +/- 5.5 s, p = 0.006), and were slower in the single-task condition at the first test (19.8 +/- 5.4 vs. 13.8 +/- 4.4 s, p = 0.003). Symptoms were significantly worse for the concussion group compared to the control group at the first (34.1 +/- 21.4 vs. 3.9 +/- 9.1, p<0.001), but not the second test (9.1 +/- 12.0 vs. 2.2 +/- 6.8; p = 0.08). Conclusions: Slower dual-task TUG and tandem gait times were detected across both time points for the concussion group relative to the control group. In contrast, single-task tandem gait deficits appeared to improve in a similar fashion as symptoms, suggesting increased complexity from the addition of a cognitive task allows for the detection of persistent post-concussion deficits that might take longer to resolve. (C) 2018 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Howell, David R.; Wilson, Julie C.] Childrens Hosp Colorado, Sports Med Ctr, Aurora, CO 80045 USA; [Howell, David R.; Wilson, Julie C.] Univ Colorado, Sch Med, Dept Orthoped, Boulder, CO 80309 USA; [Howell, David R.; Brilliant, Anna N.; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA 02453 USA; [Brilliant, Anna N.; Meehan, William P., III] Boston Childrens Hosp, Dept Orthopaed, Div Sports Med, Boston, MA USA; [Gardner, Andrew J.] Hunter New England Local Hlth Dist Sport Concuss, Newcastle, NSW, Australia; [Gardner, Andrew J.] Univ Newcastle, Fac Hlth & Med, Sch Med & Publ Hlth, Ctr Stroke & Brain Injury, Callaghan, NSW, Australia; [Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA 02115 USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, MassGen Hosp ChildrenTM Sports Concuss Program, Home Base, Boston, MA USA; [Meehan, William P., III] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Meehan, William P., III] Harvard Med Sch, Dept Orthopaed Surg, Boston, MA 02115 USA	Howell, DR (corresponding author), Childrens Hosp Colorado, Sports Med Ctr, Aurora, CO 80045 USA.; Howell, DR (corresponding author), Univ Colorado, Sch Med, Dept Orthoped, Boulder, CO 80309 USA.; Howell, DR (corresponding author), Micheli Ctr Sports Injury Prevent, Waltham, MA 02453 USA.	David.Howell@ucdenver.edu		Iverson, Grant/0000-0001-7348-9570; Howell, David/0000-0002-2955-0191	Australian Football League (AFL); NSW Sporting Injuries Committee; Brain Foundation (Australia); Hunter Medical Research Institute (HMRI); HMRI; NHMRC Early Career FellowshipNational Health and Medical Research Council of Australia; HNELHD Research, Innovation and Partnerships -Health Research & Translation Centre and Clinical Research Fellowship Scheme; University of Newcastle's Priority Research Centre for Stroke and Brain Injury; Mooney-Reed Charitable Foundation; ImPACT Applications, Inc.; Heniz Family Foundation	DRH has received research support not related to this study from the Eunice Kennedy Shriver National Institute of Child Health & Human Development (1R03HD094560-01), the National Institute of Neurological Disorders And Stroke (1R01NS100952-01A1 and 1R41NS103698-01A1), and from a research contract between Boston Children's Hospital, Cincinnati Children's Hospital Medical Center, and ElMindA Ltd.; AJG has a clinical practice in neuropsychology involving individuals who have sustained sport-related concussion (including current and former athletes). He has operated as a contracted concussion consultant to the Rugby Australia (Rugby AU) from July 2016. He has received travel funding from the Australian Football League (AFL) to present at the Concussion in Football Conference in 2013 and 2017. Previous grant funding includes the NSW Sporting Injuries Committee, the Brain Foundation (Australia), the Hunter Medical Research Institute (HMRI), supported by Jennie Thomas, and HMRI, supported by Anne Greaves. He is currently funded through an NHMRC Early Career Fellowship, the HNELHD Research, Innovation and Partnerships -Health Research & Translation Centre and Clinical Research Fellowship Scheme, and the University of Newcastle's Priority Research Centre for Stroke and Brain Injury.; GLI acknowledges unrestricted philanthropic support from the Mooney-Reed Charitable Foundation, and ImPACT Applications, Inc., and the Heniz Family Foundation. He is a strategic scientific advisor for BioDirection, Inc. He received past salary support for chairing the Brain and Behavior committee for the Harvard Integrated Program to Protect and Improve the Health of NFLPA Members.	Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Baugh CM, 2016, AM J SPORT MED, V44, P1391, DOI 10.1177/0363546516635639; Berkner J, 2017, J ATHL TRAINING, V52, P1089, DOI 10.4085/1062-6050-52.11.23; Buckley TA, 2018, CLIN J SPORT MED, V28, P174, DOI 10.1097/JSM.0000000000000426; Chin EY, 2016, AM J SPORT MED, V44, P2276, DOI 10.1177/0363546516648141; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P848, DOI 10.1136/bjsports-2017-097506; Fino PC, 2018, GAIT POSTURE, V62, P157, DOI 10.1016/j.gaitpost.2018.03.021; Grants L, 2017, INT J SPORTS PHYS TH, V12, P1011, DOI 10.26603/ijspt20171011; Horak F, 2015, PHYS THER, V95, P461, DOI 10.2522/ptj.20140253; Howell DR, 2019, CLIN J SPORT MED, V29, P238, DOI 10.1097/JSM.0000000000000509; Howell DR, 2018, SPORTS MED, V48, P1097, DOI 10.1007/s40279-018-0871-y; Howell DR, 2018, ARCH PHYS MED REHAB, V99, P1318, DOI 10.1016/j.apmr.2018.01.025; Howell DR, 2018, GAIT POSTURE, V62, P291, DOI 10.1016/j.gaitpost.2018.03.038; Howell DR, 2017, J SCI MED SPORT, V20, P622, DOI 10.1016/j.jsams.2016.11.020; Howell DR, 2016, AM J SPORT MED, V44, P1040, DOI 10.1177/0363546515625045; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; King LA, 2017, ANN BIOMED ENG, V45, P2135, DOI 10.1007/s10439-017-1856-y; Littleton A, 2013, J SPORT HEALTH SCI, V2, P227, DOI 10.1016/j.jshs.2013.04.003; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Manaseer TS, 2020, CLIN J SPORT MED, V30, pS11, DOI 10.1097/JSM.0000000000000537; Mancini M, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-59; McCrory P, 2016, BRIT J SPORT MED, V2017, P838, DOI DOI 10.1136/BJSP0RTS-2017-097699; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Nicolini-Panisson Renata D'Agostini, 2013, Rev. paul. pediatr., V31, P377, DOI 10.1590/S0103-05822013000300016; Oldham JR, 2018, MED SCI SPORT EXER, V50, P1162, DOI 10.1249/MSS.0000000000001540; Salarian A, 2010, IEEE T NEUR SYS REH, V18, P303, DOI 10.1109/TNSRE.2010.2047606; Stephens J, 2018, AM J OCCUP THER, V72, DOI 10.5014/ajot.2018.025361; Tamura K, 2018, GAIT POSTURE, V60, P22, DOI 10.1016/j.gaitpost.2017.11.002; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007	30	12	12	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	MAY	2019	22	5					521	525		10.1016/j.jsams.2018.11.014			5	Sport Sciences	Sport Sciences	HY6RB	WOS:000468256300006	30509865				2021-06-18	
J	Kreitzer, N; Ancona, R; McCullumsmith, C; Kurowski, BG; Foreman, B; Ngwenya, LB; Adeoye, O				Kreitzer, Natalie; Ancona, Rachel; McCullumsmith, Cheryl; Kurowski, Brad G.; Foreman, Brandon; Ngwenya, Laura B.; Adeoye, Opeolu			The Effect of Antidepressants on Depression After Traumatic Brain Injury: A Meta-analysis	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						antidepressant; depression; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL THERAPY; LONG-TERM DISABILITY; MAJOR DEPRESSION; HEAD-INJURY; UNITED-STATES; MOOD DISORDERS; DOUBLE-BLIND; SERTRALINE; PLACEBO	Objective: Following traumatic brain injury (TBI), depressive symptoms are common and may influence recovery. We performed a meta-analysis to estimate the benefit of antidepressants following TBI and compare the estimated effects between antidepressants and placebo. Participants: Multiple databases were searched to find prospective pharmacological treatment studies of major depressive disorder (MDD) in adults following TBI. Main Measures: Effect sizes for antidepressant medications in patients with TBI were calculated for within-subjects designs that examined change from baseline after receiving medical treatment and treatment/placebo designs that examined the differences between the antidepressants and placebo groups. Design: A random-effects model was used for both analyses. Results: Of 1028 titles screened, 11 were included. Pooled estimates showed nonsignificant difference in reduction of depression scores between medications and placebo (standardized mean difference of 5 trials = -0.3; 95% CI, -0.6 to 0.0; I-2 = 17%), and a significant reduction in depression scores for individuals after pharmacotherapy (mean change = -11.2; 95% CI, -14.7 to -7.6 on the Hamilton Depression Scale; I-2 = 87%). Conclusions: This meta-analysis found no significant benefit of antidepressant over placebo in the treatment of MDD following TBI. Pooled estimates showed a high degree of bias and heterogeneity. Prospective studies on the impact of antidepressants in well-defined cohorts of TBI patients are warranted.	[Kreitzer, Natalie; Foreman, Brandon; Adeoye, Opeolu] Univ Cincinnati, Div Neurocrit Care, Cincinnati, OH 45267 USA; [Kreitzer, Natalie; Ancona, Rachel; Adeoye, Opeolu] Univ Cincinnati, Dept Emergency Med, Cincinnati, OH 45267 USA; [McCullumsmith, Cheryl] Univ Cincinnati, Dept Psychiat, Cincinnati, OH 45267 USA; [Kurowski, Brad G.] Univ Cincinnati, Dept Pediat, Cincinnati, OH 45267 USA; [Kurowski, Brad G.] Univ Cincinnati, Dept Phys Med & Rehabil, Cincinnati, OH 45267 USA; [Foreman, Brandon; Ngwenya, Laura B.] Univ Cincinnati, Dept Neurol & Rehabil Med, Cincinnati, OH 45267 USA; [Ngwenya, Laura B.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH 45267 USA	Kreitzer, N (corresponding author), Univ Cincinnati, Med Sci Bldg,Room 1513,231 Albert Sabin Dr, Cincinnati, OH 45267 USA.	kreitzne@ucmail.uc.edu		Ngwenya, Laura/0000-0001-7103-971X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS047996] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32 NS047996] Funding Source: Medline		Ansari Ahmed, 2014, Asian J Neurosurg, V9, P182, DOI 10.4103/1793-5482.146597; Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Bailey NW, 2014, BIOL PSYCHOL, V99, P115, DOI 10.1016/j.biopsycho.2014.03.008; Bedard M, 2014, J HEAD TRAUMA REHAB, V29, pE13, DOI 10.1097/HTR.0b013e3182a615a0; Blakey SM, 2018, J PAIN, V19, P797, DOI 10.1016/j.jpain.2018.02.012; BREMNER JD, 1995, J CLIN PSYCHIAT, V56, P519; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Chen CH, 2008, NEUROPSYCHOPHARMACOL, V33, P1909, DOI 10.1038/sj.npp.1301593; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; Dyer JR, 2016, J HEAD TRAUMA REHAB, V31, P225, DOI 10.1097/HTR.0000000000000177; Entsuah R, 2002, J PSYCHIATR RES, V36, P437, DOI 10.1016/S0022-3956(02)00024-9; Failla MD, 2016, NEUROREHAB NEURAL RE, V30, P419, DOI 10.1177/1545968315600525; Failla MD, 2013, BRAIN INJURY, V27, P696, DOI 10.3109/02699052.2013.775481; Fann JR, 2017, J HEAD TRAUMA REHAB, V32, P332, DOI 10.1097/HTR.0000000000000322; Fann JR, 2015, JAMA PSYCHIAT, V72, P247, DOI 10.1001/jamapsychiatry.2014.2482; Fann JR, 2015, J NEUROTRAUM, V32, P45, DOI 10.1089/neu.2014.3423; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Fournier JC, 2010, JAMA-J AM MED ASSOC, V303, P47, DOI 10.1001/jama.2009.1943; Haagsma JA, 2015, J NEUROTRAUM, V32, P853, DOI 10.1089/neu.2013.3283; Han K, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00231; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Higgins J. P., 2011, COCHRANE HDB SYSTEMA, V4; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; Hudak A, 2011, PSYCHIAT RES-NEUROIM, V191, P160, DOI 10.1016/j.pscychresns.2010.10.003; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Juengst SB, 2017, EPILEPSY BEHAV, V73, P240, DOI 10.1016/j.yebeh.2017.06.001; Juengst SB, 2015, J HEAD TRAUMA REHAB, V30, P207, DOI 10.1097/HTR.0000000000000031; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kurowski BG, 2017, J HEAD TRAUMA REHAB, V32, P79, DOI 10.1097/HTR.0000000000000238; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]; Luby JL, 2017, JAMA PEDIATR, V171, P1168, DOI [10.1001/jamapediatrics.2017.3009, 10.1001/jamapediatri]; Lydiard RB, 1997, J CLIN PSYCHIAT, V58, P484, DOI 10.4088/JCP.v58n1104; Maas AIR, 2008, ACTA NEUROCHIR SUPPL, V101, P119; Maller JJ, 2014, BEHAV BRAIN RES, V271, P147, DOI 10.1016/j.bbr.2014.05.047; Maller JJ, 2014, HUM BRAIN MAPP, V35, P227, DOI 10.1002/hbm.22171; Marquez-Romero JM, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-77; Martinowich K, 2007, NAT NEUROSCI, V10, P1089, DOI 10.1038/nn1971; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Newburn G, 1999, BRAIN INJURY, V13, P637; Osborn AJ, 2014, NEUROSCI BIOBEHAV R, V47, P1, DOI 10.1016/j.neubiorev.2014.07.007; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Pettinati H. M., 2015, FOCUS, V13, P356; Ponsford J, 2016, PSYCHOL MED, V46, P1079, DOI 10.1017/S0033291715002640; Rao V, LEXAPRO TREATMENT TR; Rao V, 2012, J NEUROPSYCH CLIN N, V24, P309, DOI 10.1176/appi.neuropsych.11080188; Rapoport MJ, 2008, J PSYCHOPHARMACOL, V22, P860, DOI 10.1177/0269881107083845; RStudio Team, 2015, RSTUDIO INT DEV ENV; Rutherford BR, 2012, J PSYCHIATR RES, V46, P697, DOI 10.1016/j.jpsychires.2012.02.008; Salter KL, 2016, J HEAD TRAUMA REHAB, V31, pE21, DOI 10.1097/HTR.0000000000000193; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; Schonberger M, 2011, BRAIN INJURY, V25, P543, DOI 10.3109/02699052.2011.565013; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Sepehry AA, 2012, DRUG AGING, V29, P793, DOI 10.1007/s40266-012-0012-5; SILVER JM, 1990, J CLIN PSYCHIAT, V51, P33; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; VECHT CJ, 1975, ARCH NEUROL-CHICAGO, V32, P792, DOI 10.1001/archneur.1975.00490540036004; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	64	12	12	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2019	34	3			SI		E47	E54		10.1097/HTR.0000000000000439			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	IH1KG	WOS:000474249100006	30169440				2021-06-18	
J	Patil, H; Gupta, R				Patil, Harshad; Gupta, Rakesh			A Comparative Study of Bolus Dose of Hypertonic Saline, Mannitol, and Mannitol Plus Glycerol Combination in Patients with Severe Traumatic Brain Injury	WORLD NEUROSURGERY			English	Article						Hypertonic saline; Mannitol; Mannitol plus glycerol combination; Raised intracranial pressure; Severe traumatic brain injury	RAISED INTRACRANIAL-PRESSURE; CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; HEMORRHAGIC-SHOCK; RESUSCITATION; MANAGEMENT; DEXTRAN; HYPERVENTILATION; HYPERTENSION; TRIAL	BACKGROUND: This prospective randomized controlled study compared the efficacy of an equiosmolar and isovolumetric dose of 3% hypertonic saline, 20% mannitol, and 10% mannitol plus 10% glycerol combination in reducing the raised intracranial pressure (ICP) in patients with severe traumatic brain injury (TBI). METHODS: A total of 120 patients of severe TBI with increased ICP were randomized to receive an equiosmolar and isovolumetric dose of 3% hypertonic saline, 20% mannitol, and 10% mannitol plus 10% glycerol combination at a defined infusion rate, which was stopped when ICP was <15 mm Hg. RESULTS: A total of 120 patients with severe TBI (aged >18 years, Glasgow Coma Scale <= 8, and had sustained elevated ICP of >20 mm Hg for more than 5 minutes) were randomized during the study. All data were presented as mean (minimum-maximum). A one-way analysis of variance test was used to analyze the effect across the treatment group, and Tukey's method was used for multiple comparisons. A paired t-test was employed to analyze the effect of the medication within each group. All 3 drugs decreased ICP below 15 mm Hg (P < 0.0001). The maximum change in ICP occurred after a bolus dose of 3% hypertonic saline followed by 10% mannitol plus 10% glycerol combination and then 20% mannitol (60% vs. 57% vs. 55%, respectively). Mean arterial pressure and cerebral perfusion pressure were increased after the bolus dose of study medications. Maximum changes occurred after infusion of 3% hypertonic saline followed by 10% mannitol plus 10% glycerol combination and 20% mannitol (P < 0.0349 and < 0.0013, respectively). There was no statistically significant change in the hematocrit value noted after the bolus dose of any of the study medications. Serum sodium and osmolarity were raised significantly after the bolus dose of study medications. Maximum changes in serum sodium and osmolarity occurred after the bolus dose of 3% hypertonic saline. The mean dose required to reduce ICP below 15 mm Hg for 3% hypertonic saline: 1.4 mL/kg, for 10% mannitol plus 10% glycerine: 1.7 mL/kg, and for 20% mannitol: 2.0 mL/kg. The mean time required to reduce ICP below 15 mm Hg for 3% hypertonic saline: 16 minutes, for 10% mannitol plus 10% glycerine: 19 minutes, and for 20% mannitol: 23 minutes. The maximum change in the Glasgow Coma Scale occurred after the bolus dose of 3% hypertonic saline, followed by 10% mannitol plus 10% glycerol combination and then 20% mannitol. CONCLUSIONS: All 3 osmotic compounds exhibit comparable effectiveness in reducing ICP when a similar osmotic load is administrated, but 3% hypertonic saline appeared to be more effective followed by 10% mannitol plus 10% glycerol combination and 20% mannitol. A dose of 1.4 mL/kg can be recommended as an initial bolus dose for 3% hypertonic saline. Hypertonic saline can be recommended to treat patients with pretreatment hypovolemia, hyponatremia, or renal failure. There is no clear benefit compared with 20% mannitol in regard to neurologic outcome, even though there is a minor positive trend for 3% hypertonic saline and 10% mannitol plus 10% glycerol combination.	[Patil, Harshad] Bansal Hosp, Dept Neurosurg, Bhopal, India; [Gupta, Rakesh] Aurobindo Hosp, Dept Neurosurg, Indore, Madhya Pradesh, India	Patil, H (corresponding author), Bansal Hosp, Dept Neurosurg, Bhopal, India.	dr.harshadpatil@gmail.com					Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Caroli M, 2001, SURG NEUROL, V56, P82, DOI 10.1016/S0090-3019(01)00540-7; Chesnut R M, 1995, New Horiz, V3, P581; Cottenceau V, 2011, J NEUROTRAUM, V28, P2003, DOI 10.1089/neu.2011.1929; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Huang SJ, 2006, SURG NEUROL, V65, P539, DOI 10.1016/j.surneu.2005.11.019; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Kempski O, 1996, ACT NEUR S, V66, P114; MOON PF, 1995, CRIT CARE MED, V23, P323, DOI 10.1097/00003246-199502000-00019; Mortazavi MM, 2012, J NEUROSURG, V116, P210, DOI 10.3171/2011.7.JNS102142; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Otsubo K, 1993, Nihon Ika Daigaku Zasshi, V60, P231; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; Procaccio F, 2000, J Neurosurg Sci, V44, P11; Rangel-Castillo L, 2008, NEUROL CLIN, V26, P521, DOI 10.1016/j.ncl.2008.02.003; Sakellaridis N, 2011, J NEUROSURG, V114, P545, DOI 10.3171/2010.5.JNS091685; Schwab S, 1997, NEUROLOGY, V48, P1608, DOI 10.1212/WNL.48.6.1608; Schwarz S, 2002, STROKE, V33, P136, DOI 10.1161/hs0102.100877; Sheikh AA, 1996, CRIT CARE MED, V24, P1226, DOI 10.1097/00003246-199607000-00027; Soni A., 2009, Trends in Medical Research, V4, P42, DOI 10.3923/tmr.2009.42.48; Soustiel JF, 2006, ACTA NEUROCHIR, V148, P845, DOI 10.1007/s00701-006-0792-7; Tamta Anupama, 2009, Int J Biomed Sci, V5, P428; Treib J, 1997, THROMB HAEMOSTASIS, V78, P974; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Vukic M, 1999, ACTA NEUROCHIR, V141, P1203, DOI 10.1007/s007010050419; Wakai A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub4	33	12	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAY	2019	125						E221	E228		10.1016/j.wneu.2019.01.051			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HW2CX	WOS:000466491700029	30684710				2021-06-18	
J	Riley, E; Mitko, A; Stumps, A; Robinson, M; Milberg, W; McGlinchey, R; Esterman, M; DeGutis, J				Riley, Elizabeth; Mitko, Alex; Stumps, Anna; Robinson, Meghan; Milberg, William; McGlinchey, Regina; Esterman, Michael; DeGutis, Joseph			Clinically Significant Cognitive Dysfunction in OEF/OIF/OND Veterans: Prevalence and Clinical Associations	NEUROPSYCHOLOGY			English	Article						cognitive dysfunction; trauma exposure; OEF/OIF/OND Veterans; PTSD; alcohol consumption	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; METABOLIC SYNDROME; PSYCHOLOGICAL SYMPTOMS; PTSD; PERFORMANCE; MEMORY; DEPRESSION; RECOVERY; DISTRESS	Objective: Cognitive performance in trauma-exposed populations, such as combat Veterans, has been shown to be worse than in nonexposed peers. However, cognitive performance has typically been within the normal range (within 1 SD of normative mean), and the prevalence of clinically significant cognitive dysfunction (i.e., performance more than 1 SD below the mean on multiple measures in a domain) in younger adults with trauma exposure remains unknown. The objective of our study was to measure this. Method: We applied Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM-5) cutoffs for clinically significant cognitive dysfunction (>1 SD below the mean in multiple measures within a domain) in the domains of memory, executive function, and attention to a sample of combat-exposed Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND; N = 368, mean age = 31.7 years, 90% men) Veterans. We then compared psychiatric, physiological, and neural measures, as well as functional outcomes, between those with and without cognitive dysfunction. Results: Veterans with cognitive dysfunction (n = 129, 35.1%) had lower premorbid reading ability and more severe psychological distress, including increased anxiety, depression, posttraumatic stress disorder (PTSD), sleep difficulties, pain, and alcohol consumption. Those with cognitive dysfunction also had worse functional outcomes, with mild but significant disability. In contrast, we found associations between outcome and age, traumatic brain injury, physiological and neural measures to be weak or not significant. Conclusions: Together, this suggests that premorbid abilities and trauma-related psychological symptoms contribute significantly to cognitive dysfunction in OEF/OIF/OND Veterans, and that neurological insult and aging may play less of a role. Cognitive dysfunction may be at least partially ameliorated by treating trauma-related symptoms. General Scientific Summary In this study, we examined the psychological, physical and neurological health profiles of returning OEF/OIF/OND Veterans who had significant cognitive dysfunction. Though we did not find any evidence of physical or neural decline in those with cognitive dysfunction, we did find that those with cognitive dysfunction suffered from more intense psychological distress (posttraumatic stress disorder, depression, anxiety, sleep difficulties, pain) than those without. Our results suggest that cognitive dysfunction in younger returning Veterans might be ameliorated with appropriate treatment for psychological distress conditions.	[Riley, Elizabeth] Cornell Univ, Dept Human Dev, Sch Human Ecol, 162 Human Ecol Bldg, Ithaca, NY 14850 USA; [Mitko, Alex; Stumps, Anna; Robinson, Meghan; Milberg, William; McGlinchey, Regina; Esterman, Michael; DeGutis, Joseph] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, VA RR&D TBI Ctr Excellence, Boston, MA USA; [Milberg, William; McGlinchey, Regina; DeGutis, Joseph] Harvard Med Sch, Dept Psychiat, Boston, MA 02115 USA; [Esterman, Michael] Boston Univ, Dept Psychiat, Sch Med, Boston, MA 02215 USA	Riley, E (corresponding author), Cornell Univ, Dept Human Dev, Sch Human Ecol, 162 Human Ecol Bldg, Ithaca, NY 14850 USA.	er482@cornell.edu			U.S. Department of Veteran Affairs through the VA Boston Translational Research Center for TBI and Stress Disorders (TRACTS), a VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B9254-C]; Department of Veterans Affairs Clinical Sciences Research and DevelopmentUS Department of Veterans Affairs [1IK2CX000706-01A2]; Veterans AffairsUS Department of Veterans Affairs [IK2CX000706, I01CX001653] Funding Source: NIH RePORTER	This work was supported by the U.S. Department of Veteran Affairs through the VA Boston Translational Research Center for TBI and Stress Disorders (TRACTS), a VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (B9254-C), and a Career Development award from the Department of Veterans Affairs Clinical Sciences Research and Development (1IK2CX000706-01A2) to M.S.E. We thank the Veterans for their patience and diligence in participating in this intensive study.	Altena E, 2008, J SLEEP RES, V17, P335, DOI 10.1111/j.1365-2869.2008.00671.x; Amick MM, 2013, J INT NEUROPSYCH SOC, V19, P792, DOI 10.1017/S1355617713000544; Association AP, 2013, DIAGN STAT MAN MENT, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]; Aupperle RL, 2012, NEUROPHARMACOLOGY, V62, P686, DOI 10.1016/j.neuropharm.2011.02.008; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Birns J, 2006, J HYPERTENS, V24, P1907, DOI 10.1097/01.hjh.0000244934.81180.16; Borsari B, 2017, AM J ORTHOPSYCHIAT, V87, P166, DOI 10.1037/ort0000199; Brady KT, 1999, ALCOHOL RES HEALTH, V23, P263; Brady KT, 2005, AM J PSYCHIAT, V162, P1483, DOI 10.1176/appi.ajp.162.8.1483; Brandes D, 2002, PSYCHIAT RES, V110, P231, DOI 10.1016/S0165-1781(02)00125-7; Breslau N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065391; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Clark AL, 2014, CLIN NEUROPSYCHOL, V28, P802, DOI 10.1080/13854046.2014.904928; Croall ID, 2014, NEUROLOGY, V83, P494, DOI 10.1212/WNL.0000000000000666; DeGutis J, 2018, BEHAV SLEEP MED, V16, P38, DOI 10.1080/15402002.2016.1173550; DeGutis J, 2015, J INT NEUROPSYCH SOC, V21, P342, DOI 10.1017/S1355617715000235; Delis D., 2001, D KEFS EXAMINERS TEC; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Esterman M, 2013, J INT NEUROPSYCH SOC, V19, P835, DOI 10.1017/S135561771300057X; First MB., 1999, STRUCTURED CLIN INTE; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Gilbertson MW, 2001, J TRAUMA STRESS, V14, P413, DOI 10.1023/A:1011181305501; Gomez-Pinilla Fernando, 2011, Nutrition and Health (Bicester), V20, P165; Grande LJ, 2018, J INT NEUROPSYCH SOC, V24, P466, DOI 10.1017/S1355617717001242; Green A, 2010, ALCOHOL CLIN EXP RES, V34, P443, DOI 10.1111/j.1530-0277.2009.01108.x; Green P., 2004, MANUAL MED SYMPTOM V; Hayes JP, 2017, BRAIN, V140, P813, DOI 10.1093/brain/aww344; Henry GK, 2005, CLIN NEUROPSYCHOL, V19, P121, DOI 10.1080/13854040490516604; Holdnack JA, 2017, ARCH CLIN NEUROPSYCH, V32, P574, DOI 10.1093/arclin/acx032; Houston RJ, 2014, ADDICT BEHAV, V39, P345, DOI 10.1016/j.addbeh.2013.09.032; Jak AJ, 2009, AM J GERIAT PSYCHIAT, V17, P368, DOI 10.1097/JGP.0b013e31819431d5; Jeste DV, 2016, AM J GERIAT PSYCHIAT, V24, P987, DOI 10.1016/j.jagp.2016.08.009; Kalechstein AD, 2003, J CLIN EXP NEUROPSYC, V25, P1186, DOI 10.1076/jcen.25.8.1186.16723; Kubany ES, 2000, PSYCHOL ASSESSMENT, V12, P210, DOI 10.1037//1040-3590.12.2.210; Levine AB, 2014, CARDIOLOGY, V127, P1, DOI 10.1159/000354910; Levkovitz Y, 2002, BRAIN RES BULL, V58, P345, DOI 10.1016/S0361-9230(01)00780-8; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Lippa SM, 2018, ARCH CLIN NEUROPSYCH, V33, P606, DOI 10.1093/arclin/acx098; Lohr JB, 2015, AM J GERIAT PSYCHIAT, V23, P709, DOI 10.1016/j.jagp.2015.04.001; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; Mander BA, 2010, J NEUROSCI, V30, P2686, DOI 10.1523/JNEUROSCI.4010-09.2010; Marx BP, 2009, J INT NEUROPSYCH SOC, V15, P840, DOI 10.1017/S1355617709990488; McGlinchey RE, 2017, INT J METH PSYCH RES, V26, DOI 10.1002/mpr.1556; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Nietlisbach G., 2009, J AGGRESSION MALTREA, V18, P382, DOI [10.1080/10926770902881489, DOI 10.1080/10926770902881489]; O'Neil M., 2013, COMPLICATIONS MILD T, DOI [10.1017/S135561771300146X, DOI 10.1017/S135561771300146X]; Oldenburg C, 2016, BRAIN INJURY, V30, P146, DOI 10.3109/02699052.2015.1089598; Polak AR, 2012, J AFFECT DISORDERS, V141, P11, DOI 10.1016/j.jad.2012.01.001; Poole VN, 2016, NEUROPSYCHOLOGIA, V86, P176, DOI 10.1016/j.neuropsychologia.2016.04.023; Qureshi SU, 2011, J NEUROPSYCH CLIN N, V23, P16, DOI 10.1176/appi.neuropsych.23.1.16; Reppermund S, 2011, INT J GERIATR PSYCH, V26, P843, DOI 10.1002/gps.2612; Ressler KJ, 2004, ARCH GEN PSYCHIAT, V61, P1136, DOI 10.1001/archpsyc.61.11.1136; RICHARDSON JS, 1994, INT CLIN PSYCHOPHARM, V9, P35, DOI 10.1097/00004850-199400910-00006; Robinson ME, 2017, J NEUROTRAUM, V34, pS53, DOI 10.1089/neu.2016.4709; Rodriguez P, 2012, J REHABIL RES DEV, V49, P649, DOI 10.1682/JRRD.2011.09.0162; Sannibale C, 2013, ADDICTION, V108, P1397, DOI 10.1111/add.12167; Schulte MHJ, 2014, CLIN PSYCHOL REV, V34, P531, DOI 10.1016/j.cpr.2014.08.002; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Sofuoglu M, 2013, NEUROPHARMACOLOGY, V64, P452, DOI 10.1016/j.neuropharm.2012.06.021; Spielberg JM, 2017, HUM BRAIN MAPP, V38, P3249, DOI 10.1002/hbm.23587; Stavro K, 2013, ADDICT BIOL, V18, P203, DOI 10.1111/j.1369-1600.2011.00418.x; STETZ MC, 2007, AVIATION SPACE ENV M, V78, pB25; Stricker NH, 2017, J CLIN EXP NEUROPSYC, V39, P768, DOI 10.1080/13803395.2016.1264575; Stricker NH, 2016, AM J ALZHEIMERS DIS, V31, P68, DOI 10.1177/1533317515578257; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Sutherland K, 2007, BEHAV RES THER, V45, P2915, DOI 10.1016/j.brat.2007.08.009; Swick D, 2012, J INT NEUROPSYCH SOC, V18, P917, DOI 10.1017/S1355617712000458; Taylor VH, 2007, OBES REV, V8, P409, DOI 10.1111/j.1467-789X.2007.00401.x; Trivedi MH, 2014, J AFFECT DISORDERS, V152, P19, DOI 10.1016/j.jad.2013.09.012; Trotter BB, 2015, BRAIN, V138, P2278, DOI 10.1093/brain/awv139; Ullman SE, 2005, J STUD ALCOHOL, V66, P610, DOI 10.15288/jsa.2005.66.610; US Department of Veterans Affairs, 2017, AN VA HLTH CAR UT OP; Ustun TB., 2010, MEASURING HLTH DISAB, P90; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vincent AS, 2014, ALZHEIMERS DEMENT, V10, pS174, DOI 10.1016/j.jalz.2014.04.006; Weathers FW, 2018, PSYCHOL ASSESSMENT, V30, P383, DOI 10.1037/pas0000486; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wilson RS, 2007, NEUROLOGY, V68, P2085, DOI 10.1212/01.wnl.0000264930.97061.82; Wilson RS, 2005, PSYCHONEUROENDOCRINO, V30, P11, DOI 10.1016/j.psyneuen.2004.04.005; Wilson RS, 2003, NEUROLOGY, V61, P1479, DOI 10.1212/01.WNL.0000096167.56734.59; Wolf EJ, 2016, PSYCHOL MED, V46, P2215, DOI 10.1017/S0033291716000817; Wolf EJ, 2016, BIOL PSYCHIAT, V80, P363, DOI 10.1016/j.biopsych.2015.11.023; Wolf EJ, 2016, PSYCHONEUROENDOCRINO, V63, P155, DOI 10.1016/j.psyneuen.2015.09.020; Woods SP, 2006, ARCH CLIN NEUROPSYCH, V21, P413, DOI 10.1016/j.acn.2006.06.002; Xu W., 2017, ALZHEIMERS DEMENTI S, V13, pP521, DOI [10.1016/j.jalz.2017.06.603, DOI 10.1016/J.JALZ.2017.06.603]; Yaffe K, 2007, ALZ DIS ASSOC DIS, V21, P167, DOI 10.1097/WAD.0b013e318065bfd6	92	12	12	0	1	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2019	33	4					534	546		10.1037/neu0000529			13	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	HV6RI	WOS:000466110100009	30945914				2021-06-18	
J	Weber, MT; Arena, JD; Xiao, R; Wolf, JA; Johnson, VE				Weber, Maura T.; Arena, John D.; Xiao, Rui; Wolf, John A.; Johnson, Victoria E.			CLARITY reveals a more protracted temporal course of axon swelling and disconnection than previously described following traumatic brain injury	BRAIN PATHOLOGY			English	Article						traumatic brain injury; TBI; axonal pathology; CLARITY; amyloid precursor protein; axon degeneration; diffuse axonal injury	AMYLOID PRECURSOR PROTEIN; INTRAAXONAL NEUROFILAMENT COMPACTION; MEDIATED CYTOSKELETAL DEGRADATION; HEAD-INJURY; CALPAIN ACTIVATION; UNMYELINATED AXONS; CORPUS-CALLOSUM; CYCLOSPORINE-A; WHITE-MATTER; BETA-APP	Diffuse axonal injury (DAI) is an important consequence of traumatic brain injury (TBI). At the moment of trauma, axons rarely disconnect, but undergo cytoskeletal disruption and transport interruption leading to protein accumulation within swellings. The amyloid precursor protein (APP) accumulates rapidly and the standard histological evaluation of axonal pathology relies upon its detection. APP+ swellings first appear as varicosities along intact axons, which can ultimately undergo secondary disconnection to leave a terminal "axon bulb" at the disconnected, proximal end. However, sites of disconnection are difficult to determine with certainty using standard, thin tissue sections, thus limiting the comprehensive evaluation of axon degeneration. The tissue-clearing technique, CLARITY, permits three-dimensional visualization of axons that would otherwise be out of plane in standard tissue sections. Here, we examined the morphology and connection status of APP+ swellings using CLARITY at 6 h, 24 h, 1 week and 1 month following the controlled cortical impact (CCI) model of TBI in mice. Remarkably, many APP+ swellings that appeared as terminal bulbs when viewed in standard 8-mu m-thick regions of tissue were instead revealed to be varicose swellings along intact axons when three dimensions were fully visible. Moreover, the percentage of these potentially viable axon swellings differed with survival from injury and may represent the delayed onset of distinct mechanisms of degeneration. Even at 1-month post-CCI, 10% of apparently terminal bulbs were revealed as connected by CLARITY and are thus potentially salvageable. Intriguingly, the diameter of swellings decreased with survival, including varicosities along intact axons, and may reflect reversal of, or reduced, axonal transport interruption in the chronic setting. These data indicate that APP immunohistochemistry on standard thickness tissue sections overestimates axon disconnection, particularly acutely post-injury. Evaluating cleared tissue demonstrates a surprisingly delayed process of axon disconnection and thus longer window of therapeutic opportunity than previously appreciated. Intriguingly, a subset of axon swellings may also be capable of recovery.	Univ Penn, Perelman Sch Med, Penn Ctr Brain Injury & Repair, Dept Neurosurg, Philadelphia, PA 19104 USA; [Xiao, Rui] Univ Penn, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA; [Wolf, John A.] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA	Johnson, VE (corresponding author), Univ Penn, Penn Ctr Brain Injury & Repair, Dept Neurosurg, 173 Stemmler Hall,3450 Hamilton Walk, Philadelphia, PA 19104 USA.	vje@pennmedicine.upenn.edu	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Arena, John/0000-0002-4322-4472	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS092398, TL1TR001880, R01NS101108]; United States (U.S.) Department of Veterans Affairs, Rehabilitation Research and Development Service Program [RX002705]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD086984] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [TL1TR001880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092398, R01NS094003, R01NS101108] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX002705] Funding Source: NIH RePORTER	Research reported in this publication was supported by the National Institutes of Health under award numbers R01NS092398, TL1TR001880, and R01NS101108. In addition, work was supported in part by Merit Review, Award No. RX002705 (JAW)from the United States (U.S.) Department of Veterans Affairs, Rehabilitation Research and Development Service Program. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the U.S. Department of Veterans Affairs or the United States Government.	ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1984, LANCET, V2, P1420; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Chung K, 2013, NATURE, V497, P332, DOI 10.1038/nature12107; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Fujita M, 2011, J NEUROTRAUM, V28, P1209, DOI 10.1089/neu.2011.1852; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Graham DI, 2004, FORENSIC SCI INT, V146, P89, DOI 10.1016/S0379-0738(03)00274-3; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Hayashi Takahito, 2009, Leg Med (Tokyo), V11 Suppl 1, pS171, DOI 10.1016/j.legalmed.2009.01.076; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Johnson VE, 2018, ACTA NEUROPATHOL, V135, P711, DOI 10.1007/s00401-018-1824-0; Johnson VE, 2016, ACTA NEUROPATHOL, V131, P115, DOI 10.1007/s00401-015-1506-0; Johnson Victoria E, 2015, Handb Clin Neurol, V127, P115, DOI 10.1016/B978-0-444-52892-6.00008-8; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; MAXWELL WL, 1991, J ANAT, V176, P71; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Mustafa AG, 2011, J NEUROCHEM, V117, P579, DOI 10.1111/j.1471-4159.2011.07228.x; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 1999, ACT NEUR S, V73, P15; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ramon YCajalS, 1928, DEGENERATION REGENER; RAND CW, 1946, ARCH NEURO PSYCHIATR, V55, P79, DOI 10.1001/archneurpsyc.1946.02300130003001; Reeves TM, 2012, J NEUROPATH EXP NEUR, V71, P198, DOI 10.1097/NEN.0b013e3182482590; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SCHWEITZER JB, 1993, ACTA NEUROPATHOL, V85, P503; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Staal JA, 2010, J NEUROCHEM, V112, P1147, DOI 10.1111/j.1471-4159.2009.06531.x; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Tomaiuolo F, 2012, BRAIN RES BULL, V87, P373, DOI 10.1016/j.brainresbull.2012.01.008; von Reyn CR, 2009, J NEUROSCI, V29, P10350, DOI 10.1523/JNEUROSCI.2339-09.2009; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Ziogas NK, 2018, J NEUROSCI, V38, P4031, DOI 10.1523/JNEUROSCI.2343-17.2018	90	12	12	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	MAY	2019	29	3					437	450		10.1111/bpa.12677			14	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	HU7AA	WOS:000465432300011	30444552	Green Accepted, Bronze			2021-06-18	
J	Chitturi, J; Santhakumar, V; Kannurpatti, SS				Chitturi, Jyothsna; Santhakumar, Vijayalakshmi; Kannurpatti, Sridhar S.			Beneficial Effects of Kaempferol after Developmental Traumatic Brain Injury Is through Protection of Mitochondrial Function, Oxidative Metabolism, and Neural Viability	JOURNAL OF NEUROTRAUMA			English	Article						calcium uniporter; dietary flavonoid; kaempferol; metabolomics; mitochondrial; N-acetyl aspartate; oxidative metabolism; pediatric; traumatic brain injury	ACETYL-L-CARNITINE; CEREBRAL PERFUSION; RAT; MATURATION; NEUROPROTECTION; METABOANALYST; METABOLOMICS; EXCITABILITY; HOMEOSTASIS; INCREASES	Oxidative energy metabolism is depressed after mild/moderate traumatic brain injury (TBI) during early development, accompanied by behavioral debilitation and secondary neuronal death. A TBI metabolome analysis revealed broad effects with a striking impact on energy metabolism. Our studies on mitochondrial modulators and their effects on brain function have shown that kaempferol, a stimulator of the mitochondrial Ca2+ uniporter channel (mCU), enhanced neural and neurovascular activity in the normal brain and improved stimulus-induced brain activation and behavior after TBI during early development. Because kaempferol enhances mitochondrial Ca2+ uptake and cycling, with protective effects after TBI, we tested the hypothesis that kaempferol treatment during the acute/subacute stage after TBI (0-72 h) acted on mitochondria in improving TBI outcome. Developmental age rats (P31) underwent TBI and were treated with vehicle or kaempferol (1 mg/kg intraperitoneally) in three doses at 1, 24, and 48 h after TBI. Brains were harvested at 72 h and subjected to liquid chromatography mass spectrometric measurements. Decrease in pyruvate and tricarboxylic acid (TCA) cycle flux were observed in the untreated and vehicle-treated group, consistent with previously established energy metabolic decline after TBI. Kaempferol improved TCA cycle flux, maintained mitochondrial functional integrity as observed by decreased acyl carnitines, improved neural viability as evidenced by higher N-acetyl aspartate levels. The positive outcomes of kaempferol on metabolic profile corresponded with improved sensorimotor behavior.	[Chitturi, Jyothsna; Kannurpatti, Sridhar S.] Rutgers New Jersey Med Sch, Dept Radiol, Newark, NJ USA; [Santhakumar, Vijayalakshmi] Rutgers New Jersey Med Sch, Dept Pharmacol Physiol & Neurosci, Newark, NJ USA; [Santhakumar, Vijayalakshmi] Univ Calif Riverside, Mol Cell & Syst Biol, Riverside, CA 92521 USA	Kannurpatti, SS (corresponding author), Rutgers Biomed & Hlth Sci, New Jersey Med Sch, Dept Radiol, ADMC5,Room 575,30 Bergen St, Newark, NJ 07101 USA.	kannursr@njms.rutgers.edu	Santhakumar, Viji/K-4856-2019; Chitturi, Jyothsna/AAR-3986-2020	Santhakumar, Viji/0000-0001-6278-4187; 	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS097750, R01 NS069861] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS069861, R01NS097750] Funding Source: NIH RePORTER		Biagi L, 2007, J MAGN RESON IMAGING, V25, P696, DOI 10.1002/jmri.20839; Casey P, 2006, CRIT CARE MED, V34, pA17, DOI 10.1097/00003246-200612002-00067; CHIRON C, 1992, J NUCL MED, V33, P696; Chitturi J, 2018, NEUROCHEM INT, V120, P75, DOI 10.1016/j.neuint.2018.08.003; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; Di Giorgio AM, 2008, RESTOR NEUROL NEUROS, V26, P501; Di Pietro V, 2014, MOL MED, V20, P147, DOI 10.2119/molmed.2013.00153; DOBBING J, 1973, ARCH DIS CHILD, V48, P757, DOI 10.1136/adc.48.10.757; DuPont MS, 2004, EUR J CLIN NUTR, V58, P947, DOI 10.1038/sj.ejcn.1601916; Ferreira GC, 2017, NEUROCHEM RES, V42, P1661, DOI 10.1007/s11064-017-2288-7; Fluegge D, 2012, NAT NEUROSCI, V15, P754, DOI 10.1038/nn.3074; Greene JG, 1996, PROG NEUROBIOL, V48, P613, DOI 10.1016/0301-0082(96)00006-8; Gupta A, 2012, J NEUROSCI, V32, P2523, DOI 10.1523/JNEUROSCI.4141-11.2012; Hales PW, 2014, J CEREBR BLOOD F MET, V34, P776, DOI 10.1038/jcbfm.2014.17; Hosseini-Zare MS, 2017, EXP NEUROL, V295, P155, DOI 10.1016/j.expneurol.2017.05.002; Jones LL, 2010, PROG LIPID RES, V49, P61, DOI 10.1016/j.plipres.2009.08.004; Kannurpatti SS, 2017, J CEREBR BLOOD F MET, V37, P381, DOI 10.1177/0271678X16680637; Kannurpatti SS, 2015, NMR BIOMED, V28, P1579, DOI 10.1002/nbm.3421; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Labarthe DR, 2009, AM J PREV MED, V37, pS86, DOI 10.1016/j.amepre.2009.04.014; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Li Y, 2015, NEUROBIOL DIS, V74, P240, DOI 10.1016/j.nbd.2014.11.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Lifshitz J, 2012, BRAIN STRUCT FUNCT, V217, P49, DOI 10.1007/s00429-011-0323-z; Lyons DN, 2018, J NEUROTRAUM, V35, P2435, DOI 10.1089/neu.2018.5663; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; Mathiesen C, 2011, J NEUROSCI, V31, P18327, DOI 10.1523/JNEUROSCI.4526-11.2011; Moffett John R, 2013, Front Neuroenergetics, V5, P11, DOI 10.3389/fnene.2013.00011; Montero M, 2004, BIOCHEM J, V384, P19, DOI 10.1042/BJ20040990; Murugan M, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00019; Parent M., 2018, J NEUROTRAUMA; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; Paus T, 2001, BRAIN RES BULL, V54, P255, DOI 10.1016/S0361-9230(00)00434-2; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Putatunda R, 2018, CHIN J TRAUMATOL, V21, P125, DOI 10.1016/j.cjtee.2018.02.002; Reiss AL, 1996, BRAIN, V119, P1763, DOI 10.1093/brain/119.5.1763; Robertson CL, 2013, J NEUROTRAUM, V30, P2066, DOI 10.1089/neu.2013.3007; Sanganahalli BG, 2013, J CEREBR BLOOD F MET, V33, P1115, DOI 10.1038/jcbfm.2013.61; Sanganahalli BG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063317; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; Scafidi S, 2010, J NEUROCHEM, V114, P820, DOI 10.1111/j.1471-4159.2010.06807.x; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Tang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096944; Vay L, 2007, J PHYSIOL-LONDON, V580, P39, DOI 10.1113/jphysiol.2006.126391; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Viant MR, 2005, NMR BIOMED, V18, P507, DOI 10.1002/nbm.980; Winter JD, 2011, PEDIATR RES, V69, P418, DOI 10.1203/PDR.0b013e3182110f7e; Xia JG, 2015, NUCLEIC ACIDS RES, V43, pW251, DOI 10.1093/nar/gkv380; Xia JG, 2010, BIOINFORMATICS, V26, P2342, DOI 10.1093/bioinformatics/btq418; Xia JG, 2010, NUCLEIC ACIDS RES, V38, pW71, DOI 10.1093/nar/gkq329; Xia JG, 2009, NUCLEIC ACIDS RES, V37, pW652, DOI 10.1093/nar/gkp356	52	12	12	2	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2019	36	8					1264	1278		10.1089/neu.2018.6100			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HS4DK	WOS:000463812000006	30430900	Green Published			2021-06-18	
J	Muza, P; Bachmeier, C; Mouzon, B; Algamal, M; Rafi, NG; Lungmus, C; Abdullah, L; Evans, JE; Ferguson, S; Mullan, M; Crawford, F; Ojo, JO				Muza, Phillip; Bachmeier, Corbin; Mouzon, Benoit; Algamal, Moustafa; Rafi, Naomi G.; Lungmus, Carlyn; Abdullah, Laila; Evans, James E.; Ferguson, Scott; Mullan, Michael; Crawford, Fiona; Ojo, Joseph O.			APOE Genotype Specific Effects on the Early Neurodegenerative Sequelae Following Chronic Repeated Mild Traumatic Brain Injury	NEUROSCIENCE			English	Article						APOE4; astrocytes; mild TBI; microglia; phospholipid; tau	APOLIPOPROTEIN-E POLYMORPHISM; LOW-DENSITY-LIPOPROTEIN; AMYLOID-BETA PEPTIDE; ALZHEIMERS-DISEASE; MOUSE MODEL; RISK-FACTOR; OXIDIZED LDL; ENDOTHELIAL RECEPTOR; GLIAL ACTIVATION; AXONAL INJURY	Repeated mild traumatic brain injury (r-mTBI) can potentially manifest into chronic traumatic encephalopathy (CTE). The apolipoprotein E (APOE4) genotype, a well-recognized potent genetic risk factor in age-related neurodegenerative diseases such as Alzheimer's disease, has been linked to worse outcome after TBI in individuals who carry this allele. The underlying molecular modifications triggered by APOE genotype following r-mTBI remain elusive. We addressed the influence of APOE genotype on TBI dependent tau pathology in middle-aged mice. Using a previously established experimental mTBI protocol in a new repetitive injury paradigm, we report the pathological changes that occurred following one-month of repetitive injuries in APOE3/4 gene targeted mice. Firstly, pathological assessment demonstrated evidence of microgliosis and astrogliosis in the corpus callosum of injured animals, but there was no APOE dependent genotype effect on injury. However, in the parietal cortex Iba1-immunoreactivity was significantly increased in injured versus sham APOE3 mice, but not in APOE4 mice. No effects were observed in soluble amyloid levels with injury or interaction with genotype. APOE4 mice showed significant increases in the tau conformational marker MC1, neurofilament H, brain phospholipids, and endothelial specific oxidized low density lipoprotein receptor in cortical homogenates obtained from injured mice compared to sham counterparts. This pilot work suggests APOE3 and APOE4 specific effects following injury in a mouse model of r-mTBI. These changes may underlie the molecular changes that trigger the vulnerability and increased risk of developing neurodegenerative diseases in aged individuals exposed to repetitive mTBI. (C) 2019 IBRO. Published by Elsevier Ltd. All rights reserved.	[Muza, Phillip; Bachmeier, Corbin; Mouzon, Benoit; Algamal, Moustafa; Rafi, Naomi G.; Lungmus, Carlyn; Abdullah, Laila; Evans, James E.; Ferguson, Scott; Crawford, Fiona; Ojo, Joseph O.] Roskamp Inst, Sarasota, FL 34324 USA; [Bachmeier, Corbin; Mouzon, Benoit; Abdullah, Laila; Ferguson, Scott; Crawford, Fiona; Ojo, Joseph O.] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Bachmeier, Corbin; Mouzon, Benoit; Algamal, Moustafa; Abdullah, Laila; Ferguson, Scott; Mullan, Michael; Crawford, Fiona; Ojo, Joseph O.] Open Univ, Milton Keynes, England; [Bachmeier, Corbin] Bay Pines VA Healthcare Syst, Bay Pines, FL USA	Ojo, JO (corresponding author), Roskamp Inst, Expt Neuropathol, Sarasota, FL 34324 USA.	jojo@roskampinstitute.org		Algamal, Moustafa/0000-0002-6215-0122			Abdullah L, 2014, FASEB J, V28, P5311, DOI 10.1096/fj.14-258228; Abdullah L, 2013, NEUROTOXICOL TERATOL, V40, P74, DOI 10.1016/j.ntt.2013.10.002; Abdullah L, 2012, NEUROMOL MED, V14, P349, DOI 10.1007/s12017-012-8192-z; Adibhatla RM, 2007, FUTURE LIPIDOL, V2, P403, DOI 10.2217/17460875.2.4.403; Agosta F, 2009, P NATL ACAD SCI USA, V106, P2018, DOI 10.1073/pnas.0812697106; Altmann A, 2014, ANN NEUROL, V75, P563, DOI 10.1002/ana.24135; Bennett RE, 2013, J NEUROPATH EXP NEUR, V72, P396, DOI 10.1097/NEN.0b013e31828e24ab; Boutajangout A, 2011, J NEUROCHEM, V118, P658, DOI 10.1111/j.1471-4159.2011.07337.x; Brecht WJ, 2004, J NEUROSCI, V24, P2527, DOI 10.1523/JNEUROSCI.4315-03.2004; Calzada E, 2016, INT REV CEL MOL BIO, V321, P29, DOI 10.1016/bs.ircmb.2015.10.001; Cao J., 2017, SCI REP, V7; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Castellano JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002156; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Colacicco AM, 2009, NEUROBIOL AGING, V30, P1518, DOI 10.1016/j.neurobiolaging.2007.11.015; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Deane R, 2008, J CLIN INVEST, V118, P4002, DOI 10.1172/JCI36663; Deming Y, 2017, ACTA NEUROPATHOL, V133, P839, DOI 10.1007/s00401-017-1685-y; Dubal DB, 2017, JAMA NEUROL, V74, P1167, DOI 10.1001/jamaneurol.2017.1470; Emmerich T, 2016, J NEUROTRAUM, V33, P1331, DOI 10.1089/neu.2015.4061; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Ferguson S, 2010, NEUROSCIENCE, V168, P811, DOI 10.1016/j.neuroscience.2010.01.031; Fiala M, 2007, J ALZHEIMERS DIS, V11, P457; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gatson JW, 2014, J NEUROSURG, V121, P1232, DOI 10.3171/2014.7.JNS132474; Glushakova OY, 2018, J NEUROTRAUM, V35, P157, DOI 10.1089/neu.2017.4999; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Gupta RK, 2016, MOL NEUROBIOL, V53, P3377, DOI 10.1007/s12035-015-9287-y; Hevonoja T, 2000, BBA-MOL CELL BIOL L, V1488, P189, DOI 10.1016/S1388-1981(00)00123-2; Jana A, 2010, NEUROMOL MED, V12, P351, DOI 10.1007/s12017-010-8128-4; Jiang L, 2015, NEUROSCIENCE, V301, P375, DOI 10.1016/j.neuroscience.2015.06.005; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Li DY, 2000, ARTERIOSCL THROM VAS, V20, P1116, DOI 10.1161/01.ATV.20.4.1116; Li DY, 2003, ARTERIOSCL THROM VAS, V23, P816, DOI 10.1161/01.ATV.0000066685.13434.FA; Li DY, 2000, CIRCULATION, V101, P2889, DOI 10.1161/01.CIR.101.25.2889; Liu HC, 2015, EUR REV MED PHARMACO, V19, P3459; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Maroon JC, 2015, PLOS ONE, V10; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mishra A, 2017, BRAIN, V140, P1437, DOI 10.1093/brain/awx066; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2018, ANN CLIN TRANSL NEUR, V5, P64, DOI 10.1002/acn3.510; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Neselius S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081249; Neu SC, 2017, JAMA NEUROL, V74, P1178, DOI 10.1001/jamaneurol.2017.2188; Ojo JO, 2016, J NEUROPATH EXP NEUR, V75, P636, DOI 10.1093/jnen/nlw035; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Ophir G, 2003, NEUROBIOL DIS, V12, P56, DOI 10.1016/S0969-9961(02)00005-0; Parthasarathy S, 2010, METHODS MOL BIOL, V610, P403, DOI 10.1007/978-1-60327-029-8_24; Perez E, 2007, BRAIN RES, V1128, P164, DOI 10.1016/j.brainres.2006.09.109; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Pruthi N, 2010, NEUROL INDIA, V58, P264, DOI 10.4103/0028-3886.63810; Rodriguez GA, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-111; Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115; Safinia Cyrus, 2016, J Vasc Interv Neurol, V9, P34; Shi Y, 2017, NATURE, V549, P523, DOI 10.1038/nature24016; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stevens M, 1997, NEUROLOGY, V48, P1526, DOI 10.1212/WNL.48.6.1526; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Tanzi RE, 2004, NEURON, V43, P605, DOI 10.1016/j.neuron.2004.08.024; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Washington PM, 2016, J NEUROPATH EXP NEUR, V75, P770, DOI 10.1093/jnen/nlw049; Yang J, 2017, J ALZHEIMERS DIS, V57, P157, DOI 10.3233/JAD-160957; Yoshida H, 1998, BIOCHEM J, V334, P9, DOI 10.1042/bj3340009; Yousuf A, 2015, J MOL NEUROSCI, V56, P597, DOI 10.1007/s12031-015-0554-1; Yue JK, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.791; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhong JJ, 2017, NEUROSCIENCE, V343, P434, DOI 10.1016/j.neuroscience.2016.05.033; Zhu YG, 2012, GLIA, V60, P559, DOI 10.1002/glia.22289	83	12	12	2	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	APR 15	2019	404						297	313		10.1016/j.neuroscience.2019.01.049			17	Neurosciences	Neurosciences & Neurology	HR1TG	WOS:000462917500025	30711612				2021-06-18	
J	Webster, KM; Sun, M; Crack, PJ; O'Brien, TJ; Shultz, SR; Semple, BD				Webster, Kyria M.; Sun, Mujun; Crack, Peter J.; O'Brien, Terence J.; Shultz, Sandy R.; Semple, Bridgette D.			Age-dependent release of high-mobility group box protein-1 and cellular neuroinflammation after traumatic brain injury in mice	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						age; high mobility group box protein 1; inflammation; pediatric; RRID:AB_10013382; RRID:AB_10679369; RRID:AB_11212597; RRID:AB_1141557; RRID:AB_141607; RRID:AB_141637; RRID:AB_2224402; RRID:AB_2298772; RRID:AB_2305186; RRID:AB_2534105; RRID:AB_2617143; RRID:AB_444360; RRID:AB_783595; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; CEREBROSPINAL-FLUID; INFLAMMATORY RESPONSES; MULTIPLEX ASSESSMENT; YOUNG-CHILDREN; MOUSE-BRAIN; HMGB1; MICROGLIA; BARRIER; RAT	Accumulating research suggests that children may be more vulnerable to poor long-term outcomes after traumatic brain injury (TBI) compared to adults. The neuroinflammatory response, known to contribute to neuropathology after TBI, appears to differ depending upon age-at-insult, although this response has not been well-characterized. Elevated levels of a key initiator of inflammation, high-mobility group box protein 1 (HMGB1), have been associated with worsened outcomes after TBI in young patients. This study therefore aimed to characterize the acute time course of key mediators of the inflammatory cascade, including HMGB1, after pediatric and adult TBI. Male C57Bl/6 mice were subjected to severe controlled cortical impact or a sham control surgery, at either early adulthood (8-10 weeks) or a pediatric age (3 weeks). Cortical tissue was collected for Western blot detection of astrocyte and microglial activation (GFAP and CD68) and HMGB1 at 2 hr, 6 hr, 24 hr, 3 days, and 7 days postinjury, and serum was collected for enzyme-linked immunoassays to quantify peripheral HMGB1. An additional cohort of brains was harvested at 3 day postinjury for immunofluorescence staining. Results demonstrated a temporal profile of CD68, GFAP, and HMGB1 after TBI relative to sham, which differed between the adult and pediatric cohorts. An increase in peripheral HMGB1 was found in serum from pediatric TBI mice, which was not evident in adult serum. Together, these findings demonstrate that HMGB1 and the downstream cellular inflammatory response are influenced by age-at-insult, which may be an important consideration for treatment strategies aiming to ameliorate this response after TBI.	[Webster, Kyria M.; Sun, Mujun; O'Brien, Terence J.; Shultz, Sandy R.; Semple, Bridgette D.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic, Australia; [Crack, Peter J.] Univ Melbourne, Dept Pharmacol & Therapeut, Parkville, Vic, Australia; [O'Brien, Terence J.; Shultz, Sandy R.; Semple, Bridgette D.] Monash Univ, Dept Neurosci, Melbourne, Vic, Australia	Semple, BD (corresponding author), Monash Univ, Cent Clin Sch, Dept Neurosci, Alfred Ctr, 99 Commercial Rd, Melbourne, Vic 3004, Australia.	bridgette.semple@monash.edu	Crack, Peter/ABE-2065-2020	Crack, Peter/0000-0002-5030-0330; Sun, Mujun/0000-0002-9923-9913; O'Brien, Terence/0000-0002-7198-8621	Rebecca L Cooper Medical Research Foundation; University of MelbourneUniversity of Melbourne; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC)	Rebecca L Cooper Medical Research Foundation; University of Melbourne; National Health and Medical Research Council of Australia	ABS, 2004, DIS AG CAR SUMM FIND; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Alcaraz C, 1990, J Vet Diagn Invest, V2, P191; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anthony D, 1998, CURR BIOL, V8, P923, DOI 10.1016/S0960-9822(07)00373-9; Anthony DC, 1997, BRAIN, V120, P435, DOI 10.1093/brain/120.3.435; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Au AK, 2012, J NEUROTRAUM, V29, P2013, DOI 10.1089/neu.2011.2171; Bell MJ, 1997, ACT NEUR S, V70, P96; Bennett KS, 2014, CRIT CARE MED, V42, P2308, DOI 10.1097/CCM.0000000000000563; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Bianchi ME, 2007, IMMUNOL REV, V220, P35, DOI 10.1111/j.1600-065X.2007.00574.x; Bilimoria PM, 2015, BRAIN RES, V1617, P7, DOI 10.1016/j.brainres.2014.11.032; Bittigau P, 2004, EXP TOXICOL PATHOL, V56, P83, DOI 10.1016/j.etp.2004.04.006; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chaboub LS, 2013, SEMIN PEDIATR NEUROL, V20, P230, DOI 10.1016/j.spen.2013.10.003; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Claus CP, 2010, DEV NEUROSCI-BASEL, V32, P454, DOI 10.1159/000316805; Copland IB, 2004, AM J RESP CRIT CARE, V169, P739, DOI 10.1164/rccm.200310-1417OC; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; DEKABAN AS, 1978, ANN NEUROL, V4, P345, DOI 10.1002/ana.410040410; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; DOBBING J, 1973, ARCH DIS CHILD, V48, P757, DOI 10.1136/adc.48.10.757; Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; Elhofy A, 2005, J LEUKOCYTE BIOL, V77, P229, DOI 10.1189/jlb.0804465; ENG LF, 1983, PROG NEUROPATH, V5, P19; Enokido Y, 2008, BIOCHEM BIOPH RES CO, V376, P128, DOI 10.1016/j.bbrc.2008.08.108; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Feldman P, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-180; Ferriero DM, 2010, J ANAT, V217, P429, DOI 10.1111/j.1469-7580.2010.01226.x; Galea I, 2007, TRENDS IMMUNOL, V28, P12, DOI 10.1016/j.it.2006.11.004; Gao TL, 2012, J TRAUMA ACUTE CARE, V72, P643, DOI 10.1097/TA.0b013e31823c54a6; Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198; Gerlitz G, 2009, BIOCHEM CELL BIOL, V87, P127, DOI 10.1139/O08-110; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Gong G, 2012, ACTA PHARMACOL SIN, V33, P11, DOI 10.1038/aps.2011.151; Harris HE, 2012, NAT REV RHEUMATOL, V8, P195, DOI 10.1038/nrrheum.2011.222; Hayakawa K, 2012, P NATL ACAD SCI USA, V109, P7505, DOI 10.1073/pnas.1121146109; Heidebrecht F, 2009, J IMMUNOL METHODS, V345, P40, DOI 10.1016/j.jim.2009.03.018; Ieong CC, 2018, J CLIN NEUROSCI, V47, P278, DOI 10.1016/j.jocn.2017.10.034; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; KARPUS WJ, 1995, J IMMUNOL, V155, P5003; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kieslich M, 2001, DISABIL REHABIL, V23, P665; Kim JB, 2008, J NEUROSCI RES, V86, P1125, DOI 10.1002/jnr.21555; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LAWSON LJ, 1995, EUR J NEUROSCI, V7, P1584, DOI 10.1111/j.1460-9568.1995.tb01154.x; Lee S, 2014, NAT CHEM BIOL, V10, P1055, DOI 10.1038/nchembio.1669; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075; Lu B, 2012, NATURE, V488, P670, DOI 10.1038/nature11290; Luo Y, 2000, J IMMUNOL, V165, P4015, DOI 10.4049/jimmunol.165.7.4015; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Ning RZ, 2011, BRAIN RES, V1384, P140, DOI 10.1016/j.brainres.2011.01.099; Ohnishi M, 2014, NEUROCHEM INT, V75, P32, DOI 10.1016/j.neuint.2014.05.007; Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Passalacqua M, 1998, NEUROSCIENCE, V82, P1021; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Rasband W, 1997, IMAGE J; Ryan NP, 2015, HUM BRAIN MAPP, V36, P1677, DOI 10.1002/hbm.22729; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schoderboeck L, 2009, NEUROBIOL DIS, V35, P368, DOI 10.1016/j.nbd.2009.05.026; Schultz C, 2004, CLIN EXP IMMUNOL, V135, P130, DOI 10.1111/j.1365-2249.2004.02313.x; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Semple BD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143386; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Simon DW, 2018, J NEUROTRAUM, V35, P130, DOI 10.1089/neu.2017.5093; Stevenson K. L., 2000, Journal of Neurotrauma, V17, P944; Stros M, 2010, BBA-GENE REGUL MECH, V1799, P101, DOI 10.1016/j.bbagrm.2009.09.008; Thurman DJ, 2016, J CHILD NEUROL, V31, P20, DOI 10.1177/0883073814544363; Tian J, 2007, NAT IMMUNOL, V8, P487, DOI 10.1038/ni1457; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; UMEHARA F, 1990, LAB INVEST, V62, P147; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Venereau E, 2013, MOL IMMUNOL, V55, P76, DOI 10.1016/j.molimm.2012.10.037; Venereau E, 2012, J EXP MED, V209, P1519, DOI 10.1084/jem.20120189; Venters BJ, 2009, CRIT REV BIOCHEM MOL, V44, P117, DOI 10.1080/10409230902858785; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Webster KM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0786-1; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Yang H, 2013, J LEUKOCYTE BIOL, V93, P865, DOI 10.1189/jlb.1212662; Yang H, 2012, MOL MED, V18, P250, DOI 10.2119/molmed.2011.00389; Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334; Ziebell JM, 2015, METAB BRAIN DIS, V30, P393, DOI 10.1007/s11011-014-9539-y	99	12	12	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	APR 15	2019	527	6					1102	1117		10.1002/cne.24589			16	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	HK9GT	WOS:000458299300005	30499129				2021-06-18	
J	Bouley, J; Chung, DY; Ayata, C; Brown, RH; Henninger, N				Bouley, James; Chung, David Y.; Ayata, Cenk; Brown, Robert H., Jr.; Henninger, Nils			Cortical Spreading Depression Denotes Concussion Injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; cerebral microbleed; concussion; cortical spreading depolarization; traumatic brain injury	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; DEPOLARIZATIONS; CORTEX; SEIZURES; STRAIN; MODEL; MICE	Cortical spreading depression (CSD) has been described after moderate-to-severe traumatic brain injury (TBI). It is uncertain, however, whether CSD occurs after mild, concussive TBI and whether it relates to brain pathology and functional outcome. Male C57BL6/J mice (n=62) were subjected to closed head TBI with a 25g weight (n=11), 50g weight (n=45), or sham injury (n=6). Laser Doppler flowmetry and optical intrinsic signal imaging were used to determine cerebral blood flow dynamics after concussive CSD. Functional deficits were assessed at baseline, 2h, 24h, and 48h. TUNEL and Prussian blue staining were used to determine cell death and presence of cerebral microbleeds at 48h. No CSD was observed in mice subjected to a 25g weight drop whereas 58.9% of mice subjected to a 50g weight drop developed a CSD. Mice with concussive CSD displayed significantly greater numbers of apoptotic cell profiles in the ipsilesional hemisphere compared with mice without a CSD that underwent the same 50g weight drop paradigm (p<0.05, each). All investigated animals had at least one cerebral microbleed (range 1 to 24). Compared with mice without a CSD, mice with a CSD had significantly more microbleeds in the traumatized hemisphere (p<0.05, each) and showed impaired functional recovery (p<0.05). Incidence of CSD after mild TBI depended on impact severity and was associated with histological and behavioral outcomes. These observations indicate that concussive CSD may serve as viable marker for concussion severity and provide novel avenues for outcome prediction and therapeutic decision making.	[Bouley, James; Brown, Robert H., Jr.; Henninger, Nils] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA USA; [Chung, David Y.; Ayata, Cenk] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Chung, David Y.; Ayata, Cenk] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA; [Henninger, Nils] Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01655 USA	Henninger, N (corresponding author), Univ Massachusetts, Sch Med, 55 Lake Ave North, Worcester, MA 01655 USA.	nils.henninger@umassmed.edu	Chung, David/AAG-1359-2019	Chung, David/0000-0002-7149-5851	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS091499, NS055104, NS102969, NS065743, NS088689, FD004127, HD060848]; Fondation LeducqLeducq Foundation; Heitman Foundation; Ellison FoundationLawrence Ellison Foundation; Angel Fund; ALS Association; ALSFindingaCure; Cellucci Fund for ALS Research; Pierre deBourghknect ALS Fund; Project ALS; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P50HD060848, U54HD060848] Funding Source: NIH RePORTER; FOOD AND DRUG ADMINISTRATIONUnited States Department of Health & Human Services [R01FD004127] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR002541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS102969, R01NS088689, K08NS091499, R25NS065743, P01NS055104] Funding Source: NIH RePORTER	We gratefully acknowledge expert assistance provided by Y. Liu (Morphology Core Laboratory; University of Massachusetts Medical School) for histotechnological assistance, A. Weiss for animal husbandry, K. van der Marel (Department of Radiology, University of Massachusetts Medical School) for implementation of the Matlab code to process COIS images, and K. Benoit for tireless logistical assistance and administrative support. This study was supported by institutional grants, National Institutes of Health grant NS091499 to N.H., NS055104, NS102969 to C.A., NS065743 to D.Y.C., and NS088689, FD004127, HD060848 to R.H.B. N.H. serves on the advisory board of Omniox, Inc. C.A receives support from the Fondation Leducq, the Heitman Foundation, and the Ellison Foundation. R.H.B. receives support from the Angel Fund, the ALS Association, ALSFindingaCure, the Cellucci Fund for ALS Research, Project ALS and the Pierre deBourghknect ALS Fund. R.H.B. is a co-founder of AviTx.	Altamura C, 2007, CEREB CORTEX, V17, P1394, DOI 10.1093/cercor/bhl051; Ayata C, 2015, PHYSIOL REV, V95, P953, DOI 10.1152/physrev.00027.2014; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Chung D.Y., 2018, CEREB CORTEX; Dreier JP, 2015, NEURON, V86, P902, DOI 10.1016/j.neuron.2015.04.004; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; ECHLIN F, 1948, T AM NEUROL ASSOC, P199; ECHLIN FA, 1950, ARCH NEURO PSYCHIATR, V63, P830; Eikermann-Haerter K, 2009, J CLIN INVEST, V119, P99, DOI 10.1172/JCI36059; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Fabricius M, 2008, CLIN NEUROPHYSIOL, V119, P1973, DOI 10.1016/j.clinph.2008.05.025; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Hansen JM, 2013, BRAIN, V136, P3589, DOI 10.1093/brain/awt309; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Henninger N, 2016, BRAIN, V139, P1094, DOI 10.1093/brain/aww001; Hinzman JM, 2016, J NEUROTRAUM, V33, P1775, DOI 10.1089/neu.2015.4226; Hinzman JM, 2014, BRAIN, V137, P2960, DOI 10.1093/brain/awu241; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kaufmann D., 2016, J CEREB BLOOD FLOW M; Kochanek PM, 2016, J NEUROTRAUM, V33, P606, DOI 10.1089/neu.2015.4133; Kochanek PM, 2011, J TRAUMA, V71, pS15, DOI 10.1097/TA.0b013e31822117fe; Leao AAP, 1944, J NEUROPHYSIOL, V7, P391, DOI 10.1152/jn.1944.7.6.391; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Levchakov A, 2006, J NEUROTRAUM, V23, P1570, DOI 10.1089/neu.2006.23.1570; MATSUURA T, 1971, EXP BRAIN RES, V12, P238, DOI 10.1007/BF00237916; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; OKA H, 1977, BRAIN, V100, P287, DOI 10.1093/brain/100.2.287; Paxinos G., 2013, MOUSE BRAIN STEREOTA; Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111; Rowson S, 2018, J NEUROTRAUM, V35, P681, DOI 10.1089/neu.2017.5169; Samoriski GM, 1997, J NEUROSCI, V17, P5581; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Stalnacke BM, 2007, J REHABIL MED, V39, P405, DOI 10.2340/16501977-0057; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; TAKAHASHI H, 1980, CHILD BRAIN, V7, P124; WEST M, 1982, ELECTROEN CLIN NEURO, V53, P192, DOI 10.1016/0013-4694(82)90023-2; Woitzik J, 2013, NEUROLOGY, V80, P1095, DOI 10.1212/WNL.0b013e3182886932; Yuzawa I, 2012, J CEREBR BLOOD F MET, V32, P376, DOI 10.1038/jcbfm.2011.148	43	12	12	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2019	36	7					1008	1017		10.1089/neu.2018.5844			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HR6BY	WOS:000463234200004	29999455	Green Published			2021-06-18	
J	Carlozzi, NE; Kallen, MA; Hanks, R; Kratz, AL; Hahn, EA; Brickell, TA; Lange, RT; French, LM; Ianni, PA; Miner, JA; Sander, AM				Carlozzi, Noelle E.; Kallen, Michael A.; Hanks, Robin; Kratz, Anna L.; Hahn, Elizabeth A.; Brickell, Tracey A.; Lange, Rael T.; French, Louis M.; Ianni, Phillip A.; Miner, Jennifer A.; Sander, Angelle M.			The Development of a New Computer Adaptive Test to Evaluate Feelings of Being Trapped in Caregivers of Individuals With Traumatic Brain Injury: TBI-CareQOL Feeling Trapped Item Bank	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Caregiver; Health-related quality of life; Patient reported outcome measures; Psychometrics; Rehabilitation; Traumatic brain injury; Veterans	QUALITY-OF-LIFE; SOCIAL SUPPORT; TIME-COURSE; FOLLOW-UP; RECOVERY; FAMILY; HEALTH; OUTCOMES; REHABILITATION; MODEL	Objective: To develop a new patient-reported outcome measure that captures feelings of being trapped that are commonly experienced by caregivers of individuals with traumatic brain injury (TBI). Design: Cross-sectional. Setting: Three TBI Model Systems rehabilitation hospitals, an academic medical center, and a military medical treatment facility. Participants: Caregivers (N=560) of civilians with TBI (n=344) and caregivers of service members/veterans with TBI (n=216). Interventions: Not applicable. Outcome measures: Traumatic Brain Injury Caregiver Quality of Life (TBI-CareQOL) Feeling Trapped item bank. Results: From an initial item pool of 28 items, exploratory and confirmatory factor analyses supported the retention of 16 items. After graded response model (GRM) and differential item functioning analyses were conducted, 15 items were retained in the final measure. GRM calibration data, along with clinical expert input, were used to choose a 6-item, static short form (SF), and the calibration data were used for programming of the TBI-CareQOL Feeling Trapped computer adaptive test (CAT). CAT simulation analyses produced an r=0.99 correlation between CAT scores and the full item bank. Three-week short-form test-retest reliability was very good (r=0.84). Conclusions: The new TBI-CareQOL Feeling Trapped item bank was developed to provide a sensitive and efficient examination of the effect that feelings of being trapped, due to the caregiver role, have on health-related quality of life for caregivers of individuals with TBI. Both the CAT and corresponding 6-item SF demonstrate excellent psychometric properties. Future work is needed to establish the responsiveness of this measure to clinical interventions for these caregivers. (C) 2018 by the American Congress of Rehabilitation Medicine	[Carlozzi, Noelle E.; Kratz, Anna L.; Ianni, Phillip A.; Miner, Jennifer A.] Univ Michigan, Dept Phys Med & Rehabil, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [Kallen, Michael A.; Hahn, Elizabeth A.] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA; [Hanks, Robin] Rehabil Inst Michigan, Dept Psychol & Neuropsychol, Detroit, MI USA; [Hanks, Robin] Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA; [Brickell, Tracey A.; Lange, Rael T.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Brickell, Tracey A.; Lange, Rael T.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bethesda, MD USA; [Brickell, Tracey A.; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Lange, Rael T.] Univ British Columbia, Vancouver, BC, Canada; [Sander, Angelle M.] Baylor Coll Med, H Ben Taub Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Sander, Angelle M.] Harris Hlth Syst, Houston, TX 77030 USA; [Sander, Angelle M.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX USA	Carlozzi, NE (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	carlozzi@med.umich.edu	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604	National Institutes of Health-National Institute of Nursing ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR); National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000433]; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR002240, UL1TR000433] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013658] Funding Source: NIH RePORTER	Supported by the National Institutes of Health-National Institute of Nursing Research (grant no. R01NR013658), the National Center for Advancing Translational Sciences (grant no. UL1TR000433), and the Defense and Veterans Brain Injury Center.	Bailey EK, 2017, J HEAD TRAUMA REHAB, V32, P245, DOI 10.1097/HTR.0000000000000317; Bayen E, 2016, J HEAD TRAUMA REHAB, V31, pE59, DOI 10.1097/HTR.0000000000000079; BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Burns Anthony S, 2012, Handb Clin Neurol, V109, P47, DOI 10.1016/B978-0-444-52137-8.00003-6; Carlozzi NE, 2019, ARCH PHYS MED REHAB, V100, pS1, DOI 10.1016/j.apmr.2018.08.175; Carlozzi NE, 2019, ARCH PHYS MED REHAB, V100, pS85, DOI 10.1016/j.apmr.2018.05.034; Carlozzi NE, 2016, J REHABIL RES DEV, V53, P669, DOI 10.1682/JRRD.2015.07.0136; Carlozzi NE, 2015, ARCH PHYS MED REHAB, V96, P105, DOI 10.1016/j.apmr.2014.08.021; Cella D, 2007, MED CARE, V45, pS3, DOI 10.1097/01.mlr.0000258615.42478.55; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; Cook KF, 2009, QUAL LIFE RES, V18, P447, DOI 10.1007/s11136-009-9464-4; Corrigan JD, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000020; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Crane PK, 2006, MED CARE, V44, pS115, DOI 10.1097/01.mlr.0000245183.28384.ed; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Dillahunt-Aspillaga C, 2017, J HEAD TRAUMA REHAB, V32, P271, DOI 10.1097/HTR.0000000000000275; DITUNNO JF, 1992, ARCH PHYS MED REHAB, V73, P431; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Fisher LB, 2016, BRAIN INJURY, V30, P1311, DOI 10.1080/02699052.2016.1195517; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hanauer DA, 2015, J BIOMED INFORM, V55, P290, DOI 10.1016/j.jbi.2015.05.003; Hart T, 2003, ARCH PHYS MED REHAB, V84, P221, DOI 10.1053/apmr.2003.50023; Hatcher L., 1994, STEP BY STEP APPROAC; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P406, DOI 10.1016/S0003-9993(95)80568-0; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P399, DOI 10.1016/S0003-9993(95)80567-2; Jourdan C, 2017, J HEAD TRAUMA REHAB, V32, pE26, DOI 10.1097/HTR.0000000000000276; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Kline R.B., 2005, PRINCIPLES PRACTICE, V2nd; Krauss Joachim K, 2015, Handb Clin Neurol, V128, P475, DOI 10.1016/B978-0-444-63521-1.00030-3; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Manskow US, 2017, NEUROREHABILITATION, V40, P211, DOI 10.3233/NRE-161406; Martin Y, 2006, AGING MENT HEALTH, V10, P101, DOI 10.1080/13607860500311953; McDonald R. P., 1999, TEST THEORY UNIFIED; McLaughlin Anne Marie, 1993, Brain Injury, V7, P45, DOI 10.3109/02699059309008155; PEARLIN LI, 1990, GERONTOLOGIST, V30, P583, DOI 10.1093/geront/30.5.583; Pelletier PM, 2000, BRAIN COGNITION, V44, P45; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P306, DOI 10.1017/S1355617709991342; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Reise SP, 2007, QUAL LIFE RES, V16, P19, DOI 10.1007/s11136-007-9183-7; Sabaz M, 2014, J HEAD TRAUMA REHAB, V29, pE19, DOI 10.1097/HTR.0b013e31828dc590; Sady MD, 2010, ARCH PHYS MED REHAB, V91, P1542, DOI 10.1016/j.apmr.2010.07.012; Samejima F, 1996, HDB MODERN ITEM RESP, P85, DOI DOI 10.1007/978-1-4757-2691-6_5; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sander AM, 2012, ARCH PHYS MED REHAB, V93, P842, DOI 10.1016/j.apmr.2011.11.031; Seel RT, 2016, NEUROREHABILITATION, V39, P371, DOI 10.3233/NRE-161369; Smith A M, 1998, Rehabil Nurs, V23, P252; Vangel SJ, 2011, J HEAD TRAUMA REHAB, V26, P20, DOI 10.1097/HTR.0b013e318204a70d; Waters R L, 1998, J Spinal Cord Med, V21, P195; WATERS RL, 1993, ARCH PHYS MED REHAB, V74, P242; WATERS RL, 1992, ARCH PHYS MED REHAB, V73, P784; WATERS RL, 1994, ARCH PHYS MED REHAB, V75, P67; Winstanley J, 2006, J HEAD TRAUMA REHAB, V21, P453, DOI 10.1097/00001199-200611000-00001; Zaider TI, 2003, PSYCHOL MED, V33, P611, DOI 10.1017/S0033291703007414	62	12	12	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2019	100	4		1			S43	S51		10.1016/j.apmr.2018.06.025			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	HR2FV	WOS:000462951900005	30075146	Green Accepted			2021-06-18	
J	Carlozzi, NE; Ianni, PA; Tulsky, DS; Brickell, TA; Lange, RT; French, LM; Cella, D; Kallen, MA; Miner, JA; Kratz, AL				Carlozzi, Noelle E.; Ianni, Phillip A.; Tulsky, David S.; Brickell, Tracey A.; Lange, Rael T.; French, Louis M.; Cella, David; Kallen, Michael A.; Miner, Jennifer A.; Kratz, Anna L.			Understanding Health-Related Quality of Life in Caregivers of Civilians and Service Members/Veterans With Traumatic Brain Injury: Establishing the Reliability and Validity of PROMIS Fatigue and Sleep Disturbance Item Banks	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Caregiver; Fatigue; Patient reported outcome measures; Psychometrics; Rehabilitation; Sleep; Traumatic brain injury	PORTLAND ADAPTABILITY INVENTORY; ZARIT-BURDEN-INTERVIEW; FAMILY CAREGIVERS; INFORMAL CAREGIVERS; CONSTRUCT-VALIDITY; OUTCOME MEASURES; HEAD-INJURY; TIME-COURSE; RECOVERY; VALIDATION	Objective: To examine the reliability and validity of Patient-Reported Outcomes Measurement Information System (PROMIS) measures of sleep disturbance and fatigue in traumatic brain injury (TBI) caregivers and to determine the severity of fatigue and sleep disturbance in these caregivers. Design: Cross-sectional survey data collected through an online data capture platform. Setting: A total of 4 rehabilitation hospitals and Walter Reed National Military Medical Center. Participants: Caregivers (N=560) of civilians (n =344) and service member/veterans (SMVs) (n =216) with TBI. Intervention: Not applicable. Main Outcome Measures: PROMIS sleep and fatigue measures administered as both computerized adaptive tests (CATS) and 4-item short forms (SFs). Results: For both samples, floor and ceiling effects for the PROMIS measures were low (<11%), internal consistency was very good (all alpha >= 0.80), and test-retest reliability was acceptable (all r >= 0.70 except for the fatigue CAT in the SMV sample r= 0.63). Convergent validity was supported by moderate correlations between the PROMIS and related measures. Discriminant validity was supported by low correlations between PROMIS measures and measures of dissimilar constructs. PROMIS scores indicated significantly worse sleep and fatigue for those caring for someone with high levels versus low levels of impairment. Conclusions: Findings support the reliability and validity of the PROMIS CAT and SF measures of sleep disturbance and fatigue in caregivers of civilians and SMVs with TBI. (C) 2018 by the American Congress of Rehabilitation Medicine	[Carlozzi, Noelle E.; Ianni, Phillip A.; Miner, Jennifer A.; Kratz, Anna L.] Univ Michigan, Dept Phys Med & Rehabil, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [Tulsky, David S.] Univ Delaware, Dept Psychol & Brain Sci, Ctr Assessment Res & Translat, Newark, DE USA; [Brickell, Tracey A.; Lange, Rael T.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Brickell, Tracey A.; Lange, Rael T.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bethesda, MD USA; [Brickell, Tracey A.; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Lange, Rael T.] Univ British Columbia, Vancouver, BC, Canada; [Cella, David; Kallen, Michael A.] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA	Carlozzi, NE (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	carlozzi@med.umich.edu	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604; Tulsky, David/0000-0002-4335-4509	National Institutes of Health National Institute of Nursing ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR); National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000433]; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR002240, UL1TR000433] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013658] Funding Source: NIH RePORTER	Supported by the National Institutes of Health National Institute of Nursing Research (grant no. R01NR013658), the National Center for Advancing Translational Sciences (grant no. UL1TR000433), and the Defense and Veterans Brain Injury Center.	Al-Rawashdeh SY, 2016, J CARDIOVASC NURS, V31, pE21, DOI 10.1097/JCN.0000000000000348; Amtmann D, 2018, DISABIL HEALTH J, V11, P99, DOI 10.1016/j.dhjo.2017.04.008; Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS15, DOI 10.1053/apmr.2000.20619; Bayen E, 2016, J HEAD TRAUMA REHAB, V31, pE59, DOI 10.1097/HTR.0000000000000079; Berger Ann M, 2005, Oncol Nurs Forum, V32, pE98, DOI 10.1188/05.ONF.E98-E126; Bohac DL, 1997, BRAIN INJURY, V11, P469, DOI 10.1080/713802185; Burns Anthony S, 2012, Handb Clin Neurol, V109, P47, DOI 10.1016/B978-0-444-52137-8.00003-6; Buysse DJ, 2010, SLEEP, V33, P781, DOI 10.1093/sleep/33.6.781; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Carlozzi NE, 2019, ARCH PHYS MED REHAB, V100, pS1, DOI 10.1016/j.apmr.2018.08.175; Carlozzi NE, 2016, J REHABIL RES DEV, V53, P669, DOI 10.1682/JRRD.2015.07.0136; Carlozzi NE, 2015, ARCH PHYS MED REHAB, V96, P105, DOI 10.1016/j.apmr.2014.08.021; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Castro CM, 2009, BEHAV SLEEP MED, V7, P164, DOI 10.1080/15402000902976713; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Cramer D, 2004, SAGE DICT STAT; Davis LC, 2009, J HEAD TRAUMA REHAB, V24, P145, DOI 10.1097/HTR.0b013e3181a0b291; Defense and Veterans Brain Injury Center (DVBIC), DOD WORLDW NUMB TBI; Degeneffe CE, 2011, REHABIL PSYCHOL, V56, P243, DOI 10.1037/a0024465; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DeVellis R.F., 2017, SCALE DEV THEORY APP; DeVellis RF, 2006, MED CARE, V44, pS50, DOI 10.1097/01.mlr.0000245426.10853.30; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Dillahunt-Aspillaga C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082896; DITUNNO JF, 1992, ARCH PHYS MED REHAB, V73, P431; ENRIGHT RB, 1987, EMPLOYED CAREGIVERS; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Feeny D, 2005, J CLIN EPIDEMIOL, V58, P138, DOI 10.1016/j.jclinepi.2004.08.005; Fletcher BAS, 2008, ONCOL NURS FORUM, V35, P187, DOI 10.1188/08.ONF.E23-E44; Fonareva I, 2011, J GERIATR PSYCH NEUR, V24, P50, DOI 10.1177/0891988710397548; Fortune DG, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01368; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hays RD, 1995, USERS MANUAL MED OUT; Heaton RK, 2004, REVISED COMPREHENSIV; Hebert R, 2000, CAN J AGING, V19, P494, DOI 10.1017/S0714980800012484; Hoofien D, 2001, BRAIN INJURY, V15, P189; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Jensen RE, 2017, J CLIN ONCOL, V35, P1913, DOI 10.1200/JCO.2016.71.4410; Jensen RE, 2017, CANCER-AM CANCER SOC, V123, P327, DOI 10.1002/cncr.30354; Johnson JA, 2004, QUAL LIFE RES, V13, P449, DOI 10.1023/B:QURE.0000018494.72748.cf; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P406, DOI 10.1016/S0003-9993(95)80568-0; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P399, DOI 10.1016/S0003-9993(95)80567-2; Jumisko E, 2007, J FAM NURS, V13, P353, DOI 10.1177/1074840707303842; Kean J, 2011, J NEUROTRAUM, V28, P745, DOI 10.1089/neu.2010.1573; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Lange RT, 2014, ARCH CLIN NEUROPSYCH, V29, P329, DOI 10.1093/arclin/acu013; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LAWTON MP, 1989, J GERONTOL, V44, pP61, DOI 10.1093/geronj/44.3.P61; Lee K. A., 2003, PATHOPHYSIOLOGICAL P, P363; Lester P, 2010, J AM ACAD CHILD PSY, V49, P310, DOI 10.1016/j.jaac.2010.01.003; Leung YW, 2016, CANCER-AM CANCER SOC, V122, P2906, DOI 10.1002/cncr.30134; Liu S, 2017, J CLIN NURS, V26, P1291, DOI 10.1111/jocn.13601; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Maddigan SL, 2004, QUAL LIFE RES, V13, P435, DOI 10.1023/B:QURE.0000018497.06539.8f; Malec J, CTR OUTCOME MEASUREM; Malec JF, 2012, ARCH PHYS MED REHAB, V93, P2271, DOI 10.1016/j.apmr.2012.06.013; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Mansfield AJ, 2010, NEW ENGL J MED, V362, P101, DOI 10.1056/NEJMoa0900177; Manskow US, 2015, J HEAD TRAUMA REHAB, V30, P411, DOI 10.1097/HTR.0000000000000085; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Mazlan M, 2016, DISABIL REHABIL, V38, P2198, DOI 10.3109/09638288.2015.1123307; McCurry SM, 2007, SLEEP MED REV, V11, P143, DOI 10.1016/j.smrv.2006.09.002; Musil CM, 2002, WESTERN J NURS RES, V24, P815, DOI 10.1177/019394502762477004; Nagaraja V, 2018, QUAL LIFE RES, V27, P755, DOI 10.1007/s11136-017-1709-z; National Alliance for Caregiving, 2010, CAR VET SERV HOM REP; Panting A., 1972, REHABILITATION, V38, P33; Peng HL, 2013, PERSPECT PSYCHIATR C, V49, P135, DOI 10.1111/ppc.12005; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Pollak C P, 1991, J Geriatr Psychiatry Neurol, V4, P204, DOI 10.1177/089198879100400405; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Purvis TE, 2017, SPINE, V42, pE1357, DOI 10.1097/BRS.0000000000002347; Purvis TE, 1976, SPINE PHILA PA 1976; Quach CW, 2016, QUAL LIFE RES, V25, P2811, DOI 10.1007/s11136-016-1325-3; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Saban KL, 2016, J REHABIL RES DEV, V53, P681, DOI 10.1682/JRRD.2015.07.0143; Sander A. M., 2005, REHABILITATION TRAUM, P156; Sander AM, 2003, ARCH PHYS MED REHAB, V84, P197, DOI 10.1053/apmr.2003.50105; Sander AM, 2013, BRAIN IMPAIR, V14, P113, DOI 10.1017/BrImp.2013.12; Schreiner AS, 2006, AGING MENT HEALTH, V10, P107, DOI 10.1080/13607860500312142; Schulz R, 1997, ANN BEHAV MED, V19, P110, DOI 10.1007/BF02883327; Selim A, 2009, QUAL LIFE RES, V18, P43, DOI 10.1007/s11136-008-9418-2; Seng BK, 2010, ANN ACAD MED SINGAP, V39, P758; Smith MC, 1997, J AM GERIATR SOC, V45, P194, DOI 10.1111/j.1532-5415.1997.tb04506.x; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; Taft CT, 2008, J CONSULT CLIN PSYCH, V76, P648, DOI 10.1037/a0012576; Victorson D, 2016, J ALTERN COMPLEM MED, V22, P778, DOI 10.1089/acm.2015.0121; Vitaliano PP, 2003, PSYCHOL BULL, V129, P946, DOI 10.1037/0033-2909.129.6.946; Waters R L, 1998, J Spinal Cord Med, V21, P195; WATERS RL, 1993, ARCH PHYS MED REHAB, V74, P242; WATERS RL, 1992, ARCH PHYS MED REHAB, V73, P784; WATERS RL, 1994, ARCH PHYS MED REHAB, V75, P67; Whalen KJ, 2009, JBI DATABASE SYSTEMA, V7, P1373; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183; Yu L, 2012, BEHAV SLEEP MED, V10, P6, DOI 10.1080/15402002.2012.636266; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	108	12	12	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2019	100	4		1			S102	S109		10.1016/j.apmr.2018.05.020			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	HR2FV	WOS:000462951900012	29932884	Green Accepted			2021-06-18	
J	Carlozzi, NE; Ianni, PA; Lange, RT; Brickell, TA; Kallen, MA; Hahn, EA; French, LM; Cella, D; Miner, JA; Tulsky, DS				Carlozzi, Noelle E.; Ianni, Phillip A.; Lange, Rael T.; Brickell, Tracey A.; Kallen, Michael A.; Hahn, Elizabeth A.; French, Louis M.; Cella, David; Miner, Jennifer A.; Tulsky, David S.			Understanding Health-Related Quality of Life of Caregivers of Civilians and Service Members/Veterans With Traumatic Brain Injury: Establishing the Reliability and Validity of PROMIS Social Health Measures	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; traumatic; Caregivers; Patient reported outcome measures; Psychometrics; Rehabilitation; Self report; Social support; Surveys and questionnaires; Veterans	FAMILY; VETERANS; BURDEN; IMPACT; INDIVIDUALS; VALIDATION; PREDICTORS; EXPERIENCE; REVISION; PARTNERS	Objective: To examine the reliability and validity of the short form (SF) and computer adaptive test (CAT) versions of the Patient-Reported Outcomes Measurement Information System (PROMIS) measures of social health of caregivers of civilians and service members/veterans (SMVs) with traumatic brain injury (TBI). Design: Self-report questionnaires administered through an online data collection platform. Setting: Hospital and community-based outreach at 3 TBI Model Systems rehabilitation hospitals, an academic medical center, and a military medical treatment facility. Participants: Caregivers (N = 560) (344 civilians and 216 military) of individuals with a documented TBI. Intervention: Not applicable. Main Outcome Measures: A total of 5 PROMIS social health measures. Results: All 5 PROMIS social health measures exceeded the a priori criterion for internal consistency reliability (>0.70); most PROMIS measures met the criterion for test-retest reliability (>0.70) in the civilian sample; in the SMV sample, test-retest reliability was generally below this criterion, except for social isolation. For both samples, convergent validity was supported by moderate correlations between the 5 PROMIS social health measures and related measures, and discriminant validity was supported by low correlations between PROMIS social health measures and measures of dissimilar constructs. Most PROMIS scores indicated significantly worse social health in both samples of those caring for individuals who were low functioning. Finally, impairment rates in social health were elevated for those caring for low-functioning individuals, especially in the SMV sample. Conclusions: The PROMIS CAT and SF social health measures have potential clinical utility for use in caregivers of civilians and SMVs with TBI. (C) 2018 by the American Congress of Rehabilitation Medicine	[Carlozzi, Noelle E.; Ianni, Phillip A.; Miner, Jennifer A.] Univ Michigan, Dept Phys Med & Rehabil, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [Lange, Rael T.; Brickell, Tracey A.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Lange, Rael T.; Brickell, Tracey A.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bethesda, MD USA; [Lange, Rael T.] Univ British Columbia, Vancouver, BC, Canada; [Brickell, Tracey A.; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Kallen, Michael A.; Hahn, Elizabeth A.; Cella, David] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA; [Tulsky, David S.] Univ Delaware, Dept Psychol & Brain Sci, Ctr Assessment Res & Translat, Newark, DE USA	Carlozzi, NE (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	carlozzi@med.umich.edu	french, louis/AAB-2083-2020	Tulsky, David/0000-0002-4335-4509; french, louis/0000-0002-9451-0604	National Institutes of Health-National Institute of Nursing ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR); National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [ULITR000433]; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000433, UL1TR002240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013658] Funding Source: NIH RePORTER	Supported by the National Institutes of Health-National Institute of Nursing Research (grant no. R01NR013658), the National Center for Advancing Translational Sciences (grant no. ULITR000433), and the Defense and Veterans Brain Injury Center.	Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS15, DOI 10.1053/apmr.2000.20619; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Blais MC, 2005, BRAIN INJURY, V19, P1223, DOI 10.1080/02699050500309387; Bulmer M. G., 1979, PRINCIPLES STAT; Calhoun PS, 2002, J TRAUMA STRESS, V15, P205, DOI 10.1023/A:1015251210928; Campbell C H, 1988, Rehabil Nurs, V13, P320; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Carlozzi NE, 2019, ARCH PHYS MED REHAB, V100, pS1, DOI 10.1016/j.apmr.2018.08.175; Carlozzi NE, 2019, ARCH PHYS MED REHAB, V100, pS43, DOI 10.1016/j.apmr.2018.06.025; Carlozzi NE, 2019, ARCH PHYS MED REHAB, V100, pS13, DOI 10.1016/j.apmr.2018.05.033; Carlozzi NE, 2019, ARCH PHYS MED REHAB, V100, pS31, DOI 10.1016/j.apmr.2018.05.026; Carlozzi NE, 2019, ARCH PHYS MED REHAB, V100, pS22, DOI 10.1016/j.apmr.2018.05.027; Carlozzi NE, 2016, J REHABIL RES DEV, V53, P669, DOI 10.1682/JRRD.2015.07.0136; Carlozzi NE, 2015, ARCH PHYS MED REHAB, V96, P105, DOI 10.1016/j.apmr.2014.08.021; Castel LD, 2008, QUAL LIFE RES, V17, P737, DOI 10.1007/s11136-008-9352-3; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Cramer D, 2004, SAGE DICT STAT; Defense and Veterans Brain Injury Center (DVBIC), DOD WORLDW NUMB TBI; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DeVellis R.F., 2017, SCALE DEV THEORY APP; DeVellis RF, 2006, MED CARE, V44, pS50, DOI 10.1097/01.mlr.0000245426.10853.30; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Galovski T, 2004, AGGRESS VIOLENT BEH, V9, P477, DOI 10.1016/S1359-1789(03)00045-4; Griffin JM, 2009, J REHABIL RES DEV, V46, P879, DOI 10.1682/JRRD.2008.08.0104; Hahn EA, 2014, HEALTH PSYCHOL, V33, P490, DOI 10.1037/hea0000055; Hahn EA, 2010, QUAL LIFE RES, V19, P1035, DOI 10.1007/s11136-010-9654-0; Hanauer DA, 2015, J BIOMED INFORM, V55, P290, DOI 10.1016/j.jbi.2015.05.003; Hassan STS, 2011, J NEPAL MED ASSOC, V50, P53; Hassan STS, 2012, HEALTHMED, V6, P2423; Hays RD, 1995, USERS MANUAL MED OUT; Hays RD, 2018, QUAL LIFE RES, V27, P1885, DOI 10.1007/s11136-018-1842-3; Hays RD, 2009, QUAL LIFE RES, V18, P873, DOI 10.1007/s11136-009-9496-9; Heaton RK, 2004, REVISED COMPREHENSIV; Hoofien D, 2001, BRAIN INJURY, V15, P189; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Jumisko E, 2007, J FAM NURS, V13, P353, DOI 10.1177/1074840707303842; Kratz AL, 2015, NEUROPSYCHOL REHABIL, P1; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LAWTON MP, 1989, J GERONTOL, V44, pP61, DOI 10.1093/geronj/44.3.P61; MacDonell GV, 2014, AUST PSYCHOL, V49, P305, DOI 10.1111/ap.12069; Malec J., INTRO MAYO PORTLAND; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; MILLER B, 1990, RES AGING, V12, P72, DOI 10.1177/0164027590121004; MONTGOMERY RJV, 1985, FAM RELAT, V34, P19, DOI 10.2307/583753; Musil CM, 2002, WESTERN J NURS RES, V24, P815, DOI 10.1177/019394502762477004; NOVAK M, 1989, GERONTOLOGIST, V29, P798, DOI 10.1093/geront/29.6.798; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; POULSHOCK SW, 1984, J GERONTOL, V39, P230, DOI 10.1093/geronj/39.2.230; Qadeer A, 2017, CUREUS, V9, DOI 10.7759/cureus.1590; Rao V, 2009, J NEUROPSYCH CLIN N, V21, P420, DOI 10.1176/appi.neuropsych.21.4.420; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Schulz R, 2016, FAMILIES CARING FOR AN AGING AMERICA, P1, DOI 10.17226/23606; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; Ware JE., 1994, SF 36 PHYS MENTAL HL, V1st; Zarit S., 1985, HIDDEN VICTIMS ALZHE; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	62	12	12	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2019	100	4		1			S110	S118		10.1016/j.apmr.2018.06.026			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	HR2FV	WOS:000462951900013	30075148	Green Accepted			2021-06-18	
J	LaPlaca, MC; Lessing, MC; Prado, GR; Zhou, RZ; Tate, CC; Geddes-Klein, D; Meaney, DF; Zhang, LY				LaPlaca, Michelle C.; Lessing, M. Christian; Prado, Gustavo R.; Zhou, Runzhou; Tate, Ciara C.; Geddes-Klein, Donna; Meaney, David F.; Zhang, Liying			Mechanoporation is a potential indicator of tissue strain and subsequent degeneration following experimental traumatic brain injury	CLINICAL BIOMECHANICS			English	Article						Traumatic brain injury; Membrane permeability; Mechanoporation; Hippocampus; Finite element model; Neuronal degeneration	CONTROLLED CORTICAL IMPACT; FLUORO-JADE-B; SPINAL-CORD; NEURONAL INJURY; POLOXAMER 188; SELECTIVE VULNERABILITY; AXOLEMMAL PERMEABILITY; HIPPOCAMPAL-NEURONS; DEPENDENT CHANGES; RAT HIPPOCAMPUS	Background: An increases in plasma membrane permeability is part of the acute pathology of traumatic brain injury and may be a function of excessive membrane force. This membrane damage, or mechanoporation, allows non-specific flux of ions and other molecules across the plasma membrane, and may ultimately lead to cell death. The relationships among tissue stress and strain, membrane permeability, and subsequent cell degeneration, however, are not fully understood. Methods: Fluorescent molecules of different sizes were introduced to the cerebrospinal fluid space prior to injury and animals were sacrificed at either 10 min or 24 h after injury. We compared the spatial distribution of plasma membrane damage following controlled cortical impact in the rat to the stress and strain tissue patterns in a 3-D finite element simulation of the injury parameters. Findings: Permeable cells were located primarily in the ipsilateral cortex and hippocampus of injured rats at 10 min post-injury; however by 24 h there was also a significant increase in the number of permeable cells. Analysis of colocalization of permeability marker uptake and Fluorojade staining revealed a subset of permeable cells with signs of degeneration at 24 h, but plasma membrane damage was evident in the vast majority of degenerating cells. The regional and subregional distribution patterns of the maximum principal strain and shear stress estimated by the finite element model were comparable to the cell membrane damage profiles following a compressive impact. Interpretation: These results indicate that acute membrane permeability is prominent following traumatic brain injury in areas that experience high shear or tensile stress and strain due to differential mechanical properties of the cell and tissue organization, and that this mechanoporation may play a role in the initiation of secondary injury, contributing to cell death.	[LaPlaca, Michelle C.; Lessing, M. Christian; Prado, Gustavo R.; Tate, Ciara C.] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA; [LaPlaca, Michelle C.; Lessing, M. Christian; Prado, Gustavo R.; Tate, Ciara C.] Emory Univ, 313 Ferst Dr, Atlanta, GA 30332 USA; [Zhou, Runzhou; Zhang, Liying] Wayne State Univ, Dept Biomed Engn, 818 W Hancock St, Detroit, MI 48201 USA; [Geddes-Klein, Donna; Meaney, David F.] Univ Penn, Dept Bioengn, 210 South 33rd St, Philadelphia, PA 19104 USA	LaPlaca, MC (corresponding author), Georgia Inst Technol, Georgia Tech & Emory, Wallace H Coulter Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA.	michelle.laplaca@bme.gatech.edu		Meaney, David/0000-0002-0954-4122	Whitaker Foundation; Institute for Bioengineering and Bioscience at the Georgia Institute of Technology	The authors appreciate the technical support received from Dr. C.M. Simon and analysis assistance from C.K. Giardina. This work was funded by the Whitaker Foundation, the Institute for Bioengineering and Bioscience at the Georgia Institute of Technology.	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Bar-Kochba E, 2016, SCI REP-UK, V6, DOI 10.1038/srep30550; Bukhatwa S, 2009, J NEUROCHEM, V109, P52, DOI 10.1111/j.1471-4159.2009.05956.x; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cho Y, 2010, J NEUROSCI RES, V88, P1433, DOI 10.1002/jnr.22309; Choo AM, 2007, J NEUROSURG-SPINE, V6, P255, DOI 10.3171/spi.2007.6.3.255; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Cooper ST, 2015, PHYSIOL REV, V95, P1205, DOI 10.1152/physrev.00037.2014; Cullen DK, 2011, J NEUROTRAUM, V28, P2219, DOI 10.1089/neu.2011.1841; DAVSON H, 1970, Brain Behavior and Evolution, V93, P665, DOI 10.1093/brain/93.4.665; De Simoni A, 2006, NAT PROTOC, V1, P1439, DOI 10.1038/nprot.2006.228; Dixit P., 2016, ARCH COMPUT METHODS, V24, P1; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Egert U, 1998, BRAIN RES PROTOC, V2, P229, DOI 10.1016/S1385-299X(98)00013-0; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Elkin BS, 2011, J NEUROTRAUM, V28, P2235, DOI 10.1089/neu.2010.1604; Elkin BS, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000164; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Hall ED., 2015, BRAIN NEUROTRAUMA MO; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Inman CF, 2005, J IMMUNOL METHODS, V302, P156, DOI 10.1016/j.jim.2005.05.005; Jin XM, 2014, NEURAL REGEN RES, V9, P1876, DOI 10.4103/1673-5374.145475; Kilinc D, 2007, P ANN INT IEEE EMBS, P5395, DOI 10.1109/IEMBS.2007.4353562; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Kilinc D, 2009, EXP NEUROL, V219, P553, DOI 10.1016/j.expneurol.2009.07.014; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Koob A. O, 2005, J NEUROTRAUMA, V22; Koob Andrew O, 2008, J Biol Eng, V2, P9, DOI 10.1186/1754-1611-2-9; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Laplaca M. C, 2012, ANIMAL MODELS ACUTE, V2, P275; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LaPlaca MC, 2009, SUSCEPTIBILITY NEURO; LaPlaca MC, 2010, J BIOMECH, V43, P71, DOI 10.1016/j.jbiomech.2009.09.011; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Luo CL, 2013, J NEUROTRAUM, V30, P597, DOI 10.1089/neu.2012.2425; Luo J, 2002, J NEUROCHEM, V83, P471, DOI 10.1046/j.1471-4159.2002.01160.x; Mao HJ, 2013, J NEUROTRAUM, V30, P1521, DOI 10.1089/neu.2012.2520; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; Mbye LH, 2012, J CEREBR BLOOD F MET, V32, P515, DOI 10.1038/jcbfm.2011.158; Murphy MA, 2016, MODEL SIMUL MATER SC, V24, DOI 10.1088/0965-0393/24/5/055008; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Ping XJ, 2014, J NEUROTRAUM, V31, P1172, DOI 10.1089/neu.2013.3147; Pischiutta F, 2018, EXP NEUROL, V300, P167, DOI 10.1016/j.expneurol.2017.11.003; Povlishock JT, 1996, ACT NEUR S, V66, P81; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RIESELBACH RE, 1962, NEW ENGL J MED, V267, P1273, DOI 10.1056/NEJM196212202672502; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Salvador E, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00323; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Serbest G, 2005, J NEUROTRAUM, V22, P119, DOI 10.1089/neu.2005.22.119; Serbest G, 2006, FASEB J, V20, P308, DOI 10.1096/fj.05-4024fje; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 2006, J NEUROPHYSIOL, V95, P3384, DOI 10.1152/jn.00350.2005; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Simon CM, 2009, J NEUROTRAUM, V26, P563, DOI 10.1089/neu.2008.0523; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Slomka N, 2012, ANN BIOMED ENG, V40, P606, DOI 10.1007/s10439-011-0423-1; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stroetz RW, 2001, J APPL PHYSIOL, V90, P2361; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Vlahakis NE, 2002, AM J RESP CRIT CARE, V166, P1282, DOI 10.1164/rccm.200203-207OC; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Yang KH, 2003, INT J VEHICLE DES, V32, P116, DOI 10.1504/IJVD.2003.003240; Zhang L, 2001, Stapp Car Crash J, V45, P369; 2006, J NEUROTRAUMA, V23, P193; 1998, BRAIN RES, V784, P1; 2006, J NEUROSCI, V26, P3130, DOI DOI 10.1523/JNEUROSCI.5119-05.2006	80	12	12	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0268-0033	1879-1271		CLIN BIOMECH	Clin. Biomech.	APR	2019	64				SI		2	13		10.1016/j.clinbiomech.2018.05.016			12	Engineering, Biomedical; Orthopedics; Sport Sciences	Engineering; Orthopedics; Sport Sciences	HY6ON	WOS:000468249700002	29933966				2021-06-18	
J	Lee, H; Mizrahi, MA; Hartings, JA; Sharma, S; Pahren, L; Ngwenya, LB; Moseley, BD; Privitera, M; Tortella, FC; Foreman, B				Lee, Hyunjo; Mizrahi, Moshe A.; Hartings, Jed A.; Sharma, Sameer; Pahren, Laura; Ngwenya, Laura B.; Moseley, Brian D.; Privitera, Michael; Tortella, Frank C.; Foreman, Brandon			Continuous Electroencephalography After Moderate to Severe Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						continuous electroencephalography; electrographic seizures; ictal-interictal continuum; neurocritical care; neurotrauma; traumatic brain injury	INTERICTAL EPILEPTIFORM DISCHARGES; GENERALIZED PERIODIC DISCHARGES; CONTINUOUS EEG; CRITICALLY-ILL; ELECTROGRAPHIC SEIZURES; NONCONVULSIVE SEIZURES; SLEEP; COMA; PATHOPHYSIOLOGY; PROGNOSIS	Objectives: After traumatic brain injury, continuous electroencephalography is widely used to detect electrographic seizures. With the development of standardized continuous electroencephalography terminology, we aimed to describe the prevalence and burden of ictal-interictal patterns, including electrographic seizures after moderate-to-severe traumatic brain injury and to correlate continuous electroencephalography features with functional outcome. Design: Post hoc analysis of the prospective, randomized controlled phase 2 multicenter INTREPID2566 study (ClinicalTrials. gov: NCT00805818). Continuous electroencephalography was initiated upon admission to the ICU. The primary outcome was the 3-month Glasgow Outcome Scale-Extended. Consensus electroencephalography reviews were performed by raters certified in standardized continuous electroencephalography terminology blinded to clinical data. Rhythmic, periodic, or ictal patterns were referred to as " ictal-interictal continuum"; severe ictal-interictal continuum was defined as greater than or equal to 1.5 Hz lateralized rhythmic delta activity or generalized periodic discharges and any lateralized periodic discharges or electrographic seizures. Setting: Twenty U.S. level I trauma centers. Patients: Patients with nonpenetrating traumatic brain injury and postresuscitation Glasgow Coma Scale score of 4-12 were included. Interventions: None. Measurements and Main Results: Among 152 patients with continuous electroencephalography (age 34 +/- 14 yr; 88% male), 22 (14%) had severe ictal-interictal continuum including electrographic seizures in four (2.6%). Severe ictal-interictal continuum burden correlated with initial prognostic scores, including the International Mission for Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury (r = 0.51; p = 0.01) and Injury Severity Score (r = 0.49; p = 0.01), but not with functional outcome. After controlling clinical covariates, unfavorable outcome was independently associated with absence of posterior dominant rhythm (common odds ratio, 3.38; 95% CI, 1.30-9.09), absence of N2 sleep transients (3.69; 1.69-8.20), predominant delta activity (2.82; 1.32-6.10), and discontinuous background (5.33; 2.28-12.96) within the first 72 hours of monitoring. Conclusions: Severe ictal-interictal continuum patterns, including electrographic seizures, were associated with clinical markers of injury severity but not functional outcome in this prospective cohort of patients with moderate-to-severe traumatic brain injury. Importantly, continuous electroencephalography background features were independently associated with functional outcome and improved the area under the curve of existing, validated predictive models.	[Lee, Hyunjo; Mizrahi, Moshe A.; Sharma, Sameer; Foreman, Brandon] Univ Cincinnati, Dept Neurol & Rehabil Med, Div Neurocrit Care, Cincinnati, OH 45221 USA; [Hartings, Jed A.; Ngwenya, Laura B.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH USA; [Hartings, Jed A.; Ngwenya, Laura B.] Univ Cincinnati, Neurotrauma Ctr, Gardner Neurosci Inst, Cincinnati, OH USA; [Pahren, Laura] Coll Engn & Appl Sci, Cincinnati, OH USA; [Ngwenya, Laura B.; Moseley, Brian D.; Privitera, Michael] Univ Cincinnati, Dept Neurol & Rehabil Med, Cincinnati, OH USA; [Tortella, Frank C.] Walter Reed Army Inst Res, Brain Trauma Neuroprotect & Neurorestorat Branch, Silver Spring, MD USA	Foreman, B (corresponding author), Univ Cincinnati, Dept Neurol & Rehabil Med, Div Neurocrit Care, Cincinnati, OH 45221 USA.	foremabo@ucmail.uc.edu		Ngwenya, Laura/0000-0001-7103-971X	U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC); Neuren Pharmaceuticals Limited; National Institute Of Neurological Disorders And Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS101123]; DODUnited States Department of Defense; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS101123] Funding Source: NIH RePORTER	The INTREPID<SUP>2566</SUP> trial was supported, in part, by grants from the U.S. Army Medical Research and Materiel Command (to Dr. Tortella) and by Neuren Pharmaceuticals Limited. Supported, in part, by the National Institute Of Neurological Disorders And Stroke of the National Institutes of Health under Award Number K23NS101123 (to Dr. Foreman). Research funding for the parent randomized controlled trial was obtained in part through the DOD by one of the study authors (to Dr. Tortella), who served as principal investigator for the parent randomized controlled trial.	Alsherbini KA, 2017, J CLIN NEUROPHYSIOL, V34, P375, DOI 10.1097/WNP.0000000000000374; Beridze M, 2010, Georgian Med News, P28; BRICOLO A, 1979, REV EEG NEUROPHYSIOL, V9, P116, DOI 10.1016/S0370-4475(79)80066-0; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Claassen J, 2014, ANN NEUROL, V75, P771, DOI 10.1002/ana.24166; Crepeau AZ, 2013, J CLIN NEUROPHYSIOL, V30, P247, DOI 10.1097/WNP.0b013e3182933d2f; Ebus S, 2012, EUR J PAEDIATR NEURO, V16, P697, DOI 10.1016/j.ejpn.2012.05.010; EVANS BM, 1995, J NEUROL NEUROSUR PS, V59, P17, DOI 10.1136/jnnp.59.1.17; Foreman B, 2012, NEUROLOGY, V79, P1951, DOI 10.1212/WNL.0b013e3182735cd7; Gaspard N, 2013, JAMA NEUROL, V70, P1288, DOI 10.1001/jamaneurol.2013.3475; GUTLING E, 1995, NEUROLOGY, V45, P915, DOI 10.1212/WNL.45.5.915; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Herman ST, 2015, J CLIN NEUROPHYSIOL, V32, P87, DOI 10.1097/WNP.0000000000000166; Hinzman JM, 2014, BRAIN, V137, P2960, DOI 10.1093/brain/awu241; Hirsch LJ, 2013, J CLIN NEUROPHYSIOL, V30, P1, DOI 10.1097/WNP.0b013e3182784729; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Husson EC, 2010, J REHABIL MED, V42, P425, DOI 10.2340/16501977-0566; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee JW, 2016, J CLIN NEUROPHYSIOL, V33, P133, DOI 10.1097/WNP.0000000000000230; Leitinger M, 2015, EPILEPSY BEHAV, V49, P158, DOI 10.1016/j.yebeh.2015.05.007; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; Lu XCM, 2009, J CEREBR BLOOD F MET, V29, P1924, DOI 10.1038/jcbfm.2009.109; Lv YD, 2013, EPILEPSY BEHAV, V29, P205, DOI 10.1016/j.yebeh.2013.07.014; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; RAEGRANT AD, 1991, ELECTROEN CLIN NEURO, V79, P349, DOI 10.1016/0013-4694(91)90199-E; Rodriguez Ruiz A, 2017, JAMA NEUROL, V74, P181, DOI DOI 10.1001/jamaneurol.2016.4990; Ronne-Engstrom E, 2006, ACTA NEUROL SCAND, V114, P47, DOI 10.1111/j.1600-0404.2006.00652.x; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P420, DOI 10.1016/0013-4694(83)90224-9; Sandsmark DK, 2016, J HEAD TRAUMA REHAB, V31, P101, DOI 10.1097/HTR.0000000000000217; Silber MH, 2007, J CLIN SLEEP MED, V3, P121; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Struck AF, 2017, JAMA NEUROL, V74, P1419, DOI 10.1001/jamaneurol.2017.2459; Struck AF, 2016, NEUROCRIT CARE, V24, P324, DOI 10.1007/s12028-016-0245-y; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; SYNEK VM, 1988, J CLIN NEUROPHYSIOL, V5, P161, DOI 10.1097/00004691-198804000-00003; Thelin EP, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00351; Valente M, 2002, CLIN NEUROPHYSIOL, V113, P1798, DOI 10.1016/S1388-2457(02)00218-3; van Putten MJAM, 2015, EPILEPSY BEHAV, V49, P228, DOI 10.1016/j.yebeh.2015.04.007; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa P, 2016, ANN NEUROL, V79, P579, DOI 10.1002/ana.24606; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Witsch J, 2017, JAMA NEUROL, V74, P299, DOI 10.1001/jamaneurol.2016.5325	46	12	12	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2019	47	4					574	582		10.1097/CCM.0000000000003639			9	Critical Care Medicine	General & Internal Medicine	IA2IZ	WOS:000469386100037	30624278	Green Accepted			2021-06-18	
J	Mccoy, DB; Dupont, SM; Gros, C; Cohen-Adad, J; Huie, RJ; Ferguson, A; Duong-Fernandez, X; Thomas, LH; Singh, V; Narvid, J; Pascual, L; Kyritsis, N; Beattie, MS; Bresnahan, JC; Dhall, S; Whetstone, W; Talbott, JF				Mccoy, D. B.; Dupont, S. M.; Gros, C.; Cohen-Adad, J.; Huie, R. J.; Ferguson, A.; Duong-Fernandez, X.; Thomas, L. H.; Singh, V; Narvid, J.; Pascual, L.; Kyritsis, N.; Beattie, M. S.; Bresnahan, J. C.; Dhall, S.; Whetstone, W.; Talbott, J. F.		TRACK-SCI Investigators	Convolutional Neural Network-Based Automated Segmentation of the Spinal Cord and Contusion Injury: Deep Learning Biomarker Correlates of Motor Impairment in Acute Spinal Cord Injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							CLINICAL-PRACTICE GUIDELINE; RECOMMENDATIONS; MANAGEMENT; OUTCOMES; IMPACT; ROBUST	BACKGROUND AND PURPOSE: Our aim was to use 2D convolutional neural networks for automatic segmentation of the spinal cord and traumatic contusion injury from axial T2-weighted MR imaging in a cohort of patients with acute spinal cord injury. MATERIALS AND METHODS: Forty-seven patients who underwent 3T MR imaging within 24 hours of spinal cord injury were included. We developed an image-analysis pipeline integrating 2D convolutional neural networks for whole spinal cord and intramedullary spinal cord lesion segmentation. Linear mixed modeling was used to compare test segmentation results between our spinal cord injury convolutional neural network (Brain and Spinal Cord Injury Center segmentation) and current state-of-the-art methods. Volumes of segmented lesions were then used in a linear regression analysis to determine associations with motor scores. RESULTS: Compared with manual labeling, the average test set Dice coefficient for the Brain and Spinal Cord Injury Center segmentation model was 0.93 for spinal cord segmentation versus 0.80 for PropSeg and 0.90 for DeepSeg (both components of the Spinal Cord Toolbox). Linear mixed modeling showed a significant difference between Brain and Spinal Cord Injury Center segmentation compared with PropSeg (P < .001) and DeepSeg (P < .05). Brain and Spinal Cord Injury Center segmentation showed significantly better adaptability to damaged areas compared with PropSeg (P < .001) and DeepSeg (P < .02). The contusion injury volumes based on automated segmentation were significantly associated with motor scores at admission (P = .002) and discharge (P = .009). CONCLUSIONS: Brain and Spinal Cord Injury Center segmentation of the spinal cord compares favorably with available segmentation tools in a population with acute spinal cord injury. Volumes of injury derived from automated lesion segmentation with Brain and Spinal Cord Injury Center segmentation correlate with measures of motor impairment in the acute phase. Targeted convolutional neural network training in acute spinal cord injury enhances algorithm performance for this patient population and provides clinically relevant metrics of cord injury.	[Mccoy, D. B.; Dupont, S. M.; Narvid, J.; Talbott, J. F.] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [Huie, R. J.; Ferguson, A.; Duong-Fernandez, X.; Thomas, L. H.; Kyritsis, N.; Beattie, M. S.; Bresnahan, J. C.; Dhall, S.; Whetstone, W.; Talbott, J. F.] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Dept Neurol Surg, San Francisco, CA 94143 USA; [Mccoy, D. B.; Huie, R. J.; Ferguson, A.; Duong-Fernandez, X.; Thomas, L. H.; Kyritsis, N.; Beattie, M. S.; Bresnahan, J. C.; Dhall, S.; Whetstone, W.] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Singh, V] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Dept Neurol, San Francisco, CA 94143 USA; [Pascual, L.] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Dept Orthoped Surg, San Francisco, CA 94143 USA; [Gros, C.; Cohen-Adad, J.] Polytech Montreal, NeuroPoly Lab, Inst Biomed Engn, Montreal, PQ, Canada	Talbott, JF (corresponding author), Zuckerberg San Francisco Gen Hosp, 1001 Potrero Ave,Room 1X57C, San Francisco, CA 94110 USA.	jason.talbott@ucsf.edu	Kyritsis, Nikos/AAD-5187-2021	Kyritsis, Nikos/0000-0001-7801-5796; Duong Fernandez, Xuan/0000-0001-8362-4166; Ferguson, Adam/0000-0001-7102-1608; Huie, J. Russell/0000-0001-5594-4277; Thomas, Leigh/0000-0002-7593-0240; singh, vineeta/0000-0003-3470-3532	Craig H. Neilsen Foundation; Department of DefenseUnited States Department of Defense [SC120259]	This work was supported by the Craig H. Neilsen Foundation and the Department of Defense grant SC120259.	Ahuja CS, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.18; Bozzo A, 2011, J NEUROTRAUM, V28, P1401, DOI 10.1089/neu.2009.1236; Burns Anthony S, 2012, Handb Clin Neurol, V109, P47, DOI 10.1016/B978-0-444-52137-8.00003-6; De Leener B, 2017, NEUROIMAGE, V145, P24, DOI 10.1016/j.neuroimage.2016.10.009; De Leener B, 2015, IEEE T MED IMAGING, V34, P1705, DOI 10.1109/TMI.2015.2437192; De Leener B, 2014, NEUROIMAGE, V98, P528, DOI 10.1016/j.neuroimage.2014.04.051; DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409; Elizei SS, 2017, NEURAL REGEN RES, V12, P385, DOI 10.4103/1673-5374.202933; Farhadi HF, 2018, J NEUROTRAUM, V35, P1398, DOI 10.1089/neu.2017.5510; Fehlings MG, 2017, GLOB SPINE J, V7, p195S, DOI 10.1177/2192568217706367; Fehlings MG, 2017, GLOB SPINE J, V7, p221S, DOI 10.1177/2192568217703089; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; Fonov VS, 2014, NEUROIMAGE, V102, P817, DOI 10.1016/j.neuroimage.2014.08.057; Gillies RJ, 2016, RADIOLOGY, V278, P563, DOI 10.1148/radiol.2015151169; Gros C, 2019, NEUROIMAGE, V184, P901, DOI 10.1016/j.neuroimage.2018.09.081; Gros C, 2018, MED IMAGE ANAL, V44, P215, DOI 10.1016/j.media.2017.12.001; Haefeli J, 2017, AM J NEURORADIOL, V38, P648, DOI 10.3174/ajnr.A5021; Ioffe S., 2015, INT C INT C MACH LEA, P448; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Kinga D, 2015, P INT C LEARN REPR S; Kurpad S, 2017, GLOB SPINE J, V7, p151S, DOI 10.1177/2192568217703666; Martin AR, 2017, AM J NEURORADIOL, V38, P1257, DOI 10.3174/ajnr.A5163; Martin AR, 2016, NEUROIMAGE-CLIN, V10, P192, DOI 10.1016/j.nicl.2015.11.019; McCoy D, 2018, P INT SOC MAGN RES M; McCoy DB, 2017, AM J NEURORADIOL, V38, P410, DOI 10.3174/ajnr.A5044; Nair V., 2010, P 27 INT C INT C MAC, P807, DOI DOI 10.0RG/PAPERS/432.PDF; Pandit P, 2016, J ORTHOP RES, V34, P1373, DOI 10.1002/jor.23311; R Core Team, 2013, R LANG ENV STAT COMP; Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28; Shah LM, 2016, NEUROSURGERY, V79, P626, DOI 10.1227/NEU.0000000000001336; Srivastava N, 2014, J MACH LEARN RES, V15, P1929; Sukhbaatar S., 2014, TRAINING CONVOLUTION; Talekar K, 2016, SEMIN ULTRASOUND CT, V37, P431, DOI 10.1053/j.sult.2016.05.007; Zou KH, 2004, ACAD RADIOL, V11, P178, DOI 10.1016/S1076-6332(03)00671-8	34	12	12	2	7	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	APR	2019	40	4					737	744		10.3174/ajnr.A6020			8	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	HY6ZO	WOS:000468280300028	30923086	Green Published, Other Gold			2021-06-18	
J	Tominaga, T; Shimada, R; Okada, Y; Kawamata, T; Kibayashi, K				Tominaga, Tadasuke; Shimada, Ryo; Okada, Yoshikazu; Kawamata, Takakazu; Kibayashi, Kazuhiko			Senescence-associated-beta-galactosidase staining following traumatic brain injury in the mouse cerebrum	PLOS ONE			English	Article							CELLULAR SENESCENCE; CYCLIN D1; EXPRESSION; INHIBITOR; INDUCTION; APOPTOSIS; CELLS; P16	Primary and secondary traumatic brain injury (TBI) can cause tissue damage by inducing cell death pathways including apoptosis, necroptosis, and autophagy. However, similar pathways can also lead to senescence. Senescent cells secrete senescence-associated secretory phenotype proteins following persistent DNA damage response signaling, leading to cell disorders. TBI initially activates the cell cycle followed by the subsequent triggering of senescence. This study aims to clarify how the mRNA and protein expression of different markers of cell cycle and senescence are modulated and switched over time after TBI. We performed senescence-associated-beta-galactosidase (SA-beta-gal) staining, immunohistochemical analysis, and real-time PCR to examine the time-dependent changes in expression levels of proteins and mRNA, related to cell cycle and cellular senescence markers, in the cerebrum during the initial 14 days after TBI using a mouse model of controlled cortical impact (CCI). Within the area adjacent to the cerebral contusion after TBI, the protein and/or mRNA expression levels of cell cycle markers were increased significantly until 4 days after injury and senescence markers were significantly increased at 4, 7, and 14 days after injury. Our findings suggested that TBI initially activated the cell cycle in neurons, astrocytes, and microglia within the area adjacent to the hemicerebrum contusion in TBI, whereas after 4 days, such cells could undergo senescence in a cell-type-dependent manner.	[Tominaga, Tadasuke; Kawamata, Takakazu] Tokyo Womens Med Univ, Sch Med, Dept Neurosurg, Tokyo, Japan; [Shimada, Ryo; Kibayashi, Kazuhiko] Tokyo Womens Med Univ, Sch Med, Dept Legal Med, Tokyo, Japan; [Okada, Yoshikazu] St Lukes Int Hosp, Dept Neurosurg, Tokyo, Japan	Shimada, R (corresponding author), Tokyo Womens Med Univ, Sch Med, Dept Legal Med, Tokyo, Japan.	r_shimada@twmu.ac.jp	Kazuhiko, Kibayashi/F-5173-2013	Kazuhiko, Kibayashi/0000-0001-6510-5215	Japan Society for the Promotion of Science KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP16K09220]	This work was supported by the Japan Society for the Promotion of Science KAKENHI, Grant Number JP16K09220. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelalim EM, 2012, BIOCHEM BIOPH RES CO, V420, P605, DOI 10.1016/j.bbrc.2012.03.041; Abe K, 2016, NEUROL RES, V38, P358, DOI 10.1080/01616412.2015.1110402; Byrnes KR, 2007, NEUROCHEM RES, V32, P1799, DOI 10.1007/s11064-007-9312-2; Cao X, 2015, GENOM PROTEOM BIOINF, V13, P333, DOI 10.1016/j.gpb.2015.11.002; Childs BG, 2014, EMBO REP, V15, P1139, DOI 10.15252/embr.201439245; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Delou JMA, 2016, AN ACAD BRAS CIENC, V88, P2257, DOI 10.1590/0001-3765201620160127; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ding Y, 2016, INT J BIOCHEM CELL B, V71, P72, DOI 10.1016/j.biocel.2015.12.010; Herrup K, 2007, NAT REV NEUROSCI, V8, P368, DOI 10.1038/nrn2124; Hwang CY, 2012, BIOCHEM BIOPH RES CO, V425, P94, DOI 10.1016/j.bbrc.2012.07.059; Ishikawa K, 2015, FEBS J, V282, P2540, DOI 10.1111/febs.13298; Johmura Y, 2014, MOL CELL, V55, P73, DOI 10.1016/j.molcel.2014.05.003; Juers DH, 2012, PROTEIN SCI, V21, P1792, DOI 10.1002/pro.2165; Kabadi SV, 2012, J NEUROTRAUM, V29, P813, DOI 10.1089/neu.2011.1980; Katano H, 2000, NEUROREPORT, V11, P2073, DOI 10.1097/00001756-200007140-00003; Kawai S, 2011, EXP ANIM TOKYO, V60, P481, DOI 10.1538/expanim.60.481; Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371; Kochanek PM, 2001, J NEUROTRAUM, V18, P73, DOI 10.1089/089771501750055785; Kozlova EN, 2002, GLIA, V37, P337, DOI 10.1002/glia.10045; Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Ohtani N., 2015, J CLIN EXPT MED, V253, P753; Rayess H, 2012, INT J CANCER, V130, P1715, DOI 10.1002/ijc.27316; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Romanov VS, 2012, BIOCHEMISTRY-MOSCOW+, V77, P575, DOI 10.1134/S000629791206003X; Ruas M, 2007, MOL CELL BIOL, V27, P4273, DOI 10.1128/MCB.02286-06; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Schober ME, 2010, J NEUROTRAUM, V27, P2011, DOI 10.1089/neu.2009.1226; Shimada R, 2017, LEGAL MED-TOKYO, V29, P29, DOI 10.1016/j.legalmed.2017.09.004; Shimada R, 2014, NEUROL RES, V36, P239, DOI 10.1179/1743132813Y.0000000289; Shimada R, 2012, J CLIN NEUROSCI, V19, P447, DOI 10.1016/j.jocn.2011.06.033; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Stoica BA, 2009, NEUROTOX RES, V16, P221, DOI 10.1007/s12640-009-9050-0; Strzalka W, 2011, ANN BOT-LONDON, V107, P1127, DOI 10.1093/aob/mcq243; Timaru-Kast R, 2015, J NEUROTRAUM, V32, P1777, DOI 10.1089/neu.2014.3784; Tsukamoto A, 2015, EXP ANIM TOKYO, V64, P57, DOI 10.1538/expanim.14-0050; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029	38	12	12	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2019	14	3							e0213673	10.1371/journal.pone.0213673			17	Multidisciplinary Sciences	Science & Technology - Other Topics	HO6HL	WOS:000461030300058	30856215	DOAJ Gold, Green Published			2021-06-18	
J	Liao, RJ; Chen, YC; Cheng, L; Fan, LS; Chen, H; Wan, YS; You, Y; Zheng, YR; Jiang, L; Chen, Z; Zhang, X; Hu, WW				Liao, Rujia; Chen, Youchao; Cheng, Li; Fan, Lishi; Chen, Han; Wan, Yushan; You, Yi; Zheng, Yanrong; Jiang, Lei; Chen, Zhong; Zhang, Xiangnan; Hu, Weiwei			Histamine H1 Receptors in Neural Stem Cells Are Required for the Promotion of Neurogenesis Conferred by H3 Receptor Antagonism following Traumatic Brain Injury	STEM CELL REPORTS			English	Article							HIPPOCAMPAL NEUROGENESIS; CLINICAL-TRIALS; MEMORY; NEUROPROTECTION; CLOBENPROPIT; ISCHEMIA; NEURONS; SYSTEM; MODEL	The neurological recovery following traumatic brain injury (TBI) is limited, largely due to a deficiency in neurogenesis. The present study explores the effects of histamine H3 receptor (H3R) antagonism on TBI and mechanisms related to neurogenesis. H3R antagonism or H3R gene knockout alleviated neurological injury in the late phase of TBI, and also promoted neuroblast differentiation to enhance neurogenesis through activation of the histaminergic system. Histamine H1 receptor, but not H2 receptor, in neural stem cells is shown to be essential for this promotion by using Hrh1(fl/fl);Nestin(CreERT2) and Hrh2(fl/fl);Nestin(CreERT2) mice. Moreover, increase in mature and functional neurons at the penumbra area conferred by H3R antagonism was abrogated in Hrh1(fl/fl);Nestin(CreERT2) mice. Taken together, H3R antagonism provides neuroprotection against TBI in the late phase through the promotion of neurogenesis, and the H1 receptor in neural stem cells is required for this action. H3R may serve as a new target for clinical treatment of TBI.	[Liao, Rujia; Chen, Youchao; Cheng, Li; Fan, Lishi; Chen, Han; Wan, Yushan; You, Yi; Zheng, Yanrong; Jiang, Lei; Chen, Zhong; Zhang, Xiangnan; Hu, Weiwei] Zhejiang Univ, Coll Pharmaceut Sci, Sch Basic Med Sci, NHC & CAMS Key Lab Med Neurobiol,Dept Pharmacol, Hangzhou 310058, Zhejiang, Peoples R China; [Hu, Weiwei] Zhejiang Univ, Pharm Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China	Zhang, X; Hu, WW (corresponding author), Zhejiang Univ, Coll Pharmaceut Sci, Sch Basic Med Sci, NHC & CAMS Key Lab Med Neurobiol,Dept Pharmacol, Hangzhou 310058, Zhejiang, Peoples R China.; Hu, WW (corresponding author), Zhejiang Univ, Pharm Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China.	xiangnan_zhang@zju.edu.cn; huww@zju.edu.cn		liao, ru-jia/0000-0001-6928-4003	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81473186, 81673405, 81722045]; Zhejiang Provincial Natural Science Foundation of ChinaNatural Science Foundation of Zhejiang Province [LR17H310001, LY18H310003]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [2018XZZX002-13]; Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences [2017PT31038, 2018PT31041]	This work was supported by the National Natural Science Foundation of China (81473186, 81673405, 81722045), the Zhejiang Provincial Natural Science Foundation of China under grants LR17H310001 and LY18H310003, Fundamental Research Funds for the Central Universities (2018XZZX002-13), and the Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences (2017PT31038 and 2018PT31041). We are very grateful to Dr. John Hugh Snyder for language editing.	Arruda-Carvalho M, 2014, J NEUROSCI, V34, P11919, DOI 10.1523/JNEUROSCI.0652-14.2014; Bernardino L, 2012, STEM CELLS, V30, P773, DOI 10.1002/stem.1042; Blaya MO, 2015, EXP NEUROL, V264, P67, DOI 10.1016/j.expneurol.2014.11.014; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Campbell M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1852; Chen ZH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5486; Escobedo-Avila I, 2014, MOL BRAIN, V7, DOI 10.1186/s13041-014-0058-x; Giachino C, 2014, DEVELOPMENT, V141, P83, DOI 10.1242/dev.102608; Glushakov AV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113689; Guo ZY, 2014, CELL STEM CELL, V14, P188, DOI 10.1016/j.stem.2013.12.001; Haas H, 2003, NAT REV NEUROSCI, V4, P121, DOI 10.1038/nrn1034; Hagg T, 2005, TRENDS NEUROSCI, V28, P589, DOI 10.1016/j.tins.2005.08.009; Hallbergson AF, 2003, J CLIN INVEST, V112, P1128, DOI 10.1172/JCI200320098; Hesp ZC, 2015, J NEUROSCI, V35, P1274, DOI 10.1523/JNEUROSCI.2568-14.2015; Hu WW, 2012, ACS CHEM NEUROSCI, V3, P238, DOI 10.1021/cn200126p; Hu WW, 2017, PHARMACOL THERAPEUT, V175, P116, DOI 10.1016/j.pharmthera.2017.02.039; Huang YW, 2004, BEHAV BRAIN RES, V151, P287, DOI 10.1016/j.bbr.2003.09.002; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; Kee N, 2007, NAT NEUROSCI, V10, P355, DOI 10.1038/nn1847; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Li HD, 2016, NEURON, V91, P728, DOI 10.1016/j.neuron.2016.08.004; Liao RJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep15356; Liu LY, 2007, HIPPOCAMPUS, V17, P634, DOI 10.1002/hipo.20305; Molina-Hernandez A, 2008, J NEUROCHEM, V106, P706, DOI 10.1111/j.1471-4159.2008.05424.x; Niu WZ, 2013, NAT CELL BIOL, V15, P1164, DOI 10.1038/ncb2843; Ohira K, 2010, NAT NEUROSCI, V13, P173, DOI 10.1038/nn.2473; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Provensi G, 2014, P NATL ACAD SCI USA, V111, P11527, DOI 10.1073/pnas.1322016111; Rodriguez-Martinez G, 2012, NEUROSCIENCE, V216, P10, DOI 10.1016/j.neuroscience.2012.04.049; Sabirzhanov B, 2016, CELL DEATH DIFFER, V23, P654, DOI 10.1038/cdd.2015.132; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Schwartz JC, 2011, BRIT J PHARMACOL, V163, P713, DOI 10.1111/j.1476-5381.2011.01286.x; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Trounson A, 2015, CELL STEM CELL, V17, P11, DOI 10.1016/j.stem.2015.06.007; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Yan HJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4334; Zhang L, 2003, EUR J PHARMACOL, V482, P169, DOI 10.1016/j.ejphar.2003.09.066; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	40	12	13	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	2213-6711			STEM CELL REP	Stem Cell Rep.	MAR 5	2019	12	3					532	544		10.1016/j.stemcr.2019.01.004			13	Cell & Tissue Engineering; Cell Biology	Cell Biology	HN7XX	WOS:000460407800009	30745032	DOAJ Gold, Green Published			2021-06-18	
J	Haarbauer-Krupa, J; King, TZ; Wise, J; Gillam, S; Trapani, J; Weissman, B; DePompei, R				Haarbauer-Krupa, Juliet; King, Tricia Z.; Wise, Justin; Gillam, Schauna; Trapani, Julie; Weissman, Barbara; DePompei, Roberta			Early Elementary School Outcome in Children With a History of Traumatic Brain Injury Before Age 6 Years	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						outcomes; pediatrics; preschool children; TBI; traumatic brain injury	YOUNG-CHILDREN; RISK-FACTORS; HEAD-INJURY; CHILDHOOD; TERM; IMPACT; VULNERABILITY; ADOLESCENTS; PREDICTORS; SEVERITY	Objective: To describe elementary school outcomes for children who experienced a traumatic brain injury (TBI) before age 6 years compared with a control group of children with orthopedic injuries. Participants: Children ages 6 to 9 years recruited from community and trauma registries in a large southeastern state. Design: Descriptive findings from the first year of a 3-year longitudinal study. Main Measures: Child assessment and parent report measures were administered to capture cognitive, language, reading, and behavior outcomes. Medical record review confirmed injuries and injury severity. Results: The TBI group (n = 39) had a mean age of 7.55 years (standard deviation = 1.29) and was 5.15 (standard deviation = 1.56) years postinjury. The TBI group had primarily classified as mild complicated TBI (63%). On average, children in both groups performed within normal limits on most cognitive, language, and reading measures. Group differences were identified in verbal IQ, receptive language, and reading comprehension, with robust performance differences in pragmatic language, story retell and word fluency, and parent report of executive functions. Conclusions: Findings indicate the importance of in-depth follow-up specialist assessments (eg, neuropsychologist and speech and language pathologists) to identify potential nuanced difficulties in children with mild complicated TBI that may be missed by general evaluations.	[Haarbauer-Krupa, Juliet; Weissman, Barbara] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; [Weissman, Barbara] Emory Univ, Sch Med, Childrens Ctr Neurosci Res Georgia, Atlanta, GA USA; [Haarbauer-Krupa, Juliet; Gillam, Schauna; Trapani, Julie; Weissman, Barbara] Childrens Healthcare Atlanta, Atlanta, GA USA; [King, Tricia Z.] Georgia State Univ, Dept Psychol, Univ Plaza, Atlanta, GA 30303 USA; [King, Tricia Z.] Georgia State Univ, Neurosci Inst, Atlanta, GA 30303 USA; [Wise, Justin] Oglethorpe Univ, Dept Psychol, Atlanta, GA USA; [DePompei, Roberta] Univ Akron, Sch Speech Language Pathol, Akron, OH 44325 USA	Haarbauer-Krupa, J (corresponding author), Emory Univ, Sch Med, Dept Pediat, 3172 Wicks Creek Trail, Marietta, GA 30062 USA.	jhkrupa@me.com			National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services [H133G110109]	This study is sponsored by a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research (Formerly the National Institute National Institute on Disability and Rehabilitation Research), grant number H133G110109.	ABUAREFEH I, 1994, BRIT MED J, V309, P765, DOI 10.1136/bmj.309.6957.765; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson V, 2010, J PEDIATR PSYCHOL, V35, P716, DOI 10.1093/jpepsy/jsp100; Arroyos-Jurado E, 2000, J SCHOOL PSYCHOL, V38, P571, DOI 10.1016/S0022-4405(00)00053-4; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Bennett TD, 2013, ARCH PHYS MED REHAB, V94, P1268, DOI 10.1016/j.apmr.2013.02.021; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Brownell R., 2000, EXPRESSIVE ONE WORD, V3rd; Carrow-Woolfolk E., 1999, COMPREHENSIVE ASSESS; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Catroppa C, 2009, FUTUR NEUROL, V4, P811, DOI 10.2217/FNL.09.52; Catts H W, 2000, Logoped Phoniatr Vocol, V25, P3, DOI 10.1080/140154300750045858; Clark E, 1997, CHILDHOOD TRAUMATIC, P342; Crowe C, 2015, HDB CLIN NEUROLOGY, V128; Crowe LM, 2014, J HEAD TRAUMA REHAB, V29, P217, DOI 10.1097/HTR.0b013e31829babfd; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P88; DePompei R, 2003, COMMUNICATION COMMUN; Dunn L., 1981, PEABODY PICTURE VOCA; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 2003, DEV NEUROPSYCHOL, V24, P669, DOI 10.1207/S15326942DN242&3_08; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fuentes M, 2017, PM&R, V9, pS176; Gagner C, 2015, J NEUROTRAUM, V32, P1539, DOI 10.1089/neu.2014.3753; Gioia GA, 2000, BEHAV RATING SCALE E; Gioia GA, 2010, J HEAD TRAUMA REHAB, V25, P433, DOI 10.1097/HTR.0b013e3181fbc272; Greenham M, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00022; Gronwall D, 1997, J INT NEUROPSYCH SOC, V6, P592; Haarbauer-Krupa J, 1984, HEAD INJURY REHABILI, P311; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Hotz G, 2010, PEDIAT TEST BRAIN IN; Hux K, 2013, BRAIN INJURY, V27, P1348, DOI 10.3109/02699052.2013.823657; Kacperski J, 2016, SEMIN PEDIATR NEUROL, V23, P27, DOI 10.1016/j.spen.2015.08.005; Kaufman AS, 1990, KAUFMAN BRIEF TEST I; Kehle T, 1997, CHILDHOOD TRAUMATIC, P342; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Lowenthal B., 1998, TRANSDISCIPLINARY J, V8, P377; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; Prasad MR, 2017, J HEAD TRAUMA REHAB, V32, pE24, DOI 10.1097/HTR.0000000000000218; Rivara FP, 2012, ARCH PHYS MED REHAB, V93, P1371, DOI 10.1016/j.apmr.2012.02.031; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Savage RC, 1995, PERSPECT NETW, pV; Schell A, 2016, OTOLARYNG HEAD NECK, V154, P175, DOI 10.1177/0194599815609114; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Shay N, 2014, J NEUROTRAUM, V31, P1305, DOI 10.1089/neu.2013.3275; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; Taylor HG, 2015, J HEAD TRAUMA REHAB, V4, P1; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; Tonks J, 2009, DEV MED CHILD NEUROL, V51, P8, DOI 10.1111/j.1469-8749.2008.03219.x; Treble-Barna A., 2016, J NEUROTRAUM, V33, P1; Treble-Barna A, 2017, NEUROPSYCHOLOGY, V31, P486, DOI 10.1037/neu0000325; Wade SL, 2016, JAMA PEDIATR, V170, P343, DOI 10.1001/jamapediatrics.2015.4485; Wilde EA, 2012, MILD TRAUMATIC BRAIN, P3; Woodstock RW, 1987, WOODSTOCK READING MA; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	63	12	12	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2019	34	2			SI		111	121		10.1097/HTR.0000000000000414			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	HU9CK	WOS:000465590400014	30045217				2021-06-18	
J	Olby, NJ; Lim, JH; Wagner, N; Zidan, N; Early, PJ; Mariani, CL; Munana, KR; Laber, E				Olby, Natasha J.; Lim, Ji-Hey; Wagner, Nikki; Zidan, Natalia; Early, Peter J.; Mariani, Christopher L.; Munana, Karen R.; Laber, Eric			Time course and prognostic value of serum GFAP, pNFH, and S100 beta concentrations in dogs with complete spinal cord injury because of intervertebral disc extrusion	JOURNAL OF VETERINARY INTERNAL MEDICINE			English	Article						biomarker; intervertebral disc disease; myelomalacia; prognosis	TRAUMATIC BRAIN-INJURY; FLUID INFLAMMATORY CYTOKINES; SUBUNIT NF-H; CEREBROSPINAL-FLUID; STRUCTURAL BIOMARKERS; PAIN PERCEPTION; PROTEIN; SEVERITY; RECOVERY; ASSOCIATION	Background: A noninvasive biomarker is needed to predict recovery from severe spinal cord injury (SCI) because of thoracolumbar intervertebral disc extrusion (TL-IVDE). Proteins released from neural and glial cells can be detected in the blood and show promise as prognostic tools, but their concentration is influenced by time after injury. Hypothesis/Objectives: Serum concentrations of glial fibrillary acidic protein (GFAP), phosphorylated neurofilament heavy chain (pNFH), and S100 beta will follow different time courses; measurement of combinations of these proteins will predict outcome. Animals: Thirty-one dogs with TL-IVDE causing paralysis with no pain perception. Methods: Prospective study. Serum samples were taken at presentation and intervals over 56 days and banked at -80 degrees C. Glial fibrillary acidic protein, pNFH, and 5100 beta concentrations were measured using ELISA tests and plotted against time from onset of nonambulatory status. Outcome was established at 6 months. The association between biomarker concentration and outcome was examined using logistic regression, receiver operator characteristics curve analysis, and model development. Results: Thirty-one dogs participated, 3/31 (10%) developed progressive myelomalacia and 19/31 (62%) recovered ambulation. Glial fibrillary acidic protein and S100 beta concentrations rose for the first 1 to 3 days, and were undetectable by 14 and 28 days, respectively. Phosphorylated neurofilament heavy chain concentrations peaked at 14 days and were detectable at 56 days. Glial fibrillary acidic protein concentrations in the first 72 hours after onset of nonambulatory status predicted recovery with an accuracy of 76.7%-89% depending on sample timing. Conclusions and Clinical Importance: Serum GFAP concentrations can be used to predict outcome in clinically complete SCI. A rapid inexpensive bedside test is needed.	[Olby, Natasha J.; Zidan, Natalia; Early, Peter J.; Mariani, Christopher L.; Munana, Karen R.] North Carolina State Univ, Coll Vet Med, Dept Clin Sci, 1060 William Moore Dr, Raleigh, NC 27607 USA; [Olby, Natasha J.; Zidan, Natalia; Early, Peter J.; Mariani, Christopher L.; Munana, Karen R.] North Carolina State Univ, Comparat Med Inst, Raleigh, NC 27695 USA; [Lim, Ji-Hey] Univ Missouri, Coll Vet Med, Dept Vet Med & Surg, Columbia, MO 65211 USA; [Wagner, Nikki] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27515 USA; [Laber, Eric] North Carolina State Univ, Dept Stat, Raleigh, NC 27695 USA	Olby, NJ (corresponding author), North Carolina State Univ, Coll Vet Med, Dept Clin Sci, 1060 William Moore Dr, Raleigh, NC 27607 USA.	njolby@ncsu.edu		Olby, Natasha/0000-0003-1349-3484; Munana, Karen/0000-0001-9592-6276	Congressionally Directed Medical Research ProgramsUnited States Department of Defense [W81XWH-11-1-0772]; Assisi Animal Health; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P01CA142538] Funding Source: NIH RePORTER	Assisi Animal Health; Congressionally Directed Medical Research Programs, Grant/Award Number: W81XWH-11-1-0772	Aikawa T, 2014, VET SURG, V43, P301, DOI 10.1111/j.1532-950X.2014.12102.x; Aikawa T, 2012, JAVMA-J AM VET MED A, V241, P1617, DOI 10.2460/javma.241.12.1617; Chamisha Y, 2015, RES VET SCI, V100, P189, DOI 10.1016/j.rvsc.2015.03.017; De Risio L, 2008, JAVMA-J AM VET MED A, V233, P129, DOI 10.2460/javma.233.1.129; Ferreira AJA, 2002, J SMALL ANIM PRACT, V43, P158, DOI 10.1111/j.1748-5827.2002.tb00049.x; Guez M, 2003, J NEUROTRAUM, V20, P853, DOI 10.1089/089771503322385782; Hastie T, 2009, ELEMENTS STAT LEARNI, P389; Hayakawa K, 2012, SPINAL CORD, V50, P493, DOI 10.1038/sc.2011.184; Ito D, 2005, JAVMA-J AM VET MED A, V227, P1454, DOI 10.2460/javma.2005.227.1454; Jeffery ND, 2013, J VET INTERN MED, V27, P1318, DOI 10.1111/jvim.12183; Jeffery ND, 2016, JAVMA-J AM VET MED A, V248, P386, DOI 10.2460/javma.248.4.386; Kuhle J, 2015, J NEUROL NEUROSUR PS, V86, P273, DOI 10.1136/jnnp-2013-307454; Kwon BK, 2011, CLIN CHEM LAB MED, V49, P425, DOI 10.1515/CCLM.2011.068; Kwon BK, 2010, J NEUROTRAUM, V27, P669, DOI 10.1089/neu.2009.1080; Levine GJ, 2010, J VET INTERN MED, V24, P890, DOI 10.1111/j.1939-1676.2010.0531.x; Levine JM, 2009, J VET INTERN MED, V23, P1220, DOI 10.1111/j.1939-1676.2009.0393.x; Lewis MJ, 2018, J NEUROTRAUM, V35, P500, DOI 10.1089/neu.2017.5255; Lewis MJ, 2017, J NEUROTRAUM, V34, P2994, DOI 10.1089/neu.2017.5012; Ma JJ, 2001, SCAND J PLAST RECONS, V35, P355; McMahill BG, 2015, STEM CELL REV REP, V11, P180, DOI 10.1007/s12015-014-9553-9; Mercier E, 2013, BMJ-BRIT MED J, V346, P1757; Mercier E, 2018, J NEUROTRAUM, V35, P609, DOI 10.1089/neu.2017.5013; Moore SA, 2017, J NEUROTRAUM, V34, P2007, DOI 10.1089/neu.2016.4745; Nishida H, 2014, VET CLIN N AM-SMALL, V44, P1187, DOI 10.1016/j.cvsm.2014.07.014; Nishida H, 2014, VET SURG, V43, P289, DOI 10.1111/j.1532-950X.2014.12144.x; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Olby N, 2004, J NEUROTRAUM, V21, P49, DOI 10.1089/089771504772695940; Olby N, 2003, J AM VET MED ASSOC, V222, P762, DOI 10.2460/javma.2003.222.762; Olby NJ, 1999, J NEUROTRAUM, V16, P1215, DOI 10.1089/neu.1999.16.1215; Oris C, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2018-0037; Papa L, 2015, J NEUROTRAUM, V32, P661, DOI 10.1089/neu.2014.3655; Pouw MH, 2014, SPINAL CORD, V52, P428, DOI 10.1038/sc.2014.26; Ripley B.D., 2007, PATTERN RECOGN; Rodrigues LF, 2018, MOL NEUROBIOL, V12, P1; Roerig A, 2013, VET J, V197, P253, DOI 10.1016/j.tvjl.2013.02.005; Sato Y, 2013, J VET MED SCI, V75, P949, DOI 10.1292/jvms.12-0483; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Singh Ajai, 2017, Int J Crit Illn Inj Sci, V7, P212, DOI 10.4103/IJCIIS.IJCIIS_73_16; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; Taylor AR, 2014, J NEUROTRAUM, V31, P1561, DOI 10.1089/neu.2014.3405; Thelin EP, 2017, ACTA NEUROCHIR, V159, P1; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wolf H, 2014, SPINE J, V14, P2918, DOI 10.1016/j.spinee.2014.04.027; Yang Z, 2018, MOL NEUROBIOL, V55, P1; Yokobori S, 2015, WORLD NEUROSURG, V83, P867, DOI 10.1016/j.wneu.2013.03.012	45	12	13	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0891-6640	1939-1676		J VET INTERN MED	J. Vet. Intern. Med.	MAR-APR	2019	33	2					726	734		10.1111/jvim.15439			9	Veterinary Sciences	Veterinary Sciences	HS4MR	WOS:000463838000045	30758078	DOAJ Gold, Green Published			2021-06-18	
J	Vazquez-Rosa, E; Watson, MR; Sahn, JJ; Hodges, TR; Schroeder, RE; Cintron-Perez, CJ; Shin, MK; Yin, TC; Emery, JL; Martin, SF; Liebl, DJ; Pieper, AA				Vazquez-Rosa, Edwin; Watson, Michael R.; Sahn, James J.; Hodges, Timothy R.; Schroeder, Rachel E.; Cintron-Perez, Coral J.; Shin, Min-Kyoo; Yin, Terry C.; Emery, Josie L.; Martin, Stephen F.; Liebl, Daniel J.; Pieper, Andrew A.			Neuroprotective Efficacy of a Sigma 2 Receptor/TMEM97 Modulator (DKR-1677) after Traumatic Brain Injury	ACS CHEMICAL NEUROSCIENCE			English	Article						Neuroprotection; traumatic brain injury; blast injury; controlled cortical impact injury; sigma 2R/TMEM97	IDENTIFICATION; INCREASES; PROTEIN; DEATH	Compounds targeting the sigma 2 receptor, which we recently cloned and showed to be identical with transmembrane protein 97 (sigma 2R/TMEM97), are broadly applicable therapeutic agents currently in clinical trials for imaging in breast cancer and for treatment of Alzheimers disease and schizophrenia. These promising applications coupled with our previous observation that the sigma 2R/TMEM97 modulator SAS-0132 has neuroprotective attributes and improves cognition in wild-type mice suggests that modulating sigma 2R/TMEM97 may also have therapeutic benefits in other neurodegenerative conditions such as traumatic brain injury (TBI). Herein, we report that DKR-1677, a novel derivative of SAS-0132 with increased affinity and selectivity for sigma 2R/Tmem97 (K-i = 5.1 nM), is neuroprotective after blast-induced and controlled cortical impact (CCI) TBI in mice. Specifically, we discovered that treatment with DKR-1677 decreases axonal degeneration after blast-induced TBI and enhances survival of cortical neurons and oligodendrocytes after CCI injury. Furthermore, treatment with DKR-1677 preserves cognition in the Morris water maze after blast TBI. Our results support an increasingly broad role for sigma 2R/Tmem97 modulation in neuroprotection and suggest a new approach for treating patients suffering from TBI.	[Vazquez-Rosa, Edwin; Schroeder, Rachel E.; Yin, Terry C.; Emery, Josie L.; Pieper, Andrew A.] Univ Iowa, Carver Coll Med, Dept Psychiat, Radiat Biol Program,Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA; [Vazquez-Rosa, Edwin; Schroeder, Rachel E.; Yin, Terry C.; Emery, Josie L.; Pieper, Andrew A.] Univ Iowa, Carver Coll Med, Dept Free Rad, Radiat Biol Program,Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA; [Watson, Michael R.; Liebl, Daniel J.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Sahn, James J.; Hodges, Timothy R.; Martin, Stephen F.] Univ Texas Austin, Dept Chem, Austin, TX 78712 USA; [Vazquez-Rosa, Edwin; Cintron-Perez, Coral J.; Shin, Min-Kyoo; Pieper, Andrew A.] Case Western Reserve Univ, Ctr Geriatr Res Educ & Clin, Louis Stokes Cleveland VAMC,Dept Psychiat, Univ Hosp,Case Med Ctr,Harrington Discovery Inst, Cleveland, OH 44106 USA	Pieper, AA (corresponding author), Univ Iowa, Carver Coll Med, Dept Psychiat, Radiat Biol Program,Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA.; Pieper, AA (corresponding author), Univ Iowa, Carver Coll Med, Dept Free Rad, Radiat Biol Program,Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA.; Liebl, DJ (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA.; Martin, SF (corresponding author), Univ Texas Austin, Dept Chem, Austin, TX 78712 USA.; Pieper, AA (corresponding author), Case Western Reserve Univ, Ctr Geriatr Res Educ & Clin, Louis Stokes Cleveland VAMC,Dept Psychiat, Univ Hosp,Case Med Ctr,Harrington Discovery Inst, Cleveland, OH 44106 USA.	sfmartin@mail.utexas.edu; dliebl@miami.edu; Andrew.Pieper@HarringtonDiscovery.org	Martin, Stephen/U-4676-2019	Pieper, Andrew/0000-0001-6299-6577	Brockman Medical Research Foundation; Titan Neurology Research Fund; Department of Veterans Affairs Merit ReviewUS Department of Veterans Affairs [1IO1BX002444]; Robert A. Welch FoundationThe Welch Foundation [F-0652]; Dell Medical School's Texas Health Catalyst program; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS098740]; Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS098740] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002444] Funding Source: NIH RePORTER	This work was supported by funds to A.A.P. from the Brockman Medical Research Foundation, from an anonymous donor to the Mary Alice Smith Fund for Neuropsychiatry Research, from the Titan Neurology Research Fund, and from the Department of Veterans Affairs Merit Review 1IO1BX002444. The contents of this manuscript do not represent the views of the U.S. Department of Veterans Affairs or the U.S. Government. This work was also supported by the Robert A. Welch Foundation (F-0652) to S.F.M., the Dell Medical School's Texas Health Catalyst program to S.F.M. and J.J.S., NIH/NINDS NS098740 to D.J.L., and the Miami Project to Cure Paralysis to D.J.L.	Alon A, 2017, P NATL ACAD SCI USA, V114, P7160, DOI 10.1073/pnas.1705154114; Bartz F, 2009, CELL METAB, V10, P63, DOI 10.1016/j.cmet.2009.05.009; Dutca LM, 2014, INVEST OPHTH VIS SCI, V55, P8330, DOI 10.1167/iovs.14-15468; Ebrahimi-Fakhari D, 2016, HUM MOL GENET, V25, P3588, DOI 10.1093/hmg/ddw204; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Flygt J, 2016, J NEUROPATH EXP NEUR, V75, P503, DOI 10.1093/jnen/nlw025; Fuss B, 2000, DEV BIOL, V218, P259, DOI 10.1006/dbio.1999.9574; Goldstein L. E., 2012, SCI TRANSL MED, V16; Guo L, 2015, CURR MED CHEM, V22, P989, DOI 10.2174/0929867322666150114163607; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huang YS, 2014, MED RES REV, V34, P532, DOI 10.1002/med.21297; Izzo NJ, 2014, PLOS ONE, V9; Mach RH, 2013, J MED CHEM, V56, P7137, DOI 10.1021/jm301545c; Madsen T, 2018, JAMA-J AM MED ASSOC, V320, P580, DOI 10.1001/jama.2018.10211; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Martin S. F., 2015, WO, Patent No. [2015009742 A2, 2015009742]; Minerva Neurosciences Inc., 2014, STUD EV EFF SAF TOL; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Osier N, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7070088; Petrov AM, 2016, ACTA NATURAE, V8, P58, DOI 10.32607/20758251-2016-8-1-58-73; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Roozenbeek Bob, 2012, Clin Investig (Lond), V2, P153; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Sahn JJ, 2017, ACS CHEM NEUROSCI, V8, P1801, DOI 10.1021/acschemneuro.7b00200; Sahn JJ, 2017, ACS MED CHEM LETT, V8, P455, DOI 10.1021/acsmedchemlett.7b00066; Sahn JJ, 2016, CHEMMEDCHEM, V11, P556, DOI 10.1002/cmdc.201500551; Sahn JJ, 2012, ACS COMB SCI, V14, P496, DOI 10.1021/co300068a; Sanchez-Pulido L, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00439; Scott LL, 2018, NEUROPSYCHOPHARMACOL, V43, P1867, DOI 10.1038/s41386-018-0067-z; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Wager TT, 2010, ACS CHEM NEUROSCI, V1, P420, DOI 10.1021/cn100007x; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Yi BN, 2017, J NEUROCHEM, V140, P561, DOI 10.1111/jnc.13917; Yin TC, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0220-16.2016; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030	35	12	12	1	11	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	MAR	2019	10	3			SI		1595	1602		10.1021/acschemneuro.8b00543			15	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	HQ2VN	WOS:000462259900065	30421909	Green Accepted			2021-06-18	
J	Wang, Y; Tye, AE; Zhao, JL; Ma, DQ; Raddant, AC; Bu, F; Spector, BL; Winslow, NK; Wang, MY; Russo, AF				Wang, Yan; Tye, Anne E.; Zhao, Junli; Ma, Dongqing; Raddant, Ann C.; Bu, Fan; Spector, Benjamin L.; Winslow, Nolan K.; Wang, Minyan; Russo, Andrew F.			Induction of calcitonin gene-related peptide expression in rats by cortical spreading depression	CEPHALALGIA			English	Article						CGRP; migraine; traumatic brain injury; post-traumatic headache; gene expression	TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; MIGRAINE; CGRP; TRIGGERS; PATHOPHYSIOLOGY; ACTIVATION; HEMORRHAGE; ANTIBODIES; ALLODYNIA	Objective The neuropeptide calcitonin gene-related peptide (CGRP) has now been established as a key player in migraine. However, the mechanisms underlying the reported elevation of CGRP in the serum and cerebrospinal fluid of some migraineurs are not known. A candidate mechanism is cortical spreading depression (CSD), which is associated with migraine with aura and traumatic brain injury. The aim of this study was to investigate whether CGRP gene expression may be induced by experimental CSD in the rat cerebral cortex. Methods CSD was induced by topical application of KCl and monitored using electrophysiological methods. Quantitative PCR and ELISA were used to measure CGRP mRNA and peptide levels in discrete ipsilateral and contralateral cortical regions of the rat brain 24 hours following CSD events and compared with sham treatments. Results The data show that multiple, but not single, CSD events significantly increase CGRP mRNA levels at 24 hours post-CSD in the ipsilateral rat cerebral cortex. Increased CGRP was observed in the ipsilateral frontal, motor, somatosensory, and visual cortices, but not the cingulate cortex, or contralateral cortices. CSD also induced CGRP peptide expression in the ipsilateral, but not contralateral, cortex. Conclusions Repeated CSD provides a mechanism for prolonged elevation of CGRP in the cerebral cortex, which may contribute to migraine and post-traumatic headache.	[Wang, Yan; Zhao, Junli; Ma, Dongqing; Bu, Fan; Wang, Minyan] Xian Jiaotong Liverpool Univ XJTLU, Ctr Neurosci, SIP, Suzhou 215123, Peoples R China; [Ma, Dongqing; Bu, Fan; Wang, Minyan] Xian Jiaotong Liverpool Univ XJTLU, Dept Biol Sci, SIP, Suzhou 215123, Peoples R China; [Tye, Anne E.; Russo, Andrew F.] Univ Iowa, Neurosci Program, Iowa City, IA 52242 USA; [Raddant, Ann C.; Spector, Benjamin L.; Winslow, Nolan K.; Russo, Andrew F.] Univ Iowa, Dept Mol Physiol & Biophys, Iowa City, IA 52242 USA; [Russo, Andrew F.] Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA; [Russo, Andrew F.] Vet Affairs Med Ctr, Iowa City, IA 52246 USA	Russo, AF (corresponding author), Univ Iowa, Dept Mol Physiol & Biophys, Iowa City, IA 52242 USA.	andrew-russo@uiowa.edu		Bu, Fan/0000-0002-0051-6037; Russo, Andrew/0000-0002-8156-5649	Wangwenli Charitable Foundation [RD0006]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS075599]; Veterans Affairs Medical Center [1IO1RX002101]; Department of Defense USAMRAAUnited States Department of Defense [W81XWH-16-1-0071]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T35HL007485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS045549, R01NS075599] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX002101] Funding Source: NIH RePORTER	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Wangwenli Charitable Foundation (RD0006), NIH (NS075599), Veterans Affairs Medical Center (1IO1RX002101), and Department of Defense USAMRAA (W81XWH-16-1-0071).	Ayata C, 2015, PHYSIOL REV, V95, P953, DOI 10.1152/physrev.00027.2014; Ayata C, 2013, CEPHALALGIA, V33, P604, DOI 10.1177/0333102412470216; Bellamy J, 2006, EUR J NEUROSCI, V23, P2057, DOI 10.1111/j.1460-9568.2006.04742.x; Bhatt DK, 2014, NEUROSCI LETT, V559, P99, DOI 10.1016/j.neulet.2013.11.057; Bigal ME, 2015, BRIT J CLIN PHARMACO, V79, P886, DOI 10.1111/bcp.12591; Bolay H, 2002, NAT MED, V8, P136, DOI 10.1038/nm0202-136; Borkum JM, 2016, HEADACHE, V56, P12, DOI 10.1111/head.12725; Charles A, 2009, CEPHALALGIA, V29, P1115, DOI 10.1111/j.1468-2982.2009.01983.x; Costa C, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-62; Cutrer FM, 2007, NEUROLOGIST, V13, P118, DOI 10.1097/01.nrl.0000252943.82792.38; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Edvinsson L, 2015, BRIT J CLIN PHARMACO, V80, P193, DOI 10.1111/bcp.12618; Eiselt M, 2004, BRAIN RES, V1028, P83, DOI 10.1016/j.brainres.2004.09.002; Elliott MB, 2012, HEADACHE, V52, P966, DOI 10.1111/j.1526-4610.2012.02160.x; Fioravanti B, 2011, CEPHALALGIA, V31, P1090, DOI 10.1177/0333102411410609; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Hang CH, 2004, WORLD J GASTROENTERO, V10, P875; Hansen JM, 2014, CEPHALALGIA, V34, P695, DOI 10.1177/0333102413520084; Hansen JM, 2010, CEPHALALGIA, V30, P1179, DOI 10.1177/0333102410368444; Hartings JA, 2017, J CEREBR BLOOD F MET, V37, P1571, DOI 10.1177/0271678X16654495; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Jander S, 2001, J CEREBR BLOOD F MET, V21, P218, DOI 10.1097/00004647-200103000-00005; Karatas H, 2013, SCIENCE, V339, P1092, DOI 10.1126/science.1231897; Lassen LH, 2002, CEPHALALGIA, V22, P54, DOI 10.1046/j.1468-2982.2002.00310.x; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Lipton RB, 2007, NEUROLOGY, V68, P343, DOI 10.1212/01.wnl.0000252808.97649.21; Noseda R, 2013, PAIN, V154, pS44, DOI 10.1016/j.pain.2013.07.021; Park KY, 2011, CEPHALALGIA, V31, P614, DOI 10.1177/0333102410391487; Pietrobon D, 2013, ANNU REV PHYSIOL, V75, P365, DOI 10.1146/annurev-physiol-030212-183717; PIPER RD, 1993, CEPHALALGIA, V13, P180, DOI 10.1046/j.1468-2982.1993.1303180.x; Raddant AC, 2014, HEADACHE, V54, P472, DOI 10.1111/head.12301; Rangel YM, 2001, MOL BRAIN RES, V88, P103, DOI 10.1016/S0169-328X(01)00037-7; Richter F, 2014, ANN NEUROL, V76, P43, DOI 10.1002/ana.24176; Russo AF, 2015, ANNU REV PHARMACOL, V55, P533, DOI 10.1146/annurev-pharmtox-010814-124701; Shatillo A, 2013, NEUROSCIENCE, V253, P341, DOI 10.1016/j.neuroscience.2013.09.002; Song Y, 2012, MOL MED REP, V5, P432, DOI 10.3892/mmr.2011.645; Takizawa T, 2016, CEPHALALGIA, V36, P44, DOI 10.1177/0333102415580100; Tepe N, 2015, EUR J NEUROSCI, V41, P120, DOI 10.1111/ejn.12753; Tozzi A, 2012, P NATL ACAD SCI USA, V109, P18985, DOI 10.1073/pnas.1215435109; Urbach A, 2006, EUR J NEUROSCI, V24, P841, DOI 10.1111/j.1460-9568.2006.04862.x; van Dongen RM, 2017, CEPHALALGIA, V37, P49, DOI 10.1177/0333102415625614; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Viggiano A, 2011, BRAIN RES, V1368, P11, DOI 10.1016/j.brainres.2010.10.062; von Baumgarten L, 2008, J CEREBR BLOOD F MET, V28, P1353, DOI 10.1038/jcbfm.2008.30; Wang MY, 2013, NEUROPEPTIDES, V47, P463, DOI 10.1016/j.npep.2013.10.006; Yisarakun W, 2015, NEUROPEPTIDES, V51, P9, DOI 10.1016/j.npep.2015.03.008; Zhang XC, 2011, ANN NEUROL, V69, P855, DOI 10.1002/ana.22329; Zhang XC, 2010, J NEUROSCI, V30, P8807, DOI 10.1523/JNEUROSCI.0511-10.2010	49	12	12	0	4	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0333-1024	1468-2982		CEPHALALGIA	Cephalalgia	MAR	2019	39	3					333	341		10.1177/0333102416678388			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	HN6LT	WOS:000460298300002	27919019	Green Accepted			2021-06-18	
J	Cox, CS; Juranek, J; Bedi, S				Cox, Charles S., Jr.; Juranek, Jennifer; Bedi, Supinder			Clinical trials in traumatic brain injury: cellular therapy and outcome measures	TRANSFUSION			English	Article; Proceedings Paper	CTTACC Symposium	2017	San Francisco, CA	CTTACC			ACTIVATED MICROGLIAL/MACROPHAGE RESPONSE; DIFFUSION-TENSOR; MICROGLIAL ACTIVATION; INFLAMMATORY RESPONSE; RESTRICTED-DIFFUSION; CELLS; ADULT; TRANSPLANTATION; NEUROINFLAMMATION; HYPOTHERMIA	Clinical trials for traumatic brain injury (TBI) have not successfully produced a new therapeutic for neuroprotection or neurorestoration, despite multiple attempts. Stem cell-based therapies and/or cellular therapies have been developed over the past 20 years such that clinical trials are now in Phase II and III stages for neurologic diseases such as TBI and stroke. Many of the vexing issues from past clinical failures still exist today, namely, preclinical data that may not translate to clinical trial because of design and injury heterogeneity that poorly stratifies enrolled patients. Recognition of these problems has led us to advocate for outcome measures that are clinically meaningful, but do not represent a global functional "score." Specifically, we seek to measure those early physiologically relevant outcomes (intracranial pressure, edema, and therapeutic intensity) and later structural outcomes in regions of interest that are linked to putative mechanisms of action of cell based therapies. Early approval of therapeutics that are successful by these metrics would then allow further access to treatments that could be further tested via patient registries and other surveillance for ultimate adoption. Continuing to do the same thing with each iterative trial will assure the same results.	[Cox, Charles S., Jr.; Bedi, Supinder] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, McGovern Med Sch, Houston, TX 77030 USA; [Juranek, Jennifer] Univ Texas Hlth Sci Ctr Houston, Dept Pediat, McGovern Med Sch, Houston, TX 77030 USA	Cox, CS (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, 6431 Fannin St,MSB 5-236, Houston, TX 77030 USA.	Charles.S.Cox@uth.tmc.edu			Glassell Foundation; Department of Defense/Joint Warfighter Grant [JW150014]; State of Texas Emerging Technology Fund; Bentsen Foundation; Evelyn Griffin Stem Cell Laboratory; Mission Connect	Supported by the Glassell Foundation, Department of Defense/Joint Warfighter Grant JW150014, State of Texas Emerging Technology Fund, Bentsen Foundation, Evelyn Griffin Stem Cell Laboratory, and Mission Connect.	Al Brashdi YH, 2015, NEURORADIOL J, V28, P409, DOI 10.1177/1971400915598071; Bedi SS, 2013, STEM CELL TRANSL MED, V2, P953, DOI 10.5966/sctm.2013-0100; Bedi SS, 2013, J TRAUMA ACUTE CARE, V75, P410, DOI 10.1097/TA.0b013e31829617c6; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cox CS, 2017, STEM CELLS, V35, P1065, DOI 10.1002/stem.2538; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Coyne TM, 2006, STEM CELLS, V24, P2483, DOI 10.1634/stemcells.2006-0174; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Dupont AC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040785; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Guiza F, 2015, INTENS CARE MED, V41, P1067, DOI 10.1007/s00134-015-3806-1; Harriman T, 2017, NEONATAL NETW, V36, P273, DOI 10.1891/0730-0832.36.5.273; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Harting MT, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E17; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Hudak AM, 2014, BRAIN INJURY, V28, P1602, DOI 10.3109/02699052.2014.936039; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Jackson M, 2017, J NEUROTRAUM, V34, pA142; Jackson ML, 2017, J SURG RES, V214, P38, DOI 10.1016/j.jss.2017.02.078; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kota DJ, 2016, STEM CELL TRANSL MED, V5, P33, DOI 10.5966/sctm.2015-0065; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Lee ST, 2008, BRAIN, V131, P616, DOI 10.1093/brain/awm306; Liao GP, 2015, PEDIATR CRIT CARE ME, V16, P245, DOI 10.1097/PCC.0000000000000324; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Muccio CF, 2009, BRAIN INJURY, V23, P466, DOI 10.1080/02699050902841912; Nakajima K, 2001, J BIOCHEM-TOKYO, V130, P169, DOI 10.1093/oxfordjournals.jbchem.a002969; Narayan RK, 2002, J NEUROTRAUM, V17, P695; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Newcombe VFJ, 2013, J CEREBR BLOOD F MET, V33, P855, DOI 10.1038/jcbfm.2013.11; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Ohtaki H, 2008, P NATL ACAD SCI USA, V105, P14638, DOI 10.1073/pnas.0803670105; Pati S, 2011, STEM CELLS DEV, V20, P89, DOI 10.1089/scd.2010.0013; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Salter MW, 2014, CELL, V158, P15, DOI 10.1016/j.cell.2014.06.008; Sanberg PR, 2010, J CELL MOL MED, V14, P553, DOI 10.1111/j.1582-4934.2009.00903.x; Scarf AM, 2011, J NUCL MED, V52, P667, DOI 10.2967/jnumed.110.086629; Schlaug G, 1999, NEUROLOGY, V53, P1528, DOI 10.1212/WNL.53.7.1528; Selden NR, 2013, J NEUROSURG-PEDIATR, V11, P643, DOI 10.3171/2013.3.PEDS12397; Shore PM, 2006, CRIT CARE MED, V24, P75; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith HS, 2010, PAIN PHYSICIAN, V13, P295; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; Thiel A, 2010, J NUCL MED, V51, P1404, DOI 10.2967/jnumed.110.076612; Toth M, 2016, BRAIN STRUCT FUNCT, V221, P1279, DOI 10.1007/s00429-014-0970-y; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Willing AE, 2007, HISTOL HISTOPATHOL, V22, P697, DOI 10.14670/HH-22.697; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058	63	12	12	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0041-1132	1537-2995		TRANSFUSION	Transfusion	FEB	2019	59			1	SI		858	868		10.1111/trf.14834			11	Hematology	Hematology	HK9CT	WOS:000458287400006	30737818	Bronze			2021-06-18	
J	Elbourn, E; Kenny, B; Power, E; Honan, C; McDonald, S; Tate, R; Holland, A; MacWhinney, B; Togher, L				Elbourn, Elise; Kenny, Belinda; Power, Emma; Honan, Cynthia; McDonald, Skye; Tate, Robyn; Holland, Audrey; MacWhinney, Brian; Togher, Leanne			Discourse recovery after severe traumatic brain injury: exploring the first year	BRAIN INJURY			English	Article						Traumatic brain injury; speech pathology; cognitive-communication; recovery; discourse	CLOSED-HEAD INJURY; COGNITIVE REHABILITATION; STORY NARRATIVES; MAIN CONCEPTS; OUTCOMES; LANGUAGE; ADULTS; TBI; CONSCIOUSNESS; IMPAIRMENT	Objectives: Although much is known about discourse impairment, little is known about discourse recovery after severe traumatic brain injury (TBI). This paper explores discourse recovery across the critical first year, controlling for pre-injury, injury and post-injury variables. Design and methods: An inception cohort comprising 57 participants with severe TBI was examined at 3, 6, 9 and 12 months post-injury and compared to a cross-section of matched healthy control participants. A narrative discourse task was analyzed with main concept analysis (MCA). A mixed linear model approach was used to track recovery controlling for pre-injury, injury and post-injury variables. Results: An upward trajectory of recovery was observed, with peak periods of improvement between 3-6 and 9-12 months and all time points were significantly below controls. Years of education and PTA duration were significant covariates in the recovery model. Presence of aphasia also influenced the recovery model. Conclusions: Individuals with TBI typically improve over the first year, however many will continue to have discourse deficits at 12 months. Years of education, PTA duration and aphasia should be considered when planning services. The 3-6- and 9-12-month periods may offer optimal periods for discourse recovery and increased supports may be beneficial between 6-9 months.	[Elbourn, Elise; Kenny, Belinda; Power, Emma; Tate, Robyn; Togher, Leanne] Univ Sydney, Fac Hlth Sci, Lidcombe, NSW, Australia; [Honan, Cynthia] Univ Tasmania, Sch Med, Hobart, Tas, Australia; [McDonald, Skye] Univ New South Wales, Sch Psychol, Sydney, NSW, Australia; [Holland, Audrey] Univ Arizona, Speech Language & Hearing Sci, Tucson, AZ USA; [MacWhinney, Brian] Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA	Elbourn, E (corresponding author), Univ Sydney, Discipline Speech Pathol, Fac Hlth Sci, POB 170, Lidcombe, NSW 1825, Australia.	elise.elbourn@sydney.edu.au	Togher, Leanne/AAC-7083-2019; Honan, Cynthia/O-6332-2017; Power, Emma/A-9263-2015; McDonald, Skye/G-4118-2014	Honan, Cynthia/0000-0001-5735-4270; Togher, Leanne/0000-0002-4518-6748; Power, Emma/0000-0002-2638-0406; McDonald, Skye/0000-0003-0723-6094	National Health and Medical Research Council (NHMRC) Postgraduate ScholarshipNational Health and Medical Research Council of Australia [GNT1056000]; NHMRCNational Health and Medical Research Council of Australia [632681]; SEED Grant from the Moving Ahead NHMRC Centre of Research Excellence in Brain Recovery (2013)National Health and Medical Research Council of Australia; Postgraduate Student Research Grant from Speech Pathology Australia (2013)	This research was funded by a National Health and Medical Research Council (NHMRC) Postgraduate Scholarship (#GNT1056000) and an NHMRC Grant (#632681). Funding for transcription was provided by a SEED Grant from the Moving Ahead NHMRC Centre of Research Excellence in Brain Recovery (2013) and a Postgraduate Student Research Grant from Speech Pathology Australia (2013).	Behn N, 2012, BRAIN INJURY, V26, P1702, DOI 10.3109/02699052.2012.722258; Bransby JJ, 2017, PERCEIVED COMMUNICAT; Braun CMJ, 1987, SUBCLINICAL APHASIA, P326; Calamia M, 2012, CLIN NEUROPSYCHOL, V26, P543, DOI 10.1080/13854046.2012.680913; Campbell M., 2000, REHABILITATION TRAUM; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Coelho Carl A., 2007, Seminars in Speech and Language, V28, P122, DOI 10.1055/s-2007-970570; Corrigan JD, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000020; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Cupit J, 2010, APHASIOLOGY, V24, P1486, DOI 10.1080/02687031003615235; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Dillow E., 2013, THESIS; Douglas JM, 2019, NEUROPSYCHOL REHABIL, V29, P73, DOI 10.1080/09602011.2016.1259114; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Elbourn E, 2017, INT J SPEECH-LANG PA, V19, P1, DOI 10.1080/17549507.2016.1193896; Enderby P, 2007, FRENCHAY DYSARTHRIA, V2; Enders CK, 2011, PSYCHOL METHODS, V16, P1, DOI 10.1037/a0022640; Forducey PG, 2003, NEUROREHABILITATION, V18, P103; Frasca Diana, 2013, Front Hum Neurosci, V7, P31, DOI 10.3389/fnhum.2013.00031; Fromm D, 2017, AM J SPEECH-LANG PAT, V26, P762, DOI 10.1044/2016_AJSLP-16-0071; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Grimes, 2005, W DISNEYS CINDERELLA; HALPERN H, 1973, J SPEECH HEAR DISORD, V38, P162, DOI 10.1044/jshd.3802.162; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P369, DOI 10.1080/026990598122502; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P109, DOI 10.1080/026990598122746; Jacobson NS, 1999, J CONSULT CLIN PSYCH, V67, P300, DOI 10.1037/0022-006X.67.3.300; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Kertesz A, 2012, W APHASIA BATTERY; Le K, 2011, APHASIOLOGY, V25, P748, DOI 10.1080/02687038.2010.539696; LeBlanc J, 2014, BRAIN INJURY, V28, P951, DOI 10.3109/02699052.2014.888760; Lippert-Gruner M, 2002, J REHABIL MED, V34, P211, DOI 10.1080/165019702760279198; Macdonald S, 2005, BRAIN INJURY, V19, P895, DOI 10.1080/02699050400004294; MacWhinney B, 2011, APHASIOLOGY, V25, P1286, DOI 10.1080/02687038.2011.589893; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Morley S, 2014, MANUAL LEEDS RELIABL; NICHOLAS LE, 1995, J SPEECH HEAR RES, V38, P146, DOI 10.1044/jshr.3801.145; Perdices M, 2005, BRAIN IMPAIR, V6, DOI [10.1375/brim.2005.6.3.219, DOI 10.1375/brim.2005.6.3.219]; Richardson JD, 2016, APHASIOLOGY, V30, P45, DOI 10.1080/02687038.2015.1057891; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; Shek DTL, 2011, THESCIENTIFICWORLDJO, V11, P42, DOI 10.1100/tsw.2011.2; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Sloan S., 2004, BRAIN IMPAIR, V5, P12, DOI DOI 10.1375/BRIM.5.1.12.35399; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow PC, 1999, APHASIOLOGY, V13, P529, DOI 10.1080/026870399401993; Snow PC, 2000, BRAIN INJURY, V14, P397; Stark JA, 2010, APHASIOLOGY, V24, P709, DOI 10.1080/02687030903524729; Steel J, 2017, BRAIN INJURY, V31, P1889, DOI 10.1080/02699052.2017.1373200; Stubbs E, 2018, BRAIN INJURY, V32, P167, DOI 10.1080/02699052.2017.1291989; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Togher L, 2014, J HEAD TRAUMA REHAB, V29, P353, DOI 10.1097/HTR.0000000000000071; Togher L, 2013, J REHABIL MED, V45, P637, DOI 10.2340/16501977-1173; Turkstra Lyn S., 2005, Seminars in Speech and Language, V26, P215, DOI 10.1055/s-2005-922101; Wallace SJ, 2014, APHASIOLOGY, V28, P1364, DOI 10.1080/02687038.2014.930262; Young E, 2017, DISCOURSE CHANGES FO	64	12	12	1	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN 28	2019	33	2					143	159		10.1080/02699052.2018.1539246			17	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	HG9RL	WOS:000455346300005	30465440				2021-06-18	
J	Kaufmann, CN; Orff, HJ; Moore, RC; Delano-Wood, L; Depp, CA; Schiehser, DM				Kaufmann, Christopher N.; Orff, Henry J.; Moore, Raeanne C.; Delano-Wood, Lisa; Depp, Colin A.; Schiehser, Dawn M.			Psychometric Characteristics of the Insomnia Severity Index in Veterans With History of Traumatic Brain Injury	BEHAVIORAL SLEEP MEDICINE			English	Article							1ST 2 YEARS; SLEEP DISTURBANCE; SYMPTOMS; INVENTORY; FATIGUE; UTILITY; IMPACT	Objective/Background: The Insomnia Severity Index (ISI) is a widely used self-report measure of insomnia symptoms. However, to date this measure has not been validated or well-characterized in veterans who have experienced traumatic brain injury (TBI). This study assessed the psychometric properties and convergent, divergent, construct, and discriminate validity of the ISI in veterans with a history of TBI. Participants: Eighty-three veterans with history of TBI were seen in the VA San Diego Healthcare System as part of a research protocol. Methods: Measures included the ISI, Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale, Neurobehavioral Symptom Inventory, Beck Depression Inventory-II, Beck Anxiety Inventory, and PTSD Checklist-Military Version. Results: The ISI demonstrated moderate to strong or excellent convergent and divergent validity. A principal component analysis indicated a single construct with excellent internal consistency (Cronbach's alpha = 0.92). In exploratory analyses, the ISI discriminated well between those with (73%) and without (27%) sleep disturbance based on the PSQI. Conclusions: Results from this study indicate validity of the ISI in assessing insomnia in veterans with history of TBI and suggest a cutoff score not dissimilar from non-TBI populations. Findings from this study can help inform clinical applicability of the ISI, as well as future studies of insomnia in TBI.	[Kaufmann, Christopher N.; Orff, Henry J.; Moore, Raeanne C.; Delano-Wood, Lisa; Depp, Colin A.; Schiehser, Dawn M.] Vet Adm San Diego Healthcare Syst, La Jolla, CA USA; [Kaufmann, Christopher N.; Moore, Raeanne C.; Delano-Wood, Lisa; Depp, Colin A.; Schiehser, Dawn M.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Kaufmann, Christopher N.; Moore, Raeanne C.; Depp, Colin A.] Univ Calif San Diego, Stein Inst Res Aging, La Jolla, CA 92093 USA; [Orff, Henry J.; Delano-Wood, Lisa; Schiehser, Dawn M.] Vet Adm San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, La Jolla, CA USA	Schiehser, DM (corresponding author), Vet Adm San Diego Healthcare Syst 151B, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	dschiehser@ucsd.edu	depp, colin a/D-1264-2009; Moore, Raeanne/ABC-6648-2020	Moore, Raeanne/0000-0002-7499-041X	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019934, K23MH107260] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX000842, IK2RX001512] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH107260, T32 MH019934] Funding Source: Medline; CSRD VA [I01 CX000842] Funding Source: Medline; RRD VA [IK2 RX001512] Funding Source: Medline		Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cantor JB, 2012, J HEAD TRAUMA REHAB, V27, pE1, DOI 10.1097/HTR.0b013e318270f91e; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Jain A, 2014, ASIAN J PSYCHIATR, V8, P99, DOI 10.1016/j.ajp.2013.12.017; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Leyfer OT, 2006, J ANXIETY DISORD, V20, P444, DOI 10.1016/j.janxdis.2005.05.004; Mollayeva T, 2016, SLEEP MED, V20, P157, DOI 10.1016/j.sleep.2015.09.008; Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Schutte-Rodin S, 2008, J CLIN SLEEP MED, V4, P487; Spira JL, 2014, J NEUROTRAUM, V31, P1823, DOI 10.1089/neu.2014.3363; Sullivan KA, 2016, APPL NEUROPSYCH-ADUL, V23, P426, DOI 10.1080/23279095.2016.1172229; The Management of Concussion/mTBI Working Group, 2009, VA DOD CLIN PRACT GU; Weathers F., 1991, PTSD CHECKLIST MILIT	23	12	12	0	6	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1540-2002	1540-2010		BEHAV SLEEP MED	Behav. Sleep Med.	JAN 2	2019	17	1					12	18		10.1080/15402002.2016.1266490			7	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	HD7YK	WOS:000452769900002	28098495	Green Accepted			2021-06-18	
J	Chrisman, SPD; Ebel, BE; Stein, E; Lowry, SJ; Rivara, FP				Chrisman, Sara P. D.; Ebel, Beth E.; Stein, Elizabeth; Lowry, Sarah J.; Rivara, Frederick P.			Head Impact Exposure in Youth Soccer and Variation by Age and Sex	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						head impact exposure; soccer; child; adolescent; concussion; heading; brain injury; football	QUALITY-OF-LIFE; SPORTS-RELATED CONCUSSION; VISUAL SCREENING TOOL; KING-DEVICK; RELIABILITY; VALIDITY; PEDSQL(TM)-4.0; EPIDEMIOLOGY; SCALES	Objective: To examine variation in head impact exposure (HIE) by age and sex in youth soccer. Design: Prospective cohort study. Setting and Participants: Youth soccer athletes (11-14 years old) in local clubs. Exposures: Age and sex. Outcome Measures: Head impact exposure measured using adhesive-mounted accelerometers during 1 month of soccer. Results: Forty-six youth athletes (54% female) participated. No athlete reported a concussion during the study. More males than females had at least 1 head impact >= 15 g (P = 0.02). Of those who sustained a head impact above the 15-g threshold (57%), females sustained HIE of greater magnitude than males (median 47.4 g vs 33.3 g, P = 0.04). Eighty-five percent of athletes on U14 teams had at least 1 head impact >= 15 g compared with 15% of athletes on U12 teams (P < 0.001). Poisson regression stratified by sex and controlling for team-suggested age effects were significant only for females (P = 0.02). There was significant variation in HIE by team. There were no decrements in concussion symptoms, health-related quality of life, or neuropsychological testing after 1 month of soccer play. Conclusions: There is significant variation in HIE in youth soccer, which seems to be influenced by age and sex. Further studies are needed to better understand potential significance for injury prevention.	[Chrisman, Sara P. D.; Stein, Elizabeth; Lowry, Sarah J.; Rivara, Frederick P.] Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, Seattle, WA USA; [Chrisman, Sara P. D.; Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Chrisman, Sara P. D.; Ebel, Beth E.; Rivara, Frederick P.] Harborview Injury Prevent & Res Ctr, Seattle, WA USA	Chrisman, SPD (corresponding author), CW8-6,POB 5371, Seattle, WA 98145 USA.	sara.chrisman@seattlechildrens.org		Stein, Elizabeth/0000-0002-1820-3821; Chrisman, Sara/0000-0001-5373-7223; Lowry, Sarah/0000-0002-0865-635X			Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Chrisman SPD, 2016, J CHILD NEUROL, V31, P971, DOI 10.1177/0883073816634857; Cobb Bryan R, 2014, Biomed Sci Instrum, V50, P285; Comstock RD, 2015, JAMA PEDIATR, V169, P830, DOI 10.1001/jamapediatrics.2015.1062; Covassin T, 2016, J ATHL TRAINING, V51, P189, DOI 10.4085/1062-6050-51.3.05; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; FIFA Communications Division, FIFA DAT BIG COUNT 2; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Langhorst P., ENGAGE SPORTS; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lynall RC, 2016, MED SCI SPORT EXER, V48, P1772, DOI 10.1249/MSS.0000000000000951; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; McLeod TCV, 2012, J ATHL TRAINING, V47, P221; National Institutes of Health, NINDS COMM DAT EL TR; O'Kane JW, 2016, PHYSICIAN SPORTSMED, V44, P190, DOI 10.1080/00913847.2016.1149423; Oja P, 2015, BRIT J SPORT MED, V49, P434, DOI 10.1136/bjsports-2014-093885; Press JN, 2017, CLIN J SPORT MED, V27, P104, DOI 10.1097/JSM.0000000000000313; Putukian Margot, 2004, Curr Sports Med Rep, V3, P9; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Spiotta AM, 2012, NEUROSURGERY, V70, P1, DOI 10.1227/NEU.0b013e31823021b2; Tjarks BJ, 2013, J NEUROL SCI, V334, P148, DOI 10.1016/j.jns.2013.08.015; U. S. Soccer, IMPL GUID US SOCC PL; Varni James W, 2005, Expert Rev Pharmacoecon Outcomes Res, V5, P705, DOI 10.1586/14737167.5.6.705; Varni JW, 2009, CLIN TRIALS, V6, P185, DOI 10.1177/1740774509102309; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006	39	12	12	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2019	29	1					3	10		10.1097/JSM.0000000000000497			8	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	IQ4PZ	WOS:000480734000004	29064865				2021-06-18	
J	Gorgoraptis, N; Zaw-Linn, J; Feeney, C; Tenorio-Jimenez, C; Niemi, M; Malik, A; Ham, T; Goldstone, AP; Sharp, DJ				Gorgoraptis, Nikos; Zaw-Linn, Joanna; Feeney, Claire; Tenorio-Jimenez, Carmen; Niemi, Mari; Malik, Aysha; Ham, Timothy; Goldstone, Anthony P.; Sharp, David J.			Cognitive impairment and health-related quality of life following traumatic brain injury	NEUROREHABILITATION			English	Article						SF-36; cognition; depression; sleep disturbance; TBI	DEPRESSION FOLLOWING MILD; DAYTIME SLEEPINESS; MAJOR DEPRESSION; HEAD-INJURY; MODERATE; VALIDITY; SF-36; RELIABILITY; REHABILITATION; QUESTIONNAIRE	BACKGROUND: Cognitive impairment is a common and disabling consequence of traumatic brain injury (TBI) but its impact on health-related quality of life is not well understood. OBJECTIVE: To investigate the relationship between cognitive impairment and health-related quality of life (HRQoL) after TBI. METHODS: Retrospective, cross-sectional study of a specialist TBI outpatient clinic patient sample. Outcome measures: Addenbrooke's Cognitive Examination Tool - Revised (ACE-R), and SF-36 quality of life, Beck Depression Inventory II (BDI-II), Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) questionnaires. RESULTS: 240 adults were assessed: n = 172 (71.7%) moderate-severe, 41 (23.8%) mild, 27 (11.3%) symptomatic TBI, 174 (72.5%) male, median age (range): 44 (22-91) years. TBI patients reported poorer scores on all domains of SF-36 compared to age-matched UK normative data. Cognitively impaired patients reported poorer HRQoL on the physical, social role and emotional role functioning, and mental health domains. Cognitive impairment predicted poorer HRQoL on the social and emotional role functioning domains, independently of depressive symptoms, sleep disturbance, daytime sleepiness and TBI severity. Mediation analysis revealed that the effect of depressive symptoms on the emotional role functioning domain of HRQoL was partially mediated by cognitive dysfunction. CONCLUSION: Cognitive impairment is associated with worse health-related quality of life after TBI and partially mediates the effect of depressive symptoms on emotional role functioning.	[Gorgoraptis, Nikos; Ham, Timothy; Goldstone, Anthony P.; Sharp, David J.] Imperial Coll Healthcare NHS Trust, Dept Neurol, London, England; [Gorgoraptis, Nikos; Zaw-Linn, Joanna; Feeney, Claire; Tenorio-Jimenez, Carmen; Niemi, Mari; Malik, Aysha; Ham, Timothy; Goldstone, Anthony P.; Sharp, David J.] Imperial Coll London, Hammersmith Hosp, Div Brain Sci, Dept Med Computat Cognit & Clin Neuroimaging Lab, London, England; [Feeney, Claire; Goldstone, Anthony P.] Imperial Coll Healthcare NHS Trust, Charing Cross & St Marys Hosp, Imperial Ctr Endocrinol, London, England	Gorgoraptis, N (corresponding author), Hammersmith Hosp, Computat Cognit & Clin Neuroimaging Lab, 3rd Floor,Burlington Danes Bldg,Du Cane Rd, London W12 0NN, England.	n.gorgoraptis@imperial.ac.uk	Tenorio-Jimenez, Carmen/I-1550-2015; Sharp, David J/A-2119-2013	Tenorio-Jimenez, Carmen/0000-0002-1773-6036; Goldstone, Anthony/0000-0001-8179-7071	Department of HealthEuropean Commission [NIHR-RP-011-048] Funding Source: Medline; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/L022141/1, G0701951] Funding Source: Medline		Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS30, DOI 10.1053/apmr.2000.20621; Arango-Lasprilla JC, 2012, BRAIN INJURY, V26, P801, DOI 10.3109/02699052.2012.655368; Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Beck AT, 1996, MANUAL BECK DEPRESSI, V1, P82; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Beseoglu K, 2013, BRIT J NEUROSURG, V27, P202, DOI 10.3109/02688697.2012.717984; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bowling A, 1999, J PUBLIC HEALTH MED, V21, P255, DOI 10.1093/pubmed/21.3.255; Brazier J, 1999, J Health Serv Res Policy, V4, P174; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Carr AJ, 2001, BMJ-BRIT MED J, V322, P1240, DOI 10.1136/bmj.322.7296.1240; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Dougall D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009221.pub2; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; Gaber TAZK, 2008, BRAIN INJURY, V22, P589, DOI 10.1080/02699050802132461; Grauwmeijer E, 2014, ARCH PHYS MED REHAB, V95, P1268, DOI 10.1016/j.apmr.2014.02.002; Guilfoyle MR, 2010, J NEUROTRAUM, V27, P2173, DOI 10.1089/neu.2010.1353; Hays RD, 2001, ANN MED, V33, P350, DOI 10.3109/07853890109002089; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; Hoofien D, 2001, BRAIN INJURY, V15, P189; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; Imai K., 2010, ADV SOCIAL SCI RES U, P129, DOI DOI 10.1007/978-1-4419-1764-5_8; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Karimi M, 2016, PHARMACOECONOMICS, V34, P645, DOI 10.1007/s40273-016-0389-9; Killgore WDS, 2010, PROG BRAIN RES, V185, P105, DOI 10.1016/B978-0-444-53702-7.00007-5; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Marazziti D, 2010, EUR J PHARMACOL, V626, P83, DOI 10.1016/j.ejphar.2009.08.046; Maruish, 1999, USE PSYCHOL TESTING, P1227; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; MEEBERG GA, 1993, J ADV NURS, V18, P32, DOI 10.1046/j.1365-2648.1993.18010032.x; Mioshi E, 2006, INT J GERIATR PSYCH, V21, P1078, DOI 10.1002/gps.1610; Moons P, 2006, INT J NURS STUD, V43, P891, DOI 10.1016/j.ijnurstu.2006.03.015; Ohayon MM, 2002, ARCH INTERN MED, V162, P201, DOI 10.1001/archinte.162.2.201; Polinder S, 2015, POPUL HEALTH METR, V13, DOI 10.1186/s12963-015-0037-1; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; R Core Team, 2014, R LANG ENV STAT COMP; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Riemsma R. P., 2000, HLTH TECHNOLOGY ASSE, V5, P1; Sasse N, 2013, J HEAD TRAUMA REHAB, V28, P464, DOI 10.1097/HTR.0b013e318263977d; Scholten AC, 2015, INJURY, V46, P616, DOI 10.1016/j.injury.2014.10.064; Seymour DG, 2001, J EVAL CLIN PRACT, V7, P411, DOI 10.1046/j.1365-2753.2001.00296.x; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; van Heugten C, 2012, NEUROPSYCHOL REHABIL, V22, P653, DOI 10.1080/09602011.2012.680891; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE., 2000, SF 36 HLTH SURVEY MA; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246	63	12	14	1	3	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2019	44	3					321	331		10.3233/NRE-182618			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	IE8IG	WOS:000472616500001	31177238				2021-06-18	
J	He, ZJ; Zang, HX; Zhu, L; Huang, K; Yi, TL; Zhang, S; Cheng, SX				He, Zhijiang; Zang, Hongxin; Zhu, Lei; Huang, Kui; Yi, Tailong; Zhang, Sai; Cheng, Shixiang			An anti-inflammatory peptide and brain-derived neurotrophic factor-modified hyaluronan-methylcellulose hydrogel promotes nerve regeneration in rats with spinal cord injury	INTERNATIONAL JOURNAL OF NANOMEDICINE			English	Article						hyaluronan-methylcellulose hydrogel; anti-inflammatory peptide; neuroprotection; spinal cord injury	CELL-PENETRATING PEPTIDES; NEURAL STEM-CELLS; FUNCTIONAL RECOVERY; GENE-THERAPY; DELIVERY; GROWTH; METHYLPREDNISOLONE; BIOMATERIALS; INFILTRATION; INHIBITION	Background: Traumatic spinal cord injury (SCI) causes neuronal death, demyelination, axonal degeneration, inflammation, glial scar formation, and cystic cavitation resulting in interruption of neural signaling and loss of nerve function. Multifactorial targeted therapy is a promising strategy for SCI. Methods: The anti-inflammatory peptide KAFAKLAARLYRKALARQLGVAA (KAFAK) and brain-derived neurotrophic factor (BDNF)-modified hyaluronan-methylcellulose (HAMC) hydrogel was designed for minimally invasive, localized, and sustained intrathecal protein delivery. The physical and biological characteristics of HAMC-KAFAK/BDNF hydrogel were measured in vitro. SCI model was performed in rats and HAMC-KAFAK/BDNF hydrogel was injected into the injured site of spinal cord. The neuronal regeneration effect was evaluated by inflammatory cytokine levels, behavioral test and histological analysis at 8 weeks post operation. Results: HAMC-KAFAK/BDNF hydrogel showed minimally swelling property and sustained release of the KAFAK and BDNF. HAMC-KAFAK/BDNF hydrogel significantly improved the proliferation of PC12 cells in vitro without cytotoxicity. Significant recovery in both neurological function and nerve tissue morphology in SCI rats were observed in HAMC-KAFAK/BDNF group. HAMC-KAFAK/BDNF group showed significant reduction in proinflammatory cytokines expression and cystic cavitation, decreased glial scar formation, and improved neuronal survival in the rat SCI model compared to HAMC group and SCI group. Conclusion: The HAMC-KAFAK/BDNF hydrogel promotes functional recovery of rats with spinal cord injury by regulating inflammatory cytokine levels and improving axonal regeneration.	[He, Zhijiang; Huang, Kui] Logist Univ, Chinese Peoples Armed Police Force PAP, Tianjin 300309, Peoples R China; [Zang, Hongxin] Chinese Peoples Armed Police Force PAP, Dept Nursing, Characterist Med Ctr, Tianjin 300162, Peoples R China; [Zhu, Lei] Chinese Peoples Armed Police Force PAP, Characterist Med Ctr, Dept Orthopaed, Tianjin 300162, Peoples R China; [Yi, Tailong; Zhang, Sai; Cheng, Shixiang] Chinese Peoples Armed Police Force PAP, Inst TBI & Neurosci, Tianjin Key Lab Neurotrauma Repair, Characterist Med Ctr, 220 ChengLin Rd, Tianjin 300162, Peoples R China	Zhang, S; Cheng, SX (corresponding author), Chinese Peoples Armed Police Force PAP, Inst TBI & Neurosci, Tianjin Key Lab Neurotrauma Repair, Characterist Med Ctr, 220 ChengLin Rd, Tianjin 300162, Peoples R China.	zhangsai718@vip.126.com; shixiangcheng@vip.126.com		cheng, shixiang/0000-0003-4643-2899; Zhu, Lei/0000-0002-6043-7162	National Natural Science Foundation Major Program of ChinaNational Natural Science Foundation of China (NSFC) [81891003]; Science & Technology Program of Tianjin, China [15ZXLCSY00040, 16ZXHLSY00120]; Tianjin Municipal Natural Science FoundationNatural Science Foundation of Tianjin [17JCYBJC25700];  [AWS15J001]	This study was supported by the National Natural Science Foundation Major Program of China (81891003), the Science & Technology Program of Tianjin, China (15ZXLCSY00040, 16ZXHLSY00120), the Technology Research Projects (AWS15J001), and the Tianjin Municipal Natural Science Foundation (17JCYBJC25700).	An YH, 2006, BIOMED MATER, V1, pR38, DOI 10.1088/1748-6041/1/2/R02; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Bartlett RL, 2013, NANOMED-NANOTECHNOL, V9, P419, DOI 10.1016/j.nano.2012.09.003; Bartus K, 2014, J NEUROSCI, V34, P4822, DOI 10.1523/JNEUROSCI.4369-13.2014; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Blesch A, 2009, TRENDS NEUROSCI, V32, P41, DOI 10.1016/j.tins.2008.09.008; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; Brock JH, 2010, J NEUROSCI, V30, P9728, DOI 10.1523/JNEUROSCI.1924-10.2010; Brugnano JL, 2011, J CONTROL RELEASE, V155, P128, DOI 10.1016/j.jconrel.2011.05.007; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Coll-Miro M, 2016, P NATL ACAD SCI USA, V113, P1411, DOI 10.1073/pnas.1523212113; Cregg JM, 2014, EXP NEUROL, V253, P197, DOI 10.1016/j.expneurol.2013.12.024; Fouad K, 2009, J NEUROTRAUM, V26, P733, DOI 10.1089/neu.2008.0730; Gupta D, 2006, BIOMATERIALS, V27, P2370, DOI 10.1016/j.biomaterials.2005.11.015; Haggerty AE, 2013, NEUROSCI BULL, V29, P445, DOI 10.1007/s12264-013-1362-7; Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537; Khaing ZZ, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046033; Kramer AS, 2013, CELL TRANSPLANT, V22, P571, DOI 10.3727/096368912X655208; Lacroix S, 2002, J COMP NEUROL, V454, P213, DOI 10.1002/cne.10407; Hong LTA, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00583-8; Lin JB, 2016, NANOMED-NANOTECHNOL, V12, P2095, DOI 10.1016/j.nano.2016.05.010; Liu SW, 2017, ACTA BIOMATER, V60, P167, DOI 10.1016/j.actbio.2017.07.024; Lu P, 2005, EXP NEUROL, V191, P344, DOI 10.1016/j.expneurol.2004.09.018; Moon YJ, 2012, J NEUROSCI RES, V90, P243, DOI 10.1002/jnr.22734; Mothe AJ, 2013, BIOMATERIALS, V34, P3775, DOI 10.1016/j.biomaterials.2013.02.002; Oh JS, 2012, NEUROREPORT, V23, P174, DOI 10.1097/WNR.0b013e32834f4f3a; Orr MB, 2018, NEUROTHERAPEUTICS, V15, P541, DOI 10.1007/s13311-018-0631-6; Pertici V, 2014, BIOMATERIALS, V35, P6248, DOI 10.1016/j.biomaterials.2014.04.020; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; Reinhold AK, 2017, PFLUG ARCH EUR J PHY, V469, P123, DOI 10.1007/s00424-016-1920-8; Ritfeld GJ, 2015, CELL TRANSPLANT, V24, P2209, DOI 10.3727/096368915X686201; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Ropper AE, 2017, NEW ENGL J MED, V376, P1358, DOI 10.1056/NEJMra1516539; Sasaki M, 2009, J NEUROSCI, V29, P14932, DOI 10.1523/JNEUROSCI.2769-09.2009; Silver J, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020602; Song ZJ, 2018, BIOCHEM BIOPH RES CO, V496, P911, DOI 10.1016/j.bbrc.2018.01.123; Tam RY, 2012, J MATER CHEM, V22, P19402, DOI 10.1039/c2jm33680d; Tator CH, 2006, NEUROSURGERY, V59, P957, DOI 10.1227/01.NEU.0000245591.16087.89; Tsintou M, 2015, NEURAL REGEN RES, V10, P726, DOI 10.4103/1673-5374.156966; Wakao N, 2011, NEUROSCI LETT, V488, P299, DOI 10.1016/j.neulet.2010.11.051; Wang CX, 1997, BRAIN RES, V759, P190, DOI 10.1016/S0006-8993(97)00254-0; Widenfalk J, 2001, J NEUROSCI, V21, P3457, DOI 10.1523/JNEUROSCI.21-10-03457.2001; Xu HL, 2018, INT J NANOMED, V13, P681, DOI 10.2147/IJN.S152246; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Yao SL, 2018, INT J NANOMED, V13, P2883, DOI 10.2147/IJN.S159356; Yong CS, 2001, INT J PHARM, V226, P195, DOI 10.1016/S0378-5173(01)00809-2; Ziemba AM, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00245	47	12	15	2	19	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1178-2013			INT J NANOMED	Int. J. Nanomed.		2019	14						721	732		10.2147/IJN.S187854			12	Nanoscience & Nanotechnology; Pharmacology & Pharmacy	Science & Technology - Other Topics; Pharmacology & Pharmacy	HH9OJ	WOS:000456068000002	30705588	DOAJ Gold, Green Published			2021-06-18	
J	Kerr, NA; Vaccari, JPD; Umland, O; Bullock, MR; Conner, GE; Dietrich, WD; Keane, RW				Kerr, Nadine A.; Vaccari, Juan Pablo de Rivero; Umland, Oliver; Bullock, M. Ross; Conner, Gregory E.; Dietrich, W. Dalton; Keane, Robert W.			Human Lung Cell Pyroptosis Following Traumatic Brain Injury	CELLS			English	Article						pyroptosis; inflammasome; caspase-1; inflammation; brain injury; extracellular vesicles	EXTRACELLULAR VESICLES; ORGAN DYSFUNCTION; ENDOTHELIUM; MECHANISM; ASC	Approximately 30% of traumatic brain injured patients suffer from acute lung injury or acute respiratory distress syndrome. Our previous work revealed that extracellular vesicle (EV)-mediated inflammasome signaling plays a crucial role in the pathophysiology of traumatic brain injury (TBI)-induced lung injury. Here, serum-derived EVs from severe TBI patients were analyzed for particle size, concentration, origin, and levels of the inflammasome component, an apoptosis-associated speck-like protein containing a caspase-recruiting domain (ASC). Serum ASC levels were analyzed from EV obtained from patients that presented lung injury after TBI and compared them to EV obtained from patients that did not show any signs of lung injury. EVs were co-cultured with lung human microvascular endothelial cells (HMVEC-L) to evaluate inflammasome activation and endothelial cell pyroptosis. TBI patients had a significant increase in the number of serum-derived EVs and levels of ASC. Severe TBI patients with lung injury had a significantly higher level of ASC in serum and serum-derived EVs compared to individuals without lung injury. Only EVs isolated from head trauma patients with gunshot wounds were of neural origin. Delivery of serum-derived EVs to HMVEC-L activated the inflammasome and resulted in endothelial cell pyroptosis. Thus, serum-derived EVs and inflammasome proteins play a critical role in the pathogenesis of TBI-induced lung injury, supporting activation of an EV-mediated neural-respiratory inflammasome axis in TBI-induced lung injury.	[Kerr, Nadine A.; Vaccari, Juan Pablo de Rivero; Bullock, M. Ross; Dietrich, W. Dalton] Univ Miami, Dept Neurol Surg, Miami, FL 33136 USA; [Umland, Oliver] Univ Miami, Diabet Res Inst, Miami, FL 33136 USA; [Conner, Gregory E.] Univ Miami, Dept Cell Biol, Miami, FL 33136 USA; [Keane, Robert W.] Univ Miami, Dept Physiol & Biophys, Sch Med, 1600 NW 10th Ave RMSB 5054, Miami, FL 33136 USA	Keane, RW (corresponding author), Univ Miami, Dept Physiol & Biophys, Sch Med, 1600 NW 10th Ave RMSB 5054, Miami, FL 33136 USA.	N.Kerr@med.miami.edu; JDeRivero@med.miami.edu; oumland@med.miami.edu; RBullock@med.miami.edu; GConner@med.miami.edu; DDietrich@med.miami.edu; rkeane@miami.edu	Conner, Gregory/AAI-1285-2021; de Rivero Vaccari, Juan Pablo/H-5718-2019; de Rivero Vaccari, Juan Pablo/ABE-3248-2020	Conner, Gregory/0000-0003-2217-2252; de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834; Keane, Robert/0000-0003-4068-9511	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R42NS086274, HL132425];  [RO1 NS042133];  [NS089443]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS089443, R42NS086274, R01NS042133] Funding Source: NIH RePORTER	This project was supported in part with NIH grant R42NS086274 to RWK, NIH grant HL132425 to NAK, and RO1 NS042133 and NS089443 to WDD.	Aisiku IP, 2016, J TRAUMA ACUTE CARE, V80, P308, DOI 10.1097/TA.0000000000000903; Brand FJ, 2016, J INFLAMM-LOND, V13, DOI 10.1186/s12950-016-0137-0; Cheng KT, 2017, J CLIN INVEST, V127, P4124, DOI 10.1172/JCI94495; Eppensteiner J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00190; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Franklin BS, 2014, NAT IMMUNOL, V15, P727, DOI 10.1038/ni.2913; Garcia-Contreras M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05787-y; Gill SE, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0266-7; Goetzl EJ, 2015, ANN CLIN TRANSL NEUR, V2, P769, DOI 10.1002/acn3.211; Harrison EB, 2016, FEBS OPEN BIO, V6, P835, DOI 10.1002/2211-5463.12092; Hazelton I, 2018, J NEUROTRAUM, V35, P639, DOI 10.1089/neu.2017.5049; Hendrickson CM, 2016, J TRAUMA ACUTE CARE, V80, P989, DOI 10.1097/TA.0000000000000982; Hoss F, 2017, CELL MOL LIFE SCI, V74, P1211, DOI 10.1007/s00018-016-2396-6; Jong AY, 2017, J EXTRACELL VESICLES, V6, P1, DOI 10.1080/20013078.2017.1294368; Kerr NA, 2018, J NEUROTRAUM, V35, P2067, DOI 10.1089/neu.2017.5430; Lotvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913; Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9; Montecalvo A, 2012, BLOOD, V119, P756, DOI 10.1182/blood-2011-02-338004; Moyron RB, 2017, PROTEOM CLIN APPL, V11, DOI 10.1002/prca.201700061; Mrozek Segolene, 2015, World J Crit Care Med, V4, P163, DOI 10.5492/wjccm.v4.i3.163; Orfanos SE, 2004, INTENS CARE MED, V30, P1702, DOI 10.1007/s00134-004-2370-x; Ramtinfar S, 2016, INDIAN J CRIT CARE M, V20, P575, DOI 10.4103/0972-5229.192042; Razavi HM, 2004, AM J RESP CRIT CARE, V170, P227, DOI 10.1164/rccm.200306-846OC; Reategui E, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02261-1; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Tao SC, 2018, ADV SCI, V5, DOI 10.1002/advs.201700449; Turturici G, 2014, AM J PHYSIOL-CELL PH, V306, pC621, DOI 10.1152/ajpcell.00228.2013; van der Merwe Yolandi, 2017, Curr Ophthalmol Rep, V5, P276, DOI 10.1007/s40135-017-0153-0; Vestad B, 2017, J EXTRACELL VESICLES, V6, P1, DOI 10.1080/20013078.2017.1344087; Villar J, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006812; Wahlund CJE, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00039; Weber DJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009443; Willms E, 2016, SCI REP-UK, V6, DOI 10.1038/srep22519; Witwer KW, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2017.1396823; Yang J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.274; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	36	12	13	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2073-4409		CELLS-BASEL	Cells	JAN	2019	8	1							69	10.3390/cells8010069			15	Cell Biology	Cell Biology	HM8PD	WOS:000459742400068	30669285	DOAJ Gold, Green Published			2021-06-18	
J	Lempke, L; Jaffri, A; Erdman, N				Lempke, Landon; Jaffri, Abbis; Erdman, Nicholas			The Effects of Early Physical Activity Compared to Early Physical Rest on Concussion Symptoms	JOURNAL OF SPORT REHABILITATION			English	Article						traumatic brain injury; rehabilitation; recovery; return to play; brain concussion	ASSOCIATION	Clinical Scenario: Currently, rest following concussion serves as the keystone of concussion treatment, but substantial evidence to support it is lacking. Recent literature suggests that early physical activity may be beneficial in reducing concussion symptoms which may influence clinical recovery time. Clinical Question: Does early physical activity decrease postconcussion symptoms compared to physical rest following concussion? Summary of Key Findings: A total of 5 articles were included that examined symptom duration changes at multiple time points. All 5 studies utilized follow-up time points compared to initial examination, but there was variance in the specific time points reported. Two studies employed control groups and compared strict or recommended rest to early activity or limited rest. Three studies were observational studies that directly compared baseline measurements to follow-up assessments. Clinical Bottom Line: Current evidence suggests that early physical activity in the acute phase following a concussion may decrease the time needed for symptom resolution compared to immediate rest. Strength of Recommendation: Using Centre for Evidence-Based Medicine 2011 level 3 evidence and higher, the results suggest that early physical activity during the acute phase of a concussion may decrease symptom duration; however, a lack of high-quality studies and inconsistent interventions are limitations to this recommendation.	[Lempke, Landon; Jaffri, Abbis; Erdman, Nicholas] Univ Virginia, Charlottesville, VA 22902 USA; [Lempke, Landon] Univ Georgia, Athens, GA 30602 USA	Lempke, L (corresponding author), Univ Virginia, Charlottesville, VA 22902 USA.; Lempke, L (corresponding author), Univ Georgia, Athens, GA 30602 USA.	lblempke@uga.edu	Erdman, Nicholas/ABA-4554-2020; Lempke, Landon/C-4800-2018	Erdman, Nicholas/0000-0001-8109-7585; Lempke, Landon/0000-0003-0007-1362			Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Buckley TA, 2016, J HEAD TRAUMA REHAB, V31, P233, DOI 10.1097/HTR.0000000000000165; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Grool AM, 2016, JAMA-J AM MED ASSOC, V316, P2504, DOI 10.1001/jama.2016.17396; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McLeod TCV, 2017, J ATHL TRAINING, V52, P262, DOI 10.4085/1052-6050-51.6.06; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966	10	12	12	0	9	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1056-6716	1543-3072		J SPORT REHABIL	J. Sport Rehabil.	JAN	2019	28	1					99	105		10.1123/jsr.2017-0217			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	HI8SR	WOS:000456726700016	28952910	Bronze			2021-06-18	
J	Lichtenstein, JD; Flaro, L; Baldwin, FS; Rai, J; Erdodi, LA				Lichtenstein, Jonathan D.; Flaro, Lloyd; Baldwin, Fern S.; Rai, Jaspreet; Erdodi, Laszlo A.			Further Evidence for Embedded Performance Validity Tests in Children within the Conners' Continuous Performance Test - Second Edition	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							CARD SORTING TEST; TRAUMATIC BRAIN-INJURY; VERBAL-LEARNING TEST; CLINICAL UTILITY; DIGIT SPAN; TEST-II; ATTENTION; TRAIL; SPECIFICITY; INDICATORS	Objective: To replicate previous research on Conners' Continuous Performance Test - Second Edition subscales as performance validity tests (PVTs) in children.Method: Classification accuracy for the Omissions (OMI), Hit Reaction Time (HRT), and Perseverations (PER) subscales was computed for 414 children and adolescents.Results: Overall, OMI, HRT, and PER demonstrated good specificity but low and variable sensitivity across cutoffs.Conclusions: Results suggest that OMI, HRT, and PER can function as embedded PVTs in mixed clinical samples of children, although their clinical utility is limited by their low sensitivity. Implications for the use of these PVTs in the context of attention-deficit/hyperactivity disorder evaluations, medication-seeking patients, and sports concussion clinics are discussed.	[Lichtenstein, Jonathan D.; Baldwin, Fern S.] Geisel Sch Med Dartmouth, Dept Psychiat, Pediat Neuropsychol Program, Lebanon, NH USA; [Lichtenstein, Jonathan D.] Geisel Sch Med Dartmouth, Dept Pediat, Lebanon, NH USA; [Lichtenstein, Jonathan D.] Geisel Sch Med Dartmouth, Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA; [Rai, Jaspreet; Erdodi, Laszlo A.] Univ Windsor, Neuropsychol Track, Dept Psychol, Windsor, ON, Canada	Lichtenstein, JD (corresponding author), DHMC, Dept Psychiat, One Med Ctr Dr, Lebanon, NH 03756 USA.	jonathan.d.lichtenstein@hitchcock.org					Abeare CA, 2018, JAMA NEUROL, V75, P697, DOI 10.1001/jamaneurol.2018.0031; Altman D.G., 1994, BMJ, V309; An KY, 2017, CLIN NEUROPSYCHOL, V31, P193, DOI 10.1080/13854046.2016.1217046; Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Ashendorf L, 2017, CLIN NEUROPSYCHOL, V31, P857, DOI 10.1080/13854046.2017.1285961; Baker DA, 2014, CLIN NEUROPSYCHOL, V28, P116, DOI 10.1080/13854046.2013.858184; Baron I., 2004, NEUROPSYCHOLOGICAL E; Bernstein J. H., 1999, NEUROMETHODS, V17, P311; Bernstein J. H., 2010, PRINCIPLES PRACTICE, P17; Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Boone K. B., 2013, CLIN PRACTICE FORENS; Bordoff B, 2017, PSYCHOL INJ LAW, V10, P114, DOI 10.1007/s12207-017-9288-4; Brooks BL, 2016, CHILD NEUROPSYCHOL, V22, P1001, DOI 10.1080/09297049.2015.1075491; Brooks BL, 2015, ARCH CLIN NEUROPSYCH, V30, P200, DOI 10.1093/arclin/acv017; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Busse M, 2012, CLIN NEUROPSYCHOL, V26, P675, DOI 10.1080/13854046.2012.679623; Conners K. C., 2004, CONNERS CONTINUOUS P; Cowan N, 2006, MEM COGNITION, V34, P1754, DOI 10.3758/BF03195936; Donders J, 2011, CLIN NEUROPSYCHOL, V25, P173, DOI 10.1080/13854046.2010.536781; Erdodi LA, 2019, APPL NEUROPSYCH-ADUL, V26, P155, DOI 10.1080/23279095.2017.1384925; Erdodi LA, 2018, PSYCHOL ASSESSMENT, V30, P1082, DOI 10.1037/pas0000561; Erdodi LA, 2018, PSYCHOL INJ LAW, V11, P1, DOI 10.1007/s12207-017-9309-3; Erdodi LA, 2018, APPL NEUROPSYCH-ADUL, V25, P19, DOI 10.1080/23279095.2016.1232262; Erdodi LA, 2017, APPL NEUROPSYCH-CHIL, V6, P355, DOI 10.1080/21622965.2016.1198908; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Figueroa I., 2013, P HUM FACT ERG SOC A, V57, P828, DOI [10.1177/1541931213571180., DOI 10.1177/, 10.1177/1541931213571180, DOI 10.1177/1541931213571180]; GLAROS AG, 1988, J CLIN PSYCHOL, V44, P1013, DOI 10.1002/1097-4679(198811)44:6<1013::AID-JCLP2270440627>3.0.CO;2-Z; GOEBEL RA, 1983, J CLIN PSYCHOL, V39, P731, DOI 10.1002/1097-4679(198309)39:5<731::AID-JCLP2270390515>3.0.CO;2-T; Green, 2004, GREENS MED SYMPTOM V; Green P., 2003, MANUAL COMPUTERIZED; Green P., 2008, GREENS NONVERBAL MED; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Greve KW, 1996, ARCH CLIN NEUROPSYCH, V11, P215; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Greve KW, 2002, J CLIN EXP NEUROPSYC, V24, P48, DOI 10.1076/jcen.24.1.48.968; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Heaton R., 1993, WISCONSIN CARD SORTI; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heston TF, 2011, J MAGN RESON IMAGING, V33, P505, DOI 10.1002/jmri.22466; Huang-Pollock CL, 2002, DEV PSYCHOL, V38, P363, DOI 10.1037//0012-1649.38.3.363; Hurtubise JL, 2017, PSYCHOL INJ LAW, V10, P121, DOI 10.1007/s12207-017-9287-5; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; King JH, 2002, CLIN NEUROPSYCHOL, V16, P506, DOI 10.1076/clin.16.4.506.13912; Kirkwood M.W., 2015, VALIDITY TESTING CHI; Kirkwood MW, 2011, ARCH CLIN NEUROPSYCH, V26, P377, DOI 10.1093/arclin/acr040; Lange RT, 2017, CLIN NEUROPSYCHOL, V31, P1015, DOI 10.1080/13854046.2017.1335438; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lichtenstein JD., 2018, J PEDIATR NEUROPSYCH, V4, P94, DOI [10.1007/s40817-018-0057-4, DOI 10.1007/S40817-018-0057-4]; Lichtenstein JD, 2018, CHILD NEUROPSYCHOL, V24, P247, DOI 10.1080/09297049.2016.1259402; Lichtenstein JD, 2017, CHILD NEUROPSYCHOL, V23, P284, DOI 10.1080/09297049.2015.1135422; Marshall P, 2010, CLIN NEUROPSYCHOL, V24, P1204, DOI 10.1080/13854046.2010.514290; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; O'Bryant SE, 2003, CLIN NEUROPSYCHOL, V17, P69, DOI 10.1076/clin.17.1.69.15624; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Powell MR, 2011, CLIN NEUROPSYCHOL, V25, P108, DOI 10.1080/13854046.2010.532912; Qiu DQ, 2008, NEUROIMAGE, V41, P223, DOI 10.1016/j.neuroimage.2008.02.023; Ross TP, 2016, ARCH CLIN NEUROPSYCH, V31, P97, DOI 10.1093/arclin/acv062; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Sagar S, 2017, PSYCHOL INJ LAW, V10, P105, DOI 10.1007/s12207-017-9286-6; Santos OA, 2014, ARCH CLIN NEUROPSYCH, V29, P609, DOI 10.1093/arclin/acu039; Sherman E., 2015, CHILDREN ADOLESCENT; Sherman E.M.S., 2016, MEMORY VALIDITY PROF; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Somsen RJM, 2007, DEVELOPMENTAL SCI, V10, P664, DOI 10.1111/j.1467-7687.2007.00613.x; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003; Sussman ZW, 2019, APPL NEUROPSYCH-CHIL, V8, P70, DOI 10.1080/21622965.2017.1382359; Tombaugh TN, 1996, TEST MEMORY MALINGER; Welsh AJ, 2012, ARCH CLIN NEUROPSYCH, V27, P735, DOI 10.1093/arclin/acs063	72	12	12	0	2	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2019	44	2					159	171		10.1080/87565641.2019.1565535			13	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	HP3RJ	WOS:000461594600001	30646768				2021-06-18	
J	Robinson, ME; Mckee, AC; Salat, DH; Rasmusson, AM; Radigan, LJ; Catana, C; Milberg, WP; McGlinchey, RE				Robinson, Meghan E.; McKee, Ann C.; Salat, David H.; Rasmusson, Ann M.; Radigan, Lauren J.; Catana, Ciprian; Milberg, William P.; McGlinchey, Regina E.			Positron emission tomography of tau in Iraq and Afghanistan Veterans with blast neurotrauma	NEUROIMAGE-CLINICAL			English	Article						Blast; Positron emission tomography; Tau; Traumatic brain injury; Veteran	TRAUMATIC BRAIN-INJURY; SURFACE-BASED ANALYSIS; DEFAULT MODE NETWORK; WHITE-MATTER; HEAD TRAUMA; RISK-FACTOR; PET; EXPOSURE; SEGMENTATION; ACTIVATION	Military personnel are often exposed to multiple instances of various types of head trauma. As a result, there has been increasing concern recently over identifying when head trauma has resulted in a brain injury and what, if any, long-term consequences those brain injuries may have. Efforts to develop equipment to protect soldiers from these long-term consequences will first require understanding the types of head trauma that are likely responsible. In this study, we sought to identify the types of head trauma most likely to lead to the deposition of tau, a protein identified as a likely indicator of long-term negative consequences of brain injury. To define the types of head trauma in a military population, we applied a factor analysis to interviews from a larger cohort of 428 Veterans enrolled in the Translational Research Center for Traumatic Brain Injury and Stress Disorders. Three factors were identified: Blast Exposure, Symptom Duration, and Blunt Concussion. Sixteen male Veterans from this study and one additional male civilian (aged 25-69, mean 35.2 years) underwent simultaneous positron emission tomography/magnetic resonance imaging using a tracer that binds to tau protein, the ligand T807/AV-1451 (Flortaucipir). Standard uptake value ratios to the isthmus of the cingulate were calculated from a 20-minute time frame 70 min post-injection. We found that tracer uptake throughout the brain was associated with Blast Exposure factor beta weights, but not with either Symptom Duration or Blunt Concussion. Associations with uptake were located primarily in the cerebellar, occipital, inferior temporal and frontal regions. The data suggest that in this small, relatively young cohort of Veterans, elevated T807/AV-1451 uptake is associated with exposure to blast neurotrauma. These findings are unanticipated, as they do not match histopathological descriptions of tau pathology associated with head trauma. Continued work will be necessary to understand the nature of the regional T807/AV-1451 uptake and any associations with clinical symptoms.	[Robinson, Meghan E.; McKee, Ann C.; Salat, David H.; Radigan, Lauren J.; Milberg, William P.; McGlinchey, Regina E.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, Boston, MA USA; [Robinson, Meghan E.; Salat, David H.] VA Boston Healthcare Syst, Neuroimaging Res Vet NeRVe Ctr, Boston, MA USA; [Robinson, Meghan E.; McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA; [McKee, Ann C.] VA Boston Healthcare Syst, Dept Pathol & Lab Med, Boston, MA USA; [McKee, Ann C.] Boston Univ, Sch Med, CTE Program, Alzheimers Dis Ctr, Boston, MA 02215 USA; [McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02215 USA; [Salat, David H.; Catana, Ciprian] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Boston, MA 02114 USA; [Salat, David H.; Catana, Ciprian] Harvard Med Sch, Boston, MA 02115 USA; [Rasmusson, Ann M.] VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, Dept Vet Affairs, Boston, MA USA; [Rasmusson, Ann M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA; [Milberg, William P.; McGlinchey, Regina E.] VA Boston Healthcare Syst, Ctr Geriatr Res Educ & Clin, Boston, MA USA; [Milberg, William P.; McGlinchey, Regina E.] Harvard Med Sch, Dept Psychiat, Boston, MA 02115 USA; [Robinson, Meghan E.] One Baylor Plaza, Houston, TX 77030 USA	Robinson, ME (corresponding author), 150 South Huntington Ave, Boston, MA 02130 USA.	Meghan.Robinson@bcm.edu	Catana, Ciprian/A-1246-2013		Merit Review AwardUS Department of Veterans Affairs [RX000991]; TRACTS National Network Research Center for TBI research from the United States Department of Veterans Affairs Rehabilitation Research and Development Service [B9254-C]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000991] Funding Source: NIH RePORTER	This work was supported by Merit Review Award (RX000991) and the TRACTS National Network Research Center for TBI research (B9254-C) from the United States Department of Veterans Affairs Rehabilitation Research and Development Service.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beckmann C. F., 2009, NEUROIMAGE, V47, pS148, DOI [10.1016/S1053-8119(09)71511-3, DOI 10.1016/S1053-8119(09)71511-3]; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Belmont PJ, 2012, J TRAUMA ACUTE CARE, V73, P3, DOI 10.1097/TA.0b013e318250bfb4; Blake D, 2006, J TRAUMA STRESS, V8, P75; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Calhoun VD, 2009, NEUROIMAGE, V45, pS163, DOI 10.1016/j.neuroimage.2008.10.057; Chien DT, 2013, J ALZHEIMERS DIS, V34, P457, DOI 10.3233/JAD-122059; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Di X, 2012, BRAIN CONNECT, V2, P275, DOI 10.1089/brain.2012.0086; First MB, 1996, COMMUNICATION; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Goeller J, 2012, J NEUROTRAUM, V29, P1970, DOI 10.1089/neu.2011.2224; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Izquierdo-Garcia D, 2014, J NUCL MED, V55, P1825, DOI 10.2967/jnumed.113.136341; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Johnson KA, 2016, ANN NEUROL, V79, P110, DOI 10.1002/ana.24546; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Ladefoged CN, 2017, NEUROIMAGE, V147, P346, DOI 10.1016/j.neuroimage.2016.12.010; Lemoine Laetitia, 2018, Alzheimers Dement (Amst), V10, P232, DOI 10.1016/j.dadm.2018.01.007; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Marquie M, 2017, ANN NEUROL, V81, P117, DOI 10.1002/ana.24844; Marquie M, 2015, ANN NEUROL, V78, P787, DOI 10.1002/ana.24517; McGlinchey RE, 2017, INT J METH PSYCH RES, V26, DOI 10.1002/mpr.1556; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Robinson ME, 2015, DEV NEUROPSYCHOL, V40, P74, DOI 10.1080/87565641.2015.1012204; Robinson ME, 2015, HUM BRAIN MAPP, V36, P911, DOI 10.1002/hbm.22675; Salat DH, 2017, BRAIN INJURY, V31, P1204, DOI 10.1080/02699052.2017.1327672; Scholl M, 2016, NEURON, V89, P971, DOI 10.1016/j.neuron.2016.01.028; Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; SKINNER HA, 1982, J STUD ALCOHOL, V43, P1157, DOI 10.15288/jsa.1982.43.1157; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; The Management of Concussion/ mTBI Working Group, 2009, VA DOD CLIN PRACT GU; Trotter BB, 2015, BRAIN, V138, P2278, DOI 10.1093/brain/awv139; Vogel J. W., 2017, ALZHEIMERS DEMENT, V13, pP1548; Weathers F.W., 1993, PTSD CHECKLIST PCL R; Williams DJ, 1996, PATHOLOGY, V28, P102, DOI 10.1080/00313029600169653; Wooten DW, 2017, J NUCL MED, V58, P484, DOI 10.2967/jnumed.115.170910; Xia CF, 2013, ALZHEIMERS DEMENT, V9, P666, DOI 10.1016/j.jalz.2012.11.008; Zarrinkoob L, 2015, J CEREBR BLOOD F MET, V35, P648, DOI 10.1038/jcbfm.2014.241	61	12	12	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2019	21								101651	10.1016/j.nicl.2019.101651			9	Neuroimaging	Neurosciences & Neurology	HN6ZP	WOS:000460337700064	30642757	DOAJ Gold, Green Published			2021-06-18	
J	Rytter, HM; Westenbaek, K; Henriksen, H; Christiansen, P; Humle, F				Rytter, Hana Mala; Westenbaek, Klaus; Henriksen, Henriette; Christiansen, Peter; Humle, Frank			Specialized interdisciplinary rehabilitation reduces persistent post-concussive symptoms: a randomized clinical trial	BRAIN INJURY			English	Article						Concussion; persistent post-concussive symptoms; PCS; rehabilitation; interdisciplinary team	TRAUMATIC BRAIN-INJURY; COGNITIVE-BEHAVIORAL PREVENTION; MINOR HEAD-INJURY; GOOD OLD DAYS; POSTCONCUSSION-SYNDROME; NEUROPSYCHOLOGICAL REHABILITATION; ACTIVE REHABILITATION; FATIGUE; ETIOLOGY; EXERCISE	Objective: To compare the effectiveness of a specialized, interdisciplinary rehabilitation (S-REHAB) with standard care (STAND) for people with persistent post-concussive symptoms (PPCS > 6month).Design: Randomized controlled trial.Participants: Eighty-nine adults.Interventions: 22-week programme combining individual and group-based neuropsychological treatment with exercise therapy and physiotherapeutic coaching (S-REHAB), and the usual treatment offered by the public municipality services (STAND).Outcome Measures: The Rivermead Postconcussion Symptoms Questionnaire (RPSQ) (primary), The Headache Impact Test (HIT-6), Major Depression Inventory (MDI), Multidimensional Fatigue Inventory (MFI-20) and The Short Form (36) Health Survey (SF-36); all collected at baseline, post-treatment, and at 6-month follow-up.Results: The S-REHAB group showed a significant reduction in symptoms measured by RPSQ compared to the STAND immediately post-treatment (effect size [ES]=0.28) and at follow-up (ES=0.26). The S-REHAB groups also showed significant improvements regarding HIT-6 post-treatment (ES=0.38) and at follow-up (ES=0.68), MFI-20 - dimension mental fatigue' post-treatment (ES=0.42), MFI-20 - dimension reduced activities' at follow-up (ES=0.74) and SF-36 - dimension social functioning' post-treatment (ES=0.31).Conclusions: The S-REHAB is more effective than the STAND in reducing the PPCS affecting physical, cognitive and emotional domains. This symptom reduction was associated with experienced improvement in social functioning, increased levels of activity, a decrease in mental fatigue and increased life satisfaction.	[Rytter, Hana Mala] Univ Copenhagen, Dept Psychol, Copenhagen, Denmark; [Rytter, Hana Mala] Bispebjerg Hosp, Dept Neurol, Copenhagen, Denmark; [Westenbaek, Klaus; Henriksen, Henriette; Christiansen, Peter; Humle, Frank] Ctr Rehabil Brain Injury, Copenhagen, Denmark	Rytter, HM (corresponding author), Univ Copenhagen, Dept Psychol, Ctr Integrat Cognit Neurosci, Oester Farimagsgade 2A, DK-1353 Copenhagen K, Denmark.	hana.mala@psy.ku.dk		Rytter, Hana Mala/0000-0002-2910-372X	Foundation for Prevention and Maintenance, Denmark	This work was supported by the Foundation for Prevention and Maintenance, Denmark	Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; [Anonymous], 2012, LABOUR MARKET INSURA; Azulay J, 2013, J HEAD TRAUMA REHAB, V28, P323, DOI 10.1097/HTR.0b013e318250ebda; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Bech P, 2001, J AFFECT DISORDERS, V66, P159, DOI 10.1016/S0165-0327(00)00309-8; BECKER BJ, 1988, BRIT J MATH STAT PSY, V41, P257, DOI 10.1111/j.2044-8317.1988.tb00901.x; Belanger HG, 2013, CLIN NEUROPSYCHOL, V27, P159, DOI 10.1080/13854046.2012.758780; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bergersen K, 2017, BRAIN INJURY, V31, P279, DOI 10.1080/02699052.2016.1255779; Bjorner JB, 1998, J CLIN EPIDEMIOL, V51, P991, DOI 10.1016/S0895-4356(98)00091-2; Bjorner JB, 1998, J CLIN EPIDEMIOL, V51, P1001, DOI 10.1016/S0895-4356(98)00092-4; Burke MJ, 2015, BRAIN INJURY, V29, P300, DOI 10.3109/02699052.2014.974673; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Clarke LA, 2012, BRAIN INJURY, V26, P298, DOI 10.3109/02699052.2012.654588; Cooper DB, 2015, BRAIN IMAGING BEHAV, V9, P403, DOI 10.1007/s11682-015-9440-2; Edmed SL, 2012, APPL NEUROPSYCH-ADUL, V19, P164, DOI 10.1080/09084282.2011.643961; Elbin RJ, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0320-7; Ellis MJ, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00136; Gagnon I, 2016, SCAND J MED SCI SPOR, V26, P299, DOI 10.1111/sms.12441; Gatzounis R, 2012, CURR PAIN HEADACHE R, V16, P117, DOI 10.1007/s11916-012-0247-1; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Grabowski P, 2017, PHYS THER SPORT, V23, P22, DOI 10.1016/j.ptsp.2016.06.001; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hinkle J L, 1986, J Neurosci Nurs, V18, P268; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Johansson J, 2017, CLIN EXP OPTOM, V100, P234, DOI 10.1111/cxo.12458; Josefsson T, 2014, SCAND J MED SCI SPOR, V24, P259, DOI 10.1111/sms.12050; Junn C, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0519-7; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kristman VL, 2010, OPEN OCCUP HLTH SAF, V2, P1, DOI DOI 10.2174/1876216601002010001; Kurowski BG, 2017, J HEAD TRAUMA REHAB, V32, P79, DOI 10.1097/HTR.0000000000000238; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Leddy JJ, 2016, PHYS MED REH CLIN N, V27, P437, DOI 10.1016/j.pmr.2015.12.003; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Leininger S, 2014, J HEAD TRAUMA REHAB, V29, P109, DOI 10.1097/HTR.0b013e3182860506; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Losoi H, 2016, J NEUROTRAUM, V33, P766, DOI 10.1089/neu.2015.4070; Marshall S, 2015, BRAIN INJURY, V29, P688, DOI 10.3109/02699052.2015.1004755; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, NAT REV NEUROL, V9, P361, DOI 10.1038/nrneurol.2013.88; McDonnell MN, 2011, ARCH PHYS MED REHAB, V92, P1044, DOI 10.1016/j.apmr.2011.01.021; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meeus M, 2007, CLIN RHEUMATOL, V26, P465, DOI 10.1007/s10067-006-0433-9; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Nachit-Ouinekh F, 2005, EUR J NEUROL, V12, P189, DOI 10.1111/j.1468-1331.2004.00934.x; Nolin P, 2006, BRAIN INJURY, V20, P1147, DOI 10.1080/02699050601049247; Paniak C, 2000, BRAIN INJURY, V14, P219; Pinner M, 2003, CONSENSUS DRIVEN GUI, P1; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Rivara FP, 2014, JAMA-J AM MED ASSOC, V311, P239, DOI 10.1001/jama.2013.282985; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schwartzman RJ, 2001, ARCH NEUROL-CHICAGO, V58, P1547, DOI 10.1001/archneur.58.10.1547; Silverberg ND, 2018, J NEUROTRAUM, V35, P1864, DOI 10.1089/neu.2018.5662; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P313, DOI 10.1097/HTR.0b013e3182915cb5; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Sullivan K, 2011, J HEAD TRAUMA REHAB, V26, P170, DOI 10.1097/HTR.0b013e3181e47f95; Sullivan KA, 2018, J NEUROTRAUM, V35, P195, DOI 10.1089/neu.2016.4958; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Waljas M, 2014, J HEAD TRAUMA REHAB, V29, P443, DOI 10.1097/HTR.0000000000000002; Watt T, 2000, J EPIDEMIOL COMMUN H, V54, P827, DOI 10.1136/jech.54.11.827; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wijenberg MLM, 2017, BRAIN INJURY, V31, P1597, DOI 10.1080/02699052.2017.1366551; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Wogensen E, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/830871; Wood RL, 2011, BRAIN INJURY, V25, P1296, DOI 10.3109/02699052.2011.624569; Woodrome SE, 2011, J INT NEUROPSYCH SOC, V17, P317, DOI 10.1017/S1355617710001700	87	12	12	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2019	33	3					266	281		10.1080/02699052.2018.1552022			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	HM7DB	WOS:000459636400002	30500267				2021-06-18	
J	Liu, Z; Li, R; Jiang, C; Zhao, S; Li, WS; Tang, XB				Liu, Zhen; Li, Rui; Jiang, Cheng; Zhao, Sha; Li, Weishan; Tang, Xiaobo			The neuroprotective effect of lithium chloride on cognitive impairment through glycogen synthase kinase-3 beta inhibition in intracerebral hemorrhage rats	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Intracerebral hemorrhage; Excitotoxicity; Lithium chloride; Glycogen synthase kinase-3 beta; Collapsin response mediator protein-2; N-methyl-D-aspartate receptor 2B	NF-KAPPA-B; TRAUMATIC BRAIN-INJURY; NEURODEGENERATIVE DISEASES; WATER MAZE; ACTIVATION; EXCITOTOXICITY; PERFORMANCE; DISORDERS; TOXICITY; SURVIVAL	To the clinical cognitive impairment following intracerebral hemorrhage, comprehensive neuropsychological assessments and efficacious interventions have rarely been conducted. Lithium chloride, a classical treatment for bipolar disorder, has shown neuroprotective effects through glycogen synthase kinase-3 beta inhibition in a variety of central nervous system diseases, including stroke. Since neurons that contain glutamate play crucial roles in psychological functions, such as learning and memory, the glutamate-mediated excitotoxicity and consequent neuronal death and cognitive impairment in hippocampus may co-determine the clinical course of intracerebral hemorrhage. However, the potential molecular mechanisms have rarely been demonstrated in intracerebral hemorrhage researches. In this study, Male Sprague-Dawley rats, subjected to intrastriatal blood infusion, were treated with lithium chloride and underwent neurobehavioral test for equivalent injury severity and neurological functional deficits, Morris water maze test for cognitive impairment, high performance liquid chromatography analysis for excitotoxic index determination, immunohistochemistry analysis for neuronal apoptosis, and Western blot analysis for glycogen synthase kinase-3 beta activity. Our results showed lithium chloride inhibited glycogen synthase kinase-3 beta activation, which on one hand, suppressed downstream CRMP-2/NR2B, thus diminishing the excitotoxic index level; and on the other, stabilized beta-catenin, thus modulating its downstream apoptosis-related factors such as NF-kappa B, Bcl-2 and Bax. Meanwhile, glycogen synthase kinase-3 beta inactivation was paralleled by decreased neuronal death, improved neurological functional deficits and ameliorated cognitive deficits in intracerebral hemorrhage animals. These findings indicate that lithium chloride improves glutamate-mediated excitotoxicity-induced cognitive deficits after intracerebral hemorrhage and that lithium chloride might be a potential therapeutic agent for brain damages caused by intracerebral hemorrhage.	[Liu, Zhen; Li, Rui; Jiang, Cheng; Zhao, Sha; Li, Weishan; Tang, Xiaobo] Harbin Med Univ, Coll Pharm, Dept Biopharmaceut Sci, State Prov Key Labs Biomed Pharmaceut China, POB 19,157 Baojian Rd, Harbin 150081, Heilongjiang, Peoples R China	Tang, XB (corresponding author), Harbin Med Univ, Coll Pharm, Dept Biopharmaceut Sci, State Prov Key Labs Biomed Pharmaceut China, POB 19,157 Baojian Rd, Harbin 150081, Heilongjiang, Peoples R China.	ty6163@aliyun.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271287]	This work was supported by funding from the National Natural Science Foundation of China (grant no. 81271287, to Dr. X. Tang).	Al-Hallaq RA, 2007, J NEUROSCI, V27, P8334, DOI 10.1523/JNEUROSCI.2155-07.2007; Beurel E, 2015, PHARMACOL THERAPEUT, V148, P114, DOI 10.1016/j.pharmthera.2014.11.016; Brand C, 2014, BRIT J NEUROSURG, V28, P68, DOI 10.3109/02688697.2013.815314; Bretin S, 2006, J NEUROCHEM, V98, P1252, DOI 10.1111/j.1471-4159.2006.03969.x; Brittain JM, 2012, CHANNELS, V6, P52, DOI 10.4161/chan.18919; Carvajal FJ, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/2701526; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chiu CT, 2010, PHARMACOL THERAPEUT, V128, P281, DOI 10.1016/j.pharmthera.2010.07.006; Chong ZZ, 2007, INT J MOL MED, V19, P263; Chong ZZ, 2005, CURR NEUROVASC RES, V2, P387, DOI 10.2174/156720205774962683; Chuang DM, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00015; Deng J, 2004, MOL CARCINOGEN, V39, P139, DOI 10.1002/mc.10169; Dong XX, 2009, ACTA PHARMACOL SIN, V30, P379, DOI 10.1038/aps.2009.24; Freland L, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00014; GLOBUS MYT, 1991, NEUROSCI LETT, V127, P39, DOI 10.1016/0304-3940(91)90889-2; Guerriero RM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0545-1; Hensley K, 2011, MOL NEUROBIOL, V43, P180, DOI 10.1007/s12035-011-8166-4; Khanna R, 2012, FUTUR NEUROL, V7, P749, DOI 10.2217/FNL.12.68; King MK, 2014, PHARMACOL THERAPEUT, V141, P1, DOI 10.1016/j.pharmthera.2013.07.010; Lewerenz J, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00469; Liu L, 2015, NEUROL RES, V37, P874, DOI 10.1179/1743132815Y.0000000067; Liu SJ, 2006, J NEUROSCI, V26, P9332, DOI 10.1523/JNEUROSCI.2929-06.2006; Pereira IT, 2015, BEHAV NEUROSCI, V129, P533, DOI 10.1037/bne0000078; Perucho J, 2015, AMINO ACIDS, V47, P963, DOI 10.1007/s00726-015-1925-1; Planton M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178886; Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8; Righy C, 2016, CURR NEUROPHARMACOL, V14, P392, DOI 10.2174/1570159X14666151230110058; Rothstein JD, 1996, NEUROLOGY, V47, pS19, DOI 10.1212/WNL.47.4_Suppl_2.19S; Shim SS, 2016, J NEUROTRAUM, V33, P2065, DOI 10.1089/neu.2015.4177; Steinbrecher KA, 2005, MOL CELL BIOL, V25, P8444, DOI 10.1128/MCB.25.19.8444-8455.2005; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Xu RB, 2017, J NEUROSURG, V127, P522, DOI 10.3171/2016.7.JNS1668; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Zhang Hongsheng, 2016, NAT COMMUN, V7; Zhao SF, 2012, NEUROL RES, V34, P400, DOI 10.1179/1743132812Y.0000000025; Zheng J, 2017, J NEUROSURG, V127, P716, DOI 10.3171/2016.7.JNS152995	36	12	13	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	DEC 5	2018	840						50	59		10.1016/j.ejphar.2018.10.019			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	GY7QJ	WOS:000448807300007	30336136				2021-06-18	
J	Lee, SA; Kim, MK				Lee, Si A.; Kim, Myoung-Kwon			Effect of Low Frequency Repetitive Transcranial Magnetic Stimulation on Depression and Cognition of Patients with Traumatic Brain Injury: A Randomized Controlled Trial	MEDICAL SCIENCE MONITOR			English	Article						Brain Injuries; Cognition; Depression; Transcranial Magnetic Stimulation	DORSOLATERAL PREFRONTAL CORTEX; PARKINSONS-DISEASE; STROKE; NEGLECT; RELIABILITY; IMPROVEMENT; SYMPTOMS; APHASIA; TRAIL; SCALE	Background: This study was conducted to investigate the effects of low frequency repetitive transcranial magnetic stimulation (rTMS) of the right dorsolateral prefrontal cortex on depression and cognition in patients with traumatic brain injury. Material/Methods: To accomplish this, 13 patients who were diagnosed with traumatic brain injury were divided into an experimental group (n=7) and a control group (n=6). The experimental group received rTMS during a 30-minute session 5 days per week for 2 weeks; the control group received sham rTMS. The patients were then evaluated for depression using the Montgomery-Asberg Depression Rating Scale (MADRS) and for cognitive function using the Trail Making Test (TMT) and the Stroop Color Word Test (SCWT). Results: A significant decrease in MADRS, TMT, and SCWT was observed after the intervention in the experimental group (P<0.01), and there was a significant difference in the change value of MADRS, TMT, and SCWT compared to the control group (P<0.01). Moreover, the effect size for gains in the experimental group and control group was very strong for MADRS, TMT, and SCWT (effect size=1.44, 1.49, and 1.24 respectively). Conclusions: The results of this study suggest that application of low frequency rTMS to the right dorsolateral prefrontal cortex of patients with traumatic brain injury has a positive effect on depression and cognition.	[Lee, Si A.] Daegu Univ, Dept Phys Therapy, Grad Sch, Gyongsan, Gyeongbuk, South Korea; [Kim, Myoung-Kwon] Daegu Univ, Dept Phys Therapy, Coll Rehabil Sci, Gyongsan, Gyeongbuk, South Korea	Kim, MK (corresponding author), Daegu Univ, Dept Phys Therapy, Coll Rehabil Sci, Gyongsan, Gyeongbuk, South Korea.	skybird-98@hanmail.net			National Research Foundation of Korea (NRF) - Korea government (MSIT, Ministry of Science and ICT) [NRF-2017R1C1B5074052]	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT, Ministry of Science and ICT) (No. NRF-2017R1C1B5074052)	Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; Barwood CHS, 2011, NEUROREHABILITATION, V28, P113, DOI 10.3233/NRE-2011-0640; Boggio PS, 2005, MOVEMENT DISORD, V20, P1178, DOI 10.1002/mds.20508; Brighina F, 2003, NEUROSCI LETT, V336, P131, DOI 10.1016/S0304-3940(02)01283-1; Carneiro AM, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0235-3; Castel-Lacanal E, 2014, ANN FR ANESTH, V33, P83, DOI 10.1016/j.annfar.2013.11.006; Deblieck C, 2017, BRAIN STIMUL, V10, P428; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fitzgerald PB, 2011, J ECT, V27, P38, DOI 10.1097/YCT.0b013e3181eb30c6; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; George MS, 1997, AM J PSYCHIAT, V154, P1752, DOI 10.1176/ajp.154.12.1752; Herrmann N, 1998, STROKE, V29, P618, DOI 10.1161/01.STR.29.3.618; JENSEN AR, 1966, ACTA PSYCHOL, V25, P36, DOI 10.1016/0001-6918(66)90004-7; Kizilbash A, 2000, Pediatr Rehabil, V4, P71; Knoch D, 2006, J NEUROSCI, V26, P6469, DOI 10.1523/JNEUROSCI.0804-06.2006; Kortte Kathleen Bechtold, 2002, Appl Neuropsychol, V9, P106, DOI 10.1207/S15324826AN0902_5; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Li Y, 2015, J REHABIL MED, V47, P675, DOI 10.2340/16501977-1988; Lim JY, 2010, J REHABIL MED, V42, P447, DOI 10.2340/16501977-0553; Mak ADP, 2017, BRAIN STIMUL, V10, P378, DOI DOI 10.1016/J.BRS.2017.01.121; Maruo T, 2013, BRAIN STIMUL, V6, P884, DOI 10.1016/j.brs.2013.05.002; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; Miniussi C, 2008, BRAIN STIMUL, V1, P326, DOI 10.1016/j.brs.2008.07.002; Nielson DM, 2015, ARCH PHYS MED REHAB, V96, pS138, DOI 10.1016/j.apmr.2014.09.010; Oliveira-Maia AJ, 2017, BRAIN STIMUL, V10, P787, DOI 10.1016/j.brs.2017.03.013; Pallanti S, 2012, NEUROPSYCHOBIOLOGY, V65, P227, DOI 10.1159/000336999; Parikh S, 2007, INT ANESTHESIOL CLIN, V45, P119, DOI 10.1097/AIA.0b013e318078cfe7; Park IS, 2015, J PHYS THER SCI, V27, P773, DOI 10.1589/jpts.27.773; PascualLeone A, 1996, LANCET, V348, P233, DOI 10.1016/S0140-6736(96)01219-6; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reith FCM, 2016, INTENS CARE MED, V42, P3, DOI 10.1007/s00134-015-4124-3; Rektorova I, 2005, J NEUROL SCI, V229, P157, DOI 10.1016/j.jns.2004.11.021; Reti IM, 2015, BRAIN INJURY, V29, P789, DOI 10.3109/02699052.2015.1009168; Ridding MC, 2007, NAT REV NEUROSCI, V8, P559, DOI 10.1038/nrn2169; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Silvanto J, 2008, BRAIN TOPOGR, V21, P1, DOI 10.1007/s10548-008-0067-0; Spreen O, 2006, COMPENDIUM NEUROPSYC; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Tassinari CA, 2003, CLIN NEUROPHYSIOL, V114, P777, DOI 10.1016/S1388-2457(03)00004-X; VonLoh M, 2013, PARKINSONISM RELAT D, V19, P573, DOI 10.1016/j.parkreldis.2013.01.007; Wagner S, 2011, ARCH CLIN NEUROPSYCH, V26, P314, DOI 10.1093/arclin/acr024; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Wecker NS, 2000, NEUROPSYCHOLOGY, V14, P409, DOI 10.1037//0894-4105.14.3.409; Wobrock T, 2015, BIOL PSYCHIAT, V77, P979, DOI 10.1016/j.biopsych.2014.10.009; Yang W, 2015, J NEUROL SCI, V359, P219, DOI 10.1016/j.jns.2015.08.1541	47	12	13	3	11	INT SCIENTIFIC INFORMATION, INC	MELVILLE	150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	DEC 4	2018	24						8789	8794		10.12659/MSM.911385			6	Medicine, Research & Experimental	Research & Experimental Medicine	HD1FD	WOS:000452253600004	30513530	Green Published			2021-06-18	
J	Azizian, H; Khaksari, M; Karam, GA; Esmailidehaj, M; Farhadi, Z				Azizian, Hossein; Khaksari, Mohammad; Karam, Gholamreza Asadi; Esmailidehaj, Mansour; Farhadi, Zeinab			Cardioprotective and anti-inflammatory effects of G-protein coupled receptor 30 (GPR30) on postmenopausal type 2 diabetic rats	BIOMEDICINE & PHARMACOTHERAPY			English	Article						Diabetes; 17-beta estradiol; G1; G15; Cardiovascular; GPR30	HIGH-FAT DIET; TRAUMATIC BRAIN-INJURY; ESTROGEN-RECEPTORS; INSULIN-RESISTANCE; ANGIOTENSIN-II; CARDIOMYOCYTE APOPTOSIS; METABOLIC SYNDROME; BLOOD-PRESSURE; GPER FUNCTION; GLUCOSE	Diabetic cardiomyopathy is the most common chronic disease in postmenopausal women, but the mechanism(s) is unclear. G-protein coupled receptor 30 (GPR30) is one of the receptors that binds to 17-beta Estradiol (E2). To date, there is little information on GPR30 and its expression in postmenopausal type 2 diabetes (T2D) in the heart. The current study hypothesized that GPR30 mediated cardioprotective effects of E2 in ovariectomized diabetic rats. Female ovariectomized diabetic rats were divided in nine groups: Control, Vehicle, Diabetes, Proestrous, Non-proestrous, E-2, E2+Vehicle, E2+G15, and G1. G15 is a GPR30 antagonist, while G1 is an agonist of GPR30. T2D was induced by high fat diet and streptozotocin. E2, G1 and G15 were administrated for four weeks after establishment of T2D. Results showed that mean arterial pressure, fasting blood glucose and HOMA-IR in diabetic and vehicle groups were alleviated by E2 and G1, while salutary effects of E2 were inhibited by G15. Furthermore, E2 and G1 improved cardiac weight, atherogenic and cardiovascular risk indices; meanwhile G15 exacerbated cardiac weight and atherogenic indices. Also, diabetes increased cardiac levels of tumor necrosis factor-alpha and interleukin 6 and E2 only decreased interleukin 6. Significant decrement in the level of interleukin 10, and GPR30 protein were observed in diabetic group, whereas E2 and G1 increased the cardiac levels of interleukin 10, and GPR30 protein. Our study suggested that beneficial and anti-inflammatory effects of E2 on diabetic cardiomyopathy are probably mediated via non-genomic E2 pathways.	[Azizian, Hossein; Farhadi, Zeinab] Kerman Univ Med Sci, Dept Physiol, Fac Med, Kerman, Iran; [Azizian, Hossein; Esmailidehaj, Mansour] Shahid Sadoughi Univ Med Sci, Dept Physiol, Fac Med, Yazd, Iran; [Khaksari, Mohammad] Kerman Univ Med Sci, Endocrinol & Metab Res Ctr, Kerman, Iran; [Khaksari, Mohammad] Kerman Univ Med Sci, Physiol Res Ctr, Kerman, Iran; [Karam, Gholamreza Asadi] Kerman Univ Med Sci, Dept Biochem, Kerman, Iran; [Karam, Gholamreza Asadi] Kerman Univ Med Sci, Metab & Endocrinol Res Ctr, Kerman, Iran	Khaksari, M (corresponding author), Kerman Univ Med Sci, Endocrinol & Metab Res Ctr, Kerman, Iran.; Khaksari, M (corresponding author), Kerman Univ Med Sci, Physiol Res Ctr, Kerman, Iran.	mkhaksari@kmu.ac.ir	Asadikaram, Gholamreza/AAG-4437-2021; Azizian, Hossein/AAA-9554-2020; Haddad, Mohammad Khaksari/AAB-9025-2019; Esmailidehaj, Mansour/AAQ-5643-2021	Asadikaram, Gholamreza/0000-0002-9100-0756; Haddad, Mohammad Khaksari/0000-0003-0770-4281; Esmailidehaj, Mansour/0000-0001-6869-0966	 [95/105]	This study was a part of Ph.D. thesis of Hossein Azizian (Grant No. 95/105), we thank Mr. Y. Masoumi-Ardakani, Mr. P. Ghotbi and Mr. M. Gohargazi for their cooperation in this study.	Afrazi S, 2014, J STEROID BIOCHEM, V139, P98, DOI 10.1016/j.jsbmb.2013.10.010; Al-Rasheed NM, 2016, DRUG DES DEV THER, V10, P2095, DOI 10.2147/DDDT.S109287; Antony PJ, 2017, BIOMED PHARMACOTHER, V88, P1098, DOI 10.1016/j.biopha.2017.01.170; Apaijai N, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170886; Bansal S, 2018, MOL CELL ENDOCRINOL, V460, P152, DOI 10.1016/j.mce.2017.07.017; Bansal S, 2014, GEN COMP ENDOCR, V206, P51, DOI 10.1016/j.ygcen.2014.06.013; Barouch LA, 2006, CIRC RES, V98, P119, DOI 10.1161/01.RES.0000199348.10580.1d; Barton M, 2013, J CARDIOVASC PHARM, V62, P22, DOI 10.1097/FJC.0b013e31829709d4; Bell DSH, 2003, DIABETES CARE, V26, P2433, DOI 10.2337/diacare.26.8.2433; Berry B, 1997, BEHAV NEUROSCI, V111, P267, DOI 10.1037/0735-7044.111.2.267; Bhandari U, 2015, INDIAN J MED RES, V142, P598, DOI 10.4103/0971-5916.171290; Blasko E, 2009, J NEUROIMMUNOL, V214, P67, DOI 10.1016/j.jneuroim.2009.06.023; Brower GL, 2003, MOL CELL BIOCHEM, V251, P89, DOI 10.1023/A:1025438000942; Brunsing RL, 2011, IMMUNOLOGY, V134, P93, DOI 10.1111/j.1365-2567.2011.03471.x; Bryzgalova G, 2008, AM J PHYSIOL-ENDOC M, V295, pE904, DOI 10.1152/ajpendo.90248.2008; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Cheng S, 2010, CIRCULATION, V122, P570, DOI 10.1161/CIRCULATIONAHA.110.937821; Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013; Domenighetti AA, 2007, J MOL CELL CARDIOL, V42, P63, DOI 10.1016/j.yjmcc.2006.09.019; Ferder L, 2006, CURR HYPERTENS REP, V8, P191, DOI 10.1007/s11906-006-0050-7; Fielitz J, 2004, J MOL MED, V82, P809, DOI 10.1007/s00109-004-0606-4; Galipeau D, 2002, AM J PHYSIOL-HEART C, V283, pH2478, DOI 10.1152/ajpheart.00243.2002; Gillies G. E., 2010, PHARMACOL REV; GRAY P, 1982, PHYSIOL BEHAV, V29, P287, DOI 10.1016/0031-9384(82)90017-8; Gunson MJ, 2009, AM J ORTHOD DENTOFAC, V136, P772, DOI 10.1016/j.ajodo.2009.07.011; Guo R, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/430791; Haas E, 2009, CIRC RES, V104, P288, DOI 10.1161/CIRCRESAHA.108.190892; He JH, 2015, PEPTIDES, V64, P49, DOI 10.1016/j.peptides.2014.12.012; Holmes A, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/307285; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Iozzo P, 2002, DIABETES, V51, P3020, DOI 10.2337/diabetes.51.10.3020; Jessup JA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015433; Joukar S, 2012, EXCLI J, V11, P480; Kanaya AM, 2003, ANN INTERN MED, V138, P1, DOI 10.7326/0003-4819-138-1-200301070-00005; KANNEL WB, 1979, CIRCULATION, V59, P8, DOI 10.1161/01.CIR.59.1.8; Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402; Kawasaki T, 2008, MOL IMMUNOL, V45, P376, DOI 10.1016/j.molimm.2007.06.148; Khaksari M, 2015, INT IMMUNOPHARMACOL, V28, P279, DOI 10.1016/j.intimp.2015.05.046; Khaksari M, 2015, BRAIN RES, V1618, P1, DOI 10.1016/j.brainres.2015.05.017; Khaksari M, 2013, CAN J PHYSIOL PHARM, V91, P700, DOI 10.1139/cjpp-2012-0359; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI 10.1139/y10-103; Kumar R, 2012, AM J PHYSIOL-REG I, V302, pR510, DOI 10.1152/ajpregu.00512.2011; Lastra G, 2014, ENDOCRIN METAB CLIN, V43, P103, DOI 10.1016/j.ecl.2013.09.005; Lindsey SH, 2009, ENDOCRINOLOGY, V150, P3753, DOI 10.1210/en.2008-1664; Litwak SA, 2014, ENDOCRINOLOGY, V155, P4447, DOI 10.1210/en.2014-1342; Liu L, 2016, AM J PHYSIOL-HEART C, V310, pH953, DOI 10.1152/ajpheart.00631.2015; Lontchi-Yimagou E, 2013, CURR DIABETES REP, V13, P435, DOI 10.1007/s11892-013-0375-y; Maghool F, 2013, BRAIN RES, V1497, P61, DOI 10.1016/j.brainres.2012.12.014; Mahmoodzadeh S, 2010, CARDIOVASC RES, V85, P719, DOI 10.1093/cvr/cvp350; MANDL AM, 1951, J EXP BIOL, V28, P585; MANDL AM, 1951, J EXP BIOL, V28, P576; Martensson UEA, 2009, ENDOCRINOLOGY, V150, P687, DOI 10.1210/en.2008-0623; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Meoli L, 2014, GENE, V540, P210, DOI 10.1016/j.gene.2014.02.036; Meyer MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079245; Mikkola TS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063347; Muruganandan S, 2005, J ETHNOPHARMACOL, V97, P497, DOI 10.1016/j.jep.2004.12.010; Nordell VL, 2003, NEUROBIOL AGING, V24, P733, DOI 10.1016/S0197-4580(02)00193-8; O'Donnell E, 2014, AM J PHYSIOL-REG I, V307, pR498, DOI 10.1152/ajpregu.00182.2014; OBERHOLZER A, 2000, CRIT CARE MED S, V28; Packer C. Subah, 2007, ESTROGEN PROTECTION; Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90; Prossnitz ER, 2015, J STEROID BIOCHEM, V153, P114, DOI 10.1016/j.jsbmb.2015.06.014; Prossnitz ER, 2014, MOL CELL ENDOCRINOL, V389, P71, DOI 10.1016/j.mce.2014.02.002; Putnam K, 2012, AM J PHYSIOL-HEART C, V302, pH1219, DOI 10.1152/ajpheart.00796.2011; Rahman MM, 2017, BIOMED PHARMACOTHER, V92, P606, DOI 10.1016/j.biopha.2017.05.035; Recchiuti A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00298; Reichelt ME, 2013, AM J PHYSIOL-HEART C, V305, pH779, DOI 10.1152/ajpheart.00141.2013; Reimer AE, 2018, NEUROPHARMACOLOGY, V131, P104, DOI 10.1016/j.neuropharm.2017.12.015; Resanovic I, 2013, HORM METAB RES, V45, P701, DOI 10.1055/s-0033-1343478; Ribas V, 2010, AM J PHYSIOL-ENDOC M, V298, pE304, DOI 10.1152/ajpendo.00504.2009; Rubanyi GM, 1997, J CLIN INVEST, V99, P2429, DOI 10.1172/JCI119426; Salpeter SR, 2006, DIABETES OBES METAB, V8, P538, DOI 10.1111/j.1463-1326.2005.00545.x; Sharma G, 2018, J STEROID BIOCHEM, V176, P31, DOI 10.1016/j.jsbmb.2017.02.012; Singh VP, 2008, DIABETES, V57, P3297, DOI 10.2337/db08-0805; Sivasinprasasn S, 2016, MENOPAUSE, V23, P894, DOI 10.1097/GME.0000000000000640; Srinivasan K, 2004, METHOD FIND EXP CLIN, V26, P327, DOI 10.1358/mf.2004.26.5.831322; Tawfik SH, 2015, BIOCHEM RES INT, V2015, DOI 10.1155/2015/567945; Tiano JP, 2012, NAT REV ENDOCRINOL, V8, P342, DOI 10.1038/nrendo.2011.242; Tuttle HA, 2004, J DIABETES COMPLICAT, V18, P343, DOI 10.1016/S1056-8727(03)00088-6; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wang H, 2012, CARDIOVASC RES, V94, P96, DOI 10.1093/cvr/cvs090; Weng Y, 2014, J ETHNOPHARMACOL, V152, P553, DOI 10.1016/j.jep.2014.02.001; Xu Y, 2003, CARDIOVASC RES, V57, P388, DOI 10.1016/S0008-6363(02)00705-8; Yang LF, 2015, BBA-MOL BASIS DIS, V1852, P209, DOI 10.1016/j.bbadis.2014.05.006; Yang LS, 2006, MOL IMMUNOL, V43, P357, DOI 10.1016/j.molimm.2005.02.012; Yang SL, 2006, AM J PHYSIOL-HEART C, V291, pH2807, DOI 10.1152/ajpheart.00195.2006; Yates MA, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-20	88	12	12	1	4	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0753-3322	1950-6007		BIOMED PHARMACOTHER	Biomed. Pharmacother.	DEC	2018	108						153	164		10.1016/j.biopha.2018.09.028			12	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	HA2UZ	WOS:000450101800020	30218860	Other Gold			2021-06-18	
J	Degeilh, F; Bernier, A; Gravel, J; Beauchamp, MH				Degeilh, Fanny; Bernier, Annie; Gravel, Jocelyn; Beauchamp, Miriam H.			Developmental trajectories of adaptive functioning following early mild traumatic brain injury	DEVELOPMENTAL PSYCHOBIOLOGY			English	Article						concussion; growth curve modeling; preschool children; social competence; traumatic brain injury	OUTCOME 30 MONTHS; SOCIAL OUTCOMES; HEAD-INJURY; SHORT-TERM; CHILDREN; BEHAVIOR; EPIDEMIOLOGY; ADOLESCENTS; PREDICTORS; RECOVERY	Adaptive behavior impairments have been reported in children with severe traumatic brain injury (TBI) but are not typically found following mild TBI. It is possible that mild TBI induces subtle changes in adaptive functioning that are not captured in conventional group comparisons. This study aimed to explore time course changes in adaptive functioning following early mild TBI. Parents of 63 children with mild TBI and 53 children with orthopedic injuries aged between 1.5 and 5 years at the time of injury completed the Adaptive Behavior Assessment System-II at three time points: retrospectively to assess pre-injury functioning, then at 6 and 18 months post-injury. Developmental trajectories of adaptive functioning domains (practical, conceptual, and social) reported by parents were modeled using linear mixed-model analyses. Findings suggest that mild TBI may disrupt the expected developmental progression of children's social adaptive behavior, but does not appear to alter practical and conceptual domains.	[Degeilh, Fanny; Bernier, Annie; Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Degeilh, Fanny; Beauchamp, Miriam H.] St Justine Res Ctr, Montreal, PQ, Canada; [Gravel, Jocelyn] Univ Montreal, St Justine Hosp, Montreal, PQ, Canada	Beauchamp, MH (corresponding author), Univ Montreal, Dept Psychol, Montreal, PQ, Canada.	miriam.beauchamp@umontreal.ca	Degeilh, Fanny/AAA-7445-2019; Degeilh, Fanny/AAA-8353-2021	Degeilh, Fanny/0000-0002-5802-4975; 	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [MOP111036]; Fonds de Recherche du Quebec en SanteFonds de la Recherche en Sante du Quebec	Canadian Institutes of Health Research (CIHR), Grant/Award Number: MOP111036; Fonds de Recherche du Quebec en Sante	Achenbach T. M., 2000, MANUAL ASEBA PRESCHO; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson V, 2017, J NEUROTRAUM, V34, P2261, DOI 10.1089/neu.2016.4692; Anderson V, 2012, DISABIL REHABIL, V34, P1639, DOI 10.3109/09638288.2012.656789; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; [Anonymous], 2006, MONOGR SOC RES CHILD, V71, P65; Barr DJ, 2013, J MEM LANG, V68, P255, DOI 10.1016/j.jml.2012.11.001; Beauchamp MH, 2013, HAND CLINIC, V112, P913, DOI 10.1016/B978-0-444-52910-7.00013-1; Beauchamp MH, 2017, NEUROPSYCHOLOGY, V31, P981, DOI 10.1037/neu0000395; Beauchamp MH, 2017, J NEUROTRAUM, V34, P2545, DOI 10.1089/neu.2016.4868; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Bellerose J, 2017, NEUROPSYCHOLOGY, V31, P229, DOI 10.1037/neu0000341; Bellerose J, 2015, J INT NEUROPSYCH SOC, V21, P483, DOI 10.1017/S1355617715000569; Caravella KE, 2017, RES AUTISM SPECT DIS, V40, P1, DOI 10.1016/j.rasd.2017.05.002; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Curran PJ, 2010, J COGN DEV, V11, P121, DOI 10.1080/15248371003699969; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Forsyth R, 2012, CAN MED ASSOC J, V184, P1257, DOI 10.1503/cmaj.111045; Frith C, 2005, CURR BIOL, V15, pR644, DOI 10.1016/j.cub.2005.08.041; Gagner C, 2018, PSYCHOL MED, V48, P1551, DOI 10.1017/S0033291717003221; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; Gibbons RD, 2010, ANNU REV CLIN PSYCHO, V6, P79, DOI 10.1146/annurev.clinpsy.032408.153550; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hoffman L, 2015, MULTIVAR APPL SER, P1; Karver CL, 2012, REHABIL PSYCHOL, V57, P256, DOI 10.1037/a0029522; Lalonde G, 2018, J NEUROPSYCHOL, V12, P1, DOI 10.1111/jnp.12104; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; Mathias JL, 2013, BRAIN INJURY, V27, P887, DOI 10.3109/02699052.2013.793398; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; McInnes K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174847; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Mirman D., 2014, GROWTH CURVE ANAL VI; Murray A, 2014, J INTELL DISABIL RES, V58, P777, DOI 10.1111/jir.12092; Oakland T, 2008, ADAPTIVE BEHAV ASSES; Reynolds C.R., 1992, BEHAV ASSESSMENT SYS; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Ryan NP, 2016, NEUROSCI BIOBEHAV R, V64, P196, DOI 10.1016/j.neubiorev.2016.02.020; Schalock R. L., 2010, INTELLECTUAL DISABIL; Shultz EL, 2016, NEUROPSYCHOLOGY, V30, P830, DOI 10.1037/neu0000288; Singer J.D., 2003, APPL LONGITUDINAL DA; SPARROW SS, 1984, INTERVIEW EDITION EX; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Thurber S., 2012, ARCH ASSESSMENT PSYC, V2, P73; Treble-Barna A, 2017, J NEUROTRAUM, V34, P353, DOI 10.1089/neu.2016.4476; Verger K, 2000, BRAIN INJURY, V14, P495; Wade SL, 2016, JAMA PEDIATR, V170, P343, DOI 10.1001/jamapediatrics.2015.4485; Wang M. C., 2009, NEUROTRAUMA CRITICAL, P87; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	61	12	12	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0012-1630	1098-2302		DEV PSYCHOBIOL	Dev. Psychobiol.	DEC	2018	60	8					1037	1047		10.1002/dev.21786			11	Developmental Biology; Psychology	Developmental Biology; Psychology	HE8DT	WOS:000453674500014	30276812				2021-06-18	
J	Erdodi, LA; Kirsch, NL; Sabelli, AG; Abeare, CA				Erdodi, Laszlo A.; Kirsch, Ned L.; Sabelli, Alana G.; Abeare, Christopher A.			The Grooved Pegboard Test as a Validity Indicatora Study on Psychogenic Interference as a Confound in Performance Validity Research	PSYCHOLOGICAL INJURY & LAW			English	Article						Grooved Pegboard Test; Performance validity; Psychogenic interference; Manual dexterity; BDI-II; SCL-90-R	TRAUMATIC BRAIN-INJURY; PERSONALITY-ASSESSMENT INVENTORY; RECOGNITION MEMORY TEST; MALINGERED NEUROCOGNITIVE DYSFUNCTION; FORCED-CHOICE RECOGNITION; VERBAL-LEARNING TEST; EXCESSIVE COGNITIVE SYMPTOMS; RELIABLE DIGIT SPAN; COMPLEX FIGURE TEST; CARD SORTING TEST	This study was designed to replicate an earlier report on the link between low scores on the Grooved Pegboard test (GPB), invalid responding, and elevated self-reported psychiatric symptoms. A fixed battery of neuropsychological tests was administered to 100 consecutively referred outpatients (M-Age=38.3, M-Education=13.6years) following traumatic brain injury at a Midwestern academic medical center. Classification accuracy of GPB validity cutoffs was computed against a free-standing PVT and three composite measures of embedded validity indicators. Previously suggested GPB validity cutoffs (T29 in either hand) produced good combinations of sensitivity (0.25-0.55) and specificity (0.89-0.98) to psychometrically defined invalid performance. Raising the cutoff to T31 resulted in a reasonable trade-off between increased sensitivity (0.36-0.55) and decreased specificity (0.84-0.94). T31 in both hands was highly specific (0.93-0.98) to noncredible responding. GPB validity cutoffs were unrelated to psychiatric symptoms or injury severity. Failing PVTs based on forced choice recognition was associated with elevated self-reported depression, somatic concerns, and overall symptomatology. Low scores on the GPB are reliable indicators of noncredible responding. Self-reported emotional distress has a complex relationship with performance validity. Psychogenic interference is a potential mechanism behind PVT failures, and its expression is likely mediated by instrumentation and sampling artifacts. Further research on the topic is clearly needed to advance current understanding of psychogenic interference as a confound in cognitive testing.	[Erdodi, Laszlo A.; Abeare, Christopher A.] Univ Windsor, Neuropsychol Track, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada; [Kirsch, Ned L.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Sabelli, Alana G.] Univ Windsor, Brain Cognit Neurosci Program, Windsor, ON, Canada	Erdodi, LA (corresponding author), Univ Windsor, Neuropsychol Track, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com		Abeare, Christopher/0000-0002-7163-7434			An KY, 2019, J CLIN EXP NEUROPSYC, V41, P15, DOI 10.1080/13803395.2018.1483488; Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Arnold G, 2007, ASSESSMENT FEIGNED C; Ashendorf L, 2003, CLIN NEUROPSYCHOL, V17, P255, DOI 10.1076/clin.17.2.255.16502; Ashendorf L, 2017, CLIN NEUROPSYCHOL, V31, P857, DOI 10.1080/13854046.2017.1285961; Axelrod BN, 2014, CLIN NEUROPSYCHOL, V28, P876, DOI 10.1080/13854046.2014.907583; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Bearden CE, 2006, PSYCHIAT RES, V142, P139, DOI 10.1016/j.psychres.2005.08.010; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Bell-Sprinkel TL, 2013, CLIN NEUROPSYCHOL, V27, P516, DOI 10.1080/13854046.2012.744853; Berry DTR, 1996, J PERS ASSESS, V67, P26, DOI 10.1207/s15327752jpa6701_2; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Bigler ED, 2014, BRAIN INJURY, V28, P1623, DOI 10.3109/02699052.2014.947627; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Boone, 2007, ASSESSMENT FEIGNED C; Boone D, 1998, J CLIN PSYCHOL, V54, P839, DOI 10.1002/(SICI)1097-4679(199810)54:6<839::AID-JCLP12>3.3.CO;2-X; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone KB, 2007, ARCH CLIN NEUROPSYCH, V22, P675, DOI 10.1016/j.acn.2007.07.005; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Bush SS, 2014, PSYCHOL INJ LAW, V7, P197, DOI 10.1007/s12207-014-9198-7; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Chafetz MD, 2015, CLIN NEUROPSYCHOL, V29, P723, DOI 10.1080/13854046.2015.1099738; Christensen H, 1997, J Int Neuropsychol Soc, V3, P631; Conners K. C., 2004, CONNERS CONTINUOUS P; Considine CM, 2011, ARCH CLIN NEUROPSYCH, V26, P445, DOI 10.1093/arclin/acr041; Costabile T, 2018, PSYCHIAT CLIN NEUROS, V72, P189, DOI 10.1111/pcn.12630; Cottingham ME, 2014, CLIN NEUROPSYCHOL, V28, P1030, DOI 10.1080/13854046.2014.951397; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P1278, DOI 10.1080/13854046.2014.975844; Dean AC, 2009, CLIN NEUROPSYCHOL, V23, P133, DOI 10.1080/13854040701819050; DeFilippis NA, 1997, MANUAL BOOKLET CATEG; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; Derogatis L.R., 1994, SCL 90 R ADM SCORING, V3rd; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; Donders J, 2011, CLIN NEUROPSYCHOL, V25, P173, DOI 10.1080/13854046.2010.536781; Dunn L., 2007, PEABODY PICTURE VOCA, V4th ed.; Egeland J, 2005, ACTA PSYCHIAT SCAND, V112, P434, DOI 10.1111/j.1600-0447.2005.00599.x; Erdodi L. A., 2017, ARCH CLIN NEUROPSYCH, DOI [10. 1093/arclin/acx110, DOI 10.1093/ARCLIN/ACX110]; Erdodi LA, 2019, APPL NEUROPSYCH-ADUL, V26, P155, DOI 10.1080/23279095.2017.1384925; Erdodi LA, 2018, PSYCHOL ASSESSMENT, V30, P1082, DOI 10.1037/pas0000561; Erdodi LA, 2018, APPL NEUROPSYCH-ADUL, V25, P327, DOI 10.1080/23279095.2017.1298600; Erdodi LA, 2018, PSYCHOL ASSESSMENT, V30, P755, DOI 10.1037/pas0000525; Erdodi LA, 2018, PSYCHOL INJ LAW, V11, P1, DOI 10.1007/s12207-017-9309-3; Erdodi LA, 2017, BRAIN INJURY, V31, P1362, DOI 10.1080/02699052.2017.1332386; Erdodi LA, 2018, APPL NEUROPSYCH-ADUL, V25, P19, DOI 10.1080/23279095.2016.1232262; Erdodi LA, 2017, J CLIN EXP NEUROPSYC, V39, P369, DOI 10.1080/13803395.2016.1230181; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Giromini L, 2018, PSYCHOL INJ LAW, V11, P340, DOI 10.1007/s12207-018-9314-1; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 2003, GREENS WORD MEMORY T; Green P., 2008, GREENS NONVERBAL MED; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greiffenstein MF, 2008, CLIN NEUROPSYCHOL, V22, P565, DOI 10.1080/13854040701377810; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; Halstead WC., 1947, BRAIN INTELLIGENCE Q; Heaton R., 1993, WISCONSIN CARD SORTI; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Heaton RK, 2004, REVISED COMPREHENSIV; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Henry GK, 2018, J INT NEUROPSYCH SOC, V24, P735, DOI 10.1017/S1355617718000218; Hopwood CJ, 2007, J NERV MENT DIS, V195, P266, DOI 10.1097/01.nmd.0000253747.44836.61; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Jasinski LJ, 2011, J CLIN EXP NEUROPSYC, V33, P300, DOI 10.1080/13803395.2010.516743; Johnson JL, 1997, ARCH CLIN NEUROPSYCH, V12, P231, DOI 10.1016/S0887-6177(96)00040-6; JOHNSON RW, 1989, J COUNS PSYCHOL, V36, P110; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; Kalfon TBO, 2016, J PSYCHOSOM RES, V87, P30, DOI 10.1016/j.jpsychores.2016.06.004; Karlin BE, 2005, J CLIN PSYCHOL, V61, P1571, DOI 10.1002/jclp.20209; Kemp S, 2008, J PSYCHOSOM RES, V65, P319, DOI 10.1016/j.jpsychores.2008.02.010; Kiewel NA, 2012, CLIN NEUROPSYCHOL, V26, P965, DOI 10.1080/13854046.2012.694478; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; Kjaergaard M, 2014, SCAND J PSYCHOL, V55, P83, DOI 10.1111/sjop.12090; Kulas JF, 2014, PSYCHOL INJ LAW, V7, P236, DOI 10.1007/s12207-014-9200-4; Lafayette Instrument, 2015, GROOV PERGB US MAN; Lange RT, 2017, CLIN NEUROPSYCHOL, V31, P1015, DOI 10.1080/13854046.2017.1335438; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Langenecker SA, 2005, J CLIN EXP NEUROPSYC, V27, P320, DOI 10.1080/13803390490490515720; Larrabee, 2012, FORENSIC NEUROPSYCHO, P116; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P813, DOI 10.1080/13854040701625846; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Leighton A, 2014, J INT NEUROPSYCH SOC, V20, P873, DOI 10.1017/S135561771400085X; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Lichtenstein JD, 2018, CHILD NEUROPSYCHOL, V24, P247, DOI 10.1080/09297049.2016.1259402; Lichtenstein JD, 2017, CHILD NEUROPSYCHOL, V23, P284, DOI 10.1080/09297049.2015.1135422; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; MacAllister WS, 2009, CHILD NEUROPSYCHOL, V15, P521, DOI 10.1080/09297040902748226; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; McGuire BE, 2001, J CLIN PSYCHOL, V57, P1589, DOI 10.1002/jclp.1121; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Morey L. C., 1991, PERSONALITY ASSESSME; Nelson NW, 2003, CLIN NEUROPSYCHOL, V17, P263, DOI 10.1076/clin.17.2.263.16511; Odland AP, 2015, PSYCHOL INJ LAW, V8, P46, DOI 10.1007/s12207-015-9216-4; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Pearson, 2009, ADV CLIN SOLUTIONS W; Persinger VC, 2018, CLIN NEUROPSYCHOL, V32, P1039, DOI 10.1080/13854046.2017.1419507; Rapport LJ, 1998, J CLIN EXP NEUROPSYC, V20, P89, DOI 10.1076/jcen.20.1.89.1488; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Reese CS, 2012, ARCH CLIN NEUROPSYCH, V27, P176, DOI 10.1093/arclin/acr117; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Roth R.M., 2017, PSYCHOL NEUROSCI, V10, DOI [https//doi.org/10.1037/pne0000103, DOI 10.1037/PNE0000103]; Schwartz ES, 2016, J INT NEUROPSYCH SOC, V22, P851, DOI 10.1017/S1355617716000746; Shura RD, 2016, APPL NEUROPSYCH-ADUL, V23, P94, DOI 10.1080/23279095.2015.1014556; Siefert CJ, 2009, ASSESSMENT, V16, P373, DOI 10.1177/1073191109333756; Sims JA, 2013, J PERS ASSESS, V95, P495, DOI 10.1080/00223891.2013.775137; Sinclair SJ, 2015, B MENNINGER CLIN, V79, P305, DOI 10.1521/bumc.2015.79.4.305; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Sprinkle SD, 2002, J COUNS PSYCHOL, V49, P381, DOI 10.1037//0022-0167.49.3.381; Storch EA, 2004, DEPRESS ANXIETY, V19, P187, DOI 10.1002/da.20002; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr JA, 2003, J PSYCHOSOM RES, V55, P321, DOI 10.1016/S0022-3999(02)00628-1; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Suhr J, 2012, CLIN NEUROPSYCHOL, V26, P1128, DOI 10.1080/13854046.2012.713121; Sullivan K, 2010, PSYCHIAT RES, V176, P75, DOI 10.1016/j.psychres.2008.07.013; Sussman Z. W., 2017, APPL NEUROPSYCHOLOGY; Trueblood W., 1994, J CLIN EXPT NEUROPSY, V4, P697, DOI DOI 10.1080/01688639408402671; Tyson BT, 2018, EPILEPSY BEHAV, V87, P39, DOI 10.1016/j.yebeh.2018.08.010; van Gorp WG, 1999, J CLIN EXP NEUROPSYC, V21, P245; Viglione DJ, 2017, J PERS ASSESS, V99, P534, DOI 10.1080/00223891.2016.1233882; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Westcott MC, 2005, BRAIN INJURY, V19, P1261, DOI 10.1080/02699050500150104; Whiteside DM, 2015, J CLIN EXP NEUROPSYC, V37, P220, DOI 10.1080/13803395.2014.1002758; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME, V4th; Williamson DJ, 2012, CLIN NEUROPSYCHOL, V26, P588, DOI 10.1080/13854046.2012.670266; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; Zenisek R, 2016, ARCH CLIN NEUROPSYCH, V31, P426, DOI 10.1093/arclin/acw025; Zuccato BG, 2018, PSYCHOL ASSESSMENT, V30, P1491, DOI 10.1037/pas0000596	147	12	12	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1938-971X	1938-9728		PSYCHOL INJ LAW	Psychol. Inj. Law	DEC	2018	11	4					307	324		10.1007/s12207-018-9337-7			18	Psychology, Clinical	Psychology	HA8UB	WOS:000450568200001					2021-06-18	
J	Flygt, J; Ruscher, K; Norberg, A; Mir, A; Gram, H; Clausen, F; Marklund, N				Flygt, Johanna; Ruscher, Karsten; Norberg, Amanda; Mir, Anis; Gram, Hermann; Clausen, Fredrik; Marklund, Niklas			Neutralization of Interleukin-1 beta following Diffuse Traumatic Brain Injury in the Mouse Attenuates the Loss of Mature Oligodendrocytes	JOURNAL OF NEUROTRAUMA			English	Article						fluid percussion injury; inflammation; IL-1 beta; microglia; oligodendrocyte; oligodendrocyte progenitor cells; Olig2; traumatic brain injury	FLUID PERCUSSION INJURY; MICROGLIAL ACTIVATION; INFLAMMATORY RESPONSE; KINASE-ACTIVITY; AXONAL INJURY; DEATH; EXPRESSION; IL-1-BETA; PATHOLOGY; CELLS	Traumatic brain injury (TBI) commonly results in injury to the components of the white matter tracts, causing post-injury cognitive deficits. The myelin-producing oligodendrocytes (OLs) are vulnerable to TBI, although may potentially be replaced by proliferating oligodendrocyte progenitor cells (OPCs). The cytokine interleukin-1 beta (IL-1 beta) is a key mediator of the complex inflammatory response, and when neutralized in experimental TBI, behavioral outcome was improved. To evaluate the role of IL-1 beta on oligodendrocyte cell death and OPC proliferation, 116 adult male mice subjected to sham injury or the central fluid percussion injury (cFPI) model of traumatic axonal injury, were analyzed at two, seven, and 14 days post-injury. At 30 min post-injury, mice were randomly administered an IL-1 beta neutralizing or a control antibody. OPC proliferation (5-ethynyl 2 '- deoxyuridine (EdU)/Olig2 co-labeling) and mature oligodendrocyte cell loss was evaluated in injured white matter tracts. Microglia/macrophages immunohistochemistry and ramification using Sholl analysis were also evaluated. Neutralizing IL-1 beta resulted in attenuated cell death, indicated by cleaved caspase-3 expression, and attenuated loss of mature OLs from two to seven days post-injury in brain-injured animals. IL-1 beta neutralization also attenuated the early, two day post-injury increase of microglia/macrophage immunoreactivity and altered their ramification. The proliferation of OPCs in brain-injured animals was not altered, however. Our data suggest that IL-1 beta is involved in the TBI-induced loss of OLs and early microglia/macrophage activation, although not the OPC proliferation. Attenuated oligodendrocyte cell loss may contribute to the improved behavioral outcome observed by IL-1 beta neutralization in this mouse model of diffuse TBI.	[Flygt, Johanna; Norberg, Amanda; Clausen, Fredrik; Marklund, Niklas] Uppsala Univ, Sect Neurosurg, Dept Neurosci, Uppsala, Sweden; [Ruscher, Karsten] Novartis Inst Biomed Res, Basel, Switzerland; [Mir, Anis; Gram, Hermann; Marklund, Niklas] Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Neurosurg, Lund, Sweden	Marklund, N (corresponding author), Uppsala Univ Hosp, Dept Neurosurg, Sjukhusvagen 1,Ing 85,2nd Floor, SE-75185 Uppsala, Sweden.	niklas.marklund@neuro.uu.se		Clausen, Fredrik/0000-0003-3592-4417			ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; ANKARCRONA M, 1994, EXP CELL RES, V213, P172, DOI 10.1006/excr.1994.1187; Bachstetter AD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149451; Bachstetter AD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0289-5; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Bradl M, 2010, ACTA NEUROPATHOL, V119, P37, DOI 10.1007/s00401-009-0601-5; Brogi A, 1997, J CELL BIOCHEM, V66, P532, DOI 10.1002/(SICI)1097-4644(19970915)66:4<532::AID-JCB12>3.0.CO;2-D; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Dent KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121541; Desmond DW, 2002, CEREBROVASC DIS, V13, P53, DOI 10.1159/000049151; Di Iorio A, 2003, CYTOKINE, V22, P198, DOI 10.1016/S1043-4666(03)00152-2; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Ekmark-Lewen S, 2016, EUR J NEUROSCI, V43, P1016, DOI 10.1111/ejn.13190; Ekmark-Lewen S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-44; Fischer CP, 2004, J PHYSIOL-LONDON, V558, P633, DOI 10.1113/jphysiol.2004.066779; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Flygt J, 2017, RESTOR NEUROL NEUROS, V35, P251, DOI 10.3233/RNN-160675; Flygt J, 2016, J NEUROPATH EXP NEUR, V75, P503, DOI 10.1093/jnen/nlw025; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; Gutierrez H, 2007, J NEUROSCI METH, V163, P24, DOI 10.1016/j.jneumeth.2007.02.002; Haber M., 2017, J CEREB BLOOD FLOW M; Helmy A, 2016, J CEREBR BLOOD F MET, V36, P1434, DOI 10.1177/0271678X15620204; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Juurlink BHJ, 1998, GLIA, V22, P371, DOI 10.1002/(SICI)1098-1136(199804)22:4<371::AID-GLIA6>3.0.CO;2-6; Kaiser CL, 2009, LARYNGOSCOPE, V119, P1770, DOI 10.1002/lary.20557; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Karperien A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00003; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; Kuhlow CJ, 2003, GLIA, V44, P76, DOI 10.1002/glia.10273; Kumar RG, 2015, J HEAD TRAUMA REHAB, V30, P369, DOI 10.1097/HTR.0000000000000067; LI YH, 1993, CARDIOVASC RES, V27, P525, DOI 10.1093/cvr/27.3.525; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; McTigue DM, 2008, J NEUROCHEM, V107, P1, DOI 10.1111/j.1471-4159.2008.05570.x; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Mierzwa AJ, 2015, J NEUROPATH EXP NEUR, V74, P218, DOI 10.1097/NEN.0000000000000165; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nave KA, 2010, NATURE, V468, P244, DOI 10.1038/nature09614; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Qiu JH, 2002, J NEUROSCI, V22, P3504; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Ruscher K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045118; Salter MG, 2005, NATURE, V438, P1167, DOI 10.1038/nature04301; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Schneider H, 1998, P NATL ACAD SCI USA, V95, P7778, DOI 10.1073/pnas.95.13.7778; Soares HD, 1995, J NEUROSCI, V15, P8223; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Takahashi JL, 2003, ANN NEUROL, V53, P588, DOI 10.1002/ana.10519; Thelin EP, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00351; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Vela JM, 2002, MOL CELL NEUROSCI, V20, P489, DOI 10.1006/mcne.2002.1127; Wang XJ, 2005, ACTA PHARMACOL SIN, V26, P934, DOI 10.1111/j.1745-7254.2005.00152.x; Wheeler NA, 2016, EXP NEUROL, V283, P512, DOI 10.1016/j.expneurol.2016.03.019; Williams MR, 2008, ENDOTHELIUM-J ENDOTH, V15, P73, DOI 10.1080/10623320802092443; Xu X, 1997, P NATL ACAD SCI USA, V94, P12655, DOI 10.1073/pnas.94.23.12655; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yeo YA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-173; Yirmiya R, 2002, NEUROBIOL LEARN MEM, V78, P379, DOI 10.1006/nlme.2002.4072; Zeng CB, 2010, BRAIN RES, V1319, P21, DOI 10.1016/j.brainres.2009.12.092; Zhang DD, 2008, IEEE ENG MED BIO, P4712, DOI 10.1109/IEMBS.2008.4650265; Zhang XP, 2006, J NEUROTRAUM, V23, P1583, DOI 10.1089/neu.2006.23.1583; Zhao SC, 2017, ACTA PHARMACOL SIN, V38, P445, DOI 10.1038/aps.2016.162	81	12	12	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2018	35	23					2837	2849		10.1089/neu.2018.5660			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HB1WO	WOS:000450819000010	29690837	Green Published, Other Gold			2021-06-18	
J	Schneider, KJ; Meeuwisse, WH; Palacios-Derflingher, L; Emery, CA				Schneider, Kathryn J.; Meeuwisse, Willem H.; Palacios-Derflingher, Luz; Emery, Carolyn A.			Changes in Measures of Cervical Spine Function, Vestibulo-ocular Reflex, Dynamic Balance, and Divided Attention Following Sport-Related Concussion in Elite Youth Ice Hockey Players	JOURNAL OF ORTHOPAEDIC & SPORTS PHYSICAL THERAPY			English	Article						cervical spine; concussion; dynamic visual acuity; ice hockey; vestibular; youth	RISK-FACTORS; VISUAL-ACUITY; NECK PAIN; CLINICAL-TEST; RATING-SCALE; NUMERIC PAIN; INJURY; REHABILITATION; RELIABILITY; IMPLEMENTATION	BACKGROUND: Concussion is a commonly occurring injury. The extent to which the cervical spine, vestibulo-ocular reflex (VOR), dynamic balance, and divided attention are affected following concussion is not well understood. OBJECTIVES: To evaluate acute changes in measures of (1) cervical spine function, (2) VOR function, (3) dynamic balance, and (4) tasks of divided attention in elite youth ice hockey players following a sport-related concussion. METHODS: In this prospective cohort study, elite 13- to 17-year-old ice hockey players completed cervical spine measures (cervical flexor endurance test, head perturbation test, anterolateral strength, cervical flexion rotation test, joint position error), VOR function tests (head thrust test, dynamic visual acuity [clinical and computerized]), dynamic balance tests (Functional Gait Assessment), and divided-attention tasks (walking-while-talking test) both in the preseason and following concussion. RESULTS: At least 1 test was completed by 69 of 97 (71%) players (a maximum of 55 for any 1 test) at both preseason and immediately following concussion (median, 4 days post concussion). After Bonferroni corrections (alpha = .00625), using Wilcoxon signed-rank tests, cervical spine measures were significantly worse following concussion compared to baseline (cervical flexor endurance test: z = -5.20, P<.001; anterolateral neck strength: z(left) = -5.36, P<.001 and z(right) = -5.45, P<.001; and head perturbation test: z = -4.36, P<.001). Time taken to complete a complex task of divided attention relative to normal walking speed was faster (improved) compared to the preseason (z = -2.59, P<.01). There was no change in VOR or dynamic balance following concussion. CONCLUSION: Measures of cervical spine function and divided attention were altered following concussion. However, tests of VOR and dynamic balance were not significantly different from baseline. Future research to evaluate the mechanism underlying these changes is warranted.	[Schneider, Kathryn J.; Meeuwisse, Willem H.; Palacios-Derflingher, Luz; Emery, Carolyn A.] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Schneider, Kathryn J.] Univ Calgary, Cumming Sch Med, Hotchkiss Brain Inst, Calgary, AB, Canada; [Schneider, Kathryn J.; Emery, Carolyn A.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada; [Palacios-Derflingher, Luz; Emery, Carolyn A.] Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB, Canada	Schneider, KJ (corresponding author), Univ Calgary, Sport Injury Prevent Res Ctr, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	kjschnei@ucalgary.ca	Emery, Carolyn/AAI-2761-2020	Schneider, Kathryn/0000-0002-5951-5899			Armstrong B, 2008, SPORTS MED, V38, P101, DOI 10.2165/00007256-200838020-00002; Badke MB, 2004, ARCH PHYS MED REHAB, V85, P227, DOI 10.1016/j.apmr.2003.06.006; Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; Bogduk N, 2009, LANCET NEUROL, V8, P959, DOI 10.1016/S1474-4422(09)70209-1; Childs JD, 2005, SPINE, V30, P1331, DOI 10.1097/01.brs.0000164099.92112.29; Cleland JA, 2008, ARCH PHYS MED REHAB, V89, P69, DOI 10.1016/j.apmr.2007.08.126; Dannenbaum E, 2005, J OTOLARYNGOL, V34, P13, DOI 10.2310/7070.2005.03105; Dannenbaum E, 2009, OTOL NEUROTOL, V30, P368, DOI 10.1097/MAO.0b013e31819bda35; Davis GA, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097415; Edmondston SJ, 2008, J MANIP PHYSIOL THER, V31, P348, DOI 10.1016/j.jmpt.2008.04.010; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Emery C, 2009, CLIN J SPORT MED, V19, P245; Emery CA, 2009, PAED CHILD HEALT-CAN, V14, P439, DOI 10.1093/pch/14.7.439; Emery CA, 2005, AM J SPORT MED, V33, P1882, DOI 10.1177/0363546505279576; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, INJURY PREV, V16, P113, DOI 10.1136/ip.2009.022764; Feddermann-Demont N, 2017, BRIT J SPORT MED, V51, P903, DOI 10.1136/bjsports-2016-097403; Herdman S J, 2007, VESTIBULAR REHABILIT; Herdman SJ, 1998, AM J OTOL, V19, P790; Hyndman D, 2004, J NEUROL NEUROSUR PS, V75, P994, DOI 10.1136/jnnp.2003.016014; Kerr ZY, 2016, JAMA PEDIATR, V170, P647, DOI 10.1001/jamapediatrics.2016.0073; Kristjansson E, 2009, J ORTHOP SPORT PHYS, V39, P364, DOI 10.2519/jospt.2009.2834; Kumbhare DA, 2005, DISABIL REHABIL, V27, P801, DOI 10.1080/09638280400020615; Makdissi M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097470; McCrory P, 2017, BRIT J SPORT MED, V51, P877, DOI 10.1136/bjsports-2016-097393; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; Metcalfe S, 2006, J MAN MANIP THER, V14, P152, DOI 10.1179/106698106790835687; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Ogince M, 2007, MANUAL THER, V12, P256, DOI 10.1016/j.math.2006.06.016; Olson LE, 2006, J MANIP PHYSIOL THER, V29, P134, DOI 10.1016/j.jmpt.2005.12.009; Pfister T, 2016, BRIT J SPORT MED, V50, P292, DOI 10.1136/bjsports-2015-094978; REVEL M, 1991, ARCH PHYS MED REHAB, V72, P288; REVEL M, 1994, ARCH PHYS MED REHAB, V75, P895, DOI 10.1016/0003-9993(94)90115-5; Scherer M, 2008, J VESTIBUL RES-EQUIL, V18, P147; Schneider KJ, 2021, CLIN J SPORT MED, V31, P70, DOI 10.1097/JSM.0000000000000673; Schneider KJ, 2016, J ORTHOP SPORT PHYS, V46, P613, DOI 10.2519/jospt.2016.0607; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Schneider KJ, 2013, CLIN J SPORT MED, V23, P267, DOI 10.1097/JSM.0b013e318281f09f; SCHNEIDER KJ, 2017, BRIT J SPORT MED, V0051; Schneider KJ, 2017, BRIT J SPORT MED, V51, pA50, DOI [10.1136/bjsports-2016-097270.130, DOI 10.1136/BJSPORTS-2016-097270.130]; Schubert MC, 2004, PHYS THER, V84, P151, DOI 10.1093/ptj/84.2.151; TRELEAVEN J, 1994, CEPHALALGIA, V14, P273, DOI 10.1046/j.1468-2982.1994.1404273.x; Wrisley DM, 2004, PHYS THER, V84, P906, DOI 10.1093/ptj/84.10.906; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	46	12	12	0	13	J O S P T	ALEXANDRIA	1111 NORTH FAIRFAX ST, STE 100, ALEXANDRIA, VA 22314-1436 USA	0190-6011	1938-1344		J ORTHOP SPORT PHYS	J. Orthop. Sports Phys. Ther.	DEC	2018	48	12					974	982		10.2519/jospt.2018.8258			9	Orthopedics; Rehabilitation; Sport Sciences	Orthopedics; Rehabilitation; Sport Sciences	HC4JF	WOS:000451768700010	30053794				2021-06-18	
J	Wortman, RC; Meconi, A; Neale, KJ; Brady, RD; McDonald, SJ; Christie, BR; Wright, DK; Shultz, SR				Wortman, Ryan C.; Meconi, Alicia; Neale, Katie J.; Brady, Rhys D.; McDonald, Stuart J.; Christie, Brian R.; Wright, David K.; Shultz, Sandy R.			Diffusion MRI abnormalities in adolescent rats given repeated mild traumatic brain injury	ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY			English	Article							TENSOR IMAGING DETECTS; AXONAL INJURY; COGNITIVE DYSFUNCTION; CORPUS-CALLOSUM; HEAD-INJURY; CONCUSSION; SPECTRUM; IMPAIRMENT; BIOMARKERS; MODEL	Objective Mild traumatic brain injury (mTBI) is a serious health concern in the adolescent population. Repeated mTBI may result in more pronounced deficits, and has been associated with long-term neurological consequences including neurodegeneration. As such, there is a critical need for the development of objective mTBI biomarkers to help guide medical management. Diffusion-weighted imaging (DWI) is an advanced magnetic resonance imaging (MRI) technique that may detect brain abnormalities after mTBI. Diffusion tensor imaging (DTI) is the most commonly applied DWI method, and initial studies have reported DTI changes in mTBI patients. Furthermore, new DWI methods (e.g., track-weighted imaging; TWI) are being developed that may also be sensitive to mTBIs, but remain to be comprehensively studied. Methods This study utilized the Awake Closed Head Injury (ACHI) model of mTBI to investigate changes in DTI and TWI following repeated mTBI in adolescent male and female rats. A total of four ACHI impacts, two/day over two consecutive days, were delivered beginning on postnatal day 25. At 1 day and 7 days postinjury, rats were euthanized and brains were collected for DWI analyses. Results Rats given repeated mTBI displayed changes in fractional anisotropy and radial diffusivity (i.e., DTI measures), as well as track density (i.e., TWI). Interpretation These findings are consistent with initial DTI findings in mTBI patients, suggest that TWI may complement DTI, support the utility of DWI measures as biomarkers in mTBI, and further validate the ACHI rat model of mTBI.	[Wortman, Ryan C.; Meconi, Alicia; Brady, Rhys D.; Wright, David K.; Shultz, Sandy R.] Monash Univ, Cent Clin Sch, Dept Neurosci, Melbourne, Vic 3004, Australia; [Wortman, Ryan C.; Neale, Katie J.; Christie, Brian R.; Shultz, Sandy R.] Univ Victoria, Div Med Sci, Victoria, BC V8P 5C2, Canada; [McDonald, Stuart J.] La Trobe Univ, Dept Physiol Anat & Microbiol, Bundoora, Vic 3086, Australia; [Wright, David K.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia; [Shultz, Sandy R.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3010, Australia	Shultz, SR (corresponding author), Monash Univ, Cent Clin Sch, Dept Neurosci, Alfred Ctr, 6th Floor,99 Commercial Rd, Melbourne, Vic 3004, Australia.	sandy.shultz@monash.edu	Christie, Brian/AAF-3766-2019	Christie, Brian/0000-0002-6830-0160; McDonald, Stuart/0000-0001-5190-3179	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); CFICanada Foundation for Innovation; Australian NHMRCNational Health and Medical Research Council of Australia; NSERCNatural Sciences and Engineering Research Council of Canada (NSERC)	RCW and AM were supported by Canadian Institutes of Health Research graduate fellowships. The studies were funded by grants from NSERC and CFI to BRC, and the Australian NHMRC to SRS.	Adam O, 2015, NEUROLOGY, V85, P219, DOI 10.1212/WNL.0000000000001758; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Calamante F, 2012, NEUROIMAGE, V59, P2494, DOI 10.1016/j.neuroimage.2011.08.099; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Clough M, 2018, J NEUROTRAUM, V35, P730, DOI 10.1089/neu.2017.5204; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; KRAUS JF, 1990, NEUROSURGERY, V27, P334; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar A, 2014, INFLAMMOPHARMACOLOGY, V22, P155, DOI 10.1007/s10787-013-0187-3; LEBIHAN D, 1992, AM J ROENTGENOL, V159, P591, DOI 10.2214/ajr.159.3.1503032; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meconi A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197187; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Pannek K, 2011, NEUROIMAGE, V55, P133, DOI 10.1016/j.neuroimage.2010.12.010; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Qin Y, 2018, BEHAV BRAIN RES, V340, P41, DOI 10.1016/j.bbr.2016.08.008; Raffelt D, 2011, NEUROIMAGE, V56, P1171, DOI 10.1016/j.neuroimage.2011.02.014; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shultz SR, 2017, NEUROSCI BIOBEHAV R, V76, P396, DOI 10.1016/j.neubiorev.2016.09.014; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Wada T, 2012, AM J NEURORADIOL, V33, P2117, DOI 10.3174/ajnr.A3141; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wright DK, 2018, NEUROIMAGE-CLIN, V18, P315, DOI 10.1016/j.nicl.2018.01.033; Wright DK, 2017, ANN CLIN TRANSL NEUR, V4, P640, DOI 10.1002/acn3.441; Wright DK, 2017, CEREB CORTEX, V27, P4503, DOI 10.1093/cercor/bhw254; Wright DK, 2017, J NEUROTRAUM, V34, P2109, DOI 10.1089/neu.2016.4730; Wright DK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28713; Xiong KL, 2014, BRAIN IMAGING BEHAV, V8, P487, DOI 10.1007/s11682-013-9288-2; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yu FS, 2017, J NEUROTRAUM, V34, P1364, DOI 10.1089/neu.2016.4569; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	55	12	12	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2328-9503			ANN CLIN TRANSL NEUR	Ann. Clin. Transl. Neurol.	DEC	2018	5	12					1588	1598		10.1002/acn3.667			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	HE1TS	WOS:000453056900011	30564624	DOAJ Gold, Green Published			2021-06-18	
J	Zeiler, FA; Kim, DJ; Cabeleira, M; Calviello, L; Smielewski, P; Czosnyka, M				Zeiler, Frederick A.; Kim, Dong-Joo; Cabeleira, Manuel; Calviello, Leanne; Smielewski, Peter; Czosnyka, Marek			Impaired cerebral compensatory reserve is associated with admission imaging characteristics of diffuse insult in traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						Compensatory reserve; Diffuse injury; Imaging; Monitoring; TBI	MAGNETIC-RESONANCE ELASTOGRAPHY; MORPHOLOGICAL FEATURES; PULSE AMPLITUDE; PRESSURE; CLASSIFICATION	BackgroundContinuous assessment of cerebral compensatory reserve is possible using the moving correlation between pulse amplitude of intra-cranial pressure (AMP) and intra-cranial pressure (ICP), called RAP. Little is known about the behavior and associations of this index in adult traumatic brain injury (TBI). The goal of this study is to evaluate the association between admission cerebral imaging findings and RAP over the course of the acute intensive care unit stay.MethodsWe retrospectively reviewed 358 adult TBI patients admitted to the Addenbrooke's Hospital, University of Cambridge, from March 2005 to December 2016. Only non-craniectomy patients were studied. Using archived high frequency physiologic signals, RAP was derived and analyzed over the first 48h and first 10days of recording in each patient, using grand mean, percentage of time above various thresholds, and integrated area under the curve (AUC) of RAP over time. Associations between these values and admission computed tomography (CT) injury characteristics were evaluated.ResultsThe integrated AUC, based on various thresholds of RAP, was statistically associated with admission CT markers of diffuse TBI and cerebral edema. Admission CT findings of cortical gyral effacement, lateral ventricle compression, diffuse cortical subarachnoid hemorrhage (SAH), thickness of cortical SAH, presence of bilateral contusions, and subcortical diffuse axonal injury (DAI) were all associated with AUC of RAP over time. Joncheere-Terpstra testing indicated a statistically significant increase in mean RAP AUC across ordinal categories of the abovementioned associated CT findings.ConclusionsRAP is associated with cerebral CT injury patterns of diffuse injury and edema, providing some confirmation of its potential measurement of cerebral compensatory reserve in TBI.	[Zeiler, Frederick A.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England; [Zeiler, Frederick A.] Univ Manitoba, Rady Fac Hlth Sci, Sect Surg, Winnipeg, MB, Canada; [Zeiler, Frederick A.] Univ Manitoba, Rady Fac Hlth Sci, Clinician Investigator Program, Winnipeg, MB, Canada; [Kim, Dong-Joo] Korea Univ, Dept Brain & Cognit Engn, Seoul, South Korea; [Cabeleira, Manuel; Calviello, Leanne; Smielewski, Peter; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg,Sect Brain Phys, Cambridge CB2 0QQ, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland	Zeiler, FA (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England.	umzeiler@myumanitoba.ca; dongjookim@korea.ac.kr; mc916@cam.ac.uk; lac76@cam.ac.uk; ps10011@cam.ac.uk; mc141@medschl.cam.ac.uk		Zeiler, Frederick/0000-0003-1737-0510; czosnyka, marek/0000-0003-2446-8006	Cambridge Commonwealth Trust Scholarship; Royal College of Surgeons of Canada - Harry S. Morton Travelling Fellowship in Surgery; University of Manitoba Clinician Investigator Program; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea [HI17C1790]	FAZ has received salary support for dedicated research time, during which this project was completed. Such salary support came from the Cambridge Commonwealth Trust Scholarship, the Royal College of Surgeons of Canada - Harry S. Morton Travelling Fellowship in Surgery, and the University of Manitoba Clinician Investigator Program.; DJK and MC were supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (grant number: HI17C1790).	[Anonymous], 2011, GOV ARR RES ETH COMM; AVEZAAT CJJ, 1986, NEUROSURG REV, V9, P113, DOI 10.1007/BF01743061; Bianciardi M, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2015.0184; Boulet T, 2011, J NEUROSCI METH, V201, P296, DOI 10.1016/j.jneumeth.2011.08.019; Calviello L, 2018, NEUROCRIT CARE, V28, P212, DOI 10.1007/s12028-017-0475-7; Cardim D, 2017, NEUROCRIT CARE, V26, P330, DOI 10.1007/s12028-016-0356-5; Carrera E, 2010, J NEUROTRAUM, V27, P317, DOI 10.1089/neu.2009.0951; Czosnyka M, 1996, J NEUROL NEUROSUR PS, V60, P549, DOI 10.1136/jnnp.60.5.549; Czosnyka Z, 2008, ACTA NEUROCHIR SUPPL, V102, P137, DOI 10.1007/978-3-211-85578-2_28; Donnelly J, 2017, J CEREBR BLOOD F MET, V37, P694, DOI 10.1177/0271678X16639060; Glenn Thomas C, 2012, Acta Neurochir Suppl, V114, P11, DOI 10.1007/978-3-7091-0956-4_3; Hamilton R, 2009, IEEE ENG MED BIO, P4331, DOI 10.1109/IEMBS.2009.5332749; Howells T, 2012, INTENS CARE MED, V38, P1061, DOI 10.1007/s00134-012-2571-7; Hu X, 2010, PHYSIOL MEAS, V31, P679, DOI 10.1088/0967-3334/31/5/006; Kasprowicz M, 2010, J NEUROSCI METH, V190, P310, DOI 10.1016/j.jneumeth.2010.05.015; Kim DJ, 2009, NEUROSURGERY, V64, P494, DOI 10.1227/01.NEU.0000338434.59141.89; Kolipaka A, 2018, CLIN IMAG, V51, P114, DOI 10.1016/j.clinimag.2018.02.005; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Pineda B, 2018, ACTA NEUROCHIR SUPPL, V126, P297, DOI 10.1007/978-3-319-65798-1_58; Raj R, 2014, NEUROSURGERY, V75, P632, DOI 10.1227/NEU.0000000000000533; Scalzo F, 2008, IEEE ENG MED BIO, P5411, DOI 10.1109/IEMBS.2008.4650438; VANEIJNDHOVEN JHM, 1986, NEUROSURGERY, V19, P507, DOI 10.1227/00006123-198610000-00004; Zeiler FA, 2018, J NEUROTRAUM, V35, P963, DOI 10.1089/neu.2017.5241; Zeiler FA, 2018, J NEUROTRAUM, V35, P1107, DOI 10.1089/neu.2017.5472; Zeiler FA, 2018, J NEUROTRAUM, V35, P1569, DOI 10.1089/neu.2017.5595	29	12	13	0	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	DEC	2018	160	12					2277	2287		10.1007/s00701-018-3681-y			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HB3XI	WOS:000450984500001	30251196	Green Published, Other Gold			2021-06-18	
J	Hernandez, A; Tan, CF; Plattner, F; Logsdon, AF; Pozo, K; Yousuf, MA; Singh, T; Turner, RC; Luke-Wold, BP; Huber, JD; Rosen, CL; Bibb, JA				Hernandez, Adan; Tan, Chunfeng; Plattner, Florian; Logsdon, Aric F.; Pozo, Karine; Yousuf, Mohammad A.; Singh, Tanvir; Turner, Ryan C.; Luke-Wold, Brandon P.; Huber, Jason D.; Rosen, Charles L.; Bibb, James A.			Exposure to mild blast forces induces neuropathological effects, neurophysiological deficits and biochemical changes	MOLECULAR BRAIN			English	Article						Blast-induced traumatic brain injury; Neuroinflammation; Microvascular damage; Axonal swelling; Short-term plasticity; Calpain; p25	TRAUMATIC BRAIN-INJURY; AXON INITIAL SEGMENT; SYNAPTIC PLASTICITY; MOUSE MODEL; KINASE; RAT; DEGENERATION; INFLAMMATION; NEUROTRAUMA; DYSFUNCTION	Direct or indirect exposure to an explosion can induce traumatic brain injury (TBI) of various severity levels. Primary TBI from blast exposure is commonly characterized by internal injuries, such as vascular damage, neuronal injury, and contusion, without external injuries. Current animal models of blast-induced TBI (bTBI) have helped to understand the deleterious effects of moderate to severe blast forces. However, the neurological effects of mild blast forces remain poorly characterized. Here, we investigated the effects caused by mild blast forces combining neuropathological, histological, biochemical and neurophysiological analysis. For this purpose, we employed a rodent blast TBI model with blast forces below the level that causes macroscopic neuropathological changes. We found that mild blast forces induced neuroinflammation in cerebral cortex, striatum and hippocampus. Moreover, mild blast triggered microvascular damage and axonal injury. Furthermore, mild blast caused deficits in hippocampal short-term plasticity and synaptic excitability, but no impairments in long-term potentiation. Finally, mild blast exposure induced proteolytic cleavage of spectrin and the cyclin-dependent kinase 5 activator, p35 in hippocampus. Together, these findings show that mild blast forces can cause aberrant neurological changes that critically impact neuronal functions. These results are consistent with the idea that mild blast forces may induce subclinical pathophysiological changes that may contribute to neurological and psychiatric disorders.	[Hernandez, Adan; Tan, Chunfeng; Plattner, Florian; Pozo, Karine; Yousuf, Mohammad A.; Singh, Tanvir] Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Plattner, Florian] Univ Texas Southwestern Med Ctr Dallas, Ctr Translat Neurodegenerat Res, Dallas, TX 75390 USA; [Logsdon, Aric F.; Turner, Ryan C.; Luke-Wold, Brandon P.; Rosen, Charles L.] West Virginia Univ, Sch Med, Dept Neurosurg, Morgantown, WV 26506 USA; [Huber, Jason D.] West Virginia Univ, Sch Med, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA; [Bibb, James A.] Univ Alabama Birmingham, Med Ctr, Dept Surg, 1720 2nd Ave S,THT 1052, Birmingham, AL 35294 USA; [Bibb, James A.] Univ Alabama Birmingham, Med Ctr, Dept Neurobiol, 1720 2nd Ave S,THT 1052, Birmingham, AL 35294 USA; [Bibb, James A.] Univ Alabama Birmingham, Med Ctr, Dept Neurol, 1720 2nd Ave S,THT 1052, Birmingham, AL 35294 USA	Bibb, JA (corresponding author), Univ Alabama Birmingham, Med Ctr, Dept Surg, 1720 2nd Ave S,THT 1052, Birmingham, AL 35294 USA.; Bibb, JA (corresponding author), Univ Alabama Birmingham, Med Ctr, Dept Neurobiol, 1720 2nd Ave S,THT 1052, Birmingham, AL 35294 USA.; Bibb, JA (corresponding author), Univ Alabama Birmingham, Med Ctr, Dept Neurol, 1720 2nd Ave S,THT 1052, Birmingham, AL 35294 USA.	jbibb@uab.edu		Hernandez-Cortes, Adan/0000-0002-7098-870X; Turner, Ryan/0000-0001-5523-0645	National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH083711]; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [DA033485]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS073855]; Friends of the Alzheimer's Center; American Foundation for Pharmaceutical Education; American Association of Pharmaceutical Scientists; Darrell K. Royal Research Fund for Alzheimer's Disease; Texas Institute for Brain Injury and Repair; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH083711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS099918, R01NS073855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG052354] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA033485] Funding Source: NIH RePORTER	This work was supported by a Discovery Award from the Texas Institute for Brain Injury and Repair and was facilitated by grants to J.A.B. from the National Institute of Mental Health (MH083711), National Institute on Drug Abuse (DA033485) and National Institute of Neurological Disorders and Stroke (NS073855). This research was also supported in part through funding to F.P. from the Friends of the Alzheimer's Center and the Darrell K. Royal Research Fund for Alzheimer's Disease and pre-doctoral fellowships from the American Foundation for Pharmaceutical Education to A.F.L and B.P.L., as well as a pre-doctoral fellowship from the American Association of Pharmaceutical Scientists to B.P.L.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Ansari MA, 2014, FREE RADICAL BIO MED, V77, P21, DOI 10.1016/j.freeradbiomed.2014.08.025; Baalman KL, 2013, J NEUROTRAUM, V30, P741, DOI 10.1089/neu.2012.2478; Bach-y-Rita P, 2003, BRAIN INJURY, V17, P643, DOI 10.1080/0269905031000107133; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chung RS, 2005, J NEUROTRAUM, V22, P1081, DOI 10.1089/neu.2005.22.1081; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Fischer Andrew H, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot4986; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Hisanaga S, 2010, J NEUROCHEM, V115, P1309, DOI 10.1111/j.1471-4159.2010.07050.x; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Ma M, 2013, NEUROBIOL DIS, V60, P61, DOI 10.1016/j.nbd.2013.08.010; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; Miller AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00020; Miller G, 2012, SCIENCE, V336, P790, DOI 10.1126/science.336.6083.790; Mishra V, 2016, SCI REP-UK, V6, DOI 10.1038/srep26992; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Park E, 2013, NEUROBIOL DIS, V52, P150, DOI 10.1016/j.nbd.2012.12.002; Plattner F, 2006, J BIOL CHEM, V281, P25457, DOI 10.1074/jbc.M603469200; Plattner F, 2014, NEURON, V81, P1070, DOI 10.1016/j.neuron.2014.01.022; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Sahin B, 2004, EUR J BIOCHEM, V271, P3547, DOI 10.1111/j.1432-1033.2004.04291.x; Sajja VSSS, 2013, J NEUROSCI RES, V91, P593, DOI 10.1002/jnr.23179; Schafer DP, 2009, J NEUROSCI, V29, P13242, DOI 10.1523/JNEUROSCI.3376-09.2009; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6; Siedler DG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00429; SINCLAIR RA, 1981, J CLIN PATHOL, V34, P859, DOI 10.1136/jcp.34.8.859; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; Turner RC, 2013, EXP NEUROL, V248, P520, DOI 10.1016/j.expneurol.2013.07.008; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Yang F, 2014, J CEREBR BLOOD F MET, V34, P660, DOI 10.1038/jcbfm.2013.242; Yousuf MA, 2016, J NEUROCHEM, V138, P317, DOI 10.1111/jnc.13620; Zuckerman A, 2017, J NEUROTRAUM, V34, P145, DOI 10.1089/neu.2015.4310	46	12	12	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1756-6606			MOL BRAIN	Mol. Brain	NOV 9	2018	11								64	10.1186/s13041-018-0408-1			13	Neurosciences	Neurosciences & Neurology	HA0WO	WOS:000449932200001	30409147	DOAJ Gold, Green Published			2021-06-18	
J	Edlow, BL; Fins, JJ				Edlow, Brian L.; Fins, Joseph J.			Assessment of Covert Consciousness in the Intensive Care Unit: Clinical and Ethical Considerations	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						coma; consciousness; EEG; functional MRI; minimally conscious state; neuroethics; prognostication; traumatic brain injury; vegetative state	TRAUMATIC BRAIN-INJURY; VEGETATIVE STATE; THALAMIC-STIMULATION; BEDSIDE DETECTION; DISORDERS; AWARENESS; WITHDRAWAL; DIAGNOSIS; RECOVERY; SCALE	Objective: To propose a practical ethical framework for how task-based functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) may be used in the intensive care unit (ICU) to identify covert consciousness in patients with acute severe traumatic brain injury (TBI). Methods: We present 2 clinical scenarios in which investigational task-based fMRI and EEG were performed in critically ill patients with acute severe TBI who appeared unconscious on the bedside behavioral assessment. From these cases, we consider the clinical and ethical challenges that emerge and suggest how to reconcile them. We also provide recommendations regarding communication with families about ICU patients with covert consciousness. Results: Covert consciousness was detected acutely in a patient who died in the ICU due to withdrawal of life-sustaining therapy, whereas covert consciousness was not detected in a patient who subsequently recovered consciousness, communication, and functional independence. These cases raise ethical challenges about how assessment of covert consciousness in the ICU might inform treatment decisions, prognostication, and perceptions about the benefits and burdens of ongoing care. Conclusions: Given that covert consciousness can be detected acutely in the ICU, we recommend that clinicians reconsider evaluative norms for ICU patients. As our clinical appreciation of covert consciousness evolves and its ethical import unfolds, we urge prognostic humility and transparency when clinicians communicate with families in the ICU about goals of care.	[Edlow, Brian L.] Harvard Med Sch, Dept Neurol, Ctr Neurotechnol & Neurorecovery, Massachusetts Gen Hosp, Boston, MA USA; [Edlow, Brian L.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Fins, Joseph J.] Weill Cornell Med Coll, Div Med Eth & Consortium Adv Study Brain Injury, New York, NY USA; [Fins, Joseph J.] Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA; [Fins, Joseph J.] Yale Law Sch, Solomon Ctr Hlth Law & Policy, New Haven, CT USA	Edlow, BL (corresponding author), Massachusetts Gen Hosp, Ctr Neurotechnol & Neurorecovery, 175 Cambridge St,Ste 300, Boston, MA 02114 USA.	bedlow@mgh.harvard.edu			NIH National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS094538]; Jerold B. Katz Foundation; James S. McDonnell Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS094538] Funding Source: NIH RePORTER	This work was supported by grants from the NIH National Institute of Neurological Disorders and Stroke (K23NS094538), Jerold B. Katz Foundation, and the James S. McDonnell Foundation.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Beaumont JG, 2005, NEUROPSYCHOL REHABIL, V15, P184, DOI 10.1080/09602010443000489; Bodien YG, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00688; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Chakraborty R, 2017, PALLIAT SUPPORT CARE, V15, P609, DOI 10.1017/S1478951516001061; Chatelle C, 2018, CLIN NEUROPHYSIOL, V129, P1519, DOI 10.1016/j.clinph.2018.04.747; Chatelle C, 2012, J NEUROL NEUROSUR PS, V83, P1233, DOI 10.1136/jnnp-2012-302987; Chennu S, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003887; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Coleman MR, 2009, BRAIN, V132, P2541, DOI 10.1093/brain/awp183; Cruse D, 2012, NEUROLOGY, V78, P816, DOI 10.1212/WNL.0b013e318249f764; Cruse D, 2014, NEUROIMAGE-CLIN, V4, P788, DOI 10.1016/j.nicl.2014.05.001; Cruse D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049933; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Curley WH, 2018, BRAIN, V141, P1404, DOI 10.1093/brain/awy070; Curlin FA, 2008, AM J HOSP PALLIAT ME, V25, P112, DOI 10.1177/1049909107310141; Davis MH, 2007, P NATL ACAD SCI USA, V104, P16032, DOI 10.1073/pnas.0701309104; Detre JA, 2006, J MAGN RESON IMAGING, V23, P808, DOI 10.1002/jmri.20585; DONALDSON DI, 2001, FUNCTIONAL MRI INTRO; Edlow BL, 2017, BRAIN, V140, P2399, DOI 10.1093/brain/awx176; Edlow BL, 2013, NEUROCRIT CARE, V19, P364, DOI 10.1007/s12028-013-9870-x; Eklund A, 2016, P NATL ACAD SCI USA, V113, P7900, DOI 10.1073/pnas.1602413113; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Fins JJ, 2005, PROG BRAIN RES, V150, P565, DOI 10.1016/S0079-6123(05)50040-2; Fins JJ, 1997, KENNEDY INST ETHIC J, V7, P129, DOI 10.1353/ken.1997.0013; Fins JJ, 2015, OXFORD TXB PALLIATIV, P285; Fins JJ., 2015, RIGHTS COME MIND BRA; Fins JJ, 2016, REV MAKING MED KNOWL; Fins JJ, 2006, HASTINGS CENT REP, V36, P8, DOI 10.1353/hcr.2006.0094; Fins JJ, 2018, NEUROLOGY, V91, P471, DOI 10.1212/WNL.0000000000005927; Fins JJ, 2018, J HEAD TRAUMA REHAB, V33, P283, DOI 10.1097/HTR.0000000000000416; Fins JJ, 2018, CAMB Q HEALTHC ETHIC, V27, P163, DOI 10.1017/S0963180117000329; Fins JJ, 2012, ARCH NEUROL-CHICAGO, V69, P158, DOI 10.1001/archneurol.2011.1211; Fins JJ, 2009, PROG BRAIN RES, V177, P371, DOI 10.1016/S0079-6123(09)17726-9; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; Giacino JT, 2018, ARCH PHYS MED REHAB, V99, P1710, DOI 10.1016/j.apmr.2018.07.002; Giacino JT, 2018, ARCH PHYS MED REHAB, V99, P1699, DOI 10.1016/j.apmr.2018.07.001; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Goldfine AM, 2013, LANCET, V381, P289, DOI 10.1016/S0140-6736(13)60125-7; Goldfine AM, 2011, CLIN NEUROPHYSIOL, V122, P2157, DOI 10.1016/j.clinph.2011.03.022; Gosseries O, 2014, BRAIN INJURY, V28, P1141, DOI 10.3109/02699052.2014.920522; Hauger SL, 2015, BEHAV NEUROL, V2015, DOI 10.1155/2015/145913; Henninger N, 2018, J TRAUMA ACUTE CARE, V84, P473, DOI 10.1097/TA.0000000000001733; Izzy S, 2017, NEUROCRIT CARE, V27, P199, DOI 10.1007/s12028-017-0399-2; Izzy S, 2013, NEUROCRIT CARE, V19, P347, DOI 10.1007/s12028-013-9925-z; KINNEY HC, 1994, NEW ENGL J MED, V330, P1469, DOI 10.1056/NEJM199405263302101; Kirsch M, 2017, ANESTH ANALG, V124, P588, DOI 10.1213/ANE.0000000000001721; Kitzinger C, 2015, J MED ETHICS, V41, DOI 10.1136/medethics-2013-101799; KITZINGER J, 2013, SOCIOL HEALTH ILL, V35, P1095, DOI DOI 10.1111/1467-9566.12020; Kitzinger J, 2018, PALLIATIVE MED, V32, P1180, DOI 10.1177/0269216318766430; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; Laureys S, 2007, CONSCIOUS COGN, V16, P722, DOI 10.1016/j.concog.2007.04.004; Lewis LD, 2016, P NATL ACAD SCI USA, V113, pE6679, DOI 10.1073/pnas.1608117113; MacNeil SD, 2007, J MED ETHICS, V33, P549, DOI 10.1136/jme.2006.017129; Mangia AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099289; Monti MM, 2016, BRAIN STIMUL, V9, P940, DOI 10.1016/j.brs.2016.07.008; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Pew Research Center, 2013, VIEWS END LIF MED TR; Piarulli A, 2016, J NEUROL, V263, P1746, DOI 10.1007/s00415-016-8196-y; Pisa FE, 2014, J HEAD TRAUMA REHAB, V29, pE23, DOI 10.1097/HTR.0b013e3182a4469f; Richardson HS, 2012, MORAL ENTANGLEMENTS; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2015, JAMA NEUROL, V72, P1413, DOI 10.1001/jamaneurol.2015.2899; Schnakers C, 2015, NEUROREHAB NEURAL RE, V29, P308, DOI 10.1177/1545968314547767; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Setsompop K, 2012, MAGN RESON MED, V67, P1210, DOI 10.1002/mrm.23097; Stender J, 2014, LANCET, V384, P514, DOI 10.1016/S0140-6736(14)60042-8; Stevens RD, 2013, CRIT CARE MED, V41, P1104, DOI 10.1097/CCM.0b013e318287ee79; TEASDALE G, 1974, LANCET, V2, P81; Thengone DJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6113; Thibaut A, 2014, NEUROLOGY, V82, P1112, DOI 10.1212/WNL.0000000000000260; Threlkeld ZD, 2018, CORTEX, V106, P299, DOI 10.1016/j.cortex.2018.05.004; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; van Erp WS, 2014, EUR J NEUROL, V21, P1361, DOI 10.1111/ene.12483; Vanhaudenhuyse A, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.121624; Wannez S, 2017, ANN NEUROL, V81, P883, DOI 10.1002/ana.24962; Weijer C, 2016, BRAIN, V139, P292, DOI 10.1093/brain/awv272; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091	86	12	12	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2018	33	6					424	434		10.1097/HTR.0000000000000448			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	HB2QK	WOS:000450886600018	30395042	Green Accepted			2021-06-18	
J	Gong, NJ; Kuzminski, S; Clark, M; Fraser, M; Sundman, M; Guskiewicz, K; Petrella, JR; Liu, CL				Gong, Nan-Jie; Kuzminski, Samuel; Clark, Michael; Fraser, Melissa; Sundman, Mark; Guskiewicz, Kevin; Petrella, Jeffrey R.; Liu, Chunlei			Microstructural alterations of cortical and deep gray matter over a season of high school football revealed by diffusion kurtosis imaging	NEUROBIOLOGY OF DISEASE			English	Article						Diffusion kurtosis imaging (DM); Quantitative susceptibility mapping (QSM); Gray matter; Football; Head impact	HEAD IMPACT EXPOSURE; CHRONIC TRAUMATIC ENCEPHALOPATHY; MILD COGNITIVE IMPAIRMENT; GAUSSIAN WATER DIFFUSION; COMPRESSION COLLAR; ALZHEIMERS-DISEASE; BRAIN-INJURY; SUSCEPTIBILITY; IRON; QUANTIFICATION	Objectives: To probe microstructural changes that are associated with subconcussive head impact exposure in deep and cortical gray matter of high school football players over a single season. Methods: Players underwent diffusion kurtosis imaging (DKI) and quantitative susceptibility mapping (QSM) scans. Head impact data was recorded. Association between parametric changes and frequency of frontal head impact was assessed. Results: In deep gray matter, significant decreases in mean kurtosis (MK) and increases in mean diffusivity (MD) over the season were observed in the thalamus and putamen. Correlations between changes in DKI metrics and frequency of frontal impacts were observed in the putamen and caudate. In cortical gray matter, decreases in MK were observed in regions including the pars triangularis and inferior parietal. In addition, increases in MD were observed in the rostral middle frontal cortices. Negative correlations between MK and frequency of frontal impacts were observed in the posterior part of the brain including the pericalcarine, lingual and middle temporal cortices. Magnetic susceptibility values exhibited no significant difference or correlation, suggesting these diffusion changes common within the group may not be associated with iron-related mechanisms. Conclusion: Microstructural alterations over the season and correlations with head impacts were captured by DKI metrics, which suggested that DKI imaging of gray matter may yield valuable biomarkers for evaluating brain injuries associated with subconcussive head impact. Findings of associations between frontal impacts and changes in posterior cortical gray matter also indicated that contrecoup injury rather than coup injury might be the dominant mechanism underlying the observed microstructural alterations. Advances in knowledge: Significant microstructural changes, as reflected by DKI metrics, in cortical gray matter such as the rostral middle frontal cortices, and in deep gray matter such as the thalamus were observed in high school football players over the course of a single season without clinically diagnosed concussion. QSM showed no evidence of iron-related changes in the observed subconcussive brain injuries. The detected microstructural changes in cortical and deep gray matter correlated with frequency of sub concussive head impacts. Implications for patient care: DKI may yield valuable biomarkers for evaluating the severity of brain injuries associated with subconcussive head impacts in contact sport athletes.	[Gong, Nan-Jie; Liu, Chunlei] Univ Calif Berkeley, Elect Engn & Comp Sci, 550 Cory Hall, Berkeley, CA 94720 USA; [Gong, Nan-Jie; Liu, Chunlei] Duke Univ, Sch Med, Brain Imaging & Anal Ctr, Durham, NC USA; [Kuzminski, Samuel] Univ Oklahoma, Neuroradiol, Norman, OK 73019 USA; [Clark, Michael] Univ N Carolina, Sch Med, Human Movement Sci, Chapel Hill, NC 27515 USA; [Fraser, Melissa] Univ N Carolina, Sch Med, Allied Hlth Sci, Chapel Hill, NC 27515 USA; [Sundman, Mark] Univ Arizona, Dept Psychol, Tucson, AZ 85721 USA; [Guskiewicz, Kevin] Univ N Carolina, Sch Med, Exercise Sports Sci, Chapel Hill, NC 27515 USA; [Petrella, Jeffrey R.; Liu, Chunlei] Duke Univ, Sch Med, Radiol, Durham, NC USA; [Liu, Chunlei] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA	Gong, NJ; Liu, CL (corresponding author), Univ Calif Berkeley, Elect Engn & Comp Sci, 550 Cory Hall, Berkeley, CA 94720 USA.	nanjie.gong@gmail.com; sam@kuzminskis.com; michael_clark@med.unc.edu; mafraser@live.unc.edu; alexis@unc.edu; jeffrey.petrella@duke.edu; chunlei.liu@berkeley.edu	Gong, Nan-Jie/H-8002-2012	Gong, Nan-Jie/0000-0001-9249-413X; Liu, Chunlei/0000-0001-8816-4832; Fraser, Missy/0000-0002-5753-8798			Bahrami N, 2016, RADIOLOGY; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bayly PV, 2012, ANNU REV BIOMED ENG, V14, P369, DOI [10.1146/annurev-bioeng-071811-150032, 10.1146/annurev.bioeng-071811-150032]; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Bester M, 2015, MULT SCLER J, V21, P935, DOI 10.1177/1352458514556295; Budday S, 2015, J MECH BEHAV BIOMED, V46, P318, DOI 10.1016/j.jmbbm.2015.02.024; Chen WW, 2014, RADIOLOGY, V270, P496, DOI 10.1148/radiol.13122640; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Courville CB, 1942, ARCH SURG-CHICAGO, V45, P19, DOI 10.1001/archsurg.1942.01220010022002; Coutu JP, 2014, NEUROBIOL AGING, V35, P1412, DOI 10.1016/j.neurobiolaging.2013.12.001; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Davenport EM, 2016, J NEUROTRAUM, V33, P2133, DOI 10.1089/neu.2015.4267; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gong NJ, 2017, HUM BRAIN MAPP, V38, P2495, DOI 10.1002/hbm.23535; Gong NJ, 2015, NMR BIOMED, V28, P1267, DOI 10.1002/nbm.3366; Gong NJ, 2014, NEUROBIOL AGING, V35, P2203, DOI 10.1016/j.neurobiolaging.2014.03.011; Gong NJ, 2013, MAGN RESON IMAGING, V31, P688, DOI 10.1016/j.mri.2012.10.027; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; He NY, 2017, NMR BIOMED, V30, DOI 10.1002/nbm.3554; Jensen JH, 2010, NMR BIOMED, V23, P698, DOI 10.1002/nbm.1518; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Kamagata K, 2017, HUM BRAIN MAPP, V38, P3704, DOI 10.1002/hbm.23628; Kelley ME, 2017, J NEUROTRAUM, V34, P1939, DOI 10.1089/neu.2016.4812; Kuzminski SJ, 2018, AM J NEURORADIOL, V39, P245, DOI 10.3174/ajnr.A5489; Langkammer C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162460; Li W, 2016, NMR BIOMED, V29, P896, DOI 10.1002/nbm.3536; Li W, 2014, HUM BRAIN MAPP, V35, P2698, DOI 10.1002/hbm.22360; Li W, 2014, NMR BIOMED, V27, P219, DOI 10.1002/nbm.3056; Liu CL, 2015, TOMOGRAPHY, V1, P3, DOI 10.18383/j.tom.2015.00136; Liu CL, 2015, J MAGN RESON IMAGING, V42, P23, DOI [10.1002/jmri.24768, 10.3969/j.issn.1001-2400.2015.01.004]; Liu CL, 2010, MAGN RESON MED, V63, P243, DOI 10.1002/mrm.22192; Liu CL, 2004, MAGN RESON MED, V51, P924, DOI 10.1002/mrm.20071; Liu W, 2013, P INT SOC MAG RESON, V21; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; Merchant-Borna K, 2016, ANN BIOMED ENG, V44, P3679, DOI 10.1007/s10439-016-1680-9; Munce TA, 2015, MED SCI SPORT EXER, V47, P1567, DOI 10.1249/MSS.0000000000000591; Myer GD, 2016, BRIT J SPORT MED, V50, P1276, DOI 10.1136/bjsports-2016-096134; Nisenbaum EJ, 2014, J NEUROTRAUM, V31, P301, DOI 10.1089/neu.2013.3102; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Raz E, 2011, AM J NEURORADIOL, V32, P1851, DOI 10.3174/ajnr.A2637; Reuter M, 2010, NEUROIMAGE, V53, P1181, DOI 10.1016/j.neuroimage.2010.07.020; Saulle M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/816069; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Steven AJ, 2014, AM J ROENTGENOL, V202, pW26, DOI 10.2214/AJR.13.11365; Stokum JA, 2015, BRAIN INJURY, V29, P47, DOI 10.3109/02699052.2014.947628; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Young TJ, 2014, CLIN J SPORT MED, V24, P416, DOI 10.1097/JSM.0000000000000055; Yuan WH, 2018, HUM BRAIN MAPP, V39, P491, DOI 10.1002/hbm.23859; Yuan WH, 2017, J NEUROTRAUM, V34, P2432, DOI 10.1089/neu.2016.4834; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	57	12	12	1	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	NOV	2018	119						79	87		10.1016/j.nbd.2018.07.020			9	Neurosciences	Neurosciences & Neurology	GU5JV	WOS:000445322700007	30048802				2021-06-18	
J	Ge, XT; Yu, JW; Huang, S; Yin, ZY; Han, ZL; Chen, FL; Wang, ZG; Zhang, JN; Lei, P				Ge, Xintong; Yu, Jinwen; Huang, Shan; Yin, Zhenyu; Han, Zhaoli; Chen, Fanglian; Wang, Zengguang; Zhang, Jianning; Lei, Ping			A novel repetitive mild traumatic brain injury mouse model for chronic traumatic encephalopathy research	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Repetitive mild traumatic brain injury; Chronic traumatic encephalopathy; Closed-head impact; Neurodegeneration; Neuroinflammation; Cognitive dysfunction	TIME-POINTS; CONSEQUENCES; EPIDEMIOLOGY; INFLAMMATION; IMPROVES; MEMORY	Background: Athletes, military personnel and mobility-declined elderly people are prone to repetitive mild traumatic brain injury (rmTBI). The injury does not cause acute pathological changes, but leads to chronic neurodegeneration, long-term cognitive dysfunction and even chronic traumatic encephalopathy (GTE). Many existing rmTBI animal models reported uncontrollable adverse effects and long experiment period. Therefore, an improved model needs to be designed. New method: Our rmTBI mouse model is a modification of the closed head injury method using electronic controlled cortical impact system. Discontinuous 4 impacts with 48-h interval were performed. A key facet of the model is the use of our designed molded acrylic cast and concave metal disc (as a helmet). They could scatter and transmit hitting power to the whole brain, thus produced a mild diffused injury. The procedure does not require scalp incision or craniotomy, which allows the impacting to be completed in 2 min. Results: Our model did not induce acute macroscopic brain damage and brain edema. It could lead to sustained neuroinflammation and chronic neurodegeneration in injured brain, and resulted in cognitive dysfunction within 5 weeks post-injury. Comparison with existing methods: Previously reported adverse effects including skull fractures, hemorrhage and brain tissue loss were not observed in our model. An experiment period of 5 weeks was allowed for observing chronic neurodegeneration and cognitive dysfunction. Conclusions: Our model is beneficial to use for simplicity, reproducibility and time saver. It could serve as a platform for research on the pathogenesis, diagnosis and potential therapeutics for rmTBI and CTE.	[Ge, Xintong; Wang, Zengguang; Zhang, Jianning] Tianjin Med Univ Gen Hosp, Dept Neurosurg, 154 Anshan Rd, Tianjin 300052, Peoples R China; [Ge, Xintong; Chen, Fanglian; Wang, Zengguang; Zhang, Jianning] Tianjin Med Univ Gen Hosp, Tianjin Neurol Inst, Key Lab Injuries Variat & Regenerat Nervous Syst, Tianjin 300052, Peoples R China; [Ge, Xintong; Chen, Fanglian; Wang, Zengguang; Zhang, Jianning] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin 300052, Peoples R China; [Yu, Jinwen; Huang, Shan; Yin, Zhenyu; Han, Zhaoli; Lei, Ping] Tianjin Med Univ Gen Hosp, Tianjin Geriatr Inst, Lab Neurotrauma & Neurodegenerat Disorders, Tianjin 300052, Peoples R China; [Yu, Jinwen; Huang, Shan; Yin, Zhenyu; Han, Zhaoli; Lei, Ping] Tianjin Med Univ Gen Hosp, Dept Geriatr, 154 Anshan Rd, Tianjin 300052, Peoples R China	Wang, ZG; Zhang, JN (corresponding author), Tianjin Med Univ Gen Hosp, Dept Neurosurg, 154 Anshan Rd, Tianjin 300052, Peoples R China.; Lei, P (corresponding author), Tianjin Med Univ Gen Hosp, Dept Geriatr, 154 Anshan Rd, Tianjin 300052, Peoples R China.	zgwang@tmu.edu; jnzhang@tmu.edu; plei@tmu.edu	Ge, Xintong/X-4889-2019	Ge, Xintong/0000-0001-7153-952X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81501055, 81772060, 81720108015, 81471252]; Tianjin Traditional Medicine Key Research Project [2018001]; Tianjin Municipal Science and Technology Commission natural fund project [16PTSYJC00180]	This work was supported by the National Natural Science Foundation of China (grant number 81501055, 81772060, 81720108015 and 81471252), Tianjin Traditional Medicine Key Research Project (grant number 2018001), and Tianjin Municipal Science and Technology Commission natural fund project (grant number 16PTSYJC00180). The authors appreciate Daniel T. Laskowitz and Haichen Wang from Duke University Medical Center, and Shu Zhang, Li Liu, Weiyun Cui and Lei Zhou from Tianjin Neurological Institute for their technical support.	Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Ferguson S, 2017, J NEUROTRAUM, V34, P1676, DOI 10.1089/neu.2016.4636; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Ge XT, 2018, BRAIN RES, V1697, P10, DOI 10.1016/j.brainres.2018.06.008; Ge XT, 2019, J NEUROTRAUM, V36, P1291, DOI 10.1089/neu.2018.5728; Ge XT, 2016, BRAIN RES, V1650, P31, DOI 10.1016/j.brainres.2016.07.015; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Han ZL, 2015, DNA CELL BIOL, V34, P703, DOI 10.1089/dna.2015.2800; Huang S, 2018, FASEB J, V32, P512, DOI 10.1096/fj.201700673R; IRRERA N, 2017, FRONT PHARM, V8; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Laskowitz DT, 2017, SCI REP-UK, V7, DOI 10.1038/srep46461; Leger M, 2013, NAT PROTOC, V8, P2531, DOI 10.1038/nprot.2013.155; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; McAteer KM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160220; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Moulin S, 2017, CURR ALZHEIMER RES, V14, P686, DOI 10.2174/1567205012666151027141730; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2018, ANN CLIN TRANSL NEUR, V5, P64, DOI 10.1002/acn3.510; Ojo JO, 2016, J NEUROPATH EXP NEUR, V75, P636, DOI 10.1093/jnen/nlw035; Ojo JO, 2015, J NEUROPATH EXP NEUR, V74, P1012, DOI 10.1097/NEN.0000000000000247; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Yang ZH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11178; Yu FS, 2017, J NEUROTRAUM, V34, P1364, DOI 10.1089/neu.2016.4569; Zhang YL, 2017, NATURE, V548, P52, DOI 10.1038/nature23282	43	12	12	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	OCT 1	2018	308						162	172		10.1016/j.jneumeth.2018.07.021			11	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	GZ5GP	WOS:000449447500014	30076860				2021-06-18	
J	Jansman, MMT; Hosta-Rigau, L				Jansman, Michelle M. T.; Hosta-Rigau, Leticia			Recent and prominent examples of nano- and microarchitectures as hemoglobin-based oxygen carriers	ADVANCES IN COLLOID AND INTERFACE SCIENCE			English	Article						Encapsulation platforms; Hemoglobin; Hemoglobin-based oxygen carriers; Red blood cells substitutes; Oxygen delivery	LIPOSOME-ENCAPSULATED HEMOGLOBIN; SUPEROXIDE-DISMUTASE-CATALASE; RED-BLOOD-CELLS; HUMAN POLYMERIZED HEMOGLOBIN; BRAIN-BARRIER DISRUPTION; MEMBRANE EMULSIFICATION; SURFACE MODIFICATION; SEMIPERMEABLE MICROCAPSULES; POLY(ETHYLENE GLYCOL); CARBONIC-ANHYDRASE	Blood transfusions, which usually consist in the administration of isolated red blood cells (RBCs), are crucial in traumatic injuries, pre-surgical conditions and anemias. Although RBCs transfusion from donors is a safe procedure, donor RBCs can only be stored for a maximum of 42 days under refrigerated conditions and, therefore, stockpiles of RBCs for use in acute disasters do not exist. With a worldwide shortage of donor blood that is expected to increase over time, the creation of oxygen-carriers with long storage life and compatibility without typing and cross-matching, persists as one of the foremost important challenges in biomedicine. However, research has so far failed to produce FDA approved RBCs substitutes (RBCSs) for human usage. As such, due to unacceptable toxicities, the first generation of oxygen-carriers has been withdrawn from the market. Being hemoglobin (Hb) the main component of RBCs, a lot of effort is being devoted in assembling semi-synthetic RBCS utilizing Hb as the oxygen-carrier component, the so-called Hb-based oxygen carriers (HBOCs). However, a native RBC also contains a multi-enzyme system to prevent the conversion of Hb into non-functional methemoglobin (metHb). Thus, the challenge for the fabrication of next-generation HBOCs relies in creating a system that takes advantage of the excellent oxygen-carrying capabilities of Hb, while preserving the redox environment of native RBCs that prevents or reverts the conversion of Hb into metHb. In this review, we feature the most recent advances in the assembly of the new generation of HBOCs with emphasis in two main approaches: the chemical modification of Hb either by cross-linking strategies or by conjugation to other polymers, and the Hb encapsulation strategies, usually in the form of lipidic or polymeric capsules. The applications of the aforementioned HBOCs as blood substitutes or for oxygen-delivery in tissue engineering are highlighted, followed by a discussion of successes, challenges and future trends in this field. (C) 2018 Elsevier B.V. All rights reserved.	[Jansman, Michelle M. T.; Hosta-Rigau, Leticia] Tech Univ Denmark, Dept Micro & Nanotechnol, Ctr Nanomed & Theranost, DTU Nanotech, Bldg 423, DK-2800 Lyngby, Denmark	Hosta-Rigau, L (corresponding author), Tech Univ Denmark, Dept Micro & Nanotechnol, Ctr Nanomed & Theranost, DTU Nanotech, Bldg 423, DK-2800 Lyngby, Denmark.	leri@nanotech.dtu.dk	Hosta-Rigau, Leticia/C-4346-2016	Hosta-Rigau, Leticia/0000-0001-8177-4806; Jansman, Michelle/0000-0002-9269-4825	Danish Council for Independent ResearchDet Frie Forskningsrad (DFF) [6111-00298B]	This work was supported by the Danish Council for Independent Research [Grant No. 6111-00298B].	Agashe H, 2009, ADV PLANAR LIP BILAY, V9, P1, DOI 10.1016/S1554-4516(09)09001-2; Agashe H, 2010, COLLOID SURFACE B, V75, P573, DOI 10.1016/j.colsurfb.2009.09.038; Alayash AI, 2014, TRENDS BIOTECHNOL, V32, P177, DOI 10.1016/j.tibtech.2014.02.006; Alayash AI, 2004, NAT REV DRUG DISCOV, V3, P152, DOI 10.1038/nrd1307; Ariga K, 2007, PHYS CHEM CHEM PHYS, V9, P2319, DOI 10.1039/b700410a; Ariga K, 2014, CHEM LETT, V43, P36, DOI 10.1246/cl.130987; Ariga K, 2011, ADV DRUG DELIVER REV, V63, P762, DOI 10.1016/j.addr.2011.03.016; Baek JH, 2012, TOXICOL SCI, V127, P567, DOI 10.1093/toxsci/kfs109; Belcher JD, 2014, BLOOD, V123, P377, DOI 10.1182/blood-2013-04-495887; Best JP, 2012, ADV HEALTHC MATER, V1, P35, DOI 10.1002/adhm.201100012; Bian YZ, 2015, ARTIF CELL NANOMED B, V43, P1, DOI 10.3109/21691401.2014.964554; Bian YZ, 2011, ARTIF CELL BLOOD SUB, V39, P127, DOI 10.3109/10731199.2011.581052; Bjorkholm M, 2005, HAEMATOLOGICA, V90, P505; BONNEAUX F, 1995, J PROTEIN CHEM, V14, P1, DOI 10.1007/BF01902838; Bu HX, 2017, RSC ADV, V7, P48166, DOI 10.1039/c7ra09747f; Buehler PW, 2008, BBA-PROTEINS PROTEOM, V1784, P1378, DOI 10.1016/j.bbapap.2007.12.009; Buehler PW, 2010, TRENDS MOL MED, V16, P447, DOI 10.1016/j.molmed.2010.07.006; Butt OI, 2011, AM J PATHOL, V178, P1316, DOI 10.1016/j.ajpath.2010.12.006; Cabrales P, 2013, ANTIOXID REDOX SIGN, V18, P2329, DOI 10.1089/ars.2012.4922; Castro CI, 2010, ARTIF ORGANS, V34, P622, DOI 10.1111/j.1525-1594.2009.00944.x; Champion JA, 2008, PHARM RES-DORDR, V25, P1815, DOI 10.1007/s11095-008-9562-y; Chang B. S., 2010, FORMULATION PROCESS, P69, DOI [10.1002/9780470595886.ch3, DOI 10.1002/9780470595886.CH3]; Chang TMS, 2006, TRENDS BIOTECHNOL, V24, P372, DOI 10.1016/j.tibtech.2006.06.005; Chang TMS, 2010, WIRES NANOMED NANOBI, V2, P418, DOI 10.1002/wnan.95; CHANG TMS, 1968, NATURE, V218, P243, DOI 10.1038/218243a0; CHANG TMS, 1964, SCIENCE, V146, P524, DOI 10.1126/science.146.3643.524; CHANG TMS, 1976, J BIOENG, V1, P25; CHANG TMS, 1997, BLOOD SUBSTITUTES PR; Charoenphol P, 2011, ATHEROSCLEROSIS, V217, P364, DOI 10.1016/j.atherosclerosis.2011.04.016; Charoenphol P, 2010, BIOMATERIALS, V31, P1392, DOI 10.1016/j.biomaterials.2009.11.007; Chauvierre C, 2010, BIOMATERIALS, V31, P6069, DOI 10.1016/j.biomaterials.2010.04.039; Chen B, 2013, J PHYS CHEM C, V117, P19751, DOI 10.1021/jp407164q; Chen G, 2016, ARTIF CELL NANOMED B, V44, P56, DOI 10.3109/21691401.2015.1111239; Chen G, 2010, TISSUE ENG PT A, V16, P3231, DOI [10.1089/ten.tea.2010.0058, 10.1089/ten.TEA.2010.0058]; Chen JY, 2009, CLINICS, V64, P803, DOI 10.1590/S1807-59322009000800016; Chen PY, 2013, J MACROMOL SCI A, V50, P478, DOI 10.1080/10601325.2013.780947; Cheng DCH, 2004, J THORAC CARDIOV SUR, V127, P79, DOI 10.1016/j.jtcvs.2003.08.024; Cheng Y, 2002, BIOCHEMISTRY-US, V41, P11901, DOI 10.1021/bi0202880; Chu LY, 2003, J COLLOID INTERF SCI, V265, P187, DOI 10.1016/S0021-9797(03)00350-3; Colton CK, 2014, ADV DRUG DELIVER REV, V67-68, P93, DOI 10.1016/j.addr.2014.02.007; Cui JW, 2014, ADV MATER, V26, P7295, DOI 10.1002/adma.201402753; Cummings C, 2014, BIOMACROMOLECULES, V15, P763, DOI 10.1021/bm401575k; D'Agnillo F, 1998, NAT BIOTECHNOL, V16, P667, DOI 10.1038/nbt0798-667; Diamanti S, 2008, POLYMER, V49, P3770, DOI 10.1016/j.polymer.2008.06.020; DJORDJEVICH L, 1980, EXP HEMATOL, V8, P584; Doshi N, 2009, P NATL ACAD SCI USA, V106, P21495, DOI 10.1073/pnas.0907127106; Dreyer DR, 2012, LANGMUIR, V28, P6428, DOI 10.1021/la204831b; Duan L, 2015, CHEM-EUR J, V21, P520, DOI 10.1002/chem.201405439; Eaton WA, 1999, NAT STRUCT BIOL, V6, P351, DOI 10.1038/7586; Elmer J, 2012, RESUSCITATION, V83, P285, DOI 10.1016/j.resuscitation.2011.09.020; Farmer M C, 1988, Adv Exp Med Biol, V238, P161; Farris AL, 2016, J MATER CHEM B, V4, P3422, DOI 10.1039/c5tb02635k; Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200; Geng Y, 2007, NAT NANOTECHNOL, V2, P249, DOI 10.1038/nnano.2007.70; Gholipourmalekabadi M, 2016, TRENDS BIOTECHNOL, V34, P1010, DOI 10.1016/j.tibtech.2016.05.012; Goddard JM, 2007, PROG POLYM SCI, V32, P698, DOI 10.1016/j.progpolymsci.2007.04.002; GOLDSMIT.HL, 1972, PROC R SOC SER B-BIO, V182, P351, DOI 10.1098/rspb.1972.0084; Gould SA, 1998, J AM COLL SURGEONS, V187, P113, DOI 10.1016/S1072-7515(98)00095-7; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; Gu JS, 2009, ARTIF CELL BLOOD SUB, V37, P69, DOI 10.1080/10731190902742240; Guaccio A, 2008, BIOMATERIALS, V29, P1484, DOI 10.1016/j.biomaterials.2007.12.020; Guo C, 2015, ARTIF CELL NANOMED B, V43, P157, DOI 10.3109/21691401.2015.1035479; Gupta AS, 2017, WIRES NANOMED NANOBI, V9, DOI 10.1002/wnan.1464; Harrington JP, 2011, J FUNCT BIOMATER, V2, P414, DOI 10.3390/jfb2040414; Haruki R, 2015, SCI REP-UK, V5, DOI 10.1038/srep12778; Hathazi D, 2014, BIOMACROMOLECULES, V15, P1920, DOI 10.1021/bm5004256; He Q, 2009, CHEM SOC REV, V38, P2292, DOI 10.1039/b816475b; Hosaka H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110541; Huang RB, 2010, MOL MEMBR BIOL, V27, P190, DOI 10.3109/09687688.2010.499548; HUNT CA, 1985, SCIENCE, V230, P1165, DOI 10.1126/science.4071041; Jahr JS, 2008, EXPERT OPIN BIOL TH, V8, P1425, DOI [10.1517/14712598.8.9.1425, 10.1517/14712598.8.9.1425 ]; Jenkins JD, 2009, ACTA CRYSTALLOGR D, V65, P41, DOI 10.1107/S0907444908037256; Jia Y, 2016, ADV MATER, V28, P1312, DOI 10.1002/adma.201502581; Jia Y, 2015, CHEM REV, V115, P1597, DOI 10.1021/cr400559g; Jia Y, 2012, ADV FUNCT MATER, V22, P1446, DOI 10.1002/adfm.201102737; Jia YP, 2004, BBA-GEN SUBJECTS, V1672, P164, DOI 10.1016/j.bbagen.2004.03.009; Kameta N, 2011, SOFT MATTER, V7, P4539, DOI 10.1039/c0sm01559h; Kaneda S, 2009, ARTIF ORGANS, V33, P146, DOI 10.1111/j.1525-1594.2008.00699.x; Kim HW, 2013, HEMOGLOBIN BASED OXY, DOI [10.1007/978-3-642-40717-8, DOI 10.1007/978-3-642-40717-8]; Kim-Shapiro DB, 2006, ARTERIOSCL THROM VAS, V26, P697, DOI 10.1161/01.ATV.0000204350.44226.9a; Kimura T, 1998, ARTIF CELL BLOOD SUB, V26, P455, DOI 10.3109/10731199809117466; Knirsch MC, 2015, BIOPROC BIOSYST ENG, V38, P2263, DOI 10.1007/s00449-015-1463-y; Knirsch MC, 2017, BIOPROC BIOSYST ENG, V40, P431, DOI 10.1007/s00449-016-1711-9; Komatsu T, 2011, J AM CHEM SOC, V133, P3246, DOI 10.1021/ja1096122; Ku SH, 2010, BIOMATERIALS, V31, P9431, DOI 10.1016/j.biomaterials.2010.08.071; Ku SH, 2010, BIOMATERIALS, V31, P2535, DOI 10.1016/j.biomaterials.2009.12.020; Lai P, 2014, COLLOID SURFACE B, V118, P154, DOI 10.1016/j.colsurfb.2014.03.017; Lai YT, 2015, BIOTECHNOL PROGR, V31, P1676, DOI 10.1002/btpr.2170; Lai YT, 2015, COLLOID SURFACE B, V127, P1, DOI 10.1016/j.colsurfb.2015.01.018; Lam CN, 2013, SOFT MATTER, V9, P2393, DOI 10.1039/c2sm27459k; Li B, 2014, BIOMATER SCI-UK, V2, P1254, DOI 10.1039/c4bm00123k; Li B, 2014, INT J PHARMACEUT, V468, P75, DOI 10.1016/j.ijpharm.2014.04.004; Li DX, 2009, BIOCONJUGATE CHEM, V20, P2062, DOI 10.1021/bc900170e; Li TH, 2011, MACROMOL BIOSCI, V11, P865, DOI 10.1002/mabi.201000469; Liebscher J, 2013, LANGMUIR, V29, P10539, DOI 10.1021/la4020288; Liu GY, 2012, SOFT MATTER, V8, P8811, DOI 10.1039/c2sm25721a; Liu XS, 2013, ACS NANO, V7, P9384, DOI 10.1021/nn404117j; Liu YL, 2014, CHEM REV, V114, P5057, DOI 10.1021/cr400407a; Lopez-Alonso JP, 2009, BIOCONJUGATE CHEM, V20, P1459, DOI 10.1021/bc9001486; Lu MZ, 2016, COLLOID SURFACE B, V139, P171, DOI 10.1016/j.colsurfb.2015.12.012; Mackenzie CF, 2010, ANESTH ANALG, V110, P685, DOI 10.1213/ANE.0b013e3181cd473b; McCarthy MR, 2001, BIOPHYS CHEM, V92, P103, DOI 10.1016/S0301-4622(01)00194-6; Meng FT, 2003, ARTIF CELL BLOOD SUB, V31, P279, DOI 10.1081/BIO-120023158; Merkel TJ, 2011, P NATL ACAD SCI USA, V108, P586, DOI 10.1073/pnas.1010013108; Michel CC, 1996, CARDIOVASC RES, V32, P644, DOI 10.1016/0008-6363(96)00064-8; Modery-Pawlowski CL, 2013, BIOMACROMOLECULES, V14, P939, DOI 10.1021/bm400074t; Montagne K, 2011, J BIOSCI BIOENG, V112, P485, DOI 10.1016/j.jbiosc.2011.07.004; Moore EE, 2009, J AM COLL SURGEONS, V208, P1, DOI 10.1016/j.jamcollsurg.2008.09.023; Mozzarelli A, 2010, BLOOD TRANSFUS-ITALY, V8, pS59, DOI 10.2450/2010.010S; Muller R, 2005, BIOMATERIALS, V26, P6962, DOI 10.1016/j.biomaterials.2005.05.013; Muro S, 2008, MOL THER, V16, P1450, DOI 10.1038/mt.2008.127; Nag Okhil K, 2013, Pharmaceutics, V5, P542, DOI 10.3390/pharmaceutics5040542; Nag OK, 2013, INT J PHARMACEUT, V446, P119, DOI 10.1016/j.ijpharm.2013.02.026; Nagababu E, 2003, BBA-GEN SUBJECTS, V1620, P211, DOI 10.1016/S0304-4165(02)00537-8; NAGEL RL, 1971, J BIOL CHEM, V246, P69; Nahmias Y, 2006, FASEB J, V20, P2531, DOI 10.1096/fj.06-6192fje; Nakashima T, 2000, ADV DRUG DELIVER REV, V45, P47, DOI 10.1016/S0169-409X(00)00099-5; Napolitano LM, 2009, CRIT CARE CLIN, V25, P279, DOI 10.1016/j.ccc.2009.01.003; Naruto H, 2007, J BIOSCI BIOENG, V104, P343, DOI 10.1263/jbb.104.343; Natanson C, 2008, JAMA-J AM MED ASSOC, V299, P2304, DOI 10.1001/jama.299.19.jrv80007; Neamtu I, 2017, DRUG DELIV, V24, P539, DOI 10.1080/10717544.2016.1276232; Olofsson C, 2008, TRANSFUSION MED, V18, P28, DOI 10.1111/j.1365-3148.2007.00811.x; Olson JS, 2004, FREE RADICAL BIO MED, V36, P685, DOI 10.1016/j.freeradbiomed.2003.11.030; Paciello A, 2016, ADV HEALTHC MATER, V5, P2655, DOI 10.1002/adhm.201600559; Page TC, 2008, Patent No. [U57459535B2, 459535B2]; Powanda DD, 2002, ARTIF CELL BLOOD SUB, V30, P23, DOI 10.1081/BIO-120002725; Rameez S, 2008, BIOCONJUGATE CHEM, V19, P1025, DOI 10.1021/bc700465v; Rameez S, 2012, BIOTECHNOL PROGR, V28, P636, DOI 10.1002/btpr.1532; Richards MP, 2003, J AGR FOOD CHEM, V51, P3886, DOI 10.1021/jf0212082; Riess JG, 2001, CHEM REV, V101, P2797, DOI 10.1021/cr970143c; Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653; RUDOLPH AS, 1991, P NATL ACAD SCI USA, V88, P10976, DOI 10.1073/pnas.88.23.10976; RUDT S, 1993, EUR J PHARM SCI, V1, P31, DOI 10.1016/0928-0987(93)90015-3; Sakai H, 1997, BIOCONJUGATE CHEM, V8, P23, DOI 10.1021/bc960069p; Sakai Hiromi, 2012, Curr Drug Discov Technol, V9, P188; Sakai H, 2010, ADV EXP MED BIOL, V662, P433, DOI 10.1007/978-1-4419-1241-1_62; Sakai H, 2009, ARTIF ORGANS, V33, P139, DOI 10.1111/j.1525-1594.2008.00698.x; Sakai Y, 2010, BIOCHEM ENG J, V48, P348, DOI 10.1016/j.bej.2009.10.010; Sen Gupta A, 2016, WIRES NANOMED NANOBI, V8, P255, DOI 10.1002/wnan.1362; SEVERINGHAUS JW, 1966, J APPL PHYSIOL, V21, P1108; Sheng Y, 2009, J MATER SCI-MATER M, V20, P1881, DOI 10.1007/s10856-009-3746-9; Silverman TA, 2009, TRANSFUSION, V49, P2495, DOI 10.1111/j.1537-2995.2009.02356.x; Simoni J, 2014, ARTIF ORGANS, V38, P684, DOI 10.1111/aor.12337; Simoni Jan, 2012, Curr Drug Discov Technol, V9, P173; Sims C, 2001, J TRAUMA, V51, P1137, DOI 10.1097/00005373-200112000-00020; Sloan EP, 2010, J TRAUMA, V68, P1158, DOI 10.1097/TA.0b013e3181bbfaac; Smith A, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00187; Sou K, 2008, BBA-BIOMEMBRANES, V1778, P1035, DOI 10.1016/j.bbamem.2008.01.006; Squires JE, 2002, SCIENCE, V295, P1002, DOI 10.1126/science.1068443; Stadler AM, 2008, BIOPHYS J, V95, P5449, DOI 10.1529/biophysj.108.138040; Taguchi K, 2012, J DRUG METAB TOXICOL, V3, DOI [10.4172/2157-7609.1000128, DOI 10.4172/2157-7609.1000128]; Taguchi K, 2017, J FUNCT BIOMATER, V8, DOI 10.3390/jfb8010011; Taguchi K, 2009, DRUG METAB DISPOS, V37, P2197, DOI 10.1124/dmd.109.028852; Tao ZM, 2014, TRENDS BIOTECHNOL, V32, P466, DOI 10.1016/j.tibtech.2014.05.001; Tomaiuolo G, 2014, BIOMICROFLUIDICS, V8, DOI 10.1063/1.4895755; Tomita D, 2013, BIOMACROMOLECULES, V14, P1816, DOI 10.1021/bm400204y; Tronstad C, 2010, PHYSIOL MEAS, V31, P1241, DOI 10.1088/0967-3334/31/9/013; Tsuchida E, 2006, ARTIF CELL BLOOD SUB, V34, P581, DOI 10.1080/10731190600973907; Tsuchida E, 2009, BIOCONJUGATE CHEM, V20, P1419, DOI 10.1021/bc800431d; Umbreit J, 2007, AM J HEMATOL, V82, P134, DOI 10.1002/ajh.20738; Vandegriff KD, 2009, ARTIF ORGANS, V33, P133, DOI 10.1111/j.1525-1594.2008.00697.x; Vladisavljevic GT, 2005, ADV COLLOID INTERFAC, V113, P1, DOI 10.1016/j.cis.2004.10.002; Wang QN, 2018, ADV CIV ENG, V2018, DOI 10.1155/2018/3789214; Wang QQ, 2014, BBA-PROTEINS PROTEOM, V1844, P1201, DOI 10.1016/j.bbapap.2014.04.005; Wang Q, 2017, BIOMACROMOLECULES, V18, P1333, DOI 10.1021/acs.biomac.7b00077; Wang SS, 2014, RSC ADV, V4, P52940, DOI 10.1039/c4ra06397j; Wang X, 2009, ARTIF CELL BLOOD SUB, V37, P41, DOI 10.1080/10731190802674477; Wang Y, 2017, PROCESS BIOCHEM, V60, P67, DOI 10.1016/j.procbio.2017.05.021; Wei X, 2017, COLLOID SURFACE B, V155, P440, DOI 10.1016/j.colsurfb.2017.04.047; Wijekoon A, 2013, ACTA BIOMATER, V9, P5653, DOI 10.1016/j.actbio.2012.10.034; Winslow RM, 2000, ADV DRUG DELIVER REV, V40, P131, DOI 10.1016/S0169-409X(99)00045-9; Winslow RM, 2004, ARTIF ORGANS, V28, P800, DOI 10.1111/j.1525-1594.2004.07392.x; Xiong Y, 2013, ACS NANO, V7, P7454, DOI 10.1021/nn402073n; Xu F, 2009, INT J PHARMACEUT, V377, P199, DOI 10.1016/j.ijpharm.2009.05.015; YABUKI A, 1990, TRANSFUSION, V30, P516, DOI 10.1046/j.1537-2995.1990.30690333482.x; Yadav VR, 2016, EUR J PHARM SCI, V93, P97, DOI 10.1016/j.ejps.2016.08.010; Yadav VR, 2014, ARTIF ORGANS, V38, P625, DOI 10.1111/aor.12304; Yamada K, 2016, SCI REP-UK, V6, DOI 10.1038/srep36782; Yokomaku K, 2018, J MATER CHEM B, V6, P2417, DOI 10.1039/c8tb00211h; Yu CM, 2018, SENSOR ACTUAT B-CHEM, V256, P217, DOI 10.1016/j.snb.2017.09.166; Yu WP, 1996, ARTIF CELL BLOOD SUB, V24, P169, DOI 10.3109/10731199609117433; Zhang XY, 2017, CURR NANOSCI, V13, P124, DOI 10.2174/1573413712666161018144519; Zhao J, 2007, BIOMATERIALS, V28, P1414, DOI 10.1016/j.biomaterials.2006.10.012; ZUCK TF, 1977, TRANSFUSION, V17, P374, DOI 10.1046/j.1537-2995.1977.17477216866.x	184	12	12	7	47	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0001-8686	1873-3727		ADV COLLOID INTERFAC	Adv. Colloid Interface Sci.	OCT	2018	260						65	84		10.1016/j.cis.2018.08.006			20	Chemistry, Physical	Chemistry	GX9DX	WOS:000448099800005	30177214				2021-06-18	
J	Resch, JE; Schneider, MW; Cullum, CM				Resch, Jacob E.; Schneider, Mathew W.; Cullum, C. Munro			The test-retest reliability of three computerized neurocognitive tests used in the assessment of sport concussion	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						Concussion; Computerized neurocognitive test; Reliability; Mild traumatic brain injury	CNS VITAL SIGNS; NEUROPSYCHOLOGICAL ASSESSMENT; TEST BATTERY; TEST-PERFORMANCE; ASSESSMENT TOOLS; IMPACT; MANAGEMENT; SENSITIVITY; VALIDITY	Computerized neurocognitive tests (CNTs) are widely used at all competitive levels of sport to assess sport concussion (SC). Whereas there are multiple CNTs available, little is known about how some of the most popular platforms compare. The purpose of this study was to investigate the test-retest reliability of the Automated Neuropsychological Assessment Metrics (ANAM), Concussion Vital Signs (CVS) and the Immediate Postconcussion and Cognitive Testing battery (ImPACT) using clinically relevant time points in healthy college age participants. Participants were healthy college-age students (N = 128) randomly assigned into one of three groups which were administered ANAM, CVS, or ImPACT at Days 1, 45 and 50. Intraclass correlation coefficients (ICCs) and Pearson correlations were used to assess reliability of the various CNT scores and subtest scores between time points. Participants were tested approximately 47.1 +/- 2.75 days after time point 1 and approximately 7.0 +/- 2.45 days after time point 2. ICC values ranged from 0.18 (Procedural Reaction Time) to 0.53 (Mathematical Processing and Simple Reaction Time 1) for ANAM, 0.14 (Continuous Performance Test) to 0.85 (Reaction Time) for CVS, and 0.19 (Verbal Memory) to 0.89 (Visual Motor Speed) for ImPACT. Significant improvements (p < 0.05) across time were observed for (7/10) CNS Vital Signs composite scores, but no additional significant changes in performance were observed for the remaining CNTs. Overall, weak to strong reliability coefficients for ANAM, CVS, and ImPACT were observed when using clinically relevant time points of repeated administration.	[Resch, Jacob E.] Univ Virginia, Mem Gymnasium, 210 Emmet St S, Charlottesville, VA 22932 USA; [Schneider, Mathew W.] Univ Texas Arlington, 500 S Nedderman Dr, Arlington, TX USA; [Cullum, C. Munro] Univ Texas Southwestern, Med Ctr, 6333 Forest Pk Rd,1st Floor,BLA100, Dallas, TX 75235 USA	Resch, JE (corresponding author), Univ Virginia, Mem Gymnasium, 210 Emmet St S, Charlottesville, VA 22932 USA.	Jer6x@virginia.edu; Munro.cullum@utsouthwestern.edu	Cullum, C. Munro/AAC-2496-2019	Cullum, C. Munro/0000-0001-9706-5465			Alsalaheen B, 2016, J HEAD TRAUMA REHAB, V31, P242, DOI 10.1097/HTR.0000000000000175; Anastasi A, 1998, PSCYHOLOGICAL TESTIN; Baumgartner TA, 2007, MEASUREMENT EVALUATI, V8th; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; CNS Vital Signs, 2014, FAQS FREQ ASK QUEST; Cole WR, 2013, ARCH CLIN NEUROPSYCH, V28, P732, DOI 10.1093/arclin/act040; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; Green P., 2005, GREENS WORD MEMORY T; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Littleton AC, 2015, SPORTS HEALTH, V7, P443, DOI 10.1177/1941738115586997; Lovell M. R, 2011, IMMEDIATE POSTCONCUS; Lynall RC, 2013, J ATHL TRAINING, V48, P844, DOI 10.4085/1062-6050-48.6.04; Maxwell S. E., 2003, DESIGNING EXPT ANAL; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.4.390; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Nakayama Y, 2014, AM J SPORT MED, V42, P2000, DOI 10.1177/0363546514535901; Nelson L, 2015, AM J SPORTS MED; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Rahman-Filipiak AAM, 2013, NEUROPSYCHOL REV, V23, P314, DOI 10.1007/s11065-013-9241-6; Randolph C, 2005, J ATHL TRAINING, V40, P139; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Resch JE, 2013, NEUROPSYCHOL REV, V23, P335, DOI 10.1007/s11065-013-9242-5; Roebuck-Spencer T, 2007, ARCH CLIN NEUROPSYCH, V22, pS79, DOI 10.1016/j.acn.2006.10.011; Rogers C, 2015, RE CONCUSSION CNS VI; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2013, ARCH CLIN NEUROPSYCH; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Schatz P, 2010, ARCH CLIN NEUROPSYCH, V25, P285, DOI 10.1093/arclin/acq022; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805	38	12	12	1	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	OCT	2018	132		A		SI		31	38		10.1016/j.ijpsycho.2017.09.011			8	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	GV7GC	WOS:000446289000006	28935224				2021-06-18	
J	Bland, ML; McNally, C; Rowson, S				Bland, Megan L.; McNally, Craig; Rowson, Steven			Differences in Impact Performance of Bicycle Helmets During Oblique Impacts	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article						cycling; concussion; injury risk; impact attenuation; acceleration; biomechanics	SCHOOL FOOTBALL PLAYERS; HEAD-INJURIES; REAL-WORLD; CONCUSSION; RISK; ACCELERATION; DAMAGE	Cycling is a leading cause of sport-related head injuries in the U.S. Although bicycle helmets must comply with standards limiting head acceleration in severe impacts, helmets are not evaluated under more common, concussive-level impacts, and limited data are available indicating which helmets offer superior protection. Further, standards evaluate normal impacts, while real-world cyclist head impacts are oblique-involving normal and tangential velocities. The objective of this study was to investigate differences in protective capabilities of ten helmet models under common real-world accident conditions. Oblique impacts were evaluated through drop tests onto an angled anvil at common cyclist head impact velocities and locations. Linear and rotational accelerations were evaluated and related to concussion risk, which was then correlated with design parameters. Significant differences were observed in linear and rotational accelerations between models, producing concussion risks spanning >50% within single impact configurations. Risk differences were more attributable to linear acceleration, as rotational varied less between models. At the temporal location, shell thickness, vent configuration, and radius of curvature were found to influence helmet effective stiffness. This should be optimized to reduce impact kinematics. At the frontal, helmet rim location, liner thickness tapered off for some helmets, likely due to lack of standards testing at this location. This is a frequently impacted location for cyclists, suggesting that the standards testable area should be expanded to include the rim. These results can inform manufacturers, standards bodies, and consumers alike, aiding the development of improved bicycle helmet safety.	[Bland, Megan L.] Virginia Tech, Dept Biomed Engn & Mech, 440 Kelly Hall,325 Stanger St, Blacksburg, VA 24061 USA; [McNally, Craig] Virginia Tech, Ctr Injury Biomech, 2280 Kraft Dr VCOM 2 Bldg, Blacksburg, VA 24060 USA; [Rowson, Steven] Virginia Tech, Dept Biomed Engn & Mech, 343 Kelly Hall,325 Stanger St, Blacksburg, VA 24061 USA	Bland, ML (corresponding author), Virginia Tech, Dept Biomed Engn & Mech, 440 Kelly Hall,325 Stanger St, Blacksburg, VA 24061 USA.	mbland27@vt.edu; cmcnally@vt.edu; rowson@vt.edu	Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596	Virginia Tech Institute of Critical Technology and Applied Science (ICTAS, Blacksburg, VA); Insurance Institute for Highway Safety (IIHS, Ruckersville, VA)	This research was supported by the Virginia Tech Institute of Critical Technology and Applied Science (ICTAS, Blacksburg, VA) and the Insurance Institute for Highway Safety (IIHS, Ruckersville, VA).	AANS, 2014, SPORTS REL HEAD INJ; Aare Magnus, 2003, Traffic Inj Prev, V4, P240, DOI 10.1080/15389580309879; Amoros E, 2012, INJURY PREV, V18, P27, DOI 10.1136/ip.2011.031815; Bland ML, 2018, TRAFFIC INJ PREV, V19, pS158, DOI 10.1080/15389588.2017.1388915; Bourdet N, 2014, INT J CRASHWORTHINES, V19, P222, DOI 10.1080/13588265.2013.805293; Bourdet N, 2012, P I MECH ENG P-J SPO, V226, P282, DOI 10.1177/1754337112442326; Ching RP, 1997, ACCIDENT ANAL PREV, V29, P555, DOI 10.1016/S0001-4575(97)00008-0; Cobb BR, 2017, P I MECH ENG P; Cobb BR, 2016, P I MECH ENG P-J SPO, V230, P50, DOI 10.1177/1754337115599133; Cobb BR, 2015, P I MECH ENG P-J SPO, V229, P39, DOI 10.1177/1754337114548245; CPSC, 2015, NAT EL INJ SURV SYST; Cripton PA, 2014, ACCIDENT ANAL PREV, V70, P1, DOI 10.1016/j.aap.2014.02.016; Depreitere B, 2004, ACCIDENT ANAL PREV, V36, P561, DOI 10.1016/S0001-4575(03)00062-9; ECE, 1999, R2205 ECE; Elvik R, 2013, ACCIDENT ANAL PREV, V60, P245, DOI 10.1016/j.aap.2012.12.003; Fahlstedt M, 2012, P INT RES COUNC BIOM, V40, P787; Gennarelli T.A., 1971, P 15 STAPP CAR CRASH, V39, P797; Gennarelli TA, 1972, 720970 SAE; Ghajari M, 2013, ACCIDENT ANAL PREV, V50, P263, DOI 10.1016/j.aap.2012.04.016; Halldin P., 2013, HELMET PERFORMANCE D; Hansen K, 2013, ACCIDENT ANAL PREV, V59, P109, DOI 10.1016/j.aap.2013.05.019; Hering A. M, 2000, IRCOBI C MONTP FRANC, P307; King A.I., 2003, IRCOBI C LISB PORT, P1; Klug C., 2015, INT RES COUNC BIOM I; Laituri T. R., 2015, 2015011437 SAE; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McIntosh A, 1998, ACCIDENT ANAL PREV, V30, P161, DOI 10.1016/S0001-4575(97)00089-4; McIntosh AS, 2013, TRAFFIC INJ PREV, V14, P501, DOI 10.1080/15389588.2012.727217; Mertz Harold J, 2003, Stapp Car Crash J, V47, P155; Mills NJ, 2008, INT J IMPACT ENG, V35, P1075, DOI 10.1016/j.ijimpeng.2007.05.005; Mills NJ, 2008, INT J IMPACT ENG, V35, P1087, DOI 10.1016/j.ijimpeng.2007.05.006; Mills N J, 1990, Br J Sports Med, V24, P55; Mills NJ., 1996, INT J CRASHWORTHINES, V2, P7; Milne G, 2014, INT J CRASHWORTHINES, V19, P323, DOI 10.1080/13588265.2013.859470; Newman J A, 2000, Stapp Car Crash J, V44, P215; Nightingale RW, 1996, J BIOMECH, V29, P307, DOI 10.1016/0021-9290(95)00056-9; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Ommaya AK, 1966, P 10 STAPP CAR CRASH, V10, P314; Otte D, 1989, 892425 SAE; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Peng Y, 2012, SAFETY SCI, V50, P1749, DOI 10.1016/j.ssci.2012.03.005; Rowson B, 2015, ANN BIOMED ENG, V43, P2429, DOI 10.1007/s10439-015-1278-7; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; Sances A, 2002, BIOMED SCI INSTRUM, V38, P459; Schulman J, 2002, INJ PREV, V8, P47, DOI 10.1136/ip.8.1.47; SMITH TA, 1994, ACCIDENT ANAL PREV, V26, P795, DOI 10.1016/0001-4575(94)90055-8; Stigson H., 2017, INT RES COUNC BIOM I; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; Unterharnscheidt F. J., 1971, 710880 SAE; Verschueren P., 2009, BIOMECHANICAL ANAL H; WILLIAMS M, 1991, ACCIDENT ANAL PREV, V23, P119, DOI 10.1016/0001-4575(91)90043-5	56	12	12	1	16	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	SEP	2018	140	9							091005	10.1115/1.4040019			10	Biophysics; Engineering, Biomedical	Biophysics; Engineering	GW9BN	WOS:000447276700005	29801168				2021-06-18	
J	Chien, L; Liang, ML; Chang, CY; Wang, C; Chen, LY				Chien, Ling; Liang, Min-Long; Chang, Chu-Yuan; Wang, Chen; Chen, Linyi			Mitochondrial therapy promotes regeneration of injured hippocampal neurons	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE			English	Article						Brain injury; Neuronal regeneration; Mitochondrial morphogenesis	TRAUMATIC BRAIN-INJURY; ISCHEMIA-REPERFUSION INJURY; MOUSE MODEL; TRANSPLANTATION; CELLS; FUSION; DAMAGE; DYSFUNCTION; TRANSPORT; DIVISION	Due to the inhibitory microenvironment and reduced intrinsic growth capacity of neurons, neuronal regeneration of central nervous system remains challenging. Neurons are highly energy demanding and require sufficient mitochondria to support cellular activities. In response to stimuli, mitochondria undergo fusion/fission cycles to adapt to environment. It is thus logical to hypothesize that the plasticity of mitochondrial dynamics is required for neuronal regeneration. In this study, we examined the role of mitochondrial dynamics during regeneration of rat hippocampal neurons. Quantitative analysis showed that injury induced mitochondrial fission. As mitochondrial dysfunction has been implicated in neurodegenerative diseases, we tested the possibility that the mitochondrial therapy may promote neuronal regeneration. Supplying freshly isolated mitochondria to the injured hippocampal neurons not only significantly increased neurite re-growth but also restored membrane potential of injured hippocampal neurons. Together, our findings support the importance of mitochondrial dynamics during regeneration of injured hippocampal neurons and highlight the therapeutic prospect of mitochondria to the injured central nervous system.	[Chien, Ling; Liang, Min-Long; Chang, Chu-Yuan; Chen, Linyi] Natl Tsing Hua Univ, Inst Mol Med, 101,Sect 2,Kuang Fu Rd, Hsinchu 30013, Taiwan; [Wang, Chen] Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 30013, Taiwan; [Chen, Linyi] Natl Tsing Hua Univ, Dept Med Sci, 101,Sect 2,Kuang Fu Rd, Hsinchu 30013, Taiwan	Chen, LY (corresponding author), Natl Tsing Hua Univ, Inst Mol Med, 101,Sect 2,Kuang Fu Rd, Hsinchu 30013, Taiwan.; Chen, LY (corresponding author), Natl Tsing Hua Univ, Dept Med Sci, 101,Sect 2,Kuang Fu Rd, Hsinchu 30013, Taiwan.	lchen@life.nthu.edu.tw	Chen, Linyi/AAV-2632-2020	Chen, Linyi/0000-0001-7258-8817	National Health Research Institutes, TaiwanNational Health Research Institutes - Taiwan [NHRI-EX106-10206NI]	This works was supported by National Health Research Institutes, Taiwan (Grant# NHRI-EX106-10206NI).	Chang JC, 2016, TRANSL RES, V170, P40, DOI 10.1016/j.trsl.2015.12.003; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; Chen CJ, 2015, J BIOL CHEM, V290, P6010, DOI 10.1074/jbc.M114.603795; Chien L, 2015, ONCOTARGET, V6, P30628, DOI 10.18632/oncotarget.5790; Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101; Cruz-Haces M, 2017, TRANSL NEURODEGENER, V6, DOI 10.1186/s40035-017-0088-2; Di Pietro V, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09587-2; Fairless R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058260; Fischer TD, 2016, FRONT SYST NEUROSCI, V10, DOI [10.3389/fnsys.2016.00029, 10.3389/fnsys.2010.00020]; Gupta R, 2016, REV NEUROSCIENCE, V27, P93, DOI 10.1515/revneuro-2015-0017; Hayakawa K, 2016, NATURE, V535, P551, DOI 10.1038/nature18928; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Kann O, 2007, AM J PHYSIOL-CELL PH, V292, pC641, DOI 10.1152/ajpcell.00222.2006; Katrangi E, 2007, REJUV RES, V10, P561, DOI 10.1089/rej.2007.0575; Kaza AK, 2017, J THORAC CARDIOV SUR, V153, P934, DOI 10.1016/j.jtcvs.2016.10.077; Li X, 2014, AM J RESP CELL MOL, V51, P455, DOI 10.1165/rcmb.2013-0529OC; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lin HC, 2013, SHOCK, V39, P304, DOI 10.1097/SHK.0b013e318283035f; Masuzawa A, 2013, AM J PHYSIOL-HEART C, V304, pH966, DOI 10.1152/ajpheart.00883.2012; McCully JD, 2016, CLIN TRANSL MED, V5, DOI 10.1186/s40169-016-0095-4; McCully JD, 2009, AM J PHYSIOL-HEART C, V296, pH94, DOI 10.1152/ajpheart.00567.2008; Miller KE, 2004, J CELL SCI, V117, P2791, DOI 10.1242/jcs.01130; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Nguyen R, 2016, CAN J NEUROL SCI, V43, P774, DOI 10.1017/cjn.2016.290; Ni HM, 2015, REDOX BIOL, V4, P6, DOI 10.1016/j.redox.2014.11.006; Pacak CA, 2015, BIOL OPEN, V4, P622, DOI 10.1242/bio.201511478; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Plotnikov EY, 2015, BIOCHEMISTRY-MOSCOW+, V80, P542, DOI 10.1134/S0006297915050041; Rojo M, 2002, J CELL SCI, V115, P1663; Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133; Shih CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079619; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Wang X, 2015, CELL DEATH DIFFER, V22, P1181, DOI 10.1038/cdd.2014.211; Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013; Wu Q, 2016, BRAIN RES, V1630, P134, DOI 10.1016/j.brainres.2015.11.016	37	12	14	1	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-4439	0006-3002		BBA-MOL BASIS DIS	Biochim. Biophys. Acta-Mol. Basis Dis.	SEP	2018	1864	9	B				3001	3012		10.1016/j.bbadis.2018.06.012			12	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	GQ8ZR	WOS:000442056200023	29913215	Bronze			2021-06-18	
J	Huang, SX; Qiu, GZ; Cheng, FR; Pei, Z; Yang, Z; Deng, XH; Zhu, JH; Chen, L; Chen, CC; Lin, WF; Liu, Y; Liu, ZS; Zhu, FQ				Huang, Shu-Xuan; Qiu, Guozhen; Cheng, Fu-Rong; Pei, Zhong; Yang, Zhi; Deng, Xu-Hui; Zhu, Jin-Hua; Chen, Lue; Chen, Chun-Chun; Lin, Wei-Feng; Liu, Yuan; Liu, Zhengshan; Zhu, Fei-Qi			Berberine Protects Secondary Injury in Mice with Traumatic Brain Injury Through Anti-oxidative and Anti-inflammatory Modulation	NEUROCHEMICAL RESEARCH			English	Article						Traumatic brain injury; Berberine; Oxidative stress; Inflammatory; Secondary injury	NITRIC-OXIDE SYNTHASE; CEREBRAL-ISCHEMIA; NEURONAL DEATH; RATS; MODEL; NEUROPROTECTION; ACTIVATION; DISEASE; DAMAGE; PATHOPHYSIOLOGY	Traumatic brain injury (TBI) is one of the major causes of death and disability worldwide. Novel and effective therapy is needed to prevent the secondary spread of damage beyond the initial injury. The aim of this study was to investigate whether berberine has a neuroprotective effect on secondary injury post-TBI, and to explore its potential mechanism in this protection. The mice were randomly divided into Sham-saline, TBI-saline and TBI-Berberine (50 mg/kg). TBI was induced by Feeney's weight-drop technique. Saline or berberine was administered via oral gavage starting 1 h post-TBI and continuously for 21 days. Motor coordination, spatial learning and memory were assessed using beam-walking test and Morris water maze test, respectively. Brain sections were processed for lesion volume assessment, and expression of neuronal nuclei (NeuN), cyclooxygenase 2 (COX-2), inducible nitric oxide synthase (iNOS), 8-hydroxy-2-deoxyguanosine (8-OHdG), ionized calcium-binding adapter molecule 1 (Iba1) and glial fibrillary acidic protein (GFAP) were detected via immunohistochemistry and immunofluorescence. There were statistically significant improvement in motor coordination, spatial learning and memory in the TBI-Berberine group, compared to the TBI-saline group. Treatment with berberine significantly reduced cortical lesion volume, neuronal loss, COX-2, iNOS and 8-OHdG expression in both the cortical lesion border zone (LBZ) and ipsilateral hippocampal CA1 region (CA1), compared to TBI-saline. Berberine treatment also significantly decreased Iba1- and GFAP-positive cell number in both the cortical LBZ and ipsilateral CA1, relative to saline controls. These results indicated that berberine exerted neuroprotective effects on secondary injury in mice with TBI probably through anti-oxidative and anti-inflammatory properties.	[Qiu, Guozhen; Chen, Chun-Chun; Zhu, Fei-Qi] Shenzhen Univ, Cognit Impairment Ward, Neurol Dept, Affiliated Hosp 3, 47 Youyi Rd, Shenzhen 518001, Guangdong, Peoples R China; [Huang, Shu-Xuan; Yang, Zhi; Deng, Xu-Hui; Zhu, Jin-Hua; Lin, Wei-Feng; Zhu, Fei-Qi] Shantou Univ, Dept Neurol, Affiliated Yuebei Peoples Hosp, Shaoguan 512026, Guangdong, Peoples R China; [Huang, Shu-Xuan] Guangzhou Med Univ, Dept Neurol, Affiliated Hosp 1, Guangzhou 510120, Guangdong, Peoples R China; [Cheng, Fu-Rong] Luohu Dist Hlth & Family Planning Bur, Shenzhen 518001, Guangdong, Peoples R China; [Pei, Zhong] Sun Yat Sen Univ, Dept Neurol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China; [Chen, Lue] Southern Med Univ, Dept Neurol, Affiliated Shunde Peoples Hosp 1, Foshan 528300, Guangdong, Peoples R China; [Liu, Yuan] Third Hosp Hangzhou, Dept Neurol, Hangzhou 310009, Zhejiang, Peoples R China; [Liu, Zhengshan] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA; [Liu, Zhengshan] Univ Rochester, Med Ctr, Ctr Translat Neuromed, Rochester, NY 14642 USA	Zhu, FQ (corresponding author), Shenzhen Univ, Cognit Impairment Ward, Neurol Dept, Affiliated Hosp 3, 47 Youyi Rd, Shenzhen 518001, Guangdong, Peoples R China.; Zhu, FQ (corresponding author), Shantou Univ, Dept Neurol, Affiliated Yuebei Peoples Hosp, Shaoguan 512026, Guangdong, Peoples R China.	zfqzsu2004@aliyun.com	Zhu, Feiqi/AAE-2897-2020		Natural Science Foundation of Guangdong Province ChinaNational Natural Science Foundation of Guangdong Province [S2013010015786, 2015A030310294]; Natural Science Foundation of Shaoguan City, Guangdong Province, China [2010-01]	This work was supported by the Natural Science Foundation of Guangdong Province China (S2013010015786), (2015A030310294) and the Natural Science Foundation of Shaoguan City, Guangdong Province, China (2010-01).	Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Chen C, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0106248, 10.1371/journal.pone.0092271]; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Crack PJ, 2005, FREE RADICAL BIO MED, V38, P1433, DOI 10.1016/j.freeradbiomed.2005.01.019; Dalle-Donne I, 2006, CLIN CHEM, V52, P601, DOI 10.1373/clinchem.2005.061408; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Ding K, 2015, J SURG RES, V194, P239, DOI 10.1016/j.jss.2014.09.026; Dixon CE, 2016, J NEUROTRAUM, V33, P553, DOI 10.1089/neu.2015.4122; Durairajan SSK, 2012, NEUROBIOL AGING, V33, P2903, DOI 10.1016/j.neurobiolaging.2012.02.016; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Franklin JL, 2011, ANTIOXID REDOX SIGN, V14, P1437, DOI 10.1089/ars.2010.3596; Garcia JM, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00244; Haces ML, 2010, NEUROSCIENCE, V165, P28, DOI 10.1016/j.neuroscience.2009.10.003; Hong JS, 2012, J NEUROSCI RES, V90, P489, DOI 10.1002/jnr.22756; Hsieh HL, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/484613; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286; IKRAM M, 1975, PLANTA MED, V28, P353, DOI 10.1055/s-0028-1097869; Im JY, 2006, FREE RADICAL BIO MED, V41, P960, DOI 10.1016/j.freeradbiomed.2006.06.001; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kheir MM, 2010, FOOD CHEM TOXICOL, V48, P1105, DOI 10.1016/j.fct.2010.01.033; Kumar A, 2016, PSYCHOPHARMACOLOGY, V233, P137, DOI 10.1007/s00213-015-4095-7; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lee IA, 2010, EUR J PHARMACOL, V648, P162, DOI 10.1016/j.ejphar.2010.08.046; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Malkesman O, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00157; McHugh TJ, 2007, SCIENCE, V317, P94, DOI 10.1126/science.1140263; Mendez DR, 2004, J TRAUMA, V56, P1235, DOI 10.1097/01.TA.0000130759.62286.0E; Merrill DA, 2001, J COMP NEUROL, V438, P445, DOI 10.1002/cne.1327; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Siow YL, 2011, FOOD RES INT, V44, P2409, DOI 10.1016/j.foodres.2010.12.038; Thau-Zuchman O, 2012, J NEUROTRAUM, V29, P375, DOI 10.1089/neu.2010.1673; Wang JP, 2018, MOL MED REP, V17, P6881, DOI 10.3892/mmr.2018.8674; Wang XL, 2005, LIFE SCI, V77, P3058, DOI 10.1016/j.lfs.2005.02.033; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; White BC, 2000, J NEUROL SCI, V179, P1, DOI 10.1016/S0022-510X(00)00386-5; Ye MZ, 2009, J PHARM PHARMACOL, V61, P831, DOI [10.1211/jpp/61.07.0001, 10.1211/jpp.61.07.0001]; Zhang DF, 2016, PAK J PHARM SCI, V29, P1365; Zhang J, 2009, SAUDI MED J, V30, P760; Zhao Y, 2006, FASEB J, V20, P1162, DOI 10.1096/fj.05-5007com; Zhu FQ, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-78; Zilles K., 2012, CORTEX RAT STEREOTAX	53	12	14	0	10	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	SEP	2018	43	9					1814	1825		10.1007/s11064-018-2597-5			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	GQ2AV	WOS:000441447600011	30027364				2021-06-18	
J	Isacescu, J; Danckert, J				Isacescu, Julia; Danckert, James			Exploring the relationship between boredom proneness and self-control in traumatic brain injury (TBI)	EXPERIMENTAL BRAIN RESEARCH			English	Article						Boredom; Attention; Self-control; Traumatic brain injury; Aggression	ORBITOFRONTAL CORTEX; SUSTAINED ATTENTION; CONSCIOUS AWARENESS; AGGRESSION; DEPRESSION; FAILURES; REWARD; LAPSES; MIND; SENSITIVITY	Characterized as an agitated state in which the individual is motivated to engage in their environment but all attempts to do so fail to satisfy, boredom represents a disengaged attentional state that is associated with negative affect and poor self-control. There have been anecdotal reports of increased levels of boredom post-traumatic brain injury (TBI). For the first time, we provide objective evidence that TBI patients do indeed experience higher levels of boredom proneness. Hierarchical regression analyses showed that the presence and severity of head injury were a significant positive predictor of levels of boredom proneness and a negative predictor of self-control. As with healthy controls, TBI patients showed a strong negative correlation between boredom proneness and self-control-those with lower levels of self-control exhibited higher levels of boredom proneness. This was despite the fact that our TBI patients reported higher overall levels of self-control (probably concomitant with their older mean age). The TBI patients also showed strong positive correlations between boredom proneness and measures of physical aggression and anger. Together, this suggests that patients with TBI may be more susceptible to increased levels of boredom proneness and other negative affective states that arise as a consequence of failures of self-control.	[Isacescu, Julia; Danckert, James] Univ Waterloo, Dept Psychol, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada	Danckert, J (corresponding author), Univ Waterloo, Dept Psychol, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada.	jdancker@uwaterloo.ca					AHMED SMS, 1990, PERCEPT MOTOR SKILL, V71, P963, DOI 10.2466/pms.1990.71.3.963; Andersson S, 1999, BRAIN INJURY, V13, P393, DOI 10.1080/026990599121458; Arciniegas DB, 2014, PSYCHIAT CLIN N AM, V37, P31, DOI 10.1016/j.psc.2013.12.001; Bailey NW, 2015, BIOL PSYCHOL, V106, P1, DOI 10.1016/j.biopsycho.2015.01.011; Bench SW, 2013, BEHAV SCI-BASEL, V3, P459, DOI 10.3390/bs3030459; Bengtsson TT, 2012, J CONTEMP ETHNOGR, V41, P526, DOI 10.1177/0891241612449356; Berlin HA, 2004, BRAIN, V127, P1108, DOI 10.1093/brain/awh135; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI 10.1037/0022-3514.63.3.452; Carriere JSA, 2008, CONSCIOUS COGN, V17, P835, DOI 10.1016/j.concog.2007.04.008; Cheyne JA, 2006, CONSCIOUS COGN, V15, P578, DOI 10.1016/j.concog.2005.11.009; Cohen J, 2003, APPL MULTIPLE REGRES, P2012; Dahlen ER, 2004, PERS INDIV DIFFER, V37, P1615, DOI 10.1016/j.paid.2004.02.016; de Sousa A, 2012, J CLIN EXP NEUROPSYC, V34, P606, DOI 10.1080/13803395.2012.667067; DeCoster J., 2007, APPL LINEAR REGRESSI; Depue BE, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/691505; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; Eastwood JD, 2012, PERSPECT PSYCHOL SCI, V7, P482, DOI 10.1177/1745691612456044; Elliott R, 2003, J NEUROSCI, V23, P303; Elpidorou A, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01245; Fahlman SA, 2013, ASSESSMENT, V20, P68, DOI 10.1177/1073191111421303; FARMER R, 1986, J PERS ASSESS, V50, P4, DOI 10.1207/s15327752jpa5001_2; Ganesalingam K, 2007, J INT NEUROPSYCH SOC, V13, P298, DOI 10.1017/S1355617707070324; Goetz T, 2014, MOTIV EMOTION, V38, P401, DOI 10.1007/s11031-013-9385-y; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Goldberg Y, 2013, BEHAV SCI-BASEL, V3, P434, DOI 10.3390/bs3030434; Goldberg YK, 2011, J SOC CLIN PSYCHOL, V30, P647, DOI 10.1521/jscp.2011.30.6.647; Gottfried JA, 2003, SCIENCE, V301, P1104, DOI 10.1126/science.1087919; Ham TE, 2014, BRAIN, V137, P586, DOI 10.1093/brain/awt350; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Isacescu J, COGN EMOT; ISOAHOLA SE, 1991, J LEISURE RES, V23, P260; Joireman J, 2003, J PERS SOC PSYCHOL, V84, P1287, DOI 10.1037/0022-3514.84.6.1287; Jorge RE, 2014, PSYCHIAT CLIN N AM, V37, P13, DOI 10.1016/j.psc.2013.11.005; Juengst SB, 2014, AM J PHYS MED REHAB, V93, P1086, DOI 10.1097/PHM.0000000000000163; KASS SJ, 1990, PSYCHOLOGY, V27, P7; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Malkovsky E, 2012, EXP BRAIN RES, V221, P59, DOI 10.1007/s00221-012-3147-z; McDonald S, 2011, J CLIN EXP NEUROPSYC, V33, P619, DOI 10.1080/13803395.2011.553586; McDonald S, 2010, J CLIN EXP NEUROPSYC, V32, P855, DOI 10.1080/13803391003596405; Melton AMA, 2009, J PSYCHOL, V143, P493, DOI 10.3200/JRL.143.5.493-508; Mercer KB., 2010, INT GAMBL STUD, V10, P91, DOI [10.1080/1445979100 3754414, DOI 10.1080/14459791003754414, 10.1080/14459791003754414]; MISCHEL W, 1989, SCIENCE, V244, P933, DOI 10.1126/science.2658056; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; O'Doherty J, 2001, NAT NEUROSCI, V4, P95; O'Keeffe FM, 2007, EXP BRAIN RES, V180, P59, DOI 10.1007/s00221-006-0832-9; Pekrun R, 2014, J EDUC PSYCHOL, V106, P696, DOI 10.1037/a0036006; Reeves RR, 2011, J PSYCHOSOC NURS MEN, V49, P42, DOI 10.3928/02793695-20110201-03; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rosenberg H, 2014, J INT NEUROPSYCH SOC, V20, P994, DOI 10.1017/S1355617714000940; Rule RR, 2002, COGN AFFECT BEHAV NE, V2, P264, DOI 10.3758/CABN.2.3.264; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seli P, 2015, PSYCHOL RES-PSYCH FO, V79, P750, DOI 10.1007/s00426-014-0617-x; Shah JY, 2003, ONT SYMP P, V9, P247; Sherer M, 2014, ARCH PHYS MED REHAB, V95, P1162, DOI [10.1016/j.apmr.2014.02.006, 10.1016/j.apmr.2013.06.004]; Sigurdardottir S, 2014, BRAIN INJURY, V28, P1542, DOI 10.3109/02699052.2014.934285; Smallwood J, 2007, COGNITION EMOTION, V21, P816, DOI 10.1080/02699930600911531; Smallwood J, 2009, EMOTION, V9, P271, DOI 10.1037/a0014855; STARK KD, 1987, J ABNORM CHILD PSYCH, V15, P91, DOI 10.1007/BF00916468; Struk AA, 2016, COGNITION EMOTION, V30, P1388, DOI 10.1080/02699931.2015.1064363; Struk AA, 2017, ASSESSMENT, V24, P346, DOI 10.1177/1073191115609996; Swick D, 2013, NEUROPSYCHOLOGIA, V51, P3033, DOI 10.1016/j.neuropsychologia.2013.10.008; Tangney JP, 2004, J PERS, V72, P271, DOI 10.1111/j.0022-3506.2004.00263.x; TEASDALE G, 1974, LANCET, V2, P81; Vodanovich SJ, 2005, J PERS ASSESS, V85, P295, DOI 10.1207/s15327752jpa8503_05; VODANOVICH SJ, 1990, J SOC BEHAV PERS, V5, P297; Wallis JD, 2007, ANNU REV NEUROSCI, V30, P31, DOI 10.1146/annurev.neuro.30.051606.094334; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274	71	12	13	3	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	SEP	2018	236	9			SI		2493	2505		10.1007/s00221-016-4674-9			13	Neurosciences	Neurosciences & Neurology	GP4FV	WOS:000440815700006	27215775				2021-06-18	
J	Li, H; Luo, Y; Xu, Y; Yang, L; Hu, CL; Chen, Q; Yang, Y; Ma, J; Zhang, JH; Xia, H; Li, YK; Yang, JQ				Li, Huan; Luo, Ying; Xu, Ying; Yang, Lu; Hu, Congli; Chen, Qi; Yang, Yang; Ma, Jie; Zhang, Jiahua; Xia, Hui; Li, Yuke; Yang, Junqing			Meloxicam Improves Cognitive Impairment of Diabetic Rats through COX2-PGE2-EPs-cAMP/pPKA Pathway	MOLECULAR PHARMACEUTICS			English	Article						diabetes; cognitive impairment; inflammation; cyclooxygenase 2; meloxicam	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; PROSTANOID RECEPTORS; GLUCOSE-METABOLISM; SIGNALING PATHWAY; PROSTAGLANDIN E-2; SPATIAL MEMORY; RISK-FACTOR; INHIBITION; MELLITUS	Diabetics often face greater risk of cognitive impairment than nondiabetics. However, how to prevent this disease is still unconfirmed. In this study, we investigated the potential protection and mechanism of meloxicam on cognitive impairment in diabetic rats. The diabetic rat model was established with a high-fat diet and a small dose of streptozotocin (40 mg/kg). The changes of spatial learning and memory, histopathology, and the protein expressions of amyloid protein precursor (APP) and beta-amyloid (A beta) indicated that diabetic rats had neuronal injury and cognitive impairment. Tumor necrosis factor alpha (TNF alpha), interleukin 6 (IL-6), C reactive protein (CRP) and prostaglandin E2 (PGE2) levels, and microglial cell number were significantly increased in the diabetic rat brain. Meanwhile, the protein expressions of APP, A beta, cyclooxygenases2 (COX2), E-type prostanoid recptors 1 (EP1) and EP2, and the level of cyclic adenosine monophosphate (cAMP) were significantly increased, while the protein expressions of EP3 and phosphorylated protein kinase A (pPKA) were significantly decreased in the diabetic rat hippocampus and cortex. However, the EP4 protein expression had no significant changes. Meloxicam significantly improved neuronal injury and cognitive impairment, and significantly decreased inflammatory cytokines levels. Meloxicam also significantly decreased the protein expressions of APP, A beta, COX2, EP1 and EP2, and the level of cAMP and significantly increased the EP3 and pPKA protein expressions in rat hippocampus and cortex. However, meloxicam did not significantly influence the levels of blood glucose, lipids, and insulin of rats. Our results suggest that meloxicam could significantly protect diabetic rats from cognitive impairment via a mechanism that may be associated with rebalancing the COX2-PGE2-EPs-cAMP/PKA pathway.	[Li, Huan; Luo, Ying; Yang, Lu; Hu, Congli; Chen, Qi; Yang, Yang; Ma, Jie; Zhang, Jiahua; Xia, Hui; Li, Yuke; Yang, Junqing] Chongqing Med Univ, Dept Pharmacol, Key Lab Biochem & Mol Pharmacol, Chongqing 400016, Peoples R China; [Xu, Ying] SUNY Buffalo, Dept Pharmaceut Sci, Sch Pharm & Pharmaceut Sci, Buffalo, NY 14214 USA	Yang, JQ (corresponding author), Chongqing Med Univ, Dept Pharmacol, Key Lab Biochem & Mol Pharmacol, Chongqing 400016, Peoples R China.	cqyangjq@cqmu.edu.cn			Chongqing Science and Technology Commission Fund [cstc2015zdcy-ztzx120003]	The work was supported by research grants from Chongqing Science and Technology Commission Fund (cstc2015zdcy-ztzx120003).	Abe T, 2009, J CEREBR BLOOD F MET, V29, P66, DOI 10.1038/jcbfm.2008.88; Areosa Sastre A., 2017, COCHRANE DB SYST REV, V15; Benedict C, 2007, NEUROPSYCHOPHARMACOL, V32, P239, DOI 10.1038/sj.npp.1301193; Biessels GJ, 2006, LANCET NEUROL, V5, P64, DOI 10.1016/S1474-4422(05)70284-2; Brunner YF, 2015, J CLIN ENDOCR METAB, V100, P212, DOI 10.1210/jc.2014-3018; Candelario-Jalil E, 2008, CURR PHARM DESIGN, V14, P1401, DOI 10.2174/138161208784480216; Chen Q, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00609-7; Desikan RS, 2015, CIRCULATION, V131, P2061, DOI 10.1161/CIRCULATIONAHA.115.015489; Dong HQ, 2014, MOL NEUROBIOL, V49, P1487, DOI 10.1007/s12035-014-8697-6; Ferreira R, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-90; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; Galimbert D, 2003, ANN NEUROL, V53, P547, DOI 10.1002/ana.10531; Goverdhan P, 2012, INT J ALZHEIMERS DIS, V2012, P1, DOI DOI 10.1155/2012/974013; Granholm AC, 2008, J ALZHEIMERS DIS, V14, P133; Guo YX, 2016, CURR ALZHEIMER RES, V13, P1006, DOI 10.2174/1567205013666160401114601; Hakan T, 2010, NEUROL RES, V32, P629, DOI 10.1179/016164109X12464612122731; Harrison NA, 2014, BIOL PSYCHIAT, V76, P585, DOI 10.1016/j.biopsych.2014.01.005; Hendriksen E, 2017, NEUROSCI BIOBEHAV R, V79, P119, DOI 10.1016/j.neubiorev.2017.05.001; Heyer EJ, 2013, DIABETES CARE, V36, P3283, DOI 10.2337/dc12-2507; Ianiski FR, 2012, BEHAV BRAIN RES, V230, P100, DOI 10.1016/j.bbr.2012.01.055; Jahan H, 2017, CHEM-BIOL INTERACT, V273, P237, DOI 10.1016/j.cbi.2017.06.015; Johansson JU, 2015, J CLIN INVEST, V125, P350, DOI 10.1172/JCI77487; Jolliet P, 1997, PHARMACEUT RES, V14, P650, DOI 10.1023/A:1012165414610; Jun-Qing Y, 2006, EUR J PHARMACOL, V547, P52, DOI 10.1016/j.ejphar.2006.07.031; Kamer AR, 2012, EUR J ANAESTH, V29, P332, DOI 10.1097/EJA.0b013e3283534f56; Kasiewicz LN, 2016, ACTA BIOMATER, V32, P120, DOI 10.1016/j.actbio.2015.12.023; Kodl CT, 2008, ENDOCR REV, V29, P494, DOI 10.1210/er.2007-0034; Kota DJ, 2017, STEM CELLS, V35, P1416, DOI 10.1002/stem.2603; Legler DF, 2010, INT J BIOCHEM CELL B, V42, P198, DOI 10.1016/j.biocel.2009.09.015; Li W, 2016, NEUROPSYCH DIS TREAT, V12, P2489, DOI 10.2147/NDT.S111298; Liu XJ, 2015, PHARMACOL RES, V93, P43, DOI 10.1016/j.phrs.2015.01.001; Liu YW, 2014, PHARMACOL BIOCHEM BE, V117, P128, DOI 10.1016/j.pbb.2013.11.027; Luo Y, 2017, ONCOTARGET, V8, P35558, DOI 10.18632/oncotarget.16009; Ma J, 2017, SCI REP-UK, V7, DOI 10.1038/srep46628; Matboli M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02320-z; Miller SB, 2006, SEMIN ARTHRITIS RHEU, V36, P37, DOI 10.1016/j.semarthrit.2006.03.005; Muller N, 2006, MOL PSYCHIATR, V11, P680, DOI 10.1038/sj.mp.4001805; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Nemeth CL, 2016, BEHAV BRAIN RES, V303, P160, DOI 10.1016/j.bbr.2016.01.057; Nemeth CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108399; Nguyen MT, 2002, J IMMUNOL, V169, P4586, DOI 10.4049/jimmunol.169.8.4586; Pozzo L, 2016, LIFE SCI, V166, P149, DOI 10.1016/j.lfs.2016.09.022; Rawlings AM, 2017, DIABETES CARE, V40, P879, DOI 10.2337/dc16-2203; Riederer P, 2017, J NEURAL TRANSM, V124, P1431, DOI 10.1007/s00702-017-1763-2; Roberts RO, 2014, ALZHEIMERS DEMENT, V10, P18, DOI 10.1016/j.jalz.2013.01.001; Rojas A, 2016, NEUROPHARMACOLOGY, V110, P419, DOI 10.1016/j.neuropharm.2016.07.028; Roy S, 2015, N AM J MED SCI, V7, P220, DOI 10.4103/1947-2714.157627; Shi J, 2012, ANN NEUROL, V72, P788, DOI 10.1002/ana.23677; Shiow LR, 2017, GLIA, V65, P2024, DOI 10.1002/glia.23212; Soares E, 2013, NEUROSCIENCE, V250, P565, DOI 10.1016/j.neuroscience.2013.07.055; Song LL, 2017, J PROTEOME RES, V16, P3180, DOI 10.1021/acs.jproteome.7b00168; Stolk RP, 1997, DIABETES CARE, V20, P792, DOI 10.2337/diacare.20.5.792; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; Tian XY, 2016, ONCOTARGET, V7, P25304, DOI 10.18632/oncotarget.8284; Wang DB, 2010, EXP NEUROL, V224, P197, DOI 10.1016/j.expneurol.2010.03.011; Wang DY, 2017, INT J BIOL MACROMOL, V102, P396, DOI 10.1016/j.ijbiomac.2017.04.056; Wang P, 2014, AGING CELL, V13, P605, DOI 10.1111/acel.12209; Woodward DF, 2011, PHARMACOL REV, V63, P471, DOI 10.1124/pr.110.003517; Xiong XY, 2016, PROG NEUROBIOL, V142, P23, DOI 10.1016/j.pneurobio.2016.05.001; Yin F, 2016, FREE RADICAL BIO MED, V100, P108, DOI 10.1016/j.freeradbiomed.2016.04.200; Yu LJ, 2014, BEHAV BRAIN FUNCT, V10, DOI 10.1186/1744-9081-10-6; Zhang X, 2013, J NANOMATER, V2013, P1, DOI DOI 10.1155/2013/803150; Zhao XC, 2015, BRAIN BEHAV IMMUN, V46, P293, DOI 10.1016/j.bbi.2015.02.011; Zhou JY, 2016, EUR J PHARMACOL, V774, P87, DOI 10.1016/j.ejphar.2016.02.007; Zhou YP, 2013, J ALZHEIMERS DIS, V34, P937, DOI 10.3233/JAD-121762	65	12	13	0	10	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1543-8384			MOL PHARMACEUT	Mol. Pharm.	SEP	2018	15	9					4121	4131		10.1021/acs.molpharmaceut.8b00532			11	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	GS7ZC	WOS:000443923800051	30109938				2021-06-18	
J	Uivarosan, D; Abdel-Daim, MM; Endres, L; Purza, L; Iovan, C; Bungau, S; Furau, CG; Tit, DM				Uivarosan, Diana; Abdel-Daim, Mohamed M.; Endres, Laura; Purza, Lavinia; Iovan, Ciprian; Bungau, Simona; Furau, Cristian Gheorghe; Tit, Delia Mirela			EFFECTS OF A PROTEIC SWINE EXTRACT ASSOCIATED TO RECOVERY TREATMENT ON FUNCTIONAL INDEPENDENCE AND QUALITY OF LIFE IN PATIENTS POST STROKE	FARMACIA			English	Article						proteic swine extract; cerebrovascular accident; stroke; medical recovery; quality of life	TRAUMATIC BRAIN-INJURY; ACUTE ISCHEMIC-STROKE; DOUBLE-BLIND; NEUROLOGICAL DISORDERS; NEUROTROPHIC TREATMENT; CEREBROLYSIN; TRIAL; REHABILITATION; EFFICACY	Stroke is one of the leading causes of mortality and morbidity worldwide. This study investigates the effect produced by associating a proteic swine extract (PSE) with classical recovery techniques on functional independence and quality of life of post-stroke patients. 139 patients that had suffered stroke were divided into 2 groups and were evaluated initially, at 6 and at 12 months. The FIM scale (Functional Independence Measure) and the SS-QoL scale (Stroke Specific Quality of Life Scale), were used to monitor the effects of therapy. There were no significant differences (p > 0.05) in the patients' evolution in terms of functional independence, but the effect size was more obvious in the group treated with PSE. The evolution of the quality of life was significantly better (p < 0.05) after six months for patients who had PSE associated treatment. The results of this study provide a favourable evidence for the use of associated therapy of PSE and classical recovery procedures in patients who had suffered a stroke.	[Uivarosan, Diana; Endres, Laura; Iovan, Ciprian] Univ Oradea, Fac Med & Pharm, Dept Preclin Sci, 10 P Ta 1 Decembrie St, Oradea, Romania; [Abdel-Daim, Mohamed M.] Suez Canal Univ, Fac Vet Med, Pharmacol Dept, Ismailia 41522, Egypt; [Abdel-Daim, Mohamed M.] Yokohama City Univ, Dept Ophthalmol & Microtechnol, Yokohama, Kanagawa, Japan; [Purza, Lavinia] Univ Oradea, Doctoral Sch, Dept Biomed Sci, 1 Univ St, Oradea, Romania; [Purza, Lavinia; Bungau, Simona; Tit, Delia Mirela] Univ Oradea, Fac Med & Pharm, Pharm Dept, 29 Nicolae Jiga St, Oradea, Romania; [Furau, Cristian Gheorghe] Vasile Goldis Western Univ Arad, Fac Med, Dept Life Sci, 86 L Rebreanu St, Arad, Romania	Iovan, C (corresponding author), Univ Oradea, Fac Med & Pharm, Dept Preclin Sci, 10 P Ta 1 Decembrie St, Oradea, Romania.	dr.iovan@biostandard.ro	Tit, Delia Mirela/AAT-5032-2020; Uivarosan, Diana/AAT-6035-2020; Abdel-Daim, Mohamed M./B-2545-2013; Bungau, Simona Gabriela/C-1831-2015; PURZA, LAVINIA/AAB-2547-2021; endres, Laura/AAY-5100-2020	Tit, Delia Mirela/0000-0002-0296-6592; Abdel-Daim, Mohamed M./0000-0002-4341-2713; Bungau, Simona Gabriela/0000-0003-3236-1292; 			Amiri-Nikpour MR, 2014, NEUROPSYCH DIS TREAT, V10, P2299, DOI 10.2147/NDT.S75304; Bornstein N, 2012, DRUG TODAY, V48, P43, DOI 10.1358/dot.2012.48(Suppl.A).1739723; Cavanagh S J, 2000, J Neurosci Nurs, V32, P17; Chen CC, 2013, BRIT J NEUROSURG, V27, P803, DOI 10.3109/02688697.2013.793287; Denti L, 2008, EUR J PHYS REHAB MED, V44, P3; Diserens K, 2006, CEREBROVASC DIS, V22, P183, DOI 10.1159/000093453; Elmaraezy A, 2017, CNS NEUROL DISORD-DR, V16, P789, DOI 10.2174/1871527315666161213110104; Fodor K, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4147320; Hartbauer M, 2001, J NEURAL TRANSM, V108, P459, DOI 10.1007/s007020170067; Hong Z, 2009, INT J STROKE, V4, P406, DOI 10.1111/j.1747-4949.2009.00340.x; Khalili H, 2017, CLIN NEUROL NEUROSUR, V152, P34, DOI 10.1016/j.clineuro.2016.11.011; Ladurner G, 2005, J NEURAL TRANSM, V112, P415, DOI 10.1007/s00702-004-0248-2; Legg L, 2004, LANCET, V363, P352; LOPEZ J, 2012, BMC HEALTH SERV RES, V12, DOI DOI 10.1186/1471-2407-12-48; Masliah E, 2012, DRUG TODAY, V48, P3, DOI 10.1358/dot.2012.48(Suppl.A).1739716; Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350; Muresanu DF, 2016, STROKE, V47, P151, DOI 10.1161/STROKEAHA.115.009416; Muresanu DF, 2010, ACTA NEUROCHIR SUPPL, V106, P291, DOI 10.1007/978-3-211-98811-4_54; Onose G, 2017, FARMACIA, V65, P772; Uivarosan D, 2014, THESIS; Williams LS, 1999, NEUROLOGY, V53, P1839, DOI 10.1212/WNL.53.8.1839; Williams LS, 1999, STROKE, V30, P1362, DOI 10.1161/01.STR.30.7.1362	22	12	12	0	10	SOC STINTE FARMACEUTICE ROMANIA	BUCURESTI	BUCURESTI, STR TRAIAN VUIA 6, SECT 1, BUCURESTI, 020956, ROMANIA	0014-8237	2065-0019		FARMACIA	Farmacia	SEP-OCT	2018	66	5					826	830		10.31925/farmacia.2018.5.12			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	GW7VT	WOS:000447181100012		Bronze			2021-06-18	
J	Wang, C; Iashchishyn, IA; Pansieri, J; Nystrom, S; Klementieva, O; Kara, J; Horvath, I; Moskalenko, R; Rofougaran, R; Gouras, G; Kovacs, GG; Shankar, SK; Morozova-Roche, LA				Wang, Chao; Iashchishyn, Igor A.; Pansieri, Jonathan; Nystrom, Sofie; Klementieva, Oxana; Kara, John; Horvath, Istvan; Moskalenko, Roman; Rofougaran, Reza; Gouras, Gunnar; Kovacs, Gabor G.; Shankar, S. K.; Morozova-Roche, Ludmilla A.			S100A9-Driven Amyloid-Neuroinflammatory Cascade in Traumatic Brain Injury as a Precursor State for Alzheimer's Disease	SCIENTIFIC REPORTS			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PRO-INFLAMMATORY S100A9; COGNITIVE IMPAIRMENT; PROTEIN; EXPRESSION; MRP8; MECHANISMS; PATHOLOGY; MEMORY; MRP-14	Pro-inflammatory and amyloidogenic S100A9 protein is an important contributor to Alzheimer's disease (AD) pathology. Traumatic brain injury (TBI) is viewed as a precursor state for AD. Here we have shown that S100A9-driven amyloid-neuroinflammatory cascade was initiated in TBI and may serve as a mechanistic link between TBI and AD. By analyzing the TBI and AD human brain tissues, we demonstrated that in post-TBI tissues S100A9, produced by neurons and microglia, becomes drastically abundant compared to A beta and contributes to both precursor-plaque formation and intracellular amyloid oligomerization. Conditions implicated in TBI, such as elevated S100A9 concentration, acidification and fever, provide strong positive feedback for S100A9 nucleation-dependent amyloid formation and delay in its proteinase clearance. Consequently, both intracellular and extracellular S100A9 oligomerization correlated with TBI secondary neuronal loss. Common morphology of TBI and AD plaques indicated their similar initiation around multiple aggregation centers. Importantly, in AD and TBI we found S100A9 plaques without A beta. S100A9 and A beta plaque pathology was significantly advanced in AD cases with TBI history at earlier age, signifying TBI as a risk factor. These new findings highlight the detrimental consequences of prolonged post-TBI neuroinflammation, which can sustain S100A9-driven amyloid-neurodegenerative cascade as a specific mechanism leading to AD development.	[Wang, Chao; Iashchishyn, Igor A.; Pansieri, Jonathan; Kara, John; Horvath, Istvan; Moskalenko, Roman; Rofougaran, Reza; Morozova-Roche, Ludmilla A.] Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden; [Iashchishyn, Igor A.] Sumy State Univ, Dept Gen Chem, UA-40000 Sumy, Ukraine; [Nystrom, Sofie] Linkoping Univ, Dept Chem, IFM, S-58183 Linkoping, Sweden; [Klementieva, Oxana; Gouras, Gunnar] Lund Univ, Dept Expt Med Sci, S-22184 Lund, Sweden; [Moskalenko, Roman] Sumy State Univ, Dept Pathol, UA-40000 Sumy, Ukraine; [Kovacs, Gabor G.] Med Univ Vienna, Inst Neurol, A-1097 Vienna, Austria; [Shankar, S. K.] Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Human Brain Tissue Repository, Bangalore 560029, Karnataka, India	Wang, C; Morozova-Roche, LA (corresponding author), Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden.	chao.wang@wustl.edu; Ludmilla.Morozova-Roche@umu.se	Moskalenko, Roman/I-3208-2017; Iashchishyn, Igor/AAL-4677-2021; Horvath, Istvan/B-1889-2009; Gouras, Gunnar/B-3021-2010; Kovacs, Gabor G/A-7468-2013	Moskalenko, Roman/0000-0002-2342-0337; Horvath, Istvan/0000-0003-4262-1430; Gouras, Gunnar/0000-0002-5500-6325; Kovacs, Gabor G/0000-0003-3841-5511; Pansieri, Jonathan/0000-0001-8918-9943	ALF Vasterbotten Lans Landsting; Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission; FP-7 Marie Curie Action "Nano-Guard"; Insamlingsstiftelsen; Swedish Alzheimer's Foundation; Swedish Institute	We thank Peter Nilsson for the gift of amyloid specific h-FTAA fluorescence dye, Fredrik Clausen for experimental TBI work, Per Hammarstrom for helpful discussion and analysis of immunofluorescence results, Vinod K Narayana for connecting us with S.K.S. and delivering pilot samples. We thank for financial support ALF Vasterbotten Lans Landsting (L.A.M.-R.), Swedish Medical Research Council (L.A.M.-R.), FP-7 Marie Curie Action "Nano-Guard" (I.A.I., R.M., L.A.M.-R.), Insamlingsstiftelsen (L.A.M.-R.), Swedish Alzheimer's Foundation (S.N.) and Swedish Institute (R.M.).	Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Botelho HM, 2012, J BIOL CHEM, V287, P42233, DOI 10.1074/jbc.M112.396416; Bresnick AR, 2015, NAT REV CANCER, V15, P96, DOI 10.1038/nrc3893; Breunig JJ, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00026; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chen B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115828; Clark RSB, 1999, FASEB J, V13, P813; Cole GM, 2010, CNS NEUROL DISORD-DR, V9, P140, DOI 10.2174/187152710791011991; Di Virgilio TG, 2016, EBIOMEDICINE, V13, P66, DOI 10.1016/j.ebiom.2016.10.029; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Eremenko E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058218; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Fritz G, 2010, FEBS J, V277, P4578, DOI 10.1111/j.1742-4658.2010.07887.x; Frosch M, 2000, ARTHRITIS RHEUM-US, V43, P628, DOI 10.1002/1529-0131(200003)43:3<628::AID-ANR20>3.0.CO;2-X; Goldberg EL, 2017, CELL REP, V18, P2077, DOI 10.1016/j.celrep.2017.02.004; Gruden MA, 2018, ACS CHEM NEUROSCI, V9, P568, DOI 10.1021/acschemneuro.7b00379; Gruden MA, 2016, BEHAV BRAIN RES, V306, P106, DOI 10.1016/j.bbr.2016.03.016; Gupta AK, 2004, J NEUROTRAUM, V21, P678, DOI 10.1089/0897715041269722; Ha TY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008840; HESSIAN PA, 1993, J LEUKOCYTE BIOL, V53, P197; Horvath I, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1210-9; Horvath I, 2016, ACS CHEM NEUROSCI, V7, P34, DOI 10.1021/acschemneuro.5b00265; Iashchishyn IA, 2018, ACS CHEM NEUROSCI, V9, P1338, DOI 10.1021/acschemneuro.7b00512; Iashchishyn IA, 2017, ACS CHEM NEUROSCI, V8, P2152, DOI 10.1021/acschemneuro.7b00251; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Klingstedt T, 2011, ORG BIOMOL CHEM, V9, P8356, DOI 10.1039/c1ob05637a; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Leclerc Estelle, 2011, Front Biosci (Schol Ed), V3, P1232; Lodeiro M, 2017, J GERONTOL A-BIOL, V72, P319, DOI 10.1093/gerona/glw073; Ma LP, 2012, INT J CARDIOL, V155, P26, DOI 10.1016/j.ijcard.2011.01.082; Malisauskas M, 2010, J MOL BIOL, V396, P60, DOI 10.1016/j.jmb.2009.11.012; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McGeer EG, 2010, J ALZHEIMERS DIS, V19, P355, DOI 10.3233/JAD-2010-1219; Mork G, 2003, BRIT J DERMATOL, V149, P484, DOI 10.1046/j.1365-2133.2003.05536.x; Nacken W, 2003, MICROSC RES TECHNIQ, V60, P569, DOI 10.1002/jemt.10299; Nagareddy PR, 2013, CELL METAB, V17, P695, DOI 10.1016/j.cmet.2013.04.001; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; Postler E, 1997, GLIA, V19, P27, DOI 10.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-7; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Ryckman C, 2004, J LEUKOCYTE BIOL, V76, P433, DOI 10.1189/jlb.0603294; Sacho RH, 2008, BRIT J NEUROSURG, V22, P497, DOI 10.1080/02688690802245558; Schluesener HJ, 1998, ACTA NEUROPATHOL, V96, P575, DOI 10.1007/s004010050938; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; Shepherd CE, 2006, NEUROBIOL AGING, V27, P1554, DOI 10.1016/j.neurobiolaging.2005.09.033; Simard JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072138; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Soderberg L, 2005, FEBS J, V272, P2231, DOI 10.1111/j.1742-4658.2005.04647.x; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Swindell WR, 2013, SCI REP-UK, V3, DOI 10.1038/srep01215; Tutte W.T, 2001; van den Bosch MH, 2016, J RHEUMATOL, V43, P1874, DOI 10.3899/jrheum.160270; Vogl T, 2004, BLOOD, V104, P4260, DOI 10.1182/blood-2004-02-0446; Vogl T, 2006, BBA-MOL CELL RES, V1763, P1298, DOI 10.1016/j.bbamcr.2006.08.028; Vogl T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5593; Vogl T, 2012, INT J MOL SCI, V13, P2893, DOI 10.3390/ijms13032893; Wahlstrom A, 2008, FEBS J, V275, P5117, DOI 10.1111/j.1742-4658.2008.06643.x; Wang C, 2014, ACTA NEUROPATHOL, V127, P507, DOI 10.1007/s00401-013-1208-4; Washington PM, 2016, EXP NEUROL, V275, P381, DOI 10.1016/j.expneurol.2015.06.015; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yanamandra K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005562; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhao LN, 2013, RSC ADV, V3, P24081, DOI 10.1039/c3ra43665a	67	12	12	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	AUG 27	2018	8								12836	10.1038/s41598-018-31141-x			16	Multidisciplinary Sciences	Science & Technology - Other Topics	GR7LI	WOS:000442870300014	30150640	DOAJ Gold, Green Published			2021-06-18	
J	Cappelli, G; Noccetti, S; Arcara, G; Bambini, V				Cappelli, Gloria; Noccetti, Sabrina; Arcara, Giorgio; Bambini, Valentina			Pragmatic competence and its relationship with the linguistic and cognitive profile of young adults with dyslexia	DYSLEXIA			English	Article						figurative language; inference; narratives; pragmatics	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; MIND; SCHIZOPHRENIA; DISORDERS; SKILLS; NEUROPRAGMATICS; COMMUNICATION; ABILITIES	The study assessed the pragmatic skills of 19 well-compensated Italian-speaking young adults with dyslexia compared with controls. A comprehensive pragmatic assessment tool was employed, targeting production and comprehension (Assessment of Pragmatic Abilities and Cognitive Substrates [APACS]). Participants were also administered a series of standardized tests to assess verbal and non-verbal cognitive abilities, including executive functions and social cognition tests. Data were analysed with the aim of understanding whether pragmatic abilities are compromised in dyslexia and of exploring associations between pragmatic performance and other cognitive domains. The performance of the dyslexia group was poorer than that of the control group in both expressive and receptive modalities. Data showed diffuse problems across several domains, with the greatest challenge posed by inferring nonliteral meanings, which indicates that pragmatic inefficiency is an important aspect of the linguistic and communicative profile of dyslexia in adulthood. Explorative correlations highlighted a relation between pragmatic performance and reading and vocabulary abilities, as well as between pragmatics and working memory. This suggests that pragmatic difficulties are strongly tied to the most distinctive aspects of dyslexia, namely, phonological awareness, verbal short-term memory, pseudo-word repetition, whereas the link with high-level executive functions and Theory of Mind is negligible.	[Cappelli, Gloria; Noccetti, Sabrina] Univ Pisa, Dept Philol Literature & Linguist, Pisa, Italy; [Arcara, Giorgio] San Camillo Hosp IRCCS, Venice, Italy; [Bambini, Valentina] Univ Sch Adv Studies IUSS Pavia, Ctr Neurocognit & Theoret Syntax NEtS, Pavia, Italy	Bambini, V (corresponding author), Sch Adv Studies IUSS Pavia, Ctr Neurocognit Epistemol & Theoret Syntax NEtS, Piazza Vittoria 15, I-27100 Pavia, Italy.	valentina.bambini@iusspavia.it	Bambini, Valentina/K-6643-2016; CAPPELLI, GLORIA/M-6942-2017	Bambini, Valentina/0000-0001-5770-228X; CAPPELLI, GLORIA/0000-0002-2047-2596; NOCCETTI, SABRINA/0000-0003-1188-3817			Adamczyk P, 2016, SCHIZOPHR RES, V176, P331, DOI 10.1016/j.schres.2016.08.015; Arcara G, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00070; Ariel M, 2010, RES SURV LINGUIST, P1; Baddeley A. D., 1998, WORKING MEMORY; Baker SF, 2007, INT J LAW PSYCHIAT, V30, P492, DOI 10.1016/j.ijlp.2007.09.010; Bambini V, 2016, COMPR PSYCHIAT, V71, P106, DOI 10.1016/j.comppsych.2016.08.012; Bambini V, 2016, BRAIN LANG, V153, P1, DOI 10.1016/j.bandl.2015.12.002; Bambini V, 2010, ITAL J LINGUIST, V22, P1; Bambini V, 2011, BRAIN RES BULL, V86, P203, DOI 10.1016/j.brainresbull.2011.07.015; Bara BG, 2010, COGNITIVE PRAGMATICS, DOI [10.7551/mitpress/9780262014113.001.0001, DOI 10.7551/MITPRESS/9780262014113.001.0001]; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bertelli B., 2006, VAUMELF; Bosco FM, 2017, BRAIN LANG, V168, P73, DOI 10.1016/j.bandl.2017.01.007; Bosco FM, 2012, J COMMUN DISORD, V45, P181, DOI 10.1016/j.jcomdis.2012.01.005; Bryan KL., 1995, RIGHT HEMISPHERE LAN; Cain K, 2001, MEM COGNITION, V29, P850, DOI 10.3758/BF03196414; Cappelli G., 2016, MULTIMODALITY COMMUN, P37; Cardillo R, 2018, APPL NEUROPSYCH-CHIL, V7, P245, DOI 10.1080/21622965.2017.1297946; Carotenuto A, 2018, ARCH CLIN NEUROPSYCH, V33, P194, DOI 10.1093/arclin/acx061; CHINN SJ, 1995, DYSLEXIA AND STRESS, P49; Cornoldi C., 2010, MT AVANZATE 2; Dodich A, 2015, NEUROL SCI, V36, P1907, DOI 10.1007/s10072-015-2281-3; Facoetti A, 2010, J COGNITIVE NEUROSCI, V22, P1011, DOI 10.1162/jocn.2009.21232; Fawcett A.J., 1998, DYSLEXIA ADULT SCREE; Gabbatore I, 2015, J HEAD TRAUMA REHAB, V30, pE14, DOI 10.1097/HTR.0000000000000087; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GATHERCOLE SE, 1992, DEV PSYCHOL, V28, P887, DOI 10.1037//0012-1649.28.5.887; Griffiths CCB, 2007, DYSLEXIA, V13, P276, DOI 10.1002/dys.333; Hales G., 1995, DYSLEXIA AND STRESS, P73; Kalandadze T, 2018, AUTISM, V22, P99, DOI 10.1177/1362361316668652; Kormos J., 2012, TEACHING LANGUAGES S; Lallier M, 2009, BRAIN RES, V1302, P132, DOI 10.1016/j.brainres.2009.07.037; Lam K.H., 2014, ASIA PACIFIC J DEV D, V1, P4, DOI DOI 10.3850/S2345734114000027; Levinson S.C., 1983, PRAGMATICS; Lorusso M. L., 2009, APL MEDEA ABILITA PR; MacCullagh L, 2017, DYSLEXIA, V23, P3, DOI 10.1002/dys.1544; Marotta L., 2008, TEST CMFVALUTAZIONE; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; Matthews D., 2014, PRAGMATIC DEV 1 LANG, DOI [10.1075/tilar.10, DOI 10.1075/TILAR.10]; Melogno S, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7070085; Miles T.R., 2007, DYSLEXIA COLL; Nicolson R. I., 2008, DYSLEXIA LEARNING BR, DOI [10. 7551/mitpress/9780262140997. 001. 0001, DOI 10.7551/MITPRESS/9780262140997.001.0001]; NOVELLI G, 1986, Archivio di Psicologia Neurologia e Psichiatria, V47, P477; Orsini A., 2013, WAIS 4; Parola A, 2018, PSYCHIAT RES, V260, P144, DOI 10.1016/j.psychres.2017.11.051; Ransby MJ, 2003, J LEARN DISABIL-US, V36, P538, DOI 10.1177/00222194030360060501; Rinaldi M. C., 2006, BLEDBATTERIA LINGUAG; Ruffino M, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00331; Simmons F, 2000, Dyslexia, V6, P178, DOI 10.1002/1099-0909(200007/09)6:3<178::AID-DYS171>3.0.CO;2-9; Sperber D, 2002, MIND LANG, V17, P3, DOI 10.1111/1468-0017.00186; Spotorno N, 2012, NEUROIMAGE, V63, P25, DOI 10.1016/j.neuroimage.2012.06.046; Stella G., 2000, P P V T R PEABODY PI; Stemmer B, 2000, BRAIN LANG, V71, P233, DOI 10.1006/brln.1999.2257; Suraniti S., 2009, TEST RECEPTION GRAMM; Thoma P, 2006, NEUROSCI BIOBEHAV R, V30, P1182, DOI 10.1016/j.neubiorev.2006.09.001; Vulchanova M, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00024; Wampers M, 2018, SCHIZOPHR RES, V195, P97, DOI 10.1016/j.schres.2017.08.053; Wilson D., 1995, RELEVANCE COMMUNICAT	58	12	12	2	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1076-9242	1099-0909		DYSLEXIA	Dyslexia	AUG	2018	24	3					294	306		10.1002/dys.1588			13	Education, Special; Psychology, Educational; Rehabilitation	Education & Educational Research; Psychology; Rehabilitation	GP4HD	WOS:000440820300007	29993159				2021-06-18	
J	Ganjam, GK; Terpolilli, NA; Diemert, S; Eisenbach, I; Hoffmann, L; Reuther, C; Herden, C; Roth, J; Plesnila, N; Culmsee, C				Ganjam, Goutham K.; Terpolilli, Nicole Angela; Diemert, Sebastian; Eisenbach, Ina; Hoffmann, Lena; Reuther, Christina; Herden, Christiane; Roth, Joachim; Plesnila, Nikolaus; Culmsee, Carsten			Cylindromatosis mediates neuronal cell death in vitro and in vivo	CELL DEATH AND DIFFERENTIATION			English	Article							NF-KAPPA-B; TRAUMATIC BRAIN-INJURY; APOPTOSIS-INDUCING FACTOR; FOCAL CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; CASPASE-8 ACTIVATION; PROGRAMMED NECROSIS; SIGNALING COMPLEX; TNF-ALPHA; DAMAGE	The tumor-suppressor cylindromatosis (CYLD) is a deubiquitinating enzyme and key regulator of cell proliferation and inflammation. A genome-wide siRNA screen linked CYLD to receptor interacting protein-1 (RIP1) kinase-mediated necroptosis; however, the exact mechanisms of CYLD-mediated cell death remain unknown. Therefore, we investigated the precise role of CYLD in models of neuronal cell death in vitro and evaluated whether CYLD deletion affects brain injury in vivo. In vitro, downregulation of CYLD increased RIP1 ubiquitination, prevented RIP1/RIP3 complex formation, and protected neuronal cells from oxidative death. Similar protective effects were achieved by siRNA silencing of RIP1 or RIP3 or by pharmacological inhibition of RIP1 with necrostatin-1. In vivo, CYLD knockout mice were protected from trauma-induced brain damage compared to wild-type littermate controls. These findings unravel the mechanisms of CYLD-mediated cell death signaling in damaged neurons in vitro and suggest a cell death-mediating role of CYLD in vivo.	[Ganjam, Goutham K.; Diemert, Sebastian; Eisenbach, Ina; Hoffmann, Lena; Reuther, Christina; Culmsee, Carsten] Univ Marburg, Inst Pharmacol & Clin Pharm, Biochem Pharmacol Ctr Marburg, MCMBB, Marburg, Germany; [Terpolilli, Nicole Angela; Plesnila, Nikolaus] Univ Munich, Med Ctr, Inst Stroke & Dementia Res, Munich, Germany; [Herden, Christiane] Univ Giessen, Inst Veterinarian Pathol, Giessen, Germany; [Roth, Joachim] Univ Giessen, Inst Veterinarian Physiol, Giessen, Germany	Culmsee, C (corresponding author), Univ Marburg, Inst Pharmacol & Clin Pharm, Biochem Pharmacol Ctr Marburg, MCMBB, Marburg, Germany.	culmsee@uni-marburg.de	Plesnila, Nikolaus/T-7522-2019; Terpolilli, Nicole/AAG-3598-2021	Culmsee, Carsten/0000-0002-5121-5015; Plesnila, Nikolaus/0000-0001-8832-228X	DFGGerman Research Foundation (DFG)European Commission [Cu43/6-1]	This study was partly supported by the DFG (Cu43/6-1). SM-164 was a kind gift from Shamoeng Wang, University of Michigan, Ann Arbor, Michigan, USA. We thank Mathieu JM Bertrand, Inflammation Research Center, VIB, Ghent University, Gent, Belgium for valuable suggestions and comments in redrafting this manuscript. We thank the excellent technical support by Mrs. Katharina Elsasser and Ms. Eileen Daube.	Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Byun JY, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/796315; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Culmsee C, 2005, J NEUROSCI, V25, P10262, DOI 10.1523/JNEUROSCI.2818-05.2005; Davis CW, 2010, FREE RADICAL BIO MED, V48, P306, DOI 10.1016/j.freeradbiomed.2009.11.001; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Diemert S, 2012, J NEUROSCI METH, V203, P69, DOI 10.1016/j.jneumeth.2011.09.012; Dondelinger Y, 2015, MOL CELL, V60, P63, DOI 10.1016/j.molcel.2015.07.032; Fearns C, 2006, J BIOL CHEM, V281, P34592, DOI 10.1074/jbc.M604019200; Ganjam GK, 2013, J COMP PHYSIOL B, V183, P1101, DOI 10.1007/s00360-013-0772-1; Guerriero RM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0545-1; Guillen J, 2012, J AM ASSOC LAB ANIM, V51, P311; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Hentze H, 2002, J BIOL CHEM, V277, P5588, DOI 10.1074/jbc.M110766200; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Kaiser WJ, 2011, NATURE, V471, P368, DOI 10.1038/nature09857; Kalai M, 2002, CELL DEATH DIFFER, V9, P981, DOI 10.1038/sj.cdd.4401051; Kilkenny C, 2010, J PHARMACOL PHARMACO, V1, P94, DOI 10.4103/0976-500X.72351; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Landshamer S, 2008, CELL DEATH DIFFER, V15, P1553, DOI 10.1038/cdd.2008.78; Li JX, 2012, CELL, V150, P339, DOI 10.1016/j.cell.2012.06.019; Liu T, 2016, SCI REP-UK, V6, DOI 10.1038/srep24547; Mattson MP, 2006, CELL DEATH DIFFER, V13, P852, DOI 10.1038/sj.cdd.4401837; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Moquin D, 2010, TRENDS BIOCHEM SCI, V35, P434, DOI 10.1016/j.tibs.2010.03.001; Moquin DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076841; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; Neitemeier S, 2017, REDOX BIOL, V12, P558, DOI 10.1016/j.redox.2017.03.007; Neitemeier S, 2014, APOPTOSIS, V19, P1665, DOI 10.1007/s10495-014-1048-2; Northington FJ, 2011, J CEREBR BLOOD F MET, V31, P178, DOI 10.1038/jcbfm.2010.72; O'Donnell MA, 2011, NAT CELL BIOL, V13, P1437, DOI 10.1038/ncb2362; Plesnila N, 2004, J CEREBR BLOOD F MET, V24, P458, DOI 10.1097/00004647-200404000-00011; Rodriguez DA, 2016, CELL DEATH DIFFER, V23, P76, DOI 10.1038/cdd.2015.70; Schenk B, 2015, ONCOGENE, V34, P5796, DOI 10.1038/onc.2015.35; Schwaninger M, 2006, BIOCHEM SOC T, V34, P1291, DOI 10.1042/BST0341291; Schweighofer Hanna, 2016, Intensive Care Med Exp, V4, P19, DOI 10.1186/s40635-016-0091-4; Seiler A, 2008, CELL METAB, V8, P237, DOI 10.1016/j.cmet.2008.07.005; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Sun SC, 2010, CELL DEATH DIFFER, V17, P25, DOI 10.1038/cdd.2009.43; Takahashi N, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.176; Terpolilli NA, 2013, J CEREBR BLOOD F MET, V33, P311, DOI 10.1038/jcbfm.2012.176; Ting AT, 2016, TRENDS IMMUNOL, V37, P535, DOI 10.1016/j.it.2016.06.002; Tobaben S, 2011, CELL DEATH DIFFER, V18, P282, DOI 10.1038/cdd.2010.92; Vanden Berghe T, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.975093; Vanden Berghe T, 2016, CELL MOL LIFE SCI, V73, P2137, DOI 10.1007/s00018-016-2189-y; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Vandenabeele P, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3115re4; Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138; Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Wang YQ, 2012, NEUROCHEM RES, V37, P1849, DOI 10.1007/s11064-012-0791-4; Wright A, 2007, DEV CELL, V13, P705, DOI 10.1016/j.devcel.2007.09.007; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zhang HB, 2017, BRAIN INJURY, V31, P406, DOI 10.1080/02699052.2016.1225984; Zhang YY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14329	58	12	13	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1350-9047	1476-5403		CELL DEATH DIFFER	Cell Death Differ.	AUG	2018	25	8					1394	1407		10.1038/s41418-017-0046-7			14	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	GR7PM	WOS:000442884000004	29352268	Other Gold, Green Published			2021-06-18	
J	Jembrek, MJ; Radovanovic, V; Vlainic, J; Vukovic, L; Hanzic, N				Jembrek, Maja Jazvinscak; Radovanovic, Vedrana; Vlainic, Josipa; Vukovic, Lidija; Hanzic, Nikolina			Neuroprotective effect of zolpidem against glutamate-induced toxicity is mediated via the PI3K/Akt pathway and inhibited by PK11195	TOXICOLOGY			English	Article						Zolpidem; Excitotoxicity; Akt signalling; p53; PK11195; NR2B subunit of NMDA receptor	CELL-DEATH; PERMEABILITY TRANSITION; BENZODIAZEPINE-RECEPTOR; GABA(A) RECEPTORS; OXIDATIVE STRESS; ATP SYNTHASE; MITOCHONDRIAL; EXCITOTOXICITY; ACTIVATION; LIGANDS	Excitotoxicity is a pathological process in which neuronal dysfunction and death are induced by excessive glutamate stimulation, the major fast excitatory neurotransmitter in the mammalian brain. Excitotoxicity-induced neurodegeneration is a contributing factor in ischemia-induced brain damage, traumatic brain injury, and various neurodegenerative diseases. It is triggered by calcium overload due to prolonged over-activation of ionotropic N-methyl-D-aspartate (NMDA) receptors. Enhanced Ca2+ release results in neuronal vulnerability through several intertwined mechanisms, including activation of proteolytic enzymes, increased production of reactive oxygen species (ROS), mitochondrial dysfunction and modulation of intracellular signalling pathways. We investigated the neuroprotective effect of hypnotic zolpidem, a drug that exerts its central effects at the GABA(A) receptor complex, against glutamate-induced toxicity in P19 neurons. Zolpidem prevented death of P19 neurons exposed to glutamate, and abolished the glutamate-induced increase in ROS production, p53 and Bax expression, and caspase-3/7 activity. Zolpidem effects were mediated by marked over-activation of Akt kinase. The pro-survival effect, as well as the pAkt induction, were prevented in the presence of wortmannin, an inhibitor of phosphatidylinositol-3-kinase (PI3K) that functions upstream of Akt. The beneficial effect of zolpidem on neuronal survival was not prevented by fiumazenil, a GABA(A) receptor antagonist. PK11195, a drug that modulates the mitochondrial translocator protein 18 kDa (TSPO) and F0F1-ATPase, prevented the beneficial effect of zolpidem, indicating that the mechanism of zolpidem action involves preservation of mitochondrial function and integrity. Zolpidem effects were further mediated by prevention of glutamate-induced increase in the expression of the NR2B subunit of NMDA receptor. The obtained results suggest the promising therapeutic potential of zolpidem against excitotoxic insults and highlight the importance of mitochondria and the Akt pathway as valuable targets for therapeutic interventions in glutamate-mediated neuropathological conditions.	[Jembrek, Maja Jazvinscak; Radovanovic, Vedrana; Vlainic, Josipa; Hanzic, Nikolina] Rudjer Boskovic Inst, Div Mol Med, Bijenicka Cesta 54, Zagreb 10000, Croatia; [Jembrek, Maja Jazvinscak] Catholic Univ Croatia, Dept Psychol, Ilica 242, Zagreb, Croatia; [Vukovic, Lidija] Rudjer Boskovic Inst, Div Mol Biol, Bijenicka Cesta 54, Zagreb, Croatia	Jembrek, MJ (corresponding author), Rudjer Boskovic Inst, Div Mol Med, Bijenicka Cesta 54, Zagreb 10000, Croatia.	jazvin@irb.hr	Jembrek, Jazvinscak/H-3558-2019		Croatian Ministry of Science, Education and SportsMinistry of Science, Education and Sports, Republic of Croatia [098-0000000-2448]; Catholic University of Croatia [HKS-2016-2]	This work was financed by the project of Croatian Ministry of Science, Education and Sports ("Stress, GABA<INF>A</INF> receptors and mechanisms of action of neuropsychoactive drugs", 098-0000000-2448) and by the project of the Catholic University of Croatia ("The mechanism of the neuroprotective effect of zolpidem against oxidative stress induced by high concentrations of glutamate", HKS-2016-2).	Andrabi SA, 2008, ANN NY ACAD SCI, V1147, P233, DOI 10.1196/annals.1427.014; Beas-Zarate C, 2001, NEUROCHEM INT, V39, P1, DOI 10.1016/S0197-0186(01)00008-0; Bernardi P, 2015, PHYSIOL REV, V95, P1111, DOI 10.1152/physrev.00001.2015; Briston T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10673-8; Canzoniero LMT, 1996, J NEUROSCI RES, V45, P226; Celsi F, 2009, BBA-BIOENERGETICS, V1787, P335, DOI 10.1016/j.bbabio.2009.02.021; Chen RW, 1999, J BIOL CHEM, V274, P6039, DOI 10.1074/jbc.274.10.6039; Chen XP, 2012, NEURAL REGEN RES, V7, P376, DOI 10.3969/j.issn.1673-5374.2012.05.009; Cleary J, 2007, BIOORG MED CHEM LETT, V17, P1667, DOI 10.1016/j.bmcl.2006.12.102; Cong L, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2050435; Cosentino K, 2017, TRENDS CELL BIOL, V27, P266, DOI 10.1016/j.tcb.2016.11.004; Datta S, 2016, MITOCHONDRION, V30, P177, DOI 10.1016/j.mito.2016.08.002; Dong XX, 2009, ACTA PHARMACOL SIN, V30, P379, DOI 10.1038/aps.2009.24; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; Gao M, 2008, EUR J PHARMACOL, V591, P73, DOI 10.1016/j.ejphar.2008.06.071; Garcia-Santos G, 2004, FREE RADICAL RES, V38, P1289, DOI 10.1080/10715760400017343; Gatliff J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.186; Giorgio V, 2013, P NATL ACAD SCI USA, V110, P5887, DOI 10.1073/pnas.1217823110; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Grant ER, 2001, BIOCHEM PHARMACOL, V62, P283, DOI 10.1016/S0006-2952(01)00665-7; Greenblatt DJ, 2012, EXPERT OPIN PHARMACO, V13, P879, DOI 10.1517/14656566.2012.667074; Grobin AC, 1999, BRAIN RES, V827, P1; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Jayakumar AR, 2002, J NEUROCHEM, V83, P1226, DOI 10.1046/j.1471-4159.2002.01261.x; Jembrek MJ, 2015, CURR PHARM DESIGN, V21, P4943, DOI 10.2174/1381612821666150914121624; Jembrek MJ, 2012, J MOL NEUROSCI, V47, P286, DOI 10.1007/s12031-012-9737-1; Jorda EG, 2005, APOPTOSIS, V10, P91, DOI 10.1007/s10495-005-6064-9; King TD, 2008, NEUROTOX RES, V14, P367, DOI 10.1007/BF03033861; Kritis AA, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00091; Kumar A, 2008, NEUROCHEM RES, V33, P370, DOI 10.1007/s11064-007-9431-9; Lai TW, 2014, PROG NEUROBIOL, V115, P157, DOI 10.1016/j.pneurobio.2013.11.006; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Li XB, 2015, CLIN EXP PHARMACOL P, V42, P1068, DOI 10.1111/1440-1681.12460; MacPherson PA, 1997, NEUROSCIENCE, V80, P487, DOI 10.1016/S0306-4522(97)00102-4; Marcade M, 2008, J NEUROCHEM, V106, P392, DOI 10.1111/j.1471-4159.2008.05396.x; Mattner F, 2006, LIFE SCI, V79, P287, DOI 10.1016/j.lfs.2006.01.006; Mehta A, 2013, EUR J PHARMACOL, V698, P6, DOI 10.1016/j.ejphar.2012.10.032; Noormandi A, 2017, EXPERT REV CLIN PHAR, V10, P983, DOI 10.1080/17512433.2017.1347502; PAPADOPOULOS V, 1990, J BIOL CHEM, V265, P3772; Parker MA, 2002, J NEUROSCI RES, V69, P39, DOI 10.1002/jnr.10235; Prentice H, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/964518; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Rivera-Cervantes MC, 2009, INT J DEV NEUROSCI, V27, P197, DOI 10.1016/j.ijdevneu.2008.09.006; Robey RB, 2006, ONCOGENE, V25, P4683, DOI 10.1038/sj.onc.1209595; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Szado T, 2008, P NATL ACAD SCI USA, V105, P2427, DOI 10.1073/pnas.0711324105; TURETSKY DM, 1993, J NEUROBIOL, V24, P1157, DOI 10.1002/neu.480240904; Veenman L, 2012, CURR MOL MED, V12, P398; Vlainic J, 2012, ACTA PHARMACOL SIN, V33, P1469, DOI 10.1038/aps.2012.89; Vlainic J, 2012, LIFE SCI, V90, P889, DOI 10.1016/j.lfs.2012.04.021; Willard SS, 2013, INT J BIOL SCI, V9, P948, DOI 10.7150/ijbs.6426; Xilouri M, 2006, EUR J NEUROSCI, V23, P43, DOI 10.1111/j.1460-9568.2005.04548.x; Xilouri M, 2008, NEUROTOX RES, V13, P209, DOI 10.1007/BF03033504; Yoo JM, 2017, REDOX BIOL, V11, P592, DOI 10.1016/j.redox.2016.12.034; Zhai DX, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-20; Zhong ZH, 2010, J NEUROSCI, V30, P15521, DOI 10.1523/JNEUROSCI.4437-10.2010	56	12	12	2	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-483X			TOXICOLOGY	Toxicology	AUG 1	2018	406						58	69		10.1016/j.tox.2018.05.014			12	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	GT6VY	WOS:000444660200006	29859204				2021-06-18	
J	Turner-Stokes, L; Ashford, S; Esquenazi, A; Wissel, J; Ward, AB; Francisco, G; Lains, J; Suputtitada, A; Serrano, S; Baguley, IJ; Barnes, M; Simpson, DM				Turner-Stokes, Lynne; Ashford, Stephen; Esquenazi, Alberto; Wissel, Joerg; Ward, Anthony B.; Francisco, Gerard; Lains, Jorge; Suputtitada, Areerat; Serrano, Simao; Baguley, Ian J.; Barnes, Michael; Simpson, David M.			A comprehensive person-centered approach to adult spastic paresis: a consensus-based framework	EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE			English	Article						Spastic paraparesis; Muscle spasticity; Consensus; Person-centered therapy; Rehabilitation; Self-management	UPPER-LIMB SPASTICITY; QUALITY-OF-LIFE; THERAPEUTIC WORKING ALLIANCE; INDUCED MOVEMENT THERAPY; TRAUMATIC BRAIN-INJURY; BOTULINUM-TOXIN-A; GOAL ATTAINMENT; SELF-MANAGEMENT; STROKE PATIENTS; MOTOR FUNCTION	Spastic paresis is a common feature of an upper motor neuron impairment caused by stroke, brain injury, multiple sclerosis and other central nervous system (CNS) disorders. Existing national and international guidelines for the treatment of adult spastic paresis tend to focus on the treatment of muscle overactivity rather than the comprehensive approach to care, which may require life-long management. Person-centered care is increasingly adopted by healthcare systems in a shift of focus from "disease-oriented" towards "person-centered" medicine. The challenge is to apply this principle to the complex management of spastic paresis and to include an educative process that engages care providers and patients and encourages them to participate actively in the long-term management of their own disease. To address this issue, a group of 13 international clinicians and researchers used a pragmatic top-down methodology to evaluate the evidence and to formulate and grade the strength of recommendations for applying the principles of person-centered care to the management of spastic paresis. There is a distinct lack of clinical trial evidence regarding the application of person-centered medicine to the rehabilitation setting. However, the current evidence base supports the need to ensure that treatment interventions Mr spastic paresis should be centered on as far as reasonable on the patient's own priorities for treatment. Goal setting, negotiation and formal recording of agreed SMART goals should be an integral part of all spasticity management programs, and goal attainment scaling should be recorded alongside other standardized measures in the evaluation of outcome. When planning interventions for spastic paresis, the team should consider the patient and their family's capacity for self-rehabilitation, as well as ways to enhance this approach. Finally, the proposed intervention and treatment goals should consider the impact of any neuropsychological, cognitive and behavioral deficits on rehabilitation. These recommendations support a person-centric focus in the management of spastic paresis.	[Turner-Stokes, Lynne; Ashford, Stephen] Kings Coll London, Fac Life Sci & Med, Dept Palliat Care, London, England; [Turner-Stokes, Lynne; Ashford, Stephen] Northwick Pk Hosp & Clin Res Ctr, Unit Reg Hyperacute Rehabil, London, England; [Esquenazi, Alberto] MossRehab, MossRehab, PA USA; [Esquenazi, Alberto] Albert Einstein Med Ctr, MossRehab, PA USA; [Wissel, Joerg] Vivantes Hosp Berlin Spandau, Dept Neurorehabil & Phys Therapy, Berlin, Germany; [Ward, Anthony B.] Haywood Hosp, North Staffordshire Rehabil Ctr, Stoke On Trent, Staffs, England; [Ward, Anthony B.] Staffordshire Univ, Stoke On Trent, Staffs, England; [Francisco, Gerard] Mem Hermann Hosp, Inst Rehabil & Res, UTHlth NeuroRecovery Res Ctr, Houston, TX USA; [Lains, Jorge] Rovisco Pais Hosp, Ctr Rehabil Med Cent Reg, Tocha, Portugal; [Lains, Jorge] Portuguese Catholic Univ, Viseu, Portugal; [Lains, Jorge] Assoc Beneficiencia Popular Gouveia, Gouveia, Portugal; [Suputtitada, Areerat] Chulalongkorn Univ, Fac Med, Dept Rehabil Med, Bangkok, Thailand; [Serrano, Simao] Leiria Hosp Ctr, Dept Phys Med & Rehabil, Leiria, Portugal; [Baguley, Ian J.] Univ Sydney, Westmead Hosp, Western Med Sch, Brain Injury Rehabil Serv, Sydney, NSW, Australia; [Barnes, Michael] Rake House Farm, Christchurch Grp, Unit 14, North Shields, England; [Simpson, David M.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA	Turner-Stokes, L (corresponding author), Northwick Pk Hosp & Clin Res Ctr, Reg Hyperacute Rehabil Unit, Watford Rd, Harrow HA1 3UJ, Middx, England.	lynne.tumer-stokes@dial.pipex.com	Baguley, Ian/AAM-5828-2021; Turner-Stokes, Lynne/F-4418-2012; Ashford, Stephen/D-6653-2013	Turner-Stokes, Lynne/0000-0002-3302-9462; Ashford, Stephen/0000-0001-5541-7063	Ipsen PharmaIpsen	The realization of the meeting and the consensus table was made possible by an unrestricted educational grant from Ipsen Pharma, who also funded independent medical writing support from Anita Chadha-Patel PhD (ACP Clinical Communications Ltd, UK). All medical writing (literature searching, compilation of comments, collation of forms, editing and referencing) was under the full direction and supervision of the authors. No member of the consensus group received any honoraria in connection with this project and Ipsen Pharma had no influence over the content of the manuscript.	Ada L, 2005, ARCH PHYS MED REHAB, V86, P230, DOI 10.1016/j.apmr.2004.02.031; [Anonymous], 2013, PROLONGED DISORDERS; [Anonymous], 2010, MAN PAT STROK REH PR; Ashford S, 2006, PHYSIOTHER RES INT, V11, P24, DOI 10.1002/pri.36; Ashford S, 2016, CLIN REHABIL, V30, P617, DOI 10.1177/0269215515593391; Basch E, 2012, VALUE HEALTH, V15, P401, DOI 10.1016/j.jval.2012.03.1385; BECKER G, 1995, MED ANTHROPOL Q, V9, P165, DOI 10.1525/maq.1995.9.2.02a00040; Boa S, 2003, GOAL SETTING PEOPLE; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Bordin E. S., 1979, PSYCHOTHER-THEOR RES, V16, P252, DOI DOI 10.1037/H0085885; Bovend'Eerdt TJH, 2009, CLIN REHABIL, V23, P352, DOI 10.1177/0269215508101741; Brown M, 2014, DISABIL REHABIL, V36, P1020, DOI 10.3109/09638288.2013.825653; Chen C, 2013, NEUROLOGY, V80, pS27, DOI 10.1212/WNL.0b013e3182762569; Cheok G, 2015, J AM MED DIR ASSOC, V16, P923, DOI 10.1016/j.jamda.2015.06.010; Coleman MT, 2005, AM FAM PHYSICIAN, V72, P1503; Conroy S, 2009, ADV CARE PLANNING NA; D'Cruz K, 2016, INT J THER REHABIL, V23, P20, DOI 10.12968/ijtr.2016.23.1.20; Demetrios M, 2013, COCHRANE DB SYST REV, V2013; Dettmers C, 2005, ARCH PHYS MED REHAB, V86, P204, DOI 10.1016/j.apmr.2004.05.007; Doig E., 2015, REHABILITATION GOAL, P181; Esquenazi A, 2010, EUR J NEUROL, V17, P1, DOI 10.1111/j.1468-1331.2010.03125.x; Esquenazi A, 2015, TOXICON, V107, P109, DOI 10.1016/j.toxicon.2015.08.004; European Commission, EUR THEM NETW DEV ST; Flink M, 2016, CLIN REHABIL, V30, P1200, DOI 10.1177/0269215515620256; Gormley ME, 1997, MUSCLE NERVE, pS14; Gracies JM, 2015, LANCET NEUROL, V14, P992, DOI 10.1016/S1474-4422(15)00216-1; Gracies JM, 2005, MUSCLE NERVE, V31, P552, DOI 10.1002/mus.20285; Grady PA, 2014, AM J PUBLIC HEALTH, V104, pE25, DOI 10.2105/AJPH.2014.302041; Grahn B, 2000, DISABIL REHABIL, V22, P639, DOI 10.1080/096382800445443; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017; Haghgoo HA, 2013, J NEUROL SCI, V328, P87, DOI 10.1016/j.jns.2013.02.027; Harris JE, 2009, STROKE, V40, P2123, DOI 10.1161/STROKEAHA.108.544585; Hurn J, 2006, CLIN REHABIL, V20, P756, DOI 10.1177/0269215506070793; Institute of Medicine, 2001, CROSSING QUALITY CHA; Katalinic OM, 2011, PHYS THER, V91, P11, DOI 10.2522/ptj.20100265; Kelley RE, 2009, NEUROL RES, V31, P832, DOI 10.1179/016164109X12445505689689; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; Lance JW., 1980, SPASTICITY DISORDERE, P185; Langhorne P, 2002, AGE AGEING, V31, P365, DOI 10.1093/ageing/31.5.365; Laver KE, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008349.pub2; Leach E, 2010, DISABIL REHABIL, V32, P159, DOI 10.3109/09638280903036605; Levack WMM, 2006, CLIN REHABIL, V20, P739, DOI 10.1177/0269215506070791; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00009; Locke EA, 2002, AM PSYCHOL, V57, P705, DOI 10.1037//0003-066X.57.9.705; Martin DJ, 2000, J CONSULT CLIN PSYCH, V68, P438, DOI 10.1037//0022-006X.68.3.438; McCrory P, 2009, J REHABIL MED, V41, P536, DOI 10.2340/16501977-0366; McPherson K., 2015, REHABILITATION GOAL, P105; McPherson KM, 2009, CLIN REHABIL, V23, P296, DOI 10.1177/0269215509102980; Meyer S, 2016, NEUROREHAB NEURAL RE, V30, P731, DOI 10.1177/1545968315624779; Moseley AM, 1997, PHYS THER, V77, P240, DOI 10.1093/ptj/77.3.240; Moseley AM, 2008, CLIN REHABIL, V22, P406, DOI 10.1177/0269215507083795; Nannetti L, 2005, DISABIL REHABIL, V27, P170, DOI 10.1080/09638280400009378; National Institute for Health and Care Excellence, 2012, PAT EXP AD NHS SERV; NICE, 2013, FALLS OLD PEOPL ASS; Nijenhuis SM, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0080-y; Ozdemir F, 2001, AM J PHYS MED REHAB, V80, P410, DOI 10.1097/00002060-200106000-00003; Page SJ, 2004, ARCH PHYS MED REHAB, V85, P1377, DOI 10.1016/j.apmr.2003.12.031; Pandyan AD, 2005, DISABIL REHABIL, V27, P2, DOI 10.1080/09638280400014576; Pang MY, 2006, ARCH PHYS MED REHAB, V87, P1, DOI 10.1016/j.apmr.2005.08.113; Paquin K, 2016, DISABIL REHABIL, P1; Parry RH, 2004, CLIN REHABIL, V18, P668, DOI 10.1191/0269215504cr745oa; Playford ED, 2009, CLIN REHABIL, V23, P334, DOI 10.1177/0269215509103506; Plummer P, 2013, ARCH PHYS MED REHAB, V94, P2565, DOI 10.1016/j.apmr.2013.08.002; Pollock A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010820.pub2; Pollock A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001920.pub3; Pound P, 1994, Qual Health Care, V3, P69, DOI 10.1136/qshc.3.2.69; Rabadi MH, 2008, ARCH PHYS MED REHAB, V89, P441, DOI 10.1016/j.apmr.2007.11.014; Robinson W, 2008, AUST J PHYSIOTHER, V54, P33, DOI 10.1016/S0004-9514(08)70063-1; Roche N, 2015, J REHABIL MED, V47, P31, DOI 10.2340/16501977-1887; Roussel M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147602; Royal College of Physicians, 2009, SPAST AD MAN US BOT; Schonberger M, 2007, BRAIN INJURY, V21, P825, DOI 10.1080/02699050701499433; Schonberger M, 2006, BRAIN INJURY, V20, P1271, DOI 10.1080/02699050601049395; Schunemann Holger J, 2006, Health Res Policy Syst, V4, P21, DOI 10.1186/1478-4505-4-21; Sheean G, 2010, EUR J NEUROL, V17, P74, DOI 10.1111/j.1468-1331.2010.03129.x; Siegert RJ, 2014, REHABILITATION GOAL; Simpson DM, 2016, NEUROLOGY, V86, P1818, DOI 10.1212/WNL.0000000000002560; Snaphaan L, 2007, STROKE, V38, P198, DOI 10.1161/01.STR.0000251842.34322.8f; Speight J, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2921; Sterr A, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/970136; Sunnerhagen KS, 2013, ACTA NEUROL SCAND, V128, P305, DOI 10.1111/ane.12128; Sunnerhagen KS, 2013, NEUROLOGY, V80, pS35, DOI 10.1212/WNL.0b013e3182764aa2; Suputtitada A, 2005, DISABIL REHABIL, V27, P176, DOI 10.1080/09638280400009360; TATEMICHI TK, 1994, J NEUROL NEUROSUR PS, V57, P202, DOI 10.1136/jnnp.57.2.202; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; Teasell R, 2014, EVIDENCE BASED REV S; Tennant A, 2007, DISABIL REHABIL, V29, P1583, DOI 10.1080/09638280701618828; Turner-Stokes L, 2006, CLIN MED, V6, P91, DOI 10.7861/clinmedicine.6-1-91; Turner-Stokes L, 2002, CLIN MED, V2, P128, DOI 10.7861/clinmedicine.2-2-128; Turner-Stokes L, 2013, BMJ OPEN, V3; Turner-Stokes L, 2007, DISABIL REHABIL, V29, P1806, DOI 10.1080/09638280701568205; Turner-Stokes L, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011157; Turner-Stokes L, 2015, INT J THER REHABIL, V22, P210, DOI 10.12968/ijtr.2015.22.5.210; Turner-Stokes L, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002771; Turner-Stokes L, 2010, J REHABIL MED, V42, P81, DOI 10.2340/16501977-0474; Turner-Stokes L, 2010, CLIN REHABIL, V24, P66, DOI 10.1177/0269215509343846; Turner-Stokes L, 2009, CLIN REHABIL, V23, P362, DOI 10.1177/0269215508101742; Turner-Stokes L, 2009, J REHABIL MED, V41, P528, DOI 10.2340/16501977-0383; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; Veterans Association / Department of Defense, 2010, CLIN PRACT GUID MAN; Wade DT, 2009, CLIN REHABIL, V23, P291, DOI 10.1177/0269215509103551; Ward AB, 2014, J REHABIL MED, V46, P504, DOI 10.2340/16501977-1817; Watanabe T, 2004, AM J PHYS MED REHAB, V83, pS45, DOI 10.1097/01.PHM.0000141130.58285.DA; Winstein CJ, 2004, ARCH PHYS MED REHAB, V85, P620, DOI 10.1016/j.apmr.2003.06.027; Wissel J, 2009, J REHABIL MED, V41, P13, DOI 10.2340/16501977-0303; Wolf SL, 2008, LANCET NEUROL, V7, P33, DOI 10.1016/S1474-4422(07)70294-6; World Health Organization, 2001, INT CLASS FUNCT DIS; Yelnik AP, 2010, J REHABIL MED, V42, P801, DOI 10.2340/16501977-0613	109	12	13	0	5	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	1973-9087	1973-9095		EUR J PHYS REHAB MED	Eur. J. Phys. Rehabil. Med.	AUG	2018	54	4					605	617		10.23736/S1973-9087.17.04808-0			13	Rehabilitation	Rehabilitation	GU5BE	WOS:000445298800011	29265792				2021-06-18	
J	Wu, T; Merkley, TL; Wilde, EA; Barnes, A; Li, XQ; Chu, ZD; McCauley, SR; Hunter, JV; Levin, HS				Wu, Trevor; Merkley, Tricia L.; Wilde, Elisabeth A.; Barnes, Amanda; Li, Xiaoqi; Chu, Zili David; McCauley, Stephen R.; Hunter, Jill V.; Levin, Harvey S.			A preliminary report of cerebral white matter microstructural changes associated with adolescent sports concussion acutely and subacutely using diffusion tensor imaging	BRAIN IMAGING AND BEHAVIOR			English	Article						Diffusion tensor imaging (DTI); Sports concussion; MRI; Longitudinal; Mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE IMAGES; SURFACE-BASED ANALYSIS; CORTICAL SURFACE; NEUROCOGNITIVE PERFORMANCE; INTERNATIONAL-CONFERENCE; COGNITIVE SEQUELAE; COORDINATE SYSTEM; HEAD IMPACTS; SYMPTOMS	Diffusion tensor imaging (DTI) has demonstrated its utility in detecting microscopic post-concussion cerebral white matter structural changes, which are not routinely evident on conventional neuroimaging modalities. In this study, we compared 10 adolescents with sports concussion (SC) to 12 orthopedically-injured (OI) individuals within 96 h and three months post injury to 12 typically-developing (TD) participants using DTI and volumetric analyses. In terms of volume, no group differences were noted between SC, OI and TD groups at both 96 h and three months post concussion. Results did not show significant differences between SC, OI, and TD groups for both fractional anisotropy (FA) and apparent diffusion coefficient (ADC) in all regions of interest within 96 h post concussion. However, at three months post-injury, the SC group exhibited significantly lower FA than the TD group in various regions of interest. In terms of ADC, significant group differences between SC and TD groups were found in some regions, with SC group having higher ADC than TD. No group differences for FA and ADC were noted between SC and OI groups at three months post-injury. However, several moderate effect sizes on between-group analyses were noted such that FA was lower and ADC was higher in SC relative to OI. Longitudinally, the SC group demonstrated decreased FA and increased ADC in some areas. The findings highlight the fact that the brain continues to change during the post-injury recovery period, and raises the possibility that adverse changes may result from the neurometabolic cascade that purportedly ensues following SC. DTI may potentially be used to characterize the nature of brain changes that occur following sports-related concussions.	[Wu, Trevor] Michigan State Univ, Mercy Hlth St Marys, 220 Cherry St SE, Grand Rapids, MI 49503 USA; [Merkley, Tricia L.] Barrow Neurol Inst, 222 W Thomas Rd,Suite 315, Phoenix, AZ 85013 USA; [Wilde, Elisabeth A.; Li, Xiaoqi; Chu, Zili David; McCauley, Stephen R.; Hunter, Jill V.; Levin, Harvey S.] Baylor Coll Med, One Baylor Plaza BCM637, Houston, TX 77030 USA; [Barnes, Amanda] Univ Miami, Miller Sch Med, 1600 NW 10th Ave 1440, Miami, FL 33136 USA	Wilde, EA (corresponding author), Baylor Coll Med, One Baylor Plaza BCM637, Houston, TX 77030 USA.	trevor.wu@mercyhealth.com; tricia.merkley@dignityhealth.org; ewilde@bcm.edu; amandabarn@gmail.com; xiaoqil@bcm.edu; zchu@bcm.edu; mccauley@bcm.edu; jvhunter@texaschildrens.org; hlevin@bcm.edu	Merkley, Tricia/AAN-2989-2020	Merkley, Tricia/0000-0002-0897-8391	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R21-NS086714, 5P01-NS056202]	This work was supported by the National Institutes of Health grants 5R21-NS086714 and 5P01-NS056202. The funding sources had no role in the interpretation of data, writing of this paper, or in the decision to submit for publication. The contents of this paper are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health. The authors wish to thank James Montier and English Pratts, Baylor College of Medicine, for their assistance in the preparation of this manuscript, Drs. Claudia Robertson and James McCarthy for their help with recruitment, and Vipulkumar Patel for his assistance in MRI acquisition.	Arbogast KB, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0294; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Borich M, 2013, J NEUROTRAUM, V30, P1243, DOI 10.1089/neu.2012.2818; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Chrisman SPD, 2014, J ADOLESCENT HEALTH, V54, P582, DOI 10.1016/j.jadohealth.2013.10.006; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dimou S, 2014, J NEUROTRAUM, V31, P413, DOI 10.1089/neu.2013.3050; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P241, DOI 10.3171/2015.1.PEDS14510; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Ewing-Cobbs L, 2016, HUM BRAIN MAPP, V37, P3929, DOI 10.1002/hbm.23286; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Graham R., 2014, SPORTS RELATED CONCU; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Ilie G, 2015, J PSYCHIATR RES, V69, P174, DOI 10.1016/j.jpsychires.2015.08.004; Iverson GL, 2015, NEUROSCI BIOBEHAV R, V56, P276, DOI 10.1016/j.neubiorev.2015.05.008; Jovicich J, 2006, NEUROIMAGE, V30, P436, DOI 10.1016/j.neuroimage.2005.09.046; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kaya A, 2008, J INT MED RES, V36, P9, DOI 10.1177/147323000803600102; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Mansell JL, 2010, BRAIN INJURY, V24, P1070, DOI 10.3109/02699052.2010.494589; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayers LB, 2013, J NEUROPSYCH CLIN N, V25, P115, DOI 10.1176/appi.neuropsych.11120374; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCauley SR, 2014, J NEUROTRAUM, V31, P914, DOI 10.1089/neu.2012.2826; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; McCory P, 2017, BRIT J SPORT MED, V51, P838, DOI [DOI 10.1136/BJSPORTS-2017-097699, 10.1136/bjsports-2017-097699]; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; Meehan W, 2015, NEUROLOGY, V85, P1504, DOI 10.1212/WNL.0000000000001893; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Paus T, 2008, NAT REV NEUROSCI, V9, P947, DOI 10.1038/nrn2513; Pulsipher DT, 2011, CURR SPORT MED REP, V10, P14, DOI 10.1249/JSR.0b013e31820711b8; Rabinowitz AR, 2015, J NEUROTRAUM, V32, P1488, DOI 10.1089/neu.2014.3555; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Reuter M, 2010, NEUROIMAGE, V53, P1181, DOI 10.1016/j.neuroimage.2010.07.020; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Salat DH, 2009, NEUROIMAGE, V44, P1247, DOI 10.1016/j.neuroimage.2008.10.030; Schmithorst VJ, 2010, BRAIN COGNITION, V72, P16, DOI 10.1016/j.bandc.2009.06.005; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Steinberg L, 2005, TRENDS COGN SCI, V9, P69, DOI 10.1016/j.tics.2004.12.005; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Thomas TC, 2015, BRAIN NEUROTRAUMA MO, P531, DOI [10.1201/b18126-43, DOI 10.1201/B18126-43]; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Tsushima WT, 2013, APPL NEUROPSYCH-CHIL, V2, P13, DOI 10.1080/09084282.2011.643967; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2016, J NEUROTRAUM, V33, P2000, DOI 10.1089/neu.2015.4212; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	85	12	13	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	AUG	2018	12	4					962	973		10.1007/s11682-017-9752-5			12	Neuroimaging	Neurosciences & Neurology	GO6HY	WOS:000440141800004	28812290				2021-06-18	
J	Hubbard, WB; Lashof-Sullivan, M; Greenberg, S; Norris, C; Eck, J; Lavik, E; VandeVord, P				Hubbard, W. Brad; Lashof-Sullivan, Margaret; Greenberg, Shaylen; Norris, Carly; Eck, Joseph; Lavik, Erin; VandeVord, Pamela			Hemostatic nanoparticles increase survival, mitigate neuropathology and alleviate anxiety in a rodent blast trauma model	SCIENTIFIC REPORTS			English	Article							BLOOD-BRAIN-BARRIER; POSTTRAUMATIC-STRESS-DISORDER; LUNG INJURY; PSYCHIATRIC-DISORDERS; OXIDATIVE STRESS; SPINAL-CORD; MOUSE MODEL; TIME-COURSE; OPEN-FIELD; RAT MODEL	Explosions account for 79% of combat related injuries and often lead to polytrauma, a majority of which include blast-induced traumatic brain injuries (bTBI). These injuries lead to internal bleeding in multiple organs and, in the case of bTBI, long term neurological deficits. Currently, there are no treatments for internal bleeding beyond fluid resuscitation and surgery. There is also a dearth of treatments for TBI. We have developed a novel approach using hemostatic nanoparticles that encapsulate an anti-inflammatory, dexamethasone, to stop the bleeding and reduce inflammation after injury. We hypothesize that this will improve not only survival but long term functional outcomes after blast polytrauma. Poly(lactic-co-glycolic acid) hemostatic nanoparticles encapsulating dexamethasone (hDNPs) were fabricated and tested following injury along with appropriate controls. Rats were exposed to a single blast wave using an Advanced Blast Simulator, inducing primary blast lung and bTBI. Survival was elevated in the hDNPs group compared to controls. Elevated anxiety parameters were found in the controls, compared to hDNPs. Histological analysis indicated that apoptosis and blood-brain barrier disruption in the amygdala were significantly increased in the controls compared to the hDNPs and sham groups. Immediate intervention is crucial to mitigate injury mechanisms that contribute to emotional deficits.	[Hubbard, W. Brad; Norris, Carly; Eck, Joseph; VandeVord, Pamela] Virginia Tech, Biomed Engn & Mech, Blacksburg, VA 24061 USA; [Lashof-Sullivan, Margaret] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA; [Greenberg, Shaylen] Virginia Tech, Translat Biol Med & Hlth, Blacksburg, VA USA; [Lavik, Erin] Univ Maryland Baltimore Cty, Dept Chem Biochem & Environm Engn, Baltimore, MD 21228 USA; [VandeVord, Pamela] Salem VAMC, Res Serv, Salem, VA 24153 USA; [Hubbard, W. Brad] Univ Kentucky, Coll Med, SCoBIRC, Lexington, KY USA	VandeVord, P (corresponding author), Virginia Tech, Biomed Engn & Mech, Blacksburg, VA 24061 USA.; Lavik, E (corresponding author), Univ Maryland Baltimore Cty, Dept Chem Biochem & Environm Engn, Baltimore, MD 21228 USA.; VandeVord, P (corresponding author), Salem VAMC, Res Serv, Salem, VA 24153 USA.	elavik@umbc.edu; pvord@vt.edu		VandeVord, Pamela/0000-0003-3422-2704; Lavik, Erin/0000-0002-0644-744X	DOD CDMRP Program [W81XWH-11-1-0014]; NIH Director's New Innovator AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DP20D007338]	We would like to thank Dr. Michael Urban, Dr. Zachary Bailey, Bryce Dunn, and Ryan Brady for their technical assistance during blast testing. We would like to acknowledge funding support by the DOD CDMRP Program W81XWH-11-1-0014 and the NIH Director's New Innovator Award number DP20D007338 (EL).	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Ahmed FA, 2013, ELECTROPHORESIS, V34, P2229, DOI 10.1002/elps.201300077; Araz O, 2013, MULTIDISCIP RESP MED, V8, DOI 10.1186/2049-6958-8-74; Azad A, 2013, SPINE J, V13, P588, DOI 10.1016/j.spinee.2013.02.001; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bertram JP, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000397; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Carola V, 2002, BEHAV BRAIN RES, V134, P49, DOI 10.1016/S0166-4328(01)00452-1; Champion HR, 2003, J TRAUMA, V54, pS13, DOI 10.1097/01.TA.0000057151.02906.27; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Davis JJ, 2013, REHABIL PSYCHOL, V58, P36, DOI 10.1037/a0031525; Elder GA, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0591-8; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Epstein R. S., 1994, NEUROPSYCHIATRY TRAU; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Forster C, 2007, J PHYSIOL-LONDON, V580, P937, DOI 10.1113/jphysiol.2007.129007; Fung Y. C., 1984, EXPT INVESTIGATION L; Heldt SA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00002; Huang MX, 2016, PSYCHONEUROENDOCRINO, V63, P398, DOI 10.1016/j.psyneuen.2015.02.008; Hubbard WB, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5175249; Hubbard WB, 2015, ACS MACRO LETT, V4, P387, DOI 10.1021/acsmacrolett.5b00061; Hubbard William Brad, 2014, Biomed Sci Instrum, V50, P92; Huber BR, 2016, NEUROSCIENCE, V319, P206, DOI 10.1016/j.neuroscience.2016.01.022; Hue CD, 2016, J NEUROTRAUM, V33, P1202, DOI 10.1089/neu.2015.4067; Hue CD, 2015, J CEREBR BLOOD F MET, V35, P1191, DOI 10.1038/jcbfm.2015.38; Irwin RJ, 1997, J TRAUMA, V43, P650, DOI 10.1097/00005373-199710000-00015; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kaur C, 2008, CURR NEUROVASC RES, V5, P71, DOI 10.2174/156720208783565645; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Knoferl MW, 2003, SHOCK, V19, P519, DOI 10.1097/01.shk.0000070739.34700.f6; Knutson KM, 2013, NEUROPSYCHOLOGIA, V51, P686, DOI 10.1016/j.neuropsychologia.2013.01.003; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lashof-Sullivan MM, 2014, P NATL ACAD SCI USA, V111, P10293, DOI 10.1073/pnas.1406979111; Lee IN, 2015, J NEUROSCI RES, V93, P178, DOI 10.1002/jnr.23454; Liu MD, 2015, FRONT CELL NEUROSCI, V9, DOI [10.3389/fincel.2015.00168, 10.3389/fncel.2015.00168]; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Mathews ZR, 2015, J EMERG MED, V49, P573, DOI 10.1016/j.jemermed.2015.03.013; Matthews SC, 2012, PSYCHIAT RES-NEUROIM, V204, P149, DOI 10.1016/j.pscychresns.2012.04.018; Mishra V, 2016, SCI REP-UK, V6, DOI 10.1038/srep26992; Mutafchiyski VM, 2014, MILITARY MED RES, V1, DOI 10.1186/2054-9369-1-13; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Okada S, 1998, RADIAT RES, V150, P304, DOI 10.2307/3579980; Park E, 2013, NEUROBIOL DIS, V52, P150, DOI 10.1016/j.nbd.2012.12.002; Pelz J, 2013, EUR J HISTOCHEM, V57, P255, DOI 10.4081/ejh.2013.e38; Perez-Polo JR, 2015, J NEUROSCI RES, V93, P549, DOI 10.1002/jnr.23513; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Rajkowska G, 2013, BIOL PSYCHIAT, V73, P613, DOI 10.1016/j.biopsych.2012.09.024; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Regel G, 1997, Acta Anaesthesiol Scand Suppl, V110, P71; Ritenour AE, 2010, ANN SURG, V251, P1140, DOI 10.1097/SLA.0b013e3181e01270; Sajja VSSS, 2015, SHOCK, V44, P71, DOI 10.1097/SHK.0000000000000311; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Shain W, 2003, IEEE T NEUR SYS REH, V11, P186, DOI 10.1109/TNSRE.2003.814800; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Shoffstall AJ, 2012, BIOMACROMOLECULES, V13, P3850, DOI 10.1021/bm3013023; Singleton JAG, 2013, J TRAUMA ACUTE CARE, V75, pS269, DOI 10.1097/TA.0b013e318299d93e; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Skotak M, 2013, J NEUROTRAUM, V30, P1147, DOI 10.1089/neu.2012.2652; Smith JE, 2011, PHILOS T R SOC B, V366, P291, DOI 10.1098/rstb.2010.0251; Speich HE, 2013, J THROMB THROMBOLYS, V36, P31, DOI 10.1007/s11239-012-0814-7; Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Urbanska J, 2014, LIFE SCI, V96, P1, DOI 10.1016/j.lfs.2013.12.020; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Xu LY, 2016, EXP NEUROL, V277, P268, DOI 10.1016/j.expneurol.2016.01.010; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	79	12	13	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUL 13	2018	8								10622	10.1038/s41598-018-28848-2			12	Multidisciplinary Sciences	Science & Technology - Other Topics	GM8OB	WOS:000438489100007	30006635	DOAJ Gold, Green Published			2021-06-18	
J	Ondruschka, B; Sieber, M; Kirsten, H; Franke, H; Dressler, J				Ondruschka, Benjamin; Sieber, Monique; Kirsten, Holger; Franke, Heike; Dressler, Jan			Measurement of Cerebral Biomarkers Proving Traumatic Brain Injuries in Post-Mortem Body Fluids	JOURNAL OF NEUROTRAUMA			English	Article						autopsy; cerebrospinal fluid; chemiluminescent immunoassay; fatal traumatic brain injury; post-mortem biochemistry	FIBRILLARY ACIDIC PROTEIN; SERUM CONCENTRATIONS; BIOCHEMICAL MARKERS; LIPOCALIN NGAL; ACUTE-PHASE; S100B; BDNF; SEVERITY; DEATH; BLOOD	Until now, it is impossible to identify a fatal traumatic brain injury (TBI) before post-mortem radiological investigations or an autopsy take place. It would be preferable to have an additional diagnostic tool such as post-mortem biochemistry to get greater insight into the pathological pathways and survival times after sustaining TBI. Cerebrospinal fluid (CSF) and serum samples of 84 autopsy cases were collected from forensic autopsies with post-mortem intervals (PMI) of up to 148h. The cases were categorized into a fatal TBI case group (n=42) and non-TBI controls (n=42). The values of glial fibrillary acidic protein (GFAP), brain-derived neurotrophic factor (BDNF), and neutrophil gelatinase-associated lipocalin (NGAL) were analyzed by means of quantitative chemiluminescent multiplex immunoassays. The main results indicate that the usage of liquid samples with good macroscopic quality is more relevant for meaningful biomarker analyses than the length of the PMI. All three proteins were shown to differentiate TBI fatalities from the controls in CSF. In serum, only GFAP could be shown to be able to identify TBI cases. This study is the first approach to measure the three proteins together in CSF and serum in autopsy cases. Determined threshold values may differentiate between fatal TBI and control cases. The presented results emphasize the possible use of post-mortem biochemistry as a supplemental tool in everyday forensic routine.	[Ondruschka, Benjamin; Sieber, Monique; Dressler, Jan] Univ Leipzig, Med Fac, Inst Legal Med, Johannisallee 28, D-04103 Leipzig, Germany; [Kirsten, Holger] Univ Leipzig, Med Fac, Inst Med Informat Stat & Epidemiol, Leipzig, Germany; [Franke, Heike] Univ Leipzig, Med Fac, Rudolf Boehm Inst Pharmacol & Toxicol, Leipzig, Germany	Ondruschka, B (corresponding author), Univ Leipzig, Med Fac, Inst Legal Med, Johannisallee 28, D-04103 Leipzig, Germany.	benjamin.ondruschka@medizin.uni-leipzig.de	Kirsten, Holger/AAP-7250-2020	Kirsten, Holger/0000-0002-3126-7950	German Ministry of Defense	This work was partly supported by the German Ministry of Defense. BO has received reimbursement of travel costs from Randox Laboratories. The authors declare that no conflict of interest exists. The investigations were conducted in accordance with the human and ethical principles of the University of Leipzig (No. 117-12-23012012).	BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bolignano D, 2009, CLIN J AM SOC NEPHRO, V4, P337, DOI 10.2215/CJN.03530708; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Chacon-Fernandez P, 2016, J BIOL CHEM, V291, P9872, DOI 10.1074/jbc.M116.720029; Chakraborty S, 2012, BBA-REV CANCER, V1826, P129, DOI 10.1016/j.bbcan.2012.03.008; Chen A, 2013, BIOMED REP, V1, P167, DOI 10.3892/br.2012.48; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Das Abhishek, 2017, J Family Med Prim Care, V6, P191, DOI 10.4103/jfmpc.jfmpc_194_16; Di Pietro V, 2015, NEUROCHEM RES, V40, P991, DOI 10.1007/s11064-015-1554-9; Failla MD, 2016, NEUROREHAB NEURAL RE, V30, P83, DOI 10.1177/1545968315586465; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Franke H, 2012, PURINERG SIGNAL, V8, P629, DOI 10.1007/s11302-012-9300-0; Ghoneim FM, 2015, INT J CLIN EXP PATHO, V8, P7710; Goede A, 2015, RECHTSMEDIZIN, V25, P261, DOI 10.1007/s00194-015-0040-7; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Kawata K, 2016, NEUROSCI BIOBEHAV R, V68, P460, DOI 10.1016/j.neubiorev.2016.05.009; Kim H.J., 2018, CURRENT STATE BIOMAR; Laske C, 2006, J NEURAL TRANSM, V113, P1217, DOI 10.1007/s00702-005-0397-y; Li Dong-Ri, 2006, Legal Medicine, V8, P71, DOI 10.1016/j.legalmed.2005.07.004; Li Dong-Ri, 2009, Leg Med (Tokyo), V11 Suppl 1, pS273, DOI 10.1016/j.legalmed.2009.02.042; Lin HC, 2018, ANAL CHEM, V90, P2708, DOI 10.1021/acs.analchem.7b04642; Maeda Hitoshi, 2009, Leg Med (Tokyo), V11 Suppl 1, pS46, DOI 10.1016/j.legalmed.2009.01.048; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Meirelles LD, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051082; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Mimasaka S, 2001, TOHOKU J EXP MED, V193, P319, DOI 10.1620/tjem.193.319; O'Bryant SE, 2009, J ALZHEIMERS DIS, V17, P337, DOI 10.3233/JAD-2009-1051; Ondruschka B, 2018, INT J LEGAL MED, V132, P531, DOI 10.1007/s00414-017-1768-2; Ondruschka B, 2013, J NEUROTRAUM, V30, P1862, DOI 10.1089/neu.2013.2895; Palmiere C, 2013, FORENSIC SCI INT, V226, P54, DOI 10.1016/j.forsciint.2012.12.007; Papa L, 2017, J NEUROTRAUM, V34, P2187, DOI 10.1089/neu.2017.5030; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Pardridge WM, 2002, ADV EXP MED BIOL, V513, P397; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Posti JP, 2017, J NEUROTRAUM, V34, P1427, DOI 10.1089/neu.2016.4442; Rosen C, 2011, FRONT AGING NEUROSCI, V3, DOI 10.3389/fnagi.2011.00001; SANCHEZRODRIGUEZ VF, 1995, AM J FOREN MED PATH, V16, P210, DOI 10.1097/00000433-199509000-00004; Schiff L, 2012, MOL DIAGN THER, V16, P79, DOI 10.2165/11631580-000000000-00000; Sieber M, 2018, J FORENSIC LEG MED, V55, P65, DOI 10.1016/j.jflm.2018.02.016; Siuda J, 2017, NEUROL NEUROCHIR POL, V51, P24, DOI 10.1016/j.pjnns.2016.10.001; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; Wong TH, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0215-6; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wu Dafang, 2005, NeuroRx, V2, P120, DOI 10.1007/BF03206648; YAMAMOTO H, 1990, J NEUROSCI, V10, P3469; Yang ZH, 2015, TRENDS NEUROSCI, V38, P364, DOI 10.1016/j.tins.2015.04.003; Zetterberg H, 2009, BRAIN INJURY, V23, P723, DOI 10.1080/02699050903120399; Zhao JB, 2016, J NEUROL SCI, V368, P392, DOI 10.1016/j.jns.2016.07.060	51	12	12	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2018	35	17					2044	2055		10.1089/neu.2017.5441		JUL 2018	12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GQ7LU	WOS:000437806600001	29732941				2021-06-18	
J	Wu, YC; Mustafi, SM; Harezlak, J; Kodiweera, C; Flashman, LA; McAllister, TW				Wu, Yu-Chien; Mustafi, Sourajit M.; Harezlak, Jaroslaw; Kodiweera, Chandana; Flashman, Laura A.; McAllister, Thomas W.			Hybrid Diffusion Imaging in Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal density; clinical outcomes; hybrid diffusion imaging; mild traumatic brain injury; NODDI; q-space imaging	NEURITE ORIENTATION DISPERSION; WHITE-MATTER MICROSTRUCTURE; HIGH B-VALUE; FREE-WATER ELIMINATION; PROPAGATOR MAP MRI; AXONAL INJURY; MULTIPLE-SCLEROSIS; WEIGHTED MRI; NODDI; MODEL	Mild traumatic brain injury (mTBI) is an important public health problem. Although conventional medical imaging techniques can detect moderate-to-severe injuries, they are relatively insensitive to mTBI. In this study, we used hybrid diffusion imaging (HYDI) to detect white matter alterations in 19 patients with mTBI and 23 other trauma control patients. Within 15 days (standard deviation=10) of brain injury, all subjects underwent magnetic resonance HYDI and were assessed with a battery of neuropsychological tests of sustained attention, memory, and executive function. Tract-based spatial statistics (TBSS) was used for voxel-wise statistical analyses within the white matter skeleton to study between-group differences in diffusion metrics, within-group correlations between diffusion metrics and clinical outcomes, and between-group interaction effects. The advanced diffusion imaging techniques, including neurite orientation dispersion and density imaging (NODDI) and q-space analyses, appeared to be more sensitive then classic diffusion tensor imaging. Only NODDI-derived intra-axonal volume fraction (V-ic) demonstrated significant group differences (i.e., 5-9% lower in the injured brain). Within the mTBI group, V-ic and a q-space measure, P-0, correlated with 6 of 10 neuropsychological tests, including measures of attention, memory, and executive function. In addition, the direction of correlations differed significantly between groups (R-2>0.71 and p(interation) < 0.03). Specifically, in the control group, higher V-ic and P-0 were associated with better performances on clinical assessments, whereas in the mTBI group, higher V-ic and P-0 were associated with worse performances with correlation coefficients >0.83. In summary, the NODDI-derived axonal density index and q-space measure for tissue restriction demonstrated superior sensitivity to white matter changes shortly after mTBI. These techniques hold promise as a neuroimaging biomarker for mTBI.	[Wu, Yu-Chien; Mustafi, Sourajit M.] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, 355 West 16th St,Suite 4100, Indianapolis, IN 46202 USA; [Harezlak, Jaroslaw] Indiana Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Bloomington, IN USA; [Kodiweera, Chandana] Dartmouth Coll, Dartmouth Brain Imaging Ctr, Hanover, NH 03755 USA; [Flashman, Laura A.] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH USA; [Flashman, Laura A.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA	Wu, YC (corresponding author), Indiana Univ Sch Med, Dept Radiol & Imaging Sci, 355 West 16th St,Suite 4100, Indianapolis, IN 46202 USA.	yucwu@iu.edu	Harezlak, Jaroslaw/P-8557-2014	Harezlak, Jaroslaw/0000-0002-3070-7686	Indiana University-Purdue University Indianapolis ITDP; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS075791, R01 R01AG053993]; NCAA-DoD Grand Alliance [W81XWH-14-2-0151]; Project Development Team within the ICTSI NIH/NCRR Grant [UL1TR001108]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG053993] Funding Source: NIH RePORTER	The authors thank Mary L. Hynes and Marcia A. Davis for assistance with data collection. This study was supported by institutional grants from Indiana University-Purdue University Indianapolis ITDP to YCW and TWM, National Institutes of Health grant R21 NS075791 to YCW and TWM, R01 R01AG053993 to YCW, the NCAA-DoD Grand Alliance W81XWH-14-2-0151 to TWM, and a Project Development Team within the ICTSI NIH/NCRR Grant Number UL1TR001108.	Albi A, 2017, HUM BRAIN MAPP, V38, P12, DOI 10.1002/hbm.23350; Alexander AL, 2001, MAGN RESON MED, V45, P770, DOI 10.1002/mrm.1105; Alexander DC, 2002, MAGN RESON MED, V48, P331, DOI 10.1002/mrm.10209; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 2000, MAGNET RESON MED, V44, P713, DOI 10.1002/1522-2594(200011)44:5<713::AID-MRM9>3.0.CO;2-6; Assaf Y, 2005, MAGN RESON IMAGING, V23, P703, DOI 10.1016/j.mri.2005.04.008; Assaf Y, 2002, MAGNET RESON MED, V47, P115, DOI 10.1002/mrm.10040; Assaf Y, 2005, NEUROIMAGE, V27, P48, DOI 10.1016/j.neuroimage.2005.03.042; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Avram AV, 2016, NEUROIMAGE, V127, P422, DOI 10.1016/j.neuroimage.2015.11.027; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beck A.T., 1987, BECK DEPRESSION INVE; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Biton IE, 2006, MAGN RESON IMAGING, V24, P161, DOI 10.1016/j.mri.2005.10.029; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Callaghan P. T., 1991, PRINCIPLES NUCL MAGN; Chiang CW, 2014, NEUROIMAGE, V101, P310, DOI 10.1016/j.neuroimage.2014.06.064; Churchill NW, 2017, HUM BRAIN MAPP, V38, P4201, DOI 10.1002/hbm.23658; Colgan N, 2016, NEUROIMAGE, V125, P739, DOI 10.1016/j.neuroimage.2015.10.043; Daducci A, 2015, NEUROIMAGE, V105, P32, DOI 10.1016/j.neuroimage.2014.10.026; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Descoteaux M, 2011, MED IMAGE ANAL, V15, P603, DOI 10.1016/j.media.2010.07.001; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fieremans E, 2011, NEUROIMAGE, V58, P177, DOI 10.1016/j.neuroimage.2011.06.006; First M.B., 1996, STRUCTURED CLIN INTE; Grussu F, 2017, ANN CLIN TRANSL NEUR, V4, P663, DOI 10.1002/acn3.445; Guerrero J.M., 2016, ISMRM 24 ANN M EXH 2; Henninger N, 2016, BRAIN, V139, P1094, DOI 10.1093/brain/aww001; Hosseinbor AP, 2013, NEUROIMAGE, V64, P650, DOI 10.1016/j.neuroimage.2012.08.072; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jones DK, 2008, CORTEX, V44, P936, DOI 10.1016/j.cortex.2008.05.002; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kodiweera C, 2016, DATA BRIEF, V7, P1131, DOI 10.1016/j.dib.2016.03.063; Kodiweera C, 2016, NEUROIMAGE, V128, P180, DOI 10.1016/j.neuroimage.2015.12.033; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Kunz N, 2014, NEUROIMAGE, V96, P288, DOI 10.1016/j.neuroimage.2014.03.057; Lally P., 2014, ARCH DIS CHILD FE S1, V99, pA14; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaPlaca MC, 2009, IEEE ENG MED BIO, P1113, DOI 10.1109/IEMBS.2009.5334457; Levin B, 2014, NEUROCRIT CARE, V20, P334, DOI 10.1007/s12028-013-9931-1; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Manjon JV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073021; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Metzler-Baddeley C, 2012, NEUROIMAGE, V59, P1394, DOI 10.1016/j.neuroimage.2011.08.043; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mustafi S.M., 2015, ISMRM 23 ANN M EXH 2; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Ozarslan E, 2013, NEUROIMAGE, V78, P16, DOI 10.1016/j.neuroimage.2013.04.016; Oishi K, 2008, NEUROIMAGE, V43, P447, DOI 10.1016/j.neuroimage.2008.07.009; Pasternak O, 2009, MAGN RESON MED, V62, P717, DOI 10.1002/mrm.22055; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Radiological Society of North America, 2017, RSNA POS STAT TRAUM; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sepehrband F, 2015, HUM BRAIN MAPP, V36, P3687, DOI 10.1002/hbm.22872; Setsompop K, 2012, MAGN RESON MED, V67, P1210, DOI 10.1002/mrm.23097; Simon CM, 2009, J NEUROTRAUM, V26, P563, DOI 10.1089/neu.2008.0523; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Spielberger CD, 1983, STATE TRAIT ANXIETY; Stanisz GJ, 1997, MAGNET RESON MED, V37, P103, DOI 10.1002/mrm.1910370115; Timmers I, 2015, J INHERIT METAB DIS, V38, P295, DOI 10.1007/s10545-014-9780-x; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Tournier JD, 2011, MAGN RESON MED, V65, P1532, DOI 10.1002/mrm.22924; Waljas M, 2014, J NEUROTRAUM, V31, P108, DOI 10.1089/neu.2013.2941; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Wen Q., 2017, ALZH ASS INT C UNPUB; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; Wintermark M, 2015, AJNR Am J Neuroradiol, V36, pE1, DOI 10.3174/ajnr.A4181; Wu Y.C., 2016, DIFFUSION MRI TENSOR, P150; Wu YC, 2008, IEEE T MED IMAGING, V27, P858, DOI 10.1109/TMI.2008.922696; Wu YC, 2007, NEUROIMAGE, V36, P617, DOI 10.1016/j.neuroimage.2007.02.050; Wu YC, 2011, NEUROIMAGE, V58, P829, DOI 10.1016/j.neuroimage.2011.06.067; Wu YC, 2011, NEUROIMAGE, V54, P1840, DOI 10.1016/j.neuroimage.2010.09.067; Yamada H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112411; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216; Zhang H, 2012, NEUROIMAGE, V61, P1000, DOI 10.1016/j.neuroimage.2012.03.072; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	103	12	13	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2018	35	20					2377	2390		10.1089/neu.2017.5566		JUL 2018	14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GV6DE	WOS:000437869100001	29786463	Other Gold, Green Published			2021-06-18	
J	Otsuka, T; Imura, T; Nakagawa, K; Shrestha, L; Takahashi, S; Kawahara, Y; Sueda, T; Kurisu, K; Yuge, L				Otsuka, Takashi; Imura, Takeshi; Nakagawa, Kei; Shrestha, Looniva; Takahashi, Shinya; Kawahara, Yumi; Sueda, Taijiro; Kurisu, Kaoru; Yuge, Louis			Simulated Microgravity Culture Enhances the Neuroprotective Effects of Human Cranial Bone-Derived Mesenchymal Stem Cells in Traumatic Brain Injury	STEM CELLS AND DEVELOPMENT			English	Article						simulated microgravity; mesenchymal stem cells; neuroprotection	HEPATOCYTE GROWTH-FACTOR; MARROW STROMAL CELLS; TGF-BETA; HGF; DIFFERENTIATION; PROLIFERATION; CYTOKINES; BLOOD; ANGIOGENESIS; PROGENITORS	Fundamental cures of central nervous system (CNS) diseases are rarely achieved due to the low regenerative ability of the CNS. Recently, cell-based therapy using mesenchymal stem cells (MSCs) has been explored as an effective treatment for CNS diseases. Among the various tissue-derived MSCs, we have isolated human cranial bone-derived MSCs (cMSCs) in our laboratory. In addition, we have focused on simulated microgravity (MG) as a valuable culture environment of MSCs. However, detailed mechanisms underlying functional recovery from transplantation of MSCs cultured under MG conditions remain unclear. In this study, we investigated the therapeutic mechanisms of transplantation of cMSCs cultured under MG conditions in traumatic brain injury (TBI) model mice. Human cMSCs were cultured under 1G and MG conditions, and cMSCs cultured under MG conditions expressed significantly higher messenger RNA (mRNA) levels of hepatocyte growth factor (HGF) and transforming growth factor beta (TGF-). In TBI model mice, the transplantation of cMSCs cultured under MG conditions (group MG) showed greater motor functional improvement compared with only phosphate-buffered saline administration (group PBS). Moreover, the protein expression levels of tumor necrosis factor alpha (TNF-) and the Bcl-2-associated X protein (Bax)/b cell leukemia/lymphoma 2 protein (Bcl-2) ratio were significantly lower at brain injury sites in mice of group MG than those of group PBS. In addition, an in vitro study showed that the conditioned medium of cMSCs cultured under MG conditions significantly suppressed the cell death of NG108-15 cells exposed to oxidative or inflammatory stress through anti-inflammatory and antiapoptosis effects. These findings demonstrate that culturing cMSCs under simulated MG increases the neuroprotective effects, suggesting that simulated MG cultures may be a useful method for cell-based therapy strategies for CNS diseases.	[Otsuka, Takashi; Imura, Takeshi; Nakagawa, Kei; Shrestha, Looniva; Yuge, Louis] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Div Bioenvironm Adaptat Sci, Hiroshima, Japan; [Takahashi, Shinya; Sueda, Taijiro] Hiroshima Univ Hosp, Dept Cardiovasc Surg, Hiroshima, Japan; [Kawahara, Yumi; Yuge, Louis] Space Biolabs Co Ltd, Hiroshima, Japan; [Kurisu, Kaoru] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan	Yuge, L (corresponding author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Div Bioenvironm Adaptat Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	ryuge@hiroshima-u.ac.jp	Hiyama, Eiso/A-2013-2019	Hiyama, Eiso/0000-0001-9179-5037			Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Beck LS, 1991, GROWTH FACTORS, V5, DOI 10.3109/08977199109000293; Bendinelli P, 2010, J CELL PHYSIOL, V225, P757, DOI 10.1002/jcp.22274; BENVENISTE EN, 1995, INT J DEV NEUROSCI, V13, P341, DOI 10.1016/0736-5748(94)00061-7; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Caton A, 2000, DEVELOPMENT, V127, P1751; Chen NF, 2013, J PAIN, V14, P1671, DOI 10.1016/j.jpain.2013.08.010; Chen NN, 2016, NEUROCHEM RES, V41, P3052, DOI 10.1007/s11064-016-2024-8; Chen Y, 2006, CELL MOL LIFE SCI, V63, P1649, DOI 10.1007/s00018-006-6019-5; Cho SR, 2009, CELL TRANSPLANT, V18, P1359, DOI 10.3727/096368909X475329; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Cook D, 2013, ADV EXP MED BIOL, V786, P213, DOI 10.1007/978-94-007-6621-1_12; Dai YL, 2003, BLOOD, V102, P1178, DOI 10.1182/blood-2002-12-3771; De Bari C, 2001, ARTHRITIS RHEUM-US, V44, P1928, DOI 10.1002/1529-0131(200108)44:8<1928::AID-ART331>3.0.CO;2-P; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Echeverry S, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-16; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Gutierrez H, 2004, DEVELOPMENT, V131, P3717, DOI 10.1242/dev.01209; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; He F, 2008, COLLOID SURFACE B, V61, P290, DOI 10.1016/j.colsurfb.2007.09.009; Honmou O, 2011, BRAIN, V134, P1790, DOI 10.1093/brain/awr063; Hossain MA, 2002, J NEUROCHEM, V81, P365, DOI 10.1046/j.1471-4159.2002.00837.x; Hu ZX, 2010, EUR J PHARMACOL, V645, P23, DOI 10.1016/j.ejphar.2010.07.011; Huang CY, 2012, ARCH DERMATOL RES, V304, P589, DOI 10.1007/s00403-012-1278-5; Imura T, 2017, STEM CELL RES THER, V7, P375; Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806; Jiang JG, 1997, MOL CELL BIOL, V17, P5758, DOI 10.1128/MCB.17.10.5758; Jin HJ, 2013, INT J MOL SCI, V14, P17986, DOI 10.3390/ijms140917986; Kanno T, 2007, J CELL BIOCHEM, V101, P1266, DOI 10.1002/jcb.21249; Kes VB, 2008, CLIN BIOCHEM, V41, P1330, DOI 10.1016/j.clinbiochem.2008.08.080; Komatsu K, 2010, BRAIN RES, V1334, P84, DOI 10.1016/j.brainres.2010.04.006; Li H, 2007, CELL MOL IMMUNOL, V4, P407; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Mead B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109305; Mitsuhara T, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt184; MOSES HL, 1981, CANCER RES, V41, P2842; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Neirinckx V, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0202-2; Plett PA, 2004, EXP HEMATOL, V32, P773, DOI 10.1016/j.exphem.2004.03.014; Pomies P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160092; Ruiz-Ortega M, 2007, CARDIOVASC RES, V74, P196, DOI 10.1016/j.cardiores.2007.02.008; Shang JW, 2011, J NEUROSCI RES, V89, P86, DOI 10.1002/jnr.22524; Shinagawa K, 2015, NEUROSCI LETT, V606, P161, DOI 10.1016/j.neulet.2015.08.056; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Sun W, 2002, MOL BRAIN RES, V103, P36, DOI 10.1016/S0169-328X(02)00168-7; Tse WT, 2003, TRANSPLANTATION, V75, P389, DOI 10.1097/01.TP.0000045055.63901.A9; Wang PX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049720; Watabe T, 2009, CELL RES, V19, P103, DOI 10.1038/cr.2008.323; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011; Wilkins A, 2009, STEM CELL RES, V3, P63, DOI 10.1016/j.scr.2009.02.006; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731; Yenari MA, 2006, STROKE, V37, P1087, DOI 10.1161/01.STR.0000206281.77178.ac; Yuge L, 2003, IN VITRO CELL DEV-AN, V39, P89; Yuge L, 2006, STEM CELLS DEV, V15, P921, DOI 10.1089/scd.2006.15.921; Zhang P, 2016, BIOMED PHARMACOTHER, V83, P658, DOI 10.1016/j.biopha.2016.07.040	57	12	12	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287	1557-8534		STEM CELLS DEV	Stem Cells Dev.	SEP	2018	27	18			SI		1287	1297		10.1089/scd.2017.0299		JUL 2018	11	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	GT4OJ	WOS:000438206400001	29790427				2021-06-18	
J	Zan, J; Zhang, H; Lu, MY; Beng, HM; Zhong, KL; Sun, XO; Tan, W				Zan, Jie; Zhang, Hao; Lu, Min-yi; Beng, Hui-min; Zhong, Kai-lun; Sun, Xiao-ou; Tan, Wen			Isosteviol sodium injection improves outcomes by modulating TLRs/NF-B-dependent inflammatory responses following experimental traumatic brain injury in rats	NEUROREPORT			English	Article						inflammatory; isosteviol sodium; nuclear factor kappa-light-chain-enhancer of activated B cells; toll-like receptors; traumatic brain injury	TOLL-LIKE RECEPTORS; NEURAL STEM-CELLS; NF-KAPPA-B; CEREBRAL-ARTERY OCCLUSION; INNATE IMMUNE-RESPONSE; POSSIBLE INVOLVEMENT; CORTICAL CONTUSION; SIGNALING PATHWAYS; ISCHEMIA INJURY; PATHOPHYSIOLOGY	Previous studies have shown that isosteviol sodium (STVNa) protects against permanent cerebral ischemia injury by inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B)-mediated inflammatory responses. Overwhelming evidence shows that toll-like receptors (TLRs) are the upstream regulators of NF-B. On the basis of the similarity of the pathology caused by traumatic brain injury (TBI) and stroke, we speculated that STVNa may have a therapeutic effect against TBI through regulation of the TLRs/NF-B signaling-mediated inflammatory response. Thus, we studied the potential therapeutic effects of STVNa and the underlying mechanisms. Male rats, subjected to controlled cortical impact (CCI) injury, were injected intraperitoneally with STVNa (5, 10, 20, 40, and 80mg/kg, daily for 3 or 7 days) after trauma. Neurobehavioral scores, relative numbers of cortical lesions, and histology were examined. We also measured the mRNA and protein expression levels of TLRs/NF-B signaling pathway-related genes including TLR2, TLR4, and NF-B by quantitative real-time-PCR and western blotting, respectively, and concentrations of tumor necrosis factor- and interleukin-1 by an enzyme-linked immunosorbent assay. The results indicated that STVNa (20mg/kg) showed significant neuroprotective effects 3 and 7 days after TBI, including the reduction of cortical lesions, improvement of the neurological severity score, significantly increased number of restored neurons, decreased number of astrocytes, and lower concentrations of tumor necrosis factor- and interleukin-1. Results from quantitative real-time-PCR and western blotting also show that the mRNA and protein expression levels of TLR2, TLR4, and NF-B were significantly lower in STVNa-treated rats compared with the vehicle-treated rats. The administration of STVNa attenuates the TLR/NF-B signaling pathway-mediated inflammatory responses in the injured rat brain, and this may be the mechanism by which STVNa improves the outcome following TBI.	[Zan, Jie; Zhang, Hao; Lu, Min-yi; Zhong, Kai-lun; Sun, Xiao-ou; Tan, Wen] Guangdong Univ Technol, Inst Biomed & Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China; [Zhang, Hao; Beng, Hui-min] South China Univ Technol, Sch Biosci & Bioengn, Guangzhou, Guangdong, Peoples R China	Tan, W (corresponding author), Guangdong Univ Technol, Inst Biomed & Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China.	went@gdut.edu.cn		Zhang, Hao/0000-0003-3798-2979; Zhang, Hao/0000-0003-1165-8943	Science and Technology Planning Project of Guangdong Province [2015B010109004]; Science and Technology Planning Project of Guangzhou [123000068]; Natural Science Foundation of Guangdong Province of ChinaNational Natural Science Foundation of Guangdong Province [2017A030310404]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2017M622642]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31601089]	This study was supported in part by the Science and Technology Planning Project of Guangdong Province (no. 2015B010109004), the 2017 PhD Start-up Fund of the Natural Science Foundation of Guangdong Province of China (2017A030310404), the China Postdoctoral Science Foundation (no. 2017M622642), the Science and Technology Planning Project of Guangzhou (no.123000068), and the National Natural Science Foundation of China (31601089).	Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Ahmad AS, 2006, TOXICOL SCI, V89, P265, DOI 10.1093/toxsci/kfj022; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Akira S, 2001, ADV IMMUNOL, V78, P1, DOI 10.1016/S0065-2776(01)78001-7; Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bagge A, 2012, BIOCHEM BIOPH RES CO, V426, P266, DOI 10.1016/j.bbrc.2012.08.082; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Chakrabarti M, 2016, REV NEUROSCIENCE, V27, P271, DOI 10.1515/revneuro-2015-0032; Chan P, 1998, LIFE SCI, V63, P1679, DOI 10.1016/S0024-3205(98)00439-1; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Douen AG, 2004, BRAIN RES, V1008, P139, DOI 10.1016/j.brainres.2003.08.070; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Fandino-Rivera J, 2004, REV NEUROLOGIA, V38, P912, DOI 10.33588/rn.3810.2003035; Gregersen S, 2004, METABOLISM, V53, P73, DOI 10.1016/j.metabol.2003.07.013; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hu H, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1379162; Hua F, 2009, BRAIN RES, V1262, P100, DOI 10.1016/j.brainres.2009.01.018; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Itoh T, 2006, NEUROCHEM RES, V31, P1381, DOI 10.1007/s11064-006-9186-8; Itoh T, 2013, J NEURAL TRANSM, V120, P361, DOI 10.1007/s00702-012-0895-7; Itoh T, 2011, J NEURAL TRANSM, V118, P193, DOI 10.1007/s00702-010-0495-3; Jain KK, 2011, NEUROPROTECTION TRAU, P1082; Johnson GB, 2003, CRIT REV IMMUNOL, V23, P15, DOI 10.1615/CritRevImmunol.v23.i12.20; Kopp E, 2003, CURR OPIN IMMUNOL, V15, P396, DOI 10.1016/S0952-7915(03)00080-3; Lai WS, 2017, PHARM DEV TECHNOL, V22, P275, DOI 10.1080/10837450.2016.1226900; Lai YC, 2006, DEV NEUROSCI-BASEL, V28, P336, DOI 10.1159/000094159; Lee Sung Joong, 2002, Current Drug Targets - Inflammation and Allergy, V1, P181; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Runyan DK, 2008, AM J PREV MED, V34, pS112, DOI 10.1016/j.amepre.2008.01.011; SOEJARTO DD, 1982, J NAT PROD, V45, P590, DOI 10.1021/np50023a013; Sun J, 2004, ANN CLIN LAB SCI, V34, P181; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Xu DY, 2008, PLANTA MED, V74, P816, DOI 10.1055/s-2008-1074557; Yu WH, 2012, PHYTOTHER RES, V26, P1838, DOI 10.1002/ptr.4662; Zhang H, 2017, J STROKE CEREBROVASC, V26, P2603, DOI 10.1016/j.jstrokecerebrovasdis.2017.06.023; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	47	12	13	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	JUL 4	2018	29	10					794	803		10.1097/WNR.0000000000001033			10	Neurosciences	Neurosciences & Neurology	GJ4KE	WOS:000435349200002	29683870	Green Published			2021-06-18	
J	Muelbl, MJ; Slaker, ML; Shah, AS; Nawarawong, NN; Gerndt, CH; Budde, MD; Stemper, BD; Olsen, CM				Muelbl, Matthew J.; Slaker, Megan L.; Shah, Alok S.; Nawarawong, Natalie N.; Gerndt, Clayton H.; Budde, Matthew D.; Stemper, Brian D.; Olsen, Christopher M.			Effects of Mild Blast Traumatic Brain Injury on Cognitive- and Addiction-Related Behaviors	SCIENTIFIC REPORTS			English	Article							POSTTRAUMATIC-STRESS-DISORDER; CONDITIONED PLACE PREFERENCE; PREFRONTAL CORTEX; WORKING-MEMORY; NEUROPSYCHOLOGICAL OUTCOMES; PROACTIVE-INTERFERENCE; EXECUTIVE DYSFUNCTION; SUBSTANCE-ABUSE; DRUG-USE; AXIS-I	Traumatic brain injury (TBI) commonly results in cognitive and psychiatric problems. Cognitive impairments occur in approximately 30% of patients suffering from mild TBI (mTBI), and correlational evidence from clinical studies indicates that substance abuse may be increased following mTBI. However, understanding the lasting cognitive and psychiatric problems stemming from mTBI is difficult in clinical settings where pre-injury assessment may not be possible or accurate. Therefore, we used a previously characterized blast model of mTBI (bTBI) to examine cognitive-and addiction-related outcomes. We previously demonstrated that this model leads to bilateral damage of the medial prefrontal cortex (mPFC), a region critical for cognitive function and addiction. Rats were exposed to bTBI and tested in operant learning tasks several weeks after injury. bTBI rats made more errors during acquisition of a cue discrimination task compared to sham treated rats. Surprisingly, we observed no differences between groups in set shifting and delayed matching to sample, tasks known to require the mPFC. Separate rats performed cocaine self-administration. No group differences were found in intake or extinction, and only subtle differences were observed in drug-primed reinstatement 3-4 months after injury. These findings indicate that bTBI impairs acquisition of a visual discrimination task and that bTBI does not significantly increase the ability of cocaine exposure to trigger drug seeking.	[Muelbl, Matthew J.; Slaker, Megan L.; Nawarawong, Natalie N.; Gerndt, Clayton H.; Olsen, Christopher M.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Muelbl, Matthew J.; Slaker, Megan L.; Nawarawong, Natalie N.; Gerndt, Clayton H.; Olsen, Christopher M.] Med Coll Wisconsin, Neurosci Res Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Shah, Alok S.; Budde, Matthew D.; Stemper, Brian D.] Med Coll Wisconsin, Dept Neurosurg, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Shah, Alok S.; Budde, Matthew D.; Stemper, Brian D.] Clement J Zablocki Vet Affairs Med Ctr, 5000 W Natl Ave, Milwaukee, WI 53295 USA	Olsen, CM (corresponding author), Med Coll Wisconsin, Dept Pharmacol & Toxicol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.; Olsen, CM (corresponding author), Med Coll Wisconsin, Neurosci Res Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	colsen@mcw.edu	Stemper, Brian/AAX-7611-2020; Olsen, Christopher/G-9595-2013	Olsen, Christopher/0000-0003-2700-0310; gerndt, clayton/0000-0001-9226-1790	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA039276]; Veterans Affairs Medical ResearchUS Department of Veterans Affairs; Research and Education Initiative Fund, a component of the Advancing a Healthier Wisconsin Endowment at the Medical College of Wisconsin; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA042792, R21DA039276] Funding Source: NIH RePORTER	This research was supported by NIH DA039276 (C.M.O., M.D.B., B.D.S.), Veterans Affairs Medical Research (M.D.B., B.D.S.), and the Research and Education Initiative Fund, a component of the Advancing a Healthier Wisconsin Endowment at the Medical College of Wisconsin (C.M.O.). The authors wish to thank the NIDA drug supply program for providing cocaine. Behavioral studies were performed using equipment from investigator laboratories and the MCW Neuroscience Research Center Rodent Behavior Core. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298; Alwis DS, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00156; Aoki Y, 2016, NEUROSCI BIOBEHAV R, V66, P119, DOI 10.1016/j.neubiorev.2016.04.021; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Banuelos C, 2014, J NEUROSCI, V34, P3457, DOI 10.1523/JNEUROSCI.5192-13.2014; Bardo MT, 2000, PSYCHOPHARMACOLOGY, V153, P31, DOI 10.1007/s002130000569; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Beas BS, 2013, NEUROBIOL AGING, V34, P2164, DOI 10.1016/j.neurobiolaging.2013.03.019; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bernheim A, 2016, NEUROSCI BIOBEHAV R, V69, P36, DOI 10.1016/j.neubiorev.2016.07.020; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bjork JM, 2009, J NEUROTRAUM, V26, P1077, DOI 10.1089/neu.2008-0849; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Briones TL, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-57; Budde MD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00154; Cole W.R., 2016, TRANSLATIONAL RES TR; Cox BM, 2016, PSYCHOPHARMACOLOGY, V233, P2319, DOI 10.1007/s00213-016-4283-0; D'Souza MS, 2003, PHARMACOL BIOCHEM BE, V76, P335, DOI 10.1016/j.pbb.2003.08.004; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; DeMar J, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00059; EDHOUSE WV, 1988, ANIM LEARN BEHAV, V16, P461, DOI 10.3758/BF03209387; Edwards S, 2013, BEHAV PHARMACOL, V24, P356, DOI 10.1097/FBP.0b013e3283644d15; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Enomoto T, 2011, BIOL PSYCHIAT, V69, P432, DOI 10.1016/j.biopsych.2010.09.038; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Fischer H, 2010, US MILITARY CASUALTY; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Floresco SB, 2008, BEHAV BRAIN RES, V190, P85, DOI 10.1016/j.bbr.2008.02.008; Fuster JM, 2008, PREFRONTAL CORTEX, 4TH EDITION, P1; George SA, 2015, BEHAV BRAIN RES, V286, P256, DOI 10.1016/j.bbr.2015.02.051; Ghods-Sharifi S, 2008, NEUROBIOL LEARN MEM, V89, P567, DOI 10.1016/j.nlm.2007.10.007; Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119; Gourley SL, 2016, NAT NEUROSCI, V19, P656, DOI 10.1038/nn.4275; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Hannan AJ, 2014, NEUROPATH APPL NEURO, V40, P13, DOI 10.1111/nan.12102; Ikegami A, 2007, BEHAV NEUROSCI, V121, P389, DOI 10.1037/0735-7044.121.2.389; Izquierdo A, 2017, NEUROSCIENCE, V345, P12, DOI 10.1016/j.neuroscience.2016.03.021; Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kesner RP, 2011, NEUROBIOL LEARN MEM, V96, P417, DOI 10.1016/j.nlm.2011.07.002; Kline AE, 2016, PROG NEUROBIOL, V142, P45, DOI 10.1016/j.pneurobio.2016.05.002; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kraus J. F., 1994, TXB TRAUMATIC BRAIN, P3; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; Lim YW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125130; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Martens KM, 2012, J NEUROTRAUM, V29, P2505, DOI 10.1089/neu.2012.2388; Mayeux JP, 2015, BEHAV BRAIN RES, V279, P22, DOI 10.1016/j.bbr.2014.10.053; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McInnes K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174847; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; McQuail JA, 2016, J NEUROSCI, V36, P12537, DOI 10.1523/JNEUROSCI.2332-16.2016; Merkel SF, 2017, J NEUROTRAUM, V34, P165, DOI 10.1089/neu.2015.4275; Miller DR, 2016, HUM BRAIN MAPP, V37, P220, DOI 10.1002/hbm.23022; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Muelbl MJ, 2016, PSYCHOPHARMACOLOGY, V233, P2799, DOI 10.1007/s00213-016-4323-9; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Neipert L, 2014, BRAIN INJURY, V28, P1667, DOI 10.3109/02699052.2014.947623; Nelson NW, 2012, J INT NEUROPSYCH SOC, V18, P845, DOI 10.1017/S1355617712000616; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; Noel X, 2013, CURR OPIN NEUROBIOL, V23, P632, DOI 10.1016/j.conb.2013.01.018; Olsen CM, 2006, BRAIN RES, V1075, P229, DOI 10.1016/j.brainres.2006.01.003; Ommaya AK, 1996, J TRAUMA, V41, P972, DOI 10.1097/00005373-199612000-00005; Pagulayan KF, 2018, J INT NEUROPSYCH SOC, V24, P324, DOI 10.1017/S1355617717001217; Perez-Garcia G, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00176; Perry JL, 2011, BRAIN RES REV, V65, P124, DOI 10.1016/j.brainresrev.2010.09.001; Peters J, 2009, LEARN MEMORY, V16, P279, DOI 10.1101/lm.1041309; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; Richardson NR, 1996, J NEUROSCI METH, V66, P1, DOI 10.1016/0165-0270(95)00153-0; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Sajja VSSS, 2014, MOL CELL NEUROSCI, V59, P119, DOI 10.1016/j.mcn.2014.02.004; Seamans JK, 2008, NEUROTOX RES, V14, P249, DOI 10.1007/BF03033814; Shah Ms Alok S, 2012, Biomed Sci Instrum, V48, P393; Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x; Sloan HL, 2006, BEHAV BRAIN RES, V171, P116, DOI 10.1016/j.bbr.2006.03.030; Sofuoglu M, 2016, J DUAL DIAGN, V12, P90, DOI 10.1080/15504263.2016.1146383; Stemper BD, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00031; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Tanielian T, 2008, MG720CCF RAND CORP; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thomsen Morgane, 2005, Curr Protoc Neurosci, VChapter 9, DOI 10.1002/0471142301.ns0920s32; Toklu HZ, 2018, BEHAV BRAIN RES, V340, P14, DOI 10.1016/j.bbr.2017.04.025; Tzschentke TM, 2007, ADDICT BIOL, V12, P227, DOI 10.1111/j.1369-1600.2007.00070.x; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Verfaellie M, 2014, NEUROPSYCHOLOGY, V28, P337, DOI 10.1037/neu0000027; Vonder Haar C, 2014, BRAIN INJURY, V28, P235, DOI 10.3109/02699052.2013.860473; Wang Y, 2017, J NEUROTRAUM, V34, P952, DOI 10.1089/neu.2016.4465; Weil ZM, 2016, J NEUROTRAUM, V33, P895, DOI 10.1089/neu.2015.3953; West SL, 2011, NEUROREHABILITATION, V29, P1, DOI 10.3233/NRE-2011-0671; West TA, 2014, J NEUROTRAUM, V31, P159, DOI 10.1089/neu.2013.3031; White KG, 2004, J EXP PSYCHOL-ANIM B, V30, P83, DOI 10.1037/0097-7403.30.2.83	105	12	14	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUL 2	2018	8								9941	10.1038/s41598-018-28062-0			14	Multidisciplinary Sciences	Science & Technology - Other Topics	GL2MB	WOS:000436954400008	29967344	DOAJ Gold, Green Published			2021-06-18	
J	Abdul-Muneer, PM; Bhowmick, S; Briski, N				Abdul-Muneer, P. M.; Bhowmick, Saurav; Briski, Nicholas			Angiotensin II Causes Neuronal Damage in Stretch-Injured Neurons: Protective Effects of Losartan, an Angiotensin T-1 Receptor Blocker	MOLECULAR NEUROBIOLOGY			English	Article						Angiotensin II; AngT(1)R; Losartan; Oxidative stress; Neuroinflammation; Cell death	TRAUMATIC BRAIN-INJURY; ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; OXIDATIVE STRESS; TYPE-1 RECEPTOR; AT(1) RECEPTOR; HYPOTHALAMIC NEURONS; BARRIER PERMEABILITY; CARDIAC-HYPERTROPHY; OXIDASE ACTIVATION	Angiotensin II (Ang II) is a mediator of oxidative stress via activation/induction of reactive oxygen and nitrogen species-generating enzymes, NADPH oxidase (NOX) and inducible nitric oxide synthase (iNOS). We investigated the hypothesis that overproduction of Ang II during traumatic brain injury (TBI) induces the activation of the oxidative stress, which triggers neuroinflammation and cell apoptosis in a cell culture model of neuronal stretch injury. We first established that stretch injury causes a rapid increase in the level of Ang II, which causes the release of pro-inflammatory cytokines, IL-1 beta and TNF-alpha, via the induction of oxidative stress. Since angiotensin-converting enzyme (ACE) mediates the production of Ang II via the conversion of Ang I into Ang II, we analyzed the expression of ACE by western blotting. Further, we analyzed caspase-3-mediated apoptosis by TUNEL staining and annexin V western blotting. Angiotensin type I (AT(1)) receptor antagonist losartan attenuated Ang II-induced oxidative stress and associated neuroinflammation and cell death in cultured neurons. Remarkably, we noticed that the expression of Ang II type 1 receptor (AngT(1)R) upregulated in neuronal stretch injury; losartan mitigates this upregulation. Findings from this study significantly extend our understanding of the pathophysiology of TBI and may have significant implications for developing therapeutic strategies for TBI-associated brain dysfunctions.	[Abdul-Muneer, P. M.; Bhowmick, Saurav; Briski, Nicholas] JFK Med Ctr, Neurosci Inst, Lab CNS Injury & Repair, 65 James St, Edison, NJ 08820 USA	Abdul-Muneer, PM (corresponding author), JFK Med Ctr, Neurosci Inst, Lab CNS Injury & Repair, 65 James St, Edison, NJ 08820 USA.	mmuneer@jfkhealth.org	Bhowmick, Saurav/Y-6011-2019	Briski, Nicholas/0000-0003-0778-9019; Abdul-Muneer, P. M/0000-0001-8231-4385	Neuroscience Institute at JFK Medical Center, Edison, NJ	This work was funded by the Neuroscience Institute at JFK Medical Center, Edison, NJ to P.M. Abdul-Muneer.	Abdul-Muneer PM, 2017, MOL NEUROBIOL, V54, P3964, DOI 10.1007/s12035-016-9949-4; Abdul-Muneer PM, 2017, BRAIN BEHAV IMMUN, V59, P190, DOI 10.1016/j.bbi.2016.09.002; Abdul-Muneer PM, 2016, MOL NEUROBIOL, V53, P6106, DOI 10.1007/s12035-015-9520-8; Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Bar-Klein G, 2014, ANN NEUROL, V75, P864, DOI 10.1002/ana.24147; Basso N, 2001, HYPERTENSION, V38, P1246, DOI 10.1161/hy1201.101214; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Benicky J, 2011, NEUROPSYCHOPHARMACOL, V36, P857, DOI 10.1038/npp.2010.225; Benigni A, 2010, EMBO MOL MED, V2, P247, DOI 10.1002/emmm.201000080; Burnier M, 2000, LANCET, V355, P637, DOI 10.1016/S0140-6736(99)10365-9; Chen J, 2015, NEUROSCIENCE, V305, P117, DOI 10.1016/j.neuroscience.2015.07.076; Crowley SD, 2006, P NATL ACAD SCI USA, V103, P17985, DOI 10.1073/pnas.0605545103; Dikalov SI, 2014, ANTIOXID REDOX SIGN, V20, P281, DOI 10.1089/ars.2012.4918; El Bekay R, 2003, BLOOD, V102, P662, DOI 10.1182/blood-2002-09-2785; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fleegal-DeMotta MA, 2009, J CEREBR BLOOD F MET, V29, P640, DOI 10.1038/jcbfm.2008.158; FYHRQUIST F, 1995, J HUM HYPERTENS, V9, pS19; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Guo DF, 2001, CELL RES, V11, P165, DOI 10.1038/sj.cr.7290083; Guo F, 2011, J INTERF CYTOK RES, V31, P351, DOI 10.1089/jir.2010.0073; Ha YW, 2016, METAL IONS LIFE SCI, V16, P585, DOI 10.1007/978-3-319-21756-7_16; Hans VHJ, 1999, NEUROREPORT, V10, P409; Hirooka Y, 2006, HYPERTENS RES, V29, P49, DOI 10.1291/hypres.29.49; Ito H, 2001, J HYPERTENS, V19, P591, DOI 10.1097/00004872-200103001-00011; Kalra D, 2002, CIRCULATION, V105, P2198, DOI 10.1161/01.CIR.0000015603.84788.47; Kario K, 1998, J AM COLL CARDIOL, V32, P444, DOI 10.1016/S0735-1097(98)00251-4; Kim-Mitsuyama S, 2005, STROKE, V36, P1077, DOI 10.1161/01.STR.0000163084.16505.e3; Kumaria A, 2008, BRIT J NEUROSURG, V22, P200, DOI 10.1080/02688690701772413; Landmesser U, 2002, HYPERTENSION, V40, P511, DOI 10.1161/01.HYP.0000032100.23772.98; Landmesser U, 2007, ARTERIOSCL THROM VAS, V27, P943, DOI 10.1161/01.ATV.0000258415.32883.bf; Lin YJ, 2014, BIOCHEM BIOPH RES CO, V451, P263, DOI 10.1016/j.bbrc.2014.07.119; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marques-Lopes J, 2015, SYNAPSE, V69, P148, DOI 10.1002/syn.21800; Matsumoto E, 2013, GENES CELLS, V18, P544, DOI 10.1111/gtc.12055; Mitra AK, 2010, AM J PHYSIOL-CELL PH, V299, pC561, DOI 10.1152/ajpcell.00127.2010; Mollnau H, 2002, CIRC RES, V90, pE58, DOI 10.1161/01.RES.0000012569.55432.02; Ongali B, 2014, NEUROBIOL DIS, V68, P126, DOI 10.1016/j.nbd.2014.04.018; Orfanos SE, 1999, CIRCULATION, V99, P1593, DOI 10.1161/01.CIR.99.12.1593; Oudit GY, 2007, CARDIOVASC RES, V75, P29, DOI 10.1016/j.cardiores.2007.04.007; Patel RK, 2017, BRAIN BEHAV IMMUN, V64, P244, DOI 10.1016/j.bbi.2017.04.012; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Rueckschloss U, 2002, ARTERIOSCL THROM VAS, V22, P1845, DOI 10.1161/01.ATV.0000035392.38687.65; Sadoshima J, 2002, CIRC RES, V90, P754, DOI 10.1161/01.RES.0000016843.82450.8C; Salvador E, 2013, JOVE-J VIS EXP, DOI 10.3791/50928; Sauter NS, 2015, DIABETES, V64, P1273, DOI 10.2337/db14-1282; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SIEGL PKS, 1995, J HYPERTENS, V13, pS15, DOI 10.1097/00004872-199507001-00002; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soares HD, 1995, J NEUROSCI, V15, P8223; Sriramula S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138372; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Timaru-Kast R, 2012, CRIT CARE MED, V40, P935, DOI 10.1097/CCM.0b013e31822f08b9; Villapol S, 2015, BRAIN, V138, DOI 10.1093/brain/awv172; Villapol S, 2012, NEUROPSYCHOPHARMACOL, V37, P2817, DOI 10.1038/npp.2012.152; Wang HD, 2001, CIRC RES, V88, P947, DOI 10.1161/hh0901.089987; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiao L, 2013, AM J PHYSIOL-CELL PH, V304, pC1073, DOI 10.1152/ajpcell.00364.2012; Xu JA, 2010, AM J PHYSIOL-HEART C, V299, pH1328, DOI 10.1152/ajpheart.00538.2010; Xu SQ, 2011, BIOCHEM BIOPH RES CO, V410, P543, DOI 10.1016/j.bbrc.2011.06.021; Xu Y, 2007, MOL PHARMACOL, V72, P112, DOI 10.1124/mol.106.033761; Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127; Zhang M, 2010, NEUROSCIENCE, V171, P852, DOI 10.1016/j.neuroscience.2010.09.029	67	12	12	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JUL	2018	55	7					5901	5912		10.1007/s12035-017-0812-z			12	Neurosciences	Neurosciences & Neurology	GI8VY	WOS:000434805100036	29119534				2021-06-18	
J	Blakey, SM; Wagner, HR; Naylor, J; Brancu, M; Lane, I; Sallee, M; Kimbrel, NA; Elbogen, EB				Blakey, Shannon M.; Wagner, H. Ryan; Naylor, Jennifer; Brancu, Mira; Lane, Ilana; Sallee, Meghann; Kimbrel, Nathan A.; Elbogen, Eric B.		VA Mid-Atlantic MIRECC Workgrp	Chronic Pain, TBI, and PTSD in Military Veterans: A Link to Suicidal Ideation and Violent Impulses?	JOURNAL OF PAIN			English	Article						Chronic Pain; traumatic brain injury; posttraumatic stress disorder; suicide; violence	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; STRUCTURED CLINICAL INTERVIEW; MENTAL-HEALTH PROBLEMS; COMORBID CHRONIC PAIN; ABUSE SCREENING-TEST; RISK-FACTORS; RESIDENTIAL-TREATMENT; AFGHANISTAN VETERANS; ALCOHOL-CONSUMPTION	The polytrauma clinical triad refers to the co-occurrence of chronic pain, traumatic brain injury (TBI), and posttraumatic stress disorder (PTSD). Despite research implicating dyadic relationships between these conditions and adverse outcomes, scant research has examined the polytrauma clinical triad's relation to suicide or violence. The present cross-sectional study was designed to examine whether this complex clinical presentation increases risk of suicidal ideation and violent impulses after accounting for other established risk factors. Veterans who served in the military since September 11, 2001 (N = 667) who reported chronic pain completed an interview and self-report battery. Bivariate analyses showed that suicidal ideation and violent impulses both correlated with PTSD, TBI+PTSD, pain intensity and interference, drug abuse, and major depressive disorder (MDD). Multiple regression analyses showed that: 1) race, chronic pain with PTSD, alcohol abuse, and MDD significantly predicted suicidal ideation, 2) pain interference, chronic pain with TBI, chronic pain with PTSD, chronic pain with TBI+PTSD, drug abuse, and MDD significantly predicted violent impulses, and 3) pain interference was a more critical predictor of suicidal and violent ideation than pain intensity. Implications for risk assessment and treatment are discussed. Perspective: This article presents results from a study examining predictors of suicide and violence risk among a sample of post-9/11 U.S. Veterans with chronic pain. Health care professionals should assess for pain interference, TB!, PTSD, depression, and alcohol/drug abuse when conducting risk assessments with this population. (C) 2018 by the American Pain Society	[Blakey, Shannon M.] Univ North Carolina Chapel Hill, Dept Psychol & Neurosci, Davie Hall CB 3270, Chapel Hill, NC 27599 USA; [Wagner, H. Ryan; Naylor, Jennifer; Brancu, Mira; Kimbrel, Nathan A.; Elbogen, Eric B.] Mental Illness Res Educ & Clin Ctr, Vet Affairs Midatlantic, Durham, NC USA; [Wagner, H. Ryan; Naylor, Jennifer; Brancu, Mira; Lane, Ilana; Sallee, Meghann; Kimbrel, Nathan A.; Elbogen, Eric B.] Durham VA Med Ctr, Durham, NC USA; [Wagner, H. Ryan; Naylor, Jennifer; Brancu, Mira; Kimbrel, Nathan A.; Elbogen, Eric B.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA	Blakey, SM (corresponding author), Univ North Carolina Chapel Hill, Dept Psychol & Neurosci, Davie Hall CB 3270, Chapel Hill, NC 27599 USA.	sblakey@unc.edu		Blakey, Shannon/0000-0002-9291-3688	VA Mid-Atlantic Mental Illness Research, Education and Clinical Center; National Center for Complementary and Integrative Health [R34 AT008399-01]; Department of Veterans Affairs Rehabilitation Research and Development Career Development AwardUS Department of Veterans Affairs [1IK2RX000908]; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R34AT008399] Funding Source: NIH RePORTER	Preparation of this report was supported by the VA Mid-Atlantic Mental Illness Research, Education and Clinical Center and a grant from National Center for Complementary and Integrative Health (R34 AT008399-01). Dr. Naylor was funded by a Department of Veterans Affairs Rehabilitation Research and Development Career Development Award (1IK2RX000908).	Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930; Babor TF, 2001, MONTEIRO MG ALCOHOL; Bahraini NH, 2014, PSYCHIAT CLIN N AM, V37, P55, DOI 10.1016/j.psc.2013.11.002; Beck A.T., 1991, MANUAL BECK SCALE SU; Beck AT., 1996, BECK DEPRESSION INVE, V2; Bohnert ASB, 2014, CLIN J PAIN, V30, P605, DOI 10.1097/AJP.0000000000000011; BONGAR B, 1992, SUICIDE GUIDELINES A; Bradley KA, 1998, ALCOHOL CLIN EXP RES, V22, P1842, DOI 10.1097/00000374-199811000-00034; Brancu M, 2017, INT J METH PSYCH RES, V26, DOI 10.1002/mpr.1570; Brenner LA, 2011, SUICIDE LIFE-THREAT, V41, P416, DOI 10.1111/j.1943-278X.2011.00041.x; Brown GK, 2000, J CONSULT CLIN PSYCH, V68, P371, DOI 10.1037/0022-006X.68.3.371; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Buckenmaier CC, 2013, PAIN MED, V14, P110, DOI 10.1111/j.1526-4637.2012.01516.x; Calati R, 2015, J PSYCHIATR RES, V71, P16, DOI 10.1016/j.jpsychires.2015.09.004; Caldeiro RM, 2008, ADDICTION, V103, P1996, DOI 10.1111/j.1360-0443.2008.02358.x; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; Cleeland C.S., 1991, EFFECT CANC QUALITY, P293; Cochrane-Brink KA, 2000, GEN HOSP PSYCHIAT, V22, P445, DOI 10.1016/S0163-8343(00)00106-7; Cuijpers P, 2014, AM J PSYCHIAT, V171, P453, DOI 10.1176/appi.ajp.2013.13030325; Derogatis L.R, 1994, SYMPTOM CHECKLIST 90; Duchnick JJ, 2015, PSYCHOL SERV, V12, P313, DOI 10.1037/ser0000034; Elbogen EB, 2018, PSYCHOL ASSESSMENT, V30, P425, DOI 10.1037/pas0000490; Fazel S, 2015, LANCET PSYCHIAT, V2, P224, DOI 10.1016/S2215-0366(14)00128-X; Finkel EJ, 2014, ADV EXP SOC PSYCHOL, V49, P1, DOI 10.1016/B978-0-12-800052-6.00001-9; Finley EP, 2015, AM J PUBLIC HEALTH, V105, P380, DOI 10.2105/AJPH.2014.301957; Fishbain DA, 2009, PAIN MED, V10, P573, DOI 10.1111/j.1526-4637.2009.00606.x; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Gradus JL, 2015, J TRAUMA STRESS, V28, P361, DOI 10.1002/jts.22021; Guerra VS, 2011, J ANXIETY DISORD, V25, P12, DOI 10.1016/j.janxdis.2010.06.025; Heilbrun K, 2010, INT PERSP FOREN MENT, P1; Helmer DA, 2009, PAIN MED, V10, P1174, DOI 10.1111/j.1526-4637.2009.00723.x; Higgins DM, 2014, PAIN MED, V15, P782, DOI 10.1111/pme.12388; Howe CQ, 2014, GEN HOSP PSYCHIAT, V36, P99, DOI 10.1016/j.genhosppsych.2013.10.003; Ilgen MA, 2013, JAMA PSYCHIAT, V70, P692, DOI 10.1001/jamapsychiatry.2013.908; Ilgen MA, 2010, SUICIDE LIFE-THREAT, V40, P597, DOI 10.1521/suli.2010.40.6.597; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Jakupcak M, 2007, J TRAUMA STRESS, V20, P945, DOI 10.1002/jts.20258; Joiner T. E., 2005, WHY PEOPLE DIE SUICI; Kanzler KE, 2012, PAIN PRACT, V12, P602, DOI 10.1111/j.1533-2500.2012.00542.x; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelley ML, 2013, DRUG ALCOHOL DEPEN, V133, P615, DOI 10.1016/j.drugalcdep.2013.08.002; Kerns RD, 2003, J REHABIL RES DEV, V40, P371, DOI 10.1682/JRRD.2003.09.0371; Kessler RC, 1999, ARCH GEN PSYCHIAT, V56, P617, DOI 10.1001/archpsyc.56.7.617; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Maguen S, 2012, J REHABIL RES DEV, V49, P1115, DOI 10.1682/JRRD.2011.02.0015; Marshall AD, 2005, CLIN PSYCHOL REV, V25, P862, DOI 10.1016/j.cpr.2005.05.009; Martell C. R., 2010, BEHAV ACTIVATION DEP; Mosher HJ, 2015, J GEN INTERN MED, V30, P597, DOI 10.1007/s11606-014-3143-z; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nock MK, 2008, BRIT J PSYCHIAT, V192, P98, DOI 10.1192/bjp.bp.107.040113; O'Mahony S, 2005, J PAIN SYMPTOM MANAG, V29, P446, DOI 10.1016/j.jpainsymman.2004.08.010; Otis JD, 2011, J CLIN PSYCHOL MED S, V18, P145, DOI 10.1007/s10880-011-9239-2; Otis JD, 2009, PAIN MED, V10, P1300, DOI 10.1111/j.1526-4637.2009.00715.x; Pietrzak RH, 2011, J PSYCHIATR RES, V45, P720, DOI 10.1016/j.jpsychires.2010.11.015; Placidi GPA, 2001, BIOL PSYCHIAT, V50, P783, DOI 10.1016/S0006-3223(01)01170-2; Plagge JM, 2013, PAIN MED, V14, P1164, DOI 10.1111/pme.12155; Pompili M, 2013, J NERV MENT DIS, V201, P802, DOI 10.1097/NMD.0b013e3182a21458; Pugh MJ, 2016, BRAIN INJURY, V30, P1481, DOI 10.1080/02699052.2016.1219055; Rao V, 2009, J NEUROPSYCH CLIN N, V21, P420, DOI 10.1176/appi.neuropsych.21.4.420; Rogers RG, 2001, HDB DIAGNOSTIC STRUC, P103; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Runnals JJ, 2013, PAIN MED, V14, P1529, DOI 10.1111/pme.12208; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schry AR, 2015, PSYCHOL SERV, V12, P384, DOI 10.1037/ser0000053; Shipherd JC, 2007, J REHABIL RES DEV, V44, P153, DOI 10.1682/JRRD.2006.06.0065; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; SUMMERS JD, 1991, PAIN, V47, P183, DOI 10.1016/0304-3959(91)90203-A; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Vasterling JJ, 2018, J NEUROPSYCH CLIN N, V30, P91, DOI 10.1176/appi.neuropsych.17090180; Walter KH, 2012, REHABIL PSYCHOL, V57, P13, DOI 10.1037/a0026254; Watkins LE, 2017, J PSYCHIATR RES, V87, P8, DOI 10.1016/j.jpsychires.2016.12.009; Wilder CM, 2016, J ADDICT DIS, V35, P42, DOI 10.1080/10550887.2016.1107264; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; Wisco BE, 2014, J TRAUMA STRESS, V27, P244, DOI 10.1002/jts.21900; Wolf GK, 2012, J HEAD TRAUMA REHAB, V27, P26, DOI 10.1097/HTR.0b013e31823cd01f; Wortzel HS, 2013, J AM ACAD PSYCHIATRY, V41, P274; Yu W, 2003, MED CARE RES REV, V60, p146S, DOI 10.1177/1077558703257000; Yudko E, 2007, J SUBST ABUSE TREAT, V32, P189, DOI 10.1016/j.jsat.2006.08.002	82	12	14	0	8	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	JUL	2018	19	7					797	806		10.1016/j.jpain.2018.02.012			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	GM3JD	WOS:000438000000009	29526669	Green Accepted			2021-06-18	
J	Deane, AM; Lamontagne, F; Dukes, GE; Neil, D; Vasist, L; Barton, ME; Hacquoil, K; Ou, XL; Richards, D; Stelfox, HT; Mehta, S; Day, AG; Chapman, MJ; Heyland, DK				Deane, Adam M.; Lamontagne, Francois; Dukes, George E.; Neil, David; Vasist, Lakshmi; Barton, Matthew E.; Hacquoil, Kimberley; Ou, Xiaoling; Richards, Duncan; Stelfox, Henry T.; Mehta, Sangeeta; Day, Andrew G.; Chapman, Marianne J.; Heyland, Daren K.			Nutrition Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double-Blind, Placebo-Controlled Trial of the Motilin Receptor Agonist Camicinal (GSK962040): The NUTRIATE Study	JOURNAL OF PARENTERAL AND ENTERAL NUTRITION			English	Article						Critical illness; enteral nutrition; gastrointestinal agent; gastrointestinal diseases; motilin	INTENSIVE-CARE PATIENTS; ENTERAL NUTRITION; FEED INTOLERANCE; CRITICAL ILLNESS; GASTROINTESTINAL DYSMOTILITY; ERYTHROMYCIN; METOCLOPRAMIDE; PROVISION; PROTEIN; ENERGY	BackgroundCamicinal is a novel, nonmacrolide, motilin receptor agonist that accelerates gastric emptying in critically ill patients with established feed intolerance. The primary question was whether the preemptive administration of camicinal increased the provision of enteral nutrition (EN) to critically ill patients with risk factors that predisposed to feed intolerance. MethodsThis was an international, multicenter, parallel-group, blinded, randomized controlled trial. Patients at risk for feed intolerance, defined as receiving moderate to high doses of vasopressors or opiates, or admitted because of multiple traumatic injuries or with brain injury, received either enteral camicinal 50 mg or placebo daily for a maximum of 7 days, along with EN administered according to a standardized feeding protocol. The primary outcome was the daily adequacy of enteral feed delivered, as assessed by percentage of goal volume (delivered/prescribed x 100) before development of intolerance. ResultsEighty-four patients participated. The administration of camicinal did not result in a statistically significant clinical difference in the daily average percentage goal volume delivered (camicinal vs placebo: 77% [95% confidence interval: 71, 83] vs 68% (58, 78); mean difference 9% [-5, 23]; P = 0.21). Similarly, there were no differences in the percentage goal calories (76% [65, 88] vs 68% [60, 77]) and protein (76% [66, 86] vs 70% [61, 80]) administered, or the incidence of feed intolerance (15% vs 14%). ConclusionThe incidence of feed intolerance was low in both groups. In this cohort the preemptive administration of enteral camicinal did not significantly augment the provision of goal EN.	[Deane, Adam M.; Chapman, Marianne J.] Royal Adelaide Hosp, Dept Crit Care Serv, Adelaide, SA, Australia; [Deane, Adam M.; Chapman, Marianne J.] Univ Adelaide, Discipline Acute Care Med, Adelaide, SA, Australia; [Deane, Adam M.] Royal Melbourne Hosp, Intens Care Unit, Melbourne, Vic, Australia; [Lamontagne, Francois] Univ Sherbrooke, Dept Med, Sherbrooke, PQ, Canada; [Lamontagne, Francois] Ctr Hosp Univ Sherbrooke, Sherbrooke, PQ, Canada; [Dukes, George E.; Neil, David; Vasist, Lakshmi; Barton, Matthew E.] GlaxoSmithKline R&D, Res Triangle Pk, NC USA; [Barton, Matthew E.] Mallinckrodt Pharmaceut Inc, Hampton, NJ USA; [Hacquoil, Kimberley] GlaxoSmithKline R&D, Stevenage, Herts, England; [Ou, Xiaoling] Phastar, Chiswick, England; [Richards, Duncan] GlaxoSmithKline R&D, Cambridge, England; [Stelfox, Henry T.] Univ Calgary, OBrien Inst Publ Hlth, Dept Crit Care Med, Calgary, AB, Canada; [Stelfox, Henry T.] Univ Calgary, OBrien Inst Publ Hlth, Dept Med, Calgary, AB, Canada; [Stelfox, Henry T.] Univ Calgary, OBrien Inst Publ Hlth, Dept Community Hlth Sci, Calgary, AB, Canada; [Mehta, Sangeeta] Sinai Hlth Syst, Div Crit Care Med, Dept Med, Toronto, ON, Canada; [Mehta, Sangeeta] Sinai Hlth Syst, Div Crit Care Med, Interdept, Toronto, ON, Canada; [Mehta, Sangeeta] Univ Toronto, Toronto, ON, Canada; [Day, Andrew G.; Heyland, Daren K.] Kingston Gen Hosp, Clin Evaluat Res Unit, Kingston, ON, Canada; [Heyland, Daren K.] Queens Univ, Dept Crit Care Med, Kingston, ON, Canada	Heyland, DK (corresponding author), Kingston Gen Hosp, Clin Evaluat Res Unit, Kingston, ON, Canada.	dkh2@queensu.ca	Mehta, Sangeeta/C-4623-2015; Deane, Adam/AAF-7370-2020	Deane, Adam/0000-0002-7620-5577; Stelfox, Henry/0000-0003-1231-1490; Richards, Duncan/0000-0002-8093-7084			Alberda C, 2009, INTENS CARE MED, V35, P1728, DOI 10.1007/s00134-009-1567-4; Allingstrup MJ, 2012, CLIN NUTR, V31, P462, DOI 10.1016/j.clnu.2011.12.006; Berne JD, 2002, J TRAUMA, V53, P422, DOI 10.1097/00005373-200209000-00004; Blaser AR, 2015, CLIN NUTR, V34, P956, DOI 10.1016/j.clnu.2014.10.006; Cahill NE, 2010, CRIT CARE MED, V38, P395, DOI 10.1097/CCM.0b013e3181c0263d; Chapman MJ, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1420-4; Chapman MJ, 2013, CURR OPIN CLIN NUTR, V16, P209, DOI 10.1097/MCO.0b013e32835c1fa5; Deane A, 2010, CRIT CARE, V14, DOI 10.1186/cc9039; Deane AM, 2014, CRIT CARE MED, V42, P57, DOI 10.1097/CCM.0b013e318298a8af; Deane AM, 2012, AM J CLIN NUTR, V95, P1396, DOI 10.3945/ajcn.112.035691; Deane AM, 2009, CRIT CARE RESUSC, V11, P180; Deane AM, 2009, CRIT CARE RESUSC, V11, P132; DIVE A, 1995, CRIT CARE MED, V23, P1356, DOI 10.1097/00003246-199508000-00008; Fruhwald S, 2007, INTENS CARE MED, V33, P36, DOI 10.1007/s00134-006-0452-7; Gungabissoon U, 2015, JPEN-PARENTER ENTER, V39, P441, DOI 10.1177/0148607114526450; Herbert MK, 2008, CLIN NUTR, V27, P25, DOI 10.1016/j.clnu.2007.08.001; Heyland D, 2013, NEW ENGL J MED, V368, P1489, DOI 10.1056/NEJMoa1212722; Heyland DK, 2013, CRIT CARE MED, V41, P2743, DOI 10.1097/CCM.0b013e31829efef5; Heyland DK, 2011, CRIT CARE MED, V39, P2619, DOI 10.1097/CCM.0b013e318226641d; Heyland DK, 2011, CLIN NUTR, V30, P148, DOI 10.1016/j.clnu.2010.09.011; Heyland DK, 2010, JPEN-PARENTER ENTER, V34, P675, DOI 10.1177/0148607110364843; JANSSENS J, 1990, NEW ENGL J MED, V322, P1028, DOI 10.1056/NEJM199004123221502; Kar P, 2015, CLIN NUTR, V34, P557, DOI 10.1016/j.clnu.2014.11.003; MacLaren R, 2008, JPEN-PARENTER ENTER, V32, P412, DOI 10.1177/0148607108319803; McClave SA, 2016, JPEN-PARENTER ENTER, V40, P159, DOI 10.1177/0148607115621863; Nguyen NQ, 2007, CRIT CARE MED, V35, P483, DOI 10.1097/01.CCM.0000253410.36492.E9; Reignier J, 2002, CRIT CARE MED, V30, P1237, DOI 10.1097/00003246-200206000-00012; Ritz MA, 2005, INTENS CARE MED, V31, P949, DOI 10.1007/s00134-005-2663-8; Stupak DP, 2012, J CLIN GASTROENTEROL, V46, P449, DOI 10.1097/MCG.0b013e31824e14c1; van Zanten ARH, 2015, JPEN-PARENTER ENTER, V39, P763, DOI 10.1177/0148607114567711; Wei XJ, 2015, CRIT CARE MED, V43, P1569, DOI 10.1097/CCM.0000000000001000; Weijs PJM, 2012, JPEN-PARENTER ENTER, V36, P60, DOI 10.1177/0148607111415109	32	12	12	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0148-6071	1941-2444		JPEN-PARENTER ENTER	J. Parenter. Enter. Nutr.	JUL	2018	42	5					949	959		10.1002/jpen.1038			11	Nutrition & Dietetics	Nutrition & Dietetics	GM7GD	WOS:000438348900016	29957868				2021-06-18	
J	Derakhshanrad, N; Saberi, H; Yekaninejad, MS; Joghataei, MT; Sheikhrezaei, A				Derakhshanrad, Nazi; Saberi, Hooshang; Yekaninejad, Mir Saeed; Joghataei, Mohammad Taghi; Sheikhrezaei, Abdolreza			Granulocyte-colony stimulating factor administration for neurological improvement in patients with postrehabilitation chronic incomplete traumatic spinal cord injuries: a double-blind randomized controlled clinical trial	JOURNAL OF NEUROSURGERY-SPINE			English	Article						spinal cord injury; granulocyte-colony stimulating factor; neurological improvement	INDEPENDENCE MEASURE; CEREBRAL-ISCHEMIA; ICCP PANEL; CELLS; EXPRESSION; THERAPY; RATS; TRANSPLANTATION; MOBILIZATION; GUIDELINES	OBJECTIVE Granulocyte-colony stimulating factor (G-CSF) is a major growth factor for activation and differentiation of granulocyte colonies in the bone marrow. This cytokine has been widely and safely employed in different conditions over many years. The purpose of this study was to investigate the efficacy of G-CSF administration for traumatic spinal cord injury (TSCI). METHODS This double-blind parallel randomized, placebo-controlled, clinical trial, a phase III study, was performed from June 2013 to June 2016 in the Brain and Spinal Cord Injury Research (BASIR) center at Tehran University of Medical Sciences (TUMS). It included 120 patients with incomplete chronic TSCI, American Spinal Injury Association (ASIA) Impairment Scale (AIS) B, C, or D, of at least 6 months' duration. Sixty patients were allocated into the treatment group and 60 patients into the control group. All the patients had completed an outpatient rehabilitation program in the post-acute period and were in a neurological and functional plateau. Patients were assessed with the ASIA grading system, the Spinal Cord Independence Measure (SCIM-III), and the International Association of Neurorestoratology-Spinal Cord Injury Functional Rating Scale (IANR-SCIFRS) just before intervention and at 1, 3, and 6 months after 7 subcutaneous administrations of 300 mu g/day of G-CSF in the treatment group and placebo in the control group (administered once per day over the course of 1 week). Randomization was performed with randomized block design, and the patients and evaluators were blinded regarding the treatment groups. One patient did not receive the entire allocated intervention and 5 patients were lost to follow-up. Thus data from 114 patients were included in the analysis. RESULTS One hundred twenty patients were randomized and allocated into the study groups. Among them, 56 patients (93.3%) in the G-CSF group and 58 patients (96.6%) in the placebo group completed the study protocol. After 6 months of follow-up, AIS in the placebo group remained unchanged, whereas in the G-CSF group, 1 patient improved from AIS B to C, and 4 patients improved from AIS C to D. The mean (+/- SE) improvement in ASIA motor score in the G-CSF group was 5.5 +/- 0.62, which was significantly more than in the placebo group (0.77 +/- 0.20) (p < 0.001). The mean light touch and pinprick sensory scores, respectively, increased by 6.1 +/- 1.1 and 8.7 +/- 1.5 in the G-CSF group and by 1.3 +/- 0.52 and 0.89 +/- 0.44 scores in the placebo group (p < 0.001). Evaluation of functional improvement by the IANR-SCIFRS instrument revealed significantly more improvement in the G-CSF group (3.5 +/- 0.37) than in the placebo group 0.41 +/- 0.12) (p < 0.001). Also, a significant difference was observed in functional improvement between the 2 groups as measured by SCIM-III instrument (7.5 +/- 0.95 vs 2.1 +/- 0.51, p < 0.001). CONCLUSIONS Administration of G-CSF for incomplete chronic spinal cord injuries is associated with significant motor, sensory, and functional improvement.	[Derakhshanrad, Nazi; Saberi, Hooshang] Univ Tehran Med Sci, Imam Khomeini Hosp, Neurosci Inst, Brain & Spinal Cord Injury Res Ctr BASIR, Tehran, Iran; [Saberi, Hooshang; Sheikhrezaei, Abdolreza] Univ Tehran Med Sci, Imam Khomeini Hosp, Dept Neurosurg, Tehran, Iran; [Yekaninejad, Mir Saeed] Univ Tehran Med Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Tehran, Iran; [Joghataei, Mohammad Taghi] Iran Univ Med Sci, Sch Adv Technol Med, Cellular & Mol Res Ctr, Tehran, Iran; [Joghataei, Mohammad Taghi] Iran Univ Med Sci, Sch Adv Technol Med, Neurosci Dept, Tehran, Iran; Imam Hosp, Res Ctr BASIR, Brain & Spinal Cord Injury, Tehran, Iran	Saberi, H (corresponding author), Imam Hosp, Res Ctr BASIR, Brain & Spinal Cord Injury, Tehran, Iran.	hgsaberi@yahoo.com	Yekaninejad, Mir Saeed/L-6752-2016	Yekaninejad, Mir Saeed/0000-0003-3648-5276			Ackerman P, 2010, SPINAL CORD, V48, P380, DOI 10.1038/sc.2009.140; Aidinoff E, 2011, SPINAL CORD, V49, P893, DOI 10.1038/sc.2011.32; Anderlini P, 1996, TRANSFUSION, V36, P590, DOI 10.1046/j.1537-2995.1996.36796323057.x; Becker P S, 1997, Biol Blood Marrow Transplant, V3, P45; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Bryukhovetskiy Andrey S, 2015, World J Transplant, V5, P110, DOI 10.5500/wjt.v5.i3.110; Chung J, 2014, J NEUROSURG-SPINE, V21, P966, DOI 10.3171/2014.8.SPINE131090; Derakhshanrad N, 2016, SPINAL CORD, V54, P901, DOI 10.1038/sc.2016.10; Derakhshanrad N, 2015, SPINAL CORD, V53, P860, DOI 10.1038/sc.2015.136; Derakhshanrad N, 2015, BASIC CLIN NEUROSCI, V6, P299; Derakhshanrad N, 2013, CELL TRANSPLANT, V22, pS139, DOI 10.3727/096368913X672109; Dittgen T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029880; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Gibson CL, 2005, J NEUROPATH EXP NEUR, V64, P763, DOI 10.1097/01.jnen.0000179196.10032.dd; Guest J, 2012, J NEUROSURG-SPINE, V17, P94, DOI 10.3171/2012.5.AOSPINE1289; Guo XH, 2012, INT J NEUROSCI, V122, P723, DOI 10.3109/00207454.2012.716109; Guo YJ, 2014, J NEUROSCI RES, V92, P751, DOI 10.1002/jnr.23362; Harrop JS, 2012, J NEUROSURG-SPINE, V17, P230, DOI 10.3171/2012.5.AOSPINE12115; Huang HY, 2012, CELL TRANSPLANT, V21, pS23, DOI 10.3727/096368912X633734; Hyun JK, 2010, J TISSUE ENG, V1, DOI 10.4061/2010/650857; Inada T, 2014, SPINE, V39, P213, DOI 10.1097/BRS.0000000000000121; Itzkovich M, 2007, DISABIL REHABIL, V29, P1926, DOI 10.1080/09638280601046302; Kadota R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050391; Kawabe J, 2011, J NEUROSURG-SPINE, V15, P414, DOI 10.3171/2011.5.SPINE10421; Kirshblum SC, 2011, J SPINAL CORD MED, V34, P547, DOI 10.1179/107902611X13186000420242; Koda M, 2007, BRAIN RES, V1149, P223, DOI 10.1016/j.brainres.2007.02.058; NAGATA S, 1986, NATURE, V319, P415, DOI 10.1038/319415a0; NICOLA NA, 1983, J BIOL CHEM, V258, P9017; Pannu R, 2005, J NEUROSCI RES, V79, P340, DOI 10.1002/jnr.20345; Pitzer C, 2010, J NEUROCHEM, V113, P930, DOI 10.1111/j.1471-4159.2010.06659.x; Ringelstein EB, 2013, STROKE, V44, P2681, DOI 10.1161/STROKEAHA.113.001531; Saberi H, 2014, CELL TRANSPLANT, V23, pS19, DOI 10.3727/096368914X684943; Saberi H, 2011, J NEUROSURG-SPINE, V15, P515, DOI 10.3171/2011.6.SPINE10917; Sakuma T, 2012, SPINE, V37, P1475, DOI 10.1097/BRS.0b013e318260cc71; Sakuma T, 2012, EUR SPINE J, V21, P482, DOI 10.1007/s00586-011-2020-2; Salzberg CA, 1996, AM J PHYS MED REHAB, V75, P96, DOI 10.1097/00002060-199603000-00004; Schabitz WR, 2003, STROKE, V34, P745, DOI 10.1161/01.STR.0000057814.70180.17; Schneider A, 2005, CELL CYCLE, V4, P1753, DOI 10.4161/cc.4.12.2213; Takahashi H, 2012, EUR SPINE J, V21, P2580, DOI 10.1007/s00586-012-2213-3; Tuszynski MH, 2007, SPINAL CORD, V45, P222, DOI 10.1038/sj.sc.3102009	40	12	12	1	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	JUL	2018	29	1					97	107		10.3171/2017.11.SPINE17769			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GO5CK	WOS:000440035400015	29701561	Bronze			2021-06-18	
J	Lennon, A; Hugentobler, JA; Sroka, MC; Nissen, KS; Kurowski, BG; Gagnon, I; Quatman-Yates, CC				Lennon, Anne; Hugentobler, Jason A.; Sroka, Mary Claire; Nissen, Katharine S.; Kurowski, Brad G.; Gagnon, Isabelle; Quatman-Yates, Catherine C.			An Exploration of the Impact of Initial Timing of Physical Therapy on Safety and Outcomes After Concussion in Adolescents	JOURNAL OF NEUROLOGIC PHYSICAL THERAPY			English	Article						concussion; human movement system; physical therapy; rehabilitation; timing	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; RANDOMIZED CONTROLLED-TRIAL; POSTCONCUSSION SYNDROME; CERVICOVESTIBULAR REHABILITATION; VESTIBULAR REHABILITATION; ACTIVE REHABILITATION; SYMPTOMS; CHILDREN; REST	Background and Purpose: Physical therapy (PT) is a management strategy increasingly recognized to facilitate recovery after concussion. The purpose of this study was to investigate the safety and outcomes of multimodal impairment-based PT at varying time points after injury in youth diagnosed with concussion. Methods: Data were extracted retrospectively from medical records for patients who received PT for concussion-related impairments. Patient records were categorized into 3 cohorts on the basis of the timing of PT implementation: 0-20 days following injury (early intervention), 21 to 41 days following injury (middle intervention), and 42 or more days following injury (late intervention). The primary outcome measure was Post-Concussion Symptom Inventory score from the beginning to the end of the PT episode of care. Additional outcome measures included number of PT sessions, duration of PT episode of care (days), and occurrence of unplanned visits to a health care provider. Results: A total of 120 patient records (mean age of 14.77 years) were analyzed. Thirty-three, 39, and 48 individuals were categorized into the early, middle, and late intervention cohorts, respectively. There were no significant differences between intervention cohorts with regard to symptom change on the Post-Concussion Symptom Inventory from the beginning to the end of the PT episode of care, unplanned health care visits, number of PT sessions, or duration of PT episode of care. Discussion and Conclusions: Early initiation of PT may be safe and tolerable. Future prospective studies are needed to explore the efficacy of PT services administered early following injury to help characterize an optimal care plan for youth following concussion. Video Abstract available for more insights from the authors (see Supplemental Digital Content 1, available at: http://links.lww.com/JNPT/A210).	[Lennon, Anne; Hugentobler, Jason A.; Sroka, Mary Claire; Nissen, Katharine S.; Quatman-Yates, Catherine C.] Cincinnati Childrens Hosp Med Ctr, Div Occupat & Phys Therapy, Cincinnati, OH 45229 USA; [Hugentobler, Jason A.; Sroka, Mary Claire; Quatman-Yates, Catherine C.] Cincinnati Childrens Hosp Med Ctr, Div Sports Med, Cincinnati, OH 45229 USA; [Kurowski, Brad G.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Kurowski, Brad G.] Univ Cincinnati, Coll Med, Dept Pediat & Neurol & Rehabil Med, Cincinnati, OH USA; [Gagnon, Isabelle] McGill Univ, Hlth Ctr, Montreal Childrens Hosp, Montreal, PQ, Canada; [Quatman-Yates, Catherine C.] Ohio State Univ, Div Phys Therapy, 453 W 10th Ave,516 H Atwell Hall, Columbus, OH 43210 USA	Quatman-Yates, CC (corresponding author), Ohio State Univ, Div Phys Therapy, 453 W 10th Ave,516 H Atwell Hall, Columbus, OH 43210 USA.	catherine.quatman@osumc.edu	Quatman-Yates, Catherine/AAK-4507-2021; Quatman-Yates, Catherine/U-9580-2019		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [KL2 TR001426-01]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR001426] Funding Source: NIH RePORTER	Aspects of this work were funded in part by a National Institutes of Health KL2 TR001426-01.	Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Barlow KM, 2015, PEDIATR NEUROL, V53, P491, DOI 10.1016/j.pediatrneurol.2015.04.011; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Basso DM, 2017, J NEUROL PHYS THER, V41, pS24, DOI 10.1097/NPT.0000000000000165; Childs JD, 2008, J ORTHOP SPORT PHYS, V38, pA1, DOI 10.2519/jospt.2008.0303; DiFazio M, 2016, CLIN PEDIATR, V55, P443, DOI 10.1177/0009922815589914; Dobney DM, 2018, J HEAD TRAUMA REHAB, V33, pE11, DOI 10.1097/HTR.0000000000000339; Ellis MJ, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00136; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Gagnon I, 2016, SCAND J MED SCI SPOR, V26, P299, DOI 10.1111/sms.12441; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Grabowski P, 2017, PHYS THER SPORT, V23, P22, DOI 10.1016/j.ptsp.2016.06.001; Grool AM, 2016, JAMA-J AM MED ASSOC, V316, P2504, DOI 10.1001/jama.2016.17396; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hoenig JM, 2001, AM STAT, V55, P19, DOI 10.1198/000313001300339897; Hugentobler JA, 2015, INT J SPORTS PHYS TH, V10, P676; Kurowski BG, 2017, J HEAD TRAUMA REHAB, V32, P79, DOI 10.1097/HTR.0000000000000238; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; McCarthy MT, 2015, ANN NY ACAD SCI, V1345, P89, DOI 10.1111/nyas.12736; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Page P, 2011, INT J SPORTS PHYS TH, V6, P254; Quatman-Yates C, 2016, PHYS THER, V96, P1753, DOI 10.2522/ptj.20150557; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Schneider KJ, 2018, BRIT J SPORT MED, V52, P100, DOI 10.1136/bjsports-2017-098667; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; SCHNEIDER KJ, 2017, BRIT J SPORT MED, V0051; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Stein CJ, 2016, CLIN J SPORT MED, V26, P386, DOI 10.1097/JSM.0000000000000268; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986	37	12	12	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1557-0576	1557-0584		J NEUROL PHYS THER	J. Neurol. Phys. Ther.	JUL	2018	42	3			SI		123	131		10.1097/NPT.0000000000000227			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	GL1OM	WOS:000436873100002	29846269	Green Accepted			2021-06-18	
J	McCredie, VA; Alali, AS; Scales, DC; Rubenfeld, GD; Cuthbertson, BH; Nathens, AB				McCredie, Victoria A.; Alali, Aziz S.; Scales, Damon C.; Rubenfeld, Gordon D.; Cuthbertson, Brian H.; Nathens, Avery B.			Impact of ICU Structure and Processes of Care on Outcomes After Severe Traumatic Brain Injury: A Multicenter Cohort Study	CRITICAL CARE MEDICINE			English	Article						clinical protocols; delivery of healthcare; intensive care unit structure; neurocritical care; process of care; traumatic brain injury	SPECIALIST NEUROCRITICAL CARE; AMERICAN-COLLEGE; MORTALITY; EPIDEMIOLOGY; MANAGEMENT; WITHDRAWAL; UNITS; RISK	Objectives: It is uncertain whether dedicated neurocritical care units are associated with improved outcomes for critically ill neurologically injured patients in the era of collaborative protocol-driven care. We examined the association between dedicated neurocritical care units and mortality and the effects of standardized management protocols for severe traumatic brain injury. Design: We surveyed trauma medical directors from centers participating in the American College of Surgeons Trauma Quality Improvement Program to obtain information about ICU structure and processes of care. Survey data were then linked to the Trauma Quality Improvement Program registry, and random-intercept hier-archical multivariable modeling was used to evaluate the association between dedicated neurocritical care units, the presence of standardized management protocols and mortality. Setting: Trauma centers in North America participating in Trauma Quality Improvement Program. Patients: Data were analyzed from 9,773 adult patients with isolated severe traumatic brain injury admitted to 134 Trauma Quality Improvement Program centers between 2011 and 2013. Interventions: None. Measurements and Main Results: Only 50 ICUs (37%) were dedicated neurocritical care units, whereas 84 (63%) were general ICUs. Rates of standardized management protocols were similar comparing dedicated neurocritical care units and general ICUs. Among severe TBI patients admitted to trauma centers enrolled in Trauma Quality Improvement Program, care in a dedicated neurocritical care unit did not improve risk-adjusted in-hospital survival (odds ratio, 0.97; 95% CI, 0.80-1.19; p = 0.79). However, the presence of a standardized management protocol for these patients was associated with lower risk-adjusted in-hospital mortality (odds ratio, 0.77; 95% CI, 0.63-0.93; p = 0.009). Conclusions: Compared with dedicated neurocritical care models, standardized management protocols for severe traumatic brain injured patients are process-targeted intervention strategies that may improve clinical outcomes.	[McCredie, Victoria A.; Alali, Aziz S.; Scales, Damon C.; Rubenfeld, Gordon D.; Cuthbertson, Brian H.] Univ Toronto, Interdept Div Crit Care Med, Dept Med, Toronto, ON, Canada; [McCredie, Victoria A.] Univ Hlth Network, Div Crit Care Med, Dept Med, Toronto, ON, Canada; [McCredie, Victoria A.; Scales, Damon C.; Nathens, Avery B.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Scales, Damon C.; Rubenfeld, Gordon D.; Cuthbertson, Brian H.] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON, Canada; [Cuthbertson, Brian H.] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada; [Nathens, Avery B.] Sunnybrook Hlth Sci Ctr, Dept Surg, Toronto, ON, Canada; [Nathens, Avery B.] Univ Toronto, Toronto, ON, Canada	McCredie, VA (corresponding author), Univ Toronto, Interdept Div Crit Care Med, Dept Med, Toronto, ON, Canada.; McCredie, VA (corresponding author), Univ Hlth Network, Div Crit Care Med, Dept Med, Toronto, ON, Canada.	Victoria.McCredie@uhn.ca			de Souza Chair in Trauma Research	Supported, in part, by a de Souza Chair in Trauma Research.	Alali AS, 2017, J NEUROTRAUM, V34, P2760, DOI 10.1089/neu.2017.4997; Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802; American College of : Surgeons Committee on Trauma, 2007, RES OPT CAR INJ PAT; Austin PC, 2010, INT J BIOSTAT, V6, DOI 10.2202/1557-4679.1195; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Burns KEA, 2008, CAN MED ASSOC J, V179, P245, DOI 10.1503/cmaj.080372; Canadian Institutes of Health Research Natural Sciences and Engineering Research Council Canada Social Sciences and Humanities Research Council of Canada & Interagency Secretariat on Research Ethics (Canada), 2010, TRIC POL STAT ETH CO; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; Costa DK, 2015, CRIT CARE MED, V43, P2275, DOI 10.1097/CCM.0000000000001259; Damian MS, 2013, INTENS CARE MED, V39, P1405, DOI 10.1007/s00134-013-2960-6; Diringer MN, 2001, CRIT CARE MED, V29, P635, DOI 10.1097/00003246-200103000-00031; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; English SW, 2013, NEUROCRIT CARE, V18, P131, DOI 10.1007/s12028-012-9748-3; Kahn JM, 2008, MED CARE, V46, P1226, DOI 10.1097/MLR.0b013e31817d9342; Kozar RA, 2014, J TRAUMA ACUTE CARE, V76, P634, DOI 10.1097/TA.0000000000000130; Kramer AH, 2014, CURR OPIN CRIT CARE, V20, P174, DOI 10.1097/MCC.0000000000000076; Kramer AH, 2013, CAN J ANESTH, V60, P966, DOI 10.1007/s12630-013-0001-0; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; Lott JP, 2009, AM J RESP CRIT CARE, V179, P676, DOI 10.1164/rccm.200808-1281OC; Marrie RA, 2009, J CLIN EPIDEMIOL, V62, P511, DOI 10.1016/j.jclinepi.2008.05.015; McCredie VA, 2016, J TRAUMA ACUTE CARE, V80, P484, DOI 10.1097/TA.0000000000000922; Mittlbock M, 1996, STAT MED, V15, P1987, DOI 10.1002/(SICI)1097-0258(19961015)15:19<1987::AID-SIM318>3.0.CO;2-9; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Newgard CD, 2013, J AM COLL SURGEONS, V216, P147, DOI 10.1016/j.jamcollsurg.2012.08.017; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shafi S, 2009, J AM COLL SURGEONS, V209, P521, DOI 10.1016/j.jamcollsurg.2009.07.001; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Varelas PN, 2006, J NEUROSURG, V104, P713, DOI 10.3171/jns.2006.104.5.713; WARME PE, 1991, ACTA NEUROCHIR, V110, P57, DOI 10.1007/BF01402049	35	12	12	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUL	2018	46	7					1139	1149		10.1097/CCM.0000000000003149			11	Critical Care Medicine	General & Internal Medicine	GJ4AZ	WOS:000435290400050	29629983				2021-06-18	
J	Boggs, JM; Beck, A; Hubley, S; Peterson, EL; Hu, Y; Williams, LK; Prabhakar, D; Rossom, RC; Lynch, FL; Lu, CY; Waitzfelder, BE; Owen-Smith, AA; Simon, GE; Ahmedani, BK				Boggs, Jennifer M.; Beck, Arne; Hubley, Sam; Peterson, Edward L.; Hu, Yong; Williams, L. Keoki; Prabhakar, Deepak; Rossom, Rebecca C.; Lynch, Frances L.; Lu, Christine Y.; Waitzfelder, Beth E.; Owen-Smith, Ashli A.; Simon, Gregory E.; Ahmedani, Brian K.			General Medical, Mental Health, and Demographic Risk Factors Associated With Suicide by Firearm Compared With Other Means	PSYCHIATRIC SERVICES			English	Article							EMERGENCY-DEPARTMENT; COMPLETED SUICIDE; CHRONIC PAIN; CARE; POPULATION; PREVENTION; INDIVIDUALS; DEPRESSION; DISORDERS; PROVIDERS	Objective: Mitigation of suicide risk by reducing access to lethal means, such as firearms and potentially lethal medications, is a highly recommended practice. To better understand groups of patients at risk of suicide in medical settings, the authors compared demographic and clinical risk factors between patients who died by suicide by using firearms or other means with matched patients who did not die by suicide (control group). Methods: In a case-control study in 2016 from eight health care systems within the Mental Health Research Network, 2,674 suicide cases from 2010-2013 were matched to a control group (N=267,400). The association between suicide by firearm or other means and medical record information on demographic characteristics, general medical disorders, and mental disorders was assessed. Results: The odds of having a mental disorder were higher among cases of suicide involving a method other than a firearm. Fourteen general medical disorders were associated with statistically significant (p<.001) greater odds of suicide by firearm, including traumatic brain injury (TBI) (odds ratio [OR] = 23.53), epilepsy (OR = 3.17), psychogenic pain (OR = 2.82), migraine (OR = 2.35), and stroke (OR = 2.20). Fifteen general medical disorders were associated with statistically significant (p<.001) greater odds of suicide by other means, with particularly high odds for TBI (OR = 7.74), epilepsy (OR = 3.28), HIV/AIDS (OR = 6.03), and migraine (OR = 3.17). Conclusions: Medical providers should consider targeting suicide risk screening for patients with any mental disorder, TBI, epilepsy, HIV, psychogenic pain, stroke, and migraine. When suicide risk is detected, counseling on reducing access to lethal means should include both firearms and other means for at-risk groups.	[Boggs, Jennifer M.; Beck, Arne] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO 80205 USA; [Hubley, Sam] Univ Colorado, Sch Med, Dept Family Med, Boulder, CO 80309 USA; [Peterson, Edward L.] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA; [Williams, L. Keoki; Ahmedani, Brian K.] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI USA; [Williams, L. Keoki] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI USA; [Prabhakar, Deepak] Henry Ford Hlth Syst, Dept Behav Hlth Serv, Detroit, MI USA; [Rossom, Rebecca C.] Hlth Partners Inst, Bloomington, MN USA; [Lynch, Frances L.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA; [Lu, Christine Y.] Harvard Med Sch, Dept Populat Med, Boston, MA USA; [Lu, Christine Y.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Waitzfelder, Beth E.] Kaiser Permanente Hawaii, Ctr Hlth Res, Honolulu, HI USA; [Owen-Smith, Ashli A.] Kaiser Permanente Georgia, Ctr Clin & Outcomes Res, Atlanta, GA USA; [Owen-Smith, Ashli A.] Georgia State Univ, Sch Publ Hlth, Atlanta, GA 30303 USA; [Simon, Gregory E.] Kaiser Permanente Washington, Hlth Res Inst, Seattle, WA USA	Boggs, JM (corresponding author), Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO 80205 USA.	jennifer.m.boggs@kp.org	Rossom, Rebecca/R-7103-2019	Rossom, Rebecca/0000-0002-9531-914X; Hubley, Samuel/0000-0001-7188-6003	National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH103539]; MerckMerck & Company; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH103539] Funding Source: NIH RePORTER	The work was supported by a grant from the National Institute of Mental Health (R01MH103539).; Dr. Williams reports receipt of payment for serving as scientific advisor on a project from Merck. The other authors report no financial relationships with commercial interests.	Ahmedani BK, 2017, AM J PREV MED, V53, P308, DOI 10.1016/j.amepre.2017.04.001; Ahmedani BK, 2014, J GEN INTERN MED, V29, P870, DOI 10.1007/s11606-014-2767-3; [Anonymous], 2015, PUB SMA, P15; Baca-Garcia E, 2001, J CLIN PSYCHIAT, V62, P560, DOI 10.4088/JCP.v62n07a11; Basham C, 2011, SUICIDE LIFE-THREAT, V41, P287, DOI 10.1111/j.1943-278X.2011.00028.x; Beghi M, 2013, NEUROPSYCH DIS TREAT, V9, P1725, DOI 10.2147/NDT.S40213; Betz ME, 2013, DEPRESS ANXIETY, V30, P1005, DOI 10.1002/da.22071; Bostwick JM, 2016, AM J PSYCHIAT, V173, P1094, DOI 10.1176/appi.ajp.2016.15070854; Brent DA, 2003, AM BEHAV SCI, V46, P1192, DOI 10.1177/0002764202250662; Bruffaerts R, 2015, J PAIN, V16, P42, DOI 10.1016/j.jpain.2014.10.002; Bryan CJ, 2011, PROF PSYCHOL-RES PR, V42, P339, DOI 10.1037/a0025051; Cavanagh JTO, 2003, PSYCHOL MED, V33, P395, DOI 10.1017/S0033291702006943; Centers for Disease Control and Prevention Injury Prevention and Control Data and Statistics (WISQARS), 2016, FAT INJ REP; Centers for Disease Control and Prevention National Center for Health Statistics, 2014, SUIC SELF INFL INJ; Clinical Modification, 1995, INT CLASS DIS; Colman I, 2016, HEADACHE, V56, P132, DOI 10.1111/head.12710; Edlund MJ, 2010, CLIN J PAIN, V26, P1, DOI 10.1097/AJP.0b013e3181b99f35; Ferrer P, 2014, NEUROEPIDEMIOLOGY, V42, P107, DOI 10.1159/000356807; Friedman LE, 2017, CLIN J PAIN, V33, P659, DOI 10.1097/AJP.0000000000000440; Go AS, 2008, CIRC-CARDIOVASC QUAL, V1, P138, DOI 10.1161/CIRCOUTCOMES.108.801654; Hepburn L, 2007, INJURY PREV, V13, P15, DOI 10.1136/ip.2006.013607; Hornbrook Mark C, 2005, J Natl Cancer Inst Monogr, P12; http://www.sprc.org/resources-programs/calm-counseling-access-lethal-means, 2017, CALM COUNS ACC LETH; Ilgen MA, 2010, ARCH GEN PSYCHIAT, V67, P1152, DOI 10.1001/archgenpsychiatry.2010.129; Keiser O, 2010, AM J PSYCHIAT, V167, P143, DOI 10.1176/appi.ajp.2009.09050651; Kochanek Kenneth D, 2016, Natl Vital Stat Rep, V65, P1; Kruesi MJP, 1999, J AM ACAD CHILD PSY, V38, P250, DOI 10.1097/00004583-199903000-00010; Lewiecki EM, 2013, AM J PUBLIC HEALTH, V103, P27, DOI 10.2105/AJPH.2012.300964; Luoma JB, 2002, AM J PSYCHIAT, V159, P909, DOI 10.1176/appi.ajp.159.6.909; Mack KA, 2013, MMWR-MORBID MORTAL W, V62, P537; McDowell AK, 2011, MAYO CLIN PROC, V86, P792, DOI 10.4065/mcp.2011.0076; McManus BL, 1997, AM J EMERG MED, V15, P357, DOI 10.1016/S0735-6757(97)90124-8; Mula M, 2007, EPILEPSY BEHAV, V11, P130, DOI 10.1016/j.yebeh.2007.04.008; Munce SEP, 2007, PSYCHOSOMATICS, V48, P394, DOI 10.1176/appi.psy.48.5.394; Outcalt SD, 2015, J BEHAV MED, V38, P535, DOI 10.1007/s10865-015-9628-3; Rossom RC, 2016, PSYCHIAT SERV, V67, P830, DOI 10.1176/appi.ps.201600068; Sentinel Event Alert, 2016, DET TREAT SUIC ID AL; Shea SC, 2002, PRACTICAL ART SUICID; Simon TR, 2001, SUICIDE LIFE-THREAT, V32, P49, DOI 10.1521/suli.32.1.5.49.24212; Spicer RS, 2000, AM J PUBLIC HEALTH, V90, P1885, DOI 10.2105/AJPH.90.12.1885; Stone DM, 2014, AM J LIFESTYLE MED, V8, P404, DOI 10.1177/1559827614551130; Substance Abuse and Mental Health Services Administration, 2015, NSDUH SER H, VSMA 15-4927; Sullivan GR, 2004, THESIS; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Vyrostek Sara B., 2004, Morbidity and Mortality Weekly Report, V53, P1; Wagner Edward H, 2005, J Natl Cancer Inst Monogr, P3, DOI 10.1093/jncimonographs/lgi032; WHO, 2012, INT CLASS DIS	47	12	12	0	5	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	1075-2730	1557-9700		PSYCHIAT SERV	Psychiatr. Serv.	JUN	2018	69	6					677	684		10.1176/appi.ps.201700237			8	Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry	Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry	GL6TF	WOS:000437323400011	29446332	Green Accepted, Bronze			2021-06-18	
J	Cooksley, R; Maguire, E; Lannin, NA; Unsworth, CA; Farquhar, M; Galea, C; Mitra, B; Schmidt, J				Cooksley, Rebecca; Maguire, Emma; Lannin, Natasha A.; Unsworth, Carolyn A.; Farquhar, Michelle; Galea, Claire; Mitra, Biswadev; Schmidt, Julia			Persistent symptoms and activity changes three months after mild traumatic brain injury	AUSTRALIAN OCCUPATIONAL THERAPY JOURNAL			English	Article						neurology; rehabilitation services; traumatic brain injury	HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; CONCUSSION SYMPTOMS; FOLLOW-UP; CHILDREN; OUTCOMES; DISABILITY; RECOVERY; SPORT; SCALE	Background/aimApproximately, 80% of traumatic brain injuries are considered mild in severity. Mild traumatic brain injury (mTBI) may cause temporary or persisting impairments that can adversely affect an individual's ability to participate in daily occupations and life roles. This study aimed to identify symptoms, factors predicting level of symptoms and functional and psycho-social outcomes for participants with mTBI three months following injury. MethodPatients discharged from the Emergency Department of a major metropolitan hospital with a diagnosis of mTBI were contacted by telephone three months after injury. An interview with two questionnaires was administered: The Concussion Symptom Inventory (CSI) Scale and the Rivermead Head Injury Follow-Up Questionnaire (RHIFUQ). Data obtained were used to determine the type and prevalence of post-concussion symptoms and their impact on activity change. ResultsSixty-three people with mTBI participated in the study. The majority of participants (81%) reported that all symptoms had resolved within the three-month time frame. Of those still experiencing symptoms, workplace fatigue (22%) and an inability to maintain previous workload/standards (17%) were reported. ConclusionThere is a small, but clinically significant, subgroup of patients who continue to experience symptoms three-month post-mTBI. Symptoms experienced beyond the expected three-month recovery timeframe have the potential to adversely affect an individual's ability to participate in daily occupation and return to work.	[Cooksley, Rebecca; Lannin, Natasha A.; Unsworth, Carolyn A.; Schmidt, Julia] La Trobe Univ, Coll Sci Hlth & Engn, Sch Allied Hlth, Occupat Therapy, Melbourne, Vic, Australia; [Maguire, Emma; Lannin, Natasha A.; Farquhar, Michelle; Mitra, Biswadev] Alfred Hlth, Melbourne, Vic, Australia; [Mitra, Biswadev] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic, Australia; [Unsworth, Carolyn A.] Cent Queensland Univ, Sch Hlth Med & Appl Sci, Occupat Therapy, Melbourne, Vic, Australia; [Galea, Claire] Univ Sydney, Cerebral Palsy Alliance, Sydney, NSW, Australia; [Schmidt, Julia] Univ British Columbia, Fac Med, Dept Phys Therapy, 212-2177 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada	Schmidt, J (corresponding author), Univ British Columbia, Fac Med, Dept Phys Therapy, 212-2177 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	julia.schmidt@ubc.ca	Mitra, Biswadev/AAC-3724-2019; Lannin, Natasha A/A-4195-2013	Mitra, Biswadev/0000-0002-0508-2450; Lannin, Natasha A/0000-0002-2066-8345; Schmidt, Julia/0000-0003-2004-4871; Unsworth, Carolyn/0000-0001-6430-2823	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia	NAL was supported by a fellowship from the National Health and Medical Research Council. No funding for this research was provided.	AIHW, 2007, DIS AUSTR ACQ BRAIN; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Baker A, 2015, ACCIDENT ANAL PREV, V79, P50, DOI 10.1016/j.aap.2015.03.014; Berrigan L, 2011, BRAIN INJURY, V25, P742, DOI 10.3109/02699052.2011.580317; Bigler ED, 2012, NEUROSCI LETT, V509, P1, DOI 10.1016/j.neulet.2011.12.009; Blostein PA, 1997, J NEUROTRAUM, V14, P171, DOI 10.1089/neu.1997.14.171; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Helps Y. L. M., 2008, HOSP SEPERATIONS DUE; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Kraus J. F., 1999, REHABILITATION ADULT, P3; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; McCrea M, 2008, MILD TRAUMATIC BRAIN; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Monash University, 2015, VICT STAT TRAUM OUTC; Moran LM, 2011, J HEAD TRAUMA REHAB, V26, P348, DOI 10.1097/HTR.0b013e3181f8d32e; Motor Accident Authority NSW (MAA), 2008, GUID MILD TRAUM BRAI; Ownsworth T, 2006, NEUROPSYCHOL REHABIL, V16, P415, DOI 10.1080/09602010500505641; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Ponsford JL, 2016, J NEUROTRAUM, V33, P997, DOI 10.1089/neu.2015.4025; Ponsford JL, 2013, J NEUROTRAUM, V30, P1498, DOI 10.1089/neu.2012.2843; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Saini NS, 2012, INDIAN J NEUROTRAUM, V9, P45, DOI 10.1016/j.ijnt.2012.04.009; Schell BA, 2013, WILLARD SPACKMANS OC; Stalnacke BM, 2007, J REHABIL MED, V39, P405, DOI 10.2340/16501977-0057; Stuart B, 2012, J EMERG NURS, V38, P435, DOI 10.1016/j.jen.2011.04.006; Tiller J. W. G., 2001, MJA OPEN S4, V1, P28, DOI [10. 5694/mjao12. 10628, DOI 10.5694/MJA012.10628]; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Weightman MM, 2010, J HEAD TRAUMA REHAB, V25, P206, DOI 10.1097/HTR.0b013e3181dc82d3; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	39	12	13	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0045-0766	1440-1630		AUST OCCUP THER J	Aust. Occup. Ther. J.	JUN	2018	65	3					168	175		10.1111/1440-1630.12457			8	Rehabilitation	Rehabilitation	GK5SQ	WOS:000436237700002	29498077				2021-06-18	
J	Meymandi, MS; Soltani, Z; Sepehri, G; Amiresmaili, S; Farahani, F; Aghtaei, MM				Meymandi, Manzumeh Shamsi; Soltani, Zahra; Sepehri, Gholamreza; Amiresmaili, Sedigheh; Farahani, Fatemeh; Aghtaei, Mohammadmehdi Moeini			Effects of pregabalin on brain edema, neurologic and histologic outcomes in experimental traumatic brain injury	BRAIN RESEARCH BULLETIN			English	Article						Pregabalin; Traumatic brain injury; Brain edema; Neurological outcome; Intracranial pressure	SPINAL-CORD-INJURY; SEX STEROID-HORMONES; INTRACRANIAL-PRESSURE; THERAPEUTIC TARGET; HEAD-INJURY; GABAPENTIN; RATS; PROGESTERONE; ISCHEMIA; BARRIER	Brain edema and increased intracranial pressure (ICP) are among the main causes of neurological disturbance and mortality following traumatic brain injury (TBI). Since pregabalin neuroprotective effects have been shown, this study was performed to evaluate the possible neuroprotective effects of pregabalin in experimental TBI of male rats. Adult male Wistar rats were divided into 4 groups: sham, vehicle, pregabalin 30 mg/kg and pregabalin 60 mg/kg. TBI was induced in vehicle and pregabalin groups by Marmarou method. Pregabalin was administered 30 min after TBI. Sham and vehicle groups received saline. Brain water and Evans blue content and histopathological changes were evaluated 24, 5 and 24 h after TBI, respectively. The ICP and neurological outcomes (veterinary coma scale, VCS) were recorded before, 1 h and 24 h post TBI. The results showed a significant reduction in brain water content and ICP, and a significant increase in VCS of pregabalin group (60 mg/kg) as compared to vehicle group (P < 0.05). Also, pregabalin reduced brain edema and apoptosis score as compared to vehicle group. Post TBI pregabalin administration revealed a delayed but significant improvement in ICP and neurological outcomes in experimental TBI. The underlying mechanism(s) was not determined and needs further investigation.	[Meymandi, Manzumeh Shamsi; Sepehri, Gholamreza] Kerman Univ Med Sci, Neurosci Res Ctr, Neuropharmacol Inst, Kerman, Iran; [Soltani, Zahra] Kerman Univ Med Sci, Endocrinol & Metab Res Ctr, Inst Basic & Clin Physiol Sci, Kerman, Iran; [Amiresmaili, Sedigheh] Barn Univ Med Sci, Bam, Iran; [Soltani, Zahra; Farahani, Fatemeh] Kerman Univ Med Sci, Kerman Med Sch, Physiol & Pharmacol Dept, Kerman, Iran; [Meymandi, Manzumeh Shamsi; Aghtaei, Mohammadmehdi Moeini] Kerman Univ Med Sci, Stem Cell Res Ctr, Kerman Sch Med, Kerman, Iran	Soltani, Z (corresponding author), Kerman Univ Med Sci, Endocrinol & Metab Res Ctr, Inst Basic & Clin Physiol Sci, Kerman, Iran.	z.soltani@kmu.ac.ir	Sepehri, Gholamreza/AAC-9522-2019; Meymandi, Manzumeh Shamsi/AAD-3763-2020; Sheikholeslami-Farahani, Fatemeh/AAN-6125-2021; Soltani, Zahra/AAC-1350-2019; Sepehri, Gholamreza/AAZ-2101-2020	Sepehri, Gholamreza/0000-0001-7999-9934; Soltani, Zahra/0000-0002-8423-6189; Shamsi Meymandi, Manzumeh/0000-0002-4011-7364			Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; Andre V, 2003, EPILEPSIA, V44, P893, DOI 10.1046/j.1528-1157.2003.61802.x; Asci S, 2016, BALK MED J, V33, P221, DOI 10.5152/balkanmedj.2015.15742; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Calabresi P, 2003, EXP NEUROL, V182, P461, DOI 10.1016/S0014-4886(03)00117-1; Calikoglu C, 2015, MED SCI MONITOR, V21; Celik M, 2015, INT J NEUROSCI, V125, P845, DOI 10.3109/00207454.2014.978976; Dehghan F, 2013, ARCH MED RES, V44, P251, DOI 10.1016/j.arcmed.2013.04.002; Field MJ, 1997, BRIT J PHARMACOL, V121, P1513, DOI 10.1038/sj.bjp.0701320; Gajraj NM, 2007, ANESTH ANALG, V105, P1805, DOI 10.1213/01.ane.0000287643.13410.5e; Gruenthal M, 1997, SPINAL CORD, V35, P686, DOI 10.1038/sj.sc.3100481; Ha KY, 2008, EUR SPINE J, V17, P864, DOI 10.1007/s00586-008-0653-6; Ha KY, 2011, J KOREAN MED SCI, V26, P404, DOI 10.3346/jkms.2011.26.3.404; Italiano D, 2013, CLIN PHARMACOKINET, V52, P627, DOI 10.1007/s40262-013-0067-4; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Khaksari M, 2013, IRAN J BASIC MED SCI, V16, P858; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI 10.1139/y10-103; Kim YK, 2010, KOREAN J ANESTHESIOL, V58, P184, DOI 10.4097/kjae.2010.58.2.184; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Kinoshita K, 2016, J INTENSIVE CARE, V4, DOI 10.1186/s40560-016-0138-3; Knotkova H, 2007, MED CLIN N AM, V91, P113, DOI 10.1016/j.mcna.2006.10.007; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; Kusaka G, 2004, J NEUROSCI METH, V135, P121, DOI 10.1016/j.jneumeth.2003.12.013; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; Li Z, 2011, EUR J PHARMACOL, V667, P80, DOI 10.1016/j.ejphar.2011.05.054; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou Anthony, 2004, Cleve Clin J Med, V71 Suppl 1, pS6; McKee JA, 2005, NEUROCRIT CARE, V2, P342, DOI 10.1385/NCC:2:3:342; Mico JA, 2012, CNS DRUGS, V26, P637, DOI 10.2165/11634510-000000000-00000; MILDE LN, 1985, ANESTHESIOLOGY, V63, P371, DOI 10.1097/00000542-198510000-00005; Oaklander AL, 2005, ANN NEUROL, V58, P309, DOI 10.1002/ana.20583; Partridge BJ, 1998, ANESTHESIOLOGY, V88, P196, DOI 10.1097/00000542-199801000-00028; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Rekling JC, 2003, NEUROSCI LETT, V335, P167, DOI 10.1016/S0304-3940(02)01193-X; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; Schulze-Bonhage A, 2013, EXPERT OPIN DRUG MET, V9, P105, DOI 10.1517/17425255.2013.749239; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shim JK, 2014, J THORAC CARDIOV SUR, V148, P298, DOI 10.1016/j.jtcvs.2014.02.076; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soltani Z, 2015, PHYSIOL BEHAV, V152, P26, DOI 10.1016/j.physbeh.2015.08.037; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stocchetti N, 2003, Minerva Anestesiol, V69, P232; Tanabe M, 2008, J NEUROSCI RES, V86, P3258, DOI 10.1002/jnr.21786; Taylor CP, 1998, EPILEPSY RES, V29, P233, DOI 10.1016/s0920-1211(97)00084-3; Traa BS, 2008, PEDIATR RES, V64, P81, DOI 10.1203/PDR.0b013e318174e70e; Trahan E, 2006, J HEAD TRAUMA REHAB, V21, P226, DOI 10.1097/00001199-200605000-00003; Tzellos TG, 2010, HIPPOKRATIA, V14, P71; Wick Jeannette Y, 2012, Consult Pharm, V27, P392, DOI 10.4140/TCP.n.2012.392; Yakubu MA, 2002, AM J PHYSIOL-CELL PH, V283, pC1687, DOI 10.1152/ajpcell.00071.2002; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; ZUCCARELLO M, 1993, J NEUROTRAUM, V10, P397, DOI 10.1089/neu.1993.10.397	56	12	12	1	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	JUN	2018	140						169	175		10.1016/j.brainresbull.2018.05.001			7	Neurosciences	Neurosciences & Neurology	GO0ZR	WOS:000439675700022	29730418				2021-06-18	
J	Murray, GD; Brennan, PM; Teasdale, GM				Murray, Gordon D.; Brennan, Paul M.; Teasdale, Graham M.			Simplifying the use of prognostic information in traumatic brain injury. Part 2: Graphical presentation of probabilities	JOURNAL OF NEUROSURGERY			English	Article						Glasgow Coma Scale; head injury; traumatic brain injury; trauma; prognosis; charts	SEVERE HEAD-INJURY; RISK PREDICTION MODELS; COMA SCALE SCORE; COMPUTERIZED-TOMOGRAPHY; DECOMPRESSIVE CRANIECTOMY; OUTCOME PREDICTION; CLASSIFICATION; IMPACT; VALIDATION; MANAGEMENT	OBJECTIVE Clinical features such as those included in the Glasgow Coma Scale (GCS) score, pupil reactivity, and patient age, as well as CT findings, have clear established relationships with patient outcomes due to neurotrauma. Nevertheless, predictions made from combining these features in probabilistic models have not found a role in clinical practice. In this study, the authors aimed to develop a method of displaying probabilities graphically that would be simple and easy to use, thus improving the usefulness of prognostic information in neurotrauma. This work builds on a companion paper describing the GCS-Pupils score (GCS-P) as a tool for assessing the clinical severity of neurotrauma. METHODS Information about early GCS score, pupil response, patient age, CT findings, late outcome according to the Glasgow Outcome Scale, and mortality were obtained at the individual adult patient level from the CRASH (Corticosteroid Randomisation After Significant Head Injury; n = 9045) and IMPACT (International Mission for Prognosis and Clinical Trials in TBI; n = 6855) databases. These data were combined into a pooled data set for the main analysis. Logistic regression was first used to model the combined association between the GCS-P and patient age and outcome, following which CT findings were added to the models. The proportion of variability in outcomes "explained" by each model was assessed using Nagelkerke's R-2. RESULTS The authors observed that patient age and GCS-P have an additive effect on outcome. The probability of mortality 6 months after neurotrauma is greater with increasing age, and for all age groups the probability of death is greater with decreasing GCS-P. Conversely, the probability of favorable recovery becomes lower with increasing age and lessens with decreasing GCS-P. The effect of combining the GCS-P with patient age was substantially more informative than the GCS-P, age, GCS score, or pupil reactivity alone. Two-dimensional charts were produced displaying outcome probabilities, as percentages, for 5-year increments in age between 15 and 85 years, and for GCS-Ps ranging from 1 to 15; it is readily seen that the movement toward combinations at the top right of the charts reflects a decreasing likelihood of mortality and an increasing likelihood of favorable outcome. Analysis of CT findings showed that differences in outcome are very similar between patients with or without a hematoma, absent cisterns, or subarachnoid hemorrhage. Taken in combination, there is a gradation in risk that aligns with increasing numbers of any of these abnormalities. This information provides added value over age and GCS-P alone, supporting a simple extension of the earlier prognostic charts by stratifying the original charts in the following 3 CT groupings: none, only 1, and 2 or more CT abnormalities. CONCLUSIONS The important prognostic features in neurotrauma can be brought together to display graphically their combined effects on risks of death or on prospects for independent recovery. This approach can support decision making and improve communication of risk among health care professionals, patients, and their relatives. These charts will not replace clinical judgment, but they will reduce the risk of influences from biases.	[Murray, Gordon D.] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland; [Brennan, Paul M.] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland; [Teasdale, Graham M.] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland	Murray, GD (corresponding author), Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Sch Med, Edinburgh, Midlothian, Scotland.	gordon.murray@ed.ac.uk		Brennan, Paul/0000-0002-7347-830X			BARLOW P, 1986, NEUROSURGERY, V19, P989, DOI 10.1227/00006123-198612000-00014; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRAHAMS D, 1989, LANCET, V2, P632; Brennan PM, 2018, J NEUROSURG, V128, P1612, DOI 10.3171/2017.12.JNS172780; Brust-Renck Priscila G, 2013, Rev Hum Factors Ergon, V8, P235; Ceriani E, 2010, J THROMB HAEMOST, V8, P957, DOI 10.1111/j.1538-7836.2010.03801.x; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Corbett W, 1987, MED APPL MICROCOMPUT; Counsell C, 2001, CEREBROVASC DIS, V12, P159, DOI 10.1159/000047699; D'Agostino RB, 2008, CIRCULATION, V117, P743, DOI 10.1161/CIRCULATIONAHA.107.699579; Garcia-Retamero R, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00932; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; Latronico N, 2015, CRIT CARE MED, V43, P505, DOI 10.1097/CCM.0000000000000795; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Lloyd-Jones DM, 2010, CIRCULATION, V121, P1768, DOI 10.1161/CIRCULATIONAHA.109.849166; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Menon DK, 2009, CURR OPIN CRIT CARE, V15, P437, DOI 10.1097/MCC.0b013e3283307a26; Moons KGM, 2012, HEART, V98, P691, DOI 10.1136/heartjnl-2011-301247; Moore NA, 2013, BRIT J NEUROSURG, V27, P340, DOI 10.3109/02688697.2012.754402; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Pang BC, 2007, J NEUROTRAUM, V24, P136, DOI 10.1089/neu.2006.0113; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Perk J, 2012, EUR HEART J, V33, P1635, DOI 10.1093/eurheartj/ehs092; Raj R, 2014, NEUROSURGERY, V75, P632, DOI 10.1227/NEU.0000000000000533; Reith FCM, 2017, INJURY, V48, P1932, DOI 10.1016/j.injury.2017.05.038; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Steyerberg EW, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001381; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; Thelin EP, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002368; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; WYATT JC, 1995, BMJ-BRIT MED J, V311, P1539, DOI 10.1136/bmj.311.7019.1539; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	54	12	12	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2018	128	6					1621	1634		10.3171/2017.12.JNS172782			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GP2IM	WOS:000440653000003	29631517	Bronze			2021-06-18	
J	Santi, A; Genis, L; Aleman, IT				Santi, A.; Genis, L.; Torres Aleman, I.			A Coordinated Action of Blood-Borne and Brain Insulin-Like Growth Factor I in the Response to Traumatic Brain Injury	CEREBRAL CORTEX			English	Article						insulin-like growth factor I; sensorimotor function; traumatic brain injury; treatment of brain injury	PITUITARY DYSFUNCTION; IGF-I; MICE; MODEL; NEUROGENESIS; EXERCISE; BEHAVIOR; STROKE; MOTOR	In response to injury, the brain produces different neuroprotective molecules, such as insulin-like growth factor I (IGF-I). However, IGF-I is also taken up by the brain from the circulation in response to physiological stimuli. Herein, we analyzed in mice the relative contribution of circulating and locally produced IGF-I to increased brain IGF-I levels after insult. Traumatic brain injury (TBI) induced by a controlled impact resulted in increased IGF-I levels in the vicinity of the lesion, but mice with low serum IGF-I showed significantly lower increases. Indeed, in normal mice, peripheral IGF-I accumulated at the lesion site after injury, and at the same time serum IGF-I levels decreased. Collectively, these data suggest that serumIGF-I enter into the brain after TBI and contributes to increased brain IGF-I levels at the injury site. This connection between central and circulating IGF-I provides an amenable route for treatment, as subcutaneous administration of IGF-I to TBI mice led to functional recovery. These latter results add further support to the use of systemic IGF-I or its mimetics for treatment of brain injuries.	[Santi, A.; Genis, L.; Torres Aleman, I.] CSIC, Cajal Inst, Avda Dr Arce 37, Madrid 28002, Spain; [Santi, A.; Genis, L.; Torres Aleman, I.] Ciberned, C Valderrebollo 5, Madrid 28031, Spain	Aleman, IT (corresponding author), CSIC, Cajal Inst, Avda Dr Arce 37, Madrid 28002, Spain.	torres@cajal.csic.es	Torres-Aleman, Ignacio/A-1613-2008	Torres-Aleman, Ignacio/0000-0001-8107-7947; Santi, Andrea/0000-0001-9282-2340	Spanish Ministry of Economy [SAF2013-40710-R]; CIBERNEDInstituto de Salud Carlos III	The Spanish Ministry of Economy (SAF2013-40710-R) and by CIBERNED.	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Alluri H, 2015, METAB BRAIN DIS, V30, P1093, DOI 10.1007/s11011-015-9651-7; Arevalo MA, 2015, NAT REV NEUROSCI, V16, P17, DOI 10.1038/nrn3856; Balthazart J, 2006, TRENDS NEUROSCI, V29, P241, DOI 10.1016/j.tins.2006.03.004; Beilharz EJ, 1998, MOL BRAIN RES, V59, P119, DOI 10.1016/S0169-328X(98)00122-3; Bouet V, 2009, NAT PROTOC, V4, P1560, DOI 10.1038/nprot.2009.125; Brabazon F, 2017, J CEREBR BLOOD F MET, V37, P3203, DOI 10.1177/0271678X16685106; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Carro E, 2000, J NEUROSCI, V20, P2926; Ciucci F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000475; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; De Smedt A, 2011, STROKE, V42, P2180, DOI 10.1161/STROKEAHA.110.600783; Fernandez AM, 1998, P NATL ACAD SCI USA, V95, P1253, DOI 10.1073/pnas.95.3.1253; Fernandez AM, 2012, NAT REV NEUROSCI, V13, P225, DOI 10.1038/nrn3209; Garcia-Galloway E, 2003, MOL CELL NEUROSCI, V24, P1027, DOI 10.1016/j.mcn.2003.08.005; Gazit N, 2016, NEURON, V89, P583, DOI 10.1016/j.neuron.2015.12.034; Golde WT, 2005, LAB ANIMAL, V34, P39, DOI 10.1038/laban1005-39; Guan J, 2003, PROG NEUROBIOL, V70, P443, DOI 10.1016/j.pneurobio.2003.08.002; Guzzetta A, 2009, J NEUROSCI, V29, P6042, DOI 10.1523/JNEUROSCI.5548-08.2009; Hatton J, 1997, J NEUROSURG, V86, P779, DOI 10.3171/jns.1997.86.5.0779; Korley FK, 2016, J NEUROTRAUM, V33, P215, DOI 10.1089/neu.2015.3949; LEE WH, 1992, MOL CELL NEUROSCI, V3, P36, DOI 10.1016/1044-7431(92)90006-N; Lopez-Lopez C, 2004, P NATL ACAD SCI USA, V101, P9833, DOI 10.1073/pnas.0400337101; Madathil SK, 2010, J NEUROTRAUM, V27, P95, DOI 10.1089/neu.2009.1002; Mardinly AR, 2016, NATURE, V531, P371, DOI 10.1038/nature17187; Mattlage AE, 2016, J STROKE CEREBROVASC, V25, P1800, DOI 10.1016/j.jstrokecerebrovasdis.2016.03.054; Mitschelen M, 2011, NEUROSCIENCE, V185, P50, DOI 10.1016/j.neuroscience.2011.04.032; Nishijima T, 2010, NEURON, V67, P834, DOI 10.1016/j.neuron.2010.08.007; Ozdemir D, 2012, NEUROSCI LETT, V507, P84, DOI 10.1016/j.neulet.2011.11.059; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rosario ER, 2013, J HEAD TRAUMA REHAB, V28, P390, DOI 10.1097/HTR.0b013e318250eac6; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Song Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep32095; Tanriverdi F, 2015, ENDOCR REV, V36, P305, DOI 10.1210/er.2014-1065; Aleman IT, 2012, ENDOCRIN METAB CLIN, V41, P395, DOI 10.1016/j.ecl.2012.04.016; Trejo JI, 2007, MOL PSYCHIATR, V12, P1118, DOI 10.1038/sj.mp.4002076; Trejo JL, 2008, MOL CELL NEUROSCI, V37, P402, DOI 10.1016/j.mcn.2007.10.016; Trueba-Saiz A, 2016, CURR OPIN BEHAV SCI, V9, P15, DOI 10.1016/j.cobeha.2015.11.013; Wagner J, 2010, J NEUROTRAUM, V27, P1007, DOI 10.1089/neu.2009.1092; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629	43	12	12	2	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	JUN	2018	28	6					2007	2014		10.1093/cercor/bhx106			8	Neurosciences	Neurosciences & Neurology	GL4XK	WOS:000437164200008	28449086	Bronze			2021-06-18	
J	van der Horn, HJ; de Haan, S; Spikman, JM; de Groot, JC; van der Naalt, J				van der Horn, H. J.; de Haan, S.; Spikman, J. M.; de Groot, J. C.; van der Naalt, J.			Clinical relevance of microhemorrhagic lesions in subacute mild traumatic brain injury	BRAIN IMAGING AND BEHAVIOR			English	Article						Mild traumatic brain injury; MRI; Microhemorrhages; Microbleeds; Post-traumatic complaints	CT	Magnetic resonance imaging (MRI) is often performed in patients with persistent complaints after mild traumatic brain injury (mTBI). However, the clinical relevance of detected microhemorrhagic lesions is still unclear. In the current study, 54 patients with uncomplicated mTBI and 20 matched healthy controls were included. Post-traumatic complaints were measured at two weeks post-injury. Susceptibility weighted imaging and T2*-gradient echo imaging (at 3 Tesla) were performed at four weeks post-injury. Microhemorrhagic lesions (1-10 mm) were subdivided based on depth (superficial or deep) and anatomical location (frontal, temporoparietal and other regions). Twenty-eight per cent of patients with mTBI had >= 1 lesions compared to 0 % of the healthy controls. Lesions in patients with mTBI were predominantly located within the superficial frontal areas. Number, depth and anatomical location of lesions did not differ between patients with and without post-traumatic complaints. Within the group of patients with complaints, number of complaints was not correlated with number of lesions. In summary, microhemorrhages were found in one out of four patients with uncomplicated mTBI during follow-up at four weeks post-injury, but they were not related to early complaints.	[van der Horn, H. J.; van der Naalt, J.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9700 RB Groningen, Netherlands; [Spikman, J. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Neuropsychol, Groningen, Netherlands; [de Haan, S.; de Groot, J. C.] Univ Groningen, Univ Med Ctr Groningen, Dept Radiol, Groningen, Netherlands	van der Horn, HJ (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9700 RB Groningen, Netherlands.	h.j.van.der.horn@umcg.nl		Spikman, Jacoba/0000-0002-6477-0763	Dutch Brain Foundation [Ps2012-06]	This work was funded by the Dutch Brain Foundation (grant no. Ps2012-06).	Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; de Koning ME, 2016, INJURY, V47, P2041, DOI 10.1016/j.injury.2016.04.036; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Huang YL, 2015, NEUROLOGY, V84, P580, DOI 10.1212/WNL.0000000000001237; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Iverson GL, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/415740; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Matuseviciene G, 2016, J REHABIL MED, V48, P19, DOI 10.2340/16501977-2025; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Panenka WJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122746; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Verhage F., 1964, INTELLIGENCE AGE STU; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	18	12	12	0	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2018	12	3					912	916		10.1007/s11682-017-9743-6			5	Neuroimaging	Neurosciences & Neurology	GI6PB	WOS:000434491400027	28664231	Green Published, Other Gold			2021-06-18	
J	Piro, JR; Suidan, GL; Quan, J; Pi, YQ; O'Neill, SM; Ilardi, M; Pozdnyakov, N; Lanz, TA; Xi, HL; Bell, RD; Samad, TA				Piro, Justin R.; Suidan, Georgette L.; Quan, Jie; Pi, YeQing; O'Neill, Sharon M.; Ilardi, Marissa; Pozdnyakov, Nikolay; Lanz, Thomas A.; Xi, Hualin; Bell, Robert D.; Samad, Tarek A.			Inhibition of 2-AG hydrolysis differentially regulates blood brain barrier permeability after injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Monoacylglycerol lipase; 2-arachidonoylglycerol; Neuroinflammation; Blood-brain barrier; Neurovasculature	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MATRIX METALLOPROTEINASES; ISCHEMIC-STROKE; ENDOCANNABINOID SYSTEM; BACTERIAL-MENINGITIS; CEREBROSPINAL-FLUID; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; SPINAL-CORD; MOUSE MODEL	Background: Acute neurological insults caused by infection, systemic inflammation, ischemia, or traumatic injury are often associated with breakdown of the blood-brain barrier (BBB) followed by infiltration of peripheral immune cells, cytotoxic proteins, and water. BBB breakdown and extravasation of these peripheral components into the brain parenchyma result in inflammation, oxidative stress, edema, excitotoxicity, and neurodegeneration. These downstream consequences of BBB dysfunction can drive pathophysiological processes and play a substantial role in the morbidity and mortality of acute and chronic neurological insults, and contribute to long-term sequelae. Preserving or rescuing BBB integrity and homeostasis therefore represents a translational research area of high therapeutic potential. Methods: Induction of general and localized BBB disruption in mice was carried out using systemic administration of LPS and focal photothrombotic ischemic insult respectively, in the presence and absence of the monoacylglycerol lipase (MAGL) inhibitor, CPD-4645. The effects of CPD-4645 treatment were assessed by gene expression analysis performed on neurovascular-enriched brain fractions, cytokine and inflammatory mediator measurement, and functional assessment of BBB permeability. The mechanism of action of CPD-4645 was studied pharmacologically using inverse agonists/antagonists of the cannabinoid receptors CB1 and CB2. Results: Here, we demonstrate that the neurovasculature exhibits a unique transcriptional signature following inflammatory insults, and pharmacological inhibition of MAGL using a newly characterized inhibitor rescues the transcriptional profile of brain vasculature and restores its functional homeostasis. This pronounced effect of MAGL inhibition on blood-brain barrier permeability is evident following both systemic inflammatory and localized ischemic insults. Mechanistically, the protective effects of the MAGL inhibitor are partially mediated by cannabinoid receptor signaling in the ischemic brain insult. Conclusions: Our results support considering MAGL inhibitors as potential therapeutics for BBB dysfunction and cerebral edema associated with inflammatory brain insults.	[Piro, Justin R.; Suidan, Georgette L.; Quan, Jie; Pi, YeQing; O'Neill, Sharon M.; Ilardi, Marissa; Pozdnyakov, Nikolay; Lanz, Thomas A.; Xi, Hualin; Bell, Robert D.; Samad, Tarek A.] Pfizer Worldwide Res & Dev, Cambridge, MA 02139 USA; [Piro, Justin R.; Xi, Hualin] Abbvie Inc, 200 Sidney St, Cambridge, MA 02139 USA; [Suidan, Georgette L.; Pi, YeQing; O'Neill, Sharon M.; Lanz, Thomas A.] Biogen, 225 Binney St, Cambridge, MA 02142 USA; [Ilardi, Marissa] NYU, Sch Med, 550 1St Ave, New York, NY 10016 USA; [Samad, Tarek A.] Sanofi R&D, 49 New York Ave, Framingham, MA 01701 USA	Piro, JR; Samad, TA (corresponding author), Pfizer Worldwide Res & Dev, Cambridge, MA 02139 USA.	JPiro1000@gmail.com; samad.tarek@gmail.com		Lanz, Thomas/0000-0003-2483-3122	Pfizer Global ResearchPfizer	This work was supported by Pfizer Global Research.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772; Bahr BA, 2006, EXPERT OPIN INV DRUG, V15, P351, DOI 10.1517/13543784.15.4.351; Bales KR, 2016, BRAIN, V139, P563, DOI 10.1093/brain/awv313; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Blankman JL, 2007, CHEM BIOL, V14, P1347, DOI 10.1016/j.chembiol.2007.11.006; Boroujerdi A, 2013, EXP NEUROL, V250, P43, DOI 10.1016/j.expneurol.2013.09.009; Chanda PK, 2010, MOL PHARMACOL, V78, P996, DOI 10.1124/mol.110.068304; Cross AK, 2006, BRAIN RES, V1088, P19, DOI 10.1016/j.brainres.2006.02.136; Denes A, 2011, CEREBROVASC DIS, V32, P517, DOI 10.1159/000332205; Erickson MA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-150; Fegley D, 2005, J PHARMACOL EXP THER, V313, P352, DOI 10.1124/jpet.104.078980; Gottschall PE, 2015, MATRIX BIOL, V44-46, P70, DOI 10.1016/j.matbio.2015.01.014; Goumans MJ, 2009, CELL RES, V19, P116, DOI 10.1038/cr.2008.326; Jaeger LB, 2009, BRAIN BEHAV IMMUN, V23, P507, DOI 10.1016/j.bbi.2009.01.017; Jin AY, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-12; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Katz PS, 2015, J NEUROTRAUM, V32, P297, DOI 10.1089/neu.2014.3508; Kern CB, 2010, MATRIX BIOL, V29, P304, DOI 10.1016/j.matbio.2010.01.005; Kisucka J, 2009, BLOOD, V113, P6015, DOI 10.1182/blood-2008-10-186650; Lapilover EG, 2012, NEUROBIOL DIS, V48, P495, DOI 10.1016/j.nbd.2012.06.024; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Lemarchant S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-133; Leppert D, 2000, CLIN INFECT DIS, V31, P80, DOI 10.1086/313922; Leppert D, 2001, BRAIN RES REV, V36, P249, DOI 10.1016/S0165-0173(01)00101-1; Long JZ, 2009, NAT CHEM BIOL, V5, P37, DOI 10.1038/nchembio.129; Margadant C, 2010, EMBO REP, V11, P97, DOI 10.1038/embor.2009.276; Nomura DK, 2011, SCIENCE, V334, P809, DOI 10.1126/science.1209200; Nygardas PT, 2002, CLIN EXP IMMUNOL, V128, P245, DOI 10.1046/j.1365-2249.2002.01855.x; Palasik W, 2005, EUR NEUROL, V53, P188, DOI 10.1159/000086355; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Petri B, 2010, BLOOD, V116, P4712, DOI 10.1182/blood-2010-03-276311; Pihlaja R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0305-9; Piro JR, 2012, CELL REP, V1, P617, DOI 10.1016/j.celrep.2012.05.001; Rempe RG, 2016, J CEREBR BLOOD F MET, V36, P1481, DOI 10.1177/0271678X16655551; Rieckmann P, 1997, ANN NEUROL, V41, P326, DOI 10.1002/ana.410410307; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Roberts J, 2017, J CEREBR BLOOD F MET, V37, P85, DOI 10.1177/0271678X15616979; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Schubert-Unkmeir A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000874; Suidan GL, 2013, ARTERIOSCL THROM VAS, V33, P2112, DOI 10.1161/ATVBAHA.113.301362; Tchantchou F, 2013, J NEUROTRAUM, V30, P565, DOI 10.1089/neu.2012.2647; Terrone G, 2018, EPILEPSIA, V59, P79, DOI 10.1111/epi.13950; Underly RG, 2017, J NEUROSCI, V37, P129, DOI 10.1523/JNEUROSCI.2891-16.2016; Varatharaj A, 2017, BRAIN BEHAV IMMUN, V60, P1, DOI 10.1016/j.bbi.2016.03.010; Wagsater D, 2008, ATHEROSCLEROSIS, V196, P514, DOI 10.1016/j.atherosclerosis.2007.05.018; Westling J, 2004, BIOCHEM J, V377, P787, DOI 10.1042/bj20030896; Yang Y, 2015, BRAIN RES, V1623, P30, DOI 10.1016/j.brainres.2015.04.024; Zhang J, 2015, J CEREBR BLOOD F MET, V35, P706, DOI 10.1038/jcbfm.2014.247; Zhao Z, 2015, CELL, V163, P1064, DOI 10.1016/j.cell.2015.10.067	52	12	13	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAY 14	2018	15								142	10.1186/s12974-018-1166-9			15	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	GF8YA	WOS:000432260900002	29759062	DOAJ Gold, Green Published			2021-06-18	
J	Beauchamp, MH; Aglipay, M; Yeates, KO; Desire, N; Keightley, M; Anderson, P; Brooks, BL; Barrowman, N; Gravel, J; Boutis, K; Gagnon, I; Dubrovsky, AS; Zemek, R				Beauchamp, Miriam H.; Aglipay, Mary; Yeates, Keith Owen; Desire, Naddley; Keightley, Michelle; Anderson, Peter; Brooks, Brian L.; Barrowman, Nick; Gravel, Jocelyn; Boutis, Kathy; Gagnon, Isabelle; Dubrovsky, Alexander Sasha; Zemek, Roger		5P PERC Concussion Team	Predictors of Neuropsychological Outcome After Pediatric Concussion	NEUROPSYCHOLOGY			English	Article						concussion; traumatic brain injury; neuropsychology; cognition; prediction	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; MILD HEAD-INJURY; NEUROCOGNITIVE OUTCOMES; POSTCONCUSSIVE SYMPTOMS; EMERGENCY-DEPARTMENT; CHILDREN; ADOLESCENTS; RECOVERY; IMPAIRMENT	Objective: Previous research suggests that neuropsychological outcome after pediatric concussion is determined by unmodifiable, preexisting factors. This study aimed to predict neuropsychological outcome after pediatric concussion by using a sufficiently large sample to explore a vast array of predictors. Method: A total of 311 children and adolescents (6-18 years old) with concussion were assessed in the emergency department to document acute symptomatology and to screen for cognitive functioning. At 4 and 12 weeks postinjury, they completed tests of intellectual functioning, attention/working memory, executive functions, verbal memory, processing speed, and fine motor abilities. Multiple hierarchical logistic and linear regressions were performed to assess the contribution of premorbid factors, acute symptoms, and acute cognitive screening (Standardized Assessment of Concussion-Child) to aspects of neuropsychological outcome: (a) cognitive inefficiency (defined using a modified Neuropsychological Impairment Rule; Beauchamp et al., 2015) and (b) neuropsychological performance (defined using principal component analysis). Results: Neuropsychological impairment was present in 10.3% and 4.5% of participants at 4 and 12 weeks postinjury, respectively. At 4 weeks postinjury, cognitive inefficiency was predicted by premorbid factors and acute cognitive screening, whereas at 12 weeks it was predicted by acute symptoms. Neuropsychological performance at 4 weeks was predicted by a combination of premorbid factors, acute symptoms, and acute cognitive screening, whereas as at 12 weeks, only acute cognitive screening predicted performance. Conclusions: Neuropsychological outcome after pediatric concussion is not attributable solely to preexisting problems but is instead associated with a combination of preexisting and injury-related variables. Acute cognitive screening appears to be particularly useful in predicting neuropsychological status after concussion.	[Beauchamp, Miriam H.; Desire, Naddley] Univ Montreal, Dept Psychol, CP Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada; [Beauchamp, Miriam H.; Desire, Naddley; Gravel, Jocelyn] Ste Justine Hosp Res Ctr, Montreal, PQ, Canada; [Aglipay, Mary; Barrowman, Nick; Zemek, Roger] Childrens Hosp Eastern Ontario Res Inst, Clin Res Unit, Ottawa, ON, Canada; [Yeates, Keith Owen] Univ Calgary, Alberta Childrens Hosp, Res Inst, Dept Psychol, Calgary, AB, Canada; [Yeates, Keith Owen] Univ Calgary, Alberta Childrens Hosp, Res Inst, Dept Pediat, Calgary, AB, Canada; [Yeates, Keith Owen] Univ Calgary, Alberta Childrens Hosp, Res Inst, Dept Clin Neurosci, Calgary, AB, Canada; [Yeates, Keith Owen] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Keightley, Michelle] Holland Bloorview Kids Rehabil Hosp, Bloorview Res Inst, Toronto, ON, Canada; [Keightley, Michelle] Univ Toronto, Dept Occupat Sci, Toronto, ON, Canada; [Keightley, Michelle] Univ Toronto, Dept Occupat Therapy, Toronto, ON, Canada; [Keightley, Michelle] Univ Toronto, Rehabil Sci Inst, Toronto, ON, Canada; [Anderson, Peter] Childrens Hosp Eastern Ontario Res Inst, Ottawa, ON, Canada; [Anderson, Peter] Childrens Hosp Eastern Ontario, Behav Neurosci & Consultat Liaison Program, Ottawa, ON, Canada; [Brooks, Brian L.] Univ Calgary, Dept Psychol, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Pediat, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada; [Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Neurosci Program Brain Injury & Rehabil, Calgary, AB, Canada; [Barrowman, Nick; Zemek, Roger] Univ Ottawa, Dept Pediat, Ottawa, ON, Canada; [Barrowman, Nick; Zemek, Roger] Univ Ottawa, Dept Emergency Med, Ottawa, ON, Canada; [Boutis, Kathy] Hosp Sick Children, Dept Pediat, Toronto, ON, Canada; [Boutis, Kathy] Univ Toronto, Dept Paediat, Toronto, ON, Canada; [Gagnon, Isabelle] McGill Univ, Sch Phys & Occupat Therapy, Montreal, PQ, Canada; [Gagnon, Isabelle; Dubrovsky, Alexander Sasha] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Montreal, PQ, Canada; [Dubrovsky, Alexander Sasha] McGill Univ, Dept Pediat, Montreal, PQ, Canada	Beauchamp, MH (corresponding author), Univ Montreal, Dept Psychol, CP Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	miriam.beauchamp@umontreal.ca	Yeates, Keith/AAJ-4223-2020; Barrowman, Nick/AAL-3166-2020; Richer, Lawrence/D-3622-2009	Barrowman, Nick/0000-0002-4704-9595; Osmond, Martin/0000-0001-8275-8381; Yeates, Keith/0000-0001-7680-2892; Craig, William/0000-0002-4804-194X; Richer, Lawrence/0000-0002-6897-8668; Klassen, Terry/0000-0002-5309-7091	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [126197]; Canadian Institutes of Health Research - Ontario Neurotrauma FoundationMild Traumatic Brain Injury Team [TM1: 127047]	This study was supported by operating grant 126197 from the Canadian Institutes of Health Research; grant TM1: 127047 from the Canadian Institutes of Health Research - Ontario Neurotrauma FoundationMild Traumatic Brain Injury Team. Brian Brooks receives royalties for the sales of the book, Pediatric Forensic Neuropsychology (2012, Oxford University Press), and three pediatric neuropsychological tests [Child and Adolescent Memory Profile (ChAMP; Sherman and Brooks, 2015, PAR Inc.), Memory Validity Profile (MVP, Sherman and Brooks, 2015, PAR Inc.), and Multidimensional Everyday Memory Ratings for Youth (MEMRY; Sherman and Brooks, 2017, PAR Inc.)]. We would like to acknowledge the input and contributions of the entire 5P Study team, with particular thanks to the coordinators and assistants at the neuropsychology substudy sites.	Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; [Anonymous], 2013, Br J Sports Med, V47, P263; Asarnow R, 1995, TRAUMATIC BRAIN INJU, P117; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Babikian T, 2013, J INT NEUROPSYCH SOC, V19, P145, DOI 10.1017/S135561771200104X; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Baron I., 2004, NEUROPSYCHOLOGICAL E; Beauchamp MH, 2015, J INT NEUROPSYCH SOC, V21, P596, DOI 10.1017/S1355617715000636; Bigler ED, 2015, BRAIN INJURY, V29, P1062, DOI 10.3109/02699052.2015.1011234; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; Brooks BL, 2016, J INT NEUROPSYCH SOC, V22, P379, DOI 10.1017/S1355617715001368; Brooks BL, 2013, J NEUROTRAUM, V30, P1469, DOI 10.1089/neu.2012.2720; Buckley TA, 2018, CLIN J SPORT MED, V28, P174, DOI 10.1097/JSM.0000000000000426; Conners C., 2000, CONNERS CONTINUOUS P; Delis D, 1994, CALIFORNIA VERBAL LE; Delis D.C., 2001, DELIS KAPLAN EXECUTI; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Golden CJ., 2003, STROOP COLOR WORD TE; Gravel J, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-63; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Hang B, 2015, PEDIATR EMERG CARE, V31, P688, DOI 10.1097/PEC.0000000000000438; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hung Ryan, 2014, Arch Phys Med Rehabil, V95, pS174, DOI 10.1016/j.apmr.2013.08.301; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2013, J NEUROTRAUM, V30, P625, DOI 10.1089/neu.2012.2627; Lovell M.R., 2005, IMPACT IMMEDIATE POS; Martelli MF, 1998, NEUROREHABILITATION, V11, P51, DOI 10.1016/S1053-8135(98)00009-2; McCauley SR, 2014, J NEUROTRAUM, V31, P914, DOI 10.1089/neu.2012.2826; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Nance ML, 2009, ANN SURG, V249, P859, DOI 10.1097/SLA.0b013e3181a41ae5; O'Neill J. A., 2015, J PEDIAT NEUROPSYCHO, V1, P14, DOI [10.1007/s40817-015-0003-7, DOI 10.1007/S40817-015-0003-7]; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Rieger BP, 2013, BRAIN INJURY, V27, P169, DOI 10.3109/02699052.2012.729290; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Sandel NK, 2013, APPL NEUROPSYCH-CHIL, V2, P64, DOI 10.1080/21622965.2012.670580; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Scherwath A, 2011, BRAIN INJURY, V25, P401, DOI 10.3109/02699052.2011.557351; Studer M, 2014, J INT NEUROPSYCH SOC, V20, P982, DOI 10.1017/S1355617714000927; Sufrinko A, 2017, J ATHL TRAINING, V52, P676, DOI 10.4085/1062-6050-52.4.01; Taylor AM, 2012, CURR OPIN PEDIATR, V24, P717, DOI 10.1097/MOP.0b013e32835a279b; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Thomas DG, 2011, ACAD EMERG MED, V18, P246, DOI 10.1111/j.1553-2712.2011.01015.x; Trites R., 1977, GROOVED PEGBOARD TES; Wechsler D., 2005, ECHELLE INTELLIGENCE, V4th; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D., 2011, WECHSLER ABBREVIATED; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yumul JN, 2016, PM&R, V8, P1097, DOI 10.1016/j.pmrj.2016.05.005; Zasler ND, 2015, BRAIN INJURY, V29, P207, DOI 10.3109/02699052.2014.965213; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zemek R, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003550	66	12	12	0	8	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2018	32	4					495	508		10.1037/neu0000419			14	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	GH1GU	WOS:000433151900011	29809036				2021-06-18	
J	Dobney, DM; Grilli, L; Kocilowicz, H; Beaulieu, C; Straub, M; Friedman, D; Gagnon, IJ				Dobney, Danielle M.; Grilli, Lisa; Kocilowicz, Helen; Beaulieu, Christine; Straub, Meghan; Friedman, Debbie; Gagnon, Isabelle J.			Is There an Optimal Time to Initiate an Active Rehabilitation Protocol for Concussion Management in Children? A Case Series	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain concussion; exercise therapy; mild traumatic brain injury; postconcussion syndrome	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; POSTCONCUSSION SYNDROME; EXERCISE; ADOLESCENTS; RECOVERY; IMPAIRMENT; SYMPTOMS; OUTCOMES; ANXIETY	Objective: To estimate the time frame during which initiating an active rehabilitation intervention (aerobic exercise, balance, and sport specific skills) after concussion contributed to improvement in symptoms at follow-up in children and adolescents who are slow to recover (symptoms persisting beyond 2 weeks) from concussion. Setting: Concussion clinic at a tertiary care pediatric teaching hospital. Participants: A total of 677 children and adolescents with concussion aged 7 to 18 years. Design: Case series of participants starting active rehabilitation less than 2, 2, 3, 4, 5, or 6 or more weeks postconcussion. Main Measure: Symptom severity measured by the 22-item Post-Concussion Scale (PCS)-revised. Results: All patients experienced significant improvement of symptoms while participating in active rehabilitation, irrespective of the start time postonset. Patients initiating active rehabilitation at 2 (P < .001) or 3 (P = .039) weeks postinjury demonstrated lower symptom severity at follow-up than those starting at 6 weeks or later. Patients starting at 2 weeks had lower symptom severity than patients starting less than 2 (P = .02), 4 (P = .20), or 5 weeks postinjury (P = .04). Lastly, patients starting less than 2 and 6 weeks or more postinjury yielded equivalent outcomes. Conclusions: The findings support the use of active rehabilitation in children and adolescents who are slow to recover from concussion. Participants starting active rehabilitation less than 2 weeks and up to 6 or more weeks postconcussion demonstrated significant symptom improvements, but improvement was observed in all groups, regardless of the time to start active rehabilitation.	[Dobney, Danielle M.; Gagnon, Isabelle J.] McGill Univ, Sch Phys & Occupat Therapy, Fac Med, Montreal, PQ H3G 1Y5, Canada; [Grilli, Lisa; Kocilowicz, Helen; Beaulieu, Christine; Straub, Meghan; Friedman, Debbie; Gagnon, Isabelle J.] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Ctr Trauma, Montreal, PQ, Canada; [Friedman, Debbie] Publ Hlth Agcy Canada, Canadian Hosp Injury Reporting & Prevent Program, Montreal, PQ, Canada; [Friedman, Debbie; Gagnon, Isabelle J.] McGill Univ, Fac Med, Dept Pediat, Montreal, PQ, Canada	Dobney, DM (corresponding author), McGill Univ, Sch Phys & Occupat Therapy, Fac Med, Montreal, PQ H3G 1Y5, Canada.	danielle.dobney@mail.mcgill.ca			Montreal Children's Hospital Trauma Program; Research Institute of the McGill University Health Center; Fonds de recherche du Quebec-Sante (FRQS); Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR)	We would like to thank the children and their families for participating in this study and The Montreal Children's Hospital Trauma Program professionals for their support. As well, we wish to thank the Research Institute of the McGill University Health Center for its support of this research.; Supported by Fonds de recherche du Quebec-Sante (FRQS) and Canadian Institutes of Health Research (CIHR).	Asken BM, 2016, J ATHL TRAINING, V51, P329, DOI 10.4085/1062-6050-51.5.02; Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Berlin AA, 2006, PSYCHOSOM MED, V68, P224, DOI 10.1097/01.psy.0000204628.73273.23; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cordingley D, 2016, J NEUROSURG-PEDIATR, V18, P693, DOI 10.3171/2016.5.PEDS16139; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Gagnon I, 2016, SCAND J MED SCI SPOR, V26, P299, DOI 10.1111/sms.12441; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grabowski P, 2017, PHYS THER SPORT, V23, P22, DOI 10.1016/j.ptsp.2016.06.001; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Imhoff Sarah, 2016, J Sports Med (Hindawi Publ Corp), V2016, P5127374, DOI 10.1155/2016/5127374; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; Kurowski BG, 2017, J HEAD TRAUMA REHAB, V32, P79, DOI 10.1097/HTR.0000000000000238; La Fountaine MF, 2009, AUTON NEUROSCI-BASIC, V148, P101, DOI 10.1016/j.autneu.2009.03.001; Larun L, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004691.pub2; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; McCrory P, 2009, S AFR J SPORTS MED, V21; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McLeod TCV, 2012, J ATHL TRAINING, V47, P221; Mead GE, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub3; Moser Rosemarie Scolaro, 2012, Front Neurol, V3, P171, DOI 10.3389/fneur.2012.00171; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; PETRUZZELLO SJ, 1991, SPORTS MED, V11, P143, DOI 10.2165/00007256-199111030-00002; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Winkler R, 2015, J HEAD TRAUMA REHAB, V30, P324, DOI 10.1097/HTR.0000000000000114	38	12	12	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2018	33	3					E11	E17		10.1097/HTR.0000000000000339			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	GJ7HA	WOS:000435555500002	28926482				2021-06-18	
J	Grande, LJ; Robinson, ME; Radigan, LJ; Levin, LK; Fortier, CB; Milberg, WP; McGlinchey, RE				Grande, Laura J.; Robinson, Meghan E.; Radigan, Lauren J.; Levin, Laura K.; Fortier, Catherine B.; Milberg, William P.; McGlinchey, Regina E.			Verbal Memory Deficits in OEF/OIF/OND Veterans Exposed to Blasts at Close Range	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Blast; Memory; Returning Veterans; Concussion; mTBI; PTSD	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; POSTTRAUMATIC-STRESS-DISORDER; SYMPTOM VALIDITY TEST; IRAQI FREEDOM; CLINICAL CHARACTERISTICS; FUNCTIONAL CONNECTIVITY; COGNITIVE PERFORMANCE; MILITARY PERSONNEL; ENDURING FREEDOM	Objectives: This study investigated the relationship between close proximity to detonated blast munitions and cognitive functioning in OEF/OIF/OND Veterans. Methods: A total of 333 participants completed a comprehensive evaluation that included assessment of neuropsychological functions, psychiatric diagnoses and history of military and non-military brain injury. Participants were assigned to a Close-Range Blast Exposure (CBE) or Non-Close-Range Blast Exposure (nonCBE) group based on whether they had reported being exposed to at least one blast within 10 meters. Results: Groups were compared on principal component scores representing the domains of memory, verbal fluency, and complex attention (empirically derived from a battery of standardized cognitive tests), after adjusting for age, education, PTSD diagnosis, sleep quality, substance abuse disorder, and pain. The CBE group showed poorer performance on the memory component. Rates of clinical impairment were significantly higher in the CBE group on select CVLT-II indices. Exploratory analyses examined the effects of concussion and multiple blasts on test performance and revealed that number of lifetime concussions did not contribute to memory performance. However, accumulating blast exposures at distances greater than 10 meters did contribute to poorer performance. Conclusions: Close proximity to detonated blast munitions may impact memory, and Veterans exposed to close-range blast are more likely to demonstrate clinically meaningful deficits. These findings were observed after statistically adjusting for comorbid factors. Results suggest that proximity to blast should be considered when assessing for memory deficits in returning Veterans. Comorbid psychiatric factors may not entirely account for cognitive difficulties.	[Grande, Laura J.] VA Boston Healthcare Syst, Psychol Serv, Boston, MA USA; [Grande, Laura J.; Robinson, Meghan E.; Radigan, Lauren J.; Levin, Laura K.; Fortier, Catherine B.; Milberg, William P.; McGlinchey, Regina E.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, Boston, MA USA; [Grande, Laura J.; Robinson, Meghan E.; Radigan, Lauren J.; Levin, Laura K.; Fortier, Catherine B.; Milberg, William P.; McGlinchey, Regina E.] VA Boston Healthcare Syst, GRECC, Boston, MA USA; [Grande, Laura J.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Robinson, Meghan E.] VA Boston Healthcare Syst, Neuroimaging Res Vet NeRVe Ctr, Boston, MA USA; [Robinson, Meghan E.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Radigan, Lauren J.] Wayne State Univ, Dept Psychol, Detroit, MA USA; [Fortier, Catherine B.; Milberg, William P.; McGlinchey, Regina E.] Harvard Med Sch, Dept Psychiat, Boston, MA USA	Grande, LJ (corresponding author), Psychol Serv 116B, 150 South Huntington Ave, Boston, MA 02132 USA.	laura.grande@va.gov			Veterans AffairsUS Department of Veterans Affairs [I50RX003001, I01CX001327] Funding Source: NIH RePORTER; RRD VA [I50 RX003001] Funding Source: Medline; CSRD VA [I01 CX001327] Funding Source: Medline		Alosco ML, 2016, J HEAD TRAUMA REHAB, V31, P360, DOI 10.1097/HTR.0000000000000201; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Armstrong T, 2011, BEHAV RES THER, V49, P756, DOI 10.1016/j.brat.2011.08.003; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Blake D, 2006, J TRAUMA STRESS, V8, P75; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Clark AL, 2014, CLIN NEUROPSYCHOL, V28, P802, DOI 10.1080/13854046.2014.904928; Clark US, 2007, NEUROPSYCHOLOGY, V21, P346, DOI 10.1037/0894-4105.21.3.346; Cooper DB, 2014, J REHABIL RES DEV, V51, P1023, DOI [10.1682/JRRD.2013.05.0104, 10.1682/JRRD.2013.05.0140]; Cooper DB, 2012, MIL MED, V177, P1157, DOI 10.7205/MILMED-D-12-00098; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis D.C., 1999, CALIFORNIA VERBAL LE; First M.B., 1996, STRUCTURED CLIN INTE; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Fortier-Brochu E, 2012, SLEEP MED REV, V16, P83, DOI 10.1016/j.smrv.2011.03.008; GOLINKOFF M, 1989, J AFFECT DISORDERS, V17, P105, DOI 10.1016/0165-0327(89)90032-3; Green P., 2004, MED SYMPTOM VALIDITY; GREENBERG LM, 1993, J CHILD PSYCHOL PSYC, V34, P1019, DOI 10.1111/j.1469-7610.1993.tb01105.x; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Heaton RK, 2004, REVISED COMPREHENSIV; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Iudicello JE, 2011, CLIN NEUROPSYCHOL, V25, P269, DOI 10.1080/13854046.2010.546812; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; KAISER HF, 1960, EDUC PSYCHOL MEAS, V20, P141, DOI 10.1177/001316446002000116; Kim JS, 2015, NEURODEGENER DIS, V15, P294, DOI 10.1159/000430953; Koerte IK, 2015, J NEUROTRAUM, V32, P1287, DOI 10.1089/neu.2014.3715; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lippa SM, 2015, J TRAUMA STRESS, V28, P25, DOI 10.1002/jts.21979; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald CL, 2017, JAMA NEUROL, V74, P821, DOI 10.1001/jamaneurol.2017.0143; Mac Donald CL, 2017, NEUROIMAGE-CLIN, V14, P371, DOI 10.1016/j.nicl.2017.02.005; MacNamara A, 2014, J ABNORM PSYCHOL, V123, P557, DOI 10.1037/a0036997; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McCormick CL, 2013, ARCH CLIN NEUROPSYCH, V28, P808, DOI 10.1093/arclin/act050; McGlinchey RE, 2017, INT J METH PSYCH RES, V26, DOI 10.1002/mpr.1556; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Mendez MF, 2013, NEUROREHABILITATION, V32, P397, DOI 10.3233/NRE-130861; Miller MA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00224; Montgomery C, 2012, HUM PSYCHOPHARM CLIN, V27, P217, DOI 10.1002/hup.1273; Neipert L, 2014, BRAIN INJURY, V28, P1667, DOI 10.3109/02699052.2014.947623; O'Connor BP, 2000, BEHAV RES METH INS C, V32, P396, DOI 10.3758/BF03200807; O'Neil ME, 2014, J INT NEUROPSYCH SOC, V20, P249, DOI [10.1017/S1355617714000204, 10.1017/S135561771300146X]; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Piechatzek M, 2009, HUM PSYCHOPHARM CLIN, V24, P650, DOI 10.1002/hup.1069; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Robinson ME, 2015, DEV NEUROPSYCHOL, V40, P74, DOI 10.1080/87565641.2015.1012204; Robinson ME, 2015, HUM BRAIN MAPP, V36, P911, DOI 10.1002/hbm.22675; Rourke S.B., 2009, NEUROPSYCHOLOGICAL A, P398; Soble JR, 2013, J CLIN EXP NEUROPSYC, V35, P551, DOI 10.1080/13803395.2013.798398; Solowij Nadia, 2008, Curr Drug Abuse Rev, V1, P81; Stevens S. S, 2002, APPL MULTIVARIATE ST; Storzbach D, 2015, J INT NEUROPSYCH SOC, V21, P353, DOI 10.1017/S1355617715000326; Stricker NH, 2017, J CLIN EXP NEUROPSYC, V39, P768, DOI 10.1080/13803395.2016.1264575; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; Trotter BB, 2015, BRAIN, V138, P2278, DOI 10.1093/brain/awv139; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Wong YC, 2014, J NEUROTRAUM, V31, pA25	68	12	12	0	6	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2018	24	5					466	475		10.1017/S1355617717001242			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	GD5LH	WOS:000430548000006	29362020				2021-06-18	
J	Gu, F; Parada, I; Yang, T; Longo, FM; Prince, DA				Gu, Feng; Parada, Isabel; Yang, Tao; Longo, Frank M.; Prince, David A.			Partial TrkB receptor activation suppresses cortical epileptogenesis through actions on parvalbumin interneurons	NEUROBIOLOGY OF DISEASE			English	Article						Epilepsy; BDNF; Neocortical injury; Trophic; Anti-epileptogenesis	TEMPORAL-LOBE EPILEPSY; EXCITATORY SYNAPTIC-TRANSMISSION; CULTURED HIPPOCAMPAL-NEURONS; IMPAIRED GABAERGIC INHIBITION; ACTIVITY-DEPENDENT REGULATION; FAST-SPIKING INTERNEURONS; RAT VISUAL-CORTEX; NEUROTROPHIC FACTOR; RETT-SYNDROME; MOUSE MODEL	Post-traumatic epilepsy is one of the most common and difficult to treat forms of acquired epilepsy worldwide. Currently, there is no effective way to prevent post-traumatic epileptogenesis. It is known that abnormalities of interneurons, particularly parvalbumin-containing interneurons, play a critical role in epileptogenesis following traumatic brain injury. Thus, enhancing the function of existing parvalbumin interneurons might provide a logical therapeutic approach to prevention of post-traumatic epilepsy. The known positive effects of brain-derived neurotrophic factor on intemeuronal growth and function through activation of its receptor tropomyosin receptor kinase B, and its decrease after traumatic brain injury, led us to hypothesize that enhancing trophic support might improve parvalbumin interneuronal function and decrease epileptogenesis. To test this hypothesis, we used the partial neocortical isolation ('undercut', UC) model of posttraumatic epileptogenesis in mature rats that were treated for 2 weeks, beginning on the day of injury, with LM22A-4, a newly designed partial agonist at the tropomyosin receptor kinase B. Effects of treatment were assessed with Western blots to measure pAKT/AKT; immunocytochemistry and whole cell patch clamp recordings to examine functional and structural properties of GABAergic interneurons; field potential recordings of epileptiform discharges in vitro; and video EEG recordings of PTZ-induced seizures in vivo. Results showed that LM22A-4 treatment 1) increased pyramidal cell perisomatic immunoreactivity for VGAT, GAD65 and parvalbumin; 2) increased the density of close appositions of VGAT/gephyrin immunoreactive puncta (putative inhibitory synapses) on pyramidal cell somata; 3) increased the frequency of mIPSCs in pyramidal cells; and 4) decreased the incidence of spontaneous and evoked epileptiform discharges in vitro. 5) Treatment of rats with PTX BD4-3, another partial TrkB receptor agonist, reduced the incidence of bicuculline-induced ictal episodes in vitro and PTZ induced electrographic and behavioral ictal episodes in vivo. 6) Inactivation of TrkB receptors in undercut TrkB(F616A) mice with 1NMPP1 abolished both LM22A-4-induced effects on mIPSCs and on increased perisomatic VGAT-IR. Results indicate that chronic activation of the tropomyosin receptor kinase B by a partial agonist after cortical injury can enhance structural and functional measures of GABAergic inhibition and suppress posttraumatic epileptogenesis. Although the full agonist effects of brain-derived neurotrophic factor and tropomyosin receptor kinase B activation in epilepsy models have been controversial, the present results indicate that such trophic activation by a partial agonist may potentially serve as an effective therapeutic option for prophylactic treatment of posttraumatic epileptogenesis, and treatment of other neurological and psychiatric disorders whose pathogenesis involves impaired parvalbumin intemeuronal function.	[Gu, Feng; Parada, Isabel; Yang, Tao; Longo, Frank M.; Prince, David A.] Stanford Univ, Dept Neurol & Neurol Sci, Sch Med, Stanford, CA 94305 USA	Prince, DA (corresponding author), Stanford Med Ctr, 300 Pasteur Dr,Room M016, Stanford, CA 94028 USA.	daprince@stanford.edu			National Institutes of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS082644, NS039579]; George and Irene Pimley Research Fund; Jean Perkins Foundation	This study was supported by Grants NS082644 and NS039579 from the National Institutes of Neurological Disorders and Stroke (D.A.P), the George and Irene Pimley Research Fund (D. A.P.), and the Jean Perkins Foundation (F.M. L).	Abidin I, 2008, J PHYSIOL-LONDON, V586, P1885, DOI 10.1113/jphysiol.2007.148627; Aguado F, 2003, DEVELOPMENT, V130, P1267, DOI 10.1242/dev.00351; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Aronica E, 2017, EPILEPSIA, V58, P27, DOI 10.1111/epi.13783; Baldelli P, 2005, J NEUROSCI, V25, P3358, DOI 10.1523/JNEUROSCI.4227-04.2005; Baldelli P, 2002, EUR J NEUROSCI, V16, P2297, DOI 10.1046/j.1460-9568.2002.02313.x; Bartolomei F, 2017, EPILEPSIA, V58, P1131, DOI 10.1111/epi.13791; Bausch SB, 2005, EPILEPSY BEHAV, V7, P390, DOI 10.1016/j.yebeh.2005.07.019; Berghuis P, 2006, J NEUROBIOL, V66, P1437, DOI 10.1002/neu.20319; Bolton MM, 2000, J NEUROSCI, V20, P3221, DOI 10.1523/JNEUROSCI.20-09-03221.2000; Brock JH, 2010, J NEUROSCI, V30, P9728, DOI 10.1523/JNEUROSCI.1924-10.2010; Cai ZX, 2016, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2016.00129; Carmignoto G, 1997, J PHYSIOL-LONDON, V498, P153, DOI 10.1113/jphysiol.1997.sp021848; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V61, P747; Chapleau CA, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/578057; Chaudhry FA, 1998, J NEUROSCI, V18, P9733; Chen X, 2005, NEURON, V46, P13, DOI 10.1016/j.neuron.2005.03.009; Cheng PL, 2011, P NATL ACAD SCI USA, V108, P18430, DOI 10.1073/pnas.1115907108; Cossart R, 2001, NAT NEUROSCI, V4, P52; Croll SD, 1999, NEUROSCIENCE, V93, P1491, DOI 10.1016/S0306-4522(99)00296-1; CROLL SD, 1994, EUR J NEUROSCI, V6, P1343, DOI 10.1111/j.1460-9568.1994.tb00325.x; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; DeFelipe J, 1999, BRAIN, V122, P1807, DOI 10.1093/brain/122.10.1807; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Dinocourt C, 2006, EUR J NEUROSCI, V24, P1857, DOI 10.1111/j.1460-9568.2006.05067.x; Eftekhari S, 2016, BASIC CLIN NEUROSCI, V7, P115, DOI 10.15412/J.BCN.03070205; Elmariah SB, 2004, J NEUROSCI, V24, P2380, DOI 10.1523/JNEUROSCI.4112-03.2004; Faria LC, 2012, NEUROBIOL DIS, V45, P821, DOI 10.1016/j.nbd.2011.11.006; Faria LC, 2010, J NEUROPHYSIOL, V104, P280, DOI 10.1152/jn.00351.2010; Frerking M, 1998, J NEUROPHYSIOL, V80, P3383; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; Giblin KA, 2010, NEUROSCIENTIST, V16, P253, DOI 10.1177/1073858409354385; Giehl KM, 1996, EUR J NEUROSCI, V8, P1167, DOI 10.1111/j.1460-9568.1996.tb01284.x; Gill R, 2013, EUR J NEUROSCI, V38, P3554, DOI 10.1111/ejn.12367; Glaze DG, 2010, NEUROLOGY, V74, P909, DOI 10.1212/WNL.0b013e3181d6b852; Gottmann K, 2009, EXP BRAIN RES, V199, P203, DOI 10.1007/s00221-009-1994-z; Graber KD, 2004, ANN NEUROL, V55, P860, DOI 10.1002/ana.20124; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; Graber KD, 2006, MODELS OF SEIZURES AND EPILEPSY, P477, DOI 10.1016/B978-012088554-1/50040-2; Gu B, 2015, NEURON, V88, P484, DOI 10.1016/j.neuron.2015.09.032; Gu F, 2017, NEUROBIOL DIS, V108, P100, DOI 10.1016/j.nbd.2017.08.008; Guye M, 2006, BRAIN, V129, P1917, DOI 10.1093/brain/awl151; Han J, 2012, STROKE, V43, P1918, DOI 10.1161/STROKEAHA.111.641878; HARRIS KM, 1995, NEUROPHARMACOLOGY, V34, P1387, DOI 10.1016/0028-3908(95)00142-S; Hashemi E, 2017, CEREB CORTEX, V27, P1931, DOI 10.1093/cercor/bhw021; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; He J, 2005, CELL PHYSIOL BIOCHEM, V16, P69, DOI 10.1159/000087733; Henderson KW, 2014, J NEUROSCI, V34, P13492, DOI 10.1523/JNEUROSCI.0005-14.2014; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762; Holm MM, 2009, J NEUROSCI, V29, P12412, DOI 10.1523/JNEUROSCI.2978-09.2009; Hong EJ, 2008, NEURON, V60, P610, DOI 10.1016/j.neuron.2008.09.024; Jiang B, 2004, EUR J NEUROSCI, V20, P709, DOI 10.1111/j.1460-9568.2004.03523.x; Jiao YY, 2006, J NEUROSCI, V26, P8691, DOI 10.1523/JNEUROSCI.2478-06.2006; Jiao YY, 2011, P NATL ACAD SCI USA, V108, P12131, DOI 10.1073/pnas.1105296108; Jin X, 2003, J NEUROSCI, V23, P5662; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kang SK, 2015, EUR J NEUROSCI, V42, P2792, DOI 10.1111/ejn.13094; Khoshkhoo S, 2017, NEURON, V93, P291, DOI 10.1016/j.neuron.2016.11.043; Kohara K, 2003, J NEUROSCI, V23, P6123; Kohara K, 2007, J NEUROSCI, V27, P7234, DOI 10.1523/JNEUROSCI.1943-07.2007; KOKAIA M, 1995, EXP NEUROL, V133, P215, DOI 10.1006/exnr.1995.1024; Kron M, 2014, DIS MODEL MECH, V7, P1047, DOI 10.1242/dmm.016030; Kumar SS, 2006, J NEUROSCI, V26, P4613, DOI 10.1523/JNEUROSCI.0064-06.2006; Kuriu T, 2012, MOL CELL NEUROSCI, V49, P184, DOI 10.1016/j.mcn.2011.11.002; Lemtiri-Chlieh F, 2010, J NEUROPHYSIOL, V104, P1923, DOI 10.1152/jn.00472.2010; Lewis DA, 2012, TRENDS NEUROSCI, V35, P57, DOI 10.1016/j.tins.2011.10.004; Li HF, 2002, J NEUROPHYSIOL, V88, P2, DOI 10.1152/jn.00507.2001; Li HF, 2012, NEUROBIOL DIS, V48, P429, DOI 10.1016/j.nbd.2012.06.019; Li HF, 2011, NEUROSCI LETT, V497, P172, DOI 10.1016/j.neulet.2011.02.042; Li W, 2017, DIS MODEL MECH, V10, P837, DOI 10.1242/dmm.029959; Li YX, 1998, J NEUROSCI, V18, P10231; Li YX, 1998, P NATL ACAD SCI USA, V95, P10884, DOI 10.1073/pnas.95.18.10884; Lin YX, 2008, NATURE, V455, P1198, DOI 10.1038/nature07319; Lippmann K, 2017, J CEREBR BLOOD F MET, V37, P1803, DOI 10.1177/0271678X16652631; Liu GM, 2013, NEURON, V79, P31, DOI 10.1016/j.neuron.2013.04.027; Ma YY, 2012, NEUROBIOL DIS, V47, P102, DOI 10.1016/j.nbd.2012.03.027; Marty S, 1997, TRENDS NEUROSCI, V20, P198, DOI 10.1016/S0166-2236(96)01026-0; Marty S, 1996, J NEUROSCI, V16, P675; Massa SM, 2010, J CLIN INVEST, V120, P1774, DOI 10.1172/JCI41356; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; McNamara J. O., 2012, JASPERS BASIC MECH E, V4 th; Novikov LN, 2000, NEUROSCIENCE, V100, P171, DOI 10.1016/S0306-4522(00)00256-6; Numakawa T, 2002, J BIOL CHEM, V277, P6520, DOI 10.1074/jbc.M109139200; Palizvan MR, 2004, NEUROSCIENCE, V126, P955, DOI 10.1016/j.neuroscience.2004.03.053; Paradiso B, 2009, P NATL ACAD SCI USA, V106, P7191, DOI 10.1073/pnas.0810710106; Peng ZC, 2013, J NEUROSCI, V33, P14392, DOI 10.1523/JNEUROSCI.2045-13.2013; Ping XJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158231; Pitkanen A, 2012, JASPERS BASIC MECH E; Prince DA, 2016, PROG BRAIN RES, V226, P209, DOI 10.1016/bs.pbr.2016.03.013; Prince D. A., 2012, JASPERS BASIC MECH E, V4, P315; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Puskarjov M, 2015, NEUROPHARMACOLOGY, V88, P103, DOI 10.1016/j.neuropharm.2014.09.005; Reibel S, 2003, HIPPOCAMPUS, V13, P557, DOI 10.1002/hipo.10110; RIBAK CE, 1982, CAN J PHYSIOL PHARM, V60, P864, DOI 10.1139/y82-122; Rico B, 2002, NAT NEUROSCI, V5, P225, DOI 10.1038/nn808; Rivera C, 2004, J NEUROSCI, V24, P4683, DOI 10.1523/JNEUROSCI.5265-03.2004; Rutherford LC, 1998, NEURON, V21, P521, DOI 10.1016/S0896-6273(00)80563-2; Rutherford LC, 1997, J NEUROSCI, V17, P4527; Sakata K, 2009, P NATL ACAD SCI USA, V106, P5942, DOI 10.1073/pnas.0811431106; Salin PA, 1996, J NEUROPHYSIOL, V75, P1589; Sanchez-Munoz I, 2011, BRAIN RES, V1375, P28, DOI 10.1016/j.brainres.2010.12.031; Schmid DA, 2012, J NEUROSCI, V32, P1803, DOI 10.1523/JNEUROSCI.0865-11.2012; Seil FJ, 2000, J NEUROSCI, V20, P5367, DOI 10.1523/JNEUROSCI.20-14-05367.2000; Simmons DA, 2013, J NEUROSCI, V33, P18712, DOI 10.1523/JNEUROSCI.1310-13.2013; Steullet P, 2017, MOL PSYCHIATR, V22, P936, DOI 10.1038/mp.2017.47; Takahashi DK, 2016, NEUROBIOL DIS, V91, P166, DOI 10.1016/j.nbd.2016.03.003; Tripp A, 2012, AM J PSYCHIAT, V169, P1194, DOI 10.1176/appi.ajp.2012.12020248; Turrigiano GG, 1999, TRENDS NEUROSCI, V22, P221, DOI 10.1016/S0166-2236(98)01341-1; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Uematsu M, 2008, CEREB CORTEX, V18, P315, DOI 10.1093/cercor/bhm056; Verret L, 2012, CELL, V149, P708, DOI 10.1016/j.cell.2012.02.046; Vezzani A, 2013, EXP NEUROL, V244, P11, DOI 10.1016/j.expneurol.2011.09.033; Vicario-Abejon C, 1998, J NEUROSCI, V18, P7256; Wang XD, 2009, J NEUROSCI, V29, P5508, DOI 10.1523/JNEUROSCI.4288-08.2009; Wardle RA, 2003, J NEUROSCI, V23, P8722; Yu GZ, 2015, INT J CLIN EXP PATHO, V8, P6526; Zhang W, 2009, J NEUROSCI, V29, P7846, DOI 10.1523/JNEUROSCI.6199-08.2009; Zhu WJ, 2001, ANN NEUROL, V50, P188, DOI 10.1002/ana.1074	120	12	13	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	MAY	2018	113						45	58		10.1016/j.nbd.2018.01.018			14	Neurosciences	Neurosciences & Neurology	GD6SU	WOS:000430639500005	29408225	Other Gold			2021-06-18	
J	Johnson, BD; O'Leary, MC; McBryde, M; Sackett, JR; Schlader, ZJ; Leddy, JJ				Johnson, Blair D.; O'Leary, Morgan C.; McBryde, Muhamed; Sackett, James R.; Schlader, Zachary J.; Leddy, John J.			Face cooling exposes cardiac parasympathetic and sympathetic dysfunction in recently concussed college athletes	PHYSIOLOGICAL REPORTS			English	Article						Autonomic nervous system; blood pressure; heart rate; heart rate variability; mild traumatic brain injury; sympathetic nervous system	TRAUMATIC BRAIN-INJURY; HEART-RATE-VARIABILITY; TEMPORAL WINDOW; BLOOD-PRESSURE; NERVE ACTIVITY; EXERCISE; VULNERABILITY; INCREASES; RECOVERY; LIGHT	We tested the hypothesis that concussed college athletes (CA) have attenuated parasympathetic and sympathetic responses to face cooling (FC). Eleven symptomatic CA (age: 20 +/- 2 years, 5 women) who were within 10 days of concussion diagnosis and 10 healthy controls (HC; age: 24 +/- 4 years, 5 women) participated. During FC, a plastic bag filled with ice water (similar to 0 degrees C) was placed on the forehead, eyes, and cheeks for 3 min. Heart rate (ECG) and blood pressure (photoplethysmography) were averaged at baseline and every 60 sec during FC. High-frequency (HF) power was obtained from spectral analysis of the R-R interval. Data are presented as a change from baseline. Baseline heart rate (HC: 61 +/- 12, CA: 57 +/- 12 bpm; P = 0.69), mean arterial pressure (MAP) (HC: 94 +/- 10, CA: 96 +/- 13 mmHg; P = 0.74), and HF (HC: 2294 +/- 2314, CA: 2459 +/- 2058 msec(2); P = 0.86) were not different between groups. Heart rate in HC decreased at 2 min (+/- 7 +/- 11 bpm; P = 0.02) but did not change in CA (P > 0.43). MAP increased at 1 min (HC: 12 +/- 6, CA: 6 +/- 6 mmHg), 2 min (HC: 21 +/- 7, CA: 11 +/- 7 mmHg), and 3 min (HC: 20 +/- 6, CA: 13 +/- 7 mmHg) in both groups (P < 0.01 for all) but the increase was greater at each interval in HC (P < 0.02). HF increased at 1 min (12354 +/- 11489 msec(2); P < 0.01) and 2 min (5832 +/- 8002 msec(2); P = 0.02) in HC but did not change in CA (P > 0.58). The increase in HF at 1 min was greater in HC versus CA (P < 0.01). These data indicate that symptomatic concussed patients have impaired cardiac parasympathetic and sympathetic activation.	[Johnson, Blair D.; O'Leary, Morgan C.; McBryde, Muhamed; Sackett, James R.; Schlader, Zachary J.] Univ Buffalo, Dept Exercise & Nutr Sci, Ctr Res & Educ Special Environm, 208A Kimball Tower, Buffalo, NY 14214 USA; [Leddy, John J.] Univ Buffalo, Dept Orthopaed & Sports Med, UBMD, Buffalo, NY USA	Johnson, BD (corresponding author), Univ Buffalo, Dept Exercise & Nutr Sci, Ctr Res & Educ Special Environm, 208A Kimball Tower, Buffalo, NY 14214 USA.	blairjoh@buffalo.edu		Schlader, Zachary/0000-0003-3590-3958; Sackett, James/0000-0002-1817-651X	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS094444]; National Center for Advancing Translational Sciences of the National Institutes of Health Pilot Grants Award Program [UL1TR001412]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001412] Funding Source: NIH RePORTER	Research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award number 1R01NS094444 and by the National Center for Advancing Translational Sciences of the National Institutes of Health Pilot Grants Award Program under award Number UL1TR001412.	Abaji JP, 2016, J NEUROTRAUM, V33, P811, DOI 10.1089/neu.2015.3989; ALBENTOSA M, 1994, AQUACULTURE, V126, P315, DOI 10.1016/0044-8486(94)90048-5; Clausen M, 2016, J HEAD TRAUMA REHAB, V31, P215, DOI 10.1097/HTR.0000000000000145; Darling SR, 2014, CLIN J SPORT MED, V24, P128, DOI 10.1097/JSM.0000000000000026; Dobson JL, 2017, AM J PHYSIOL-REG I, V312, pR575, DOI 10.1152/ajpregu.00499.2016; FINLEY JP, 1979, J APPL PHYSIOL, V47, P1218; Fisher JP, 2015, AM J PHYSIOL-HEART C, V308, pH367, DOI 10.1152/ajpheart.00728.2014; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Goldstein B, 1996, CRIT CARE MED, V24, P234, DOI 10.1097/00003246-199602000-00009; Hayashi N, 1997, EUR J APPL PHYSIOL O, V76, P394, DOI 10.1007/s004210050267; HEISTAD DD, 1968, J APPL PHYSIOL, V25, P542; Hilz MJ, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0584-5; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; Hilz MJ, 1999, AM J PHYSIOL-REG I, V276, pR1833, DOI 10.1152/ajpregu.1999.276.6.R1833; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnson BD, 2017, AM J PHYSIOL-REG I, V313, pR594, DOI 10.1152/ajpregu.00253.2017; Joyner MJ, 2016, J PHYSIOL-LONDON, V594, P4009, DOI 10.1113/JP271875; King ML, 1997, BRAIN INJURY, V11, P445; Kozlowski KF, 2013, J ATHL TRAINING, V48, P627, DOI 10.4085/1062-6050-48.5.02; La Fountaine MF, 2009, AUTON NEUROSCI-BASIC, V148, P101, DOI 10.1016/j.autneu.2009.03.001; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; LOWENSOHN RI, 1977, LANCET, V1, P626; Mainwaring L, 2018, INT J PSYCHOPHYSIOL; Michael S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00301; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Pendergast DR, 2015, COMPR PHYSIOL, V5, P1705, DOI 10.1002/cphy.c140018; Polak P, 2015, J HEAD TRAUMA REHAB, V30, pE32, DOI 10.1097/HTR.0000000000000037; Rickards CA, 2010, J CLIN MONIT COMPUT, V24, P61, DOI 10.1007/s10877-009-9210-z; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schlader ZJ, 2018, EXP PHYSIOL, V103, P701, DOI 10.1113/EP086865; Schlader ZJ, 2016, AM J PHYSIOL-REG I, V311, pR643, DOI 10.1152/ajpregu.00164.2016; Shamsuzzaman A, 2014, AUTON NEUROSCI-BASIC, V181, P74, DOI 10.1016/j.autneu.2013.12.001; Sung CW, 2016, CLIN NEUROPHYSIOL, V127, P1629, DOI 10.1016/j.clinph.2015.08.006; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Thiagarajan P, 2015, BRAIN INJURY, V29, P1420, DOI 10.3109/02699052.2015.1045029; Truong JQ, 2016, BRAIN INJURY, V30, P1378, DOI 10.1080/02699052.2016.1195922; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; WESSELING KH, 1993, J APPL PHYSIOL, V74, P2566	44	12	12	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2051-817X			PHYSIOL REP	PHYSIOL. REP.	MAY	2018	6	9							e13694	10.14814/phy2.13694			11	Physiology	Physiology	GF5SR	WOS:000432028600009	29741235	DOAJ Gold, Green Published			2021-06-18	
J	Jourdan, C; Azouvi, P; Genet, F; Selly, N; Josseran, L; Schnitzler, A				Jourdan, Claire; Azouvi, Philippe; Genet, Francois; Selly, Nicolas; Josseran, Loic; Schnitzler, Alexis			Disability and Health Consequences of Traumatic Brain Injury National Prevalence	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						Brain Injuries; Epidemiology; Prevalence; Disability	ALZHEIMERS-DISEASE; UNITED-STATES; BIRTH COHORT; YOUNG-ADULTS; HEAD-INJURY; PARIS-TBI; EPIDEMIOLOGY; POPULATION; REHABILITATION; DISORDERS	Objective: The aim of the study was to measure the prevalence of traumatic brain injury (TBI)-related disability and health status in the general population. Design: The French National Survey, conducted in households and institutions, assessed 33,896 adults. Data included sequelae from TBI, impairments, current health conditions, and uses of health services. Analyses, adjusted for age and sex, compared subjects who declared sequelae from TBI (n = 479) with the remaining survey population (n = 33,287). Use of weighting factors ensured that results were representative of the national population. Results: Prevalence of persistent sequelae from TBI in France was 704/100,000. Median time since injury was 14 yrs. For all Core Set items of the International Classification of Functioning, subjects with TBI reported more impairments than the control population: adjusted odds ratios from 1.7 (behavioral difficulties) to 8.6 (motor difficulties). Rates of cardiovascular, respiratory, musculoskeletal, digestive, urological, neurological, and psychiatric conditions were higher in the TBI population. Use of health services was greater, and women with TBI had higher rates of unmet health needs. Conclusions: Persistent sequelae from TBI significantly affect health in the general population. Planning of post-TBI care should address the chronic needs of these persons.	[Jourdan, Claire] CHU Montpellier, Dept Med Phys & Readaptat, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France; [Jourdan, Claire; Azouvi, Philippe; Selly, Nicolas; Josseran, Loic; Schnitzler, Alexis] Univ Versailles St Quentin, HANDIReSP EA 4047, Le Bretonneux, France; [Azouvi, Philippe; Genet, Francois; Josseran, Loic; Schnitzler, Alexis] APHP CHU Raymond Poincare, Serv Med Phys & Readaptat, Garches, France; [Genet, Francois] CIC IT 1429, Garches, France; [Genet, Francois] Univ Versailles St Quentin Yvelines, UFR Sci, INSERM U1179, Le Bretonneux, France; [Josseran, Loic] Hop Raymond Poincare, AP HP, Dept Informat Med, Garches, France	Jourdan, C (corresponding author), CHU Montpellier, Dept Med Phys & Readaptat, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France.		josseran, loic/F-3190-2019	josseran, loic/0000-0002-9021-1818	French National Institute of Statistics (INSEE); Head Office of Research, Studies, Evaluation and Statistics (DREES) of the Social Affairs Ministry of France	The Disability and Health Survey was designed, undertaken, and financed by the French National Institute of Statistics (INSEE) and the Head Office of Research, Studies, Evaluation and Statistics (DREES) of the Social Affairs Ministry of France. These institutes did not finance the data analysis or the preparation of the article.	[Anonymous], 2010, MISS INT VUE EL PLAN; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Bouvier G, 2011, ENQUETE HANDICAP SAN, V61; Cameron CM, 2005, B WORLD HEALTH ORGAN, V83, P345; Chen YH, 2011, STROKE, V42, P2733, DOI 10.1161/STROKEAHA.111.620112; Colantonio A, 2016, ARCH PHYS MED REHAB, V97, pS1, DOI 10.1016/j.apmr.2015.12.002; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000020; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dams-O'Connor K, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000073; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gustavsson A, 2011, EUR NEUROPSYCHOPHARM, V21, P718, DOI 10.1016/j.euroneuro.2011.08.008; Ilie G, 2015, J NEUROTRAUM, V32, P1130, DOI 10.1089/neu.2014.3619; JENNETT B, 1975, LANCET, V1, P480; Jourdan C, 2013, BRAIN INJURY, V27, P1000, DOI 10.3109/02699052.2013.794971; Jourdan C, 2017, J HEAD TRAUMA REHAB, V32, pE26, DOI 10.1097/HTR.0000000000000276; Knight M, 2001, J PUBLIC HEALTH MED, V23, P179, DOI 10.1093/pubmed/23.3.179; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laursen B, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001521; Laxe S, 2013, BRAIN INJURY, V27, P379, DOI 10.3109/02699052.2012.750757; Li LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084336; Marwitz JH, 2001, J HEAD TRAUMA REHAB, V16, P307, DOI 10.1097/00001199-200108000-00002; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Schnitzler A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115375; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Steel Z, 2014, INT J EPIDEMIOL, V43, P476, DOI 10.1093/ije/dyu038; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; United Nations. UN Department of Economic and Social Affairs Statistics Division, 2001, GUID PRINC DEV DIS S; vanBalen HGG, 1996, DISABIL REHABIL, V18, P181, DOI 10.3109/09638289609166298; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Whiteneck GG, 2016, J HEAD TRAUMA REHAB, V31, pE55, DOI 10.1097/HTR.0000000000000140; Willer B, 1996, NEUROREHABILITATION, V6, P219, DOI 10.3233/NRE-1996-6308; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Winqvist S, 2007, NEUROEPIDEMIOLOGY, V29, P136, DOI 10.1159/000110741; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	45	12	12	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAY	2018	97	5					323	331		10.1097/PHM.0000000000000848			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	GE4HI	WOS:000431175800010	29016402				2021-06-18	
J	Kirkpatrick, CT; Wang, YX; Juarez, MML; Shivshankar, P; Garcia, JP; Plumer, AK; Kulkarni, VV; Ware, HH; Gulraiz, F; Cavasos, MAC; Zayes, GM; Wali, S; Rice, AP; Liu, HB; Tour, JM; Sikkema, WKA; Solbes, ASC; Youker, KA; Tuvim, MJ; Dickey, BF; Evans, SE				Kirkpatrick, Carson T.; Wang, Yongxing; Juarez, Miguel M. Leiva; Shivshankar, Pooja; Pantaleon Garcia, Jezreel; Plumer, Alexandria K.; Kulkarni, Vikram V.; Ware, Hayden H.; Gulraiz, Fahad; Cavasos, Miguel A. Chavez; Martinez Zayes, Gabriela; Wali, Shradha; Rice, Andrew P.; Liu, Hongbing; Tour, James M.; Sikkema, William K. A.; Solbes, Ana S. Cruz; Youker, Keith A.; Tuvim, Michael J.; Dickey, Burton F.; Evans, Scott E.			Inducible Lung Epithelial Resistance Requires Multisource Reactive Oxygen Species Generation To Protect against Viral Infections	MBIO			English	Article						inducible resistance; Toll-like receptors; lung epithelium; mucosal immunity; reactive oxygen species; viral pneumonia	INFLUENZA-A VIRUS; COMMUNITY-ACQUIRED PNEUMONIA; HYDROPHILIC CARBON CLUSTERS; TRAUMATIC BRAIN-INJURY; INNATE IMMUNE-RESPONSE; CEREBROVASCULAR DYSFUNCTION; BACTERICIDAL ACTIVITY; HYDROGEN-PEROXIDE; AIRWAY EPITHELIUM; NADPH OXIDASES	Viral pneumonias cause profound worldwide morbidity, necessitating novel strategies to prevent and treat these potentially lethal infections. Stimulation of intrinsic lung defenses via inhalation of synergistically acting Toll-like receptor (TLR) agonists protects mice broadly against pneumonia, including otherwise-lethal viral infections, providing a potential opportunity to mitigate infectious threats. As intact lung epithelial TLR signaling is required for the inducible resistance and as these cells are the principal targets of many respiratory viruses, the capacity of lung epithelial cells to be therapeutically manipulated to function as autonomous antiviral effectors was investigated. Our work revealed that mouse and human lung epithelial cells could be stimulated to generate robust antiviral responses that both reduce viral burden and enhance survival of isolated cells and intact animals. The antiviral protection required concurrent induction of epithelial reactive oxygen species (ROS) from both mitochondrial and dual oxidase sources, although neither type I interferon enrichment nor type I interferon signaling was required for the inducible protection. Taken together, these findings establish the sufficiency of lung epithelial cells to generate therapeutically inducible antiviral responses, reveal novel antiviral roles for ROS, provide mechanistic insights into inducible resistance, and may provide an opportunity to protect patients from viral pneumonia during periods of peak vulnerability. IMPORTANCE Viruses are the most commonly identified causes of pneumonia and inflict unacceptable morbidity, despite currently available therapies. While lung epithelial cells are principal targets of respiratory viruses, they have also been recently shown to contribute importantly to therapeutically inducible antimicrobial responses. This work finds that lung cells can be stimulated to protect themselves against viral challenges, even in the absence of leukocytes, both reducing viral burden and improving survival. Further, it was found that the protection occurs via unexpected induction of reactive oxygen species (ROS) from spatially segregated sources without reliance on type I interferon signaling. Coordinated multisource ROS generation has not previously been described against viruses, nor has ROS generation been reported for epithelial cells against any pathogen. Thus, these findings extend the potential clinical applications for the strategy of inducible resistance to protect vulnerable people against viral infections and also provide new insights into the capacity of lung cells to protect against infections via novel ROS-dependent mechanisms.	[Kirkpatrick, Carson T.; Wang, Yongxing; Juarez, Miguel M. Leiva; Shivshankar, Pooja; Kulkarni, Vikram V.; Ware, Hayden H.; Gulraiz, Fahad; Cavasos, Miguel A. Chavez; Tuvim, Michael J.; Dickey, Burton F.; Evans, Scott E.] Univ Texas MD Anderson Canc Ctr, Dept Pulm Med, Houston, TX 77030 USA; [Pantaleon Garcia, Jezreel; Martinez Zayes, Gabriela] Tecnol Monterrey Sch Med, Monterrey, Mexico; [Plumer, Alexandria K.; Wali, Shradha; Dickey, Burton F.; Evans, Scott E.] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA; [Rice, Andrew P.; Liu, Hongbing] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Tour, James M.; Sikkema, William K. A.] Rice Univ, Smalley Inst Nanoscale Sci & Technol, Houston, TX USA; [Solbes, Ana S. Cruz; Youker, Keith A.] Houston Methodist Hosp, Michael E Debakey Heart & Vasc Inst, Houston, TX USA	Evans, SE (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pulm Med, Houston, TX 77030 USA.; Evans, SE (corresponding author), Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA.	seevans@mdanderson.org		Wali, Shradha/0000-0002-6077-7618; Kulkarni, Vikram/0000-0002-0498-3871; Plumer, Alexandria/0000-0002-7889-7378	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HL117976, DP2 HL123229, P30 CA016672]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA016672] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [DP2HL123229, R01HL117976] Funding Source: NIH RePORTER	This study was supported by NIH grants R01 HL117976 and DP2 HL123229 to S.E.E. and P30 CA016672 to the MD Anderson Cancer Center.	Alfaro VY, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00008; Bals R, 2004, EUR RESPIR J, V23, P327, DOI 10.1183/09031936.03.00098803; Bartlett Jennifer A., 2008, V15, P147, DOI 10.1159/000136349; Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387-2656(05)11004-7; Bitner BR, 2012, ACS NANO, V6, P8007, DOI 10.1021/nn302615f; Cegolon L, 2014, INT J HYG ENVIR HEAL, V217, P17, DOI 10.1016/j.ijheh.2013.03.001; Cleaver JO, 2014, MUCOSAL IMMUNOL, V7, P78, DOI 10.1038/mi.2013.26; Cordero-Reyes AM, 2014, J MOL CELL CARDIOL, V68, P98, DOI 10.1016/j.yjmcc.2013.12.029; Dikalov SI, 2014, ANTIOXID REDOX SIGN, V20, P372, DOI 10.1089/ars.2012.4886; Duggan JM, 2011, J IMMUNOL, V186, P5916, DOI 10.4049/jimmunol.1002122; Dushoff J, 2006, AM J EPIDEMIOL, V163, P181, DOI 10.1093/aje/kwj024; Evans SE, 2011, BRIT J PHARMACOL, V163, P195, DOI 10.1111/j.1476-5381.2011.01237.x; Evans SE, 2010, ANNU REV PHYSIOL, V72, P413, DOI 10.1146/annurev-physiol-021909-135909; Evans SE, 2010, AM J RESP CELL MOL, V42, P40, DOI 10.1165/rcmb.2008-0260OC; Fahy JV, 2011, AM J RESP CRIT CARE, V184, P390, DOI 10.1164/rccm.201107-1258ED; Fang FC, 2011, MBIO, V2, DOI 10.1128/mBio.00141-11; Fischer AJ, 2011, AM J RESP CELL MOL, V45, P874, DOI 10.1165/rcmb.2010-0329OC; Fischer H, 2009, ANTIOXID REDOX SIGN, V11, P2453, DOI [10.1089/ars.2009.2558, 10.1089/ARS.2009.2558]; Forteza R, 2005, AM J RESP CELL MOL, V32, P462, DOI 10.1165/rcmb.2004-0302OC; Gattas MV, 2009, FREE RADICAL BIO MED, V47, P1450, DOI 10.1016/j.freeradbiomed.2009.08.017; Geng J, 2015, NAT IMMUNOL, V16, P1142, DOI 10.1038/ni.3268; Grandvaux N, 2015, CLIN SCI, V128, P337, DOI 10.1042/CS20140321; Hamanaka RB, 2010, TRENDS BIOCHEM SCI, V35, P505, DOI 10.1016/j.tibs.2010.04.002; Hippenstiel S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-97; Holtzman MJ, 2011, CURR OPIN IMMUNOL, V23, P487, DOI 10.1016/j.coi.2011.05.010; Ibricevic A, 2006, J VIROL, V80, P7469, DOI 10.1128/JVI.02677-05; Iwasaki A, 2014, NAT REV IMMUNOL, V14, P315, DOI 10.1038/nri3665; Jain S, 2015, NEW ENGL J MED, V373, P415, DOI 10.1056/NEJMoa1500245; Jain S, 2015, NEW ENGL J MED, V372, P835, DOI 10.1056/NEJMoa1405870; Jennings LC, 2008, THORAX, V63, P42, DOI 10.1136/thx.2006.075077; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Kim HJ, 2013, AM J RESP CELL MOL, V49, P855, DOI 10.1165/rcmb.2013-0003OC; Kim S, 2015, ANTIVIR RES, V119, P78, DOI 10.1016/j.antiviral.2015.04.011; Knust J, 2009, ANAT REC, V292, P113, DOI 10.1002/ar.20747; Leigh R, 2015, PHARMACOL THERAPEUT, V148, P185, DOI 10.1016/j.pharmthera.2014.12.005; Maghzal GJ, 2012, FREE RADICAL BIO MED, V53, P1903, DOI 10.1016/j.freeradbiomed.2012.09.002; Marcano DC, 2013, J NEUROTRAUM, V30, P789, DOI 10.1089/neu.2011.2301; Mizgerd JP, 2006, PLOS MED, V3, P155, DOI 10.1371/journal.pmed.0030076; Moron CG, 2005, P AM THORAC SOC, V2, pA452; Patton JS, 2010, J AEROSOL MED PULM D, V23, pS71, DOI 10.1089/jamp.2010.0836; Rahman I, 2006, EUR J PHARMACOL, V533, P222, DOI 10.1016/j.ejphar.2005.12.087; Rudan I, 2004, B WORLD HEALTH ORGAN, V82, P891; Ruuskanen O, 2011, LANCET, V377, P1264, DOI 10.1016/S0140-6736(10)61459-6; Samuel ELG, 2015, P NATL ACAD SCI USA, V112, P2343, DOI 10.1073/pnas.1417047112; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; Shin N, 2015, BIOCHEM BIOPH RES CO, V459, P699, DOI 10.1016/j.bbrc.2015.03.010; Shornick LP, 2008, J IMMUNOL, V180, P3319, DOI 10.4049/jimmunol.180.5.3319; Strengert M, 2014, ANTIOXID REDOX SIGN, V20, P2695, DOI 10.1089/ars.2013.5353; Tsukagoshi H, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00278; Tuvim MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030596; van der Vliet A, 2008, FREE RADICAL BIO MED, V44, P938, DOI 10.1016/j.freeradbiomed.2007.11.016; West AP, 2011, NATURE, V472, P476, DOI 10.1038/nature09973; Wijkstrom-Frei C, 2003, AM J RESP CELL MOL, V29, P206, DOI 10.1165/rcmb.2002-0152OC; Wojtala A, 2014, METHOD ENZYMOL, V542, P243, DOI 10.1016/B978-0-12-416618-9.00013-3; World Health Organization, 2004, WORLD HLTH REPORT 20; WYDE PR, 1977, INFECT IMMUN, V15, P221, DOI 10.1128/IAI.15.1.221-229.1977; Yoshizumi T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5713; Zamojc K, 2016, CRIT REV ANAL CHEM, V46, P171, DOI 10.1080/10408347.2015.1014085; Zhang X, 2015, FREE RADICAL RES, V49, P374, DOI 10.3109/10715762.2015.1014813	59	12	12	0	2	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	2150-7511			MBIO	mBio	MAY-JUN	2018	9	3							e00696-18	10.1128/mBio.00696-18			18	Microbiology	Microbiology	GG9WG	WOS:000433051200043	29764948	DOAJ Gold, Green Published			2021-06-18	
J	Esenaliev, RO; Petrov, IY; Petrov, Y; Guptarak, J; Boone, DR; Mocciaro, E; Weisz, H; Parsley, MA; Sell, SL; Hellmich, H; Ford, JM; Pogue, C; DeWitt, D; Prough, DS; Micci, MA				Esenaliev, Rinat O.; Petrov, Irene Y.; Petrov, Yuriy; Guptarak, Jutatip; Boone, Debbie R.; Mocciaro, Emanuele; Weisz, Harris; Parsley, Margaret A.; Sell, Stacy L.; Hellmich, Helen; Ford, Jonathan M.; Pogue, Connor; DeWitt, Douglas; Prough, Donald S.; Micci, Maria-Adelaide			Nano-Pulsed Laser Therapy Is Neuroprotective in a Rat Model of Blast-Induced Neurotrauma	JOURNAL OF NEUROTRAUMA			English	Article						blast injury; near-infrared light; neuroprotection; non-invasive transcranial laser therapy; optoacoustics; traumatic brain injury	TRAUMATIC BRAIN-INJURY; VENOUS-BLOOD OXYGENATION; LONG-TERM POTENTIATION; DENTATE GYRUS; HIPPOCAMPAL NEUROGENESIS; ADULT NEUROGENESIS; CELL-PROLIFERATION; AQUEOUS-SOLUTIONS; LIGHT; MECHANISMS	We have developed a novel, non-invasive nano-pulsed laser therapy (NPLT) system that combines the benefits of near-infrared laser light (808 nm) and ultrasound (optoacoustic) waves, which are generated with each short laser pulse within the tissue. We tested NPLT in a rat model of blast-induced neurotrauma (BINT) to determine whether transcranial application of NPLT provides neuroprotective effects. The laser pulses were applied on the intact rat head 1h after injury using a specially developed fiber-optic system. Vestibulomotor function was assessed on post-injury days (PIDs) 1-3 on the beam balance and beam walking tasks. Cognitive function was assessed on PIDs 6-10 using a working memory Morris water maze (MWM) test. BDNF and caspase-3 messenger RNA (mRNA) expression was measured by quantitative real-time PCR (qRT-PCR) in laser-captured cortical neurons. Microglia activation and neuronal injury were assessed in brain sections by immunofluorescence using specific antibodies against CD68 and active caspase-3, respectively. In the vestibulomotor and cognitive (MWM) tests, NPLT-treated animals performed significantly better than the untreated blast group and similarly to sham animals. NPLT upregulated mRNA encoding BDNF and downregulated the pro-apoptotic protein caspase-3 in cortical neurons. Immunofluorescence demonstrated that NPLT inhibited microglia activation and reduced the number of cortical neurons expressing activated caspase-3. NPLT also increased expression of BDNF in the hippocampus and the number of proliferating progenitor cells in the dentate gyrus. Our data demonstrate a neuroprotective effect of NPLT and prompt further studies aimed to develop NPLT as a therapeutic intervention after traumatic brain injury (TBI).	[Esenaliev, Rinat O.; Guptarak, Jutatip; Boone, Debbie R.; Mocciaro, Emanuele; Weisz, Harris; Parsley, Margaret A.; Sell, Stacy L.; Hellmich, Helen; Ford, Jonathan M.; Pogue, Connor; DeWitt, Douglas; Prough, Donald S.; Micci, Maria-Adelaide] Univ Texas Med Branch, Dept Anesthesiol, 301 Univ Blvd, Galveston, TX 77555 USA; [Esenaliev, Rinat O.] Univ Texas Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; [Esenaliev, Rinat O.; Petrov, Irene Y.; Petrov, Yuriy] Univ Texas Med Branch, Ctr Biomed Engn, Galveston, TX 77555 USA	Micci, MA (corresponding author), Univ Texas Med Branch, Dept Anesthesiol, 301 Univ Blvd, Galveston, TX 77555 USA.	mmicci@utmb.edu	Esenaliev, Rinat/Y-4361-2019; Prough, Donald S/G-5793-2013; Mocciaro, Emanuele/AAA-7650-2020	Esenaliev, Rinat/0000-0002-2848-5906; Prough, Donald S/0000-0001-7994-532X; Mocciaro, Emanuele/0000-0002-4287-8933	Moody Project for Translational Traumatic Brain Injury Research	These studies were completed as part of an interdisciplinary research team funded by The Moody Project for Translational Traumatic Brain Injury Research.	ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Barrett DW, 2013, NEUROSCIENCE, V230, P13, DOI 10.1016/j.neuroscience.2012.11.016; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Briley D, 2016, SCI REP-UK, V6, DOI 10.1038/srep27812; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; Desmoulin GT, 2009, J TRAUMA, V67, P1113, DOI 10.1097/TA.0b013e3181bb8e84; DOBROV EN, 1989, PHOTOCHEM PHOTOBIOL, V49, P595, DOI 10.1111/j.1751-1097.1989.tb08429.x; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; ESENALIEV RO, 1994, APPL PHYS B-LASERS O, V59, P73, DOI 10.1007/BF01081730; ESENALIEV RO, 1993, LASER SURG MED, V13, P470, DOI 10.1002/lsm.1900130412; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Glushakova OY, 2018, J NEUROTRAUM, V35, P157, DOI 10.1089/neu.2017.4999; Hamblin MR, 2016, BBA CLIN, V6, P113, DOI 10.1016/j.bbacli.2016.09.002; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Hoge CW, 2008, AM J EPIDEMIOL, V168, P1095, DOI 10.1093/aje/kwn261; Hyatt K, 2014, MIL MED, V179, P849, DOI 10.7205/MILMED-D-13-00526; KARU T, 1994, J PHOTOCH PHOTOBIO B, V24, P155, DOI 10.1016/1011-1344(94)07016-4; Karu TI, 1996, LASER SURG MED, V18, P171, DOI 10.1002/(SICI)1096-9101(1996)18:2<171::AID-LSM7>3.0.CO;2-P; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lopes CDF, 2017, BIOMATERIALS, V121, P83, DOI 10.1016/j.biomaterials.2016.12.025; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McCarthy TJ, 2010, PHOTOMED LASER SURG, V28, P663, DOI 10.1089/pho.2009.2581; MESTER E, 1976, ACTA CHIR HUNG, V17, P49; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Miyamoto N, 2015, J NEUROSCI, V35, P14002, DOI 10.1523/JNEUROSCI.1592-15.2015; Morries LD, 2015, NEUROPSYCH DIS TREAT, V11, P2159, DOI 10.2147/NDT.S65809; Naeser MA, 2014, J NEUROTRAUM, V31, P1008, DOI 10.1089/neu.2013.3244; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Ohl F, 1999, COGNITIVE BRAIN RES, V7, P379, DOI 10.1016/S0926-6410(98)00042-1; Oraevsky AA, 1996, LASER SURG MED, V18, P231, DOI 10.1002/(SICI)1096-9101(1996)18:3<231::AID-LSM3>3.0.CO;2-T; Pang AL, 2017, CELL TRANSPLANT, V26, P1262, DOI 10.1177/0963689717715168; Petrov A, 2014, PHOTOACOUSTICS, V2, P75, DOI 10.1016/j.pacs.2014.04.001; Petrov IY, 2012, OPT EXPRESS, V20, P4159, DOI 10.1364/OE.20.004159; Petrov IY, 2012, BIOMED OPT EXPRESS, V3, P125, DOI 10.1364/BOE.3.000125; Petrov Y., 2017, P SPIE, P10064; Petrova IY, 2009, OPT EXPRESS, V17, P7285, DOI 10.1364/OE.17.007285; Rafaels K, 2011, J NEUROTRAUM, V28, P2319, DOI 10.1089/neu.2009.1207; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Ramagiri Sruthi, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P1, DOI 10.1515/jbcpp-2015-0021; Rao MS, 1999, ANAT RECORD, V257, P137; Rao MS, 2006, AGING CELL, V5, P545, DOI 10.1111/j.1474-9726.2006.00243.x; Rojo DR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023111; Sajja VSSS, 2014, NEUROSCI LETT, V570, P33, DOI 10.1016/j.neulet.2014.03.072; Sell SL, 2017, J NEUROTRAUM, V34, P1086, DOI 10.1089/neu.2016.4616; Stein MB, 2016, J NEUROTRAUM, V33, P2125, DOI 10.1089/neu.2015.4320; Su WS, 2015, ONCOTARGET, V6, P42290, DOI 10.18632/oncotarget.5978; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2016, EXP NEUROL, V275, P405, DOI 10.1016/j.expneurol.2015.04.017; Sun D, 2015, J NEUROTRAUM, V32, P495, DOI 10.1089/neu.2014.3545; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Tedford CE, 2015, LASER SURG MED, V47, P312, DOI 10.1002/lsm.22343; Thunshelle C, 2016, PHOTOMED LASER SURG, V34, P587, DOI 10.1089/pho.2015.4051; Tyler WJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003511; Van Kanegan MJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep25626; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wojtowicz JM, 2006, NAT PROTOC, V1, P1399, DOI 10.1038/nprot.2006.224; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Wurzelmann M, 2017, NEURAL REGEN RES, V12, P7, DOI 10.4103/1673-5374.198964; Yoon SH, 2012, PEDIATR NEUROSURG, V48, P102, DOI 10.1159/000343011; Zhao MR, 2007, BIOL PSYCHIAT, V62, P381, DOI 10.1016/j.biopsych.2006.10.019; Zhao XY, 2003, P NATL ACAD SCI USA, V100, P6777, DOI 10.1073/pnas.1131928100	73	12	12	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2018	35	13					1510	1522		10.1089/neu.2017.5249		APR 2018	13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GJ4CQ	WOS:000431108300001	29562823	Green Published, Bronze			2021-06-18	
J	Kenzie, ES; Parks, EL; Bigler, ED; Wright, DW; Lim, MM; Chesnutt, JC; Hawryluk, GWJ; Gordon, W; Wakeland, W				Kenzie, Erin S.; Parks, Elle L.; Bigler, Erin D.; Wright, David W.; Lim, Miranda M.; Chesnutt, James C.; Hawryluk, Gregory W. J.; Gordon, Wayne; Wakeland, Wayne			The Dynamics of concussion: Mapping Pathophysiology, Persistence, and recovery With causal-loop Diagramming	FRONTIERS IN NEUROLOGY			English	Article						concussion; traumatic brain injury; systems science; complexity; recovery; causal-loop diagram; models of injury; systems medicine	TRAUMATIC BRAIN-INJURY; MAJOR DEPRESSIVE DISORDER; DIFFUSE AXONAL INJURY; DEFAULT MODE NETWORK; SYSTEMS SCIENCE; COMPLEX WORLD; RESTING-STATE; CONNECTIVITY; SYMPTOMS; MILITARY	Despite increasing public awareness and a growing body of literature on the subject of concussion, or mild traumatic brain injury, an urgent need still exists for reliable diagnostic measures, clinical care guidelines, and effective treatments for the condition. Complexity and heterogeneity complicate research efforts and indicate the need for innovative approaches to synthesize current knowledge in order to improve clinical outcomes. Methods from the interdisciplinary field of systems science, including models of complex systems, have been increasingly applied to biomedical applications and show promise for generating insight for traumatic brain injury. The current study uses causal-loop diagramming to visualize relationships between factors influencing the pathophysiology and recovery trajectories of concussive injury, including persistence of symptoms and deficits. The primary output is a series of preliminary systems maps detailing feedback loops, intrinsic dynamics, exogenous drivers, and hubs across several scales, from micro-level cellular processes to social influences. Key system features, such as the role of specific restorative feedback processes and cross-scale connections, are examined and discussed in the context of recovery trajectories. This systems approach integrates research findings across disciplines and allows components to be considered in relation to larger system influences, which enables the identification of research gaps, supports classification efforts, and provides a framework for interdisciplinary collaboration and communication-all strides that would benefit diagnosis, prognosis, and treatment in the clinic.	[Kenzie, Erin S.; Parks, Elle L.; Wakeland, Wayne] Portland State Univ, Syst Sci Program, Portland, OR 97207 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Neurosci Ctr, Provo, UT 84602 USA; [Wright, David W.] Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA USA; [Lim, Miranda M.] VA Portland Hlth Care Syst, Res Serv, Div Hosp & Specialty Med, Sleep Disorders Clin, Portland, OR USA; [Lim, Miranda M.] Oregon Hlth & Sci Univ, Dept Neurol, Oregon Inst Occupat Hlth Sci, Portland, OR 97201 USA; [Lim, Miranda M.] Oregon Hlth & Sci Univ, Dept Med, Oregon Inst Occupat Hlth Sci, Portland, OR 97201 USA; [Lim, Miranda M.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Oregon Inst Occupat Hlth Sci, Portland, OR 97201 USA; [Chesnutt, James C.] Oregon Hlth & Sci Univ, TBI Concuss Program, Orthoped & Rehabil, Neurol & Family Med, Portland, OR 97201 USA; [Hawryluk, Gregory W. J.] Univ Utah, Dept Neurosurg, Salt Lake City, UT USA; [Gordon, Wayne] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA	Kenzie, ES (corresponding author), Portland State Univ, Syst Sci Program, Portland, OR 97207 USA.	erin.kenzie@pdx.edu			US Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division [W911QY-14-C-0086]; VA Career Development Award [IK2 BX002712]; Portland VA Research Foundation; Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-13-2-0095]	This material is based upon work supported by the US Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, through a contract awarded to Stanford University (W911QY-14-C-0086), and a subcontract awarded to the Brain Trauma Foundation. This material is in part the result of work supported with resources and the use of facilities at the VA Portland Health Care System, the VA Career Development Award #IK2 BX002712, and Portland VA Research Foundation (MML). In part, the Brain Imaging and Behavior Lab that EB directs was supported by the Army Medical Research and Material Command under Award No. W81XWH-13-2-0095 (Chronic Effects of Neurotrauma Consortium). Also, EB co-directs the Neuropsychological Assessment and Research Laboratory at Brigham Young University which includes forensic consultation. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the US Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, Stanford University, the Brain Trauma Foundation, U.S. Department of Veterans Affairs or the United States Government.	[Anonymous], 2007, THINKING SYSTEMS PRI; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Asken BM, 2018, BRAIN IMAGING BEHAV, V12, P585, DOI 10.1007/s11682-017-9708-9; Astafiev SV, 2016, NEUROIMAGE-CLIN, V11, P10, DOI 10.1016/j.nicl.2016.01.004; Bandak F A, 2015, Handb Clin Neurol, V127, P89, DOI 10.1016/B978-0-444-52892-6.00006-4; Barbey AK, 2015, CURR OPIN BEHAV SCI, V4, P92, DOI 10.1016/j.cobeha.2015.04.002; Bassett DS, 2017, NAT NEUROSCI, V20, P353, DOI 10.1038/nn.4502; Bigler ED, 2016, BRAIN, V139, P3054, DOI 10.1093/brain/aww277; Bigler Erin D, 2015, Handb Clin Neurol, V128, P691, DOI 10.1016/B978-0-444-63521-1.00043-1; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Calabrese F, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00430; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2010, J NEUROL NEUROSUR PS, V81, pE12, DOI 10.1136/jnnp.2010.217554.28; Chen Y, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00119; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Cohen JR, 2016, J NEUROSCI, V36, P12083, DOI 10.1523/JNEUROSCI.2965-15.2016; Crossley NA, 2016, PSYCHOL MED, V46, P897, DOI 10.1017/S0033291715002895; Crowe Louise M, 2015, Handb Clin Neurol, V128, P661, DOI 10.1016/B978-0-444-63521-1.00041-8; Davidson RJ, 2004, PHILOS T R SOC B, V359, P1395, DOI 10.1098/rstb.2004.1510; Dougan BK, 2014, J INT NEUROPSYCH SOC, V20, P64, DOI 10.1017/S1355617712001464; Dougherty Joseph D, 2017, Curr Opin Syst Biol, V3, P67, DOI 10.1016/j.coisb.2017.04.011; Dulla CG, 2016, NEUROSCIENTIST, V22, P295, DOI 10.1177/1073858415585108; Fisher JAN, 2016, IEEE T NEUR SYS REH, V24, P1003, DOI 10.1109/TNSRE.2016.2529663; Fonzo GA, 2017, DIALOGUES CLIN NEURO, V19, P169; Ganpule S, 2017, J NEUROTRAUM, V34, P2154, DOI 10.1089/neu.2016.4744; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gordon Wayne A, 2015, Handb Clin Neurol, V127, P423, DOI 10.1016/B978-0-444-52892-6.00027-1; Hack D., 2016, BRIDGE NATL ACAD ENG, V46, P34; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Hawryluk Gregory W J, 2015, Handb Clin Neurol, V128, P761, DOI 10.1016/B978-0-444-63521-1.00047-9; Hawryluk Gregory W J, 2015, Handb Clin Neurol, V127, P15, DOI 10.1016/B978-0-444-52892-6.00002-7; Heine L, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00295; Hemphill MA, 2015, NEURON, V85, P1177, DOI 10.1016/j.neuron.2015.02.041; Hillary FG, 2017, TRENDS COGN SCI, V21, P385, DOI 10.1016/j.tics.2017.03.003; Hiploylee C, 2017, J NEUROTRAUM, V34, P1511, DOI 10.1089/neu.2016.4677; Hladky SB, 2019, HANDB EXP PHARMACOL, V253, P385, DOI 10.1007/164_2017_37; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Hwang K, 2017, J NEUROSCI, V37, P5594, DOI 10.1523/JNEUROSCI.0067-17.2017; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Insel TR, 2015, SCIENCE, V348, P499, DOI 10.1126/science.aab2358; Jackson CE, 2017, BRAIN INJURY, V31, P485, DOI 10.1080/02699052.2017.1280740; Jiang HD, 2017, CEREB CORTEX, V27, P4083, DOI 10.1093/cercor/bhw220; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnston LM, 2014, AM J PUBLIC HEALTH, V104, P1270, DOI 10.2105/AJPH.2014.301884; Jones NA, 2011, ECOL SOC, V16; Katz Douglas I, 2015, Handb Clin Neurol, V127, P131, DOI 10.1016/B978-0-444-52892-6.00009-X; Kenzie ES, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00513; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Kurowski BG, 2017, J NEUROTRAUM, V34, P2280, DOI 10.1089/neu.2016.4856; Lafrenaye AD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0405-6; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Lee SW, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00843; Ling G, 2015, Handb Clin Neurol, V127, P173, DOI 10.1016/B978-0-444-52892-6.00011-8; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Lippa SM, 2018, ARCH CLIN NEUROPSYCH, V33, P606, DOI 10.1093/arclin/acx098; Logsdon AF, 2015, COMPR PHYSIOL, V5, P1147, DOI 10.1002/cphy.c140057; Losoi H, 2015, J NEUROTRAUM, V32, P942, DOI 10.1089/neu.2014.3799; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas Andrew I R, 2015, Handb Clin Neurol, V128, P455, DOI 10.1016/B978-0-444-63521-1.00029-7; Mabry PL, 2008, AM J PREV MED, V35, pS211, DOI 10.1016/j.amepre.2008.05.018; Mabry PL, 2013, HEALTH EDUC BEHAV, V40, p9S, DOI 10.1177/1090198113503469; Malhotra RK, 2017, NEUROL CLIN, V35, P547, DOI 10.1016/j.ncl.2017.03.002; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Mayer AR, 2017, NEUROLOGY, V89, P623, DOI 10.1212/WNL.0000000000004214; Mayer CL, 2013, HEADACHE, V53, P1523, DOI 10.1111/head.12173; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McCarty CA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0459; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McGinn Melissa J, 2015, Handb Clin Neurol, V127, P67, DOI 10.1016/B978-0-444-52892-6.00005-2; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Muresanu DF, 2012, J CELL MOL MED, V16, P2861, DOI 10.1111/j.1582-4934.2012.01605.x; Oehr L, 2017, ARCH PHYS MED REHAB, V98, P2308, DOI 10.1016/j.apmr.2017.03.019; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Raskin SA, 2014, UNDERSTANDING TRAUMA, P370; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; Reynolds Erin, 2014, Neurosurgery, V75 Suppl 4, pS71, DOI 10.1227/NEU.0000000000000471; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Sacher J, 2012, J AFFECT DISORDERS, V140, P142, DOI 10.1016/j.jad.2011.08.001; Seung S., 2013, CONNECTOME BRAINS WI; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Smith Douglas H, 2016, Bridge (Wash D C), V46, P79; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Sporns O, 2016, ANNU REV PSYCHOL, V67, P613, DOI 10.1146/annurev-psych-122414-033634; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stein DG, 2015, BRAIN INJURY, V29, P1259, DOI 10.3109/02699052.2015.1065344; Stein Donald G, 2015, Handb Clin Neurol, V127, P433, DOI 10.1016/B978-0-444-52892-6.00028-3; Sterman JD, 2006, AM J PUBLIC HEALTH, V96, P505, DOI 10.2105/AJPH.2005.066043; Sterman JD, 2001, CALIF MANAGE REV, V43, P8, DOI 10.2307/41166098; Stone JR, 2016, BRAIN INJURY, V30, P1458, DOI 10.1080/02699052.2016.1222080; Su Y, 2014, NEUROSCIENCE, V266, P56, DOI 10.1016/j.neuroscience.2014.02.006; Sullivan KA, 2016, NEUROPSYCHOL REV, V26, P173, DOI 10.1007/s11065-016-9317-1; van den Heuvel MP, 2011, J NEUROSCI, V31, P15775, DOI 10.1523/JNEUROSCI.3539-11.2011; Waljas M, 2014, J NEUROTRAUM, V31, P108, DOI 10.1089/neu.2013.2941; Wakeland W, 2015, AM J DRUG ALCOHOL AB, V41, P508, DOI 10.3109/00952990.2015.1043435; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Wittenborn AK, 2016, PSYCHOL MED, V46, P551, DOI 10.1017/S0033291715002044; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Yamawaki S, 2012, INT J NEUROPSYCHOPH, V15, P681, DOI 10.1017/S1461145711000757; Yuan WH, 2017, J HEAD TRAUMA REHAB, V32, P378, DOI 10.1097/HTR.0000000000000318; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	113	12	12	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	APR 4	2018	9								203	10.3389/fneur.2018.00203			16	Clinical Neurology; Neurosciences	Neurosciences & Neurology	GB6KY	WOS:000429179300002	29670568	DOAJ Gold, Green Published			2021-06-18	
J	Abou El Fadl, MH; O'Phelan, KH				Abou El Fadl, Mohamed H.; O'Phelan, Kristine H.			Management of Traumatic Brain Injury: An Update	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article						TBI; ICP; Sedation; PSH; Monitors; Multimodality; Informatics	PAROXYSMAL SYMPATHETIC HYPERACTIVITY; RAISED INTRACRANIAL-PRESSURE; DECOMPRESSIVE CRANIECTOMY; DIAGNOSTIC-CRITERIA; NEUROCRITICAL CARE; HYPERTONIC SALINE; METAANALYSIS; TRIAL; HYPERTENSION; HYPOTHERMIA	The care of patients with traumatic brain injury can be one of the most challenging and rewarding aspects of clinical neurocritical care. This article reviews the approach to unique aspects specific to the care of this patient population. These aspects include appropriate use of sedation and analgesia, and the principles and the clinical use of intracranial monitors. Common clinical challenges encountered in these patients are also discussed, including the treatment of intracranial hypertension, temperature management, and control of sympathetic hyperactivity.	[Abou El Fadl, Mohamed H.; O'Phelan, Kristine H.] Univ Miami, Neurocrit Care, Dept Neurol, Miller Sch Med, 1120 Northwest 14th St,Suite 1356, Miami, FL 33136 USA	O'Phelan, KH (corresponding author), Univ Miami, Neurocrit Care, Dept Neurol, Miller Sch Med, 1120 Northwest 14th St,Suite 1356, Miami, FL 33136 USA.	KOPhelan@med.miami.edu					Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Ayodele M, PITTSBURGH IN PRESS; Badri S, 2012, INTENS CARE MED, V38, P1800, DOI 10.1007/s00134-012-2655-4; Baguley IJ, 2014, J NEUROTRAUM, V31, P1515, DOI 10.1089/neu.2013.3301; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Bouzat P, 2015, CRIT CARE MED, V43, P445, DOI 10.1097/CCM.0000000000000720; Cardim D, 2016, NEUROCRIT CARE, V25, P473, DOI 10.1007/s12028-016-0258-6; Carney N, 2016, MANAGEMENT SEVERE TR; Chesnut R, 2014, NEUROCRIT CARE, V21, P64, DOI 10.1007/s12028-014-0048-y; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Citerio G, 2015, CURR OPIN CRIT CARE, V21, P113, DOI 10.1097/MCC.0000000000000179; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Cooper DJ, 2011, NEW ENGL J MED, V365, P2040; Cottenceau V, 2011, J NEUROTRAUM, V28, P2003, DOI 10.1089/neu.2011.1929; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Farahvar A, 2011, J NEUROSURG, V115, P191, DOI 10.3171/2011.4.JNS101116a; Fernandez-Ortega JF, 2017, J NEUROTRAUM, V34, P109, DOI 10.1089/neu.2015.4364; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Honeybul S, 2013, WORLD NEUROSURG, V79, P159, DOI 10.1016/j.wneu.2012.08.012; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Kramer CL, 2014, NEUROCRIT CARE, V21, P309, DOI 10.1007/s12028-014-9988-5; Le Roux P, 2014, INTENS CARE MED, V40, P1189, DOI 10.1007/s00134-014-3369-6; Lyden P, 2016, STROKE, V47, P2888, DOI 10.1161/STROKEAHA.116.014200; Makarenko S, 2016, J CLIN NEUROSCI, V26, P8, DOI 10.1016/j.jocn.2015.05.065; Mangat HS, 2015, J NEUROSURG, V122, P202, DOI 10.3171/2014.10.JNS132545; Mathew MJ, 2016, ACTA NEUROCHIR, V158, P2047, DOI 10.1007/s00701-016-2934-x; Melhem S, 2014, CRIT CARE, V18, DOI 10.1186/cc13713; O'Phelan Kristine H, 2015, World J Crit Care Med, V4, P296, DOI 10.5492/wjccm.v4.i4.296; Oddo M, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1294-5; Ohle R, 2015, J ULTRAS MED, V34, P1285, DOI 10.7863/ultra.34.7.1285; Perkes IE, 2011, BRAIN INJURY, V25, P925, DOI 10.3109/02699052.2011.589797; Rabinstein AA, 2008, CURR TREAT OPTION N, V10, P151, DOI 10.1007/s11940-008-0016-y; Rajajee V, 2011, NEUROCRIT CARE, V15, P506, DOI 10.1007/s12028-011-9606-8; Rickard AC, 2014, EMERG MED J, V31, P679, DOI 10.1136/emermed-2013-202679; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Sahuquillo J, 2013, CURR OPIN CRIT CARE, V19, P101, DOI 10.1097/MCC.0b013e32835eba1a; Shutter LA, 2016, NEW ENGL J MED, V375, P1183, DOI 10.1056/NEJMe1609722; Sivaganesan A, 2014, NEUROCRIT CARE, V20, P132, DOI 10.1007/s12028-013-9872-8; SYDENHAM E, 2009, COCHRANE DATABASE SY; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Zacchetti L, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1137-9	43	12	12	1	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	APR	2018	29	2					213	+		10.1016/j.nec.2017.11.002			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GB6MJ	WOS:000429183000003	29502712				2021-06-18	
J	Ambaw, A; Zheng, LX; Tambe, MA; Strathearn, KE; Acosta, G; Hubers, SA; Liu, F; Herr, SA; Tang, J; Truong, A; Walls, E; Pond, A; Rochet, JC; Shi, RY				Ambaw, Abeje; Zheng, Lingxing; Tambe, Mitali A.; Strathearn, Katherine E.; Acosta, Glen; Hubers, Scott A.; Liu, Fang; Herr, Seth A.; Tang, Jonathan; Truong, Alan; Walls, Elwood; Pond, Amber; Rochet, Jean-Christophe; Shi, Riyi			Acrolein-mediated neuronal cell death and alpha-synuclein aggregation: Implications for Parkinson's disease	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						Oxidative stress; 3-HPMA; Aldehyde; Inflammation; Lipid peroxidation	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; SUBSTANTIA-NIGRA; MYELIN DAMAGE; LEWY BODIES; PC12 CELLS; HYDRALAZINE	Growing evidence suggests that oxidative stress plays a critical role in neuronal destruction characteristic of Parkinson's disease (PD). However, the molecular mechanisms of oxidative stress-mediated dopaminergic cell death are far from clear. In the current investigation, we tested the hypothesis that acrolein, an oxidative stress and lipid peroxidation (LPO) product, is a key factor in the pathogenesis of PD. Using a combination of in vitro, in vivo, and cell free models, coupled with anatomical, functional, and behavioral examination, we found that acrolein was elevated in 6-OHDA-injected rats, and behavioral deficits associated with 6-OHDA could be mitigated by the application of the acrolein scavenger hydralazine, and mimicked by injection of acrolein in healthy rats. Furthermore, hydralazine alleviated neuronal cell death elicited by 6-OHDA and another PD-related toxin, rotenone, in vitro. We also show that acrolein can promote the aggregation of alpha-synuclein, suggesting that alpha-synuclein self-assembly, a key pathological phenomenon in human PD, could play a role in neurotoxic effects of acrolein in PD models. These studies suggest that acrolein is involved in the pathogenesis of PD, and the administration of anti-acrolein scavengers such as hydralazine could represent a novel strategy to alleviate tissue damage and motor deficits associated with this disease.	[Ambaw, Abeje; Zheng, Lingxing; Acosta, Glen; Herr, Seth A.; Tang, Jonathan; Walls, Elwood; Pond, Amber; Shi, Riyi] Purdue Univ, Sch Vet Med, Dept Basic Med Sci, W Lafayette, IN 47907 USA; [Tang, Jonathan; Truong, Alan; Shi, Riyi] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Tambe, Mitali A.; Strathearn, Katherine E.; Hubers, Scott A.; Liu, Fang; Rochet, Jean-Christophe] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; [Herr, Seth A.] Purdue Univ, Interdisciplinary Life Sci Program PULSe, W Lafayette, IN 47907 USA	Shi, RY (corresponding author), Purdue Univ, Weldon Sch Biomed Engn, Dept Basic Med Sci, W Lafayette, IN 47907 USA.	riyi@purdue.edu		Tambe, Mitali/0000-0001-9389-2308; Rochet, Jean-Christophe/0000-0002-6484-1541	Indiana State Department of Health [204200]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS073636, NS049221]; Bradman Family Foundation; National Institutes of Health, National Center for Advancing Translational Sciences [UL1TR001108]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049221, R01NS073636] Funding Source: NIH RePORTER	This work was supported by the Indiana State Department of Health (Grant # 204200 to RS), National Institutes of Health (R01 grant # NS073636 to RS, and R01 grant # NS049221 and a grant from the Bradman Family Foundation to J.-C. R.). This publication was also made possible by the Stark Neurosciences Research Institute, Eli Lilly and Company, and by the Indiana Clinical and Translational Sciences Institute, funded in part by grant # UL1TR001108 from the National Institutes of Health, National Center for Advancing Translational Sciences.	Ayton S, 2013, NEUROSCI LETT, V543, P105, DOI 10.1016/j.neulet.2013.02.066; Bramlett HM, 2003, EXP NEUROL, V184, P27, DOI 10.1016/S0014-4886(03)00401-1; BROCK N, 1979, ARZNEIMITTEL-FORSCH, V29-1, P659; Burcham PC, 2000, REDOX REP, V5, P47, DOI 10.1179/rer.2000.5.1.47; Burcham PC, 2006, MOL PHARMACOL, V69, P1056, DOI 10.1124/mol.105.018168; Burcham PC, 2017, CHEM RES TOXICOL, V30, P145, DOI 10.1021/acs.chemrestox.6b00310; Cai J, 2009, CHEM RES TOXICOL, V22, P708, DOI 10.1021/tx800465m; Calingasan NY, 1999, J NEUROCHEM, V72, P751, DOI 10.1046/j.1471-4159.1999.0720751.x; Carley DW, 1997, J APPL PHYSIOL, V83, P1954; Chi YC, 2014, J BIOL CHEM, V289, P15474, DOI 10.1074/jbc.M113.544049; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; CRAWFORD GD, 1992, J NEUROSCI, V12, P3392; Daiber A, 2005, BIOCHEM BIOPH RES CO, V338, P1865, DOI 10.1016/j.bbrc.2005.10.106; Daimon M, 2003, ENDOCR J, V50, P61, DOI 10.1507/endocrj.50.61; Decressac M, 2012, EXP NEUROL, V235, P306, DOI 10.1016/j.expneurol.2012.02.012; Due MR, 2014, J NEUROCHEM, V128, P776, DOI 10.1111/jnc.12500; Eckert E, 2010, J CHROMATOGR B, V878, P2506, DOI 10.1016/j.jchromb.2009.09.003; Eller M, 2011, CLIN CHEM LAB MED, V49, P403, DOI 10.1515/CCLM.2011.077; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Feng ZH, 2006, P NATL ACAD SCI USA, V103, P15404, DOI 10.1073/pnas.0607031103; Ghilarducci DP, 1995, REV ENVIRON CONTAM T, V144, P95; Goldman SM, 2012, ANN NEUROL, V71, P40, DOI 10.1002/ana.22499; Hamann K, 2008, J NEUROCHEM, V107, P712, DOI 10.1111/j.1471-4159.2008.05622.x; Hamann K, 2008, J NEUROCHEM, V104, P708, DOI 10.1111/j.1471-4159.2007.05002.x; Hamann K, 2009, J NEUROCHEM, V111, P1348, DOI 10.1111/j.1471-4159.2009.06395.x; Henchcliffe C, 2008, NAT CLIN PRACT NEURO, V4, P600, DOI 10.1038/ncpneuro0924; Hirsch EC, 2009, LANCET NEUROL, V8, P382, DOI 10.1016/S1474-4422(09)70062-6; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; Kalia LV, 2013, ANN NEUROL, V73, P155, DOI 10.1002/ana.23746; Kehrer JP, 2000, TOXICOL SCI, V57, P6, DOI 10.1093/toxsci/57.1.6; Khalaf O, 2014, J BIOL CHEM, V289, P21856, DOI 10.1074/jbc.M114.553297; Koob AO, 2006, J NEUROSCI METH, V157, P330, DOI 10.1016/j.jneumeth.2006.04.020; Leung G, 2011, NEUROSCIENCE, V173, P150, DOI 10.1016/j.neuroscience.2010.11.018; Liu F, 2008, FREE RADICAL BIO MED, V45, P242, DOI 10.1016/j.freeradbiomed.2008.03.022; Liu F, 2008, J NEUROCHEM, V105, P2435, DOI 10.1111/j.1471-4159.2008.05333.x; Liu-Snyder P, 2006, J NEUROSCI RES, V84, P209, DOI 10.1002/jnr.20863; Liu-Snyder P, 2006, J NEUROSCI RES, V84, P219, DOI 10.1002/jnr.20862; Lovell MA, 2001, NEUROBIOL AGING, V22, P187, DOI 10.1016/S0197-4580(00)00235-9; Luo H, 2004, NEUROCHEM INT, V44, P475, DOI 10.1016/j.neuint.2003.09.006; Luo J, 2005, NEUROCHEM INT, V46, P243, DOI 10.1016/j.neuint.2004.09.001; Luo J, 2005, NEUROCHEM INT, V47, P449, DOI 10.1016/j.neuint.2005.07.002; Luo J, 2005, NEUROCHEM RES, V30, P291, DOI 10.1007/s11064-005-2602-7; LYLES GA, 1983, BIOCHEM PHARMACOL, V32, P2515, DOI 10.1016/0006-2952(83)90012-6; McNaught KSP, 2002, EUR J NEUROSCI, V16, P2136, DOI 10.1046/j.1460-9568.2002.02301.x; Montine TJ, 2002, FREE RADICAL BIO MED, V33, P620, DOI 10.1016/S0891-5849(02)00807-9; Muqit MMK, 2004, HUM MOL GENET, V13, P117, DOI 10.1093/hmg/ddh012; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1263, DOI 10.1097/00005072-199912000-00007; Norris EH, 2003, J BIOL CHEM, V278, P27230, DOI 10.1074/jbc.M212436200; Park J, 2014, J NEUROCHEM, V129, P339, DOI 10.1111/jnc.12628; Przedborski S, 2005, PARKINSONISM RELAT D, V11, pS3, DOI 10.1016/j.parkreldis.2004.10.012; Recasens A, 2014, ANN NEUROL, V75, P351, DOI 10.1002/ana.24066; Rochet JC, 2000, BIOCHEMISTRY-US, V39, P10619, DOI 10.1021/bi001315u; Rochet JC, 2012, PROG MOL BIOL TRANSL, V107, P125, DOI 10.1016/B978-0-12-385883-2.00011-4; Rutherford NJ, 2014, J NEUROCHEM, V131, P859, DOI 10.1111/jnc.12806; Schapira AHV, 2009, NEUROL CLIN, V27, P583, DOI 10.1016/j.ncl.2009.04.004; Schober A, 2004, CELL TISSUE RES, V318, P215, DOI 10.1007/s00441-004-0938-y; Shamoto-Nagai M, 2007, J NEURAL TRANSM, V114, P1559, DOI 10.1007/s00702-007-0789-2; Shi R, 2002, NEUROSCIENCE, V115, P337, DOI 10.1016/S0306-4522(02)00457-8; Shi R., 2006, APPL NEUROL, V2, P22; Shi RY, 2011, MOL NUTR FOOD RES, V55, P1320, DOI 10.1002/mnfr.201100217; Shi YZ, 2011, J NEUROCHEM, V117, P554, DOI 10.1111/j.1471-4159.2011.07226.x; Stevens JF, 2008, MOL NUTR FOOD RES, V52, P7, DOI 10.1002/mnfr.200700412; Strathearn KE, 2014, BRAIN RES, V1555, P60, DOI 10.1016/j.brainres.2014.01.047; Takalo Mari, 2013, Am J Neurodegener Dis, V2, P1; Tamamizu-Kato S, 2007, BIOCHEMISTRY-US, V46, P8392, DOI 10.1021/bi700289k; Trojanowski JQ, 1998, ARCH NEUROL-CHICAGO, V55, P151, DOI 10.1001/archneur.55.2.151; Tully M, 2013, INT J MOL SCI, V14, P20037, DOI 10.3390/ijms141020037; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wigley WC, 1999, J CELL BIOL, V145, P481; Zarbiv Y, 2014, NEUROBIOL DIS, V70, P90, DOI 10.1016/j.nbd.2014.05.031; Zhang HY, 2013, BIOPHYS J, V104, P2706, DOI 10.1016/j.bpj.2013.04.050; Zheng J, 2010, FREE RADICAL RES, V44, P258, DOI 10.3109/10715760903456092; Zheng LX, 2013, J NEUROTRAUM, V30, P1334, DOI 10.1089/neu.2013.2888	75	12	13	3	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	APR	2018	88						70	82		10.1016/j.mcn.2018.01.006			13	Neurosciences	Neurosciences & Neurology	GE3ET	WOS:000431097300008	29414104				2021-06-18	
J	Cai, HL; Zhou, X; Dougherty, GG; Reddy, RD; Haas, GL; Montrose, DM; Keshavan, M; Yao, JK				Cai, HuaLin; Zhou, Xiang; Dougherty, George G.; Reddy, Ravinder D.; Haas, Gretchen L.; Montrose, Debra M.; Keshavan, Matcheri; Yao, Jeffrey K.			Pregnenolone-progesterone-allopregnanolone pathway as a potential therapeutic target in first-episode antipsychotic-naive patients with schizophrenia	PSYCHONEUROENDOCRINOLOGY			English	Article						Schizophrenia; First-episode antipsychotic-naive; Neurosteroids; Pregnenolone; Progesterone; Allopregnanolone; Cortisol dehydroepiandrosterone dehydroepiandrosterone sulfate	TRAUMATIC BRAIN-INJURY; RAT NUCLEUS-ACCUMBENS; NEUROACTIVE STEROIDS; DOPAMINE RELEASE; CEREBRAL-CORTEX; NEUROSTEROID ALLOPREGNANOLONE; MASS-SPECTROMETRY; GABA(A) RECEPTORS; NEGATIVE SYMPTOMS; FEMALE RATS	Neurosteroids are both endogenous and exogenous steroids that rapidly alter neuronal excitability through interactions with ligand-gated ion channels and other cell surface receptors. They are originated from cholesterol and have important implications for schizophrenia (SZ) pathophysiology and treatment strategies. Specifically, pregnenolone (PREG), progesterone (PROG) and allopregnanolone (ALLO) exhibit similar psychotropic properties. Using enzyme immunoassay, we compared the neurosteroids in PREG downstream pathways in plasma between healthy controls (HC, n = 43) and first-episode antipsychotic-naive patients with SZ (FEAN-SZ, n = 53) before antipsychotic drug (API)) treatment. Comparisons were also made particularly along PREG-PROG-ALLO pathway in the same FEAN-SZ patients across multiple time points following initiation of treatment for 12 months (m). Firstly, at baseline, levels of PREG were significantly higher and those of ALLO were lower in FEAN-SZ than in HC, whereas PROG, cortisol, dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) were not different. Consequently, the molar ratios of ALLO/PREG and ALLO/PROG in FEAN-SZ were significantly reduced. Secondly, in response to APD at 1 month, ALLO levels in FEAN-SZ were markedly elevated, whereas PREG and PROG levels decreased. Thirdly, among FEAN-SZ, lower levels of PROG (reflecting higher conversion to ALLO) at baseline may predict better therapeutic outcome after 1 month of APD treatment. These findings point to the perturbations of the PREG-PROG-ALLO pathway early in psychosis, and further study of this pathway may inform alternative and innovative therapeutic targets for SZ.	[Cai, HuaLin; Zhou, Xiang; Dougherty, George G.; Haas, Gretchen L.; Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA 15240 USA; [Cai, HuaLin; Zhou, Xiang; Yao, Jeffrey K.] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15216 USA; [Cai, HuaLin] Cent S Univ, Xiangya Hosp 2, Changsha, Hunan, Peoples R China; [Cai, HuaLin] Cent S Univ, Inst Clin Pharm, Changsha, Hunan, Peoples R China; [Dougherty, George G.; Haas, Gretchen L.; Montrose, Debra M.; Keshavan, Matcheri; Yao, Jeffrey K.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA; [Reddy, Ravinder D.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Keshavan, Matcheri] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02115 USA; [Keshavan, Matcheri] Harvard Med Sch, Boston, MA 02115 USA	Yao, JK (corresponding author), VA Pittsburgh Healthcare Syst, Bldg 1,Room 2E-140,Univ Dr C, Pittsburgh, PA 15240 USA.	jkyao@pitt.edu			Department of Veterans AffairsUS Department of Veterans Affairs; VA Pittsburgh Healthcare System, National Institute of Health [MH58141, MH64023, K02 MH 01180, MH45156]; NIH/NCRR/GCRCUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00056]; Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [NSFC81401113]; Specialized Research Fund for the Doctoral Program of Higher Education of ChinaSpecialized Research Fund for the Doctoral Program of Higher Education (SRFDP) [SRFDP20130162120060]; Hunan Provincial Natural Science Foundation of ChinaNatural Science Foundation of Hunan Province [2017JJ3444]; Chinese Scholarship CouncilChina Scholarship Council; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH058141, P50MH045156, R01MH064023, K02MH001180] Funding Source: NIH RePORTER	This work was supported in part by Department of Veterans Affairs [Merit Reviews (JKY) and Senior Research Career Scientist Award (JKY)], the VA Pittsburgh Healthcare System, National Institute of Health [MH58141 (JKY), MH64023 (MK), K02 MH 01180 (MK), MH45156 (David Lewis, MD, Director), NIH/NCRR/GCRC M01 RR00056 (Arthur Levine, MD)], Nature Science Foundation of China [NSFC81401113 (HLC)], the Specialized Research Fund for the Doctoral Program of Higher Education of China [SRFDP20130162120060 (HLC)], Hunan Provincial Natural Science Foundation of China [2017JJ3444 (HLC)], and the Chinese Scholarship Council for oversea study program (HLC).	ANDREASEN NC, 1982, ARCH GEN PSYCHIAT, V39, P789; Barbaccia ML, 1997, BRIT J PHARMACOL, V120, P1582, DOI 10.1038/sj.bjp.0701046; Barbaccia ML, 2001, NEUROPSYCHOPHARMACOL, V25, P489, DOI 10.1016/S0893-133X(01)00254-8; Brambilla DJ, 2009, J CLIN ENDOCR METAB, V94, P907, DOI 10.1210/jc.2008-1902; BREIER A, 1992, LIFE SCI, V51, P1527, DOI 10.1016/0024-3205(92)90563-5; Broccardo CJ, 2013, J CHROMATOGR B, V934, P16, DOI 10.1016/j.jchromb.2013.06.031; Cai HL, 2010, PROG NEURO-PSYCHOPH, V34, P1273, DOI 10.1016/j.pnpbp.2010.07.006; Caruso D, 2013, PSYCHONEUROENDOCRINO, V38, P2278, DOI 10.1016/j.psyneuen.2013.04.016; CHENEY DL, 1995, J NEUROSCI, V15, P4641; Chesnoy-Marchais D, 2009, EUR J NEUROSCI, V30, P2100, DOI 10.1111/j.1460-9568.2009.07013.x; Condray R, 2011, INT J NEUROPSYCHOPH, V14, P756, DOI 10.1017/S1461145710001689; David SR, 2000, CLIN THER, V22, P1085, DOI 10.1016/S0149-2918(00)80086-7; Dazzi L, 2002, BRAIN RES, V932, P135, DOI 10.1016/S0006-8993(02)02290-4; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Do Rego JL, 2009, FRONT NEUROENDOCRIN, V30, P259, DOI 10.1016/j.yfrne.2009.05.006; Dorgan JF, 2002, STEROIDS, V67, P151, DOI 10.1016/S0039-128X(01)00147-7; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; Farnbach-Pralong D, 1998, EUR J PHARMACOL, V349, pR7, DOI 10.1016/S0014-2999(98)00285-4; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Guy W., ECDEU ASSESSMENT MAN; Hatzimanikatis V, 2004, CURR OPIN STRUC BIOL, V14, P300, DOI 10.1016/j.sbi.2004.04.004; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Jaworska-Feil L, 1998, POL J PHARMACOL, V50, P449; JOHNSON RA, 1998, APPL MULTIVARIATE ST, P193; Khisti RT, 2002, PSYCHOPHARMACOLOGY, V161, P120, DOI 10.1007/s00213-002-1006-5; Kim YS, 2000, ANAL BIOCHEM, V277, P187, DOI 10.1006/abio.1999.4384; Kinon BJ, 2003, PSYCHONEUROENDOCRINO, V28, P69, DOI 10.1016/S0306-4530(02)00128-2; LAN NC, 1994, HORM BEHAV, V28, P537, DOI 10.1006/hbeh.1994.1052; Lehmann E.L., 1975, NONPARAMETRICS STAT; Lewis DA, 2004, PSYCHOPHARMACOLOGY, V174, P143, DOI 10.1007/s00213-003-1673-x; MacKenzie EM, 2007, CELL MOL NEUROBIOL, V27, P541, DOI 10.1007/s10571-006-9086-0; Marx CE, 2011, NEUROSCIENCE, V191, P78, DOI 10.1016/j.neuroscience.2011.06.076; Marx CE, 2000, BIOL PSYCHIAT, V47, P1000, DOI 10.1016/S0006-3223(99)00305-4; Marx CE, 2006, PHARMACOL BIOCHEM BE, V84, P598, DOI 10.1016/j.pbb.2006.07.026; Marx CE, 2006, PHARMACOL BIOCHEM BE, V84, P609, DOI 10.1016/j.pbb.2006.07.032; Marx CE, 2014, PSYCHOPHARMACOLOGY, V231, P3647, DOI 10.1007/s00213-014-3673-4; Marx CE, 2006, NEUROPSYCHOPHARMACOL, V31, P1249, DOI 10.1038/sj.npp.1300952; Marx CE, 2009, NEUROPSYCHOPHARMACOL, V34, P1885, DOI 10.1038/npp.2009.26; Mensah-Nyagan AG, 1999, PHARMACOL REV, V51, P63; Miyamoto S, 2012, MOL PSYCHIATR, V17, P1206, DOI 10.1038/mp.2012.47; Motzo C, 1996, J PSYCHOPHARMACOL, V10, P266, DOI 10.1177/026988119601000402; Ohnuma T, 2005, PROG NEURO-PSYCHOPH, V29, P887, DOI 10.1016/j.pnpbp.2005.04.038; OVERALL JE, 1962, PSYCHOL REP, V10, P799; Paba S, 2011, CURR PHARM DESIGN, V17, P151, DOI 10.2174/138161211795049589; Plitman E, 2014, EUR NEUROPSYCHOPHARM, V24, P1591, DOI 10.1016/j.euroneuro.2014.07.015; Ritsner M, 2007, EUR NEUROPSYCHOPHARM, V17, P358, DOI 10.1016/j.euroneuro.2006.10.001; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Rouge-Pont F, 2002, EUR J NEUROSCI, V16, P169, DOI 10.1046/j.1460-9568.2002.02084.x; Sayeed I, 2009, BRAIN RES, V1263, P165, DOI 10.1016/j.brainres.2009.01.045; Schotte A, 1996, PSYCHOPHARMACOLOGY, V124, P57, DOI 10.1007/BF02245606; SERAFINI P, 1986, FERTIL STERIL, V45, P41; Shirayama Y, 2002, SCHIZOPHR RES, V58, P69, DOI 10.1016/S0920-9964(01)00367-X; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Ugale RR, 2004, NEUROPSYCHOPHARMACOL, V29, P1597, DOI 10.1038/sj.npp.1300460; VanLandingham JW, 2008, J CEREBR BLOOD F MET, V28, P1786, DOI 10.1038/jcbfm.2008.73; Verma SK, 2009, J CLIN PSYCHIAT, V70, P997, DOI 10.4088/JCP.08m04508; Wadenberg MLG, 2001, NEUROPSYCHOPHARMACOL, V25, P633, DOI 10.1016/S0893-133X(01)00261-5; WELCH BL, 1947, BIOMETRIKA, V34, P28, DOI 10.1093/biomet/34.1-2.28; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; Wong ML, 2005, MOL PSYCHIATR, V10, P421, DOI 10.1038/sj.mp.4001674; Xi ZX, 1998, BRAIN RES, V798, P156, DOI 10.1016/S0006-8993(98)00406-5; Zhang YL, 2010, BRAIN RES, V1353, P249, DOI 10.1016/j.brainres.2010.07.046	63	12	12	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4530			PSYCHONEUROENDOCRINO	Psychoneuroendocrinology	APR	2018	90						43	51		10.1016/j.psyneuen.2018.02.004			9	Endocrinology & Metabolism; Neurosciences; Psychiatry	Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry	GD8LV	WOS:000430764800006	29433072	Other Gold, Green Accepted			2021-06-18	
J	Chandrasekar, A; Aksan, B; Heuvel, FO; Forstner, P; Sinske, D; Rehman, R; Palmer, A; Ludolph, A; Huber-Lang, M; Bockers, T; Mauceri, D; Knoll, B; Roselli, F				Chandrasekar, Akila; Aksan, Bahar; Heuvel, Florian Olde; Foerstner, Philip; Sinske, Daniela; Rehman, Rida; Palmer, Annette; Ludolph, Albert; Huber-Lang, Markus; Boeckers, Tobias; Mauceri, Daniela; Knoell, Bernd; Roselli, Francesco			Neuroprotective effect of acute ethanol intoxication in TBI is associated to the hierarchical modulation of early transcriptional responses	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Ethanol intoxication; Immediate early genes; Transcription; Neuroprotection; c-Fos	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; GENE-EXPRESSION; C-FOS; ALCOHOL EXPOSURE; GATED CURRENTS; BLOOD-ALCOHOL; CELL-DEATH; MICE; PLASTICITY	Ethanol intoxication is a risk factor for traumatic brain injury (TBI) but clinical evidence suggests that it may actually improve the prognosis of intoxicated TBI patients.& para;& para;We have employed a closed, weight-drop TBI model of different severity (2 cm or 3 cm falling height), preceded (- 30 min) or followed (+ 20 min) by ethanol administration (5 g/Kg). This protocol allows us to study the interaction of binge ethanol intoxication in TBI, monitoring behavioral changes, histological responses and the transcriptional regulation of a series of activity-regulated genes (immediate early genes, IEGs). We demonstrate that ethanol pretreatment before moderate TBI (2 cm) significantly reduces neurological impairment and accelerates recovery. In addition, better preservation of neuronal numbers and cFos + cells was observed 7 days after TBI. At transcriptional level, ethanol reduced the upregulation of a subset of IEGs encoding for transcription factors such as Atf3, c-Fos, FosB, Egr1, Egr3 and Npas4 but did not affect the upregulation of others (e.g. Gadd45b and Gadd45c). While a subset of IEGs encoding for effector proteins (such as Bdnf, InhbA and Dusp5) were downregulated by ethanol, others (such as 11-6) were unaffected. Notably, the majority of genes were sensitive to ethanol only when administered before TBI and not afterwards (the exceptions being c-Fos, Egr1 and Dusp5). Furthermore, while severe TBI (3 cm) induced a qualitatively similar (but quantitatively larger) transcriptional response to moderate TBI, it was no longer sensitive to ethanol pretreatment. Thus, we have shown that a subset of the TBI-induced transcriptional responses were sensitive to ethanol intoxication at the instance of trauma (ultimately resulting in beneficial outcomes) and that the effect of ethanol was restricted to a certain time window (pre TBI treatment) and to TBI severity (moderate). This information could be critical for the translational value of ethanol in TBI and for the design of clinical studies aimed at disentangling the role of ethanol intoxication in TBI.	[Chandrasekar, Akila; Heuvel, Florian Olde; Rehman, Rida; Ludolph, Albert; Roselli, Francesco] Ulm Univ, Dept Neurol, Ulm, Germany; [Aksan, Bahar; Mauceri, Daniela] Heidelberg Univ, IZN, Dept Neurobiol, Heidelberg, Germany; [Foerstner, Philip; Sinske, Daniela; Knoell, Bernd] Ulm Univ, Inst Physiol Chem, Ulm, Germany; [Palmer, Annette; Huber-Lang, Markus] Ulm Univ, Inst Clin & Expt Trauma Immunol, Ulm, Germany; [Boeckers, Tobias] Ulm Univ, Dept Anat & Cell Biol, Ulm, Germany	Roselli, F (corresponding author), Ulm Univ, Ctr Biomed Res ZBF, Dept Neurol, Helmholtzstr 8-2 R1-44, D-89081 Ulm De, Germany.	francesco.roselli@uni-ulm.de	Mauceri, Daniela/C-4969-2014; Rehman, Rida/AAR-4811-2020; Huber-Lang, Markus/AAJ-2209-2020; roselli, francesco/O-8847-2019	Mauceri, Daniela/0000-0003-1225-4633; Rehman, Rida/0000-0003-0518-5051; roselli, francesco/0000-0001-9935-6899	Deutsche Forschungs Gemeinschaft (DFG)German Research Foundation (DFG); ERANET-NEURON initiative "External Insults to the Nervous System", MICRONET consortium; Baustein Program of Ulm University; Ulm University-Bundeswehr Krankenhaus Ulm research initiative; DFGGerman Research Foundation (DFG)European Commission [SFB1158, FOR2325]	The work by FR and BK has been supported by the Deutsche Forschungs Gemeinschaft (DFG) as part of the Collaborative Research Center 1149 "Danger Response, Disturbance Factors and Regenerative Potential after Acute Trauma". FR is also supported by the ERANET-NEURON initiative "External Insults to the Nervous System" as part of the MICRONET consortium and by the Baustein Program of Ulm University. BK is supported by an Ulm University-Bundeswehr Krankenhaus Ulm research initiative. The work performed by DM is supported by DFG grants SFB1158 and FOR2325. DM is a member of the Excellence Cluster CellNetworks at Heidelberg University.	Ahlgren H, 2014, J BIOL CHEM, V289, P9970, DOI 10.1074/jbc.M113.502914; Atkins CM, 2009, NEUROSCI LETT, V459, P52, DOI 10.1016/j.neulet.2009.04.064; Berry C, 2011, AM SURGEON, V77, P1416; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Botta P, 2014, FRONT INTEGR NEUROSC, V8, DOI 10.3389/fnint.2014.00010; Brennan JH, 2015, J CLIN NEUROSCI, V22, P1375, DOI 10.1016/j.jocn.2015.02.030; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Chandrasekar A, 2017, INT IMMUNOPHARMACOL, V51, P66, DOI 10.1016/j.intimp.2017.08.002; Cho JS, 2016, ALCOHOL CLIN EXP RES, V40, P1290, DOI 10.1111/acer.13065; Corbett BF, 2017, CELL REP, V20, P344, DOI 10.1016/j.celrep.2017.06.040; Criswell HE, 2004, BRAIN RES, V1015, P107, DOI 10.1016/j.brainres.2004.04.050; Criswell HE, 2003, J PHARMACOL EXP THER, V304, P192, DOI 10.1124/jpet.102.041590; Cummings P, 2006, INJURY PREV, V12, P148, DOI 10.1136/ip.2005.010975; Czigner A, 2004, INT J MOL MED, V14, P247; Dorsett CR, 2017, J NEUROTRAUM, V34, P263, DOI 10.1089/neu.2015.4373; Dutcher SA, 1999, NEUROL RES, V21, P234, DOI 10.1080/01616412.1999.11740924; Flavell SW, 2008, ANNU REV NEUROSCI, V31, P563, DOI 10.1146/annurev.neuro.31.060407.125631; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Folkersma H, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-67; Gey M, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160091; Gill R, 2013, EUR J NEUROSCI, V38, P3554, DOI 10.1111/ejn.12367; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Goodman MD, 2013, J SURG RES, V184, P1053, DOI 10.1016/j.jss.2013.04.058; Grassi D, 2017, CEREB CORTEX, V27, P4166, DOI 10.1093/cercor/bhx095; Hanchar HJ, 2005, NAT NEUROSCI, V8, P339, DOI 10.1038/nn1398; Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911; He Q, 2013, J NEUROPHYSIOL, V109, P1333, DOI 10.1152/jn.00350.2012; Hinzman JM, 2016, J NEUROTRAUM, V33, P1775, DOI 10.1089/neu.2015.4226; Honkaniemi J, 1999, EUR J NEUROSCI, V11, P10, DOI 10.1046/j.1460-9568.1999.00401.x; Hu BR, 2004, J CEREBR BLOOD F MET, V24, P934, DOI 10.1097/01.WCB.0000125888.56462.A1; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Joseph B, 2015, J TRAUMA ACUTE CARE, V78, P403, DOI 10.1097/TA.0000000000000504; Karelina K, 2017, BRAIN BEHAV IMMUN, V60, P304, DOI 10.1016/j.bbi.2016.11.009; Katada R, 2009, J NEUROTRAUM, V26, P2015, DOI 10.1089/neu.2008.0552; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Kidger AM, 2017, P NATL ACAD SCI USA, V114, pE317, DOI 10.1073/pnas.1614684114; Kigar SL, 2015, BRAIN BEHAV IMMUN, V46, P60, DOI 10.1016/j.bbi.2015.02.018; Kumar S, 2009, PSYCHOPHARMACOLOGY, V205, P529, DOI 10.1007/s00213-009-1562-z; Li L, 2007, MOL CELL NEUROSCI, V35, P76, DOI 10.1016/j.mcn.2007.02.004; Losing P, 2017, MOL BRAIN, V10, DOI 10.1186/s13041-017-0310-2; Luong TN, 2011, JOVE-J VIS EXP, DOI 10.3791/2376; Ma J, 2017, CELL MOL NEUROBIOL, V37, P111, DOI 10.1007/s10571-016-0351-6; Mauceri D, 2011, NEURON, V71, P117, DOI 10.1016/j.neuron.2011.04.022; Mellstrom B, 2014, MOL CELL BIOL, V34, P877, DOI 10.1128/MCB.00360-13; Morris TA, 2000, MOL BRAIN RES, V79, P138, DOI 10.1016/S0169-328X(00)00112-1; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Nomaru H, 2014, GLIA, V62, P1284, DOI 10.1002/glia.22680; Oshitari T, 2002, INVEST OPHTH VIS SCI, V43, P2442; Pandit V, 2014, J SURG RES, V190, P634, DOI 10.1016/j.jss.2014.04.039; Raj R, 2016, J NEUROSURG, V124, P1684, DOI 10.3171/2015.4.JNS141746; Raj R, 2015, J NEUROTRAUM, V32, P95, DOI 10.1089/neu.2014.3488; Ramanan N, 2005, NAT NEUROSCI, V8, P759, DOI 10.1038/nn1462; Rawat V, 2016, MOL NEUROBIOL, V53, P1165, DOI 10.1007/s12035-014-9058-1; Relja B, 2013, SCAND J GASTROENTERO, V48, P448, DOI 10.3109/00365521.2013.772228; Renaudineau S, 2009, P NATL ACAD SCI USA, V106, P11771, DOI 10.1073/pnas.0900484106; Salim A, 2009, J TRAUMA, V67, P697, DOI 10.1097/TA.0b013e3181b5dcf2; Samal BB, 2015, J MOL NEUROSCI, V57, P282, DOI 10.1007/s12031-015-0626-2; Sato S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082891; Savola O, 2005, ALCOHOL ALCOHOLISM, V40, P269, DOI 10.1093/alcalc/agh159; Shin GT, 2012, INFLAMM RES, V61, P1195, DOI 10.1007/s00011-012-0515-x; Teng SX, 2015, BRAIN BEHAV IMMUN, V45, P145, DOI 10.1016/j.bbi.2014.11.006; Vaagenes IC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120356; Wagner N, 2017, ALCOHOL CLIN EXP RES, V41, P1559, DOI 10.1111/acer.13446; Wang L, 2012, NEUROSCIENCE, V220, P100, DOI 10.1016/j.neuroscience.2012.06.010; Wang T, 2013, J NEUROSURG, V118, P390, DOI 10.3171/2012.8.JNS12736; Wang YP, 2014, NEUROREPORT, V25, P954, DOI 10.1097/WNR.0000000000000219; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; YUAN X-Q, 1990, Journal of Neurotrauma, V7, P141, DOI 10.1089/neu.1990.7.141; Yutsudo N, 2013, NEUROPSYCHOPHARMACOL, V38, P895, DOI 10.1038/npp.2012.260; Zhang JH, 2002, NAT GENET, V30, P416, DOI 10.1038/ng859; Zhang SJ, 2011, J NEUROSCI, V31, P4978, DOI 10.1523/JNEUROSCI.2672-10.2011; Zhang SJ, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000604; Zhang X. F., 2014, J ANHUI AGR SCI, V7, P2014, DOI DOI 10.1039/C3EE43278E; Zimprich A, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00125	76	12	12	1	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	2018	302						34	45		10.1016/j.expneurol.2017.12.017			12	Neurosciences	Neurosciences & Neurology	GD1MZ	WOS:000430265300004	29306704				2021-06-18	
J	Hellewell, SC; Mondello, S; Conquest, A; Shaw, G; Madorsky, I; Deng, JV; Little, L; Kobeissy, F; Bye, N; Bellomo, R; Cooper, DJ; Vallance, S; Board, J; Morganti-Kossmann, MC				Hellewell, Sarah C.; Mondello, Stefania; Conquest, Alison; Shaw, Gerry; Madorsky, Irina; Deng, Jay V.; Little, Lorraine; Kobeissy, Firas; Bye, Nicole; Bellomo, Rinaldo; Cooper, David J.; Vallance, Shirley; Board, Jasmine; Morganti-Kossmann, Maria C.			Erythropoietin Does Not Alter Serum Profiles of Neuronal and Axonal Biomarkers After Traumatic Brain Injury: Findings From the Australian EPO-TBI Clinical Trial	CRITICAL CARE MEDICINE			English	Article						biomarker; erythropoietin; phosphorylated neurofilament heavy-chain; traumatic brain injury; ubiquitin carboxy-terminal hydrolase L1	C-TERMINAL HYDROLASE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; INTRACRANIAL LESIONS; DOUBLE-BLIND; PNF-H; NF-H; SUBUNIT; BLOOD; RECOVERY; THERAPY	Objective: To determine profiles of serum ubiquitin carboxy-terminal hydrolase L1 and phosphorylated neurofilament heavy-chain, examine whether erythropoietin administration reduce their concentrations, and whether biomarkers discriminate between erythropoietin and placebo treatment groups. Design: Single-center, prospective observational study. Setting: A sub-study of the erythropoietin-traumatic brain injury clinical trial, conducted at the Alfred Hospital, Melbourne, Australia. Patients: Forty-four patients with moderate-to-severe traumatic brain injury. Interventions: Epoetin alfa 40,000 IU or 1 mL sodium chloride 0.9 as subcutaneous injection within 24 hours of traumatic brain injury. Measurements and Main Results: Ubiquitin carboxy-terminal hydrolase L1, phosphorylated neurofilament heavy-chain, and erythropoietin concentrations were measured in serum by enzyme-linked immunosorbent assay from D0 (within 24 hr of injury, prior to erythropoietin/vehicle administration) to D5. Biomarker concentrations were compared between injury severities, diffuse versus focal traumatic brain injury and erythropoietin or placebo treatment groups. Ubiquitin carboxy-terminal hydrolase L1 peaked at 146.0 ng/mL on D0, significantly decreased to 84.30 ng/mL on D1, and declined thereafter. Phosphorylated neurofilament heavy-chain levels were lowest at D0 and peaked on D5 at 157.9 ng/mL. D0 ubiquitin carboxy-terminal hydrolase L1 concentrations were higher in diffuse traumatic brain injury. Peak phosphorylated neurofilament heavy-chain levels on D3 and D4 correlated with Glasgow Outcome Score-Extended, predicting poor outcome. Erythropoietin did not reduce concentrations of ubiquitin carboxy-terminal hydrolase L1 or phosphorylated neurofilament heavy-chain. Conclusions: Serum ubiquitin carboxy-terminal hydrolase L1 and phosphorylated neurofilament heavy-chain increase after traumatic brain injury reflecting early neuronal and progressive axonal injury. Consistent with lack of improved outcome in traumatic brain injury patients treated with erythropoietin, biomarker concentrations and profiles were not affected by erythropoietin. Pharmacokinetics of erythropoietin suggest that the dose given was possibly too low to exert neuroprotection.	[Hellewell, Sarah C.] Univ Alberta, Fac Rehabil Med, Edmonton, AB, Canada; [Hellewell, Sarah C.; Bye, Nicole] Alfred Hosp, Dept Surg, Melbourne, Vic, Australia; [Hellewell, Sarah C.; Conquest, Alison; Bellomo, Rinaldo; Cooper, David J.] Monash Univ, Dept Med Nursing & Hlth Sci, Melbourne, Vic, Australia; [Mondello, Stefania] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Italy; [Shaw, Gerry; Madorsky, Irina; Deng, Jay V.] EnCor Biotechnol Inc, Gainesville, FL USA; [Little, Lorraine; Cooper, David J.; Vallance, Shirley; Board, Jasmine; Morganti-Kossmann, Maria C.] Australian New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia; [Kobeissy, Firas] Univ Florida, McKnight Brain Inst, Dept Psychiat & Neurosci, Gainesville, FL USA; [Bellomo, Rinaldo] Austin Hlth, Dept Intens Care Res, Melbourne, Vic, Australia; [Cooper, David J.] Alfred Hosp, Dept Intens Care, Melbourne, Vic, Australia; [Morganti-Kossmann, Maria C.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; [Morganti-Kossmann, Maria C.] Univ Arizona, Dept Child Hlth, Barrow Neurol Inst, Phoenix, AZ USA	Hellewell, SC (corresponding author), Univ Alberta, Fac Rehabil Med, Edmonton, AB, Canada.; Hellewell, SC (corresponding author), Alfred Hosp, Dept Surg, Melbourne, Vic, Australia.; Hellewell, SC (corresponding author), Monash Univ, Dept Med Nursing & Hlth Sci, Melbourne, Vic, Australia.	hellewel@ualberta.ca	, Gerry/X-2377-2019; Cooper, D. James/G-7961-2013; Mondello, Stefania/A-1813-2012	Cooper, D. James/0000-0002-5872-9051; Mondello, Stefania/0000-0002-8587-3614; Morganti-Kossmann, Cristina/0000-0002-0807-2063	Centre of Excellence in Traumatic Brain Injury Research (CETBIR) Postdoctoral Fellowship; National Health and Medical Research Council (NHMRC) AustraliaNational Health and Medical Research Council of Australia; Transport Accident Commission (TAC); Monash University from the NHMRC; TAC grants; Victorian Neurotrauma Initiative	Dr. Hellewell was supported by a Centre of Excellence in Traumatic Brain Injury Research (CETBIR) Postdoctoral Fellowship.; Drs. Little and Cooper's institutions received funding from National Health and Medical Research Council (NHMRC) Australia. Dr. Little's institution received funding from the Transport Accident Commission (TAC), and she disclosed that she project-managed the EPO-TBI RCT and received a salary via Monash University from the NHMRC and TAC grants for her work. Drs. Bellomo and Cooper disclosed off-label product use of erythropoietin in traumatic brain injury. Dr. Cooper's institution received funding from Victorian Neurotrauma Initiative. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Adamcio B, 2008, BMC BIOL, V6, DOI 10.1186/1741-7007-6-37; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Berger RP, 2011, PM&R, V3, pS31, DOI 10.1016/j.pmrj.2011.03.016; Bian XX, 2010, NEUROL MED-CHIR, V50, P361, DOI 10.2176/nmc.50.361; Blennow K, 2014, NEUROPSYCHOPHARMACOL, V39, P189, DOI 10.1038/npp.2013.154; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Boylan K, 2009, J NEUROCHEM, V111, P1182, DOI 10.1111/j.1471-4159.2009.06386.x; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Brophy G, 2009, J NEUROTRAUM, V26, pA14; Cai JY, 2013, CLIN CHIM ACTA, V424, P182, DOI 10.1016/j.cca.2013.06.019; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2011, MOL MED, V17, P1306, DOI 10.2119/molmed.2011.00259; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; HARRIS J, 1991, J NEUROSCI RES, V30, P47, DOI 10.1002/jnr.490300107; Hellewell SC, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-156; Kiiski H, 2016, J NEUROL SCI, V361, P144, DOI 10.1016/j.jns.2015.12.046; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; Li ZM, 2016, CLIN NEUROL NEUROSUR, V150, P80, DOI 10.1016/j.clineuro.2016.09.001; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Minnerup J, 2009, STROKE, V40, P3113, DOI 10.1161/STROKEAHA.109.555789; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Nichol A, 2015, TRIALS, V16, DOI 10.1186/s13063-014-0528-6; Nirula R, 2010, CRIT CARE RES PRACT, V2010, DOI 10.1155/2010/209848; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Shaw G., 2015, BRAIN NEUROTRAUMA MO; Shibahashi K, 2016, J NEUROTRAUM, V33, P1826, DOI 10.1089/neu.2015.4237; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Sosna J, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-76; Tongaonkar P, 2000, MOL CELL BIOL, V20, P4691, DOI 10.1128/MCB.20.13.4691-4698.2000; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wang KKW, 2013, PROC SPIE, V8723, DOI 10.1117/12.2020030; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510	46	12	13	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2018	46	4					554	561		10.1097/CCM.0000000000002938			8	Critical Care Medicine	General & Internal Medicine	FZ7IZ	WOS:000427775500032	29278529				2021-06-18	
J	Kroshus, E; Stellino, MB; Chrisman, SPD; Rivara, FP				Kroshus, Emily; Stellino, Megan Babkes; Chrisman, Sara P. D.; Rivara, Frederick P.			Threat, Pressure, and Communication About Concussion Safety: Implications for Parent Concussion Education	HEALTH EDUCATION & BEHAVIOR			English	Article						communication; concussion; parents; pressure; sport	YOUTH SPORTS; INJURY; RISK; BEHAVIOR; METAANALYSIS; PERCEPTIONS; PROTECTION; ATTITUDES; BELIEFS; FATHERS	Background. Parental communication about the importance of reporting concussion symptoms can influence a child's attitudes about such reporting, and is likely related to perceived threat of concussion. However, parental investment in child sport achievement might impede this communication. Purpose. To examine the relationship between perceived threat of concussion and parent-child communication regarding concussion symptom reporting, and the potential interaction with parental pressure regarding child sport achievement. Method. A total of 236 parents of youth soccer players completed an anonymous online survey. Results. There were greater odds of encouraging concussion reporting among parents who perceived that their child had a greater likelihood of sustaining a concussion (OR = 1.03, 95% CI [1.01, 1.04]) and lower odds among parents who exhibited greater parental sport pressure (OR = 0.88, 95% CI [0.78, 0.99]). Parents whose child had a prior concussion were much more likely to communicate with their child about concussion reporting (OR = 7.86, 95% CI [3.00, 20.55]). Conclusion. Initiatives are needed to support healthy sport parenting, particularly focusing on parental encouragement of concussion reporting. Possible directions for concussion education for parents based on the results of this study include providing parents with concrete guidance about the important role they can play in encouraging their child to report symptoms of a concussion, communicating the athletic consequences of continued sport involvement while experiencing symptoms of a concussion, and using narrative messaging with exemplars to personalize the information for parents of youth who have not previously sustained a concussion.	[Kroshus, Emily; Chrisman, Sara P. D.; Rivara, Frederick P.] Univ Washington, Seattle, WA 98195 USA; [Kroshus, Emily; Chrisman, Sara P. D.; Rivara, Frederick P.] Seattle Childrens Res Inst, 2001 W 8th Ave,Suite 400, Seattle, WA 98121 USA; [Stellino, Megan Babkes] Univ Colorado, Greeley, CO USA; [Chrisman, Sara P. D.; Rivara, Frederick P.] Harborview Injury Prevent & Res Ctr, Seattle, WA USA	Kroshus, E (corresponding author), Seattle Childrens Res Inst, 2001 W 8th Ave,Suite 400, Seattle, WA 98121 USA.	ekroshus@uw.edu		Chrisman, Sara/0000-0001-5373-7223			Asken BM, 2016, J ATHL TRAINING, V51, P329, DOI 10.4085/1062-6050-51.5.02; Babkes ML, 1999, PEDIATR EXERC SCI, V11, P44, DOI 10.1123/pes.11.1.44; Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136; Brussoni M, 2013, CHILD CARE HLTH DEV, V39, P237, DOI 10.1111/j.1365-2214.2011.01361.x; Brussoni M, 2013, AM J MENS HEALTH, V7, P77, DOI 10.1177/1557988312462739; Brussoni M, 2011, J DEV BEHAV PEDIATR, V32, P491, DOI 10.1097/DBP.0b013e31821bd1f5; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Creighton G, 2017, J FAM ISSUES, V38, P1043, DOI 10.1177/0192513X15584679; Dahlstrom MF, 2014, P NATL ACAD SCI USA, V111, P13614, DOI 10.1073/pnas.1320645111; DIEFENBACH MA, 1993, HEALTH EDUC RES, V8, P181, DOI 10.1093/her/8.2.181; DiFiori JP, 2014, BRIT J SPORT MED, V48, DOI 10.1136/bjsports-2013-093299; Eccles J., 1983, ACHIEVEMENT ACHIEVEM, P75, DOI DOI 10.1007/S11251-015-9352-Y; ECCLES JS, 1993, NEBR SYM MOTIV, V40, P145; Eckner JT, 2014, BRIT J SPORT MED, V48, P112, DOI 10.1136/bjsports-2012-091579; Elbin RJ, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0910; Faigenbaum AD, 2009, J STRENGTH COND RES, V23, pS60, DOI 10.1519/JSC.0b013e31819df407; Fraser-Thomas J. L., 2005, Physical Education and Sport Pedagogy, V10, P19, DOI 10.1080/1740898042000334890; Fredericks J. A., 2004, DEV SPORT EXERCISE P, P165; Gielen AC, 2004, J URBAN HEALTH, V81, P545, DOI 10.1093/jurban/jth139; Glang A, 2010, INT J SPORTS SCI COA, V5, P1, DOI 10.1260/1747-9541.5.1.1; GLIK D, 1991, HEALTH EDUC QUART, V18, P285, DOI 10.1177/109019819101800303; Gottzen L, 2012, GENDER SOC, V26, P639, DOI 10.1177/0891243212446370; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Kroshus E, 2015, SOC SCI MED, V134, P66, DOI 10.1016/j.socscimed.2015.04.011; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Malina RM, 2010, CURR SPORT MED REP, V9, P364, DOI 10.1249/JSR.0b013e3181fe3166; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marshall Stephen W, 2015, Inj Epidemiol, V2, P13; O'Rourke DJ, 2014, J APPL SPORT PSYCHOL, V26, P395, DOI 10.1080/10413200.2014.907838; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P354, DOI 10.1177/109019817400200405; Sanchez-Miguel PA, 2013, J HUM KINET, V36, P169, DOI 10.2478/hukin-2013-0017; TINSLEY BJ, 1992, CHILD DEV, V63, P1043, DOI 10.2307/1131518; US Soccer, 2015, KEY STAT; Wheeler S, 2014, LEISURE STUD, V33, P267, DOI 10.1080/02614367.2012.707227; White SA, 2004, SCAND J MED SCI SPOR, V14, P57, DOI 10.1111/j.1600-0838.2003.00314.x; Witte K, 2000, HEALTH EDUC BEHAV, V27, P591, DOI 10.1177/109019810002700506	39	12	12	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1090-1981	1552-6127		HEALTH EDUC BEHAV	Health Educ. Behav.	APR	2018	45	2					254	261		10.1177/1090198117715669			8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	GC5EX	WOS:000429809500011	28789571				2021-06-18	
J	Ma, DL; Wang, N; Fan, XT; Zhang, L; Luo, Y; Huang, R; Zhang, L; Li, YL; Zhao, GG; Li, L				Ma, Denglei; Wang, Na; Fan, Xiaotong; Zhang, Lan; Luo, Yi; Huang, Rui; Zhang, Li; Li, Yali; Zhao, Guoguang; Li, Lin			Protective Effects of Cornel Iridoid Glycoside in Rats After Traumatic Brain Injury	NEUROCHEMICAL RESEARCH			English	Article						Cornel iridoid glycoside; Traumatic brain injury; Behavior impairment; Apoptosis; Neurotrophic factor; Synaptic protein	NERVE GROWTH-FACTOR; NEUROLOGICAL FUNCTION; NEUROTROPHIC FACTORS; OBJECT RECOGNITION; CORTICAL IMPACT; MESSENGER-RNA; RODENT MODEL; IN-VITRO; APOPTOSIS; EXPRESSION	Cornel iridoid glycoside (CIG) is the active ingredient extracted from Cornus officinalis. Our previous studies showed that CIG had protective effects on several brain injury models. In the present study, we aimed to examine the effects and elucidate the mechanisms of CIG against traumatic brain injury (TBI). TBI was induced in the right cerebral cortex of male adult rats. The neurological and cognitive functions were evaluated by modified neurological severity score (mNSS) and object recognition test (ORT), respectively. The level of serum S100 beta was measured by an ELISA method. Nissl staining was used to estimate the neuron survival in the brain. The expression of proteins was determined by western blot and/or immunohistochemical staining. We found that intragastric administration of CIG in TBI rats ameliorated the neurological defects and cognitive impairment, and alleviated the neuronal loss in the injured brain. In the acute stage of TBI (24-72 h), CIG decreased the level of S100 beta in the serum and brain, increased the ratio of Bcl-2/Bax and decreased the expression of caspase-3 in the injured cortex. Moreover, the treatment with CIG for 30 days increased the levels of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), enhanced the expression of synapsin I, synaptophysin and postsynaptic density protein 95 (PSD-95), and inhibited the apoptosis-regulating factors in the chronic stage of TBI. The present study demonstrated that CIG had neuroprotective effects against TBI through inhibiting apoptosis in the acute stage and promoting neurorestoration in the chronic stage. The results suggest that CIG may be beneficial to TBI therapy.	[Ma, Denglei; Wang, Na; Zhang, Lan; Luo, Yi; Huang, Rui; Zhang, Li; Li, Yali; Li, Lin] Capital Med Univ, Xuanwu Hosp, Dept Pharmacol, Beijing 100053, Peoples R China; [Ma, Denglei; Wang, Na; Zhang, Lan; Luo, Yi; Huang, Rui; Zhang, Li; Li, Yali; Li, Lin] Beijing Engn Res Ctr Nerve Syst Drugs, Beijing 100053, Peoples R China; [Ma, Denglei; Wang, Na; Zhang, Lan; Luo, Yi; Huang, Rui; Zhang, Li; Li, Yali; Li, Lin] Minist Educ, Key Lab Neurodegenerat Dis, Beijing 100053, Peoples R China; [Fan, Xiaotong; Zhao, Guoguang] Capital Med Univ, Dept Neurosurg, Xuanwu Hosp, Beijing 100053, Peoples R China; [Zhao, Guoguang] Beijing Inst Brain Disorders, Beijing 100053, Peoples R China	Li, L (corresponding author), Capital Med Univ, Xuanwu Hosp, Dept Pharmacol, Beijing 100053, Peoples R China.; Li, L (corresponding author), Beijing Engn Res Ctr Nerve Syst Drugs, Beijing 100053, Peoples R China.; Li, L (corresponding author), Minist Educ, Key Lab Neurodegenerat Dis, Beijing 100053, Peoples R China.; Zhao, GG (corresponding author), Capital Med Univ, Dept Neurosurg, Xuanwu Hosp, Beijing 100053, Peoples R China.; Zhao, GG (corresponding author), Beijing Inst Brain Disorders, Beijing 100053, Peoples R China.	ggzhao@vip.sina.com; linlixw@126.com	MA, DENGLEI/AAN-2435-2021; Li, Lin/S-4015-2019		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81273498, 81341087, 81473373]; National Key Research and Development Program of China [2016YFC0103909]; Beijing Municipal Science & Technology Commission projectBeijing Municipal Science & Technology Commission [Z161100000516008]; Beijing High-level Health and Technical Personal Plan [2011-1-7, 2014-2-014]	This research was supported by National Natural Science Foundation of China (81273498, 81341087, 81473373); National Key Research and Development Program of China (2016YFC0103909); Beijing Municipal Science & Technology Commission project (Z161100000516008); Beijing High-level Health and Technical Personal Plan (2011-1-7, 2014-2-014).	Aloe L, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-239; Alonso M, 2004, LEARN MEMORY, V11, P172, DOI 10.1101/lm.67804; Bamji SX, 2006, J CELL BIOL, V174, P289, DOI 10.1083/jcb.200601087; Berninger B, 1999, LEARN MEMORY, V6, P232; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Campbell SJ, 2007, NEUROBIOL DIS, V27, P151, DOI 10.1016/j.nbd.2007.04.013; Chen Zhi-gang, 2003, Chin J Traumatol, V6, P23; Chiaretti A, 2017, BRAIN INJURY, V31, P1538, DOI 10.1080/02699052.2017.1376760; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Conti AC, 1998, J NEUROSCI, V18, P5663; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Di Pietro V, 2015, NEUROCHEM RES, V40, P991, DOI 10.1007/s11064-015-1554-9; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Feng Y, 2016, MOL MED REP, V13, P5248, DOI 10.3892/mmr.2016.5201; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Geyer C, 2009, J NEUROS-PEDIATR, V4, P339, DOI 10.3171/2009.5.PEDS08481; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Hilfiker S, 1999, PHILOS T ROY SOC B, V354, P269, DOI 10.1098/rstb.1999.0378; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Lin T, 2008, HEILONGJIANG MED PHA, V31, P3; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Logsdon AE, 2016, BRAIN RES, V1643, P140, DOI 10.1016/j.brainres.2016.04.063; Lu B, 2014, Handb Exp Pharmacol, V220, P223, DOI 10.1007/978-3-642-45106-5_9; Luikart BW, 2008, J NEUROSCI, V28, P7006, DOI 10.1523/JNEUROSCI.0195-08.2008; Ma DL, 2016, BEHAV BRAIN RES, V312, P20, DOI 10.1016/j.bbr.2016.06.008; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Merlo L, 2014, J NEUROTRAUM, V31, P1375, DOI 10.1089/neu.2014.3385; Minambres E, 2008, J NEUROTRAUM, V25, P581, DOI 10.1089/neu.2007.0398; Nathoo N, 2004, J NEUROSURG, V101, P233, DOI 10.3171/jns.2004.101.2.0233; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Riggio S, 2011, NEUROL CLIN, V29, P35, DOI 10.1016/j.ncl.2010.10.008; Rigon A, 2016, COGN AFFECT BEHAV NE, V16, P866, DOI 10.3758/s13415-016-0437-0; Rubovitch V, 2017, SCI REP-UK, V7, DOI 10.1038/srep41269; Song S. Q., 2006, JILIN J TRADITIONAL, V26, P3; Stoica B, 2009, NEUROTHERAPEUTICS, V6, P14, DOI 10.1016/j.nurt.2008.10.029; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tamaoki S, 2016, EUR J PHARMACOL, V779, P168, DOI 10.1016/j.ejphar.2016.03.024; Tang WJ, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6725381; Thau-Zuchman O, 2012, NEUROSCIENCE, V202, P334, DOI 10.1016/j.neuroscience.2011.11.071; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; [王娜 Wang Na], 2010, [中国临床药理学与治疗学, Chinese Journal of Clinical Pharmacology and Therapeutics], V15, P255; Wen ZJ, 2017, NEURAL PLAST, V2017, DOI 10.1155/2017/4296075; Winters BD, 2005, J NEUROSCI, V25, P52, DOI 10.1523/JNEUROSCI.3827-04.2005; Wu QL, 2016, NEUROCHEM RES, V41, P2810, DOI 10.1007/s11064-016-1997-7; Xiong Y, 2010, DISCOV MED, V10, P434; Ya BL, 2010, NEUROCHEM RES, V35, P773, DOI 10.1007/s11064-010-0134-2; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Yao RQ, 2009, BRAIN RES BULL, V79, P69, DOI 10.1016/j.brainresbull.2008.12.010; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang GX, 2016, NEUROCHEM RES, V41, P2948, DOI 10.1007/s11064-016-2013-y; Zhang L, 2006, BEHAV BRAIN RES, V173, P246, DOI 10.1016/j.bbr.2006.06.034; Zhao LH, 2010, EUR J PHARMACOL, V647, P68, DOI 10.1016/j.ejphar.2010.08.016; Zhao ZR, 2015, J NEUROTRAUM, V32, P1347, DOI 10.1089/neu.2014.3739; Zuo DY, 2016, NEUROTOX RES, V30, P159, DOI 10.1007/s12640-016-9611-y; 赵耀武, 2010, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V21, P677	63	12	13	0	14	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	APR	2018	43	4					959	971		10.1007/s11064-018-2501-3			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	GB9US	WOS:000429420200018	29492766				2021-06-18	
J	Moskowitz, EE; Burlew, CC; Moore, EE; Pieracci, FM; Fox, CJ; Campion, EM; Lawless, RA; Cohen, MJ				Moskowitz, Eliza E.; Burlew, Clay Cothren; Moore, Ernest E.; Pieracci, Fredric M.; Fox, Charles J.; Campion, Eric M.; Lawless, Ryan A.; Cohen, Mitchell J.			Preperitoneal pelvic packing is effective for hemorrhage control in open pelvic fractures	AMERICAN JOURNAL OF SURGERY			English	Article						Preperitoneal pelvic packing; Pelvic fractures; Open pelvic fractures; Trauma; Hemorrhage; Shock	HEMODYNAMICALLY UNSTABLE PATIENTS; LIFE-THREATENING HEMORRHAGE; MANAGEMENT; MORTALITY; ANGIOEMBOLIZATION; MULTICENTER; IMPROVEMENT; CARE	Background: Open pelvic fractures are life-threatening injuries. Preperitoneal pelvic packing (PPP) has been suggested to be ineffective for hemorrhage control in open pelvic fractures. We hypothesize that PPP is effective at hemorrhage control in patients with open pelvic fractures and reduces mortality. Methods: Patients undergoing PPP from 2005 to 2015 were analyzed. Patients with open pelvic fractures were defined as direct communication of the bony injury with overlying soft tissue, vagina, or rectum. Results: During the 10-year study, 126 patients underwent PPP; 14 (11%) sustained an open pelvic fracture. After PPP, 1 patient (7%) underwent angioembolization with a documented arterial blush. PPP controlled pelvic hemorrhage in all patients. Overall mortality rate was 7% with one death due to traumatic brain injury. Conclusions: PPP is effective for hemorrhage control in patients with open pelvic fractures. PPP should be used in a standard protocol for hemodynamically unstable patients with pelvic fractures regardless of associated perineal injuries. (C) 2017 Elsevier Inc. All rights reserved.	[Burlew, Clay Cothren] Denver Hlth Med Ctr, Dept Surg, 777 Bannock St, Denver, CO 80204 USA; Univ Colorado Denver, Denver, CO USA	Burlew, CC (corresponding author), Denver Hlth Med Ctr, Dept Surg, 777 Bannock St, Denver, CO 80204 USA.	clay.cothren@dhha.org		Campion, Eric/0000-0002-4563-7748			Bircher M., 2005, EUR J TRAUMA, V6, P526; BIRCHER M, 2004, EUR J TRAUMA, V30, P74; Black Emily Anne, 2011, Iowa Orthop J, V31, P193; Brenneman FD, 1997, J TRAUMA, V42, P773, DOI 10.1097/00005373-199705000-00003; Burlew CC, 2017, J TRAUMA ACUTE CARE, V82, P233, DOI 10.1097/TA.0000000000001324; Burlew CC, 2011, J AM COLL SURGEONS, V212, P628, DOI 10.1016/j.jamcollsurg.2010.12.020; Cannada LK, 2013, J TRAUMA ACUTE CARE, V74, P901, DOI 10.1097/TA.0b013e3182827496; Cannada Lisa K, 2011, Am J Orthop (Belle Mead NJ), V40, P415; Cheng M, 2015, EMERG MED J, V32, P214, DOI 10.1136/emermed-2012-202009; Chiara O, 2016, WORLD J EMERG SURG, V11, DOI 10.1186/s13017-016-0077-2; Dente CJ, 2005, AM J SURG, V190, P830, DOI 10.1016/j.amjsurg.2005.05.050; Dong JL, 2011, INJURY, V42, P1003, DOI 10.1016/j.injury.2011.01.032; Giordano Vincenzo, 2016, Open Orthop J, V10, P772, DOI 10.2174/1874325001610010772; Grotz MRW, 2005, INJURY, V36, P1, DOI 10.1016/j.injury.2004.05.029; Heetveld MJ, 2004, WORLD J SURG, V28, P904, DOI 10.1007/s00268-004-7357-9; Jones AL, 1997, ORTHOP CLIN N AM, V28, P345, DOI 10.1016/S0030-5898(05)70293-5; Li QH, 2016, INJURY, V47, P395, DOI 10.1016/j.injury.2015.10.008; Magnone S, 2014, WORLD J EMERG SURG, V9, DOI 10.1186/1749-7922-9-18; Marzi I, 2014, SCAND J SURG, V103, P104, DOI 10.1177/1457496914525604; Perkins ZB, 2014, BONE JOINT J, V96B, P1090, DOI 10.1302/0301-620X.96B8.33383; Tai DKC, 2011, J TRAUMA, V71, pE79, DOI 10.1097/TA.0b013e31820cede0; Velmahos GC, 2013, TRAUMA	22	12	14	1	7	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	APR	2018	215	4					675	677		10.1016/j.amjsurg.2017.11.024			3	Surgery	Surgery	GA2US	WOS:000428181800024	29179908				2021-06-18	
J	Pedersen, AL; Brownrout, JL; Saldanha, CJ				Pedersen, Alyssa L.; Brownrout, Jenna L.; Saldanha, Colin J.			Neuroinflammation and neurosteroidogenesis: Reciprocal modulation during injury to the adult zebra finch brain	PHYSIOLOGY & BEHAVIOR			English	Article						Estrogen; Songbird; TBI	MALIGNANT BREAST TISSUES; AROMATASE MESSENGER-RNA; CENTRAL-NERVOUS-SYSTEM; ESTROGEN-RECEPTOR 1; GROWTH-FACTOR-I; SEX-DIFFERENCES; TAENIOPYGIA-GUTTATA; NEUROPROTECTIVE ACTIONS; MONONUCLEAR-CELLS; ISCHEMIC-STROKE	Estrogens like estradiol (E-2) via their receptors are pluripotent steroid hormones that exert a profound influence on the developing and adult brain in many vertebrates. In songbirds and mammals, acute brain injury resulting from mechanical damage, anoxia and ischemia rapidly upregulates aromatase and E-2 synthesis. Interestingly, this E-2 provision occurs due to the induction of aromatase expression in reactive astrocytes in areas surrounding brain injury. The resultant increase in E-2 is neuroprotective with established influences on apoptosis, gliosis, cytogenesis, neurogenesis and neuroinflammation. Correspondingly, E-2 decreases secondary damage following acute brain trauma and may improve recovery. Until very recently however, the signals responsible for the induction of astrocytic aromatase expression in reactive astrocytes were unknown. In the current review, we discuss what is known about the role of astrocytic E-2 in neuroprotection with a particular emphasis on a recently discovered interaction between neuroinflammatory and steroidogenic signaling in the zebra finch. We first describe the role of acute inflammatory signaling in the regulation of astrocytic aromatase and central E-2 levels. Next, we discuss the emerging role of central E-2 in the control of chronic neuroinflammation. Finally, we provide a framework for further work investigating the important role of the interaction between inflammatory and steroidogenic signaling in the protection of neural circuits and behavior following traumatic brain injury (TBI). We also highlight dimorphisms that point to important aspects of sex-specific pathways that underlie the interactions of neuroinflammation and neurosteroidogenesis.	[Pedersen, Alyssa L.; Brownrout, Jenna L.; Saldanha, Colin J.] Amer Univ, Dept Biol, Washington, DC 20016 USA; [Pedersen, Alyssa L.; Brownrout, Jenna L.; Saldanha, Colin J.] Amer Univ, Ctr Behav Neurosci, Washington, DC 20016 USA	Saldanha, CJ (corresponding author), Dept Biol, 4400 Massachusetts Ave NW, Washington, DC 20016 USA.	saldanha@american.edu	Brownrout, Jenna/N-6563-2019	Brownrout, Jenna/0000-0002-8385-7151	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 042787, 080585]	The work from our laboratory discussed herein was supported by NIH, NS 042787 & 080585.	ADKINSREGAN E, 1990, HORM BEHAV, V24, P114, DOI 10.1016/0018-506X(90)90031-R; Arevalo MA, 2015, NAT REV NEUROSCI, V16, P17, DOI 10.1038/nrn3856; ARNOLD AP, 1984, ANNU REV NEUROSCI, V7, P413, DOI 10.1146/annurev.ne.07.030184.002213; Azcoitia I, 2003, AGING CELL, V2, P31, DOI 10.1046/j.1474-9728.2003.00013.x; Azcoitia I, 2001, J NEUROBIOL, V47, P318, DOI 10.1002/neu.1038; Azcoitia I, 2002, NEUROTOX RES, V4, P235, DOI 10.1080/10298420290033232; BALTHAZART J, 1983, GEN COMP ENDOCR, V51, P191, DOI 10.1016/0016-6480(83)90072-2; BALTHAZART J, 1984, J EXP ZOOL, V232, P595, DOI 10.1002/jez.1402320328; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; Benkovic SA, 2006, BRAIN RES, V1070, P215, DOI 10.1016/j.brainres.2005.11.065; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; BREEDLOVE SM, 1981, BRAIN RES, V225, P297; Brotfain E, 2016, CURR NEUROPHARMACOL, V14, P641, DOI 10.2174/1570159X14666160309123554; Brown CM, 2010, ENDOCRINOLOGY, V151, P4916, DOI 10.1210/en.2010-0371; Bulun SE, 2012, SEMIN REPROD MED, V30, P39, DOI 10.1055/s-0031-1299596; Chakrabarti M, 2015, REV NEUROSCI; Che Q, 2014, INT J CANCER, V135, P282, DOI 10.1002/ijc.28679; Day NL, 2013, J NEUROTRAUM, V30, P1531, DOI 10.1089/neu.2013.2854; Dean SL, 2012, ENDOCRINOLOGY, V153, P5415, DOI 10.1210/en.2012-1350; Dean SL, 2012, EUR J NEUROSCI, V35, P1218, DOI 10.1111/j.1460-9568.2012.08032.x; Delpy L, 2005, J IMMUNOL, V175, P5050, DOI 10.4049/jimmunol.175.8.5050; Denes A, 2010, BRAIN BEHAV IMMUN, V24, P708, DOI 10.1016/j.bbi.2009.09.010; Duncan KA, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-81; Fairbanks SL, 2012, NEUROSCIENCE, V219, P183, DOI 10.1016/j.neuroscience.2012.05.048; Feeser VR, 2011, J NEUROIMMUNOL, V237, P4, DOI 10.1016/j.jneuroim.2011.06.007; Garcia-Segura LM, 1999, J NEUROBIOL, V40, P574, DOI 10.1002/(SICI)1097-4695(19990915)40:4<574::AID-NEU12>3.0.CO;2-8; Garcia-Segura LM, 1999, NEUROSCIENCE, V89, P567, DOI 10.1016/S0306-4522(98)00340-6; Garcia-Segura LM, 2004, ENDOCRINOLOGY, V145, P1082, DOI 10.1210/en.2003-1383; Garcia-Segura LM, 2006, GLIA, V54, P485, DOI 10.1002/glia.20404; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Green PS, 1996, NEUROSCI LETT, V218, P165, DOI 10.1016/S0304-3940(96)13148-7; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; GURNEY ME, 1980, SCIENCE, V208, P1380, DOI 10.1126/science.208.4450.1380; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; Herson PS, 2009, SEMIN REPROD MED, V27, P229, DOI 10.1055/s-0029-1216276; Irahara N, 2006, INT J CANCER, V118, P1915, DOI 10.1002/ijc.21562; Keselman A, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00568; Li JM, 1996, SCIENCE, V272, P398, DOI 10.1126/science.272.5260.398; Lin C, 2015, SCI REP-UK, V5, DOI 10.1038/srep13442; Liu FD, 2012, NEUROCHEM INT, V61, P1255, DOI 10.1016/j.neuint.2012.10.003; LYNCH EA, 1994, J IMMUNOL, V153, P300; MACLUSKY NJ, 1981, SCIENCE, V211, P1294, DOI 10.1126/science.6163211; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; McEwen B, 2002, RECENT PROG HORM RES, V57, P357, DOI 10.1210/rp.57.1.357; McEwen BS, 2017, J NEUROSCI RES, V95, P24, DOI 10.1002/jnr.23809; Mehos C. J., 2015, J NEUROENDOCRINOL; Miki T, 2010, MOL CANCER RES, V8, P665, DOI 10.1158/1541-7786.MCR-09-0351; Mirzatoni A, 2010, J NEUROTRAUM, V27, P1875, DOI 10.1089/neu.2010.1330; Mize AL, 2003, ENDOCRINOLOGY, V144, P306, DOI 10.1210/en.2002-220698; Morris PG, 2011, CANCER PREV RES, V4, P1021, DOI 10.1158/1940-6207.CAPR-11-0110; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; Pedersen AL, 2017, ENDOCRINOLOGY, V158, P2585, DOI 10.1210/en.2017-00346; Pedersen AL, 2016, ENDOCRINOLOGY, V157, P2041, DOI 10.1210/en.2015-1991; Perry VH, 2007, NAT REV IMMUNOL, V7, P161, DOI 10.1038/nri2015; Perry VH, 2004, BRAIN BEHAV IMMUN, V18, P407, DOI 10.1016/j.bbi.2004.01.004; Peterson RS, 2004, J COMP NEUROL, V475, P261, DOI 10.1002/cne.20157; Peterson RS, 2001, J NEUROENDOCRINOL, V13, P317, DOI 10.1046/j.1365-2826.2001.00647.x; Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90; PHILLIPS CA, 1978, FEBS LETT, V94, P115, DOI 10.1016/0014-5793(78)80919-3; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Purohit A, 2005, J STEROID BIOCHEM, V94, P167, DOI 10.1016/j.jsbmb.2005.01.015; PUROHIT A, 1995, J CLIN ENDOCR METAB, V80, P3052, DOI 10.1210/jc.80.10.3052; Ramachandran B, 1999, GENE, V240, P209, DOI 10.1016/S0378-1119(99)00399-6; Rau SW, 2003, J NEUROSCI, V23, P11420; Robic A, 2014, J STEROID BIOCHEM, V140, P44, DOI 10.1016/j.jsbmb.2013.11.001; ROTHWELL NJ, 1995, INT J DEV NEUROSCI, V13, P179, DOI 10.1016/0736-5748(95)00018-C; Saldanha CJ, 2013, J NEUROENDOCRINOL, V25, P1032, DOI 10.1111/jne.12067; Saldanha CJ, 2005, J NEUROBIOL, V64, P192, DOI 10.1002/neu.20147; Saldanha CJ, 2009, FRONT NEUROENDOCRIN, V30, P106, DOI 10.1016/j.yfrne.2009.04.016; Sapir-Koren R, 2017, BONE, V103, P102, DOI 10.1016/j.bone.2017.06.020; Sarkari A, 2010, INDIAN J NEUROTRAUM, V7, P135, DOI 10.1016/S0973-0508(10)80028-0; Scotland RS, 2011, BLOOD, V118, P5918, DOI 10.1182/blood-2011-03-340281; Selvamani A, 2010, J NEUROSCI, V30, P6852, DOI 10.1523/JNEUROSCI.0761-10.2010; Shahrokhi N., 2010, EFFECT SEX STEROID H; Simpson ER, 2002, ANNU REV PHYSIOL, V64, P93, DOI 10.1146/annurev.physiol.64.081601.142703; Singh A, 1997, J STEROID BIOCHEM, V61, P185; Sohrabji F, 2013, J NEUROENDOCRINOL, V25, P1173, DOI 10.1111/jne.12059; Stein DG, 2015, BRAIN INJURY, V29, P1259, DOI 10.3109/02699052.2015.1065344; Stein DG, 2013, HORM BEHAV, V63, P291, DOI 10.1016/j.yhbeh.2012.05.004; Turgeon JL, 2006, ENDOCR REV, V27, P575, DOI 10.1210/er.2005-0020; Veerapaneni P, 2009, GYNECOL ONCOL, V114, P496, DOI 10.1016/j.ygyno.2009.05.041; Walters BJ, 2011, DEV NEUROBIOL, V71, P170, DOI 10.1002/dneu.20839; Wang ZF, 2017, BIOCHEM BIOPH RES CO, V482, P948, DOI 10.1016/j.bbrc.2016.11.138; Wynne RD, 2004, J NEUROENDOCRINOL, V16, P676, DOI 10.1111/j.1365-2826.2004.01217.x; Wynne RD, 2008, GLIA, V56, P97, DOI 10.1002/glia.20594; Yague JG, 2006, NEUROSCIENCE, V138, P389, DOI 10.1016/j.neuroscience.2005.11.054; Yeung JHH, 2011, ARCH SURG-CHICAGO, V146, P436, DOI 10.1001/archsurg.2011.46; Zeng YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140624	90	12	13	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0031-9384			PHYSIOL BEHAV	Physiol. Behav.	APR 1	2018	187				SI		51	56		10.1016/j.physbeh.2017.10.013			6	Psychology, Biological; Behavioral Sciences	Psychology; Behavioral Sciences	GA7DH	WOS:000428494300009	29031551				2021-06-18	
J	Schranz, AL; Manning, KY; Dekaban, GA; Fischer, L; Jevremovic, T; Blackney, K; Barreira, C; Doherty, TJ; Fraser, DD; Brown, A; Holmes, J; Menon, RS; Bartha, R				Schranz, Amy L.; Manning, Kathryn Y.; Dekaban, Gregory A.; Fischer, Lisa; Jevremovic, Tatiana; Blackney, Kevin; Barreira, Christy; Doherty, Timothy J.; Fraser, Douglas D.; Brown, Arthur; Holmes, Jeff; Menon, Ravi S.; Bartha, Robert			Reduced brain glutamine in female varsity rugby athletes after concussion and in non-concussed athletes after a season of play	HUMAN BRAIN MAPPING			English	Article						athlete brain; concussion; creatine; diffusion tensor imaging; female; glutamine; magnetic resonance imaging; magnetic resonance spectroscopy; white matter; rugby	PROFESSIONAL SOCCER PLAYERS; SPORTS-RELATED CONCUSSION; TEMPORAL WINDOW; WHITE-MATTER; INJURY; RECOVERY; IMPACT; VULNERABILITY; MYOINOSITOL; METABOLISM	The purpose of this study was to use non-invasive proton magnetic resonance spectroscopy (MRS) and diffusion tensor imaging (DTI) to monitor changes in prefrontal white matter metabolite levels and tissue microstructure in female rugby players with and without concussion (ages 18-23, n = 64). Evaluations including clinical tests and 3 T MRI were performed at the beginning of a season (in-season) and followed up at the end of the season (off-season). Concussed athletes were additionally evaluated 24-72 hr (n = 14), three months (n = 11), and six months (n = 8) post-concussion. Reduced glutamine at 24-72 hr and three months post-concussion, and reduced glutamine/creatine at three months post-concussion were observed. In non-concussed athletes (n = 46) both glutamine and glutamine/creatine were lower in the off-season compared to in-season. Within the MRS voxel, an increase in fractional anisotropy (FA) and decrease in radial diffusivity (RD) were also observed in the non-concussed athletes, and correlated with changes in glutamine and glutamine/creatine. Decreases in glutamine and glutamine/creatine suggest reduced oxidative metabolism. Changes in FA and RD may indicate neuroinflammation or re-myelination. The observed changes did not correlate with clinical test scores suggesting these imaging metrics may be more sensitive to brain injury and could aid in assessing recovery of brain injury from concussion.	[Schranz, Amy L.; Manning, Kathryn Y.; Menon, Ravi S.; Bartha, Robert] Univ Western Ontario, Ctr Funct & Metab Mapping, Robarts Res Inst, 1151 Richmond St North, London, ON N6A 5B7, Canada; [Schranz, Amy L.; Manning, Kathryn Y.; Menon, Ravi S.; Bartha, Robert] Univ Western Ontario, Schulich Sch Med & Dent, Dept Med Biophys, 1151 Richmond St North,Med Sci Bldg, London, ON N6A 5C1, Canada; [Dekaban, Gregory A.; Blackney, Kevin; Barreira, Christy; Brown, Arthur] Univ Western Ontario, Robarts Res Inst, Mol Med Res Labs, 1151 Richmond St North, London, ON N6A 5B7, Canada; [Dekaban, Gregory A.; Blackney, Kevin] Univ Western Ontario, Schulich Sch Med & Dent, Dept Microbiol & Immunol, 1151 Richmond St North,Dent Sci Bldg, London, ON N6A 3K7, Canada; [Fischer, Lisa; Jevremovic, Tatiana] Univ Western Ontario, Ctr 3M, Dept Family Med, 1151 Richmond St North, London, ON N6A 3K7, Canada; [Fischer, Lisa; Jevremovic, Tatiana] Univ Western Ontario, Ctr 3M, Fowler Kennedy Sport Med Clin, 1151 Richmond St North, London, ON N6A 3K7, Canada; [Doherty, Timothy J.] Univ Western Ontario, Parkwood Inst, Schulich Sch Med & Dent, Dept Phys Med & Rehabil, 550 Wellington Rd,Hobbins Bldg, London, ON N6C 0A7, Canada; [Fraser, Douglas D.] Childrens Hosp, London Hlth Sci Ctr, Paediat Crit Care Med, 800 Commissioners Rd East, London, ON N6A 5W9, Canada; [Brown, Arthur] Univ Western Ontario, Dept Anat & Cell Biol, 1151 Richmond St North,Med Sci Bldg, London, ON N6A 3K7, Canada; [Holmes, Jeff] Univ Western Ontario, Elborn Coll, Sch Occupat Therapy, 1201 Western Rd, London, ON N6A 1H1, Canada	Bartha, R (corresponding author), Univ Western Ontario, Robarts Res Inst, 1151 Richmond St, London, ON N6A 5B7, Canada.	rbartha@robarts.ca	Fischer, Lisa K/H-3999-2015; Menon, Ravi S/K-5500-2013; Bartha, Robert/K-3611-2013; Brown, Arthur/K-8328-2013; Dekaban, Gregory A./L-1987-2013	Fischer, Lisa K/0000-0001-5992-0176; Menon, Ravi S/0000-0002-7916-0263; Bartha, Robert/0000-0002-7118-9096; Brown, Arthur/0000-0002-8725-3195; Dekaban, Gregory A./0000-0002-3087-4660	Schulich School of Medicine and Dentistry, Western University; Brain Canada; Canada First Research Excellence Fund	Schulich School of Medicine and Dentistry, Western University; Brain Canada; Canada First Research Excellence Fund	[Anonymous], 2013, BRIT J SPORT MED, V47, P259; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/neu.2004.21.1539; Bartha R, 1999, NMR BIOMED, V12, P205, DOI 10.1002/(SICI)1099-1492(199906)12:4<205::AID-NBM558>3.0.CO;2-1; Bartha R, 2000, MAGN RESON MED, V44, P641, DOI 10.1002/1522-2594(200010)44:4<641::AID-MRM19>3.0.CO;2-G; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bey T, 2009, WEST J EMERG MED, V10, P6; Brook EM, 2016, PHYSICIAN SPORTSMED, V44, P20, DOI 10.1080/00913847.2016.1142834; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; DAVIE CA, 1995, J NEUROL NEUROSUR PS, V58, P688, DOI 10.1136/jnnp.58.6.688; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409; Dougan BK, 2014, J INT NEUROPSYCH SOC, V20, P64, DOI 10.1017/S1355617712001464; Echemendia R., 2015, MAGNETIC RESONANCE S; Gao R. A. D., 2017, INT J PATHOLOGY CLIN, V3; George EO, 2014, J NEUROTRAUM, V31, P1018, DOI 10.1089/neu.2013.3224; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goncalves S, 2016, J NEUROSURG-SPINE, V25, P436, DOI 10.3171/2016.2.SPINE15944; Harris AD, 2017, MAGN RESON MED, V77, P1377, DOI 10.1002/mrm.26619; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hertz L, 2017, BIOLOGY-BASEL, V6, DOI 10.3390/biology6010017; Hirrlinger J, 2014, GLIA, V62, P1749, DOI 10.1002/glia.22737; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kierans AS, 2014, NEUROLOGY, V82, P521, DOI 10.1212/WNL.0000000000000105; Koerte IK, 2015, J NEUROTRAUM, V32, P1287, DOI 10.1089/neu.2014.3715; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Kreis R, 2016, MAGN RESON MED, V75, P15, DOI 10.1002/mrm.25568; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Manning KY, 2017, NEUROLOGY, V89, P2157, DOI 10.1212/WNL.0000000000004669; Mayer AR, 2015, J NEUROTRAUM, V32, P1759, DOI 10.1089/neu.2014.3833; MAZZIOTTA JC, 1995, NEUROIMAGE, V2, P89, DOI 10.1006/nimg.1995.1012; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrory P., 2017, BRIT J SPORTS MED; Moreau WJ, 2015, J CHIROPR MED, V14, P169, DOI 10.1016/j.jcm.2015.08.003; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Reynolds BB, 2017, ORTHOP J SPORTS MED, V5, DOI 10.1177/2325967117701708; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tator CH, 2014, BRIT J SPORT MED, V48, P81, DOI 10.1136/bjsports-2013-093040; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	51	12	13	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	APR	2018	39	4					1489	1499		10.1002/hbm.23919			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	FY8LW	WOS:000427117300002	29271016	Green Published			2021-06-18	
J	Ghazale, H; Ramadan, N; Mantash, S; Zibara, K; El-Sitt, S; Darwish, H; Chamaa, F; Boustany, RM; Mondello, S; Abou-Kheir, W; Soueid, J; Kobeissy, F				Ghazale, Hussein; Ramadan, Naify; Mantash, Sara; Zibara, Kazem; El-Sitt, Sally; Darwish, Hala; Chamaa, Farah; Boustany, Rose Mary; Mondello, Stefania; Abou-Kheir, Wassim; Soueid, Jihane; Kobeissy, Firas			Docosahexaenoic acid (DHA) enhances the therapeutic potential of neonatal neural stem cell transplantation post-Traumatic brain injury	BEHAVIOURAL BRAIN RESEARCH			English	Article						Traumatic brain injury; Neural stem cells; Docosahexaenoic acid; Neurogenesis; Reactive ghosts; Motor function	CENTRAL-NERVOUS-SYSTEM; CONTROLLED CORTICAL IMPACT; STEM/PROGENITOR CELLS; NEURONAL DIFFERENTIATION; IN-VITRO; PROGENITOR CELLS; MOUSE MODEL; AGED RATS; HIPPOCAMPAL NEUROGENESIS; BREAKDOWN PRODUCTS	Traumatic Brain Injury (TBI) is a major cause of death and disability worldwide with 1.5 million people inflicted yearly. Several neurotherapeutic interventions have been proposed including drug administration as well as cellular therapy involving neural stem cells (NSCs). Among the proposed drugs is docosahexaenoic acid (DHA), a polyunsaturated fatty acid, exhibiting neuroprotective properties. In this study, we utilized an innovative intervention of neonatal NSCs transplantation in combination with DHA injections in order to ameliorate brain damage and promote functional recovery in an experimental model of TBI. Thus, NSCs derived from the sub ventricular zone of neonatal pups were cultured into neurospheres and transplanted in the cortex of an experimentally controlled cortical impact mouse model of TBI. The effect of NSC transplantation was assessed alone and/or in combination with DHA administration. Motor deficits were evaluated using pole climbing and rotarod tests. Using immunohistochemistry, the effect of transplanted NSCs and DHA treatment was used to assess astrocytic (Glial fibrillary acidic protein, GFAP) and microglial (ionized calcium binding adaptor molecule-1, IBA-1) activity. In addition, we quantified neuroblasts (doublecortin; DCX) and dopaminergic neurons (tyrosine hydroxylase; TH) expression levels. Combined NSC transplantation and DHA injections significantly attenuated TBI-induced motor function deficits (pole climbing test), promoted neurogenesis, coupled with an increase in glial reactivity at the cortical site of injury. In addition, the number of tyrosine hydroxylase positive neurons was found to increase markedly in the ventral tegmental area and substantia nigra in the combination therapy group. Immunoblotting analysis indicated that DHA + NSCs treated animals showed decreased levels of 38 kDa GFAP-BDP (breakdown product) and 145 kDa all-spectrin SBDP indicative of attenuated calpain/caspase activation. These data demonstrate that prior treatment with DHA may be a desirable strategy to improve the therapeutic efficacy of NSC transplantation in TBI.	[Ghazale, Hussein; Ramadan, Naify; Mantash, Sara; El-Sitt, Sally; Darwish, Hala; Boustany, Rose Mary; Soueid, Jihane; Kobeissy, Firas] Amer Univ Beirut, Fac Med, Dept Biochem & Mol Genet, Beirut, Lebanon; [Zibara, Kazem] Lebanese Univ, DSST, Lab Stem Cells, ER045, Beirut, Lebanon; [Zibara, Kazem] Lebanese Univ, Fac Sci 1, Dept Biol, Beirut, Lebanon; [Chamaa, Farah; Abou-Kheir, Wassim] Amer Univ Beirut, Fac Med, Dept Anat Cell Biol & Physiol Sci, Beirut, Lebanon; [Kobeissy, Firas] Univ Florida, Ctr Neuroprote & Biomarkers Res, Dept Psychiat, Gainesville, FL USA; [Boustany, Rose Mary] Amer Univ Beirut Med Ctr, Special Kids Clin, Neurogenet Program, Beirut, Lebanon; [Boustany, Rose Mary] Amer Univ Beirut Med Ctr, Special Kids Clin, Div Pediat Neurol, Dept Pediat, Beirut, Lebanon; [Boustany, Rose Mary] Amer Univ Beirut Med Ctr, Special Kids Clin, Div Pediat Neurol, Dept Adolescent Med, Beirut, Lebanon; [Mondello, Stefania] Univ Messina, AOU Policlin G Martino, Dept Biomed & Dent Sci & Morphofunct Imaging, Via Consolare Valeria, I-98125 Messina, Italy	Abou-Kheir, W; Soueid, J; Kobeissy, F (corresponding author), Amer Univ Beirut, Dept Biochem & Mol Genet, DTS Bldg,Room 419,POB 11-0236, Beirut 11072020, Lebanon.	wa12@aub.edu.lb; js61@aub.edu.lb; Firasko@gmail.com	Mondello, Stefania/A-1813-2012; Abou-Kheir, Wassim/AAP-2587-2020	Mondello, Stefania/0000-0002-8587-3614; Abou-Kheir, Wassim/0000-0001-9719-9324; Darwish, Hala/0000-0001-5744-6466; Zibara, Kazem/0000-0002-9887-072X; Ramadan, Naify/0000-0001-7339-0263	Lebanese National Council for Scientific Research (CNRS)Centre National de la Recherche Scientifique (CNRS); AUB-MPP grant "Dual Neurotherapeutic Effects of Docosahexaenoic Acid (DHA) and Arachidonic Acid (AA) with Neonatal Neural Stem Cell transplantation Post-Traumatic Brain Injury"	This work was undertaken at the American University of Beirut (AUB) and is supported by a grant from the Lebanese National Council for Scientific Research (CNRS) [Grant title: Cell-Based Therapy Using Neural Stem Cell Coupled with BMP-4 as New treatment in traumatic Brain Injury; Lead PI: Firas Kobeissy, Co-PIs:Jihane Soueid & Wassim Abou-Kheir. In addition, this work was supported by the AUB-MPP grant "Dual Neurotherapeutic Effects of Docosahexaenoic Acid (DHA) and Arachidonic Acid (AA) with Neonatal Neural Stem Cell transplantation Post-Traumatic Brain Injury" PI: FK.	Ahmad SO, 2009, NEUROSCI LETT, V450, P102, DOI 10.1016/j.neulet.2008.11.065; Aligholi H, 2016, BRAIN RES, V1642, P197, DOI 10.1016/j.brainres.2016.03.043; Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940; Arsenault D., PLOS ONE, V6; Bellenchi GC, 2013, J NEUROCHEM, V124, P159, DOI 10.1111/jnc.12084; BLANCHARD V, 1995, J NEUROCHEM, V64, P1669; Blaya MO, 2015, EXP NEUROL, V264, P67, DOI 10.1016/j.expneurol.2014.11.014; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Boutte AM, 2016, J NEUROTRAUM, V33, P147, DOI 10.1089/neu.2014.3672; BURKE DC, 1995, BRAIN INJURY, V9, P735, DOI 10.3109/02699059509008229; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Cacci E, 2008, GLIA, V56, P412, DOI 10.1002/glia.20616; Cao DH, 2009, J NEUROCHEM, V111, P510, DOI 10.1111/j.1471-4159.2009.06335.x; Chang YL, 2012, CELL TRANSPLANT, V21, P313, DOI 10.3727/096368911X580572; Chen SY, 2016, EXP THER MED, V11, P2049, DOI 10.3892/etm.2016.3153; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; De Feo D, 2012, CURR OPIN NEUROL, V25, P322, DOI 10.1097/WCO.0b013e328352ec45; Decimo I, 2012, CURR PHARM DESIGN, V18, P1755, DOI 10.2174/138161212799859611; Deierborg T, 2010, NEUROSCIENCE, V171, P1386, DOI 10.1016/j.neuroscience.2010.09.045; Desai AJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085237; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dixon KJ, 2015, J NEUROTRAUM, V32, P753, DOI 10.1089/neu.2014.3390; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Fleming SM, 2013, JOVE-J VIS EXP, DOI 10.3791/50303; Gamoh S, 1999, NEUROSCIENCE, V93, P237, DOI 10.1016/S0306-4522(99)00107-4; Gamoh S, 2001, CLIN EXP PHARMACOL P, V28, P266, DOI 10.1046/j.1440-1681.2001.03437.x; GILAD GM, 1995, LIFE SCI, V58, pPL41, DOI 10.1016/0024-3205(95)02274-0; Goodus MT, 2015, DEV NEUROSCI-BASEL, V37, P29, DOI 10.1159/000367784; Green P, 1998, J NEUROSCI RES, V52, P129, DOI 10.1002/(SICI)1097-4547(19980415)52:2<129::AID-JNR1>3.0.CO;2-C; Hagan M, 2003, NEUROSCI LETT, V351, P149, DOI 10.1016/j.neulet.2003.07.021; Halford J, 2017, J CEREBR BLOOD F MET, V37, P3278, DOI 10.1177/0271678X17724681; Hall ED, 2016, TRANSLATIONAL RES TR; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969; Hattiangady B, 2007, STEM CELLS, V25, P2104, DOI 10.1634/stemcells.2006-0726; Haus DL, 2016, EXP NEUROL, V281, P1, DOI 10.1016/j.expneurol.2016.04.008; He QQ, 2016, BEHAV BRAIN FUNCT, V12, DOI 10.1186/s12993-016-0093-0; Heile Anna, 2011, Dialogues Clin Neurosci, V13, P279; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Ikemoto A, 1999, ARCH BIOCHEM BIOPHYS, V364, P67, DOI 10.1006/abbi.1999.1110; Itoh T, 2013, J NEURAL TRANSM, V120, P361, DOI 10.1007/s00702-012-0895-7; Katakura M, 2009, NEUROSCIENCE, V160, P651, DOI 10.1016/j.neuroscience.2009.02.057; Katakura M, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/490476; Kawakita E, 2006, NEUROSCIENCE, V139, P991, DOI 10.1016/j.neuroscience.2006.01.021; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; Kindler V, 2005, J LEUKOCYTE BIOL, V78, P836, DOI 10.1189/jlb.0505272; Koutsoudaki PN, 2016, GLIA, V64, P763, DOI 10.1002/glia.22959; Lam PK, 2016, ACTA NEUROCHIR SUPPL, V122, P21, DOI 10.1007/978-3-319-22533-3_4; Lam PK, 2013, J CLIN NEUROSCI, V20, P300, DOI 10.1016/j.jocn.2012.03.028; Lee IS, 2010, PEDIATR INT, V52, P855, DOI 10.1111/j.1442-200X.2010.03266.x; Leon-Carrion Jose, 2005, Pituitary, V8, P197, DOI 10.1007/s11102-006-6041-5; Li MF, 2013, CELL PHYSIOL BIOCHEM, V32, P1776, DOI 10.1159/000356611; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu SJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-66; Lo Van A, 2016, BIOCHIMIE, V130, P163, DOI 10.1016/j.biochi.2016.07.011; Madhavan L, 2010, NEUROPHARMACOLOGY, V58, P835, DOI 10.1016/j.neuropharm.2009.10.005; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; MARSHALL JF, 1974, J COMP PHYSIOL PSYCH, V87, P808, DOI 10.1037/h0037223; Matsuura K, 1997, J NEUROSCI METH, V73, P45, DOI 10.1016/S0165-0270(96)02211-X; Maxwell WL, 2013, BRAIN SCI, V3, P1374, DOI 10.3390/brainsci3031374; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Miller AP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173167; Monaco CM, 2013, EXP NEUROL, V247, P410, DOI 10.1016/j.expneurol.2013.01.007; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Mura A, 2003, MOVEMENT DISORD, V18, P860, DOI 10.1002/mds.10472; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nakagawa H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.62; Ngalula KP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00212; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Osier ND, 2015, BRAIN NEUROTRAUMA MO; Osier ND, 2015, J NEUROTRAUM, V32, P1861, DOI 10.1089/neu.2014.3680; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Pan JP, 2011, BRAIN RES, V1412, P18, DOI 10.1016/j.brainres.2011.07.015; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2011, J NEUROTRAUM, V28, pA63; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Park DH, 2010, STEM CELLS DEV, V19, P175, DOI 10.1089/scd.2009.0172; Peron S, 2017, J NEUROSCI, V37, P1820, DOI 10.1523/JNEUROSCI.2936-16.2017; Picard-Riera N, 2004, J NEUROSCI RES, V76, P223, DOI 10.1002/jnr.20040; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Reeves TM, 2010, BRAIN PATHOL, V20, P1055, DOI 10.1111/j.1750-3639.2010.00412.x; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Sakayori N, 2011, GENES CELLS, V16, P778, DOI 10.1111/j.1365-2443.2011.01527.x; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shear DA, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00073; Shinoyama M, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00128; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2011, J NEUROTRAUM, V28, P961, DOI 10.1089/neu.2010.1697; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Tan KKB, 2015, BIOMATERIALS, V43, P32, DOI 10.1016/j.biomaterials.2014.11.036; Tan XF, 2014, NEUROSCI LETT, V571, P23, DOI 10.1016/j.neulet.2014.04.019; Tate CC, 2009, J TISSUE ENG REGEN M, V3, P208, DOI 10.1002/term.154; Wagner AK., 2015, BRAIN NEUROTRAUMA MO; Wallenquist U, 2009, RESTOR NEUROL NEUROS, V27, P323, DOI 10.3233/RNN-2009-0481; Wang JY, 2015, SCI REP-UK, V5, DOI 10.1038/srep09621; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Wu A, 2008, NEUROSCIENCE, V155, P751, DOI 10.1016/j.neuroscience.2008.05.061; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu KJ, 2015, CELL TRANSPLANT, V24, P459, DOI 10.3727/096368915X686922; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yan ZJ, 2013, NEUROCHEM RES, V38, P1022, DOI 10.1007/s11064-013-1012-5; Yang H, 2012, NEUROCHEM INT, V61, P175, DOI 10.1016/j.neuint.2012.04.020; Yang ZH, 2015, TRENDS NEUROSCI, V38, P364, DOI 10.1016/j.tins.2015.04.003; Zhang ZH, 2014, PLOS ONE, V9	118	12	14	0	33	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	MAR 15	2018	340				SI		1	13		10.1016/j.bbr.2017.11.007			13	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	FU9JY	WOS:000424173400001	29126932				2021-06-18	
J	Toklu, HZ; Yang, ZH; Oktay, S; Sakarya, Y; Kirichenko, N; Matheny, MK; Muller-Delp, J; Strang, K; Scarpace, PJ; Wang, KKW; Tumer, N				Toklu, Hale Z.; Yang, Zhihui; Oktay, Sehkar; Sakarya, Yasemin; Kirichenko, Nataliya; Matheny, Michael K.; Muller-Delp, Judy; Strang, Kevin; Scarpace, Philip J.; Wang, Kevin K. W.; Tumer, Nihal			Overpressure blast injury-induced oxidative stress and neuroinflammation response in rat frontal cortex and cerebellum	BEHAVIOURAL BRAIN RESEARCH			English	Article						Overpressure blast injury; Brain; Trauma; Lung; Edema; NGF; NF kappa B; GFAP; Iba1; NSE	TRAUMATIC BRAIN-INJURY; SUBARACHNOID HEMORRHAGE; BARRIER PERMEABILITY; BLOOD; MODEL; INFLAMMATION; DAMAGE; EXPRESSION; BIOMARKERS; SEVERITY	Background & aim: Overpressure blast-wave induced brain injury (OBI) and its long-term neurological outcome pose significant concerns for military personnel. Our aim is to investigate the mechanism of injury due to OBI. Methods: Rats were divided into 3 groups: (1) Control, (2) OBI (exposed 30 psi peak pressure, 2-2.5 ms), (3) Repeated OBI (r-OBI) (three exposures over one-week period). Lung and brain (cortex and cerebellum) tissues were collected at 24 h post injury. Results: The neurological examination score was worse in OBI and r-OBI (4.2 +/- 0.6 and 3.7 +/- 0.5, respectively) versus controls (0.7 +/- 0.2). A significant positive correlation between lung and brain edema was found. Malondialdehyde (index for lipid peroxidation), significantly increased in OBI and r-OBI groups in cortex (p < 0.05) and cerebellum (p < 0.01-0.001). The glutathione (endogenous antioxidant) level decreased in cortex (p < 0.01) and cerebellum (p < 0.05) of r-OBI group when compared with the controls. Myeloperoxidase activity indicating neutrophil infiltration, was significantly (p < 0.01-0.05) elevated in r-OBI. Additionally, tissue thromboplastin activity, a coagulation marker, was elevated, indicating a tendency to bleed. NGF and NF-kappa B proteins along with Iba-1 and GFAP immunoreactivity significantly augmented in the frontal cortex demonstrating microglial activation. Serum biomarkers of injury, NSE, TNF-alpha and leptin, were also elevated. Conclusion: OBI triggers both inflammation and oxidative injury in the brain. This data in conjunction with our previous observations suggests that OBI triggers a cascade of events beginning with impaired cerebral vascular function leading to ischemia and chronic neurological consequences.	[Toklu, Hale Z.; Sakarya, Yasemin; Kirichenko, Nataliya; Tumer, Nihal] Malcom Randall Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, St Augustine, FL USA; [Toklu, Hale Z.; Oktay, Sehkar; Sakarya, Yasemin; Kirichenko, Nataliya; Matheny, Michael K.; Scarpace, Philip J.; Tumer, Nihal] Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA; [Yang, Zhihui; Strang, Kevin; Wang, Kevin K. W.] Univ Florida, Coll Med, McKnight Brain Inst, Ctr Neuroprote & Biomarker Res, Gainesville, FL 32610 USA; [Yang, Zhihui; Strang, Kevin; Wang, Kevin K. W.] Univ Florida, Coll Med, Dept Psychiat & Neurosci, Gainesville, FL 32610 USA; [Oktay, Sehkar] Marmara Univ, Sch Dent, Dept Biochem, Istanbul, Turkey; [Muller-Delp, Judy] Florida State Univ, Coll Med, Dept Biomed Sci, Tallahassee, FL 32306 USA	Tumer, N (corresponding author), Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA.; Toklu, HZ (corresponding author), North Florida Reg Med Ctr, Dept Grad Med Educ, 6500 Newberry Rd, Gainesville, FL 32605 USA.	haletoklu@yahoo.com; ntumer@ufl.edu	Toklu, Hale/AAR-2330-2020	Toklu, Hale/0000-0002-9797-3591; Wang, Kevin/0000-0002-9343-6473; Muller-Delp, Judy/0000-0001-5322-0611	North Florida/South Georgia Veterans Health System, Research/GRECC, Gainesville, Florida; McKnight Brain Institute, University of Florida, Gainesville, Florida	This study was supported by the North Florida/South Georgia Veterans Health System, Research/GRECC, Gainesville, Florida and McKnight Brain Institute, University of Florida, Gainesville, Florida. The authors would like to express their special thanks to Prof. Russell M. Bauer for his leadership for the support of the project.	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; Biber N, 2009, BRAIN INJURY, V23, P577, DOI 10.1080/02699050902926317; Brown R, 2008, NEUROSCI LETT, V432, P73, DOI 10.1016/j.neulet.2007.12.008; Buege J A, 1978, Methods Enzymol, V52, P302; Cemak I, 2011, NEUROBIOL DIS, V41, P538; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Chhabra Gaurav, 2013, J Emerg Trauma Shock, V6, P180, DOI 10.4103/0974-2700.115332; Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Covey Dana C, 2010, J Surg Orthop Adv, V19, P8; Daoud H, 2014, NEUROCRIT CARE, V20, P427, DOI 10.1007/s12028-013-9879-1; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Elsayed NM, 2007, TOXICOL SCI, V95, P289, DOI 10.1093/toxsci/kfl138; Engelmann C, 2014, NEURAL REGEN RES, V9, P707, DOI 10.4103/1673-5374.131572; Ersahin M, 2011, TURK NEUROSURG, V21, P599, DOI [10.5137/1019-5149.JTN.4736-11.0, 10.5137/1019-5149.JTN .4736-11.0]; Ersahin M, 2010, J NEUROTRAUM, V27, P1143, DOI 10.1089/neu.2009.1210; Fan XF, 2013, PEPTIDES, V48, P70, DOI 10.1016/j.peptides.2013.08.002; Gonzalvo R., CRIT CARE, V11; HILLEGASS LM, 1990, J PHARMACOL METHOD, V24, P285, DOI 10.1016/0160-5402(90)90013-B; INGRAM GIC, 1976, THROMB HAEMOSTASIS, V36, P237, DOI 10.1055/s-0038-1648029; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Kamnaksh A., 2014, TRANSL PROTEOM, V3, P22, DOI [10.1016/j.trprot.2013.11.001, DOI 10.1016/J.TRPROT.2013.11.001]; Kamnaksh A, 2014, SCI REP-UK, V4, DOI 10.1038/srep04809; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kobeissy F, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00186; Lin C, 2012, PEPTIDES, V35, P166, DOI 10.1016/j.peptides.2012.03.024; Liu MD, 2015, FRONT CELL NEUROSCI, V9, DOI [10.3389/fincel.2015.00168, 10.3389/fncel.2015.00168]; Pathak A, 2005, Neurol India, V53, P178; Pelosi P, 2011, CRIT CARE, V15, DOI 10.1186/cc10259; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Sajja VSSS, 2016, FRONT INTEGR NEUROSC, V10, DOI [10.3389/fnint.2016.00007, 10.3389/fnint.7016.00007]; Svetlov S. I., J TRAUMA INJ INFECT, V69; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Toklu H.Z., 2015, BRAIN NEUROTRAUMA MO; Toklu HZ, 2015, J CEREBR BLOOD F MET, V35, P1950, DOI 10.1038/jcbfm.2015.151; Toklu HZ, 2009, J SURG RES, V152, P238, DOI 10.1016/j.jss.2008.03.013; Tran LV, 2014, J TRAUMA NURS, V21, P30, DOI 10.1097/JTN.0000000000000026; Verein M, 2010, SEMIN CARDIOTHORAC V, V14, P226, DOI 10.1177/1089253210388295; Vuceljic M, 2005, CLIN CHIM ACTA, V355, pS318; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; Yang ZH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11178; Yang ZH, 2014, J CEREBR BLOOD F MET, V34, P1444, DOI 10.1038/jcbfm.2014.105	49	12	13	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	MAR 15	2018	340				SI		14	22		10.1016/j.bbr.2017.04.025			9	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	FU9JY	WOS:000424173400002	28419850				2021-06-18	
J	Adler, CM; DelBello, MP; Weber, W; Williams, M; Duran, LRP; Fleck, D; Boespflug, E; Eliassen, J; Strakowski, SM; Divine, J				Adler, Caleb M.; DelBello, Melissa P.; Weber, Wade; Williams, Miranda; Patino Duran, Luis Rodrigo; Fleck, David; Boespflug, Erin; Eliassen, James; Strakowski, Stephen M.; Divine, Jon			MRI Evidence of Neuropathic Changes in Former College Football Players	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						college football; concussion; brain injury; magnetic resonance imaging; diffusion tensor imaging	CHRONIC TRAUMATIC ENCEPHALOPATHY; SELF-REPORTED CONCUSSIONS; SUPERIOR TEMPORAL SULCUS; SURFACE-BASED ANALYSIS; HIGH-SCHOOL; NEUROPSYCHOLOGICAL PERFORMANCE; MULTIPLE CONCUSSIONS; SOCIAL COGNITION; BRAIN-INJURY; ATTENTION	Objective: To examine effects of participating in collegiate football on neural health several years after retirement. We hypothesized that relative cortical thinning and loss of white matter integrity would be observed in former players. Design: Former NCAA Division I football players were compared with demographically similar track-and-field athletes with regard to cortical thickness and white matter integrity. Setting: Participants participated in MRI scans at the Center for Imaging Research at the University of Cincinnati. Participants: Eleven former football players and 10 demographically similar track-and-field athletes, Main Outcome Measures: Normalized cortical thickness was compared between groups using 2-tailed Student t test. As a secondary analysis, Spearman correlation coefficient was calculated between cortical thickness and number of concussions. Fractional anisotropy for regions-of-interest placed in frontal white matter tracts and internal capsule were compared between groups using 2-tailed Student t test. Results: Football players showed significantly lower cortical thickness within portions of both the frontal and temporal cortex. Affected frontal regions included left frontal pole and right superior frontal gyrus. Affected temporal regions included portions of the superior temporal gyrus, left inferior temporal gyrus, and right middle and superior temporal gyri. Cortical thickness inversely correlated with number of reported concussions over most of these regions. In addition, fractional anisotropy was lower in the right internal capsule of tamer football players, relative to controls. Conclusions: These findings suggest that at least some consequences of high-level collegiate football play persist even after the cessation of regular head blows. Longer-term studies are warranted to examine potential cognitive and functional implications of sustained cortical atrophy.	[Adler, Caleb M.; DelBello, Melissa P.; Weber, Wade; Williams, Miranda; Patino Duran, Luis Rodrigo; Fleck, David; Boespflug, Erin; Eliassen, James; Strakowski, Stephen M.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA; [Adler, Caleb M.; Fleck, David; Boespflug, Erin; Eliassen, James; Strakowski, Stephen M.] Univ Cincinnati, Coll Med, Ctr Imaging Res, Cincinnati, OH USA; [Adler, Caleb M.; DelBello, Melissa P.; Fleck, David; Strakowski, Stephen M.] Univ Cincinnati, Mood Disorders Ctr, UC Hlth, Neurosci Inst, Cincinnati, OH USA; [Divine, Jon] Univ Cincinnati, Coll Med, Dept Orthoped & Sports Med, Cincinnati, OH USA	Adler, CM (corresponding author), Dept Psychiat & Behav Neurosci, 260 Stetson St,Suite 3200, Cincinnati, OH 45219 USA.	adlercb@ucmail.uc.edu			University of Cincinnati Neuroscience Institute; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001425] Funding Source: NIH RePORTER	Supported by the University of Cincinnati Neuroscience Institute.	Adams J, 2007, CLIN J SPORT MED, V17, P304, DOI 10.1097/JSM.0b013e31803202c8; Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Albaugh MD, 2015, J PEDIATR-US, V166, P394, DOI 10.1016/j.jpeds.2014.10.016; Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; [Anonymous], 2011, AN FUNCT NEUR COMP P; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Boespflug EL, 2014, BRAIN STRUCT FUNCT, V219, P367, DOI 10.1007/s00429-013-0506-x; Bright P, 2002, J INT NEUROPSYCH SOC, V8, P847, DOI 10.1017/S1355617702860131; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Coutlee CG, 2012, BRAIN RES, V1428, P3, DOI 10.1016/j.brainres.2011.05.053; Cox RW, 1999, MAGNET RESON MED, V42, P1014, DOI 10.1002/(SICI)1522-2594(199912)42:6<1014::AID-MRM4>3.0.CO;2-F; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Dick R, 2007, J ATHL TRAINING, V42, P221; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; First MB., 1997, STRUCTURED CLIN INTE; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gladsjo JA, 1999, J INT NEUROPSYCH SOC, V5, P247, DOI 10.1017/S1355617799533079; Hammeke TA, 2013, J INT NEUROPSYCH SOC, V19, P863, DOI 10.1017/S1355617713000702; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Narumoto J, 2001, COGNITIVE BRAIN RES, V12, P225, DOI 10.1016/S0926-6410(01)00053-2; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; National Collegiate Athletic Association, 2014, CONC GUID DIAGN MAN; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Onnink AMH, 2015, PROG NEURO-PSYCHOPH, V63, P14, DOI 10.1016/j.pnpbp.2015.04.008; Pedersen HA, 2014, AM J ALZHEIMERS DIS, V29, P201, DOI 10.1177/1533317513517036; Pfeifer JH, 2012, DEV COGN NEUROS-NETH, V2, P55, DOI 10.1016/j.dcn.2011.07.012; Podberesky DJ, 2009, PEDIATR RADIOL, V39, P1264; Pontifex MB, 2012, RES Q EXERCISE SPORT, V83, P553; Rosen Howard J, 2008, Handb Clin Neurol, V88, P41, DOI 10.1016/S0072-9752(07)88003-1; Saitovitch A, 2012, REV NEUROL-FRANCE, V168, P762, DOI 10.1016/j.neurol.2012.07.017; Schmithorst VJ, 2001, IEEE T MED IMAGING, V20, P535, DOI 10.1109/42.929619; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Soliva JC, 2009, ANN NY ACAD SCI, V1167, P212, DOI 10.1111/j.1749-6632.2009.04604.x; Strawn JR, 2014, J ANXIETY DISORD, V28, P717, DOI 10.1016/j.janxdis.2014.07.012; Sundman MH., 2014, J ALZHEIMERS DIS PAR, V4, P137; Terry DP, 2015, ARCH CLIN NEUROPSYCH, V30, P341, DOI 10.1093/arclin/acv020; Terry DP, 2012, BRAIN INJURY, V26, P1684, DOI 10.3109/02699052.2012.722259; Tremblay S, 2014, CLIN NEUROPHYSIOL, V125, P1371, DOI 10.1016/j.clinph.2013.11.040; Veeramuthu V, 2015, J NEUROTRAUM, V32, P1497, DOI 10.1089/neu.2014.3750; Xiao J, 2015, SCI REP-UK, V5, DOI 10.1038/srep09738	59	12	13	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2018	28	2					100	105		10.1097/JSM.0000000000000391			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	GP1HC	WOS:000440564900003	27755011				2021-06-18	
J	Brodsky, JR; Lipson, S; Wilber, J; Zhou, GW				Brodsky, Jacob R.; Lipson, Sophie; Wilber, Jared; Zhou, Guangwei			Benign Paroxysmal Positional Vertigo (BPPV) in Children and Adolescents: Clinical Features and Response to Therapy in 110 Pediatric Patients	OTOLOGY & NEUROTOLOGY			English	Article						Benign paroxysmal positional vertigo; BPPV; Pediatric vertigo	VITAMIN-D; MIGRAINE; EPIDEMIOLOGY; NYSTAGMUS; DIAGNOSIS	Objective:This study aimed to characterize the clinical features and outcomes of benign paroxysmal positional vertigo (BPPV) in the pediatric population.Study Design:Retrospective case review.Setting:Tertiary care center.Patients:One hundred ten patients, aged 5 to 19 years old, diagnosed with BPPV.Main Outcome Measures:Patient demographics, comorbidities, canal involvement, response to treatment, and incidence of recurrence.Results:BPPV was diagnosed in 19.8% of patients seen for dizziness during the study period. Patient age ranged 5 to 19 years old (mean=13.43.4 yr). Female:male ratio was 3:2. The most prevalent comorbidities were concussion (n=42, 38.2%) and migraine disorders (n=33, 30.0%). Average time to diagnosis from symptom onset was 178.2 +/- 190.8 days. The posterior canal was most frequently affected (n=80, 72.7%), followed by the lateral canal (n=37, 33.6%) and superior canal (n=21, 19.1%), and 36.4% (n=40) of patients had multiple canals affected. Treatment requiring more than or equal to five maneuvers to achieve resolution was observed in 11.8% of cases (n=13). Recurrence was observed in 18.2% of cases. A logistic regression analysis demonstrated that patients with vestibular migraine or benign paroxysmal vertigo of childhood had five times higher odds of recurrence of BPPV, p=0.003, 95% [1.735, 15.342], than those who did not have either.Conclusions:BPPV is a relatively common cause of dizziness in the pediatric population. Children and adolescents with BPPV can be successfully treated with repositioning maneuvers but may be at risk for treatment resistance and recurrence. Increased awareness of BPPV in pediatric patients may reduce delays in identification and treatment.	[Brodsky, Jacob R.; Lipson, Sophie; Wilber, Jared; Zhou, Guangwei] Boston Childrens Hosp, Dept Otolaryngol & Commun Enhancement, Boston, MA USA; [Brodsky, Jacob R.; Zhou, Guangwei] Harvard Med Sch, Dept Otol & Laryngol, Boston, MA USA; [Wilber, Jared] Emory Univ, Atlanta, GA 30322 USA	Brodsky, JR (corresponding author), Dept Otolaryngol & Commun Enhancement, 300 Longwood Ave, Boston, MA 02115 USA.	jacob.brodsky@childrens.harvard.edu		Brodsky, Jacob/0000-0001-9656-5855; Lipson, Sophie/0000-0001-5609-8156	Department of Otolaryngology and Communication Enhancement at Boston Children's Hospital	All financial support for this study was provided by the Department of Otolaryngology and Communication Enhancement at Boston Children's Hospital.	Aksoy Songul, 2007, Kulak Burun Bogaz Ihtis Derg, V17, P307; Anagnostou E, 2015, J CLIN NEUROL, V11, P262, DOI 10.3988/jcn.2015.11.3.262; Bachor E, 2002, LARYNGOSCOPE, V112, P147, DOI 10.1097/00005537-200201000-00026; Balatsouras DG, 2007, INT J PEDIATR OTORHI, V71, P487, DOI 10.1016/j.ijporl.2006.11.024; Balatsouras DG, 2017, ANN OTO RHINOL LARYN, V126, P54, DOI 10.1177/0003489416674961; BALOH RW, 1987, NEUROLOGY, V37, P371, DOI 10.1212/WNL.37.3.371; Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658; Bhattacharyya N, 2017, OTOLARYNG HEAD NECK, V156, pS1, DOI 10.1177/0194599816689667; Caruso G, 2005, AUDIOL MED, V3, P7, DOI DOI 10.1080/16513860510028310; Chu CH, 2015, J HEADACHE PAIN, V16, DOI 10.1186/s10194-015-0547-z; D'Agostino R, 2003, INT J PEDIATR OTORHI, V67, P549, DOI 10.1016/S0165-5876(03)00009-0; Dieterich M, 2017, CURR OPIN NEUROL, V30, P107, DOI 10.1097/WCO.0000000000000417; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Faralli M, 2014, B-ENT, V10, P133; Fay JL, 2016, PEDIATR PHYS THER, V28, P355, DOI 10.1097/PEP.0000000000000249; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Hamilton SS, 2015, INT J PEDIATR OTORHI, V79, P1283, DOI 10.1016/j.ijporl.2015.05.033; Hilton MP, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003162.pub3; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Holick MF, 2017, REV ENDOCR METAB DIS, V18, P153, DOI 10.1007/s11154-017-9424-1; Hunt WT, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008675.pub2; Kim JS, 2014, NEW ENGL J MED, V370, P1138, DOI 10.1056/NEJMcp1309481; Koo JW, 2006, CEPHALALGIA, V26, P1310, DOI 10.1111/j.1468-2982.2006.01208.x; Lee JD, 2017, INT J PEDIATR OTORHI, V94, P36, DOI 10.1016/j.ijporl.2017.01.012; Marcelli V, 2006, BRAIN DEV-JPN, V28, P80, DOI 10.1016/j.braindev.2005.05.003; Naganuma H, 1996, ACTA OTO-LARYNGOL, P9; O'Reilly RC, 2011, OTOLARYNG HEAD NECK, V144, P142, DOI 10.1177/0194599810393679; Okumura T, 2016, INT J PEDIATR OTORHI, V88, P89, DOI 10.1016/j.ijporl.2016.06.046; PARNES LS, 1992, LARYNGOSCOPE, V102, P988; Rhim GI, 2016, LARYNSCOPE INVESTIG, V1, P150, DOI 10.1002/lio2.35; Saka N, 2013, INT J PEDIATR OTORHI, V77, P233, DOI 10.1016/j.ijporl.2012.11.003; Schuknecht H F, 1973, Adv Otorhinolaryngol, V20, P434; Shetye Anuradha, 2012, Cochlear Implants Int, V13, P177, DOI 10.1179/1754762811Y.0000000011; Silva C, 2015, ACTA OTORRINOLAR ESP, V66, P205, DOI 10.1016/j.otorri.2014.09.003; Skatvedt Olav, 2009, Tidsskr Nor Laegeforen, V129, P634, DOI 10.4045/tidsskr.09.33787; Song JJ, 2012, ACTA OTO-LARYNGOL, V132, pS109, DOI 10.3109/00016489.2012.662714; Steenerson RL, 2005, LARYNGOSCOPE, V115, P226, DOI 10.1097/01.mlg.0000154723.55044.b5; Teixido M, 2017, J LARYNGOL OTOL, V131, P508, DOI 10.1017/S0022215117000536; von Brevern M, 2007, J NEUROL NEUROSUR PS, V78, P710, DOI 10.1136/jnnp.2006.100420; Yetiser Sertac, 2015, Int Tinnitus J, V19, P64, DOI 10.5935/0946-5448.20150011	40	12	13	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1531-7129	1537-4505		OTOL NEUROTOL	Otol. Neurotol.	MAR	2018	39	3					344	350		10.1097/MAO.0000000000001673			7	Clinical Neurology; Otorhinolaryngology	Neurosciences & Neurology; Otorhinolaryngology	HK2WC	WOS:000457772600023	29287036				2021-06-18	
J	Kerr, ZY; Kroshus, E; Lee, JGL; Yeargin, SW; Dompier, TP				Kerr, Zachary Y.; Kroshus, Emily; Lee, Joseph G. L.; Yeargin, Susan W.; Dompier, Thomas P.			Coaches' Implementation of the USA Football "Heads Up Football" Educational Program	HEALTH PROMOTION PRACTICE			English	Article						process evaluation; program planning and evaluation; injury prevention; safety; unintentional injury	TRAIN-THE-TRAINER; SPORTS-RELATED INJURIES; FOR-DISEASE-CONTROL; HIGH-SCHOOL SPORTS; RECURRENT CONCUSSION; UNITED-STATES; OPINION LEADERS; NCAA CONCUSSION; PLAYERS; RISK	An integral part of the Heads Up Football (HUF) educational program is the Player Safety Coach (PSC), who is responsible for teaching other coaches within a youth football league about safer blocking/tackling and injury prevention. This study examines the association between youth football coaches' interactions with the PSC (i.e., attending the PSC clinic at the beginning of the season and seeing the PSC on-field during practices) and their subsequent implementation of the HUF educational program. Data were collected via online questionnaire completed by 1,316 youth football coaches from HUF leagues. Data were analyzed with frequencies and logistic regression. Nearly half of coaches (44.8%) did not attend the PSC clinic; 25.9% reported not seeing their league's PSC on the field on a regular basis. The lack of PSC on-site presence was significantly associated with worse implementation for concussion recognition and response, heat preparedness and hydration, and sudden cardiac event preparedness. PSC clinic attendance was not associated with implementation. Opportunities exist for improvement in the HUF educational program as there appears to be inconsistent implementation. Further research is warranted to understand how to optimize the role of the PSC in the youth sports context.	[Kerr, Zachary Y.] Univ North Carolina Chapel Hill, Chapel Hill, NC USA; [Kroshus, Emily] Univ Washington, Seattle, WA 98195 USA; [Kroshus, Emily] Seattle Childrens Res Inst, Seattle, WA USA; [Lee, Joseph G. L.] East Carolina Univ, Greenville, NC USA; [Yeargin, Susan W.] Univ South Carolina, Columbia, SC USA; [Dompier, Thomas P.] Datalys Ctr Sports Injury Res & Prevent, Indianapolis, IN USA	Kerr, ZY (corresponding author), Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, 313 Woollen Gym,CB 8700, Chapel Hill, NC 27599 USA.	zkerr@email.unc.edu					Asken BM, 2016, J ATHL TRAINING, V51, P329, DOI 10.4085/1062-6050-51.5.02; Bailey R, 2006, J SCHOOL HEALTH, V76, P397, DOI 10.1111/j.1746-1561.2006.00132.x; Bergeron MF, 2005, MED SCI SPORT EXER, V37, P1421, DOI 10.1249/01.mss.0000174891.46893.82; Brown TD, 2006, J ORTHOP TRAUMA, V20, P739, DOI 10.1097/01.bot.0000246468.80635.ef; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Corelli RL, 2007, AM J PHARM EDUC, V71, DOI 10.5688/aj7106109; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Finch CF, 2015, OSTEOARTHR CARTILAGE, V23, P1138, DOI 10.1016/j.joca.2015.02.165; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; KELLY JA, 1991, AM J PUBLIC HEALTH, V81, P168, DOI 10.2105/AJPH.81.2.168; Kerr ZY, 2016, ORTHOP J SPORTS MED, V4, DOI 10.1177/2325967116648441; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115603979; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115594578; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115610545; Kerr ZY, 2015, MMWR-MORBID MORTAL W, V64, P1330, DOI 10.15585/mmwr.mm6448a2; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Kreck Carol, 2014, STATES ADDRESS CONCU; Li L, 2013, AIDS EDUC PREV, V25, P327, DOI 10.1521/aeap.2013.25.4.327; Maron BJ, 2009, CIRCULATION, V119, P1085, DOI 10.1161/CIRCULATIONAHA.108.804617; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; Mearns Bryony M, 2011, Nat Rev Cardiol, V8, P244, DOI 10.1038/nrcardio.2011.57; National Council of Youth Sports, 2008, REP TRENDS PART ORG; Orfaly RA, 2005, J PUBLIC HEALTH MAN, pS123; Pop Warner Football, 2012, RUL CHANG REG PRACT; Powell JW, 2004, J ATHL TRAINING, V39, P56; Rogers EM., 2010, DIFFUSION INNOVATION, V5; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Sawyer RJ, 2010, HEALTH PROMOT PRACT, V11, P34, DOI 10.1177/1524839907309377; Simon JE, 2016, J ATHL TRAINING, V51, P205, DOI 10.4085/1062-6050-51.4.05; Toresdahl BG, 2013, J ATHL TRAINING, V48, P242, DOI 10.4085/1062-6050-48.1.20; Trabeau M, 2008, AM J IND MED, V51, P130, DOI 10.1002/ajim.20499; Valente TW, 2007, HEALTH EDUC BEHAV, V34, P881, DOI 10.1177/1090198106297855; Wikstrom EA, 2013, SPORTS MED, V43, P385, DOI 10.1007/s40279-013-0043-z	37	12	12	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1524-8399	1552-6372		HEALTH PROMOT PRACT	Health Promot. Pract.	MAR	2018	19	2					184	193		10.1177/1524839917700398			10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	GC5FA	WOS:000429809900005	28351166				2021-06-18	
J	Liu, C; Zhang, CW; Zhou, Y; Wong, WQ; Lee, LC; Ong, WY; Yoon, SO; Hong, WJ; Fu, XY; Soong, TW; Koo, EH; Stanton, LW; Lim, KL; Xiao, ZC; Dawe, GS				Liu, Chao; Zhang, Cheng-Wu; Zhou, Yi; Wong, Wan Qing; Lee, Liying Corinne; Ong, Wei Yi; Yoon, Sung Ok; Hong, Wanjin; Fu, Xin-Yuan; Soong, Tuck Wah; Koo, Edward H.; Stanton, Lawrence W.; Lim, Kah-Leong; Xiao, Zhi-Cheng; Dawe, Gavin S.			APP upregulation contributes to retinal ganglion cell degeneration via JNK3	CELL DEATH AND DIFFERENTIATION			English	Article							AMYLOID PRECURSOR PROTEIN; OPTIC-NERVE TRANSECTION; INTRACELLULAR DOMAIN; TRANSGENIC MICE; AXONAL INJURY; ADULT-RATS; PATHOLOGICAL FEATURES; OCULAR HYPERTENSION; ALZHEIMERS-DISEASE; POSSIBLE TARGET	Axonal injury is a common feature of central nervous system insults. Upregulation of amyloid precursor protein (APP) is observed following central nervous system neurotrauma and is regarded as a marker of central nervous system axonal injury. However, the underlying mechanism by which APP mediates neuronal death remains to be elucidated. Here, we used mouse optic nerve axotomy (ONA) to model central nervous system axonal injury replicating aspects of retinal ganglion cell (RGC) death in optic neuropathies. APP and APP intracellular domain (AICD) were upregulated in retina after ONA and APP knockout reduced Tuj1(+) RGC loss. Pathway analysis of microarray data combined with chromatin immunoprecipitation and a luciferase reporter assay demonstrated that AICD interacts with the JNK3 gene locus and regulates JNK3 expression. Moreover, JNK3 was found to be upregulated after ONA and to contribute to Tuj1(+) RGC death. APP knockout reduced the ONA-induced enhanced expression of JNK3 and phosphorylated JNK (pJNK). Gamma-secretase inhibitors prevented production of AICD, reduced JNK3 and pJNK expression similarly, and protected Tuj1(+) RGCs from ONA-induced cell death. Together these data indicate that ONA induces APP expression and that gamma-secretase cleavage of APP releases AICD, which upregulates JNK3 leading to RGC death. This pathway may be a novel target for neuronal protection in optic neuropathies and other forms of neurotrauma.	[Liu, Chao; Wong, Wan Qing; Dawe, Gavin S.] Natl Univ Singapore, Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Pharmacol, 16 Med Dr, Singapore 117600, Singapore; [Liu, Chao; Zhou, Yi; Wong, Wan Qing; Ong, Wei Yi; Fu, Xin-Yuan; Soong, Tuck Wah; Lim, Kah-Leong; Dawe, Gavin S.] Natl Univ Singapore, Life Sci Inst, Ctr Life Sci, Neurobiol & Ageing Programme, 28 Med Dr, Singapore 117456, Singapore; [Liu, Chao; Wong, Wan Qing; Dawe, Gavin S.] Natl Univ Singapore, Singapore Inst Neurotechnol SINAPSE, Ctr Life Sci, 28 Med Dr, Singapore 117456, Singapore; [Liu, Chao; Lee, Liying Corinne; Soong, Tuck Wah; Koo, Edward H.; Lim, Kah-Leong] Natl Univ Singapore, Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Physiol, 2 Med Dr, Singapore 117597, Singapore; [Zhang, Cheng-Wu] Nanjing Tech Univ Nanjing Tech, Jiangsu Natl Synerget Innovat Ctr Adv Mat SICAM, Key Lab Flexible Elect KLOFE, 30 South Puzhu Rd, Nanjing 211816, Jiangsu, Peoples R China; [Zhang, Cheng-Wu] Nanjing Tech Univ Nanjing Tech, Jiangsu Natl Synerget Innovat Ctr Adv Mat SICAM, IAM, 30 South Puzhu Rd, Nanjing 211816, Jiangsu, Peoples R China; [Zhang, Cheng-Wu; Lim, Kah-Leong] Natl Neurosci Inst, Neurodegenerat Res Lab, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore; [Zhou, Yi; Fu, Xin-Yuan] Natl Univ Singapore, Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Biochem, 8 Med Dr, Singapore 117596, Singapore; [Wong, Wan Qing; Stanton, Lawrence W.] Genome Inst Singapore, Stem Cell & Regenerat Biol Grp, 60 Biopolis St, Singapore 138672, Singapore; [Ong, Wei Yi] Natl Univ Singapore, Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Anat, 4 Med Dr, Singapore 117594, Singapore; [Yoon, Sung Ok] Ohio State Univ, Dept Biol Chem & Pharmacol, Wexner Med Ctr, Columbus, OH 43210 USA; [Hong, Wanjin] ASTAR, Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore; [Koo, Edward H.] Natl Univ Singapore, Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Med, 12 Sci Dr 2, Singapore 117549, Singapore; [Xiao, Zhi-Cheng] Monash Univ Clayton, Dept Anat & Dev Biol, Melbourne, Vic 3800, Australia; [Xiao, Zhi-Cheng] Kunming Med Coll, Inst Mol & Clin Med, Key Lab Stem Cell & Regenerat Med, Kunming 650031, Yunnan, Peoples R China	Dawe, GS (corresponding author), Natl Univ Singapore, Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Pharmacol, 16 Med Dr, Singapore 117600, Singapore.; Dawe, GS (corresponding author), Natl Univ Singapore, Life Sci Inst, Ctr Life Sci, Neurobiol & Ageing Programme, 28 Med Dr, Singapore 117456, Singapore.; Dawe, GS (corresponding author), Natl Univ Singapore, Singapore Inst Neurotechnol SINAPSE, Ctr Life Sci, 28 Med Dr, Singapore 117456, Singapore.; Xiao, ZC (corresponding author), Monash Univ Clayton, Dept Anat & Dev Biol, Melbourne, Vic 3800, Australia.; Xiao, ZC (corresponding author), Kunming Med Coll, Inst Mol & Clin Med, Key Lab Stem Cell & Regenerat Med, Kunming 650031, Yunnan, Peoples R China.	zhicheng.xiao@monash.edu; gavindawe@nus.edu.sg	Liu, Chao/AAL-6454-2021; Lim, Kah/L-5426-2019; Lim, Kah-Leong/AAY-3308-2020	xiao, zhicheng/0000-0001-5172-762X; Lim, Kah-Leong/0000-0002-5440-2588; Dawe, Gavin/0000-0001-6119-701X	National Medical Research Council, Ministry of Health, SingaporeNational Medical Research Council, Singapore [NMRC/1059/2006]; NMRC NUHS Centre Grant-Memory, Ageing, and Cognition Centre [NMRC/CG/013/2013]	This work was supported by the National Medical Research Council, Ministry of Health, Singapore, with grant NMRC/1059/2006 and with NMRC NUHS Centre Grant-Memory, Ageing, and Cognition Centre Seed Funding, NMRC/CG/013/2013. We thank Miss Maying Tsemay Tse for the APP-null mice required for the additional experiments necessary for revision of the manuscript. We thank Dr M. Goedert (Cambridge, UK) for the rabbit anti-AICD antibody (BR188). We thank Mr Woon Fei Ho for excellent technical and administrative assistance. We thank Dr Zhong-Can Chen for assisting in generating the SH-SY5Y-APP cell line and Ms Jayakody Pathirannehelage Tharindunee Jayakody for technical assistance in detecting JNK3 expression in SH-SY5Y cells. We thank Dr Huck-Hui Ng and Dr Yun-Shen Chan for helpful advice on luciferase assays.	Anderson JJ, 2005, BIOCHEM PHARMACOL, V69, P689, DOI 10.1016/j.bcp.2004.11.015; Arnhold M, 2016, CLIN AUTON RES, V26, P211, DOI 10.1007/s10286-016-0358-6; Asai M, 2011, FASEB J, V25, P3720, DOI 10.1096/fj.11-182154; Bahr M, 2000, TRENDS NEUROSCI, V23, P483, DOI 10.1016/S0166-2236(00)01637-4; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Borsello T, 2007, CURR PHARM DESIGN, V13, P1875; Brecht S, 2005, EUR J NEUROSCI, V21, P363, DOI 10.1111/j.1460-9568.2005.03857.x; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chaon BC, 2015, CURR OPIN OPHTHALMOL, V26, P445, DOI 10.1097/ICU.0000000000000198; Chintala SK, 2015, INVEST OPHTH VIS SCI, V56, P505, DOI 10.1167/iovs.14-15539; Choi WS, 2010, J NEUROPATH EXP NEUR, V69, P511, DOI 10.1097/NEN.0b013e3181db8100; Christensen DP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0519-5; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Craner MJ, 2004, P NATL ACAD SCI USA, V101, P8168, DOI 10.1073/pnas.0402765101; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Fernandes KA, 2012, NEUROBIOL DIS, V46, P393, DOI 10.1016/j.nbd.2012.02.003; Fu QL, 2008, INVEST OPHTH VIS SCI, V49, P975, DOI 10.1167/iovs.07-1199; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Ghosal K, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.04.020; Ghosal K, 2009, P NATL ACAD SCI USA, V106, P18367, DOI 10.1073/pnas.0907652106; Haenold R, 2014, J CELL SCI, V127, P3052, DOI 10.1242/jcs.140731; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; He Y, 2015, NEURAL REGEN RES, V10, P432, DOI 10.4103/1673-5374.153692; Johnson R, 2008, PLOS BIOL, V6, P2205, DOI 10.1371/journal.pbio.0060256; Kato T, 2008, J INTERF CYTOK RES, V28, P235, DOI 10.1089/jir.2007.0075; Kim D, 2009, CELL, V137, P997, DOI 10.1016/j.cell.2009.05.042; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kipfer-Kauer A, 2010, CURR EYE RES, V35, P828, DOI 10.3109/02713683.2010.494240; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Kuan CY, 2003, P NATL ACAD SCI USA, V100, P15184, DOI 10.1073/pnas.2336254100; Kwong JMK, 2006, EXP EYE RES, V82, P576, DOI 10.1016/j.exer.2005.08.017; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Levin LA, 2007, CAN J OPHTHALMOL, V42, P403, DOI 10.3129/i07-046; Liu C, 2015, J BIOL CHEM, V290, P12048, DOI 10.1074/jbc.M114.617092; Lukas TJ, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-5; Ma QH, 2008, NAT CELL BIOL, V10, P283, DOI 10.1038/ncb1690; Magharious M. M., 2011, JOVE-J VIS EXP, V51, P2241, DOI DOI 10.3791/2241; MANSOURROBAEY S, 1994, P NATL ACAD SCI USA, V91, P1632, DOI 10.1073/pnas.91.5.1632; Margevicius DR, 2015, NEUROBIOL AGING, V36, P2370, DOI 10.1016/j.neurobiolaging.2015.04.013; Martin JH, 1996, MOL BRAIN RES, V35, P47, DOI 10.1016/0169-328X(95)00181-Q; MISANTONE LJ, 1984, J NEUROCYTOL, V13, P449, DOI 10.1007/BF01148334; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; Nadal-Nicolas FM, 2015, INVEST OPHTH VIS SCI, V56, P6095, DOI 10.1167/iovs.15-17195; Osborne NN, 2004, EYE, V18, P1075, DOI 10.1038/sj.eye.6701588; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Repici M, 2006, ADV EXP MED BIOL, V588, P145; Ryan KA, 2005, J CELL BIOL, V171, P327, DOI 10.1083/jcb.200505078; Sanchez-Migallon MC, 2016, INVEST OPHTH VIS SCI, V57, P81, DOI 10.1167/iovs.15-17841; Selkoe DJ, 2004, ANN INTERN MED, V140, P627, DOI 10.7326/0003-4819-140-8-200404200-00047; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; Tezel G, 2003, INVEST OPHTH VIS SCI, V44, P3025, DOI 10.1167/iovs.02-1136; Vidal-Sanz M, 2012, PROG RETIN EYE RES, V31, P1, DOI 10.1016/j.preteyeres.2011.08.001; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	60	12	13	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1350-9047	1476-5403		CELL DEATH DIFFER	Cell Death Differ.	MAR	2018	25	4					661	676		10.1038/s41418-017-0005-3			16	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	FZ9IJ	WOS:000427923400005	29238071	Green Published, Other Gold			2021-06-18	
J	Niu, HX; Wang, JZ; Wang, DL; Miao, JJ; Li, H; Liu, ZG; Yuan, X; Liu, W; Zhou, JR				Niu, Hong-Xia; Wang, Jun-Zhe; Wang, Dong-Liang; Miao, Jun-Jie; Li, Hua; Liu, Zhi-Gang; Yuan, Xing; Liu, Wei; Zhou, Jing-Ru			The Orally Active Noncompetitive AMPAR Antagonist Perampanel Attenuates Focal Cerebral Ischemia Injury in Rats	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Stroke; Perampanel; Neuroprotection; Nitric oxide synthase	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; RECEPTOR ANTAGONIST; INFLAMMATORY NEURODEGENERATION; ANTIEPILEPTIC DRUG; STROKE; EPILEPSY; NEUROPROTECTION; ACTIVATION; MECHANISMS	Inhibition of ionotropic glutamate receptors (iGluRs) is a potential target of therapy for ischemic stroke. Perampanel is a potent noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor (AMPAR) antagonist with good oral bioavailability and favorable pharmacokinetic properties. Here, we investigated the potential protective effects of perampanel against focal cerebral ischemia in a middle cerebral artery occlusion (MCAO) model in rats. Oral administration with perampanel significantly reduced MCAO-induced brain edema, brain infarct volume, and neuronal apoptosis. These protective effects were associated with improved functional outcomes, as measured by foot-fault test, adhesive removal test, and modified neurological severity score (mNSS) test. Importantly, perampanel was effective even when the administration was delayed to 1 h after reperfusion. The results of enzyme-linked immunosorbent assay (ELISA) showed that perampanel significantly decreased the expression of pro-inflammatory cytokines IL-1 beta and TNF-alpha, whereas it increased the levels of anti-inflammatory cytokines IL-10 and TGF-beta 1 after MCAO. In addition, perampanel treatment markedly decreased the expression of inducible nitric oxide synthase (iNOS) and neuronal nitric oxide synthase (nNOS), and also inhibited nitric oxide (NO) generation in MCAO-injured rats at 24 and 72 h after reperfusion. In conclusion, this study demonstrated that the orally active AMPAR antagonist perampanel protects against experimental ischemic stroke via regulating inflammatory cytokines and NOS pathways.	[Wang, Dong-Liang; Miao, Jun-Jie; Zhou, Jing-Ru] Peking Univ, Dept Neurosurg, Peoples Hosp, Beijing 100044, Peoples R China; [Niu, Hong-Xia] Beijing Elect Power Hosp, Emergency Dept, Beijing 100071, Peoples R China; [Wang, Jun-Zhe; Liu, Wei] Shaanxi Fourth Peoples Hosp, Basic Med Sci Res Ctr, Xian 710043, Shaanxi, Peoples R China; [Li, Hua; Liu, Zhi-Gang; Yuan, Xing; Liu, Wei] Shaanxi Fourth Peoples Hosp, Dept Neurosurg, Xian 710043, Shaanxi, Peoples R China	Zhou, JR (corresponding author), Peking Univ, Dept Neurosurg, Peoples Hosp, Beijing 100044, Peoples R China.; Liu, W (corresponding author), Shaanxi Fourth Peoples Hosp, Basic Med Sci Res Ctr, Xian 710043, Shaanxi, Peoples R China.; Liu, W (corresponding author), Shaanxi Fourth Peoples Hosp, Dept Neurosurg, Xian 710043, Shaanxi, Peoples R China.	vincelau@163.com; zhoujingru_peking@163.com					Appireddy RMR, 2015, J CLIN NEUROL, V11, P1, DOI 10.3988/jcn.2015.11.1.1; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Brown GC, 2007, BIOCHEM SOC T, V35, P1119, DOI 10.1042/BST0351119; Brown GC, 2006, BIOCHEM SOC T, V34, P953, DOI 10.1042/BST0340953; Ceolin L, 2012, NEUROCHEM INT, V61, P517, DOI 10.1016/j.neuint.2012.02.035; Chen T, 2017, CELL MOL NEUROBIOL, V37, P43, DOI 10.1007/s10571-016-0341-8; Chen T, 2012, NEUROCHEM RES, V37, P983, DOI 10.1007/s11064-011-0691-z; Chen T, 2012, INT J MOL MED, V29, P630, DOI 10.3892/ijmm.2011.870; Chen ZC, 2014, J NEUROSCI, V34, P9621, DOI 10.1523/JNEUROSCI.3991-13.2014; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; Dias RB, 2012, HIPPOCAMPUS, V22, P276, DOI 10.1002/hipo.20894; Erdo F, 2006, BRAIN RES BULL, V68, P269, DOI 10.1016/j.brainresbull.2005.08.018; Frenkel D, 2003, J IMMUNOL, V171, P6549, DOI 10.4049/jimmunol.171.12.6549; Ginsberg MD, 2008, NEUROPHARMACOLOGY, V55, P363, DOI 10.1016/j.neuropharm.2007.12.007; Hamilton TA, 2002, IMMUNOL RES, V25, P229, DOI 10.1385/IR:25:3:229; Hanada T, 2014, EXPERT OPIN DRUG DIS, V9, P449, DOI 10.1517/17460441.2014.891580; Hanada T, 2011, EPILEPSIA, V52, P1331, DOI 10.1111/j.1528-1167.2011.03109.x; Krauss GL, 2012, ACTA NEUROL SCAND, V125, P8, DOI 10.1111/j.1600-0404.2011.01588.x; Kwan P, 2015, EPILEPSY RES, V117, P117, DOI 10.1016/j.eplepsyres.2015.09.002; Lambertsen KL, 2012, J CEREBR BLOOD F MET, V32, P1677, DOI 10.1038/jcbfm.2012.88; Langan YM, 2003, EPILEPSIA, V44, P46, DOI 10.1046/j.1528-1157.2003.128902.x; Licinio J, 1999, MOL MED TODAY, V5, P225, DOI 10.1016/S1357-4310(99)01453-7; Lin MP, 2015, CARDIOL CLIN, V33, P99, DOI 10.1016/j.ccl.2014.09.009; Liu PK, 2002, ANN NY ACAD SCI, V962, P226, DOI 10.1111/j.1749-6632.2002.tb04071.x; Lv JM, 2016, CELL MOL NEUROBIOL, V36, P745, DOI 10.1007/s10571-015-0257-8; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Menon DK, 2009, CURR OPIN CRIT CARE, V15, P437, DOI 10.1097/MCC.0b013e3283307a26; Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350; Ning R, 2014, NEUROSCIENCE, V257, P76, DOI 10.1016/j.neuroscience.2013.10.071; O'Collins VE, 2006, ANN NEUROL, V59, P467, DOI 10.1002/ana.20741; Ooboshi H, 2005, CIRCULATION, V111, P913, DOI 10.1161/01.CIR.0000155622.68580.DC; Pandya Rachna S., 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P81; Pang L, 2001, STROKE, V32, P544, DOI 10.1161/01.STR.32.2.544; Patsalos PN, 2015, EPILEPSIA, V56, P12, DOI 10.1111/epi.12865; Rogawski MA, 2013, ACTA NEUROL SCAND, V127, P19, DOI 10.1111/ane.12100; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Smith S E, 1993, Funct Neurol, V8, P43; Traynor K, 2012, AM J HEALTH-SYST PH, V69, P2024, DOI 10.2146/news120080; Vannucchi MG, 2007, BRAIN RES, V1132, P218, DOI 10.1016/j.brainres.2006.11.029; Yung HW, 2004, J NEUROCHEM, V89, P812, DOI 10.1111/j.1471-4159.2004.02395.x; Zaharchuk G, 1997, MAGNET RESON MED, V37, P170, DOI 10.1002/mrm.1910370204; Zhang BJ, 2013, CHINESE MED J-PEKING, V126, P2354, DOI 10.3760/cma.j.issn.0366-6999.20122483; Zhang Y, 2012, MOLECULES, V17, P341, DOI 10.3390/molecules17010341	44	12	12	0	3	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	MAR	2018	38	2					459	466		10.1007/s10571-017-0489-x			8	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	FX4WL	WOS:000426079300006	28401316				2021-06-18	
J	Paniccia, M; Wilson, KE; Hunt, A; Keightley, M; Zabjek, K; Taha, T; Gagnon, I; Reed, N				Paniccia, Melissa; Wilson, Katherine E.; Hunt, Anne; Keightley, Michelle; Zabjek, Karl; Taha, Tim; Gagnon, Isabelle; Reed, Nick			Postural Stability in Healthy Child and Youth Athletes: The Effect of Age, Sex, and Concussion-Related Factors on Performance	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						postural stability; youth; athletes; concussion; symptom	BASE-LINE; ADOLESCENTS; BALANCE; SYMPTOMS; INJURY; GENDER	Background: Postural stability plays a key role in sport performance, especially after concussion. Specific to healthy child and youth athletes, little is known about the influence development and sex may have on postural stability while considering other subjective clinical measures used in baseline/preinjury concussion assessment. This study aims to describe age- and sex-based trends in postural stability in uninjured child and youth athletes at baseline while accounting for concussion-related factors. Hypotheses: (1) Postural stability performance will improve with age, (2) females will display better postural stability compared to males, and (3) concussion-like symptoms will affect postural stability performance in healthy children and youth. Study Design: Cross-sectional study. Level of Evidence: Level 3. Methods: This study comprised 889 healthy/uninjured child and youth athletes (54% female, 46% male) between the ages of 9 and 18 years old. Participants completed preseason baseline testing, which included demographic information (age, sex, concussion history), self-report of concussion-like symptoms (Post-Concussion Symptom Inventory [PCSI]-Child and PCSI-Youth), and measures of postural stability (BioSway; Biodex Medical Systems). Two versions of the PCSI were used (PCSI-C, 9- to 12-year-olds; PCSI-Y, 13- to 18-year-olds). Postural stability was assessed via sway index under 4 sway conditions of increasing difficulty by removing visual and proprioceptive cues. Results: In children aged 9 to 12 years old, there were significant age- (P < 0.05) and sex-based effects (P < 0.05) on postural stability. Performance improved with age, and girls performed better than boys. For youth ages 13 to 18 years old, postural stability also improved with age (P < 0.05). In both child and youth subgroups, postural stability worsened with increasing concussion-like symptoms (P < 0.05). Conclusion: There are developmental and baseline symptom trends regarding postural stability performance. Clinical Relevance: These findings provide a preliminary foundation for postconcussion comparisons and highlight the need for a multimodal approach in assessing and understanding physical measures such as postural stability.	[Paniccia, Melissa] Univ Toronto, Fac Med, Rehabil Sci Inst, 500 Univ Ave, Toronto, ON M5G 1V7, Canada; [Paniccia, Melissa; Wilson, Katherine E.; Hunt, Anne; Reed, Nick] Holland Bloorview Kids Rehabil Hosp, Bloorview Res Inst, Concuss Ctr, Toronto, ON, Canada; [Keightley, Michelle] Holland Bloorview Kids Rehabil Hosp, Bloorview Res Inst, Toronto, ON, Canada; [Keightley, Michelle] Univ Toronto, Fac Med, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Zabjek, Karl] Univ Toronto, Fac Med, Dept Phys Therapy, Toronto, ON, Canada; [Taha, Tim] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Gagnon, Isabelle] McGill Univ, Sch Phys & Occupat Therapy, Montreal, PQ, Canada; [Reed, Nick] Univ Toronto, Fac Med, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada	Paniccia, M (corresponding author), Univ Toronto, Fac Med, Rehabil Sci Inst, 500 Univ Ave, Toronto, ON M5G 1V7, Canada.	melissa.paniccia@utoronto.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [127048]; Ontario Neurotrauma Foundation (Ontario, Canada); Ontario Brain Institute (Ontario, Canada)	This work was funded by the Canadian Institutes of Health Research (No. 127048) with support from the Ontario Neurotrauma Foundation (Ontario, Canada) and the Ontario Brain Institute (Ontario, Canada).	Biodex Medical Systems Inc, BIOSWAY PORT BAL SYS; Borah Diganta, 2007, Indian J Physiol Pharmacol, V51, P395; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; Butz SM, 2015, PEDIATR PHYS THER, V27, P126, DOI 10.1097/PEP.0000000000000128; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Cottle JE, 2017, J ATHL TRAINING, V52, P77, DOI 10.4085/1062-6050-51.12.21; Custer A, 2016, J ATHL TRAINING, V51, P136, DOI 10.4085/1062-6050-51.2.12; Demura S.P., 2006, SPORT SCI HLTH, V1, P158, DOI DOI 10.1007/S11332-006-0028-5; Eime RM, 2013, INT J BEHAV NUTR PHY, V10, DOI 10.1186/1479-5868-10-98; Geldhof E, 2006, EUR J PEDIATR, V165, P779, DOI 10.1007/s00431-006-0173-5; George D., 2010, SPSS WINDOWS STEP ST, V10; Guskiewicz Kevin M, 2015, Handb Clin Neurol, V127, P157, DOI 10.1016/B978-0-444-52892-6.00010-6; HIRABAYASHI S, 1995, BRAIN DEV-JPN, V17, P111, DOI 10.1016/0387-7604(95)00009-Z; Holden S, 2016, GAIT POSTURE, V48, P171, DOI 10.1016/j.gaitpost.2016.04.019; Holden S, 2014, PEDIATR PHYS THER, V26, P447, DOI 10.1097/PEP.0000000000000071; Hue O, 2007, GAIT POSTURE, V26, P32, DOI 10.1016/j.gaitpost.2006.07.005; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Lee AJY, 2007, J APPL BIOMECH, V23, P173, DOI 10.1123/jab.23.3.173; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Nolan L, 2005, DEV MED CHILD NEUROL, V47, P449, DOI 10.1017/S0012162205000873; Ontario Neurotrauma Foundation, 2014, GUID DIAGN MAN PED C; Peterson ML, 2006, GAIT POSTURE, V23, P455, DOI 10.1016/j.gaitpost.2005.05.003; Quatman-Yates CC, 2012, BRIT J SPORT MED, V46, P649, DOI 10.1136/bjsm.2010.079616; Reed N, 2014, JOVE-J VIS EXP, DOI 10.3791/51892; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Steindl R, 2006, DEV MED CHILD NEUROL, V48, P477, DOI 10.1017/S0012162206001022; US Department of Health and Human Services, 2008, PHYS ACT GUID ADV CO; Hunt AW, 2016, J ATHL TRAINING, V51, P749, DOI 10.4085/1062-6050-51.11.12	30	12	12	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	MAR-APR	2018	10	2					175	182		10.1177/1941738117741651			8	Sport Sciences	Sport Sciences	GC7BT	WOS:000429947700013	29131721	Green Published			2021-06-18	
J	Piromkraipak, P; Sangpairoj, K; Tirakotai, W; Chaithirayanon, K; Unchern, S; Supavilai, P; Power, C; Vivithanaporn, P				Piromkraipak, Pannaree; Sangpairoj, Kant; Tirakotai, Wuttipong; Chaithirayanon, Kulathida; Unchern, Supeenun; Supavilai, Porntip; Power, Christopher; Vivithanaporn, Pornpun			Cysteinyl Leukotriene Receptor Antagonists Inhibit Migration, Invasion, and Expression of MMP-2/9 in Human Glioblastoma	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Montelukast; Zafirlukast; Gelatinase; Migration; Invasion; Glioma	5-LIPOXYGENASE TRIGGERS APOPTOSIS; TRAUMATIC BRAIN-INJURY; FACTOR-KAPPA-B; MATRIX-METALLOPROTEINASE-9 EXPRESSION; MATRIX METALLOPROTEINASES; GLIOMA-CELLS; DOWN-REGULATION; IDH2 MUTATIONS; BREAST-CANCER; P38 MAPK	Glioblastoma is one of the most malignant and aggressive types of brain tumors. 5-lipoxygenase and cysteinyl leukotriene receptor 1 (CysLT1) play a role in human carcinogenesis. Leukotriene receptor antagonists (LTRAs), anti-asthmatic drugs with mild side effects, have anti-metastatic activity in epidermoid carcinoma, lung carcinoma, and colon cancers as well as neuroprotective effects. Herein, anti-migratory effects of two LTRAs, montelukast and zafirlukast, were investigated in glioblastoma cells. The level of CysLT1 in A172 cells was increased by 3.13 folds after IL-1 beta treatment. The median toxic concentration of LTRAs in A172, U373, and primary astrocytes ranged from 7.17 to 26.28 mu M at 24-h post-exposure. Both LTRAs inhibited migration and invasion of glioma. Additionally, both drugs significantly inhibited the expression and activities of MMP-2 and MMP-9 in A172 and U373 glioblastoma cells and primary human astrocytes, suggesting that CysLT1 plays a role in migration and invasion of glioma, and LTRAs are potential drugs to reduce migration and invasion.	[Piromkraipak, Pannaree; Unchern, Supeenun; Supavilai, Porntip; Vivithanaporn, Pornpun] Mahidol Univ, Dept Pharmacol, Fac Sci, Bangkok, Thailand; [Sangpairoj, Kant; Chaithirayanon, Kulathida] Mahidol Univ, Dept Anat, Fac Sci, Bangkok, Thailand; [Sangpairoj, Kant] Thammasat Univ, Div Anat, Dept Preclin Sci, Fac Med, Pathum Thani, Thailand; [Tirakotai, Wuttipong] Prasat Neurol Inst, Bangkok, Thailand; [Power, Christopher] Univ Alberta, Fac Med & Dent, Dept Med, Edmonton, AB, Canada	Vivithanaporn, P (corresponding author), Mahidol Univ, Dept Pharmacol, Fac Sci, Bangkok, Thailand.	pornpun.viv@mahidol.ac.th		Sangpairoj, Kant/0000-0003-2398-1262	Mahidol University; Department of Medical Services, Ministry of Public Health, Thailand [59-59-407308]	We thank Mr. Piyadon Sathavorasmith and Ms. Suttinee Phuagkhaopong for technical assistance. We thank Ms. Nanapas Bhagaman, a biostatistician at the Department of Epidemiology, Faculty of Public Health, Mahidol University for advice on statistic. This work was supported by research grant from Mahidol University to PP and KC. WT was supported by the Department of Medical Services, Ministry of Public Health, Thailand (Grant Number 59-59-407308).	Allavena P, 2008, CURR OPIN GENET DEV, V18, P3, DOI 10.1016/j.gde.2008.01.003; Anderson R, 2009, BRIT J PHARMACOL, V156, P105, DOI 10.1111/j.1476-5381.2008.00012.x; Aroui S, 2016, TUMOR BIOL, V37, P3831, DOI 10.1007/s13277-015-4230-4; Bjorklund M, 2005, BBA-REV CANCER, V1755, P37, DOI 10.1016/j.bbcan.2005.03.001; Chen XX, 2004, CLIN CANCER RES, V10, P6703, DOI 10.1158/1078-0432.CCR-04-0838; Cheng HY, 1996, PHARM RES-DORDR, V13, P445, DOI 10.1023/A:1016056912698; Choe GY, 2002, CLIN CANCER RES, V8, P2894; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; Cohen AL, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0345-4; Cuperlovic-Culf M, 2012, J BIOL CHEM, V287, P20164, DOI 10.1074/jbc.M111.337196; De Vita F, 1998, J EXP CLIN CANC RES, V17, P413; Duran A, 2013, ACTA CHIR BELG, V113, P401, DOI 10.1080/00015458.2013.11680954; El-Sisi AEE, 2015, TOXICOL IND HEALTH, V31, P1024, DOI 10.1177/0748233713485884; Esteve PO, 1998, BBA-MOL CELL RES, V1403, P85, DOI 10.1016/S0167-4889(98)00020-2; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Fanjul-Fernandez M, 2010, BBA-MOL CELL RES, V1803, P3, DOI 10.1016/j.bbamcr.2009.07.004; Ferrari CC, 2004, AM J PATHOL, V165, P1827, DOI 10.1016/S0002-9440(10)63438-4; Friedberg MH, 1998, CANCER, V82, P923, DOI 10.1002/(SICI)1097-0142(19980301)82:5<923::AID-CNCR18>3.0.CO;2-2; Fu YJ, 2012, BIOTECHNOL LETT, V34, P441, DOI 10.1007/s10529-011-0800-8; Funao K, 2008, MOL MED REP, V1, P185; Funk CD, 2005, NAT REV DRUG DISCOV, V4, P664, DOI 10.1038/nrd1796; Germano G, 2008, CYTOKINE, V43, P374, DOI 10.1016/j.cyto.2008.07.014; Gounaris E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121402; Griffin WST, 2002, J LEUKOCYTE BIOL, V72, P233; Gunning WT, 2002, CANCER RES, V62, P4199; Hagemann C, 2012, WORLD J CLIN ONCOL, V3, P67, DOI 10.5306/wjco.v3.i5.67; Hagemann Carsten, 2010, BMC Res Notes, V3, P293, DOI 10.1186/1756-0500-3-293; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Holland EC, 2000, TOXICOL PATHOL, V28, P171, DOI 10.1177/019262330002800122; Hu H, 2005, ACTA PHARMACOL SIN, V26, P685, DOI 10.1111/j.1745-7254.2005.00092.x; Huang XQ, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-145; Hung CH, 2006, PEDIAT ALLERG IMM-UK, V17, P250, DOI 10.1111/j.1399-3038.2006.00385.x; Ichimura K, 2012, BRAIN TUMOR PATHOL, V29, P131, DOI 10.1007/s10014-012-0090-4; Ishii K, 2009, CLIN NEUROPATHOL, V28, P445; Jose MA, 2013, INDIAN J PHARMACOL, V45, P286, DOI 10.4103/0253-7613.111897; Kahnt AS, 2013, BIOCHEM PHARMACOL, V86, P286, DOI 10.1016/j.bcp.2013.05.005; Kumar R, 2016, CARCINOGENESIS, V37, P912, DOI 10.1093/carcin/bgw075; Kunishio Katsuzo, 2003, Brain Tumor Pathol, V20, P39, DOI 10.1007/BF02483445; Lai JE, 2014, NEUROPHARMACOLOGY, V79, P707, DOI 10.1016/j.neuropharm.2014.01.011; Langlois A, 2006, J ALLERGY CLIN IMMUN, V118, P113, DOI 10.1016/j.jaci.2006.03.010; Lin YC, 2018, J MICROBIOL IMMUNOL, V51, P18, DOI 10.1016/j.jmii.2016.04.005; Luchman HA, 2012, NEURO-ONCOLOGY, V14, P184, DOI 10.1093/neuonc/nor207; Magi S, 2014, CANCER SCI, V105, P290, DOI 10.1111/cas.12340; Magnusson C, 2011, INT J CANCER, V129, P9, DOI 10.1002/ijc.25648; Manev H, 2011, PROG NEURO-PSYCHOPH, V35, P315, DOI 10.1016/j.pnpbp.2010.07.032; Massova I, 1998, FASEB J, V12, P1075; Matsuyama M, 2009, MOL MED REP, V2, P163, DOI 10.3892/mmr_00000078; Melstrom LG, 2008, CLIN CANCER RES, V14, P6525, DOI 10.1158/1078-0432.CCR-07-4631; Mendes O, 2005, CLIN EXP METASTAS, V22, P237, DOI 10.1007/s10585-005-8115-6; Meng Z, 2013, UROLOGY, V82, DOI 10.1016/j.urology.2013.08.060; Merched AJ, 2008, FASEB J, V22, P3595, DOI 10.1096/fj.08-112201; Musumeci G, 2015, CELL TISSUE RES, V362, P45, DOI 10.1007/s00441-015-2197-5; Nakada M, 2003, FRONT BIOSCI, V8, pE261, DOI 10.2741/1016; NAKANO A, 1995, J NEUROSURG, V83, P298, DOI 10.3171/jns.1995.83.2.0298; Nishio K, 2016, J ORAL SCI, V58, P59, DOI 10.2334/josnusd.58.59; Nozaki Masako, 2010, Keio Journal of Medicine, V59, P10; Ostrom QT, 2013, NEURO-ONCOLOGY, V15, P1, DOI 10.1093/neuonc/not151; Paruchuri S, 2006, ONCOGENE, V25, P6660, DOI 10.1038/sj.onc.1209666; Patel A, 2016, BRAIN STRUCT FUNCT, V221, P1845, DOI 10.1007/s00429-015-1007-x; Patil V, 2015, ONCOTARGET, V6, P43452, DOI 10.18632/oncotarget.6171; Peters-Golden M, 2005, ANN ALLERG ASTHMA IM, V94, P609, DOI 10.1016/S1081-1206(10)61317-8; Piaskowski S, 2011, BRIT J CANCER, V104, P968, DOI 10.1038/bjc.2011.27; Poeckel D, 2010, CARDIOVASC RES, V86, P243, DOI 10.1093/cvr/cvq016; Rahme GJ, 2015, ONCOGENE, V34, P53, DOI 10.1038/onc.2013.531; Raithatha SA, 2000, NEURO-ONCOLOGY, V2, P145, DOI 10.1093/neuonc/2.3.145; Ramires R, 2004, BIOCHEM BIOPH RES CO, V324, P815, DOI 10.1016/j.bbrc.2004.09.125; Sarkar S, 2009, J NEURO-ONCOL, V91, P157, DOI 10.1007/s11060-008-9695-1; Sarveswaran S, 2011, BBA-MOL CELL RES, V1813, P2108, DOI 10.1016/j.bbamcr.2011.07.015; Savari S, 2014, WORLD J GASTROENTERO, V20, P968, DOI 10.3748/wjg.v20.i4.968; Savari S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073466; Shaftel SS, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-7; Sharma V, 2011, J MOL MED, V89, P123, DOI 10.1007/s00109-010-0683-5; Spinozzi F, 2004, CLIN EXP ALLERGY, V34, P1876, DOI 10.1111/j.1365-2222.2004.02119.x; Sveinbjornsson B, 2008, FASEB J, V22, P3525, DOI 10.1096/fj.07-103457; Tahan F, 2008, CLIN EXP ALLERGY, V38, P805, DOI 10.1111/j.1365-2222.2008.02963.x; Tejima E, 2007, J CEREBR BLOOD F MET, V27, P460, DOI 10.1038/sj.jcbfm.9600354; Thakkar JP, 2014, CANCER EPIDEM BIOMAR, V23, P1985, DOI 10.1158/1055-9965.EPI-14-0275; Theron AJ, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/608930; Thorns V, 2003, ANTICANCER RES, V23, P3937; Tintinger GR, 2010, THESCIENTIFICWORLDJO, V10, P2403, DOI 10.1100/tsw.2010.229; Tsai MJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep25880; Tsang DS, 2015, CLIN ONCOL-UK, V27, P176, DOI 10.1016/j.clon.2014.11.026; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Vivithanaporn P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012856; Wang Maode, 2003, Brain Tumor Pathol, V20, P65, DOI 10.1007/BF02483449; Wang MD, 2005, J NEURO-ONCOL, V72, P1, DOI 10.1007/s11060-004-1392-0; Wen Z, 2015, ONCOGENE, V34, P1241, DOI 10.1038/onc.2014.85; Wenzel SE, 2003, PROSTAG LEUKOTR ESS, V69, P145, DOI 10.1016/S0952-3278(03)00075-9; Wild-Bode C, 2001, J NEUROSURG, V94, P976, DOI 10.3171/jns.2001.94.6.0978; Woszczek G, 2010, J IMMUNOL, V184, P2219, DOI 10.4049/jimmunol.0900071; Wu CY, 2008, J NEUROCHEM, V105, P1499, DOI 10.1111/j.1471-4159.2008.05318.x; Wu CY, 2009, GLIA, V57, P1775, DOI 10.1002/glia.20890; Wu CY, 2004, J NEUROCHEM, V90, P1477, DOI 10.1111/j.1471-4159.2004.02682.x; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yang CM, 2015, MOL NEUROBIOL, V52, P303, DOI 10.1007/s12035-014-8838-y; Yeung YT, 2013, BRIT J PHARMACOL, V168, P591, DOI 10.1111/bph.12008; Yeung YT, 2012, J NEURO-ONCOL, V109, P35, DOI 10.1007/s11060-012-0875-7; Zhang WP, 2004, NEUROSCI LETT, V363, P247, DOI 10.1016/j.neulet.2004.03.088; Zhao JP, 2012, JPN J CLIN ONCOL, V42, P1060, DOI 10.1093/jjco/hys142; Zhou GX, 2015, ONCOL REP, V33, P661, DOI 10.3892/or.2014.3650	100	12	13	0	7	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	MAR	2018	38	2					559	573		10.1007/s10571-017-0507-z			15	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	FX4WL	WOS:000426079300016	28600709				2021-06-18	
J	Yang, ZH; Bramlett, HM; Moghieb, A; Yu, DN; Wang, P; Lin, F; Bauer, C; Selig, TM; Jaalouk, E; Weissman, AS; Rathore, DS; Romo, P; Zhang, ZQ; Hayes, RL; Wang, MY; Dietrich, WD; Wang, KKW				Yang, Zhihui; Bramlett, Helen M.; Moghieb, Ahmed; Yu, Dongnan; Wang, Ping; Lin, Fan; Bauer, Carl; Selig, Tyler M.; Jaalouk, Emily; Weissman, Amanda S.; Rathore, Disa S.; Romo, Pammela; Zhang, Zhiqun; Hayes, Ronald L.; Wang, Michael Y.; Dietrich, W. Dalton; Wang, Kevin K. W.			Temporal Profile and Severity Correlation of a Panel of Rat Spinal Cord Injury Protein Biomarkers	MOLECULAR NEUROBIOLOGY			English	Article						Spinal cord injury; Biomarkers; Neuronal injury; Glial injury; Systems biology	TRAUMATIC AXONAL INJURY; BRAIN-INJURY; CEREBROSPINAL-FLUID; PLASMA; INTERLEUKIN-6; CALPAIN; ALPHA; SERUM	In the USA, there are approximately 12,000 new cases of spinal cord injury (SCI) each year and some 1.2 million people living with paralysis due to SCI. Seven percent of them are paralyzed due to an accident or injury occurring while serving in the military. Here, we report a systematic study on protein biomarker candidates in a rat SCI model with either moderate or severe injury. Tissue, cerebrospinal fluid (CSF), and serum samples were obtained at 4 h, 24 h, and 7 days post-injury. The candidate biomarkers included axonal injury markers alpha II-spectrin breakdown products (SBDP150/145/120), neuronal cell body injury marker ubiquitin C-terminal hydrolase-L1 (UCH-L1), astrogliosis/astroglial injury markers S100 calcium-binding protein-beta (S100 beta), glial fibrillary acidic protein (GFAP) and GFAP breakdown products (GBDPs), demyelination marker myelin basic protein (MBP), axonal injury marker phosphorylated neurofilament-H (pNF-H), and neuroinflammation marker interleukin-6 (IL-6). SBDP150/145, UCH-L1, GFAP, and S100 beta were found as acute biomarkers with significantly elevated levels within 24 h. GBDP44, GBDP38, and pNF-H are acute and subacute biomarkers that were found to have increased at 4 h, 24 h, and 7 days. MBP and SBDP120 were considered subacute biomarkers which were only detectable at 7 days post-injury. These results not only allow us to gain important insight into the patho-mechanisms of SCI but also showcase the possibility of using some of the protein biomarkers to track injury severity and disease progression and resolution. These biomarkers can potentially serve as tools that assist therapy development and clinical trials.	[Yang, Zhihui; Yu, Dongnan; Wang, Ping; Lin, Fan; Bauer, Carl; Selig, Tyler M.; Jaalouk, Emily; Weissman, Amanda S.; Rathore, Disa S.; Romo, Pammela; Zhang, Zhiqun; Wang, Kevin K. W.] Program Neurotrauma Neuroprote & Biomarkers Res, Dept Psychiat, Gainesville, FL 32611 USA; [Yang, Zhihui; Yu, Dongnan; Wang, Ping; Lin, Fan; Bauer, Carl; Selig, Tyler M.; Jaalouk, Emily; Weissman, Amanda S.; Rathore, Disa S.; Romo, Pammela; Zhang, Zhiqun; Wang, Kevin K. W.] Program Neurotrauma Neuroprote & Biomarkers Res, Dept Neurosci, Gainesville, FL 32611 USA; [Bramlett, Helen M.; Wang, Michael Y.; Dietrich, W. Dalton] Univ Miami, Leonard M Miller Sch Med, Miami, FL 33136 USA; [Bramlett, Helen M.] Vet Affairs Med Ctr, Bruce W Carter Dept, Miami, FL 33125 USA; [Moghieb, Ahmed; Wang, Kevin K. W.] Univ Florida, Physiol Sci & Chem, Gainesville, FL 32611 USA; [Yu, Dongnan] Guangdong Gen Hosp, Guangzhou 510080, Guangdong, Peoples R China; [Wang, Ping] Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou 325027, Zhejiang, Peoples R China; [Hayes, Ronald L.] Banyan Biomarkers Inc, Alachua, FL 32615 USA	Yang, ZH; Wang, KKW (corresponding author), Program Neurotrauma Neuroprote & Biomarkers Res, Dept Psychiat, Gainesville, FL 32611 USA.; Yang, ZH; Wang, KKW (corresponding author), Program Neurotrauma Neuroprote & Biomarkers Res, Dept Neurosci, Gainesville, FL 32611 USA.; Wang, KKW (corresponding author), Univ Florida, Physiol Sci & Chem, Gainesville, FL 32611 USA.	zhihuiyang@ufl.edu; kwang@ufl.edu		Weissman, Amanda/0000-0002-5873-1995; Wang, Kevin/0000-0002-9343-6473	DOD grants from the US Army [W81XWH-12-1-0276, W81XWH-12-1-0277]	This study is supported in part by the DOD grants W81XWH-12-1-0276 (WDD, MSW) and W81XWH-12-1-0277 (KKW) from the US Army.	Basu S, 2004, J ANDROL, V25, P250; Biglari B, 2015, SPINAL CORD, V53, P510, DOI 10.1038/sc.2015.28; Chatzipanteli K, 2012, THER HYPOTHERMIA TEM, V2, P167, DOI 10.1089/ther.2012.0016; Hajdukova L, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/379071; Huh JW, 2006, DEV NEUROSCI-BASEL, V28, P466, DOI 10.1159/000094172; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; Kato S, 2015, J CLIN NEUROSCI, V22, P1638, DOI 10.1016/j.jocn.2015.03.047; Kinoshita T, 2013, SPINAL CORD, V51, P508, DOI 10.1038/sc.2013.4; Kwon BK, 2011, CLIN CHEM LAB MED, V49, P425, DOI 10.1515/CCLM.2011.068; Kwon BK, 2010, J NEUROTRAUM, V27, P669, DOI 10.1089/neu.2009.1080; Merisson E, 2016, NEUROCHEM INT, V93, P1, DOI 10.1016/j.neuint.2015.12.003; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Puentes F, 2014, J NEUROL NEUROSUR PS, V85, P274, DOI [10.1136/jnnp-2013-305494, 10.1136/jnnp-2013-307454]; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wolf H, 2014, SPINE J, V14, P2918, DOI 10.1016/j.spinee.2014.04.027; Yang ZH, 2015, TRENDS NEUROSCI, V38, P364, DOI 10.1016/j.tins.2015.04.003; Yokobori S, 2015, WORLD NEUROSURG, V83, P867, DOI 10.1016/j.wneu.2013.03.012; Zhang ZQ, 2009, APOPTOSIS, V14, P1289, DOI 10.1007/s10495-009-0405-z	20	12	12	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	MAR	2018	55	3					2174	2184		10.1007/s12035-017-0424-7			11	Neurosciences	Neurosciences & Neurology	FY5TG	WOS:000426897800029	28290147				2021-06-18	
J	Lipponen, A; El-Osta, A; Kaspi, A; Ziemann, M; Khurana, I; Harikrishnan, KN; Navarro-Ferrandis, V; Puhakka, N; Paananen, J; Pitkanen, A				Lipponen, Anssi; El-Osta, Assam; Kaspi, Antony; Ziemann, Mark; Khurana, Ishant; Harikrishnan, K. N.; Navarro-Ferrandis, Vicente; Puhakka, Noora; Paananen, Jussi; Pitkanen, Asla			Transcription factors Tp73, Cebpd, Pax6, and Spi1 rather than DNA methylation regulate chronic transcriptomics changes after experimental traumatic brain injury	ACTA NEUROPATHOLOGICA COMMUNICATIONS			English	Article						DNA methylation; LINCS analysis; MBD-seq; Recovery; RNA-seq; Treatment	HISTONE DEACETYLASE INHIBITOR; ACTIVATED PROTEIN-KINASE; CLOSED-HEAD INJURY; GENE-EXPRESSION; MICROGLIAL ACTIVATION; CANNABINOID RECEPTOR; CEREBRAL-CORTEX; MESSENGER-RNA; IN-VITRO; CORTICAL IMPACT	Traumatic brain injury (TBI) induces a wide variety of cellular and molecular changes that can continue for days to weeks to months, leading to functional impairments. Currently, there are no pharmacotherapies in clinical use that favorably modify the post-TBI outcome, due in part to limited understanding of the mechanisms of TBI-induced pathologies. Our system biology analysis tested the hypothesis that chronic transcriptomics changes induced by TBI are controlled by altered DNA-methylation in gene promoter areas or by transcription factors. We performed genome-wide methyl binding domain (MBD)-sequencing (seq) and RNA-seq in perilesional, thalamic, and hippocampal tissue sampled at 3 months after TBI induced by lateral fluid percussion in adult male Sprague-Dawley rats. We investigated the regulated molecular networks and mechanisms underlying the chronic regulation, particularly DNA methylation and transcription factors. Finally, we identified compounds that modulate the transcriptomics changes and could be repurposed to improve recovery. Unexpectedly, DNA methylation was not a major regulator of chronic post-TBI transcriptomics changes. On the other hand, the transcription factors Cebpd, Pax6, Spi1, and Tp73 were upregulated at 3 months after TBI (False discovery rate < 0.05), which was validated using digital droplet polymerase chain reaction. Transcription regulatory network analysis revealed that these transcription factors regulate apoptosis, inflammation, and microglia, which are well-known contributors to secondary damage after TBI. Library of Integrated Network-based Cellular Signatures (LINCS) analysis identified 118 pharmacotherapies that regulate the expression of Cebpd, Pax6, Spi1, and Tp73. Of these, the antidepressant and/or antipsychotic compounds trimipramine, rolipramine, fluspirilene, and chlorpromazine, as well as the anti-cancer therapies pimasertib, tamoxifen, and vorinostat were strong regulators of the identified transcription factors, suggesting their potential to modulate the regulated transcriptomics networks to improve post-TBI recovery.	[Lipponen, Anssi; Navarro-Ferrandis, Vicente; Puhakka, Noora; Pitkanen, Asla] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Epilepsy Res Lab, POB 1627, FIN-70211 Kuopio, Finland; [El-Osta, Assam; Kaspi, Antony; Ziemann, Mark; Khurana, Ishant; Harikrishnan, K. N.] Monash Univ, Fac Med, Cent Clin Sch, Epigenet Human Hlth & Dis Lab, Melbourne, Vic, Australia; [El-Osta, Assam] Chinese Univ Hong Kong, Prince Wales Hosp, Sha Tin, Hong Kong, Peoples R China; [Paananen, Jussi] Univ Eastern Finland, Inst Biomed, Kuopio, Finland; [Paananen, Jussi] Univ Eastern Finland, Bioinformat Ctr, Kuopio, Finland	Pitkanen, A (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Epilepsy Res Lab, POB 1627, FIN-70211 Kuopio, Finland.	asla.pitkanen@uef.fi		Khurana, Ishant/0000-0001-9050-2749; El-Osta, Assam/0000-0003-2969-9137; Ziemann, Mark/0000-0002-7688-6974; Lipponen, Anssi/0000-0002-4403-9084; Kaspi, Antony/0000-0001-6576-5862; El-Osta, Assam/0000-0001-7968-7375	Academy of FinlandAcademy of FinlandEuropean Commission; EpiGENet EUROEPINOMICS; FP7-HEALTH project [602102]	This study was supported by the Academy of Finland (A.P.), EpiGENet EUROEPINOMICS (A.P.), and FP7-HEALTH project 602102 (EPITARGET)(AP).	Abbruscato TJ, 1999, J PHARMACOL EXP THER, V289, P668; Amenta PS, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0191-6; Andrews S, 2010, FASTQC QUALITY CONTR; Aras AB, 2015, INFLAMMATION, V38, P1311, DOI 10.1007/s10753-014-0102-0; Arcaro A, 1993, BIOCHEM J, V296, P279; Atmaca A, 2007, BRIT J CANCER, V97, P177, DOI 10.1038/sj.bjc.6603851; Lopez-Rodriguez AB, 2016, EXP NEUROL, V279, P274, DOI 10.1016/j.expneurol.2016.03.018; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Buffo A, 2005, P NATL ACAD SCI USA, V102, P18183, DOI 10.1073/pnas.0506535102; Cai LP, 2017, MOL NEUROBIOL, V54, P1263, DOI 10.1007/s12035-016-9695-7; CAPDEVILA J, 1988, ARCH BIOCHEM BIOPHYS, V261, P257, DOI 10.1016/0003-9861(88)90340-2; Castellino RC, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-127; CHERAMY A, 1970, EUR J PHARMACOL, V10, P206, DOI 10.1016/0014-2999(70)90274-8; Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Colak T, 2012, INJURY, V43, P1264, DOI 10.1016/j.injury.2012.01.021; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Crack P, 2009, J NEURAL TRANSM, V116, P1, DOI 10.1007/s00702-008-0145-1; Crawford F, 2009, NEUROSCIENCE, V159, P1349, DOI 10.1016/j.neuroscience.2009.01.033; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; De Jager PL, 2014, NAT NEUROSCI, V17, P1156, DOI 10.1038/nn.3786; Debski KJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep25668; Diamond M, 2006, EUR NEUROPSYCHOPHARM, V16, P481, DOI 10.1016/j.euroneuro.2005.11.011; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dixon RA, 2002, PHYTOCHEMISTRY, V60, P205, DOI 10.1016/S0031-9422(02)00116-4; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dougall D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009221.pub2; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Farrokhnia N, 2008, EUR J CLIN INVEST, V38, P679, DOI 10.1111/j.1365-2362.2008.01990.x; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fava M, 2000, NEURON, V28, P335, DOI 10.1016/S0896-6273(00)00112-4; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fazekas D, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-7; Figueroa-Romero C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052672; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Frieling H, 2006, EUR ARCH PSY CLIN N, V256, P268, DOI 10.1007/s00406-006-0660-8; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; Goodman JC, 2008, ACTA NEUROCHIR SUPPL, V102, P389, DOI 10.1007/978-3-211-85578-2_75; Haghighi F, 2015, J NEUROTRAUM, V32, P1200, DOI 10.1089/neu.2014.3640; Hamalainen M, 2008, PULM PHARMACOL THER, V21, P331, DOI 10.1016/j.pupt.2007.08.003; Han JW, 2000, CANCER RES, V60, P6068; Hellmich HL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053230; HONG SL, 1980, J BIOL CHEM, V255, P9538; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; Im JY, 2008, CHEM-BIOL INTERACT, V172, P235, DOI 10.1016/j.cbi.2008.01.007; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; Ishikawa Y, 2006, ACTA NEUROCHIR SUPPL, V96, P163; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Johnson V.E., 2017, ADVANCES IN NEUROBIO, V15; Jost CA, 1997, NATURE, V389, P191; Jowaed A, 2010, J NEUROSCI, V30, P6355, DOI 10.1523/JNEUROSCI.6119-09.2010; Kang YJ, 2011, J NAT PROD, V74, P701, DOI 10.1021/np1007735; KATO H, 1995, EUR J PHARMACOL, V272, P107, DOI 10.1016/0014-2999(94)00694-3; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kim HJ, 2007, J PHARMACOL EXP THER, V321, P892, DOI 10.1124/jpet.107.120188; Kim K, 2010, BRIT J HAEMATOL, V149, P537, DOI 10.1111/j.1365-2141.2010.08127.x; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Korcsmaros T, 2010, BIOINFORMATICS, V26, P2042, DOI 10.1093/bioinformatics/btq310; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Kraft P, 2013, EXP NEUROL, V247, P80, DOI 10.1016/j.expneurol.2013.03.026; Kukacka J, 2006, NEUROENDOCRINOL LETT, V27, P116; Laing AJ, 2007, J ORTHOP RES, V25, P44, DOI 10.1002/jor.20228; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee AF, 2004, J NEUROSCI, V24, P9174, DOI 10.1523/JNEUROSCI.1588-04.2004; Lee B, 2009, PHARMACOL BIOCHEM BE, V93, P121, DOI 10.1016/j.pbb.2009.04.021; Li HJ, 2014, EUR J PHARMACOL, V735, P38, DOI 10.1016/j.ejphar.2014.04.017; Lipponen A, 2016, SCI REP-UK, V6, DOI 10.1038/srep31570; Logan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059250; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu K, 2007, J THORAC CARDIOV SUR, V133, P934, DOI 10.1016/j.jtcvs.2006.11.038; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Madathil SK., 2015, BRAIN NEUROTRAUMA MO; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; McDonald SJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0555-1; McGinn Melissa J, 2015, Handb Clin Neurol, V127, P67, DOI 10.1016/B978-0-444-52892-6.00005-2; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Meng QY, 2017, EBIOMEDICINE, V16, P184, DOI 10.1016/j.ebiom.2017.01.046; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; Michael DB, 2005, J CLIN NEUROSCI, V12, P284, DOI 10.1016/j.jocn.2004.11.003; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Offertaler L, 2003, MOL PHARMACOL, V63, P699, DOI 10.1124/mol.63.3.699; Pena-Llopis S, 2013, NAT PROTOC, V8, P2240, DOI 10.1038/nprot.2013.141; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P286, DOI 10.1007/s13311-014-0260-7; Polkowski K, 2000, Acta Pol Pharm, V57, P135; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Pozniak CD, 2002, J NEUROSCI, V22, P9800; Puche JE, 2016, BIOFACTORS, V42, P60, DOI 10.1002/biof.1255; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rosa A, 2007, P NATL ACAD SCI USA, V104, P19849, DOI 10.1073/pnas.0706963104; Roy SK, 2000, J BIOL CHEM, V275, P12626, DOI 10.1074/jbc.275.17.12626; Sagarkar S, 2017, NEUROBIOL DIS, V106, P101, DOI 10.1016/j.nbd.2017.06.016; SALZMANN MM, 1965, BRIT J PSYCHIAT, V111, P1105, DOI 10.1192/bjp.111.480.1105; Samal BB, 2015, J MOL NEUROSCI, V57, P282, DOI 10.1007/s12031-015-0626-2; Sandhir R, 2010, NEUROCHEM INT, V56, P188, DOI 10.1016/j.neuint.2009.10.002; Schober ME, 2012, J NEUROTRAUM, V29, P2075, DOI 10.1089/neu.2011.2276; Scholar EM, 2015, XPHARM COMPREHENSIVE; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shin SS, 2011, BRAIN RES, V1369, P208, DOI 10.1016/j.brainres.2010.10.096; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Smith AM, 2013, GLIA, V61, P929, DOI 10.1002/glia.22486; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soltani Z, 2015, PHYSIOL BEHAV, V152, P26, DOI 10.1016/j.physbeh.2015.08.037; SOMMER N, 1995, NAT MED, V1, P244, DOI 10.1038/nm0395-244; Statham AL, 2010, BIOINFORMATICS, V26, P1662, DOI 10.1093/bioinformatics/btq247; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sukumari-Ramesh S, 2016, TRANSL STROKE RES, V7, P141, DOI 10.1007/s12975-015-0421-y; Sy LK, 2008, CANCER RES, V68, P10229, DOI 10.1158/0008-5472.CAN-08-1983; Thomas MG, 2016, CNS NEUROL DISORD-DR, V15, P73, DOI 10.2174/1871527314666150821101757; Tien LT, 2017, DEV NEUROSCI-BASEL, V39, P443, DOI 10.1159/000477898; Tsai YT, 2014, J SURG RES, V189, P106, DOI 10.1016/j.jss.2014.02.009; Valiyaveettil M, 2013, CHEM-BIOL INTERACT, V203, P371, DOI 10.1016/j.cbi.2012.10.022; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Vonder Haar C, 2014, J NEUROTRAUM, V31, P961, DOI 10.1089/neu.2013.3119; Walton MR, 2000, J NEUROIMMUNOL, V104, P109, DOI 10.1016/S0165-5728(99)00262-3; Wang L, 2016, J MOL NEUROSCI, V59, P68, DOI 10.1007/s12031-016-0735-6; White TE, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2412-0; White TE, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-282; Wong YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020216; Wu J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021966; Xuan AG, 2012, LIFE SCI, V90, P463, DOI 10.1016/j.lfs.2012.01.001; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YONEDA T, 1991, CANCER RES, V51, P4430; Zakrzeska A, 2010, BRIT J PHARMACOL, V160, P574, DOI 10.1111/j.1476-5381.2009.00579.x; Zhang XY, 2014, GENET MOL RES, V13, P9220, DOI 10.4238/2014.November.7.9	135	12	12	1	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2051-5960			ACTA NEUROPATHOL COM	Acta Neuropathol. Commun.	FEB 27	2018	6								17	10.1186/s40478-018-0519-z			16	Neurosciences	Neurosciences & Neurology	FY2QL	WOS:000426660400001	29482641	DOAJ Gold, Green Published			2021-06-18	
J	Handy, JD; Avcu, P; Ko, N; Ortiz, A; Doria, MJ; Servatius, RJ				Handy, Justin D.; Avcu, Pelin; Ko, Nora; Ortiz, Alejandro; Doria, Michael J.; Servatius, Richard J.			Facilitated acquisition of the classically conditioned eyeblink response in active duty military expressing posttraumatic stress disorder symptoms	BEHAVIOURAL BRAIN RESEARCH			English	Article						PTSD; Eyeblink conditioning; Associative learning; Extinction; Personality	TRAUMATIC BRAIN-INJURY; BEHAVIORALLY INHIBITED TEMPERAMENT; ENVIRONMENTAL-INFLUENCES; FUNCTIONAL CONNECTIVITY; INDIVIDUAL-DIFFERENCES; PERSONALITY-TRAITS; AMYGDALAR RESPONSE; ANXIETY DISORDERS; FEAR INHIBITION; WAR VETERANS	Objective: Learning diathesis models underscore the role of hyper-conditioning in the development of PTSD following trauma exposure. Eyeblink classical conditioning is one method of examining associative learning biases independent of fear and threat produced by trauma. Facilitated learning is apparent in individuals self expressing PTSD symptoms, as well as behaviorally inhibited (BI) temperament, a vulnerability factor for PTSD. Here, we examine eyeblink conditioning in active duty military personnel and relate learning with PTSD symptomology. Method: Volunteers were 83 active duty United States Coast Guard personnel (18 females) recruited from small boat stations. Personnel were administered the PTSD Checklist (PCL) to assess current PTSD symptoms using DSM-IV criteria. BI temperament was assessed with the Adult Measure of Behavioural Inhibition (AMBI). Eyeblink conditioning was conducted using a partial reinforcement schedule, whereby paired trials (500-ms pure tone conditioned stimulus co-terminating with a 50-ms air-puff unconditional stimulus) were interpolated with 50% CS-alone trials. Results: Consistent with previous work, there was a high degree of concordance between BI and incidence of PTSD. Further, PTSD was associated with faster learning during the acquisition period, with conditioned responding sustained through the extinction period. Conclusions: These results reinforce the relationship between BI and PTSD in an active duty military sample, supporting previous observations in veteran and civilian samples. The conditioning data are consistent with predictions derived from a learning diathesis model of stress and anxiety, suggesting facilitated associative learning may represent an additional vulnerability for the development and maintenance of stress-related pathology.	[Handy, Justin D.; Ortiz, Alejandro; Servatius, Richard J.] Syracuse Vet Affairs Med Ctr, Dept Vet Affairs, Syracuse, NY USA; [Handy, Justin D.; Avcu, Pelin; Ko, Nora; Ortiz, Alejandro; Servatius, Richard J.] Rutgers State Univ, Dept Pharmacol Physiol & Neurosci, Rutgers Biomed Hlth Sci, Newark, NJ USA; [Avcu, Pelin; Ko, Nora] Rutgers State Univ, Grad Sch Biomed Sci, Newark, NJ USA; [Doria, Michael J.] USt Coast Guard, Washington, DC USA	Servatius, RJ (corresponding author), 800 Irving Ave, Syracuse, NY 13210 USA.	richard.servatius@va.gov		Servatius, Richard/0000-0002-7023-4895	Department of Veterans AffairsUS Department of Veterans Affairs; Stress & Motivated Behavior Institute; Medical Research funds	The research team is indebted for immeasurable support in conducting the research study to Admirals Dollymoore and Schwartz and CAPT Harnon as well as onsite access and support from: CWO Thomas Moore (CG Station Golden Gate), BMCS Eamon McCormak and BMC Jeremy Jarvis (Station St. Petersburg), LCDR William (Bill) Walsh and LT Leo Danaher (Station New York), BMCM Devin Spencer (Station San Francisco), LT Ben Crowell and LT Alexandria Richardson (Station Seattle), CWO Eric (Bee) Perry (Station Port Canaveral), CW04 Mark Helmers (Station, New Orleans), and LTJG Anthony Ippolito (Station Fort Lauderdale). Financial support was provided by Department of Veterans Affairs, Medical Research funds and the Stress & Motivated Behavior Institute.	Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Allen MT, 2016, BEHAV BRAIN RES, V304, P86, DOI 10.1016/j.bbr.2016.02.007; Allen MT, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00347; Avcu P, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00334; Beck K. D., 2011, BIOL PSYCHIAT, V35; Bell JD, 2007, BRAIN, V130, P2528, DOI 10.1093/brain/awm164; BIEDERMAN J, 1993, J AM ACAD CHILD PSY, V32, P814, DOI 10.1097/00004583-199307000-00016; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Blechert J, 2007, BEHAV RES THER, V45, P2019, DOI 10.1016/j.brat.2007.02.012; Blumenthal T. D., 1986, PSYCHOPHYSIOLOGY, V23; Bolton AN, 2014, J NEUROPATH EXP NEUR, V73, P933, DOI 10.1097/NEN.0000000000000115; Bonne O, 2003, BIOL PSYCHIAT, V54, P1077, DOI 10.1016/S0006-3223(03)00525-0; Bowman ML, 1999, CAN J PSYCHIAT, V44, P21, DOI 10.1177/070674379904400103; Breslau N, 2009, TRAUMA VIOLENCE ABUS, V10, P198, DOI 10.1177/1524838009334448; Caulfield MD, 2015, BEHAV BRAIN RES, V278, P476, DOI 10.1016/j.bbr.2014.10.027; Caulfield MD, 2016, BRAIN STRUCT FUNCT, V221, P3081, DOI 10.1007/s00429-015-1088-6; Caulfield MD, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00348; Cheng DT, 2008, P NATL ACAD SCI USA, V105, P8108, DOI 10.1073/pnas.0800374105; Cheng DT, 2014, HUM BRAIN MAPP, V35, P1390, DOI 10.1002/hbm.22261; Christian KM, 2003, LEARN MEMORY, V10, P427, DOI 10.1101/lm.59603; Clark R, 2013, J PSYCHIATR RES, V47, P1849, DOI 10.1016/j.jpsychires.2013.08.013; Degnan KA, 2007, DEV PSYCHOPATHOL, V19, P729, DOI 10.1017/S0954579407000363; Denollet J, 2005, PSYCHOSOM MED, V67, P89, DOI 10.1097/01.psy.0000149256.81953.49; Donald C. Mac, 2013, PLOS ONE, V8; EYSENCK HJ, 1979, BEHAV BRAIN SCI, V2, P155, DOI 10.1017/S0140525X00061653; Fauerbach JA, 2000, J NERV MENT DIS, V188, P510, DOI 10.1097/00005053-200008000-00006; Fernandez M, 2001, NEUROSCI LETT, V297, P101, DOI 10.1016/S0304-3940(00)01674-8; Fox NA, 2005, PSYCHOL SCI, V16, P921, DOI 10.1111/j.1467-9280.2005.01637.x; Freeman JH, 2015, BRAIN RES, V1621, P260, DOI 10.1016/j.brainres.2014.09.062; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; Gil S, 2006, PSYCHOSOM MED, V68, P904, DOI 10.1097/01.psy.0000242124.21796.f8; Ginsberg JP, 2008, J ANXIETY DISORD, V22, P809, DOI 10.1016/j.janxdis.2007.08.009; Ginsberg Jay P, 2008, Neuropsychiatr Dis Treat, V4, P635; Gladstone G, 2005, PSYCHIAT RES, V135, P133, DOI 10.1016/j.psychres.2005.03.005; Glatt SJ, 2013, AM J MED GENET B, V162B, P313, DOI 10.1002/ajmg.b.32167; Greer TL, 2005, J AFFECT DISORDERS, V86, P235, DOI 10.1016/j.jad.2005.02.006; Grillon C, 1999, J ABNORM PSYCHOL, V108, P134, DOI 10.1037/0021-843X.108.1.134; Hermann C, 2002, BIOL PSYCHIAT, V52, P328, DOI 10.1016/S0006-3223(02)01385-9; Hirshfeld D. R., 1992, J AM ACAD CHILD ADOL, V31; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holloway JL, 2014, BEHAV BRAIN RES, V261, P49, DOI 10.1016/j.bbr.2013.10.041; Holloway JL, 2012, FRONT BEHAV NEUROSCI, V6, DOI 10.3389/fnbeh.2012.00076; Hunt EJF, 2014, EUR J PSYCHOTRAUMATO, V5, DOI 10.3402/ejpt.v5.23617; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Jovanovic T, 2005, BIOL PSYCHIAT, V57, P1559, DOI 10.1016/j.biopsych.2005.02.025; Jovanovic T, 2009, PSYCHIAT RES, V167, P151, DOI 10.1016/j.psychres.2007.12.014; KAGAN J, 1987, CHILD DEV, V58, P1459, DOI 10.1111/j.1467-8624.1987.tb03858.x; Kashdan TB, 2009, J ANXIETY DISORD, V23, P185, DOI 10.1016/j.janxdis.2008.06.006; Ke J, 2016, ACTA RADIOL, V57, P1387, DOI 10.1177/0284185115585848; Kroenke K, 2009, J AFFECT DISORDERS, V114, P163, DOI 10.1016/j.jad.2008.06.026; Liberman LC, 2006, BEHAV RES THER, V44, P1491, DOI 10.1016/j.brat.2005.11.004; Lissek S, 2005, BEHAV RES THER, V43, P1391, DOI 10.1016/j.brat.2004.10.007; Liu W, 2013, NMR BIOMED, V26, P651, DOI 10.1002/nbm.2910; MASSARO DW, 1967, J EXP PSYCHOL, V75, P151, DOI 10.1037/h0024973; McLeod DS, 2001, J TRAUMA STRESS, V14, P259, DOI 10.1023/A:1011157800050; Meabon JS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaa9585; Michael T, 2007, J ABNORM PSYCHOL, V116, P612, DOI 10.1037/0021-843X.116.3.612; Mommersteeg PMC, 2011, INT J BEHAV MED, V18, P131, DOI 10.1007/s12529-010-9096-7; Monaco J, 2014, EUR J NEUROSCI, V40, P3363, DOI 10.1111/ejn.12700; Morgan Barak E, 2006, Curr Psychiatry Rep, V8, P270, DOI 10.1007/s11920-006-0062-7; Myers CE, 2012, PSYCHIAT RES, V196, P271, DOI 10.1016/j.psychres.2011.11.015; Myers CE, 2012, STRESS, V15, P31, DOI 10.3109/10253890.2011.578184; Nathan DE, 2015, BRAIN CONNECT, V5, P102, DOI 10.1089/brain.2014.0273; Norrholm SD, 2011, BIOL PSYCHIAT, V69, P556, DOI 10.1016/j.biopsych.2010.09.013; O'Reilly JX, 2010, CEREB CORTEX, V20, P953, DOI 10.1093/cercor/bhp157; Ordek G, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00197; Orr SP, 2000, J ABNORM PSYCHOL, V109, P290, DOI 10.1037//0021-843X.109.2.290; Paris J, 2000, HARVARD REV PSYCHIAT, V8, P175, DOI 10.1093/hrp/8.4.175; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Peri T, 2000, BIOL PSYCHIAT, V47, P512, DOI 10.1016/S0006-3223(99)00144-4; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; PITMAN RK, 1988, PSYCHIAT ANN, V18, P182, DOI 10.3928/0048-5713-19880301-11; PITMAN RK, 1986, J ABNORM PSYCHOL, V95, P208, DOI 10.1037/0021-843X.95.3.208; Rademaker AR, 2011, J ABNORM PSYCHOL, V120, P299, DOI 10.1037/a0021806; Robleto K, 2008, J NEUROSCI, V28, P2651, DOI 10.1523/JNEUROSCI.4781-07.2008; ROSENBAUM JF, 1993, HARVARD REV PSYCHIAT, V1, P2, DOI 10.3109/10673229309017052; Rubin DC, 2008, PSYCHOL REV, V115, P985, DOI 10.1037/a0013397; Schlund MW, 2010, NEUROIMAGE, V53, P769, DOI 10.1016/j.neuroimage.2010.06.058; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Schwartz CE, 2003, BIOL PSYCHIAT, V53, P854, DOI 10.1016/S0006-3223(02)01906-6; Schwartz CE, 2003, SCIENCE, V300, P1952, DOI 10.1126/science.1083703; Servatius RJ, 2016, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00015; Servatius RJ, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00168; SERVATIUS RJ, 1994, BEHAV NEUROSCI, V108, P1101, DOI 10.1037/0735-7044.108.6.1101; Servatius RJ, 2005, BIOL PSYCHIAT, V57, P865, DOI 10.1016/j.biopsych.2005.01.015; SPENCE KW, 1953, J EXP PSYCHOL, V45, P265, DOI 10.1037/h0056392; Spielberg JM, 2011, NEUROIMAGE, V54, P661, DOI 10.1016/j.neuroimage.2010.08.037; Stein MB, 2002, AM J PSYCHIAT, V159, P1675, DOI 10.1176/appi.ajp.159.10.1675; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; THOMPSON RF, 1991, NEUROPSYCHOLOGIA, V29, P571, DOI 10.1016/0028-3932(91)90011-V; Utz A, 2015, NEUROSCI LETT, V604, P173, DOI 10.1016/j.neulet.2015.07.026; VanElzakker MB, 2014, NEUROBIOL LEARN MEM, V113, P3, DOI 10.1016/j.nlm.2013.11.014; Vythilingam M, 2006, NEUROPSYCHOPHARMACOL, V31, P182, DOI 10.1038/sj.npp.1300843; Wang T., 2016, SCI REP, V6; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Yan H, 2009, NEUROIMAGE, V47, P1579, DOI 10.1016/j.neuroimage.2009.05.080	97	12	12	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	FEB 26	2018	339						106	113		10.1016/j.bbr.2017.11.014			8	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	FU9JX	WOS:000424173300012	29154809				2021-06-18	
J	Lin, HF; Chen, YD; Chen, SC				Lin, Heng-Fu; Chen, Ying-Da; Chen, Shyr-Chyr			Value of diagnostic and therapeutic laparoscopy for patients with blunt abdominal trauma: A 10-year medical center experience	PLOS ONE			English	Article							NONOPERATIVE MANAGEMENT; INJURIES; SURGERY; ASSOCIATION; GUIDELINES	Laparoscopy has been used for the diagnosis and treatment for hemodynamically stable patients with penetrating abdominal trauma. This study evaluated whether diagnostic and therapeutic laparoscopy can be used as effectively in select patients with blunt abdominal trauma. All hemodynamically stable patients undergoing operations for blunt abdominal trauma over a 10-year period (2006-2015) at a tertiary medical center were included. Patients undergoing laparotomy were categorized as group A. Patients who underwent laparoscopy were categorized as group B. The clinical outcomes of the 2 groups were compared. There were 139 patients in group A and 126 patients in group B. Group A patients were more severely injured (mean injury severity score of 23.3 vs. 18.9, P < .001) and had a higher frequency of traumatic brain injuries (25.2% vs. 14.3%, P = .039). The sensitivity and specificity of diagnostic laparoscopy for patients in group B was 99.1% and 100.0%, respectively. No non-therapeutic laparotomies were performed in group B, and the success rate of therapeutic laparoscopy was 92.0% (103/112) for patients with significant intra-abdominal injuries. Patients in the 2 groups had similar perioperative and postoperative outcomes in terms of operation times, blood loss, blood transfusion requirements, mortality, and complications (all, P > .05). Laparoscopy is a feasible and safe tool for the diagnosis and treatment of hemodynamically stable patients with blunt abdominal trauma who require surgery.	[Lin, Heng-Fu; Chen, Ying-Da] Far Eastern Mem Hosp, Dept Surg, New Taipei, Taiwan; [Lin, Heng-Fu; Chen, Shyr-Chyr] Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan; [Lin, Heng-Fu; Chen, Shyr-Chyr] Natl Taiwan Univ, Coll Med, Taipei, Taiwan	Chen, SC (corresponding author), Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan.; Chen, SC (corresponding author), Natl Taiwan Univ, Coll Med, Taipei, Taiwan.	scchen@ntu.edu.tw		Lin, Heng Fu/0000-0002-5466-9231; CHEN, SHYR-CHYR/0000-0002-5858-3013			Ahmed N, 2005, J AM COLL SURGEONS, V201, P213, DOI 10.1016/j.jamcollsurg.2005.04.021; Carobbi A, 2010, SURG ENDOSC, V24, P1325, DOI 10.1007/s00464-009-0768-9; Chen RJ, 1998, J TRAUMA, V44, P691, DOI 10.1097/00005373-199804000-00024; Chestovich PJ, 2015, J TRAUMA ACUTE CARE, V78, P1076, DOI 10.1097/TA.0000000000000655; Choi YB, 2003, SURG ENDOSC, V17, P421, DOI 10.1007/s00464-002-8808-8; Como JJ, 2010, J TRAUMA, V68, P721, DOI 10.1097/TA.0b013e3181cf7d07; IVATURY RR, 1993, J TRAUMA, V34, P822, DOI 10.1097/00005373-199306000-00013; Johnson JJ, 2013, AM J SURG, V205, P317, DOI 10.1016/j.amjsurg.2012.10.021; JOSEPHS LG, 1994, J TRAUMA, V36, P815, DOI 10.1097/00005373-199406000-00011; Kawahara NT, 2009, J TRAUMA, V67, P589, DOI 10.1097/TA.0b013e3181a60593; Koto MZ, 2015, J LAPAROENDOSC ADV S, V25, P730, DOI 10.1089/lap.2015.0042; Lee PC, 2014, SURG INNOV, V21, P155, DOI 10.1177/1553350612474496; Lim KH, 2015, WORLD J EMERG SURG, V10, DOI 10.1186/s13017-015-0007-8; Lin HF, 2015, AM J SURG, V210, P326, DOI 10.1016/j.amjsurg.2014.11.009; Lin HF, 2014, SURG INNOV, V21, P355, DOI 10.1177/1553350613505717; Lin HF, 2010, WORLD J SURG, V34, P1653, DOI 10.1007/s00268-010-0485-5; Nicolau AE, 2011, CHIRURGIA-BUCHAREST, V106, P59; O'Malley E, 2013, WORLD J SURG, V37, P113, DOI 10.1007/s00268-012-1790-y; Peitzman AB, 2000, J TRAUMA, V49, P177, DOI 10.1097/00005373-200008000-00002; Sauerland S, 2006, SURG ENDOSC, V20, P14, DOI 10.1007/s00464-005-0564-0; Sitnikov V, 2009, SURG ENDOSC, V23, P125, DOI 10.1007/s00464-008-9910-3; SMITH RS, 1995, AM J SURG, V170, P632; Uranues S, 2015, WORLD J SURG, V39, P1381, DOI 10.1007/s00268-014-2904-5; Velmahos GC, 2003, ARCH SURG-CHICAGO, V138, P844, DOI 10.1001/archsurg.138.8.844; Zafar SN, 2015, AM J SURG, V209, P627, DOI 10.1016/j.amjsurg.2014.12.011	25	12	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2018	13	2							e0193379	10.1371/journal.pone.0193379			14	Multidisciplinary Sciences	Science & Technology - Other Topics	FX1SB	WOS:000425831000051	29470527	DOAJ Gold, Green Published			2021-06-18	
J	Albrecht, JS; Afshar, M; Stein, DM; Smith, GS				Albrecht, Jennifer S.; Afshar, Majid; Stein, Deborah M.; Smith, Gordon S.			Association of Alcohol With Mortality After Traumatic Brain Injury	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						alcohol; mortality; traumatic brain injury	SUBSTANCE-ABUSE; HEAD-INJURY; ETHANOL; INTOXICATION; OUTCOMES; MODERATE; LEVEL; SCALE; RISK; COMA	Although alcohol exposure results in reducedmortality after traumatic brain injury (TBI) in animal models, clinical trials based on proposed mechanisms have been disappointing and have reported conflicting results. Methodological issues common to many of these clinical studies may have contributed to the spurious results. Our objective was to evaluate the association between blood alcohol concentration (BAC) and in-hospitalmortality after TBI, and overcome methodological problems of prior studies. We conducted a retrospective cohort study on individuals treated for isolated TBI (n = 1,084) at the R Adams Cowley Shock Trauma Center (Baltimore, Maryland) from 1997 to 2012. We excluded individuals with injury to other body regions and examined multiple cutpoints of BAC. Our primary outcome was in-hospital mortality. In adjusted logistic regression models, the upper level of each blood alcohol categorization from 0.10 g/dL (odds ratio = 0.63, 95% confidence interval: 0.40, 0.97) through 0.30 g/dL (odds ratio = 0.25, 95% confidence interval: 0.08, 0.84) was associated with reduced risk of mortality after TBI compared with individuals with undetectable BAC. In sensitivity analyses among individuals without penetrating brain injuries (95% firearm-related) (n = 899), the protective association was eliminated. This study provides evidence that the observed protective association between BAC and in-hospitalmortality after TBI resulted from bias introduced by inclusion of penetrating injuries.	[Albrecht, Jennifer S.; Smith, Gordon S.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA; [Afshar, Majid] Loyola Univ, Dept Publ Hlth Sci, Chicago, IL 60611 USA; [Stein, Deborah M.] Univ Maryland, Med Ctr, R Adams Cowley Shock Trauma Ctr, Dept Surg,Div Surg Crit Care, Baltimore, MD 21201 USA; [Smith, Gordon S.] Univ Maryland, Natl Study Ctr Trauma & Emergency Med Serv, Shock Trauma & Anesthesiol Res STAR Organized Res, Baltimore, MD 21201 USA	Albrecht, JS (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Med Sch Teaching Facil 334C, 10 South Pine St, Baltimore, MD 21201 USA.	jalbrecht@som.umaryland.edu	Afshar, Majid/AAD-8365-2019	Afshar, Majid/0000-0002-6368-4652; Stein, Deborah/0000-0003-3683-3963; Albrecht, Jennifer/0000-0003-4838-2274; Smith, Gordon/0000-0002-2911-3071	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12HD43489, K23AA024503, R01AA18707]; Agency for Healthcare Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [1K01HS024560]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K01HS024560] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD043489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA018707, K23AA024503] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (grants K12HD43489 (to J.S.A.), K23AA024503 (to M.A.), and R01AA18707 (to G.S.S.)) and the Agency for Healthcare Research and Quality (grant 1K01HS024560 (to J.S.A.)).	Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; Berry C, 2011, AM SURGEON, V77, P1416; Berry C, 2010, AM SURGEON, V76, P1067; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Branas CC, 2016, EPIDEMIOL REV, V38, P32, DOI 10.1093/epirev/mxv010; Brennan JH, 2015, J CLIN NEUROSCI, V22, P1375, DOI 10.1016/j.jocn.2015.02.030; Carroll CP, 2012, NEUROSURGERY, V71, P1064, DOI 10.1227/NEU.0b013e31826f7c16; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; Chen CM, 2012, J STUD ALCOHOL DRUGS, V73, P531, DOI 10.15288/jsad.2012.73.531; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kim H, 2008, J TRAUMA, V65, P1287, DOI 10.1097/TA.0b013e31817196f5; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Lange RT, 2007, NEUROPSYCHOLOGY, V21, P590, DOI 10.1037/0894-4105.21.5.590; Lustenberger T, 2011, J NEUROTRAUM, V28, P1699, DOI 10.1089/neu.2011.1866; Marr AL., 2004, CENTRAL NERVOUS SYST; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; No authors listed. Rating the severity of tissue damage, 1971, JAMA-J AM MED ASSOC, V215, P277; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Opreanu RC, 2010, J AM COLL SURGEONS, V210, P997, DOI 10.1016/j.jamcollsurg.2010.01.036; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Pruitt BA, 2001, J TRAUMA, V51, pS1, DOI 10.1097/00005373-200108001-00001; Raj R, 2015, J NEUROTRAUM, V32, P95, DOI 10.1089/neu.2014.3488; Rapoport MJ, 2012, CNS DRUGS, V26, P111, DOI 10.2165/11599560-000000000-00000; Rothman K, MODERN EPIDEMIOLOGY; Rundhaug NP, 2015, J NEUROSURG, V122, P211, DOI 10.3171/2014.9.JNS14322; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; Schisterman EF, 2009, EPIDEMIOLOGY, V20, P488, DOI 10.1097/EDE.0b013e3181a819a1; Shandro JR, 2009, J TRAUMA, V66, P1584, DOI 10.1097/TA.0b013e318182af96; Talving P, 2010, J TRAUMA, V68, P357, DOI 10.1097/TA.0b013e3181bb80bf; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ., 1995, GUIDELINES SURVEILLA; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Willis C., 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003986.PUB2; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275	40	12	12	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262	1476-6256		AM J EPIDEMIOL	Am. J. Epidemiol.	FEB	2018	187	2					233	241		10.1093/aje/kwx254			9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	FU4KD	WOS:000423821100007	28641392	Green Published, Bronze			2021-06-18	
J	Fitzpatrick, AC; Naylor, AS; Myler, P; Robertson, C				Fitzpatrick, Anna C.; Naylor, Adam S.; Myler, Peter; Robertson, Colin			A three-year epidemiological prospective cohort study of rugby league match injuries from the European Super League	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Epidemiology; Sports injuries; Injury incidence; Injury severity	DATA-COLLECTION PROCEDURES; CONSENSUS STATEMENT; TRAINING INJURIES; TEAM SPORTS; DEFINITIONS; FOOTBALL; SURVEILLANCE; DEBATE; UNION; RATES	Objectives: Conduct a comprehensive epidemiological study of match injury characteristics (incidence, severity, causes, diagnostics, and temporal trends) in professional rugby league. Design: Prospective cohort design. Methods: Data was captured over the 2013, '14, and '15 seasons, collected via an online-reporting survey tool, and underpinned by nominal group technique-agreed definitions. Injury details were provided by club medical staff in accordance to the survey fields from all European Super League teams (e.g. injury occurrence/return dates, diagnosis, mechanism, recurrence). All time-loss injuries have been reported. Results: Injury incidence of 57 injuries/1000 h has been observed over the three-year period, with an average of 34 days missed per injury. The final 20-min period was the most significant period for injury occurrence, and higher incidence of injury/1000 h played was during the start of the season in February, although an absolute injury risk for injury frequency was shown in April due to the greatest playing time. Forward positions reported the highest injury incidence whilst tackle activities were the most frequent mechanism of injury. Concussions and hamstring strains (5 injuries/1000 h) were the most commonly diagnosed injuries, although the knee joint region (10 injuries/1000 H) was the most frequently injured area. Conclusions: In light of the most common injury diagnoses, mechanisms, identified seasonal risk, and time of match, the data should look to inform player preparation in terms of physical conditioning and tackle technique in order to optimise player welfare and availability for participation. (C) 2017 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Fitzpatrick, Anna C.; Naylor, Adam S.; Myler, Peter; Robertson, Colin] Univ Bolton, Sch Sport & Biomed Sci, Bolton, England	Fitzpatrick, AC (corresponding author), Univ Bolton, Sch Sport & Biomed Sci, Bolton, England.	A.Fitzpatrick@bolton.ac.uk		Naylor, Adam/0000-0002-7340-8109; Robertson, Colin/0000-0002-6186-8466; Myler, Peter/0000-0003-3611-1979; Fitzpatrick, Anna/0000-0002-4200-2886	Rugby Football League	Part funded by the Rugby Football League.	Brooks JHM, 2006, SPORTS MED, V36, P459, DOI 10.2165/00007256-200636060-00001; Ekegren CL, 2016, SPORTS MED, V46, P49, DOI 10.1007/s40279-015-0410-z; England professional rugby injury surveillance steering group (RFU), 201516 RFU; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; Fuller CW, 2007, CLIN J SPORT MED, V17, P177, DOI 10.1097/JSM.0b013e31803220b3; Fuller CW, 2006, SCAND J MED SCI SPOR, V16, P83, DOI 10.1111/j.1600-0838.2006.00528.x; Gabbett TJ, 2011, J SCI MED SPORT, V14, P210, DOI 10.1016/j.jsams.2011.01.002; Gabbett TJ, 2008, J STRENGTH COND RES, V22, P625, DOI 10.1519/JSC.0b013e3181635a6a; Gissane C, 2003, OCCUP MED-OXFORD, V53, P512, DOI 10.1093/occmed/kqg103; Gissane C, 1998, BRIT J SPORT MED, V32, P149, DOI 10.1136/bjsm.32.2.149; Gissane C, 2003, AM J SPORT MED, V31, P954, DOI 10.1177/03635465030310063501; Gissane C, 2001, CLEVE MED J, V4, P147; Hodgson L, 2007, CLIN J SPORT MED, V17, P188, DOI 10.1097/JSM.0b013e3180547513; Hodgson L, 2006, CLIN J SPORT MED, V16, P305, DOI 10.1097/00042752-200607000-00004; Hoskins W, 2006, J SCI MED SPORT, V9, P46, DOI 10.1016/j.jsams.2006.03.013; King DA, 2009, J SCI MED SPORT, V12, P12, DOI 10.1016/j.jsams.2007.12.001; King D, 2014, INT J SPORTS SCI COA, V9, P417, DOI 10.1260/1747-9541.9.2.417; King DA, 2010, SPORTS MED, V40, P163, DOI 10.2165/11319740-000000000-00000; McKay CD, 2014, BRIT J SPORT MED, V48, P57, DOI 10.1136/bjsports-2013-092860; O'Connor D., 2011, SPORT HLTH, V29, P17; Orchard J, 2002, BRIT J SPORT MED, V36, P39, DOI 10.1136/bjsm.36.1.39; Orchard J., 2004, SPORT HLTH, V22, P11; Orchard J, 2007, CLIN J SPORT MED, V17, P192, DOI 10.1097/JSM.0b013e3180547527; Orchard JW, 2013, AM J SPORT MED, V41, P734, DOI 10.1177/0363546513476270; Phillips LH, 2000, BRIT J SPORT MED, V34, P133, DOI 10.1136/bjsm.34.2.133; Twist C, 2014, INT J SPORT PHYSIOL, V9, P925, DOI 10.1123/ijspp.2013-0270; Williams S, 2013, SPORTS MED, V43, P1043, DOI 10.1007/s40279-013-0078-1	27	12	12	1	14	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	FEB	2018	21	2					160	165		10.1016/j.jsams.2017.08.012			6	Sport Sciences	Sport Sciences	FX5TZ	WOS:000426144600011	28866109				2021-06-18	
J	Jackson, TC; Kotermanski, SE; Jackson, EK; Kochanek, PM				Jackson, Travis C.; Kotermanski, Shawn E.; Jackson, Edwin K.; Kochanek, Patrick M.			BrainPhys (R) increases neurofilament levels in CNS cultures, and facilitates investigation of axonal damage after a mechanical stretch-injury in vitro	EXPERIMENTAL NEUROLOGY			English	Article						Mechanical stretch-injury; BrainPhys (R); Neurofilaments; TBI; RBM5	TRAUMATIC BRAIN-INJURY; CORTICAL-NEURONS; MILD; ACTIVATION; PROTEIN; CELLS; ASTROCYTES; MODEL; CREB; TAU	Neurobasal (R)/B27 is a gold standard culture media used to study primary neurons in vitro. An alternative media (BrainPhys (R)/SM1) was recently developed which robustly enhances neuronal activity vs. Neurobasal (R) or DMEM. To the best of our knowledge BrainPhys (R) has not been explored in the setting of neuronal injury. Here we characterized the utility of BrainPhys (R) in a model of in vitro mechanical-stretch injury. Methods/results: Primary rat cortical neurons were maintained in classic Neurobasal (R), or sequentially maintained in Neurocult (R) followed by BrainPhys (R) (hereafter simply referred to as "BrainPhys (R) maintained neurons"). The levels of axonal markers and proteins involved in neurotransmission were compared on day in vitro 10 (DIV10). BrainPhys (R) maintained neurons had higher levels of GluN2B, GluR1, Neurofilament light/heavy chain (NF-L & NF-H), and protein phosphatase 2 A (PP2A) vs. neurons in Neurobasal (R). Mechanical stretch-injury (50 ms/54% biaxial stretch) to BrainPhys (R) maintained neurons modestly (albeit significantly) increased 24 h lactate dehydrogenase (LDH) levels but markedly decreased axonal NF-L levels post-injury vs. uninjured controls or neurons given a milder 38% stretch-injury. Furthermore, two 54% stretch-injuries (in tandem) exacerbated 24 h LDH release, increased alpha-spectrin breakdown products (SBDPs), and decreased Tau levels. Also, BrainPhys (R) maintained cultures had decreased markers of cell damage 24 h after a single 54% stretch-injury vs. neurons in Neurobasal (R). Finally, we tested the hypothesis that lentivirus mediated overexpression of the pro-death protein RBM5 exacerbates neuronal and/or axonal injury in primary CNS cultures. RBM5 overexpression vs. empty-vector controls increased 24 h LDH release, and SBDP levels, after a single 54% stretch-injury but did not affect NF-L levels or Tau. Conclusion: BrainPhys (R) is a promising new reagent which facilities the investigation of molecular targets involved in axonal and/or neuronal injury in vitro.	[Jackson, Travis C.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Childrens Hosp Pittsburgh,UPMC,John G Rangos Res, 6th Floor,4401 Penn Ave, Pittsburgh, PA 15224 USA; [Jackson, Travis C.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Scaife Hall,3550 Terrace St, Pittsburgh, PA USA; [Kotermanski, Shawn E.; Jackson, Edwin K.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Bridgeside Point Bldg 1,100 Technol Dr, Pittsburgh, PA USA	Jackson, TC (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Childrens Hosp Pittsburgh,UPMC,John G Rangos Res, 6th Floor,4401 Penn Ave, Pittsburgh, PA 15224 USA.	jacksontc@upmc.edu		Jackson, Edwin/0000-0002-8101-6009	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS088145];  [R21NS098057]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS088145, R21NS098057] Funding Source: NIH RePORTER	This work was supported by NIH/NINDS grant R21NS088145 to TCJ and by grant R21NS098057 to TCJ.	Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Al Nimer F., 2015, PLOS ONE, V10; Amin N, 1997, NEUROCHEM INT, V30, P271, DOI 10.1016/S0197-0186(96)00092-7; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Bahrami Farideh, 2013, Iranian Biomedical Journal, V17, P101, DOI 10.6091/ibj.11242.2013; Bardy C, 2015, P NATL ACAD SCI USA, V112, pE2725, DOI 10.1073/pnas.1504393112; Bergman J., 2016, NEUROL NEUROIMMUNOL, V3; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Cavalcanti-Adam EA, 2002, J BONE MINER RES, V17, P2130, DOI 10.1359/jbmr.2002.17.12.2130; Cheng P, 2015, J NEUROL SCI, V359, P48, DOI 10.1016/j.jns.2015.10.025; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Ellis EF, 2007, J NEUROCHEM, V101, P1463, DOI 10.1111/j.1471-4159.2007.04515.x; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Ferrario CR, 2013, J NEUROPHYSIOL, V110, P131, DOI 10.1152/jn.01011.2012; Geranmayeh M. H., 2015, Iranian Journal of Veterinary Medicine, V9, P163; Goddeyne C, 2015, J NEUROPHYSIOL, V113, P3268, DOI 10.1152/jn.00970.2014; Goforth PB, 2011, J NEUROPHYSIOL, V105, P2350, DOI 10.1152/jn.00467.2010; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Guo GJ, 2016, CELL REP, V14, P956, DOI 10.1016/j.celrep.2015.12.089; Hall ANB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159442; Harrill JA, 2015, IN VITRO CELL DEV-AN, V51, P612, DOI 10.1007/s11626-015-9873-3; Hogins J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025633; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Jackson TC, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.187; Jackson TC, 2015, J CEREBR BLOOD F MET, V35, P655, DOI 10.1038/jcbfm.2014.242; Kevenaar JT, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00044; Kobayashi T, 2011, INT J CANCER, V128, P304, DOI 10.1002/ijc.25345; KOSIK KS, 1987, J NEUROSCI, V7, P3142; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Loiselle JJ, 2016, HELIYON, V2, DOI 10.1016/j.heliyon.2016.e00204; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Marx V, 2013, NATURE, V496, P253, DOI 10.1038/496253a; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Otani N, 2006, J CLIN NEUROSCI, V13, P934, DOI 10.1016/j.jocn.2005.10.018; Petry FR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094251; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Ren Ping, 2007, Fen Zi Xi Bao Sheng Wu Xue Bao, V40, P79; Rintala-Maki ND, 2004, APOPTOSIS, V9, P475, DOI 10.1023/B:APPT.0000031455.79352.57; Sakamoto K, 2011, J NEUROCHEM, V116, P1, DOI 10.1111/j.1471-4159.2010.07080.x; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Shao C, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-123; Shao C, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-160; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shin SJ, 2006, STEM CELLS, V24, P125, DOI 10.1634/stemcells.2004-0150; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; Smith M, 2016, EXP NEUROL, V286, P107, DOI 10.1016/j.expneurol.2016.10.002; Su ZZ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0815-7; Sun Y, 2012, BIOINTERPHASES, V7, DOI 10.1007/s13758-012-0029-7; Tan XL, 2016, NEUROPHARMACOLOGY, V108, P382, DOI 10.1016/j.neuropharm.2016.05.001; Tauskela JS, 2008, J BIOL CHEM, V283, P34667, DOI 10.1074/jbc.M805624200; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; Thomson CE, 2006, J NEUROSCI RES, V84, P1703, DOI 10.1002/jnr.21084; Tzekov R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153608; Valor LM, 2010, CELL DEATH DIFFER, V17, P1636, DOI 10.1038/cdd.2010.40; Wang CC, 2011, NEURON, V72, P789, DOI 10.1016/j.neuron.2011.09.023; Wang Ke, 2012, J Cell Death, V5, P1, DOI 10.4137/JCD.S9073; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Wright AD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150215; Yang WJ, 2017, ACTA NEUROL SCAND, V135, P622, DOI 10.1111/ane.12644; Ye ZC, 1998, GLIA, V22, P237, DOI 10.1002/(SICI)1098-1136(199803)22:3<237::AID-GLIA3>3.0.CO;2-2; Yuan A, 2015, MOL PSYCHIATR, V20, P986, DOI [10.1038/mp.2015.99, 10.1038/mp.2015.45]; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang JL, 2015, INT J BIOCHEM CELL B, V60, P43, DOI 10.1016/j.biocel.2014.12.020; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhu QZ, 1997, EXP NEUROL, V148, P299, DOI 10.1006/exnr.1997.6654	75	12	12	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2018	300						232	246		10.1016/j.expneurol.2017.11.013			15	Neurosciences	Neurosciences & Neurology	FT1JZ	WOS:000422893300022	29199132	Green Accepted, Other Gold			2021-06-18	
J	Keasey, MP; Jia, CH; Pimentel, LF; Sante, RR; Lovins, C; Hagg, T				Keasey, Matthew P.; Jia, Cuihong; Pimentel, Lylyan F.; Sante, Richard R.; Lovins, Chiharu; Hagg, Theo			Blood vitronectin is a major activator of LIF and IL-6 in the brain through integrin-FAK and uPAR signaling	JOURNAL OF CELL SCIENCE			English	Article						FAK; IL-6; Integrin; LIF; Vitronectin; uPAR	LEUKEMIA INHIBITORY FACTOR; FOCAL ADHESION KINASE; FACTOR MESSENGER-RNA; NECROSIS-FACTOR-ALPHA; CELL SELF-RENEWAL; UROKINASE RECEPTOR; INFLAMMATORY RESPONSES; EXTRACELLULAR-MATRIX; BINDING-SITE; SPINAL-CORD	We defined how blood-derived vitronectin (VTN) rapidly and potently activates leukemia inhibitory factor (LIF) and pro-inflammatory interleukin 6 (IL-6) in vitro and after vascular injury in the brain. Treatment with VTN (but not fibrinogen, fibronectin, laminin-111 or collagen-I) substantially increased LIF and IL-6 within 4 h in C6-astroglioma cells, while VTN-/- mouse plasma was less effective than that from wild-type mice. LIF and IL-6 were induced by intracerebral injection of recombinant human (rh)VTN in mice, but induction seen upon intracerebral hemorrhage was less in VTN-/- mice than in wild-type littermates. In vitro, VTN effects were inhibited by RGD, alpha v beta 3 and alpha v beta 5 integrin-blocking peptides and antibodies. VTN activated focal adhesion kinase (FAK; also known as PTK2), whereas pharmacological-or siRNA-mediated inhibition of FAK, but not PYK2, reduced the expression of LIF and IL-6 in C6 and endothelial cells and after traumatic cell injury. Dominant-negative FAK (Y397F) reduced the amount of injury-induced LIF and IL-6. Pharmacological inhibition or knockdown of uPAR (also known as PLAUR), which binds VTN, also reduced cytokine expression, possibly through a common target of uPAR and integrins. We propose that VTN leakage into tissues promotes inflammation. Integrin-FAK signaling is therefore a novel IL-6 and LIF regulation mechanism relevant to the inflammation and stem cell fields.	[Keasey, Matthew P.; Jia, Cuihong; Pimentel, Lylyan F.; Sante, Richard R.; Lovins, Chiharu; Hagg, Theo] East Tennessee State Univ, Quillen Coll Med, Dept Biomed Sci, Johnson City, TN 37614 USA; [Pimentel, Lylyan F.] Univ Fed Pernambuco, Keizo Asami Lab LIKA, Recife, PE, Brazil	Hagg, T (corresponding author), East Tennessee State Univ, Quillen Coll Med, Dept Biomed Sci, Johnson City, TN 37614 USA.	haggt1@etsu.edu		Jia, Cuihong/0000-0002-9693-0012	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG29493, C06RR0306551]; Quillen College of Medicine at East Tennessee State University; Conselho Nacional de Desenvolvimento Cientifico e TecnologicoConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [454077/2014-9]; Fundacao do Amparo a Ciencia e Tecnologia [AMD-0291-2.00/14]; Coordenadoria de Aperfeicoamento de Pessoal de Nivel Superior [88881.133822/2016-01]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR030651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG029493] Funding Source: NIH RePORTER	Funding was provided by National Institutes of Health (NIH) (R01 grant AG29493, and in part by C06RR0306551) and the Quillen College of Medicine at East Tennessee State University. L.F.P. was supported by grants from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (454077/2014-9), Fundacao do Amparo a Ciencia e Tecnologia (AMD-0291-2.00/14) and Coordenadoria de Aperfeicoamento de Pessoal de Nivel Superior (88881.133822/2016-01). Deposited in PMC for release after 12 months.	Antonov AS, 2011, J CELL PHYSIOL, V226, P469, DOI 10.1002/jcp.22356; Bang JY, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.005264; Banner LR, 1997, EXP NEUROL, V147, P1, DOI 10.1006/exnr.1997.6536; BANNER LR, 1994, P NATL ACAD SCI USA, V91, P7109, DOI 10.1073/pnas.91.15.7109; Bauer S, 2006, J NEUROSCI, V26, P12089, DOI 10.1523/JNEUROSCI.3047-06.2006; BORISH L, 1986, J IMMUNOL, V137, P1897; Butler B, 2005, J BIOL CHEM, V280, P14556, DOI 10.1074/jbc.M411765200; Carlson CD, 1996, GLIA, V18, P141, DOI 10.1002/(SICI)1098-1136(199610)18:2<141::AID-GLIA6>3.0.CO;2-3; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Cattavarayane S, 2015, BMC CELL BIOL, V16, DOI 10.1186/s12860-015-0051-y; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; Choi Y, 2010, PROTEOMICS, V10, P72, DOI 10.1002/pmic.200900146; Degryse B, 2005, J BIOL CHEM, V280, P24792, DOI 10.1074/jbc.M413954200; del Zoppo GJ, 2012, J CEREBR BLOOD F MET, V32, P919, DOI 10.1038/jcbfm.2012.11; Delimont D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099083; DERIGS HG, 1993, LEUKEMIA, V7, P630; Dowsing BJ, 2001, J NEUROTRAUM, V18, P1279, DOI 10.1089/089771501317095313; Erta M, 2012, INT J BIOL SCI, V8, P1254, DOI 10.7150/ijbs.4679; Gertz K, 2012, BRAIN, V135, P1964, DOI 10.1093/brain/aws075; Ghiso JAA, 2002, ONCOGENE, V21, P2513, DOI 10.1038/sj/onc/1205342; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Hayashi Y, 2007, STEM CELLS, V25, P3005, DOI 10.1634/stemcells.2007-0103; HAYMAN EG, 1985, EXP CELL RES, V160, P245, DOI 10.1016/0014-4827(85)90173-9; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; Herrera-Molina R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034295; Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153; Ishibashi T, 2006, NEURON, V49, P823, DOI 10.1016/j.neuron.2006.02.006; Iwasaki H, 2011, NAT IMMUNOL, V12, P1167, DOI 10.1038/ni.2137; Jang YC, 2000, SURGERY, V127, P696, DOI 10.1067/msy.2000.105858; Kang SS, 2013, TRANSL STROKE RES, V4, P533, DOI 10.1007/s12975-013-0265-2; Kang SS, 2012, J NEUROSCI, V32, P9277, DOI 10.1523/JNEUROSCI.1746-12.2012; Kang WS, 2008, BRAIN RES, V1228, P208, DOI 10.1016/j.brainres.2008.06.106; Keasey MP, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-35; Kerr BJ, 2004, EXP NEUROL, V188, P391, DOI 10.1016/j.expneurol.2004.04.012; Krueger M, 2015, J CEREBR BLOOD F MET, V35, P292, DOI 10.1038/jcbfm.2014.199; Lacroix S, 2002, J COMP NEUROL, V454, P213, DOI 10.1002/cne.10407; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; Leavesley DI, 2013, IUBMB LIFE, V65, P807, DOI 10.1002/iub.1203; Lee Y, 2004, J BIOMOL SCREEN, V9, P687, DOI 10.1177/1087057104268125; Li RG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037127; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Lin ZQ, 2003, J LEUKOCYTE BIOL, V73, P713, DOI 10.1189/jlb.0802397; Linker RA, 2002, NAT MED, V8, P620, DOI 10.1038/nm0602-620; Liu E, 2003, EMBO J, V22, P5036, DOI 10.1093/emboj/cdg503; Liu YK, 1997, FEBS LETT, V420, P112, DOI 10.1016/S0014-5793(97)01498-1; Longo A, 2015, MOLECULES, V20, P9879, DOI 10.3390/molecules20069879; Madsen CD, 2007, J CELL BIOL, V177, P927, DOI 10.1083/jcb.200612058; Magnussen S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105929; Magnussen SN, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3349-7; Matsuoka I, 1997, BRAIN RES, V776, P170, DOI 10.1016/S0006-8993(97)01015-9; Mauer J, 2015, TRENDS IMMUNOL, V36, P92, DOI 10.1016/j.it.2014.12.008; Memmo LM, 1998, J CELL SCI, V111, P425; Mi HY, 2001, J NEUROSCI, V21, P1538; Milner R, 2003, J IMMUNOL, V170, P3850, DOI 10.4049/jimmunol.170.7.3850; Milner R, 2007, J IMMUNOL, V178, P8158, DOI 10.4049/jimmunol.178.12.8158; Milner R, 2009, GLIA, V57, P714, DOI 10.1002/glia.20799; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Mracsko E, 2014, STROKE, V45, P2107, DOI 10.1161/STROKEAHA.114.005801; MURPHY GM, 1995, NEUROSCI LETT, V184, P48, DOI 10.1016/0304-3940(94)11165-F; Nagamoto-Combs K, 1999, J NEUROCHEM, V72, P1871, DOI 10.1046/j.1471-4159.1999.0721871.x; Nakanishi M, 2007, EUR J NEUROSCI, V25, P649, DOI 10.1111/j.1460-9568.2007.05309.x; Ochel HJ, 1999, MOL GENET METAB, V66, P24, DOI 10.1006/mgme.1998.2774; OSTBERG CO, 1995, FEBS LETT, V367, P93, DOI 10.1016/0014-5793(95)00509-8; Pan WH, 2008, AM J PHYSIOL-CELL PH, V294, pC1436, DOI 10.1152/ajpcell.00489.2007; Peruzzi B, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1651; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Rothaug M, 2016, BBA-MOL CELL RES, V1863, P1218, DOI 10.1016/j.bbamcr.2016.03.018; Schlaepfer DD, 2007, J BIOL CHEM, V282, P17450, DOI 10.1074/jbc.M610672200; SEIFFERT D, 1995, DEV DYNAM, V203, P71, DOI 10.1002/aja.1002030108; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; Shimamura N, 2006, STROKE, V37, P1902, DOI 10.1161/01.STR.0000226991.27540.f2; Sieg DJ, 2000, NAT CELL BIOL, V2, P249; Slack-Davis JK, 2007, J BIOL CHEM, V282, P14845, DOI 10.1074/jbc.M606695200; Sugiura S, 2000, EUR J NEUROSCI, V12, P457, DOI 10.1046/j.1460-9568.2000.00922.x; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; Suzuki S, 2009, J CEREBR BLOOD F MET, V29, P464, DOI 10.1038/jcbfm.2008.141; Tofaris GK, 2002, J NEUROSCI, V22, P6696; Tomasini-Johansson BR, 1998, BRIT J RHEUMATOL, V37, P620; Tornatore TF, 2011, AM J PHYSIOL-HEART C, V300, pH902, DOI 10.1152/ajpheart.00319.2010; Tsuruta Y, 2007, J IMMUNOL, V179, P7079, DOI 10.4049/jimmunol.179.10.7079; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; Vandenberghe M, 2013, P NATL ACAD SCI USA, V110, pE4839, DOI 10.1073/pnas.1310394110; Vogiagis D, 1999, J ENDOCRINOL, V160, P181, DOI 10.1677/joe.0.1600181; Wang J, 2006, J NEUROCHEM, V96, P148, DOI 10.1111/j.1471-4159.2005.03521.x; WEI Y, 1994, J BIOL CHEM, V269, P32380; Welser-Alves JV, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-157; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yang P, 2008, J NEUROSCI, V28, P2231, DOI 10.1523/JNEUROSCI.3574-07.2008; Zheng XX, 1995, P NATL ACAD SCI USA, V92, P12426, DOI 10.1073/pnas.92.26.12426; Zigmond RE, 2012, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00062	92	12	13	0	8	COMPANY BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND	0021-9533	1477-9137		J CELL SCI	J. Cell Sci.	FEB	2018	131	3							jcs202580	10.1242/jcs.202580			13	Cell Biology	Cell Biology	FX2UF	WOS:000425917200002	29222114	Green Published, Bronze			2021-06-18	
J	Song, H; Fang, SH; Gao, J; Wang, JX; Can, ZZ; Guo, ZY; Huang, QP; Qu, YQ; Zhou, H; Yu, JY				Song, Hai; Fang, Shanhua; Gao, Jing; Wang, Jiaxong; Can, Zhenzhen; Guo, Zeyun; Huang, Qiongping; Qu, Yongqang; Zhou, Hu; Yu, Jianyun			Quantitative Proteomic Study Reveals Up-Regulation of cAMP Signaling Pathway-Related Proteins in Mild Traumatic Brain Injury	JOURNAL OF PROTEOME RESEARCH			English	Article						mTBI; iTRAQ; proteomic analysis; cAMP signal process; Pde10a; Gnal	ITRAQ; PHOSPHODIESTERASE; EXPRESSION; PDE10A; PHOSPHORYLATION; CHROMATOGRAPHY; MECHANISMS; RECEPTORS; STRESS; SILAC	Traumatic brain injury (TBI), as a neurological injury, becomes a leading cause of disability and mortality due to lacking effective therapy. About 75% of TBI is mild traumatic brain injury (mTBI). However, the complex molecular mechanisms underlying mTBI pathophysiology remains to be elucidated. In this study, iTRAQ-based quantitative proteomic approach was employed to measure temporal-global proteome changes of rat brain tissues from different time points (1 day, 7 day and 6 months) post single mTBI (smTBI) and repetitive mTBI (rmTBI). A total of 5169 proteins were identified, of which, 237 proteins were significantly changed between control rats and mTBI model rats. Fuzzy c-means (FCM) clustering analysis classified these 237 proteins into six clusters according to their temporal pattern of protein abundance. Functional bioinformatics analysis and protein-protein interaction (PPI) network mapping of these FCM clusters showed that phosphodiesterase 10A (Pde10a) and guanine nucleotide-binding protein G (olf) subunit alpha (Gnal) were the node proteins in the cAMP signaling pathway. Other biological processes, such as cell adhesion, autophagy, myelination, microtubule depolymerization and brain development, were also over-represented in FCM clusters. Further Western Blot experiments confirmed that Pde10a and Gnal were acutely up-regulated in severity-dependent manner by mTBI, but these two proteins could not be down-regulated to basal level at the time point of 6 months post repetitive mTBI. Our study demonstrated that different severity of mTBI cause significant temporal profiling change at the proteomic level and pointed out the cAMP signaling pathway-related proteins, Pde10a and Gnal, may play important roles in the pathogenesis and recovery of mTBI.	[Song, Hai; Wang, Jiaxong; Qu, Yongqang; Yu, Jianyun] Kunming Med Univ, Dept Forens Med, Kunming 650032, Yunnan, Peoples R China; [Can, Zhenzhen; Guo, Zeyun] Kunming Med Univ, Dept Anat & Histol, Kunming 650032, Yunnan, Peoples R China; [Fang, Shanhua; Zhou, Hu] Shanghai Univ Tradit Chinese Med, E Inst Shanghai Municipal Educ Comm, 1200 Cai Lun Rd, Shanghai 201203, Peoples R China; [Gao, Jing; Huang, Qiongping; Zhou, Hu] Chinese Acad Sci, Shanghai Inst Mat Med, Dept Analyt Chem, Shanghai 201203, Peoples R China; [Gao, Jing; Huang, Qiongping; Zhou, Hu] Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China; [Song, Hai; Wang, Jiaxong] Kunming Med Univ, Affiliated Hosp 1, Dept Neurosurg, Kunming 650032, Yunnan, Peoples R China	Yu, JY (corresponding author), Kunming Med Univ, Dept Forens Med, Kunming 650032, Yunnan, Peoples R China.; Zhou, H (corresponding author), Shanghai Univ Tradit Chinese Med, E Inst Shanghai Municipal Educ Comm, 1200 Cai Lun Rd, Shanghai 201203, Peoples R China.; Zhou, H (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Dept Analyt Chem, Shanghai 201203, Peoples R China.; Zhou, H (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China.	zhouhu@simm.ac.cn; jianyunyu@sina.com			National Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81360467, 21375138]; Key Project of Application and Basis Research of Yunnan Province, China [2013FB104]; Chinese Academy of SciencesChinese Academy of Sciences; Chinese Academy of SciencesChinese Academy of Sciences [XDA12030203]	This research was supported by the National Nature Science Foundation of China (No. 81360467 and No. 21375138); the Key Project of Application and Basis Research of Yunnan Province, China (No. 2013FB104); the "one hundred talent program" of the Chinese Academy of Sciences and the Strategic Priority Research Program (No. XDA12030203) of the Chinese Academy of Sciences.	Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Butler D, 2006, AUTOPHAGY, V2, P234, DOI 10.4161/auto.2729; Chen ZG, 2017, ADDICT BIOL, V22, P1731, DOI 10.1111/adb.12435; Corvol JC, 2001, J NEUROCHEM, V76, P1585, DOI 10.1046/j.1471-4159.2001.00201.x; Coskran TM, 2006, J HISTOCHEM CYTOCHEM, V54, P1205, DOI 10.1369/JHC.6A6930.2006; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Deschamps C, 2009, EXP NEUROL, V219, P466, DOI 10.1016/j.expneurol.2009.06.020; DeSouza L, 2005, J PROTEOME RES, V4, P377, DOI 10.1021/pr049821j; Evans Teresa M, 2014, Transl Proteom, V3, P10; Fuchs T, 2013, NAT GENET, V45, P88, DOI 10.1038/ng.2496; Fujishige K, 1999, J BIOL CHEM, V274, P18438, DOI 10.1074/jbc.274.26.18438; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Geiger T, 2010, NAT METHODS, V7, P383, DOI 10.1038/nmeth.1446; Giorgi M, 2011, NEUROBIOL DIS, V43, P293, DOI 10.1016/j.nbd.2011.04.006; Girault JA, 2012, ADV EXP MED BIOL, V970, P407, DOI 10.1007/978-3-7091-0932-8_18; Gonsalvez D, 2016, NEUROPHARMACOLOGY, V110, P586, DOI 10.1016/j.neuropharm.2015.04.024; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Himanen JP, 2003, INT J BIOCHEM CELL B, V35, P130, DOI 10.1016/S1357-2725(02)00096-1; Imanishi T, 1997, EUR J PHARMACOL, V321, P273, DOI 10.1016/S0014-2999(96)00969-7; Karp NA, 2010, MOL CELL PROTEOMICS, V9, P1885, DOI 10.1074/mcp.M900628-MCP200; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lakshmanan R, 2010, NEUROCRIT CARE, V12, P324, DOI 10.1007/s12028-010-9342-5; Lizhnyak P. N., 2015, BRAIN NEUROTRAUMA MO; Lizhnyak PN, 2015, EXPERT REV PROTEOMIC, V12, P75, DOI 10.1586/14789450.2015.1000869; Lv L, 2017, J PROTEOMICS, V160, P74, DOI 10.1016/j.jprot.2017.03.012; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; Nakamura K, 2006, J CHROMATOGR A, V1106, P181, DOI 10.1016/j.chroma.2005.12.068; Nave KA, 2014, ANNU REV CELL DEV BI, V30, P503, DOI 10.1146/annurev-cellbio-100913-013101; Niccolini F, 2015, BRAIN, V138, P3016, DOI 10.1093/brain/awv214; Nishi A, 2008, J NEUROSCI, V28, P10460, DOI 10.1523/JNEUROSCI.2518-08.2008; Oliva AA, 2012, J NEUROCHEM, V123, P1019, DOI 10.1111/jnc.12049; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Poliak S, 2003, NAT REV NEUROSCI, V4, P968, DOI 10.1038/nrn1253; Rodriguez-Collazo PR, 2008, EXP CELL RES, V314, P1, DOI 10.1016/j.yexcr.2007.09.011; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Scheiermann C, 2007, SCIENCE, V318, P1472, DOI 10.1126/science.1149276; Schmidt C, 2014, RNA, V20, P406, DOI 10.1261/rna.041244.113; Song H, 2016, NEUROSCI LETT, V622, P95, DOI 10.1016/j.neulet.2016.04.048; Song XM, 2008, J PROTEOME RES, V7, P2952, DOI 10.1021/pr800072x; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Tao YM, 2013, PROTEOMICS, V13, P1314, DOI 10.1002/pmic.201200437; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Tzekov R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153608; Vemula SR, 2013, HUM MOL GENET, V22, P2510, DOI 10.1093/hmg/ddt102; Vuoristo JT, 2000, MOL PSYCHIATR, V5, P495, DOI 10.1038/sj.mp.4000758; Wang HX, 2012, J PROTEOME RES, V11, P487, DOI 10.1021/pr2008225; Wang YX, 2011, PROTEOMICS, V11, P2019, DOI 10.1002/pmic.201000722; Wisniewski JR, 2010, J PROTEOME RES, V9, P3280, DOI 10.1021/pr1002214; Yu CL, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00635; Zupanc GKH, 2007, PROTEOM CLIN APPL, V1, P1362, DOI 10.1002/prca.200700420	56	12	12	0	6	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1535-3893	1535-3907		J PROTEOME RES	J. Proteome Res.	FEB	2018	17	2					858	869		10.1021/acs.jproteome.7b00618			12	Biochemical Research Methods	Biochemistry & Molecular Biology	FV6ZK	WOS:000424730700010	29215295	Bronze			2021-06-18	
J	Wade, SL; Taylor, HG; Yeates, KO; Kirkwood, M; Zang, HY; McNally, K; Stacin, T; Zhang, NH				Wade, Shari L.; Taylor, Hudson Gerry; Yeates, Keith Owen; Kirkwood, Michael; Zang, Huaiyu; McNally, Kelly; Stacin, Terry; Zhang, Nanhua			Online Problem Solving for Adolescent Brain Injury: A Randomized Trial of 2 Approaches	JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS			English	Article						brain injury; problem solving; adolescence; randomized clinical trial	EXECUTIVE DYSFUNCTION; SOCIAL COMPETENCE; BEHAVIOR PROBLEMS; INTERVENTION; CHILDREN; TEEN; OUTCOMES; EFFICACY; DEFICITS; THERAPY	Objective: Adolescent traumatic brain injury (TBI) contributes to deficits in executive functioning and behavior, but few evidence-based treatments exist. We conducted a randomized clinical trial comparing Teen Online Problem Solving with Family (TOPS-Family) with Teen Online Problem Solving with Teen Only (TOPS-TO) or the access to Internet Resources Comparison (IRC) group. Methods: Children, aged 11 to 18 years, who sustained a complicated mild-to-severe TBI in the previous 18 months were randomly assigned to the TOPS-Family (49), TOPS-TO (51), or IRC group (52). Parent and self-report measures of externalizing behaviors and executive functioning were completed before treatment and 6 months later. Treatment effects were examined using linear regression models, adjusting for baseline symptom levels. Age, maternal education, and family stresses were examined as moderators. Results: The TOPS-Family group had lower levels of parent-reported executive dysfunction at follow-up than the TOPS-TO group, and differences between the TOPS-Family and IRC groups approached significance. Maternal education moderated improvements in parent-reported externalizing behaviors, with less educated parents in the TOPS-Family group reporting fewer symptoms. On the self-report Behavior Rating Inventory of Executive Functions, treatment efficacy varied with the level of parental stresses. The TOPS-Family group reported greater improvements at low stress levels, whereas the TOPS-TO group reported greater improvement at high-stress levels. The TOPS-TO group did not have significantly lower symptoms than the IRC group on any comparison. Conclusion: Findings support the efficacy of online family problem solving to address executive dysfunction and improve externalizing behaviors among youth with TBI from less advantaged households. Treatment with the teen alone may be indicated in high-stress families.	[Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA; [Taylor, Hudson Gerry] Case Western Univ, Dept Pediat, Cleveland, OH USA; [Taylor, Hudson Gerry] Univ Hosp Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA; [Yeates, Keith Owen] Univ Calgary, Dept Psychol, Calgary, AB, Canada; [Yeates, Keith Owen] Univ Calgary, Dept Pediat & Clin Neurosci, Calgary, AB, Canada; [Kirkwood, Michael] Childrens Hosp Colorado, Dept Phys Med & Rehabil, Aurora, CO USA; [Kirkwood, Michael] Univ Colorado, Sch Med, Aurora, CO USA; [Zang, Huaiyu; Zhang, Nanhua] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Zang, Huaiyu; Zhang, Nanhua] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [McNally, Kelly] Nationwide Childrens Hosp, Sect Pediat Psychol & Neuropsychol, Columbus, OH USA; [Stacin, Terry] Metrohlth Med Ctr, Dept Pediat, Cleveland, OH USA; [Stacin, Terry] Case Western Reserve Univ, Cleveland, OH 44106 USA	Wade, SL (corresponding author), Cincinnati Childrens Hosp Med Ctr, Dept Pediat, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892; McNally, Kelly/0000-0001-9278-9413; Zhang, Nanhua/0000-0001-5796-3404	National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services [H133B090010]	This study was supported by the National Institute on Disability, Independent Living, and Rehabilitation Research, formerly known as the National Institute on Disability and Rehabilitation Research (Grant No. H133B090010).	Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Achenbach TM, 1991, MANUAL SELF REPORT A; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; CDC, 2010, WEB BAS INJ STAT QUE; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gan C, 2010, BRAIN INJURY, V24, P651, DOI 10.3109/02699051003692142; Gioia G. A., 2000, BRIEF BEHAV RATING I; Isquith PK, 2004, BRIEF SR BEHAV RATIN; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Kurowski BG, 2014, JAMA PEDIATR, V168, P523, DOI 10.1001/jamapediatrics.2013.5070; Kurowski BG, 2013, PEDIATRICS, V132, pE158, DOI 10.1542/peds.2012-4040; Kurowski BG, 2013, ARCH PHYS MED REHAB, V94, P543, DOI 10.1016/j.apmr.2012.10.029; Kurowski BG, 2011, PM&R, V3, P836, DOI 10.1016/j.pmrj.2011.05.016; Luna B, 2009, ADV CHILD DEV BEHAV, V37, P233, DOI 10.1016/S0065-2407(09)03706-9; Moos R, 1994, LIFE STRESSORS SOCIA; Narad ME, 2015, J DEV BEHAV PEDIATR, V36, P700, DOI 10.1097/DBP.0000000000000208; Novakovic-Agopian T, 2011, J HEAD TRAUMA REHAB, V26, P325, DOI 10.1097/HTR.0b013e3181f1ead2; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2017, REHABIL PSYCHOL, V62, P290, DOI 10.1037/rep0000160; Wade SL, 2015, PEDIATRICS, V135, pE487, DOI 10.1542/peds.2014-1386; Wade SL, 2014, J HEAD TRAUMA REHAB, V29, P198, DOI 10.1097/HTR.0b013e31828f9fe8; Wade SL, 2012, HEALTH PSYCHOL, V31, P767, DOI 10.1037/a0028440; Wade SL, 2011, PEDIATRICS, V128, pE947, DOI 10.1542/peds.2010-3721; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d	30	12	12	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0196-206X	1536-7312		J DEV BEHAV PEDIATR	J. Dev. Behav. Pediatr.	FEB-MAR	2018	39	2					154	162					9	Behavioral Sciences; Psychology, Developmental; Pediatrics	Behavioral Sciences; Psychology; Pediatrics	GB9DU	WOS:000429375100082	29076889				2021-06-18	
J	Wang, YJ; Chen, KY; Kuo, LN; Wang, WC; Hsu, YW; Wong, HSC; Lin, CM; Liao, KH; Zhang, YF; Chiang, YH; Chang, WC				Wang, Yu-Jia; Chen, Kai-Yun; Kuo, Li-Na; Wang, Wen-Chang; Hsu, Yu-Wen; Wong, Henry Sung-Ching; Lin, Chien-Min; Liao, Kuo-Hsing; Zhang, Yan-Feng; Chiang, Yung-Hsiao; Chang, Wei-Chiao			The association between BDNF Val66Met polymorphism and emotional symptoms after mild traumatic brain injury	BMC MEDICAL GENETICS			English	Article						Mild traumatic brain injury; Genetic polymorphism; Brain-derived neurotrophic factor; Anxiety; Depression	MAJOR DEPRESSIVE DISORDER; NEUROTROPHIC FACTOR GENE; PSYCHIATRIC-DISORDERS; SEX-DIFFERENCES; HUMAN-MEMORY; ANXIETY; STRESS; ALLELE; METAANALYSIS; RECOVERY	Background: Brain-derived neurotrophic factor (BDNF) is one of the most abundant neurotrophins in the adult brain, and it plays important roles in modulating synaptic plasticity and synaptogenesis. This study attempted to elucidate the role of the BDNF variant rs6265 in emotional symptoms following mild traumatic brain injury (mTBI). Methods: To investigate the association between BDNF Val66Met polymorphism (rs6265) and emotional symptoms in mTBI patients, we recruited 192 mTBI patients and evaluated their Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) scores in the first and sixth week after mTBI. Results: The patients carrying the T allele of rs6265 had significantly higher BAI scores in the first week following mTBI. In addition, the patients carrying the T allele also showed higher scores of BDI in the first week. In the gender-specific subgroup analysis, the male patients carrying the T allele of rs6265 had higher scores of both BAI and BDI in the first and sixth week. Meanwhile, female patients carrying the T allele also had significantly higher scores of BDI in the first week following mTBI. Conclusions: This study provides evidence for the association between the BDNF variant rs6265 and emotional symptoms following mTBI.	[Wang, Yu-Jia; Chen, Kai-Yun; Chiang, Yung-Hsiao; Chang, Wei-Chiao] Taipei Med Univ, Coll Med Sci & Technol, Program Neural Regenerat Med, Taipei, Taiwan; [Wang, Yu-Jia; Kuo, Li-Na; Chang, Wei-Chiao] Taipei Med Univ, Wan Fang Hosp, Dept Pharm, Taipei, Taiwan; [Wang, Wen-Chang] Taipei Med Univ, Coll Med Sci & Technol, Program Translat Med, Taipei, Taiwan; [Kuo, Li-Na; Wong, Henry Sung-Ching; Chang, Wei-Chiao] Taipei Med Univ, Sch Pharm, Dept Clin Pharm, Taipei, Taiwan; [Hsu, Yu-Wen] Taipei Med Univ, Coll Med Sci & Technol, Program Translat Med, Taipei, Taiwan; [Hsu, Yu-Wen] Acad Sinica, Taipei, Taiwan; [Lin, Chien-Min] Taipei Med Univ, Shuang Ho Hosp, Dept Neurosurg, New Taipei, Taiwan; [Liao, Kuo-Hsing] Taipei Med Univ, Wan Fang Hosp, Dept Neurosurg, Taipei, Taiwan; [Zhang, Yan-Feng] HudsonAlpha Inst Biotechnol, Huntsville, AL USA; [Chiang, Yung-Hsiao] Taipei Med Univ Hosp, Dept Surg, Div Neurosurg, Taipei, Taiwan; [Chang, Wei-Chiao] Taipei Med Univ, Sch Pharm, Master Program Clin Pharmacogen & Pharmacoprote, Taipei, Taiwan; [Chang, Wei-Chiao] Kaohsiung Med Univ, Ctr Biomarkers & Biotech Drugs, Kaohsiung, Taiwan	Chiang, YH; Chang, WC (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, Program Neural Regenerat Med, Taipei, Taiwan.; Chang, WC (corresponding author), Taipei Med Univ, Wan Fang Hosp, Dept Pharm, Taipei, Taiwan.; Chang, WC (corresponding author), Taipei Med Univ, Sch Pharm, Dept Clin Pharm, Taipei, Taiwan.; Chiang, YH (corresponding author), Taipei Med Univ Hosp, Dept Surg, Div Neurosurg, Taipei, Taiwan.; Chang, WC (corresponding author), Taipei Med Univ, Sch Pharm, Master Program Clin Pharmacogen & Pharmacoprote, Taipei, Taiwan.; Chang, WC (corresponding author), Kaohsiung Med Univ, Ctr Biomarkers & Biotech Drugs, Kaohsiung, Taiwan.	ychiang@tmu.edu.tw; wcc@tmu.edu.tw	Zhang, Yanfeng/AAW-3915-2020	Zhang, Yanfeng/0000-0002-3859-3839; Chang, Wei-Chiao/0000-0002-8573-5924; Wang, Wen-Chang/0000-0003-3124-2136	Ministry of Health and WelfareMinistry of Health, Labour and Welfare, Japan [MOHW103-TDU-B-212-113001]; Ministry of Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [MOST105-2628-B-038-001-MY4]; National Health Research InstitutesNational Health Research Institutes, JapanNational Health Research Institutes - Taiwan [06D1-MMMOHW08]	This work was supported by grants from Ministry of Health and Welfare (MOHW103-TDU-B-212-113001), from Ministry of Science and Technology (MOST105-2628-B-038-001-MY4) and from National Health Research Institutes (06D1-MMMOHW08).	Advani T, 2009, INT J NEUROPSYCHOPH, V12, P583, DOI 10.1017/S1461145709000248; Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Autry AE, 2009, BIOL PSYCHIAT, V66, P84, DOI 10.1016/j.biopsych.2009.02.007; Balaratnasingam S, 2012, PHARMACOL THERAPEUT, V134, P116, DOI 10.1016/j.pharmthera.2012.01.006; Barbey AK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088733; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Boulle F, 2012, MOL PSYCHIATR, V17, P584, DOI 10.1038/mp.2011.107; Brunoni AR, 2008, INT J NEUROPSYCHOPH, V11, P1169, DOI 10.1017/S1461145708009309; Caldieraro MA, 2017, WORLD J BIOL PSYCHIA; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chan CB, 2017, J NEUROSCI RES, V95, P328, DOI 10.1002/jnr.23863; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cunha C, 2010, FRONT MOL NEUROSCI, V3, DOI 10.3389/neuro.02.001.2010; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Dincheva I, 2017, AM J PSYCHIAT, V174, P1203, DOI 10.1176/appi.ajp.2017.15121592; Duman CH, 2007, BIOL PSYCHIAT, V61, P661, DOI 10.1016/j.biopsych.2006.05.047; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Elzinga BM, 2011, PSYCHOPHARMACOLOGY, V214, P319, DOI 10.1007/s00213-010-1961-1; Gatt JM, 2009, MOL PSYCHIATR, V14, P681, DOI 10.1038/mp.2008.143; Hao R, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00306; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Herbert J, 2012, BRIT J PSYCHIAT, V201, P313, DOI 10.1192/bjp.bp.111.107037; Jiang R, 2017, PSYCHONEUROENDOCRINO, V79, P13, DOI 10.1016/j.psyneuen.2017.02.005; Jin HJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13929-5; Kaufman J, 2006, BIOL PSYCHIAT, V59, P673, DOI 10.1016/j.biopsych.2005.10.026; Kim JM, 2007, BIOL PSYCHIAT, V62, P423, DOI 10.1016/j.biopsych.2006.11.020; Korley FK, 2015, J HEAD TRAUMA REHABI; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; Li K., 2017, NEUROSCI B; Marshall S, 2015, BRAIN INJURY, V29, P688, DOI 10.3109/02699052.2015.1004755; Martinowich K, 2007, NAT NEUROSCI, V10, P1089, DOI 10.1038/nn1971; McAllister TW, 2012, J NEUROTRAUM, V29, P1111, DOI 10.1089/neu.2011.1930; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Moreno-Piovano GS, 2014, J STEROID BIOCHEM, V144, P243, DOI 10.1016/j.jsbmb.2014.08.001; Nagahara AH, 2011, NAT REV DRUG DISCOV, V10, P209, DOI 10.1038/nrd3366; Schosser A, 2017, INT J NEUROPSYCHOPH, V20, P782, DOI 10.1093/ijnp/pyx028; Smarr KL, 2011, ARTHRIT CARE RES, V63, pS454, DOI 10.1002/acr.20556; SOHRABJI F, 1995, P NATL ACAD SCI USA, V92, P11110, DOI 10.1073/pnas.92.24.11110; Taliaz D, 2010, MOL PSYCHIATR, V15, P80, DOI 10.1038/mp.2009.67; TEASDALE G, 1974, LANCET, V2, P81; Tripp A, 2012, AM J PSYCHIAT, V169, P1194, DOI 10.1176/appi.ajp.2012.12020248; Verhagen M, 2010, MOL PSYCHIATR, V15, P260, DOI 10.1038/mp.2008.109; Weaver SM, 2012, NEUROSCIENTIST, V18, P631, DOI 10.1177/1073858411435706; Webster MJ, 2002, DEV BRAIN RES, V139, P139, DOI 10.1016/S0165-3806(02)00540-0; Wei YC, 2017, J NEUROSCI RES, V95, P336, DOI 10.1002/jnr.23897; Wilson M, 2007, BRIT J ANAESTH, V99, P43, DOI 10.1093/bja/aem142; Zai CC, 2012, INT J NEUROPSYCHOPH, V15, P1037, DOI 10.1017/S1461145711001313; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	53	12	12	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2350			BMC MED GENET	BMC Med. Genet.	JAN 22	2018	19								13	10.1186/s12881-017-0518-0			7	Genetics & Heredity	Genetics & Heredity	FT4LG	WOS:000423126000001	29357818	DOAJ Gold, Green Published			2021-06-18	
J	Hagmeyer, S; Cristovao, JS; Mulvihill, JJE; Boeckers, TM; Gomes, CM; Grabrucker, AM				Hagmeyer, Simone; Cristovao, Joana S.; Mulvihill, John J. E.; Boeckers, Tobias M.; Gomes, Claudio M.; Grabrucker, Andreas M.			Zinc Binding to S100B Affords Regulation of Trace Metal Homeostasis and Excitotoxicity in the Brain	FRONTIERS IN MOLECULAR NEUROSCIENCE			English	Article						Zn; zinc; S100B; DAMP; synapse; calcium; excitotoxicity; zinc sensor	CALCIUM-BINDING; NEURITE OUTGROWTH; NEURONAL SURVIVAL; PROTEIN; S100-BETA; RECEPTOR; ASTROCYTES; MICE; ACTIVATION; CONTRIBUTE	Neuronal metal ions such as zinc are essential for brain function. In particular synaptic processes are tightly related to metal and protein homeostasis, for example through extracellular metal-binding proteins. One such protein is neuronal S100B, a calcium and zinc binding damage-associated molecular pattern (DAMP), whose chronic upregulation is associated with aging, Alzheimer's disease (AD), motor neuron disease and traumatic brain injury (TBI). Despite gained insights on the structure of S100B, it remains unclear how its calcium and zinc binding properties regulate its function on cellular level. Here we report a novel role of S100B in trace metal homeostasis, in particular the regulation of zinc levels in the brain. Our results show that S100B at increased extracellular levels is not toxic, persists at high levels, and is taken up into neurons, as shown by cell culture and biochemical analysis. Combining protein bioimaging and zinc quantitation, along with a zinc-binding impaired S100B variant, we conclude that S100B effectively scavenges zinc ions through specific binding, resulting in a redistribution of the intracellular zinc pool. Our results indicate that scavenging of zinc by increased levels of S100B affects calcium levels in vitro. Thereby S100B is able to mediate the cross talk between calcium and zinc homeostasis. Further, we investigated a possible new neuroprotective role of S100B in excitotoxicity via its effects on calcium and zinc homeostasis. Exposure of cells to zinc-S100B but not the zinc-binding impaired S100B results in an inhibition of excitotoxicity. We conclude that in addition to its known functions, S100B acts as sensor and regulator of elevated zinc levels in the brain and this metal-buffering activity is tied to a neuroprotective role.	[Hagmeyer, Simone] Ulm Univ, WG Mol Anal Synaptopathies, Dept Neurol, Neuroctr, Ulm, Germany; [Hagmeyer, Simone; Grabrucker, Andreas M.] Univ Limerick, Dept Biol Sci, Cellular Neurobiol & Neuronanotechnol Lab, Limerick, Ireland; [Hagmeyer, Simone; Mulvihill, John J. E.; Grabrucker, Andreas M.] Univ Limerick, Bernal Inst, Limerick, Ireland; [Cristovao, Joana S.; Gomes, Claudio M.] Univ Lisbon, Biosyst & Integrat Sci Inst, Fac Ciencias, Lisbon, Portugal; [Cristovao, Joana S.; Gomes, Claudio M.] Univ Lisbon, Dept Quim & Bioquim, Fac Ciencias, Lisbon, Portugal; [Mulvihill, John J. E.; Grabrucker, Andreas M.] Univ Limerick, HRI, Limerick, Ireland; [Boeckers, Tobias M.] Ulm Univ, Inst Anat & Cell Biol, Ulm, Germany	Grabrucker, AM (corresponding author), Univ Limerick, Dept Biol Sci, Cellular Neurobiol & Neuronanotechnol Lab, Limerick, Ireland.; Grabrucker, AM (corresponding author), Univ Limerick, Bernal Inst, Limerick, Ireland.; Grabrucker, AM (corresponding author), Univ Limerick, HRI, Limerick, Ireland.	andreas.grabrucker@ul.ie	Mulvihill, John/T-8131-2019; Mulvihill, John/AAA-9805-2021; Gomes, Claudio M/A-8152-2008; Cristovao, Joana/B-6179-2018	Mulvihill, John/0000-0003-0437-0351; Gomes, Claudio M/0000-0003-4662-6933; Cristovao, Joana/0000-0003-3833-0016; Grabrucker, Andreas/0000-0003-0005-4810	Evangelisches Studienwerk Villigst e.V; Else KronerFresenius Stiftung; Bial FoundationBial Foundation [PT/FB/BL-2014-343]; Fundacao para a Ciencia e a Tecnologia (Portugal)Portuguese Foundation for Science and Technology [UID/MULTI/04046/2013, PTDC/NEU-NMC/2138/2014, IF/01046/2014, SFRH/BD/101171/2014]	SH is a member of the international PhD program in molecular medicine of Ulm University and funded by Evangelisches Studienwerk Villigst e.V. AMG is supported by the Else KronerFresenius Stiftung. Bial Foundation is acknowledged through grant PT/FB/BL-2014-343 (to CMG), as well as Fundacao para a Ciencia e a Tecnologia (Portugal) for the support through projects UID/MULTI/04046/2013 (to BioISI), PTDC/NEU-NMC/2138/ 2014 and IF/01046/2014 (to CMG) and for the Ph.D. grant SFRH/BD/101171/2014 (to JSC). The authors gratefully acknowledge the professional technical assistance of Katharina Mangus (Ulm) and Rodrigo David (Lisbon). G. Fritz (University Freiburg) is gratefully acknowledged for the kind gift of the S100B plasmid. The authors would like to acknowledge networking support and STSM Grant (to JSC and SH) by the COST Action TD1304-the Network for the Biology of Zinc (Zinc-Net).	Adlard PA, 2010, J NEUROSCI, V30, P1631, DOI 10.1523/JNEUROSCI.5255-09.2010; Ahlgren H, 2014, J BIOL CHEM, V289, P9970, DOI 10.1074/jbc.M113.502914; Bajor M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154822; Barnham KJ, 2014, CHEM SOC REV, V43, P6727, DOI 10.1039/c4cs00138a; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; Bianchi R, 2011, J BIOL CHEM, V286, P7214, DOI 10.1074/jbc.M110.169342; Bluhm B, 2015, CEREBELLUM, V14, P119, DOI 10.1007/s12311-014-0606-z; Botelho HM, 2012, J BIOL CHEM, V287, P42233, DOI 10.1074/jbc.M112.396416; Botelho HM, 2012, METHODS MOL BIOL, V849, P373, DOI 10.1007/978-1-61779-551-0_25; Bush AI, 2013, J ALZHEIMERS DIS, V33, pS277, DOI 10.3233/JAD-2012-129011; Carvalho S.B., 2014, BIONANOIMAGING, P197, DOI [10.1016/B978-0-12-394431-3.00018-3, DOI 10.1016/B978-0-12-394431-3.00018-3]; Carvalho SB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076629; Charpentier TH, 2008, J MOL BIOL, V382, P56, DOI 10.1016/j.jmb.2008.06.047; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; Cristovao JS, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/9812178; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donato Rosario, 2010, Cardiovasc Psychiatry Neurol, V2010, P929712, DOI 10.1155/2010/929712; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; Frederickson C. J., 1994, Biological Signals, V3, P127; Frederickson CJ, 2006, EXP NEUROL, V198, P285, DOI 10.1016/j.expneurol.2005.08.030; Frederickson CJ, 2004, NEUROSCIENTIST, V10, P18, DOI 10.1177/1073858403255840; Frederickson CJ, 2001, BIOMETALS, V14, P353, DOI 10.1023/A:1012934207456; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; Fritz G, 2010, FEBS J, V277, P4578, DOI 10.1111/j.1742-4658.2010.07887.x; GERLAI R, 1995, LEARN MEMORY, V2, P26, DOI 10.1101/lm.2.1.26; Grabrucker A, 2009, CELL TISSUE RES, V338, P333, DOI 10.1007/s00441-009-0881-z; Grabrucker AM, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-65; Grabrucker S, 2014, BRAIN, V137, P137, DOI 10.1093/brain/awt303; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Kim CH, 2003, TOXICOL APPL PHARM, V190, P189, DOI 10.1016/S0041-008X(03)00167-4; Kim HSR, 2011, NEUROSCI LETT, V489, P148, DOI 10.1016/j.neulet.2010.12.005; Kleindienst A, 2013, ACTA NEUROCHIR, V155, P1351, DOI 10.1007/s00701-013-1720-2; Kocyla A, 2015, J INORG BIOCHEM, V152, P82, DOI 10.1016/j.jinorgbio.2015.08.024; Kubista H, 1999, NEUROSCIENCE, V90, P493, DOI 10.1016/S0306-4522(98)00422-9; Lasic E, 2016, J NEUROCHEM, V139, P309, DOI 10.1111/jnc.13754; Leal SS, 2013, J BIOL CHEM, V288, P25219, DOI 10.1074/jbc.M113.470740; Leclerc Estelle, 2010, Cardiovasc Psychiatry Neurol, V2010, P539581, DOI 10.1155/2010/539581; Leclerc E, 2009, BBA-MOL CELL RES, V1793, P993, DOI 10.1016/j.bbamcr.2008.11.016; Mazzone GL, 2014, J NEUROCHEM, V130, P598, DOI 10.1111/jnc.12748; Michetti F, 2012, J NEUROCHEM, V120, P644, DOI 10.1111/j.1471-4159.2011.07612.x; Mori T, 2010, GLIA, V58, P300, DOI 10.1002/glia.20924; Nishiyama H, 2002, NEUROSCI LETT, V321, P49, DOI 10.1016/S0304-3940(01)02549-6; Nishiyama H, 2002, P NATL ACAD SCI USA, V99, P4037, DOI 10.1073/pnas.052020999; Nuttall JR, 2012, NEUROTOX RES, V21, P128, DOI 10.1007/s12640-011-9291-6; Ostendorp T, 2007, EMBO J, V26, P3868, DOI 10.1038/sj.emboj.7601805; Ostendorp T, 2011, BBA-MOL CELL RES, V1813, P1083, DOI 10.1016/j.bbamcr.2010.10.006; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; Park JS, 1996, NEUROBIOL DIS, V3, P215, DOI 10.1006/nbdi.1996.0022; Pfaender S, 2014, METALLOMICS, V6, P960, DOI 10.1039/c4mt00008k; Ponath G, 2007, J NEUROIMMUNOL, V184, P214, DOI 10.1016/j.jneuroim.2006.12.011; Prakash A, 2015, FUND CLIN PHARMACOL, V29, P131, DOI 10.1111/fcp.12110; Sabel CE, 2009, ANAL BIOCHEM, V391, P74, DOI 10.1016/j.ab.2009.05.007; Saleh A, 2013, EXP NEUROL, V249, P149, DOI 10.1016/j.expneurol.2013.08.018; Sorci G, 1998, BBA-MOL CELL RES, V1448, P277, DOI 10.1016/S0167-4889(98)00134-7; Takeda Atsushi, 2010, Int J Alzheimers Dis, V2011, P491597, DOI 10.4061/2011/491597; Villarreal A, 2014, J NEUROCHEM, V131, P190, DOI 10.1111/jnc.12790; Villarreal A, 2011, J NEUROCHEM, V117, P321, DOI 10.1111/j.1471-4159.2011.07207.x; Vincent AM, 2007, ENDOCRINOLOGY, V148, P548, DOI 10.1210/en.2006-0073; Wang C, 2014, ACTA NEUROPATHOL, V127, P507, DOI 10.1007/s00401-013-1208-4; Wilder PT, 2005, BIOCHEMISTRY-US, V44, P5690, DOI 10.1021/bi0475830; Wilder PT, 2003, BIOCHEMISTRY-US, V42, P13410, DOI 10.1021/bi035334q; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Yanamandra K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005562; Yu WH, 2001, J NEUROSCI, V21, P2240; Zimmer Danna B, 2010, Cardiovasc Psychiatry Neurol, V2010, DOI 10.1155/2010/728052	67	12	12	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5099			FRONT MOL NEUROSCI	Front. Molec. Neurosci.	JAN 17	2018	10								456	10.3389/fnmol.2017.00456			15	Neurosciences	Neurosciences & Neurology	FS9YG	WOS:000422775200001	29386995	DOAJ Gold, Green Published			2021-06-18	
J	Davies, M; Jacobs, A; Brody, DL; Friess, SH				Davies, McKenzie; Jacobs, Addison; Brody, David L.; Friess, Stuart H.			Delayed Hypoxemia After Traumatic Brain Injury Exacerbates Long-Term Behavioral Deficits	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; delayed hypoxemia; long-term behavior; secondary injury; traumatic brain injury	CONTROLLED CORTICAL IMPACT; TAIL SUSPENSION TEST; COGNITIVE DEFICITS; CELL-DEATH; MODEL; MILD; DYSFUNCTION; HYPOXIA; ERYTHROPOIETIN; PROGESTERONE	Hypoxemia during initial stabilization of patients with severe traumatic brain injury (TBI) has been associated with poorer outcomes. However, the effects of delayed hypoxemia occurring during intensive care post-TBI on outcome is unclear. Pre-clinical models of TBI have rarely shown cognitive or behavioral deficits beyond 6 weeks post-injury and commonly have not included modeling of secondary insults. We have previously developed a murine model of TBI followed by delayed hypoxemia to model the secondary insult of hypoxemia and brain hypoxia occurring in the intensive care setting. Understanding long-term effects of delayed hypoxemia post-TBI in our murine model is critical for future testing of candidate therapeutics targeting secondary brain hypoxia. For this study, forty 5-week-old male mice were randomized to controlled cortical impact (CCI; N=24) or sham surgery (N=16). One day later, awake animals were randomized to 60min of hypoxemia or normoxemia. Six months after initial injury, animals underwent behavior testing (Morris water maze, social interaction, and tail suspension) before euthanasia for immunohistochemistry (IHC) assessments. At 6 months post-injury, mice experiencing CCI and hypoxemia (CCI+H) had longer swim distances to the hidden platform (51cm) compared to CCI alone (26cm) or sham animals (22cm). During social interaction assessments, CCI+H mice spent less time interacting with novel stimulus mice (79sec) than CCI alone (101sec) or sham animals (139sec). CCI+H had larger lesion volumes compared to CCI alone (14.0% vs. 9.9%; p<0.003). Glial fibrillary acidic protein IHC at 6 months post-injury demonstrated increased astrogliosis in the ipsilateral white matter of CCI+H compared to CCI alone. To summarize, this clinically relevant model of delayed hypoxia post-TBI resulted in long-term behavioral deficits and evidence of exacerbated structural injury.	[Davies, McKenzie; Jacobs, Addison; Friess, Stuart H.] Washington Univ, Dept Pediat, Sch Med, St Louis, MO 63110 USA; [Brody, David L.] Washington Univ, Dept Neurol, Sch Med, St Louis, MO 63110 USA	Friess, SH (corresponding author), Washington Univ, Sch Med, Campus Box 8208,One Childrens Pl, St Louis, MO 63110 USA.	Friess@wustl.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08-NS064051, R01 NS097721, R01 NS065069]; Department of Pediatrics, Washington University School of Medicine; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS097721, R01NS065069] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health grants K08-NS064051 (to S.H.F.), R01 NS097721 (to S.H.F.), R01 NS065069 (to D.L.B.), and the Department of Pediatrics, Washington University School of Medicine (to S.H.F.)	Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Arango MF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005400.pub3; Bajwa NM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146886; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bramlett HM, 2016, J NEUROTRAUM, V33, P538, DOI 10.1089/neu.2015.4116; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Browning M, 2014, J NEUROTRAUM, V31, pA108; Bruins B, 2013, ANESTH ANALG, V116, P838, DOI 10.1213/ANE.0b013e3182860fe7; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Cohen J., 2013, STAT POWER ANAL BEHA, V2       nd ed, DOI 10.4324/9780203771587.; CRAWLEY J, 1980, PHARMACOL BIOCHEM BE, V13, P167, DOI 10.1016/0091-3057(80)90067-2; Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P571, DOI 10.1016/j.neubiorev.2005.03.009; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; de Sousa A, 2012, J CLIN EXP NEUROPSYC, V34, P606, DOI 10.1080/13803395.2012.667067; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dixon CE, 2016, J NEUROTRAUM, V33, P553, DOI 10.1089/neu.2015.4122; Fang Raymond, 2015, J Trauma Acute Care Surg, V79, pS181, DOI 10.1097/TA.0000000000000769; Feng JF, 2012, J NEUROTRAUM, V29, P1167, DOI 10.1089/neu.2011.1867; Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Friess SH, 2015, J NEUROTRAUM, V32, P791, DOI 10.1089/neu.2014.3564; HANDLEY SL, 1984, N-S ARCH PHARMACOL, V327, P1, DOI 10.1007/BF00504983; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Heron M, 2010, PEDIATRICS, V125, P4, DOI 10.1542/peds.2009-2416; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Huang RQ, 2010, NEUROSCI LETT, V473, P22, DOI 10.1016/j.neulet.2010.02.011; Huh JW, 2007, J NEUROTRAUM, V24, P1460, DOI 10.1089/neu.2006.3787; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Liu NK, 2014, BRAIN RES, V1576, P18, DOI 10.1016/j.brainres.2014.05.042; Mannix R, 2017, J NEUROTRAUM, V34, P495, DOI 10.1089/neu.2016.4457; Mannix R, 2014, J NEUROSURG, V121, P1342, DOI 10.3171/2014.7.JNS14272; McSwain NE, 2004, J TRAUMA, V57, P8; Mondello S, 2013, J NEUROTRAUM, V30, pA167; MORRIS RGM, 1990, EUR J NEUROSCI, V2, P1016, DOI 10.1111/j.1460-9568.1990.tb00014.x; Muthuswamy J, 2002, NEUROSCIENCE, V115, P917, DOI 10.1016/S0306-4522(02)00369-X; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1889, DOI 10.1089/neu.2007.9967; Nollet M, 2011, NEUROPHARMACOLOGY, V61, P336, DOI 10.1016/j.neuropharm.2011.04.022; Parikh U, 2016, J NEUROPATH EXP NEUR, V75, P731, DOI 10.1093/jnen/nlw045; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; RINK A, 1995, AM J PATHOL, V147, P1575; Semple BD, 2016, DEV NEUROSCI-BASEL, V38, P220, DOI 10.1159/000448089; Semple BD, 2012, J NEUROTRAUM, V29, P2672, DOI 10.1089/neu.2012.2595; Shear DA, 2016, J NEUROTRAUM, V33, P523, DOI 10.1089/neu.2015.4115; Shoykhet M, 2012, J NEUROSCI, V32, P4972, DOI 10.1523/JNEUROSCI.5597-11.2012; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STERU L, 1985, PSYCHOPHARMACOLOGY, V85, P367, DOI 10.1007/BF00428203; Stiefel MF, 2006, J NEUROSURG, V105, P281, DOI 10.3171/ped.2006.105.4.281; Struchen MA, 2011, J HEAD TRAUMA REHAB, V26, P4, DOI 10.1097/HTR.0b013e3182048e98; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Yan HQ, 2012, J NEUROTRAUM, V29, pA58	60	12	12	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2018	35	5					790	801		10.1089/neu.2017.5354		JAN 2018	12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FX4ZY	WOS:000419869900001	29149808	Green Published			2021-06-18	
J	Blixt, J; Gunnarson, E; Wanecek, M				Blixt, Jonas; Gunnarson, Eli; Wanecek, Michael			Erythropoietin Attenuates the Brain Edema Response after Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						aquaporin; BBB; brain edema; EPO; TBI	AQUAPORIN-4 EXPRESSION; BARRIER DISRUPTION; RAT MODEL; NEUROPROTECTION; INFLAMMATION; PERMEABILITY; HYPOXIA; FLUID; MODULATION; ASTROCYTES	Erythropoietin (EPO) has neuroprotective effects in multiple central nervous system (CNS) injury models; however EPO's effects on traumatic brain edema are elusive. To explore EPO as an intervention in traumatic brain edema, male Sprague-Dawley (SD) rats were subjected to blunt, controlled traumatic brain injury (TBI). Animals were randomized to EPO 5000 IU/kg or saline (control group) intraperitoneally within 30min after trauma and once daily for 4 consecutive days. Brain MRI, immunohistofluorescence, immunohistochemistry, and quantitative protein analysis were performed at days 1 and 4 post- trauma. EPO significantly prevented the loss of the tight junction protein zona occludens 1 (ZO-1) observed in control animals after trauma. The decrease of ZO-1 in the control group was associated with an immunoglobulin (Ig)G increase in the perilesional parenchyma, indicating blood-brain barrier (BBB) dysfunction and increased permeability. EPO treatment attenuated decrease in apparent diffusion coefficient (ADC) after trauma, suggesting a reduction of cytotoxic edema, and reduced the IgG leakage, indicating that EPO contributed to preserve BBB integrity and attenuated vasogenic edema. Animals treated with EPO demonstrated conserved levels of aquaporin 4 (AQP4) protein expression in the perilesional area, whereas control animals showed a reduction of AQP4. We show that post TBI administration of EPO decreases early cytotoxic brain edema and preserves structural and functional properties of the BBB, leading to attenuation of the vasogenic edema response. The data support that the mechanisms involve preservation of the tight junction protein ZO-1 and the water channel AQP4, and indicate that treatment with EPO may have beneficial effects on the brain edema response following TBI.	[Blixt, Jonas] Karolinska Univ Hosp, Karolinska Inst, Perioperat Med & Intens Care, Stockholm, Sweden; [Blixt, Jonas; Wanecek, Michael] Karolinska Univ Hosp, Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden; [Gunnarson, Eli] Karolinska Univ Hosp, Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden	Blixt, J (corresponding author), Karolinska Univ Hosp, Perioperat Med & Intens Care, SE-17176 Stockholm, Sweden.	jonas.blixt@sll.se	Wanecek, Michael/AAE-7998-2021		Swedish Medical Research FoundationSwedish Medical Research Council (SMRC); Swedish Society of Medicine; Magn. Bergvalls Foundation; Marta och Gunnar V. Philipsons Stiftelse; Trygg Hansa Forskningsfond; Karolinska InstitutetKarolinska Institutet; Sallskapet Barnavard; Stockholm County CouncilStockholm County Council	The authors thank Tim Baker for proofreading and language help, and Britt Meijer and Anette Ebberyd for excellent technical assistance. This study was supported by the Swedish Medical Research Foundation, the Swedish Society of Medicine, Magn. Bergvalls Foundation, Marta och Gunnar V. Philipsons Stiftelse, Trygg Hansa Forskningsfond, Funds from the Karolinska Institutet, Sallskapet Barnavard, and the Regional Agreement on Medical Training and Clinical Research (ALF) between the Stockholm County Council and Karolinska Institutet.	Aloizos S, 2015, TURK NEUROSURG, V25, P552, DOI 10.5137/1019-5149.JTN.9685-14.4; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Blixt J, 2015, BRAIN RES, V1611, P18, DOI 10.1016/j.brainres.2015.03.004; Bramlett HM, 2016, J NEUROTRAUM, V33, P538, DOI 10.1089/neu.2015.4116; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Brissaud O, 2010, PEDIATR RES, V68, P123, DOI 10.1203/00006450-201011001-00237; BROADWELL RD, 1993, EXP NEUROL, V120, P245, DOI 10.1006/exnr.1993.1059; Candelario-Jalil E, 2009, NEUROSCIENCE, V158, P983, DOI 10.1016/j.neuroscience.2008.06.025; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Cherian L, 2011, J PHARMACOL EXP THER, V337, P451, DOI 10.1124/jpet.110.176602; Chi OZ, 2008, PHARMACOLOGY, V82, P38, DOI 10.1159/000127839; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Collino M, 2015, PHARMACOL THERAPEUT, V151, P32, DOI 10.1016/j.pharmthera.2015.02.005; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Grasso G, 2001, J Neurosurg Sci, V45, P7; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Grasso G, 2015, MOL MED, V21, P979, DOI 10.2119/molmed.2015.00177; Gunnarson E, 2009, P NATL ACAD SCI USA, V106, P1602, DOI 10.1073/pnas.0812708106; Hellewell SC, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-156; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Honeybul S, 2011, J NEUROSURG SCI, V55, P343; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; Jelkmann W, 2007, EUR J HAEMATOL, V78, P183, DOI 10.1111/j.1600-0609.2007.00818.x; Jou IM, 2000, J APPL PHYSIOL, V89, P1766; Juul SE, 1998, PEDIATR RES, V43, P40, DOI 10.1203/00006450-199801000-00007; Kanagy NL, 2003, J CARDIOVASC PHARM, V42, P527, DOI 10.1097/00005344-200310000-00011; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Koyama Junji, 2007, Kobe J Med Sci, V53, P199; Kumral A, 2005, BIOL NEONATE, V87, P15, DOI 10.1159/000080490; Lee ST, 2006, J NEUROCHEM, V96, P1728, DOI 10.1111/j.1471-4159.2006.03697.x; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mark KS, 2002, AM J PHYSIOL-HEART C, V282, pH1485, DOI 10.1152/ajpheart.00645.2001; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Marti HH, 1997, KIDNEY INT, V51, P416, DOI 10.1038/ki.1997.55; MASUDA S, 1994, J BIOL CHEM, V269, P19488; Matsushita H, 2003, NEUROREPORT, V14, P1757, DOI 10.1097/00001756-200309150-00020; Nagai A, 2001, J NEUROPATH EXP NEUR, V60, P386, DOI 10.1093/jnen/60.4.386; Navarro JC, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00494; Neal CJ, 2007, J NEUROTRAUM, V24, P1609, DOI 10.1089/neu.2007.0301; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Oliva AA, 2011, NEUROSCIENCE, V180, P272, DOI 10.1016/j.neuroscience.2011.02.020; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Teng RF, 2011, BASIC RES CARDIOL, V106, P343, DOI 10.1007/s00395-011-0158-z; Tsai TH, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0761-8; Umeda K, 2004, J BIOL CHEM, V279, P44785, DOI 10.1074/jbc.M406563200; Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Villasenor R, 2016, SCI REP-UK, V6, DOI 10.1038/srep25658; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Weidemann A, 2009, J CLIN INVEST, V119, P3373, DOI 10.1172/JCI39378; Wen JF, 2014, EXP THER MED, V8, P881, DOI 10.3892/etm.2014.1818; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	71	12	13	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2018	35	4					671	680		10.1089/neu.2017.5015		JAN 2018	10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FV3OH	WOS:000419868100001	29179621	Green Published, Bronze			2021-06-18	
J	Bird, ET; Bowden, AE; Seeley, MK; Fullwood, DT				Bird, Evan T.; Bowden, Anton E.; Seeley, Matthew K.; Fullwood, David T.			Materials selection of flexible open-cell foams in energy absorption applications	MATERIALS & DESIGN			English	Article						Energy absorption; Materials selection; Foam; Football helmet; Ashby methods	HIGH-SCHOOL FOOTBALL; POLYMERIC FOAMS; HELMETS; PERFORMANCE; CONCUSSION	Foam must be engineered to absorb a particular range of energy in various impact-related applications. Since energy absorption is dependent upon the unique stress-strain response of each foam specimen, it is difficult to quantify analytically; thus, energy absorption cannot be easily compared across materials. Current methods accomplish this using an experimental approach, individually testing foam materials, densities, and geometries to quantify how each influences energy absorption. Such methods require large amounts of time and money to characterize a narrow range of foams. This paper facilitates foam selection by deriving generalized energy absorption material indices. Assuming Euler buckling of columns in the open-cell foam structure, this paper applies equations derived by Maiti et al. to a typical impact scenario wherein the indices are extracted. Using existing Ashby charts, these indices allow polymers to be ranked by the mass and cost each would require as a foamed structure to satisfy specific energy absorption constraints. The presented method allows the energy absorption of a wide range of flexible foams to be compared and relieves the need for extensive factor-specific testing. This method is applied to football helmet foam selection; however, it can be used for many applications where energy absorption is of interest. (C) 2017 Elsevier Ltd. All rights reserved	[Bird, Evan T.; Bowden, Anton E.; Fullwood, David T.] Brigham Young Univ, Dept Mech Engn, Provo, UT 84602 USA; [Seeley, Matthew K.] Brigham Young Univ, Dept Exercise Sci, Provo, UT 84602 USA	Fullwood, DT (corresponding author), Brigham Young Univ, Dept Mech Engn, Provo, UT 84602 USA.	dfullwood@byu.edu			National Science FoundationNational Science Foundation (NSF) [CMMI 1538447]; REU supplements; Directorate For EngineeringNational Science Foundation (NSF)NSF - Directorate for Engineering (ENG) [1538447] Funding Source: National Science Foundation	This work was funded by the National Science Foundation [grant number CMMI 1538447] and related REU supplements. This paper represents work done by students of the Brigham Young University Mechanical Engineering Department's Design and Materials Applications class over the last three years. The authors would like to specifically thank Parker Rosquist, Cory Newton, and David Wood for their contributions to the methods presented in this work.	Ashby M. F., 1993, J PHYS, VIV; Ashby M.F, 2011, MAT SELECTION MECH D; ASHBY MF, 1989, ACTA METALL MATER, V37, P1273, DOI 10.1016/0001-6160(89)90158-2; Avalle M, 2001, INT J IMPACT ENG, V25, P455, DOI 10.1016/S0734-743X(00)00060-9; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Caswell SV, 2007, MATERIALS IN SPORTS EQUIPMENT, VOL 2, P87, DOI 10.1533/9781845693664.1.87; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Cournoyer J, 2016, J ATHL TRAINING, V51, P258, DOI 10.4085/1062-6050-51.4.08; Daneshvar DH, 2011, CLIN SPORT MED, V30, P145, DOI 10.1016/j.csm.2010.09.006; DeMarco AL, 2010, ACCIDENT ANAL PREV, V42, P1778, DOI 10.1016/j.aap.2010.04.019; Ghaedizadeh A., 2017, MAT DES; Gibson L.J., 1999, CELLULAR SOLIDS STRU; Gimbel G, 2008, INT J SPORT SCI ENG, V2, P154; Gong L, 2005, INT J SOLIDS STRUCT, V42, P1355, DOI 10.1016/j.ijsolstr.2004.07.023; Hernandez F, 2015, ANN BIOMED ENG, V43, P1918, DOI 10.1007/s10439-014-1212-4; Honarmandi Peyman, 2015, International Journal of Experimental and Computational Biomechanics, V3, P267; Hoshizaki T Blaine, 2014, Neurosurgery, V75 Suppl 4, pS136, DOI 10.1227/NEU.0000000000000496; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; Liu DS, 2003, ENG FAIL ANAL, V10, P581, DOI 10.1016/S1350-6307(03)00040-2; Maiti SK, 1984, ACTA METALL, V11, P1963; McIntosh AS, 2015, BRIT J SPORT MED, V49, P1113, DOI 10.1136/bjsports-2015-095093; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; Mills NJ., 2003, MAT SPORTS EQUIPMENT, V1, P20; Ozturk UE, 2009, MATER DESIGN, V30, P15, DOI 10.1016/j.matdes.2008.04.054; Post A., 2014, P I MECH ENG P-J SPO; Post A, 2013, MATER DESIGN, V45, P653, DOI 10.1016/j.matdes.2012.09.017; Saha MC, 2005, MAT SCI ENG A-STRUCT, V406, P328, DOI 10.1016/j.msea.2005.07.006; Shuaeib FM, 2002, J MATER PROCESS TECH, V123, P422, DOI 10.1016/S0924-0136(02)00047-X; Wanner A, 2010, MATER DESIGN, V31, P2834, DOI 10.1016/j.matdes.2009.12.052	30	12	12	2	61	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-1275	1873-4197		MATER DESIGN	Mater. Des.	JAN 5	2018	137						414	421		10.1016/j.matdes.2017.10.054			8	Materials Science, Multidisciplinary	Materials Science	FM0PO	WOS:000414669500041					2021-06-18	
J	Adams, C; Bazzigaluppi, P; Beckett, TL; Bishay, J; Weisspapir, I; Dorr, A; Mester, JR; Steinman, J; Hirschler, L; Warnking, JM; Barbier, EL; McLaurin, J; Sled, JG; Stefanovic, B				Adams, Conner; Bazzigaluppi, Paolo; Beckett, Tina L.; Bishay, Jossana; Weisspapir, Iliya; Dorr, Adrienne; Mester, James R.; Steinman, Joe; Hirschler, Lydiane; Warnking, Jan M.; Barbier, Emmanuel L.; McLaurin, JoAnne; Sled, John G.; Stefanovic, Bojana			Neurogliovascular dysfunction in a model of repeated traumatic brain injury	THERANOSTICS			English	Article						repeated TBI; neurovascular; optogenetics; closed head injury	MILD HEAD-INJURY; NEUROBEHAVIORAL CHANGES; ANGIOGENESIS; MEMORY; MICE; VULNERABILITY; ACTIVATION; DISEASE	Traumatic brain injury (TBI) research has focused on moderate to severe injuries as their outcomes are significantly worse than those of a mild TBI (mTBI). However, recent epidemiological evidence has indicated that a series of even mild TBIs greatly increases the risk of neurodegenerative and psychiatric disorders. Neuropathological studies of repeated TBI have identified changes in neuronal ionic concentrations, axonal injury, and cytoskeletal damage as important determinants of later life neurological and mood compromise; yet, there is a paucity of data on the contribution of neurogliovascular dysfunction to the progression of repeated TBI and alterations of brain function in the intervening period. Methods: Here, we established a mouse model of repeated TBI induced via three electromagnetically actuated impacts delivered to the intact skull at three-day intervals and determined the long-term deficits in neurogliovascular functioning in Thy1-ChR2 mice. Two weeks post the third impact, cerebral blood flow and cerebrovascular reactivity were measured with arterial spin labelling magnetic resonance imaging. Neuronal function was investigated through bilateral intracranial electrophysiological responses to optogenetic photostimulation. Vascular density of the site of impacts was measured with in vivo two photon fluorescence microscopy. Pathological analysis of neuronal survival and astrogliosis was performed via NeuN and GFAP immunofluorescence. Results: Cerebral blood flow and cerebrovascular reactivity were decreased by 50 +/- 16% and 70 +/- 20%, respectively, in the TBI cohort relative to sham-treated animals. Concomitantly, electrophysiological recordings revealed a 97 +/- 1% attenuation in peri-contusional neuronal reactivity relative to sham. Peri-contusional vascular volume was increased by 33 +/- 2% relative to sham-treated mice. Pathological analysis of the peri-contusional cortex demonstrated astrogliosis, but no changes in neuronal survival. Conclusion: This work provides the first in-situ characterization of the long-term deficits of the neurogliovascular unit following repeated TBI. The findings will help guide the development of diagnostic markers as well as therapeutics targeting neurogliovascular dysfunction.	[Adams, Conner; Bazzigaluppi, Paolo; Bishay, Jossana; Mester, James R.; Steinman, Joe; Sled, John G.; Stefanovic, Bojana] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Adams, Conner; Bazzigaluppi, Paolo; Beckett, Tina L.; Bishay, Jossana; Weisspapir, Iliya; Dorr, Adrienne; Mester, James R.; McLaurin, JoAnne; Stefanovic, Bojana] Sunnybrook Res Inst, Toronto, ON, Canada; [Bazzigaluppi, Paolo] Univ Hlth Network, Krembil Res Inst, Fundamental Neurobiol, Toronto, ON M5T 2S8, Canada; [Steinman, Joe; Sled, John G.] Hosp Sick Children, Mouse Imaging Ctr, Toronto, ON, Canada; [Hirschler, Lydiane; Warnking, Jan M.; Barbier, Emmanuel L.] Univ Grenoble Alpes, Grenoble Inst Neurosci, Grenoble, France; [Hirschler, Lydiane] Bruker Biospin MRI, Ettlingen, Germany; [Hirschler, Lydiane; Warnking, Jan M.; Barbier, Emmanuel L.] INSERM, U1216, Grenoble, France; [McLaurin, JoAnne] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	Adams, C (corresponding author), Sunnybrook Hlth Sci Ctr, 2075 Bayview Ave,S636, Toronto, ON M4N 3M5, Canada.	Conner.adams@mail.utoronto.ca	Hirschler, Lydiane/AAA-4136-2020; Sled, John G/D-8268-2012; Barbier, Emmanuel/E-6302-2011; Warnking, Jan M/M-1736-2014	Hirschler, Lydiane/0000-0003-2379-0861; Sled, John G/0000-0002-4461-283X; Barbier, Emmanuel/0000-0002-4952-1240; Warnking, Jan M/0000-0002-1683-5163; Steinman, Joe/0000-0002-1354-4221; Mester, James/0000-0001-9878-092X	Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR) [FRN 148521]	This work was funded by the Canadian Institute of Health Research (FRN 148521).	Agoston DV, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00092; Amyot F, 2018, J NEUROTRAUM, V35, P1116, DOI 10.1089/neu.2017.5114; [Anonymous], 2012, DOD POLICY GUIDANCE; Arenkiel BR, 2007, NEURON, V54, P205, DOI 10.1016/j.neuron.2007.03.005; Baron JC, 2014, J CEREBR BLOOD F MET, V34, P2, DOI 10.1038/jcbfm.2013.188; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Bey T, 2009, WEST J EMERG MED, V10, P6; Bolker BM, 2009, TRENDS ECOL EVOL, V24, P127, DOI 10.1016/j.tree.2008.10.008; Bolton AN, 2014, J NEUROPATH EXP NEUR, V73, P933, DOI 10.1097/NEN.0000000000000115; Bouzat P, 2013, CRIT CARE MED, V41, P1316, DOI 10.1097/CCM.0b013e31827ca64e; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Donovan V, 2012, NEUROIMAGE-CLIN, V1, P18, DOI 10.1016/j.nicl.2012.08.001; Ellis MJ, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00061; Fehily B, 2017, CELL TRANSPLANT, V26, P1131, DOI 10.1177/0963689717714092; Ferguson SA, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00416; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Guo XB, 2009, J NEUROTRAUM, V26, P1337, DOI [10.1089/neu.2008.0733, 10.1089/neu.2008-0733]; Hawrylycz M, 2014, SPRINGER HANDBOOK OF BIO-/NEUROINFORMATICS, P1111; Hayward NMEA, 2011, J CEREBR BLOOD F MET, V31, P166, DOI 10.1038/jcbfm.2010.67; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Hirschler L, 2018, MAGN RESON MED, V79, P1314, DOI 10.1002/mrm.26767; Hsu HL, 2015, RADIOLOGY, V276, P828, DOI 10.1148/radiol.2015142549; Hylin MJ, 2013, J NEUROTRAUM, V30, P716, DOI 10.1089/neu.2012.2717; Jullienne A, 2016, J NEUROSCI RES, V94, P609, DOI 10.1002/jnr.23732; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Lake EMR, 2017, J MAGN RESON IMAGING, V46, P505, DOI 10.1002/jmri.25541; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lee CY, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00082; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Li N, 2014, J NEUROTRAUM, V31, P395, DOI 10.1089/neu.2013.3059; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Mutch WAC, 2016, J NEUROSURG, V125, P648, DOI 10.3171/2015.6.JNS15972; Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100; Obenaus A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00161-4; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Ostergaard L, 2014, J CEREBR BLOOD F MET, V34, P1585, DOI 10.1038/jcbfm.2014.131; Parkes LM, 2002, MAGN RESON MED, V48, P27, DOI 10.1002/mrm.10180; Pries AR, 2005, HYPERTENSION, V46, P725, DOI 10.1161/01.HYP.0000184428.16429.be; Scopaz KA, 2013, SPORTS HEALTH, V5, P537, DOI 10.1177/1941738112473059; Sword J, 2013, BRAIN, V136, P1446, DOI 10.1093/brain/awt026; Tarantini S, 2015, J CEREBR BLOOD F MET, V35, P1871, DOI 10.1038/jcbfm.2015.162; Tucker LB, 2016, J NEUROTRAUM, V33, P880, DOI 10.1089/neu.2015.3977; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Vazquez AL, 2014, CEREB CORTEX, V24, P2908, DOI 10.1093/cercor/bht147; Velosky AG, 2017, BEHAV BRAIN RES, V324, P115, DOI 10.1016/j.bbr.2017.02.017; Weiller C, 2006, J MAGN RESON IMAGING, V23, P840, DOI 10.1002/jmri.20591; Wu G, 2010, TRANSL STROKE RES, V1, P31, DOI 10.1007/s12975-009-0008-6; Yang ZH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11178	59	12	12	3	11	IVYSPRING INT PUBL	LAKE HAVEN	PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA	1838-7640			THERANOSTICS	Theranostics		2018	8	17					4824	4836		10.7150/thno.24747			13	Medicine, Research & Experimental	Research & Experimental Medicine	GT0FX	WOS:000444107300018	30279740	DOAJ Gold, Green Published			2021-06-18	
J	Arun, P; Rittase, WB; Wilder, DM; Wang, Y; Gist, ID; Long, JB				Arun, Peethambaran; Rittase, William B.; Wilder, Donna M.; Wang, Ying; Gist, Irene D.; Long, Joseph B.			Defective methionine metabolism in the brain after repeated blast exposures might contribute to increased oxidative stress	NEUROCHEMISTRY INTERNATIONAL			English	Article						Blast exposure; Traumatic brain injury; Oxidative stress; Antioxidants; Methionine; Cysteine; Glutathione; Ascorbic acid	N-ACETYLCYSTEINE; ASCORBIC-ACID; ANTIOXIDANT DEFENSE; RAT MODEL; INJURY; OVERPRESSURE; INFLAMMATION; MECHANISMS; EXPRESSION; INDUCTION	Blast-induced traumatic brain injury (bTBI) is one of the major disabilities in Service Members returning from recent military operations. The neurobiological underpinnings of bTBI, which are associated with acute and chronic neuropathological and neurobehavioral deficits, are uncertain. Increased oxidative stress in the brain is reported to play a significant role promoting neuronal damage associated with both brain injury and neurodegenerative disorders. In this study, brains of rats exposed to repeated blasts in a shock tube underwent untargeted profiling of primary metabolism by automatic linear exchange/cold injection GC-TOF mass spectrometry and revealed acute and sub-acute disruptions in the metabolism of the essential amino acid methionine and associated antioxidants. Methionine sulfoxide, the oxidized metabolite of methionine, showed a sustained increase in the brain after blast exposure which Was associated with a significant decrease in cysteine, the amino acid derived from methionine. Glutathione, the antioxidant synthesized from cysteine, also concomitantly decreased as did the antioxidant ascorbic acid. Reductions in ascorbic acid were accompanied by increased levels of its oxidized metabolite, dehydroascorbic acid and other metabolites such as threonic acid, isothreonic acid, glycolic acid and oxalic acid. Fluorometric analysis of the brains showed acute and sub-acute increase in total reactive oxygen species. In view of the fundamental importance of glutathione in the brain as an antioxidant, including its role in the reduction of dehydroascorbic acid to ascorbic acid, the disruptions in methionine metabolism elicited by blast exposure might prominently contribute to neuronal injury by promoting increased and sustained oxidative stress. (C) 2017 Elsevier Ltd. All rights reserved.	[Arun, Peethambaran; Rittase, William B.; Wilder, Donna M.; Wang, Ying; Gist, Irene D.; Long, Joseph B.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Blast Induced Neurotrauma Branch, Silver Spring, MD 20910 USA	Arun, P; Long, JB (corresponding author), Walter Reed Army Inst Res, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	peethambaran.arun.ctr@mail.mil; joseph.b.long.civ@mail.mil			Congressionally Directed Medical Research ProgramUnited States Department of Defense [W81XWH-08-2-0018, W81XWH-11-2-0127]	This work was supported by Congressionally Directed Medical Research Program [award numbers W81XWH-08-2-0018 and W81XWH-11-2-0127].	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Calabrese E, 2014, J NEUROTRAUM, V31, P938, DOI 10.1089/neu.2013.3144; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Costa MZ, 2013, MOL CELL BIOCHEM, V384, P21, DOI 10.1007/s11010-013-1777-5; Dash PK, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00036; Deutsch JC, 2000, J CHROMATOGR A, V881, P299, DOI 10.1016/S0021-9673(00)00166-7; Du XP, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4159357; Eakin K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090617; GAMBARDELLA RL, 1977, BIOCHIM BIOPHYS ACTA, V499, P156, DOI 10.1016/0304-4165(77)90238-0; Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163; Jansson PJ, 2004, FREE RADICAL RES, V38, P855, DOI 10.1080/10715760410001700497; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Levine RL, 2000, IUBMB LIFE, V50, P301, DOI 10.1080/15216540051081056; Li X, 2001, ANTIOXID REDOX SIGN, V3, P1089, DOI 10.1089/152308601317203594; Ling G, 2015, Handb Clin Neurol, V127, P173, DOI 10.1016/B978-0-444-52892-6.00011-8; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lu SC, 2013, BBA-GEN SUBJECTS, V1830, P3143, DOI 10.1016/j.bbagen.2012.09.008; Lucke-Wold BP, 2015, TRANSL RES, V166, P509, DOI 10.1016/j.trsl.2015.08.005; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Meabon JS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaa9585; Meaney DF, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026364; MEISTER A, 1994, J BIOL CHEM, V269, P9397; Melkani GC, 2006, BIOCHEM BIOPH RES CO, V347, P534, DOI 10.1016/j.bbrc.2006.06.136; Moskovitz J, 2005, BBA-PROTEINS PROTEOM, V1703, P213, DOI 10.1016/j.bbapap.2004.09.003; Paul BD, 2014, NATURE, V509, P96, DOI 10.1038/nature13136; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Sajja VSSS, 2012, NMR BIOMED, V25, P1331, DOI 10.1002/nbm.2805; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Shahripour RB, 2014, BRAIN BEHAV, V4, P108, DOI 10.1002/brb3.208; Stadtman ER, 2005, BBA-PROTEINS PROTEOM, V1703, P135, DOI 10.1016/j.bbapap.2004.08.010; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Yi JH, 2006, J NEUROTRAUM, V23, P86, DOI 10.1089/neu.2006.23.86; Yi JH, 2005, BRAIN RES, V1033, P13, DOI 10.1016/j.brainres.2004.10.055; Zhang MY, 2013, J MOL NEUROSCI, V51, P57, DOI 10.1007/s12031-012-9948-5	41	12	12	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	JAN	2018	112						234	238		10.1016/j.neuint.2017.07.014			5	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	FU1ZZ	WOS:000423649300024	28774719				2021-06-18	
J	Baker-Sparr, C; Hart, T; Bergquist, T; Bogner, J; Dreer, L; Juengst, S; Mellick, D; O'Neil-Pirozzi, TM; Sander, AM; Whiteneck, GG				Baker-Sparr, Christina; Hart, Tessa; Bergquist, Thomas; Bogner, Jennifer; Dreer, Laura; Juengst, Shannon; Mellick, David; O'Neil-Pirozzi, Therese M.; Sander, Angelle M.; Whiteneck, Gale G.			Internet and Social Media Use After Traumatic Brain Injury: A Traumatic Brain Injury Model Systems Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; communication; community reintegration; Internet; social media; social participation	COLLEGE-STUDENTS; ASSISTIVE TECHNOLOGY; SUBSTANCE USE; FACEBOOK USE; DEPRESSION; NETWORKING; PEOPLE; TBI; INTERVENTION; INDIVIDUALS	Objectives: To characterize Internet and social media use among adults with moderate to severe traumatic brain injury (TBI) and to compare demographic and socioeconomic factors associated with Internet use between those with and without TBI. Setting: Ten Traumatic Brain Injury Model Systems centers. Participants: Persons with moderate to severe TBI (N = 337) enrolled in the TBI Model Systems National Database and eligible for follow-up from April 1, 2014, to March 31, 2015. Design: Prospective cross-sectional observational cohort study. Main Measures: Internet usage survey. Results: The proportion of Internet users with TBI was high (74%) but significantly lower than those in the general population (84%). Smartphones were the most prevalent means of Internet access for persons with TBI. The majority of Internet users with TBI had a profile account on a social networking site (79%), with more than half of the sample reporting multiplatform use of 2 or more social networking sites. Conclusion: Despite the prevalence of Internet use among persons with TBI, technological disparities remain in comparison with the general population. The extent of social media use among persons with TBI demonstrates the potential of these platforms for social engagement and other purposes. However, further research examining the quality of online activities and identifying potential risk factors of problematic use is recommended.	[Baker-Sparr, Christina; Mellick, David; Whiteneck, Gale G.] Craig Hosp, Englewood, CO USA; [Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Bergquist, Thomas] Mayo Clin, Coll Med, Rochester, MN USA; [Bogner, Jennifer] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Dreer, Laura] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Juengst, Shannon] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [O'Neil-Pirozzi, Therese M.] Harvard Med Sch, Spaulding Rehabil Hosp, Boston, MA USA; [O'Neil-Pirozzi, Therese M.] Northeastern Univ, Dept Commun Sci & Disorders, Boston, MA 02115 USA; [Sander, Angelle M.] Baylor Coll Med, TIRR Mem Hermann, Houston, TX 77030 USA; [Sander, Angelle M.] Baylor Coll Med, Harris Hlth Syst, Houston, TX 77030 USA	Baker-Sparr, C (corresponding author), Craig Hosp, 3425 S Clarkson St, Englewood, CO 80113 USA.	cbaker-sparr@craighospital.org	Juengst, Shannon B/AAC-5891-2019	Juengst, Shannon/0000-0003-4709-545X	National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR)United States Department of Health & Human Services [90DP0028, 90DP0030, 90DP0034, 90DP0037, 90DP0040, 90DP0041, H133A120085, H133A120096]	This work was supported by the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) grants 90DP0028, 90DP0030, 90DP0034, 90DP0037, 90DP0040, 90DP0041, H133A120085, andH133A120096. Public data set provided by the Pew Research Center. Pew Research bears no responsibility for interpretations presented or conclusions reached on the basis of analysis of the data. The authors express appreciation to the data collection personnel who interviewed participants at each collaborating site.	[Anonymous], 2009, TRAUM BRAIN INJ MOD; Banjanin N, 2015, COMPUT HUM BEHAV, V43, P308, DOI 10.1016/j.chb.2014.11.013; Boyd DM, 2007, J COMPUT-MEDIAT COMM, V13, P210, DOI 10.1111/j.1083-6101.2007.00393.x; Brunner M, 2015, DISABIL REHABIL, V37, P1511, DOI 10.3109/09638288.2015.1045992; Carey JC, 2008, CYBERPSYCHOL BEHAV, V11, P188, DOI 10.1089/cpb.2007.0025; Casale S, 2016, ADDICT BEHAV, V59, P84, DOI 10.1016/j.addbeh.2016.03.014; Crisp R., 1994, J APPL REHABILITATIO, V25, P16; de Joode E, 2010, CLIN REHABIL, V24, P701, DOI 10.1177/0269215510367551; Dobransky K., 2006, Information Communication & Society, V9, P313, DOI 10.1080/13691180600751298; Duggan M, 2015, SOCIAL MEDIA UPDATE; Duggan M, 2015, DEMOGRAPHICS SOCIAL; Egan J, 2005, BRAIN INJURY, V19, P555, DOI 10.1080/02699050400013659; Evald L, 2015, NEUROPSYCHOL REHABIL, V25, P283, DOI 10.1080/09602011.2014.970557; Fichten CS, 2001, J POSTSECONDARY ED D, V15, P28; File T, 2013, COMPUTER INTERNET US; Fox S., 2011, AM LIVING DISABILITY; Fox S, 2014, WEB 25 US; Gamez-Guadix M, 2013, J ADOLESCENT HEALTH, V53, P446, DOI 10.1016/j.jadohealth.2013.03.030; Gillespie A, 2012, J INT NEUROPSYCH SOC, V18, P1, DOI 10.1017/S1355617711001548; Hoofien D, 2001, BRAIN INJURY, V15, P189; Israel G. D., 1992, DETERMINING SAMPLE S; Jelenchick LA, 2013, J ADOLESCENT HEALTH, V52, P128, DOI 10.1016/j.jadohealth.2012.05.008; Leung L, 2012, NEW MEDIA SOC, V14, P117, DOI 10.1177/1461444811410406; Li Q, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00370; Manago AM, 2012, DEV PSYCHOL, V48, P369, DOI 10.1037/a0026338; NCDDR, 2001, RES EXCH, V6; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Pantic I, 2012, PSYCHIAT DANUB, V24, P90; Perrin A., 2015, AM INTERNET ACCESS 2; Rainie L., 2012, JUST IN TIME INFORM; Rietdijk R, 2012, J REHABIL MED, V44, P913, DOI 10.2340/16501977-1058; Rotondi AJ, 2005, J HEAD TRAUMA REHAB, V20, P173, DOI 10.1097/00001199-200503000-00005; Rucker J, 2015, ACTA PAEDIATR, V104, P504, DOI 10.1111/apa.12971; Suris JC, 2014, SWISS MED WKLY, V144, DOI 10.4414/smw.2014.14061; Tandoc EC, 2015, COMPUT HUM BEHAV, V43, P139, DOI 10.1016/j.chb.2014.10.053; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; Traumatic Brain Injury Model Systems National data and Statistical Center, 2016, TBI MOD SYST PRES; Tsaousides T, 2011, BRAIN INJURY, V25, P1155, DOI 10.3109/02699052.2011.613086; Vaccaro M, 2007, DISABIL REHABIL-ASSI, V2, P85, DOI 10.1080/17483100601167586; Wartberg L, 2016, PSYCHIAT RES, V240, P272, DOI 10.1016/j.psychres.2016.04.057; Wellman B, 2001, AM BEHAV SCI, V45, P436, DOI 10.1177/00027640121957286; Wright B.A., 1983, PHYS DISABILITY PSYC, V2nd edition; Zickuhr K, 2012, DIGITAL DIFFERENCES, P13	43	12	12	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2018	33	1					E9	E17		10.1097/HTR.0000000000000305			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	GB0QS	WOS:000428752300002	28422898				2021-06-18	
J	Barker-Collo, S; Theadom, A; Starkey, N; Kahan, M; Jones, K; Feigin, V				Barker-Collo, Suzanne; Theadom, Alice; Starkey, Nicola; Kahan, Michael; Jones, Kelly; Feigin, Valery			Factor structure of the Rivermead Post-Concussion Symptoms Questionnaire over the first year following mild traumatic brain injury	BRAIN INJURY			English	Article						Mild traumatic brain injury; factor structure; Rivermead Post-Concussion Symptom Questionnaire	POSTCONCUSSIVE SYMPTOMS; HEAD-INJURY; PREVALENCE	Background: We examined the factor structure of the Rivermead Post-Concussion Symptom Questionnaire (RPQ), the most commonly used measure of post-concussive symptoms, over the first year post-injury.Method: Factor analysis (orthogonal rotation) was used to examine the RPQ items that form coherent subsets/factors within 2-weeks, and 1, 6, and 12-months post-mTBI in 527 adults (age >16years).Results: At baseline, three factors accounted for 63.95% of the variance; factor 1 reflected cognitive and physiological disturbances; factor 2 included items reflecting mood, sleep, and nausea/vomiting; and factor 3 included visual/auditory disturbances, dizziness, and headaches. At 1 month, three factors were again extracted (63.26% variance). Factor 1 reflected cognitive and mood symptoms, factor 2 reflected mood with headache, nausea, and dizziness; and factor 3 reflected visual disturbances. Two factors were obtained at 6 and 12 months (63.7% and 63.38% of variance): factor 1 included mood/cognitive items, restlessness, sleep disturbance, and noise sensitivity; whereas, factor 2 included physiological symptoms.Conclusions: The factor structure of the RPQ changes over time; however, it was relatively stable from 6 to 12-months post-injury. Subject to further evaluation, assessments conducted from 6 months could consider using these two factors as subscales. Changing the factor structure of RPQ before 6 months suggests that timing of assessment should be considered in applying these factors.	[Barker-Collo, Suzanne] Univ Auckland, Sch Psychol, Fac Sci, Auckland 1141, New Zealand; [Theadom, Alice; Jones, Kelly; Feigin, Valery] AUT Univ, Natl Inst Stroke & Appl Neurosci, Sch Rehabil & Occupat Studies, Auckland, New Zealand; [Starkey, Nicola] Univ Waikato, Sch Psychol, Fac Arts & Social Sci, Hamilton, New Zealand; [Kahan, Michael] Waikato Occupat Serv Ltd, Hamilton, New Zealand	Barker-Collo, S (corresponding author), Univ Auckland, Sch Psychol, Fac Sci, Auckland 1141, New Zealand.	s.barker-collo@auckland.ac.nz	Jones, Kelly/I-5199-2019; Starkey, Nicola/AAJ-3795-2020; Feigin, Valery/AAF-2313-2019	Starkey, Nicola/0000-0002-4370-8186; Feigin, Valery L./0000-0002-6372-1740	New Zealand Health Research CouncilHealth Research Council of New Zealand [09/063A, 11/192]	This study was funded by the New Zealand Health Research Council; References 09/063A and 11/192.	Barker-Collo S, 2016, JSM BURNS TRAUMA, V1, P1006; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carroll LJ, 2014, ARCH PHYS MED REH S3, V95; Cernich AN, 2012, J HEAD TRAUMA REHAB, V27, P253, DOI 10.1097/HTR.0b013e3182585cd5; Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Ettenhofer ML, 2012, J INT NEUROPSYCH SOC, V18, P451, DOI 10.1017/S1355617711001895; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Franke LM, 2015, J HEAD TRAUMA REHAB, V30, pE34, DOI 10.1097/HTR.0000000000000042; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Iverson G.L., 2007, BRAIN INJURY MED PRI; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Rimel RW, 1981, J HEAD TRAUMA REHAB, V6, P86; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Sveen U, 2010, SCAND J OCCUP THER, V17, P225, DOI 10.3109/11038120903171295; Tabachnick B., 2001, USING MULTIVARIATE S; Theadom A, 2012, NEUROEPIDEMIOLOGY, V38, P18, DOI 10.1159/000334746; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3	24	12	12	1	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2018	32	4					453	458		10.1080/02699052.2018.1429659			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FV9WZ	WOS:000424942400008	29355392				2021-06-18	
J	Brunner, M; Hemsley, B; Dann, S; Togher, L; Palmer, S				Brunner, Melissa; Hemsley, Bronwyn; Dann, Stephen; Togher, Leanne; Palmer, Stuart			Hashtag #TBI: A content and network data analysis of tweets about Traumatic Brain Injury	BRAIN INJURY			English	Article						Communication disorder; cognitive disorder; rehabilitation; social networks; twitter; traumatic brain injury	ALTERNATIVE COMMUNICATION AAC; FOOTBALL-LEAGUE PLAYER; SOCIAL MEDIA; COGNITIVE-COMMUNICATION; TWITTER NETWORKS; VIRTUAL WORLDS; YOUNG-PEOPLE; HEAD-INJURY; ADULTS; HEALTH	Objective: The aims of this study were to: (a) determine how Twitter is used by people with traumatic brain injury (TBI) and TBI organisations, (b) analyse the Twitter networks and content of tweets tagged with TBI-related hashtags, and (c) identify any challenges people with TBI encounter in using Twitter. Research Design: Mixed methods in a Twitter hashtag study. Methods: Mixed methods in a Twitter hashtag study. Tweets tagged with TBI-related hashtags were harvested from the Twitter website over a one-month period in 2016 and analysed qualitatively and quantitatively. Results: The sample of 29,199 tweets included tweets sent by 893 @ users, 219 of whom had a brain injury. Twitter was used to: (a) discuss health issues, (b) raise awareness of TBI, (c) talk about life after TBI, (d) talk about sport and concussion, and (e) communicate inspirational messages. Conclusions: Twitter is an important platform for research and knowledge translation on TBI, and for hearing the voices of people with TBI as they express their personal views and stories of living with TBI and become more visible and influential in Twitter communities. TBI clinicians could use these narratives of people with TBI in Twitter to develop more effective and personally meaningful rehabilitation goals.	[Brunner, Melissa; Hemsley, Bronwyn] Univ Newcastle, Fac Educ & Arts, Speech Pathol, Newcastle, NSW, Australia; [Dann, Stephen] Australian Natl Univ, Coll Business & Econ, Canberra, ACT, Australia; [Togher, Leanne] Univ Sydney, Fac Hlth Sci, Speech Pathol, Sydney, NSW, Australia; [Togher, Leanne] Univ New South Wales, NHMRC Ctr Res Excellence Brain Recovery, Sydney, NSW, Australia; [Palmer, Stuart] Deakin Univ, Fac Sci Engn & Built Environm, Deans Off, Geelong, Vic, Australia	Hemsley, B (corresponding author), Univ Newcastle, Fac Educ & Arts, Sch Humanities & Social Sci, Level 2,Sch Off McMullin Bldg,Univ Dr, Callaghan, NSW 2308, Australia.	melissa.brunner@uon.edu.au	Brunner, Melissa/AAS-5965-2020; Togher, Leanne/AAC-7083-2019; Hemsley, Bronwyn/A-7427-2010	Hemsley, Bronwyn/0000-0002-6255-3140; Togher, Leanne/0000-0002-4518-6748	Australian Government Research Training Program scholarshipAustralian GovernmentDepartment of Industry, Innovation and Science; Discovery Early Career Research Award (Australian Research Council)	This research is funded through an Australian Government Research Training Program scholarship to the first author and a Discovery Early Career Research Award (Australian Research Council) to the second author.	Aladwani AM, 2015, INT J INFORM MANAGE, V35, P15, DOI 10.1016/j.ijinfomgt.2014.09.003; Australian Bureau of Statistics, 2017, 2015 SURV DIS AG CAR; Australian Institute of Health and Welfare, 2016, AUSTR BURD DIS STUD, V3; Baker-Sparr Christina, 2017, J HEAD TRAUMA REHAB, P1; Balandin S, 2015, DISABIL REHABIL, V37, P1543, DOI 10.3109/09638288.2015.1052574; Barnes Henry, 2016, GUARDIAN; BBC Two, 2016, BBC 2; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brown S., 2011, ISJLP, V7, P457; Brunner M, 2017, INT COGN COMM DIS C; Brunner M, 2017, BRAIN INJURY, V31, P1028, DOI 10.1080/02699052.2017.1292429; Brunner M, 2015, DISABIL REHABIL, V37, P1511, DOI 10.3109/09638288.2015.1045992; Bruns A., 2014, TWITTER AND SOC, P15; Bruns A, 2016, COMMUN RES PRACT, V2, P20, DOI 10.1080/22041451.2016.1155328; Bruns A, 2013, INT J SOC RES METHOD, V16, P91, DOI 10.1080/13645579.2012.756095; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Buddy Media, 2012, STRAT EFF TWEET STAT; Chen LS, 2009, J AM STAT ASSOC, V104, P209, DOI 10.1198/jasa.2009.0111; Choo EK, 2015, MED TEACH, V37, P411, DOI 10.3109/0142159X.2014.993371; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Coelho C, 2013, AM J SPEECH-LANG PAT, V22, pS438, DOI 10.1044/1058-0360(2013/12-0076); Coelho Carl A., 2007, Seminars in Speech and Language, V28, P122, DOI 10.1055/s-2007-970570; College of Audiologists and Speech-Language Pathologists of Ontario (CASLPO), 2015, PREF PRACT GUID COGN, V02, P08; Conneeley AL, 2012, BRAIN IMPAIR, V13, P72, DOI 10.1017/BrImp.2012.3; Dann S., 2015, MAXIMIZING COMMERCE, P313; Dann S., 2014, EVIDENCE BASED COMMU, V8, P187, DOI [DOI 10.1080/17489539.2015.1023988, 10.1080/17489539.2015.1023988]; Dann S., 2015, MAXIMIZING COMMERCE, P280; DiAntonio A, 2016, HASHTAG ETIQUETTE US; Dollaghan C.A., 2007, HDB EVIDENCE BASED P; Donelle Lorie, 2012, Online J Issues Nurs, V17, P4; Douglas J, 2015, INT J SPEECH-LANG PA, V17, P199, DOI 10.3109/17549507.2015.1016113; Douglas JM, 2013, BRAIN INJURY, V27, P60, DOI 10.3109/02699052.2012.722254; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Fraas MR, 2015, TOP LANG DISORD, V35, P210, DOI 10.1097/TLD.0000000000000063; Fraas MR, 2009, AM J SPEECH-LANG PAT, V18, P315, DOI 10.1044/1058-0360(2009/08-0008); FRUCHTERMAN TMJ, 1991, SOFTWARE PRACT EXPER, V21, P1129, DOI 10.1002/spe.4380211102; Glasgow RE, 2007, ANNU REV PUBL HEALTH, V28, P413, DOI 10.1146/annurev.publhealth.28.021406.144145; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; Greenfield B, 2011, TOP STROKE REHABIL, V18, P35, DOI 10.1310/tsr1801-35; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Grimshaw JM, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-50; Hanna R, 2011, BUS HORIZONS, V54, P265, DOI 10.1016/j.bushor.2011.01.007; Hemsley B., 2017, 50 HAW INT C SYST SC; Hemsley B, 2017, AUGMENT ALTERN COMM, V33, P14, DOI 10.1080/07434618.2016.1273386; Hemsley B, 2016, STUD HEALTH TECHNOL, V227, P41, DOI 10.3233/978-1-61499-666-8-41; Hemsley B, 2015, DISABIL REHABIL, V37, P1531, DOI 10.3109/09638288.2015.1045990; Hemsley B, 2014, DEV NEUROREHABIL, V17, P84, DOI 10.3109/17518423.2013.861529; Higuchi K., 2015, KH CODER VERSION VER; Ho K, 2014, J MED INTERNET RES, V16, DOI 10.2196/jmir.2969; Hu X., 2012, TEXT ANAL SOCIAL MED, P385; Hynan A., 2013, I USE INTERNET ONLIN; Hynan A, 2015, DISABIL REHABIL, V37, P1559, DOI 10.3109/09638288.2015.1056387; Hynan A, 2014, CHILD LANG TEACH THE, V30, P175, DOI 10.1177/0265659013519258; Jacobs N, 2005, J COMPUT ASSIST LEAR, V21, P317, DOI 10.1111/j.1365-2729.2005.00142.x; Kaplan AM, 2010, BUS HORIZONS, V53, P59, DOI 10.1016/j.bushor.2009.09.003; Krueger EA, 2015, JMIR MENT HEALTH, V2, DOI 10.2196/mental.4113; Kuipers P, 2014, NEUROREHABILITATION, V35, P475, DOI 10.3233/NRE-141139; Laskas J. M., 2015, CONCUSSION; Lee Carmen K. M., 2011, DIGITAL DISCOURSE LA, P110, DOI [DOI 10.1093/ACPROF:OSO/9780199795437.003.0006, 10.1093/acprof:oso/9780199795437.003.0006]; Lee JL, 2014, J MED INTERNET RES, V16, P251, DOI 10.2196/jmir.3765; Lukow HR, 2015, J HEAD TRAUMA REHAB, V30, P241, DOI 10.1097/HTR.0000000000000137; MacDonald S, 2010, BRAIN INJURY, V24, P486, DOI 10.3109/02699050903518118; Mairs K, 2013, HEALTH INFO LIBR J, V30, P261, DOI 10.1111/hir.12048; McDonald S, 2014, SOCIAL COMMUNICATION; McLellan T, 2010, J INT NEUROPSYCH SOC, V16, P705, DOI 10.1017/S1355617710000524; McNeil K, 2012, EPILEPSY TWITTER ERA, V2; Microsoft, 2013, EXC VERS 15 0 4779 1; Mossberg Walt, 2016, THE VERGE; Nguyen R, 2016, CAN J NEUROL SCI, V43, P774, DOI 10.1017/cjn.2016.290; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; O'Callaghan AM, 2011, INT J SPEECH-LANG PA, V13, P218, DOI 10.3109/17549507.2011.549240; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Oyesanya TO, 2016, HEALTH CARE WOMEN IN, V37, P45, DOI 10.1080/07399332.2015.1005307; Palmer S, 2015, AUSTR ASS ENG ED C G; Palmer S, 2014, J MARK HIGH EDUC, V24, P257, DOI 10.1080/08841241.2014.907220; Park H, 2016, J HEALTH COMMUN, V21, P188, DOI 10.1080/10810730.2015.1058435; Paterson H, 2015, DISABIL REHABIL, V37, P1522, DOI 10.3109/09638288.2015.1052575; Paterson HL, 2017, AUGMENT ALTERN COMM, V33, P23, DOI 10.1080/07434618.2016.1275789; QSR International, 2011, NCAPTURE VERS 1 0 17; QSR International, 2012, NVIVO VERS 10 0 638; Ralph A, 2013, BRAIN INJURY, V27, P1475, DOI 10.3109/02699052.2013.823653; Retallack H., 2016, LEARNING BODIES BODY, P85, DOI [10.1007/978-981-10-0306-6_6, DOI 10.1007/978-981-10-0306-6_6]; Richards R., 2010, MERLOT J ONLINE LEAR, V6, P516; Ross C, 2011, J DOC, V67, P214, DOI 10.1108/00220411111109449; Saxton G.D., 2015, ADV SOC WORK, V16, P154; Scanfeld D, 2010, AM J INFECT CONTROL, V38, P182, DOI 10.1016/j.ajic.2009.11.004; Schellinger S., 2015, PUBLIC PERCEPTIONS T; Schmidt J.H., 2014, TWITTER SOC, P3; Shibasaki S, 2016, JMIR MHEALTH UHEALTH, V4, DOI 10.2196/mhealth.5987; Sony Pictures Digital Productions Inc, 2016, CONC; Stendal K, 2015, DISABIL REHABIL, V37, P1591, DOI 10.3109/09638288.2015.1052577; Sullivan SJ, 2012, BRIT J SPORT MED, V46, P258, DOI 10.1136/bjsm.2010.080341; The Gephi Consortium, 2012, GEPH VERS 0 8 2 1; Theroux L., 2017, L THEROUXS BIOGRAPHY; Togher L, 2001, J COMMUN DISORD, V34, P131, DOI 10.1016/S0021-9924(00)00045-9; Togher L, 2014, J HEAD TRAUMA REHAB, V29, P353, DOI 10.1097/HTR.0000000000000071; Twitter, 2016, GETT START TWITT; VENTOLA E, 1979, J PRAGMATICS, V3, P267, DOI 10.1016/0378-2166(79)90034-1; Watermeyer R, 2010, JCOM-J SCI COMMUN, V9; Whiffin CJ, 2015, J ADV NURS, V71, P849, DOI 10.1111/jan.12551; Wiseman-Hakes C, 2010, NEUROREHABILITATION, V26, P355, DOI 10.3233/NRE-2010-0573; Yadron Danny, 2016, GUARDIAN; Ylvisaker M, 2000, BRAIN IMPAIR, V1, P12, DOI DOI 10.1375/BRIM.1.1.12; Zimmer M, 2014, TWITTER AND SOC, V89, P169	110	12	12	1	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2018	32	1					49	63		10.1080/02699052.2017.1403047			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FY7VS	WOS:000427072300005	29219635				2021-06-18	
J	Churchill, NW; Hutchison, MG; Graham, SJ; Schweizer, TA				Churchill, Nathan W.; Hutchison, Michael G.; Graham, Simon J.; Schweizer, Tom A.			Connectomic markers of symptom severity in sport-related concussion: Whole-brain analysis of resting-state fMRI	NEUROIMAGE-CLINICAL			English	Article						fMRI; Functional connectivity; Concussion; Brain injury; Symptoms	FUNCTIONAL CONNECTIVITY; WHITE-MATTER; NETWORK; FOOTBALL; GYRUS	Concussion is associated with significant adverse effects within the first week post-injury, including physical complaints and altered cognition, sleep and mood. It is currently unknown whether these subjective disturbances have reliable functional brain correlates. Resting-state functional magnetic resonance imaging (rs-fMRI) has been used to measure functional connectivity of individuals after traumatic brain injury, but less is known about the relationship between functional connectivity and symptom assessments after a sport concussion. In this study, rs-fMRI was used to evaluate whole-brain functional connectivity for seventy (70) university-level athletes, including 35 with acute concussion and 35 healthy matched controls. Univariate analyses showed that greater symptom severity was mainly associated with lower pairwise connectivity in frontal, temporal and insular regions, along with higher connectivity in a sparser set of cerebellar regions. A novel multivariate approach also extracted two components that showed reliable covariation with symptom severity: (1) a network of frontal, temporal and insular regions where connectivity was negatively correlated with symptom severity (replicating the univariate findings); and (2) a network with anti-correlated elements of the default-mode network and sensorimotor system, where connectivity was positively correlated with symptom severity. These findings support the presence of connectomic signatures of symptom complaints following a sport-related concussion, including both increased and decreased functional connectivity within distinct functional brain networks.	[Churchill, Nathan W.; Hutchison, Michael G.; Schweizer, Tom A.] St Michaels Hosp, Neurosci Res Program, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON, Canada; [Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Graham, Simon J.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Graham, Simon J.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Phys Sci Platform, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Fac Med Neurosurg, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Inst Biomat & Biomed Engn IBBME, Toronto, ON, Canada	Churchill, NW (corresponding author), 209 Victoria St, Toronto, ON M5B 1M8, Canada.	ChurchillN@smh.ca			Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [RN294001-367456]; Canadian Institutes of Military and Veterans Health (CIMVHR) [W7714-145967]; Siemens Canada Ltd.	This work was supported by the Canadian Institutes of Health Research (CIHR) [grant number RN294001-367456]; the Canadian Institutes of Military and Veterans Health (CIMVHR) [grant number W7714-145967]; and pilot funding from Siemens Canada Ltd.	Badre D, 2008, TRENDS COGN SCI, V12, P193, DOI 10.1016/j.tics.2008.02.004; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bro R, 1996, MULTILINEAR PLS J CH, V10; Broyd SJ, 2009, NEUROSCI BIOBEHAV R, V33, P279, DOI 10.1016/j.neubiorev.2008.09.002; Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9; Churchill NW, 2017, NEUROIMAGE-CLIN, V14, P480, DOI 10.1016/j.nicl.2017.02.015; Critchley HD, 2005, J COMP NEUROL, V493, P154, DOI 10.1002/cne.20749; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P895, DOI 10.1136/bjsports-2016-097466; Garrity AG, 2007, AM J PSYCHIAT, V164, P450, DOI 10.1176/appi.ajp.164.3.450; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Graham D, 2002, TRAUMA GREENFIELDS N; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Guskiewicz KM, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P65, DOI 10.1007/0-387-32565-4_4; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hillary FG, 2015, NEUROPSYCHOLOGY, V29, P59, DOI 10.1037/neu0000110; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kelly AMC, 2008, NEUROIMAGE, V39, P527, DOI 10.1016/j.neuroimage.2007.08.008; Krishnan A, 2011, NEUROIMAGE, V56, P455, DOI 10.1016/j.neuroimage.2010.07.034; Li W, 2013, NEUROIMAGE, V78, P46, DOI 10.1016/j.neuroimage.2013.04.011; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Mummery CJ, 2000, ANN NEUROL, V47, P36; Pearlson GD, 1997, PROG NEURO-PSYCHOPH, V21, P1203, DOI 10.1016/S0278-5846(97)00159-0; Putukian M, 2015, CLIN J SPORT MED, V25, P36, DOI 10.1097/JSM.0000000000000102; Rosipal R, 2006, LECT NOTES COMPUT SC, V3940, P34, DOI 10.1007/11752790_2; Sala-Llonch R, 2012, CORTEX, V48, P1187, DOI 10.1016/j.cortex.2011.07.006; Schweizer TA, 2008, NEUROREHAB NEURAL RE, V22, P72, DOI 10.1177/1545968307305303; Schweizer TA, 2007, NEUROPSYCHOLOGIA, V45, P3068, DOI 10.1016/j.neuropsychologia.2007.05.018; Shenton ME, 2001, SCHIZOPHR RES, V49, P1, DOI 10.1016/S0920-9964(01)00163-3; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Strick PL, 2009, ANNU REV NEUROSCI, V32, P413, DOI 10.1146/annurev.neuro.31.060407.125606; van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Vogt BA, 2016, J CHEM NEUROANAT, V74, P28, DOI 10.1016/j.jchemneu.2016.01.010; Wong CW, 2012, NEUROIMAGE, V63, P356, DOI 10.1016/j.neuroimage.2012.06.035; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	48	12	12	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2018	18						518	526		10.1016/j.nicl.2018.02.011			9	Neuroimaging	Neurosciences & Neurology	GH1NG	WOS:000433169000053	29560308	DOAJ Gold, Green Published			2021-06-18	
J	Cullen, B; Pownall, J; Cummings, J; Baylan, S; Broomfield, N; Haig, C; Kersel, D; Murray, H; Evans, JJ				Cullen, Breda; Pownall, Jaycee; Cummings, Joanne; Baylan, Satu; Broomfield, Niall; Haig, Caroline; Kersel, Denyse; Murray, Heather; Evans, Jonathan J.			Positive PsychoTherapy in ABI Rehab (PoPsTAR): A pilot randomised controlled trial	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Brain injury; stroke; positive psychology; psychotherapy; randomised controlled trial	TRAUMATIC BRAIN-INJURY; BEHAVIORAL-THERAPY; DEPRESSION; METAANALYSIS; PSYCHOLOGY; PEOPLE; STROKE; REHABILITATION; INTERVENTIONS; POSTSTROKE	Psychological distress is common following acquired brain injury (ABI), but the evidence base for psychotherapeutic interventions is small and equivocal. Positive psychotherapy aims to foster well-being by increasing experiences of pleasure, engagement and meaning. In this pilot trial, we investigated the feasibility and acceptability of brief positive psychotherapy in adults with ABI and emotional distress. Participants were randomised to brief positive psychotherapy plus usual treatment, or usual treatment only. Brief positive psychotherapy was delivered over eight individual out-patient sessions, by one research psychologist. A blinded assessor administered the Depression Anxiety Stress Scales (DASS-21) and the Authentic Happiness Inventory (AHI) at 5, 9 and 20 weeks post-baseline. Of 27 participants randomised (median age 57; 63% male; 82% ischaemic stroke survivors; median 5.7 months post-injury), 14 were assigned to positive psychotherapy, of whom 8 completed treatment. The intervention was feasible to deliver with excellent fidelity, and was acceptable to participants. Retention at 20 weeks was 63% overall. A full-scale trial would need to retain n=39 per group to end-point, to detect a significant difference in change scores on the DASS-21 Depression scale of 7 points (two-tailed alpha=.05, power=.80). Trials including an active control arm would require larger sample sizes. We conclude that a full-scale trial to investigate efficacy is warranted.	[Cullen, Breda; Pownall, Jaycee; Cummings, Joanne; Baylan, Satu; Broomfield, Niall; Evans, Jonathan J.] Univ Glasgow, Inst Hlth & Wellbeing, Mental Hlth & Wellbeing, Glasgow, Lanark, Scotland; [Cummings, Joanne] Univ Strathclyde, Sch Psychol Sci & Hlth, Glasgow, Lanark, Scotland; [Broomfield, Niall] NHS Greater Glasgow & Clyde, Stroke Psychol Serv, Glasgow, Lanark, Scotland; [Haig, Caroline; Murray, Heather] Univ Glasgow, Inst Hlth & Wellbeing, Robertson Ctr Biostat, Glasgow, Lanark, Scotland; [Kersel, Denyse] NHS Greater Glasgow & Clyde, Community Treatment Ctr Brain Injury, Glasgow, Lanark, Scotland	Evans, JJ (corresponding author), Univ Glasgow, Gartnavel Royal Hosp, Acad Ctr, Mental Hlth & Wellbeing, Glasgow G12 0XH, Lanark, Scotland.	jonathan.evans@glasgow.ac.uk	Cullen, Breda/C-9154-2012; Cullen, Breda/N-3449-2019	Cullen, Breda/0000-0002-7259-9505; Cullen, Breda/0000-0002-7259-9505; Broomfield, Niall/0000-0003-2599-3435	Scottish Executive Health Department, Chief Scientist Office [CZH/4/778]; Chief Scientist Office [CZH/4/778] Funding Source: researchfish	This study was funded by the Scottish Executive Health Department, Chief Scientist Office [ref. CZH/4/778]. Support with sample recruitment was received through the Scottish Stroke Research Network.	Andrewes HE, 2014, BRAIN INJURY, V28, P965, DOI 10.3109/02699052.2014.888764; Bedard M, 2014, J HEAD TRAUMA REHAB, V29, pE13, DOI 10.1097/HTR.0b013e3182a615a0; Bolier L, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-119; Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Broomfield NM, 2011, CLIN PSYCHOL PSYCHOT, V18, P202, DOI 10.1002/cpp.711; Burton CAC, 2013, INT J STROKE, V8, P545, DOI 10.1111/j.1747-4949.2012.00906.x; Craig P., 2008, DEV EVALUATING COMPL; Enderby P, 2013, FRENCHAY APHASIA SCR; Evans JJ, 2011, BRAIN IMPAIR, V12, P117, DOI 10.1375/brim.12.2.117; Gracey F, 2009, NEUROPSYCHOL REHABIL, V19, P867, DOI 10.1080/09602010903027763; Hackett ML, 2014, INT J STROKE, V9, P1017, DOI 10.1111/ijs.12357; Hackett ML, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003437.pub3; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kneebone II, 2016, COGN BEHAV PRACT, V23, P99, DOI 10.1016/j.cbpra.2015.02.001; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; Malec JF., 2005, The Mayo-Portland Adaptability Inventory; Osborn AJ, 2014, NEUROSCI BIOBEHAV R, V47, P1, DOI 10.1016/j.neubiorev.2014.07.007; Peterson C., 2004, BRIEF STRENGTHS TEST; Peterson C., 2005, AUTHENTIC HAPPINESS; Pohjasvaara T, 2001, EUR J NEUROL, V8, P315, DOI 10.1046/j.1468-1331.2001.00182.x; Randolph C, 1998, REPEATABLE BATTERY A; Rashid T, 2013, CURRENT PSYCHOTHERAP, P461; Rogan C, 2013, NEUROPSYCHOL REHABIL, V23, P639, DOI 10.1080/09602011.2013.799076; Schiffrin HH, 2010, J HAPPINESS STUD, V11, P33, DOI 10.1007/s10902-008-9104-7; Seligman M, 2011, **DROPPED REF**; Seligman MEP, 2000, AM PSYCHOL, V55, P5, DOI 10.1037/0003-066X.55.1.5; Sherer M., 2004, The Awareness Questionnaire. The center for outcome measurement in brain injury; Soo C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005239.pub2; Swift JK, 2012, J CONSULT CLIN PSYCH, V80, P547, DOI 10.1037/a0028226; Thomas SA, 2013, CLIN REHABIL, V27, P398, DOI 10.1177/0269215512462227; Thornton M, 2003, J GERONTOL B-PSYCHOL, V58, pS127, DOI 10.1093/geronb/58.2.S127; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Wechsler D., 2011, TEST PREMORBID FUNCT; Wechsler D, 2010, WECHSLER ADULT INTEL; Wechsler D., 2011, WECHSLER ABBREVIATED; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; WIERZBICKI M, 1993, PROF PSYCHOL-RES PR, V24, P190, DOI 10.1037/0735-7028.24.2.190	38	12	12	2	24	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2018	28	1					17	33		10.1080/09602011.2015.1131722			17	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	FR0UL	WOS:000418779100002	26726854	Green Accepted			2021-06-18	
J	Dong, C; Helton, ES; Zhou, P; Ouyang, X; de Tassigny, XD; Pascual, A; Lopez-Barneo, J; Ubogu, EE				Dong, Chaoling; Helton, E. Scott; Zhou, Ping; Ouyang, Xuan; d Anglemont de Tassigny, Xavier; Pascual, Alberto; Lopez-Barneo, Jose; Ubogu, Eroboghene E.			Glial-derived neurotrophic factor is essential for blood-nerve barrier functional recovery in an experimental murine model of traumatic peripheral neuropathy	TISSUE BARRIERS			English	Article						Animal model; blood-nerve barrier; conditional knockout; glial-derived neurotrophic factor; mouse; peripheral neuropathy; permeability; sciatic nerve crush injury; trauma	BRAIN-BARRIER; PHENOTYPIC HETEROGENEITY; VESICULAR TRANSPORT; TYROSINE KINASE; SCHWANN-CELLS; GDNFR-ALPHA; EXPRESSION; INJURY; PAIN; PERMEABILITY	There is emerging evidence that glial-derived neurotrophic factor (GDNF) is a potent inducer of restrictive barrier function in tight junction-forming microvascular endothelium and epithelium, including the human blood-nerve barrier (BNB) in vitro. We sought to determine the role of GDNF in restoring BNB function in vivo by evaluating sciatic nerve horseradish peroxidase (HRP) permeability in tamoxifen-inducible GDNF conditional knockout (CKO) adult mice following non-transecting crush injury via electron microscopy, with appropriate wildtype (WT) and heterozygous (HET) littermate controls. A total of 24 age-, genotype-and sex-matched mice >12 weeks of age were injected with 30 mg/kgHRP via tail vein injection 7 or 14 days following unilateral sciatic nerve crush, and both sciatic nerves were harvested 30 minutes later for morphometric assessment by light and electron microscopy. The number and percentage of HRP-permeable endoneurial microvessels were ascertained to determine the effect of GDNF in restoring barrier function in vivo. Following sciatic nerve crush, there was significant upregulation in GDNF protein expression in WT and HET mice that was abrogated in CKO mice. GDNF significantly restored sciatic nerve BNB HRP impermeability to near normal levels by day 7, with complete restoration seen by day 14 in WT and HET mice. A significant recovery lag was observed in CKO mice. This effect was independent on VE-Cadherin or claudin-5 expression on endoneurial microvessels. These results imply an important role of GDNF in restoring restrictive BNB function in vivo, suggesting a potential strategy to re-establish the restrictive endoneurial microenvironment following traumatic peripheral neuropathies.	[Dong, Chaoling; Helton, E. Scott; Zhou, Ping; Ouyang, Xuan; Ubogu, Eroboghene E.] Univ Alabama Birmingham, Dept Neurol, Div Neuromuscular Dis, Neuromuscular Immunopathol Res Lab, UAB Stn, Birmingham, AL 35294 USA; [d Anglemont de Tassigny, Xavier; Pascual, Alberto; Lopez-Barneo, Jose] Univ Seville, CSIC, Hosp Univ Virgen Rocio, Inst Biomed Sevilla IBiS, Seville, Spain	Ubogu, EE (corresponding author), Univ Alabama Birmingham, Dept Neurol, Div Neuromuscular Dis, 1720 7th Ave South,Sparks Ctr 200, Birmingham, AL 35294 USA.	eeubogu@uabmc.edu	Ubogu, Eroboghene/R-3894-2019; Pascual, Alberto/E-9609-2015	Ubogu, Eroboghene/0000-0002-8307-9994; Pascual, Alberto/0000-0001-5459-6207; ouyang, xuan/0000-0003-0356-4883	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS075212]; University of Alabama at Birmingham; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS075212] Funding Source: NIH RePORTER	This project was supported by National Institutes of Health (NIH) under Grant R01 NS075212 [2012-2017] and institutional funds from the University of Alabama at Birmingham. The funding sources had no involvement in the conduct of the research, manuscript preparation, data collection/analyses or decision to submit this work for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a; Aird WC, 2007, CIRC RES, V100, P174, DOI 10.1161/01.RES.0000255690.03436.ae; Allen SJ, 2013, PHARMACOL THERAPEUT, V138, P155, DOI 10.1016/j.pharmthera.2013.01.004; Amer Diabet Assoc, 2013, DIABETES CARE, V36, P1033, DOI 10.2337/dc12-2625; Argoff CE, 2006, MAYO CLIN PROC, V81, pS3, DOI 10.1016/S0025-6196(11)61474-2; Bar KJ, 1998, NEUROREPORT, V9, P43; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; Bennett DLH, 1998, J NEUROSCI, V18, P3059; Bennett GJ, 1998, HOSP PRACT, V33, P95, DOI 10.3810/hp.1998.10.114; BRIDGE PM, 1994, EXP NEUROL, V127, P284, DOI 10.1006/exnr.1994.1104; Brun P, 2013, GASTROENTEROLOGY, V145, P1323, DOI 10.1053/j.gastro.2013.08.047; Callaghan BC, 2015, JAMA-J AM MED ASSOC, V314, P2172, DOI 10.1001/jama.2015.13611; Chen ZY, 2001, BRAIN RES, V902, P272, DOI 10.1016/S0006-8993(01)02395-2; Dong CL, 2017, EXP NEUROL, V292, P35, DOI 10.1016/j.expneurol.2017.02.012; Dong CL, 2016, ACTA NEUROPATHOL, V132, P739, DOI 10.1007/s00401-016-1599-0; Dworkin RH, 2002, CLIN J PAIN, V18, P343, DOI 10.1097/00002508-200211000-00001; Feldman EL, 2017, NEURON, V93, P1296, DOI 10.1016/j.neuron.2017.02.005; Frenzen PD, 2008, NEUROLOGY, V71, P21, DOI 10.1212/01.wnl.0000316393.54258.d1; Gordois A, 2003, DIABETES CARE, V26, P1790, DOI 10.2337/diacare.26.6.1790; Grinsell D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/698256; Hammarberg H, 1996, NEUROREPORT, V7, P857, DOI 10.1097/00001756-199603220-00004; Hashizume K, 2002, J NEUROPATH EXP NEUR, V61, P725, DOI 10.1093/jnen/61.8.725; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Hoke A, 2000, NEUROREPORT, V11, P1651; Hoke A, 2002, EXP NEUROL, V173, P77, DOI 10.1006/exnr.2001.7826; Ibanez CF, 2017, NEUROBIOL DIS, V97, P80, DOI 10.1016/j.nbd.2016.01.021; Ibanez CF, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009134; Igarashi Y, 1999, BIOCHEM BIOPH RES CO, V261, P108, DOI 10.1006/bbrc.1999.0992; Igarashi Y, 2000, CELL STRUCT FUNCT, V25, P237, DOI 10.1247/csf.25.237; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Jubran M, 2003, EXP NEUROL, V181, P204, DOI 10.1016/S0014-4886(03)00041-4; Kamimura Yasuhiro, 2002, Medical Electron Microscopy, V35, P139, DOI 10.1007/s007950200017; Kaya M, 2011, METHODS MOL BIOL, V763, P369, DOI 10.1007/978-1-61779-191-8_25; Ma NL, 1996, AM J PATHOL, V149, P1745; Magill CK, 2009, J RECONSTR MICROSURG, V25, P345, DOI 10.1055/s-0029-1215526; Marconi S, 2012, TISSUE ENG PT A, V18, P1264, DOI [10.1089/ten.tea.2011.0491, 10.1089/ten.TEA.2011.0491]; Martins T, 2013, NEUROPHARMACOLOGY, V65, P74, DOI 10.1016/j.neuropharm.2012.08.021; Meir M, 2016, AM J PHYSIOL-GASTR L, V310, pG1118, DOI 10.1152/ajpgi.00125.2016; Meir M, 2015, AM J PHYSIOL-GASTR L, V309, pG613, DOI 10.1152/ajpgi.00357.2014; Mizisin AP, 2011, ACTA NEUROPATHOL, V121, P291, DOI 10.1007/s00401-010-0783-x; Mukhamedshina YO, 2017, NEURAL PLAST, V2017, DOI 10.1155/2017/9857918; Natsume A, 2003, EXP NEUROL, V184, P878, DOI 10.1016/S0014-4886(03)00334-0; Naveilhan P, 1997, EUR J NEUROSCI, V9, P1450, DOI 10.1111/j.1460-9568.1997.tb01499.x; Nico B, 2003, GLIA, V42, P235, DOI 10.1002/glia.10216; Noble J, 1998, J TRAUMA, V45, P116, DOI 10.1097/00005373-199807000-00025; Palispis WA, 2017, EXP NEUROL, V290, P106, DOI 10.1016/j.expneurol.2017.01.009; Palladino SP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17475-y; Pascual A, 2008, NAT NEUROSCI, V11, P755, DOI 10.1038/nn.2136; Peltonen S, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.24956; Potente M, 2017, NAT REV MOL CELL BIO, V18, P477, DOI 10.1038/nrm.2017.36; Reddy CL, 2013, CELL MOL NEUROBIOL, V33, P789, DOI 10.1007/s10571-013-9946-3; Reina M A, 2003, Rev Esp Anestesiol Reanim, V50, P80; Reina M A, 2000, Rev Esp Anestesiol Reanim, V47, P464; Saadoun S, 2009, NEUROSCIENCE, V161, P764, DOI 10.1016/j.neuroscience.2009.03.069; Sadosky A, 2015, J DIABETES COMPLICAT, V29, P212, DOI 10.1016/j.jdiacomp.2014.10.013; Shimizu F, 2012, NEUROCHEM RES, V37, P401, DOI 10.1007/s11064-011-0626-8; Smith BH, 2012, CURR PAIN HEADACHE R, V16, P191, DOI 10.1007/s11916-012-0256-0; Smith CE, 2001, MICROSURG, V21, P290, DOI 10.1002/micr.1055; Steinkamp M, 2003, GASTROENTEROLOGY, V124, P1748, DOI 10.1016/S0016-5085(03)00404-9; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Tannemaat MR, 2008, EUR J NEUROSCI, V28, P1467, DOI 10.1111/j.1460-9568.2008.06452.x; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Ubogu EE, 2015, ACTA NEUROPATHOL, V130, P445, DOI 10.1007/s00401-015-1466-4; Ubogu EE, 2013, J VASC RES, V50, P289, DOI 10.1159/000353293; Ubogu EE, 2012, TRANSL NEUROSCI, V3, P373, DOI 10.2478/s13380-012-0039-4; Ubogu EE, 2012, J PERIPHER NERV SYST, V17, P53, DOI 10.1111/j.1529-8027.2012.00375.x; Ueno M, 2001, NEUROBIOL AGING, V22, P469, DOI 10.1016/S0197-4580(01)00213-5; Watson JC, 2015, MAYO CLIN PROC, V90, P940, DOI 10.1016/j.mayocp.2015.05.004; Xia RH, 2010, NEUROPATH APPL NEURO, V36, P388, DOI 10.1111/j.1365-2990.2010.01092.x; Xia RH, 2010, J NEUROIMMUNOL, V219, P54, DOI 10.1016/j.jneuroim.2009.11.019; Xu P, 2013, GLIA, V61, P1029, DOI 10.1002/glia.22491; Yano K, 2007, BLOOD, V109, P613, DOI 10.1182/blood-2006-05-026401; Yawn BP, 2009, PAIN MED, V10, P586, DOI 10.1111/j.1526-4637.2009.00588.x; Yosef N, 2012, MICROVASC RES, V83, P298, DOI 10.1016/j.mvr.2012.01.005; Yuan FR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090463	76	12	12	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	2168-8370			TISSUE BARRIERS	Tissue Barriers		2018	6	2							e1479570	10.1080/21688370.2018.1479570			22	Medicine, Research & Experimental	Research & Experimental Medicine	GW0GH	WOS:000446541000004	29913111	Bronze, Green Published			2021-06-18	
J	Downey, RI; Hutchison, MG; Comper, P				Downey, Rachel I.; Hutchison, Michael G.; Comper, Paul			Determining sensitivity and specificity of the Sport Concussion Assessment Tool 3 (SCAT3) components in university athletes	BRAIN INJURY			English	Article						Sport-related concussion; Balance Error Scoring System (BESS); Standardized Assessment of Concussion (SAC); Post Concussion Symptom Scale (PCSS); Sport Concussion Assessment Tool (SCAT-3)	BASE-LINE VALUES; HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; POSTURAL STABILITY; FOOTBALL PLAYERS; STATEMENT; ASSOCIATION; HISTORY	Objective: To examine the clinical utility of the Sport Concussion Assessment Tool-3 (SCAT3) in university athletes with concussion in the absence and presence of baseline data over time. Methods: Athletes with concussion (n = 23) and uninjured controls (n = 22) were prospectively evaluated at three time-points (baseline, 3-5 days, 3 weeks post-injury) with the SCAT3 components: (1) Post-Concussion Symptom Scale (PCSS); (2) Standardized Assessment of Concussion (SAC); and (3) modified Balance Error Scoring System (m-BESS). Sensitivity and specificity were calculated using reliable change indices and normative data from 458 athletes who completed baseline testing. Results: The PCSS total symptom score yielded highest sensitivity (47.4-72.2%) and specificity (78.6-91.7%) 3-5 days post-injury, with the SAC and m-BESS demonstrating little discriminative ability when used more than 3 days post-concussion. The utility of the SCAT3 was comparable when baseline or normative data was used for predicting concussion. Conclusion: The SCAT is a clinically useful tool for assessing concussion in the absence or presence of baseline data within the first 3-5 days post-injury. Clinical utility of the SCAT3 was driven by symptoms, which remains consistent in the SCAT5. Future research should explore whether additional cognitive elements in the SCAT5 improve utility beyond this timeframe.	[Downey, Rachel I.; Comper, Paul] Univ Toronto, Rehabil Sci Inst, Toronto, ON, Canada; [Hutchison, Michael G.; Comper, Paul] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Comper, Paul] Toronto Rehabil Inst, Neuropsychol Dept, Toronto, ON, Canada	Downey, RI (corresponding author), Concordia Univ, Dept Psychol, 7141 Sherbrooke St West, Montreal, PQ H4B 1R6, Canada.	downeyr01@gmail.com			Canadian Institutes of Military and Veterans Health (CIMVHR) [W7714-145967]	This work was supported by the Canadian Institutes of Military and Veterans Health (CIMVHR) [grant number W7714-145967].	Chin EY, 2016, AM J SPORT MED, V44, P2276, DOI 10.1177/0363546516648141; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Davis G.A., 2017, BR J SPORTS MED, V5, P1, DOI DOI 10.1136/BJSPORTS-2017-097506; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory PR, 2017, BRIT J SPORT MED, V51; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; Okonkwo David O, 2014, Neurosurgery, V75 Suppl 4, pS82, DOI 10.1227/NEU.0000000000000493; Putukian M, 2015, CLIN J SPORT MED, V25, P36, DOI 10.1097/JSM.0000000000000102; Register-Mihalik JK, 2009, SPORTS HEALTH, V1, P61, DOI 10.1177/1941738108325920; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Snyder AR, 2014, CLIN NEUROPSYCHOL, V28, P1091, DOI 10.1080/13854046.2014.952667; Zimmer A, 2015, APPL NEUROPSYCH-ADUL, V22, P132, DOI 10.1080/23279095.2013.867265	21	12	12	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2018	32	11					1345	1352		10.1080/02699052.2018.1484166			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	GZ6GX	WOS:000449534000005	29902070				2021-06-18	
J	Dragojevic, T; Hollmann, JL; Tamborini, D; Portaluppi, D; Buttafava, M; Culver, JP; Villa, F; Durduran, T				Dragojevic, Tanja; Hollmann, Joseph L.; Tamborini, Davide; Portaluppi, Davide; Buttafava, Mauro; Culver, Joseph P.; Villa, Federica; Durduran, Turgut			Compact, multi-exposure speckle contrast optical spectroscopy (SCOS) device for measuring deep tissue blood flow	BIOMEDICAL OPTICS EXPRESS			English	Article							OBSTRUCTIVE SLEEP-APNEA; CEREBRAL METABOLIC-RATE; LASER-DOPPLER; RESOLUTION; OXYGEN	Speckle contrast optical spectroscopy (SCOS) measures absolute blood flow in deep tissue, by taking advantage of multi-distance (previously reported in the literature) or multi-exposure (reported here) approach. This method promises to use inexpensive detectors to obtain good signal-to-noise ratio, but it has not yet been implemented in a suitable manner for a mass production. Here we present a new, compact, low power consumption, 32 by 2 single photon avalanche diode (SPAD) array that has no readout noise, low dead lime and has high sensitivity in low light conditions, such as in vivo measurements. To demonstrate the capability to measure blood flow in deep tissue, healthy volunteers were measured, showing no significant differences from the diffuse correlation spectroscopy. In the future, this array can be miniaturized to a low-cost, robust, battery operated wireless device paving the way for measuring blood flow in a wide-range of applications from sport injury recovery and training to, on-field concussion detection to wearables. (c) 2017 Optical Society of America under the terms of the OSA Open Access Publishing Agreement	[Dragojevic, Tanja; Hollmann, Joseph L.; Durduran, Turgut] Barcelona Inst Sci & Technol, ICFO Inst Ciencies Foton, Av Carl Friedrich Gauss 3, Castelldefels 08860, Barcelona, Spain; [Tamborini, Davide; Portaluppi, Davide; Buttafava, Mauro; Villa, Federica] Politecn Milan, Dipartimento Elettron Informat & Bioingn, Piazza Leonardo Da Vinci 32, I-20133 Milan, Italy; [Culver, Joseph P.] Washington Univ, Dept Radiol, Sch Med, St Louis, MO 63110 USA; [Culver, Joseph P.] Washington Univ, Dept Phys, St Louis, MO 63130 USA; [Durduran, Turgut] ICREA, Barcelona 08015, Spain	Dragojevic, T (corresponding author), Barcelona Inst Sci & Technol, ICFO Inst Ciencies Foton, Av Carl Friedrich Gauss 3, Castelldefels 08860, Barcelona, Spain.	tanja.dragojevic@icfo.eu	Dragojevic, Tanja/AAA-5923-2019; Villa, Federica A/G-9558-2014; Dragojevic, Tanja/G-5136-2015	Villa, Federica A/0000-0002-9840-0269; Dragojevic, Tanja/0000-0002-7643-0846	Fundacio CELLEX BarcelonaFoundation CELLEXEuropean Commission; Instituto de Salud Carlos III/FEDER (MEDPHOTAGE) [DTS16/00087]; "Severe Ochoa" Programme for Centres of Excellence in RD [SEV-2015-0522]; Obra social "la Caixa" Foundation (LlumMedBcn); LASERLAB-EUROPE IV; Marie Curie COFUND (FP7-PEOPLE-COFUND) fellowship; Ministerio de Economia y Competitividad (PHOTODEMENTIA) [DPI2015-64358-c1, DPI2015-64358-c2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS090874, R01NS078223, R01NS099429] Funding Source: NIH RePORTER	Fundacio CELLEX Barcelona, Ministerio de Economia y Competitividad (PHOTODEMENTIA (DPI2015-64358-c1 and c2 (MINECO/FEDER)), Instituto de Salud Carlos III/FEDER (MEDPHOTAGE DTS16/00087), the "Severe Ochoa" Programme for Centres of Excellence in R&D (SEV-2015-0522), the Obra social "la Caixa" Foundation (LlumMedBcn), LASERLAB-EUROPE IV. J.L.Hollmann acknowledges the Marie Curie COFUND (FP7-PEOPLE-2013-COFUND) fellowship.	Atsumori H, 2009, REV SCI INSTRUM, V80, DOI 10.1063/1.3115207; Bandyopadhyay R, 2005, REV SCI INSTRUM, V76, DOI 10.1063/1.2037987; Bi R, 2013, OPT EXPRESS, V21, P22854, DOI 10.1364/OE.21.022854; Bi RZ, 2013, OPT LETT, V38, P1401, DOI 10.1364/OL.38.001401; Boas D. A., 2010, J BIOMED OPT, V15; Boas D. A., 1996, THESIS; BOAS DA, 1995, PHYS REV LETT, V75, P1855, DOI 10.1103/PhysRevLett.75.1855; Boas DA, 2016, NEUROPHOTONICS, V3, DOI 10.1117/1.NPh.3.3.031412; Boas DA, 2011, PHILOS T R SOC A, V369, P4407, DOI 10.1098/rsta.2011.0250; Briers JD, 2001, PHYSIOL MEAS, V22, pR35, DOI 10.1088/0967-3334/22/4/201; Bronzi D, 2014, IEEE J SEL TOP QUANT, V20, DOI 10.1109/JSTQE.2014.2341562; Bronzi D, 2013, IEEE PHOTONIC TECH L, V25, P776, DOI 10.1109/LPT.2013.2251621; Devor A, 2012, J CEREBR BLOOD F MET, V32, P1259, DOI 10.1038/jcbfm.2011.195; Dietsche G, 2007, APPL OPTICS, V46, P8506, DOI 10.1364/AO.46.008506; Dragojevic T, 2015, BIOMED OPT EXPRESS, V6, P2865, DOI 10.1364/BOE.6.002865; Duchna HW, 2000, AM J RESP CRIT CARE, V161, P187, DOI 10.1164/ajrccm.161.1.9810062; Dunn AK, 2001, J CEREBR BLOOD F MET, V21, P195, DOI 10.1097/00004647-200103000-00002; Dunn AK, 2012, ANN BIOMED ENG, V40, P367, DOI 10.1007/s10439-011-0469-0; Durduran T, 2010, REP PROG PHYS, V73, DOI 10.1088/0034-4885/73/7/076701; Giavarina D, 2015, BIOCHEM MEDICA, V25, P141, DOI 10.11613/BM.2015.015; Kameyama M, 2004, NEUROIMAGE, V22, P1715, DOI 10.1016/j.neuroimage.2004.03.050; Kazmi SMS, 2013, J CEREBR BLOOD F MET, V33, P798, DOI 10.1038/jcbfm.2013.57; Parthasarathy AB, 2010, BIOMED OPT EXPRESS, V1, P246, DOI 10.1364/BOE.1.000246; Pinti P, 2015, JOVE-J VIS EXP, DOI 10.3791/53336; Piper SK, 2014, NEUROIMAGE, V85, P64, DOI 10.1016/j.neuroimage.2013.06.062; Quaresima V., 2016, ORGAN RES METH; Rajan V, 2009, LASER MED SCI, V24, P269, DOI 10.1007/s10103-007-0524-0; Rodgers ZB, 2016, J CEREBR BLOOD F MET, V36, P755, DOI 10.1177/0271678X15605855; Rodgers ZB, 2013, J CEREBR BLOOD F MET, V33, P1514, DOI 10.1038/jcbfm.2013.110; Scarcella C, 2013, REV SCI INSTRUM, V84, DOI 10.1063/1.4850677; Sun S, 2015, OPT LETT, V40, P4587, DOI 10.1364/OL.40.004587; Takeuchi N, 2016, BMC NEUROSCI, V17, DOI 10.1186/s12868-016-0244-0; Tamborini D, 2016, IEEE SENS J, V16, P3827, DOI 10.1109/JSEN.2016.2535403; Valdes CP, 2014, BIOMED OPT EXPRESS, V5, P2769, DOI 10.1364/BOE.5.002769; van Beek AHEA, 2011, J NEUROIMAGING, V21, P340, DOI 10.1111/j.1552-6569.2010.00517.x; Walsh B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04357-6; Yu GQ, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1884603; Zauner A., 1997, HEAD INJURY, P89	38	12	12	0	9	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	2156-7085			BIOMED OPT EXPRESS	Biomed. Opt. Express	JAN 1	2018	9	1					322	334		10.1364/BOE.9.000322			13	Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging	Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging	FQ8US	WOS:000418639300024	29359106	DOAJ Gold, Green Published			2021-06-18	
J	Emelifeonwu, JA; Reid, K; Rhodes, JKJ; Myles, L				Emelifeonwu, John A.; Reid, Kirsten; Rhodes, Jonathan K. J.; Myles, Lynn			Saved by the Pupillometer! - A role for pupillometry in the acute assessment of patients with traumatic brain injuries?	BRAIN INJURY			English	Article						Traumatic brain injury; TBI; acute subdural haematoma; neuroICU; pupillometer; NPi; uncal herniation	REACTIVITY	There is good evidence that pupil reactivity is useful for prognostication in acute head injuries. Despite this, most pupil assessments are subjective and are performed by physicians who may not be experts. They can therefore be unreliable. We present a case of a patient with seemingly irreversible demise from an acute traumatic subdural haematoma. This was determined by assessment of his pupils, which were non-reactive to light at the time of arrival to the neurosurgical theatre. He was transferred to the neurointensive care for brainstem death testing, where assessment by objective pupillometry determined that his pupils were in fact reactive. He made a good recovery following subsequent surgery to evacuate his subdural haematoma. We propose the widespread adoption of objective pupillometers in the assessment of acute head-injured patients and offer our case as an example of how an objective and accurate assessment can make a difference to patients' outcome.	[Emelifeonwu, John A.; Myles, Lynn] Western Gen Hosp, Dept Neurosurg, Crewe Rd South, Edinburgh EH4 2XU, Midlothian, Scotland; [Reid, Kirsten; Rhodes, Jonathan K. J.] Western Gen Hosp, Dept Neurointens Care, Edinburgh, Midlothian, Scotland	Emelifeonwu, JA (corresponding author), Western Gen Hosp, Dept Neurosurg, Crewe Rd South, Edinburgh EH4 2XU, Midlothian, Scotland.	johnemelifeonwu@gmail.com					ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010; Chen Jeff W, 2011, Surg Neurol Int, V2, P82, DOI 10.4103/2152-7806.82248; Clusmann H, 2001, J NEUROL NEUROSUR PS, V71, P175, DOI 10.1136/jnnp.71.2.175; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Kramer CL, 2014, NEUROCRIT CARE, V21, P309, DOI 10.1007/s12028-014-9988-5; Kuo JR, 2011, J FORMOS MED ASSOC, V110, P258, DOI 10.1016/S0929-6646(11)60038-7; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; Litvan I, 2000, NEUROLOGY, V54, P530, DOI 10.1212/WNL.54.2.530; Meeker Michele, 2005, J Neurosci Nurs, V37, P34; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y	10	12	13	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2018	32	5					675	677		10.1080/02699052.2018.1429021			3	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FY7WL	WOS:000427074200020	29388863				2021-06-18	
J	Ferris, CF; Morrison, TR; Iriah, S; Malmberg, S; Kulkarni, P; Hartner, JC; Trivedi, M				Ferris, Craig F.; Morrison, Thomas R.; Iriah, Sade; Malmberg, Samantha; Kulkarni, Praveen; Hartner, Jochen C.; Trivedi, Malav			Evidence of Neurobiological Changes in the Presymptomatic PINK1 Knockout Rat	JOURNAL OF PARKINSONS DISEASE			English	Article						PTEN-induced putative kinase 1; diffusion weighted imaging; biomarkers; Parkinson's disease; quantitative; anisotropy; substantia nigra	TRAUMATIC BRAIN-INJURY; IDIOPATHIC PARKINSONS-DISEASE; DORSAL COLUMN NUCLEI; MITOCHONDRIAL DYSFUNCTION; BASAL GANGLIA; ALPHA-SYNUCLEIN; OLFACTORY DYSFUNCTION; SELECTIVE HYPOSMIA; MOTOR DYSFUNCTION; MUTATION CARRIERS	Background: Genetic models of Parkinson's disease (PD) coupled with advanced imaging techniques can elucidate neurobiological disease progression, and can help identify early biomarkers before clinical signs emerge. PTEN-induced putative kinase 1 (PINK1) helps protect neurons from mitochondrial dysfunction, and a mutation in the associated gene is a risk factor for recessive familial PD. The PINK1 knockout (KO) rat is a novel model for familial PD that has not been neuroradiologically characterized for alterations in brain structure/function, alongside behavior, prior to 4 months of age. Objective: To identify biomarkers of presymptomatic PD in the PINK1 -/- rat at 3 months using magnetic resonance imaging techniques. Methods: At postnatal weeks 12-13; one month earlier than previously reported signs of motor and cognitive dysfunction, this study combined imaging modalities, including assessment of quantitative anisotropy across 171 individual brain areas using an annotated MRI rat brain atlas to identify sites of gray matter alteration between wild-type and PINK1 -/- rats. Results: The olfactory system, hypothalamus, thalamus, nucleus accumbens, and cerebellum showed differences in anisotropy between experimental groups. Molecular analyses revealed reduced levels of glutathione, ATP, and elevated oxidative stress in the substantia nigra, striatum and deep cerebellar nuclei. Mitochondrial genes encoding proteins in Complex IV, along with mRNA levels associated with mitochondrial function and genes involved in glutathione synthesis were reduced. Differences in brain structure did not align with any cognitive or motor impairment. Conclusions: These data reveal early markers, and highlight novel brain regions involved in the pathology of PD in the PINK1 -/- rat before behavioral dysfunction occurs.	[Ferris, Craig F.; Morrison, Thomas R.; Iriah, Sade; Malmberg, Samantha; Kulkarni, Praveen] Northeastern Univ, Ctr Translat NeuroImaging, Boston, MA 02115 USA; [Ferris, Craig F.] Northeastern Univ, Dept Psychol & Pharmaceut Sci, Boston, MA 02115 USA; [Trivedi, Malav] Nova Southeastern Univ, Ft Lauderdale, FL 33314 USA; [Hartner, Jochen C.] Horizon Discovery, Cambridge, England	Ferris, CF (corresponding author), Northeastern Univ, Ctr Translat NeuroImaging, Dept Psychol, Boston, MA 02115 USA.	c.ferris@neu.edu		Kulkarni, Praveen/0000-0002-8876-4544			ALLEN GI, 1974, PHYSIOL REV, V54, P957; Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Aumann TD, 1996, J COMP NEUROL, V376, P420; Aumann TD, 1996, J COMP NEUROL, V368, P608, DOI 10.1002/(SICI)1096-9861(19960513)368:4<608::AID-CNE11>3.0.CO;2-D; Balan IS, 2013, J NEUROTRAUM, V30, P367, DOI 10.1089/neu.2012.2339; Baluchnejadmojarad T, 2017, EXP GERONTOL, V100, P70, DOI 10.1016/j.exger.2017.10.023; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Barrot M, 2002, P NATL ACAD SCI USA, V99, P11435, DOI 10.1073/pnas.172091899; Batlevi Y, 2011, NEUROBIOL DIS, V43, P46, DOI 10.1016/j.nbd.2010.09.009; Benito-Leon J, 2011, J NEUROL SCI, V310, P176, DOI 10.1016/j.jns.2011.06.054; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; Bohnen NI, 2007, J NEUROL, V254, P84, DOI 10.1007/s00415-006-0284-y; Bohnen NI, 2008, NEUROSCI LETT, V447, P12, DOI 10.1016/j.neulet.2008.09.070; Bonifati Vincenzo, 2012, Parkinsonism Relat Disord, V18 Suppl 1, pS4, DOI 10.1016/S1353-8020(11)70004-9; Bostan AC, 2010, P NATL ACAD SCI USA, V107, P8452, DOI 10.1073/pnas.1000496107; Brevard ME, 2003, MAGN RESON IMAGING, V21, P995, DOI 10.1016/S0730-725X(03)00204-2; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Cerasa A, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0687-9; Chen CH, 2014, NAT NEUROSCI, V17, P1767, DOI 10.1038/nn.3868; Chen YS, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00009; Dave KD, 2014, NEUROBIOL DIS, V70, P190, DOI 10.1016/j.nbd.2014.06.009; de Lau LML, 2006, LANCET NEUROL, V5, P525, DOI 10.1016/S1474-4422(06)70471-9; DOTY RL, 1988, NEUROLOGY, V38, P1237, DOI 10.1212/WNL.38.8.1237; Double KL, 2003, ARCH NEUROL-CHICAGO, V60, P545, DOI 10.1001/archneur.60.4.545; Eggers C, 2010, NEUROLOGY, V74, P1798, DOI 10.1212/WNL.0b013e3181e0f79c; Elkon H, 2002, J MOL NEUROSCI, V18, P229, DOI 10.1385/JMN:18:3:229; Ephraty L, 2007, MOVEMENT DISORD, V22, P566, DOI 10.1002/mds.21319; Etkin A, 2011, TRENDS COGN SCI, V15, P85, DOI 10.1016/j.tics.2010.11.004; FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Freichel C, 2007, NEUROBIOL AGING, V28, P1421, DOI 10.1016/j.neurobiolaging.2006.06.013; Gaenslen A, 2011, MOVEMENT DISORD, V26, P653, DOI 10.1002/mds.23499; Gan-Or Z, 2015, AUTOPHAGY, V11, P1443, DOI 10.1080/15548627.2015.1067364; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Gispert S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005777; Glasl L, 2012, EXP NEUROL, V235, P214, DOI 10.1016/j.expneurol.2012.01.002; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Goldberg MS, 2005, NEURON, V45, P489, DOI 10.1016/j.neuron.2005.01.041; Grant LM, 2015, J NEUROSCI RES, V93, P1713, DOI 10.1002/jnr.23625; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; Greffard S, 2006, ARCH NEUROL-CHICAGO, V63, P584, DOI 10.1001/archneur.63.4.584; Haehner A, 2009, PARKINSONISM RELAT D, V15, P490, DOI 10.1016/j.parkreldis.2008.12.005; Haehner A, 2007, MOVEMENT DISORD, V22, P839, DOI 10.1002/mds.21413; Harrison FE, 2009, BEHAV BRAIN RES, V198, P247, DOI 10.1016/j.bbr.2008.10.015; HARTLEY A, 1994, J NEUROCHEM, V63, P1987; Hernandez DG, 2016, J NEUROCHEM, V139, P59, DOI 10.1111/jnc.13593; Hoshi E, 2005, NAT NEUROSCI, V8, P1491, DOI 10.1038/nn1544; Hu QS, 2016, TRANSL NEURODEGENER, V5, DOI 10.1186/s40035-016-0060-6; Hummel T, 2010, FRONT INTEGR NEUROSC, V4, DOI 10.3389/fnint.2010.00125; Jost WH, 2003, J NEUROL, V250, P28, DOI 10.1007/s00415-003-1105-z; KALIL K, 1981, J COMP NEUROL, V195, P25, DOI 10.1002/cne.901950105; Kelm-Nelson CA, 2016, NEUROSCI LETT, V621, P75, DOI 10.1016/j.neulet.2016.04.003; King JA, 2005, J NEUROSCI METH, V148, P154, DOI 10.1016/j.jneumeth.2005.04.011; Kitada T, 2009, J NEUROCHEM, V111, P696, DOI 10.1111/j.1471-4159.2009.06350.x; Kranick SM, 2008, NEUROSIGNALS, V16, P35, DOI 10.1159/000109757; Kulkarni P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125748; Kulkarni P, 2012, BEHAV BRAIN RES, V230, P201, DOI 10.1016/j.bbr.2012.02.002; Li SJ, 2017, HUM BRAIN MAPP, V38, P4064, DOI 10.1002/hbm.23648; Li XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071341; Madiha S, 2017, PAK J PHARM SCI, V30, P943; Masliah E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019338; Mentis MJ, 2003, NEUROLOGY, V60, P612, DOI 10.1212/01.WNL.0000044154.92143.DC; Mirdamadi JL, 2016, J NEUROPHYSIOL, V116, P917, DOI 10.1152/jn.01132.2015; MOSELEY ME, 1991, MAGNET RESON MED, V19, P321, DOI 10.1002/mrm.1910190222; Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298; Nuber S, 2008, J NEUROSCI, V28, P2471, DOI 10.1523/JNEUROSCI.3040-07.2008; Onuki Y, 2015, CEREB CORTEX, V25, P313, DOI 10.1093/cercor/bht221; Palikaras Konstantinos, 2012, Frontiers in Genetics, V3, P297, DOI 10.3389/fgene.2012.00297; Pandya JD, 2014, EXP NEUROL, V257, P106, DOI 10.1016/j.expneurol.2014.04.020; Parrao T, 2012, NEURODEGENER DIS, V10, P179, DOI 10.1159/000335915; Peng J, 2005, J BIOL CHEM, V280, P29194, DOI 10.1074/jbc.M500984200; Pham TT, 2010, GENES BRAIN BEHAV, V9, P305, DOI 10.1111/j.1601-183X.2009.00559.x; Ponsen MM, 2004, ANN NEUROL, V56, P173, DOI 10.1002/ana.20160; Reetz K, 2008, BIOL PSYCHIAT, V64, P241, DOI 10.1016/j.biopsych.2007.12.010; Rial D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114216; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Sengupta P, 2013, INT J PREVENTIVE MED, V4, P624; Shear DA, 2010, J NEUROTRAUM, V27, P1911, DOI 10.1089/neu.2010.1399; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Siuda J, 2014, PARKINSONISM RELAT D, V20, P1274, DOI 10.1016/j.parkreldis.2014.08.019; Sommer U, 2004, MOVEMENT DISORD, V19, P1196, DOI 10.1002/mds.20141; Tanner CM, 2003, ADV NEUROL, V91, P133; Torsdottir G, 1999, PHARMACOL TOXICOL, V85, P239, DOI 10.1111/j.1600-0773.1999.tb02015.x; Trivedi M, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.52; Trivedi M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02816-8; Trivedi M, 2014, MOL PHARMACOL, V85, P747, DOI 10.1124/mol.114.091728; Trivedi MS, 2014, J NUTR BIOCHEM, V25, P1011, DOI 10.1016/j.jnutbio.2014.05.004; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Vila M, 1996, NEUROSCIENCE, V71, P903, DOI 10.1016/0306-4522(95)00549-8; Villeneuve LM, 2016, MOL NEUROBIOL, V53, P171, DOI 10.1007/s12035-014-8927-y; Walker MD, 2014, J PARKINSON DIS, V4, P483, DOI 10.3233/JPD-140344; Westermann B, 2008, J NEUROL NEUROSUR PS, V79, P19, DOI 10.1136/jnnp.2006.113860; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Witter L, 2015, CURR OPIN NEUROBIOL, V33, P150, DOI 10.1016/j.conb.2015.03.017; Wu T, 2005, BRAIN, V128, P2250, DOI 10.1093/brain/awh569; Wu T, 2013, BRAIN, V136, P696, DOI 10.1093/brain/aws360; Yamaguchi H, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-10; Yang KM, 2018, BEHAV BRAIN RES, V339, P47, DOI 10.1016/j.bbr.2017.10.036; Yao Q, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00266; Zhang JQ, 2003, P 11 INT SOC MAG RES; Zheng Z, 2014, HUM BRAIN MAPP, V35, P1325, DOI 10.1002/hbm.22256; Zhou W, 2008, J BIOL CHEM, V283, P9863, DOI 10.1074/jbc.M710232200	104	12	12	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1877-7171	1877-718X		J PARKINSON DIS	J. Parkinsons Dis.		2018	8	2					281	301		10.3233/JPD-171273			21	Neurosciences	Neurosciences & Neurology	GJ6AR	WOS:000435465600010	29710734				2021-06-18	
J	Haid, T; Federolf, P				Haid, Thomas; Federolf, Peter			Human Postural Control: Assessment of Two Alternative Interpretations of Center of Pressure Sample Entropy through a Principal Component Factorization of Whole-Body Kinematics	ENTROPY			English	Article						neuromuscular control; motor control; center of pressure COP; principal component analysis PCA; degrees of freedom; complexity; balance; neuroscience	MULTISCALE ENTROPY; CEREBRAL CONCUSSION; APPROXIMATE ENTROPY; COMPLEXITY; VARIABILITY; BALANCE; RECOVERY; FEEDBACK; MOTION; STANCE	Sample entropy (SaEn), calculated for center of pressure (COP) trajectories, is often distinct for compromised postural control, e.g., in Parkinson, stroke, or concussion patients, but the interpretation of COP-SaEn remains subject to debate. The purpose of this paper is to test the hypotheses that COP-SaEn is related (Hypothesis 1; H1) to the complexity of the postural movement structures, i.e., to the utilization and coordination of the mechanical degrees of freedom; or (Hypothesis 2; H2) to the irregularity of the individual postural movement strategies, i.e., to the neuromuscular control of these movements. Twenty-one healthy volunteers (age 26.4 +/- 2.4; 10 females), equipped with 27 reflective markers, stood on a force plate and performed 2-min quiet stances. Principal movement strategies (PMs) were obtained from a principal component analysis (PCA) of the kinematic data. Then SaEn was calculated for the COP and PM time-series. H1 was tested by correlating COP-SaEn to the relative contribution of the PMs to the subject specific overall movement and H2 by correlating COP-SaEn and PM-SaEn. Both hypotheses were supported. This suggests that in a healthy population the COP-SaEn is linked to the complexity of the coordinative structure of postural movements, as well as to the irregularity of the neuromuscular control of specific movement components.	[Haid, Thomas; Federolf, Peter] Univ Innsbruck, Dept Sport Sci, A-6020 Innsbruck, Austria	Haid, T (corresponding author), Univ Innsbruck, Dept Sport Sci, A-6020 Innsbruck, Austria.	thomas.haid@uibk.ac.at; peter.federolf@uibk.ac.at	Federolf, Peter/H-4481-2019	Federolf, Peter/0000-0002-0266-6813			Bockemuhl T, 2010, HUM MOVEMENT SCI, V29, P73, DOI 10.1016/j.humov.2009.03.003; Browne J, 2000, PHYSIOL MEAS, V21, P515, DOI 10.1088/0967-3334/21/4/308; Busa M.A., 2016, J MULT SCLER, V3, P1, DOI [10. 4172/2376-0389. 1000177, DOI 10.4172/2376-0389.1000177]; Busa MA, 2016, J SPORT HEALTH SCI, V5, P44, DOI 10.1016/j.jshs.2016.01.018; Busa MA, 2016, GAIT POSTURE, V45, P7, DOI 10.1016/j.gaitpost.2015.12.007; Cavanaugh JT, 2007, J NEUROENG REHABIL, V4, DOI 10.1186/1743-0003-4-42; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chen M.-S., RESISTANCE TRAININGI; Costa M, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.021906; Daffertshofer A, 2004, CLIN BIOMECH, V19, P415, DOI 10.1016/j.clinbiomech.2004.01.005; de Carvalho M, 2012, CLIN NEUROPHYSIOL, V123, P2312, DOI 10.1016/j.clinph.2012.04.016; Dinkel D, 2017, GAIT POSTURE, V55, P167, DOI 10.1016/j.gaitpost.2017.04.017; Duchateau J, 2011, BRAIN RES, V1409, P42, DOI 10.1016/j.brainres.2011.06.011; Duclos Y, 2008, J NEUROSCI METH, V172, P231, DOI 10.1016/j.jneumeth.2008.05.001; Estrada L, 2017, ENTROPY-SWITZ, V19, DOI 10.3390/e19090460; Federolf P, 2013, J BIOMECH, V46, P2626, DOI 10.1016/j.jbiomech.2013.08.008; Federolf P, 2012, J BIOMECH, V45, P1127, DOI 10.1016/j.jbiomech.2012.02.008; Federolf PA, 2016, J BIOMECH, V49, P364, DOI 10.1016/j.jbiomech.2015.12.030; Fournier KA, 2014, GAIT POSTURE, V39, P420, DOI 10.1016/j.gaitpost.2013.08.016; Gao JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024446; GlOersen O., 2017, J SPORTS SCI, P1, DOI [10.1080/02640414.2017.1298826, DOI 10.1080/02640414.2017.129882628287028, DOI 10.1080/02640414.2017.1298826]; GOLDIE PA, 1989, ARCH PHYS MED REHAB, V70, P510; Hansen C, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00206; Hodson-Tole EF, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00679; Hoffmann CP, 2017, GAIT POSTURE, V54, P236, DOI 10.1016/j.gaitpost.2017.03.015; Kanekar N, 2014, J NEUROSCI METH, V222, P91, DOI 10.1016/j.jneumeth.2013.10.020; Lakhani B, 2015, GAIT POSTURE, V41, P499, DOI 10.1016/j.gaitpost.2014.12.003; Ramdani S, 2009, MED ENG PHYS, V31, P1023, DOI 10.1016/j.medengphy.2009.06.004; Senthinathan A, 2017, CLIN J SPORT MED, V27, P288, DOI 10.1097/JSM.0000000000000337; Todorov E, 2002, NAT NEUROSCI, V5, P1226, DOI 10.1038/nn963; Troje NF, 2002, J VISION, V2, P371, DOI 10.1167/2.5.2; Verrel J, 2009, PSYCHOL AGING, V24, P75, DOI 10.1037/a0014272; Yamagata M, 2017, CLIN INTERV AGING, V12, P499, DOI 10.2147/CIA.S132425; Yang Y, 2010, LECT NOTES COMPUT SC, V6298, P538, DOI 10.1007/978-3-642-15696-0_50	35	12	12	0	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1099-4300			ENTROPY-SWITZ	Entropy	JAN	2018	20	1							30	10.3390/e20010030			8	Physics, Multidisciplinary	Physics	FV8ZJ	WOS:000424876200030	33265120	DOAJ Gold, Green Published			2021-06-18	
J	Lambregts, SAM; Smetsers, JEM; Verhoeven, IMAJ; de Kloet, AJ; van de Port, IGL; Ribbers, GM; Catsman-Berrevoets, CE				Lambregts, S. A. M.; Smetsers, J. E. M.; Verhoeven, I. M. A. J.; de Kloet, A. J.; van de Port, I. G. L.; Ribbers, G. M.; Catsman-Berrevoets, C. E.			Cognitive function and participation in children and youth with mild traumatic brain injury two years after injury	BRAIN INJURY			English	Article						Acquired Brain Injury; adolescents; young adults; long-term	NEUROCOGNITIVE OUTCOMES; POSTCONCUSSIVE SYMPTOMS; HEAD-INJURY; CHILDHOOD; RECOVERY; ADOLESCENTS; PERFORMANCE; RESERVE; SCALE; TBI	Background: 10-20% of children and youth with mild traumatic brain injury (mTBI) suffer from long-term cognitive impairments with, supposedly, a negative impact on most domains of functioning. Objectives: To describe cognitive functioning and participation in children and youth two-years post-mTBI and to determine associated risk factors. Methods: Cross-sectional study among 73 patients (aged 6-22 years), hospital diagnosed with mTBI. Linear regression modelling was used to investigate the effect of potential predictors on cognitive functioning as measured with a neuropsychological assessment (NPA), two-years post-injury. Extent of participation was assessed using the Child and Adolescent Scale of Participation and correlation analysis was conducted to examine its association with level of cognitive functioning. Results: 7-15% of all participants had impaired cognitive functions, especially in the domains of processing speed, inhibitory control, cognitive flexibility, visuospatial constructional ability and visuospatial memory. Lower level of education and pre-injury cognitive problems were predictive for a lower level of long-term cognitive functioning. Slower inhibition speed, impaired visuospatial and verbal working memory were associated with reduced participation. Discussion and conclusions: Persisting cognitive problems two years after mTBI were mostly related to the lower level of education and to pre-injury cognitive problems. Although participation of the patients was reported by parents to be relatively high, slower inhibition speed, impaired visuospatial and verbal working memory were associated with reduced participation.	[Lambregts, S. A. M.; Ribbers, G. M.] Erasmus MC Univ, Med Ctr, Dept Rehabil Med, Rotterdam, Netherlands; [Lambregts, S. A. M.; van de Port, I. G. L.] Revant Rehabil Ctr, Dept Rehabil Med, Breda, Netherlands; [Smetsers, J. E. M.] Univ Utrecht, Dept Neuropsychol, Utrecht, Netherlands; [Verhoeven, I. M. A. J.; de Kloet, A. J.] The Hague Univ Appl Sci, Expertise Grp, The Hague, Netherlands; [de Kloet, A. J.] Sophia Rehabil Ctr, Dept Rehabil Med, The Hague, Netherlands; [Ribbers, G. M.] Rijndam Rehabil Inst, Dept Rehabil Med, Rotterdam, Netherlands; [Catsman-Berrevoets, C. E.] Erasmus MC Univ, Med Ctr, Dept Pediat Neurol, Rotterdam, Netherlands	Lambregts, SAM (corresponding author), Evant Rehabil Ctr, Brabantlaan 1, NL-4817 JW Breda, Netherlands.	s.lambregts@revant.nl	Ribbers, Gerard/N-3623-2019; Ribbers, Gerard M/C-1454-2014	Ribbers, Gerard M/0000-0002-6114-349X	Revalidatiefonds [2010/0029]; Johanna KinderFonds and Kinderrevalidatie Fonds Adriaanstichting (JKF/KFA Grant) [2009/0075]	The authors report no declarations of interest. This study was supported by the Revalidatiefonds (Grant 2010/0029), Johanna KinderFonds and Kinderrevalidatie Fonds Adriaanstichting (JKF/KFA Grant 2009/0075).	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson V, 2012, J NEUROTRAUM, V29, P143, DOI 10.1089/neu.2011.2012; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barlow KM, 2016, J CHILD NEUROL, V31, P57, DOI 10.1177/0883073814543305; Bedell G, 2009, DEV NEUROREHABIL, V12, P342, DOI 10.3109/17518420903087277; Bedell GM, 2004, NEUROREHABILITATION, V19, P191; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Catroppa C, 2015, J NEUROTRAUM, V32, P109, DOI 10.1089/neu.2013.3276; Crowe LM, 2012, J PEDIATR PSYCHOL, V37, P745, DOI 10.1093/jpepsy/jss070; de Kloet AJ, 2013, BRAIN INJURY, V27, P843, DOI 10.3109/02699052.2013.775496; de Kloet AJ, 2015, BRAIN INJURY, P1; de Kloet AJ, 2015, DEV NEUROREHABIL, V18, P357, DOI 10.3109/17518423.2013.850749; De Sonneville L.M.J., 2005, TIJDSCHR NEUROPSYCHO, V1, P27; De Sonneville L.M.J, 2014, HDB AMSTERDAMSE NEUR; de Sonneville LMJ, 1999, COMP PSYCH, V6, P187; Di Battista A, 2012, J NEUROTRAUM, V29, P1717, DOI 10.1089/neu.2011.2157; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Farmer JE, 2002, DEV NEUROPSYCHOL, V22, P455, DOI 10.1207/S15326942DN2202_2; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Forsyth RJ, 2010, ARCH DIS CHILD, V95, P554, DOI 10.1136/adc.2009.161083; Gerstman B., 2009, BASIC BIOSTATISTICS; Hackman DA, 2014, CHILD DEV, V85, P1433, DOI 10.1111/cdev.12242; Hageman G., 2010, MANAGEMENT PATIENTS; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hung Ryan, 2014, Arch Phys Med Rehabil, V95, pS174, DOI 10.1016/j.apmr.2013.08.301; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Iverson GL, 2000, ARCH CLIN NEUROPSYCH, V15, P643, DOI 10.1016/S0887-6177(99)00048-7; Konigs M, 2015, PEDIATRICS, V136, P534, DOI 10.1542/peds.2015-0437; Kosch Y, 2010, BRAIN INJURY, V24, P479, DOI 10.3109/02699051003610417; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Law M, 2011, BRAIN INJURY, V25, P587, DOI 10.3109/02699052.2011.572945; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; LIBERMAN J, 1994, J CLIN PSYCHOL, V50, P615, DOI 10.1002/1097-4679(199407)50:4<615::AID-JCLP2270500419>3.0.CO;2-R; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Noble KG, 2005, DEVELOPMENTAL SCI, V8, P74, DOI 10.1111/j.1467-7687.2005.00394.x; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Rivara FP, 2012, J NEUROTRAUM, V29, P2499, DOI 10.1089/neu.2012.2434; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; RUFF RM, 1993, PERCEPT MOTOR SKILL, V76, P1219, DOI 10.2466/pms.1993.76.3c.1219; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Stern Y, 2013, FOLIA PHONIATR LOGO, V65, P49, DOI 10.1159/000353443; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M; van Pelt ED, 2011, EUR J PAEDIATR NEURO, V15, P519, DOI 10.1016/j.ejpn.2011.05.005; van Velzen JM, 2009, BRAIN INJURY, V23, P385, DOI 10.1080/02699050902838165; Vos PE, 2012, EUR J NEUROL, V19, P191, DOI 10.1111/j.1468-1331.2011.03581.x; Wechsler D., 2005, MANUAL WECHSLER INTE; World Health Organization [WHO], 2007, INT CLASS FUNCT DIS; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64	57	12	12	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2018	32	2					230	241		10.1080/02699052.2017.1406990			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FY7WF	WOS:000427073600009	29190153				2021-06-18	
J	Lee, JJ; Segar, DJ; Morrison, JF; Mangham, WM; Lee, S; Asaad, WF				Lee, Jonathan J.; Segar, David J.; Morrison, John F.; Mangham, William M.; Lee, Shane; Asaad, Wael F.			Subdural hematoma as a major determinant of short-term outcomes in traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						head injury; traumatic brain injury; subdural hematoma; trauma	GLASGOW COMA SCALE; SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; COMPUTERIZED-TOMOGRAPHY; CLASSIFICATION-SYSTEM; ODDS RATIOS; PREDICTION; SEVERITY; SCORE; AGE	OBJECTIVE Early radiographic findings in patients with traumatic brain injury (TBI) have been studied in hopes of better predicting injury severity and outcome. However, prior attempts have generally not considered the various types of intracranial hemorrhage in isolation and have typically not excluded patients with potentially confounding extracranial injuries. Therefore, the authors examined the associations of various radiographic findings with short-term outcome to assess the potential utility of these findings in future prognostic models. METHODS The authors retrospectively identified 1716 patients who had experienced TBI without major extracranial injuries, and categorized them into the following TBI subtypes: subdural hematoma (SDH), traumatic subarachnoid hemorrhage, intraparenchymal hemorrhage (which included intraventricular hemorrhage), and epidural hematoma. They specifically considered isolated forms of hemorrhage, in which only 1 subtype was present. RESULTS In general, the presence of an isolated SDH was more likely to result in worse outcomes than the presence of other isolated forms of traumatic intracranial hemorrhage. Discharge to home was less likely and perihospital mortality rates were generally higher in patients with SDH. These findings were not simply related to age and were not fully captured by the admission Glasgow Coma Scale (GCS) score. The presence of SDH had a much higher sensitivity for poor outcome than the presence of other TBI subtypes, and was more sensitive for these poor outcomes than having a low GCS score (3-8). CONCLUSIONS In these ways, SDH was the most important finding associated with poor outcome, and the authors show that consideration of SDH, specifically, can augment age and GCS score in classification and prognostic models for TBI. https://thejns.org/doi/abs/10.3171/2016.5.JNS16255	[Lee, Jonathan J.; Segar, David J.; Morrison, John F.; Mangham, William M.; Asaad, Wael F.] Brown Univ, Warren Alpert Med Sch, Providence, RI USA; [Morrison, John F.; Asaad, Wael F.] Rhode Isl Hosp, Dept Neurosurg, 593 Eddy St, Providence, RI 02903 USA; [Lee, Shane] Brown Univ, Brown Inst Brain Sci, Providence, RI 02912 USA; [Lee, Shane] Brown Univ, Dept Neurosci, Providence, RI 02912 USA; [Asaad, Wael F.] Rhode Isl Hosp, Norman Prince Neurosci Inst, Providence, RI 02903 USA	Asaad, WF (corresponding author), Rhode Isl Hosp, Dept Neurosurg, 593 Eddy St, Providence, RI 02903 USA.	wael_asaad@brown.edu	Asaad, Wael/I-8485-2012	Asaad, Wael/0000-0003-4406-9096	Department of Neurosurgery; Alpert Medical School of Brown University; Rhode Island Hospital	We thank the Department of Neurosurgery, the Alpert Medical School of Brown University, and Rhode Island Hospital for their support.	ACourt C, 2012, BR J GEN PRACT, V62, pe220; Altman DG, 1998, BRIT MED J, V317, P1318, DOI 10.1136/bmj.317.7168.1318; AMACHER AL, 1987, NEUROSURGERY, V20, P954; [Anonymous], 1990, PRACTICAL STAT MED R; BRAAKMAN R, 1992, ACTA NEUROCHIR, V116, P161, DOI 10.1007/BF01540870; Brennan JH, 2015, J CLIN NEUROSCI, V22, P1375, DOI 10.1016/j.jocn.2015.02.030; Chieregato A, 2010, ACTA ANAESTH SCAND, V54, P696, DOI 10.1111/j.1399-6576.2010.02234.x; D'Amato L, 2007, J Neurosurg Sci, V51, P107; Davies HTO, 1998, BRIT MED J, V316, P989, DOI 10.1136/bmj.316.7136.989; Epstein DS, 2014, BR J NEUROSURG; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; Holcomb WL, 2001, OBSTET GYNECOL, V98, P685, DOI 10.1016/S0029-7844(01)01488-0; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Lee JJ, 2014, J NEUROTRAUM, V31, P595, DOI 10.1089/neu.2013.3152; Lee YB, 2011, KOREAN J NEUROTRAUMA, V7, P12; Leitgeb J, 2012, J NEUROSURG, V117, P324, DOI 10.3171/2012.4.JNS111448; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mata-Mbemba D, 2014, ACAD RADIOL, V21, P605, DOI 10.1016/j.acra.2014.01.017; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel P, 2007, J EVAL CLIN PRACT, V13, P464, DOI 10.1111/j.1365-2753.2006.00713.x; Perrin PB, 2015, J HEAD TRAUMA REHAB, V30, P136, DOI 10.1097/HTR.0000000000000026; Phelan HA, 2014, J NEUROTRAUM, V31, P1733, DOI 10.1089/neu.2014.3377; Quigley MR, 2013, J TRAUMA ACUTE CARE, V74, P581, DOI 10.1097/TA.0b013e31827d6088; Raj R, 2014, NEUROSURGERY, V75, P632, DOI 10.1227/NEU.0000000000000533; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Salottolo K, 2014, JAMA SURG, V149, P727, DOI 10.1001/jamasurg.2014.13; TEASDALE G, 1978, ANESTHESIOLOGY, V49, P225, DOI 10.1097/00000542-197809000-00023; Tian HL, 2008, CHINESE MED J-PEKING, V121, P1080, DOI 10.1097/00029330-200806020-00007; Van Gent JM, 2014, J TRAUMA ACUTE CARE, V77, P238, DOI 10.1097/TA.0000000000000294; Varano P, 2015, J TRAUMA ACUTE CARE, V78, P1039, DOI 10.1097/TA.0000000000000604	41	12	12	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2018	128	1					236	249		10.3171/2016.5.JNS16255			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FR3AW	WOS:000418939300029	28186445				2021-06-18	
J	Maheras, AL; Dix, B; Carmo, OMS; Young, AE; Gill, VN; Sun, JL; Booker, AR; Thomason, HA; Ibrahim, AE; Stanislaw, L; Dallego, JC; Ngo, CN; Chen, A; Fortini, BK; Spence, RD				Maheras, Amanda L.; Dix, Brian; Carmo, Olivia M. S.; Young, Aleena E.; Gill, Vanessa N.; Sun, Julia L.; Booker, Aleah R.; Thomason, Helen A.; Ibrahim, Anastasia E.; Stanislaw, Lauren; Dallego, Jennifer C.; Ngo, Cat N.; Chen, Audrey; Fortini, Barbara K.; Spence, Rory D.			Genetic Pathways of Neuroregeneration in a Novel Mild Traumatic Brain Injury Model in Adult Zebrafish	ENEURO			English	Article						Concussion; DEG; mTBI; RNA-seq; TBI; zebrafish	ELEMENT-BINDING PROTEIN; STIMULATES NEUROGENESIS; REGENERATIVE RESPONSE; SUBVENTRICULAR ZONE; EFFECTOR DOMAIN; RADIAL GLIA; LONG-TERM; C-FOS; EXPRESSION; JUNB	[GRAPHICS] Mild traumatic brain injuries (mTBIs) are one of the most prevalent neurological disorders, and humans are severely limited in their ability to repair and regenerate central nervous system (CNS) tissue postinjury. However, zebrafish (Danio rerio) maintain the remarkable ability to undergo complete and functional neuroregeneration as an adult. We wish to extend knowledge of the known mechanisms of neuroregeneration by analyzing the differentially expressed genes (DEGs) in a novel adult zebrafish model of mTBI. In this study, a rodent weight drop model of mTBI was adapted to the adult zebrafish. A memory test showed significant deficits in spatial memory in the mTBI group. We identified DEGs at 3 and 21 days postinjury (dpi) through RNA-sequencing analysis. The resulting DEGs were categorized according to gene ontology (GO) categories. At 3 dpi, GO categories consisted of peak injury response pathways. Significantly, at 21 dpi, GO categories consisted of neuroregeneration pathways. Ultimately, these results validate a novel zebrafish model of mTBI and elucidate significant DEGs of interest in CNS injury and neuroregeneration.	[Maheras, Amanda L.; Sun, Julia L.; Booker, Aleah R.; Thomason, Helen A.; Stanislaw, Lauren] Scripps Coll, Claremont, CA 91711 USA; [Dix, Brian; Carmo, Olivia M. S.; Young, Aleena E.; Gill, Vanessa N.; Ibrahim, Anastasia E.; Dallego, Jennifer C.] Claremont McKenna Coll, Claremont, CA 91711 USA; [Maheras, Amanda L.; Dix, Brian; Carmo, Olivia M. S.; Young, Aleena E.; Gill, Vanessa N.; Sun, Julia L.; Booker, Aleah R.; Thomason, Helen A.; Ibrahim, Anastasia E.; Stanislaw, Lauren; Dallego, Jennifer C.; Ngo, Cat N.; Spence, Rory D.] Keck Sci Dept, Claremont, CA 91711 USA; [Ngo, Cat N.] Harvey Mudd Coll, Claremont, CA 91711 USA; [Chen, Audrey] Univ Calif Irvine, Ayala Sch Biol Sci, Dept Neurobiol & Behav, Irvine, CA USA; [Fortini, Barbara K.] Keck Grad Inst, Sch Pharm, Claremont, CA 91711 USA	Spence, RD (corresponding author), Keck Sci Dept, Off 124, 925 N Mills Ave, Claremont, CA 91711 USA.	rory.spence@gmail.com		Fortini, Barbara/0000-0003-3230-2604; Carmo, Olivia M. S./0000-0002-0132-3843; Maheras, Amanda/0000-0003-0027-7440	Keck Science Department; Rose Hills Foundation; Libby Faculty-Student Collaboration Fund; Libby Faculty-Student Collaboration Fund, HHMI	Our funding was provided by start-up lab funds provided by the Keck Science Department. Student research support was provided by the Rose Hills Foundation, The Libby Faculty-Student Collaboration Fund, HHMI, and the Keck Science Department.	Abrous DN, 1999, BRAIN RES, V826, P181, DOI 10.1016/S0006-8993(99)01259-7; Afgan E, 2016, NUCLEIC ACIDS RES, V44, pW3, DOI 10.1093/nar/gkw343; Arai S, 2007, P NATL ACAD SCI USA, V104, P2289, DOI 10.1073/pnas.0611167104; Barba-Escobedo PA, 2012, GENES BRAIN BEHAV, V11, P366, DOI 10.1111/j.1601-183X.2012.00770.x; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Castellano JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002156; Chen CJ, 2012, RADIOLOGY, V264, P844, DOI 10.1148/radiol.12112154; Collymore C, 2014, J AM ASSOC LAB ANIM, V53, P198; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; Darwish H, 2012, BRAIN INJURY, V26, P1763, DOI [10.3109/02699052.2012.741452, 10.3109/02699052.2011.635362]; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; Than-Trong E, 2015, GLIA, V63, P1406, DOI 10.1002/glia.22856; Givogri MI, 2006, DEV NEUROSCI-BASEL, V28, P81, DOI 10.1159/000090755; Hansen MR, 2003, J NEUROSCI RES, V72, P169, DOI 10.1002/jnr.10551; Howe K, 2013, NATURE, V496, P498, DOI 10.1038/nature12111; Ishida T, 2010, DEV BIOL, V340, P468, DOI 10.1016/j.ydbio.2010.01.036; Iturbide A, 2015, MOL CELL, V58, P755, DOI 10.1016/j.molcel.2015.04.012; Iwata A, 2005, J NEUROSCI RES, V82, P103, DOI 10.1002/jnr.20607; Kishimoto N, 2012, DIS MODEL MECH, V5, P200, DOI 10.1242/dmm.007336; Kroehne V, 2011, DEVELOPMENT, V138, P4831, DOI 10.1242/dev.072587; Kyritsis N, 2012, SCIENCE, V338, P1353, DOI 10.1126/science.1228773; Lee JC, 2002, J CELL BIOL, V158, P1051, DOI 10.1083/jcb.200112124; Lee SW, 2000, MOL MICROBIOL, V35, P1540, DOI 10.1046/j.1365-2958.2000.01824.x; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lien CL, 2006, PLOS BIOL, V4, P1386, DOI 10.1371/journal.pbio.0040260; Lieschke GJ, 2007, NAT REV GENET, V8, P353, DOI 10.1038/nrg2091; Liu YQ, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-141; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu KT, 2015, PFLUG ARCH EUR J PHY, V467, P1651, DOI 10.1007/s00424-014-1588-x; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Luo Y, 2017, SCI REP, V7, P1077; Marz M, 2011, DEV DYNAM, V240, P2221, DOI 10.1002/dvdy.22710; Maisel M, 2007, STEM CELLS, V25, P1231, DOI 10.1634/stemcells.2006-0617; Martin A, 2015, EMBO J, V34, P1090, DOI 10.15252/embj.201489975; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; Miller N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048865; Mokalled MH, 2016, SCIENCE, V354, P630, DOI 10.1126/science.aaf2679; Monnot MJ, 1999, DEV DYNAM, V214, P207, DOI 10.1002/(SICI)1097-0177(199903)214:3<207::AID-AJA4>3.3.CO;2-X; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Mychasiuk R, 2014, JOVE-J VIS EXP, V94, P1; Nakagawa S, 2002, J NEUROSCI, V22, P9868; Norton W, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-90; Oleinik NV, 2007, ONCOGENE, V26, P7222, DOI 10.1038/sj.onc.1210526; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Piya S, 2012, FEBS LETT, V586, P4233, DOI 10.1016/j.febslet.2012.10.031; Poss KD, 2000, DEV DYNAM, V219, P282, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1045>3.3.CO;2-3; Puhakka N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172521; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Samuels IS, 2008, J NEUROSCI, V28, P6983, DOI 10.1523/JNEUROSCI.0679-08.2008; Skaggs K, 2014, GLIA, V62, P2061, DOI 10.1002/glia.22726; Stewart AM, 2014, TRENDS NEUROSCI, V37, P264, DOI 10.1016/j.tins.2014.02.011; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Veth KN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001310; Wang XM, 2009, J CEREBR BLOOD F MET, V29, P1644, DOI 10.1038/jcbfm.2009.83; Yates A, 2016, NUCLEIC ACIDS RES, V44, pD710, DOI 10.1093/nar/gkv1157; Zhu DY, 2004, P NATL ACAD SCI USA, V101, P9453, DOI 10.1073/pnas.0401063101	65	12	12	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA		2373-2822		ENEURO	eNeuro	JAN-FEB	2018	5	1							UNSP e0208-17.2017	10.1523/ENEURO.0208-17.2017			17	Neurosciences	Neurosciences & Neurology	FS8FF	WOS:000422645100003	29302617	DOAJ Gold, Green Published			2021-06-18	
J	Measelle, JR; Ablow, JC				Measelle, Jeffrey R.; Ablow, Jennifer C.			Contributions of early adversity to pro-inflammatory phenotype in infancy: the buffer provided by attachment security	ATTACHMENT & HUMAN DEVELOPMENT			English	Article						Inflammation; infancy; pro-inflammatory cytokines; C-reactive protein; early adversity	C-REACTIVE PROTEIN; ADULT SOCIOECONOMIC-STATUS; INTIMATE PARTNER VIOLENCE; AUTONOMIC NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; AGE-RELATED DISEASE; EARLY-LIFE; PSYCHOLOGICAL STRESS; PROINFLAMMATORY PHENOTYPE; CARDIOVASCULAR-DISEASE	Adversity early in life is associated with systemic inflammation by adolescence and beyond. At present, few studies have investigated the associations between different forms of adversity and inflammation during infancy, making it difficult to specify the origins of disease vulnerability. This study examined the association between multiple forms of early adversity - socioeconomic status disadvantage, familial stress, maternal depression, and security of attachment - and individual differences in a composite measure of pro-inflammatory cytokines (IL-1 beta, IL-6, IL-8, and tumor necrosis factor-alpha) and the inflammatory protein C-reactive protein that were collected via saliva when (n = 49) children were 17 months old. In addition to gauging the direct effects of adversity, we also tested the hypothesis that infants' attachment relationship with their mother might buffer infants against the immunologic effects of early adversity. Results show that familial stress, maternal depression, and security of attachment were directly associated with infant salivary inflammation and that attachment status moderated the effect of maternal depression. The findings suggest that exposure to certain forms of adversity very early in life may engender a pro-inflammatory phenotype with possible life-long implications for health.	[Measelle, Jeffrey R.; Ablow, Jennifer C.] Univ Oregon, Psychol, Eugene, OR 97403 USA	Measelle, JR (corresponding author), Univ Oregon, Psychol, Eugene, OR 97403 USA.	measelle@uoregon.edu		Ablow, Jennifer/0000-0002-4868-9156	National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [1 R03 MH068692-01A1]; National Science FoundationNational Science Foundation (NSF) [BCS-0643393]	This research was supported by a grant from the National Institute of Mental Health: [Grant Number 1 R03 MH068692-01A1] and the National Science Foundation: [Grant Number BCS-0643393] to the second author.	Abidin RR., 1995, PARENTING STRESS IND; Ainsworth M. D. S., 1978, PATTERNS ATTACHMENT; Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725; Bernard K, 2010, DEV PSYCHOL, V46, P1771, DOI 10.1037/a0020660; BOYCE WT, 1995, PSYCHOSOM MED, V57, P411, DOI 10.1097/00006842-199509000-00001; Brennan PA, 2008, J CHILD PSYCHOL PSYC, V49, P1099, DOI 10.1111/j.1469-7610.2008.01914.x; Byrne ML, 2017, HEALTH PSYCHOL, V36, P641, DOI 10.1037/hea0000502; Byrne ML, 2017, J FAM PSYCHOL, V31, P374, DOI 10.1037/fam0000254; Byrne ML, 2013, BRAIN BEHAV IMMUN, V34, P164, DOI 10.1016/j.bbi.2013.08.010; Casey BJ, 2005, CURR OPIN NEUROBIOL, V15, P239, DOI 10.1016/j.conb.2005.03.012; Chen E, 2011, MOL PSYCHIATR, V16, P729, DOI 10.1038/mp.2010.53; Cicchetti D, 2005, ANNU REV CLIN PSYCHO, V1, P409, DOI 10.1146/annurev.clinpsy.1.102803.144029; Conradt E, 2016, CHILD DEV, V87, P73, DOI 10.1111/cdev.12483; Conradt E, 2013, PSYCHOL SCI, V24, P235, DOI 10.1177/0956797612457381; Danese A, 2007, P NATL ACAD SCI USA, V104, P1319, DOI 10.1073/pnas.0610362104; Danese A, 2012, PHYSIOL BEHAV, V106, P29, DOI 10.1016/j.physbeh.2011.08.019; Danese A, 2009, ARCH PEDIAT ADOL MED, V163, P1135, DOI 10.1001/archpediatrics.2009.214; Deinzer R, 2005, BRIT J HEALTH PSYCH, V10, P269, DOI 10.1348/135910705X26858; DiCorcia JA, 2011, NEUROSCI BIOBEHAV R, V35, P1593, DOI 10.1016/j.neubiorev.2011.04.008; Dixon Denise, 2009, J Pediatr Nurs, V24, P378, DOI 10.1016/j.pedn.2008.02.034; Dowd JB, 2010, AM J PREV MED, V39, P314, DOI 10.1016/j.amepre.2010.05.014; DUNST CJ, 1987, CHILD CARE HLTH DEV, V13, P111, DOI 10.1111/j.1365-2214.1987.tb00528.x; Ehrlich K., 2016, HDB ATTACHMENT THEOR, V3rd, P180; Eklund CM, 2009, ADV CLIN CHEM, V48, P111, DOI 10.1016/S0065-2423(09)48005-3; Fernandez-Botran R, 2011, BRAIN BEHAV IMMUN, V25, P314, DOI 10.1016/j.bbi.2010.09.023; Fuligni AJ, 2009, PSYCHOSOM MED, V71, P329, DOI 10.1097/PSY.0b013e3181921b1f; Galobardes B, 2006, ANN EPIDEMIOL, V16, P91, DOI 10.1016/j.annepidem.2005.06.053; Garcia RI, 2001, PERIODONTOL 2000, V25, P21, DOI 10.1034/j.1600-0757.2001.22250103.x; Giedd JN, 2010, NEURON, V67, P728, DOI 10.1016/j.neuron.2010.08.040; Gouin JP, 2009, BRAIN BEHAV IMMUN, V23, P898, DOI 10.1016/j.bbi.2008.09.016; Granger DA, 2007, PHYSIOL BEHAV, V92, P583, DOI 10.1016/j.physbeh.2007.05.004; Hansel A, 2010, NEUROSCI BIOBEHAV R, V35, P115, DOI 10.1016/j.neubiorev.2009.12.012; Hennessy MB, 2010, NEUROSCI BIOBEHAV R, V34, P782, DOI 10.1016/j.neubiorev.2009.03.012; Herberth G, 2008, PEDIAT ALLERG IMM-UK, V19, P722, DOI 10.1111/j.1399-3038.2008.00727.x; Hertzman C, 1999, ANN NY ACAD SCI, V896, P85, DOI 10.1111/j.1749-6632.1999.tb08107.x; Hill-Soderlund AL, 2015, PSYCHONEUROENDOCRINO, V52, P311, DOI 10.1016/j.psyneuen.2014.08.011; HOROWITZ M, 1977, PSYCHOSOM MED, V39, P413, DOI 10.1097/00006842-197711000-00005; Hostinar CE, 2014, PSYCHOL BULL, V140, P256, DOI 10.1037/a0032671; Howe LD, 2010, INT J OBESITY, V34, P1149, DOI 10.1038/ijo.2010.52; Howren MB, 2009, PSYCHOSOM MED, V71, P171, DOI 10.1097/PSY.0b013e3181907c1b; Iyengar A, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00131; Johnson SB, 2013, PEDIATRICS, V131, P319, DOI 10.1542/peds.2012-0469; Juengst SB, 2015, J HEAD TRAUMA REHAB, V30, P207, DOI 10.1097/HTR.0000000000000031; Karrow NA, 2006, BRAIN BEHAV IMMUN, V20, P144, DOI 10.1016/j.bbi.2005.05.003; Kiecolt-Glaser JK, 2010, NEUROSCI BIOBEHAV R, V35, P33, DOI 10.1016/j.neubiorev.2009.09.003; Kiecolt-Glaser JK, 2003, P NATL ACAD SCI USA, V100, P9090, DOI 10.1073/pnas.1531903100; Laurent HK, 2012, DEV PSYCHOL, V48, P35, DOI 10.1037/a0025518; Laurent HK, 2011, DEV PSYCHOPATHOL, V23, P521, DOI 10.1017/S0954579411000083; Li XJ, 2000, CLIN MICROBIOL REV, V13, P547, DOI 10.1128/CMR.13.4.547-558.2000; Luecken LJ, 2004, CLIN PSYCHOL REV, V24, P171, DOI 10.1016/j.cpr.2004.01.003; McDade TW, 2005, AM J PHYS ANTHROPOL, V128, P906, DOI 10.1002/ajpa.20222; McEwen BS, 2012, P NATL ACAD SCI USA, V109, P17180, DOI 10.1073/pnas.1121254109; McEwen BS, 2011, ANNU REV MED, V62, P431, DOI 10.1146/annurev-med-052209-100430; McEwen BS, 2000, NEUROPSYCHOPHARMACOL, V22, P108, DOI 10.1016/S0893-133X(99)00129-3; McEwen BS, 2003, HORM BEHAV, V43, P2, DOI 10.1016/S0018-506X(02)00024-7; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; Meaney MJ, 1996, DEV NEUROSCI-BASEL, V18, P49, DOI 10.1159/000111395; Miller AH, 2013, DEPRESS ANXIETY, V30, P297, DOI 10.1002/da.22084; Miller G, 2007, PSYCHOSOM MED, V69, P402, DOI 10.1097/PSY.0b013e318068fcf9; Miller GE, 2013, CHILD DEV PERSPECT, V7, P67, DOI 10.1111/cdep.12021; Miller GE, 2011, PSYCHOL BULL, V137, P959, DOI 10.1037/a0024768; Miller GE, 2010, PSYCHOL SCI, V21, P848, DOI 10.1177/0956797610370161; Minetto M, 2005, EUR J APPL PHYSIOL, V93, P679, DOI 10.1007/s00421-004-1241-z; Murasko JE, 2008, SOC SCI MED, V67, P1889, DOI 10.1016/j.socscimed.2008.09.018; Navarro VP, 2006, PFLUG ARCH EUR J PHY, V453, P73, DOI 10.1007/s00424-006-0113-2; Nazmi A, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-212; O'Connor MF, 2009, NEUROIMAGE, V47, P891, DOI 10.1016/j.neuroimage.2009.05.049; Opacka-Juffry J, 2012, STRESS, V15, P1, DOI 10.3109/10253890.2011.560309; Ouellet-Morin I, 2011, BRAIN BEHAV IMMUN, V25, P640, DOI 10.1016/j.bbi.2010.12.020; Out D, 2012, BRAIN BEHAV IMMUN, V26, P543, DOI 10.1016/j.bbi.2012.01.019; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; Pfaffe T, 2011, CLIN CHEM, V57, P675, DOI 10.1373/clinchem.2010.153767; Pollitt RA, 2008, J EPIDEMIOL COMMUN H, V62, P484, DOI 10.1136/jech.2006.054106; Pollitt RA, 2007, EUR J EPIDEMIOL, V22, P55, DOI 10.1007/s10654-006-9082-1; Preacher KJ, 2006, J EDUC BEHAV STAT, V31, P437, DOI 10.3102/10769986031004437; Propper CB, 2013, DEV REV, V33, P151, DOI 10.1016/j.dr.2013.05.001; Punt J, 2001, Trends Immunol, V22, P419, DOI 10.1016/S1471-4906(01)02010-5; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Repetti RL, 2002, PSYCHOL BULL, V128, P330, DOI 10.1037/0033-2909.128.2.330; Riis JL, 2016, SOC SCI MED, V151, P206, DOI 10.1016/j.socscimed.2015.12.043; Riis JL, 2015, DEV PSYCHOBIOL, V57, P153, DOI 10.1002/dev.21271; Santarsieri M, 2015, BRAIN BEHAV IMMUN, V45, P15, DOI 10.1016/j.bbi.2014.09.003; Segerstrom SC, 2004, PSYCHOL BULL, V130, P601, DOI 10.1037/0033-2909.130.4.601; Shirtcliff EA, 2009, P NATL ACAD SCI USA, V106, P2963, DOI 10.1073/pnas.0806660106; Shonkoff JP, 2010, CHILD DEV, V81, P357, DOI 10.1111/j.1467-8624.2009.01399.x; Sjogren E, 2006, BRAIN BEHAV IMMUN, V20, P270, DOI 10.1016/j.bbi.2005.08.001; Slopen N, 2013, PSYCHONEUROENDOCRINO, V38, P2854, DOI 10.1016/j.psyneuen.2013.07.012; Slopen N, 2013, PSYCHONEUROENDOCRINO, V38, P188, DOI 10.1016/j.psyneuen.2012.05.013; Slopen N, 2012, BRAIN BEHAV IMMUN, V26, P239, DOI 10.1016/j.bbi.2011.11.003; Sroufe L. A., 2005, DEV PERSON MINNESOTA; Sroufe LA, 2005, ATTACH HUM DEV, V7, P349, DOI 10.1080/14616730500365928; Suh KI, 2009, ARCH ORAL BIOL, V54, P797, DOI 10.1016/j.archoralbio.2009.05.007; Taylor SE, 2006, BIOL PSYCHIAT, V60, P819, DOI 10.1016/j.biopsych.2006.03.016; Vermeer HJ, 2012, PHYSIOL BEHAV, V105, P161, DOI 10.1016/j.physbeh.2011.08.017; Wakelkamp IMMJ, 2003, CLIN ENDOCRINOL, V58, P280, DOI 10.1046/j.1365-2265.2003.01708.x; Waschul B, 2003, J CLIN PERIODONTOL, V30, P238, DOI 10.1034/j.1600-051X.2003.00270.x; Weinberg MK, 1998, J CLIN PSYCHIAT, V59, P53; Williamson S, 2012, NURS RES PRACT, V2012, DOI 10.1155/2012/246178; Wolf JM, 2008, BRAIN BEHAV IMMUN, V22, P433, DOI 10.1016/j.bbi.2007.10.016	99	12	12	0	4	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1461-6734	1469-2988		ATTACH HUM DEV	Attach. Hum. Dev.		2018	20	1					1	23		10.1080/14616734.2017.1362657			23	Psychology, Developmental	Psychology	GB0KN	WOS:000428734900001	28797194				2021-06-18	
J	Merritt, VC; Bradson, ML; Meyer, JE; Arnett, PA				Merritt, Victoria C.; Bradson, Megan L.; Meyer, Jessica E.; Arnett, Peter A.			Evaluating the test-retest reliability of symptom indices associated with the ImPACT post-concussion symptom scale (PCSS)	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						ImPACT; post-concussion symptoms; reliable change; sports concussion; test-retest reliability	POSTCONCUSSION-LIKE SYMPTOMS; SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; SEX-DIFFERENCES; NEUROPSYCHOLOGICAL ASSESSMENT; NEUROCOGNITIVE PERFORMANCE; FOOTBALL PLAYERS; BASE-LINE; COLLEGIATE; PREDICTORS	Objective: The Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) is a commonly used tool in sports concussion assessment. While test-retest reliabilities have been established for the ImPACT cognitive composites, few studies have evaluated the psychometric properties of the ImPACT's Post-Concussion Symptom Scale (PCSS). The purpose of this study was to establish the test-retest reliability of symptom indices associated with the PCSS.Participants and Methods: Participants included 38 undergraduate students (50.0% male) who underwent neuropsychological testing as part of their participation in their psychology department's research subject pool. The majority of the participants were Caucasian (94.7%) and had no history of concussion (73.7%). All participants completed the ImPACT at two time points, approximately 6weeks apart. The PCSS was the main outcome measure, and eight symptom indices were calculated (a total symptom score, three symptom summary indices, and four symptom clusters).Results: Pearson correlations (r) and intraclass correlation coefficients (ICCs) were computed as measures of test-retest reliability. Overall, reliabilities ranged from low to high (r=.44 to .80; ICC=.44 to .77). The cognitive symptom cluster exhibited the highest test-retest reliability (r=.80, ICC=.77), followed by the positive symptom total (PST) index, an indicator of the total number of symptoms endorsed (r=.71, ICC=.69). In contrast, the commonly used total symptom score showed lower test-retest reliability (r=.67, ICC=.62). Paired-samples ttests revealed no significant differences between test and retest for any of the symptom variables (all p>.01). Finally, reliable change indices (RCI) were computed to determine whether differences observed between test and retest represented clinically significant change. RCI values were provided for each symptom index at the 80%, 90%, and 95% confidence intervals.Conclusion: These results suggest that evaluating additional symptom indices beyond the total symptom score from the PCSS is beneficial. Findings from this study can be applied to athlete samples to assess reliable change in symptoms following concussion.	[Merritt, Victoria C.; Bradson, Megan L.; Meyer, Jessica E.; Arnett, Peter A.] Penn State Univ, Dept Psychol, 372 Moore Bldg, University Pk, PA 16802 USA	Merritt, VC (corresponding author), Penn State Univ, Dept Psychol, 372 Moore Bldg, University Pk, PA 16802 USA.	vcabarnes@gmail.com		Merritt, Victoria/0000-0001-5683-4168			Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; Alla S, 2012, BRIT J SPORT MED, V46, P562, DOI 10.1136/bjsm.2010.081299; Anastasi A., 1998, PSYCHOL TESTING; Brett BL, 2017, J CLIN EXP NEUROPSYC, V39, P286, DOI 10.1080/13803395.2016.1224322; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Bruce J, 2014, CLIN NEUROPSYCHOL, V28, P14, DOI 10.1080/13854046.2013.866272; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Cicchetti D.V., 1994, PSYCHOL ASSESS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]; Cole WR, 2013, ARCH CLIN NEUROPSYCH, V28, P732, DOI 10.1093/arclin/act040; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2004, NEUROSURGERY, V55, P891, DOI 10.1227/01.NEU.0000143800.49798.19; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Iverson GL, 2015, BRAIN INJURY, V29, P263, DOI 10.3109/02699052.2014.965214; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell M. R, 2016, ADM INTERPRETATION M; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR., 2000, IMPACT IMMEDIATE POS; MacFarlane MP, 2015, BRAIN INJURY, V29, P139, DOI 10.3109/02699052.2014.965208; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P., 2017, BRIT J SPORT MED, DOI [10.1136/brsports-2017-098699, DOI 10.1136/BRSPORTS-2017-098699]; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.4.390; Meier TB, 2015, J SCI MED SPORT, V18, P507, DOI 10.1016/j.jsams.2014.07.008; Merritt VC, 2015, J CLIN EXP NEUROPSYC, V37, P764, DOI 10.1080/13803395.2015.1060950; Merritt VC, 2015, J CLIN EXP NEUROPSYC, V37, P265, DOI 10.1080/13803395.2015.1004303; Merritt VC, 2014, J CLIN EXP NEUROPSYC, V36, P1098, DOI 10.1080/13803395.2014.983463; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; Pardini D., 2004, BR J SPORTS MED, V38, P661; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Shoukri MM, 2004, STAT METHODS MED RES, V13, P251, DOI 10.1191/0962280204sm365ra; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Spreen O., 2006, COMPENDIUM NEUROPSYC; Topolovec-Vranic J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141699; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Tsushima WT, 2016, ARCH CLIN NEUROPSYCH, V31, P105, DOI 10.1093/arclin/acv066; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Watkins M. P., 1993, FDN CLIN RES APPL PR; Weir JP, 2005, J STRENGTH COND RES, V19, P231, DOI 10.1519/15184.1; Ziegler M, 2009, PSYCHOL SPORT EXERC, V10, P344, DOI 10.1016/j.psychsport.2008.12.004	66	12	13	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2018	40	4					377	388		10.1080/13803395.2017.1353590			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	GA3XR	WOS:000428264300006	28728465				2021-06-18	
J	Ren, C; Li, XH; Wang, SB; Wang, LX; Dong, N; Wu, Y; Yao, YM				Ren, Chao; Li, Xiu-hua; Wang, Shi-bin; Wang, Li-xue; Dong, Ning; Wu, Yao; Yao, Yong-ming			Activation of Central Alpha 7 Nicotinic Acetylcholine Receptor Reverses Suppressed Immune Function of T Lymphocytes and Protects Against Sepsis Lethality	INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES			English	Article						Alpha 7 nicotinic acetylcholine receptor; sepsis; immune response; multiple organ dysfunction syndrome; prognosis	TRAUMATIC BRAIN-INJURY; IMMUNOSUPPRESSION; INFLAMMATION; AGONIST; GTS-21; ENDOTOXEMIA; MANAGEMENT; RELEASE; MICE	Sepsis remains the leading cause of high mortality and huge financial burden in intensive care units (ICU), but with scarce effective treatments due to refractory multiple organ dysfunction and persistent immunosuppression. Treatments that aim at modulating immune function and attenuating multiple organ injury will certainly benefit septic cases. Alpha 7 nicotinic acetylcholine receptor (alpha 7nAchR) has been reported with potent immunomodulatory properties in various diseases as the essential mediator of the cholinergic anti-inflammatory pathway (CAP). Few studies have demonstrated the potential effect of central alpha 7nAchR on the progression and prognosis of septic response, while its expression was first discovered on neurons and most abundant in the central nervous system. In the present study, it was found severe damage of multiple organs under the operation of cecal ligation and puncture (CLP) in rats, including heart, liver, kidneys, and lungs, as evidenced by abnormal histomorphology and notable elevation of injury markers. Concurrently, the function of spleen CD4(+)T cells was disrupted under septic challenge, accompanied by polarization of helper T cell (Th)2, which exhibited outward signs of immunosuppression. Intracerebroventricular injection of PNU282987, a selective agonist of alpha 7nAchR, significantly alleviated multiple organ injury, reversed immunosuppressive state, and improved the outcome of septic rats, while they were exacerbated by treatment with methyllycaconitine, a selective antagonist of alpha 7nAchR. This study provides the first evidence that activation of central alpha 7nAchR is beneficial for attenuating multiple organ dysfunction as well as abnormal immune response, and improving the prognosis of rats when exposed with sepsis.	[Ren, Chao; Li, Xiu-hua; Wang, Shi-bin; Wang, Li-xue; Dong, Ning; Wu, Yao; Yao, Yong-ming] Chinese Peoples Liberat Army Gen Hosp, Hosp 1, Trauma Res Ctr, 51 Fucheng Rd, Beijing 100048, Peoples R China; [Ren, Chao; Yao, Yong-ming] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China; [Li, Xiu-hua] Jin Hua Municipal Cent Hosp, Emergency Dept, Jinhua 321001, Peoples R China; [Yao, Yong-ming] Chinese Peoples Liberat Army Gen Hosp, State Key Lab Kidney Dis, Beijing 100853, Peoples R China	Yao, YM (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Hosp 1, Trauma Res Ctr, 51 Fucheng Rd, Beijing 100048, Peoples R China.	c_ff@sina.com	wang, xl/Y-8251-2019		National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81730057, 81501664, 81372054]; National Key Research and Development Program of China [2017YFC1103302]	This work was supported by grants from the National Natural Science Foundation (Nos. 81730057, 81501664, 81372054), and the National Key Research and Development Program of China (No. 2017YFC1103302).	Andersen N, 2013, P NATL ACAD SCI USA, V110, P20819, DOI 10.1073/pnas.1315775110; Andersson U, 2012, J EXP MED, V209, P1057, DOI 10.1084/jem.20120571; Antonakos N, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1625-1; Beinat C, 2015, CNS DRUGS, V29, P529, DOI 10.1007/s40263-015-0260-0; Bencherif M, 2011, CELL MOL LIFE SCI, V68, P931, DOI 10.1007/s00018-010-0525-1; Boomer JS, 2011, JAMA-J AM MED ASSOC, V306, P2594, DOI 10.1001/jama.2011.1829; Deng DM, 2017, INT IMMUNOPHARMACOL, V42, P49, DOI 10.1016/j.intimp.2016.11.011; Fujii T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01085; Gotts JE, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1585; Hall S, 2014, BRIT J NEUROSURG, V28, P181, DOI 10.3109/02688697.2013.835373; Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552; Hotchkiss RS, 2013, LANCET INFECT DIS, V13, P260, DOI 10.1016/S1473-3099(13)70001-X; Hu SQ, 2015, ACS CHEM NEUROSCI, V6, P1536, DOI 10.1021/acschemneuro.5b00108; Kim TH, 2014, J INFECT DIS, V209, P1668, DOI 10.1093/infdis/jit669; Kong FJ, 2015, J SURG RES, V194, P255, DOI 10.1016/j.jss.2014.09.043; Kox M, 2008, NEUROLOGY, V70, P480, DOI 10.1212/01.wnl.0000279479.69502.3e; Livingstone PD, 2009, BIOCHEM PHARMACOL, V78, P744, DOI 10.1016/j.bcp.2009.06.004; Martin GS, 2006, CRIT CARE MED, V34, P15, DOI 10.1097/01.CCM.0000194535.82812.BA; Nullens S, 2016, SHOCK, V45, P450, DOI 10.1097/SHK.0000000000000519; Parrish WR, 2008, MOL MED, V14, P567, DOI 10.2119/2008-00079.Parrish; Pavlov VA, 2006, BIOCHEM SOC T, V34, P1037, DOI 10.1042/BST0341037; Pavlov VA, 2006, P NATL ACAD SCI USA, V103, P5219, DOI 10.1073/pnas.0600506103; Pavlov VA, 2007, CRIT CARE MED, V35, P1139, DOI 10.1097/01.CCM.0000259381.56526.96; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; Rousseau SJ, 2005, NEUROPHARMACOLOGY, V49, P59, DOI 10.1016/j.neuropharm.2005.01.030; Russell JA, 2006, NEW ENGL J MED, V355, P1699, DOI 10.1056/NEJMra043632; Sitapara RA, 2014, MOL MED, V20, DOI 10.2119/molmed.2013.00086; Su X, 2010, J IMMUNOL, V184, P401, DOI 10.4049/jimmunol.0901808; Sussman ES, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.2.FOCUS1315; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Tsoyi K, 2011, ANTIOXID REDOX SIGN, V14, P2057, DOI 10.1089/ars.2010.3555; Uteshev VV, 2012, ADV EXP MED BIOL, V740, P603, DOI 10.1007/978-94-007-2888-2_27; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Wallace TL, 2011, BIOCHEM PHARMACOL, V82, P891, DOI 10.1016/j.bcp.2011.06.034; Ward PA, 2012, EMBO MOL MED, V4, P1234, DOI 10.1002/emmm.201201375; Zhang JL, 2011, J BIOL CHEM, V286, P25331, DOI 10.1074/jbc.M111.221754	36	12	12	1	5	IVYSPRING INT PUBL	LAKE HAVEN	PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA	1449-2288			INT J BIOL SCI	Int. J. Biol. Sci.		2018	14	7					748	759		10.7150/ijbs.24576			12	Biochemistry & Molecular Biology; Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics	GH2WD	WOS:000433261800006	29910685	DOAJ Gold, Green Published			2021-06-18	
J	Rickards, TA; Cranston, CC; Touradji, P; Bechtold, KT				Rickards, Tyler A.; Cranston, Christopher C.; Touradji, Pegah; Bechtold, Kathleen T.			Embedded performance validity testing in neuropsychological assessment: Potential clinical tools	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						Assessment; clinical neuropsychology; effort; embedded measures; malingering	TRAUMATIC BRAIN-INJURY; CARD SORTING TEST; RELIABLE DIGIT SPAN; MALINGERED NEUROCOGNITIVE DYSFUNCTION; SURVEY PROFESSIONAL PRACTICES; FORCED-CHOICE RECOGNITION; FALSE-POSITIVE RATES; COMPLEX FIGURE TEST; SYMPTOM VALIDITY; MULTIPLE PERFORMANCE	The article aims to suggest clinically-useful tools in neuropsychological assessment for efficient use of embedded measures of performance validity. To accomplish this, we integrated available validity-related and statistical research from the literature, consensus statements, and survey-based data from practicing neuropsychologists. We provide recommendations for use of 1) Cutoffs for embedded performance validity tests including Reliable Digit Span, California Verbal Learning Test (Second Edition) Forced Choice Recognition, Rey-Osterrieth Complex Figure Test Combination Score, Wisconsin Card Sorting Test Failure to Maintain Set, and the Finger Tapping Test; 2) Selecting number of performance validity measures to administer in an assessment; and 3) Hypothetical clinical decision-making models for use of performance validity testing in a neuropsychological assessment collectively considering behavior, patient reporting, and data indicating invalid or noncredible performance. Performance validity testing helps inform the clinician about an individual's general approach to tasks: response to failure, task engagement and persistence, compliance with task demands. Data-driven clinical suggestions provide a resource to clinicians and to instigate conversation within the field to make more uniform, testable decisions to further the discussion, and guide future research in this area.	[Rickards, Tyler A.; Cranston, Christopher C.; Touradji, Pegah; Bechtold, Kathleen T.] Johns Hopkins Sch Med, Div Rehabil Psychol & Neuropsychol, Dept Phys Med & Rehabil, 600 N Wolfe St,Phipps Bldg 174, Baltimore, MD 21287 USA	Bechtold, KT (corresponding author), Johns Hopkins Sch Med, Div Rehabil Psychol & Neuropsychol, Dept Phys Med & Rehabil, 600 N Wolfe St,Phipps Bldg 174, Baltimore, MD 21287 USA.	kbechto1@jhmi.edu	Cranston, Christopher/AAH-2628-2019				Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Axelrod BN, 2007, INT J NEUROSCI, V117, P1591, DOI 10.1080/00207450600941189; Axelrod BN, 2014, CLIN NEUROPSYCHOL, V28, P876, DOI 10.1080/13854046.2014.907583; Axelrod BN, 2011, APPL NEUROPSYCHOL, V18, P27, DOI 10.1080/09084282.2010.523369; Bashem JR, 2014, CLIN NEUROPSYCHOL, V28, P851, DOI 10.1080/13854046.2014.927927; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Bilder RM, 2014, CLIN NEUROPSYCHOL, V28, P1212, DOI 10.1080/13854046.2014.969774; Blaskewitz N, 2009, APPL NEUROPSYCHOL, V16, P54, DOI 10.1080/09084280802644227; Boone, 2007, ASSESSMENT FEIGNED C; Boone KB, 2003, CLIN NEUROPSYCHOL, V17, P244, DOI 10.1076/clin.17.2.244.16497; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Butters MA, 1998, ARCH CLIN NEUROPSYCH, V13, P721, DOI 10.1016/S0887-6177(98)00010-9; Dandachi-FitzGerald B, 2017, J CLIN EXP NEUROPSYC, V39, P257, DOI 10.1080/13803395.2016.1223278; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; DAWES RM, 1989, SCIENCE, V243, P1668, DOI 10.1126/science.2648573; Delis DC, 2000, CALIFORNIA VERBAL LE; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Donders J, 2011, CLIN NEUROPSYCHOL, V25, P173, DOI 10.1080/13854046.2010.536781; DSM-V American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]; EYSENCK HJ, 1952, J CONSULT PSYCHOL, V16, P319, DOI DOI 10.1037/H0063633; Glassmire DM, 2016, ASSESSMENT, V23, P292, DOI 10.1177/1073191115587551; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2003, J FORENSIC NEUROPSYC, V2, P97, DOI DOI 10.1300/J151V02N03_05; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Greve KW, 2002, J CLIN EXP NEUROPSYC, V24, P48, DOI 10.1076/jcen.24.1.48.968; Heaton R., 1981, MANUAL WISCONSIN CAR; Heaton R., 1993, WISCONSIN CARD SORTI; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Iverson GL, 2006, APPL NEUROPSYCHOL, V13, P77, DOI 10.1207/s15324826an1302_3; King JH, 2002, CLIN NEUROPSYCHOL, V16, P506, DOI 10.1076/clin.16.4.506.13912; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2014, CLIN NEUROPSYCHOL, V28, P1230, DOI 10.1080/13854046.2014.988754; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Loring DW, 2016, ARCH CLIN NEUROPSYCH, V31, P313, DOI 10.1093/arclin/acw014; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Martin PK, 2015, CLIN NEUROPSYCHOL, V29, P741, DOI 10.1080/13854046.2015.1087597; Meyers J., 1995, REY COMPLEX FIGURE T; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Nelson NW, 2003, CLIN NEUROPSYCHOL, V17, P263, DOI 10.1076/clin.17.2.263.16511; Odland AP, 2015, PSYCHOL INJ LAW, V8, P46, DOI 10.1007/s12207-015-9216-4; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Reese CS, 2012, ARCH CLIN NEUROPSYCH, V27, P176, DOI 10.1093/arclin/acr117; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Schroeder RW, 2012, ASSESSMENT, V19, P21, DOI 10.1177/1073191111428764; Schutte C., 2013, MILD TRAUMATIC BRAIN, P159; Schutte C, 2011, CLIN NEUROPSYCHOL, V25, P454, DOI 10.1080/13854046.2010.550635; Schwartz ES, 2016, J INT NEUROPSYCH SOC, V22, P851, DOI 10.1017/S1355617716000746; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Sherman E.M., 2013, MILD TRAUMATIC BRAIN, P57; Shura RD, 2016, APPL NEUROPSYCH-ADUL, V23, P94, DOI 10.1080/23279095.2015.1014556; Silk-Eglit G. M., 2015, APPL NEUROPSYCHOL, V22, P1; Slick D.J., 2012, PEDIAT FORENSIC NEUR, P113; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Smith J. P, 2007, THESIS; Smith K, 2014, CLIN NEUROPSYCHOL, V28, P1048, DOI 10.1080/13854046.2014.931465; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Spencer R. J., 2010, 8 ANN M AM AC CLIN N; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Sweet JJ, 2015, CLIN NEUROPSYCHOL, V29, P1069, DOI 10.1080/13854046.2016.1140228; Sweet JJ, 2011, CLIN NEUROPSYCHOL, V25, P12, DOI 10.1080/13854046.2010.544165; Tombaugh TN, 1996, TEST MEMORY MALINGER; Van Dyke SA, 2013, CLIN NEUROPSYCHOL, V27, P1234, DOI 10.1080/13854046.2013.835447; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Webb JW, 2012, CLIN NEUROPSYCHOL, V26, P1377, DOI 10.1080/13854046.2012.728248; Wechsler D., 1981, WAIS R MANUAL WECHSL; Whearty KM, 2015, J PSYCHIATR RES, V68, P397, DOI 10.1016/j.jpsychires.2015.04.018; Young JC, 2012, CLIN NEUROPSYCHOL, V26, P147, DOI 10.1080/13854046.2011.647083; Zenisek R, 2016, ARCH CLIN NEUROPSYCH, V31, P426, DOI 10.1093/arclin/acw025	84	12	13	3	13	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult		2018	25	3					219	230		10.1080/23279095.2017.1278602			12	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	FY7NK	WOS:000427049000004	28139144				2021-06-18	
J	Sharp, AL; Huang, BZ; Tang, T; Shen, E; Melnick, ER; Venkatesh, AK; Kanter, MH; Gould, MK				Sharp, Adam L.; Huang, Brian Z.; Tang, Tania; Shen, Ernest; Melnick, Edward R.; Venkatesh, Arjun K.; Kanter, Michael H.; Gould, Michael K.			Implementation of the Canadian CT Head Rule and Its Association With Use of Computed Tomography Among Patients With Head Injury	ANNALS OF EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; CLINICAL DECISION-SUPPORT; INTERRUPTED TIME-SERIES; ADULTS; CARE	Study objective: Approximately 1 in 3 computed tomography (CT) scans performed for head injury may be avoidable. We evaluate the association of implementation of the Canadian CT Head Rule on head CT imaging in community emergency departments (EDs). Methods: We conducted an interrupted time-series analysis of encounters from January 2014 to December 2015 in 13 Southern California EDs. Adult health plan members with a trauma diagnosis and Glasgow Coma Scale score at ED triage were included. A multicomponent intervention included clinical leadership endorsement, physician education, and integrated clinical decision support. The primary outcome was the proportion of patients receiving a head CT. The unit of analysis was ED encounter, and we compared CT use pre- and postintervention with generalized estimating equations segmented logistic regression, with physician as a clustering variable. Secondary analysis described the yield of identified head injuries pre- and postintervention. Results: Included were 44,947 encounters (28,751 preintervention and 16,196 postintervention), resulting in 14,633 (32.6%) head CTs (9,758 preintervention and 4,875 postintervention), with an absolute 5.3% (95% confidence interval [CI] 2.5% to 8.1%) reduction in CT use postintervention. Adjusted pre-post comparison showed a trend in decreasing odds of imaging (odds ratio 0.98; 95% CI 0.96 to 0.99). All but one ED reduced CTs postintervention (0.3% to 8.7%, one ED 0.3% increase), but no interaction between the intervention and study site over time existed (P=.34). After the intervention, diagnostic yield of CT-identified intracranial injuries increased by 2.3% (95% CI 1.5% to 3.1%). Conclusion: A multicomponent implementation of the Canadian CT Head Rule was associated with a modest reduction in CT use and an increased diagnostic yield of head CTs for adult trauma encounters in community EDs.	[Sharp, Adam L.; Huang, Brian Z.; Tang, Tania; Shen, Ernest; Gould, Michael K.] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA; [Sharp, Adam L.] Kaiser Permanente Southern Calif, Los Angeles Med Ctr, Dept Emergency Med, Los Angeles, CA 90027 USA; [Melnick, Edward R.; Venkatesh, Arjun K.] Yale Univ, Dept Emergency Med, New Haven, CT USA; [Kanter, Michael H.] Southern Calif Permanente Med Grp, Pasadena, CA USA	Sharp, AL (corresponding author), Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA.; Sharp, AL (corresponding author), Kaiser Permanente Southern Calif, Los Angeles Med Ctr, Dept Emergency Med, Los Angeles, CA 90027 USA.	adam.l.sharp@kp.org	kanter, michael howard/W-2753-2019	Huang, Brian/0000-0001-8645-5142	Kaiser Permanente Southern California Care Improvement Research Team; Agency for Healthcare Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K08HS021271]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K08HS021271] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001863] Funding Source: NIH RePORTER	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist. Internal funding from the Kaiser Permanente Southern California Care Improvement Research Team supported this project. Dr. Melnick is supported, in part, by grant K08HS021271 from the Agency for Healthcare Research and Quality.	ABIM Foundation, 2014, AM COLL EM PHYS CHOO; Austin SR, 2015, MED CARE, V53, pE65, DOI 10.1097/MLR.0b013e318297429c; Barrett MSC, 2015, METHODS SERIES REPOR; Carroll CP, 2012, NEUROSURGERY, V71, P1064, DOI 10.1227/NEU.0b013e31826f7c16; Cawood TJ, 2009, EUR J ENDOCRINOL, V161, P513, DOI 10.1530/EJE-09-0234; Fretheim A, 2015, J CLIN EPIDEMIOL, V68, P324, DOI 10.1016/j.jclinepi.2014.10.003; Harnan SE, 2011, J TRAUMA, V71, P245, DOI 10.1097/TA.0b013e31820d090f; Ip IK, 2015, AM J EMERG MED, V33, P320, DOI 10.1016/j.ajem.2014.11.005; Ivers N, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000259.pub3; Korley FK, 2013, ACAD EMERG MED, V20, P463, DOI 10.1111/acem.12136; Lang ES, 2007, ANN EMERG MED, V49, P355, DOI 10.1016/j.annemergmed.2006.08.022; Li B, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-12; Melnick ER, 2012, JT COMM J QUAL PATIE, V38, P483, DOI 10.1016/S1553-7250(12)38064-1; Mitchell J, 2005, SEMIN ULTRASOUND CT, V26, P37, DOI 10.1053/j.sult.2004.10.004; Pape UJ, 2013, J ROY SOC MED, V106, P124, DOI 10.1258/jrsm.2012.110319; Parma C, 2014, AM SURGEON, V80, P664; Rivara FP, 2015, JAMA-J AM MED ASSOC, V314, P2629, DOI 10.1001/jama.2015.17298; Rogers RL, 2015, AM J EMERG MED, V33, P1505, DOI 10.1016/j.ajem.2015.07.039; Rosenberg A, 2015, JAMA INTERN MED, V175, P1913, DOI 10.1001/jamainternmed.2015.5441; Schriger DL, 2001, ANN EMERG MED, V37, P75, DOI 10.1067/mem.2001.111570; Sharp AL, 2017, ACAD EMERG MED, V24, P22, DOI 10.1111/acem.13061; Sharp AL, 2014, J EMERG MED, V47, P333, DOI 10.1016/j.jemermed.2014.04.017; Sierzenski PR, 2014, ANN EMERG MED, V63, P25, DOI 10.1016/j.annemergmed.2013.08.027; Stiell IG, 2010, CAN MED ASSOC J, V182, P1527, DOI 10.1503/cmaj.091974; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Taljaard M, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-77; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x	27	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JAN	2018	71	1					54	63		10.1016/j.annemergmed.2017.06.022			10	Emergency Medicine	Emergency Medicine	FS6UH	WOS:000419933100016	28739290	Green Accepted			2021-06-18	
J	Struebing, FL; King, R; Li, Y; Chrenek, MA; Lyuboslavsky, PN; Sidhu, CS; Iuvone, PM; Geisert, EE				Struebing, Felix L.; King, Rebecca; Li, Ying; Chrenek, Micah A.; Lyuboslavsky, Polina N.; Sidhu, Curran S.; Iuvone, P. Michael; Geisert, Eldon E.			Transcriptional Changes in the Mouse Retina after Ocular Blast Injury: A Role for the Immune System	JOURNAL OF NEUROTRAUMA			English	Article						axon injury; ocular blast injury; ocular immune system; systems genetics; transcriptome	TRAUMATIC BRAIN-INJURY; COMPLEMENT GENE-EXPRESSION; INFLAMMATION; NETWORK; MODEL; MICROGLIA; MIGRATION; ANTERIOR; DISEASE; CELLS	Ocular blast injury is a major medical concern for soldiers and explosion victims due to poor visual outcomes. To define the changes in gene expression following a blast injury to the eye, we examined retinal ribonucleic acid (RNA) expression in 54 mouse strains 5 days after a single 50-psi overpressure air wave blast injury. We observe that almost 40% of genes are differentially expressed with a false discovery rate (FDR) of <0.001, even though the nominal changes in RNA expression are rather small. Moreover, we find through machine learning approaches that genetic networks related to the innate and acquired immune system are activated. Accompanied by lymphocyte invasion into the inner retina, blast injury also results in progressive loss of visual function and retinal ganglion cells (RGCs). Collectively, these data demonstrate how systems genetics can be used to put meaning to the transcriptome changes following ocular blast injury that eventually lead to blindness.	[Struebing, Felix L.; King, Rebecca; Li, Ying; Chrenek, Micah A.; Lyuboslavsky, Polina N.; Sidhu, Curran S.; Iuvone, P. Michael; Geisert, Eldon E.] Emory Univ, Dept Ophthalmol, 1365B Clifton Rd NE,Room 5500, Atlanta, GA 30305 USA	Geisert, EE (corresponding author), Emory Univ, Dept Ophthalmol, 1365B Clifton Rd NE,Room 5500, Atlanta, GA 30305 USA.	egeiser@emory.edu		Struebing, Felix/0000-0002-9436-6294	Department of Defense CDMRP Grant from the U.S. Army Medical Research and Materiel Command [W81XWH1210255, W81XWH-12-1-0436]; Department of Defense CDMRP Grant from Telemedicine and Advanced Technology; NEIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY178841, R01EY004864, P30EY06360]; Research to Prevent BlindnessResearch to Prevent Blindness (RPB); institutional training grant [T32EY007092-30]; Emory Integrated Genomics Core (EIGC); Emory University School of Medicine as one of the Emory Integrated Core Facilities; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY021592, P30EY006360, T32EY007092, R01EY017841] Funding Source: NIH RePORTER	This study was supported by the Department of Defense CDMRP Grants W81XWH1210255 and W81XWH-12-1-0436 from the U.S. Army Medical Research and Materiel Command and the Telemedicine and Advanced Technology (EEG, PMI), NEI grants R01EY178841 (EEG), R01EY004864 (PMI), P30EY06360 (Emory Vision Core, PMI), and unrestricted funds from Research to Prevent Blindness. FLS is supported by the institutional training grant T32EY007092-30 (PMI). Additional support was provided by the Emory Integrated Genomics Core (EIGC), which is subsidized by the Emory University School of Medicine as one of the Emory Integrated Core Facilities. We thank Dr. Robert Williams and Arthur Centeno (University of Tennessee Health Science Center) for maintaining the data on GeneNetwork, Dr. Xiangdi Wang and Dr. Justin Templeton for their technical assistance, as well as April Brooke Still for her help in breeding some BXD animals at Emory University.	Balu R, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-014-0484-2; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Blake JA, 2015, NUCLEIC ACIDS RES, V43, pD1049, DOI 10.1093/nar/gku1179; Bricker-Anthony C, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0192-5; Bricker-Anthony C, 2014, INVEST OPHTH VIS SCI, V55, P4853, DOI 10.1167/iovs.14-14353; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Casanova T, 2015, J INTERF CYTOK RES, V35, P808, DOI 10.1089/jir.2014.0237; CHARTERIS DG, 1992, BRIT J OPHTHALMOL, V76, P499, DOI 10.1136/bjo.76.8.499; Chattopadhyay S, 2008, INT IMMUNOL, V20, P509, DOI 10.1093/intimm/dxn008; Cheadle C, 2003, J MOL DIAGN, V5, P73, DOI 10.1016/S1525-1578(10)60455-2; CHEN DH, 1978, J COMP NEUROL, V177, P635, DOI 10.1002/cne.901770407; Cockerham GC, 2011, NEW ENGL J MED, V364, P2172, DOI 10.1056/NEJMc1010683; Curreri AG, 2009, CLIN SPORT MED, V28, P591, DOI 10.1016/j.csm.2009.07.004; Dougherty AL, 2011, BRAIN INJURY, V25, P8, DOI 10.3109/02699052.2010.536195; Douglas RM, 2005, VISUAL NEUROSCI, V22, P677, DOI 10.1017/S0952523805225166; Fischer TD, 2016, FRONT SYST NEUROSCI, V10, DOI [10.3389/fnsys.2016.00029, 10.3389/fnsys.2010.00020]; Fuller TF, 2007, MAMM GENOME, V18, P463, DOI 10.1007/s00335-007-9043-3; Glasstone S., 1977, The Effects of Nuclear Weapons; Gusnanto A, 2007, CURR OPIN LIPIDOL, V18, P187, DOI 10.1097/MOL.0b013e3280895d6f; Ha Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.281; Haga S, 1996, NEUROSCI LETT, V216, P191, DOI 10.1016/0304-3940(96)13040-8; Hines-Beard J, 2012, EXP EYE RES, V99, P63, DOI 10.1016/j.exer.2012.03.013; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Imagawa T, 2003, J VET MED SCI, V65, P23, DOI 10.1292/jvms.65.23; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jeon CJ, 1998, J NEUROSCI, V18, P8936; Kanehisa M, 2016, NUCLEIC ACIDS RES, V44, pD457, DOI 10.1093/nar/gkv1070; King R, 2015, MOL VIS, V21, P1235; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Langfelder P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061505; Luo C, 2011, MOL VIS, V17, P1588; Miyairi I, 2007, J IMMUNOL, V179, P1814, DOI 10.4049/jimmunol.179.3.1814; Mohan K, 2013, INVEST OPHTH VIS SCI, V54, P3440, DOI 10.1167/iovs.12-11522; Mulligan MK, 2017, METHODS MOL BIOL, V1488, P75, DOI 10.1007/978-1-4939-6427-7_4; Nemet AY, 2016, ISR MED ASSOC J, V18, P27; Richardson PRS, 1996, BRIT J OPHTHALMOL, V80, P1092, DOI 10.1136/bjo.80.12.1092; Rutar M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0224-1; Schwarzmaier SM, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-32; Stahl T, 2003, J NEUROIMMUNOL, V137, P67, DOI 10.1016/S0165-5728(03)00044-4; STREILEIN JW, 1981, J EXP MED, V153, P1058, DOI 10.1084/jem.153.5.1058; Struebing FL, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00169; Templeton JP, 2013, INVEST OPHTH VIS SCI, V54, P2599, DOI 10.1167/iovs.12-11175; Templeton JP, 2012, MOL VIS, V18, P2147; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; Wang J, 2013, NUCLEIC ACIDS RES, V41, pW77, DOI 10.1093/nar/gkt439; Weichel ED, 2008, CURR OPIN OPHTHALMOL, V19, P519, DOI 10.1097/ICU.0b013e3283140e98; Wickham H., 2009, GGPLOT2 ELEGANT GRAP, Vviii, P212; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Zhao S, 2017, NEUROSCI LETT, V643, P125, DOI 10.1016/j.neulet.2016.12.006; Zhao W, 2010, J BIOPHARM STAT, V20, P281, DOI 10.1080/10543400903572753; Zinkernagel MS, 2013, AM J PATHOL, V182, P875, DOI 10.1016/j.ajpath.2012.11.031	51	12	12	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2018	35	1					118	129		10.1089/neu.2017.5104			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FS1WO	WOS:000419569700014	28599600	Green Published			2021-06-18	
J	Tsyben, A; Guilfoyle, M; Timofeev, I; Anwar, F; Allanson, J; Outtrim, J; Menon, D; Hutchinson, P; Helmy, A				Tsyben, Anastasia; Guilfoyle, Mathew; Timofeev, Ivan; Anwar, Fahim; Allanson, Judith; Outtrim, Joanne; Menon, David; Hutchinson, Peter; Helmy, Adel			Spectrum of outcomes following traumatic brain injury-relationship between functional impairment and health-related quality of life	ACTA NEUROCHIRURGICA			English	Article						Traumatic brain injury; Quality of life; SF-36; Glasgow Outcome Scale	HEAD-INJURY; PROSPECTIVE COHORT; MODERATE; PREDICTORS; VALIDITY; ADULTS; SCALE; SENSITIVITY; DISABILITY; COSTS	The outcome following traumatic brain injury (TBI) is heterogeneous and poorly defined and physical disability scales like the extended Glasgow Outcome Score (GOSE) while providing valuation information in terms of broad categorisation of outcome are unlikely to capture the full spectrum of deficits. Quality of life questionnaires such as SF-36 are emerging as potential tools to help characterise factors important to patients' recovery. This study assessed the association between physical disability and subjective health rating. The relationship is of value as it may help evaluate the impact of TBI on patients' lives and facilitate the delivery of appropriate neuro-rehabilitation services. A single-centre retrospective study was undertaken to assess the relationship between physical outcome as measured by GOSE and quality of life captured by the SF-36 questionnaire. Cronbach's alpha was calculated for each of the eight SF-36 domains to measure internal consistency of the test. Multivariate analysis of variance was conducted to look at the association between GOSE and the physical (PCS) and mental (MCS) component scores on the SF-36. Finally, we performed a generalised linear mixed model (GLMM) to assess the relative contribution of GOSE score, age at the time of trauma, sex and TBI duration towards MCS and PCS rating. There is a statistically significant difference in the MCS and PCS scores based on patients' GOSE scores. The mean scores of the eight SF-36 domains showed significant association with GOSE. GLMM demonstrated that GOSE was the strongest predictor of PCS and MCS. Age was an important variable in the PCS score while time following trauma was a significant predictor of MCS rating. This study highlights that patients' physical outcome following TBI is a strong predictor of the subjective mental and physical health. Nevertheless, there remains tremendous variability in individual SF-36 scores for each GOSE category, highlighting that additional factors play a role in determining quality of life.	[Tsyben, Anastasia; Guilfoyle, Mathew; Timofeev, Ivan; Hutchinson, Peter; Helmy, Adel] Addenbrookes Hosp, Dept Neurosurg, Hills Rd, Cambridge CB2 0QQ, England; [Tsyben, Anastasia; Guilfoyle, Mathew; Timofeev, Ivan; Hutchinson, Peter; Helmy, Adel] Cambridge Biomed Campus, Dept Clin Neurosci, Div Neurosurg, Cambridge, England; [Anwar, Fahim; Allanson, Judith] Addenbrookes Hosp, Dept Neurorehabil, Cambridge, England; [Outtrim, Joanne; Menon, David] Cambridge Biomed Campus, Dept Med, Div Anaesthesia, Cambridge, England	Tsyben, A (corresponding author), Addenbrookes Hosp, Dept Neurosurg, Hills Rd, Cambridge CB2 0QQ, England.; Tsyben, A (corresponding author), Cambridge Biomed Campus, Dept Clin Neurosci, Div Neurosurg, Cambridge, England.	anastasia.tsyben@cantab.net	Timofeev, Ivan/AAE-7019-2019; Anwar, Fahim/ABH-5525-2020; Helmy, Adel/AAS-3084-2020	Anwar, Fahim/0000-0002-1176-0975; Helmy, Adel/0000-0002-0531-0556; Timofeev, Ivan/0000-0002-1168-0393	National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Center; NIHRNational Institute for Health Research (NIHR); European Union Framework Program 7 grant (CENTER-TBI) [602150]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0802251]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0802251] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2006-14-004, NF-SI-0512-10090] Funding Source: researchfish	This study was supported by National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Center to PH and AH, an NIHR Senior Investigator Award to DM and an NIHR Research Professorship to PH. Authors were also supported by a European Union Framework Program 7 grant (CENTER-TBI; Grant Agreement No. 602150). AH is supported by MRC (G0802251).	ASHLEY MJ, 1990, J INSURANCE MED, V22, P156; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brown AW, 2011, J NEUROTRAUM, V28, P167, DOI 10.1089/neu.2010.1400; Burke SN, 2006, NAT REV NEUROSCI, V7, P30, DOI 10.1038/nrn1809; Callaway DW, 2007, EMERG MED CLIN N AM, V25, P837, DOI 10.1016/j.emc.2007.06.005; Chaytor N, 2007, J INT NEUROPSYCH SOC, V13, P377, DOI 10.1017/S1355617707070592; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Cotelli M, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00038; Edwards SGM, 2002, BRIT MED J, V324, P1493, DOI 10.1136/bmj.324.7352.1493; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Fayers P.M., 2005, ASSESSING QUALITY LI; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Forslund MV, 2013, ACTA NEUROL SCAND, V128, P220, DOI 10.1111/ane.12130; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; Grauwmeijer E, 2014, ARCH PHYS MED REHAB, V95, P1268, DOI 10.1016/j.apmr.2014.02.002; Guilfoyle MR, 2010, J NEUROTRAUM, V27, P2173, DOI 10.1089/neu.2010.1353; Hajfey WJ, 1991, HEAD TRAUMA REHABIL; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; Johnstone B, 1999, J HEAD TRAUMA REHAB, V14, P220, DOI 10.1097/00001199-199906000-00003; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Likert R., 1932, ARCH PSYCHOL; McCauley SR, 2013, J NEUROTRAUM, V30, P1506, DOI 10.1089/neu.2013.2925; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Moore DW, 2010, NEUROPSYCHOL REHABIL, V20, P340, DOI 10.1080/09602010903250928; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; Polinder S, 2015, POPUL HEALTH METR, V13, DOI 10.1186/s12963-015-0037-1; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Schonberger M, 2011, BRAIN INJURY, V25, P543, DOI 10.3109/02699052.2011.565013; Scholten AC, 2015, INJURY, V46, P616, DOI 10.1016/j.injury.2014.10.064; Slewa-Younan S, 2008, J NEUROL NEUROSUR PS, V79, P1197, DOI 10.1136/jnnp.2008.147983; Subramanian L, 2011, J NEUROSCI, V31, P16309, DOI 10.1523/JNEUROSCI.3498-11.2011; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; von Steinbuechel N, 2016, BEHAV NEUROL, V2016, DOI 10.1155/2016/7928014; Ware JE, 1993, F 36 HLTH SURVEY MAN; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wilson L, 2017, J NEUROTRAUM, V34, P59, DOI 10.1089/neu.2015.4287; Wood RL, 2013, NEUROREHABILITATION, V32, P699, DOI 10.3233/NRE-130895	43	12	12	1	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JAN	2018	160	1					107	115		10.1007/s00701-017-3334-6			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FQ3UW	WOS:000418283800015	28988342	Other Gold, Green Published			2021-06-18	
J	Kawata, K; Rubin, LH; Wesley, L; Lee, JH; Sim, T; Takahagi, M; Bellamy, A; Tierney, R; Langford, D				Kawata, Keisuke; Rubin, Leah H.; Wesley, Leroy; Lee, Jong Hyun; Sim, Thomas; Takahagi, Masahiro; Bellamy, Al; Tierney, Ryan; Langford, Dianne			Acute Changes in Plasma Total Tau Levels Are Independent of Subconcussive Head Impacts in College Football Players	JOURNAL OF NEUROTRAUMA			English	Article						biomarker; head impact kinematics; subconcussion; Tau; traumatic brain injury	BRAIN-INJURY; BLOOD; GPS; ASSOCIATION; CONCUSSION; BIOMARKERS; EXPOSURE; PROTEIN; SEASON	Athletes in contact sports sustain repetitive subconcussive head impacts in a brief window, yet neurophysiological sequelae from repetitive subconcussion remain unclear. This prospective longitudinal study examined a relationship between changes in plasma Tau protein levels and subconcussive impact kinematic data in 23 Division I collegiate football players during a series of pre-season practices. Plasma measures for Tau and S100 beta proteins, symptom scores, and near point of convergence were obtained at pre-season baseline and pre-/post-practices. During each practice, impact frequency and linear and rotational head accelerations were recorded via an accelerometer-embedded mouth guard. There were significant elevations in plasma Tau levels at all post-practice time-points, compared with those of pre-practice and baseline levels. However, the highest degree of elevation in plasma Tau was observed after the first practice, for which players sustained the lowest number of hits and magnitudes for these hits. Subconcussive impact exposure during practice (e.g., head impact frequency and magnitude) did not predict increased plasma Tau levels. Concussion history and years of football experience also were unrelated to changes in plasma Tau levels. Increases in plasma Tau levels were associated with increases in S100 beta levels only after the first practice. There were no significant associations between changes in Tau levels, symptom scores, or near point of convergence. These data suggest that the changes in levels of circulating Tau protein were independent of subconcussive head impact exposure, pointing to the possibility that other factors may have played roles in changes in plasma Tau levels.	[Kawata, Keisuke] Indiana Univ, Dept Kinesiol, Sch Publ Hlth, Bloomington, IN 47405 USA; [Rubin, Leah H.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Wesley, Leroy; Lee, Jong Hyun; Tierney, Ryan; Langford, Dianne] Temple Univ, Dept Neurosci, Lewis Katz Sch Med, MERB 750,3500 North Broad St, Philadelphia, PA 19140 USA; [Sim, Thomas] Temple Univ, Dept Kinesiol, Coll Publ Hlth, Philadelphia, PA 19122 USA; [Takahagi, Masahiro; Bellamy, Al] Temple Univ, Dept Athlet, Philadelphia, PA 19122 USA	Langford, D (corresponding author), Temple Univ, Dept Neurosci, Lewis Katz Sch Med, MERB 750,3500 North Broad St, Philadelphia, PA 19140 USA.	tdl@temple.edu			Pennsylvania Athletic Trainers' Society research grant; Marianne Garman Burton Foundation for Caregivers; Temple University Office of the Vice Provost for Research	This work was supported by the Pennsylvania Athletic Trainers' Society research grant (to K. Kawata), generous support from Athole G. Jacobi, MD, and the Marianne Garman Burton Foundation for Caregivers (to D. Langford), and a seed grant from Temple University Office of the Vice Provost for Research (to D. Langford). Sponsors had no role in the design or execution of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.	Ahmadzadeh H, 2014, BIOPHYS J, V106, P1123, DOI 10.1016/j.bpj.2014.01.024; Alosco Michael L, 2017, Alzheimers Dement (Amst), V7, P33, DOI 10.1016/j.dadm.2016.11.003; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Bulut M, 2006, ADV THER, V23, P12, DOI 10.1007/BF02850342; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Gill J, 2017, NEUROLOGY, V88, P595, DOI 10.1212/WNL.0000000000003587; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; HUNG GK, 1986, DOC OPHTHALMOL, V62, P165, DOI 10.1007/BF00229128; Hwang S, 2017, J NEUROTRAUM, V34, P8, DOI 10.1089/neu.2015.4238; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Kawata K, 2016, INT J SPORTS MED, V37, P405, DOI 10.1055/s-0035-1569290; Kawata K, 2017, J NEUROTRAUM, V34, P2254, DOI 10.1089/neu.2016.4786; Kawata K, 2016, JAMA OPHTHALMOL, V134, P763, DOI 10.1001/jamaophthalmol.2016.1085; Macutkiewicz D, 2011, J SPORT SCI, V29, P967, DOI 10.1080/02640414.2011.570774; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2016, NEUROSURG CLIN N AM, V27, P529, DOI 10.1016/j.nec.2016.05.009; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Rissin DM, 2011, ANAL CHEM, V83, P2279, DOI 10.1021/ac103161b; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Slobounov SM, 2017, NEUROIMAGE-CLIN, V14, P708, DOI 10.1016/j.nicl.2017.03.006; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Waldron M, 2011, J SPORT SCI, V29, P1223, DOI 10.1080/02640414.2011.587445; Wisbey B, 2010, J SCI MED SPORT, V13, P531, DOI 10.1016/j.jsams.2009.09.002; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224	39	12	12	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2018	35	2					260	266		10.1089/neu.2017.5376		DEC 2017	7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FT1TA	WOS:000418128000001	29073820				2021-06-18	
J	DeMaster, D; Johnson, C; Juranek, J; Ewing-Cobbs, L				DeMaster, Dana; Johnson, Chad; Juranek, Jenifer; Ewing-Cobbs, Linda			Memory and the hippocampal formation following pediatric traumatic brain injury	BRAIN AND BEHAVIOR			English	Article						hippocampal development; memory; traumatic brain injury	CLOSED-HEAD-INJURY; DEVELOPMENTAL DIFFERENCES; ACADEMIC-ACHIEVEMENT; EPISODIC MEMORY; NEUROCOGNITIVE OUTCOMES; CORTICAL CONTRIBUTIONS; COGNITIVE PREDICTORS; AEROBIC FITNESS; EARLY-CHILDHOOD; TEMPORAL-LOBE	IntroductionPrevious research indicates disruption of learning and memory in children who have experienced traumatic brain injury (TBI). ObjectiveThis research evaluates the impact of pediatric TBI on volumetric differences along the long axis of the hippocampus, a region of the brain that is critical for explicit memory. MethodsStructural brain data and behavioral measures were collected 6weeks following TBI or extracranial injury (EI), in children aged 8-15years and from a group of age matched typically developing controls (TDC). Total hippocampal volume and hippocampal subregion volumes corresponding to hippocampal head, body, and tail were compared across groups and were examined in relation to verbal and visual memory. ResultsGroup differences were evident such that hippocampal body volume was found to be smaller for TBI and EI groups compared to the TDC group. Analysis restricted to the TBI group indicated that hippocampal head volume was associated with severity of injury. The relation between severity of injury and hippocampal head volume is particularly important considering results from our investigation of hippocampal volume-to-memory performance relations indicating positive correlations between hippocampal head volume and performance on memory measures for both the TBI group and the TDC group. Significant negative correlations between hippocampal body volume and memory were evident for the TBI group but not EI or TDC groups. Correlations between memory performance and hippocampal tail volume were not significant for the TBI or TDC groups, although for the EI group, a positive correlation was found between hippocampal tail volume and memory. ConclusionTogether these results underscore an important relation between hippocampal structure and memory function during the subacute stage of recovery from pediatric TBI.	[DeMaster, Dana; Johnson, Chad; Juranek, Jenifer; Ewing-Cobbs, Linda] Univ Texas Houston, Childrens Leaning Inst, Dept Pediat, McGovern Med Sch, Houston, TX 77004 USA	DeMaster, D (corresponding author), Univ Texas Houston, Childrens Leaning Inst, Dept Pediat, McGovern Med Sch, Houston, TX 77004 USA.	Dana.M.Demaster@uth.tmc.edu		DeMaster, Dana/0000-0002-8655-7517	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS43608]	National Institutes of Health, Grant/Award Number: R01 NS43608	Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Arnett AB, 2013, J INT NEUROPSYCH SOC, V19, P881, DOI 10.1017/S1355617713000635; Arroyos-Jurado E., 2006, EXCEPTIONALITY, V14, P125; Avants B, 2008, ACAD RADIOL, V15, P1360, DOI 10.1016/j.acra.2008.07.007; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Campbell CGN, 2004, CAN J NEUROL SCI, V31, P213, DOI 10.1017/S0317167100053853; Casella EM, 2014, CHILD NERV SYST, V30, P1333, DOI 10.1007/s00381-014-2446-z; Chaddock L, 2010, DEV NEUROSCI-BASEL, V32, P249, DOI 10.1159/000316648; Daugherty AM, 2016, HIPPOCAMPUS, V26, P220, DOI 10.1002/hipo.22517; DeMaster D, 2014, CEREB CORTEX, V24, P3036, DOI 10.1093/cercor/bht160; DeMaster D, 2013, NEUROPSYCHOLOGIA, V51, P2415, DOI 10.1016/j.neuropsychologia.2013.05.026; DeMaster DM, 2013, CORTEX, V49, P1482, DOI 10.1016/j.cortex.2012.08.004; Dennis EL, 2016, J NEUROTRAUM, V33, P840, DOI 10.1089/neu.2015.4012; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Duvernoy H. M., 2013, HUMAN HIPPOCAMPUS FU; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Ewing-Cobbs L, 2016, HUM BRAIN MAPP, V37, P3929, DOI 10.1002/hbm.23286; EWINGCOBBS L, 1985, J CLIN EXP NEUROPSYC, V7, P612; Farmer JE, 2002, DEV NEUROPSYCHOL, V22, P455, DOI 10.1207/S15326942DN2202_2; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; Farovik A, 2010, LEARN MEMORY, V17, P801, DOI 10.1101/lm.1616209; Fulton JB, 2012, NEUROPSYCHOLOGY, V26, P314, DOI 10.1037/a0027973; Ghetti S, 2010, J NEUROSCI, V30, P9548, DOI 10.1523/JNEUROSCI.3500-09.2010; Giedd JN, 1996, J COMP NEUROL, V366, P223, DOI 10.1002/(SICI)1096-9861(19960304)366:2<223::AID-CNE3>3.0.CO;2-7; Gogtay N, 2006, HIPPOCAMPUS, V16, P664, DOI 10.1002/hipo.20193; Hassevoort KM, 2016, MIND BRAIN EDUC, V10, P162, DOI 10.1111/mbe.12108; Herting MM, 2012, BEHAV BRAIN RES, V233, P517, DOI 10.1016/j.bbr.2012.05.012; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; Insausti R, 2010, ADV ANAT EMBRYOL CEL, V206, P71; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Knight RG, 2009, J CLIN EXP NEUROPSYC, V31, P575, DOI 10.1080/13803390802363710; Lee JK, 2014, NEUROIMAGE, V94, P162, DOI 10.1016/j.neuroimage.2014.03.019; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; Luby JL, 2016, P NATL ACAD SCI USA, V113, P5742, DOI 10.1073/pnas.1601443113; Maguire EA, 2006, HIPPOCAMPUS, V16, P1091, DOI 10.1002/hipo.20233; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Ofen N, 2012, NEUROSCI BIOBEHAV R, V36, P1708, DOI 10.1016/j.neubiorev.2012.02.016; Ofen N, 2012, J NEUROSCI, V32, P10012, DOI 10.1523/JNEUROSCI.1082-11.2012; Ostby Y, 2012, CEREB CORTEX, V22, P381, DOI 10.1093/cercor/bhr116; Ostby Y, 2009, J NEUROSCI, V29, P11772, DOI 10.1523/JNEUROSCI.1242-09.2009; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Phillipou A, 2014, DEV MED CHILD NEUROL, V56, P337, DOI 10.1111/dmcn.12345; Poppenk J, 2011, NEURON, V72, P931, DOI 10.1016/j.neuron.2011.10.014; Rao U, 2010, BIOL PSYCHIAT, V67, P357, DOI 10.1016/j.biopsych.2009.10.017; Reynolds C., 2007, J PSYCHOEDUCATIONAL, V27, P157; Riggins T, 2015, CHILD DEV, V86, P1710, DOI 10.1111/cdev.12445; Royo NC, 2006, EUR J NEUROSCI, V23, P1089, DOI 10.1111/j.1460-9568.2006.04642.x; Rushby JA, 2016, NEUROIMAGE-CLIN, V12, P607, DOI 10.1016/j.nicl.2016.09.017; Schlichting ML, 2017, J COGNITIVE NEUROSCI, V29, P37, DOI 10.1162/jocn_a_01028; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Staff RT, 2012, ANN NEUROL, V71, P653, DOI 10.1002/ana.22631; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TEASDALE G, 1974, LANCET, V2, P81; Thaler NS, 2011, APPL NEUROPSYCHOL, V18, P168, DOI 10.1080/09084282.2011.595443; Van Petten C, 2004, NEUROPSYCHOLOGIA, V42, P1394, DOI 10.1016/j.neuropsychologia.2004.04.006; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Yurgelun-Todd DA, 2003, PERCEPT MOTOR SKILL, V96, P3, DOI 10.2466/pms.2003.96.1.3; Zagorchev L, 2016, J NEUROTRAUM, V33, P29, DOI 10.1089/neu.2014.3831	67	12	12	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	2162-3279			BRAIN BEHAV	Brain Behav.	DEC	2017	7	12							e00832	10.1002/brb3.832			12	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	FR1UP	WOS:000418853300002	29299377	DOAJ Gold, Green Published			2021-06-18	
J	Ding, H; Wang, XL; Wang, HD; Zhu, L; Wang, Q; Jia, Y; Wei, WT; Zhou, CH; Wu, HM; Ding, K				Ding, Hui; Wang, Xiaoliang; Wang, Handong; Zhu, Lin; Wang, Qiang; Jia, Yue; Wei, Wuting; Zhou, Chenhui; Wu, Heming; Ding, Ke			Nrf2-ARE signaling provides neuroprotection in traumatic brain injury via modulation of the ubiquitin proteasome system	NEUROCHEMISTRY INTERNATIONAL			English	Article						Traumatic brain injury; Nrf2; Ubiquitin-proteasome; Redox homeostasis	RAT CEREBRAL-CORTEX; CLOSED-HEAD INJURY; OXIDATIVE STRESS; NEURODEGENERATIVE DISEASE; TERT-BUTYLHYDROQUINONE; GLUTATHIONE SYNTHESIS; RESPONSE ELEMENTS; CELL-DEATH; IN-VIVO; PATHWAY	The nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element (ARE) pathway exhibits protective effects in a variety of neurological diseases. However, the role of this pathway in traumatic brain injury (TBI) is not fully understood. This study investigates whether the Nrf2-ARE pathway provides neuroprotection following TBI via regulation of the ubiquitin proteasome system (UPS), and examines the involvement of this pathway in redox homeostasis. We found that activation the Nrf2-ARE pathway can mitigate secondary brain injury induced by TBI. Furthermore, we found that inhibiting the Nrf2-ARE pathway weakened the UPS following TBI. Treatment of TBI with the proteasome inhibitor, MG132, increased neuronal apoptosis, and evidence of brain water content was found. These data suggest that the Nrf2-ARE pathway provides neuroprotection following TBI via modulation of the UPS. In addition, the results indicated that the content of glutathione (GSH) was significantly increased after activation of Nrf2, and the level of ROS decreased; however, this effect contradictory in the Nrf2 knockout mice. Further studies found that treatment with the ROS agonist, ferric ammonium citrate (FAC), resulted in additional damage exerted by the ubiquitin proteasome pathways, and a significant increase in the amount of ubiquitinated proteins. In contrast, the activity of the ubiquitin proteasome pathways was vastly enhanced, and the level of ubiquitination proteins was significantly decreased following treatment with the inhibitor, N-acetylcysteine (NAC). The above mentioned results were also verified in in vitro experiments. In conclusion, the activation the Nrf2-ARE pathway improves neurological impairment caused by TBI via modulation of the UPS, and the redox homeostasis is one of the vital regulatory mechanisms. (C) 2017 Elsevier Ltd. All rights reserved.	[Ding, Hui; Wang, Xiaoliang; Wang, Handong; Zhu, Lin; Wang, Qiang; Jia, Yue; Wei, Wuting; Zhou, Chenhui; Wu, Heming; Ding, Ke] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China	Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com			Jiangsu Planned Projects for Postdoctoral Research Funds [1401002A]; Natural Science Fund of ChinaNational Natural Science Foundation of China (NSFC) [81371357, 81401026]; PLA medical science and technology youth training project plan [14QNP035]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2015T81136]	The authors would like to Dr. Chunxi Wang and Dr. Yanlin Han for their assistance with the experiments described herein. This work was supported by grants from the Natural Science Fund of China (grant Nos. 81371357 and 81401026), PLA medical science and technology youth training project plan (grant No.14QNP035) and Jiangsu Planned Projects for Postdoctoral Research Funds (grant No.1401002A), and a Special Financial Grant from the China Postdoctoral Science Foundation (grant No.2015T81136).	Abdul-Aziz A, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/454659; Aoyama K, 2013, INT J MOL SCI, V14, P21021, DOI 10.3390/ijms141021021; Bryan HK, 2013, BIOCHEM PHARMACOL, V85, P705, DOI 10.1016/j.bcp.2012.11.016; Chen M, 2009, J NEUROCHEM, V111, P1094, DOI 10.1111/j.1471-4159.2009.06401.x; Chi L, 2007, NEUROSCIENCE, V144, P991, DOI 10.1016/j.neuroscience.2006.09.064; De Clercq I, 2013, PLANT CELL, V25, P3472, DOI 10.1105/tpc.113.117168; de Vries HE, 2008, FREE RADICAL BIO MED, V45, P1375, DOI 10.1016/j.freeradbiomed.2008.09.001; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Escartin C, 2011, J NEUROSCI, V31, P7392, DOI 10.1523/JNEUROSCI.6577-10.2011; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gibney G., 2000, J PHARM EXP THER, V296; Gonzalez C, 2002, RESP PHYSIOL NEUROBI, V132, P17, DOI 10.1016/S1569-9048(02)00047-2; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Hayter CL, 2004, NEUROSCI LETT, V362, P182, DOI 10.1016/j.neulet.2004.02.024; Herrmann J, 2007, CIRC RES, V100, P1276, DOI 10.1161/01.RES.0000264500.11888.f0; Hu BR, 2000, J NEUROSCI, V20, P3191, DOI 10.1523/JNEUROSCI.20-09-03191.2000; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Itoh K, 2004, FREE RADICAL BIO MED, V36, P1208, DOI 10.1016/j.freeradbiomed.2004.02.075; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi M, 2006, ADV ENZYME REGUL, V46, P113, DOI 10.1016/j.advenzreg.2006.01.007; Li HY, 2011, J APPL TOXICOL, V31, P690, DOI 10.1002/jat.1654; Lu H, 2009, J CLIN NEUROSCI, V16, P684, DOI 10.1016/j.jocn.2008.04.021; Lu XY, 2014, J SURG RES, V188, P206, DOI 10.1016/j.jss.2013.11.1106; Ma YH, 2011, BRAIN RES BULL, V86, P441, DOI 10.1016/j.brainresbull.2011.07.007; Majetschak M, 2005, CRIT CARE MED, V33, P1589, DOI 10.1097/01.CCM.0000169883.41245.23; Martinez BA, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.270; Miller DM, 2014, J NEUROTRAUM, V31, P1194, DOI 10.1089/neu.2013.3218; Park WH, 2012, ONCOL REP, V27, P1284, DOI 10.3892/or.2012.1642; Patel SP, 2014, EXP NEUROL, V257, P95, DOI 10.1016/j.expneurol.2014.04.026; Petrucelli L, 2004, ANN MED, V36, P315, DOI 10.1080/07853890410031948; Rada P, 2012, MOL CELL BIOL, V32, P3486, DOI 10.1128/MCB.00180-12; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Raza H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103379; Reddy NM, 2007, AM J RESP CELL MOL, V37, P3, DOI 10.1165/rcmb.2007-0004RC; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Saykally JN, 2012, NEUROSCIENCE, V223, P305, DOI 10.1016/j.neuroscience.2012.07.070; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Song Juhyun, 2014, Exp Neurobiol, V23, P93, DOI 10.5607/en.2014.23.1.93; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Sun KJ, 2013, BRAIN RES, V1506, P132, DOI 10.1016/j.brainres.2013.02.011; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; Yao XL, 2008, J NEUROCHEM, V104, P353, DOI 10.1111/j.1471-4159.2007.04970.x; Yao XL, 2007, BRAIN RES, V1182, P116, DOI 10.1016/j.brainres.2007.08.076; You LH, 2015, NEUROSCIENCE, V284, P234, DOI 10.1016/j.neuroscience.2014.09.071; Zhang X, 2012, HUM EXP TOXICOL, V31, P931, DOI 10.1177/0960327112438287; Zorov DB, 2006, BBA-BIOENERGETICS, V1757, P509, DOI 10.1016/j.bbabio.2006.04.029	52	12	13	1	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	DEC	2017	111				SI		32	44		10.1016/j.neuint.2017.04.016			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	FR3OS	WOS:000418976600005	28465088				2021-06-18	
J	Donders, J; Pendery, A				Donders, Jacobus; Pendery, Adriene			Clinical Utility of the Patient Health Questionnaire-9 in the Assessment of Major Depression After Broad-Spectrum Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							RISK-FACTORS; SYMPTOM VALIDITY; FORM MMPI-2-RF; ANXIETY; PREVALENCE; VALIDATION; PREDICTORS; SCALES	Objective: To determine the predictive validity of the Patient Health Questionnaire-9 (PHQ-9) when screening for symptoms of depression after traumatic brain injury. Design: Retrospective analysis of data collected as part of routine clinical outpatient care over a period of 30 months. Setting: Regional rehabilitation facility. Participants: Persons (N=137) with mild to severe traumatic brain injury who were referred for neuropsychological evaluation within 1 to 12 months. Interventions: Not applicable. Main Outcome Measures: PHQ-9 and Minnesota Multiphasic Personality Inventory-2-Restructured Form. Results: PHQ-9 scores >= 10 had a sensitivity of 91.7 and a specificity of 60.2 for predicting a diagnosis of major depression. Correlations between scores of PHQ-9 and Minnesota Multiphasic Personality Inventory-2-Restructured Form Demoralization (.64) and Low Positive Emotions (.48) scales ranged from large to medium. Premorbid outpatient psychiatric treatment was the most consistent predictor of PHQ-9 elevations as well as final diagnoses of major depression. Conclusions: The PHQ-9 has adequate clinical utility as a screening instrument for depression in outpatients with traumatic brain injury. Elevations on this instrument cannot, however, be automatically attributed to neuropathology, especially not in the context of premorbid psychiatric dysfunction. Clinicians should conduct more thorough follow-up assessment in those with highly elevated PHQ-9 scores. (C) 2017 by the American Congress of Rehabilitation Medicine	[Donders, Jacobus] Mary Free Bed Rehabil Hosp, Grand Rapids, MI USA; [Pendery, Adriene] Calvin Coll, Grand Rapids, MI USA	Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy St SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com	tan, janie/AAH-9283-2021				Ben-Porath Y. S., 2008, MINNESOTA MULTIPHASI; Ben-Porath Y.S., 2012, INTERPRETING MMPI 2; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Centers for Disease Control and Prevention, 2015, REP C TRAUM BRAIN IN; Cook KF, 2011, ARCH PHYS MED REHAB, V92, P818, DOI 10.1016/j.apmr.2010.12.008; de Man-van Ginkel JM, 2012, STROKE, V43, P854, DOI 10.1161/STROKEAHA.111.640276; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Dyer JR, 2016, J HEAD TRAUMA REHAB, V31, P225, DOI 10.1097/HTR.0000000000000177; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Haber JC, 2014, S AFR J PSYCHOL, V44, P439, DOI 10.1177/0081246314532788; Hart T, 2016, ARCH PHYS MED REHAB, V97, P701, DOI 10.1016/j.apmr.2015.08.436; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kumar RG, 2014, AM J PHYS MED REHAB, V93, P687, DOI 10.1097/PHM.0000000000000077; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Martin PK, 2015, CLIN NEUROPSYCHOL, V29, P741, DOI 10.1080/13854046.2015.1087597; Murphy KR., 2004, STAT POWER ANAL SIMP, V2; Osborn AJ, 2014, NEUROSCI BIOBEHAV R, V47, P1, DOI 10.1016/j.neubiorev.2014.07.007; Pennello G, 2016, J BIOPHARM STAT, V26, P1083, DOI 10.1080/10543406.2016.1226335; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Rapoport MJ, 2012, CNS DRUGS, V26, P111, DOI 10.2165/11599560-000000000-00000; Sakakibara BM, 2009, SPINAL CORD, V47, P841, DOI 10.1038/sc.2009.93; Scholten AC, 2016, J NEUROTRAUM, V33, P1969, DOI 10.1089/neu.2015.4252; Schroeder RW, 2012, CLIN NEUROPSYCHOL, V26, P129, DOI 10.1080/13854046.2011.639314; Spitzer, 2015, STRUCTURED CLIN INTE; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Tarescavage AM, 2015, PSYCHOL ASSESSMENT, V27, P433, DOI 10.1037/pas0000056; Tarescavage AM, 2015, J AFFECT DISORDERS, V174, P549, DOI 10.1016/j.jad.2014.12.018; Watson C, 2011, J PSYCHOPATHOL BEHAV, V33, P368, DOI 10.1007/s10862-010-9212-7; Youngjohn JR, 2011, CLIN NEUROPSYCHOL, V25, P463, DOI [10.1080/13854046.2011.554444, 10.1080/13854046.2010.550635]; Zaninotto AL, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00095	32	12	12	1	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2017	98	12					2514	2519		10.1016/j.apmr.2017.05.019			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	FO5FK	WOS:000416878700022	28647552				2021-06-18	
J	Haltmeier, T; Benjamin, E; Siboni, S; Dilektasli, E; Inaba, K; Demetriades, D				Haltmeier, Tobias; Benjamin, Elizabeth; Siboni, Stefano; Dilektasli, Evren; Inaba, Kenji; Demetriades, Demetrios			Prehospital intubation for isolated severe blunt traumatic brain injury: worse outcomes and higher mortality	EUROPEAN JOURNAL OF TRAUMA AND EMERGENCY SURGERY			English	Article						Traumatic brain injury; Prehospital endotracheal intubation; Prehospital care; Outcome; Matched-pair analysis	SEVERE HEAD-INJURY; EMERGENCY TRACHEAL INTUBATION; RAPID-SEQUENCE INTUBATION; ENDOTRACHEAL INTUBATION; UNRECOGNIZED MISPLACEMENT; AIRWAY MANAGEMENT; SUCCESS RATES; VENTILATION; PRESSURE; TUBES	Purpose Prehospital endotracheal intubation (ETI) for traumatic brain injury (TBI) is a controversial issue. The aim of this study was to investigate the effect of prehospital ETI in patients with TBI. Methods Cohort-matched study using the US National Trauma Data Bank (NTDB) 2008-2012. Patients with isolated severe blunt TBI (AIS head >= 3, AIS chest/abdomen < 3) and a field GCS <= 8 were extracted from NTDB. A 1:1 matching of patients with and without prehospital ETI was performed. Matching criteria were sex, age, exact field GCS, exact AIS head, field hypotension, field cardiac arrest, and the brain injury type (according PREDOT-code). The matched cohorts were compared with univariable and multivariable regression analysis. Results A total of 27,714 patients were included. Matching resulted in 8139 cases with and 8139 cases without prehospital ETI. Prehospital ETI was associated with significantly longer scene (median 9 vs. 8 min, p < 0.001) and transport times (median 26 vs. 19 min, p < 0.001), lower Emergency Department (ED) GCS scores (in patients without sedation; mean 3.7 vs. 3.9, p = 0.026), more ventilator days (mean 7.3 vs. 6.9, p = 0.006), longer ICU (median 6.0 vs. 5.0 days, p < 0.001) and total hospital length of stay (median 10.0 vs. 9.0 days, p < 0.001), and higher in-hospital mortality (31.4 vs. 27.5 %, p < 0.001). In regression analysis prehospital ETI was independently associated with lower ED GCS scores (RC -4.213, CI -4.562/-3.864, p < 0.001) and higher in-hospital mortality (OR 1.399, CI 1.205/1.624, p < 0.001). Conclusion In this large cohort-matched analysis, prehospital ETI in patients with isolated severe blunt TBI was independently associated with lower ED GCS scores and higher mortality.	[Haltmeier, Tobias; Benjamin, Elizabeth; Siboni, Stefano; Dilektasli, Evren; Inaba, Kenji; Demetriades, Demetrios] Los Angeles Cty, Dept Surg, Div Acute Care Surg & Surg Crit Care, 1200 N State St,Inpatient Tower C Rm C5L100, Los Angeles, CA 90033 USA; [Haltmeier, Tobias; Benjamin, Elizabeth; Siboni, Stefano; Dilektasli, Evren; Inaba, Kenji; Demetriades, Demetrios] Univ Southern Calif, Med Ctr, 1200 N State St,Inpatient Tower C Rm C5L100, Los Angeles, CA 90033 USA	Demetriades, D (corresponding author), Los Angeles Cty, Dept Surg, Div Acute Care Surg & Surg Crit Care, 1200 N State St,Inpatient Tower C Rm C5L100, Los Angeles, CA 90033 USA.; Demetriades, D (corresponding author), Univ Southern Calif, Med Ctr, 1200 N State St,Inpatient Tower C Rm C5L100, Los Angeles, CA 90033 USA.	demetria@usc.edu	Siboni, Stefano/AAF-5456-2019; Benjamin, Elizabeth/AAD-2457-2020	Siboni, Stefano/0000-0003-0532-3135; 			[Anonymous], 2000, ADV CARDIOVASCULAR 6; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Black KL, 2002, J HEAD TRAUMA REHAB, V17, P489, DOI 10.1097/00001199-200212000-00001; Bledsoe Bryan E, 2009, JEMS, V34, P88, DOI 10.1016/S0197-2510(09)70075-0; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Boer C, 2012, CURR OPIN ANESTHESIO, V25, P556, DOI 10.1097/ACO.0b013e328357225c; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; Branas CC, 2005, JAMA-J AM MED ASSOC, V293, P2626, DOI 10.1001/jama.293.21.2626; Breckwoldt J, 2012, RESUSCITATION, V83, P434, DOI 10.1016/j.resuscitation.2011.10.011; Bulger EM, 2007, ANN EMERG MED, V49, P293, DOI 10.1016/j.annemergmed.2006.06.038; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; BURNEY RG, 1975, ANESTH ANALG, V54, P687; Burton John H, 2003, Prehosp Emerg Care, V7, P352, DOI 10.1080/10903120390936554; Cady CE, 2005, AM J EMERG MED, V23, P868, DOI 10.1016/j.ajem.2005.07.013; Cudnik MT, 2007, PREHOSP EMERG CARE, V11, P224, DOI 10.1080/10903120701205208; Davis DP, 2011, PREHOSP EMERG CARE, V15, P184, DOI 10.3109/10903127.2010.545473; Davis DP, 2010, J TRAUMA, V69, P294, DOI 10.1097/TA.0b013e3181dc6c7f; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Dinsmore J., 2013, TRAUMATIC BRAIN INJU; Dumont TM, 2010, J NEUROTRAUM, V27, P1233, DOI 10.1089/neu.2009.1216; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Falcone R E, 1996, Air Med J, V15, P163, DOI 10.1016/S1067-991X(96)90024-3; Geisser W, 2009, ANAESTHESIA, V64, P973, DOI 10.1111/j.1365-2044.2009.06007.x; Harris T, 2011, EMERG MED J, V28, P225, DOI 10.1136/emj.2009.088302; Helm M, 2002, BRIT J ANAESTH, V88, P345, DOI 10.1093/bja/88.3.345; Huang YH, 2013, INJURY, V44, P1226, DOI 10.1016/j.injury.2012.12.029; Jean Hailes for Women's Health on behalf of the PCOS Australian Alliance, 2015, EVIDENCE BASED GUIDE; Jemmett ME, 2003, ACAD EMERG MED, V10, P961, DOI 10.1197/S1069-6563(03)00315-4; Karamanos E, 2014, PREHOSP DISASTER MED, V29, P32, DOI 10.1017/S1049023X13008947; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Lockey D, 2014, BRIT J ANAESTH, V113, P220, DOI 10.1093/bja/aeu227; Lossius HM, 2012, CRIT CARE, V16, DOI 10.1186/cc11189; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mayglothling J, 2012, J TRAUMA ACUTE CARE, V73, pS333, DOI 10.1097/TA.0b013e31827018a5; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Oestern HJ, 2013, GEN TRAUMA CARE RELA; Perkins ZB, 2013, J TRAUMA ACUTE CARE, V74, P1074, DOI 10.1097/TA.0b013e3182827305; Peters J, 2015, EUR J EMERG MED, V22, P391, DOI 10.1097/MEJ.0000000000000161; Prekker ME, 2014, CRIT CARE MED, V42, P1372, DOI 10.1097/CCM.0000000000000213; Rognas L, 2014, EUR J EMERG MED, V21, P418, DOI 10.1097/MEJ.0000000000000103; Samaha T, 1996, ANN FR ANESTH, V15, P36, DOI 10.1016/0750-7658(96)89400-7; Santiago LA, 2012, BRAIN INJURY, V26, P107, DOI 10.3109/02699052.2011.635363; Shafi S, 2005, J TRAUMA, V59, P1140, DOI 10.1097/01.ta.0000196434.88182.77; Shafi S, 2005, J TRAUMA, V59, P5; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Sollid SJM, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-30; Surgeons ACo, 2015, NATL TRAUMA DATA BAN; Timmermann A, 2007, ANESTH ANALG, V104, P619, DOI 10.1213/01.ane.0000253523.80050.e9; Trauma TEAftSo, 2015, EM TRACH INT IMM FOL; Ufberg JW, 2005, AM J EMERG MED, V23, P379, DOI 10.1016/j.ajem.2005.02.005; Vandromme MJ, 2011, J TRAUMA, V71, P1615, DOI 10.1097/TA.0b013e31822a30a1; von Elm E, 2009, BRIT J ANAESTH, V103, P371, DOI 10.1093/bja/aep202; Wang HE, 2005, CRIT CARE MED, V33, P1718, DOI 10.1097/01.CCM.0000171208.07895.2A; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Warner KJ, 2007, J TRAUMA, V62, P1330, DOI 10.1097/TA.0b013e31804a8032; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592; Wirtz DD, 2007, PREHOSP EMERG CARE, V11, P213, DOI 10.1080/10903120701205935; Yeh DD, 2012, ANZ J SURG, V82, P484, DOI 10.1111/j.1445-2197.2012.06130.x	60	12	12	0	11	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-9933	1863-9941		EUR J TRAUMA EMERG S	Eur. J. Trauma Emerg. Surg.	DEC	2017	43	6					731	739		10.1007/s00068-016-0718-x			9	Emergency Medicine	Emergency Medicine	FO1PF	WOS:000416534600002	27567923				2021-06-18	
J	Ichkova, A; Rodriguez-Grande, B; Bar, C; Villega, F; Konsman, JP; Badaut, J				Ichkova, Aleksandra; Rodriguez-Grande, Beatriz; Bar, Claire; Villega, Frederic; Konsman, Jan Pieter; Badaut, Jerome			Vascular impairment as a pathological mechanism underlying long-lasting cognitive dysfunction after pediatric traumatic brain injury	NEUROCHEMISTRY INTERNATIONAL			English	Article						Traumatic brain injury; Pediatric; Development; Cerebrovascular dysfunction; Neurovascular unit	CONTROLLED CORTICAL IMPACT; CENTRAL-NERVOUS-SYSTEM; BETA FIBRIL FORMATION; OF-THE-LITERATURE; CEREBRAL AUTOREGULATION; BARRIER PERMEABILITY; ALZHEIMERS-DISEASE; P-GLYCOPROTEIN; HEAD-INJURY; FUNCTIONAL RECOVERY	Traumatic brain injury (TBI) is the leading cause of death and disability in children. Indeed, the acute mechanical injury often evolves to a chronic brain disorder with long-term cognitive, emotional and social dysfunction even in the case of mild TBI. Contrary to the commonly held idea that children show better recovery from injuries than adults, pediatric TBI patients actually have worse outcome than adults for the same injury severity. Acute trauma to the young brain likely interferes with the fine-tuned developmental processes and may give rise to long-lasting consequences on brain's function. This review will focus on cerebrovascular dysfunction as an important early event that may lead to long-term phenotypic changes in the brain after pediatric TBI. These, in turn may be associated with accelerated brain aging and cognitive dysfunction. Finally, since no effective treatments are currently available, understanding the unique pathophysiological mechanisms of pediatric TBI is crucial for the development of new therapeutic options. (C) 2017 Elsevier Ltd. All rights reserved.	[Ichkova, Aleksandra; Rodriguez-Grande, Beatriz; Bar, Claire; Konsman, Jan Pieter; Badaut, Jerome] Univ Bordeaux, CNRS UMR 5287, INCIA, Bordeaux, France; [Bar, Claire; Villega, Frederic] Univ Childrens Hosp Bordeaux, Dept Pediat Neurol, Bordeaux, France; [Badaut, Jerome] Loma Linda Univ, Sch Med, Dept Basic Sci, Loma Linda, CA USA	Badaut, J (corresponding author), Bordeaux Univ, CNRS UMR 5287, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	jerome.badaut@u-bordeaux.fr	; Rodriguez-Grande, Beatriz/I-5397-2015	VILLEGA, frederic/0000-0002-5423-3171; Konsman, Jan Pieter/0000-0001-7247-0472; Rodriguez-Grande, Beatriz/0000-0002-4638-7576	ANR-TRAIL Vasc-TBIFrench National Research Agency (ANR); CNRSCentre National de la Recherche Scientifique (CNRS)European Commission; Fondation des gueules cassees; ERA-NET NEURON JTC CnsA-flame	The authors wish to acknowledge the following funding: Fondation des gueules cassees (JB), ERA-NET NEURON JTC2014 CnsA-flame (JB), ANR-TRAIL Vasc-TBI (JB) and CNRS support.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Adelson PD, 2011, CHILD NERV SYST, V27, P1465, DOI 10.1007/s00381-011-1476-z; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Ajao D., 2011, SOC NEUROSCI ABSTR V, V41; Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson V, 2013, J INT NEUROPSYCH SOC, V19, P539, DOI 10.1017/S1355617712001543; Anderson V, 2012, INT J DEV NEUROSCI, V30, P217, DOI 10.1016/j.ijdevneu.2011.09.008; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Armstead WM, 2011, NEUROL RES, V33, P726, DOI 10.1179/016164110X12807570509853; Armstead WM, 2011, NEUROL RES, V33, P133, DOI 10.1179/016164111X12881719352174; Armstead WM, 2011, NEUROL RES, V33, P127, DOI 10.1179/016164111X12881719352138; Armstead WM, 2011, J NEUROTRAUM, V28, P451, DOI 10.1089/neu.2010.1659; Armstead WM, 1999, EXP TOXICOL PATHOL, V51, P137, DOI 10.1016/S0940-2993(99)80087-6; Armstead WM, 2004, EXP TOXICOL PATHOL, V56, P75, DOI 10.1016/j.etp.2004.04.003; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1999, J NEUROTRAUM, V16, P391, DOI 10.1089/neu.1999.16.391; Babikian T, 2015, J NEUROTRAUM, V32, P1849, DOI 10.1089/neu.2015.3971; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Badaut J, 2015, NEUROSCIENCE, V285, P215, DOI 10.1016/j.neuroscience.2014.10.035; Badaut J, 2014, TRANSL STROKE RES, V5, P394, DOI 10.1007/s12975-013-0304-z; Badaut J, 2014, BBA-GEN SUBJECTS, V1840, P1554, DOI 10.1016/j.bbagen.2013.10.032; Bakker MJ, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-43; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P171; Bell RD, 2009, ACTA NEUROPATHOL, V118, P103, DOI 10.1007/s00401-009-0522-3; Biagi L, 2007, J MAGN RESON IMAGING, V25, P696, DOI 10.1002/jmri.20839; Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6; Bundgaard M, 2008, GLIA, V56, P699, DOI 10.1002/glia.20642; Castillo GM, 1997, J NEUROCHEM, V69, P2452; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Chevignard M., 2016, ANN PHYS REHABIL MED, V59, DOI [10.1016/j.rehab.2016.07.298, DOI 10.1016/J.REHAB.2016.07.298]; Cirrito JR, 2005, J CLIN INVEST, V115, P3285, DOI 10.1172/JCI25247; Cotman SL, 2000, MOL CELL NEUROSCI, V15, P183, DOI 10.1006/mcne.1999.0816; CSERR HF, 1984, AM J PHYSIOL, V246, pR277; Daneman R, 2010, NATURE, V468, P562, DOI 10.1038/nature09513; De Bock M, 2016, GLIA, V64, P1097, DOI 10.1002/glia.22960; Dewan MC, 2016, WORLD NEUROSURG, V91, P497, DOI 10.1016/j.wneu.2016.03.045; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Fernandez-Lopez D, 2012, J NEUROSCI, V32, P9588, DOI 10.1523/JNEUROSCI.5977-11.2012; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Freeman SS, 2008, ANESTHESIOLOGY, V108, P588, DOI 10.1097/ALN.0b013e31816725d7; Fukuda AM, 2012, NEUROSCIENCE, V222, P366, DOI 10.1016/j.neuroscience.2012.06.033; Fukuda AM, 2013, J CEREBR BLOOD F MET, V33, P1621, DOI 10.1038/jcbfm.2013.118; Garcia D, 2015, J PEDIATR PSYCHOL, V40, P391, DOI 10.1093/jpepsy/jsu093; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Giza CC, 2009, DEV NEUROREHABIL, V12, P255, DOI 10.3109/17518420903087558; Greco T, 2016, J CEREBR BLOOD F MET, V36, P1603, DOI 10.1177/0271678X15610584; Gu XH, 2015, EXP NEUROL, V267, P135, DOI 10.1016/j.expneurol.2015.02.029; Hanlon LA, 2016, J NEUROPATH EXP NEUR, V75, P214, DOI 10.1093/jnen/nlv021; Harati R, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-273; Hawkes CA, 2014, NEURODEGENER DIS, V13, P17, DOI 10.1159/000351096; Hawkes CA, 2013, AGING CELL, V12, P224, DOI 10.1111/acel.12045; Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; Jernigan TL, 2011, PROG BRAIN RES, V189, P77, DOI 10.1016/B978-0-444-53884-0.00019-1; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Jodoin J, 2003, J NEUROCHEM, V87, P1010, DOI 10.1046/j.1471-4159.2003.02081.x; Jullienne A, 2016, J NEUROSCI RES, V94, P609, DOI 10.1002/jnr.23732; Jullienne A, 2014, J CEREBR BLOOD F MET, V34, P1637, DOI 10.1038/jcbfm.2014.124; Kamper JE, 2013, EXP NEUROL, V250, P8, DOI 10.1016/j.expneurol.2013.09.016; Kasemsri T, 1997, AM J PHYSIOL-HEART C, V273, pH2639; Keightley ML, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00139; Knowland D, 2014, NEURON, V82, P603, DOI 10.1016/j.neuron.2014.03.003; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Leung J, 2016, J PHYSIOL-LONDON, V594, P2681, DOI 10.1113/JP271056; Maa T, 2016, J NEUROSURG-PEDIATR, V18, P73, DOI 10.3171/2016.1.PEDS15564; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mannix R, 2014, J NEUROSURG, V121, P1337, DOI 10.3171/2014.8.JNS14715; Margulies S, 2016, J NEUROTRAUM, V33, P101, DOI 10.1089/neu.2014.3855; McCaffrey G, 2007, J NEUROCHEM, V103, P2540, DOI 10.1111/j.1471-4159.2007.04943.x; McCaffrey G, 2012, J NEUROCHEM, V122, P962, DOI 10.1111/j.1471-4159.2012.07831.x; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; Mhanna MJ, 2015, J NEUROSURG PEDIAT, V16, P1; Muramatsu K, 1997, STROKE, V28, P2281, DOI 10.1161/01.STR.28.11.2281; Nagel C, 2016, ACTA NEUROCHIR SUPPL, V122, P239, DOI 10.1007/978-3-319-22533-3_48; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Philip S, 2009, J TRAUMA, V67, pS128, DOI 10.1097/TA.0b013e3181ad32c7; Pierre K, 2005, J NEUROCHEM, V94, P1, DOI 10.1111/j.1471-4159.2005.03168.x; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Pop V, 2013, J CEREBR BLOOD F MET, V33, P205, DOI 10.1038/jcbfm.2012.154; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Quintard H, 2016, J NEUROTRAUM, V33, P681, DOI 10.1089/neu.2015.4057; Raz L, 2016, J CEREBR BLOOD F MET, V36, P172, DOI 10.1038/jcbfm.2015.164; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Robertson CL, 2015, J BIOENERG BIOMEMBR, V47, P43, DOI 10.1007/s10863-014-9585-5; ROBERTSON PL, 1985, DEV BRAIN RES, V23, P219, DOI 10.1016/0165-3806(85)90044-6; Rossi JL, 2015, J NEUROTRAUM, V32, P1101, DOI 10.1089/neu.2014.3611; Roumeliotis N, 2016, CHILD NERV SYST, V32, P2363, DOI 10.1007/s00381-016-3231-y; Ryan NP, 2016, NEUROSCI BIOBEHAV R, V64, P196, DOI 10.1016/j.neubiorev.2016.02.020; Ryan NP, 2015, NEUROPSYCHOLOGIA, V66, P32, DOI 10.1016/j.neuropsychologia.2014.10.040; Sahuquillo J, 2007, CURR PHARM DESIGN, V13, P2310; Salonia R, 2010, J NEUROTRAUM, V27, P1819, DOI 10.1089/neu.2010.1402; Saunders NR, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00046; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Stonestreet BS, 2000, AM J PHYSIOL-REG I, V279, pR468; Sysyn GD, 2001, AM J PHYSIOL-REG I, V280, pR547; Taylor ZE, 2013, DEV PSYCHOBIOL, V55, P869, DOI 10.1002/dev.21079; Thurman DJ, 2016, J CHILD NEUROL, V31, P20, DOI 10.1177/0883073814544363; Toga AW, 2006, TRENDS NEUROSCI, V29, P148, DOI 10.1016/j.tins.2006.01.007; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala MS, 2008, NEUROCRIT CARE, V9, P45, DOI 10.1007/s12028-007-9036-9; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Vavilala MS, 2003, J NEUROSURG ANESTH, V15, P307, DOI 10.1097/00008506-200310000-00003; Vavilala MS, 2002, ACTA ANAESTH SCAND, V46, P393, DOI 10.1034/j.1399-6576.2002.460411.x; Wang ML, 2016, J NEUROL SCI, V370, P244, DOI 10.1016/j.jns.2016.09.049; Wei ZZ, 2016, CELL TRANSPLANT, V25, P797, DOI 10.3727/096368916X690403; Winkler EA, 2011, NAT NEUROSCI, V14, P1398, DOI 10.1038/nn.2946; Winkler EA, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-32; Zhang BF, 2015, WORLD NEUROSURG, V83, P567, DOI 10.1016/j.wneu.2014.12.010; Zhang JH, 2012, NAT REV NEUROL, V8, P711, DOI 10.1038/nrneurol.2012.210	121	12	12	1	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	DEC	2017	111				SI		93	102		10.1016/j.neuint.2017.03.022			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	FR3OS	WOS:000418976600010	28377126				2021-06-18	
J	Liu, XF; Zhao, ZQ; Ji, RH; Zhu, J; Sui, QQ; Knight, GE; Burnstock, G; He, C; Yuan, HB; Xiang, ZH				Liu, Xiaofeng; Zhao, Zhengqing; Ji, Ruihua; Zhu, Jiao; Sui, Qian-Qian; Knight, Gillian E.; Burnstock, Geoffrey; He, Cheng; Yuan, Hongbin; Xiang, Zhenghua			Inhibition of P2X7 receptors improves outcomes after traumatic brain injury in rats	PURINERGIC SIGNALLING			English	Article						Traumatic brain injury; P2X7R; Microglial cells; Microvesicles; Neuroinflammation	MICROGLIAL ACTIVATION; EXTRACELLULAR ATP; WATER-MAZE; ASTROGLIOSIS; INVOLVEMENT; RELEASE; EPIDEMIOLOGY; ANTAGONIST; ASTROCYTES; EXPRESSION	Traumatic brain injury (TBI) is the leading cause of death and disability for people under the age of 45 years worldwide. Neuropathology after TBI is the result of both the immediate impact injury and secondary injury mechanisms. Secondary injury is the result of cascade events, including glutamate excitotoxicity, calcium overloading, free radical generation, and neuroinflammation, ultimately leading to brain cell death. In this study, the P2X7 receptor (P2X7R) was detected predominately in microglia of the cerebral cortex and was up-regulated on microglial cells after TBI. The microglia transformed into amoeba-like and discharged many microvesicle (MV)-like particles in the injured and adjacent regions. A P2X7R antagonist (A804598) and an immune inhibitor (FTY720) reduced significantly the number of MV-like particles in the injured/adjacent regions and in cerebrospinal fluid, reduced the number of neurons undergoing apoptotic cell death, and increased the survival of neurons in the cerebral cortex injured and adjacent regions. Blockade of the P2X7R and FTY720 reduced interleukin-1 beta expression, P38 phosphorylation, and glial activation in the cerebral cortex and improved neurobehavioral outcomes after TBI. These data indicate that MV-like particles discharged by microglia after TBI may be involved in the development of local inflammation and secondary nerve cell injury.	[Liu, Xiaofeng; Zhu, Jiao; Sui, Qian-Qian; He, Cheng; Xiang, Zhenghua] Second Mil Med Univ, Dept Neurobiol, Neurosci Res Ctr, MOE Key Lab Mol Neurobiol,Changzheng Hosp,Minist, Shanghai 200433, Peoples R China; [Zhao, Zhengqing] Second Mil Med Univ Shanghai, Dept Neurol, Neurosci Res Ctr, Changzheng Hosp, Shanghai, Yangpu Qu, Peoples R China; [Ji, Ruihua; Yuan, Hongbin] Second Mil Med Univ, Changzheng Hosp, Dept Anesthesiol, 415 Fengyang Rd, Shanghai 200003, Peoples R China; [Knight, Gillian E.; Burnstock, Geoffrey] UCL, Auton Neurosci Ctr, Sch Med, Rowland Hill St, London NW3 2PF, England; [Burnstock, Geoffrey] Univ Melbourne, Dept Pharmacol, Parkville, Vic, Australia	Xiang, ZH (corresponding author), Second Mil Med Univ, Dept Neurobiol, Neurosci Res Ctr, MOE Key Lab Mol Neurobiol,Changzheng Hosp,Minist, Shanghai 200433, Peoples R China.; Yuan, HB (corresponding author), Second Mil Med Univ, Changzheng Hosp, Dept Anesthesiol, 415 Fengyang Rd, Shanghai 200003, Peoples R China.	jfjczyy@aliyun.com; xiang-zhenghua@163.com		, yuan/0000-0001-8468-4005	National Natural Science Foundation of the People's Republic of ChinaNational Natural Science Foundation of China (NSFC) [81471260]; Qingnian Science Foundation of Changzheng Hospital, Shanghai, People's Republic of China [2016CZQN05]	This work was supported by the National Natural Science Foundation of the People's Republic of China (81471260 to Z. Xiang) and by the Qingnian Science Foundation of Changzheng Hospital, Shanghai, People's Republic of China (2016CZQN05 to R. Ji).	Abbracchio Maria P, 2006, Novartis Found Symp, V276, P91; ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267; Bianco F, 2005, J IMMUNOL, V174, P7268, DOI 10.4049/jimmunol.174.11.7268; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Burnstock G, 2015, CURR MED CHEM, V22, P819, DOI 10.2174/0929867321666140706130415; Burnstock G, 2008, NAT REV DRUG DISCOV, V7, P575, DOI 10.1038/nrd2605; Burnstock G, 2007, PHYSIOL REV, V87, P659, DOI 10.1152/physrev.00043.2006; Burnstock G, 2011, PROG NEUROBIOL, V95, P229, DOI 10.1016/j.pneurobio.2011.08.006; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chavez-Valdez R, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/257563; Ciccarelli R, 2001, INT J DEV NEUROSCI, V19, P395, DOI 10.1016/S0736-5748(00)00084-8; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Dawson G, 2011, BIOCHEM BIOPH RES CO, V404, P321, DOI 10.1016/j.bbrc.2010.11.115; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Fields RD, 2002, SCIENCE, V298, P556, DOI 10.1126/science.298.5593.556; FILIPPINI A, 1990, J BIOL CHEM, V265, P334; Franke H, 2007, PURINERG SIGNAL, V3, P435, DOI 10.1007/s11302-007-9082-y; Franke H, 2006, INT J DEV NEUROSCI, V24, P123, DOI 10.1016/j.ijdevneu.2005.11.016; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GIULIAN D, 1988, J NEUROSCI, V8, P2485; Hansson E, 2003, FASEB J, V17, P341, DOI 10.1096/fj.02-0429rev; Hoegen T, 2011, J IMMUNOL, V187, P5440, DOI 10.4049/jimmunol.1100790; Inoue K, 2002, GLIA, V40, P156, DOI 10.1002/glia.10150; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Jimenez-Pacheco A, 2013, EPILEPSIA, V54, P1551, DOI 10.1111/epi.12257; Kim JE, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-65; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li J, 2017, PURINERG SIGNAL, V13, P13, DOI 10.1007/s11302-016-9537-0; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mullershausen F, 2009, NAT CHEM BIOL, V5, P428, DOI 10.1038/nchembio.173; Peng WG, 2009, P NATL ACAD SCI USA, V106, P12489, DOI 10.1073/pnas.0902531106; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Robson Simon C, 2006, Purinergic Signal, V2, P409, DOI 10.1007/s11302-006-9003-5; Ryu JK, 2008, NEUROREPORT, V19, P1715, DOI 10.1097/WNR.0b013e3283179333; Sadallah S, 2011, CLIN EXP IMMUNOL, V163, P26, DOI 10.1111/j.1365-2249.2010.04271.x; Sharp AJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-33; Sikora A, 1999, J IMMUNOL, V163, P558; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sun LQ, 2015, BEHAV BRAIN RES, V291, P315, DOI 10.1016/j.bbr.2015.05.049; Turola E, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00149; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Wang YC, 2015, MOL MED REP, V12, P2149, DOI 10.3892/mmr.2015.3607; Woiciechowsky C, 2004, MED SCI MONITOR, V10, pBR325; Xiang ZH, 2006, J NEUROSCI RES, V83, P91, DOI 10.1002/jnr.20709; Zhang ZJ, 2007, NAT CELL BIOL, V9, P945, DOI 10.1038/ncb1620; Zimmermann H, 1999, PROG BRAIN RES, V120, P371	57	12	13	0	9	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1573-9538	1573-9546		PURINERG SIGNAL	Purinergic Signal.	DEC	2017	13	4					529	544		10.1007/s11302-017-9579-y			16	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	FO7UL	WOS:000417082600011	28823092	Green Published			2021-06-18	
J	Rajan, TS; Diomede, F; Bramanti, P; Trubiani, O; Mazzon, E				Rajan, Thangavelu Soundara; Diomede, Francesca; Bramanti, Placido; Trubiani, Oriana; Mazzon, Emanuela			Conditioned medium from human gingival mesenchymal stem cells protects motor-neuron-like NSC-34 cells against scratch-injury-induced cell death	INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY			English	Article						apoptosis; gingival mesenchymal stem cells conditioned medium; in vitro CNS injury model; inflammation; neurotrophic factors; NSC-34 cells; oxidative stress	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; IN-VITRO; PERIODONTAL-LIGAMENT; CORTICAL-NEURONS; SCIATIC-NERVE; APOPTOSIS; MODEL; REGENERATION; MYELINATION	Neuronal cell death is a normal process during central nervous system (CNS) development and is also involved in the death of motor neurons in diverse spinal motor neuron degenerative diseases. Here, we investigated the neuroprotective effect of secretory factors released from human gingival mesenchymal stem cells (hGMSCs) in mechanically injured murine motor-neuron-like NSC-34 cells. The cells were exposed to scratch injury and the markers for apoptosis and oxidative stress were examined. Immunocytochemistry results showed that proapoptotic markers cleaved caspase-3 and Bax were elevated while anti-apoptotic protein Bcl-2 was suppressed in scratch-injured NSC-34 cells. Oxidative stress markers SOD-1, inducible nitric oxide synthase (iNOS), Cox-2, and proinflammatory cytokine tumor necrosis factor alpha (TNF-) were activated. Conditioned medium (CM) derived from hGMSCs (hGMSC-CM) significantly blocked the cell death by suppressing SOD-1, iNOS, TNF-, cleaved caspase-3, and Bax. Bcl-2 and anti-inflammatory cytokine anti-interleukin 10 (IL-10) were increased in hGMSC-CM-treated injured cells. Moreover, hGMSC-CM treatment upregulated neurotrophins anti-brain-derived neurotrophic factor (BDNF) and NT3. Western blot data of hGMSC-CM revealed the presence of neurotrophins nerve growth factor (NGF), NT3, anti-inflammatory cytokines IL-10, and transforming growth factor beta (TGF-), suggesting their positive role to elicit neuroprotection. Our results propose that hGMSC-CM may serve as a simple and potential autologous therapeutic tool to treat motor neuron injury.	[Rajan, Thangavelu Soundara; Bramanti, Placido; Mazzon, Emanuela] IRCCS Ctr Neurolesi Bonino Pulejo, Via Prov Palermo, I-98124 Messina, Italy; [Diomede, Francesca; Trubiani, Oriana] G dAnnnzio Univ Chieti Pescara, Dept Med Oral & Biotechnol Sci, Stem Cells & Regenerat Med Lab, Chieti, Italy	Mazzon, E (corresponding author), IRCCS Ctr Neurolesi Bonino Pulejo, Via Prov Palermo, I-98124 Messina, Italy.	emazzon.irccs@gmail.com	Mazzon, Emanuela/AAL-4334-2020; Rajan, Thangavelu Soundara/J-9840-2016; Bramanti, Placido/K-5117-2016; Gao, Jing/M-8264-2018; Diomede, Francesca/AAL-6840-2020	Rajan, Thangavelu Soundara/0000-0001-8728-6176; Diomede, Francesca/0000-0002-0384-6509; mazzon, emanuela/0000-0002-5073-717X	IRCCS Centro Neurolesi "Bonino-Pulejo," Messina, Italy	This study has been supported by current research funds 2016 of IRCCS Centro Neurolesi "Bonino-Pulejo," Messina, Italy.	Ahmed NEB, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/8102478; Aly LAA, 2015, WORLD J STEM CELLS, V7, P1047, DOI 10.4252/wjsc.v7.i7.1047; Bansal Ramta, 2015, J Nat Sci Biol Med, V6, P29, DOI 10.4103/0976-9668.149074; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; Chen H, 2001, INVEST OPHTH VIS SCI, V42, P966; Citron BA, 1997, NEUROSCI LETT, V230, P25, DOI 10.1016/S0304-3940(97)00468-0; Dasari Venkata Ramesh, 2014, World J Stem Cells, V6, P120, DOI 10.4252/wjsc.v6.i2.120; Diomede F, 2017, STEM CELLS INT, V2017, DOI DOI 10.1155/2017/5651287; Ernfors P, 1996, NAT MED, V2, P463, DOI 10.1038/nm0496-463; Fawzy El-Sayed KM, 2016, GEM STEM CELLS INT, V2016, DOI DOI 10.1155/2016/7154327; Foran E, 2009, ANTIOXID REDOX SIGN, V11, P1587, DOI 10.1089/ars.2009.2444; Giacoppo S, 2017, EUROPEAN J HISTOCHEM, V61; Giacoppo S, 2017, FASEB J, V31, P5592, DOI 10.1096/fj.201700524R; Hajivalili M, 2016, CURR STEM CELL RES T, V11, P41, DOI 10.2174/1574888X10666150902095031; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Jia Z, 2012, SPINAL CORD, V50, P264, DOI 10.1038/sc.2011.111; Konala VBR, 2016, CYTOTHERAPY, V18, P13, DOI 10.1016/j.jcyt.2015.10.008; Libro R, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00559; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; Ma J, 2016, AM J TRANSL RES, V8, P1895; Ma YH, 2012, NEUROSCI LETT, V510, P14, DOI 10.1016/j.neulet.2011.12.061; Maier O, 2013, NEUROCHEM INT, V62, P1029, DOI 10.1016/j.neuint.2013.03.008; Matusica D, 2008, J NEUROSCI RES, V86, P553, DOI 10.1002/jnr.21507; McCombe PA, 2011, CURR MOL MED, V11, P246; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Mekhemar MK, 2018, CELL IMMUNOL, V326, P60, DOI 10.1016/j.cellimm.2017.01.007; Park YJ, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9305986; Payette DJ, 2008, INT J CLIN EXP PATHO, V1, P44; Rajan TS, 2017, J CELL BIOCHEM, V118, P819, DOI 10.1002/jcb.25757; Rajan TS, 2016, SCI REP-UK, V6, DOI 10.1038/srep38743; Rajan TS, 2016, EXP CELL RES, V349, P152, DOI 10.1016/j.yexcr.2016.10.008; Sathasivam S, 2005, LANCET NEUROL, V4, P500, DOI 10.1016/S1474-4422(05)70142-3; Sharpe PT, 2016, DEVELOPMENT, V143, P2273, DOI 10.1242/dev.134189; Soler-Botija C, 2002, BRAIN, V125, P1624, DOI 10.1093/brain/awf155; Trubiani O, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-015-0253-4; Trubiani O, 2015, TISSUE ENG PART C-ME, V21, P52, DOI [10.1089/ten.tec.2014.0024, 10.1089/ten.TEC.2014.0024]; Ulusoy C, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0451-0; Villanova M, 2015, AM J PHYS MED REHAB, V94, P410, DOI 10.1097/PHM.0000000000000309; Xu X, 2013, J DENT RES, V92, P825, DOI 10.1177/0022034513497961; Zhang JY, 2000, EUR J NEUROSCI, V12, P4171, DOI 10.1046/j.1460-9568.2000.01312.x; Zhang N, 2012, INDIAN J MED RES, V135, P287; Zhang QZ, 2017, STEM CELL TRANSL MED, V6, P458, DOI 10.5966/sctm.2016-0177; Zhang QZ, 2012, STEM CELLS DEV, V21, P937, DOI 10.1089/scd.2011.0252; Zhang QZ, 2009, J IMMUNOL, V183, P7787, DOI 10.4049/jimmunol.0902318; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004	45	12	12	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0394-6320	2058-7384		INT J IMMUNOPATH PH	Int. J. Immunopathol. Pharmacol.	DEC	2017	30	4					383	394		10.1177/0394632017740976			12	Immunology; Pathology; Pharmacology & Pharmacy	Immunology; Pathology; Pharmacology & Pharmacy	FQ8ZC	WOS:000418650800006	29140156	DOAJ Gold, Green Published			2021-06-18	
J	Zhang, D; Han, S; Wang, SZ; Luo, YL; Zhao, L; Li, JF				Zhang, Dan; Han, Song; Wang, Shizun; Luo, Yanlin; Zhao, Li; Li, Junfa			cPKC gamma-mediated down-regulation of UCHL1 alleviates ischaemic neuronal injuries by decreasing autophagy via ERK-mTOR pathway	JOURNAL OF CELLULAR AND MOLECULAR MEDICINE			English	Article						ischaemic stroke; conventional protein kinase C (cPKC)gamma; ubiquitin C-terminal hydrolase L1; autophagy; mammalian target of rapamycin; extracellular signal-regulated kinase	PROTEIN-KINASE-C; NF-KAPPA-B; CARBOXYL-TERMINAL HYDROLASE; OXYGEN-GLUCOSE DEPRIVATION; TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; PARKINSONS-DISEASE; INDUCED NEUROPROTECTION; CELL INJURY; MEMBRANE TRANSLOCATION	Stroke is one of the leading causes of death in the world, but its underlying mechanisms remain unclear. Both conventional protein kinase C (cPKC)gamma and ubiquitin C-terminal hydrolase L1 (UCHL1) are neuron-specific proteins. In the models of 1-hr middle cerebral artery occlusion (MCAO)/24-hr reperfusion in mice and 1-hr oxygen-glucose deprivation (OGD)/24-hr reoxygenation in cortical neurons, we found that cPKC gamma gene knockout remarkably aggravated ischaemic injuries and simultaneously increased the levels of cleaved (Cl)-caspase-3 and LC3-I proteolysis product LC3-II, and the ratio of TUNEL-positive cells to total neurons. Moreover, cPKC gene knockout could increase UCHL1 protein expression via elevating its mRNA level regulated by the nuclear factor B inhibitor alpha (I kappa B-alpha)/nuclear factor kappa B (NF-kappa B) pathway in cortical neurons. Both inhibitor and shRNA of UCHL1 significantly reduced the ratio of LC3-II/total LC3, which contributed to neuronal survival after ischaemic stroke, but did not alter the level of Cl-caspase-3. In addition, UCHL1 shRNA reversed the effect of cPKC gamma on the phosphorylation levels of mTOR and ERK rather than that of AMPK and GSK-3 beta. In conclusion, our results suggest that cPKC gamma activation alleviates ischaemic injuries of mice and cortical neurons through inhibiting UCHL1 expression, which may negatively regulate autophagy through ERK-mTOR pathway.	[Zhao, Li; Li, Junfa] Capital Med Univ, Beijing Inst Brain Disorders, Dept Neurobiol, Beijing, Peoples R China; Capital Med Univ, Beijing Inst Brain Disorders, Ctr Stroke, Beijing, Peoples R China	Zhao, L; Li, JF (corresponding author), Capital Med Univ, Beijing Inst Brain Disorders, Dept Neurobiol, Beijing, Peoples R China.	zhaoli@ccmu.edu.cn; junfali@ccmu.edu.cn	; Li, Junfa/H-8707-2013	Zhao, Li/0000-0002-2578-9533; Li, Junfa/0000-0002-1930-9724	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81400948, 31471142, 31671205]; Beijing Natural Science FoundationBeijing Natural Science Foundation [7141001]; Scientific Research Common Program of Beijing Municipal Commission of EducationBeijing Municipal Commission of Education [KM201410025004]	The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: National Natural Science Foundation of China (Grant No. 81400948, 31471142 and 31671205), Beijing Natural Science Foundation (Grant No. 7141001) and Scientific Research Common Program of Beijing Municipal Commission of Education (KM201410025004).	Aveleira CA, 2010, DIABETES, V59, P2872, DOI 10.2337/db09-1606; Avila A, 2002, MOL CELL BIOL, V22, P8787, DOI 10.1128/MCB.22.24.8787-8795.2002; Balkaya M, 2013, J NEUROSCI METH, V213, P179, DOI 10.1016/j.jneumeth.2012.12.021; Bu XN, 2011, J NEUROCHEM, V117, P346, DOI 10.1111/j.1471-4159.2011.07209.x; Carrieri C, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00114; Cartier AE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034713; Chen H, 2011, ANTIOXID REDOX SIGN, V14, P1505, DOI 10.1089/ars.2010.3576; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Du Ping, 2014, Shengli Xuebao, V66, P528; Goncharova EA, 2013, FASEB J, V27, P1796, DOI 10.1096/fj.12-222224; Gong X, 2016, AM J TRANSL RES, V8, P2127; Gordon R, 2016, NEUROBIOL DIS, V93, P96, DOI 10.1016/j.nbd.2016.04.008; Guglielmotto M, 2012, AGING CELL, V11, P834, DOI 10.1111/j.1474-9726.2012.00854.x; Gutierrez H, 2011, TRENDS NEUROSCI, V34, P316, DOI 10.1016/j.tins.2011.03.001; Hamabe W, 2005, J PHARMACOL EXP THER, V313, P1027, DOI 10.1124/jpet.104.082735; Hassanian SM, 2016, J THROMB HAEMOST, V14, P2261, DOI 10.1111/jth.13477; Hayashi S, 2005, J NEUROCHEM, V93, P883, DOI 10.1111/j.1471-4159.2005.03080.x; Huang XP, 2015, J INTEGR MED-JIM, V13, P289, DOI 10.1016/S2095-4964(15)60187-X; Huang X, 2009, J IMMUNOL, V182, P5810, DOI 10.4049/jimmunol.0804073; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Kim HJ, 2015, ONCOTARGET, V6, P16287, DOI 10.18632/oncotarget.3843; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Krupinski J, 1998, ACTA NEUROBIOL EXP, V58, P13; Li JF, 2005, BRAIN RES, V1060, P62, DOI 10.1016/j.brainres.2005.08.047; Liu M, 2007, LANCET NEUROL, V6, P456, DOI 10.1016/S1474-4422(07)70004-2; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Liu RJ, 2013, NEUROPSYCHOPHARMACOL, V38, P2268, DOI 10.1038/npp.2013.128; Liu Y, 2008, NEUROSCI LETT, V444, P87, DOI 10.1016/j.neulet.2008.08.014; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lubjuhn J, 2009, J NEUROSCI METH, V184, P95, DOI 10.1016/j.jneumeth.2009.07.029; Matsumoto S, 2004, J CEREBR BLOOD F MET, V24, P54, DOI 10.1097/01.WCB.0000095920.70924.F5; Matsumoto S, 2008, NEUROCHEM RES, V33, P2302, DOI 10.1007/s11064-008-9727-4; Mincheva-Tasheva S, 2013, NEUROSCIENTIST, V19, P175, DOI 10.1177/1073858412444007; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350; Niu CC, 2005, NEUROSCI LETT, V384, P1, DOI 10.1016/j.neulet.2005.03.071; Osaka H, 2003, HUM MOL GENET, V12, P1945, DOI 10.1093/hmg/ddg211; Ren CH, 2013, BRAIN RES, V1540, P84, DOI 10.1016/j.brainres.2013.09.051; Rodriguez R, 2005, J NEUROSCI METH, V147, P22, DOI 10.1016/j.jneumeth.2005.02.013; Saito N, 2002, J BIOCHEM, V132, P683, DOI 10.1093/oxfordjournals.jbchem.a003274; Setsuie R, 2007, NEUROCHEM INT, V51, P105, DOI 10.1016/j.neuint.2007.05.007; Spalenza V, 2011, VET J, V189, P278, DOI 10.1016/j.tvjl.2010.11.017; Tennant KA, 2009, J NEUROSCI METH, V181, P18, DOI 10.1016/j.jneumeth.2009.04.009; Tramutola A, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2756068; Wan FY, 2010, CELL RES, V20, P24, DOI 10.1038/cr.2009.137; Wang G, 2015, J CELL MOL MED, V19, P1637, DOI 10.1111/jcmm.12538; Wang P, 2012, AUTOPHAGY, V8, P77, DOI 10.4161/auto.8.1.18274; Wang RT, 2011, J NEUROCHEM, V116, P1160, DOI 10.1111/j.1471-4159.2011.07172.x; Wang Y, 2016, NEUROREPORT, V27, P1072, DOI 10.1097/WNR.0000000000000659; Wang YX, 2013, J BIOL CHEM, V288, P12852, DOI 10.1074/jbc.M112.410357; Wei HP, 2016, TRANSL STROKE RES, V7, P497, DOI 10.1007/s12975-016-0484-4; Wexler EJ, 2002, J NEUROSCI METH, V113, P51, DOI 10.1016/S0165-0270(01)00476-9; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; WILSON POG, 1988, BRIT J EXP PATHOL, V69, P91; Wullaert A, 2011, CELL RES, V21, P146, DOI 10.1038/cr.2010.175; Xiang TX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029783; Xu EH, 2009, J CLIN NEUROSCI, V16, P1473, DOI 10.1016/j.jocn.2009.03.027; Zhang LS, 2017, ENVIRON POLLUT, V220, P843, DOI 10.1016/j.envpol.2016.10.067; Zhang N, 2011, NEUROCHEM INT, V58, P684, DOI 10.1016/j.neuint.2011.02.007; Zhao L, 2013, NEUROSCIENCE, V255, P203, DOI 10.1016/j.neuroscience.2013.10.001; Zhao YQ, 2016, J NUTR BIOCHEM, V38, P41, DOI 10.1016/j.jnutbio.2016.08.009; Zhao YQ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081196	64	12	12	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA		1582-4934		J CELL MOL MED	J. Cell. Mol. Med.	DEC	2017	21	12					3641	3657		10.1111/jcmm.13275			17	Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	FQ7WP	WOS:000418574500045	28726275	DOAJ Gold, Green Published			2021-06-18	
J	Navarro, SM; Sokunbi, OF; Haeberle, HS; Schickendantz, MS; Mont, MA; Figler, RA; Ramkumar, PN				Navarro, Sergio M.; Sokunbi, Olumide F.; Haeberle, Heather S.; Schickendantz, Mark S.; Mont, Michael A.; Figler, Richard A.; Ramkumar, Prem N.			Short-term Outcomes Following Concussion in the NFL: A Study of Player Longevity, Performance, and Financial Loss	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						concussion; NFL; football; performance; economic and decision analysis	FOOTBALL LEAGUE PLAYERS; BASKETBALL ASSOCIATION PLAYERS; PROFESSIONAL FOOTBALL; TIME; DEPRESSION; RETURN	Background: A short-term protocol for evaluation of National Football League (NFL) athletes incurring concussion has yet to be fully defined and framed in the context of the short-term potential team and career longevity, financial risk, and performance. Purpose: To compare the short-term career outcomes for NFL players with concussions by analyzing the effect of concussions on (1) franchise release rate, (2) career length, (3) salary, and (4) performance. Study Design: Cohort study; Level of evidence, 3. Methods: NFL player transaction records and publicly available injury reports from August 2005 to January 2016 were analyzed. All players sustaining documented concussions were evaluated for a change to inactive or DNP (did not participate) status. A case-control design compared franchise release rates and remaining NFL career span. Career length was analyzed via survival analysis. Salary and performance differences were analyzed with publicly available contract data and a performance-scoring algorithm based on position/player level. Results: Of the 5894 eligible NFL players over the 11-year period, 307 sustained publicly reported concussions resulting in the DNP injury protocol. Analysis of the probability of remaining in the league demonstrated a statistically significantly shorter career length for the concussion group at 3 and 5 years after concussion. The year-over-year change in contract value for the concussion group resulted in a mean overall salary reduction of $300,000 $1,300,000 per year (interquartile range, -$723,000 to $450,000 per year). The performance score reduction for all offensive scoring players sustaining concussions was statistically significant. Conclusion: This retrospective study demonstrated that NFL players who sustain a concussion face a higher overall franchise release rate and shorter career span. Players who sustained concussions may incur significant salary reductions and perform worse after concussion. Short-term reductions in longevity, performance, and salary after concussion exist and deserve additional consideration.	[Navarro, Sergio M.; Sokunbi, Olumide F.; Haeberle, Heather S.; Schickendantz, Mark S.; Mont, Michael A.; Figler, Richard A.; Ramkumar, Prem N.] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA; [Navarro, Sergio M.; Sokunbi, Olumide F.; Haeberle, Heather S.] Baylor Coll Med, Dept Orthoped Surg, Houston, TX 77030 USA; [Schickendantz, Mark S.; Mont, Michael A.; Figler, Richard A.; Ramkumar, Prem N.] Cleveland Clin, Dept Orthoped Surg, Cleveland, OH USA	Ramkumar, PN (corresponding author), 2049 E 100th St, Cleveland, OH 44195 USA.	premramkumar@gmail.com	Navarro, Sergio M/B-4287-2019; Navarro, Sergio M/K-8923-2019	Navarro, Sergio M/0000-0003-3455-1567; Haeberle, Heather/0000-0001-8341-8389			American Academy of Neurology website, STUD MOR 40 PERC RET; [Associated Press Goodell issues memo changing return to play rules for concussions National Football League website], GOODELL ISSUES MEMO; Bradley B, NEW NFL RULES CROWNO; Bradley B., NFLS 2013 PROTOCOL P; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Izraelski Jason, 2014, J Can Chiropr Assoc, V58, P346; Kontos AP, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-1633; Kuhn AW, 2016, AM J SPORT MED, V44, P2152, DOI 10.1177/0363546516638327; Kumar NS, 2014, AM J SPORT MED, V42, P2050, DOI 10.1177/0363546514539449; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; National Football League, NEL PLAY HLTH SAF FA; National Football League, NFL ANN NEW SID CONC; National Football League . NFL, NFL NFLPA ANN POL EN; National Football League website, NFL MOV KICK 35 YARD; NFL Head Neck and Spine Committee, NEL HEAD NECK SPIN C; Padaki AS, 2016, AM J SPORT MED, V44, P2263, DOI 10.1177/0363546516634679; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Plancher KD, 2014, ORTHOP J SPORTS MED, V2, DOI 10.1177/2325967114550623; Reams N, 2017, INT J SPORT PHYSIOL, V12, P1100, DOI 10.1123/ijspp.2016-0508; Secrist ES., 2016, ORTHOP J SPORTS MED, V4; Stites A, DOES NFLS CONCUSSION; Teramoto M, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115620365; Wasserman EB, 2015, AM J SPORT MED, V43, P1127, DOI 10.1177/0363546515576130; Wennberg RA, 2008, CAN J NEUROL SCI, V35, P647, DOI 10.1017/S031716710000946X; Yengo-Kahn AM, 2016, PHYSICIAN SPORTSMED, V44, P297, DOI 10.1080/00913847.2016.1200956	28	12	12	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2325-9671			ORTHOP J SPORTS MED	Orthop. J. Sports Med.	NOV 27	2017	5	11							2325967117740847	10.1177/2325967117740847			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	FN9MP	WOS:000416361900001	29226164	DOAJ Gold, Green Published			2021-06-18	
J	Roselli, F; Karasu, E; Volpe, C; Huber-Lang, M				Roselli, Francesco; Karasu, Ebru; Volpe, Clara; Huber-Lang, Markus			Medusa's Head: The Complement System in Traumatic Brain and Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						complement; neuroinflammation; spinal cord injury; traumatic brain injury	MEMBRANE ATTACK COMPLEX; MANNOSE-BINDING LECTIN; C3 CONVERTASES; MOTOR FUNCTION; FRAGMENTS C5A; RECEPTOR; ACTIVATION; INHIBITOR; INFLAMMATION; RECOVERY	Traumatic brain injury (TBI) and spinal cord injury (SCI) are critical medical conditions and a public health problem for which limited therapeutic options are available. The complement cascade is activated after TBI and SCI, and the resulting effects have been investigated in gene-knockout and pharmacological models. Multiple experimental studies support a net detrimental role of C3 and C5 activation in the early stages of TBI and SCI. Less firm experimental evidence suggests that, downstream of C3/C5, effector mechanisms, including the generation of membrane-activated complex and direct damage to membranes and neutrophils infiltration, may bring about the direct damage of central nervous system tissue and enhancement of neuroinflammation. The role of upstream classical, alternative, or extrinsic complement activation cascades remains unclear. Although several issues remain to be investigated, current evidence supports the investigation of a number of complement-targeting agents targeting C3 or C5, such as eculizumab, for repurposing in TBI and SCI treatment.	[Roselli, Francesco; Volpe, Clara] Univ Ulm, Med Sch, Dept Neurol, Ulm, Germany; [Roselli, Francesco] Univ Ulm, Med Sch, Dept Anat & Cell Biol, Ulm, Germany; [Karasu, Ebru; Huber-Lang, Markus] Univ Ulm, Med Sch, Inst Clin & Expt Trauma Immunol, Ulm, Germany	Roselli, F (corresponding author), Ulm Univ, Ctr Biomed Res ZBF, Sch Med, Dept Neurol, Helmholtzstr 8-2 R1-44, D-89081 Ulm, Germany.	francesco.roselli@uni-ulm.de	Huber-Lang, Markus/AAJ-2209-2020; roselli, francesco/O-8847-2019	roselli, francesco/0000-0001-9935-6899	DFG as part of the Collaborative Research Center 1149 "Danger Response, Disturbance Factors and Regenerative Potential after Acute Trauma'' at Ulm University (Ulm, Germany); ERANET-NEURON "European Research Projects on External Insults to the Nervous System'' initiative as part of the MICRO-NET consortium; Baustein Program of Ulm University	F.R., E.K., and M.H. are supported by DFG as part of the Collaborative Research Center 1149 "Danger Response, Disturbance Factors and Regenerative Potential after Acute Trauma'' at Ulm University (Ulm, Germany). F.R. is also supported by the ERANET-NEURON "European Research Projects on External Insults to the Nervous System'' initiative as part of the MICRO-NET consortium and by the Baustein Program of Ulm University. The authors thank Akila Chandrasekar and Rida Rehman for the critical review of the manuscript.	ALPER CA, 1969, SCIENCE, V163, P286, DOI 10.1126/science.163.3864.286; Amara U, 2010, J IMMUNOL, V185, P5628, DOI 10.4049/jimmunol.0903678; Ames RS, 1996, J BIOL CHEM, V271, P20231, DOI 10.1074/jbc.271.34.20231; Baufreton C, 2005, ANN THORAC SURG, V79, P1597, DOI 10.1016/j.athoracsur.2004.08.061; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; Bekker P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164646; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Benard M, 2004, J BIOL CHEM, V279, P43487, DOI 10.1074/jbc.M404124200; Biberthaler Peter, 2016, MMW Fortschr Med, V158, P53, DOI 10.1007/s15006-016-8148-6; Biggins PJC, 2017, J NEUROTRAUM, V34, P2075, DOI 10.1089/neu.2016.4701; BJORNSON AB, 1980, ANN SURG, V191, P323, DOI 10.1097/00000658-198003000-00011; Brennan FH, 2015, J NEUROSCI, V35, P6517, DOI 10.1523/JNEUROSCI.5218-14.2015; Burk AM, 2012, SHOCK, V37, P348, DOI 10.1097/SHK.0b013e3182471795; Cain SA, 2002, J BIOL CHEM, V277, P7165, DOI 10.1074/jbc.C100714200; Carron SF, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00047; Crane JW, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-34; Crehan H, 2013, NEUROBIOL DIS, V54, P139, DOI 10.1016/j.nbd.2013.02.003; DALMASSO AP, 1992, AM J PATHOL, V140, P1157; Ehrnthaller C, 2011, MOL MED, V17, P317, DOI 10.2119/molmed.2010.00149; Ekdahl KN, 2016, IMMUNOL REV, V274, P245, DOI 10.1111/imr.12471; FEARON DT, 1975, J EXP MED, V142, P856, DOI 10.1084/jem.142.4.856; Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793; Galvan MD, 2008, J NEUROSCI, V28, P13876, DOI 10.1523/JNEUROSCI.2823-08.2008; Gasque P, 2004, MOL IMMUNOL, V41, P1089, DOI 10.1016/j.molimm.2004.06.011; GASQUE P, 1995, J IMMUNOL, V155, P4882; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GEWURZ H, 1993, BEHR INST MITT, P138; Guo Q, 2013, CLIN EXP IMMUNOL, V174, P318, DOI 10.1111/cei.12175; Guo Q, 2013, SCAND J IMMUNOL, V77, P224, DOI 10.1111/sji.12001; Guo QA, 2010, NEUROSCI LETT, V485, P32, DOI 10.1016/j.neulet.2010.08.056; Haeffner-Cavaillon N, 1998, REV MED INTERNE, V19, P585, DOI 10.1016/S0248-8663(99)80033-2; Hajela K, 2002, IMMUNOBIOLOGY, V205, P467, DOI 10.1078/0171-2985-00147; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hoehlig K, 2013, MOL THER, V21, P2236, DOI 10.1038/mt.2013.178; Hong S, 2016, SCIENCE, V352, P712, DOI 10.1126/science.aad8373; Hourcade DE, 2006, J BIOL CHEM, V281, P2128, DOI 10.1074/jbc.M508928200; Huber-Lang M, 2016, SEMIN IMMUNOL, V28, P278, DOI 10.1016/j.smim.2016.04.005; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jore MM, 2016, NAT STRUCT MOL BIOL, V23, P378, DOI 10.1038/nsmb.3196; Karver CL, 2012, REHABIL PSYCHOL, V57, P256, DOI 10.1037/a0029522; KAWASAKI T, 1978, BIOCHEM BIOPH RES CO, V81, P1018, DOI 10.1016/0006-291X(78)91452-3; Klussmann S, 1996, NAT BIOTECHNOL, V14, P1112, DOI 10.1038/nbt0996-1112; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Li LM, 2010, SPINAL CORD, V48, P105, DOI 10.1038/sc.2009.104; Longhi L, 2014, CRIT CARE MED, V42, P1910, DOI 10.1097/CCM.0000000000000399; Lu JH, 1998, IMMUNOBIOLOGY, V199, P190, DOI 10.1016/S0171-2985(98)80026-0; Marr A. L., 2005, CENTRAL NERVOUS SYST; Mastellos DC, 2015, EUR J CLIN INVEST, V45, P423, DOI 10.1111/eci.12419; Mathern DR, 2015, CLIN J AM SOC NEPHRO, V10, P1636, DOI 10.2215/CJN.06230614; Mead RJ, 2002, J IMMUNOL, V168, P458, DOI 10.4049/jimmunol.168.1.458; Michailidou I, 2015, ANN NEUROL, V77, P1007, DOI 10.1002/ana.24398; Miyabe Y, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aaj2195; Mollnes TE, 2006, MOL IMMUNOL, V43, P107, DOI 10.1016/j.molimm.2005.06.014; Mollnes Tom E., 2002, Trends in Immunology, V23, P61, DOI 10.1016/S1471-4906(01)02129-9; Moriyama M, 2011, J NEUROSCI, V31, P3981, DOI 10.1523/JNEUROSCI.3617-10.2011; Neher MD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-95; Nguyen HX, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-26; Noris M, 2013, SEMIN NEPHROL, V33, P479, DOI 10.1016/j.semnephrol.2013.08.001; O'Barr SA, 2001, J IMMUNOL, V166, P4154, DOI 10.4049/jimmunol.166.6.4154; PANGBURN MK, 1981, J EXP MED, V154, P856, DOI 10.1084/jem.154.3.856; Peterson SL, 2015, J NEUROSCI, V35, P4332, DOI 10.1523/JNEUROSCI.4473-12.2015; Pittock SJ, 2013, LANCET NEUROL, V12, P554, DOI 10.1016/S1474-4422(13)70076-0; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Qiao F, 2006, AM J PATHOL, V169, P1039, DOI 10.2353/ajpath.2006.060248; Qiao F, 2010, AM J PATHOL, V177, P3061, DOI 10.2353/ajpath.2010.100158; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Reis ES, 2015, IMMUNOBIOLOGY, V220, P476, DOI 10.1016/j.imbio.2014.10.026; Reis ES, 2006, SCAND J IMMUNOL, V63, P155, DOI 10.1111/j.1365-3083.2006.01729.x; Rich MC, 2016, NEUROSCI LETT, V617, P188, DOI 10.1016/j.neulet.2016.02.025; Ricklin D, 2008, ADV EXP MED BIOL, V632, P273, DOI 10.1007/978-0-387-78952-1_20; Ricklin D, 2013, J IMMUNOL, V190, P3831, DOI 10.4049/jimmunol.1203487; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Riggio S, 2009, MT SINAI J MED, V76, P163, DOI 10.1002/msj.20097; Rostami E, 2013, J NEUROTRAUM, V30, P1954, DOI 10.1089/neu.2012.2583; Rother RP, 2007, NAT BIOTECHNOL, V25, P1256, DOI 10.1038/nbt1344; Ruseva MM, 2015, P NATL ACAD SCI USA, V112, P14319, DOI 10.1073/pnas.1513698112; SCHREIBER RD, 1975, J EXP MED, V142, P760, DOI 10.1084/jem.142.3.760; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Stahel PF, 1997, MOL BRAIN RES, V50, P205, DOI 10.1016/S0169-328X(97)00189-7; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; Strainic MG, 2008, IMMUNITY, V28, P425, DOI 10.1016/j.immuni.2008.02.001; Takano M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-40; TEASDALE G, 1974, LANCET, V2, P81; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; Vasek MJ, 2016, NATURE, V534, P538, DOI 10.1038/nature18283; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Weston-Davies W. H., 2014, P 56 ANN M AM SOC HE; Yager PH, 2008, J CEREBR BLOOD F MET, V28, P1030, DOI 10.1038/sj.jcbfm.9600605; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497	99	12	13	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2018	35	2					226	240		10.1089/neu.2017.5168		NOV 2017	15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FT1TA	WOS:000416451600001	28816089				2021-06-18	
J	Xu, B; Sandrini, M; Levy, S; Volochayev, R; Awosika, O; Butman, JA; Pham, DL; Cohen, LG				Xu, Benjamin; Sandrini, Marco; Levy, Sarah; Volochayev, Rita; Awosika, Oluwole; Butman, John A.; Pham, Dzung L.; Cohen, Leonardo G.			Lasting deficit in inhibitory control with mild traumatic brain injury	SCIENTIFIC REPORTS			English	Article							INFERIOR FRONTAL-CORTEX; RESPONSE-INHIBITION; STOP-SIGNAL; SUSTAINED ATTENTION; COGNITIVE CONTROL; ERROR-AWARENESS; HUMANS; MRI; CONNECTIVITY; ACTIVATIONS	Being able to focus on a complex task and inhibit unwanted actions or interfering information (i.e., inhibitory control) are essential human cognitive abilities. However, it remains unknown the extent to which mild traumatic brain injury (mTBI) may impact these critical functions. In this study, seventeen patients and age-matched healthy controls (HC) performed a variant of the Stroop task and attention-demanding 4-choice response tasks (4CRT) with identical stimuli but two contexts: one required only routine responses and the other with occasional response conflicts. The results showed that mTBI patients performed equally well as the HC when the 4CRT required only routine responses. However, when the task conditions included occasional response conflicts, mTBI patients with even a single concussion showed a significant slow-down in all responses and higher error rates relative to the HC. Results from event-related functional magnetic resonance imaging (efMRI) revealed altered neural activity in the mTBI patients in the cerebellum-thalamo-cortical and the fronto-basal-ganglia networks regulating inhibitory control. These results suggest that even without apparent difficulties in performing complex attention-demanding but routine tasks, patients with mTBI may experience long-lasting deficits in regulating inhibitory control when situations call for rapid conflict resolutions.	[Xu, Benjamin; Sandrini, Marco; Volochayev, Rita; Awosika, Oluwole; Cohen, Leonardo G.] NINDS, Human Cort Physiol & Neurorehabil Sect, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Xu, Benjamin; Sandrini, Marco; Levy, Sarah; Butman, John A.; Pham, Dzung L.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Butman, John A.] NIH, Radiol & Imaging Sci, Clin Ctr, Bldg 10, Bethesda, MD 20892 USA	Xu, B (corresponding author), NINDS, Human Cort Physiol & Neurorehabil Sect, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.; Xu, B (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA.	benxu1@mail.nih.gov	Butman, John A/A-2694-2008; Sandrini, Marco/J-2276-2014; Butman, John/J-2780-2013; Pham, Dzung/AAR-8263-2020	Sandrini, Marco/0000-0002-1664-5722; Butman, John/0000-0002-1547-9195; 	Department of Defense through the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [G189AN, G189BK]; National Institute of Neurological Disorders and Stroke, at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003030] Funding Source: NIH RePORTER	This work was supported by the Department of Defense through the Center for Neuroscience and Regenerative Medicine (G189AN and G189BK) and by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke, at the National Institutes of Health.	Aron AR, 2007, J NEUROSCI, V27, P3743, DOI 10.1523/JNEUROSCI.0519-07.2007; Aron AR, 2016, J NEUROSCI, V36, P11489, DOI 10.1523/JNEUROSCI.2348-16.2016; Aron AR, 2014, TRENDS COGN SCI, V18, P177, DOI 10.1016/j.tics.2013.12.003; Aron AR, 2011, BIOL PSYCHIAT, V69, pE55, DOI 10.1016/j.biopsych.2010.07.024; Aron AR, 2003, NAT NEUROSCI, V6, P115, DOI 10.1038/nn1003; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bharath RD, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00513; Brunia CHM, 1999, ACTA PSYCHOL, V101, P213, DOI 10.1016/S0001-6918(99)00006-2; Chikazoe J, 2009, CEREB CORTEX, V19, P146, DOI 10.1093/cercor/bhn065; DeHaan A, 2007, NEUROPSYCHOLOGIA, V45, P406, DOI 10.1016/j.neuropsychologia.2006.06.008; Dimoska-Di Marco A, 2011, J CLIN EXP NEUROPSYC, V33, P471, DOI 10.1080/13803395.2010.533158; Dunkley BT, 2015, NEUROIMAGE-CLIN, V7, P611, DOI 10.1016/j.nicl.2015.02.020; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Eickhoff SB, 2007, NEUROIMAGE, V36, P511, DOI 10.1016/j.neuroimage.2007.03.060; Eklund A, 2016, P NATL ACAD SCI USA, V113, P7900, DOI 10.1073/pnas.1602413113; Girgis F, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00008; Hermans L., 2016, NEUROREHABIL NEURAL; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jahfari S, 2010, J COGNITIVE NEUROSCI, V22, P1479, DOI 10.1162/jocn.2009.21307; Kenner NM, 2010, J NEUROSCI, V30, P8512, DOI 10.1523/JNEUROSCI.1096-10.2010; Kinomura S, 1996, SCIENCE, V271, P512, DOI 10.1126/science.271.5248.512; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P69, DOI 10.1016/j.ijpsycho.2011.02.018; Lepage C, 2017, BRAIN IMAGING BEHAV; Leunissen I, 2014, CORTEX, V51, P67, DOI 10.1016/j.cortex.2013.10.009; Leunissen I, 2013, HUM BRAIN MAPP, V34, P1254, DOI 10.1002/hbm.21508; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Nachev P, 2007, NEUROIMAGE, V36, pT155, DOI 10.1016/j.neuroimage.2007.03.034; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Niemann H, 1996, NEUROPSYCHOL REV, V6, P11, DOI 10.1007/BF01875418; O'Keeffe FM, 2007, EXP BRAIN RES, V180, P59, DOI 10.1007/s00221-006-0832-9; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Petersen SE, 2012, ANNU REV NEUROSCI, V35, P73, DOI 10.1146/annurev-neuro-062111-150525; Portas CM, 1998, J NEUROSCI, V18, P8979; Prevosto V, 2013, FRONT SYST NEUROSCI, V7, DOI 10.3389/fnsys.2013.00056; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Roche RAP, 2004, NEUROSCI LETT, V362, P1, DOI 10.1016/j.neulet.2003.11.064; Sarter M, 2001, BRAIN RES REV, V35, P146, DOI 10.1016/S0165-0173(01)00044-3; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Stewart JAL, 1999, BRAIN COGNITION, V41, P411, DOI 10.1006/brcg.1999.1141; Sumner P, 2007, NEURON, V54, P697, DOI 10.1016/j.neuron.2007.05.016; Thomas C, 2014, P NATL ACAD SCI USA, V111, P16574, DOI 10.1073/pnas.1405672111; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Vascak M, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00157; Vascak M, 2018, CEREB CORTEX, V28, P1625, DOI 10.1093/cercor/bhx058; Verbruggen F, 2008, TRENDS COGN SCI, V12, P418, DOI 10.1016/j.tics.2008.07.005; Verbruggen F, 2009, NEUROSCI BIOBEHAV R, V33, P647, DOI 10.1016/j.neubiorev.2008.08.014; Woods DL, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00595; Xu BJM, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00034; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020	56	12	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	NOV 2	2017	7								14902	10.1038/s41598-017-14867-y			10	Multidisciplinary Sciences	Science & Technology - Other Topics	FL5GR	WOS:000414261500019	29097755	DOAJ Gold, Green Published			2021-06-18	
J	Kearney, PE; See, J				Kearney, Philip E.; See, James			Misunderstandings of concussion within a youth rugby population	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Head injuries; Adolescent; Sports safety; Return to sport; England	SCHOOL FOOTBALL PLAYERS; UNION PLAYERS; SPORTS CONCUSSION; KNOWLEDGE; ATTITUDES; EDUCATION; PREVENTION; MANAGEMENT; STUDENTS; BEHAVIOR	Objectives: The recognition and management of concussion has become a major health concern within rugby union. Identifying misconceptions and attitudes regarding concussion is valuable for informing player education. Therefore, the purpose of this study was to explore the knowledge of, and attitudes towards, concussion in subgroups of youth rugby players. Design: Cross-sectional survey. Methods: Information sheets and consent forms were distributed at training sessions for multiple teams at each of three schools and three clubs. Players who returned consent forms completed a custom-designed survey at a subsequent session. Results: Two hundred and fifty-five English players, aged 11-17 years, completed the anonymous survey. Sixty-one participants reported a total of 77 concussions. Self-reported return to play ranged from 0 to 365 days; only seven players (11%) reported a return to play after the Rugby Football Union's recommendation of 23 days. Although the majority of findings relating to players' knowledge of concussion were positive, a number of important misunderstandings were revealed. While the majority of players reported positive attitudes towards concussion, a substantial minority (up to 30%) reported inappropriate attitudes in response to specific questions. Participants who played at multiple venues did report superior knowledge and attitudes relative to their peers who played at a single venue. Conclusion: Despite generally positive results, youth rugby players were found to hold a number of misconceptions regarding concussion which should be the focus for education initiatives. Considering general subgroups of players by concussion history, age, or playing position appears unlikely to enhance the design of concussion education programmes. (C) 2017 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Kearney, Philip E.; See, James] Univ Chichester, Inst Sport, Chichester, England	Kearney, PE (corresponding author), Univ Chichester, Inst Sport, Chichester, England.	p.kearney@chi.ac.uk		Kearney, Philip/0000-0003-3425-663X			Baker JF, 2013, IRISH J MED SCI, V182, P121, DOI 10.1007/s11845-012-0846-1; CARIFIO J, 1994, J ALCOHOL DRUG EDUC, V39, P74; Cote J., 2016, HDB YOUTH SPORT; Cournoyer J, 2014, J ATHL TRAINING, V49, P654, DOI 10.4085/1062-6050-49.3.34; Cusimano MD, 2014, BRIT J SPORT MED, V48, P141, DOI 10.1136/bjsports-2012-091660; Delahunty SE, 2015, J SCHOOL HEALTH, V85, P17, DOI 10.1111/josh.12219; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Edens JF, 2001, LAW HUMAN BEHAV, V25, P235, DOI 10.1023/A:1010793810896; Finch C, 2002, INJ PREV, V8, P151, DOI 10.1136/ip.8.2.151; Gardner AJ, 2014, SPORTS MED, V44, P1717, DOI 10.1007/s40279-014-0233-3; Gourley MM., 2010, ATHL TRAIN SPORTS HL, V2, P208, DOI DOI 10.3928/19425864-20100524-03; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hendricks S, 2012, SAFETY SCI, V50, P266, DOI 10.1016/j.ssci.2011.08.061; Hollis SJ, 2012, BRIT J SPORT MED, V46, P735, DOI 10.1136/bjsm.2011.085332; HOLM S, 1979, SCAND J STAT, V6, P65; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; Kirkwood G, 2015, BRIT J SPORT MED, V49, P506, DOI 10.1136/bjsports-2014-093774; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kurowski B, 2014, J TRAUMA ACUTE CARE, V77, pS12, DOI 10.1097/TA.0000000000000316; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Miyashita TL, 2014, ORTHOP J SPORTS MED, V2, DOI 10.1177/2325967114554549; Mrazik M, 2015, BRIT J SPORT MED, V49, DOI 10.1136/bjsports-2015-094848; Provvidenza C, 2013, BRIT J SPORT MED, V47, P332, DOI 10.1136/bjsports-2012-092099; Quarrie KL, 2013, J SCI MED SPORT, V16, P353, DOI 10.1016/j.jsams.2012.08.005; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Sullivan SJ, 2009, CLIN J SPORT MED, V19, P228, DOI 10.1097/JSM.0b013e3181a41e43; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Tator CH, 2012, J CLIN SPORT PSYCHOL, V6, P293, DOI 10.1123/jcsp.6.3.293; White P, 2014, JSCI MED SPORT, V18, pe102	30	12	12	0	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	NOV	2017	20	11					981	985		10.1016/j.jsams.2017.04.019			5	Sport Sciences	Sport Sciences	FL4YS	WOS:000414238100006	28476439	Green Accepted			2021-06-18	
J	Keenan, HT; Cook, LJ; Olson, LM; Bardsley, T; Campbell, KA				Keenan, Heather T.; Cook, Lawrence J.; Olson, Lenora M.; Bardsley, Tyler; Campbell, Kristine A.			Social Intuition and Social Information in Physical Child Abuse Evaluation and Diagnosis	PEDIATRICS			English	Article							DECISION-MAKING; DISPARITIES; STRATEGIES; INFANTS; INJURY	BACKGROUND: Poor and minority children with injuries concerning for abuse are evaluated and diagnosed for abuse differentially. We hypothesized that 2 steps in the decision-making process would influence evaluation and diagnosis: social intuition from meeting the family and objective social information associated with child abuse risk. METHODS: Between 2009 and 2013, 32 child abuse pediatricians (CAPs) submitted 730 child abuse consultations including original medical evaluations and diagnoses. CAPs evaluated and diagnosed each other's cases. Comparisons of evaluations and diagnoses were made by levels of social understanding available to the CAP: meeting the family (social intuition and information), reading the case (social information), and reading the case without social information. Evaluations were compared with a consensus gold standard by using logistic regression modeling adjusting for child and CAP characteristics. Diagnostic categories were compared by level of social understanding and diagnostic certainty by using contingency tables. RESULTS: CAPs without access to social intuition were approximately twice as likely to perform gold standard evaluations for neurotrauma and long bone fracture compared with CAPs who met families. Diagnostic agreement fell from 73.3% (95% confidence interval [CI]: 70.1%-76.5%) when social information was present to 66.5% (95% CI: 63.1%-70.0%) when social information was restricted. In cases with less certainty, agreement dropped to 51.3% (95% CI: 46.0%-56.7%). CONCLUSIONS: Social intuition and information play a role in the physical child abuse decision-making process, which may contribute to differential diagnosis. Simple interventions including decision tools, check lists, and peer review may structure evaluations to ensure children's equal treatment.	[Keenan, Heather T.; Cook, Lawrence J.; Olson, Lenora M.; Bardsley, Tyler; Campbell, Kristine A.] Univ Utah, Dept Pediat, 295 Chipeta Way,POB 581289, Salt Lake City, UT 84158 USA	Keenan, HT (corresponding author), Univ Utah, Dept Pediat, 295 Chipeta Way,POB 581289, Salt Lake City, UT 84158 USA.	heather.keenan@hsc.utah.edu			Eunice Kennedy Shriver Institute of Child Health and Human Development of the National Institutes of Health [R01 HD061373]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061373] Funding Source: NIH RePORTER	Supported by the Eunice Kennedy Shriver Institute of Child Health and Human Development of the National Institutes of Health grant R01 HD061373 (principal investigator Dr Keenan). Funded by the National Institutes of Health (NIH).	AAMC, 2004, STAT NEW AAMC DEF UN, P1; Campbell KA, 2015, PEDIATRICS, V136, P35, DOI 10.1542/peds.2014-4192; Cavalcanti RB, 2014, ACAD MED, V89, P107, DOI 10.1097/ACM.0000000000000074; Chaiyachati BH, 2016, CHILD ABUSE NEGLECT, V51, P87, DOI 10.1016/j.chiabu.2015.11.001; Croskerry P, 2013, BMJ QUAL SAF, V22, pii65, DOI 10.1136/bmjqs-2012-001713; Croskerry P, 2013, NEW ENGL J MED, V368, P2445, DOI 10.1056/NEJMp1303712; Croskerry Pat, 2012, Healthc Q, V15 Spec No, P50; Dovidio JF, 2012, AM J PUBLIC HEALTH, V102, P945, DOI 10.2105/AJPH.2011.300601; Ely JW, 2011, ACAD MED, V86, P307, DOI 10.1097/ACM.0b013e31820824cd; Eva KW, 2007, MED EDUC, V41, P1152, DOI 10.1111/j.1365-2923.2007.02923.x; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Kostopoulou O, 2012, MED DECIS MAKING, V32, P831, DOI 10.1177/0272989X12447241; Lane WG, 2002, JAMA-J AM MED ASSOC, V288, P1603, DOI 10.1001/jama.288.13.1603; Laskey AL, 2012, J PEDIATR-US, V160, P1003, DOI 10.1016/j.jpeds.2011.11.042; Rangel EL, 2009, J PEDIATR SURG, V44, P1229, DOI 10.1016/j.jpedsurg.2009.02.044; Redelmeier DA, 2005, ANN INTERN MED, V142, P115, DOI 10.7326/0003-4819-142-2-200501180-00010; Starling SP, 2013, CHILD ABUSE NEGLECT, V37, P456, DOI 10.1016/j.chiabu.2013.01.002; Thenappan A, 2017, PEDIATR BLOOD CANCER, V64, P254, DOI 10.1002/pbc.26201; Van den Bruel A, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6144; Wood JN, 2010, PEDIATRICS, V126, P408, DOI 10.1542/peds.2010-0031	20	12	12	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	NOV	2017	140	5							e20171188	10.1542/peds.2017-1188			7	Pediatrics	Pediatrics	FL3JO	WOS:000414119600030	29074609	Bronze, Green Published			2021-06-18	
J	Landry-Roy, C; Bernier, A; Gravel, J; Beauchamp, MH				Landry-Roy, Catherine; Bernier, Annie; Gravel, Jocelyn; Beauchamp, Miriam H.			Predictors of Sleep Outcomes Following Mild Traumatic Brain Injury in Preschoolers: Subjective and Objective Assessment of Outcome	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						actigraphy; concussion; pediatric; sleep; traumatic brain injury	MINOR HEAD-INJURY; YOUNG-CHILDREN; POSTCONCUSSIVE SYMPTOMS; BEHAVIORAL OUTCOMES; ADOLESCENTS; DISTURBANCES; PATTERNS; PREVALENCE; ACTIGRAPHY; CONSCIOUSNESS	Objectives: To investigate sleep and its predictors in preschoolers with mild traumatic brain injury (mTBI). Participants and procedure: The sample included 225 children, aged 18 to 60 months, divided into 3 groups: children with accidental mTBI (n = 85), children with orthopedic injury (n = 58), and typically developing children (n = 82). Retrospective reports of preinjury sleep and family functioning were obtained as part of a baseline assessment at the time of recruitment. Parental ratings of sleep problems were collected 6 months postinjury on the full sample, and actigraphy data were collected on a subset of children. Demographic, preinjury, and periinjury factors were examined as potential predictors of sleep outcomes. Results: No group differences were found in ratings of sleep problems or for nighttime sleep duration and sleep efficiency, as measured by actigraphy. Besides, preexisting sleep disturbances and brain injury resulting in alteration of consciousness were identified as predictors of poorer sleep in the mTBI group. Conclusion: Although mTBI did not result in group-level sleep disturbances 6 months postinjury, the findings suggest that premorbid and injury-related factors place some children at risk for poorer sleep after mTBI. These factors should be documented so clinicians can intervene early.	[Landry-Roy, Catherine; Bernier, Annie; Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada; [Landry-Roy, Catherine; Gravel, Jocelyn; Beauchamp, Miriam H.] CHU St Justine Res Ctr, Montreal, PQ, Canada	Landry-Roy, C (corresponding author), Univ Montreal, Dept Psychol, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	miriam.beauchamp@umontreal.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP11036]	Preparation of this article was supported by the Canadian Institutes of Health Research (MOP11036 to M.H.B).	Abidin RR., 1995, PARENTING STRESS IND; Acebo C, 2005, SLEEP, V28, P1568, DOI 10.1093/sleep/28.12.1568; Acebo C, 1999, SLEEP, V22, P95, DOI 10.1093/sleep/22.1.95; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Astill RG, 2012, PSYCHOL BULL, V138, P1109, DOI 10.1037/a0028204; ATKINSON E, 1995, CHILD CARE HLTH DEV, V21, P233, DOI 10.1111/j.1365-2214.1995.tb00754.x; Beauchamp MH, 2013, HAND CLINIC, V112, P913, DOI 10.1016/B978-0-444-52910-7.00013-1; Beebe DW, 2007, J PEDIATR PSYCHOL, V32, P845, DOI 10.1093/jpepsy/jsm003; Beebe DW, 2011, PEDIATR CLIN N AM, V58, P649, DOI 10.1016/j.pcl.2011.03.002; Belanger ME, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00158; Belanger ME, 2013, J CLIN SLEEP MED, V9, P701, DOI 10.5664/jcsm.2844; Biggs SN, 2013, SLEEP MED, V14, P1304, DOI 10.1016/j.sleep.2013.06.014; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; BLISHEN BR, 1987, CAN REV SOC ANTHROP, V24, P465; Blyth BJ, 2010, EMERG MED CLIN N AM, V28, P571, DOI 10.1016/j.emc.2010.03.003; Byars KC, 2011, SLEEP MED, V12, P898, DOI 10.1016/j.sleep.2011.05.002; Cassidy JD, 2004, J REHABIL MED, pS28; Catroppa C, 2015, NEW FRONTIERS PEDIAT; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Dahl RE, 2007, J FAM PSYCHOL, V21, P1, DOI 10.1037/0893-3200.21.1.1; Dewald JF, 2010, SLEEP MED REV, V14, P179, DOI 10.1016/j.smrv.2009.10.004; Duclos C, 2014, PATHOL BIOL, V62, P252, DOI 10.1016/j.patbio.2014.05.014; El-Sheikh M., 2011, SLEEP AND DEVELOPMEN; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Evans BM, 2002, J ROY SOC MED, V95, P591, DOI 10.1258/jrsm.95.12.591; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gagner C, 2015, J NEUROTRAUM, V32, P1539, DOI 10.1089/neu.2014.3753; Garcia D, 2015, J PEDIATR PSYCHOL, V40, P391, DOI 10.1093/jpepsy/jsu093; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Hobson JA, 2002, NAT REV NEUROSCI, V3, P679, DOI 10.1038/nrn915; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Jenni OG, 2007, PEDIATRICS, V120, pe769, DOI 10.1542/peds.2006-3300; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Meltzer LJ, 2012, SLEEP, V35, P159, DOI 10.5665/sleep.1608; Milroy G, 2008, J PEDIATR PSYCHOL, V33, P242, DOI 10.1093/jpepsy/jsm099; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Myers R., 1990, CLASSICAL MODERN REG; National Sleep Foundation, 2004, CHILDR SLEEP SLEEP A; Owens Judith A, 2005, Behav Sleep Med, V3, P18, DOI 10.1207/s15402010bsm0301_4; OwensStively J, 1997, J DEV BEHAV PEDIATR, V18, P314, DOI 10.1097/00004703-199710000-00005; Pillar G, 2003, PEDIATR NEUROL, V29, P131, DOI 10.1016/S0887-8994(03)00149-8; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Sadeh A, 2015, MONOGR SOC RES CHILD, V80, P33, DOI 10.1111/mono.12143; Sadeh A, 2007, SLEEP MED CLIN, V2, P513, DOI 10.1016/j.jsmc.2007.05.012; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Shay N, 2014, J NEUROTRAUM, V31, P1305, DOI 10.1089/neu.2013.3275; SPANIER GB, 1976, J MARRIAGE FAM, V38, P15, DOI 10.2307/350547; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; Thurber S., 2012, ARCH ASSESSMENT PSYC, V2, P73; Werner H, 2008, ARCH PEDIAT ADOL MED, V162, P350, DOI 10.1001/archpedi.162.4.350; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	57	12	12	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2017	32	6					E13	E23		10.1097/HTR.0000000000000303			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FQ8BO	WOS:000418588100002	28422896				2021-06-18	
J	Meisel, JE; Chang, M				Meisel, Jayda E.; Chang, Mayland			Selective small-molecule inhibitors as chemical tools to define the roles of matrix metalloproteinases in disease	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH			English	Article						Matrix metalloproteinases; Gelatinases; Thiiranes; ND-322; ND-336; MMP roles	BLOOD-BRAIN-BARRIER; LONG-TERM PROGNOSIS; GELATINASE INHIBITOR; INFLAMMATORY ARTHRITIS; FUNCTIONAL RECOVERY; TISSUE INHIBITOR; MICE DEFICIENT; TETHERED RESIN; FOOT ULCERS; CANCER	The focus of this article is to highlight novel inhibitors and current examples where the use of selective small molecule inhibitors has been critical in defining the roles of matrix metalloproteinases (MMPs) in disease. Selective small-molecule inhibitors are surgical chemical tools that can inhibit the targeted enzyme; they are the method of choice to ascertain the roles of MMPs and complement studies with knockout animals. This strategy can identify targets for therapeutic development as exemplified by the use of selective small-molecule MMP inhibitors in diabetic wound healing, spinal cord injury, stroke, traumatic brain injury, cancer metastasis, and viral infection. This article is part of a Special Issue entitled: Matrix Metalloproteinases edited by Rafael Fridman.	[Meisel, Jayda E.; Chang, Mayland] Univ Notre Dame, 354C McCourtney Hall, Notre Dame, IN 46556 USA	Chang, M (corresponding author), Univ Notre Dame, 354C McCourtney Hall, Notre Dame, IN 46556 USA.	mchang@nd.edu			American Diabetes AssociationAmerican Diabetes Association [1-15-ACN-06]	This work was supported by the American Diabetes Association Pathway to Stop Diabetes grant 1-15-ACN-06.	[Anonymous], 2011, J Spinal Cord Med, V34, P620, DOI 10.1179/204577211X13218754005537; APELQVIST J, 1993, J INTERN MED, V233, P485, DOI 10.1111/j.1365-2796.1993.tb01003.x; Armstrong David G, 2007, Int Wound J, V4, P286; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Aureli L, 2008, CURR MED CHEM, V15, P2192, DOI 10.2174/092986708785747490; Baranger K, 2016, CELL MOL LIFE SCI, V73, P217, DOI 10.1007/s00018-015-1992-1; BAUER EA, 1985, P NATL ACAD SCI USA, V82, P4132, DOI 10.1073/pnas.82.12.4132; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Biswas MHU, 2016, STEM CELL REP, V7, P316, DOI 10.1016/j.stemcr.2016.08.006; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; Bonfil RD, 2007, AM J PATHOL, V170, P2100, DOI 10.2353/ajpath.2007.060720; Bonfil RD, 2006, INT J CANCER, V118, P2721, DOI 10.1002/ijc.21645; Bracken MB, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001046.pub2; Brown S, 2000, J AM CHEM SOC, V122, P6799, DOI 10.1021/ja001461n; Butler GS, 2009, BIOCHEMISTRY-US, V48, P10830, DOI 10.1021/bi901656f; Castro-Castro A., 2016, ANN REV CELL DEV BIO, V32; CDC NCHS, 2011, FACT FACTS DIAB; Celenza G, 2008, CHEM BIOL DRUG DES, V71, P187, DOI [10.1111/j.1747-0285.2008.00632.x, 10.1111/j.1747-0277.2008.00632.x]; Centers for Disease Control and Prevention and NCHS, 2015, UND CAUS DEATH 1999; Chen YC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002672; Copeland RA, 2006, NAT REV DRUG DISCOV, V5, P730, DOI 10.1038/nrd2082; Coronado VG, 2010, TRAUMATIC BRAIN INJU, P891, DOI [10.1016/B978-0-444-52910-7.00011-8, DOI 10.1016/B978-0-444-52910-7.00011-8]; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Cox JH, 2010, ARTHRITIS RHEUM-US, V62, P3645, DOI 10.1002/art.27757; Cui JK, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-21; Devel L, 2006, J BIOL CHEM, V281, P11152, DOI 10.1074/jbc.M600222200; Devel L, 2010, J BIOL CHEM, V285, P35900, DOI 10.1074/jbc.M110.139634; Ding DR, 2014, MEDCHEMCOMM, V5, P1381, DOI 10.1039/c4md00172a; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Donnan GA, 2011, NAT REV NEUROL, V7, P400, DOI 10.1038/nrneurol.2011.89; Fanjul-Fernandez M, 2010, BBA-MOL CELL RES, V1803, P3, DOI 10.1016/j.bbamcr.2009.07.004; Feldinger K, 2014, ONCOTARGET, V5, P6633, DOI 10.18632/oncotarget.1955; Fisher JF, 2010, METHODS MOL BIOL, V622, P471, DOI 10.1007/978-1-60327-299-5_27; Forbes C, 2009, CHEM BIOL DRUG DES, V74, P527, DOI 10.1111/j.1747-0285.2009.00881.x; Gao M, 2016, ACS CHEM NEUROSCI, V7, P1482, DOI 10.1021/acschemneuro.6b00217; Gao M, 2015, P NATL ACAD SCI USA, V112, P15226, DOI 10.1073/pnas.1517847112; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; Gooyit M., 2015, SCAFFOLDS MED CHEM, P262; Gooyit M.D., 2013, GELATINASE INHIBITIO; Gooyit M, 2014, ACS CHEM BIOL, V9, P105, DOI 10.1021/cb4005468; Gooyit M, 2013, J MED CHEM, V56, P8139, DOI 10.1021/jm401217d; Gooyit M, 2012, ACS CHEM NEUROSCI, V3, P730, DOI 10.1021/cn300062w; Gooyit M, 2011, J MED CHEM, V54, P6676, DOI 10.1021/jm200566e; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Guo JL, 2012, ONCOL REP, V28, P1709, DOI 10.3892/or.2012.2003; Guo ZD, 2010, NEUROL RES, V32, P715, DOI 10.1179/016164109X12478302362491; Gutierrez-Fernandez A, 2007, FASEB J, V21, P2580, DOI 10.1096/fj.06-7860com; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; He ZJ, 2009, CHINESE MED J-PEKING, V122, P2346, DOI 10.3760/cma.j.issn.0366-6999.2009.19.029; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hesek D, 2006, CHEM BIOL, V13, P379, DOI 10.1016/j.chembiol.2006.01.012; Hesek D, 2006, J ORG CHEM, V71, P5848, DOI 10.1021/jo060058h; Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993-06.2006; I.Af.RoCancer, 2014, WORLD CANC REPORT 20; Ikejiri M, 2005, J BIOL CHEM, V280, P33992, DOI 10.1074/jbc.M504303200; Ikejiri M, 2005, J ORG CHEM, V70, P5709, DOI 10.1021/jo050339+; Johnson JL, 2011, ARTERIOSCL THROM VAS, V31, P528, DOI 10.1161/ATVBAHA.110.219147; Johnson JL, 2005, P NATL ACAD SCI USA, V102, P15575, DOI 10.1073/pnas.0506201102; Jorissen E, 2010, J NEUROSCI, V30, P4833, DOI 10.1523/JNEUROSCI.5221-09.2010; Kaneko K, 2016, ARTHRITIS RHEUMATOL, V68, P521, DOI 10.1002/art.39414; Kawahara R, 2017, J PROTEOMICS, V151, P53, DOI 10.1016/j.jprot.2016.08.017; Kehrli P, 1999, NEUROCHIRURGIE, V45, P357; Kruger A, 2005, CANCER RES, V65, P3523, DOI 10.1158/0008-5472.CAN-04-3570; Lafleur MA, 2001, BIOCHEM J, V357, P107, DOI 10.1042/0264-6021:3570107; Lazaro JL, 2016, J WOUND CARE, V25, P277, DOI 10.12968/jowc.2016.25.5.277; Lee M, 2007, CHEM BIOL DRUG DES, V70, P371, DOI 10.1111/j.1747-0285.2007.00577.x; Lee M, 2015, ACS CHEM NEUROSCI, V6, P1658, DOI 10.1021/acschemneuro.5b00140; Lee M, 2012, ACS MED CHEM LETT, V3, P490, DOI 10.1021/ml300050b; Lee M, 2009, CHEM BIOL DRUG DES, V73, P189, DOI 10.1111/j.1747-0285.2008.00750.x; Liu Y, 2009, DIABETES CARE, V32, P117, DOI 10.2337/dc09-1394; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lobmann R, 2002, DIABETOLOGIA, V45, P1011, DOI 10.1007/s00125-002-0868-8; Luplerdlop N, 2006, EMBO REP, V7, P1176, DOI 10.1038/sj.embor.7400814; Marchant DJ, 2014, NAT MED, V20, P497, DOI 10.1038/nm.3508; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Martin MD, 2008, CANCER RES, V68, P6251, DOI 10.1158/0008-5472.CAN-08-0537; Marusak C, 2016, PHARMACOL RES, V113, P515, DOI 10.1016/j.phrs.2016.09.033; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; Mochizuki S, 2007, CANCER SCI, V98, P621, DOI 10.1111/j.1349-7006.2007.00434.x; Mohan V., 2016, MEDICINE, V3, P31, DOI 10.2147/mnm.s65143; Mohanan V, 2013, CLIN EXP METASTAS, V30, P507, DOI 10.1007/s10585-012-9555-4; Morbach S, 2012, DIABETES CARE, V35, P2021, DOI 10.2337/dc12-0200; Mozaffarian D, 2015, HEART DIS STROKE STA; Mullooly M, 2015, BRIT J CANCER, V113, P945, DOI 10.1038/bjc.2015.288; Nayak L, 2012, CURR ONCOL REP, V14, P48, DOI 10.1007/s11912-011-0203-y; Nguyen M, 2000, J BIOL CHEM, V275, P9095, DOI 10.1074/jbc.275.13.9095; Nieder C, 2011, CANCER-AM CANCER SOC, V117, P2505, DOI 10.1002/cncr.25707; Noble LJ, 2002, J NEUROSCI, V22, P7526; Nuti E, 2007, CURR PHARM DESIGN, V13, P2087; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Ota R, 2009, J CEREBR BLOOD F MET, V29, P1547, DOI 10.1038/jcbfm.2009.77; Otrock ZK, 2007, BLOOD CELL MOL DIS, V39, P212, DOI 10.1016/j.bcmd.2007.04.001; Pajouhesh Hassan, 2005, NeuroRx, V2, P541, DOI 10.1602/neurorx.2.4.541; Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013; Pirila E., WOUND REPAIR; Pochetti G, 2009, J MED CHEM, V52, P1040, DOI 10.1021/jm801166j; Rice JB, 2014, DIABETES CARE, V37, P651, DOI 10.2337/dc13-2176; Rocks N, 2008, BIOCHIMIE, V90, P369, DOI 10.1016/j.biochi.2007.08.008; Rodriguez D, 2010, BBA-MOL CELL RES, V1803, P39, DOI 10.1016/j.bbamcr.2009.09.015; Saftig P, 2011, EUR J CELL BIOL, V90, P527, DOI 10.1016/j.ejcb.2010.11.005; Saghatelian A, 2004, P NATL ACAD SCI USA, V101, P10000, DOI 10.1073/pnas.0402784101; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Semple BD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143386; Shaverdashvili K, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12201; Shibui S, 1999, JPN J CLIN ONCOL, V29, P243, DOI 10.1093/jjco/29.5.243; Sifringer M, 2007, NEUROBIOL DIS, V25, P526, DOI 10.1016/j.nbd.2006.10.019; Singh N, 2005, JAMA-J AM MED ASSOC, V293, P217, DOI 10.1001/jama.293.2.217; Skiles JW, 2004, CURR MED CHEM, V11, P2911, DOI 10.2174/0929867043364018; Song W, 2013, ACS CHEM NEUROSCI, V4, P1168, DOI 10.1021/cn400077d; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Tang JP, 2004, J CEREBR BLOOD F MET, V24, P1133, DOI 10.1097/01.WCB.0000135593.05952.DE; Testero SA, 2011, ACS MED CHEM LETT, V2, P177, DOI 10.1021/ml100254e; Dinh T, 2012, DIABETES, V61, P2937, DOI 10.2337/db12-0227; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Trivedi A., 2005, INT J NEUROPROTECT N, V2, P30; Vafadari B, 2016, J NEUROCHEM, V139, P91, DOI 10.1111/jnc.13415; Vandenbroucke RE, 2014, NAT REV DRUG DISCOV, V13, P904, DOI 10.1038/nrd4390; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wilhelm I, 2013, INT J MOL SCI, V14, P1383, DOI 10.3390/ijms14011383; Xie TX, 2006, CANCER RES, V66, P3188, DOI 10.1158/0008-5472.CAN-05-2674; Yan YG, 2015, BIOORGAN MED CHEM, V23, P6632, DOI 10.1016/j.bmc.2015.09.013; Yang Y, 2015, BRAIN RES, V1623, P30, DOI 10.1016/j.brainres.2015.04.024; Yu F, 2008, J NEUROTRAUM, V25, P184, DOI 10.1089/neu.2007.0438; Zhang HQ, 2011, NEUROTHERAPEUTICS, V8, P206, DOI 10.1007/s13311-011-0038-0; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Ziyadeh N, 2011, ADV SKIN WOUND CARE, V24, P31, DOI 10.1097/01.ASW.0000392922.30229.b3; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	131	12	12	1	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-4889	1879-2596		BBA-MOL CELL RES	Biochim. Biophys. Acta-Mol. Cell Res.	NOV	2017	1864	11	A		SI		2001	2014		10.1016/j.bbamcr.2017.04.011			14	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	FK6JN	WOS:000413610100008	28435009	Bronze			2021-06-18	
J	Mishra, VR; Zhuang, XW; Sreenivasan, KR; Banks, SJ; Yang, ZS; Bernick, C; Cordes, D				Mishra, Virendra R.; Zhuang, Xiaowei; Sreenivasan, Karthik R.; Banks, Sarah J.; Yang, Zhengshi; Bernick, Charles; Cordes, Dietmar			Multimodal MR Imaging Signatures of Cognitive Impairment in Active Professional Fighters	RADIOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; MATTER TRACT DAMAGE; WHITE-MATTER; HEAD TRAUMA; DIFFUSION; PERFORMANCE; INFERENCE; FEATURES; BOXERS; MODELS	Purpose: To investigate whether combining multiple magnetic resonance (MR) imaging modalities such as T1-weighted and diffusion-weighted MR imaging could reveal imaging biomarkers associated with cognition in active professional fighters. Materials and Methods: Active professional fighters (n = 297; 24 women and 273 men) were recruited at one center. Sixty-two fighters (six women and 56 men) returned for a follow-up examination. Only men were included in the main analysis of the study. On the basis of computerized testing, fighters were separated into the cognitively impaired and nonimpaired groups on the basis of computerized testing. T1-weighted and diffusion-weighted imaging were performed, and volume and cortical thickness, along with diffusion-derived metrics of 20 major white matter tracts were extracted for every subject. A classifier was designed to identify imaging biomarkers related to cognitive impairment and was tested in the follow-up dataset. Results: The classifier allowed identification of seven imaging biomarkers related to cognitive impairment in the cohort of active professional fighters. Areas under the curve of 0.76 and 0.69 were obtained at baseline and at follow-up, respectively, with the optimized classifier. The number of years of fighting had a significant (P = 8.8 3 10(27)) negative association with fractional anisotropy of the forceps major (effect size [d] = 0.34) and the inferior longitudinal fasciculus (P = .03; d = 0.17). A significant difference was observed between the impaired and nonimpaired groups in the association of fractional anisotropy in the forceps major with number of fights (P = .03, d = 0.38) and years of fighting (P = 6 3 1028, d = 0.63). Fractional anisotropy of the inferior longitudinal fasciculus was positively associated with psychomotor speed (P = .04, d = 0.16) in nonimpaired fighters but no association was observed in impaired fighters. Conclusion: Without enforcement of any a priori assumptions on the MR imaging-derived measurements and with a multivariate approach, the study revealed a set of seven imaging biomarkers that were associated with cognition in active male professional fighters. (C) RSNA, 2017	[Mishra, Virendra R.; Zhuang, Xiaowei; Sreenivasan, Karthik R.; Banks, Sarah J.; Yang, Zhengshi; Bernick, Charles; Cordes, Dietmar] Cleveland Clin Lou Ruvo Ctr Brain Hlth, Dept Imaging Res, 888 W Bonneville Ave, Las Vegas, NV 89106 USA	Mishra, VR (corresponding author), Cleveland Clin Lou Ruvo Ctr Brain Hlth, Dept Imaging Res, 888 W Bonneville Ave, Las Vegas, NV 89106 USA.	mishrav@ccf.org	Yang, Zhengshi/AAM-6739-2021; Mishra, Virendra R./ABE-1942-2020; Sreenivasan, Karthik/ABA-7605-2020	Mishra, Virendra R./0000-0002-0452-6400; Cordes, Dietmar/0000-0001-6574-5546; Banks, Sarah/0000-0001-7536-2370	Lincy Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5P20GM109025 COBRE]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM109025] Funding Source: NIH RePORTER	Study supported by Lincy Foundation and the National Institutes of Health Institutional Development Award (5P20GM109025 COBRE).	Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Bernick C, 2015, BRIT J SPORT MED, V49, P1007, DOI 10.1136/bjsports-2014-093877; Bernick C, 2013, AM J EPIDEMIOL, V178, P280, DOI 10.1093/aje/kws456; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Broomhead D. S., 1988, Complex Systems, V2, P321; Chanraud S, 2010, NEUROPSYCHOL REV, V20, P209, DOI 10.1007/s11065-010-9129-7; Davis A E, 2000, Crit Care Nurs Q, V23, P1; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Draganski B, 2011, NEUROIMAGE, V55, P1423, DOI 10.1016/j.neuroimage.2011.01.052; Dunst B, 2014, BRAIN COGNITION, V91, P71, DOI 10.1016/j.bandc.2014.08.006; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gooijers J, 2016, NEUROREHAB NEURAL RE, V30, P603, DOI 10.1177/1545968315613448; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hartberg CB, 2011, J INT NEUROPSYCH SOC, V17, P1080, DOI 10.1017/S1355617711001081; Hartley T, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00338; Heilbronner RL, 2009, ARCH CLIN NEUROPSYCH, V24, P11, DOI 10.1093/arclin/acp005; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Joel D, 2015, P NATL ACAD SCI USA, V112, P15468, DOI 10.1073/pnas.1509654112; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Keightley ML, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00139; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Lopez-Larson Melissa, 2013, Front Psychiatry, V4, P83, DOI 10.3389/fpsyt.2013.00083; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Meng DW, 2017, RADIOLOGY, V282, P502, DOI 10.1148/radiol.2016152685; Montenigro PH, 2015, BRAIN PATHOL, V25, P304, DOI 10.1111/bpa.12250; Ng TSC, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt239; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Pakkenberg B, 2003, EXP GERONTOL, V38, P95, DOI 10.1016/S0531-5565(02)00151-1; Papoulis A., 1991, PROBABILITY RANDOM V; PAYNE EE, 1968, NEUROCHIRURGIA, V11, P173; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; Sarro L, 2011, AM J NEURORADIOL, V32, P1866, DOI 10.3174/ajnr.A2658; Schinka JA, 2010, AM J GERIAT PSYCHIAT, V18, P684, DOI 10.1097/JGP.0b013e3181e56d5a; Shin W, 2014, AM J NEURORADIOL, V35, P285, DOI 10.3174/ajnr.A3676; Strangman GE, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00182; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Uher T, 2014, J NEUROL, V261, P1735, DOI 10.1007/s00415-014-7413-9; Winkler AM, 2016, NEUROIMAGE, V141, P502, DOI 10.1016/j.neuroimage.2016.05.068; Wintermark M, 2015, AJNR Am J Neuroradiol, V36, pE1, DOI 10.3174/ajnr.A4181; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	49	12	12	0	4	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	NOV	2017	285	2					555	567		10.1148/radiol.2017162403			13	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	FK4NL	WOS:000413472000023	28741982	Bronze, Green Published			2021-06-18	
J	Rau, CS; Wu, SC; Chen, YC; Chien, PC; Hsieh, HY; Kuo, PJ; Hsieh, CH				Rau, Cheng-Shyuan; Wu, Shao-Chun; Chen, Yi-Chun; Chien, Peng-Chen; Hsieh, Hsiao-Yun; Kuo, Pao-Jen; Hsieh, Ching-Hua			Effect of Age on Glasgow Coma Scale in Patients with Moderate and Severe Traumatic Brain Injury: An Approach with Propensity Score-Matched Population	INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH			English	Article						traumatic brain injury (TBI); Glasgow Coma Scale (GCS); age; elderly; propensity-score matching	HEAD-INJURY; MOTOR SCORE; MANAGEMENT; MORTALITY; HYPONATREMIA; PREDICTOR; DISEASE; IMPACT; TRIAL	Background: The most widely used methods of describing traumatic brain injury (TBI) are the Glasgow Coma Scale (GCS) and the Abbreviated Injury Scale (AIS). Recent evidence suggests that presenting GCS in older patients may be higher than that in younger patients for an equivalent anatomical severity of TBI. This study aimed to assess these observations with a propensity-score matching approach using the data from Trauma Registry System in a Level I trauma center. Methods: We included all adult patients (aged 20 years old) with moderate to severe TBI from 1 January 2009 to 31 December 2016. Patients were categorized into elderly (aged 65 years) and young adults (aged 20-64 years). The severity of TBI was defined by an AIS score in the head (AIS 34 and 5 indicate moderate and severe TBI, respectively). We examined the differences in the GCS scores by age at each head AIS score. Unpaired Student's t- and Mann-Whitney U-tests were used to analyze normally and non-normally distributed continuous data, respectively. Categorical data were compared using either the Pearson chi-square or two-sided Fisher's exact tests. Matched patient populations were allocated in a 1:1 ratio according to the propensity scores calculated using NCSS software with the following covariates: sex, pre-existing chronic obstructive pulmonary disease, systolic blood pressure, hemoglobin, sodium, glucose, and alcohol level. Logistic regression was used to evaluate the effects of age on the GCS score in each head AIS stratum. Results: The study population included 2081 adult patients with moderate to severe TBI. These patients were categorized into elderly (n = 847) and young adults (n = 1234): each was exclusively further divided into three groups of patients with head AIS of 3, 4, or 5. In the 162 well-balanced pairs of TBI patients with head AIS of 3, the elderly demonstrated a significantly higher GCS score than the young adults (14.1 +/- 2.2 vs. 13.1 +/- 3.3, respectively; p = 0.002). In the 362 well-balanced pairs of TBI patients with head AIS of 4, the elderly showed a significantly higher GCS score than the young adults (13.1 +/- 3.3 vs. 12.2 +/- 3.8, respectively; p = 0.002). In the 89 well-balance pairs of TBI patients with head AIS of 5, no significant differences were observed for the GCS scores. Conclusions: This study demonstrated that elderly patients with moderate TBI present higher GCS score than younger patients. This study underscores the importance of determining of TBI severity in this group of elderly patients based on the GCS score alone. A lower threshold of GCS cutoff should be adopted in the management of the elderly patients with TBI.	[Rau, Cheng-Shyuan] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Neurosurg, Kaohsiung 83301, Taiwan; [Wu, Shao-Chun] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Anesthesiol, Kaohsiung 83301, Taiwan; [Chen, Yi-Chun; Chien, Peng-Chen; Hsieh, Hsiao-Yun; Kuo, Pao-Jen; Hsieh, Ching-Hua] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Plast Surg, Kaohsiung 83301, Taiwan	Hsieh, CH (corresponding author), Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Plast Surg, Kaohsiung 83301, Taiwan.	ersh2127@cloud.cgmh.org.tw; shaochunwu@gmail.com; libe320@yahoo.com.tw; VENU_CHIEN@hotmail.com; sylvia19870714@hotmail.com; bow110470@gmail.com; m93chinghua@gmail.com		WU, Shaochun/0000-0002-0984-6921; Hsieh, Ching-Hua/0000-0002-0945-2746	 [CMRPG8F0261]	We would like to extend our gratitude to the Biostatistics Center of Kaohsiung Chang Gung Memorial Hospital for their assistance with statistical analyses. This research was supported by a grant from CMRPG8F0261.	Bledsoe BE, 2015, PREHOSP DISASTER MED, V30, P46, DOI 10.1017/S1049023X14001289; Brady WJ, 1999, AM J EMERG MED, V17, P4, DOI 10.1016/S0735-6757(99)90002-5; Caterino JM, 2011, ACAD EMERG MED, V18, P1014, DOI 10.1111/j.1553-2712.2011.01164.x; Ciccone MM, 2010, VASC HEALTH RISK MAN, V6, P297; CoMAoA, 1971, JAMA-J AM MED ASSOC, V215, P277; Dhandapani SS, 2012, J NEUROSCI RURAL PRA, V3, P131, DOI 10.4103/0976-3147.98208; Feldman A, 2015, ANN EMERG MED, V65, P325, DOI 10.1016/j.annemergmed.2014.07.454; Fu TS, 2015, J TRAUMA ACUTE CARE, V79, P449, DOI 10.1097/TA.0000000000000733; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Hsieh CH, 2017, BIOMED J, V40, P113, DOI 10.1016/j.bj.2016.10.005; Hsieh CH, 2017, BIOMED J, V40, P121, DOI 10.1016/j.bj.2016.10.006; Huang CY, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13020236; Karnath B, 2004, GERIATRICS, V59, P18; Kehoe A, 2016, EMERG MED J, V33, P381, DOI 10.1136/emermed-2015-205180; Kehoe A, 2015, EMERG MED J, V32, P613, DOI 10.1136/emermed-2013-203488; Kotera A, 2014, J INTENSIVE CARE, V2, DOI 10.1186/2052-0492-2-1; Lai WH, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13040357; Lohani S, 2011, WORLD NEUROSURG, V76, P355, DOI 10.1016/j.wneu.2011.03.042; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; McNett Molly, 2007, J Neurosci Nurs, V39, P68; Meng XF, 2016, J NEUROSURG ANESTH, V28, P21, DOI 10.1097/ANA.0000000000000192; Moore L, 2006, J TRAUMA, V60, P1238, DOI 10.1097/01.ta.0000195593.60245.80; Moore MM, 2012, J TRAUMA ACUTE CARE, V73, P126, DOI 10.1097/TA.0b013e31824b01af; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Osler T, 2016, INJURY, V47, P1879, DOI 10.1016/j.injury.2016.04.016; Potter D, 2013, J R Nav Med Serv, V99, P16; Ronning P, 2015, BRAIN INJURY, V29, P1648, DOI 10.3109/02699052.2015.1075154; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Salottolo K, 2014, JAMA SURG, V149, P727, DOI 10.1001/jamasurg.2014.13; Savitsky B, 2016, BRAIN INJURY, V30, P1194, DOI 10.1080/02699052.2016.1187290; Sekhon MS, 2012, CRIT CARE, V16, DOI 10.1186/cc11431; Sheridan PL, 2007, DEMENT GERIATR COGN, V24, P125, DOI 10.1159/000105126; Singh B, 2013, BRAIN INJURY, V27, P293, DOI 10.3109/02699052.2012.743182; Smith Bryce D., 2012, Morbidity and Mortality Weekly Report, V61, P1; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Wells AR, 2013, POPUL HEALTH MANAG, V16, P35, DOI 10.1089/pop.2011.0104; Wu X, 2015, INJURY, V46, P35, DOI 10.1016/j.injury.2014.08.002; Yee KF, 2016, CAN RESPIR J, V2016, DOI 10.1155/2016/6803860	42	12	12	0	5	MDPI AG	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1660-4601			INT J ENV RES PUB HE	Int. J. Environ. Res. Public Health	NOV	2017	14	11							1378	10.3390/ijerph14111378			12	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	FO1SQ	WOS:000416545200094	29137197	DOAJ Gold, Green Published			2021-06-18	
J	Wilson, SL; Gangathimmaiah, V				Wilson, Stephanie Laura; Gangathimmaiah, Vinay			Does prehospital management by doctors affect outcome in major trauma? A systematic review	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	33rd Annual Meeting of the Australasian-College-of-Emergency-Medicine	NOV 20-24, 2016	Queenstown, NEW ZEALAND	Australasian Coll Emergency Med		Prehospital; trauma; physician; mortality; disability	RAPID-SEQUENCE INTUBATION; SEVERELY INJURED PATIENTS; EMERGENCY MEDICAL-SERVICES; QUALITY-OF-LIFE; BRAIN-INJURY; ENDOTRACHEAL INTUBATION; SEVERITY SCORE; BLUNT TRAUMA; CARE; PHYSICIAN	BACKGROUND: There is substantial variation worldwide in prehospital management of trauma and the role of doctors is controversial. The objective of this review was to determine whether prehospital management by doctors affects outcomes in major trauma, including the prespecified subgroup of severe traumatic brain injuries when compared with management by other advanced life support providers. METHODS: EMBASE, MEDLINE(R), PubMed, SciELO, Trip, Web of Science, and Zetoc were searched for published articles. HSRProj, OpenGrey, and the World Health Organization International Clinical Trials Registry Platform were searched for unpublished data. Relevant reference lists were hand-searched. There were no limits on publication year, but articles were limited to the English language. Authors were contacted for further information as required. Quality was assessed using the Downs and Black criteria. Mortality was the primary outcome, and disability was the secondary outcome of interest. Studies were subjected to a descriptive analysis alone without a meta-analysis due to significant study heterogeneity. All searches, quality assessment, data abstraction, and data analysis was performed by two reviewers independently. RESULTS: Two thousand thirty-seven articles were identified, 49 full-text articles assessed and eight studies included. The included studies consisted of one randomized controlled trial with 375 participants and seven observational studies with over 4,451 participants. All included studies were at a moderate to high risk of bias. Six of the eight included studies showed an improved outcome with prehospital management by doctors, five in terms of mortality and one in terms of disability. Two studies found no significant difference. CONCLUSION: There appears to be an association between prehospital management by doctors and improved survival in major trauma. There may also be an association with improved survival and better functional outcomes in severe traumatic brain injury. Further high-quality evidence is needed to confirm these findings. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.	[Wilson, Stephanie Laura] Townsville Hosp, Emergency Dept, Townsville Base, Qld, Australia; [Gangathimmaiah, Vinay] Lifeflight Retrieval Med, Townsville Base, Qld, Australia	Wilson, SL (corresponding author), Townsville Hosp, Emergency Dept, Townsville Base, Qld, Australia.	stephanielaurawilson@gmail.com		Wilson, Stephanie/0000-0002-9559-9276			Anke AGW, 2003, CLIN REHABIL, V17, P431, DOI 10.1191/0269215503cr629oa; Apodaca A, 2013, J TRAUMA ACUTE CARE, V75, pS157, DOI 10.1097/TA.0b013e318299da3e; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015; BAXT WG, 1987, JAMA-J AM MED ASSOC, V257, P3246, DOI 10.1001/jama.257.23.3246; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Bieler D, 2017, INJURY, V48, P32, DOI 10.1016/j.injury.2016.08.015; Botker MT, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-12; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Cameron PA, 2008, MED J AUSTRALIA, V189, P546, DOI 10.5694/j.1326-5377.2008.tb02176.x; CHAMPION HR, 1995, J TRAUMA, V38, P94, DOI 10.1097/00005373-199501000-00024; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; Chesters A, 2016, TRAUMA, V18, P124, DOI 10.1177/1460408615619197; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Clinical Quality and Patient Safety Unit Queensland Ambulance Service, 2016, CLIN PRACT GUID TRAU; Crewdson K, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1603-7; Curtis KA, 2012, MED J AUSTRALIA, V197, P233, DOI 10.5694/mja11.11351; Davies GE, 2011, J TRAUMA, V70, pE75, DOI 10.1097/TA.0b013e3181f6f72f; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Ellis DY, 2007, EMERG MED J, V24, P139, DOI 10.1136/emj.2006.040428; Evans SA, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-8; Frankema SPG, 2004, BRIT J SURG, V91, P1520, DOI 10.1002/bjs.4756; Franschman G, 2013, INJURY, V44, P1232, DOI 10.1016/j.injury.2013.06.002; Franschman G, 2012, INJURY, V43, P1838, DOI 10.1016/j.injury.2012.05.020; Gabbe BJ, 2012, ANN SURG, V255, P1009, DOI 10.1097/SLA.0b013e31824c4b91; Galvagno SM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009228.pub3; Garner A, 1999, AUST NZ J SURG, V69, P697, DOI 10.1046/j.1440-1622.1999.01688.x; Garner Alan A, 2004, Emerg Med Australas, V16, P318, DOI 10.1111/j.1742-6723.2004.00636.x; Garner AA, 2015, EMERG MED J, V32, P869, DOI 10.1136/emermed-2014-204390; Halcomb Elizabeth, 2005, Aust Crit Care, V18, P17, DOI 10.1016/S1036-7314(05)80020-7; Hubble MW, 2010, PREHOSP EMERG CARE, V14, P377, DOI 10.3109/10903121003790173; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; JENNETT B, 1975, LANCET, V1, P480; Lossius HM, 2012, CRIT CARE, V16, DOI 10.1186/cc11189; MacDonald Russell D, 2015, Air Med J, V34, P134, DOI 10.1016/j.amj.2015.02.004; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Morris S, 2000, J TRAUMA, V49, P461, DOI 10.1097/00005373-200009000-00013; Open Grey, SYST INF GREY LIT EU; Oppe S, 2001, ACCIDENT ANAL PREV, V33, P129, DOI 10.1016/S0001-4575(00)00023-3; Pakkanen T, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0256-x; Post RB, 2006, DISABIL REHABIL, V28, P1399, DOI 10.1080/09638280600641392; Potter D, 2013, J R Nav Med Serv, V99, P16; Rinburg AN, 2009, BRIT J SURG, V96, P1365, DOI 10.1002/bjs.6720; Ringburg AN, 2011, J TRAUMA, V70, P916, DOI 10.1097/TA.0b013e3181f6bce8; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Roudsari BS, 2007, INJURY, V38, P993, DOI 10.1016/j.injury.2007.03.028; Roudsari BS, 2007, INJURY, V38, P1001, DOI 10.1016/j.injury.2007.04.008; Royal Australasian College of Surgeons NZ Trauma Committee, 2012, GUID STRUCT APPR PRO; Sasser S., 2005, PREHOSPITAL TRAUMA C; South Western Ambulance Service, 2014, TRAUM CAR ACC TRAUM; Strote J, 2009, AM J EMERG MED, V27, P1142, DOI 10.1016/j.ajem.2008.08.011; US National Library of Medicine, HLTH SERV RES PROJ P; W.H. Organization, GLOB STAT REP ROAD S; Wang Henry E, 2005, Prehosp Emerg Care, V9, P156; Warner KJ, 2010, PREHOSP EMERG CARE, V14, P103, DOI 10.3109/10903120903144858; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; World Health Organization website, INT CLIN TRIALS REG	60	12	12	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	NOV	2017	83	5					965	974		10.1097/TA.0000000000001559			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	FP2IO	WOS:000417440900033	28590350				2021-06-18	
J	Wang, C; Costanzo, ME; Rapp, PE; Darmon, D; Nathan, DE; Bashirelahi, K; Pham, DL; Roy, MJ; Keyser, DO				Wang, Chao; Costanzo, Michelle E.; Rapp, Paul E.; Darmon, David; Nathan, Dominic E.; Bashirelahi, Kylee; Pham, Dzung L.; Roy, Michael J.; Keyser, David O.			Disrupted gamma synchrony after Mild Traumatic Brain injury and its correlation with White Matter abnormality	FRONTIERS IN NEUROLOGY			English	Article						mild traumatic brain injury; EEG; neural synchronization; functional connectivity; white matter integrity	FUNCTIONAL CONNECTIVITY; PHASE-SYNCHRONIZATION; CONSCIOUS PERCEPTION; CEREBELLAR CIRCUITRY; COGNITIVE DYSMETRIA; NEURONAL COHERENCE; VOLUME-CONDUCTION; NEURAL ACTIVITY; AXONAL INJURY; ACUTE STAGE	Mild traumatic brain injury (mTBI) has been firmly associated with disrupted white matter integrity due to induced white matter damage and degeneration. However, comparatively less is known about the changes of the intrinsic functional connectivity mediated via neural synchronization in the brain after mTBI. Moreover, despite the presumed link between structural and functional connectivity, no existing studies in mTBI have demonstrated clear association between the structural abnormality of white matter axons and the disruption of neural synchronization. To investigate these questions, we recorded resting state EEG and diffusion tensor imaging (DTI) from a cohort of military service members. A newly developed synchronization measure, the weighted phase lag index was applied on the EEG data for estimating neural synchronization. Fractional anisotropy was computed from the DTI data for estimating white matter integrity. Fifteen service members with a history of mTBI within the past 3 years were compared to 22 demographically similar controls who reported no history of head injury. We observed that synchronization at low-gamma frequency band (25-40 Hz) across scalp regions was significantly decreased in mTBI cases compared with controls. The synchronization in theta (4-7 Hz), alpha (8-13 Hz), and beta (15-23 Hz) frequency bands were not significantly different between the two groups. In addition, we found that across mTBI cases, the disrupted synchronization at low-gamma frequency was significantly correlated with the white matter integrity of the inferior cerebellar peduncle, which was also significantly reduced in the mTBI group. These findings demonstrate an initial correlation between the impairment of white matter integrity and alterations in EEG synchronization in the brain after mTBI. The results also suggest that disruption of intrinsic neural synchronization at low-gamma frequency may be a characteristic functional pathology following mTBI and may prove useful for developing better methods of diagnosis and treatment.	[Wang, Chao; Rapp, Paul E.; Darmon, David; Nathan, Dominic E.; Bashirelahi, Kylee; Keyser, David O.] Uniformed Serv Univ Hlth Sci, Dept Mil & Emergency Med, Traumat Injury Res Program, Bethesda, MD 20814 USA; [Wang, Chao; Costanzo, Michelle E.; Darmon, David; Nathan, Dominic E.; Bashirelahi, Kylee] Mil Med Inc, Henry M Jackson Fdn Adv, Bethesda, MD 20889 USA; [Costanzo, Michelle E.; Roy, Michael J.] Uniformed Serv Univ Hlth Sci, Dept Med, Room A3060, Bethesda, MD 20814 USA; [Nathan, Dominic E.] Uniformed Serv Univ Hlth Sci, Grad Sch Nursing, Bethesda, MD 20814 USA; [Pham, Dzung L.] Mil Med Inc, Henry M Jackson Fdn Adv, Ctr Neurosci & Regenerat Med, Bethesda, MD USA	Wang, C (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Mil & Emergency Med, Traumat Injury Res Program, Bethesda, MD 20814 USA.; Wang, C (corresponding author), Mil Med Inc, Henry M Jackson Fdn Adv, Bethesda, MD 20889 USA.	chaowang.ufl@gmail.com	Pham, Dzung/AAR-8263-2020; Wang, Chao/M-3165-2016	Wang, Chao/0000-0002-1313-2569	Department of Defense Center for Neuroscience and Regenerative Medicine [3006018.0160855510005]; Non-Invasive Neuro-Assessment Device (NINAD) Test and Evaluation Support Group from US Army Medical Research and Materiel Command [MEM-91-2714]; Development of Predictive Models and Analytic Strategies,from the US Army medical Research and Materiel Command [MEM-91-3097]	Funds for this effort came from the Department of Defense Center for Neuroscience and Regenerative Medicine 3006018.0160855510005, the Non-Invasive Neuro-Assessment Device (NINAD) Test and Evaluation Support Group MEM-91-2714 from US Army Medical Research and Materiel Command, and Development of Predictive Models and Analytic Strategies, MEM-91-3097 from the US Army medical Research and Materiel Command. Any opinions or assertions expressed are those of the authors and do not necessarily reflect the official policy or position of Uniformed Services University, the US Army, US Navy, Department of Defense, or the US Government.	Alhilali LM, 2014, RADIOLOGY, V272, P224, DOI 10.1148/radiol.14132670; Andreasen NC, 1996, P NATL ACAD SCI USA, V93, P9985, DOI 10.1073/pnas.93.18.9985; Andreasen NC, 1998, SCHIZOPHRENIA BULL, V24, P203, DOI 10.1093/oxfordjournals.schbul.a033321; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bazin PL, 2011, NEUROIMAGE, V58, P458, DOI 10.1016/j.neuroimage.2011.06.020; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; BRESSLER SL, 1995, BRAIN RES REV, V20, P288, DOI 10.1016/0165-0173(94)00016-I; Bressler SL, 2010, TRENDS COGN SCI, V14, P277, DOI 10.1016/j.tics.2010.04.004; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Croft RJ, 1998, ELECTROEN CLIN NEURO, V107, P387, DOI 10.1016/S0013-4694(98)00086-8; Dimitriadis SI, 2015, NEUROIMAGE-CLIN, V9, P519, DOI 10.1016/j.nicl.2015.09.011; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Fell J, 2011, NAT REV NEUROSCI, V12, P105, DOI 10.1038/nrn2979; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; French L., 2008, J SPEC OPER MED, V8, P68; Fries P, 2005, TRENDS COGN SCI, V9, P474, DOI 10.1016/j.tics.2005.08.011; Fries P, 2007, TRENDS NEUROSCI, V30, P309, DOI 10.1016/j.tins.2007.05.005; Gregoriou GG, 2009, SCIENCE, V324, P1207, DOI 10.1126/science.1171402; Hayes JP, 2015, NEUROIMAGE-CLIN, V8, P148, DOI 10.1016/j.nicl.2015.04.001; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoshino S, 2003, NEUROL MED-CHIR, V43, P165, DOI 10.2176/nmc.43.165; HOUK JC, 2003, FUNDAMENTAL NEUROSCI, P841; Iraji A, 2016, NEUROIMAGE-CLIN, V12, P100, DOI 10.1016/j.nicl.2016.06.012; Iraji A, 2015, J NEUROTRAUM, V32, P1031, DOI 10.1089/neu.2014.3610; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kaminski M, 2001, BIOL CYBERN, V85, P145, DOI 10.1007/s004220000235; Kopell N, 2000, P NATL ACAD SCI USA, V97, P1867, DOI 10.1073/pnas.97.4.1867; Landman BA, 2013, NEUROINFORMATICS, V11, P91, DOI 10.1007/s12021-012-9159-9; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee KH, 2003, BRAIN RES REV, V41, P57, DOI 10.1016/S0165-0173(02)00220-5; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Meabon JS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaa9585; Melloni L, 2007, J NEUROSCI, V27, P2858, DOI 10.1523/JNEUROSCI.4623-06.2007; Miltner WHR, 1999, NATURE, V397, P434, DOI 10.1038/17126; Mori S., 2005, MRI ATLAS HUMAN WHIT; Nolte G, 2004, CLIN NEUROPHYSIOL, V115, P2292, DOI 10.1016/j.clinph.2004.04.029; Nunez PL, 1997, ELECTROEN CLIN NEURO, V103, P499, DOI 10.1016/S0013-4694(97)00066-7; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pang EW, 2016, ANN CLIN TRANSL NEUR, V3, P124, DOI 10.1002/acn3.280; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Popa D, 2013, J NEUROSCI, V33, P6552, DOI 10.1523/JNEUROSCI.5521-12.2013; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Senkowski D, 2008, TRENDS NEUROSCI, V31, P401, DOI 10.1016/j.tins.2008.05.002; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100108-02, 10.3928/02793695-20100107-01]; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Srinivasan R, 1999, J NEUROSCI, V19, P5435; Stam CJ, 2007, HUM BRAIN MAPP, V28, P1178, DOI 10.1002/hbm.20346; Steriade M, 2000, NEUROSCIENCE, V101, P243, DOI 10.1016/S0306-4522(00)00353-5; Tarapore PE, 2013, J NEUROSURG, V118, P1306, DOI 10.3171/2013.3.JNS12398; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; Uhlhaas PJ, 2010, NAT REV NEUROSCI, V11, P100, DOI 10.1038/nrn2774; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; Veraart J, 2011, MAGN RESON MED, V65, P138, DOI 10.1002/mrm.22603; Vinck M, 2011, NEUROIMAGE, V55, P1548, DOI 10.1016/j.neuroimage.2011.01.055; von Stein A, 2000, INT J PSYCHOPHYSIOL, V38, P301, DOI 10.1016/S0167-8760(00)00172-0; Wang C, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00071; Wang C, 2016, J NEUROSCI, V36, P3919, DOI 10.1523/JNEUROSCI.3652-15.2016; Wang C, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00015; Wang ZQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151489; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Womelsdorf T, 2006, J PHYSIOL-PARIS, V100, P182, DOI 10.1016/j.jphysparis.2007.01.005; Womelsdorf T, 2007, SCIENCE, V316, P1609, DOI [10.1126/science.1139597, 10.1126/science.1139178]	74	12	12	0	5	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	OCT 30	2017	8								571	10.3389/fneur.2017.00571			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FL1EU	WOS:000413958100004	29163337	DOAJ Gold, Green Published			2021-06-18	
J	Liu, CC; Hajra, SG; Cheung, TPL; Song, XW; D'Arcy, RCN				Liu, Careesa C.; Hajra, Sujoy Gosh; Cheung, Teresa P. L.; Song, Xiaowei; D'Arcy, Ryan C. N.			Spontaneous Blinks Activate the Precuneus: Characterizing Blink-Related Oscillations Using Magnetoencephalography	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						blink; blink-related oscillations; precuneus; environmental monitoring; awareness; magnetoencephalography	DEFAULT-MODE NETWORK; TRAUMATIC BRAIN-INJURY; EYE BLINKING; RESTING-STATE; FUNCTIONAL CONNECTIVITY; STRUCTURAL CONNECTIVITY; DELTA OSCILLATIONS; VISUAL SUPPRESSION; CINGULATE CORTEX; EYEBLINKS	Spontaneous blinking occurs 15-20 times per minute. Although blinking has often been associated with its physiological role of corneal lubrication, there is now increasing behavioral evidence suggesting that blinks are also modulated by cognitive processes such as attention and information processing. Recent low-density electroencephalography (EEG) studies have reported so-called blink-related oscillations (BROs) associated with spontaneous blinking at rest. Delta-band (0.5-4Hz) BROs are thought to originate from the precuneus region involved in environmental monitoring and awareness, with potential clinical utility in evaluation of disorders of consciousness. However, the neural mechanisms of BROs have not been elucidated. Using magnetoencephalography (MEG), we characterized delta-band BROs in 36 healthy individuals while controlling for background brain activity. Results showed that, compared to pre-blink baseline, delta-band BROs resulted in increased global field power (p < 0.001) and time-frequency spectral power (p < 0.05) at the sensor level, peaking at similar to 250ms post-blink maximum. Source localization showed that spontaneous blinks activated the bilateral precuneus (p < 0.05 FWE), and source activity within the precuneus was also consistent with sensor-space results. Crucially, these effects were only observed in the blink condition and were absent in the control condition, demonstrating that results were due to spontaneous blinks rather than as part of the inherent brain activity. The current study represents the first MEG examination of BROs. Our findings suggest that spontaneous blinks activate the precuneus regions consistent with environmental monitoring and awareness, and provide important neuroimaging support for the cognitive role of spontaneous blinks.	[Liu, Careesa C.; Hajra, Sujoy Gosh; Cheung, Teresa P. L.; D'Arcy, Ryan C. N.] Simon Fraser Univ, Sch Engn Sci, Burnaby, BC, Canada; [Cheung, Teresa P. L.; Song, Xiaowei; D'Arcy, Ryan C. N.] Fraser Hlth Author, Surrey Mem Hosp, Hlth Sci & Innovat, Surrey, BC, Canada	D'Arcy, RCN (corresponding author), Simon Fraser Univ, Sch Engn Sci, Burnaby, BC, Canada.; D'Arcy, RCN (corresponding author), Fraser Hlth Author, Surrey Mem Hosp, Hlth Sci & Innovat, Surrey, BC, Canada.	rdarcy@sfu.ca		Ghosh Hajra, Sujoy/0000-0002-8347-6578	Surrey Memorial Hospital Foundation; Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR [RGPIN-2015-04018]; Canadian Institutes for Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [GSD-140381]	This study was funded by a grant from the Surrey Memorial Hospital Foundation and the Natural Sciences and Engineering Research Council of Canada (Grant #RGPIN-2015-04018). CL is supported by a scholarship from the Canadian Institutes for Health Research (CIHR, Grant # GSD-140381).	Andrews-Hanna JR, 2012, NEUROSCIENTIST, V18, P251, DOI 10.1177/1073858411403316; Barbato G, 2000, PSYCHIAT RES, V93, P145, DOI 10.1016/S0165-1781(00)00108-6; Bardouille T, 2006, CLIN NEUROPHYSIOL, V117, P952, DOI 10.1016/j.clinph.2006.01.021; Bentivoglio AR, 1997, MOVEMENT DISORD, V12, P1028, DOI 10.1002/mds.870120629; Berman BD, 2012, NEUROIMAGE, V59, P1441, DOI 10.1016/j.neuroimage.2011.08.050; Bethmann A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047626; Bodis-Wollner I, 1999, NEUROLOGY, V53, P1800, DOI 10.1212/WNL.53.8.1800; Bologna M, 2013, J NEUROL NEUROSUR PS, V84, P681, DOI 10.1136/jnnp-2012-303993; Boly M, 2009, HUM BRAIN MAPP, V30, P2393, DOI 10.1002/hbm.20672; Boly M, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00625; Bonfiglio L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093252; Bonfiglio L, 2013, HUM BRAIN MAPP, V34, P2178, DOI 10.1002/hbm.22056; Bonfiglio L, 2011, INT J PSYCHOPHYSIOL, V80, P44, DOI 10.1016/j.ijpsycho.2011.01.002; Bonfiglio L, 2009, NEUROSCI LETT, V449, P57, DOI 10.1016/j.neulet.2008.10.039; Bristow D, 2005, NEUROIMAGE, V27, P136, DOI 10.1016/j.neuroimage.2005.03.037; Bristow D, 2005, CURR BIOL, V15, P1296, DOI 10.1016/j.cub.2005.06.025; Brookes MJ, 2011, NEUROIMAGE, V56, P1082, DOI 10.1016/j.neuroimage.2011.02.054; Brunet D, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/813870; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Chan K K S, 2010, East Asian Arch Psychiatry, V20, P174; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Crone JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026373; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; DEJONG PJ, 1990, INT J NEUROSCI, V51, P89, DOI 10.3109/00207459009000513; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Farrer C, 2002, NEUROIMAGE, V15, P596, DOI 10.1006/nimg.2001.1009; Fransson P, 2008, NEUROIMAGE, V42, P1178, DOI 10.1016/j.neuroimage.2008.05.059; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Gilboa A, 2004, CEREB CORTEX, V14, P1214, DOI 10.1093/cercor/bhh082; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; HALL A, 1945, BRIT J OPHTHALMOL, V29, P445, DOI 10.1136/bjo.29.9.445; HARI R, 1994, NATURE, V367, P121, DOI 10.1038/367121b0; Hauk O, 2004, NEUROIMAGE, V21, P1612, DOI 10.1016/j.neuroimage.2003.12.018; Hebart MN, 2012, J NEUROSCI, V32, P8107, DOI 10.1523/JNEUROSCI.1462-12.2012; HEUSERLINK M, 1992, NEUROSCI LETT, V143, P31, DOI 10.1016/0304-3940(92)90226-W; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Hillebrand A, 2005, HUM BRAIN MAPP, V25, P199, DOI 10.1002/hbm.20102; Hupe JM, 2012, NEUROIMAGE, V61, P149, DOI 10.1016/j.neuroimage.2012.03.001; Kato M, 2003, NEUROIMAGE, V18, P749, DOI 10.1016/S1053-8119(03)00005-3; Kircher TTJ, 2000, COGNITIVE BRAIN RES, V10, P133, DOI 10.1016/S0926-6410(00)00036-7; Kjaer TW, 2002, NEUROIMAGE, V17, P1080, DOI 10.1006/nimg.2002.1230; Laureys S, 2012, NEUROIMAGE, V61, P478, DOI 10.1016/j.neuroimage.2011.12.041; Litvak V, 2008, NEUROIMAGE, V42, P1490, DOI 10.1016/j.neuroimage.2008.06.022; Litvak V, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/852961; Luking KR, 2017, BIOL PSYCHIAT-COGN N, V2, P289, DOI 10.1016/j.bpsc.2016.12.004; Lundstrom BN, 2005, NEUROIMAGE, V27, P824, DOI 10.1016/j.neuroimage.2005.05.008; Makeig S, 1996, ADV NEUR IN, V8, P145; Malouin F, 2003, HUM BRAIN MAPP, V19, P47, DOI 10.1002/hbm.10103; MANNING KA, 1983, PERCEPT PSYCHOPHYS, V34, P250, DOI 10.3758/BF03202953; Margulies DS, 2009, P NATL ACAD SCI USA, V106, P20069, DOI 10.1073/pnas.0905314106; Marinova I., 2010, INT J MED HLTH BIOME, V4, P140; Mitchell DJ, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00018; Nagahama Y, 1999, NEUROIMAGE, V10, P193, DOI 10.1006/nimg.1999.0451; Nakano T, 2013, P NATL ACAD SCI USA, V110, P702, DOI 10.1073/pnas.1214804110; Nakano T, 2010, EXP BRAIN RES, V205, P577, DOI 10.1007/s00221-010-2387-z; Nakano T, 2009, P ROY SOC B-BIOL SCI, V276, P3635, DOI 10.1098/rspb.2009.0828; NUNEZ PL, 1994, ELECTROEN CLIN NEURO, V90, P40, DOI 10.1016/0013-4694(94)90112-0; Oh J, 2012, HUM MOVEMENT SCI, V31, P1353, DOI 10.1016/j.humov.2012.06.003; ORCHARD L N, 1991, Integrative Physiological and Behavioral Science, V26, P108, DOI 10.1007/BF02691032; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Raz S, 2014, ASSESSMENT, V21, P108, DOI 10.1177/1073191112443409; Reiman EM, 1997, AM J PSYCHIAT, V154, P918; RIGGS LA, 1981, VISION RES, V21, P1075, DOI 10.1016/0042-6989(81)90012-2; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; SKRANDIES W, 1990, Brain Topography, V3, P137, DOI 10.1007/BF01128870; Snowden JS, 2004, BRAIN, V127, P860, DOI 10.1093/brain/awh099; Tsubota K, 1999, EXP EYE RES, V69, P1, DOI 10.1006/exer.1999.0660; Tsubota K, 1996, ARCH OPHTHALMOL-CHIC, V114, P715, DOI 10.1001/archopht.1996.01100130707012; Utevsky AV, 2014, J NEUROSCI, V34, P932, DOI 10.1523/JNEUROSCI.4227-13.2014; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Veltman JA, 1998, ERGONOMICS, V41, P656, DOI 10.1080/001401398186829; Viggiano MP, 2000, NEUROPSYCHOLOGIA, V38, P1098, DOI 10.1016/S0028-3932(99)00159-1; VOLKMANN FC, 1986, VISION RES, V26, P1401, DOI 10.1016/0042-6989(86)90164-1; Wenderoth N, 2005, EUR J NEUROSCI, V22, P235, DOI 10.1111/j.1460-9568.2005.04176.x; Yoon HW, 2005, NEUROSCI LETT, V381, P26, DOI 10.1016/j.neulet.2005.01.077; Zahn R, 2007, P NATL ACAD SCI USA, V104, P6430, DOI 10.1073/pnas.0607061104; Zhang S, 2012, NEUROIMAGE, V59, P3548, DOI 10.1016/j.neuroimage.2011.11.023	82	12	12	0	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	OCT 11	2017	11								489	10.3389/fnhum.2017.00489			12	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	FJ4MD	WOS:000412712400001	29085289	DOAJ Gold, Green Published			2021-06-18	
J	Warren, M; Subramani, K; Schwartz, R; Raju, R				Warren, Marie; Subramani, Kumar; Schwartz, Richard; Raju, Raghavan			Mitochondrial dysfunction in rat splenocytes following hemorrhagic shock	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE			English	Article						Trauma; Hemorrhage; Shock; Mitochondrial function	TRAUMATIC BRAIN-INJURY; ACUTE LUNG INJURY; NF-KAPPA-B; INFLAMMATORY RESPONSE; STERILE INFLAMMATION; IMMUNE-RESPONSE; HYPOXIA; ACTIVATION; CELLS; HMGB1	The regulation of mitochondrial function is critical in cellular homeostasis following hemorrhagic shock. Hemorrhagic shock results in fluid loss and reduced availability of oxygen and nutrients to tissues. The spleen is a secondary lymphoid organ playing a key role in 'filtering the blood' and in the innate and adaptive immune responses. To understand the molecular basis of hemorrhagic shock, we investigated the changes in splenocyte mitochondrial respiration, and concomitant immune and metabolic alterations. The hemorrhagic injury (HI) in our rat model was induced by bleeding 60% of the total blood volume followed by resuscitation with Ringers lactate. Another group of animals was subjected to hemorrhage, but did not receive fluid resuscitation. Oxygen consumption rate of splenocytes were determined using a Seahorse analyzer. We found a significantly reduced oxygen consumption rate in splenocytes following HI compared to sham operated rats. The mitochondrial stress test revealed a decreased basal oxygen consumption rate, ATP production, maximal respiration and spare respiratory capacity. The mitochondrial membrane potential, and citrate synthase activity, were also reduced in the splenocytes following HI. Hypoxic response in the splenocyte was confirmed by increased gene expression of Hif1 alpha. Elevated level of mitochondrial stress protein, hsp60 and induction of high mobility group box1 protein (HMGB1) were observed in splenocytes following HI. An increased inflammatory response was demonstrated by significantly increased expression of IL-6, IFN-beta, Mip-1 alpha, IL-10 and NF kappa bp65. In summary, we conclude that splenocyte oxidative phosphorylation and metabolism were severely compromised following HI.	[Warren, Marie; Subramani, Kumar; Schwartz, Richard; Raju, Raghavan] Augusta Univ, CB 2601,Sanders Bldg,1460 Laney Walker Blvd, Augusta, GA 30912 USA	Raju, R (corresponding author), Augusta Univ, CB 2601,Sanders Bldg,1460 Laney Walker Blvd, Augusta, GA 30912 USA.	rraju@augusta.edu	Subramani, Kumar/AAM-6765-2020	Subramani, Kumar/0000-0002-8478-3625; Raju, Raghavan/0000-0002-4516-8654	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 GM101927, R01 GM122059]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM122059, R01GM101927] Funding Source: NIH RePORTER	Authors acknowledge the assistance of Sumin Lu in ATP and lactate determination. RR acknowledges the support of the National Institutes of Health (R01 GM101927 and R01 GM122059) and laboratory start up assistance from the Augusta University, Augusta, GA, USA.	Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Angele MK, 1999, AM J PHYSIOL-CELL PH, V276, pC145; Antonelli M, 2007, CRIT CARE, V11, DOI 10.1186/cc6132; Aronowski J, 2005, NEUROL RES, V27, P268, DOI 10.1179/016164105X25225; Ayala A, 2002, AM J PATHOL, V161, P2283, DOI 10.1016/S0002-9440(10)64504-X; AYALA A, 1991, AM J PHYSIOL, V260, pR167; Ayub A, 2015, MOL MED, V21, P305, DOI 10.2119/molmed.2015.00013; Baker TA, 2012, CRIT CARE MED, V40, P876, DOI 10.1097/CCM.0b013e318232e314; Bakovic D, 2003, J APPL PHYSIOL, V95, P1460, DOI 10.1152/japplphysiol.00221.2003; Bartels K, 2013, P NATL ACAD SCI USA, V110, P18351, DOI 10.1073/pnas.1318345110; Betensley A, 2017, J CLIN MED, V6, DOI 10.3390/jcm6010002; Bhandari T, 2014, INFECT DIS THER, V3, P159, DOI 10.1007/s40121-014-0030-1; Bierly AL, 2008, J IMMUNOL, V181, P8485, DOI 10.4049/jimmunol.181.12.8485; Bursa F, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/1757-7241-22-11; Chen KB, 2012, J TRAUMA ACUTE CARE, V72, P660, DOI 10.1097/TA.0b013e3182318551; Choudhry MA, 2005, SHOCK, V24, P101, DOI 10.1097/01.shk.0000191341.31530.5e; Colgan SP, 2016, ANNU REV PATHOL-MECH, V11, P77, DOI 10.1146/annurev-pathol-012615-044231; Dobson GP, 2015, FRONT SURG, V2, DOI 10.3389/fsurg.2015.00043; Ham P.B., 2016, PROG NEUROBIOL; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hsieh CH, 2009, AM J PATHOL, V175, P1504, DOI 10.2353/ajpath.2009.081174; Hsieh YC, 2006, J MOL CELL CARDIOL, V41, P511, DOI 10.1016/j.yjmcc.2006.06.001; Hubbard WJ, 2004, SHOCK, V22, P395, DOI 10.1097/01.shk.0000143407.90473.cc; Jaffer U, 2010, HEART LUNG VESSEL, V2, P161; Jian BX, 2014, MOL MED, V20, P10, DOI 10.2119/molmed.2013.00077; Jian BX, 2008, BBA-MOL BASIS DIS, V1782, P621, DOI 10.1016/j.bbadis.2008.08.007; Kan WH, 2008, J APPL PHYSIOL, V105, P595, DOI 10.1152/japplphysiol.00012.2008; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Li YQ, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/523481; Loftus RM, 2016, J BIOL CHEM, V291, P1, DOI 10.1074/jbc.R115.693903; Lord JM, 2014, LANCET, V384, P1455, DOI 10.1016/S0140-6736(14)60687-5; Lu SM, 2016, CYTOKINE, V81, P35, DOI 10.1016/j.cyto.2016.01.022; Luciano JA, 2015, SHOCK, V44, P149, DOI 10.1097/SHK.0000000000000412; McNamee EN, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf4630; Mebius RE, 2005, NAT REV IMMUNOL, V5, P606, DOI 10.1038/nri1669; Molina PE, 2015, ALCOHOL RES-CURR REV, V37, P263; Molina PE, 2013, SHOCK, V39, P240, DOI 10.1097/SHK.0b013e318285b86d; Mommsen P, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/186709; Neeland IJ, 2017, METABOLISM, V67, P80, DOI 10.1016/j.metabol.2016.11.008; Niatsetskaya ZV, 2012, J NEUROSCI, V32, P3235, DOI 10.1523/JNEUROSCI.6303-11.2012; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Poulose N, 2014, AGING DIS, V5, P101, DOI 10.14336/AD.2014.0500101; Raymond S. L., 2017, BIOCH BIOPHYS ACTA; Rio D. C., 2010, COLD SPRING HARB PRO; ROUMEN RMH, 1993, ANN SURG, V218, P769, DOI 10.1097/00000658-199312000-00011; Shenkar R, 1996, AM J PHYSIOL-LUNG C, V270, pL729; Shoemaker W. C., 1988, CRIT CARE MED, V16; Sitkovsky M, 2005, NAT REV IMMUNOL, V5, P712, DOI 10.1038/nri1685; Sodhi CP, 2015, J IMMUNOL, V194, P4931, DOI 10.4049/jimmunol.1402490; Spinella PC, 2009, BLOOD REV, V23, P231, DOI 10.1016/j.blre.2009.07.003; Subramani K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02495-5; Thiessen S. E., 2017, BIOCH BIOPHYS ACTA; Villarroel J. P., J TRAUMA ACUTE CARE, V75; Wang HC, 2014, EXPERT OPIN THER TAR, V18, P257, DOI 10.1517/14728222.2014.863876; Wang H, 2015, SHOCK, V44, P173, DOI 10.1097/SHK.0000000000000390; Wu RQ, 2006, CRIT CARE MED, V34, P1273, DOI 10.1097/01.CCM.0000208437.93725.18; Xu Lin, 2016, Med Sci Monit, V22, P2561; Zheng Y, 2011, ARTERIOSCL THROM VAS, V31, P2781, DOI 10.1161/ATVBAHA.111.224907	60	12	14	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-4439	1879-260X		BBA-MOL BASIS DIS	Biochim. Biophys. Acta-Mol. Basis Dis.	OCT	2017	1863	10	B		SI		2526	2533		10.1016/j.bbadis.2017.08.024			8	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	FN1VK	WOS:000415779100002	28844961	Green Accepted, Bronze			2021-06-18	
J	Yang, L; Liu, ZJ; Ren, HL; Zhang, L; Gao, SM; Ren, L; Chai, Z; Meza-Romero, R; Benedek, G; Vandenbark, AA; Offner, H; Li, MS				Yang, Liu; Liu, Zhijia; Ren, Honglei; Zhang, Lei; Gao, Siman; Ren, Li; Chai, Zhi; Meza-Romero, Roberto; Benedek, Gil; Vandenbark, Arthur A.; Offner, Halina; Li, Minshu			DR alpha 1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury	METABOLIC BRAIN DISEASE			English	Article						Traumatic brain injury; DRa1-MOG-alpha 35-55 therapy; Neurological deficits; CD74; Infiltrating macrophages/microglia	EXPERIMENTAL STROKE; CD74 EXPRESSION; ISCHEMIC-STROKE; CELL; INFLAMMATION; CONSTRUCTS; ACTIVATION	Traumatic brain injury (TBI) results in severe neurological impairments without effective treatments. Inflammation appears to be an important contributor to key pathogenic events such as secondary brain injury following TBI and therefore serves as a promising target for novel therapies. We have recently demonstrated the ability of a molecular construct comprised of the human leukocyte antigen (HLA)-DR alpha 1 domain linked covalently to mouse (m)MOG-35-55 peptide (DR alpha 1-MOG-35-55 construct) to reduce CNS inflammation and tissue injury in animal models of multiple sclerosis and ischemic stroke. The aim of the current study was to determine if DR alpha 1-MOG-35-55 treatment of a fluid percussion injury (FPI) mouse model of TBI could reduce the lesion size and improve disease outcome measures. Neurodeficits, lesion size, and immune responses were determined to evaluate the therapeutic potential and mechanisms of neuroprotection induced by DR alpha 1-MOG-35-55 treatment. The results demonstrated that daily injections of DR alpha 1-MOG-35-55 given after FPI significantly reduced numbers of infiltrating CD74(+) and CD86(+) macrophages and increased numbers of CD206(+) microglia in the brain concomitant with smaller lesion sizes and improvement in neurodeficits. Conversely, DR alpha 1-MOG-35-55 treatment of TBI increased numbers of circulating CD11b(+) monocytes and their expression of CD74 but had no detectable effect on cell numbers or marker expression in the spleen. These results demonstrate that DR alpha 1-MOG-35-55 therapy can reduce CNS inflammation and significantly improve histological and clinical outcomes after TBI. Future studies will further examine the potential of DR alpha 1-MOG-35-55 for treatment of TBI.	[Yang, Liu; Liu, Zhijia; Ren, Honglei; Zhang, Lei; Gao, Siman; Ren, Li; Li, Minshu] Tianjin Med Univ, Tianjin Neurol Inst, Dept Neurol, Gen Hosp, Tianjin 300052, Peoples R China; [Yang, Liu; Li, Minshu] St Josephs Hosp, Phoenix, AZ 85013 USA; [Chai, Zhi] Shanxi Univ Tradit Chinese Med, Collaborat Innovat Ctr 2011, Neurobiol Res Ctr, Taiyuan 030619, Shanxi, Peoples R China; [Meza-Romero, Roberto; Benedek, Gil; Vandenbark, Arthur A.; Offner, Halina] VA Portland Hlth Care Syst, Neuroimmunol Res, Portland, OR 97239 USA; [Meza-Romero, Roberto; Benedek, Gil; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol UHS 46, Tykeson MS Res Lab, Portland, OR 97201 USA; [Benedek, Gil; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA; [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA; [Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA	Li, MS (corresponding author), Tianjin Med Univ, Tianjin Neurol Inst, Dept Neurol, Gen Hosp, Tianjin 300052, Peoples R China.; Li, MS (corresponding author), St Josephs Hosp, Phoenix, AZ 85013 USA.; Offner, H (corresponding author), VA Portland Hlth Care Syst, Neuroimmunol Res, Portland, OR 97239 USA.; Offner, H (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol UHS 46, Tykeson MS Res Lab, Portland, OR 97201 USA.; Offner, H (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.; Offner, H (corresponding author), Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA.	offnerva@ohsu.edu; minshuli2012@163.com			National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81,471,535]; US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS092713, AI 122574]; Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R42AI122574, R41AI122574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS076013, R01NS075887, R01NS092713] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX000226] Funding Source: NIH RePORTER	This study was supported in part by the National Science Foundation of China grant 81,471,535 (to ML); US National Institutes of Health grants R01NS092713 (to HO) and AI 122574 (to AAV); Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. The contents do not represent the views of the Department of Veterans Affairs or the United States Government.	Basrai HS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153418; Benedek G, 2017, NEUROCHEM INT, V107, P138, DOI 10.1016/j.neuint.2016.10.007; Benedek G, 2014, METAB BRAIN DIS, V29, P37, DOI 10.1007/s11011-013-9440-0; Burrows GG, 2001, J IMMUNOL, V167, P4386, DOI 10.4049/jimmunol.167.8.4386; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Dziennis S, 2011, METAB BRAIN DIS, V26, P123, DOI 10.1007/s11011-011-9241-2; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Meng YL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106238; Meza-Romero R, 2016, METAB BRAIN DIS, V31, P249, DOI 10.1007/s11011-016-9798-x; Meza-Romero R, 2014, J IMMUNOL, V192, P4164, DOI 10.4049/jimmunol.1303118; Pan J, 2014, TRANSL STROKE RES, V5, P577, DOI 10.1007/s12975-014-0345-y; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Subramanian S, 2009, STROKE, V40, P2539, DOI 10.1161/STROKEAHA.108.543991; Tobin RP, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0143-5; Tsukano H, 2016, SCI REP-UK, V6, DOI 10.1038/srep22315; Vandenbark AA, 2013, J AUTOIMMUN, V40, P96, DOI 10.1016/j.jaut.2012.08.004; Wang CH, 2003, J IMMUNOL, V171, P1934, DOI 10.4049/jimmunol.171.4.1934; Wang JY, 2017, TRANSL STROKE RES, V8, P284, DOI 10.1007/s12975-016-0514-2; Zhu WB, 2015, TRANSL STROKE RES, V6, P60, DOI 10.1007/s12975-014-0373-7; Zhu WB, 2014, TRANSL STROKE RES, V5, P612, DOI 10.1007/s12975-014-0348-8	23	12	12	0	5	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0885-7490	1573-7365		METAB BRAIN DIS	Metab. Brain Dis.	OCT	2017	32	5					1395	1402		10.1007/s11011-017-9991-6			8	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	FG9BD	WOS:000410732300006	28303450	Green Accepted			2021-06-18	
J	Chan, YL; Saad, S; Machaalani, R; Oliver, BG; Vissel, B; Pollock, C; Jones, NM; Chen, H				Chan, Yik L.; Saad, Sonia; Machaalani, Rita; Oliver, Brian G.; Vissel, Bryce; Pollock, Carol; Jones, Nicole M.; Chen, Hui			Maternal Cigarette Smoke Exposure Worsens Neurological Outcomes in Adolescent Offspring with Hypoxic-Ischemic Injury	FRONTIERS IN MOLECULAR NEUROSCIENCE			English	Article						mitophagy; apoptosis; cognition; motor behavior	TRAUMATIC BRAIN-INJURY; DELAYED NEURONAL DEATH; TRANSGENERATIONAL INHERITANCE; OXIDATIVE STRESS; NEONATAL RAT; PREGNANCY; NICOTINE; EXPRESSION; DEFICITS; IMPACT	Hypoxic-ischemic (HI) encephalopathy occurs in approximately 6 per 1000 term newborns leading to devastating neurological consequences, such as cerebral palsy and seizures. Maternal smoking is one of the prominent risk factors contributing to HI injury. Mitochondrial integrity plays a critical role in neural injury and repair during HI. We previously showed that maternal cigarette smoke exposure (SE) can reduce brain mitochondrial fission and autophagosome markers in male offspring. This was accompanied by increased brain cell apoptosis (active caspase-3) and DNA fragmentation (TUNEL staining). Here, we aimed to investigate whether maternal SE leads to more severe neurological damage after HI brain injury in male offspring. Female BALB/c mice (8 weeks) were exposed to cigarette smoke prior to mating, during gestation, and lactation. At postnatal day 10, half of the pups from each litter underwent left carotid artery occlusion, followed by exposure to 8% oxygen (92% nitrogen). At postnatal day 40-44, maternal SE reduced grip strength in grip traction and foot fault tests, which were also reduced by HI injury to similar levels regardless of the maternal group. Limb coordination was impaired by maternal SE which was not worsened by HI injury. Maternal SE increased anxiety level in the offspring, which was normalized by HI injury. Apoptosis markers were increased in different brain regions by maternal SE, with the cortex having further increased TUNEL by HI injury, along with increased markers of inflammation and mitophagy. We conclude that maternal SE can worsen HI-induced cellular damage in male offspring well into adolescence.	[Chan, Yik L.; Saad, Sonia; Oliver, Brian G.; Vissel, Bryce; Chen, Hui] Univ Technol Sydney, Sch Life Sci, Fac Sci, Sydney, NSW, Australia; [Chan, Yik L.; Oliver, Brian G.] Univ Sydney, Woolcock Inst Med Res, Resp Cellular & Mol Biol, Sydney, NSW, Australia; [Saad, Sonia; Pollock, Carol] Royal North Shore Hosp, Kolling Inst, Renal Res Grp, St Leonards, NSW, Australia; [Machaalani, Rita] Univ Sydney, Dept Med, Sydney, NSW, Australia; [Vissel, Bryce] Univ Technol Sydney, Ctr Neurosci & Regenerat Med, Fac Sci, Sydney, NSW, Australia; [Jones, Nicole M.] Univ New South Wales, Sch Med Sci, Dept Pharmacol, Sydney, NSW, Australia	Chan, YL; Chen, H (corresponding author), Univ Technol Sydney, Sch Life Sci, Fac Sci, Sydney, NSW, Australia.; Chan, YL (corresponding author), Univ Sydney, Woolcock Inst Med Res, Resp Cellular & Mol Biol, Sydney, NSW, Australia.	yik.chan@uts.edu.au; hui.chen-1@uts.edu.au	Chen, Hui/D-2005-2014; Oliver, Brian/E-7939-2010; Chen, Hui/R-6137-2019; Jones, Nicole/C-8216-2015	Chen, Hui/0000-0001-6883-3752; Oliver, Brian/0000-0002-7122-9262; Chen, Hui/0000-0001-6883-3752; Vissel, Bryce/0000-0001-8860-8050; Chan, Yik Lung/0000-0002-9605-4200; Jones, Nicole/0000-0001-6738-6022; Saad, Sonia/0000-0001-8067-8046			Akar F, 2014, MED SCI MONIT BASIC, V20, P27, DOI 10.12659/MSMBR.890438; ALBERTSSON AM, 2014, J NEUROINFLAMM, V11; Ashrafi G, 2013, CELL DEATH DIFFER, V20, P31, DOI 10.1038/cdd.2012.81; Baek SH, 2014, STROKE, V45, P2438, DOI 10.1161/STROKEAHA.114.005183; Bale TL, 2015, NAT REV NEUROSCI, V16, P332, DOI 10.1038/nrn3818; Bereiter-Hahn J., 1990, International Review of Cytology, V122, P1, DOI 10.1016/S0074-7696(08)61205-X; Brennan PA, 1999, ARCH GEN PSYCHIAT, V56, P215, DOI 10.1001/archpsyc.56.3.215; BUREAU MA, 1983, PEDIATRICS, V72, P22; Chan YL, 2016, CLIN EXP PHARMACOL P, V43, P1168, DOI 10.1111/1440-1681.12659; Chan YL, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00033; Chan YL, 2016, SCI REP-UK, V6, DOI 10.1038/srep25881; Cheeta S, 2001, NEUROPSYCHOPHARMACOL, V25, P601, DOI 10.1016/S0893-133X(01)00258-5; Chen H, 2016, CLIN EXP PHARMACOL P, V43, P1107, DOI 10.1111/1440-1681.12650; COLE PV, 1972, J OBSTET GYN BR COMM, V79, P782; Cotten C Michael, 2010, Expert Rev Obstet Gynecol, V5, P227, DOI 10.1586/eog.10.7; Dagda RK, 2009, J BIOL CHEM, V284, P13843, DOI 10.1074/jbc.M808515200; Dutta S, 2016, LIFE SCI, V152, P244, DOI 10.1016/j.lfs.2015.10.025; Elgass K, 2013, BBA-MOL CELL RES, V1833, P150, DOI 10.1016/j.bbamcr.2012.05.002; Eriksson C, 1999, NEUROSCIENCE, V93, P915, DOI 10.1016/S0306-4522(99)00178-5; Fatemi A, 2009, CLIN PERINATOL, V36, P835, DOI 10.1016/j.clp.2009.07.011; Fergusson DM, 1998, ARCH GEN PSYCHIAT, V55, P721, DOI 10.1001/archpsyc.55.8.721; Habek D, 2002, FETAL DIAGN THER, V17, P367, DOI 10.1159/000065387; Hei MY, 2012, BRAZ J MED BIOL RES, V45, P13, DOI [10.1590/S0100-879X2012000100003, 10.1590/S0100-879X2011007500161]; Holley AK, 2011, INT J MOL SCI, V12, P7114, DOI 10.3390/ijms12107114; Huizink AC, 2006, NEUROSCI BIOBEHAV R, V30, P24, DOI 10.1016/j.neubiorev.2005.04.005; Jacobsen LK, 2006, NEUROPSYCHOPHARMACOL, V31, P1550, DOI 10.1038/sj.npp.1300981; Jones NM, 2008, PEDIATR RES, V63, P620, DOI 10.1203/PDR.0b013e31816d9117; Jones NM, 2001, J CEREBR BLOOD F MET, V21, P1105, DOI 10.1097/00004647-200109000-00008; Kaminsky LM, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.06.026; Kanazawa T, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000022; Kim Y, 2008, BIOCHEM BIOPH RES CO, V377, P975, DOI 10.1016/j.bbrc.2008.10.104; Knopik VS, 2009, DEV NEUROPSYCHOL, V34, P1, DOI 10.1080/87565640802564366; Komada Munekazu, 2008, J Vis Exp, DOI 10.3791/1088; Kouno T, 2005, J BIOL CHEM, V280, P24610, DOI 10.1074/jbc.M413565200; Kravitz AV, 2015, BRAIN RES, V1628, P186, DOI 10.1016/j.brainres.2015.03.048; Lambe M, 2006, EPIDEMIOLOGY, V17, P524, DOI 10.1097/01.ede.0000231561.49208.be; Larsson M, 2011, J EPIDEMIOL COMMUN H, V65, P1151, DOI 10.1136/jech.2008.085241; Li Y, 2012, STROKE, V43, P2483, DOI 10.1161/STROKEAHA.112.664698; Li Y, 2012, PROG NEUROBIOL, V98, P145, DOI 10.1016/j.pneurobio.2012.05.010; Liu FD, 2013, ACTA PHARMACOL SIN, V34, P1121, DOI 10.1038/aps.2013.89; Liu J, 2010, J TROP PEDIATRICS, V56, P178, DOI 10.1093/tropej/fmp098; Machaalani R, 2014, TOXICOL APPL PHARM, V276, P204, DOI 10.1016/j.taap.2014.02.015; Moylan S, 2015, BMC MED, V13, DOI 10.1186/s12916-014-0257-4; Mueller BR, 2008, J NEUROSCI, V28, P9055, DOI 10.1523/JNEUROSCI.1424-08.2008; Mueller BR, 2007, PHYSIOL BEHAV, V91, P55, DOI 10.1016/j.physbeh.2007.01.017; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Northington FJ, 2001, NEUROBIOL DIS, V8, P207, DOI 10.1006/nbdi.2000.0371; Onoue K, 2013, J CELL SCI, V126, P176, DOI 10.1242/jcs.111211; Orlebeke JF, 1999, ARCH ENVIRON HEALTH, V54, P15, DOI 10.1080/00039899909602231; Osadchy A, 2009, J OBSTET GYNAECOL CA, V31, P744, DOI 10.1016/S1701-2163(16)34281-5; PHILIPP K, 1984, GYNECOL OBSTET INVES, V17, P179, DOI 10.1159/000299145; Quinn HR, 2008, NEUROPSYCHOPHARMACOL, V33, P1113, DOI 10.1038/sj.npp.1301475; Reinboth BS, 2016, EXP NEUROL, V283, P264, DOI 10.1016/j.expneurol.2016.06.024; Rocha-Ferreira E, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/4901014; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Sanchez V, 2015, DRUG ALCOHOL DEPEN, V156, P193, DOI 10.1016/j.drugalcdep.2015.09.022; Savard A, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0330-8; Shen Y, 2016, BIOL PSYCHIAT, V80, pE13, DOI 10.1016/j.biopsych.2016.02.006; Shi RY, 2014, CNS NEUROSCI THER, V20, P1045, DOI 10.1111/cns.12325; Shiba-Fukushima K, 2012, SCI REP-UK, V2, DOI 10.1038/srep01002; SOCOL ML, 1982, AM J OBSTET GYNECOL, V142, P214, DOI 10.1016/S0002-9378(16)32339-0; Streja E, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.06.023; SUGIOKA K, 1988, BIOCHIM BIOPHYS ACTA, V936, P377, DOI 10.1016/0005-2728(88)90014-X; Sukjamnong S, 2017, AM J PHYSIOL-LUNG C, V313, pL416, DOI 10.1152/ajplung.00134.2017; Tang YC, 2016, PROTEIN CELL, V7, P699, DOI 10.1007/s13238-016-0307-0; Thanos PK, 2015, SYNAPSE, V69, P356, DOI 10.1002/syn.21822; Trasti N, 1999, EARLY HUM DEV, V55, P137, DOI 10.1016/S0378-3782(99)00017-1; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Ubaldi Massimo, 2016, Prog Brain Res, V224, P251, DOI 10.1016/bs.pbr.2015.07.018; Valente EM, 2009, FUTUR NEUROL, V4, P575, DOI 10.2217/FNL.09.39; Vassoler FM, 2014, NEUROSCIENCE, V264, P198, DOI 10.1016/j.neuroscience.2013.07.064; Vivekanandarajah A, 2016, NEUROTOXICOLOGY, V53, P53, DOI 10.1016/j.neuro.2015.12.017; Wang DB, 2013, J NEUROSCI, V33, P1357, DOI 10.1523/JNEUROSCI.3365-12.2013; Wang YJ, 2016, J PSYCHIATR RES, V79, P1, DOI 10.1016/j.jpsychires.2016.04.001; Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013; Yang SH, 2013, SHOCK, V40, P471, DOI 10.1097/SHK.0000000000000037; Yohn NL, 2015, PROG BIOPHYS MOL BIO, V118, P21, DOI 10.1016/j.pbiomolbio.2015.03.002; Yuan TF, 2016, MOL NEUROBIOL, V53, P6367, DOI 10.1007/s12035-015-9526-2	78	12	12	0	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5099			FRONT MOL NEUROSCI	Front. Molec. Neurosci.	SEP 26	2017	10								306	10.3389/fnmol.2017.00306			17	Neurosciences	Neurosciences & Neurology	FI1WN	WOS:000411726500001	29018327	DOAJ Gold, Green Published			2021-06-18	
J	Shahim, P; Holleran, L; Kim, JH; Brody, DL				Shahim, Pashtun; Holleran, Laurena; Kim, Joong H.; Brody, David L.			Test-retest reliability of high spatial resolution diffusion tensor and diffusion kurtosis imaging	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; PRINCIPAL EIGENVECTOR MEASUREMENTS; FRACTIONAL ANISOTROPY; AXONAL INJURY; NEUROCHEMICAL AFTERMATH; MEAN DIFFUSIVITY; REPRODUCIBILITY; MRI; DAMAGE; TISSUE	We assessed the test-retest reliability of high spatial resolution diffusion tensor imaging (DTI) and diffusion kurtosis imaging (DKI). Diffusion MRI was acquired using a Siemens 3 Tesla Prisma scanner with 80 mT/m gradients and a 32-channel head coil from each of 3 concussive traumatic brain injury (cTBI) patients and 4 controls twice 0 to 24 days apart. Coefficients of variation (CoV) for DTI parameters were calculated in each DTI Studio parcellated white matter tract at 1.25 mm and 1.75 mm isotropic voxel resolution, as well as DKI parameters at 1.75 mm isotropic. Overall, fractional anisotropy had the best reliability, with mean CoV at 5% for 1.25 mm and 3.5% for 1.75 mm isotropic voxels. Mean CoV for the other DTI metrics were <7.0% for both 1.25 and 1.75 mm isotropic voxels. The mean CoV was <= 4.5% across the DKI metrics. In the commonly injured orbitofrontal and temporal pole regions CoV was <3.5% for all parameters. Thus, with appropriate processing, high spatial resolution advanced diffusion MRI has good to excellent test-retest reproducibility in both human cTBI patients and controls. However, further technical improvements will be needed to reliably discern the most subtle diffusion abnormalities, especially at high spatial resolution.	[Shahim, Pashtun; Holleran, Laurena; Kim, Joong H.; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Shahim, Pashtun] Univ Gothenburg, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Sahlgrenska Acad, Molndal, Sweden; [Shahim, Pashtun] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Brody, David L.] Washington Univ, Sch Med, Hope Ctr Neurol Disorders, St Louis, MO USA	Shahim, P (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.; Shahim, P (corresponding author), Univ Gothenburg, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Sahlgrenska Acad, Molndal, Sweden.; Shahim, P (corresponding author), Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden.	shahimp@wustl.edu			Health South Inc.; NIH U01United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Mallinckrodt Institute of Radiology	We would like to thank the study participants. We would also like to thank Linda Hood and Mark Harms at Mallinckrodt Institute of Radiology for technical assistance in acquiring the diffusion images, Shiran Su for assistance with test-retest reliability, and Dr. Carlo Pierpaoli for technical assistance with regard to the MRI data analysis protocol. The study was funded by Health South Inc., NIH U01, and Mallinckrodt Institute of Radiology.	Acheson A, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.615; Adam O, 2015, NEUROLOGY, V85, P219, DOI 10.1212/WNL.0000000000001758; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Blain CRV, 2006, NEUROLOGY, V67, P2199, DOI 10.1212/01.wnl.0000249307.59950.f8; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bonekamp D, 2007, NEUROIMAGE, V34, P733, DOI 10.1016/j.neuroimage.2006.09.020; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; Farrell JAD, 2007, J MAGN RESON IMAGING, V26, P756, DOI 10.1002/jmri.21053; Fox RJ, 2012, AM J NEURORADIOL, V33, P695, DOI 10.3174/ajnr.A2844; Grinberg F, 2011, NEUROIMAGE, V57, P1087, DOI 10.1016/j.neuroimage.2011.04.050; Heiervang E, 2006, NEUROIMAGE, V33, P867, DOI 10.1016/j.neuroimage.2006.07.037; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Holleran L, 2017, ACTA NEUROPATHOL, V133, P367, DOI 10.1007/s00401-017-1686-x; Irfanoglu MO, 2015, NEUROIMAGE, V106, P284, DOI 10.1016/j.neuroimage.2014.11.042; Irfanoglu MO, 2014, LECT NOTES COMPUT SC, V8673, P218, DOI 10.1007/978-3-319-10404-1_28; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Jezzard P, 1998, MAGNET RESON MED, V39, P801, DOI 10.1002/mrm.1910390518; Kantarci K, 2014, JAMA NEUROL, V71, P1547, DOI 10.1001/jamaneurol.2014.1482; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Lawrenz M, 2015, NEUROIMAGE, V109, P283, DOI 10.1016/j.neuroimage.2015.01.025; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Mysliwiec V, 2013, SLEEP, V36, P167, DOI 10.5665/sleep.2364; Oishi K, 2010, MRI ATLAS HUMAN WHIT; OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076; Palacios E. M., 2016, AJNR AM J NEURORADIO; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Shahim P, 2016, JAMA NEUROL, V73, P1308, DOI 10.1001/jamaneurol.2016.2038; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Sotiropoulos SN, 2013, NEUROIMAGE, V80, P125, DOI 10.1016/j.neuroimage.2013.05.057; Taylor PA, 2016, HUM BRAIN MAPP, V37, P4405, DOI 10.1002/hbm.23318; Tu TW, 2016, ANN NEUROL, V79, P907, DOI 10.1002/ana.24641; Veenith TV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065941; Veraart J, 2013, NEUROIMAGE, V81, P335, DOI 10.1016/j.neuroimage.2013.05.028; Veraart J, 2011, MAGN RESON MED, V65, P138, DOI 10.1002/mrm.22603; Wu EX, 2010, NMR BIOMED, V23, P836, DOI 10.1002/nbm.1506; Wu WC, 2016, NEUROIMAGE, V143, P1, DOI 10.1016/j.neuroimage.2016.08.054; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	52	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	SEP 11	2017	7								11141	10.1038/s41598-017-11747-3			14	Multidisciplinary Sciences	Science & Technology - Other Topics	FG3LX	WOS:000410063400070	28894296	DOAJ Gold, Green Published			2021-06-18	
J	Zhou, J; Burns, MP; Huynh, L; Villapol, S; Taub, DD; Saavedra, JM; Blackman, MR				Zhou, June; Burns, Mark P.; Huynh, Linda; Villapol, Sonia; Taub, Daniel D.; Saavedra, Juan M.; Blackman, Marc R.			Temporal changes in cortical and hippocampal expression of genes important for Brain glucose Metabolism Following controlled cortical impact injury in Mice	FRONTIERS IN ENDOCRINOLOGY			English	Article						gene expression; glucose metabolism; lactate; hexokinase; GPR81; angiotensin II AT1 receptor; telmisartan; traumatic brain injury	SPONTANEOUSLY HYPERTENSIVE-RATS; POSITRON-EMISSION-TOMOGRAPHY; RECEPTOR-GAMMA ACTIVATION; ALZHEIMERS-DISEASE; ENERGY-METABOLISM; DIABETIC MICE; IN-VIVO; LACTATE; BLOCKADE; TRAUMA	Traumatic brain injury (TBI) causes transient increases and subsequent decreases in brain glucose utilization. The underlying molecular pathways are orchestrated processes and poorly understood. In the current study, we determined temporal changes in cortical and hippocampal expression of genes important for brain glucose/lactate metabolism and the effect of a known neuroprotective drug telmisartan on the expression of these genes after experimental TBI. Adult male C57BL/6J mice (n = 6/group) underwent sham or unilateral controlled cortical impact (CCI) injury. Their ipsilateral and contralateral cortex and hippocampus were collected 6 h, 1, 3, 7, 14, 21, and 28 days after injury. Expressions of several genes important for brain glucose utilization were determined by qRT-PCR. In results, (1) mRNA levels of three key enzymes in glucose metabolism [ hexo kinase (HK) 1, pyruvate kinase, and pyruvate dehydrogenase (PDH)] were all increased 6 h after injury in the contralateral cortex, followed by decreases at subsequent times in the ipsilateral cortex and hippocampus; (2) capillary glucose transporter Glut-1 mRNA increased, while neuronal glucose transporter Glut-3 mRNA decreased, at various times in the ipsilateral cortex and hippocampus; (3) astrocyte lactate transporter MCT-1 mRNA increased, whereas neuronal lactate transporter MCT-2 mRNA decreased in the ipsilateral cortex and hippocampus; (4) HK2 (an isoform of hexokinase) expression increased at all time points in the ipsilateral cortex and hippocampus. GPR81 (lactate receptor) mRNA increased at various time points in the ipsilateral cortex and hippocampus. These temporal alterations in gene expression corresponded closely to the patterns of impaired brain glucose utilization reported in both TBI patients and experimental TBI rodents. The observed changes in hippocampal gene expression were delayed and prolonged, when compared with those in the cortex. The patterns of alterations were specific to different brain regions and exhibited different recovery periods following TBI. Oral administration of telmisartan (1 mg/kg, for 7 days, n = 10 per group) ameliorated cortical or hippocampal mRNA for Glut-1/3, MCT-1/2 and PDH in CCI mice. These data provide molecular evidence for dynamic alteration of multiple critical factors in brain glucose metabolism post-TBI and can inform further research for treating brain metabolic disorders post-TBI.	[Zhou, June; Huynh, Linda; Blackman, Marc R.] Washington DC VA Med Ctr, Res Serv, Washington, DC 20422 USA; [Zhou, June; Blackman, Marc R.] George Washington Univ, Dept Biochem & Mol Med, Sch Med, Washington, DC 20052 USA; [Burns, Mark P.; Villapol, Sonia] Georgetown Univ, Sch Med, Dept Neurosci, Washington, DC USA; [Taub, Daniel D.] Washington DC VA Med Ctr, Translat Med Sect, Washington, DC USA; [Taub, Daniel D.] Georgetown Univ, Dept Biochem & Mol & Cell Biol, Sch Med, Washington, DC USA; [Saavedra, Juan M.] Georgetown Univ, Dept Physiol & Pharmacol, Sch Med, Washington, DC USA; [Blackman, Marc R.] George Washington Univ, Dept Med, Sch Med, Washington, DC USA; [Blackman, Marc R.] Georgetown Univ, Dept Med, Sch Med, Washington, DC USA	Zhou, J (corresponding author), Washington DC VA Med Ctr, Res Serv, Washington, DC 20422 USA.; Zhou, J (corresponding author), George Washington Univ, Dept Biochem & Mol Med, Sch Med, Washington, DC 20052 USA.	june.zhou@va.gov	Saavedra, Juan/AAO-7149-2020; Villapol, Sonia/D-1949-2014	Villapol, Sonia/0000-0002-6174-4113; Burns, Mark P/0000-0003-4750-2000	National Center for Advancing Translational Sciences (NCATS), NIH, through the Clinical and Translational Science Awards Program; Federal funds [UL1TR000101]; VA Office of Research and Development Biomedical Laboratory Research & Development Program [I01BX007080]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001409] Funding Source: NIH RePORTER	This research was supported by the National Center for Advancing Translational Sciences (NCATS), NIH, through the Clinical and Translational Science Awards Program, Federal funds UL1TR000101; and by VA Office of Research and Development Biomedical Laboratory Research & Development Program, Award Number I01BX007080.	Alessandri B, 2012, J NEUROTRAUM, V29, P2181, DOI 10.1089/neu.2011.2067; Ando H, 2004, STROKE, V35, P1726, DOI 10.1161/01.STR.0000129788.26346.18; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Applied Biosysterms, 2016, TAQMAN GEN EXPR ASS; Bak LK, 2006, J CEREBR BLOOD F MET, V26, P1285, DOI 10.1038/sj.jcbfm.9600281; Belousov AB, 2012, NEUROSCI LETT, V524, P16, DOI 10.1016/j.neulet.2012.06.065; Benicky J, 2011, NEUROPSYCHOPHARMACOL, V36, P857, DOI 10.1038/npp.2010.225; Bergersen LH, 2015, J CEREBR BLOOD F MET, V35, P176, DOI 10.1038/jcbfm.2014.206; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6; Cai TQ, 2008, BIOCHEM BIOPH RES CO, V377, P987, DOI 10.1016/j.bbrc.2008.10.088; Carpenter KLH, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00112; Cureton EL, 2010, J SURG RES, V159, P468, DOI 10.1016/j.jss.2009.04.020; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Elkahloun AG, 2016, ALZHEIMERS RES THER, V8, DOI 10.1186/s13195-015-0167-5; Fitzgerald DP, 2008, CLIN EXP METASTAS, V25, P799, DOI 10.1007/s10585-008-9193-z; Garrido-Gil P, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-38; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; Imabayashi E, 2011, BRAIN BEHAV, V1, P63, DOI 10.1002/brb3.13; Iwanami J, 2010, J HYPERTENS, V28, P1730, DOI 10.1097/HJH.0b013e32833a551a; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Lakshmanan R, 2010, NEUROCRIT CARE, V12, P324, DOI 10.1007/s12028-010-9342-5; Lauritzen KH, 2014, CEREB CORTEX, V24, P2784, DOI 10.1093/cercor/bht136; Lerch MM, 2014, GASTROENTEROLOGY, V146, P1602, DOI 10.1053/j.gastro.2014.04.025; Liu CL, 2009, J BIOL CHEM, V284, P2811, DOI 10.1074/jbc.M806409200; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Magistretti PJ, 2006, J EXP BIOL, V209, P2304, DOI 10.1242/jeb.02208; Marklund N, 2002, J NEUROTRAUM, V19, P1139, DOI 10.1089/08977150260337958; Mergenthaler P, 2012, P NATL ACAD SCI USA, V109, P1518, DOI 10.1073/pnas.1108225109; Min LJ, 2012, HYPERTENSION, V59, P1079, DOI 10.1161/HYPERTENSIONAHA.112.192401; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Morland C, 2015, J NEUROSCI RES, V93, P1045, DOI 10.1002/jnr.23593; Mosienko V, 2015, J CEREBR BLOOD F MET, V35, P1069, DOI 10.1038/jcbfm.2015.77; Nishimura Y, 2000, STROKE, V31, P2478, DOI 10.1161/01.STR.31.10.2478; O'Connell MT, 2005, ACTA NEUROCHIR SUPPL, V95, P165; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Orhan N, 2016, BRAIN RES, V1631, P113, DOI 10.1016/j.brainres.2015.11.038; Ottens AK, 2010, J NEUROTRAUM, V27, P1837, DOI 10.1089/neu.2010.1374; Palmieri D, 2009, MOL CANCER RES, V7, P1438, DOI 10.1158/1541-7786.MCR-09-0234; Pang T, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-102; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Saavedra JM, 2005, REGUL PEPTIDES, V128, P227, DOI 10.1016/j.regpep.2004.12.015; Saavedra JM, 2006, NEUROPSYCHOPHARMACOL, V31, P1123, DOI 10.1038/sj.npp.1300921; Saavedra JM, 2016, CELL MOL NEUROBIOL, V36, P259, DOI 10.1007/s10571-015-0327-y; Saavedra JM, 2012, CLIN SCI, V123, P567, DOI 10.1042/CS20120078; Saavedra JM, 2012, CELL MOL NEUROBIOL, V32, P667, DOI 10.1007/s10571-011-9754-6; Saavedra JM, 2011, PSYCHONEUROENDOCRINO, V36, P1, DOI 10.1016/j.psyneuen.2010.10.001; Sasaki T, 2008, HYPERTENS RES, V31, P921, DOI 10.1291/hypres.31.921; Selwyn RG, 2016, J NEUROTRAUM, V33, P1479, DOI 10.1089/neu.2015.4129; Semple RK, 2006, J CLIN INVEST, V116, P581, DOI 10.1172/JCI28003; Serres S, 2003, NMR BIOMED, V16, P430, DOI 10.1002/nbm.838; Shen Z, 2015, CNS NEUROSCI THER, V21, P271, DOI 10.1111/cns.12362; Simpson IA, 2007, J CEREBR BLOOD F MET, V27, P1766, DOI 10.1038/sj.jcbfm.9600521; SOKOLOFF L, 1977, J NEUROCHEM, V29, P13, DOI 10.1111/j.1471-4159.1977.tb03919.x; Tabernero A, 2006, J NEUROCHEM, V96, P973, DOI 10.1111/j.1471-4159.2005.03623.x; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Tweedie D, 2016, J NEUROSCI METH, V272, P4, DOI 10.1016/j.jneumeth.2016.02.003; Vannucci SJ, 1997, GLIA, V21, P2, DOI 10.1002/(SICI)1098-1136(199709)21:1<2::AID-GLIA2>3.0.CO;2-C; Villapol S, 2015, BRAIN, V138, DOI 10.1093/brain/awv172; Villapol S, 2015, AM J HYPERTENS, V28, P289, DOI 10.1093/ajh/hpu197; Villapol S, 2012, NEUROPSYCHOPHARMACOL, V37, P2817, DOI 10.1038/npp.2012.152; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Wang J, 2014, NEUROPHARMACOLOGY, V79, P249, DOI 10.1016/j.neuropharm.2013.11.022; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wolf A, 2011, NEUROBIOL DIS, V44, P84, DOI 10.1016/j.nbd.2011.06.007; Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470; Wu P, 2013, J NEUROTRAUM, V30, P775, DOI 10.1089/neu.2012.2391; Xing GQ, 2009, NEUROSCI LETT, V454, P38, DOI 10.1016/j.neulet.2009.01.047	72	12	12	0	8	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-2392			FRONT ENDOCRINOL	Front. Endocrinol.	SEP 11	2017	8								231	10.3389/fendo.2017.00231			13	Endocrinology & Metabolism	Endocrinology & Metabolism	FG4WD	WOS:000410276100001	28955302	DOAJ Gold, Green Published			2021-06-18	
J	Belkacemi, T; Niermann, A; Hofmann, L; Wissenbach, U; Birnbaumer, L; Leidinger, P; Backes, C; Meese, E; Keller, A; Bai, XS; Scheller, A; Kirchhoff, F; Philipp, SE; Weissgerber, P; Flockerzi, V; Beck, A				Belkacemi, Thabet; Niermann, Alexander; Hofmann, Laura; Wissenbach, Ulrich; Birnbaumer, Lutz; Leidinger, Petra; Backes, Christina; Meese, Eckart; Keller, Andreas; Bai, Xianshu; Scheller, Anja; Kirchhoff, Frank; Philipp, Stephan E.; Weissgerber, Petra; Flockerzi, Veit; Beck, Andreas			TRPC1-and TRPC3-dependent Ca2+ signaling in mouse cortical astrocytes affects injury-evoked astrogliosis in vivo	GLIA			English	Article						glia; ion channels; membrane currents; migration; proliferation; stab wound injury	TRAUMATIC BRAIN-INJURY; OPERATED CALCIUM-ENTRY; TRPC3 CHANNELS; RECEPTOR; ACTIVATION; INFLUX; PROLIFERATION; EXPRESSION; DIFFERENTIATION; INHIBITION	Following brain injury astrocytes change into a reactive state, proliferate and grow into the site of lesion, a process called astrogliosis, initiated and regulated by changes in cytoplasmic Ca2+. Transient receptor potential canonical (TRPC) channels may contribute to Ca2+ influx but their presence and possible function in astrocytes is not known. By RT-PCR and RNA sequencing we identified transcripts of Trpc1, Trpc2, Trpc3, and Trpc4 in FACS-sorted glutamate aspartate transporter (GLAST)-positive cultured mouse cortical astrocytes and subcloned full-length Trpc1 and Trpc3 cDNAs from these cells. Ca2+ entry in cortical astrocytes depended on TRPC3 and was increased in the absence of Trpc1. After co-expression of Trpc1 and Trpc3 in HEK-293 cells both proteins co-immunoprecipitate and form functional heteromeric channels, with TRPC1 reducing TRPC3 activity. In vitro, lack of Trpc3 reduced astrocyte proliferation and migration whereas the TRPC3 gain-of-function moonwalker mutation and Trpc1 deficiency increased astrocyte migration. In vivo, astrogliosis and cortex edema following stab wound injury were reduced in Trpc3(-/-) but increased in Trpc1(-/-) mice. In summary, our results show a decisive contribution of TRPC3 to astrocyte Ca2+ signaling, which is even augmented in the absence of Trpc1, in particular following brain injury. Targeted therapies to reduce TRPC3 channel activity in astrocytes might therefore be beneficial in traumatic brain injury.	[Belkacemi, Thabet; Niermann, Alexander; Hofmann, Laura; Wissenbach, Ulrich; Philipp, Stephan E.; Weissgerber, Petra; Flockerzi, Veit; Beck, Andreas] Expt & Klin Pharmakol & Toxikol, D-66421 Homburg, Germany; [Birnbaumer, Lutz] Natl Inst Environm Hlth Sci, Neurobiol Lab, Res Triangle Pk, NC 27709 USA; [Birnbaumer, Lutz] Catholic Univ Argentina, Inst Biomed Res BIOMED, C1107AFF, Buenos Aires, DF, Argentina; [Leidinger, Petra; Meese, Eckart] Inst Human Genet & Anthropol, D-66421 Homburg, Germany; [Backes, Christina; Keller, Andreas] Univ Saarland, Klin Bioinformat, D-66123 Saarbrucken, Germany; [Bai, Xianshu; Scheller, Anja; Kirchhoff, Frank] Univ Saarland, Mol Physiol, D-66421 Homburg, Germany; [Beck, Andreas] Zentrum Human & Mol Biol, D-66421 Homburg, Germany	Beck, A (corresponding author), Univ Saarland, Expt & Klin Pharmakol & Toxikol, D-66421 Homburg, Germany.	andreas.beck@uniklinikum-saarland.de	Scheller, Anja/B-8577-2018; Philipp, Stephan/AAR-7519-2020; Bai, Xianshu/AAN-8029-2021; Kirchhoff, Frank/B-9335-2008	Scheller, Anja/0000-0001-8955-2634; Bai, Xianshu/0000-0002-4758-1645; Kirchhoff, Frank/0000-0002-2324-2761	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [GRK1326, IRTG1830, SFB894]; Homburg Forschungsforderungsprogramm HOMFOR; Forschungskommission der Universitat des Saarlandes; Intramural Research Program of the NIH Project [ZO1-ES101684]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [Z01ES101684] Funding Source: NIH RePORTER	The Deutsche Forschungsgemeinschaft, Grant/Award Numbers: GRK1326 (T.B., A.B.), IRTG1830 (L.H., V.F.), SFB894 (A.B., V.F., P.W., S.E.P., F.K.); The Homburg Forschungsforderungsprogramm HOMFOR (A.B., A.S., S.E.P.); The Forschungskommission der Universitat des Saarlandes (A.B., P.W., S.E.P., V.F.); The Intramural Research Program of the NIH Project, Grant/Award Number: ZO1-ES101684 (L.B.).	Ait-Lounis A, 2010, DIABETES, V59, P1674, DOI 10.2337/db09-0986; Akita T, 2011, J PHYSIOL-LONDON, V589, P3909, DOI 10.1113/jphysiol.2011.208173; Bardehle S, 2013, NAT NEUROSCI, V16, P580, DOI 10.1038/nn.3371; Beck A, 2013, J BIOL CHEM, V288, P19471, DOI 10.1074/jbc.M113.478305; Becker EBE, 2014, CEREBELLUM, V13, P628, DOI 10.1007/s12311-014-0564-5; Becker EBE, 2009, P NATL ACAD SCI USA, V106, P6706, DOI 10.1073/pnas.0810599106; Beskina O, 2007, AM J PHYSIOL-CELL PH, V293, pC1103, DOI 10.1152/ajpcell.00249.2007; Bhattaram P, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1008; Bomben VC, 2011, J CELL PHYSIOL, V226, P1879, DOI 10.1002/jcp.22518; Bomben VC, 2010, GLIA, V58, P1145, DOI 10.1002/glia.20994; Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034; Cheung KK, 2011, MUSCLE NERVE, V44, P358, DOI 10.1002/mus.22060; Chun C, 2016, CELL CYCLE, V15, P957, DOI 10.1080/15384101.2016.1151585; Deliot N, 2015, BBA-BIOMEMBRANES, V1848, P2512, DOI 10.1016/j.bbamem.2015.06.009; Dietrich A, 2007, PFLUG ARCH EUR J PHY, V455, P465, DOI 10.1007/s00424-007-0314-3; Dutton Richard P, 2003, Curr Opin Crit Care, V9, P503, DOI 10.1097/00075198-200312000-00007; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Gao K, 2013, GLIA, V61, P2063, DOI 10.1002/glia.22577; Gatza ML, 2014, NAT GENET, V46, P1051, DOI 10.1038/ng.3073; Golovina VA, 2005, J PHYSIOL-LONDON, V564, P737, DOI 10.1113/jphysiol.2005.085035; Grimaldi M, 2003, J NEUROSCI, V23, P4737; Hartmann J, 2008, NEURON, V59, P392, DOI 10.1016/j.neuron.2008.06.009; Hofmann T, 1999, NATURE, V397, P259; Kanemaru K, 2013, P NATL ACAD SCI USA, V110, P11612, DOI 10.1073/pnas.1300378110; Kiyonaka S, 2009, P NATL ACAD SCI USA, V106, P5400, DOI 10.1073/pnas.0808793106; Kuang CY, 2012, STEM CELLS DEV, V21, P487, DOI 10.1089/scd.2011.0027; Kwiatkowski AV, 2003, TRENDS CELL BIOL, V13, P386, DOI 10.1016/S0962-8924(03)00130-2; Lee MP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029758; Li BM, 2011, CELL CALCIUM, V50, P42, DOI 10.1016/j.ceca.2011.05.001; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Liu XB, 2005, J BIOL CHEM, V280, P21600, DOI 10.1074/jbc.c400492200; Loikkanen I, 2005, DIFFERENTIATION, V73, P303, DOI 10.1111/j.1432-0436.2005.00036.x; Malarkey EB, 2008, GLIA, V56, P821, DOI 10.1002/glia.20656; Miyano K, 2010, NEUROCHEM INT, V57, P923, DOI 10.1016/j.neuint.2010.09.012; Munakata M, 2013, STROKE, V44, P1981, DOI 10.1161/STROKEAHA.113.679332; Nakao K, 2008, J NEUROSCI RES, V86, P2722, DOI 10.1002/jnr.21711; Peters M, 2012, J NEUROTRAUM, V29, P2831, DOI 10.1089/neu.2012.2575; Pizzo P, 2001, J NEUROCHEM, V79, P98, DOI 10.1046/j.1471-4159.2001.00539.x; Quick K, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120068; Reyes RC, 2013, CELL CALCIUM, V54, P120, DOI 10.1016/j.ceca.2013.05.005; Schaefer M, 2005, PFLUG ARCH EUR J PHY, V451, P35, DOI 10.1007/s00424-005-1467-6; Schleifer H, 2012, BRIT J PHARMACOL, V167, P1712, DOI 10.1111/j.1476-5381.2012.02126.x; Shirakawa H, 2010, J NEUROSCI, V30, P13116, DOI 10.1523/JNEUROSCI.1890-10.2010; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Song XY, 2005, GLIA, V49, P418, DOI 10.1002/glia.20128; Storch U, 2012, J BIOL CHEM, V287, P3530, DOI 10.1074/jbc.M111.283218; Streifel KM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110996; Streifel KM, 2013, NEUROTOXICOLOGY, V34, P160, DOI 10.1016/j.neuro.2012.10.014; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Tsvilovskyy VV, 2009, GASTROENTEROLOGY, V137, P1415, DOI 10.1053/j.gastro.2009.06.046; Van Huyen JPD, 2008, J AM SOC NEPHROL, V19, P1965, DOI 10.1681/ASN.2007070781; Wang YQ, 2016, J FUNCT SPACE, V2016, DOI [10.1155/2016/2543268, 10.1155/2016/2319741, 10.1155/2016/5639129]; WINDLE WF, 1952, J COMP NEUROL, V96, P359, DOI 10.1002/cne.900960207; Woo JS, 2014, BIOCHEM BIOPH RES CO, V446, P454, DOI 10.1016/j.bbrc.2014.02.127; Wu XY, 2004, J BIOL CHEM, V279, P43392, DOI 10.1074/jbc.M408959200; Zhan JS, 2017, NEUROCHEM RES, V42, P272, DOI 10.1007/s11064-016-2089-4; Zhao ZK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045215; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zimmermann J, 2014, J BIOL CHEM, V289, P9766, DOI 10.1074/jbc.M114.557066	62	12	12	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	SEP	2017	65	9					1535	1549		10.1002/glia.23180			15	Neurosciences	Neurosciences & Neurology	FA5IL	WOS:000405476300010	28636132	Green Accepted			2021-06-18	
J	Fuller, CW; Taylor, A; Raftery, M				Fuller, Colin W.; Taylor, Aileen; Raftery, Martin			2016 Rio Olympics: an epidemiological study of the men's and women's Rugby-7s tournaments	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SEVENS WORLD SERIES; SPORTS INJURIES; CONCUSSION; UNION; MATCH; CUP	Objective To determine the incidence, severity and nature of injuries sustained during the men's and women's 2014/2015 and 2015/2016 Sevens World Series (SWS) and 2016 Olympic Games Rugby Sevens tournaments. Design A prospective cohort study. Participants All players from the core teams competing in the men's and women's 2014/2015 and 2015/2016 SWS (men: 15 teams; women: 11 teams) and all players from the men's (12 teams) and women's (12 teams) 2016 Rio Olympics tournaments. Results The gold, silver and bronze medal-winning women's teams contained bigger players (body mass and stature) than other teams but the men's medal winning teams came from across the size spectrum of men's teams competing at Rio 2016. The incidences of injury in the men's tournaments (2014/2015 SWS: 107.7 injuries/1000 player-match-hours (95% CI 90.9 to 127.4); 2015/2016 SWS: 109.7 (95% CI 93.7 to 128.6); Rio 2016: 124.5 (95% CI 73.7 to 210.2)) were higher but not statistically significant than those in the equivalent women's tournaments (2014/2015 SWS: 88.5 (95% CI 68.4 to 114.5), p=0.250; 2015/2016 SWS: 109.4 (95% CI 84.2 to 142.2), p=0.984; Rio 2016: 71.1 (95% CI 35.6 to 142.2), p=0.208). There were no statistically significant differences between the incidences of injury at the men's and women's 2016 Rio Olympics and the equivalent 2014/2015 (men: p=0.603; women: p=0.562) and 2015/2016 (men: p=0.652; women: p=0.254) SWS. Conclusions The incidence, severity and nature of the injuries sustained during the men's and women's Rio 2016 Rugby-7s tournaments fell within the normal range of values for international Rugby-7s tournaments.	[Fuller, Colin W.; Taylor, Aileen; Raftery, Martin] World Rugby, World Rugby House,Pembroke St Lower, Dublin 2, Ireland; [Fuller, Colin W.] Colin Fuller Consultancy Ltd, Loughborough, England	Fuller, CW (corresponding author), World Rugby, World Rugby House,Pembroke St Lower, Dublin 2, Ireland.	colin.fuller@f-marc.com			World Rugby, Dublin, Ireland	The study was funded by World Rugby, Dublin, Ireland.	Best JP, 2003, BRIT J SPORT MED, V2005, P812; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Brooks JHM, 2008, J SPORT SCI, V26, P863, DOI 10.1080/02640410701832209; Chalmers DJ, 2004, J SCI MED SPORT, V7, P74, DOI 10.1016/S1440-2440(04)80046-X; Engebretsen L, 2013, BRIT J SPORT MED, V47, P407, DOI 10.1136/bjsports-2013-092380; Fuller CW, 2008, BRIT J SPORT MED, V42, P452, DOI 10.1136/bjsm.2008.047035; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2016, BRIT J SPORT MED, V50, P682, DOI 10.1136/bjsports-2016-096043; Fuller CW, 2015, BRIT J SPORT MED, V49, P458, DOI 10.1136/bjsports-2014-094369; Fuller CW, 2015, BRIT J SPORT MED, V49, P478, DOI 10.1136/bjsports-2013-093381; Fuller CW, 2013, BRIT J SPORT MED, V47, P1184, DOI 10.1136/bjsports-2012-091155; Fuller CW, 2016, BR J SPORTS MED; Fuller CW, 2016, BRIT J SPORT MED, P1; Fuller GW, 2015, BRIT J SPORT MED, V49, P529, DOI 10.1136/bjsports-2014-093498; Jakoet I, 1998, S AFR MED J, V88, P45; Junge A, 2009, AM J SPORT MED, V37, P2165, DOI 10.1177/0363546509339357; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Orchard J., 1995, SPORT HLTH, V11, P39; Quarrie KL, 2007, BRIT MED J, V334, P1150, DOI 10.1136/bmj.39185.605914.AE; Quarrie KL, 2016, BR J SPORTS MED; Rugby Football Union, 2016, ENGL PROF RUGB INJ S; Rugby W, HIST RUGBY 7; Rugby W, WORLD RUGBY RES FUND; Rugby W, HSBC WORLD RUGB 7 SE; WALLER AE, 1994, BRIT J SPORT MED, V28, P223, DOI 10.1136/bjsm.28.4.223; Windt J, 2016, BR J SPORTS MED	26	12	12	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	SEP	2017	51	17					1272	+		10.1136/bjsports-2016-097301			8	Sport Sciences	Sport Sciences	FE1ZB	WOS:000408015000006	28137789	Bronze			2021-06-18	
J	Knowles, BM; Dennison, CR				Knowles, Brooklynn M.; Dennison, Christopher R.			Predicting Cumulative and Maximum Brain Strain Measures From HybridIII Head Kinematics: A Combined Laboratory Study and Post-Hoc Regression Analysis	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Head injury; Brain injury; Brain strain; Injury biomechanics; Concussion; Helmet assessment; Sport biomechanics	UNITED-STATES; ICE HOCKEY; INJURY; CONCUSSION; ACCELERATION; EPIDEMIOLOGY; SPORTS	Due to growing concern on brain injury in sport, and the role that helmets could play in preventing brain injury caused by impact, biomechanics researchers and helmet certification organizations are discussing how helmet assessment methods might change to assess helmets based on impact parameters relevant to brain injury. To understand the relationship between kinematic measures and brain strain, we completed hundreds of impacts using a 50th percentile Hybrid III head-neck wearing an ice hockey helmet and input three-dimensional impact kinematics to a finite element brain model called the Simulated Injury Monitor (SIMon) (n = 267). Impacts to the helmet front, back and side included impact speeds from 1.2 to 5.8 ms(-1). Linear regression models, compared through multiple regression techniques, calculating adjusted R-2 and the F-statistic, determined the most efficient set of kinematics capable of predicting SIMon-computed brain strain, including the cumulative strain damage measure (specifically CSDM-15) and maximum principal strain (MPS). Resultant change in angular velocity, Delta omega(R), better predicted CSDM-15 and MPS than the current helmet certification metric, peak g, and was the most efficient model for predicting strain, regardless of impact location. In nearly all cases, the best two-variable model included peak resultant angular acceleration, alpha(R), and Delta omega(R).	[Knowles, Brooklynn M.; Dennison, Christopher R.] Univ Alberta, Biomed Instrumentat Lab, Dept Mech Engn, Edmonton, AB, Canada	Knowles, BM (corresponding author), Univ Alberta, Biomed Instrumentat Lab, Dept Mech Engn, Edmonton, AB, Canada.	brooklyn@ualberta.ca			Natural Science and Engineering Research Council (NSERC) of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC) [435921]; Pashby Sport Safety Fund [RES0028760]; Banting Research Foundation [31214]; Faculty of Engineering and Department of Mechanical Engineering at the University of Alberta	We gratefully acknowledge funding from the Natural Science and Engineering Research Council (NSERC) of Canada (Discovery Grants 435921), the Pashby Sport Safety Fund (2016: RES0028760), the Banting Research Foundation (Discovery Award 31214), and the Faculty of Engineering and Department of Mechanical Engineering at the University of Alberta.	[Anonymous], F104507 ASTM; [Anonymous], 2015, ND00213M15 NOCSAE; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; BS, 1960, 18691960 BS; CPSC, 1998, SAF STAND BIC HELM F; CSA, 2012, Z262109 CSA; Daneshvar DH, 2011, CLIN SPORT MED, V30, P145, DOI 10.1016/j.csm.2010.09.006; Devore JL, 2000, PROBABILITY STAT ENG; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Gennarelli T. A., 1972, PATHOPHYSIOLOGIC RES; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; Halldin P., 2014, 158 CENTC; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Holbourn AHS, 1943, LANCET, V2, P438; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Kimpara H., 2011, INT J AUTOMOT ENG, V2, P13; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Mueller F. O., 2011, AM FOOTB COACH ASS N; Newman J A, 2000, Stapp Car Crash J, V44, P215; Newman J.A, 1986, P 1986 INT IRCOBI C; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Rowson B, 2015, ANN BIOMED ENG, V43, P2429, DOI 10.1007/s10439-015-1278-7; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; SAE J211, J211 SAE; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Takhounts EG, 2008, STAPP CAR C, V52, P1; Tarlochan F., 2013, INT J SCI TECHNOL RE, V2, P17; Wennberg RA, 2008, CAN J NEUROL SCI, V35, P647, DOI 10.1017/S031716710000946X; YARNELL P, 1969, B NEW YORK ACAD MED, V45, P39	33	12	12	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	SEP	2017	45	9					2146	2158		10.1007/s10439-017-1848-y			13	Engineering, Biomedical	Engineering	FE4QF	WOS:000408197700009	28497321	Other Gold, Green Published			2021-06-18	
J	Poveda, B; Osborne-Crowley, K; Laidlaw, K; Macleod, F; Power, K				Poveda, Blanca; Osborne-Crowley, Katherine; Laidlaw, Kenneth; Macleod, Fiona; Power, Kevin			Social Cognition, Behaviour and Relationship Continuity in Dementia of the Alzheimer Type	BRAIN IMPAIRMENT			English	Article						social cognition; Alzheimer's disease; dementia; theory of mind; emotion recognition	TRAUMATIC BRAIN-INJURY; VARIANT FRONTOTEMPORAL DEMENTIA; MINI-MENTAL STATE; NEUROPSYCHIATRIC INVENTORY; EMOTION PERCEPTION; FACIAL EXPRESSIONS; SEMANTIC DEMENTIA; DISEASE; RECOGNITION; PSYCHOPATHOLOGY	Social cognition can be impaired in a range of neuro-degenerative conditions, yet the impact of these difficulties on behaviour and social relationships is not yet fully understood. This study assessed social cognition in 27 participants with Dementia of the Alzheimer Type (DAT) and their co-residing partners (N = 27) and explored the relationships between social cognition, cognitive ability, relationship continuity and behaviour following diagnosis. In line with previous research, participants with dementia scored lower on social cognition tasks compared to their partners. Behaviour changes such as apathy, disinhibition and agitation in participants with dementia were significantly related to relationship continuity; however, no significant associations were found with measures of social cognition. The results of this study are discussed within a therapeutic context and in line with current guidelines and policies.	[Poveda, Blanca] Astley Ainslie Hosp, Clin Neuropsychol Dept, NHS Lothian, Edinburgh, Midlothian, Scotland; [Osborne-Crowley, Katherine] Univ South Wales, Sch Psychol, Syndney, Australia; [Laidlaw, Kenneth] Univ East Anglia, Norwich Med Sch, Fac Med & Hlth Sci, Norwich Res Pk, Norwich, Norfolk, England; [Macleod, Fiona] Stracathro Hosp, NHS Tayside Older People, Psychol Therapies Serv, Brechin, Scotland; [Power, Kevin] Univ Stirling, Stirling, Scotland	Poveda, B (corresponding author), Astley Ainslie Hosp, Clin Neuropsychol Dept, NHS Lothian, Edinburgh, Midlothian, Scotland.	blanca.poveda@nhslothian.nhs.scot.uk		Osborne-Crowley, Katherine/0000-0003-0295-1849	Scottish Dementia Clinical Research Network; Chief Scientist Office	This research was conducted as part of the Doctorate in Clinical Psychology at the University of Edinburgh. This work was supported by the Scottish Dementia Clinical Research Network, who received funding from Scottish Ministers through the Chief Scientist Office. The views expressed in this publication are those of the authors and not necessarily those of Scottish Ministers or the Chief Scientist Office.	Adolphs R., 2001, CURRENT OPINIONS NEU, V11, P11231; Alzheimers Society, 2012, OPT TREATM CAR PEOPL; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Bornhofen C, 2008, NEUROPSYCHOL REHABIL, V18, P22, DOI 10.1080/09602010601061213; Bozeat S, 2000, J NEUROL NEUROSUR PS, V69, P178, DOI 10.1136/jnnp.69.2.178; Bucks RS, 2004, AGING MENT HEALTH, V8, P222, DOI 10.1080/13607860410001669750; Burke JR, 1999, POSTGRAD MED, V106, P131, DOI 10.3810/pgm.1999.10.15.748; Burnham H, 2004, DEMENT GERIATR COGN, V18, P75, DOI 10.1159/000077813; Chow TW, 2009, ARCH NEUROL-CHICAGO, V66, P888, DOI 10.1001/archneurol.2009.92; Coen RF, 1997, INT J GERIATR PSYCH, V12, P331, DOI 10.1002/(SICI)1099-1166(199703)12:3<331::AID-GPS495>3.3.CO;2-A; COHEN CA, 1993, GERONTOLOGIST, V33, P714, DOI 10.1093/geront/33.6.714; Cummings JL, 1997, NEUROLOGY, V48, pS10, DOI 10.1212/WNL.48.5_Suppl_6.10S; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Department of Health, 2009, LIVING WELL DEMENTIA; Duff K, 2011, ARCH CLIN NEUROPSYCH, V26, P701, DOI 10.1093/arclin/acr083; Ekman P., 1976, PICTURES FACIAL AFFE; FEHER EP, 1992, ARCH NEUROL-CHICAGO, V49, P87, DOI 10.1001/archneur.1992.00530250091022; Field A. P, 2009, DISCOVERING STAT USI; Finkel S I, 1996, Int Psychogeriatr, V8 Suppl 3, P497; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gallagher-Thompson D, 2001, J GERONTOL B-PSYCHOL, V56, pS140, DOI 10.1093/geronb/56.3.S140; Garand L, 2007, WESTERN J NURS RES, V29, P976, DOI 10.1177/0193945907303086; Gregory C, 2002, BRAIN, V125, P752, DOI 10.1093/brain/awf079; Hargrave R, 2002, J NEUROPSYCH CLIN N, V14, P64, DOI 10.1176/jnp.14.1.64; Hebert R, 2001, J GERONTOL A-BIOL, V56, pM693, DOI 10.1093/gerona/56.11.M693; Henry JD, 2008, NEUROPSYCHOLOGIA, V46, P1363, DOI 10.1016/j.neuropsychologia.2007.12.012; Hodges JR, 1999, NEUROPSYCHOLOGY, V13, P31, DOI 10.1037/0894-4105.13.1.31; Honan C. A., 2016, CLIN NEUROPSYCHOL, V30, P1; Hsieh S, 2013, J GERIATR PSYCH NEUR, V26, P174, DOI 10.1177/0891988713495448; Jalbert JJ, 2008, EPIDEMIOL REV, V30, P15, DOI 10.1093/epirev/mxn008; Kaufer DI, 1998, J AM GERIATR SOC, V46, P210, DOI 10.1111/j.1532-5415.1998.tb02542.x; Keane J, 2002, NEUROPSYCHOLOGIA, V40, P655, DOI 10.1016/S0028-3932(01)00156-7; Kipps CM, 2009, BRAIN, V132, P592, DOI 10.1093/brain/awn314; Kipps CM, 2009, NEUROCASE, V15, P182, DOI 10.1080/13554790802632892; Koff E, 1999, J INT NEUROPSYCH SOC, V5, P32, DOI 10.1017/S1355617799511053; Kumfor F, 2014, J NEUROL NEUROSUR PS, V85, P1076, DOI 10.1136/jnnp-2013-307098; Lavenu I, 1999, ALZ DIS ASSOC DIS, V13, P96, DOI 10.1097/00002093-199904000-00007; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S., 2002, AWARENESS SOCIAL INF; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M., 2006, J INT NEUROPSYCH SOC, V14, P318; Mioshi E, 2006, INT J GERIATR PSYCH, V21, P1078, DOI 10.1002/gps.1610; Morris J C, 1997, Int Psychogeriatr, V9 Suppl 1, P173, DOI 10.1017/S1041610297004870; Morris R. G., 2000, ADV PSYCHIAT TREAT, V6, P362, DOI [10.1192/apt.6.5.362, DOI 10.1192/APT.6.5.362]; O'Donnell B F, 1992, J Geriatr Psychiatry Neurol, V5, P45; Osborne-Crowley K, 2016, NEUROPSYCHOLOGY, V30, P820, DOI 10.1037/neu0000293; Osborne-Crowley K, 2016, J CLIN EXP NEUROPSYC, V38, P341, DOI 10.1080/13803395.2015.1115824; Phillips LH, 2010, PSYCHOL AGING, V25, P38, DOI 10.1037/a0017369; Psychological Corporation, 2001, WECHSLER TEST ADULT; Rankin KP, 2009, NEUROIMAGE, V47, P2005, DOI 10.1016/j.neuroimage.2009.05.077; Rascovsky K, 2011, BRAIN, V134, P2456, DOI 10.1093/brain/awr179; Riley GA, 2013, INT PSYCHOGERIATR, V25, P263, DOI 10.1017/S1041610212001743; Roberts VJ, 1996, NEUROLOGY, V47, P1482, DOI 10.1212/WNL.47.6.1482; Rosen HJ, 2004, ALZ DIS ASSOC DIS, V18, P202; Rosenberg H, 2014, J INT NEUROPSYCH SOC, V20, P994, DOI 10.1017/S1355617714000940; Seeley WW, 2008, ARCH NEUROL-CHICAGO, V65, P249, DOI 10.1001/archneurol.2007.38; Shany-Ur T, 2012, CORTEX, V48, P1329, DOI 10.1016/j.cortex.2011.08.003; Shimokawa A, 2001, BRAIN COGNITION, V47, P423, DOI 10.1006/brcg.2001.1318; STEELE C, 1990, AM J PSYCHIAT, V147, P1049; Van Hoesen G. W., 2000, CEREB CORTEX, V10, P1047; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	64	12	12	0	14	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1443-9646	1839-5252		BRAIN IMPAIR	Brain Impair.	SEP	2017	18	2			SI		175	187		10.1017/BrImp.2016.35			13	Clinical Neurology; Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FD5GN	WOS:000407559000001		Bronze			2021-06-18	
J	Smoliga, JM; Zavorsky, GS				Smoliga, James M.; Zavorsky, Gerald S.			Team Logo Predicts Concussion Risk Lessons in Protecting a Vulnerable Sports Community from Misconceived, but Highly Publicized Epidemiologic Research	EPIDEMIOLOGY			English	Article							HIGHER ALTITUDES; FOOTBALL	Background: Observational research has linked altitude to concussion risk, but the physiologic and epidemiologic bases for this association remain questionable. Methods: We performed a retrospective cohort study by analyzing four seasons of National Football League data from a widely used database (Concussion Watch) to determine if previous claims that altitude >= 196 m reduced concussion risk were replicable and whether an arbitrary predictor variable (animal vs. non-animal team logo) was related to concussion risk. Relative risk (RR) and 95% confidence intervals (95% CIs) were computed. Results: The previous association with altitude was reproduced for earlier seasons, but not replicable for recent seasons (RR = 0.92 [ 95% CI = 0.70, 1.22]). Across four combined seasons, "higher altitude" (RR = 0.78 [ 0.64, 0.96]) and animal logo (RR = 0.75 [0.63, 0.89]) were similarly associated with reduced concussion risk. Conclusions: Inconsistent epidemiologic effects, combined with weak physiologic rationale, suggest links between altitude and concussion are coincidental. Interdisciplinary critique of concussion research is necessary to ensure that marketing claims and clinical recommendations are scientifically justified.	[Smoliga, James M.] High Point Univ, Dept Phys Therapy, One Univ Pkwy, High Point, NC 27268 USA; [Zavorsky, Gerald S.] Georgia State Univ, Dept Resp Therapy, Atlanta, GA 30303 USA	Smoliga, JM (corresponding author), High Point Univ, Dept Phys Therapy, One Univ Pkwy, High Point, NC 27268 USA.	jsmoliga@highpoint.edu	Zavorsky, Gerald S./I-7753-2013; Zavorsky, Gerald/AAI-1422-2021	Zavorsky, Gerald S./0000-0002-4473-1601; 			Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Branch J, 2016, NY TIMES; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Carson D, 2015, T BRADY ONCE ENDORSE; Frontline, 2015, CONCUSSION WATCH; Iannetta J, 2015, US SOCCERS A KRIEGER; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Karr A., 2011, SIGNIFICANCE, V8, P116, DOI [10.1111/j.1740-9713.2011.00506.x, DOI 10.1111/J.1740-9713.2011.00506.X]; Kerr ZY, 2017, J ATHL TRAINING, V52, P167, DOI 10.4085/1062-6050-51.6.05; Lawrence DW, 2016, ORTHOP J SPORTS MED, V4, DOI 10.1177/2325967116639222; Lohmander LS, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.g7835; Lynn RC, 2015, LANCET NEUROL, V14, P14, DOI 10.1016/S1474-4422(14)70308-4; Myer GD, 2016, BRIT J SPORT MED, V50, P1276, DOI 10.1136/bjsports-2016-096134; Myer GD, 2014, J ORTHOP SPORT PHYS, V44, P164, DOI 10.2519/jospt.2014.5298; Nathanson JT, 2016, ORTHOP J SPORTS MED, V4, DOI 10.1177/2325967115622621; Nuzzo R, 2015, NATURE, V526, P182, DOI 10.1038/526182a; Nuzzo R, 2014, NATURE, V506, P150, DOI 10.1038/506150a; Orcutt M, 2016, NEW COLLAR PROMISES; Pearce N, 2014, LANCET NEUROL, V13, P969, DOI 10.1016/S1474-4422(14)70146-2; Schwarz A., 2016, NY TIMES; Schwarz A, 2016, N F L S FLAWED CONCU; Singal J, 2016, U MARYLAND HAS BURGE; Smoliga JM, 2017, J APPL PHYSIOL, V122, P215, DOI 10.1152/japplphysiol.00661.2016; Teramoto M, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115620365; United States Food and Drug Administration, 2015, CAN DIET SUPPL TREAT; Willett WC, 2008, EPIDEMIOLOGY, V19, P655, DOI 10.1097/EDE.0b013e318181b877; Zavorsky GS, 2017, JAMA NEUROL, V74, P485, DOI 10.1001/jamaneurol.2016.6068; Zavorsky GS, 2016, JAMA NEUROL, V73, P1368, DOI 10.1001/jamaneurol.2016.0795	28	12	12	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1044-3983	1531-5487		EPIDEMIOLOGY	Epidemiology	SEP	2017	28	5					753	757		10.1097/EDE.0000000000000694			5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	FC2PA	WOS:000406679200024	28570384				2021-06-18	
J	Taylor, BC; Campbell, EH; Nugent, S; Bidelspach, DE; Kehle-Forbes, SM; Scholten, J; Stroupe, KT; Sayer, NA				Taylor, Brent C.; Campbell, Emily Hagel; Nugent, Sean; Bidelspach, Douglas E.; Kehle-Forbes, Shannon M.; Scholten, Joel; Stroupe, Kevin T.; Sayer, Nina A.			Three Year Trends in Veterans Health Administration Utilization and Costs after Traumatic Brain Injury Screening among Veterans with Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injuries; healthcare costs; traumatic injury; utilization; veterans	WAR; IRAQ; AFGHANISTAN; SEQUELAE; OUTCOMES	Examination of trends in Veterans Health Administration (VHA) healthcare utilization and costs among veterans with mild traumatic brain injury (mTBI) is needed to inform policy, resource allocation, and treatment planning. The objective of this study was to assess the patterns of VHA healthcare utilization and costs in the 3 years following TBI screening among veterans with mTBI, compared with veterans without TBI. A retrospective cohort study of veterans who underwent TBI screening in fiscal year 2010 was conducted. We used VHA healthcare utilization and associated costs by categories of care to compare veterans diagnosed with mTBI (n = 7318) with those who screened negative (n = 75,294) and those who screened positive but had TBI ruled out (n = 3324). Utilization and costs were greatest in year 1, dropped in year 2, and then leveled off. mTBI diagnosis was associated with high rates of utilization. Each year, healthcare costs for those with mTBI were two to three times higher than for those who screened negative, and 20-25% higher than for those who screened positive but had TBI ruled out. A significant proportion of healthcare use and costs for veterans with mTBI were associated with mental health service utilization. The relatively high rate of VHA utilization and costs associated with mTBI over time demonstrates the importance of long-term planning to meet these veterans' needs. Identifying and engaging patients with mTBI in effective mental health treatments should be considered a critical component of treatment planning.	[Taylor, Brent C.; Campbell, Emily Hagel; Nugent, Sean; Kehle-Forbes, Shannon M.; Sayer, Nina A.] Dept Vet Affairs Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; [Taylor, Brent C.; Kehle-Forbes, Shannon M.; Sayer, Nina A.] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA; [Taylor, Brent C.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA; [Sayer, Nina A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [Bidelspach, Douglas E.] VA Med Ctr, Vet Hlth Adm, Phys Med Serv, Lebanon, PA USA; [Bidelspach, Douglas E.] VA Med Ctr, Vet Hlth Adm, Rehabil Serv, Lebanon, PA USA; [Bidelspach, Douglas E.; Scholten, Joel] Dept Vet Affairs, Phys Med & Rehabil Program Off, Washington, DC USA; [Scholten, Joel] Washington DC VA Med Ctr, Dept Phys Med & Rehabil, Washington, DC USA; [Stroupe, Kevin T.] Hines VA Hosp, Ctr Innovat Complex Chron Healthcare, Hines, IL USA; [Stroupe, Kevin T.] Loyola Univ Chicago, Dept Publ Hlth Sci, Maywood, IL USA	Taylor, BC (corresponding author), VA Hlth Care Syst 152, 1 Vet Dr, Minneapolis, MN 55417 USA.	Brent.Taylor2@va.gov	Taylor, Brent C/A-8069-2009	Taylor, Brent C/0000-0002-2140-8377	United States Department of Veterans Affairs, Office of Research and DevelopmentUS Department of Veterans Affairs [PLY05-2010-2]	Funding for the study was provided by the United States Department of Veterans Affairs, Office of Research and Development, Health Services Research & Development Service (HSR&D), Washington, DC through a locally initiated project grant (#PLY05-2010-2) from the Polytrauma and Blast-Related Injuries (PT/BRI) Quality Enhancement Research Initiative (QUERI). The funding source had no role in the study design, analysis, interpretation of the data, writing of the article, or decision to submit the article for publication. Preliminary results related to this article were presented at the VA HSR&D Annual Meeting July 8-10, 2015, in Philadelphia, PA.	Belanger HG, 2016, J HEAD TRAUMA REHAB, V31, P204, DOI 10.1097/HTR.0000000000000168; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Defense and Veterans Brain Injury Center, 2016, TBI BAS; [Department of Health and Human Services Centers for Disease Control Prevention National Center for Injury Prevention and Control Division of Unintentional Injury Prevention], 2014, REP C TRAUM BRAIN IN; Department of Veterans Affairs & Department of Defense, 2016, VA DOD CLIN PRACT GU; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Eibner C., 2008, INVISIBLE WOUNDS WAR, P169; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Hendricks A, 2012, PTSD MILD TRAUMATIC, P260; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; Kehle-Forbes SM, 2017, J HEAD TRAUMA REHAB, V32, pE16, DOI 10.1097/HTR.0000000000000227; McCrea M, 2008, MILD TRAUMATIC BRAIN; Mild Traumatic Brain Injury Committee American Congress of Rehabilitation Medicine Head Injury Interdisciplinary Special Interest Group, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; O'Neil M. E., 2012, 05225 VAESP DEP VET; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Phibbs C. S., 2015, RES GUIDE MANAGERIAL; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Sripada RK, 2013, J TRAUMA STRESS, V26, P369, DOI 10.1002/jts.21813; Stroupe KT, 2013, J REHABIL RES DEV, V50, P1047, DOI 10.1682/JRRD.2012.06.0107; Taylor B., 2015, FISCAL YEAR 2014 VA; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Veterans Health Administration, 2010, SCREEN EV POSS TRAUM; Wagner TH, 2003, MED CARE RES REV, V60, p15S, DOI 10.1177/1077558703256485	31	12	12	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2017	34	17					2567	2574		10.1089/neu.2016.4910			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FE6HI	WOS:000408310200010	28482747				2021-06-18	
J	Hayakawa, M; Maekawa, K; Kushimoto, S; Kato, H; Sasaki, J; Ogura, H; Matsuoka, T; Uejima, T; Morimura, N; Ishikura, H; Hagiwara, A; Takeda, M; Kaneko, N; Saitoh, D; Kudo, D; Kanemura, T; Shibusawa, T; Furugori, S; Nakamura, Y; Shiraishi, A; Murata, K; Mayama, G; Yaguchi, A; Kim, S; Takasu, O; Nishiyama, K				Hayakawa, Mineji; Maekawa, Kunihiko; Kushimoto, Shigeki; Kato, Hiroshi; Sasaki, Junichi; Ogura, Hiroshi; Matsuoka, Tetsuya; Uejima, Toshifumi; Morimura, Naoto; Ishikura, Hiroyasu; Hagiwara, Akiyoshi; Takeda, Munekazu; Kaneko, Naoyuki; Saitoh, Daizoh; Kudo, Daisuke; Kanemura, Takashi; Shibusawa, Takayuki; Furugori, Shintaro; Nakamura, Yoshihiko; Shiraishi, Atsushi; Murata, Kiyoshi; Mayama, Gou; Yaguchi, Arino; Kim, Shiei; Takasu, Osamu; Nishiyama, Kazutaka			Hyperfibrinolysis in severe isolated traumatic brain injury may occur without tissue hypoperfusion: a retrospective observational multicentre study	CRITICAL CARE			English	Article						Coagulopathy; Disseminated intravascular coagulation; Hypoperfusion; Hyperfibrinolysis; Traumatic brain injury	DISSEMINATED INTRAVASCULAR COAGULATION; HEAD-INJURY; LACTATE-DEHYDROGENASE; ACUTE COAGULOPATHY; PREDICTIVE-VALUE; MULTIPLE TRAUMA; LUNG INJURY; T-PA; FIBRINOLYSIS; DIAGNOSIS	Background: Hyperfibrinolysis is a critical complication in severe trauma. Hyperfibrinolysis is traditionally diagnosed via elevated D-dimer or fibrin/fibrinogen degradation product levels, and recently, using thromboelastometry. Although hyperfibrinolysis is observed in patients with severe isolated traumatic brain injury (TBI) on arrival at the emergency department (ED), it is unclear which factors induce hyperfibrinolysis. The present study aimed to investigate the factors associated with hyperfibrinolysis in patients with isolated severe TBI. Methods: We conducted a multicentre retrospective review of data for adult trauma patients with an injury severity score >= 16, and selected patients with isolated TBI (TBI group) and extra-cranial trauma (non-TBI group). The TBI group included patients with an abbreviated injury score (AIS) for the head >= 4 and an extra-cranial AIS < 2. The non-TBI group included patients with an extra-cranial AIS >= 3 and head AIS < 2. Hyperfibrinolysis was defined as a D-dimer level >= 38 mg/L on arrival at the ED. We evaluated the relationships between hyperfibrinolysis and injury severity/tissue injury/tissue perfusion in TBI patients by comparing them with non-TBI patients. Results: We enrolled 111 patients in the TBI group and 126 in the non-TBI group. In both groups, patients with hyperfibrinolysis had more severe injuries and received transfusion more frequently than patients without hyperfibrinolysis. Tissue injury, evaluated on the basis of lactate dehydrogenase and creatine kinase levels, was associated with hyperfibrinolysis in both groups. Among patients with TBI, the mortality rate was higher in those with hyperfibrinolysis than in those without hyperfibrinolysis. Tissue hypoperfusion, evaluated on the basis of lactate level, was associated with hyperfibrinolysis in only the non-TBI group. Although the increase in lactate level was correlated with the deterioration of coagulofibrinolytic variables (prolonged prothrombin time and activated partial thromboplastin time, decreased fibrinogen levels, and increased D-dimer levels) in the non-TBI group, no such correlation was observed in the TBI group. Conclusions: Hyperfibrinolysis is associated with tissue injury and trauma severity in TBI and non-TBI patients. However, tissue hypoperfusion is associated with hyperfibrinolysis in non-TBI patients, but not in TBI patients. Tissue hypoperfusion may not be a prerequisite for the occurrence of hyperfibrinolysis in patients with isolated TBI.	[Hayakawa, Mineji; Maekawa, Kunihiko] Hokkaido Univ Hosp, Emergency & Crit Care Ctr, Kita Ku, N14W5, Sapporo, Hokkaido 0608648, Japan; [Kushimoto, Shigeki; Kudo, Daisuke] Tohoku Univ, Grad Sch Med, Div Emergency & Crit Care Med, Sendai, Miyagi, Japan; [Kato, Hiroshi; Kanemura, Takashi] Natl Hosp Org, Disaster Med Ctr, Dept Crit Care & Traumatol, Tokyo, Japan; [Sasaki, Junichi; Shibusawa, Takayuki] Keio Univ, Sch Med, Dept Emergency & Crit Care Med, Tokyo, Japan; [Ogura, Hiroshi] Osaka Univ, Grad Sch Med, Dept Traumatol & Acute Crit Med, Osaka, Japan; [Matsuoka, Tetsuya] Rinku Gen Med Ctr, Senshu Trauma & Crit Care Ctr, Osaka, Japan; [Uejima, Toshifumi] Kinki Univ, Fac Med, Dept Emergency & Crit Care Med, Osaka, Japan; [Morimura, Naoto] Tokyo Univ Hosp, Dept Emergency & Crit Care Med, Tokyo, Japan; [Ishikura, Hiroyasu; Nakamura, Yoshihiko] Fukuoka Univ, Fac Med, Dept Emergency & Crit Care Med, Fukuoka, Japan; [Hagiwara, Akiyoshi; Mayama, Gou] Natl Ctr Global Hlth & Med, Dept Emergency Med & Crit Care, Tokyo, Japan; [Takeda, Munekazu; Yaguchi, Arino] Tokyo Womens Med Univ, Dept Crit Care & Emergency Med, Tokyo, Japan; [Kaneko, Naoyuki] Fukaya Red Cross Hosp, Trauma & Emergency Ctr, Saitama, Japan; [Saitoh, Daizoh] Natl Def Med Coll, Res Inst, Div Traumatol, Saitama, Japan; [Furugori, Shintaro] Yokohama City Univ, Grad Sch Med, Dept Emergency Med, Yokohama, Kanagawa, Japan; [Shiraishi, Atsushi; Murata, Kiyoshi] Tokyo Med & Dent Univ Hosp Med, Trauma & Acute Crit Care Med Ctr, Tokyo, Japan; [Kim, Shiei] Nippon Med Sch, Dept Emergency Crit Care Med, Tokyo, Japan; [Takasu, Osamu] Kurume Univ, Sch Med, Dept Emergency & Crit Care Med, Kurume, Fukuoka, Japan; [Nishiyama, Kazutaka] Juntendo Univ, Urayasu Hosp, Dept Emergency & Crit Care Med, Chiba, Japan	Hayakawa, M (corresponding author), Hokkaido Univ Hosp, Emergency & Crit Care Ctr, Kita Ku, N14W5, Sapporo, Hokkaido 0608648, Japan.	mineji@dream.com	Kudo, Daisuke/AAE-4019-2020; Sasaki, Junichi/E-6992-2016	Kudo, Daisuke/0000-0001-8213-5176; Sasaki, Junichi/0000-0002-5190-8524	Japan Society for the Promotion of Science KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [25462810, 24592731]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15K10969, 15K10964] Funding Source: KAKEN	This study was supported in part by the Japan Society for the Promotion of Science KAKENHI (grant numbers 25462810 and 24592731).	Abrams ST, 2013, AM J RESP CRIT CARE, V187, P160, DOI 10.1164/rccm.201206-1037OC; Bilgic I, 2014, AM J EMERG MED, V32, P705, DOI 10.1016/j.ajem.2014.03.052; Feng JF, 2009, CLIN CHEM LAB MED, V47, P590, DOI 10.1515/CCLM.2009.127; Gando S, 1997, CRIT CARE MED, V25, P1820, DOI 10.1097/00003246-199711000-00019; Gando S, 2013, J THROMB HAEMOST, V11, P826, DOI 10.1111/jth.12190; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; GANDO S, 1992, CRIT CARE MED, V20, P594, DOI 10.1097/00003246-199205000-00009; Gando S, 2016, SEMIN THROMB HEMOST, V42, P155, DOI 10.1055/s-0035-1564831; Hagiwara A, 2016, SHOCK, V45, P495, DOI 10.1097/SHK.0000000000000536; Hayakawa M, 2016, SHOCK, V45, P308, DOI 10.1097/SHK.0000000000000542; Hayakawa M, 2013, SHOCK, V39, P514, DOI 10.1097/SHK.0b013e318293980d; Huber D, 2002, BLOOD, V99, P3637, DOI 10.1182/blood.V99.10.3637; KANEMITSU F, 1988, J CHROMATOGR-BIOMED, V429, P399, DOI 10.1016/S0378-4347(00)83880-3; Karakus A, 2012, ULUS TRAVMA ACIL CER, V18, P289, DOI 10.5505/tjtes.2012.81488; Kashuk JL, 2010, ANN SURG, V252, P434, DOI 10.1097/SLA.0b013e3181f09191; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; KOOISTRA T, 1994, INT J HEMATOL, V59, P233; Kraut JA, 2014, NEW ENGL J MED, V371, P2309, DOI 10.1056/NEJMra1309483; Kudo D, 2017, AM J EMERG MED, V35, P62, DOI 10.1016/j.ajem.2016.10.002; Kushimoto S, 2003, J NEUROTRAUM, V20, P357, DOI 10.1089/089771503765172318; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P1389, DOI 10.1097/TA.0b013e318270d595; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P87, DOI 10.1097/TA.0b013e3182598c70; Levrat A, 2008, BRIT J ANAESTH, V100, P792, DOI 10.1093/bja/aen083; Lowenstein CJ, 2005, TRENDS CARDIOVAS MED, V15, P302, DOI 10.1016/j.tcm.2005.09.005; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; MAEKAWA M, 1988, J CHROMATOGR-BIOMED, V429, P373, DOI 10.1016/S0378-4347(00)83879-7; Medved L, 2003, THROMB HAEMOSTASIS, V89, P409; Naganathar S, 2015, J TRAUMA ACUTE CARE, V79, P71, DOI 10.1097/TA.0000000000000694; Nekludov M, 2014, J NEUROTRAUM, V31, P1927, DOI 10.1089/neu.2013.3168; Ostrowski SR, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-64; RAO CJ, 1978, J NEUROL NEUROSUR PS, V41, P948, DOI 10.1136/jnnp.41.10.948; Raza I, 2013, J THROMB HAEMOST, V11, P307, DOI 10.1111/jth.12078; RISBERG B, 1986, CRIT CARE MED, V14, P917, DOI 10.1097/00003246-198611000-00001; Sawamura A, 2009, THROMB RES, V124, P608, DOI 10.1016/j.thromres.2009.06.034; Schochl H, 2009, J TRAUMA, V67, P125, DOI 10.1097/TA.0b013e31818b2483; Schrieber M, 2007, J TRAUMA, V63, P1261; Story DA, 2004, BRIT J ANAESTH, V92, P54, DOI 10.1093/bja/aeh018; Suehiro E, 2014, CLIN NEUROL NEUROSUR, V127, P97, DOI 10.1016/j.clineuro.2014.10.007; Theusinger OM, 2015, ANESTH ANALG, V120, P627, DOI 10.1213/ANE.0000000000000561; Theusinger OM, 2011, ANESTH ANALG, V113, P1003, DOI 10.1213/ANE.0b013e31822e183f; Tian Y, 2015, BLOOD, V125, P2151, DOI 10.1182/blood-2014-09-598805; VECHT CJ, 1975, J NEUROL NEUROSUR PS, V38, P567, DOI 10.1136/jnnp.38.6.567; Wada H, 2008, SEMIN THROMB HEMOST, V34, P33, DOI 10.1055/s-2008-1066021; Yasui H, 2016, AM J PHYSIOL-LUNG C, V311, pL74, DOI 10.1152/ajplung.00429.2015; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780	47	12	13	1	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	AUG 23	2017	21								222	10.1186/s13054-017-1811-1			9	Critical Care Medicine	General & Internal Medicine	FE7RV	WOS:000408405500001	28830477	DOAJ Gold, Green Published			2021-06-18	
J	Zhao, WY; Chen, SB; Wang, JJ; Xu, C; Zhao, ML; Dong, HJ; Liang, HQ; Li, XH; Tu, Y; Zhang, S; Chen, C; Sun, HT				Zhao, Wan-Yong; Chen, Shao-Bo; Wang, Jing-Jing; Xu, Chao; Zhao, Ming-Liang; Dong, Hua-Jiang; Liang, Hai-Qian; Li, Xiao-Hong; Tu, Yue; Zhang, Sai; Chen, Chong; Sun, Hong-Tao			Establishment of an ideal time window model in hypothermic-targeted temperature management after traumatic brain injury in rats	BRAIN RESEARCH			English	Article						Hypothermic-targeted temperature management; Traumatic brain injury; Time window; Effect	MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; NEURON APOPTOSIS; CARDIAC-ARREST; DENTATE GYRUS; ADULT MICE; EXPRESSION; PROTEIN	Although hypothermic-targeted temperature management (HTTM) holds great potential for the treatment of traumatic brain injury (TBI), translation of the efficacy of hypothermia from animal models to TBI patients has no entire consistency. This study aimed to find an ideal time window model in experimental rats which was more in accordance with clinical practice through the delayed HTTM intervention. Sprague-Dawley rats were subjected to unilateral cortical contusion injury and received therapeutic hypothermia at 15 mins, 2 h, 4 h respectively after TBI. The neurological function was evaluated with the modified neurological severity score and Morris water maze test. The brain edema and morphological changes were measured with the water content and H&E staining. Brain sections were immunostained with antibodies against DCX (a neuroblast marker) and GFAP (an astrocyte marker). The apoptosis levels in the ipsilateral hippocampi and cortex were examined with antibodies against the apoptotic proteins Bcl-2, Bax, and cleaved caspase-3 by the immunofluorescence and western blotting. The results indicated that each hypothermia therapy group could improve neurobehavioral and cognitive function, alleviate brain edema and reduce inflammation. Furthermore, we observed that therapeutic hypothermia increased DCX expression, decreased GFAP expression, upregulated Bcl-2 expression and downregulated Bax and cleaved Caspase-3 expression. The above results suggested that HTTM at 2 h or even at 4 h post injury revealed beneficial brain protection similarly, despite the best effect at 15 min post-injury. These findings may provide relatively ideal time window models, further making the following experimental results more credible and persuasive. (C) 2017 Elsevier B.V. All rights reserved.	[Zhao, Wan-Yong; Wang, Jing-Jing; Xu, Chao; Zhao, Ming-Liang; Liang, Hai-Qian; Li, Xiao-Hong; Tu, Yue; Zhang, Sai; Chen, Chong; Sun, Hong-Tao] Logist Univ PAPF, Pingjin Hosp, Tianjin Key Lab Neurotrauma Repair, Brain Ctr, Tianjin 300162, Peoples R China; [Chen, Shao-Bo] Logist Univ PAPF, Pingjin Hosp, Heart Ctr, Tianjin Key Lab Cardiovasc Remodeling & Target Or, Tianjin 300162, Peoples R China; [Dong, Hua-Jiang] Tianjin Univ, State Key Lab Precis Measurement Technol & Instru, Tianjin 300072, Peoples R China	Chen, C; Sun, HT (corresponding author), Logist Univ PAPF, Pingjin Hosp, Tianjin Key Lab Neurotrauma Repair, Brain Ctr, Tianjin 300162, Peoples R China.	chongchen12@hotmail.com; chenmo333@163.com		, Dong/0000-0002-4141-3077	National Nature Scientific Fund of China [81471275, 81401067, 81301050]; National Nature Scientific Fund of Tianjin [14JCQNJC10200, 15JCQNJC11100, 15JCYBJC28100, 16JCYBJC27600]	This work was supported by the National Nature Scientific Fund of China (81471275, 81401067, 81301050) and the National Nature Scientific Fund of Tianjin (14JCQNJC10200, 15JCQNJC11100, 15JCYBJC28100, 16JCYBJC27600).	Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Bramlett HM, 2012, THER HYPOTHERMIA TEM, V2, P14, DOI 10.1089/ther.2012.0002; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Chen C, 2016, NEUROSCIENCE, V335, P114, DOI 10.1016/j.neuroscience.2016.08.038; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Feng JF, 2010, NEUROSURGERY, V67, P730, DOI 10.1227/01.NEU.0000378023.81727.6E; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Guo C, 2016, NEUROSCI LETT, V635, P17, DOI 10.1016/j.neulet.2016.10.031; Hifumi T, 2016, J NEUROTRAUM, V33, P1047, DOI 10.1089/neu.2015.4033; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Jensen EC, 2013, ANAT REC, V296, P378, DOI 10.1002/ar.22641; Jia F, 2014, J NEUROTRAUM, V31, P387, DOI 10.1089/neu.2008.0814; Jia F, 2009, J NEUROTRAUM, V26, P243, DOI 10.1089/neu.2008.0670; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kwak M, 2015, DEV NEUROSCI-BASEL, V37, P428, DOI 10.1159/000430862; Lee JH, 2017, NEURAL REGEN RES, V12, P341, DOI 10.4103/1673-5374.202915; Magavi SS, 2000, NATURE, V405, P951; Mao WF, 2014, INT J NEUROSCI, V124, P281, DOI 10.3109/00207454.2013.838236; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Pilchova I, 2015, CELL MOL NEUROBIOL, V35, P23, DOI 10.1007/s10571-014-0104-3; Polderman KH, 2015, THER HYPOTHERMIA TEM, V5, P73, DOI 10.1089/ther.2014.0031; Radabaugh HL, 2016, EXP NEUROL, V286, P61, DOI 10.1016/j.expneurol.2016.09.015; Robertson CL, 2000, CRIT CARE MED, V28, P3218, DOI 10.1097/00003246-200009000-00017; Schober ME, 2016, J NEUROTRAUM, V33, P390, DOI 10.1089/neu.2015.3945; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Stocchetti N, 2014, LANCET NEUROL, V13, P14, DOI 10.1016/S1474-4422(13)70280-1; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun HT, 2016, NEUROPSYCH DIS TREAT, V12, DOI 10.2147/NDT.S106915; Tado M, 2014, J NEUROTRAUM, V31, P691, DOI 10.1089/neu.2013.2940; Wang G, 2016, NEURAL REGEN RES, V11, P771, DOI 10.4103/1673-5374.182704; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Yokobori S, 2016, J INTENSIVE CARE, V4, DOI 10.1186/s40560-016-0137-4; Yokobori Shoji, 2013, Acta Neurochir Suppl, V118, P77, DOI 10.1007/978-3-7091-1434-6_13; Zheng SG, 2015, EUR J PHARMACOL, V750, P52, DOI 10.1016/j.ejphar.2015.01.031	41	12	16	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 15	2017	1669						141	149		10.1016/j.brainres.2017.06.006			9	Neurosciences	Neurosciences & Neurology	FC3HM	WOS:000406729700017	28629741				2021-06-18	
J	Bangma, DF; Fuermaier, ABM; Tucha, L; Tucha, O; Koerts, J				Bangma, Dorien F.; Fuermaier, Anselm B. M.; Tucha, Lara; Tucha, Oliver; Koerts, Janneke			The effects of normal aging on multiple aspects of financial decision-making	PLOS ONE			English	Article							MILD COGNITIVE IMPAIRMENT; PARKINSONS-DISEASE PATIENTS; IOWA GAMBLING TASK; TRAUMATIC BRAIN-INJURY; ADULT AGE-DIFFERENCES; OLDER-ADULTS; LIFE-SPAN; INDIVIDUAL-DIFFERENCES; EXTERNAL VALIDATION; ALZHEIMERS-DISEASE	Objectives Financial decision-making (FDM) is crucial for independent living. Due to cognitive decline that accompanies normal aging, older adults might have difficulties in some aspects of FDM. However, an improved knowledge, personal experience and affective decision-making, which are also related to normal aging, may lead to a stable or even improved age-related performance in some other aspects of FDM. Therefore, the present explorative study examines the effects of normal aging on multiple aspects of FDM. Methods One-hundred and eighty participants (range 18-87 years) were assessed with eight FDM tests and several standard neuropsychological tests. Age effects were evaluated using hierarchical multiple regression analyses. The validity of the prediction models was examined by internal validation (i.e. bootstrap resampling procedure) as well as external validation on another, independent, sample of participants (n = 124). Multiple regression and correlation analyses were applied to investigate the mediation effect of standard measures of cognition on the observed effects of age on FDM. Results On a relatively basic level of FDM (e.g., paying bills or using FDM styles) no significant effects of aging were found. However more complex FDM, such as making decisions in accordance with specific rules, becomes more difficult with advancing age. Furthermore, an older age was found to be related to a decreased sensitivity for impulsive buying. These results were confirmed by the internal and external validation analyses. Mediation effects of numeracy and planning were found to explain parts of the association between one aspect of FDM (i.e. Competence in decision rules) and age; however, these cognitive domains were not able to completely explain the relation between age and FDM. Conclusion Normal aging has a negative influence on a complex aspect of FDM, however, other aspects appear to be unaffected by normal aging or improve.	[Bangma, Dorien F.; Fuermaier, Anselm B. M.; Tucha, Lara; Tucha, Oliver; Koerts, Janneke] Univ Groningen, Dept Clin & Dev Neuropsychol, Groningen, Netherlands	Koerts, J (corresponding author), Univ Groningen, Dept Clin & Dev Neuropsychol, Groningen, Netherlands.	janneke.koerts@rug.nl	Tucha, Oliver/AAD-1403-2019	Bangma, Dorien/0000-0003-4187-3679; Fuermaier, Anselm/0000-0002-2331-0840			APPELBAUM PS, 1988, NEW ENGL J MED, V319, P1635, DOI 10.1056/NEJM198812223192504; Barkley R.A., 2008, ADHD ADULTS WHAT SCI; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Beatty SE, 1998, J RETAILING, V74, P169, DOI 10.1016/S0022-4359(99)80092-X; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; Beitz KM, 2014, J EXP PSYCHOL GEN, V143, P1677, DOI 10.1037/a0035823; Bleeker SE, 2003, J CLIN EPIDEMIOL, V56, P826, DOI 10.1016/S0895-4356(03)00207-5; Bouma A, 2012, HDB NEUROPSYCHOLOGIS, P717; Brand M, 2006, NEURAL NETWORKS, V19, P1266, DOI 10.1016/j.neunet.2006.03.001; Braver T. S., 2008, HDB AGING COGNITION, P311; Brickenkamp R, 2007, D2 AANDACHTS CONCENT; Brickenkamp R., 1998, D2 TEST ATTENTION, V1st US ed; Buelow MT, 2009, NEUROPSYCHOL REV, V19, P102, DOI 10.1007/s11065-009-9083-4; Chen YW, 2014, EDUC GERONTOL, V40, P825, DOI 10.1080/03601277.2014.900263; Cohen J., 2003, APPL MULTIPLE CORREL; Coley A., 2003, J FASH MARK MANAG, V7, P282, DOI [10.1108/13612020310484834, DOI 10.1108/13612020310484834]; Davis C, 2008, J INT NEUROPSYCH SOC, V14, P1063, DOI 10.1017/S1355617708081204; de Bruin WB, 2015, MED DECIS MAKING, V35, P22, DOI 10.1177/0272989X14542485; De Bruin WB, 2012, J BEHAV DECIS MAKING, V25, P352, DOI 10.1002/bdm.712; de Bruin WB, 2007, J PERS SOC PSYCHOL, V92, P938, DOI 10.1037/0022-3514.92.5.938; Del Missier F, 2013, J EXP PSYCHOL LEARN, V39, P1344, DOI 10.1037/a0032379; Del Missier F, 2010, THINK REASONING, V16, P69, DOI 10.1080/13546781003630117; Denburg N. L., 2015, AGING DECISION MAKIN; Denburg NL, 2005, NEUROPSYCHOLOGIA, V43, P1099, DOI 10.1016/j.neuropsychologia.2004.09.012; Dennis NA, 2008, HDB AGING COGNITION, P1, DOI DOI 10.4324/9780203837665.CH1; Dijksterhuis A, 2006, SCIENCE, V311, P1005, DOI 10.1126/science.1121629; Dijksterhuis A, 2004, J PERS SOC PSYCHOL, V87, P586, DOI 10.1037/0022-3514.87.5.586; Dreer LE, 2012, REHABIL PSYCHOL, V57, P5, DOI 10.1037/a0025818; Earnst KS, 2001, AGING NEUROPSYCHOL C, V8, P109, DOI 10.1076/anec.8.2.109.839; Evans JSBT, 2008, ANNU REV PSYCHOL, V59, P255, DOI 10.1146/annurev.psych.59.103006.093629; Fein G, 2007, J INT NEUROPSYCH SOC, V13, P480, DOI 10.1017/S135561770707052X; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fry J, 2009, S AFR J PSYCHOL, V39, P122, DOI 10.1177/008124630903900111; Glimcher PW, 2014, NEUROECONOMICS DECIS, P63; Grasman R. P. P. P., 2005, DHTML IMPLEMENTATION; GREEN L, 1994, PSYCHOL SCI, V5, P33, DOI 10.1111/j.1467-9280.1994.tb00610.x; Green L, 1996, PSYCHOL AGING, V11, P79, DOI 10.1037/0882-7974.11.1.79; GRISSO T, 1995, LAW HUMAN BEHAV, V19, P149, DOI 10.1007/BF01499323; HARREN VA, 1979, J VOCAT BEHAV, V14, P119, DOI 10.1016/0001-8791(79)90065-4; Henrich J, 2010, BEHAV BRAIN SCI, V33, P111, DOI 10.1017/S0140525X10000725; Hess TM, 2015, AGING DECISION MAKIN, P189, DOI DOI 10.1016/B978-0-12-417148-0.00010-8; Hindmarch T, 2013, BMC MED ETHICS, V14, DOI 10.1186/1472-6939-14-54; Karlawish J, 2013, NEUROLOGY, V81, P801, DOI 10.1212/WNL.0b013e3182a05ba5; Kennerley SW, 2011, BEHAV NEUROSCI, V125, P297, DOI 10.1037/a0023575; Kershaw MM, 2008, PSYCHIAT PSYCHOL LAW, V15, P40, DOI 10.1080/13218710701873965; Kershaw MM., 2004, PSYCHIAT PSYCHOL LAW, V11, P338, DOI [10.1375/pplt.2004.11.2.338, DOI 10.1375/PPLT.2004.11.2.338]; Kim SYH, 2001, AM J PSYCHIAT, V158, P712, DOI 10.1176/appi.ajp.158.5.712; Krawczyk DC, 2002, NEUROSCI BIOBEHAV R, V26, P631, DOI 10.1016/S0149-7634(02)00021-0; Li SC, 2004, PSYCHOL SCI, V15, P155, DOI 10.1111/j.0956-7976.2004.01503003.x; Lockenhoff CE, 2011, PSYCHOL AGING, V26, P274, DOI 10.1037/a0023280; LOEWENSTEIN DA, 1989, J GERONTOL, V44, pP114, DOI 10.1093/geronj/44.4.P114; Loewenstein G, 2015, DECISION, V2, P55, DOI [DOI 10.1037/dec0000029, 10.1037/dec0000029, DOI 10.1037/DEC0000029]; Loewenstein GF, 2001, PSYCHOL BULL, V127, P267, DOI 10.1037//0033-2909.127.2.267; Loo R, 2000, PERS INDIV DIFFER, V29, P895, DOI 10.1016/S0191-8869(99)00241-X; Lui VWC, 2013, J GERIATR PSYCH NEUR, V26, P69, DOI 10.1177/0891988713481268; Luteijn F., 2004, GIT 2 GRONINGER INTE; Maillet D, 2013, AGEING RES REV, V12, P479, DOI 10.1016/j.arr.2012.11.001; Marson DC, 2000, ARCH NEUROL-CHICAGO, V57, P877, DOI 10.1001/archneur.57.6.877; Martin RC, 2008, MOVEMENT DISORD, V23, P1867, DOI 10.1002/mds.22170; Martin RC, 2013, PARKINSONISM RELAT D, V19, P986, DOI 10.1016/j.parkreldis.2013.06.017; Mather M, 2005, PSYCHOL AGING, V20, P554, DOI 10.1037/0882-7974.20.4.554; Mather M., 2006, REV DECISION MAKING, P145; MEYER BJF, 1995, PSYCHOL AGING, V10, P84, DOI 10.1037/0882-7974.10.1.84; Mikels JA, 2013, EMOTION, V13, P189, DOI 10.1037/a0030441; Mikels JA, 2011, EMOTION, V11, P743, DOI 10.1037/a0023986; Nieuwenstein MR, 2015, JUDGM DECIS MAK, V10, P1; Orgeta V, 2009, AGING MENT HEALTH, V13, P818, DOI 10.1080/13607860902989661; Parker AM, 2005, J BEHAV DECIS MAKING, V18, P1, DOI 10.1002/bdm.481; Pereira FS, 2010, J INT NEUROPSYCH SOC, V16, P297, DOI 10.1017/S1355617709991330; Peters E, 2007, PERSPECT PSYCHOL SCI, V2, P1, DOI 10.1111/j.1745-6916.2007.00025.x; Pirogovsky E, 2014, NEUROPSYCHOLOGY, V28, P229, DOI 10.1037/neu0000045; Read D, 2004, ORGAN BEHAV HUM DEC, V94, P22, DOI 10.1016/j.obhdp.2004.01.002; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reyna VF, 2009, PSYCHOL BULL, V135, P943, DOI 10.1037/a0017327; Roelofs J, 2013, J PSYCHOPATHOL BEHAV, V35, P93, DOI 10.1007/s10862-012-9309-2; ROOK DW, 1987, J CONSUM RES, V14, P189, DOI 10.1086/209105; SALTHOUSE TA, 1995, J GERONTOL B-PSYCHOL, V50, pP297, DOI 10.1093/geronb/50B.6.P297; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Schmand B, 2008, Tijdschr Gerontol Geriatr, V39, P64; SCOTT SG, 1995, EDUC PSYCHOL MEAS, V55, P818, DOI 10.1177/0013164495055005017; Sherod MG, 2009, J INT NEUROPSYCH SOC, V15, P258, DOI 10.1017/S1355617709090365; Spicer DP., 2005, J MANAGE PSYCHOL, V20, P137, DOI DOI 10.1108/02683940510579777; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW, 2003, J CLIN EPIDEMIOL, V56, P441, DOI 10.1016/S0895-4356(03)00047-7; Suto WMI, 2005, J INTELL DISABIL RES, V49, P199, DOI 10.1111/j.1365-2788.2005.00635.x; Triebel KL, 2009, NEUROLOGY, V73, P928, DOI 10.1212/WNL.0b013e3181b87971; Van der Elst W, 2006, ASSESSMENT, V13, P62, DOI 10.1177/1073191105283427; Van der Elst W, 2005, J INT NEUROPSYCH SOC, V11, P290, DOI 10.1017/S1355617705050344; Van der Elst W, 2006, PSYCHOL ASSESSMENT, V18, P424, DOI 10.1037/1040-3590.18.4.424; van der Elst W, 2006, J CLIN EXP NEUROPSYC, V28, P998, DOI 10.1080/13803390591004428; Vellinga A, 2005, AGING MENT HEALTH, V9, P40, DOI 10.1080/13607860512331334059; Verplanken B, 2001, EUR J PERSONALITY, V15, pS71, DOI 10.1002/per.423; Webber LS., 2002, PSYCHIAT PSYCHOL LAW, V9, P248, DOI [10.1375/pplt.2002.9.2.248, DOI 10.1375/PPLT.2002.9.2.248]; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wechsler D. WAIS-IV-NL, 2012, WAIS 4 NL WECHLER AD; Whelan R, 2009, PSYCHOL REC, V59, P247, DOI 10.1007/BF03395661; Wood RL, 2013, J INT NEUROPSYCH SOC, V19, P181, DOI 10.1017/S135561771200118X	98	12	12	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2017	12	8							e0182620	10.1371/journal.pone.0182620			18	Multidisciplinary Sciences	Science & Technology - Other Topics	FC9YJ	WOS:000407196700055	28792973	DOAJ Gold, Green Published			2021-06-18	
J	Xu, ZM; Liu, YL; Yang, DX; Yuan, F; Ding, J; Chen, H; Tian, HL				Xu, Zhiming; Liu, Yingliang; Yang, Dianxu; Yuan, Fang; Ding, Jun; Chen, Hao; Tian, Hengli			Sesamin protects SH-SY5Y cells against mechanical stretch injury and promoting cell survival	BMC NEUROSCIENCE			English	Article						Sesamin; Apoptosis; Oxidative stress; Mechanical stretch injury	TRAUMATIC BRAIN-INJURY; INDUCED OXIDATIVE STRESS; PARKINSONS-DISEASE; CORTICAL-NEURONS; MITOCHONDRIAL DYSFUNCTION; DELAYED DEPOLARIZATION; SUPEROXIDE-DISMUTASE; MODEL; DEATH; ASTROCYTES	Background: Sesamin is a well-known antioxidant extracted from sesame seeds that exhibits various curative effects. The present study investigated whether sesamin would protect neuroblastoma SH-SY5Y cells against mechanical stretch injury-induced increases in reactive oxygen species (ROS) and apoptosis. Additionally, the mechanisms underlying these actives were investigated. Following exposure to mechanical stretch injury, cells were incubated for further investigations. Lactate dehydrogenase and Cell Counting Kit-8 assays were used to assess cell viability, and a terminal deoxynucleotidyl transferase dUTP nick end labeling assay and flow cytometric analysis were performed to evaluate changes in mitochondrial membrane potential (Delta Psi m). Furthermore, intracellular levels of ROS production were measured by 20, 70-dichlorofluorescein diacetate staining, the mRNA levels of matrix metallopeptidase 9 (MMP-9) were evaluated using real-time polymerase chain reaction analysis, and the determinations had also been made on related proteins by Western blot analysis. Results: Exposure to mechanical stretch injury significantly decreased cell viability but this decrease was attenuated by pretreatment with sesamin (50 mu M). Sesamin also significantly inhibited mechanical stretch injury-induced increases in intracellular ROS production, attenuated declines Delta Psi m, diminished the expressions of pro-apoptotic proteins, and decreased cell apoptosis. Stretch injury increased Bax and cleaved caspase 3 levels, enhanced the gene expression of MMP-9, increased the phosphorylation levels of Akt, p38, and JNK and decreased Bcl-2 levels in the cells. However, pretreatment with sesamin reduced the mechanical stretch injury-induced overexpression of MMP-9. Conclusions: Sesamin protected SH-SY5Y cells against stretch injury by attenuating increases in ROS levels and suppressing apoptosis. Accordingly, sesamin seems to be a potentially therapeutic agent in the treatment of traumatic brain injury.	[Xu, Zhiming; Liu, Yingliang; Yang, Dianxu; Yuan, Fang; Ding, Jun; Chen, Hao; Tian, Hengli] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Neurosurg, 600 Yi Shan Rd, Shanghai 200030, Peoples R China	Tian, HL (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Neurosurg, 600 Yi Shan Rd, Shanghai 200030, Peoples R China.	tianhlsh@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81471245, 81501048, 81271383]	This work was supported by grants from National Natural Science Foundation of China (Nos. 81471245, 81501048) in the process of study design, experiment implementation and data collection. Data interpretation and article writing were supported by the grant from National Natural Science Foundation of China (No. 81271383).	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Ali ZA, 2014, J CLIN INVEST, V124, P5159, DOI 10.1172/JCI77484; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Galati G, 2002, TOXICOLOGY, V177, P91, DOI 10.1016/S0300-483X(02)00198-1; Hou RCW, 2004, NEUROSCI LETT, V367, P10, DOI 10.1016/j.neulet.2004.05.073; Hou RCW, 2003, NEUROREPORT, V14, P1815, DOI 10.1097/00001756-200310060-00011; Hou RCW, 2003, J NEUROSCI RES, V74, P123, DOI 10.1002/jnr.10749; Hsieh HL, 2014, MOL NEUROBIOL, V50, P520, DOI 10.1007/s12035-013-8628-y; Hsieh PF, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-57; Jeng KCG, 2005, IMMUNOL LETT, V97, P101, DOI 10.1016/j.imlet.2004.10.004; Kabu S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127971; Kim MJ, 2015, BIOMATERIALS, V64, P45, DOI 10.1016/j.biomaterials.2015.06.015; Kim MJ, 2013, FREE RADICAL BIO MED, V63, P432, DOI 10.1016/j.freeradbiomed.2013.06.005; Kim SY, 2010, NEUROCHEM INT, V56, P437, DOI 10.1016/j.neuint.2009.11.019; Lahaie-Collins V, 2008, OXID MED CELL LONGEV, V1, P54, DOI 10.4161/oxim.1.1.6958; Lamb RG, 1997, J NEUROCHEM, V68, P1904; Lee YP, 2012, FEBS J, V279, P1929, DOI 10.1111/j.1742-4658.2012.08574.x; Loh Kok Poh, 2006, Current Alzheimer Research, V3, P327; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Pfister Bryan, 2004, Mech Chem Biosyst, V1, P233; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Song H, 2016, NEUROSCI LETT, V622, P95, DOI 10.1016/j.neulet.2016.04.048; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; Tian PC, 2016, HUM EXP TOXICOL, V35, P124, DOI 10.1177/0960327115578974; Vali S, 2007, NEUROSCIENCE, V149, P917, DOI 10.1016/j.neuroscience.2007.08.028; von Leden RE, 2017, J NEUROTRAUM, V34, P755, DOI 10.1089/neu.2016.4486; Wang F, 2014, NEUROTOXICOLOGY, V41, P54, DOI 10.1016/j.neuro.2014.01.002; Wang ZR, 2016, ASIAN PAC J TROP MED, V9, P269, DOI 10.1016/j.apjtm.2016.01.027; Webster Gregory D, 2008, Biomed Sci Instrum, V44, P483; Xia Q, 2011, J NEUROCHEM, V117, P38, DOI 10.1111/j.1471-4159.2010.07162.x; Xu XH, 2015, BRAIN RES, V1614, P38, DOI 10.1016/j.brainres.2015.04.014; Zhang H, 2011, BRAIN RES, V1370, P89, DOI 10.1016/j.brainres.2010.11.019	36	12	12	0	9	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	AUG 7	2017	18								57	10.1186/s12868-017-0378-8			10	Neurosciences	Neurosciences & Neurology	FD5OO	WOS:000407579900001	28784087	DOAJ Gold, Green Published			2021-06-18	
J	Dong, XQ; Yu, WH; Du, Q; Wang, H; Zhu, Q; Yang, DB; Che, ZH; Shen, YF; Jiang, L				Dong, Xiao-Qiao; Yu, Wen-Hua; Du, Quan; Wang, Hao; Zhu, Qiang; Yang, Ding-Bo; Che, Zhi-Hao; Shen, Yong-Feng; Jiang, Li			Serum periostin concentrations and outcomes after severe traumatic brain injury	CLINICA CHIMICA ACTA			English	Article						Traumatic brain injury; Periostin; Severity; Mortality; Outcome; Prognosis; Biomarker	PROGNOSTIC VALUE; MORTALITY; EXPRESSION; CANCER; RISK; PERFORMANCE; MECHANISMS; HEMORRHAGE; PREDICTION; INFARCTION	Background: Periostin, a neurite outgrowth-promoting factor, is increasingly expressed in rat brain tissues after cerebral ischemia or subarachnoid hemorrhage. However, periostin concentrations are undetermined in peripheral blood from patients with traumatic brain injury (TBI). Methods: In this prospective, observational study, serum periostin concentrations were measured in 130 controls and 130 severe TBI patients. We investigated its association with trauma severity reflected by Glasgow Coma Scale (GCS) score and prognosis (i.e., 30-day mortality and 30-day overall survival). Results: As compared with the controls, serum periostin concentrations were significantly increased in the patients [(median, 246.5 ng/ml; interquartile range, 164.5-328.6 ng/ml) vs. (median, 61.8 ng/ml; interquartile range, 37.9-77.9 ng/ml), P < 0.001]. Periostin concentrations independently correlated with GCS scores (t = -6.199, P < 0.001). Serum periostin concentrations higher than 308.2 ng/ml predicted 30-day mortality with a sensitivity of 72.4% and a specificity of 78.2% [area under curve, 815; 95% confidence interval (CI), 0.737-0.878]. Periostin concentrations higher than 246.5 ng/ml were independently related to 30-day mortality and 30-day overall survival with odds ratio value of 3.829 (95% CI, 1.104-13.281) and hazard ratio value of 5.667 (95% CI, 1.953-16.443) respectively. Conclusions: Increased serum periostin concentrations clearly reflect trauma severity and mortality following TBI.	[Dong, Xiao-Qiao; Yu, Wen-Hua; Du, Quan; Wang, Hao; Zhu, Qiang; Yang, Ding-Bo; Che, Zhi-Hao; Shen, Yong-Feng; Jiang, Li] Nanjing Med Univ, Hangzhou Peoples Hosp 1, Dept Neurosurg, 261 Huansha Rd, Hangzhou 310006, Zhejiang, Peoples R China	Yu, WH (corresponding author), Nanjing Med Univ, Hangzhou Peoples Hosp 1, Dept Neurosurg, 261 Huansha Rd, Hangzhou 310006, Zhejiang, Peoples R China.	hzwenhuayu@163.com			Zhejiang Province Medical and Health Project [2014KYA177, 2016RCB016]; Hangzhou Medical Research Fund Project [2014Z06, 2016Z10]	We thank all staffs in Department of Neurosurgery, The Hangzhou First People's Hospital (Hangzhou, China) for their technical support. This study was supported financially by Zhejiang Province Medical and Health Project ( 2014KYA177, 2016RCB016) and Hangzhou Medical Research Fund Project (2014Z06, 2016Z10).	Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Amoroso T, 2017, J NERV MENT DIS, V205, P318, DOI 10.1097/NMD.0000000000000621; Andrews PJD, 2017, CRIT CARE MED, V45, P883, DOI 10.1097/CCM.0000000000002376; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Azar S, 2017, METHODS MOL BIOL, V1598, P45, DOI 10.1007/978-1-4939-6952-4_3; BERNARD GR, 1994, INTENS CARE MED, V20, P225, DOI 10.1007/BF01704707; Dong XQ, 2011, J TRAUMA, V71, P1194, DOI 10.1097/TA.0b013e31821283f2; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Franschman G, 2012, J NEUROTRAUM, V29, P128, DOI 10.1089/neu.2011.2044; Gorska K, 2016, POL ARCH MED WEWN, V126, P124, DOI 10.20452/pamw.3299; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Guo XF, 2016, ONCOTARGET, V7, P80521, DOI 10.18632/oncotarget.11825; Katsuragi N, 2004, CIRCULATION, V110, P1806, DOI 10.1161/01.CIR.0000142607.33398.54; Kou K, 2014, BRIT J DERMATOL, V171, P283, DOI 10.1111/bjd.12943; Ling L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088755; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; Liu L, 2017, STROKE, V48, P1108, DOI 10.1161/STROKEAHA.117.016629; Ma SK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0113130; Majdan M, 2017, J NEUROSCI RURAL PRA, V8, P20, DOI 10.4103/0976-3147.193543; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Matsunaga E, 2015, DEV GROWTH DIFFER, V57, P200, DOI 10.1111/dgd.12194; Mikheev AM, 2015, NEURO-ONCOLOGY, V17, P372, DOI 10.1093/neuonc/nou161; MIRVIS SE, 1990, AM J ROENTGENOL, V154, P1293, DOI 10.2214/ajr.154.6.2110744; Moniuszko T, 2016, ONCOL LETT, V12, P783, DOI 10.3892/ol.2016.4692; Morita H, 2016, HYPERTENSION, V67, P504, DOI 10.1161/HYPERTENSIONAHA.115.06449; Nuzzo PV, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2139-y; Oka T, 2007, CIRC RES, V101, P313, DOI 10.1161/CIRCRESAHA.107.149047; Oku E, 2008, INT J HEMATOL, V88, P57, DOI 10.1007/s12185-008-0095-2; Ozyurt E, 2015, TURK NEUROSURG, V25, P877, DOI 10.5137/1019-5149.JTN.9181-13.0; Qin JB, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0126-x; Qiu F, 2013, J BIOCHEM MOL TOXIC, V27, P364, DOI 10.1002/jbt.21498; Ruan K, 2009, CELL MOL LIFE SCI, V66, P2219, DOI 10.1007/s00018-009-0013-7; Semprini R, 2017, J ALLERGY CLIN IMMUN, V139, P1687, DOI 10.1016/j.jaci.2016.11.041; Shen LJ, 2014, CLIN CHIM ACTA, V427, P37, DOI 10.1016/j.cca.2013.09.047; Shi HY, 2014, J NEUROSURG, V121, P1323, DOI 10.3171/2014.8.JNS131526; Shimamura M, 2012, STROKE, V43, P1108, DOI 10.1161/STROKEAHA.111.636662; Tajiri M, 2015, RESPIR INVESTIG, V53, P73, DOI 10.1016/j.resinv.2014.12.003; Taniyama Y, 2016, HYPERTENSION, V67, P356, DOI 10.1161/HYPERTENSIONAHA.115.06265; Tian BX, 2014, TUMOR BIOL, V35, P5877, DOI 10.1007/s13277-014-1778-3; Wang KY, 2012, CLIN CHIM ACTA, V413, P1737, DOI 10.1016/j.cca.2012.07.002; Xu CH, 2017, ONCOTARGET, V8, P18746, DOI 10.18632/oncotarget.13004; Zhang ZY, 2014, PEPTIDES, V60, P13, DOI 10.1016/j.peptides.2014.07.016	42	12	12	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0009-8981	1873-3492		CLIN CHIM ACTA	Clin. Chim. Acta	AUG	2017	471						298	303		10.1016/j.cca.2017.06.020			6	Medical Laboratory Technology	Medical Laboratory Technology	FD2ZK	WOS:000407403100049	28668564				2021-06-18	
J	Gugliandolo, A; Caio, C; Mezzatesta, ML; Rifici, C; Bramanti, P; Stefani, S; Mazzon, E				Gugliandolo, Agnese; Caio, Carla; Mezzatesta, Maria Lina; Rifici, Carmela; Bramanti, Placido; Stefani, Stefania; Mazzon, Emanuela			Successful ceftazidime-avibactam treatment of MDR-KPC-positive Klebsiella pneumoniae infection in a patient with traumatic brain injury A case report	MEDICINE			English	Article						ceftazidime-avibactam; chest trauma; Enterobacteriaceae; Klebsiella pneumoniae; traumatic brain injury	CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; BLOOD-STREAM INFECTIONS; BETA-LACTAMASES; COMBINATION; BACTEREMIA; MORTALITY; EMERGENCE; THERAPY; STRAINS; OPTIONS	Rationale: Carbapenem-resistant Enterobacteriaceae infections are a serious health care problem, because of the high mortality. Carbapenem resistance is mainly caused by carbapenemases production, including Klebsiella pneumoniae carbapenemase (KPC). Ceftazidime-avibactam is a new cephalosporin/beta-lactamase inhibitor combination for the treatment of complicated urinary, intra-abdominal infections, and nosocomial pneumonia caused by gram negative, or other serious gram-negative infections. Patient concerns: We showed the case of a 27-year-old patient, hospitalized for traumatic brain injury and chest trauma, with KPC-producing Klebsiella pneumoniae infection. Diagnoses: Blood and bronchial aspirate culture analysis detected an infection caused by MDR Klebsiella pneumoniae, resistant to meropenem, ertapenem, piperacillin/tazobactam, amoxicillin/clavulanic acid, aztreonam, ceftazidime, cefotaxime, cefepime, amikacin, ciprofloxacin, trimethoprim/sulfamethoxazole, colistin while it showed an intermediate sensitivity to gentamicin and was sensitive to ceftazidime-avibactam. Molecular analyses revealed that the isolate belonged to the epidemic clone sequence type 258 (ST258) carrying blaKPC-3, blaTEM-1, and blaSHV-11genes. Interventions: After various combined antibiotic therapies without improvements, he was treated with ceftazidime-avibactam, on a compassionate-use basis. Outcomes: With ceftazidime-avibactam monotherapy clinical and microbiological clearance was obtained. A week after the end of the therapy microbiological analysis was repeated and a positive rectal swab for KPC-Klebsiella pneumoniae was found, becoming negative after 1 month. Moreover, the patient did not show any relapses for up to 18 weeks. Lessons: This case indicates that ceftazidime-avibactam monotherapy could be efficacious against KPC positive Klebsiella pneumoniae infections.	[Gugliandolo, Agnese; Rifici, Carmela; Bramanti, Placido; Mazzon, Emanuela] IRCCS Ctr Neurolesi Bonino Pulejo, Via Provinciale Palermo, I-98124 Messina, Italy; [Caio, Carla; Mezzatesta, Maria Lina; Stefani, Stefania] Univ Catania, Sect Microbiol, Dept Biomed & Biotechnol Sci, Catania, Italy	Mazzon, E (corresponding author), IRCCS Ctr Neurolesi Bonino Pulejo, Via Provinciale Palermo, I-98124 Messina, Italy.	emazzon.irccs@gmail.com	Bramanti, Placido/K-5117-2016; Gugliandolo, Agnese/AAA-5466-2019; Rifici, Carmela/ABH-4398-2020; Mazzon, Emanuela/AAL-4334-2020	GUGLIANDOLO, AGNESE/0000-0002-7868-3353; mazzon, emanuela/0000-0002-5073-717X			Camargo JF, 2015, ANTIMICROB AGENTS CH, V59, P5903, DOI 10.1128/AAC.00655-15; da Silva RM, 2012, EXPERT OPIN BIOL TH, V12, P663, DOI 10.1517/14712598.2012.681369; Daikos GL, 2014, ANTIMICROB AGENTS CH, V58, P2322, DOI 10.1128/AAC.02166-13; Daikos GL, 2009, ANTIMICROB AGENTS CH, V53, P1868, DOI 10.1128/AAC.00782-08; Diancourt L, 2005, J CLIN MICROBIOL, V43, P4178, DOI 10.1128/JCM.43.8.4178-4182.2005; Doi Y, 2015, SEMIN RESP CRIT CARE, V36, P74, DOI 10.1055/s-0035-1544208; Falcone M, 2016, J ANTIMICROB CHEMOTH, V71, P2713, DOI 10.1093/jac/dkw239; Gona F, 2014, CLIN MICROBIOL INFEC, V20, pO633, DOI 10.1111/1469-0691.12577; Gootz TD, 2009, ANTIMICROB AGENTS CH, V53, P1998, DOI 10.1128/AAC.01355-08; Hackel M, 2016, ANTIMICROB AGENTS CH, V60, P4677, DOI 10.1128/AAC.02841-15; Jacobs DM, 2016, INT J ANTIMICROB AG, V48, P225, DOI 10.1016/j.ijantimicag.2016.06.002; Krapp F, 2017, INT J ANTIMICROB AG, V49, P770, DOI 10.1016/j.ijantimicag.2017.01.018; Lee CH, 2015, CLIN MICROBIOL INFEC, V21, DOI 10.1016/j.cmi.2015.07.025; Lee CR, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00895; Levasseur P, 2015, ANTIMICROB AGENTS CH, V59, P1931, DOI 10.1128/AAC.04218-14; Levasseur P, 2014, ANTIMICROB AGENTS CH, V58, P6490, DOI 10.1128/AAC.03579-14; Mezzatesta ML, 2016, MICROB DRUG RESIST, V22, P360, DOI 10.1089/mdr.2015.0160; Mezzatesta ML, 2013, J ANTIMICROB CHEMOTH, V68, P1932, DOI 10.1093/jac/dkt116; Monari C, 2016, ADV EXP MED BIOL, V901, P91, DOI 10.1007/5584_2015_5018; Pagani L, 2003, J CLIN MICROBIOL, V41, P4264, DOI 10.1128/JCM.41.9.4264-4269.2003; Perilli M, 2008, MICROB DRUG RESIST, V14, P45, DOI 10.1089/mdr.2008.0765; Qureshi ZA, 2012, ANTIMICROB AGENTS CH, V56, P2108, DOI 10.1128/AAC.06268-11; Sharma R, 2016, CLIN THER, V38, P431, DOI 10.1016/j.clinthera.2016.01.018; Trecarichi EM, 2017, VIRULENCE, V8, P470, DOI 10.1080/21505594.2017.1292196; Tumbarello M, 2015, J ANTIMICROB CHEMOTH, V70, P2133, DOI 10.1093/jac/dkv086; Tumbarello M, 2012, CLIN INFECT DIS, V55, P943, DOI 10.1093/cid/cis588; Tuon FF, 2017, BRAZ J INFECT DIS, V21, P1, DOI 10.1016/j.bjid.2016.09.008; Veillette JJ, 2016, PHARMACOTHERAPY, V36, pE172, DOI 10.1002/phar.1840; Woodford N, 2011, FEMS MICROBIOL REV, V35, P736, DOI 10.1111/j.1574-6976.2011.00268.x; Wu G, 2016, CLIN INFECT DIS, V63, P1147, DOI 10.1093/cid/ciw491; Zacharczuk K, 2011, ANTIMICROB AGENTS CH, V55, P443, DOI 10.1128/AAC.00386-10	31	12	13	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	AUG	2017	96	31							e7664	10.1097/MD.0000000000007664			6	Medicine, General & Internal	General & Internal Medicine	FD0GC	WOS:000407216800024	28767588	DOAJ Gold, Green Published			2021-06-18	
J	Higgins, GA; Georgoff, P; Nikolian, V; Allyn-Feuer, A; Pauls, B; Higgins, R; Athey, BD; Alam, HE				Higgins, Gerald A.; Georgoff, Patrick; Nikolian, Vahagn; Allyn-Feuer, Ari; Pauls, Brian; Higgins, Richard; Athey, Brian D.; Alam, Hasan E.			Network Reconstruction Reveals that Valproic Acid Activates Neurogenic Transcriptional Programs in Adult Brain Following Traumatic Injury	PHARMACEUTICAL RESEARCH			English	Article						bioinformatics; network modeling; pharmacoepigenomics	HISTONE DEACETYLASE; FUNCTIONAL-NEURONS; CHROMATIN DOMAINS; DIRECT CONVERSION; GENE-EXPRESSION; ASSOCIATION; DATABASE; VARIANTS; GENOME; DIFFERENTIATION	To determine the mechanism of action of valproic acid (VPA) in the adult central nervous system (CNS) following traumatic brain injury (TBI) and hemorrhagic shock (HS). Data were analyzed from different sources, including experiments in a porcine model, data from postmortem human brain, published studies, public and commercial databases. The transcriptional program in the CNS following TBI, HS, and VPA treatment includes activation of regulatory pathways that enhance neurogenesis and suppress gliogenesis. Genes which encode the transcription factors (TFs) that specify neuronal cell fate, including MEF2D, MYT1L, NEUROD1, PAX6 and TBR1, and their target genes, are induced by VPA. VPA represses genes responsible for oligodendrogenesis, maintenance of white matter, T-cell activation, angiogenesis, and endothelial cell proliferation, adhesion and chemotaxis. NEUROD1 has regulatory interactions with 38% of the genes regulated by VPA in a swine model of TBI and HS in adult brain. Hi-C spatial mapping of a VPA pharmacogenomic SNP in the GRIN2B gene shows it is part of a transcriptional hub that contacts 12 genes that mediate chromatin-mediated neurogenesis and neuroplasticity. Following TBI and HS, this study shows that VPA administration acts in the adult brain through differential activation of TFs responsible for neurogenesis, genes responsible for neuroplasticity, and repression of TFs that specify oligodendrocyte cell fate, endothelial cell chemotaxis and angiogenesis. Short title: Mechanism of action of valproic acid in traumatic brain injury.	[Higgins, Gerald A.; Allyn-Feuer, Ari; Athey, Brian D.] Univ Michigan, Sch Med, Dept Computat Med & Bioinformat, Ann Arbor, MI USA; [Georgoff, Patrick; Nikolian, Vahagn; Alam, Hasan E.] Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI USA; [Pauls, Brian] Univ Michigan, Coll Pharm, 428 Church St, Ann Arbor, MI 48109 USA; [Higgins, Richard] Univ Maryland, Dept Comp Sci, College Pk, MD 20742 USA; [Athey, Brian D.] Michigan Inst Data Sci MIDAS, Ann Arbor, MI USA	Higgins, GA (corresponding author), Univ Michigan, Sch Med, Dept Computat Med & Bioinformat, Ann Arbor, MI USA.	gehiggin@med.umich.edu; georgoff@med.umich.edu; vnikolia@med.umich.edu; ariallyn@umich.edu; brianobi@med.umich.edu; richard@relh.net; bleu@med.umich.edu; alamh@med.umich.edu		Higgins, Gerry/0000-0002-0434-1465			Berto S, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00031; Bharadwaj R, 2014, NEURON, V84, P997, DOI 10.1016/j.neuron.2014.10.032; Boley N, 2014, METHODS, V68, P38, DOI 10.1016/j.ymeth.2014.03.007; Cerami EG, 2011, NUCLEIC ACIDS RES, V39, pD685, DOI 10.1093/nar/gkq1039; Chu TC, 2015, BRAIN RES, V1596, P31, DOI 10.1016/j.brainres.2014.11.029; Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Dawson HD, 2012, MINIPIG IN BIOMEDICAL RESEARCH, P323; Dekker SE, 2014, J TRAUMA ACUTE CARE, V77, P906, DOI 10.1097/TA.0000000000000345; di Iulio J, 2016, BIORXIV; Ghodke-Puranik Y, 2013, PHARMACOGENET GENOM, V23, P236, DOI 10.1097/FPC.0b013e32835ea0b2; Gonzalez-Sandoval A, 2016, TRENDS GENET, V32, P485, DOI 10.1016/j.tig.2016.05.004; Gopalakrishnan S, 2017, BRAIN RES, V1656, P2, DOI 10.1016/j.brainres.2015.10.012; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Guida M, 2015, EXPERT REV NEUROTHER, V15, P947, DOI 10.1586/14737175.2015.1065180; Guo ZY, 2014, CELL STEM CELL, V14, P188, DOI 10.1016/j.stem.2013.12.001; Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008-5472.CAN-03-0799; Hadjab S, 2013, J NEUROSCI, V33, P17656, DOI 10.1523/JNEUROSCI.1090-13.2013; Halaweish I, 2015, J TRAUMA ACUTE CARE, V79, P911, DOI 10.1097/TA.0000000000000789; Halsall JA, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/s13072-015-0021-9; He XL, 2013, EPILEPTIC DISORD, V15, P272, DOI 10.1684/epd.2013.0603; Higgins GA, 2015, PHARMACOGENOMICS, V16, P1565, DOI 10.2217/pgs.15.105; Hung CC, 2011, PHARMACOGENOMICS, V12, P1107, DOI [10.2217/PGS.11.64, 10.2217/pgs.11.64]; Jessen WJ, 2015, PEERJ, V3, pe1802; Jones B, 2015, NAT REV GENET, V16, P438, DOI 10.1038/nrg3985; Kaplun A, 2016, PHARMACOGENOMICS J, V16, P124, DOI 10.1038/tpj.2015.32; Kelkhoff D, 2016, PHYSIOL HEALTH DIS, P163, DOI 10.1007/978-1-4939-5617-3_8; Kestler HA, 2008, BIOESSAYS, V30, P1110, DOI 10.1002/bies.20834; Kim B, 2009, PSYCHIAT RES, V168, P209, DOI 10.1016/j.psychres.2008.05.010; Kim HJ, 2009, J NEUROCHEM, V110, P1226, DOI 10.1111/j.1471-4159.2009.06212.x; Kulkarni AV, 2009, JAMA-J AM MED ASSOC, V302, P1092, DOI 10.1001/jama.2009.1307; Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lee D, 2015, NAT GENET, V47, P955, DOI 10.1038/ng.3331; Li H, 2016, BIORXIV; Liu XS, 2012, NEUROSCIENCE, V220, P313, DOI 10.1016/j.neuroscience.2012.06.012; Lupianez DG, 2015, CELL, V161, P1012, DOI 10.1016/j.cell.2015.04.004; Lv L, 2011, BRAIN RES, V1396, P60, DOI 10.1016/j.brainres.2011.03.040; Manuel MN, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00070; Marchion DC, 2005, CANCER RES, V65, P3815, DOI 10.1158/0008-5472.CAN-04-2478; Mi HY, 2016, NUCLEIC ACIDS RES, V44, pD336, DOI 10.1093/nar/gkv1194; Mihalas AB, 2017, CURR TOP DEV BIOL, V122, P279, DOI 10.1016/bs.ctdb.2016.08.001; Neph S, 2012, CELL, V150, P1274, DOI 10.1016/j.cell.2012.04.040; Ninkovic J, 2013, CELL STEM CELL, V13, P403, DOI 10.1016/j.stem.2013.07.002; Notwell JH, 2016, GENOME RES, V26, P1013, DOI 10.1101/gr.203612.115; Perucca E, 2002, CNS DRUGS, V16, P695, DOI 10.2165/00023210-200216100-00004; Phillips ML, 2014, AM J PSYCHIAT, V171, P829, DOI 10.1176/appi.ajp.2014.13081008; Rackham OJL, 2016, NAT GENET, V48, P331, DOI 10.1038/ng.3487; Ramani V, 2016, GENOM PROTEOM BIOINF, V14, P7, DOI 10.1016/j.gpb.2016.01.002; Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021; Roy S, 2010, SCIENCE, V330, P1787, DOI 10.1126/science.1198374; Saint-Andre V, 2016, GENOME RES, V26, P385, DOI 10.1101/gr.197590.115; Schurr J, 2017, BRAIN PATHOL, V27, P26, DOI 10.1111/bpa.12347; Son EY, 2014, AM J MED GENET C, V166, P333, DOI 10.1002/ajmg.c.31416; Speir ML, 2016, NUCLEIC ACIDS RES, V44, pD717, DOI 10.1093/nar/gkv1275; Sunkin SM, 2013, NUCLEIC ACIDS RES, V41, pD996, DOI 10.1093/nar/gks1042; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Teng L, 2015, BIOINFORMATICS, V31, P2560, DOI 10.1093/bioinformatics/btv158; Tesar Paul J., 2012, U.S. Patent Application, Patent No. [13/280,562, 13280562]; Thakurela S, 2015, GENOME RES, V25, P1309, DOI 10.1101/gr.190926.115; Vehlow C, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S19-S2; Vierbuchen T, 2010, NATURE, V463, P1035, DOI 10.1038/nature08797; Wang SY, 2016, SCIENCE, V353, P598, DOI 10.1126/science.aaf8084; Yi JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054792; Zarin DA, 2011, NEW ENGL J MED, V364, P852, DOI 10.1056/NEJMsa1012065	66	12	12	1	14	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0724-8741	1573-904X		PHARM RES-DORDR	Pharm. Res.	AUG	2017	34	8					1658	1672		10.1007/s11095-017-2130-6			15	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	EZ8RZ	WOS:000404996100014	28271248	Green Published, Other Gold			2021-06-18	
J	Murphy, AM; Askew, KL; Sumner, KE				Murphy, Ashley M.; Askew, Kevin L.; Sumner, Kenneth E.			Parents' Intentions to Allow Youth Football Participation: Perceived Concussion Risk and the Theory of Planned Behavior	SPORT EXERCISE AND PERFORMANCE PSYCHOLOGY			English	Article						youth sports; attitude; sport psychology; athletes; decision-making	SPORT-RELATED CONCUSSION; HIGH-SCHOOL; DEVELOPING INTERVENTIONS; EDUCATION; BELIEFS; INITIATIVES; MAGNITUDE; CHILDREN; SOCCER	Despite many benefits, participation in youth football has declined, with many blaming concussion risk. While there is risk, not participating in youth football leads to missing out on the sport's physical, social, and psychological benefits. Understanding the reasons behind the decline in football participation is important to reversing the trend. The goals of this study were to understand parents' intentions to allow their children to participate in organized football and to create a theoretical platform from which interventions may be implemented to promote participation. Based on research in related areas, we proposed and tested an augmented Theory of Planned Behavior with parents of youth-football-age children (n = 497). We found the hypothesized model accounted for over half the variance in intention to allow football participation (R-2 = .58), and that four factors predict a parent's intention to let his or her child play football: social norms, attitudes toward youth football participation, behavioral control, and the perceived risk of concussion. This study helps better explain parents' decisions regarding youth football participation. These findings provide a promising theoretical platform for new interventions that can promote continued youth football participation.	[Murphy, Ashley M.; Askew, Kevin L.; Sumner, Kenneth E.] Montclair State Univ, Psychol Dept, 1 Normal Ave,Dickson Hall 219, Montclair, NJ 07043 USA	Murphy, AM (corresponding author), Montclair State Univ, Psychol Dept, 1 Normal Ave,Dickson Hall 219, Montclair, NJ 07043 USA.	murphya5.montclair@gmail.com					Ajzen I., 2012, HDB THEORIES SOCIAL, V1, P438, DOI DOI 10.4135/9781446249215.N22; Ajzen I., 2002, CONSTRUCTING TPB QUE; Angelopoulos PD, 2009, EUR J PUBLIC HEALTH, V19, P319, DOI 10.1093/eurpub/ckp004; Askew K, 2014, COMPUT HUM BEHAV, V36, P510, DOI 10.1016/j.chb.2014.04.006; Cantu R. C., 2012, NY TIMES; Cheung BY, 2015, PERS SOC PSYCHOL B, V41, P1723, DOI 10.1177/0146167215610520; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Deroche T, 2009, ACCIDENT ANAL PREV, V41, P1064, DOI 10.1016/j.aap.2009.06.016; Elliott MA, 2009, BRIT J PSYCHOL, V100, P111, DOI 10.1348/000712608X318626; Fainaru S., 2013, YOUTHFOOTBALL PARTIC; Findler P, 2015, J PHILOS SPORT, V42, P443, DOI 10.1080/00948705.2015.1079132; French DP, 2012, BRIT J HEALTH PSYCH, V17, P1, DOI 10.1111/j.2044-8287.2010.02010.x; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilbert Frederic, 2011, AM J BIOTH NEUROSCI, p[48, 54], DOI DOI 10.1080/21507740.2011.611125; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Iversen MD, 2009, SCAND J MED SCI SPOR, V19, P595, DOI 10.1111/j.1600-0838.2008.00817.x; Kanten AB, 2015, PERS SOC PSYCHOL B, V41, P1712, DOI 10.1177/0146167215609894; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115610545; Kroshus E, 2015, CLIN J SPORT MED, V25, P243, DOI 10.1097/JSM.0000000000000137; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Levy ML, 2012, WORLD NEUROSURG, V78, P535, DOI 10.1016/j.wneu.2011.10.032; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGlashan AJ, 2010, SPORTS MED, V40, P841, DOI 10.2165/11534960-000000000-00000; Pabian S, 2014, EUR J DEV PSYCHOL, V11, P463, DOI 10.1080/17405629.2013.858626; Pop Warner National Office, 2012, RUL CHANG REG PRACT; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Rigby J, 2013, J ATHL TRAINING, V48, P636, DOI 10.4085/1062-6050-48.3.10; Sarmiento K, 2014, J SAFETY RES, V50, P143, DOI 10.1016/j.jsr.2014.05.003; University of Pittsburg Medical Center, 2015, KNOWL AR AM CONC ASS; White KM, 2015, PREV MED, V72, P19, DOI 10.1016/j.ypmed.2014.12.025; Wilkinson L, 1999, AM PSYCHOL, V54, P594, DOI 10.1037/0003-066X.54.8.594; Wong RH, 2014, CLIN NEUROL NEUROSUR, V118, P1, DOI 10.1016/j.clineuro.2013.11.036	34	12	12	3	29	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	2157-3905	2157-3913		SPORT EXERC PERFORM	Sport Exerc. Perform. Psychol.	AUG	2017	6	3					230	242		10.1037/spy0000102			13	Hospitality, Leisure, Sport & Tourism; Psychology, Applied	Social Sciences - Other Topics; Psychology	FD8RW	WOS:000407792800003					2021-06-18	
J	Turner, S; Langdon, J; Shaver, G; Graham, V; Naugle, K; Buckley, T				Turner, Samantha; Langdon, Jody; Shaver, George; Graham, Victoria; Naugle, Kelly; Buckley, Thomas			Comparison of Psychological Response Between Concussion and Musculoskeletal Injury in Collegiate Athletes	SPORT EXERCISE AND PERFORMANCE PSYCHOLOGY			English	Article						profile of mood states; state-trait anxiety inventory; concussion; recovery	SPORT-RELATED CONCUSSION; MANAGEMENT PRACTICE PATTERNS; CONSENSUS STATEMENT; POSTURAL CONTROL; BRAIN-INJURY; DEPRESSION; RECOVERY; SYMPTOMS; RELIABILITY; PREVALENCE	The psychological response to musculoskeletal injuries has been well documented; however, research on the psychological response to concussion is limited. The Profile of Mood States (POMS) and the State-Trait Anxiety Inventory (STAI) have recently been used to assess the psychological recovery of concussions (CONC). Although some studies indicate that psychological response is different for musculoskeletal injuries and concussion, there is currently not enough information to indicate this difference occurs at specific clinical milestones. The purpose of this study was to compare the psychological responses of student-athletes who have been diagnosed with a concussion to those of athletes diagnosed with musculoskeletal injuries with similar recovery duration. Fifteen collegiate athletes who sustained a musculoskeletal injury were recruited and matched with 15 previously collected concussion participants. The main outcome measures were the scores of POMS constructs: tension-anxiety, anger-hostility, fatigue-inertia, depression-dejection, vigor-activity, confusion- bewilderment, and total mood disturbance and STAI (state anxiety only). Two-way MANOVAs were run to determine the effects of group and time on POMS and STAI constructs. There were no significant interactions identified, but follow-up ANOVAs identified a main effect for time for most POMS subscales, with POMS scores improving over time in both groups. Analyses also revealed that tension-anxiety, vigor-activity and the STAI were not affected by time or group. The findings of this study that both groups' psychological response to injury improves over time and at similar clinical milestones suggests reduction in sports and team-related activities may play a substantial role in the psychological response to either concussion or musculoskeletal injury.	[Turner, Samantha] Keiser Univ, Athlet Dept, Ft Lauderdale, FL USA; [Langdon, Jody] Georgia Southern Univ, Sch Hlth & Kinesiol, Statesboro, GA 30460 USA; [Shaver, George] Georgia Southern Univ, Dept Psychol, Statesboro, GA 30460 USA; [Graham, Victoria] Sport Safety Consulting, Cromwell, CT USA; [Naugle, Kelly] Indiana Univ Purdue Univ Indianapolis, Sch Phys Educ & Tourism Management, Indianapolis, IN USA; [Buckley, Thomas] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE 19716 USA	Langdon, J (corresponding author), Georgia Southern Univ, Sch Hlth & Kinesiol, Statesboro, GA 30460 USA.	jlangdon@georgiasouthern.edu	Buckley, Thomas A/B-7525-2016; Naugle, Kelly/AAQ-1628-2021	Buckley, Thomas A/0000-0002-0515-0150; Langdon, Jody/0000-0002-5589-1694	National Institute of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R15NS070744-01A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS070744] Funding Source: NIH RePORTER	This study was supported by the National Institute of Health/National Institute of Neurological Disorders and Stroke (1R15NS070744-01A1). The funding source had no role in the study design, data collection and interpretation, or decision to submit this article for publication.	Abend R, 2014, J BEHAV THER EXP PSY, V45, P447, DOI 10.1016/j.jbtep.2014.06.004; Antony M.M., 2001, PRACTITIONERS GUIDE; Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Buckley TA, 2016, J HEAD TRAUMA REHAB, V31, P233, DOI 10.1097/HTR.0000000000000165; Buckley TA, 2016, J SPORT HEALTH SCI, V5, P61, DOI 10.1016/j.jshs.2016.01.007; Buckley TA, 2015, J ATHL TRAINING, V50, P879, DOI 10.4085/1062-6050-50.7.04; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Covassin T, 2014, J ATHL TRAINING, V49, P462, DOI 10.4085/1062-6059-49.2.03; Gilbert FC, 2016, SPORTS HEALTH, V8, P661, DOI 10.1177/1941738116666509; Gouttebarge V., 2016, CLIN J SPORT MED, V12, P12; GROVE JR, 1992, INT J SPORT PSYCHOL, V23, P93; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Hutchison MG, 2017, J HEAD TRAUMA REHAB, V32, pE38, DOI 10.1097/HTR.0000000000000252; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Kelly KC, 2014, J ATHL TRAINING, V49, P665, DOI 10.4085/1062-6050-49.3.25; Kontos AP, 2016, BRIT J SPORT MED, V50, P139, DOI 10.1136/bjsports-2015-095564; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Leddy J, 2016, PM&R, V8, pS91, DOI 10.1016/j.pmrj.2015.10.017; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; Mainwaring L, 2012, J CLIN SPORT PSYCHOL, V6, P247, DOI 10.1123/jcsp.6.3.247; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Moore RD, 2016, BRAIN IMAGING BEHAV, V10, P1108, DOI 10.1007/s11682-015-9473-6; Moreau M. S., 2014, INT J EXERCISE SCI, V7, P62; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Neal TL, 2013, J ATHL TRAINING, V48, P716, DOI 10.4085/1062-6050-48.4.13; Novak Z, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.2900; Oldham JR, 2016, GAIT POSTURE, V49, P437, DOI 10.1016/j.gaitpost.2016.07.327; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Sheline YI, 1996, P NATL ACAD SCI USA, V93, P3908, DOI 10.1073/pnas.93.9.3908; Singh R, 2016, J NEUROL NEUROSUR PS, V87, P670, DOI 10.1136/jnnp-2015-311369; Spielberger CD, 1970, STATE TRAIT ANXIETY; Spielberger CD., 1989, MANUAL STATE TRAIT A, V2; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Udry E, 1997, J SPORT EXERCISE PSY, V19, P368, DOI 10.1123/jsep.19.4.368; van der Horn HJ, 2016, J NEUROTRAUM, V33, P1, DOI 10.1089/neu.2015.3905; Vincent HK, 2015, PM&R, V7, P978, DOI 10.1016/j.pmrj.2015.03.007; Wiese-Bjornstal D., 2015, KINESIOLOGY REV, V4, P169; Williams JM, 2016, J SPORT HEALTH SCI, V5, P197, DOI 10.1016/j.jshs.2015.01.009; Yang JZ, 2007, CLIN J SPORT MED, V17, P481, DOI 10.1097/JSM.0b013e31815aed6b	47	12	12	0	12	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	2157-3905	2157-3913		SPORT EXERC PERFORM	Sport Exerc. Perform. Psychol.	AUG	2017	6	3					277	288		10.1037/spy0000099			12	Hospitality, Leisure, Sport & Tourism; Psychology, Applied	Social Sciences - Other Topics; Psychology	FD8RW	WOS:000407792800007	29250458	Bronze, Green Accepted			2021-06-18	
J	Wilkinson, AA; Dennis, M; Simic, N; Taylor, MJ; Morgan, BR; Frndova, H; Choong, K; Campbell, C; Fraser, D; Anderson, V; Guerguerian, AM; Schachar, R; Hutchison, J				Wilkinson, Amy A.; Dennis, Maureen; Simic, Nevena; Taylor, Margot J.; Morgan, Benjamin R.; Frndova, Helena; Choong, Karen; Campbell, Craig; Fraser, Douglas; Anderson, Vicki; Guerguerian, Anne-Marie; Schachar, Russell; Hutchison, Jamie		Canadian Critical Care Trials Grp; Canadian Critical Care Translation	Brain biomarkers and pre-injury cognition are associated with long-term cognitive outcome in children with traumatic brain injury	BMC PEDIATRICS			English	Article						Attention; Executive functions; Traumatic brain injury; Serum biomarkers	SPONDYLOEPIPHYSEAL DYSPLASIA CONGENITA; II COLLAGEN; COL2A1 GENE; SPONDYLOEPIMETAPHYSEAL DYSPLASIA; PHENOTYPIC SPECTRUM; HIP-DYSPLASIA; MUTATION; DISORDERS; SEDC	Background: Children with traumatic brain injury (TBI) are frequently at risk of long-term impairments of attention and executive functioning but these problems are difficult to predict. Although deficits have been reported to vary with injury severity, age at injury and sex, prognostication of outcome remains imperfect at a patient-specific level. The objective of this proof of principle study was to evaluate a variety of patient variables, along with six brain-specific and inflammatory serum protein biomarkers, as predictors of long-term cognitive outcome following paediatric TBI. Method: Outcome was assessed in 23 patients via parent-rated questionnaires related to attention deficit hyperactivity disorder (ADHD) and executive functioning, using the Conners 3rd Edition Rating Scales (Conners-3) and Behaviour Rating Inventory of Executive Function (BRIEF) at a mean time since injury of 3.1 years. Partial least squares (PLS) analyses were performed to identify factors measured at the time of injury that were most closely associated with outcome on (1) the Conners-3 and (2) the Behavioural Regulation Index (BRI) and (3) Metacognition Index (MI) of the BRIEF. Results: Higher levels of neuron specific enolase (NSE) and lower levels of soluble neuron cell adhesion molecule (sNCAM) were associated with higher scores on the inattention, hyperactivity/impulsivity and executive functioning scales of the Conners-3, as well as working memory and initiate scales of the MI from the BRIEF. Higher levels of NSE only were associated with higher scores on the inhibit scale of the BRI. Conclusions: NSE and sNCAM show promise as reliable, early predictors of long-term attention-related and executive functioning problems following paediatric TBI.	[Wilkinson, Amy A.; Dennis, Maureen; Taylor, Margot J.] Univ Toronto, Dept Psychol, Toronto, ON, Canada; [Wilkinson, Amy A.; Dennis, Maureen; Taylor, Margot J.; Guerguerian, Anne-Marie; Schachar, Russell; Hutchison, Jamie] Hosp Sick Children, Program Neurosci Mental Hlth, Toronto, ON, Canada; [Dennis, Maureen] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Simic, Nevena] Hamilton Hlth Sci Corp, Comprehens Pediat Epilepsy Program, Hamilton, ON, Canada; [Taylor, Margot J.; Morgan, Benjamin R.] Hosp Sick Children, Dept Diagnost Imaging, Toronto, ON, Canada; [Frndova, Helena; Guerguerian, Anne-Marie; Hutchison, Jamie] Hosp Sick Children, Dept Crit Care Med, Toronto, ON, Canada; [Choong, Karen] Childrens Hosp Hamilton, Div Pediat Intens Care, Dept Pediat, Hamilton, ON, Canada; [Campbell, Craig; Fraser, Douglas] Western Univ, Schulich Sch Med, Pediat Clin Neurol Sci & Epidemiol, London, ON, Canada; [Anderson, Vicki] Murdoch Childrens Res Inst, Clin Sci, Melbourne, Vic, Australia; [Anderson, Vicki] Univ Melbourne, Psychol Sci & Pediat, Melbourne, Vic, Australia; [Schachar, Russell] Hosp Sick Children, Dept Psychiat, Toronto, ON, Canada	Wilkinson, AA (corresponding author), Univ Toronto, Dept Psychol, Toronto, ON, Canada.; Wilkinson, AA; Hutchison, J (corresponding author), Hosp Sick Children, Program Neurosci Mental Hlth, Toronto, ON, Canada.; Hutchison, J (corresponding author), Hosp Sick Children, Dept Crit Care Med, Toronto, ON, Canada.	amy.wilkinson@sickkids.ca; jamie.hutchison@sickkids.ca			Natural Science FoundationNational Natural Science Foundation of China (NSFC) [2015D012]; Natural Science Foundation of Fujian ProvinceNatural Science Foundation of Fujian Province [2014D003]; Medical Innovation Foundation of Fujian Province [2014-CXB-46]; Science and Technology Project of Xiamen City [3502Z20164029]	This work was supported by the Natural Science Foundation for Distinguished Young Scholars of Fujian Province (project no. 2015D012), Natural Science Foundation of Fujian Province (project no. 2014D003), the Medical Innovation Foundation of Fujian Province (project no. 2014-CXB-46), and the Science and Technology Project of Xiamen City (project no. 3502Z20164029).	Al Kaissi A, 2013, ORTHOPADE, V42, P963, DOI 10.1007/s00132-013-2182-1; ANDERSON IJ, 1990, AM J HUM GENET, V46, P896; Barat-Houari M, 2016, EUR J HUM GENET, V24, P992, DOI 10.1038/ejhg.2015.250; BEIGHTON P, 1984, AM J MED GENET, V19, P161, DOI 10.1002/ajmg.1320190116; BOGAERT R, 1992, J BIOL CHEM, V267, P22522; Chung BHY, 2013, AM J MED GENET A, V161A, P918, DOI 10.1002/ajmg.a.35793; Deng H, 2016, MUTAT RES-REV MUTAT, V768, P1, DOI 10.1016/j.mrrev.2016.02.003; Hoornaert KP, 2006, J MED GENET, V43, P406, DOI 10.1136/jmg.2005.035717; Kaitila I, 1996, AM J MED GENET, V63, P111; Matsubayashi S, 2013, MOL SYNDROMOL, V4, P148, DOI 10.1159/000346644; Mortier GR, 2000, J MED GENET, V37, P263, DOI 10.1136/jmg.37.4.263; Nishimura G, 2005, HUM MUTAT, V26, P36, DOI 10.1002/humu.20179; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Silveira KC, 2015, AM J MED GENET A, V167, P894, DOI 10.1002/ajmg.a.36954; SPRANGER J, 1994, EUR J PEDIATR, V153, P56, DOI 10.1007/s004310050086; STICKLER GB, 1965, MAYO CLIN PROC, V40, P433; Terhal PA, 2015, AM J MED GENET A, V167, P461, DOI 10.1002/ajmg.a.36922; TILLER GE, 1995, NAT GENET, V11, P87, DOI 10.1038/ng0995-87; VIKKULA M, 1993, GENOMICS, V16, P282, DOI 10.1006/geno.1993.1179; Walter K, 2007, AM J MED GENET A, V143A, P161, DOI 10.1002/ajmg.a.31516; Warman ML, 2011, AM J MED GENET A, V155A, P943, DOI 10.1002/ajmg.a.33909; Xu LL, 2014, EUR SPINE J, V23, pS271, DOI 10.1007/s00586-014-3292-0	22	12	12	0	13	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2431			BMC PEDIATR	BMC Pediatr.	JUL 24	2017	17								173	10.1186/s12887-017-0925-6			26	Pediatrics	Pediatrics	FB7QA	WOS:000406333900001	28738850	DOAJ Gold, Green Published			2021-06-18	
J	Budnick, HC; Tyroch, AH; Milan, SA				Budnick, Hailey C.; Tyroch, Alan H.; Milan, Stacey A.			Ethnic disparities in traumatic brain injury care referral in a Hispanic-majority population	JOURNAL OF SURGICAL RESEARCH			English	Article							INPATIENT REHABILITATION; RACIAL DISPARITIES; INSURANCE STATUS; FAMILY NEEDS; OUTCOMES; DISCHARGE; INTENSITY; TBI; EPIDEMIOLOGY; CAREGIVERS	Background: Functional outcomes after traumatic brain injury (TBI) can be significantly improved by discharge to posthospitalization care facilities. Many variables influence the discharge disposition of the TBI patient, including insurance status, patient condition, and patient prognosis. The literature has demonstrated an ethnic disparity in posthospitalization care referral, with Hispanics being discharged to rehabilitation and nursing facilities less often than non-Hispanics. However, this relationship has not been studied in a Hispanicmajority population, and thus, this study seeks to determine if differences in neurorehabilitation referrals exist among ethnic groups in a predominately Hispanic region. Methods: This study is a retrospective cohort that includes 1128 TBI patients who presented to University Medical Center El Paso, Texas, between the years 2005 and 2015. The patients' age, sex, race, residence, admission Glasgow Coma Scale (GCS), GCS motor, Injury Severity Score (ISS), hospital and intensive care unit length of stay (LOS), mechanism of injury, and discharge disposition were analyzed in univariate and multivariate models. Results: Our study population had an insurance rate of 55.5%. Insurance status and markers of injury severity (hospital LOS, intensive care unit LOS, ISS, GCS, and GCS motor) were predictive of discharge disposition to rehabilitation facilities. The study population was 70% Hispanic, yet Hispanics were discharged to rehabilitation facilities (relative risk: 0.56, P:0.001) and to long- term acute care/nursing facilities (relative risk: 0.35, P < 0.0001) less than non- Hispanics even after LOS, ISS, ethnicity, insurance status, and residence were adjusted for in multivariate analysis. Conclusions: This study suggests that patients of different ethnicities but comparable traumatic severity and insurance status receive different discharge dispositions post-TBI even in regions in which Hispanics are the demographic majority. (C) 2017 Elsevier Inc. All rights reserved.	[Budnick, Hailey C.; Tyroch, Alan H.; Milan, Stacey A.] Texas Tech Univ, Hlth Sci Ctr, Dept Surg, 900 Myrtle Ave 2107, El Paso, TX 79901 USA	Budnick, HC (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Surg, 900 Myrtle Ave 2107, El Paso, TX 79901 USA.	hailey.budnick@ttuhsc.edu					Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Arango-Lasprilla JC, 2010, BRAIN INJURY, V24, P1017, DOI 10.3109/02699052.2010.490516; Asemota AO, 2013, J NEUROTRAUM, V30, P2057, DOI 10.1089/neu.2013.3091; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; Chang PFJ, 2008, ARCH PHYS MED REHAB, V89, P231, DOI 10.1016/j.apmr.2007.08.143; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Cooper Z, 2012, J HEALTH CARE POOR U, V23, P857, DOI 10.1353/hpu.2012.0064; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gary KW, 2009, BRAIN INJURY, V23, P775, DOI 10.1080/02699050903200563; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; Kane WG, 2014, J HEAD TRAUMA REHAB, V29, pE10, DOI 10.1097/HTR.0000000000000028; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; Lehan T, 2012, NEUROREHABILITATION, V30, P87, DOI 10.3233/NRE-2011-0730; McQuistion K, 2016, J SURG RES, V205, P261, DOI 10.1016/j.jss.2016.06.087; Meagher AD, 2015, J NEUROSURG, V122, P595, DOI 10.3171/2014.10.JNS14187; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Norup A, 2015, NEUROREHABILITATION, V36, P203, DOI 10.3233/NRE-151208; Pappadis MR, 2011, J HEAD TRAUMA REHAB, V26, P301, DOI 10.1097/HTR.0b013e3181e7832b; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Rubin MA, 2014, J CRIT CARE, V29, P49, DOI 10.1016/j.jcrc.2013.08.023; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Salottolo K, 2017, J CRIT CARE, V38, P197, DOI 10.1016/j.jcrc.2016.11.034; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; US Census Bureau, 2015, PAS COUNT; Valdivieso-Mora E, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01632; Zanaty M, 2015, J NEUROSURG, P1	30	12	12	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	JUL	2017	215						231	238		10.1016/j.jss.2017.03.062			8	Surgery	Surgery	FA3RZ	WOS:000405363400034	28688653				2021-06-18	
J	Gaskin, J; Gomes, J; Darshan, S; Krewski, D				Gaskin, J.; Gomes, J.; Darshan, S.; Krewski, D.			Burden of neurological conditions in Canada	NEUROTOXICOLOGY			English	Article							PARKINSONS-DISEASE; COST; PROGRESSION; DISORDERS; DEMENTIA	Neurological conditions are among the leading causes of disability in the Canadian population and are associated with a large public health burden. An increase in life expectancy and a declining birth rate has resulted in an aging Canadian population, and the proportion of age-adjusted mortality due to non-communicable diseases has been steadily increasing. These conditions are frequently associated with chronic disability and an increasing burden of care for patients, their families and caregivers. The National Population Health Study of Neurological Conditions (NPHSNC) aims to improve knowledge about neurological conditions and their impacts on individuals, their families, caregivers and health care system. The Systematic Review of Determinants of Neurological Conditions, a specific objective within the NPHSNC, is a compendium of systematic reviews on risk factors affecting onset and progression of the following 14 priority neurological conditions: Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), brain tumours (BT), cerebral palsy (CP), dystonia, epilepsy, Huntington's disease (HD), hydrocephalus, multiple sclerosis (MS), muscular dystrophies (MD), neurotrauma, Parkinson's disease (PD), spina bifida (SB), and Tourette's syndrome (TS). The burden of neurological disease is expected to increase as the population ages, and this trend is presented in greater detail for Alzheimer's and Parkinson's disease because the incidence of these two common neurological diseases increases significantly with age over 65 years. This article provides an overview of burden of neurological diseases in Canada to set the stage for the in-depth systematic reviews of the 14 priority neurological conditions presented in subsequent articles in this issue. (C) 2016 Published by Elsevier B.V.	[Gaskin, J.; Gomes, J.; Darshan, S.; Krewski, D.] Univ Ottawa, McLaughlin Ctr Populat Hlth Risk Assessment, Ottawa, ON, Canada; [Gomes, J.] Univ Ottawa, Fac Hlth Sci, Interdisciplinary Sch Hlth Sci, Ottawa, ON, Canada; [Gomes, J.] Univ Ottawa, Environm Hlth Res Unit, Ottawa, ON, Canada; [Gaskin, J.; Krewski, D.] Univ Ottawa, Fac Med, Dept Epidemiol & Community Med, Ottawa, ON, Canada; Risk Sci Int, Ottawa, ON, Canada	Gaskin, J (corresponding author), Univ Ottawa, McLaughlin Ctr Populat Hlth Risk Assessment, Ottawa, ON, Canada.; Gaskin, J (corresponding author), Univ Ottawa, Fac Med, Dept Epidemiol & Community Med, Ottawa, ON, Canada.	jgaskin@uottawa.ca	Gomes, James/R-8363-2017	Gomes, James/0000-0002-9818-5984; Gaskin, Janet/0000-0001-5326-4921	Neurological Health Charities Canada; Public Health Agency of Canada; Neurological Health Charities Canada; Public Health Agency of Canada	Support for the project was provided by the Public Health Agency of Canada in association with Neurological Health Charities Canada. D. Krewski is the Natural Sciences and Engineering Research Council of Canada Chair in Risk Science at the University of Ottawa.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Black SE, 2010, INT J GERIATR PSYCH, V25, P807, DOI 10.1002/gps.2421; Chin JH, 2014, NEUROLOGY, V83, P349, DOI 10.1212/WNL.0000000000000610; CIHI, 2007, BURD NEUR DIS DIS IN; Collins PY, 2011, NATURE, V475, P27, DOI 10.1038/475027a; Gustavsson A, 2011, EUR NEUROPSYCHOPHARM, V21, P718, DOI 10.1016/j.euroneuro.2011.08.008; Guttman M, 2003, MOVEMENT DISORD, V18, P313, DOI 10.1002/mds.10333; Hebert R, 2001, J GERONTOL A-BIOL, V56, pM693, DOI 10.1093/gerona/56.11.M693; Herrmann N, 2010, CAN J PSYCHIAT, V55, P768, DOI 10.1177/070674371005501204; Herrmann N, 2006, INT J GERIATR PSYCH, V21, P972, DOI 10.1002/gps.1594; Hersi M, 2017, NEUROTOXICOLOGY, V61, P12, DOI 10.1016/j.neuro.2016.06.017; Jones CA, 2012, PARKINSONISM RELAT D, V18, P327, DOI 10.1016/j.parkreldis.2011.11.018; Krewski D, 2017, NEUROTOXICOLOGY, V61, P266, DOI 10.1016/j.neuro.2017.04.002; Little J, 2017, NEUROTOXICOLOGY, V61, P243, DOI [10.1016/j.neuro.2016.09.018, 10.1016/j.neuro.2016.09.01]; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; MCDOWELL I, 1994, CAN MED ASSOC J, V150, P899; Public Health Agency of Canada (PHAC), 2014, EC BURD ILLN CAN 200, P111; Public Health Agency of Canada (PHAC), 2014, MAPP CONN UND NEUR C, P110; Public Health Agency of Canada (PHAC), 2012, NAT POP HLTH STUD NE; Statistics Canada, 2016, CAN DEM GLANC, V2nd; Tator C, 2007, CAN J NEUROL SCI, V34, P268, DOI 10.1017/S0317167100006673; Turcotte M., 2013, FAMILY CAREGIVING WH; Van Den Eeden SK, 2003, AM J EPIDEMIOL, V157, P1015, DOI 10.1093/aje/kwg068; WHO (WorldHealthOrganization), 1993, ICD CLASS MENT BEH D; Wong S.L., 2014, HLTH REPORTS; World Health Organization (WHO), 2016, MENT HLTH STRENGTH O	26	12	12	1	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0161-813X	1872-9711		NEUROTOXICOLOGY	Neurotoxicology	JUL	2017	61				SI		2	10		10.1016/j.neuro.2016.05.001			9	Neurosciences; Pharmacology & Pharmacy; Toxicology	Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology	FI3IG	WOS:000411851800003	27153747				2021-06-18	
J	Konigs, M; van Heurn, LWE; Bakx, R; Vermeulen, RJ; Goslings, JC; Poll-The, BT; van der Wees, M; Catsman-Berrevoets, CE; Oosterlaan, J; Pouwels, PJW				Konigs, Marsh; van Heurn, L. W. Ernest; Bakx, Roel; Vermeulen, R. Jeroen; Goslings, J. Carel; Poll-The, Bwee Tien; van der Wees, Marleen; Catsman-Berrevoets, Coriene E.; Oosterlaan, Jaap; Pouwels, Petra J. W.			The Structural Connectome of Children With Traumatic Brain Injury	HUMAN BRAIN MAPPING			English	Article						pediatrics; traumatic brain injury; structural connectivity; functional outcome	CONNECTIVITY; NETWORKS; OUTCOMES; IMPAIRMENT; TBI	This study aimed to investigate the impact of mild to severe pediatric TBI on the structural connectome. Children aged 8-14 years with trauma control (TC) injury (n = 27) were compared to children with mild TBI and risk factors for complicated TBI (mild(RF+), n = 20) or moderate/severe TBI (n=16) at 2.8 years post-injury. Probabilistic tractography on diffusion tensor imaging data was used in combination with graph theory to study structural connectivity. Functional outcome was measured using neurocognitive tests and parent and teacher questionnaires for behavioral functioning. The results revealed no evidence for an impact of mild(RF+) TBI on the structural connectome. In contrast, the moderate/severe TBI group showed longer characteristic path length (P=0.022, d=0.82) than the TC group. Furthermore, longer characteristic path length was related to poorer intelligence and poorer working memory in children with TBI. In conclusion, children have abnormal organization of the structural connectome moderate/severe TBI, which may be implicated in neurocognitive dysfunction associated with pediatric TBI. These findings should be interpreted in the context of our exploratory analyses, which indicate that the definition and weighting of connectivity (e.g., streamline density, fractional anisotropy) influence the properties of the reconstructed connectome and its sensitivity to the impact and outcome of pediatric TBI. (C) 2017 Wiley Periodicals, Inc.	[Konigs, Marsh; Oosterlaan, Jaap] Vrije Univ Amsterdam, Clin Neuropsychol Sect, Amsterdam, Netherlands; [Konigs, Marsh; Oosterlaan, Jaap] Emma Childrens Hosp, Acad Med Ctr, Amsterdam, Netherlands; [van Heurn, L. W. Ernest; Bakx, Roel] Emma Childrens Hosp, Acad Med Ctr, Pediat Surg Ctr Amsterdam, Amsterdam, Netherlands; [van Heurn, L. W. Ernest; Bakx, Roel] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [Vermeulen, R. Jeroen] Vrije Univ Amsterdam, Med Ctr, Dept Pediat Neurol, Amsterdam, Netherlands; [Vermeulen, R. Jeroen] Maastricht UMC, Dept Pediat Neurol, Maastricht, Netherlands; [Goslings, J. Carel] Acad Med Ctr, Trauma Unit, Amsterdam, Netherlands; [Poll-The, Bwee Tien] Emma Childrens Hosp, Acad Med Ctr, Dept Pediat Neurol, Amsterdam, Netherlands; [van der Wees, Marleen] Blixembosch, Libra Rehabil Med & Audiol, Eindhoven, Netherlands; [Catsman-Berrevoets, Coriene E.] Sophia Childrens Univ Hosp, Erasmus Univ Hosp, Dept Pediat Neurol, Rotterdam, Netherlands; [Oosterlaan, Jaap] Vrije Univ Amsterdam, Med Ctr, Dept Pediat, Amsterdam, Netherlands; [Pouwels, Petra J. W.] Vrije Univ Amsterdam, Med Ctr, Dept Phys & Med Technol, Amsterdam, Netherlands; [Pouwels, Petra J. W.] Neurosci Campus Amsterdam, Amsterdam, Netherlands	Konigs, M (corresponding author), Vrije Univ Amsterdam, Clin Neuropsychol Sect, Amsterdam, Netherlands.	m.konigs@vu.nl		Vermeulen, R. Jeroen/0000-0002-3503-3625	Netherlands' Organization for Scientific Research (NWO)Netherlands Organization for Scientific Research (NWO) [022.003.010]	Contract grant sponsor: Netherlands' Organization for Scientific Research (NWO, http://www.nwo.nl); Contract grant number: 022.003.010.	American College of Surgeons, 2004, ADV TRAUM LIF SUPP P; Babcock L, 2015, J PEDIATR REHAB MED, V8, P285, DOI 10.3233/PRM-150347; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Caeyenberghs K, 2012, NEUROIMAGE-CLIN, V1, P106, DOI 10.1016/j.nicl.2012.09.011; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Dall'Acqua P, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00127; Epskamp S, 2012, J STAT SOFTW, V48, P1, DOI 10.18637/jss.v048.i04; Fagerholm ED, 2015, BRAIN, V138, P1696, DOI 10.1093/brain/awv075; Fornito A, 2015, NAT REV NEUROSCI, V16, P159, DOI 10.1038/nrn3901; Gong GL, 2009, CEREB CORTEX, V19, P524, DOI 10.1093/cercor/bhn102; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Kim J, 2014, J INT NEUROPSYCH SOC, V20, P887, DOI 10.1017/S1355617714000812; Konigs M., 2017, BRAIN IMAGING BEHAV, P1, DOI [10.1007/s11682-017-9673-3, DOI 10.1007/S11682-017-9673-3]; Konigs M, 2015, PEDIATRICS, V136, P534, DOI 10.1542/peds.2015-0437; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; Max J, 1998, CHILD ADOLESC PSYCHI, V37, P932; Max JE, 2012, J AM ACAD CHILD PSY, V51, P1208, DOI 10.1016/j.jaac.2012.08.026; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Park HJ, 2013, SCIENCE, V342, P579, DOI 10.1126/science.1238411; Patenaude B, 2011, NEUROIMAGE, V56, P907, DOI 10.1016/j.neuroimage.2011.02.046; Qi SL, 2015, J NEUROSCI METH, V253, P170, DOI 10.1016/j.jneumeth.2015.06.016; Roberts RM, 2014, DEV NEUROPSYCHOL, V39, P600, DOI 10.1080/87565641.2014.973958; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Sattler JM, 2001, ASSESSMENT CHILDREN, P774; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Squarcina L, 2012, NEUROIMAGE, V63, P779, DOI 10.1016/j.neuroimage.2012.07.016; Statistics Netherlands, 2006, ED CAT STAND; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Van Beek L, 2015, BRAIN INJURY, V29, P1701, DOI 10.3109/02699052.2015.1075172; van den Burg W, 1999, ARCH CLIN NEUROPSYCH, V14, P545, DOI 10.1016/S0887-6177(98)00042-0; Verhulst F.C., 2013, HANDLEIDING ASEBA VR; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Vu JA, 2011, EXCEPT CHILDREN, V77, P263, DOI 10.1177/001440291107700301; Wechsler D., 1991, WISC 3 WECHSLER INTE; World Health Organization, 2006, NEUR DIS PUBL HLTH C; Yuan WH, 2017, NEUROREHAB NEURAL RE, V31, P190, DOI 10.1177/1545968316675430; Yuan WH, 2015, HUM BRAIN MAPP, V36, P779, DOI 10.1002/hbm.22664; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424; Zhang ZQ, 2011, BRAIN, V134, P2912, DOI 10.1093/brain/awr223	42	12	12	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	JUL	2017	38	7					3603	3614		10.1002/hbm.23614			12	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EZ8GR	WOS:000404963400022	28429381	Bronze, Green Published			2021-06-18	
J	Liu, DZ; Waldau, B; Ander, BP; Zhan, XH; Stamova, B; Jickling, GC; Lyeth, BG; Sharp, FR				Liu, Da Zhi; Waldau, Ben; Ander, Bradley P.; Zhan, Xinhua; Stamova, Boryana; Jickling, Glen C.; Lyeth, Bruce G.; Sharp, Frank R.			Inhibition of Src family kinases improves cognitive function after intraventricular hemorrhage or intraventricular thrombin	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Intraventricular hemorrhage; Src family kinases; Fyn; spatial memory deficits; PP2	PHASE-II TRIAL; INTRACEREBRAL HEMORRHAGE; BRAIN; ACTIVATION; PROTECTS; INJURY; RHO	Intraventricular hemorrhage causes spatial memory loss, but the mechanism remains unknown. Our recent studies demonstrated that traumatic brain injury activates Src family kinases, which cause spatial memory loss. To test whether the spatial memory loss was due to blood in the ventricles, which activated Src family kinases, we infused autologous whole blood or thrombin into the lateral ventricles of adult rats to model non-traumatic intraventricular hemorrhage. Hippocampal neuron loss was examined 1day to 5 weeks later. Spatial memory function was assessed 29 to 33 days later using the Morris water maze. Five weeks after the ventricular injections of blood or thrombin, there was death of most hippocampal neurons and significant memory deficits compared with sham operated controls. These data show that intraventricular thrombin is sufficient to kill hippocampal neurons and produce spatial memory loss. In addition, systemic administration of the non-specific Src family kinase inhibitor PP2 or intraventricular injection of siRNA-Fyn, a Src family kinase family member, prevented hippocampal neuronal loss and spatial memory deficits following intraventricular hemorrhage. The data support the conclusions that thrombin mediates the hippocampal neuronal cell death and spatial memory deficits produced by intraventricular blood and that these can be blocked by non-specific inhibition of Src family kinases or by inhibiting Fyn.	[Liu, Da Zhi; Ander, Bradley P.; Zhan, Xinhua; Stamova, Boryana; Jickling, Glen C.; Sharp, Frank R.] Univ Calif Davis, Dept Neurol, Sacramento, CA 95817 USA; [Liu, Da Zhi; Ander, Bradley P.; Zhan, Xinhua; Stamova, Boryana; Jickling, Glen C.; Sharp, Frank R.] Univ Calif Davis, MIND Inst, Sacramento, CA 95817 USA; [Waldau, Ben; Lyeth, Bruce G.] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA	Liu, DZ (corresponding author), UC Davis Med Ctr, Dept Neurol, MIND Inst, Wet Labs, Room 2417,2805 50th St, Sacramento, CA 95817 USA.	dzliu@ucdavis.edu	Stamova, Boryana/ABA-2981-2020; Jickling, Glen/J-8790-2019	Jickling, Glen/0000-0003-3543-0820; Lyeth, Bruce/0000-0003-4811-1474	American Heart AssociationAmerican Heart Association; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS089901, R01NS066845]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS089901, R01NS066845] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by American Heart Association Beginning Grant in Aid (DZL), NIH grants R01NS089901 (DZL) and R01NS066845 (FRS).	AKIYAMA H, 1992, NEUROSCI LETT, V146, P152, DOI 10.1016/0304-3940(92)90065-F; Ardizzone TD, 2004, STROKE, V35, P2587, DOI 10.1161/01.STR.0000143451.14228.ff; Ardizzone TD, 2007, STROKE, V38, P1621, DOI 10.1161/STROKEAHA.106.478966; Badjatia N, 2005, NEUROLOGIST, V11, P311, DOI 10.1097/01.nrl.0000178757.68551.26; Chen QW, 2015, STROKE, V46, P2902, DOI 10.1161/STROKEAHA.115.009713; Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956; Diemer NH, 1997, MATURATION PHENOMENON IN CEREBRAL ISCHEMIA II, P53; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; Eifler AC, 2011, METHODS MOL BIOL, V726, P325, DOI 10.1007/978-1-61779-052-2_21; Flaherty ML, 2006, NEUROLOGY, V66, P1182, DOI 10.1212/01.wnl.0000208400.08722.7c; Fogelholm R, 2005, J NEUROL NEUROSUR PS, V76, P1534, DOI 10.1136/jnnp.2004.055145; Gucalp A, 2011, CLIN BREAST CANCER, V11, P306, DOI 10.1016/j.clbc.2011.03.021; Hanley DF, 2009, STROKE, V40, P1533, DOI 10.1161/STROKEAHA.108.535419; Herold CI, 2011, CLIN CANCER RES, V17, P6061, DOI 10.1158/1078-0432.CCR-11-1071; Jeon BT, 2013, NEUROTOX RES, V23, P238, DOI 10.1007/s12640-012-9339-2; Joshi AD, 2014, AM J RESP CELL MOL, V50, P170, DOI 10.1165/rcmb.2012-0496OC; Liu DZ, 2014, J NEUROTRAUM, V31, P1268, DOI 10.1089/neu.2013.3250; Liu DZ, 2008, NEUROBIOL DIS, V30, P201, DOI 10.1016/j.nbd.2008.01.006; Liu DZ, 2012, SCI WORLD J, DOI 10.1100/2012/491737; Liu DZ, 2011, ACTA NEUROCHIR SUPPL, V111, P77, DOI 10.1007/978-3-7091-0693-8_13; Liu DZ, 2010, ANN NEUROL, V67, P526, DOI 10.1002/ana.21924; Liu DZ, 2010, NEUROBIOL DIS, V37, P549, DOI 10.1016/j.nbd.2009.11.013; Liu DZ, 2011, J CYTOL HISTOL, V2, pe101; Lu W, 2015, J BIOL CHEM, V290, P22945, DOI 10.1074/jbc.M115.663450; Misra A, 2003, J PHARM PHARM SCI, V6, P252; Nys GMS, 2007, CEREBROVASC DIS, V23, P408, DOI 10.1159/000101464; Oda H, 1999, P NATL ACAD SCI USA, V96, P9557, DOI 10.1073/pnas.96.17.9557; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Rodriguez PL, 2007, CELL SIGNAL, V19, P2361, DOI 10.1016/j.cellsig.2007.07.021; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; Tatosyan AG, 2000, BIOCHEMISTRY-MOSCOW+, V65, P49; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Trepanier CH, 2012, FEBS J, V279, P12, DOI 10.1111/j.1742-4658.2011.08391.x; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; Wang H, 2003, J NEUROCHEM, V84, P1349, DOI 10.1046/j.1471-4159.2003.01637.x; Wong GKC, 2009, ACTA NEUROCHIR, V151, P1601, DOI 10.1007/s00701-009-0425-z	37	12	12	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2017	37	7					2359	2367		10.1177/0271678X16666291			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	EY3XE	WOS:000403907700005	27624844	Bronze, Green Published			2021-06-18	
J	Mower, WR; Gupta, M; Rodriguez, R; Hendey, GW				Mower, William R.; Gupta, Malkeet; Rodriguez, Robert; Hendey, Gregory W.			Validation of the sensitivity of the National Emergency X-Radiography Utilization Study (NEXUS) Head computed tomographic (CT) decision instrument for selective imaging of blunt head injury patients: An observational study	PLOS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; NEW-ORLEANS CRITERIA; UNITED-STATES; RULE; DEPARTMENTS; MULTICENTER; TRENDS; TRIAL	Background Clinicians, afraid of missing intracranial injuries, liberally obtain computed tomographic (CT) head imaging in blunt trauma patients. Prior work suggests that clinical criteria (National Emergency X-Radiography Utilization Study [NEXUS] Head CT decision instrument [DI]) can reliably identify patients with important injuries, while excluding injury, and the need for imaging in many patients. Validating this DI requires confirmation of the hypothesis that the lower 95% confidence limit for its sensitivity in detecting serious injury exceeds 99.0%. A secondary goal of the study was to complete an independent validation and comparison of the Canadian and NEXUS Head CT rules among the subgroup of patients meeting the inclusion and exclusion criteria. Methods and findings We conducted a prospective observational study of the NEXUS Head CT DI in 4 hospital emergency departments between April 2006 and December 2015. Implementation of the rule requires that patients satisfy 8 criteria to achieve "low-risk" classification. Patients are excluded from "low-risk" classification and assigned "high-risk" status if they fail to meet 1 or more criteria. We examined the instrument's performance in assigning "high-risk" status to patients requiring neurosurgical intervention among a cohort of 11,770 blunt head injury patients. The NEXUS Head CT DI assigned high-risk status to 420 of 420 patients requiring neurosurgical intervention (sensitivity, 100.0% [95% confidence interval [CI]: 99.1%-100.0%]). The instrument assigned low-risk status to 2,823 of 11,350 patients who did not require neurosurgical intervention (specificity, 24.9% [95% CI: 24.1%-25.7%]). None of the 2,823 low-risk patients required neurosurgical intervention (negative predictive value [NPV], 100.0% [95% CI: 99.9%-100.0%]). The DI assigned high-risk status to 759 of 767 patients with significant intracranial injuries (sensitivity, 99.0% [95% CI: 98.0%-99.6%]). The instrument assigned low-risk status to 2,815 of 11,003 patients who did not have significant injuries (specificity, 25.6% [95% CI: 24.8%-26.4%]). Significant injuries were absent in 2,815 of the 2,823 patients assigned low-risk status (NPV, 99.7% [95% CI: 99.4%-99.9%]). Of our patients, 7,759 (65.9%) met the inclusion and exclusion criteria of the Canadian Head CT rule, including 111 patients (1.43%) who required neurosurgical intervention and 306 (3.94%) who had significant intracranial injuries. In our study, the Canadian criteria for neurosurgical intervention identified 108 of 111 patients requiring neurosurgical intervention to yield a sensitivity of 97.3% (95% CI: 92.3%-99.4%) and exhibited a specificity of 58.8% (95% CI: 57.7%-59.9%). The NEXUS rule, when applied to this same cohort, identified all 111 patients requiring neurosurgical intervention, yielding a sensitivity of 100% (95% CI: 96.7%-100.0%) with a specificity of 32.6% (95% CI: 31.5%-33.6%). Our study found that the Canadian medium-risk factors identified 301 of 306 patients with significant injuries (sensitivity = 98.4%; 95% CI: 96.2%-99.5%), while the NEXUS rule identified 299 of these patients (sensitivity = 97.7%; 95% CI: 95.3%-99.1%). In our study, the Canadian medium-risk rule exhibited a specificity of 12.3% (95% CI: 11.6%-13.1%), while the NEXUS rule exhibited a specificity of 33.3% (95% CI: 32.3%-34.4%). Limitations of the study may arise from application of the rule by different clinicians in different environments. Clinicians may vary in their interpretation and application of the instrument's criteria and risk assignment and may also vary in deciding which patients require intervention. The instrument's specificity is also subject to spectrum bias and may change with variations in the proportion of "low-risk" patients seen in other centers. Conclusions The NEXUS Head CT DI reliably identifies blunt trauma patients who require head CT imaging and could significantly reduce the use of CT imaging.	[Mower, William R.; Gupta, Malkeet; Hendey, Gregory W.] Univ Calif Los Angeles, Dept Emergency Med, Ronald Reagan UCLA Med Ctr, Los Angeles, CA 90095 USA; [Gupta, Malkeet] Antelope Valley Hosp, Emergency Dept, Lancaster, CA USA; [Rodriguez, Robert] UCSF, Sch Med, Dept Emergency Med, San Francisco Gen Hosp, San Francisco, CA USA; [Hendey, Gregory W.] UCSF Fresno, Community Reg Med Ctr, Fresno, CA USA	Mower, WR (corresponding author), Univ Calif Los Angeles, Dept Emergency Med, Ronald Reagan UCLA Med Ctr, Los Angeles, CA 90095 USA.	wmower@ucla.edu		Mower, William/0000-0003-1468-6501	Agency for Health Care Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [HS09699]; National Center for Injury Prevention and ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [CE001589]; UC Center for Health Quality and Innovation [HL120466]	This work was funded, in part, by the following grants: Agency for Health Care Research and Quality (www.ahrq.gov) HS09699, National Center for Injury Prevention and Control (https://www.cdc.gov/injury) CE001589, UC Center for Health Quality and Innovation (health.universityotcalifornia.edu/innovation-center) HL120466. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Board of Internal Medicine, CHOOS WIS IN ABIM FD; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Brenner DJ, 2010, RADIAT RES, V174, P809, DOI 10.1667/RR1859.1; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Fleiss Joseph L., 2003, STAT METHODS RATES P; Gaw CE, 2016, BMC EMERG MED, V16, DOI 10.1186/s12873-016-0071-8; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hussein W, 2015, ACAD EMERG MED, V22, P663, DOI 10.1111/acem.12684; Korley FK, 2016, J HEAD TRAUMA REHAB, V31, P379, DOI 10.1097/HTR.0000000000000187; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Melnick ER, 2015, JT COMM J QUAL PATIE, V41, P313, DOI 10.1016/S1553-7250(15)41041-4; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; Mower WR, 2002, ANN EMERG MED, V40, P505, DOI 10.1067/mem.2002.129245; National Research Council, 1990, HLTH EFF EXP LOW LEV; Prowse SJ, 2010, EMERG MED J, V27, P277, DOI 10.1136/emj.2008.070649; Ro YS, 2011, ACAD EMERG MED, V18, P597, DOI 10.1111/j.1553-2712.2011.01094.x; Shetty VS, 2016, J AM COLL RADIOL, V13, P668, DOI 10.1016/j.jacr.2016.02.023; Sierink JC, 2016, LANCET, V388, P673, DOI 10.1016/S0140-6736(16)30932-1; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Stiell IG, 2010, CAN MED ASSOC J, V182, P1527, DOI 10.1503/cmaj.091974; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	24	12	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1676			PLOS MED	PLos Med.	JUL	2017	14	7							e1002313	10.1371/journal.pmed.1002313			19	Medicine, General & Internal	General & Internal Medicine	FC1QA	WOS:000406611200002	28700585	DOAJ Gold, Green Published			2021-06-18	
J	Nikoo, M; Gadermann, A; To, MJ; Krausz, M; Hwang, SW; Palepu, A				Nikoo, Mohammadali; Gadermann, Anne; To, Matthew J.; Krausz, Michael; Hwang, Stephen W.; Palepu, Anita			Incidence and Associated Risk Factors of Traumatic Brain Injury in a Cohort of Homeless and Vulnerably Housed Adults in 3 Canadian Cities	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						homeless; incidence; prevalence; risk factor; traumatic brain injury	PSYCHIATRIC-DISORDERS; COGNITIVE DYSFUNCTION; MENTAL-ILLNESS; ALCOHOL; POPULATION; VETERANS; HEALTH; INDIVIDUALS; ADOLESCENCE; IMPAIRMENT	Objective: To examine the factors associated with incident traumatic brain injury (TBI) among homeless and vulnerably housed persons over a 3-year follow-up period. Setting and participants: Data were obtained from the Health andHousing in Transition study, which tracked the health and housing status of 1190 homeless or vulnerably housed individuals in 3 Canadian cities for 3 years. Design and Main Measures: Main measure was self-reported incident TBI during the follow-up period. Factors associated with TBI were ascertained using mixed-effects logistic regression. Results: During first, second, and third years of follow-up, 187 (19.4%), 166 (17.1%), and 172 (17.9%) participants reported a minimum of 1 incident TBI, respectively. Among 825 participants with available data for all 3 years of follow-up, 307 (37.2%) reported at least 1 incident TBI during the 3-year follow-up period. Lifetime prevalence of TBI, endorsing a history of mental health diagnoses at baseline, problematic alcohol and drug use, younger age, poorer mental health, and residential instability were associated with increased risk of incident TBI during follow-up period. Conclusion: Mental health support and addressing residential instability and problematic substance use may reduce further risk of TBI and its associated poor health and social outcomes in this population.	[Nikoo, Mohammadali] Univ British Columbia, Dept Med, Ctr Hlth Evaluat & Outcome Sci, Inst Mental Hlth, David Strangway Bldg 430-5950,Univ Blvd, Vancouver, BC V6T 1Z3, Canada; [Gadermann, Anne] Univ British Columbia, Dept Med, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC, Canada; [Krausz, Michael] Univ British Columbia, Inst Mental Hlth, Addict Res, Vancouver, BC, Canada; [Palepu, Anita] Univ British Columbia, Dept Med, Ctr Hlth Evaluat & Outcome Sci, Div Gen Internal Med, Vancouver, BC, Canada; [To, Matthew J.; Hwang, Stephen W.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Ctr Res Inner City Hlth, Toronto, ON, Canada	Nikoo, M (corresponding author), Univ British Columbia, Dept Med, Ctr Hlth Evaluat & Outcome Sci, Inst Mental Hlth, David Strangway Bldg 430-5950,Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	mnikoo@cheos.ubc.ca			Canadian Institute of Health Research (CIHR)Canadian Institutes of Health Research (CIHR)	Canadian Institute of Health Research (CIHR) has funded the Health and Housing in Transition study (HHiT). We thank the following individuals from our community partner organizations: Laura Cowan, Liz Evans, Stephanie Gee, Clare Hacksel, Erika Khandor, and Wendy Muckle. The authors also thank the study coordinators and interviewers in each of the 3 cities as well as the shelter, drop-in, and municipal and provincial staff for their assistance with participant recruitment and follow-up. We thank theHealth and Housing in Transition study participants for their contribution to these data. We also thank Marc Vogel, Fiona Choi, and Kerry Jang and Monica Norena for their contribution to the idea formulation and discussion to develop this manuscript.	Andersen J, 2014, DISABIL REHABIL, V36, P2210, DOI 10.3109/09638288.2014.895870; Aron L, 2002, 1996 NATL SURVEY HOM; Babor T.F., 1992, GUIDELINES USE PRIMA; Barnes SM, 2015, J HEALTH CARE POOR U, V26, P92, DOI 10.1353/hpu.2015.0010; Brady KT, 2005, AM J PSYCHIAT, V162, P1483, DOI 10.1176/appi.ajp.162.8.1483; Chandler RA, 2009, BIOL PSYCHIAT, V66, P840, DOI 10.1016/j.biopsych.2009.05.011; Corrigan John D., 2003, American Journal of Obstetrics and Gynecology, V188, pS71, DOI 10.1067/mob.2003.404; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Donovan DM, 2006, ADDICTION, V101, P1696, DOI 10.1111/j.1360-0443.2006.01606.x; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; GUALTIERI T, 1991, Brain Injury, V5, P219, DOI 10.3109/02699059109008093; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; Hwang SW, 2011, INT J PUBLIC HEALTH, V56, P609, DOI 10.1007/s00038-011-0283-3; Karriker-Jaffe KJ, 2008, J ABNORM CHILD PSYCH, V36, P1227, DOI 10.1007/s10802-008-9245-5; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Mackelprang JL, 2014, AM J PUBLIC HEALTH, V104, P1986, DOI 10.2105/AJPH.2014.302087; Maisto SA, 2000, PSYCHOL ASSESSMENT, V12, P186, DOI 10.1037/1040-3590.12.2.186; McKinlay A, 2014, J HEAD TRAUMA REHAB, V29, P498, DOI 10.1097/HTR.0000000000000001; McMillan TM, 2015, J NEUROTRAUM, V32, P116, DOI 10.1089/neu.2014.3387; Millan MJ, 2012, NAT REV DRUG DISCOV, V11, P141, DOI 10.1038/nrd3628; Nikoo N, 2015, J HLTH DISPARITIES R, V8, P17; Nordstrom A, 2013, BMJ, V346; Oddy M, 2012, BRAIN INJURY, V26, P1058, DOI 10.3109/02699052.2012.667595; Olson-Madden J. H., 2012, REHABIL RES PRACT, V2012; Ponsford J, 2013, J CLIN EXP NEUROPSYC, V35, P103, DOI 10.1080/13803395.2012.752437; Russell LM, 2013, AM J PUBLIC HEALTH, V103, pS211, DOI 10.2105/AJPH.2013.301485; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Statistics Canada, 2009, CAN COMM HLTH SURV C; Stergiopoulos V, 2015, ACTA PSYCHIAT SCAND, V131, P256, DOI 10.1111/acps.12391; Teasdale TW, 1997, BRIT MED J, V315, P569; The Health and Housing in Transition (HHiT) Study Team, 2015, STUD TEAM HOUS DEF H; To MJ, 2015, J HEAD TRAUMA REHAB, V30, P270, DOI 10.1097/HTR.0000000000000044; Topolovec-Vranic Jane, 2014, CMAJ Open, V2, pE69, DOI 10.9778/cmajo.20130046; Topolovec-Vranic J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1059; Tsemberis S, 2007, J COMMUNITY PSYCHOL, V35, P29, DOI 10.1002/jcop.20132; Twamley EW, 2015, J HEAD TRAUMA REHAB, V30, P391, DOI 10.1097/HTR.0000000000000076; UCLA: Statistical Consulting Group, 2016, R DAT AN EX MIX EFF; Vaaramo K, 2014, EUR J NEUROL, V21, P293, DOI 10.1111/ene.12302; Ware JE, 2002, SF 12 SCORE SF 12 PH, V4th; Winn JL, 2013, PSYCHOL SERV, V10, P233, DOI 10.1037/a0031051	42	12	12	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2017	32	4					E19	E26		10.1097/HTR.0000000000000262			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FA2KB	WOS:000405269200003	28489699				2021-06-18	
J	Povysheva, T; Shmarov, M; Logunov, D; Naroditsky, B; Shulman, I; Ogurcov, S; Kolesnikov, P; Islamov, R; Chelyshev, Y				Povysheva, Tatyana; Shmarov, Maksim; Logunov, Denis; Naroditsky, Boris; Shulman, Ilya; Ogurcov, Sergey; Kolesnikov, Pavel; Islamov, Rustem; Chelyshev, Yuri			Post-spinal cord injury astrocyte-mediated functional recovery in rats after intraspinal injection of the recombinant adenoviral vectors Ad5-VEGF and Ad5-ANG	JOURNAL OF NEUROSURGERY-SPINE			English	Article						spinal cord injury; adenovirus vector; angiogenin; vascular endothelial growth factor; VEGF; astrocyte	AMYOTROPHIC-LATERAL-SCLEROSIS; ENDOTHELIAL GROWTH-FACTOR; GENE-THERAPY; VEGF-A; ANGIOGENIN; BRAIN; CELLS; REGENERATION; DISORDERS; OUTGROWTH	OBJECTIVE The most actively explored therapeutic strategy for overcoming spinal cord injury (SCI) is the delivery of genes encoding molecules that stimulate regeneration. In a mouse model of amyotrophic lateral sclerosis and in preliminary clinical trials in patients with amyotrophic lateral sclerosis, the combined administration of recombinant adenoviral vectors (Ad5-VEGF+Ad5-ANG) encoding the neurotrophic/angiogenic factors vascular endothelial growth factor (VEGF) and angiogenin (ANG) was found to slow the development of neurological deficits. These results suggest that there may be positive effects of this combination of genes in posttraumatic spinal cord regeneration. The objective of the present study was to determine the effects of Ad5-VEGF+Ad5-ANG combination therapy on motor function recovery and reactivity of astrocytes in a rat model of SCI. METHODS Spinal cord injury was induced in adult Wistar rats by the weight-drop method. Rats (n = 51) were divided into 2 groups: the experimental group (Ad5-VEGF+Ad5-ANG) and the control group (Ad5-GFP [green fluorescent protein]). Recovery of motor function was assessed using the Basso, Beattie, and Bresnahan scale. The duration and intensity of infectivity and gene expression from the injected vectors were assessed by immunofluorescent detection of GFP. Reactivity of glial cells was assessed by changes in the number of immunopositive cells expressing glial fibrillary acidic protein (GFAP), S100B, aquaporin 4 (AQP4), oligodendrocyte transcription factor 2, and chondroitin sulfate proteoglycan 4. The level of S100/3 mRNA expression in the spinal cord was estimated by real-time polymerase chain reaction. RESULTS Partial recovery of motor function was observed 30 days after surgery in both groups. However, Basso, Beattie, and Bresnahan scores were 35.9% higher in the Ad5-VEGF+Ad5-ANG group compared with the control group. Specific GFP signal was observed at distances of up to 5 mm in the rostra! and caudal directions from the points of injection. A 1.5 to 2.0 fold increase in the number of GFAP+, S10013+, and AQP4+ cells was observed in the white and gray matter at a distance of up to 5 mm from the center of the lesion site in the caudal and rostral directions. At 30 days after injury, a 2-fold increase in S100/3 transcripts was observed in the Ad5-VEGF+Ad5-ANG group compared with the control group. CONCLUSIONS Intraspinal injection of recombinant adenoviral vectors encoding VEGF and ANG stimulates functional recovery after traumatic SCI. The increased number of S10013+ astrocytes induced by this approach may be a beneficial factor for maintaining the survival and function of neurons. Therefore, gene therapy with Ad5-VEGF+Ad5-ANG vectors is an effective therapeutic method for SCI treatment.	[Povysheva, Tatyana; Kolesnikov, Pavel; Islamov, Rustem; Chelyshev, Yuri] Kazan State Med Univ, 49 Butlerova Str, Kazan 420009, Russia; [Shmarov, Maksim; Logunov, Denis; Naroditsky, Boris] Republican Clin Hosp, Dept Neurosurg, Kazan, Russia; [Shulman, Ilya; Ogurcov, Sergey] Gamaleya Res Inst Epidemiol & Microbiol, Moscow, Russia	Povysheva, T (corresponding author), Kazan State Med Univ, 49 Butlerova Str, Kazan 420009, Russia.	t.povysheva@gmail.com	Islamov, Rustem R/H-8722-2015; Islamov, Rustem R/A-3581-2019; Povysheva, Tatyana/R-1086-2016; Chelyshev, Yuri/P-9412-2015; Logunov, Denis/E-8300-2014	Islamov, Rustem R/0000-0002-6632-4636; Povysheva, Tatyana/0000-0002-3384-1450; Shmarov, Maxim/0000-0002-5268-1296; Naroditsky, Boris/0000-0001-5522-8238; Logunov, Denis/0000-0003-4035-6581	Russian Science FoundationRussian Science Foundation (RSF) [16-15-00010]	We thank Y. O. Mukhamedshina and E. E. Cherenkova (Open lab Gene and Cell Technologies, Kazan [Volga Region] Federal University, Kazan, Russia) for their assistance in some experiments. The study was supported by grant no. 16-15-00010 from the Russian Science Foundation.	Allaman I, 2011, TRENDS NEUROSCI, V34, P76, DOI 10.1016/j.tins.2010.12.001; Aparicio-Erriu IM, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00167; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; CHAMOUX M, 1991, BIOCHEM BIOPH RES CO, V176, P833, DOI 10.1016/S0006-291X(05)80261-X; Chelyshev YA, 2014, NEUROSCIENCE, V280, P328, DOI 10.1016/j.neuroscience.2014.09.004; Costa S, 2002, GLIA, V37, P105, DOI 10.1002/glia.10015; Cregg JM, 2014, EXP NEUROL, V253, P197, DOI 10.1016/j.expneurol.2013.12.024; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Facchiano F, 2002, J NEUROSURG, V97, P161, DOI 10.3171/jns.2002.97.1.0161; Figley SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096137; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; Herrera JJ, 2010, J NEUROTRAUM, V27, P2067, DOI 10.1089/neu.2010.1403; Islamov RR, 2004, NEUROREPORT, V15, P2117, DOI 10.1097/00001756-200409150-00024; Ismailov SM, 2014, RUSS J GENET+, V50, P518, DOI 10.1134/S1022795414050056; Iwasaki Y, 1997, J NEUROL SCI, V151, P7, DOI 10.1016/S0022-510X(97)00073-7; Jin H, 2009, SPINE, V34, pE952, DOI 10.1097/BRS.0b013e3181c4af80; Kawano H, 2012, CELL TISSUE RES, V349, P169, DOI 10.1007/s00441-012-1336-5; Lebedev SV, 2008, B EXP BIOL MED+, V146, P489, DOI 10.1007/s10517-009-0328-2; Liu Y, 2010, NEUROBIOL DIS, V37, P384, DOI 10.1016/j.nbd.2009.10.018; Mackenzie F, 2012, DEVELOPMENT, V139, P1371, DOI 10.1242/dev.072348; MACMILLAN M, 1991, J SPINAL DISORD, V4, P449; Nesic O, 2010, NEUROSCIENCE, V168, P1019, DOI 10.1016/j.neuroscience.2010.01.037; Qiang Hui, 2012, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V26, P724; Rosenstein JM, 1998, P NATL ACAD SCI USA, V95, P7086, DOI 10.1073/pnas.95.12.7086; Rossi D, 2009, BRAIN RES BULL, V80, P224, DOI 10.1016/j.brainresbull.2009.07.012; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Sebastia J, 2009, CELL DEATH DIFFER, V16, P1238, DOI 10.1038/cdd.2009.52; Shaymardanova GF, 2013, B EXP BIOL MED+, V154, P544, DOI 10.1007/s10517-013-1996-5; Skorupa A, 2013, J PROTEOMICS, V91, P274, DOI 10.1016/j.jprot.2013.07.028; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Sorci Guglielmo, 2013, World J Biol Chem, V4, P1, DOI 10.4331/wjbc.v4.i1.1; Steidinger TU, 2011, J NEUROCHEM, V116, P334, DOI 10.1111/j.1471-4159.2010.07112.x; Subramanian V, 2007, HUM MOL GENET, V16, P1445, DOI 10.1093/hmg/ddm095; Tsai MC, 2008, MOL CELL PROTEOMICS, V7, P1668, DOI 10.1074/mcp.M800076-MCP200; Wang XF, 2011, J NEUROTRAUM, V28, P635, DOI 10.1089/neu.2010.1566; Zavalishin IA, 2008, B EXP BIOL MED+, V145, P483, DOI 10.1007/s10517-008-0124-4	36	12	15	0	19	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	JUL	2017	27	1					105	115		10.3171/2016.9.SPINE15959			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EY6IY	WOS:000404087200015	28452633	Bronze			2021-06-18	
J	Smith, S; Devine, M; Taddeo, J; McAlister, VC				Smith, Shane; Devine, Melissa; Taddeo, Joseph; McAlister, Vivian Charles			Injury profile suffered by targets of antipersonnel improvised explosive devices: prospective cohort study	BMJ OPEN			English	Article							INTERNATIONAL-COMMITTEE; RED-CROSS; AFGHANISTAN; EXPERIENCE; BASTION; MINES	Objective To describe pattern 1 injuries caused by the antipersonnel improvised explosive device (AP-IED) in comparison to those previously described for antipersonnel mines (APM). Design Prospective cohort study of 100 consecutive pedestrian victims of an AP-IED, with traumatic amputation without regard for gender, nationality or military status. Setting Multinational Medical Unit at Kandahar Air Field, Afghanistan. Participants One hundred consecutive patients, all male, 6-44 years old. Main outcome measures The details of injuries were recorded to describe the pattern and characterise the injuries suffered by the target of AP-IEDs. The level of amputation, the level of soft tissue injury, the fracture pattern (including pelvic fractures) as well as perineal, gluteal, genital and other injuries were recorded. Results Victims of AP-IED were more likely, compared with APM victims, to have multiple amputations (70.0% vs 10.4%; p<0.001) or genital injury (26% vs 13%; p=0.007). Multiple amputations occurred in 70 patients: 5 quadruple amputations, 27 triple amputations and 38 double amputations. Pelvic fracture occurred in 21 victims, all but one of whom had multiple amputations. Severe perineal, gluteal or genital injuries were present in 46 patients. Severe soft tissue injury was universal, with injection of contaminated soil along tissue planes well above entry sites. There were 13 facial injuries, 9 skull fractures and 3 traumatic brain injuries. Eleven eye injuries were seen; none of the victims with eye injuries were wearing eye protection. The casualty fatality rate was at least 19%. The presence of more than one amputation was associated with a higher rate of pelvic fracture (28.6% vs 3.3%; p=0.005) and perineal-gluteal injury (32.6% vs 11.1%; p=0.009). Conclusion The injury pattern suffered by the target of the AP-IED is markedly worse than that of conventional APM. Pelvic binders and tourniquets should be applied at the point of injury to patients with multiple amputations or perineal injuries.	[Smith, Shane; McAlister, Vivian Charles] Royal Canadian Med Serv, London, ON, Canada; [Smith, Shane; McAlister, Vivian Charles] Univ Western Ontario, Div Gen Surg, London, ON, Canada; [Devine, Melissa] Royal Canadian Med Serv, Halifax, NS, Canada; [Taddeo, Joseph] Maine Vet Affairs Med Ctr, Dept Surg, Augusta, MD USA	McAlister, VC (corresponding author), Royal Canadian Med Serv, London, ON, Canada.; McAlister, VC (corresponding author), Univ Western Ontario, Div Gen Surg, London, ON, Canada.	vmcalist@uwo.ca	McAlister, Vivian/B-9881-2008	McAlister, Vivian/0000-0002-2479-6862			Beckett A, 2012, INJURY, V43, P2072, DOI 10.1016/j.injury.2012.01.005; Brisebois R, 2011, CAN J SURG, V54, pS20, DOI 10.1503/cjs.024811; Bryusov PG, 1996, COMBAT INJURIES EXTR; COUPLAND RM, 1989, ANN ROY COLL SURG, V71, P404; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; Giannou C, 2013, WAR SURG WORKING LTD, V2; Jacobs N, 2014, INJURY, V45, P1422, DOI 10.1016/j.injury.2012.05.001; Jacobs N, 2012, INJURY, V43, P1037, DOI 10.1016/j.injury.2011.12.017; Korver AJH, 1996, INJURY, V27, P477, DOI 10.1016/0020-1383(96)00066-6; Morrison JJ, 2012, BRIT J SURG, V99, P362, DOI 10.1002/bjs.7765; Nations U, 1999, UN TREATY SERIES, V2056, P211; O'Shea MK, 2012, INT J ANTIMICROB AG, V39, P363, DOI 10.1016/j.ijantimicag.2012.01.018; Penn-Barwell JG, 2014, INJURY, V45, P1105, DOI 10.1016/j.injury.2014.01.025; Soroush Ahmadreza, 2008, Arch Iran Med, V11, P595; Taddeo Joseph, 2015, Can J Surg, V58, pS104, DOI 10.1503/cjs.013114	15	12	12	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open	JUL	2017	7	7							e014697	10.1136/bmjopen-2016-014697			7	Medicine, General & Internal	General & Internal Medicine	FG4HQ	WOS:000410203700053	28835410	DOAJ Gold, Green Published			2021-06-18	
J	Jackson, ML; Srivastava, AK; Cox, CS				Jackson, Margaret L.; Srivastava, Amit K.; Cox, Charles S., Jr.			Preclinical progenitor cell therapy in traumatic brain injury: a meta-analysis	JOURNAL OF SURGICAL RESEARCH			English	Article						Meta-analysis; Traumatic brain injury; Progenitor cells; Animal TBI model; Preclinical studies	MESENCHYMAL STEM-CELLS; MARROW STROMAL CELLS; ACTIVATED MICROGLIAL/MACROPHAGE RESPONSE; RAT MODEL; FUNCTIONAL RECOVERY; COGNITIVE FUNCTION; TRANSPLANTATION; MICE; PATHOPHYSIOLOGY; EFFICACY	Background: No treatment is available to reverse injury associated with traumatic brain injury (TBI). Progenitor cell therapies show promise in both preclinical and clinical studies.We conducted a meta-analysis of preclinical studies using progenitor cells to treat TBI. Methods: EMBASE, MEDLINE, Cochrane Review, Biosis, and Google Scholar were searched for articles using prespecified search strategies. Studies meeting inclusion criteria underwent data extraction. Analysis was performed using Review Manager 5.3 according to a fixed-effects model, and all studies underwent quality scoring. Results: Of 430 abstracts identified, 38 met inclusion criteria and underwent analysis. Average quality score was 4.32 of 8 possible points. No study achieved a perfect score. Lesion volume (LV) and neurologic severity score (NSS) outcomes favored cell treatment with standard mean difference (SMD) of 0.86 (95% CI: 0.64-1.09) and 1.36 (95% CI: 1.11-1.60),respectively.Rotarod and Morris water maze outcomes also favored treatment with improvements in SMD of 0.34 (95% CI: 0.02-0.65) and 0.46 (95% CI: 0.17-74), respectively. Although LV and NSS were robust to publication bias assessments, rotarod and Morris water maze tests were not.Heterogeneity (I-2) ranged from 74%-85% among the analyses, indicating a high amount of heterogeneity among studies. Precision as a function of quality score showed a statistically significant increase in the size of the confidence interval as quality improved. Conclusions: Our meta-analysis study reveals an overall positive effect of progenitor cell therapies on LV and NSS with a trend toward improved motor function and spatial learning in different TBI animal models. (C) 2017 Elsevier Inc. All rights reserved.	[Jackson, Margaret L.; Srivastava, Amit K.; Cox, Charles S., Jr.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, Houston, TX 77030 USA	Jackson, ML (corresponding author), UTHlth McGovern Med Sch, Dept Pediat Surg, 6431 Fannin St, Houston, TX 77030 USA.	margaret.l.jackson@uth.tmc.edu	Srivastava, Amit/L-7019-2019	Srivastava, Amit/0000-0001-7554-7201	Department of Health and Human Services [5T32GM008792-13, 4T3200GM8792-14]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER	This work was supported by the Department of Health and Human Services, grant numbers 5T32GM008792-13 and 4T3200GM8792-14.	Aertker BM, 2016, EXP NEUROL, V275, P411, DOI 10.1016/j.expneurol.2015.01.008; Anbari F, 2014, NEURAL REGEN RES, V9, P919, DOI 10.4103/1673-5374.133133; Arien-Zakay H, 2014, J NEUROTRAUM, V31, P1405, DOI 10.1089/neu.2013.3270; Arrowsmith J, 2013, NAT REV DRUG DISCOV, V12, P568, DOI 10.1038/nrd4090; Bakhtiary Mehrdad, 2010, Iranian Biomedical Journal, V14, P142; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bedi SS, 2013, STEM CELL TRANSL MED, V2, P953, DOI 10.5966/sctm.2013-0100; Bedi SS, 2013, J TRAUMA ACUTE CARE, V75, P410, DOI 10.1097/TA.0b013e31829617c6; Bonilla C, 2014, CYTOTHERAPY, V16, P1501, DOI 10.1016/j.jcyt.2014.07.007; Chang J, 2015, EXP NEUROL, V273, P225, DOI 10.1016/j.expneurol.2015.08.020; Chen SH, 2014, CELL TRANSPLANT, V23, P959, DOI 10.3727/096368913X667006; Cheng T, 2015, CELL MOL NEUROBIOL, V35, P641, DOI 10.1007/s10571-015-0159-9; Cole TB, 2004, JAMA-J AM MED ASSOC, V291, P2531, DOI 10.1001/jama.291.21.2531; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Cox Jr CS, 2016, STEM CELLS; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Fu XM, 2015, CELL TRANSPLANT, V24, P1533, DOI 10.3727/096368914X679345; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Gibb SL, 2015, STEM CELLS, V33, P3530, DOI 10.1002/stem.2189; Goodman JC, 2008, ACTA NEUROCHIR SUPPL, V102, P437, DOI 10.1007/978-3-211-85578-2_85; Han EY, 2013, CURR STEM CELL RES T, V8, P172; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Higgins JP, 2010, COLLABORATION SMGOTC; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hong SQ, 2011, NEUROCHEM RES, V36, P2391, DOI 10.1007/s11064-011-0567-2; Jiang JD, 2012, NEURAL REGEN RES, V7, P46, DOI 10.3969/j.issn.1673-5374.2012.01.008; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556; Li LA, 2011, J NEUROTRAUM, V28, P535, DOI 10.1089/neu.2010.1619; Liao GP, 2015, PEDIATR CRIT CARE ME, V16, P245, DOI 10.1097/PCC.0000000000000324; Liao GP, 2014, J SURG RES, V190, P628, DOI 10.1016/j.jss.2014.05.011; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2003, NEUROSURGERY, V53, P702; Mahmood A, 2013, J NEUROSURG, V118, P381, DOI 10.3171/2012.11.JNS12753; McIntosh TK, 1996, LAB INVEST, V74, P315; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Moher D, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-13; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Muthuraju S, 2012, BASAL GANGLIA, V2, P143, DOI 10.1016/j.baga.2012.06.004; Muthuraju S, 2013, J BIOSCIENCES, V38, P93, DOI 10.1007/s12038-012-9290-7; Nichols JE, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt151; Osanai T, 2012, NEUROSURGERY, V70, P435, DOI 10.1227/NEU.0b013e318230a795; Peng WJ, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0034-0; Pischiutta F, 2014, NEUROPHARMACOLOGY, V79, P119, DOI 10.1016/j.neuropharm.2013.11.001; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Prinz F, 2011, NAT REV DRUG DISCOV, V10, P712, DOI 10.1038/nrd3439-c1; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Riess P, 2007, J NEUROTRAUM, V24, P216, DOI 10.1089/neu.2006.0141; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Silachev DN, 2015, B EXP BIOL MED+, V159, P528, DOI 10.1007/s10517-015-3009-3; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Turtzo LC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126551; van der Worp HB, 2011, J MOL CELL CARDIOL, V51, P449, DOI 10.1016/j.yjmcc.2011.04.008; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Walker PA, 2010, STEM CELLS DEV, V19, P867, DOI 10.1089/scd.2009.0188; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Watanabe J, 2013, NEUROBIOL DIS, V59, P86, DOI 10.1016/j.nbd.2013.06.017; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Xu HS, 2014, EUR REV MED PHARMACO, V18, P520; Xue S, 2010, NEUROSCI LETT, V473, P186, DOI 10.1016/j.neulet.2010.02.035; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhao J, 2012, J NEUROTRAUM, V29, P1209, DOI 10.1089/neu.2011.1858; Zhao JJ, 2012, NEURAL REGEN RES, V7, P741, DOI 10.3969/j.issn.1673-5374.2012.10.004; Zhao YH, 2016, STEM CELLS, V34, P1263, DOI 10.1002/stem.2310	76	12	12	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	JUN 15	2017	214						38	48		10.1016/j.jss.2017.02.078			11	Surgery	Surgery	FA3RX	WOS:000405363200006	28624058	Green Accepted			2021-06-18	
J	Carelli, S; Giallongo, T; Viaggi, C; Latorre, E; Gombalova, Z; Raspa, A; Mazza, M; Vaglini, F; Di Giulio, AM; Gorio, A				Carelli, Stephana; Giallongo, Toniella; Viaggi, Cristina; Latorre, Elisa; Gombalova, Zuzana; Raspa, Andrea; Mazza, Massimiliano; Vaglini, Francesca; Di Giulio, Anna Maria; Gorio, Alfredo			Recovery from experimental parkinsonism by intrastriatal application of erythropoietin or EPO-releasing neural precursors	NEUROPHARMACOLOGY			English	Article						Erythropoietin; Parkinson's disease; Adult stem cells; Cell therapy; Regenerative medicine; MPTP	RECOMBINANT-HUMAN-ERYTHROPOIETIN; TRAUMATIC BRAIN-INJURY; MESENCHYMAL STEM-CELLS; DOPAMINE NEURONS; MOUSE MODEL; CYTOCHROME-P450 2E1; FUNCTIONAL RECOVERY; PRIMATE MODEL; IN-VITRO; DISEASE	An extensive literature has shown a powerful neuroprotective action of Erythropoietin (EPO) both in vivo and in vitro. This study shows that EPO, whether ectopically administered or released by neural precursors, does reverse MPTP-induced parkinsonism in mice. Unilateral stereotaxic injection of 2.5 x 10(5) erythropoietin-releasing neural precursor cells (Er-NPCs) rescued degenerating striatal dopaminergic neurons and promoted behavioral recovery as shown by three independent behavioral tests. These effects were replicated through direct intrastriatal administration of recombinant human EPO. At the end of the observational period, most of the transplanted Er-NPCs were vital and migrated via the striatum to reach Substantia Nigra. The restorative effects appear to be mediated by EPO since co-injection of anti-EPO or anti-EPOR antibodies antagonized the positive outcomes. Furthermore, this report supports the neuroprotective action of EPO, which may also be achieved via administration of EPO-releasing cells such as Er-NPCs. (C) 2017 Elsevier Ltd. All right's reserved.	[Carelli, Stephana; Giallongo, Toniella; Latorre, Elisa; Gombalova, Zuzana; Raspa, Andrea; Di Giulio, Anna Maria; Gorio, Alfredo] Univ Milan, Dept Hlth Sci, Labs Pharmacol, Milan, Italy; [Viaggi, Cristina; Vaglini, Francesca] Univ Pisa, Dipartimento Ric Traslaz & Nuove Tecnol Med & Chi, Pisa, Italy; [Mazza, Massimiliano] European Inst Oncol, Expt Oncol Dept, Via Adamello 16, I-20139 Milan, Italy	Carelli, S (corresponding author), Univ Milan, Lab Pharmacol, Dept Hlth Sci, Via A Rudini 8, I-20142 Milan, Italy.	stephana.carelli@guest.unimi.it; alfredo.gorio@unimi.it	Carelli, Stephana/AAB-2365-2021; Mazza, Massimiliano/AAA-4420-2021; raspa, andrea/J-9909-2016	Carelli, Stephana/0000-0003-4603-396X; Mazza, Massimiliano/0000-0001-9053-5743; Di Giulio, Anna Maria/0000-0002-5702-4623; Latorre, Elisa/0000-0002-8297-1219; raspa, andrea/0000-0003-2599-2424	"Neurogel-en-Marche" Foundation (France); AUS Niguarda Onlus (Italy); Fondazione "Romeo and Enrica Invernizzi"	The authors acknowledge the economic support of the "Neurogel-en-Marche" Foundation (France) and AUS Niguarda Onlus (Italy) to AG, and Fondazione "Romeo and Enrica Invernizzi" to AMDG.	Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Barker RA, 2014, CELL STEM CELL, V15, P539, DOI 10.1016/j.stem.2014.09.016; Barker RA, 2013, PROG NEUROBIOL, V110, P63, DOI 10.1016/j.pneurobio.2013.04.003; Barker RA, 2013, LANCET NEUROL, V12, P84, DOI 10.1016/S1474-4422(12)70295-8; Barzilay R, 2009, STEM CELLS DEV, V18, P591, DOI 10.1089/scd.2008.0138; Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Block ML, 2007, BIOCHEM SOC T, V35, P1127, DOI 10.1042/BST0351127; Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Brundin P, 2012, PROG BRAIN RES, V200, P221, DOI 10.1016/B978-0-444-59575-1.00010-7; Cai JL, 2009, STEM CELLS, V27, P220, DOI 10.1634/stemcells.2008-0734; Carelli S., 2014, J STEM CELL RES TRAN, V1, P1008; Carelli S, 2015, CELL TRANSPLANT, V24, P703, DOI 10.3727/096368914X685140; Carelli S, 2014, JOVE-J VIS EXP, DOI 10.3791/52141; Chandra G, 2016, J BIOL CHEM, V291, P15267, DOI 10.1074/jbc.M116.714824; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; CORSINI GU, 1985, EUR J PHARMACOL, V119, P127, DOI 10.1016/0014-2999(85)90331-0; Cui YF, 2010, BRAIN, V133, P189, DOI 10.1093/brain/awp290; Dhanushkodi A, 2013, GENES BRAIN BEHAV, V12, P224, DOI 10.1111/gbb.12001; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Doi D, 2014, STEM CELL REP, V2, P337, DOI 10.1016/j.stemcr.2014.01.013; Erbas O, 2015, NEUROPEPTIDES, V49, P1, DOI 10.1016/j.npep.2014.10.003; Erbayraktar S, 2003, P NATL ACAD SCI USA, V100, P6741, DOI 10.1073/pnas.1031753100; Friling S, 2009, P NATL ACAD SCI USA, V106, P7613, DOI 10.1073/pnas.0902396106; Gao H. M., 2003, OFFICIAL PUBLICATION, V13, P1957, DOI DOI 10.1096/FJ.03-0203FJE; Goldberg NRS, 2011, NEUROSCIENCE, V180, P256, DOI 10.1016/j.neuroscience.2011.02.027; Gorio A, 2005, P NATL ACAD SCI USA, V102, P16379, DOI 10.1073/pnas.0508479102; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Hallett PJ, 2015, CELL STEM CELL, V16, P269, DOI 10.1016/j.stem.2015.01.018; Hallett PJ, 2014, CELL REP, V7, P1755, DOI 10.1016/j.celrep.2014.05.027; HANTRAYE P, 1992, NEUROREPORT, V3, P265, DOI 10.1097/00001756-199203000-00013; Haque NSK, 1997, CELL TRANSPLANT, V6, P239, DOI 10.1016/S0963-6897(97)86921-7; Heikal L, 2016, HYPOXIA, V4, P121, DOI 10.2147/HP.S104377; Jang W, 2016, MOL NEUROBIOL, V53, P3812, DOI 10.1007/s12035-015-9316-x; Jang W, 2014, J NEUROL SCI, V337, P47, DOI 10.1016/j.jns.2013.11.015; Jelkmann W, 2011, J PHYSIOL-LONDON, V589, P1251, DOI 10.1113/jphysiol.2010.195057; Jensen EC, 2013, ANAT REC, V296, P378, DOI 10.1002/ar.22641; Jia Y, 2014, J MOL NEUROSCI, V53, P117, DOI 10.1007/s12031-013-0208-0; Kanaan NM, 2006, BRAIN RES, V1068, P221, DOI 10.1016/j.brainres.2005.10.078; Kefalopoulou Z, 2014, JAMA NEUROL, V71, P83, DOI 10.1001/jamaneurol.2013.4749; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Kim ST, 2010, BRAIN RES, V1306, P176, DOI 10.1016/j.brainres.2009.09.103; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; Kriks S, 2011, NATURE, V480, P547, DOI 10.1038/nature10648; Li ZM, 2016, CLIN NEUROL NEUROSUR, V150, P80, DOI 10.1016/j.clineuro.2016.09.001; Liang CL, 2004, J COMP NEUROL, V473, P97, DOI 10.1002/cne.20098; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; Marfia G, 2011, NEUROBIOL DIS, V43, P86, DOI 10.1016/j.nbd.2011.02.004; Marti HH, 2004, J EXP BIOL, V207, P3233, DOI 10.1242/jeb.01049; Martinez-Cerdeno V, 2010, CELL STEM CELL, V6, P238, DOI 10.1016/j.stem.2010.01.004; Martino G, 2006, NAT REV NEUROSCI, V7, P395, DOI 10.1038/nrn1908; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MORSE JK, 1993, J NEUROSCI, V13, P4146; Ortiz LA, 2007, P NATL ACAD SCI USA, V104, P11002, DOI 10.1073/pnas.0704421104; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Pedroso I, 2012, MEDICC REV, V14, P11; Petroske E, 2001, NEUROSCIENCE, V106, P589, DOI 10.1016/S0306-4522(01)00295-0; Phani S, 2010, BRAIN RES, V1343, P1, DOI 10.1016/j.brainres.2010.04.061; Puskovic V, 2006, MOL THER, V14, P710, DOI 10.1016/j.ymthe.2006.07.004; Romeo S, 2013, SCI REP-UK, V3, DOI 10.1038/srep01395; Schintu N, 2009, NEUROTOX RES, V16, P127, DOI 10.1007/s12640-009-9061-x; SCHULTZBERG M, 1984, NEUROSCIENCE, V12, P17, DOI 10.1016/0306-4522(84)90134-9; Sekiyama K, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/271732; Shen Y, 2010, TRANSPL P, V42, P1595, DOI 10.1016/j.transproceed.2009.11.050; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Signore AP, 2006, J NEUROCHEM, V96, P428, DOI 10.1111/j.1471-4159.2005.03587.x; Sundberg M, 2013, STEM CELLS, V31, P1548, DOI 10.1002/stem.1415; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tayra JT, 2013, BRAIN RES, V1502, P55, DOI 10.1016/j.brainres.2013.01.042; Tillerson JL, 2003, J NEUROSCI METH, V123, P189, DOI 10.1016/S0165-0270(02)00360-6; Tsui A., 2001, J NEUROL, V258, P1393; Vaglini F, 2004, J NEUROCHEM, V91, P285, DOI 10.1111/j.1471-4159.2004.02720.x; Viaggi C, 2009, NEUROPHARMACOLOGY, V56, P1075, DOI 10.1016/j.neuropharm.2009.03.003; Wernig M, 2008, P NATL ACAD SCI USA, V105, P5856, DOI 10.1073/pnas.0801677105; Wirdefeldt K, 2011, EUR J EPIDEMIOL, V26, pS1, DOI 10.1007/s10654-011-9581-6; Yang DL, 2008, STEM CELLS, V26, P55, DOI 10.1634/stemcells.2007-0494; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526	78	12	14	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	JUN	2017	119						76	90		10.1016/j.neuropharm.2017.03.035			15	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	EX8PX	WOS:000403513800007	28373075				2021-06-18	
J	Jackson, EK; Kotermanski, SE; Menshikova, EV; Dubey, RK; Jackson, TC; Kochanek, PM				Jackson, Edwin K.; Kotermanski, Shawn E.; Menshikova, Elizabeth V.; Dubey, Raghvendra K.; Jackson, Travis C.; Kochanek, Patrick M.			Adenosine production by brain cells	JOURNAL OF NEUROCHEMISTRY			English	Article						5 '-AMP; adenosine; astrocytes; hypoxanthine; inosine; microglia; neurons	RAT HIPPOCAMPAL SLICES; OXYGEN-GLUCOSE DEPRIVATION; CEREBROSPINAL-FLUID; CORTICAL-NEURONS; CULTURED NEURONS; OXIDATIVE-STRESS; DIFFERENT ROLES; FREE-RADICALS; INJURY; RELEASE	The early release of adenosine following traumatic brain injury (TBI) suppresses seizures and brain inflammation; thus, it is important to elucidate the cellular sources of adenosine following injurious stimuli triggered by TBI so that therapeutics for enhancing the early adenosine-release response can be optimized. Using mass spectrometry with C-13-labeled standards, we investigated in cultured rat neurons, astrocytes, and microglia the effects of oxygen-glucose deprivation (OGD; models energy failure), H2O2 (produces oxidative stress), and glutamate (induces excitotoxicity) on intracellular and extracellular levels of 50-AMP (adenosine precursor), adenosine, and inosine and hypoxanthine (adenosine metabolites). In neurons, OGD triggered increases in intracellular 50-AMP (2.8-fold), adenosine (2.6-fold), inosine (2.2-fold), and hypoxanthine (5.3-fold) and extracellular 50-AMP (2.2-fold), adenosine (2.4-fold), and hypoxanthine (2.5-fold). In neurons, H2O2 did not affect intracellular or extracellular purines; yet, glutamate increased intracellular adenosine, inosine, and hypoxanthine (1.7-fold, 1.7-fold, and 1.6-fold, respectively) and extracellular adenosine, inosine, and hypoxanthine (2.9-fold, 2.1-fold, and 1.6-fold, respectively). In astrocytes, neither H2O2 nor glutamate affected intracellular or extracellular purines, and OGD only slightly increased intracellular and extracellular hypoxanthine. Microglia were unresponsive to OGD and glutamate, but were remarkably responsive to H2O2, which increased intracellular 50-AMP (1.6-fold), adenosine (1.6-fold), inosine (2.1-fold), and hypoxanthine (1.6-fold) and extracellular 50-AMP (5.9-fold), adenosine (4.0-fold), inosine (4.3-fold), and hypoxanthine (1.9-fold). Conclusion: Under these particular experimental conditions, cultured neurons are the main contributors to adenosine production/release in response to OGD and glutamate, whereas cultured microglia are the main contributors upon oxidative stress. Developing therapeutics that recruit astrocytes to produce/release adenosine could have beneficial effects in TBI.	[Jackson, Edwin K.; Kotermanski, Shawn E.; Menshikova, Elizabeth V.; Dubey, Raghvendra K.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Dubey, Raghvendra K.] Univ Zurich, Dept Reprod Endocrinol, Univ Zurich Hosp, Zurich, Switzerland; [Dubey, Raghvendra K.] Univ Zurich, Zurich Ctr Integrat Human Physiol ZIHP, Zurich, Switzerland; [Jackson, Travis C.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Jackson, Travis C.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Jackson, EK (corresponding author), Dept Pharmacol & Chem Biol, 100 Technol Dr,Room 514, Pittsburgh, PA 15219 USA.	edj@pitt.edu		Jackson, Edwin/0000-0002-8101-6009	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS070003, DK068575, DK079307, DK091190, HL109002, HL069846, NS38087, NS30318]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL109002, R01HL069846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK068575, R01DK091190, P30DK079307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R21NS070003, R01NS087978, R01NS038087, P01NS030318] Funding Source: NIH RePORTER	This work was supported by NIH grants NS070003 (PMK/EKJ), DK068575 (EKJ), DK079307 (EKJ), DK091190 (EKJ), HL109002 (EKJ), HL069846 (EKJ), NS38087 (PMK), and NS30318 (PMK). The authors have no conflicts of interest to disclose.	Agostinho P, 2000, NEUROCHEM INT, V36, P255, DOI 10.1016/S0197-0186(99)00113-8; Almeida CG, 2003, NEUROSCI LETT, V339, P127, DOI 10.1016/S0304-3940(02)01478-7; Andreev DE, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0651-z; Baldus S, 2006, FREE RADICAL BIO MED, V41, P1282, DOI 10.1016/j.freeradbiomed.2006.07.010; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Broad RM, 2000, J AUTONOM NERV SYST, V81, P82, DOI 10.1016/S0165-1838(00)00124-7; Bzowska A, 2000, PHARMACOL THERAPEUT, V88, P349, DOI 10.1016/S0163-7258(00)00097-8; Canals S, 2008, J CEREBR BLOOD F MET, V28, P1835, DOI 10.1038/jcbfm.2008.71; Carswell HV, 1997, J NEUROCHEM, V68, P240; Choo AM, 2013, BRAIN, V136, P65, DOI 10.1093/brain/aws286; Chu S, 2014, PURINERG SIGNAL, V10, P603, DOI 10.1007/s11302-014-9421-8; Cunha RA, 2001, NEUROCHEM INT, V38, P107, DOI 10.1016/S0197-0186(00)00034-6; Cunha RA, 2016, J NEUROCHEM, V139, P1019, DOI 10.1111/jnc.13724; Dale N, 2009, CURR NEUROPHARMACOL, V7, P160, DOI 10.2174/157015909789152146; Eltzschig HK, 2005, J EXP MED, V202, P1493, DOI 10.1084/jem.20050177; Eltzschig HK, 2013, J MOL MED, V91, P141, DOI 10.1007/s00109-013-0999-z; Eltzschig HK, 2012, NEW ENGL J MED, V367, P2322, DOI 10.1056/NEJMra1205750; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Ferreira JM, 2001, BRAIN RES, V900, P169, DOI 10.1016/S0006-8993(01)02279-X; Fujita T, 2012, J CEREBR BLOOD F MET, V32, pE1, DOI 10.1038/jcbfm.2011.142; Gomes CV, 2011, BBA-BIOMEMBRANES, V1808, P1380, DOI 10.1016/j.bbamem.2010.12.001; Grenz A, 2007, J AM SOC NEPHROL, V18, P833, DOI 10.1681/ASN.2006101141; Grenz A, 2007, FASEB J, V21, P2863, DOI 10.1096/fj.06-7947com; Grenz A, 2011, ANTIOXID REDOX SIGN, V15, P2221, DOI 10.1089/ars.2010.3665; Hasel P, 2015, BBA-MOL CELL RES, V1853, P2066, DOI 10.1016/j.bbamcr.2014.12.021; Haselkorn ML, 2010, J NEUROTRAUM, V27, P901, DOI 10.1089/neu.2009.1075; Jackson EK, 2009, J BIOL CHEM, V284, P33097, DOI 10.1074/jbc.M109.053876; Jackson TC, 2015, NEUROSCIENCE, V305, P268, DOI 10.1016/j.neuroscience.2015.08.012; Jackson TC, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.187; Jackson TC, 2015, J CEREBR BLOOD F MET, V35, P655, DOI 10.1038/jcbfm.2014.242; Jackson TC, 2010, J NEUROCHEM, V115, P941, DOI 10.1111/j.1471-4159.2010.06984.x; Kilbaugh TJ, 2015, EXP NEUROL, V271, P136, DOI 10.1016/j.expneurol.2015.05.009; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kulik TB, 2010, GLIA, V58, P1335, DOI 10.1002/glia.21011; Lauro C, 2010, NEUROPSYCHOPHARMACOL, V35, P1550, DOI 10.1038/npp.2010.26; Lei BP, 1997, NEUROSCI LETT, V222, P91, DOI 10.1016/S0304-3940(97)13349-3; Lin YC, 2002, J NEUROSCI RES, V67, P484, DOI 10.1002/jnr.10077; Lobner D, 2002, NEUROREPORT, V13, P2075, DOI 10.1097/00001756-200211150-00017; LOBNER D, 1994, STROKE, V25, P2085, DOI 10.1161/01.STR.25.10.2085; Lu Y, 2003, EUR J NEUROSCI, V17, P1213, DOI 10.1046/j.1460-9568.2003.02554.x; Lynch JJ, 1998, NEUROSCI LETT, V252, P207, DOI 10.1016/S0304-3940(98)00376-0; Ma J, 2014, BIOCHEM J, V462, P489, DOI 10.1042/BJ20140235; Maines Mahin D., 2010, CURRENT PROTOCOLS TO; Martin ED, 2007, GLIA, V55, P36, DOI 10.1002/glia.20431; Masino SA, 1999, NEUROSCI LETT, V274, P91, DOI 10.1016/S0304-3940(99)00693-X; Parkinson FE, 2002, NEUROPHARMACOLOGY, V43, P836, DOI 10.1016/S0028-3908(02)00083-7; Parkinson FE, 2004, J NEUROCHEM, V88, P1305, DOI 10.1046/j.1471-4159.2003.02266.x; Rebola N, 2005, NEUROCHEM INT, V47, P317, DOI 10.1016/j.neuint.2005.05.009; Robertson CL, 2001, CRIT CARE MED, V29, P2287, DOI 10.1097/00003246-200112000-00009; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Sparvero LJ, 2010, J NEUROCHEM, V115, P1322, DOI 10.1111/j.1471-4159.2010.07055.x; Stone TW, 2002, ADV EXP MED BIOL, V513, P249; Theofilas P, 2011, EPILEPSIA, V52, P589, DOI 10.1111/j.1528-1167.2010.02947.x; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; VansDycke A., 2010, SEIZURE, V19, P390; Verrier JD, 2012, J NEUROCHEM, V122, P115, DOI 10.1111/j.1471-4159.2012.07705.x; Verrier JD, 2011, J NEUROCHEM, V118, P979, DOI 10.1111/j.1471-4159.2011.07392.x	59	12	12	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUN	2017	141	5					676	693		10.1111/jnc.14018			18	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	EU7AL	WOS:000401187000004	28294336	Bronze, Green Accepted			2021-06-18	
J	Mann, A; Tator, CH; Carson, JD				Mann, Aneetinder; Tator, Charles H.; Carson, James D.			Concussion diagnosis and management Knowledge and attitudes of family medicine residents	CANADIAN FAMILY PHYSICIAN			English	Article							EMERGENCY-DEPARTMENT; ATHLETIC TRAINERS; SPORT; COACHES; GUIDELINES; PLAYERS; RETURN	Objective To assess the knowledge of, attitudes toward, and learning needs for concussion diagnosis and management among family medicine residents. Design E-mail survey. Setting University of Toronto in Ontario. Participants Family medicine residents (N = 348). Main outcome measures To describe relationships between awareness of concussion management and lifestyle, education background, and residency placement, t tests and x(2) tests were used as appropriate. Linear regression was used to compare self-reported concussion knowledge with knowledge scores. Thematic analysis was used to interpret answers to the qualitative question asking residents to describe challenges they foresee physicians facing when diagnosing and managing concussion. Results The residents who responded (n = 73, response rate 21%) correctly answered an average of 5.2 questions out of 9 (58%) regarding the diagnosis and management of concussion. Postgraduate year, sex, personal history of concussion, and clinical exposure to concussion were not significant factors in predicting the number of correct answers. Several misconceptions and knowledge gaps were revealed. Of residents who responded, 71% did not recognize chronic traumatic encephalopathy and only 63% recognized second-impact syndrome as consequences of repetitive concussions. Moreover, 32% of residents did not think that every individual with a concussion should see a physician as part of management. Knowledge scores did not predict self-reported concussion knowledge. Thematic analysis revealed 4 themes related to the challenges of concussion diagnosis and management: the nonspecificity and vagueness of symptoms, lack of formal diagnostic criteria, patient compliance with management, and counseling patients with respect to return to play, work, or learning. Conclusion We found substantial gaps in knowledge surrounding concussion diagnosis and management among family medicine residents. This lack of knowledge should be addressed at both the undergraduate medical education level and the residency training level to improve concussion-related care and patient outcomes.	[Mann, Aneetinder] Univ Toronto, Fac Med, Toronto, ON, Canada; [Tator, Charles H.] Univ Toronto, Div Neurosurg, Toronto, ON, Canada; [Tator, Charles H.] Toronto Western Hosp, Canadian Concuss Ctr, Toronto, ON, Canada; [Tator, Charles H.] Krembil Res Inst, Toronto, ON, Canada; [Tator, Charles H.] Parachute Canada, Toronto, ON, Canada; [Carson, James D.] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Carson, James D.] Markham Stouffville Hosp, Markham, ON, Canada; [Carson, James D.] Scarborough & Rouge Hosp, Scarborough, ON, Canada	Mann, A (corresponding author), Univ Toronto, Fac Med, Toronto, ON, Canada.	aneet.mann@mail.utoronto.ca					Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Boggild M, 2012, CAN J NEUROL SCI, V39, P361, DOI 10.1017/S0317167100013524; Burke MJ, 2012, CAN J NEUROL SCI, V39, P763, DOI 10.1017/S0317167100015584; Chrisman SP, 2011, CLIN PEDIATR, V50, P1031, DOI 10.1177/0009922811410970; Donaldson L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069122; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12286; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Fraas MR, 2015, IRISH J MED SCI, V184, P425, DOI 10.1007/s11845-014-1137-9; Hollis SJ, 2012, BRIT J SPORT MED, V46, P735, DOI 10.1136/bjsm.2011.085332; LaBond Virginia, 2014, NASN Sch Nurse, V29, P194; Lebrun CM, 2013, BRIT J SPORT MED, V47, P54, DOI 10.1136/bjsports-2012-091480; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Macpherson A, 2014, PAED CHILD HEALT-CAN, V19, P543, DOI 10.1093/pch/19.10.543; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mrazik M, 2011, CLIN J SPORT MED, V21, P315, DOI 10.1097/JSM.0b013e31821e2b78; Murphy A, 2012, PM&R, V4, P419, DOI 10.1016/j.pmrj.2012.03.013; Naftel KG, 2014, SOUTH MED J, V107, P418, DOI 10.14423/SMJ.0000000000000136; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Radhakrishna R, 2008, J EXT, V46; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; *STAT CAN, 2010, GEN SOC SURV 2010 CY; Stoller J, 2014, CAN FAM PHYSICIAN, V60, P548; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Tator CH, 2013, CAN MED ASSOC J, V185, P975, DOI 10.1503/cmaj.120039; Williams RM, 2014, SPORTS HEALTH, V6, P434, DOI 10.1177/1941738114545612; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	28	12	12	1	7	COLL FAMILY PHYSICIANS CANADA	MISSISSAUGA	2630 SKYMARK AVE, MISSISSAUGA, ONTARIO L4W 5A4, CANADA	0008-350X	1715-5258		CAN FAM PHYSICIAN	Can. Fam. Phys.	JUN	2017	63	6					460	466					7	Primary Health Care; Medicine, General & Internal	General & Internal Medicine	FA3FP	WOS:000405328300014	28615399				2021-06-18	
J	Oyesanya, TO; Brown, RL; Turkstra, LS				Oyesanya, Tolu O.; Brown, Roger L.; Turkstra, Lyn S.			Caring for Patients with traumatic brain injury: a survey of nurses' perceptions	JOURNAL OF CLINICAL NURSING			English	Article						latent class analysis; nursing attitudes; nursing care; nursing education; structural equationmodelling; survey research; traumatic brain injuries	KNOWLEDGE; REHABILITATION; MILITARY; CLUSTERS; ALPHA; MODEL	Aims and objectivesThe purpose of this study was to determine nurses' perceptions about caring for patients with traumatic brain injury. BackgroundAnnually, it is estimated that over 10 million people sustain a traumatic brain injury around the world. Patients with traumatic brain injury and their families are often concerned with expectations about recovery and seek information from nurses. Nurses' perceptions of care might influence information provided to patients and families, particularly if inaccurate knowledge and perceptions are held. Thus, nurses must be knowledgeable about care of these patients. MethodsA cross-sectional survey, the Perceptions of Brain Injury Survey (PBIS), was completed electronically by 513 nurses between October and December 2014. Data were analysed with structural equationmodelling, factor analysis, and pairwise comparisons. ResultsUsing latent class analysis, authors were able to divide nurses into three homogeneous sub-groups based on perceived knowledge: low, moderate and high. Findings showed that nurses who care for patients with traumatic brain injury the most have the highest perceived confidence but the lowest perceived knowledge. Nurses also had significant variations in training. ConclusionsAs there is limited literature on nurses' perceptions of caring for patients with traumatic brain injury, these findings have implications for training and educating nurses, including direction for development of nursing educational interventions. Relevance to clinical practiceAs the incidence of traumatic brain injury is growing, it is imperative that nurses be knowledgeable about care of patients with these injuries. The traumatic brain injury PBIS can be used to determine inaccurate perceptions about caring for patients with traumatic brain injury before educating and training nurses.	[Oyesanya, Tolu O.; Brown, Roger L.] Univ Wisconsin Madison, Sch Nursing, 5130 Signe Skott Cooper Hall,701 Highland Ave, Madison, WI 53705 USA; [Turkstra, Lyn S.] Univ Wisconsin Madison, Dept Commun Sci & Disorders, Madison, WI USA	Oyesanya, TO (corresponding author), Univ Wisconsin Madison, Sch Nursing, 5130 Signe Skott Cooper Hall,701 Highland Ave, Madison, WI 53705 USA.	toyesanya@wisc.edu		Oyesanya, Tolu/0000-0001-8821-4510	University of Wisconsin-Madison, School of Nursing; NIH/NIGMS Initiative for Maximizing Student Development [R25GM083252]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R25GM083252] Funding Source: NIH RePORTER	This research was supported by the University of Wisconsin-Madison, School of Nursing and the NIH/NIGMS Initiative for Maximizing Student Development (PI, M. Carnes) Grant# R25GM083252.	Borenstein M., 2009, INTRO META ANALYSIS, P33, DOI [https://doi.org/10.1002/9780470743386, DOI 10.1002/9780470743386, DOI 10.2196/JMIR.2636]; Brain Injury Association of America, 2014, GUID REH CHRON DIS M; Brain Injury Association of America, 2015, LIV BRAIN INJ; Brain Injury Association of America, 2012, BIAA FREQ ASK QUEST; Cannon HM, 2014, DEV BUSINESS SIMULAT, V37; Celeux G, 1996, J CLASSIF, V13, P195, DOI 10.1007/BF01246098; Centers for Disease Control and Prevention, 2014, C TRAUM BRAIN INJ US; Clogg C.C., 1995, HDB STAT MODELING SO, P311, DOI DOI 10.1007/978-1-4899-1292-3_6; Coco K, 2011, J NEUROSCI NURS, V43, P337, DOI 10.1097/JNN.0b013e318234ea0b; Cook RS, 2013, J NEUROSCI NURS, V45, P108, DOI 10.1097/JNN.0b013e318282906e; Cooper H, 2009, HDB RES SYNTHESIS ME; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Couper MP, 2008, PUBLIC OPIN QUART, V72, P831, DOI 10.1093/poq/nfn066; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Fraley C, 1998, COMPUT J, V41, P578, DOI 10.1093/comjnl/41.8.578; Grol R, 1997, BRIT MED J, V315, P418, DOI 10.1136/bmj.315.7105.418; Hux K, 1996, LANG SPEECH HEAR SER, V27, P171, DOI 10.1044/0161-1461.2702.171; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Kroonenberg P.M., 1982, J ED STAT, V7, P69; Linden MA, 2012, NURS RES, V61, P58, DOI 10.1097/NNR.0b013e31823ca253; Long AF, 2002, J ADV NURS, V37, P70, DOI 10.1046/j.1365-2648.2002.02059.x; MCDONALD RP, 1970, BRIT J MATH STAT PSY, V23, P1, DOI 10.1111/j.2044-8317.1970.tb00432.x; McQuillan K. A., 2002, TRAUMA NURSING RESUS, P394; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Muthen LK., 2010, MPLUS USERS GUIDE ST; NOVICK MR, 1967, PSYCHOMETRIKA, V32, P1, DOI 10.1007/BF02289400; Oyesanya TO, NURSES PERCEPTIONS C; Pieper P, 2011, J TRAUMA NURS, V18, P11; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Seel RT, 2015, ARCH PHYS MED REHAB, V96, pS197, DOI 10.1016/j.apmr.2015.02.034; Shih TH, 2009, EDUC RES REV-NETH, V4, P26, DOI 10.1016/j.edurev.2008.01.003; Suhr DD., 2006, EXPLORATORY CONFIRMA, P1; Thoroddsen A, 2010, INT J NURS TERMIN CL, V21, P69, DOI 10.1111/j.1744-618X.2010.01148.x; Turner BJ, 2011, DISABIL REHABIL, V33, P818, DOI 10.3109/09638288.2010.513422; Tyler J, 1999, TEACHING STRATEGIES; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015; Verhoeven KJF, 2005, OIKOS, V108, P643, DOI 10.1111/j.0030-1299.2005.13727.x; Watts DD, 2011, J NEUROSCI NURS, V43, P122, DOI 10.1097/JNN.0b013e3182135af6	40	12	12	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0962-1067	1365-2702		J CLIN NURS	J. Clin. Nurs.	JUN	2017	26	11-12					1562	1574		10.1111/jocn.13457			13	Nursing	Nursing	EU4IG	WOS:000400992400013	27346166	Green Accepted			2021-06-18	
J	Post, A; Hoshizaki, TB; Zemek, R; Gilchrist, MD; Koncan, D; Dawson, L; Chen, W; Ledoux, AA				Post, Andrew; Hoshizaki, T. Blaine; Zemek, Roger; Gilchrist, Michael D.; Koncan, David; Dawson, Lauren; Chen, Wesley; Ledoux, Andree-Anne		Pediat Emergency Res Canada PERC 5	Pediatric concussion: biomechanical differences between outcomes of transient and persistent (> 4 weeks) postconcussion symptoms	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						concussion; persistent postconcussion symptoms; biomechanics; youth; pediatric; trauma	TRAUMATIC BRAIN-INJURY; HEAD IMPACT EXPOSURE; ANGULAR ACCELERATION; AXONAL DAMAGE; CHILDREN; RECONSTRUCTION; TISSUE; FALLS; PREDICTORS; CIRCUMFERENCE	OBJECTIVE Currently, little is known about the biomechanics of head impact for concussion in youths (ages 5 to 18 years). Even less is known about the biomechanical characteristics and variables related to head impacts that may be useful in differentiating between transient and persistent postconcussion symptoms in a youth population. The purpose of this research was to examine the differences in biomechanics of youth head impact for transient postconcussion symptoms (TPCSs) and persistent postconcussion symptoms (PPCSs) by using data from a hospital population. METHODS In a laboratory setting and using physical, computational, and finite element models, the authors reconstructed falling events in a large cohort of patients who had sustained a brain injury that resulted in transient or persistent postconcussion symptoms. The falling events and resulting concussions for the TPCS and PPCS patient groups were analyzed in terms of force, energy, peak resultant linear and rotational accelerations, and maximum principal strain in the gray and white matter of the brain, as well as measurements of cumulative strain damage. RESULTS The results indicated that there were no significant differences between the groups for any of the variables analyzed. CONCLUSIONS With methods derived for use in an adult population, the magnitudes of peak linear acceleration for the youth data set were determined to be above the 50% risk of injury. The youth data set showed higher brain tissue strain responses for lower energy and impact velocities than measured in adults, suggesting that youths are at higher risk of concussive injury at lower event seventies. A trend shown by some variables indicated that larger magnitudes of response were associated with PPCSs, but no single measurement variable consistently differentiated between the TPCS and PPCS groups. It is possible that using the biomechanics of head and brain responses to predict a subjective symptom load may not be appropriate. To enhance future biomechanical analyses, further investigations should include the use of quantifiable measures of brain injury linked to clinical outcomes and possible confounding factors such as history of brain injury and patient predisposition.	[Post, Andrew; Zemek, Roger; Ledoux, Andree-Anne] Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON, Canada; [Post, Andrew; Hoshizaki, T. Blaine; Koncan, David; Dawson, Lauren; Chen, Wesley] Univ Ottawa, Human Kinet, Ottawa, ON, Canada; [Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin, Ireland	Post, A (corresponding author), 200 Lees Ave,Rm A106, Ottawa, ON K1N 6N5, Canada.	apost@uottawa.ca	Zemek, Roger/H-1039-2018		Canadian Institutes of Health Research Operating Grant TM1 [127047]; Canadian Institutes of Health Research-Ontario Neurotrauma Foundation Mild Traumatic Brain Injury Team Grant [126197]	This study was supported by Canadian Institutes of Health Research Operating Grant TM1 No. 127047 and Canadian Institutes of Health Research-Ontario Neurotrauma Foundation Mild Traumatic Brain Injury Team Grant No. 126197.	Adamec J, 2010, J FORENSIC SCI, V55, P1615, DOI 10.1111/j.1556-4029.2010.01445.x; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bandak FA, 1994, STAPP CAR CRASH J, V38, P279; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Chrisman SPD, 2016, J CHILD NEUROL, V31, P971, DOI 10.1177/0883073816634857; Concussion in Sports Group, 2013, BRIT J SPORT MED, V47, P263; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Dawson L, 2016, THESIS; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Doorly MC, 2007, THESIS; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Gennarelli TA, 2015, 2015 IRCOBI C P, pIX; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Giordano Chiara, 2014, Stapp Car Crash J, V58, P29; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Holbourn AHS, 1943, LANCET, V242, P468; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hoshizaki B, 2013, J NEUROL NEUROPHYS, V5, P1; Juliusson PB, 2013, ANN HUM BIOL, V40, P220, DOI 10.3109/03014460.2012.759276; Kendall M, 2012, P I MECH ENG P-J SPO, V226, P260, DOI 10.1177/1754337112436901; King A.I., 2003, IRCOBI C LISB PORT, P1; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Mennes M, 2014, NEUROIMAGE, V98, P513, DOI 10.1016/j.neuroimage.2014.04.030; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller R.T., 1998, STAPP CAR CRASH J, P155; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Morrison III B, 2003, STAPP CAR CRASH J, V47, P39; Nahum AM., 1977, P 21 STAPP CAR CRASH, P339, DOI [10.4271/770922., DOI 10.4271/770922]; National Centre for Injury Prevention, 2003, REP C MILD TRAUM BRA; NELLHAUS G, 1968, PEDIATRICS, V41, P106; Newman J A, 2000, Stapp Car Crash J, V44, P215; Nguyen AKD, 2012, INT J MORPHOL, V30, P1474, DOI 10.4067/S0717-95022012000400033; O'Riordain K, 2003, CLIN BIOMECH, V18, P590, DOI 10.1016/S0268-0033(03)00111-6; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Patton DA, 2015, J APPL BIOMECH, V31, P264, DOI 10.1123/jab.2014-0223; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Post A, 2015, J BIOMECH ENG-T ASME, V137, DOI 10.1115/1.4028983; Post A, 2015, J MECH BEHAV BIOMED, V41, P325, DOI 10.1016/j.jmbbm.2014.07.034; Post A, 2014, J NEUROSURG, V120, P453, DOI 10.3171/2013.10.JNS131101; Post A, 2012, J BIOMECH, V45, P679, DOI 10.1016/j.jbiomech.2011.12.005; Roth S, 2009, COMPUT METH PROG BIO, V93, P32, DOI 10.1016/j.cmpb.2008.08.001; Rousseau P., 2014, THESIS; Ruan J, 1994, THESIS; [阮世捷 Ruan Shijie], 2012, [中国生物医学工程学报, Chinese Journal of Biomedical Engineering], V31, P502; Rueda MAF, 2009, FORENSIC SCI INT, V191, P52, DOI 10.1016/j.forsciint.2009.06.007; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Seifert TD, 2010, CURR PAIN HEADACHE R, V14, P292, DOI 10.1007/s11916-010-0117-7; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Sullivan S, 2015, ACCIDENT ANAL PREV, V82, P143, DOI 10.1016/j.aap.2015.05.020; THOMAS LM, 1966, J NEUROL NEUROSUR PS, V29, P404, DOI 10.1136/jnnp.29.5.404; Uchiyama HT, 2013, BRAIN DEV-JPN, V35, P228, DOI 10.1016/j.braindev.2012.04.005; Weeks D, 2014, J NEUROTRAUM, V31, P206, DOI 10.1089/neu.2013.3113; Willinger R, 1995, P IRCOBI, V23, P245; Wong RH, 2014, CLIN NEUROL NEUROSUR, V118, P1, DOI 10.1016/j.clineuro.2013.11.036; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019; Yue JK, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15612; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhou C, 1995, P 39 STAPP CAR CRASH, V39, P121, DOI DOI 10.4271/952714; Zong XN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059569	74	12	12	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	JUN	2017	19	6					641	651		10.3171/2016.11.PEDS16383			11	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	EV6OW	WOS:000401889700005	28347202	Bronze			2021-06-18	
J	Post, A; Clark, JM; Robertson, DGE; Hoshizaki, TB; Gilchrist, MD				Post, Andrew; Clark, J. Michio; Robertson, D. G. E.; Hoshizaki, T. Blaine; Gilchrist, Michael D.			The effect of acceleration signal processing for head impact numeric simulations	SPORTS ENGINEERING			English	Article						Signal processing; Filtering; Concussion; mTBI; Biomechanics; Ice hockey; American football	TRAUMATIC BRAIN-INJURY; ANGULAR ACCELERATION; HELMET IMPACTS; FOOTBALL; RECONSTRUCTION; VALIDATION; CONCUSSION; EXPOSURES; DIRECTION; LOCATION	Brain injury research in sport employs a variety of physical models equipped with accelerometers. These acceleration signals are commonly processed using filters. The purpose of this research was to determine the effect of applying filters with different cutoff frequencies to the acceleration signals used as input for finite element modeling of the brain. Signals were generated from reconstructions of concussion events from American football and ice hockey in the laboratory using a Hybrid III headform. The resulting acceleration signals were used as input for the University College Dublin Brain Trauma Model after being processed with filters. The results indicated that using a filter with a cutoff of 300 Hz or higher had little effect on the resulting strain measures. In some cases there was some effect of the filters on the peak linear (8-30g) and rotational measures (1000-4000 rad/s(2)), but little effect on the finite element strain result (approximately 2-6 %). The short duration and high magnitude accelerations, such as the puck impact, were most affected by the cutoff frequency of different filters.	[Post, Andrew; Clark, J. Michio; Robertson, D. G. E.; Hoshizaki, T. Blaine; Gilchrist, Michael D.] Univ Ottawa, Human Kinet, 200 Lees Ave,Room A106, Ottawa, ON K1N 6N5, Canada; [Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin, Ireland	Post, A (corresponding author), Univ Ottawa, Human Kinet, 200 Lees Ave,Room A106, Ottawa, ON K1N 6N5, Canada.	apost@uottawa.ca		Post, Andrew/0000-0002-5960-5552			Aare Magnus, 2003, Traffic Inj Prev, V4, P240, DOI 10.1080/15389580309879; Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Cournoyer J, 2014, P SPORT CONC C CHIC; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hutchison M. G., 2011, THESIS; Karton C, 2013, J ASTM INT, DOI [10.1520/STP155220120175, DOI 10.1520/STP155220120175]; Kendall M, 2012, P I MECH ENG P-J SPO, V226, P260, DOI 10.1177/1754337112436901; King A., 2003, P IRCOBI C LISB PORT; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller R.T., 1998, STAPP CAR CRASH J, P155; Nahum AM, 1977, P 21 STAPP CAR CRASH, P337; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; Oeur RA, 2015, J NEUROSURG, V123, P415, DOI 10.3171/2014.10.JNS14440; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Post A, 2014, P IRCOBI BERL GERM 1; Post A, 2011, COMPUT METHOD BIOMEC, V16, P511; Post A, 2015, J BIOMECH ENG-T ASME, V137, DOI 10.1115/1.4028983; Post A, 2015, NEUROSURGERY, V76, P81, DOI 10.1227/NEU.0000000000000554; Post A, 2015, J MECH BEHAV BIOMED, V41, P325, DOI 10.1016/j.jmbbm.2014.07.034; Post A, 2012, J BIOMECH, V45, P679, DOI 10.1016/j.jbiomech.2011.12.005; Rousseau P., 2014, THESIS; Rousseau P, 2015, SPORT BIOMECH, V14, P57, DOI 10.1080/14763141.2015.1025236; Ruan J, 1994, THESIS; Rueda MAF, 2011, COMPUT METHOD BIOMEC, V14, P1021, DOI 10.1080/10255842.2010.504922; Walsh E. S., 2012, ASTM S MECH CONC SPO; Willinger R, 1995, P IRCOBI C; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhou C, 1995, P 39 STAPP CAR CRASH, V39, P121, DOI DOI 10.4271/952714	39	12	12	0	6	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	1369-7072	1460-2687		SPORTS ENG	Sports Eng.	JUN	2017	20	2					111	119		10.1007/s12283-016-0219-5			9	Sport Sciences	Sport Sciences	EV2ZE	WOS:000401625300002					2021-06-18	
J	Seifert, T; Sufrinko, A; Cowan, R; Black, WS; Watson, D; Edwards, B; Livingston, S; Webster, K; Akers, D; Lively, M; Kontos, AP				Seifert, Tad; Sufrinko, Alicia; Cowan, Robert; Black, W. Scott; Watson, Dave; Edwards, Bill; Livingston, Scott; Webster, Keith; Akers, David; Lively, Mathew; Kontos, Anthony P.			Comprehensive Headache Experience in Collegiate Student-Athletes: An Initial Report From the NCAA Headache Task Force	HEADACHE			English	Article						headache; college; NCAA; concussion; migraine	MILD TRAUMATIC BRAIN; QUALITY-OF-LIFE; UNITED-STATES; POSTTRAUMATIC HEADACHE; CHRONIC MIGRAINE; PREVALENCE; PAIN; CONCUSSION; BURDEN; IMPACT	BackgroundThe prevalence of primary headache disorders in the general population provides a unique challenge in the evaluation of headache occurring in the context of sport. Despite a wealth of studies exploring the epidemiology of headache in the layperson, little is known about the prevalence and nature of headaches in collegiate student-athletes. These scenarios are challenging in the return to play context, as it is often unclear whether an athlete has an exacerbation of a primary headache disorder, new onset headache unrelated to trauma, or has suffered a concussive injury. PurposeTo establish the prevalence and nature of headaches in collegiate student-athletes. Study DesignRetrospective cross-sectional survey. MethodsThis cross-sectional survey evaluated the characteristics and prevalence of headache in 834 student-athletes from four NCAA Division-I institutions. Because headache occurrence may vary by sport (collision, contact, non-contact), by sex, and medical history, our sample included male and female athletes in a variety of sports, with differing degrees of contact exposure. The 20 question survey collected data on personal and family history of headache, as well as concussion history. ResultsA total of 23.7% (n=198) of participants reported having a personal history of migraine, 25.2% (n=210) history of sinus headache, and 12.3% (n=103) history of tension type headache. Among athletes with a prior history of concussion, 46.3% (n=25) of females reported a history of migraine, while only 32.2% of males reported history of migraine ((2)=3.421, P=.064). ConclusionsThe etiology of increased prevalence of migraine in our study is unclear. Whether this is due to increased awareness of headache disorders, a consequence of contact exposure, or a predisposition for migraine development in this age group remains unclear. Further studies are indicated.	[Seifert, Tad] Norton Healthcare, Louisville, KY USA; [Sufrinko, Alicia; Kontos, Anthony P.] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA 15260 USA; [Cowan, Robert] Stanford Univ, Dept Neurol, Stanford, CA 94305 USA; [Black, W. Scott] Univ Kentucky, Dept Family & Commun Med, Lexington, KY 40506 USA; [Watson, Dave] West Virginia Univ, Dept Neurol, Morgantown, WV USA; [Edwards, Bill] Western Kentucky Univ, Dept Athlet, Bowling Green, KY 42101 USA; [Livingston, Scott] Univ Kentucky, Def & Vet Brain Injury Ctr, Lexington, KY 40506 USA; [Webster, Keith] Univ Kentucky, Dept Athlet, Lexington, KY 40506 USA; [Akers, David] Univ Kentucky, Dept Stat, Lexington, KY 40506 USA; [Lively, Mathew] West Virginia Univ, Dept Med & Pediat, Morgantown, WV USA	Seifert, T (corresponding author), 3991 Dutchmans Lane,Suite 310, Louisville, KY 40222 USA.	Tad.Seifert@nortonhealthcare.org		Kontos, Anthony/0000-0002-3749-4310			American Headache Society, 2014, EP IMP HEAD MIGR; Asken BM, 2016, J ATHL TRAINING, V51, P329, DOI 10.4085/1062-6050-51.5.02; Aurora SK, 2007, HEADACHE, V47, P996, DOI 10.1111/j.1526-4610.2007.00853.x; Bigal ME, 2001, HEADACHE, V41, P710, DOI 10.1046/j.1526-4610.2001.041007710.x; Burch RC, 2015, HEADACHE, V55, P21, DOI 10.1111/head.12482; Dayan PS, 2015, PEDIATRICS, V135, P504, DOI 10.1542/peds.2014-2695; de Tommaso M, 2012, CNS NEUROL DISORD-DR, V11, P110, DOI 10.2174/187152712800269759; Defrin R, 2015, J NEUROTRAUM, V32, P28, DOI 10.1089/neu.2014.3359; Defrin R, 2014, J MAN MANIP THER, V22, P36, DOI 10.1179/2042618613Y.0000000053; Dick R, 2007, J ATHL TRAINING, V42, P173; Eross E, 2007, HEADACHE, V47, P213, DOI 10.1111/j.1526-4610.2006.00688.x; Evers S, 2010, LANCET NEUROL, V9, P391, DOI 10.1016/S1474-4422(10)70008-9; Fumal A, 2006, BRAIN, V129, P543, DOI 10.1093/brain/awh691; Gilkey SJ, 1997, HEADACHE, V37, P583, DOI 10.1046/j.1526-4610.1997.3709583.x; Gordon KE, 2006, BRIT J SPORT MED, V40, P184, DOI 10.1136/bjsm.2005.022251; Haque B, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-82; Heyer GL, 2014, PEDIATR NEUROL, V50, P464, DOI 10.1016/j.pediatrneurol.2014.01.040; Hussain A, 2010, HEADACHE, V50, P669, DOI 10.1111/j.1526-4610.2009.01436.x; Kelman L, 2007, CEPHALALGIA, V27, P394, DOI 10.1111/j.1468-2982.2007.01303.x; Kinart CM, 2002, HEADACHE, V42, P620, DOI 10.1046/j.1526-4610.2002.02149.x; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; Levine H, 2014, OTOLARYNG CLIN N AM, V47, P169, DOI 10.1016/j.otc.2013.11.003; Lipton RB, 2003, CEPHALALGIA, V23, P429, DOI 10.1046/j.1468-2982.2003.00543.x; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; Lucas S, 2011, PM&R, V3, pS406, DOI 10.1016/j.pmrj.2011.07.016; Lund N, 2014, CEPHALALGIA; MacGregor EA, 2011, HEADACHE, V51, P843, DOI 10.1111/j.1526-4610.2011.01904.x; Matheson GO, 2015, AM J SPORT MED, V43, P1518, DOI 10.1177/0363546515572144; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meehan WP, 2011, CLIN SPORT MED, V30, P115, DOI 10.1016/j.csm.2010.08.003; Nahman-Averbuch H, 2013, HEADACHE, V53, P1104, DOI 10.1111/head.12117; National Institute of Neurological Disorders and Stroke, 2016, COMM DAT EL; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; Pietrobon D, 2003, NAT REV NEUROSCI, V4, P386, DOI 10.1038/nrn1102; Piovesan Elcio J, 2003, Curr Pain Headache Rep, V7, P377, DOI 10.1007/s11916-003-0037-x; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Sabin MJ, 2011, CLIN J SPORT MED, V21, P411, DOI 10.1097/JSM.0b013e318223f3a4; Sallis RE, 2000, MED SCI SPORT EXER, V32, P1820, DOI 10.1097/00005768-200011000-00002; Schneider KJ, 2013, CLIN J SPORT MED, V23, P267, DOI 10.1097/JSM.0b013e318281f09f; Seifert T, 2014, CURR PAIN HEADACHE R, V18, DOI 10.1007/s11916-014-0448-x; Sjaastad O, 2002, CEPHALALGIA, V22, P784, DOI 10.1046/j.1468-2982.2002.00466.x; Smitherman TA, 2011, HEADACHE, V51, P581, DOI 10.1111/j.1526-4610.2011.01857.x; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; Stovner LJ, 2007, CEPHALALGIA, V27, P193, DOI 10.1111/j.1468-2982.2007.01288.x; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Victor TW, 2010, CEPHALALGIA, V30, P1065, DOI 10.1177/0333102409355601; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; WILLIAMS SJ, 1994, BRIT J SPORT MED, V28, P96, DOI 10.1136/bjsm.28.2.96	50	12	12	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	JUN	2017	57	6					877	886		10.1111/head.13104			10	Clinical Neurology	Neurosciences & Neurology	EX2II	WOS:000403049200006	28480575				2021-06-18	
J	Solmaz, B; Tunc, B; Parker, D; Whyte, J; Hart, T; Rabinowitz, A; Rohrbach, M; Kim, J; Verma, R				Solmaz, Berkan; Tunc, Birkan; Parker, Drew; Whyte, John; Hart, Tessa; Rabinowitz, Amanda; Rohrbach, Morgan; Kim, Junghoon; Verma, Ragini			Assessing Connectivity Related Injury Burden in Diffuse Traumatic Brain Injury	HUMAN BRAIN MAPPING			English	Article						diffuse axonal injury; brain network; structural connectivity; diffusion; behavior; cognition	WHITE-MATTER INTEGRITY; AXONAL INJURY; STRUCTURAL CONNECTIVITY; COGNITIVE IMPAIRMENT; NETWORK CONNECTIVITY; CLASS DISCOVERY; HEAD-INJURY; MILD; CLASSIFICATION; TRACTOGRAPHY	Many of the clinical and behavioral manifestations of traumatic brain injury (TBI) are thought to arise from disruption to the structural network of the brain due to diffuse axonal injury (DAI). However, a principled way of summarizing diffuse connectivity alterations to quantify injury burden is lacking. In this study, we developed a connectome injury score, Disruption Index of the Structural Connectome (DISC), which summarizes the cumulative effects of TBI-induced connectivity abnormalities across the entire brain. Forty patients with moderate-to-severe TBI examined at 3 months postinjury and 35 uninjured healthy controls underwent magnetic resonance imaging with diffusion tensor imaging, and completed behavioral assessment including global clinical outcome measures and neuropsychological tests. TBI patients were selected to maximize the likelihood of DAI in the absence of large focal brain lesions. We found that hub-like regions, with high betweenness centrality, were most likely to be impaired as a result of diffuse TBI. Clustering of participants revealed a subgroup of TBI patients with similar connectivity abnormality profiles who exhibited relatively poor cognitive performance. Among TBI patients, DISC was significantly correlated with post-traumatic amnesia, verbal learning, executive function, and processing speed. Our experiments jointly demonstrated that assessing structural connectivity alterations may be useful in development of patient-oriented diagnostic and prognostic tools. (C) 2017 Wiley Periodicals, Inc.	[Solmaz, Berkan; Tunc, Birkan; Parker, Drew; Verma, Ragini] Univ Penn, Perelman Sch Med, Dept Radiol, Ctr Biomed Image Comp & Analyt, Philadelphia, PA 19104 USA; [Whyte, John; Hart, Tessa; Rabinowitz, Amanda; Rohrbach, Morgan; Kim, Junghoon] Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA; [Kim, Junghoon] CUNY, Sch Med, City Coll New York, New York, NY 10031 USA	Kim, J (corresponding author), Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA.; Kim, J (corresponding author), CUNY, Sch Med, City Coll New York, New York, NY 10031 USA.	jkim@med.cuny.edu	Kim, Junghoon John/I-6702-2019	Kim, Junghoon John/0000-0001-5729-8993	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS065980, R01-NS096606, R01-MH092862]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH092862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065980, R01NS096606] Funding Source: NIH RePORTER	Contract grant sponsor: National Institutes of Health (NIH), Contract grant number: R01-NS065980, R01-NS096606, and R01-MH092862	Aerts H, 2016, BRAIN, V139, P3063, DOI 10.1093/brain/aww194; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Benton A., 1994, MULTILINGUAL APHASIA; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2013, NEUROPSYCHOLOGY, V27, P438, DOI 10.1037/a0032837; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Cote MA, 2013, MED IMAGE ANAL, V17, P844, DOI 10.1016/j.media.2013.03.009; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Fagerholm ED, 2015, BRAIN, V138, P1696, DOI 10.1093/brain/awv075; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Fillard P, 2011, NEUROIMAGE, V56, P220, DOI 10.1016/j.neuroimage.2011.01.032; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Girvan M, 2002, P NATL ACAD SCI USA, V99, P7821, DOI 10.1073/pnas.122653799; Hayes JP, 2016, J INT NEUROPSYCH SOC, V22, P120, DOI 10.1017/S1355617715000740; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Irimia A, 2012, NEUROIMAGE-CLIN, V1, P1, DOI 10.1016/j.nicl.2012.08.002; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Kim J, 2014, J INT NEUROPSYCH SOC, V20, P887, DOI 10.1017/S1355617714000812; Kim N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059382; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kuceyeski A, 2011, NEUROIMAGE, V58, P109, DOI 10.1016/j.neuroimage.2011.05.087; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mayer AR, 2014, HUM BRAIN MAPP, V35, P5457, DOI 10.1002/hbm.22563; McIntosh TK, 1996, LAB INVEST, V74, P315; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; Monti S, 2003, MACH LEARN, V52, P91, DOI 10.1023/A:1023949509487; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Pal D, 2012, CLIN NEUROL NEUROSUR, V114, P564, DOI 10.1016/j.clineuro.2011.12.002; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A, 1958, EXAMEN CLIN PSYCHOL, P139; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Salthouse TA, 2003, J EXP PSYCHOL GEN, V132, P566, DOI 10.1037/0096-3445.132.4.566; Senbabaoglu Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep06207; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sporns O, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001049; STEIGER JH, 1980, PSYCHOL BULL, V87, P245, DOI 10.1037/0033-2909.87.2.245; Tang CY, 2012, TRANSL NEUROSCI, V3, P9, DOI 10.2478/s13380-012-0003-3; Tournier JD, 2012, INT J IMAG SYST TECH, V22, P53, DOI 10.1002/ima.22005; Tuch D.S., 1999, P ANN M ISMRM; Tuch DS, 2002, MAGNET RESON MED, V48, P577, DOI 10.1002/mrm.10268; Vergara VM, 2017, J NEUROTRAUM, V34, P1045, DOI 10.1089/neu.2016.4526; VONLUXBURG U, 2006, TUTORIAL SPECTRAL CL; Wagner Amy K, 2013, Pathophysiology, V20, P39, DOI 10.1016/j.pathophys.2012.02.007; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Warren DE, 2014, P NATL ACAD SCI USA, V111, P14247, DOI 10.1073/pnas.1322173111; Watanabe T, 2016, MED IMAGE COMPUTING; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; White T, 2009, PSYCHIAT RES-NEUROIM, V174, P110, DOI 10.1016/j.pscychresns.2009.04.014; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yang JA, 2010, NAT GENET, V42, P565, DOI 10.1038/ng.608; Yuan WH, 2015, HUM BRAIN MAPP, V36, P779, DOI 10.1002/hbm.22664	72	12	12	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	JUN	2017	38	6					2913	2922		10.1002/hbm.23561			10	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EZ7XV	WOS:000404939900009	28294464	Green Published, Green Accepted			2021-06-18	
J	Spurlock, MS; Ahmed, AI; Rivera, KN; Yokobori, S; Lee, SW; Sam, PN; Shear, DA; Hefferan, MP; Hazel, TG; Johe, KK; Gajavelli, S; Tortella, FC; Bullock, RM				Spurlock, Markus S.; Ahmed, Aminul I.; Rivera, Karla N.; Yokobori, Shoji; Lee, Stephanie W.; Sam, Pingdewinde N.; Shear, Deborah A.; Hefferan, Michael P.; Hazel, Thomas G.; Johe, Karl K.; Gajavelli, Shyam; Tortella, Frank C.; Bullock, Ross M.			Amelioration of Penetrating Ballistic-Like Brain Injury Induced Cognitive Deficits after Neuronal Differentiation of Transplanted Human Neural Stem Cells	JOURNAL OF NEUROTRAUMA			English	Article						behavior deficit; cell transplantation; hNSC; neuronal differentiation; PBBI; TBI	AMYOTROPHIC-LATERAL-SCLEROSIS; PHASE-I TRIAL; RAT MODEL; FUNCTIONAL RECOVERY; STEM/PROGENITOR CELLS; PROGENITOR CELLS; SYNAPTIC PROTEIN; GUNSHOT WOUNDS; STROMAL CELLS; RODENT MODEL	Penetrating traumatic brain injury (PTBI) is one of the major cause of death and disability worldwide. Previous studies with penetrating ballistic-like brain injury (PBBI), a PTBI rat model revealed widespread perilesional neurodegeneration, similar to that seen in humans following gunshot wound to the head, which is unmitigated by any available therapies to date. Therefore, we evaluated human neural stem cell (hNSC) engraftment to putatively exploit the potential of cell therapy that has been seen in other central nervous system injury models. Toward this objective, green fluorescent protein (GFP) labeled hNSC (400,000 per animal) were transplanted in immunosuppressed Sprague-Dawley (SD), Fisher, and athymic (ATN) PBBI rats 1 week after injury. Tacrolimus (3 mg/kg 2 days prior to transplantation, then 1 mg/kg/day), methylprednisolone (10 mg/kg on the day of transplant, 1 mg/kg/week thereafter), and mycophenolate mofetil (30 mg/kg/day) for 7 days following transplantation were used to confer immunosuppression. Engraftment in SD and ATN was comparable at 8 weeks post-transplantation. Evaluation of hNSC differentiation and distribution revealed increased neuronal differentiation of transplanted cells with time. At 16 weeks post-transplantation, neither cell proliferation nor glial lineage markers were detected. Transplanted cell morphology was similar to that of neighboring host neurons, and there was relatively little migration of cells from the peritransplant site. By 16 weeks, GF-positive processes extended both rostrocaudally and bilaterally into parenchyma, spreading along host white matter tracts, traversing the internal capsule, and extending similar to 13mm caudally from transplantation site reaching into the brainstem. In a Morris water maze test at 8 weeks post-transplantation, animals with transplants had shorter latency to platform than vehicle-treated animals. However, weak injury-induced cognitive deficits in the control group at the delayed time point confounded benefits of durable engraftment and neuronal differentiation. Therefore, these results justify further studies to progress towards clinical translation of hNSC therapy for PTBI.	[Spurlock, Markus S.; Ahmed, Aminul I.; Rivera, Karla N.; Yokobori, Shoji; Lee, Stephanie W.; Sam, Pingdewinde N.; Gajavelli, Shyam; Bullock, Ross M.] Miami Project Cure Paralysis, 1095 NW 14th Terrace, Miami, FL 33136 USA; [Shear, Deborah A.; Tortella, Frank C.] Walter Reed Army Inst Res, Branch Brain Trauma Neuroprotect & Neurorestorat, Ctr Mil Psychiat & Neurosci, Silver Spring, MD USA; [Hefferan, Michael P.; Hazel, Thomas G.; Johe, Karl K.] Neuralstem Inc, Germantown, MD USA	Gajavelli, S (corresponding author), Miami Project Cure Paralysis, 1095 NW 14th Terrace, Miami, FL 33136 USA.	shyam@miami.edu	Gajavelli, Shyam/AAI-1374-2019	Gajavelli, Shyam/0000-0002-5947-6973; Ahmed, Aminul/0000-0001-6670-0438	Department of Health State of Florida General Revenue Funds; NIH Morehouse College Minority Biomedical Research Support - Research Initiative for Scientific Enhancement (MBRS-RISE) Fellowship; NIH Summer Student Fellowship;  [W81XWH-16-2-0008-BAA-150111]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R25NS083064] Funding Source: NIH RePORTER; Academy of Medical Sciences (AMS)Academy of Medical Sciences (AMS) [AMS-SGCL9-Ahmed] Funding Source: researchfish	These studies were supported in part by W81XWH-16-2-0008-BAA-150111 to R.M.B. and by the Department of Health State of Florida General Revenue Funds to The Miami Project to Cure Paralysis. P.N.S., a student volunteer from San Francisco State University (SFSU), was supported by an NIH Morehouse College Minority Biomedical Research Support - Research Initiative for Scientific Enhancement (MBRS-RISE) Fellowship and in part by an NIH Summer Student Fellowship. The authors thank Dr. Khadil Hosein, Dr. Meghan O Blaya, Dr. Lai Yee Leung, Dr. Ying Deng-Bryant, Dr. Stanislava Jergova, Dr. Melissa Carballosa-Gautam, Dr. Guobin Zhang, Dr. Adaikkalasamy David (Titus), Dr. Philip Ruiz, Dr. Alex Marcillo, Dr. Donna Avison, David Joel Sequeira, Yoelvis Hernandez, Jessica Monterrosa Mena, Nuan Song, Matthew Aguirre, and Julia Janecki for technical contributions to this study, and Nathan Bryant Schoen, Dr. Meghan O Blaya, and Maria Muniz for proofreading the manuscript.	Ahmed AI, 2016, J ROY ARMY MED CORPS, V162, P98, DOI 10.1136/jramc-2015-000475; Al Nimer F, 2004, NEUROREPORT, V15, P1871, DOI 10.1097/00001756-200408260-00007; Anderson AJ, 2011, REGEN MED, V6, P367, DOI [10.2217/RME.11.22, 10.2217/rme.11.22]; Bailey AM, 2014, NAT BIOTECHNOL, V32, P721, DOI 10.1038/nbt.2971; Blaya MO, 2015, EXP NEUROL, V264, P67, DOI 10.1016/j.expneurol.2014.11.014; Bonaventura G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140790; Boutte AM, 2012, ELECTROPHORESIS, V33, P3693, DOI 10.1002/elps.201200196; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Chang J, 2015, EXP NEUROL, V273, P225, DOI 10.1016/j.expneurol.2015.08.020; Chen ZY, 2011, BRAIN RES, V1368, P71, DOI 10.1016/j.brainres.2010.10.028; Chen ZY, 2009, J NEUROTRAUM, V26, P1987, DOI 10.1089/neu.2008.0863; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cumming G, 2007, J CELL BIOL, V177, P7, DOI 10.1083/jcb.200611141; Defense and Veterans Brain Injury Center, 2016, DOD WORLDW NUMB TBI; Deng-Bryant Y, 2015, RESTOR NEUROL NEUROS, V33, P189, DOI 10.3233/RNN-140455; Dixon CE, 2016, J NEUROTRAUM, V33, P553, DOI 10.1089/neu.2015.4122; Elias PZ, 2015, J TISSUE ENG REGEN M, V9, P137, DOI 10.1002/term.1621; Elias PZ, 2012, J NEUROSCI METH, V209, P199, DOI 10.1016/j.jneumeth.2012.06.003; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feldman EL, 2014, ANN NEUROL, V75, P363, DOI 10.1002/ana.24113; Gage FH, 2013, NEURON, V80, P588, DOI 10.1016/j.neuron.2013.10.037; Gajavelli S, 2015, J CEREBR BLOOD F MET, V35, P773, DOI 10.1038/jcbfm.2014.243; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Gao JL, 2016, CELL TRANSPLANT, V25, P1863, DOI 10.3727/096368916X691150; Gennai S, 2015, BRIT J ANAESTH, V115, P203, DOI 10.1093/bja/aev229; Giusto E, 2014, EXP NEUROL, V260, P19, DOI 10.1016/j.expneurol.2013.03.009; Glass JD, 2012, STEM CELLS, V30, P1144, DOI 10.1002/stem.1079; Gold EM, 2013, REGEN MED, V8, P483, DOI 10.2217/rme.13.41; Gressot LV, 2014, J NEUROSURG, V121, P645, DOI 10.3171/2014.5.JNS131872; Guevara AB, 2016, J HEAD TRAUMA REHAB, V31, pE48, DOI 10.1097/HTR.0000000000000151; Guo XF, 2010, J TISSUE ENG REGEN M, V4, P181, DOI 10.1002/term.223; Hagan M, 2003, NEUROSCI LETT, V351, P149, DOI 10.1016/j.neulet.2003.07.021; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Haus DL, 2016, EXP NEUROL, V281, P1, DOI 10.1016/j.expneurol.2016.04.008; Hefferan MP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042614; Hefferan MP, 2011, CELL TRANSPLANT, V20, P1153, DOI 10.3727/096368910X564553; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Hyun I, 2008, CELL STEM CELL, V3, P607, DOI 10.1016/j.stem.2008.11.009; Jena AB, 2014, J GEN INTERN MED, V29, P1065, DOI 10.1007/s11606-014-2779-z; Joseph B, 2014, J AM COLL SURGEONS, V218, P58, DOI 10.1016/j.jamcollsurg.2013.08.018; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Khan MB, 2014, WORLD NEUROSURG, V82, P14, DOI 10.1016/j.wneu.2013.01.026; Kochanek PM, 2015, SEMIN NEUROL, V35, P83, DOI 10.1055/s-0035-1544237; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee DH, 2013, CHILD NERV SYST, V29, P403, DOI 10.1007/s00381-012-1969-4; Lee GQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099000; Leong WK, 2013, STEM CELLS, V31, P1040, DOI 10.1002/stem.1348; Lin David J, 2012, Surg Neurol Int, V3, P98, DOI 10.4103/2152-7806.100187; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lu P, 2012, CELL, V150, P1264, DOI 10.1016/j.cell.2012.08.020; Lu X.C., 2015, J NEUROTRAUMA; Lundberg J, 2012, CELL TRANSPLANT, V21, P333, DOI 10.3727/096368911X576036; Ma HY, 2012, NEUROCHEM RES, V37, P69, DOI 10.1007/s11064-011-0584-1; Ma HY, 2011, MOL MED REP, V4, P849, DOI 10.3892/mmr.2011.510; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; Oehmichen Manfred, 2009, Leg Med (Tokyo), V11 Suppl 1, pS50, DOI 10.1016/j.legalmed.2009.01.113; Office of Cellular Tissue and Gene Therapy (OCTGT), 2013, GUID IND PRECL ASS I; Pendharkar AV, 2010, STROKE, V41, P2064, DOI 10.1161/STROKEAHA.109.575993; Peng WJ, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0034-0; Pruitt BA, 2001, J TRAUMA, V51, pS1, DOI 10.1097/00005373-200108001-00001; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Riley J, 2014, NEUROSURGERY, V74, P77, DOI 10.1227/NEU.0000000000000156; Riley J, 2012, NEUROSURGERY, V71, P405, DOI 10.1227/NEU.0b013e31825ca05f; Rolfe A., 2015, BRAIN NEUROTRAUMA MO, P587; Rosenfeld JV, 2015, WORLD J SURG, V39, P1352, DOI 10.1007/s00268-014-2874-7; Roshal LM, 2009, B EXP BIOL MED+, V148, P140, DOI 10.1007/s10517-009-0642-8; Shear DA, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00073; Shear DA, 2010, J NEUROTRAUM, V27, P1911, DOI 10.1089/neu.2010.1399; Skardelly M, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00318; Skardelly M, 2011, J NEUROTRAUM, V28, P401, DOI 10.1089/neu.2010.1526; Steinbeck JA, 2015, NEURON, V86, P187, DOI 10.1016/j.neuron.2015.03.002; Streib E, 2016, J TRAUMA ACUTE CARE, V80, P849, DOI 10.1097/TA.0000000000001090; Tadesse T, 2014, ANN CLIN TRANSL NEUR, V1, P900, DOI 10.1002/acn3.134; Tajiri N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091408; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Tasigiorgos S, 2015, J AM COLL SURGEONS, V221, P1005, DOI 10.1016/j.jamcollsurg.2015.08.430; Tennstaedt A, 2015, BIOMATERIALS, V44, P143, DOI 10.1016/j.biomaterials.2014.12.038; Tsyb AF, 2009, B EXP BIOL MED+, V147, P132, DOI 10.1007/s10517-009-0432-3; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wang EY, 2012, J NEUROTRAUM, V29, P295, DOI 10.1089/neu.2011.2043; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Wennersten A, 2006, EXP NEUROL, V199, P339, DOI 10.1016/j.expneurol.2005.12.035; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Winn H.R, 2011, YOUMANS NEUROLOGICAL, V4; Wu P, 2002, GENE THER, V9, P245, DOI 10.1038/sj.gt.3301646; Xiong Y, 2010, DISCOV MED, V10, P434; Yan J, 2007, PLOS MED, V4, P318, DOI 10.1371/journal.pmed.0040039; Yan J, 2006, STEM CELLS, V24, P1976, DOI 10.1634/stemcells.2005-0518; Yan ZJ, 2013, NEUROCHEM RES, V38, P1022, DOI 10.1007/s11064-013-1012-5; Yavagal DR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093735; Young NH, 2008, PLOS MED, V5, P1186, DOI 10.1371/journal.pmed.0050168; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770	96	12	12	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2017	34	11					1981	1995		10.1089/neu.2016.4602			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EV4KD	WOS:000401727500008	28249550	Green Published			2021-06-18	
J	Tang, CH; Bao, Y; Qi, M; Zhou, LZ; Liu, F; Mao, J; Lei, QM; Qi, ST; Qiu, BH				Tang, Chunhai; Bao, Yun; Qi, Min; Zhou, Lizhi; Liu, Fan; Mao, Jian; Lei, Qingmei; Qi, Songtao; Qiu, Binghui			Mild induced hypothermia for patients with severe traumatic brain injury after decompressive craniectomy	JOURNAL OF CRITICAL CARE			English	Article						Traumatic brain injury; Hypothermia; Craniectomy; Intracranial pressure; Outcome	THERAPEUTIC HYPOTHERMIA; INTRACRANIAL-PRESSURE; MODERATE HYPOTHERMIA; OUTCOMES; HYPERTENSION; IMPACT	Purpose: To evaluate the efficacy and safety of mild induced hypothermia for intracranial hypertension in patients with traumatic brain injury after decompressive craniectomy. Methods: A total of 60 adults with intracranial pressure (ICP) of more than 20 mm Hg after decompressive craniectomy were randomly assigned to standard care (control group) or hypothermia (32 degrees C-35 degrees C) plus standard care. Then, ICP, cerebral perfusion pressure, Glasgow Outcome Scale score, and complications were assessed. Results: There was a significant difference in ICP and cerebral perfusion pressure between the 2 groups. Favorable outcomes occurred in 12 (40.0%) and 7 (36.5%) patients in the hypothermia and control groups, respectively (P =.267). Kaplan-Meier curves revealed a marked difference in survival between the hypothermia and control groups (P =.032). There were significant differences in pulmonary infection and electrolyte disorders between the hypothermia and control groups (P =.038 and.033, respectively). Conclusion: Mild induced hypothermia can reduce intracranial hypertension after decompressive craniectomy, decreasing patient mortality. Hypothermia should be considered one of the main treatments for intracranial hypertension after decompressive craniectomy in patients with traumatic brain injury. (C) 2016 Elsevier Inc. All rights reserved.	[Tang, Chunhai; Bao, Yun; Qi, Min; Zhou, Lizhi; Liu, Fan; Mao, Jian; Lei, Qingmei; Qi, Songtao; Qiu, Binghui] Southern Med Univ, Nanfang Hosp, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China; [Tang, Chunhai] Guangxi Med Univ, Affiliated Hosp 10, Dept Neurosurg, Nanning, Guangdong, Peoples R China; [Qi, Min] Southern Med Univ, Coll Clin Med 1, Guangzhou, Guangdong, Peoples R China; [Zhou, Lizhi] Southern Med Univ, Sch Biostat, Dept Biostat, Guangzhou, Guangdong, Peoples R China; [Lei, Qingmei] Southern Med Univ, Nanfang Hosp, Dept Nursing, Guangzhou, Guangdong, Peoples R China	Qi, ST; Qiu, BH (corresponding author), Guangzhou Dadao Bei St 1838, Guangzhou, Guangdong, Peoples R China.	qisongtaonfyy@126.com			key Clinical Specialty Discipline Construction Program, President Foundation of Nanfang Hospital, Southern Medical University [2015C028]; Science and Technology Planning Project of Guangdong Province, China [2012B091100463, 2013B021800304]	This study was supported by key Clinical Specialty Discipline Construction Program, President Foundation of Nanfang Hospital, Southern Medical University (2015C028). Science and Technology Planning Project of Guangdong Province, China (2012B091100463, 2013B021800304).	Andrews PJD, 2016, NEW ENGL J MED, V374, P1385, DOI 10.1056/NEJMc1600339; Brain Trauma Foundation, 2007, METHODS J NEUROTR S1, V24, pS3; Burger R, 2004, NEUROSURGERY, V54, P701, DOI 10.1227/01.NEU.0000108784.80585.EE; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; Georgoff P, 2010, WORLD NEUROSURG, V74, P331, DOI 10.1016/j.wneu.2010.03.025; Han JS, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002827; Hofman K, 2005, AM J PUBLIC HEALTH, V95, P13, DOI 10.2105/AJPH.2004.039354; Kahveci FS, 2001, SURG NEUROL, V56, P206, DOI 10.1016/S0090-3019(01)00555-9; Kelts EA, 2010, NEUROREHABILITATION, V27, P223, DOI 10.3233/NRE-2010-0601; Konstantinidis A, 2011, J TRAUMA, V71, P1627, DOI 10.1097/TA.0b013e3182159e31; Kramer C, 2012, NEUROLOGIST, V18, P173, DOI 10.1097/NRL.0b013e318253f8ef; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Popugaev KA, 2014, J NEUROL SURG REP, V75, pE224, DOI 10.1055/s-0034-1387188; Sandestig A, 2014, THER HYPOTHERMIA TEM, V4, P10, DOI 10.1089/ther.2013.0024; Stocchetti N, 2008, INTENS CARE MED, V34, P461, DOI 10.1007/s00134-007-0948-9; Tang A, 2015, J SURG RES, V194, P565, DOI 10.1016/j.jss.2014.11.017; Wang JW, 2016, J CLIN NEUROSCI, V27, P1, DOI 10.1016/j.jocn.2015.06.037; Wang R, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001733	20	12	12	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	JUN	2017	39						267	270		10.1016/j.jcrc.2016.12.012			4	Critical Care Medicine	General & Internal Medicine	EW4KR	WOS:000402470900045	28069320				2021-06-18	
J	Yasen, AL; Howell, DR; Chou, LS; Pazzaglia, AM; Christie, AD				Yasen, Alia L.; Howell, David R.; Chou, Li-Shan; Pazzaglia, Angela M.; Christie, Anita D.			Cortical and Physical Function after Mild Traumatic Brain Injury	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						MILD TRAUMATIC BRAIN INJURY; GAIT; TRANSCRANIAL MAGNETIC STIMULATION	TRANSCRANIAL MAGNETIC STIMULATION; COLLEGIATE FOOTBALL PLAYERS; GAIT BALANCE CONTROL; SILENT PERIOD; PARKINSONS-DISEASE; SPORTS CONCUSSION; LONG-TERM; MOTOR; INHIBITION; ATTENTION	Purpose The aim of this study was to prospectively examine the association between intracortical inhibition and functional recovery after mild traumatic brain injury (mTBI). Methods Twenty individuals with mTBI and 20 matched control participants were assessed using transcranial magnetic stimulation, the Attentional Network Test, and gait analysis. Hierarchical linear modeling was used to longitudinally examine potential differences between groups and relationships in the pattern of recovery in cortical silent period (CSP) duration, cognitive reaction time, and single- and dual-task walking speeds across five testing time points. Individuals with mTBI were assessed within 72 h of injury, and again at 1 wk, 2 wk, 1 month, and 2 months postinjury. After initial testing, control participants followed a similar timeline. Results At the 72-h time point, the group with mTBI had longer reaction time (b = -91.76, P = 0.01), similar single-task walking speed (b = 0.055, P = 0.10), and slower dual-task walking speed (b = 0.10, P = 0.012) compared with control participants. The CSP duration also tended to be longer in individuals with mTBI than controls at the 72-h time point (b = -16.34, P = 0.062). The change is CSP duration over time was not significantly associated with the change in reaction time (b = -0.19, P = 0.47), single-task walking speed (b = 0.0001, P = 0.53), or dual-task walking speed (b < 0.001, P = 0.68). Conclusion Although cognitive and motor functions were significantly impaired in the mTBI group acutely after injury, levels of intracortical inhibition were not associated with recovery in either functional domain.	[Yasen, Alia L.; Howell, David R.; Chou, Li-Shan; Christie, Anita D.] Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA; [Howell, David R.] Childrens Hosp Boston, Dept Orthoped, Div Sports Med, Boston, MA USA; [Howell, David R.] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Pazzaglia, Angela M.] Educ Dev Ctr Inc, Waltham, MA USA	Christie, AD (corresponding author), Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA.	adc1@uoregon.edu					Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bryk AS, 1996, HLM 4 FOR WINDOWS; CANTELLO R, 1991, NEUROLOGY, V41, P1449, DOI 10.1212/WNL.41.9.1449; Cantu RC, 2006, NEUROSURG FOCUS, V21, P1, DOI [DOI 10.3171/FOC.2006.21.4.4, 10.3171/foc.2006.21.4.4]; Catena RD, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-8; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Chou LS, 2003, GAIT POSTURE, V18, P125, DOI 10.1016/S0966-6362(02)00067-X; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gray C, 1998, BRAIN INJURY, V12, P429, DOI 10.1080/026990598122548; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Holste KG, 2014, MED SCI SPORT EXER, V46, P672, DOI 10.1249/01.mss.0000495489.69232.e0; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Ives JC, 2003, CLIN BIOMECH, V18, P543, DOI 10.1016/S0268-0033(03)00089-5; Kimberley TJ, 2009, NEUROSCI LETT, V464, P84, DOI 10.1016/j.neulet.2009.08.029; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Martini D., 2011, BRIT J SPORT MED, V45, P361; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J SCI MED SPORT, V16, P178, DOI 10.1016/j.jsams.2013.02.009; Miller NR, 2014, BRAIN INJURY, P1; Orth M, 2004, CLIN NEUROPHYSIOL, V115, P1076, DOI 10.1016/j.clinph.2003.12.025; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; PRIORI A, 1994, BRAIN, V117, P317, DOI 10.1093/brain/117.2.317; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Rossi S, 2011, CLIN NEUROPHYSIOL, V122, P1686, DOI 10.1016/j.clinph.2010.12.037; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x; Winter D., 1995, GAIT POSTURE, V3, P193, DOI 10.1016/0966-6362(96)82849-9	34	12	12	1	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JUN	2017	49	6					1066	1071		10.1249/MSS.0000000000001217			6	Sport Sciences	Sport Sciences	EV0KI	WOS:000401427800002	28509819				2021-06-18	
J	Zhong, WT; Cristofori, I; Bulbulia, J; Krueger, F; Grafman, J				Zhong, Wanting; Cristofori, Irene; Bulbulia, Joseph; Krueger, Frank; Grafman, Jordan			Biological and cognitive underpinnings of religious fundamentalism	NEUROPSYCHOLOGIA			English	Article						Traumatic brain injury; Prefrontal cortex; Religious beliefs; Fundamentalism	SOCIAL COGNITION; INTELLIGENCE; FLEXIBILITY; OPENNESS; DISTINCT; NEED; AUTHORITARIANISM; ASSOCIATIONS; IDEOLOGY; DEFICITS	Beliefs profoundly affect people's lives, but their cognitive and neural pathways are poorly understood. Although previous research has identified the ventromedial prefrontal cortex (vmPFC) as critical to representing religious beliefs, the means by which vmPFC enables religious belief is uncertain. We hypothesized that the vmPFC represents diverse religious beliefs and that a vmPFC lesion would be associated with religious fundamentalism, or the narrowing of religious beliefs. To test this prediction, we assessed religious adherence with a widely-used religious fundamentalism scale in a large sample of 119 patients with penetrating traumatic brain injury (pTBI). If the vmPFC is crucial to modulating diverse personal religious beliefs, we predicted that pTBI patients with lesions to the vmPFC would exhibit greater fundamentalism, and that this would be modulated by cognitive flexibility and trait openness. Instead, we found that participants with dorsolateral prefrontal cortex (dlPFC) lesions have fundamentalist beliefs similar to patients with vmPFC lesions and that the effect of a dlPFC lesion on fundamentalism was significantly mediated by decreased cognitive flexibility and openness. These findings indicate that cognitive flexibility and openness are necessary for flexible and adaptive religious commitment, and that such diversity of religious thought is dependent on dlPFC functionality.	[Zhong, Wanting; Cristofori, Irene; Grafman, Jordan] Shirley Ryan AbilityLab, Brain Injury Res, Cognit Neurosci Lab, Chicago, IL 60611 USA; [Zhong, Wanting; Cristofori, Irene; Grafman, Jordan] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Bulbulia, Joseph] Victoria Univ New Zealand, Sch Art Hist Class & Religious Studies, Wellington 6140, New Zealand; [Krueger, Frank] George Mason Univ, Mol Neurosci Dept, Fairfax, VA 22030 USA; [Krueger, Frank] George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA; [Grafman, Jordan] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA; [Grafman, Jordan] Northwestern Univ, Feinberg Sch Med, Dept Psychiat, Chicago, IL 60611 USA; [Grafman, Jordan] Northwestern Univ, Feinberg Sch Med, Dept Cognit Neurol & Alzheimers Dis, Chicago, IL 60611 USA	Grafman, J (corresponding author), Shirley Ryan AbilityLab, Cognit Neurosci Lab, Brain Injury Res Program, Think & Speak Lab, 355 E Erie St, Chicago, IL 60611 USA.	jgrafman@northwestern.edu		Zhong, Wanting/0000-0002-6025-1739; Bulbulia, Joseph/0000-0002-5861-2056; Cristofori, Irene/0000-0003-2339-1457	National Naval Medical Center; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [Z01NS002792] Funding Source: NIH RePORTER	We are grateful to our Vietnam veterans for their dedicated participation in the study. We thank J. Solomon for his assistance with ABLe, as well as V. Raymont, S. Bonifant, B. Cheon, C. Ngo, A. Greathouse, K. Reding, and G. Tasick for testing and evaluating participants. We would also like to thank the National Naval Medical Center and the National Institute of Neurological Disorders and Stroke for providing support and facilities. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, the Department of Defense, or the U.S. Government.	Adelstein JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027633; AFQT-7A, 1960, DEP DEF FORM 1293; Altemeyer B., 1992, INT J PSYCHOL RELIG, V2, P113, DOI [10.1207/s15327582ijpr0202_5, DOI 10.1207/S15327582IJPR0202_5, DOI 10.1207/S153]; Altemeyer B., 2005, FUNDAMENTALISM AUTHO; Alvarez JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI 10.1007/s11065-006-9002-x; Amodio DM, 2007, NAT NEUROSCI, V10, P1246, DOI 10.1038/nn1979; Asp E, 2012, NEUROPSYCHOLOGY, V26, P414, DOI 10.1037/a0028526; Bader C., 2006, AM PIETY 21 CENTURY; Barbey AK, 2013, NEUROIMAGE, V82, P547, DOI 10.1016/j.neuroimage.2013.05.087; BATSON CD, 1991, J SCI STUD RELIG, V30, P416, DOI 10.2307/1387277; BATSON CD, 1991, J SCI STUD RELIG, V30, P430, DOI 10.2307/1387278; Brandt MJ, 2010, PERS SOC PSYCHOL B, V36, P715, DOI 10.1177/0146167210366306; Bulbulia J., 2009, BELIEVING PRIMATE SC, P44, DOI DOI 10.1093/ACPROF:OSO/9780199557028.003.0003; Bulbulia J, 2013, CONT TOP COGN NEUROS, P169; Bulbulia J, 2009, BEHAV BRAIN SCI, V32, P515, DOI 10.1017/S0140525X09991403; Bunge SA, 2009, NEUROIMAGING IN DEVELOPMENTAL CLINICAL NEUROSCIENCE, P22, DOI 10.1017/CBO9780511757402.005; Calogero RM, 2009, PERS INDIV DIFFER, V46, P154, DOI 10.1016/j.paid.2008.09.019; Canas JJ, 2003, ERGONOMICS, V46, P482, DOI 10.1080/0014013031000061640; Chapman B, 2012, AM J GERIAT PSYCHIAT, V20, P612, DOI 10.1097/JGP.0b013e31822cc9cb; Connelly BS, 2014, J PERS ASSESS, V96, P17, DOI 10.1080/00223891.2013.809355; Costa PT, 1992, NEO PI R PROFESSIONA; Cristofori I., 2017, PROCESSES BELIEVING; Cristofori I, 2016, NEUROPSYCHOLOGIA, V80, P212, DOI 10.1016/j.neuropsychologia.2015.11.021; Cristofori I, 2015, SOC COGN AFFECT NEUR, V10, P1038, DOI 10.1093/scan/nsu155; Delis D.C., 2001, DELIS KAPLAN EXECUTI; DeYoung C., 2014, APA HDB PERSONALITY, P369, DOI [10.1037/14343-017, DOI 10.1037/14343-017]; DeYoung CG, 2005, J PERS, V73, P825, DOI 10.1111/j.1467-6494.2005.00330.x; DeYoung CG, 2011, J RES PERS, V45, P364, DOI 10.1016/j.jrp.2011.04.002; DeYoung CG, 2009, J PERS SOC PSYCHOL, V97, P883, DOI 10.1037/a0016615; Duckitt J, 2001, ADV EXP SOC PSYCHOL, V33, P41, DOI 10.1016/S0065-2601(01)80004-6; Forbes CE, 2010, ANNU REV NEUROSCI, V33, P299, DOI 10.1146/annurev-neuro-060909-153230; Foster KR, 2009, P ROY SOC B-BIOL SCI, V276, P31, DOI 10.1098/rspb.2008.0981; Gervais WM, 2012, SCIENCE, V336, P493, DOI 10.1126/science.1215647; Ginges J, 2009, PSYCHOL SCI, V20, P224, DOI 10.1111/j.1467-9280.2009.02270.x; Gozzi M, 2009, NEUROPSYCHOLOGIA, V47, P2125, DOI 10.1016/j.neuropsychologia.2009.04.002; Guthrie Steven., 1993, FACES CLOUDS NEW THE; Harris S., 2009, PLOS ONE, P4; Hayes A.F., 2018, INTRO MEDIATION MODE, V2nd ed.; Hunsberger B, 2005, J SOC ISSUES, V61, P807, DOI 10.1111/j.1540-4560.2005.00433.x; Inzlicht M, 2011, RELIG BRAIN BEHAV, V1, P192, DOI 10.1080/2153599X.2011.647849; Inzlicht M, 2009, PSYCHOL SCI, V20, P385, DOI 10.1111/j.1467-9280.2009.02305.x; Jost JT, 2003, PSYCHOL BULL, V129, P339, DOI 10.1037/0033-2909.129.3.339; Kay AC, 2008, J PERS SOC PSYCHOL, V95, P18, DOI 10.1037/0022-3514.95.1.18; Kim C, 2011, J NEUROSCI, V31, P4771, DOI 10.1523/JNEUROSCI.5923-10.2011; Krueger F, 2013, CONT TOP COGN NEUROS, P225; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; Kruglanski AW, 1996, PSYCHOL REV, V103, P263, DOI 10.1037/0033-295X.103.2.263; Kunisato Y, 2011, NEUROSCI LETT, V492, P109, DOI 10.1016/j.neulet.2011.01.067; Lewis GJ, 2011, INTELLIGENCE, V39, P468, DOI 10.1016/j.intell.2011.08.002; Lynn R, 2009, INTELLIGENCE, V37, P11, DOI 10.1016/j.intell.2008.03.004; Mah LWY, 2005, J NEUROPSYCH CLIN N, V17, P66, DOI 10.1176/appi.neuropsych.17.1.66; Mayr U, 2000, J EXP PSYCHOL GEN, V129, P4, DOI 10.1037/0096-3445.129.1.4; McCrae RR, 1996, PSYCHOL BULL, V120, P323, DOI 10.1037/0033-2909.120.3.323; McCullough ME, 2009, PSYCHOL BULL, V135, P69, DOI 10.1037/a0014213; McNeil M. M., 1994, REVISED TOKEN TEST; Monchi O, 2006, ANN NEUROL, V59, P257, DOI 10.1002/ana.20742; Monsell S, 2003, TRENDS COGN SCI, V7, P134, DOI 10.1016/S1364-6613(03)00028-7; Moretti L, 2009, J COGNITIVE NEUROSCI, V21, P128, DOI 10.1162/jocn.2009.21011; Neyrinck B, 2006, MOTIV EMOTION, V30, P323, DOI 10.1007/s11031-006-9048-3; Norenzayan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036880; Passamonti L, 2015, NEUROIMAGE, V104, P301, DOI 10.1016/j.neuroimage.2014.09.017; Ravizza SM, 2008, NEUROPSYCHOLOGIA, V46, P2924, DOI 10.1016/j.neuropsychologia.2008.06.006; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; Saroglou V., 2002, MENTAL HLTH RELIG CU, V5, P183, DOI [DOI 10.1080/13674670210144130, 10.1080/13674670210144130]; Scheufele DA, 2009, NAT NANOTECHNOL, V4, P91, DOI 10.1038/NNANO.2008.361; Schjoedt U, 2011, SOC COGN AFFECT NEUR, V6, P119, DOI 10.1093/scan/nsq023; Schjoedt U, 2009, SOC COGN AFFECT NEUR, V4, P199, DOI 10.1093/scan/nsn050; Schretlen DJ, 2010, J CLIN EXP NEUROPSYC, V32, P1068, DOI 10.1080/13803391003689770; Sibley CG, 2006, POLIT PSYCHOL, V27, P755, DOI 10.1111/j.1467-9221.2006.00531.x; Toepper M, 2010, NEUROSCIENCE, V165, P1244, DOI 10.1016/j.neuroscience.2009.11.019; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; van Elk M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130422; Vecchione M, 2009, PERS INDIV DIFFER, V46, P487, DOI 10.1016/j.paid.2008.11.021; von Stumm S, 2013, J INDIVID DIFFER, V34, P82, DOI 10.1027/1614-0001/a000101; Whiting DL, 2017, NEUROPSYCHOL REHABIL, V27, P263, DOI 10.1080/09602011.2015.1062115; Willard AK, 2013, COGNITION, V129, P379, DOI 10.1016/j.cognition.2013.07.016; Yeung N, 2004, PSYCHOL REV, V111, P931, DOI [10.1037/0033-295X.111.4.931, 10.1037/0033-295x.111.4.931]; Zuckerman M, 2013, PERS SOC PSYCHOL REV, V17, P325, DOI 10.1177/1088868313497266	78	12	12	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	JUN	2017	100						18	25		10.1016/j.neuropsychologia.2017.04.009			8	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	EX3GL	WOS:000403120500003	28392301	Bronze, Green Accepted			2021-06-18	
J	Badawy, MK; Dayan, PS; Tunik, MG; Nadel, FM; Lillis, KA; Miskin, M; Borgialli, DA; Bachman, MC; Atabaki, SM; Hoyle, JD; Holmes, JF; Kuppermann, N				Badawy, Mohamed K.; Dayan, Peter S.; Tunik, Michael G.; Nadel, Frances M.; Lillis, Kathleen A.; Miskin, Michelle; Borgialli, Dominic A.; Bachman, Michael C.; Atabaki, Shireen M.; Hoyle, John D., Jr.; Holmes, James F.; Kuppermann, Nathan		PECARN	Prevalence of Brain Injuries and Recurrence of Seizures in Children With Posttraumatic Seizures	ACADEMIC EMERGENCY MEDICINE			English	Article							MINOR HEAD-INJURY; REQUIRE HOSPITALIZATION; INTRACRANIAL INJURY; TRAUMA; PREDICTION; MANAGEMENT; YOUNGER	Objectives: Computed tomography (CT) is often used in the emergency department (ED) evaluation of children with posttraumatic seizures (PTS); however, the frequency of traumatic brain injuries (TBIs) and short-term seizure recurrence is lacking. Our main objective was to evaluate the frequency of TBIs on CT and short-term seizure recurrence in children with PTS. We also aimed to determine the associations between the likelihood of TBI on CT with the timing of onset of PTS after the traumatic event and duration of PTS. Finally, we aimed to determine whether patients with normal CT scans and normal neurological examinations are safe for discharge from the ED. Methods: This was a planned secondary analysis from a prospective observational cohort study to derive and validate a neuroimaging decision rule for children after blunt head trauma at 25 EDs in the Pediatric Emergency Care Applied Research Network. We evaluated children < 18 years with head trauma and PTS between June 2004 and September 2006. We assessed TBI on CT, neurosurgical interventions, and recurrent seizures within 1 week. Patients discharged from the ED were contacted by telephone 1 week to 3 months later. Results: Of 42,424 children enrolled, 536 (1.3%, 95% confidence interval [CI] = 1.2%-1.4%) had PTS. A total of 466 of 536 (86.9%, 95% CI = 83.8%-89.7%) underwent CT in the ED. TBIs on CT were identified in 72 (15.5%, 95% CI = 12.3%-19.1%), of whom 20 (27.8%, 95% CI = 17.9%-39.6%) underwent neurosurgical intervention and 15 (20.8%, 95% CI = 12.2%-32.0%) had recurrent seizures. Of the 464 without TBIs on CT (or no CTs performed), 457 had recurrent seizure status known, and five (1.1%, 95 CI = 0.4%-2.5%) had recurrent seizures; four of five presented with Glasgow Coma Scale scores < 15. None of the 464 underwent neurosurgical intervention. We found significant associations between likelihood of TBI on CT with longer time until the PTS after the traumatic event (p = 0.006) and longer duration of PTS (p < 0.001). Conclusions: Children with PTS have a high likelihood of TBI on CT, and those with TBI on CT frequently require neurosurgical interventions and frequently have recurrent seizures. Those without TBIs on CT, however, are at low risk of short-term recurrent seizures, and none required neurosurgical interventions. Therefore, if CT-negative and neurologically normal, patients with PTS may be safely considered for discharge from the ED.	[Badawy, Mohamed K.] Univ Texas Southwestern Med Sch, Dept Pediat, Dallas, TX USA; [Dayan, Peter S.] Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; [Tunik, Michael G.] NYU, Sch Med, Dept Emergency Med, New York, NY USA; [Tunik, Michael G.] NYU, Dept Pediat, Sch Med, New York, NY 10016 USA; [Nadel, Frances M.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Lillis, Kathleen A.] SUNY Buffalo, Sch Med & Biomed Sci, Dept Pediat, Buffalo, NY USA; [Lillis, Kathleen A.] SUNY Buffalo, Sch Med & Biomed Sci, Dept Emergency Med, Buffalo, NY USA; [Miskin, Michelle] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Miskin, Michelle] PECARN Data Coordinating Ctr, Salt Lake City, UT USA; [Borgialli, Dominic A.] Univ Michigan, Sch Med, Dept Emergency Med, Flint, MI 48503 USA; [Borgialli, Dominic A.] Hurley Med Ctr, Flint, MI USA; [Bachman, Michael C.] Newark Beth Israel Med Ctr, Dept Emergency Med, Newark, NJ USA; [Bachman, Michael C.] Newark Beth Israel Med Ctr, Dept Pediat, Newark, NJ USA; [Atabaki, Shireen M.] George Washington Univ, Sch Med, Dept Pediat, Washington, DC 20052 USA; [Atabaki, Shireen M.] George Washington Univ, Sch Med, Dept Emergency Med, Washington, DC USA; [Hoyle, John D., Jr.] Michigan State Univ, Sch Med, Div Emergency Med, Helen Devos Childrens Hosp, Grand Rapids, MI USA; [Holmes, James F.; Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Emergency Med, Sacramento, CA 95817 USA; [Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Pediat, Sacramento, CA 95817 USA	Kuppermann, N (corresponding author), Univ Calif Davis, Sch Med, Dept Emergency Med, Sacramento, CA 95817 USA.; Kuppermann, N (corresponding author), Univ Calif Davis, Sch Med, Dept Pediat, Sacramento, CA 95817 USA.	nkuppermann@ucdavis.edu		Powell, Elizabeth/0000-0003-3147-9889; Alpern, Elizabeth/0000-0001-7887-3563; Tunik, Michael/0000-0002-2368-5933	Health Resources and Services Administration/Maternal and Child Health Bureau (HRSA/MCHB), Division of Research, Education, and TrainingUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA); Emergency Medical Services of Children (EMSC) Program [R40MC02461]; HRSAUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA); MCHB; EMSC Network Development Demonstration Program [U03MC00008, U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC22684, U03MC22685]	This work was supported by a grant from the Health Resources and Services Administration/Maternal and Child Health Bureau (HRSA/MCHB), Division of Research, Education, and Training and the Emergency Medical Services of Children (EMSC) Program (R40MC02461). This project was also supported in part by HRSA, MCHB, and the EMSC Network Development Demonstration Program under cooperative agreements U03MC00008, U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC22684, and U03MC22685. The information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS, or the U.S. Government.	[Anonymous], 1997, PEDIATRICS; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Dias MS, 1999, PEDIATR NEUROSURG, V30, P232, DOI 10.1159/000028803; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Faul M, TRAUMATIC BRAIN INJU; Gorelick MH, 2008, ACAD EMERG MED, V15, P812, DOI 10.1111/j.1553-2712.2008.00206.x; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Holmes JF, 2011, ANN EMERG MED, V58, P315, DOI 10.1016/j.annemergmed.2011.03.060; Holmes JF, 2004, ANN EMERG MED, V43, P706, DOI 10.1016/j.annemergmed.2003.11.008; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Mandal K, 2001, CHILD NERV SYST, V17, P670, DOI 10.1007/s00381-001-0520-9; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; RAMUNDO ML, 1995, PEDIATR EMERG CARE, V11, P1, DOI 10.1097/00006565-199502000-00001; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983	19	12	12	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	MAY	2017	24	5					595	605		10.1111/acem.13168			11	Emergency Medicine	Emergency Medicine	EU6SY	WOS:000401165800007	28170143	Green Published, Bronze			2021-06-18	
J	Bennett, TD; DeWitt, PE; Dixon, RR; Kartchner, C; Sierra, Y; Ladell, D; Srivastava, R; Riva-Cambrin, J; Kempe, A; Runyan, DK; Keenan, HT; Dean, JM				Bennett, Tellen D.; DeWitt, Peter E.; Dixon, Rebecca R.; Kartchner, Cory; Sierra, Yamila; Ladell, Diane; Srivastava, Rajendu; Riva-Cambrin, Jay; Kempe, Allison; Runyan, Desmond K.; Keenan, Heather T.; Dean, J. Michael			Development and Prospective Validation of Tools to Accurately Identify Neurosurgical and Critical Care Events in Children With Traumatic Brain Injury	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						brain injuries; craniocerebral trauma; electronic health records; pediatrics; validation studies as topic	LOGISTIC-REGRESSION ANALYSIS; ADMINISTRATIVE DATABASES; EXISTING DATA; SELECTION; MODELS; REGULARIZATION; SURVEILLANCE; VARIABILITY; INFECTIONS; RECORDS	Objective: To develop and validate case definitions (computable phenotypes) to accurately identify neurosurgical and critical care events in children with traumatic brain injury. Design: Prospective observational cohort study, May 2013 to September 2015. Setting: Two large U.S. children's hospitals with level 1 Pediatric Trauma Centers. Patients: One hundred seventy-four children less than 18 years old admitted to an ICU after traumatic brain injury. Measurements and Main Results: Prospective data were linked to database codes for each patient. The outcomes were prospectively identified acute traumatic brain injury, intracranial pressure monitor placement, craniotomy or craniectomy, vascular catheter placement, invasive mechanical ventilation, and new gastrostomy tube or tracheostomy placement. Candidate predictors were database codes present in administrative, billing, or trauma registry data. For each clinical event, we developed and validated penalized regression and Boolean classifiers (models to identify clinical events that take database codes as predictors). We externally validated the best model for each clinical event. The primary model performance measure was accuracy, the percent of test patients correctly classified. The cohort included 174 children who required ICU admission after traumatic brain injury. Simple Boolean classifiers were greater than or equal to 94% accurate for seven of nine clinical diagnoses and events. For central venous catheter placement, no classifier achieved 90% accuracy. Classifier accuracy was dependent on available data fields. Five of nine classifiers were acceptably accurate using only administrative data but three required trauma registry fields and two required billing data. Conclusions: In children with traumatic brain injury, computable phenotypes based on simple Boolean classifiers were highly accurate for most neurosurgical and critical care diagnoses and events. The computable phenotypes we developed and validated can be used in any observational study of children with traumatic brain injury and can reasonably be applied in studies of these interventions in other patient populations.	[Bennett, Tellen D.] Univ Colorado, Sch Med, Dept Pediat, Sect Pediat Crit Care, Aurora, CO 80045 USA; [Bennett, Tellen D.; Sierra, Yamila; Ladell, Diane; Kempe, Allison] Childrens Hosp Colorado, Aurora, CO 80045 USA; [Bennett, Tellen D.; Kempe, Allison] Univ Colorado, Sch Med, Adult & Child Consortium Hlth Outcomes Res & Deli, Aurora, CO 80045 USA; [DeWitt, Peter E.] Colorado Sch Publ Hlth, Div Pediat Crit Care, Dept Pediat, Aurora, CO USA; [Dixon, Rebecca R.; Keenan, Heather T.; Dean, J. Michael] Univ Utah, Sch Med, Pediat Crit Care, Salt Lake City, UT USA; [Kartchner, Cory] Primary Childrens Med Ctr, Dept Bioinformat & Biostat, Salt Lake City, UT USA; [Srivastava, Rajendu] Univ Utah, Sch Med, Dept Pediat, Div Pediat Inpatient Med, Salt Lake City, UT USA; [Srivastava, Rajendu] Intermt Healthcare, Off Res, Salt Lake City, UT USA; [Riva-Cambrin, Jay] Univ Calgary, Dept Clin Neurosci, Div Pediat Neurosurg, Calgary, AB, Canada; [Riva-Cambrin, Jay] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada; [Runyan, Desmond K.] Univ Colorado, Sch Med, Dept Pediat, Kempe Ctr, Aurora, CO USA	Bennett, TD (corresponding author), Univ Colorado, Sch Med, Dept Pediat, Sect Pediat Crit Care, Aurora, CO 80045 USA.; Bennett, TD (corresponding author), Childrens Hosp Colorado, Aurora, CO 80045 USA.; Bennett, TD (corresponding author), Univ Colorado, Sch Med, Adult & Child Consortium Hlth Outcomes Res & Deli, Aurora, CO 80045 USA.	tell.bennett@ucdenver.edu	Runyan, Desmond/S-3974-2016	Runyan, Desmond/0000-0001-5571-9029; DeWitt, Peter/0000-0002-6391-0795; Bennett, Tellen/0000-0003-1483-4236	Eunice Kennedy Shriver National Institute for Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074620]; National Center for Research Resources (Colorado Clinical and Translational Sciences Institute Grant) [UL1 TR001082]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); NIH, Agency for Healthcare Research and Quality; Children's Hospital Association; NIH/NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074620] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001082] Funding Source: NIH RePORTER	Supported, in part, by the Eunice Kennedy Shriver National Institute for Child Health and Human Development (Grant K23HD074620 to Dr. Bennett) and the National Center for Research Resources (Colorado Clinical and Translational Sciences Institute Grant UL1 TR001082).; Drs. Bennett, Kempe, and Dean received support for article research from the National Institutes of Health (NIH). Dr. Bennett's institution received funding from Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and National Center for Research Resources. Dr. Srivastava disclosed that he is the Past Chair of the Pediatric Hospitalist Research (PRIS) Network (http://www.prisnetwork.org) that conducts a variety of research studies funded by the NIH, Agency for Healthcare Research and Quality, and the Children's Hospital Association. Dr. Keenan's institution received funding from NIH/NICHD and from the Centers for Disease Control and Prevention. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Agarwal V, 2016, J AM MED INFORM ASSN, V23, P1166, DOI 10.1093/jamia/ocw028; Allaire J.J., 2016, RMARKDOWN DYNAMIC DO; American College of Surgeons Committee on Trauma, 2010, NAT TRAUM DAT BANK R; Arabian SS, 2015, J TRAUMA ACUTE CARE, V79, P359, DOI 10.1097/TA.0000000000000788; Bennett TD, 2015, METHOD INFORM MED, V54, P328, DOI 10.3414/ME14-01-0093; Bennett TD, 2016, PEDIATR CRIT CARE ME, V17, P1147, DOI 10.1097/PCC.0000000000000934; Bennett TD, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00079; Bratton SL, 2012, PEDIATR CRIT CARE ME, V13, P407, DOI 10.1097/PCC.0b013e318238b428; Brier G.W., 1950, MONTHLY WEATHER REV, V78, P1, DOI 2.0.CO;2; Carroll CP, 2012, NEUROSURGERY, V71, P1064, DOI 10.1227/NEU.0b013e31826f7c16; Conway PH, 2009, J PEDIATR-US, V154, P789, DOI 10.1016/j.jpeds.2009.01.010; Cooke CR, 2013, CRIT CARE MED, V41, P886, DOI 10.1097/CCM.0b013e31827bfc3c; COX DR, 1958, BIOMETRIKA, V45, P562, DOI 10.1093/biomet/45.3-4.562; De Coster C, 2008, MED CARE, V46, P627, DOI 10.1097/MLR.0b013e3181649439; Dreyer NA, 2011, EPIDEMIOLOGY, V22, P295, DOI 10.1097/EDE.0b013e3182126569; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Friedman J., 2016, GLMNET LASSO ELASTIC; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Hastie T., 2008, ELEMENTS STAT LEARNI, V2nd; HOCKING RR, 1976, BIOMETRICS, V32, P1, DOI 10.2307/2529336; HOERL AE, 1970, TECHNOMETRICS, V12, P55, DOI 10.1080/00401706.1970.10488634; Kamkar I, 2015, J BIOMED INFORM, V53, P277, DOI 10.1016/j.jbi.2014.11.013; Kirby JC, 2016, J AM MED INFORM ASSN, V23, P1046, DOI 10.1093/jamia/ocv202; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Lahiri S, 2015, NEUROCRIT CARE, V23, P28, DOI 10.1007/s12028-014-0082-9; Moons KGM, 2015, ANN INTERN MED, V162, pW1, DOI 10.7326/M14-0698; O'Malley KJ, 2005, HEALTH SERV RES, V40, P1620, DOI 10.1111/j.1475-6773.2005.00444.x; Patrick SW, 2013, PEDIATRICS, V131, pS75, DOI 10.1542/peds.2012-1427i; R Core Team (2018), R LANG ENV STAT COMP; Roberts RJ, 2007, CRIT CARE MED, V35, P949, DOI 10.1097/01.CCM.0000257461.17112.89; Shivade C, 2014, J AM MED INFORM ASSN, V21, P221, DOI 10.1136/amiajnl-2013-001935; Slonim AD, 2010, PEDIATRICS, V125, P1208, DOI 10.1542/peds.2009-1451; Steyerberg EW, 2001, MED DECIS MAKING, V21, P45, DOI 10.1177/0272989X0102100106; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Weiss NS, 2011, EPIDEMIOLOGY, V22, P292, DOI 10.1097/EDE.0b013e318210aca5; Wright SB, 2003, INFECT CONT HOSP EP, V24, P946, DOI 10.1086/502164; Xie Y, 2016, KNITR GEN PURPOSE PA, Vversion 1.13; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	40	12	12	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAY	2017	18	5					442	451		10.1097/PCC.0000000000001120			10	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	EW8BF	WOS:000402742400012	28252524	Green Accepted			2021-06-18	
J	Charry, JD; Tejada, JH; Pinzon, MA; Tejada, WA; Ochoa, JD; Falla, M; Tovar, JH; Cuellar-Bahamon, AM; Solano, JP				Charry, Jose D.; Tejada, Jorman H.; Pinzon, Miguel A.; Tejada, Wilson A.; Ochoa, Juan D.; Falla, Manuel; Tovar, Jesus H.; Cuellar-Bahamon, Ana M.; Solano, Juan P.			Predicted Unfavorable Neurologic Outcome Is Overestimated by the Marshall Computed Tomography Score, Corticosteroid Randomization After Significant Head Injury (CRASH), and International Mission for Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury (IMPACT) Models in Patients with Severe Traumatic Brain Injury Managed with Early Decompressive Craniectomy	WORLD NEUROSURGERY			English	Article						Neurologic outcome; Prognosis models; Traumatic brain injury	MORTALITY; PROTOCOL; ADULTS; CARE	INTRODUCTION: Traumatic brain injury (TBI) is of public health interest and produces significant mortality and disability in Colombia. Calculators and prognostic models have been developed to establish neurologic outcomes. We tested prognostic models (the Marshall computed tomography [CT] score, International Mission for Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury (IMPACT), and Corticosteroid Randomization After Significant Head Injury) for 14-day mortality, 6-month mortality, and 6-month outcome in patients with TBI at a university hospital in Colombia. METHODS: A 127-patient cohort with TBI was treated in a regional trauma center in Colombia over 2 years and bivariate and multivariate analyses were used. Discriminatory power of the models, their accuracy, and precision was assessed by both logistic regression and area under the receiver operating characteristic curve (AUC). Shapiro-Wilk, chi(2), and Wilcoxon test were used to compare real outcomes in the cohort against predicted outcomes. RESULTS: The group's median age was 33 years, and 84.25% were male. The injury severity score median was 25, and median Glasgow Coma Scale motor score was 3. Six-month mortality was 29.13%. Six-month unfavorable outcome was 37%. Mortality prediction by Marshall CT score was 52.8%, P=0.104 (AUC 0.585; 95% confidence interval [CI] 0 0.489-0.681), the mortality prediction by CRASH prognosis calculator was 59.9%, P < 0.001 (AUC 0.706; 95% CI 0.590-0.821), and the unfavorable outcome prediction by IMPACT was 77%, P < 0.048 (AUC 0.670; 95% CI 0.575-0.763). CONCLUSIONS: In a university hospital in Colombia, the Marshall CT score, IMPACT, and Corticosteroid Randomization After Significant Head Injury models overestimated the adverse neurologic outcome in patients with severe head trauma.	[Charry, Jose D.] Fdn Univ Navarra Uninavarra, Dept Med, Neiva, Colombia; [Charry, Jose D.] Univ Jaen, Jaen, Spain; [Tejada, Jorman H.; Pinzon, Miguel A.; Tovar, Jesus H.] Univ Surcolombiana, Dept Anesthesiol & Resuscitat, Neiva, Colombia; [Tejada, Wilson A.; Ochoa, Juan D.; Falla, Manuel; Cuellar-Bahamon, Ana M.] Univ Surcolombiana, Dept Med, Neiva, Colombia; [Solano, Juan P.] Neiva Univ Hosp, Dept Neurosurg, Neiva, Colombia	Charry, JD (corresponding author), Fdn Univ Navarra Uninavarra, Dept Med, Neiva, Colombia.; Charry, JD (corresponding author), Univ Jaen, Jaen, Spain.	danielcharry06@gmail.com		Pinzon Pinzon, Miguel Angel/0000-0001-5828-9212; Charry, Jose D./0000-0002-8789-7281			Byass P, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001477; Charry JD, 2016, BRIT J NEUROSURG, V30, P235, DOI 10.3109/02688697.2015.1096905; Charry JD, 2016, J NEUROSCI RURAL PRA, V7, P7, DOI 10.4103/0976-3147.172151; Coughlan MD, 2003, CHILD NERV SYST, V19, P348, DOI 10.1007/s00381-003-0736-y; De la Hoz GA, 2013, FORENSIS, P79; Edwards P, 2005, LANCET, V365, P1957; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Honeybul S, 2014, J NEUROSURG, V120, P1131, DOI 10.3171/2014.1.JNS131559; Honeybul S, 2011, J NEUROTRAUM, V28, P2199, DOI 10.1089/neu.2011.1907; Horton R, 2012, LANCET, V380, P2053, DOI 10.1016/S0140-6736(12)62133-3; Hutchinson PJ, 2011, BRIT J NEUROSURG, V25, P441, DOI 10.3109/02688697.2011.583366; Kesinger MR, 2014, INJURY, V45, P1350, DOI 10.1016/j.injury.2014.04.037; Kesinger MR, 2014, WORLD J SURG, V38, P1869, DOI 10.1007/s00268-014-2534-y; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mata-Mbemba D, 2014, ACAD RADIOL, V21, P605, DOI 10.1016/j.acra.2014.01.017; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Norton R, 2013, NEW ENGL J MED, V368, P1723, DOI 10.1056/NEJMra1109343; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; TIMMONS SD, 2011, NEW ENGL J MED, V365, P373	20	12	13	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAY	2017	101						554	558		10.1016/j.wneu.2017.02.051			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EV7CR	WOS:000401932500072	28223249				2021-06-18	
J	Eapen, BC; Georgekutty, J; Subbarao, B; Bavishi, S; Cifu, DX				Eapen, Blessen C.; Georgekutty, Jason; Subbarao, Bruno; Bavishi, Sheital; Cifu, David X.			Disorders of Consciousness	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Disorder of consciousness; Rehabilitation; Coma; Vegetative state; Minimally conscious state; Traumatic brain injury	COMA RECOVERY SCALE; VEGETATIVE STATE; BRAIN-INJURY; STIMULATION; METHYLPHENIDATE; DISABILITY; AMANTADINE; ZOLPIDEM; OUTCOMES; TRIAL	Disorder of consciousness (DOC) is a state of prolonged altered consciousness, which can be categorized into coma, vegetative state, or minimally conscious state based on neurobehavioral function. The pathophysiology of DOC is poorly understood but recent advances in neuroimaging and advanced electrophysiological techniques may provide an improved understanding for the neural network involved with consciousness. The primary aim of DOC rehabilitation programs is to promote arousal while preventing secondary medical complications while providing education and training to families. Treatment interventions include both pharmacologic and nonpharmacologic programs, but there are currently no consensus treatment guidelines for individuals with DOC.	[Eapen, Blessen C.; Subbarao, Bruno] South Texas Vet Healthcare Syst, Polytrauma Rehabil Ctr, 7400 Merton Minter, San Antonio, TX 78229 USA; [Georgekutty, Jason] Kessler Inst Rehabil, 201 Pleasant Hill Rd, Chester, NJ 07930 USA; [Bavishi, Sheital] Ohio State Univ, Dept Phys Med & Rehabil, Traumat Brain Injury Rehabil Program, Wexner Med Ctr, 480 Med Ctr Dr, Columbus, OH 43210 USA; [Cifu, David X.] Virginia Commonwealth Univ, Dept PM&R, US Dept Vet Affairs, VA DoD Chron Effects NeuroTrauma Consortium, 1223 E Marshall St,POB 980677, Richmond, VA 23284 USA	Eapen, BC (corresponding author), South Texas Vet Healthcare Syst, Polytrauma Rehabil Ctr, 7400 Merton Minter, San Antonio, TX 78229 USA.	blessen.eapen2@va.gov		Cifu, David/0000-0003-1600-9387			Angelakis E, 2014, ARCH PHYS MED REHAB, V95, P283, DOI 10.1016/j.apmr.2013.09.002; [Anonymous], 1995, Neurology, V45, P1012; BAUER G, 1979, J NEUROL, V221, P77, DOI 10.1007/BF00313105; Bernat JL, 2009, ANNU REV MED, V60, P381, DOI 10.1146/annurev.med.60.060107.091250; Boly M, 2008, LANCET NEUROL, V7, P1013, DOI 10.1016/S1474-4422(08)70219-9; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Cavanna AE, 2011, BEHAV NEUROL, V24, P107, DOI [10.1155/2011/645159, 10.3233/BEN-2011-0322]; Cavanna AE, 2011, BEHAV NEUROL, V24, P3, DOI [10.3233/BEN-2011-0311, 10.1155/2011/374507]; Crone JS, 2014, NEUROIMAGE-CLIN, V4, P240, DOI 10.1016/j.nicl.2013.12.005; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; Eapen BC, 2017, EXP NEUROL, V287, P479, DOI 10.1016/j.expneurol.2016.08.004; Eapen Blessen C, 2015, Semin Neurol, V35, pe1, DOI 10.1055/s-0035-1549094; Fisher CE, 2010, J LAW MED ETHICS, V38, P374, DOI 10.1111/j.1748-720X.2010.00496.x; Giacino J, 2012, NEUROMODULATION, V15, P339, DOI 10.1111/j.1525-1403.2012.00458.x; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gill-Thwaites H, 2004, BRAIN INJURY, V18, P1255, DOI 10.1080/02699050410001719952; Goldfine AM, 2011, CLIN NEUROPHYSIOL, V122, P2157, DOI 10.1016/j.clinph.2011.03.022; Gray M, 2011, J TRAUMA, V71, P1465, DOI 10.1097/TA.0b013e31821f82f5; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; Kalmar K, 2005, NEUROPSYCHOL REHABIL, V15, P454, DOI 10.1080/09602010443000425; Kim YW, 2009, CLIN NEUROPHARMACOL, V32, P335, DOI 10.1097/WNF.0b013e3181b40678; Krimchansky BZ, 2004, BRAIN INJURY, V18, P1099, DOI 10.1080/02699050310001646206; Landsness E, 2011, BRAIN, V134, P2222, DOI 10.1093/brain/awr152; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Lovstad M, 2010, J HEAD TRAUMA REHAB, V25, P349, DOI 10.1097/HTR.0b013e3181cec841; Matsuda W, 2005, NEUROPSYCHOL REHABIL, V15, P414, DOI 10.1080/09602010443000588; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; ODell MW, 1996, NEUROREHABILITATION, V6, P45, DOI 10.3233/NRE-1996-6106; Page SJ, 2015, ARCH PHYS MED REHAB, V96, pS89, DOI 10.1016/j.apmr.2014.09.019; Pape TLB, 2009, BRAIN STIMUL, V2, P22, DOI 10.1016/j.brs.2008.09.004; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Plum F, 1966, DIAGNOSIS STUPOR COM, P5; RADER MA, 1994, BRAIN INJURY, V8, P309, DOI 10.3109/02699059409150982; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; Reynolds JC, 2013, RESUSCITATION, V84, P818, DOI 10.1016/j.resuscitation.2012.11.014; Rosenbaum Amy M, 2015, Handb Clin Neurol, V127, P395, DOI 10.1016/B978-0-444-52892-6.00025-8; Schnakers C, 2008, BRAIN INJURY, V22, P926, DOI 10.1080/02699050802530565; Seel RT, 2013, ARCH PHYS MED REHAB, V94, P1908, DOI 10.1016/j.apmr.2012.11.052; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; Shiel A, 2000, CLIN REHABIL, V14, P408, DOI 10.1191/0269215500cr326oa; Thibaut A, 2014, NEUROLOGY, V82, P1112, DOI 10.1212/WNL.0000000000000260; Tucker C, 2016, NEUROCRIT CARE, V24, P488, DOI 10.1007/s12028-015-0227-5; Vanhaudenhuyse A, 2007, Rev Med Liege, V62 Spec No, P15; Whyte J, 2014, AM J PHYS MED REHAB, V93, P101, DOI 10.1097/PHM.0000000000000069; Whyte J, 2013, ARCH PHYS MED REHAB, V94, P1855, DOI 10.1016/j.apmr.2012.10.041; Wijdicks EFM, 2010, NEUROLOGY, V74, P1911, DOI 10.1212/WNL.0b013e3181e242a8; Zasler ND, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P1	52	12	17	1	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	MAY	2017	28	2					245	258		10.1016/j.pmr.2016.12.003			14	Rehabilitation	Rehabilitation	EU5AJ	WOS:000401043700005	28390511				2021-06-18	
J	Hertelendy, P; Menyhart, A; Makra, P; Sule, Z; Kiss, T; Toth, G; Ivankovits-Kiss, O; Bari, F; Farkas, E				Hertelendy, Peter; Menyhart, Akos; Makra, Peter; Sule, Zoltan; Kiss, Tamas; Toth, Gergely; Ivankovits-Kiss, Orsolya; Bari, Ferenc; Farkas, Eszter			Advancing age and ischemia elevate the electric threshold to elicit spreading depolarization in the cerebral cortex of young adult rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Age; cerebral blood flow; electrophysiology; spreading depolarization; threshold	ANEURYSMAL SUBARACHNOID HEMORRHAGE; BLOOD-FLOW; BRAIN TRAUMA; DEPRESSION; INJURY; MODULATION; STROKE; DAMAGE; HYPOPERFUSION; PROPAGATION	Spreading depolarizations of long cumulative duration have been implicated in lesion development and progression in patients with stroke and traumatic brain injury. Spreading depolarizations evolve less likely in the aged brain, but it remains to be determined at what age the susceptibility to spreading depolarizations starts to decline, especially in ischemia. Spreading depolarizations were triggered by epidural electric stimulation prior and after ischemia induction in the cortex of 7-30 weeks old anesthetized rats (n=38). Cerebral ischemia was achieved by occlusion of both common carotid arteries. Spreading depolarization occurrence was confirmed by the acquisition of DC potential and electrocorticogram. Cerebral blood flow variations were recorded by laser-Doppler flowmetry. Dendritic spine density in the cortex was determined in Golgi-COX stained sections. Spreading depolarization initiation required increasingly greater electric charge with older age, a potential outcome of consolidation of cortical connections, indicated by altered dendritic spine distribution. The threshold of spreading depolarization elicitation increased with ischemia in all age groups, which may be caused by tissue acidosis and increased K+ conductance, among other factors. In conclusion, the brain appears to be the most susceptible to spreading depolarizations at adolescent age; therefore, spreading depolarizations may occur in young patients of ischemic or traumatic brain injury at the highest probability.	[Hertelendy, Peter; Menyhart, Akos; Makra, Peter; Kiss, Tamas; Toth, Gergely; Ivankovits-Kiss, Orsolya; Bari, Ferenc; Farkas, Eszter] Univ Szeged, Fac Med, Dept Med Phys & Informat, Koranyi Fasor 9, H-6720 Szeged, Hungary; [Hertelendy, Peter; Menyhart, Akos; Makra, Peter; Kiss, Tamas; Toth, Gergely; Ivankovits-Kiss, Orsolya; Bari, Ferenc; Farkas, Eszter] Univ Szeged, Fac Sci & Informat, Koranyi Fasor 9, H-6720 Szeged, Hungary; [Sule, Zoltan] Univ Szeged, Fac Med, Dept Anat Histol & Embryol, Szeged, Hungary	Farkas, E (corresponding author), Univ Szeged, Fac Med, Dept Med Phys & Informat, Koranyi Fasor 9, H-6720 Szeged, Hungary.; Farkas, E (corresponding author), Univ Szeged, Fac Sci & Informat, Koranyi Fasor 9, H-6720 Szeged, Hungary.	farkas.eszter.1@med.u-szeged.hu		Kiss, Tamas/0000-0001-5339-5227; Farkas, Eszter/0000-0002-8478-9664; Menyhart, Akos/0000-0002-1355-3208	Hungarian Scientific Research FundOrszagos Tudomanyos Kutatasi Alapprogramok (OTKA) [K111923]; Hungarian Brain Research Program [KTIA_13_NAP-A-I/13]; Bolyai Janos Research Scholarship of the Hungarian Academy of SciencesHungarian Academy of Sciences [BO/00327/14/5];  [TAMOP-4.2.2.D-15/1/KONV-2015-0024]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants from the Hungarian Scientific Research Fund (Grant No. K111923); the Hungarian Brain Research Program (Grant No. KTIA_13_NAP-A-I/13); TAMOP-4.2.2.D-15/1/KONV-2015-0024; and the Bolyai Janos Research Scholarship of the Hungarian Academy of Sciences (BO/00327/14/5, to EF).	Ayata C, 2015, PHYSIOL REV, V95, P953, DOI 10.1152/physrev.00027.2014; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Buzsaki G, 2012, NAT REV NEUROSCI, V13, P407, DOI 10.1038/nrn3241; Chen RL, 2010, NAT REV NEUROL, V6, P256, DOI 10.1038/nrneurol.2010.36; Cippola MJ, 2009, CEREBRAL CIRCULATION; Clark D, 2014, NEUROBIOL AGING, V35, P2803, DOI 10.1016/j.neurobiolaging.2014.06.013; Dickstein DL, 2013, NEUROSCIENCE, V251, P21, DOI 10.1016/j.neuroscience.2012.09.077; Dijkhuizen RM, 1999, BRAIN RES, V840, P194, DOI 10.1016/S0006-8993(99)01769-2; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Dreier JP, 1998, J CEREBR BLOOD F MET, V18, P978; Faber JE, 2011, ARTERIOSCL THROM VAS, V31, P1748, DOI 10.1161/ATVBAHA.111.227314; Farkas E, 2011, NEUROBIOL AGING, V32, P1707, DOI 10.1016/j.neurobiolaging.2009.10.002; Feuerstein D, 2014, J CEREBR BLOOD F MET, V34, P1117, DOI 10.1038/jcbfm.2014.53; GLASER EM, 1981, J NEUROSCI METH, V4, P117, DOI 10.1016/0165-0270(81)90045-5; HARRIS KM, 1992, J NEUROSCI, V12, P2685; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; HERRERAS O, 1993, BRAIN RES, V610, P276, DOI 10.1016/0006-8993(93)91411-K; Hinzman JM, 2014, BRAIN, V137, P2960, DOI 10.1093/brain/awu241; Hoffmann U, 2013, J CEREBR BLOOD F MET, V33, P191, DOI 10.1038/jcbfm.2012.132; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Ingall T, 2000, STROKE, V31, P1054, DOI 10.1161/01.STR.31.5.1054; Lanzino G, 1996, J NEUROSURG, V85, P410, DOI 10.3171/jns.1996.85.3.0410; Lapi D, 2015, J VASC RES, V52, P22, DOI 10.1159/000381096; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Maslarova A, 2011, STROKE, V42, P2917, DOI 10.1161/STROKEAHA.111.621581; Menyhart A, 2015, NEUROBIOL AGING, V36, P3269, DOI 10.1016/j.neurobiolaging.2015.08.014; Nedergaard M, 1996, ADV NEUROL, V71, P75; Richter F, 1998, DEV BRAIN RES, V106, P217, DOI 10.1016/S0165-3806(98)00018-2; Risher WC, 2010, J NEUROSCI, V30, P9859, DOI 10.1523/JNEUROSCI.1917-10.2010; Sengupta P, 2013, INT J PREVENTIVE MED, V4, P624; Shah NH, 2014, TRANSL STROKE RES, V5, P38, DOI 10.1007/s12975-013-0297-7; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Sukhotinsky I, 2008, J CEREBR BLOOD F MET, V28, P1369, DOI 10.1038/jcbfm.2008.35; TANG CM, 1990, P NATL ACAD SCI USA, V87, P6445, DOI 10.1073/pnas.87.16.6445; Tong CK, 2000, J NEUROPHYSIOL, V84, P2449; von Bornstadt D, 2015, NEURON, V85, P1117, DOI 10.1016/j.neuron.2015.02.007; Woitzik J, 2013, NEUROLOGY, V80, P1095, DOI 10.1212/WNL.0b013e3182886932	40	12	12	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2017	37	5					1763	1775		10.1177/0271678X16643735			13	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	ET8CG	WOS:000400525200015	27189902	Bronze, Green Accepted, Green Published			2021-06-18	
J	Karr, JE; Garcia-Barrera, MA; Holdnack, JA; Iverson, GL				Karr, Justin E.; Garcia-Barrera, Mauricio A.; Holdnack, James A.; Iverson, Grant L.			Using Multivariate Base Rates to Interpret Low Scores on an Abbreviated Battery of the Delis-Kaplan Executive Function System	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Executive functions; Assessment; Norms/normative studies	HEALTHY OLDER-ADULTS; NEUROPSYCHOLOGICAL ASSESSMENT; FRONTOTEMPORAL DEMENTIA; SUPPLEMENTARY METHODS; MEMORY SCORES; WAIS-IV; PREVALENCE; VARIABILITY; DYSFUNCTION; IMPAIRMENT	Objective: Executive function consists of multiple cognitive processes that operate as an interactive system to produce volitional goaloriented behavior, governed in large part by frontal microstructural and physiological networks. Identification of deficits in executive function in those with neurological or psychiatric conditions can be difficult because the normal variation in executive function test scores, in healthy adults when multiple tests are used, is largely unknown. This study addresses that gap in the literature by examining the prevalence of low scores on a brief battery of executive function tests. Method: The sample consisted of 1,050 healthy individuals (ages 16-89) from the standardization sample for the Delis-Kaplan Executive Function System (D-KEFS). Seven individual test scores from the Trail Making Test, Color-Word Interference Test, and Verbal Fluency Test were analyzed. Results: Low test scores, as defined by commonly used clinical cut-offs (i. e., <= 25th, 16th, 9th, 5th, and 2nd percentiles), occurred commonly among the adult portion of the D-KEFS normative sample (e.g., 62.8% of the sample had one or more scores <= 16th percentile, 36.1% had one or more scores <= 5th percentile), and the prevalence of low scores increased with lower intelligence and fewer years of education. Conclusions: The multivariate base rates (BR) in this article allow clinicians to understand the normal frequency of low scores in the general population. By use of these BRs, clinicians and researchers can improve the accuracy with which they identify executive dysfunction in clinical groups, such as those with traumatic brain injury or neurodegenerative diseases.	[Karr, Justin E.; Garcia-Barrera, Mauricio A.] Univ Victoria, Dept Psychol, POB 1700 STN CSC, Victoria, BC V8W 2Y2, Canada; [Holdnack, James A.] Pearson, Clin Assessment, Bear, DE 19701 USA; [Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA 02129 USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA 02129 USA; [Iverson, Grant L.] MassGen Hosp Children, Sports Concuss Program, Boston, MA 02129 USA; [Iverson, Grant L.] Red Sox Fdn, Home Base, Boston, MA 02129 USA; [Iverson, Grant L.] Massachusetts Gen Hosp Program, Boston, MA 02129 USA	Karr, JE (corresponding author), Univ Victoria, Dept Psychol, POB 1700 STN CSC, Victoria, BC V8W 2Y2, Canada.	jkarr@uvic.ca	Garcia-Barrera, Mauricio A./AAO-9757-2021	Garcia-Barrera, Mauricio A./0000-0002-4302-4964; Iverson, Grant/0000-0001-7348-9570	Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR	Standardization data from the Delis-Kaplan Executive Function System (D-KEFS), (C) 2001 NCS Pearson, Inc. Used with permission. All rights reserved. J.E.K. is a Vanier Canada Graduate Scholar and thanks the Natural Sciences and Engineering Research Council of Canada for their support of his graduate studies. G.L.I. notes that this work is related in part to the TBI Endpoints Development Initiative and a grant entitled Development and Validation of a Cognition Endpoint for Traumatic Brain Injury Clinical Trials. He acknowledges unrestricted philanthropic support from the Mooney-Reed Charitable Foundation and ImPACT Applications, Inc. M.G.B. also note that this work is related in part to his grant entitled Characteristics and Correlates of Intraindividual Variability in Executive Control Processes (Natural Sciences and Engineering Research Council of Canada).	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Aron AR, 2008, CURR DIR PSYCHOL SCI, V17, P124, DOI 10.1111/j.1467-8721.2008.00561.x; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; Brooks B. L., 2012, PEDIAT FORENSIC NEUR, P66; Brooks BL, 2008, J INT NEUROPSYCH SOC, V14, P463, DOI 10.1017/S1355617708080521; Brooks BL, 2007, J INT NEUROPSYCH SOC, V13, P490, DOI 10.1017/D1355617707070531; Brooks BL, 2013, PRACT RESOUR MENT, P75, DOI 10.1016/B978-0-12-386934-0.00002-X; Brooks BL, 2012, APPL NEUROPSYCH-ADUL, V19, P61, DOI 10.1080/09084282.2012.651951; Brooks BL, 2011, ASSESSMENT, V18, P156, DOI 10.1177/1073191110385316; Brooks BL, 2010, ARCH CLIN NEUROPSYCH, V25, P182, DOI 10.1093/arclin/acq005; Brooks BL, 2009, DEMENT GERIATR COGN, V27, P439, DOI 10.1159/000215390; Bush G, 2005, BIOL PSYCHIAT, V57, P1273, DOI 10.1016/j.biopsych.2005.01.034; Collette F, 2005, HUM BRAIN MAPP, V25, P409, DOI 10.1002/hbm.20118; Crawford JR, 2012, J NEUROPSYCHOL, V6, P192, DOI 10.1111/j.1748-6653.2011.02022.x; Crawford JR, 2011, PSYCHOL ASSESSMENT, V23, P888, DOI 10.1037/a0023712; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Homack S, 2005, J CLIN EXP NEUROPSYC, V27, P599, DOI 10.1080/13803390490918444; Iverson GL, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P923, DOI 10.1007/978-0-387-76978-3_32; Jurado MB, 2007, NEUROPSYCHOL REV, V17, P213, DOI 10.1007/s11065-007-9040-z; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; Lorenzetti V, 2009, J AFFECT DISORDERS, V117, P1, DOI 10.1016/j.jad.2008.11.021; MacDonald SWS, 2006, TRENDS NEUROSCI, V29, P474, DOI 10.1016/j.tins.2006.06.011; McKhann GM, 2001, ARCH NEUROL-CHICAGO, V58, P1803, DOI 10.1001/archneur.58.11.1803; Pearson Inc., 2001, STAND DAT DEL KAPL E; Psychological Corporation, 1999, WECHSLER ABBREVIATED; Rabin LA, 2016, ARCH CLIN NEUROPSYCH, V31, P206, DOI 10.1093/arclin/acw007; Reynolds C. R., 2006, TEST VERBAL CONCEPTU; Rosen HJ, 2002, NEUROLOGY, V58, P198, DOI 10.1212/WNL.58.2.198; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Shunk A.W., 2006, APPL NEUROPSYCHOL, V13, P275, DOI [10.1207/s15324826an1304_9, DOI 10.1207/S15324826AN1304_9, DOI 10.1207/S15324826AN1304_]; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; Wechsler D., 2009, WECHSLER MEMORY SCAL	35	12	12	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2017	32	3					297	305		10.1093/arclin/acw105			9	Psychology, Clinical; Psychology	Psychology	EU2WN	WOS:000400890700005	28431030	Bronze			2021-06-18	
J	Odgaard, L; Johnsen, SP; Pedersen, AR; Nielsen, JF				Odgaard, Lene; Johnsen, Soren Paaske; Pedersen, Asger Roer; Nielsen, Jorgen Feldbaek			Return to Work After Severe Traumatic Brain Injury: A Nationwide Follow-up Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						craniocerebral trauma; employment; health benefits; injury outcomes; matched-pair analysis; population-based; prevalence; register; rehabilitation	POPULATION; EMPLOYMENT; EPIDEMIOLOGY; UNEMPLOYMENT; PREDICTORS; COHORT	Objective: To determine return to work (RTW) after severe traumatic brain injury (TBI) and to compare long-term labor market attachment (LMA) with the general population. Participants: All persons aged 18 to 64 years who received highly specialized neurorehabilitation after severe TBI between 2004 and 2012 (n = 637) were matched to general population controls on age, sex, preinjury employment status, educational level, and residence (n = 2497). Design: Nationwide follow-up study using weekly records on public assistance benefits. Main Measures: Both RTW and LMA were defined as having no public assistance benefits except education grants/leave. Stable LMA was defined as weeks with LMA of 75% or more. LMA among persons with severe TBI and controls was compared using multivariable conditional logistic regression. Results: RTW mainly occurred within first 2 years after severe TBI, with 30% of the people attempting RTW and 16% achieving stable LMA within 2 years. The prevalence of people with LMA decreased to 11% from 21/2 years to 5 years postinjury. Adjusted odds ratios were 0.01 for LMA up to 2 years postinjury and 0.05 for stable LMA for persons with severe TBI compared with the general population. Conclusion: Both RTW and long-term LMA after severe TBI were low in Denmark when compared with the general population and other countries.	[Odgaard, Lene; Pedersen, Asger Roer; Nielsen, Jorgen Feldbaek] Aarhus Univ, Hammel Neurorehabil Ctr, Res Dept, Voldbyvej 15, DK-8450 Hammel, Denmark; [Odgaard, Lene; Pedersen, Asger Roer; Nielsen, Jorgen Feldbaek] Aarhus Univ, Univ Res Clin, Voldbyvej 15, DK-8450 Hammel, Denmark; [Johnsen, Soren Paaske] Aarhus Univ Hosp, Dept Clin Epidemiol, Aarhus, Denmark	Odgaard, L (corresponding author), Aarhus Univ, Hammel Neurorehabil Ctr, Res Dept, Voldbyvej 15, DK-8450 Hammel, Denmark.; Odgaard, L (corresponding author), Aarhus Univ, Univ Res Clin, Voldbyvej 15, DK-8450 Hammel, Denmark.	lenehell@rm.dk	Nielsen, Jorgen Feldbak/AAR-6384-2021; Odgaard, Lene/AAF-1909-2020	Nielsen, Jorgen Feldbak/0000-0001-5339-171X; Odgaard, Lene/0000-0002-9830-3282			Access Economics, 2009, EC COST SPINAL CORD, P31; Andelic N, 2012, NEUROEPIDEMIOLOGY, V38, P259, DOI 10.1159/000338032; Annoni J M, 1992, Disabil Rehabil, V14, P23; Arango-Lasprilla JC, 2009, PM&R, V1, P41, DOI 10.1016/j.pmrj.2008.07.001; Biering K, 2013, J OCCUP REHABIL, V23, P400, DOI 10.1007/s10926-012-9405-x; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P1400, DOI 10.1016/j.apmr.2007.08.006; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cuthbert JP, 2015, J HEAD TRAUMA REHAB, V30, P160, DOI 10.1097/HTR.0000000000000090; de Kloet AJ, 2013, BRAIN INJURY, V27, P843, DOI 10.3109/02699052.2013.775496; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; Engberg AW, 2007, J HEAD TRAUMA REHAB, V22, P221, DOI 10.1097/01.HTR.0000281837.62226.54; European Commission, 2015, PERS DIS EMPL SOC AF; Eurostat, 2013, EUR COM EUR STAT ACC, V2013th ed., P5; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Hart T, 2014, ARCH PHYS MED REHAB, V95, P2103, DOI 10.1016/j.apmr.2014.07.001; Hjollund NH, 2007, SCAND J PUBLIC HEALT, V35, P497, DOI 10.1080/14034940701271882; Jourdan C, 2013, BRAIN INJURY, V27, P1000, DOI 10.3109/02699052.2013.794971; Jourdan C, 2016, J HEAD TRAUMA REHAB, V31, pE42, DOI 10.1097/HTR.0000000000000147; Ketchum JM, 2012, NEUROREHABILITATION, V30, P13, DOI 10.3233/NRE-2011-0723; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Ministry of Employment, UN INS DENM; Ministry of Employment, ACT LAB MARK POL; Odgaard L, 2015, CLIN EPIDEMIOL, V7, P225, DOI 10.2147/CLEP.S78141; OECD, 2010, SECURITY SYSTEM REFO, P9; OECD, 2010, SICKN DIS WORK BREAK, P49; OECD, 2008, SICKN DIS WORK BREAK, V3, P52; Office of Special Education and Rehabilitative Services Department of Education, 2013, Fed Regist, V78, P27036; Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965; Ponsford JL, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000033; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Saltychev M, 2013, BRAIN INJURY, V27, P1516, DOI 10.3109/02699052.2013.831131; Sjolander A, 2013, STAT MED, V32, P4696, DOI 10.1002/sim.5879; Thygesen LC, 2011, SCAND J PUBLIC HEALT, V39, P12, DOI 10.1177/1403494811399956	38	12	12	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2017	32	3					E57	E64		10.1097/HTR.0000000000000239			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EV4GM	WOS:000401716900013	27323216				2021-06-18	
J	Pinczolits, A; Zdunczyk, A; Dengler, NF; Hecht, N; Kowoll, CM; Dohmen, C; Graf, R; Winkler, MKL; Major, S; Hartings, JA; Dreier, JP; Vajkoczy, P; Woitzik, J				Pinczolits, Alexandra; Zdunczyk, Anna; Dengler, Nora F.; Hecht, Nils; Kowoll, Christina M.; Dohmen, Christian; Graf, Rudolf; Winkler, Maren K. L.; Major, Sebastian; Hartings, Jed A.; Dreier, Jens P.; Vajkoczy, Peter; Woitzik, Johannes			Standard-sampling microdialysis and spreading depolarizations in patients with malignant hemispheric stroke	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Malignant hemispheric stroke; cortical spreading depolarization; spreading depression; cerebral ischemia; microdialysis; glutamate	TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; ANEURYSMAL SUBARACHNOID HEMORRHAGE; INTRACEREBRAL MICRODIALYSIS; PERIINFARCT DEPOLARIZATIONS; ANOXIC DEPOLARIZATION; ONLINE MICRODIALYSIS; DC SHIFTS; DEPRESSION; CORTEX	Spreading depolarizations (SD) occur in high frequency in patients with malignant hemispheric stroke (MHS). Experimentally, SDs cause marked increases in glutamate and lactate, whereas glucose decreases. Here, we studied extracellular brain glutamate, glucose, lactate, pyruvate and the lactate/pyruvate ratio in relationship to SDs after MHS. We inserted two microdialysis probes in peri-infarct tissue at 5 and 15 mm to the infarct in close proximity to a subdural electrode strip. During 2356.6 monitoring hours, electrocorticography (ECoG) revealed 697 SDs in 16 of 18 patients. Ninety-nine SDs in electrically active tissue (spreading depressions, SDd) were single (SDds) and 485 clustered (SDdc), whereas 10 SDs with at least one electrode in electrically inactive tissue (isoelectric SDs, SDi) were single (SDis) and 103 clustered (SDic). More SDs and a significant number of clustered SDs occurred during the first 36 h post-surgery when glutamate was significantly elevated (> 100 mu M). In a grouped analysis, we observed minor glutamate elevations with more than two SDs per hour. Glucose slightly decreased during SDic at 5 mm from the infarct. Directions of SD-related metabolic changes correspond to the experimental setting but the long sampling time of standard microdialysis precludes a more adequate account of the dynamics revealed by ECoG.	[Pinczolits, Alexandra; Zdunczyk, Anna; Dengler, Nora F.; Hecht, Nils; Vajkoczy, Peter; Woitzik, Johannes] Charite, Dept Neurosurg, Berlin, Germany; [Pinczolits, Alexandra; Zdunczyk, Anna; Dengler, Nora F.; Hecht, Nils; Winkler, Maren K. L.; Major, Sebastian; Dreier, Jens P.; Vajkoczy, Peter; Woitzik, Johannes] Charite, Ctr Stroke Res Berlin, Berlin, Germany; [Kowoll, Christina M.; Dohmen, Christian] Univ Cologne, Dept Neurol, Cologne, Germany; [Kowoll, Christina M.; Dohmen, Christian; Graf, Rudolf] Max Planck Inst Neurol Res, Cologne, Germany; [Winkler, Maren K. L.; Major, Sebastian; Dreier, Jens P.] Charite, Dept Neurol, Berlin, Germany; [Hartings, Jed A.] Univ Cincinnati, Coll Med, Dept Neurosurg, Mayfield Clin, Cincinnati, OH 45267 USA	Woitzik, J (corresponding author), Dept Neurosurg, Charite Univ Med Berlin Campus,Hindenburgdamm 30, D-12200 Berlin, Germany.	johannes.woitzik@charite.de	Major, Sebastian/I-1838-2019	Major, Sebastian/0000-0003-0970-1308; Hartings, Jed/0000-0001-8583-3471; Zdunczyk, Anna/0000-0002-9836-6080; Dengler, Nora F./0000-0001-7783-8053	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [DFG-WO 1704/1-1, DFG-WO 1704/1-2, DFG DR 323/5-1]; Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin)Federal Ministry of Education & Research (BMBF) [01 EO 0801]; Era-Net Neuron [01EW1212]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: J. Woitzik received research support from the Deutsche Forschungsgemeinschaft (DFG-WO 1704/1-1; DFG-WO 1704/1-2). A. Pinczolits is funded by the Deutsche Forschungsgemeinschaft (DFG-WO 1704/1-1). JP. Dreier received research support from the Deutsche Forschungsgemeinschaft (DFG DR 323/5-1), Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin, 01 EO 0801), and Era-Net Neuron 01EW1212.	AYAD M, 1994, J NEUROSURG ANESTH, V6, P98; Balanca B, 2017, J CEREBR BLOOD F MET, V37, P1670, DOI 10.1177/0271678X16657571; Burmeister JJ, 2001, ANAL CHEM, V73, P1037, DOI 10.1021/ac0010429; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; Dijkhuizen RM, 1999, BRAIN RES, V840, P194, DOI 10.1016/S0006-8993(99)01769-2; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2007, EXP BIOL MED, V232, P204; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2017, J CEREBR BLOOD F MET, V37, P1595, DOI 10.1177/0271678X16654496; Dreier JP, 2015, NEURON, V86, P902, DOI 10.1016/j.neuron.2015.04.004; Dreier JP, 2013, STROKE, V44, P490, DOI 10.1161/STROKEAHA.112.660589; Dreier JP, 2012, BRAIN, V135, P259, DOI 10.1093/brain/awr303; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; FABRICIUS M, 1993, BRAIN RES, V612, P61, DOI 10.1016/0006-8993(93)91644-8; Farkas E, 2010, NEUROIMAGE, V51, P734, DOI 10.1016/j.neuroimage.2010.02.055; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Guyot LL, 2001, NEUROSCI LETT, V299, P37, DOI 10.1016/S0304-3940(01)01510-5; Hartings JA, 2003, J NEUROSCI, V23, P11602; Hartings JA, 2017, J CEREBR BLOOD F MET, V37, P1571, DOI 10.1177/0271678X16654495; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hecht N, 2016, J CEREBR BLOOD F MET, V36, P1022, DOI 10.1177/0271678X15612487; Hertle DN, 2012, BRAIN, V135, P2390, DOI 10.1093/brain/aws152; Hinzman JM, 2016, J NEUROTRAUM, V33, P1775, DOI 10.1089/neu.2015.4226; Hinzman JM, 2015, EXP NEUROL, V267, P243, DOI 10.1016/j.expneurol.2015.03.014; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Kang EJ, 2013, NEUROBIOL DIS, V52, P204, DOI 10.1016/j.nbd.2012.12.007; Knowland D, 2014, NEURON, V82, P603, DOI 10.1016/j.neuron.2014.03.003; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; LEAO AAP, 1947, J NEUROPHYSIOL, V10, P409, DOI 10.1152/jn.1947.10.6.409; Liu JYW, 2012, BRAIN, V135, P3115, DOI 10.1093/brain/aws147; MARSHALL WH, 1959, PHYSIOL REV, V39, P239; MIES G, 1993, NEUROREPORT, V4, P709, DOI 10.1097/00001756-199306000-00027; Nozari A, 2010, ANN NEUROL, V67, P221, DOI 10.1002/ana.21871; Obrenovitch TP, 1996, ACT NEUR S, V67, P21; Oliveira-Ferreira AI, 2010, J CEREBR BLOOD F MET, V30, P1504, DOI 10.1038/jcbfm.2010.40; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; PULSINELLI WA, 1985, PROG BRAIN RES, V63, P29; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Sahuquillo J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102540; Sakowitz OW, 2013, STROKE, V44, P220, DOI 10.1161/STROKEAHA.112.672352; Somjen GG, 2004, IONS IN THE BRAIN, P338; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; SYMON L, 1977, ACTA NEUROL SCAND, V56, P110; Takano K, 1996, ANN NEUROL, V39, P308, DOI 10.1002/ana.410390307; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Tzingounis AV, 2007, NAT REV NEUROSCI, V8, P935, DOI 10.1038/nrn2274; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; von Bornstadt D, 2015, NEURON, V85, P1117, DOI 10.1016/j.neuron.2015.02.007; WAHL F, 1994, J NEUROCHEM, V63, P1003; Woitzik J, 2014, STROKE, V45, P1183, DOI 10.1161/STROKEAHA.113.004475; Woitzik J, 2013, NEUROLOGY, V80, P1095, DOI 10.1212/WNL.0b013e3182886932; Woitzik J, 2012, J CEREBR BLOOD F MET, V32, P203, DOI 10.1038/jcbfm.2011.169	56	12	12	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2017	37	5					1896	1905		10.1177/0271678X17699629			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	ET8CG	WOS:000400525200025	28350195	Bronze, Green Published			2021-06-18	
J	Walker, WC; Franke, LM; Sima, AP; Cifu, DX				Walker, William C.; Franke, Laura M.; Sima, Adam P.; Cifu, David X.			Symptom Trajectories After Military Blast Exposure and the Influence of Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; concussion; diagnosis; explosive blast; longitudinal studies; military injury; military personnel; postconcussion symptoms; symptom assessment; veterans	POSTTRAUMATIC-STRESS-DISORDER; SPORTS-RELATED CONCUSSION; OPERATION ENDURING FREEDOM; IRAQI FREEDOM; COMBAT VETERANS; SOLDIERS; QUESTIONNAIRE; RELIABILITY; PERSONNEL; ACCURACY	Background: Blast-related mild traumatic brain injury (blast mTBI) is a signature wound of recent US military conflicts in the Middle East, but the relatedness of postconcussive symptoms (PCS) to the blast mTBI is unclear, and longitudinal symptom data are sparse. Objectives: To characterize postdeployment symptom levels and trajectories and to determine relationship to blast mTBI. Methods: A total of 216 participants within 2 years of blast exposure during deployment underwent structured interviews or algorithmic questionnaires for blast mTBI. Detailed symptom inventories for PCS, pain, posttraumatic stress disorder, and depression were taken serially at enrollment, 6 months, and 12 months later. Repeated-measure analysis of variance models were built. Results: Up to 50% of participants had at least 1 high-grade blast mTBI (with posttraumatic amnesia), 31% had low-grade only, and 19% had neither. Within the entire cohort, all 4 composite symptom scores started high and stayed unchanged. Between blast mTBI groups, symptom scores differed at every time point with some evidence of convergence over time. The PCS groups, different by definition to start, diverged further over time with those initially more symptomatic becoming relatively more so. Conclusions: History of blast mTBI accompanied by posttraumatic amnesia is associated with greater nonspecific symptoms after deployment, and prognosis for improvement when symptoms are prominent is poor.	[Walker, William C.; Franke, Laura M.; Cifu, David X.] Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Walker, William C.; Franke, Laura M.] Def & Vet Brain Injury Ctr, Richmond, VA USA; [Walker, William C.; Franke, Laura M.; Cifu, David X.] Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA; [Sima, Adam P.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23298 USA	Walker, WC (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Richmond, VA 23298 USA.	wwalker@mcvh-vcu.edu	Franke, Lude/P-7036-2016	Franke, Lude/0000-0002-5159-8802; Cifu, David/0000-0003-1600-9387; Sima, Adam/0000-0001-8426-9987	Defense and Veterans Brain Injury Center, US Army Medical Research and Material Command; US Army Medical Research & Material Command, Congressionally Directed Medical Research Program (CDMRP) grant [W91ZSQ8118N6200001]	This material is based upon work supported with resources and the use of facilities at the Hunter Holmes McGuire Veterans Affairs Medical Center in Richmond, Virginia; and is based upon work supported in part by the Defense and Veterans Brain Injury Center, US Army Medical Research and Material Command.; This study was supported by a grant from US Army Medical Research & Material Command, Congressionally Directed Medical Research Program (CDMRP) grant# W91ZSQ8118N6200001; Epidemiological Study of Mild Traumatic Brain Injury Sequelae Caused by Blast Exposure during Operations Iraq Freedom and Enduring Freedom.	Andrikopoulos J, 2014, JAMA NEUROL, V71, P654, DOI 10.1001/jamaneurol.2013.6408; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0; Betthauser LM, 2012, NEUROPSYCHOL REV, V22, P35, DOI 10.1007/s11065-012-9191-4; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Centers for Disease Control and Prevention, DOD VA COD PROP DOD; Cifu D, 2011, OVERCOMING POSTDEPLO; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Cripps A, 2013, J SPORT REHABIL, V22, P67, DOI 10.1123/jsr.22.1.67; Defense and Veterans Brain Injury Center (DVBIC), DOD WORLDW NUMB TBI; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Dimou S, 2014, J NEUROTRAUM, V31, P413, DOI 10.1089/neu.2013.3050; Dretsch MN, 2015, J NEUROTRAUM, V32, P1217, DOI 10.1089/neu.2014.3637; Edwards LJ, 2008, STAT MED, V27, P6137, DOI 10.1002/sim.3429; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fitzmaurice GM, 2012, APPL LONGITUDINAL AN; Harvey AG, 2002, PSYCHOL BULL, V128, P886, DOI 10.1037//0033-2909.128.6.886; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kelley CL, 2014, PSYCHOL SERV, V11, P229, DOI 10.1037/a0034892; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Macera CA, 2012, J REHABIL RES DEV, V49, P1197, DOI 10.1682/JRRD.2011.07.0131; MacGregor AJ, 2013, J HEAD TRAUMA REHAB, V28, P59, DOI 10.1097/HTR.0b013e3182596382; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Meyer KS, 2010, PSYCHIAT CLIN N AM, V33, P783, DOI 10.1016/j.psc.2010.08.007; Nelson NW, 2015, BRIT J PSYCHIAT, V206, P237, DOI 10.1192/bjp.bp.114.149096; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Pigeon WR, 2013, J PSYCHOSOM RES, V75, P546, DOI 10.1016/j.jpsychores.2013.09.004; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Reijnen A, 2015, EUR PSYCHIAT, V30, DOI 10.1016/j.eurpsy.2014.05.003; Scherer M, 2007, MIL MED, V172, P731, DOI 10.7205/MILMED.172.7.731; Silver JM, 2014, PSYCHIAT CLIN N AM, V37, P91, DOI 10.1016/j.psc.2013.11.001; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Waldron-Perrine B, 2014, MIL MED, V179, P856, DOI 10.7205/MILMED-D-13-00282; Walker WC, 2015, J NEUROTRAUM, V32, P464, DOI 10.1089/neu.2014.3433; Walker WC, 2014, J REHABIL RES DEV, V51, P1203, DOI 10.1682/JRRD.2013.12.0271; Walker WC, 2013, J HEAD TRAUMA REHAB, V28, P68, DOI 10.1097/HTR.0b013e318255dfd0; Wares JR, 2015, J REHABIL RES DEV, V52, P591, DOI 10.1682/JRRD.2014.08.0197; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298	47	12	12	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2017	32	3					E16	E26		10.1097/HTR.0000000000000251			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EV4GM	WOS:000401716900009	27603760				2021-06-18	
J	Farina, B; Di Sorbo, G; Chambery, A; Caporale, A; Leoni, G; Russo, R; Mascanzoni, F; Raimondo, D; Fattorusso, R; Ruvo, M; Doti, N				Farina, Biancamaria; Di Sorbo, Gianluigi; Chambery, Angela; Caporale, Andrea; Leoni, Guido; Russo, Rosita; Mascanzoni, Fabiola; Raimondo, Domenico; Fattorusso, Roberto; Ruvo, Menotti; Doti, Nunzianna			Structural and biochemical insights of CypA and AIF interaction	SCIENTIFIC REPORTS			English	Article							APOPTOSIS-INDUCING FACTOR; CELL-DEATH; CYCLOPHILIN; PROTEIN; BINDING; CATALYSIS; NETWORK	The Cyclophilin A (CypA)/Apoptosis Inducing Factor (AIF) complex is implicated in the DNA degradation in response to various cellular stress conditions, such as oxidative stress, cerebral hypoxia-ischemia and traumatic brain injury. The pro-apoptotic form of AIF (AIF(Delta 1-121)) mainly interacts with CypA through the amino acid region 370-394. The AIF(370-394) synthetic peptide inhibits complex formation in vitro by binding to CypA and exerts neuroprotection in a model of glutamate-mediated oxidative stress. Here, the binding site of AIF(Delta 1-121) and AIF(370-394) on CypA has been mapped by NMR spectroscopy and biochemical studies, and a molecular model of the complex has been proposed. We show that AIF(370-394) interacts with CypA on the same surface recognized by AIF(Delta 1-121) protein and that the region is very close to the CypA catalytic pocket. Such region partially overlaps with the binding site of cyclosporin A (CsA), the strongest catalytic inhibitor of CypA. Our data point toward distinct CypA structural determinants governing the inhibitor selectivity and the differential biological effects of AIF and CsA, and provide new structural insights for designing CypA/AIF selective inhibitors with therapeutic relevance in neurodegenerative diseases.	[Farina, Biancamaria; Di Sorbo, Gianluigi; Caporale, Andrea; Mascanzoni, Fabiola; Ruvo, Menotti; Doti, Nunzianna] CNR, Ist Biostrutture & Bioimmagini, Via Mezzocannone 16, I-80134 Naples, Italy; [Farina, Biancamaria; Di Sorbo, Gianluigi; Caporale, Andrea; Mascanzoni, Fabiola; Ruvo, Menotti; Doti, Nunzianna] CIRPEB, Via Mezzocannone 16, I-80134 Naples, Italy; [Di Sorbo, Gianluigi; Chambery, Angela; Russo, Rosita; Fattorusso, Roberto] Univ Campania Luigi Vanvitelli, Dipartimento Sci & Tecnol Ambientali Biol & Farma, Via Vivaldi 46, I-81100 Caserta, Italy; [Leoni, Guido] Nouscom Srl, Via Castel Romano 100, I-00128 Rome, Italy; [Raimondo, Domenico] Sapienza Univ Roma, Viale Regina Elena 324, I-00161 Rome, Italy	Doti, N (corresponding author), CNR, Ist Biostrutture & Bioimmagini, Via Mezzocannone 16, I-80134 Naples, Italy.; Doti, N (corresponding author), CIRPEB, Via Mezzocannone 16, I-80134 Naples, Italy.	nunzianna.doti@cnr.it	Leoni, Guido/AAX-6544-2020; Doti, Nunzianna/ABC-9948-2020	Leoni, Guido/0000-0003-0502-1962; raimondo, domenico/0000-0002-1780-7295; Russo, Rosita/0000-0002-2235-6302; Caporale, Andrea/0000-0002-7827-3960	European Grid Initiative (EGI) through the national GRID Initiative of Belgium [261572]; European Grid Initiative (EGI) through the national GRID Initiative of France [261572]; European Grid Initiative (EGI) through the national GRID Initiative of Italy [261572]; European Grid Initiative (EGI) through the national GRID Initiative of Germany [261572]; European Grid Initiative (EGI) through the national GRID Initiative of Netherlands [261572]; European Grid Initiative (EGI) through the national GRID Initiative of Poland [261572]; European Grid Initiative (EGI) through the national GRID Initiative of Portugal [261572]; European Grid Initiative (EGI) through the national GRID Initiative of Spain [261572]; European Grid Initiative (EGI) through the national GRID Initiative of UK [261572]; European Grid Initiative (EGI) through the national GRID Initiative of South Africa [261572]; European Grid Initiative (EGI) through the national GRID Initiative of Malaysia [261572]; European Grid Initiative (EGI) through the national GRID Initiative of Taiwan [261572]; Latin America GRID infrastructure via the Gisela project	The authors thank Leopoldo Zona, Maurizio Amendola, Giouse Sorrentino and Luca De Luca for the technical assistance. We also thanks the group of Dr. Valentina Bonetto of the "Department of Molecular Biochemistry and Pharmacology" IRCCS "Mario Negri", Milano, Italy, that kindly provided the construct pCMV6-AC-Myc-CypA<SUP>R55A</SUP> used as template for the amplification of cypA<SUP>R55A</SUP> gene. The WeNMR project (European FP7 eInfrastructure grant, contract no. 261572, www.wenmr.eu), supported by the European Grid Initiative (EGI) through the national GRID Initiatives of Belgium, France, Italy, Germany, the Netherlands, Poland, Portugal, Spain, UK, South Africa, Malaysia, Taiwan, the Latin America GRID infrastructure via the Gisela project and the US Open Science Grid (OSG) are acknowledged for the use of web portals, computing and storage facilities.	Artus C, 2010, EMBO J, V29, P1585, DOI 10.1038/emboj.2010.43; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Caporale A, 2017, J PEPT SCI, V23, P272, DOI 10.1002/psc.2977; Caporale A, 2016, J BIOMOL SCREEN, V21, P701, DOI 10.1177/1087057116650402; Doshi U, 2016, P NATL ACAD SCI USA, V113, P4735, DOI 10.1073/pnas.1523573113; Doti N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.518; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Fanghanel J, 2003, BIOPHYS CHEM, V100, P351, DOI 10.1016/S0301-4622(02)00292-2; Farina B, 2013, BBA-PROTEINS PROTEOM, V1834, P1572, DOI 10.1016/j.bbapap.2013.04.012; Fuchs Y, 2011, CELL, V147, P742, DOI 10.1016/j.cell.2011.10.033; Fukui M, 2009, EUR J PHARMACOL, V617, P1, DOI 10.1016/j.ejphar.2009.06.059; Galat A, 2003, CURR TOP MED CHEM, V3, P1315, DOI 10.2174/1568026033451862; Hangen E, 2015, MOL CELL, V58, P1001, DOI 10.1016/j.molcel.2015.04.020; Houry WA, 1998, P NATL ACAD SCI USA, V95, P4299, DOI 10.1073/pnas.95.8.4299; Keller RLJ, 2004, COMPUTER AIDED RESON; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kozakov D, 2015, NAT PROTOC, V10, P733, DOI 10.1038/nprot.2015.043; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Leone M, 2004, BIOCHEMISTRY-US, V43, P6043, DOI 10.1021/bi036261d; Li GH, 2003, J AM CHEM SOC, V125, P15028, DOI 10.1021/ja0367851; McInnes C, 2000, PROTEIN ENG, V13, P143, DOI 10.1093/protein/13.3.143; Mckee CJ, 2009, METHODS, V47, P304, DOI 10.1016/j.ymeth.2008.10.023; NERI P, 1991, FEBS LETT, V290, P195, DOI 10.1016/0014-5793(91)81258-A; Nigro P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.410; Oppermann S, 2014, J PHARMACOL EXP THER, V350, P273, DOI 10.1124/jpet.114.213777; Ottiger M, 1997, J MOL BIOL, V272, P64, DOI 10.1006/jmbi.1997.1220; Ow YLP, 2008, NAT REV MOL CELL BIO, V9, P532, DOI 10.1038/nrm2434; Perkins JR, 2010, STRUCTURE, V18, P1233, DOI 10.1016/j.str.2010.08.007; Piao CS, 2012, NEUROBIOL DIS, V46, P745, DOI 10.1016/j.nbd.2012.03.018; Polster BM, 2013, NEUROCHEM INT, V62, P695, DOI 10.1016/j.neuint.2012.12.002; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; Severino V, 2011, J PROTEOME RES, V10, P3212, DOI 10.1021/pr200244f; Thal SE, 2011, NEUROSCI LETT, V499, P1, DOI 10.1016/j.neulet.2011.05.016; van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014; Wang YF, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2000902; Williamson MP, 2013, PROG NUCL MAG RES SP, V73, P1, DOI 10.1016/j.pnmrs.2013.02.001; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Zhu CL, 2007, J EXP MED, V204, P1741, DOI 10.1084/jem.20070193	42	12	15	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	APR 25	2017	7								1138	10.1038/s41598-017-01337-8			13	Multidisciplinary Sciences	Science & Technology - Other Topics	ET2LL	WOS:000400104200027	28442737	DOAJ Gold, Green Published			2021-06-18	
J	Chen, YH; Huang, EYK; Kuo, TT; Hoffer, BJ; Miller, J; Chou, YC; Chiang, YH				Chen, Yuan-Hao; Huang, Eagle Yi-Kung; Kuo, Tung-Tai; Hoffer, Barry J.; Miller, Jonathan; Chou, Yu-Ching; Chiang, Yung-Hsiao			DOPAMINE RELEASE IN THE NUCLEUS ACCUMBENS IS ALTERED FOLLOWING TRAUMATIC BRAIN INJURY	NEUROSCIENCE			English	Article						dopamine; nucleus accumbens; traumatic brain injury; fast-scan cyclic voltammetry	VENTRAL STRIATAL COMPARTMENTS; FLUID PERCUSSION INJURY; TOPOGRAPHICAL ORGANIZATION; EFFERENT PROJECTIONS; BASAL GANGLIA; RAT; REWARD; NEURONS; CORTEX; SHELL	Mild-to-severe traumatic brain injury (TBI) is frequently associated with prolonged dysfunction of reward circuitry, including motivation and salience, which suggests alterations of dopamine (DA) processing within the core and shell of the nucleus accumbens (NAC). Using fast -scan cyclic voltammetry in a rodent model of traumatic brain injury, we found that stimulus-evoked DA release is distinct in the core and shell of the NAC, with the shell being less responsive to tonic stimulation and more sensitive to the number of pulses when phasic stimulation is applied. Exposure to TBI was associated with major changes in both release and reuptake of DA in both the core and shell of NAC, with greater changes seen in the core. These alterations evolved over time, becoming most severe 1-2 weeks after injury with subsequent recovery, and the extent and progression of these abnormalities was correlated with severity of injury. Taken together, these data support behavior and anatomical studies suggesting the NAC core and striatum may subserve parallel functions, whereas the shell is distinct. These data offer a unique window on how different neurological systems respond to TBI and may help explain affective and cognitive changes that are seen. (C) 2017 IBRO. Published by Elsevier Ltd. All rights reserved.	[Chen, Yuan-Hao] Natl Def Med Ctr, Triserv Gen Hosp, Dept Neurol Surg, Taipei, Taiwan; [Huang, Eagle Yi-Kung] Natl Def Med Ctr, Dept Pharmacol, Taipei, Taiwan; [Kuo, Tung-Tai] Natl Taipei Univ Technol, Grad Inst Comp & Commun Engn, Taipei, Taiwan; [Hoffer, Barry J.; Miller, Jonathan] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH USA; [Chou, Yu-Ching] Natl Def Med Ctr, Sch Publ Hlth, Taipei, Taiwan; [Hoffer, Barry J.; Chiang, Yung-Hsiao] Taipei Med Univ, Grad Program Neuroregenerat, Taipei, Taiwan	Chen, YH (corresponding author), Natl Def Med Ctr, Triserv Gen Hosp, Dept Neurol Surg, Taipei, Taiwan.	chenyh178@gmail.com	Chen, Yuan-Hao/U-6870-2019	Chen, Yuan-Hao/0000-0002-0570-4328	Ministry of Science and Technology of Taiwan, ROC [NSC102-2314-13-016-030-MY3, NSC105-2314-8-016-001-MY3]; Tri-Service General Hospital of Taiwan [TSGH-C105-075, TSGH-C105-078]; National Defense Medical Center [MAB-105-105]; Medical Research Project grants; George R. and Constance P. Lincoln family	This work was supported by the Ministry of Science and Technology of Taiwan, ROC under grant NSC102-2314-13-016-030-MY3, NSC105-2314-8-016-001-MY3, and by Medical Research Project grants; TSGH-C105-075 and TSGH-C105-078 from the Tri-Service General Hospital of Taiwan and MAB-105-105 from National Defense Medical Center. And this project was also supported in part by philanthropic support from the George R. and Constance P. Lincoln family.	ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Alexander GE, 1990, PROG BRAIN RES, V85, P85; Alheid GF, 2003, ANN NY ACAD SCI, V985, P185; BERENDSE HW, 1990, J COMP NEUROL, V299, P187, DOI 10.1002/cne.902990206; BERENDSE HW, 1992, J COMP NEUROL, V316, P314, DOI 10.1002/cne.903160305; Berridge KC, 2012, EUR J NEUROSCI, V35, P1124, DOI 10.1111/j.1460-9568.2012.07990.x; Bjork JM, 2009, J NEUROTRAUM, V26, P1077, DOI 10.1089/neu.2008-0849; Bogner J, 2015, BRAIN INJURY, V29, P905, DOI 10.3109/02699052.2015.1005136; BURSTEIN R, 1989, BRAIN RES, V497, P149, DOI 10.1016/0006-8993(89)90981-5; Cacciapaglia F, 2012, NEUROPHARMACOLOGY, V62, P2050, DOI 10.1016/j.neuropharm.2011.12.027; Chen YH, 2008, FASEB J, V22, P261, DOI 10.1096/fj.07-8797com; Chen YH, 2015, CELL TRANSPLANT, V24, P2113, DOI 10.3727/096368914X683584; CLIFFER KD, 1991, J NEUROSCI, V11, P852; Dreyer JK, 2010, J NEUROSCI, V30, P14273, DOI 10.1523/JNEUROSCI.1894-10.2010; Floresco SB, 2015, ANNU REV PSYCHOL, V66, P25, DOI 10.1146/annurev-psych-010213-115159; Good CH, 2013, J NEUROSCI, V 33, P16853, DOI 10.1523/JNEUROSCI.1844-13.2013; Good CH, 2011, FASEB J, V25, P1333, DOI 10.1096/fj.10-173625; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; Hammond FM, 2014, J HEAD TRAUMA REHAB, V29, P391, DOI 10.1097/01.HTR.0000438116.56228.de; HEIMER L, 1991, NEUROSCIENCE, V41, P89, DOI 10.1016/0306-4522(91)90202-Y; Huang EYK, 2014, BEHAV BRAIN RES, V267, P156, DOI 10.1016/j.bbr.2014.03.033; Huang EYK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086354; HURLEY KM, 1991, J COMP NEUROL, V308, P249, DOI 10.1002/cne.903080210; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; KAWAGOE KT, 1993, J NEUROSCI METH, V48, P225, DOI 10.1016/0165-0270(93)90094-8; Kelley AE, 1999, ANN NY ACAD SCI, V877, P71, DOI 10.1111/j.1749-6632.1999.tb09262.x; Malenka R.C., 2009, MOL NEUROPHARMACOLOG, P364; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; MOGENSON GJ, 1980, PROG NEUROBIOL, V14, P69, DOI 10.1016/0301-0082(80)90018-0; Pan WX, 2005, J NEUROSCI, V25, P6235, DOI 10.1523/JNEUROSCI.1478-05.2005; Ponsford JL, 2013, J NEUROTRAUM, V30, P1498, DOI 10.1089/neu.2012.2843; Sabeti J, 2002, J NEUROSCI METH, V121, P41, DOI 10.1016/S0165-0270(02)00229-7; Saddoris Michael P, 2013, Front Biosci (Elite Ed), V5, P273; SESACK SR, 1989, J COMP NEUROL, V290, P213, DOI 10.1002/cne.902900205; Tsai HC, 2009, SCIENCE, V324, P1080, DOI 10.1126/science.1168878; Walder B, 2013, J NEUROTRAUM, V30, P1934, DOI 10.1089/neu.2013.2955; West EA, 2016, J NEUROSCI, V36, P1128, DOI 10.1523/JNEUROSCI.2976-15.2016; Wightman RM, 2002, J NEUROCHEM, V82, P721, DOI 10.1046/j.1471-4159.2002.01005.x; ZABORSZKY L, 1985, NEUROSCIENCE, V14, P427, DOI 10.1016/0306-4522(85)90302-1; ZAHM DS, 1992, NEUROSCIENCE, V50, P751, DOI 10.1016/0306-4522(92)90202-D	41	12	13	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	APR 21	2017	348						180	190		10.1016/j.neuroscience.2017.02.001			11	Neurosciences	Neurosciences & Neurology	ER2VF	WOS:000398651200017	28196657				2021-06-18	
J	Abas, S; Erdozain, AM; Keller, B; Rodriguez-Arevalo, S; Callado, LF; Garcia-Sevilla, JA; Escolano, C				Abas, Sonia; Erdozain, Amaia M.; Keller, Benjamin; Rodriguez-Arevalo, Sergio; Callado, Luis F.; Garcia-Sevilla, Jesus A.; Escolano, Carmen			Neuroprotective Effects of a Structurally New Family of High Affinity Imidazoline l(2) Receptor Ligands	ACS CHEMICAL NEUROSCIENCE			English	Article						(2-Imidazolin-4-yl)phosphonates; imidazoline I-2 receptors; neuroprotection	IDAZOXAN BINDING-SITES; TRAUMATIC BRAIN-INJURY; APOPTOTIC PATHWAYS; ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; PREFRONTAL CORTEX; POSTMORTEM BRAIN; SUICIDE VICTIMS; OPIATE ABUSERS; P25	The imidazoline l(2) receptors (I-2-IRs) are widely distributed in the brain, and l(2)-IR ligancls may have therapeutic potential as neuroprotective agents. Since structural data for l(2)-IR remains unknown, the discovery of selective l(2)-IR ligands devoid of alpha(2)-drenoceptor (alpha(2)-AR) affinity is likely to provide valuable tools in defining the pharmacological characterization of these receptors. We report the pharmacological characterization of a new family of (2-imidazolin-4-yl)phosphonates. Radioligand binding studies showed that they displayed a higher affinity for I-2-IRs than idazoxan, and high l(2)/alpha(2) selectivity. In vivo studies in mice showed that acute treatments with lb and 2c significantly increased p-FADD/FADD ratio (an index of cell survival) in the hippocampus when compared with vehicle treated controls. Additionally, acute and repeated treatments with 2c, but not with lb, markedly reduced hippocampal p35 cleavage into neurotoxic p25. The present results indicate a neuroprotective potential of (2-imidazolin-4-yl)phosphonates acting at l(2)-IRs.	[Abas, Sonia; Rodriguez-Arevalo, Sergio; Escolano, Carmen] Univ Barcelona, Dept Pharmacol Toxicol & Med Chem, Fac Pharm & Food Sci, Lab Med Chem,Associated Unit CSIC, Av Joan 23 27-31, E-08028 Barcelona, Spain; [Abas, Sonia; Rodriguez-Arevalo, Sergio; Escolano, Carmen] Univ Barcelona, Inst Biomed IBUB, Av Joan 23 27-31, E-08028 Barcelona, Spain; [Erdozain, Amaia M.; Callado, Luis F.] Univ Basque Country, Dept Pharmacol, UPV EHU, E-48940 Leioa, Bizkaia, Spain; [Erdozain, Amaia M.; Callado, Luis F.] CIBERSAM, Ctr Invest Biomed Red Salud Mental, Madrid, Spain; [Keller, Benjamin; Garcia-Sevilla, Jesus A.] Univ Balearic Isl UIB, ILab Neuropharmacol, IUNICS IdISPa, Cra Valldemossa Km 7-5, E-07122 Palma De Mallorca, Spain	Escolano, C (corresponding author), Univ Barcelona, Dept Pharmacol Toxicol & Med Chem, Fac Pharm & Food Sci, Lab Med Chem,Associated Unit CSIC, Av Joan 23 27-31, E-08028 Barcelona, Spain.; Escolano, C (corresponding author), Univ Barcelona, Inst Biomed IBUB, Av Joan 23 27-31, E-08028 Barcelona, Spain.	cescolano@ub.edu	Blanco, Leire/O-5114-2017; Callado, Luis F/A-7024-2008; Erdozain, Amaia/AAD-1883-2021; escolano, carmen/F-3073-2016; Erdozain, Amaia M/Q-9664-2018	Callado, Luis F/0000-0001-9941-012X; escolano, carmen/0000-0002-9117-8239; Abas Prades, Sonia/0000-0002-3005-3539; Erdozain, Amaia Maite/0000-0003-0207-9122	Ministerio de Economia y Competitividad and Fondo Europeo de Desarrollo Regional (MINECO-FEDER) [SAF2011-29918, SAF-201348586-R, SAF2014-55903-R, SAF2016-77703-C2-1-R, BFU2015-66030-R]; Generalitat de CatalunyaGeneralitat de Catalunya [2014-SGR-0155]; Basque GovernmentBasque Government [IT616/13]; Redes Ternaticas de Investigacion Cooperativa en Salud - Red de Trastornos Adictivos (RETICS-RTA) [RD12/0028/0011]; Instituto de Salud Carlos III (ISCIII, MINECO/FEDER) SpainInstituto de Salud Carlos III; Institut d'Estudis Catalans (Barcelona, Catalonia, Spain); Basque GovernmentBasque Government	This study was supported by the Ministerio de Economia y Competitividad and Fondo Europeo de Desarrollo Regional (MINECO-FEDER) (Projects SAF2011-29918, SAF-201348586-R, SAF2014-55903-R, SAF2016-77703-C2-1-R, BFU2015-66030-R), Generalitat de Catalunya (Grant 2014-SGR-0155), and the Basque Government (IT616/13). B.K. was supported by a predoctoral contract from Redes Ternaticas de Investigacion Cooperativa en Salud - Red de Trastornos Adictivos (RETICS-RTA, RD12/0028/0011), Instituto de Salud Carlos III (ISCIII, MINECO/FEDER), Spain. JAG.-S. is a member of the Institut d'Estudis Catalans (Barcelona, Catalonia, Spain). A.M.E. was recipient of a postdoctoral fellowship from the Basque Government.	Abas S, 2015, TETRAHEDRON, V71, P2872, DOI 10.1016/j.tet.2015.03.065; Alvaro-Bartolome M, 2011, NEUROSCIENCE, V196, P1, DOI 10.1016/j.neuroscience.2011.08.074; BOUSQUET P, 1984, J PHARMACOL EXP THER, V230, P232; Callado LF, 2004, J NEUROL NEUROSUR PS, V75, P785, DOI 10.1136/jnnp.2003.020446; CHAN SLF, 1994, BRIT J PHARMACOL, V112, P1065, DOI 10.1111/j.1476-5381.1994.tb13191.x; Craven JA, 1997, CLIN EXP PHARMACOL P, V24, P204, DOI 10.1111/j.1440-1681.1997.tb01808.x; Dardonville C, 2004, MED RES REV, V24, P639, DOI 10.1002/med.20007; Ernsberger P, 1995, Ann N Y Acad Sci, V763, P22, DOI 10.1111/j.1749-6632.1995.tb32388.x; Garau C, 2013, J PSYCHOPHARMACOL, V27, P123, DOI 10.1177/0269881112450785; Garcia-Fuster MJ, 2008, NEUROSCIENCE, V157, P105, DOI 10.1016/j.neuroscience.2008.09.002; Garcia-Sevilla JA, 1998, NEUROSCI LETT, V247, P95, DOI 10.1016/S0304-3940(98)00265-1; GarciaSevilla JA, 1996, ARCH GEN PSYCHIAT, V53, P803; GargalidisMoudanos C, 1997, NEUROCHEM INT, V30, P31, DOI 10.1016/S0197-0186(96)00035-6; Grijalba B, 1996, EUR J PHARMACOL, V310, P83, DOI 10.1016/0014-2999(96)00381-0; ILLIEVICH UM, 1994, ANESTH ANALG, V78, P905; Keller B, 2016, J PSYCHOPHARMACOL, V30, P875, DOI 10.1177/0269881116652579; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Li JX, 2011, EUR J PHARMACOL, V658, P49, DOI 10.1016/j.ejphar.2011.02.038; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MartinGomez JI, 1996, NEUROREPORT, V7, P1393, DOI 10.1097/00001756-199605310-00013; McDonald GR, 2010, PHARMACOL RES, V62, P475, DOI 10.1016/j.phrs.2010.09.001; MEANA JJ, 1993, BIOL PSYCHIAT, V34, P498; Mitsios N, 2007, BRAIN PATHOL, V17, P11, DOI 10.1111/j.1750-3639.2006.00031.x; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Ramos-Miguel A, 2009, NEUROSCIENCE, V161, P23, DOI 10.1016/j.neuroscience.2009.03.028; Ramos-Miguel A, 2010, EUR NEUROPSYCHOPHARM, V20, P49, DOI 10.1016/j.euroneuro.2009.08.005; Regunathan S, 1999, ANN NY ACAD SCI, V881, P410, DOI 10.1111/j.1749-6632.1999.tb09389.x; RUIZ J, 1993, NEUROSCI LETT, V160, P109, DOI 10.1016/0304-3940(93)90925-B; Thorn DA, 2012, BRIT J PHARMACOL, V166, P1936, DOI 10.1111/j.1476-5381.2012.01894.x; Yousuf MA, 2016, J NEUROCHEM, V138, P317, DOI 10.1111/jnc.13620	32	12	14	0	4	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	APR	2017	8	4					737	742		10.1021/acschemneuro.6b00426			6	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	ET0QL	WOS:000399968400008	28029766				2021-06-18	
J	Albrecht, JS; Mullins, DC; Smith, GS; Rao, V				Albrecht, Jennifer S.; Mullins, Daniel C.; Smith, Gordon S.; Rao, Vani			Psychotropic Medication Use among Medicare Beneficiaries Following Traumatic Brain Injury	AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY			English	Article						Traumatic brain injury; psychotropic medications; older adults; neuropsychiatric disorders	OLDER-ADULTS; PHARMACOLOGICAL MANAGEMENT; UNITED-STATES; DEPRESSION; FALLS; PATTERNS; RISK; CARE; AGE	Objectives: To characterize psychotropic medication use before and after traumatic brain injury (TBI) hospitalization among older adults. A secondary objective is to determine how receipt of indicated pharmacologic treatment for anxiety and post-traumatic stress disorder (PTSD) differs following TBI. Design: Retrospective cohort. Setting: United States. Participants: Medicare beneficiaries aged >= 65 years hospitalized with TBI between 2006 and 2010 with continuous drug coverage for 12 months before and after TBI (N = 60,276). Measurements: We obtained monthly psychotropic medication use by drug class and specific drugs from Medicare Part D drug event files. ICD-9 codes were used to define anxiety (300.0x) and PTSD (309.81). Results: Average monthly prevalence of psychotropic medication use among all patients hospitalized for TBI was 44.8%; antidepressants constituted 73%. Prevalence of psychotropic medication use increased from 2006 to 2010. Following TBI, psychotropic medication use increased slightly (OR: 1.05; 95% CI: 1.03, 1.06.) Tricyclic antidepressant use decreased post-TBI (OR: 0.76; 95% CI: 0.73, 0.79) whereas use of the sedating antidepressants mirtazapine (OR: 1.31; 95% CI: 1.25, 1.37) and trazadone (OR: 1.11; 95% CI: 1.06, 1.17) increased. Antipsychotic (OR: 1.15; 95% CI: 1.12, 1.19) use also increased post-TBI. Beneficiaries newly diagnosed with anxiety (OR: 0.42; 95% CI: 0.36, 0.48) and/or PTSD (OR: 0.39; 95% CI: 0.18, 0.84) post-TBI were less likely to receive indicated pharmacologic treatment. Conclusions: Older adults hospitalized with TBI have a high prevalence of psychotropic medication use yet are less likely to receive indicated pharmacological treatment for newly diagnosed anxiety and PTSD following TBI.	[Albrecht, Jennifer S.; Smith, Gordon S.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, MSTF 334C,10 S Pine St, Baltimore, MD 21201 USA; [Mullins, Daniel C.] Univ Maryland, Sch Pharm, Dept Pharmaceut Hlth Serv Res, MSTF 334C,10 S Pine St, Baltimore, MD 21201 USA; [Smith, Gordon S.] Univ Maryland, Natl Study Ctr Trauma & Emergency Med Serv, Shock Trauma & Anesthesiol Res Organized Res Ctr, MSTF 334C,10 S Pine St, Baltimore, MD 21201 USA; [Rao, Vani] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA	Albrecht, JS (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, MSTF 334C,10 S Pine St, Baltimore, MD 21201 USA.	jalbrecht@epi.umaryland.edu		Albrecht, Jennifer/0000-0003-4838-2274; Smith, Gordon/0000-0002-2911-3071	AHRQUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [1K01HS024560]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AA18707]; DODUnited States Department of Defense [W81XWH-13-1-0469]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K01HS024560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM104942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA018707, R01AA018313] Funding Source: NIH RePORTER	Dr. Albrecht was supported by AHRQ grant 1K01HS024560. Dr. Smith was supported by NIH grant R01AA18707. Dr. Rao was supported by DOD grant W81XWH-13-1-0469. The authors declare no conflicts of interest.	Akincigil A, 2011, J AM GERIATR SOC, V59, P1042, DOI 10.1111/j.1532-5415.2011.03447.x; Albrecht JS, 2016, J HEAD TRAUMA REHAB, V31, pE1, DOI 10.1097/HTR.0000000000000190; Albrecht JS, 2015, J NEUROTRAUM, V32, P1223, DOI 10.1089/neu.2014.3651; Centers for Medicare and Medicaid Services, 2012, CHRON COND MED BEN C; Dams-O'Connor K, 2016, J AM GERIATR SOC, V64, P844, DOI 10.1111/jgs.14014; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Harvey LA, 2012, INJURY, V43, P1821, DOI 10.1016/j.injury.2012.07.188; Jorge RE, 2014, PSYCHIAT CLIN N AM, V37, P13, DOI 10.1016/j.psc.2013.11.005; Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766; Klap R, 2003, AM J GERIAT PSYCHIAT, V11, P517, DOI 10.1176/appi.ajgp.11.5.517; Lee HCB, 2003, INT REV PSYCHIATR, V15, P359, DOI 10.1080/09540260310001606746; Marcum ZA, 2016, ANN PHARMACOTHER, V50, P525, DOI 10.1177/1060028016644466; Marr AL., 2004, CENTRAL NERVOUS SYST; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Maust DT, 2014, J AM GERIATR SOC, V62, P358, DOI 10.1111/jgs.12640; Menant JC, 2016, J AM GERIATR SOC, V64, P1073, DOI 10.1111/jgs.14104; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rao V, 2015, SEMIN NEUROL, V35, P64, DOI 10.1055/s-0035-1544241; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Sanglier T, 2011, J AM GERIATR SOC, V59, P1197, DOI 10.1111/j.1532-5415.2011.03457.x; Shippee ND, 2014, AHRQ PUBLICATION; Sterke CS, 2012, BRIT J CLIN PHARMACO, V73, P812, DOI 10.1111/j.1365-2125.2011.04124.x; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thompson HJ, 2012, J NEUROTRAUM, V29, P1864, DOI 10.1089/neu.2011.2284; Thurman DJ., 1995, GUIDELINES SURVEILLA; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206; Yeh CC, 2013, J NEUROL NEUROSUR PS, V84, P441, DOI 10.1136/jnnp-2012-302547	35	12	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1064-7481	1545-7214		AM J GERIAT PSYCHIAT	Am. J. Geriatr. Psychiatr.	APR	2017	25	4					415	424		10.1016/j.jagp.2016.11.018			10	Geriatrics & Gerontology; Gerontology; Psychiatry	Geriatrics & Gerontology; Psychiatry	ET6XE	WOS:000400435800016	28111062	Green Accepted, Bronze			2021-06-18	
J	Arshad, Q; Roberts, RE; Ahmad, H; Lobo, R; Patel, M; Ham, T; Sharp, DJ; Seemungal, BM				Arshad, Q.; Roberts, R. E.; Ahmad, H.; Lobo, R.; Patel, M.; Ham, T.; Sharp, D. J.; Seemungal, B. M.			Patients with chronic dizziness following traumatic head injury typically have multiple diagnoses involving combined peripheral and central vestibular dysfunction	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Vestibular dysfunction; Traumatic head injury; Chronic dizziness		Objective: We hypothesised that chronic vestibular symptoms (CVS) of imbalance and dizziness post-traumatic head injury (THI) may relate to: (i) the occurrence of multiple simultaneous vestibular diagnoses including both peripheral and central vestibular dysfunction in individual patients increasing the chance of missed diagnoses and suboptimal treatment; (ii) an impaired response to vestibular rehabilitation since the central mechanisms that mediate rehabilitation related brain plasticity may themselves be disrupted. Methods: We report the results of a retrospective analysis of both the comprehensive clinical and vestibular laboratory testing of 20 consecutive THI patients with prominent and persisting vestibular symptoms still present at least 6 months post THI. Results: Individual THI patients typically had multiple vestibular diagnoses and unique to this group of vestibular patients, often displayed both peripheral and central vestibular dysfunction. Despite expert neuro-otological management, at two years 20% of patients still had persisting vestibular symptoms. Conclusion: In summary, chronic vestibular dysfunction in THI could relate to: (i) the presence of multiple vestibular diagnoses, increasing the risk of 'missed' vestibular diagnoses leading to persisting symptoms; (ii) the impact of brain trauma which may impair brain plasticity mediated repair mechanisms. Apart from alerting physicians to the potential for multiple vestibular diagnoses in THI, future work to identify the specific deficits in brain function mediating poor recovery from post-THI vestibular dysfunction could provide the rationale for developing new therapy for head injury patients whose vestibular symptoms are resistant to treatment. (C) 2017 Published by Elsevier B.V.	[Arshad, Q.; Roberts, R. E.; Ahmad, H.; Lobo, R.; Patel, M.; Seemungal, B. M.] Imperial Coll, Charing Cross Hosp Campus, Acad Dept Neurootol, Div Brain Sci, Fulham Palace Rd, London W6 8RF, England; [Ham, T.; Sharp, D. J.] Imperial Coll London, Hammersmith Hosp, Computat Cognit & Clin Neuroimaging Lab, London W12 0NN, England	Seemungal, BM (corresponding author), Imperial Coll, Charing Cross Hosp Campus, Acad Dept Neurootol, Div Brain Sci, Fulham Palace Rd, London W6 8RF, England.	b.seemungal@imperial.ac.uk	Sharp, David J/A-2119-2013	Patel, Mitesh/0000-0001-6926-941X; Seemungal, Barry/0000-0002-6578-0904; Patel, Mitesh/0000-0002-3594-5448	Health Foundation and Academy of Medical Sciences Clinician Scientist Fellowship; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission; NIHR Imperial BRC; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/P006493/1] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish	The authors would like to thank the patients for participating in this study. This work was supported by a Health Foundation and Academy of Medical Sciences Clinician Scientist Fellowship (B.M.S.); the Medical Research Council (B.M.S., D.J.S., H.A., R.E.R., T.H.) and the NIHR Imperial BRC.	BERMAN JM, 1978, J OTOLARYNGOL, V7, P237; Drijkoningen D, 2015, NEUROIMAGE-CLIN, V7, P240, DOI 10.1016/j.nicl.2014.12.006; Fife TD, 2009, SEMIN NEUROL, V29, P500, DOI 10.1055/s-0029-1241041; Fotuhi M, 2009, J NEUROL, V256, P711, DOI 10.1007/s00415-009-5050-5; Hoffer Michael E, 2007, Int Tinnitus J, V13, P69; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lempert T, 2012, J VESTIBUL RES-EQUIL, V22, P167, DOI 10.3233/VES-2012-0453; Maskell F., 2006, BRAIN INJ, V20; Nigmatullina Y, 2015, CEREB CORTEX, V25, P554, DOI 10.1093/cercor/bht266; Ochi K, 2003, OTOLARYNG HEAD NECK, V129, P655, DOI 10.1016/S0194-5998(03)01578-X	10	12	13	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	APR	2017	155						17	19		10.1016/j.clineuro.2017.01.021			3	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	ER4FD	WOS:000398753600005	28212927	Green Accepted			2021-06-18	
J	Esopenko, C; Levine, B				Esopenko, Carrie; Levine, Brian			Autobiographical memory and structural brain changes in chronic phase TBI	CORTEX			English	Article						Naturalistic memory; Autobiographical interview; Head injury; Structural neuroimaging; Diffuse injury	MEDIAL-TEMPORAL-LOBE; CLOSED-HEAD-INJURY; EPISODIC MEMORY; RETROGRADE-AMNESIA; FRONTOTEMPORAL DEMENTIA; BEHAVIORAL-VARIANT; ALZHEIMERS-DISEASE; LESION LOCATION; QUANTIFIED MRI; RETRIEVAL	Traumatic brain injury (TBI) is associated with a range of neuropsychological deficits, including attention, memory, and executive functioning attributable to diffuse axonal injury (DAI) with accompanying focal frontal and temporal damage. Although the memory deficit of TBI has been well characterized with laboratory tests, comparatively little research has examined retrograde autobiographical memory (AM) at the chronic phase of TBI, with no prior studies of unselected patients drawn directly from hospital admissions for trauma. Moreover, little is known about the effects of TBI on canonical episodic and non-episodic (e.g., semantic) AM processes. In the present study, we assessed the effects of chronic-phase TBI on AM in patients with focal and DAI spanning the range of TBI severity. Patients and socioeconomic- and age-matched controls were administered the Autobiographical Interview (AI) (Levine, Svoboda, Hay, Winocur, & Moscovitch, 2002) a widely used method for dissociating episodic and semantic elements of AM, along with tests of neuropsychological and functional outcome. Measures of episodic and non-episodic AM were compared with regional brain volumes derived from high-resolution structural magnetic resonance imaging (MRI). Severe TBI (but not mild or moderate TBI) was associated with reduced recall of episodic autobiographical details and increased recall of non-episodic details relative to healthy comparison participants. There were no significant associations between AM performance and neuropsychological or functional outcome measures. Within the full TBI sample, autobiographical episodic memory was associated with reduced volume distributed across temporal, parietal, and prefrontal regions considered to be part of the brain's AM network. These results suggest that TBI-related distributed volume loss affects episodic autobiographical recollection. (C) 2017 Elsevier Ltd. All rights reserved.	[Esopenko, Carrie] Rutgers State Univ, Dept Rehabil & Movement Sci, New Brunswick, NJ USA; [Levine, Brian] Baycrest Hlth Sci, Rotman Res Inst, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada; [Levine, Brian] Univ Toronto, Toronto, ON, Canada	Levine, B (corresponding author), Baycrest Hlth Sci, Rotman Res Inst, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	blevine@research.baycrest.org	Levine, Brian/O-2725-2019; Levine, Brian/G-4328-2010	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; Esopenko, Carrie/0000-0001-8607-5633	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [sMT-14744, MOP-37535, MOP-108540]; NIH-NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD42385-01]; Alzheimer's Society of Canada's Research Program Post Doctoral Fellowship awarded	Ann Campbell, Catherine Hynes, Sabitha Kanagasabai, Charlene O'Connor, Colleen O'Toole, Marina Mandic, Karen Philp, Adriana Fecko, Jovanka Skocic, and Gary Turner are thanked for technical assistance. Natasa Kovacevic, Fuqiang Gao, Joel Ramirez, and Sandra Black are thanked for assistance with the neuroimaging pipeline. We gratefully thank the TBI participants and non-injured volunteers for participating in this research. This research was supported by grants from the Canadian Institutes of Health Research (Grant #sMT-14744, MOP-37535, and MOP-108540), and the NIH-NICHD (Grant #HD42385-01) to B.L., and an Alzheimer's Society of Canada's Research Program Post Doctoral Fellowship awarded to C.E.	Addis DR, 2008, PSYCHOL SCI, V19, P33, DOI 10.1111/j.1467-9280.2008.02043.x; Addis DR, 2007, BRAIN, V130, P2327, DOI 10.1093/brain/awm166; Army Individual Test Battery, 1944, MAN DIR SCOR; ARNDT S, 1991, PSYCHIAT RES-NEUROIM, V40, P79; Barry NC, 2015, J CLIN EXP NEUROPSYC, V37, P994, DOI 10.1080/13803395.2015.1038981; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Berryhill ME, 2007, J NEUROSCI, V27, P14415, DOI 10.1523/JNEUROSCI.4163-07.2007; Bright P, 2006, LEARN MEMORY, V13, P545, DOI 10.1101/lm.265906; Buckner RL, 2007, TRENDS COGN SCI, V11, P49, DOI 10.1016/j.tics.2006.11.004; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cabeza R, 2004, J COGNITIVE NEUROSCI, V16, P1583, DOI 10.1162/0898929042568578; Cabeza R, 2007, TRENDS COGN SCI, V11, P219, DOI 10.1016/j.tics.2007.02.005; Carlesimo GA, 1998, CORTEX, V34, P1, DOI 10.1016/S0010-9452(08)70734-2; Conway MA, 2000, PSYCHOL REV, V107, P261, DOI 10.1037//0033-295X.107.2.261; Conway MA, 2001, PHILOS T R SOC B, V356, P1375, DOI 10.1098/rstb.2001.0940; Coste C, 2011, CORTEX, V47, P771, DOI 10.1016/j.cortex.2010.07.004; Davidson PSR, 2008, NEUROPSYCHOLOGIA, V46, P1743, DOI 10.1016/j.neuropsychologia.2008.01.011; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gilboa A, 2005, HIPPOCAMPUS, V15, P535, DOI 10.1002/hipo.20090; Goste C., 2015, NEUROPSYCHOLOGIA, V71, P133, DOI http://dx.doi.org/10.1016/; Greenberg DL, 2014, MEM COGNITION, V42, P922, DOI 10.3758/s13421-014-0402-5; Guild EB, 2015, J INT NEUROPSYCH SOC, V21, P650, DOI 10.1017/S1355617715000600; HENDERSON DA, 1989, PSYCHOL REP, V64, P251, DOI 10.2466/pr0.1989.64.1.251; Irish M, 2011, NEUROPSYCHOLOGIA, V49, P2694, DOI 10.1016/j.neuropsychologia.2011.05.017; Irish M, 2013, CORTEX, V49, P2377, DOI 10.1016/j.cortex.2013.03.002; Judd C. M., 2008, DATA ANAL MODEL COMP; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Knight RG, 2009, J CLIN EXP NEUROPSYC, V31, P575, DOI 10.1080/13803390802363710; Kopelman MD, 2003, HIPPOCAMPUS, V13, P879, DOI 10.1002/hipo.10140; KOPELMAN MD, 1989, J CLIN EXP NEUROPSYC, V11, P724, DOI 10.1080/01688638908400928; Kopelman MD, 1999, NEUROPSYCHOLOGIA, V37, P939, DOI 10.1016/S0028-3932(98)00143-2; Kovacevic N, 2013, SPRINGER P MATH STAT, V56, P159, DOI 10.1007/978-1-4614-8283-3_10; Krishnan A, 2011, NEUROIMAGE, V56, P455, DOI 10.1016/j.neuroimage.2010.07.034; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; Levine B, 2002, PSYCHOL AGING, V17, P677, DOI 10.1037//0882-7974.17.4.677; Levine B, 2013, NEUROIMAGE-CLIN, V2, P534, DOI 10.1016/j.nicl.2013.03.015; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; McDermott KB, 2009, NEUROPSYCHOLOGIA, V47, P2290, DOI 10.1016/j.neuropsychologia.2008.12.025; McKinnon MC, 2008, J COGNITIVE NEUROSCI, V20, P1839, DOI 10.1162/jocn.2008.20126; McKinnon MC, 2015, CLIN PSYCHOL SCI, V3, P487, DOI 10.1177/2167702614542280; Moscovitch M, 2016, ANNU REV PSYCHOL, V67, P105, DOI 10.1146/annurev-psych-113011-143733; Murphy K, 2008, NEUROPSYCHOLOGIA, V46, P3116, DOI 10.1016/j.neuropsychologia.2008.07.004; Palombo DJ, 2015, NEUROPSYCHOLOGY, V29, P543, DOI 10.1037/neu0000198; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; Piolino P, 2002, MEMORY, V10, P239, DOI 10.1080/09658210143000353; Piolino P, 2007, CORTEX, V43, P176, DOI 10.1016/S0010-9452(08)70474-X; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rasmussen KW, 2014, J NEUROPSYCHOL, V8, P34, DOI 10.1111/jnp.12003; Renoult L, 2012, TRENDS COGN SCI, V16, P550, DOI 10.1016/j.tics.2012.09.003; Rosenbaum RS, 2008, J COGNITIVE NEUROSCI, V20, P1490, DOI 10.1162/jocn.2008.20105; Rubin DC, 1997, MEM COGNITION, V25, P859, DOI 10.3758/BF03211330; Rubin DC, 1998, P NATL ACAD SCI USA, V95, P5413, DOI 10.1073/pnas.95.9.5413; Rugg MD, 2013, CURR OPIN NEUROBIOL, V23, P255, DOI 10.1016/j.conb.2012.11.005; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; Sheldon S, 2016, ANN NY ACAD SCI, V1369, P76, DOI 10.1111/nyas.13006; Sheldon S, 2016, CORTEX, V74, P206, DOI 10.1016/j.cortex.2015.11.005; Simons JS, 2010, CEREB CORTEX, V20, P479, DOI 10.1093/cercor/bhp116; Simons JS, 2003, NAT REV NEUROSCI, V4, P637, DOI 10.1038/nrn1178; Smith A., 1978, SYMBOL DIGIT MODALIT; Soderlund H, 2014, J ABNORM PSYCHOL, V123, P51, DOI 10.1037/a0035610; Spreen O., 1998, COMPENDIUM NEUROPSYC; Starkstein SE, 1997, NEUROCASE, V3, P105, DOI 10.1093/neucas/3.2.105; Stuss D.T., 1994, NEUROPSYCHOLOGY, V8, P355, DOI [DOI 10.1037/0894-4105.8.3.355, 10.1037/0894-4105.8.3.355]; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Svoboda E, 2006, NEUROPSYCHOLOGIA, V44, P2189, DOI 10.1016/j.neuropsychologia.2006.05.023; TEASDALE G, 1974, LANCET, V2, P81; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1053/apmr.2000.4436; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P404, DOI 10.1007/s11682-012-9150-y; Willoughby KA, 2013, J INT NEUROPSYCH SOC, V19, P419, DOI 10.1017/S1355617712001488; Winocur G, 2011, J INT NEUROPSYCH SOC, V17, P766, DOI 10.1017/S1355617711000683; Zachary R., 1986, SHIPLEY I LIVING SCA	76	12	12	1	12	ELSEVIER MASSON	MILANO	VIA PALEOCAPA 7, 20121 MILANO, ITALY	0010-9452	1973-8102		CORTEX	Cortex	APR	2017	89						1	10		10.1016/j.cortex.2017.01.007			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	ES1AT	WOS:000399261000001	28189664				2021-06-18	
J	Gutierrez-de la Iglesia, D; Perez-Lopez, LM; Cabrera-Gonzalez, M; Knorr-Gimenez, J				Gutierrez-de la Iglesia, Diego; Perez-Lopez, Laura M.; Cabrera-Gonzalez, Marisa; Knorr-Gimenez, Jorge			Surgical Techniques for Displaced Radial Neck Fractures: Predictive Factors of Functional Results	JOURNAL OF PEDIATRIC ORTHOPAEDICS			English	Article						radius fractures; child; surgical procedures; open surgery; treatment outcome	PERCUTANEOUS REDUCTION; CHILDREN; FIXATION; MANAGEMENT; METAIZEAU	Background: Fractures of the radial neck represent about 1% of all childhood fractures and 5% to 10% of childhood traumatic lesions involving the elbow. Management of these fractures in children is still controversial. Intramedullary percutaneous nail reduction (Metaizeau technique) is considered the most effective surgical technique because of its excellent results and easy learning curve. Complications may arise, however, especially in Bohler technique, in which a percutaneous pin is placed over the radial head. When this technique does not provide correct reduction, open reduction must be performed. Because open reduction is traditionally associated with a high risk of complications, however, its use is restricted to severely displaced fractures and only when the percutaneous techniques have failed or their application contraindicated because of associated injuries to the distal radius. Methods: In this retrospective study, we evaluated 51 children between the ages of 6 and 15 years who presented to our institution from 1996 to 2012 with Metaizeau-modified Judet grades 3, 4a, and 4b radial head fractures. The surgical techniques used were closed reduction and casting under general anesthesia (n = 7), closed reduction and intramedullary nailing using Metaizeau technique (n = 27), and Metaizeau technique and open reduction with intramedullary nailing (n = 17). Functional results of the 3 surgical techniques were evaluated using the Mayo Elbow Performance Score (MEPS) and compared by modified Judet classification using chi(2) analysis. Results: No statistic significant association was found between type of surgery and final MEPS was observed (P = 0.110). However, a significant association was found between initial modified Judet grade and final MEPS. Conclusions: In the present study, final functional outcome seems to be not affected by open reduction but was significantly associated with initial modified Judet grade. Level of Evidence: Level III-retrospective study comparing closed and open reduction techniques, performed at the same institution.	[Gutierrez-de la Iglesia, Diego; Perez-Lopez, Laura M.; Cabrera-Gonzalez, Marisa; Knorr-Gimenez, Jorge] Univ Barcelona, Pediat Upper Limb Unit, Pediat Orthopaed Surg Dept, St Joan de Deu Childrens Hosp, Passeig St Joan de Deu 2, Barcelona 08950, Spain	Gutierrez-de la Iglesia, D (corresponding author), Univ Barcelona, Pediat Upper Limb Unit, Pediat Orthopaed Surg Dept, St Joan de Deu Childrens Hosp, Passeig St Joan de Deu 2, Barcelona 08950, Spain.	dgutierrez@hsjdbcn.org		Perez-Lopez, Laura M./0000-0001-8261-3297; Perez-Lopez, Laura M./0000-0002-3881-4048			Basmajian HG, 2014, J PEDIATR ORTHOP B, V23, P369, DOI 10.1097/BPB.0000000000000057; BERNSTEIN SM, 1993, J PEDIATR ORTHOPED, V13, P85, DOI 10.1097/01241398-199301000-00017; Bither Nitin, 2015, Eur J Orthop Surg Traumatol, V25, P99, DOI 10.1007/s00590-014-1452-x; Brandao GF, 2010, J PEDIATR ORTHOPED, V30, P110, DOI 10.1097/BPO.0b013e3181cf118a; Cha SM, 2012, INT ORTHOP, V36, P803, DOI 10.1007/s00264-011-1387-3; Colovic H, 2008, VOJNOSANIT PREGL, V65, P27, DOI 10.2298/VSP0801027C; Cornwall Roger, 2013, J Bone Joint Surg Am, V95, pe157, DOI 10.2106/JBJS.M.01063; DSOUZA S, 1993, J PEDIATR ORTHOPED, V13, P232; Eberl R, 2010, CHIRURG, V81, P915, DOI 10.1007/s00104-010-1915-5; Falciglia F, 2014, J PEDIATR ORTHOPED, V34, P756, DOI 10.1097/BPO.0000000000000299; Fuentes-Salguero L, 2012, Rev Esp Cir Ortop Traumatol, V56, P300, DOI 10.1016/j.recot.2012.01.002; Garcia-Alvarez F, 2001, Chir Organi Mov, V86, P211; GonzalezHerranz P, 1997, J PEDIATR ORTHOPED, V17, P325, DOI 10.1097/00004694-199705000-00011; Klitscher D, 2009, J PEDIATR ORTHOPED, V29, P698, DOI 10.1097/BPO.0b013e3181b76895; Matuszewski Lukasz, 2012, Ortop Traumatol Rehabil, V14, P261, DOI 10.5604/15093492.1002260; METAIZEAU JP, 1993, J PEDIATR ORTHOPED, V13, P355, DOI 10.1097/01241398-199305000-00015; Monson R, 2009, J PEDIATR ORTHOPED, V29, P243, DOI 10.1097/BPO.0b013e3181990745; Pring Maya E, 2012, J Pediatr Orthop, V32 Suppl 1, pS14, DOI 10.1097/BPO.0b013e31824b251d; Radomisli TE, 1998, CLIN ORTHOP RELAT R, P30; Schmittenbecher PP, 2005, J PEDIATR ORTHOPED, V25, P45; Song KS, 2015, J PEDIATR ORTHOPED, V35, pE26, DOI 10.1097/BPO.0000000000000305; Sun Jianhua, 2012, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V26, P661; Tan Bryan Hsi Ming, 2011, J Orthop Surg (Hong Kong), V19, P209; Tarallo L, 2013, J ORTHOP TRAUMATOL, V14, P291, DOI 10.1007/s10195-013-0252-0; TIBONE JE, 1981, J BONE JOINT SURG AM, V63, P100, DOI 10.2106/00004623-198163010-00013; Ugutmen E, 2010, J PEDIATR ORTHOP B, V19, P289, DOI 10.1097/BPB.0b013e32833918a0; Ursei Monica, 2006, Acta Orthop Belg, V72, P131; Wang J, 2013, J PEDIATR ORTHOP B, V22, P127, DOI 10.1097/BPB.0b013e32835b5700; Wilkins K, 1991, FRACTURES CHILDREN, P728; Zimmerman RM, 2013, J BONE JOINT SURG AM, V95A, P1825, DOI 10.2106/JBJS.L.01130	30	12	12	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0271-6798	1539-2570		J PEDIATR ORTHOPED	J. Pediatr. Orthop.	APR-MAY	2017	37	3					159	165		10.1097/BPO.0000000000000617			7	Orthopedics; Pediatrics	Orthopedics; Pediatrics	EN3XS	WOS:000395941800016	26296224				2021-06-18	
J	Maria, NSS; Reger, ML; Cai, Y; Baquing, MAT; Buen, F; Ponnaluri, A; Hovda, DA; Harris, NG; Giza, CC				Maria, Naomi S. Sta; Reger, Maxine L.; Cai, Yan; Baquing, Mary Anne T.; Buen, Floyd; Ponnaluri, Aditya; Hovda, David A.; Harris, Neil G.; Giza, Christopher C.			D-Cycloserine Restores Experience-Dependent Neuroplasticity after Traumatic Brain Injury in the Developing Rat Brain	JOURNAL OF NEUROTRAUMA			English	Article						behavioral assessments; learning and memory; neuroplasticity; receptors; TBI	IMPROVES FUNCTIONAL RECOVERY; RECEPTOR SUBUNIT COMPOSITION; LATERAL FLUID PERCUSSION; SYNAPTIC NMDA RECEPTORS; D-ASPARTATE RECEPTORS; CLOSED-HEAD INJURY; CLINICAL-TRIALS; POSTNATAL-DEVELOPMENT; OBJECT RECOGNITION; GLUR2 ENDOCYTOSIS	Traumatic brain injury (TBI) in children can cause persisting cognitive and behavioral dysfunction, and inevitably raises concerns about lost potential in these injured youth. Lateral fluid percussion injury (FPI) in weanling rats pathologically affects hippocampal N-methyl-D-aspartate receptor (NMDAR)- and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-mediated glutamatergic neurotransmission subacutely within the first post-injury week. FPI to weanling rats has also been shown to impair enriched-environment (EE) induced enhancement of Morris water maze (MWM) learning and memory in adulthood. Recently, improved outcomes can be achieved using agents that enhance NMDAR function. We hypothesized that administering D-cycloserine (DCS), an NMDAR co-agonist, every 12 h (i.p.) would restore subacute glutamatergic neurotransmission and reinstate experience-dependent plasticity. Postnatal day 19 (P19) rats received either a sham or FPI. On post-injury day (PID) 1-3, animals were randomized to saline (Sal) or DCS. Firstly, immunoblotting of hippocampal NMDAR and AMPAR proteins were measured on PID4. Second, PID4 novel object recognition, an NMDAR-and hippocampal-mediated working memory task, was assessed. Third, P19 rats were placed in an EE (17 days), and MWM performance was measured, starting on PID30. On PID4, DCS restored reduced NR2A and increased GluR2 by 54%, and also restored diminished recognition memory in FPI pups. EE significantly improved MWM performance in shams, regardless of treatment. In contrast, FPI-EE-Sal animals only performed to the level of standard housed animals, whereas FPI-EE-DCS animals were comparable with sham-EE counterparts. This study shows that NMDAR agonist use during reduced glutamatergic transmission after developmental TBI can reinstate early molecular and behavioral responses that subsequently manifest in experience-dependent plasticity and rescued potential.	[Maria, Naomi S. Sta; Reger, Maxine L.; Cai, Yan; Baquing, Mary Anne T.; Buen, Floyd; Ponnaluri, Aditya; Hovda, David A.; Harris, Neil G.; Giza, Christopher C.] Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Neurosurg, Box 957039,58-125 CHS, Los Angeles, CA 90095 USA; [Maria, Naomi S. Sta] Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Bioengn, Box 957039,58-125 CHS, Los Angeles, CA 90095 USA; [Reger, Maxine L.] Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Psychol, Los Angeles, CA USA; [Buen, Floyd] Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Head & Neck Surg, Los Angeles, CA USA; [Ponnaluri, Aditya] Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Mech Engn, Los Angeles, CA USA; [Hovda, David A.] Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Med & Mol Pharmacol, Los Angeles, CA USA; [Giza, Christopher C.] Univ Calif Los Angeles, Brain Injury Res Ctr, Div Pediat Neurol, Los Angeles, CA USA; [Baquing, Mary Anne T.] Univ Calif Los Angeles, Brain Injury Res Ctr, Harbor UCLA Dept Obstet & Gynecol, Los Angeles, CA USA	Maria, NSS (corresponding author), Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Neurosurg, Box 957039,58-125 CHS, Los Angeles, CA 90095 USA.; Maria, NSS (corresponding author), Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Bioengn, Box 957039,58-125 CHS, Los Angeles, CA 90095 USA.	naomi.santamaria@gmail.com		Harris, Neil/0000-0002-1965-6750; Sta Maria, Naomi/0000-0001-9710-2908	UCLA Brain Injury Research Center (BIRC) [NS27544, NS057420]; NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS091222-01]; Winokur Family Foundation/Child Neurology Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02NS057420, R01NS027544, R01NS091222] Funding Source: NIH RePORTER	We thank David Garfinkel for his excellent technical assistance. This work was supported by the UCLA Brain Injury Research Center (BIRC), NS27544, NS057420, NIH NINDS 1R01NS091222-01, and the Winokur Family Foundation/Child Neurology Foundation.	Adeleye A, 2010, EUR J PHARMACOL, V629, P25, DOI 10.1016/j.ejphar.2009.11.066; Albers GV, 2001, JAMA-J AM MED ASSOC, V286, P2673, DOI 10.1001/jama.286.21.2673; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Bell JD, 2007, BRAIN, V130, P2528, DOI 10.1093/brain/awm164; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Clark RE, 2000, J NEUROSCI, V20, P8853; CORDOBA F, 1984, PHARMACOL BIOCHEM BE, V21, P349, DOI 10.1016/S0091-3057(84)80093-3; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Cull-Candy S, 2006, CURR OPIN NEUROBIOL, V16, P288, DOI 10.1016/j.conb.2006.05.012; Dennis M, 2010, CORTEX, V46, P1043, DOI 10.1016/j.cortex.2009.10.008; Dere E, 2007, NEUROSCI BIOBEHAV R, V31, P673, DOI 10.1016/j.neubiorev.2007.01.005; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Flint AC, 1997, J NEUROSCI, V17, P2469; Gilchrist J., 2011, NONFATAL TRAUMATIC B, P1337; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Greenough W.T., 1976, NEURAL MECH LEARNING, P255; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hammond RS, 2004, NEUROBIOL LEARN MEM, V82, P26, DOI 10.1016/j.nlm.2004.03.005; Han RZ, 2009, NEUROSCI BULL, V25, P367, DOI 10.1007/s12264-009-0608-x; HOOD WF, 1989, NEUROSCI LETT, V98, P91, DOI 10.1016/0304-3940(89)90379-0; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Johnson MW, 1997, J NEUROSCI METH, V77, P151, DOI 10.1016/S0165-0270(97)00120-9; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kennard MA, 1936, AM J PHYSIOL, V115, P138; Kennard MA, 1938, J NEUROPHYSIOL, V1, P477; Kennard MA, 1942, MT SINAI J MED, V9, P594; KOLB B, 1988, BEHAV BRAIN RES, V28, P259, DOI 10.1016/0166-4328(88)90129-5; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; LANTHORN TH, 1994, AMINO ACIDS, V6, P247, DOI 10.1007/BF00813745; Laurie DJ, 1997, MOL BRAIN RES, V51, P23, DOI 10.1016/S0169-328X(97)00206-4; Liu D, 2000, NAT NEUROSCI, V3, P799; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Maei Hamid R, 2009, Front Integr Neurosci, V3, P4, DOI 10.3389/neuro.07.004.2009; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Quinlan EM, 1999, P NATL ACAD SCI USA, V96, P12876, DOI 10.1073/pnas.96.22.12876; Quinlan EM, 1999, NAT NEUROSCI, V2, P352; R Development Core Team, 2010, R LANG ENV STAT COMP; Rao VLR, 2001, BRAIN RES, V911, P96; Reger ML, 2009, DEV PSYCHOBIOL, V51, P672, DOI 10.1002/dev.20402; Roberts EB, 1999, J NEUROPHYSIOL, V81, P2587; ROSENZWEIG MR, 1972, SCI AM, V226, P22, DOI 10.1038/scientificamerican0272-22; Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2; Schumann J, 2008, J NEUROTRAUM, V25, P945, DOI 10.1089/neu.2008.0521; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Temple MD, 1996, BRAIN RES, V741, P246, DOI 10.1016/S0006-8993(96)00940-7; Wenzel A, 1997, J NEUROCHEM, V68, P469; Wilcox KS, 1996, J NEUROPHYSIOL, V76, P3415; Wolosker H, 2007, MOL NEUROBIOL, V36, P152, DOI 10.1007/s12035-007-0038-6; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com	63	12	12	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	8					1692	1702		10.1089/neu.2016.4747			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ES1ZM	WOS:000399325500020	27931146	Green Published			2021-06-18	
J	Mashhadizadeh, S; Farbood, Y; Dianat, M; Khodadadi, A; Sarkaki, A				Mashhadizadeh, Shahram; Farbood, Yaghoub; Dianat, Mahin; Khodadadi, Ali; Sarkaki, Alireza			Therapeutic effects of ellagic acid on memory, hippocampus electrophysiology deficits, and elevated TNF-alpha level in brain due to experimental traumatic brain injury	IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES			English	Article						Blood-brain barrier; Ellagic acid; LTP; Memory; TNF-alpha; Traumatic brain injury	TUMOR-NECROSIS-FACTOR; LONG-TERM POTENTIATION; INTRACRANIAL-PRESSURE; SYNAPTIC-TRANSMISSION; ANTIOXIDANT ACTIVITY; OXIDATIVE STRESS; NEURON DEATH; RAT; INFLAMMATION; EXPRESSION	Objective(s): Cognitive defects such as learning and memory impairment are amongst the most repetitious sequelae after sever and moderate traumatic brain injury (TBI). It was suggested that ellagic acid (EA), an innate phenol product, display neuroprotective properties against oxidative and inflammatory damages after brain injury. The object of the current study was therapeutic properties of EA on blood-brain barrier (BBB) interruption and elevated content of TNF-alpha in brain tissue followed by neurologic aftereffects, cognitive and brain electrophysiology deficits as outcomes of diffuse TBI in rat. Materials and Methods: TBI was induced by a 200 g weight falling by a 2-m height through a free-falling tube onto the head of anesthetized rat. TBI rats treated immediately after trauma with EA (100 mg/kg, IP) once every 8 hr until 48 hr later. Neurologic outcomes, passive avoidance task (PAT), hippocampal long-term potentiation (LTP), BBB permeability and content of TNF-alpha in brain tissue were evaluated. Results: TBI induced significant impairments in neurological score, BBB function, PAT and hippocampal LTP in TBI+Veh group in compare with Sham+Veh (P<0.001). EA treatment decreased neurologic severity score (NSS), restored increased BBB permeability, cognitive and hippocampal LTP abnormalities, and elevated brain content of TNF-alpha due to TBI significantly (P<0.001). Conclusion: Our findings propose that EA can restore NSS, cognitive and LTP deficits and prevent brain inflammation may by restore BBB permeability as well as lowering brain content of TNF-alpha following TBI.	[Mashhadizadeh, Shahram; Farbood, Yaghoub; Dianat, Mahin; Sarkaki, Alireza] Ahvaz Jundishapur Univ Med Sci, Physiol Res Ctr, Golestan Blvd, Ahwaz, Iran; [Mashhadizadeh, Shahram; Farbood, Yaghoub; Dianat, Mahin; Sarkaki, Alireza] Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Physiol, Golestan Blvd, Ahwaz, Iran; [Khodadadi, Ali] Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Immunol, Golestan Blvd, Ahwaz, Iran	Sarkaki, A (corresponding author), Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Physiol, Golestan Blvd, Ahwaz, Iran.; Sarkaki, A (corresponding author), Ahvaz Jundishapur Univ Med Sci, Ahvaz Physiol Res Ctr, Golestan Blvd, Ahwaz, Iran.	sarkaki145@gmail.com	Mashhadizadeh, Shahram/AAN-2926-2021; Sarkaki, Alireza/Q-8363-2017; khodadadi, ali/N-2130-2017; Farbood, Yaghoob/M-3076-2017	Mashhadizadeh, Shahram/0000-0003-2614-5657; Sarkaki, Alireza/0000-0001-9272-6228; khodadadi, ali/0000-0003-0442-273X; Farbood, Yaghoob/0000-0002-6390-0079	Ahvaz Jundishapur University of Medical Sciences Ahvaz, Iran [PRC-147]	The results reported in this paper were part of Dr Shahram Mashhadizadeh's PhD thesis. This study was accomplished in Physiology Research Centers, Ahvaz, Iran. It was supported by the Vice-Chancellor for Research, Ahvaz Jundishapur University of Medical Sciences (Grant No: PRC-147), Ahvaz, Iran. Funding sources had no involvement in the conduct of the research and/or preparation of the article.	Al Nimer F, 2013, BRAIN BEHAV IMMUN, V27, P109, DOI 10.1016/j.bbi.2012.10.002; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Alvarez A, 2007, NEUROBIOL AGING, V28, P533, DOI 10.1016/j.neurobiolaging.2006.02.012; Atta-Ur-Rahman, 2001, PLANTA MED, V67, P335, DOI 10.1055/s-2001-14306; Babu GN, 2008, NEUROCHEM RES, V33, P1145, DOI 10.1007/s11064-007-9564-x; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baune BT, 2008, AM J MED GENET B, V147B, P1056, DOI 10.1002/ajmg.b.30712; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; BenNasr C, 1996, Z LEBENSM UNTERS FOR, V203, P374, DOI 10.1007/BF01231077; Beste C, 2010, J NEUROPHYSIOL, V104, P2523, DOI 10.1152/jn.00561.2010; BOKA G, 1994, NEUROSCI LETT, V172, P151, DOI 10.1016/0304-3940(94)90684-X; Butler MP, 2004, NEUROSCIENCE, V124, P319, DOI 10.1016/j.neuroscience.2003.11.040; Chao PC, 2009, NUTR METAB, V6, DOI 10.1186/1743-7075-6-33; Chen HS, 2011, J FOOD SCI, V76, pT192, DOI 10.1111/j.1750-3841.2011.02373.x; Clifford MN, 2000, J SCI FOOD AGR, V80, P1118, DOI [10.1002/(SICI)1097-0010(20000515)80:7<1118::AID-JSFA570>3.0.CO;2-9, 10.1002/(SICI)1097-0010(20000515)80:7&lt;1118::AID-JSFA570&gt;3.0.CO;2-9, 10.1002/(SICI)1097-0010(20000515)80:7&lt;1033::AID-JSFA595&gt;3.0.CO;2-T, 10.1002/(SICI)1097-0010(20000515)80:7&lt;1063::AID-JSFA605&gt;3.0.CO;2-Q]; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Farbood Y, 2015, LIFE SCI, V124, P120, DOI 10.1016/j.lfs.2015.01.013; Festa F, 2001, ANTICANCER RES, V21, P3903; Floden AM, 2005, J NEUROSCI, V25, P2566, DOI 10.1523/JNEUROSCI.4998-04.2005; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Golan H, 2004, CEREB CORTEX, V14, P97, DOI 10.1093/cercor/bhg108; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Hamad AWR., 2009, Pak J Nutr, V8, P1661, DOI 10.3923/pjn.2009.1661.1664; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Huh JW, 2011, J NEUROTRAUM, V28, P245, DOI 10.1089/neu.2010.1639; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; Kaneko M, 2008, NEURON, V58, P673, DOI 10.1016/j.neuron.2008.04.023; Khaksari M, 2013, IRAN J BASIC MED SCI, V16, P858; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI 10.1139/y10-103; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Kostrzewa RM, 2003, NEUROTOX RES, V5, P375, DOI 10.1007/BF03033166; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lashgari R, 2006, BEHAV BRAIN RES, V171, P324, DOI 10.1016/j.bbr.2006.04.013; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Mansouri MT, 2013, EUR J PHARMACOL, V707, P46, DOI 10.1016/j.ejphar.2013.03.031; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; McCoy MK, 2008, J NEUROINFLAMM, V5, P1; Montgomery SL, 2012, J NEUROIMMUNE PHARM, V7, P42, DOI 10.1007/s11481-011-9287-2; Morton LW, 2000, CLIN EXP PHARMACOL P, V27, P152, DOI 10.1046/j.1440-1681.2000.03214.x; Narayanan BA, 1999, CANCER LETT, V136, P215, DOI 10.1016/S0304-3835(98)00323-1; Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; O'Connor JJ, 2005, BRAIN RES, V1062, P171; Olmos G, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/861231; Paxinos G, 2006, NEUROBIOL DIS; Pickering M, 2005, EXP PHYSIOL, V90, P663, DOI 10.1113/expphysiol.2005.030734; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Ribbers GM, 2010, INT ENCY REHABILITAT, P1; Rogerio AP, 2006, J PHARM PHARMACOL, V58, P1265, DOI 10.1211/jpp.58.9.0014; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Santello M, 2012, TRENDS NEUROSCI, V35, P638, DOI 10.1016/j.tins.2012.06.001; Santello M, 2011, NEURON, V69, P988, DOI 10.1016/j.neuron.2011.02.003; Sarkaki A, 2014, Pak J Biol Sci, V17, P978, DOI 10.3923/pjbs.2014.991.998; Sarkaki A, 2008, BEHAV BRAIN RES, V186, P72, DOI 10.1016/j.bbr.2007.07.041; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; Selig DK, 1996, LEARN MEMORY, V3, P42, DOI 10.1101/lm.3.1.42; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Stellwagen D, 2005, J NEUROSCI, V25, P3219, DOI 10.1523/JNEUROSCI.4486-04.2005; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; TANCREDI V, 1992, NEUROSCI LETT, V146, P176, DOI 10.1016/0304-3940(92)90071-E; Umesalma S, 2010, BASIC CLIN PHARMACOL, V107, P650, DOI 10.1111/j.1742-7843.2010.00565.x; Uzar E, 2012, NEUROL SCI, V33, P567, DOI 10.1007/s10072-011-0775-1; Wada L, 2002, J AGR FOOD CHEM, V50, P3495, DOI 10.1021/jf011405l; WANG XK, 1994, MOL CHEM NEUROPATHOL, V23, P103, DOI 10.1007/BF02815404; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Yang LB, 2002, J NEUROSCI, V22, P3025, DOI 10.1523/JNEUROSCI.22-08-03025.2002; Yu YM, 2005, J NUTR BIOCHEM, V16, P675, DOI 10.1016/j.jnutbio.2005.03.013	69	12	12	0	5	MASHHAD UNIV MED SCIENCES	MASHHAD	VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 - 445, MASHHAD, 00000, IRAN	2008-3866	2008-3874		IRAN J BASIC MED SCI	Iran. J. Basic Med. Sci.	APR	2017	20	4					399	407		10.22038/IJBMS.2017.8581			9	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	EX5JG	WOS:000403276600008	28804609	DOAJ Gold			2021-06-18	
J	Portbury, SD; Hare, DJ; Sgambelloni, CJ; Bishop, DP; Finkelstein, DI; Doble, PA; Adlard, PA				Portbury, Stuart D.; Hare, Dominic J.; Sgambelloni, Charlotte J.; Bishop, David P.; Finkelstein, David I.; Doble, Philip A.; Adlard, Paul A.			Age modulates the injury-induced metallomic profile in the brain	METALLOMICS			English	Article							LA-ICP-MS; ALZHEIMERS-DISEASE; REGIONAL-DISTRIBUTION; TRACE-ELEMENTS; HEAD-INJURY; ZINC; IRON; COPPER; NEUROPROTECTION; ABLATION	The biological transition metals iron (Fe), copper (Cu) and zinc (Zn) are thought to contribute to the neuronal pathologies that occur following traumatic brain injury (TBI), and indeed our previously published work in young (3 month-old) mice clearly demonstrates a significant spatiotemporal modulation of metals following TBI. Of note, however, is the literature observation that there is both an apparent detrimental effect of aging on TBI outcomes and an alteration in metals and their various transporters with normal advancing age. Therefore, to determine whether there was an interaction between aging, metals and TBI, we have utilised laser ablation-inductively coupled plasma-mass spectrometry to examine the spatial and temporal distribution of Fe, Zn and Cu following an acute controlled cortical impact brain injury in aged (24 months) rodents. The relative abundance of metals in corresponding regions within the ipsilateral and contralateral hemispheres as well as the hippocampus was assessed. Substantial region and time point specific alterations in Fe, Zn and Cu were identified immediately and up to 28 days post-TBI. The data from this follow-up study has also been compared to our previous data from young animals, and aged mice exhibit an appreciably enhanced and persistent elevation of all metals in every region surveyed, with individual metal disparities at various time points observed post-injury. This may potentially contribute to the acceleration in the onset of cognitive decline and neurological disease that has been observed in the aged population following head trauma.	[Portbury, Stuart D.; Hare, Dominic J.; Sgambelloni, Charlotte J.; Finkelstein, David I.; Adlard, Paul A.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Kenneth Myer Bldg,30 Royal Parade, Parkville, Vic 3052, Australia; [Hare, Dominic J.; Bishop, David P.; Doble, Philip A.] Univ Technol Sydney, Elemental Bioimaging Facil, Thomas St, Broadway, NSW 2007, Australia	Adlard, PA (corresponding author), Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Kenneth Myer Bldg,30 Royal Parade, Parkville, Vic 3052, Australia.	paul.adlard@florey.edu.au	Hare, Dominic/H-2481-2011; Doble, Philip/A-8812-2012; Bishop, David P/F-2891-2019; Finkelstein, David/B-9617-2009	Hare, Dominic/0000-0002-5922-7643; Doble, Philip/0000-0002-8472-1301; Bishop, David P/0000-0002-6533-4410; Finkelstein, David/0000-0002-8167-4917; Portbury, Stuart/0000-0002-5470-6100	Australian Research Council (ARC)Australian Research Council; Ramaciotti Foundation; ARCAustralian Research Council; Agilent Technologies; Operational Infrastructure Support Grant; ESI Ltd.	PAA is supported by Australian Research Council (ARC) Future Fellowship. DJH wishes to acknowledge support from the Ramaciotti Foundation. DJH and PAD were also supported by an ARC Linkage Project with Agilent Technologies and ESI Ltd. In addition, the Florey Institute of Neuroscience and Mental Health acknowledge the strong support from the Victorian Government and in particular the funding from the Operational Infrastructure Support Grant.	Adlard PA, 2006, J ALZHEIMERS DIS, V10, P145; Adlard PA, 2010, J NEUROSCI, V30, P1631, DOI 10.1523/JNEUROSCI.5255-09.2010; Aizenman E, 2000, J NEUROCHEM, V75, P1878, DOI 10.1046/j.1471-4159.2000.0751878.x; Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; [Anonymous], 2004, WORLD REP TRAFF INJ; Ayton S, 2014, FREE RADICAL BIO MED, V69, P331, DOI 10.1016/j.freeradbiomed.2014.01.041; Barnham KJ, 2014, CHEM SOC REV, V43, P6727, DOI 10.1039/c4cs00138a; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Bolognin S, 2009, NEUROMOL MED, V11, P223, DOI 10.1007/s12017-009-8102-1; Bouras C, 1997, EUR NEUROL, V38, P53, DOI 10.1159/000112903; Capasso M, 2005, J ALZHEIMERS DIS, V8, P93; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; CONNOR JR, 1992, J NEUROSCI RES, V31, P327, DOI 10.1002/jnr.490310214; Cope EC, 2012, NEUROREHAB NEURAL RE, V26, P907, DOI 10.1177/1545968311435337; Cope EC, 2012, NUTR REV, V70, P410, DOI 10.1111/j.1753-4887.2012.00486.x; Cope EC, 2011, PHYSIOL BEHAV, V104, P942, DOI 10.1016/j.physbeh.2011.06.007; Cope EC, 2010, CURR OPIN CLIN NUTR, V13, P685, DOI 10.1097/MCO.0b013e32833df61a; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Deibel MA, 1996, J NEUROL SCI, V143, P137, DOI 10.1016/S0022-510X(96)00203-1; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Doering P, 2007, NEUROSCIENCE, V150, P93, DOI 10.1016/j.neuroscience.2007.09.066; Doering P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010131; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Frederickson CJ, 2004, NEUROSCIENTIST, V10, P18, DOI 10.1177/1073858403255840; Gaggelli E, 2006, CHEM REV, V106, P1995, DOI 10.1021/cr040410w; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hare DJ, 2016, ANAL METHODS-UK, V8, P7552, DOI 10.1039/c6ay02545e; Hare DJ, 2013, ANAL METHODS-UK, V5, P1915, DOI 10.1039/c3ay26248k; Hare DJ, 2012, ANAL CHEM, V84, P3990, DOI 10.1021/ac300374x; Hare DJ, 2010, METALLOMICS, V2, P745, DOI 10.1039/c0mt00039f; Hegde ML, 2006, ARCH BIOCHEM BIOPHYS, V449, P143, DOI 10.1016/j.abb.2006.02.018; Hellmich HL, 2004, NEUROSCI LETT, V355, P221, DOI 10.1016/j.neulet.2003.10.074; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jafari S, 2013, MOVEMENT DISORD, V28, P1222, DOI 10.1002/mds.25458; Johnson VE, 2015, NAT REV NEUROL, V11, DOI 10.1038/nrneurol.2014.241; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Lear J, 2012, ANAL CHEM, V84, P6707, DOI 10.1021/ac301156f; Lear J, 2012, J ANAL ATOM SPECTROM, V27, P159, DOI 10.1039/c1ja10301f; Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453; Liu HD, 2013, NEUROL SCI, V34, P1173, DOI 10.1007/s10072-012-1214-7; Lu L., 2015, BIOMED RES INT, V2015, DOI DOI 10.1155/2015/470676; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; Mason PRD, 2002, J ANAL ATOM SPECTROM, V17, P858, DOI 10.1039/b202964b; MASSIE HR, 1979, MECH AGEING DEV, V10, P93, DOI 10.1016/0047-6374(79)90073-3; Matusch A, 2010, J AM SOC MASS SPECTR, V21, P161, DOI 10.1016/j.jasms.2009.09.022; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; Menzel JC, 2008, BRAIN INJURY, V22, P375, DOI 10.1080/02699050802001492; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Morris DR, 2013, CURR OPIN CLIN NUTR, V16, P708, DOI 10.1097/MCO.0b013e328364f39c; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Pena MMO, 1999, J NUTR, V129, P1251; PLANTIN LO, 1987, BIOL TRACE ELEM RES, V13, P69, DOI 10.1007/BF02796622; Portbury SD, 2016, METALLOMICS, V8, P193, DOI 10.1039/c5mt00234f; Portbury SD, 2015, J ALZHEIMERS DIS, V46, P297, DOI 10.3233/JAD-143048; Raz E, 2011, AM J NEURORADIOL, V32, P1851, DOI 10.3174/ajnr.A2637; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sandhir R, 2010, NEUROCHEM INT, V56, P188, DOI 10.1016/j.neuint.2009.10.002; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Suram A, 2002, NEUROMOL MED, V2, P289, DOI 10.1385/NMM:2:3:289; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Szewczyk B, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00033; Takahashi S, 2001, BIOL TRACE ELEM RES, V80, P145, DOI 10.1385/BTER:80:2:145; Tarohda T, 2004, ANAL BIOANAL CHEM, V380, P240, DOI 10.1007/s00216-004-2697-8; Tatton WG, 1999, BBA-BIOENERGETICS, V1410, P195, DOI 10.1016/S0005-2728(98)00167-4; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Vasudevaraju P, 2010, Indian J Psychiatry, V52, P140, DOI 10.4103/0019-5545.64590; Zecca L, 2001, J NEUROCHEM, V76, P1766, DOI 10.1046/j.1471-4159.2001.00186.x; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	80	12	12	1	12	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	1756-5901	1756-591X		METALLOMICS	Metallomics	APR 1	2017	9	4					402	410		10.1039/c6mt00260a			9	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	ES8AA	WOS:000399771300007	28170006	Green Published, Other Gold			2021-06-18	
J	Munoz, MJ; Kumar, RG; Oh, BM; Conley, YP; Wang, ZS; Failla, MD; Wagner, AK				Munoz, Miranda J.; Kumar, Raj G.; Oh, Byung-Mo; Conley, Yvette P.; Wang, Zhensheng; Failla, Michelle D.; Wagner, Amy K.			Cerebrospinal Fluid Cortisol Mediates Brain-Derived Neurotrophic Factor Relationships to Mortality after Severe TBI: A Prospective Cohort Study	FRONTIERS IN MOLECULAR NEUROSCIENCE			English	Article						cortisol; BDNF; TBI; biomarkers; genetics; cerebrospinal fluid	HEART-RATE-VARIABILITY; MESSENGER-RNA EXPRESSION; AGE-RELATED-CHANGES; VAL66MET POLYMORPHISM; RAT HIPPOCAMPUS; LIFE-SPAN; GLUCOCORTICOIDS MODULATE; PROGNOSTIC BIOMARKER; OUTCOME PREDICTION; AGING HIPPOCAMPUS	Distinct regulatory signaling mechanisms exist between cortisol and brain derived neurotrophic factor (BDNF) that may influence secondary injury cascades associated with traumatic brain injury (TBI) and predict outcome. We investigated concurrent CSF BDNF and cortisol relationships in 117 patients sampled days 0-6 after severe TBI while accounting for BDNF genetics and age. We also determined associations between CSF BDNF and cortisol with 6-month mortality. BDNF variants, rs6265 and rs7124442, were used to create a gene risk score (GRS) in reference to previously published hypothesized risk for mortality in "younger patients" (<48 years) and hypothesized BDNF production/secretion capacity with these variants. Group based trajectory analysis (TRAJ) was used to create two cortisol groups (high and low trajectories). A Bayesian estimation approach informed the mediation models. Results show CSF BDNF predicted patient cortisol TRAJ group (P = 0.001). Also, GRS moderated BDNF associations with cortisol TRAJ group. Additionally, cortisol TRAJ predicted 6-month mortality (P = 0.001). In a mediation analysis, BDNF predicted mortality, with cortisol acting as the mediator (P = 0.011), yielding a mediation percentage of 29.92%. Mediation effects increased to 45.45% among younger patients. A BDNF*GRS interaction predicted mortality in younger patients (P = 0.004). Thus, we conclude 6-month mortality after severe TBI can be predicted through a mediation model with CSF cortisol and BDNF, suggesting a regulatory role for cortisol with BDNF's contribution to TBI pathophysiology and mortality, particularly among younger individuals with severe TBI. Based on the literature, cortisol modulated BDNF effects on mortality after TBI may be related to known hormone and neurotrophin relationships to neurological injury severity and autonomic nervous system imbalance.	[Munoz, Miranda J.; Kumar, Raj G.; Oh, Byung-Mo; Conley, Yvette P.; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Munoz, Miranda J.] Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA USA; [Kumar, Raj G.; Conley, Yvette P.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA USA; [Oh, Byung-Mo] Seoul Natl Univ Hosp, Dept Rehabil Med, Seoul, South Korea; [Wang, Zhensheng] Univ Pittsburgh, Dept Nursing, Pittsburgh, PA USA; [Wang, Zhensheng; Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Failla, Michelle D.] Vanderbilt Univ Sch Med, Dept Psychiat, Nashville, TN USA; [Wagner, Amy K.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA USA; [Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA.; Wagner, AK (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA.; Wagner, AK (corresponding author), Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA USA.; Wagner, AK (corresponding author), Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA USA.	wagnerak@upmc.edu	Failla, Michelle/AAI-3788-2021	Failla, Michelle/0000-0001-9734-3373; Conley, Yvette/0000-0002-1784-6067; Munoz, Miranda/0000-0002-3782-6530	Department of DefenseUnited States Department of Defense [DODW81XWH-071-0701]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD048162, R01NR008424, 5P01NS030318]; Centers for Disease Control (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CCR 323155]; National Institute for Disability, Independent Living, and Rehabilitation Research [NIDILRR 90DP0041]	This work was supported in part by the Department of Defense (DODW81XWH-071-0701); National Institutes of Health (NIH R01 HD048162, R01NR008424, 5P01NS030318; Centers for Disease Control (CDC) R49 CCR 323155); National Institute for Disability, Independent Living, and Rehabilitation Research (NIDILRR 90DP0041).	Alboni S, 2011, NEUROPHARMACOLOGY, V60, P1337, DOI 10.1016/j.neuropharm.2011.01.050; Alexander N, 2010, PSYCHONEUROENDOCRINO, V35, P949, DOI 10.1016/j.psyneuen.2009.12.008; Antonawich FJ, 1999, NEUROSCIENCE, V88, P319, DOI 10.1016/S0306-4522(98)00213-9; Arango-Lievano M, 2015, P NATL ACAD SCI USA, V112, P15737, DOI 10.1073/pnas.1509045112; Armbruster D, 2016, PSYCHONEUROENDOCRINO, V66, P39, DOI 10.1016/j.psyneuen.2015.12.020; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Barnes P. J., 1979, CLIN SCI LOND ENGL, V94, P557; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Caporali A, 2009, PHYSIOL REV, V89, P279, DOI 10.1152/physrev.00007.2008; Centers for Disease Control and Prevention, 2016, TRAUMATIC BRAIN INJU; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Clark CG, 2011, J NEUROSCI, V31, P12318, DOI 10.1523/JNEUROSCI.0746-11.2011; Duman RS, 1997, ARCH GEN PSYCHIAT, V54, P597; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Erickson KI, 2012, NEUROSCIENTIST, V18, P82, DOI 10.1177/1073858410397054; Failla MD, 2016, NEUROREHAB NEURAL RE, V30, P83, DOI 10.1177/1545968315586465; Failla MD, 2015, NEUROREHAB NEURAL RE, V29, P234, DOI 10.1177/1545968314542617; Ferrari E, 2001, EUR J ENDOCRINOL, V144, P319, DOI 10.1530/eje.0.1440319; Freedman ML, 2004, NAT GENET, V36, P388, DOI 10.1038/ng1333; Fujimura H, 2002, THROMB HAEMOSTASIS, V87, P728; Gomes JR, 2012, J NEUROSCI, V32, P4610, DOI 10.1523/JNEUROSCI.0374-12.2012; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; Grundy PL, 2000, NEUROREPORT, V11, P3381, DOI 10.1097/00001756-200010200-00023; Grundy PL, 2001, BRAIN RES, V892, P386, DOI 10.1016/S0006-8993(00)03258-3; Hamra G, 2013, INT J EPIDEMIOL, V42, P627, DOI 10.1093/ije/dyt043; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Janssens ACJW, 2011, ANN INTERN MED, V154, P421, DOI 10.7326/0003-4819-154-6-201103150-00008; Jeanneteau F, 2008, P NATL ACAD SCI USA, V105, P4862, DOI 10.1073/pnas.0709102105; Jeanneteau FD, 2012, P NATL ACAD SCI USA, V109, P1305, DOI 10.1073/pnas.1114122109; Joels M, 2008, EUR J PHARMACOL, V583, P312, DOI 10.1016/j.ejphar.2007.11.064; Kennedy KM, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.019.2009; Kim JM, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.01.018; Kumamaru E, 2008, MOL ENDOCRINOL, V22, P546, DOI 10.1210/me.2007-0264; Kumamaru E, 2011, FEBS LETT, V585, P3224, DOI 10.1016/j.febslet.2011.09.010; Kumar RG, 2015, BRAIN BEHAV IMMUN, V45, P253, DOI 10.1016/j.bbi.2014.12.021; Kumar RG, 2016, BRAIN BEHAV IMMUN, V53, P183, DOI 10.1016/j.bbi.2015.12.008; Liston C, 2011, P NATL ACAD SCI USA, V108, P16074, DOI 10.1073/pnas.1110444108; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Marmigere F, 2003, HIPPOCAMPUS, V13, P646, DOI 10.1002/hipo.10109; McEwen BS, 2015, P NATL ACAD SCI USA, V112, P15544, DOI 10.1073/pnas.1521416112; McEwen BS, 2012, DEV NEUROBIOL, V72, P878, DOI 10.1002/dneu.20968; McEwen BS, 1999, FRONT NEUROENDOCRIN, V20, P49, DOI 10.1006/frne.1998.0173; Morris JA, 2007, J AM COLL SURGEONS, V204, P885, DOI 10.1016/j.jamcollsurg.2007.01.019; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Nakahashi T, 2000, FEBS LETT, V470, P113, DOI 10.1016/S0014-5793(00)01302-8; Nettiksimmons J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091339; Niyonkuru C, 2013, J NEUROTRAUM, V30, P938, DOI 10.1089/neu.2012.2578; Notaras MJ, 2017, SCHIZOPHRENIA BULL, V43, P665, DOI 10.1093/schbul/sbw077; Numakawa T, 2009, P NATL ACAD SCI USA, V106, P647, DOI 10.1073/pnas.0800888106; Orefice LL, 2013, J NEUROSCI, V33, P11618, DOI 10.1523/JNEUROSCI.0012-13.2013; Pal R, 2014, AGE, V36, DOI 10.1007/s11357-014-9683-7; Ranganathan P, 2016, BRAIN INJURY, V30, P452, DOI 10.3109/02699052.2016.1144081; Revest JM, 2014, MOL PSYCHIATR, V19, P1001, DOI 10.1038/mp.2013.134; Romanczyk TB, 2002, EUR J NEUROSCI, V15, P269, DOI 10.1046/j.0953-816x.2001.01858.x; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Rostami E, 2014, BRAIN RES, V1542, P195, DOI 10.1016/j.brainres.2013.10.047; Rothman SM, 2013, NEUROSCIENCE, V239, P228, DOI 10.1016/j.neuroscience.2012.10.014; Ryan ML, 2011, J TRAUMA, V70, P1371, DOI 10.1097/TA.0b013e31821858e6; Santarsieri M, 2015, BRAIN BEHAV IMMUN, V45, P15, DOI 10.1016/j.bbi.2014.09.003; Santarsieri M, 2014, J NEUROTRAUM, V31, P699, DOI 10.1089/neu.2013.3177; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Schule C, 2006, PSYCHONEUROENDOCRINO, V31, P1019, DOI 10.1016/j.psyneuen.2006.06.002; Sebastiani A, 2015, J NEUROTRAUM, V32, P1599, DOI 10.1089/neu.2014.3751; SMITH MA, 1995, J NEUROSCI, V15, P1768; Stranahan AM, 2011, NEUROENDOCRINOLOGY, V93, P58, DOI 10.1159/000322808; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Tapia-Arancibia L, 2004, FRONT NEUROENDOCRIN, V25, P77, DOI 10.1016/j.yfrne.2004.04.001; Tapia-Arancibia L, 2008, BRAIN RES REV, V59, P201, DOI 10.1016/j.brainresrev.2008.07.007; Vidaurre OG, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.143; Wagner AK, 2005, CRIT CARE MED, V33, P407, DOI 10.1097/01.CCM.0000153931.23488.DD; Wagner AK, 2007, J NEUROSURG, V106, P538, DOI 10.3171/jns.2007.106.4.538; Wagner AK, 2011, J CEREBR BLOOD F MET, V31, P1886, DOI 10.1038/jcbfm.2011.31; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Webster MJ, 2006, GENE EXPR PATTERNS, V6, P941, DOI 10.1016/j.modgep.2006.03.009; Werdan K, 2009, CAN J PHYSIOL PHARM, V87, P266, DOI 10.1139/Y09-012; Yang AC, 2010, AM J MED GENET B, V153B, P1024, DOI 10.1002/ajmg.b.31069; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Yeager MP, 2004, ACTA ANAESTH SCAND, V48, P799, DOI 10.1111/j.1399-6576.2004.00434.x	79	12	15	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5099			FRONT MOL NEUROSCI	Front. Molec. Neurosci.	MAR 9	2017	10								44	10.3389/fnmol.2017.00044			16	Neurosciences	Neurosciences & Neurology	EN1QX	WOS:000395786000001	28337122	DOAJ Gold, Green Published			2021-06-18	
J	Bragin, DE; Kameneva, MV; Bragina, OA; Thomson, S; Statom, GL; Lara, DA; Yang, YR; Nemoto, EM				Bragin, Denis E.; Kameneva, Marina V.; Bragina, Olga A.; Thomson, Susan; Statom, Gloria L.; Lara, Devon A.; Yang, Yirong; Nemoto, Edwin M.			Rheological effects of drag-reducing polymers improve cerebral blood flow and oxygenation after traumatic brain injury in rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Brain metabolism; cerebral blood microcirculation; drag-reducing polymers; rheology; traumatic brain injury	FLUID SHEAR-STRESS; ADENOSINE RECEPTOR AGONISTS; HIGH INTRACRANIAL-PRESSURE; SEVERE HEAD-INJURY; MICROVASCULAR PERFUSION; ISCHEMIA; MECHANISMS; RESPONSES; MICROCIRCULATION; CIRCULATION	Cerebral ischemia has been clearly demonstrated after traumatic brain injury (TBI); however, neuroprotective therapies have not focused on improvement of the cerebral microcirculation. Blood soluble drag-reducing polymers (DRP), prepared from high molecular weight polyethylene oxide, target impaired microvascular perfusion by altering the rheological properties of blood and, until our recent reports, has not been applied to the brain. We hypothesized that DRP improve cerebral microcirculation and oxygenation after TBI. DRP were studied in healthy and traumatized rat brains and compared to saline controls. Using in-vivo two-photon laser scanning microscopy over the parietal cortex, we showed that after TBI, nanomolar concentrations of intravascular DRP significantly enhanced microvascular perfusion and tissue oxygenation in peri-contusional areas, preserved blood-brain barrier integrity and protected neurons. The mechanisms of DRP effects were attributable to reduction of the near-vessel wall cell-free layer which increased near-wall blood flow velocity, microcirculatory volume flow, and number of erythrocytes entering capillaries, thereby reducing capillary stasis and tissue hypoxia as reflected by a reduction in NADH. Our results indicate that early reduction in CBF after TBI is mainly due to ischemia; however, metabolic depression of contused tissue could be also involved.	[Bragin, Denis E.; Bragina, Olga A.; Thomson, Susan; Statom, Gloria L.; Lara, Devon A.; Nemoto, Edwin M.] Univ New Mexico, Sch Med, Dept Neurosurg, 1 Univ New Mexico,MSC10 5615, Albuquerque, NM 87131 USA; [Kameneva, Marina V.] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA USA; [Kameneva, Marina V.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA; [Kameneva, Marina V.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA; [Yang, Yirong] Univ New Mexico, Coll Pharm, Albuquerque, NM 87131 USA	Bragin, DE (corresponding author), Univ New Mexico, Sch Med, Dept Neurosurg, 1 Univ New Mexico,MSC10 5615, Albuquerque, NM 87131 USA.	dbragin@salud.unm.edu	Bragina, Olga A/H-6696-2016; Bragin, Denis/E-5494-2016	Bragina, Olga A/0000-0003-2810-9764; Bragin, Denis/0000-0003-4894-0061	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R21NS091600-01A1, 8P30GM103400, P20GM109089-01A1]; American Heart AssociationAmerican Heart Association [14GRNT20380496]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM109089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS091600] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Institutes of Health (1R21NS091600-01A1, 8P30GM103400 and P20GM109089-01A1) and American Heart Association (14GRNT20380496).	BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bragin DE, 2016, ACTA NEUROCHIR SUPPL, V122, P25, DOI 10.1007/978-3-319-22533-3_5; Bragin DE, 2013, STROKE, V44, P177, DOI 10.1161/STROKEAHA.112.668293; Bragin DE, 2011, J NEUROTRAUM, V28, P775, DOI 10.1089/neu.2010.1692; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brands J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077252; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; CHANCE B, 1962, SCIENCE, V137, P499, DOI 10.1126/science.137.3529.499; Chance B, 1973, Adv Exp Med Biol, V37A, P277; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Fahraeus R, 1931, AM J PHYSIOL, V96, P562; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gannushkina I. V., 1984, Soviet Physics - Doklady, V29, P274; Gannushkina I. V., 1981, Soviet Physics - Doklady, V26; Golub' A. S., 1987, Soviet Physics - Doklady, V32, P620; Hu F, 2011, BIORHEOLOGY, V48, P149, DOI 10.3233/BIR-2011-0592; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Kameneva MV, 2012, INT J ENG SCI, V59, P168, DOI 10.1016/j.ijengsci.2012.03.014; Kameneva MV, 2004, BIORHEOLOGY, V41, P53; Kochanek PM, 2005, J CEREBR BLOOD F MET, V25, P1596, DOI 10.1038/sj.jcbfm.9600154; Kochanek PM, 2001, MAGNET RESON MED, V45, P924, DOI 10.1002/mrm.1123; Marascalco PJ, 2009, ASAIO J, V55, P503, DOI 10.1097/MAT.0b013e3181b1840f; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Martini RP, 2013, RESP CARE, V58, P162, DOI 10.4187/respcare.01942; Ostergaard L, 2014, J CEREBR BLOOD F MET, V34, P1585, DOI 10.1038/jcbfm.2014.131; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Pacella JJ, 2006, EUR HEART J, V27, P2362, DOI 10.1093/eurheartj/ehl165; Pacella JJ, 2012, MICROCIRCULATION, V19, P580, DOI 10.1111/j.1549-8719.2012.00190.x; Resnick N, 2003, PROG BIOPHYS MOL BIO, V81, P177, DOI 10.1016/S0079-6107(02)00052-4; RINK A, 1995, AM J PATHOL, V147, P1575; Sakai T, 2007, BRIT J ANAESTH, V98, P23, DOI 10.1093/bja/ael307; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Topper JN, 1999, MOL MED TODAY, V5, P40, DOI 10.1016/S1357-4310(98)01372-0; Varma MR, 2002, BRAIN RES, V951, P191, DOI 10.1016/S0006-8993(02)03161-X; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Wu HM, 2013, J NEUROTRAUM, V30, P352, DOI 10.1089/neu.2012.2610; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Yamawaki H, 2005, J CLIN INVEST, V115, P733, DOI 10.1172/JCI200523001; Zhao R, 2010, BIORHEOLOGY, V47, P193, DOI 10.3233/BIR-2010-0570	55	12	14	0	16	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2017	37	3					762	775		10.1177/0271678X16684153			14	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	EL5KQ	WOS:000394660400002	28155574	Green Published, Bronze			2021-06-18	
J	Klee, R; Brandt, C; Tollner, K; Loscher, W				Klee, Rebecca; Brandt, Claudia; Toellner, Kathrin; Loescher, Wolfgang			Various modifications of the intrahippocampal kainate model of mesial temporal lobe epilepsy in rats fail to resolve the marked rat-to-mouse differences in type and frequency of spontaneous seizures in this model	EPILEPSY & BEHAVIOR			English	Article						Kainic acid; Hippocampus; Electrographic seizures; EEG; Anesthesia; Isoflurane	KAINIC ACID INJECTION; HIPPOCAMPAL SCLEROSIS; RECURRENT SEIZURES; STATUS EPILEPTICUS; ACQUIRED EPILEPSY; ANIMAL-MODELS; EPILEPTOGENESIS; MICE; NEURONS; CONTRIBUTES	Temporal lobe epilepsy (TLE) is the most common type of acquired epilepsy in adults. TLE can develop after diverse brain insults, including traumatic brain injury, infections, stroke, or prolonged status epilepticus (SE). Post SE rodent models of TLE are widely used to understand mechanisms of epileptogenesis and develop treatments for epilepsy prevention. In this respect, the intrahippocampal kainate model of TLE in mice is of interest, because highly frequent spontaneous electrographic seizures develop in the kainate focus, allowing evaluation of both anti-seizure and anti-epileptogenic effects of novel drugs with only short EEG recording periods, which is not possible in any other model of TLE, including the intrahippocampal kainate model in rats. In the present study, we investigated whether the marked mouse-to-rat difference in occurrence and frequency of spontaneous seizures is due to a species difference or to technical variables, such as anesthesia during kainate injection, kainate dose, or location of kainate injection and EEG electrode in the hippocampus. When, as in the mouse model, anesthesia was used during kainate injection, only few rats developed epilepsy, although severity or duration of SE was not affected by isoflurane. In contrast, most rats developed epilepsy when kainate was injected without anesthesia. However, frequent electrographic seizures as observed in mice did not occur in rats, irrespective of location of kainate injection (CA1, CA3) or EEG recording electrode (CA1, CA3, dentate gyrus) or dose of kainate injected. These data indicate marked phenotypic differences between mice and rats in this model. Further studies should explore the mechanisms underlying this species difference. (C) 2016 Elsevier Inc. All rights reserved.	[Klee, Rebecca; Brandt, Claudia; Toellner, Kathrin; Loescher, Wolfgang] Univ Vet Med Hannover, Dept Pharmacol Toxicol & Pharm, Bunteweg 17, D-30559 Hannover, Germany; Ctr Syst Neurosci, Hannover, Germany	Loscher, W (corresponding author), Univ Vet Med Hannover, Dept Pharmacol Toxicol & Pharm, Bunteweg 17, D-30559 Hannover, Germany.	wolfgang.loescher@tiho-hannover.de	Loscher, Wolfgang/G-9824-2016	Loscher, Wolfgang/0000-0002-9648-8973	European UnionEuropean Commission [602102]; FAZIT-Foundation (Frankfurt a.M., Germany)	We thank Edith Kaczmarek, Dr. Friederike Twele, and Philip Hampel for skillful technical assistance. The research leading to these results has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 602102 (EPITARGET). R. Klee thanks the FAZIT-Foundation (Frankfurt a.M., Germany) for a PhD scholarship.	ANDERSSON PB, 1991, NEUROSCIENCE, V42, P201, DOI 10.1016/0306-4522(91)90159-L; Arabadzisz D, 2005, EXP NEUROL, V194, P76, DOI 10.1016/j.expneurol.2005.01.029; Balosso S, 2005, ANN NEUROL, V57, P804, DOI 10.1002/ana.20480; Bar-Klein G, 2016, ANN NEUROL, V80, P896, DOI 10.1002/ana.24804; Ben-Ari Y, 2000, TRENDS NEUROSCI, V23, P580, DOI 10.1016/S0166-2236(00)01659-3; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; Bishop KM, 1999, BRAIN RES, V815, P358, DOI 10.1016/S0006-8993(98)01088-9; Bouilleret V, 1999, NEUROSCIENCE, V89, P717, DOI 10.1016/S0306-4522(98)00401-1; Bragin A, 2005, EPILEPSIA, V46, P1592, DOI 10.1111/j.1528-1167.2005.00268.x; Bragin A, 2004, EPILEPSIA, V45, P1017, DOI 10.1111/j.0013-9580.2004.17004.x; CAVALHEIRO EA, 1982, ELECTROEN CLIN NEURO, V53, P581, DOI 10.1016/0013-4694(82)90134-1; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Dudek FE, 2006, MODELS OF SEIZURES AND EPILEPSY, P415, DOI 10.1016/B978-012088554-1/50036-0; Gernert M, 2001, EUR J PHARMACOL, V432, P35, DOI 10.1016/S0014-2999(01)01458-3; Gouder N, 2003, EPILEPSIA, V44, P877, DOI 10.1046/j.1528-1157.2003.03603.x; Groticke I, 2008, EXP NEUROL, V213, P71, DOI 10.1016/j.expneurol.2008.04.036; Guillemain I, 2012, EPILEPTIC DISORD, V14, P217, DOI 10.1684/epd.2012.0528; Heinrich C, 2006, J NEUROSCI, V26, P4701, DOI 10.1523/JNEUROSCI.5516-05.2006; Hirshler Y, 2010, EXP NEUROL, V222, P42, DOI 10.1016/j.expneurol.2009.12.006; Jarrard LE, 2002, HIPPOCAMPUS, V12, P405, DOI 10.1002/hipo.10054; Karoly N, 2011, ACTA HISTOCHEM, V113, P656, DOI 10.1016/j.acthis.2010.08.005; Klee R, 2015, EPILEPSY RES, V118, P34, DOI 10.1016/j.eplepsyres.2015.11.003; Klein S, 2015, NEUROPHARMACOLOGY, V90, P53, DOI 10.1016/j.neuropharm.2014.11.008; Kucker S, 2010, NEUROBIOL DIS, V37, P661, DOI 10.1016/j.nbd.2009.12.002; Levesque M, 2013, NEUROSCI BIOBEHAV R, V37, P2887, DOI 10.1016/j.neubiorev.2013.10.011; Loscher W, 2016, EPILEPSY RES, V126, P157, DOI 10.1016/j.eplepsyres.2016.05.016; Loscher W, 2015, EPILEPSY BEHAV, V52, P78, DOI 10.1016/j.yebeh.2015.08.037; Loscher W, 2013, NAT REV DRUG DISCOV, V12, P757, DOI 10.1038/nrd4126; Loscher W, 2009, EUR J PHARMACOL, V610, P1, DOI 10.1016/j.ejphar.2009.03.025; Maroso M, 2011, NEUROTHERAPEUTICS, V8, P304, DOI 10.1007/s13311-011-0039-z; Maroso M, 2010, NAT MED, V16, P413, DOI 10.1038/nm.2127; Mitsuya K, 2009, EPILEPSIA, V50, P1979, DOI 10.1111/j.1528-1167.2009.02055.x; Ndode-Ekane XE, 2013, MOL NEUROBIOL, V47, P914, DOI 10.1007/s12035-012-8386-2; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Polikov VS, 2005, J NEUROSCI METH, V148, P1, DOI 10.1016/j.jneumeth.2005.08.015; Potter KA, 2012, J NEURAL ENG, V9, DOI 10.1088/1741-2560/9/4/046020; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Raedt R, 2009, ACTA NEUROL SCAND, V119, P293, DOI 10.1111/j.1600-0404.2008.01108.x; Rattka M, 2013, EPILEPSY RES, V103, P135, DOI 10.1016/j.eplepsyres.2012.09.015; Rattka M, 2012, EUR J NEUROSCI, V36, P2505, DOI 10.1111/j.1460-9568.2012.08143.x; Rattka M, 2011, NEUROPHARMACOLOGY, V60, P505, DOI 10.1016/j.neuropharm.2010.11.005; Riban V, 2002, NEUROSCIENCE, V112, P101, DOI 10.1016/S0306-4522(02)00064-7; Snyder JS, 2009, J NEUROSCI, V29, P14484, DOI 10.1523/JNEUROSCI.1768-09.2009; SUZUKI F, 1995, NEUROSCIENCE, V64, P665, DOI 10.1016/0306-4522(94)00463-F; Tollner K, 2014, ANN NEUROL, V75, P550, DOI 10.1002/ana.24124; Topfer M, 2014, EUR J NEUROSCI, V39, P673, DOI 10.1111/ejn.12424; Twele F, 2016, EPILEPSY BEHAV, V55, P47, DOI 10.1016/j.yebeh.2015.11.027; Twele F, 2015, NEUROPHARMACOLOGY, V95, P234, DOI 10.1016/j.neuropharm.2015.03.014; Vezzani A, 1999, J NEUROSCI, V19, P5054; Vezzani A, 2016, ACTA NEUROPATHOL, V131, P211, DOI 10.1007/s00401-015-1481-5; Whishaw IQ, 2001, DEV PSYCHOBIOL, V39, P151, DOI 10.1002/dev.1041; Wlaz P., 2000, Naunyn-Schmiedeberg's Archives of Pharmacology, V362, pR49; Zattoni M, 2011, J NEUROSCI, V31, P4037, DOI 10.1523/JNEUROSCI.6210-10.2011	53	12	12	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	MAR	2017	68						129	140		10.1016/j.yebeh.2016.11.035			12	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	EQ9TA	WOS:000398426900021	28167446				2021-06-18	
J	Seeger, TA; Kirton, A; Esser, MJ; Gallagher, C; Dunn, J; Zewdie, E; Damji, O; Ciechanski, P; Barlow, KM				Seeger, Trevor A.; Kirton, Adam; Esser, Michael J.; Gallagher, Clare; Dunn, Jeff; Zewdie, Ephrem; Damji, Omar; Ciechanski, Patrick; Barlow, Karen M.			Cortical excitability after pediatric mild traumatic brain injury	BRAIN STIMULATION			English	Article						Transcranial magnetic stimulus; Mild traumatic brain injury; Pediatrics; Cortical silent period; Long interval intracortical inhibition	TRANSCRANIAL MAGNETIC STIMULATION; PRIMARY MOTOR CORTEX; HEAD-INJURY; SPORTS CONCUSSION; BASIC MECHANISMS; IFCN COMMITTEE; CHILDREN; SYMPTOMS; EPIDEMIOLOGY; METAANALYSIS	Introduction: Mild traumatic brain injury (mTBI) outcomes are variable, and 10-15% may suffer from prolonged symptoms beyond 3 months that impair the child's return to normal activities. Neurophysiological mechanisms of mTBI are incompletely understood, particularly in children, but alterations in cortical excitability have been proposed to underlie post-concussion syndrome. Improved understanding is required to advance interventions and improve outcomes. Objective/Hypothesis: To determine if cortical excitability is altered in children with mTBI, and its association with clinical symptoms. Methods: This was a cross-sectional controlled cohort study. School-aged children (8-18 years) with mTBI were compared to healthy controls. Cortical excitability was measured using multiple TMS paradigms in children with (symptomatic) and without (recovered) persistent symptoms one-month post injury. Primary outcome was the cortical silent period (cSP), a potential neurophysiological biomarlcer of GABAergic inhibition. Secondary outcomes included additional TMS neurophysiology, safety and tolerability. Associations between neurophysiology parameters and clinical symptoms were evaluated. Results: Fifty-three children with mTBI (55% male; mean age 14.1 SD: 2.4 years; 35 symptomatic and 27 asymptomatic participants) and 28 controls (46% male; mean age 14.3 SD: 3.1 years) were enrolled. cSP duration was similar between groups (F (2, 73) = 0.55, p = 0.582). Log(10) long interval intracortical inhibition (LICI) was reduced in symptomatic participants compared to healthy controls (F (2, 59) = 3.83, p = 0.027). Procedures were well tolerated with no serious adverse events. Conclusions: TMS measures of cortical excitability are altered at one month in children with mTBI. Long interval cortical inhibition is decreased in children who remain symptomatic at one month post-injury. (C) 2016 Elsevier Inc. All rights reserved.	[Seeger, Trevor A.; Kirton, Adam; Esser, Michael J.; Gallagher, Clare; Dunn, Jeff; Zewdie, Ephrem; Damji, Omar; Ciechanski, Patrick; Barlow, Karen M.] Univ Calgary, Cumming Sch Med, Calgary, AB, Canada; [Seeger, Trevor A.; Kirton, Adam; Gallagher, Clare; Dunn, Jeff; Zewdie, Ephrem; Ciechanski, Patrick; Barlow, Karen M.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Seeger, Trevor A.; Kirton, Adam; Esser, Michael J.; Gallagher, Clare; Dunn, Jeff; Zewdie, Ephrem; Ciechanski, Patrick; Barlow, Karen M.] Alberta Childrens Prov Gen Hosp, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada	Barlow, KM (corresponding author), Univ Calgary, Cumming Sch Med, Calgary, AB, Canada.	karen.barlow@albertahealthservices.ca	Barlow, Karen/I-6492-2019; Barlow, Karen/C-1323-2014	Barlow, Karen/0000-0003-2612-8507	Alberta Innovates [201400252] Funding Source: researchfish		Adeyemo BO, 2014, J ATTEN DISORD, V18, P576, DOI 10.1177/1087054714543371; Barlow KM, 2016, J CHILD NEUROL, V31, P57, DOI 10.1177/0883073814543305; Barlow KM, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-271; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barlow KM, PEDIAT BRAIN STIMULA; Barlow KM, 2015, PEDIAT NEUROL; Boroojerdi B, 2001, CLIN NEUROPHYSIOL, V112, P931, DOI 10.1016/S1388-2457(01)00523-5; Boroojerdi B, 2001, P NATL ACAD SCI USA, V98, P14698, DOI 10.1073/pnas.251357198; Brooks BL, 2014, J NEUROTRAUM, V1749, P1; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Chen R, 2008, CLIN NEUROPHYSIOL, V119, P504, DOI 10.1016/j.clinph.2007.10.014; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dennis EL, 2015, J NEUROSCI, V35, P10202, DOI 10.1523/JNEUROSCI.1595-15.2015; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Faul M, 2010, TRAUMATIC BRAIN INJU, P74; Garvey MA, 2003, CLIN NEUROPHYSIOL, V114, P1662, DOI 10.1016/S1388-2457(03)00130-5; Garvey MA, 2001, J CHILD NEUROL, V16, P891, DOI 10.1177/088307380101601205; Garvey MA, 2001, CLIN NEUROPHYSIOL, V112, P1451, DOI 10.1016/S1388-2457(01)00581-8; Garvey MA, 2008, CLIN NEUROPHYSIOL, V119, P973, DOI 10.1016/j.clinph.2007.11.048; Gilbert DL, 2011, NEUROLOGY, V76, P615, DOI 10.1212/WNL.0b013e31820c2ebd; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Giza CC, 2009, DEV NEUROREHABIL, V12, P255, DOI 10.3109/17518420903087558; Groppa S, 2012, CLIN NEUROPHYSIOL, V123, P858, DOI 10.1016/j.clinph.2012.01.010; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Huusko N, 2014, NEUROSCIENCE, V267, P30, DOI 10.1016/j.neuroscience.2014.02.026; Jung P, 2006, MUSCLE NERVE, V34, P431, DOI 10.1002/mus.20604; Keel JC, 2001, CLIN NEUROPHYSIOL, V112, P720, DOI 10.1016/S1388-2457(00)00518-6; King N, 2014, NEUROREHABILITATION, V34, P741, DOI 10.3233/NRE-141072; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lao Y, 2015, PROCSPIE INTSOCOPTEN, V9287, P1, DOI DOI 10.1117/12.20; Lefebvre G, 2015, BRAIN INJURY, V29, P1032, DOI 10.3109/02699052.2015.1028447; Liepert J, 1997, J NEURAL TRANSM, V104, P1207, DOI 10.1007/BF01294721; Livingston SC, 2012, J CLIN NEUROPHYSIOL, V29, P23, DOI 10.1097/WNP.0b013e318246ae46; Macpherson A, 2014, PAED CHILD HEALT-CAN, V19, P543, DOI 10.1093/pch/19.10.543; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Miller J, 2014, NEUROSURGERY S1, V61, P222; Miller NR, 2014, BRAIN INJURY, V28, P1270, DOI 10.3109/02699052.2014.915987; Mohammadi B, 2006, MUSCLE NERVE, V33, P778, DOI 10.1002/mus.20531; Moran LM, 2012, J PEDIATR PSYCHOL, V37, P736, DOI 10.1093/jpepsy/jsr087; Nardone R, 2004, NEUROSCI LETT, V355, P65, DOI 10.1016/j.neulet.2003.10.055; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pearce AJ, 2014, J NEUROTRAUM, V31, P1139, DOI 10.1089/neu.2013.3219; Powers KC, 2014, BRAIN INJURY, V28, P465, DOI 10.3109/02699052.2014.888759; Raible DJ, 2012, J NEUROTRAUMA, V2554; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Sady MD, 2014, ARCH CLIN NEUROPSYCH; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; Solinas C, 2008, EUR J NEUROL, V15, P501, DOI 10.1111/j.1468-1331.2008.02110.x; Takeuchi N, 2006, BRAIN INJURY, V20, P991, DOI 10.1080/02699050600909771; Terao Y, 2002, J CLIN NEUROPHYSIOL, V19, P322, DOI 10.1097/00004691-200208000-00006; Tremblay S, 2011, CLIN NEUROPHYSIOL, V122, pS185; Tremblay S, 2014, CLIN NEUROPHYSIOL, V125, P1371, DOI 10.1016/j.clinph.2013.11.040; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; Urban KJ, 2015, J NEUROTRAUM, V32, P833, DOI 10.1089/neu.2014.3577; Wu P, 2013, J NEUROTRAUM, V30, P775, DOI 10.1089/neu.2012.2391; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	67	12	12	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1935-861X	1876-4754		BRAIN STIMUL	Brain Stimul.	MAR-APR	2017	10	2					305	314		10.1016/j.brs.2016.11.011			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EN2LN	WOS:000395841800016	27916406				2021-06-18	
J	Sherer, M; Nick, TG; Sander, AM; Melguizo, M; Hanks, R; Novack, TA; Tulsky, D; Kisala, P; Luo, CQ; Tang, XY				Sherer, Mark; Nick, Todd G.; Sander, Angelle M.; Melguizo, Maria; Hanks, Robin; Novack, Thomas A.; Tulsky, David; Kisala, Pamela; Luo, Chunqiao; Tang, Xinyu			Groupings of Persons With Traumatic Brain Injury: A New Approach to Classifying Traumatic Brain Injury in the Post-Acute Period	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						classification; environment; outcome; quality of life; traumatic brain injury; treatment	CLOSED-HEAD-INJURY; REHABILITATION; CLUSTERS; NUMBER; LIFE	Objective: To (1) identify groups of persons with traumatic brain injury (TBI) who differ on 12 dimensions of cognitive function: cognitive, emotional, and physical symptoms; personal strengths; physical functioning; environmental supports; and performance validity; and (2) describe patterns of differences among the groups on these dimensions and on participation outcome. Setting: Three centers for rehabilitation of persons with TBI. Participants: A total of 504 persons with TBI living in the community who were an average (standard deviation) of 6.3 (6.8) years postinjury and who had capacity to give consent, could be interviewed and tested in English, and were able to participate in an assessment lasting up to 4 hours. Design: Observational study of a convenience sample of persons with TBI. Main Measures: Selected scales from the Traumatic Brain Injury Quality of Life measures, Neurobehavioral Symptom Inventory, Economic Quality of Life Scale, Family Assessment Device General Functioning Scale, measures of cognitive function, Word Memory Test, and Participation Assessment with Recombined Tools-Objective (PART-O) scale. Results: Cluster analysis identified 5 groups of persons with TBI who differed in clinically meaningful ways on the 12 dimension scores and the PART-O scale. Conclusion: Cluster groupings identified in this study could assist clinicians with case conceptualization and treatment planning.	[Sherer, Mark; Sander, Angelle M.] TIRR Mem Hermann, 1333 Moursund St, Houston, TX 77030 USA; [Sherer, Mark; Sander, Angelle M.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Nick, Todd G.; Melguizo, Maria; Luo, Chunqiao; Tang, Xinyu] Univ Arkansas Med Sci, Dept Pediat & Biostat, Little Rock, AR 72205 USA; [Sander, Angelle M.] Harris Hlth Syst, Ctr Trauma Rehabil, Dept Phys Med & Rehabil, Houston, TX USA; [Hanks, Robin] Wayne State Univ, Sch Med, Rehabil Inst Michigan, Dept Phys Med & Rehabil, Detroit, MI USA; [Novack, Thomas A.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Tulsky, David; Kisala, Pamela] Univ Delaware, Coll Hlth Sci, Dept Phys Therapy, Newark, DE 19716 USA; [Tulsky, David] Kessler Fdn, W Orange, NJ USA	Sherer, M (corresponding author), TIRR Mem Hermann, 1333 Moursund St, Houston, TX 77030 USA.	Mark.Sherer@memorialhermann.org		Tulsky, David/0000-0002-4335-4509	US Department of Education National Institute on Disability and Rehabilitation Research grants [H133B090023, H133A120020]	This research was supported by US Department of Education National Institute on Disability and Rehabilitation Research grants H133B090023 and H133A120020.	BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; BenYishay Y, 1996, NEUROPSYCHOL REHABIL, V6, P327, DOI 10.1080/713755514; Bergquist T.F., 2014, HDB NEUROPSYCHOLOGY, P77; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Charrad M, 2014, J STAT SOFTW, V61, P1; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Dams-O'Connor K, 2013, BRAIN IMPAIR, V14, P51, DOI 10.1017/BrImp.2013.9; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Green P., 1996, WORD MEMORY TEST USE; Harabasz, 1974, COMMUN STAT, V3, P1, DOI DOI 10.1080/03610927408827101; Marion DW, 2006, NEUROSURGERY, V58, P655; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; R Core Team, 2018, R LANG ENV STAT COMP; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A, 1958, EXAMIN CLIN PSYCHOL; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sherer M, 2000, J HEAD TRAUMA REHAB, V15, P767, DOI 10.1097/00001199-200004000-00002; Sherer M, 2003, DEMONSTRATING UTILIT, P39; Sherer M, 2015, REHABIL PSYCHOL, V60, P138, DOI 10.1037/rep0000030; TEASDALE G, 1974, LANCET, V2, P81; Tibshirani R, 2001, J ROY STAT SOC B, V63, P411, DOI 10.1111/1467-9868.00293; Tulsky DS, 2016, J HEAD TRAUMA REHAB, V31, P40, DOI 10.1097/HTR.0000000000000131; Tulsky DS, 2015, ARCH PHYS MED REHAB, V96, P604, DOI 10.1016/j.apmr.2014.02.030; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002	27	12	12	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2017	32	2					125	133		10.1097/HTR.0000000000000207			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EN3YU	WOS:000395944700014	26709583				2021-06-18	
J	Zhu, Y				Zhu, Yong			Design and Validation of a Low-Cost Portable Device to Quantify Postural Stability	SENSORS			English	Article						human balance; postural stability; approximate entropy (ApEn); center-of-pressure (COP); portable device; low-cost assessment device	APPROXIMATE ENTROPY; CEREBRAL CONCUSSION; HUMAN BALANCE; SWAY; REGULARITY	Measurement of the displacement of the center-of-pressure (COP) is an important tool used in biomechanics to assess postural stability and human balance. The goal of this research was to design and validate a low-cost portable device that can offer a quick indication of the state of postural stability and human balance related conditions. Approximate entropy (ApEn) values reflecting the amount of irregularity hiding in COP oscillations were used to calculate the index. The prototype adopted a portable design using the measurements of the load cells located at the four corners of a low-cost force platform. The test subject was asked to stand on the device in a quiet, normal, upright stance for 30 s with eyes open and subsequently for 30 s with eyes closed. Based on the COP displacement signals, the ApEn values were calculated. The results indicated that the prototype device was capable of capturing the increase in regularity of postural control in the visual-deprivation conditions. It was also able to decipher the subtle postural control differences along anterior-posterior and medial-lateral directions. The data analysis demonstrated that the prototype would enable the quantification of postural stability and thus provide a low-cost portable device to assess many conditions related to postural stability and human balance such as aging and pathologies.	[Zhu, Yong] Wilkes Univ, Dept Mech Engn, Wilkes Barre, PA 18766 USA	Zhu, Y (corresponding author), Wilkes Univ, Dept Mech Engn, Wilkes Barre, PA 18766 USA.	yong.zhu@wilkes.edu			Wilkes University	This research was partly supported by the Wilkes University mentoring project fund. Funds are received from Wilkes University for covering the costs to publish in open access. The author would like to thank the anonymous reviewers for their careful reading of the manuscript and their many insightful comments and suggestions.	Abrahamova D, 2008, PHYSIOL RES, V57, P957, DOI 10.33549/physiolres.931238; Garcia RB, 2012, ACTA OTORRINOLAR ESP, V63, P332, DOI 10.1016/j.otorri.2012.03.006; Balasubramaniam R, 2000, GAIT POSTURE, V11, P12, DOI 10.1016/S0966-6362(99)00051-X; Bartlett R, 2010, ENCY INT SPORTS STUD; Borg FG, 2010, J NEUROENG REHABIL, V7, DOI 10.1186/1743-0003-7-38; Buckley TA, 2016, J SPORT HEALTH SCI, V5, P61, DOI 10.1016/j.jshs.2016.01.007; Cavanaugh JT, 2007, J NEUROENG REHABIL, V4, DOI 10.1186/1743-0003-4-42; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chon KH, 2009, IEEE ENG MED BIOL, V28, P18, DOI 10.1109/MEMB.2009.934629; Donker SF, 2007, EXP BRAIN RES, V181, P1, DOI 10.1007/s00221-007-0905-4; Gaerlan MG, 2010, THESIS; Ghomashchi H, 2011, INT J BIFURCAT CHAOS, V21, P1163, DOI 10.1142/S021812741102891X; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; HASAN SS, 1990, J BIOMECH, V23, P783, DOI 10.1016/0021-9290(90)90025-X; Horak FB, 2006, AGE AGEING, V35, P7, DOI 10.1093/ageing/afl077; Huang CW, 2013, SENSORS-BASEL, V13, P10151, DOI 10.3390/s130810151; Jauregui-Renaud K., 2013, POSTURAL BALANCE PER; Johnson M. L., 2004, NUMERICAL COMPUTER M, V384; Lamoth CJC, 2009, GAIT POSTURE, V29, P546, DOI 10.1016/j.gaitpost.2008.12.006; Lizama LEC, 2016, J NEUROPHYSIOL, V115, P907, DOI 10.1152/jn.00103.2014; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; Raymakers JA, 2005, GAIT POSTURE, V21, P48, DOI 10.1016/j.gaitpost.2003.11.006; Richman JS, 2000, AM J PHYSIOL-HEART C, V278, pH2039; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Roerdink M, 2011, HUM MOVEMENT SCI, V30, P203, DOI 10.1016/j.humov.2010.04.005; Stins JF, 2011, HUM MOVEMENT SCI, V30, P190, DOI 10.1016/j.humov.2010.05.013; Strang A. J., 2010, PROFESS SAF, V55, P27; Valle MS, 2016, SCI REP-UK, V6, DOI 10.1038/srep37040; Yentes JM, 2013, ANN BIOMED ENG, V41, P349, DOI 10.1007/s10439-012-0668-3	31	12	12	0	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		1424-8220		SENSORS-BASEL	Sensors	MAR	2017	17	3								10.3390/s17030619			12	Chemistry, Analytical; Engineering, Electrical & Electronic; Instruments & Instrumentation	Chemistry; Engineering; Instruments & Instrumentation	ER5CJ	WOS:000398818700192	28335461	DOAJ Gold, Green Published			2021-06-18	
J	Cui, DM; Zeng, T; Ren, J; Wang, K; Jin, Y; Zhou, L; Gao, L				Cui, Da-Ming; Zeng, Tao; Ren, Jie; Wang, Ke; Jin, Yi; Zhou, Lin; Gao, Liang			KLF4 Knockdown Attenuates TBI-Induced Neuronal Damage through p53 and JAK-STAT3 Signaling	CNS NEUROSCIENCE & THERAPEUTICS			English	Article						Kruppel-like factor 4; Nrf2; P53; STAT3; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; TUMOR-SUPPRESSOR; INHIBITION; ACTIVATION; INDUCTION; APOPTOSIS; PROTECTS; PATHWAY; CELLS	AimsTraumatic brain injury (TBI) is induced by complex primary and secondary mechanisms that give rise to cell death, inflammation, and neurological dysfunction. Understanding the mechanisms that drive neurological damage as well as those that promote repair can guide the development of therapeutic drugs for TBI. Kruppel-like factor 4 (KLF4) has been reported to negatively regulate axon regeneration of injured retinal ganglion cells (RGCs) through inhibition of JAK-STAT3 signaling. However, the role of KLF4 in TBI remains unreported. Reactive oxygen species (ROS)-induced neuronal death is a pathophysiological hallmark of TBI. MethodsIn this study, we used H2O2-treated RGCs in vitro and the optic nerve crush model in vivo to simulate neuronal damage in TBI. The function of KLF4 in RGC survival and axon regeneration in these models was investigated. In addition, the effects of KLF4 knockdown on neuronal damage after a brain impact that mimics moderate TBI were studied. ResultsThe results show that H2O2 induces p53-dependent apoptosis of RGCs in vitro through upregulation of KLF4. Additionally, KLF4 knockdown in vivo significantly enhances CNTF-induced axon regeneration of RGCs after optic nerve crush, and more importantly, prevents neuronal damage after a moderate brain impact in rats. Our Western blot analysis and immunoprecipitation assay results indicate that these effects of KLF4 knockdown are mediated by the p53 and JAK-STAT3 pathways. ConclusionThese findings provide evidence that KLF4 plays an important role in the pathophysiology of TBI. Blocking KLF4 may be a potential therapeutic strategy for the treatment of TBI, either alone or in combination with agents that target complementary mechanisms.	[Cui, Da-Ming; Zeng, Tao; Ren, Jie; Wang, Ke; Jin, Yi; Zhou, Lin; Gao, Liang] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Neurosurg, 301 Middle Yanchang Rd, Shanghai 200072, Peoples R China	Gao, L (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Neurosurg, 301 Middle Yanchang Rd, Shanghai 200072, Peoples R China.	kalantes@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81201979]	This study was supported by the Youth Fund of the National Natural Science Foundation of China (81201979).	Brandt T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048252; Cardaci S, 2010, BIOCHEM J, V430, P439, DOI 10.1042/BJ20100503; CDC, 2014, INJ PREV CONTR TRAUM; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.t01-1-00220.x; Hybertson BM, 2011, MOL ASPECTS MED, V32, P234, DOI 10.1016/j.mam.2011.10.006; Kim SO, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054790, 10.1371/journal.pone.0053908]; Lee S, 2015, INT J MOL SCI, V16, P19657, DOI 10.3390/ijms160819657; Leibinger M, 2009, J NEUROSCI, V29, P14334, DOI 10.1523/JNEUROSCI.2770-09.2009; Liu Y, 2005, J BIOL CHEM, V280, P9719, DOI 10.1074/jbc.M412862200; Michikami I, 2012, EXP CELL RES, V318, P311, DOI 10.1016/j.yexcr.2011.12.013; Moore DL, 2009, SCIENCE, V326, P298, DOI 10.1126/science.1175737; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Qin S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3633; Qin S, 2012, MOL CELL BIOL, V32, P4297, DOI 10.1128/MCB.00838-12; Qin S, 2011, P NATL ACAD SCI USA, V108, P21117, DOI 10.1073/pnas.1112351109; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Smith PD, 2009, NEURON, V64, P617, DOI 10.1016/j.neuron.2009.11.021; Song YX, 2014, APOPTOSIS, V19, P984, DOI 10.1007/s10495-014-0982-3; Wassmann S, 2007, J MOL CELL CARDIOL, V43, P301, DOI 10.1016/j.yjmcc.2007.06.001; Yoshida T, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000622; Yoshida T, 2012, J BIOL CHEM, V287, P25706, DOI 10.1074/jbc.M112.361360; Yoshida T, 2008, AM J PHYSIOL-CELL PH, V295, pC1175, DOI 10.1152/ajpcell.00288.2008; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001; Zhou GJ, 2012, J CLIN INVEST, V122, P4727, DOI 10.1172/JCI66056	31	12	13	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1755-5930	1755-5949		CNS NEUROSCI THER	CNS Neurosci. Ther.	FEB	2017	23	2					106	118		10.1111/cns.12633			13	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	EK8EY	WOS:000394157900001	27671232	Green Published, Bronze			2021-06-18	
J	Edwards, AB; Anderton, RS; Knuckey, NW; Meloni, BP				Edwards, Adam B.; Anderton, Ryan S.; Knuckey, Neville W.; Meloni, Bruno P.			Characterisation of neuroprotective efficacy of modified poly-arginine-9 (R9) peptides using a neuronal glutamic acid excitotoxicity model	MOLECULAR AND CELLULAR BIOCHEMISTRY			English	Article						Poly-arginine peptides; Arginine-rich peptides; Cortical neurons; Neuroprotection; Glutamate excitotoxicity; Cortical neurons; Cell-penetrating peptides	CELL-PENETRATING PEPTIDES; MEDIATOR PROTEIN-2 CRMP2; TRAUMATIC BRAIN-INJURY; ARGININE-RICH PEPTIDES; NMDA RECEPTOR; POLY-ARGININE; STROKE; DEATH; MITOCHONDRIA; INHIBITION	In a recent study, we highlighted the importance of cationic charge and arginine residues for the neuroprotective properties of poly-arginine and arginine-rich peptides. In this study, using cortical neuronal cultures and an in vitro glutamic acid excitotoxicity model, we examined the neuroprotective efficacy of different modifications to the poly-arginine-9 peptide (R9). We compared an unmodified R9 peptide with R9 peptides containing the following modifications: (i) C-terminal amidation (R9-NH2); (ii) N-terminal acetylation (Ac-R9); (iii) C-terminal amidation with N-terminal acetylation (Ac-R9-NH2); and (iv) C-terminal amidation with D-amino acids (R9D-NH2). The three C-terminal amidated peptides (R9-NH2, Ac-R9-NH2, and R9D-NH2) displayed neuroprotective effects greater than the unmodified R9 peptide, while the N-terminal acetylated peptide (Ac-R9) had reduced efficacy. Using the R9-NH2 peptide, neuroprotection could be induced with a 10 min peptide pre-treatment, 1-6 h before glutamic acid insult, or when added to neuronal cultures up to 45 min post-insult. In addition, all peptides were capable of reducing glutamic acid-mediated neuronal intracellular calcium influx, in a manner that reflected their neuroprotective efficacy. This study further highlights the neuroprotective properties of poly-arginine peptides and provides insight into peptide modifications that affect efficacy.	[Edwards, Adam B.; Anderton, Ryan S.; Knuckey, Neville W.; Meloni, Bruno P.] QEII Med Ctr, Western Australian Neurosci Res Inst, A Block,4th Floor,Verdun St, Nedlands, WA 6009, Australia; [Edwards, Adam B.; Anderton, Ryan S.] Univ Notre Dame Australia, Sch Hlth Sci, Fremantle, WA 6160, Australia; [Knuckey, Neville W.; Meloni, Bruno P.] Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Nedlands, WA 6009, Australia; [Edwards, Adam B.; Knuckey, Neville W.; Meloni, Bruno P.] QEII Med Ctr, Sir Charles Gardiner Hosp, Dept Neurosurg, Nedlands, WA 6009, Australia	Edwards, AB (corresponding author), QEII Med Ctr, Western Australian Neurosci Res Inst, A Block,4th Floor,Verdun St, Nedlands, WA 6009, Australia.; Edwards, AB (corresponding author), Univ Notre Dame Australia, Sch Hlth Sci, Fremantle, WA 6160, Australia.; Edwards, AB (corresponding author), QEII Med Ctr, Sir Charles Gardiner Hosp, Dept Neurosurg, Nedlands, WA 6009, Australia.	adam.edwards1@my.nd.edu.au	Edwards, Adam/U-3386-2019	Edwards, Adam/0000-0002-7503-3232	University of Notre Dame Australia RIS grant; Neurotrauma Research Program of Western Australia grant; Department of Neurosurgery, Sir Charles Gairdner Hospital	This study in part was supported by the Department of Neurosurgery, Sir Charles Gairdner Hospital, and a University of Notre Dame Australia RIS grant, and a Neurotrauma Research Program of Western Australia grant.	Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Birk AV, 2013, J AM SOC NEPHROL, V24, P1250, DOI 10.1681/ASN.2012121216; Brittain JM, 2011, J BIOL CHEM, V286, P37778, DOI 10.1074/jbc.M111.255455; BRUGIDOU J, 1995, BIOCHEM BIOPH RES CO, V214, P685, DOI 10.1006/bbrc.1995.2340; Brustovetsky T, 2014, J BIOL CHEM, V289, P7470, DOI 10.1074/jbc.M113.518472; Doranz BJ, 2001, AIDS RES HUM RETROV, V17, P475, DOI 10.1089/08892220151126508; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fan J, 2009, J NEUROSCI, V29, P10928, DOI 10.1523/JNEUROSCI.2491-09.2009; Favretto ME, 2014, J CONTROL RELEASE, V180, P81, DOI 10.1016/j.jconrel.2014.02.011; Feldman P, 2013, NEUROSCI LETT, V557, P27, DOI 10.1016/j.neulet.2013.06.057; Ferrer-Montiel AV, 1998, NAT BIOTECHNOL, V16, P286, DOI 10.1038/nbt0398-286; Garcia-Caballero A, 2014, NEURON, V83, P1144, DOI 10.1016/j.neuron.2014.07.036; Hoque A, 2016, PHARMACOL THERAPEUT, V160, P159, DOI 10.1016/j.pharmthera.2016.02.009; Horton KL, 2008, CHEM BIOL, V15, P375, DOI 10.1016/j.chembiol.2008.03.015; Marshall J, 2015, J BIOL CHEM, V290, P22030, DOI 10.1074/jbc.M115.662791; McDougall G, 2016, J MOL NEURO IN PRESS; Meloni BP, 2015, PHARMACOL THERAPEUT, V153, P36, DOI 10.1016/j.pharmthera.2015.06.002; Meloni BP, 2015, J CEREBR BLOOD F MET, V35, P993, DOI 10.1038/jcbfm.2015.11; Meloni BP, 2014, CELL MOL NEUROBIOL, V34, P173, DOI 10.1007/s10571-013-9999-3; Milani D, 2016, STROKE RES TREAT, V2016, DOI 10.1155/2016/2372710; Milani D, 2016, BMC NEUROSCI, V17, DOI 10.1186/s12868-016-0253-z; Planells-Cases R, 2000, FEBS LETT, V481, P131, DOI 10.1016/S0014-5793(00)01982-7; RIGOBELLO MP, 1995, BIOCHEM BIOPH RES CO, V217, P144, DOI 10.1006/bbrc.1995.2756; Rothbard JB, 2005, ADV DRUG DELIVER REV, V57, P495, DOI 10.1016/j.addr.2004.10.003; Sinai L, 2010, LEARN MEMORY, V17, P364, DOI 10.1101/lm.1765710; Tu WH, 2010, CELL, V140, P222, DOI 10.1016/j.cell.2009.12.055; Vaslin A, 2011, J NEUROCHEM, V119, P1243, DOI 10.1111/j.1471-4159.2011.07535.x; Wallbrecher R, 2014, CELL MOL LIFE SCI, V71, P2717, DOI 10.1007/s00018-013-1517-8; Wu QF, 2015, DRUG DISCOV TODAY, V20, P1372, DOI 10.1016/j.drudis.2015.09.001; Zhao KS, 2004, J BIOL CHEM, V279, P34682, DOI 10.1074/jbc.M402999200	30	12	12	1	13	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0300-8177	1573-4919		MOL CELL BIOCHEM	Mol. Cell. Biochem.	FEB	2017	426	1-2					75	85		10.1007/s11010-016-2882-z			11	Cell Biology	Cell Biology	EK8IY	WOS:000394168300008	27844251				2021-06-18	
J	Ferbert, T; Child, C; Graeser, V; Swing, T; Akbar, M; Heller, R; Biglari, B; Moghaddam, A				Ferbert, Thomas; Child, Christopher; Graeser, Viola; Swing, Tyler; Akbar, Michael; Heller, Raban; Biglari, Bahram; Moghaddam, Arash			Tracking Spinal Cord Injury: Differences in Cytokine Expression of IGF-1, TGF-B1, and sCD95I Can Be Measured in Blood Samples and Correspond to Neurological Remission in a 12-Week Follow-Up	JOURNAL OF NEUROTRAUMA			English	Article						inflammation; spinal cord injury; traumatic spinal cord injury	FAS-MEDIATED APOPTOSIS; CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR-I; FUNCTIONAL RECOVERY; INTERNATIONAL STANDARDS; INFLAMMATORY CYTOKINES; MESSENGER-RNA; GLIAL SCAR; RAT-BRAIN; DEGENERATION	Neuroinflammation presumably has an important impact on the secondary phase of spinal cord injury and is regulated by pro-and anti-inflammatory cytokines. We analyzed serum levels of three different cytokines (insulin-like-growth-factor [IGF]-1, tumor growth factor [TGF]-beta 1, and soluble CD 95 ligand [sCD95L]), in blood samples of 23 patients admitted with acute traumatic spinal cord injury between November 2010 and July 2013 with a follow-up period of 12 weeks. Quantification was performed using Human Quantikine Immunoassays, classification of neurological impairment was performed using the American Spinal Cord Injury Impairment Scale at time of admission and after 12 weeks. After an initial drop of all three cytokine serum levels, IGF-1, TGF-beta 1, and sCD95L showed significantly increased serum levels during the acute and sub-acute phases. For IGF-1 and sCD95L, we could also observe significantly higher serum levels in patients without neurological improvement compared with patients who had improvement after 12 weeks. In this study, we were able to show differences in cytokine serum levels in patients with different neurological outcome. Measuring the serum level patterns of IGF-1, TGF-beta 1, and sCD95L might be a useful tool for prognosis in patients with neurological improvement and tracking the pathophysiology in further studies. Further, our observations might link promising therapeutic efforts in numerous animal studies and future studies in human patients.	[Ferbert, Thomas; Child, Christopher; Graeser, Viola; Swing, Tyler; Akbar, Michael; Heller, Raban; Moghaddam, Arash] Univ Heidelberg Hosp, HTRG Heidelberg Trauma Res Grp, Trauma & Reconstruct Surg, Ctr Orthoped Trauma Surg & Spinal Cord Injury, Heidelberg, Germany; [Biglari, Bahram] Berufsgenossenschaftl Unfallklin Ludwigshaf, Dept Paraplegiol, Ludwigshafen, Germany	Ferbert, T (corresponding author), Univ Heidelberg Hosp, HTRG Heidelberg Trauma Res Grp, Trauma & Reconstruct Surg, Dept Orthoped Traumatol & Paraplegiol, Schlierbacherlandstr 200a, D-69118 Heidelberg, Germany.	thomas.ferbert@med.uni-heidelberg.de	Heller, Raban/P-4152-2019	Heller, Raban/0000-0001-8006-9742			Acarin L, 2000, EUR J NEUROSCI, V12, P3505, DOI 10.1046/j.1460-9568.2000.00226.x; Ackery A, 2006, J NEUROTRAUM, V23, P604, DOI 10.1089/neu.2006.23.604; Ashcroft GS, 1999, MICROBES INFECT, V1, P1275, DOI 10.1016/S1286-4579(99)00257-9; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bethea JR, 1998, J NEUROSCI, V18, P3251; Biglari B, 2015, SPINAL CORD, V53, P510, DOI 10.1038/sc.2015.28; Biglari B, 2013, SPINAL CORD, V51, P183, DOI 10.1038/sc.2012.139; Buss A, 2008, SPINAL CORD, V46, P364, DOI 10.1038/sj.sc.3102148; Casha S, 2005, EXP NEUROL, V196, P390, DOI 10.1016/j.expneurol.2005.08.020; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Demjen D, 2004, NAT MED, V10, P389, DOI 10.1038/nm1007; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; Hellal F, 2011, SCIENCE, V331, P928, DOI 10.1126/science.1201148; Hu R, 2010, J NEUROSURG-SPINE, V13, P169, DOI 10.3171/2010.3.SPINE09190; Kawano H, 2012, CELL TISSUE RES, V349, P169, DOI 10.1007/s00441-012-1336-5; Kirshblum S, 2014, PHYS MED REH CLIN N, V25, P505, DOI 10.1016/j.pmr.2014.04.001; Kirshblum SC, 2011, J SPINAL CORD MED, V34, P547, DOI 10.1179/107902611X13186000420242; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; Kohta M, 2009, NEUROSCI RES, V65, P393, DOI 10.1016/j.neures.2009.08.017; Kurokawa R, 2011, SPINE, V36, P865, DOI 10.1097/BRS.0b013e3181e878a1; Letellier E, 2010, IMMUNITY, V32, P240, DOI 10.1016/j.immuni.2010.01.011; Li GL, 2000, ACTA NEUROPATHOL, V100, P75, DOI 10.1007/s004010051195; Liu D, 1999, NEUROSCIENCE, V93, P1383, DOI 10.1016/S0306-4522(99)00278-X; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; Madathil SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067204; Magerl F, 1994, Eur Spine J, V3, P184, DOI 10.1007/BF02221591; Marino RJ, 1999, ARCH PHYS MED REHAB, V80, P1391, DOI 10.1016/S0003-9993(99)90249-6; Moghaddam A, 2015, INT J MOL SCI, V16, P7900, DOI 10.3390/ijms16047900; Nakamura M, 2003, EXP NEUROL, V184, P313, DOI 10.1016/S0014-4886(03)00361-3; Nakao Y, 2001, J THORAC CARDIOV SUR, V122, P136, DOI 10.1067/mtc.2001.114101; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Robins-Steele S, 2012, J NEUROTRAUM, V29, P1586, DOI 10.1089/neu.2011.2005; Russell JW, 1998, J NEUROBIOL, V36, P455, DOI 10.1002/(SICI)1097-4695(19980915)36:4<455::AID-NEU1>3.0.CO;2-V; Schwab ME, 1996, PHYSIOL REV, V76, P319; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Stammers AT, 2012, J NEUROSCI RES, V90, P782, DOI 10.1002/jnr.22820; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; Tan ZQ, 2001, NEUROREPORT, V12, P1979, DOI 10.1097/00001756-200107030-00040; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; Tei R, 2005, NEUROL RES, V27, P403, DOI 10.1179/016164105X25180; TURNER M, 1990, Cytokine, V2, P211, DOI 10.1016/1043-4666(90)90018-O; Umemura T, 2010, TRANSL RES, V156, P292, DOI 10.1016/j.trsl.2010.08.002; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; Westhauser F, 2015, ARCH ORTHOP TRAUM SU, V135, P1107, DOI 10.1007/s00402-015-2253-3; Yoshino O, 2004, SPINE, V29, P1394, DOI 10.1097/01.BRS.0000129894.34550.48; Yu WR, 2011, ACTA NEUROPATHOL, V122, P747, DOI 10.1007/s00401-011-0882-3; Zurita M, 2001, J NEUROSURG, V94, P257, DOI 10.3171/spi.2001.94.2.0257	54	12	13	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2017	34	3					607	614		10.1089/neu.2015.4294			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EI9GJ	WOS:000392815600008	27533262				2021-06-18	
J	Gross, BW; Edavettal, MM; Cook, AD; Rinehart, CD; Lynch, CA; Bradburn, EH; Wu, D; Rogers, FB				Gross, Brian W.; Edavettal, Mathew M.; Cook, Alan D.; Rinehart, Cole D.; Lynch, Caitlin A.; Bradburn, Eric H.; Wu, Daniel; Rogers, Frederick B.			Big children or little adults? A statewide analysis of adolescent isolated severe traumatic brain injury outcomes at pediatric versus adult trauma centers	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	29th Annual Scientific Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 09-16, 2016	San Antonio, TX	Eastern Assoc Surg Trauma		Adolescent; traumatic brain injury; mortality; pediatric trauma center; adult trauma center	SYSTEM REDUCES MORTALITY; RATES; CARE; IMPACT	BACKGROUND: The appropriate managing center for adolescent trauma patients is debated. We sought to determine whether outcome differences existed for adolescent severe traumatic brain injury (sTBI) patients treated at pediatric versus adult trauma centers. We hypothesized that no difference in mortality, functional status at discharge (FSD), or overall complication rate would be observed between center types. METHODS: All adolescent trauma patients (aged 15-17 years) presenting with isolated sTBI (head Abbreviated Injury Scale [AIS] score >= 3; all other AIS body region scores <= 2) to accredited Levels I to II trauma centers in Pennsylvania from 2003 to 2015 were extracted from the Pennsylvania Trauma Outcome Study database. Dead on arrival, transfer, and penetrating trauma patients were excluded from analysis. Adult trauma centerswere defined as non-pediatirc (PED) (n = 24), whereas standalone pediatric hospitals and adult centers with pediatric affiliation were considered Pediatric (n = 9). Multilevel mixed effects logistic regression models and a generalized linear mixed models assessed the adjusted impact of center type on mortality, overall complications, and FSD. Significance was defined as a p value less than 0.05. RESULTS: A total of 1,109 isolated sTBI patients aged 15 to 17 years presented over the 13-year study period (non-PED, 685; PED, 424). In adjusted analysis controlling for age, shock index, head AIS, Glasgow Coma Scale motor, trauma center level of managing facility, case volume of managing facility, and injury year, no significant difference in mortality (adjusted odds ratio, 0.82; 95% confidence interval [CI], 0.23-2.86; p = 0.754), FSD (coefficient, -0.85; 95% CI, -2.03 to 0.28; p = 0.136), or total complication rate (adjusted odds ratio, 1.21; 95% CI, 0.43-3.39; p = 0.714) was observed between center types. CONCLUSION: Although the optimal treatment facility for adolescent patients is frequently debated, patients aged 15 to 17 years presenting with isolated sTBI may experience similar outcomes when managed at pediatric and adult trauma centers. (Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.)	[Gross, Brian W.; Rinehart, Cole D.; Lynch, Caitlin A.; Bradburn, Eric H.; Wu, Daniel; Rogers, Frederick B.] Penn Med Lancaster Gen Hlth, Trauma Serv, Lancaster, PA USA; [Edavettal, Mathew M.; Cook, Alan D.] Chandler Reg Med Ctr, Trauma Res Program, Chandler, AZ USA	Rogers, FB (corresponding author), 555N Duke St, Lancaster, PA 17602 USA.	frogers2@lghealth.org					BENSARD DD, 1994, J PEDIATR SURG, V29, P11, DOI 10.1016/0022-3468(94)90514-2; Committee on Trauma, 2006, RESOURCES OPTIMAL CA; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gabbe BJ, 2011, ANN SURG, V253, P138, DOI 10.1097/SLA.0b013e3181f6685b; GUSS DA, 1989, ANN EMERG MED, V18, P1141, DOI 10.1016/S0196-0644(89)80048-4; Hall JR, 1996, J PEDIATR SURG, V31, P72, DOI 10.1016/S0022-3468(96)90322-X; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Matsushima K, 2013, AM SURGEON, V79, P267; Mullins RJ, 1996, J TRAUMA, V40, P536, DOI 10.1097/00005373-199604000-00004; Notrica DM, 2012, J TRAUMA ACUTE CARE, V73, P566, DOI 10.1097/TA.0b013e318265ca6f; Osler TM, 2001, J TRAUMA, V50, P96, DOI 10.1097/00005373-200101000-00017; Potoka DA, 2001, J TRAUMA, V51, P824, DOI 10.1097/00005373-200111000-00002; Potoka DA, 2000, J TRAUMA, V49, P237, DOI 10.1097/00005373-200008000-00009; Pracht EE, 2008, J PEDIATR SURG, V43, P212, DOI 10.1016/j.jpedsurg.2007.09.047; Sampalis JS, 1999, J TRAUMA, V46, P565, DOI 10.1097/00005373-199904000-00004; Twijnstra MJ, 2010, ANN SURG, V251, P339, DOI 10.1097/SLA.0b013e3181c0e910; Walther AE, 2014, J TRAUMA ACUTE CARE, V77, P109, DOI 10.1097/TA.0000000000000277; Wang NE, 2013, J TRAUMA ACUTE CARE, V75, P704, DOI 10.1097/TA.0b013e31829a0a65	18	12	12	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2017	82	2					368	373		10.1097/TA.0000000000001291			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	EJ8GO	WOS:000393463600024	27805998				2021-06-18	
J	Peterson, AR; Kruse, AJ; Meester, SM; Olson, TS; Riedle, BN; Slayman, TG; Domeyer, TJ; Cavanaugh, JE; Smoot, MK				Peterson, Andrew R.; Kruse, Adam J.; Meester, Scott M.; Olson, Tyler S.; Riedle, Benjamin N.; Slayman, Tyler G.; Domeyer, Todd J.; Cavanaugh, Joseph E.; Smoot, M. Kyle			Youth Football Injuries A Prospective Cohort	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						youth football; flag football; concussion; youth sports	SCHOOL FOOTBALL; RISK-FACTORS; SPORTS; CONCUSSION; YOUNG; AGE	Background: There are approximately 2.8 million youth football players between the ages of 7 and 14 years in the United States. Rates of injury in this population are poorly described. Recent studies have reported injury rates between 2.3% and 30.4% per season and between 8.5 and 43 per 1000 exposures. Hypothesis: Youth flag football has a lower injury rate than youth tackle football. The concussion rates in flag football are lower than in tackle football. Study Design: Cohort study; Level of evidence, 3. Methods: Three large youth (grades 2-7) football leagues with a total of 3794 players were enrolled. Research personnel partnered with the leagues to provide electronic attendance and injury reporting systems. Researchers had access to deidentified player data and injury information. Injury rates for both the tackle and flag leagues were calculated and compared using Poisson regression with a log link. The probability an injury was severe and an injury resulted in a concussion were modeled using logistic regression. For these 2 responses, best subset model selection was performed, and the model with the minimum Akaike information criterion value was chosen as best. Kaplan-Meier curves were examined to compare time loss due to injury for various subgroups of the population. Finally, time loss was modeled using Cox proportional hazards regression models. Results: A total of 46,416 exposures and 128 injuries were reported. The mean age at injury was 10.64 years. The hazard ratio for tackle football (compared with flag football) was 0.45 (95% CI, 0.25-0.80; P = 0065). The rate of severe injuries per exposure for tackle football was 1.1 (95% CI, 0.33-3.4; P = 93) times that of the flag league. The rate for concussions in tackle football per exposure was 0.51 (95% CI, 0.16-1.7; P = 27) times that of the flag league. Conclusion: Injury is more likely to occur in youth flag football than in youth tackle football. Severe injuries and concussions were not significantly different between leagues. Concussion was more likely to occur during games than during practice. Players in the sixth or seventh grade were more likely to suffer a concussion than were younger players.	[Peterson, Andrew R.; Kruse, Adam J.; Meester, Scott M.; Olson, Tyler S.; Riedle, Benjamin N.; Slayman, Tyler G.; Domeyer, Todd J.; Cavanaugh, Joseph E.; Smoot, M. Kyle] Univ Iowa, 200 Hawkins Dr, Iowa City, IA 52246 USA	Peterson, AR (corresponding author), Univ Iowa, 200 Hawkins Dr, Iowa City, IA 52246 USA.	andrew-r-peterson@uiowa.edu		Peterson, Andrew/0000-0003-4555-7366; Kruse, Adam/0000-0002-8287-4048	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T35HL007485] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T35 HL007485] Funding Source: Medline		AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Alic S., 2013, US FOOTBALL RELEASES; BIJUR PE, 1995, ARCH PEDIAT ADOL MED, V149, P1009, DOI 10.1001/archpedi.1995.02170220075010; COUNCIL SPORTS MED FITNESS, 2015, PEDIATRICS, V136, pE1419, DOI 10.1542/peds.2015-3282; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Dompier TP, 2007, J ATHL TRAINING, V42, P395; ELLISON LF, 1993, CHRONIC DIS CANADA, V14, P96; GOLDBERG B, 1988, PEDIATRICS, V81, P255; Kontos AP, 2013, J PEDIATR-US, V163, P717, DOI 10.1016/j.jpeds.2013.04.011; LINDER MM, 1995, CLIN J SPORT MED, V5, P167, DOI 10.1097/00042752-199507000-00006; Malina RM, 2007, CLIN J SPORT MED, V17, P362, DOI 10.1097/JSM.0b013e31815400f4; Malina RM, 2006, CLIN J SPORT MED, V16, P214, DOI 10.1097/00042752-200605000-00005; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Mello MJ, 2009, ACAD EMERG MED, V16, P243, DOI 10.1111/j.1553-2712.2009.00357.x; Nation AD, 2011, CLIN PEDIATR, V50, P200, DOI 10.1177/0009922810388511; Radelet MA, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.3.e28; ROCHELLE RH, 1961, RES QUART, V32, P78, DOI 10.1080/10671188.1961.10762074; ROSER LA, 1970, CLIN ORTHOP RELAT R, P219; Silverstein B, 1979, PHYSICIAN SPORTSMED, V7, P105; Stuart MJ, 2002, MAYO CLIN PROC, V77, P317, DOI 10.4065/77.4.317; Turbeville SD, 2003, AM J SPORT MED, V31, P276, DOI 10.1177/03635465030310022001; ZARICZNYJ B, 1980, AM J SPORT MED, V8, P318, DOI 10.1177/036354658000800504	22	12	12	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA		2325-9671		ORTHOP J SPORTS MED	Orthop. J. Sports Med.	FEB	2017	5	2							2325967116686784	10.1177/2325967116686784			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	EL5QY	WOS:000394677100011	28255566	DOAJ Gold, Green Published			2021-06-18	
J	Sun, P; Murphy, RKJ; Gamble, P; George, A; Song, SK; Ray, WZ				Sun, Peng; Murphy, Rory K. J.; Gamble, Paul; George, Ajit; Song, Sheng-Kwei; Ray, Wilson Z.			Diffusion Assessment of Cortical Changes, Induced by Traumatic Spinal Cord Injury	BRAIN SCIENCES			English	Article						magnetic resonance imaging; diffusion tensor imaging; diffusion basis spectrum imaging; spinal cord injury	CERVICAL SPONDYLOTIC MYELOPATHY; WHITE-MATTER PATHOLOGY; EPIDURAL STIMULATION; MULTIPLE-SCLEROSIS; CORPUS-CALLOSUM; IMAGING DETECTS; OPTIC-NERVE; MOUSE MODEL; BRAIN; DEMYELINATION	Promising treatments are being developed to promote functional recovery after spinal cord injury (SCI). Magnetic resonance imaging, specifically Diffusion Tensor Imaging (DTI) has been shown to non-invasively measure both axonal and myelin integrity following traumatic brain and SCI. A novel data-driven model-selection algorithm known as Diffusion Basis Spectrum Imaging (DBSI) has been proposed to more accurately delineate white matter injury. The objective of this study was to investigate whether DTI/DBSI changes that extend to level of the cerebral peduncle and internal capsule following a SCI could be correlated with clinical function. A prospective non-randomized cohort of 23 patients with chronic spinal cord injuries and 17 control subjects underwent cranial diffusion weighted imaging, followed by whole brain DTI and DBSI computations. Region-based analyses were performed on cerebral peduncle and internal capsule. Three subgroups of patients were included in the region-based analysis. Tract-Based Spatial Statistics (TBSS) was also applied to allow whole-brain white matter analysis between controls and all patients. Functional assessments were made using International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) as modified by the American Spinal Injury Association (ASIA) Scale. Whole brain white matter analysis using TBSS finds no statistical difference between controls and all patients. Only cervical ASIA A/B patients in cerebral peduncle showed differences from controls in DTI and DBSI results with region-based analysis. Cervical ASIA A/B SCI patients had higher levels of axonal injury and edema/tissue loss as measured by DBSI at the level of the cerebral peduncle. DTI Fractional Anisotropy (FA), Axial Diffusivity (AD) and Radial Diffusivity (RD) was able to detect differences in cervical ASIA A/B patients, but were non-specific to pathologies. Increased water fraction indicated by DBSI non-restricted isotropic diffusion fraction in the cerebral peduncle, explains the simultaneously increased DTI AD and DTI RD values. Our results further demonstrate the utility of DTI to detect disruption in axonal integrity in white matter, yet a clear shortcoming in differentiating true axonal injury from inflammation/tissue loss. Our results suggest a preservation of axonal integrity at the cortical level and has implications for future regenerative clinical trials.	[Sun, Peng; George, Ajit; Song, Sheng-Kwei] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA; [Murphy, Rory K. J.; Ray, Wilson Z.] Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63110 USA; [Gamble, Paul] Washington Univ, Sch Med, St Louis, MO 63110 USA	Ray, WZ (corresponding author), Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63110 USA.	pengsun@wustl.edu; murphyr@wudosis.wustl.edu; gamblep@wusm.wustl.edu; ajitgeorge@wustl.edu; ssong@wustl.edu; rayz@wudosis.wustl.edu			University of Missouri Spinal Cord Injury Research Program; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23NS084932]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047592, K23NS084932] Funding Source: NIH RePORTER	This study was supported by University of Missouri Spinal Cord Injury Research Program (Wilson Z. Ray) and National Institute of Health K23NS084932 (Wilson Z. Ray).	Ackery A, 2004, J NEUROTRAUM, V21, P1355, DOI 10.1089/neu.2004.21.1355; Alkadhi H, 2005, CEREB CORTEX, V15, P131, DOI 10.1093/cercor/bhh116; Andersson J. L. R., TR07JA2; Andersson JLR, 2003, NEUROIMAGE, V20, P870, DOI 10.1016/S1053-8119(03)00336-7; Andersson JLR, 2007, TR07JA1 FMRIB; Barker GJ, 2001, J NEUROL SCI, V186, pS45, DOI 10.1016/S0022-510X(01)00490-7; Bruehlmeier M, 1998, EUR J NEUROSCI, V10, P3918, DOI 10.1046/j.1460-9568.1998.00454.x; Budde MD, 2007, MAGN RESON MED, V57, P688, DOI 10.1002/mrm.21200; Castro A, 2007, EUR J NEUROSCI, V25, P2927, DOI 10.1111/j.1460-9568.2007.05532.x; Chavakula V, 2016, NEUROSURGERY, V78, pN19, DOI 10.1227/01.neu.0000484059.58417.dc; Chiang CW, 2014, NEUROIMAGE, V101, P310, DOI 10.1016/j.neuroimage.2014.06.064; Cramer SC, 2005, BRAIN, V128, P2941, DOI 10.1093/brain/awh648; Deo AA, 2006, J NEUROSCI RES, V83, P801, DOI 10.1002/jnr.20783; Freund P, 2012, J NEUROL NEUROSUR PS, V83, P629, DOI 10.1136/jnnp-2011-301875; Freund P, 2011, BRAIN, V134, P1610, DOI 10.1093/brain/awr093; Gad P, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-2; Gao SJ, 2013, EUR J RADIOL, V82, P1940, DOI 10.1016/j.ejrad.2013.06.011; Halder P, 2006, NEUROIMAGE, V31, P692, DOI 10.1016/j.neuroimage.2005.12.018; Hawasli AH, 2015, GLOB SPINE J, V5, P110, DOI 10.1055/s-0034-1396760; Hotz-Boenden-Naker S, 2008, NEUROIMAGE, V39, P383, DOI 10.1016/j.neuroimage.2007.07.065; Hou JM, 2014, NEUROSCIENCE, V277, P446, DOI 10.1016/j.neuroscience.2014.07.045; Jin Bo, 2014, Zhonghua Yi Xue Za Zhi, V94, P3082; Kim JH, 2006, NEUROBIOL DIS, V21, P626, DOI 10.1016/j.nbd.2005.09.009; Kim JH, 2007, MAGN RESON MED, V58, P253, DOI 10.1002/mrm.21316; Kirshblum S, 2014, PHYS MED REH CLIN N, V25, P505, DOI 10.1016/j.pmr.2014.04.001; Kokotilo KJ, 2009, J NEUROTRAUM, V26, P2113, DOI 10.1089/neu.2008.0688; Koskinen E, 2013, J NEUROTRAUM, V30, P1587, DOI 10.1089/neu.2013.2943; Kuo LW, 2008, NEUROIMAGE, V41, P7, DOI 10.1016/j.neuroimage.2008.02.016; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Li X, 2014, SPINE, V39, pE615, DOI 10.1097/BRS.0000000000000288; Mackinnon SE, 2012, J NEUROSURG, V117, P176, DOI 10.3171/2012.3.JNS12328; Mattia D, 2006, HUM BRAIN MAPP, V27, P510, DOI 10.1002/hbm.20195; Min YS, 2015, J NEUROTRAUM, V32, P1422, DOI 10.1089/neu.2014.3661; Minassian K, 2016, NEUROTHERAPEUTICS, V13, P284, DOI 10.1007/s13311-016-0421-y; Miyanji F, 2007, RADIOLOGY, V243, P820, DOI 10.1148/radiol.2433060583; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Moxon KA, 2014, NEUROSCIENCE, V283, P78, DOI 10.1016/j.neuroscience.2014.06.056; Naismith RT, 2013, NEUROLOGY, V80, P2201, DOI 10.1212/WNL.0b013e318296e8f1; Oishi K, 2008, NEUROIMAGE, V43, P447, DOI 10.1016/j.neuroimage.2008.07.009; Oni-Orisan A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150351; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Sabbah P, 2002, J NEUROTRAUM, V19, P53, DOI 10.1089/089771502753460231; Shepard MJ, 1999, SPINAL CORD, V37, P833, DOI 10.1038/sj.sc.3100927; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sotak CH, 2002, NMR BIOMED, V15, P561, DOI 10.1002/nbm.786; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; Vasudeva VS, 2014, NEUROSURGERY, V75, pN14, DOI 10.1227/01.neu.0000457194.09781.8a; Vedantam A, 2015, WORLD NEUROSURG, V83, P824, DOI 10.1016/j.wneu.2013.09.017; Vedantam A, 2014, NEUROSURGERY, V74, P1, DOI 10.1227/NEU.0000000000000171; Wang XJ, 2014, NMR BIOMED, V27, P843, DOI 10.1002/nbm.3129; Wang Y, 2015, BRAIN, V138, P1223, DOI 10.1093/brain/awv046; Wang Y, 2011, BRAIN, V134, P3587, DOI 10.1093/brain/awr307; Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Wrigley PJ, 2009, CEREB CORTEX, V19, P224, DOI 10.1093/cercor/bhn072; Zalesky A, 2011, MAGN RESON IMAGING, V29, P111, DOI 10.1016/j.mri.2010.06.027	61	12	12	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	2076-3425			BRAIN SCI	Brain Sci.	FEB	2017	7	2							21	10.3390/brainsci7020021			13	Neurosciences	Neurosciences & Neurology	EO9QG	WOS:000397022600008	28218643	DOAJ Gold, Green Published			2021-06-18	
J	Dang, H; Stayman, JW; Sisniega, A; Zbijewski, W; Xu, J; Wang, XH; Foos, DH; Aygun, N; Koliatsos, VE; Siewerdsen, JH				Dang, Hao; Stayman, J. Webster; Sisniega, Alejandro; Zbijewski, Wojciech; Xu, Jennifer; Wang, Xiaohui; Foos, David H.; Aygun, Nafi; Koliatsos, Vassilis E.; Siewerdsen, Jeffrey H.			Multi-resolution statistical image reconstruction for mitigation of truncation effects: application to cone-beam CT of the head	PHYSICS IN MEDICINE AND BIOLOGY			English	Article						intracranial hemorrhage; cone-beam computed tomography; iterative reconstruction; projection truncation; truncation correction; scatter correction	TOMOGRAPHIC RECONSTRUCTION; TECHNICAL ASSESSMENT; COMPUTED-TOMOGRAPHY; ARTIFACT-CORRECTION; HILBERT TRANSFORM; OF-INTEREST; BREAST CT; QUALITY; MOBILE; SCANNER	A prototype cone-beam CT (CBCT) head scanner featuring model-based iterative reconstruction (MBIR) has been recently developed and demonstrated the potential for reliable detection of acute intracranial hemorrhage (ICH), which is vital to diagnosis of traumatic brain injury and hemorrhagic stroke. However, data truncation (e.g. due to the head holder) can result in artifacts that reduce image uniformity and challenge ICH detection. We propose a multi-resolution MBIR method with an extended reconstruction field of view (RFOV) to mitigate truncation effects in CBCT of the head. The image volume includes a fine voxel size in the (inner) nontruncated region and a coarse voxel size in the (outer) truncated region. This multi-resolution scheme allows extension of the RFOV to mitigate truncation effects while introducing minimal increase in computational complexity. The multi-resolution method was incorporated in a penalized weighted least-squares (PWLS) reconstruction framework previously developed for CBCT of the head. Experiments involving an anthropomorphic head phantom with truncation due to a carbonfiber holder were shown to result in severe artifacts in conventional single-resolution PWLS, whereas extending the RFOV within the multi-resolution framework strongly reduced truncation artifacts. For the same extended RFOV, the multi-resolution approach reduced computation time compared to the single-resolution approach (viz. time reduced by 40.7%, 83.0%, and over 95% for an image volume of 600(3), 800(3), 1000(3) voxels). Algorithm parameters (e.g. regularization strength, the ratio of the fine and coarse voxel size, and RFOV size) were investigated to guide reliable parameter selection. The findings provide a promising method for truncation artifact reduction in CBCT and may be useful for other MBIR methods and applications for which truncation is a challenge.	[Dang, Hao; Stayman, J. Webster; Sisniega, Alejandro; Zbijewski, Wojciech; Xu, Jennifer; Siewerdsen, Jeffrey H.] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA; [Wang, Xiaohui; Foos, David H.] Carestream Hlth, Rochester, NY 14608 USA; [Aygun, Nafi; Siewerdsen, Jeffrey H.] Johns Hopkins Univ, Russell H Morgan Dept Radiol, Baltimore, MD 21205 USA; [Koliatsos, Vassilis E.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21205 USA	Siewerdsen, JH (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA.; Siewerdsen, JH (corresponding author), Johns Hopkins Univ, Russell H Morgan Dept Radiol, Baltimore, MD 21205 USA.	jeff.siewerdsen@jhu.edu	Dang, Hao/U-4865-2018	Dang, Hao/0000-0001-5861-6535; Stayman, Joseph/0000-0003-4358-378X; Sisniega, Alejandro/0000-0003-2030-2711	Carestream Health (Rochester, NY); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-EB-018896]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB018896] Funding Source: NIH RePORTER	This work was supported by academic-industry partnership with Carestream Health (Rochester, NY) and by the National Institutes of Health Grant R01-EB-018896. The authors thank Mr Qian Cao for useful discussion of multi-resolution image reconstruction.	Boone JM, 2001, RADIOLOGY, V221, P657, DOI 10.1148/radiol.2213010334; Cao Q, 2015, INT M FULL 3 DIM IM, P452; Cao Q, 2016, PHYS MED BIOL, V61, DOI 10.1088/0031-9155/61/20/7263; Carrino JA, 2014, RADIOLOGY, V270, P816, DOI 10.1148/radiol.13130225; Dang H, 2016, Conf Proc Int Conf Image Form Xray Comput Tomogr, V2016, P557; Dang H, 2015, PHYS MED BIOL, V60, P6153, DOI 10.1088/0031-9155/60/16/6153; Dang H, 2012, MED PHYS, V39, P6484, DOI 10.1118/1.4754589; Defrise M, 2006, INVERSE PROBL, V22, P1037, DOI 10.1088/0266-5611/22/3/019; DELANEY AH, 1995, IEEE T IMAGE PROCESS, V4, P799, DOI 10.1109/83.388081; DUBLIN AB, 1977, RADIOLOGY, V122, P365, DOI 10.1148/122.2.365; Hamelin B, 2007, P ANN INT IEEE EMBS, P739, DOI 10.1109/IEMBS.2007.4352396; Hsieh J, 2004, MED PHYS, V31, P2385, DOI 10.1118/1.1776673; Huber P., 1981, ROBUST STAT; INDECK M, 1988, J TRAUMA, V28, P1020, DOI 10.1097/00005373-198807000-00018; JOSEPH PM, 1978, J COMPUT ASSIST TOMO, V2, P100, DOI 10.1097/00004728-197801000-00017; Kidwell CS, 2008, LANCET NEUROL, V7, P256, DOI 10.1016/S1474-4422(08)70041-3; Kolditz D, 2011, PHYS MED BIOL, V56, P39, DOI 10.1088/0031-9155/56/1/003; Koskinen SK, 2013, SKELETAL RADIOL, V42, P649, DOI 10.1007/s00256-012-1516-0; Kudo H, 2008, PHYS MED BIOL, V53, P2207, DOI 10.1088/0031-9155/53/9/001; Li TF, 2004, IEEE T NUCL SCI, V51, P2505, DOI 10.1109/TNS.2004.834824; Long Y, 2010, IEEE T MED IMAGING, V29, P1839, DOI 10.1109/TMI.2010.2050898; Masaryk Thomas, 2008, Radiol Manage, V30, P50; Navab N, 2010, IEEE T MED IMAGING, V29, P1412, DOI 10.1109/TMI.2009.2021947; Noo F, 2004, PHYS MED BIOL, V49, P3903, DOI 10.1088/0031-9155/49/17/006; Ohnesorge B, 2000, MED PHYS, V27, P39, DOI 10.1118/1.598855; Pan XC, 2005, MED PHYS, V32, P673, DOI 10.1118/1.1844171; Parizel PM, 2001, EUR RADIOL, V11, P1770, DOI 10.1007/s003300000800; Penninger RT, 2011, OTOL NEUROTOL, V32, P453, DOI 10.1097/MAO.0b013e31820d962c; SAUER K, 1993, IEEE T SIGNAL PROCES, V41, P534, DOI 10.1109/78.193196; Schafer S, 2011, MED PHYS, V38, P4563, DOI 10.1118/1.3597566; Siewerdsen J. H., 2009, SPIE MED IMAGING, V7261; Sisniega A, 2015, PHYS MED BIOL, V60, P1415, DOI 10.1088/0031-9155/60/4/1415; SMITH I, 1990, CRIT CARE MED, V18, P278, DOI 10.1097/00003246-199003000-00006; Stayman JW, 2012, IEEE T MED IMAGING, V31, P1837, DOI 10.1109/TMI.2012.2199763; Wang AS, 2014, PHYS MED BIOL, V59, P1005, DOI 10.1088/0031-9155/59/4/1005; Xu J, 2016, PHYS MED BIOL, V61, P3180, DOI 10.1088/0031-9155/61/8/3180; Xu J, 2012, MED PHYS, V39, P4932, DOI 10.1118/1.4736805; Xu J, 2016, MED PHYS, V43, P5745, DOI 10.1118/1.4963220; Xu J, 2016, PHYS MED BIOL, V61, P5973, DOI 10.1088/0031-9155/61/16/5973; Yang WT, 2007, AM J ROENTGENOL, V189, P1312, DOI 10.2214/AJR.07.2403; Yu HY, 2006, MED PHYS, V33, P3640, DOI 10.1118/1.2348767; Yu HY, 2009, PHYS MED BIOL, V54, P2791, DOI 10.1088/0031-9155/54/9/014; Zou Y, 2004, PHYS MED BIOL, V49, P941, DOI 10.1088/0031-9155/49/6/006	43	12	12	0	8	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0031-9155	1361-6560		PHYS MED BIOL	Phys. Med. Biol.	JAN 21	2017	62	2					539	559		10.1088/1361-6560/aa52b8			21	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging	Engineering; Radiology, Nuclear Medicine & Medical Imaging	EH4NV	WOS:000391748800001	28033118	Green Accepted			2021-06-18	
J	Alosco, ML; Jarnagin, J; Tripodis, Y; Martin, B; Chaisson, C; Baugh, CM; Torres, A; Nowinski, CJ; Cantu, RC; Stern, RA				Alosco, Michael L.; Jarnagin, Johnny; Tripodis, Yorghos; Martin, Brett; Chaisson, Christine; Baugh, Christine M.; Torres, Alcy; Nowinski, Christopher J.; Cantu, Robert C.; Stern, Robert A.			Utility of providing a concussion definition in the assessment of concussion history in former NFL players	BRAIN INJURY			English	Article						American football; concussion knowledge; depression; impulsivity; mild traumatic brain injury	RECURRENT CONCUSSION; SPORTS; DEPRESSION; FREQUENCY; IMPACT; GUIDELINES; INCREASES; STATEMENT; DIAGNOSIS; EDUCATION	Objective: Former National Football League (NFL) players' working knowledge of concussion has not yet been evaluated, despite this population being a major clinical research target due to the association between repetitive head impacts (RHI) and long-term clinical impairments. This study examined former NFL players' understanding of the current concussion definition, and the association between number of concussions with, clinical function. Methods: 95 former NFL players (mean age = 55.29; mean NFL year = 8.10) self-reported number of concussions before being provided with a concussion definition and after being read a modern definition of concussion. Subjects reported number of concussions with loss of consciousness (LOC), Principal Component Analysis of a battery of tests generated behaviour/mood, psychomotor speed/executive function, and verbal and visual memory factor scores. Restilts: Post-definition number of concussions (median = 50); Was five times the pre-definition (median = 10; p < 0.001). Greater pre- (p = 0.019) and post-definition concussions (p = 0.036) correlated with worse behaviour/Mood scores, after controlling for years of football played, with specific effects for depressive symptoms and impulsivity. LOC did not account for variance beyond number of concussions. Conclusions: Practitioners and clinical researchers should provide a definition of concussion in the assessment of concussion history in former football players to facilitate accuracy and standardization.	[Alosco, Michael L.; Jarnagin, Johnny; Martin, Brett; Chaisson, Christine; Baugh, Christine M.; Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Alzheimers Dis & CTE Ctr, 72 East Concord St,87800, Boston, MA 02118 USA; [Alosco, Michael L.; Jarnagin, Johnny; Baugh, Christine M.; Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Tripodis, Yorghos; Chaisson, Christine] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA; [Martin, Brett; Chaisson, Christine] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA 02118 USA; [Baugh, Christine M.] Harvard Univ, Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA; [Torres, Alcy] Boston Univ, Sch Med, Pediat Neurol, Boston, MA 02118 USA; [Torres, Alcy] Boston Med Ctr, Pediat Neurol, Boston, MA USA; [Nowinski, Christopher J.; Cantu, Robert C.] Concuss Legacy Fdn, Waltham, MA USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA	Stern, RA (corresponding author), Boston Univ, Sch Med, Alzheimers Dis & CTE Ctr, 72 East Concord St,87800, Boston, MA 02118 USA.	bobstern@bu.edu	Baugh, Christine/AAG-2324-2020; , Bob/ABA-8507-2020	Baugh, Christine/0000-0002-9340-6338; Tripodis, Yorghos/0000-0003-2190-7608	NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR001430] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG019610, P30 AG013846] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32 MH019733] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS078337, R56 NS078337, U01 NS093334, F32 NS096803] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337, U01NS093334, R56NS078337, F32NS096803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG019610, P30AG013846] Funding Source: NIH RePORTER		Alosco ML, 2016, J NEUROTRAUMA; Baugh CM, 2016, CONCUSSION, V1, P1; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Casson IR, 2011, SPORTS HEALTH, V3, P11, DOI 10.1177/1941738110391413; Cheng G, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/205903; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Denny-Brown D, 1943, Bull N Y Acad Med, V19, P3; Gardner Raquel C, 2015, Neurol Clin Pract, V5, P285; Goswami R, 2015, BRAIN STRUCT FUNCT; Guo WB, 2012, PROG NEURO-PSYCHOPH, V38, P201, DOI 10.1016/j.pnpbp.2012.03.012; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kerr ZY, 2015, AM J SPORT MED, V43, P606, DOI 10.1177/0363546514562180; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Kroshus E, 2016, HEALTH EDUC BEHAV, V43, P182, DOI 10.1177/1090198115599380; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Lawrence DW, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115583653; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Mannings C, 2014, J TRAUMA ACUTE CARE, V77, pS18, DOI 10.1097/TA.0000000000000371; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Montenigro P. H., 2016, J NEUROTRAUM, V33, P1; Oldham J, 2015, NEUROLOGY S, V84; Peng HJ, 2012, J AFFECT DISORDERS, V136, P249, DOI 10.1016/j.jad.2011.12.006; Peper JS, 2013, CEREB CORTEX, V23, P1695, DOI 10.1093/cercor/bhs163; Pietrosimone B, 2015, MED SCI SPORT EXER, V47, P2366, DOI 10.1249/MSS.0000000000000684; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Stein TD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0522-z; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wright MJ, 2016, J CLIN EXP NEUROPSYC, V38, P561, DOI 10.1080/13803395.2016.1139057	40	12	12	3	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	8					1116	1123		10.1080/02699052.2017.1294709			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FC3JI	WOS:000406734500012	28471243	Green Accepted			2021-06-18	
J	Beretta, S; Cunningham, KM; Haus, DL; Gold, EM; Perez, H; Lopez-Velazquez, L; Cummings, BJ				Beretta, Stefania; Cunningham, Kelly M.; Haus, Daniel L.; Gold, Eric M.; Perez, Harvey; Lopez-Velazquez, Luci; Cummings, Brian J.			Effects of Human ES-Derived Neural Stem Cell Transplantation and Kindling in a Rat Model of Traumatic Brain Injury	CELL TRANSPLANTATION			English	Article						traumatic brain injury (TBI); controlled cortical impact (CCI); human neural stem cell; cell transplantation; posttraumatic hyperexcitability; kindling model; spatial-hippocampal memory; emotional memory	SPINAL-CORD; POSTTRAUMATIC EPILEPSY; ELECTRICAL-STIMULATION; ANIMAL-MODELS; UNITED-STATES; SEIZURES; DISEASE; PILOCARPINE; ENGRAFTMENT; MECHANISMS	Traumatic brain injury (TBI) is one of the leading causes of death and disability in the population worldwide, with a broad spectrum of symptoms and disabilities. Posttraumatic hyperexcitability is one of the most common neurological disorders that affect people after a head injury. A reliable animal model of posttraumatic hyperexcitability induced by TBI which allows one to test effective treatment strategies is yet to be developed. To address these issues, in the present study, we tested human embryonic stem cell-derived neural stem cell (NSC) transplantation in an animal model of posttraumatic hyperexcitability in which the brain injury was produced in one hemisphere of immunodeficient athymic nude rats by controlled cortical impact, and spontaneous seizures were produced by repeated electrical stimulation (kindling) in the contralateral hemisphere. At 14 wk posttransplantation, we report human NSC (hNSC) survival and differentiation into all 3 neural lineages in both sham and injured animals. We observed twice as many surviving hNSCs in the injured versus sham brain, and worse survival on the kindled side in both groups, indicating that kindling/seizures are detrimental to survival or proliferation of hNSCs. We also replicated our previous finding that hNSCs can ameliorate deficits on the novel place recognition task, 33 but such improvements are abolished following kindling. We found no significant differences pre-or post-kindling on the elevated plus maze. No significant correlations were observed between hNSC survival and cognitive performance on either task. Together these findings suggest that Shef6-derived hNSCs may be beneficial as a therapy for TBI, but not in animals or patients with posttraumatic hyperexcitability.	[Beretta, Stefania] Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, Milan, Italy; [Cunningham, Kelly M.; Perez, Harvey; Lopez-Velazquez, Luci; Cummings, Brian J.] Univ Calif Irvine, UCI Inst Memory Impairments & Neurol Disorders MI, Irvine, CA USA; [Haus, Daniel L.; Gold, Eric M.; Cummings, Brian J.] Univ Calif Irvine, Sue & Bill Gross Cell Ctr, Irvine, CA USA; [Haus, Daniel L.; Gold, Eric M.; Cummings, Brian J.] Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92717 USA; [Cummings, Brian J.] Univ Calif Irvine, Phys & Med Rehabil, Irvine, CA USA	Cummings, BJ (corresponding author), Univ Calif Irvine, Room 2026,Gross Hall,845 Hlth Sci Rd, Irvine, CA 92697 USA.	cummings@uci.edu	Cummings, Brian J/C-9180-2012	Cummings, Brian J/0000-0003-3628-5290; beretta, stefania/0000-0003-1334-119X	Early Translation Award grant from CIRM [TR2-01767]; CIRM Bridges award [TB1-01182]; University of Milano-Bicocca	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funded by an Early Translation Award grant from CIRM (TR2-01767) to BJC, a CIRM Bridges award to L Klig at CUSLB (TB1-01182) to support KMC, and a fellowship from the University of Milano-Bicocca to SB.	Ager RR, 2015, HIPPOCAMPUS, V25, P813, DOI 10.1002/hipo.22405; Ahmed AI, 2016, J ROY ARMY MED CORPS, V162, P98, DOI 10.1136/jramc-2015-000475; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Basso A., 2006, NEUROL DISORD PUBLIC, P164; CAVALHEIRO EA, 1991, EPILEPSIA, V32, P778, DOI 10.1111/j.1528-1157.1991.tb05533.x; Chang J, 2015, EXP NEUROL, V273, P225, DOI 10.1016/j.expneurol.2015.08.020; Chu K, 2004, BRAIN RES, V1023, P213, DOI 10.1016/j.brainres.2004.07.045; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Echegoyen J, 2009, EPILEPSY RES, V85, P123, DOI 10.1016/j.eplepsyres.2009.02.019; Englander Jeffrey, 2014, Arch Phys Med Rehabil, V95, P1223, DOI 10.1016/j.apmr.2013.06.002; Erkec OE, 2015, EPILEPSI, V21, P6, DOI 10.5505/epilepsi.2015.08108; Eslami M, 2016, NEUROL RES, V38, P269, DOI 10.1179/1743132815Y.0000000086; Faul M, 2010, TRAUMATIC BRAIN INJU, P11; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Gerberding J, 2003, REPORT C MILD TRAUMA, P1; Ghafouri S, 2016, EPILEPSY RES, V126, P37, DOI 10.1016/j.eplepsyres.2016.06.010; Glushakov AV, 2016, METHODS MOL BIOL, V1462, P481, DOI 10.1007/978-1-4939-3816-2_27; Golarai G, 2001, J NEUROSCI, V21, P8523; Gold EM, 2013, REGEN MED, V8, P483, DOI 10.2217/rme.13.41; Haus DL, 2016, EXP NEUROL, V281, P1, DOI 10.1016/j.expneurol.2016.04.008; Haus DL, 2014, STEM CELL RES, V13, P214, DOI 10.1016/j.scr.2014.06.008; Hefferan MP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042614; Hooshmand MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005871; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Kirmani BF, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00032; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P187, DOI 10.1097/00001199-200505000-00001; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Majores M, 2007, EPILEPSIA, V48, P4, DOI 10.1111/j.1528-1167.2007.01062.x; McHugh SB, 2004, BEHAV NEUROSCI, V118, P63, DOI 10.1037/0735-7044.118.1.63; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Morales JC, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00200; Mumby DG, 2002, LEARN MEMORY, V9, P49, DOI 10.1101/lm.41302; Okano H, 2003, SEMIN CELL DEV BIOL, V14, P191, DOI 10.1016/S1084-9521(03)00011-9; Parent JM, 1997, J NEUROSCI, V17, P3727; Peng WJ, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0034-0; Pires F, 2015, BBA-GEN SUBJECTS, V1850, P1158, DOI 10.1016/j.bbagen.2015.01.020; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Salazar DL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012272; Sontag CJ, 2014, STEM CELL REP, V2, P620, DOI 10.1016/j.stemcr.2014.03.005; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Watson NF, 2004, EPILEPSIA, V45, P690, DOI 10.1111/j.0013-9580.2004.59403.x; Widerstrom-Noga EG, 2009, J REHABIL RES DEV, V46, P1, DOI 10.1682/JRRD.2008.03.0038; Xiang Y, 2014, NEURAL REGEN RES, V9, P243, DOI 10.4103/1673-5374.128215; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407	53	12	12	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2017	26	7					1247	1261		10.1177/0963689717714107			15	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Cell Biology; Research & Experimental Medicine; Transplantation	EZ4GO	WOS:000404671800012	28933218	DOAJ Gold, Green Published			2021-06-18	
J	Chen, YH; Zhang, X; Zhang, BD; He, GD; Zhou, LF; Xie, YB				Chen, Yanhua; Zhang, Xu; Zhang, Bingdong; He, Guodong; Zhou, Lifang; Xie, Yubo			Dexmedetomidine reduces the neuronal apoptosis related to cardiopulmonary bypass by inhibiting activation of the JAK2-STAT3 pathway	DRUG DESIGN DEVELOPMENT AND THERAPY			English	Article						apoptosis; cardiopulmonary bypass; dexmedetomidine; neuroprotective effect; JAK2; STAT3	ISCHEMIA-REPERFUSION INJURY; TRAUMATIC BRAIN-INJURY; CARDIAC-SURGERY; ISCHEMIA/REPERFUSION INJURY; JAK2/STAT3 PATHWAY; CEREBRAL-ISCHEMIA; NEONATAL-RATS; INFLAMMATORY RESPONSE; SIGNALING PATHWAY; ORGAN DAMAGE	Cardiopulmonary bypass (CPB) constitutes one of the primary methodologies pertaining to cardiac surgery. However, this form of surgery can cause damage to the body. Many studies have reported that dexmedetomidine confers cerebral protection. In this study, we aimed to investigate the effect and mechanism of dexmedetomidine on neuronal apoptosis caused by CPB. Here, rats were treated with different doses of dexmedetomidine by intravenous infusion 2 hours after CPB. We observed that dexmedetomidine treatment to rats reduces the S100 beta, NSE levels in plasma, and neuronal apoptosis following CPB in a dose-dependent manner. Furthermore, we observed that the beneficial effect of dexmedetomidine treatment following CPB was associated with a reduction in IL6, an inflammatory cytokine in plasma and cortex. Our results suggest that dexmedetomidine provides neuroprotective effects by inhibiting inflammation and reducing neuronal apoptosis. There was a correlation between the protective effect on the brain and the dose of dexmedetomidine. In addition, dexmedetomidine administration inhibits phosphorylation of JAK2 and STAT3 proteins in the hippocampus of rats 2 hours after CPB. Therefore, we speculate that the JAK2-STAT3 pathway plays an important role in the neuroprotective effects of dexmedetomidine following brain injury induced by CPB.	[Chen, Yanhua; Zhang, Bingdong] Guangxi Med Univ, Affiliated Hosp 1, Cardiovasc Inst, Dept Anesthesiol, Nanning, Peoples R China; [Zhang, Xu; He, Guodong; Zhou, Lifang; Xie, Yubo] Guangxi Med Univ, Affiliated Hosp 1, Dept Anesthesiol, 6 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China	Xie, YB (corresponding author), Guangxi Med Univ, Affiliated Hosp 1, Dept Anesthesiol, 6 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.	xybdoctor@163.com			Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81373498]; Science Study and Technology Development Program of Guangxi [1355005-4-2]; Natural Science Foundation of GuangxiNational Natural Science Foundation of Guangxi Province [2015GXNS-FBA139139]; Youth Science Foundation of Guangxi Medical University [GXMUYSF2014041]; Department of Education Scientific Research Subject of Guangxi, China [KY2016YB079]	This work was supported by the Natural Science Foundation of China (81373498), Science Study and Technology Development Program of Guangxi (1355005-4-2), Natural Science Foundation of Guangxi (2015GXNS-FBA139139), Youth Science Foundation of Guangxi Medical University (GXMUYSF2014041) and the Department of Education Scientific Research Subject of Guangxi (KY2016YB079), China.	Bulow NMH, 2016, BRAZ J MED BIOL RES, V49, DOI 10.1590/1414-431X20154646; Caputo M, 2014, J THORAC CARDIOV SUR, V148, P792, DOI 10.1016/j.jtcvs.2014.06.001; Cheng XY, 2016, MOL MED REP, V14, P797, DOI 10.3892/mmr.2016.5345; de Jong PR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035070; Deng HL, 2015, MOL MED REP, V11, P3659, DOI 10.3892/mmr.2015.3170; Fujii Y, 2013, ARTIF ORGANS, V37, P136, DOI 10.1111/j.1525-1594.2012.01535.x; HATASHITA S, 1988, J CEREBR BLOOD F MET, V8, P552, DOI 10.1038/jcbfm.1988.96; Homi HM, 2010, J THORAC CARDIOV SUR, V140, P660, DOI 10.1016/j.jtcvs.2009.10.063; Hori D, 2015, ANESTH ANALG, V121, P1187, DOI 10.1213/ANE.0000000000000930; Howell KW, 2016, J SURG RES, V201, P76, DOI 10.1016/j.jss.2015.10.016; Hristova M, 2016, J NEUROCHEM, V136, P981, DOI 10.1111/jnc.13490; Hwang L, 2013, INT J MOL MED, V31, P1047, DOI 10.3892/ijmm.2013.1301; Jia LL, 2017, BRAIN RES, V1657, P202, DOI 10.1016/j.brainres.2016.12.015; Jongman RM, 2014, SHOCK, V42, P121, DOI 10.1097/SHK.0000000000000190; Kim HC, 2017, J NEUROSURG ANESTH, V29, P37, DOI 10.1097/ANA.0000000000000331; Kim J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112012; Kim YR, 2013, INT J MOL MED, V32, P1303, DOI 10.3892/ijmm.2013.1511; Komine-Kobayashi M, 2006, J CEREBR BLOOD F MET, V26, P402, DOI 10.1038/sj.jcbfm.9600195; Kunisawa T, 2011, J ANESTH, V25, P818, DOI 10.1007/s00540-011-1215-3; Li LL, 2015, INT J CLIN EXP MED, V8, P14985; Liao ZX, 2014, BRAIN RES BULL, V107, P69, DOI 10.1016/j.brainresbull.2014.07.001; Liu X, 2014, NEUROSCIENCE, V268, P318, DOI 10.1016/j.neuroscience.2014.03.032; Luo XH, 2016, CLIN NEUROL NEUROSUR, V146, P105, DOI 10.1016/j.clineuro.2016.05.004; Lv J, 2017, ENVIRON TOXICOL PHAR, V52, P121, DOI 10.1016/j.etap.2017.03.017; Matata BM, 2015, J CARDIOTHOR VASC AN, V29, P1236, DOI 10.1053/j.jvca.2015.02.020; McDonagh DL, 2014, LANCET NEUROL, V13, P490, DOI 10.1016/S1474-4422(14)70004-3; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Ouk T, 2016, VASC PHARMACOL, V80, P59, DOI 10.1016/j.vph.2015.12.005; Owais K, 2015, ANN THORAC SURG, V100, P1636, DOI 10.1016/j.athoracsur.2015.05.013; Pan WY, 2016, CELL MOL NEUROBIOL, V36, P1179, DOI 10.1007/s10571-015-0315-2; Patel N, 2015, CARDIOVASC PSYCHIAT, V2015, P370612, DOI DOI 10.1155/2015/370612; Podgoreanu MV, 2006, CIRCULATION, V114, pI275, DOI 10.1161/CIRCULATIONAHA.105.001032; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Si YN, 2014, EUR REV MED PHARMACO, V18, P1843; Si YN, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-141; Sifringer M, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/530371; Steinbrenner H, 2016, INFLAMMATION, V39, P1363, DOI 10.1007/s10753-016-0368-5; Sugita S, 2013, J NIPPON MED SCH, V80, P131, DOI 10.1272/jnms.80.131; Tao Z, 2015, INT J CLIN EXP PATHO, V8, P6732; Trop S, 2014, J SURG RES, V187, P43, DOI 10.1016/j.jss.2013.09.035; Wang YJ, 2016, MOL MED REP, V14, P769, DOI 10.3892/mmr.2016.5321; Zeng XZ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151620; Zhang WW, 2016, EXP BIOL MED, V241, P1819, DOI 10.1177/1535370216648804; Zhang XK, 2015, IRAN J BASIC MED SCI, V18, P604; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001; Zhao JB, 2011, CYTOKINE, V56, P343, DOI 10.1016/j.cyto.2011.07.018; Zhu YJ, 2016, BRAIN RES, V1644, P1, DOI 10.1016/j.brainres.2016.04.074	47	12	15	0	3	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1177-8881			DRUG DES DEV THER	Drug Des. Dev. Ther.		2017	11						2787	2799		10.2147/DDDT.S140644			13	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	GP1IW	WOS:000440570000001	29033541	DOAJ Gold, Green Published			2021-06-18	
J	Cook, NE; Huang, DS; Silverberg, ND; Brooks, BL; Maxwell, B; Zafonte, R; Berkner, PD; Iverson, GL				Cook, Nathan E.; Huang, Donna S.; Silverberg, Noah D.; Brooks, Brian L.; Maxwell, Bruce; Zafonte, Ross; Berkner, Paul D.; Iverson, Grant L.			Baseline cognitive test performance and concussion-like symptoms among adolescent athletes with ADHD: examining differences based on medication use	CLINICAL NEUROPSYCHOLOGIST			English	Article						Attention-deficit; hyperactivity disorder (ADHD); concussion; mild traumatic brain injury; adolescents	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; HIGH-SCHOOL; CHILDREN; METAANALYSIS; DISABILITY; SPORTS; SCORES	Objective: Youth with attention deficit hyperactivity disorder (ADHD) perform more poorly on preseason cognitive testing and report more baseline concussion-like symptoms but prior studies have not examined the influence of medication use on test performance or symptom reporting. This study investigated whether medication use is relevant when interpreting baseline ImPACT (R) results from student athletes with ADHD. Method: Participants were 39,247 adolescent athletes, ages 13-18 (mean age=15.5years, SD=1.3), who completed baseline cognitive testing with ImPACT (R). The sample included slightly more boys (54.4%) than girls. Differences in ImPACT (R) composite scores and concussion-like symptom reporting (between ADHD/No medication, ADHD/Medication, No ADHD/Medication, and Control groups) were examined with ANOVAs, conducted separately by gender. Results: In this large, state-wide data-set, youth with ADHD had greater rates of invalid ImPACT results compared to control subjects (ADHD/No Medication: girls=10.9%, boys=10%; ADHD/Medication: girls=8.1%, boys=9.1%; Controls: girls=5.2%, boys=6.7%). Groups differed across all ImPACT (R) composites (invalid profiles were removed), in the following order (from worse to better performance): ADHD/No Medication, ADHD/Medication, and Control participants. Pairwise effect sizes indicated that the largest differences were on the Visual Motor Speed composite, with the ADHD/No medication group performing worse than the ADHD/Medication group and the Controls. The ADHD/Medication group did not differ meaningfully from Controls on any composite, for either sex (d=0 to .19). The ADHD groups did not differ on total symptom scores but both ADHD groups endorsed significantly more symptoms compared to Controls. Conclusions: Contrary to our hypothesis, we found medication use had only a subtle effect on cognitive performance and no significant effect on concussion-like symptom reporting. Student athletes reporting medication use for ADHD performed comparably to student athletes with no ADHD on baseline testing.	[Cook, Nathan E.] Harvard Med Sch, Dept Psychiat, Boston, MA 02115 USA; [Cook, Nathan E.] Massachusetts Gen Hosp, Dept Psychiat, Learning & Emot Assessment Program, Boston, MA 02114 USA; [Cook, Nathan E.; Silverberg, Noah D.; Iverson, Grant L.] MassGeneral Hosp, Children Sport Concuss Program, Boston, MA 02114 USA; [Huang, Donna S.; Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Huang, Donna S.; Silverberg, Noah D.; Zafonte, Ross; Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC, Canada; [Silverberg, Noah D.] GF Strong Rehab Ctr, Vancouver, BC, Canada; [Silverberg, Noah D.; Zafonte, Ross; Iverson, Grant L.] Home Base, Boston, MA USA; [Silverberg, Noah D.; Zafonte, Ross; Iverson, Grant L.] Massachusetts Gen Hosp Program, Boston, MA USA; [Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Neurosci & Vi Riddell Childrens Pain & Rehabil Pr, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Paediat, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Psychol, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Alberta Childrens Hosp Res Inst, Calgary, AB, Canada; [Maxwell, Bruce] Colby Coll, Dept Comp Sci, Waterville, ME 04901 USA; [Zafonte, Ross] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Zafonte, Ross] Massachusetts Gen Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA; [Zafonte, Ross] Brigham & Womens Hosp, Dept Phys Med & Rehabil, 75 Francis St, Boston, MA 02115 USA; [Berkner, Paul D.] Colby Coll, Hlth Serv, Waterville, ME 04901 USA; [Berkner, Paul D.] Colby Coll, Dept Biol, Waterville, ME 04901 USA	Cook, NE (corresponding author), Harvard Med Sch, Dept Psychiat, Boston, MA 02115 USA.; Cook, NE (corresponding author), Massachusetts Gen Hosp, Dept Psychiat, Learning & Emot Assessment Program, Boston, MA 02114 USA.	necook@mgh.harvard.edu		Huang, Donna/0000-0001-8620-639X; Iverson, Grant/0000-0001-7348-9570	Goldfarb Center for Public Policy and Civic Engagement at Colby College; Bill and Joan Alfond Foundation	This work was supported in part by the Goldfarb Center for Public Policy and Civic Engagement at Colby College, and the Bill and Joan Alfond Foundation.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Brooks BL, 2016, APPL NEUROPSYCH-CHIL, V5, P119, DOI 10.1080/21622965.2014.1003066; Chinn S, 2000, STAT MED, V19, P3127, DOI 10.1002/1097-0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M; Coghill DR, 2014, BIOL PSYCHIAT, V76, P603, DOI 10.1016/j.biopsych.2013.10.005; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Ellis P.D., 2009, EFFECT SIZE CALCULAT; Faraone SV, 2010, EUR CHILD ADOLES PSY, V19, P353, DOI 10.1007/s00787-009-0054-3; Goth-Owens TL, 2010, CHILD NEUROPSYCHOL, V16, P577, DOI 10.1080/09297049.2010.485126; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; ImPACT Applications Inc, 2011, IMM POSTC ASS COGN T; Iverson G. L., 2014, J NEUROTRAUM, V33, P2077, DOI [10.1089/neu.2014.3424, DOI 10.1089/NEU.2014.3424.]; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Littleton AC, 2015, ARCH CLIN NEUROPSYCH, V30, P683, DOI 10.1093/arclin/acv043; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Mautner K, 2015, CLIN J SPORT MED, V25, P355, DOI 10.1097/JSM.0000000000000151; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Nelson LD, 2015, AM J SPORT MED, V43, P2018, DOI 10.1177/0363546515587714; Shanahan MA, 2006, J ABNORM CHILD PSYCH, V34, P585, DOI 10.1007/s10802-006-9037-8; Sussman W. I., 2014, AM J PHYS MED REHABI, V93, pa94; Visser SN, 2014, J AM ACAD CHILD PSY, V53, P34, DOI 10.1016/j.jaac.2013.09.001; Willcutt EG, 2005, BIOL PSYCHIAT, V57, P1336, DOI 10.1016/j.biopsych.2005.02.006; Yengo-Kahn AM, 2015, PHYSICIAN SPORTSMED, V43, P227, DOI 10.1080/00913847.2015.1071638; Zuckerman SL, 2013, J NEUROSURG-PEDIATR, V12, P103, DOI 10.3171/2013.5.PEDS12524	24	12	12	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2017	31	8					1341	1352		10.1080/13854046.2017.1317031			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	FM2JR	WOS:000414811500006	28429656				2021-06-18	
J	Gardner, RM; Yengo-Kahn, A; Bonfield, CM; Solomon, GS				Gardner, Ryan M.; Yengo-Kahn, Aaron; Bonfield, Christopher M.; Solomon, Gary S.			Comparison of baseline and post-concussion ImPACT test scores in young athletes with stimulant-treated and untreated ADHD	PHYSICIAN AND SPORTSMEDICINE			English	Article						Attention Deficit Hyperactivity Disorder (ADHD); sports-related; concussion; ImPACT; stimulant; baseline; post-concussion; mild traumatic brain injury	DEFICIT HYPERACTIVITY DISORDER; SPORTS-RELATED CONCUSSION; ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER; NEUROCOGNITIVE TEST-PERFORMANCE; METABOLIC BRAIN VULNERABILITY; PREDICT PROTRACTED RECOVERY; HIGH-SCHOOL; TEMPORAL WINDOW; NEUROPSYCHOLOGICAL FUNCTION; CLINICAL ARTICLE	Objectives: Baseline and post-concussion neurocognitive testing is useful in managing concussed athletes. Attention deficit hyperactivity disorder (ADHD) and stimulant medications are recognized as potential modifiers of performance on neurocognitive testing by the Concussion in Sport Group. Our goal was to assess whether individuals with ADHD perform differently on post-concussion testing and if this difference is related to the use of stimulants. Methods: Retrospective case-control study in which 4373 athletes underwent baseline and post-concussion testing using the ImPACT battery. 277 athletes self-reported a history of ADHD, of which, 206 reported no stimulant treatment and 69 reported stimulant treatment. Each group was matched with participants reporting no history of ADHD or stimulant use on several biopsychosocial characteristics. Non-parametric tests were used to assess ImPACT composite score differences between groups. Results: Participants with ADHD had worse verbal memory, visual memory, visual motor speed, and reaction time scores than matched controls at baseline and post-concussion, all with p <=.001 and vertical bar r vertical bar >= 0.100. Athletes without stimulant treatment had lower verbal memory, visual memory, visual motor speed, and reaction time scores than controls at baseline (p <= 0.01, vertical bar r vertical bar >= 0.100 [except verbal memory, r=-0.088]) and post-concussion (p=0.000, vertical bar r vertical bar> 0.100). Athletes with stimulant treatment had lower verbal memory (Baseline: p=0.047, r=-0.108; Post-concussion: p=0.023, r=-0.124) and visual memory scores (Baseline: p=0.013, r=-0.134; Post-concussion: p=0.003, r=-0.162) but equivalent visual motor speed and reaction time scores versus controls at baseline and post-concussion. Conclusions: ADHD-specific baseline and post-concussion neuropsychological profiles, as well as stimulant medication status, may need to be considered when interpreting ImPACT test results. Further investigation into the effects of ADHD and stimulant use on recovery from sport-related concussion (SRC) is warranted.	[Gardner, Ryan M.; Yengo-Kahn, Aaron; Bonfield, Christopher M.; Solomon, Gary S.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, 3000 Vanderbilt Pl,Apartment 147, Nashville, TN 37212 USA; [Yengo-Kahn, Aaron; Bonfield, Christopher M.; Solomon, Gary S.] Vanderbilt Univ, Sch Med, Dept Neurol Surg, Nashville, TN 37212 USA	Gardner, RM (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, 3000 Vanderbilt Pl,Apartment 147, Nashville, TN 37212 USA.	ryan.m.gardner@vanderbilt.edu	Yengo-Kahn, Aaron/AAV-7647-2020; Solomon, Gary/K-9011-2019	Yengo-Kahn, Aaron/0000-0002-5989-3064; 			Advokat C, 2010, NEUROSCI BIOBEHAV R, V34, P1256, DOI 10.1016/j.neubiorev.2010.03.006; Allen BJ, 2011, BRAIN INJURY, V25, P179, DOI 10.3109/02699052.2010.541897; AMADOBOCCARA I, 1995, NEUROSCI BIOBEHAV R, V19, P479, DOI 10.1016/0149-7634(94)00068-C; Bailey CM, 2010, CLIN J SPORT MED, V20, P272, DOI 10.1097/JSM.0b013e3181e8f8d8; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Baune BT, 2014, PSYCHIAT RES, V219, P25, DOI 10.1016/j.psychres.2014.05.013; Bay E, 2012, ARCH PSYCHIAT NURS, V26, P477, DOI 10.1016/j.apnu.2012.06.002; Bonfield CM, 2013, J NEUROSURG-PEDIATR, V12, P97, DOI 10.3171/2013.5.PEDS12424; Cohen J, 1977, STAT POWER ANAL BEHA, p[xv, 474]; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Dougan BK, 2014, J INT NEUROPSYCH SOC, V20, P64, DOI 10.1017/S1355617712001464; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fritz CO, 2012, J EXP PSYCHOL GEN, V141, P2, DOI 10.1037/a0024338; GADDIS GM, 1990, ANN EMERG MED, V19, P1054, DOI 10.1016/S0196-0644(05)82571-5; Greydanus DE, 2009, NEUROPSYCH DIS TREAT, V5, P171; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harvey Philip D, 2012, Dialogues Clin Neurosci, V14, P91; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kessler RC, 2006, AM J PSYCHIAT, V163, P716, DOI 10.1176/appi.ajp.163.4.716; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Lakhan SE, 2012, BRAIN BEHAV, V2, P661, DOI 10.1002/brb3.78; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lezak MD, 2004, NEUROPSYCHOLOGICAL A, V2; Littleton AC, 2015, ARCH CLIN NEUROPSYCH, V30, P683, DOI 10.1093/arclin/acv043; Lovell M, 2016, IMPACT VERSION 6 0 C; Mautner K, 2015, CLIN J SPORT MED, V25, P355, DOI 10.1097/JSM.0000000000000151; McCrory P, 2012, BRIT J SPORT MED, V47, P9; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Merikangas KR, 2013, JAMA PEDIATR, V167, P141, DOI 10.1001/jamapediatrics.2013.431; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Moser RS, 2015, APPL NEUROPSYCH-CHIL, V4, P41, DOI 10.1080/21622965.2013.791825; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Olfson M, 2014, JAMA PSYCHIAT, V71, P81, DOI 10.1001/jamapsychiatry.2013.3074; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Ramtekkar UP, 2010, J AM ACAD CHILD PSY, V49, P217, DOI 10.1016/j.jaac.2009.11.011; Reardon CL, 2016, SPORTS MED, V46, P611, DOI 10.1007/s40279-015-0456-y; Salinas CM, 2016, APPL NEUROPSYCH-CHIL, V5, P264, DOI 10.1080/21622965.2015.1052814; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Thomas R, 2015, PEDIATRICS, V135, pE994, DOI 10.1542/peds.2014-3482; Tucha O, 2006, J NEURAL TRANSM, V113, P1575, DOI 10.1007/s00702-005-0437-7; Turner DC, 2005, PSYCHOPHARMACOLOGY, V178, P286, DOI 10.1007/s00213-004-1993-5; Vagnozzi R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Wilson HK, 2006, ARCH CLIN NEUROPSYCH, V21, P797, DOI 10.1016/j.acn.2006.06.016; Wobbrock J.O., 2011, ACM C HUM FACT COMP; Yengo-Kahn AM, 2015, PHYSICIAN SPORTSMED, V43, P227, DOI 10.1080/00913847.2015.1071638; Zuckerman SL, 2013, J NEUROSURG-PEDIATR, V12, P103, DOI 10.3171/2013.5.PEDS12524	60	12	12	1	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0091-3847	2326-3660		PHYSICIAN SPORTSMED	Physician Sportsmed.		2017	45	1					1	10		10.1080/00913847.2017.1248221			10	Primary Health Care; Orthopedics; Sport Sciences	General & Internal Medicine; Orthopedics; Sport Sciences	EL4VJ	WOS:000394618700001	27736285				2021-06-18	
J	Hellstrom, T; Westlye, LT; Sigurdardottir, S; Brunborg, C; Soberg, HL; Holthe, O; Server, A; Lund, MJ; Andreassen, OA; Andelic, N				Hellstrom, T.; Westlye, L. T.; Sigurdardottir, S.; Brunborg, C.; Soberg, H. L.; Holthe, O.; Server, A.; Lund, M. J.; Andreassen, O. A.; Andelic, N.			Longitudinal changes in brain morphology from 4 weeks to 12 months after mild traumatic brain injury: Associations with cognitive functions and clinical variables	BRAIN INJURY			English	Article						Mild brain injury; longitudinal; radiology; neuroimaging; intracranial injury; cortical thickness	POST-CONCUSSION SYMPTOMS; HUMAN CEREBRAL-CORTEX; HEAD-INJURY; MRI; VOLUME; SEGMENTATION; METAANALYSIS; THICKNESS; PATHOLOGY; CINGULATE	Objective: To investigate longitudinal changes in cortical and subcortical volumes in patients with mild traumatic brain injury (MTBI) and to evaluate whether such changes were associated with self-reported post-concussive symptoms, global functional outcomes and neuropsychological functioning.Methods: This was a prospecitve, longitudinal cohort study of patients with complicated (i.e presence of intracranial abnormalities on the day of injury CT) and uncomplicated MTBI (i.e, absence of intracranial abnormalities). Magnetic resonance imaging (MRI) was performed at approximately 4 weeks and 12 months. We utilized a 3T MRI system, cortical reconstruction and volumetric segmentation by FreeSurfer software. We included 33 patients with uncomplicated and 29 with complicated MTBI, who were aged 16-65 years.Results: 12 months after MTBI, significant within-group volume reductions were detected in the left accumbens area and right caudate nucleus for both patients groups, but no significant differences between the groups were revealed. No associations between volumetric variables and post-concussive symptoms or global functioning were found. The left temporal thickness was significantly associated with executive functioning.Conclusion: Structural subcortical alterations occur after complicated and uncomplicated MTBIs but these findings were not associated with symptoms burden or functional outcomes. Nonetheless, worse executive functioning was found in patients with shrinkage of the left temporal lobe.	[Hellstrom, T.; Soberg, H. L.; Holthe, O.; Andelic, N.] Oslo Univ Hosp, Dept Phys Med & Rehabil, N-0407 Oslo, Norway; [Westlye, L. T.; Lund, M. J.; Andreassen, O. A.] Oslo Univ Hosp, Div Mental Hlth & Addict, KG Jebsen Ctr Psychosis Res, Norwegian Ctr Mental Disorder Res NORMENT, Oslo, Norway; [Westlye, L. T.] Univ Oslo, Dept Psychol, Oslo, Norway; [Sigurdardottir, S.] Sunnaas Rehabil Hosp, Dept Res, Nesoddtangen, Norway; [Sigurdardottir, S.; Andelic, N.] CHARM Resarch Ctr Habilitat & Rehabil Models & Se, Oslo, Norway; [Brunborg, C.] Oslo Univ Hosp, Oslo Ctr Biostat & Epidemiol, Res Support Serv, Oslo, Norway; [Server, A.] Oslo Univ Hosp, Dept Radiol & Nucl Med, Oslo, Norway	Hellstrom, T (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, N-0407 Oslo, Norway.	torgeir.hellstrom@ous-hf.no	Andreassen, Ole A./AAY-7531-2020	Andelic, Nada/0000-0002-3719-4406; Westlye, Lars T./0000-0001-8644-956X	Department of Physical Medicine and Rehabilitation, Oslo University Hospital	The authors thank the Department of Physical Medicine and Rehabilitation, Oslo University Hospital for institutional and financial support. The authors report no conflict of interest. The authors alone are responsible for the content and writing of this paper.	Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Ansell EB, 2012, BIOL PSYCHIAT, V72, P57, DOI 10.1016/j.biopsych.2011.11.022; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Benson RR, 2012, NEUROREHABILITATION, V31, P261, DOI 10.3233/NRE-2012-0795; Bigler E.D., 2015, BRAIN NEUROTRAUMA MO; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Byrnes Kimberly R, 2014, Front Neuroenergetics, V5, P13, DOI 10.3389/fnene.2013.00013; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Fjell AM, 2013, NEUROBIOL AGING, V34, P2239, DOI 10.1016/j.neurobiolaging.2013.04.006; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Lannsjo M, 2013, J REHABIL MED, V45, P721, DOI 10.2340/16501977-1169; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Narayana PA, 2015, NEUROIMAGE-CLIN, V7, P87, DOI 10.1016/j.nicl.2014.07.010; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; Ross DE, 2011, BRAIN INJURY, V25, P1271, DOI 10.3109/02699052.2011.624568; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Silver JM., 2011, TXB TRAUMATIC BRAIN, V2nd ed.; Taylor LA, 2003, BRAIN INJURY, V17, P295, DOI 10.1080/0269905021000038401; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Wang X, 2015, J NEUROTRAUM, V32, P455, DOI 10.1089/neu.2014.3492; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wu WC, 2011, NEUROIMAGE, V56, P1244, DOI 10.1016/j.neuroimage.2011.02.080; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Zagorchev L, 2016, J NEUROTRAUM, V33, P29, DOI 10.1089/neu.2014.3831; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	46	12	12	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	5					674	685		10.1080/02699052.2017.1283537			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EV8OA	WOS:000402039900013	28414250	Green Accepted			2021-06-18	
J	Kikinis, Z; Muehlmann, M; Pasternak, O; Peled, S; Kulkarni, P; Ferris, C; Bouix, S; Rathi, Y; Koerte, IK; Pieper, S; Yarmarkovich, A; Porter, CL; Kristal, BS; Shenton, ME				Kikinis, Zora; Muehlmann, Marc; Pasternak, Ofer; Peled, Sharon; Kulkarni, Praveen; Ferris, Craig; Bouix, Sylvain; Rathi, Yogesh; Koerte, Inga K.; Pieper, Steve; Yarmarkovich, Alexander; Porter, Caryn L.; Kristal, Bruce S.; Shenton, Martha E.			Diffusion imaging of mild traumatic brain injury in the impact accelerated rodent model: A pilot study	BRAIN INJURY			English	Article						Animal model; mild traumatic brain injury (mTBI); diffusion tensor magnetic resonance imaging (dMRI); fractional anisotropy (FA); impact acceleration injury	AXONAL INJURY; HEAD-INJURY; RATS; DYSFUNCTION; EDEMA	Primary Objective: There is a need to understand pathologic processes of the brain following mild traumatic brain injury (mTBI). Previous studies report axonal injury and oedema in the first week after injury in a rodent model. This study aims to investigate the processes occurring 1 week after injury at the time of regeneration and degeneration using diffusion tensor imaging (DTI) in the impact acceleration rat mTBI model.Research Design: Eighteen rats were subjected to impact acceleration injury, and three rats served as sham controls. Seven days post injury, DTI was acquired from fixed rat brains using a 7T scanner. Group comparison of Fractional Anisotropy (FA) values between traumatized and sham animals was performed using Tract-Based Spatial Statistics (TBSS), a method that we adapted for rats.Main Outcomes and Results: TBSS revealed white matter regions of the brain with increased FA values in the traumatized versus sham rats, localized mainly to the contrecoup region. Regions of increased FA included the pyramidal tract, the cerebral peduncle, the superior cerebellar peduncle and to a lesser extent the fibre tracts of the corpus callosum, the anterior commissure, the fimbria of the hippocampus, the fornix, the medial forebrain bundle and the optic chiasm.Conclusion: Seven days post injury, during the period of tissue reparation in the impact acceleration rat model of mTBI, microstructural changes to white matter can be detected using DTI.	[Kikinis, Zora; Muehlmann, Marc; Pasternak, Ofer; Bouix, Sylvain; Rathi, Yogesh; Koerte, Inga K.; Shenton, Martha E.] Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat, Psychiat Neuroimaging Lab, Boston, MA USA; [Muehlmann, Marc; Koerte, Inga K.] Ludwig Maximilians Univ Munchen, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany; [Pasternak, Ofer; Peled, Sharon; Bouix, Sylvain; Rathi, Yogesh; Shenton, Martha E.] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Boston, MA USA; [Kulkarni, Praveen; Ferris, Craig] Northeastern Univ, Dept Psychol, Ctr Translat NeuroImaging, Boston, MA 02115 USA; [Pieper, Steve; Yarmarkovich, Alexander] Isomics Inc, Cambridge, MA USA; [Porter, Caryn L.; Kristal, Bruce S.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA USA; [Shenton, Martha E.] Harvard Med Sch, VA Boston Healthcare Syst, Dept Psychiat, Boston, MA USA	Kikinis, Z (corresponding author), Brigham & Womens Hosp, Dept Psychiat, Psychiat Neuroimaging Lab, 1249 Boylston St, Boston, MA 02115 USA.	zora@bwh.harvard.edu	Shenton, Martha/V-8780-2019	Kulkarni, Praveen/0000-0002-8876-4544	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD090641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015902] Funding Source: NIH RePORTER; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41 EB015902] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD090641] Funding Source: Medline		Angoa-Perez M, 2014, J NEUROCHEM, V129, P916, DOI 10.1111/jnc.12690; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beauchamp MH, 2011, BRAIN INJURY, V25, P950, DOI 10.3109/02699052.2011.589791; Bigler ED, 2014, BRAIN INJURY, P1; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Cai Yu, 2011, Front Psychiatry, V2, P54, DOI 10.3389/fpsyt.2011.00054; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chang EY, 2014, J MAGN RESON IMAGING, V40, P496, DOI 10.1002/jmri.24360; Cook GA, 2014, MIL MED, V179, P1083, DOI 10.7205/MILMED-D-13-00435; Croall ID, 2014, NEUROLOGY, V83, P494, DOI 10.1212/WNL.0000000000000666; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Drew LB, 2004, NEUROCRIT CARE, V1, P385, DOI 10.1385/NCC:1:3:385; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Guilfoyle DN, 2003, NMR BIOMED, V16, P77, DOI 10.1002/nbm.814; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132093, 10.3171/2013.12.JNS132090]; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Laalo JP, 2014, BRAIN INJURY, V28, P66, DOI 10.3109/02699052.2013.857791; Li SX, 2013, INT J LEGAL MED, V127, P159, DOI 10.1007/s00414-012-0712-8; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Miller KL, 2011, NEUROIMAGE, V57, P167, DOI 10.1016/j.neuroimage.2011.03.070; Morrison AL, 1998, AM J FOREN MED PATH, V19, P109, DOI 10.1097/00000433-199806000-00002; National Institute for Health and Clinical Excellence: Guidance, 2014, HEAD INJ TRIAG ASS I; Reis C, 2015, INT J MOL SCI, V16, P11903, DOI 10.3390/ijms160611903; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Sun SW, 2003, MAGN RESON MED, V50, P743, DOI 10.1002/mrm.10605; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; van de Looij Y, 2012, NMR BIOMED, V25, P93, DOI 10.1002/nbm.1721; Vik Anne, 2006, Tidsskr Nor Laegeforen, V126, P2940	40	12	12	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	10					1376	1381		10.1080/02699052.2017.1318450			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FN4GH	WOS:000415961800016	28627942	Green Accepted			2021-06-18	
J	Mikkelsen, R; Rodevand, LN; Wiig, US; Zahl, SM; Berntsen, T; Skarbo, AB; Egge, A; Helseth, E; Andersson, S; Wester, K				Mikkelsen, Rebecka; Rodevand, Linn Nilsen; Wiig, Ulrikke Straume; Zahl, Sverre Morten; Berntsen, Torhild; Skarbo, Anne-Britt; Egge, Arild; Helseth, Eirik; Andersson, Stein; Wester, Knut			Neurocognitive and psychosocial function in children with benign external hydrocephalus (BEH)-a long-term follow-up study	CHILDS NERVOUS SYSTEM			English	Article						Benign external hydrocephalus (BEH); Cognition; Neuropsychology; Psychosocial function; Quality of life	TRAUMATIC BRAIN-INJURY; GENERIC CORE SCALES; QUALITY-OF-LIFE; EXECUTIVE FUNCTION; INFANTS; RELIABILITY; VALIDITY; VERSION	Long-term impact of benign external hydrocephalus (BEH) on cognition is largely unknown, and indication for neurosurgical CSF diversion procedure is debated. This study reports neuropsychological and psychosocial function in operated and non-operated BEH children. Eighty-six children (76 males) between 8 and 18 years (mean 13.9) diagnosed with BEH before 12 months were included, of whom 30.2 % were operated. Participants completed neuropsychological tests and questionnaires covering quality of life (PedsQL) and executive function (BRIEF). Both operated and non-operated BEH children performed significantly below normative means on several neuropsychological tests. The children scored themselves higher than the norm average on PedsQL; however, the parents reported life quality comparable to other children. Operated children performed poorer compared with non-operated children on tests of psychomotor speed, attention span, executive function, motor speed and coordination, and on the BRIEF subscale Monitoring. Operated children, but not their parents, reported more problems on PedsQL subscale School than non-operated children. Children with BEH display long-term subtle neurocognitive difficulties. Non-operated children performed significantly better on some neuropsychological measures and reported less psychosocial problems. This difference may be caused by a selection bias: neurosurgical intervention was more likely in children with clinically more pronounced symptoms.	[Mikkelsen, Rebecka; Rodevand, Linn Nilsen; Andersson, Stein] Univ Oslo, Dept Psychol, Oslo, Norway; [Wiig, Ulrikke Straume; Egge, Arild; Helseth, Eirik] Oslo Univ Hosp, Dept Neurosurg, Oslo, Norway; [Zahl, Sverre Morten] Aalesund Hosp, Dept Ear Nose & Throat, Alesund, Norway; [Zahl, Sverre Morten; Wester, Knut] Univ Bergen, Dept Clin Med K1, Bergen, Norway; [Berntsen, Torhild; Skarbo, Anne-Britt] Oslo Univ Hosp, Dept Clin Neurosci Children, Oslo, Norway; [Andersson, Stein] Oslo Univ Hosp, Dept Psychosomat Med, Oslo, Norway; [Wester, Knut] Haukeland Hosp, Dept Neurosurg, N-5021 Bergen, Norway	Wester, K (corresponding author), Univ Bergen, Dept Clin Med K1, Bergen, Norway.; Wester, K (corresponding author), Haukeland Hosp, Dept Neurosurg, N-5021 Bergen, Norway.	kgwe@helse-bergen.no	Helseth, Eirik/AAH-2466-2020	Wester, Knut/0000-0001-8489-3931; Zahl, Sverre Morten/0000-0003-3303-6977	Grieg Foundation, Bergen, Norway; Western Norway Regional Health Authority [911439]	This study was supported by a grant from the Grieg Foundation, Bergen, Norway. Sverre Morten Zahl was supported by a Ph.D. grant from the Western Norway Regional Health Authority, project no. 911439.	Anderson V., 2008, EXECUTIVE FUNCTIONS; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; ANDERSSON H, 1984, CHILD BRAIN, V11, P398; Boaz JC, 1999, NEUROIMAG CLIN N AM, V9, P73; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; DANDY WE, 1946, ARCH SURG-CHICAGO, V52, P421, DOI 10.1001/archsurg.1946.01230050428003; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Fallmyr O, 2011, J NORWEGIAN PSYCHOL, V48, P339; Follmer DJ, 2014, SCH PSYCHOL, V68; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; LAUBSCHER B, 1990, EUR J PEDIATR, V149, P502, DOI 10.1007/BF01959405; Muenchberger H, 2006, CHILD NERV SYST, V22, P1242, DOI 10.1007/s00381-006-0080-0; ODITA JC, 1992, CHILD NERV SYST, V8, P36, DOI 10.1007/BF00316560; Reinfjell T, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-61; Rekate HL, 2009, SEMIN PEDIATR NEUROL, V16, P9, DOI 10.1016/j.spen.2009.01.002; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Talley JL, 1992, CHILDRENS AUDITORY V; Trites R, 1977, NEUROPSYCHOLOGICAL T; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wechsler D., 2009, WECHSLER INTELLIGENC, VWechsler, D., 2009. Wechsler Intelligence Scale for Children, (third ed.) Pearson, San Antonio, TX.; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D, 2011, WECHSLER ADULT INTEL; Yew AY, 2011, PEDIATR NEUROSURG, V47, P1, DOI 10.1159/000322357; Zahl SM, 2008, PEDIATRICS, V121, pE416, DOI 10.1542/peds.2007-1598; Zahl SM, 2011, NEUROSURG REV, V34, P417, DOI 10.1007/s10143-011-0327-4	27	12	13	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	JAN	2017	33	1					91	99		10.1007/s00381-016-3267-z			9	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	EL0YS	WOS:000394348300014	27848005				2021-06-18	
J	Mors, K; Horauf, JA; Kany, S; Wagner, N; Sturm, R; Woschek, M; Perl, M; Marzi, I; Relja, B				Moers, Katharina; Hoerauf, Jason-Alexander; Kany, Shinwan; Wagner, Nils; Sturm, Ramona; Woschek, Mathias; Perl, Mario; Marzi, Ingo; Relja, Borna			Ethanol Decreases Inflammatory Response in Human Lung Epithelial Cells by Inhibiting the Canonical NF-kappa B-Pathway	CELLULAR PHYSIOLOGY AND BIOCHEMISTRY			English	Article						Inflammation; Trauma; Alcohol; Intoxication; NF-kappa B; Canonical; Non-canonical; Lung	TRAUMATIC BRAIN-INJURY; TUMOR-NECROSIS-FACTOR; BLOOD-ALCOHOL CONCENTRATION; SYSTEMIC INTERLEUKIN-6; MAJOR TRAUMA; FACTOR-ALPHA; INTOXICATION; EPIDEMIOLOGY; ACTIVATION; BETA	Background/Aims: Alcohol (ethanol, EtOH) as significant contributor to traumatic injury is linked to suppressed inflammatory response, thereby influencing clinical outcomes. Alcohol-induced immune-suppression during acute inflammation (trauma) was linked to nuclear factor-kappaB (NF-kappa B). Here, we analyzed alcohol's effects and mechanisms underlying its influence on NF-kappa B-signaling during acute inflammation in human lung epithelial cells. Methods: A549-cells were stimulated with interleukin (IL)-1 beta, or sera from trauma patients (TP) or healthy volunteers, with positive/negative blood alcohol concentrations (BAC), and subsequently exposed to EtOH (170 Mm, 1h). IL-6-release and neutrophil adhesion to A549 were analyzed. Specific siRNA-NIK mediated downregulation of non-canonical, and IKK-NBD-inhibition of canonical NF-kappa B signaling were performed. Nuclear levels of activated p50 and p52 NF-kappa B-subunits were detected using TransAm ELISA. Results: Both stimuli significantly induced IL-6-release (39.79 +/- 4.70 vs. 0.58 +/- 0.8 pg/ml) and neutrophil adhesion (132.30 +/- 8.80 vs. 100% control, p < 0.05) to A549-cells. EtOH significantly decreased IL-6-release (22.90 +/- 5.40, p < 0.05) and neutrophil adherence vs. controls (105.40 +/- 14.5%, p < 0.05). IL-1 beta-induced significant activation of canonical/p50 and non-canonical/p52 pathways. EtOH significantly reduced p50 (34.90 +/- 23.70 vs. 197.70 +/- 36.43, p < 0.05) not p52 activation. Inhibition of canonical pathway was further increased by EtOH (less p50-activation), while p52 remained unaltered. Inhibition of non-canonical pathway was unchanged by EtOH. Conclusion: Here, alcohol's anti-inflammatory effects are mediated via decreasing nuclear levels of activated p50-subunit and canonical NF-kappa B signaling pathway. (C) 2017 The Author(s) Published by S. Karger AG, Basel	[Moers, Katharina; Hoerauf, Jason-Alexander; Kany, Shinwan; Wagner, Nils; Sturm, Ramona; Woschek, Mathias; Marzi, Ingo; Relja, Borna] Goethe Univ, Dept Trauma Hand & Reconstruct Surg, Frankfurt, Germany; [Perl, Mario] Trauma Ctr Murnau, Dept Trauma Surg, Murnau, Germany	Relja, B (corresponding author), Goethe Univ, Univ Hosp Frankfurt, Dept Trauma Hand & Reconstruct Surg, Frankfurt, Germany.	info@bornarelja.com	Relja, Borna/B-6642-2016	Relja, Borna/0000-0002-5625-8823	DFGGerman Research Foundation (DFG)European Commission [PE908/3-1, RE3304/5-1]	We thank Katrin Jurida and Kerstin Kontradowitz for outstanding technical assistance. This work was supported by DFG PE908/3-1 and RE3304/5-1.	Alberdi F, 2014, MED INTENSIVA, V38, P580, DOI 10.1016/j.medin.2014.06.012; Bardenheuer M, 2000, UNFALLCHIRURG, V103, P355, DOI 10.1007/s001130050550; Berry C, 2010, AM SURGEON, V76, P1067; Beydoun H, 2014, J EMERG MED, V47, P387, DOI 10.1016/j.jemermed.2014.06.024; Boe DM, 2001, J INFECT DIS, V184, P1134, DOI 10.1086/323661; Brasier AR, 2006, CARDIOVASC TOXICOL, V6, P111, DOI 10.1385/CT:6:2:111; Crofford LJ, 1997, ARTHRITIS RHEUM-US, V40, P226, DOI 10.1002/art.1780400207; Driessler F, 2004, CLIN EXP IMMUNOL, V135, P64, DOI 10.1111/j.1365-2249.2004.02342.x; Elsharkawy AM, 2010, J HEPATOL, V53, P519, DOI 10.1016/j.jhep.2010.03.025; Field CA, 2001, J TRAUMA, V50, P13, DOI 10.1097/00005373-200101000-00002; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Goral J, 2005, J IMMUNOL, V174, P456, DOI 10.4049/jimmunol.174.1.456; Goral J, 2008, ALCOHOL, V42, P237, DOI 10.1016/j.alcohol.2008.02.003; Hadjibashi AA, 2012, J SURG RES, V173, P212, DOI 10.1016/j.jss.2011.05.029; Handel ML, 1995, ARTHRITIS RHEUM, V38, P1762, DOI 10.1002/art.1780381209; Hietbrink F, 2006, World J Emerg Surg, V1, P15, DOI 10.1186/1749-7922-1-15; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; Lefering R, 2012, UNFALLCHIRURG, V115, P30, DOI 10.1007/s00113-011-2141-4; Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003; Lustenberger T, 2011, J NEUROTRAUM, V28, P1699, DOI 10.1089/neu.2011.1866; Mandrekar P, 2006, ALCOHOL CLIN EXP RES, V30, P135, DOI 10.1111/j.1530-0277.2006.00012.x; Mandrekar P, 1999, INT IMMUNOL, V11, P1781, DOI 10.1093/intimm/11.11.1781; Mandrekar P, 1997, ALCOHOL CLIN EXP RES, V21, P988, DOI 10.1097/00000374-199709000-00007; Mandrekar P, 1996, CYTOKINE, V8, P567, DOI 10.1006/cyto.1996.0076; Mandrekar P, 2007, J IMMUNOL, V178, P7686, DOI 10.4049/jimmunol.178.12.7686; Maraslioglu M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/808695; Mimasaka S, 2007, INJURY, V38, P1047, DOI 10.1016/j.injury.2007.02.045; NELSON S, 1989, J INFECT DIS, V160, P422, DOI 10.1093/infdis/160.3.422; Pandit V, 2014, J SURG RES, V190, P634, DOI 10.1016/j.jss.2014.04.039; Pickett W, 2002, ARCH PEDIAT ADOL MED, V156, P786, DOI 10.1001/archpedi.156.8.786; Relja B, 2016, INJURY, V47, P640, DOI 10.1016/j.injury.2016.01.016; Relja B, 2016, INT J MOL MED, V37, P517, DOI 10.3892/ijmm.2015.2431; Relja B, 2015, J MOL MED, V93, P1391, DOI 10.1007/s00109-015-1320-0; Relja B, 2012, BRIT J PHARMACOL, V165, P1188, DOI 10.1111/j.1476-5381.2011.01595.x; Relja B, 2014, MEDIAT INFLAMM, V2014, DOI DOI 10.1155/2014/781519; Relja B, 2015, MOL MED REP, V12, P2991, DOI 10.3892/mmr.2015.3764; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; Rivara FP, 1993, ARCH SURG-CHICAGO, V128, P912; Robin MA, 2005, HEPATOLOGY, V42, P1280, DOI 10.1002/hep.20949; Singh AK, 2004, MEDIAT INFLAMM, V13, P255, DOI 10.1080/09629350400003035; Sun SC, 2011, CELL RES, V21, P71, DOI 10.1038/cr.2010.177; Szabo G, 1996, ALCOHOL CLIN EXP RES, V20, P900, DOI 10.1111/j.1530-0277.1996.tb05269.x; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; Torices S, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1113-z; Varfolomeev E, 2016, CYTOKINE; Verzola D, 2017, J CACHEXIA SARCOPENI, V8, P131, DOI 10.1002/jcsm.12129; Volpin G, 2014, INT ORTHOP, V38, P1303, DOI 10.1007/s00264-013-2261-2; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013; Wagner N, 2016, SHOCK, V46, P261, DOI 10.1097/SHK.0000000000000620; WALKER DW, 1980, SCIENCE, V209, P711, DOI 10.1126/science.7394532; Wang F, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0274-0; Wang HF, 2016, CELL PHYSIOL BIOCHEM, V39, P1129, DOI 10.1159/000447820; Wutzler S, 2013, CHIRURG, V84, P753, DOI 10.1007/s00104-013-2477-0; YANNI G, 1994, ANN RHEUM DIS, V53, P39, DOI 10.1136/ard.53.1.39; Zhang JF, 2016, CELL PHYSIOL BIOCHEM, V38, P2230, DOI 10.1159/000445578; Zhou DY, 2016, SHOCK VIB, V2016, DOI 10.1155/2016/8215696	59	12	13	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1015-8987	1421-9778		CELL PHYSIOL BIOCHEM	Cell. Physiol. Biochem.		2017	43	1					17	30		10.1159/000480313			14	Cell Biology; Physiology	Cell Biology; Physiology	FM7GA	WOS:000415240500002	28848184	DOAJ Gold, Green Published			2021-06-18	
J	Naci, L; Graham, M; Owen, AM; Weijer, C				Naci, Lorina; Graham, Mackenzie; Owen, Adrian M.; Weijer, Charles			Covert narrative capacity: Mental life in patients thought to lack consciousness	ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; SPATIAL NORMALIZATION; DETECTING AWARENESS; EXECUTIVE FUNCTIONS; RESTING-STATE; FMRI; DISORDERS; CONNECTIVITY; INTELLIGENCE; ACCURACY	Despite the apparent absence of external signs of consciousness, a significant proportion of behaviorally nonresponsive patients can respond to commands by willfully modulating their brain activity. However, little is known about the mental life of these patients. We discuss a recent innovative approach, which sheds light on the preserved cognitive capacities of these patients, including executive function, theory of mind, and the experience of affective states. This research represents a fundamental shift in our understanding of these patients, and has important implications for both their continued treatment and care. Moreover, this research marks out avenues for future inquiry into the residual cognitive capacities of these patients.	[Naci, Lorina; Owen, Adrian M.] Western Univ, Brain & Mind Inst, London, ON N6A 5B7, Canada; [Graham, Mackenzie; Weijer, Charles] Western Univ, Rotman Inst Philosophy, London, ON N6A 5B8, Canada	Naci, L (corresponding author), Univ Western Ontario, Dept Psychol, Brain & Mind Inst, London, ON N6A 5B7, Canada.	lnaci@uwo.ca	Weijer, Charles/ABC-5433-2020	Weijer, Charles/0000-0002-5510-1074; Naci, Lorina/0000-0001-9630-3978	Canada Excellence Research Chairs (CERC) program; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP133705]; Tier I Canada Research ChairCanada Research Chairs	This research was supported by the Canada Excellence Research Chairs (CERC) program. This work was also supported by the Canadian Institutes of Health Research (grant number MOP133705). C. W. holds a Tier I Canada Research Chair.	Andrews K, 1996, BMJ-BRIT MED J, V313, P136; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Barbey AK, 2012, BRAIN, V135, P1154, DOI 10.1093/brain/aws021; Bardin JC, 2012, ARCH NEUROL-CHICAGO, V69, P176, DOI 10.1001/archneurol.2011.892; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; Barttfeld P, 2015, P NATL ACAD SCI USA, V112, P887, DOI 10.1073/pnas.1418031112; Beisteiner R, 2010, HUM BRAIN MAPP, V31, P1951, DOI 10.1002/hbm.20990; Berkman L.F., 2000, SOCIAL EPIDEMIOLOGY, V1, P137; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; Bruno MA, 2010, COGN NEUROSCI-UK, V1, P193, DOI 10.1080/17588928.2010.485677; Carroll N., 1996, LEA COMMUN SER, P71; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Chow HM, 2008, NEUROIMAGE, V40, P940, DOI 10.1016/j.neuroimage.2007.11.044; Cohen S, 2004, AM PSYCHOL, V59, P676, DOI 10.1037/0003-066X.59.8.676; Collins, 1998, COGNITIVE STRUCTURE; Comte A, 2015, NEUROSCIENCE, V300, P448, DOI 10.1016/j.neuroscience.2015.05.059; Crinion J, 2007, NEUROIMAGE, V37, P866, DOI 10.1016/j.neuroimage.2007.04.065; Crone JS, 2014, NEUROIMAGE-CLIN, V4, P240, DOI 10.1016/j.nicl.2013.12.005; Crone JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026373; Cruse D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049933; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Demertzi A, 2015, BRAIN, V138, P2619, DOI 10.1093/brain/awv169; Demertzi A, 2014, CORTEX, V52, P35, DOI 10.1016/j.cortex.2013.11.005; Diener E, 2002, PSYCHOL SCI, V13, P81, DOI 10.1111/1467-9280.00415; Duncan J, 2010, TRENDS COGN SCI, V14, P172, DOI 10.1016/j.tics.2010.01.004; Elliott R, 2003, BRIT MED BULL, V65, P49, DOI 10.1093/bmb/65.1.49; Fernandez-Espejo D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095082; Fernandez-Espejo D, 2013, NAT REV NEUROSCI, V14, P801, DOI 10.1038/nrn3608; Gabriel D, 2015, NEUROSCIENCE, V290, P435, DOI 10.1016/j.neuroscience.2015.01.053; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Graham M, 2015, AJOB NEUROSCIENCE, V6, P31, DOI [https://doi.org/10.1080/21507740.2015.1014072, DOI 10.1080/21507740.2015.1014072]; Guglielmo S, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01637; Hampshire A, 2006, CEREB CORTEX, V16, P1679, DOI 10.1093/cercor/bhj116; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Kahane G, 2009, J MED PHILOS, V34, P6, DOI 10.1093/jmp/jhn038; Lehne M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124550; Lehne M, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00079; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Naci L., 2015, NEUROIMAGE IN PRESS; Naci L, 2014, P NATL ACAD SCI USA, V111, P14277, DOI 10.1073/pnas.1407007111; Naci L, 2013, JAMA NEUROL, V70, P1235, DOI 10.1001/jamaneurol.2013.3686; Naci L, 2013, J NEUROSCI, V33, P9385, DOI 10.1523/JNEUROSCI.5577-12.2013; Naci L, 2012, ANN NEUROL, V72, P312, DOI 10.1002/ana.23656; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; Owen AM, 2016, FINDING CONSCIOUSNES, P100; Owen AM, 2016, BRAIN FUNCTION RESPO, P67; Peterson A, 2015, NEUROIMAGE-CLIN, V7, P588, DOI 10.1016/j.nicl.2015.02.008; Pinquart M, 2000, PSYCHOL AGING, V15, P187, DOI 10.1037//0882-7974.15.2.187; Ptak R, 2012, NEUROSCIENTIST, V18, P502, DOI 10.1177/1073858411409051; Sauseng P, 2005, INT J PSYCHOPHYSIOL, V57, P97, DOI 10.1016/j.ijpsycho.2005.03.018; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Siedlecki KL, 2014, SOC INDIC RES, V117, P561, DOI 10.1007/s11205-013-0361-4; Sinai L, 2017, FRONT BIOSCI-LANDMRK, V22, P815, DOI 10.2741/4518; Stender J, 2014, LANCET, V384, P514, DOI 10.1016/S0140-6736(14)60042-8; VORDERER P, 1996, LEA COMMUN SER, P233; Woolgar A, 2010, P NATL ACAD SCI USA, V107, P14899, DOI 10.1073/pnas.1007928107; Young GB, 2009, ANN NY ACAD SCI, V1157, P32, DOI 10.1111/j.1749-6632.2009.04471.x; Zillmann D., 1991, RESPONDING SCREEN RE, P281	63	12	12	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2328-9503			ANN CLIN TRANSL NEUR	Ann. Clin. Transl. Neurol.	JAN	2017	4	1					61	70		10.1002/acn3.376			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EK1CY	WOS:000393664600007	28078316	DOAJ Gold, Green Published			2021-06-18	
J	Parrott, DJ; Swartout, KM; Eckhardt, CI; Subramani, OS				Parrott, Dominic J.; Swartout, Kevin M.; Eckhardt, Christopher I.; Subramani, Olivia S.			Deconstructing the associations between executive functioning, problematic alcohol use and intimate partner aggression: A dyadic analysis	DRUG AND ALCOHOL REVIEW			English	Article						intimate partner violence; heavy drinking; domestic violence; emotion regulation; actor-partner interdependence model	BEHAVIOR RATING INVENTORY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; CONFIRMATORY FACTOR-ANALYSIS; TRAUMATIC BRAIN-INJURY; FUNCTION-ADULT VERSION; NEUROPSYCHOLOGICAL MEASURES; CONCEPTUAL-FRAMEWORK; ANTISOCIAL-BEHAVIOR; PHYSICAL AGGRESSION; DOMESTIC VIOLENCE	Introduction and AimsProblematic drinking and executive functioning deficits are two known risk factors for intimate partner aggression (IPA). However, executive functioning is a multifaceted construct, and it is not clear whether deficits in specific components of executive functioning are differentially associated with IPA perpetration generally and within the context of problematic alcohol use. To address this question, the present study investigated the effects of problematic drinking and components of executive functioning on physical IPA perpetration within a dyadic framework. Design and MethodsParticipants were 582 heavy drinking couples (total n=1164) with a recent history of psychological and/or physical IPA recruited from two metropolitan cities in the USA. Multilevel models were used to examine effects within an actor-partner interdependence framework. ResultsThe highest levels of physical IPA were observed among actors who reported everyday consequences of executive functioning deficits related to emotional dysregulation whose partners were problematic drinkers. However, the association between executive functioning deficits related to emotional dysregulation and IPA was stronger towards partners who were non-problematic drinkers relative to partners who were problematic drinkers. No such effect was found for executive functioning deficits related to behavioural regulation. Discussion and ConclusionsResults provide insight into how problematic drinking and specific executive functioning deficits interact dyadically in relation to physical IPA perpetration. [Parrott DJ, Swartout KM, Eckhardt CI, Subramani OS. Deconstructing the associations between executive functioning, problematic alcohol use and intimate partner aggression: A dyadic analysis. Drug Alcohol Rev 2017;36:88-96]	[Parrott, Dominic J.; Swartout, Kevin M.; Subramani, Olivia S.] Georgia State Univ, Dept Psychol, POB 5010, Atlanta, GA 30302 USA; [Eckhardt, Christopher I.] Purdue Univ, Dept Psychol Sci, W Lafayette, IN 47907 USA	Parrott, DJ (corresponding author), Georgia State Univ, Dept Psychol, POB 5010, Atlanta, GA 30302 USA.	parrott@gsu.edu		Eckhardt, Christopher/0000-0001-6118-3611	National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01-AA-020578]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA020578] Funding Source: NIH RePORTER	This research was supported by grant R01-AA-020578 from the National Institute on Alcohol Abuse and Alcoholism awarded to the 1st and 3rd authors.	Aiken L.S., 1991, MULTIPLE REGRESSION; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Anderson V., 2008, EXECUTIVE FUNCTIONS; Babor TF., 2001, AUDIT ALCOHOL USE DI, V2nd; Birkley EL, 2015, CLIN PSYCHOL REV, V37, P40, DOI 10.1016/j.cpr.2015.01.002; Black M.C., 2011, NATL INTIMATE PARTNE; Bueso-Izquierdo N, 2015, AGGRESS VIOLENT BEH, V25, P243, DOI 10.1016/j.avb.2015.09.009; Chang WP, 2009, J PSYCHOPHYSIOL, V23, P113, DOI 10.1027/0269-8803.23.3.113; Cook WL, 2005, INT J BEHAV DEV, V29, P101, DOI 10.1080/01650250444000405; Corvo K, 2014, PARTN ABUSE, V5, P342, DOI 10.1891/1946-6560.5.3.342; Corvo K, 2013, AGGRESS VIOLENT BEH, V18, P175, DOI 10.1016/j.avb.2012.11.017; Crane CA, 2014, AGGRESSIVE BEHAV, V40, P440, DOI 10.1002/ab.21533; Denckla MB, 2002, CHILD NEUROPSYCHOL, V8, P304, DOI 10.1076/chin.8.4.304.13512; Devries KM, 2014, ADDICTION, V109, P379, DOI 10.1111/add.12393; DeWall CN, 2011, PSYCHOL VIOLENCE, V1, P245, DOI 10.1037/a0023842; Donders J, 2016, ARCH CLIN NEUROPSYCH, V31, P29, DOI 10.1093/arclin/acv048; Eckhardt CI, 2007, J CONSULT CLIN PSYCH, V75, P61, DOI 10.1037/0022-006X.75.1.61; Eckhardt CI, 2015, VIOLENCE AGAINST WOM, V21, P939, DOI 10.1177/1077801215589376; Egeland J, 2010, CHILD NEUROPSYCHOL, V16, P326, DOI 10.1080/09297041003601462; Ellis ML, 2009, J ABNORM CHILD PSYCH, V37, P945, DOI 10.1007/s10802-009-9321-5; Finkel E.J., 2013, OXFORD HDB CLOSE REL, P452, DOI DOI 10.1093/OXFORDHB/9780195398694.013.0020; Finkel EJ, 2007, REV GEN PSYCHOL, V11, P193, DOI 10.1037/1089-2680.11.2.193; Fishbein D, 2000, CRIM JUSTICE BEHAV, V27, P139, DOI 10.1177/0093854800027002001; Foran HM, 2008, J FAM VIOLENCE, V23, P141, DOI 10.1007/s10896-007-9136-5; Giancola PR, 2006, ADDICT BEHAV, V31, P2169, DOI 10.1016/j.addbeh.2006.02.019; Giancola PR, 2012, PSYCHOL ADDICT BEHAV, V26, P201, DOI 10.1037/a0025207; Giancola PR, 2000, EXP CLIN PSYCHOPHARM, V8, P576, DOI 10.1037//1064-1297.8.4.576; Giancola PR, 2004, J ABNORM PSYCHOL, V113, P541, DOI 10.1037/0021-843X.113.4.541; Gioia G., 2002, J INT NEUROPSYCH SOC, V8, P229; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Goldberg E., 2002, EXECUTIVE BRAIN FRON; Harper FWK, 2005, J INTERPERS VIOLENCE, V20, P1648, DOI 10.1177/0886260505278717; Hoaken PNS, 1998, J STUD ALCOHOL, V59, P599, DOI 10.15288/jsa.1998.59.599; Jarvis B. G., 2006, DIRECTRT VERSION 200; Kashy D. A., 2012, The Oxford handbook of personality and social psychology, DOI [10.1093/oxfordhb/9780195398991.013.0009, DOI 10.1093/OXFORDHB/9780195398991.013.0009]; Kenny DA, 1999, PERS RELATIONSHIP, V6, P433, DOI 10.1111/j.1475-6811.1999.tb00202.x; Leonard KE, 2005, ADDICTION, V100, P422, DOI 10.1111/j.1360-0443.2005.00994.x; McAuley T, 2010, J INT NEUROPSYCH SOC, V16, P495, DOI 10.1017/S1355617710000093; MOFFITT TE, 1993, DEV PSYCHOPATHOL, V5, P135, DOI 10.1017/S0954579400004302; Morgan AB, 2000, CLIN PSYCHOL REV, V20, P113, DOI 10.1016/S0272-7358(98)00096-8; Ogilvie JM, 2011, CRIMINOLOGY, V49, P1063, DOI 10.1111/j.1745-9125.2011.00252.x; Parrott DJ, 2017, DRUG ALCOHOL REV, V36, P88, DOI 10.1111/dar.12454; Pinto LA, 2010, AGGRESS VIOLENT BEH, V15, P387, DOI 10.1016/j.avb.2010.07.001; Rabin LA, 2011, J CLIN EXP NEUROPSYC, V33, P344, DOI 10.1080/13803395.2010.518597; Roth R.M., 2005, BEHAV RATING INVENTO; Roth RM, 2013, ARCH CLIN NEUROPSYCH, V28, P425, DOI 10.1093/arclin/act031; Shorey RC, 2015, PREV SCI, V16, P873, DOI 10.1007/s11121-015-0568-5; Shorey RC, 2012, AGGRESS VIOLENT BEH, V17, P289, DOI 10.1016/j.avb.2012.03.001; Shorey RC, 2011, J INTERPERS VIOLENCE, V26, P2681, DOI 10.1177/0886260510388289; Slep AMS, 2005, J CONSULT CLIN PSYCH, V73, P435, DOI 10.1037/0022-006X.73.3.435; Stanford MS, 1997, PERS INDIV DIFFER, V23, P961, DOI 10.1016/S0191-8869(97)00120-7; Straus MA, 1996, J FAM ISSUES, V17, P283, DOI 10.1177/019251396017003001; Swartout KM, 2015, PSYCHOL VIOLENCE, V5, P305, DOI 10.1037/a0038316; Testa M, 2014, PSYCHOL ADDICT BEHAV, V28, P127, DOI 10.1037/a0032988; Testa M, 2012, J STUD ALCOHOL DRUGS, V73, P268, DOI 10.15288/jsad.2012.73.268; Watkins LE, 2015, PSYCHOL ADDICT BEHAV, V29, P653, DOI 10.1037/adb0000074; Watkins LE, 2014, AGGRESSIVE BEHAV, V40, P369, DOI 10.1002/ab.21528; Woodin EM, 2014, ADDICT BEHAV, V39, P1890, DOI 10.1016/j.addbeh.2014.07.033	58	12	12	2	11	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-5236	1465-3362		DRUG ALCOHOL REV	Drug Alcohol Rev.	JAN	2017	36	1					88	96		10.1111/dar.12454			9	Substance Abuse	Substance Abuse	EK5PB	WOS:000393977200013	28116760	Green Accepted			2021-06-18	
J	Peters, ME; Rao, V; Bechtold, KT; Roy, D; Sair, HI; Leoutsakos, JM; Diaz-Arrastia, R; Stevens, RD; Batty, DS; Falk, H; Fernandez, C; Ofoche, U; Vassila, A; Hall, AJ; Anderson, B; Bessman, E; Lyketsos, CG; Everett, AD; Van Eyk, J; Korley, FK				Peters, Matthew E.; Rao, Vani; Bechtold, Kathleen T.; Roy, Durga; Sair, Haris I.; Leoutsakos, Jeannie-Marie; Diaz-Arrastia, Ramon; Stevens, Robert D.; Batty, D. Scott, Jr.; Falk, Hayley; Fernandez, Christopher; Ofoche, Uju; Vassila, Alexandra; Hall, Anna J.; Anderson, Braden; Bessman, Edward; Lyketsos, Constantine G.; Everett, Allen D.; Van Eyk, Jennifer; Korley, Frederick K.			Head injury serum markers for assessing response to trauma: Design of the HeadSMART study	BRAIN INJURY			English	Article						Traumatic brain injury; TBI; blunt head trauma; biomarkers	COMMON DATA ELEMENTS; BRAIN-INJURY; RATING SCALE; BIOMARKERS; RELIABILITY; DIAGNOSIS; VALIDITY; METALLOTHIONEIN; QUESTIONNAIRE; PROTEIN	Background: Accurate diagnosis and risk stratification of traumatic brain injury (TBI) at time of presentation remains a clinical challenge. The Head Injury Serum Markers for Assessing Response to Trauma study (HeadSMART) aims to examine blood-based biomarkers for diagnosing and determining prognosis in TBI. Methods: HeadSMART is a 6-month prospective cohort study comparing emergency department patients evaluated for TBI (exposure group) to (1) emergency department patients evaluated for traumatic injury without head trauma and (2) healthy persons. Study methods and characteristics of the first 300 exposure participants are discussed. Results: Of the first 300 participants in the exposure arm, 70% met the American Congress of Rehabilitation Medicine criteria for TBI, with the majority (80.1%) classified as mild TBI. The majority of subjects in the exposure arm had Glasgow Coma Scale scores of 13-15 (98.9%), normal head computed tomography (81.3%) and no prior history of concussion (71.7%). Conclusion: With systematic phenotyping, HeadSMART will facilitate diagnosis and risk-stratification of the heterogeneous group of individuals currently diagnosed with TBI.	[Peters, Matthew E.; Rao, Vani; Bechtold, Kathleen T.; Roy, Durga; Sair, Haris I.; Leoutsakos, Jeannie-Marie; Stevens, Robert D.; Falk, Hayley; Fernandez, Christopher; Ofoche, Uju; Vassila, Alexandra; Hall, Anna J.; Anderson, Braden; Bessman, Edward; Lyketsos, Constantine G.; Everett, Allen D.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Batty, D. Scott, Jr.] ImmunArray, Richmond, VA USA; [Van Eyk, Jennifer] Cedars Sinai, Dept Med, Inst Heart, Los Angeles, CA USA; [Korley, Frederick K.] Univ Michigan Hlth Syst, North Campus Res Bldg,Bldg 026-333N, Ann Arbor, MI 48105 USA	Korley, FK (corresponding author), Univ Michigan Hlth Syst, North Campus Res Bldg,Bldg 026-333N, Ann Arbor, MI 48105 USA.	korley@med.umich.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	Harold Amos Medical Faculty Development Award from the Robert Wood Johnson Foundation; ImmunArray; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG027668] Funding Source: NIH RePORTER	Frederick Korley, M.D., Ph.D. was supported by the Harold Amos Medical Faculty Development Award from the Robert Wood Johnson Foundation. HeadSMART was funded by ImmunArray. ImmunArray has licensed patents to biomarkers described in this article. Under a licensing agreement between ImmunArray and the Johns Hopkins University, Drs Everett, Van Eyk and Korley are entitled to royalties on biomarkers described in this article. Dr Batty is an officer, shareholder, and employee of ImmunArray.	Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Arnould A, 2015, ANN PHYS REHABIL MED; Benedict RHB, 1996, PSYCHOL ASSESSMENT, V8, P145, DOI 10.1037/1040-3590.8.2.145; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; Buonora JE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00068; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Centers for Disease Control and Prevention (CDC) National Center for Health Statistics, 2010, 2010 NAT HOSP AMB ME; Chou SHY, 2014, NEUROCRIT CARE, V21, P187, DOI 10.1007/s12028-014-0039-z; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Davidson JRT, 1997, PSYCHOL MED, V27, P153, DOI 10.1017/S0033291796004229; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Failla MD, 2015, BRAIN DERIVED NEUROT; Golden C. J., 1978, STROOP COLOR WORD TE, P1; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Heaton R. K, 1981, WISCONSIN CARD SORTI; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Hicks R, 2013, J NEUROTRAUM, V30, P1852, DOI 10.1089/neu.2013.2938; Holdnack H, 2001, WECHSLER TEST ADULT; Hornik K, PACKAGE RWEKA; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; JENNETT B, 1975, LANCET, V1, P480; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Korley F.K., 2015, J NEUROTRAUMA; Korley FK, 2015, J HEAD TRAUMA REHABI; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kukacka J, 2006, NEUROENDOCRINOL LETT, V27, P116; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Lyketsos CG, 1999, J AM GERIATR SOC, V47, P487, DOI 10.1111/j.1532-5415.1999.tb07245.x; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; O'Neil M.E., 2013, COMPLICATIONS MILD T; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; Quinlan JR, 1993, J R C4 5 PROGRAMS MA; Rao V, 2015, SEMIN NEUROL, V35, P64, DOI 10.1055/s-0035-1544241; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Schretlen D, 1996, CLIN NEUROPSYCHOL, V10, P80, DOI 10.1080/13854049608406666; SPITZER RL, 1983, COMPR PSYCHIAT, V24, P399, DOI 10.1016/0010-440X(83)90032-9; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; Surgucheva I, 2014, MOL CELL NEUROSCI, V63, P114, DOI 10.1016/j.mcn.2014.10.005; Yang J, 2015, CLIN BIOCH; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	51	12	12	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	3					370	378		10.1080/02699052.2016.1231344			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EQ3WY	WOS:000398005900014	28140672	Green Accepted			2021-06-18	
J	Petrone, AB; Gionis, V; Giersch, R; Barr, TL				Petrone, Ashley B.; Gionis, Valerie; Giersch, Richard; Barr, Taura L.			Immune biomarkers for the diagnosis of mild traumatic brain injury	NEUROREHABILITATION			English	Article						Traumatic brain injury; inflammation; neutrophil-lymphocyte ratio	GENE-EXPRESSION; ISCHEMIC-STROKE	BACKGROUND: In 2010, there were approximately 2.2 million emergency room visits associated with traumatic brain injury (TBI), with 80 percent diagnosed as mild TBI or concussion. In addition, there are a large number of TBIs, especially mild TBIs, which go either unreported by patients or initially undiagnosed by clinicians. Our team has previously identified a panel of immune-related genes that can diagnose ischemic stroke at triage, and due to shared pathophysiological mechanisms of TBI and stroke, we hypothesized that this panel of genes may also be utilized for the diagnosis of TBI. OBJECTIVES: The primary aims of this pilot study were to: (1) characterize changes in a panel of immune-related genes in TBI; (2) identify immune-related biomarkers that may be used to diagnose TBI and (3) describe the peripheral immune response following TBI. METHODS: Blood was drawn from TBI patients no later than 24 h of injury onset and matched control subjects. Real-time PCR was used to measure gene expression, and a white blood cell differential was performed to obtain neutrophil and lymphocyte percentages. RESULTS: Relative mRNA expression of ARG1, LY96, MMP9, s100a12 was significantly increased and CCR7 was significantly decreased in peripheral blood of TBI patients within 24 hours of injury compared to control subjects. We also observed a different pattern of leukocyte dynamics following TBI between mild and severe TBI. CONCLUSIONS: We have described a panel of immune-related genes that can accurately predict/diagnose TBI with higher sensitivity and specificity of other biomarkers to date.	[Petrone, Ashley B.] West Virginia Univ, Dept Family Med, Morgantown, WV 26506 USA; [Petrone, Ashley B.] West Virginia Clin & Translat Sci Inst, Morgantown, WV USA; [Gionis, Valerie; Giersch, Richard; Barr, Taura L.] Valtari BioTM Inc, Morgantown, WV USA	Petrone, AB (corresponding author), One Med Ctr Dr,1387 Hlth Sci Ctr, Morgantown, WV 26506 USA.	abpetrone@wvumedicine.org			Robert Wood Johnson FoundationRobert Wood Johnson Foundation (RWJF) [70319]; Intramural NINR/NIH [HHSN263201100872P]; WVU Stroke COBRE Award Sub-Project [2P20 GM109098]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM104942] Funding Source: NIH RePORTER	The data in this manuscript was partially funded by a Robert Wood Johnson Foundation Nurse Faculty Scholar award to T. Barr ID: 70319, an Intramural NINR/NIH Contract ID: HHSN263201100872P to T. Barr and a WVU Stroke COBRE Award Sub-Project 2P20 GM109098 to T. Barr.	Al Nimer F, 2011, BRAIN BEHAV IMMUN, V25, P981, DOI 10.1016/j.bbi.2010.10.017; Barr TL, 2010, NEUROLOGY, V75, P1009, DOI 10.1212/WNL.0b013e3181f2b37f; CDC, 2010, TRAUMATIC BRAIN INJU; Croall ID, 2014, NEUROLOGY, V83, P494, DOI 10.1212/WNL.0000000000000666; Dilektasli E, 2016, J TRAUMA ACUTE CARE, V81, P882, DOI 10.1097/TA.0000000000000980; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Guardado P, 2016, J ANXIETY DISORD, V38, P9, DOI 10.1016/j.janxdis.2015.12.004; Kawata K, 2016, NEUROSCI BIOBEHAV R, V68, P460, DOI 10.1016/j.neubiorev.2016.05.009; Kelso ML, 2014, CURR PHARM DESIGN, V20, P4284; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Lattanzi S, 2016, STROKE, V47, P1654, DOI 10.1161/STROKEAHA.116.013627; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Petrone AB, 2016, TRANSL STROKE RES, V7, P103, DOI 10.1007/s12975-015-0431-9; Souter MJ, 2015, NEUROCRIT CARE, V23, P4, DOI 10.1007/s12028-015-0137-6; Tang Y, 2006, J CEREBR BLOOD F MET, V26, P1089, DOI 10.1038/sj.jcbfm.9600264; Tobin RP, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0143-5	17	12	12	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2017	40	4					501	508		10.3233/NRE-171437			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EX7SC	WOS:000403447500005	28222567	Green Accepted			2021-06-18	
J	Pu, HJ; Jiang, XY; Wei, ZS; Hong, DD; Hassan, S; Zhang, WT; Liu, JL; Meng, HX; Shi, YJ; Chen, L; Chen, J				Pu, Hongjian; Jiang, Xiaoyan; Wei, Zhishuo; Hong, Dandan; Hassan, Sulaiman; Zhang, Wenting; Liu, Jialin; Meng, Hengxing; Shi, Yejie; Chen, Ling; Chen, Jun			Repetitive and Prolonged Omega-3 Fatty Acid Treatment After Traumatic Brain Injury Enhances Long-Term Tissue Restoration and Cognitive Recovery	CELL TRANSPLANTATION			English	Article; Proceedings Paper	23rd Annual Meeting of the American-Society-for-Neural-Therapy-and-Repair (ASNTR)	APR 29-30, 2016	Clearwater, FL	Amer Soc Neural Therapy & Repair		Omega-3 polyunsaturated fatty acid (n-3 PUFA); Water maze; Hippocampus; Angiogenesis; Oligodendrogenesis	POLYUNSATURATED FATTY-ACIDS; FOCAL CEREBRAL-ISCHEMIA; WHITE-MATTER INJURY; DOCOSAHEXAENOIC ACID; DIETARY SUPPLEMENTATION; NEUROGENESIS; THERAPIES; MECHANISMS; STROKE; PERFORMANCE	Traumatic brain injury (TBI) is one of the most disabling clinical conditions that could lead to neurocognitive disorders in survivors. Our group and others previously reported that prophylactic enrichment of dietary omega-3 polyunsaturated fatty acids (n-3 PUFAs) markedly ameliorate cognitive deficits after TBI. However, it remains unclear whether a clinically relevant therapeutic regimen with n-3 PUFAs administered after TBI would still offer significant improvement of long-term cognitive recovery. In the present study, we employed the decline of spatial cognitive function as a main outcome after TBI to investigate the therapeutic efficacy of post-TBI n-3 PUFA treatment and the underlying mechanisms. Mice were subjected to sham operation or controlled cortical impact, followed by random assignment to receive the following four treatments: (1) vehicle control; (2) daily intraperitoneal injections of n-3 PUFAs for 2 weeks, beginning 2 h after TBI; (3) fish oil dietary supplementation throughout the study, beginning 1 day after TBI; or (4) combination of treatments (2) and (3). Spatial cognitive deficits and chronic brain tissue loss, as well as endogenous brain repair processes such as neurogenesis, angiogenesis, and oligodendrogenesis, were evaluated up to 35 days after TBI. The results revealed prominent spatial cognitive deficits and massive tissue loss caused by TBI. Among all mice receiving post-TBI n-3 PUFA treatments, the combined treatment of fish oil dietary supplement and n-3 PUFA injections demonstrated a reproducible beneficial effect in attenuating cognitive deficits although without reducing gross tissue loss. Mechanistically, the combined treatment promoted post-TBI restorative processes in the brain, including generation of immature neurons, microvessels, and oligodendrocytes, each of which was significantly correlated with the improved cognitive recovery. These results indicated that repetitive and prolonged n-3 PUFA treatments after TBI are capable of enhancing brain remodeling and could be developed as a potential therapy to treat TBI victims in the clinic.	[Pu, Hongjian; Liu, Jialin; Meng, Hengxing; Chen, Ling] PLA, Gen Hosp, Dept Neurosurg, 28 Fuxing Rd, Beijing 100853, Peoples R China; [Pu, Hongjian; Jiang, Xiaoyan; Wei, Zhishuo; Hong, Dandan; Hassan, Sulaiman; Shi, Yejie; Chen, Jun] Univ Pittsburgh, Pittsburgh Inst Brain Disorders & Recovery, S507 Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15213 USA; [Pu, Hongjian; Jiang, Xiaoyan; Wei, Zhishuo; Hong, Dandan; Hassan, Sulaiman; Shi, Yejie; Chen, Jun] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; [Jiang, Xiaoyan; Zhang, Wenting; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai, Peoples R China; [Jiang, Xiaoyan; Zhang, Wenting; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai, Peoples R China	Chen, L (corresponding author), PLA, Gen Hosp, Dept Neurosurg, 28 Fuxing Rd, Beijing 100853, Peoples R China.; Chen, J (corresponding author), Univ Pittsburgh, Pittsburgh Inst Brain Disorders & Recovery, S507 Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15213 USA.	chen_ling301@163.com; chenj2@upmc.edu	Pu, Hongjian/AAW-3322-2020; Shi, Yejie/C-2355-2018	Shi, Yejie/0000-0001-7502-9201	US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS045048, NS095671, NS095029]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30970939, 81272804, 81529002, 81100978]; US Department of Veterans Affairs Senior Research Career Scientist AwardUS Department of Veterans Affairs; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS095671, R01NS095029, R01NS045048] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX003377] Funding Source: NIH RePORTER	This project was supported by the US National Institutes of Health grants NS045048, NS095671, and NS095029 (to J.C.), and the National Natural Science Foundation of China grants 30970939 and 81272804 (to L.C.), 81529002 (to J.C.), and 81100978 (to W.Z.). J.C. is also supported by the US Department of Veterans Affairs Senior Research Career Scientist Award. The authors are indebted to Pat Strickler for the excellent administrative support. J.C., L.C., and H.P. designed the research. H.P., X.J., Z.W., S.H., W.Z., J.L., and H.M. performed the research. X.J. and Y.S. analyzed the data. H.P., X.J., YS., D.H., and J.C. wrote the manuscript. All authors reviewed and approved the manuscript. The authors declare no conflicts of interest.	Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; BLOCK F, 1993, NEUROSCI LETT, V149, P126, DOI 10.1016/0304-3940(93)90752-7; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chen JL, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00382; Chen SH, 2014, CELL TRANSPLANT, V23, P959, DOI 10.3727/096368913X667006; Dallerac G, 2016, PROG NEUROBIOL, V144, P48, DOI 10.1016/j.pneurobio.2016.01.003; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Dietrich WD, 2016, BRAIN RES, V1640, P94, DOI 10.1016/j.brainres.2015.12.034; El Waly B, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00145; Fancy SPJ, 2014, NAT NEUROSCI, V17, P506, DOI 10.1038/nn.3676; Franco R, 2015, PROG NEUROBIOL, V131, P65, DOI 10.1016/j.pneurobio.2015.05.003; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Gibson CL, 2005, J CEREBR BLOOD F MET, V25, P431, DOI 10.1038/sj.jcbfm.9600033; Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969; Hasadsri L, 2013, J NEUROTRAUM, V30, P897, DOI 10.1089/neu.2012.2672; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; Hering H, 2003, J NEUROSCI, V23, P3262; Jiang XY, 2016, TRANSL STROKE RES, V7, P548, DOI 10.1007/s12975-016-0502-6; Kline AE, 2016, PROG NEUROBIOL, V142, P45, DOI 10.1016/j.pneurobio.2016.05.002; Kris-Etherton PM, 2000, AM J CLIN NUTR, V71, p179S, DOI 10.1093/ajcn/71.1.179S; Lazarov O, 2016, PROG NEUROBIOL, V138, P1, DOI 10.1016/j.pneurobio.2015.12.006; Lewis M, 2013, AM J EMERG MED, V31, DOI 10.1016/j.ajem.2012.05.014; Liu XF, 2014, PROG NEUROBIOL, V115, P92, DOI 10.1016/j.pneurobio.2013.11.007; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; OKADA M, 1995, J CEREBR BLOOD F MET, V15, P1012, DOI 10.1038/jcbfm.1995.127; Osier ND, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00134; Patel K, 2016, BRAIN RES, V1640, P104, DOI 10.1016/j.brainres.2016.01.055; Prakash R, 2015, CURR OPIN NEUROL, V28, P556, DOI 10.1097/WCO.0000000000000248; Pu HJ, 2016, TRANSL STROKE RES, V7, P521, DOI 10.1007/s12975-016-0498-y; Pu HJ, 2013, J CEREBR BLOOD F MET, V33, P1474, DOI 10.1038/jcbfm.2013.108; Ren H, 2016, MOL NEUROBIOL; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Roberts L, 2008, J AM COLL SURGEONS, V207, P276, DOI 10.1016/j.jamcollsurg.2008.02.015; Rossi D, 2015, PROG NEUROBIOL, V130, P86, DOI 10.1016/j.pneurobio.2015.04.003; Shi H, 2015, EXP NEUROL, V272, P17, DOI 10.1016/j.expneurol.2015.03.017; Shin SS, 2011, NEUROSCI LETT, V496, P168, DOI 10.1016/j.neulet.2011.04.009; Silverberg ND, 2017, J NEUROTRAUM, V34, P363, DOI 10.1089/neu.2016.4443; Stein DG, 2015, BRAIN INJURY, V29, P1259, DOI 10.3109/02699052.2015.1065344; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Verkhratsky A, 2016, PROG NEUROBIOL, V144, P188, DOI 10.1016/j.pneurobio.2015.09.003; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wang GH, 2013, NEUROTHERAPEUTICS, V10, P124, DOI 10.1007/s13311-012-0157-2; Wang X, 2003, NEUROREPORT, V14, P2457, DOI 10.1097/00001756-200312190-00033; Wang XT, 2016, J NEUROTRAUM, V33, P721, DOI 10.1089/neu.2015.4097; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Xiong Y, 2010, DISCOV MED, V10, P434; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Yonemori F, 1999, J CEREBR BLOOD F MET, V19, P483, DOI 10.1097/00004647-199905000-00002; Zhang WT, 2015, EXP NEUROL, V272, P170, DOI 10.1016/j.expneurol.2015.03.005; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4; Zuloaga KL, 2015, TRANSL STROKE RES, V6, P390, DOI 10.1007/s12975-015-0412-z	56	12	12	0	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2017	26	4			SI		555	569		10.3727/096368916X693842			15	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Cell Biology; Research & Experimental Medicine; Transplantation	ET2SP	WOS:000400124700004	27938482	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Rigon, J; Burro, R; Guariglia, C; Maini, M; Marin, D; Ciurli, P; Bivona, U; Formisano, R				Rigon, Jessica; Burro, Roberto; Guariglia, Cecilia; Maini, Manuela; Marin, Dario; Ciurli, Paola; Bivona, Umberto; Formisano, Rita			Self-awareness rehabilitation after Traumatic Brain Injury: A pilot study to compare two group therapies	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Self-awareness disorders; traumatic brain injury; group therapy; rehabilitation; GLMMs	DISABILITY RATING-SCALE; REJECTIVE MULTIPLE TEST; FALSE DISCOVERY RATE; IMPAIRED AWARENESS; BONFERRONI PROCEDURE; EXECUTIVE FUNCTION; HEAD-INJURY; DEFICITS; RELIABILITY; RECOVERY	Background and Purpose: Deficits of self-awareness (SA) are very common after severe acquired brain injury (sABI), especially in traumatic brain injury (TBI), playing an important role in the efficacy of the rehabilitation process. This pilot study provides information regarding two structured group therapies for disorders of SA. Methods: Nine patients with severe TBI were consecutively recruited and randomly assigned to one SA group therapy programme, according either to the model proposed by Ben-Yishay & Lakin (1989) (B&L Group), or by Sohlberg & Mateer (1989) (S&M Group). Neuropsychological tests and self-awareness questionnaires were administered before and after a 10 weeks group therapy. Results: Results showed that both SA and neuropsychological functioning significantly improved in both groups. Conclusion: It is important to investigate and treat self-awareness, also to improve the outcome of neuropsychological disorders. The two group therapies proposed seem to be specific for impulsivity and emotional dyscontrol and for cognitive disorders.	[Rigon, Jessica] Osped San Camillo, IRCCS Fdn, Via Alberoni 70, I-30126 Venezia Lido, Italy; [Burro, Roberto] Univ Verona, Dipartimento Sci Umane, Verona, Italy; [Guariglia, Cecilia; Ciurli, Paola; Bivona, Umberto; Formisano, Rita] IRCCS Santa Lucia, Rome, Italy; [Maini, Manuela] CRA Nucleo Speciale Gravissime Disabil Virginia G, Bologna, Italy; [Marin, Dario] IRCCS E Medea, Pordenone, Italy	Rigon, J (corresponding author), Osped San Camillo, IRCCS Fdn, Via Alberoni 70, I-30126 Venezia Lido, Italy.	jessica.rigon@ospedalesancamillo.net		guariglia, cecilia/0000-0001-7474-6030			ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; Basso A, 1987, Funct Neurol, V2, P189; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Ben-Yishay Y., 1989, NEUROPSYCHOLOGICAL T, P271; Benjamini Y, 2001, ANN STAT, V29, P1165; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; Bianchi I, 2014, ACTA PSYCHOL, V151, P117, DOI 10.1016/j.actpsy.2014.06.003; Bianchi I, 2013, ACTA PSYCHOL, V144, P121, DOI 10.1016/j.actpsy.2013.05.005; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; Bivona U, 2015, RESTOR NEUROL NEUROS, V33, P335, DOI 10.3233/RNN-140484; Bivona U, 2014, J HEAD TRAUMA REHAB, V29, P157, DOI 10.1097/HTR.0b013e3182864f0b; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; Branchini E, 2015, THINK REASONING, V21, P397, DOI 10.1080/13546783.2014.994035; CARBERRY H, 1983, COGNITIVE REHABILITA, V1, P5; Carlesimo GA, 1996, EUR NEUROL, V36, P378, DOI 10.1159/000117297; Cicerone K. D., 1991, J HEAD TRAUMA REHAB, V6, P30, DOI DOI 10.1097/00001199-199112000-00007; Ciurli P, 2010, J INT NEUROPSYCH SOC, V16, P360, DOI 10.1017/S135561770999141X; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Eakin Paul J., 1991, DUAL CITY RESTRUCTUR, P3, DOI DOI 10.4095/134069; Fisher JE, 2004, J RES PERS, V38, P24, DOI 10.1016/j.jrp.2003.09.014; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Freeland J, 1996, MAGAZINE, V4, P32; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Hagen C., 1972, LEVELS COGNITIVE FUN; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; HOLM S, 1979, SCAND J STAT, V6, P65; HOMMEL G, 1988, BIOMETRIKA, V75, P383, DOI 10.1093/biomet/75.2.383; JENNETT B, 1975, LANCET, V1, P480; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KRIKORIAN R, 1994, J CLIN EXP NEUROPSYC, V16, P840, DOI 10.1080/01688639408402697; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lundqvist A, 2010, BRAIN INJURY, V24, P823, DOI 10.3109/02699051003724986; Markova IS, 2006, NEUROPSYCHOL REHABIL, V16, P439, DOI 10.1080/09602010500373396; Mazzucchi A., 1997, RIABILITAZIONE NEURO, P75; McDonald J.H., 2014, HDB BIOL STAT; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; NOVACK DH, 1992, ARCH INTERN MED, V152, P1814, DOI 10.1001/archinte.152.9.1814; NOVELLI G, 1986, Archivio di Psicologia Neurologia e Psichiatria, V47, P477; ORSINI A, 1987, ITAL J NEUROL SCI, V8, P539; Orsini A., 2003, B PSICOL APPL, V239, P73; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; R Core Team, 2018, R LANG ENV STAT COMP; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Raven J. C., 1954, STANDARD PROGR MATRI; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Schmidt J, 2011, J REHABIL MED, V43, P673, DOI 10.2340/16501977-0846; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SIMES RJ, 1986, BIOMETRIKA, V73, P751, DOI 10.2307/2336545; Simmond M, 2003, BRAIN INJURY, V17, P325, DOI 10.1080/0269905021000013219; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; Spencer E. A., 1993, WILLARD SPACKMANS OC; Stuss D.T., 1986, FRONTAL LOBES; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Wood RL, 2008, EUR J ANAESTH, V25, P115, DOI 10.1017/S0265021507003432; Zimmerman P., 1992, TEST BATTERIE AUFMER	74	12	12	0	10	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2017	35	1					115	127		10.3233/RNN-150538			13	Neurosciences	Neurosciences & Neurology	EM5CG	WOS:000395328900008	28059799	Green Published, Bronze			2021-06-18	
J	Sashika, H; Takada, K; Kikuchi, N				Sashika, Hironobu; Takada, Kaoruko; Kikuchi, Naohisa			Rehabilitation needs and participation restriction in patients with cognitive disorder in the chronic phase of traumatic brain injury	MEDICINE			English	Article						psychosocial problems; qualitative research; quality of life; rehabilitation; social participation; traumatic brain injury	JAPANESE	The purpose of this study was to clarify psychosocial factors/problems, social participation, quality of life (QOL), and rehabilitation needs in chronic-phase traumatic brain injury (TBI) patients with cognitive disorder discharged from the level-1 trauma center (L1-TC), and to inspect the effects of rehabilitation intervention to these subjects. A mixed-method research (cross-sectional and qualitative study) was conducted at an outpatient rehabilitation department. Inclusion criteria of subjects were transfer to the L1-TC due to TBI; acute-stage rehabilitation treatment received in the L1-TC from November 2006 to October 2011; age of >= 18 and < 70 years at the time of injury; a score of 0-3 on the Modified Rankin Scale at discharge and that of 4-5 due to physical or severe aggressive behavioral comorbid disorders. Study details were sent, via mail, to 84 suitable candidates, of whom 36 replied. Thirty-one subjects (median age: 33.4 years; male: 17; and average time since injury: 48.1 months), who had consented to study participation, were participated. Cognitive function, social participation, QOL, psychosocial factors/problems, rehabilitation needs, and chronic-phase rehabilitation outcomes were evaluated using the Wechsler Adult Intelligence Scale, Third Edition, the Wechsler Memory Scale-Revised, the Zung Self-Rating Depression Scale, the Sydney Psychosocial Reintegration Scale, Version 2, and the Short Form 36, Version 2, qualitative analysis of semistructured interviews, etc. Participants were classified into achieved-social-participation (n= 11; employed: 8), difficult-social-participation (n= 12; unemployed: 8), and no-cognitive-dysfunction groups (n= 8; no social participation restriction). Relative to the achieved-socialparticipation group, the difficult-social-participation group showed greater injury and cognitive dysfunction and lower Sydney Psychosocial Reintegration Scale and Short Form 36 role/social component summary scores (64.9/49.1 vs 44.3/30.4, respectively, P< 0.05). Linear regression analysis showed that the social participation status was greatly affected by the later cognitive disorders and psychosocial factors/problems not by the severity of TBI. No changes were observed in these scores following chronic-phase rehabilitation intervention. Chronic-phase TBI with cognitive disorder led to rehabilitation needs, and improvement of subjects' psychosocial problems and QOL was difficult.	[Sashika, Hironobu] Yokohama City Univ, Assoc Med Sci, Grad Sch Med, Dept Rehabil Med,Kanazawa Ward, Yokohama, Kanagawa, Japan; [Takada, Kaoruko] Yokohama City Univ, Grad Sch Med, Kanazawa Ward, Yokohama, Kanagawa, Japan; [Kikuchi, Naohisa] Yokohama City Univ, Assoc Med Sci, Med Ctr, Dept Rehabil Med,Minami Ward, Yokohama, Kanagawa, Japan	Sashika, H (corresponding author), Yokohama City Univ, Assoc Med Sci, Grad Sch Med, Dept Rehabil Med, Yokohama, Kanagawa, Japan.	s3024@urahp.yokohama-cu.ac.jp			Japanese Ministry of Education, Culture, Sports, Science, and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [24500599]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15K01379] Funding Source: KAKEN	This work was supported by a Grant-in-Aid for Scientific Research (C) from the Japanese Ministry of Education, Culture, Sports, Science, and Technology: "A qualitative study of rehabilitation needs and participation restriction of chronic-phase subjects with cognitive disorder due to traumatic brain injury" (2012-2014), Project Number: 24500599.	BenYishay Y, 1996, NEUROPSYCHOL REHABIL, V6, P327, DOI 10.1080/713755514; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; Bushnik T, 2000, LEVEL COGNITIVE FUNC; Cattelani R, 2010, NEUROPSYCHOL REV, V20, P52, DOI 10.1007/s11065-009-9125-y; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Corbin J., 2014, BASICS QUALITATIVE R; Creswell JW, BEST PRACTICES MIXED; de Koning ME, 2015, BRAIN INJURY, V29, P423, DOI 10.3109/02699052.2014.982188; Frieden TR, REPORTED C REPORT C; Frieden TR, 2010, TRAUMATIC BRAIN INJU; Fukuhara S, 1998, J CLIN EPIDEMIOL, V51, P1045, DOI 10.1016/S0895-4356(98)00096-1; Fukuhara S, 2004, MANUAL SF 36V2 JAPAN; Kinoshita Y, 2003, PRACTICE MODIFIED GR; Kubo Y, 2007, SOGO RIHABIRITESHON, V35, P921; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Ohira T, 2001, STROKE, V32, P903, DOI 10.1161/01.STR.32.4.903; Salter K, 2008, BRAIN INJURY, V22, P820, DOI 10.1080/02699050802425428; Sherer M, 2014, ARCH PHYS MED REHAB, V95, P1162, DOI [10.1016/j.apmr.2014.02.006, 10.1016/j.apmr.2013.06.004]; Shimura K., 2005, B SOCIAL WELFARE DEP, V5, P46; Tate RL, MANUAL SYDNEY PSYCHO; Tate RL, 2011, J REHABIL MED, V43, P609, DOI 10.2340/16501977-0829; Watanabe Syu, 2009, JAPANESE J REHABILIT, V46, P118; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	25	12	13	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	JAN	2017	96	4							e5968	10.1097/MD.0000000000005968			12	Medicine, General & Internal	General & Internal Medicine	EK1WT	WOS:000393717200037	28121947	DOAJ Gold, Green Published			2021-06-18	
J	Shibahashi, K; Sugiyama, K; Houda, H; Takasu, Y; Hamabe, Y; Morita, A				Shibahashi, Keita; Sugiyama, Kazuhiro; Houda, Hidenori; Takasu, Yuichi; Hamabe, Yuichi; Morita, Akio			The effect of tracheostomy performed within 72 h after traumatic brain injury	BRITISH JOURNAL OF NEUROSURGERY			English	Article						Head trauma; neurosurgical intensive care; head injury; severer head injury; tracheostomy; traumatic brain injury	RECEIVING MECHANICAL VENTILATION; SEVERE HEAD-INJURY; TRIAL; METAANALYSIS; INTUBATION; SURVIVAL; COHORT; CARE	The optimal timing of tracheostomy in patients with traumatic brain injury (TBI) remains unclear. The purpose of this study was to examine the effects of tracheostomy performed within 72 h after admission. In this retrospective cohort study, the authors reviewed the data for a series of 120 consecutive patients who underwent tracheostomy after suffering TBI with an Abbreviated Injury Scale (AIS) score of >= 4. The exclusion criteria were as follows: age <18 years, severe chest injury with an AIS score of >= 4, and a requirement for intubation because of upper airway obstruction. Patients who underwent tracheostomy <= 72 h and >72 h after admission were classified into early group and control groups, respectively. The duration of mechanical ventilation, length of stay (LOS) in intensive care unit (ICU), incidence of pneumonia, adverse event rate, unnecessary tracheostomy and outcomes were compared between the two groups. Of the 120 patients, 29 were excluded from the study, 40 were classified into the early group, and 51 were classified into the control group. The duration of mechanical ventilation and LOS in ICU were significantly less in the early group than in the control group. The 30-day mortality rates were 3% and 8% for the early and control groups, respectively. There was no significant difference in the adverse event rate, incidence of pneumonia, unnecessary tracheostomy rate and the rate of favorable outcome between groups. The results of this study suggest that the performance of tracheostomy within 72 h of admission may decrease the duration of mechanical ventilation and LOS in ICU, with acceptable mortality and morbidity rates.	[Shibahashi, Keita; Sugiyama, Kazuhiro; Houda, Hidenori; Takasu, Yuichi; Hamabe, Yuichi] Tokyo Metropolitan Bokutoh Hosp, Dept Emergency, Sumida Ku, 4-23-15 Kotobashi, Tokyo 1308575, Japan; [Shibahashi, Keita; Sugiyama, Kazuhiro; Houda, Hidenori; Takasu, Yuichi; Hamabe, Yuichi] Tokyo Metropolitan Bokutoh Hosp, Intens Care Ctr, Sumida Ku, 4-23-15 Kotobashi, Tokyo 1308575, Japan; [Morita, Akio] Nippon Med Sch, Dept Neurol Surg, Bunkyou Ku, Tokyo, Japan	Shibahashi, K (corresponding author), Tokyo Metropolitan Bokutoh Hosp, Dept Emergency, Sumida Ku, 4-23-15 Kotobashi, Tokyo 1308575, Japan.; Shibahashi, K (corresponding author), Tokyo Metropolitan Bokutoh Hosp, Intens Care Ctr, Sumida Ku, 4-23-15 Kotobashi, Tokyo 1308575, Japan.	kshibahashi@yahoo.co.jp		Sugiyama, Kazuhiro/0000-0003-4543-3064; Morita, Akio/0000-0002-2497-5772			Barquist ES, 2006, J TRAUMA, V60, P91, DOI 10.1097/01.ta.0000196743.37261.3f; Bouderka MA, 2004, J TRAUMA, V57, P251, DOI 10.1097/01.TA.0000087646.68382.9A; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Carney N, 2016, NEUROSURGERY, P1, DOI DOI 10.1227/NEU.0000000000001432; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Dunham CM, 2014, INT J BURNS TRAUMA, V4, P14; Griffiths J, 2005, BMJ-BRIT MED J, V330, P1243, DOI 10.1136/bmj.38467.485671.E0; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kocaeli H, 2008, ACTA NEUROCHIR, V150, P1263, DOI 10.1007/s00701-008-0153-9; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McCredie V, 2017, NEUROCRIT CARE, V26, P14, DOI 10.1007/s12028-016-0297-z; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; PLUMMER AL, 1989, CHEST, V96, P178, DOI 10.1378/chest.96.1.178; Scales DC, 2008, CRIT CARE MED, V36, P2547, DOI 10.1097/CCM.0b013e31818444a5; Stocchetti N, 2000, J NEUROSURG ANESTH, V12, P307, DOI 10.1097/00008506-200010000-00002; Sugerman HJ, 1997, J TRAUMA, V43, P741, DOI 10.1097/00005373-199711000-00002; Wang HK, 2012, INJURY, V43, P1432, DOI 10.1016/j.injury.2011.03.059; Young D, 2013, JAMA-J AM MED ASSOC, V309, P2121, DOI 10.1001/jama.2013.5154	18	12	12	1	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.		2017	31	5					564	568		10.1080/02688697.2017.1302071			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FP8UT	WOS:000417922300008	28301956				2021-06-18	
J	Stepanichev, M; Onufriev, M; Aniol, V; Freiman, S; Brandstaetter, H; Winter, S; Lazareva, N; Guekht, A; Gulyaeva, N				Stepanichev, Mikhail; Onufriev, Mikhail; Aniol, Viktor; Freiman, Sofia; Brandstaetter, Hemma; Winter, Stefan; Lazareva, Natalia; Guekht, Alla; Gulyaeva, Natalia			Effects of cerebrolysin on nerve growth factor system in the aging rat brain	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Aging; brain; Cerebrolysin; neurotrophin; NGF; BDNF; TrkA; TrkB; p75NTR; neocortex; hippocampus; memory; rat	NEUROTROPHIC TREATMENT; DOUBLE-BLIND; RECEPTOR; BDNF; EXPRESSION; RECOVERY; YOUNG; NGF; PROTEINS; STROKE	Background: Aging is associated with some cognitive decline and enhanced risk of development of neurodegenerative diseases. It is assumed that altered metabolism and functions of neurotrophin systems may underlie these age-related functional and structural modifications. Cerebrolysin(TM) (CBL) is a neuropeptide mixture with neurotrophic effects, which is widely used for the treatment of stroke and traumatic brain injury patients. It is also evident that CBL has an overall beneficial effect and a favorable benefit-risk ratio in patients with dementia. However, the effects of CBL on cognition and brain neurotrophin system in normal aging remain obscure. Objective: The aim of the present study was to examine the age-related modifications of endogenous neurotrophin systems in the brain of male Wistar rats and the effects of CBL on learning and memory as well as the levels neurotrophins and their receptors. Methods: Old (23-24 months) and young (2-3 months) male Wistar rats were used for the study. A half of animals were subjected to CBL course (2.5 ml/kg, 20 i.p. injections). Behavior of rats was studied using the open field test and simple water maze training. The contents of NGF and BDNF were studied using enzyme-linked immunosorbent assay; the expression of neurotrophin receptors was estimated by Western-blot analysis. Results: CBL treatment did not affect general status, age-related weight changes, general locomotor activity as well as general brain histology. In a water maze task, a minor effect of CBL was observed in old rats at the start of training and no effect on memory retention was found. Aging induced a decrease in neurotrophin receptors TrkA, TrkB, and p75NTR in the neocortex. CBL counteracted effects of aging on neocortical TrkA and p75NTR receptors and decreased expression of proNGF without influencing overall NGF levels. BDNF system was not significantly affected by CBL. Conclusion: The pro-neuroplastic "antiaging" effects of CBL in the neocortex of old animals were generally related to the NGF rather than the BDNF system.	[Stepanichev, Mikhail; Onufriev, Mikhail; Aniol, Viktor; Freiman, Sofia; Lazareva, Natalia; Gulyaeva, Natalia] Russian Acad Sci, Inst Higher Nervous Act & Neurophysiol, 5A Butlerov Str, Moscow 117485, Russia; [Onufriev, Mikhail; Freiman, Sofia; Guekht, Alla; Gulyaeva, Natalia] Moscow Res & Clin Ctr Neuropsychiat, Healthcare Dept Moscow, Moscow State Budgetary Hlth Inst, Moscow, Russia; [Brandstaetter, Hemma; Winter, Stefan] EVER Neuro Pharma GmbH, Dept Res & Med, Unterach, Austria	Gulyaeva, N (corresponding author), Russian Acad Sci, Inst Higher Nervous Act & Neurophysiol, 5A Butlerov Str, Moscow 117485, Russia.	nata_gul@yahoo.com	Gulyaeva, Natalia V/R-7959-2016; Freiman, Sofia/F-1284-2019; Guekht, Alla B./Y-6725-2018; Stepanichev, Mikhail/J-8022-2018; Aniol, Victor/AAO-3220-2020; Guekht, Alla/N-3422-2019	Freiman, Sofia/0000-0002-8759-9719; Stepanichev, Mikhail/0000-0001-8109-8692; Guekht, Alla/0000-0002-1170-6127; Onufriev, Mikhail/0000-0003-2533-1263	EVER Neuro Pharma GmbH; Russian Science FoundationRussian Science Foundation (RSF) [14-25-00136]	This work was partly funded by EVER Neuro Pharma GmbH and Russian Science Foundation (grant #14-25-00136; studies on receptors of neurotrophins).	Bimonte-Nelson HA, 2008, EXP AGING RES, V34, P13, DOI 10.1080/03610730701761908; Bornstein N, 2012, DRUG TODAY, V48, P43, DOI 10.1358/dot.2012.48(Suppl.A).1739723; Bothwell M, 2014, Handb Exp Pharmacol, V220, P3, DOI 10.1007/978-3-642-45106-5_1; Bucci C, 2014, MEMBRANES, V4, P642, DOI 10.3390/membranes4040642; Budni J, 2015, AGING DIS, V6, P331, DOI 10.14336/AD.2015.0825; Chao MV, 2006, CLIN SCI, V110, P167, DOI 10.1042/CS20050163; Chen CC, 2013, BRIT J NEUROSURG, V27, P803, DOI 10.3109/02688697.2013.793287; Chen N., 2013, COCHRANE DB SYST REV, V1, P1; CRUTCHER KA, 1991, NEUROBIOL AGING, V12, P449, DOI 10.1016/0197-4580(91)90072-R; Cuello AC, 2007, CURR ALZHEIMER RES, V4, P351, DOI 10.2174/156720507781788774; Eder P, 2001, HISTOCHEM J, V33, P605, DOI 10.1023/A:1016394031947; Gschanes A, 2000, HISTOCHEM J, V32, P71, DOI 10.1023/A:1004003008683; Gschanes A, 1998, J NEURAL TRANSM-SUPP, P313; HutterPaier B, 1996, ARZNEIMITTELFORSCH, V46, P237; Kelley A.E, 1993, BEHAV NEUROSCIENCE P, V2, P1; Kraemer B R, 2014, Handb Exp Pharmacol, V220, P121, DOI 10.1007/978-3-642-45106-5_6; LAPCHAK PA, 1993, NEUROBIOL AGING, V14, P121, DOI 10.1016/0197-4580(93)90087-R; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; Masliah E, 2012, DRUG TODAY, V48, P3, DOI 10.1358/dot.2012.48(Suppl.A).1739716; Maurice T, 1996, BRAIN RES, V706, P181, DOI 10.1016/0006-8993(95)01032-7; Meeker RB, 2015, NEURAL REGEN RES, V10, P721, DOI 10.4103/1673-5374.156967; Muresanu DF, 2016, STROKE, V47, P151, DOI 10.1161/STROKEAHA.115.009416; Muresanu DF, 2015, CNS NEUROL DISORD-DR, V14, P587, DOI 10.2174/1871527314666150430162531; Niewiadomska G, 2011, BEHAV BRAIN RES, V221, P515, DOI 10.1016/j.bbr.2010.02.024; Perovic M, 2013, AGE, V35, P2057, DOI 10.1007/s11357-012-9495-6; Reinprecht I, 1999, HISTOCHEM J, V31, P394; Shi SS, 2010, YONSEI MED J, V51, P661, DOI 10.3349/ymj.2010.51.5.661; Terry AV, 2011, PHYSIOL BEHAV, V102, P149, DOI 10.1016/j.physbeh.2010.11.005; Ubhi K, 2013, J NEUROSCI RES, V91, P167, DOI 10.1002/jnr.23142; Ukraintseva SV, 2004, ANN NY ACAD SCI, V1019, P64, DOI 10.1196/annals.1297.014; Watson FL, 1999, J NEUROBIOL, V39, P323, DOI 10.1002/(SICI)1097-4695(199905)39:2<323::AID-NEU15>3.0.CO;2-4	32	12	17	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2017	35	6					571	581		10.3233/RNN-170724			11	Neurosciences	Neurosciences & Neurology	FN6RY	WOS:000416144800002	29172008	Green Published, Bronze			2021-06-18	
J	Stricker, NH; Lippa, SM; Green, DL; McGlynn, SM; Grande, LJ; Milberg, WP; McGlinchey, RE				Stricker, Nikki H.; Lippa, Sara M.; Green, Deborah L.; McGlynn, Susan M.; Grande, Laura J.; Milberg, William P.; McGlinchey, Regina E.			Elevated rates of memory impairment in military service-members and veterans with posttraumatic stress disorder	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Memory; Military personnel; Neuropsychological tests; Posttraumatic stress disorder; Veterans	TRAUMATIC-BRAIN-INJURY; STRUCTURED CLINICAL INTERVIEW; NEUROPSYCHOLOGICAL OUTCOMES; COGNITIVE IMPAIRMENT; PERFORMANCE VALIDITY; POSTCONCUSSIVE SYMPTOMS; COMBAT VETERANS; NEUROCOGNITIVE FUNCTION; PSYCHOMETRIC PROPERTIES; PSYCHOLOGICAL SYMPTOMS	Introduction: Studies investigating the neurocognitive effects of posttraumatic stress disorder (PTSD) routinely find deficits in various cognitive domains. However, the rate of cognitive impairment in individuals with PTSD remains unclear, as studies have focused on null hypothesis testing (NHT) and inferring patterns of impairment rather than empirically determining the rate of cognitive impairment in this sample. Method: This study examined rates of cognitive impairment using a domain-specific approach in non-treatment-seeking Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn service members and veterans with (n=92) and without (n=79) PTSD and without substance abuse/dependence who passed a performance validity measure and were matched on age, education, estimated IQ, and ethnicity. Chi-square analyses were used to compare the rate of cognitive impairment across groups based on normative scores using three cutoffs (-1, -1.5, and -2SDs). NHT was also used to compare performances across groups. Results: Individuals with PTSD showed higher rates of impairment in memory (-1-SD cutoff) than controls, but equivalent rates of impairment in attention, processing speed, and executive functioning; no significant differences were found on NHT. Impairment in any domain was also more prevalent in PTSD (-1-, -1.5-, and -2-SD cutoffs). No differences were found on NHT or rates of impairment in individuals with PTSD with (n=34) and without (n=58) depression. Conclusions: Patients with PTSD were more likely to meet criteria for memory impairment and to show impairment in any domain than controls. Patients with PTSD and comorbid depression were no more likely to be impaired in any cognitive domain or to have lower scores on individual cognitive tasks than patients with PTSD alone. Clinicians noting cognitive impairment in individuals with PTSD should exercise caution before ascribing that impairment to another etiology if deficits are limited to memory.	[Stricker, Nikki H.; Green, Deborah L.; McGlynn, Susan M.] VA Boston Healthcare Syst, Boston, MA USA; [Stricker, Nikki H.; McGlynn, Susan M.; Grande, Laura J.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Stricker, Nikki H.] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA; [Lippa, Sara M.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Milberg, William P.; McGlinchey, Regina E.] Translat Res Ctr TBI & Stress Disorders TRACTS, Boston, MA USA; [Milberg, William P.; McGlinchey, Regina E.] GRECC, Boston, MA USA; [Milberg, William P.; McGlinchey, Regina E.] Harvard Med Sch, Dept Psychiat, Boston, MA USA	Stricker, NH (corresponding author), Mayo Clin, 200 First St SW, Rochester, MN 55905 USA.	stricker.nikki@mayo.edu		Stricker, Nikki/0000-0001-9034-1252	Translational Research Center for TBI and Stress Disorders (TRACTS); VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B9254-C]; Department of Veterans Affairs, Veterans Health Administration, VISN 1 Career Development AwardUS Department of Veterans Affairs	This work was supported by the Translational Research Center for TBI and Stress Disorders (TRACTS), a VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [grant number B9254-C]; and a Department of Veterans Affairs, Veterans Health Administration, VISN 1 Career Development Award to Nikki Stricker.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Aupperle RL, 2002, MULT SCLER J, V8, P382, DOI 10.1191/1352458502ms832oa; Aupperle RL, 2012, NEUROPHARMACOLOGY, V62, P686, DOI 10.1016/j.neuropharm.2011.02.008; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benedict R., 1997, BRIEF VISUOSPATIAL M; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Blake D. D., 1990, BEHAV THER, V13, P187; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Brady KT, 2000, J CLIN PSYCHIAT, V61, P22; Brandes D, 2002, PSYCHIAT RES, V110, P231, DOI 10.1016/S0165-1781(02)00125-7; BREMNER JD, 1993, AM J PSYCHIAT, V150, P1015; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Brooks BL, 2007, J INT NEUROPSYCH SOC, V13, P490, DOI 10.1017/D1355617707070531; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown TA, 1997, BEHAV RES THER, V35, P79, DOI 10.1016/S0005-7967(96)00068-X; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Bustamante V, 2001, J TRAUMA STRESS, V14, P791, DOI 10.1023/A:1013050423901; Cambridge Cognition Ltd, 2013, NEUORPS TEST AUT BAT; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Davis JJ, 2012, CLIN NEUROPSYCHOL, V26, P850, DOI 10.1080/13854046.2012.686631; DeGutis J, 2015, J INT NEUROPSYCH SOC, V21, P342, DOI 10.1017/S1355617715000235; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; Department of Defense and Department of Veterans Affairs, 2009, VA DOD CLIN PRACT GU; Esterman M, 2013, J INT NEUROPSYCH SOC, V19, P835, DOI 10.1017/S135561771300057X; First M.B., 1996, STRUCTURED CLIN INTE; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Franklin CL, 2001, J NERV MENT DIS, V189, P548, DOI 10.1097/00005053-200108000-00008; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gilbertson MW, 2006, J ABNORM PSYCHOL, V115, P484, DOI 10.1037/0021-843X.115.3.484; Gilbertson MW, 2001, J TRAUMA STRESS, V14, P413, DOI 10.1023/A:1011181305501; Gill T., 1990, J TRAUMA STRESS, V3, P29, DOI DOI 10.1002/JTS.2490030104; Gordon SN, 2011, CLIN NEUROPSYCHOL, V25, P337, DOI 10.1080/13854046.2010.550634; Green, 2004, GREENS MED SYMPTOM V; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Gualtieri CT, 2008, J CLIN PSYCHIAT, V69, P1122, DOI 10.4088/JCP.v69n0712; Heaton RK, 2004, REVISED COMPREHENSIV; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hudetz JA, 2010, J CARDIOTHOR VASC AN, V24, P964, DOI 10.1053/j.jvca.2010.02.019; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P923, DOI 10.1007/978-0-387-76978-3_32; Jak AJ, 2009, AM J GERIAT PSYCHIAT, V17, P368, DOI 10.1097/JGP.0b013e31819431d5; Jamora CW, 2012, BRAIN INJURY, V26, P36, DOI 10.3109/02699052.2011.635352; Jelinek L, 2006, J CLIN EXP NEUROPSYC, V28, P940, DOI 10.1080/13803390591004347; Jenkins MA, 2000, CLIN NEUROPSYCHOL, V14, P7, DOI 10.1076/1385-4046(200002)14:1;1-8;FT007; Johnsen GE, 2008, J AFFECT DISORDERS, V111, P74, DOI 10.1016/j.jad.2008.02.007; Johnsen GE, 2008, J ANXIETY DISORD, V22, P464, DOI 10.1016/j.janxdis.2007.04.007; Kane KD, 2014, AM J ALZHEIMERS DIS, V29, P601, DOI 10.1177/1533317514524812; Koenen KC, 2001, BRAIN COGNITION, V45, P64, DOI 10.1006/brcg.2000.1256; Lange RT, 2013, J NEUROTRAUM, V30, P237, DOI 10.1089/neu.2012.2685; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Leark R. A., 2011, TEST VARIABLES ATTEN; Leskin LP, 2007, NEUROPSYCHOLOGY, V21, P275, DOI 10.1037/0894-4105.21.3.275; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lippa SM, 2015, J TRAUMA STRESS, V28, P25, DOI 10.1002/jts.21979; Lippa SM, 2014, ARCH CLIN NEUROPSYCH, V29, P236, DOI 10.1093/arclin/acu002; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Lobbestael J, 2011, CLIN PSYCHOL PSYCHOT, V18, P75, DOI 10.1002/cpp.693; Marx BP, 2009, J INT NEUROPSYCH SOC, V15, P840, DOI 10.1017/S1355617709990488; McCormick CL, 2013, ARCH CLIN NEUROPSYCH, V28, P808, DOI 10.1093/arclin/act050; Nijdam MJ, 2013, EUR J PSYCHOTRAUMATO, V4, DOI 10.3402/ejpt.v4i0.19979; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Proto DA, 2014, ARCH CLIN NEUROPSYCH, V29, P614, DOI 10.1093/arclin/acu044; Qureshi SU, 2011, J NEUROPSYCH CLIN N, V23, P16, DOI 10.1176/appi.neuropsych.23.1.16; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Scott JC, 2015, PSYCHOL BULL, V141, P105, DOI 10.1037/a0038039; Shandera-Ochsner AL, 2013, CLIN NEUROPSYCHOL, V27, P881, DOI 10.1080/13854046.2013.802017; Shucard JL, 2008, BIOL PSYCHOL, V79, P223, DOI 10.1016/j.biopsycho.2008.05.005; Soble JR, 2013, J CLIN EXP NEUROPSYC, V35, P551, DOI 10.1080/13803395.2013.798398; Stricker NH, 2015, J TRAUMA STRESS, V28, P102, DOI 10.1002/jts.22000; STUSS D. T., 1988, CLIN NEUROPSYCHOL, V2, P246, DOI DOI 10.1080/13854048808520107; Swick D, 2012, J INT NEUROPSYCH SOC, V18, P917, DOI 10.1017/S1355617712000458; Twamley EW, 2009, J INT NEUROPSYCH SOC, V15, P879, DOI 10.1017/S135561770999049X; Vanderploeg RD, 2013, J HEAD TRAUMA REHAB, V28, P211, DOI 10.1097/HTR.0b013e31828b50db; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Verfaellie M, 2014, NEUROPSYCHOLOGY, V28, P337, DOI 10.1037/neu0000027; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Weber R, 2012, COMMUN METHODS MEAS, V6, P190, DOI 10.1080/19312458.2012.703834; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; Wisdom NM, 2014, CLIN NEUROPSYCHOL, V28, P128, DOI 10.1080/13854046.2013.863977; Yehuda R, 2005, J CLIN EXP NEUROPSYC, V27, P504, DOI 10.1080/138033990520223	99	12	12	2	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2017	39	8					768	785		10.1080/13803395.2016.1264575			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	FA7HI	WOS:000405616100004	27976973				2021-06-18	
J	Varner, CE; McLeod, S; Nahiddi, N; Lougheed, RE; Dear, TE; Borgundvaag, B				Varner, Catherine E.; McLeod, Shelley; Nahiddi, Negine; Lougheed, Rosamond E.; Dear, Taylor E.; Borgundvaag, Bjug			Cognitive Rest and Graduated Return to Usual Activities Versus Usual Care for Mild Traumatic Brain Injury: A Randomized Controlled Trial of Emergency Department Discharge Instructions	ACADEMIC EMERGENCY MEDICINE			English	Article							SYMPTOMS 3 MONTHS; POSTCONCUSSIVE SYMPTOMS; HEAD-INJURY; CONCUSSION; MANAGEMENT; PREDICTION; VALIDATION; ADULTS; SCALE	ObjectivesIt is estimated that 15%-25% of patients with a mild traumatic brain injury (MTBI) diagnosed in the emergency department (ED) will develop postconcussive syndrome. The objective of this study was to determine if patients randomized to graduated return to usual activity discharge instructions had a decrease in their Post-Concussion Symptom Score (PCSS) 2 weeks after MTBI compared to patients who received usual care MTBI discharge instructions. MethodsThis was a pragmatic, randomized trial of adult (18-64 years) patients of an academic ED (annual census 60,000) diagnosed with MTBI occurring within 24 hours of ED visit. The intervention group received cognitive rest and graduated return to usual activity discharge instructions, and the control group received usual care discharge instructions that did not instruct cognitive rest or graduated return. Patients were contacted by text message or phone 2 and 4 weeks post-ED discharge and asked to complete the PCSS, a validated, 22-item questionnaire, to determine if there was a change in their symptoms. Secondary outcomes included change in PCSS at 4 weeks, number follow-up physician visits, and time off work/school. ResultsA total of 118 patients were enrolled in the study (58 in the control group and 60 in the intervention). The mean (SD) age was 35.2 (+/- 13.7) years and 43 (36.4%) were male. There was no difference with respect to change in PCSS at 2 weeks (10.5 vs. 12.8; 2.3, 95% confidence interval [CI]= 7.0 to 11.7) and 4 weeks post-ED discharge (21.1 vs 18.3; 2.8, 95% CI= 6.9 to 12.7) for the intervention and control groups, respectively. The number of follow-up physician visits and time off work/school were similar when the groups were compared. Thirty-eight (42.2%) and 23 (30.3%) of patients in this cohort had ongoing MTBI symptoms (PCSS>20) at 2 and 4 weeks, respectively. ConclusionsResults from this study suggest graduated return to usual activity discharge instructions do not impact rate of resolution of MTBI symptoms 2 weeks after ED discharge. Given that patients continue to experience symptoms 2 and 4 weeks after MTBI, more investigation is needed to determine how best to counsel and treat patients with postconcussive symptoms.	[Varner, Catherine E.; McLeod, Shelley; Nahiddi, Negine; Lougheed, Rosamond E.; Borgundvaag, Bjug] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Varner, Catherine E.; McLeod, Shelley; Borgundvaag, Bjug] Mt Sinai Hosp, Dept Emergency Med, Toronto, ON, Canada; [Varner, Catherine E.; McLeod, Shelley; Dear, Taylor E.; Borgundvaag, Bjug] Mt Sinai Hosp, Schwartz Reisman Emergency Med Inst, Toronto, ON, Canada	Varner, CE (corresponding author), Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada.; Varner, CE (corresponding author), Mt Sinai Hosp, Dept Emergency Med, Toronto, ON, Canada.; Varner, CE (corresponding author), Mt Sinai Hosp, Schwartz Reisman Emergency Med Inst, Toronto, ON, Canada.	catherine.varner@sinaihealthsystem.ca	Borgundvaag, Bjug/AAH-4446-2020; Borgundvaag, Bjug/AAE-8228-2020; McLeod, Shelley/AAE-9636-2019	McLeod, Shelley/0000-0003-2686-6307; Varner, Catherine/0000-0002-9696-1329	College of Family Physicians of Canada Janus Research Grant Training Level 1	Funded by the College of Family Physicians of Canada Janus Research Grant Training Level 1.	[Anonymous], 2006, AC CONS EV AC CAR PL; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Centers for Disease Control and Prevention, 2007, HEADS FACTS PHYS MIL; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Eliyahu L, 2016, ACAD EMERG MED, V23, P531, DOI 10.1111/acem.12924; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; Grafstein E, 2008, CAN J EMERG MED, V10, P151; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Injury Prevention and Control, INJ PREV CONTR TRAUM; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lucas S, 2011, PM&R, V3, pS406, DOI 10.1016/j.pmrj.2011.07.016; Marshall S, 2012, CAN FAM PHYSICIAN, V58, P257; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; Ontario Neurotrauma Foundation, 2013, GUID CONC MILD TRAUM; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Scorza KA, 2012, AM FAM PHYSICIAN, V85, P123; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Valentine V, 2012, AM FAM PHYSICIAN, V85, P100	25	12	12	0	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	JAN	2017	24	1					75	82		10.1111/acem.13073			8	Emergency Medicine	Emergency Medicine	EK4DD	WOS:000393876400008	27792852	Bronze			2021-06-18	
J	Vikane, E; Hellstrom, T; Roe, C; Bautz-Holter, E; Assmus, J; Skouen, S				Vikane, Eirik; Hellstrom, Torgeir; Roe, Cecilie; Bautz-Holter, Erik; Assmus, Jorg; Skouen, Sture			Multidisciplinary outpatient treatment in patients with mild traumatic brain injury: A randomised controlled intervention study	BRAIN INJURY			English	Article						Mild traumatic brain injury; post-concussion symptoms; randomised controlled trial; return-to-work; vocational rehabilitation	POST-CONCUSSION SYMPTOMS; MODERATE HEAD-INJURY; SICKNESS ABSENCE; CONTROLLED-TRIAL; FOLLOW-UP; WORK; RETURN; DISABILITY; SUPPORT; REHABILITATION	Objective: To evaluate the efficacy of a multidisciplinary outpatient follow-up programme compared to follow-up by a general practitioner for patients being at-risk or sick-listed with persistent post-concussion symptoms two months after a mild traumatic brain injury. Design: Randomised controlled trial. Patients: One hundred fifty-one patients, 16-56 years. Methods: Multidisciplinary outpatient rehabilitation with individual contacts and a psycho-educational group intervention at two outpatient rehabilitation clinics compared to follow-up by a general practitioner after the multidisciplinary examination. Primary outcome was sustainable return-to-work first year post-injury. Secondary outcomes were post-concussion symptoms, disability, the patient's impressions of change and psychological distress. Results: Days to sustainable return-to-work was 90 in the intervention and 71 in the control group (p = 0.375). The number of post-concussion symptoms were fewer in the intervention (6) compared to the control group (8) at 12 months (p = 0.041). No group differences were observed for disability (p = 0.193), patients impression of change (p = 0.285) or psychological distress (p = 0.716). Conclusion: The multidisciplinary outpatient follow-up programme focusing on better understanding and reassurance of favourable outcome for mild traumatic brain injury did not improve return-to-work, but may have reduced the development of post-concussion symptoms. Additional studies should focus on which factors exhibit a direct impact on return-to-work.	[Vikane, Eirik; Skouen, Sture] Haukeland Hosp, Dept Phys Med & Rehabil, POB 1400, N-5021 Bergen, Norway; [Vikane, Eirik; Skouen, Sture] Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway; [Hellstrom, Torgeir; Roe, Cecilie; Bautz-Holter, Erik] Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway; [Roe, Cecilie; Bautz-Holter, Erik] Univ Oslo, Fac Med, Oslo, Norway; [Assmus, Jorg] Haukeland Hosp, Ctr Clin Res, Bergen, Norway	Vikane, E (corresponding author), Haukeland Hosp, Dept Phys Med & Rehabil, POB 1400, N-5021 Bergen, Norway.	eirik.vikane@gmail.com			Norwegian Extra Foundation for Health and Rehabilitation	Eirik Vikane, MD, PhD, was supported by the Norwegian Extra Foundation for Health and Rehabilitation. The authors report no other declarations of interest.	Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bonneterre V., 2013, Annals of Physical and Rehabilitation Medicine, V56, P652, DOI 10.1016/j.rehab.2013.10.001; Browne AL, 2013, DISABIL REHABIL, V35, P1149, DOI 10.3109/09638288.2012.721047; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Fadyl JK, 2015, DISABIL REHABIL, V37, P247, DOI 10.3109/09638288.2014.914586; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Fourtassi M, 2011, CLIN NEUROL NEUROSUR, V113, P716, DOI 10.1016/j.clineuro.2011.07.010; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Gravel J, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-63; Hellstrom T, 2013, INT J PHYS MED REHAB, V1, P143; Hensing G, 1998, SCAND J SOC MED, V26, P133, DOI 10.1177/14034948980260020201; Heskestad B, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-10; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Krane L, 2014, HUM RESOUR HEALTH, V12, DOI 10.1186/1478-4491-12-37; Lannsjo M, 2011, J REHABIL MED, V43, P997, DOI 10.2340/16501977-0875; Marshall S, 2015, BRAIN INJURY, V29, P688, DOI 10.3109/02699052.2015.1004755; Matuseviciene G, 2015, J REHABIL MED; Matuseviciene G, 2013, BRAIN INJURY, V27, P318, DOI 10.3109/02699052.2012.750740; Miller RS, 2015, JAMA INTERN MED, V175, P43, DOI 10.1001/jamainternmed.2014.5479; Mott TF, 2012, AM FAM PHYSICIAN, V86, P1045; Nygren-de Boussard Catharina, 2014, Arch Phys Med Rehabil, V95, pS257, DOI 10.1016/j.apmr.2013.10.009; Paniak C, 2000, BRAIN INJURY, V14, P219; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Radford K, 2013, BRAIN INJURY, V27, P507, DOI 10.3109/02699052.2013.766929; Saltychev M, 2013, BRAIN INJURY, V27, P1516, DOI 10.3109/02699052.2013.831131; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Sveen U, 2010, SCAND J OCCUP THER, V17, P225, DOI 10.3109/11038120903171295; TEASDALE G, 1974, LANCET, V2, P81; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van Houwelingen HC, 2007, SCAND J STAT, V34, P70, DOI 10.1111/j.1467-9469.2006.00529.x; van Velzen JM, 2009, BRAIN INJURY, V23, P385, DOI 10.1080/02699050902838165; van Velzen JM, 2015, DISABIL REHABIL, P1; Vikane E, 2014, BRAIN INJURY, V28, P1374, DOI 10.3109/02699052.2014.919532; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Waljas M, 2014, J HEAD TRAUMA REHAB, V29, P443, DOI 10.1097/HTR.0000000000000002; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	47	12	12	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	4					475	484		10.1080/02699052.2017.1280852			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ES9TD	WOS:000399902900006	28296510				2021-06-18	
J	Workewych, AM; Muzzi, MC; Jing, R; Zhang, S; Topolovec-Vranic, J; Cusimano, MD				Workewych, Adriana M.; Muzzi, Madeline Ciuffetelli; Jing, Rowan; Zhang, Stanley; Topolovec-Vranic, Jane; Cusimano, Michael D.		Canadian Brain Injury Violence Res	Twitter and traumatic brain injury: A content and sentiment analysis of tweets pertaining to sport-related brain injury	SAGE OPEN MEDICINE			English	Article						Concussion; traumatic brain injury; sport-related traumatic brain injuries; Twitter; social media	CONCUSSION EDUCATION; SCHOOL; PLAYERS; HOCKEY; COACH	Objectives: Sport-related traumatic brain injuries are a significant public health burden, with hundreds of thousands sustained annually in North America. While sports offer numerous physical and social health benefits, traumatic brain injuries such as concussion can seriously impact a player's life, athletic career, and sport enjoyment The culture in many sports encourages winning at all costs, placing athletes at risk for traumatic brain injuries. As social media has become a central part of everyday life, the content of users' messages often reflects the prevailing culture related to a particular event or health issue. Methods: We hypothesized that Twitter data might be useful for understanding public perceptions and misperceptions of sport-related traumatic brain injuries. We performed a content and sentiment analysis of 7483 Twitter (R) tweets related to traumatic brain injuries in sports collected during June and July 2013. Results: We identified five major themes. Users tweeted about personal traumatic brain injuries experiences, reported traumatic brain injuries in professional athletes, shared research about sport-related concussions, and discussed policy and safety in injury prevention, such as helmet use. We identified mixed perceptions of and sentiment toward traumatic brain injuries in sports: both an understanding that brain injuries are serious and disregard for activities that might reduce the public burden of traumatic brain injuries were prevalent in our Twitter analysis. Conclusion: While the scientific and medical community considers a concussion a form of traumatic brain injuries, our study demonstrates a misunderstanding of this fact among the public. In our current digital age, social media can provide useful insight into the culture around a health issue, facilitating implementation of prevention and treatment strategies.	[Workewych, Adriana M.; Jing, Rowan; Zhang, Stanley; Cusimano, Michael D.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Div Neurosurg, Injury Prevent Res Off, 30 Bond St, Toronto, ON M5B 1W8, Canada; [Workewych, Adriana M.; Jing, Rowan; Zhang, Stanley; Cusimano, Michael D.] St Michaels Hosp, Trauma & Neurosurg Program, 30 Bond St, Toronto, ON M5B 1W8, Canada; [Muzzi, Madeline Ciuffetelli] Queens Univ, Queens Econ Dept, Kingston, ON, Canada; [Topolovec-Vranic, Jane] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Cusimano, Michael D.] Univ Toronto, Fac Med, Toronto, ON, Canada; [Cusimano, Michael D.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Cusimano, Michael D.] Univ Toronto, Dept Surg, Toronto, ON, Canada	Cusimano, MD (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Div Neurosurg, Injury Prevent Res Off, 30 Bond St, Toronto, ON M5B 1W8, Canada.; Cusimano, MD (corresponding author), St Michaels Hosp, Trauma & Neurosurg Program, 30 Bond St, Toronto, ON M5B 1W8, Canada.	injuryprevention@smh.ca	Topolovec-Vranic, Jane/A-5293-2013; Cusimano, Michael/X-4059-2019	Topolovec-Vranic, Jane/0000-0001-7695-4212; 	Canadian Brain Injury and Violence Research Team; Canadian Institutes of Health Research Strategic Team Grant in Applied Injury ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946]; Ontario Neurotrauma Foundation	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by the Canadian Brain Injury and Violence Research Team, the Canadian Institutes of Health Research Strategic Team Grant in Applied Injury Research #TIR-103946, and the Ontario Neurotrauma Foundation. The funders had no involvement in study conception or design; data collection, interpretation, or analysis; manuscript preparation; or decision to submit to publication.	Ahmed OH, 2010, DISABIL REHABIL, V32, P1877, DOI 10.3109/09638281003734409; Berg GM, 2014, JAAPA-J AM ACAD PHYS, V27, DOI 10.1097/01.JAA.0000442712.05009.b1; Bosley JC, 2013, RESUSCITATION, V84, P206, DOI 10.1016/j.resuscitation.2012.10.017; Bramley H, 2012, CLIN PEDIATR, V51, P332, DOI 10.1177/0009922811425233; Carroll-Alfano M, 2017, J ATHL TRAINING, V52, P689, DOI 10.4085/1062-6050-52.3.08; Chew C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014118; Chrisman SP, 2014, AM J SPORT MED, V42, P1190, DOI 10.1177/0363546513519073; Collier Nigel, 2011, J Biomed Semantics, V2 Suppl 5, pS9, DOI 10.1186/2041-1480-2-S5-S9; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Cusimano MD, 2017, CLIN J SPORT MED, V27, P375, DOI 10.1097/JSM.0000000000000372; Cusimano MD, 2016, PLOS ONE, V11, DOI [10.1371/journal.pone.0156683, 10.1371/journal.pone.015]; Cusimano MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061865; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Delaney JS, 2015, CLIN J SPORT MED, V25, P113, DOI 10.1097/JSM.0000000000000112; Duggan M., 2014, SOCIAL MEDIA UPDATE; Gerberding JL, 2003, REP C MILD TRAUM BRA; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Graff DM, 2016, J CHILD NEUROL, V31, P1569, DOI 10.1177/0883073816666205; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harris JK, 2013, PREV CHRONIC DIS, V10, DOI 10.5888/pcd10.120215; Hobbs JG, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15617; Kaplan AM, 2010, BUS HORIZONS, V53, P59, DOI 10.1016/j.bushor.2009.09.003; Kelleher E, 2014, J PEDIATR SURG, V49, P341, DOI 10.1016/j.jpedsurg.2013.10.016; Kind T, 2015, INT REV PSYCHIATR, V27, P124, DOI 10.3109/09540261.2014.990421; Kuhn AW, 2017, BRIT J SPORT MED, V51, P1732, DOI 10.1136/bjsports-2016-096508; Leo P, 2016, EPIDEMIOLOGY; Lew HL, 2007, J REHABIL RES DEV, V44, P963, DOI 10.1682/JRRD.2006.12.0169; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McCrea HJ, 2013, SPORTS HEALTH, V5, P160, DOI 10.1177/1941738112462203; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Miyashita TL, 2014, ORTHOP J SPORTS MED, V2, DOI 10.1177/2325967114554549; Moorhead SA, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.1933; Patton M.Q., 2002, QUALITATIVE RES EVAL; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Sharp David J, 2015, Pract Neurol, V15, P172, DOI 10.1136/practneurol-2015-001087; Signorini A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019467; Strauss A, 2008, BASICS QUALITATIVE R; Sullivan SJ, 2012, BRIT J SPORT MED, V46, P258, DOI 10.1136/bjsm.2010.080341; Tator CH, 2012, J CLIN SPORT PSYCHOL, V6, P293, DOI 10.1123/jcsp.6.3.293; Topolovec-Vranic J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141699; Voss JD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0506-z	45	12	12	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2050-3121			SAGE OPEN MED	SAGE Open Med.	JAN-DEC	2017	5								2050312117720057	10.1177/2050312117720057			11	Medicine, General & Internal	General & Internal Medicine	GS3AT	WOS:000443441700051	28890783	DOAJ Gold, Green Published			2021-06-18	
J	Wright, WG; McDevitt, J; Tierney, R; Haran, FJ; Appiah-Kubi, KO; Dumont, A				Wright, W. Geoffrey; McDevitt, Jane; Tierney, Ryan; Haran, F. Jay; Appiah-Kubi, Kwadwo Osei; Dumont, Alex			Assessing subacute mild traumatic brain injury with a portable virtual reality balance device	DISABILITY AND REHABILITATION			English	Article						Visual-vestibular processing; virtual reality; concussion; posture; sensory organization test	TEST-RETEST RELIABILITY; POSTURAL STABILITY; HEAD-INJURY; VESTIBULAR REHABILITATION; CONCUSSION ASSESSMENT; FOOTBALL PLAYERS; RECOVERY; DEFICITS; ENVIRONMENT; RESPONSES	Purpose: Balance impairment is a common sensorimotor symptom in mild traumatic brain injury (mTBI). We designed an affordable, portable virtual reality (VR)-based balance screening device (Virtual Environment TBI Screen [VETS]), which will be validated relative to the Neurocom Sensory Organization Test (SOT) to determine if it can replace commonly used postural assessments. Methods: This preliminary study examines healthy adults (n=56) and adults with mTBI (n=11). Participants performed six upright postural tasks on the VETS and the SOT. Analysis of variance was used to determine between-group differences. Pearson's correlations were used to establish construct validity. Known-groups approach was used to establish classification accuracy. Results: The mTBI cohort performed significantly worse than the healthy cohort on the new device (p=0.001). The new device has 91.0% accuracy and an ROC curve with a significant area-under-the-curve (AUC=0.865, p<0.001). Conditions with dynamic visual stimulation were the most sensitive to health status. The SOT had an 84.8% accuracy and AUC =0.703 (p=0.034). Conclusions: The new VR-based device is a valid measure for detecting balance impairment following mTBI and can potentially replace more expensive and cumbersome equipment. Assessments that test visual-vestibular processing, such as VETS, increase sensitivity to mTBI-related balance deficits, which can be used to guide rehabilitation. Implications for rehabilitation Emerging technology using virtual reality can be economically integrated into the clinical setting for easy testing of postural control in neurologically impaired populations. Tailoring postural assessments to include tasks that rely on visual and vestibular integration will increase the accuracy of detecting balance impairment following mild traumatic brain injury.	[Wright, W. Geoffrey; Appiah-Kubi, Kwadwo Osei] Temple Univ, Dept Phys Therapy, Philadelphia, PA 19122 USA; [McDevitt, Jane] East Stroudsburg Univ, Dept Athlet Training, East Stroudsburg, PA USA; [McDevitt, Jane; Tierney, Ryan] Temple Univ, Dept Kinesiol, Philadelphia, PA 19122 USA; [Haran, F. Jay] Univ North Carolina Greensboro, Dept Kinesiol, Greensboro, NC USA; [Wright, W. Geoffrey; Dumont, Alex] Temple Univ, Dept Bioengn, Philadelphia, PA 19122 USA	Wright, WG (corresponding author), Temple Univ, Dept Phys Therapy, Philadelphia, PA 19122 USA.	wrightw@temple.edu	Appiah-Kubi, Kwadwo/ABF-9527-2020	Appiah-Kubi, Kwadwo/0000-0001-6566-9758	Congressionally Directed Medical Research ProgramsUnited States Department of Defense [W81XWH-13-C-0189]	This work was supported, in part, by the Congressionally Directed Medical Research Programs [W81XWH-13-C-0189].	Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Baker C.S., 2014, PHYSL REP, V2, P1; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Brandt T, 1999, ANN NY ACAD SCI, V871, P293, DOI 10.1111/j.1749-6632.1999.tb09193.x; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Clark RA, 2010, GAIT POSTURE, V31, P307, DOI 10.1016/j.gaitpost.2009.11.012; DICHGANS J, 1972, SCIENCE, V178, P1217, DOI 10.1126/science.178.4066.1217; Field A., 1998, BRIT PSYCHOL SOC MAT, V6, P13; Gottshall K, 2003, LARYNGOSCOPE, V113, P1746, DOI 10.1097/00005537-200310000-00016; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; Gurley JM, 2013, NEUROREHABILITATION, V32, P519, DOI 10.3233/NRE-130874; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Haran FJ, 2013, INT J SPORTS MED, V34, P350, DOI 10.1055/s-0032-1304647; Haran FJ, 2016, J NEUROTRAUM, V33, P705, DOI 10.1089/neu.2015.4060; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Jacobs SM, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0389-5; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Kaufman DR, 2014, PHYS THER SPORT, V15, P181, DOI 10.1016/j.ptsp.2013.10.002; Keshner EA, 2000, J VESTIBUL RES-EQUIL, V10, P207; Kirsch V, 2016, BRAIN STRUCT FUNCT, V221, P1291, DOI 10.1007/s00429-014-0971-x; LISHMAN JR, 1973, PERCEPTION, V2, P287, DOI 10.1068/p020287; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McDevitt J, 2016, INT J SPORTS MED, V37, P738, DOI 10.1055/s-0042-100470; Murray N, 2014, J ATHL TRAINING, V49, P540, DOI 10.4085/1062-6050-49.3.32; NeuroCom, DIV NAT SETT STAND B; Rabago CA, 2011, J NEUROL PHYS THER, V35, P185, DOI 10.1097/NPT.0b013e318235d7e6; Register-Mihalik JK, 2008, NEUROSURGERY, V63, P76, DOI 10.1227/01.NEU.0000335073.39728.CE; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Ruhe A, 2014, SPORTS HEALTH, V6, P427, DOI 10.1177/1941738114541238; Ruhe A, 2010, GAIT POSTURE, V32, P436, DOI 10.1016/j.gaitpost.2010.09.012; Scherer MR, 2011, OTOL NEUROTOL, V32, P571, DOI 10.1097/MAO.0b013e318210b8fa; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Teel EF, 2015, CLIN J SPORT MED, V25, P144, DOI 10.1097/JSM.0000000000000109; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wright WG, 2015, 2015 INTERNATIONAL CONFERENCE ON VIRTUAL REHABILITATION PROCEEDINGS (ICVR), P72, DOI 10.1109/ICVR.2015.7358591; Young W, 2011, GAIT POSTURE, V33, P303, DOI 10.1016/j.gaitpost.2010.10.089	42	12	13	0	16	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2017	39	15					1564	1572		10.1080/09638288.2016.1226432			9	Rehabilitation	Rehabilitation	EU3KS	WOS:000400929200014	27718642				2021-06-18	
J	Zhang, PJ; Ye, YQ; Qian, YH; Yin, BX; Zhao, JM; Zhu, SX; Zhang, L; Yan, MJ				Zhang, Pengju; Ye, Yongqi; Qian, Yuhang; Yin, Baoxin; Zhao, Jianmei; Zhu, Shunxing; Zhang, Li; Yan, Meijuan			The Effect of Pyrroloquinoline Quinone on Apoptosis and Autophagy in Traumatic Brain Injury	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Apoptosis; autophagy; electroencephalogram; pyrroloquinoline quinone; rat; traumatic brain injury	FLUID PERCUSSION INJURY; OXIDATIVE STRESS; RAT; PROTECTS; NEUROPROTECTION; ASTROCYTES; RECEPTOR; IMPROVES; HYPOXIA; DAMAGE	Background: Pyrroloquinoline quinone is an anionic, water-soluble compound with antioxidant characteristic. The role of pyrroloquinoline quinone in pharmacology and nutrition has attracted wide attention of researchers. Although a few experiments have confirmed that pyrroloquinoline quinone plays an obvious effective role in neuroprotection. There are few reports about the effect of pyrroloquinoline quinone on traumatic brain injury. Traumatic brain injury is one of the leading causes for adult disability and death. So far, there are no effective treatment methods for the injury because of its complex pathophysiology. Method: In the present study, a model of traumatic brain injury in rat was established to study the role of pyrroloquinoline quinone in central nervous system injury. Results: The results showed that the protein expression of cleaved-Caspase 3/Caspase 3 increased after traumatic brain injury and the expression decreased by treatment with 2mM pyrroloquinoline quinone. Terminal-deoxynucleoitidyl transferase mediated nick end labeling (TUNEL) staining displayed that the TUNEL positive signals were up-regulated after traumatic brain injury and were down-regulated after treatment with 2mM pyrroloquinoline quinone. The protein expression of LC3II/LC3I or lysosome-associated membrane protein 2(LAMP2) was elevated after traumatic brain injury and reduced after administration with 2mM pyrroloquinoline quinone. Transmission electron microscopy showed that the number of autophagosomes increased markedly after traumatic brain injury and decreased on administration of 2mM pyrroloquinoline quinone. Electroencephalogram indicated that pyrroloquinoline quinone improved brain electrophysiological function after traumatic brain injury. The results of CCK-8 test showed that pyrroloquinoline quinone could increase the viability of primary astrocyte treated with Glutamate. Lactate dehydrogenase (LDH) assay demonstrated that pyrroloquinoline quinone decreased LDH content in primary astrocyte exposed to Glutamate. Conclusion: Pyrroloquinoline quinone could play a neuroprotective role after traumatic brain injury in rat, which might be associated with inhibiting apoptosis and autophagy caused by traumatic brain injury.	[Zhang, Pengju; Ye, Yongqi; Qian, Yuhang; Yin, Baoxin; Zhao, Jianmei; Zhu, Shunxing; Zhang, Li; Yan, Meijuan] Nantong Univ, Jiangsu Key Lab Neuroregenerat, 19 Qi Xiu Rd, Nantong 226001, Jiangsu, Peoples R China	Yan, MJ (corresponding author), Nantong Univ, Jiangsu Key Lab Neuroregenerat, 19 Qi Xiu Rd, Nantong 226001, Jiangsu, Peoples R China.	ymz@ntu.edu.cn			National Natural Scientific Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31370803, 81101178]; Natural Scientific Foundation of Jiangsu Province [BK2011188]; Application Study Program of Nantong City [BK2013004]; Nantong University [10ZY013, 12B035]	This work was supported by the National Natural Scientific Foundation of China (31370803, 81101178), Natural Scientific Foundation of Jiangsu Province (BK2011188), Application Study Program of Nantong City (BK2013004), Early Pre-research Program of Nantong University (10ZY013), Doctoral Program of Nantong University (12B035).	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081585; Chen HY, 2015, APOPTOSIS, V20, P821, DOI 10.1007/s10495-015-1111-7; Chowanadisai W, 2010, J BIOL CHEM, V285, P142, DOI 10.1074/jbc.M109.030130; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; De Ford C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.413; Evans MK, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.412; Haque A, 2015, APOPTOSIS, V20, P986, DOI 10.1007/s10495-015-1126-0; Hu BY, 2014, J ETHNOPHARMACOL, V155, P1243, DOI 10.1016/j.jep.2014.07.009; Huang CF, 2016, PATHOL ONCOL RES, V22, P109, DOI 10.1007/s12253-015-9981-0; Huang EYK, 2014, BEHAV BRAIN RES, V267, P156, DOI 10.1016/j.bbr.2014.03.033; Huang YQ, 2015, EXP THER MED, V10, P451, DOI 10.3892/etm.2015.2532; Jiang X, 2015, APOPTOSIS, V20, P1033, DOI 10.1007/s10495-015-1130-4; Kumar N, 2015, CHEM-BIOL INTERACT, V240, P278, DOI 10.1016/j.cbi.2015.08.027; Kuo YT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143600; Lee SC, 2016, AM J TRANSPLANT; Li AH, 2013, J MOL NEUROSCI, V51, P208, DOI 10.1007/s12031-013-9994-7; Li FR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147810; Li MM, 2015, APOPTOSIS, V20, P769, DOI 10.1007/s10495-015-1110-8; Lim EJ, 2015, APOPTOSIS, V20, P1087, DOI 10.1007/s10495-015-1135-z; Lin CJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.123; Liu ZB, 2016, INFLAMMATION, V39, P248, DOI 10.1007/s10753-015-0245-7; Nakano M, 2015, J NUTR SCI VITAMINOL, V61, P241, DOI 10.3177/jnsv.61.241; Nichols J, 2015, CNS NEUROSCI THER, V21, P193, DOI 10.1111/cns.12351; Ferreira APO, 2014, PSYCHOPHARMACOLOGY, V231, P1935, DOI 10.1007/s00213-013-3336-x; Pilipovic K, 2015, PROG NEURO-PSYCHOPH, V59, P8, DOI 10.1016/j.pnpbp.2015.01.003; Qin AP, 2010, AUTOPHAGY, V6, P738, DOI 10.4161/auto.6.6.12573; Qin GQ, 2015, APOPTOSIS, V20, P1072, DOI 10.1007/s10495-015-1132-2; Qin JJ, 2015, TOXICOL LETT, V238, P70, DOI 10.1016/j.toxlet.2015.08.011; Rau TF, 2014, EXP NEUROL, V253, P31, DOI 10.1016/j.expneurol.2013.12.001; Senol N, 2014, NEUROCHEM RES, V39, P685, DOI 10.1007/s11064-014-1255-9; Szydlowska K, 2010, J NEUROCHEM, V113, P904, DOI 10.1111/j.1471-4159.2010.06656.x; Tao R, 2007, BIOCHEM BIOPH RES CO, V363, P257, DOI 10.1016/j.bbrc.2007.08.041; Tiwari M, 2015, APOPTOSIS, V20, P1019, DOI 10.1007/s10495-015-1136-y; Tsai YT, 2014, J SURG RES, V189, P106, DOI 10.1016/j.jss.2014.02.009; Wang CC, 2013, J SURG RES, V185, P753, DOI 10.1016/j.jss.2013.07.002; Wang HQ, 2014, NEUROPHARMACOLOGY, V86, P9, DOI 10.1016/j.neuropharm.2014.06.018; Xiao YW, 2015, SEIZURE-EUR J EPILEP, V33, P29, DOI 10.1016/j.seizure.2015.10.005; Zhang LL, 2012, J NEUROTRAUM, V29, P851, DOI 10.1089/neu.2011.1882; Zhang Q, 2013, NEUROCHEM RES, V38, P1661, DOI 10.1007/s11064-013-1068-2; Zhang Q, 2011, TOXICOL APPL PHARM, V252, P62, DOI 10.1016/j.taap.2011.02.006; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0; Zhao GW, 2014, J ETHNOPHARMACOL, V151, P694, DOI 10.1016/j.jep.2013.11.041; Zhou S, 2013, FEBS LETT, V587, P254, DOI 10.1016/j.febslet.2012.12.003	43	12	12	2	13	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2017	16	6					724	736		10.2174/1871527316666170124164306			13	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	FE8JR	WOS:000408451900011	28124619				2021-06-18	
J	Frohlich, M; Driessen, A; Bhmer, A; Nienaber, U; Igressa, A; Probst, C; Bouillon, B; Maegele, M; Mutschler, M				Froehlich, Matthias; Driessen, Arne; Bhmer, Andreas; Nienaber, Ulrike; Igressa, Alhadi; Probst, Christian; Bouillon, Bertil; Maegele, Marc; Mutschler, Manuel		TraumaRegister DGU	Is the shock index based classification of hypovolemic shock applicable in multiple injured patients with severe traumatic brain injury?-an analysis of the TraumaRegister DGU (R)	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Haemorrhagic shock; Shock index; Traumatic brain injury; Multiple trauma	EUROPEAN GUIDELINE; MASSIVE TRANSFUSION; MAJOR TRAUMA; COAGULOPATHY; MANAGEMENT; MORTALITY; RESPONSES; REGISTRY; UTILITY	Background: A new classification of hypovolemic shock based on the shock index (SI) was proposed in 2013. This classification contains four classes of shock and shows good correlation with acidosis, blood product need and mortality. Since their applicability was questioned, the aim of this study was to verify the validity of the new classification in multiple injured patients with traumatic brain injury. Methods: Between 2002 and 2013, data from 40 888 patients from the TraumaRegister DGU (R) were analysed. Patients were classified according to their initial SI at hospital admission (Class I: SI < 0.6, class II: SI >= 0.6 to <1.0, class III SI >= 1.0 to <1.4, class IV: SI >= 1.4). Patients with an additional severe TBI (AIS >= 3) were compared to patients without severe TBI. Results: 16,760 multiple injured patients with TBI (AIS(head) >= 3) were compared to 24,128 patients without severe TBI. With worsening of SI class, mortality rate increased from 20 to 53% in TBI patients. Worsening SI classes were associated with decreased haemoglobin, platelet counts and Quick's values. The number of blood units transfused correlated with worsening of SI. Massive transfusion rates increased from 3% in class I to 46% in class IV. The accuracy for predicting transfusion requirements did not differ between TBI and Non TBI patients. Discussion: The use of the SI based classification enables a quick assessment of patients in hypovolemic shock based on universally available parameters. Although the pathophysiology in TBI and Non TBI patients and early treatment methods such as the use of vasopressors differ, both groups showed an identical probability of recieving blood products within the respective SI class. Conclusion: Regardless of the presence of TBI, the classification of hypovolemic shock based on the SI enables a fast and reliable assessment of hypovolemic shock in the emergency department. Therefore, the presented study supports the SI as a feasible tool to assess patients at risk for blood product transfusions, even in the presence of severe TBI.	[Froehlich, Matthias; Driessen, Arne; Probst, Christian; Bouillon, Bertil; Maegele, Marc; Mutschler, Manuel] Univ Witten Herdecke, Dept Orthopaed Surg Traumatol & Sports Traumatol, Cologne Merheim Med Ctr, Ostmerheimer Str 200, D-51109 Cologne, Germany; [Froehlich, Matthias] Univ Witten Herdecke, Cologne Merheim Med Ctr, Inst Res Operat Med IFOM, Ostmerheimerstr 200, D-51109 Cologne, Germany; [Bhmer, Andreas] Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Anaesthesiol & Intens Care Med, Ostmerheimer Str 200, D-51109 Cologne, Germany; [Nienaber, Ulrike] AUC Acad Trauma Surg, Str 17 Juni 106-108, D-10623 Berlin, Germany; [Igressa, Alhadi] Cologne Merheim Med Ctr, Dept Neurosurg, Ostmerheimer Str 200, D-51109 Cologne, Germany; [Froehlich, Matthias; Driessen, Arne; Bhmer, Andreas; Nienaber, Ulrike; Igressa, Alhadi; Probst, Christian; Bouillon, Bertil; Maegele, Marc; Mutschler, Manuel; TraumaRegister DGU] German Trauma Soc, Comm Emergency Med Intens Care & Trauma Managemen, Sekt NIS, Berlin, Germany	Frohlich, M (corresponding author), Univ Witten Herdecke, Dept Orthopaed Surg Traumatol & Sports Traumatol, Cologne Merheim Med Ctr, Ostmerheimer Str 200, D-51109 Cologne, Germany.; Frohlich, M (corresponding author), Univ Witten Herdecke, Cologne Merheim Med Ctr, Inst Res Operat Med IFOM, Ostmerheimerstr 200, D-51109 Cologne, Germany.; Frohlich, M (corresponding author), German Trauma Soc, Comm Emergency Med Intens Care & Trauma Managemen, Sekt NIS, Berlin, Germany.	froehlichm@kliniken-koeln.de					20 years TraumaRegister DGU((R)), 2014, INJURY S3, V45, pS6; Bruijns SR, 2013, J TRAUMA ACUTE CARE, V74, P1432, DOI 10.1097/TA.0b013e31829246c7; Cannon CM, 2009, J TRAUMA, V67, P1426, DOI 10.1097/TA.0b013e3181bbf728; Chen B, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-77; Driessen A, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0233-4; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Grote S, 2011, J NEUROTRAUM, V28, P527, DOI 10.1089/neu.2010.1433; Guly HR, 2011, RESUSCITATION, V82, P556, DOI 10.1016/j.resuscitation.2011.01.013; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Lefering R, 2014, INJURY, V45, pS83, DOI 10.1016/j.injury.2014.08.023; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; McMahon CG, 2008, CRIT CARE MED, V36, P216, DOI 10.1097/01.CCM.0000295425.41831.85; McMahon CG, 2011, SHOCK, V35, P53, DOI 10.1097/SHK.0b013e3181e687c6; McMahon CG, 2010, J TRAUMA, V69, P1169, DOI 10.1097/TA.0b013e3181cc8889; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Mutschler M, 2013, RESUSCITATION, V84, P309, DOI 10.1016/j.resuscitation.2012.07.012; Mutschler M, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/1757-7241-22-28; Mutschler M, 2013, CRIT CARE, V17, DOI 10.1186/cc12851; Olaussen A, 2015, INJURY, V46, P822, DOI 10.1016/j.injury.2014.12.009; Pacagnella RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057594; Rossaint R, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1265-x; Spahn DR, 2007, CRIT CARE, V11, DOI 10.1186/cc5686; Spahn DR, 2013, CRIT CARE, V17, DOI 10.1186/cc12685; Subcommittee A, 2013, J TRAUMA ACUTE CARE, V74, P1363; Vandromme MJ, 2011, J TRAUMA, V70, P384, DOI 10.1097/TA.0b013e3182095a0a; Wafaisade A, 2010, EMERG MED J, V27, P934, DOI 10.1136/emj.2009.088484; YUAN XQ, 1991, CIRC SHOCK, V35, P231; Zarzaur BL, 2008, J SURG RES, V147, P229, DOI 10.1016/j.jss.2008.03.025	29	12	12	0	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	DEC 12	2016	24								148	10.1186/s13049-016-0340-2			9	Emergency Medicine	Emergency Medicine	EG6GD	WOS:000391141700001	27955692	DOAJ Gold, Green Published			2021-06-18	
J	Brady, RD; Grills, BL; Romano, T; Wark, JD; O'Brien, TJ; Shultz, SR; McDonald, SJ				Brady, R. D.; Grills, B. L.; Romano, T.; Wark, J. D.; O'Brien, T. J.; Shultz, S. R.; McDonald, S. J.			Sodium selenate treatment mitigates reduction of bone volume following traumatic brain injury in rats	JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS			English	Article						Neurotrauma; Bone Metabolism; Endochondral Ossification; Bone Growth; Osteoporosis	GROWTH-HORMONE; HYPERPHOSPHORYLATED TAU; MINERAL DENSITY; MOUSE MODEL; NEUROINFLAMMATION; SELENITE; SKELETON; DEFICITS; OUTCOMES; FEMALE	Objectives: Administration of sodium selenate to rats given traumatic brain injury (TBI) attenuates brain damage and improves long-term behavioural outcomes. We have previously provided evidence that TBI causes bone loss in rats, however the effect of sodium selenate treatment on bone quantity following TBI is unknown. Methods: Rats were randomly assigned into sham injury or fluid percussion injury (FPI) groups and administered saline or sodium selenate for 12 weeks post-injury. Femora were analysed using histomorphometry, peripheral quantitative computed tomography (pQCT) and biomechanical testing. Results: Distal metaphyseal trabecular bone volume fraction of FPI-selenate rats was higher than FPI-vehicle rats (41.8%; p<0.01), however, femora from selenate-treated groups were shorter in length (4.3%; p<0.01) and had increased growth plate width (22.1%; p<0.01), indicating that selenate impaired long bone growth. pQCT analysis demonstrated that distal metaphyseal cortical thickness was decreased in TBI rats compared to shams (11.7%; p<0.05), however selenate treatment to TBI animals offset this reduction (p<0.05). At the midshaft we observed no differences in biomechanical measures. Conclusion: These are the first findings to indicate that mitigating TBI-induced neuropathology may have the added benefit of preventing osteoporosis and associated fracture risk following TBI.	[Brady, R. D.; Grills, B. L.; Romano, T.; McDonald, S. J.] La Trobe Univ, Dept Physiol Anat & Microbiol, Bundoora, Vic 3086, Australia; [Wark, J. D.; O'Brien, T. J.; Shultz, S. R.] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Melbourne, Vic 3010, Australia	McDonald, SJ (corresponding author), La Trobe Univ, Dept Physiol Anat & Microbiol, Bundoora, Vic 3086, Australia.	stuart.mcdonald@latrobe.edu.au		O'Brien, Terence/0000-0002-7198-8621; McDonald, Stuart/0000-0001-5190-3179	NHMRCNational Health and Medical Research Council of Australia; CIHRCanadian Institutes of Health Research (CIHR); La Trobe University	This work was supported by grants to SRS and TJO from the NHMRC, a fellowship to SRS from CIHR, and funding from La Trobe University to BLG and SJM.	Anevska K, 2015, BONE, V74, P199, DOI 10.1016/j.bone.2015.01.018; Beaupre GS, 2006, AM J PHYS MED REHAB, V85, P464, DOI 10.1097/01.phm.0000214275.69286.7a; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Brady RD, 2015, J NEUROTRAUMA; Brady RD, 2014, J ORTHOP RES, V32, P1277, DOI 10.1002/jor.22686; CAMPO RD, 1971, CALC TISS RES, V7, P318, DOI 10.1007/BF02062621; Chung YW, 2006, TOXICOL LETT, V160, P143, DOI 10.1016/j.toxlet.2005.06.019; Corcoran NM, 2010, BRIT J CANCER, V103, P462, DOI 10.1038/sj.bjc.6605798; Corcoran NM, 2010, J CLIN NEUROSCI, V17, P1025, DOI 10.1016/j.jocn.2010.04.020; Evans K D, 2008, Open Orthop J, V2, P121, DOI 10.2174/1874325000802010121; Evans KD, 2003, BONE, V32, P268, DOI 10.1016/S8756-3282(02)00974-2; Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007-0036; Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507; GRONBAEK H, 1995, J ENDOCRINOL, V145, P105, DOI 10.1677/joe.0.1450105; Hardy R, 2009, J ENDOCRINOL, V201, P309, DOI 10.1677/JOE-08-0568; Hinson HE, 2012, CURR OPIN CRIT CARE, V18, P139, DOI 10.1097/MCC.0b013e3283513290; HOLMES SJ, 1994, J CLIN ENDOCR METAB, V78, P669, DOI 10.1210/jc.78.3.669; Johnstone VPA, 2015, J NEUROTRAUM, V32, P1333, DOI 10.1089/neu.2014.3785; Johnstone VPA, 2014, J NEUROTRAUM, V31, P1881, DOI 10.1089/neu.2014.3343; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee JI, 2005, BRAIN INJURY, V19, P1207, DOI 10.1080/02699050500309338; Lee SH, 2008, BMB REP, V41, P495, DOI 10.5483/BMBRep.2008.41.7.495; Leppanen O, 2006, J BONE MINER RES, V21, P1231, DOI 10.1359/JBMR.060511; Lin HL, 2015, ACTA NEUROL SCAND, V131, P158, DOI 10.1111/ane.12301; Mackie EJ, 2008, INT J BIOCHEM CELL B, V40, P46, DOI 10.1016/j.biocel.2007.06.009; McDonald SJ, 2012, ACTA ORTHOP, V83, P93, DOI 10.3109/17453674.2011.652891; MUNDY GR, 1991, J PERIODONTAL RES, V26, P213, DOI 10.1111/j.1600-0765.1991.tb01647.x; Nagao M, 2011, P NATL ACAD SCI USA, V108, P17767, DOI 10.1073/pnas.1109402108; Romano T, 2014, REPROD FERT DEVELOP, V26, P385, DOI 10.1071/RD12378; Romano T, 2010, BONE, V47, P1054, DOI 10.1016/j.bone.2010.08.020; Shultz SR, 2015, J CEREBR BLOOD F MET, V35, P1339, DOI 10.1038/jcbfm.2015.56; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Smith EM, 2009, ARCH PHYS MED REHAB, V90, P1127, DOI 10.1016/j.apmr.2008.09.578; Szulc P, 2009, OSTEOPOROSIS INT, V20, P1281, DOI 10.1007/s00198-009-0994-y; THORLACIUSUSSING O, 1987, ENDOCRINOLOGY, V120, P659, DOI 10.1210/endo-120-2-659; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yu H, 2013, BRAIN INJ; Zheng P, 2014, MOL NEUROBIOL, V49, P1532, DOI 10.1007/s12035-013-8601-9	39	12	13	0	2	JMNI	NAFPLION	7 SPILIADOU SQ, NAFPLION, 21 100, GREECE	1108-7161			J MUSCULOSKEL NEURON	J. Musculoskelet. Neuronal Interact.	DEC	2016	16	4					369	376					8	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	EJ1VB	WOS:000392997200011	27973389				2021-06-18	
J	Brett, BL; Smyk, N; Solomon, G; Baughman, BC; Schatz, P				Brett, Benjamin L.; Smyk, Nathan; Solomon, Gary; Baughman, Brandon C.; Schatz, Philip			Long-term Stability and Reliability of Baseline Cognitive Assessments in High School Athletes Using ImPACT at 1-, 2-, and 3-year Test-Retest Intervals	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Head injury; Traumatic brain injury; Practice effects/reliable change; Assessment; Childhood brain insult; Norms/normative studies; Test construction	SPORT-RELATED CONCUSSION; NEUROPSYCHOLOGICAL ASSESSMENT; INTERPRETING CHANGE; CONSTRUCT-VALIDITY; ONLINE VERSION; SCORES; AGE; SPECIFICITY; SENSITIVITY; STATEMENT	Objective: The ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing) neurocognitive testing battery is a widely used tool used for the assessment and management of sports-related concussion. Research on the stability of ImPACT in high school athletes at a 1- and 2-year intervals have been inconsistent, requiring further investigation. We documented 1-, 2-, and 3-year test-retest reliability of repeated ImPACT baseline assessments in a sample of high school athletes, using multiple statistical methods for examining stability. Methods: A total of 1,510 high school athletes completed baseline cognitive testing using online ImPACT test battery at three time periods of approximately 1- (N = 250), 2-(N = 1146), and 3-year (N = 114) intervals. No participant sustained a concussion between assessments. Results: Intraclass correlation coefficients (ICCs) ranged in composite scores from 0.36 to 0.90 and showed little change as intervals between assessments increased. Reliable change indices and regression-based measures (RBMs) examining the test-retest stability demonstrated a lack of significant change in composite scores across the various time intervals, with very few cases (0%-6%) falling outside of 95% confidence intervals. Conclusion: The results suggest ImPACT composites scores remain considerably stability across 1-, 2-, and 3-year test-retest intervals in high school athletes, when considering both ICCs and RBM. Annually ascertaining baseline scores continues to be optimal for ensuring accurate and individualized management of injury for concussed athletes. For instances in which more recent baselines are not available (12 years), clinicians should seek to utilize more conservative range estimates in determining the presence of clinically meaningful change in cognitive performance.	[Brett, Benjamin L.; Baughman, Brandon C.] Semmes Murphey Neurol & Spine Inst, Memphis, TN USA; [Brett, Benjamin L.] Univ Memphis, Dept Counseling Educ Psychol & Res, 100 Ball Hall, Memphis, TN 38152 USA; [Smyk, Nathan; Schatz, Philip] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA; [Solomon, Gary] Vanderbilt Univ, Sch Med, Dept Neurol Surg, Nashville, TN 37212 USA; [Solomon, Gary] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Nashville, TN 37212 USA; [Baughman, Brandon C.] Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, Memphis, TN 38163 USA	Brett, BL (corresponding author), Univ Memphis, Dept Counseling Educ Psychol & Res, 100 Ball Hall, Memphis, TN 38152 USA.	blbrett@memphis.edu	Solomon, Gary/K-9011-2019				Allen BJ, 2011, BRAIN INJURY, V25, P179, DOI 10.3109/02699052.2010.541897; Alsalaheen B, 2015, J HEAD TRAUMA REHABI; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr William B, 2002, CNS Spectr, V7, P300; Bauer RM, 2012, ARCH CLIN NEUROPSYCH, V27, P362, DOI 10.1093/arclin/acs027; Baumgartner T.A., 2001, MEAS PHYS EDUC EXERC, V5, P179, DOI [10.1207/S15327841MPEE0503_4, DOI 10.1207/S15327841MPEE0503_4]; Bonate P.L., 2000, ANAL PRETEST POSTTES; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Bruce J, 2014, CLIN NEUROPSYCHOL, V28, P14, DOI 10.1080/13854046.2013.866272; Calamia M, 2012, CLIN NEUROPSYCHOL, V26, P543, DOI 10.1080/13854046.2012.680913; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024; Cicchetti D.V., 1994, PSYCHOL ASSESS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]; Cioni G, 2013, HAND CLINIC, V111, P3, DOI 10.1016/B978-0-444-52891-9.00001-4; Cole WR, 2013, ARCH CLIN NEUROPSYCH, V28, P732, DOI 10.1093/arclin/act040; Collie A., 2009, J INT NEUROPSYCH SOC, V9, P419; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Crone EA, 2015, WIRES COGN SCI, V6, P53, DOI 10.1002/wcs.1327; Duff K, 2012, ARCH CLIN NEUROPSYCH, V27, P248, DOI 10.1093/arclin/acr120; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; FLIN RH, 1985, J EARLY ADOLESC, V5, P259, DOI DOI 10.1177/0272431685052009; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; Guskiewicz KM, 2004, NEUROSURGERY, V55, P891, DOI 10.1227/01.NEU.0000143800.49798.19; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Heilbronner RL, 2010, CLIN NEUROPSYCHOL, V24, P1267, DOI 10.1080/13854046.2010.526785; Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT), 2012, IMM POSTCONC ASS TES; Isbell E, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00696; Iverson GL, 2004, ARCH CLIN NEUROPSYCH, V19, P961; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2001, ARCH CLIN NEUROPSYCH, V16, P183, DOI 10.1016/S0887-6177(00)00060-3; Iverson GL, 2015, BRAIN INJURY, V29, P263, DOI 10.3109/02699052.2014.965214; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kelly JP, 1997, NEUROLOGY, V48, P581; Kirschen MP, 2014, NEUROLOGY, V83, P352, DOI 10.1212/WNL.0000000000000613; Kumar Sharma V., 2014, STUDY EFFECT AGE GEN; Lichtenstein JD, 2014, AM J SPORT MED, V42, P479, DOI 10.1177/0363546513509225; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Maerlender A, 2015, DEV NEUROPSYCHOL, V40, P69, DOI 10.1080/87565641.2015.1014089; Maril A, 2010, NEUROLOGY, V75, P2110, DOI 10.1212/WNL.0b013e318201526e; McClure DJ, 2014, AM J SPORT MED, V42, P472, DOI 10.1177/0363546513510389; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; MCSWEENY AJ, 1993, CLIN NEUROPSYCHOL, V7, P460; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Moser RS, 2015, APPL NEUROPSYCH-CHIL, V4, P41, DOI 10.1080/21622965.2013.791825; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Nakayama Y, 2014, AM J SPORT MED, V42, P2000, DOI 10.1177/0363546514535901; Parsons TD, 2009, INT J NEUROSCI, V119, P492, DOI 10.1080/00207450802330876; Register-Mihalik JK, 2012, J ATHL TRAINING, V47, P297, DOI 10.4085/1062-6050-47.3.13; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2014, ARCH CLIN NEUROPSYCH, V29, P625, DOI 10.1093/arclin/acu041; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schneider W, 2002, J EDUC PSYCHOL, V94, P751, DOI 10.1037//0022-0663.94.4.751; SLICK D, 2006, COMPENDIUM NEUROPSYC, P1; Sullivan Gail M, 2012, J Grad Med Educ, V4, P279, DOI 10.4300/JGME-D-12-00156.1; Tsushima WT, 2016, ARCH CLIN NEUROPSYCH, V31, P105, DOI 10.1093/arclin/acv066; Vas S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059809; Vaughan CG, 2014, AM J SPORT MED, V42, P1716, DOI 10.1177/0363546514531732	63	12	12	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	DEC	2016	31	8					904	914		10.1093/arclin/acw055			11	Psychology, Clinical; Psychology	Psychology	EJ1MM	WOS:000392974600007	27538440	Bronze			2021-06-18	
J	Carron, SF; Yan, EB; Alwis, DS; Rajan, R				Carron, Simone F.; Yan, Edwin B.; Alwis, Dasuni S.; Rajan, Ramesh			Differential Susceptibility of Cortical and Subcortical Inhibitory Neurons and Astrocytes in the Long Term Following Diffuse Traumatic Brain Injury	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						diffuse TBI; inhibition; E:I ratio; cortex; hippocampus; interneurons; astrocytes. parvalbumin (RRID:AB_10000343); calbindin (RRID:AB_10000347); calretinin (RRID:AB_10000320); neuropeptide Y (RRID:AB_1566510); somatostatin (RRID:AB_2255365); GFAP (RRID:AB_11212369)	CALRETININ-CONTAINING INTERNEURONS; CALCIUM-BINDING PROTEINS; EXCITATORY AMINO-ACIDS; DENTATE GRANULE CELLS; GABAERGIC INTERNEURONS; SYNAPTIC CONNECTIONS; PARVALBUMIN IMMUNOREACTIVITY; EPILEPTIFORM ACTIVITY; RECEPTOR SUBUNITS; PYRAMIDAL NEURONS	Long-term diffuse traumatic brain injury (dTBI) causes neuronal hyperexcitation in supragranular layers in sensory cortex, likely through reduced inhibition. Other forms of TBI affect inhibitory interneurons in subcortical areas but it is unknown if this occurs in cortex, or in any brain area in dTBI. We investigated dTBI effects on inhibitory neurons and astrocytes in somatosensory and motor cortex, and hippocampus, 8 weeks post-TBI. Brains were labeled with antibodies against calbindin (CB), parvalbumin (PV), calretinin (CR) and neuropeptide Y (NPY), and somatostatin (SOM) and glial fibrillary acidic protein (GFAP), a marker for astrogliosis during neurodegeneration. Despite persistent behavioral deficits in rotarod performance up to the time of brain extraction (TBI = 73.13 +/- 5.23% mean +/- SEM, Sham = 92.29 +/- 5.56%, P < 0.01), motor cortex showed only a significant increase, in NPY neurons in supragranular layers (mean cells/mm(2) +/- SEM, Sham = 16 +/- 0.971, TBI = 25 +/- 1.51, P = 0.001). In somatosensory cortex, only CR+ neurons showed changes, being decreased in supragranular (TBI = 19 +/- 1.18, Sham = 25 +/- 1.10, P < 0.01) and increased in infragranular (TBI = 28 +/- 1.35, Sham = 24 +/- 1.07, P < 0.05) layers. Heterogeneous changes were seen in hippocampal staining: CB+ decreased in dentate gyrus (TBI = 2 +/- 0.382, Sham = 4 +/- 0.383, P < 0.01), PV+ increased in CA1 (TBI = 39 +/- 1.26, Sham = 33 +/- 1.69, P < 0.05) and CA2/3 (TBI = 26 +/- 2.10, Sham = 20 +/- 1.49, P < 0.05), and CR+ decreased in CA1 (TBI = 10 +/- 1.02, Sham = 14 +/- 1.14, P < 0.05). Astrogliosis significantly increased in corpus callosum (TBI = 6.7 +/- 0.69, Sham = 2.5 +/- 0.38; P = 0.007). While dTBI effects on inhibitory neurons appear region- and type-specific, a common feature in all cases of decrease was that changes occurred in dendrite targeting interneurons involved in neuronal integration. (C) 2016 Wiley Periodicals, Inc.	[Carron, Simone F.; Yan, Edwin B.; Alwis, Dasuni S.; Rajan, Ramesh] Monash Univ, Dept Physiol, Melbourne, Vic 3800, Australia	Rajan, R (corresponding author), Monash Univ, Dept Physiol, Melbourne, Vic 3800, Australia.	Ramesh.Rajan@monash.edu	rajan, ramesh/L-4842-2019	Rajan, Ramesh/0000-0001-9862-0520	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [APP 1029311]	Grant sponsor: National Health and Medical Research Council of Australia; Grant number: APP 1029311.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Alwis DS, 2013, CLIN EXP PHARMACOL P, V40, P473, DOI 10.1111/1440-1681.12100; Alwis DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052169; Andre V, 2001, HIPPOCAMPUS, V11, P452, DOI 10.1002/hipo.1060.abs; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Avoli M, 2011, PROG NEUROBIOL, V95, P104, DOI 10.1016/j.pneurobio.2011.07.003; Axelson HW, 2013, RESTOR NEUROL NEUROS, V31, P73, DOI 10.3233/RNN-2012-120242; BAIMBRIDGE KG, 1982, BRAIN RES, V245, P223, DOI 10.1016/0006-8993(82)90804-6; Barinka F, 2010, PHYSIOL RES, V59, P665, DOI 10.33549/physiolres.931930; Bashir S, 2012, RESTOR NEUROL NEUROS, V30, P277, DOI 10.3233/RNN-2012-110207; Beers DR, 2001, J NEUROCHEM, V79, P499, DOI 10.1046/j.1471-4159.2001.00582.x; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Buritica E, 2009, J NEUROTRAUM, V26, P2145, DOI 10.1089/neu.2009.0894; Cabungcal JH, 2013, P NATL ACAD SCI USA, V110, P9130, DOI 10.1073/pnas.1300454110; Cantu D, 2015, CEREB CORTEX, V25, P2306, DOI 10.1093/cercor/bhu041; Carter DS, 2008, EPILEPSY RES, V79, P213, DOI 10.1016/j.eplepsyres.2008.02.006; CHARD PS, 1993, J PHYSIOL-LONDON, V472, P341, DOI 10.1113/jphysiol.1993.sp019950; Clarke LE, 2013, NAT REV NEUROSCI, V14, P311, DOI 10.1038/nrn3484; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; Collin T, 2005, J NEUROSCI, V25, P96, DOI 10.1523/JNEUROSCI.3748-04.2005; CONDE F, 1994, J COMP NEUROL, V341, P95, DOI 10.1002/cne.903410109; Cossart R, 2001, NAT NEUROSCI, V4, P52; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P263, DOI 10.1016/0166-2236(87)90170-6; Croce N, 2012, ACS CHEM NEUROSCI, V3, P312, DOI 10.1021/cn200127e; DeFelipe J, 1997, J CHEM NEUROANAT, V14, P1, DOI 10.1016/S0891-0618(97)10013-8; Deidda G, 2015, NAT NEUROSCI, V18, P87, DOI 10.1038/nn.3890; Dekkers J, 2004, NEUROSCIENCE, V123, P459, DOI 10.1016/j.neuroscience.2003.07.013; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; delRio MR, 1997, J NEUROSCI, V17, P5143; DEMEULEMEESTER H, 1989, NEUROSCI LETT, V99, P6, DOI 10.1016/0304-3940(89)90255-3; Ding MC, 2011, J NEUROSCI, V31, P14085, DOI 10.1523/JNEUROSCI.3572-11.2011; Drexel M, 2015, NEUROPHARMACOLOGY, V88, P122, DOI 10.1016/j.neuropharm.2014.08.023; Edmonds B, 2000, NAT NEUROSCI, V3, P786, DOI 10.1038/77687; Ellender TJ, 2014, J NEUROSCI, V34, P15208, DOI 10.1523/JNEUROSCI.1747-14.2014; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fan YF, 2007, J CEREBR BLOOD F MET, V27, P719, DOI 10.1038/sj.jcbfm.9600373; Finnanger TG, 2013, BRAIN INJURY, V27, P1606, DOI 10.3109/02699052.2013.831127; Freund TF, 2007, NEURON, V56, P33, DOI 10.1016/j.neuron.2007.09.012; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Galvin J, 2009, AM J OCCUP THER, V63, P701, DOI 10.5014/ajot.63.6.701; GARCIASEGURA LM, 1984, BRAIN RES, V296, P75, DOI 10.1016/0006-8993(84)90512-2; Gentet LJ, 2012, NAT NEUROSCI, V15, P607, DOI 10.1038/nn.3051; Gonchar Y, 1999, CEREB CORTEX, V9, P683, DOI 10.1093/cercor/9.7.683; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; GULYAS AI, 1992, NEUROSCIENCE, V48, P1, DOI 10.1016/0306-4522(92)90334-X; Gulyas AI, 1996, HIPPOCAMPUS, V6, P525, DOI 10.1002/(SICI)1098-1063(1996)6:5<525::AID-HIPO5>3.0.CO;2-H; GULYAS AI, 1991, J COMP NEUROL, V312, P371, DOI 10.1002/cne.903120305; Gulyas AI, 1996, J NEUROSCI, V16, P3397; Gupta A, 2000, SCIENCE, V287, P273, DOI 10.1126/science.287.5451.273; Gupta RK, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00059; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HALL S, 1991, J NEUROSURG, V75, P378, DOI 10.3171/jns.1991.75.3.0378; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; HENDRY SHC, 1984, P NATL ACAD SCI-BIOL, V81, P6526, DOI 10.1073/pnas.81.20.6526; Heo DH, 2012, J NEURO-ONCOL, V108, P45, DOI 10.1007/s11060-012-0801-z; Hestrin S, 1996, J NEUROSCI, V16, P5290; Hooks BM, 2013, J NEUROSCI, V33, P748, DOI 10.1523/JNEUROSCI.4338-12.2013; Hunt RF, 2011, J NEUROSCI, V31, P6880, DOI 10.1523/JNEUROSCI.0032-11.2011; Huusko N, 2014, NEUROSCIENCE, V267, P30, DOI 10.1016/j.neuroscience.2014.02.026; Huusko N, 2015, BRAIN STRUCT FUNCT, V220, P153, DOI 10.1007/s00429-013-0644-1; Isaacs KR, 2000, EXP NEUROL, V163, P311, DOI 10.1006/exnr.2000.7347; Isaacson JS, 2011, NEURON, V72, P231, DOI 10.1016/j.neuron.2011.09.027; JACOBOWITZ DM, 1991, J COMP NEUROL, V304, P198, DOI 10.1002/cne.903040205; Jin XM, 2011, CEREB CORTEX, V21, P1094, DOI 10.1093/cercor/bhq181; Johnstone VPA, 2014, J NEUROTRAUM, V31, P1881, DOI 10.1089/neu.2014.3343; Johnstone VPA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063454; Kang SS, 2012, J NEUROSCI, V32, P9277, DOI 10.1523/JNEUROSCI.1746-12.2012; Kawaguchi Y, 1997, CEREB CORTEX, V7, P476, DOI 10.1093/cercor/7.6.476; Kawaguchi Y, 2002, J NEUROCYTOL, V31, P277, DOI 10.1023/A:1024126110356; KOSAKA T, 1987, BRAIN RES, V419, P119, DOI 10.1016/0006-8993(87)90575-0; KUBOTA Y, 1994, BRAIN RES, V649, P159, DOI 10.1016/0006-8993(94)91060-X; KUBOTA Y, 1994, JPN J PHYSIOL, V44, pS145; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Kuruba R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024493; Lamy Michael, 2011, Ann Adv Automot Med, V55, P125; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Li QJ, 2014, NEURAL REGEN RES, V9, P959, DOI 10.4103/1673-5374.133140; Li Y, 2011, J NEUROTRAUM, V28, P1767, DOI 10.1089/neu.2010.1687; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lifshitz J, 2012, BRAIN STRUCT FUNCT, V217, P49, DOI 10.1007/s00429-011-0323-z; Long LL, 2011, INT J NEUROSCI, V121, P69, DOI 10.3109/00207454.2010.530007; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MAGLOCZKY Z, 1993, NEUROSCIENCE, V56, P317, DOI 10.1016/0306-4522(93)90334-C; Magloczky Z, 1997, NEUROSCIENCE, V76, P377, DOI 10.1016/S0306-4522(96)00440-X; Marin O, 2012, NAT REV NEUROSCI, V13, P107, DOI 10.1038/nrn3155; Markram H, 2004, NAT REV NEUROSCI, V5, P793, DOI 10.1038/nrn1519; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marx M, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00167; MCINTOSH TK, 1992, J CEREBR BLOOD F MET, V12, P697, DOI 10.1038/jcbfm.1992.95; Meaney DF, 2001, J NEUROSURG, V95, P1108; Meyer HS, 2011, P NATL ACAD SCI USA, V108, P16807, DOI 10.1073/pnas.1113648108; Miles R, 1996, NEURON, V16, P815, DOI 10.1016/S0896-6273(00)80101-4; Monti JM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00041; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Noe F, 2008, BRAIN, V131, P1506, DOI 10.1093/brain/awn079; Ouh In-Ohk, 2013, Lab Anim Res, V29, P156, DOI 10.5625/lar.2013.29.3.156; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pavlov I, 2011, NEUROSCIENCE, V194, P208, DOI 10.1016/j.neuroscience.2011.07.074; Paxinos G., 1999, CHEMOARCHITECTONIC A; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; Perrenoud Q, 2012, FRONT NEURAL CIRCUIT, V6, DOI 10.3389/fncir.2012.00036; Pirone A, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00099; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Raymond MJ, 1996, NEUROREHABILITATION, V6, P229, DOI 10.3233/NRE-1996-6309; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; RIBAK CE, 1990, J COMP NEUROL, V300, P449, DOI 10.1002/cne.903000402; RIBAK CE, 1985, BRAIN RES, V326, P251, DOI 10.1016/0006-8993(85)90034-4; Ritt JT, 2008, NEURON, V57, P599, DOI 10.1016/j.neuron.2007.12.024; ROGERS JH, 1992, BRAIN RES, V587, P147, DOI 10.1016/0006-8993(92)91439-L; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rusnak M, 2013, NAT REV NEUROL, V9, P186, DOI 10.1038/nrneurol.2013.38; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Savin C, 2009, J R SOC INTERFACE, V6, P655, DOI 10.1098/rsif.2008.0387; Schiffmann SN, 1999, P NATL ACAD SCI USA, V96, P5257, DOI 10.1073/pnas.96.9.5257; Schubert D, 2007, BRAIN STRUCT FUNCT, V212, P107, DOI 10.1007/s00429-007-0147-z; Schwaller B, 1997, J BIOL CHEM, V272, P29663, DOI 10.1074/jbc.272.47.29663; Schwaller B, 1999, AM J PHYSIOL-CELL PH, V276, pC395; Schwaller Beat, 2002, Cerebellum, V1, P241, DOI 10.1080/147342202320883551; Schwaller B, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a004051; Semchenko V V, 2006, Neurosci Behav Physiol, V36, P613, DOI 10.1007/s11055-006-0065-1; Sherman A, 2006, EXPLORING THALAMUS I; Somogyi P, 2005, J PHYSIOL-LONDON, V562, P9, DOI 10.1113/jphysiol.2004.078915; Somogyi P, 1998, BRAIN RES REV, V26, P113, DOI 10.1016/S0165-0173(97)00061-1; Spruston N, 2008, NAT REV NEUROSCI, V9, P206, DOI 10.1038/nrn2286; Tanaka YH, 2011, FRONT NEURAL CIRCUIT, V5, DOI 10.3389/fncir.2011.00012; Toth K, 2010, BRAIN, V133, P2763, DOI 10.1093/brain/awq149; Toth Z, 1997, J NEUROSCI, V17, P8106; TRAUB RD, 1994, J PHYSIOL-LONDON, V481, P79, DOI 10.1113/jphysiol.1994.sp020420; Urban Z, 2002, ACTA BIOL HUNG, V53, P205, DOI 10.1556/ABiol.53.2002.1-2.19; Van den Bosch L, 2002, EXP NEUROL, V174, P150, DOI 10.1006/exnr.2001.7858; VANBREDERODE JFM, 1991, NEUROSCIENCE, V44, P157, DOI 10.1016/0306-4522(91)90258-P; vandenPol AN, 1996, J NEUROSCI, V16, P4283; Vezzani A, 2004, NEUROPEPTIDES, V38, P245, DOI 10.1016/j.npep.2004.05.004; VOLTERRA A, 1994, J NEUROSCI, V14, P2924; WELKER C, 1974, J COMP NEUROL, V158, P437, DOI 10.1002/cne.901580405; Yan EB, 2013, NEUROSCIENCE, V248, P17, DOI 10.1016/j.neuroscience.2013.05.045; Yang L, 2010, J NEUROTRAUM, V27, P1541, DOI 10.1089/neu.2009.1244; Yenari MA, 2001, STROKE, V32, P1028, DOI 10.1161/01.STR.32.4.1028; Zhang BL, 2011, CHINESE MED J-PEKING, V124, P740, DOI 10.3760/cma.j.issn.0366-6999.2011.05.020; Zhu YH, 2004, J NEUROSCI, V24, P5101, DOI 10.1523/JNEUROSCI.0544-04.2004	146	12	12	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	DEC 1	2016	524	17					3530	3560		10.1002/cne.24014			31	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	DZ4BU	WOS:000385803400004	27072754				2021-06-18	
J	DellaValle, B; Brix, GS; Brock, B; Geji, M; Rungby, J; Larsen, A				DellaValle, Brian; Brix, Gitte S.; Brock, Birgitte; Geji, Michael; Rungby, Jorgen; Larsen, Agnete			Oral Administration of Sitagliptin Activates CREB and Is Neuroprotective in Murine Model of Brain Trauma	FRONTIERS IN PHARMACOLOGY			English	Article						GLP-1; traumatic brain injury; TBI; sitagliptin; liraglutide; CREB; GIP; DPP-IV	GLUCAGON-LIKE PEPTIDE-1; MITOCHONDRIAL-FUNCTION; RECEPTOR AGONISTS; INHIBITOR; GLP-1; LIRAGLUTIDE; METABOLISM; ISCHEMIA; INJURY; TYPE-2	Introduction: Traumatic brain injury is a major cause of mortality and morbidity. We have previously shown that the injectable glucagon-like peptide-1 (GLP-1) analog, liraglutide, significantly improved the outcome in mice after severe traumatic brain injury (TBI). In this study we are interested in the effects of oral treatment of a different class of GLP-1 based therapy, dipeptidyl peptidase IV (DPP-IV) inhibition on mice after TBI. DPP-IV inhibitors reduce the degradation of endogenous GLP-1 and extend circulation of this protective peptide in the bloodstream. This class has yet to be investigated as a potential therapy for TBI. Methods: Mice were administrated once-daily 50 mg/kg of sitagliptin in a Nutellatm (R) ball or Nutella (R) alone throughout the study, beginning 2 days before severe trauma was induced with a stereotactic cryo-lesion. At 2 days post trauma, lesion size was determined. Brains were isolated for immunoblotting for assessment of selected biomarkers for pathology and protection. Results: Sitagliptin treatment reduced lesion size at day 2 post-injury by similar to 28% (p < 0.05). Calpain-driven necrotic tone was reduced similar to 2-fold in sitagliptin treated brains (p < 0.001) and activation of the protective cAMP-response element binding protein (CREB) system was significantly more pronounced (similar to 1.5-fold, p 9 0.05). The CREB-regulated, mitochondrial antioxidant protein manganese superoxide dismutase (MnSOD) was increased in sitagliptin-treated mice (p < 0.05). Conversely, apoptotic tone (alpha-spectrin fragmentation, Bcl-2 levels) and the neuroinflammatory markers IL-6, and lba-1 were not affected by treatment. Conclusions: This study shows, for the first time, that DPP-IV inhibition ameliorates both anatomical and biochemical consequences of TBI and activates CREB in the brain. Moreover, this work supports previous studies suggesting that the effect of GLP-1 analogs in models of brain damage relates to GLP-1 receptor stimulation in a dose-dependent manner.	[DellaValle, Brian; Brix, Gitte S.; Brock, Birgitte; Geji, Michael; Rungby, Jorgen; Larsen, Agnete] Aarhus Univ, Dept Biomed Pharmacol, Aarhus, Denmark; [DellaValle, Brian] Copenhagen Univ Hosp, Dept Clin Microbiol, Ctr Med Parasitol, Copenhagen, Denmark; [Brock, Birgitte; Geji, Michael] Aarhus Univ Hosp, Dept Clin Biochem, Aarhus, Denmark; [Rungby, Jorgen] Bispebjerg Hosp, Dept Endocrinol, Copenhagen, Denmark	DellaValle, B (corresponding author), Aarhus Univ, Dept Biomed Pharmacol, Aarhus, Denmark.; DellaValle, B (corresponding author), Copenhagen Univ Hosp, Dept Clin Microbiol, Ctr Med Parasitol, Copenhagen, Denmark.	briandellavalle@gmail.com	Rungby, Jorgen/AAQ-4332-2021	Larsen, Agnete/0000-0001-8765-8443; DellaValle, Brian/0000-0002-1427-8244	A. P. Moller foundation; Novo Nordisk FoundationNovo Nordisk Foundation; Novo NordiskNovo Nordisk	The authors thank A. P. Moller foundation for the financial support. The supplemental material is new, original work on tissue from a study conducted when BD was partly funded by Novo Nordisk Foundation, and Novo Nordisk.	Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Bao Y, 2015, CELL PHYSIOL BIOCHEM, V36, P2366, DOI 10.1159/000430199; Candeias EM, 2015, WORLD J DIABETES, V6, P807, DOI 10.4239/wjd.v6.i6.807; Chowen JA, 1999, NEUROPEPTIDES, V33, P212, DOI 10.1054/npep.1999.0757; De Marinis E, 2013, J NEUROENDOCRINOL, V25, P260, DOI 10.1111/jne.12007; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; DellaValle B, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1486-0; DellaValle B, 2014, ANN CLIN TRANSL NEUR, V1, P721, DOI 10.1002/acn3.99; Dellavalle B, 2010, GLIA, V58, P1220, DOI 10.1002/glia.21002; Drucker DJ, 2006, LANCET, V368, P1696, DOI 10.1016/S0140-6736(06)69705-5; Drucker DJ, 2006, CELL METAB, V3, P153, DOI 10.1016/j.cmet.2006.01.004; El-Sahar AE, 2015, LIFE SCI, V126, P81, DOI 10.1016/j.lfs.2015.01.030; Galeotti T, 2005, BIOMED PHARMACOTHER, V59, P197, DOI 10.1016/j.biopha.2005.03.002; Gault VA, 2015, DIABETES OBES METAB, V17, P403, DOI 10.1111/dom.12432; Gejl M, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00108; Gejl M, 2014, BASIC CLIN PHARMACOL, V115, P162, DOI 10.1111/bcpt.12240; Gejl M, 2012, J CEREBR BLOOD F MET, V32, P2146, DOI 10.1038/jcbfm.2012.118; Glushakov AV, 2016, FRONT MOL BIOSCI, V3, DOI 10.3389/fmolb.2016.00034; Hakon J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120074; Holst JJ, 2008, TRENDS MOL MED, V14, P161, DOI 10.1016/j.molmed.2008.01.003; Ihara M, 2015, AM J PHYSIOL-HEART C, V308, pH1287, DOI 10.1152/ajpheart.00835.2014; Jhala US, 2003, GENE DEV, V17, P1575, DOI 10.1101/gad.1097103; Kimura R, 2009, NEUROSCIENCE, V162, P1212, DOI 10.1016/j.neuroscience.2009.05.025; Knudsen LB, 2016, J DIABETES INVEST, V7, P56, DOI 10.1111/jdi.12463; Lerche S, 2008, DIABETES, V57, P325, DOI 10.2337/db07-1162; Ma M, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933-015-0218-z; Pintana H, 2013, J ENDOCRINOL, V218, P1, DOI 10.1530/JOE-12-0521; Pipatpiboon N, 2013, EUR J NEUROSCI, V37, P839, DOI 10.1111/ejn.12088; Rachmany L, 2013, AGE, V35, P1621, DOI 10.1007/s11357-012-9464-0; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Samikannu B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082639; Sharma MK, 2014, J NEUROCHEM, V128, P459, DOI 10.1111/jnc.12469; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Tsai TH, 2015, J HYPERTENS, V33, P1001, DOI 10.1097/HJH.0000000000000529; Yang D, 2013, BRAIN RES, V1517, P104, DOI 10.1016/j.brainres.2013.04.015; Ye YM, 2010, AM J PHYSIOL-HEART C, V298, pH1454, DOI 10.1152/ajpheart.00867.2009; Yu YW, 2016, J NEUROTRAUM, V33, P2044, DOI 10.1089/neu.2015.4229	37	12	12	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-9812			FRONT PHARMACOL	Front. Pharmacol.	DEC 1	2016	7								450	10.3389/fphar.2016.00450			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	ED7UB	WOS:000389075800001	27990119	DOAJ Gold, Green Published			2021-06-18	
J	Fernandez-Cabello, S; Valls-Pedret, C; Schurz, M; Vidal-Pineiro, D; Sala-Llonch, R; Bargallo, N; Ros, E; Bartres-Faz, D				Fernandez-Cabello, Sara; Valls-Pedret, Cinta; Schurz, Matthias; Vidal-Pineiro, Didac; Sala-Llonch, Roser; Bargallo, Nuria; Ros, Emilio; Bartres-Faz, David			White matter hyperintensities and cognitive reserve during a working memory task: a functional magnetic resonance imaging study in cognitively normal older adults	NEUROBIOLOGY OF AGING			English	Article						Aging; Cognitive reserve; fMRI; Compensation; Neural efficiency; White matter hyperintensities; Education; Working memory	TRAUMATIC BRAIN-INJURY; SMALL VESSEL DISEASE; BASAL GANGLIA; PREFRONTAL CORTEX; AGE-DIFFERENCES; LESIONS; COMPENSATION; PERFORMANCE; EDUCATION; MAINTENANCE	Cognitive reserve (CR) models posit that lifestyle factors such as education modulate the relationship between brain damage and cognition. However, the functional correlates of CR in healthy aging are still under investigation. White matter hyperintensities (WMHs) are a common age-associated finding that impacts cognition. In this study, we used functional magnetic resonance imaging to characterize the patterns of brain activation during a working memory task in older participants with high and low levels of education (as a proxy of CR) and high and low WMH volumes. Ninety older volunteers (aged 63-76 years) and 16 young adults (aged 21-27) completed the study. We found that older adults with higher education had better working memory performance than their less educated peers. Among the highly educated participants, those with WMH over-recruited areas engaged by young volunteers and showed activation in additional cortical and subcortical structures. However, those with low WMH differed little with respect to their younger counterparts. Our findings demonstrate that the functional mechanisms subtending the effects of education, as a proxy of CR, are modulated according to the WMH burden. (C) 2016 Elsevier Inc. All rights reserved.	[Fernandez-Cabello, Sara; Schurz, Matthias] Salzburg Univ, Dept Psychol, Salzburg, Austria; [Fernandez-Cabello, Sara; Schurz, Matthias] Salzburg Univ, Ctr Cognit Neurosci, Salzburg, Austria; [Fernandez-Cabello, Sara; Bartres-Faz, David] Univ Barcelona, Fac Med & Hlth Sci, Dept Med, Barcelona, Spain; [Valls-Pedret, Cinta; Ros, Emilio] Hosp Clin Barcelona, Endocrinol & Nutr Serv, Lipid Clin, Barcelona, Spain; [Valls-Pedret, Cinta; Bargallo, Nuria; Ros, Emilio; Bartres-Faz, David] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain; [Valls-Pedret, Cinta; Ros, Emilio] Inst Salud Carlos III, Ciber Fisiopatol Obesidad & Nutr CIBEROBN, Barcelona, Spain; [Vidal-Pineiro, Didac; Sala-Llonch, Roser] Univ Oslo, Dept Psychol, Res Grp Lifespan Changes Brain & Cognit, Oslo, Norway; [Bargallo, Nuria] Hosp Clin Barcelona, Ctr Diagnost Imatge, Serv Radiol, Neuroradiol Sect, Barcelona, Spain	Bartres-Faz, D (corresponding author), Univ Barcelona, Fac Med, Dept Psychiat & Clin Psychobiol, C Casanova 143, E-08036 Barcelona, Spain.	dbartres@ub.edu	Sala-Llonch, Roser/E-7882-2012; cohorts, Doctoral College Imaging the Mind - all/I-4689-2018; Bartres-Faz, David/C-8997-2011; Vidal-Pineiro, Didac/O-5012-2016; Bargallo, Nuria/G-6854-2016	Sala-Llonch, Roser/0000-0003-3576-0475; Bartres-Faz, David/0000-0001-6020-4118; Vidal-Pineiro, Didac/0000-0001-9997-9156; Fernandez Rodriguez-Cabello, Sara/0000-0002-2589-8449; Bargallo, Nuria/0000-0001-6284-5402; Valls-Pedret, Cinta/0000-0001-5005-0653; Ros, Emilio/0000-0002-2573-1294	Doctoral College "Imaging the Mind" of the Austrian Science Foundation [FWF-W1233]; Spanish Ministry of Economy and Competitiveness (MINECO) [PSI2015-64227-R]; Walnuts and Healthy Aging (WAHA) - California Walnut Commission, Sacramento, California, USA [NCT01634841]	Sara Fernandez-Cabello was supported by the Doctoral College "Imaging the Mind" (FWF-W1233) of the Austrian Science Foundation (FWF-W1233). Partially funded by a Spanish Ministry of Economy and Competitiveness (MINECO) grant to David Bartres-Faz (PSI2015-64227-R) and the Walnuts and Healthy Aging (WAHA) study (http://www.clinicaltrials.gov NCT01634841) funded by the California Walnut Commission, Sacramento, California, USA.	Anguera JA, 2013, NATURE, V501, P97, DOI 10.1038/nature12486; Bartres-Faz D, 2011, BRAIN TOPOGR, V24, P340, DOI 10.1007/s10548-011-0195-9; Bartres-Faz D, 2009, BIOL PSYCHOL, V80, P256, DOI 10.1016/j.biopsycho.2008.10.005; Barulli D, 2013, TRENDS COGN SCI, V17, P502, DOI 10.1016/j.tics.2013.08.012; Bennett DA, 2014, ACTA NEUROPATHOL, V127, P137, DOI 10.1007/s00401-013-1226-2; Birdsill AC, 2014, NEUROBIOL AGING, V35, P769, DOI 10.1016/j.neurobiolaging.2013.10.072; Brickman AM, 2011, NEUROBIOL AGING, V32, P1588, DOI 10.1016/j.neurobiolaging.2009.10.013; Cabeza R, 2002, PSYCHOL AGING, V17, P85, DOI 10.1037//0882-7974.17.1.85; Cappell KA, 2010, CORTEX, V46, P462, DOI 10.1016/j.cortex.2009.11.009; Carlson MC, 2008, GERONTOLOGIST, V48, P793, DOI 10.1093/geront/48.6.793; Chan AS, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00050; D'Esposito M, 2015, ANNU REV PSYCHOL, V66, P115, DOI 10.1146/annurev-psych-010814-015031; Dahlin E, 2008, SCIENCE, V320, P1510, DOI 10.1126/science.1155466; Dahlin E, 2008, PSYCHOL AGING, V23, P720, DOI 10.1037/a0014296; de Leeuw FE, 2001, J NEUROL NEUROSUR PS, V70, P9, DOI 10.1136/jnnp.70.1.9; Debette S, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3666; Dufouil C, 2003, NEUROLOGY, V60, P831, DOI 10.1212/01.WNL.0000049456.33231.96; Frank MJ, 2001, COGN AFFECT BEHAV NE, V1, P137, DOI 10.3758/CABN.1.2.137; Griebe M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103359; Guo LH, 2013, ALZHEIMERS DEMENT, V9, P580, DOI 10.1016/j.jalz.2012.10.002; Holtzer R, 2009, BRAIN RES, V1249, P148, DOI 10.1016/j.brainres.2008.10.009; Kim MA, 2010, SCHIZOPHR RES, V117, P42, DOI 10.1016/j.schres.2009.12.014; Kruschke JK, 2013, J EXP PSYCHOL GEN, V142, P573, DOI 10.1037/a0029146; Kruschke JK, 2011, PERSPECT PSYCHOL SCI, V6, P299, DOI 10.1177/1745691611406925; Lockhart SN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122445; Lovden M, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.02.013; McDonough IM, 2015, RESTOR NEUROL NEUROS, V33, P865, DOI 10.3233/RNN-150533; Mcnab F, 2008, NAT NEUROSCI, V11, P103, DOI 10.1038/nn2024; Moore AB, 2013, BRAIN LANG, V125, P316, DOI 10.1016/j.bandl.2012.05.003; Nagel IE, 2011, J COGNITIVE NEUROSCI, V23, P2030, DOI 10.1162/jocn.2010.21560; Nagel IE, 2009, P NATL ACAD SCI USA, V106, P22552, DOI 10.1073/pnas.0908238106; Nebes RD, 2006, AGING NEUROPSYCHOL C, V13, P326, DOI 10.1080/138255890969294; Nordahl CW, 2006, J COGNITIVE NEUROSCI, V18, P418, DOI 10.1162/089892906775990552; Nunnari D, 2014, NEUROL SCI, V35, P1513, DOI 10.1007/s10072-014-1897-z; Nyberg L, 2012, TRENDS COGN SCI, V16, P292, DOI 10.1016/j.tics.2012.04.005; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Park DC, 2014, PSYCHOL SCI, V25, P103, DOI 10.1177/0956797613499592; Perez-Nievas BG, 2013, BRAIN, V136, P2510, DOI 10.1093/brain/awt171; Poldrack RA, 2015, DEV COGN NEUROS-NETH, V11, P12, DOI 10.1016/j.dcn.2014.06.001; Prins ND, 2015, NAT REV NEUROL, V11, DOI 10.1038/nrneurol.2015.10; Reuter-Lorenz PA, 2008, CURR DIR PSYCHOL SCI, V17, P177, DOI 10.1111/j.1467-8721.2008.00570.x; Rouder JN, 2009, PSYCHON B REV, V16, P225, DOI 10.3758/PBR.16.2.225; Sala-Llonch R, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00663; Sala-Llonch R, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00152; Schmidt P, 2012, NEUROIMAGE, V59, P3774, DOI 10.1016/j.neuroimage.2011.11.032; SEEMAN P, 1987, J PHARMACOL METHOD, V17, P347, DOI 10.1016/0160-5402(87)90048-9; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Steffener J, 2012, BBA-MOL BASIS DIS, V1822, P467, DOI 10.1016/j.bbadis.2011.09.012; Steffener J, 2011, BRAIN IMAGING BEHAV, V5, P212, DOI 10.1007/s11682-011-9125-4; Stern Y, 2005, CEREB CORTEX, V15, P394, DOI 10.1093/cercor/bhh142; Stern Y, 2003, J CLIN EXP NEUROPSYC, V25, P589, DOI 10.1076/jcen.25.5.589.14571; Stern Y, 2009, NEUROPSYCHOLOGIA, V47, P2015, DOI 10.1016/j.neuropsychologia.2009.03.004; Sumowski JF, 2013, ARCH PHYS MED REHAB, V94, P2562, DOI 10.1016/j.apmr.2013.07.023; Sumowski JF, 2013, NEUROLOGY, V80, P2186, DOI 10.1212/WNL.0b013e318296e98b; Sumowski JF, 2009, J CLIN EXP NEUROPSYC, V31, P913, DOI 10.1080/13803390902740643; Tekin S, 2002, J PSYCHOSOM RES, V53, P647, DOI 10.1016/S0022-3999(02)00428-2; Tuladhar AM, 2015, NEUROIMAGE-CLIN, V7, P518, DOI 10.1016/j.nicl.2015.02.003; Tullberg M, 2004, NEUROLOGY, V63, P246, DOI 10.1212/01.WNL.0000130530.55104.B5; Valenzuela MJ, 2006, PSYCHOL MED, V36, P441, DOI 10.1017/S0033291705006264; Van Essen DC, 2001, J AM MED INFORM ASSN, V8, P443, DOI 10.1136/jamia.2001.0080443; Vemuri P, 2015, BRAIN, V138, P761, DOI 10.1093/brain/awu393; Venkatraman VK, 2010, NEUROIMAGE, V49, P3436, DOI 10.1016/j.neuroimage.2009.11.019; Vidal-Pineiro D, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00256; Wardlaw JM, 2013, LANCET NEUROL, V12, P483, DOI 10.1016/S1474-4422(13)70060-7	65	12	12	0	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	DEC	2016	48						23	33		10.1016/j.neurobiolaging.2016.08.008			11	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	EA9PW	WOS:000386977300003	27636672				2021-06-18	
J	Jones, TM; Dear, BF; Hush, JM; Titov, N; Dean, CM				Jones, Taryn M.; Dear, Blake F.; Hush, Julia M.; Titov, Nickolai; Dean, Catherine M.			myMoves Program: Feasibility and Acceptability Study of a Remotely Delivered Self-Management Program for Increasing Physical Activity Among Adults With Acquired Brain Injury Living in the Community	PHYSICAL THERAPY			English	Article							RANDOMIZED CONTROLLED-TRIAL; TRANSDIAGNOSTIC INTERNET TREATMENT; ALL-CAUSE MORTALITY; PSYCHOLOGICAL DISTRESS; PAIN-COURSE; STROKE; POPULATION; ACCELEROMETRY; PREVENTION; DEPRESSION	Background. People living with acquired brain injury (ABI) are more likely to be physically inactive and highly sedentary and, therefore, to have increased risks of morbidity and mortality. However, many adults with ABI experience barriers to participation in effective physical activity interventions. Remotely delivered self-management programs focused on teaching patients how to improve and maintain their physical activity levels have the potential to improve the overall health of adults with AB!. Objective. The study objective was to evaluate remotely delivered self-management program aimed adults who dwell in the community and have ABI. the acceptability and feasibility of a at increasing physical activity among adults who dwell in the community and have ABI. Design. A single-group design involving comparison of baseline measures with those taken immediately after intervention and at a 3-month follow-up was used in this study. Methods. The myMoves Program comprises 6 modules delivered over 8 weeks via email. Participants were provided with regular weekly contact with an experienced physical therapist via email and telephone. The primary outcomes were the feasibility (participation, attrition, clinician time, accessibility, and adverse events) and acceptability (satisfaction, worthiness of time, and recommendation) of the myMoves Program. The secondary outcomes were objective physical activity data collected from accelerometers, physical activity selkfficacy, psychological distress, and participation. Results. Twenty-four participants commenced the program (20 with stroke, 4 with traumatic injury), and outcomes were collected for 23 and 22 participants immediately after the program' and at a 3-month follow-up, respectively. The program required very little clinician contact time, with an average of 32.8 minutes (SD=22.8) per participant during the 8-week program. Acceptability was very high, with more than 95% of participants being either very satisfied or satisfied with the myMoves Program and stating that it was worth their time. All participants stated that they would recommend the program to others with A131. Limitations. The results were obtained from a small sample; hence, the results may not be generalizable to a larger ABI population. Conclusions. A remotely delivered self-management program aimed at increasing physical activity is feasible and acceptable for adults with ABI. Further large-scale efficacy trials are warranted.	[Jones, Taryn M.; Hush, Julia M.; Dean, Catherine M.] Macquarie Univ, Dept Hlth Profess, Fac Med & Hlth Sci, Ground Floor,75 Talavera Rd, Sydney, NSW 2109, Australia; [Jones, Taryn M.; Dear, Blake F.; Hush, Julia M.; Titov, Nickolai; Dean, Catherine M.] Macquarie Univ, Ctr Phys Hlth, Sydney, NSW, Australia; [Dear, Blake F.; Titov, Nickolai] Macquarie Univ, Dept Psychol, ECentreClin, Sydney, NSW, Australia	Jones, TM (corresponding author), Macquarie Univ, Dept Hlth Profess, Fac Med & Hlth Sci, Ground Floor,75 Talavera Rd, Sydney, NSW 2109, Australia.; Jones, TM (corresponding author), Macquarie Univ, Ctr Phys Hlth, Sydney, NSW, Australia.	taryn.jones@mq.edu.au		Dear, Blake/0000-0001-9324-3092; Dean, Catherine/0000-0001-7502-1138; Hush, Julia/0000-0002-2805-0339; Titov, Nickolai/0000-0002-7268-729X	Macquarie University; National Health and Medical Research Council Australian Public Health FellowshipNational Health and Medical Research Council of Australia	Dr Jones was supported by a Macquarie University Research Excellence Scholarship. Dr Dear was supported by a National Health and Medical Research Council Australian Public Health Fellowship.	Andrews G, 2001, AUST NZ J PUBL HEAL, V25, P494, DOI 10.1111/j.1467-842X.2001.tb00310.x; Australian Bureau of Statistics, 2011, AUSTR STAND GEOGR CL; Australian Bureau of Statistics, 2012, US KESSL PSYCH DISTR; Bartholomew LK, 2011, PLANNING HLTH PROMOT, P704; Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205; Cadilhac DA, 2011, STROKE, V42, P1673, DOI 10.1161/STROKEAHA.110.601997; Choi L, 2011, MED SCI SPORT EXER, V43, P357, DOI 10.1249/MSS.0b013e3181ed61a3; Craig P, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1655; Damush TM, 2011, TRANSL BEHAV MED, V1, P561, DOI 10.1007/s13142-011-0070-y; de Silva D, 2011, EVIDENCE HELPING PEO, P44; Dear BF, 2015, PAIN, V156, P1920, DOI 10.1097/j.pain.0000000000000251; Dear BF, 2013, PAIN, V154, P942, DOI 10.1016/j.pain.2013.03.005; Dear BF, 2011, BEHAV RES THER, V49, P830, DOI 10.1016/j.brat.2011.09.007; Department of Health Australian Government, 2006, ASGC REM AR; Driver S, 2008, ADAPT PHYS ACT Q, V25, P289, DOI 10.1123/apaq.25.4.289; Driver S, 2012, DISABIL HEALTH J, V5, P117, DOI 10.1016/j.dhjo.2011.11.002; English C, 2016, TOP STROKE REHABIL, V23, P62, DOI 10.1179/1945511915Y.0000000009; Foster C, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010395.pub2; Gordon NF, 2004, STROKE, V35, P1230, DOI 10.1161/01.STR.0000127303.19261.19; Grant PM, 2008, J AGING PHYS ACTIV, V16, P201, DOI 10.1123/japa.16.2.201; Gulsvik AK, 2012, INT J EPIDEMIOL, V41, P521, DOI 10.1093/ije/dyr205; Haskell WL, 2009, PREV MED, V49, P280, DOI 10.1016/j.ypmed.2009.05.002; Hornnes N, 2010, INT J STROKE, V5, P157, DOI 10.1111/j.1747-4949.2010.00424.x; IBM Corp, 2013, IBM SPSS STAT MAC CO; Jones F, 2011, DISABIL REHABIL, V33, P797, DOI 10.3109/09638288.2010.511415; Jones TM, 2016, PHYS THER, V96, P1994, DOI 10.2522/ptj.20150387; Jones TM, 2016, DISABIL HEALTH J, V9, P54, DOI 10.1016/j.dhjo.2015.08.004; Jones TM, 2015, SYST REV-LONDON, V4, DOI 10.1186/s13643-015-0039-x; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; Kim H, 2013, J KOREAN ACAD NURS, V43, P331, DOI 10.4040/jkan.2013.43.3.331; Kozey-Keadle S, 2011, MED SCI SPORT EXER, V43, P1561, DOI 10.1249/MSS.0b013e31820ce174; Kroll T, 2007, INT J BEHAV NUTR PHY, V4, DOI 10.1186/1479-5868-4-34; Kunkel D, 2015, DISABIL REHABIL, V37, P304, DOI 10.3109/09638288.2014.918190; LANSKA DJ, 1993, DEMENTIA, V4, P117, DOI 10.1159/000107307; Lee IM, 2001, MED SCI SPORT EXER, V33, pS459, DOI 10.1097/00005768-200106001-00016; Lorig K, 2013, HEALTH EDUC BEHAV, V40, P67, DOI 10.1177/1090198112436969; Lorig KR, 2008, ARTHRIT RHEUM-ARTHR, V59, P1009, DOI 10.1002/art.23817; Macera CA, 2001, MED SCI SPORT EXER, V33, pS635, DOI 10.1097/00005768-200106001-00032; Matthews CE, 2002, MED SCI SPORT EXER, V34, P1376, DOI 10.1097/00005768-200208000-00021; Miller A, 2011, DISABIL REHABIL, V33, P1968, DOI 10.3109/09638288.2011.553707; Nicholson S, 2013, INT J STROKE, V8, P357, DOI 10.1111/j.1747-4949.2012.00880.x; O'Rance L., 2007, BULLETIN, V55, P28; PAL Technologies Ltd, ACTIVPAL SPEC BROCH; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; Rand D, 2009, STROKE, V40, P163, DOI 10.1161/STROKEAHA.108.523621; Ridgers ND, 2011, EUR J SPORT SCI, V11, P205, DOI 10.1080/17461391.2010.501116; Santos-Lozano A, 2013, INT J SPORTS MED, V34, P975, DOI 10.1055/s-0033-1337945; Sasaki JE, 2011, J SCI MED SPORT, V14, P411, DOI 10.1016/j.jsams.2011.04.003; Sit JWH, 2007, J CLIN NURS, V16, P272, DOI 10.1111/j.1365-2702.2005.01522.x; Taraldsen K, 2011, PHYS THER, V91, P277, DOI 10.2522/ptj.20100159; Titov N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089591; Titov N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062873; Titov N, 2011, BEHAV RES THER, V49, P441, DOI 10.1016/j.brat.2011.03.007; Tweedy SM, 2005, MED SCI SPORT EXER, V37, P1474, DOI 10.1249/01.mss.0000177584.43330.ae; Warburton DER, 2006, CAN MED ASSOC J, V174, P801, DOI 10.1503/cmaj.051351; Wootton BM, 2011, J ANXIETY DISORD, V25, P1102, DOI 10.1016/j.janxdis.2011.07.009; World Health Organization, 2010, 9789241599979 WHO	57	12	12	0	8	AMER PHYSICAL THERAPY ASSOC	ALEXANDRIA	1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA	0031-9023	1538-6724		PHYS THER	Phys. Ther.	DEC	2016	96	12					1982	1993		10.2522/ptj.20160028			12	Orthopedics; Rehabilitation	Orthopedics; Rehabilitation	EE2FM	WOS:000389399100013	27515944	Bronze			2021-06-18	
J	Kim, N; Krasner, A; Kosinski, C; Wininger, M; Qadri, M; Kappus, Z; Danish, S; Craelius, W				Kim, Nam; Krasner, Alex; Kosinski, Colin; Wininger, Michael; Qadri, Maria; Kappus, Zachary; Danish, Shabbar; Craelius, William			Trending autoregulatory indices during treatment for traumatic brain injury	JOURNAL OF CLINICAL MONITORING AND COMPUTING			English	Article						Traumatic brain injury; TBI; Autoregulation; Informatics SICU; ABP; ICP; PRx	CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; WAVE-FORM; CEREBROVASCULAR AUTOREGULATION; ONLINE ANALYSIS; INTENSIVE-CARE; CHALLENGES; SOFTWARE	Our goal is to use automatic data monitoring for reliable prediction of episodes of intracranial hypertension in patients with traumatic brain injury. Here we test the validity of our method on retrospective patient data. We developed the Continuous Hemodynamic Autoregulatory Monitor (CHARM), that siphons and stores signals from existing monitors in the surgical intensive care unit (SICU), efficiently compresses them, and standardizes the search for statistical relationships between any proposed index and adverse events. CHARM uses an automated event detector to reliably locate episodes of elevated intracranial pressure (ICP), while eliminating artifacts within retrospective patient data. A graphical user interface allowed data scanning, selection of criteria for events, and calculating indices. The pressure reactivity index (PRx), defined as the least square linear regression slope of intracranial pressure versus arterial BP, was calculated for a single case that spanned 259 h. CHARM collected continuous records of ABP, ICP, ECG, SpO2, and ventilation from 29 patients with TBI over an 18-month period. Analysis of a single patient showed that PRx data distribution in the single hours immediately prior to all 16 intracranial hypertensive events, significantly differed from that in the 243 h that did not precede such events (p < 0.0001). The PRx index, however, lacked sufficient resolution as a real-time predictor of IH in this patient. CHARM streamlines the search for reliable predictors of intracranial hypertension. We report statistical evidence supporting the predictive potential of the pressure reactivity index.	[Kim, Nam; Krasner, Alex; Kosinski, Colin; Qadri, Maria; Kappus, Zachary; Craelius, William] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA; [Wininger, Michael] Univ Hartford, Rehabil Sci, Hartford, CT 06117 USA; [Danish, Shabbar] Rutgers RWJ Med Sch, Rutgers Canc Inst, Dept Neurosurg, New Brunswick, NJ 08901 USA	Craelius, W (corresponding author), Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA.	craelius@rci.rutgers.edu	Wininger, Michael/K-8985-2012	Wininger, Michael/0000-0002-7871-3292; Qadri, Maria/0000-0002-4921-6924	New Jersey Commission on Traumatic Brain Injury	Drs. Nicki Newby and Min-ge Xie for statistical help, and Dr. Lloyd Marks for clinical guidance. The New Jersey Commission on Traumatic Brain Injury for support.	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Aries MJH, 2012, NEUROCRIT CARE, V17, P67, DOI 10.1007/s12028-012-9687-z; Bellazzi R, 2014, Yearb Med Inform, V9, P8, DOI 10.15265/IY-2014-0024; Bellazzi R, 2011, WIRES DATA MIN KNOWL, V1, P416, DOI 10.1002/widm.23; Budohoski KP, 2012, NEUROCRIT CARE, V17, P211, DOI 10.1007/s12028-011-9572-1; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Burykin A, 2011, COMPUT METH PROG BIO, V103, P151, DOI 10.1016/j.cmpb.2010.10.004; Cohen MJ, 2010, CRIT CARE, V14, DOI 10.1186/cc8864; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Dias C, 2014, J NEUROTRAUM, V31, P1872, DOI 10.1089/neu.2014.3376; Feigin V, 2009, NEUROEPIDEMIOLOGY, V33, P296, DOI 10.1159/000252942; Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276; Guendling K, 2006, ACTA NEUROCHIR SUPPL, V96, P108; Guiza F, 2013, CRIT CARE MED, V41, P554, DOI 10.1097/CCM.0b013e3182742d0a; Halpern NA, 2014, CHEST, V145, P903, DOI 10.1378/chest.13-0005; Hu X, 2006, IEEE T BIO-MED ENG, V53, P195, DOI 10.1109/TBME.2005.862546; Hu X, 2010, IEEE T BIO-MED ENG, V57, P1070, DOI 10.1109/TBME.2009.2037607; Johnson U, 2011, NEUROSURGERY, V68, P714, DOI 10.1227/NEU.0b013e3182077313; Kirkman MA, 2014, BRIT J ANAESTH, V112, P35, DOI 10.1093/bja/aet418; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS3, DOI 10.1097/PCC.0b013e31823f437e; Lazaridis C, 2014, J NEUROSURG, V120, P892; Le Roux P, 2014, INTENS CARE MED, V40, P1189, DOI 10.1007/s00134-014-3369-6; Le Roux P, 2014, CURR OPIN CRIT CARE, V20, P141, DOI 10.1097/MCC.0000000000000078; Lee JK, 2009, STROKE, V40, P1820, DOI 10.1161/STROKEAHA.108.536094; Liu J, 2010, PHYSIOL MEAS, V31, P1291, DOI 10.1088/0967-3334/31/10/001; Lu CW, 2012, BRAIN, V135, P2399, DOI 10.1093/brain/aws155; Marmarelis Vz, 2012, Open Biomed Eng J, V6, P42, DOI 10.2174/1874230001206010042; Miller RA, 2009, ADV HEALTH SCI EDUC, V14, P89, DOI 10.1007/s10459-009-9186-y; Narayanan N, 2008, J APPL PHYSIOL, V105, P152, DOI 10.1152/japplphysiol.00988.2007; Neamatullah I, 2008, BMC MED INFORM DECIS, V8, DOI 10.1186/1472-6947-8-32; Rogatsky GG, 2005, BRAIN RES, V1047, P131, DOI 10.1016/j.brainres.2005.02.049; Saeed M, 2011, CRIT CARE MED, V39, P952, DOI 10.1097/CCM.0b013e31820a92c6; Sanchez-Porras R, 2012, ACTA NEUROCHIR, V154, P1575, DOI 10.1007/s00701-012-1423-0; Sivaganesan A, 2014, NEUROCRIT CARE, V20, P132, DOI 10.1007/s12028-013-9872-8; Smielewski P, 2005, ACT NEUR S, V95, P43; Stein PK, 2013, CRIT CARE MED, V41, P666, DOI 10.1097/CCM.0b013e318270e6f0; Stylianides N, 2011, IEEE T INF TECHNOL B, V15, P26, DOI 10.1109/TITB.2010.2091141; Von Mises R., 1964, MATH THEORY PROBABIL; Wakeland W, 2009, CRIT CARE MED, V37, P1079, DOI 10.1097/CCM.0b013e31819b629d; WARNER HR, 1961, JAMA-J AM MED ASSOC, V177, P177, DOI 10.1001/jama.1961.03040290005002; Zweifel C, 2014, MED ENG PHYS, V36, P638, DOI 10.1016/j.medengphy.2014.03.002; Zweifel C, 2010, STROKE, V41, P1963, DOI 10.1161/STROKEAHA.109.577320	42	12	12	1	6	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1387-1307	1573-2614		J CLIN MONIT COMPUT	J. Clin. Monitor. Comp.	DEC	2016	30	6					821	831		10.1007/s10877-015-9779-3			11	Anesthesiology	Anesthesiology	EB2YV	WOS:000387229400010	26446002				2021-06-18	
J	Sener, S; Van Hecke, W; Feyen, BFE; Van der Steen, G; Pullens, P; Van de Hauwe, L; Menovsky, T; Parizel, PM; Jorens, PG; Maas, AIR				Sener, Suleyman; Van Hecke, Wim; Feyen, Bart F. E.; Van der Steen, Gregory; Pullens, Pim; Van de Hauwe, Luc; Menovsky, Tomas; Parizel, Paul M.; Jorens, Philippe G.; Maas, Andrew I. R.			Diffusion Tensor Imaging: A Possible Biomarker in Severe Traumatic Brain Injury and Aneurysmal Subarachnoid Hemorrhage?	NEUROSURGERY			English	Article						Aneurysmal subarachnoid hemorrhage; Biomarker; Diffusion tensor imaging; Outcome; Prognosis; Traumatic brain injury	WHITE-MATTER INJURY; OUTCOME PREDICTION; AXONAL INJURY; VASOSPASM; MODERATE; ABNORMALITIES; INTEGRITY	BACKGROUND: A great need exists in traumatic brain injury (TBI) and aneurysmal subarachnoid hemorrhage (aSAH) for objective biomarkers to better characterize the disease process and to serve as early endpoints in clinical studies. Diffusion tensor imaging (DTI) has shown promise in TBI, but much less is known about aSAH. OBJECTIVE: To explore the use of whole-brain DTI tractography in TBI and aSAH as a biomarker and early endpoint. METHODS: Of a cohort of 43 patients with severe TBI (n = 20) or aSAH (n = 23) enrolled in a prospective, observational, multimodality monitoring study, DTI data were acquired at approximately day 12 (median, 12 days; interquartile range, 12-14 days) after injury in 22 patients (TBI, n = 12; aSAH, n = 10). Whole-brain DTI tractography was performed, and the following parameters quantified: average fractional anisotropy, mean diffusivity, tract length, and the total number of reconstructed fiber tracts. These were compared between TBI and aSAH patients and correlated with mortality and functional outcome assessed at 6 months by the Glasgow Outcome Scale Extended. RESULTS: Significant differences were found for fractional anisotropy values (P = .01), total number of tracts (P = .03), and average tract length (P = .002) between survivors and nonsurvivors. A sensitivity analysis showed consistency of results between the TBI and aSAH patients for the various DTI measures. CONCLUSION: DTI parameters, assessed at approximately day 12 after injury, correlated with mortality at 6 months in patients with severe TBI or aSAH. Similar patterns were found for both TBI and aSAH patients. This supports a potential role of DTI as early endpoint for clinical studies and a predictor of late mortality.	[Sener, Suleyman; Feyen, Bart F. E.; Van der Steen, Gregory; Menovsky, Tomas; Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium; [Van Hecke, Wim; Pullens, Pim; Van de Hauwe, Luc; Parizel, Paul M.] Univ Antwerp Hosp, Dept Radiol, Edegem, Belgium; [Jorens, Philippe G.] Univ Antwerp Hosp, Dept Intens Care, Edegem, Belgium; [Sener, Suleyman; Feyen, Bart F. E.; Menovsky, Tomas; Parizel, Paul M.; Jorens, Philippe G.; Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium	Sener, S (corresponding author), Univ Antwerp Hosp, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium.	suleyman.sener@uza.be		Pullens, Pim/0000-0003-2014-7248; Parizel, Paul M./0000-0002-0221-2854	IWT-the Flemish Agency for Innovation by Science and Technology	Andrew I. R. Maas received financial support from IWT-the Flemish Agency for Innovation by Science and Technology. The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.	Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Bullock AR, 2006, NEUROSURGERY, V58, pVI; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Frontera JA, 2009, STROKE, V40, P1963, DOI 10.1161/STROKEAHA.108.544700; Galanaud D, 2012, ANESTHESIOLOGY, V117, P1300, DOI 10.1097/ALN.0b013e3182755558; Hadeishi H, 2002, NEUROSURGERY, V50, P741, DOI 10.1097/00006123-200204000-00010; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jang SH, 2014, MBJ OPEN, V4; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Kochunov P, 2007, NEUROIMAGE, V35, P478, DOI 10.1016/j.neuroimage.2006.12.021; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2014, MYMENSINGH MED J, V4, P223; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Kummer TT, 2015, BRAIN, V138, P2608, DOI 10.1093/brain/awv180; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Macdonald RL, 2010, NEUROCRIT CARE, V13, P416, DOI 10.1007/s12028-010-9433-3; Mukherjee P, 2006, NEUROIMAG CLIN N AM, V16, P19, DOI 10.1016/j.nic.2005.11.004; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Parmentier-Decrucq E, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-10; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Rordorf G, 1999, STROKE, V30, P599, DOI 10.1161/01.STR.30.3.599; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schweizer TA, 2012, CLIN NEUROL NEUROSUR, V114, P798, DOI 10.1016/j.clineuro.2011.12.045; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shinohara Y, 2011, J STROKE CEREBROVASC, V20, pS100, DOI 10.1016/j.jstrokecerebrovasdis.2011.05.011; Soares JM, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00031; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wouters A, 2015, J CEREBR BLOOD F MET, V35, P1681, DOI 10.1038/jcbfm.2015.108; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yeo SS, 2012, STROKE, V43, P2239, DOI 10.1161/STROKEAHA.112.661116; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171	41	12	12	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2016	79	6					786	793		10.1227/NEU.0000000000001325			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EI6OH	WOS:000392614700018	27352277				2021-06-18	
J	van der Horn, HJ; Liemburg, EJ; Scheenen, ME; de Koning, ME; Spikman, JM; van der Naalt, J				van der Horn, Harm J.; Liemburg, Edith J.; Scheenen, Myrthe E.; de Koning, Myrthe E.; Spikman, Jacoba M.; van der Naalt, Joukje			Post-concussive complaints after mild traumatic brain injury associated with altered brain networks during working memory performance	BRAIN IMAGING AND BEHAVIOR			English	Article						Mild traumatic brain injury; Post-concussive complaints; Brain networks; Working memory	RESTING-STATE FMRI; HEAD-INJURY; DEPRESSION SCALE; HOSPITAL ANXIETY; DEFAULT NETWORK; FUNCTIONAL MRI; CONNECTIVITY; SYMPTOMS; METAANALYSIS; VALIDATION	The aim was to investigate brain network function during working memory (WM) task performance in patients with uncomplicated mild traumatic brain injury (mTBI) in the sub-acute phase post-injury. We were particularly interested in differences between patients with (PCC-present) and without post-concussive complaints (PCC-absent). Fifty-two patients and twenty healthy controls (HCs) (matched for age, sex, education and handedness) were included. Two patient groups were created based on reported post-concussive complaints at two weeks post-injury: PCC-present (n = 32) and PCC-absent (n = 20). Functional MRI scans were made at approximately four weeks post-injury. Participants performed an n-back task consisting of three conditions (0-, 1- and 2-back) with increasing difficulty. General linear model analysis was performed to investigate activation patterns. Independent component analysis was used to identify brain networks. The frontal executive network (FEN), frontoparietal network (FPN) and default mode network (DMN) were selected for further analyses based on their highest task-relatedness. Task accuracy and reaction times were similar for patients with mTBI and HCs. During high WM load (2-vs.0-back contrast), mTBI patients exhibited lower activation within the medial prefrontal cortex compared to HCs. No differences were found between PCC-present and PCC-absent patients. Regarding network function, PCC-absent patients showed stronger deactivation of the DMN compared to PCC-present patients and HCs, especially during difficult task conditions. Furthermore, functional connectivity between the DMN and FEN was lower in PCC-absent patients compared to PCC-present patients. Interestingly, network function did not differ between PCC-present patients and HCs, suggesting that non-injury related factors may underlie post-concussive complaints after mTBI.	[van der Horn, Harm J.; de Koning, Myrthe E.; van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9700 RB Groningen, Netherlands; [Liemburg, Edith J.] Univ Groningen, Univ Med Ctr Groningen, BCN NeuroImaging Ctr, Groningen, Netherlands; [Liemburg, Edith J.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurosci, Groningen, Netherlands; [Scheenen, Myrthe E.; Spikman, Jacoba M.] Univ Groningen, Univ Med Ctr Groningen, Dept Neuropsychol, Groningen, Netherlands	van der Horn, HJ (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9700 RB Groningen, Netherlands.	h.j.van.der.horn@umcg.nl		Spikman, Jacoba/0000-0002-6477-0763	de Hersenstichting Nederland [Ps2012-06]	This study was supported by de Hersenstichting Nederland (grant no. Ps2012-06). The authors thank R.J. Renken, PhD, for his assistance in the development of Matlab scrips for statistical analyses and the lively discussions about fMRI analyses, and J.C. de Groot, MD, PhD, for the assessment of structural imaging.	Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bennett CM, 2009, SOC COGN AFFECT NEUR, V4, P417, DOI 10.1093/scan/nsp053; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bocran C, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0354-0; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Borich M, 2015, J NEUROTRAUM, V32, P265, DOI 10.1089/neu.2013.3269; Bryer EJ, 2013, J INT NEUROPSYCH SOC, V19, P751, DOI 10.1017/S1355617713000490; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Chen CJ, 2012, RADIOLOGY, V264, P844, DOI 10.1148/radiol.12112154; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Cole DM, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00008; Cole MW, 2014, NEUROSCIENTIST, V20, P652, DOI 10.1177/1073858414525995; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Euston DR, 2012, NEURON, V76, P1057, DOI 10.1016/j.neuron.2012.12.002; Himberg J, 2004, NEUROIMAGE, V22, P1214, DOI 10.1016/j.neuroimage.2004.03.027; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Jafri MJ, 2008, NEUROIMAGE, V39, P1666, DOI 10.1016/j.neuroimage.2007.11.001; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Koshino H, 2014, SCI REP-UK, V4, DOI 10.1038/srep05954; Kullmann S, 2013, CEREB CORTEX, V23, P1247, DOI 10.1093/cercor/bhs124; Lange RT, 2015, ARCH CLIN NEUROPSYCH, V30, P7, DOI 10.1093/arclin/acu060; LI Y, 2006, SAMPLE DEPENDENCE CO; Lieberman MD, 2009, SOC COGN AFFECT NEUR, V4, P423, DOI 10.1093/scan/nsp052; Mayer AR, 2015, J NEUROTRAUM, V32, P1046, DOI 10.1089/neu.2014.3542; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Messina I, 2015, FRONT PSYCHOL, V6, DOI [10.3389/fpsyg.2015.00956, 10.3389/fpsyg.2015.01909]; Michopoulos Ioannis, 2008, Ann Gen Psychiatry, V7, P4, DOI 10.1186/1744-859X-7-4; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Servaas MN, 2014, HUM BRAIN MAPP, V35, P4303, DOI 10.1002/hbm.22476; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Sonuga-Barke EJS, 2007, NEUROSCI BIOBEHAV R, V31, P977, DOI 10.1016/j.neubiorev.2007.02.005; Sours C, 2015, BRAIN IMAGING BEHAV, V9, P190, DOI 10.1007/s11682-014-9295-y; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Spinhoven P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; van der Horn HJ, 2016, J NEUROTRAUM, V33, P1, DOI 10.1089/neu.2015.3905; Veer IM, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00041; Vos PE, 2012, EUR J NEUROL, V19, P191, DOI 10.1111/j.1468-1331.2011.03581.x; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Whitfield-Gabrieli S, 2012, ANNU REV CLIN PSYCHO, V8, P49, DOI 10.1146/annurev-clinpsy-032511-143049; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Wylie GR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126110; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	59	12	12	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	DEC	2016	10	4					1243	1253		10.1007/s11682-015-9489-y			11	Neuroimaging	Neurosciences & Neurology	EF0LC	WOS:000390015900029	26667033	Green Published, Other Gold			2021-06-18	
J	Muehlschlegel, S; Ayturk, D; Ahlawat, A; Izzy, S; Scalea, TM; Stein, DM; Emhoff, T; Sheth, KN				Muehlschlegel, Susanne; Ayturk, Didem; Ahlawat, Aditi; Izzy, Saef; Scalea, Thomas M.; Stein, Deborah M.; Emhoff, Timothy; Sheth, Kevin N.			Predicting survival after acute civilian penetrating brain injuries The SPIN score	NEUROLOGY			English	Article							GLASGOW COMA SCALE; GUNSHOT WOUNDS; HEAD; PROGESTERONE; IMPACT; WITHDRAWAL; TRAUMA; CARE	Objective: To identify predictors associated with survival in civilian penetrating traumatic brain injury (pTBI) utilizing a contemporary, large, diverse 2-center cohort, and to develop a parsimonious survival prediction score for pTBI. Methods: Our cohort comprised 413 pTBI patients retrospectively identified from the local trauma registries at 2 US level 1 trauma centers, of which one was predominantly urban and the other predominantly rural. Predictors of in-hospital and 6-month survival identified in univariate and multivariable logistic regression were used to develop the simple Surviving Penetrating Injury to the Brain (SPIN) score. Results: The mean age was 33 6 16 years and patients were predominantly male (87%). Survival at hospital discharge as well as 6 months post pTBI was 42.4%. Higher motor Glasgow Coma Scale subscore, pupillary reactivity, lack of self-inflicted injury, transfer from other hospital, female sex, lower Injury Severity Score, and lower international normalized ratio were independently associated with survival (all p < 0.001; model area under the curve 0.962). Important radiologic factors associated with survival were also identified but their addition to the full multivariable would have resulted in model overfitting without much gain in the area under the curve. Conclusions: The SPIN score, a logistic regression-based clinical risk stratification scale estimating survival after pTBI, was developed in this large, diverse 2-center cohort. While this preliminary clinical survival prediction tool does not include radiologic factors, it may support clinical decision-making after civilian pTBI if external validation confirms the probability estimates.	[Muehlschlegel, Susanne; Ahlawat, Aditi] Univ Massachusetts, Sch Med, Dept Neurol Neurocrit Care, Worcester, MA 01655 USA; [Muehlschlegel, Susanne; Ayturk, Didem; Emhoff, Timothy] Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01655 USA; [Muehlschlegel, Susanne] Univ Massachusetts, Sch Med, Dept Anesthesia Crit Care, Worcester, MA 01655 USA; [Izzy, Saef] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Div Neurocrit Care, Boston, MA USA; Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA; [Scalea, Thomas M.; Stein, Deborah M.] Univ Maryland, R Adams Cowley Shock Trauma Ctr, Dept Surg, Baltimore, MD USA; [Sheth, Kevin N.] Yale Univ, Dept Neurol Neurocrit Care & Emergency Neurol, New Haven, CT USA; [Sheth, Kevin N.] Yale Univ, Dept Neurosurg, New Haven, CT USA	Muehlschlegel, S (corresponding author), Univ Massachusetts, Sch Med, Dept Neurol Neurocrit Care, Worcester, MA 01655 USA.; Muehlschlegel, S (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01655 USA.; Muehlschlegel, S (corresponding author), Univ Massachusetts, Sch Med, Dept Anesthesia Crit Care, Worcester, MA 01655 USA.	susanne.muehlschlegel@umassmemorial.org		Stein, Deborah/0000-0003-3683-3963	NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR001863] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23 HD080971] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD080971] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001863] Funding Source: NIH RePORTER		Aarabi B, 2014, J NEUROSURG, V120, P1138, DOI 10.3171/2014.1.JNS131869; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; [Anonymous], 2001, J TRAUMA, V51, pS12; [Anonymous], 2001, J Trauma, V51, pS3; [Anonymous], 2001, J TRAUMA, V51, pS16; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Carney N, 2016, NEUROSURGERY; CDC, FAST STATS INJ; Deutsch ER, 2013, BRAIN RES, V1530, P82, DOI 10.1016/j.brainres.2013.07.014; Giffords G., 2011, GABBY STORY COURAGE; Gressot LV, 2014, J NEUROSURG, V121, P645, DOI 10.3171/2014.5.JNS131872; Hemphill JC, 2009, EMERG MED CLIN N AM, V27, P27, DOI 10.1016/j.emc.2008.08.009; Izzy S, 2013, NEUROCRIT CARE, V19, P347, DOI 10.1007/s12028-013-9925-z; Joseph B, 2014, J AM COLL SURGEONS, V218, P58, DOI 10.1016/j.jamcollsurg.2013.08.018; Lin David J, 2012, Surg Neurol Int, V3, P98, DOI 10.4103/2152-7806.100187; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Martins RS, 2003, SURG NEUROL, V60, P98, DOI 10.1016/S0090-3019(03)00302-1; McNatt SA, 2005, NEUROSURGERY, V57, pE191, DOI [10.1227/01.NEU.0000175727.76530.94, 10.1227/01.NEU.0000164174.07281.F9]; Meredith W, 1998, J TRAUMA, V44, P839, DOI 10.1097/00005373-199805000-00016; Muehlschlegel S, 2013, NEUROCRIT CARE, V18, P318, DOI 10.1007/s12028-013-9817-2; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sheth KN, 2013, NEUROCRIT CARE, V18, P26, DOI 10.1007/s12028-012-9780-3; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Wohltmann CD, 2001, AM J SURG, V181, P297, DOI 10.1016/S0002-9610(01)00582-7; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304	28	12	12	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	NOV 22	2016	87	21					2244	2253		10.1212/WNL.0000000000003355			10	Clinical Neurology	Neurosciences & Neurology	EI1LE	WOS:000392238000017	27784772	Green Published			2021-06-18	
J	Walsh, DV; Capo-Aponte, JE; Beltran, T; Cole, WR; Ballard, A; Dumayas, JY				Walsh, David V.; Capo-Aponte, Jose E.; Beltran, Thomas; Cole, Wesley R.; Ballard, Ashley; Dumayas, Joseph Y.			Assessment of the King-Devick (R) (KD) test for screening acute mTBI/concussion in warfighters	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						King-Devick (KD) test; Saccades; Mild traumatic brain injury (mTBI); Military	TRAUMATIC BRAIN-INJURY; KING-DEVICK TEST; RUGBY LEAGUE; RECOVERY; REHABILITATION; CONCUSSION; SYMPTOMS; IRAQ	Objectives: The Department of Defense reported that 344,030 cases of traumatic brain injury (TBI) were clinically confirmed from 2000 to 2015, with mild TBI (mTBI) accounting for 82.3% of all cases. Unfortunately, warfighters with TBI are often identified only when moderate or severe head injuries have occurred, leaving more subtle mTBI cases undiagnosed. This study aims to identify and validate an eye-movement visual test for screening acute mTBI. Methods: Two-hundred active duty military personnel were recruited to perform the King-Devick (R) (KD) test. Subjects were equally divided into two groups: those with diagnosed acute mTBI (<= 72 h) and age-matched controls. The KD test was administered twice for test-retest reliability, and the outcome measure was total cumulative time to complete each test. Results: The mTBI group had approximately 36% mean slower performance time with significant differences between the groups (p < 0.001) in both tests. There were significant differences between the two KD test administrations in each group, however, a strong correlation was observed between each test administration. Conclusions: Significant differences in KD test performance were seen between the acute mTBI and control groups. The results suggest the KD test can be utilized for screening acute mTBI. A validated and rapidly administered mTBI screening test with results that are easily interpreted by providers is essential in making return-to duty decisions in the injured warfighter. Published by Elsevier B.V.	[Walsh, David V.] US Army Aeromed Res Lab, Vis Protect & Performance Div, 6901 Farrel Rd, Ft Rucker, AL 36362 USA; [Capo-Aponte, Jose E.; Ballard, Ashley; Dumayas, Joseph Y.] Womack Army Med Ctr, Dept Optometry, 2817 Reilly Rd,Stop A, Ft Bragg, NC 28310 USA; [Beltran, Thomas] Womack Army Med Ctr, Dept Clin Invest, 2817 Reilly Rd,Stop A, Ft Bragg, NC 28310 USA; [Cole, Wesley R.] Womack Army Med Ctr, Def & Vet Brain Injury Ctr, Dept Brain Injury Med, 2817 Reilly Rd,Stop A, Ft Bragg, NC 28310 USA	Walsh, DV (corresponding author), US Army Aeromed Res Lab, Vis Protect & Performance Div, 6901 Farrel Rd, Ft Rucker, AL 36362 USA.	david.v.walsh.mil@mail.mil			Military Operational Medicine Research Program of the U.S. Army Medical Research and Materiel Command (USAMRMC); Department of Defense Army Rapid Innovation Fund Research Program of the Office of the Congressionally Directed Medical Research Programs (CDMRP) [W81XWH-14-C-0048]; Geneva Foundation; Defense and Veterans Brain Injury Center (DVBIC)US Department of Veterans Affairs	This research was funded by the Military Operational Medicine Research Program of the U.S. Army Medical Research and Materiel Command (USAMRMC), and FY13 Department of Defense Army Rapid Innovation Fund Research Program of the Office of the Congressionally Directed Medical Research Programs (CDMRP) under contract No. W81XWH-14-C-0048. This research was conducted with support from the Geneva Foundation as well as the Defense and Veterans Brain Injury Center (DVBIC) and staffing support from General Dynamics Information Technology.	[Anonymous], 2004, VISUAL NEUROSCIENCES, V1, P507; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Capo-Aponte JE, 2012, J REHABIL RES DEV, V49, P1377, DOI 10.1682/JRRD.2011.07.0128; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Defense and Veterans Brain Injury Center (DVBIC), DOD WORLDW NUMB TBI; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iaccarino Mary Alexis, 2015, Handb Clin Neurol, V127, P411, DOI 10.1016/B978-0-444-52892-6.00026-X; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; King D, 2015, J NEUROL SCI, V357, P75, DOI 10.1016/j.jns.2015.06.069; King D, 2015, J NEUROL SCI, V351, P58, DOI 10.1016/j.jns.2015.02.035; Lin TP, 2014, PARKINSONISM RELAT D, V20, P226, DOI 10.1016/j.parkreldis.2013.10.009; Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638; Moster S, 2014, J NEUROL SCI, V343, P105, DOI 10.1016/j.jns.2014.05.047; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Schmid Kara E, 2012, Front Neurol, V3, P90, DOI 10.3389/fneur.2012.00090; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Silverberg ND, 2014, BRAIN INJURY, V28, P1590, DOI 10.3109/02699052.2014.943287; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Vandiver VL, 2003, J HEAD TRAUMA REHAB, V18, P457, DOI 10.1097/00001199-200309000-00007; VanEssen DC, 1997, J NEUROSCI, V17, P7079	25	12	12	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	NOV 15	2016	370						305	309		10.1016/j.jns.2016.09.014			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EB8FV	WOS:000387627800063	27646958	Other Gold			2021-06-18	
J	Dienel, GA; Rothman, DL; Nordstrom, CH				Dienel, Gerald A.; Rothman, Douglas L.; Nordstroem, Carl-Henrik			Microdialysate concentration changes do not provide sufficient information to evaluate metabolic effects of lactate supplementation in brain-injured patients	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Cerebral microdialysis; brain metabolism; glucose; lactate supplementation; traumatic brain injury	CEREBRAL GLUCOSE-UTILIZATION; HUMAN VISUAL-CORTEX; INTRACRANIAL HYPERTENSIVE EPISODES; POSITRON-EMISSION-TOMOGRAPHY; NUCLEAR-MAGNETIC-RESONANCE; PENTOSE-PHOSPHATE PATHWAY; ENERGY-METABOLISM; RAT-BRAIN; AEROBIC GLYCOLYSIS; WHITE-MATTER	Cerebral microdialysis is a widely used clinical tool for monitoring extracellular concentrations of selected metabolites after brain injury and to guide neurocritical care. Extracellular glucose levels and lactate/pyruvate ratios have high diagnostic value because they can detect hypoglycemia and deficits in oxidative metabolism, respectively. In addition, patterns of metabolite concentrations can distinguish between ischemia and mitochondrial dysfunction, and are helpful to choose and evaluate therapy. Increased intracranial pressure can be life-threatening after brain injury, and hypertonic solutions are commonly used for pressure reduction. Recent reports have advocated use of hypertonic sodium lactate, based on claims that it is glucose sparing and provides an oxidative fuel for injured brain. However, changes in extracellular concentrations in microdialysate are not evidence that a rise in extracellular glucose level is beneficial or that lactate is metabolized and improves neuroenergetics. The increase in glucose concentration may reflect inhibition of glycolysis, glycogenolysis, and pentose phosphate shunt pathway fluxes by lactate flooding in patients with mitochondrial dysfunction. In such cases, lactate will not be metabolizable and lactate flooding may be harmful. More rigorous approaches are required to evaluate metabolic and physiological effects of administration of hypertonic sodium lactate to brain-injured patients.	[Dienel, Gerald A.] Univ Arkansas Med Sci, Dept Neurol, Little Rock, AR 72205 USA; [Dienel, Gerald A.] Univ New Mexico, Dept Cell Biol & Physiol, Albuquerque, NM USA; [Rothman, Douglas L.] Yale Univ Sch Med, Dept Radiol & Biomed Imaging, Magnet Resonance Res Ctr, New Haven, CT USA; [Nordstroem, Carl-Henrik] Univ Lund Hosp, Dept Neurosurg, Lund, Sweden; [Nordstroem, Carl-Henrik] Odense Univ Hosp, Dept Neurosurg, Odense, Denmark	Dienel, GA (corresponding author), Univ Arkansas Med Sci, Dept Neurol, Little Rock, AR 72205 USA.	gadienel@uams.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS087568A]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001863] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: GD and C-HN received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. DLR was supported by the National Institutes of Health (grant number R01NS087568A).	ADACHI K, 1995, J CEREBR BLOOD F MET, V15, P97, DOI 10.1038/jcbfm.1995.11; AGARDH CD, 1978, J NEUROCHEM, V31, P1135, DOI 10.1111/j.1471-4159.1978.tb06236.x; Amer-Wahlin I, 2010, J MATERN-FETAL NEO M, V23, P158, DOI 10.3109/14767050903067360; Bak LK, 2012, ASN NEURO, V4, DOI 10.1042/AN20120004; Ball KK, 2010, J CEREBR BLOOD F MET, V30, P162, DOI 10.1038/jcbfm.2009.206; BORGSTROM L, 1976, J NEUROCHEM, V27, P971, DOI 10.1111/j.1471-4159.1976.tb05165.x; Boumezbeur F, 2010, J NEUROSCI, V30, P13983, DOI 10.1523/JNEUROSCI.2040-10.2010; Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6; Bozzo L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071721; Carpenter KLH, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00112; CAVAZZUTI M, 1991, BRIT J ANAESTH, V66, P490, DOI 10.1093/bja/66.4.490; CHAPMAN AG, 1977, J NEUROCHEM, V28, P1025, DOI 10.1111/j.1471-4159.1977.tb10665.x; CHEN W, 1993, P NATL ACAD SCI USA, V90, P9896, DOI 10.1073/pnas.90.21.9896; Chih CP, 2003, J CEREBR BLOOD F MET, V23, P1263, DOI 10.1097/01.WCB.0000081369.51727.6F; CHUGANI HT, 1991, J CEREBR BLOOD F MET, V11, P35, DOI 10.1038/jcbfm.1991.4; COX DWG, 1988, EXP BRAIN RES, V69, P368; Cruz NF, 1999, J CEREBR BLOOD F MET, V19, P380, DOI 10.1097/00004647-199904000-00004; DAHLGREN N, 1980, BRAIN RES, V184, P143, DOI 10.1016/0006-8993(80)90593-4; DAM M, 1990, ANESTHESIOLOGY, V73, P499, DOI 10.1097/00000542-199009000-00021; de Graaf RA, 2001, J CEREBR BLOOD F MET, V21, P483, DOI 10.1097/00004647-200105000-00002; DIENEL GA, 1991, J CEREBR BLOOD F MET, V11, P25, DOI 10.1038/jcbfm.1991.3; Dienel GA, 2007, J NEUROCHEM, V102, P466, DOI 10.1111/j.1471-4159.2007.04595.x; Dienel GA, 2016, J NEUROCHEM, V138, P14, DOI 10.1111/jnc.13630; Dienel GA, 2014, J CEREBR BLOOD F MET, V34, P1736, DOI 10.1038/jcbfm.2014.153; Dienel GA, 2012, ASN NEURO, V4, P267, DOI 10.1042/AN20120021; Dienel GA, 2012, J CEREBR BLOOD F MET, V32, P1107, DOI 10.1038/jcbfm.2011.175; DiNuzzo M, 2010, J CEREBR BLOOD F MET, V30, P586, DOI 10.1038/jcbfm.2009.232; Diringer MN, 2013, CURR OPIN CRIT CARE, V19, P77, DOI 10.1097/MCC.0b013e32835eba30; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Ederoth P, 2004, BRIT J CLIN PHARMACO, V57, P427, DOI 10.1046/j.1365-2125.2003.02032.x; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Feuerstein D, 2016, J CEREBR BLOOD F MET, V36, P1965, DOI 10.1177/0271678X15612779; FOLBERGR.J, 1970, J NEUROCHEM, V17, P1155, DOI 10.1111/j.1471-4159.1970.tb03363.x; FOLBERGROVA J, 1969, J NEUROCHEM, V16, P191, DOI 10.1111/j.1471-4159.1969.tb05937.x; Frahm J, 1996, MAGNET RESON MED, V35, P143, DOI 10.1002/mrm.1910350202; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Galow Lukas V, 2014, Front Neurosci, V8, P398, DOI 10.3389/fnins.2014.00398; GATFIELD PD, 1966, J NEUROCHEM, V13, P185, DOI 10.1111/j.1471-4159.1966.tb07512.x; Gilbert E, 2006, BRAIN RES, V1117, P213, DOI 10.1016/j.brainres.2006.07.107; GJEDDE A, 1983, J CEREBR BLOOD F MET, V3, P303, DOI 10.1038/jcbfm.1983.45; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Glenn TC, 2015, J NEUROTRAUM, V32, P820, DOI 10.1089/neu.2014.3483; Glenn TC, 2015, J NEUROTRAUM, V32, P811, DOI 10.1089/neu.2014.3482; Gordon GRJ, 2008, NATURE, V456, P745, DOI 10.1038/nature07525; HALPERIN ML, 1969, J BIOL CHEM, V244, P384; Hein TW, 2006, INVEST OPHTH VIS SCI, V47, P693, DOI 10.1167/iovs.05-1224; HEISS WD, 1984, J CEREBR BLOOD F MET, V4, P212, DOI 10.1038/jcbfm.1984.30; Helbok R, 2011, J NEUROL NEUROSUR PS, V82, P378, DOI 10.1136/jnnp.2009.198754; Hertz L, 2015, METAB BRAIN DIS, V30, P317, DOI 10.1007/s11011-014-9536-1; HOLDEN JE, 1991, J CEREBR BLOOD F MET, V11, P171, DOI 10.1038/jcbfm.1991.50; Hu YB, 1997, J NEUROCHEM, V68, P1745; Hu YB, 1997, J NEUROCHEM, V69, P1484; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Hyder F, 2016, J CEREBR BLOOD F MET, V36, P903, DOI 10.1177/0271678X15625349; Ichai C, 2013, INTENS CARE MED, V39, P1413, DOI 10.1007/s00134-013-2978-9; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Ivanov AI, 2014, J CEREBR BLOOD F MET, V34, P397, DOI 10.1038/jcbfm.2013.222; Jalloh I, 2015, J CEREBR BLOOD F MET, V35, P111, DOI 10.1038/jcbfm.2014.177; Jalloh I, 2013, J NEUROTRAUM, V30, P2031, DOI 10.1089/neu.2013.2947; Lauritzen KH, 2014, CEREB CORTEX, V24, P2784, DOI 10.1093/cercor/bht136; LEHMENKUHLER A, 1993, NEUROSCIENCE, V55, P339, DOI 10.1016/0306-4522(93)90503-8; Leloup C, 2015, J NEUROCHEM, V135, P639, DOI 10.1111/jnc.13276; Li BW, 2015, J NEUROCHEM, V135, P742, DOI 10.1111/jnc.13143; Madsen PL, 1999, J CEREBR BLOOD F MET, V19, P393, DOI 10.1097/00004647-199904000-00005; Madsen PL, 1998, J CEREBR BLOOD F MET, V18, P742, DOI 10.1097/00004647-199807000-00005; Mangia S, 2007, J CEREBR BLOOD F MET, V27, P1055, DOI 10.1038/sj.jcbfm.9600401; Mangia S, 2011, J CEREBR BLOOD F MET, V31, P1346, DOI 10.1038/jcbfm.2011.29; Mangia S, 2009, J NEUROCHEM, V109, P55, DOI 10.1111/j.1471-4159.2009.06003.x; Marko NF, 2012, CRIT CARE, V16, DOI 10.1186/cc11182; Mintun MA, 2002, NEUROIMAGE, V16, P531, DOI 10.1006/nimg.2002.1114; Mortazavi MM, 2012, J NEUROSURG, V116, P210, DOI 10.3171/2011.7.JNS102142; Muller MS, 2014, BIOCHEM SOC T, V42, P1311, DOI 10.1042/BST20140157; Nakanishi H, 1996, J CEREBR BLOOD F MET, V16, P439, DOI 10.1097/00004647-199605000-00010; NEDERGAARD M, 1993, AM J PHYSIOL, V265, pR282; Nielsen TH, 2014, NEUROCRIT CARE, V21, P35, DOI 10.1007/s12028-013-9875-5; Nielsen TH, 2013, ACTA ANAESTH SCAND, V57, P793, DOI 10.1111/aas.12092; Nordstrom CH, 2014, J NEUROTRAUM, V31, P1528, DOI 10.1089/neu.2013.3229; Nordstrom CH, 2014, INTENS CARE MED, V40, P919, DOI 10.1007/s00134-014-3297-5; Nordstrom CH, 2013, J REHABIL MED, V45, P710, DOI 10.2340/16501977-1157; Nordstrom CH, 2010, CHILD NERV SYST, V26, P465, DOI 10.1007/s00381-009-1035-z; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; Okada Y, 2007, BRAIN ENERGETICS INT, P17, DOI [10.1007/978-0-387-30411-3_2, DOI 10.1007/978-0-387-30411-3_2]; Osborne DM, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00164; Patel AB, 2014, P NATL ACAD SCI USA, V111, P5385, DOI 10.1073/pnas.1403576111; Patet C, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0638-5; Patet C, 2015, J NEUROTRAUM, V32, P1560, DOI 10.1089/neu.2014.3781; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PRICHARD J, 1991, P NATL ACAD SCI USA, V88, P5829, DOI 10.1073/pnas.88.13.5829; Quintard H, 2016, J NEUROTRAUM, V33, P681, DOI 10.1089/neu.2015.4057; Quistorff B, 2008, FASEB J, V22, P3443, DOI 10.1096/fj.08-106104; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Reinstrup P, 2011, NEUROCRIT CARE, V14, P441, DOI 10.1007/s12028-010-9486-3; Rothman DL, 2011, NMR BIOMED, V24, P943, DOI 10.1002/nbm.1772; Schaller B, 2014, NEUROIMAGE, V93, P138, DOI 10.1016/j.neuroimage.2014.02.016; Seifert T, 2011, PROG NEUROBIOL, V95, P406, DOI 10.1016/j.pneurobio.2011.09.008; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Sykova E, 2008, PHYSIOL REV, V88, P1277, DOI 10.1152/physrev.00027.2007; Tang F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4284; Tholance Y, 2011, CLIN CHIM ACTA, V412, P647, DOI 10.1016/j.cca.2010.12.025; Timofeev I, 2011, J NEUROTRAUM, V28, P849, DOI 10.1089/neu.2010.1656; TRIVEDI B, 1966, J BIOL CHEM, V241, P4110; van Hall G, 2009, J CEREBR BLOOD F MET, V29, P1121, DOI 10.1038/jcbfm.2009.35; VEECH RL, 1991, NMR BIOMED, V4, P53, DOI 10.1002/nbm.1940040204; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; Winkler U, 2015, NEUROCHEM RES, V40, P2394, DOI 10.1007/s11064-015-1526-0; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038; Yamanishi S, 2006, AM J PHYSIOL-HEART C, V290, pH925, DOI 10.1152/ajpheart.01012.2005	110	12	12	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2016	36	11					1844	1864		10.1177/0271678X16666552			21	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	EB3KL	WOS:000387263300002	27604313	Bronze, Green Published			2021-06-18	
J	Hugentobler, JA; Gupta, R; Slater, R; Paterno, MV; Riley, MA; Quatman-Yates, C				Hugentobler, Jason A.; Gupta, Resmi; Slater, Robert; Paterno, Mark V.; Riley, Michael A.; Quatman-Yates, Catherine			Influence of Age on Postconcussive Postural Control Measures and Future Implications for Assessment	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; postural sway; balance; adolescents	SPORT-RELATED CONCUSSION; ERROR SCORING SYSTEM; CEREBRAL CONCUSSION; BRAIN-INJURY; BALANCE; CHILDREN; MANAGEMENT; STABILITY; ADOLESCENTS; VARIABILITY	Objective: To examine the influence of age, sex, attention-deficit hyperactivity disorder (ADHD) status, previous history of concussion, and days since injury on postconcussion postural control assessment in adolescents who have suffered a concussion. Design: Prospective cohort study. Setting: Hospital-based outpatient clinic. Participants: Seventy-one participants (42 males; 29 females) with mean age 14.14 +/- 2.44. Independent Variables: Age, sex, previous concussion history, ADHD status, total and severity of postconcussion symptoms, and days since injury. Main Outcome Measures: Total Balance Error Scoring System score, path length, center-of-pressure (COP) area, sample entropy, and Romberg quotient. Results: Pearson product-moment correlation coefficients were calculated to test for potential associations between the continuous participant characteristics and the postural control variables. Spearman correlation was used to test the association between symptom severity and the postural control variables. Standard multiple regression was used to model the extent to which participant characteristics accounted for the variance in the postural sway variables. Age was significantly associated with all of the postural sway variables except COP area for the eyes open condition and sample entropy in the anterior-posterior direction for the eyes closed condition. Sex, ADHD status, and previous concussion history did not significantly predict postural control scores. Conclusions: Age significantly influences scores on common postconcussion postural control assessments.	[Hugentobler, Jason A.; Paterno, Mark V.; Quatman-Yates, Catherine] Cincinnati Childrens Hosp Med Ctr, Dept Occupat Therapy & Phys Therapy, Cincinnati, OH 45229 USA; [Gupta, Resmi] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Slater, Robert] Univ Cincinnati, Cincinnati, OH USA; [Paterno, Mark V.; Quatman-Yates, Catherine] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Riley, Michael A.] Univ Cincinnati, Dept Psychol, Cincinnati, OH 45221 USA; [Riley, Michael A.] Univ Cincinnati, Ctr Cognit Act & Percept, Cincinnati, OH USA	Hugentobler, JA (corresponding author), Cincinnati Childrens Hosp Med Ctr, 2800 Winslow Ave,Suite 3100,MLC 10001, Cincinnati, OH 45206 USA.	jason.hugentobler@cchmc.org	Quatman-Yates, Catherine/U-9580-2019; Quatman-Yates, Catherine/AAK-4507-2021		CCHMC Patient Services	C.Q.-Y. received internal grant funding from CCHMC Patient Services that provided equipment, human resources, and PI time to pursue this project. The other authors report no conflicts of interest.	[Anonymous], 2014, J ORTHOP SPORT PHYS, V44, pA159; [Anonymous], 2012, J ORTHOP SPORT PHYS, V42, pA41; [Anonymous], YOUTH SPORTS STAT; Barozzi S, 2014, EUR ARCH OTO-RHINO-L, V271, P2069, DOI 10.1007/s00405-014-2930-9; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Claeys K, 2011, EUR J APPL PHYSIOL, V111, P115, DOI 10.1007/s00421-010-1637-x; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Cumberworth VL, 2007, J LARYNGOL OTOL, V121, P449, DOI 10.1017/S0022215106004051; Davis GA, 2014, BRIT J SPORT MED, V48, P98, DOI 10.1136/bjsports-2012-092132; Dusing SC, 2013, DEV PSYCHOBIOL, V55, P404, DOI 10.1002/dev.21045; Forte R, 2014, AGING CLIN EXP RES, V26, P645, DOI 10.1007/s40520-014-0216-0; Gao JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024446; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Jeter PE, 2014, J ALTERN COMPLEM MED, V20, P221, DOI 10.1089/acm.2013.0378; Kuznetsov N., 2014, COMPLEX SYSTEMS SPOR; Legrand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035301; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; Ni M, 2014, ARCH PHYS MED REHAB, V95, P1620, DOI 10.1016/j.apmr.2014.04.022; Palmieri RM, 2002, J SPORT REHABIL, V11, P51, DOI 10.1123/jsr.11.1.51; Paterno MV, 2010, AM J SPORT MED, V38, P1968, DOI 10.1177/0363546510376053; Quatman-Yates C, 2014, PHYSICIAN SPORTSMED, V42, P32, DOI 10.3810/psm.2014.09.2073; Quatman-Yates CC, 2013, INT J SPORTS PHYS TH, V8, P741; Quatman-Yates CC, 2015, PEDIATR PHYS THER, V27, P316, DOI 10.1097/PEP.0000000000000193; Ramdani S, 2009, MED ENG PHYS, V31, P1023, DOI 10.1016/j.medengphy.2009.06.004; Riley MA, 2002, J MOTOR BEHAV, V34, P99, DOI 10.1080/00222890209601934; Runge Larsen L, 2014, BRIT J SPORT MED, V48, P622; Schmit JM, 2005, EXP BRAIN RES, V163, P370, DOI 10.1007/s00221-004-2185-6; Shorer Z, 2012, EUR J PEDIATR, V171, P1087, DOI 10.1007/s00431-012-1695-7; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Steindl R, 2006, DEV MED CHILD NEUROL, V48, P477, DOI 10.1017/S0012162206001022; Stergiou Nicholas, 2006, J Neurol Phys Ther, V30, P120; Tsai CL, 2008, HUM MOVEMENT SCI, V27, P142, DOI 10.1016/j.humov.2007.08.002; Valovich TC, 2003, J ATHL TRAINING, V38, P51	45	12	12	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2016	26	6					510	517		10.1097/JSM.0000000000000286			8	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	EB6DO	WOS:000387471600012	27347855				2021-06-18	
J	Ramli, R; Oxley, J				Ramli, Roszalina; Oxley, Jennie			Motorcycle helmet fixation status is more crucial than helmet type in providing protection to the head	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Helmet fixation; Helmet type; Motorcycle; Head injury	TRAUMATIC BRAIN-INJURY; FACIAL INJURIES; CRASH SEVERITY; COLLISIONS; ACCIDENTS; DESIGN; RIDERS; RISK; PAIN	Introduction: In Malaysia, motorcyclists continue to outnumber other road users in injuries and deaths. The objective of this study was to determine the association between helmet fixation and helmet type with head injury and severity of head injury among Malaysian motorcyclists. Methods: The study design was a prospective cross-sectional study. The participants involved injured motorcyclists who were admitted in five selected hospitals in Klang Valley, Malaysia. Participants who sustained head injury were selected as the cases while those with injury below the neck (IBN) were selected as the controls. Questionnaire comprising motorcyclist, vehicle, helmet and crash factors was examined. Diagnoses of injuries were obtained from the participants' medical records. Results: The total subjects with head injuries were 404 while those with IBN were 235. Majority of the cases (76.2%) and controls (80.4%) wore the half-head and open-face helmets, followed by the tropical helmets (5.4% and 6.0% of the cases and controls, respectively). Full-face helmets were used by 1.2% of the cases and 4.7% of the controls. 5.7% of the cases and 6.0% of the controls did not wear a helmet. 32.7% of the cases and 77.4% of the controls had their helmets fixed. Motorcyclists with ejected helmets were five times as likely to sustain head injury [adjusted odds ratio, AOR 5.73 (95% CI 3.38-9.73)] and four times as likely to sustain severe head injury [AOR of 4.83 (95% CI 2.76-8.45)]. The half head and open face helmets had AOR of 0.24 (95% CI 0.10-0.56) for severe head injury when compared to motorcyclists who did not wear a helmet. Conclusion: Helmet fixation is more effective than helmet type in providing protection to the motorcyclists. (C) 2016 Elsevier Ltd. All rights reserved.	[Ramli, Roszalina] Univ Kebangsaan Malaysia, Med Ctr, Dept Oral & Maxillofacial Surg, Kuala Lumpur, Malaysia; [Oxley, Jennie] Monash Univ, MIRI, Clayton, Vic, Australia	Ramli, R (corresponding author), Univ Kebangsaan Malaysia, Med Ctr, Dept Oral & Maxillofacial Surg, Kuala Lumpur, Malaysia.	roszalina@ppukm.ukm.edu.my; jennie.oxley@monash.edu		Ramli, Roszalina/0000-0001-7445-0205; Oxley, Jennie/0000-0002-7519-1994			APROSYS, 2006, REP PERF RID PROT DE; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; CANNELL H, 1982, BRIT J ORAL SURG, V20, P183, DOI 10.1016/S0007-117X(82)80036-X; Clay FJ, 2010, J PAIN, V11, P420, DOI 10.1016/j.jpain.2009.12.002; Conrad P, 1996, ACCIDENT ANAL PREV, V28, P193, DOI 10.1016/0001-4575(95)00056-9; Croft AC, 2005, MED SCI MONITOR, V11, pRA316; Department of Statistics (Malaysia), 2010, POP HOUS CENS MAL 20; Elliott MR, 2003, ACCIDENT ANAL PREV, V35, P833, DOI 10.1016/S0001-4575(02)00088-X; Fitzharris M, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-11; Fleiss JL., 2004, STAT METHODS RATES P; GILCHRIST A, 1988, ERGONOMICS, V31, P1395, DOI 10.1080/00140138808966784; Gustafsson H, SAE TECHNICAL PAPER; Hung DV, 2006, INJURY PREV, V12, P409, DOI 10.1136/ip.2006.012724; Hurt H.J., 1981, MOTORCYCLE ACCIDENT, V1; Hurt HH, 1998, P 16 ENH SAF VEH C, P2323; Kelsey J. L., 1996, METHODS OBSERVATIONA, V2nd; Kuala Lumpur City Hall, 2003, KUAL LUMP STRUCT PLA; Kulanthayan S., 2001, CRASH PREVENTION INJ, V2, P239, DOI DOI 10.1080/10286580108902568; Leong BK, 2013, DISABIL REHABIL, V35, P1546, DOI 10.3109/09638288.2012.748832; Li LP, 2008, ACCIDENT ANAL PREV, V40, P1937, DOI 10.1016/j.aap.2008.06.019; Lin MR, 2004, NEUROEPIDEMIOLOGY, V23, P269, DOI 10.1159/000080091; Liu BC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004333.pub3; Luchter S, SAE TECHNICAL PAPER, P1; Nunn S, 2011, J FORENSIC SCI, V56, P429, DOI 10.1111/j.1556-4029.2010.01657.x; OpenEpi,, 2011, OP SOURC EP STAT PUB; ORSAY EM, 1994, ANN EMERG MED, V23, P802, DOI 10.1016/S0196-0644(94)70317-5; PATEL R, 1993, APPL ERGON, V24, P427, DOI 10.1016/0003-6870(93)90175-9; Pedder J, P IRCOBI C; Ramli R, 2013, THESIS; Ramli R, 2008, J CRANIOFAC SURG, V19, P316, DOI 10.1097/SCS.0b013e318163f94d; Ramli R, 2014, BMC EMERG MED, V14, DOI 10.1186/1471-227X-14-17; Rivara F P, 1999, Inj Prev, V5, P194; Rowland J, 1996, AM J PUBLIC HEALTH, V86, P41, DOI 10.2105/AJPH.86.1.41; Royal Malaysia Police, 2013, COMMUNICATION; Royal Malaysian Police, 2010, STAT REP ROAD ACC MA; RUTLEDGE R, 1993, ACCIDENT ANAL PREV, V25, P347, DOI 10.1016/0001-4575(93)90028-U; Sarani A, 2011, ADSA FACT SHEET, V1, P1; Sauter Carley, 2005, WMJ, V104, P39; SHIBATA A, 1994, ACCIDENT ANAL PREV, V26, P391, DOI 10.1016/0001-4575(94)90013-2; Thai KT, P 17 WORLD C ERG; THOMPSON DC, 2002, COCHRANE DB SYST REV; TSAI YJ, 1995, AM J EPIDEMIOL, V142, P974, DOI 10.1093/oxfordjournals.aje.a117746; Van den Oord MHAH, 2012, APPL ERGON, V43, P958, DOI 10.1016/j.apergo.2012.01.004; VAUGHAN RG, 1977, MED J AUSTRALIA, V1, P125, DOI 10.5694/j.1326-5377.1977.tb130562.x; World Health Organization, 2006, HELM ROAD SAF MAN DE; World Health Organization, 2009, GLOB STAT REP ROAD S; Xuequn Y, 2011, ACCIDENT ANAL PREV, V43, P214, DOI 10.1016/j.aap.2010.08.012; Yen P. T., 1999, INT MED RES J, V3, P115; Yu WY, 2011, INT J EPIDEMIOL, V40, P794, DOI 10.1093/ije/dyr040	49	12	12	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	NOV	2016	47	11					2442	2449		10.1016/j.injury.2016.09.022			8	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	EC5IE	WOS:000388167000007	27645615				2021-06-18	
J	Salisbury, DB; Parsons, TD; Monden, KR; Trost, Z; Driver, SJ				Salisbury, David B.; Parsons, Thomas D.; Monden, Kimberley R.; Trost, Zina; Driver, Simon J.			Brain-Computer Interface for Individuals After Spinal Cord Injury	REHABILITATION PSYCHOLOGY			English	Article						virtual reality; disability; inpatient rehabilitation; technology	REALITY EXPOSURE THERAPY; NEUROPATHIC PAIN; PATIENT; SYSTEM; ENVIRONMENT; TECHNOLOGY; VALIDATION; PRIORITIES; OUTCOMES	Purpose/Objective: To investigate the feasibility of brain-computer interface (BCI) with patients on an inpatient spinal cord injury (SCI) unit. Research Method/Design: This study included 25 participants aged 18-64 who sustained traumatic or nontraumatic SCI and did not have severe cognitive or psychiatric impairment. Participants completed a variety of screening measures related to cognition, psychological disposition, pain, and technology experience/interest. The Emotiv electroencephalography system was used in conjunction with a cube rotation and manipulation game presented on a laptop computer. Results: The majority of participants successfully completed the BCI game and reported enjoyment of the experience. Outside of a mild trend of lower performance among participants with a past or present head injury, there were no demographic variables, injury variables or screening measures significantly associated with BCI performance. Conclusions/Implications: The BCI paradigm demonstrated feasibility and safety across participant age range, educational and vocational background, and level of injury. Despite the rapid integration of technology into rehabilitation health care settings, there are few evidence-based studies regarding the feasibility of technology with specific inpatient populations. Clinical implications and challenges of using this technology in a rehabilitation setting are discussed.	[Salisbury, David B.] Baylor Inst Rehabil, Dept Neuropsychol, 411 North Washington Ave,Suite 5000, Dallas, TX 75246 USA; [Parsons, Thomas D.] Univ North Texas, Computat Neuropsychol & Simulat Lab, Denton, TX 76203 USA; [Monden, Kimberley R.] Baylor Univ, Med Ctr, Dept Surg, Waco, TX 76798 USA; [Trost, Zina] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA; [Driver, Simon J.] Baylor Inst Rehabil, Dept Res, Dallas, TX USA	Salisbury, DB (corresponding author), Baylor Inst Rehabil, Dept Neuropsychol, 411 North Washington Ave,Suite 5000, Dallas, TX 75246 USA.	dsalisbury@bir-rehab.com	Monden, Kimberley/AAE-9831-2020	Monden, Kimberley/0000-0002-5207-0452; driver, simon/0000-0003-2356-432X			Alphonso AL, 2012, STUD HEALTH TECHNOL, V181, P305, DOI 10.3233/978-1-61499-121-2-305; Andujar M., 2011, P E LEARN WORLD C L, P539; Badcock NA, 2013, PEERJ, V1, DOI 10.7717/peerj.38; Burns A, 2014, NEUROSCIENTIST, V20, P639, DOI 10.1177/1073858414549015; Cinar E, 2013, NEURAL COMPUT APPL, V22, P29, DOI 10.1007/s00521-011-0744-x; Cincotti F, 2008, BRAIN RES BULL, V75, P796, DOI 10.1016/j.brainresbull.2008.01.007; Collinger JL, 2013, J REHABIL RES DEV, V50, P145, DOI 10.1682/JRRD.2011.11.0213; Danziger Z, 2014, BIOL CYBERN, V108, P183, DOI 10.1007/s00422-014-0589-3; Dobkin BH, 2007, J PHYSIOL-LONDON, V579, P637, DOI 10.1113/jphysiol.2006.123067; Dutta Arindam, 2013, Depress Res Treat, V2013, P640861, DOI 10.1155/2013/640861; Duvinage M, 2013, BIOMED ENG ONLINE, V12, DOI 10.1186/1475-925X-12-56; Enzinger C, 2008, EXP BRAIN RES, V190, P215, DOI 10.1007/s00221-008-1465-y; Felix ER, 2014, PHYS MED REH CLIN N, V25, P545, DOI 10.1016/j.pmr.2014.04.007; Finnerup NB, 2013, PAIN, V154, pS71, DOI 10.1016/j.pain.2012.12.007; Hammell KRW, 2010, DISABIL REHABIL, V32, P1209, DOI 10.3109/09638280903420325; Hill NJ, 2014, J NEURAL ENG, V11, DOI 10.1088/1741-2560/11/2/026018; Ikegami S, 2011, CLIN NEUROPHYSIOL, V122, P991, DOI 10.1016/j.clinph.2010.08.021; Inventado S., 2011, RES PRACT TECHNOL EN, V6, P107; Jatupaiboon N, 2013, SCI WORLD J, DOI 10.1155/2013/618649; Kaufmann T, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00129; Kiper P, 2011, NEUROL NEUROCHIR POL, V45, P436; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kubler A, 2008, CLIN NEUROPHYSIOL, V119, P2658, DOI 10.1016/j.clinph.2008.06.019; Lin CT, 2010, GERONTOLOGY, V56, P112, DOI 10.1159/000230807; Mak Joseph N, 2009, IEEE Rev Biomed Eng, V2, P187, DOI 10.1109/RBME.2009.2035356; McMahan T., 2015, P 6 INT C APPL HUM F; McMahan T., 2015, P FDN DIG GAM C JUN; McNair D, 1971, MANUAL PROFILE MOOD; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Millan JDR, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00161; Motraghi TE, 2014, J CLIN PSYCHOL, V70, P197, DOI 10.1002/jclp.22051; Murray C. D., 2009, J CYBER THERAPY REHA, V2, P105; Parsons TD, 2008, J BEHAV THER EXP PSY, V39, P250, DOI 10.1016/j.jbtep.2007.07.007; Rao JS, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/753061; Ricker JH, 1996, NEUROPSY NEUROPSY BE, V9, P50; Rosas-Cholula G., 2010, SIGNAL P 300 DETECTI; Rupp Rudiger, 2014, Front Neuroeng, V7, P38, DOI 10.3389/fneng.2014.00038; Schreuder M, 2013, ARTIF INTELL MED, V59, P71, DOI 10.1016/j.artmed.2013.07.005; Shih JJ, 2012, MAYO CLIN PROC, V87, P268, DOI 10.1016/j.mayocp.2011.12.008; Tate DG, 2002, ARCH PHYS MED REHAB, V83, pS18, DOI 10.1053/apmr.2002.36835; TELLEGEN A, 1974, J ABNORM PSYCHOL, V83, P268, DOI 10.1037/h0036681; Tidoni E, 2015, NEUROPSYCHOLOGIA, V79, P301, DOI 10.1016/j.neuropsychologia.2015.06.029; Pham TD, 2012, LECT NOTES COMPUT SC, V7667, P394, DOI 10.1007/978-3-642-34500-5_47; Vi C. T., 2012, DETECTING ERROR RELA; Wechsler D, 2001, MANUAL WECHSLER TEST; Wechsler D., 1997, MANUAL WECHSLER ADUL; Wrigley PJ, 2009, PAIN, V141, P52, DOI 10.1016/j.pain.2008.10.007	47	12	12	0	18	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2016	61	4					435	441		10.1037/rep0000099			7	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	EC3BK	WOS:000387999200010	27684465				2021-06-18	
J	Silverberg, ND; Iverson, GL; Brubacher, JR; Holland, E; Hoshino, LC; Aquino, A; Lange, RT				Silverberg, Noah D.; Iverson, Grant L.; Brubacher, Jeffrey R.; Holland, Elizabeth; Hoshino, Lisa Casagrande; Aquino, Angela; Lange, Rael T.			The Nature and Clinical Significance of Preinjury Recall Bias Following Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain concussion; good-old-days bias; postconcussion syndrome; psychological models; recall bias	GOOD-OLD-DAYS; POST-CONCUSSION SYMPTOMS; COGNITIVE-BEHAVIORAL PREVENTION; HEAD-INJURY; POSTCONCUSSION-SYNDROME; ETIOLOGY; EXPECTATION; PERCEPTION; SAMPLE	Objective: Patients with mild traumatic brain injury (MTBI) often underestimate their preinjury symptoms. This study aimed to clarify the mechanism underlying this recall bias and its contribution to MTBI outcome. Setting: Level I trauma center. Participants: Patients with uncomplicated MTBI (N = 88) and orthopedic injury (N = 67). Design: Prospective longitudinal. Main Measures: Current and retrospective ratings on the British Columbia Postconcussion Symptom Inventory, completed at 6 weeks and 1 year postinjury. Results: Preinjury symptom reporting was comparable across groups, static across time, and associated with compensation-seeking. High preinjury symptom reporting was related to high postinjury symptom reporting in the orthopedic injury group but less so in the MTBI group, indicating a stronger positive recall bias in highly symptomatic MTBI patients. Low preinjury symptom reporting was not a risk factor for poor MTBI outcome. Conclusion: The recall bias was stronger and more likely clinically significant in MTBI patients with high postinjury symptoms. Multiple mechanisms appear to contribute to recall bias after MTBI, including the reattribution of preexisting symptoms to MTBI as well as processes that are not specific to MTBI (eg, related to compensation-seeking).	[Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC, Canada; [Iverson, Grant L.; Lange, Rael T.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Brubacher, Jeffrey R.] Univ British Columbia, Dept Emergency Med, Vancouver, BC, Canada; [Aquino, Angela] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Silverberg, Noah D.] GF Strong Rehab Ctr, Rehabil Res Program, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada; [Iverson, Grant L.] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Hoshino, Lisa Casagrande] Simon Fraser Univ, Dept Psychol, Burnaby, BC, Canada; [Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bethesda, MD USA	Silverberg, ND (corresponding author), GF Strong Rehab Ctr, Rehabil Res Program, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada.	noah.silverberg@vch.ca		Brubacher, Jeffrey/0000-0002-4866-4231; Iverson, Grant/0000-0001-7348-9570	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [200903 MOP-200377-BSB-CAAA-161276]; Vancouver Coastal Health Research Institute; INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium - Department of Defense Psychological Health/Traumatic Brain Injury Research Program [X81XWH-07-CC-CSDoD]; MTBI	Primary funding for this study was provided by the Canadian Institutes of Health Research (200903 MOP-200377-BSB-CAAA-161276); provided to R.T.L. as principal investigator). N.D.S. received salary support from the Vancouver Coastal Health Research Institute. G.L.I. was supported in part by the INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium funded by the Department of Defense Psychological Health/Traumatic Brain Injury Research Program (X81XWH-07-CC-CSDoD). The authors thank Jan Buchanan for assistance with patient recruitment.; G.L.I. has been reimbursed by the government, professional scientific bodies, and commercial organizations for discussing or presenting research relating to mild traumatic brain injury (MTBI) and sport-related concussion at meetings, scientific conferences, and symposiums. He has a clinical practice in forensic neuropsychology involving individuals who have sustained MTBIs. He has received honorariums for serving on research panels that provide scientific peer review of programs. He is a coinvestigator, collaborator, or consultant on grants relating to MTBI funded by several organizations.	Alla S, 2012, BRIT J SPORT MED, V46, P562, DOI 10.1136/bjsm.2010.081299; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Barsky AJ, 2002, JAMA-J AM MED ASSOC, V287, P622, DOI 10.1001/jama.287.5.622; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Brooks BL, 2014, ARCH CLIN NEUROPSYCH, V29, P186, DOI 10.1093/arclin/act083; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; GREENWALD AG, 1980, AM PSYCHOL, V35, P603, DOI 10.1037//0003-066X.35.7.603; Greiffenstein MF, 2002, PSYCHOL ASSESSMENT, V14, P202, DOI 10.1037//1040-3590.14.2.202; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; King NS, 2014, BRAIN INJURY, V28, P1639, DOI 10.3109/02699052.2014.954271; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lange RT, 2014, ARCH CLIN NEUROPSYCH, V29, P478, DOI 10.1093/arclin/acu027; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Langley J, 2010, BRAIN INJURY, V24, P939, DOI 10.3109/02699052.2010.491494; LeesHaley PR, 1997, BRAIN INJURY, V11, P791; Mitchell TR, 1997, J EXP SOC PSYCHOL, V33, P421, DOI 10.1006/jesp.1997.1333; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Panayiotou A, 2011, AUST PSYCHOL, V46, P210, DOI 10.1111/j.1742-9544.2010.00018.x; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P313, DOI 10.1097/HTR.0b013e3182915cb5; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Sullivan K, 2011, J HEAD TRAUMA REHAB, V26, P170, DOI 10.1097/HTR.0b013e3181e47f95; Sullivan KA, 2012, BRAIN INJURY, V26, P1098, DOI 10.3109/02699052.2012.666367; Vanderploeg RD, 2014, PSYCHOL INJ LAW, V7, P245, DOI 10.1007/s12207-014-9201-3; Vikane E, 2014, BRAIN INJURY, V28, P1374, DOI 10.3109/02699052.2014.919532; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Yang CC, 2014, J CLIN EXP NEUROPSYC, V36, P399, DOI 10.1080/13803395.2014.903899	39	12	12	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2016	31	6					388	396		10.1097/HTR.0000000000000198			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EC0IW	WOS:000387784800010	26580693				2021-06-18	
J	Tayim, FM; Flashman, LA; Wright, MJ; Roth, RM; McAllister, TW				Tayim, Fadi M.; Flashman, Laura A.; Wright, Matthew J.; Roth, Robert M.; McAllister, Thomas W.			Recovery of episodic memory subprocesses in mild and complicated mild traumatic brain injury at 1 and 12 months post injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Neuropsychology; traumatic brain injury; postconcussion syndrome; encoding; memory	WORKING-MEMORY; HEAD-INJURY; CONSOLIDATION DEFICITS; FUNCTIONAL MRI; DYSFUNCTION	Introduction: Episodic memory complaints are commonly reported after traumatic brain injury (TBI). The contributions of specific memory subprocesses (encoding, consolidation, and retrieval), however, are not well understood in mild TBI (mTBI). In the present study, we evaluated subprocesses of episodic memory in patients with mTBI using the item-specific deficit approach (ISDA), which analyzes responses on list learning tasks at an item level. We also conducted exploratory analyses to evaluate the effects of complicated mTBI (comp-mTBI) on memory. Method: We compared episodic verbal memory performance in mTBI (n = 92) at approximately 1 and 12 months post TBI, as well as in a healthy comparison (HC) group (n = 40) at equivalent time points. Episodic memory was assessed using the California Verbal Learning Test-2nd Edition (CVLT-II), and both standard CVLT-II scores and ISDA indices were evaluated. Results: Compared to the HC group, the mTBI group showed significantly poorer encoding and learning across time, as measured by ISDA and CVLT-II. Further analyses of these mTBI subgroups [(noncomplicated mTBI (NC-mTBI, n = 77) and comp-mTBI (n = 15)], indicated that it was the comp-mTBI group who continued to demonstrate poorer encoding ability than the HC group. When the patient groups were directly compared, the NC-mTBI group improved slightly on the ISDA Encoding Deficit Index. While the comp-mTBI group worsened slightly over time, their poorer encoding ability was not likely clinically meaningful. Conclusions: These findings indicate that, while the NC-mTBI and HC groups' performances were comparable by 12 months, a primary, long-term deficit in encoding of auditory verbal information remained problematic in the comp-mTBI group.	[Tayim, Fadi M.; Flashman, Laura A.; Roth, Robert M.; McAllister, Thomas W.] Geisel Sch Med Dartmouth, Sect Neuropsychiat, Dept Psychiat, Brain Imaging Lab, Lebanon, NH USA; [Wright, Matthew J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; [Wright, Matthew J.] Harbor UCLA Med Ctr, Div Psychol, Dept Psychiat, Torrance, CA 90509 USA; [Wright, Matthew J.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA	Tayim, FM (corresponding author), Wright State Univ, 30 East Apple St,Suite 6257, Dayton, OH 45409 USA.; Tayim, FM (corresponding author), Premier Hlth Clin Neurosci Inst, 30 East Apple St,Suite 6257, Dayton, OH 45409 USA.	fmtayim@premierhealth.com			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD048176]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048176] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health [grant number R01 HD048176].	Baddeley A, 2003, J COMMUN DISORD, V36, P189, DOI 10.1016/S0021-9924(03)00019-4; Baddeley A., 1974, PSYCHOL LEARN MOTIV, P47, DOI [10.1016/s0079-7421(08)60452-1, DOI 10.1016/S0079-7421(08)60452-1]; Beck A.T., 1996, MANUAL BECK DEPRESSI; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Blakesley RE, 2009, NEUROPSYCHOLOGY, V23, P255, DOI 10.1037/a0012850; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Delis DC, 2000, CALIFORNIA VERBAL LE; ELLIS HC, 1983, FUNDAMENTALS HUMAN M; Faul M.D., 2010, TRAUMATIC BRAIN INJU; First M.B., 1996, STRUCTURED CLIN INTE; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; HITCH GJ, 1978, COGNITIVE PSYCHOL, V10, P302, DOI 10.1016/0010-0285(78)90002-6; HOLM S, 1979, SCAND J STAT, V6, P65; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P1, DOI 10.1016/S0887-6177(01)00176-7; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; Miotto EC, 2010, ARQ NEURO-PSIQUIAT, V68, P862, DOI 10.1590/S0004-282X2010000600006; Mott TF, 2012, AM FAM PHYSICIAN, V86, P1045; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Silver JM, 2012, AM J PSYCHIAT, V169, P1230, DOI 10.1176/appi.ajp.2012.12091230; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Vanderploeg RD, 2014, J CLIN EXP NEUROPSYC, V36, P58, DOI 10.1080/13803395.2013.864600; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wright MJ, 2011, J HEAD TRAUMA REHAB, V26, P182, DOI 10.1097/HTR.0b013e318218dcf9; Wright MJ, 2010, J CLIN EXP NEUROPSYC, V32, P728, DOI 10.1080/13803390903512652; Wright MJ, 2009, J CLIN EXP NEUROPSYC, V31, P790, DOI 10.1080/13803390802508918	39	12	12	0	34	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	NOV	2016	38	9					1005	1014		10.1080/13803395.2016.1182968			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	DT6FA	WOS:000381577900007	27191799				2021-06-18	
J	Young, AMH; Guilfoyle, MR; Fernandes, H; Garnett, MR; Agrawal, S; Hutchinson, PJ				Young, Adam M. H.; Guilfoyle, Mathew R.; Fernandes, Helen; Garnett, Matthew R.; Agrawal, Shruti; Hutchinson, Peter J.			The application of adult traumatic brain injury models in a pediatric cohort	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						brain; injury; acute; prediction; trauma	MINOR HEAD-INJURY; PROGNOSTIC MODELS; PATIENT; IMPACT; RULE; AGE	OBJECTIVE There is increasing interest in the use of predictive models of outcome in adult head injury. Two international models have been identified to be reliable modalities for predicting outcome: the Corticosteroid Randomisation After Significant Head Injury (CRASH) model, and the International Mission on Prognosis and Analysis of randomized Controlled Trials in TBI (IMPACT) model. However, these models are designed only to identify outcomes in adult populations. METHODS A retrospective analysis was performed on pediatric patients with severe traumatic brain injury (TBI) admitted to the pediatric intensive care unit (PICU) of Addenbrooke's Hospital between January 2009 and December 2013. The individual risk of 14-day mortality was calculated using the CRASH-Basic and -CT models, and the risk of 6-month mortality calculated using the IMPACT-Core and-Extended (including CT findings) models. Model accuracy was determined by standardized mortality ratio (SMtR; observed/expected deaths), discrimination was evaluated as the area under the receiver operating curve (AUROC), and calibration assessed using the Hosmer-Lemeshow chi(2) test. RESULTS Ninety-four patients with an average age of 7.3 years were admitted to the PICU with a TBI. The mortality rate was 12.7% at 14 days and at 6 months. For the CRASH-Basic model, the SMtR was 1.42 and both calibration (chi(2) = 6.1, p = 0.64) and discrimination (AUROC = 0.92) were good. For the IMPACT-Core model, the SMtR was 1.03 and the model was also well calibrated (chi(2) = 8.99, p = 0.34) and had good discrimination (AUROC = 0.85). Poor outcome was observed in 17% of the cohort and identified with the CRASH-Basic and IMPACT-Core models to varying degrees: standardized morbidity ratio = 0.89 vs 0.67, respectively; calibration = 6.5 (chi(2)) and 0.59 (p value) versus 8.52 (chi(2)) and 0.38 (p value), respectively; and discrimination (AUROC) = 0.92 versus 0.83, respectively. CONCLUSIONS Adult head injury models may be applied with sufficient accuracy to identify predictors of morbidity and mortality in pediatric TBI.	[Young, Adam M. H.; Guilfoyle, Mathew R.; Fernandes, Helen; Garnett, Matthew R.; Hutchinson, Peter J.] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Acad Neurosurg, Cambridge, England; [Agrawal, Shruti] Univ Cambridge, Addenbrookes Hosp, Dept Paediat Intens Care, Cambridge, England	Young, AMH (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Acad Neurosurg, Cambridge, England.	ay276@cam.ac.uk			Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986 ID79068, G1002277 ID98489]; National Institute for Health Research Biomedical Research Centre Cambridge (Neuroscience Theme, and Brain Injury and Repair Theme); NIHR Research Professorship; Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2014-14-005, NIHR-RP-R3-12-013] Funding Source: researchfish	We gratefully acknowledge financial support as follows. Research support was provided by the Medical Research Council (grant nos. G0600986 ID79068 and G1002277 ID98489) and the National Institute for Health Research Biomedical Research Centre Cambridge (Neuroscience Theme, and Brain Injury and Repair Theme). Dr. Hutchinson is supported by an NIHR Research Professorship and an Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS9; Bouras T, 2007, J NEUROTRAUM, V24, P1355, DOI 10.1089/neu.2005.370; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Han JL, 2014, J NEUROTRAUM, V31, P1146, DOI 10.1089/neu.2013.3003; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kolias Angelos G, 2013, Pract Neurol, V13, P228, DOI 10.1136/practneurol-2012-000268; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; LINGSMA HF, 2010, NED TIJDSCHR GENEES, V154, P107; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Maas Andrew I R, 2015, Handb Clin Neurol, V128, P455, DOI 10.1016/B978-0-444-63521-1.00029-7; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Mitra B, 2008, ANZ J SURG, V78, P588, DOI 10.1111/j.1445-2197.2008.04579.x; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X	20	12	12	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	NOV	2016	18	5					558	564		10.3171/2016.5.PEDS15427			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	DZ8FL	WOS:000386106200006	27564785	Bronze			2021-06-18	
J	Bartels, AN; Johnson, C; Lewis, J; Clevenger, JW; Barnes, SL; Hammer, RD; Ahmad, S				Bartels, Ashley N.; Johnson, Cory; Lewis, Julie; Clevenger, James W.; Barnes, Stephen L.; Hammer, Richard D.; Ahmad, Salman			Platelet adenosine diphosphate inhibition in trauma patients by thromboelastography correlates with paradoxical increase in platelet dense granule content by flow cytometry	SURGERY			English	Article							BRAIN-INJURY; INDUCED COAGULOPATHY; DYSFUNCTION; RELEASE; ASSAY	Background. The mechanism of platelet dysfunction in acute traumatic coagulopathy is unknown. Traumatic brain injury is hypothesized as a cause, while some investigators presume platelets become "exhausted." We hypothesized that platelet hyperstimulation and consumption resulting from trauma leads to decreased platelet function secondary to depletion of platelet granules. Methods. Twenty-five trauma patients were divided into traumatic brain injury and no traumatic brain injury groups. Healthy volunteers served as controls. All had thromboelastography with platelet mapping and flow cytometric assays of mepacrine performed. Mepacrine uptake in unstimulated platelets was used for quantification of platelet content of dense granules. Results. Twelve patients with traumatic brain injury and 13 patients without traumatic brain injury were enrolled. Twenty-one trauma patients showed adenosine diphosphate inhibition (>30%) on thromboelastography with platelet mapping compared with the healthy volunteers who served as controls (P < .01). Mepacrine assay showed a difference in mean fluorescent intensity for all trauma patients of 4,259 +/- 1,341 compared with controls of 3,143 +/- 709 (P = .044), correlating with greater quantities of dense granules. Neither adenosine diphosphate inhibition nor average difference in mean fluorescent intensity between traumatic brain injury and no traumatic brain injury groups were significant (P = .2). Conclusion. Trauma patients maintain their dense granule, contradicting the theory of platelet granule exhaustion as the etiology for platelet dysfunction in traumatic brain injury.	Univ Missouri, Hosp & Clin, Dept Surg, Div Acute Care Surg, Columbia, MO USA; Univ Missouri, Hosp & Clin, Dept Pathol & Anat Sci, Columbia, MO USA	Bartels, AN (corresponding author), One Hosp Dr,McHaney Hall 404, Columbia, MO 65212 USA.	bartelsan@health.missouri.edu		Barnes, Stephen/0000-0001-6186-1435; Ahmad, Salman/0000-0003-3862-0937; Hammer, Richard D./0000-0002-7173-9414	internal department of surgery grant	Supported by an internal department of surgery grant. The testing equipment for thromboelastography in controls was donated by Haeomoscope Corporation.	Briggs A, 2015, J SURG RES, V193, P802, DOI 10.1016/j.jss.2014.08.016; Cap A, 2015, ANAESTHESIA, V70, DOI 10.1111/anae.12914; Cardenas JC, 2014, CURR OPIN HEMATOL, V21, P404, DOI 10.1097/MOH.0000000000000063; Chapman M, 2016, AC SURG C 2016 JACKS; Chen LQ, 2004, J THORAC CARDIOV SUR, V128, P425, DOI 10.1016/j.jtcvs.2004.02.019; Cohen MJ, 2014, THROMB RES, V133, pS25, DOI 10.1016/j.thromres.2014.03.013; Davis PK, 2013, NEUROCRIT CARE, V18, P201, DOI 10.1007/s12028-012-9745-6; Epstein DS, 2014, INJURY, V45, P819, DOI 10.1016/j.injury.2014.01.011; Hammer RD, 2016, MODERN PATH IN PRESS; Kornblith LZ, 2014, J TRAUMA ACUTE CARE, V76, P255, DOI 10.1097/TA.0000000000000108; Kumar MA, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0391-y; Kunio NR, 2012, AM J SURG, V203, P584, DOI 10.1016/j.amjsurg.2011.12.011; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; McCully SP, 2013, SEMIN THROMB HEMOST, V39, P896, DOI 10.1055/s-0033-1357484; Michelson AD, 1996, BLOOD, V87, P4925, DOI 10.1182/blood.V87.12.4925.bloodjournal87124925; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Noel P, 2013, SEMIN HEMATOL, V50, P259, DOI 10.1053/j.seminhematol.2013.06.009; PARETI FI, 1980, AM J MED, V69, P235, DOI 10.1016/0002-9343(80)90383-6; Ramstrom AS, 1999, PLATELETS, V10, P153, DOI 10.1080/09537109976239; WALL JE, 1995, BRIT J HAEMATOL, V89, P380, DOI 10.1111/j.1365-2141.1995.tb03315.x; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050	22	12	12	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	OCT	2016	160	4					954	958		10.1016/j.surg.2016.07.012			5	Surgery	Surgery	DW6CG	WOS:000383733400028	27531317				2021-06-18	
J	Chen, C; Ma, TZ; Wang, LN; Wang, JJ; Tu, Y; Zhao, ML; Zhang, S; Sun, HT; Li, XH				Chen, Chong; Ma, Tie-Zhu; Wang, Li-Na; Wang, Jing-Jing; Tu, Yue; Zhao, Ming-Liang; Zhang, Sai; Sun, Hong-Tao; Li, Xiao-Hong			MILD HYPOTHERMIA FACILITATES THE LONG-TERM SURVIVAL OF NEWBORN CELLS IN THE DENTATE GYRUS AFTER TRAUMATIC BRAIN INJURY BY DIMINISHING A PRO-APOPTOTIC MICROENVIRONMENT	NEUROSCIENCE			English	Article						traumatic brain injury; mild hypothermia; survival; neurogenesis; apoptosis	ADULT HIPPOCAMPAL NEUROGENESIS; ENHANCED NEUROGENESIS; GRANULE CELLS; NEURONS; PROLIFERATION; MECHANISMS; FOREBRAIN; ISCHEMIA; NETWORK; STROKE	Although previous research has demonstrated that traumatic brain injury (TBI) accelerates the proliferation of neural stem cells in dentate gyrus of the hippocampus, most of these newborn cells undergo apoptosis in a traumatic microenvironment. Thus, promoting the long-term survival of newborn cells during neurogenesis is a compelling goal for the treatment of TBI. In this study, we investigated whether mild hypothermia (MHT) therapy, which mitigates the multiple secondary injury cascades of TBI, enhances the survival of newborn cells. SD rats were subjected to unilateral fluid percussion injury and received MHT therapy for 4 h (33.5 degrees C). Bromodeoxyuridine (BrdU) was administered to label the mitotic cells. Spatial learning and memory were evaluated with the Morris water maze test. Brain sections were immunostained with antibodies against BrdU, DCX (a neuroblast marker) or NeuN (a mature neuron marker). The apoptosis levels in the dentate gyrus were examined with antibodies against the apoptotic proteins FAS, FASL, Bcl-2 and cleaved caspase 3. The results indicated that MHT could significantly prevent TBI-induced cognitive impairments. At 1 week after injury, the density of BrdU-immunoreactive cells significantly increased in both TBI and TBI + MHT rats. At 4 weeks after injury, the density of BrdU-positive cells further increased in TBI + MHT rats, whereas the density declined in the TBI rats. The density of DCX-positive cells in SGZ of the hippocampus at 1 week after injury in the TBI + MHT rats was significantly greater than in the TBI rats. Moreover, the density of NeuN-positive cells in the subgranular zone at 4 weeks after injury and in the granule cell layer at 7 weeks after injury was significantly increased in the TBI + MHT rats. The TBI + MHT rats displayed a lower level of apoptosis in the dentate gyrus compared with the TBI rats. These data indicate that TBI could only facilitate a burst of proliferation and short-term survival of newborn cells, whereas TBI + MHT could facilitate long-term survival and maturation of newborn cells through diminishing pro-apoptotic microenvironment. These results suggest that MHT-mediated neurogenesis may have an important therapeutic potential for the endogenous repair of TBI. (C) 2016 IBRO. Published by Elsevier Ltd. All rights reserved.	[Sun, Hong-Tao; Li, Xiao-Hong] Logist Univ Chinese Peoples Armed Police Forces, Inst Traumat Brain Injury & Neurol, Pingjin Hosp, Tianjin 300162, Peoples R China; Key Lab Neurotrauma Repair Tianjin, Tianjin 300162, Peoples R China	Sun, HT; Li, XH (corresponding author), Logist Univ Chinese Peoples Armed Police Forces, Inst Traumat Brain Injury & Neurol, Pingjin Hosp, Tianjin 300162, Peoples R China.	chenmo333@163.com; lixiaohong12@hotmail.com			National Nature Scientific Fund of China [81301050, 81401067, 81271392, 81471275, 81541034]; National Nature Scientific Fund of Tianjin [14JCQNJC10200, 15JCQNJC11100]	This work was supported by the National Nature Scientific Fund of China (81301050, 81401067, 81271392, 81471275, 81541034) and the National Nature Scientific Fund of Tianjin (14JCQNJC10200, 15JCQNJC11100).	Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Cameron HA, 1998, J NEUROBIOL, V36, P287, DOI 10.1002/(SICI)1097-4695(199808)36:2<287::AID-NEU13>3.0.CO;2-B; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chen C, 2014, NEUROSCIENCE, V257, P1, DOI 10.1016/j.neuroscience.2013.10.056; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Choi HA, 2012, NAT REV NEUROL, V8, P214, DOI 10.1038/nrneurol.2012.21; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dayer AG, 2003, J COMP NEUROL, V460, P563, DOI 10.1002/cne.10675; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Eisch AJ, 2002, PROG BRAIN RES, V138, P315, DOI 10.1016/S0079-6123(02)38085-3; Faridar Alireza, 2011, Front Neurol, V2, P80, DOI 10.3389/fneur.2011.00080; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; Gould E, 2007, NAT REV NEUROSCI, V8, P481, DOI 10.1038/nrn2147; Harburg GC, 2007, NEUROSCIENCE, V144, P77, DOI 10.1016/j.neuroscience.2006.09.018; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Li XH, 2013, MOL NEUROBIOL, V48, P490, DOI 10.1007/s12035-013-8437-3; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Miyazawa T, 2003, NEUROL RES, V25, P457, DOI 10.1179/016164103101201850; Mouret A, 2008, J NEUROSCI, V28, P11511, DOI 10.1523/JNEUROSCI.2954-08.2008; Okano HJ, 1996, DEV NEUROSCI-BASEL, V18, P199, DOI 10.1159/000111408; Olsen TS, 2003, LANCET NEUROL, V2, P410, DOI 10.1016/S1474-4422(03)00436-8; Platel JC, 2010, NEURON, V65, P859, DOI 10.1016/j.neuron.2010.03.009; Potts MB, 2009, J NEUROSCI RES, V87, P1848, DOI 10.1002/jnr.21996; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Sierra A, 2010, CELL STEM CELL, V7, P483, DOI 10.1016/j.stem.2010.08.014; Sun W, 2004, J NEUROSCI, V24, P11205, DOI 10.1523/JNEUROSCI.1436-04.2004; Tsukamoto K, 2006, NATURE, V439, P929, DOI 10.1038/439929a; Tu Y, 2012, J NEUROTRAUM, V29, P2393, DOI 10.1089/neu.2012.2374; van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhang YL, 2012, EXP NEUROL, V235, P336, DOI 10.1016/j.expneurol.2012.02.015; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	40	12	16	2	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	OCT	2016	335						114	121		10.1016/j.neuroscience.2016.08.038			8	Neurosciences	Neurosciences & Neurology	DW9XR	WOS:000384016600011	27583772				2021-06-18	
J	Chen, YN; Holstein, DM; Aime, S; Bollo, M; Lechleiter, JD				Chen, Yanan; Holstein, Deborah M.; Aime, Sofia; Bollo, Mariana; Lechleiter, James D.			Calcineurin beta protects brain after injury by activating the unfolded protein response	NEUROBIOLOGY OF DISEASE			English	Article						Calcium; Stress; Ischemia; Traumatic brain injury; Endoplasmic reticulum	ENDOPLASMIC-RETICULUM STRESS; CELL-DEATH; OXIDATIVE STRESS; AMYLOID-BETA; ER STRESS; A-ALPHA; PERK; KINASE; GENE; INHIBITION	The Ca2+-dependent phosphatase, calcineurin (CN) is thought to play a detrimental role in damaged neurons; however, its role in astrocytes is unclear. In cultured astrocytes, CN beta expression increased after treatment with a sarco/endoplasmic reticulum Ca2+-ATPase inhibitor, thapsigargin, and with oxygen and glucose deprivation, an in vitro model of ischemia. Similarly, CN beta was induced in astrocytes in vivo in two different mouse models of brain injury - photothrombotic stroke and traumatic brain injury (TBI). Immunoprecipitation and chemical activation dimerization methods pointed to physical interaction of CN beta with the unfolded protein response (UPR) sensor, protein kinase RNA-like endoplasmic reticulum kinase (PERK). In accordance, induction of CN beta resulted in oligomerization and activation of PERK. Strikingly, the presence of a phosphatase inhibitor did not interfere with CN beta-mediated activation of PERK, suggesting a hitherto undiscovered non-enzymatic role for CN beta. Importantly, the cytoprotective function of CN beta was PERK-dependent both in vitro and in vivo. Loss of CN beta in vivo resulted in a significant increase in cerebral damage, and correlated with a decrease in astrocyte size, PERK activity and glial fibrillary acidic protein (GFAP) expression. Taken together, these data reveal a critical role for the CN beta-PERK axis in not only prolonging astrocyte cell survival but also in modulating astrogliosis after brain injury. (C) 2016 The Authors. Published by Elsevier Inc.	[Chen, Yanan; Holstein, Deborah M.; Lechleiter, James D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA; [Aime, Sofia; Bollo, Mariana] Univ Nacl Cordoba, INIMEC CONICET, Inst Invest Med M&M Ferreyra, Cordoba, Argentina; [Lechleiter, James D.] Univ Texas Hlth Sci Ctr San Antonio, Ctr Biomed Neurosci, San Antonio, TX 78229 USA	Bollo, M; Lechleiter, JD (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.; Bollo, M; Lechleiter, JD (corresponding author), Univ Nacl Cordoba, INIMEC CONICET, Inst Invest Med M&M Ferreyra, Cordoba, Argentina.	lechleiter@uthscsa.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS085732, 155726/155448]; National Institutes of Health (UTHASCA/Institute Ferreyra)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Ministerio de Ciencia y Tecnologia de Cordoba, Argentina [PID-2010]; Fulbright/CONICET (Argentina) Fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS085732] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (NS085732, 2013 Subaward Agreement 155726/155448; UTHASCA/Institute Ferreyra), Ministerio de Ciencia y Tecnologia de Cordoba, Argentina (PID-2010) and Fulbright/CONICET (Argentina) Fellowship.	Abdul HM, 2009, J NEUROSCI, V29, P12957, DOI 10.1523/JNEUROSCI.1064-09.2009; Agostinho P, 2008, NEUROCHEM INT, V52, P1226, DOI 10.1016/j.neuint.2008.01.005; Axten JM, 2012, J MED CHEM, V55, P7193, DOI 10.1021/jm300713s; Badiola N, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.31; Bertolotti A, 2000, NAT CELL BIOL, V2, P326; Bollo M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011925; Brostrom MA, 2003, CELL CALCIUM, V34, P345, DOI 10.1016/S0143-4160(03)00127-1; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Fernandez AM, 2007, J NEUROSCI, V27, P8745, DOI 10.1523/JNEUROSCI.1002-07.2007; Gotoh T, 2002, J BIOL CHEM, V277, P12343, DOI 10.1074/jbc.M107988200; Han D, 2009, CELL, V138, P562, DOI 10.1016/j.cell.2009.07.017; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Hashimoto T, 1998, J NEUROCHEM, V70, P1289; He SK, 2008, GRAEF ARCH CLIN EXP, V246, P677, DOI 10.1007/s00417-008-0770-2; Holguin A, 2004, J CLIN VIROL, V31, P215, DOI 10.1016/j.jcv.2004.03.015; Honsho M, 1998, J BIOL CHEM, V273, P20860, DOI 10.1074/jbc.273.33.20860; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; Kaufman RJ, 2004, TRENDS BIOCHEM SCI, V29, P152, DOI 10.1016/j.tibs.2004.01.004; KLEE CB, 1978, BIOCHEMISTRY-US, V17, P120, DOI 10.1021/bi00594a017; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Komatsu T, 2010, NAT METHODS, V7, P206, DOI [10.1038/nmeth.1428, 10.1038/NMETH.1428]; Kovacs GG, 2005, AM J PHYSIOL-CELL PH, V289, pC361, DOI 10.1152/ajpcell.00280.2004; Krajewska M, 2011, BRAIN RES, V1370, P227, DOI 10.1016/j.brainres.2010.11.015; Kumar R, 2003, J CEREBR BLOOD F MET, V23, P462, DOI 10.1097/01.WCB.0000056064.25434.CA; Kumar R, 2001, J NEUROCHEM, V77, P1418, DOI 10.1046/j.1471-4159.2001.00387.x; KUNO T, 1992, J NEUROCHEM, V58, P1643, DOI 10.1111/j.1471-4159.1992.tb10036.x; Kurz JE, 2005, J NEUROTRAUM, V22, P476, DOI 10.1089/neu.2005.22.476; Lei H, 2011, FOOD CHEM, V127, P1169, DOI 10.1016/j.foodchem.2011.01.119; Li YF, 2012, PROTEIN EXPRES PURIF, V82, P162, DOI 10.1016/j.pep.2011.12.008; Lim D, 2013, GLIA, V61, P1134, DOI 10.1002/glia.22502; Lin DT, 2007, NEUROBIOL AGING, V28, P99, DOI 10.1016/j.neurobiolaging.2005.11.004; Lin JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004170; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; Ma K, 2002, J BIOL CHEM, V277, P18728, DOI 10.1074/jbc.M200903200; Moreno JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006767; Moreno JA, 2012, NATURE, V485, P507, DOI 10.1038/nature11058; Mounir Z, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001630; Nakka VP, 2014, MOL NEUROBIOL, V9; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; Norris CM, 2005, J NEUROSCI, V25, P4649, DOI 10.1523/JNEUROSCI.0365-05.2005; Owen CR, 2005, J NEUROCHEM, V94, P1235, DOI 10.1111/j.1471-4159.2005.03276.x; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Paredes RM, 2013, CELL CALCIUM, V53, P286, DOI 10.1016/j.ceca.2013.01.002; PARKER MW, 1990, J MOL BIOL, V213, P221, DOI 10.1016/S0022-2836(05)80183-4; Paschen W, 2004, CURR NEUROVASC RES, V1, P173, DOI 10.2174/1567202043480125; Pennuto M, 2008, NEURON, V57, P393, DOI 10.1016/j.neuron.2007.12.021; Polley S, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001581; POLLI JW, 1991, DEV BRAIN RES, V63, P105, DOI 10.1016/0165-3806(91)90071-P; Pyrzynska B, 2001, NEUROCHEM INT, V38, P409, DOI 10.1016/S0197-0186(00)00105-4; Reese LC, 2008, AGING CELL, V7, P824, DOI 10.1111/j.1474-9726.2008.00434.x; RICHARME G, 1982, BIOCHEM BIOPH RES CO, V105, P476, DOI 10.1016/0006-291X(82)91459-0; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Ryu EJ, 2002, J NEUROSCI, V22, P10690; Shioda N, 2011, YAKUGAKU ZASSHI, V131, P13, DOI 10.1248/yakushi.131.13; Stanley SK, 2004, SPINE, V29, pE510, DOI 10.1097/01.brs.0000145417.94357.39; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; Tajiri S, 2004, CELL DEATH DIFFER, V11, P403, DOI 10.1038/sj.cdd.4401365; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Trendelenburg G, 2005, GLIA, V50, P307, DOI 10.1002/glia.20204; Volmer R, 2013, P NATL ACAD SCI USA, V110, P4628, DOI 10.1073/pnas.1217611110; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang H, 2010, J BIOCHEM, V147, P185, DOI 10.1093/jb/mvp163; Wang R, 2013, J BIOL CHEM, V288, P33824, DOI 10.1074/jbc.M113.503664; Watts LT, 2013, J NEUROTRAUM, V30, P55, DOI 10.1089/neu.2012.2488; Welihinda AA, 1996, J BIOL CHEM, V271, P18181, DOI 10.1074/jbc.271.30.18181; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Yamani L, 2014, MOL BIOL CELL, V25, P702, DOI 10.1091/mbc.E13-09-0511; Zheng W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014401; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	71	12	12	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	OCT	2016	94						139	156		10.1016/j.nbd.2016.06.011			18	Neurosciences	Neurosciences & Neurology	DT9QF	WOS:000381836700014	27334877	Other Gold, Green Accepted, Green Published			2021-06-18	
J	Hamed, M; Schuss, P; Daher, FH; Borger, V; Guresir, A; Vatter, H; Guresir, E				Hamed, Motaz; Schuss, Patrick; Daher, Frederick H.; Borger, Valeri; Gueresir, Agi; Vatter, Hartmut; Gueresir, Erdem			Acute Traumatic Subdural Hematoma: Surgical Management in the Presence of Cerebral Herniation-A Single-Center Series and Multivariate Analysis	WORLD NEUROSURGERY			English	Article						Acute subdural hematoma; Cerebral herniation; Surgical treatment; Traumatic brain injury	DECOMPRESSIVE CRANIECTOMY; BRAIN-INJURY; POSTOPERATIVE COMPLICATIONS; INTRACRANIAL HEMORRHAGE; FUNCTIONAL RECOVERY; COMATOSE PATIENTS; BONE FLAP; MORTALITY; CRANIOTOMY; CRANIOPLASTY	BACKGROUND: Traumatic acute subdural hematoma (aSDH) is a severe disease. Surgical treatment is still controversially discussed, especially in patients with additional signs of cerebral herniation. However, previously investigated patient populations were heterogeneous. We therefore performed an analysis of our institutional data in a large homogenous selection of patients with traumatic aSDH to analyze factors determining clinical outcome. METHODS: Between 2010 and 2014, 196 patients with aSDH underwent surgical treatment in our department. Information including patient characteristics, treatment modality, radiologic features, and functional outcome were analyzed. Outcome was assessed according to the Glasgow Outcome Scale (GOS) at 6 months and was dichotomized into favorable (GOS score, 1-3) and unfavorable (GOS score 4-5) outcome. Furthermore, a multivariate analysis was performed to identify independent predictors of functional outcome. RESULTS: Overall, 26% of patients with aSDH achieved favorable outcome. In further analysis, unilateral or bilateral dilated pupils as a sign of cerebral herniation were present in 47% of the included patients. In the multivariate analysis, age >70 years and the presence of cerebral herniation were significant prognostic predictors for unfavorable outcome in patients with aSDH. However, 15% of patients with aSDH and signs of cerebral herniation achieved favorable outcome during follow-up. CONCLUSIONS: We provide detailed data on patients with aSDH and signs of cerebral herniation. Despite mydriasis, favorable outcome may be achieved in many patients. Nevertheless, careful individual decision making is necessary for each patient, especially when signs of cerebral herniation have persisted for a long time.	[Hamed, Motaz; Schuss, Patrick; Daher, Frederick H.; Borger, Valeri; Gueresir, Agi; Vatter, Hartmut; Gueresir, Erdem] Rhein Friedrich Wilhelms Univ, Dept Neurosurg, Bonn, Germany	Schuss, P (corresponding author), Rhein Friedrich Wilhelms Univ, Dept Neurosurg, Bonn, Germany.	patrick.schuss@ukb.uni-bonn.de	guresir, erdem/AAL-4484-2020; Schuss, Patrick/ABC-6469-2020	guresir, erdem/0000-0002-6624-6885; Schuss, Patrick/0000-0002-5806-2576; Guresir, Erdem/0000-0001-8319-0847			ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010; Arifin MZ, 2013, J NEUROSURG SCI, V57, P277; Campbell PG, 2010, WORLD NEUROSURG, V74, P279, DOI 10.1016/j.wneu.2010.05.030; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Guresir E, 2011, J NEUROSURG, V114, P954, DOI 10.3171/2009.12.JNS091065; Herou E, 2015, WORLD NEUROSURG, V83, P996, DOI 10.1016/j.wneu.2015.02.023; Honeybul S, 2016, ACTA NEUROCHIR, V158, P1251, DOI 10.1007/s00701-016-2818-0; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P817, DOI 10.1097/TA.0b013e3182aafcf0; Karibe H, 2014, NEUROL MED-CHIR, V54, P887, DOI 10.2176/nmc.cr.2014-0204; Kim KH, 2009, J KOREAN NEUROSURG S, V45, P143, DOI 10.3340/jkns.2009.45.3.143; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Kolias AG, 2013, BRIT J NEUROSURG, V27, P330, DOI 10.3109/02688697.2013.779365; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; Leong BK, 2013, DISABIL REHABIL, V35, P1546, DOI 10.3109/09638288.2012.748832; Li LM, 2012, ACTA NEUROCHIR, V154, P1555, DOI 10.1007/s00701-012-1428-8; Marion DW, 2006, NEUROSURGERY, V58, P655; Nishijima DK, 2012, J TRAUMA ACUTE CARE, V72, P1658, DOI 10.1097/TA.0b013e318256dfc5; Panczykowski DM, 2011, J NEUROSURG, V114, P47, DOI 10.3171/2010.7.JNS10446; Raj R, 2016, WORLD NEUROSURG, V88, P592, DOI 10.1016/j.wneu.2015.10.095; Rush B, 2016, WORLD NEUROSURG, V88, P25, DOI 10.1016/j.wneu.2015.12.034; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; Schuss P, 2015, WORLD NEUROSURG, V84, P1051, DOI 10.1016/j.wneu.2015.05.066; Schuss P, 2013, J NEUROTRAUM, V30, P91, DOI 10.1089/neu.2012.2542; Schuss P, 2012, J NEUROTRAUM, V29, P1090, DOI 10.1089/neu.2011.2176; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Senft C, 2009, NEUROL RES, V31, P1012, DOI 10.1179/174313209X409034; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Tsermoulas G, 2016, WORLD NEUROSURG, V88, P569, DOI 10.1016/j.wneu.2015.10.045; Woertgen C, 2006, J CLIN NEUROSCI, V13, P718, DOI 10.1016/j.jocn.2005.08.019	30	12	14	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	OCT	2016	94						501	506		10.1016/j.wneu.2016.07.061			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EF5EJ	WOS:000390353200066	27465422				2021-06-18	
J	Jang, SH; Kim, SY				Jang, Sung Ho; Kim, Sung Yup			Injury of the Corticospinal Tract in Patients with Mild Traumatic Brain Injury: A Diffusion Tensor Tractography Study	JOURNAL OF NEUROTRAUMA			English	Article						corticospinal tract; diffusion tensor imaging; hand function; mild traumatic brain injury; motor weakness	AXONAL INJURY; WHITE-MATTER; MAGNETIC STIMULATION; CLINICAL-APPLICATION; IMAGING FINDINGS; MOTOR WEAKNESS; REHABILITATION; EPIDEMIOLOGY; MULTICENTER; IMPAIRMENT	Motor weakness is an important sequela after traumatic brain injury (TBI). Although the majority of cases of TBI are classified as mild TBI, little is known about motor weakness in mild TBI. In this study, we attempted to investigate injury of the corticospinal tract (CST), an important neural tract for motor function, in patients with mild TBI, using diffusion tensor tractography (DTT). There were 53 patients with mild TBI and 36 control subjects who were recruited. The patients were assigned to two groups according to the presence of abnormality of the right (dominant) hand function in terms of fine motor activity and grip strength: group A-abnormal hand function, group B-normal hand function. The left CST was reconstructed, and DTT parameters (fractional anisotropy [FA] and fiber number) and configuration were estimated. There were 35 (66%) patients who had an abnormal function of the right hand. The values of FA and fiber number of patient group A were significantly lower than those of patient group B and the control group (p < 0.001). On configurational analysis of DTT for the left CST in patient group A, 80% showed partial tearing at the subcortical white matter and 20% showed narrowing. We found that in terms of DTT parameters and configuration, a significant portion of patients with mild TBI showed injury of the CST. These results suggest that DTT could provide useful information in detecting injury of the CST, and evaluation of the CST using DTT would be necessary for patients who complain of hand weakness after mild TBI.	[Jang, Sung Ho; Kim, Sung Yup] Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, 317-1 Daemyungdong, Taegu 705717, South Korea	Kim, SY (corresponding author), Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, 317-1 Daemyungdong, Taegu 705717, South Korea.	yup331@hanmail.net					ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Bonnard M, 2007, EUR J NEUROSCI, V25, P872, DOI 10.1111/j.1460-9568.2007.05320.x; Brown AW, 2007, BRAIN INJURY, V21, P673, DOI 10.1080/02699050701468925; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cho HK, 2011, BRAIN INJURY, V25, P1005, DOI 10.3109/02699052.2011.605095; Choi GS, 2012, ARCH NEUROL-CHICAGO, V69, P363, DOI 10.1001/archneurol.2011.1930; Compston A, 2010, BRAIN, V133, P2835, DOI 10.1093/brain/awq274; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; DAVIDOFF RA, 1990, NEUROLOGY, V40, P332; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Jang SH, 2014, NEUROSCI LETT, V572, P1, DOI 10.1016/j.neulet.2014.04.044; Jang SH, 2014, J REHABIL MED, V46, P193, DOI 10.2340/16501977-1782; Jang SH, 2011, NEUROREHABILITATION, V29, P339, DOI 10.3233/NRE-2011-0710; Jang SH, 2011, YONSEI MED J, V52, P553, DOI 10.3349/ymj.2011.52.4.553; Jang SH, 2009, NEUROREHABILITATION, V25, P229, DOI 10.3233/NRE-2009-0519; Jang SH, 2009, NEUROREHABILITATION, V24, P285, DOI 10.3233/NRE-2009-0480; Jang SH, 2009, NEUROREHABILITATION, V24, P273, DOI 10.3233/NRE-2009-0478; Kasahara K, 2012, MAGN RESON IMAGING, V30, P496, DOI 10.1016/j.mri.2011.12.018; Kim DG, 2007, NEUROREHABILITATION, V22, P273; Kim YT, 1994, J KOREAN ACAD REHAB, V18, P780; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kunimatsu Akira, 2004, Magn Reson Med Sci, V3, P11, DOI 10.2463/mrms.3.11; Lee AY, 2012, NEUROSCI LETT, V528, P16, DOI 10.1016/j.neulet.2012.08.053; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Neil JJ, 2008, J MAGN RESON IMAGING, V27, P1, DOI 10.1002/jmri.21087; Pagani E, 2008, NEUROIMAGE, V41, P657, DOI 10.1016/j.neuroimage.2008.03.021; Parker GJM, 2005, PHILOS T R SOC B, V360, P893, DOI 10.1098/rstb.2005.1639; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Seo JP, 2015, BRAIN INJURY, V29, P110, DOI 10.3109/02699052.2014.973447; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Skoglund TS, 2008, ACTA RADIOL, V49, P98, DOI 10.1080/02841850701561372; SMITH RO, 1985, AM J OCCUP THER, V39, P531, DOI 10.5014/ajot.39.8.531; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Tiffin J, 1948, J APPL PSYCHOL, V32, P234, DOI 10.1037/h0061266; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Yasokawa YT, 2007, J NEUROTRAUM, V24, P163, DOI 10.1089/neu.2006.0073; Yoo JS, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-121; YORK DH, 1987, NEUROSURGERY, V20, P70	45	12	12	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2016	33	19					1790	1795		10.1089/neu.2015.4298			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DY8KP	WOS:000385379100008					2021-06-18	
J	Ohsawa, M; Ishikura, K; Mutoh, J; Hisa, H				Ohsawa, Masahiro; Ishikura, Kei-ichiro; Mutoh, Junpei; Hisa, Hiroaki			INVOLVEMENT OF INHIBITION OF RhoA/Rho KINASE SIGNALING IN SIMVASTATIN-INDUCED AMELIORATION OF NEUROPATHIC PAIN	NEUROSCIENCE			English	Article						Rho kinase (ROCK); RhoA; myristoylated alanine-rich protein kinase C substrate (MARCKS); astrocyte; neuropathic pain; simvastatin	SPINAL-CORD ASTROCYTES; TRAUMATIC BRAIN-INJURY; SCIATIC-NERVE LIGATION; PROTEIN-KINASE; RHO-KINASE; SUBSTRATE PHOSPHORYLATION; NOCICEPTIVE TRANSMISSION; REDUCTASE INHIBITORS; THERMAL HYPERALGESIA; RAT MODEL	Small molecular G-protein plays a key role in several diseases. This study was designed to reveal the role of RhoA signaling in the pathophysiology of neuropathic pain in mice. Partial sciatic nerve injury caused thermal hyperalgesia, mechanical allodynia, and increased plasma membrane translocation of RhoA in the lumber spinal cord. GFAP-immunoreactivity (ir), Iba-1-ir, and Rho kinase 2 (ROCK2-ir) was also increased in the ipsilateral spinal dorsal horn of nerve-ligated mice. Moreover, partial nerve ligation increased the expression of phosphorylated myristoylated alanine-rich protein kinase C substrate (MARCKS)-ir in the ipsilateral spinal dorsal horn. Daily intrathecal administration of simvastatin, beginning 3 days before nerve injury, completely blocked all these changes in nerve-ligated mice. Pharmacological inhibition of ROCK also attenuated the increased expression of GFAP-ir and phosphorylated MARCKS-ir. Together, it is suggested that astrogliosis initiated by the activation of RhoA/ROCK signaling results in MARCKS phosphorylation in nerve terminals, which leads to hyperalgesia in neuropathic pain. Furthermore, simvastatin exerts antihyperalgesic and antiallodynic effects through the inhibition of spinal RhoA activation. (C) 2016 IBRO. Published by Elsevier Ltd. All rights reserved.	[Ohsawa, Masahiro; Mutoh, Junpei; Hisa, Hiroaki] Kyushu Univ Hlth & Welf, Sch Pharmaceut Sci, Dept Pharmacol 2, 1714-1 Yoshino Machi, Nobeoka, Miyazaki 8828508, Japan; [Ohsawa, Masahiro; Ishikura, Kei-ichiro] Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Neuropharmacol, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan	Ohsawa, M (corresponding author), Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Neuropharmacol, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.	ohsawa@phar.nagoya-cu.ac.jp			Ministry of Education, Science, Sports and Culture of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [25460724, 18790187, 23790646]; Nakatomi Foundation	This study was supported by a Grant-in-Aid for Scientific Research (C) Grant Number 25460724 (MO) and a Grant-in-Aid for Young Scientist (B) Grant Numbers 18790187 (MO) and 23790646 (MO) from the Ministry of Education, Science, Sports and Culture of Japan and the Nakatomi Foundation to M. O. We express our appreciation to Ms. Mari Oji, Ms. Aki Kihara, and Ms. Eiko Uematsu for their technical assistance.	Arbuzova A, 2002, BIOCHEM J, V362, P1, DOI 10.1042/0264-6021:3620001; Barsante MM, 2005, EUR J PHARMACOL, V516, P282, DOI 10.1016/j.ejphar.2005.05.005; Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028; Brabeck C, 2004, J NEUROTRAUM, V21, P697, DOI 10.1089/0897715041269597; Bubb MR, 1999, J BIOL CHEM, V274, P36472, DOI 10.1074/jbc.274.51.36472; Buyukafsar K, 2006, EUR J PHARMACOL, V541, P49, DOI 10.1016/j.ejphar.2006.04.042; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chen XY, 2013, J PAIN, V14, P1310, DOI 10.1016/j.jpain.2013.05.011; Deyts C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008287; Ding J, 2010, J NEUROCHEM, V114, P1619, DOI 10.1111/j.1471-4159.2010.06876.x; DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; Inoue M, 2004, NAT MED, V10, P712, DOI 10.1038/nm1060; Ji RR, 2009, BRAIN RES REV, V60, P135, DOI 10.1016/j.brainresrev.2008.12.011; Malmberg AB, 1997, SCIENCE, V278, P279, DOI 10.1126/science.278.5336.279; Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617; Narita M, 2004, EUR J NEUROSCI, V19, P479, DOI 10.1111/j.0953-816X.2003.03119.x; Ohkawara H, 2005, J BIOL CHEM, V280, P10182, DOI 10.1074/jbc.M409547200; Ohsawa M, 2000, EUR J PHARMACOL, V403, P81, DOI 10.1016/S0014-2999(00)00571-9; Ohsawa M, 2002, PAIN, V100, P27, DOI 10.1016/S0304-3959(02)00207-5; Ohsawa M, 2008, PAIN, V134, P285, DOI 10.1016/j.pain.2007.04.031; Ohsawa M, 2014, NEUROSCI LETT, V564, P27, DOI 10.1016/j.neulet.2014.01.039; Ohsawa M, 2012, J PHARMACOL SCI, V119, P102, DOI 10.1254/jphs.12007SC; Ohsawa M, 2011, PAIN, V152, P114, DOI 10.1016/j.pain.2010.10.005; Ohsawa M, 2010, EUR J PHARMACOL, V644, P1, DOI 10.1016/j.ejphar.2010.07.007; Piao C, 2015, EXP NEUROL, V273, P288, DOI 10.1016/j.expneurol.2015.09.009; Raghavendra V, 2003, PAIN, V104, P655, DOI 10.1016/S0304-3959(03)00138-6; Raghavendra V, 2003, J PHARMACOL EXP THER, V306, P624, DOI 10.1124/jpet.103.052407; Ramer LM, 2004, J NEUROSCI, V24, P10796, DOI 10.1523/JNEUROSCI.3337-04.2004; Rose SD, 2001, J BIOL CHEM, V276, P36757, DOI 10.1074/jbc.M006518200; Santodomingo-Garzon T, 2006, BRIT J PHARMACOL, V149, P14, DOI 10.1038/sj.bjp.0706836; Sasaki Y, 2003, J PHARMACOL SCI, V93, P35, DOI 10.1254/jphs.93.35; Scholz J, 2002, NAT NEUROSCI, V5, P1062, DOI 10.1038/nn942; SELTZER Z, 1990, PAIN, V43, P205, DOI 10.1016/0304-3959(90)91074-S; Shi XQ, 2011, PAIN, V152, P1033, DOI 10.1016/j.pain.2011.01.006; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; Tatsumi S, 2005, NEUROSCIENCE, V131, P491, DOI 10.1016/j.neuroscience.2004.10.022; Willey JZ, 2010, ARCH NEUROL-CHICAGO, V67, P1062, DOI 10.1001/archneurol.2010.199; Xu M, 2007, J NEUROSCI, V27, P2570, DOI 10.1523/JNEUROSCI.3728-06.2007; Yang H, 2002, HYPERTENSION, V39, P567, DOI 10.1161/hy0202.103052; Zhang ZR, 2008, ACTA NEUROPATHOL, V115, P335, DOI 10.1007/s00401-007-0301-y	41	12	12	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	OCT 1	2016	333						204	213		10.1016/j.neuroscience.2016.07.029			10	Neurosciences	Neurosciences & Neurology	DU1BU	WOS:000381942000019	27457035				2021-06-18	
J	Liao, KH; Sung, CW; Chu, SF; Chiu, WT; Chiang, YH; Hoffer, B; Ou, JC; Chen, KY; Tsai, SH; Lin, CM; Chen, GS; Li, WJ; Wang, JY				Liao, Kuo-Hsing; Sung, Chih-Wei; Chu, Shu-Fen; Chiu, Wen-Ta; Chiang, Yung-Hsiao; Hoffer, Barry; Ou, Ju-Chi; Chen, Kai-Yun; Tsai, Shin-Han; Lin, Chien-Min; Chen, Gunng-Shinng; Li, Wei-Jiun; Wang, Jia-Yi			Reduced power spectra of heart rate variability are correlated with anxiety in patients with mild traumatic brain injury	PSYCHIATRY RESEARCH			English	Article						mTBI; Anxiety; Heart rate variability; Low-frequency (LF) power	FREQUENCY-DOMAIN PARAMETERS; UNITED-STATES; MAJOR DEPRESSION; PSYCHOMETRIC PROPERTIES; RISK FACTOR; VAGAL TONE; DISORDERS; INVENTORY; DISEASE; IMPACT	Anxiety is one of the most frequently diagnosed emotional disorders after a mild traumatic brain injury (mTBI); however, predictors of anxiety after an mTBI remain uncertain. Recent research indicated that anxiety is associated with abnormalities in the autonomic nervous system (ANS) which can be evaluated by a power spectral analysis of heart rate variability (HRV). In this study, we investigated whether a frequency-domain analysis of HRV could correlate with the occurrence of anxiety in mTBI patients. We recruited 165 Taiwanese patients diagnosed with an mTBI and 82 volunteer healthy controls from three affiliated hospitals of Taipei Medical University during 2010-2014. The Beck Anxiety Inventory (BAI) was assessed at the 1st, 6th, and 12th weeks. We found that mTBI patients were more vulnerable to anxiety compared to healthy controls. The power spectral density of HRV was significantly lower in mTBI patients than in healthy controls. A correlation analysis indicated that anxiety was negatively significantly correlated with low- and high-frequency power at the 6th week. Our study suggests the clinical usefulness of HRV as a potential noninvasive tool for evaluating later anxiety in mTBI patients. (C) 2016 Elsevier Ireland Ltd. All rights reserved.	[Liao, Kuo-Hsing] Taipei Med Univ, Wan Fang Hosp, Dept Surg, Div Neurosurg, Taipei, Taiwan; [Sung, Chih-Wei; Chen, Gunng-Shinng; Wang, Jia-Yi] Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taipei, Taiwan; [Sung, Chih-Wei; Li, Wei-Jiun] Taipei Med Univ, Sch Med, Coll Med, Taipei, Taiwan; [Chu, Shu-Fen; Chiu, Wen-Ta; Tsai, Shin-Han] Taipei Med Univ, Grad Inst Injury & Prevent, Coll Publ Hlth, Taipei, Taiwan; [Chiang, Yung-Hsiao] Taipei Med Univ, Taipei Med Univ Hosp, Dept Surg, Div Neurosurg, Taipei, Taiwan; [Chiang, Yung-Hsiao] Taipei Med Univ, Coll Med Sci & Technol, Grad Program Neuroregenerat, Taipei, Taiwan; [Chiang, Yung-Hsiao] Taipei Med Univ, Ctr Neurotrauma & Neuroregenerat, Taipei, Taiwan; [Hoffer, Barry; Chen, Kai-Yun] Taipei Med Univ, Shuang Ho Hosp, Dept Emergency Med, New Taipei, Taiwan; [Ou, Ju-Chi; Lin, Chien-Min] Taipei Med Univ, Shuang Ho Hosp, Dept Surg, Div Neurosurg, New Taipei, Taiwan; [Chen, Gunng-Shinng] Triserv Gen Hosp, Dept Dent, Div Orthodont & Dentofacial Orthoped & Pedodont, Taipei, Taiwan; [Wang, Jia-Yi] Taipei Med Univ, Sch Med, Dept Physiol, Coll Med, 250 Wu Xing St, Taipei 110, Taiwan	Wang, JY (corresponding author), Taipei Med Univ, Sch Med, Dept Physiol, Coll Med, 250 Wu Xing St, Taipei 110, Taiwan.; Wang, JY (corresponding author), Taipei Med Univ, Coll Med, Sch Med, Grad Inst Med Sci, 250 Wu Xing St, Taipei 110, Taiwan.	jywang2010@tmu.edu.tw		Wang, Jia-Yi/0000-0002-9106-3351; Sung, Chih-Wei/0000-0003-3312-2752	Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST-103-2321-B-038-002, MOST-104-2923-B-038-001-MY3, MOST-102-2815-C-038-071-B]; Taipei Medical University, Taiwan; Wan Fang Hospital, Taipei, Taiwan [99TMU-WFH-11]	This work was supported in part by Grants from the Ministry of Science and Technology, Taiwan (MOST-103-2321-B-038-002 and MOST-104-2923-B-038-001-MY3) to JYW and (MOST-102-2815-C-038-071-B) to CWS and from Taipei Medical University, Taiwan and Wan Fang Hospital (99TMU-WFH-11), Taipei, Taiwan.	Alvares GA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070468; Arciniegas DB, 2001, BRAIN INJURY, V15, P649, DOI 10.1080/02699050010019800; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; BECK AT, 1991, AM J PSYCHIAT, V148, P1195; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Berntson GG, 2007, BIOL PSYCHOL, V74, P295, DOI 10.1016/j.biopsycho.2006.08.006; Berntson GG, 1997, PSYCHOPHYSIOLOGY, V34, P623, DOI 10.1111/j.1469-8986.1997.tb02140.x; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Blom EH, 2010, ACTA PAEDIATR, V99, P604, DOI 10.1111/j.1651-2227.2009.01657.x; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P255, DOI 10.1053/apmr.2003.50092; Butcher I, 2007, J NEUROTRAUM, V24, P281, DOI 10.1089/neu.2006.0030; Cameron O, 1996, PSYCHOSOM MED, V58, P111, DOI 10.1097/00006842-199603000-00002; Carney RM, 2002, J PSYCHOSOM RES, V53, P897, DOI 10.1016/S0022-3999(02)00311-2; CARNEY RM, 1995, ANN BEHAV MED, V17, P142, DOI 10.1007/BF02895063; Carroll L.J., 2004, J REHABIL MED S, pS113; Casati D, 2014, EXP PHYSIOL, V99, P466, DOI 10.1113/expphysiol.2013.076539; Chang HA, 2013, PSYCHIAT INVEST, V10, P326, DOI 10.4306/pi.2013.10.4.326; Chen CF, 2013, J CLIN NEUROSCI, V20, P406, DOI 10.1016/j.jocn.2012.02.047; Chiu WT, 1997, NEUROL RES, V19, P261, DOI 10.1080/01616412.1997.11740811; Chlu WT, 2007, J CLIN NEUROSCI, V14, P930, DOI 10.1016/j.jocn.2006.08.004; Cox BJ, 1996, BEHAV RES THER, V34, P949, DOI 10.1016/S0005-7967(96)00037-X; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Friedman BH, 1998, BIOL PSYCHOL, V49, P303; Friedman BH, 2007, BIOL PSYCHOL, V74, P185, DOI 10.1016/j.biopsycho.2005.08.009; Glassman AH, 1998, AM J PSYCHIAT, V155, P4, DOI 10.1176/ajp.155.1.4; Gray J A, 1996, Nebr Symp Motiv, V43, P61; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kendler KS, 2001, PSYCHOL MED, V31, P605, DOI 10.1017/S0033291701003907; Kurtoglu E, 2014, ACTA ANAESTH SCAND, V58, P370, DOI 10.1111/aas.12261; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Larrabee GJ, 2013, BEHAV SCI LAW, V31, P686, DOI 10.1002/bsl.2087; Licht CMM, 2009, PSYCHOSOM MED, V71, P508, DOI 10.1097/PSY.0b013e3181a292a6; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Ma VY, 2014, ARCH PHYS MED REHAB, V95, P986, DOI 10.1016/j.apmr.2013.10.032; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; Maetzler W, 2015, J NEURAL TRANSM, V122, P419, DOI 10.1007/s00702-014-1276-1; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; Meyer DL, 2012, EXP NEUROL, V235, P574, DOI 10.1016/j.expneurol.2012.03.012; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Norris PR, 2005, J SURG RES, V129, P122, DOI 10.1016/j.jss.2005.04.024; Osman A, 1997, J CLIN PSYCHOL, V53, P7, DOI 10.1002/(SICI)1097-4679(199701)53:1<7::AID-JCLP2>3.0.CO;2-S; Piccinelli M, 1999, J PSYCHOSOM RES, V46, P455, DOI 10.1016/S0022-3999(98)00126-3; Piccinelli M, 2000, BRIT J PSYCHIAT, V177, P486, DOI 10.1192/bjp.177.6.486; PODRID PJ, 1990, CIRCULATION, V82, P103; Ruff RL, 2012, JAMA-J AM MED ASSOC, V308, P2032, DOI 10.1001/jama.2012.14008; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Scholten A.C., 2016, J NEUROTRAUMA; SCHWARTZ PJ, 1981, J CARDIOVASC PHARM, V3, P1251, DOI 10.1097/00005344-198111000-00012; Sosin DM, 1996, BRAIN INJURY, V10, P47; Su CF, 2005, CLIN NEUROPHYSIOL, V116, P1273, DOI 10.1016/j.clinph.2005.01.010; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Sung C.W., 2015, PSYCHOPHYSIOLOGY; van der Horn HJ, 2013, ARCH PHYS MED REHAB, V94, P867, DOI 10.1016/j.apmr.2012.11.039; van Zyl LT, 2008, BIOPSYCHOSOC MED, V2, DOI 10.1186/1751-0759-2-12; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Yien HW, 1997, CRIT CARE MED, V25, P258, DOI 10.1097/00003246-199702000-00011; Zheng A, 2008, J NUTR SCI VITAMINOL, V54, P148, DOI 10.3177/jnsv.54.148	63	12	12	1	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	SEP 30	2016	243						349	356		10.1016/j.psychres.2016.07.001			8	Psychiatry	Psychiatry	DW7EA	WOS:000383812800055	27449003				2021-06-18	
J	Rusciano, D; Roszkowska, AM; Gagliano, C; Pezzino, S				Rusciano, Dario; Roszkowska, Anna Maria; Gagliano, Caterina; Pezzino, Salvatore			Free amino acids: an innovative treatment for ocular surface disease	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Dry eye; Aminoacids; Proline; Lysine; Leucine; Glycine; Taurine	DYSFUNCTIONAL TEAR SYNDROME; DRY EYE PATIENTS; MEIBOMIAN GLAND DYSFUNCTION; CRITICALLY-ILL PATIENTS; IN-SITU KERATOMILEUSIS; TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; RETINAL DEGENERATION; TAURINE DEFICIENCY; ENTERAL NUTRITION	Amino acids are the basic constituents of living organisms, and have both a structural and an active dynamic role in tissue and cell physiology. Human tears contain 23 amino acids, the relative proportion of which may change with the different physiological states of the eye surface. In this review, we present a collection of data from the published literature that indicate an active role of amino acids in the maintenance of eye surface homeostasis. Moreover, another series of published clinical data indicate that supplementation of amino acids, either as food supplements or as a topical treatment in enriched eye drops, is beneficial to the eye surface, and may improve its healing in cases of eye surface disease due to different causes. (C) 2016 Elsevier B.V. All rights reserved.	[Rusciano, Dario] Sooft Italia SpA, Dept Sci, Via Salvatore Quasimodo 136, I-00144 Rome, Italy; [Roszkowska, Anna Maria] Univ Hosp Messina, Cornea & Refract Surg Sect, Ophthalmol Unit, Messina, Italy; [Gagliano, Caterina] Univ Catania, Dept Ophthalmol, Catania, Italy; [Pezzino, Salvatore] Sooft Lab, Viale Andrea Doria 21, I-95125 Catania, Italy	Rusciano, D (corresponding author), Sooft Italia SpA, Dept Sci, Via Salvatore Quasimodo 136, I-00144 Rome, Italy.	dario.rusciano@sooft.it	roszkowska, anna/X-2998-2019; Rusciano, Dario/AAP-7450-2020; Gagliano, Caterina/AAV-6358-2020	Rusciano, Dario/0000-0002-9577-2585; Gagliano, Caterina/0000-0001-8424-0068			ALTSHULER D, 1993, DEVELOPMENT, V119, P1317; Amjadi S., 2013, ISRN OPHTHALMOL, V2013; Aquilani R, 2005, ARCH PHYS MED REHAB, V86, P1729, DOI 10.1016/j.apmr.2005.03.022; Aquilani R, 2004, AM J CARDIOL, V93, p21A, DOI 10.1016/j.amjcard.2003.11.005; Aquilani R, 2008, ARCH PHYS MED REHAB, V89, P1642, DOI 10.1016/j.apmr.2008.02.023; Aquilani R, 2008, AM J CARDIOL, V101, p104E, DOI 10.1016/j.amjcard.2008.03.008; Aragona P, 2002, BRIT J OPHTHALMOL, V86, P181, DOI 10.1136/bjo.86.2.181; Aragona P, 2006, BRIT J OPHTHALMOL, V90, P166, DOI 10.1136/bjo.2005.078865; Aragona P, 2005, INVEST OPHTH VIS SCI, V46, P4474, DOI 10.1167/iovs.04-1394; Aragona P, 2015, OPHTHALMOLOGY, V122, P62, DOI 10.1016/j.ophtha.2014.07.048; Aragona P, 2014, BRIT J OPHTHALMOL, V98, P1001, DOI 10.1136/bjophthalmol-2013-304728; Aragona P, 2013, ACTA OPHTHALMOL, V91, pe437, DOI 10.1111/aos.12134; Aragona P, 2013, EUR J OPHTHALMOL, V23, P368, DOI 10.5301/ejo.5000229; Atkinson M, 2003, Crit Care Resusc, V5, P109; BASKIN SI, 1977, EXP EYE RES, V24, P315, DOI 10.1016/0014-4835(77)90170-1; Berthoud VM, 2009, ANTIOXID REDOX SIGN, V11, P339, DOI 10.1089/ars.2008.2119; Bollhalder L, 2013, CLIN NUTR, V32, P213, DOI 10.1016/j.clnu.2012.11.003; BONANNO JA, 1987, INVEST OPHTH VIS SCI, V28, P1514; Brignole-Baudouin F, 2011, ACTA OPHTHALMOL, V89, pE591, DOI 10.1111/j.1755-3768.2011.02196.x; Caparros T, 2001, JPEN-PARENTER ENTER, V25, P299, DOI 10.1177/0148607101025006299; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; ChenZuo L, 2002, ADV EXP MED BIOL, V506, P617; Cho Yang Kyeung, 2009, Korean J Ophthalmol, V23, P65, DOI 10.3341/kjo.2009.23.2.65; Chotikavanich S, 2009, INVEST OPHTH VIS SCI, V50, P3203, DOI 10.1167/iovs.08-2476; De Bandt JP, 2006, J NUTR, V136, p308S, DOI 10.1093/jn/136.1.308S; De Paiva CS, 2006, AM J OPHTHALMOL, V141, P438, DOI 10.1016/j.ajo.2005.10.006; Degim Z, 2002, AMINO ACIDS, V22, P187, DOI 10.1007/s007260200007; Di Leo MAS, 2004, AMINO ACIDS, V27, P187, DOI 10.1007/s00726-004-0108-2; Dogru M, 2013, EXPERT OPIN INV DRUG, V22, P1581, DOI 10.1517/13543784.2013.838557; Doughty MJ, 2016, CONTACT LENS ANTERIO, V39, P2, DOI 10.1016/j.clae.2015.08.002; Efron David, 2000, Journal of Gastroenterology, V35, P20; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Favia G, 2008, J BIOL REG HOMEOS AG, V22, P109; Fernstrom JD, 2007, J NUTR, V137, p1539S, DOI 10.1093/jn/137.6.1539S; FIETZEK PP, 1975, MOL CELL BIOCHEM, V8, P141, DOI 10.1007/BF01792765; Fillmann H, 2007, TOXICOLOGY, V236, P217, DOI 10.1016/j.tox.2007.04.012; Foulks GN, 2007, OCUL SURF, V5, P5, DOI 10.1016/S1542-0124(12)70047-2; Fuchs SA, 2005, MOL GENET METAB, V85, P168, DOI 10.1016/j.ymgme.2005.03.003; Funke S, 2012, J PROTEOMICS, V75, P3177, DOI 10.1016/j.jprot.2012.03.018; Gibala MJ, 2000, CAN J APPL PHYSIOL, V25, P524, DOI 10.1139/h00-034; Grus Franz H, 2005, Cont Lens Anterior Eye, V28, P103, DOI 10.1016/j.clae.2005.06.004; Han KE, 2014, AM J OPHTHALMOL, V157, P1144, DOI 10.1016/j.ajo.2014.02.036; Hasegawa S, 2012, CLIN EXP IMMUNOL, V167, P269, DOI 10.1111/j.1365-2249.2011.04519.x; Hasegawa S, 2011, INFLAMM RES, V60, P1013, DOI 10.1007/s00011-011-0362-1; HAYES KC, 1975, SCIENCE, V188, P949, DOI 10.1126/science.1138364; HEINAMAKI AA, 1986, NEUROCHEM RES, V11, P535, DOI 10.1007/BF00965323; Hessen Michelle, 2014, J Ophthalmic Vis Res, V9, P240; Holecek M, 2010, NUTRITION, V26, P482, DOI 10.1016/j.nut.2009.06.027; Houdijk APJ, 1998, LANCET, V352, P772, DOI 10.1016/S0140-6736(98)02007-8; Huang JCC, 2012, J REFRACT SURG, V28, P625, DOI 10.3928/1081597X-20120815-07; Hubert-Buron A, 2006, J NUTR, V136, P1461; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101; IMAKI H, 1987, J NEUROSCI RES, V18, P602, DOI 10.1002/jnr.490180414; Jager K, 2010, DEV OPHTHALMOL, V45, P12, DOI 10.1159/000315015; Jager K, 2010, ANN ANAT, V192, P65, DOI 10.1016/j.aanat.2010.01.006; Jager K, 2009, INVEST OPHTH VIS SCI, V50, P1112, DOI 10.1167/iovs.08-2368; Jammoul F, 2009, ANN NEUROL, V65, P98, DOI 10.1002/ana.21526; Jones C, 1999, NUTRITION, V15, P108, DOI 10.1016/S0899-9007(98)00172-5; Jong CJ, 2012, AMINO ACIDS, V42, P2223, DOI 10.1007/s00726-011-0962-7; Kantorow M, 2004, P NATL ACAD SCI USA, V101, P9654, DOI 10.1073/pnas.0403532101; KAPPRELL HP, 1985, EUR J CELL BIOL, V36, P217; Kedik SA, 2011, PHARM CHEM J+, V45, P245; Kilic F, 1999, EXP EYE RES, V69, P291, DOI 10.1006/exer.1999.0697; Kim JC, 2002, ADV EXP MED BIOL, V506, P687; Kohlhaas M, 1998, J CATARACT REFR SURG, V24, P1399, DOI 10.1016/S0886-3350(98)80237-X; Koyama I, 1996, ADV EXP MED BIOL, V403, P9; LACEY JM, 1990, NUTR REV, V48, P297, DOI 10.1111/j.1753-4887.1990.tb02967.x; Lam H, 2009, AM J OPHTHALMOL, V147, P198, DOI 10.1016/j.ajo.2008.08.032; Li XM, 2007, CORNEA, V26, pS16, DOI 10.1097/ICO.0b013e31812f67ca; Luong, 2012, J NEUROL RES; MacKay Douglas, 2003, Altern Med Rev, V8, P359; Madl JE, 2005, AM J VET RES, V66, P791, DOI 10.2460/ajvr.2005.66.791; Marcinkiewicz J, 2006, ADV EXP MED BIOL, V583, P481; Marcinkiewicz J, 2014, AMINO ACIDS, V46, P7, DOI 10.1007/s00726-012-1361-4; Meduri A, 2009, OPHTHALMIC RES, V41, P76, DOI 10.1159/000187623; MEHTA S, 1995, CIRCULATION, V92, P1539, DOI 10.1161/01.CIR.92.6.1539; Meloni M, 2011, MOL VIS, V17, P113; Militante J, 2004, NEUROCHEM RES, V29, P151, DOI 10.1023/B:NERE.0000010444.97959.1b; NAKADA T, 1991, NEUROREPORT, V2, P325; Nakatsukasa M, 2011, AM J OPHTHALMOL, V151, P799, DOI 10.1016/j.ajo.2010.11.003; Nejima R, 2005, AM J OPHTHALMOL, V139, P64, DOI 10.1016/j.ajo.2004.08.039; Njie-Mbye YF, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00366; Obrosova IG, 1999, INVEST OPHTH VIS SCI, V40, P680; OEPEN G, 1982, ARCH PSYCHIAT NERVEN, V231, P131, DOI 10.1007/BF00343834; Ozmeric N, 2000, J BIOMED MATER RES, V51, P500, DOI 10.1002/1097-4636(20000905)51:3<500::AID-JBM26>3.0.CO;2-P; PANJWANI NA, 1978, BIOCHEM J, V171, P687, DOI 10.1042/bj1710687; Pasantes-Morales H, 2002, METAB BRAIN DIS, V17, P183, DOI 10.1023/A:1019926122125; PASANTESMORALES H, 1983, J NEUROSCI RES, V9, P135, DOI 10.1002/jnr.490090205; Pasini E, 2008, AM J CARDIOL, V101, p11E, DOI 10.1016/j.amjcard.2008.02.074; Platell C, 2000, J GASTROEN HEPATOL, V15, P706, DOI 10.1046/j.1440-1746.2000.02205.x; POLATNICK J, 1957, BIOCHIM BIOPHYS ACTA, V26, P365, DOI 10.1016/0006-3002(57)90017-3; Rascher K, 2004, VISION RES, V44, P2091, DOI 10.1016/j.visres.2004.03.027; Rathore M. S., 2010, ASIAN J PHARM CLIN R, V3, P166; REDDY VN, 1990, EXP EYE RES, V50, P771, DOI 10.1016/0014-4835(90)90127-G; Ripps H, 2012, MOL VIS, V18, P2673; SAXENA R N, 1984, Indian Journal of Physiology and Pharmacology, V28, P299; Scognamiglio R, 2008, AM J CARDIOL, V101, p78E, DOI 10.1016/j.amjcard.2008.03.005; Shioda R, 2002, INVEST OPHTH VIS SCI, V43, P2916; Stonecipher KG, 2013, THER CLIN RISK MANAG, V9, P409, DOI 10.2147/TCRM.S49754; Sun M, 2008, CELL MOL NEUROBIOL, V28, P593, DOI 10.1007/s10571-007-9183-8; Takatani T, 2004, AM J PHYSIOL-CELL PH, V287, pC949, DOI 10.1152/ajpcell.00042.2004; Teuchner B, 2005, J OCUL PHARMACOL TH, V21, P157, DOI 10.1089/jop.2005.21.157; Varma SD, 1998, J OCUL PHARMACOL TH, V14, P423, DOI 10.1089/jop.1998.14.423; Verzola D, 2002, J INVEST MED, V50, P443, DOI 10.1136/jim-50-06-04; Vinciguerra P, 2003, J REFRACT SURG, V19, pS227; Vinciguerra P, 2002, J REFRACT SURG, V18, pS374; Wilby J, 2005, HEALTH TECHNOL ASSES, V9, P1; Wilson SE, 2001, OPHTHALMOLOGY, V108, P1082, DOI 10.1016/S0161-6420(01)00587-5; Wu GY, 2011, AMINO ACIDS, V40, P1053, DOI 10.1007/s00726-010-0715-z; Wu GY, 2009, AMINO ACIDS, V37, P153, DOI 10.1007/s00726-008-0210-y; Wu JY, 2009, ADV EXP MED BIOL, V643, P169, DOI 10.1007/978-0-387-75681-3_17; Yildirim ZL, 2007, ANN NY ACAD SCI, V1100, P553, DOI 10.1196/annals.1395.061; Young TL, 2004, NEURON, V41, P867, DOI 10.1016/S0896-6273(04)00141-2	113	12	12	1	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	SEP 15	2016	787				SI		9	19		10.1016/j.ejphar.2016.04.029			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DW0EX	WOS:000383314800003	27090927				2021-06-18	
J	Christensen, PC; Samadi-Bahrami, Z; Pavlov, V; Stys, PK; Moore, GRW				Christensen, Pia Crone; Samadi-Bahrami, Zahra; Pavlov, Vlady; Stys, Peter K.; Moore, G. R. Wayne			Ionotropic glutamate receptor expression in human white matter	NEUROSCIENCE LETTERS			English	Article						CNS; White matter; NMDA; AMPA; Ionotropic glutamate receptor; Spectral confocal microscopy	OPTIC-NERVE AXONS; NMDA RECEPTORS; MULTIPLE-SCLEROSIS; OLIGODENDROCYTE PROGENITORS; CEREBROSPINAL-FLUID; BRAIN-INJURY; EXCITOTOXICITY; MYELINATION; ASTROCYTES; MECHANISMS	Glutamate is the key excitatory neurotransmitter of the central nervous system (CNS). Its role in human grey matter transmission is well understood, but this is less clear in white matter (WM). Ionotropic glutamate receptors (iGluR) are found on both neuronal cell bodies and glia as well as on myelinated axons in rodents, and rodent WM tissue is capable of glutamate release. Thus, rodent WM expresses many of the components of the traditional grey matter neuron-to-neuron synapse, but to date this has not been shown for human WM. We demonstrate the presence of iGluRs in human WM by immunofluorescence employing high-resolution spectral confocal imaging. We found that the obligatory N-methyl-D-aspartic acid (NMDA) receptor subunit GluN1 and the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunit GluA4 co-localized with myelin, oligodendroglial cell bodies and processes. Additionally, GluA4 colocalized with axons, often in distinct clusters. These findings may explain why human WM is vulnerable to excitotoxic events following acute insults such as stroke and traumatic brain injury and in more chronic inflammatory conditions such as multiple sclerosis (MS). Further exploration of human WM glutamate signalling could pave the way for developing future therapies modulating the glutamate-mediated damage in these and other CNS disorders. (C) 2016 Elsevier Ireland Ltd. All rights reserved.	[Christensen, Pia Crone; Stys, Peter K.] Univ Calgary, Dept Clin Neurosci, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada; [Samadi-Bahrami, Zahra; Pavlov, Vlady; Moore, G. R. Wayne] Univ British Columbia, Dept Pathol & Lab Med, ICORD, Vancouver, BC V5Z 1M9, Canada	Stys, PK (corresponding author), Univ Calgary, Dept Clin Neurosci, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada.	pstys@ucalgary.ca			MS Society of Canada; CIHRCanadian Institutes of Health Research (CIHR); Canada Research ChairsCanada Research ChairsCGIAR; AI-HS Scientist Award	This work was supported in part by the MS Society of Canada, CIHR and Canada Research Chairs. PKS was supported by an AI-HS Scientist Award.	Alix JJP, 2008, J PHYSIOL-LONDON, V586, P4069, DOI 10.1113/jphysiol.2008.155077; Alix JJP, 2009, ANN NEUROL, V66, P682, DOI 10.1002/ana.21767; [Anonymous], 2003, NEUROSCI LETT, V345, P126; Arranz AM, 2008, GLIA, V56, P1353, DOI 10.1002/glia.20703; Baraban M., 2015, BRAIN RES; Bengtsson SL, 2005, NAT NEUROSCI, V8, P1148, DOI 10.1038/nn1516; Brand-Schieber E, 2003, GLIA, V42, P12, DOI 10.1002/glia.10136; Catts V.S., 2015, BIOL PSYCHOL; Christensen P. C., 2016, MUSCLE NERVE; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Court FA, 2008, J NEUROSCI, V28, P11024, DOI 10.1523/JNEUROSCI.2429-08.2008; Court FA, 2011, GLIA, V59, P1529, DOI 10.1002/glia.21196; De Biase LM, 2011, J NEUROSCI, V31, P12650, DOI 10.1523/JNEUROSCI.2455-11.2011; Dewar D, 2003, J CEREBR BLOOD F MET, V23, P263, DOI 10.1097/01.WCB.0000053472.41007.F9; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Fields RD, 2008, TRENDS NEUROSCI, V31, P361, DOI 10.1016/j.tins.2008.04.001; Fields R Douglas, 2006, Novartis Found Symp, V276, P148; Gautier HOB, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9518; Giuditta A, 2002, TRENDS NEUROSCI, V25, P400, DOI 10.1016/S0166-2236(02)02188-4; Guo FZ, 2012, J NEUROSCI, V32, P639, DOI 10.1523/JNEUROSCI.4073-11.2012; Hofstetter S, 2013, J NEUROSCI, V33, P12844, DOI 10.1523/JNEUROSCI.4520-12.2013; Ishibashi T, 2006, NEURON, V49, P823, DOI 10.1016/j.neuron.2006.02.006; Karadottir R, 2005, NATURE, V438, P1162, DOI 10.1038/nature04302; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; Kostic M, 2013, REV NEUROSCIENCE, V24, P71, DOI 10.1515/revneuro-2012-0062; Kukley M, 2007, NAT NEUROSCI, V10, P311, DOI 10.1038/nn1850; Lagopoulos J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059108; Lalo U, 2006, J NEUROSCI, V26, P2673, DOI 10.1523/JNEUROSCI.4689-05.2006; Lebel C, 2012, NEUROIMAGE, V60, P340, DOI 10.1016/j.neuroimage.2011.11.094; Li C, 2013, GLIA, V61, P732, DOI 10.1002/glia.22469; Li SX, 2000, J NEUROSCI, V20, P1190, DOI 10.1523/JNEUROSCI.20-03-01190.2000; Lundgaard I, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001743; Matute C, 1997, P NATL ACAD SCI USA, V94, P8830, DOI 10.1073/pnas.94.16.8830; Mehta A, 2013, EUR J PHARMACOL, V698, P6, DOI 10.1016/j.ejphar.2012.10.032; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; Micu I, 2006, NATURE, V439, P988, DOI 10.1038/nature04474; Micu I, 2015, EXP NEUROL; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Ouardouz M, 2009, ANN NEUROL, V65, P151, DOI 10.1002/ana.21533; Ouardouz M, 2009, ANN NEUROL, V65, P160, DOI 10.1002/ana.21539; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; Parpura V, 2004, NEUROCHEM INT, V45, P259, DOI 10.1016/j.neuint.2003.12.011; PATNEAU DK, 1994, NEURON, V12, P357, DOI 10.1016/0896-6273(94)90277-1; Paus T, 1999, SCIENCE, V283, P1908, DOI 10.1126/science.283.5409.1908; Petersen SC, 2015, CURR BIOL, V25, pR562, DOI 10.1016/j.cub.2015.04.054; Pina-Crespo JC, 2010, J NEUROSCI, V30, P11501, DOI 10.1523/JNEUROSCI.1593-10.2010; Pitt D, 2003, NEUROLOGY, V61, P1113, DOI 10.1212/01.WNL.0000090564.88719.37; Purger D., 2015, NEUROPHARMACOLOGY; Saab AS, 2013, CURR OPIN NEUROBIOL, V23, P1065, DOI 10.1016/j.conb.2013.09.008; Salter MG, 2005, NATURE, V438, P1167, DOI 10.1038/nature04301; Sarchielli P, 2003, ARCH NEUROL-CHICAGO, V60, P1082, DOI 10.1001/archneur.60.8.1082; Scholz J, 2009, NAT NEUROSCI, V12, P1370, DOI 10.1038/nn.2412; Simons M, 2007, CURR OPIN NEUROBIOL, V17, P533, DOI 10.1016/j.conb.2007.08.003; Srinivasan R, 2005, BRAIN, V128, P1016, DOI 10.1093/brain/awh467; Steullet P, 2014, SCHIZOPHR RES; Stirling DP, 2010, TRENDS MOL MED, V16, P160, DOI 10.1016/j.molmed.2010.02.002; Stover JF, 1997, EUR J CLIN INVEST, V27, P1038, DOI 10.1046/j.1365-2362.1997.2250774.x; Stys PK, 2007, TRENDS PHARMACOL SCI, V28, P561, DOI 10.1016/j.tips.2007.10.003; Stys PK, 2004, CURR MOL MED, V4, P113, DOI 10.2174/1566524043479220; Sun Y., 2015, CEREB CORTEX; Tekkok SB, 2001, J NEUROSCI, V21, P4237, DOI 10.1523/JNEUROSCI.21-12-04237.2001; Tisell A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061817; Verkhratsky A, 2007, NEUROSCIENTIST, V13, P28, DOI 10.1177/1073858406294270; Wegner M, 2001, MICROSC RES TECHNIQ, V52, P746, DOI 10.1002/jemt.1059; Willard SS, 2013, INT J BIOL SCI, V9, P948, DOI 10.7150/ijbs.6426; Willard SS, 2013, INT J BIOL SCI, V9, P728, DOI 10.7150/ijbs.6475; Willis D, 2005, J NEUROSCI, V25, P778, DOI 10.1523/JNEUROSCI.4235-04.2005; Yeung MSY, 2014, CELL, V159, P766, DOI 10.1016/j.cell.2014.10.011; Zalc B, 2000, NEUROSCIENTIST, V6, P5, DOI 10.1177/107385840000600109; Zhang JD, 2013, J NEUROSCI RES, V91, P240, DOI 10.1002/jnr.23150; Ziskin JL, 2007, NAT NEUROSCI, V10, P321, DOI 10.1038/nn1854	71	12	14	0	11	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	SEP 6	2016	630						1	8		10.1016/j.neulet.2016.07.030			8	Neurosciences	Neurosciences & Neurology	DV5ZG	WOS:000383008600001	27443784				2021-06-18	
J	Anandalwar, SP; Mau, CY; Gordhan, CG; Majmundar, N; Meleis, A; Prestigiacomo, CJ; Sifri, ZC				Anandalwar, Seema P.; Mau, Christine Y.; Gordhan, Chirag G.; Majmundar, Neil; Meleis, Ahmed; Prestigiacomo, Charles J.; Sifri, Ziad C.			Eliminating unnecessary routine head CT scanning in neurologically intact mild traumatic brain injury patients: implementation and evaluation of a new protocol	JOURNAL OF NEUROSURGERY			English	Article						mild traumatic brain injury; computed tomography; repeat head computed tomography	CRANIAL COMPUTED-TOMOGRAPHY; INTRACRANIAL HEMORRHAGE; REPEAT; PROGRESSION; UTILITY; SCANS	OBJECTIVE The utility of routine repeat head CT (HCT) scans in the management of minimal head injury (MHI) patients with an intracranial hemorrhage (ICH) has been questioned in multiple studies. All these studies analyzed this by obtaining a repeat HCT study, and none examined the effects of eliminating these routine HCT studies in neurologically intact patients. The authors' institution implemented a new "Neurologic Observation without Repeat HCT" (NORH) protocol with no repeat HCT scanning for patients admitted for MHI and ICH whose neurological status was maintained or improved to a Glasgow Coma Scale score of 15 at 24 hours after admission. This purpose of this study was to assess the outcomes and safety of this novel protocol. METHODS Records of patients who sustained blunt trauma MHI and an ICH and/or skull fracture on initial HCT between January 1, 2009, and December 31, 2012, were retrieved from the trauma registry of a Level I trauma center. The authors analyzed 95 patients in whom the NORH protocol was followed. Outcome measures included death, emergency department readmission, neurosurgical intervention, delayed repeat HCT, and length of stay. RESULTS The NORH protocol was followed for 95 patients; 83% of the patients were male, the average age was 38 +/- 16.0 years old, and the most common cause of trauma was assault (35%). Of the 95 patients in whom the NORH protocol was followed, 8 (8%) had a delayed repeat HCT study (> 24 hours) after admission, but none resulted in neurosurgical intervention because of progression of ICH. The average length of stay was 4 +/- 7.2 days. None of the patients were readmitted to the hospital. CONCLUSIONS Implementation of the NORH protocol (eliminating routine follow-up HCT) resulted in very low rates of delayed neurological deterioration, no late neurosurgical interventions resulting from ICH progression, very few emergency department revisits, and no readmissions. For a select group of MHI patients with ICH, the NORH protocol is safe and effective, and can reduce radiation exposure and costs.	[Anandalwar, Seema P.; Gordhan, Chirag G.; Sifri, Ziad C.] Rutgers New Jersey Med Sch, Dept Trauma Surg, Newark, NJ USA; [Mau, Christine Y.; Majmundar, Neil; Meleis, Ahmed; Prestigiacomo, Charles J.] Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ USA	Sifri, ZC (corresponding author), New Jersey Trauma Ctr, Div Trauma & Crit Care, 150 Bergen St,M232, Newark, NJ 07101 USA.	sifrizi@njms.rutgers.edu	Prestigiacomo, Charles J/B-3911-2018	Prestigiacomo, Charles J/0000-0002-5979-2378; Majmundar, Neil/0000-0001-5910-6094			AbdelFattah KR, 2012, J TRAUMA ACUTE CARE, V73, P685, DOI 10.1097/TA.0b013e318265ccd9; Almenawer SA, 2013, NEUROSURGERY, V72, P56, DOI 10.1227/NEU.0b013e318276f899; Bee TK, 2009, J TRAUMA, V66, P1015, DOI 10.1097/TA.0b013e31819adbc8; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Ding J, 2012, BRAIN INJURY, V26, P1211, DOI 10.3109/02699052.2012.667591; Homnick A, 2012, INJURY, V43, P2122, DOI 10.1016/j.injury.2012.04.013; Huynh T, 2006, AM SURGEON, V72, P1162; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Levin HS, 1996, NEUROTRAUMA, P749; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Nishijima DK, 2011, J TRAUMA, V70, pE101, DOI 10.1097/TA.0b013e3181e88bcb; Park HK, 2009, BRIT J NEUROSURG, V23, P617, DOI 10.3109/02688690902999302; Sharifuddin Ashraf, 2012, Med J Malaysia, V67, P305; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Sifri ZC, 2012, J TRAUMA, V72, P538; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Sifri ZC, 2011, J TRAUMA, V71, P1605, DOI 10.1097/TA.0b013e31822b3728; Stein SC, 2008, J TRAUMA, V65, P66, DOI 10.1097/TA.0b013e318068d75f; Thomas BW, 2010, J AM COLL SURGEONS, V210, P824, DOI 10.1016/j.jamcollsurg.2009.12.039; Thorson CM, 2013, J TRAUMA ACUTE CARE, V74, P967, DOI 10.1097/TA.0b013e3182877fed; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Vos PE, 2012, EUR J NEUROL, V19, P191, DOI 10.1111/j.1468-1331.2011.03581.x; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092	26	12	12	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2016	125	3					667	673		10.3171/2015.9.JNS151379			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DT8YS	WOS:000381782300018	26771855	Bronze			2021-06-18	
J	Eagles, ME; Bradbury-Squires, DJ; Powell, MF; Murphy, JR; Campbell, GD; Maroun, FB				Eagles, Matthew E.; Bradbury-Squires, David J.; Powell, Maria F.; Murphy, Justin R.; Campbell, Graeme D.; Maroun, Falah B.			The Impact of a Concussion-U Educational Program on Knowledge of and Attitudes about Concussion	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article						Concussion; Sports injuries; Education; Head trauma; Brain injury; Traumatic	CHRONIC TRAUMATIC ENCEPHALOPATHY; HOCKEY PLAYERS; HEAD-INJURY; SPORT; VIDEO; STATEMENT; BEHAVIOR	Background: The diagnosis of a sports-related concussion is often dependent on the athlete self-reporting their symptoms. It has been suggested that improving youth athlete knowledge and attitudes toward concussion may increase self-reporting behaviour. The objective of this study was to determine if a novel Concussion-U educational program improves knowledge of and attitudes about concussion among a cohort of elite male Bantam and Midget AAA hockey players. Methods: Fifty-seven male Bantam and Midget AAA-level hockey players (mean age=14.521.13 years) were recruited from the local community. Each participant completed a modified version of the Rosenbaum Concussion Knowledge and Attitudes Survey-Student Version immediately before and after a Concussion-U educational presentation. Follow-up sessions were arranged 4 to 6 months after the presentation, and assessed retention of knowledge and attitude changes. Results: Forty-three players completed all three surveys. Concussion knowledge and attitude scores significantly (p<0.01) increased from pre- to post-presentation by 12.79 and 8.41%, respectively. At long-term follow-up, knowledge levels remained significantly (p<0.01) higher than baseline by 8.49%. Mean attitude scores were also increased at follow-up; however, this increase was not statistically significant. Conclusions: A Concussion-U educational program led to an immediate improvement in concussion knowledge and attitudes among elite male Bantam and Midget AAA hockey players. Increased knowledge was maintained at long-term follow-up, but improved attitude was not. Future studies should investigate whether similar educational programs influence symptom reporting and concussion incidence. In addition, they should focus on how to maintain improved concussion attitudes.	[Eagles, Matthew E.; Bradbury-Squires, David J.; Powell, Maria F.; Murphy, Justin R.; Campbell, Graeme D.; Maroun, Falah B.] Mem Univ Newfoundland, Fac Med, Dept Neurosurg, St John, NF, Canada	Eagles, ME (corresponding author), Mem Univ Newfoundland, Fac Med, 300 Prince Phillip Dr, St John, NF A1B 3V6, Canada.	meagles@mun.ca	Eagles, Matthew E/I-9547-2019	Eagles, Matthew E/0000-0003-2585-7230			Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Bramley H, 2012, CLIN PEDIATR, V51, P332, DOI 10.1177/0009922811425233; Caron JG, 2015, INJURY PREV, V21, P301, DOI 10.1136/injuryprev-2014-041479; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Cusimano MD, 2014, BRIT J SPORT MED, V48, P141, DOI 10.1136/bjsports-2012-091660; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Echlin PS, 2014, J NEUROSURG, V121, P1331, DOI 10.3171/2014.8.JNS132804; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Gerhardstein D, 2007, SCI NURS, V24; Ginns P, 2005, LEARN INSTR, V15, P313, DOI 10.1016/j.learninstruc.2005.07.001; Goodman D, 2006, J ADOLESCENCE, V29, P351, DOI 10.1016/j.adolescence.2005.07.004; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Kroshus E, 2015, CLIN J SPORT MED, V25, P243, DOI 10.1097/JSM.0000000000000137; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Kurowski B, 2014, J TRAUMA ACUTE CARE, V77, pS12, DOI 10.1097/TA.0000000000000316; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McNaughton-Filion L, 2015, INQUEST DEATH ROWAN; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Weinstein E, 2013, J NEUROSURG-PEDIATR, V11, P331, DOI 10.3171/2012.11.PEDS12343; Zazryn T, 2007, SPORTS MED, V37, P467	28	12	12	1	8	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0317-1671	2057-0155		CAN J NEUROL SCI	Can. J. Neurol. Sci.	SEP	2016	43	5					659	664		10.1017/cjn.2016.263			6	Clinical Neurology	Neurosciences & Neurology	DZ2KQ	WOS:000385671100007	27464985	Bronze			2021-06-18	
J	Herweh, C; Hess, K; Meyding-Lamade, U; Bartsch, AJ; Stippich, C; Jost, J; Friedmann-Bette, B; Heiland, S; Bendszus, M; Hahnel, S				Herweh, Christian; Hess, Klaus; Meyding-Lamade, Uta; Bartsch, Andreas J.; Stippich, Christoph; Jost, Joachim; Friedmann-Bette, Birgit; Heiland, Sabine; Bendszus, Martin; Haehnel, Stefan			Reduced white matter integrity in amateur boxers	NEURORADIOLOGY			English	Article						Diffusion tensor imaging; Traumatic brain injury; White matter disturbance; Olympic boxing; Neuropsychology	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; SPORTS-RELATED CONCUSSION; PROFESSIONAL BOXERS; CEREBRAL MICROHEMORRHAGES; MICROSTRUCTURAL DAMAGE; NERVOUS-SYSTEM; HEAD-INJURY; MRI; MICROBLEEDS	Professional boxing can lead to chronic traumatic encephalopathy, a variant of traumatic brain injury (TBI). Its occurrence in amateur boxers is a matter of debate since amateur boxing is considered to be less harmful due to more strict regulations. However, several studies using different methodological approaches have revealed subtle signs of TBI even in amateurs. Diffusion tensor imaging (DTI) is sensitive to microscopic white matter changes and has been proven useful in TBI when routine MR imaging often is unrevealing. DTI, with tract-based spatial statistics (TBSS) together with neuropsychological examination of executive functions and memory, was used to investigate a collective of 31 male amateur boxers and 31 age-matched controls as well as a subgroup of 19 individuals, respectively, who were additionally matched for intellectual performance (IQ). All participants had normal findings in neurological examination and conventional MR. Amateur boxers did not show deficits in neuropsychological tests when their IQ was taken into account. Fractional anisotropy was significantly reduced, while diffusivity measures were increased along central white matter tracts in the boxers group. These changes were in part associated with the number of fights. TBSS revealed widespread white matter disturbance partially related to the individual fighting history in amateur boxers. These findings closely resemble those in patients with accidental TBI and indicate similar histological changes in amateur boxers.	[Herweh, Christian; Bartsch, Andreas J.; Heiland, Sabine; Bendszus, Martin; Haehnel, Stefan] Heidelberg Univ, Dept Neuroradiol, Sch Med, Neuenheimer Feld 400, D-69120 Heidelberg, Germany; [Hess, Klaus] Heidelberg Univ, Dept Neurol, Sch Med, Heidelberg, Germany; [Meyding-Lamade, Uta] Krankenhaus NW Frankfurt, Dept Neurol, Frankfurt, Germany; [Stippich, Christoph] Univ Basel Hosp, Dept Neuroradiol, Basel, Switzerland; [Jost, Joachim] Natl Training Ctr Boxing, Heidelberg, Germany; [Friedmann-Bette, Birgit] Heidelberg Univ, Dept Sports Med, Sch Med, Heidelberg, Germany	Herweh, C (corresponding author), Heidelberg Univ, Dept Neuroradiol, Sch Med, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	christian.herweh@med.uni-heidelberg.de	Friedmann-Bette, Birgit/AAF-7772-2020				Adamson C, 2013, BRAIN INJURY, V27, P454, DOI 10.3109/02699052.2012.750756; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Bender A.R., 2015, NEUROIMAGE; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BROOKS N, 1987, J NEUROL NEUROSUR PS, V50, P997, DOI 10.1136/jnnp.50.8.997; BUTLER RJ, 1993, J NEUROL NEUROSUR PS, V56, P1055, DOI 10.1136/jnnp.56.10.1055; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; Chamard E, 2015, J NEUROTRAUMA; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Chappell MH, 2008, MAGN RESON IMAGING, V26, P1398, DOI 10.1016/j.mri.2008.04.004; Cheng AL, 2013, STROKE, V44, P2782, DOI 10.1161/STROKEAHA.113.002267; Chiang MC, 2011, NEUROIMAGE, V55, P448, DOI 10.1016/j.neuroimage.2010.12.053; CORSELLIS JAN, 1959, J MENT SCI, V105, P714; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Douaud G, 2011, NEUROIMAGE, V55, P880, DOI 10.1016/j.neuroimage.2010.12.008; DREW RH, 1986, J CLIN PSYCHOL, V42, P520, DOI 10.1002/1097-4679(198605)42:3<520::AID-JCLP2270420319>3.0.CO;2-6; Forstl H, 2010, DTSCH ARZTEBL INT, V107, P835, DOI 10.3238/arztebl.2010.0835; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Guo LF, 2013, CLIN NEURORADIOL, V23, P121, DOI 10.1007/s00062-012-0185-7; Hahnel S, 2008, AM J NEURORADIOL, V29, P388, DOI 10.3174/ajnr.A0799; Hasiloglu ZI, 2011, AM J NEURORADIOL, V32, P99, DOI 10.3174/ajnr.A2250; HEILBRONNER RL, 1991, AM J SPORT MED, V19, P376, DOI 10.1177/036354659101900409; Heilbronner RL, 2009, ARCH CLIN NEUROPSYCH, V24, P11, DOI 10.1093/arclin/acp005; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Helmstaedter C., 2001, VERBALER LERN MERKFA; HOLZGRAEFE M, 1992, INT J SPORTS MED, V13, P616, DOI 10.1055/s-2007-1024576; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jako P, 2002, BRIT J SPORT MED, V36, P394, DOI 10.1136/bjsm.36.6.394; JORDAN BD, 1988, ARCH NEUROL-CHICAGO, V45, P1207, DOI 10.1001/archneur.1988.00520350045014; KASTE M, 1982, LANCET, V2, P1186; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Koenis MMG, 2015, HUM BRAIN MAPP, V36, P4938, DOI 10.1002/hbm.22988; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Kourtidou P, 2013, J HEAD TRAUMA REHAB, V28, P433, DOI 10.1097/HTR.0b013e3182585d06; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Liu GB, 2015, ACTA RADIOL, V56, P1256, DOI 10.1177/0284185114552883; Loosemore M, 2007, BMJ-BRIT MED J, V335, P809, DOI 10.1136/bmj.39342.690220.55; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MCLATCHIE G, 1987, J NEUROL NEUROSUR PS, V50, P96, DOI 10.1136/jnnp.50.1.96; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497; Moriarity JM, 2012, BRIT J SPORT MED, V46, P1011, DOI 10.1136/bjsports-2011-090893; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Navas-Sanchez FJ, 2014, HUM BRAIN MAPP, V35, P2619, DOI 10.1002/hbm.22355; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Perianez JA, 2007, ARCH CLIN NEUROPSYCH, V22, P433, DOI 10.1016/j.acn.2007.01.022; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Shams S, 2015, AM J NEURORADIOL, V36, P1089, DOI 10.3174/ajnr.A4248; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shin W, 2014, AM J NEURORADIOL, V35, P285, DOI 10.3174/ajnr.A3676; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; STEWART WF, 1994, AM J EPIDEMIOL, V139, P573, DOI 10.1093/oxfordjournals.aje.a117047; Stiller JW, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00069; Stojsih S, 2010, BRIT J SPORT MED, V44, P725, DOI 10.1136/bjsm.2008.052845; Tewes U, 1994, HAWIE R HAMBURG WECH; Wilde EA, 2015, J NEUROTRAUMA; Wolf D, 2014, HUM BRAIN MAPP, V35, P309, DOI 10.1002/hbm.22177; Zhang L, 2006, AM J NEURORADIOL, V27, P2000; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52; Zimmermann P, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P110	75	12	12	0	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-3940	1432-1920		NEURORADIOLOGY	Neuroradiology	SEP	2016	58	9					911	920		10.1007/s00234-016-1705-y			10	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	DY4JP	WOS:000385065100009	27230917				2021-06-18	
J	Paredes, I; Castano, AM; Cepeda, S; Alen, JAF; Salvador, E; Millan, JM; Lagares, A				Paredes, Igor; Maria Castano, Ana; Cepeda, Santiago; Fernandez Alen, Jose Antonio; Salvador, Elena; Maria Millan, Jose; Lagares, Alfonso			The Effect of Cranioplasty on Cerebral Hemodynamics as Measured by Perfusion Computed Tomography and Doppler Ultrasonography	JOURNAL OF NEUROTRAUMA			English	Article						cranioplasty; Lindegaard ratio; perfusion computed tomography; transcranial doppler sonography; trephined syndrome	SINKING SKIN-FLAP; TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; NEUROLOGICAL IMPROVEMENT; SURGICAL COMPLICATIONS; PARADOXICAL HERNIATION; INTRACRANIAL-PRESSURE; ARTERY INFARCTION; CONTROLLED-TRIAL; BODY POSITION	Cranioplasties are performed to protect the brain and correct cosmetic defects, but there is growing evidence that this procedure may result in neurological improvement. We prospectively studied cranioplasties performed at our hospital over a 5-year period. The National Institute of Health Stroke Scale and Barthel index were recorded prior to and within 72 h after the cranioplasty. A perfusion computed tomography (PCT) and transcranial Doppler sonography (TCDS) were performed prior to and 72 h after the surgery. For the PCT, regions irrigated by the anterior cerebral artery, the middle cerebral artery (MCA), the posterior cerebral artery, and the basal ganglia were selected, as well as the mean values for the hemisphere. The sonography was performed in the sitting and the supine position for the MCA and internal carotid. The velocities, pulsatility index, resistance index, and Lindegaard ratio (LR) were obtained, as well as a variation value for the LR (Delta LR = LR sitting - LR supine). Fifty-four patients were included in the study. Of these, 23 (42.6%) patients presented with objective improvement. The mean cerebral blood flow of the defective side (m-CBF-d) increased from 101.86 to 117.17mL/100 g/min (p = 0.064), and the m-CBF of the healthy side (m-CBF-h) increased from 128.14 to 145.73mL/100 g/min (p = 0.028). With regard to the TCDS, the DLR was greater on the defective side prior the surgery in those patients who showed improvement (1.295 vs. -0.714; p = 0.002). Cranioplasty resulted in clinical improvement in 40% of the patients, with an increase in the post-surgical CBF. The larger variations in the LR when the patient is moved from the sitting to the supine position might predict the clinical improvement.	[Paredes, Igor; Maria Castano, Ana; Cepeda, Santiago; Fernandez Alen, Jose Antonio; Lagares, Alfonso] Univ Hosp 12 Octubre, Dept Neurosurg, Carretera Andalucia Km 5-400, Madrid 28041, Spain; [Salvador, Elena; Maria Millan, Jose] Univ Hosp 12 Octubre, Dept Neuroradiol, Madrid, Spain	Paredes, I (corresponding author), Univ Hosp 12 Octubre, Dept Neurosurg, Carretera Andalucia Km 5-400, Madrid 28041, Spain.	igor.paredes@salud.madrid.org	Cepeda, Santiago/AAE-3200-2021; Castano-Leon, Ana M/ABF-6322-2020; ALEN, JOSE A FERNANDEZ/G-4990-2018; Lagares, Alfonso/B-2969-2011; Sansinenea, Igor Paredes/S-6281-2019	Cepeda, Santiago/0000-0003-1667-8548; Castano-Leon, Ana M/0000-0002-7918-5049; ALEN, JOSE A FERNANDEZ/0000-0002-3321-983X; Lagares, Alfonso/0000-0003-3996-0554; Salvador, Elena/0000-0002-8324-6502			Agner C, 2002, ACTA NEUROCHIR, V144, P1033, DOI 10.1007/s00701-002-0996-4; Akins PT, 2008, NEUROCRIT CARE, V9, P269, DOI 10.1007/s12028-007-9033-z; Bijlenga P, 2007, J NEUROL NEUROSUR PS, V78, P430, DOI 10.1136/jnnp.2006.099242; Bor-Seng-Shu E, 2012, J NEUROSURG, V117, P589, DOI 10.3171/2012.6.JNS101400; Chalouhi N, 2012, NEUROLOGIST, V18, P423, DOI 10.1097/NRL.0b013e318272f7be; Coelho F, 2014, NEUROPSYCH DIS TREAT, V10, P695, DOI 10.2147/NDT.S52875; de Araujo AS, 2013, ARQ NEURO-PSIQUIAT, V71, P963, DOI 10.1590/0004-282X20130176; Decaminada N, 2008, NEURORADIOL J, V21, P459, DOI 10.1177/197140090802100402; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; Erdogan E, 2003, NEUROL INDIA, V51, P479; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Fodstad H, 1979, Acta Neurochir Suppl (Wien), V28, P514; Gadde Judith, 2012, Del Med J, V84, P213; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Hofmeijer J, 2006, TRIALS, V7, DOI 10.1186/1745-6215-7-29; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Honeybul S, 2014, INJURY, V45, P1332, DOI 10.1016/j.injury.2014.03.007; Honeybul S, 2013, BRIT J NEUROSURG, V27, P636, DOI 10.3109/02688697.2013.817532; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Huang YH, 2013, INT J SURG, V11, P886, DOI 10.1016/j.ijsu.2013.07.013; Isago T, 2004, ANN PLAS SURG, V53, P288, DOI 10.1097/01.sap.0000106433.89983.72; Janzen C, 2012, BRAIN INJURY, V26, P101, DOI 10.3109/02699052.2011.635357; Joseph V, 2009, J NEUROSURG, V111, P650, DOI 10.3171/2009.3.JNS0984; Kemmling A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-80; Kuo JR, 2004, J CLIN NEUROSCI, V11, P486, DOI 10.1016/j.jocn.2003.06.005; Lin C. H., 2013, J FORMOS MED ASSOC, V114, P577; Maekawa M, 1999, NEUROL SURG TOKYO, V27, P717; MAGNAES B, 1976, J NEUROSURG, V44, P687, DOI 10.3171/jns.1976.44.6.0687; Narro-Donate JM, 2015, NEUROCIRUGIA, V26, P95, DOI 10.1016/j.neucir.2014.09.006; Mokri B, 2010, HEADACHE, V50, P1206, DOI 10.1111/j.1526-4610.2010.01715.x; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; NAKAMURA T, 1980, Neurologia Medico-Chirurgica, V20, P89, DOI 10.2176/nmc.20.89; Nalbach SV, 2012, J CLIN NEUROSCI, V19, P1222, DOI 10.1016/j.jocn.2012.01.016; Ng D, 1997, J CLIN NEUROSCI, V4, P346, DOI 10.1016/S0967-5868(97)90103-X; Paredes I, 2015, NEUROCIRUGIA, V26, P115, DOI 10.1016/j.neucir.2014.10.001; Paredes Igor, 2011, Surg Neurol Int, V2, P88, DOI 10.4103/2152-7806.82370; Piedra MP, 2013, J NEUROSURG, V118, P109, DOI 10.3171/2012.10.JNS121037; Romero FR, 2013, INT J SURG CASE REP, V4, P1007, DOI 10.1016/j.ijscr.2013.08.013; Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012; Sarov M, 2010, STROKE, V41, P560, DOI 10.1161/STROKEAHA.109.568543; Sarubbo S, 2014, NEURORADIOLOGY, V56, P237, DOI 10.1007/s00234-014-1318-2; Schwarz S, 2002, STROKE, V33, P497, DOI 10.1161/hs0202.102376; Sinha S, 2015, NEUROL INDIA, V63, P175, DOI 10.4103/0028-3886.156277; Song J, 2014, ACTA NEUROCHIR, V156, P193, DOI 10.1007/s00701-013-1908-5; Stelling H, 2011, BRIT J NEUROSURG, V25, P407, DOI 10.3109/02688697.2011.566385; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; STULA D, 1982, J MAXILLOFAC SURG, V10, P142, DOI 10.1016/S0301-0503(82)80030-1; SUZUKI N, 1993, ACTA NEUROCHIR, V122, P49, DOI 10.1007/BF01446986; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Winkler PA, 2000, NEUROSURG FOCUS, V8, pe9, DOI DOI 10.3171/INS.2000.93.1.0053; Won YD, 2008, ACTA NEUROCHIR SUPPL, V102, P15, DOI 10.1007/978-3-211-85578-2_3; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	55	12	13	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2016	33	17					1586	1597		10.1089/neu.2015.4261			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DU6EH	WOS:000382306300004	26541365	Green Published			2021-06-18	
J	Schneider, BL; Ghoddoussi, F; Charlton, JL; Kohler, RJ; Galloway, MP; Perrine, SA; Conti, AC				Schneider, Brandy L.; Ghoddoussi, Farhad; Charlton, Jennifer L.; Kohler, Robert J.; Galloway, Matthew P.; Perrine, Shane A.; Conti, Alana C.			Increased Cortical Gamma-Aminobutyric Acid Precedes Incomplete Extinction of Conditioned Fear and Increased Hippocampal Excitatory Tone in a Mouse Model of Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						fear conditioning; GABA; glutamate; post-traumatic stress disorder; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; MEDIAL PREFRONTAL CORTEX; BASOLATERAL AMYGDALA; VENTRAL HIPPOCAMPUS; MEMORY RETRIEVAL; DENTATE GYRUS; RAT; NEURONS; DEFICITS; IMPAIRMENT	Mild traumatic brain injury (mTBI) contributes to development of affective disorders, including post-traumatic stress disorder (PTSD). Psychiatric symptoms typically emerge in a tardive fashion post-TBI, with negative effects on recovery. Patients with PTSD, as well as rodent models of PTSD, demonstrate structural and functional changes in brain regions mediating fear learning, including prefrontal cortex (PFC), amygdala (AMYG), and hippocampus (HC). These changes may reflect loss of top-down control by which PFC normally exhibits inhibitory influence over AMYG reactivity to fearful stimuli, with HC contribution. Considering the susceptibility of these regions to injury, we examined fear conditioning (FC) in the delayed post-injury period, using a mouse model of mTBI. Mice with mTBI displayed enhanced acquisition and delayed extinction of FC. Using proton magnetic resonance spectroscopy ex vivo, we examined PFC, AMYG, and HC levels of gamma-aminobutyric acid (GABA) and glutamate as surrogate measures of inhibitory and excitatory neurotransmission, respectively. Eight days post-injury, GABA was increased in PFC, with no significant changes in AMYG. In animals receiving FC and mTBI, glutamate trended toward an increase and the GABA/glutamate ratio decreased in ventral HC at 25 days post-injury, whereas GABA decreased and GABA/glutamate decreased in dorsal HC. These neurochemical changes are consistent with early TBI-induced PFC hypoactivation facilitating the fear learning circuit and exacerbating behavioral fear responses. The latent emergence of overall increased excitatory tone in the HC, despite distinct plasticity in dorsal and ventral HC fields, may be associated with disordered memory function, manifested as incomplete extinction and enhanced FC recall.	[Schneider, Brandy L.; Charlton, Jennifer L.; Conti, Alana C.] John D Dingell Vet Affairs Med Ctr, Res & Dev Serv, Detroit, MI USA; [Schneider, Brandy L.; Charlton, Jennifer L.; Conti, Alana C.] Wayne State Univ, Sch Med, Dept Neurosurg, Detroit, MI USA; [Ghoddoussi, Farhad; Galloway, Matthew P.] Wayne State Univ, Sch Med, Dept Anesthesiol, Detroit, MI USA; [Kohler, Robert J.; Galloway, Matthew P.; Perrine, Shane A.] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI USA; [Ghoddoussi, Farhad] Wayne State Univ, Sch Med, Magnet Resonance Core, Detroit, MI USA	Conti, AC (corresponding author), John D Dingell VA Med Ctr, 4646 John R St 11R, Detroit, MI 48201 USA.	aconti@med.wayne.edu			RRD VA [I01 RX001511] Funding Source: Medline; Veterans AffairsUS Department of Veterans Affairs [I01RX001511] Funding Source: NIH RePORTER		Abela AR, 2013, CEREB CORTEX, V23, P1396, DOI 10.1093/cercor/bhs121; Beckonert O, 2010, NAT PROTOC, V5, P1019, DOI 10.1038/nprot.2010.45; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Chudasama Y, 2012, J NEUROSCI, V32, P10915, DOI 10.1523/JNEUROSCI.1463-12.2012; Conti AC, 1998, J NEUROSCI, V18, P5663; Depue BE, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/691505; Dettwiler A, 2014, J NEUROTRAUM, V31, P180, DOI 10.1089/neu.2013.2983; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Esmaeili B, 2013, NEUROPSYCHOPHARMACOL, V38, P1871, DOI 10.1038/npp.2013.64; Fanselow MS, 2010, NEURON, V65, P7, DOI 10.1016/j.neuron.2009.11.031; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Franklin KBJ, 2007, MOUSE BRAIN STEREOTA; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Gerberding J.L., 2003, REPORT C MILD TRAUMA; Ghoddoussi F, 2010, J NEUROL SCI, V290, P41, DOI 10.1016/j.jns.2009.11.013; Goforth PB, 2011, J NEUROPHYSIOL, V105, P2350, DOI 10.1152/jn.00467.2010; Griesbach GS, 2011, NEUROSCIENCE, V178, P147, DOI 10.1016/j.neuroscience.2011.01.028; Guerriero RM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0545-1; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Higley MJ, 2014, NAT REV NEUROSCI, V15, P567, DOI 10.1038/nrn3803; Hobin JA, 2006, HIPPOCAMPUS, V16, P174, DOI 10.1002/hipo.20144; Hoffman A., 2015, IMMEDIATE PERSISTENT; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Ishikawa A, 2006, J NEUROPHYSIOL, V96, P2134, DOI 10.1152/jn.00069.2006; Karl A, 2010, NEUROSCI BIOBEHAV R, V34, P7, DOI 10.1016/j.neubiorev.2009.06.008; Kheirbek MA, 2013, NEURON, V77, P955, DOI 10.1016/j.neuron.2012.12.038; Knox D, 2012, NEUROSCIENCE, V223, P163, DOI 10.1016/j.neuroscience.2012.07.047; Knox D, 2010, NEUROSCI LETT, V480, P16, DOI 10.1016/j.neulet.2010.05.052; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Kyd RJ, 2005, CEREB CORTEX, V15, P720, DOI 10.1093/cercor/bhh173; Lanteaume L, 2007, CEREB CORTEX, V17, P1307, DOI 10.1093/cercor/bhl041; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; Likhtik E, 2008, NATURE, V454, P642, DOI 10.1038/nature07167; Logothetis NK, 2008, NATURE, V453, P869, DOI 10.1038/nature06976; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Macera CA, 2012, J REHABIL RES DEV, V49, P1197, DOI 10.1682/JRRD.2011.07.0131; Mahan AL, 2012, TRENDS NEUROSCI, V35, P24, DOI 10.1016/j.tins.2011.06.007; Maren S, 2000, BEHAV BRAIN RES, V110, P97, DOI 10.1016/S0166-4328(99)00188-6; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; Maroun M, 2013, EUR J NEUROSCI, V38, P2611, DOI 10.1111/ejn.12259; Meyer DL, 2012, EXP NEUROL, V235, P574, DOI 10.1016/j.expneurol.2012.03.012; Michels L, 2014, PSYCHIAT RES-NEUROIM, V224, P288, DOI 10.1016/j.pscychresns.2014.09.007; Milad MR, 2009, BIOL PSYCHIAT, V66, P1075, DOI 10.1016/j.biopsych.2009.06.026; Moench KM, 2015, NEUROSCI LETT, V601, P41, DOI 10.1016/j.neulet.2014.12.035; MOSER E, 1993, J NEUROSCI, V13, P3916; Norrholm SD, 2011, BIOL PSYCHIAT, V69, P556, DOI 10.1016/j.biopsych.2010.09.013; Orsini CA, 2011, J NEUROSCI, V31, P17269, DOI 10.1523/JNEUROSCI.4095-11.2011; Perrine SA, 2014, PROG NEURO-PSYCHOPH, V51, P9, DOI 10.1016/j.pnpbp.2013.11.003; Pitkanen A, 2000, ANN NY ACAD SCI, V911, P369; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Quirk GJ, 2003, J NEUROSCI, V23, P8800, DOI 10.1523/jneurosci.23-25-08800.2003; Radulovic J, 2010, REV NEUROSCIENCE, V21, P1; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Rockhill CM, 2012, J NEUROTRAUM, V29, P1038, DOI 10.1089/neu.2010.1562; Sajja VSSS, 2014, MOL CELL NEUROSCI, V59, P119, DOI 10.1016/j.mcn.2014.02.004; Sajja VSSS, 2012, NMR BIOMED, V25, P1331, DOI 10.1002/nbm.2805; Shin LM, 2006, ANN NY ACAD SCI, V1071, P67, DOI 10.1196/annals.1364.007; Shumyatsky GP, 2005, CELL, V123, P697, DOI 10.1016/j.cell.2005.08.038; Sierra-Mercado D, 2015, BRAIN RES, V1606, P133, DOI 10.1016/j.brainres.2015.02.031; Sierra-Mercado D, 2011, NEUROPSYCHOPHARMACOL, V36, P529, DOI 10.1038/npp.2010.184; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; Stanley JA, 2000, BIOL PSYCHIAT, V48, P357, DOI 10.1016/S0006-3223(00)00949-5; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Vertes RP, 2006, NEUROSCIENCE, V142, P1, DOI 10.1016/j.neuroscience.2006.06.027; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Woon FL, 2010, PROG NEURO-PSYCHOPH, V34, P1181, DOI 10.1016/j.pnpbp.2010.06.016	73	12	12	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2016	33	17					1614	1624		10.1089/neu.2015.4190			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DU6EH	WOS:000382306300007	26529240				2021-06-18	
J	Sepahvand, E; Jalali, R; Mirzaei, M; Ebrahimzadeh, F; Ahmadi, M; Amraii, E				Sepahvand, Elham; Jalali, Rostam; Mirzaei, Maryam; Ebrahimzadeh, Farzad; Ahmadi, Mahnaz; Amraii, Esmail			Glasgow Coma Scale Versus Full Outline of UnResponsiveness Scale for Prediction of Outcomes in Patients with Traumatic Brain Injury in the Intensive Care Unit	TURKISH NEUROSURGERY			English	Article						Traumatic brain injuries; coma; Full outline of unresponsiveness; Glasgow coma scale	4 SCORE; NEUROSURGICAL PATIENTS; VALIDATION; VERSION	AIM: Glasgow Coma Scale (GCS) is the most applied tool for classifying intensity of coma and predicting patient outcomes with traumatic brain injuries. The present study was conducted with the aim of comparing two criteria of Full Outline of UnResponsiveness (FOUR) scale and GCS in predicting prognosis in patients with traumatic brain injuries. MATERIAL and METHODS: In this prospective study, 198 patients with traumatic brain injuries were investigated. FOUR and GCS criteria for each patient were determined by four well-educated nurses. The area under receiver operating characteristic (ROC) curve was determined for in-hospital mortality outcomes. RESULTS: Of all patients, 65.2% survived and 34.8% died, and FOUR had correctly predicted 82% of them. FOUR had 0.76 sensitivity and GCS had a sensitivity 0.85. Mean scores for mortality and survival rates were 4.59 +/- 2.36 and 10.71 +/- 2.24 in GCS, and 3.15 +/- 3.52 and 12.77 +/- 2.43 in FOUR, respectively. The area under ROC curve was 0.961 for FOUR and 0.928 for GCS. The area under the curve was high for FOUR in scores 6 and 7, and for GCS in scores 5 and 6. CONCLUSION: FOUR score is a valuable, sensitive and specific diagnostic criterion for predicting outcomes in patients with traumatic brain injuries.	[Sepahvand, Elham] Univ Social Welf & Rehabil Sci, Nursing, Tehran, Iran; [Jalali, Rostam; Ahmadi, Mahnaz] Kermanshah Univ Med Sci, Dept Nursing, Kermanshah, Iran; [Mirzaei, Maryam] Jahrom Univ Med Sci, Dept Nursing, Jahrom, Iran; [Ebrahimzadeh, Farzad; Amraii, Esmail] Lorestan Univ Med Sci, Dept Paramed, Khorramabad, Iran	Sepahvand, E (corresponding author), Univ Social Welf & Rehabil Sci, Nursing, Tehran, Iran.	swt_f@farasa.org	sepahvand, elham/AAY-5107-2020; Jalali, Rostam/V-5820-2017	Jalali, Rostam/0000-0003-1781-9939			Akavipat P, 2011, ACTA MED OKAYAMA, V65, P205; Bruno MA, 2011, NEUROCRIT CARE, V15, P447, DOI 10.1007/s12028-011-9547-2; Chan MF, 2013, J NURS MANAGE, V21, P31, DOI 10.1111/j.1365-2834.2011.01344.x; Chen BX, 2013, ACTA NEUROCHIR, V155, P2133, DOI 10.1007/s00701-013-1854-2; Fischer M, 2010, CRIT CARE, V14, DOI 10.1186/cc8963; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Fugate JE, 2010, NEUROCRIT CARE, V13, P205, DOI 10.1007/s12028-010-9407-5; Ghayeghran A, 2009, J GUILAN U MED SCI, V72, P70; Idrovo Freire L, 2012, INTERN EMERG MED, V7, P203; Idrovo L, 2010, EUR NEUROL, V63, P364, DOI 10.1159/000292498; Iyer VN, 2009, MAYO CLIN PROC, V84, P694, DOI 10.1016/S0025-6196(11)60519-3; Izadi Avanji F, 2010, J KASHAN U MED SCI, V14, P112; Jalali R, 2014, CRIT CARE RES PRACT, V2014, DOI 10.1155/2014/289803; Kevric J, 2011, EMERG MED J, V28, P486, DOI 10.1136/emj.2009.085845; Ledoux D, 2009, CRITICAL CARE, V13, P107; Marcati E, 2012, INTERN EMERG MED, V7, P145, DOI 10.1007/s11739-011-0583-x; Mercy SA, 2013, NURS MIDWIFERY RES J, V9, P63; Sacco S, 2010, EUR NEUROL, V63, P370, DOI 10.1159/000313952; Sadaka F, 2012, NEUROCRIT CARE, V16, P95, DOI 10.1007/s12028-011-9617-5; Tadrisi SD, 2012, IRAN J CRIT CARE NUR, V5, P95; Tindall S C, 1990, CLIN METHODS HIST PH, P371; Weiss N, 2012, J NEUROL, V259, P70, DOI 10.1007/s00415-011-6120-z	22	12	12	0	5	TURKISH NEUROSURGICAL SOC	BAHCELIEVLER	TASKENT CADDESI 13-4, BAHCELIEVLER, ANKARA 06500, TURKEY	1019-5149			TURK NEUROSURG	Turk. Neurosurg.	SEP	2016	26	5					720	724		10.5137/1019-5149.JTN.13536-14.0			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DY7VY	WOS:000385338600011	27476914	Bronze			2021-06-18	
J	Sorg, SF; Schiehser, DM; Bondi, MW; Luc, N; Clark, AL; Jacobson, MW; Frank, LR; Delano-Wood, L				Sorg, Scott F.; Schiehser, Dawn M.; Bondi, Mark W.; Luc, Norman; Clark, Alexandra L.; Jacobson, Mark W.; Frank, Lawrence R.; Delano-Wood, Lisa			White Matter Microstructural Compromise Is Associated With Cognition But Not Posttraumatic Stress Disorder Symptoms in Military Veterans With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						diffusion tensor imaging; mild traumatic brain injury; neuropsychology; posttraumatic stress disorder	DIFFUSE AXONAL INJURY; AFGHANISTAN WAR VETERANS; ANTERIOR CINGULATE; TENSOR ANISOTROPY; CORPUS-CALLOSUM; FOLLOW-UP; IRAQ; INTEGRITY; TRACTOGRAPHY; MODERATE	Objective: To investigate white matter microstructure compromise in Veterans with a history of traumatic brain injury (TBI) and its possible contribution to posttraumatic stress disorder (PTSD) symptomatology and neuropsychological functioning via diffusion tensor imaging. Participants and Methods: Thirty-eight Veterans with mild (n = 33) and moderate (n = 5) TBI and 17 military control participants without TBI completed neuropsychological testing and psychiatric screening and underwent magnetic resonance imaging an average of 4 years following their TBI event(s). Fractional anisotropy (FA) and diffusivity measures were extracted from 9 white matter tracts. Results: Compared with military control participants, TBI participants reported higher levels of PTSD symptoms and performed worse on measures of memory and psychomotor-processing speed. Traumatic brain injury was associated with lower FA in the genu of the corpus callosum and left cingulum bundle. Fractional anisotropy negatively correlated with processing speed and/or executive functions in 7 of the 8 tracts. Regional FA did not correlate with memory or PTSD symptom ratings. Conclusion: Results suggest that current PTSD symptoms are independent of TBI-related white matter alterations, as measured by diffusion tensor imaging. In addition, white matter microstructural compromise may contribute to reduced processing speed in our sample of participants with history of neurotrauma. Findings of the current study add insight into the factors associated with complicated recovery from mild to moderate TBI.	[Sorg, Scott F.; Schiehser, Dawn M.; Bondi, Mark W.; Luc, Norman; Jacobson, Mark W.; Delano-Wood, Lisa] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Delano-Wood, Lisa] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Sorg, Scott F.; Schiehser, Dawn M.; Bondi, Mark W.; Jacobson, Mark W.; Delano-Wood, Lisa] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Clark, Alexandra L.] Univ Calif San Diego, Joint Doctoral Program Clin Psychol, San Diego State Univ, La Jolla, CA 92093 USA; [Frank, Lawrence R.] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA	Delano-Wood, L (corresponding author), VA San Diego Healthcare Syst 116B, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	ldelano@ucsd.edu			Veterans AffairsUS Department of Veterans Affairs; Department of DefenseUnited States Department of Defense; VA Advanced Fellowship Program in Interprofessional Polytrauma and Traumatic Brain Injury Rehabilitation; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH096100] Funding Source: NIH RePORTER	This work was supported by grants awarded by the Veterans Affairs (Career Development Awards [CDA]: LD-W, DS; Merit Award, LD-W) as well as the Department of Defense (Investigator-Initiated Research Grant [IIRG]: LD-W). This material is further supported with resources of the Veterans Affairs Center of Excellence for Stress and Mental Health (CESAMH: LD-W). For the remaining authors, none were declared.; The work was further supported by the VA Advanced Fellowship Program in Interprofessional Polytrauma and Traumatic Brain Injury Rehabilitation (SS).	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Beaulieu C, 2009, DIFFUSION MRI: FROM QUANTITATIVE MEASUREMENT TO IN VIVO NEUROANATOMY, P105, DOI 10.1016/B978-0-12-374709-9.00006-7; Beck AT., 1996, BECK DEPRESSION INVE, V2; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bremner J Douglas, 2004, Expert Rev Neurother, V4, P275, DOI 10.1586/14737175.4.2.275; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Concha L, 2005, AM J NEURORADIOL, V26, P2267; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Deoni SCL, 2008, MAGN RESON MED, V60, P1372, DOI 10.1002/mrm.21704; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gelman N, 2001, MAGNET RESON MED, V45, P71, DOI 10.1002/1522-2594(200101)45:1<71::AID-MRM1011>3.0.CO;2-2; Heaton R. K, 1981, WISCONSIN CARD SORTI; Hofer S, 2006, NEUROIMAGE, V32, P989, DOI 10.1016/j.neuroimage.2006.05.044; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kim MJ, 2005, NEUROREPORT, V16, P1049, DOI 10.1097/00001756-200507130-00004; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; Lindauer RJL, 2008, PSYCHOL MED, V38, P543, DOI 10.1017/S0033291707001432; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Madler B, 2008, MAGN RESON IMAGING, V26, P874, DOI 10.1016/j.mri.2008.01.047; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Protopopescu X, 2005, BIOL PSYCHIAT, V57, P464, DOI 10.1016/j.biopsych.2004.12.026; Ragsdale KA, 2013, J ANXIETY DISORD, V27, P420, DOI 10.1016/j.janxdis.2013.04.003; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schuff N, 2011, NEUROIMAGE, V54, pS62, DOI 10.1016/j.neuroimage.2010.05.024; Shin LM, 2005, ARCH GEN PSYCHIAT, V62, P273, DOI 10.1001/archpsyc.62.3.273; Shin LM, 2001, BIOL PSYCHIAT, V50, P932, DOI 10.1016/S0006-3223(01)01215-X; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sorg SF, 2014, J HEAD TRAUMA REHAB, V29, P21, DOI 10.1097/HTR.0b013e31828a1aa4; Spreen O., 1998, COMPENDIUM NEUROPSYC; TEASDALE G, 1974, LANCET, V2, P81; Tombaugh TN, 1996, TEST MEMORY MALINGER; Traumatic Brain Injury Task Force, 2008, REP SURG GEN TRAUM B; Twamley EW, 2014, J REHABIL RES DEV, V51, P59, DOI 10.1682/JRRD.2013.01.0020; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Wang R, 2007, P INT SOC MAG RESON, V15, P3720; Weathers F. W., 1993, ANN M INT SOC TRAUM; Wechsler D, 2008, WECHSLER AFULT INTEL; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME, V4th; Yarnykh VL, 2015, RADIOLOGY, V274, P210, DOI 10.1148/radiol.14140528; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	81	12	12	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2016	31	5					297	308		10.1097/HTR.0000000000000189			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DX2ZY	WOS:000384243600008	26360008	Green Accepted			2021-06-18	
J	Spong, KE; Rodriguez, EC; Robertson, RM				Spong, Kristin E.; Rodriguez, Esteban C.; Robertson, R. Meldrum			Spreading depolarization in the brain of Drosophila is induced by inhibition of the Na+/K+-ATPase and mitigated by a decrease in activity of protein kinase G	JOURNAL OF NEUROPHYSIOLOGY			English	Article						anoxic depolarization; Drosophila; extracellular potassium; PKG; spreading depolarization	RAT HIPPOCAMPAL SLICES; EXTRACELLULAR POTASSIUM CONCENTRATION; DEPRESSION-LIKE DEPOLARIZATION; LOCUST CNS; CEREBRAL-CORTEX; CORTICAL DEPRESSION; K+ HOMEOSTASIS; ISCHEMIA; ANOXIA; MELANOGASTER	Spreading depolarization (SD) is characterized by a massive redistribution of ions accompanied by an arrest in electrical activity that slowly propagates through neural tissue. It has been implicated in numerous human pathologies, including migraine, stroke, and traumatic brain injury, and thus the elucidation of control mechanisms underlying the phenomenon could have many health benefits. Here, we demonstrate the occurrence of SD in the brain of Drosophila melanogaster, providing a model system, whereby cellular mechanisms can be dissected using molecular genetic approaches. Propagating waves of SD were reliably induced by disrupting the extracellular potassium concentration ([K+](o)), either directly or by inhibition of the Na+/K+-ATPase with ouabain. The disturbance was monitored by recording the characteristic surges in [K+](o) using K+-sensitive microelectrodes or by monitoring brain activity by measuring direct current potential. With the use of wildtype flies, we show that young adults are more resistant to SD compared with older adults, evidenced by shorter bouts of SD activity and attenuated [K+](o) disturbances. Furthermore, we show that the susceptibility to SD differs between wild- type flies and w1118 mutants, demonstrating that our ouabain model is influenced by genetic strain. Lastly, flies with low levels of protein kinase G (PKG) had increased latencies to onset of both ouabain- induced SD and anoxic depolarization compared with flies with higher levels. Our findings implicate the PKG pathway as a modulator of SD in the fly brain, and given the conserved nature of the signaling pathway, it could likely play a similar role during SD in the mammalian central nervous system.	[Spong, Kristin E.; Rodriguez, Esteban C.; Robertson, R. Meldrum] Queens Univ, Dept Biol, Biosci Complex,Rm 3404, Kingston, ON K7L 3N6, Canada	Spong, KE (corresponding author), Queens Univ, Dept Biol, Biosci Complex,Rm 3404, Kingston, ON K7L 3N6, Canada.	9ks26@queensu.ca	Robertson, Robert M/B-2482-2009	Robertson, Robert M/0000-0002-2666-7861	Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR	Funding for this work was provided by a Discovery Grant from the Natural Sciences and Engineering Research Council of Canada.	Armstrong GAB, 2012, J INSECT PHYSIOL, V58, P1511, DOI 10.1016/j.jinsphys.2012.09.006; Armstrong GAB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028994; Armstrong GAB, 2009, J NEUROSCI, V29, P8225, DOI 10.1523/JNEUROSCI.1652-09.2009; Balestrino M, 1999, BRAIN RES, V838, P37, DOI 10.1016/S0006-8993(99)01674-1; Campbell JL, 2001, J NEUROBIOL, V49, P339, DOI 10.1002/neu.10009; Chai Y, 2008, PFLUG ARCH EUR J PHY, V456, P897, DOI 10.1007/s00424-008-0447-z; CHEBABO SR, 1995, BRAIN RES, V695, P203, DOI 10.1016/0006-8993(95)00778-O; Dawson-Scully K, 2010, J EXP BIOL, V213, P2410, DOI 10.1242/jeb.041319; Dreier JP, 2015, NEURON, V86, P902, DOI 10.1016/j.neuron.2015.04.004; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; GRAFSTEIN B, 1956, J NEUROPHYSIOL, V19, P154; Haddad GG, 2006, EXP PHYSIOL, V91, P277, DOI 10.1113/expphysiol.2005.030767; HANSEN AJ, 1977, ACTA PHYSIOL SCAND, V99, P412, DOI 10.1111/j.1748-1716.1977.tb10394.x; Isagai T, 1999, J NEUROPHYSIOL, V81, P1866; Kang Y, 2007, J NEUROPHYSIOL, V98, P3397, DOI 10.1152/jn.00536.2007; Krnjevic K, 2008, NEUROPHARMACOLOGY, V55, P319, DOI 10.1016/j.neuropharm.2008.01.002; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; LEBLOND J, 1989, J NEUROPHYSIOL, V62, P1; MARES P, 1976, EXP NEUROL, V53, P12, DOI 10.1016/0014-4886(76)90277-6; MARSHALL WH, 1959, PHYSIOL REV, V39, P239; Muller M, 2000, J NEUROPHYSIOL, V83, P735, DOI 10.1152/jn.2000.83.2.735; Osborne KA, 1997, SCIENCE, V277, P834, DOI 10.1126/science.277.5327.834; Payne RS, 1996, BRAIN RES, V723, P210, DOI 10.1016/0006-8993(96)00254-5; Pietrobon D, 2014, NAT REV NEUROSCI, V15, P379, DOI 10.1038/nrn3770; Renger JJ, 1999, J NEUROSCI, V19; Rodgers CI, 2010, J INSECT PHYSIOL, V56, P980, DOI 10.1016/j.jinsphys.2010.03.030; Rodgers CI, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001366; Rodgers CI, 2009, J INSECT PHYSIOL, V55, P599, DOI 10.1016/j.jinsphys.2009.03.004; Rodriguez EC, 2012, J EXP BIOL, V215, P4157, DOI 10.1242/jeb.074468; Sitaraman D, 2008, P NATL ACAD SCI USA, V105, P5579, DOI 10.1073/pnas.0710168105; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Spong KE, 2016, J EXP BIOL, V219, P626, DOI 10.1242/jeb.132456; Spong KE, 2015, J NEUROPHYSIOL, V114, P3111, DOI 10.1152/jn.00804.2015; Spong KE, 2014, J INSECT PHYSIOL, V66, P1, DOI 10.1016/j.jinsphys.2014.05.009; Spong KE, 2013, J INSECT PHYSIOL, V59, P1031, DOI 10.1016/j.jinsphys.2013.07.007; VYSKOCIL F, 1972, BRAIN RES, V39, P255, DOI 10.1016/0006-8993(72)90802-5; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8; Xiao CF, 2016, GENETICS, V203, P787, DOI 10.1534/genetics.115.185066; Xiao CF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135825; Xie MJ, 2008, J CEREBR BLOOD F MET, V28, P456, DOI 10.1038/sj.jcbfm.9600545	41	12	12	0	5	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077	1522-1598		J NEUROPHYSIOL	J. Neurophysiol.	SEP	2016	116	3					1152	1160		10.1152/jn.00353.2016			9	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	DZ6ET	WOS:000385955100021	27358319	Green Published, Bronze			2021-06-18	
J	Yee, MK; Seichepine, DR; Janulewicz, PA; Sullivan, KA; Proctor, SP; Krengel, MH				Yee, Megan K.; Seichepine, Daniel R.; Janulewicz, Patricia A.; Sullivan, Kimberly A.; Proctor, Susan P.; Krengel, Maxine H.			Self-Reported Traumatic Brain Injury, Health and Rate of Chronic Multisymptom Illness in Veterans From the 1990-1991 Gulf War	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						chronic multisymptom illness; Gulf War; traumatic brain injury	QUALITY-OF-LIFE; POSTTRAUMATIC-STRESS-DISORDER; NEURON-SPECIFIC ENOLASE; US ARMY VETERANS; PSYCHIATRIC-DISORDERS; FOLLOW-UP; SERUM CONCENTRATIONS; BIOCHEMICAL MARKERS; CARE UTILIZATION; DAMAGE S-100B	Background: Traumatic brain injury (TBI) was not considered to be common in the 1990-1991 Gulf War (GW). Therefore, the relationship between TBI and chronic health symptoms experienced by GW veterans is unknown. Health symptoms reported by veterans deployed more recently to this region (Operations Enduring and Iraqi Freedom) are similar to those of GW veterans and have been primarily attributed to TBI. Objective: To examine the relationships among self-reported TBI, health symptoms, chronic multisymptom illness (CMI), and health-related quality of life among GW veterans. Participants: Participants included 1 274 GW veterans from the Devens Cohort Study, 156 of whom self-reported a history of TBI (12.2% of the sample). Design: Cross-sectional retrospective analysis of existing survey data. Main Measures: A 52-item health symptom checklist and the RAND 36-Item Health short Form Survey. Results: Self-reported TBI in GW Veterans is related to increased rates of health symptoms, CMI, and poorer health-related quality of life. Conclusions: Gulf War veterans' self-reported exposure to TBI is related to increased rates of chronic health symptoms and CMI, which interfere with everyday activities of daily living.	[Yee, Megan K.; Proctor, Susan P.] VA Boston Healthcare Syst, Res Serv, 150 S Huntington Ave,D12-87, Boston, MA 02130 USA; [Krengel, Maxine H.] VA Boston Healthcare Syst, Psychol Res, Boston, MA 02130 USA; [Yee, Megan K.] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Seichepine, Daniel R.] Univ New Hampshire, Div Social Sci, Manchester, NH USA; [Janulewicz, Patricia A.; Sullivan, Kimberly A.; Proctor, Susan P.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Proctor, Susan P.] US Army, Environm Med Res Inst, Mil Performance Div, Natick, MA 01760 USA; [Krengel, Maxine H.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA	Yee, MK (corresponding author), VA Boston Healthcare Syst, Res Serv, 150 S Huntington Ave,D12-87, Boston, MA 02130 USA.	meganyee@bu.edu		Sullivan, Kimberly/0000-0001-7940-6123			[Anonymous], 2014, VA DOD CLIN PRACTICE; [Anonymous], 2009, J REHABIL RES DEV, V46, pCP1; Barrientos RM, 2006, NEUROBIOL AGING, V27, P723, DOI 10.1016/j.neurobiolaging.2005.03.010; Barrientos RM, 2009, BRAIN BEHAV IMMUN, V23, P450, DOI 10.1016/j.bbi.2009.01.016; Chase RP, 2015, J HEAD TRAUMA REHAB, V30, pE57, DOI 10.1097/HTR.0000000000000061; Deb S, 1999, AM J PSYCHIAT, V156, P374; Defense and Veterans Brain Injury Center, 2014, DOD WORLDW NUMB TBI; DeSalvo KB, 2005, HEALTH SERV RES, V40, P1234, DOI 10.1111/j.1475-6773.2005.00404.x; DUNN OJ, 1959, ANN MATH STAT, V30, P192, DOI 10.1214/aoms/1177706374; DUNN OJ, 1961, J AM STAT ASSOC, V56, P52, DOI 10.2307/2282330; Falvo MJ, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1124; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Fukuda K, 1998, JAMA-J AM MED ASSOC, V280, P981, DOI 10.1001/jama.280.11.981; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Guilfoyle MR, 2010, J NEUROTRAUM, V27, P2173, DOI 10.1089/neu.2010.1353; Hartvigsen Jan, 2014, Arch Phys Med Rehabil, V95, pS286, DOI 10.1016/j.apmr.2013.07.029; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Institute of Medicine, 2014, CHRON MULT ILLN GULF; Institute of Medicine, 2010, GULF WAR HLTH UPD HL; Ismail K, 2011, OCCUP MED-OXFORD, V61, P483, DOI 10.1093/occmed/kqr086; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kang HK, 2009, J OCCUP ENVIRON MED, V51, P401, DOI 10.1097/JOM.0b013e3181a2feeb; Kazis LE, 1998, ARCH INTERN MED, V158, P626, DOI 10.1001/archinte.158.6.626; Kelsall HL, 2009, AM J EPIDEMIOL, V170, P1048, DOI 10.1093/aje/kwp238; Khanna D, 2007, AM J MANAG CARE, V13, pS218; Kosinski M, 2000, ARTHRITIS RHEUM, V43, P1478, DOI 10.1002/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kraus JF, 2014, BRAIN INJURY, P1; Li B, 2011, AM J EPIDEMIOL, V174, P761, DOI 10.1093/aje/kwr154; MAIER SF, 1993, BRAIN RES, V623, P321, DOI 10.1016/0006-8993(93)91446-Y; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; Milligan ED, 2009, NAT REV NEUROSCI, V10, P23, DOI 10.1038/nrn2533; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Ozakinci G, 2006, ENVIRON HEALTH PERSP, V114, P1553, DOI 10.1289/ehp.9251; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Proctor SP, 2001, MIL MED, V166, P510; Proctor SP, 2001, J OCCUP ENVIRON MED, V43, P259, DOI 10.1097/00043764-200103000-00014; Proctor SP, 1998, INT J EPIDEMIOL, V27, P1000, DOI 10.1093/ije/27.6.1000; Proctor SP, 2006, NEUROTOXICOLOGY, V27, P931, DOI 10.1016/j.neuro.2006.08.001; Report to Congress on Mild Traumatic Brain Injury in the United States, 2003, REP C MILD TRAUM BRA; Research Advisory Committee on Gulf War Veterans Illnesses, 2013, GULF WAR ILLN HLTH G; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Salamon R, 2006, INT J EPIDEMIOL, V35, P479, DOI 10.1093/ije/dyi318; Scholten JD, 2012, BRAIN INJURY, V26, P1177, DOI 10.3109/02699052.2012.661914; Schwartz DA, 1997, JAMA-J AM MED ASSOC, V277, P238; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Singh JA, 2005, J AM GERIATR SOC, V53, P108, DOI 10.1111/j.1532-5415.2005.53020.x; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Smith BN, 2013, J OCCUP ENVIRON MED, V55, P116, DOI 10.1097/JOM.0b013e318270d709; Smith TC, 2014, AM J EPIDEMIOL, V180, P1176, DOI 10.1093/aje/kwu240; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Ware JE., 1993, HLTH SURVEY MANUAL I; Ware JE., 1994, SF 36 PHYS MENTAL HL, V1st; White RF, 2001, AM J IND MED, V40, P42, DOI 10.1002/ajim.1070; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wolfe J, 1999, PSYCHOSOM MED, V61, P532, DOI 10.1097/00006842-199907000-00018; Wolfe J, 1998, AM J IND MED, V33, P104, DOI 10.1002/(SICI)1097-0274(199802)33:2<104::AID-AJIM2>3.0.CO;2-Y; WOLFE J, 1993, J SOC ISSUES, V49, P15, DOI 10.1111/j.1540-4560.1993.tb01179.x; Wolfe J, 2002, J OCCUP ENVIRON MED, V44, P271, DOI 10.1097/00043764-200203000-00015	67	12	12	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2016	31	5					320	328		10.1097/HTR.0000000000000173			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DX2ZY	WOS:000384243600010	26291628				2021-06-18	
J	Fahoum, F; Omer, N; Kipervasser, S; Bar-Adon, T; Neufeld, M				Fahoum, Firas; Omer, Nurit; Kipervasser, Svetlana; Bar-Adon, Tal; Neufeld, Miri			Safety in the epilepsy monitoring unit: A retrospective study of 524 consecutive admissions	EPILEPSY & BEHAVIOR			English	Article						Epilepsy monitoring unit; Safety adverse events; Antiepileptic drugs; Seizure clusters; Psychogenic nonepileptic seizure; Status epilepticus	ADVERSE EVENTS; VIDEO; TELEMETRY; TIME	The yield of monitoring patients at an epilepsy monitoring unit (EMU) depends on the recording of paroxysmal events in a timely fashion, however, increasing the risk of safety adverse events (AEs). We aimed to retrospectively study the frequency and risk factors for AE occurrences in all consecutive admissions to an adult EMU in a tertiary medical center. We also compared our findings with published data from other centers. Between January 2011 and June 2014, there were 524 consecutive admissions to the adult EMU at the Tel Aviv Sourasky Medical Center. Adverse events were recorded in 47 (9.0%) admissions. The most common AE was 4-hour seizure cluster (58.7% of AEs) and, in decreasing frequency, AEs related to antiepileptic drugs (AEDs, 11.1%), falls and traumatic injuries (9.5%), intravenous line complications (9.5%), electrode-related (4.8%), status epilepticus (SE, 3.2%), and cardiac (1.6%) and psychiatric (1.6%) complications. There were significantly more AEs among patients with a younger age at disease onset (p = 0.005), a history of temporal lobe epilepsy (p = 0.046), a history of focal seizures with altered consciousness (p = 0.008), a history of SE (p = 0.022), use of a vagal nerve stimulator (p = 0.039), and intellectual disability (p = 0.016) and when the indication for EMU monitoring was noninvasive or invasive presurgical evaluation (p = 0.001). Adverse events occurred more frequently when patients had more events in the EMU (p = 0.001) and among those administered carbamazepine (p = 0.037), levetiracetam (p = 0.004), clobazam (p = 0.008), and sulthiame (p = 0.016). Patients with a history of psychogenic nonepileptic seizures (PNESs) had significantly fewer AEs (p = 0.013). Adverse events were not associated with the age, gender, duration of hospitalization or monitoring, AED withdrawal and renewal, seizure frequency by history, presence of major psychiatric comorbidities, abnormal neurological exam, or the presence of a lesion as on brain magnetic resonance imaging. In conclusion, this study reveals that AEs are not unusual in the EMU and that seizure clustering is the most common among them. Adverse events occur more frequently in patients with more severe epilepsy and intellectual disability and in patients undergoing presurgical evaluations and less frequently in patients with PNESs. (C) 2016 Elsevier Inc. All rights reserved.	[Fahoum, Firas; Omer, Nurit; Kipervasser, Svetlana; Bar-Adon, Tal; Neufeld, Miri] Tel Aviv Sourasky Med Ctr, Epilepsy & EEG Unit, Dept Neurol, 6 Weizmann St, IL-6423906 Tel Aviv, Israel; [Kipervasser, Svetlana; Neufeld, Miri] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Fahoum, F (corresponding author), Tel Aviv Sourasky Med Ctr, Epilepsy & EEG Unit, Dept Neurol, 6 Weizmann St, IL-6423906 Tel Aviv, Israel.	firasf@tlvmc.gov.il		Fahoum, Firas/0000-0003-2262-5530			[Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Atkinson M, 2012, SEIZURE-EUR J EPILEP, V21, P124, DOI 10.1016/j.seizure.2011.10.004; Blum DE, 1996, NEUROLOGY, V47, P260, DOI 10.1212/WNL.47.1.260; Dericioglu N, 2000, SEIZURE-EUR J EPILEP, V9, P124, DOI 10.1053/seiz.1999.0341; Di Gennaro G, 2012, CLIN NEUROPHYSIOL, V123, P486, DOI 10.1016/j.clinph.2011.08.011; Dobesberger J, 2011, EPILEPSIA, V52, P443, DOI 10.1111/j.1528-1167.2010.02782.x; Hoppe C, 2007, ARCH NEUROL-CHICAGO, V64, P1595, DOI 10.1001/archneur.64.11.1595; Kandler R, 2013, SEIZURE-EUR J EPILEP, V22, P872, DOI 10.1016/j.seizure.2013.08.001; Lowenstein DH, 1999, EPILEPSIA, V40, P120, DOI 10.1111/j.1528-1157.1999.tb02000.x; Martz GU, 2014, EPILEPSIA, V55, P1800, DOI 10.1111/epi.12796; McCabe PH, 2003, NEUROLOGY, V60, P975, DOI 10.1212/01.WNL.0000053748.83309.28; Mohan KK, 1996, ACTA NEUROL SCAND, V94, P320, DOI 10.1111/j.1600-0404.1996.tb07073.x; Moien-Afshari F, 2009, CAN J NEUROL SCI, V36, P587, DOI 10.1017/S0317167100008088; Noe KH, 2009, MAYO CLIN PROC, V84, P495, DOI 10.1016/S0025-6196(11)60580-6; Pati S, 2013, EPILEPSY BEHAV, V29, P1, DOI 10.1016/j.yebeh.2013.06.013; Rheims S, 2014, CURR OPIN NEUROL, V27, P213, DOI 10.1097/WCO.0000000000000076; Sauro KM, 2014, EPILEPSY BEHAV, V33, P7, DOI 10.1016/j.yebeh.2014.01.021; Spanaki MV, 2012, EPILEPSY BEHAV, V25, P185, DOI 10.1016/j.yebeh.2012.06.028; Spritzer SD, 2015, EPILEPSY BEHAV, V48, P75, DOI 10.1016/j.yebeh.2015.05.026; Yen DJ, 2001, EPILEPSIA, V42, P251, DOI 10.1046/j.1528-1157.2001.15100.x	20	12	12	1	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	AUG	2016	61						162	167		10.1016/j.yebeh.2016.06.002			6	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	DT1MY	WOS:000381248000029	27351727				2021-06-18	
J	Jodoin, M; Rouleau, DM; Charlebois-Plante, C; Benoit, B; Leduc, S; Laflamme, GY; Gosselin, N; Larson-Dupuis, C; De Beaumont, L				Jodoin, Marianne; Rouleau, Dominique M.; Charlebois-Plante, Camille; Benoit, Benoit; Leduc, Stephane; Laflamme, G-Yves; Gosselin, Nadia; Larson-Dupuis, Camille; De Beaumont, Louis			Incidence rate of mild traumatic brain injury among patients who have suffered from an isolated limb fracture: Upper limb fracture patients are more at risk	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Mild traumatic brain injury; Orthopaedic monotrauma; Incidence rate	PERSISTENT SYMPTOMS; EPIDEMIOLOGY; CONCUSSION; DIAGNOSIS; RECOVERY; SPORTS	Objectives: This study compares the incidence rate of mild traumatic brain injury (mild TBI) detected at follow-up visits (retrospective diagnosis) in patients suffering from an isolated limb trauma, with the incidence rate held by the hospital records (prospective diagnosis) of the sampled cohort. This study also seeks to determine which types of fractures present with the highest incidence of mild TBI. Patients and methods: Retrospective assessment of mild TBI among orthopaedic monotrauma patients, randomly selected for participation in an Orthopaedic clinic of a Level I Trauma Hospital. Patients in the remission phase of a limb fracture were recruited between August 2014 and May 2015. No intervention was done (observational study). Main outcome measurements: Standardized semi-structured interviews were conducted with all patients to retrospectively assess for mild TBI at the time of the fracture. Emergency room related medical records of all patients were carefully analyzed to determine whether a prospective mild TBI diagnosis was made following the accident. Results: A total of 251 patients were recruited (54% females, Mean age = 49). Study interview revealed a 23.5% incidence rate of mild TBI compared to an incidence rate of 8.8% for prospective diagnosis (chi(2) = 78.47; p < 0.0001). Patients suffering from an upper limb monotrauma (29.6%; n = 42/142) are significantly more at risk of sustaining a mild TBI compared to lower limb fractures (15.6%; n = 17/109) (chi(2) = 6.70; p = 0.010). More specifically, patients with a proximal upper limb injury were significantly more at risk of sustaining concomitant mild TBI (40.6%; 26/64) compared to distal upper limb fractures (20.25%; 16/79) (chi(2) = 7.07; p = 0.008). Conclusions: Results suggest an important concomitance of mild TBI among orthopaedic trauma patients, the majority of which go undetected during acute care. Patients treated for an upper limb fracture are particularly at risk of sustaining concomitant mild TBI. (C) 2016 Elsevier Ltd. All rights reserved.	[Jodoin, Marianne; Gosselin, Nadia; Larson-Dupuis, Camille] Univ Montreal, Dept Psychol, Res Ctr Neuropsychol & Cognit CERNEC, Montreal, PQ, Canada; [Jodoin, Marianne; Rouleau, Dominique M.; Benoit, Benoit; Leduc, Stephane; Laflamme, G-Yves; Gosselin, Nadia; Larson-Dupuis, Camille; De Beaumont, Louis] Montreal Sacred Heart Hosp, Res Ctr, Montreal, PQ, Canada; [De Beaumont, Louis] Univ Quebec Trois Rivieres, Dept Psychol, Trois Rivieres, PQ, Canada; [Rouleau, Dominique M.; Charlebois-Plante, Camille; Benoit, Benoit; Leduc, Stephane; Laflamme, G-Yves] Univ Montreal, Dept Surg, Montreal, PQ, Canada	Rouleau, DM (corresponding author), 5400 Gouin Ouest,Suite C-2095, Montreal, PQ H4J 1C5, Canada.	dominique.rouleau@umontreal.ca			UQTR Research Chair on the Neurobiology of Mild Traumatic Brain Injury	UQTR Research Chair on the Neurobiology of Mild Traumatic Brain Injury awarded to LDB.	Andruszkow H, 2013, CLIN ORTHOP RELAT R, V471, P2899, DOI 10.1007/s11999-013-3031-6; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Buck PW, 2011, HEALTH SOC WORK, V36, P299, DOI 10.1093/hsw/36.4.299; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Court-Brown CM, 2011, OSTEOPOROSIS INT, V22, P1211, DOI 10.1007/s00198-010-1315-1; Court-Brown CM, 2012, INJURY, V43, P891, DOI 10.1016/j.injury.2011.12.007; De Beaumont L, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-109; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dhawan P, 2006, BCMJ, V9, P442; Ferree Steven, 2014, J Trauma Manag Outcomes, V8, P17, DOI 10.1186/1752-2897-8-17; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Foundation ON, 2013, GUID MILD TRAUM BRAI, P156; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Gross T, 2012, ACTA ANAESTH SCAND, V56, P1163, DOI 10.1111/j.1399-6576.2012.02724.x; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mamaril Myrna Eileen, 2007, J Perianesth Nurs, V22, P184; Manara JR, 2015, J SHOULDER ELB SURG, V24, P823, DOI 10.1016/j.jse.2014.12.003; Marshall S, 2012, CAN FAM PHYSICIAN, V58, P257; Marshall S, 2012, CAN FAM PHYSICIAN, V58, pE128; Mkandawire NC, 2002, INJURY, V33, P111, DOI 10.1016/S0020-1383(01)00047-X; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Sobin L, 2015, JAMA FACIAL PLAST SU, P1; Stuart B, 2012, J EMERG NURS, V38, P435, DOI 10.1016/j.jen.2011.04.006; Uhl RL, 2013, J AM ACAD ORTHOP SUR, V21, P624, DOI 10.5435/JAAOS-21-10-624; Urquhart DM, 2006, ANZ J SURG, V76, P600, DOI 10.1111/j.1445-2197.2006.03785.x; von Holst H, 2004, J REHABIL MED, V36, P8, DOI 10.1080/16501960410023633	34	12	13	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	AUG	2016	47	8					1835	1840		10.1016/j.injury.2016.05.036			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	DS9GG	WOS:000381090300040	27291349				2021-06-18	
J	Lajunen, T				Lajunen, Timo			Barriers and facilitators of bicycle helmet use among children and their parents	TRANSPORTATION RESEARCH PART F-TRAFFIC PSYCHOLOGY AND BEHAVIOUR			English	Article						Bicycle helmet use; Barriers; Facilitators; Risk; School children; Adults	HEALTH BELIEF MODEL; HEAD-INJURY; ADOLESCENTS; ATTITUDES; RISK; LEGISLATION; TEENAGERS; EFFICACY; STUDENTS; BEHAVIOR	Despite the fact that bicycle helmet use protects against head injuries, helmet use rate is still low even in countries with high concern for traffic safety. Earlier research shows that helmet use declines with age and that helmet use is low especially among teenagers. The aim of the present study was to investigate barriers and facilitators of helmet use among primary and secondary school pupils and their parents. Identical surveys were conducted among school children (n = 235) and their parents (n =106). Children's and adults' responses concerning cycling, helmet use, helmet ownership, risk assessment and barriers and facilitators were compared and separate regression analyses conducted. Helmet use rate was lower among pupils than adults and they scored higher in most of the barrier items. The results of regression analyses showed that among children, age, gender, barriers and facilitators predicted helmet use while among adults only frequency of cycling and barriers were related to helmet use. Among children, the strongest correlates of not using a helmet were the belief of not needing a helmet and wish to use a cap or a hat instead. Having a helmet wearing as a habit and feeling safer were the strongest correlates of using helmet. Among adults, the strongest correlates of not using a helmet were "helmet looks ridiculous", "just going to short trip" and riding close to home while the strongest correlate of using a helmet was the habit of helmet use. It was concluded that targeting the barriers in helmet wearing campaigns might work better both among children and adults than emphasising the benefits at least among Norwegian child and adult cyclists. (C) 2015 Elsevier Ltd. All rights reserved.	[Lajunen, Timo] Norwegian Univ Sci & Technol NTNU, Dept Psychol, N-7491 Trondheim, Norway	Lajunen, T (corresponding author), Norwegian Univ Sci & Technol NTNU, Dept Psychol, N-7491 Trondheim, Norway.	timo.lajunen@svt.ntnu.no		Lajunen, Timo/0000-0001-5967-5254	Department of Psychology, Norwegian University for Science and Technology (NTNU)	I would like to thank Professors Tornbjorn Rundmo and Hermundur Sigmundsson for their most valuabe support for this study. This study was supported by Department of Psychology, Norwegian University for Science and Technology (NTNU). The study is part of COST Action TU1101 "Towards safer bicycling through optimization of bicycle helmets and usage".	Amoros E, 2012, INJURY PREV, V18, P27, DOI 10.1136/ip.2011.031815; Attewell RG, 2001, ACCIDENT ANAL PREV, V33, P345, DOI 10.1016/S0001-4575(00)00048-8; Bambach MR, 2013, ACCIDENT ANAL PREV, V53, P78, DOI 10.1016/j.aap.2013.01.005; Cripton PA, 2014, ACCIDENT ANAL PREV, V70, P1, DOI 10.1016/j.aap.2014.02.016; Curnow WJ, 2003, ACCIDENT ANAL PREV, V35, P287, DOI 10.1016/S0001-4575(02)00012-X; Dellinger AM, 2010, J SAFETY RES, V41, P375, DOI 10.1016/j.jsr.2010.05.003; Elvik R, 2011, ACCIDENT ANAL PREV, V43, P1245, DOI 10.1016/j.aap.2011.01.007; Finnoff JT, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.1.e4; Fishman E, 2012, TRANSPORT RES F-TRAF, V15, P686, DOI 10.1016/j.trf.2012.08.002; Forjuoh Samuel N, 2003, Med Sci Monit, V9, pCR436; Hagel BE, 2011, INJURY PREV, V17, P114, DOI 10.1136/ip.2010.029165; HOWLAND J, 1989, AM J DIS CHILD, V143, P741, DOI 10.1001/archpedi.1989.02150180123033; Klein KS, 2005, INJURY PREV, V11, P288, DOI 10.1136/ip.2004.007013; Lajunen T, 2004, J SAFETY RES, V35, P115, DOI 10.1016/j.jsr.2003.09.020; Lajunen T, 2001, J SAFETY RES, V32, P323, DOI 10.1016/S0022-4375(01)00056-1; Lang IA, 2007, INJURY PREV, V13, P355, DOI 10.1136/ip.2007.015941; Lastennet F, 2001, ARCH PEDIATRIE, V8, P1246; Lindsay G, 2011, AUST NZ J PUBL HEAL, V35, P54, DOI 10.1111/j.1753-6405.2010.00621.x; Loubeau PR, 2000, ACCIDENT ANAL PREV, V32, P111, DOI 10.1016/S0001-4575(99)00059-7; Muskaug R., 2009, RES BEH OBS 2008; O'Callaghan FV, 2006, J SAFETY RES, V37, P425, DOI 10.1016/j.jsr.2006.08.001; OECD, 2004, KEEP CHILDR SAF TRAF; OECD, 2014, OECD FACTB 2014 EC E; Page RM, 1996, AM J HEALTH BEHAV, V20, P33; Parkin PC, 2003, PEDIATRICS, V112, pE192, DOI 10.1542/peds.112.3.e192; Persaud N, 2012, CAN MED ASSOC J, V184, pE921, DOI 10.1503/cmaj.120988; Pierce SR, 2014, HEALTH PROMOT PRACT, V15, P406, DOI 10.1177/1524839913512329; Rezendes Jennifer L, 2006, J Pediatr Nurs, V21, P35, DOI 10.1016/j.pedn.2005.06.005; Robertson DW, 2014, ACCIDENT ANAL PREV, V70, P314, DOI 10.1016/j.aap.2014.04.011; Ross TP, 2010, J AM COLL HEALTH, V59, P29, DOI 10.1080/07448481.2010.483702; Schejbalova Z, 2013, NEURAL NETW WORLD, V23, P609, DOI 10.14311/NNW.2013.23.036; Secginli S., 2013, INT J INJURY CONTROL; Sinha CK, 2013, SURGERY UK, V31, P123; Sleet DA, 2010, ANNU REV PUBL HEALTH, V31, P195, DOI 10.1146/annurev.publhealth.012809.103616; STEVENSON T, 1992, HEALTH EDUC RES, V7, P555, DOI 10.1093/her/7.4.555; Thompson D.C., 1999, COCHRANE DATABASE SY, V4; Towner P, 1992, Fam Med, V24, P156; Trygg Trafikk, 2014, SYKK; World Health Organization, 2008, WORLD REPORT CHILD I	39	12	12	2	31	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1369-8478	1873-5517		TRANSPORT RES F-TRAF	Transp. Res. Pt. F-Traffic Psychol. Behav.	AUG	2016	41		B				294	301		10.1016/j.trf.2015.03.005			8	Psychology, Applied; Transportation	Psychology; Transportation	DU6TK	WOS:000382347300010					2021-06-18	
J	Liu, GM; Xu, K; Li, J; Luo, YG				Liu, Guo-min; Xu, Kun; Li, Juan; Luo, Yun-gang			Curcumin upregulates S100 expression and improves regeneration of the sciatic nerve following its complete amputation in mice	NEURAL REGENERATION RESEARCH			English	Article						nerve regeneration; electrophysiology; complete nerve amputation; spinal cord; myelin sheath; myelinated fiber; epineurium anatomosis; neural regeneration	TRAUMATIC BRAIN-INJURY; NF-KAPPA-B; RAT MODEL; FUNCTIONAL RECOVERY; PROTEIN; HIPPOCAMPUS; DEPRESSION; PREDICTION; BIOMARKER; RESPONSES	The repair of peripheral nerve injury after complete amputation is difficult, and even with anastomosis, the rapid recovery of nerve function remains challenging. Curcumin, extracted from plants of the genus Curcuma, has been shown to have anti-oxidant and anti-inflammatory properties and to improve sciatic nerve crush injury in rats. Here, we determined whether curcumin had neuroprotective effects following complete peripheral nerve amputation injury. BALB/c mice underwent complete sciatic nerve amputation, followed by an immediate epineurium anastomosis. Mice were intragastrically administered curcumin at doses of 40 (high), 20 (moderate), and 10 mg/kg/d (low) for 1 week. We found that myelin in the mice of the high-and moderate-dose curcumin groups appeared with regular shape, uniform thickness, clear boundary, and little hyperplasia surrounding the myelin. High and moderate doses of curcumin markedly improved both action potential amplitude of the sciatic nerves and the conduction velocity of the corresponding motor neurons, and upregulated mRNA and protein expression of S100, a marker for Schwann cell proliferation, in L 4-6 spinal cord segments. These results suggest that curcumin is effective in promoting the repair of complete sciatic nerve amputation injury and that the underlying mechanism may be associated with upregulation of S100 expression.	[Liu, Guo-min] Jilin Univ, Dept Orthoped, Hosp 2, Changchun, Jilin Province, Peoples R China; [Xu, Kun; Li, Juan] Jilin Univ, Dept Hlth Lab, Sch Publ Hlth, Changchun, Jilin Province, Peoples R China; [Luo, Yun-gang] Jilin Univ, Dept Stomatol, Hosp 2, Changchun, Jilin Province, Peoples R China	Luo, YG (corresponding author), Jilin Univ, Dept Stomatol, Hosp 2, Changchun, Jilin Province, Peoples R China.	luoygjlu@sina.com			Jilin Provincial Science & Technology Development Project Fund of China [20150311038YY]	This research was supported by the Jilin Provincial Science & Technology Development Project Fund of China, No. 20150311038YY.	Agthong S, 2015, EXP NEUROBIOL, V24, P139, DOI 10.5607/en.2015.24.2.139; Ahmed T, 2011, SYNAPSE, V65, P572, DOI 10.1002/syn.20876; Angius D, 2012, BIOMATERIALS, V33, P8034, DOI 10.1016/j.biomaterials.2012.07.056; Arora V, 2011, PSYCHONEUROENDOCRINO, V36, P1570, DOI 10.1016/j.psyneuen.2011.04.012; Babu A, 2015, PHARM BIOL, V53, P838, DOI 10.3109/13880209.2014.943247; Cao J, 2012, BIOMED RES-INDIA, V23, P199; Cox KHM, 2015, J PSYCHOPHARMACOL, V29, P642, DOI 10.1177/0269881114552744; Morrone MDS, 2016, J NUTR BIOCHEM, V32, P181, DOI 10.1016/j.jnutbio.2016.03.010; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Du JS, 2013, MOL MED REP, V8, P1525, DOI 10.3892/mmr.2013.1682; Fang B, 2014, INT J MOL SCI, V15, P6378, DOI 10.3390/ijms15046378; Goel A, 2008, BIOCHEM PHARMACOL, V75, P787, DOI 10.1016/j.bcp.2007.08.016; Goozee KG, 2016, BRIT J NUTR, V115, P449, DOI 10.1017/S0007114515004687; He YK, 2016, INT J IMMUNOPATH PH, V29, P217, DOI 10.1177/0394632016638099; Heidari K, 2015, BRAIN INJURY, V29, P33, DOI 10.3109/02699052.2014.948068; Hsu CH, 2007, ADV EXP MED BIOL, V595, P471; Huang HC, 2016, J ALZHEIMERS DIS, V52, P899, DOI 10.3233/JAD-150872; Jaisin Y, 2011, NEUROSCI LETT, V489, P192, DOI 10.1016/j.neulet.2010.12.014; Jangra A, 2016, INFLAMMATION, V39, P1025, DOI 10.1007/s10753-016-0332-4; Jeon Younghoon, 2013, Curr Ther Res Clin Exp, V74, P1, DOI 10.1016/j.curtheres.2012.10.001; Jia YX, 2014, EXP THER MED, V7, P1141, DOI 10.3892/etm.2014.1546; Jiang X, 2016, EVID-BASED COMPL ALT, V2016; Khuwaja G, 2011, BRAIN RES, V1368, P254, DOI 10.1016/j.brainres.2010.10.023; Krohn M, 2015, J NEUROTRAUM, V32, P430, DOI 10.1089/neu.2014.3524; Kuo YC, 2015, INT J NANOMED, V10, P2653, DOI 10.2147/IJN.S79528; 김지수, 2013, Management Science & Financial Engineering, V19, P19, DOI 10.7737/MSFE.2013.19.2.019; Lesko MM, 2014, BRAIN INJURY, V28, P987, DOI 10.3109/02699052.2014.890743; Liu HY, 2010, NEUROSCI LETT, V485, P83, DOI 10.1016/j.neulet.2010.08.035; Ma JX, 2016, NEUROSCI LETT, V610, P139, DOI 10.1016/j.neulet.2015.11.005; Ma JX, 2013, NEUROSCI LETT, V547, P26, DOI 10.1016/j.neulet.2013.04.054; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Mazzone GL, 2014, J NEUROCHEM, V130, P598, DOI 10.1111/jnc.12748; Menon VP, 2007, ADV EXP MED BIOL, V595, P105; Ozdemir M, 2012, CURR STEM CELL RES T, V7, P364, DOI 10.2174/157488812802481481; Sandur SK, 2007, CARCINOGENESIS, V28, P1765, DOI 10.1093/carcin/bgm123; Shakeril M, 2013, ARCH TRAUMA RES, V2, P76, DOI 10.5812/atr.8549; Song SL, 2016, PATHOL RES PRACT, V212, P247, DOI 10.1016/j.prp.2015.11.012; Stankowska DL, 2017, NUTR NEUROSCI, V20, P273, DOI [10.1080/1028415X.2015.1119377, 10.1080/1028415x.2015.1119377]; Uher T, 2012, NEUROSCI LETT, V529, P139, DOI 10.1016/j.neulet.2012.09.003; Wang HM, 2010, J ALZHEIMERS DIS, V20, P1189, DOI 10.3233/JAD-2010-091336; Wang L, 2015, CELL MOL NEUROBIOL, V35, P827, DOI 10.1007/s10571-015-0177-7; Wang PW, 2014, J NEUROSCI RES, V92, P218, DOI 10.1002/jnr.23322; Wolf H, 2015, J NEUROTRAUM, V32, P23, DOI 10.1089/neu.2013.3202; Wu SH, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/372819; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; Yang JQ, 2014, PATHOL RES PRACT, V210, P357, DOI 10.1016/j.prp.2014.02.005; Yu LS, 2016, EXP THER MED, V11, P709, DOI 10.3892/etm.2016.3022; Zanjani TM, 2014, KOREAN J PAIN, V27, P246, DOI 10.3344/kjp.2014.27.3.246; Zhang C, 2010, J BIOL CHEM, V285, P28472, DOI 10.1074/jbc.M110.133520	49	12	13	0	12	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	1673-5374	1876-7958		NEURAL REGEN RES	Neural Regen. Res.	AUG	2016	11	8					1304	1311		10.4103/1673-5374.189196			8	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	DX1RZ	WOS:000384146000027	27651779	DOAJ Gold, Green Published			2021-06-18	
